<SEC-DOCUMENT>0001493152-23-015184.txt : 20230502
<SEC-HEADER>0001493152-23-015184.hdr.sgml : 20230502
<ACCEPTANCE-DATETIME>20230502162602
ACCESSION NUMBER:		0001493152-23-015184
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		118
CONFORMED PERIOD OF REPORT:	20221231
FILED AS OF DATE:		20230502
DATE AS OF CHANGE:		20230502

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Qualigen Therapeutics, Inc.
		CENTRAL INDEX KEY:			0001460702
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				263474527
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-37428
		FILM NUMBER:		23879475

	BUSINESS ADDRESS:	
		STREET 1:		2042 CORTE DEL NOGAL
		STREET 2:		CARLSBAD
		CITY:			CALIFORNIA
		STATE:			CA
		ZIP:			92011
		BUSINESS PHONE:		(760) 918-9165

	MAIL ADDRESS:	
		STREET 1:		2042 CORTE DEL NOGAL
		STREET 2:		CARLSBAD
		CITY:			CALIFORNIA
		STATE:			CA
		ZIP:			92011

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	RITTER PHARMACEUTICALS INC
		DATE OF NAME CHANGE:	20090402
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>form10-k.htm
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:us-gaap-supplement="http://fasb.org/us-gaap-sup/2022q3" xmlns:srt-supplement="http://fasb.org/srt-sup/2022q3" xmlns:us-roles="http://fasb.org/us-roles/2022" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:country="http://xbrl.sec.gov/country/2022" xmlns:srt="http://fasb.org/srt/2022" xmlns:QLGN="http://qualigeninc.com/20221231">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html" />
</head>
<!-- Field: Set; Name: xdx; ID: xdx_02B_US%2DGAAP%2D2022 -->
<!-- Field: Set; Name: xdx; ID: xdx_037_QLGN_qualigeninc.com_20221231 -->
<!-- Field: Set; Name: xdx; ID: xdx_048_20220101_20221231 -->
<!-- Field: Set; Name: xdx; ID: xdx_055_edei%2D%2DEntityCentralIndexKey_0001460702 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_05A_edei%2D%2DDocumentFiscalPeriodFocus_FY -->
<!-- Field: Set; Name: xdx; ID: xdx_076_XDX_form10%2Dk.xdx -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_065_Pure_0_xbrli%2D%2Dpure -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Sqft_0_utr%2D%2Dsqft -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="dei:EntityCentralIndexKey">0001460702</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="dei:AmendmentFlag">false</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="dei:DocumentFiscalPeriodFocus">FY</ix:nonNumeric>
  <ix:nonFraction name="us-gaap:RestrictedCashAndCashEquivalents" contextRef="AsOf2021-12-31" id="xdx2ixbrl0070" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:Goodwill" contextRef="AsOf2021-12-31" id="xdx2ixbrl0082" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="QLGN:ResearchAndDevelopmentGrantLiability" contextRef="AsOf2021-12-31" id="xdx2ixbrl0106" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShortTermBorrowings" contextRef="AsOf2021-12-31" id="xdx2ixbrl0115" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="QLGN:WarrantLiabilitiesRelatedParty" contextRef="AsOf2021-12-31" id="xdx2ixbrl0121" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ConvertibleDebt" contextRef="AsOf2021-12-31" id="xdx2ixbrl0124" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DeferredIncomeTaxLiabilitiesNet" contextRef="AsOf2021-12-31" id="xdx2ixbrl0136" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:CommitmentsAndContingencies" contextRef="AsOf2022-12-31" id="xdx2ixbrl0141" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:CommitmentsAndContingencies" contextRef="AsOf2021-12-31" id="xdx2ixbrl0142" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="AsOf2021-12-31" id="xdx2ixbrl0173" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:MinorityInterest" contextRef="AsOf2021-12-31" id="xdx2ixbrl0182" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2022-01-012022-12-31_custom_LicenseRevenueMember" id="xdx2ixbrl0196" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:GoodwillImpairmentLoss" contextRef="From2021-01-012021-12-31" id="xdx2ixbrl0218" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" contextRef="From2021-01-012021-12-31" id="xdx2ixbrl0251" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="From2021-01-012021-12-31" id="xdx2ixbrl0269" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" contextRef="From2021-01-012021-12-31" id="xdx2ixbrl0275" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2021-12-31_us-gaap_PreferredStockMember_custom_SeriesAlphaConvertiblePreferredStockMember" id="xdx2ixbrl0280" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2021-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0283" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2021-12-31_us-gaap_NoncontrollingInterestMember" id="xdx2ixbrl0286" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="QLGN:StockIssuedUponCashExerciseOfWarrants" contextRef="From2022-01-012022-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0294" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="QLGN:StockIssuedUponCashExerciseOfWarrants" contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0295" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="QLGN:StockIssuedUponCashExerciseOfWarrants" contextRef="From2022-01-012022-12-31_us-gaap_NoncontrollingInterestMember" id="xdx2ixbrl0297" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions" contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0303" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions" contextRef="From2022-01-012022-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0305" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions" contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0306" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions" contextRef="From2022-01-012022-12-31_us-gaap_NoncontrollingInterestMember" id="xdx2ixbrl0308" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="QLGN:CommonStockAndPrefundedWarrantsIssuedForBusinessAcquisition" contextRef="From2022-01-012022-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0314" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="QLGN:CommonStockAndPrefundedWarrantsIssuedForBusinessAcquisition" contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0315" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="QLGN:NoncontrollingInterestAdjustmentsRelatingToStockbasedCompensationAndOther" contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0323" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="QLGN:NoncontrollingInterestAdjustmentsRelatingToStockbasedCompensationAndOther" contextRef="From2022-01-012022-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0325" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="QLGN:NoncontrollingInterestAdjustmentsRelatingToStockbasedCompensationAndOther" contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0326" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="QLGN:NoncontrollingInterestAdjustmentsRelatingToStockbasedCompensationAndOther" contextRef="From2022-01-01to2022-12-31" id="xdx2ixbrl0329" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0332" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0333" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0335" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="From2022-01-012022-12-31_us-gaap_NoncontrollingInterestMember" id="xdx2ixbrl0337" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="QLGN:FairValueOfWarrantModificationForProfessionalServices" contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0341" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="QLGN:FairValueOfWarrantModificationForProfessionalServices" contextRef="From2022-01-012022-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0343" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="QLGN:FairValueOfWarrantModificationForProfessionalServices" contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0344" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="QLGN:FairValueOfWarrantModificationForProfessionalServices" contextRef="From2022-01-012022-12-31_us-gaap_NoncontrollingInterestMember" id="xdx2ixbrl0346" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="QLGN:FairValueOfWarrantModificationForBusinessAcquisition" contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0350" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="QLGN:FairValueOfWarrantModificationForBusinessAcquisition" contextRef="From2022-01-012022-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0352" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="QLGN:FairValueOfWarrantModificationForBusinessAcquisition" contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0353" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="QLGN:FairValueOfWarrantModificationForBusinessAcquisition" contextRef="From2022-01-012022-12-31_us-gaap_NoncontrollingInterestMember" id="xdx2ixbrl0355" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="QLGN:StockIssuedDuringPeriodValuesReverseStockSplits" contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0359" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="QLGN:StockIssuedDuringPeriodValuesReverseStockSplits" contextRef="From2022-01-012022-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0361" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="QLGN:StockIssuedDuringPeriodValuesReverseStockSplits" contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0362" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="QLGN:StockIssuedDuringPeriodValuesReverseStockSplits" contextRef="From2022-01-012022-12-31_us-gaap_NoncontrollingInterestMember" id="xdx2ixbrl0364" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2022-01-012022-12-31_us-gaap_PreferredStockMember_custom_SeriesAlphaConvertiblePreferredStockMember" id="xdx2ixbrl0369" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0370" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0371" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2022-01-012022-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0372" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2022-12-31_us-gaap_PreferredStockMember_custom_SeriesAlphaConvertiblePreferredStockMember" id="xdx2ixbrl0378" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="QLGN:StockIssuedUponCashExerciseOfWarrants" contextRef="From2021-01-012021-12-31_us-gaap_PreferredStockMember_custom_SeriesAlphaConvertiblePreferredStockMember" id="xdx2ixbrl0409" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="QLGN:StockIssuedUponCashExerciseOfWarrants" contextRef="From2021-01-012021-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0412" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="QLGN:StockIssuedUponNetexerciseOfWarrants" contextRef="From2021-01-012021-12-31_us-gaap_PreferredStockMember_custom_SeriesAlphaConvertiblePreferredStockMember" id="xdx2ixbrl0417" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="QLGN:StockIssuedUponNetexerciseOfWarrants" contextRef="From2021-01-012021-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0420" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="QLGN:StockIssuedUponNetexerciseOfWarrants" contextRef="From2021-01-012021-12-31" id="xdx2ixbrl0421" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="QLGN:IssuanceOfCommonStockForConversionOfPreferredStock" contextRef="From2021-01-012021-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0428" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="QLGN:FairValueOfWarrantsIssuedForProfessionalServices" contextRef="From2021-01-012021-12-31_us-gaap_PreferredStockMember_custom_SeriesAlphaConvertiblePreferredStockMember" id="xdx2ixbrl0435" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="QLGN:FairValueOfWarrantsIssuedForProfessionalServices" contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0436" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="QLGN:FairValueOfWarrantsIssuedForProfessionalServices" contextRef="From2021-01-012021-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0438" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="QLGN:SharesIssuedPursuantToSecuritiesPurchaseAgreements" contextRef="From2021-01-012021-12-31_us-gaap_PreferredStockMember_custom_SeriesAlphaConvertiblePreferredStockMember" id="xdx2ixbrl0441" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="QLGN:SharesIssuedPursuantToSecuritiesPurchaseAgreements" contextRef="From2021-01-012021-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0444" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="QLGN:CommissionAndOfferingCostsOfSecuritiesPurchaseAgreements" contextRef="From2021-01-012021-12-31_us-gaap_PreferredStockMember_custom_SeriesAlphaConvertiblePreferredStockMember" id="xdx2ixbrl0449" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="QLGN:CommissionAndOfferingCostsOfSecuritiesPurchaseAgreements" contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0450" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="QLGN:CommissionAndOfferingCostsOfSecuritiesPurchaseAgreements" contextRef="From2021-01-012021-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0452" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="QLGN:FairValueOfWarrantModificationsPursuantToSecuritiesPurchaseAgreements" contextRef="From2021-01-012021-12-31_us-gaap_PreferredStockMember_custom_SeriesAlphaConvertiblePreferredStockMember" id="xdx2ixbrl0455" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="QLGN:FairValueOfWarrantModificationsPursuantToSecuritiesPurchaseAgreements" contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0456" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="QLGN:FairValueOfWarrantModificationsPursuantToSecuritiesPurchaseAgreements" contextRef="From2021-01-012021-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0458" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2021-01-012021-12-31_us-gaap_PreferredStockMember_custom_SeriesAlphaConvertiblePreferredStockMember" id="xdx2ixbrl0461" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2021-01-012021-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0464" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="From2021-01-012021-12-31_us-gaap_PreferredStockMember_custom_SeriesAlphaConvertiblePreferredStockMember" id="xdx2ixbrl0469" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0470" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="From2021-01-012021-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0472" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2021-01-012021-12-31_us-gaap_PreferredStockMember_custom_SeriesAlphaConvertiblePreferredStockMember" id="xdx2ixbrl0475" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0476" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2021-01-012021-12-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0477" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2021-12-31_us-gaap_PreferredStockMember_custom_SeriesAlphaConvertiblePreferredStockMember" id="xdx2ixbrl0481" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2021-12-31_us-gaap_PreferredStockMember_custom_SeriesAlphaConvertiblePreferredStockMember" id="xdx2ixbrl0487" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2021-12-31_us-gaap_PreferredStockMember_custom_SeriesAlphaConvertiblePreferredStockMember" id="xdx2ixbrl0491" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2021-12-31_us-gaap_PreferredStockMember_custom_SeriesAlphaConvertiblePreferredStockMember" id="xdx2ixbrl0497" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims" contextRef="From2022-01-01to2022-12-31" id="xdx2ixbrl0522" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="QLGN:FairValueOfWarrantsIssuedForProfessionalServices" contextRef="From2022-01-01to2022-12-31" id="xdx2ixbrl0525" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="QLGN:FairValueOfWarrantModificationForProfessionalServices" contextRef="From2021-01-012021-12-31" id="xdx2ixbrl0532" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:GoodwillImpairmentLoss" contextRef="From2021-01-012021-12-31" id="xdx2ixbrl0535" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="QLGN:IncreaseDecreaseInResearchAndDevelopmentGrantLiability" contextRef="From2021-01-012021-12-31" id="xdx2ixbrl0559" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:IncreaseDecreaseInDeferredLiabilities" contextRef="From2021-01-012021-12-31" id="xdx2ixbrl0568" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="QLGN:PurchasesOfEquipmentHeldForLease" contextRef="From2021-01-012021-12-31" id="xdx2ixbrl0580" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:PaymentsToAcquireIntangibleAssets" contextRef="From2022-01-01to2022-12-31" id="xdx2ixbrl0582" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:CashAcquiredFromAcquisition" contextRef="From2021-01-012021-12-31" id="xdx2ixbrl0586" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="QLGN:ProceedsFromIssuanceOfSharesAndWarrantsPursuantToSecuritiesPurchaseAgreements" contextRef="From2022-01-01to2022-12-31" id="xdx2ixbrl0597" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="QLGN:ProceedsFromIssuanceOfConvertibleDebt" contextRef="From2021-01-012021-12-31" id="xdx2ixbrl0601" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:PaymentsOfStockIssuanceCosts" contextRef="From2022-01-01to2022-12-31" id="xdx2ixbrl0603" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:RepaymentsOfNotesPayable" contextRef="From2022-01-01to2022-12-31" id="xdx2ixbrl0606" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="QLGN:FractionalSharePaymentsRelatedToReverseStockSplit" contextRef="From2021-01-012021-12-31" id="xdx2ixbrl0610" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="From2021-01-012021-12-31" id="xdx2ixbrl0619" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:InterestPaidNet" contextRef="From2022-01-01to2022-12-31" id="xdx2ixbrl0633" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="QLGN:IssuanceOfCommonStockForConversionOfPreferredStockBeforeClosingOfReverseRecapitalization" contextRef="From2022-01-01to2022-12-31" id="xdx2ixbrl0642" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="QLGN:RightofuseAssetsObtainedInExchangeForOperatingLeaseLiabilities" contextRef="From2022-01-01to2022-12-31" id="xdx2ixbrl0645" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="QLGN:SharesIssuedForCashlessWarrantsAmount" contextRef="From2022-01-01to2022-12-31" id="xdx2ixbrl0648" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="QLGN:TransfersOfInventoryFromEquipmentHeldForLease" contextRef="From2022-01-01to2022-12-31" id="xdx2ixbrl0651" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="QLGN:FairValueOfWarrantModificationsForBusinessAcquisition" contextRef="From2021-01-012021-12-31" id="xdx2ixbrl0661" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:FairValueOfAssetsAcquired" contextRef="From2021-01-012021-12-31" id="xdx2ixbrl0667" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:LiabilitiesAssumed1" contextRef="From2021-01-012021-12-31" id="xdx2ixbrl0670" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="QLGN:FairValueOfWarrantsRepricedDueToAcquisition" contextRef="From2021-01-012021-12-31" id="xdx2ixbrl0673" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="QLGN:FairValueOfQualigenPrefundedWarrantIssuedInExchangeForNanosynexStock" contextRef="From2021-01-012021-12-31" id="xdx2ixbrl0676" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssued1" contextRef="From2021-01-012021-12-31" id="xdx2ixbrl0679" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:BusinessCombinationConsiderationTransferred1" contextRef="From2021-01-012021-12-31" id="xdx2ixbrl0682" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2022-01-012022-12-31_custom_LicenseRevenuesMember" id="xdx2ixbrl0752" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="QLGN:FixedAssetImpairments" contextRef="AsOf2021-12-31" id="xdx2ixbrl0996" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:Goodwill" contextRef="AsOf2021-12-31" id="xdx2ixbrl1012" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:IntangibleAssetsNetExcludingGoodwill" contextRef="AsOf2021-12-31_us-gaap_InProcessResearchAndDevelopmentMember" id="xdx2ixbrl1033" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="QLGN:AccruedEquipmentHeldForLease" contextRef="AsOf2021-12-31" id="xdx2ixbrl1086" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:InterestPayableCurrent" contextRef="AsOf2021-12-31" id="xdx2ixbrl1095" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="QLGN:AccruedLicenseFees" contextRef="AsOf2021-12-31" id="xdx2ixbrl1113" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" contextRef="From2022-01-012022-12-31_custom_SeriesCWarrantsMember_custom_CommonStockWarrantsMember" id="xdx2ixbrl1171" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInPeriodWeightedAverageExercisePrice" contextRef="From2022-01-012022-12-31_custom_SeriesCWarrantsMember_custom_CommonStockWarrantsMember" id="xdx2ixbrl1173" unitRef="USDPShares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" contextRef="From2021-01-012021-12-31_custom_SeriesCWarrantsMember_custom_CommonStockWarrantsMember" id="xdx2ixbrl1209" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInPeriodWeightedAverageExercisePrice" contextRef="From2021-01-012021-12-31_custom_SeriesCWarrantsMember_custom_CommonStockWarrantsMember" id="xdx2ixbrl1211" unitRef="USDPShares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" contextRef="From2021-01-012021-12-31_custom_SeriesCWarrantsMember_custom_CommonStockWarrantsMember" id="xdx2ixbrl1213" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice" contextRef="From2021-01-012021-12-31_custom_SeriesCWarrantsMember_custom_CommonStockWarrantsMember" id="xdx2ixbrl1215" unitRef="USDPShares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="QLGN:FairValueAdjustmentOfWarrant" contextRef="AsOf2021-12-31_us-gaap_FairValueInputsLevel1Member" id="xdx2ixbrl1231" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="QLGN:FairValueAdjustmentOfWarrant" contextRef="AsOf2021-12-31_us-gaap_FairValueInputsLevel2Member" id="xdx2ixbrl1233" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="QLGN:FairValueOfWarrantLiabilitiesOnDateOfExercise" contextRef="From2022-01-012022-12-31_us-gaap_FairValueInputsLevel1Member" id="xdx2ixbrl1239" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="QLGN:FairValueOfWarrantLiabilitiesOnDateOfExercise" contextRef="From2022-01-012022-12-31_us-gaap_FairValueInputsLevel2Member" id="xdx2ixbrl1241" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="QLGN:FairValueOfWarrantLiabilitiesIssuanceOfAlphaWarrants" contextRef="From2022-01-012022-12-31_us-gaap_FairValueInputsLevel1Member" id="xdx2ixbrl1247" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="QLGN:FairValueOfWarrantLiabilitiesIssuanceOfAlphaWarrants" contextRef="From2022-01-012022-12-31_us-gaap_FairValueInputsLevel2Member" id="xdx2ixbrl1249" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="QLGN:ChangeInFairValueOfWarrantLiabilities" contextRef="From2022-01-012022-12-31_us-gaap_FairValueInputsLevel1Member" id="xdx2ixbrl1255" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="QLGN:ChangeInFairValueOfWarrantLiabilities" contextRef="From2022-01-012022-12-31_us-gaap_FairValueInputsLevel2Member" id="xdx2ixbrl1257" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="QLGN:FairValueAdjustmentOfWarrant" contextRef="AsOf2022-12-31_us-gaap_FairValueInputsLevel1Member" id="xdx2ixbrl1263" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="QLGN:FairValueAdjustmentOfWarrant" contextRef="AsOf2022-12-31_us-gaap_FairValueInputsLevel2Member" id="xdx2ixbrl1265" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="QLGN:FairValueAdjustmentOfWarrant" contextRef="AsOf2020-12-31_us-gaap_FairValueInputsLevel1Member" id="xdx2ixbrl1271" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="QLGN:FairValueAdjustmentOfWarrant" contextRef="AsOf2020-12-31_us-gaap_FairValueInputsLevel2Member" id="xdx2ixbrl1273" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="QLGN:FairValueOfWarrantLiabilitiesOnDateOfExercise" contextRef="From2021-01-012021-12-31_us-gaap_FairValueInputsLevel1Member" id="xdx2ixbrl1279" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="QLGN:FairValueOfWarrantLiabilitiesOnDateOfExercise" contextRef="From2021-01-012021-12-31_us-gaap_FairValueInputsLevel2Member" id="xdx2ixbrl1281" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="QLGN:ChangeInFairValueOfWarrantLiabilities" contextRef="From2021-01-012021-12-31_us-gaap_FairValueInputsLevel1Member" id="xdx2ixbrl1287" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="QLGN:ChangeInFairValueOfWarrantLiabilities" contextRef="From2021-01-012021-12-31_us-gaap_FairValueInputsLevel2Member" id="xdx2ixbrl1289" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="QLGN:FairValueAdjustmentOfWarrant" contextRef="AsOf2021-12-31_us-gaap_FairValueInputsLevel1Member" id="xdx2ixbrl1295" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="QLGN:FairValueAdjustmentOfWarrant" contextRef="AsOf2021-12-31_us-gaap_FairValueInputsLevel2Member" id="xdx2ixbrl1297" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="AsOf2022-12-31_srt_MinimumMember_us-gaap_MeasurementInputRiskFreeInterestRateMember" id="xdx2ixbrl1305" decimals="INF" unitRef="Pure">3.906</ix:nonFraction>
  <ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="AsOf2022-12-31_srt_MinimumMember_us-gaap_MeasurementInputPriceVolatilityMember" id="xdx2ixbrl1317" decimals="INF" unitRef="Pure">88</ix:nonFraction>
  <ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="AsOf2021-12-31_srt_MinimumMember_us-gaap_MeasurementInputPriceVolatilityMember" id="xdx2ixbrl1323" decimals="INF" unitRef="Pure">84</ix:nonFraction>
  <ix:nonFraction name="us-gaap:SecuredDebt" contextRef="AsOf2021-12-31_custom_SeniorSecuredConvertibleDebtMember" id="xdx2ixbrl1386" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DebtInstrumentUnamortizedDiscount" contextRef="AsOf2021-12-31_custom_SeniorSecuredConvertibleDebtMember" id="xdx2ixbrl1389" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ConvertibleDebt" contextRef="AsOf2021-12-31_custom_SeniorSecuredConvertibleDebtMember" id="xdx2ixbrl1392" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="QLGN:DilutivePotentialSharesIssuableFromStockOptionsAndWarrants" contextRef="From2022-01-01to2022-12-31" id="xdx2ixbrl1404" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="QLGN:DilutivePotentialSharesIssuableFromStockOptionsAndWarrants" contextRef="From2021-01-012021-12-31" id="xdx2ixbrl1405" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" contextRef="From2021-01-012021-12-31_custom_EmployeesAndNonemployeeServiceProviderMember" id="xdx2ixbrl1744" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" contextRef="From2021-01-012021-12-31_custom_EmployeesAndNonemployeeServiceProviderMember" id="xdx2ixbrl1746" unitRef="USDPShares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExpirationsInPeriodWeightedAverageExercisePrice" contextRef="From2021-01-012021-12-31_custom_EmployeesAndNonemployeeServiceProviderMember" id="xdx2ixbrl1748" unitRef="USDPShares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" contextRef="From2022-01-012022-12-31_custom_CompensatoryWarrantActivityMember" id="xdx2ixbrl1882" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice" contextRef="From2022-01-012022-12-31_custom_CompensatoryWarrantActivityMember" id="xdx2ixbrl1884" unitRef="USDPShares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" contextRef="From2022-01-012022-12-31_custom_CompensatoryWarrantActivityMember" id="xdx2ixbrl1886" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedInPeriodWeightedAverageExercisePrice" contextRef="From2022-01-012022-12-31_custom_CompensatoryWarrantActivityMember" id="xdx2ixbrl1888" unitRef="USDPShares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" contextRef="From2022-01-012022-12-31_custom_CompensatoryWarrantActivityMember" id="xdx2ixbrl1890" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInPeriodWeightedAverageExercisePrice" contextRef="From2022-01-012022-12-31_custom_CompensatoryWarrantActivityMember" id="xdx2ixbrl1892" unitRef="USDPShares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures" contextRef="From2022-01-012022-12-31_custom_CompensatoryWarrantActivityMember" id="xdx2ixbrl1894" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedInPeriodWeightedAverageExercisePrice" contextRef="From2022-01-012022-12-31_custom_CompensatoryWarrantActivityMember" id="xdx2ixbrl1896" unitRef="USDPShares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNonVestedNumber" contextRef="AsOf2022-12-31_custom_CompensatoryWarrantActivityMember" id="xdx2ixbrl1915" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageNonVestedExercise" contextRef="AsOf2022-12-31_custom_CompensatoryWarrantActivityMember" id="xdx2ixbrl1917" unitRef="USDPShares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="QLGN:RangeOfExercisePriceNonexercisableNonvested" contextRef="AsOf2022-12-31_custom_CompensatoryWarrantActivityMember" id="xdx2ixbrl1919" unitRef="USDPShares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" contextRef="From2021-01-012021-12-31_custom_CompensatoryWarrantActivityMember72031656" id="xdx2ixbrl1933" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInPeriodWeightedAverageExercisePrice" contextRef="From2021-01-012021-12-31_custom_CompensatoryWarrantActivityMember" id="xdx2ixbrl1935" unitRef="USDPShares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNonVestedNumber" contextRef="AsOf2021-12-31_custom_CompensatoryWarrantActivityMember" id="xdx2ixbrl1959" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageNonVestedExercise" contextRef="AsOf2021-12-31_custom_CompensatoryWarrantActivityMember" id="xdx2ixbrl1961" unitRef="USDPShares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="QLGN:RangeOfExercisePriceNonexercisableNonvested" contextRef="AsOf2021-12-31_custom_CompensatoryWarrantActivityMember" id="xdx2ixbrl1963" unitRef="USDPShares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures" contextRef="From2022-01-012022-12-31_custom_NonCompensatoryWarrantActivityMember72032375" id="xdx2ixbrl2045" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedInPeriodWeightedAverageExercisePrice" contextRef="From2022-01-012022-12-31_custom_NonCompensatoryWarrantActivityMember72032375" id="xdx2ixbrl2047" unitRef="USDPShares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedInRangeOfExercisePrice" contextRef="From2022-01-012022-12-31_custom_NonCompensatoryWarrantActivityMember72032375" id="xdx2ixbrl2049" unitRef="USDPShares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsNonExercisableNumber" contextRef="AsOf2022-12-31_custom_NonCompensatoryWarrantActivityMember" id="xdx2ixbrl2069" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageVestedNonExercisePrice" contextRef="AsOf2022-12-31_custom_NonCompensatoryWarrantActivityMember" id="xdx2ixbrl2071" unitRef="USDPShares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="QLGN:RangeOfExercisePriceNonExercisableVested" contextRef="AsOf2022-12-31_custom_NonCompensatoryWarrantActivityMember" id="xdx2ixbrl2073" unitRef="USDPShares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" contextRef="From2021-01-012021-12-31_custom_NonCompensatoryWarrantActivityMember" id="xdx2ixbrl2079" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice" contextRef="From2021-01-012021-12-31_custom_NonCompensatoryWarrantActivityMember" id="xdx2ixbrl2081" unitRef="USDPShares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures" contextRef="From2021-01-012021-12-31_custom_NonCompensatoryWarrantActivityMember" id="xdx2ixbrl2091" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedInPeriodWeightedAverageExercisePrice" contextRef="From2021-01-012021-12-31_custom_NonCompensatoryWarrantActivityMember" id="xdx2ixbrl2093" unitRef="USDPShares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNonVestedNumber" contextRef="AsOf2021-12-31_custom_NonCompensatoryWarrantActivityMember" id="xdx2ixbrl2108" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageNonVestedExercise" contextRef="AsOf2021-12-31_custom_NonCompensatoryWarrantActivityMember" id="xdx2ixbrl2110" unitRef="USDPShares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="QLGN:RangeOfExercisePriceNonexercisableNonvested" contextRef="AsOf2021-12-31_custom_NonCompensatoryWarrantActivityMember" id="xdx2ixbrl2112" unitRef="USDPShares" xs:nil="true"></ix:nonFraction>
  <ix:nonNumeric contextRef="From2021-01-012021-12-31_custom_NonCompensatoryWarrantActivityMember" id="xdx2ixbrl2114" name="QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNonExercisableWeightedAverageRemainingContractualTerm1" xs:nil="true"></ix:nonNumeric>
  <ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" contextRef="From2021-01-012021-12-31" id="xdx2ixbrl2160" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:CurrentFederalTaxExpenseBenefit" contextRef="From2022-01-01to2022-12-31" id="xdx2ixbrl2202" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:CurrentFederalTaxExpenseBenefit" contextRef="From2021-01-012021-12-31" id="xdx2ixbrl2203" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:CurrentForeignTaxExpenseBenefit" contextRef="From2022-01-01to2022-12-31" id="xdx2ixbrl2208" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:CurrentForeignTaxExpenseBenefit" contextRef="From2021-01-012021-12-31" id="xdx2ixbrl2209" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DeferredForeignIncomeTaxExpenseBenefit" contextRef="From2021-01-012021-12-31" id="xdx2ixbrl2221" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets" contextRef="AsOf2022-12-31" id="xdx2ixbrl2243" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="QLGN:DeferredTaxAssetsResearchAndDevelopmentExpenses" contextRef="AsOf2021-12-31" id="xdx2ixbrl2250" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DeferredTaxAssetsLiabilitiesNet" contextRef="AsOf2021-12-31" id="xdx2ixbrl2274" unitRef="USD" xs:nil="true"></ix:nonFraction>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="qlgn-20221231.xsd" xlink:type="simple" />
  </ix:references>
 <ix:resources>
    <xbrli:context id="From2022-01-01to2022-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-04-11">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-04-11</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_NetProductSalesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">QLGN:NetProductSalesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_custom_NetProductSalesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">QLGN:NetProductSalesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_LicenseRevenueMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">QLGN:LicenseRevenueMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_custom_LicenseRevenueMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">QLGN:LicenseRevenueMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_PreferredStockMember_custom_SeriesAlphaConvertiblePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">QLGN:SeriesAlphaConvertiblePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_ParentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_NoncontrollingInterestMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_us-gaap_PreferredStockMember_custom_SeriesAlphaConvertiblePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">QLGN:SeriesAlphaConvertiblePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_PreferredStockMember_custom_SeriesAlphaConvertiblePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">QLGN:SeriesAlphaConvertiblePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_ParentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_NoncontrollingInterestMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_us-gaap_PreferredStockMember_custom_SeriesAlphaConvertiblePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">QLGN:SeriesAlphaConvertiblePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_PreferredStockMember_custom_SeriesAlphaConvertiblePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">QLGN:SeriesAlphaConvertiblePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_ParentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_NoncontrollingInterestMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-05-242022-05-26_custom_NanoSynexLtdMember_custom_SeriesAOnePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">QLGN:NanoSynexLtdMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">QLGN:SeriesAOnePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-05-24</xbrli:startDate>
        <xbrli:endDate>2022-05-26</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-05-242022-05-26_custom_NanoSynexLtdMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">QLGN:NanoSynexLtdMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-05-24</xbrli:startDate>
        <xbrli:endDate>2022-05-26</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-05-26_custom_PrefundedWarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">QLGN:PrefundedWarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-05-26</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-05-252022-05-26">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-05-25</xbrli:startDate>
        <xbrli:endDate>2022-05-26</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-05-242022-05-26_custom_NanoSynexLtdMember_us-gaap_SeriesBPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">QLGN:NanoSynexLtdMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-05-24</xbrli:startDate>
        <xbrli:endDate>2022-05-26</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-05-26_custom_NanoSynexLtdMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">QLGN:NanoSynexLtdMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-05-26</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_ShippingAndHandlingMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ShippingAndHandlingMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_us-gaap_ShippingAndHandlingMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ShippingAndHandlingMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_GeneralAdministrativeResearchAndDevelopmentExpensesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">QLGN:GeneralAdministrativeResearchAndDevelopmentExpensesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_custom_GeneralAdministrativeResearchAndDevelopmentExpensesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">QLGN:GeneralAdministrativeResearchAndDevelopmentExpensesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_LicenseRevenuesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">QLGN:LicenseRevenuesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_custom_LicenseRevenuesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">QLGN:LicenseRevenuesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_srt_MinimumMember_custom_PatentsAndLicensesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">QLGN:PatentsAndLicensesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_srt_MaximumMember_custom_PatentsAndLicensesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">QLGN:PatentsAndLicensesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_NanoSynexLtdMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">QLGN:NanoSynexLtdMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_custom_NanoSynexLtdMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">QLGN:NanoSynexLtdMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_MachineryAndEquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_ComputerEquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_MoldsAndToolingMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">QLGN:MoldsAndToolingMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_FurnitureAndFixturesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-12-012021-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-12-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-12-012022-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-12-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-05-242022-05-26_custom_SeriesAOnePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">QLGN:SeriesAOnePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-05-24</xbrli:startDate>
        <xbrli:endDate>2022-05-26</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-05-26_custom_NanoSynexLtdMember_custom_PrefundedWarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">QLGN:NanoSynexLtdMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">QLGN:PrefundedWarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-05-26</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_NanoSynexMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">QLGN:NanoSynexMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-05-242022-05-26_custom_AlphaCapitalAnstaltMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">QLGN:AlphaCapitalAnstaltMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-05-24</xbrli:startDate>
        <xbrli:endDate>2022-05-26</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-05-242022-05-26">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-05-24</xbrli:startDate>
        <xbrli:endDate>2022-05-26</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-05-26">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-05-26</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_MachineryAndEquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_MachineryAndEquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_ComputerEquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_ComputerEquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_LeaseholdImprovementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_LeaseholdImprovementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_MoldsAndToolingMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">QLGN:MoldsAndToolingMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_MoldsAndToolingMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">QLGN:MoldsAndToolingMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_FurnitureAndFixturesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_FurnitureAndFixturesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_EquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_EquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_SekisuiDistributionAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">QLGN:SekisuiDistributionAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_DevelopedProductTechnologyRightsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">QLGN:DevelopedProductTechnologyRightsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_DevelopedProductTechnologyRightsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">QLGN:DevelopedProductTechnologyRightsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_DevelopedProductTechnologyRightsMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">QLGN:DevelopedProductTechnologyRightsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_DevelopedProductTechnologyRightsMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">QLGN:DevelopedProductTechnologyRightsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_LicensingRightsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">QLGN:LicensingRightsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_LicensingRightsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">QLGN:LicensingRightsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_LicensingRightsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">QLGN:LicensingRightsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_InProcessResearchAndDevelopmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_InProcessResearchAndDevelopmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_PatentsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_PatentsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_PatentsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_us-gaap_PatentsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_LicenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_LicenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_LicenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_us-gaap_LicenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-09-02_custom_NotesPayableMember_custom_NanoSynexMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">QLGN:NotesPayableMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">QLGN:NanoSynexMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-09-02</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_NotesPayableMember_custom_NanoSynexMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">QLGN:NotesPayableMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">QLGN:NanoSynexMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-03-262021-09-02_custom_NotesPayableMember_custom_NanoSynexMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">QLGN:NotesPayableMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">QLGN:NanoSynexMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-03-26</xbrli:startDate>
        <xbrli:endDate>2021-09-02</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_SeriesCWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">QLGN:SeriesCWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_srt_MinimumMember_custom_SeriesCWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">QLGN:SeriesCWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_srt_MaximumMember_custom_SeriesCWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">QLGN:SeriesCWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-04-25_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-04-25</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-04-25_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-04-25</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-04-232022-04-25_custom_SeriesCWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">QLGN:SeriesCWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-04-23</xbrli:startDate>
        <xbrli:endDate>2022-04-25</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-05-26_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-05-26</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-05-26_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-05-26</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-05-232022-05-26_custom_SeriesCWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">QLGN:SeriesCWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-05-23</xbrli:startDate>
        <xbrli:endDate>2022-05-26</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-22_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-22</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-22_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-22</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-12-192022-12-22_custom_SeriesCWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">QLGN:SeriesCWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-12-19</xbrli:startDate>
        <xbrli:endDate>2022-12-22</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-22_custom_SeriesCWarrantsMember_custom_AlphaCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">QLGN:SeriesCWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">QLGN:AlphaCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-22</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-12-192022-12-22_custom_SeriesCWarrantsMember_custom_AlphaCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">QLGN:SeriesCWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">QLGN:AlphaCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-12-19</xbrli:startDate>
        <xbrli:endDate>2022-12-22</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_SeriesCWarrantsMember_custom_CommonStockWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">QLGN:SeriesCWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">QLGN:CommonStockWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_custom_SeriesCWarrantsMember_custom_CommonStockWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">QLGN:SeriesCWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">QLGN:CommonStockWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_SeriesCWarrantsMember_custom_CommonStockWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">QLGN:SeriesCWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">QLGN:CommonStockWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_SeriesCWarrantsMember_custom_CommonStockWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">QLGN:SeriesCWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">QLGN:CommonStockWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_SeriesCWarrantsMember_custom_CommonStockWarrantsMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">QLGN:SeriesCWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">QLGN:CommonStockWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_SeriesCWarrantsMember_custom_CommonStockWarrantsMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">QLGN:SeriesCWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">QLGN:CommonStockWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_SeriesCWarrantsMember_custom_CommonStockWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">QLGN:SeriesCWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">QLGN:CommonStockWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_FairValueInputsLevel1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_FairValueInputsLevel2Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_FairValueInputsLevel3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_FairValueInputsLevel1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_FairValueInputsLevel2Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_FairValueInputsLevel3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_FairValueInputsLevel1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_FairValueInputsLevel2Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_FairValueInputsLevel3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_us-gaap_FairValueInputsLevel1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_us-gaap_FairValueInputsLevel2Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_us-gaap_FairValueInputsLevel3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_us-gaap_FairValueInputsLevel1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_us-gaap_FairValueInputsLevel2Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_us-gaap_FairValueInputsLevel3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_srt_MinimumMember_us-gaap_MeasurementInputRiskFreeInterestRateMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_srt_MaximumMember_us-gaap_MeasurementInputRiskFreeInterestRateMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_MeasurementInputRiskFreeInterestRateMember_srt_WeightedAverageMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_srt_MinimumMember_us-gaap_MeasurementInputRiskFreeInterestRateMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_srt_MaximumMember_us-gaap_MeasurementInputRiskFreeInterestRateMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_MeasurementInputRiskFreeInterestRateMember_srt_WeightedAverageMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_srt_MinimumMember_us-gaap_MeasurementInputPriceVolatilityMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_srt_MaximumMember_us-gaap_MeasurementInputPriceVolatilityMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_srt_WeightedAverageMember_us-gaap_MeasurementInputPriceVolatilityMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_srt_MinimumMember_us-gaap_MeasurementInputPriceVolatilityMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_srt_MaximumMember_us-gaap_MeasurementInputPriceVolatilityMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_srt_WeightedAverageMember_us-gaap_MeasurementInputPriceVolatilityMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_srt_MinimumMember_us-gaap_MeasurementInputExpectedTermMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_srt_MaximumMember_us-gaap_MeasurementInputExpectedTermMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_srt_WeightedAverageMember_us-gaap_MeasurementInputExpectedTermMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_srt_MinimumMember_us-gaap_MeasurementInputExpectedTermMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_srt_MaximumMember_us-gaap_MeasurementInputExpectedTermMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_srt_WeightedAverageMember_us-gaap_MeasurementInputExpectedTermMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_MeasurementInputExpectedDividendRateMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_MeasurementInputExpectedDividendRateMember_srt_WeightedAverageMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_MeasurementInputExpectedDividendRateMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_MeasurementInputExpectedDividendRateMember_srt_WeightedAverageMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-12-222022-12-22_custom_AlphaCapitalMember_custom_SeniorConvertibleDebentureMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">QLGN:AlphaCapitalMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">QLGN:SeniorConvertibleDebentureMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-12-22</xbrli:startDate>
        <xbrli:endDate>2022-12-22</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-22_custom_AlphaCapitalMember_custom_SeniorConvertibleDebentureMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">QLGN:AlphaCapitalMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">QLGN:SeniorConvertibleDebentureMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-22</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-12-222022-12-22_custom_SeniorConvertibleDebentureMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">QLGN:SeniorConvertibleDebentureMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-12-22</xbrli:startDate>
        <xbrli:endDate>2022-12-22</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-22">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-22</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-30_custom_AlphaCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">QLGN:AlphaCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_AlphaCapitalOtherThirdPartiesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">QLGN:AlphaCapitalOtherThirdPartiesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_AlphaCapitalOtherThirdPartiesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">QLGN:AlphaCapitalOtherThirdPartiesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_SeniorSecuredConvertibleDebtMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">QLGN:SeniorSecuredConvertibleDebtMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_SeniorSecuredConvertibleDebtMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">QLGN:SeniorSecuredConvertibleDebtMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_SharesOfCommonStockSubjectToOutstandingOptionsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">QLGN:SharesOfCommonStockSubjectToOutstandingOptionsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_custom_SharesOfCommonStockSubjectToOutstandingOptionsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">QLGN:SharesOfCommonStockSubjectToOutstandingOptionsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_SharesOfCommonStockSubjectToOutstandingWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">QLGN:SharesOfCommonStockSubjectToOutstandingWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_custom_SharesOfCommonStockSubjectToOutstandingWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">QLGN:SharesOfCommonStockSubjectToOutstandingWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-15">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-15</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-12-142021-12-15">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-12-14</xbrli:startDate>
        <xbrli:endDate>2021-12-15</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-12-142021-12-15_custom_FirstTwelveMonthsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">QLGN:FirstTwelveMonthsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-12-14</xbrli:startDate>
        <xbrli:endDate>2021-12-15</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_SekisuiDistributionAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">QLGN:SekisuiDistributionAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_NanoSynexMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">QLGN:NanoSynexMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_NanoSynexMember72014625">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">QLGN:NanoSynexMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-02-28_custom_NanoSynexMember_us-gaap_SubsequentEventMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">QLGN:NanoSynexMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-02-28</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-04-042022-04-05">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-04-04</xbrli:startDate>
        <xbrli:endDate>2022-04-05</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_LongtermOperatingLeaseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">QLGN:LongtermOperatingLeaseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_LongtermOperatingLeaseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">QLGN:LongtermOperatingLeaseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_LongtermOperatingLeaseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">QLGN:LongtermOperatingLeaseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-03-012019-03-31_custom_SponsoredResearchAgreementAndLicenseMember_custom_UniversityOfLouisvilleResearchFoundationMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">QLGN:SponsoredResearchAgreementAndLicenseMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">QLGN:UniversityOfLouisvilleResearchFoundationMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-03-01</xbrli:startDate>
        <xbrli:endDate>2019-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-02-012021-02-28_custom_SponsoredResearchAgreementAndLicenseMember_custom_UniversityOfLouisvilleResearchFoundationMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">QLGN:SponsoredResearchAgreementAndLicenseMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">QLGN:UniversityOfLouisvilleResearchFoundationMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-02-01</xbrli:startDate>
        <xbrli:endDate>2021-02-28</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-03-012019-03-31_srt_MinimumMember_custom_LicenseAndSponsoredResearchAgreementsMember_custom_UniversityOfLouisvilleResearchFoundationMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">QLGN:LicenseAndSponsoredResearchAgreementsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">QLGN:UniversityOfLouisvilleResearchFoundationMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-03-01</xbrli:startDate>
        <xbrli:endDate>2019-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-03-012019-03-31_srt_MaximumMember_custom_LicenseAndSponsoredResearchAgreementsMember_custom_UniversityOfLouisvilleResearchFoundationMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">QLGN:LicenseAndSponsoredResearchAgreementsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">QLGN:UniversityOfLouisvilleResearchFoundationMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-03-01</xbrli:startDate>
        <xbrli:endDate>2019-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-03-012019-03-31_custom_LicenseAndSponsoredResearchAgreementsMember_custom_UniversityOfLouisvilleResearchFoundationMember_custom_PhaseOneClinicalTrialMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">QLGN:LicenseAndSponsoredResearchAgreementsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">QLGN:UniversityOfLouisvilleResearchFoundationMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">QLGN:PhaseOneClinicalTrialMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-03-01</xbrli:startDate>
        <xbrli:endDate>2019-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-03-012019-03-31_custom_LicenseAndSponsoredResearchAgreementsMember_custom_UniversityOfLouisvilleResearchFoundationMember_custom_PhaseTwoClinicalTrialMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">QLGN:LicenseAndSponsoredResearchAgreementsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">QLGN:UniversityOfLouisvilleResearchFoundationMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">QLGN:PhaseTwoClinicalTrialMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-03-01</xbrli:startDate>
        <xbrli:endDate>2019-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-03-012019-03-31_custom_LicenseAndSponsoredResearchAgreementsMember_custom_UniversityOfLouisvilleResearchFoundationMember_custom_PhaseThreeClinicalTrialMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">QLGN:LicenseAndSponsoredResearchAgreementsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">QLGN:UniversityOfLouisvilleResearchFoundationMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">QLGN:PhaseThreeClinicalTrialMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-03-01</xbrli:startDate>
        <xbrli:endDate>2019-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-03-012019-03-31_custom_LicensedProductSalesMember_custom_LicenseAndSponsoredResearchAgreementsMember_custom_UniversityOfLouisvilleResearchFoundationMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">QLGN:LicensedProductSalesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">QLGN:LicenseAndSponsoredResearchAgreementsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">QLGN:UniversityOfLouisvilleResearchFoundationMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-03-01</xbrli:startDate>
        <xbrli:endDate>2019-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-03-31_srt_MinimumMember_custom_LicenseAgreementMember_custom_UniversityOfLouisvilleResearchFoundationMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">QLGN:LicenseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">QLGN:UniversityOfLouisvilleResearchFoundationMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-03-31_srt_MaximumMember_custom_LicenseAgreementMember_custom_UniversityOfLouisvilleResearchFoundationMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">QLGN:LicenseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">QLGN:UniversityOfLouisvilleResearchFoundationMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_LicenseAndSponsoredResearchAgreementsMember_custom_UniversityOfLouisvilleResearchFoundationMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">QLGN:LicenseAndSponsoredResearchAgreementsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">QLGN:UniversityOfLouisvilleResearchFoundationMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_custom_LicenseAndSponsoredResearchAgreementsMember_custom_UniversityOfLouisvilleResearchFoundationMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">QLGN:LicenseAndSponsoredResearchAgreementsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">QLGN:UniversityOfLouisvilleResearchFoundationMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-06-012020-09-30_custom_LicenseAndSponsoredResearchAgreementsMember_custom_UniversityOfLouisvilleResearchFoundationMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">QLGN:LicenseAndSponsoredResearchAgreementsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">QLGN:UniversityOfLouisvilleResearchFoundationMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-06-01</xbrli:startDate>
        <xbrli:endDate>2020-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-06-012018-06-30_srt_MinimumMember_custom_LicenseAndSponsoredResearchAgreementsMember_custom_UniversityOfLouisvilleResearchFoundationMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">QLGN:LicenseAndSponsoredResearchAgreementsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">QLGN:UniversityOfLouisvilleResearchFoundationMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-06-01</xbrli:startDate>
        <xbrli:endDate>2018-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-06-012018-06-30_srt_MaximumMember_custom_LicenseAndSponsoredResearchAgreementsMember_custom_UniversityOfLouisvilleResearchFoundationMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">QLGN:LicenseAndSponsoredResearchAgreementsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">QLGN:UniversityOfLouisvilleResearchFoundationMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-06-01</xbrli:startDate>
        <xbrli:endDate>2018-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-06-012018-06-30_custom_PhaseOneClinicalTrialMember_custom_LicenseAndSponsoredResearchAgreementsMember_custom_UniversityOfLouisvilleResearchFoundationMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">QLGN:PhaseOneClinicalTrialMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">QLGN:LicenseAndSponsoredResearchAgreementsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">QLGN:UniversityOfLouisvilleResearchFoundationMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-06-01</xbrli:startDate>
        <xbrli:endDate>2018-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-06-012018-06-30_custom_PhaseTwoClinicalTrialMember_custom_LicenseAndSponsoredResearchAgreementsMember_custom_UniversityOfLouisvilleResearchFoundationMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">QLGN:PhaseTwoClinicalTrialMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">QLGN:LicenseAndSponsoredResearchAgreementsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">QLGN:UniversityOfLouisvilleResearchFoundationMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-06-01</xbrli:startDate>
        <xbrli:endDate>2018-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-06-012018-06-30_custom_PhaseThreeClinicalTrialMember_custom_LicenseAndSponsoredResearchAgreementsMember_custom_UniversityOfLouisvilleResearchFoundationMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">QLGN:PhaseThreeClinicalTrialMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">QLGN:LicenseAndSponsoredResearchAgreementsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">QLGN:UniversityOfLouisvilleResearchFoundationMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-06-01</xbrli:startDate>
        <xbrli:endDate>2018-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-06-012018-06-30_custom_PhaseClinicalTrialMember_custom_LicenseAndSponsoredResearchAgreementsMember_custom_UniversityOfLouisvilleResearchFoundationMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">QLGN:PhaseClinicalTrialMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">QLGN:LicenseAndSponsoredResearchAgreementsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">QLGN:UniversityOfLouisvilleResearchFoundationMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-06-01</xbrli:startDate>
        <xbrli:endDate>2018-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-06-012018-06-30_custom_LicensedProductSalesMember_custom_LicenseAndSponsoredResearchAgreementsMember_custom_UniversityOfLouisvilleResearchFoundationMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">QLGN:LicensedProductSalesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">QLGN:LicenseAndSponsoredResearchAgreementsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">QLGN:UniversityOfLouisvilleResearchFoundationMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-06-01</xbrli:startDate>
        <xbrli:endDate>2018-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-06-012018-06-30_custom_SponsoredResearchAgreementAndLicenseMember_custom_UniversityOfLouisvilleResearchFoundationMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">QLGN:SponsoredResearchAgreementAndLicenseMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">QLGN:UniversityOfLouisvilleResearchFoundationMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-06-01</xbrli:startDate>
        <xbrli:endDate>2018-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-06-012020-09-30_srt_MinimumMember_custom_LicenseAndSponsoredResearchAgreementsMember_custom_UniversityOfLouisvilleResearchFoundationMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">QLGN:LicenseAndSponsoredResearchAgreementsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">QLGN:UniversityOfLouisvilleResearchFoundationMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-06-01</xbrli:startDate>
        <xbrli:endDate>2020-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-06-012020-09-30_srt_MaximumMember_custom_LicenseAndSponsoredResearchAgreementsMember_custom_UniversityOfLouisvilleResearchFoundationMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">QLGN:LicenseAndSponsoredResearchAgreementsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">QLGN:UniversityOfLouisvilleResearchFoundationMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-06-01</xbrli:startDate>
        <xbrli:endDate>2020-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_SponsoredResearchAgreementAndLicenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">QLGN:SponsoredResearchAgreementAndLicenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_custom_SponsoredResearchAgreementAndLicenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">QLGN:SponsoredResearchAgreementAndLicenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-06-30_custom_LicenseAgreementMember_custom_UniversityOfLouisvilleResearchFoundationMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">QLGN:LicenseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">QLGN:UniversityOfLouisvilleResearchFoundationMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-11-012020-11-30_srt_MaximumMember_custom_LicenseAgreementMember_custom_UniversityOfLouisvilleResearchFoundationMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">QLGN:LicenseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">QLGN:UniversityOfLouisvilleResearchFoundationMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-11-01</xbrli:startDate>
        <xbrli:endDate>2020-11-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_UniversityOfLouisvilleResearchFoundationMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">QLGN:UniversityOfLouisvilleResearchFoundationMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_custom_UniversityOfLouisvilleResearchFoundationMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">QLGN:UniversityOfLouisvilleResearchFoundationMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-12-012018-12-31_custom_LicenseAgreementMember_custom_AdvancedCancerTherapeuticsLLCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">QLGN:LicenseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">QLGN:AdvancedCancerTherapeuticsLLCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-12-01</xbrli:startDate>
        <xbrli:endDate>2018-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-12-012018-12-31_custom_CEMarkMember_custom_LicenseAgreementMember_custom_AdvancedCancerTherapeuticsLLCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">QLGN:CEMarkMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">QLGN:LicenseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">QLGN:AdvancedCancerTherapeuticsLLCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-12-01</xbrli:startDate>
        <xbrli:endDate>2018-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_LicenseAgreementMember_custom_AdvancedCancerTherapeuticsLLCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">QLGN:LicenseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">QLGN:AdvancedCancerTherapeuticsLLCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_custom_LicenseAgreementMember_custom_AdvancedCancerTherapeuticsLLCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">QLGN:LicenseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">QLGN:AdvancedCancerTherapeuticsLLCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_YiXinZhenDuanJishuLtdMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">QLGN:YiXinZhenDuanJishuLtdMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_custom_LicenseRevenueMember_custom_YiXinZhenDuanJishuLtdMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">QLGN:LicenseRevenueMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">QLGN:YiXinZhenDuanJishuLtdMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_custom_YiXinZhenDuanJishuLtdMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">QLGN:YiXinZhenDuanJishuLtdMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_STAPharmaceuticalCoLtdMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">QLGN:STAPharmaceuticalCoLtdMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_STAPharmaceuticalCoLtdMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">QLGN:STAPharmaceuticalCoLtdMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_custom_STAPharmaceuticalCoLtdMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">QLGN:STAPharmaceuticalCoLtdMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-01-31_custom_UpfrontPaymentMember_custom_LicenseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">QLGN:UpfrontPaymentMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">QLGN:LicenseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-01-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-01-31_custom_LicenseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">QLGN:LicenseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-01-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_LicenseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">QLGN:LicenseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_custom_LicenseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">QLGN:LicenseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-12-012021-12-01_custom_SecuritiesPurchaseAgreementMember_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">QLGN:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-12-01</xbrli:startDate>
        <xbrli:endDate>2021-12-01</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-01_custom_SecuritiesPurchaseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">QLGN:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-01</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-12-012021-12-01_custom_SecuritiesPurchaseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">QLGN:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-12-01</xbrli:startDate>
        <xbrli:endDate>2021-12-01</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_SeriesAlphaConvertiblePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">QLGN:SeriesAlphaConvertiblePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_custom_SeriesAlphaConvertiblePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">QLGN:SeriesAlphaConvertiblePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_StockOptionMember_custom_TwoThousandTwentyStockIncentivePlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">QLGN:TwoThousandTwentyStockIncentivePlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_StockOptionMember_custom_TwoThousandTwentyStockIncentivePlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">QLGN:TwoThousandTwentyStockIncentivePlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_EmployeesAndNonemployeeServiceProviderMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">QLGN:EmployeesAndNonemployeeServiceProviderMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_EmployeesAndNonemployeeServiceProviderMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">QLGN:EmployeesAndNonemployeeServiceProviderMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_EmployeesAndNonemployeeServiceProviderMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">QLGN:EmployeesAndNonemployeeServiceProviderMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_custom_EmployeesAndNonemployeeServiceProviderMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">QLGN:EmployeesAndNonemployeeServiceProviderMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_custom_EmployeesAndNonemployeeServiceProviderMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">QLGN:EmployeesAndNonemployeeServiceProviderMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_custom_EmployeesAndNonemployeeServiceProviderMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">QLGN:EmployeesAndNonemployeeServiceProviderMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_EmployeesAndNonemployeeServiceProviderMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">QLGN:EmployeesAndNonemployeeServiceProviderMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_EmployeesAndNonemployeeServiceProviderMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">QLGN:EmployeesAndNonemployeeServiceProviderMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_EmployeesAndNonemployeeServiceProviderMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">QLGN:EmployeesAndNonemployeeServiceProviderMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_EmployeeStockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_us-gaap_EmployeeStockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_StockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_us-gaap_StockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_StockOptionMember_custom_TwoThousandTwentyStockIncentivePlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">QLGN:TwoThousandTwentyStockIncentivePlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_CompensatoryWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">QLGN:CompensatoryWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_CompensatoryWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">QLGN:CompensatoryWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-12-31_custom_CompensatoryWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">QLGN:CompensatoryWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-04-25_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-04-25</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-04-24_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-04-24</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-04-232022-04-25_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-04-23</xbrli:startDate>
        <xbrli:endDate>2022-04-25</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-04-232022-04-25_us-gaap_GeneralAndAdministrativeExpenseMember_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-04-23</xbrli:startDate>
        <xbrli:endDate>2022-04-25</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-05-26_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-05-26</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-05-26_us-gaap_WarrantMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-05-26</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-05-26_us-gaap_WarrantMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-05-26</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-05-232022-05-26_us-gaap_GeneralAndAdministrativeExpenseMember_custom_WarrantOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">QLGN:WarrantOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-05-23</xbrli:startDate>
        <xbrli:endDate>2022-05-26</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-22_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-22</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-22_us-gaap_WarrantMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-22</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-22_us-gaap_WarrantMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-22</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-12-202022-12-22_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-12-20</xbrli:startDate>
        <xbrli:endDate>2022-12-22</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_CompensatoryWarrantActivityMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">QLGN:CompensatoryWarrantActivityMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_custom_CompensatoryWarrantActivityMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">QLGN:CompensatoryWarrantActivityMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-05-31_custom_NoncompensatoryEquityClassifiedWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">QLGN:NoncompensatoryEquityClassifiedWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-05-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-12-012020-12-31_custom_NoncompensatoryEquityClassifiedWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">QLGN:NoncompensatoryEquityClassifiedWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-12-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-07-31_custom_NoncompensatoryEquityClassifiedWarrantsMember_custom_AlphaCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">QLGN:NoncompensatoryEquityClassifiedWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">QLGN:AlphaCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-07-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-07-31_custom_NoncompensatoryEquityClassifiedWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">QLGN:NoncompensatoryEquityClassifiedWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-07-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-08-31_custom_NoncompensatoryEquityClassifiedWarrantsMember_custom_AlphaCapitalMember_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">QLGN:NoncompensatoryEquityClassifiedWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">QLGN:AlphaCapitalMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-08-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_NoncompensatoryEquityClassifiedWarrantsMember_custom_AlphaCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">QLGN:NoncompensatoryEquityClassifiedWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">QLGN:AlphaCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-05-31_custom_NoncompensatoryEquityClassifiedWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">QLGN:NoncompensatoryEquityClassifiedWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-05-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-11-29_custom_NoncompensatoryEquityClassifiedWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">QLGN:NoncompensatoryEquityClassifiedWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-11-29</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-11-29_custom_NoncompensatoryEquityClassifiedWarrantsMember_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">QLGN:NoncompensatoryEquityClassifiedWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-11-29</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_NoncompensatoryEquityClassifiedWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">QLGN:NoncompensatoryEquityClassifiedWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-09-30_custom_NoncompensatoryEquityClassifiedWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">QLGN:NoncompensatoryEquityClassifiedWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-04-25_custom_NanoSynexMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">QLGN:NanoSynexMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-04-25</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_NoncompensatoryEquityClassifiedWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">QLGN:NoncompensatoryEquityClassifiedWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-04-232022-04-25_custom_NanoSynexMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">QLGN:NanoSynexMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-04-23</xbrli:startDate>
        <xbrli:endDate>2022-04-25</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-05-26_custom_NanoSynexMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">QLGN:NanoSynexMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-05-26</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-05-232022-05-26_custom_NanoSynexMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">QLGN:NanoSynexMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-05-23</xbrli:startDate>
        <xbrli:endDate>2022-05-26</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-22_custom_NanoSynexMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">QLGN:NanoSynexMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-22</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-12-202022-12-22_custom_NanoSynexMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">QLGN:NanoSynexMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-12-20</xbrli:startDate>
        <xbrli:endDate>2022-12-22</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_NonCompensatoryWarrantActivityMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">QLGN:NonCompensatoryWarrantActivityMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_StockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_WarrantMember72029296">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_EmployeesAndNonemployeeServiceProviderMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">QLGN:EmployeesAndNonemployeeServiceProviderMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_EmployeesAndNonemployeeServiceProviderMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">QLGN:EmployeesAndNonemployeeServiceProviderMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_EmployeesAndNonemployeeServiceProviderMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">QLGN:EmployeesAndNonemployeeServiceProviderMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_EmployeesAndNonemployeeServiceProviderMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">QLGN:EmployeesAndNonemployeeServiceProviderMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_EmployeesAndNonemployeeServiceProviderMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">QLGN:EmployeesAndNonemployeeServiceProviderMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_EmployeesAndNonemployeeServiceProviderMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">QLGN:EmployeesAndNonemployeeServiceProviderMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_GeneralAndAdministrativeExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_us-gaap_GeneralAndAdministrativeExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_ResearchAndDevelopmentExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_us-gaap_ResearchAndDevelopmentExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_CompensatoryWarrantActivityMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">QLGN:CompensatoryWarrantActivityMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_CompensatoryWarrantActivityMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">QLGN:CompensatoryWarrantActivityMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_CompensatoryWarrantActivityMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">QLGN:CompensatoryWarrantActivityMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_CompensatoryWarrantActivityMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">QLGN:CompensatoryWarrantActivityMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_CompensatoryWarrantActivityMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">QLGN:CompensatoryWarrantActivityMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_CompensatoryWarrantActivityMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">QLGN:CompensatoryWarrantActivityMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_CompensatoryWarrantActivityMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">QLGN:CompensatoryWarrantActivityMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_CompensatoryWarrantActivityMember72031578">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">QLGN:CompensatoryWarrantActivityMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_custom_CompensatoryWarrantActivityMember72031656">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">QLGN:CompensatoryWarrantActivityMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_CompensatoryWarrantActivityMember72031921">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">QLGN:CompensatoryWarrantActivityMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_NonCompensatoryWarrantActivityMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">QLGN:NonCompensatoryWarrantActivityMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_srt_MinimumMember_custom_NonCompensatoryWarrantActivityMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">QLGN:NonCompensatoryWarrantActivityMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_srt_MaximumMember_custom_NonCompensatoryWarrantActivityMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">QLGN:NonCompensatoryWarrantActivityMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_custom_NonCompensatoryWarrantActivityMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">QLGN:NonCompensatoryWarrantActivityMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_NonCompensatoryWarrantActivityMember72032375">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">QLGN:NonCompensatoryWarrantActivityMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_NonCompensatoryWarrantActivityMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">QLGN:NonCompensatoryWarrantActivityMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_srt_MinimumMember_custom_NonCompensatoryWarrantActivityMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">QLGN:NonCompensatoryWarrantActivityMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_srt_MaximumMember_custom_NonCompensatoryWarrantActivityMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">QLGN:NonCompensatoryWarrantActivityMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_NonCompensatoryWarrantActivityMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">QLGN:NonCompensatoryWarrantActivityMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_ForeignCountryMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_DomesticCountryMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_StateAndLocalJurisdictionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-01-12_us-gaap_SubsequentEventMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-01-12</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-092023-01-12_us-gaap_SubsequentEventMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-09</xbrli:startDate>
        <xbrli:endDate>2023-01-12</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-132023-01-13_us-gaap_SubsequentEventMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-13</xbrli:startDate>
        <xbrli:endDate>2023-01-13</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
    <xbrli:unit id="Pure">
      <xbrli:measure>xbrli:pure</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Sqft">
      <xbrli:measure>utr:sqft</xbrli:measure>
    </xbrli:unit>
  <ix:relationship fromRefs="Fact000879" toRefs="Footnote000884"></ix:relationship>
  </ix:resources>
 </ix:header>
</div>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Rule-Page --><div style="width: 100%"><div style="border-top: Black 4pt solid; font-size: 1pt; border-bottom: Black 1.5pt solid">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b>UNITED
STATES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b>SECURITIES
AND EXCHANGE COMMISSION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 12pt"><b>WASHINGTON,
D.C. 20549</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b>FORM
<span id="xdx_902_edei--DocumentType_c20220101__20221231_zhjXjN5SmlVa"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="dei:DocumentType">10-K</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90A_edei--DocumentAnnualReport_c20220101__20221231_zjo12o5VEyv1"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" format="ixt:booleantrue" name="dei:DocumentAnnualReport">&#9746;</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ANNUAL
    REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>For
the fiscal year ended <span id="xdx_908_edei--DocumentPeriodEndDate_c20220101__20221231_z7ndP7Ps0Oyb"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate"><span id="xdx_90B_edei--CurrentFiscalYearEndDate_c20220101__20221231_zC3GzefBdoLd"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" format="ixt:datemonthdayen" name="dei:CurrentFiscalYearEndDate">December 31</ix:nonNumeric></span>, <span id="xdx_909_edei--DocumentFiscalYearFocus_c20220101__20221231_zv90SOudD175"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="dei:DocumentFiscalYearFocus">2022</ix:nonNumeric></span></ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>or</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_905_edei--DocumentTransitionReport_c20220101__20221231_zg2W39oUkVw9"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" format="ixt:booleanfalse" name="dei:DocumentTransitionReport">&#9744;</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>TRANSITION
    REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Commission
File Number <span id="xdx_909_edei--EntityFileNumber_c20220101__20221231_zOyEQLR3gkf4"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="dei:EntityFileNumber">001-37428</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b><span id="xdx_901_edei--EntityRegistrantName_c20220101__20221231_zdBk5tROjx95"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="dei:EntityRegistrantName">Qualigen
Therapeutics, Inc.</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Exact
name of registrant as specified in its charter)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; width: 49%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_90C_edei--EntityIncorporationStateCountryCode_c20220101__20221231_znFil7bnHpsf"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode">Delaware</ix:nonNumeric></span></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; width: 49%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_905_edei--EntityTaxIdentificationNumber_c20220101__20221231_zNH8sa9YAZx8"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="dei:EntityTaxIdentificationNumber">26-3474527</ix:nonNumeric></span></b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(State
                                            or other jurisdiction of</b></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>incorporation
    or organization)</b></span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(I.R.S.
                                            Employer</b></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Identification
    No.)</b></span></p></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_90F_edei--EntityAddressAddressLine1_c20220101__20221231_zQadKjnjXkm7"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="dei:EntityAddressAddressLine1">2042
Corte Del Nogal</ix:nonNumeric></span>, <span id="xdx_90D_edei--EntityAddressCityOrTown_c20220101__20221231_zmETJfPRnRu4"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="dei:EntityAddressCityOrTown">Carlsbad</ix:nonNumeric></span>, <span id="xdx_903_edei--EntityAddressStateOrProvince_c20220101__20221231_zWQ6EkTKMb7d"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" format="ixt-sec:stateprovnameen" name="dei:EntityAddressStateOrProvince">California</ix:nonNumeric></span> <span id="xdx_903_edei--EntityAddressPostalZipCode_c20220101__20221231_zeQlWGolLHQd"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="dei:EntityAddressPostalZipCode">92011</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Address
of principal executive offices) (Zip Code)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_90C_edei--CityAreaCode_c20220101__20221231_zRnD7YtPgpRl"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="dei:CityAreaCode">(760)</ix:nonNumeric></span>
<span id="xdx_908_edei--LocalPhoneNumber_c20220101__20221231_zxJMjbtDzGO"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="dei:LocalPhoneNumber">918-9165</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Registrant&#8217;s
telephone number, including area code</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Securities
registered pursuant to Section 12(b) of the Act:</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-left: 0pt; width: 38%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Title
    of Each Class</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt 0pt 1.5pt; width: 2%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-left: 0pt; width: 18%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Trading
    Symbol</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt 0pt 1.5pt; width: 2%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-left: 0pt; width: 40%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Name
    of Exchange on Which Registered</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_901_edei--Security12bTitle_c20220101__20221231_znj5pLh9bFJ1"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="dei:Security12bTitle">Common
    Stock, par value $0.001 per share</ix:nonNumeric></span></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_900_edei--TradingSymbol_c20220101__20221231_z55UVUuOAJJb"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="dei:TradingSymbol">QLGN</ix:nonNumeric></span></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>The
    <span id="xdx_908_edei--SecurityExchangeName_c20220101__20221231_z2TQL2qPrGJi"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName">Nasdaq</ix:nonNumeric></span> Capital Market</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Securities
registered pursuant to Section 12(g) of the Act:</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>None</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes &#9744; <span id="xdx_908_edei--EntityWellKnownSeasonedIssuer_c20220101__20221231_zWi1leFVtRO6"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="dei:EntityWellKnownSeasonedIssuer">No</ix:nonNumeric></span> &#9746;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes &#9744; <span id="xdx_90B_edei--EntityVoluntaryFilers_c20220101__20221231_zM3Ta1gZIsIl"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="dei:EntityVoluntaryFilers">No</ix:nonNumeric></span> &#9746;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange
Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports) and (2)
has been subject to such filing requirements for the past 90 days. <span id="xdx_908_edei--EntityCurrentReportingStatus_c20220101__20221231_zY9Tl5dKOiM5"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="dei:EntityCurrentReportingStatus">Yes</ix:nonNumeric></span> &#9746; No &#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule
405 of Regulation S-T (&#167; 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant
was required to submit such files). <span id="xdx_901_edei--EntityInteractiveDataCurrent_c20220101__20221231_zlRXVhB4NkBg"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="dei:EntityInteractiveDataCurrent">Yes</ix:nonNumeric></span> &#9746; No &#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting
company, or emerging growth company. See definitions of &#8220;large accelerated filer, &#8220;accelerated filer,&#8221; &#8220;smaller
reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; width: 25%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Large
    accelerated filer</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; width: 3%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; width: 44%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; width: 25%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accelerated
    filer</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; width: 3%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_905_edei--EntityFilerCategory_c20220101__20221231_zY8afqvdS1n3"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" format="ixt-sec:entityfilercategoryen" name="dei:EntityFilerCategory">Non-accelerated
    filer</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9746;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Smaller
    reporting company</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_903_edei--EntitySmallBusiness_c20220101__20221231_z2EPi98zK9u3"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" format="ixt:booleantrue" name="dei:EntitySmallBusiness">&#9746;</ix:nonNumeric></span></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Emerging
    growth company</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90B_edei--EntityEmergingGrowthCompany_c20220101__20221231_z2KS1818pwv6"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" format="ixt:booleanfalse" name="dei:EntityEmergingGrowthCompany">&#9744;</ix:nonNumeric></span></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness
of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered
public accounting firm that prepared or issued its audit report. <span id="xdx_909_edei--IcfrAuditorAttestationFlag_c20220101__20221231_zq0gPLnNzZQ4"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" format="ixt:booleanfalse" name="dei:IcfrAuditorAttestationFlag">&#9744;</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant
included in the filing reflect the correction of an error to previously issued financial statements. &#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation
received by any of the registrant&#8217;s executive officers during the relevant recovery period pursuant to &#167;240.10D-1(b).
&#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). Yes &#9744; <span id="xdx_901_edei--EntityShellCompany_c20220101__20221231_zToKMbQKCKIb"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" format="ixt:booleanfalse" name="dei:EntityShellCompany">No</ix:nonNumeric></span> &#9746;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of June 30, 2022, the aggregate market value of the registrant&#8217;s common stock held by non-affiliates was approximately $<span id="xdx_90A_edei--EntityPublicFloat_iI_c20220630_zcDDzHfE5wQ3"><ix:nonFraction name="dei:EntityPublicFloat" contextRef="AsOf2022-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">21,943,148</ix:nonFraction></span>
based on the closing price for the common stock of $5.70 on that date. Shares of common stock held by the registrant&#8217;s executive
officers and directors have been excluded from this calculation, as such persons may be deemed to be affiliates of the registrant. This
determination of affiliate status is not necessarily a conclusive determination for other purposes.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of April 11, 2023, there were <span id="xdx_901_edei--EntityCommonStockSharesOutstanding_iI_c20230411_z3zQRCsIA8Qa"><ix:nonFraction name="dei:EntityCommonStockSharesOutstanding" contextRef="AsOf2023-04-11" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">5,052,463</ix:nonFraction></span> shares of the registrant&#8217;s common stock outstanding.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>DOCUMENTS
INCORPORATED BY REFERENCE</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span id="xdx_909_edei--DocumentsIncorporatedByReferenceTextBlock_c20220101__20221231_z5Tk6jaGKt1f" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="dei:DocumentsIncorporatedByReferenceTextBlock">None.</ix:nonNumeric></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Rule-Page --><div style="width: 100%"><div style="border-top: Black 1.5pt solid; font-size: 1pt; border-bottom: Black 4pt solid">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%"></td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>TABLE
OF CONTENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; width: 0.65in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; width: 0.1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; padding: 0pt; font: 10pt Times New Roman, Times, Serif; width: 0.6in; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Page
    Number</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><a href="#bs_001">Part I</a></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#bs_002">Business</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    1A</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#bs_003">Risk Factors</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">13</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    1B</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#bs_004">Unresolved Staff Comments</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">27</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    2</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#bs_005">Properties</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">27</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    3</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#bs_006">Legal Proceedings</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">27</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    4</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#bs_007">Mine Safety Disclosures</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">27</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><a href="#bs_008">Part II</a></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    5</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#bs_009">Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">28</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    6</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#bs_010">[Reserved]</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">28</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    7</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#bs_011">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">28</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    7A</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#bs_012">Quantitative and Qualitative Disclosure About Market Risk</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">37</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    8</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#bs_013">Financial Statements and Supplementary Data</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">38</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    9</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#psi_001">Changes in and Disagreements With Accountants on Accounting and Financial Disclosure</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">71</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    9A</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#psi_002">Controls and Procedures</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">71</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    9B</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#psi_003">Other Information</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">71</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    9C</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#psi_004">Disclosure Regarding Foreign Jurisdictions that Prevent Inspections</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">71</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><a href="#psi_005">Part III</a></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    10</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#psi_006">Directors, Executive Officers and Corporate Governance</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">72</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    11</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#ax_001">Executive Compensation</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">75</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    12</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#ax_002">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">83</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    13</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#ax_003">Certain Relationships and Related Transactions, and Director Independence</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">85</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    14</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#ax_004">Principal Accounting Fees and Services</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">85</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><a href="#psi_011">Part IV</a></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    15</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#psi_012">Exhibits and Financial Statement Schedules</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">87</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    16</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#sj_008">Form 10-K Summary</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">90</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify"><a href="#sj_007"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Signatures</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">91</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CAUTIONARY
NOTE REGARDING FORWARD-LOOKING STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Annual Report on Form 10-K (&#8220;Annual Report&#8221;) contains forward-looking statements by Qualigen Therapeutics, Inc. that involve
risks and uncertainties and reflect our judgment as of the date of this Report. These statements generally relate to future events or
our future financial or operating performance. In some cases, you can identify forward-looking statements because they contain words
such as &#8220;may,&#8221; &#8220;will,&#8221; &#8220;should,&#8221; &#8220;expects,&#8221; &#8220;plans,&#8221; &#8220;anticipates,&#8221;
&#8220;could,&#8221; &#8220;intends,&#8221; &#8220;target,&#8221; or &#8220;continue&#8221; or the negative of these words or other similar
terms or expressions that concern our expectations, strategy, plans or intentions. Such forward-looking statements may relate to, among
other things, potential future development, testing and launch of products and product candidates. Actual events or results may differ
from our expectations due to a number of factors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
forward-looking statements include, but are not limited to, statements about:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; width: 0.3in"></td><td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; width: 0.3in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
                                            ability to successfully develop any drugs or therapeutic devices;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; width: 0.3in"></td><td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; width: 0.3in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
                                            ability to progress our drug candidates or therapeutic devices through preclinical and clinical
                                            development;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; width: 0.3in"></td><td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; width: 0.3in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
                                            ability to obtain the requisite regulatory approvals for our clinical trials and to begin
                                            and complete such trials according to any projected timeline;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; width: 0.3in"></td><td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; width: 0.3in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
                                            ability to complete enrollment in our clinical trials as contemplated by any projected timeline;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; width: 0.3in"></td><td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; width: 0.3in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            likelihood that future clinical trial data will be favorable or that such trials will confirm
                                            any improvements over other products or lack negative impacts;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; width: 0.3in"></td><td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; width: 0.3in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
                                            ability to successfully commercialize any drugs or therapeutic devices;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; width: 0.3in"></td><td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; width: 0.3in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
                                            ability to procure or earn sufficient working capital to complete the development, testing
                                            and launch of our prospective therapeutic products;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; width: 0.3in"></td><td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; width: 0.3in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            likelihood that patents will issue on our owned and in-licensed patent applications;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; width: 0.3in"></td><td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; width: 0.3in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
                                            ability to protect our intellectual property;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; width: 0.3in"></td><td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; width: 0.3in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
                                            ability to compete;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; width: 0.3in"></td><td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; width: 0.3in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
                                            ability to maintain or expand market demand and/or market share for our diagnostic products;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; width: 0.3in"></td><td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; width: 0.3in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
                                            ability to maintain our diagnostic sales and marketing engine without interruption once our
                                            distribution agreement with Sekisui expires.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By
their nature, forward-looking statements involve risks and uncertainties because they relate to events, competitive dynamics, and healthcare,
regulatory and scientific developments and depend on the economic circumstances that may or may not occur in the future or may occur
on longer or shorter timelines than anticipated. In light of the significant uncertainties in these forward-looking statements, you should
not rely upon forward-looking statements as predictions of future events. Although we believe that we have a reasonable basis for each
forward-looking statement contained in this Annual Report, we caution you that forward-looking statements are not guarantees of future
performance and that our actual results of operations, financial condition and liquidity, and the development of the industry in which
we operate may differ materially from the forward-looking statements contained in this Annual Report. In addition, even if our results
of operations, financial condition and liquidity, and the development of the industry in which we operate, are consistent in some future
periods with the forward-looking statements contained in this Annual Report, they may not be predictive of results or developments in
other future periods. Any forward-looking statement that we make in this Annual Report speaks only as of the date of this Annual Report,
and we disclaim any intent or obligation to update these forward-looking statements beyond the date of this Annual Report, except as
required by law. This caution is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Future
filings with the Securities and Exchange Commission (the &#8220;SEC&#8221;), future press releases and future oral or written statements
made by us or with our approval, which are not statements of historical fact, may also contain forward-looking statements. Because such
statements include risks and uncertainties, many of which are beyond our control, actual results may differ materially from those expressed
or implied by such forward-looking statements. The forward-looking statements speak only as of the date on which they are made, and we
undertake no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they
are made.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 3; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="bs_001"></span>PART
I</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>As
used in this Annual Report, unless the context suggests otherwise, &#8220;we,&#8221; &#8220;us,&#8221; &#8220;our,&#8221; &#8220;the
Company&#8221; or &#8220;Qualigen&#8221; refer to Qualigen Therapeutics, Inc.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="bs_002"></span>Item
1. Business</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Overview</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are a diversified life sciences company focused on developing treatments for adult and pediatric cancers with potential for Orphan Drug
designation, while also commercializing diagnostics.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
cancer therapeutics pipeline includes QN-302, RAS (formerly RAS-F) and QN-247.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
lead oncology therapeutics program, QN-302, is an investigational small molecule G-quadruplexes (G4)-selective transcription
inhibitor with strong binding affinity to G4s prevalent in cancer cells. Such binding could, by stabilizing the G4s against DNA
&#8220;unwinding,&#8221; help inhibit cancer cell proliferation. QN-302 is currently undergoing Good Laboratory Practice (GLP) toxicology
studies.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
RAS portfolio consists of a family of RAS oncogene protein-protein interaction inhibitor small molecules believed to inhibit or block
mutated RAS genes&#8217; proteins from binding to their effector proteins. Preventing this binding could stop tumor growth, especially
in RAS-driven tumors such as pancreatic, colorectal and lung cancers.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
investigational QN-247 compound binds nucleolin, a key multi-functional regulatory phosphoprotein that is overexpressed in cancer cells.
Such binding could inhibit the cancer cells&#8217; proliferation. The foundational aptamer of QN-247 is QN-165 (formerly referred to
as AS1411), which the Company has deprioritized as a drug candidate for treating COVID-19 and other viral-based infectious diseases.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition to our oncology drug pipeline, we have an established diagnostics business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
revenue driver is our FastPack proprietary blood-based diagnostics platform which includes diagnostic instruments and test kits that
are sold commercially primarily in the United States, as well as certain European countries. The FastPack System menu includes a rapid,
highly accurate immunoassay diagnostic testing system for cancer, men&#8217;s health, hormone function, and vitamin D status. We provide
analyzers to our customers (physician offices, clinics and small hospitals) at low cost in order to increase sales volumes of higher-margin
test kits.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
May 26, 2022, we acquired a 52.8% interest in NanoSynex, Ltd. (&#8220;NanoSynex&#8221;). NanoSynex is a micro-biologics diagnostic company
domiciled in Israel. NanoSynex&#8217;s technology is an Antimicrobial Susceptibility Testing (AST) that aims to enable better targeting
of antibiotics for their most suitable uses to ultimately result in faster and more efficacious treatment, hence reducing hospitals mortality
and morbidity rates. See Part II, Item 7 &#8220;<i>Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</i>&#8221;
for additional details.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Completion
of Reverse Recapitalization Transaction with Ritter Pharmaceuticals, Inc.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
May 22, 2020, we completed a &#8220;reverse recapitalization&#8221; transaction with Qualigen, Inc. (not to be confused with the Company);
pursuant to which our merger subsidiary merged with and into Qualigen, Inc. with Qualigen, Inc. surviving as a wholly owned subsidiary
of the Company. The Company, which had previously been known as Ritter Pharmaceuticals, Inc., was renamed Qualigen Therapeutics, Inc.,
and the former stockholders of Qualigen, Inc. acquired, via the recapitalization, a substantial majority of the shares of the Company.
Ritter/Qualigen Therapeutics common stock, which was previously traded on the Nasdaq Capital Market under the ticker symbol &#8220;RTTR,&#8221;
commenced trading on Nasdaq, on a post-reverse-stock-split adjusted basis, under the ticker symbol &#8220;QLGN&#8221; on May 26, 2020.
We are no longer pursuing the gastrointestinal disease treatment business on which Ritter Pharmaceuticals, Inc. had focused before the
reverse recapitalization transaction.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 4; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Cancer
Drug Pipeline and Diagnostic Products</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Therapeutics
Pipeline</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><img src="form10-k_001.jpg" alt="" style="height: 184px; width: 720px" /></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
lead drug compound QN-302 (formerly SOP1812) is being developed to target regulatory regions of cancer genes that down-regulate gene
expression in multiple cancer pathways for potential treatment of G4-targeted tumors (<i>e.g.</i>, pancreatic cancer). The investigational
compounds within our RAS portfolio are designed to suppress the interaction of endogenous RAS with c-RAF, upstream of the KRAS, HRAS
and NRAS effector pathways. Our anticancer drug candidate, QN-247 (formerly referred to as ALAN or AS1411-GNP) is aptamer-based and currently
in development to treat a variety of cancer types, including liquid and solid tumors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
deprioritized programs (and thus not featured in the chart above) include QN-165 (formerly referred to as AS1411), a drug candidate for
the potential broad-spectrum treatment of infectious diseases such as COVID-19, and our Selective Target Antigen Removal System (STARS),
a therapeutic device product concept, currently in discovery stage, designed to remove circulating tumor cells, viruses, inflammation
factors and immune checkpoints.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>QN-302
(formerly referred to as SOP1812)</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
exclusively in-licensed the global rights to the G4 selective transcription inhibitor platform from University College London
(&#8220;UCL&#8221;) in January 2022. The licensed technology comprises lead compound QN-302 (formerly SOP1812) and back-up compounds
that target regulatory regions of cancer genes that down-regulate gene expression in multiple cancer pathways. Developed by Dr.
Stephen Neidle and his group at UCL, the G-Quadruplex (G4) binding concept is derived from over 30 years in nucleic acid research,
including research on G4s, which are higher order DNA and RNA structures formed by sequences containing guanine-rich repeats. G4s
are overrepresented in telomeres (a region of repetitive DNA sequences at the end of a chromosome) as well as promoter sequences and
untranslated regions of many oncogenes. Their prevalence is therefore significantly greater in cancer cells compared to normal human
cells.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">G4-selective
small molecules such as QN-302 and backup compounds target the regulatory regions of cancer genes, which have a high prevalence of enriched
G4s. Stable G4-QN-302 complexes can be impediments to replication, transcription or translation of those cancer genes containing G4s,
and the drugs&#8217; binding to G4s are believed to stabilize the G4s against possible &#8220;unwinding.&#8221; G4 binders like QN-302
could be efficacious in a variety of cancer types with a high prevalence of G4s.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pancreatic
cancer is the tenth most common cancer and third deadliest cancer in the United States and has one of the lowest rates of survival of
all cancer types, with 91% of those diagnosed dying from the disease and one in four dying within the first month of diagnosis. The chemotherapy
drug Gemcitabine has been standard of care for patients with metastatic pancreatic cancer for more than 15 years. Numerous clinical trials
have tested new drugs, either alone or in combination, with Gemcitabine. We believe that QN-302 has the potential to demonstrate superior
efficacy and activity against pancreatic ductal adenocarcinoma (&#8220;PDAC&#8221;) compared to existing agents, with a distinct mechanism
of action and promising preclinical target profile.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>In-vitro
</i>and <i>in-vivo</i> studies have shown that G4 stabilization by QN-302 resulted in inhibition of target gene expression and cessation
of cell growth in various cancers, including PDAC, which represents 98% of pancreatic cancers. In <i>in-vitro</i> studies, QN-302 was
potent in inhibiting the growth of several PDAC cell lines at low nanomolar concentrations. Similarly, in <i>in-vivo</i> studies, QN-302
showed a longer survival duration in a KPC genetic mouse model for pancreatic cancer than Gemcitabine has historically shown. Additional
preclinical <i>in-vivo</i> studies suggest activity in gemcitabine-resistant PDAC. Data further demonstrated that QN-302 had significant
anti-tumor activity in three patient-derived PDAC xenograft models. Early safety indicators suggest no significant adverse toxic effects at
proposed therapeutic doses in pancreatic cancer mouse <i>in-vivo</i> models.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 9, 2023, the U.S. Food and Drug Administration (&#8220;FDA&#8221;) granted Orphan Drug Designation (&#8220;ODD&#8221;) to QN-302
for the indication of pancreatic cancer. ODD provides advantages to pharmaceutical companies that are developing investigational drugs
or biological products that show promise in treating rare diseases or conditions that affect fewer than 200,000 people in the United
States, including seven-year marketing exclusivity and eligibility to receive regulatory support and guidance from the FDA in the design
of an overall drug development plan.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 5; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
are also economic advantages to receiving ODD, including a 25% federal tax credit for expenses incurred in conducting clinical research
on the orphan designated product within the United States. Tax credits may be applied to the prior year or applied to up to 20 years
of future taxes. ODD recipients may also have their Prescription Drug User Fee Act (PDUFA) application fees waived, a potential savings
of around $3.2 million (as of fiscal year 2023) for applications requiring covered clinical data, and may qualify to compete for research
grants from the Office of Orphan Products Development that support clinical studies.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>RAS
(formerly RAS-F)</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
July 2020, we entered into an exclusive worldwide license agreement with University of Louisville (&#8220;UofL&#8221;) for the intellectual
property covering the &#8220;RAS&#8221; family of pan RAS inhibitor small molecule drug candidates,
which are believed to work by blocking RAS mutations directly, thereby inhibiting tumor formation (especially in pancreatic, colorectal
and lung cancers). Pursuant to the license agreement, we in-licensed the &#8220;RAS&#8221; compound family of drug candidates and will
seek to identify and develop a lead drug candidate from the compound family and, upon commercialization, will pay UofL royalties in the
low-to-mid-single-digit percentages on net sales of RAS inhibitor licensed products.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">RAS
is the most common oncogene in human cancer. Activating mutations in one of the three human RAS gene isoforms (KRAS, HRAS or NRAS) are
present in about one-fourth to one-third of all cancers. For example, mutant KRAS is found in 98% of pancreatic ductal adenocarcinomas,
52% of colon cancers, and 32% of lung adenocarcinomas. For these three cancer types, cancers with mutant KRAS are diagnosed in more than
170,000 people each year in the United States and cause more than 120,000 deaths. Drugs that target signaling downstream of RAS are available; however, such drugs have shown disappointing clinical
durability because RAS is a &#8220;hub&#8221; that activates multiple effectors, so drugs that block a single pathway downstream may
not account for the many other activated pathways.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
March 2022 and October 2022, we signed amendments to our sponsored research agreement with UofL to extend our partnership. Under the
amended agreement, the collaboration extends until the third quarter of 2023 and commits additional resources to support ongoing discovery
and preclinical efforts for the RAS platform.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>QN-247
(formerly referred to as ALAN or AS1411-GNP)</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">QN-247
is an oligonucleotide-based drug candidate that is designed to treat different types of nucleolin-expressing cancers, including liquid and solid tumors. QN-247
inhibits nucleolin, a key multi-functional regulatory phosphoprotein that is overexpressed in cancer cells, and may thereby be able to inhibit
the cells&#8217; proliferation. QN-247 has shown promise in preclinical studies for the treatment of acute myeloid leukemia (&#8220;AML&#8221;).
This novel technology may have several other potential applications, including enhancement of radiation therapy, enhancement of tumor
imaging, and delivery of other anti-cancer compounds directly to tumor cells.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">QN-247 is an enhanced version of QN-165 (which in turn was formerly referred
to as AS1411), where the DNA oligonucleotide aptamer is conjugated. A key component of QN-247, DNA oligonucleotide aptamer QN-165, has
been shown, primarily on a preclinical basis, to have the potential to target and destroy cancer cells. This component has been administered
in Phase 1 and Phase 2 clinical trials to over 100 AML or renal cell carcinoma cancer patients and appears to be well tolerated with no
evidence of severe adverse events in such trials, with at least seven patients appearing to have clinical responses.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">An in vivo efficacy study with
a triple negative breast cancer (TNBC) MDA-MB-231 xenograft mouse model was performed with 12 daily doses (1 mg/kg) of QN-247. This study
showed statistically significant reductions in mean tumor volumes for all QN-247 formulations compared to baseline and to vehicle control.
QN-247 formulations with higher oligonucleotide loading appeared to reduce tumor volumes more than lower oligonucleotide loading. No evidence
of adverse toxicity was observed.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
entered into a sponsored research agreement with UofL in August 2018 which was subsequently amended in October 2020, pursuant to which
UofL performed various animal studies to assess antitumor efficacy and safety of different QN-247 compositions. The sponsored research
agreement with UofL for QN-247 expired on August 31, 2022, and the license agreement with UofL for QN-247 was amended on January 9, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 6; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>QN-165
(formerly referred to as AS1411)</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
June 2020, we entered into an exclusive royalty-bearing license agreement with UofL for UofL&#8217;s intellectual property for the use
of QN-165 as a drug candidate for the treatment of COVID-19. In September 2020 we and UofL jointly filed a U.S. provisional patent application,
entitled &#8220;Methods of inhibiting or treating coronavirus infection, and methods for delivering an anti-nucleolin agent.&#8221; The
application was filed in conjunction with Drs. Paula J. Bates and Kenneth E. Palmer from UofL, and covers methods for using QN-165 as
an antiviral drug candidate to prevent SARS-CoV-2 from entering the body through mucous membranes in the nose, mouth and eyes. As stated
in the patent application, we believe that QN-165 could be administered by means of inhalers, nose spray or eye drops to individuals
who have recently come in contact with SARS-CoV-2, or are at high risk of contracting the virus.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
believe that the mechanism by which QN-165 is believed to work, by blocking the ability of viruses to replicate in the body, may also
make the drug candidate effective against future mutations in COVID-19 as well as against other dangerous viruses including seasonal
influenza. Moreover, we believe that in addition to its proposed use as a therapeutic, QN-165 might be able to be used as a protective
defense or prophylaxis against COVID-19 and/or other viral-based diseases such as seasonal influenza.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
July 13, 2021, we submitted an Investigational New Drug (&#8220;IND&#8221;) application with the FDA seeking approval to commence Phase
1b/2a clinical studies of QN-165 in hospitalized COVID-19 patients. On August 11, 2021, the FDA informed us that additional preclinical
studies would be required for the IND application to be cleared to proceed into the clinic with QN-165. We then decided to allocate our
resources to focus on our oncology pipeline, and deprioritized the development of QN-165 program. Qualigen is seeking to out-license
QN-165 to a partner that has interest and expertise in antiviral development, such as dengue, influenza, RSV and other infectious diseases.
Due to its mechanism and in vivo potency, we believe that QN-165 could potentially be developed as a first-line treatment against emerging
viruses and biothreats.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>FastPack<sup>&#174;</sup></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
FastPack System is a patent-protected rapid, onsite immunoassay testing system consisting of the FastPack Analyzer and the FastPack test
pouch, a single-use, disposable, foil packet which includes the FastPack reagent chemistry. Since the initial conception of the system,
we have developed successive versions of the analyzer and test pouch, known as &#8220;1.0,&#8221; &#8220;IP&#8221; and &#8220;PRO&#8221;,
and have expanded our assay menu to nine tests, including tests for prostate cancer, thyroid function, metabolic disorders, and research
applications. We have sold FastPack products in the United States and overseas for over 20 years, and since inception, our sales of FastPack
products have exceeded $127 million. We manufacture the FastPack products at our FDA and International Standards Organization (&#8220;ISO&#8221;)
certified Carlsbad, California facility. As of April 2022 most FastPack sales are distributed through various distribution partners in
North America as well as in Europe (primarily Axon Labs in Germany and Switzerland). We also sell direct to clinics and physician offices
located throughout North America.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
July 2020, we submitted an official notification to the FDA to commence sales in the United States of our FastPack SARS-CoV-2 IgG test
for COVID-19 antibodies, which was designed for use with our new FastPack PRO. The test was previously submitted to the FDA for Emergency
Use Authorization (&#8220;EUA&#8221;). In April 2021, we withdrew this EUA. During the nine months during which the EUA was with the
FDA, alternative tests and testing practices became widespread and we determined that there was no longer a viable business case for
scale-up of the test.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Strategic
Partners</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
January 2022, we entered into a royalty-bearing license agreement with UCL, with respect to intellectual property and know-how covering
lead and backup compounds for our G4 selective transcription inhibitor program, QN-302.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are party to a royalty-bearing license agreement with UofL for the development of RAS and the QN-247 program.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
in-license patents from DIAsource ImmunoAssays S.A. and Future Diagnostics B.V., for reagents that are used in our FastPack Vitamin D
assay.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Sales
Channels</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prior
to April 2022, most of our FastPack sales were through our diagnostics distribution partner Sekisui Diagnostics, LLC (&#8220;Sekisui&#8221;)
pursuant to a distribution agreement. The distribution agreement with Sekisui expired on March 31, 2022, at which time the activities
formerly provided by Sekisui reverted to us. As of April 2022, most of our FastPack sales are through various distribution partners in
North America, including McKesson Medical-Surgical, Henry Schein Medical, Medline Industries and National Distribution &amp; Contracting,
the largest distributors of physician office laboratory products in the United States. Outside of the United States, we sell the FastPack
product line through a network of distributors in Europe (primarily Axon Labs in Germany and Switzerland). We also continue to sell our
testosterone test kits directly to Low T Center, Inc. (&#8220;Low T&#8221;), the largest men&#8217;s health group in the United States,
with 40 locations. Low T was acquired by SynergenX in September 2022. The combined company currently operates 64 locations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 7; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Product
sales to McKesson accounted for 48% of our total revenues and product sales to Low T accounted for 26% of our total revenues during the
fiscal year ended December 31, 2022. The remaining revenue was comprised of product sales and warranties to other distributors and direct
sales accounts.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
October 2020, we entered into an agreement with Yi Xin Zhen Duan Jishu (Suzhou) Ltd (&#8220;Yi Xin&#8221;), pursuant to which we granted
Yi Xin exclusive rights to manufacture and sell new generations of FastPack-based products as well as Yi Xin-manufactured versions of
our existing FastPack 1.0, IP and PRO product lines in China. We are entitled to receive royalties on any such sales. After May 1, 2022,
Yi Xin has the right to sell its new generations of FastPack-based diagnostic test systems throughout the world, other than to our then-current
FastPack customers; and on a worldwide basis, except in the United States, Yi Xin also has the right to sell Yi Xin-manufactured versions
of our existing FastPack 1.0, IP and PRO product lines. We are entitled to receive royalties on any of these sales. After March 31, 2022,
Yi Xin has the right to buy Qualigen FastPack 1.0, IP and PRO products from us at distributor prices for resale in the United States,
again excluding resales toward our then-current FastPack customers.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Manufacturing</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
develop, manufacture and assemble our diagnostic products at our approximately 23,000 square feet facility in Carlsbad, California. Our
laboratory and manufacturing practices are governed by a series of internally published Standard Operating Procedures, in accordance
with FDA and ISO guidelines. While we produce many of our own raw materials and sub-components for diagnostic products, we also purchase
certain materials from third-party suppliers such as Amcor, Enstrom, Gilson, Hi-Tech Products, Hamamatsu, Sigma Aldrich, Surmodics, 3M,
Thermo Fisher Scientific, and VWR International.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
do not have in-house manufacturing capability for our therapeutics product candidates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Research
and Development</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
research and development of our drug candidates, we are leveraging the scientific and technical resources and laboratory facilities of
UofL and UCL, through technology licensing, sponsored research, and other consulting agreements, which are focused on aptamer technology
and applications. We would engage contract research organizations (&#8220;CROs&#8221;) for any clinical trials of our drug candidates.
We intend to focus our internal research and development on oversight of these organizations and continuing support of the FastPack diagnostic
line.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Regulatory
Matters</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have obtained 17 FDA clearances/approvals and 28 CE Marks for our diagnostic products (FastPack analyzers, immunoassays, control kits,
calibration kits and verifications kits) to date. We have not obtained FDA or other regulatory approval for any drug candidate.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Medical
Device Regulatory Clearances and Approvals</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
medical devices that we manufacture and market are subject to regulation by numerous worldwide regulatory bodies, including the FDA and
comparable international regulatory agencies. These agencies require manufacturers of medical devices to comply with applicable laws
and regulations governing development, testing, manufacturing, labeling, marketing and distribution. Medical devices are also generally
subject to varying levels of regulatory control based on the risk level of the device.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the United States, unless an exemption applies, before we can commercially distribute medical devices, we must obtain, depending on the
type of device, either premarket notification clearance or premarket approval (&#8220;PMA&#8221;) from the FDA. The FDA classifies medical
devices into one of three classes. Devices deemed to pose lower risks are placed in either class I or II, which typically requires the
manufacturer to submit to the FDA a premarket notification requesting permission to commercially distribute the device. Some low-risk
devices are exempted from this requirement. Devices deemed by the FDA to pose the greatest risks, such as life-sustaining, life-supporting
or implantable devices, or devices deemed not substantially equivalent to a previously cleared device, are placed in class III, generally
requiring PMA.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
premarket notification process requires that a premarket notification (510(k)) be made to the FDA to demonstrate that a new device is
as safe and effective as, or substantially equivalent to, a legally marketed device (the &#8220;predicate&#8221; device). This process
is generally known as obtaining 510(k) clearance for a new device. Under this process, applicants must submit performance data to establish
substantial equivalence. In some instances, data from human clinical trials must also be submitted in support of a 510(k) premarket notification.
If so, these data must be collected in a manner that conforms to the applicable Investigational Device Exemption (&#8220;IDE&#8221;)
regulations. The FDA must issue a decision finding substantial equivalence before commercial distribution can occur. Changes to cleared
devices that do not significantly affect the safety or effectiveness of the device can generally be made without additional 510(k) premarket
notifications; otherwise, a new 510(k) is required.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 8; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
PMA approval process requires the submission of a PMA application to the FDA to demonstrate that the new device is safe and effective
for its intended use. This approval process applies to most Class III devices and generally requires clinical data to support the safety
and effectiveness of the device, obtained in adherence with IDE requirements. The FDA will approve the PMA application if it finds that
there is a reasonable assurance that the device is safe and effective for its intended purpose and that the proposed manufacturing is
in compliance with the Quality System Regulation (&#8220;QSR&#8221;). For novel technologies, the FDA may seek input from an advisory
panel of medical experts and seek their views on the safety, effectiveness and benefit-risk of the device. The PMA process is generally
more detailed, lengthier and more expensive than the 510(k) process.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the European Union (&#8220;EU&#8221;), we are required to comply with the In-Vitro Diagnostic Regulation (&#8220;IVDR&#8221;), which
became effective May 2021, superseding existing Medical Device Directives. Medical devices that have a valid EC Certificate to the prior
Directives (issued before May 2021) can continue to be sold until May 2025 or until the EC Certificate expires, whichever comes first,
providing there are no significant changes to the design or intended use. The CE Mark, which is required to sell medical devices in the
EU is affixed following a Conformity Assessment and either approval from the appointed independent Notified Body or through self-certification
by the manufacturer. The selected pathway to CE marking is based on device risk classification. CE marking indicates conformity to the
applicable General Safety and Performance Requirements (&#8220;GSPRs&#8221;) for the IVDR. The IVDR changes multiple aspects of the regulatory
framework for CE marking, such as increased clinical evidence requirements, changes to labeling, and new requirements, including Unique
Device Identification (&#8220;UDI&#8221;), and many new post-market reporting obligations. IVDR also modifies and increases the compliance
requirements for the medical device industry and will continue to require significant investment to transition all products by May 2025.
The CE mark continues to be a prerequisite for successful registration in many other global geographies.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are also required to comply with the regulations of every other country where we commercialize products before we can launch or maintain
new products on the market.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
FDA and other worldwide regulatory agencies and competent authorities actively monitor compliance to local laws and regulations through
review and inspection of design and manufacturing practices, record-keeping, reporting of adverse events, labeling and promotional practices.
The FDA can ban certain medical devices, detain or seize adulterated or misbranded medical devices, order recall or market withdrawal
of these devices and require notification of health professionals and others with regard to medical devices that present unreasonable
risks of substantial harm to the public health. The FDA may also enjoin and restrain a company for certain violations of the Food, Drug
and Cosmetic Act (&#8220;FDCA&#8221;) and the Safe Medical Devices Act, pertaining to medical devices, or initiate action for criminal
prosecution of such violations. Regulatory agencies and authorities in the countries where we do business can halt production in or distribution
within their respective country or otherwise take action in accordance with local laws and regulations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">International
sales of medical devices manufactured in the United States that are not approved by the FDA for use in the United States, or that are
banned or deviate from lawful performance standards, are subject to FDA export requirements. Additionally, exported devices are subject
to the regulatory requirements of each country to which the device is exported. Some countries do not have medical device regulations,
but in most foreign countries, medical devices are regulated. Frequently, regulatory approval may first be obtained in a foreign country
prior to application in the United States due to differing regulatory requirements; however, other countries, require approval in the
country of origin first. Most countries outside of the United States require that product approvals be recertified on a regular basis.
The recertification process requires the evaluation of any device changes and any new regulations or standards relevant to the device
and, where needed, conduct appropriate testing to document continued compliance. Where recertification applications are required, they
must be approved in order to continue selling our products in those countries.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Medical
Device Quality Assurance</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are committed to providing high quality products to our customers and the patients they serve. Our quality system starts with the initial
product specification and continues through the design of the product, component specification process and the manufacturing, sale and
servicing of the product. Our quality system is intended to build in quality and process control and to utilize continuous improvement
concepts throughout the product life. Our quality system is also designed to enable us to satisfy various international quality system
regulations, including those of the FDA with respect to products sold in the United States. All of our medical device manufacturing facilities
and distribution centers are certified under the ISO 13485 quality system standard, established by the ISO for medical devices, which
includes requirements for an implemented quality system that applies to component quality, supplier control, product design and manufacturing
operations. This certification can be obtained only after a complete audit of a company&#8217;s quality system by an independent outside
auditor, and maintenance of the certification requires that these facilities undergo periodic re-examination.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>United
States&#8212;FDA Drug Approval Process</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
research, development, testing, and manufacture of product candidates are extensively regulated by governmental authorities in the United
States and other countries. In the United States, the FDA regulates drugs under the FDCA and its implementing regulations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 9; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
steps required to be completed before a drug may be marketed in the United States include, among others:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; width: 0.3in"></td><td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; width: 0.3in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">preclinical
                                            laboratory tests, animal studies, and formulation studies, all performed in accordance with
                                            the FDA&#8217;s Good Laboratory Practice (&#8220;GLP&#8221;) regulations;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; width: 0.3in"></td><td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; width: 0.3in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">submission
                                            to the FDA of an IND application for human clinical testing, which must become effective
                                            before human clinical trials may begin and for which progress reports must be submitted annually
                                            to the FDA;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; width: 0.3in"></td><td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; width: 0.3in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">approval
                                            by an independent institutional review board (&#8220;IRB&#8221;) or Ethics Committee (&#8220;EC&#8221;)
                                            at each clinical trial site before each trial may be initiated;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; width: 0.3in"></td><td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; width: 0.3in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">adequate
                                            and well-controlled human clinical trials, conducted in accordance with applicable IND regulations,
                                            Good Clinical Practices (&#8220;GCP&#8221;), and other clinical trial related regulations,
                                            to establish the safety and efficacy of the drug for each proposed indication to the FDA&#8217;s
                                            satisfaction;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; width: 0.3in"></td><td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; width: 0.3in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">submission
                                            to the FDA of a New Drug Application (&#8220;NDA&#8221;) and payment of user fees for FDA
                                            review of the NDA (unless a fee waiver applies);</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; width: 0.3in"></td><td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; width: 0.3in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">satisfactory
                                            completion of an FDA pre-approval inspection of one or more clinical trial site(s) at which
                                            the drug was studied in a clinical trial(s) and/or of us as a clinical trial sponsor to assess
                                            compliance with GCP regulations;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; width: 0.3in"></td><td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; width: 0.3in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">satisfactory
                                            completion of an FDA pre-approval inspection of the manufacturing facility or facilities
                                            at which the drug is produced to assess compliance with current GMPs regulations;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; width: 0.3in"></td><td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; width: 0.3in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">agreement
                                            with the FDA on the final labeling for the product and the design and implementation of any
                                            required Risk Evaluation and Mitigation Strategy (&#8220;REMS&#8221;); and</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; width: 0.3in"></td><td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; width: 0.3in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">FDA
                                            review and approval of the NDA, including satisfactory completion of an FDA advisory committee
                                            review, if applicable, based on a determination that the drug is safe and effective for the
                                            proposed indication(s).</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Preclinical
tests include laboratory evaluation of product chemistry, toxicity, and formulation, as well as animal studies. The conduct of the preclinical
tests and formulation of the compounds for testing must comply with federal regulations and requirements, including GLP regulations.
The results of the preclinical tests, together with manufacturing information and analytical data, are submitted to the FDA as part of
an IND application, which must become effective before human clinical trials may begin. An IND application will automatically become
effective 30 days after receipt by the FDA, unless before that time the FDA raises concerns or questions about issues such as the conduct
of the trials as outlined in the IND application, and places the clinical trial(s) on a clinical hold. In such a case, the IND application
sponsor and the FDA must resolve any outstanding FDA concerns or questions before clinical trials can proceed. We cannot be certain that
submission of an IND application will result in the FDA allowing clinical trials to begin.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 10; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Clinical
trials necessary for product approval are typically conducted in three sequential phases, but the Phases may overlap or be combined.
The study protocol and informed consent information for study subjects in clinical trials must also be approved by an IRB for each institution
where the trials will be conducted, and each IRB must monitor the study until completion. Study subjects must provide informed consent
and sign an informed consent form before participating in a clinical trial. Clinical testing also must satisfy the extensive GCP regulations
for, among other things, informed consent and privacy of individually identifiable information.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; width: 0.3in"></td><td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; width: 0.3in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Phase
                                            1&#8212;Phase 1 clinical trials involve initial introduction of the study drug in a limited
                                            population of healthy human volunteers or patients with the target disease or condition.
                                            These studies are typically designed to test the safety, dosage tolerance, absorption, metabolism
                                            and distribution of the study drug in humans, evaluate the side effects associated with increasing
                                            doses, and, if possible, to gain early evidence of effectiveness.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; width: 0.3in"></td><td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; width: 0.3in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Phase
                                            2&#8212;Phase 2 clinical trials typically involve administration of the study drug to a limited
                                            patient population with a specified disease or condition to evaluate the preliminary efficacy,
                                            optimal dosages and dosing schedule and to identify possible adverse side effects and safety
                                            risks. Multiple Phase 2 clinical trials may be conducted to obtain information prior to beginning
                                            larger and more expensive Phase 3 clinical trials.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; width: 0.3in"></td><td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; width: 0.3in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Phase
                                            3&#8212;Phase 3 clinical trials typically involve administration of the study drug to an
                                            expanded patient population to further evaluate dosage, to provide substantial evidence of
                                            clinical efficacy and to further test for safety, generally at multiple geographically dispersed
                                            clinical trial sites. These clinical trials are intended to establish the overall risk/benefit
                                            ratio of the study drug and to provide an adequate basis for product approval. Generally,
                                            two adequate and well-controlled Phase 3 clinical trials are required by the FDA for approval
                                            of an NDA.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Post-approval
trials, sometimes referred to as Phase 4 clinical trials, may be conducted after receiving initial marketing approval. These trials are
used to gain additional experience from the treatment of patients in the intended therapeutic indication and are commonly intended to
generate additional safety data regarding use of the product in a clinical setting. In certain instances, the FDA may mandate the performance
of Phase 4 clinical trials as a condition of approval of an NDA or, in certain circumstances, post-approval.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
FDA has various programs, including fast track designation, breakthrough therapy designation, priority review and accelerated approval,
which are intended to expedite or simplify the process for the development, and the FDA&#8217;s review of drugs (<i>e.g.,</i> approving
an NDA on the basis of surrogate endpoints subject to post-approval trials). Generally, drugs that may be eligible for one or more of
these programs are those intended to treat serious or life-threatening diseases or conditions, those with the potential to address unmet
medical needs for those disease or conditions, and/or those that provide a meaningful benefit over existing treatments. For example,
a sponsor may be granted FDA designation of a drug candidate as a &#8220;breakthrough therapy&#8221; if the drug candidate is intended,
alone or in combination with one or more other drugs, to treat a serious or life-threatening disease or condition and preliminary clinical
evidence indicates that the drug may demonstrate substantial improvement over existing therapies on one or more clinically significant
endpoints, such as substantial treatment effects observed early in clinical development. If a drug is designated as breakthrough therapy,
the FDA will take actions to help expedite the development and review of such drug. Moreover, if a sponsor submits an NDA for a product
intended to treat certain rare pediatric or tropical diseases or for use as a medical countermeasure for a material threat, and that
meets other eligibility criteria, upon approval such sponsor may be granted a priority review voucher that can be used for a subsequent
NDA. From time to time, we anticipate applying for such programs where we believe we meet the applicable FDA criteria. A company cannot
be sure that any of its drugs will qualify for any of these programs, or even if a drug does qualify, that the review time will be reduced.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
results of the preclinical studies and of the clinical studies, together with other detailed information, including information on the
manufacture and composition of the drug, are submitted to the FDA in the form of an NDA requesting approval to market the product for
one or more proposed indications. The testing and approval process requires substantial time, effort and financial resources. Unless
the applicant qualifies for an exemption, the filing of an NDA typically must be accompanied by a substantial &#8220;user fee&#8221;
payment to the FDA. To support marketing approval, the data submitted must be sufficient in quality and quantity to establish the safety
and efficacy of the product in the proposed patient population to the satisfaction of the FDA. After an NDA is accepted for filing, the
FDA substantively reviews the application and may deem it to be inadequate, and companies cannot be sure that any approval will be granted
on a timely basis, if at all. The FDA may also refer the application to an appropriate advisory committee, typically a panel of clinicians,
for review, evaluation and a recommendation as to whether the application should be approved, but is not bound by the recommendations
of the advisory committee.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 11; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Before
approving an NDA, the FDA usually will inspect the facility or the facilities at which the drug is manufactured and determine whether
the manufacturing and production and testing facilities are in compliance with cGMP regulations. The FDA also may audit the clinical
trial sponsor and one or more sites at which clinical trials have been conducted to determine compliance with GCPs and data integrity.
If the NDA and the manufacturing facilities are deemed acceptable by the FDA, it may issue an approval letter, and, if not, the Agency
may issue a Complete Response Letter (&#8220;CRL&#8221;). An approval letter authorizes commercial marketing of the drug with specific
prescribing information for a specific indication(s). A CRL indicates that the review cycle of the application is complete and the application
is not ready for approval. A CRL may require additional clinical data and/or an additional pivotal Phase 3 clinical trial(s), and/or
other significant, expensive and time-consuming requirements related to clinical trials, preclinical studies or manufacturing. Even if
such additional information is submitted, the FDA may ultimately decide that the NDA does not satisfy the criteria for approval. The
FDA could also require, as a condition of NDA approval, post-marketing testing and surveillance to monitor the drug&#8217;s safety or
efficacy or impose other conditions, or a REMS that may include both special labeling and controls, known as Elements to Assure Safe
Use, on the distribution, prescribing, dispensing and use of a drug product. Once issued, the FDA may withdraw product approval if, among
other things, ongoing regulatory requirements are not met, certain defects exist in the NDA, or safety or efficacy problems occur after
the product reaches the market.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Intellectual
Property</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Information
regarding the issued patents and pending patent applications, as of December 31, 2022, is as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: white">
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-left: 0pt; text-align: left; width: 28%; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Subject
    Matter</b></span></td>
    <td style="padding-bottom: 1.5pt; text-align: left; width: 1%; vertical-align: bottom">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-left: 0pt; vertical-align: bottom; width: 6%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Issued</b></span></td>
    <td style="padding-bottom: 1.5pt; text-align: left; width: 1%; vertical-align: bottom">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-left: 0pt; vertical-align: bottom; width: 6%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Pending</b></span></td>
    <td style="padding-bottom: 1.5pt; text-align: left; width: 1%; vertical-align: bottom">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-left: 0pt; text-align: left; width: 46%; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Geographic
    Scope</b></span></td>
    <td style="padding-bottom: 1.5pt; text-align: left; width: 1%; vertical-align: bottom">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-left: 0pt; vertical-align: bottom; width: 10%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Patent&#160;Term</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CFF0FC">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Qualigen
    Patents and Trademarks</i></b></span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-left: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-left: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-left: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt 0pt 0pt 10pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">FastPack
    1.0, IP, and PRO</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">U.S.,
    Japan</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2024-2032</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CFF0FC">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt 0pt 0pt 10pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">FastPack
    2.0</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">23</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">U.S.,
    Europe, China, Japan</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2032-2042</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt 0pt 0pt 10pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">STARS</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">9</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">U.S.,
    Europe, Canada, China, Japan, Korea</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2030-2045</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CFF0FC">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Qualigen
    Trademarks</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">13</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">9</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">U.S.,
    Europe, Canada, China, Japan, Korea</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">N/A</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt 0pt 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Qualigen
    + Gen-Probe (Joint)</span></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-left: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">24</span></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-left: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0</span></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt 0pt 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">U.S.,
    Austrialia, Canada, China, Japan</span></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt 0pt 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2028</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CFF0FC">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt 0pt 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Total
    Qualigen</i></b></span></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-left: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>71</b></span></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-left: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>15</b></span></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt 0pt 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt 0pt 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>In-Licensed
    Patents</i></b></span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-left: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-left: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-left: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CFF0FC">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt 0pt 0pt 10pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">FastPack
    1.0, IP, and PRO</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Europe</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2030</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Univ
    College London (UCL)</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CFF0FC">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; padding: 0pt 0pt 0pt 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">QN-302</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">11</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">U.S.,
    Europe, Australia, Canada, China, Hong Kong, India, Japan, Korea, Russia</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; padding: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2030-2040</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Univ
    of Louisville (ULRF)</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CFF0FC">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; padding: 0pt 0pt 0pt 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">RAS</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">12</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">U.S,
    Europe, Australia, Canada, China, Hong Kong, India, Israel, Japan, Korea, Mexico, Russia, South Africa</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; padding: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2039*</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt 0pt 0pt 10pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">QN-247</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">44</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">U.S.,
    Europe, Canada, China, Hong Kong, Japan</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2032-2038</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CFF0FC">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt 0pt 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">DiaSource</span></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-left: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-left: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt 0pt 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt 0pt 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt 0pt 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Total
    In-Licensed</i></b></span></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-left: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>47</b></span></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-left: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>26</b></span></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt 0pt 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt 0pt 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CFF0FC">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt 0pt 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>TOTAL</b></span></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-left: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>118</b></span></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-left: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>41</b></span></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt 0pt 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt 0pt 2.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*<i>Anticipated
patent term</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Human
Capital Management</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of March 31, 2023, we had 38 employees, 31 of whom were full-time employees. None of our employees is represented by a labor union or
covered by a collective bargaining agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Employee
Engagement, Benefits &amp; Development.</i> We recognize that attracting, motivating and retaining talent at all levels is vital to our
continued success. Our employees are a significant asset and we aim to create an equitable, inclusive and empowering environment in which
our employees can grow and advance their careers, with the overall goal of developing, retaining and expanding our workforce, as needed,
to support our current pipeline and future business goals. By focusing on employee retention and engagement, we also improve our ability
to support our business and operations, our pipeline, and also protect the long-term interests of our shareholders. We frequently benchmark
our compensation practices and benefits programs against those of comparable companies in our industry and in the geographic area where
we are located. In our efforts to recruit and retain a diverse and exceptional workforce, we provide our employees with competitive cash
compensation, opportunities to own equity, and an employee benefit program that promotes well-being, including healthcare, a 401(k) Plan,
and paid time-off.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Diversity
&amp; Inclusion</i>. Our success also depends on our ability to attract, engage and retain a diverse group of employees. We value diversity
across our workforce and we will continue to focus on diversity and inclusion initiatives. With respect to our employees overall, approximately
fifty percent (50%) are people of color and approximately forty-five percent (45%) are women. We seek to have an inclusive and positive
culture that is centered on our shared corporate mission and values, and that is free from discrimination of any kind, including sexual
or other discriminatory harassment. Our employees have multiple avenues available through which inappropriate behavior can be reported.
All reports of inappropriate behavior are promptly investigated with appropriate action taken to stop such behavior.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Additional
Information</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ritter
Pharmaceuticals, Inc. (our predecessor) was formed as a Nevada limited liability company on March 29, 2004 under the name Ritter Natural
Sciences, LLC. In September 2008, this company converted into a Delaware corporation under the name Ritter Pharmaceuticals, Inc. On May
22, 2020, upon completing the &#8220;reverse recapitalization&#8221; transaction with Qualigen, Inc., Ritter Pharmaceuticals, Inc. was
renamed Qualigen Therapeutics, Inc. Qualisys Diagnostics, Inc. was formed as a Minnesota corporation in 1996, reincorporated to become
a Delaware corporation in 1999, and then changed its name to Qualigen, Inc. in 2000. Qualigen, Inc. is now a wholly-owned subsidiary
of the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
website address is <i>www.qualigeninc.com</i>. We post links to our website to the following filings as soon as reasonably practicable
after they are electronically filed with or furnished to the SEC: annual reports on Form 10-K, quarterly reports on Form 10-Q, current
reports on Form 8-K, proxy statements, information statements, beneficial ownership reports and any amendments to those reports or statements
filed or furnished pursuant to Sections 13(a), 14 or 15(d) of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;).
All such filings are available through our website free of charge. However, the information contained on or accessed through our website
does not constitute part of this Annual Report, and references to our website address in this Annual Report are inactive textual references
only. All such reports are also available free of charge via EDGAR through the SEC website at <i>www.sec.gov</i>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>


<!-- Field: Page; Sequence: 12; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="bs_003"></span>Item
1A. Risk Factors</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>An
investment in our common stock involves risks. You should carefully consider the risks described below, together with all of the other
information included in this Annual Report, as well as in our other filings with the SEC, in evaluating our business. If any of the following
risks actually occur, our business, financial condition, operating results and future prospects could be materially and adversely affected.
In that case, the trading price of our common stock may decline and you might lose all or part of your investment. The risks described
below, which are the risks we judge (rightly or wrongly) to be the most significant to investors, are not the only ones we face. Additional
risks that we currently do not judge to be among the &#8220;most significant&#8221; may also impair our business, financial condition,
operating results and prospects.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 45pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 45pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Certain
statements below are forward-looking statements. For additional information, see the section of this Annual Report under the caption
&#8220;Cautionary Note Regarding Forward-Looking Statements.&#8221;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 45pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risks
Related to Our Business Generally</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
business strategy is high-risk</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are focusing our resources and efforts primarily on development of therapeutic product candidates, which requires extensive cash needs
for research and development activities. This is a high-risk strategy because there is no assurance that our products will ever become
commercially viable, that we will prevent other companies from depriving us of market share and profit margins by selling products based
on our inventions and developments, that we will successfully manage a company in a new area of business and on a different scale than
we have operated in the past, that our product candidates will be able to achieve the desired therapeutic results, or that our cash resources
will be adequate to develop our product candidates until we become profitable, if ever. This may make our stock an unsuitable investment
for many investors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
do not currently have enough working capital to fully execute our strategic plan</i>.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have suffered recurring losses from operations, and we will need capital to support our intended development of our therapeutics business.
We believe that future financings will be necessary in order for us to properly execute our strategic plan. However, there can be no
assurance that such future financings will be available to us (or, if they are, that they can be consummated on desirable terms).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may, in the short and long-term, seek to raise capital through the issuance of equity securities or through other financing sources.
To the extent that we seek to raise additional funds by issuing equity securities, our stockholders may experience significant
dilution. Any debt financing, if available, may include financial and other covenants that could restrict our use of the proceeds
from such financing or impose other business and financial restrictions on us. In addition, we may consider alternative approaches
such as licensing, joint venture, or partnership arrangements to provide long term capital. Additional funding may not be available
to us on acceptable terms, or at all. In addition, any future financing (depending on the terms and conditions) may be subject to
the approval of Alpha Capital Anstalt (&#8220;Alpha&#8221;), a related party and the holder of our 8% Senior Convertible Debenture
(the &#8220;Debenture&#8221;), and/or trigger certain adjustments to the Debenture or warrants held by Alpha. See Part II, Item 7
&#8220;<i>Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</i>&#8221; for additional
details regarding the Debenture.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Servicing
our debt will require a significant amount of cash, and we may not have sufficient cash flow from our business to pay this debt.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
ability to make payments to Alpha of principal or interest on our indebtedness or to make any potential prepayments for the Debenture,
to the extent applicable, depends on our future performance, which is subject to economic, financial, competitive and other factors beyond
our control. If the assumptions underlying our cash flow guidance are incorrect, our business may not continue to generate cash flow
from operations in the future sufficient to service our indebtedness and make necessary capital expenditures.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Commencing
June 1, 2023 and continuing on the first day of each month thereafter until the earlier of (i) December 22, 2025 and (ii) the full redemption
of the Debenture (each such date, a &#8220;Monthly Redemption Date&#8221;), we must redeem $110,000 plus accrued but unpaid interest,
liquidated damages and any amounts then owing under the Debenture (the &#8220;Monthly Redemption Amount&#8221;). The Monthly Redemption
Amount must be paid in cash; provided that after the first two monthly redemptions, we may elect to pay all or a portion of a Monthly
Redemption Amount in shares of our common stock, based on a conversion price equal to the lesser of (i) the then applicable conversion
price of the Debenture and (ii) 85% of the average of the VWAPs (as defined in the Debenture) for the five consecutive trading days ending
on the trading day that is immediately prior to the applicable Monthly Redemption Date. We may also redeem some or all of the then outstanding
principal amount of the Debenture at any time for cash in an amount equal to 105% of the then outstanding principal amount of the Debenture
being redeemed plus accrued but unpaid interest, liquidated damages and any amounts then owing under the Debenture. These monthly redemption
and optional redemptions are subject to the satisfaction of the Equity Conditions (as defined in the Debenture), which include a condition
that we have obtained stockholder approval for such share issuances.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 13; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Debenture accrues interest at the rate of 8% per annum, which begins accruing on December 1, 2023, and will be payable on a quarterly
basis. Interest may be paid in cash or shares of common stock or a combination thereof at our option; provided that interest may only
be paid in shares if the Equity Conditions have been satisfied, including the stockholder approval condition as described above.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we are unable to obtain stockholder approval for the issuance of shares of common stock under the Debenture, we will required to make
any required payments to Alpha in cash. If we are unable to generate cash flow sufficient to service our indebtedness and make necessary
capital expenditures, we may be required to adopt one or more alternatives, such as selling assets, restructuring debt or issuing additional
equity, equity-linked or debt instruments on terms that may be onerous or highly dilutive. Our ability to refinance our indebtedness
will depend on the capital markets and our financial condition at such time. If we are unable to engage in any of these activities or
engage in these activities on desirable terms, we may be unable to meet our debt obligations, which would materially and adversely impact
our business, financial condition and operating results.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risks
Related to Our Therapeutics and Diagnostics Pipeline</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
product candidates are still in the early stages of development. We have not begun clinical trials or obtained regulatory approval for
any drug candidate. We may never obtain approval for any of our drug candidates.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are still early in our development efforts and have not yet begun enrollment in any clinical trials evaluating QN-302, RAS, or QN-247.
There can be no assurance that QN-302, RAS, and/or QN-247 will achieve success in their clinical trials or obtain regulatory approval.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
ability to generate revenues from QN-302, RAS, and/or QN-247 will depend on the successful development and eventual commercialization
of such drug candidates. The success of these products will depend on several factors, including the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">successful
                                            completion of preclinical studies and clinical trials;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">acceptance
                                            of an IND application by the FDA or other clinical trial or similar applications from foreign
                                            regulatory authorities for our future clinical trials for our pipeline;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">timely
                                            and successful enrollment of patients in, and completion of, clinical trials with favorable
                                            results;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">demonstration
                                            of safety, efficacy and acceptable risk-benefit profiles of our products to the satisfaction
                                            of the FDA and foreign regulatory agencies;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">receipt
                                            and related terms of marketing approvals from applicable regulatory authorities, including
                                            the completion of any required post-marketing studies or trials;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">obtaining
                                            and maintaining patent, trade secret and other intellectual property protection and regulatory
                                            exclusivity for our products;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">developing
                                            and implementing marketing and reimbursement strategies;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">establishing
                                            sales, marketing and distribution capabilities and launching commercial sales of our products,
                                            if and when approved, whether alone or in collaboration with others;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">acceptance
                                            of our drugs, if and when approved, by patients, the medical community and third-party payors;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">effectively
                                            competing with other therapies;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">obtaining
                                            and maintaining third-party payor coverage and adequate reimbursement; and</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">maintaining
                                            a continued acceptable safety profile of the products following approval.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Many
of these factors are beyond our control, and it is possible that none of our drug candidates will ever obtain regulatory approval even
if we expend substantial time and resources seeking such approval. If we do not achieve one or more of these factors in a timely manner
or at all, we could experience significant delays or an inability to successfully commercialize our drug candidates. For example, our
business could be harmed if results of the clinical trials of QN-302, RAS, QN-247, any other drug candidates vary adversely from our
expectations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 14; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Drug
development involves a lengthy and expensive process. We may incur additional costs or experience delays in completing, or ultimately
be unable to complete, the development and commercialization of QN-302, RAS, and/or QN-247.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Most
drug candidates fail, and taking a drug candidate from concept through clinical trials and regulatory approval is not easy or guaranteed.
We are unable to predict when or if our drug candidates, will prove effective or safe in humans or will obtain marketing approval. Before
obtaining marketing approval from regulatory authorities for the sale of these products, we must complete preclinical development and
then conduct extensive clinical trials to demonstrate the safety and efficacy of these products for humans. Clinical testing is expensive,
difficult to design and implement, can take many years to complete and is uncertain as to the outcome. A failure of one or more clinical
trials can occur at any stage of testing. The outcome of preclinical testing and early clinical trials may not be predictive of the success
of later clinical trials, and interim or preliminary results of a clinical trial do not necessarily predict final results.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may experience numerous unforeseen events that could delay or prevent our ability to obtain marketing approval or commercialize our drug
candidates, including:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">regulators
                                            or IRBs or ECs may not authorize us or our investigators to commence a clinical trial or
                                            conduct a clinical trial at a prospective trial site;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
                                            may experience delays in reaching, or fail to reach, agreement on acceptable clinical trial
                                            contracts or clinical trial protocols with prospective trial sites;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">clinical
                                            trials for our drug candidates may produce negative or inconclusive results, and we may decide,
                                            or regulators may require us, to conduct additional clinical trials, delay clinical trials
                                            or abandon product development programs;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            number of patients required for clinical trials for our drug candidates may be larger than
                                            we anticipate, enrollment in these clinical trials may be slower than we anticipate, participants
                                            may drop out of these clinical trials at a higher rate than we anticipate or the duration
                                            of these clinical trials may be longer than we anticipate;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">competition
                                            for clinical trial participants from investigational and approved therapies may make it more
                                            difficult to enroll patients in our clinical trials;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
                                            third-party contractors may fail to meet their contractual obligations to us in a timely
                                            manner, or at all, or may fail to comply with regulatory requirements;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
                                            may have to suspend or terminate clinical trials for our drug candidates for various reasons,
                                            including a finding that the participants are being exposed to unacceptable health risks;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
                                            drug candidates may have undesirable or unexpected side effects or other unexpected characteristics,
                                            causing us or our investigators, regulators or IRBs/ECs to suspend or terminate the trials;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            cost of clinical trials for our drug candidates may be greater than we anticipate; and</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            supply or quality of our drug candidates, or other materials necessary to conduct clinical
                                            trials may be insufficient or inadequate and result in delays or suspension of our clinical
                                            trials.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -12.75pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
product development costs will increase if we experience delays in preclinical studies or clinical trials or in obtaining marketing approvals.
We do not know whether any of our planned preclinical studies or clinical trials will begin on a timely basis or at all, will need to
be restructured or will be completed on schedule, or at all. For example, the FDA may place a partial or full clinical hold on any of
our clinical trials for a variety of reasons.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Significant
preclinical or clinical trial delays also could shorten any periods during which we may have the exclusive right to commercialize our
drug candidates or allow our competitors to bring products to market before we do and impair our ability to successfully commercialize
our drug candidates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Any
delays in the commencement or completion, or termination or suspension, of our future clinical trials, if any, could result in increased
costs to us, delay or limit our ability to generate revenue and adversely affect our commercial prospects.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Before
we can initiate clinical trials of a drug candidate, we must submit the results of preclinical studies to the FDA along with other information
as part of an IND or IDE application or similar regulatory filing, and the FDA (or corresponding foreign regulatory body) must approve
the application. We have not yet submitted our IND application for QN-302 for pancreatic cancer. While we expect to submit the IND application
during the first half of 2023, we cannot guarantee the timing for submitting the IND application for QN-302, and we do not know when
this IND application (or any other IND application) would be approved, if ever.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 15; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Before
obtaining marketing approval from the FDA for the sale of QN-302, RAS, QN-247, or any other future drug candidate, we must conduct extensive
clinical studies to demonstrate safety and efficacy. Clinical testing is expensive, time consuming and uncertain as to outcome. The FDA
may require us to conduct additional preclinical studies for any drug candidate before it allows us to initiate clinical trials under
any IND application, which may lead to additional delays and increase the costs of our preclinical development programs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
delays in the commencement or completion of our ongoing, planned or future clinical trials could significantly increase our costs, slow
down our development and approval process and jeopardize our ability to commence product sales and generate revenues. We do not know
whether our planned trials will begin on time or at all, or be completed on schedule, if at all. The commencement and completion of clinical
trials can be delayed for a number of reasons, including delays related to:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            FDA disagreeing as to the design or implementation of our clinical trials or with our recommended
                                            dose for any of our pipeline programs;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">obtaining
                                            FDA authorization to commence a trial or reaching a consensus with the FDA on trial design;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">obtaining
                                            approval from one or more IRBs/ECs;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">IRBs/ECs
                                            refusing to approve, suspending or terminating the trial at an investigational site, precluding
                                            enrollment of additional subjects, or withdrawing their approval of the trial;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes
                                            to clinical trial protocol;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">clinical
                                            sites deviating from trial protocol or dropping out of a trial;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">failing
                                            to manufacture or obtain sufficient quantities of drug candidate, or, if applicable, combination
                                            therapies for use in clinical trials;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">patients
                                            failing to enroll or remain in our trial at the rate we expect, or failing to return for
                                            post-treatment follow-up;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">patients
                                            choosing an alternative treatment, or participating in competing clinical trials;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">lack
                                            of adequate funding to continue the clinical trial;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">patients
                                            experiencing severe or unexpected drug-related adverse effects;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">occurrence
                                            of serious adverse events in trials of the same class of agents conducted by other companies;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">selecting
                                            or being required to use clinical end points that require prolonged periods of clinical observation
                                            or analysis of the resulting data;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
                                            facility manufacturing our drug candidates, or any of their components, including without
                                            limitation, our own facilities being ordered by the FDA to temporarily or permanently shut
                                            down due to violations of cGMP, regulations or other applicable requirements, or infections
                                            or cross-contaminations in the manufacturing process;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">lack
                                            of stability of our clinical trial material or any quality issues that arise with the clinical
                                            trial material;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
                                            changes to our manufacturing process that may be necessary or desired;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our,
                                            or our third-party contractors, not performing data collection or analysis in a timely or
                                            accurate manner or improperly disclosing data prematurely or otherwise in violation of a
                                            clinical trial protocol; or</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
                                            third-party contractors becoming debarred or suspended or otherwise penalized by the FDA
                                            or other government or regulatory authorities for violations of regulatory requirements,
                                            in which case we may need to find a substitute contractor, and we may not be able to use
                                            some or all of the data produced by such contractors in support of our marketing applications.</span></td></tr></table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>


<!-- Field: Page; Sequence: 16; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
could also encounter delays if a clinical trial is suspended or terminated by us, by the IRBs/ECs of the institutions in which such trials
are being conducted, by a Data Safety Monitoring Board for such trial or by the FDA. Such authorities may impose such a suspension or
termination due to a number of factors, including failure to conduct the clinical trial in accordance with regulatory requirements or
our clinical protocols, inspection of the clinical trial operations or trial site by the FDA resulting in the imposition of a clinical
hold, unforeseen safety issues or adverse side effects, failure to demonstrate a benefit from using the product under investigation,
changes in governmental regulations or administrative actions or lack of adequate funding to continue the clinical trial. In addition,
changes in regulatory requirements and policies may occur, and we may need to amend clinical trial protocols to comply with these changes.
Amendments may require us to resubmit our clinical trial protocols to IRBs/ECs for reexamination, which may impact the costs, timing
or successful completion of a clinical trial.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If
we experience delays or difficulties enrolling patients in our ongoing or planned clinical trials, our receipt of necessary regulatory
approval could be delayed or prevented.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may not be able to initiate or continue our ongoing or planned clinical trials for our products if we are unable to identify and enroll
a sufficient number of eligible patients to participate in these trials as required by the FDA. In addition, some of our competitors
may have ongoing clinical trials for products that would treat the same patients as QN-302, RAS or QN-247, and patients who would otherwise
be eligible for our clinical trials may instead enroll in clinical trials of our competitors&#8217; products. In addition, introduction
of new drugs or devices to the marketplace may have an effect on the number of patients available or timing of the availability of the
patients.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
inability to enroll a sufficient number of patients for our clinical trials would result in significant delays or may require us to abandon
one or more clinical trials altogether.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Adverse
side effects or other safety risks associated with QN-302, RAS, and/or QN-247 product candidates could delay or preclude approval, cause
us to suspend or discontinue any clinical trials or abandon further development, limit the commercial profile of an approved label, or
result in significant negative consequences following regulatory approval, if any.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Results
of our planned clinical trials could reveal a high and unacceptable severity and prevalence of side effects or unexpected characteristics.
Undesirable side effects caused by our products could result in the delay, suspension or termination of clinical trials by us or the
FDA for a number of reasons.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Moreover,
if our products are associated with undesirable side effects in clinical trials or have characteristics that are unexpected, we may elect
to abandon or limit their development to more narrow uses or subpopulations in which the undesirable side effects or other characteristics
are less prevalent, less severe or more acceptable from a risk-benefit perspective, which may limit the commercial expectations for our
products, if approved. We may also be required to modify our study plans based on findings in our clinical trials. Many drug candidates
that initially showed promise in early stage testing have later been found to cause side effects that prevented further development.
In addition, regulatory authorities may draw different conclusions or require additional testing to confirm these determinations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">It
is possible that as we test our drug candidates in larger, longer and more extensive clinical trials, including with different dosing
regimens, or as the use of our drug candidates becomes more widespread following any regulatory approval, illnesses, injuries, discomforts
and other adverse events that were observed in earlier trials, as well as conditions that did not occur or went undetected in previous
trials, will be reported by patients.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>The
development and commercialization of pharmaceutical and device products are subject to extensive regulation, and we may not obtain regulatory
approvals for QN-302, RAS, QN-247 or any other product candidates, on a timely basis or at all.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
clinical development, manufacturing, labeling, packaging, storage, recordkeeping, advertising, promotion, export, import, marketing,
distribution, adverse event reporting, including the submission of safety and other post-marketing information and reports, and other
possible activities relating to QN-302, RAS and QN-247, as well as any other product candidate that we may develop in the future, are
subject to extensive regulation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Regulatory
approval of drugs in the United States requires the submission of an NDA to the FDA and we are not permitted to market any pharmaceutical
product candidate in the United States until we obtain approval from the FDA of the NDA for that product. An NDA must be supported by
extensive clinical and preclinical data, as well as extensive information regarding pharmacology, chemistry, manufacturing and controls.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 17; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">FDA
approval of an NDA or PMA is not guaranteed, and the review and approval process is an expensive and uncertain process that may take
several years. The FDA also has substantial discretion in the approval process. The number and types of preclinical studies and clinical
trials that will be required for NDA or PMA approval varies depending on the product candidate, the disease or the condition that the
product candidate is designed to treat and the regulations applicable to any particular product candidate. Despite the time and expense
associated with preclinical studies and clinical trials, failure can occur at any stage. The results of preclinical and any clinical
trials of QN-302, RAS or QN-247 or any other future product candidate may not be predictive of the results of our later-stage clinical
trials.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Clinical
trial failure may result from a multitude of factors including flaws in trial design, dose selection, placebo effect, patient enrollment
criteria and failure to demonstrate favorable safety or efficacy traits, and failure in clinical trials can occur at any stage. Companies
in the pharmaceutical and device industry frequently suffer setbacks in the advancement of clinical trials due to lack of efficacy or
adverse safety profiles, notwithstanding promising results in earlier trials. Based upon negative or inconclusive results, we may decide,
or regulators may require us, to conduct additional clinical trials or preclinical studies. In addition, data obtained from clinical
trials are susceptible to varying interpretations, and regulators may not interpret our data as favorably as we do, which may further
delay, limit or prevent regulatory approval.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Even
if we are able to commercialize any drug candidates, the products may become subject to unfavorable pricing regulations, third-party
reimbursement practices or healthcare reform initiatives, which would harm our business.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
regulations that govern marketing approvals, pricing, coverage and reimbursement for new drug products vary widely from country to country.
Current and future legislation may significantly change the approval requirements in ways that could involve additional costs and cause
delays in obtaining approvals. Some countries require approval of the sale price of a drug before it can be marketed. In many countries,
the pricing review period begins after marketing or product licensing approval is granted. To obtain reimbursement or pricing approval
in some countries, we may be required to conduct a clinical trial that compares the cost-effectiveness of our drug candidate to other
available therapies. In some foreign markets, prescription pharmaceutical pricing remains subject to continuing governmental control
even after initial approval is granted. As a result, we might obtain marketing approval for a drug candidate in a particular country,
but then be subject to price regulations that delay commercial launch of the product, possibly for lengthy time periods, and negatively
impact the revenues, if any, we are able to generate from the sale of the product in that country. Adverse pricing limitations may hinder
our ability to recoup our investment in one or more drug candidates, even if such drug candidates obtain regulatory approval.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
ability to commercialize any drug candidates successfully also will depend in part on the extent to which coverage and adequate reimbursement
for these products and related treatments will be available from third-party payors, including government healthcare programs, private
health insurers and other organizations. Third-party payors decide which medications they will pay for and establish reimbursement levels.
A primary trend in the U.S. healthcare industry and elsewhere has been cost containment. Third-party payors have attempted to control
costs by limiting coverage and the amount of reimbursement for particular medications. Increasingly, third-party payors are requiring
that drug companies provide them with predetermined discounts from list prices and are challenging the prices charged for medical products.
Coverage and reimbursement may not be available for any product that we commercialize and, even if these are available, the level of
reimbursement may not be satisfactory. Reimbursement may affect the demand for, or the price of, any drug candidate for which we obtain
regulatory approval. Obtaining and maintaining coverage and adequate reimbursement for our products may be difficult. We may be required
to conduct expensive pharmacoeconomic studies to justify coverage and reimbursement or the level of reimbursement relative to other therapies.
If coverage and adequate reimbursement are not available or reimbursement is available only to limited levels, we may not be able to
successfully commercialize any drug candidate for which we obtain regulatory approval.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
may also be significant delays in obtaining coverage and reimbursement for newly approved drugs, and coverage may be more limited than
the purposes for which the drug is approved by the FDA or similar regulatory authorities outside of the United States. Moreover, eligibility
for coverage and reimbursement does not imply that a drug will be paid for in all cases or at a rate that covers our costs, including
research, development, intellectual property, manufacture, sale and distribution expenses. Interim reimbursement levels for new drugs,
if applicable, may also not be sufficient to cover our costs and may not be made permanent. Reimbursement rates may vary according to
the use of the drug and the clinical setting in which it is used, may be based on reimbursement levels already set for lower cost drugs
and may be incorporated into existing payments for other services. Net prices for drugs may be reduced by mandatory discounts or rebates
required by government healthcare programs or private payors and by any future relaxation of laws that presently restrict imports of
drugs from countries where they may be sold at lower prices than in the United States. Third-party payors often rely upon Medicare coverage
policy and payment limitations in setting their own reimbursement policies, but also have their own methods and approval process apart
from Medicare determinations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
expect that the Affordable Care Act, as well as other healthcare reform measures that may be adopted in the future, may continue to result
in more rigorous coverage criteria and in additional downward pressure on the price that providers receive for any approved therapeutics
products of ours. This would adversely affect the prices we receive and could also adversely affect providers&#8217; willingness to prescribe
our therapeutics products, if any.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 18; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
may not be able to obtain or maintain orphan drug designation or exclusivity for our drug candidates.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Regulatory
authorities in some jurisdictions, including the United States, may designate drugs for relatively small patient populations as &#8220;orphan
drugs.&#8221; Under the Orphan Drug Act of 1983, as amended, the FDA may designate a drug candidate as an orphan drug if it is intended
to treat a rare disease or condition, which is generally defined as a patient population of fewer than 200,000 individuals in the United
States, or if the disease or condition affects more than 200,000 individuals in the United States and there is no reasonable expectation
that the cost of developing and making a drug product available in the United States for the type of disease or condition will be recovered
from sales of the product.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Orphan
drug designation entitles a party to financial incentives, such as opportunities for grant funding towards clinical trial costs, tax
advantages and user-fee waivers. Additionally, if a product that has orphan designation subsequently receives the first FDA approval
for the disease or condition for which it has such designation, the product is entitled to orphan drug exclusivity. This means that the
FDA may not approve any other applications to market the same drug or biological product for the same indication for seven years, except
in certain circumstances, including proving clinical superiority (<i>i.e</i>., another product is safer, more effective or makes a major
contribution to patient care) to the product with orphan exclusivity. Competitors, however, may receive approval of different products
for the indication for which the orphan product has exclusivity, or obtain approval for the same product but for a different indication
than that for which the orphan product has exclusivity. In addition, exclusive marketing rights in the United States may be limited if
we seek approval for an indication broader than the orphan-designated indication or may be lost if the FDA later determines that the
request for designation was materially defective.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span>We
have received orphan drug designation in the United States for QN-302 for
the indication of pancreatic cancer. Following having data that supports other rare cancer indications, we intend to seek orphan drug
designation in the United States for QN-302 for additional indications, and will also seek orphan drug designations for RAS for one or
more indications. Orphan drug status does not ensure that we will receive marketing exclusivity in a particular market, and there is no
assurance that any application for orphan drug designation will be granted. Orphan drug designation neither shortens the development time
or regulatory review time of a drug, nor gives the drug any advantage in the regulatory review or approval process.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
rely, and intend to continue to rely, on third parties to conduct our preclinical studies and clinical trials and perform some of our
research and preclinical studies. If these third parties do not satisfactorily carry out their contractual duties, fail to comply with
applicable regulatory requirements or do not meet expected deadlines, our development programs may be delayed or subject to increased
costs or we may be unable to obtain regulatory approval.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are dependent on third parties to conduct our planned preclinical studies and clinical trials of QN-302, RAS and QN-247. The timing of
the initiation and completion of these trials will therefore be partially controlled by such third parties and may result in delays to
our development programs. We have relied heavily, and expect to continue to rely, on UofL for preclinical studies related to RAS, and
we expect to rely heavily on CROs and sponsored academic researchers for preclinical studies related to QN-302. As to any clinical trials,
we expect to rely on CROs, sponsored academic researchers, clinical investigators and consultants to play a significant role in the conduct
of these trials and the subsequent collection and analysis of data. However, we will not be able to control all aspects of their activities.
Nevertheless, we are responsible for ensuring that each clinical trial is conducted in accordance with the applicable protocol and legal,
regulatory and scientific standards, including GCP, requirements, and our reliance on the CROs and other third parties does not relieve
us of our regulatory responsibilities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
is no guarantee that any such CROs, clinical trial investigators or other third parties on which we rely will devote adequate time and
resources to our development activities or perform as contractually required. If any of these third parties fail to meet expected deadlines,
adhere to our clinical protocols or meet regulatory requirements, otherwise perform in a substandard manner, or terminate their engagements
with us, the timelines for our development programs may be extended or delayed or our development activities may be suspended or terminated.
If one of our clinical trial site terminates for any reason, we may experience the loss of follow-up information on subjects enrolled
in such clinical trial unless we are able to transfer those subjects to another qualified clinical trial site, which may be difficult
or impossible.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
these third parties do not successfully carry out their contractual duties, meet expected deadlines or conduct clinical trials in accordance
with regulatory requirements or our stated protocols, we will not be able to obtain, or may be delayed in obtaining, regulatory approvals
for QN-302, RAS and/or QN-247 and will not be able to, or may be delayed in our efforts to, successfully commercialize our products.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 19; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Manufacturing
pharmaceutical products is complex and subject to product loss for a variety of reasons. We contract with third parties for the manufacture
of our product candidates for preclinical testing and clinical trials and expect to continue to do so for commercialization. This reliance
on third parties increases the risk that we will not have sufficient quantities of our product candidates or such quantities at an acceptable
cost or quality, which could delay, prevent or impair our development or commercialization efforts.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
rely, and expect to continue to rely, on third parties for the manufacture of our products for preclinical and any clinical testing,
as well as for commercial manufacture if any of our product candidates obtain regulatory approval. This reliance on third parties increases
the risk that we will not have sufficient quantities of our product candidates or such quantities at an acceptable cost or quality, which
could delay, prevent or impair our development or commercialization efforts.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may be unable to establish any agreements with third-party manufacturers or to do so on favorable terms. Even if we are able to establish
agreements with third-party manufacturers, reliance on third-party manufacturers entails additional risks, including:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reliance
                                            on the third-party for regulatory, compliance and quality assurance;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">operations
                                            of our third-party manufacturers or suppliers could be disrupted by conditions unrelated
                                            to our business or operations, including the bankruptcy of the manufacturer or supplier or
                                            the issuance of an FDA Form 483 notice or warning letter;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            possible breach of the manufacturing agreement by the third-party; and</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            possible termination or nonrenewal of the agreement by the third-party at a time that is
                                            costly or inconvenient for us.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -12.75pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
do not have manufacturing agreements in place for any of our current drug candidates. We acquire many key materials on a purchase order
basis. As a result, we do not have long-term committed arrangements with respect to our product candidates and other materials. If we
obtain regulatory approval for any of our product candidates, we will need to establish an agreement for commercial manufacture with
a third-party.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
performance failure on the part of our existing or future manufacturers could delay clinical development or regulatory approval. We do
not currently have arrangements in place for redundant supply or a second source for bulk drug substance for QN-302, RAS or QN-247.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
may enter into collaborations with third parties for the development and commercialization of our products. If those collaborations are
not successful, we may not be able to capitalize on the market potential of these products. Even if they are successful, they may result
in a limitation of our upside potential.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="background-color: white">We
may in the future seek third-party collaborators for the development and commercialization of some of our products on a selected basis.
For example, we expect that we will require partners to continue the development of </span><span>QN-247
</span> <span style="background-color: white">which </span>is <span style="background-color: white">in early-stage development.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
likely collaborators for any collaboration arrangements include large and mid-size pharmaceutical companies, regional and national pharmaceutical
companies and biotechnology companies. We face significant competition in seeking appropriate collaborators. Our ability to reach a definitive
agreement for a collaboration will depend, among other things, upon our assessment of the collaborator&#8217;s resources and expertise,
the terms and conditions of the proposed collaboration and the proposed collaborator&#8217;s evaluation of a number of factors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we do enter into any such arrangements with any third parties, we will likely have limited control over the amount and timing of resources
that such collaborators dedicate to the development or commercialization of our products. Our ability to generate revenues from these
arrangements will depend on our collaborators&#8217; abilities and efforts to successfully perform the functions assigned to them in
these arrangements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
collaboration will necessarily result in a sharing of economics with the collaborator, which might otherwise have been captured by us
directly.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 20; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Even
if any of our product candidates receives regulatory approval, we may fail to achieve the degree of market acceptance by physicians,
patients, third-party payors and others in the medical community necessary for commercial success.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
any of our product candidates receives regulatory approval, we may nonetheless fail to gain sufficient market acceptance by physicians,
patients, third-party payors and others in the medical community. For example, current cancer treatments, such as existing targeted therapies,
chemotherapy, and radiation therapy, are well established in the medical community, and doctors may continue to rely on these treatments.
If our product candidates do not achieve an adequate level of acceptance, we may not generate significant product revenues and we may
not become profitable. The degree of market acceptance of our product candidates, if approved for commercial sale, will depend on a number
of factors, including:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            efficacy and potential advantages compared to alternative treatments;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            prevalence and severity of any side effects, in particular compared to alternative treatments;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">limitations
                                            or warnings contained in the labeling approved for our product candidates by the FDA;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            size of the target patient population;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            willingness of the target patient population to try new therapies and of physicians to prescribe
                                            these therapies;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; width: 0.25in">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
                                            ability to offer our products for sale at competitive prices;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            convenience and ease of administration compared to alternative treatments;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            strength of marketing and distribution support;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: left; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">publicity
                                            for our product candidates and competing products and treatments;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            existence of distribution and/or use restrictions, such as through a Risk Evaluation and
                                            Mitigation Strategy;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            availability of third-party payor coverage and adequate reimbursement and the willingness
                                            of patients to pay for our products in the absence of such coverage and adequate reimbursement;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            timing of any marketing approval in relation to other product approvals;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">support
                                            from patient advocacy groups; and</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
                                            restrictions on the use of our products together with other medications.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
face substantial competition, which may result in others discovering, developing or commercializing products before or more successfully
than we do.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
development and commercialization of pharmaceutical products is highly competitive. We face competition from major pharmaceutical companies,
specialty pharmaceutical and and biotechnology companies worldwide. There are a number of large pharmaceutical and biotechnology companies
that currently market and sell products or are pursuing the development of products for the treatment of the disease indications for
which we are developing our product candidates that may be effective in developing therapeutics. Some of these competitive products,
therapies are based on scientific approaches that are similar to our approach, and others are based on entirely different approaches.
Potential competitors also include academic institutions, government agencies and other public and private research organizations that
conduct research, seek patent protection and establish collaborative arrangements for research, development, manufacturing and commercialization.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
expect that our oncology drug product candidates will face competition from traditional small or large molecule drugs that target specific
cancers that are FDA-approved and marketed for the indications that we are pursuing, in addition to off-label use of current therapeutics
and therapeutics in development; and from other drugs using targeted approaches to direct payloads to cancerous tumors, as well as newer
approaches, such as immuno-oncology, which attempts to harness the patient&#8217;s own immune system to fight cancer itself.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 21; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Many
of the companies against which we are competing or against which we may compete in the future have significantly greater financial resources
and expertise in research and development, manufacturing, preclinical testing, conducting clinical trials, obtaining regulatory approvals
and marketing and selling approved products than we do. Mergers and acquisitions in the pharmaceutical and biotechnology industries may
result in even more resources being concentrated among a smaller number of our competitors. Smaller and other early-stage companies may
also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. These
third parties compete with us in recruiting and retaining qualified scientific, management and sales and marketing personnel, establishing
clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary to, or necessary
for, our programs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
commercial opportunity could be reduced or eliminated if our competitors develop and commercialize products that are safer, more effective,
have fewer or less severe side effects, are approved for broader indications or patient populations, are more convenient or are less
expensive than any products that we may develop. Our competitors also may obtain FDA or other marketing approval for their products more
rapidly than any approval we may obtain, which could result in our competitors establishing a strong market position before we are able
to enter the market. In addition, our ability to compete may be affected in many cases by insurers or other third-party payors seeking
to encourage the use of generic products. The key competitive factors affecting the success of QN-302, RAS, QN-247 are likely to be efficacy,
safety, scope and limitations of marketing approval, and availability of reimbursement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
maintain our cash at financial institutions, often in balances that exceed federally insured limits.<br />
<br />
</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
maintain our cash at financial institutions, often in balances that exceed federally insured limits.We maintain the majority of our cash
and cash equivalents in accounts at banking institutions in the United States that we believe are of high quality. Cash held in these
accounts often exceed the Federal Deposit Insurance Corporation (&#8220;FDIC&#8221;) insurance limits. If such banking institutions were
to fail, we could lose all or a portion of amounts held in excess of such insurance limitations. The FDIC recently took control of two
such banking institutions, Silicon Valley Bank (&#8220;SVB&#8221;) on March 10, 2023 and Signature Bank (&#8220;Signature Bank&#8221;)
on March 12, 2023. While we did not have an account at either of these two banks, in the event of failure of any of the financial institutions
where we maintain our cash and cash equivalents, there can be no assurance that we would be able to access uninsured funds in a timely
manner or at all. Any inability to access or delay in accessing these funds could adversely affect our business and financial position.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risks
Related to Our Diagnostics Business</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
may face challenges distributing our FastPack System.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
distribution agreement with Sekisui for our FastPack System expired on March 31, 2022. We have and will continue to incur costs re-establishing
and maintaining a direct sales force, and we may also face logistical issues and relationship issues with customers during the transition
period. In addition, there is the risk that the direct sales force assembled and used by us will not be as efficient and effective as
Sekisui&#8217;s distribution efforts.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
may provide inadequate training to our sales force and/or fail to increase our sales and marketing capabilities.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
rely on our direct sales force to sell our FastPack System in targeted geographic regions, territories and distribution channels, and
any failure to maintain our direct sales force could harm our business. The members of our direct sales force are specifically trained
to market and sell our FastPack System and they possess technical expertise, which we believe is critical in driving the awareness and
adoption of our product. The members of our sales force are at-will employees. The loss of these personnel to competitors, or otherwise,
could materially harm our business. If we are unable to retain our direct sales force personnel or replace them with individuals of comparable
expertise and qualifications, or if we are unable to successfully instill such expertise in replacement personnel, our product sales,
revenues and results of operations could be materially harmed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Identifying
and recruiting qualified sales and marketing professionals and training them on our FastPack System, on applicable federal and state
laws and regulations and on our internal policies and procedures requires significant time, expense and attention. It can take several
months or more before a sales representative is fully trained and productive. Our sales force may subject us to higher fixed costs than
those of companies with competing products that can utilize independent third parties, placing us at a competitive disadvantage. Our
business may be harmed if our efforts to expand and train our sales force do not generate a corresponding increase in product sales and
revenue, and our higher fixed costs may slow our ability to reduce costs in the face of a sudden decline in demand for our products.
Any failure to hire, develop and retain talented sales personnel, to achieve desired productivity levels in a reasonable period of time
or timely reduce fixed costs, could have material adverse effect on our business, financial condition and results of operations.<br />
<br /></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
diagnostic products face heavy competition.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
FastPack System is a mature technology and faces heavy competition from manufacturers of more complex immunoassay systems designed primarily
for central laboratory use, but that also are sold to physician offices. Many of our competitors have substantially greater financial,
technical, research and other resources and capabilities. We also face competition from companies that have developed or are developing
newer blood testing systems for use in physician offices. The FastPack system may not continue to be competitive in light of future technological
developments by others.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 22; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
diagnostic products are disadvantaged by reduced Medicare reimbursement and third-party payer pricing.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
noted above, a primary trend in the U.S. healthcare industry and elsewhere is cost containment. Third-party payors have attempted to
control costs by limiting coverage and the amount of reimbursement for particular medical devices, especially mature ones such as ours.
Decreases in Medicare and private-insurer reimbursement for diagnostic tests such as ours in recent years are a negative factor in our
attempts to maintain and grow our diagnostics business. This factor constrains the price that we can charge to providers for our diagnostic
products. Moreover, if adequate reimbursement is not available or reimbursement is available only to limited levels, some physician offices,
clinics and small hospitals may choose not to offer (or to discontinue offering) some or all of our diagnostic products.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Yi
Xin may not meet expectations in its China/overseas FastPack business.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Yi
Xin is a new and untested company and there is no assurance that its financial and other capabilities will enable it to succeed in commercializing
FastPack-based diagnostic products. We will receive royalties from Yi Xin if and only if Yi Xin achieves sales of FastPack-based diagnostic
products.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risks
Related to our Intellectual Property</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If
we are unable to obtain and maintain sufficient patent protection for our therapeutic product candidates and diagnostic technologies,
or if the scope of the patent protection is not sufficiently broad, third parties, including our competitors, could develop and commercialize
products similar or identical to ours, and our ability to commercialize our product candidates successfully may be adversely affected.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
commercial success depends significantly on our ability to protect our proprietary (and exclusively in-licensed) product candidates or
technologies that we believe are important to our business, including pursuing, obtaining and maintaining patent protection in the United
States and other countries intended to cover the composition of matter of our product candidates, the methods of use, related technologies,
and other inventions that are important to our business. In addition to patent protection, we also rely on trade secrets to protect aspects
of our business that are not amenable to, or that we do not consider appropriate for, patent protection. If we do not adequately pursue,
obtain, maintain, protect or enforce our intellectual property, third parties, including our competitors and/or collaborators, may be
able to erode or negate any competitive advantage we may have, which could harm our business and ability to achieve profitability.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
protect our proprietary position, we file patent applications in the United States and abroad related to our product candidates and technologies,
their methods of manufacture and use. The patent application and approval process is expensive, time-consuming and complex. We may not
be able to prepare, file, prosecute and maintain all necessary or desirable patent applications at a reasonable cost or in a timely manner
or in all jurisdictions. It is also possible that we will fail to identify patentable aspects of our research and development output
before it is too late to obtain patent protection. Moreover, depending on the terms of any future license agreements to which we may
become a party, we may not have the right to control the preparation, filing, and prosecution of patent applications, or to maintain
or defend the patents, covering technology licensed from third parties. Therefore, these patents and patent applications may not be prosecuted
and enforced in a manner consistent with the best interests of our business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
cannot offer any assurances about which, if any, patents will issue, the breadth of any such patents, whether any issued patents will
be found invalid and unenforceable or will be threatened by third parties or whether any issued patents will effectively prevent others
from commercializing competing technologies and product candidates. We have not filed patent applications in every jurisdiction, and
some filings are only pending in the United States.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Because
patent applications in the United States and most other countries are confidential for a period of time after filing, and some remain
so until issued, we cannot be certain that we were the first to file or invent (before March 16, 2013) the invention disclosed in any
patent application related to our product candidates or technology.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Moreover,
because the issuance of a patent, although presumptive, is not conclusive as to its inventorship, scope, validity or enforceability,
our patents or pending patent applications may be challenged in the courts or patent offices in the United States and abroad. Such challenges
may result in loss of exclusivity or in our patent claims being narrowed, invalidated or held unenforceable, in whole or in part, which
could limit our ability to stop others from using or commercializing similar or identical products and technologies or limit the duration
of the patent protection of our products and technologies. Such challenges also may result in substantial cost and require significant
time from our scientists and management, even if the eventual outcome is favorable to us.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 23; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
and our licensors&#8217; pending and future patent applications may not result in patents being issued that protect our product candidates
and technologies, in whole or in part, or that effectively prevent others from commercializing competitive products and technologies.
Even if our patent applications issue as patents, they may not issue in a form that will provide us with any meaningful protection, prevent
competitors or other third parties from competing with us or otherwise provide us with any competitive advantage. Our competitors and
other third parties may be able to circumvent our patents by developing similar or alternative products or technologies in a non-infringing
manner. Our competitors and other third parties may also seek approval to market their own products and technologies similar to or otherwise
competitive with our products and technologies. Alternatively, our competitors or other third parties may seek to market generic versions
of any approved products by submitting abbreviated NDAs to the FDA during which process they may claim that patents owned by us are invalid,
unenforceable or not infringed. In these circumstances, we may need to defend or assert our patents, or both, including by filing lawsuits
alleging patent infringement. In any of these types of proceedings, a court or other agency with jurisdiction may find our patents invalid
or unenforceable, or that our competitors are competing in a non-infringing manner. Thus, even if we have valid and enforceable patents,
these patents still may not provide protection against competing products or processes sufficient to achieve our business objectives.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>The
term of our patents may be inadequate to protect our competitive position on our products.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Given
the amount of time required for the development, testing and regulatory review of drug candidates, patents protecting such candidates
might expire before or shortly after such candidates are commercialized. In such an event (and if we are unable to obtain patent term
extension or the term of any such extension is less than we request), our competitors and other third parties may be able to obtain approval
of competing products following patent expiration and take advantage of our investment in development and clinical trials by referencing
our clinical and preclinical data and launch their product earlier than might otherwise be the case. Generic competition usually results
in serious price erosion for the original drug brand.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risks
Related to Employee Matters, Managing Growth, Potential Dilution, Stock Price Variability and Other Risks Related to Our Business</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
future success depends on our ability to retain key employees and to attract, retain and motivate qualified personnel.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are highly dependent on Michael Poirier, our Chief Executive Officer and Chairman, as well as other members of our management, scientific,
operations and corporate development teams.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
previously disclosed, in January 2023, as part of certain cost-cutting measures, we approved a temporary 20% reduction to the base salaries
of all executive officers of the Company, effective immediately. As part of these cost-cutting measures, we terminated the employment
of certain employees, including our former Chief Operating Officer and former Vice President and Chief Scientific Officer. These cost-cutting
measures could make us vulnerable to attrition among our current senior management team and other key employees, and may make it difficult
for us to hire additional senior managers and other key employees.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
ability to compete depends upon our ability to attract, retain and motivate highly skilled and experienced personnel with scientific,
clinical, regulatory, manufacturing and management skills and experience. We may not be able to attract or retain qualified personnel
in the future. Many of the companies against which we compete have greater financial and other resources, different risk profiles and
a longer history in the industry than we do. Our competitors may provide higher compensation, more diverse opportunities and/or better
opportunities for career advancement. Any or all of these competing factors may limit our ability to continue to attract and retain high
quality personnel, which could negatively affect our ability to successfully develop and commercialize our product candidates and to
grow our business and operations as currently contemplated.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
expect that we will need to expand our development and regulatory capabilities as our product candidates progress through the clinic,
or additional product candidates are developed; if any products are approved, we would have to implement sales, marketing and distribution
capabilities, and as a result, we may encounter difficulties in managing growth, which could disrupt our operations.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of March 31, 2023, we had 38 employees, 31 of whom were full-time employees. Although we outsource many drug development functions and
may choose to continue to do so in the future, we expect to experience growth in the number of employees and the scope of our operations,
particularly in the areas of clinical development, clinical operations, manufacturing, and regulatory affairs as we progress QN-302,
RAS and QN-247 through the clinic and develop additional product candidates. If any of our therapeutics product candidates receives regulatory
approval, we may need to expand into sales, marketing and distribution. To manage anticipated future growth, we must continue to implement
and improve our managerial, operational and financial systems, expand our facilities and continue to recruit and train additional qualified
personnel. We may not be able to effectively manage the expansion of our operations or recruit and train additional qualified personnel.
The expansion of our operations may lead to significant costs and may divert management and business development resources.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 24; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
currently rely, and for the foreseeable future will continue to rely, in substantial part, on certain third-party contract research organizations,
sponsored academic researchers, advisors and consultants to provide certain services, including assuming substantial responsibilities
for the conduct of our clinical trials and the manufacture of QN-302, RAS and QN-247 or any future product candidates. We cannot assure
that the services of such third-party contract research organizations, sponsored academic researchers, advisors and consultants will
continue to be available to us on a timely basis when needed, or that we can find qualified replacements. In addition, if we are unable
to effectively manage our outsourced activities or if the quality or accuracy of the services provided by our vendors or consultants
is compromised for any reason, our clinical trials may be extended, delayed or terminated, and we may not be able to obtain regulatory
approval of QN-302, RAS and/or QN-247 or any of future product candidates or otherwise advance our business. We cannot assure that we
will be able to properly manage our existing vendors or consultants or find other competent outside vendors and consultants on economically
reasonable terms, or at all.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
may engage in strategic transactions that could impact liquidity, increase expenses and present significant distractions to management.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="background-color: white">From
time to time, we may consider strategic transactions, such as acquisitions of companies, businesses or assets and out-licensing or in-licensing
of products, drug candidates or technologies. Potential transactions that we may consider include a variety of different business arrangements,
including spin-offs, in-licensing, strategic partnerships, joint ventures, restructurings, divestitures, business combinations and investments.
Any such transaction may require us to incur non-recurring or other charges, may increase near term or long-term expenditures and may
pose significant integration challenges or disrupt management or business, which could adversely affect our operations and financial results.
For example, </span>as a result of annual goodwill impairment testing, we recognized a $4.2 million non-cash goodwill impairment charge
in the valuation of our business acquisition of Nanosynex for the year ended December 31, 2022. These trans<span style="background-color: white">actions
may entail numerous operational and financial risks, including:</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">exposure
                                            to unknown liabilities;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">disruption
                                            of business and diversion of management&#8217;s time and attention in order to develop acquired
                                            products, drug candidates or technologies;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">incurrence
                                            of substantial debt or dilutive issuances of equity securities to pay for acquisitions;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">higher
                                            than expected acquisition and integration costs;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">write-downs
                                            of assets or impairment charges;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">increased
                                            amortization expenses;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">difficulty
                                            and cost in combining the operations, systems and personnel of any acquired businesses with
                                            our operations, systems and personnel;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">impairment
                                            of relationships with key suppliers or customers of any acquired businesses due to changes
                                            in management and ownership; and</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">inability
                                            to retain key employees of any acquired businesses.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
investment in NanoSynex, our majority owned indirect subsidiary, has a number of risks associated with it.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
investment in NanoSynex, our majority owned indirect subsidiary domiciled in Israel, has a number of risks associated with it, including,
among others, the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; width: 0.3in"></td><td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; width: 0.3in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
                                            history of operating losses, with no assurance of future revenues or operating profits;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; width: 0.3in"></td><td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; width: 0.3in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">risks
                                            associated with the development of medical devices and NanoSynex&#8217;s ability to obtain
                                            the necessary regulatory approvals for the development and commercialization of its antimicrobial
                                            susceptibility test platform;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; width: 0.3in"></td><td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; width: 0.3in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">very
                                            limited manufacturing, marketing, distribution and sales capabilities;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; width: 0.3in"></td><td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; width: 0.3in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">competition
                                            from both public and private companies and academic collaborators, many of which have significantly
                                            greater experience and financial resources;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; width: 0.3in"></td><td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; width: 0.3in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">acceptance
                                            by life sciences research and diagnostic communities is not assured;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; width: 0.3in"></td><td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; width: 0.3in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">commercial
                                            development of its antimicrobial susceptibility test platform is not assured;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; width: 0.3in"></td><td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; width: 0.3in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">an
                                            inability to manufacture, market or sell its proposed products if it is unsuccessful in entering
                                            into strategic alliances or joint ventures with third parties; and</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; width: 0.3in"></td><td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; width: 0.3in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">risks
                                            related to the political, economic and military conditions in Israel.</span></td></tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 25; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, as a condition to our acquisition of NanoSynex, we agreed to provide NanoSynex with up to $10.4 million of future funding in
the form of promissory notes to us based on NanoSynex&#8217;s achievement of certain future development milestones and subject to other
terms and conditions described in the funding agreement. See Part II, Item 7 &#8220;<i>Management&#8217;s Discussion and Analysis of
Financial Condition and Results of Operations</i>&#8221; for additional details. If we are unable to make these payments, if and when
required, and if NanoSynex is unable to find alternative sources of funding, NanoSynex&#8217;s operations may be negatively impacted,
which would ultimately have a negative impact on us.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
reported financial condition and results of operations may fluctuate significantly from quarter to quarter and year to year, which makes
them difficult to predict or understand.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
expect our financial condition and results of operations to fluctuate from quarter to quarter and year to year due to a variety of factors,
many of which are beyond our control. In particular, the warrant liabilities (and change in the fair value of warrant liabilities, over
a reporting period) may result in distortions and sharp variability in reported periodic results. Accordingly, you should not blindly
rely upon the results of any quarterly or annual periods as indications of future operating performance. Other investors may, however,
attach undue significance to reported results which are heavily influenced by such distortions and variability, which in turn could cause
our stock price to rise or fall despite there being no corresponding change in our prospects or position as a practical matter.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
have a substantial amount of derivative securities outstanding.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2022 there were 608,012 stock options outstanding under our equity incentive plans. and 4,575,617 outstanding warrants.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, the Debenture issued to Alpha in December 2022 is convertible, at any time, and from time to time, at Alpha&#8217;s option,
into shares of our common stock, subject to our receipt of the necessary stockholder approvals and other terms and conditions described
in the Debenture. Furthermore, subject to our receipt of the necessary stockholder approvals and other terms and conditions described
in the Debenture, we may elect to pay all or a portion of the Monthly Redemption Amount and/or interest required by the Debenture in
shares of our common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
issuance of shares upon the exercise or conversion of outstanding stock options, warrants and the Debenture (or our election to pay amounts
owed under the Debenture in shares of our common stock) could result in significant dilution to the holders of our existing outstanding
common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
rely significantly upon information technology, and any failure, inadequacy, interruption or security lapse of that technology, including
any cyber security incidents, could harm our ability to operate our business effectively and result in a material disruption of our product
development programs.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
utilize complex IT systems to transmit and store information, including sensitive personal information and proprietary or confidential
information, and otherwise to support our business and process. In the future, our systems may prove inadequate to our business needs
and necessary upgrades may not operate as designed, which could result in excessive costs or disruptions in portions of our business.
In particular, any disruptions, delays or deficiencies from our enterprise resource planning systems could adversely affect our ability
to, among other matters, process orders, procure supplies, manufacture and ship products, track inventory, provide services and customer
support, send invoices and track payments, fulfill contractual obligations or otherwise operate our business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
could also be subject to risks caused by misappropriation, misuse, leakage, falsification or intentional or accidental release or loss
of information maintained in the information systems and networks of our company. Outside parties may attempt to penetrate our systems
or those of our partners or fraudulently induce our employees or employees of our partners to disclose sensitive information to gain
access to our data. Like other companies, we may experience threats to our data and systems, including malicious codes and computer viruses,
cyber-attacks or other system failures. Furthermore, a security breach could be facilitated by ineffective protection measures, employee
errors or omissions, and malfeasance. Despite our efforts to protect against cyber-attacks and security breaches, hackers and other cyber
criminals are using increasingly sophisticated and constantly evolving techniques, and we may need to expend substantial additional resources
to continue to protect against potential security breaches or to remediate problems caused by such attacks or any breach of our safeguards.
Any system failure, accident or security breach that causes interruptions in our operations, for us or our partners, could result in
a material disruption of our product development programs and business operations, in addition to possibly requiring substantial expenditures
of resources to remedy. For example, the loss of clinical trial data from completed clinical trials could result in delays in our regulatory
approval efforts and we could incur significant increases in costs to recover or reproduce the data. The risk of cyber incidents could
also be increased by cyberwarfare in connection with the ongoing war in Ukraine, including potential proliferation of malware from the
conflict into systems unrelated to the conflict. To the extent that any disruption or security breach results in a loss of, or damage
to, our data or applications, or inappropriate public disclosure of confidential or proprietary information, we may incur liabilities
and the further development of our product candidates may be delayed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 26; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
number and complexity of these security threats continue to increase over time. The costs of maintaining adequate protection against
such threats are significant and are expected to continue to increase in the future and may be material to our financial statements.
If a breach of our security systems or that of our partners occurs, the market perception of the effectiveness of our security measures
could be harmed, we could lose business and our reputation and credibility could be damaged. We could be required to expend significant
amounts of money and other resources to repair or replace information systems or networks. We may also be required to comply with disparate
state and foreign breach notification laws and otherwise subject to liability under laws that protect personal data, resulting in increased
costs or loss of revenue. In addition, a data security breach or ransomware attack could distract management or other key personnel from
performing their primary operational duties. Although we develop and maintain systems and controls designed to prevent these events from
occurring, and we have a process to identify and mitigate threats, the development and maintenance of these systems, controls and processes
is costly and requires ongoing monitoring and updating as technologies change and efforts to overcome security measures become more sophisticated.
Moreover, despite our efforts, the possibility of these events occurring cannot be eliminated entirely.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
business, financial condition, results of operations and growth have been adversely impacted by the effects of the COVID-19 pandemic
and may be adversely impacted by COVID-19 or another pandemic, epidemic or infectious disease outbreak in the future.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
COVID-19 pandemic and related governmental and business responses had and may again have an adverse effect on the markets we derive project
opportunities from, our customers, and our operations. The extent to which the COVID-19 pandemic could again impact us will depend on
numerous evolving factors and future developments that are uncertain and that we are not able to predict at this time, including: the
timing, extent, trajectory and duration of the pandemic; the emergence of new variants; the development, availability, distribution and
effectiveness of vaccines and treatments; the imposition of protective public safety measures; and the impact of the pandemic on the
global economy and demand for our products and services. Although the COVID-19 pandemic has subsided, we could again experience adverse
impacts to our business as a result of any related economic recession that occurred or may occur in the future from COVID-19 or other
similar global pandemics.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Adverse
global conditions, including economic uncertainty, may negatively impact our financial results.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Global
conditions, disruptions in the financial markets, or inflation could adversely impact our business. In addition, the global macroeconomic
environment has been and may continue to be negatively affected by, among other things, instability in global economic markets, increased
U.S. trade tariffs and trade disputes with other countries, instability in the global credit markets, supply chain weaknesses, instability
in the geopolitical environment as a result of the war in Ukraine, the withdrawal of the United Kingdom from the European Union, and
other political tensions, and foreign governmental debt concerns. Such challenges have caused, and may continue to cause, uncertainty
and instability in local economies and in global financial markets, which may adversely affect our business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
or the third parties upon whom we depend may be adversely affected by natural disasters and our business continuity and disaster recovery
plans may not adequately protect us from a serious disaster.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are located in southern California, and are subject to risks posed by natural disasters, including wildfires, earthquakes and severe
weather that may interfere with our operations. Extreme weather events and other natural disasters could severely disrupt our operations,
and have a material adverse effect on our business, results of operations, financial condition and prospects. If a natural disaster,
power outage or other event occurred that prevented Qualigen from using all or a significant portion of our headquarters, that damaged
critical infrastructure, such as the manufacturing facilities of our third-party contract manufacturers, or that otherwise disrupted
operations, it may be difficult or, in certain cases, impossible for Qualigen to continue our business for a substantial period of time.
Any disaster recovery and business continuity plans we have in place may prove inadequate in the event of a serious disaster or similar
event.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Any
failure to develop or maintain effective internal controls over financial reporting or difficulties encountered in implementing or improving
our internal controls over financial reporting could harm our operating results and prevent us from meeting our reporting obligations.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Moreover,
effective internal controls, particularly those related to financial reporting, are necessary for us to produce reliable financial reports.
If we cannot provide reliable financial reports, our business and operating results could be harmed, investors could lose confidence
in our reported financial information, and the trading price of our common stock could drop significantly. In addition, investors relying
upon this misinformation could make an uninformed investment decision, and we could be subject to sanctions or investigations by the
SEC or other regulatory authorities or to stockholder class action securities litigation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, discovery and disclosure of a material weakness, by definition, could have a material adverse impact on our financial
statements. As previously described in our annual report on Form 10-K for the year ended December 31, 2021, in connection with the
audit of our financial statements as of and for the year ended December 31, 2021 (the &#8220;2021 audit&#8221;), our management identified a material weakness in our internal control over financial reporting related to the lack of
accounting department resources and/or policies and procedures to ensure recording and disclosure of items in compliance with U.S.
GAAP. This material weakness resulted in adjustments to our warrant valuations in connection with the 2021 audit. In response to the
material weakness, we took a number of remediation steps to enhance our internal controls, including <span style="background-color: white">implementing
additional procedures and utilizing external consulting resources with experience and expertise in U.S. GAAP and public company
accounting and reporting requirements to assist management with its accounting and reporting of complex and/or non-recurring
transactions and related disclosures. However, in connection with the audit of our financial statements as of and for the year ended
December 31, 2022 (the &#8220;2022 audit&#8221;), our management determined that that the material weakness identified in connection
with the 2021 audit has not been fully remediated and has resulted in adjustments to</span> the accounting treatment related to
convertible debt, the business combination and goodwill impairment during the 2022 audit, which resulted in the late filing of this
Annual Report (see Item 9A. Controls and Procedures).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">If we are unable to remediate the material weakness and achieve and maintain
effective internal control over financial reporting and effective disclosure controls, our business could be adversely affected. Certain
customers and/or suppliers may choose not to do business with us and the price of our common stock could be adversely impacted. This could,
in turn, negatively affect our ability to access equity capital markets.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
failure to be current in our filings with the SEC could pose significant risks to our business, which could materially and adversely
affect our financial condition and results of operations.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are required, as a public reporting company, to provide investors on a regular basis with periodic reports that contain important financial
and business information, including annual reports on Form 10-K and other periodic reports. Periodic reports help investors to make informed
investment decisions about the purchase or sale of a reporting company&#8217;s securities. Our inability to timely file periodic reports
with the SEC could have an adverse impact on our ability to, among other things, (i) raise funds in the public markets and (ii) attract
and retain key employees, which could materially and adversely affect our financial condition and results of operations. In addition,
the late filing of our Annual Report has also adversely affected our eligibility to use our Form S-3 registration statement. Use of that
Form requires, among other things, that the issuer be current in its reports under the Exchange Act for at least 12 months. As a result
of our being unable to use Form S-3, we will have to meet more demanding requirements to register our securities, so it will be more
difficult for us to effect public offering transactions, and our range of available financing alternatives could be narrowed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
failure to meet the continued listing requirements of Nasdaq could result in a delisting of our common stock.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we fail to satisfy the continued listing requirements of Nasdaq, Nasdaq may take steps to delist our common stock. Such a delisting would
likely have a negative effect on the price of our common stock and would impair your ability to sell or purchase our common stock when
you wish to do so.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
April 20, 2023, we received a notification letter from the Listing Qualifications Department of Nasdaq indicating that, as a result of
our delay in filing this Annual Report, we were not in compliance with the timely filing requirements for continued listing under Nasdaq
Listing Rule 5250(c)(1). The notification letter has no immediate effect on the listing or trading of our common stock on the Nasdaq
Capital Market. The notification letter states that, under Nasdaq rules, we have 60 calendar days, or until June 20, 2023, to submit
a plan to regain compliance with Nasdaq&#8217;s continued listing requirements. Alternatively, we may also regain compliance with Nasdaq&#8217;s
continued listing requirements at any time before June 20, 2023, by filing this Annual Report with the SEC, as well as any subsequent
periodic financial reports that may become due, and continuing to comply with Nasdaq&#8217;s other continued listing requirements. We
expect that the filing of this Annual Report will be sufficient to avoid the delisting of our common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have in the past been in noncompliance with other Nasdaq continued listing rules. For example, on November 23, 2022, we effected a 1-for-10
reverse stock split of our outstanding common stock to cure our noncompliance, for a period of more than 30 consecutive business days,
with <span style="background-color: white">Nasdaq Listing Rule 5550(a)(2), which requires listed securities to maintain a minimum bid
price of $1.00 per share. </span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we are unable to maintain compliance with Nasdaq&#8217;s continued listing requirements. In the event of a delisting, we would take action
to restore our compliance with Nasdaq&#8217;s listing requirements, but we can provide no assurance that any such action taken by us
would allow our common stock to become listed again, stabilize the market price or improve the liquidity of our common stock, prevent
our common stock from dropping below the Nasdaq minimum bid price requirement or prevent future non-compliance with Nasdaq&#8217;s other
listing requirements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="bs_004"></span>Item
1B. Unresolved Staff Comments.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
applicable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="bs_005"></span>Item
2. Properties.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our wholly-owned subsidiary Qualigen, Inc. currently leases an all-purpose facility in Carlsbad, California. Our partially owned subsidiary NanoSynex currently leases an R&amp;D facility in Ness Ziona, Israel.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="bs_006"></span>Item
3. Legal Proceedings.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">None.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="bs_007"></span>Item
4. Mine Safety Disclosures.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
applicable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 27; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="bs_008"></span>PART
II</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="bs_009"></span>Item
5. Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
common stock has been listed and traded on the Nasdaq Capital Market under the symbol &#8220;QLGN&#8221; since May 26, 2020.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Holders</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of April 11, 2023, there were 627 registered holders of record of our common stock. This figure does not reflect the beneficial ownership
of shares held in nominee name.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Securities
Authorized for Issuance Under Equity Compensation Plans</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">See
Part III, Item 12 &#8220;Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters&#8221; for information
relating to our equity compensation plans.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Recent
Sales of Unregistered Securities</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">None.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Purchases
of Equity Securities by the Issuer and Affiliated Purchasers</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">None.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="bs_010"></span>Item
6. [Reserved]</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="bs_011"></span>Item
7. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>You
should read the following discussion and analysis of our financial condition and results of operations together with the consolidated
financial statements and related notes that are included elsewhere in this Annual Report. This discussion contains forward-looking statements
based upon current expectations that involve risks and uncertainties. Our actual results may differ materially from those anticipated
in these forward-looking statements as a result of various factors, including those set forth under &#8220;Risk Factors&#8221; or in
other parts of this Annual Report. See &#8220;Cautionary Note Regarding Forward-Looking Statements&#8221; for additional information.
Unless otherwise indicated, all information in this Annual Report on Form 10-K gives effect to a 1-for-10 reverse stock split of our
common stock that became effective on November 23, 2022, and all references to shares of common stock outstanding and per share amounts
give effect to the reverse stock split.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Overview</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are a diversified life sciences company focused on developing treatments for adult and pediatric cancers with potential for Orphan Drug
designation, while also commercializing diagnostics.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
cancer therapeutics pipeline includes QN-302, RAS and QN-247.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 28; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
lead oncology therapeutics program, QN-302, is an investigational small molecule G4-selective transcription inhibitor with strong binding
affinity to G4s prevalent in cancer cells. Such binding could, by stabilizing the G4s against DNA &#8220;unwinding,&#8221; help inhibit
cancer cell proliferation. QN-302 is currently undergoing Good Laboratory Practice (GLP) toxicology studies.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
RAS portfolio consists of a family of RAS oncogene protein-protein interaction inhibitor small molecules believed to inhibit or block
mutated RAS genes&#8217; proteins from binding to their effector proteins. Preventing this binding could stop tumor growth, especially
in RAS-driven tumors such as pancreatic, colorectal and lung cancers.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
investigational QN-247 compound binds nucleolin, a key multi-functional regulatory phosphoprotein that is overexpressed in cancer cells.
Such binding could inhibit the cancer cells&#8217; proliferation. The foundational aptamer of QN-247 is QN-165 (formerly referred to
as AS1411), which the Company has deprioritized as a drug candidate for treating COVID-19 and other viral-based infectious diseases.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
May 26, 2022, we acquired 2,232,861 shares of Series A-1 Preferred Stock of NanoSynex from Alpha in exchange for 3,500,000 shares of
our common stock and a prefunded warrant to purchase 3,314,641 shares of our common stock at an exercise price of $0.001 per share.
These warrants were subsequently exercised on September 13, 2022 and the shares of our common stock were subsequently subject to a 1 for 10 reverse split on November 23, 2022. Concurrently with this
transaction, we also purchased 381,786 shares of Series B preferred stock from NanoSynex for a total purchase price of $600,000. The
transactions resulted in our acquiring a 52.8% interest in NanoSynex. NanoSynex is a micro-biologics diagnostics company domiciled
in Israel.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Because
our therapeutic candidates are all still in the pre-clinical development stage, our only products that are currently commercially available
are the for sale FastPack System diagnostic instruments and test kits. Our FastPack System diagnostic instruments and test kits are sold
commercially primarily in the United States, as well as certain European countries. The FastPack System menu includes a rapid, highly
accurate immunoassay diagnostic testing system for cancer, men&#8217;s health, hormone function, and vitamin D status. We provide analyzers
to our customers (physician offices, clinics and small hospitals) at low cost in order to increase sales volumes of higher-margin test
kits.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have always utilized a &#8220;razor and blades&#8221; pricing strategy, providing analyzers to our customers (physician offices, clinics
and small hospitals) at low cost in order to increase sales volumes of higher-margin test kits. Through the first quarter of 2022, we
relied on our diagnostics distribution partner, Sekisui, for most FastPack distribution worldwide pursuant to a distribution agreement.
We maintained direct distribution for certain house accounts, including selling our total testosterone test kits to Low T, the largest
men&#8217;s health group in the United States, with 40 locations. The Distribution Agreement with Sekisui expired on March 31, 2022,
and after that date the activities previously provided by Sekisui have reverted back to us and we have recognized 100% of the revenue
from the sales of our FastPack diagnostic instruments and test kits. We have licensed and technology-transferred our FastPack System
technology to Yi Xin Zhen Duan Jishu (Suzhou) Ltd. for the China diagnostics market.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
do not expect to be profitable before products from our therapeutics pipeline are commercialized, because we foresee that research and
development expenses on the therapeutics programs will significantly exceed the profits, if any, that we will generate from our diagnostics
products. To experience losses while therapeutic products are still under development is, of course, typical for biotechnology companies.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
consolidated financial statements do not separate our diagnostics-related activities from our therapeutics-related activities. Although
to date all of our reported revenue is diagnostics-related, our reported expenses represent the total of our diagnostics-related and
therapeutics-related expenses</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Reverse
Stock Split</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
November 23, 2022, we effected a 1-for-10, as determined by our board of directors, reverse stock split of our outstanding shares of
common stock (the &#8220;Reverse Stock Split&#8221;). The Reverse Stock Split reduced our shares of outstanding common stock, stock options,
and warrants to purchase shares of our common stock. Fractional shares of common stock that would have otherwise resulted from the Reverse
Stock Split were rounded down to the nearest whole share and cash in lieu of payments were made to stockholders. All share and per share
data for all periods presented in this section and the accompanying financial statements and related disclosures have been adjusted retrospectively
to reflect the Reverse Stock Split. The number of authorized shares of common stock and the par value per share remains unchanged.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 29; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Impact
of COVID-19 Pandemic</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
COVID-19 pandemic had, and it or similar pandemics, epidemics or infectious disease outbreaks may, in the future, have, adverse impacts
on the U.S. and world economy, health care systems, personnel availability, supply chains, social and political assumptions, and capital
markets. The impacts from the pandemic were particularly serious for smaller companies such as ours. Sales of our diagnostic products
fell significantly during 2020 as deferral of patients&#8217; non-emergency visits to physician offices, clinics and small hospitals
sharply reduced demand for our FastPack tests. While our FastPack sales began to rebound in 2021, the extent to which the COVID-19 pandemic,
or similar pandemics, epidemic or infectious disease outbreak, could impact us in the future will depend on numerous evolving factors
and future developments that we are unable to predict at this time, including: the timing, extent, trajectory and duration of the pandemic;
the emergence of new variants; the development, availability, distribution and effectiveness of vaccines and treatments; the imposition
of protective public safety measures; and the impact of the pandemic on the global economy and demand for our products and services.
We could again experience adverse impacts to our business as a result of any related economic recession that may occur in the future
from COVID-19 or other similar global pandemic, epidemic or infectious disease outbreak.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Critical
Accounting Policies and Estimates</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
discussion and analysis is based on our consolidated financial statements, which have been prepared in accordance with U.S. GAAP. The
preparation of these consolidated financial statements requires us to make estimates and judgments that affect the reported amounts of
assets, liabilities, revenues and expenses and the disclosure of contingent assets and liabilities in our consolidated financial statements.
On an ongoing basis, we evaluate our estimates and judgments, including those related to impairment of goodwill and other intangible assets, fair value of warrant liabilities, stock-based
compensation, amortization and depreciation, inventory reserves, allowances for doubtful accounts and returns, and warranty costs. We
base our estimates on historical experience, known trends and events and various other factors we believe to be reasonable under the
circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are
not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 30; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">While
our significant accounting policies are more fully described in Note 1 to our consolidated financial statements appearing in &#8220;Item
8. Financial Statements and Supplementary Data,&#8221; we believe that the following accounting policies are the most critical to aid
you in fully understanding and evaluating our financial condition and results of operations:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; width: 0.3in"></td><td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; width: 0.3in">&#9679;<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Convertible
                                            debt</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; width: 0.3in"></td><td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; width: 0.3in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
                                            and development</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; width: 0.3in"></td><td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; width: 0.3in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Revenue
                                            recognition</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; width: 0.3in"></td><td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; width: 0.3in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Allowance
                                            for doubtful accounts and returns</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; width: 0.3in"></td><td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; width: 0.3in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inventory</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; width: 0.3in"></td><td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; width: 0.3in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Impairment of long-lived
                                            assets</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; width: 0.3in"></td><td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; width: 0.3in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Business
                                            combination</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; width: 0.3in"></td><td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; width: 0.3in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Goodwill</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; width: 0.3in"></td><td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; width: 0.3in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
                                                                                                                                                                                                                                                                    Process R&amp;D</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; width: 0.3in"></td><td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; width: 0.3in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Derivative financial instruments and warrant
                                            liabilities</span></td></tr></table>

<p style="margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
                                                                                                 <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; width: 0.3in">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; width: 0.3in">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify">Stock-based compensation</td></tr>
                                                                                                 </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; width: 0.3in"></td><td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; width: 0.3in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Income
                                            taxes</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Warrant
Liabilities</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
2004, Qualigen, Inc. issued Series C preferred stock warrants to investors and brokers in connection with a private placement. These
warrants were subsequently extended and survived the May 2020 Ritter reverse recapitalization transaction and are now exercisable for
Qualigen Therapeutics common stock. These warrants contain a provision that if Qualigen, Inc. issues shares (except in certain defined
scenarios) at a price below the warrants&#8217; exercise price, the exercise price will be re-set to such new price and the number of
shares underlying the warrants will be increased in the same proportion as the exercise price decrease. For accounting purposes, such
warrants give rise to warrant liabilities. The operation of the &#8220;double-ratchet&#8221; provisions in these warrants in connection
with the NanoSynex acquisition and the convertible debenture financing transaction in 2022 now allow the holders to exercise for a significantly
higher number of shares than before. Accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;)
require us to recognize the fair value of these warrants as warrant liabilities on our Consolidated Balance Sheets and to reflect period-to-period
changes in the fair value of the warrant liabilities on our Consolidated Statements of Operations. </span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The estimated fair value of these
warrant liabilities was $0.8 million and $1.7 million at December&#160;31, 2022 and 2021, respectively. There were 1,349,571 of these
warrants outstanding at December&#160;31, 2022 and 248,162 of these warrants outstanding at December&#160;31, 2021.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On December 22, 2022, as part of the convertible debenture financing, the Company issued to
Alpha a common stock warrant to purchase a number of shares of the common stock of the Company equal to the number of Conversion Shares
issuable upon conversion of the Debenture as of the closing date. The exercise price of the warrant is $1.65 (equal to 125% of the Conversion
Price of the Debenture on the closing date). The warrant entitles Alpha to purchase up to 2,500,000 shares of common stock of the Company
and may be exercised by Alpha, in whole or in part, at any time on or after June 22, 2023 and before June 22, 2028. U.S. GAAP requires
us to recognize the fair value of these warrants as warrant liabilities on our Consolidated Balance Sheets and to reflect period-to-period
changes in the fair value of the warrant liabilities on our Consolidated Statements of Operations. The estimated fair value of this warrant
liability was $2.8 million and $0 at December&#160;31, 2022 and 2021, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Because
the fair value of the above liability classified warrants will be determined each quarter on a &#8220;mark-to-market&#8221; basis , it
could result in significant variability in our future quarterly and annual Consolidated Statement of Operations and Consolidated Balance
Sheets based on changes in our public market common stock price. Pursuant to U.S. GAAP, a quarter-to-quarter increase in our stock price
would result in an increase (possibly quite large) in the fair value of the warrant liabilities and a quarter-to-quarter decrease in
our stock price would result in a decrease (possibly quite large) in the fair value of the warrant liabilities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 31; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Results
of Operations</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Comparison
of the Years Ended December 31, 2022 and 2021</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">For the Years Ended<br /> December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; padding-left: 0pt">REVENUES</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 60%; text-align: left; padding-left: 10pt">Net product sales</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">4,983,556</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">5,021,721</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt">License revenue</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">632,004</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 20pt">Total revenues</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,983,556</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,653,725</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; padding-left: 0pt">EXPENSES</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10pt">Cost of product sales</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,302,755</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,332,485</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt">General and administrative</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">10,835,647</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">11,724,964</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10pt">Research and development</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6,837,133</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">11,716,718</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt">Sales and marketing</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">950,420</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">542,594</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt">Goodwill and fixed asset impairment</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">4,239,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 20pt">Total expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">27,164,955</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">28,316,761</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; padding-left: 0pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-left: 0pt">LOSS FROM OPERATIONS</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(22,181,399</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(22,663,036</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; padding-left: 0pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-left: 0pt">OTHER EXPENSE (INCOME), NET</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10pt">(Gain) loss on change in fair value of warrant liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(907,203</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(4,723,187</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt">Interest (income) expense, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">26,646</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(42,693</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt">Other income, net</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1,125</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(5,446</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 20pt">Total other expense (income), net</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(881,682</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(4,771,326</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; padding-left: 0pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-left: 0pt">LOSS BEFORE (BENEFIT) PROVISION FOR INCOME TAXES</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(21,299,717</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(17,891,710</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; padding-left: 0pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt; padding-left: 0pt">(BENEFIT) PROVISION FOR INCOME TAXES</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(265,074</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">5,427</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; padding-left: 0pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-left: 0pt">NET LOSS</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(21,034,643</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(17,897,137</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0pt">Net loss attributable to noncontrolling interest</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(2,394,100</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; padding-left: 0pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt; padding-left: 0pt">Net loss attributable to Qualigen Therapeutics, Inc.</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(18,640,543</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(17,897,137</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; padding-left: 0pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-left: 0pt">Other comprehensive loss, net of tax</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0pt">Net loss</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(21,034,643</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(17,897,137</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt">Foreign currency translation adjustment</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">50,721</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0pt">Other comprehensive loss</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(20,983,923</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(17,897,137</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0pt">Comprehensive loss attributable to noncontrolling interest</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(2,394,100</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt; padding-left: 0pt">Comprehensive loss attributable to Qualigen Therapeutics, Inc.</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(18,589,823</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(17,897,137</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Revenues</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
operating revenues are primarily generated from sales of our FastPack diagnostic tests. Revenues for the year ended December 31,
2022 were approximately $5.0 million compared to approximately $5.7 million for the year ended December 31, 2021, a decrease of $0.7
million. This decrease was primarily due to the recognition of approximately $0.6 million in license revenue from Yi Xin under the
Technology Transfer Agreement for the year ended December 31, 2021, compared with no license revenue for the year ended December 31,
2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Net
product sales</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
product sales are primarily generated from sales of our diagnostic tests. Net product sales for the year ended December 31, 2022 were
$5.0 million, which remained largely consistent with $5.0 million for the year ended December 31, 2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 32; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>License
Revenue</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">License
revenue for the year ended December 31, 2021 was $0.6 million, due to the recognition of revenue from Yi Xin under the Technology Transfer
Agreement. There was no license revenue for the year ended December 31, 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Expenses</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Cost
of Product Sales</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cost
of product sales for the year ended December 31, 2022 were $4.3 million, which remained largely consistent with $4.3 million for the
year ended December 31, 2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>General
and Administrative Expenses</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">General
and administrative expenses decreased from $11.7 million for the year ended December 31, 2021 to $10.8 million the year ended December
31, 2022. This decrease was due to a $0.3 million decrease in professional fees, a $0.3 million decrease in payroll-related expenses,
a $0.3 million decrease in insurance expenses, and a $0.3 million decrease in investor relations expenses, offset by increases of $0.2
million in legal expenses and $0.1 million in rent.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Research
and Development Costs</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and development costs include therapeutics and diagnostics research and product development costs. Research and development costs decreased
from $11.7 million for the year ended December 31, 2021 to $6.8 million for the year ended December 31, 2022. Of the $6.8 million of
research and development costs for year ended December 31, 2022, $4.5 million (66%) was attributable to therapeutics and $2.3 million
(34%) was attributable to diagnostics. Of the $11.7 million of research and development costs for the year ended December 31, 2021, $10.3
million (88%) was attributable to therapeutics and $1.4 million (12%) was attributable to diagnostics.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
increase in diagnostic research and development costs was primarily due to $0.9 million in R&amp;D expenses assumed in connection with
the acquisition of NanoSynex. The decrease in therapeutics research and development costs was primarily due to a decrease of $6.4 million
in expenses related to the potential application of QN-165 for the treatment of COVID-19 ($4.6 million in drug compound manufacturing
costs, and  $1.8 million in other pre-clinical research costs), as well as pre-clinical research and development cost decreases
of $0.2 million for QN-247, a decrease in legal expenses of $0.3 million, a decrease of $0.3 million in payroll-related expenses, offset
by an increase in QN-302 spending of $1.1 million and an increase in RAS expenses of $0.3 million.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the future, we expect our therapeutic research and development costs to continue to significantly outweigh our diagnostic research and
development costs, and to be relatively lower in periods when we are focusing on pre-clinical activities and meaningfully higher in periods
when we are provisioning for and conducting clinical trials, if any.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Sales
and Marketing Expenses</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sales
and marketing expenses for the year ended December 31, 2022 increased to $1.0 million as compared to $0.5 million for the year ended
December 31, 2021, primarily due to an increase in payroll-related expenses as a result of the termination of the Sekisui distribution
agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Goodwill
and Fixed Asset Impairment</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a result of annual goodwill impairment testing, we recognized a $4.2 million non-cash goodwill and fixed asset impairment charge in the valuation of
our business acquisition of NanoSynex for the year ended December 31, 2022. For more information, refer to Note 1 - Organization and
Summary of Significant Accounting Policies and Estimates and Note 7 - Goodwill, IPR&amp;D and other Intangibles of the consolidated financial
statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 33; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Other
Expense (Income)</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Change
in Fair Value of Warrant Liabilities</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year ended December 31, 2022 we experienced (primarily due to a decrease in our stock price during the period) a $0.9 million gain
in other income because of the change in fair value of the warrant liabilities arising from our liability classified warrants described
above. The estimated fair value of these warrants increased to $3.6 million as of December 31, 2022 from $1.7 million as of December
31, 2021 primarily due to the issuance of a new warrant as part of the convertible debt-related party financing transaction, offset by a reduction
in fair value of the other liability classified warrants. For the year ended December 31, 2021, the gain on change in fair value of warrant
liabilities was $4.7 million due to an associated decrease in the market price of our common stock. Typically, a decline in our stock
price would result in a decline in the fair value of our warrant liabilities, generating a gain, while an increase in our stock price
would result in an increase in the fair value of our warrant liabilities, generating a loss.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Because
the fair value of the warrant liabilities will be determined each quarter on a &#8220;mark-to-market&#8221; basis, this item is likely
to continue to result in significant variability in our future quarterly and annual Consolidated Statements of Operations based on unpredictable
changes in our public market common stock price and the number of warrants outstanding at the end of each quarter.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Interest
(Income) Expense, Net</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
was $27,000 in net interest expense during the year ended December 31, 2022 compared to net interest income of $43,000 during the year
ended December 31, 2021. During the year ended December 31, 2022, we issued convertible debt which resulted in an increase of $47,000
in interest expense offset by a reduction of $20,000 in interest income compared to the year ended December 31, 2021, primarily due to
lower interest bearing cash balances.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Other Income, Net</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other income was immaterial during the years ended December 31, 2022 and 2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Liquidity
and Going Concern</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2022, we had approximately $7.0 million in cash. We have incurred recurring losses from operations and have an accumulated
deficit of $103.4 million at December 31, 2022. We expect to continue to incur losses subsequent to the consolidated balance sheet date
of December 31, 2022. For the years ended December 31, 2022 and 2021, we used cash of $13.2 million and $14.7 million, respectively,
in operations. We currently expect our cash balances to fund operations into the third quarter of 2023. As a pre-clinical development-stage
therapeutics biotechnology company, we expect to continue to have net losses and negative cash flow from operations, which over time
will challenge our liquidity. These factors raise substantial doubt regarding our ability to continue as a going concern for the one-year
period following the date that these financial statements were issued.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">There is no assurance that we
will ever achieve profitable operations, or, if achieved, could be sustained on a continuing basis. In order to fully execute our business
plan, we will require significant additional financing for planned research and development activities, capital expenditures, clinical
and pre-clinical testing for QN-302 clinical trials, to continue preclinical development of RAS, and to continue funding the NanoSynex
operations (See Note 3-Acquisition), as well as commercialization activities.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Historically, our principal sources
of cash have, in addition to revenue from FastPack product sales and license revenues, included proceeds from the issuance of common and
preferred equity and proceeds from the issuance of debt. In December 2021, we raised $8.8 million from the issuance of common stock to
several institutional investors, and in December 2022 we raised approximately $3.0 million from the sale of a convertible debenture to Alpha.
There can be no assurance that further financing can be obtained on favorable terms, or at all. If we are unable to obtain funding, we
could be required to delay, reduce or eliminate research and development programs, product portfolio expansion or future commercialization
efforts, which could adversely affect our business prospects.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
the extent that we raise additional capital through the sale of equity or convertible debt securities, the ownership interests of our
common stockholders will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect
the rights of our common stockholders. Debt financing, if available, may involve agreements that include covenants limiting or restricting
our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. If we raise
additional funds through government or other third-party funding, commercialization, marketing and distribution arrangements or other
collaborations, strategic alliances or licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies,
future revenue streams, research programs or product candidates or to grant licenses on terms that may not be favorable to us. In addition,
any future financing (depending on the terms and conditions) may be subject to the approval of Alpha under the terms of the Debenture
and/or trigger certain adjustments to the Debenture or warrants held by Alpha.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">As a condition to the
NanoSynex closing, the Company agreed to provide NanoSynex with up to $10.4 million of future funding based on NanoSynex&#8217;s
achievement of certain future development milestones and subject to other terms and conditions described in the Master Agreement for
the Operational and Technological Funding of NanoSynex (the &#8220;Funding Agreement&#8221;) entered into with NanoSynex. These
funding commitments are in the form of convertible promissory notes to be issued to the Company with a face value equal to the
amount paid by the Company to NanoSynex upon satisfaction of the applicable performance milestone, bearing interest at the rate of
9% per annum on the principal balance from time to time outstanding under the particular promissory note, convertible at the option
of the Company into additional shares of NanoSynex in order for the Company to maintain at least a 50.1% controlling ownership
interest in NanoSynex, should NanoSynex issue additional shares. The principal of the convertible notes are due and payable upon the
sooner to occur of: i) five years from the date of issuance of the particular promissory note; ii) the acquisition by any person or
entity of all or substantially all of the share capital of NanoSynex, through share purchase, issuance or shares or merger of
NanoSynex, or the purchase of all or substantially all of the assets of NanoSynex; or iii) the initial public offering of NanoSynex.
The Company provided funding to NanoSynex of $2.4 million during 2022 and an additional $0.5 million in February 2023 pursuant to
this agreement. The Company may terminate the Funding Agreement upon 120 days&#8217; notice, but would still be liable for any
payments due for milestones achieved prior to termination.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying financial statements have been prepared assuming that the Company will continue as a going concern. The financial statements
do not include any adjustments that would be necessary should the Company be unable to continue as a going concern, and therefore, be
required to liquidate its assets and discharge its liabilities in other than the normal course of business and at amounts that may differ
from those reflected in the accompanying financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 34; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
consolidated balance sheet at December 31, 2022 includes $3.6 million of current warrant liabilities. We do not consider the warrant
liabilities to constrain our liquidity, as a practical matter. Our current liabilities at December 31, 2022 also include $0.9
million of accounts payable, $0.5 million of accrued vacation pay, $1.5 million of accrued expenses and other current liabilities, a $0.8 million R&amp;D grant
liability, $0.2 million in operating lease liabilities, $0.1 million of notes payable (convertible debt to a related party), and $1.0 million in short term debt to a related party.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Contractual
Obligations and Commitments</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have no material contractual obligations that are not fully recorded on our consolidated balance sheets or fully disclosed in the notes
to the financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Lease
Agreement with Bond Ranch LP</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 15, 2021, our wholly-owned subsidiary Qualigen, Inc. entered into a Second Amendment to Lease with Bond Ranch LP. This Amendment
extended the Company&#8217;s triple-net leasehold on its existing 22,624-square-foot headquarters/manufacturing facility at 2042 Corte
del Nogal, Carlsbad, California for the 61-month period of November 1, 2022 to November 30, 2027. Over the 61 months, the base rent payable
will total $1,950,710; however, the base rent for the first 12 months of the 61-month period will be only $335,966. Additionally, Qualigen,
Inc. was entitled to a $339,360 tenant improvement allowance. See Note 13-Commitments and Contingencies of the consolidated financial
statements for additional details.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>License
and Sponsored Research Agreements</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We have obligations under various
license and sponsored research agreements to make future payments to third parties that become due and payable on the achievement of certain
development, regulatory and commercial milestones (such as the start of a clinical trial, filing for product approval with the FDA or
other regulatory agencies, product approval by the FDA or other regulatory agencies, product launch or product sales) or on the sublicense
of our rights to another party. We have not included these commitments on our balance sheet because the achievement and timing of these
events is not determinable. Certain milestones are in advance of receipt of revenue from the sale of products and, therefore, we may require
additional debt or equity capital to make such payments.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have multiple license and sponsored research agreements with UofL Research Foundation (&#8220;ULRF&#8221;). Under these agreements, we
have taken over development, regulatory approval and commercialization of various drug compounds from ULRF and are responsible for maintenance
of the related intellectual property portfolio. We agreed to reimburse ULRF for sponsored research expenses of up to $2.7 million and
prior patent costs of up to $112,000 for RAS. As of December 31, 2022 we had up to $748,000 remaining due under this sponsored research
agreement for RAS. We also agreed to reimburse ULRF for sponsored research expenses of up to $830,000 and prior patent costs of up to
$200,000 for QN-247. As of December 31, 2022, there were no remaining un-expensed amounts under this sponsored research agreement for
QN-247 and the agreement was terminated effective August 31, 2022. We also agreed to reimburse ULRF for sponsored research expenses of
up to $430,000 and prior patent costs of up to $24,000 for QN-165. As of December 31, 2022 we had no remaining un-expensed amounts under
this sponsored research agreement for QN-165, and the agreement was terminated effective November 30, 2021. Under the terms of these
agreements, we are required to make patent maintenance payments and payments based upon development, regulatory and commercial milestones
for any products covered by the in-licensed intellectual property. The maximum aggregate milestone payments we may be obligated to make
per product are $5 million. We will also be required to pay a royalty on net sales of products covered by the in-licensed intellectual
property in the low single digits. The royalty is subject to reduction for any third-party payments required to be made, with a minimum
floor in the low single digits. We have the right to sublicense our rights under these agreements, and we will be required to pay a percentage
of any sublicense income.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 13, 2022, we entered into a License Agreement with UCL Business Limited to obtain an exclusive worldwide in-license of a genomic
quadruplex (G4)-selective transcription inhibitor drug development program which had been developed at University College London, including
lead and back-up compounds, preclinical data and a patent estate. (UCL Business Limited is the commercialization company for University
College London.) The program&#8217;s lead compound will be further developed at Qualigen under the name QN-302 as a candidate for treatment
of pancreatic ductal adenocarcinoma (PDAC), which represents the vast majority of pancreatic cancers. The Agreement requires (if and
when applicable) tiered royalty payments in the low to mid-single digits, clinical/regulatory/sales milestone payments, and a percentage
of any non-royalty sublicensing consideration paid to Qualigen.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Termination
of Sekisui Distribution Agreement</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Following
the expiration of the Sekisui Distribution Agreement on March 31, 2022, the Company has a commitment to purchase leased FastPack rental
systems back from Sekisui at its net book value, in the amount of $154,000 which is included in equipment held for lease and accrued
expenses and other current liabilities on the consolidated balance sheet.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Technology
Transfer Agreement with Yi Xin</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Through
our wholly-owned diagnostics subsidiary Qualigen, Inc., we entered into a Technology Transfer Agreement dated as of October 7, 2020,
with Yi Xin, of Suzhou, China, which authorizes Yi Xin to develop, manufacture and sell new generations of diagnostic test systems based
on our core FastPack technology. In addition, the Technology Transfer Agreement authorizes Yi Xin to manufacture and sell our current
generations of FastPack System diagnostic products (1.0, IP and PRO) in China. We have provided technology transfer and patent/know-how
license rights to facilitate Yi Xin&#8217;s development and commercialization.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 35; Options: NewSection; Value: 35 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the terms of the Technology Transfer Agreement, we have provided Yi Xin the exclusive rights for China &#8211; which is a market we have
not otherwise entered &#8211; both for Yi Xin&#8217;s new generations of FastPack-based products and for Yi Xin-manufactured versions
of our existing FastPack product lines. Yi Xin has the right to sell its new generations of FastPack-based diagnostic test systems throughout
the world (but not to or toward current customers of our existing generations of FastPack products); provided that any non-China sales
would, until March 31, 2022, need to be through Sekisui. As of April 1, 2022, Yi Xin has right to sell Yi Xin-manufactured versions of
existing FastPack 1.0, IP and PRO product lines worldwide (other than in the United States and other than to or toward current non-US
customers of those products). Yi Xin also has the right, as of April 1, 2022, to buy Qualigen-manufactured FastPack 1.0, IP and PRO products
from us at distributor prices for resale in and for the United States (but not to or toward current U.S. customers of those products).
We did not license Yi Xin to sell in the United States market any Yi Xin-manufactured versions of those legacy FastPack product lines,
even after March 31, 2022. We agreed in the Technology Transfer Agreement that we would not, after March 31, 2022, seek new FastPack
customers outside the United States.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the Technology Transfer Agreement, we have received total net cash payments of approximately $670,000, of which approximately $632,000
was classified as license revenue, and approximately $38,000 is classified as product sales on the statement of operations for the fiscal
year ended December 31, 2021. There were no revenues under this agreement for the fiscal year ended December 31, 2022. We will receive
low- to mid-single-digit royalties on any future new-generations and current-generations product sales by Yi Xin.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Yi
Xin is a newly-formed company and is subject to many risks. There can be no assurance that Yi Xin will successfully commercialize any
products or that we will receive any royalties from Yi Xin.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><b><i>Alpha
Convertible Debt</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 22, 2022, we issued an 8% Senior Convertible Debenture in the aggregate principal amount of $3,300,000 to Alpha for a purchase
price of $3,000,000 pursuant to the terms of a Securities Purchase Agreement, dated December 21, 2022 (the &#8220;Alpha Purchase Agreement&#8221;).
The Debenture is convertible, at any time, and from time to time, at Alpha&#8217;s option, into shares of our common stock (the &#8220;Conversion
Shares&#8221;), at a price equal to $1.32 per share, subject to adjustment as described in the Debenture (the &#8220;Conversion Price&#8221;)
and other terms and conditions described in the Debenture, including the Company&#8217;s receipt of the requisite stockholder approvals.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Commencing
June 1, 2023 and continuing on the first day of each month thereafter until the earlier of (i) December 22, 2025 and (ii) the full redemption
of the Debenture, we must redeem $110,000 plus accrued but unpaid interest, liquidated damages and any amounts then owing under the Debenture.
The Monthly Redemption Amount must be paid in cash; provided that after the first two monthly redemptions, we may elect to pay all or
a portion of a Monthly Redemption Amount in shares of our common stock, based on a conversion price equal to the lesser of (i) the then
applicable conversion price of the Debenture and (ii) 85% of the average of the VWAPs (as defined in the Debenture) for the five consecutive
trading days ending on the trading day that is immediately prior to the applicable Monthly Redemption Date. We may also redeem some or
all of the then outstanding principal amount of the Debenture at any time for cash in an amount equal to 105% of the then outstanding
principal amount of the Debenture being redeemed plus accrued but unpaid interest, liquidated damages and any amounts then owing under
the Debenture. These monthly redemption and optional redemptions are subject to the satisfaction of the Equity Conditions (as defined
in the Debenture), which includes a condition that we have obtained stockholder approval for such share issuances.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Debenture accrues interest at the rate of 8% per annum, which does not begin accruing until December 1, 2023, and will be payable on
a quarterly basis. Interest may be paid in cash or shares of common stock of the Company or a combination thereof at the option of the
Company; provided that interest may only be paid in shares if the Equity Conditions have been satisfied, including the stockholder approval
condition as described above.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Nanosynex
Funding Agreement</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a condition to the NanoSynex acquisition, we entered into a Master Agreement for the Operational and Technological Funding of NanoSynex
(the &#8220;Funding Agreement&#8221;), on May 26, 2022, pursuant to which we have agreed to fund NanoSynex up to an aggregate of approximately
$10.4 million over the next three years, subject to NanoSynex&#8217;s achievement of certain performance milestones specified in the
Funding Agreement and the satisfaction of other terms and conditions described in the Funding Agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 36; Value: 35 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
will receive in exchange for any payment made to NanoSynex under the Funding Agreement one or more promissory notes (which may contain
convertible features) with a face value equal to the amount paid by the Company to NanoSynex upon satisfaction of the applicable performance
milestones. Any promissory notes issued to us by NanoSynex under the Funding Agreement will bear interest at a rate of 9.00% per annum
on the principal balance from time to time outstanding under the promissory note. The principal and interest under any promissory note
issued to us under the Funding Agreement will be due and payable upon the sooner to occur of: (i) five years from the date of the particular
promissory note; (ii) the acquisition by any person or entity of all or substantially all of the share capital of NanoSynex, through
share purchase, issuance of shares or merger of NanoSynex or the purchase of all or substantially all of the assets of NanoSynex; or
(iii) the initial public offering of NanoSynex. If at any time, our ownership of the share capital of NanoSynex on an issued and outstanding
basis falls or is reasonably expected to fall below 50.1%, solely as a result of the exercise of existing or future options (or an equivalent
instrument) or as a result of issuance of restricted, shares, restricted stock units (or an equivalent instruments), we, in our sole
discretion, may elect to convert all or any portion of the outstanding principal amount of any promissory note into shares of NanoSynex&#8217;s
most senior class of preferred shares existing immediately prior to such conversion, subject to the terms and conditions described in
the promissory notes so that, following such conversion, we will regain 50.1% ownership of NanoSynex&#8217;s issued and outstanding share
capital. During the year ended December 31, 2022 a total of approximately $2.4 million was funded and in February 2023 and additional $0.5 million was funded to NanoSynex under the Funding Agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Other
Service Agreements</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
enter into contracts in the normal course of business, including with clinical sites, contract research organizations, and other professional
service providers for the conduct of clinical trials, contract manufacturers for the production of our product candidates, contract research
service providers for preclinical research studies, professional consultants for expert advice and vendors for the sourcing of clinical
and laboratory supplies and materials. These contracts generally provide for termination on notice, and therefore are cancelable contracts.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Cash
Flows</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table sets forth the significant sources and uses of cash for the periods set forth below:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center">For the Years Ended</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Net cash (used in) provided by:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 60%; text-align: left; padding-left: 10pt">Operating activities</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">(13,247,540</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">(14,730,742</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10pt">Investing activities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(183,763</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(141,364</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt">Financing activities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,910,515</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">8,433,808</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt">Effect of exchange rate on cash</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">22,639</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Net decrease in cash and restricted cash</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">(10,498,149</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">(6,438,298</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Net
Cash Used in Operating Activities</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year ended December 31, 2022, operating activities used $13.2 million of cash, primarily resulting from a net loss of $21.0 million.
Cash flows from operating activities (as opposed to net loss) for the year ended December 31, 2022 were positively impacted by adjustments
for $5.4 million in non cash stock-based compensation expense, a $4.2 million non cash goodwill impairment charge related to the acquisition
of Nanosynex, $0.1 million in depreciation and amortization, as well as $0.4 million decrease in accounts receivable. Cash flows from
operating activities (as opposed to net loss) for the year ended December 31, 2022 were negatively impacted by a $1.0 million gain on
change in fair value of warrant liabilities (as described above), a $0.6 million increase in inventory and equipment held for lease,
a $0.5 million decrease in R&amp;D grant liability which was offset against NanoSynex R&amp;D expenses, a $0.3 million decrease in deferred
tax liability, a $0.1 million increase in prepaid expenses and other assets, and a $0.1 million decrease in accounts payable and accrued
expenses.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year ended December 31, 2021, operating activities used $14.7 million of cash, primarily resulting from a net loss of $17.9 million.
Cash flows from operating activities (as opposed to net loss) for the twelve months ended December 31, 2021 were positively impacted
by adjustments for $5.6 million in non cash stock-based compensation expenses, a $1.3 million decrease in prepaid expenses and other
assets, a $1.0 million increase in accrued expenses and other current liabilities and a $0.4 million increase in accounts payable, due
to higher costs related to therapeutics research and development. The decrease in prepaid expenses reflected in the statements of cash
flows from operating activities was primarily due to the expensing during the period of $1.2 million of previous prepayments to STA Pharmaceutical
Co., Ltd., a subsidiary of WuXi AppTec, which was our manufacturer of QN-165 drug compounds. Cash flows from operating activities (as
opposed to net loss) for the twelve months ended December 31, 2021 were negatively impacted by a $4.7 million gain on change in fair
value of warrant liabilities (as described above), and a $0.4 million decrease in deferred revenue primarily resulting from recognition
of Yi Xin license revenue.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Net
Cash Used in Investing Activities</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year ended December 31, 2022, net cash used in investing activities was approximately $0.2 million, due to capital expenditures offset
by cash acquired in the NanoSynex acquisition.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year ended December 31, 2021, net cash used in investing activities was approximately $0.1 million, primarily related to the purchase
of property and equipment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Net
Cash Provided by Financing Activities</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
cash provided by financing activities for the year ended December 31, 2022, was approximately $2.9 million, due to the issuance of convertible
debt to Alpha.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
cash provided by financing activities for the year ended December 31, 2021 was approximately $8.4 million, due to $8.8 million of proceeds
from sales of equity securities in a registered-direct offering to several institutional investors, and $0.5 million of net proceeds
from warrant exercises, offset by $0.7 million in payments for offering costs related to the registered-direct offering and $0.1 million
of principal payments on notes payable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="bs_012"></span>Item
7A. Quantitative and Qualitative Disclosures about Market Risk.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We are a <i>smaller reporting</i> company as defined by Rule <span style="text-decoration: underline">12b-2</span> of the Exchange Act and are not required
to provide the information otherwise required under this Item.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span>&#160;</p>


<!-- Field: Page; Sequence: 37; Value: 35 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="bs_013"></span>Item
8. Consolidated Financial Statements and Supplementary Data</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><b>INDEX TO CONSOLIDATED FINANCIAL STATEMENTS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><b>&#160;<br /></b></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; width: 92%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-align: center; width: 8%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Page</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#sj_001">Report of Independent Registered Public Accounting Firm</a> (PCAOB ID: <span id="xdx_903_edei--AuditorFirmId_c20220101__20221231_zdcV3m1r7e5c"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="dei:AuditorFirmId">23</ix:nonNumeric></span>)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">38</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#sj_002">Consolidated Balance Sheets</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">41</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#sj_003">Consolidated Statements of Operations and Comprehensive Loss</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">42</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#sj_004">Consolidated Statements of Stockholders&#8217; Equity</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">43</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#sj_005">Consolidated Statements of Cash Flows</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">44</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#sj_006">Notes to Consolidated Financial Statements</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">45</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="sj_001"></span>REPORT
OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM (PCAOB ID <span id="xdx_906_edei--AuditorFirmId_c20220101__20221231_z2ZHByUYlbFj"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="dei:AuditorFirmId">23</ix:nonNumeric></span>)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
the Board of Directors and Stockholders of Qualigen Therapeutics, Inc.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Opinion
on the Financial Statements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have audited the accompanying consolidated balance sheets of Qualigen Therapeutics, Inc. (the &#8220;Company&#8221;) as of December
31, 2022 and December 31, 2021, the related consolidated statements of operations and comprehensive loss, stockholders&#8217; equity
and cash flows for each of the two years in the period ended December 31, 2022, and the related notes (collectively referred to as
the &#8220;consolidated financial statements&#8221;). In our opinion, the consolidated financial statements present fairly, in all
material respects, the financial position of the Company as of December 31, 2022 and December 31, 2021, and the results of its
operations and its cash flows for each of the two years in the period ended December 31, 2022, in conformity with accounting
principles generally accepted in the United States of America.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Going
Concern Uncertainty</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The accompanying
consolidated financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note
2 to the consolidated financial statements, the Company&#8217;s current liquidity position and projected cash needs raise substantial
doubt about its ability to continue as a going concern. Management&#8217;s plans regarding these matters are also described in Note 2.
The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Basis
for Opinion</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
consolidated financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an
opinion on the Company&#8217;s consolidated financial statements based on our audits. We are a public accounting firm registered with the Public
Company Accounting Oversight Board (United States) (&#8220;PCAOB&#8221;) and are required to be independent with respect to the
Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange
Commission and the PCAOB.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to
obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to
error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial
reporting. As part of our audits, we are required to obtain an understanding of internal control over financial reporting but not for
the purpose of expressing an opinion on the effectiveness of the Company&#8217;s internal control over financial reporting.
Accordingly, we express no such opinion.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
audits included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether
due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis,
evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the
accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the
consolidated financial statements. We believe that our audits provide a reasonable basis for our opinion.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Critical
Audit Matters</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
critical audit matters communicated below are matters arising from the current period audit of the financial statements that were communicated
or required to be communicated to the audit committee and that: (1) relate to accounts or disclosures that are material to the financial
statements and (2) involved our especially challenging, subjective, or complex judgments. The communication of critical audit matters
does not alter in any way our opinion on the financial statements, taken as a whole, and we are not, by communicating the critical audit
matters below, providing separate opinions on the critical audit matters or on the accounts or disclosures to which they relate.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt">Valuation of Intangible Assets &#8211; Business Combination<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Critical
Audit Matter Description</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
described in Note 3 of the consolidated financial statements, the Company completed its majority interest acquisition of NanoSynex,
Ltd. (&#8220;NanoSynex&#8221;) on May 26, 2022, in a business combination. In connection with this acquisition, the Company recorded
an in-process research and development (&#8220;IPR&amp;D&#8221;) intangible asset in the amount of $5.7 million based
on the fair value of the IPR&amp;D at the acquisition date. The fair value of this acquired intangible asset was estimated using the excess
earnings method which is a form of an income-based approach. The excess earnings valuation model requires certain significant assumptions in estimating fair value of the IPR&amp;D.</span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 38; Value: 35 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
identified the assessment of the fair value of the IPR&amp;D intangible asset as a critical audit matter. This required a high
degree of auditor judgment and an increased audit effort in determining the reasonableness of the fair value of the IPR&amp;D due to
the measurement uncertainty related to the selection of the valuation methodology and the significant assumptions used in the estimation.</span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>How
We Addressed the Matter in Our Audit</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
primary procedures we performed to address this critical audit matter included:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>



<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="text-align: justify; width: 0.5in"></td><td style="text-align: justify; width: 0.5in">&#9679;</td><td style="text-align: justify">Obtaining an understanding of the Company&#8217;s process and control over the valuation of
                                                                                                                                                         IPR&amp;D intangible asset including the significant assumptions used in the valuation.</td></tr>
<tr style="vertical-align: top">
<td style="text-align: justify">&#160;</td><td style="text-align: justify">&#160;</td><td style="text-align: justify">&#160;</td></tr>
<tr style="vertical-align: top">
<td style="text-align: justify"></td><td style="text-align: justify">&#9679;</td><td style="text-align: justify">Testing the clerical accuracy of the valuation model prepared by the Company&#8217;s specialist.</td></tr>
<tr style="vertical-align: top">
<td style="text-align: justify">&#160;</td><td style="text-align: justify">&#160;</td><td style="text-align: justify">&#160;</td></tr>
<tr style="vertical-align: top">
<td style="text-align: justify"></td><td style="text-align: justify">&#9679;</td><td style="text-align: justify">Evaluating the reasonableness of the key assumptions by considering past performance and third-party market data where appropriate,
and whether such assumptions were consistent with our understanding and evidence obtained in other areas of the audit.</td></tr>
<tr style="vertical-align: top">
<td style="text-align: justify">&#160;</td><td style="text-align: justify">&#160;</td><td style="text-align: justify">&#160;</td></tr>
<tr style="vertical-align: top">
<td style="text-align: justify"></td><td style="text-align: justify">&#9679;</td><td style="text-align: justify">Involving internal valuation professionals as an auditor&#8217;s specialist to assist in evaluating the valuation methodology used
by management by comparing with methodologies commonly used to value IPR&amp;D intangible assets and to review and opine on significant
assumptions utilized in the valuation model.</td></tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Goodwill and IPR&amp;D Impairment Assessment</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><i>Critical Audit Matter Description</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify">As described in Notes 1 and 7 to the consolidated
financial statements, the Company recorded goodwill and indefinite-lived intangible assets in connection with its acquisition of majority
ownership of NanoSynex. Goodwill represents the excess of the purchase price over the fair market value of assets acquired and liabilities
assumed, and the intangible asset represents the estimated acquisition date fair value of acquired IPR&amp;D. Goodwill and indefinite-lived
intangible assets are tested for impairment at least annually, or more frequently if events or changes in circumstances indicate that
these assets may be impaired. Goodwill is tested for impairment at the reporting unit level and indefinite-lived intangible assets are
tested at the individual asset level. The Company determined that its goodwill was impaired and recorded an impairment loss of approximately
$4.2 million.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify">Management&#8217;s estimates of the fair value
of the reporting unit and of the IPR&amp;D were determined using the discounted cash flow method and excess earnings method, respectively.
The determination of fair value using these income approach techniques involves significant assumptions which are highly subjective.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify">We identified goodwill and IPR&amp;D impairment
assessments as a critical audit matter due to the significant judgment and subjectivity exercised by management when developing the fair
value measurements, and a high degree of auditor judgment and an increased audit effort required in evaluating management&#8217;s significant
assumptions.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><i>How We Addressed the Matter in Our Audit</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify">The primary procedures we performed to address this critical
audit matter included:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="text-align: justify; width: 0.5in"></td><td style="text-align: justify; width: 0.5in">&#9679;</td><td style="text-align: justify">Obtaining an understanding and evaluating the design of internal controls related to the impairment of goodwill and IPR&amp;D.</td></tr>
<tr style="vertical-align: top">
<td style="text-align: justify">&#160;</td><td style="text-align: justify">&#160;</td><td style="text-align: justify">&#160;</td></tr>
<tr style="vertical-align: top">
<td style="text-align: justify"></td><td style="text-align: justify">&#9679;</td><td style="text-align: justify">Evaluating the appropriateness of methods used in developing the fair value measurements by management.</td></tr>
<tr style="vertical-align: top">
<td style="text-align: justify">&#160;</td><td style="text-align: justify">&#160;</td><td style="text-align: justify">&#160;</td></tr>
<tr style="vertical-align: top">
<td style="text-align: justify"></td><td style="text-align: justify">&#9679;</td><td style="text-align: justify">Testing the completeness and accuracy of underlying data used in management&#8217;s fair value estimates, including mathematical accuracy.</td></tr>
<tr style="vertical-align: top">
<td style="text-align: justify">&#160;</td><td style="text-align: justify">&#160;</td><td style="text-align: justify">&#160;</td></tr>
<tr style="vertical-align: top">
<td style="text-align: justify"></td><td style="text-align: justify">&#9679;</td><td style="text-align: justify">Evaluating the reasonableness of the key assumptions by considering past performance and third-party market data where appropriate,
and whether such assumptions were consistent with our understanding and evidence obtained in other areas of the audit.</td></tr>
<tr style="vertical-align: top">
<td style="text-align: justify">&#160;</td><td style="text-align: justify">&#160;</td><td style="text-align: justify">&#160;</td></tr>
<tr style="vertical-align: top">
<td style="text-align: justify"></td><td style="text-align: justify">&#9679;</td><td style="text-align: justify">Involving internal valuation professionals as an auditor&#8217;s specialist to assist in evaluating the valuation methodologies used
by management for the goodwill impairment assessment by comparing the methodologies to those utilized by other companies holding similar
assets, and to review and opine on significant assumptions utilized in the valuation model.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<!-- Field: Page; Sequence: 39; Value: 35 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Accounting for Financial Instruments &#8211; Convertible Debt with Warrants</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><i>Critical Audit Matter Description</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify">As described in Notes 11 to the consolidated
financial statements, the Company issued a convertible debenture and common stock purchase warrants in the principal amount of $3.3M during
the year ended December 31, 2022.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify">We identified the accounting for this complex
financial instrument as a critical audit matter. This includes both the evaluation of the various features as potential embedded derivatives
and the determination of the respective fair value of the instruments and the embedded features, as well as the determination of the appropriate
classification of warrants between equity and liabilities. The application of the accounting guidance applicable to issuing a complex
financial instrument requires significant judgment.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify">Determination of appropriate classification
of warrants requires management&#8217;s judgments relating to the interpretations of relevant accounting guidance based on specific provisions
of the warrant agreement. And accounting for the convertible notes and embedded conversion features requires management&#8217;s judgments
related to initial and subsequent recognition of the debt and related features, use of a valuation model, and key inputs used in the selected
valuation model.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><i>How We Addressed the Matter in Our Audit</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify">The primary procedures we performed to address this critical
audit matter included:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="text-align: justify; width: 0.5in"></td><td style="text-align: justify; width: 0.5in">&#9679;</td><td style="text-align: justify">Obtaining an understanding of the Company&#8217;s process and controls over the execution of complex financial instruments.</td></tr>
<tr style="vertical-align: top">
<td style="text-align: justify">&#160;</td><td style="text-align: justify">&#160;</td><td style="text-align: justify">&#160;</td></tr>
<tr style="vertical-align: top">
<td style="text-align: justify"></td><td style="text-align: justify">&#9679;</td><td style="text-align: justify">Inspecting the agreements associated with the transactions and evaluating management&#8217;s technical accounting analysis, including
the identification of potential embedded derivatives, and the application of the relevant accounting literature.</td></tr>
<tr style="vertical-align: top">
<td style="text-align: justify">&#160;</td><td style="text-align: justify">&#160;</td><td style="text-align: justify">&#160;</td></tr>
<tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
  <td style="text-align: justify">&#9679;</td>
  <td style="text-align: justify">Utilizing an auditor&#8217;s specialist to assist in
  assessing management&#8217;s analysis of the transaction, including (i) evaluating the contracts to identify relevant terms that affect
  the recognition of the financial instruments, (ii) assessing the appropriateness of conclusions reached by management, and (iii)
  reviewing the valuation model for derivatives, performing independent calculations, and examining the significant assumptions
  utilized in the valuation model.</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>/s/
<span id="xdx_905_edei--AuditorName_c20220101__20221231_zzUdthd7LUgg"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="dei:AuditorName">BAKER TILLY US, LLP</ix:nonNumeric></span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have served as the Company&#8217;s auditor since 2018.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_902_edei--AuditorLocation_c20220101__20221231_zgOjT6pedPI1"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="dei:AuditorLocation">San
Diego, California</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">May 2, 2023</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>


<!-- Field: Page; Sequence: 40; Value: 35 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="sj_002"></span>QUALIGEN
THERAPEUTICS, INC.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CONSOLIDATED
BALANCE SHEETS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_30D_111_zMBE8C0vWZW7" summary="xdx: Statement - Consolidated Balance Sheets" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_494_20221231_zn7vDRgJG4C4" style="font-weight: bold; text-align: center">December 31,</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_495_20211231_zKPz65WYMI13" style="font-weight: bold; text-align: center">December 31,</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--AssetsAbstract_iB_zNRmzGEvqXNj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold">ASSETS</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--AssetsCurrentAbstract_i01B_zcBRxxBd8pt2" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">Current assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--Cash_i02I_maACzrC9_zPTV5UonyhM9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; width: 60%">Cash</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:Cash" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,034,434</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:Cash" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">17,538,272</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--AccountsReceivableNetCurrent_i02I_maACzrC9_zzw53jWIRuh1" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Accounts receivable, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccountsReceivableNetCurrent" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">538,587</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccountsReceivableNetCurrent" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">822,351</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--InventoryNet_i02I_maACzrC9_zKxS5pcvlTF1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Inventory, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:InventoryNet" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,586,297</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:InventoryNet" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,055,878</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_i02I_maACzrC9_z8jwqc5bEm28" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Prepaid expenses and other current assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,661,220</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,379,896</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--AssetsCurrent_i02TI_maAztQP_mtACzrC9_zAjYioY2ZlZ2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; text-align: left">Total current assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,820,538</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">20,796,397</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--RestrictedCashAndCashEquivalents_i01I_maAztQP_zVT4uGgDEhf9" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Restricted cash</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:RestrictedCashAndCashEquivalents" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,690</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0070">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--OperatingLeaseRightOfUseAsset_i01I_maAztQP_zjyDX6EaUOuc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Right-of-use assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,422,538</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,645,568</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--PropertyPlantAndEquipmentNet_i01I_maAztQP_zgWbuRM5IbP8" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Property and equipment, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">345,087</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">204,217</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--IntangibleAssetsNetExcludingGoodwill_i01I_maAztQP_zLNPcVjOiycl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Intangible assets, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IntangibleAssetsNetExcludingGoodwill" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,845,702</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IntangibleAssetsNetExcludingGoodwill" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">171,190</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--Goodwill_i01I_maAztQP_zbhUW0GgLYJg" style="vertical-align: bottom; background-color: White">
    <td>Goodwill</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:Goodwill" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">625,602</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0082">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--OtherAssetsNoncurrent_i01I_maAztQP_z75sjmYuLZB4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Other assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherAssetsNoncurrent" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">18,334</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherAssetsNoncurrent" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">18,334</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--Assets_i01TI_mtAztQP_zUooMWPEd0Oc" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Total Assets</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:Assets" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">19,083,491</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:Assets" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">22,835,705</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--LiabilitiesAndStockholdersEquityAbstract_iB_zkTiFoFB3pc8" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--LiabilitiesCurrentAbstract_i01B_z2JTIDP4kWCl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Current liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--AccountsPayableCurrent_i02I_maLCzXtx_zbj9Hs2mYQc8" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Accounts payable</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccountsPayableCurrent" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">857,311</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccountsPayableCurrent" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">886,224</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_ecustom--AccruedVacation_i02I_maLCzXtx_zNoEwwLymdTc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Accrued vacation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="QLGN:AccruedVacation" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">467,948</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="QLGN:AccruedVacation" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">282,910</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--AccruedLiabilitiesAndOtherLiabilities_i02I_maLCzXtx_zwPsf3VlTNee" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Accrued expenses and other current liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccruedLiabilitiesAndOtherLiabilities" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,511,856</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccruedLiabilitiesAndOtherLiabilities" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,510,990</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_ecustom--ResearchAndDevelopmentGrantLiability_i02I_maLCzXtx_zgNtYFdGc569" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">R&amp;D grant liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="QLGN:ResearchAndDevelopmentGrantLiability" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">780,682</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0106">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--DeferredIncomeCurrent_i02I_maLCzXtx_zAZ4ZYUltvri" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Deferred revenue, current portion</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredIncomeCurrent" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">116,161</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredIncomeCurrent" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">135,063</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--OperatingLeaseLiabilityCurrent_i02I_maLCzXtx_zaCMOhyR7F5k" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Operating lease liability, current portion</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">240,645</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">134,091</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--ShortTermBorrowings_i02I_maLCzXtx_zF6N659zjyF7" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Short term debt - related party</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ShortTermBorrowings" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">950,722</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0115">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--HedgingLiabilitiesCurrent_i02I_maLCzXtx_zP2fiqDlYuse" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Warrant liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:HedgingLiabilitiesCurrent" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">788,100</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:HedgingLiabilitiesCurrent" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,686,200</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_ecustom--WarrantLiabilitiesRelatedParty_i02I_maLCzXtx_z3LazdY4dTc4" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left"><p style="margin: 0">Warrant liabilities - related party</p></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="QLGN:WarrantLiabilitiesRelatedParty" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,834,547</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0121">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--ConvertibleDebt_i02I_maLCzXtx_zKJ5MwaxRST8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Convertible debt - related party</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:ConvertibleDebt" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">60,197</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0124">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--LiabilitiesCurrent_i02TI_mtLCzXtx_maLzjv3_zAlWkLNkdsd2" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left">Total current liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,608,169</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,635,479</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--OperatingLeaseLiabilityNoncurrent_i01I_maLzjv3_zgy20NYNktO7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Operating lease liability, net of current portion</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,301,919</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,542,564</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--DeferredRevenueNoncurrent_i01I_maLzjv3_zoTpTFpYyVYk" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Deferred revenue, net of current portion</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredRevenueNoncurrent" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">49,056</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredRevenueNoncurrent" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">92,928</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--DeferredIncomeTaxLiabilitiesNet_i01I_maLzjv3_zv8su2BUnd1b" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Deferred tax liability</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:DeferredIncomeTaxLiabilitiesNet" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">357,757</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0136">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--Liabilities_i01TI_mtLzjv3_maLASEz8vg_zpbQTkZIKVR1" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left">Total liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:Liabilities" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,316,901</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:Liabilities" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,270,971</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--CommitmentsAndContingencies_i01I_maLASEz8vg_zZMRBnSlwHne" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Commitments and Contingencies (Note 13)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0141">-</span></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0142">-</span></span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_i01B_zH6DkOS0XUO8" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">Stockholders&#8217; equity</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--StockholdersEquityAbstract_i01B_zsdbCUGd6VAg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Qualigen Therapeutics, Inc. stockholders&#8217; equity:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--CommonStockValue_i02I_maSEzEYY_zX6G7roHpVX1" style="vertical-align: bottom; background-color: White">
    <td>Common stock, $<span id="xdx_901_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20221231_zqDmZjBDmcaa" title="Common stock, par value"><span id="xdx_90B_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20211231_zQGlLnvQ6sU6" title="Common stock, par value"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.001</ix:nonFraction></ix:nonFraction></span></span> par value; <span id="xdx_90C_eus-gaap--CommonStockSharesAuthorized_iI_c20221231_zSHotc3b7Zai" title="Common stock, shares authorized"><span id="xdx_90A_eus-gaap--CommonStockSharesAuthorized_iI_c20211231_zqm6AwmOCZ29" title="Common stock, shares authorized"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">225,000,000</ix:nonFraction></ix:nonFraction></span></span> shares authorized; <span id="xdx_90B_eus-gaap--CommonStockSharesIssued_iI_c20221231_zabU79iDQTZ6" title="Common stock, shares issued"><span id="xdx_901_eus-gaap--CommonStockSharesOutstanding_iI_pid_c20221231_zOFnMrMbHGF" title="Common stock, shares outstanding"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">4,210,737</ix:nonFraction></ix:nonFraction></span></span> and <span id="xdx_90F_eus-gaap--CommonStockSharesIssued_iI_pid_c20211231_zUm9e0c8dZP5" title="Common stock, shares issued"><span id="xdx_90F_eus-gaap--CommonStockSharesOutstanding_iI_pid_c20211231_zd0r6UioABE7" title="Common stock, shares outstanding"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,529,018</ix:nonFraction></ix:nonFraction></span></span> shares issued and outstanding as of December 31, 2022 and December 31, 2021, respectively</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">42,110</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">35,290</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--AdditionalPaidInCapital_i02I_maSEzEYY_zvKdxTQgevgb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Additional paid-in capital</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdditionalPaidInCapital" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">110,528,050</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdditionalPaidInCapital" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">101,274,073</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--AccumulatedOtherComprehensiveIncomeLossNetOfTax_i02I_maSEzEYY_zUwq98AnBQK5" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Accumulated other comprehensive income</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">50,721</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0173">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--RetainedEarningsAccumulatedDeficit_i02I_maSEzEYY_zpRd9hw6SbC9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Accumulated deficit</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">103,385,172</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">84,744,629</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>

  <tr id="xdx_404_eus-gaap--StockholdersEquity_i02TI_mtSEzEYY_maSEIPAzxa8_zLZmWItLNX0d" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left; padding-bottom: 1.5pt">Total Qualigen Therapeutics, Inc. stockholders&#8217; equity</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,235,709</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">16,564,734</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>

  <tr id="xdx_40E_eus-gaap--MinorityInterest_i02I_maSEIPAzxa8_z0d5fUJDG9mh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Noncontrolling interest</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:MinorityInterest" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,530,881</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0182">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>

  <tr id="xdx_409_eus-gaap--StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_i02TI_mtSEIPAzxa8_maLASEz8vg_z5wxdPEgnPD4" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left; padding-bottom: 1.5pt">Total Stockholders&#8217; Equity</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,766,590</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">16,564,734</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>

  <tr id="xdx_401_eus-gaap--LiabilitiesAndStockholdersEquity_i01TI_mtLASEz8vg_zlovGe8kH8E8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Total Liabilities &amp; Stockholders&#8217; Equity</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">19,083,491</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">22,835,705</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying notes are an integral part of these consolidated financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>


<!-- Field: Page; Sequence: 41; Value: 35 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="sj_003"></span>QUALIGEN
THERAPEUTICS, INC.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CONSOLIDATED
STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<table cellpadding="0" cellspacing="0" id="xdx_304_113_zLCgqgIPApvj" summary="xdx: Statement - Consolidated Statements of Operations and Comprehensive Loss" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_495_20220101__20221231_zXlWhnHMuu5g" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_498_20210101__20211231_z5TxeJHBpcPk" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">For the Years Ended<br /> December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--RevenuesAbstract_iB_zWr9vN95fjlj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold">REVENUES</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_i01_hsrt--ProductOrServiceAxis__custom--NetProductSalesMember_zDViQxsKwTbh" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; width: 60%; text-align: left">Net product sales</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2022-01-012022-12-31_custom_NetProductSalesMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,983,556</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2021-01-012021-12-31_custom_NetProductSalesMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,021,721</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_i01_hsrt--ProductOrServiceAxis__custom--LicenseRevenueMember_zDqDhNzmRimc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">License revenue</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0196">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2021-01-012021-12-31_custom_LicenseRevenueMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">632,004</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_i01_maOILz69L_zSJLes3vf3mi" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left">Total revenues</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,983,556</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,653,725</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--OperatingCostsAndExpensesAbstract_iB_zlr36ytg0oU6" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold">EXPENSES</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_ecustom--CostOfProductSales_i01_maOEzcz3_zf7O3QK6MFC" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Cost of product sales</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="QLGN:CostOfProductSales" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,302,755</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="QLGN:CostOfProductSales" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,332,485</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--GeneralAndAdministrativeExpense_i01_maOEzcz3_ztMhvAoQj4Xb" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">General and administrative</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,835,647</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">11,724,964</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--ResearchAndDevelopmentExpense_i01_maOEzcz3_zrLO14wTmTf1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Research and development</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,837,133</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">11,716,718</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--MarketingAndAdvertisingExpense_i01_maOEzcz3_zMWklMyRwLqd" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Sales and marketing</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:MarketingAndAdvertisingExpense" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">950,420</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:MarketingAndAdvertisingExpense" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">542,594</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--GoodwillImpairmentLoss_i01_maOEzcz3_zWLrFMyz1zX6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Goodwill and fixed asset impairment</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:GoodwillImpairmentLoss" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,239,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0218">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--OperatingExpenses_i01T_mtOEzcz3_msOILz69L_z3cVOtWmLcol" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left; padding-bottom: 1.5pt">Total expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">27,164,955</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">28,316,761</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--OperatingIncomeLoss_iT_mtOILz69L_maILFCOzaCE_zbbJZzGcOMCk" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">LOSS FROM OPERATIONS</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">22,181,399</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">22,663,036</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--NonoperatingIncomeExpenseAbstract_iB_zyI82M8oyQ5j" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">OTHER EXPENSE (INCOME), NET</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--DerivativeGainLossOnDerivativeNet_i01N_di_maNIEz072_znYzdJbI3Z26" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Gain on change in fair value of warrant liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:DerivativeGainLossOnDerivativeNet" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">907,203</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:DerivativeGainLossOnDerivativeNet" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,723,187</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_404_eus-gaap--InterestIncomeExpenseNet_i01N_di_maNIEz072_zxiD4kc4THCa" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Interest (income) expense, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:InterestIncomeExpenseNet" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">26,646</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:InterestIncomeExpenseNet" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">42,693</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_401_eus-gaap--OtherNonoperatingIncomeExpense_i01N_di_maNIEz072_zlYAfD2vVRob" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Other income, net</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,125</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,446</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_40C_eus-gaap--NonoperatingIncomeExpense_i01NT_di_mtNIEz072_maILFCOzaCE_zZAK4rxv1ihd" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left; padding-bottom: 1.5pt">Total other expense (income), net</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">881,682</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,771,326</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_iT_mtILFCOzaCE_maPLzywM_zmzJabHSEUc2" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">LOSS BEFORE (BENEFIT) PROVISION FOR INCOME TAXES</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">21,299,717</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">17,891,710</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--IncomeTaxExpenseBenefit_msPLzywM_zB2AqXyf6BJ" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">(BENEFIT) PROVISION FOR INCOME TAXES</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">265,074</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,427</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--ProfitLoss_iT_mtPLzywM_maNILzqKi_zjmolVL0NO6c" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">NET LOSS</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">21,034,643</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">17,897,137</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--NetIncomeLossAttributableToNoncontrollingInterest_msNILzqKi_zBerU4m4tLxj" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Net loss attributable to noncontrolling interest</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,394,100</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0251">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--NetIncomeLoss_iT_mtNILzqKi_z7qrBrKANdHd" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Net loss attributable to Qualigen Therapeutics, Inc.</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">18,640,543</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">17,897,137</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--EarningsPerShareBasic_zij4w2aZSYqi" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Net loss per common share, basic and diluted</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">4.85</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">6.10</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  <tr id="xdx_40E_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_z6O6xJRpNUsc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Weighted&#8212;average number of shares outstanding, basic and diluted</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,840,340</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,933,487</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_iB_ztAKzjTmwgH9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Other comprehensive loss, net of tax</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--ProfitLoss_iT_maCINOTzYUh_zLyCuZrLr7Zh" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Net loss</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">21,034,643</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">17,897,137</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_408_eus-gaap--OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_i01_maCINOTzYUh_zfKjALP2Gbrk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Foreign currency translation adjustment</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">50,721</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0269">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_i01T_mtCINOTzYUh_maCINOTztU0_zJ9LAAJIFTn5" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Other comprehensive loss</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">20,983,922</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">17,897,137</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_407_eus-gaap--ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_i01_msCINOTztU0_zfajEkfjUhKk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Comprehensive loss attributable to noncontrolling interest</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,394,100</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0275">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--ComprehensiveIncomeNetOfTax_i01T_mtCINOTztU0_z5y1eUizWwIg" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Comprehensive loss attributable to Qualigen Therapeutics, Inc.</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">18,589,822</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">17,897,137</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying notes are an integral part of these consolidated financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 42; Value: 35 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="sj_004"></span>QUALIGEN
THERAPEUTICS, INC.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CONSOLIDATED
STATEMENTS OF CHANGES IN STOCKHOLDERS&#8217; EQUITY</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<table cellpadding="0" cellspacing="0" id="xdx_306_114_z9mv5XSimIhe" summary="xdx: Statement - Consolidated Statements of Changes in Stockholders&apos; Equity" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="font-weight: bold; text-align: center">&#160;</td><td id="xdx_4BA_us-gaap--StatementEquityComponentsAxis_us-gaap--PreferredStockMember_us-gaap--StatementClassOfStockAxis_custom--SeriesAlphaConvertiblePreferredStockMember_zuOeaYJneAeg" style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_4B2_us-gaap--StatementEquityComponentsAxis_us-gaap--CommonStockMember_zvunxr3kMfA8" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_4B2_us-gaap--StatementEquityComponentsAxis_us-gaap--AdditionalPaidInCapitalMember_zKQetjUqMZ45" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_4B2_us-gaap--StatementEquityComponentsAxis_us-gaap--AccumulatedOtherComprehensiveIncomeMember_z149yI1yNut8" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_4B1_us-gaap--StatementEquityComponentsAxis_us-gaap--RetainedEarningsMember_zB1v5AYsLZie" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_4B8_us-gaap--StatementEquityComponentsAxis_us-gaap--ParentMember_zT5uxk1CB039" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_4B1_us-gaap--StatementEquityComponentsAxis_us-gaap--NoncontrollingInterestMember_zxFNSvupSB5e" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_4BC_zVFotLDmsvm1" style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: center"><span style="font-size: 9pt"><b>&#160;</b></span></td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 9pt"><b>&#160;</b></span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 9pt"><b>Common
    Stock</b></span></td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 9pt"><b>&#160;</b></span></td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 9pt"><b>&#160;</b></span></td>
    <td colspan="2" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center"><span style="font-size: 9pt"><b>Additional<br />
    Paid-In</b></span></td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 9pt"><b>&#160;</b></span></td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 9pt"><b>&#160;</b></span></td>
    <td colspan="2" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center"><span style="font-size: 9pt"><b>Accumulated
    Other Comprehensive</b></span></td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 9pt"><b>&#160;</b></span></td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 9pt"><b>&#160;</b></span></td>
    <td colspan="2" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center"><span style="font-size: 9pt"><b>Accumulated</b></span></td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 9pt"><b>&#160;</b></span></td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 9pt"><b>&#160;</b></span></td>
    <td colspan="2" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center"><span style="font-size: 9pt"><b>Total Qualigen Therapeutics, Inc. Stockholders&#8217;</b></span></td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 9pt"><b>&#160;</b></span></td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 9pt"><b>&#160;</b></span></td>
    <td colspan="2" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center"><span style="font-size: 9pt"><b>Noncontrolling</b></span></td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 9pt"><b>&#160;</b></span></td>
    <td>&#160;</td>
    <td style="text-align: center"><b>&#160;</b></td>
    <td style="text-align: center"><p style="text-align: center; margin-top: 0; margin-bottom: 0"><b>Total Stockholders&#8217;</b></p></td>
    <td style="text-align: center"><b>&#160;</b></td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: center"><span style="font-size: 9pt"><b>&#160;</b></span></td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 9pt"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 9pt"><b>Shares</b></span></td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 9pt"><b>&#160;</b></span></td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 9pt"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 9pt"><b>Amount</b></span></td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 9pt"><b>&#160;</b></span></td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 9pt"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 9pt"><b>Capital</b></span></td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 9pt"><b>&#160;</b></span></td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 9pt"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 9pt"><b>Income</b></span></td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 9pt"><b>&#160;</b></span></td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 9pt"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 9pt"><b>Deficit</b></span></td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 9pt"><b>&#160;</b></span></td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 9pt"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 9pt"><b>Equity</b></span></td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 9pt"><b>&#160;</b></span></td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 9pt"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 9pt"><b>Interest</b></span></td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 9pt"><b>&#160;</b></span></td>
    <td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: center"><b>&#160;</b></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: center"><b>Equity</b></td>
    <td style="text-align: center"><b>&#160;</b></td></tr>
  <tr id="xdx_43C_c20220101__20221231_eus-gaap--StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_iS_zHRphOpeabEe" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 36%"><span style="font-size: 9pt">Balance at December 31, 2021</span></td><td style="width: 1%"><span style="font-size: 9pt">&#160;</span><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0280">-</span></span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td id="xdx_98E_eus-gaap--SharesOutstanding_iS_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z8U62oZn4I94" title="Balance, shares" style="width: 5%; text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2021-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,529,018</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="width: 1%"><span style="font-size: 9pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 9pt">$</span></td><td style="width: 5%; text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2021-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">35,290</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="width: 1%"><span style="font-size: 9pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 9pt">$</span></td><td style="width: 5%; text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2021-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">101,274,073</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="width: 1%"><span style="font-size: 9pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 9pt">$</span></td><td style="width: 5%; text-align: right"><span style="font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0283">&#8212;</span></span></td><td style="width: 1%; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="width: 1%"><span style="font-size: 9pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 9pt">$</span></td><td style="width: 5%; text-align: right"><span style="font-size: 9pt">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2021-12-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">84,744,629</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-size: 9pt">)</span></td><td style="width: 1%"><span style="font-size: 9pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><p style="margin: 0">$</p></td><td style="width: 5%; text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2021-12-31_us-gaap_ParentMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">16,564,734</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="width: 1%"><span style="font-size: 9pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 9pt">$</span></td><td style="width: 5%; text-align: right"><span style="font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0286">&#8212;</span></span></td><td style="width: 1%; text-align: left"><span style="font-size: 9pt">&#160;</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">$</td>
    <td style="text-align: right; width: 5%"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">16,564,734</ix:nonFraction></td>
    <td style="width: 1%">&#160;</td></tr>
  <tr id="xdx_405_ecustom--StockIssuedUponCashExerciseOfWarrants_zhUldomHsgNj" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-size: 9pt">Stock issued upon exercise of warrants</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td id="xdx_985_ecustom--StockIssuedUponCashExerciseOfWarrantsShares_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zv4nN5te1ee5" title="Balance, shares" style="text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="QLGN:StockIssuedUponCashExerciseOfWarrantsShares" contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">332,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="QLGN:StockIssuedUponCashExerciseOfWarrants" contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,320</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="QLGN:StockIssuedUponCashExerciseOfWarrants" contextRef="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,711</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0294">&#8212;</span></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0295">&#8212;</span></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="QLGN:StockIssuedUponCashExerciseOfWarrants" contextRef="From2022-01-012022-12-31_us-gaap_ParentMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,031</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0297">&#8212;</span></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="QLGN:StockIssuedUponCashExerciseOfWarrants" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,031</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions_zFLuXE41C2V2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-size: 9pt">Stock-based compensation</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td title="Balance, shares" style="text-align: right"><span style="font-size: 9pt">&#8212;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0303">&#8212;</span></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions" contextRef="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,484,044</ix:nonFraction></p></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0305">&#8212;</span></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0306">&#8212;</span></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions" contextRef="From2022-01-012022-12-31_us-gaap_ParentMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,484,044</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0308">&#8212;</span></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,484,044</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr id="xdx_400_ecustom--CommonStockAndPrefundedWarrantsIssuedForBusinessAcquisition_zEsihx2kh06a" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-size: 9pt">Common stock and prefunded warrants issued for business acquisition</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td id="xdx_986_ecustom--CommonStockAndPrefundedWarrantsIssuedSharesForBusinessAcquisition_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z5M8arM3dwob" title="Balance, shares" style="text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="QLGN:CommonStockAndPrefundedWarrantsIssuedSharesForBusinessAcquisition" contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">350,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="QLGN:CommonStockAndPrefundedWarrantsIssuedForBusinessAcquisition" contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,500</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="QLGN:CommonStockAndPrefundedWarrantsIssuedForBusinessAcquisition" contextRef="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,740,417</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0314">&#8212;</span></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0315">&#8212;</span></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="QLGN:CommonStockAndPrefundedWarrantsIssuedForBusinessAcquisition" contextRef="From2022-01-012022-12-31_us-gaap_ParentMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,743,917</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="QLGN:CommonStockAndPrefundedWarrantsIssuedForBusinessAcquisition" contextRef="From2022-01-012022-12-31_us-gaap_NoncontrollingInterestMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,882,225</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="QLGN:CommonStockAndPrefundedWarrantsIssuedForBusinessAcquisition" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,626,142</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr id="xdx_403_ecustom--NoncontrollingInterestAdjustmentsRelatingToStockbasedCompensationAndOther_zoIp1Qf8imDc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-size: 9pt">&#160;Noncontrolling interest adjustments relating to Stock-based compensation
    and other</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td title="Balance, shares" style="text-align: right"><span style="font-size: 9pt">&#8212;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0323">&#8212;</span></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">(<ix:nonFraction name="QLGN:NoncontrollingInterestAdjustmentsRelatingToStockbasedCompensationAndOther" contextRef="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">42,756</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 9pt">)</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0325">&#8212;</span></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0326">&#8212;</span></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">(<ix:nonFraction name="QLGN:NoncontrollingInterestAdjustmentsRelatingToStockbasedCompensationAndOther" contextRef="From2022-01-012022-12-31_us-gaap_ParentMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">42,756</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 9pt">)</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="QLGN:NoncontrollingInterestAdjustmentsRelatingToStockbasedCompensationAndOther" contextRef="From2022-01-012022-12-31_us-gaap_NoncontrollingInterestMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">42,756</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0329">&#8212;</span></td>
    <td>&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_zmNwhGgtKgRh" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-size: 9pt">Foreign currency translation adjustment</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td title="Balance, shares" style="text-align: right"><span style="font-size: 9pt">&#8212;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0332">&#8212;</span></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0333">&#8212;</span></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="From2022-01-012022-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">50,721</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0335">&#8212;</span></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="From2022-01-012022-12-31_us-gaap_ParentMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">50,721</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0337">&#8212;</span></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">50,721</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr id="xdx_400_ecustom--FairValueOfWarrantModificationForProfessionalServices_zW0baJErL27c" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-size: 9pt">Fair value of warrant modification for professional services</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td title="Balance, shares" style="text-align: right"><span style="font-size: 9pt">&#8212;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0341">&#8212;</span></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="QLGN:FairValueOfWarrantModificationForProfessionalServices" contextRef="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">67,370</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0343">&#8212;</span></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0344">&#8212;</span></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="QLGN:FairValueOfWarrantModificationForProfessionalServices" contextRef="From2022-01-012022-12-31_us-gaap_ParentMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">67,370</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0346">&#8212;</span></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="QLGN:FairValueOfWarrantModificationForProfessionalServices" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">67,370</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr id="xdx_400_ecustom--FairValueOfWarrantModificationForBusinessAcquisition_zssPuROHcAP2" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-size: 9pt">Fair value of warrant modification for business acquisition</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td title="Balance, shares" style="text-align: right"><span style="font-size: 9pt">&#8212;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0350">&#8212;</span></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="QLGN:FairValueOfWarrantModificationForBusinessAcquisition" contextRef="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">696</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0352">&#8212;</span></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0353">&#8212;</span></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="QLGN:FairValueOfWarrantModificationForBusinessAcquisition" contextRef="From2022-01-012022-12-31_us-gaap_ParentMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">696</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0355">&#8212;</span></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="QLGN:FairValueOfWarrantModificationForBusinessAcquisition" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">696</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr id="xdx_401_ecustom--StockIssuedDuringPeriodValuesReverseStockSplits_zmv1BAbFhi7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-size: 9pt">Issuance of rounded shares as a result of the reverse stock split</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td id="xdx_980_eus-gaap--StockIssuedDuringPeriodSharesReverseStockSplits_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zfSgfW3Epqsc" title="Balance, shares" style="text-align: right"><span style="font-size: 9pt">(<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesReverseStockSplits" contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="Shares">281</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 9pt">)</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0359">&#8212;</span></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">(<ix:nonFraction name="QLGN:StockIssuedDuringPeriodValuesReverseStockSplits" contextRef="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">505</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 9pt">)</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0361">&#8212;</span></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0362">&#8212;</span></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">(<ix:nonFraction name="QLGN:StockIssuedDuringPeriodValuesReverseStockSplits" contextRef="From2022-01-012022-12-31_us-gaap_ParentMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">505</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 9pt">)</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0364">&#8212;</span></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">(<ix:nonFraction name="QLGN:StockIssuedDuringPeriodValuesReverseStockSplits" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">505</ix:nonFraction></td>
    <td>)</td></tr>
  <tr id="xdx_407_eus-gaap--ProfitLoss_zfuhFsv2gNza" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-size: 9pt">Net loss</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 9pt">&#160;</span><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0369">-</span></span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td title="Balance, shares" style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 9pt">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0370">&#8212;</span></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0371">&#8212;</span></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0372">&#8212;</span></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 9pt">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">18,640,543</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 9pt">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 9pt">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2022-01-012022-12-31_us-gaap_ParentMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">18,640,543</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 9pt">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 9pt">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2022-01-012022-12-31_us-gaap_NoncontrollingInterestMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,394,100</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 9pt">)</span></td>
    <td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">21,034,643</ix:nonFraction></td>
    <td>)</td></tr>
  <tr id="xdx_438_c20220101__20221231_eus-gaap--StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_iE_z6YsqPItMsUb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt"><span style="font-size: 9pt">Balance at December 31, 2022</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 9pt">&#160;</span><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0378">-</span></span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td id="xdx_988_eus-gaap--SharesOutstanding_iE_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zprUI6FNPEzi" title="Balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2022-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">4,210,737</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 9pt">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 9pt">&#160;&#160;<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2022-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">42,110</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 9pt">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 9pt">&#160;&#160;<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2022-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">110,528,050</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 9pt">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2022-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">50,721</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 9pt">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 9pt">&#160;&#160;(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2022-12-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">103,385,172</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 9pt">)</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 9pt">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2022-12-31_us-gaap_ParentMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,235,709</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 9pt">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2022-12-31_us-gaap_NoncontrollingInterestMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,530,881</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 9pt">&#160;</span></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double">$</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,766,590</ix:nonFraction></td>
    <td style="padding-bottom: 2.5pt">&#160;</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="font-weight: bold; text-align: center"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 9pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"><span style="font-size: 9pt">Shares</span></td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 9pt">&#160;</span></td>
    <td colspan="2" id="xdx_4B2_us-gaap--StatementEquityComponentsAxis_us-gaap--PreferredStockMember_us-gaap--StatementClassOfStockAxis_custom--SeriesAlphaConvertiblePreferredStockMember_zTrLkzH3jydb" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"><span style="font-size: 9pt">Amount</span></td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 9pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"><span style="font-size: 9pt">Shares</span></td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 9pt">&#160;</span></td>
    <td colspan="2" id="xdx_4B3_us-gaap--StatementEquityComponentsAxis_us-gaap--CommonStockMember_zUhjsnDjYYae" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"><span style="font-size: 9pt">Amount</span></td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 9pt">&#160;</span></td>
    <td colspan="2" id="xdx_4B5_us-gaap--StatementEquityComponentsAxis_us-gaap--AdditionalPaidInCapitalMember_zNbTWvvLIIja" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"><span style="font-size: 9pt">Capital</span></td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 9pt">&#160;</span></td>
    <td colspan="2" id="xdx_4B7_us-gaap--StatementEquityComponentsAxis_us-gaap--RetainedEarningsMember_zaGtJBohTU7d" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"><span style="font-size: 9pt">Deficit</span></td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 9pt">&#160;</span></td>
    <td colspan="2" id="xdx_4B7_zKnqD8MePBUl" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"><span style="font-size: 9pt">Equity</span></td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: center"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 9pt">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"><span style="font-size: 9pt">Series
    Alpha Convertible</span></td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: center; padding-bottom: 1.5pt"><span style="font-size: 9pt">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: center; padding-bottom: 1.5pt"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: center; padding-bottom: 1.5pt"><span style="font-size: 9pt">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: center; padding-bottom: 1.5pt"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: center; padding-bottom: 1.5pt"><span style="font-size: 9pt">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="font-size: 9pt"><b>Additional</b></span></td><td style="text-align: center; padding-bottom: 1.5pt"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: center; padding-bottom: 1.5pt"><span style="font-size: 9pt">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: center; padding-bottom: 1.5pt"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 9pt">&#160;</span></td>
    <td colspan="2" style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"><span style="font-size: 9pt">Total</span></td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: center"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 9pt">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"><span style="font-size: 9pt">Preferred
    Stock</span></td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 9pt">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"><span style="font-size: 9pt">Common
    Stock</span></td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 9pt">&#160;</span></td>
    <td colspan="2" style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"><span style="font-size: 9pt">Paid-In</span></td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 9pt">&#160;</span></td>
    <td colspan="2" style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"><span style="font-size: 9pt">Accumulated</span></td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 9pt">&#160;</span></td>
    <td colspan="2" style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"><span style="font-size: 9pt">Stockholders&#8217;</span></td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: center"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 9pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"><span style="font-size: 9pt">Shares</span></td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 9pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"><span style="font-size: 9pt">Amount</span></td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 9pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"><span style="font-size: 9pt">Shares</span></td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 9pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"><span style="font-size: 9pt">Amount</span></td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 9pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"><span style="font-size: 9pt">Capital</span></td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 9pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"><span style="font-size: 9pt">Deficit</span></td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 9pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"><span style="font-size: 9pt">Equity</span></td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr id="xdx_43A_c20210101__20211231_eus-gaap--StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_iS_zUX86NU4Ggf1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 37%"><span style="font-size: 9pt">Balance at December 31, 2020</span></td><td style="width: 2%"><span style="font-size: 9pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td id="xdx_987_eus-gaap--SharesOutstanding_iS_pid_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__us-gaap--StatementClassOfStockAxis__custom--SeriesAlphaConvertiblePreferredStockMember_zHTmI2OCTzzc" title="Balance, shares" style="width: 5%; text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2020-12-31_us-gaap_PreferredStockMember_custom_SeriesAlphaConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">18</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="width: 2%"><span style="font-size: 9pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 9pt">$</span></td><td style="width: 5%; text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2020-12-31_us-gaap_PreferredStockMember_custom_SeriesAlphaConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="width: 2%"><span style="font-size: 9pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td id="xdx_98A_eus-gaap--SharesOutstanding_iS_pid_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zFqnYF67TuSl" title="Balance, shares" style="width: 5%; text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2020-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,729,606</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="width: 2%"><span style="font-size: 9pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 9pt">$</span></td><td style="width: 5%; text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2020-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">27,296</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="width: 2%"><span style="font-size: 9pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 9pt">$</span></td><td style="width: 5%; text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2020-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">85,114,755</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="width: 2%"><span style="font-size: 9pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 9pt">$</span></td><td style="width: 5%; text-align: right"><span style="font-size: 9pt">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2020-12-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">66,847,492</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-size: 9pt">)</span></td><td style="width: 2%"><span style="font-size: 9pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 9pt">$</span></td><td style="width: 5%; text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">18,294,560</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr id="xdx_433_c20210101__20211231_eus-gaap--StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_iS_zD9ZsTnWdJH" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-size: 9pt">Balance. value</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td id="xdx_983_eus-gaap--SharesOutstanding_iS_pid_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__us-gaap--StatementClassOfStockAxis__custom--SeriesAlphaConvertiblePreferredStockMember_zrXUXIJbCLO7" title="Balance, shares" style="text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2020-12-31_us-gaap_PreferredStockMember_custom_SeriesAlphaConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">18</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">$</span></td><td style="text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2020-12-31_us-gaap_PreferredStockMember_custom_SeriesAlphaConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td id="xdx_988_eus-gaap--SharesOutstanding_iS_pid_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zd7rh05zi2l9" title="Balance, shares" style="text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2020-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,729,606</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">$</span></td><td style="text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2020-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">27,296</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">$</span></td><td style="text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2020-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">85,114,755</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">$</span></td><td style="text-align: right"><span style="font-size: 9pt">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2020-12-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">66,847,492</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 9pt">)</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">$</span></td><td style="text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">18,294,560</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
<tr id="xdx_407_ecustom--StockIssuedUponCashExerciseOfWarrants_z7hJAB8CtSX2" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-size: 9pt">Stock issued upon cash-exercise of warrants</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#8212;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0409">&#8212;</span></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td id="xdx_985_ecustom--StockIssuedUponCashExerciseOfWarrantsShares_pid_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zKVeFQ34ek56" title="Stock issued upon cash exercise of warrants, shares" style="text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="QLGN:StockIssuedUponCashExerciseOfWarrantsShares" contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">161,830</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="QLGN:StockIssuedUponCashExerciseOfWarrants" contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,619</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="QLGN:StockIssuedUponCashExerciseOfWarrants" contextRef="From2021-01-012021-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,358,570</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0412">&#8212;</span></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="QLGN:StockIssuedUponCashExerciseOfWarrants" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,360,189</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr id="xdx_408_ecustom--StockIssuedUponNetexerciseOfWarrants_z6lbvepmMTO8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-size: 9pt">Stock issued upon net-exercise of warrants</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#8212;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0417">&#8212;</span></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td id="xdx_98A_ecustom--StockIssuedUponNetexerciseOfWarrantsShares_pid_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zmj6hzv6p9cd" title="Stock issued upon net-exercise of warrants, shares" style="text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="QLGN:StockIssuedUponNetexerciseOfWarrantsShares" contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">22,740</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="QLGN:StockIssuedUponNetexerciseOfWarrants" contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">227</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">(<ix:nonFraction name="QLGN:StockIssuedUponNetexerciseOfWarrants" contextRef="From2021-01-012021-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">227</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 9pt">)</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0420">&#8212;</span></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0421">&#8212;</span></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr id="xdx_40D_ecustom--IssuanceOfCommonStockForConversionOfPreferredStock_zwGd8QxxILRg" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-size: 9pt">Issuance of common stock for conversion of preferred stock</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td id="xdx_986_ecustom--IssuanceOfCommonStockSharesForConversionOfPreferredStock_pid_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__us-gaap--StatementClassOfStockAxis__custom--SeriesAlphaConvertiblePreferredStockMember_z9YRTUTEr521" title="Issuance of common stock for conversion of preferred stock, shares" style="text-align: right"><span style="font-size: 9pt">(<ix:nonFraction name="QLGN:IssuanceOfCommonStockSharesForConversionOfPreferredStock" contextRef="From2021-01-012021-12-31_us-gaap_PreferredStockMember_custom_SeriesAlphaConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="Shares">18</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 9pt">)</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">(<ix:nonFraction name="QLGN:IssuanceOfCommonStockForConversionOfPreferredStock" contextRef="From2021-01-012021-12-31_us-gaap_PreferredStockMember_custom_SeriesAlphaConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 9pt">)</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td id="xdx_980_ecustom--IssuanceOfCommonStockSharesForConversionOfPreferredStock_pid_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zKOV76roos3i" title="Issuance of common stock for conversion of preferred stock, shares" style="text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="QLGN:IssuanceOfCommonStockSharesForConversionOfPreferredStock" contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">24,342</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="QLGN:IssuanceOfCommonStockForConversionOfPreferredStock" contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">243</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">(<ix:nonFraction name="QLGN:IssuanceOfCommonStockForConversionOfPreferredStock" contextRef="From2021-01-012021-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">243</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 9pt">)</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0428">&#8212;</span></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">(<ix:nonFraction name="QLGN:IssuanceOfCommonStockForConversionOfPreferredStock" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 9pt">)</span></td></tr>
  <tr id="xdx_40F_ecustom--FairValueOfWarrantsIssuedForProfessionalServices_zg9b64S184yi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-size: 9pt">Fair value of warrants issued for professional services</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#8212;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0435">&#8212;</span></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#8212;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0436">&#8212;</span></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="QLGN:FairValueOfWarrantsIssuedForProfessionalServices" contextRef="From2021-01-012021-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">298,651</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0438">&#8212;</span></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="QLGN:FairValueOfWarrantsIssuedForProfessionalServices" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">298,651</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr id="xdx_408_ecustom--SharesIssuedPursuantToSecuritiesPurchaseAgreements_zpH54fEeBosh" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-size: 9pt">Shares issued pursuant to Securities Purchase Agreements</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#8212;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0441">&#8212;</span></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td id="xdx_98C_ecustom--SharesIssuedPursuantToSecuritiesPurchaseShareAgreements_pid_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zFmXVWUPO1Uh" title="Shares issued pursuant to Securities Purchase Agreements, Shares" style="text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="QLGN:SharesIssuedPursuantToSecuritiesPurchaseShareAgreements" contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">588,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="QLGN:SharesIssuedPursuantToSecuritiesPurchaseAgreements" contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,880</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="QLGN:SharesIssuedPursuantToSecuritiesPurchaseAgreements" contextRef="From2021-01-012021-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,814,120</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0444">&#8212;</span></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="QLGN:SharesIssuedPursuantToSecuritiesPurchaseAgreements" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,820,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr id="xdx_409_ecustom--CommissionAndOfferingCostsOfSecuritiesPurchaseAgreements_zYivEyYjnVue" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-size: 9pt">Commission and offering costs of Securities Purchase Agreements</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#8212;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0449">&#8212;</span></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#8212;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0450">&#8212;</span></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">(<ix:nonFraction name="QLGN:CommissionAndOfferingCostsOfSecuritiesPurchaseAgreements" contextRef="From2021-01-012021-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,960,465</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 9pt">)</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0452">&#8212;</span></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">(<ix:nonFraction name="QLGN:CommissionAndOfferingCostsOfSecuritiesPurchaseAgreements" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,960,465</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 9pt">)</span></td></tr>
  <tr id="xdx_409_ecustom--FairValueOfWarrantModificationsPursuantToSecuritiesPurchaseAgreements_zk6nAvb183D3" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-size: 9pt">Fair value of warrant modifications pursuant to Securities Purchase Agreements</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#8212;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0455">&#8212;</span></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#8212;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0456">&#8212;</span></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="QLGN:FairValueOfWarrantModificationsPursuantToSecuritiesPurchaseAgreements" contextRef="From2021-01-012021-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,253,536</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0458">&#8212;</span></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="QLGN:FairValueOfWarrantModificationsPursuantToSecuritiesPurchaseAgreements" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,253,536</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr id="xdx_403_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_zMsZIQXUZhJa" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-size: 9pt">Stock issued for professional services</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#8212;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0461">&#8212;</span></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td id="xdx_98E_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_pid_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z4MMfK40OICd" title="Stock issued for professional services, shares" style="text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,500</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">25</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2021-01-012021-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">101,725</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0464">&#8212;</span></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">101,750</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr id="xdx_402_eus-gaap--AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_znNdyXleMyV6" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-size: 9pt">Stock-based compensation</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#8212;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0469">&#8212;</span></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#8212;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0470">&#8212;</span></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="From2021-01-012021-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,293,651</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0472">&#8212;</span></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,293,651</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr id="xdx_40C_eus-gaap--ProfitLoss_zujKpDzAAwQ5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-size: 9pt">Net Loss</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 9pt">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0475">&#8212;</span></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 9pt">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0476">&#8212;</span></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0477">&#8212;</span></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 9pt">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2021-01-012021-12-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">17,897,137</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 9pt">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 9pt">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">17,897,137</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 9pt">)</span></td></tr>
  <tr id="xdx_43B_c20210101__20211231_eus-gaap--StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_iE_zYPEvBA41Vjd" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt"><span style="font-size: 9pt">Balance at December 31, 2021</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td id="xdx_98D_eus-gaap--SharesOutstanding_iE_pid_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__us-gaap--StatementClassOfStockAxis__custom--SeriesAlphaConvertiblePreferredStockMember_zI0HGu77SUJ4" title="Balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0487">&#8212;</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 9pt">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0481">&#8212;</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td id="xdx_983_eus-gaap--SharesOutstanding_iE_pid_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zd3DqCpBxAmi" title="Balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2021-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,529,018</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 9pt">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2021-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">35,290</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 9pt">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2021-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">101,274,073</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 9pt">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 9pt">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2021-12-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">84,744,629</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 9pt">)</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 9pt">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">16,564,734</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr id="xdx_43F_c20210101__20211231_eus-gaap--StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_iE_zzAHRCT4Bqdh" style="display: none; vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt"><span style="font-size: 9pt">Balance, value</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td id="xdx_981_eus-gaap--SharesOutstanding_iE_pid_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__us-gaap--StatementClassOfStockAxis__custom--SeriesAlphaConvertiblePreferredStockMember_zt29yb6F1Fgh" title="Balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0497">&#8212;</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 9pt">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0491">&#8212;</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td id="xdx_98A_eus-gaap--SharesOutstanding_iE_pid_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zFSld6m3Wcsl" title="Balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2021-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,529,018</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 9pt">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2021-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">35,290</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 9pt">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2021-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">101,274,073</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 9pt">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 9pt">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2021-12-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">84,744,629</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 9pt">)</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 9pt">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">16,564,734</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying notes are an integral part of these consolidated financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 43; Value: 35 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="sj_005"></span>QUALIGEN
THERAPEUTICS, INC.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CONSOLIDATED
STATEMENTS OF CASH FLOWS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_30B_112_zAOlRDAmydv" summary="xdx: Statement - Consolidated Statements of Cash Flows" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49A_20220101__20221231_zLRqYYmQF7m3" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49A_20210101__20211231_zpouHYBplfa9" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">For the Years Ended December 31</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--NetCashProvidedByUsedInOperatingActivitiesAbstract_iB_znNArImT1cF6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">CASH FLOWS FROM OPERATING ACTIVITIES</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--ProfitLoss_i01_maNCPBUzji9_zmuFNZMItZXg" style="vertical-align: bottom; background-color: White">
    <td style="width: 60%; text-align: left">Net loss</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">21,034,643</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">17,897,137</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td></tr>
  <tr id="xdx_404_eus-gaap--AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_i01B_zYVXjQ1su4Tb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Adjustments to reconcile net loss to net cash used in operating activities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--DepreciationDepletionAndAmortization_i02_maNCPBUzji9_zf0mZTkQToxh" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Depreciation and amortization</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DepreciationDepletionAndAmortization" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">152,573</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DepreciationDepletionAndAmortization" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">113,218</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--OperatingLeaseRightOfUseAssetAmortizationExpense_i02_maNCPBUzji9_zdPc6SWPDzYc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Amortization of right-of-use assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">223,030</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">225,059</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--ProvisionForDoubtfulAccounts_i02_maNCPBUzji9_zmtGizcWqEX" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Accounts receivable reserves and allowances</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:ProvisionForDoubtfulAccounts" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">59,982</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:ProvisionForDoubtfulAccounts" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">247,845</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_408_eus-gaap--InventoryWriteDown_i02_maNCPBUzji9_z0DhhrLTGzWe" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Inventory reserves</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:InventoryWriteDown" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">18,943</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:InventoryWriteDown" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">108,138</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_401_eus-gaap--IssuanceOfStockAndWarrantsForServicesOrClaims_i02_maNCPBUzji9_zaig46bz0pC6" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Common stock issued for professional services</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0522">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">101,750</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_ecustom--FairValueOfWarrantsIssuedForProfessionalServices_i02_maNCPBUzji9_zHDijOZ889A4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Fair value of warrants issued for professional services</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0525">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="QLGN:FairValueOfWarrantsIssuedForProfessionalServices" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">298,651</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--ShareBasedCompensation_i02_maNCPBUzji9_zj76xwbblLZ" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Stock-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,484,044</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,293,651</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_ecustom--FairValueOfWarrantModificationForProfessionalServices_i02_maNCPBUzji9_zrhtuQiYcA88" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Fair value of warrant modification for professional services</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><p style="margin: 0"><ix:nonFraction name="QLGN:FairValueOfWarrantModificationForProfessionalServices" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">67,370</ix:nonFraction></p></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><p style="margin: 0"><span style="-sec-ix-hidden: xdx2ixbrl0532">&#8212;</span></p></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--GoodwillImpairmentLoss_i02_maNCPBUzji9_zvXYrro4Lf53" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Goodwill and fixed asset impairment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:GoodwillImpairmentLoss" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,239,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0535">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--FairValueAdjustmentOfWarrants_i02_maNCPBUzji9_z2CAVulkP8h2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Change in fair value of warrant liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">906,345</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">4,723,187</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--IncreaseDecreaseInOperatingCapitalAbstract_i02B_zNXwmeW8NjP1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Changes in operating assets and liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--IncreaseDecreaseInAccountsReceivable_i03N_di_msNCPBUzji9_zvTtix7fj8hc" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Accounts receivable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsReceivable" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">417,708</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsReceivable" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">41,250</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_ecustom--IncreaseDecreaseInInventoryAndEquipmentHeldForLeases_i03N_di_msNCPBUzji9_zyMg8RDJi2gi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Inventory and equipment held for lease</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="QLGN:IncreaseDecreaseInInventoryAndEquipmentHeldForLeases" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">637,410</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="QLGN:IncreaseDecreaseInInventoryAndEquipmentHeldForLeases" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">111,422</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_i03N_di_msNCPBUzji9_zW1eOhBaWR78" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Prepaid expenses and other assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">99,251</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,298,998</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--IncreaseDecreaseInAccountsPayable_i03_maNCPBUzji9_zfEhMja70Q52" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Accounts payable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayable" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">33,397</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayable" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">385,455</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities_i03_maNCPBUzji9_zaA0Y2dWQFbf" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Accrued expenses and other current liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">76,266</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,047,163</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_ecustom--IncreaseDecreaseInResearchAndDevelopmentGrantLiability_i03_maNCPBUzji9_zHFkvGwx2Lok" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">R&amp;D grant liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="QLGN:IncreaseDecreaseInResearchAndDevelopmentGrantLiability" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">534,426</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0559">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--IncreaseDecreaseInOperatingLeaseLiability_i03_maNCPBUzji9_zRFjmHOpUUdb" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Operating lease liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">134,091</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">254,740</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_405_eus-gaap--IncreaseDecreaseInContractWithCustomerLiability_i03_maNCPBUzji9_z1wNgnF2MPk1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Deferred revenue</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">62,775</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">416,312</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_403_eus-gaap--IncreaseDecreaseInDeferredLiabilities_i03_maNCPBUzji9_zqesOXwNzWv4" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Deferred tax liability</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInDeferredLiabilities" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">271,622</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0568">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--NetCashProvidedByUsedInOperatingActivities_i01T_mtNCPBUzji9_maCCERCzoIr_zSXjoIIxck34" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Net cash used in operating activities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">13,247,540</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">14,730,742</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--NetCashProvidedByUsedInInvestingActivitiesAbstract_iB_z3J6dNNbt42h" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">CASH FLOWS FROM INVESTING ACTIVITIES:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--PaymentsToAcquirePropertyPlantAndEquipment_i01N_di_msNCPBUzn2B_zYoxR1PKzjsh" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Purchases of property and equipment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">164,684</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">134,471</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_408_ecustom--PurchasesOfEquipmentHeldForLease_i01N_di_msNCPBUzn2B_z1ePEoTYPsE2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Purchases of equipment held for lease</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="QLGN:PurchasesOfEquipmentHeldForLease" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">154,433</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0580">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--PaymentsToAcquireIntangibleAssets_i01N_di_msNCPBUzn2B_zIpIZH35lfJh" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Payments for patents and licenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0582">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:PaymentsToAcquireIntangibleAssets" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,893</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_404_eus-gaap--CashAcquiredFromAcquisition_i01_maNCPBUzn2B_zDb2C3e3oGc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Net cash acquired in business combination</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:CashAcquiredFromAcquisition" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">135,354</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0586">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--NetCashProvidedByUsedInInvestingActivities_i01T_mtNCPBUzn2B_maCCERCzoIr_zjdkWTWAU4Qh" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Net cash used in investing activities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">183,763</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">141,364</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--NetCashProvidedByUsedInFinancingActivitiesAbstract_iB_z3S5f5f5yFK3" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">CASH FLOWS FROM FINANCING ACTIVITIES:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--ProceedsFromWarrantExercises_i01_maNCPBUzZOb_zlxnYWtvIO4i" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Net proceeds from warrant exercises</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromWarrantExercises" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,173</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromWarrantExercises" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">459,476</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_ecustom--ProceedsFromIssuanceOfSharesAndWarrantsPursuantToSecuritiesPurchaseAgreements_i01_maNCPBUzZOb_z0YYFimFgqnc" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Proceeds from issuance of shares and warrants pursuant to Securities Purchase Agreements</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0597">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="QLGN:ProceedsFromIssuanceOfSharesAndWarrantsPursuantToSecuritiesPurchaseAgreements" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,820,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_ecustom--ProceedsFromIssuanceOfConvertibleDebt_i01_maNCPBUzZOb_zwmxjsOYTi04" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Proceeds from issuance of convertible debt - related party</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="QLGN:ProceedsFromIssuanceOfConvertibleDebt" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,903,847</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0601">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--PaymentsOfStockIssuanceCosts_i01N_di_msNCPBUzZOb_z9ok3SiMM7F5" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Offering costs of Securities Purchase Agreements</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0603">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:PaymentsOfStockIssuanceCosts" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">706,929</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_403_eus-gaap--RepaymentsOfNotesPayable_i01N_di_msNCPBUzZOb_zo4kXF85pkYe" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Principal payments on notes payable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0606">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:RepaymentsOfNotesPayable" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">138,739</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40D_ecustom--FractionalSharePaymentsRelatedToReverseStockSplit_i01N_di_msNCPBUzZOb_z4j5pyVEDd8" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Fractional share payments related to the reverse stock split</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="QLGN:FractionalSharePaymentsRelatedToReverseStockSplit" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">505</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0610">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--NetCashProvidedByUsedInFinancingActivities_i01T_mtNCPBUzZOb_maCCERCzoIr_zGe4arcmOgv" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Net cash provided by financing activities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,910,515</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,433,808</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_iT_mtCCERCzoIr_zxeEfXGZPnUj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Net change in cash and restricted cash</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">10,520,787</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">6,438,298</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_404_eus-gaap--EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_zy4awP64eyBb" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">Effect of exchange rate changes on cash and restricted cash</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">22,639</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0619">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_iS_zoEwIwD6Jjei" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Cash and restricted cash - beginning of period</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">17,538,272</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">23,976,570</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_iE_ztvMJhrsMM8g" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Cash and restricted cash - end of period</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,040,123</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">17,538,272</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--SupplementalCashFlowInformationAbstract_iB_zlBE3LCqLVvg" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_ecustom--CashPaidForAbstract_iB_zIniEACjOOT1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Cash paid during the year for:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--InterestPaidNet_i01_zq879PwW6MWl" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; padding-bottom: 2.5pt">Interest</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0633">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:InterestPaidNet" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,233</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--IncomeTaxesPaidNet_i01_zA59HqieXrK2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; padding-bottom: 2.5pt">Taxes</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:IncomeTaxesPaidNet" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,571</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:IncomeTaxesPaidNet" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,133</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_iB_zSLDr0zDTRvb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">NONCASH FINANCING AND INVESTING ACTIVITIES:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_ecustom--IssuanceOfCommonStockForConversionOfPreferredStockBeforeClosingOfReverseRecapitalization_i01_zl9w0KrwIpSk" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Issuance of common stock for conversion of preferred stock after closing of reverse recapitalization</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0642">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="QLGN:IssuanceOfCommonStockForConversionOfPreferredStockBeforeClosingOfReverseRecapitalization" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">243</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_ecustom--RightofuseAssetsObtainedInExchangeForOperatingLeaseLiabilities_i01_zg4KWGdo12wi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Right-of-use assets obtained in exchange for operating lease liabilities</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0645">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="QLGN:RightofuseAssetsObtainedInExchangeForOperatingLeaseLiabilities" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,439,830</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_ecustom--SharesIssuedForCashlessWarrantsAmount_i01_zP4nkwxEZDH4" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Fair value of shares issued for cashless warrant exercises</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0648">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="QLGN:SharesIssuedForCashlessWarrantsAmount" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">764,657</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_ecustom--TransfersOfInventoryFromEquipmentHeldForLease_i01_zW8zfpFy3eia" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Net transfers to inventory from equipment held for lease</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0651">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="QLGN:TransfersOfInventoryFromEquipmentHeldForLease" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,304</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_ecustom--FairValueOfWarrantModificationsPursuantToSecuritiesPurchaseAgreements_i01_zokoddM6cri2" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Fair value of warrant modifications pursuant to Securities Purchase Agreements</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="QLGN:FairValueOfWarrantModificationsPursuantToSecuritiesPurchaseAgreements" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">9,439</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="QLGN:FairValueOfWarrantModificationsPursuantToSecuritiesPurchaseAgreements" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,253,536</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_ecustom--FairValueOfWarrantLiabilitiesOnDateOfExercise_i01_zf14r9Vd3uc3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Fair value of warrant liabilities on date of exercise</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="QLGN:FairValueOfWarrantLiabilitiesOnDateOfExercise" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">858</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="QLGN:FairValueOfWarrantLiabilitiesOnDateOfExercise" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,900,713</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_ecustom--FairValueOfWarrantModificationsForBusinessAcquisition_i01_zKzAELxxlpG2" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Fair value of warrant modifications for business acquisition</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="QLGN:FairValueOfWarrantModificationsForBusinessAcquisition" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">33,543</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0661">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--NoncashInvestingAndFinancingItemsAbstract_iB_z4XNrnRpJna5" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold">ACQUISITION:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--FairValueOfAssetsAcquired_i01N_di_zD8ygc88T2sk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Fair value of assets acquired</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:FairValueOfAssetsAcquired" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,896,278</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0667">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--LiabilitiesAssumed1_i01_zOZGeXLWTqal" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Fair value of liabilities assumed, net of goodwill</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesAssumed1" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,321,845</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0670">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_ecustom--FairValueOfWarrantsRepricedDueToAcquisition_i01_zRYUj8JkJyc7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Fair value of Alpha Capital/Qualigen warrants repriced due to acquisition</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="QLGN:FairValueOfWarrantsRepricedDueToAcquisition" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">696</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0673">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_ecustom--FairValueOfQualigenPrefundedWarrantIssuedInExchangeForNanosynexStock_i01_zPX1p4gd42U7" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Fair value of Qualigen prefunded warrant issued in exchange for NanoSynex stock</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="QLGN:FairValueOfQualigenPrefundedWarrantIssuedInExchangeForNanosynexStock" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,804,102</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0676">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--StockIssued1_i01_zMcoW7VEhqEj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Fair value of Qualigen common stock issued in exchange for NanoSynex stock</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:StockIssued1" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,904,989</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0679">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--BusinessCombinationConsiderationTransferred1_i01_zJoZ3doyAdS2" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Net cash acquired in business combination (Note 3)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:BusinessCombinationConsiderationTransferred1" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">135,354</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0682">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying notes are an integral part of these consolidated financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>


<!-- Field: Page; Sequence: 44; Value: 35 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="sj_006"></span>QUALIGEN
THERAPEUTICS, INC.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock"><p id="xdx_80D_eus-gaap--OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_zFtXKJBIDe11" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
1 &#8212; <span id="xdx_829_zkOtCUiAh3ch">ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND ESTIMATES</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="QLGN:OrganizationPolicyTextBlock"><p id="xdx_84C_ecustom--OrganizationPolicyTextBlock_zeWI3RRbueC4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86A_z2jwwuWoT1kg">Organization</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Qualigen,
Inc., now a subsidiary of Qualigen Therapeutics, Inc., was incorporated in Minnesota in 1996 to design, develop, manufacture and sell
Physician Office Laboratory (&#8220;POL&#8221;) market quantitative immunoassay diagnostic products for use in physician offices and
other point-of-care settings worldwide, and was reincorporated in Delaware in 1999. In May 2020, Qualigen, Inc. completed a reverse recapitalization
transaction with Ritter Pharmaceuticals, Inc. (&#8220;Ritter&#8221;) and Ritter was renamed Qualigen Therapeutics, Inc. All shares of
Qualigen, Inc.&#8217;s capital stock were exchanged for Qualigen Therapeutics, Inc.&#8217;s capital stock in the merger. Ritter/Qualigen
Therapeutics common stock, which was previously traded on the Nasdaq Capital Market under the ticker symbol &#8220;RTTR,&#8221; commenced
trading on the Nasdaq Capital Market, on a post-reverse-stock-split adjusted basis, under the trading symbol &#8220;QLGN&#8221; on May
26, 2020. Qualigen Therapeutics, Inc. (the &#8220;Company&#8221;) operates in one business segment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">On
May 26, 2022, the Company acquired <span id="xdx_903_eus-gaap--StockIssuedDuringPeriodSharesAcquisitions_c20220524__20220526__us-gaap--BusinessAcquisitionAxis__custom--NanoSynexLtdMember__us-gaap--StatementClassOfStockAxis__custom--SeriesAOnePreferredStockMember_zfMeIdzOzlJa" title="Number of common stock acquired shares"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesAcquisitions" contextRef="From2022-05-242022-05-26_custom_NanoSynexLtdMember_custom_SeriesAOnePreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,232,861</ix:nonFraction></span> shares of Series A-1 Preferred Stock of NanoSynex, Ltd. (&#8220;NanoSynex&#8221;) from Alpha
Capital Anstalt (&#8220;Alpha Capital&#8221;), a related party, in exchange for <span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodSharesAcquisitions_c20220524__20220526__us-gaap--BusinessAcquisitionAxis__custom--NanoSynexLtdMember_zks2Cx6r38pd" title="Number of common stock acquired shares"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesAcquisitions" contextRef="From2022-05-242022-05-26_custom_NanoSynexLtdMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">350,000</ix:nonFraction></span> reverse split adjusted shares of the Company&#8217;s common stock and a prefunded warrant
to purchase <span id="xdx_904_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_c20220526__us-gaap--StatementEquityComponentsAxis__custom--PrefundedWarrantMember_zrdIBprn3PV4" title="Warrants to purchase common stock"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" contextRef="AsOf2022-05-26_custom_PrefundedWarrantMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">331,464</ix:nonFraction> reverse split adjusted shares of the Company&#8217;s common stock at an exercise price of $<span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20220526__us-gaap--StatementEquityComponentsAxis__custom--PrefundedWarrantMember_zHeVCJY9m9L4" title="Class of Warrant or Right, Exercise Price of Warrants or Rights"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2022-05-26_custom_PrefundedWarrantMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.001</ix:nonFraction></span> per share. <span id="xdx_901_eus-gaap--StockholdersEquityReverseStockSplit_c20220525__20220526_zPIU0Z15PR81" title="Reverse split, description"><ix:nonNumeric contextRef="From2022-05-252022-05-26" name="us-gaap:StockholdersEquityReverseStockSplit">These warrants were subsequently exercised on September 13, 2022</ix:nonNumeric></span>. Concurrently with this transaction,
the Company also purchased <span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodSharesAcquisitions_c20220524__20220526__us-gaap--BusinessAcquisitionAxis__custom--NanoSynexLtdMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zotzw9HT11Zf" title="Stock issued during period shares acquisitions"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesAcquisitions" contextRef="From2022-05-242022-05-26_custom_NanoSynexLtdMember_us-gaap_SeriesBPreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">381,786</ix:nonFraction></span> shares of Series B preferred stock from NanoSynex for a total purchase price of $<span id="xdx_909_eus-gaap--StockIssuedDuringPeriodValueAcquisitions_pp0p0_c20220524__20220526__us-gaap--BusinessAcquisitionAxis__custom--NanoSynexLtdMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zdCN0AghKGfa" title="Stock issued during period, value, acquisitions"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" contextRef="From2022-05-242022-05-26_custom_NanoSynexLtdMember_us-gaap_SeriesBPreferredStockMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">600,000</ix:nonFraction></span>. The transactions
resulted in the Company acquiring a <span id="xdx_902_eus-gaap--BusinessAcquisitionPercentageOfVotingInterestsAcquired_iI_pid_dp_uPure_c20220526__us-gaap--BusinessAcquisitionAxis__custom--NanoSynexLtdMember_zxyij6GwHYRj" title="Voting interests acquired"><ix:nonFraction name="us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired" contextRef="AsOf2022-05-26_custom_NanoSynexLtdMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">52.8</ix:nonFraction></span>% interest in NanoSynex. The Company envisions future synergies from the integration of its own
proprietary results-proven FastPack diagnostics platform with the innovative NanoSynex technology. NanoSynex is a micro-biologics diagnostics
company domiciled in Israel.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock"><p id="xdx_845_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_z1Pi6ADgTcDe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86C_zG5TuUfpYqN8">Basis
of Presentation</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying consolidated financial statements of the Company have been prepared in conformity with accounting principles generally accepted
in the United States of America (&#8220;U.S. GAAP&#8221;), Regulation S-X and rules and regulations of the Securities and Exchange Commission
(&#8220;SEC&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:ConsolidationPolicyTextBlock"><p id="xdx_844_eus-gaap--ConsolidationPolicyTextBlock_zc9xiQDmxLdj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_865_zMvhOGZXViX">Principles
of Consolidation</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying consolidated financial statements include the accounts of the Company and its majority owned subsidiaries. All intercompany
balances and transactions have been eliminated in consolidation. Any reference in these notes to applicable guidance is meant to refer
to U.S. GAAP. The Company views its operations and manages its business in one operating segment. In general, the functional currency
of the Company and its subsidiaries is the U.S. dollar, however for NanoSynex, the functional currency is the local currency, New Israeli
Shekels (NIS). As such, assets and liabilities for NanoSynex are translated into U.S. dollars and the effects of foreign currency translation
adjustments are reflected as a component of accumulated other comprehensive income within the Company&#8217;s consolidated statements
of changes in stockholders&#8217; equity.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:UseOfEstimates"><p id="xdx_84F_eus-gaap--UseOfEstimates_zp75wf8bIeGk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_868_zng6SGdCYpk5">Accounting
Estimates</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management
uses estimates and assumptions in preparing its consolidated financial statements in accordance with U.S. GAAP. Those estimates and assumptions
affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities, and the reported revenues
and expenses. The most significant estimates relate to the estimated fair value of in-process research and development, goodwill, warrant
liabilities, stock-based compensation, amortization and depreciation, inventory reserves, allowances for doubtful accounts and returns,
and warranty costs. Actual results could vary from the estimates that were used.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="us-gaap:StockholdersEquityReverseStockSplit"><p id="xdx_844_eus-gaap--StockholdersEquityReverseStockSplit_zDVn316Ow2Cb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86B_zyCSoAvlK6Ie">Reverse
Stock Split</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
November 23, 2022, the Company effected a 1-for-10, as determined by the Company&#8217;s board of directors, reverse stock split of its
outstanding shares of common stock (the &#8220;Reverse Stock Split&#8221;). The Reverse Stock Split reduced the Company&#8217;s shares
of outstanding common stock, stock options, and warrants to purchase shares of our common stock. Fractional shares of common stock that
would have otherwise resulted from the Reverse Stock Split were rounded down to the nearest whole share and cash in lieu of payments
were made to stockholders. All share and per share data for all periods presented in the accompanying financial statements and the related
disclosures have been adjusted retrospectively to reflect the Reverse Stock Split. The number of authorized shares of common stock and
the par value per share remains unchanged.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:nonNumeric>


<ix:exclude><!-- Field: Page; Sequence: 45; Value: 35 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock"><p id="xdx_84F_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_z37X8m4Hmt6e" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86C_zpPLvuZmDhz6">Cash</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company considers all highly liquid investments purchased with an initial maturity of 90 days or less and money market funds to be cash
equivalents. Restricted cash includes cash that is restricted due to Israeli banking regulations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company maintains the majority of its cash in accounts at banking institutions in the U.S. that are of high quality.
Cash held in these accounts often exceed the FDIC insurance limits. If such banking institutions were to fail, the Company could lose
all or a portion of amounts held in excess of such insurance limitations. The FDIC recently took control of two such banking institutions,
Silicon Valley Bank on March 10, 2023 and Signature Bank on March 12, 2023. While the Company did not have an account at either of these two banks, in
the event of failure of any of the financial institutions where the Company maintains its cash and cash equivalents, there can be no
assurance that the Company would be able to access uninsured funds in a timely manner or at all. Any inability to access or delay in
accessing these funds could adversely affect our business and financial position.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:InventoryPolicyTextBlock"><p id="xdx_847_eus-gaap--InventoryPolicyTextBlock_zGf7dL4h9BTf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_866_z33yerdHlCCf">Inventory,
Net</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inventory
is recorded at the lower of cost or net realizable value. Cost is determined using the first-in, first-out method. The Company reviews
the components of its inventory on a periodic basis for excess or obsolete inventory, and records reserves for inventory components identified
as excess or obsolete.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"><p id="xdx_848_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_zk9MLFjdKX3c" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_864_zQs6GPn4XfVb">Impairment
of Long-Lived Assets</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company assesses potential impairments to its long-lived assets when there is evidence that events or changes in circumstances indicate
that assets may not be recoverable. An impairment loss would be recognized when the sum of the expected future undiscounted cash flows
is less than the carrying amount of the assets. The amount of impairment loss, if any, will generally be measured as the difference between
the net book value of the assets and their estimated fair values. During the fiscal year ending December 31, 2022 the Company recorded
an impairment loss of $<span id="xdx_907_eus-gaap--AssetImpairmentCharges_c20220101__20221231_z1ZrkrruzaJd" title="Impairment losses on construction-in-progress"><ix:nonFraction name="us-gaap:AssetImpairmentCharges" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,239,000</ix:nonFraction></span> related to the NanoSynex acquisition.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:SegmentReportingPolicyPolicyTextBlock"><p id="xdx_84C_eus-gaap--SegmentReportingPolicyPolicyTextBlock_zZfhfcFxJmJ6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_860_zxtDXJfGGB1e">Segment
Reporting</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating
segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation
by the chief operating decision-maker in making decisions regarding resource allocation and assessing performance. To date, the Company
has viewed its operations and managed its business as one segment operating primarily within the United States and Israel.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:TradeAndOtherAccountsReceivablePolicy"><p id="xdx_840_eus-gaap--TradeAndOtherAccountsReceivablePolicy_zsaXR112070d" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_865_zY0FbtBxe95i">Accounts
Receivable, Net</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company grants credit to domestic physicians, clinics, and distributors. The Company performs ongoing credit evaluations of its customers
and generally requires no collateral. Customers can purchase certain products through a financing agreement that the Company has with
an outside leasing company. Under the agreement, the leasing company evaluates the credit worthiness of the customer. Upon acceptance
of the product by the customer, the leasing company remits payment to the Company at a discount. This financing arrangement is without
recourse to the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company records an allowance for doubtful accounts and returns equal to the estimated uncollectible amounts or expected returns. The
Company&#8217;s estimates are based on historical collections and returns and a review of the current status of trade accounts receivable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock"><p id="xdx_893_eus-gaap--ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_zQIpz9BhMTj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accounts
receivable is comprised of the following at:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span id="xdx_8B0_zE01wFmfI8La" style="display: none">SCHEDULE
OF ACCOUNTS RECEIVABLE</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_49C_20221231_zvfQMHAuvDj7" style="font-weight: bold; text-align: center">December 31,</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_492_20211231_zxut4lxKKfY1" style="font-weight: bold; text-align: center">December 31,</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--AccountsReceivableGrossCurrent_iI_pp0p0_maARNCz1PU_maARNCzMpq_zouIgJCiaAvj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Accounts Receivable</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:AccountsReceivableGrossCurrent" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">726,449</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:AccountsReceivableGrossCurrent" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">958,448</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--AllowanceForDoubtfulAccountsReceivableCurrent_iNI_pp0p0_di_msARNCz1PU_msARNCzMpq_zKWim65hnST7" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Less Reserves and Allowances</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">187,862</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">136,097</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_40C_eus-gaap--AccountsReceivableNetCurrent_iTI_pp0p0_mtARNCzMpq_zJsnp5ZYOKe2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Accounts receivable,
    net</span></td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:AccountsReceivableNetCurrent" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">538,587</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:AccountsReceivableNetCurrent" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">822,351</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A7_zNcz49UOgnh7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:ResearchAndDevelopmentExpensePolicy"><p id="xdx_84E_eus-gaap--ResearchAndDevelopmentExpensePolicy_ztMuZpwk3j0d" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86F_z19JFpz1Rujl">Research
and Development</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Except
for acquired in process research and development (IPR&amp;D), the Company expenses research and development costs as incurred including
therapeutics license costs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 46; Value: 35 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->46<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="QLGN:ResearchAndDevelopmentGrantsPolicyTextBlock"><p id="xdx_844_ecustom--ResearchAndDevelopmentGrantsPolicyTextBlock_zxQP3l4NISq8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86A_zkHH9mEzbZCg">R&amp;D
Grants</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NanoSynex
has received R&amp;D grants from Israel Innovation Authority (IIA) and from the European Commission. These grants may provide cash funding
to NanoSynex from time to time in advance of the applicable costs being incurred. When such cash funding is received from these grants
in advance, the proceeds are recorded as a current or non-current R&amp;D grant liability based on the time from the consolidated balance
sheets date to the expected future date of recognition as a reduction to research and development expenses.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="QLGN:PatentCostsPolicyTextBlock"><p id="xdx_841_ecustom--PatentCostsPolicyTextBlock_zBCruCgfuRp3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_868_z37jRTIWlBl4">Patent
Costs</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company expenses all costs as incurred in connection with patent applications (including direct application fees, and the legal and consulting
expenses related to making such applications) and such costs are included in general and administrative expenses in the consolidated
statement of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="QLGN:ShippingAndHandlingCostsPolicyTextBlock"><p id="xdx_841_ecustom--ShippingAndHandlingCostsPolicyTextBlock_zwI40cOosWhg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_868_zOB31OSRUN04">Shipping
and Handling Costs</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company includes shipping and handling fees billed to customers in net sales. Shipping and handling costs associated with inbound and
outbound freight are generally recorded in cost of sales; such shipping and handling costs totaled approximately $<span id="xdx_904_eus-gaap--CostOfGoodsAndServicesSold_c20220101__20221231__srt--ProductOrServiceAxis__us-gaap--ShippingAndHandlingMember_zdk8CCBRyhze" title="Cost of Goods and Services Sold"><ix:nonFraction name="us-gaap:CostOfGoodsAndServicesSold" contextRef="From2022-01-012022-12-31_us-gaap_ShippingAndHandlingMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">267,000</ix:nonFraction></span> and $<span id="xdx_904_eus-gaap--CostOfGoodsAndServicesSold_c20210101__20211231__srt--ProductOrServiceAxis__us-gaap--ShippingAndHandlingMember_zCWJOmSRtr47" title="Cost of Goods and Services Sold"><ix:nonFraction name="us-gaap:CostOfGoodsAndServicesSold" contextRef="From2021-01-012021-12-31_us-gaap_ShippingAndHandlingMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">113,000</ix:nonFraction></span>,
respectively, for the years December 31, 2022 and 2021. Other shipping and handling costs included in general and administrative, research
and development, and sales and marketing expenses totaled approximately $<span id="xdx_901_eus-gaap--CostOfGoodsAndServicesSold_c20220101__20221231__us-gaap--IncomeStatementLocationAxis__custom--GeneralAdministrativeResearchAndDevelopmentExpensesMember_zNAiaPKLGGPg" title="Other shipping and handling costs"><ix:nonFraction name="us-gaap:CostOfGoodsAndServicesSold" contextRef="From2022-01-012022-12-31_custom_GeneralAdministrativeResearchAndDevelopmentExpensesMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">14,000</ix:nonFraction></span> and $<span id="xdx_908_eus-gaap--CostOfGoodsAndServicesSold_c20210101__20211231__us-gaap--IncomeStatementLocationAxis__custom--GeneralAdministrativeResearchAndDevelopmentExpensesMember_z9cn1bTADg3d" title="Other shipping and handling costs"><ix:nonFraction name="us-gaap:CostOfGoodsAndServicesSold" contextRef="From2021-01-012021-12-31_custom_GeneralAdministrativeResearchAndDevelopmentExpensesMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">12,000</ix:nonFraction></span> for the years ended December 31, 2022 and
2021, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:RevenueRecognitionPolicyTextBlock"><p id="xdx_84E_eus-gaap--RevenueRecognitionPolicyTextBlock_zABQ76nng5rl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86B_zk6ye9FRqsz3">Revenue
from Contracts with Customers</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company applies the following five-step model in accordance with ASC 606, Revenue from Contracts with Customers, in order to determine
revenue: (i) identification of the promised goods or services in the contract; (ii) determination of whether the promised goods or services
are performance obligations, including whether they are distinct in the context of the contract; (iii) measurement of the transaction
price, including the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations; and
(v) recognition of revenue when (or as) the Company satisfies each performance obligation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Product
Sales</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company generates revenue from selling FastPack System analyzers, accessories and disposable products used with the FastPack System.
Disposable products include reagent packs, which are diagnostic tests for prostate-specific antigen, testosterone, thyroid disorders,
pregnancy, and Vitamin D.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company provides disposable products and equipment in exchange for consideration, which occurs when a customer submits a purchase order
and the Company provides disposable products and equipment at the agreed upon prices in the invoice. Generally, customers purchase disposable
products using separate purchase orders after the equipment (&#8220;analyzer&#8221;) has been provided to the customer. The initial delivery
of the equipment and reagent packs represents a single performance obligation and is completed upon receipt by the customer. The delivery
of each subsequent individual reagent pack represents a separate performance obligation because the reagent packs are standardized, are
not interrelated in any way, and the customer can benefit from each reagent pack without any other product. There are no significant
discounts, rebates, returns or other forms of variable consideration. Customers are generally required to pay within 30 days.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
performance obligation arising from the delivery of the equipment is satisfied upon the delivery of the equipment to the customer. The
disposable products are shipped Free on Board (&#8220;FOB&#8221;) shipping point. For disposable products that are shipped FOB shipping
point, the customer has the significant risks and rewards of ownership and legal title to the assets when the disposable products leave
the Company&#8217;s shipping facilities, thus the customer obtains control and revenue is recognized at that point in time.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has elected the practical expedient and accounting policy election to account for the shipping and handling as activities to
fulfill the promise to transfer the disposable products and not as a separate performance obligation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s contracts with customers generally have an expected duration of one year or less, and therefore the Company has elected
the practical expedient in ASC 606 to not disclose information about its remaining performance obligations. Any incremental costs to
obtain contracts are recorded as selling, general and administrative expense as incurred due to the short duration of the Company&#8217;s
contracts.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>License
Revenue</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company entered into an out-license agreement with Yi Xin to develop and/or commercialize its products in exchange for nonrefundable
upfront license fees and/or sales-based royalties.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 47; Value: 35 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->47<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
the license to the Company&#8217;s intellectual property is determined to be distinct from the other performance obligations identified
in the arrangement, the Company recognizes revenue from nonrefundable upfront fees allocated to the license when the license is transferred
to the customer and the customer can benefit from the license. For licenses that are bundled with other performance obligations, management
uses judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is
satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing
revenue from nonrefundable upfront fees. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts
the measure of progress and related revenue recognition. During years ended December 31, 2022 and 2021, the Company recognized license
revenue of approximately $<span id="xdx_90D_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_dxL_c20220101__20221231__srt--ProductOrServiceAxis__custom--LicenseRevenuesMember_zFBg85urxvHl" title="::XDX::-"><span style="-sec-ix-hidden: xdx2ixbrl0752">0</span></span> and $<span id="xdx_90A_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20210101__20211231__srt--ProductOrServiceAxis__custom--LicenseRevenuesMember_zIZj4c0axwf4"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2021-01-012021-12-31_custom_LicenseRevenuesMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">632,000</ix:nonFraction></span>, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Contract
Asset and Liability Balances</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
timing of the Company&#8217;s revenue recognition may differ from the timing of payment by the Company&#8217;s customers. The Company
records a receivable when revenue is recognized prior to payment and there is an unconditional right to payment. Alternatively, when
payment precedes the performance of the related services, the Company records deferred revenue until the performance obligations are
satisfied.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Multiple
performance obligations include contracts that combine both the Company&#8217;s analyzer and a customer&#8217;s future reagent purchases
under a single contract. In some sales contracts, the Company provides analyzers at no charge to customers. Title to the analyzer is
maintained by the Company and the analyzer is returned by the customer to the Company at the end of the purchase agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the years December 31, 2022 and 2021, product sales are stated net of an allowance for estimated returns of approximately $<span id="xdx_90F_ecustom--AllowancesForSalesReturn_c20220101__20221231_z3orAMfHfQTa" title="Allowance for estimated returns"><ix:nonFraction name="QLGN:AllowancesForSalesReturn" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">96,000</ix:nonFraction></span> and
$<span id="xdx_90C_ecustom--AllowancesForSalesReturn_c20210101__20211231_zplKcwOU6s79" title="Allowance for estimated returns"><ix:nonFraction name="QLGN:AllowancesForSalesReturn" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">150,000</ix:nonFraction></span>, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="QLGN:DeferredRevenuePolicyTextBlock"><p id="xdx_84E_ecustom--DeferredRevenuePolicyTextBlock_zoQqOxBjcdPg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86C_zN6oYNVEGld1">Deferred
Revenue</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Payments
received in advance from customers pursuant to certain collaborative research license agreements, deposits against future product sales,
multiple element arrangements and extended warranties are recorded as a current or non-current deferred revenue liability based on the
time from the Consolidated Balance Sheet date to the future date of revenue recognition.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:LesseeLeasesPolicyTextBlock"><p id="xdx_848_eus-gaap--LesseeLeasesPolicyTextBlock_zwgVxRU1aNrj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_860_ztpvsNrpeia6">Operating
Leases</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effective
April 1, 2020, the Company adopted Accounting Standards Update (&#8220;ASU&#8221;) No. 2018-11, <i>Leases (Topic 842) Targeted Improvements
</i>(&#8220;Topic 842&#8221;). In accordance with the guidance in Topic 842, the Company recognizes lease liabilities and corresponding
right-of-use-assets for all leases with terms of greater than 12 months. Leases with a term of 12 months or less will be accounted for
in a manner similar to the guidance for operating leases prior to the adoption of Topic 842. (See Note 13-Commitments and Contingencies).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock"><p id="xdx_84B_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zxkFwQXeVvI3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86E_zUjoRKE3YoLk">Property
and Equipment, Net</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="QLGN:ScheduleOfUsefulLivesOfPropertyAndEquipmentTableTextBlock"><p id="xdx_89A_ecustom--ScheduleOfUsefulLivesOfPropertyAndEquipmentTableTextBlock_zFBqhrfk1vIi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property
and equipment are stated at cost and are presented net of accumulated depreciation. Depreciation is provided for on a straight-line basis
over the estimated useful lives of the related assets as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span id="xdx_8B2_zAPA13MDyEXg" style="display: none">SCHEDULE
OF USEFUL LIVES OF PROPERTY AND EQUIPMENT</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 77%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Machinery
    and equipment</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 23%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_904_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20220101__20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--MachineryAndEquipmentMember_zqufBTavuQy3" title="Property and equipment, useful life"><ix:nonNumeric contextRef="From2022-01-012022-12-31_us-gaap_MachineryAndEquipmentMember" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife">5</ix:nonNumeric></span>
    years</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Computer
    equipment</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_908_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20220101__20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember_zawkBQjlOUM3" title="Property and equipment, useful life"><ix:nonNumeric contextRef="From2022-01-012022-12-31_us-gaap_ComputerEquipmentMember" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife">3</ix:nonNumeric></span>
    years</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Molds
    and tooling</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90A_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20220101__20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--MoldsAndToolingMember_zIvIh9XUZzWi" title="Property and equipment, useful life"><ix:nonNumeric contextRef="From2022-01-012022-12-31_custom_MoldsAndToolingMember" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife">5</ix:nonNumeric></span>
    years</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Furniture
    and fixtures</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_906_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20220101__20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_z5DGlGqVKWNg" title="Property and equipment, useful life"><ix:nonNumeric contextRef="From2022-01-012022-12-31_us-gaap_FurnitureAndFixturesMember" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife">5</ix:nonNumeric></span>
    years</span></td></tr>
  </table>
</ix:nonNumeric><p id="xdx_8A6_zffzxAM1cCy5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Leasehold
improvements are amortized on a straight-line basis over the shorter of the lease term or their estimated useful lives. The Company occasionally
designs and builds its own machinery. The costs of these projects, which includes the cost of construction and other direct costs attributable
to the construction, are capitalized as construction in progress. No provision for depreciation is made on construction in progress until
the relevant assets are completed and placed in service.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s policy is to evaluate the remaining lives and recoverability of long-term assets on at least an annual basis or when
conditions are present that indicate impairment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 48; Value: 35 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->48<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:BusinessCombinationsPolicy"><p id="xdx_841_eus-gaap--BusinessCombinationsPolicy_zvdZiwqEUsXg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86F_zfZHqhXQ1spi">Business
Combinations</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounts for business combinations using the acquisition method pursuant to FASB ASC Topic 805. This method requires, among other
things, that results of operations of acquired companies are included in Qualigen&#8217;s financial results beginning on the respective
acquisition dates, and that assets acquired and liabilities assumed and noncontrolling interests are recognized at fair value as of the
acquisition date. Intangible assets acquired in a business combination are recorded at fair value using a discounted cash flow model.
We have third-party valuations completed for intangible assets in a business combination using a discounted cash flow analysis, incorporating
various assumptions. The discounted cash flow model requires assumptions about the timing and amount of future net cash flows, the cost
of capital and terminal values from the perspective of a market participant. Each of these factors can significantly affect the value
of the intangible asset. Any excess of the fair value of consideration transferred (the &#8220;Purchase Price&#8221;) over the fair values
of the net assets acquired is recognized as goodwill. The fair value of assets acquired and liabilities assumed in certain cases may
be subject to revision based on the final determination of fair value during a period of time not to exceed 12 months from the acquisition
date. Legal costs, due diligence costs, business valuation costs and all other acquisition-related costs are expensed when incurred.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock"><p id="xdx_845_eus-gaap--GoodwillAndIntangibleAssetsPolicyTextBlock_zbYKJt4uxjJi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_862_zcL6YjOj8s15">Goodwill</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Goodwill
represents the difference between the purchase price and the fair value of the identifiable tangible and intangible net assets
acquired, when accounted for using the purchase method of accounting. Goodwill has an indefinite useful life and is not amortized
but is reviewed for impairment annually and whenever events or changes in circumstances indicate that the carrying value of the
goodwill may not be recoverable. In testing for impairment, the fair value of the reporting unit is compared to the carrying value.
If the net assets assigned to the reporting unit exceed the fair value of the reporting unit, an impairment loss equal to the
difference is recorded. As a result of the annual goodwill impairment analysis, the Company recognized a $<span id="xdx_905_eus-gaap--GoodwillImpairmentLoss_c20220101__20221231_zPKuBPchBib5" title="Goodwill impairment charges"><ix:nonFraction name="us-gaap:GoodwillImpairmentLoss" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,239,000</ix:nonFraction></span>
non-cash goodwill and fixed asset impairment charge in the valuation of its business acquisition of NanoSynex for the year ended
December 30, 2022. For more information, refer to Note 1 - Organization and Summary of Significant Accounting Policies and Estimates
and Note 7 - Goodwill, IPR&amp;D and other Intangibles.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:IntangibleAssetsFiniteLivedPolicy"><p id="xdx_844_eus-gaap--IntangibleAssetsFiniteLivedPolicy_zwDMssJ6GRgf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86C_zQvb0w9eUW4c">Intangible
Assets</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>In
Process R&amp;D</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Acquired
in process R&amp;D (IPR&amp;D) represents the fair value assigned to the research and development assets that have not reached technological
feasibility. The value assigned to IPR&amp;D is determined by estimating the costs to develop the acquired technology into commercially
viable products, estimating the resulting revenue from the projects, and discounting the net cash flow to present value. The revenue
and cost projections used to value acquired IPR&amp;D are, as applicable, reduced based on the probability of success of developing the
new product. Additionally, projections consider relevant market sizes and growth factors, expected trends in technology and the nature
and expected timing of new product introductions. The rates utilized to discount the net cash flow to its present value are commensurate
with the stage of development of the project and uncertainties in the economic estimates used in the projections. Upon the acquisition
of acquired IPR&amp;D, an assessment is completed as to whether the acquisition constitutes an acquisition of a single asset or a group
of assets. Multiple factors are considered in this assessment, including the nature of the technology acquired, the presence or absence
of separate cash flows, the development process and stage of completion, quantitative significance, and the Company&#8217;s rationale
for entering into the transaction.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
a business is acquired, as defined under the applicable accounting standards, then the acquired IPR&amp;D is capitalized as an intangible
asset. If an asset or group of assets is acquired that do not meet the definition under the applicable accounting standards, then the
acquired IPR&amp;D is expensed on its acquisition date. Future costs to develop these assets are recorded to research and development
expense in the Company&#8217;s consolidated statements of operations and comprehensive loss as they are incurred.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">IPR&amp;D
is evaluated for impairment annually using the same methodology as described above for calculating fair value. If the carrying value
of the acquired IPR&amp;D exceeds the fair value, then the intangible asset is written down to its fair value, with the resulting adjustment
recorded as a charge to operations. Changes in estimates and assumptions used in determining the fair value of acquired IPR&amp;D could
result in an impairment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Other
Intangible Assets, Net</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
intangible assets consist of patent-related costs and costs for license agreements. Management reviews the carrying value of other intangible
assets that are being amortized on an annual basis or sooner when there is evidence that events or changes in circumstances may indicate
that impairment exists. The Company considers relevant cash flow and profitability information, including estimated future operating
results, trends and other available information, in assessing whether the carrying value of intangible assets being amortized can be
recovered.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
the Company determines that the carrying value of other intangible assets will not be recovered from the undiscounted future cash flows
expected to result from the use and eventual disposition of the underlying assets, the Company considers the carrying value of such intangible
assets as impaired and reduces them by a charge to operations in the amount of the impairment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 49; Value: 35 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->49<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Costs
related to acquiring patents and licenses are capitalized and amortized over their estimated useful lives, which is generally<span id="xdx_90C_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dtY_c20220101__20221231__srt--RangeAxis__srt--MinimumMember__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PatentsAndLicensesMember_zkxYMMM8Ak3f" title="Estimated useful lives"> <ix:nonNumeric contextRef="From2022-01-012022-12-31_srt_MinimumMember_custom_PatentsAndLicensesMember" format="ixt-sec:duryear" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife">5</ix:nonNumeric></span> to <span id="xdx_902_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dtY_c20220101__20221231__srt--RangeAxis__srt--MaximumMember__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PatentsAndLicensesMember_zWMNAhPGgml7" title="Estimated useful lives"><ix:nonNumeric contextRef="From2022-01-012022-12-31_srt_MaximumMember_custom_PatentsAndLicensesMember" format="ixt-sec:duryear" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife">17</ix:nonNumeric></span>
years, using the straight-line method. Amortization of patents and licenses commences once final approval of the patent or license has
been obtained. Patent and license costs are charged to operations if it is determined that the patent or license will not be obtained.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="QLGN:DerivativeFinancialInstrumentsAndWarrantLiabilitiesPolicyTextBlock"><p id="xdx_84A_ecustom--DerivativeFinancialInstrumentsAndWarrantLiabilitiesPolicyTextBlock_zYk7vHQpnWp7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86A_zNtcOzvKQ3g7">Derivative
Financial Instruments and Warrant Liabilities</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company does not use derivative instruments to hedge exposures to cash flow, market, or foreign currency risks. The Company evaluates
all of its financial instruments, including issued stock purchase warrants, to determine if such instruments are derivatives or contain
features that qualify as embedded derivatives. For derivative financial instruments that are accounted for as liabilities, the derivative
instrument is initially recorded at its fair value and is then re-valued at each reporting date, with changes in the fair value reported
in the consolidated statements of operations and comprehensive loss. Depending on the features of the derivative financial instrument,
the Company uses either the Black-Scholes option-pricing model or a Monte-Carlo simulation to value the derivative instruments at inception
and subsequent valuation dates. The classification of derivative instruments, including whether such instruments should be recorded as
liabilities or as equity, is re-assessed at the end of each reporting period (See Note 10-Warrant Liabilities and Note 11- Convertible
Debt - Related Party).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Fair
Value Measurements</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company determines the fair value measurements of applicable assets and liabilities based on a three-tier fair value hierarchy established
by accounting guidance and prioritizes the inputs used in measuring fair value. The Company discloses and recognizes the fair value of
its assets and liabilities using a hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy
gives the highest priority to valuations based upon unadjusted quoted prices in active markets for identical assets or liabilities (Level
1 measurements) and the lowest priority to valuations based upon unobservable inputs that are significant to the valuation (Level 3 measurements).
The guidance establishes three levels of the fair value hierarchy as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
                                            1 - Inputs that reflect unadjusted quoted prices in active markets for identical assets or
                                            liabilities that the Company has the ability to access at the measurement date;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
                                            2 - Inputs other than quoted prices that are observable for the assets or liability either
                                            directly or indirectly, including inputs in markets that are not considered to be active;
                                            and</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
                                            3 - Inputs that are unobservable.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:FairValueOfFinancialInstrumentsPolicy"><p id="xdx_84D_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zP6ZVVYW4Vx8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_861_z3ymfQ7hS3v4">Fair
Value of Financial Instruments</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash,
accounts receivable, prepaids, accounts payable, and accrued liabilities are carried at cost, which management believes approximates
fair value due to the short-term nature of these instruments.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:AdvertisingCostsPolicyTextBlock"><p id="xdx_840_eus-gaap--AdvertisingCostsPolicyTextBlock_zYVNkMB16xgf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_867_zXo6xMwPUfAi">Advertising</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Advertising
expense consists primarily of print and digital media promotional materials for a distributor. Advertising costs are expensed as incurred.
Advertising expense for the years ended December 31, 2022 and 2021 amounted to $<span id="xdx_90B_eus-gaap--AdvertisingExpense_c20220101__20221231_zbt2JY0VnqH" title="Advertising expense"><ix:nonFraction name="us-gaap:AdvertisingExpense" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">50,000</ix:nonFraction></span> and $<span id="xdx_90C_eus-gaap--AdvertisingExpense_c20210101__20211231_zSf9jmc2eJw7" title="Advertising expense"><ix:nonFraction name="us-gaap:AdvertisingExpense" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">0</ix:nonFraction></span>, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 50; Value: 35 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->50<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:ComprehensiveIncomePolicyPolicyTextBlock"><p id="xdx_845_eus-gaap--ComprehensiveIncomePolicyPolicyTextBlock_zaraFTgm9v08" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_862_zP4m4XVUM4R">Comprehensive
Loss</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Comprehensive
loss consists of net income and foreign currency translation adjustments. Comprehensive gains (losses) have been reflected in the statements
of operations and comprehensive loss and as a separate component in the statements of stockholders&#8217; equity for all periods presented.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:CompensationRelatedCostsPolicyTextBlock"><p id="xdx_84B_eus-gaap--CompensationRelatedCostsPolicyTextBlock_zuMCtZNK0dV" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86B_z93HuhI6ZM32">Stock-Based
Compensation</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock-based
compensation cost for equity awards granted to employees and non-employees is measured at the grant date based on the calculated fair
value of the award using the Black-Scholes option-pricing model, and is recognized as an expense, under the straight-line method, over
the requisite service period (generally the vesting period of the equity grant). If the Company determines that other methods are more
reasonable, or other methods for calculating these assumptions are prescribed by regulators, the fair value calculated for the Company&#8217;s
stock options could change significantly. Higher volatility, lower risk-free interest rates, and longer expected lives would result in
an increase to stock-based compensation expense to employees and non-employees determined at the date of grant.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:IncomeTaxPolicyTextBlock"><p id="xdx_84C_eus-gaap--IncomeTaxPolicyTextBlock_z0GYTOjzvE98" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86B_zajN575xWrPk">Income
Taxes</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deferred
income taxes are recognized for temporary differences in the basis of assets and liabilities for financial statement and income tax reporting
that arise due to net operating loss carry forwards, research and development credit carry forwards and from using different methods
and periods to calculate depreciation and amortization, allowance for doubtful accounts, accrued vacation, research and development expenses,
and state taxes. A provision has been made for income taxes due on taxable income and for the deferred taxes on the temporary differences.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deferred
tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion or all
of the deferred tax assets will not be realized. Deferred tax assets and liabilities are adjusted for the effects of changes in tax laws
and rates on the date of enactment. Realization of the deferred income tax asset is dependent on generating sufficient taxable income
in future years. For more information, refer to Note 17-Income Taxes.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="QLGN:SalesAndExciseTaxesPolicyTextBlock"><p id="xdx_841_ecustom--SalesAndExciseTaxesPolicyTextBlock_zFjBkSfE43Z" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86C_zJc7M9MEsVh2">Sales
and Excise Taxes</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sales
and other taxes collected from customers and subsequently remitted to government authorities are recorded as accounts receivable with
corresponding tax payable. These balances are removed from the consolidated balance sheet as cash is collected from customers and remitted
to the tax authority.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="QLGN:WarrantyReservePolicyTextBlock"><p id="xdx_84B_ecustom--WarrantyReservePolicyTextBlock_zuXhILNGtyr7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86F_zZFzrwafMcV7">Warranty
Costs</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s warranty policy generally provides for one year of coverage against defects and nonperformance within published specifications
for sold analyzers and for the term of the contract for equipment held for lease. The Company accrues for estimated warranty costs in
the period in which the revenue is recognized based on historical data and the Company&#8217;s best estimates of analyzer failure rates
and costs to repair.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accrued
warranty liabilities were approximately $<span id="xdx_901_eus-gaap--ProductWarrantyAccrual_iI_c20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zYMTyRdVoxbf" title="Accrued warranty liabilities"><ix:nonFraction name="us-gaap:ProductWarrantyAccrual" contextRef="AsOf2022-12-31_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">138,000</ix:nonFraction></span> and $<span id="xdx_90E_eus-gaap--ProductWarrantyAccrual_iI_c20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z5rpvRsY2Bhe" title="Accrued warranty liabilities"><ix:nonFraction name="us-gaap:ProductWarrantyAccrual" contextRef="AsOf2021-12-31_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">60,000</ix:nonFraction></span>, respectively, at December 31, 2022 and December 31, 2021 and are included
in accrued expenses and other current liabilities on the Consolidated Balance Sheets. Warranty costs were approximately $<span id="xdx_908_eus-gaap--ProductWarrantyExpense_c20220101__20221231_zjAeybIH7LRb" title="Warranty costs"><ix:nonFraction name="us-gaap:ProductWarrantyExpense" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">69,000</ix:nonFraction></span> and $<span id="xdx_90C_eus-gaap--ProductWarrantyExpense_c20210101__20211231_zgQ7NMp3UHI6" title="Warranty costs"><ix:nonFraction name="us-gaap:ProductWarrantyExpense" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">57,000</ix:nonFraction></span>
for the years ended December 31, 2022 and 2021, respectively, and are included in cost of product sales in the Consolidated Statements
of Operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"><p id="xdx_84D_eus-gaap--ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_zQ6eZKfREUnf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_861_zr4gZVO6OLT1">Foreign
Currency Translation</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
functional currency for the Company is the U.S. dollar. The functional currency for NanoSynex, the Company&#8217;s newly acquired majority
owned subsidiary, is the New Israeli Shekel (NIS). The financial statements of NanoSynex are translated into U.S. dollars using exchange
rates in effect at each period end for assets and liabilities; using exchange rates in effect during the period for results of operations;
and using historical exchange rates for certain equity accounts. The adjustment resulting from translating the financial statements of
NanoSynex is reflected as a separate component of other comprehensive income (loss).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
comprehensive loss related to the effects of foreign currency translation adjustments attributable to NanoSynex was $<span id="xdx_901_eus-gaap--OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_c20220101__20221231__us-gaap--BusinessAcquisitionAxis__custom--NanoSynexLtdMember_zdomOdXwjkPi" title="Adjustment net of tax"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="From2022-01-012022-12-31_custom_NanoSynexLtdMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">50,721</ix:nonFraction></span> and $<span id="xdx_900_eus-gaap--OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_c20210101__20211231__us-gaap--BusinessAcquisitionAxis__custom--NanoSynexLtdMember_znsm1pjH0QU7" title="Adjustment net of tax"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="From2021-01-012021-12-31_custom_NanoSynexLtdMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">0</ix:nonFraction></span> at
December 31, 2022 and 2021, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>


<ix:exclude><!-- Field: Page; Sequence: 51; Value: 35 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->51<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock"><p id="xdx_844_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zIJBrwoB7uI3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86E_zP8oTscRYrR2">Recent
Accounting Pronouncements</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
June 2016, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued ASU No. 2016-13, <i>Measurement of Credit Losses on Financial
Instruments</i>, which supersedes current guidance by requiring recognition of credit losses when it is probable that a loss has been
incurred. The new standard requires the establishment of an allowance for estimated credit losses on financial assets including trade
and other receivables at each reporting date. The new standard will result in earlier recognition of allowances for losses on trade and
other receivables and other contractual rights to receive cash. In November 2019, the FASB issued ASU No. 2019-10, <i>Financial Instruments
&#8211; Credit Losses (Topic 326), Derivatives and Hedging (Topic 815) </i>and <i>Leases (Topic 842)</i>, which extended the effective
date of Topic 326 for certain companies until fiscal years beginning after December 15, 2022. The new standard will be effective for
the Company in the first quarter of fiscal year beginning January 1, 2023, and early adoption is permitted. The Company adopted ASU 2016-13
on January 1, 2023. Adoption did not have a material impact on the Company&#8217;s consolidated financial statements and related disclosures.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="QLGN:GlobalEconomicConditionsPolicyTextBlock"><p id="xdx_84A_ecustom--GlobalEconomicConditionsPolicyTextBlock_z9Nrhk6J8AMl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86D_zY9GyuybJgi8">Global
Economic Conditions</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>War
in Ukraine</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
February 2022, Russia invaded Ukraine. While the Company has no direct exposure in Russia and Ukraine, the Company continues to monitor
any broader impact to the global economy, including with respect to inflation, supply chains and fuel prices. The full impact of the
conflict on the Company&#8217;s business and financial results remains uncertain and will depend on the severity and duration of the
conflict and its impact on regional and global economic conditions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Inflationary
Cost Environment</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year ended 2022 and continuing into the current fiscal year, global commodity and labor markets experienced significant inflationary
pressures attributable to ongoing economic recovery and supply chain issues. The Company is subject to inflationary pressures with respect
to raw materials, labor and transportation. Accordingly, the Company continues to take actions with its customers and suppliers to mitigate
the impact of these inflationary pressures in the future. Actions to mitigate inflationary pressures with suppliers include aggregation
of purchase requirements to achieve optimal volume benefits, negotiation of cost-reductions and identification of more cost competitive
suppliers. While these actions are designed to offset the impact of inflationary pressures, the Company cannot provide assurance that
it will be successful in fully offsetting increased costs resulting from inflationary pressure.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Impact of
COVID-19 Pandemic</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
COVID-19 pandemic has had a dramatic impact on businesses globally and on the Company&#8217;s business as well. Sales of diagnostic products
fell significantly during 2020 and the Company&#8217;s net loss increased significantly, as deferral of patients&#8217; non-emergency
visits to physician offices, clinics and small hospitals sharply reduced demand for FastPack tests. Since then we have experienced some recovery in demand.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
accounting standard updates are either not applicable to the Company or are not expected to have a material impact on the Company&#8217;s
consolidated financial statements.</span></p>

</ix:nonNumeric><p id="xdx_853_zHs18ScsZ2f5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:SubstantialDoubtAboutGoingConcernTextBlock"><p id="xdx_804_eus-gaap--SubstantialDoubtAboutGoingConcernTextBlock_z3ue2rwHlAt3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
2 &#8212; <span id="xdx_822_zeUG5Zah2X08">LIQUIDITY AND GOING CONCERN</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2022, the Company had approximately $<span id="xdx_903_eus-gaap--Cash_iI_pn5n6_c20221231_zQqdfCVC1aJ1" title="Cash"><ix:nonFraction name="us-gaap:Cash" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">7.0</ix:nonFraction></span> million in cash and an accumulated deficit of $<span id="xdx_90F_eus-gaap--RetainedEarningsAccumulatedDeficit_iNI_pn5n6_di_c20221231_zPnOkApQF176" title="Accumulated deficit"><ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-5" scale="6" sign="-" unitRef="USD">103.4</ix:nonFraction></span> million. For the years
ended December 31, 2022 and 2021, the Company used cash of $<span id="xdx_90C_eus-gaap--NetCashProvidedByUsedInOperatingActivities_iN_pn5n6_di_c20220101__20221231_zWTPslDhDkGe" title="Net cash used in operating activities"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="-5" scale="6" sign="-" unitRef="USD">13.2</ix:nonFraction></span> million and $<span id="xdx_903_eus-gaap--NetCashProvidedByUsedInOperatingActivities_iN_pn5n6_di_c20210101__20211231_znn9cGD4qqT7" title="Net cash used in operating activities"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="-5" scale="6" sign="-" unitRef="USD">14.7</ix:nonFraction></span> million, respectively, in operations. The Company&#8217;s
cash balances are expected to fund operations into the third quarter of 2023. As a pre-clinical development-stage therapeutics biotechnology
company, the Company expects to continue to have net losses and negative cash flow from operations, which over time will challenge its
liquidity. These factors raise substantial doubt about the Company&#8217;s ability to continue as a going concern for the one-year period
following the date that these financial statements were issued.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
is no assurance that profitable operations will ever be achieved, or, if achieved, could be sustained on a continuing basis. In order
to fully execute its business plan, the Company will require significant additional financing for planned research and development activities,
capital expenditures, clinical and pre-clinical testing for its QN-302 clinical trials, preclinical development of RAS and QN-247, and
funding for NanoSynex operations (See Note 3-Acquisition), as well as commercialization activities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Historically,
the Company&#8217;s principal sources of cash have included proceeds from the issuance of common and preferred equity and proceeds
from the issuance of debt. In December 2021, the Company raised $<span id="xdx_907_eus-gaap--ProceedsFromIssuanceOfCommonStock_pn5n6_c20211201__20211231_zHtwcTNjb6t9" title="Proceeds from issuance of common stock"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="From2021-12-012021-12-31" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">8.8</ix:nonFraction></span>
million from the issuance of common stock to several institutional investors, and in December 2022 the Company raised $<span id="xdx_904_eus-gaap--ProceedsFromConvertibleDebt_pn5n6_c20221201__20221231_z3gJr5eZpxk3" title="Proceeds from issuance of debt"><ix:nonFraction name="us-gaap:ProceedsFromConvertibleDebt" contextRef="From2022-12-012022-12-31" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">3.0</ix:nonFraction></span>
million from the sale of a convertible debt - related party (see Note 11-Convertible Debt - Related Party).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 52; Value: 35 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->52<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
can be no assurance that further financing can be obtained on favorable terms, or at all. If we are unable to obtain funding, we could
be required to delay, reduce or eliminate research and development programs, product portfolio expansion or future commercialization
efforts, which could adversely affect our business prospects.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a condition to the NanoSynex closing, the Company agreed to provide NanoSynex with up to $<span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodValueAcquisitions_pn5n6_c20220101__20221231__us-gaap--BusinessAcquisitionAxis__custom--NanoSynexLtdMember_zwXw0OgDeosj" title="Stock issued during period value acquisitions"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" contextRef="From2022-01-012022-12-31_custom_NanoSynexLtdMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">10.4</ix:nonFraction></span> million of future funding based on NanoSynex&#8217;s
achievement of certain future development milestones and subject to other terms and conditions described in the Master Agreement for
the Operational and Technological Funding of NanoSynex (the &#8220;Funding Agreement&#8221;) entered into with NanoSynex. These funding
commitments are in the form of convertible promissory notes to be issued to <span id="xdx_908_eus-gaap--StockholdersEquityNoteStockSplit_c20220101__20221231_zUODpnZ8KXKj" title="Stockholders equity note stock split"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="us-gaap:StockholdersEquityNoteStockSplit">the Company with a face value equal to the amount paid by
the Company to NanoSynex upon satisfaction of the applicable performance milestone, bearing interest at the rate of 9% per annum on the
principal balance from time to time outstanding under the particular promissory note, convertible at the option of the Company into additional
shares of NanoSynex in order for the Company to maintain at least a 50.1% controlling ownership interest in NanoSynex, should NanoSynex
issue additional shares. The principal of the convertible notes are due and payable upon the sooner to occur of: i) five years from the
date of issuance of the particular promissory note; ii) the acquisition by any person or entity of all or substantially all of the share
capital of NanoSynex, through share purchase, issuance or shares or merger of NanoSynex, or the purchase of all or substantially all
of the assets of NanoSynex; or iii) the initial public offering of NanoSynex.</ix:nonNumeric></span> The Company provided funding to NanoSynex of $<span id="xdx_905_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pn5n6_c20220101__20221231__us-gaap--BusinessAcquisitionAxis__custom--NanoSynexLtdMember_zJ4TP8Nrzlh4" title="Stock issued during period value new issues"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2022-01-012022-12-31_custom_NanoSynexLtdMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">2.4</ix:nonFraction></span> million
during 2022 pursuant to this agreement. The Company may terminate the Funding Agreement upon 120 days&#8217; notice, but would still
be liable for any payments due for milestones achieved prior to termination.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
the extent that the Company raises additional capital through the sale of equity or convertible debt securities, the ownership interests
of its common stockholders will be diluted, and the terms of these securities may include liquidation or other preferences that adversely
affect the rights of our common stockholders. Debt financing, if available, may involve agreements that include covenants limiting or
restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends.
If the Company raises additional funds through government or other third-party funding, commercialization, marketing and distribution
arrangements or other collaborations, strategic alliances or licensing arrangements with third parties, it may have to relinquish valuable
rights to its technologies, future revenue streams, research programs or product candidates or grant licenses on terms that may not be
favorable to the Company. Additional funding may not be available to the Company on acceptable terms, or at all. In addition, any future
financing (depending on the terms and conditions) may be subject to the approval of Alpha Capital, the holder of the Company&#8217;s
8% Senior Convertible Debenture (the &#8220;Debenture&#8221;), or trigger certain adjustments to the Debenture or warrants held by Alpha
Capital.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying financial statements have been prepared assuming that the Company will continue as a going concern. The financial statements
do not include any adjustments that would be necessary should the Company be unable to continue as a going concern, and therefore, be
required to liquidate its assets and discharge its liabilities in other than the normal course of business and at amounts that may differ
from those reflected in the accompanying financial statements</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:BusinessCombinationDisclosureTextBlock"><p id="xdx_803_eus-gaap--BusinessCombinationDisclosureTextBlock_z9GfJCFJd2Zc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
3 &#8212; <span id="xdx_822_z7BJAxPkbEQb">ACQUISITION</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Business
Combination</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">The Company acquired a <span id="xdx_903_eus-gaap--BusinessAcquisitionPercentageOfVotingInterestsAcquired_iI_pid_dp_uPure_c20220526__us-gaap--BusinessAcquisitionAxis__custom--NanoSynexLtdMember_ziE1aWhduCsh" title="Business acquisition, voting equity rate"><ix:nonFraction name="us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired" contextRef="AsOf2022-05-26_custom_NanoSynexLtdMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">52.8</ix:nonFraction></span>%
voting equity interest in NanoSynex on May 26, 2022 (the &#8220;NanoSynex Acquisition Date&#8221;) through: (1) the purchase of <span id="xdx_901_eus-gaap--StockIssuedDuringPeriodSharesAcquisitions_c20220524__20220526__us-gaap--StatementClassOfStockAxis__custom--SeriesAOnePreferredStockMember_z2KnsEtsvxT5" title="Number of shares of stock issued"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesAcquisitions" contextRef="From2022-05-242022-05-26_custom_SeriesAOnePreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,232,861</ix:nonFraction></span>
shares Preferred A-1 Stock of NanoSynex from Alpha Capital (a related party) for <span id="xdx_903_eus-gaap--StockIssuedDuringPeriodSharesAcquisitions_c20220524__20220526__us-gaap--BusinessAcquisitionAxis__custom--NanoSynexLtdMember_z5ZdbQdIRa37" title="Stock issued during period shares acquisitions"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesAcquisitions" contextRef="From2022-05-242022-05-26_custom_NanoSynexLtdMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">350,000</ix:nonFraction></span>
reverse split adjusted shares of the Company&#8217;s common stock and a prefunded warrant to purchase <span id="xdx_901_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20220526__us-gaap--StatementEquityComponentsAxis__custom--PrefundedWarrantMember_zia7g6kOVve5" title="Warrants to purchase shares"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2022-05-26_custom_PrefundedWarrantMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">331,464</ix:nonFraction>
reverse split adjusted shares of the Company&#8217;s common stock at a purchase price of $<span id="xdx_909_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20220526__us-gaap--BusinessAcquisitionAxis__custom--NanoSynexLtdMember__us-gaap--StatementEquityComponentsAxis__custom--PrefundedWarrantMember_z8HidDJfpUx4" title="Warrants or rights"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2022-05-26_custom_NanoSynexLtdMember_custom_PrefundedWarrantMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.001</ix:nonFraction></span>
per share (<span id="xdx_90B_eus-gaap--StockholdersEquityReverseStockSplit_c20220524__20220526__us-gaap--BusinessAcquisitionAxis__custom--NanoSynexLtdMember_zfcy0ZSHZbZh" title="Reverse split, description"><ix:nonNumeric contextRef="From2022-05-242022-05-26_custom_NanoSynexLtdMember" name="us-gaap:StockholdersEquityReverseStockSplit">these warrants were subsequently exercised on September 13, 2022)</ix:nonNumeric></span>, and (2) the purchase of <span id="xdx_902_eus-gaap--StockIssuedDuringPeriodSharesAcquisitions_c20220524__20220526__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember__us-gaap--BusinessAcquisitionAxis__custom--NanoSynexLtdMember_zyVm1ZSvx9G5" title="Stock issued during period shares acquisitions"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesAcquisitions" contextRef="From2022-05-242022-05-26_custom_NanoSynexLtdMember_us-gaap_SeriesBPreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">381,786</ix:nonFraction></span>
shares of Series B preferred stock of NanoSynex from NanoSynex in exchange for $<span id="xdx_901_eus-gaap--StockIssuedDuringPeriodValueAcquisitions_c20220524__20220526__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember__us-gaap--BusinessAcquisitionAxis__custom--NanoSynexLtdMember_zAhUPKw0qxh2" title="Stock issued during period value acquisitions"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" contextRef="From2022-05-242022-05-26_custom_NanoSynexLtdMember_us-gaap_SeriesBPreferredStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">600,000</ix:nonFraction></span></span>
(collectively, the &#8220;NanoSynex Acquisition&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
acquisition of the majority interest of NanoSynex was accounted for as a business combination using the acquisition method, in accordance
with FASB ASC Topic 805. Identifiable assets acquired, liabilities assumed and any noncontrolling interest in the acquiree are recognized
and measured as of the acquisition date at fair value. Determining the fair value of assets acquired, liabilities assumed and noncontrolling
interest requires management&#8217;s judgment and often involves the use of significant estimates and assumptions, including assumptions
with respect to future cash flows, discount rates and asset lives among other items. The Company uses third-party valuations for intangible
assets in a business combination using a discounted cash flow analysis, incorporating various assumptions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 53; Value: 35 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->53<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>
<!-- Field: Split-Segment; Name: Sp_001 -->
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock"><p id="xdx_890_eus-gaap--ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_zOsbLs4POgyk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
summary of the consideration transferred and fair value of assets acquired and liabilities assumed in the NanoSynex Acquisition is as
follows (all shares shown post 1 for 10 reverse split on November 23, 2022):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B8_zhGesOfCesRi" style="display: none">SCHEDULE
OF CONSIDERATION TRANSFERRED</span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Consideration transferred, net of cash acquired</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 80%; text-align: left; padding-bottom: 1.5pt">Cash paid for NanoSynex preferred stock:</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td id="xdx_986_ecustom--PaymentsToAcquireBusinesses_pp0p0_c20220524__20220526__us-gaap--BusinessAcquisitionAxis__custom--NanoSynexLtdMember_zs1OfV4i1qV1" title="Cash paid for NanoSynex preferred stock:" style="border-bottom: Black 1.5pt solid; width: 16%; text-align: right"><ix:nonFraction name="QLGN:PaymentsToAcquireBusinesses" contextRef="From2022-05-242022-05-26_custom_NanoSynexLtdMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">600,000</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">FMV of <span id="xdx_905_eus-gaap--StockIssuedDuringPeriodSharesAcquisitions_c20220524__20220526__us-gaap--BusinessAcquisitionAxis__custom--NanoSynexLtdMember_zkEfDIX9oqbc" title="Common stock issued for business acquisition" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIENPTlNJREVSQVRJT04gVFJBTlNGRVJSRUQgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesAcquisitions" contextRef="From2022-05-242022-05-26_custom_NanoSynexLtdMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">350,000</ix:nonFraction></span> shares of Qualigen stock issued to Alpha Capital Anstalt</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_987_eus-gaap--StockIssuedDuringPeriodValueAcquisitions_pp0p0_c20220524__20220526__us-gaap--BusinessAcquisitionAxis__custom--NanoSynexLtdMember_zxs0bN5NF5Ui" title="FMV of 3,500,000 shares of Qualigen stock issued to Alpha Capital Anstalt" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" contextRef="From2022-05-242022-05-26_custom_NanoSynexLtdMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,904,989</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">FMV of <span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodSharesAcquisitions_c20220524__20220526__us-gaap--BusinessAcquisitionAxis__custom--AlphaCapitalAnstaltMember_zdIwRg5Vz5Jl" title="Common stock issued for business acquisition" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIENPTlNJREVSQVRJT04gVFJBTlNGRVJSRUQgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesAcquisitions" contextRef="From2022-05-242022-05-26_custom_AlphaCapitalAnstaltMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">331,464</ix:nonFraction></span>
    shares of Qualigen stock related to prefunded warrant issued to Alpha Capital Anstalt (See Note 15)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td id="xdx_986_ecustom--PrefundedWarrantsIssuedForBusinessAcquisition_pp0p0_c20220524__20220526__us-gaap--BusinessAcquisitionAxis__custom--NanoSynexLtdMember_zjG0dIRqPrIe" title="FMV of 3,314,641 shares of Qualigen stock related to prefunded warrant issued to Alpha Capital Anstalt" style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="QLGN:PrefundedWarrantsIssuedForBusinessAcquisition" contextRef="From2022-05-242022-05-26_custom_NanoSynexLtdMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,804,102</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Total consideration paid for NanoSynex preferred stock</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td id="xdx_982_eus-gaap--BusinessCombinationConsiderationTransferred1_pp0p0_c20220524__20220526__us-gaap--BusinessAcquisitionAxis__custom--NanoSynexLtdMember_zf0PuKozuuF2" title="Total consideration paid for NanoSynex common stock" style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:BusinessCombinationConsiderationTransferred1" contextRef="From2022-05-242022-05-26_custom_NanoSynexLtdMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">3,709,091</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td id="xdx_F47_zewy4rTtnOag" style="text-align: left; padding-bottom: 1.5pt">FMV of consideration related to related to repricing of <span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesAcquisitions_c20220524__20220526_zZyBkxTCAyp7" title="Common stock issued for business acquisition" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIENPTlNJREVSQVRJT04gVFJBTlNGRVJSRUQgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesAcquisitions" contextRef="From2022-05-242022-05-26" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">7,048</ix:nonFraction></span> shares of Alpha Capital/Qualigen warrants *</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td id="xdx_98E_ecustom--FairValueOfWarrantModificationForBusinessAcquisition_pp0p0_c20220524__20220526__us-gaap--BusinessAcquisitionAxis__custom--NanoSynexLtdMember_fKg_____zeuMe7mz3ow5" title="FMV of consideration related to related to repricing of 70,478 shares of Alpha Capital/Qualigen warrants *" style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="QLGN:FairValueOfWarrantModificationForBusinessAcquisition" contextRef="From2022-05-242022-05-26_custom_NanoSynexLtdMember" id="Fact000879" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">696</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">NanoSynex cash acquired</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--CashAcquiredFromAcquisition_iN_pp0p0_di_c20220524__20220526__us-gaap--BusinessAcquisitionAxis__custom--NanoSynexLtdMember_zdeO6GLj5Olf" title="NanoSynex cash acquired" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:CashAcquiredFromAcquisition" contextRef="From2022-05-242022-05-26_custom_NanoSynexLtdMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">735,354</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Total consideration transferred, net of cash acquired</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td id="xdx_98B_eus-gaap--PaymentsToAcquireBusinessesNetOfCashAcquired_pp0p0_c20220524__20220526__us-gaap--BusinessAcquisitionAxis__custom--NanoSynexLtdMember_z9onq8HthZe4" title="Total consideration transferred, net of cash acquired" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" contextRef="From2022-05-242022-05-26_custom_NanoSynexLtdMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">3,574,433</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td id="xdx_F01_zHAnwfOGCQR6" style="width: 15pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="text-align: justify"><span id="xdx_F19_z5NxVo6luna4" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:footnote id="Footnote000884" xml:lang="en-US">See disclosure
under <i>Noncompensatory Equity Classified Warrants</i> regarding May 26, 2022 transaction-Note 15-Stockholders&#8217; Equity</ix:footnote></span></td>
</tr></table>


</ix:nonNumeric><p id="xdx_8A6_zhome0atFQBl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock"><p id="xdx_892_eus-gaap--ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_zZYSY9jhcOy9" style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B2_zP1gRBl98nNb" style="display: none">SCHEDULE
OF ASSETS ACQUIRED AND LIABILITIES</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_497_20220526_zyjYIFjvvDcl" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Purchase Price Allocation</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_iI_ziI0KgaE9ZF" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; width: 80%; text-align: left">Accounts receivable</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" contextRef="AsOf2022-05-26" format="ixt:numdotdecimal" decimals="0" unitRef="USD">75,336</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_iI_z9T12KJnysSj" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Property and equipment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" contextRef="AsOf2022-05-26" format="ixt:numdotdecimal" decimals="0" unitRef="USD">120,942</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_ecustom--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedResearchAndDevelopmentExpense_iI_zHDGLPvjxUth" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">In process R&amp;D</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="QLGN:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedResearchAndDevelopmentExpense" contextRef="AsOf2022-05-26" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,700,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_iNI_di_zDPdWepmReW9" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Accounts payable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" contextRef="AsOf2022-05-26" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,588</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40A_ecustom--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpensesAndOtherPayables_iI_zTQOiTkoF3m4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Accrued expenses and other payables</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="QLGN:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpensesAndOtherPayables" contextRef="AsOf2022-05-26" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">291,093</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_409_ecustom--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedResearchAndDevelopmentGrantLiability_iI_z3fOD7mPKuek" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">R&amp;D grant liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="QLGN:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedResearchAndDevelopmentGrantLiability" contextRef="AsOf2022-05-26" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,362,264</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40E_ecustom--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesShortTermDebt_iI_zYMnPbk7tEMk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Short term debt</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="QLGN:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesShortTermDebt" contextRef="AsOf2022-05-26" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">941,898</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40A_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_iNI_di_zuieaCdeGej4" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Deferred tax liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" contextRef="AsOf2022-05-26" format="ixt:numdotdecimal" decimals="0" unitRef="USD">629,379</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40B_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedLessNoncontrollingInterest_iI_zGNbjPAzXf98" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Noncontrolling interest assumed</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedLessNoncontrollingInterest" contextRef="AsOf2022-05-26" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">3,882,225</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_40F_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_iNI_di_z8X9huu3FFX4" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left">Identifiable net assets acquired</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" contextRef="AsOf2022-05-26" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,215,169</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40E_eus-gaap--Goodwill_iI_zm5gS7WIrxP2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; padding-bottom: 1.5pt">Goodwill</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:Goodwill" contextRef="AsOf2022-05-26" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,789,602</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_iI_zQUA13f31O1e" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Total consideration transferred, net of cash acquired</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" contextRef="AsOf2022-05-26" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,574,433</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A7_zaHtMPVNz2O" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year ended December 31, 2022, the Company made measurement period adjustments to the preliminary purchase price allocation which
included: (i) a decrease to noncontrolling interest of $<span id="xdx_90B_eus-gaap--MinorityInterestDecreaseFromRedemptions_c20220101__20221231_zWO1JSzS0fM9" title="Decrease to noncontrolling interest"><ix:nonFraction name="us-gaap:MinorityInterestDecreaseFromRedemptions" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">117,775</ix:nonFraction></span>, (ii) a decrease to goodwill of $<span id="xdx_908_eus-gaap--GoodwillPeriodIncreaseDecrease_c20220101__20221231_z528J6raPBXh" title="Decrease in good will"><ix:nonFraction name="us-gaap:GoodwillPeriodIncreaseDecrease" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">106,621</ix:nonFraction></span>. The measurement period adjustments
were made to reflect facts and circumstances that existed as of the acquisition date and is reflected in the table above.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Company
transaction costs, which were immaterial, have been expensed as incurred and charged to the Company&#8217;s consolidated statements of
operations and comprehensive loss. There was no provision for reimbursement of transaction costs from the Company to NanoSynex.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Goodwill
represents the excess of the purchase price over the fair value of the net assets acquired as of the acquisition date. Goodwill represents
the value of the future technology to be developed in excess of the identifiable assets as well as the operational synergies of the combined
companies to be recognized. Goodwill has an indefinite useful life and is not amortized. None of the Goodwill is expected to be deductible
for tax purposes.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a condition to the closing, the Company agreed to provide NanoSynex with up to $<span id="xdx_904_eus-gaap--StockIssuedDuringPeriodValueAcquisitions_pn5n6_c20220101__20221231__dei--LegalEntityAxis__custom--NanoSynexMember_zH9nhBrzmzDb" title="Stock issued during period value acquisitions"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" contextRef="From2022-01-012022-12-31_custom_NanoSynexMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">10.4</ix:nonFraction></span> million of future funding based on NanoSynex&#8217;s
achievement of certain future development milestones and subject to other terms and conditions described in the Funding Agreement entered
into with NanoSynex. (See Note 2-Liquidity for further details regarding the terms and conditions of the Funding Agreement).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">The
Company&#8217;s consolidated statements of operations and comprehensive loss for the years ended December 31, 2022 and 2021 include
approximately $<span id="xdx_90A_eus-gaap--OtherComprehensiveIncomeLossTax_pn5n6_c20220101__20221231__us-gaap--BusinessAcquisitionAxis__custom--NanoSynexLtdMember_z2dz503bU9c" title="Other comprehensive income loss tax"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossTax" contextRef="From2022-01-012022-12-31_custom_NanoSynexLtdMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">5.1</ix:nonFraction> million and $<span id="xdx_908_eus-gaap--OtherComprehensiveIncomeLossTax_c20210101__20211231__us-gaap--BusinessAcquisitionAxis__custom--NanoSynexLtdMember_zvxypw86ddQj" title="Other comprehensive income loss tax"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossTax" contextRef="From2021-01-012021-12-31_custom_NanoSynexLtdMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">0</ix:nonFraction></span>, respectively, of net loss associated with the results of operations of NanoSynex from the NanoSynex
Acquisition Date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 54; Value: 35 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->54<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following proforma information has been prepared as if the NanoSynex Acquisition occurred on January 1, 2021. The following unaudited
supplemental proforma consolidated results do not purport to reflect what the combined Company&#8217;s results of operations would have
been, nor do they project the future results of operations of the combined Company. The unaudited supplemental proforma consolidated
results reflect the historical financial information of the Company and NanoSynex, adjusted to give effect to the NanoSynex Acquisition
as if it had occurred on January 1, 2021, as well as to record NanoSynex stock compensation expense and to record the net loss related
to the non-controlling interest, in accordance with generally accepted accounting principles:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></p><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:BusinessAcquisitionProFormaInformationTextBlock"><p id="xdx_89D_eus-gaap--BusinessAcquisitionProFormaInformationTextBlock_zXMOHqz5Mwlb" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BD_zFvG4O9lWCI5" style="display: none">SCHEDULE
OF PRO FORMA INFORMATION</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center">Consolidated Pro Forma Financial</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center">Results for the Years Ending</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Net revenue</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98B_eus-gaap--BusinessAcquisitionsProFormaRevenue_c20220101__20221231_zzNPb9cAfb91" title="Business acquisitions pro forma revenue" style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:BusinessAcquisitionsProFormaRevenue" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,983,556</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_986_eus-gaap--BusinessAcquisitionsProFormaRevenue_c20210101__20211231_znICUMbVL3Gd" title="Business acquisitions pro forma revenue" style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:BusinessAcquisitionsProFormaRevenue" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,653,725</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Net loss attributable to Qualigen Therapeutics, Inc.</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98F_eus-gaap--BusinessAcquisitionsProFormaNetIncomeLoss_c20220101__20221231_z8b3BcgWawu2" title="Business acquisitions pro forma net income loss" style="text-align: right">(<ix:nonFraction name="us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">19,538,959</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_986_eus-gaap--BusinessAcquisitionsProFormaNetIncomeLoss_c20210101__20211231_zqf918hBz2tg" title="Business acquisitions pro forma net income loss" style="text-align: right">(<ix:nonFraction name="us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">17,897,137</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AA_z9jgqHEF2Haa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:InventoryDisclosureTextBlock"><p id="xdx_807_eus-gaap--InventoryDisclosureTextBlock_zM22F3ZlaLD3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
4 &#8212; <span id="xdx_820_zmgcWUUon9si">INVENTORY, NET</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:ScheduleOfInventoryCurrentTableTextBlock"><p id="xdx_89A_eus-gaap--ScheduleOfInventoryCurrentTableTextBlock_zBA3nzCi8nXf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inventory,
net consisted of the following at December 31, 2022 and December 31, 2021:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B4_zl936wY2g2zk" style="display: none">SCHEDULE OF INVENTORY</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49D_20221231_zPIw4EdGbJF5" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31,<br />
 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_492_20211231_zBFmkgZkZj17" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31,<br />
 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--InventoryRawMaterials_iI_maIFGz0my_ztIAItWFXVpe" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Raw materials</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:InventoryRawMaterials" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">949,796</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:InventoryRawMaterials" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">823,315</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--InventoryWorkInProcess_iI_maIFGz0my_zqzR4p4q4kz6" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Work in process</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:InventoryWorkInProcess" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">200,318</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:InventoryWorkInProcess" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">188,135</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--InventoryFinishedGoods_iI_maIFGz0my_zOgIAUswNtX7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Finished goods</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:InventoryFinishedGoods" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">436,183</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:InventoryFinishedGoods" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">44,428</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--InventoryNet_iTI_mtIFGz0my_zzqttACnIBTg" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Total inventory</span></td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:InventoryNet" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,586,297</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:InventoryNet" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,055,878</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A7_z4ocf0uz3Wv6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="QLGN:PrepaidExpensesAndOtherCurrentAssetsTextBlock"><p id="xdx_80D_ecustom--PrepaidExpensesAndOtherCurrentAssetsTextBlock_z8Ubvmm1KKsa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
5 &#8212; <span id="xdx_82D_zGnIs5Onxrlf">PREPAID EXPENSES AND OTHER CURRENT ASSETS</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock"><p id="xdx_896_eus-gaap--DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_zbCZypHtjnw1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prepaid
expenses and other current assets consisted of the following at December 31, 2022 and December 31, 2021:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B4_z8X22FW3VM7h" style="display: none">SCHEDULE OF PREPAID EXPENSES AND OTHER CURRENT ASSETS</span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_493_20221231_zz71PbAaF8C8" style="font-weight: bold; text-align: center">December 31,</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_49B_20211231_zTidS1QDTV7a" style="font-weight: bold; text-align: center">December 31,</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--PrepaidInsurance_iI_pp0p0_maPECzoJ5_zBmCuDbCnSld" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Prepaid insurance</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:PrepaidInsurance" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,377,323</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:PrepaidInsurance" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,197,726</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_ecustom--PrepaidManufacturingExpenses_iI_maPECzoJ5_zOVYhOPv484d" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Prepaid manufacturing expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="QLGN:PrepaidManufacturingExpenses" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">43,820</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="QLGN:PrepaidManufacturingExpenses" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">67,410</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--OtherPrepaidExpenseCurrent_iI_pp0p0_maPECzoJ5_zuORQtWfNO6h" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Other prepaid expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OtherPrepaidExpenseCurrent" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">227,451</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OtherPrepaidExpenseCurrent" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">111,183</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--OtherAssetsCurrent_iI_pp0p0_maPECzoJ5_zYtyYb3022Ri" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Other current assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherAssetsCurrent" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">12,626</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherAssetsCurrent" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">3,577</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_iTI_pp0p0_mtPECzoJ5_znJgfhRZQd8f" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Prepaid expenses and
    other current assets</span></td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,661,220</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,379,896</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric></ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock"><p id="xdx_80D_eus-gaap--PropertyPlantAndEquipmentDisclosureTextBlock_zyIuG3aX4Hy6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
6 &#8212; <span id="xdx_82A_zj9JWUvK6HB2">PROPERTY AND EQUIPMENT, NET</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:PropertyPlantAndEquipmentTextBlock"><p id="xdx_896_eus-gaap--PropertyPlantAndEquipmentTextBlock_zwUq8vngJ0o6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property
and equipment, net consisted of the following at December 31, 2022 and December 31, 2021:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span id="xdx_8B7_zwHYaspSTkb4" style="display: none">SCHEDULE OF PROPERTY AND EQUIPMENT</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_49F_20221231_zJU1p80YDKNl" style="font-weight: bold; text-align: center">December 31,</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_497_20211231_zgVH9Cax4sOc" style="font-weight: bold; text-align: center">December 31,</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--PropertyPlantAndEquipmentGross_iI_pp0p0_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--MachineryAndEquipmentMember_zpueYdQY8YF8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Machinery and equipment</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2022-12-31_us-gaap_MachineryAndEquipmentMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,510,148</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2021-12-31_us-gaap_MachineryAndEquipmentMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,482,841</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--PropertyPlantAndEquipmentGross_iI_pp0p0_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember_zSOYXrFAcKA9" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Computer equipment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2022-12-31_us-gaap_ComputerEquipmentMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">395,836</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2021-12-31_us-gaap_ComputerEquipmentMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">345,117</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--PropertyPlantAndEquipmentGross_iI_pp0p0_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zOCk7Ja6f9A1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Leasehold improvements</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2022-12-31_us-gaap_LeaseholdImprovementsMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">333,271</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2021-12-31_us-gaap_LeaseholdImprovementsMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">333,271</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--PropertyPlantAndEquipmentGross_iI_pp0p0_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--MoldsAndToolingMember_zT1y1bTnjWfh" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Molds and tooling</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2022-12-31_custom_MoldsAndToolingMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">260,002</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2021-12-31_custom_MoldsAndToolingMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">260,002</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--PropertyPlantAndEquipmentGross_iI_pp0p0_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_zd9DJwDk3yI4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Furniture and fixtures</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2022-12-31_us-gaap_FurnitureAndFixturesMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">144,832</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2021-12-31_us-gaap_FurnitureAndFixturesMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">143,013</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--PropertyPlantAndEquipmentGross_iI_pp0p0_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--EquipmentMember_zP3Rohjc16D" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Equipment held for lease</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2022-12-31_us-gaap_EquipmentMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,399,444</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2021-12-31_us-gaap_EquipmentMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,181,211</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--PropertyPlantAndEquipmentGross_iI_ze0HrC0A1zqf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Property and equipment, gross</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,043,533</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,745,455</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_di_msPPAENzZdO_zYseZPs8KDK7" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Accumulated depreciation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,623,446</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,541,238</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_402_ecustom--FixedAssetImpairments_iI_msPPAENzZdO_zA9FKaxLJSac" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Fixed asset impairment</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="QLGN:FixedAssetImpairments" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">75,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0996">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--PropertyPlantAndEquipmentNet_iI_zsy8xKqFo83a" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Property and equipment,
    net</span></td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">345,087</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">204,217</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A4_ztzrh9YppC0j" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Depreciation
expense relating to property and equipment was approximately $<span id="xdx_90F_eus-gaap--Depreciation_pp0p0_c20220101__20221231_zGvndBEQgQVb" title="Depreciation expense"><ix:nonFraction name="us-gaap:Depreciation" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">92,000</ix:nonFraction></span> and $<span id="xdx_909_eus-gaap--Depreciation_pp0p0_c20210101__20211231_zElf27B7nkce" title="Depreciation expense"><ix:nonFraction name="us-gaap:Depreciation" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">73,000</ix:nonFraction></span> for the years ended December 31, 2022 and 2021, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon
termination of the Sekisui Distribution Agreement on March 31, 2022, the Company had a commitment to purchase leased FastPack rental
systems back from Sekisui at Sekisui&#8217;s net book value, which was determined to be approximately $<span id="xdx_90D_eus-gaap--PaymentsToAcquirePropertyPlantAndEquipment_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--SekisuiDistributionAgreementMember_zr2s6Wg1tnW7" title="Payments to acquire assets"><ix:nonFraction name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="From2022-01-012022-12-31_custom_SekisuiDistributionAgreementMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">154,000</ix:nonFraction></span>. This amount is included
in equipment held for lease in the table above and in accrued expenses at December 31, 2022. An assignment agreement is to be executed
by both parties to legally transfer title to this equipment from Sekisui to Qualigen.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>


<ix:exclude><!-- Field: Page; Sequence: 55; Value: 35 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->55<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock"><p id="xdx_80A_eus-gaap--GoodwillAndIntangibleAssetsDisclosureTextBlock_zs0p0XkWM4ji" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
7 &#8212; <span id="xdx_826_zwBe5NfUt4D2">GOODWILL, IPR&amp;D AND OTHER INTANGIBLES</span></b></span></p>

<ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock"><p id="xdx_890_eus-gaap--ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_zb1Z4BLWS9rd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span id="xdx_8BC_zBUOXlS71fsg" style="display: none">SCHEDULE
OF GOODWILL AND OTHER INTANGIBLE</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_496_20221231_zdHCMRDRg7f7" style="font-weight: bold; text-align: center">December 31,</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_495_20211231_z5dz6BcG59Sg" style="font-weight: bold; text-align: center">December 31,</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">2022</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">2021</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Estimated Useful Lives</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Gross carrying amounts</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Gross carrying amounts</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--Goodwill_iI_zXcKA7UVsgHf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 48%; padding-bottom: 2.5pt">Goodwill</td><td style="width: 2%; padding-bottom: 2.5pt">&#160;</td>
    <td style="width: 14%; padding-bottom: 2.5pt">&#160;</td><td style="width: 2%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 14%; text-align: right"><ix:nonFraction name="us-gaap:Goodwill" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">625,602</ix:nonFraction></td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 14%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1012">&#8212;</span></td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: center">&#160;</td><td>&#160;</td>
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Finite-lived intangible assets:</td><td>&#160;</td>
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_hus-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--DevelopedProductTechnologyRightsMember_zWed598pIel5" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Developed-product-technology rights</td><td>&#160;</td>
    <td style="text-align: center"><span id="xdx_906_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dtY_c20220101__20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--DevelopedProductTechnologyRightsMember__srt--RangeAxis__srt--MinimumMember_zaqWF5dt3oFl" title="Finite lived intangible asset useful life"><ix:nonNumeric contextRef="From2022-01-012022-12-31_custom_DevelopedProductTechnologyRightsMember_srt_MinimumMember" format="ixt-sec:duryear" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife">8</ix:nonNumeric></span> - <span id="xdx_909_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dtY_c20220101__20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--DevelopedProductTechnologyRightsMember__srt--RangeAxis__srt--MaximumMember_z6JFgJEVb2zg" title="Finite lived intangible asset useful life"><ix:nonNumeric contextRef="From2022-01-012022-12-31_custom_DevelopedProductTechnologyRightsMember_srt_MaximumMember" format="ixt-sec:duryear" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife">17</ix:nonNumeric></span> years</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="AsOf2022-12-31_custom_DevelopedProductTechnologyRightsMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">479,103</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="AsOf2021-12-31_custom_DevelopedProductTechnologyRightsMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">479,103</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_hus-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LicensingRightsMember_z4iPpECocP7a" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Licensing rights</td><td>&#160;</td>
    <td style="text-align: center"><span id="xdx_905_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dtY_c20220101__20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LicensingRightsMember_z4fGm9PcNJgb" title="Finite lived intangible asset useful life"><ix:nonNumeric contextRef="From2022-01-012022-12-31_custom_LicensingRightsMember" format="ixt-sec:duryear" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife">10</ix:nonNumeric></span> years</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="AsOf2022-12-31_custom_LicensingRightsMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">418,836</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="AsOf2021-12-31_custom_LicensingRightsMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">418,836</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iNI_di_zCWaIq8XEbjl" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Less: Accumulated amortization</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">752,237</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">726,749</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_403_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_zKjOgTu1Ams7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Total finite-lived intangible assets, net</td><td>&#160;</td>
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">145,702</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">171,190</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Indefinite-lived intangible assets:</td><td>&#160;</td>
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_hus-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--InProcessResearchAndDevelopmentMember_zkdNsPD4tnbi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; text-align: left; padding-bottom: 1.5pt">In-process research and development</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:IntangibleAssetsNetExcludingGoodwill" contextRef="AsOf2022-12-31_us-gaap_InProcessResearchAndDevelopmentMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,700,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1033">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_zQnV9t4KQpJi" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Total other intangible assets, net</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:IntangibleAssetsNetExcludingGoodwill" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,845,702</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:IntangibleAssetsNetExcludingGoodwill" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">171,190</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AA_zMiu2tkjPu0g" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company periodically reviews goodwill for impairment in accordance with relevant accounting standards. Goodwill is attributable to
the NanoSynex Acquisition. Goodwill and intangible assets are recognized at fair value during the period in which an acquisition is
completed, from updated estimates during the measurement period, or when they are considered to be impaired. These non-recurring
fair value measurements, primarily for goodwill and intangible assets acquired, were based on Level 3 inputs. The Company estimates
the fair value of long-lived assets on a non-recurring basis based on a market valuation approach, engaging independent valuation
experts to assist in the determination of fair value. In the fourth quarter of fiscal 2022, in conjunction with the annual
impairment assessment, the Company determined that the fair value of the reporting unit was less than the carrying value. In
addition to continued losses in the reporting unit, the Company considered macroeconomic conditions including a deterioration in the
equity markets evidenced by sustained declines in the Company&#8217;s stock price, peer companies, and major market indices since
the acquisition date. The Company engaged independent valuation experts to assist in determining the fair value of the reporting
unit. As a result of this analysis, the Company recorded a $<span id="xdx_906_eus-gaap--GoodwillImpairmentLoss_c20220101__20221231_zA2nmoahhgj8"><ix:nonFraction name="us-gaap:GoodwillImpairmentLoss" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,239,000</ix:nonFraction> </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">goodwill and fixed asset impairment charge associated with the reporting unit.</span> There were <span id="xdx_90B_eus-gaap--ImpairmentOfIntangibleAssetsFinitelived_do_c20210101__20211231_zA7G4J7NFlJh"><ix:nonFraction name="us-gaap:ImpairmentOfIntangibleAssetsFinitelived" contextRef="From2021-01-012021-12-31" format="ixt-sec:numwordsen" decimals="0" unitRef="USD">no </ix:nonFraction></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">impairments
to intangible assets and goodwill during the year ended December 31, 2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
carrying value of the patents of approximately $<span id="xdx_901_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_c20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zL2k9bRE9po8" title="Assets gross"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="AsOf2022-12-31_us-gaap_PatentsMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">140,000</ix:nonFraction></span> and $<span id="xdx_909_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_c20211231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zNKyGi9WYK89" title="Assets gross"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="AsOf2021-12-31_us-gaap_PatentsMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">159,000</ix:nonFraction></span> at December 31, 2022 and December 31, 2021, respectively, are stated
net of accumulated amortization of approximately $<span id="xdx_908_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_c20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_z1eUTIF91ZRe" title="Accumulated amortization"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="AsOf2022-12-31_us-gaap_PatentsMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">339,000</ix:nonFraction></span> and $<span id="xdx_902_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_c20211231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_z8I9qIoO5ria" title="Accumulated amortization"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="AsOf2021-12-31_us-gaap_PatentsMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">320,000</ix:nonFraction></span>, respectively. Amortization of patents charged to operations for
the year ended December 31, 2022 and December 31, 2021 were approximately $<span id="xdx_903_eus-gaap--AmortizationOfIntangibleAssets_c20220101__20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zleS6mV8cZGf" title="Amortization of intangible assets"><ix:nonFraction name="us-gaap:AmortizationOfIntangibleAssets" contextRef="From2022-01-012022-12-31_us-gaap_PatentsMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">18,000</ix:nonFraction></span> and $<span id="xdx_900_eus-gaap--AmortizationOfIntangibleAssets_c20210101__20211231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zROdRa2puvGh" title="Amortization of intangible assets"><ix:nonFraction name="us-gaap:AmortizationOfIntangibleAssets" contextRef="From2021-01-012021-12-31_us-gaap_PatentsMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">17,000</ix:nonFraction></span>, respectively. Total future estimated amortization
of patent costs for the five succeeding years is approximately $<span id="xdx_90A_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_iI_c20221231_zOobvQzNfBcl" title="Future estimated amortization of patent costs Year 2023"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">18,000</ix:nonFraction></span> for the year ending December 31, 2023, approximately $<span id="xdx_90B_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_iI_c20221231_zyssy5GjxBhc" title="Future estimated amortization of patent costs Year 2024"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">15,000</ix:nonFraction></span> for
the year ending December 31, 2024, approximately $<span id="xdx_905_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_iI_c20221231_zX83EZKGhb5j" title="Future estimated amortization of patent costs Year 2025"><span id="xdx_904_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_iI_c20221231_zUhPFiV1BBQk" title="Future estimated amortization of patent costs Year 2026"><span id="xdx_905_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_iI_c20221231_zgZ1rdjuARUb" title="Future estimated amortization of patent costs Year 2027"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">14,000</ix:nonFraction></ix:nonFraction></ix:nonFraction></span></span></span> for years 2025, 2026 and 2027, and approximately $<span id="xdx_90E_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_iI_c20221231_zgBXLNEi5rz5" title="Future estimated amortization of patent costs thereafter"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">65,000</ix:nonFraction></span> thereafter.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
carrying value of the licenses of approximately $<span id="xdx_904_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_c20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicenseMember_zokqiRXfUkk5" title="Finite lived intangible assets gross"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="AsOf2022-12-31_us-gaap_LicenseMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,000</ix:nonFraction></span> and $<span id="xdx_90E_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_c20211231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicenseMember_z9113trqX9Hh" title="Finite lived intangible assets gross"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="AsOf2021-12-31_us-gaap_LicenseMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">12,000</ix:nonFraction></span> at December 31, 2022 and December 31, 2021 are stated net of accumulated
amortization of approximately $<span id="xdx_90E_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_c20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicenseMember_zf73ANwZ6VV3" title="Accumulated amortization"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="AsOf2022-12-31_us-gaap_LicenseMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">414,000</ix:nonFraction></span> and $<span id="xdx_90F_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_c20211231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicenseMember_zojlMSaT70Tg" title="Accumulated amortization"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="AsOf2021-12-31_us-gaap_LicenseMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">407,000</ix:nonFraction></span>, respectively. Amortization of licenses charged to operations for the year ended
December 31, 2022 and December 31, 2021 was approximately $<span id="xdx_903_eus-gaap--AmortizationOfIntangibleAssets_c20220101__20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicenseMember_zHeLVHwO1lwj" title="Licenses charged"><ix:nonFraction name="us-gaap:AmortizationOfIntangibleAssets" contextRef="From2022-01-012022-12-31_us-gaap_LicenseMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,000</ix:nonFraction></span> and $<span id="xdx_904_eus-gaap--AmortizationOfIntangibleAssets_c20210101__20211231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicenseMember_zwQVdoDKyGCb" title="Licenses charged"><ix:nonFraction name="us-gaap:AmortizationOfIntangibleAssets" contextRef="From2021-01-012021-12-31_us-gaap_LicenseMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,000</ix:nonFraction></span>, respectively. Total future estimated amortization of license
costs for the five succeeding years is approximately $<span id="xdx_903_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_iI_c20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicenseMember_z1mo1wC09943" title="Future estimated amortization of license costs 2023"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" contextRef="AsOf2022-12-31_us-gaap_LicenseMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,000</ix:nonFraction></span> for the year ending December 31, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>


<ix:exclude><!-- Field: Page; Sequence: 56; Value: 35 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->56<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock"><p id="xdx_80D_eus-gaap--AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_zgaL5IHNqmMd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
8 &#8212; <span id="xdx_824_zYcXxQ8gw5Bi">ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock"><p id="xdx_899_eus-gaap--ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_zDIhix1BX3Tf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accrued
expenses and other current liabilities consisted of the following at December 31, 2022 and December 31, 2021:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span id="xdx_8B9_zKHaUW9L91Hh" style="display: none">SCHEDULE OF ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_49D_20221231_zBbMkbGrB9md" style="font-weight: bold; text-align: center">December 31,</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_494_20211231_ztpKeTIDF99j" style="font-weight: bold; text-align: center">December 31,</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_402_ecustom--AccruedCompensation_iI_pp0p0_maALCzkYM_zOLE87lWqRI5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Board compensation</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="QLGN:AccruedCompensation" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">70,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="QLGN:AccruedCompensation" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">17,500</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_ecustom--AccruedEquipmentHeldForLease_iI_pp0p0_maALCzkYM_zYeN16y7xf98" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Equipment held for lease</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="QLGN:AccruedEquipmentHeldForLease" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">154,433</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1086">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_ecustom--AccruedFranchiseSalesAndUseTaxes_iI_pp0p0_maALCzkYM_zhmSlBQL4EWg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Franchise, sales and use taxes</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="QLGN:AccruedFranchiseSalesAndUseTaxes" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">27,531</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="QLGN:AccruedFranchiseSalesAndUseTaxes" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">14,090</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--AccruedIncomeTaxesCurrent_iI_pp0p0_maALCzkYM_zP28APwIULVa" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Income taxes</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccruedIncomeTaxesCurrent" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">4,663</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccruedIncomeTaxesCurrent" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">3,620</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--InterestPayableCurrent_iI_pp0p0_maALCzkYM_zOzKyyIb5kF4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Interest (Convertible debt - related party)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:InterestPayableCurrent" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,829</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1095">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--AccruedPayrollTaxesCurrent_iI_pp0p0_maALCzkYM_zJNRO73693I4" style="vertical-align: bottom; background-color: White">
    <td>Payroll</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccruedPayrollTaxesCurrent" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">209,303</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccruedPayrollTaxesCurrent" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">682,036</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--AccruedProfessionalFeesCurrent_iI_pp0p0_maALCzkYM_zrpYF7asHehb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Professional fees</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccruedProfessionalFeesCurrent" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">238,211</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccruedProfessionalFeesCurrent" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">225,308</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_ecustom--AccruedResearchAndDevelopmentCurrent_iI_pp0p0_maALCzkYM_zk7F9NtWCfb4" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Research and development</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="QLGN:AccruedResearchAndDevelopmentCurrent" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">322,987</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="QLGN:AccruedResearchAndDevelopmentCurrent" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">232,712</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--AccruedRoyaltiesCurrent_iI_pp0p0_maALCzkYM_zB4ANgfhV2xe" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Royalties</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccruedRoyaltiesCurrent" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">13,158</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccruedRoyaltiesCurrent" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">10,152</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--ProductWarrantyAccrual_iI_pp0p0_maALCzkYM_zMzNOQPLAo4j" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Warranty liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ProductWarrantyAccrual" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">137,568</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ProductWarrantyAccrual" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">60,281</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_ecustom--AccruedLicenseFees_iI_pp0p0_maALCzkYM_zPQndZ4yZ6yh" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">License fees</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="QLGN:AccruedLicenseFees" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">150,130</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1113">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--OtherAccruedLiabilitiesCurrent_iI_pp0p0_maALCzkYM_zNkSVNMli169" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Other</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherAccruedLiabilitiesCurrent" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">181,043</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherAccruedLiabilitiesCurrent" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">265,292</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--AccruedLiabilitiesCurrent_iTI_mtALCzkYM_zAYI6VOc0MWe" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Accrued liabilities</span></td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,511,856</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,510,990</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A8_zueUm56vJTLa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:ShortTermDebtTextBlock"><p id="xdx_803_eus-gaap--ShortTermDebtTextBlock_zDQGZEWRdpE3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
9 &#8211; <span id="xdx_82F_zfilWLp0PCqg">SHORT TERM DEBT - RELATED PARTY</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NanoSynex
has four separate Notes Payable (the &#8220;Notes&#8221;) outstanding to Alpha Capital, dated between March 26, 2020 and September 2,
2021, aggregating to a total principal outstanding balance of $<span id="xdx_900_eus-gaap--DebtInstrumentFaceAmount_iI_c20210902__us-gaap--ShortTermDebtTypeAxis__custom--NotesPayableMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NanoSynexMember_zQrNlMRSVo13" title="Short term debt principal outstanding"><ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="AsOf2021-09-02_custom_NotesPayableMember_custom_NanoSynexMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">905,000</ix:nonFraction></span>, and aggregate accrued interest of $<span id="xdx_90C_eus-gaap--InterestPayableCurrent_iI_pp0p0_c20221231__us-gaap--ShortTermDebtTypeAxis__custom--NotesPayableMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NanoSynexMember_zsHnjDV8n9W9" title="Accrued interest"><ix:nonFraction name="us-gaap:InterestPayableCurrent" contextRef="AsOf2022-12-31_custom_NotesPayableMember_custom_NanoSynexMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">45,722</ix:nonFraction></span> for a total outstanding
balance of $<span id="xdx_90C_eus-gaap--ShortTermBorrowings_iI_pp0p0_c20221231__us-gaap--ShortTermDebtTypeAxis__custom--NotesPayableMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NanoSynexMember_zk1r2mvHgOzf" title="Short term debt outstanding balance"><ix:nonFraction name="us-gaap:ShortTermBorrowings" contextRef="AsOf2022-12-31_custom_NotesPayableMember_custom_NanoSynexMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">950,722</ix:nonFraction></span> as of December 31, 2022. The Notes all accrue interest at <span id="xdx_90A_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20210902__us-gaap--ShortTermDebtTypeAxis__custom--NotesPayableMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NanoSynexMember_z3fZvCpt3kw5" title="Accrued interest rate"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateStatedPercentage" contextRef="AsOf2021-09-02_custom_NotesPayableMember_custom_NanoSynexMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">2.62</ix:nonFraction>%</span> per annum, accrued daily, and provide that the full
amount of principal and interest under each Note shall be due immediately prior to a Liquidation Event (the Maturity Date) unless due
earlier in accordance with the terms of the Notes. &#8220;Liquidation Event&#8221; means either i) the merger or consolidation of NanoSynex
into any other entity, other than one in control or under control of NanoSynex or NanoSynex&#8217;s majority shareholder; ii) a transaction
or series of transactions resulting in the transfer of all or substantially all of NanoSynex&#8217;s assets or issued and outstanding
share capital (other than to a company under the control of NanoSynex or NanoSynex&#8217;s majority shareholders; or iii) an underwritten
public offering by NanoSynex of its ordinary shares. Notwithstanding the above, if NanoSynex receives subsequent debt, convertible debt,
or equity funding with gross proceeds of USD $<span id="xdx_90C_eus-gaap--ProceedsFromRelatedPartyDebt_pp0p0_c20210326__20210902__us-gaap--ShortTermDebtTypeAxis__custom--NotesPayableMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NanoSynexMember_zDc0R3RsSkVj" title="Proceeds from related party debt"><ix:nonFraction name="us-gaap:ProceedsFromRelatedPartyDebt" contextRef="From2021-03-262021-09-02_custom_NotesPayableMember_custom_NanoSynexMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">3,000,000</ix:nonFraction></span> or more, then these Notes shall be due and payable upon the actual receipt of
such funding.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="margin: 0"></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="QLGN:WarrantLiabilitiesTextBlock"><p id="xdx_800_ecustom--WarrantLiabilitiesTextBlock_zTNKi3pAAyR" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
10 &#8211; <span id="xdx_823_zr13o4sFvmg6">WARRANT LIABILITIES</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
2004, the Company issued warrants to various investors and brokers for the purchase of Series C preferred stock in connection with a
private placement (the &#8220;Series C Warrants&#8221;). The Series C Warrants were subsequently extended and, upon closing of the reverse
recapitalization transaction with Ritter, exchanged for warrants to purchase common stock of the Company, pursuant to the Series C Warrant
terms as adjusted.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
exchange for the Series C Warrants, upon closing of the merger with Ritter, the holders received warrants to purchase shares of the Company&#8217;s
common stock at $<span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20221231__us-gaap--StatementEquityComponentsAxis__custom--SeriesCWarrantsMember_z2NoJyddELoi"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2022-12-31_custom_SeriesCWarrantsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">7.195</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per share, subject to adjustment. As of December
31, 2022, the warrants have remaining terms ranging from <span id="xdx_90E_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20221231__srt--RangeAxis__srt--MinimumMember__us-gaap--StatementEquityComponentsAxis__custom--SeriesCWarrantsMember_z6gB9ujWHnN3"><ix:nonNumeric contextRef="AsOf2022-12-31_srt_MinimumMember_custom_SeriesCWarrantsMember" format="ixt-sec:duryear" name="us-gaap:WarrantsAndRightsOutstandingTerm">0.90</ix:nonNumeric>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">to <span id="xdx_90C_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20221231__srt--RangeAxis__srt--MaximumMember__us-gaap--StatementEquityComponentsAxis__custom--SeriesCWarrantsMember_zI59ZOuW8Nra"><ix:nonNumeric contextRef="AsOf2022-12-31_srt_MaximumMember_custom_SeriesCWarrantsMember" format="ixt-sec:duryear" name="us-gaap:WarrantsAndRightsOutstandingTerm">1.49</ix:nonNumeric>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">years. The warrants were determined to be liability-classified
pursuant to the guidance in ASC 480 and ASC 815-40, resulting from inclusion of a leveraged ratchet provision for subsequent dilutive
issuances. On April 25, 2022 the warrants were repriced from $<span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20220425__srt--RangeAxis__srt--MaximumMember_zjDFXDHgRwOh"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2022-04-25_srt_MaximumMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">7.195</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">to $<span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20220425__srt--RangeAxis__srt--MinimumMember_zGbBu03voTtl"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2022-04-25_srt_MinimumMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">6.00</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">with an additional <span id="xdx_903_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20220423__20220425__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember_zc1BDoKqkEFl"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2022-04-232022-04-25_custom_SeriesCWarrantsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">49,318</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ratchet shares issued, and on May 26 2022 the
warrants were repriced from $<span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20220526__srt--RangeAxis__srt--MaximumMember_zTC0bcXzw7Ef"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2022-05-26_srt_MaximumMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">6.00</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">to $<span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20220526__srt--RangeAxis__srt--MinimumMember_zwTvwWquk3k3"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2022-05-26_srt_MinimumMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">5.136</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">with an additional <span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20220523__20220526__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember_zPaScz4ZUk0f"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2022-05-232022-05-26_custom_SeriesCWarrantsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">49,952</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ratchet shares issued. On December 22, 2022 the
warrants were repriced again from $<span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20221222__srt--RangeAxis__srt--MaximumMember_zl0Lk6bDRGG2"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2022-12-22_srt_MaximumMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">5.136</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">to $<span id="xdx_901_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20221222__srt--RangeAxis__srt--MinimumMember_z1GvwYAJ8Eh2"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2022-12-22_srt_MinimumMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.32</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">with an additional <span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20221219__20221222__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember_zcgnKiHGAeNk"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2022-12-192022-12-22_custom_SeriesCWarrantsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,002,717</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ratchet shares issued.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additionally,
on December 22, 2022, in conjunction with the issuance of Convertible Debt - Related Party (Note 11), the Company issued to
Alpha Capital a warrant to purchase <span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20221222__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember_z5ojSDPH9vd1" title="Warrant to purchase shares"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2022-12-22_custom_SeriesCWarrantsMember_custom_AlphaCapitalMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,500,000</ix:nonFraction></span>
shares of the Company&#8217;s common stock. The exercise price of the warrant is $<span id="xdx_905_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20221222__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember_zyiFGSys0NIj" title="Exercise price of warrant"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2022-12-22_custom_SeriesCWarrantsMember_custom_AlphaCapitalMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.65</ix:nonFraction></span>
(equal to <span id="xdx_90A_ecustom--ConversionPricePercentage_dp_uPure_c20221219__20221222__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember_zlZOsLU6OjP7" title="Conversion price percentage"><ix:nonFraction name="QLGN:ConversionPricePercentage" contextRef="From2022-12-192022-12-22_custom_SeriesCWarrantsMember_custom_AlphaCapitalMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">125</ix:nonFraction>%</span>
of the conversion price of the Debenture on the closing date). The warrant may be exercised by Alpha, in whole or in part, at any
time on or after June 22, 2023 and before June 22, 2028, subject to certain terms conditions described in the warrant, including the
Company&#8217;s receipt of the necessary stockholder approvals.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 57; Value: 35 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->57<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock"><p id="xdx_892_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zi4R4vr76wV6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes the activity in liability classified warrants for the year ended December 31, 2022:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span id="xdx_8B9_zlbDiViAHMLj" style="display: none">SCHEDULE OF WARRANTS ACTIVITY</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Common Stock Warrants</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Shares</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted&#8211;<br /> Average<br /> Exercise<br />
    Price</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Range of Exercise<br /> Price</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted&#8211;<br /> Average<br /> Remaining
    Life (Years)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%">Total outstanding &#8211; December 31, 2021</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20220101__20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zgRZ9lBrrAU4" title="Number of Shares, Warrants Outstanding Beginning" style="width: 11%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" contextRef="AsOf2021-12-31_custom_SeriesCWarrantsMember_custom_CommonStockWarrantsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">248,162</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iS_c20220101__20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zdHaBnbdKIxk" title="Weighted Average Exercise Price Per Share Warrants Outstanding Beginning" style="width: 11%; text-align: right"><ix:nonFraction name="QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2021-12-31_custom_SeriesCWarrantsMember_custom_CommonStockWarrantsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">7.20</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right"><span id="xdx_90B_ecustom--RangeOfExercisePrice_iS_c20220101__20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zDEOdKz4r8sd" title="Range of Exercise Beginning"><ix:nonFraction name="QLGN:RangeOfExercisePrice" contextRef="AsOf2021-12-31_custom_SeriesCWarrantsMember_custom_CommonStockWarrantsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">7.20</ix:nonFraction></span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 11%; text-align: right"><span id="xdx_907_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAveragRemainingContractualTerm1_dtY_c20210101__20211231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zEg9rAw2F3tg" title="Weighted Averag Remaining Contractual Term"><ix:nonNumeric contextRef="From2021-01-012021-12-31_custom_SeriesCWarrantsMember_custom_CommonStockWarrantsMember" format="ixt-sec:duryear" name="QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAveragRemainingContractualTerm1">2.00</ix:nonNumeric></span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt">Exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_di_c20220101__20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_z4v1hFTq5Sdf" title="Number of Shares, Warrants Exercised" style="text-align: right">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" contextRef="From2022-01-012022-12-31_custom_SeriesCWarrantsMember_custom_CommonStockWarrantsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">536</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedInPeriodWeightedAverageExercisePrice_c20220101__20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zNez6fhlXGcj" title="Weighted Average Exercise Price Per Share Warrants Exercised" style="text-align: right"><ix:nonFraction name="QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedInPeriodWeightedAverageExercisePrice" contextRef="From2022-01-012022-12-31_custom_SeriesCWarrantsMember_custom_CommonStockWarrantsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">7.20</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt">Forfeited</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_iN_di_c20220101__20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zwKh1cVFEL3e" title="Number of Shares, Warrants Forfeited" style="text-align: right">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures" contextRef="From2022-01-012022-12-31_custom_SeriesCWarrantsMember_custom_CommonStockWarrantsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">247,625</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedInPeriodWeightedAverageExercisePrice_c20220101__20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zMKKnE0lOn3l" title="Weighted Average Exercise Price Per Share Warrants Forfeited" style="text-align: right"><ix:nonFraction name="QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedInPeriodWeightedAverageExercisePrice" contextRef="From2022-01-012022-12-31_custom_SeriesCWarrantsMember_custom_CommonStockWarrantsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">7.20</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt">Expired</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_c20220101__20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zly3pspvqndi" title="Number of Shares, Warrants Expired" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1171">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInPeriodWeightedAverageExercisePrice_c20220101__20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zN1SodGJJ9H4" title="Weighted Average Exercise Price Per Share Warrants Expired" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1173">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; padding-bottom: 1.5pt">Granted</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20220101__20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zIovgXO5mrPg" title="Number of Shares, Warrants Granted" style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" contextRef="From2022-01-012022-12-31_custom_SeriesCWarrantsMember_custom_CommonStockWarrantsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,849,570</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice_c20220101__20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zBUeAcTQIYuj" title="Weighted Average Exercise Price Per Share Warrants Granted" style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice" contextRef="From2022-01-012022-12-31_custom_SeriesCWarrantsMember_custom_CommonStockWarrantsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.53</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Total outstanding &#8211; December 31, 2022</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_c20220101__20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zFsS5v1SLk0h" title="Number of Shares, Warrants Outstanding Ending" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" contextRef="AsOf2022-12-31_custom_SeriesCWarrantsMember_custom_CommonStockWarrantsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,849,571</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_982_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iE_c20220101__20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zP8I6u5b9Rfg" title="Weighted Average Exercise Price Per Share Warrants Outstanding Ending" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2022-12-31_custom_SeriesCWarrantsMember_custom_CommonStockWarrantsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.53</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right"><span id="xdx_90F_ecustom--RangeOfExercisePrice_iE_c20220101__20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember__srt--RangeAxis__srt--MinimumMember_ziMXfIKHccal" title="Range of Exercise Ending"><ix:nonFraction name="QLGN:RangeOfExercisePrice" contextRef="AsOf2022-12-31_custom_SeriesCWarrantsMember_custom_CommonStockWarrantsMember_srt_MinimumMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.32</ix:nonFraction></span> - <span id="xdx_900_ecustom--RangeOfExercisePrice_iE_c20220101__20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember__srt--RangeAxis__srt--MaximumMember_ztM5JNlu8qog" title="Range of Exercise Ending"><ix:nonFraction name="QLGN:RangeOfExercisePrice" contextRef="AsOf2022-12-31_custom_SeriesCWarrantsMember_custom_CommonStockWarrantsMember_srt_MaximumMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.65</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right"><span id="xdx_909_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAveragRemainingContractualTerm1_dtY_c20220101__20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_z5ISRz135JAi" title="Weighted Averag Remaining Contractual Term"><ix:nonNumeric contextRef="From2022-01-012022-12-31_custom_SeriesCWarrantsMember_custom_CommonStockWarrantsMember" format="ixt-sec:duryear" name="QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAveragRemainingContractualTerm1">3.9</ix:nonNumeric></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Exercisable</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_iE_c20220101__20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zQgOSvu364ug" title="Number of Shares, Warrants Exercisable" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber" contextRef="AsOf2022-12-31_custom_SeriesCWarrantsMember_custom_CommonStockWarrantsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,349,571</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageVestedExercisePrice_iE_c20220101__20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_z51QXKjozQH9" title="Weighted Average Exercise Price Per Share Exercisable" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageVestedExercisePrice" contextRef="AsOf2022-12-31_custom_SeriesCWarrantsMember_custom_CommonStockWarrantsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.32</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_987_ecustom--RangeOfExercisePriceExercisableVested_iE_c20220101__20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zwFbKLcsDzlc" title="Range of Exercise Price, Exercisable" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="QLGN:RangeOfExercisePriceExercisableVested" contextRef="AsOf2022-12-31_custom_SeriesCWarrantsMember_custom_CommonStockWarrantsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.32</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNonExercisableWeightedAverageRemainingContractualTerm1_dtY_c20220101__20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zqzXgGiB5XWk" title="Exercisable Weighted Average Remaining Contractual Term"><ix:nonNumeric contextRef="From2022-01-012022-12-31_custom_SeriesCWarrantsMember_custom_CommonStockWarrantsMember" format="ixt-sec:duryear" name="QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNonExercisableWeightedAverageRemainingContractualTerm1">1.00</ix:nonNumeric></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes the activity in the Common Stock Warrants received in exchange for the Series C Warrants for the year ended
December 31, 2021:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Common Stock Warrants</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Shares</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted&#8211; Average<br /> Exercise<br />
    Price</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Range of Exercise<br /> Price</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted&#8211;<br /> Average<br /> Remaining<br />
    Life (Years)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; text-align: left">Total outstanding &#8211;December 31, 2020</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_pid_c20210101__20211231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zH77yzJp8ctc" title="Number of Shares, Warrants Outstanding Beginning" style="width: 11%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" contextRef="AsOf2020-12-31_custom_SeriesCWarrantsMember_custom_CommonStockWarrantsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">337,860</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iS_c20210101__20211231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zImbi4AYEEEh" title="Weighted Average Exercise Price Per Share Warrants Outstanding Beginning" style="width: 11%; text-align: right"><ix:nonFraction name="QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2020-12-31_custom_SeriesCWarrantsMember_custom_CommonStockWarrantsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">7.20</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 11%; text-align: right">&#160;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 11%; text-align: right">&#160;</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt">Exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_pid_di_c20210101__20211231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zfpK04P8y6g3" title="Number of Shares, Warrants Exercised" style="text-align: right">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" contextRef="From2021-01-012021-12-31_custom_SeriesCWarrantsMember_custom_CommonStockWarrantsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">80,731</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedInPeriodWeightedAverageExercisePrice_c20210101__20211231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zD3Kkx3xf4s2" title="Weighted Average Exercise Price Per Share Warrants Exercised" style="text-align: right"><ix:nonFraction name="QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedInPeriodWeightedAverageExercisePrice" contextRef="From2021-01-012021-12-31_custom_SeriesCWarrantsMember_custom_CommonStockWarrantsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">7.20</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt">Forfeited</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_iN_pid_di_c20210101__20211231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zobya8eIBZu4" title="Number of Shares, Warrants Forfeited" style="text-align: right">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures" contextRef="From2021-01-012021-12-31_custom_SeriesCWarrantsMember_custom_CommonStockWarrantsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">8,967</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedInPeriodWeightedAverageExercisePrice_c20210101__20211231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zDjLjuPENNR6" title="Weighted Average Exercise Price Per Share Warrants Forfeited" style="text-align: right"><ix:nonFraction name="QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedInPeriodWeightedAverageExercisePrice" contextRef="From2021-01-012021-12-31_custom_SeriesCWarrantsMember_custom_CommonStockWarrantsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">7.20</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt">Expired</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_pid_c20210101__20211231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zFC5SgAGzsEf" title="Number of Shares, Warrants Expired" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1209">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInPeriodWeightedAverageExercisePrice_c20210101__20211231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_z7nycVmTb8B" title="Weighted Average Exercise Price Per Share Warrants Expired" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1211">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; padding-bottom: 1.5pt">Granted</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pid_c20210101__20211231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zHOeD4mc3zk8" title="Number of Shares, Warrants Granted" style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1213">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice_c20210101__20211231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_z8XNUGVPEb2" title="Weighted Average Exercise Price Per Share Warrants Granted" style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1215">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Total outstanding &#8211; December 31, 2021</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_pid_c20210101__20211231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zvGIKed08Dji" title="Number of Shares, Warrants Outstanding Ending" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" contextRef="AsOf2021-12-31_custom_SeriesCWarrantsMember_custom_CommonStockWarrantsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">248,162</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iE_c20210101__20211231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zCk65p5rvzGj" title="Weighted Average Exercise Price Per Share Warrants Outstanding Ending" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2021-12-31_custom_SeriesCWarrantsMember_custom_CommonStockWarrantsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">7.20</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Exercisable</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_iE_c20210101__20211231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zBkvGyDabBh5" title="Number of Shares, Warrants Exercisable" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber" contextRef="AsOf2021-12-31_custom_SeriesCWarrantsMember_custom_CommonStockWarrantsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">248,162</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_984_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageVestedExercisePrice_iE_c20210101__20211231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_ztQSbDCkta6l" title="Weighted Average Exercise Price Per Share Exercisable" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageVestedExercisePrice" contextRef="AsOf2021-12-31_custom_SeriesCWarrantsMember_custom_CommonStockWarrantsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">7.20</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_985_ecustom--RangeOfExercisePriceExercisableVested_iI_c20211231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zEu6lMmQ7Yj" title="Range of Exercise Price, Exercisable" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="QLGN:RangeOfExercisePriceExercisableVested" contextRef="AsOf2021-12-31_custom_SeriesCWarrantsMember_custom_CommonStockWarrantsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">7.20</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_901_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNonExercisableWeightedAverageRemainingContractualTerm1_dtY_c20210101__20211231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zoFCBLkRSPC9" title="Exercisable Weighted Averag Remaining Contractual Term"><ix:nonNumeric contextRef="From2021-01-012021-12-31_custom_SeriesCWarrantsMember_custom_CommonStockWarrantsMember" format="ixt-sec:duryear" name="QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNonExercisableWeightedAverageRemainingContractualTerm1">2.00</ix:nonNumeric></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A0_zIsFfauJIwP7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="QLGN:ScheduleOfFairValueHierarchyForWarrantLiabilitiesTableTextBlock"><p id="xdx_891_ecustom--ScheduleOfFairValueHierarchyForWarrantLiabilitiesTableTextBlock_ztNQLBf0mxnf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table presents the Company&#8217;s fair value hierarchy for its Common Stock Warrant liabilities measured at fair value on
a recurring basis as of December 31, 2022:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span id="xdx_8BC_zcaqBHalynh3" style="display: none">SCHEDULE OF FAIR VALUE HIERARCHY FOR WARRANT LIABILITIES</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Quoted</td><td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Market</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Significant</td><td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Prices for</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Other</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Significant</td><td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Identical</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Observable</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Unobservable</td><td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Assets</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Inputs</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Inputs</td><td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Common Stock Warrant liabilities</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">(Level 1)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">(Level 2)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">(Level 3)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%">Balance as of December 31, 2021</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_986_ecustom--FairValueAdjustmentOfWarrant_iS_pp0p0_c20220101__20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zA7XDLaSeJp7" title="Fair value for warrant liabilities" style="width: 11%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1231">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_987_ecustom--FairValueAdjustmentOfWarrant_iS_pp0p0_c20220101__20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_z9ZvtjE2OlEl" title="Fair value for warrant liabilities" style="width: 11%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1233">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">$</td><td id="xdx_98C_ecustom--FairValueAdjustmentOfWarrant_iS_pp0p0_c20220101__20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z4eVzr78nfqg" title="Fair value for warrant liabilities" style="width: 11%; font-weight: bold; text-align: right"><ix:nonFraction name="QLGN:FairValueAdjustmentOfWarrant" contextRef="AsOf2021-12-31_us-gaap_FairValueInputsLevel3Member" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,686,200</ix:nonFraction></td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 2%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">$</td><td id="xdx_98E_ecustom--FairValueAdjustmentOfWarrant_iS_pp0p0_c20220101__20221231_zQW5z8Rhuhi8" title="Fair value for warrant liabilities, beginning balance" style="width: 11%; font-weight: bold; text-align: right"><ix:nonFraction name="QLGN:FairValueAdjustmentOfWarrant" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,686,200</ix:nonFraction></td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Exercises</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_ecustom--FairValueOfWarrantLiabilitiesOnDateOfExercise_iN_pp0p0_di_c20220101__20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zGCennZ52Y2b" title="Common Stock Warrant liabilities, Exercises" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1239">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_ecustom--FairValueOfWarrantLiabilitiesOnDateOfExercise_iN_pp0p0_di_c20220101__20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zdSg6uJAd9a2" title="Common Stock Warrant liabilities, Exercises" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1241">&#8212;</span></td><td style="text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td id="xdx_981_ecustom--FairValueOfWarrantLiabilitiesOnDateOfExercise_iN_pp0p0_di_c20220101__20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zeARMJfHa1kf" title="Common Stock Warrant liabilities, Exercises" style="font-weight: bold; text-align: right">(<ix:nonFraction name="QLGN:FairValueOfWarrantLiabilitiesOnDateOfExercise" contextRef="From2022-01-012022-12-31_us-gaap_FairValueInputsLevel3Member" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">858</ix:nonFraction></td><td style="font-weight: bold; text-align: left">)</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td id="xdx_987_ecustom--FairValueOfWarrantLiabilitiesOnDateOfExercise_iN_pp0p0_di_c20220101__20221231_zuK1t4bnPMHi" title="Common Stock Warrant liabilities, Exercises" style="font-weight: bold; text-align: right">(<ix:nonFraction name="QLGN:FairValueOfWarrantLiabilitiesOnDateOfExercise" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">858</ix:nonFraction></td><td style="font-weight: bold; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Issuance of Alpha warrants</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td id="xdx_980_ecustom--FairValueOfWarrantLiabilitiesIssuanceOfAlphaWarrants_iN_pp0p0_di_c20220101__20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_z3KPQHnVEkj6" title="Issuance of Alpha warrants" style="font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1247">&#8212;</span></td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td id="xdx_984_ecustom--FairValueOfWarrantLiabilitiesIssuanceOfAlphaWarrants_iN_pp0p0_di_c20220101__20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_ziP3TcxufO4b" title="Issuance of Alpha warrants" style="font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1249">&#8212;</span></td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td id="xdx_985_ecustom--FairValueOfWarrantLiabilitiesIssuanceOfAlphaWarrants_iN_pp0p0_di_c20220101__20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zC4IQi7vMGL9" title="Issuance of Alpha warrants" style="font-weight: bold; text-align: right"><ix:nonFraction name="QLGN:FairValueOfWarrantLiabilitiesIssuanceOfAlphaWarrants" contextRef="From2022-01-012022-12-31_us-gaap_FairValueInputsLevel3Member" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">2,834,547</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td id="xdx_98D_ecustom--FairValueOfWarrantLiabilitiesIssuanceOfAlphaWarrants_iN_pp0p0_di_c20220101__20221231_zkJjn6nyDGFc" title="Issuance of Alpha warrants" style="font-weight: bold; text-align: right"><ix:nonFraction name="QLGN:FairValueOfWarrantLiabilitiesIssuanceOfAlphaWarrants" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">2,834,547</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Gain on change in fair value of warrant liabilities</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td id="xdx_984_ecustom--ChangeInFairValueOfWarrantLiabilities_pdp0_c20220101__20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_z4oIucfXRdvj" title="Change in fair value of warrant liabilities" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1255">&#8212;</span></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td id="xdx_98E_ecustom--ChangeInFairValueOfWarrantLiabilities_pdp0_c20220101__20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zSDM0xe7XeJ1" title="Change in fair value of warrant liabilities" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1257">&#8212;</span></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td id="xdx_98D_ecustom--ChangeInFairValueOfWarrantLiabilities_pp0p0_c20220101__20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zF5xzgPb65c7" title="Change in fair value of warrant liabilities" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(<ix:nonFraction name="QLGN:ChangeInFairValueOfWarrantLiabilities" contextRef="From2022-01-012022-12-31_us-gaap_FairValueInputsLevel3Member" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">897,242</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td id="xdx_983_ecustom--ChangeInFairValueOfWarrantLiabilities_pp0p0_c20220101__20221231_zE61mt7RQZUg" title="Change in fair value of warrant liabilities" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(<ix:nonFraction name="QLGN:ChangeInFairValueOfWarrantLiabilities" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">897,242</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Balance as of December 31, 2022</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td id="xdx_980_ecustom--FairValueAdjustmentOfWarrant_iE_pp0p0_c20220101__20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zch8P99usN7j" title="Fair value for warrant liabilities" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1263">&#8212;</span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td id="xdx_981_ecustom--FairValueAdjustmentOfWarrant_iE_pp0p0_c20220101__20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zh60I5eW81yc" title="Fair value for warrant liabilities" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1265">&#8212;</span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td id="xdx_980_ecustom--FairValueAdjustmentOfWarrant_iE_pp0p0_c20220101__20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zUga1nycgLLh" title="Fair value for warrant liabilities" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><ix:nonFraction name="QLGN:FairValueAdjustmentOfWarrant" contextRef="AsOf2022-12-31_us-gaap_FairValueInputsLevel3Member" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">3,622,647</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td id="xdx_98B_ecustom--FairValueAdjustmentOfWarrant_iE_pp0p0_c20220101__20221231_zP2mygjPKjpa" title="Fair value for warrant liabilities, ending balance" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><ix:nonFraction name="QLGN:FairValueAdjustmentOfWarrant" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">3,622,647</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table presents the Company&#8217;s fair value hierarchy for its Common Stock Warrant liabilities (all of which arose under
the warrants received in exchange for the Series C Warrants) measured at fair value on a recurring basis as of December 31, 2021:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Quoted</td><td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Market</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Significant</td><td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Prices for</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Other</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Significant</td><td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Identical</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Observable</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Unobservable</td><td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Assets</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Inputs</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Inputs</td><td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Common Stock Warrant liabilities</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">(Level 1)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">(Level 2)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">(Level 3)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%">Balance as of December 31, 2020</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_982_ecustom--FairValueAdjustmentOfWarrant_iS_pdp0_c20210101__20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zM0g0w5THkD8" title="Fair value for warrant liabilities" style="width: 11%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1271">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_981_ecustom--FairValueAdjustmentOfWarrant_iS_pdp0_c20210101__20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zA6XmeoqnPg5" title="Fair value for warrant liabilities" style="width: 11%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1273">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">$</td><td id="xdx_985_ecustom--FairValueAdjustmentOfWarrant_iS_pdp0_c20210101__20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zwEyPxSvBSel" title="Fair value for warrant liabilities" style="width: 11%; font-weight: bold; text-align: right"><ix:nonFraction name="QLGN:FairValueAdjustmentOfWarrant" contextRef="AsOf2020-12-31_us-gaap_FairValueInputsLevel3Member" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">8,310,100</ix:nonFraction></td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 2%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">$</td><td id="xdx_982_ecustom--FairValueAdjustmentOfWarrant_iS_pdp0_c20210101__20211231_zcqAWIAU3JA" title="Fair value for warrant liabilities" style="width: 11%; font-weight: bold; text-align: right"><ix:nonFraction name="QLGN:FairValueAdjustmentOfWarrant" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">8,310,100</ix:nonFraction></td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Exercises</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_ecustom--FairValueOfWarrantLiabilitiesOnDateOfExercise_iN_di_c20210101__20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_z46tU59ZOJMh" title="Common Stock Warrant liabilities, Exercises" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1279">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_ecustom--FairValueOfWarrantLiabilitiesOnDateOfExercise_iN_di_c20210101__20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_ztEJ6mZBI9fl" title="Common Stock Warrant liabilities, Exercises" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1281">&#8212;</span></td><td style="text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td id="xdx_983_ecustom--FairValueOfWarrantLiabilitiesOnDateOfExercise_iN_pp0p0_di_c20210101__20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zSMlhmnylCFk" title="Common Stock Warrant liabilities, Exercises" style="font-weight: bold; text-align: right">(<ix:nonFraction name="QLGN:FairValueOfWarrantLiabilitiesOnDateOfExercise" contextRef="From2021-01-012021-12-31_us-gaap_FairValueInputsLevel3Member" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,900,713</ix:nonFraction></td><td style="font-weight: bold; text-align: left">)</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td id="xdx_98A_ecustom--FairValueOfWarrantLiabilitiesOnDateOfExercise_iN_pdp0_di_c20210101__20211231_z4iQ5tt73t8j" title="Common Stock Warrant liabilities, Exercises" style="font-weight: bold; text-align: right">(<ix:nonFraction name="QLGN:FairValueOfWarrantLiabilitiesOnDateOfExercise" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,900,713</ix:nonFraction></td><td style="font-weight: bold; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Gain on change in fair value of warrant liabilities</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td id="xdx_986_ecustom--ChangeInFairValueOfWarrantLiabilities_pdp0_c20210101__20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_z5WZCTIomEEe" title="Change in fair value of warrant liabilities" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1287">&#8212;</span></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td id="xdx_98B_ecustom--ChangeInFairValueOfWarrantLiabilities_pdp0_c20210101__20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zxU6GLyUYMXf" title="Change in fair value of warrant liabilities" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1289">&#8212;</span></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td id="xdx_98D_ecustom--ChangeInFairValueOfWarrantLiabilities_pp0p0_c20210101__20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zr8rKFav1sw3" title="Change in fair value of warrant liabilities" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(<ix:nonFraction name="QLGN:ChangeInFairValueOfWarrantLiabilities" contextRef="From2021-01-012021-12-31_us-gaap_FairValueInputsLevel3Member" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">4,723,187</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td id="xdx_988_ecustom--ChangeInFairValueOfWarrantLiabilities_pp0p0_c20210101__20211231_zwTo0iwheP79" title="Change in fair value of warrant liabilities" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(<ix:nonFraction name="QLGN:ChangeInFairValueOfWarrantLiabilities" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">4,723,187</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Balance as of December 31, 2021</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td id="xdx_989_ecustom--FairValueAdjustmentOfWarrant_iE_pdp0_c20210101__20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zWuKHKzFgNV1" title="Fair value for warrant liabilities" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1295">&#8212;</span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td id="xdx_980_ecustom--FairValueAdjustmentOfWarrant_iE_pdp0_c20210101__20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zi58ZANZKaEf" title="Fair value for warrant liabilities" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1297">&#8212;</span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td id="xdx_989_ecustom--FairValueAdjustmentOfWarrant_iE_pdp0_c20210101__20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zKOUQjYDEWL9" title="Fair value for warrant liabilities" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><ix:nonFraction name="QLGN:FairValueAdjustmentOfWarrant" contextRef="AsOf2021-12-31_us-gaap_FairValueInputsLevel3Member" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,686,200</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td id="xdx_986_ecustom--FairValueAdjustmentOfWarrant_iE_pdp0_c20210101__20211231_z9XQoM1ibaw7" title="Fair value for warrant liabilities" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><ix:nonFraction name="QLGN:FairValueAdjustmentOfWarrant" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,686,200</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AB_zzS6BEzkcisd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 58; Value: 35 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->58<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
were no transfers of financial assets or liabilities between category levels for the year ended December 31, 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
value of the warrant liabilities was based on a valuation received from an independent valuation firm determined using a Monte-Carlo
simulation. For volatility, the Company considers comparable public companies as a basis for its expected volatility to calculate the
fair value of common stock warrants and transitions to its own volatility as the Company develops sufficient appropriate history as a
public company. The risk-free interest rate is based on U.S. Treasury notes with a term approximating the expected term of the common
stock warrant. The Company uses an expected dividend yield of zero based on the fact that the Company has never paid cash dividends and
does not expect to pay cash dividends in the foreseeable future. Any significant changes in the inputs may result in significantly higher
or lower fair value measurements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="QLGN:ScheduleOfAssumptionsOfWarrantLiabilitiesTableTextBlock"><p id="xdx_893_ecustom--ScheduleOfAssumptionsOfWarrantLiabilitiesTableTextBlock_zUrjGat2pOm7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following are the weighted average and the range of assumptions used in estimating the fair value of warrant liabilities (weighted average
calculated based on the number of outstanding warrants on each issuance) as of December 31, 2022 and December 31, 2021:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span id="xdx_8B8_zXu2zfSuQhk8" style="display: none">SCHEDULE
OF ASSUMPTIONS OF WARRANT LIABILITIES</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="font-size: 11pt; text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">December 31, 2022</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">December 31, 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 11pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Range</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Weighted<br /> Average</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Range</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Weighted<br /> Average</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 11pt; text-align: center">&#160;</td><td style="font-size: 11pt; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-size: 11pt">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 11pt">&#160;</td><td style="font-size: 11pt; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-size: 11pt">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 11pt">&#160;</td><td style="font-size: 11pt; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-size: 11pt">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 11pt">&#160;</td><td style="font-size: 11pt; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-size: 11pt">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 11pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 38%; text-align: left">Risk-free interest rate</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 13%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90F_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20221231__srt--RangeAxis__srt--MinimumMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zSh0YEfZ8bD2" title="Fair value assumptions, measurement input, percentages"><span style="-sec-ix-hidden: xdx2ixbrl1305">3.906%</span></span>
                                            &#8212; <span id="xdx_909_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20221231__srt--RangeAxis__srt--MaximumMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_z2M90k7YyeQa" title="Fair value assumptions, measurement input, percentages"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="AsOf2022-12-31_srt_MaximumMember_us-gaap_MeasurementInputRiskFreeInterestRateMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">4.628</ix:nonFraction></span>&#160;</span></td><td style="width: 1%; text-align: left">%</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 11%; text-align: right"><span id="xdx_907_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20221231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--WeightedAverageMember_znbc0RjerXb7" title="Fair value assumptions, measurement input, percentages"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="AsOf2022-12-31_us-gaap_MeasurementInputRiskFreeInterestRateMember_srt_WeightedAverageMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">4.15</ix:nonFraction></span></td><td style="width: 1%; text-align: left">%</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 11%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_905_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20211231__srt--RangeAxis__srt--MinimumMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zJI6idtaQfU5" title="Fair value assumptions, measurement input, percentages"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="AsOf2021-12-31_srt_MinimumMember_us-gaap_MeasurementInputRiskFreeInterestRateMember" format="ixt:numunitdecimalin" decimals="INF" unitRef="Pure">0.69</ix:nonFraction>%</span>
                                            &#8212; <span id="xdx_902_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20211231__srt--RangeAxis__srt--MaximumMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zSmNpTAFL4Gg" title="Fair value assumptions, measurement input, percentages"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="AsOf2021-12-31_srt_MaximumMember_us-gaap_MeasurementInputRiskFreeInterestRateMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">0.84</ix:nonFraction></span></span></td><td style="width: 1%; text-align: left">&#160;%</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 11%; text-align: right"><span id="xdx_90C_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20211231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--WeightedAverageMember_z6QdufRA9ndh" title="Fair value assumptions, measurement input, percentages"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="AsOf2021-12-31_us-gaap_MeasurementInputRiskFreeInterestRateMember_srt_WeightedAverageMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">0.72</ix:nonFraction></span></td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Expected volatility (peer group)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_908_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20221231__srt--RangeAxis__srt--MinimumMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zit3kgSqXrtb" title="Expected volatility"><span style="-sec-ix-hidden: xdx2ixbrl1317">88%</span></span>
                                            &#8212; <span id="xdx_908_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20221231__srt--RangeAxis__srt--MaximumMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zLsHapTdV8Z6" title="Expected volatility"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="AsOf2022-12-31_srt_MaximumMember_us-gaap_MeasurementInputPriceVolatilityMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">103</ix:nonFraction></span></span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_903_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20221231__srt--RangeAxis__srt--WeightedAverageMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zF6rWT0z5K69" title="Expected volatility"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="AsOf2022-12-31_srt_WeightedAverageMember_us-gaap_MeasurementInputPriceVolatilityMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">98</ix:nonFraction></span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_909_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20211231__srt--RangeAxis__srt--MinimumMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zoHjfNGTL03i" title="Expected volatility"><span style="-sec-ix-hidden: xdx2ixbrl1323">84%</span></span>
                                            &#8212; <span id="xdx_90A_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20211231__srt--RangeAxis__srt--MaximumMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_z9PatBOSI5Tc" title="Expected volatility"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="AsOf2021-12-31_srt_MaximumMember_us-gaap_MeasurementInputPriceVolatilityMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">87</ix:nonFraction></span></span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90D_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20211231__srt--RangeAxis__srt--WeightedAverageMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zahxBsQHA2Kk" title="Expected volatility"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="AsOf2021-12-31_srt_WeightedAverageMember_us-gaap_MeasurementInputPriceVolatilityMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">85</ix:nonFraction></span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Term of warrants (in years)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90D_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20221231__srt--RangeAxis__srt--MinimumMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_z0eLWOuKRvbc" title="Fair value assumptions, measurement input, term"><ix:nonNumeric contextRef="AsOf2022-12-31_srt_MinimumMember_us-gaap_MeasurementInputExpectedTermMember" format="ixt-sec:duryear" name="us-gaap:WarrantsAndRightsOutstandingTerm">.90</ix:nonNumeric></span>
                                            &#8212; <span id="xdx_905_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20221231__srt--RangeAxis__srt--MaximumMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_zR6KYxzz12Jb" title="Fair value assumptions, measurement input, term"><ix:nonNumeric contextRef="AsOf2022-12-31_srt_MaximumMember_us-gaap_MeasurementInputExpectedTermMember" format="ixt-sec:duryear" name="us-gaap:WarrantsAndRightsOutstandingTerm">5.48</ix:nonNumeric></span></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_906_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20221231__srt--RangeAxis__srt--WeightedAverageMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_zDr2I1FtDGdj" title="Fair value assumptions, measurement input, term"><ix:nonNumeric contextRef="AsOf2022-12-31_srt_WeightedAverageMember_us-gaap_MeasurementInputExpectedTermMember" format="ixt-sec:duryear" name="us-gaap:WarrantsAndRightsOutstandingTerm">3.9</ix:nonNumeric></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90E_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20211231__srt--RangeAxis__srt--MinimumMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_zDR8E7tt1go8" title="Fair value assumptions, measurement input, term"><ix:nonNumeric contextRef="AsOf2021-12-31_srt_MinimumMember_us-gaap_MeasurementInputExpectedTermMember" format="ixt-sec:duryear" name="us-gaap:WarrantsAndRightsOutstandingTerm">1.90</ix:nonNumeric></span>
                                            &#8212; <span id="xdx_902_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20211231__srt--RangeAxis__srt--MaximumMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_zZURLdhnmmP7" title="Fair value assumptions, measurement input, term"><ix:nonNumeric contextRef="AsOf2021-12-31_srt_MaximumMember_us-gaap_MeasurementInputExpectedTermMember" format="ixt-sec:duryear" name="us-gaap:WarrantsAndRightsOutstandingTerm">2.50</ix:nonNumeric></span></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90A_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20211231__srt--RangeAxis__srt--WeightedAverageMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_zP51RGjPTRe7" title="Fair value assumptions, measurement input, term"><ix:nonNumeric contextRef="AsOf2021-12-31_srt_WeightedAverageMember_us-gaap_MeasurementInputExpectedTermMember" format="ixt-sec:duryear" name="us-gaap:WarrantsAndRightsOutstandingTerm">2.01</ix:nonNumeric></span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Expected dividend yield</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_902_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20221231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zK2qdLEmQqJ7" title="Fair value assumptions, measurement input, percentages"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="AsOf2022-12-31_us-gaap_MeasurementInputExpectedDividendRateMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">0.00</ix:nonFraction></span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_901_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20221231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember__srt--RangeAxis__srt--WeightedAverageMember_zwosA5i5B0sc" title="Fair value assumptions, measurement input, percentages"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="AsOf2022-12-31_us-gaap_MeasurementInputExpectedDividendRateMember_srt_WeightedAverageMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">0.00</ix:nonFraction></span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_902_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20211231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zZTTgQ114pN1" title="Fair value assumptions, measurement input, percentages"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="AsOf2021-12-31_us-gaap_MeasurementInputExpectedDividendRateMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">0.00</ix:nonFraction></span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_900_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20211231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember__srt--RangeAxis__srt--WeightedAverageMember_zW3iPjqQxj3f" title="Fair value assumptions, measurement input, percentages"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="AsOf2021-12-31_us-gaap_MeasurementInputExpectedDividendRateMember_srt_WeightedAverageMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">0.00</ix:nonFraction></span></td><td style="text-align: left">%</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></p>

</ix:nonNumeric><p id="xdx_8AD_z4Tsxf65hVLh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
value of the warrant liabilities is based on a valuation received from an independent valuation firm determined using a Monte-Carlo simulation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:DebtDisclosureTextBlock"><p id="xdx_80B_eus-gaap--DebtDisclosureTextBlock_z9OmxLFhk9A1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
11 &#8212; <span id="xdx_828_zn2ByDMuxcoh">CONVERTIBLE DEBT - RELATED PARTY</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 22, 2022, the Company issued to Alpha Capital, an <span id="xdx_902_eus-gaap--ShortTermDebtInterestRateIncrease_pid_dp_uPure_c20221222__20221222__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember__us-gaap--DebtInstrumentAxis__custom--SeniorConvertibleDebentureMember_zuFRI2SmP6aj" title="Senior convertible debenture rate"><ix:nonFraction name="us-gaap:ShortTermDebtInterestRateIncrease" contextRef="From2022-12-222022-12-22_custom_AlphaCapitalMember_custom_SeniorConvertibleDebentureMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">8</ix:nonFraction>%</span> Senior Convertible Debenture in the aggregate principal amount of $<span id="xdx_902_eus-gaap--SecuredDebt_iI_c20221222__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember__us-gaap--DebtInstrumentAxis__custom--SeniorConvertibleDebentureMember_zFjlBePNcWbg" title="Principal amount"><ix:nonFraction name="us-gaap:SecuredDebt" contextRef="AsOf2022-12-22_custom_AlphaCapitalMember_custom_SeniorConvertibleDebentureMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,300,000</ix:nonFraction></span>
for a purchase price of $<span id="xdx_90C_ecustom--PurchasePrice_iI_c20221222__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember__us-gaap--DebtInstrumentAxis__custom--SeniorConvertibleDebentureMember_zdLia0UcJPnd" title="Purchase Price"><ix:nonFraction name="QLGN:PurchasePrice" contextRef="AsOf2022-12-22_custom_AlphaCapitalMember_custom_SeniorConvertibleDebentureMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,000,000</ix:nonFraction></span> pursuant to the terms of a Securities Purchase Agreement, dated December 21, 2022 (the &#8220;Alpha
Purchase Agreement&#8221;). The Debenture is convertible, at any time, and from time to time, at Alpha&#8217;s option, into shares of
common stock of the Company (the &#8220;Conversion Shares&#8221;), at a price equal to $<span id="xdx_904_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pid_c20221222__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember__us-gaap--DebtInstrumentAxis__custom--SeniorConvertibleDebentureMember_zKupsPjE5LY4" title="Conversion price"><ix:nonFraction name="us-gaap:DebtInstrumentConvertibleConversionPrice1" contextRef="AsOf2022-12-22_custom_AlphaCapitalMember_custom_SeniorConvertibleDebentureMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.32</ix:nonFraction></span> per share, subject to adjustment as described
in the Debenture (the &#8220;Conversion Price&#8221;) and other terms and conditions described in the Debenture, including the Company&#8217;s
receipt of the requisite stockholder approvals. Additionally, on December 22, 2022, the Company issued to Alpha Capital a liability classified warrant to purchase
<span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20221222__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember_zvrBJUvRVqJ5" title="Warrant to purchase shares"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2022-12-22_custom_SeriesCWarrantsMember_custom_AlphaCapitalMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,500,000</ix:nonFraction></span> shares of the Company&#8217;s common stock (see Note 10-Warrant Liabilities). The exercise price of the warrant is $<span id="xdx_905_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20221222__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember_zIBuKGkTrdF9" title="Exercise price of warrant"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2022-12-22_custom_SeriesCWarrantsMember_custom_AlphaCapitalMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.65</ix:nonFraction></span> (equal to <span id="xdx_904_ecustom--ConversionPricePercentage_dp_uPure_c20221219__20221222__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember_zOPPXckyWKaj" title="Conversion price percentage"><ix:nonFraction name="QLGN:ConversionPricePercentage" contextRef="From2022-12-192022-12-22_custom_SeriesCWarrantsMember_custom_AlphaCapitalMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">125</ix:nonFraction></span>% of the conversion
price of the Debenture on the closing date). The warrant may be exercised by Alpha Capital, in whole or in part, at any time on or after
June 22, 2023 and before June 22, 2028, subject to certain terms conditions described in the warrant, including the Company&#8217;s receipt
of the necessary stockholder approvals.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
proceeds from the transaction will be dedicated to the Company&#8217;s efforts of advancing its QN-302 Investigative New Drug candidate
towards clinical trials and other working capital purposes.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Commencing
June 1, 2023 and continuing on the first day of each month thereafter until the earlier of (i) December 22, 2025 and (ii) the full redemption
of the Debenture (each such date, a &#8220;Monthly Redemption Date&#8221;), the Company will redeem $<span id="xdx_903_eus-gaap--DebtInstrumentIncreaseAccruedInterest_c20221222__20221222__us-gaap--DebtInstrumentAxis__custom--SeniorConvertibleDebentureMember_z2DarAAqVvs7" title="Unpaid interest"><ix:nonFraction name="us-gaap:DebtInstrumentIncreaseAccruedInterest" contextRef="From2022-12-222022-12-22_custom_SeniorConvertibleDebentureMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">110,000</ix:nonFraction></span> plus accrued but unpaid
interest, liquidated damages and any amounts then owing under the Debenture (the &#8220;Monthly Redemption Amount&#8221;). The Monthly
Redemption Amount will be paid in cash; provided that after the first two monthly redemptions, the Company may elect to pay all or a
portion of a Monthly Redemption Amount in shares of common stock of the Company, based on a conversion price equal to the lesser of (i)
the then Conversion Price of the Debenture and (ii) <span id="xdx_908_eus-gaap--DebtConversionConvertedInstrumentRate_pid_dp_uPure_c20221222__20221222__us-gaap--DebtInstrumentAxis__custom--SeniorConvertibleDebentureMember_zzSyfBCM6PRa" title="Conversion rate"><ix:nonFraction name="us-gaap:DebtConversionConvertedInstrumentRate" contextRef="From2022-12-222022-12-22_custom_SeniorConvertibleDebentureMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">85</ix:nonFraction>%</span> of the average of the VWAPs (as defined in the Debenture) for the five consecutive
trading days ending on the trading day that is immediately prior to the applicable Monthly Redemption Date. The Company may also redeem
some or all of the then outstanding principal amount of the Debenture at any time for cash in an amount equal to <span id="xdx_90F_ecustom--PrincipalAmountPercentage_pid_dp_uPure_c20221222__20221222__us-gaap--DebtInstrumentAxis__custom--SeniorConvertibleDebentureMember_zuo1xCjerRd4" title="Principal amount percentage"><ix:nonFraction name="QLGN:PrincipalAmountPercentage" contextRef="From2022-12-222022-12-22_custom_SeniorConvertibleDebentureMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">105</ix:nonFraction>%</span> of the then outstanding
principal amount of the Debenture being redeemed plus accrued but unpaid interest, liquidated damages and any amounts then owing under
the Debenture. These monthly redemption and optional redemptions are subject to the satisfaction of the Equity Conditions (as defined
in the Debenture), which includes a condition that we have obtained stockholder approval for such share issuances.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Debenture accrues interest at the rate of <span id="xdx_908_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_dp_uPure_c20221222_zqktQaiukE0e" title="Debenture accrues interest rate"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateStatedPercentage" contextRef="AsOf2022-12-22" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">8</ix:nonFraction>%</span> per annum, which does not begin accruing until December 1, 2023, and will be payable on
a quarterly basis. Interest may be paid in cash or shares of common stock of the Company or a combination thereof at the option of the
Company; provided that interest may only be paid in shares if the Equity Conditions have been satisfied, including the stockholder approval
condition as described above.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Both
the Debenture and the Alpha Warrant provide for adjustments to the Conversion Price and Exercise Price, respectively, in connection with
stock dividends and splits, subsequent equity sales and rights offerings, pro rata distributions, and certain fundamental transactions.
Both the Debenture and the Alpha Warrant include a beneficial ownership blocker of 9.99%, which may only be waived by Alpha Capital upon
61 days&#8217; notice to the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 59; Value: 35 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->59<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company filed a registration statement on Form S-3 (No. 333-269088) with the Securities and Exchange Commission on December 30, 2022
registering the resale by Alpha Capital of an aggregate of <span id="xdx_90D_eus-gaap--CommonStockSharesIssued_iI_c20221230__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember_z8Hbnh4pDkBb" title="Shares of Common stock, issued"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2022-12-30_custom_AlphaCapitalMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">5,157,087</ix:nonFraction></span> shares of our common stock, which may be issuable to the selling
stockholder pursuant to the terms of the Debenture and Alpha Warrant.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company evaluated the Debenture and Alpha Warrants (&#8220;Warrants&#8221;) and determined that the Warrants are freestanding financial
instruments. The Warrants are not considered indexed to an entity&#8217;s own stock, because the settlement amount would not equal the
difference between the fair value of a fixed number of the entity&#8217;s equity shares and a fixed strike price and all of the adjustment
features in Section 3(b) of the warrant agreement are not down round provisions, as defined in ASU 2017-11. Accordingly, the warrants
are classified as a liability and recognized at fair value, with subsequent changes in fair value recognized in earnings.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
proceeds were allocated to the initial fair value of the Warrants, with the residual balance allocated to the initial carrying value
of the Debenture. The Company has not elected the fair value option for the Debenture. The Debenture was recognized at proceeds received
after allocating the proceeds to the Warrants, and then allocating remaining proceeds to a suite of bifurcated embedded derivative features
(conversion option, contingent acceleration upon an Event of Default, and contingent interest upon an Event of Default), with the resulting
difference, if any, allocated to the loan host instrument. The suite of derivative features was measured and determined to have no fair
value.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
original issue discount ($<span id="xdx_90F_eus-gaap--AmortizationOfDebtDiscountPremium_pn5n6_c20220101__20221231__srt--TitleOfIndividualAxis__custom--AlphaCapitalOtherThirdPartiesMember_zp4lvSqRUHC6" title="Debt discount"><ix:nonFraction name="us-gaap:AmortizationOfDebtDiscountPremium" contextRef="From2022-01-012022-12-31_custom_AlphaCapitalOtherThirdPartiesMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.3</ix:nonFraction></span> million), the initial fair value of the Warrant ($<span id="xdx_90D_eus-gaap--FairValueAdjustmentOfWarrants_pn5n6_c20220101__20221231__srt--TitleOfIndividualAxis__custom--AlphaCapitalOtherThirdPartiesMember_zO2owtL4DxRk" title="Fair value of warrants"><ix:nonFraction name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="From2022-01-012022-12-31_custom_AlphaCapitalOtherThirdPartiesMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">2.8</ix:nonFraction></span> million), the initial fair value of the suite of
bifurcated embedded derivative features ($<span id="xdx_909_eus-gaap--EmbeddedDerivativeFairValueOfEmbeddedDerivativeNet_iI_c20221231__srt--TitleOfIndividualAxis__custom--AlphaCapitalOtherThirdPartiesMember_zI0TkalCerC5" title="Fair value of embedded derivative features"><ix:nonFraction name="us-gaap:EmbeddedDerivativeFairValueOfEmbeddedDerivativeNet" contextRef="AsOf2022-12-31_custom_AlphaCapitalOtherThirdPartiesMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">0</ix:nonFraction></span>), and the fees and costs paid to Alpha Capital and other third parties ($<span id="xdx_90D_ecustom--FeesAndCostsPaid_pn5n6_c20220101__20221231__srt--TitleOfIndividualAxis__custom--AlphaCapitalOtherThirdPartiesMember_zScSabRjudtg" title="Fees and costs paid"><ix:nonFraction name="QLGN:FeesAndCostsPaid" contextRef="From2022-01-012022-12-31_custom_AlphaCapitalOtherThirdPartiesMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.1</ix:nonFraction></span> million) comprise
the debt discount.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
debt discount shall be amortized to interest expense over the expected term of the Debenture using the effective interest method, in
accordance with ASC 835-30. The debt host instrument of the Debenture will subsequently be measured at amortized cost using the effective
interest method to accrete interest over its term to bring the Debenture&#8217;s initial carrying value to the principal balance at maturity.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:ConvertibleDebtTableTextBlock"><p id="xdx_893_eus-gaap--ConvertibleDebtTableTextBlock_ztEJAzIDLiAf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
senior secured convertible debt comprises the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span id="xdx_8BC_z1WPDg8CZWAc" style="display: none">SCHEDULE OF SENIOR SECURED CONVERTIBLE DEBT</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49B_20221231__us-gaap--DebtInstrumentAxis__custom--SeniorSecuredConvertibleDebtMember_zeAxq957M6G" style="border-bottom: Black 1.5pt solid; text-align: center">December 31, 2022</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49A_20211231__us-gaap--DebtInstrumentAxis__custom--SeniorSecuredConvertibleDebtMember_zH6RVIUHly2d" style="border-bottom: Black 1.5pt solid; text-align: center">December 31, 2021</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--SecuredDebt_iI_zAbA2kDFz948" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Senior secured convertible debenture</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:SecuredDebt" contextRef="AsOf2022-12-31_custom_SeniorSecuredConvertibleDebtMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,300,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1386">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--DebtInstrumentUnamortizedDiscount_iNI_di_zxkB9aHFk1al" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Discount on convertible debenture</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:DebtInstrumentUnamortizedDiscount" contextRef="AsOf2022-12-31_custom_SeniorSecuredConvertibleDebtMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,239,803</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1389">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--ConvertibleDebt_iI_zRqBAw6xB991" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt">Total convertible debt - related party</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ConvertibleDebt" contextRef="AsOf2022-12-31_custom_SeniorSecuredConvertibleDebtMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">60,197</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1392">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A8_zt7yx6G1i148" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2022, there were no events of default or violation of any covenants under our financing obligations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:EarningsPerShareTextBlock"><p id="xdx_805_eus-gaap--EarningsPerShareTextBlock_zHY7egubaLke" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
12 &#8212; <span id="xdx_82F_zPGZC2l028Hh">EARNINGS (LOSS) PER SHARE</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basic
earnings (loss) per share (&#8220;EPS&#8221;) is computed by dividing net income (loss) by the weighted-average number of common
shares outstanding. Diluted EPS is computed based on the sum of the weighted-average number of common shares and potentially
dilutive common shares outstanding during the period. Potentially dilutive common shares consist of shares issuable from stock
options and warrants as shown below.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"><p id="xdx_89B_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_zaoyhmNBTzl3" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table reconciles net loss and the weighted-average shares used in computing basic and diluted EPS in the respective periods:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span id="xdx_8BD_z7LQ3fmEIrCi" style="display: none">SCHEDULE OF EARNINGS PER SHARE BASIC AND DILUTED</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_497_20220101__20221231_z6dwpAP8J93c" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49A_20210101__20211231_z9KIausBOqgc" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">For the Years Ended<br /> December
    31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--NetIncomeLoss_zJ7l70jhJT83" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left; padding-bottom: 1.5pt">Net loss used for basic earnings per share</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt double; width: 16%; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">18,640,543</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">)</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt double; width: 16%; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">17,897,137</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_zu7PiFAlXhde" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Basic weighted-average common shares outstanding</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,840,340</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,933,487</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_ecustom--DilutivePotentialSharesIssuableFromStockOptionsAndWarrants_zAYVlK9dICj5" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Dilutive potential shares issuable from stock options and warrants</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1404">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1405">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--WeightedAverageNumberDilutedSharesOutstandingAdjustment_zGRAE7ZM1bQi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Diluted weighted-average common shares outstanding</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,840,340</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,933,487</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>


</ix:nonNumeric><p id="xdx_8A6_zuXyI6L94J1a" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"><p id="xdx_892_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zBltfnfiJ6zd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span id="xdx_8B1_zEGCJvcq8ezb" style="display: none">SCHEDULE
OF DILUTIVE SECURITIES EXCLUDED FROM DILUTED NET LOSS PER SHARE</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">As of December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Shares of common stock subject to outstanding options</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20220101__20221231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--SharesOfCommonStockSubjectToOutstandingOptionsMember_ztotXvbX597a" title="Total common stock equivalents" style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2022-01-012022-12-31_custom_SharesOfCommonStockSubjectToOutstandingOptionsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">608,012</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20210101__20211231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--SharesOfCommonStockSubjectToOutstandingOptionsMember_zlSKky8vBqE7" title="Total common stock equivalents" style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2021-01-012021-12-31_custom_SharesOfCommonStockSubjectToOutstandingOptionsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">484,186</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Shares of common stock subject to outstanding warrants</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20220101__20221231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--SharesOfCommonStockSubjectToOutstandingWarrantsMember_zpZnNV69Vlba" title="Total common stock equivalents" style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2022-01-012022-12-31_custom_SharesOfCommonStockSubjectToOutstandingWarrantsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">4,575,617</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20210101__20211231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--SharesOfCommonStockSubjectToOutstandingWarrantsMember_zYNSh0cCai5j" title="Total common stock equivalents" style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2021-01-012021-12-31_custom_SharesOfCommonStockSubjectToOutstandingWarrantsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">982,140</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Total common stock equivalents</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20220101__20221231_z4StuYQKGSP5" title="Total common stock equivalents" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">5,183,629</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20210101__20211231_zZ2vqFx77pi6" title="Total common stock equivalents" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,466,326</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>



</ix:nonNumeric><p id="xdx_8A9_zvcqruAJdDuf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 60; Value: 35 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->60<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Potentially
dilutive common shares excluded from the calculation above represent stock options and warrants because their effect would be anti-dilutive.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock"><p id="xdx_806_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_z9iGw5PtcN4f" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
13 &#8212; <span id="xdx_821_zjEMbMiCADH3">COMMITMENTS AND CONTINGENCIES</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Leases</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company leases its facilities under a long-term operating lease agreement. On December 15, 2021, our wholly-owned subsidiary Qualigen,
Inc. entered into a Second Amendment to Lease with Bond Ranch LP. This Amendment extended the Company&#8217;s triple-net leasehold on
the Company&#8217;s existing <span id="xdx_907_eus-gaap--AreaOfLand_iI_pid_uSqft_c20211215_zaAbtsgHCJIi" title="Area of land"><ix:nonFraction name="us-gaap:AreaOfLand" contextRef="AsOf2021-12-15" format="ixt:numdotdecimal" decimals="INF" unitRef="Sqft">22,624</ix:nonFraction></span>-square-feet headquarters/manufacturing facility at 2042 Corte del Nogal, Carlsbad, California for
the <span id="xdx_907_eus-gaap--LesseeOperatingLeaseTermOfContract_iI_dtM_c20211215_zmFD2xTsFte8" title="Lessee operating lease term of contract"><ix:nonNumeric contextRef="AsOf2021-12-15" format="ixt-sec:durmonth" name="us-gaap:LesseeOperatingLeaseTermOfContract">61</ix:nonNumeric></span>-month period of <span id="xdx_90F_eus-gaap--LesseeOperatingLeaseDescription_c20211214__20211215_z6AeFyO5EqWc" title="Operating lease term description"><ix:nonNumeric contextRef="From2021-12-142021-12-15" name="us-gaap:LesseeOperatingLeaseDescription">November 1, 2022 to November 30, 2027</ix:nonNumeric></span>. Over the <span id="xdx_907_eus-gaap--LesseeOperatingLeaseTermOfContract_iI_dtM_c20211215_zVIwr4pGAJNi" title="Operating lease term"><ix:nonNumeric contextRef="AsOf2021-12-15" format="ixt-sec:durmonth" name="us-gaap:LesseeOperatingLeaseTermOfContract">61</ix:nonNumeric></span> months, the base rent payable by Qualigen, Inc. will total
$<span id="xdx_908_eus-gaap--PaymentsForRent_pp0p0_c20211214__20211215_zD87jiSScl8l" title="Payments for Rent"><ix:nonFraction name="us-gaap:PaymentsForRent" contextRef="From2021-12-142021-12-15" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,950,710</ix:nonFraction></span>; however, the base rent for the first 12 months of the <span id="xdx_907_eus-gaap--LesseeOperatingLeaseTermOfContract_iI_dtM_c20211215_zvVNz8xyQE5h" title="Operating lease term"><ix:nonNumeric contextRef="AsOf2021-12-15" format="ixt-sec:durmonth" name="us-gaap:LesseeOperatingLeaseTermOfContract">61</ix:nonNumeric></span>-month period is only $<span id="xdx_906_eus-gaap--PaymentsForRent_pp0p0_c20211214__20211215__us-gaap--AwardTypeAxis__custom--FirstTwelveMonthsMember_zRstPgwarKb1" title="Payments for Rent"><ix:nonFraction name="us-gaap:PaymentsForRent" contextRef="From2021-12-142021-12-15_custom_FirstTwelveMonthsMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">335,966</ix:nonFraction></span>. Additionally, under the Second Amendment
to Lease Qualigen, Inc. is entitled to a $<span id="xdx_90D_ecustom--TenantImprovementAllowance_pp0p0_c20211214__20211215_z109P4LxiNbe" title="Tenant improvement allowance"><ix:nonFraction name="QLGN:TenantImprovementAllowance" contextRef="From2021-12-142021-12-15" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">339,360</ix:nonFraction></span> tenant improvement allowance.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="QLGN:ScheduleOfOperatingLeaseRightOfUseAssetsAndLiabilitiesTableTextBlock"><p id="xdx_899_ecustom--ScheduleOfOperatingLeaseRightOfUseAssetsAndLiabilitiesTableTextBlock_z0ulwQjfH8U4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
tables below show the operating lease right-of-use assets and operating lease liabilities and the balances as of December 31, 2022 and 2021,
including the changes during the periods:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span id="xdx_8BA_ziFz6VW0TG05" style="display: none">SCHEDULE OF OPERATING LEASE RIGHT OF USE ASSETS AND OPERATING LEASE LIABILITIES</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="font-size: 11pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Operating lease<br />
 right-of-use assets</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Net right-of-use assets at December 31, 2021</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_980_eus-gaap--OperatingLeaseRightOfUseAsset_iS_pp0p0_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--LongtermOperatingLeaseAgreementMember_zoWJJfQiX20c" title="Operating lease right-of-use assets" style="width: 20%; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="AsOf2021-12-31_custom_LongtermOperatingLeaseAgreementMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,645,568</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Less amortization of operating lease right-of-use assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--OperatingLeaseRightOfUseAssetAmortizationExpense_iN_pp0p0_di_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--LongtermOperatingLeaseAgreementMember_zRBGziJpQXff" title="Less amortization of operating lease right-of-use assets" style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" contextRef="From2022-01-012022-12-31_custom_LongtermOperatingLeaseAgreementMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">223,030</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Operating lease right-of-use assets at December 31, 2022</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98E_eus-gaap--OperatingLeaseRightOfUseAsset_iE_pp0p0_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--LongtermOperatingLeaseAgreementMember_z9nu3gT7HO9i" title="Operating lease right-of-use assets" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="AsOf2022-12-31_custom_LongtermOperatingLeaseAgreementMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,422,538</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="font-size: 11pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Operating lease <br />
liabilities</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify">Lease liabilities at December 31, 2021</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--OperatingLeaseLiability_iS_pp0p0_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--LongtermOperatingLeaseAgreementMember_z3PIOEpBaz6c" title="Lease liabilities at December 31, 2021" style="width: 20%; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiability" contextRef="AsOf2021-12-31_custom_LongtermOperatingLeaseAgreementMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,676,655</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Less principal payments on operating lease liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--OperatingLeasePayments_iN_pp0p0_di_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--LongtermOperatingLeaseAgreementMember_z7BsWNkVCFb3" title="Less principal payments on operating lease liabilities" style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:OperatingLeasePayments" contextRef="From2022-01-012022-12-31_custom_LongtermOperatingLeaseAgreementMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">134,091</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Lease liabilities at December 31, 2022</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--OperatingLeaseLiability_iE_pp0p0_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--LongtermOperatingLeaseAgreementMember_z2BlWDvHWsEe" title="Lease liabilities at December 31, 2022" style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiability" contextRef="AsOf2022-12-31_custom_LongtermOperatingLeaseAgreementMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,542,564</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Less non-current portion</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--OperatingLeaseLiabilityNoncurrent_iNI_pp0p0_di_c20221231__us-gaap--TypeOfArrangementAxis__custom--LongtermOperatingLeaseAgreementMember_zhXkVZb3zUD4" title="Less non-current portion" style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="AsOf2022-12-31_custom_LongtermOperatingLeaseAgreementMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,301,919</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Current portion at December 31, 2022</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_985_eus-gaap--OperatingLeaseLiabilityCurrent_iI_pp0p0_c20221231__us-gaap--TypeOfArrangementAxis__custom--LongtermOperatingLeaseAgreementMember_zN5pWBRG2zJe" title="Current portion at Decebmer 31, 2022" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="AsOf2022-12-31_custom_LongtermOperatingLeaseAgreementMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">240,645</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AE_zes6jdNH188a" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2022, the Company&#8217;s operating leases have a weighted-average remaining lease term of <span id="xdx_900_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20221231_zSqpD6tjQxyi" title="Weighted-average remaining lease term"><ix:nonNumeric contextRef="AsOf2022-12-31" format="ixt-sec:duryear" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1">4.9</ix:nonNumeric></span> years and a weighted-average
discount rate of <span id="xdx_908_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pid_dp_uPure_c20221231_zbSLh6l6MEQ2" title="Weighted-average discount rate"><ix:nonFraction name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">8.9</ix:nonFraction>%</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock"><p id="xdx_896_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_zSBkOaWTrCPh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2022, the maturities of operating lease liabilities are as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span id="xdx_8BE_z9uHZNcDlUZ4" style="display: none">SCHEDULE OF MATURITIES OF OPERATING LEASE LIABILITIES</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; text-align: left; font-weight: bold">Year Ending December 31,</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49E_20221231_zn3gN7h6B1nl" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Amount</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_pp0p0_maLOLLPzeyI_zIWHtmgJn8Ia" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">2023</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 20%; text-align: right"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">368,341</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_pp0p0_maLOLLPzeyI_zZMNmVXDq436" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">2024</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">379,392</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_pp0p0_maLOLLPzeyI_zC64ZeHfUxLe" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">2025</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">390,773</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFour_iI_pp0p0_maLOLLPzeyI_z00UeWrsMc3i" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">2026</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">402,497</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFive_iI_pp0p0_maLOLLPzeyI_zTPS48niBBhi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">2027</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">379,164</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_pp0p0_mtLOLLPzeyI_z2xGUrk62F7k" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Total</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,920,168</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_pp0p0_di_zO7AcWnTUBmh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Less present value discount</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">377,604</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_407_eus-gaap--OperatingLeaseLiability_iI_pp0p0_zYZMazngQ4g2" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Operating lease liabilities</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiability" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,542,564</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AA_zvYjPd46qM0g" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
lease expense was approximately $<span id="xdx_900_eus-gaap--OperatingLeaseExpense_c20220101__20221231_zjr6RpIrW6X5"><ix:nonFraction name="us-gaap:OperatingLeaseExpense" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">462,000</ix:nonFraction></span> and $<span id="xdx_90D_eus-gaap--OperatingLeaseExpense_c20210101__20211231_zgZOSCr6uhje"><ix:nonFraction name="us-gaap:OperatingLeaseExpense" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">342,000</ix:nonFraction></span>, respectively, for the years ended December 31, 2022 and December 31, 2021. Lease
expense was recorded in cost of product sales, general and administrative expenses, research and development and sales and marketing
expenses.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Termination
of Sekisui Distribution Agreement</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sekisui&#8217;s
Distribution Arrangement expired on March 31, 2022. Following the expiration of the Sekisui Distribution Agreement on March 31, 2022,
the Company had a commitment to purchase leased FastPack rental systems back from Sekisui at Sekisui&#8217;s net book value, in the amount
of $<span id="xdx_901_eus-gaap--AccruedLiabilitiesAndOtherLiabilities_iI_c20221231__srt--TitleOfIndividualAxis__custom--SekisuiDistributionAgreementMember_zQ7KZ4Ig9A6b" title="Accrued expenses"><ix:nonFraction name="us-gaap:AccruedLiabilitiesAndOtherLiabilities" contextRef="AsOf2022-12-31_custom_SekisuiDistributionAgreementMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">154,000</ix:nonFraction></span> which is included in equipment held for lease and accrued expenses on the consolidated balance sheet.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>NanoSynex
Funding Commitment</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a condition to the NanoSynex Acquisition, the Company agreed to provide NanoSynex with up to $<span id="xdx_908_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iI_pn5n6_c20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NanoSynexMember_zMLqrzeE72Ol" title="Maximum future funding amount"><ix:nonFraction name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" contextRef="AsOf2022-12-31_custom_NanoSynexMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">10.4</ix:nonFraction></span> million of future funding in the form
of promissory notes to the Company based on NanoSynex&#8217;s achievement of certain future development milestones and subject to other
terms and conditions described in the Funding Agreement entered into with NanoSynex. Of this amount approximately $<span id="xdx_903_ecustom--DevelopmentFund_pn5n6_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NanoSynexMember_zZAk0FaQXX4f" title="Development fund"><ix:nonFraction name="QLGN:DevelopmentFund" contextRef="From2022-01-012022-12-31_custom_NanoSynexMember72014625" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">2.4</ix:nonFraction></span> million was funded
during the year ended December 31, 2022, and an additional $<span id="xdx_906_eus-gaap--LineOfCreditFacilityCurrentBorrowingCapacity_iI_pn5n6_c20230228__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NanoSynexMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zqegjOgAERag" title="Additional funding amount"><ix:nonFraction name="us-gaap:LineOfCreditFacilityCurrentBorrowingCapacity" contextRef="AsOf2023-02-28_custom_NanoSynexMember_us-gaap_SubsequentEventMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.5</ix:nonFraction></span> million was funded in February 2023 (See Note 2-Liquidity for further details regarding the terms and conditions of the Funding Agreement).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 61; Value: 35 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->61<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Litigation
and Other Legal Proceedings</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
November 9, 2021, the Company was named as a defendant in an action brought by Mediant Communications Inc. (&#8220;Mediant&#8221;) in
the U.S. District Court for the Southern District of New York. The complaint alleged that Qualigen entered into an implied contract with
Mediant, whereby Qualigen retained Mediant to distribute proxy materials and subsequently conduct shareholder vote tabulations. The Company
filed a Motion to Dismiss with the District Court and on March 14, 2022 a hearing was held during which the presiding judge ruled in
favor of the Motion to Dismiss. The Company and Mediant settled the litigation on April 5, 2022 in the amount of $<span id="xdx_905_eus-gaap--LitigationSettlementAmountAwardedToOtherParty_pp0p0_c20220404__20220405_z40tOhfkOwOk" title="Litigation settlement amount"><ix:nonFraction name="us-gaap:LitigationSettlementAmountAwardedToOtherParty" contextRef="From2022-04-042022-04-05" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">96,558</ix:nonFraction></span>, at which time
the amount was paid.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="QLGN:ResearchAndLicenseAgreementsTextBlock"><p id="xdx_80A_ecustom--ResearchAndLicenseAgreementsTextBlock_zVAoYUU74L9j" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
14 &#8212; <span id="xdx_829_zwvo1fWa5Cz9">RESEARCH AND LICENSE AGREEMENTS</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>The
University of Louisville Research Foundation</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
March 2019, the Company entered into a sponsored research agreement and an option for a license agreement with ULRF for development of
several small-molecule RAS interaction inhibitor drug candidates. Under the terms of this agreement, the Company was to reimburse ULRF
for sponsored research expenses of up to $<span id="xdx_90A_ecustom--ReimbursementOfResearchExpenses_pp0p0_c20190301__20190331__us-gaap--TypeOfArrangementAxis__custom--SponsoredResearchAgreementAndLicenseMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember_zCLvzpzjMyik"><ix:nonFraction name="QLGN:ReimbursementOfResearchExpenses" contextRef="From2019-03-012019-03-31_custom_SponsoredResearchAgreementAndLicenseMember_custom_UniversityOfLouisvilleResearchFoundationMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">693,000</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">for this program. In February 2021, March 2022,
and October 2022, the Company extended the term of this agreement until September 2023 and increased the amount that the Company will
reimburse ULRF for sponsored research expenses to approximately $<span id="xdx_906_ecustom--ReimbursementOfResearchExpenses_pn5n6_c20210201__20210228__us-gaap--TypeOfArrangementAxis__custom--SponsoredResearchAgreementAndLicenseMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember_zgeRqiu8lyGl"><ix:nonFraction name="QLGN:ReimbursementOfResearchExpenses" contextRef="From2021-02-012021-02-28_custom_SponsoredResearchAgreementAndLicenseMember_custom_UniversityOfLouisvilleResearchFoundationMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">2.7</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million. <span id="xdx_908_ecustom--AgreementTermPaymentDescription_c20190301__20190331__us-gaap--TypeOfArrangementAxis__custom--SponsoredResearchAgreementAndLicenseMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember_zvNNEzQiBlJi"><ix:nonNumeric contextRef="From2019-03-012019-03-31_custom_SponsoredResearchAgreementAndLicenseMember_custom_UniversityOfLouisvilleResearchFoundationMember" name="QLGN:AgreementTermPaymentDescription">In
July 2020, the Company entered into an exclusive license agreement with ULRF for RAS interaction inhibitor drug candidates. Under the
agreement, the Company will take over development, regulatory approval and commercialization of the candidates from ULRF and is responsible
for maintenance of the related intellectual property portfolio. In return, ULRF received approximately $112,000 for an upfront license
fee and reimbursement of prior patent costs. In addition, the Company has agreed to pay ULRF (i) royalties, on patent-covered net sales
associated with the commercialization, of 4% (on net sales up to a cumulative $250,000,000) or 5% (on net sales above a cumulative $250,000,000),
until expiration of the licensed patent, and 2.5% (on net sales for any sales not covered by Licensed Patents), (ii) 30% to 50% of any
non-royalty sublicensee income received (50% for sublicenses granted in the first two years of the ULRF license agreement, 40% for sublicenses
granted in the third or fourth years of the ULRF license agreement, and 30% for sublicenses granted in the fifth year of the ULRF license
agreement or thereafter), (iii) reimbursements for ongoing costs associated with the preparation, filing, prosecution and maintenance
of licensed patents, incurred prior to July 2020, and (iv) payments ranging from $</ix:nonNumeric></span></span><span id="xdx_904_ecustom--MilestonePayment_pp0p0_c20190301__20190331__srt--RangeAxis__srt--MinimumMember__us-gaap--TypeOfArrangementAxis__custom--LicenseAndSponsoredResearchAgreementsMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember_zi75rTkpdRO7" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="QLGN:MilestonePayment" contextRef="From2019-03-012019-03-31_srt_MinimumMember_custom_LicenseAndSponsoredResearchAgreementsMember_custom_UniversityOfLouisvilleResearchFoundationMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">50,000</ix:nonFraction>
</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">to
$</span><span id="xdx_908_ecustom--MilestonePayment_pp0p0_c20190301__20190331__srt--RangeAxis__srt--MaximumMember__us-gaap--TypeOfArrangementAxis__custom--LicenseAndSponsoredResearchAgreementsMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember_zzisbQOnJ7W" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="QLGN:MilestonePayment" contextRef="From2019-03-012019-03-31_srt_MaximumMember_custom_LicenseAndSponsoredResearchAgreementsMember_custom_UniversityOfLouisvilleResearchFoundationMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">5,000,000</ix:nonFraction>
</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">upon
the achievement of certain regulatory and commercial milestones.</span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Milestone
payments for the first therapeutic indication would be $<span id="xdx_90B_ecustom--MilestonePayment_c20190301__20190331__us-gaap--TypeOfArrangementAxis__custom--LicenseAndSponsoredResearchAgreementsMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember__us-gaap--AwardTypeAxis__custom--PhaseOneClinicalTrialMember_zjG7RTmAlUl6"><ix:nonFraction name="QLGN:MilestonePayment" contextRef="From2019-03-012019-03-31_custom_LicenseAndSponsoredResearchAgreementsMember_custom_UniversityOfLouisvilleResearchFoundationMember_custom_PhaseOneClinicalTrialMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">50,000</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">for first dosing in a Phase 1 clinical trial,
$<span id="xdx_90B_ecustom--MilestonePayment_c20190301__20190331__us-gaap--TypeOfArrangementAxis__custom--LicenseAndSponsoredResearchAgreementsMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember__us-gaap--AwardTypeAxis__custom--PhaseTwoClinicalTrialMember_z1Fq5VC7aWu3"><ix:nonFraction name="QLGN:MilestonePayment" contextRef="From2019-03-012019-03-31_custom_LicenseAndSponsoredResearchAgreementsMember_custom_UniversityOfLouisvilleResearchFoundationMember_custom_PhaseTwoClinicalTrialMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">100,000</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">for first dosing in a Phase 2 clinical trial,
$<span id="xdx_90D_ecustom--MilestonePayment_c20190301__20190331__us-gaap--TypeOfArrangementAxis__custom--LicenseAndSponsoredResearchAgreementsMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember__us-gaap--AwardTypeAxis__custom--PhaseThreeClinicalTrialMember_zFC5HQXQnMcg"><ix:nonFraction name="QLGN:MilestonePayment" contextRef="From2019-03-012019-03-31_custom_LicenseAndSponsoredResearchAgreementsMember_custom_UniversityOfLouisvilleResearchFoundationMember_custom_PhaseThreeClinicalTrialMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">150,000</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">for first dosing in a Phase 3 clinical trial,
$<span id="xdx_908_ecustom--RegulatoryMarketingApprovalExpenses_pp0p0_c20190301__20190331__us-gaap--TypeOfArrangementAxis__custom--SponsoredResearchAgreementAndLicenseMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember_zXrv7UsytLp9"><ix:nonFraction name="QLGN:RegulatoryMarketingApprovalExpenses" contextRef="From2019-03-012019-03-31_custom_SponsoredResearchAgreementAndLicenseMember_custom_UniversityOfLouisvilleResearchFoundationMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">300,000</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">for regulatory marketing approval and $<span id="xdx_90B_ecustom--CumulativeSales_pp0p0_c20190301__20190331__srt--ProductOrServiceAxis__custom--LicensedProductSalesMember__us-gaap--TypeOfArrangementAxis__custom--LicenseAndSponsoredResearchAgreementsMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember_zsH40GEqRIvh"><ix:nonFraction name="QLGN:CumulativeSales" contextRef="From2019-03-012019-03-31_custom_LicensedProductSalesMember_custom_LicenseAndSponsoredResearchAgreementsMember_custom_UniversityOfLouisvilleResearchFoundationMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">5,000,000</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">upon achieving a cumulative $<span id="xdx_902_eus-gaap--RevenueFromContractWithCustomerIncludingAssessedTax_pp0p0_c20190301__20190331__us-gaap--TypeOfArrangementAxis__custom--SponsoredResearchAgreementAndLicenseMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember_z8mvC1jWDDeb"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" contextRef="From2019-03-012019-03-31_custom_SponsoredResearchAgreementAndLicenseMember_custom_UniversityOfLouisvilleResearchFoundationMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">500,000,000</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">of Licensed Product sales. The Company also must
pay ULRF shortfall payments if the total amounts actually paid with respect to royalties and non-royalty sublicensee income for any year
is less than the applicable annual minimum (ranging from $<span id="xdx_905_ecustom--UpfrontLicenseFee_iI_pp0p0_c20190331__srt--RangeAxis__srt--MinimumMember__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember_z9Wb1eJfRII2" title="Upfront license fee"><ix:nonFraction name="QLGN:UpfrontLicenseFee" contextRef="AsOf2019-03-31_srt_MinimumMember_custom_LicenseAgreementMember_custom_UniversityOfLouisvilleResearchFoundationMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">20,000</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">to $<span id="xdx_90D_ecustom--UpfrontLicenseFee_iI_pp0p0_c20190331__srt--RangeAxis__srt--MaximumMember__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember_zd4MF4c7bOL8" title="Upfront license fee"><ix:nonFraction name="QLGN:UpfrontLicenseFee" contextRef="AsOf2019-03-31_srt_MaximumMember_custom_LicenseAgreementMember_custom_UniversityOfLouisvilleResearchFoundationMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">100,000</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)
for such year.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sponsored
research expenses related to these agreements for the years ended December 31, 2022 and December 31, 2021 were approximately $<span id="xdx_904_eus-gaap--ResearchAndDevelopmentExpense_pp0p0_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--LicenseAndSponsoredResearchAgreementsMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember_zXcTVKWgpgwc" title="Research and development"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2022-01-012022-12-31_custom_LicenseAndSponsoredResearchAgreementsMember_custom_UniversityOfLouisvilleResearchFoundationMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">758,000</ix:nonFraction></span>
and $<span id="xdx_907_eus-gaap--ResearchAndDevelopmentExpense_pp0p0_c20210101__20211231__us-gaap--TypeOfArrangementAxis__custom--LicenseAndSponsoredResearchAgreementsMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember_ziPv1zw7Wp1g" title="Research and development"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2021-01-012021-12-31_custom_LicenseAndSponsoredResearchAgreementsMember_custom_UniversityOfLouisvilleResearchFoundationMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">646,000</ix:nonFraction></span>, respectively, and are recorded in research and development expenses in the Consolidated Statements of Operations. License
costs related to these agreements for the years ended December 31, 2022 and December 31, 2021 were approximately $<span id="xdx_903_ecustom--LicenseCost_pp0p0_c20220101__20221231_zeBCXcxnnH5b" title="License costs"><ix:nonFraction name="QLGN:LicenseCost" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">40,000</ix:nonFraction></span> and $<span id="xdx_90D_ecustom--LicenseCost_pp0p0_c20210101__20211231_zTb5XJrhEAVb" title="License costs"><ix:nonFraction name="QLGN:LicenseCost" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">60,000</ix:nonFraction></span>,
respectively, and are included in research and development expenses in the Consolidated Statements of Operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Between
June 2018 and September 2020, the Company entered into license and sponsored research agreements with the University of Louisville
Research Foundation (&#8220;ULRF&#8221;) for QN-247, a novel aptamer-based compound that has shown promise as an anticancer drug.
Under the agreements, the Company took over development, regulatory approval and commercialization of the compound from ULRF and is
responsible for maintenance of the related intellectual property portfolio. In return, ULRF received a $<span id="xdx_90A_eus-gaap--ProceedsFromConvertibleDebt_pp0p0_c20180601__20200930__us-gaap--TypeOfArrangementAxis__custom--LicenseAndSponsoredResearchAgreementsMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember_zyVH2yPJzTV2" title="Proceeds from convertible debt"><ix:nonFraction name="us-gaap:ProceedsFromConvertibleDebt" contextRef="From2018-06-012020-09-30_custom_LicenseAndSponsoredResearchAgreementsMember_custom_UniversityOfLouisvilleResearchFoundationMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">50,000</ix:nonFraction></span>
convertible promissory note in payment of an upfront license fee, which was subsequently converted into the Company&#8217;s common
stock, and the Company agreed to reimburse ULRF for sponsored research expenses of up to $<span id="xdx_902_ecustom--ReimbursementOfResearchExpenses_pp0p0_c20180601__20200930__us-gaap--TypeOfArrangementAxis__custom--LicenseAndSponsoredResearchAgreementsMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember_z25ifum6bXJ7" title="Reimbursement of research expenses"><ix:nonFraction name="QLGN:ReimbursementOfResearchExpenses" contextRef="From2018-06-012020-09-30_custom_LicenseAndSponsoredResearchAgreementsMember_custom_UniversityOfLouisvilleResearchFoundationMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">830,000</ix:nonFraction></span>
and prior patent costs of up to $<span id="xdx_90C_ecustom--PatentCosts_pp0p0_c20180601__20200930__us-gaap--TypeOfArrangementAxis__custom--LicenseAndSponsoredResearchAgreementsMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember_z8nQBpxyEjzj" title="Patent costs"><ix:nonFraction name="QLGN:PatentCosts" contextRef="From2018-06-012020-09-30_custom_LicenseAndSponsoredResearchAgreementsMember_custom_UniversityOfLouisvilleResearchFoundationMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">200,000</ix:nonFraction></span>.
The sponsored research agreement ended on August 31, 2022. <span id="xdx_90A_ecustom--AgreementTermPaymentDescription_c20180601__20200930__us-gaap--TypeOfArrangementAxis__custom--LicenseAndSponsoredResearchAgreementsMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember_zOxTiAHB57Di" title="Agreement term payment, description"><ix:nonNumeric contextRef="From2018-06-012020-09-30_custom_LicenseAndSponsoredResearchAgreementsMember_custom_UniversityOfLouisvilleResearchFoundationMember" name="QLGN:AgreementTermPaymentDescription">In
addition, the Company agreed to pay ULRF (i) royalties, on patent-covered net sales associated with the commercialization of
anti-nucleolin agent-conjugated nanoparticles, of 4% (on net sales up to a cumulative $250,000,000) or 5% (on net sales above a
cumulative $250,000,000), until expiration of the last to expire of the licensed patents, (ii) 30% to 50% of any non-royalty
sublicensee income received (50% for sublicenses granted in the first two years of the ULRF license agreement, 40% for sublicenses
granted in the third or fourth years of the ULRF license agreement, and 30% for sublicenses granted in the fifth year of the ULRF
license agreement or thereafter), (iii) reimbursements for ongoing costs associated with the preparation, filing, prosecution and
maintenance of licensed patents, incurred prior to June 2018, and (iv) payments ranging from $<span id="xdx_900_ecustom--MilestonePayment_pp0p0_c20180601__20180630__srt--RangeAxis__srt--MinimumMember__us-gaap--TypeOfArrangementAxis__custom--LicenseAndSponsoredResearchAgreementsMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember_z6JELV5a6zL6" title="Milestone payment"><ix:nonFraction name="QLGN:MilestonePayment" contextRef="From2018-06-012018-06-30_srt_MinimumMember_custom_LicenseAndSponsoredResearchAgreementsMember_custom_UniversityOfLouisvilleResearchFoundationMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">100,000</ix:nonFraction></span>
to $<span id="xdx_909_ecustom--MilestonePayment_pp0p0_c20180601__20180630__srt--RangeAxis__srt--MaximumMember__us-gaap--TypeOfArrangementAxis__custom--LicenseAndSponsoredResearchAgreementsMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember_zQeDmNDDTMa6" title="Milestone payment"><ix:nonFraction name="QLGN:MilestonePayment" contextRef="From2018-06-012018-06-30_srt_MaximumMember_custom_LicenseAndSponsoredResearchAgreementsMember_custom_UniversityOfLouisvilleResearchFoundationMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">5,000,000</ix:nonFraction></span>
upon the achievement of certain regulatory and commercial milestones.</ix:nonNumeric></span> Milestone payments for the first therapeutic indication
would be $<span id="xdx_90C_ecustom--MilestonePayment_pp0p0_c20180601__20180630__us-gaap--AwardTypeAxis__custom--PhaseOneClinicalTrialMember__us-gaap--TypeOfArrangementAxis__custom--LicenseAndSponsoredResearchAgreementsMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember_zI2d4t7SZST" title="Milestone payment"><ix:nonFraction name="QLGN:MilestonePayment" contextRef="From2018-06-012018-06-30_custom_PhaseOneClinicalTrialMember_custom_LicenseAndSponsoredResearchAgreementsMember_custom_UniversityOfLouisvilleResearchFoundationMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">100,000</ix:nonFraction></span>
for first dosing in a Phase 1 clinical trial, $<span id="xdx_909_ecustom--MilestonePayment_pp0p0_c20180601__20180630__us-gaap--AwardTypeAxis__custom--PhaseTwoClinicalTrialMember__us-gaap--TypeOfArrangementAxis__custom--LicenseAndSponsoredResearchAgreementsMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember_zNL8atpu6O93" title="Milestone payment"><ix:nonFraction name="QLGN:MilestonePayment" contextRef="From2018-06-012018-06-30_custom_PhaseTwoClinicalTrialMember_custom_LicenseAndSponsoredResearchAgreementsMember_custom_UniversityOfLouisvilleResearchFoundationMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">200,000</ix:nonFraction></span>
for first dosing in a Phase 2 clinical trial, $<span id="xdx_90E_ecustom--MilestonePayment_pp0p0_c20180601__20180630__us-gaap--AwardTypeAxis__custom--PhaseThreeClinicalTrialMember__us-gaap--TypeOfArrangementAxis__custom--LicenseAndSponsoredResearchAgreementsMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember_z29VWeREQaqa" title="Milestone payment"><ix:nonFraction name="QLGN:MilestonePayment" contextRef="From2018-06-012018-06-30_custom_PhaseThreeClinicalTrialMember_custom_LicenseAndSponsoredResearchAgreementsMember_custom_UniversityOfLouisvilleResearchFoundationMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">350,000</ix:nonFraction></span>
for first dosing in a Phase 3 clinical trial, $<span id="xdx_909_ecustom--MilestonePayment_c20180601__20180630__us-gaap--AwardTypeAxis__custom--PhaseClinicalTrialMember__us-gaap--TypeOfArrangementAxis__custom--LicenseAndSponsoredResearchAgreementsMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember_zVcVfqTkcXXj" title="Milestone payment"><ix:nonFraction name="QLGN:MilestonePayment" contextRef="From2018-06-012018-06-30_custom_PhaseClinicalTrialMember_custom_LicenseAndSponsoredResearchAgreementsMember_custom_UniversityOfLouisvilleResearchFoundationMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">500,000</ix:nonFraction></span>
for regulatory marketing approval and $<span id="xdx_90A_ecustom--RegulatoryMarketingApprovalExpenses_pp0p0_c20180601__20180630__srt--ProductOrServiceAxis__custom--LicensedProductSalesMember__us-gaap--TypeOfArrangementAxis__custom--LicenseAndSponsoredResearchAgreementsMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember_zE3AIOiJE55k" title="Regulatory marketing approval, expenses"><ix:nonFraction name="QLGN:RegulatoryMarketingApprovalExpenses" contextRef="From2018-06-012018-06-30_custom_LicensedProductSalesMember_custom_LicenseAndSponsoredResearchAgreementsMember_custom_UniversityOfLouisvilleResearchFoundationMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">5,000,000</ix:nonFraction></span>
upon achieving a cumulative $<span id="xdx_903_ecustom--CumulativeSales_pp0p0_c20180601__20180630__us-gaap--TypeOfArrangementAxis__custom--SponsoredResearchAgreementAndLicenseMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember_zZwARTQp1OPd" title="Cumulative sales"><ix:nonFraction name="QLGN:CumulativeSales" contextRef="From2018-06-012018-06-30_custom_SponsoredResearchAgreementAndLicenseMember_custom_UniversityOfLouisvilleResearchFoundationMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">500,000,000</ix:nonFraction></span>
of Licensed Product sales; the Company would also pay another $<span id="xdx_905_ecustom--RegulatoryMarketingApprovalExpensesOne_pp0p0_c20180601__20180630__srt--ProductOrServiceAxis__custom--LicensedProductSalesMember__us-gaap--TypeOfArrangementAxis__custom--LicenseAndSponsoredResearchAgreementsMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember_zecFxuofTmj7" title="Regulatory marketing approval, expenses"><ix:nonFraction name="QLGN:RegulatoryMarketingApprovalExpensesOne" contextRef="From2018-06-012018-06-30_custom_LicensedProductSalesMember_custom_LicenseAndSponsoredResearchAgreementsMember_custom_UniversityOfLouisvilleResearchFoundationMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">500,000</ix:nonFraction></span>
milestone payment for any additional regulatory marketing approval for each additional therapeutic (or diagnostic) indication. The
Company also must pay ULRF shortfall payments if the total amounts actually paid with respect to royalties and non-royalty
sublicensee income for any year is less than the applicable annual minimum (ranging from $<span id="xdx_901_ecustom--ShortfallPayments_pp0p0_c20180601__20200930__srt--RangeAxis__srt--MinimumMember__us-gaap--TypeOfArrangementAxis__custom--LicenseAndSponsoredResearchAgreementsMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember_zWGKg4JlYkvi" title="Shortfall payments"><ix:nonFraction name="QLGN:ShortfallPayments" contextRef="From2018-06-012020-09-30_srt_MinimumMember_custom_LicenseAndSponsoredResearchAgreementsMember_custom_UniversityOfLouisvilleResearchFoundationMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">10,000</ix:nonFraction></span>
to $<span id="xdx_907_ecustom--ShortfallPayments_c20180601__20200930__srt--RangeAxis__srt--MaximumMember__us-gaap--TypeOfArrangementAxis__custom--LicenseAndSponsoredResearchAgreementsMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember_zmPotP7EeEt1" title="Shortfall payments"><ix:nonFraction name="QLGN:ShortfallPayments" contextRef="From2018-06-012020-09-30_srt_MaximumMember_custom_LicenseAndSponsoredResearchAgreementsMember_custom_UniversityOfLouisvilleResearchFoundationMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">50,000</ix:nonFraction></span>)
for such year.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sponsored
research expenses related to these agreements for the years ended December 31, 2022 and December 31, 2021 were approximately $<span id="xdx_907_eus-gaap--ResearchAndDevelopmentExpense_pp0p0_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--SponsoredResearchAgreementAndLicenseMember_zDcCfjwJb3Fh" title="Research and development"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2022-01-012022-12-31_custom_SponsoredResearchAgreementAndLicenseMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">164,000</ix:nonFraction></span>
and $<span id="xdx_901_eus-gaap--ResearchAndDevelopmentExpense_pp0p0_c20210101__20211231__us-gaap--TypeOfArrangementAxis__custom--SponsoredResearchAgreementAndLicenseMember_zHhXERwipNul" title="Research and development"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2021-01-012021-12-31_custom_SponsoredResearchAgreementAndLicenseMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">325,000</ix:nonFraction></span>, respectively, and these amounts are recorded in research and development expenses in the Consolidated Statements of Operations.
Minimum annual royalties of $<span id="xdx_90F_eus-gaap--RoyaltyExpense_pp0p0_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--SponsoredResearchAgreementAndLicenseMember_zZJb9QDsbLfa" title="Minimum annual royalties"><ix:nonFraction name="us-gaap:RoyaltyExpense" contextRef="From2022-01-012022-12-31_custom_SponsoredResearchAgreementAndLicenseMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">0</ix:nonFraction></span> and $<span id="xdx_901_eus-gaap--RoyaltyExpense_c20210101__20211231__us-gaap--TypeOfArrangementAxis__custom--SponsoredResearchAgreementAndLicenseMember_z9GOmSy2etHg" title="Minimum annual royalties"><ix:nonFraction name="us-gaap:RoyaltyExpense" contextRef="From2021-01-012021-12-31_custom_SponsoredResearchAgreementAndLicenseMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">0</ix:nonFraction></span> related to these agreements are included in research and development expenses in the Consolidated
Statements of Operations for the years ended December 31, 2022 and December 31, 2021, respectively. License costs related to these agreements
were approximately $<span id="xdx_90F_ecustom--LicenseCost_pp0p0_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--SponsoredResearchAgreementAndLicenseMember_zhNOCabKEKW6" title="License costs"><ix:nonFraction name="QLGN:LicenseCost" contextRef="From2022-01-012022-12-31_custom_SponsoredResearchAgreementAndLicenseMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">94,000</ix:nonFraction></span> and $<span id="xdx_908_ecustom--LicenseCost_pp0p0_c20210101__20211231__us-gaap--TypeOfArrangementAxis__custom--SponsoredResearchAgreementAndLicenseMember_zjJi6dMlb7va" title="License costs"><ix:nonFraction name="QLGN:LicenseCost" contextRef="From2021-01-012021-12-31_custom_SponsoredResearchAgreementAndLicenseMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">118,000</ix:nonFraction></span> for the years ended December 31, 2022 and December 31, 2021, respectively, and are included in
research and development expenses in the Consolidated Statements of Operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<ix:exclude><!-- Field: Page; Sequence: 62; Value: 35 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->62<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
June 2020, the Company entered into an exclusive license agreement with ULRF for its intellectual property in the use of QN-165 as a
treatment for COVID-19. Under the agreement, the Company took over development, regulatory approval and commercialization of the
compound (for such use) from ULRF and was responsible for maintenance of the related intellectual property portfolio. In return,
ULRF received approximately $<span id="xdx_907_ecustom--UpfrontLicenseFee_iI_pp0p0_c20200630__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember_z8HdOcgnzqd4" title="Upfront license fee"><ix:nonFraction name="QLGN:UpfrontLicenseFee" contextRef="AsOf2020-06-30_custom_LicenseAgreementMember_custom_UniversityOfLouisvilleResearchFoundationMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">24,000</ix:nonFraction> </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">for
an upfront license fee and reimbursement of prior patent costs. In addition, the Company executed a sponsored research agreement
with ULRF (for QN-165 as a treatment for COVID-19) supporting up to $<span id="xdx_90E_eus-gaap--ResearchAndDevelopmentExpense_pp0p0_c20201101__20201130__srt--RangeAxis__srt--MaximumMember__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember_zLZYohcJBbf6"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2020-11-012020-11-30_srt_MaximumMember_custom_LicenseAgreementMember_custom_UniversityOfLouisvilleResearchFoundationMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">430,000</ix:nonFraction></span>. </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This sponsored research agreement expired in November 2021 and effective October 31, 2022 the license agreement for
QN-165 was terminated.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sponsored
research expenses related to these agreements for the years ended December 31, 2022 and December 31, 2021 were approximately $<span id="xdx_90D_eus-gaap--ResearchAndDevelopmentExpense_pp0p0_c20220101__20221231__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember_zDkvbJNgCrMk" title="Research and Development Expense"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2022-01-012022-12-31_custom_UniversityOfLouisvilleResearchFoundationMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">14,000</ix:nonFraction></span> and $<span id="xdx_906_eus-gaap--ResearchAndDevelopmentExpense_pp0p0_c20210101__20211231__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember_z8y24e1EHbXj" title="Research and Development Expense"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2021-01-012021-12-31_custom_UniversityOfLouisvilleResearchFoundationMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">243,000</ix:nonFraction></span>,
respectively, and are recorded in research and development expenses in the Consolidated Statements of Operations. License costs related
to these agreements for the years ended December 31, 2022 and December 31, 2021 were approximately $<span id="xdx_904_ecustom--LicenseCost_pp0p0_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--LicenseAndSponsoredResearchAgreementsMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember_zomdtHB2ueha" title="License cost"><ix:nonFraction name="QLGN:LicenseCost" contextRef="From2022-01-012022-12-31_custom_LicenseAndSponsoredResearchAgreementsMember_custom_UniversityOfLouisvilleResearchFoundationMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,000</ix:nonFraction></span> and $<span id="xdx_90B_ecustom--LicenseCost_pp0p0_c20210101__20211231__us-gaap--TypeOfArrangementAxis__custom--LicenseAndSponsoredResearchAgreementsMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember_ze91Ty8znN8l" title="License cost"><ix:nonFraction name="QLGN:LicenseCost" contextRef="From2021-01-012021-12-31_custom_LicenseAndSponsoredResearchAgreementsMember_custom_UniversityOfLouisvilleResearchFoundationMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">28,000</ix:nonFraction></span>, respectively,
and are included in research and development expenses in the Consolidated Statements of Operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Advanced
Cancer Therapeutics</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
December 2018, <span id="xdx_90E_ecustom--AgreementDescription_c20181201__20181231__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember__dei--LegalEntityAxis__custom--AdvancedCancerTherapeuticsLLCMember_zW2Af8FERock" title="Agreement description"><ix:nonNumeric contextRef="From2018-12-012018-12-31_custom_LicenseAgreementMember_custom_AdvancedCancerTherapeuticsLLCMember" name="QLGN:AgreementDescription">the Company entered into a license agreement with Advanced Cancer Therapeutics, LLC (&#8220;ACT&#8221;), granting the
Company exclusive rights to develop and commercialize QN-165, an aptamer-based drug candidate</ix:nonNumeric></span>. In return, ACT received a $<span id="xdx_902_eus-gaap--ProceedsFromConvertibleDebt_pp0p0_c20181201__20181231__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember__dei--LegalEntityAxis__custom--AdvancedCancerTherapeuticsLLCMember_z8Q75pH4KISg" title="Proceeds from convertible debt"><ix:nonFraction name="us-gaap:ProceedsFromConvertibleDebt" contextRef="From2018-12-012018-12-31_custom_LicenseAgreementMember_custom_AdvancedCancerTherapeuticsLLCMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">25,000</ix:nonFraction></span> convertible
promissory note in payment of an upfront license fee, which was subsequently converted into the Company&#8217;s common stock. In addition,
the Company agreed to pay ACT (i) royalties, on net sales associated with the commercialization of QN-165, of 2% (only if patent-covered
and only on net sales above a cumulative $<span id="xdx_90F_ecustom--CumulativeSales_pp0p0_c20181201__20181231__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember__dei--LegalEntityAxis__custom--AdvancedCancerTherapeuticsLLCMember_zqXDrko20eDc" title="Cumulative sales"><ix:nonFraction name="QLGN:CumulativeSales" contextRef="From2018-12-012018-12-31_custom_LicenseAgreementMember_custom_AdvancedCancerTherapeuticsLLCMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">3,000,000</ix:nonFraction></span>) or 1% (if not patent-covered, but only on net sales above a cumulative $<span id="xdx_90A_ecustom--CumulativeSales_pp0p0_c20181201__20181231__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember__dei--LegalEntityAxis__custom--AdvancedCancerTherapeuticsLLCMember_zUD4zsAXDgRd" title="Cumulative sales"><ix:nonFraction name="QLGN:CumulativeSales" contextRef="From2018-12-012018-12-31_custom_LicenseAgreementMember_custom_AdvancedCancerTherapeuticsLLCMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">3,000,000</ix:nonFraction></span>),
until the 15th anniversary of the ACT license agreement and (ii) milestone payments of $<span id="xdx_90C_ecustom--MilestonePaymentForCumulativeMarketingExpenses_pp0p0_c20181201__20181231__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember__dei--LegalEntityAxis__custom--AdvancedCancerTherapeuticsLLCMember_zZeQymAmRl8" title="Milestone payment for cumulative marketing expenses"><ix:nonFraction name="QLGN:MilestonePaymentForCumulativeMarketingExpenses" contextRef="From2018-12-012018-12-31_custom_LicenseAgreementMember_custom_AdvancedCancerTherapeuticsLLCMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">100,000</ix:nonFraction></span> for the Company raising a cumulative
total of $<span id="xdx_901_eus-gaap--RevenueFromContractWithCustomerIncludingAssessedTax_pp0p0_c20181201__20181231__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember__dei--LegalEntityAxis__custom--AdvancedCancerTherapeuticsLLCMember_zqd072Tcu4rk" title="Cumulative amount"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" contextRef="From2018-12-012018-12-31_custom_LicenseAgreementMember_custom_AdvancedCancerTherapeuticsLLCMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,000,000</ix:nonFraction></span> in new equity financing after the date of the ACT license agreement, $<span id="xdx_90A_ecustom--MilestoneMethodRevenueRecognized_pp0p0_c20181201__20181231__srt--TitleOfIndividualAxis__custom--CEMarkMember__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember__dei--LegalEntityAxis__custom--AdvancedCancerTherapeuticsLLCMember_zD10HCcn3qKd" title="Milestone method revenue recognized"><ix:nonFraction name="QLGN:MilestoneMethodRevenueRecognized" contextRef="From2018-12-012018-12-31_custom_CEMarkMember_custom_LicenseAgreementMember_custom_AdvancedCancerTherapeuticsLLCMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">100,000</ix:nonFraction></span> upon any first QN-165-based licensed
product receiving the CE Mark or similar FDA status, and $<span id="xdx_90B_ecustom--CumulativeSales_pp0p0_c20181201__20181231__srt--TitleOfIndividualAxis__custom--CEMarkMember__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember__dei--LegalEntityAxis__custom--AdvancedCancerTherapeuticsLLCMember_zKE7WypjOpJ3" title="Cumulative sales"><ix:nonFraction name="QLGN:CumulativeSales" contextRef="From2018-12-012018-12-31_custom_CEMarkMember_custom_LicenseAgreementMember_custom_AdvancedCancerTherapeuticsLLCMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">500,000</ix:nonFraction></span> upon cumulative worldwide QN-165-based licensed product net sales reaching
$<span id="xdx_90B_eus-gaap--RevenueFromContractWithCustomerIncludingAssessedTax_pp0p0_c20181201__20181231__srt--TitleOfIndividualAxis__custom--CEMarkMember__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember__dei--LegalEntityAxis__custom--AdvancedCancerTherapeuticsLLCMember_zzAk2tbZUUAc" title="Licensed product net sale"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" contextRef="From2018-12-012018-12-31_custom_CEMarkMember_custom_LicenseAgreementMember_custom_AdvancedCancerTherapeuticsLLCMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">3,000,000</ix:nonFraction></span>. For the years ended December 31, 2022 and December 31, 2021, there were approximately $<span id="xdx_902_ecustom--LicenseCost_pp0p0_do_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember__dei--LegalEntityAxis__custom--AdvancedCancerTherapeuticsLLCMember_zLBc8V231CYd" title="License cost"><ix:nonFraction name="QLGN:LicenseCost" contextRef="From2022-01-012022-12-31_custom_LicenseAgreementMember_custom_AdvancedCancerTherapeuticsLLCMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">0</ix:nonFraction></span> and $<span id="xdx_90C_ecustom--LicenseCost_pp0p0_do_c20210101__20211231__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember__dei--LegalEntityAxis__custom--AdvancedCancerTherapeuticsLLCMember_z6ZbkeVYPWpc" title="License cost"><ix:nonFraction name="QLGN:LicenseCost" contextRef="From2021-01-012021-12-31_custom_LicenseAgreementMember_custom_AdvancedCancerTherapeuticsLLCMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,000</ix:nonFraction></span>, respectively in costs
related to this agreement which are included in research and development expenses in the Consolidated Statements of Operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Yi
Xin</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In October 2020, through our wholly-owned diagnostics subsidiary Qualigen, Inc. we entered into a Technology Transfer
Agreement with Yi Xin Zhen Duan Jishu (Suzhou) Ltd. (&#8220;Yi Xin&#8221;), of Suzhou, China, for Yi Xin to develop, manufacture and sell
new generations of diagnostic test systems based on the Company&#8217;s core FastPack technology. In addition, the Technology Transfer Agreement
authorized Yi Xin to manufacture and sell the Company&#8217;s current generations of FastPack System diagnostic products (1.0, IP and PRO) in
China.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company will receive low- to mid-single-digit royalties on any future new-generations and current-generations
product sales by Yi Xin. We received total net cash payments of approximately $<span id="xdx_908_eus-gaap--DeferredRevenue_iI_pp0p0_c20211231__dei--LegalEntityAxis__custom--YiXinZhenDuanJishuLtdMember_zCeceoVHCbg6" title="Deferred revenue"><ix:nonFraction name="us-gaap:DeferredRevenue" contextRef="AsOf2021-12-31_custom_YiXinZhenDuanJishuLtdMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">670,000</ix:nonFraction></span>, of which approximately $<span id="xdx_906_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20210101__20211231__srt--ProductOrServiceAxis__custom--LicenseRevenueMember__dei--LegalEntityAxis__custom--YiXinZhenDuanJishuLtdMember_zCb5e3Vm5vL5" title="Product sales"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2021-01-012021-12-31_custom_LicenseRevenueMember_custom_YiXinZhenDuanJishuLtdMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">632,000</ix:nonFraction></span>
is classified as license revenue, and approximately $<span id="xdx_90C_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20210101__20211231__dei--LegalEntityAxis__custom--YiXinZhenDuanJishuLtdMember_zq6MARk7I1S3" title="Product sales"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2021-01-012021-12-31_custom_YiXinZhenDuanJishuLtdMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">38,000</ix:nonFraction></span> is classified as product sales on the Consolidated Statements of Operations for the fiscal year ended December&#160;31,
2021. The Company provided technology transfer and patent/know-how license rights to facilitate Yi Xin&#8217;s development and commercialization.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 63; Value: 35 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->63<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company gave Yi Xin the exclusive rights for China &#8211; which is
a market we have not otherwise entered &#8211; both for Yi Xin&#8217;s new generations of FastPack-based products and for Yi Xin-manufactured
versions of our existing FastPack product lines. Yi Xin also has the right to sell its new generations of FastPack-based diagnostic test
systems throughout the world (but not to or toward current customers of our existing generations of FastPack products). After March 31,
2022, Yi Xin has the right to sell Yi Xin-manufactured versions of existing FastPack 1.0, IP and PRO product lines worldwide (other than
in the United States and other than to or toward current non-US customers of those products), as well as the right to buy Qualigen-manufactured
FastPack 1.0, IP and PRO products from us at distributor prices for resale in and for the United States (but not to or toward current
U.S. customers of those products). The Company did not license Yi Xin to sell in the U.S. market any Yi Xin-manufactured versions of those
legacy FastPack 1.0, IP and PRO product lines. In the Technology Transfer Agreement the Company also confirmed that after March 31, 2022
it would not seek new FastPack customers outside the U.S.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>STA
Pharmaceutical</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
November 2020, the Company entered into a contract with STA Pharmaceutical Co., Ltd., a subsidiary of WuXi AppTec, for GMP production
of QN-165, which was the Company&#8217;s lead drug candidate for the treatment of COVID-19 and other viral diseases. In connection with
this agreement, the Company paid an upfront deposit of approximately $<span id="xdx_907_eus-gaap--DepositAssets_iI_pn5n6_c20201231__dei--LegalEntityAxis__custom--STAPharmaceuticalCoLtdMember_zSeIjxwRVih6" title="Upfront deposit"><ix:nonFraction name="us-gaap:DepositAssets" contextRef="AsOf2020-12-31_custom_STAPharmaceuticalCoLtdMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">1.1</ix:nonFraction></span> million which was classified as a prepaid expense on the December
31, 2020 Consolidated Balance Sheet date, and all of which was included in research and development expenses in the statement of operations
for the year ended December 31, 2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and development expenses related to this agreement for the years ended December 31, 2022 and December 31, 2021 were approximately $<span id="xdx_90F_eus-gaap--ResearchAndDevelopmentExpense_c20220101__20221231__dei--LegalEntityAxis__custom--STAPharmaceuticalCoLtdMember_ziJaZGX2iDce" title="Research and development"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2022-01-012022-12-31_custom_STAPharmaceuticalCoLtdMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">9,000</ix:nonFraction></span>
and $<span id="xdx_902_eus-gaap--ResearchAndDevelopmentExpense_pn5n6_c20210101__20211231__dei--LegalEntityAxis__custom--STAPharmaceuticalCoLtdMember_zUJAjf06Gs4g" title="Research and development"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2021-01-012021-12-31_custom_STAPharmaceuticalCoLtdMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">3.2</ix:nonFraction></span> million, respectively, and are recorded in research and development expenses in the Consolidated Statements of Operations.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>UCL Business Limited</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In January 2022, the Company entered into a License
Agreement with UCL Business Limited to obtain an exclusive worldwide in-license of a genomic quadruplex (G4)-selective transcription inhibitor
drug development program which had been developed at University College London, including lead and back-up compounds, preclinical data
and a patent estate. (UCL Business Limited is the commercialization company for University College London.) The program&#8217;s lead compound
is now being developed at Qualigen under the name QN-302 as a candidate for treatment for pancreatic ductal adenocarcinoma (PDAC), which
represents the vast majority of pancreatic cancers. The License Agreement required a $<span id="xdx_907_ecustom--ReimbursementOfPatent_c20220101__20220131__us-gaap--AwardTypeAxis__custom--UpfrontPaymentMember__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember_ztgkoq21V9V6" title="Reimbursement of patent"><ix:nonFraction name="QLGN:ReimbursementOfPatent" contextRef="From2022-01-012022-01-31_custom_UpfrontPaymentMember_custom_LicenseAgreementMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">150,000</ix:nonFraction></span> upfront payment, reimbursement of past patent
prosecution expenses (approximately $<span id="xdx_907_ecustom--ReimbursementOfPatent_c20220101__20220131__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember_zNYvUJX1HZGf" title="Reimbursement of patent"><ix:nonFraction name="QLGN:ReimbursementOfPatent" contextRef="From2022-01-012022-01-31_custom_LicenseAgreementMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">160,000</ix:nonFraction></span>), and (if and when applicable) tiered royalty payments in the low to mid-single digits, clinical/regulatory/sales
milestone payments and a percentage of any non-royalty sublicensing consideration paid to Qualigen.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="margin: 0">For the years ended December 31, 2022 and 2021 there were license costs of approximately $<span id="xdx_905_ecustom--LicenseCost_pp0p0_do_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember_zBjRqmr4W2Id" title="License cost"><ix:nonFraction name="QLGN:LicenseCost" contextRef="From2022-01-012022-12-31_custom_LicenseAgreementMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">338,000</ix:nonFraction></span> and $<span id="xdx_900_ecustom--LicenseCost_pp0p0_do_c20210101__20211231__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember_z0WdYlIwavA7" title="License cost"><ix:nonFraction name="QLGN:LicenseCost" contextRef="From2021-01-012021-12-31_custom_LicenseAgreementMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">0</ix:nonFraction></span>, respectively,
related to this agreement which are included in research and development expenses in the Consolidated Statements of Operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock"><p id="xdx_809_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zjzuQwYLCyBa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
15 &#8212; <span id="xdx_82A_zV1ZI9B4TKI5">STOCKHOLDERS&#8217; EQUITY</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2022, and 2021 the Company had two classes of capital stock: common stock and preferred stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Common
Stock</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Holders
of common stock generally vote as a class with the holders of the preferred stock and are entitled to one vote for each share held. Subject
to the rights of the holders of the preferred stock to receive preferential dividends, the holders of common stock are entitled to receive
dividends when and if declared by the Board of Directors. Following payment of the liquidation preference of the preferred stock, any
remaining assets will be distributed ratably among the holders of the common stock and, on an as-if-converted basis, the holders of any
preferred stock upon liquidation, dissolution or winding up of the affairs of the Company. The holders of common stock have no preemptive,
subscription or conversion rights and there are no redemption or sinking fund provisions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 1, 2021, the Company closed a Securities Purchase Agreement (dated November 29, 2021) with several institutional investors
for the purchase and sale of <span id="xdx_905_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20211201__20211201__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_zXvFBZ25PmQh" title="Shares issued, shares"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2021-12-012021-12-01_custom_SecuritiesPurchaseAgreementMember_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">588,000</ix:nonFraction></span>
reverse split adjusted shares of Company common stock at a reverse split adjusted exercise price of $<span id="xdx_90D_eus-gaap--SharePrice_iI_pid_c20211201__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zB5FISyNOSJh" title="Share Price"><ix:nonFraction name="us-gaap:SharePrice" contextRef="AsOf2021-12-01_custom_SecuritiesPurchaseAgreementMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">15.00</ix:nonFraction></span>
per share, for aggregate gross proceeds of $<span id="xdx_90A_eus-gaap--ProceedsFromIssuanceOfCommonStock_pn4n6_c20211201__20211201__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zYELsj42bDth" title="Proceeds from issuance of common stock"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="From2021-12-012021-12-01_custom_SecuritiesPurchaseAgreementMember" format="ixt:numdotdecimal" decimals="-4" scale="6" unitRef="USD">8.82</ix:nonFraction></span>
million.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 22, 2022, the Company issued to Alpha Capital, an <span id="xdx_900_eus-gaap--ShortTermDebtInterestRateIncrease_pid_dp_uPure_c20221222__20221222__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember__us-gaap--DebtInstrumentAxis__custom--SeniorConvertibleDebentureMember_zCLUosOzRfQg" title="Senior convertible debenture rate"><ix:nonFraction name="us-gaap:ShortTermDebtInterestRateIncrease" contextRef="From2022-12-222022-12-22_custom_AlphaCapitalMember_custom_SeniorConvertibleDebentureMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">8</ix:nonFraction></span>%
Senior Convertible Debenture in the aggregate principal amount of $<span id="xdx_902_eus-gaap--SecuredDebt_iI_c20221222__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember__us-gaap--DebtInstrumentAxis__custom--SeniorConvertibleDebentureMember_zgyBCJ3DxKt" title="Principal amount"><ix:nonFraction name="us-gaap:SecuredDebt" contextRef="AsOf2022-12-22_custom_AlphaCapitalMember_custom_SeniorConvertibleDebentureMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,300,000</ix:nonFraction></span>
for a purchase price of $<span id="xdx_90C_ecustom--PurchasePrice_iI_c20221222__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember__us-gaap--DebtInstrumentAxis__custom--SeniorConvertibleDebentureMember_z0YPpYvHvrr3" title="Purchase Price"><ix:nonFraction name="QLGN:PurchasePrice" contextRef="AsOf2022-12-22_custom_AlphaCapitalMember_custom_SeniorConvertibleDebentureMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,000,000</ix:nonFraction></span>
pursuant to the terms of a Securities Purchase Agreement, dated December 21, 2022. The Debenture is convertible, at any time, and
from time to time, at Alpha&#8217;s option, into shares of common stock of the Company, at a price equal to $<span id="xdx_904_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pid_c20221222__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember__us-gaap--DebtInstrumentAxis__custom--SeniorConvertibleDebentureMember_z4dEgdCRWaza" title="Conversion price"><ix:nonFraction name="us-gaap:DebtInstrumentConvertibleConversionPrice1" contextRef="AsOf2022-12-22_custom_AlphaCapitalMember_custom_SeniorConvertibleDebentureMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.32</ix:nonFraction></span>
per share, and other terms and conditions described in the Debenture (see Note 11 -Convertible Debt - Related Party). As part of
this transaction, the Company issued to Alpha Capital a warrant to purchase <span id="xdx_907_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20221222__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember_zze5nSNHwkmb" title="Warrant to purchase shares"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2022-12-22_custom_SeriesCWarrantsMember_custom_AlphaCapitalMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,500,000</ix:nonFraction></span>
shares of the Company&#8217;s common stock (see Note 10-Warrant Liabilities).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
December 31, 2022, the Company has reserved <span id="xdx_904_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_c20221231_zb8yzrO0mbvc" title="Common stock, shares reserved for future issuance"><ix:nonFraction name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">5,183,629</ix:nonFraction></span> shares of authorized but unissued common stock for possible future issuance. At
December 31, 2022, <span id="xdx_909_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_c20221231_zUzMHDYiHo81" title="Common stock, shares reserved for future issuance"><ix:nonFraction name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">5,183,629</ix:nonFraction></span> shares were reserved as follows:</span></p>

<ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="QLGN:ScheduleOfReservedSharesTableTextBlock"><p id="xdx_89B_ecustom--ScheduleOfReservedSharesTableTextBlock_zimAAIToJ9Ea" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B7_zax3uzRUfCia" style="display: none">SCHEDULE
OF RESERVED SHARES</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
  <tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_49C_20221231_zNuw65UoxOj9" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_hus-gaap--AwardTypeAxis__us-gaap--StockOptionMember_z3ZC73O4yVG8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 78%; text-align: left">Exercise of issued and future grants of stock options</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 18%; text-align: right"><ix:nonFraction name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="AsOf2022-12-31_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">608,012</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_hus-gaap--AwardTypeAxis__us-gaap--WarrantMember_zkBEyoRIIQza" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">Exercise of stock warrants</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="AsOf2022-12-31_us-gaap_WarrantMember72029296" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">4,575,617</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_zDujkcYLn797" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt; padding-left: 10pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">5,183,629</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AF_z9Le9WWtUHcb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>


<ix:exclude><!-- Field: Page; Sequence: 64; Value: 35 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->64<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Preferred
Stock</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
December 31, 2022 and 2021, there were no shares of preferred stock outstanding. All shares of Series A, B, C, D, D-1 convertible preferred
stock were converted into common stock at the time of the May 2020 reverse recapitalization transaction.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year ended December 31, 2021, the holder of Series Alpha convertible preferred stock converted <span id="xdx_903_eus-gaap--ConvertiblePreferredStockSharesIssuedUponConversion_iI_pid_c20211231__us-gaap--StatementClassOfStockAxis__custom--SeriesAlphaConvertiblePreferredStockMember_z4p1JV3satYc" title="Convertible preferred stock, shares"><ix:nonFraction name="us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion" contextRef="AsOf2021-12-31_custom_SeriesAlphaConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">180</ix:nonFraction></span> of its shares of Series Alpha
convertible preferred stock into an aggregate of <span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodSharesOther_pid_c20210101__20211231__us-gaap--StatementClassOfStockAxis__custom--SeriesAlphaConvertiblePreferredStockMember_zKqE7rP9O0mj" title="Shares issued during conversion, shares"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesOther" contextRef="From2021-01-012021-12-31_custom_SeriesAlphaConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">243,416</ix:nonFraction></span> shares of the Company&#8217;s common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Stock
Options and Equity Classified Warrants</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Stock
Options</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company recognizes all compensatory stock-based payments as compensation expense over the service period, which is generally the vesting
period.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
April 2020, the Company adopted the 2020 Stock Incentive Plan (the &#8220;2020 Plan&#8221;) which provides for the grant of incentive
or non-statutory common stock options, restricted stock, stock bonus awards, stock appreciation rights, restricted stock units and performance
awards to qualified employees, officers, directors, consultants and other service providers. At December 31, 2022 and December 31, 2021
there were <span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20221231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--PlanNameAxis__custom--TwoThousandTwentyStockIncentivePlanMember_zHfLhUpRqNWk" title="Options outstanding"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2022-12-31_us-gaap_StockOptionMember_custom_TwoThousandTwentyStockIncentivePlanMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">608,012</ix:nonFraction></span> and <span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20211231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--PlanNameAxis__custom--TwoThousandTwentyStockIncentivePlanMember_z8NOvTtLyl0h" title="Options outstanding"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2021-12-31_us-gaap_StockOptionMember_custom_TwoThousandTwentyStockIncentivePlanMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">484,186</ix:nonFraction></span> outstanding stock options, respectively, under the 2020 Plan and there were <span id="xdx_908_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_pid_c20221231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--PlanNameAxis__custom--TwoThousandTwentyStockIncentivePlanMember_zYMFBxZIt9ok" title="Plan shares available"><ix:nonFraction name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="AsOf2022-12-31_us-gaap_StockOptionMember_custom_TwoThousandTwentyStockIncentivePlanMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">147,690</ix:nonFraction></span> and <span id="xdx_901_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_pid_c20211231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--PlanNameAxis__custom--TwoThousandTwentyStockIncentivePlanMember_zJoKk2UrZhn1" title="Plan shares available"><ix:nonFraction name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="AsOf2021-12-31_us-gaap_StockOptionMember_custom_TwoThousandTwentyStockIncentivePlanMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">280,916</ix:nonFraction></span> of Plan
shares available, respectively, for future grant.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"><p id="xdx_892_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_z2FB81mZIsEk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following represents a summary of the options granted to employees and non-employee service providers that were outstanding at December
31, 2022, and changes during the twelve months then ended:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B8_zD3cw60EzoEa" style="display: none">SCHEDULE
OF STOCK OPTION ACTIVITY</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Shares</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted&#8211;<br /> Average<br /> Exercise<br />
    Price</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Range of<br /> Exercise<br /> Price</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted&#8211;<br /> Average<br /> Remaining<br />
    Life (Years)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 32%">Total outstanding &#8211; December 31, 2021</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20220101__20221231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zqnBPyfdF0z1" title="Number of shares, options outstanding, beginning" style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2021-12-31_custom_EmployeesAndNonemployeeServiceProviderMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">484,186</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20220101__20221231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zSo8odCfMjb9" title="Weighted Average Exercise Price, Outstanding, Beginning" style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2021-12-31_custom_EmployeesAndNonemployeeServiceProviderMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">60.70</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$<span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20220101__20221231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember__srt--RangeAxis__srt--MinimumMember_zNVJxn68qcaf" title="Range of Exercise price, Options Outstanding"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2021-12-31_custom_EmployeesAndNonemployeeServiceProviderMember_srt_MinimumMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">12.40</ix:nonFraction></span>
                                            &#8212; $<span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20220101__20221231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember__srt--RangeAxis__srt--MaximumMember_zwIjOyKur9uj" title="Range of Exercise price, Options Outstanding"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2021-12-31_custom_EmployeesAndNonemployeeServiceProviderMember_srt_MaximumMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">14,657.50</ix:nonFraction></span></span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right"><span id="xdx_90E_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm3_dtY_c20220101__20221231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zj7EqTYG69L9" title="Weighted- Average Remaining Contractual Life (in Years), Outstanding, Beginning"><ix:nonNumeric contextRef="From2022-01-012022-12-31_custom_EmployeesAndNonemployeeServiceProviderMember" format="ixt-sec:duryear" name="QLGN:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm3">8.52</ix:nonNumeric></span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt">Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20220101__20221231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_z1RPE2CQS8d2" title="Number of shares, options granted" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" contextRef="From2022-01-012022-12-31_custom_EmployeesAndNonemployeeServiceProviderMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">134,469</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20220101__20221231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zkvwQJ0CQG36" title="Weighted average exercise price, options granted" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="From2022-01-012022-12-31_custom_EmployeesAndNonemployeeServiceProviderMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">5.24</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_908_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionGrantedWeightedAverageExercisePrice_c20220101__20221231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember__srt--RangeAxis__srt--MinimumMember_zmSEZ3YUzaA2" title="Range of Exercise price, Options Outstanding"><ix:nonFraction name="QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionGrantedWeightedAverageExercisePrice" contextRef="From2022-01-012022-12-31_custom_EmployeesAndNonemployeeServiceProviderMember_srt_MinimumMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">5.14</ix:nonFraction></span>
                                            &#8212; <span id="xdx_907_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionGrantedWeightedAverageExercisePrice_c20220101__20221231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember__srt--RangeAxis__srt--MaximumMember_zdkGibkxK343" title="Range of Exercise price, Options Outstanding"><ix:nonFraction name="QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionGrantedWeightedAverageExercisePrice" contextRef="From2022-01-012022-12-31_custom_EmployeesAndNonemployeeServiceProviderMember_srt_MaximumMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">10.50</ix:nonFraction></span></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_904_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm2_dtY_c20220101__20221231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_ztVfDUW1dy94" title="Weighted- Average Remaining Contractual Life (in Years), Options Granted"><ix:nonNumeric contextRef="From2022-01-012022-12-31_custom_EmployeesAndNonemployeeServiceProviderMember" format="ixt-sec:duryear" name="QLGN:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm2">5.99</ix:nonNumeric></span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt">Expired</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_iN_di_c20220101__20221231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zKuj5b6rQuu" title="Number of shares, options expired" style="text-align: right">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" contextRef="From2022-01-012022-12-31_custom_EmployeesAndNonemployeeServiceProviderMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">9,379</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_c20220101__20221231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_z30ZbFDj4F7i" title="Weighted average exercise price, options expired" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" contextRef="From2022-01-012022-12-31_custom_EmployeesAndNonemployeeServiceProviderMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">932.75</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_906_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExpirationsInPeriodWeightedAverageExercisePrice_c20220101__20221231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember__srt--RangeAxis__srt--MinimumMember_zQRRIzsHx5N4" title="Range of Exercise price, Options Expired"><ix:nonFraction name="QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExpirationsInPeriodWeightedAverageExercisePrice" contextRef="From2022-01-012022-12-31_custom_EmployeesAndNonemployeeServiceProviderMember_srt_MinimumMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">57.50</ix:nonFraction></span>
                                            - <span id="xdx_908_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExpirationsInPeriodWeightedAverageExercisePrice_pid_c20220101__20221231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember__srt--RangeAxis__srt--MaximumMember_zDNvdUlW7dcc" title="Range of exercise price, options expired"><ix:nonFraction name="QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExpirationsInPeriodWeightedAverageExercisePrice" contextRef="From2022-01-012022-12-31_custom_EmployeesAndNonemployeeServiceProviderMember_srt_MaximumMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">14,657.50</ix:nonFraction></span></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; padding-left: 10pt">Forfeited</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_di_c20220101__20221231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zRDjr5XQ9nlb" title="Number of shares, options forfeited" style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" contextRef="From2022-01-012022-12-31_custom_EmployeesAndNonemployeeServiceProviderMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,264</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20220101__20221231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zTrLEmJH9Gnf" title="Weighted average exercise price, options forfeited" style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" contextRef="From2022-01-012022-12-31_custom_EmployeesAndNonemployeeServiceProviderMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">22.64</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_c20220101__20221231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember__srt--RangeAxis__srt--MinimumMember_zhh9NAU4Ppec" title="Range of Exercise price, Options Forfeited"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" contextRef="From2022-01-012022-12-31_custom_EmployeesAndNonemployeeServiceProviderMember_srt_MinimumMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">5.14</ix:nonFraction></span>
                                            - <span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_c20220101__20221231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember__srt--RangeAxis__srt--MaximumMember_zuki1SvKVugj" title="Range of Exercise price, Options Forfeited"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" contextRef="From2022-01-012022-12-31_custom_EmployeesAndNonemployeeServiceProviderMember_srt_MaximumMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">49.70</ix:nonFraction></span></span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Total outstanding &#8211; December 31, 2022</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20220101__20221231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zHQHex6Q7moe" title="Number of Shares, Options Outstanding at Ending" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2022-12-31_custom_EmployeesAndNonemployeeServiceProviderMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">608,012</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20220101__20221231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zkOS9mXytQXa" title="Weighted Average Exercise Price, Outstanding at Ending" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2022-12-31_custom_EmployeesAndNonemployeeServiceProviderMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">35.02</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$<span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20220101__20221231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember__srt--RangeAxis__srt--MinimumMember_zDgugfq7l8k9" title="Range of Exercise price, Options Outstanding"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2022-12-31_custom_EmployeesAndNonemployeeServiceProviderMember_srt_MinimumMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">5.14</ix:nonFraction></span>
                                            &#8212; $<span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20220101__20221231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember__srt--RangeAxis__srt--MaximumMember_znYSLY54sQRk" title="Range of Exercise price, Options Outstanding"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2022-12-31_custom_EmployeesAndNonemployeeServiceProviderMember_srt_MaximumMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">51.30</ix:nonFraction></span></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20220101__20221231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_z48fHiVCqQ4b" title="Weighted- Average Remaining Contractual Life (in Years), Outstanding at Ending"><ix:nonNumeric contextRef="From2022-01-012022-12-31_custom_EmployeesAndNonemployeeServiceProviderMember" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">8.09</ix:nonNumeric></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Exercisable (vested)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_iI_c20221231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_z7oIvggtyFlh" title="Number of shares, options exercisable (vested)" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" contextRef="AsOf2022-12-31_custom_EmployeesAndNonemployeeServiceProviderMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">288,704</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_c20221231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zAkadtWfXRtk" title="Range of exercise price, options exercisable (vested)" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" contextRef="AsOf2022-12-31_custom_EmployeesAndNonemployeeServiceProviderMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">46.32</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$<span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_c20221231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember__srt--RangeAxis__srt--MinimumMember_zFQiWU7oOUwe" title="Range of exercise price, options exercisable (vested)"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" contextRef="AsOf2022-12-31_custom_EmployeesAndNonemployeeServiceProviderMember_srt_MinimumMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">12.40</ix:nonFraction></span>
                                            &#8212; $<span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_c20221231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember__srt--RangeAxis__srt--MaximumMember_zk4vMa0xUGHe" title="Range of exercise price, options exercisable (vested)"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" contextRef="AsOf2022-12-31_custom_EmployeesAndNonemployeeServiceProviderMember_srt_MaximumMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">51.30</ix:nonFraction></span></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_906_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_dtY_c20220101__20221231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zbxpgyXpO7sc" title="Weighted- Average Remaining Contractual Life (in Years), Options Exercisable (vested)"><ix:nonNumeric contextRef="From2022-01-012022-12-31_custom_EmployeesAndNonemployeeServiceProviderMember" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1">7.59</ix:nonNumeric></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Non-Exercisable (non-vested)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iI_c20221231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zvZPeCoYNwCe" title="Number of shares, options non-exercisable (non-vested)" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" contextRef="AsOf2022-12-31_custom_EmployeesAndNonemployeeServiceProviderMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">319,308</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToNonVestExercisableWeightedAverageExercisePrice_iI_c20221231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zFFoxY8BCaj9" title="Weighted average exercise price, options non-exercisable (non-vested)" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToNonVestExercisableWeightedAverageExercisePrice" contextRef="AsOf2022-12-31_custom_EmployeesAndNonemployeeServiceProviderMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">24.80</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">$<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_iI_c20221231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember__srt--RangeAxis__srt--MinimumMember_zqbVRgVjO6ad" title="Range of exercise price, options non-exercisable (non-vested)"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" contextRef="AsOf2022-12-31_custom_EmployeesAndNonemployeeServiceProviderMember_srt_MinimumMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">5.14</ix:nonFraction></span>
                                            &#8212; $<span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_iI_c20221231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember__srt--RangeAxis__srt--MaximumMember_zDcdUCBXQ7x2" title="Range of exercise price, options non-exercisable (non-vested)"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" contextRef="AsOf2022-12-31_custom_EmployeesAndNonemployeeServiceProviderMember_srt_MaximumMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">10.50</ix:nonFraction></span></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_908_ecustom--WeightedAverageRemainingContractualLifeInYearsOptionsNonexercisableNonvested_dtY_c20220101__20221231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_z5KM8vgvprkf" title="Weighted- Average Remaining Contractual Life (in Years), Options Non-exercisable (non-vested)"><ix:nonNumeric contextRef="From2022-01-012022-12-31_custom_EmployeesAndNonemployeeServiceProviderMember" format="ixt-sec:duryear" name="QLGN:WeightedAverageRemainingContractualLifeInYearsOptionsNonexercisableNonvested">8.59</ix:nonNumeric></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AA_zseIMDhlGu28" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following represents a summary of the options granted (under the 2020 Plan and otherwise) to employees and non-employee service providers
that were outstanding at December 31, 2021, and changes during the twelve months then ended:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Shares</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Weighted&#8211;<br />
    Average<br /> Exercise<br /> Price</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font: bold 10pt Times New Roman, Times, Serif">Range
    of<br /> Exercise<br /> Price</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Weighted&#8211;<br />
    Average<br /> Remaining<br /> Life (Years)</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 32%">Total outstanding &#8211; December 31, 2020</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20210101__20211231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zlnTNVLyRFpg" title="Number of shares, options outstanding, beginning" style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2020-12-31_custom_EmployeesAndNonemployeeServiceProviderMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">401,136</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20210101__20211231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zHaziYuPldph" title="Weighted Average Exercise Price, Outstanding, Beginning" style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2020-12-31_custom_EmployeesAndNonemployeeServiceProviderMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">70.50</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$<span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20210101__20211231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember__srt--RangeAxis__srt--MinimumMember_zKwvVnwVjRL1" title="Range of Exercise price, Options Outstanding"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2020-12-31_custom_EmployeesAndNonemployeeServiceProviderMember_srt_MinimumMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">35.20</ix:nonFraction></span>
                                            &#8212; $<span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20210101__20211231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember__srt--RangeAxis__srt--MaximumMember_zhxpaEnRRPRg" title="Range of Exercise price, Options Outstanding"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2020-12-31_custom_EmployeesAndNonemployeeServiceProviderMember_srt_MaximumMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">14,657.50</ix:nonFraction></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"><span id="xdx_903_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm3_dtY_c20210101__20211231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zZFjNkCETqXl" title="Weighted- Average Remaining Contractual Life (in Years), Outstanding, Beginning"><ix:nonNumeric contextRef="From2021-01-012021-12-31_custom_EmployeesAndNonemployeeServiceProviderMember" format="ixt-sec:duryear" name="QLGN:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm3">9.29</ix:nonNumeric></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt">Granted</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20210101__20211231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_z2MqQeJ1z484" title="Number of shares, options granted" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" contextRef="From2021-01-012021-12-31_custom_EmployeesAndNonemployeeServiceProviderMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">83,500</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20210101__20211231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zxyPRlmnsw6g" title="Weighted average exercise price, options granted" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="From2021-01-012021-12-31_custom_EmployeesAndNonemployeeServiceProviderMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">13.70</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_905_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionGrantedWeightedAverageExercisePrice_c20210101__20211231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember__srt--RangeAxis__srt--MinimumMember_zOLEWJPrpGV5" title="Range of Exercise price, Options Outstanding"><ix:nonFraction name="QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionGrantedWeightedAverageExercisePrice" contextRef="From2021-01-012021-12-31_custom_EmployeesAndNonemployeeServiceProviderMember_srt_MinimumMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">12.40</ix:nonFraction></span>
                                            &#8212; <span id="xdx_907_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionGrantedWeightedAverageExercisePrice_c20210101__20211231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember__srt--RangeAxis__srt--MaximumMember_zIgleUIHQg02" title="Range of Exercise price, Options Outstanding"><ix:nonFraction name="QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionGrantedWeightedAverageExercisePrice" contextRef="From2021-01-012021-12-31_custom_EmployeesAndNonemployeeServiceProviderMember_srt_MaximumMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">32.90</ix:nonFraction></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_909_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm2_dtY_c20210101__20211231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zBlmxS6bsdGb" title="Weighted- Average Remaining Contractual Life (in Years), Options Granted"><ix:nonNumeric contextRef="From2021-01-012021-12-31_custom_EmployeesAndNonemployeeServiceProviderMember" format="ixt-sec:duryear" name="QLGN:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm2">9.79</ix:nonNumeric></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt">Expired</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_iN_di_c20210101__20211231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zI7xBpgmoeFi" title="Number of shares, options expired" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1744">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_c20210101__20211231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zYXSPv8ok47k" title="Weighted average exercise price, options expired" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1746">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_905_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExpirationsInPeriodWeightedAverageExercisePrice_pid_c20210101__20211231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zXSx1gzCejZ4" title="Range of Exercise price, Options Expired"><span style="-sec-ix-hidden: xdx2ixbrl1748">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#8212;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; padding-left: 10pt">Forfeited</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_di_c20210101__20211231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zwHpz37AiXV4" title="Number of shares, options forfeited" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" contextRef="From2021-01-012021-12-31_custom_EmployeesAndNonemployeeServiceProviderMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">450</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20210101__20211231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zoua4IVotl38" title="Weighted average exercise price, options forfeited" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" contextRef="From2021-01-012021-12-31_custom_EmployeesAndNonemployeeServiceProviderMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">36.80</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_c20210101__20211231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember__srt--RangeAxis__srt--MinimumMember_z7pjlwC3o4sh" title="Range of Exercise price, Options Forfeited"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" contextRef="From2021-01-012021-12-31_custom_EmployeesAndNonemployeeServiceProviderMember_srt_MinimumMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">35.20</ix:nonFraction></span>
                                            &#8212; <span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_c20210101__20211231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember__srt--RangeAxis__srt--MaximumMember_zffNW6BQTM0k" title="Range of Exercise price, Options Forfeited"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" contextRef="From2021-01-012021-12-31_custom_EmployeesAndNonemployeeServiceProviderMember_srt_MaximumMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">49.70</ix:nonFraction></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">&#8212;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">Total outstanding &#8211; December 31, 2021</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20210101__20211231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zIFAVcwX0f04" title="Number of Shares, Options Outstanding at Ending" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2021-12-31_custom_EmployeesAndNonemployeeServiceProviderMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">484,186</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20210101__20211231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zBJouRvbgPqb" title="Weighted Average Exercise Price, Outstanding at Ending" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2021-12-31_custom_EmployeesAndNonemployeeServiceProviderMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">60.70</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$<span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20210101__20211231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember__srt--RangeAxis__srt--MinimumMember_z8hAg45JY5Kb" title="Range of Exercise price, Options Outstanding"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2021-12-31_custom_EmployeesAndNonemployeeServiceProviderMember_srt_MinimumMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">12.40</ix:nonFraction></span>
                                            &#8212; $<span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20210101__20211231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember__srt--RangeAxis__srt--MaximumMember_zkyaelHb6GU8" title="Range of Exercise price, Options Outstanding"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2021-12-31_custom_EmployeesAndNonemployeeServiceProviderMember_srt_MaximumMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">14,657.50</ix:nonFraction></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20210101__20211231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zeZsbAxIcF7d" title="Weighted- Average Remaining Contractual Life (in Years), Outstanding at Ending"><ix:nonNumeric contextRef="From2021-01-012021-12-31_custom_EmployeesAndNonemployeeServiceProviderMember" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">8.52</ix:nonNumeric></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Exercisable (vested)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_iI_c20211231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zsdgVzadx08k" title="Number of shares, options exercisable (vested)" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" contextRef="AsOf2021-12-31_custom_EmployeesAndNonemployeeServiceProviderMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">140,820</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_c20211231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zuUPP8744Yk7" title="Range of exercise price, options exercisable (vested)" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" contextRef="AsOf2021-12-31_custom_EmployeesAndNonemployeeServiceProviderMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">108.80</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">$<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_c20211231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember__srt--RangeAxis__srt--MinimumMember_zClFjuotgPLc" title="Range of exercise price, options exercisable (vested)"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" contextRef="AsOf2021-12-31_custom_EmployeesAndNonemployeeServiceProviderMember_srt_MinimumMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">35.20</ix:nonFraction></span>
                                            &#8212; $<span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_c20211231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember__srt--RangeAxis__srt--MaximumMember_zNlHtSLqUBrk" title="Range of exercise price, options exercisable (vested)"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" contextRef="AsOf2021-12-31_custom_EmployeesAndNonemployeeServiceProviderMember_srt_MaximumMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">14,657.50</ix:nonFraction></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_dtY_c20210101__20211231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zr0KmYVSOCN9" title="Weighted- Average Remaining Contractual Life (in Years), Options Exercisable (vested)"><ix:nonNumeric contextRef="From2021-01-012021-12-31_custom_EmployeesAndNonemployeeServiceProviderMember" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1">7.94</ix:nonNumeric></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Non-Exercisable (non-vested)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iI_c20211231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zmWVhhGC6U12" title="Number of shares, options non-exercisable (non-vested)" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" contextRef="AsOf2021-12-31_custom_EmployeesAndNonemployeeServiceProviderMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">343,366</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToNonVestExercisableWeightedAverageExercisePrice_iI_c20211231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zBywnFXAAj8f" title="Weighted average exercise price, options non-exercisable (non-vested)" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToNonVestExercisableWeightedAverageExercisePrice" contextRef="AsOf2021-12-31_custom_EmployeesAndNonemployeeServiceProviderMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">41.00</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">$<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_iI_c20211231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember__srt--RangeAxis__srt--MinimumMember_zk9HGnKXZZsd" title="Range of exercise price, options non-exercisable (non-vested)"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" contextRef="AsOf2021-12-31_custom_EmployeesAndNonemployeeServiceProviderMember_srt_MinimumMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">12.40</ix:nonFraction></span>
                                            &#8212; $<span id="xdx_906_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_iI_c20211231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember__srt--RangeAxis__srt--MaximumMember_zFQLWXItfD7c" title="Range of exercise price, options non-exercisable (non-vested)"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" contextRef="AsOf2021-12-31_custom_EmployeesAndNonemployeeServiceProviderMember_srt_MaximumMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">51.30</ix:nonFraction></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_908_ecustom--WeightedAverageRemainingContractualLifeInYearsOptionsNonexercisableNonvested_dtY_c20210101__20211231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zkdl0OaBs8Hl" title="Weighted- Average Remaining Contractual Life (in Years), Options Non-exercisable (non-vested)"><ix:nonNumeric contextRef="From2021-01-012021-12-31_custom_EmployeesAndNonemployeeServiceProviderMember" format="ixt-sec:duryear" name="QLGN:WeightedAverageRemainingContractualLifeInYearsOptionsNonexercisableNonvested">8.81</ix:nonNumeric></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
was approximately $<span id="xdx_90D_eus-gaap--ShareBasedCompensation_pn5n6_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zuWnPueaqHp5" title="Compensation cost"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2022-01-012022-12-31_us-gaap_EmployeeStockOptionMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">5.4</ix:nonFraction></span> million and $<span id="xdx_90C_eus-gaap--ShareBasedCompensation_pn5n6_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zykv4IKU9abf" title="Compensation cost"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2021-01-012021-12-31_us-gaap_EmployeeStockOptionMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">5.3</ix:nonFraction></span> million of compensation costs related to outstanding options for the year ended December 31,
2022 and December 31, 2021, respectively. As of December 31, 2022, there was approximately $<span id="xdx_901_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_iI_pn5n6_c20221231_zlXSZYNG6LK8" title="Unrecognized compensation cost"><ix:nonFraction name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">3.3</ix:nonFraction></span> million of total unrecognized compensation
cost related to unvested stock-based compensation arrangements. This cost is expected to be recognized over a weighted average period
of <span id="xdx_906_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20220101__20221231_zmlZSvswkSAa" title="Cost is expected to be recognized over a weighted average period"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">0.93</ix:nonNumeric></span> years.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_906_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_do_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zoAYorNYuci3" title="Stock options exercised"><span id="xdx_904_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_do_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zQBCDmXkTzf1" title="Stock options exercised"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="From2022-01-012022-12-31_us-gaap_StockOptionMember" format="ixt-sec:numwordsen" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="From2021-01-012021-12-31_us-gaap_StockOptionMember" format="ixt-sec:numwordsen" decimals="INF" unitRef="Shares">No</ix:nonFraction></ix:nonFraction></span></span>
stock options were exercised during the year ended December 31, 2022 or 2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--PlanNameAxis__custom--TwoThousandTwentyStockIncentivePlanMember_zVADe2p1sLcl" title="Stock options description"><ix:nonNumeric contextRef="From2022-01-012022-12-31_us-gaap_StockOptionMember_custom_TwoThousandTwentyStockIncentivePlanMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription">The
exercise price for an option issued under the 2020 Plan is determined by the Board of Directors, but will be (i) in the case of an incentive
stock option (A) granted to an employee who, at the time of grant of such option, is a 10% stockholder, no less than 110% of the fair
market value per share on the date of grant; or (B) granted to any other employee, no less than 100% of the fair market value per share
on the date of grant; and (ii) in the case of a non-statutory stock option, no less than 100% of the fair market value per share on the
date of grant.</ix:nonNumeric></span> The options awarded under the 2020 Plan will vest as determined by the Board of Directors but will not exceed a 10-year
period. The weighted average grant date fair value per share of the shares underlying options granted during the year ended December
31, 2022 was $<span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zY5vuAG3Uoe7" title="Stock option granted exercise price"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="From2022-01-012022-12-31_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.96</ix:nonFraction></span> and during the year ended December 31, 2021 was $<span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zAGRhIfrlSy4" title="Stock option granted exercise price"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="From2021-01-012021-12-31_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">11.00</ix:nonFraction></span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 65; Value: 35 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->65<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Fair
Value of Equity Awards</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company utilizes the Black-Scholes option pricing model to value awards under the 2020 Plan, and for equity classified compensatory warrants.
Key valuation assumptions include:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Expected
    dividend yield.</i> The expected dividend is assumed to be zero, as the Company has never paid dividends and has no current plans
    to pay any dividends on the Company&#8217;s common stock.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Expected
    stock-price volatility.</i> The Company&#8217;s expected volatility is derived from the average historical volatilities of publicly
    traded companies within the Company&#8217;s industry that the Company considers to be comparable to the Company&#8217;s business
    over a period approximately equal to the expected term.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Risk-free
    interest rate. </i>The risk-free interest rate is based on the U.S. Treasury yield in effect at the time of grant for zero coupon
    U.S. Treasury notes with maturities approximately equal to the expected term.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Expected
    term.</i> The expected term represents the period that the stock-based awards are expected to be outstanding. The Company&#8217;s
    historical share option exercise experience does not provide a reasonable basis upon which to estimate an expected term because of
    a lack of sufficient data. Therefore, the Company estimates the expected term by using the simplified method provided by the SEC.
    The simplified method calculates the expected term as the average of the time-to-vesting and the contractual life of the options.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"><p id="xdx_898_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zXJHUhXRyRX8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
material factors incorporated in the Black-Scholes model in estimating the fair value of the options granted for the periods presented
were as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8BA_z7qII3f5qwu3" style="display: none">SCHEDULE
OF ASSUMPTION USED IN BLACK-SCHOLES OPTION-PRICING METHOD</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">For the Years Ended<br /> December
    31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Expected dividend yield</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20220101__20221231_zhag32jN4YRf" title="Expected dividend yield" style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">0.00</ix:nonFraction></td><td style="width: 1%; text-align: left">%</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20210101__20211231_zTIEJPQ084o4" title="Expected dividend yield" style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">0.00</ix:nonFraction></td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Expected stock-price volatility</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20220101__20221231_zKtIwKVsS3U" title="Expected stock-price volatility" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">103</ix:nonFraction></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20210101__20211231_zuEHSOgSMVc6" title="Expected stock-price volatility" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">102</ix:nonFraction></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Risk-free interest rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_pid_dp_uPure_c20220101__20221231_zLvLnQPVePo9" title="Risk-free interest rate, minimum"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">1.58</ix:nonFraction></span>%
                                            &#8212; <span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_pid_dp_uPure_c20220101__20221231_zjt5MWct8SE7" title="Risk-free interest rate, maximum"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">3.77</ix:nonFraction></span>%</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_pid_dp_uPure_c20210101__20211231_zJBi7nhkA5E" title="Risk-free interest rate, minimum"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">0.84</ix:nonFraction></span>%
                                            &#8212; <span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_pid_dp_uPure_c20210101__20211231_z829pG31GkU2" title="Risk-free interest rate, maximum"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">1.51</ix:nonFraction></span>%</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Expected average term of options (in years)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20220101__20221231_zKzJtlwDIcD8" title="Expected average term of options (in years)"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">5.99</ix:nonNumeric></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20210101__20211231_z7gMe5DCjO56" title="Expected average term of options (in years)"><ix:nonNumeric contextRef="From2021-01-012021-12-31" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">6.27</ix:nonNumeric></span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Stock price</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_900_eus-gaap--SharePrice_iI_c20221231__srt--RangeAxis__srt--MinimumMember_zGc28BFmmRvg" title="Share price"><ix:nonFraction name="us-gaap:SharePrice" contextRef="AsOf2022-12-31_srt_MinimumMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">5.14</ix:nonFraction></span>
                                            - <span id="xdx_902_eus-gaap--SharePrice_iI_c20221231__srt--RangeAxis__srt--MaximumMember_zgkx93Yfjlue" title="Share price"><ix:nonFraction name="us-gaap:SharePrice" contextRef="AsOf2022-12-31_srt_MaximumMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">10.50</ix:nonFraction></span></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_903_eus-gaap--SharePrice_iI_c20211231__srt--RangeAxis__srt--MinimumMember_z5tPoCaiZ4C2" title="Share price"><ix:nonFraction name="us-gaap:SharePrice" contextRef="AsOf2021-12-31_srt_MinimumMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">12.40</ix:nonFraction></span>
                                            &#8212; <span id="xdx_904_eus-gaap--SharePrice_iI_c20211231__srt--RangeAxis__srt--MaximumMember_ztiGNvk1kf9k" title="Share price"><ix:nonFraction name="us-gaap:SharePrice" contextRef="AsOf2021-12-31_srt_MaximumMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">32.90</ix:nonFraction></span></span></td><td style="text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A1_zGLJGlfc0sjj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock"><p id="xdx_89C_eus-gaap--ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_zh066EzBM4zd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company recorded stock-based compensation expense and classified it in the Consolidated Statements of Operations as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B7_zhN52oK5Tr13" style="display: none">SCHEDULE
OF SHARE-BASED COMPENSATION EXPENSE</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_491_20220101__20221231_zWbgOUKJSTsa" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_497_20210101__20211231_zC4rKQvO8pf5" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">For the Years Ended<br /> December
    31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--AllocatedShareBasedCompensationExpense_hus-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_z6NjOKdlH8xk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">General and administrative</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2022-01-012022-12-31_us-gaap_GeneralAndAdministrativeExpenseMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,649,649</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2021-01-012021-12-31_us-gaap_GeneralAndAdministrativeExpenseMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,465,911</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--AllocatedShareBasedCompensationExpense_hus-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zQQRXIbMtjSl" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Research and development</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2022-01-012022-12-31_us-gaap_ResearchAndDevelopmentExpenseMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">834,395</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2021-01-012021-12-31_us-gaap_ResearchAndDevelopmentExpenseMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">827,740</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--AllocatedShareBasedCompensationExpense_z8koch4cNqm9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt; padding-left: 10pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,484,044</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,293,651</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A5_zV04WYauZgVl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Equity
Classified Compensatory Warrants</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with the $<span id="xdx_907_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_pn5n6_c20220101__20221231__us-gaap--AwardTypeAxis__custom--CompensatoryWarrantsMember_zwMsTE61gQFk"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOrSaleOfEquity" contextRef="From2022-01-012022-12-31_custom_CompensatoryWarrantsMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">4.0</ix:nonFraction> </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million
equity capital raise as part of the May 2020 reverse recapitalization transaction, the Company issued common stock warrants to an
advisor and its designees for the purchase of <span id="xdx_901_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_c20221231__us-gaap--AwardTypeAxis__custom--CompensatoryWarrantsMember_zjgTNrzmiqZ4"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" contextRef="AsOf2022-12-31_custom_CompensatoryWarrantsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">81,143</ix:nonFraction>
reverse split adjusted </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of the
Company&#8217;s common stock at a reverse split adjusted exercise price of $<span id="xdx_900_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20221231__us-gaap--AwardTypeAxis__custom--CompensatoryWarrantsMember_zNjdEUO6etbc"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2022-12-31_custom_CompensatoryWarrantsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">11.1</ix:nonFraction><span style="background-color: white">0 </span></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per
share. The issuance cost of these warrants was charged to additional paid-in capital, and did not result in expense in the
Company&#8217;s consolidated <span style="background-color: white">statements of operations and comprehensive
loss.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, various service providers hold equity classified compensatory warrants issued in 2017 and earlier (originally exercisable to
purchase Series C convertible preferred stock, and now instead exercisable to purchase common stock) for the purchase of <span id="xdx_900_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_c20171231__us-gaap--AwardTypeAxis__custom--CompensatoryWarrantsMember_zReF2tUb7Ixg" title="Purchase of warrants"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" contextRef="AsOf2017-12-31_custom_CompensatoryWarrantsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">66,802</ix:nonFraction> reverse split adjusted s</span>hares
of Company common stock at a weighted average exercise price of $<span id="xdx_901_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20171231__us-gaap--AwardTypeAxis__custom--CompensatoryWarrantsMember_zdZ90OV21Emd" title="Exercise price of warrants"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2017-12-31_custom_CompensatoryWarrantsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">23.40</ix:nonFraction></span> per share. These are to be differentiated from the Series C Warrants
described in Note 10- Warrant Liabilities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year ended December 31, 2021, the Company issued equity classified compensatory warrants to a service provider for the purchase of
<span id="xdx_906_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20211231_zAW9cFKMDrj5"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">60,000</ix:nonFraction></span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reverse split adjusted shares of Company common stock at a
reverse split adjusted exercise price of $<span id="xdx_907_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20211231_zInLCdDgEsGh"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">13.20</ix:nonFraction></span>
per share. The fair value issuance cost of approximately $</span><span id="xdx_900_ecustom--FairValueOfIssuanceCost_pn5n6_c20210101__20211231_zJDERWaiZi3c" title="Fair value of issuance cost" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="QLGN:FairValueOfIssuanceCost" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.3</ix:nonFraction>
</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million
using the Black-Scholes options pricing model for these warrants was charged to general and administrative expenses in the Company&#8217;s
consolidated statements of operations and comprehensive loss. On April 25, 2022, </span><span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20220425__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zVEDdVaiyjOc" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2022-04-25_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">60,000</ix:nonFraction>
</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">warrants
were repriced from $</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_909_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20220424__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zsFyZ1STGzv1"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2022-04-24_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">13.20</ix:nonFraction></span>
to </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
reverse split adjusted exercise price of $6.00</span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">and
extended from </span><span id="xdx_905_ecustom--WarrantsExtendedDateDescription_c20220423__20220425__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zNBBNOSezz4e" title="Warrants extended date description" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonNumeric contextRef="From2022-04-232022-04-25_us-gaap_WarrantMember" name="QLGN:WarrantsExtendedDateDescription">June
3, 2023 to September 14, 2023</ix:nonNumeric></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.
The increase in fair value of $</span><span id="xdx_90C_eus-gaap--FairValueAdjustmentOfWarrants_c20220423__20220425__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zzNzyneGvfi6" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="From2022-04-232022-04-25_us-gaap_GeneralAndAdministrativeExpenseMember_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">67,370</ix:nonFraction>
</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">using
a Monte Carlo pricing model for the modification of these warrants was charged to general and administrative expenses in the Company&#8217;s
consolidated statements of operations and comprehensive loss. On April 25, 2022 and May 26, 2022 an additional </span><span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_c20220526__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z4jnGGNLlJVb" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" contextRef="AsOf2022-05-26_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">67,619</ix:nonFraction> reverse split adjusted
</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">warrants
were repriced from reverse split adjusted $11</span><span id="xdx_902_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20220526__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MinimumMember_zFUMTHnRFl4a" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2022-05-26_us-gaap_WarrantMember_srt_MinimumMember" decimals="INF" unitRef="USDPShares">.10</ix:nonFraction>
</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">to
$</span><span id="xdx_907_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20220526__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MaximumMember_z7pL3aTTTANk" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2022-05-26_us-gaap_WarrantMember_srt_MaximumMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">5.136</ix:nonFraction></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.
The increase in fair value of $</span><span id="xdx_90A_eus-gaap--FairValueAdjustmentOfWarrants_c20220523__20220526__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember__us-gaap--StatementEquityComponentsAxis__custom--WarrantOneMember_zk9GJs6d5TX7" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="From2022-05-232022-05-26_us-gaap_GeneralAndAdministrativeExpenseMember_custom_WarrantOneMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">31,010</ix:nonFraction>
</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">using
a Monte Carlo pricing model for the modification of these warrants was charged to additional paid-in capital and did not result in expense
on the Company&#8217;s consolidated statements of operations and comprehensive loss. On December 22, 2022 </span><span id="xdx_902_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_c20221222__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zmS18vwC5u43" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" contextRef="AsOf2022-12-22_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">67,620</ix:nonFraction>
</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">warrants
were repriced from $</span><span id="xdx_903_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20221222__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MinimumMember_zLYsaYYaalN4" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2022-12-22_us-gaap_WarrantMember_srt_MinimumMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">5.136</ix:nonFraction>
</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">to
$</span><span id="xdx_902_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20221222__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MaximumMember_z9Mt5Rbq8Aih" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2022-12-22_us-gaap_WarrantMember_srt_MaximumMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.32</ix:nonFraction></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.
The increase in fair value of $</span><span id="xdx_906_eus-gaap--FairValueAdjustmentOfWarrants_c20221220__20221222__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zvWYdjs2ZGS" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="From2022-12-202022-12-22_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,548</ix:nonFraction>
</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">using
a Monte Carlo pricing model for the modification of these warrants was charged to additional paid-in capital and did not result in expense
on the Company&#8217;s consolidated statements of operations and comprehensive loss.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 66; Value: 35 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->66<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">No
new compensatory warrants were issued during the year ended December 31, 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2022-01-012022-12-31_custom_CompensatoryWarrantActivityMember" escape="true" name="QLGN:SummaryOfWarrantActivityTableTextBlock"><p id="xdx_890_ecustom--SummaryOfWarrantActivityTableTextBlock_hus-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zm91MkMsDeuf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes the equity classified compensatory warrant activity for the year ended December 31, 2022:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B3_zXMa6WS7uYJ2" style="display: none">SCHEDULE
OF WARRANT ACTIVITY</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Common Stock</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Shares</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted&#8211; Average<br /> Exercise<br />
    Price</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Range of<br /> Exercise Price</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted&#8211;<br /> Average<br /> Remaining<br />
    Life (Years)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 32%">Total outstanding &#8211; December 31, 2021</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zc6X8p6TnZK2" title="Number of Shares, Warrants Outstanding Beginning" style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" contextRef="AsOf2021-12-31_custom_CompensatoryWarrantActivityMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">179,046</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iS_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_z6ZXiyP4CFQg" title="Weighted Average Exercise Price Per Share Warrants Outstanding Beginning" style="width: 12%; text-align: right"><ix:nonFraction name="QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2021-12-31_custom_CompensatoryWarrantActivityMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">15.20</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="width: 16%; text-align: right"><span id="xdx_901_ecustom--RangeOfExercisePriceOutstanding_iS_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember__srt--RangeAxis__srt--MinimumMember_zfDlRJ4MFaAl" title="Range of exercise price - beginning"><ix:nonFraction name="QLGN:RangeOfExercisePriceOutstanding" contextRef="AsOf2021-12-31_custom_CompensatoryWarrantActivityMember_srt_MinimumMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">11.10</ix:nonFraction></span>
                                            &#8212; $<span id="xdx_905_ecustom--RangeOfExercisePriceOutstanding_iS_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember__srt--RangeAxis__srt--MaximumMember_zUOo2hZXtozc"><ix:nonFraction name="QLGN:RangeOfExercisePriceOutstanding" contextRef="AsOf2021-12-31_custom_CompensatoryWarrantActivityMember_srt_MaximumMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">25.40</ix:nonFraction></span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right"><span id="xdx_90C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAveragRemainingContractualTerm1_dtY_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zIwhEPjpTkIj" title="Weighted Average Remaining Life (Years) - outstanding"><ix:nonNumeric contextRef="From2022-01-012022-12-31_custom_CompensatoryWarrantActivityMember" format="ixt-sec:duryear" name="QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAveragRemainingContractualTerm1">2.64</ix:nonNumeric></span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt">Granted to advisor and its designees</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_z6ayF8s7k1u5" title="Number of shares, warrants granted" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1882">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zTsDqkiT7ug2" title="Weighted average exercise price per share warrants granted" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1884">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt">Exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_di_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zsXfVyH9frHj" title="Number of Shares, Warrants Exercised" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1886">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedInPeriodWeightedAverageExercisePrice_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zpp0ZfLX7rS1" title="Weighted average exercise price per share warrants exercised" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1888">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt">Expired</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zmAmgvhiTLmc" title="Number of Shares, Warrants Expired" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1890">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInPeriodWeightedAverageExercisePrice_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zIxcQeJ9pkNe" title="Weighted average exercise price per share warrants expired" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1892">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; padding-left: 10pt">Forfeited</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_iN_di_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_z5uADim7WDt3" title="Number of Shares, Warrants Forfeited" style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1894">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedInPeriodWeightedAverageExercisePrice_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zpEak3XxjT87" title="Weighted average exercise price per share warrants forfeited" style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1896">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Total outstanding &#8211; December 31, 2022</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zmok0BDWJap7" title="Number of Shares, Warrants Outstanding Ending" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" contextRef="AsOf2022-12-31_custom_CompensatoryWarrantActivityMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">179,046</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iE_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_ztctxxBQvZl7" title="Weighted Average Exercise Price Per Share Warrants Outstanding Ending" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2022-12-31_custom_CompensatoryWarrantActivityMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">9.12</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="padding-bottom: 2.5pt; text-align: right"><span id="xdx_906_ecustom--RangeOfExercisePriceOutstanding_iE_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember__srt--RangeAxis__srt--MinimumMember_zBdMA35yQnne" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="QLGN:RangeOfExercisePriceOutstanding" contextRef="AsOf2022-12-31_custom_CompensatoryWarrantActivityMember_srt_MinimumMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.32</ix:nonFraction>
</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212; $<span id="xdx_902_ecustom--RangeOfExercisePriceOutstanding_iE_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember__srt--RangeAxis__srt--MaximumMember_zD11N8oa9I98"><ix:nonFraction name="QLGN:RangeOfExercisePriceOutstanding" contextRef="AsOf2022-12-31_custom_CompensatoryWarrantActivityMember_srt_MaximumMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">25.40</ix:nonFraction></span></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right"><span id="xdx_90C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAveragRemainingContractualTerm1_dtY_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zHI1aNvl8JV7" title="Weighted Average Remaining Life (Years) - outstanding"><ix:nonNumeric contextRef="From2022-01-012022-12-31_custom_CompensatoryWarrantActivityMember" format="ixt-sec:duryear" name="QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAveragRemainingContractualTerm1">1.73</ix:nonNumeric></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Exercisable</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_iI_c20221231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zlw5vYR1cbVd" title="Number of Shares, Warrants Exercisable" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber" contextRef="AsOf2022-12-31_custom_CompensatoryWarrantActivityMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">179,046</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_981_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageVestedExercisePrice_iI_c20221231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zGkDkIc0xBt7" title="Weighted Average Exercise Price Per Share Exercisable" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageVestedExercisePrice" contextRef="AsOf2022-12-31_custom_CompensatoryWarrantActivityMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">9.12</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_903_ecustom--RangeOfExercisePriceExercisableVested_iI_c20221231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember__srt--RangeAxis__srt--MinimumMember_zs7o9GJr1DMb"><ix:nonFraction name="QLGN:RangeOfExercisePriceExercisableVested" contextRef="AsOf2022-12-31_custom_CompensatoryWarrantActivityMember_srt_MinimumMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.32</ix:nonFraction></span>-
                                            $<span id="xdx_90B_ecustom--RangeOfExercisePriceExercisableVested_iI_c20221231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember__srt--RangeAxis__srt--MaximumMember_zlcUR6iJK9dd" title="Range of exercise price - ending"><ix:nonFraction name="QLGN:RangeOfExercisePriceExercisableVested" contextRef="AsOf2022-12-31_custom_CompensatoryWarrantActivityMember_srt_MaximumMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">25.40</ix:nonFraction></span></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAveragRemainingContractualTerm1_dtY_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zq2PDHCWcnYa" title="Weighted Average Remaining Life (Years) Exercisable"><ix:nonNumeric contextRef="From2022-01-012022-12-31_custom_CompensatoryWarrantActivityMember" format="ixt-sec:duryear" name="QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAveragRemainingContractualTerm1">1.73</ix:nonNumeric></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Non-Exercisable</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNonVestedNumber_iI_c20221231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_z9JCQxPvZMe3" title="Number of shares, warrants non-exercisable" style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1915">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_984_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageNonVestedExercise_iI_c20221231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zIQo5bxFh7l8" title="Weighted Average Exercise Price Per Share Non-Exercisable" style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1917">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98E_ecustom--RangeOfExercisePriceNonexercisableNonvested_iI_c20221231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_z3PBkLPWv78e" title="Range of Exercise Price, Non-Exercisable" style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1919">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">&#8212;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes the equity classified compensatory warrant activity for the year ended December 31, 2021:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Common Stock</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Shares</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted&#8211; Average<br /> Exercise<br />
    Price</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Range of<br /> Exercise Price</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted&#8211;<br /> Average<br /> Remaining<br />
    Life (Years)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 32%">Total outstanding &#8211; December 31, 2020</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20210101__20211231__us-gaap--AwardTypeAxis__custom--CompensatoryWarrantActivityMember_zXEEiX2Ns9ij" title="Number of shares, warrants outstanding beginning" style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" contextRef="AsOf2020-12-31_custom_CompensatoryWarrantActivityMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">129,403</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iS_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zsAprVVc6pza" title="Weighted Average Exercise Price Per Share Warrants Outstanding Beginning" style="width: 12%; text-align: right"><ix:nonFraction name="QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2020-12-31_custom_CompensatoryWarrantActivityMember72031578" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">16.60</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right">&#160;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right">&#160;</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt">Granted to advisor and its designees</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20210101__20211231__us-gaap--AwardTypeAxis__custom--CompensatoryWarrantActivityMember_zPTolTwgpNl1" title="Number of shares, warrants outstanding beginning" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" contextRef="From2021-01-012021-12-31_custom_CompensatoryWarrantActivityMember72031656" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">60,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zpjy7tjjG7lg" title="Weighted average exercise price per share warrants granted" style="text-align: right"><ix:nonFraction name="QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice" contextRef="From2021-01-012021-12-31_custom_CompensatoryWarrantActivityMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">13.20</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt">Exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_di_c20210101__20211231__us-gaap--AwardTypeAxis__custom--CompensatoryWarrantActivityMember_zY5fckfJX907" title="Number of shares, warrants outstanding beginning" style="text-align: right">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" contextRef="From2021-01-012021-12-31_custom_CompensatoryWarrantActivityMember72031656" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,839</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedInPeriodWeightedAverageExercisePrice_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zwvyAfJJtXIb" title="Weighted average exercise price per share warrants exercised" style="text-align: right"><ix:nonFraction name="QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedInPeriodWeightedAverageExercisePrice" contextRef="From2021-01-012021-12-31_custom_CompensatoryWarrantActivityMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">20.90</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt">Expired</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_iN_di_c20210101__20211231__us-gaap--AwardTypeAxis__custom--CompensatoryWarrantActivityMember_zqkBZSUcrDc8" title="Number of shares, warrants outstanding beginning" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1933">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInPeriodWeightedAverageExercisePrice_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_z4fOBs5hLglk" title="Weighted average exercise price per share warrants expired" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1935">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; padding-left: 10pt">Forfeited</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_iN_di_c20210101__20211231__us-gaap--AwardTypeAxis__custom--CompensatoryWarrantActivityMember_zJXVwXTfBsLf" title="Number of shares, warrants outstanding beginning" style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures" contextRef="From2021-01-012021-12-31_custom_CompensatoryWarrantActivityMember72031656" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">6,518</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedInPeriodWeightedAverageExercisePrice_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zbskeWqjnywl" title="Weighted average exercise price per share warrants forfeited" style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedInPeriodWeightedAverageExercisePrice" contextRef="From2021-01-012021-12-31_custom_CompensatoryWarrantActivityMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">20.70</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Total outstanding &#8211; December 31, 2021</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_c20210101__20211231__us-gaap--AwardTypeAxis__custom--CompensatoryWarrantActivityMember_zc65SVAw9uPg" title="Number of shares, warrants outstanding beginning" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" contextRef="AsOf2021-12-31_custom_CompensatoryWarrantActivityMember72031921" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">179,046</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iE_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zKVVPYIXz5lh" title="Weighted Average Exercise Price Per Share Warrants Outstanding Ending" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2021-12-31_custom_CompensatoryWarrantActivityMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">15.20</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 2.5pt; text-align: right">$<span id="xdx_907_ecustom--RangeOfExercisePriceOutstanding_iE_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember__srt--RangeAxis__srt--MinimumMember_zFtZ5QShHcE2"><ix:nonFraction name="QLGN:RangeOfExercisePriceOutstanding" contextRef="AsOf2021-12-31_custom_CompensatoryWarrantActivityMember_srt_MinimumMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">11.10</ix:nonFraction></span>
                                            &#8212; $<span id="xdx_90E_ecustom--RangeOfExercisePriceOutstanding_iE_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember__srt--RangeAxis__srt--MaximumMember_zqDqBD5TT456" title="Range of exercise price - ending"><ix:nonFraction name="QLGN:RangeOfExercisePriceOutstanding" contextRef="AsOf2021-12-31_custom_CompensatoryWarrantActivityMember_srt_MaximumMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">25.40</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right"><span id="xdx_90A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAveragRemainingContractualTerm1_dtY_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zJmgIMArS5u7" title="Weighted Average Remaining Life (Years) - outstanding"><ix:nonNumeric contextRef="From2021-01-012021-12-31_custom_CompensatoryWarrantActivityMember" format="ixt-sec:duryear" name="QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAveragRemainingContractualTerm1">2.64</ix:nonNumeric></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Exercisable</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_iI_c20211231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zYINqjRAnRv3" title="Number of Shares, Warrants Exercisable" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber" contextRef="AsOf2021-12-31_custom_CompensatoryWarrantActivityMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">179,046</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_982_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageVestedExercisePrice_iI_c20211231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zRAneQeqjhv7" title="Weighted Average Exercise Price Per Share Exercisable" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageVestedExercisePrice" contextRef="AsOf2021-12-31_custom_CompensatoryWarrantActivityMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">15.20</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 2.5pt double; text-align: right">$<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90A_ecustom--RangeOfExercisePriceExercisableVested_iI_c20211231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember__srt--RangeAxis__srt--MinimumMember_z4MNabjtCaf5"><ix:nonFraction name="QLGN:RangeOfExercisePriceExercisableVested" contextRef="AsOf2021-12-31_custom_CompensatoryWarrantActivityMember_srt_MinimumMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">11.10</ix:nonFraction></span>
                                            &#8212; $<span id="xdx_900_ecustom--RangeOfExercisePriceExercisableVested_iI_c20211231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember__srt--RangeAxis__srt--MaximumMember_zNvjGiy4ITMk" title="Range of exercise price - ending"><ix:nonFraction name="QLGN:RangeOfExercisePriceExercisableVested" contextRef="AsOf2021-12-31_custom_CompensatoryWarrantActivityMember_srt_MaximumMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">25.40</ix:nonFraction></span></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAveragRemainingContractualTerm1_dtY_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zR4QFPoIUOA7" title="Weighted Average Remaining Life (Years) Exercisable"><ix:nonNumeric contextRef="From2021-01-012021-12-31_custom_CompensatoryWarrantActivityMember" format="ixt-sec:duryear" name="QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAveragRemainingContractualTerm1">2.64</ix:nonNumeric></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Non-Exercisable</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNonVestedNumber_iI_c20211231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_z7ZZNsmCWqp8" title="Number of shares, warrants non-exercisable" style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1959">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageNonVestedExercise_iI_c20211231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_ziPEgq6dUs4b" title="Weighted Average Exercise Price Per Share Non-Exercisable" style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1961">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_980_ecustom--RangeOfExercisePriceNonexercisableNonvested_iI_c20211231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zJ0O7U0xHvIh" title="Range of Exercise Price, Non-Exercisable" style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1963">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">&#8212;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AA_zlgfXByNtr9k" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
were $<span id="xdx_902_eus-gaap--AllocatedShareBasedCompensationExpense_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zGO8KZPVkVLj" title="Compensation cost"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2022-01-012022-12-31_custom_CompensatoryWarrantActivityMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">67,370</ix:nonFraction></span> in compensation costs related to outstanding warrants for the year ended December 31, 2022 and $<span id="xdx_902_eus-gaap--AllocatedShareBasedCompensationExpense_pn5n6_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zh0Q6NAeRwe2" title="Compensation cost"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2021-01-012021-12-31_custom_CompensatoryWarrantActivityMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.3</ix:nonFraction></span> million for the year
ended December 31, 2021. As of December 31, 2022 and December 31, 2021, there was no unrecognized compensation cost related to nonvested
warrants.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Noncompensatory
Equity Classified Warrants</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
May 2020, as a commitment fee, the Company issued noncompensatory equity classified warrants to Alpha Capital (a related party) for the purchase of <span id="xdx_906_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_c20200531__us-gaap--AwardTypeAxis__custom--NoncompensatoryEquityClassifiedWarrantsMember_z2MZLezvuRn3"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" contextRef="AsOf2020-05-31_custom_NoncompensatoryEquityClassifiedWarrantsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">27,048</ix:nonFraction>
reverse split adjusted shares of Company common stock at a reverse split adjusted exercise price of $</span></span><span id="xdx_909_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20200531__us-gaap--AwardTypeAxis__custom--NoncompensatoryEquityClassifiedWarrantsMember_zvbebgmQQKb4" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2020-05-31_custom_NoncompensatoryEquityClassifiedWarrantsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">11.10</ix:nonFraction> </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per
share (of which warrants for </span><span id="xdx_903_ecustom--WarrantsExercised_c20201201__20201231__us-gaap--AwardTypeAxis__custom--NoncompensatoryEquityClassifiedWarrantsMember_z8LpI3z0Zar2" title="Warrants exercised" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="QLGN:WarrantsExercised" contextRef="From2020-12-012020-12-31_custom_NoncompensatoryEquityClassifiedWarrantsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">20,000</ix:nonFraction> </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares
were subsequently exercised in December 2020). In July 2020 the Company issued noncompensatory equity classified warrants to Alpha Capital for the purchase of </span><span id="xdx_909_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_c20200731__us-gaap--AwardTypeAxis__custom--NoncompensatoryEquityClassifiedWarrantsMember__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember_zijiCBZozBs5" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" contextRef="AsOf2020-07-31_custom_NoncompensatoryEquityClassifiedWarrantsMember_custom_AlphaCapitalMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">78,019</ix:nonFraction>
reverse split adjusted</span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares
of Company common stock at a reverse split adjusted exercise price of $</span><span id="xdx_904_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20200731__us-gaap--AwardTypeAxis__custom--NoncompensatoryEquityClassifiedWarrantsMember__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember_zQfcjhzOozug" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2020-07-31_custom_NoncompensatoryEquityClassifiedWarrantsMember_custom_AlphaCapitalMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.01</ix:nonFraction> </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per
share (which were subsequently exercised in July 2020), and <span id="xdx_905_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_c20200731__us-gaap--AwardTypeAxis__custom--NoncompensatoryEquityClassifiedWarrantsMember_zHh7kJ5Uuas3"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" contextRef="AsOf2020-07-31_custom_NoncompensatoryEquityClassifiedWarrantsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">192,068</ix:nonFraction></span> reverse split adjusted shares of Company common stock at a
reverse split adjusted exercise price of $</span><span id="xdx_900_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20200731__us-gaap--AwardTypeAxis__custom--NoncompensatoryEquityClassifiedWarrantsMember_z8lt0Jmnzu26" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2020-07-31_custom_NoncompensatoryEquityClassifiedWarrantsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">52.50</ix:nonFraction> </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per
share. In August 2020, the Company issued noncompensatory equity classified warrants to Alpha Capital for the purchase of </span><span id="xdx_903_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_c20200831__us-gaap--AwardTypeAxis__custom--NoncompensatoryEquityClassifiedWarrantsMember__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zgU8GMM1UD52" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" contextRef="AsOf2020-08-31_custom_NoncompensatoryEquityClassifiedWarrantsMember_custom_AlphaCapitalMember_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">128,783</ix:nonFraction>
reverse split adjusted shares of Company common stock at a reverse split adjusted exercise price of $</span><span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20200831__us-gaap--AwardTypeAxis__custom--NoncompensatoryEquityClassifiedWarrantsMember__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zmF05Pr6KTR3" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2020-08-31_custom_NoncompensatoryEquityClassifiedWarrantsMember_custom_AlphaCapitalMember_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">60.00</ix:nonFraction> </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per
share. In December 2020, the Company issued noncompensatory equity classified warrants to Alpha Capital for the purchase of </span><span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_c20201231__us-gaap--AwardTypeAxis__custom--NoncompensatoryEquityClassifiedWarrantsMember__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember_zOoKzGlJGis4" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" contextRef="AsOf2020-12-31_custom_NoncompensatoryEquityClassifiedWarrantsMember_custom_AlphaCapitalMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">100,000</ix:nonFraction> </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reverse
split adjusted shares of Company common stock at a reverse split adjusted exercise price of $</span><span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20201231__us-gaap--AwardTypeAxis__custom--NoncompensatoryEquityClassifiedWarrantsMember__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember_zwreAXqRa7ye" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2020-12-31_custom_NoncompensatoryEquityClassifiedWarrantsMember_custom_AlphaCapitalMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.10</ix:nonFraction> </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per
share (which were exercised in February 2021) and </span><span id="xdx_909_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_c20201231_zEfuGpcs7FA3" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">219,101</ix:nonFraction>
reverse split adjusted</span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares
of Company common stock at a reverse split adjusted exercise price of $</span><span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20201231_z3QyJ92TdD9e" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">40.70</ix:nonFraction> </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per
share. In May 2022, the Company issued noncompensatory equity classified warrants to Alpha Capital for the purchase of </span><span id="xdx_901_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_c20220531__us-gaap--AwardTypeAxis__custom--NoncompensatoryEquityClassifiedWarrantsMember_z5LoGPTOrvE1" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" contextRef="AsOf2022-05-31_custom_NoncompensatoryEquityClassifiedWarrantsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">331,464</ix:nonFraction>
reverse split adjusted</span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares
of Company common stock at a reverse split adjusted exercise price of $</span><span id="xdx_900_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20220531__us-gaap--AwardTypeAxis__custom--NoncompensatoryEquityClassifiedWarrantsMember_zzERc0VKrLB2" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2022-05-31_custom_NoncompensatoryEquityClassifiedWarrantsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.01</ix:nonFraction> </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per
share (See Note 3 -Acquisition).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 67; Value: 35 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->67<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">On
November 29, 2021, with the exception of the warrants to purchase <span id="xdx_903_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_c20211129__us-gaap--AwardTypeAxis__custom--NoncompensatoryEquityClassifiedWarrantsMember_zeIeAtZFYJkb" title="Number of securities called by Each warrant or right"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" contextRef="AsOf2021-11-29_custom_NoncompensatoryEquityClassifiedWarrantsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">27,048</ix:nonFraction>
reverse split adjusted shares of the Company&#8217;s common stock at a reverse split adjusted exercise price of $<span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20211129__us-gaap--AwardTypeAxis__custom--NoncompensatoryEquityClassifiedWarrantsMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z0wnOdvdTm5i" title="Exercise price of warrants"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2021-11-29_custom_NoncompensatoryEquityClassifiedWarrantsMember_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">11.10</ix:nonFraction></span>
per share, the exercise prices of all outstanding warrants to purchase a total of <span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20211129__us-gaap--AwardTypeAxis__custom--NoncompensatoryEquityClassifiedWarrantsMember_zZIlHOnBCSWa" title="Number of outstanding warrants to purchase, shares"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2021-11-29_custom_NoncompensatoryEquityClassifiedWarrantsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">539,951</ix:nonFraction>
reverse split adjusted</span> shares of the Company&#8217;s common stock were modified to a reverse split adjusted exercise price of
$<span id="xdx_908_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20211129__us-gaap--AwardTypeAxis__custom--NoncompensatoryEquityClassifiedWarrantsMember_zEcNBEAtthCg" title="Exercise price of warrants"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2021-11-29_custom_NoncompensatoryEquityClassifiedWarrantsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">20.00</ix:nonFraction></span>
per share and each of their remaining terms extended by six months. The fair value of the modification cost of these warrant
modifications of approximately $<span id="xdx_907_eus-gaap--FairValueAdjustmentOfWarrants_pn5n6_c20220101__20221231__us-gaap--AwardTypeAxis__custom--NoncompensatoryEquityClassifiedWarrantsMember_zUHKcymBIuIg" title="Fair value of warrants"><ix:nonFraction name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="From2022-01-012022-12-31_custom_NoncompensatoryEquityClassifiedWarrantsMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">2.3</ix:nonFraction></span>
million was charged to additional paid-in capital and did not result in expense on the Company&#8217;s consolidated statements of
operations and comprehensive loss. In May 2022, pre-funded warrants to purchase <span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_c20220930__us-gaap--AwardTypeAxis__custom--NoncompensatoryEquityClassifiedWarrantsMember_zAa5DJ8XHQrh" title="Purchase of warrants"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" contextRef="AsOf2022-09-30_custom_NoncompensatoryEquityClassifiedWarrantsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">331,464</ix:nonFraction>
reverse split adjusted</span> shares of the Company&#8217;s common stock at a reverse split adjusted exercise price of $<span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20220930__us-gaap--AwardTypeAxis__custom--NoncompensatoryEquityClassifiedWarrantsMember_z9sDvAuGwgH1" title=" Exercise price of warrants or rights"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2022-09-30_custom_NoncompensatoryEquityClassifiedWarrantsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.01</ix:nonFraction></span>
per share with no expiration date were issued. These warrants were subsequently exercised during the period ended September 30,
2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">In
conjunction with the NanoSynex Acquisition (See Note 3-Acquisition), on April 25, 2022 the exercise price of <span id="xdx_907_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_c20220425__us-gaap--BusinessAcquisitionAxis__custom--NanoSynexMember_z9yALRVQV102" title="Purchase of warrants"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" contextRef="AsOf2022-04-25_custom_NanoSynexMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">7,048</ix:nonFraction>
reverse split adjusted outstanding warrants at $<span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20211231__us-gaap--AwardTypeAxis__custom--NoncompensatoryEquityClassifiedWarrantsMember_zT420ek5Kjpf" title="Exercise price of warrants"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2021-12-31_custom_NoncompensatoryEquityClassifiedWarrantsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">11.10</ix:nonFraction></span>
was modified to a reverse split adjusted exercise price of $<span id="xdx_900_ecustom--ModifiedToExercisePrice_iI_c20220425__us-gaap--BusinessAcquisitionAxis__custom--NanoSynexMember_zN4BuVTwIfSe" title="Modified to exercise price"><ix:nonFraction name="QLGN:ModifiedToExercisePrice" contextRef="AsOf2022-04-25_custom_NanoSynexMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">6.00</ix:nonFraction></span>.
The increase in fair value of $<span id="xdx_90D_eus-gaap--FairValueAdjustmentOfWarrants_c20220423__20220425__us-gaap--BusinessAcquisitionAxis__custom--NanoSynexMember_zJEIpQn8FNp3" title="Fair value of warrants"><ix:nonFraction name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="From2022-04-232022-04-25_custom_NanoSynexMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,533</ix:nonFraction></span>,
using a Monte Carlo pricing model for the modification of these warrants, was charged to additional paid-in capital and did not
result in expense on the Company&#8217;s consolidated statements of operations and comprehensive loss. On May 26, 2022, the
reverse split adjusted exercise price of these warrants was modified again to $<span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20220526__us-gaap--BusinessAcquisitionAxis__custom--NanoSynexMember_zurAVj0Qtuxa" title="Class of warrant or right, exercise"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2022-05-26_custom_NanoSynexMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">5.136</ix:nonFraction></span>,
and the increase in fair value of $<span id="xdx_90A_eus-gaap--FairValueAdjustmentOfWarrants_c20220523__20220526__us-gaap--BusinessAcquisitionAxis__custom--NanoSynexMember_zK1wcBgwQFU8" title="Fair value adjustment of warrants"><ix:nonFraction name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="From2022-05-232022-05-26_custom_NanoSynexMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">696</ix:nonFraction></span>,
using a Monte Carlo pricing model for the modification of these warrants, was included in consideration transferred in the NanoSynex
Acquisition. On December 22, 2022 the exercise price of these warrants was modified again to $<span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20221222__us-gaap--BusinessAcquisitionAxis__custom--NanoSynexMember_zo7wHeVdlDSa" title="Class of warrant or right, exercise"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2022-12-22_custom_NanoSynexMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.32</ix:nonFraction></span>.
The increase in fair value of $<span id="xdx_90D_eus-gaap--FairValueAdjustmentOfWarrants_c20221220__20221222__us-gaap--BusinessAcquisitionAxis__custom--NanoSynexMember_zIdwFZZ7rdOk" title="Fair value adjustment of warrants"><ix:nonFraction name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="From2022-12-202022-12-22_custom_NanoSynexMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">891</ix:nonFraction></span>,
using a Monte Carlo pricing model for the modification of those warrants, was charged to additional paid-in capital and did not
result in expense on the Company&#8217;s consolidated statements of operations and comprehensive loss.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2022-01-012022-12-31_custom_NonCompensatoryWarrantActivityMember" escape="true" name="QLGN:SummaryOfWarrantActivityTableTextBlock"><p id="xdx_896_ecustom--SummaryOfWarrantActivityTableTextBlock_hus-gaap--StatementEquityComponentsAxis__custom--NonCompensatoryWarrantActivityMember_z3Ezp2e9l6U5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes the noncompensatory equity classified warrant activity for the year ended December 31, 2022:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8BD_z7kPo6hRT5N9" style="display: none">SCHEDULE
OF WARRANT ACTIVITY</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Common
    Stock</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif">Shares</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Weighted&#8211;<br />
    Average<br /> Exercise<br /> Price</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Range
    of<br /> Exercise Price</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Weighted&#8211;<br />
    Average<br /> Remaining<br /> Life (Years)</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 32%; padding-bottom: 2.5pt">Total outstanding &#8211; December 31, 2021</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 2.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; width: 1%; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20220101__20221231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zwjFSRJNVUW9" title="Number of shares, warrants outstanding beginning" style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; width: 12%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" contextRef="AsOf2021-12-31_custom_NonCompensatoryWarrantActivityMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">554,914</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 2.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; width: 1%; text-align: left">$</td><td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iS_c20220101__20221231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zVikSZesbGu9" title="Weighted Average exercise price per share warrants outstanding beginning" style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; width: 12%; text-align: right"><ix:nonFraction name="QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2021-12-31_custom_NonCompensatoryWarrantActivityMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">20.10</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 2.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_903_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsRangeOfExercisePrice_iS_c20220101__20221231__srt--RangeAxis__srt--MinimumMember__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zMUMmCqTfd85" title="Range of exercise price"><ix:nonFraction name="QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsRangeOfExercisePrice" contextRef="AsOf2021-12-31_srt_MinimumMember_custom_NonCompensatoryWarrantActivityMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">11.10</ix:nonFraction></span>&#8212;
                                            <span id="xdx_909_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsRangeOfExercisePrice_iS_c20220101__20221231__srt--RangeAxis__srt--MaximumMember__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_z7eX7LOBnGI3" title="Range of exercise price"><ix:nonFraction name="QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsRangeOfExercisePrice" contextRef="AsOf2021-12-31_srt_MaximumMember_custom_NonCompensatoryWarrantActivityMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">37.78</ix:nonFraction></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 2.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; width: 12%; text-align: right"><span id="xdx_90D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAveragRemainingContractualTerm1_dtY_c20210101__20211231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zL0eZezEfLbh" title="Weighted average remaining life (Years) exercisable"><ix:nonNumeric contextRef="From2021-01-012021-12-31_custom_NonCompensatoryWarrantActivityMember" format="ixt-sec:duryear" name="QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAveragRemainingContractualTerm1">1.32</ix:nonNumeric></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt">Granted</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20220101__20221231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zleoRD6BR5kc" title="Number of shares, warrants granted" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" contextRef="From2022-01-012022-12-31_custom_NonCompensatoryWarrantActivityMember72032375" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">331,464</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_981_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice_c20220101__20221231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zzuzx14V31M9" title="Weighted average exercise price per share warrants granted" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice" contextRef="From2022-01-012022-12-31_custom_NonCompensatoryWarrantActivityMember72032375" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.01</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_980_ecustom--RangeOfExercisePriceGranted_c20220101__20221231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zVOw8zcBTcrc" title="Range of exercise price - granted" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="QLGN:RangeOfExercisePriceGranted" contextRef="From2022-01-012022-12-31_custom_NonCompensatoryWarrantActivityMember72032375" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.01</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt">Exercised</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_di_c20220101__20221231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zCes61SgT65l" title="Number of Shares, Warrants Exercised" style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" contextRef="From2022-01-012022-12-31_custom_NonCompensatoryWarrantActivityMember72032375" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">331,464</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedInPeriodWeightedAverageExercisePrice_c20220101__20221231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zTuzD7PPoiFa" title="Weighted average exercise price per share warrants exercised" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedInPeriodWeightedAverageExercisePrice" contextRef="From2022-01-012022-12-31_custom_NonCompensatoryWarrantActivityMember72032375" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.01</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_989_ecustom--RangeOfExercisePriceExpired_c20220101__20221231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zfa6QtYaCcGe" title="Range of exercise price - Expired" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="QLGN:RangeOfExercisePriceExpired" contextRef="From2022-01-012022-12-31_custom_NonCompensatoryWarrantActivityMember72032375" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.01</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt">Expired</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_iN_di_c20220101__20221231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zT83qno96T8k" title="Number of Shares, Warrants Expired" style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" contextRef="From2022-01-012022-12-31_custom_NonCompensatoryWarrantActivityMember72032375" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">7,911</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInPeriodWeightedAverageExercisePrice_c20220101__20221231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zCWvJvJpGnle" title="Weighted average exercise price per share warrants expired" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInPeriodWeightedAverageExercisePrice" contextRef="From2022-01-012022-12-31_custom_NonCompensatoryWarrantActivityMember72032375" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">37.78</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInRangeOfExercisePrice_c20220101__20221231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zreaXubl0vi3" title="Weighted average exercise price per share warrants expired" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInRangeOfExercisePrice" contextRef="From2022-01-012022-12-31_custom_NonCompensatoryWarrantActivityMember72032375" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">37.78</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; padding-left: 10pt">Forfeited</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_iN_di_c20220101__20221231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zUfyKeYAqJh7" title="Number of Shares, Warrants Forfeited" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2045">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedInPeriodWeightedAverageExercisePrice_c20220101__20221231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_z18TDDCOaWL5" title="Weighted average exercise price per share warrants forfeited" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2047">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedInRangeOfExercisePrice_c20220101__20221231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zOYk6TDl4qP3" title="Weighted average exercise price per share warrants forfeited" style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2049">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">Total outstanding &#8211; December 31, 2022</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_c20220101__20221231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zubz5owdsLu7" title="Number of shares, warrants outstanding ending" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" contextRef="AsOf2022-12-31_custom_NonCompensatoryWarrantActivityMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">547,003</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iE_c20220101__20221231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zmgV7gzBuov4" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2022-12-31_custom_NonCompensatoryWarrantActivityMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">19.76</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_907_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsRangeOfExercisePrice_iE_c20220101__20221231__srt--RangeAxis__srt--MinimumMember__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zFFcgD4S67i5" title="Range of exercise price"><ix:nonFraction name="QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsRangeOfExercisePrice" contextRef="AsOf2022-12-31_srt_MinimumMember_custom_NonCompensatoryWarrantActivityMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.32</ix:nonFraction></span>
                                            - <span id="xdx_90A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsRangeOfExercisePrice_iE_c20220101__20221231__srt--RangeAxis__srt--MaximumMember__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zKF9YJmyPbOh" title="Range of exercise price"><ix:nonFraction name="QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsRangeOfExercisePrice" contextRef="AsOf2022-12-31_srt_MaximumMember_custom_NonCompensatoryWarrantActivityMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">20.00</ix:nonFraction></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right"><p style="margin: 0"><span id="xdx_903_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAveragRemainingContractualTerm1_dtY_c20220101__20221231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_z3ZFJGZrIQ3j" title="Weighted average remaining life (Years) exercisable"><ix:nonNumeric contextRef="From2022-01-012022-12-31_custom_NonCompensatoryWarrantActivityMember72032375" format="ixt-sec:duryear" name="QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAveragRemainingContractualTerm1">0.33</ix:nonNumeric></span></p></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">Exercisable</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_iI_c20221231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zlrYJwXik0Lk" title="Number of Shares, Warrants Exercisable" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber" contextRef="AsOf2022-12-31_custom_NonCompensatoryWarrantActivityMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">547,003</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"></td><td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageVestedExercisePrice_iI_c20221231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zdNu49nlWmh8" title="Weighted Average Exercise Price Per Share Exercisable" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageVestedExercisePrice" contextRef="AsOf2022-12-31_custom_NonCompensatoryWarrantActivityMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">19.76</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90C_ecustom--RangeOfExercisePriceExercisableVested_iI_c20221231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember__srt--RangeAxis__srt--MinimumMember_z75s4PgkKA08"><ix:nonFraction name="QLGN:RangeOfExercisePriceExercisableVested" contextRef="AsOf2022-12-31_srt_MinimumMember_custom_NonCompensatoryWarrantActivityMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.32</ix:nonFraction></span>
                                            - <span id="xdx_908_ecustom--RangeOfExercisePriceExercisableVested_iI_c20221231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember__srt--RangeAxis__srt--MaximumMember_z53sjGNxbes" title="Range of exercise price - Exercisable"><ix:nonFraction name="QLGN:RangeOfExercisePriceExercisableVested" contextRef="AsOf2022-12-31_srt_MaximumMember_custom_NonCompensatoryWarrantActivityMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">20.00</ix:nonFraction></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_902_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAveragRemainingContractualTerm1_dtY_c20220101__20221231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zY5i18pnUj9g" title="Weighted average remaining life (Years) exercisable"><ix:nonNumeric contextRef="From2022-01-012022-12-31_custom_NonCompensatoryWarrantActivityMember72032375" format="ixt-sec:duryear" name="QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAveragRemainingContractualTerm1">0.33</ix:nonNumeric></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">Non-Exercisable</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><p id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsNonExercisableNumber_iI_c20221231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_z9QB1DrWVd54" title="Number of Shares, Warrants Exercisable" style="margin: 0"><span style="-sec-ix-hidden: xdx2ixbrl2069">&#8212;</span></p></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageVestedNonExercisePrice_iI_c20221231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zRUYi3jgb2T" title="Weighted Average Exercise Price Per Share Exercisable" style="border-bottom: Black 2.5pt double; text-align: right"><p style="margin: 0"><span style="-sec-ix-hidden: xdx2ixbrl2071">&#8212;</span></p></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><p style="margin: 0"><span id="xdx_905_ecustom--RangeOfExercisePriceNonExercisableVested_iI_c20221231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zS6McpAPGdJ8" title="Range of exercise price - Exercisable"><span style="-sec-ix-hidden: xdx2ixbrl2073">&#8212;</span></span></p></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><p style="margin: 0">&#8212;</p></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes the noncompensatory equity classified warrant activity for the year ended December 31, 2021:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Common
    Stock</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Shares</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Weighted&#8211;<br />
    Average<br /> Exercise<br /> Price</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Range
    of<br /> Exercise Price</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Weighted&#8211;<br />
    Average<br /> Remaining<br /> Life (Years)</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 32%">Total outstanding &#8211; December 31, 2020</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20210101__20211231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zrgu3znl8ir8" title="Number of shares, warrants outstanding beginning" style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" contextRef="AsOf2020-12-31_custom_NonCompensatoryWarrantActivityMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">654,978</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iS_c20210101__20211231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zuq0DGS0fNgc" title="Weighted Average exercise price per share warrants outstanding beginning" style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"><ix:nonFraction name="QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2020-12-31_custom_NonCompensatoryWarrantActivityMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">43.60</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right">&#160;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right">&#160;</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt">Granted</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20210101__20211231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zseVSSaR3om2" title="Number of shares, warrants granted" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2079">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice_c20210101__20211231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zd7XDgXX7v0e" title="Weighted average exercise price per share warrants granted" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2081">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt">Exercised</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_di_c20210101__20211231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_z4VTL9fYAHg7" title="Number of Shares, Warrants Exercised" style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" contextRef="From2021-01-012021-12-31_custom_NonCompensatoryWarrantActivityMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">100,000</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_984_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedInPeriodWeightedAverageExercisePrice_c20210101__20211231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zk9RebS1SFOa" title="Weighted average exercise price per share warrants exercised" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedInPeriodWeightedAverageExercisePrice" contextRef="From2021-01-012021-12-31_custom_NonCompensatoryWarrantActivityMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.01</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt">Expired</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_iN_di_c20210101__20211231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zMrt5FX6PAk7" title="Number of Shares, Warrants Expired" style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" contextRef="From2021-01-012021-12-31_custom_NonCompensatoryWarrantActivityMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">64</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInPeriodWeightedAverageExercisePrice_c20210101__20211231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_z4PGH6tMj7L" title="Weighted average exercise price per share warrants expired" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInPeriodWeightedAverageExercisePrice" contextRef="From2021-01-012021-12-31_custom_NonCompensatoryWarrantActivityMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">23,250.00</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; padding-left: 10pt">Forfeited</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_iN_di_c20210101__20211231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zWrrkA6OrSX4" title="Number of Shares, Warrants Forfeited" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2091">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_984_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedInPeriodWeightedAverageExercisePrice_c20210101__20211231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zHFgSqFaYdF" title="Weighted average exercise price per share warrants forfeited" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2093">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">Total outstanding &#8211; December 31, 2021</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_c20210101__20211231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zzvbBfvHzVw9" title="Number of shares, warrants outstanding ending" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" contextRef="AsOf2021-12-31_custom_NonCompensatoryWarrantActivityMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">554,914</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iE_c20210101__20211231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_z5YMpRUmKmxb" title="Weighted average exercise price per share warrants outstanding ending" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2021-12-31_custom_NonCompensatoryWarrantActivityMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">20.10</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">Exercisable</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_iI_c20211231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zRtonYIo0gr" title="Number of Shares, Warrants Exercisable" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber" contextRef="AsOf2021-12-31_custom_NonCompensatoryWarrantActivityMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">554,914</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageVestedExercisePrice_iI_c20211231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_z4XqDAu7DU09" title="Weighted Average Exercise Price Per Share Exercisable" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageVestedExercisePrice" contextRef="AsOf2021-12-31_custom_NonCompensatoryWarrantActivityMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">20.10</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90A_ecustom--RangeOfExercisePriceExercisableVested_iI_c20211231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember__srt--RangeAxis__srt--MinimumMember_z2Cgb5GcUwU1"><ix:nonFraction name="QLGN:RangeOfExercisePriceExercisableVested" contextRef="AsOf2021-12-31_srt_MinimumMember_custom_NonCompensatoryWarrantActivityMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">11.10</ix:nonFraction></span>&#8212;
                                            <span id="xdx_90E_ecustom--RangeOfExercisePriceExercisableVested_iI_c20211231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember__srt--RangeAxis__srt--MaximumMember_zT9QG9krjKff" title="Range of exercise price - Exercisable"><ix:nonFraction name="QLGN:RangeOfExercisePriceExercisableVested" contextRef="AsOf2021-12-31_srt_MaximumMember_custom_NonCompensatoryWarrantActivityMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">37.78</ix:nonFraction></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_909_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAveragRemainingContractualTerm1_dtY_c20210101__20211231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zhxtRGlF0sia" title="Weighted average remaining life (Years) exercisable"><ix:nonNumeric contextRef="From2021-01-012021-12-31_custom_NonCompensatoryWarrantActivityMember" format="ixt-sec:duryear" name="QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAveragRemainingContractualTerm1">1.32</ix:nonNumeric></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">Non-Exercisable</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNonVestedNumber_iI_c20211231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zsRMNxUJolef" title="Number of shares, warrants non-exercisable" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2108">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageNonVestedExercise_iI_c20211231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_z6BDf9VNYLpb" title="Weighted Average Exercise Price Per Share Non-Exercisable" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2110">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_98A_ecustom--RangeOfExercisePriceNonexercisableNonvested_iI_c20211231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zh4z4Kxg5TPh" title="Range of Exercise Price, Non-Exercisable" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2112">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNonExercisableWeightedAverageRemainingContractualTerm1_dtY_c20210101__20211231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zxT9GOV6SKZb" title="Weighted average remaining life (Years) non-exercisable" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2114">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A7_zsJm35GUamO2" style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock"><p id="xdx_806_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_zw8BAxRq9xI3" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>NOTE 16 &#8212; <span id="xdx_829_ztv8nxMGTeY9">RELATED PARTY TRANSACTIONS</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Convertible Debt </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">On December 22, 2022, the Company issued to Alpha
Capital, an <span id="xdx_902_eus-gaap--ShortTermDebtInterestRateIncrease_pid_dp_uPure_c20221222__20221222__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember__us-gaap--DebtInstrumentAxis__custom--SeniorConvertibleDebentureMember_zCYtEOlEyKWg" title="Senior convertible debenture rate"><ix:nonFraction name="us-gaap:ShortTermDebtInterestRateIncrease" contextRef="From2022-12-222022-12-22_custom_AlphaCapitalMember_custom_SeniorConvertibleDebentureMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">8</ix:nonFraction></span>% Senior Convertible Debenture in the aggregate principal amount of $<span id="xdx_902_eus-gaap--SecuredDebt_iI_c20221222__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember__us-gaap--DebtInstrumentAxis__custom--SeniorConvertibleDebentureMember_zKrKJCk27pOc" title="Principal amount"><ix:nonFraction name="us-gaap:SecuredDebt" contextRef="AsOf2022-12-22_custom_AlphaCapitalMember_custom_SeniorConvertibleDebentureMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,300,000</ix:nonFraction></span> for a purchase price of $<span id="xdx_902_ecustom--PurchasePrice_iI_c20221222__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember__us-gaap--DebtInstrumentAxis__custom--SeniorConvertibleDebentureMember_zs7z0yaWDZV9" title="Purchase Price"><ix:nonFraction name="QLGN:PurchasePrice" contextRef="AsOf2022-12-22_custom_AlphaCapitalMember_custom_SeniorConvertibleDebentureMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,000,000</ix:nonFraction></span> pursuant
to the terms of a Securities Purchase Agreement, dated December 21, 2022 (the &#8220;Alpha Purchase Agreement&#8221;). The Debenture is
convertible, at any time, and from time to time, at Alpha&#8217;s option, into shares of common stock of the Company (the &#8220;Conversion
Shares&#8221;), at a price equal to $<span id="xdx_904_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pid_c20221222__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember__us-gaap--DebtInstrumentAxis__custom--SeniorConvertibleDebentureMember_zeDshKsge7zf" title="Conversion price"><ix:nonFraction name="us-gaap:DebtInstrumentConvertibleConversionPrice1" contextRef="AsOf2022-12-22_custom_AlphaCapitalMember_custom_SeniorConvertibleDebentureMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.32</ix:nonFraction> </span>per share, subject to adjustment as described in the Debenture (the &#8220;Conversion Price&#8221;)
and other terms and conditions described in the Debenture, including the Company&#8217;s receipt of the requisite stockholder approvals
(See Note 11 -Convertible Debt - Related Party).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Short-Term Debt</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">NanoSynex has four separate notes payable (the &#8220;Notes&#8221;) outstanding to Alpha Capital, dated between March
26, 2020 and September 2, 2021, aggregating to a total principal outstanding balance of $<span id="xdx_90B_eus-gaap--DebtInstrumentFaceAmount_iI_c20210902__us-gaap--ShortTermDebtTypeAxis__custom--NotesPayableMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NanoSynexMember_zq1GyqxWFFfd" title="Short term debt principal outstanding"><ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="AsOf2021-09-02_custom_NotesPayableMember_custom_NanoSynexMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">905,000</ix:nonFraction></span>, and aggregate accrued interest of $<span id="xdx_90C_eus-gaap--InterestPayableCurrent_iI_pp0p0_c20221231__us-gaap--ShortTermDebtTypeAxis__custom--NotesPayableMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NanoSynexMember_zL0FRomOK44d" title="Accrued interest"><ix:nonFraction name="us-gaap:InterestPayableCurrent" contextRef="AsOf2022-12-31_custom_NotesPayableMember_custom_NanoSynexMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">45,722</ix:nonFraction></span>
for a total outstanding balance of $<span id="xdx_90B_eus-gaap--ShortTermBorrowings_iI_pp0p0_c20221231__us-gaap--ShortTermDebtTypeAxis__custom--NotesPayableMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NanoSynexMember_zffaPZB0t9r6" title="Short term debt outstanding balance"><ix:nonFraction name="us-gaap:ShortTermBorrowings" contextRef="AsOf2022-12-31_custom_NotesPayableMember_custom_NanoSynexMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">950,722</ix:nonFraction></span> as of December&#160;31, 2022. The Notes all accrue interest at<span id="xdx_90A_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20210902__us-gaap--ShortTermDebtTypeAxis__custom--NotesPayableMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NanoSynexMember_z2M0M949Qbed" title="Accrued interest rate"> <ix:nonFraction name="us-gaap:DebtInstrumentInterestRateStatedPercentage" contextRef="AsOf2021-09-02_custom_NotesPayableMember_custom_NanoSynexMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">2.62</ix:nonFraction></span>% per annum, accrued daily,
and provide that the full amount of principal and interest under each Note shall be due immediately prior to a Liquidation Event (the
Maturity Date) unless due earlier in accordance with the terms of the Notes. &#8220;Liquidation Event&#8221; means either i) the merger
or consolidation of NanoSynex into any other entity, other than one in control or under control of NanoSynex or NanoSynex&#8217;s majority shareholder;
ii) a transaction or series of transactions resulting in the transfer of all or substantially all of NanoSynex&#8217;s assets or issued and
outstanding share capital (other than to a company under the control of NanoSynex or NanoSynex&#8217;s majority shareholders; or iii) an underwritten
public offering by NanoSynex of its ordinary shares. Notwithstanding the above, if NanoSynex receives subsequent debt, convertible debt,
or equity funding with gross proceeds of USD $<span id="xdx_901_eus-gaap--ProceedsFromRelatedPartyDebt_pp0p0_c20210326__20210902__us-gaap--ShortTermDebtTypeAxis__custom--NotesPayableMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NanoSynexMember_zNJI6se0a2Tg" title="Proceeds from related party debt"><ix:nonFraction name="us-gaap:ProceedsFromRelatedPartyDebt" contextRef="From2021-03-262021-09-02_custom_NotesPayableMember_custom_NanoSynexMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">3,000,000</ix:nonFraction></span> or more, then these Notes shall be due and payable upon the actual receipt of
such funding (See Note 9 -Short-term Debt - Related Party).</p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Nanosynex Acquisition</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company acquired a <span id="xdx_903_eus-gaap--BusinessAcquisitionPercentageOfVotingInterestsAcquired_iI_pid_dp_uPure_c20220526__us-gaap--BusinessAcquisitionAxis__custom--NanoSynexLtdMember_z3qyVFVo5SJg" title="Business acquisition, voting equity rate"><ix:nonFraction name="us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired" contextRef="AsOf2022-05-26_custom_NanoSynexLtdMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">52.8</ix:nonFraction></span>% voting equity interest
in NanoSynex on May 26, 2022 (the &#8220;NanoSynex Acquisition Date&#8221;) through: (1) the purchase of <span id="xdx_901_eus-gaap--StockIssuedDuringPeriodSharesAcquisitions_c20220524__20220526__us-gaap--StatementClassOfStockAxis__custom--SeriesAOnePreferredStockMember_z5BJO4JXkBvh" title="Number of shares of stock issued"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesAcquisitions" contextRef="From2022-05-242022-05-26_custom_SeriesAOnePreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,232,861</ix:nonFraction></span> shares Preferred A-1
Stock of NanoSynex from Alpha Capital (a related party) for <span id="xdx_900_eus-gaap--StockIssuedDuringPeriodSharesAcquisitions_c20220524__20220526__us-gaap--BusinessAcquisitionAxis__custom--NanoSynexLtdMember_zcfpx0LwPU74" title="Stock issued during period shares acquisitions"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesAcquisitions" contextRef="From2022-05-242022-05-26_custom_NanoSynexLtdMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">350,000</ix:nonFraction></span> reverse split adjusted shares of the Company&#8217;s common stock and a
prefunded warrant to purchase <span id="xdx_901_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20220526__us-gaap--StatementEquityComponentsAxis__custom--PrefundedWarrantMember_zmIDxCjjYZr8" title="Warrants to purchase shares"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2022-05-26_custom_PrefundedWarrantMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">331,464</ix:nonFraction> reverse split adjusted shares of the Company&#8217;s common stock at a purchase price of $<span id="xdx_909_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20220526__us-gaap--BusinessAcquisitionAxis__custom--NanoSynexLtdMember__us-gaap--StatementEquityComponentsAxis__custom--PrefundedWarrantMember_zV0i1KkZvyZe" title="Warrants or rights"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2022-05-26_custom_NanoSynexLtdMember_custom_PrefundedWarrantMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.001</ix:nonFraction></span> per share
(<span id="xdx_90B_eus-gaap--StockholdersEquityReverseStockSplit_c20220524__20220526__us-gaap--BusinessAcquisitionAxis__custom--NanoSynexLtdMember_zHFGo44DRS7k" title="Reverse split, description"><ix:nonNumeric contextRef="From2022-05-242022-05-26_custom_NanoSynexLtdMember" name="us-gaap:StockholdersEquityReverseStockSplit">these warrants were subsequently exercised on September 13, 2022)</ix:nonNumeric></span>, and (2) the purchase of <span id="xdx_902_eus-gaap--StockIssuedDuringPeriodSharesAcquisitions_c20220524__20220526__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember__us-gaap--BusinessAcquisitionAxis__custom--NanoSynexLtdMember_zL544l13VBX8" title="Stock issued during period shares acquisitions"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesAcquisitions" contextRef="From2022-05-242022-05-26_custom_NanoSynexLtdMember_us-gaap_SeriesBPreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">381,786</ix:nonFraction></span> shares of Series B preferred stock
of NanoSynex from NanoSynex in exchange for $<span id="xdx_901_eus-gaap--StockIssuedDuringPeriodValueAcquisitions_c20220524__20220526__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember__us-gaap--BusinessAcquisitionAxis__custom--NanoSynexLtdMember_zPey05GwWsja" title="Stock issued during period value acquisitions"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" contextRef="From2022-05-242022-05-26_custom_NanoSynexLtdMember_us-gaap_SeriesBPreferredStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">600,000</ix:nonFraction></span></span> (See Note 3 - Acquisition).</p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:IncomeTaxDisclosureTextBlock"><p id="xdx_806_eus-gaap--IncomeTaxDisclosureTextBlock_zXkjUdIAk7a8" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
17 &#8212; <span id="xdx_824_zCH2Y3cvJuEi">INCOME TAXES</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock"><p id="xdx_89D_eus-gaap--ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_zC5WzqnHGoG" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table presents domestic and foreign components of consolidated loss before income taxes for the periods presented:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span><span id="xdx_8BE_zZJmOpqAkPFh" style="display: none">SCHEDULE
OF DOMESTIC AND FOREIGN COMPONENTS</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_498_20220101__20221231_zCIo0y8ZD4Cc" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_494_20210101__20211231_zA5yjKw0koBj" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_z37fmY4jBFv4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%">Domestic</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">15,954,750</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">17,891,710</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td></tr>
  <tr id="xdx_401_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_zifcygSnRYn6" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">Foreign</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">5,344,967</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2160">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_zbeeiP0iNXBh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Loss before provision for income taxes</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">21,299,717</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">17,891,710</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A2_z2FlujSNayk7" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 68; Value: 35 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->68<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"><p id="xdx_89D_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zno2KvHtuSh3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
reconciliation of the statutory income tax rates and the Company&#8217;s effective tax rate is as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8BB_zJ7HCURHx36a" style="display: none">SCHEDULE
OF RECONCILIATIONS OF STATUTORY INCOME TAX RATE</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_498_20220101__20221231_zXdooMsJEywk" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_492_20210101__20211231_zLf6HVlYXzf2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_uPure_zIeBXIwCOqH" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Statutory federal income tax rate</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">21.00</ix:nonFraction></td><td style="width: 1%; text-align: left">%</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">21.00</ix:nonFraction></td><td style="width: 1%; text-align: left">%</td></tr>
  <tr id="xdx_400_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_pid_dp_uPure_zJIAGKaGcMX" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">State taxes, net of federal tax benefit</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">5.46</ix:nonFraction></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">6.63</ix:nonFraction></td><td style="text-align: left">%</td></tr>
  <tr id="xdx_40B_eus-gaap--EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepletion_pid_dp_uPure_zR0JUoqHu6o1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Non-deductible expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepletion" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" sign="-" unitRef="Pure">1.36</ix:nonFraction></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepletion" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" sign="-" unitRef="Pure">1.19</ix:nonFraction></td><td style="text-align: left">%</td></tr>
  <tr id="xdx_408_ecustom--EffectiveIncomeTaxRateReconciliationNonOperatingLossExpiration_pid_dp_uPure_z2f8h7JF900b" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">NOL expiration</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-<ix:nonFraction name="QLGN:EffectiveIncomeTaxRateReconciliationNonOperatingLossExpiration" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" sign="-" unitRef="Pure">12.96</ix:nonFraction></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-<ix:nonFraction name="QLGN:EffectiveIncomeTaxRateReconciliationNonOperatingLossExpiration" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" sign="-" unitRef="Pure">2.71</ix:nonFraction></td><td style="text-align: left">%</td></tr>
  <tr id="xdx_40E_eus-gaap--EffectiveIncomeTaxRateReconciliationTaxCredits_pid_dp_uPure_zfEWJloNJUJd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Tax credit</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">2.42</ix:nonFraction></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">0.86</ix:nonFraction></td><td style="text-align: left">%</td></tr>
  <tr id="xdx_400_eus-gaap--EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses_pid_dp_uPure_zRgn6HftpuW6" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Goodwill impairment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" sign="-" unitRef="Pure">4.50</ix:nonFraction></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">0.00</ix:nonFraction></td><td style="text-align: left">%</td></tr>
  <tr id="xdx_406_eus-gaap--EffectiveIncomeTaxRateReconciliationTaxSettlementsForeign_pid_dp_uPure_zTFGuDKMxGJ" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Foreign rate differential</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxSettlementsForeign" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">0.50</ix:nonFraction></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxSettlementsForeign" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">0.00</ix:nonFraction></td><td style="text-align: left">%</td></tr>
  <tr id="xdx_40B_ecustom--EffectiveIncomeTaxRateReconciliationFairValueOfWarrant_pid_dp_uPure_zQoQFFPXWgm2" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Change in FV of warrant liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="QLGN:EffectiveIncomeTaxRateReconciliationFairValueOfWarrant" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">0.89</ix:nonFraction></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="QLGN:EffectiveIncomeTaxRateReconciliationFairValueOfWarrant" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">5.54</ix:nonFraction></td><td style="text-align: left">%</td></tr>
  <tr id="xdx_40C_eus-gaap--EffectiveIncomeTaxRateReconciliationTaxCreditsOther_pid_dp_uPure_zDHCM6gQLox8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>True-up</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsOther" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">1.47</ix:nonFraction></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsOther" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" sign="-" unitRef="Pure">2.72</ix:nonFraction></td><td style="text-align: left">%</td></tr>
  <tr id="xdx_404_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_pid_dp_uPure_zL6RGqQhU227" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Change in valuation allowance</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" sign="-" unitRef="Pure">11.68</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" sign="-" unitRef="Pure">27.44</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">%</td></tr>
  <tr id="xdx_401_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_pid_dp_uPure_zhMdntHmS9rd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Income taxes provision (benefit)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">1.24</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">%</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">-<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" sign="-" unitRef="Pure">0.03</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">%</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A9_z98hbu2gEOFh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"><p id="xdx_891_eus-gaap--ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_zz2iHIEA3rO1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Income
tax expense for the year ended December 31, 2022 and 2021 consisted of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B5_zrvQuSeeDsud" style="display: none">SCHEDULE
OF PROVISION FOR INCOME TAXES</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49E_20220101__20221231_zfGOltlCv5L8" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_495_20210101__20211231_zRwty91B7ob" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">For the Years Ended</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Current</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--CurrentFederalTaxExpenseBenefit_maCITEBz1MC_zWa9bmB5ez1a" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">US Federal</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2202">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2203">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--CurrentStateAndLocalTaxExpenseBenefit_maCITEBz1MC_zs53W0Vutu4a" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">US State</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--CurrentForeignTaxExpenseBenefit_maCITEBz1MC_zmIFaJ38JYcc" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">Foreign</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2208">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2209">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--CurrentIncomeTaxExpenseBenefit_iT_mtCITEBz1MC_zmsyTOrYMKqf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10pt">Total current provision</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:CurrentIncomeTaxExpenseBenefit" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:CurrentIncomeTaxExpenseBenefit" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Deferred</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--DeferredFederalIncomeTaxExpenseBenefit_maDITEBzCKf_zEjGPYIO4jae" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">US Federal</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">236,000</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,268,000</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_402_eus-gaap--DeferredStateAndLocalIncomeTaxExpenseBenefit_maDITEBzCKf_z9jvGGv8uVSc" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">US State</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,252,000</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">3,641,000</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_400_eus-gaap--DeferredForeignIncomeTaxExpenseBenefit_maDITEBzCKf_zaz4C0dB2JDh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Foreign</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:DeferredForeignIncomeTaxExpenseBenefit" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">272,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2221">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--DeferredIncomeTaxExpenseBenefit_iT_mtDITEBzCKf_maITEBzWbu_zpUmzlIz4zlg" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt">Total deferred benefit</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:DeferredIncomeTaxExpenseBenefit" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,760,000</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:DeferredIncomeTaxExpenseBenefit" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">4,909,000</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_409_eus-gaap--ValuationAllowanceDeferredTaxAssetChangeInAmount_iN_di_msITEBzWbu_zqClhg5UPcqe" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt">Change in valuation allowance</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,488,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">4,909,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--IncomeTaxExpenseBenefit_iT_pn3d_mtITEBzWbu_zQCM7qvLFCth" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 10pt">Total provision (benefit) for income taxes</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="-3" sign="-" unitRef="USD">265,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="-3" unitRef="USD">5,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A6_zTO9prVN39h5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"><p id="xdx_896_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zeTmu6uRlQPe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
components of deferred tax assets and liabilities are as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8BF_z3dFPzGVRSH2" style="display: none">SCHEDULE
OF DEFERRED TAX ASSETS AND LIABILITIES</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_496_20221231_zZGWMXRDemS6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_491_20211231_zBm7PHs84ebh" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Deferred tax assets:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_maDTATDzYdX_znrofrP5Xlre" style="vertical-align: bottom; background-color: White">
    <td style="width: 60%; text-align: left; padding-left: 10pt">Net operating loss</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">33,540,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">33,362,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--DeferredTaxAssetsInProcessResearchAndDevelopment_iI_maDTATDzYdX_z2tuGmtJmegd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10pt">Research and development credits</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,857,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,185,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_ecustom--DefferdTaxAssetsAccruedExpenses_iI_maDTATDzYdX_z6JoyJ0i7os9" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt">Accrued expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="QLGN:DefferdTaxAssetsAccruedExpenses" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,020,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="QLGN:DefferdTaxAssetsAccruedExpenses" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">757,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--DeferredTaxAssetsGoodwillAndIntangibleAssets_iI_maDTATDzYdX_zDuKcQEhBRof" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt">Patent</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2243">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">262,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_iI_maDTATDzYdX_zzxLy03Czow" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt">Stock compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,069,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,747,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_ecustom--DeferredTaxAssetsResearchAndDevelopmentExpenses_iI_maDTATDzYdX_zxSJdg5AvK3a" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10pt">Research and development expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="QLGN:DeferredTaxAssetsResearchAndDevelopmentExpenses" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,196,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2250">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--DeferredTaxAssetsPropertyPlantAndEquipment_iI_maDTATDzYdX_zJIaj0YTTjCb" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt">Fixed assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">280,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">282,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--DeferredTaxAssetsTaxDeferredExpense_iTI_mtDTATDzYdX_maDTAGzJfc_z7vYln7SyRlk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 20pt">Total deferred income tax assets</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxDeferredExpense" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">46,962,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxDeferredExpense" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">43,595,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Deferred tax liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_iNI_di_maDITLzOxa_zNVXxDQARH21" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt">Intangible assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,324,000</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">34,000</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_401_eus-gaap--DeferredTaxLiabilitiesLeasingArrangements_iNI_di_maDITLzOxa_zYhrq6gYXyog" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt">Right-of-use asset</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:DeferredTaxLiabilitiesLeasingArrangements" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">382,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:DeferredTaxLiabilitiesLeasingArrangements" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">436,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_40B_eus-gaap--DeferredIncomeTaxLiabilities_iNTI_di_mtDITLzOxa_msDTAGzJfc_zyOXhtPGufhj" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 10pt">Total deferred income tax liabilities</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:DeferredIncomeTaxLiabilities" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,706,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:DeferredIncomeTaxLiabilities" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">470,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--DeferredTaxAssetsGross_iTI_mtDTAGzJfc_maDTALNzbeu_zuHVng7UZHZj" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Net deferred income tax assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsGross" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">45,256,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsGross" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">43,125,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_di_msDTALNzbeu_zpSSzdtVNXlf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Valuation allowance</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">45,614,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">43,125,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_402_eus-gaap--DeferredTaxAssetsLiabilitiesNet_iNTI_di_mtDTALNzbeu_zPeqin1vXMda" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Deferred tax asset, net of allowance</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:DeferredTaxAssetsLiabilitiesNet" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">358,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2274">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AB_zDZsKxpqeVi9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
on the available objective evidence, including the Company&#8217;s history of cumulative losses, management believes it is likely that
the Company&#8217;s U.S. federal and state net deferred tax assets will not be realizable. Accordingly, the Company provided for a full
valuation allowance against its U.S. federal and state net deferred tax assets at December 31, 2022 and December 31, 2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 69; Value: 35 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->69<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Due
to the full valuation allowance already in place on the Company&#8217;s U.S. federal and state net deferred tax assets, the Company does
not anticipate significant changes in the Company&#8217;s effective tax rate. However, there is no valuation allowance recorded against
the Company&#8217;s foreign net operating loss deferred tax assets, as the Company&#8217;s foreign IPR&amp;D deferred tax liabilities
and foreign net operating loss deferred tax assets are both indefinite-lived and thus they may be netted to arrive at a net foreign deferred
tax liability. This results in $<span id="xdx_906_eus-gaap--DeferredForeignIncomeTaxExpenseBenefit_iN_di_c20220101__20221231_z4J4CGvC0Ix3" title="Foreign deferred tax benefit"><ix:nonFraction name="us-gaap:DeferredForeignIncomeTaxExpenseBenefit" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">272,000</ix:nonFraction></span> of foreign deferred tax benefit recorded to the income statement in 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Tax Cuts and Jobs Act resulted in significant changes to the treatment of research or experimental (&#8220;R&amp;E&#8221;) expenditures
under Section 174. For tax years beginning after December 31, 2021, taxpayers are required to capitalize and amortize all R&amp;E expenditures
that are paid or incurred in connection with their trade or business which represent costs in the experimental or laboratory sense. Specifically,
costs for U.S. based R&amp;E activities must be amortized over five years and costs for foreign R&amp;E activities must be amortized
over 15 years; both using a midyear convention. The Company has incorporated the impact of this new tax legislation into its 2022 consolidated
financial statements, noting that the impact on the Company&#8217;s consolidated financial statements was immaterial.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
December 31, 2022, the Company has U.S. federal and state net operating loss carryforwards of approximately $<span id="xdx_90B_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_iI_c20221231_zNp7gpV8pwxc" title="Operating loss carryforwards"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">119,254,000</ix:nonFraction></span> and $<span id="xdx_90B_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_iI_c20211231_zkiPkHs24gWd" title="Operating loss carryforwards"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">110,227,000</ix:nonFraction></span>,
respectively, which are available to offset future taxable income. U.S. federal and state net operating loss carryovers began to expire
in 2020. As a result of the May 2020 reverse recapitalization, an ownership change has occurred. The Company has not completed an Internal
Revenue Code Section 382 analysis. As a result, there could be substantial limitations on the Company&#8217;s ability to utilize its
pre-ownership change net operating loss and tax credit carryforwards. These substantial limitations may result in both a permanent loss
of certain tax benefits related to net operating loss carryforwards and federal research and development credits, and an annual utilization
limitation. At December 31, 2022, the Company has foreign net operating loss carryforwards of approximately $<span id="xdx_90E_eus-gaap--OperatingLossCarryforwards_iI_c20221231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--ForeignCountryMember_zchcYg8podU9" title="Net operating loss carryforwards"><ix:nonFraction name="us-gaap:OperatingLossCarryforwards" contextRef="AsOf2022-12-31_us-gaap_ForeignCountryMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">953,000</ix:nonFraction></span>, which are available
to offset future taxable income. Foreign net operating loss carryovers are indefinite lived and do not expire.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company also has research and development credit carryforwards for federal and state tax purposes of approximately $<span id="xdx_90F_eus-gaap--DeferredTaxAssetsTaxCreditCarryforwardsResearch_iI_c20221231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--DomesticCountryMember_zIkejkX2Nh1b" title="Research and development credit carryforwards"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" contextRef="AsOf2022-12-31_us-gaap_DomesticCountryMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,484,000</ix:nonFraction></span> and $<span id="xdx_90D_eus-gaap--DeferredTaxAssetsTaxCreditCarryforwardsResearch_iI_c20221231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--StateAndLocalJurisdictionMember_z2NHT4EcUhvf" title="Research and development credit carryforwards"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" contextRef="AsOf2022-12-31_us-gaap_StateAndLocalJurisdictionMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,373,000</ix:nonFraction></span>,
respectively. <span id="xdx_907_eus-gaap--TaxCreditCarryforwardLimitationsOnUse_c20220101__20221231_zfQmsPXr41Me" title="Tax credit carryforward, limitations on use"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="us-gaap:TaxCreditCarryforwardLimitationsOnUse">The research and development credit carryforwards began to expire in 2020 for federal tax purposes and have an indefinite
life for state tax purposes</ix:nonNumeric></span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">U.S.
income tax has not been recognized on the excess of the amount for financial reporting over the tax basis of investments in foreign subsidiaries
that is indefinitely reinvested outside the United States. This amount becomes taxable upon a repatriation of assets from the subsidiary
or a sale or liquidation of the subsidiary. Determination of the amount of any unrecognized deferred income tax liability on this temporary
difference is not practicable because of the complexities of the hypothetical calculation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company files income tax returns in the U.S. federal jurisdiction and in various states. The Company&#8217;s U.S. federal income tax
returns remain subject to examination by the Internal Revenue Service. The Company&#8217;s California income tax returns remain subject
to examination by the California Franchise Tax Board. Due to net operating losses, research and development credits and other tax credit
carryforwards that may be utilized in future years, all U.S. federal and state tax years are open to examination.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Generally
accepted accounting principles clarify the accounting for uncertainty in income taxes recognized in the Company&#8217;s financial statements
and prescribe thresholds for financial statement recognition and measurement of a tax position taken or expected to be taken in a tax
return, and also provide guidance on de-recognition and measurement of a tax position taken or expected to be taken in a tax return.
The Company adopted these provisions effective April 1, 2009.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company did <span id="xdx_900_eus-gaap--UnrecognizedTaxBenefits_iI_do_c20221231_zM8VQdjlj4b" title="Unrecognized tax benefits"><span id="xdx_90A_eus-gaap--UnrecognizedTaxBenefits_iI_do_c20211231_zIDyRoiZlTKd" title="Unrecognized tax benefits"><ix:nonFraction name="us-gaap:UnrecognizedTaxBenefits" contextRef="AsOf2022-12-31" format="ixt-sec:numwordsen" decimals="0" unitRef="USD"><ix:nonFraction name="us-gaap:UnrecognizedTaxBenefits" contextRef="AsOf2021-12-31" format="ixt-sec:numwordsen" decimals="0" unitRef="USD">no</ix:nonFraction></ix:nonFraction></span></span>t have any unrecognized tax benefits as of December 31, 2022 and December 31, 2021 and does not expect this to change significantly
over the next 12 months. In accordance with generally accepted accounting principles, the Company will recognize interest and penalties
accrued on any unrecognized tax benefits as a component of income tax expense. As of December 31, 2022, the Company has not accrued any
interest or penalties related to uncertain tax positions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:SubsequentEventsTextBlock"><p id="xdx_80B_eus-gaap--SubsequentEventsTextBlock_zmFV7KP8YqY9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
18 &#8212; <span id="xdx_82D_z1nZVeCrSx02">SUBSEQUENT EVENTS</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Between
January 9 and 12, 2023 Alpha Capital voluntarily converted $<span id="xdx_906_eus-gaap--DebtInstrumentFaceAmount_iI_c20230112__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zZExaEB2DUH3" title="Debenture voluntarily converted"><ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="AsOf2023-01-12_us-gaap_SubsequentEventMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,111,078</ix:nonFraction></span>
of its outstanding Senior Convertible Debenture principal into <span id="xdx_90B_eus-gaap--CommonStockDividendsShares_c20230109__20230112__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zmGQ3orIfXSi" title="Shares of common stock"><ix:nonFraction name="us-gaap:CommonStockDividendsShares" contextRef="From2023-01-092023-01-12_us-gaap_SubsequentEventMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">841,726</ix:nonFraction></span>
shares of common stock at a conversion price of $<span id="xdx_90D_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pid_c20230112__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zTTmQBPGRwbe" title="Conversion price"><ix:nonFraction name="us-gaap:DebtInstrumentConvertibleConversionPrice1" contextRef="AsOf2023-01-12_us-gaap_SubsequentEventMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.32</ix:nonFraction></span>
per share.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 13, 2023, the Company&#8217;s board of directors, as part of certain cost-cutting measures, approved a temporary <span id="xdx_902_ecustom--BaseSalaryPercentage_dp_uPure_c20230113__20230113__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zOqPQRfD2kKa" title="Base salary percentage"><ix:nonFraction name="QLGN:BaseSalaryPercentage" contextRef="From2023-01-132023-01-13_us-gaap_SubsequentEventMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">20</ix:nonFraction></span>% reduction
to the base salaries of all executive officers of the Company and a <span id="xdx_906_ecustom--AnnualCashCompensation_dp_uPure_c20230113__20230113__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zfYg1rIIZu1j" title="Annual cash compensation"><ix:nonFraction name="QLGN:AnnualCashCompensation" contextRef="From2023-01-132023-01-13_us-gaap_SubsequentEventMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">20</ix:nonFraction></span>% reduction to the non-employee directors&#8217; annual cash compensation.
The Company also terminated the employment of certain employees, including its Senior Vice President/Chief Operating Officer and Vice President/Chief Scientific
Officer.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company filed a Notification of Late Filing on Form 12b-25 on March 31, 2023, indicating that the filing of this Annual Report would
be delayed on account of the Company and its registered public accounting firm requiring additional time to complete the
accounting and disclosures related to the Company&#8217;s acquisition of a majority interest in NanoSynex, Ltd., which accounting and disclosures have been included in this
Annual Report. On April 20, 2023, the Company received a notification
letter from the Listing Qualifications Department of Nasdaq indicating that, as a result of the Company&#8217;s delay in filing this
Annual Report, the Company was not in compliance with the timely filing requirements for continued listing under Nasdaq Listing Rule
5250(c)(1). The notification letter has no immediate effect on the listing or trading of the Company&#8217;s common stock on the
Nasdaq Capital Market. The notification letter stated that, under Nasdaq rules, the Company has 60 calendar days, or until June 20,
2023, to submit a plan to regain compliance with Nasdaq&#8217;s continued listing requirements. The Company may also regain
compliance with Nasdaq&#8217;s continued listing requirements at any time before June 20, 2023, by filing this Annual Report with
the SEC, as well as any subsequent periodic financial reports that may become due, and continuing to comply with Nasdaq&#8217;s
other continued listing requirements. The filing of this Annual Report was the Company&#8217;s action to regain
compliance.</span></p>

</ix:nonNumeric><p id="xdx_81B_zn4c1XWfAY18" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 70; Value: 35 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->70<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="psi_001"></span>Item
9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
applicable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="psi_002"></span>Item
9A. Controls and Procedures.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Evaluation
of Disclosure Controls and Procedures</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
management, with the participation of our principal executive officer and principal financial officer, evaluated the effectiveness of
our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) as of December 31, 2022,
the end of the year covered by this Annual Report. Based on this evaluation, our principal executive officer and principal financial
officer concluded that, as of December 31, 2022, our disclosure controls and procedures were not effective due to the continuing
material weakness described below. We believe that a disclosure controls system, no matter how well designed and operated, cannot provide
absolute assurance that the objectives of the disclosure controls system are met, and no evaluation of disclosure controls can provide
absolute assurance that all disclosure control issues, if any, within a company have been detected.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Management&#8217;s
Report on Internal Control over Financial Reporting</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b>Our
management is responsible for establishing and maintaining adequate internal control over financial reporting as defined in Rules 13a-15(f)
and 15d-15(f) under the Exchange Act. Internal control over financial reporting is a process designed under the supervision and with
the participation of our management, including our principal executive officer and principal financial officer, to provide reasonable
assurance regarding the reliability of financial reporting and the preparation of consolidated financial statements for external purposes
in accordance with accounting principles generally accepted in the United States of America.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2022, our management assessed the effectiveness of our internal control over financial reporting using the criteria
set forth by the Committee of Sponsoring Organizations of the Treadway Commission in Internal Control-Integrated Framework. Based on
the continuing material weakness described below, our management concluded that as of December 31, 2022, our internal control over
financial reporting was not effective.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Description
of Material Weakness</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As <span style="font-size: 10pt">previously
described in our annual report on Form 10-K for the year ended December 31, 2021, in connection with the audit of our financial
statements as of and for the year ended December 31, 2021 (the &#8220;2021 audit&#8221;), our management and registered independent
public accounting firm </span><span style="font-size: 8pt"></span><span style="font-size: 10pt">identified a material weakness in
our internal control over financial reporting related to the lack of accounting department resources and/or policies and procedures
to ensure recording and disclosure of items in compliance with U.S. GAAP. This material weakness resulted in adjustments to our
warrant valuations in connection with the 2021 audit. In response to the material weakness, we took a number of remediation steps to
enhance our internal controls, including implementing additional procedures and utilizing external consulting resources with
experience and expertise in U.S. GAAP and public company accounting and reporting requirements to assist management with its
accounting and reporting of complex and/or non-recurring transactions and related disclosures. However, in connection with the audit
of our financial statements as of and for the year ended December 31, 2022 (the &#8220;2022 audit&#8221;), our management determined
that that the material weakness identified in connection with the 2021 audit has not been fully remediated and resulted in
adjustments to the accounting treatment related to convertible debt, the business combination and goodwill impairment during the
2022 audit, which resulted in the late filing of this Annual Report.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Remediation
of Material Weakness</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As described above, following the 2021 audit, we evaluated and implemented
additional procedures in order to remediate this material weakness, including utilizing external consulting resources with experience
and expertise in U.S. GAAP and public company accounting and reporting requirements to assist management with its accounting and reporting
of complex and/or non-recurring transactions and related disclosures. However, due, in part, to a number of unfortunate staffing adjustments
and departures at the consulting firms we utilized, these changes have not completely remediated the material weakness identified and
reported. We intend to continue to take steps to enhance our internal controls, including implementing additional internal procedures
and utilizing well-established external consulting resources with experience and expertise in U.S. GAAP and public company accounting
and reporting requirements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">However, we cannot assure you that these or other measures will fully remediate
the material weakness in a timely manner. Notwithstanding the identified material weakness, our management believes that (the indicated
adjustments having been made) the consolidated financial statements included in this report fairly represent in all material respects
our financial condition, results of operations and cash flows at and for the periods presented in accordance with U.S. GAAP.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Changes
in Internal Control over Financial Reporting</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
than as described above, there were no changes in our internal control over financial reporting identified in management&#8217;s evaluation
pursuant to Rules 13a-15(d) or 15d-15(d) of the Exchange Act during the year ended December 31, 2022 that materially affected, or are
reasonably likely to materially affect, our internal control over financial reporting.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Limitation
on Effectiveness of Controls</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
designing and evaluating our controls and procedures, management recognized that any controls and procedures, no matter how well designed
and operated, can provide only reasonable and not absolute assurance of achieving the desired control objectives. No evaluation of internal
control can provide absolute assurance that all internal control issues and instances of fraud, if any, within a company are detected.
In reaching a reasonable level of assurance, management necessarily was required to apply its judgment in evaluating the cost-benefit
relationship of possible controls and procedures. There are inherent limitations to the effectiveness of any system of disclosure controls
and procedures, including the possibility of human error and the circumvention or overriding of the controls and procedures. In addition,
the design of any system of controls is based in part upon certain assumptions about the likelihood of future events, and there can be
no assurance that any design will succeed in achieving its stated goals under all potential future conditions. Over time, controls may
become inadequate because of changes in conditions, or the degree of compliance with policies or procedures may deteriorate. Because
of the inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur and not be detected.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="psi_003"></span>Item
9B. Other Information.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">None.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="psi_004"></span>Item
9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">None.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>


<!-- Field: Page; Sequence: 71; Options: NewSection; Value: 71 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->71<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="psi_005"></span>PART
III</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="psi_006"></span>Item
10. Directors, Executive Officers and Corporate Governance.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>The
Board of Directors</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
board of directors currently consists of seven members, each of whose current term of office as a director expires at the 2023 annual
meeting of stockholders. Biographical information with respect to our directors is provided below.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
directors hold office for one year or until their respective successors have been duly elected or until their death, resignation or removal.
Our amended and restated bylaws provide that the authorized number of directors comprising our board of directors will be fixed, from
time to time, by a majority of the total number of directors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
are no family relationships among any of our directors or executive officers.  There is no arrangement or understanding between any director and any other person pursuant to which the director was selected.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Name</b></span></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Position with the Company</b></span></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Age</b></span></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Director Since</b></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Michael Poirier</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chairman and Chief Executive Officer</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">67</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2020</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amy Broidrick</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">President, Chief Strategy Officer and Director</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">64</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2020</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Richard David</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">63</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2020</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sidney Emery, Jr.</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">76</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2020</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Matthew Korenberg</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">48</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2020</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Kurt Kruger</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">67</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2020</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ira Ritter</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">74</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2008</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Michael
S. Poirier</b>. Mr. Poirier founded the Qualigen business in 1996 and is its Chairman and Chief Executive Officer. Before founding
Qualigen, Mr. Poirier had relevant operating, marketing and sales positions with Ashirus Technologies, Inc., EnSys, Inc., Sanofi Pasteur
and Abbott Laboratories, Inc. Before working at Abbott, Mr. Poirier served as an officer in the United States Navy, assigned to the US
Atlantic Fleet. Mr. Poirier holds a B.A. from Providence College and attended the University of Z&#252;rich, Switzerland, School of Law.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr.
Poirier&#8217;s commitment to our strategic goals, his long experience leading our company and his deep knowledge of its technologies
and business contributed to our board of directors&#8217; conclusion that he should serve as a director of our company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Amy
S. Broidrick</b>. Ms. Broidrick has served as our President, Chief Strategy and Operating Officer since February 2023. She previously
served as our President and Chief Strategy Officer since December 2021, and Executive Vice President/Chief Strategy Officer since December
2020. From 2016 to July 2020, Ms. Broidrick served as Senior Vice President, Global Head of Corporate Development of Viking Therapeutics,
Inc. (Nasdaq: VKTX), a clinical-stage biopharmaceutical company. Before that, she was Vice President, Head of Global Marketing Excellence
and Business Innovation with EMD Serono (part of Merck KGaA). Earlier, she was Vice President, Head of Marketing and Commercialization
at Arena Pharmaceuticals, Inc., and had significant roles and responsibilities at Merck &amp; Co., Inc. and G.D. Searle &amp; Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ms.
Broidrick&#8217;s executive experience with large and smaller public companies in the therapeutics industry contributed to our board
of directors&#8217; conclusion that she should serve as a director of our company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Richard
A. David, MD FACS</b>. Dr. David serves as Chief Medical Officer for the Los Angeles Division of Genesis Healthcare Partners,
the largest urology group in Southern California. He also serves as medical director for Genesis&#8217; Advanced Prostate Cancer Center
of Excellence. In addition, Dr. David serves as Clinical Professor of Urology for the David Geffen School of Medicine at UCLA. Dr. David
obtained his undergraduate education at Stanford University and his medical degree at Thomas Jefferson University in Philadelphia. He
also holds a Master&#8217;s degree in Medical Management (MMM) from the Marshall School of Business at the University of Southern California.
He trained in general surgery and completed his urology residency at UCLA Medical Center in Los Angeles. Dr. David is a fellow of the
American College of Surgeons.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr.
David&#8217;s experience as an executive of a large healthcare organization, including his background as a medical doctor, contributed
to our board of directors&#8217; conclusion that he should serve as a director of our company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 72; Value: 71 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->72<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Sidney
W. Emery, Jr.</b> Mr. Emery acquired Supply Chain Services in 2010 and, as its Chief Executive Officer, grew it into a premier
provider of automatic identification and data capture and factory automation solutions before selling the business to Sole Source
Capital LLC in May 2020. Before Supply Chain Services, he served as Chairman and Chief Executive Officer of MTS Systems Corporation
(Nasdaq-GS: MTSC), a leading global supplier of mechanical testing systems and high-performance industrial position sensors. Mr.
Emery served on the Board of Directors of Allete, Inc. (NYSE: ALE), a Minnesota-based utilities and energy company, from 2006 to
2018. Mr. Emery chairs the University of St. Thomas School of Engineering Board of Governors. Mr. Emery holds a PhD in Industrial
Engineering from Stanford University and a B.S. in Engineering from the US Naval Academy. He served for 10 years in the US Navy
(including on gunboats in Vietnam).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr.
Emery&#8217;s extensive board service with and executive leadership of major companies contributed to our board of directors&#8217; conclusion
that he should serve as a director of our company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Matthew
E. Korenberg</b>. Mr. Korenberg has served as President and Chief Operating Officer of Ligand Pharmaceuticals Incorporated (Nasdaq: LGND),
a biopharmaceutical company focused on developing or acquiring technologies that help pharmaceutical companies discover and develop medicines,
since November 2022, and before that as Executive Vice President, Finance and Chief Financial Officer of Ligand Pharmaceuticals Incorporated
since August 2015. Before joining Ligand, commencing in September 2013, Mr. Korenberg was the founder, Chief Executive Officer and a
director of NeuroCircuit Therapeutics, a company focused on developing drugs to treat genetic disorders of the brain with an initial
focus on Down syndrome. Before founding NeuroCircuit Therapeutics, Mr. Korenberg was a Managing Director and member of the healthcare
investment banking team at Goldman Sachs from July 1999 through August 2013. During his 14 year tenure at Goldman Sachs, Mr. Korenberg
was focused on advising and financing companies in the biotechnology and pharmaceutical sectors and was based in New York, London and
San Francisco. Before Goldman Sachs, Mr. Korenberg was a healthcare investment banker at Dillon, Read &amp; Co. Inc. where he spent two
years working with healthcare companies in the biotechnology and pharmaceutical sectors and industrial companies. Mr. Korenberg holds
a B.B.A. in Finance and Accounting from the University of Michigan.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr.
Korenberg&#8217;s financial and accounting expertise, his experience as chief financial officer of a large public biopharmaceutical company
and his investment banking background contributed to our board of directors&#8217; conclusion that he should serve as a director of our
company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Kurt
H. Kruger</b>. Mr. Kruger has enjoyed a 30-year career in medical technology. His deep involvement in the field has ranged from product
design and development as a biomedical engineer to raising capital for, and following, publicly traded medical product companies as an
equities research analyst. As a marketing manager at Guidant, now a part of Boston Scientific, he developed the launch plans for the
first-ever implantable defibrillator. As a securities analyst he showed perspicuity leading Hambrecht &amp; Quist in providing venture
funds for, and then taking public, Ventritex, which was later acquired by St. Jude Medical. After Hambrecht &amp; Quist, Mr. Kruger worked
as an analyst for Montgomery Securities and Bank of America. Across 20 years of research work, Mr. Kruger has overseen the IPOs of over
30 medical products companies, including leadership of the Life Sciences banking effort for WR Hambrecht &amp; Co. Mr. Kruger received
a Sc.B. degree in Biomedical Engineering from Brown University; a Master&#8217;s degree in Bioengineering from the University of Michigan;
and a business degree (S.M.) from the Sloan School at the Massachusetts Institute of Technology (MIT). He also completed the premedical
post-baccalaureate program at Columbia University.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr.
Kruger&#8217;s long experience in investment banking and securities analysis with a life sciences focus contributed to our board of directors&#8217;
conclusion that he should serve as a director of our company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Ira
E. Ritter.</b> Mr. Ritter served as Co-Founder, Chief Strategic Officer and Executive Chairman of our predecessor, Ritter Pharmaceuticals,
Inc., from its inception in 2004 through the formation of Ritter Pharmaceuticals, Inc. in 2008 and served in those positions with Ritter
Pharmaceuticals, Inc. from 2008 until the May 22, 2020 reverse recapitalization transaction (the &#8220;Reverse Recapitalization Transaction&#8221;)
in which Ritter Pharmaceuticals, Inc. changed its name to Qualigen Therapeutics, Inc. Mr. Ritter has extensive experience creating and
building diverse business enterprises and since 1987 through Andela Corporation, of which he is the CEO, has provided corporate management,
strategic planning and financial consulting for a wide range of market segments including; health product related national distribution
and private label production, television and publishing. He assisted taking Ritter Pharmaceuticals, Inc. public on Nasdaq and Martin
Lawrence Art Galleries public on the New York Stock Exchange. Since 2010, Mr. Ritter has also acted as a managing partner of Stonehenge
Partners, LLC. Mr. Ritter has a long history of public service that includes appointments by three Governors to several State of California
Commissions including eight years as Commissioner on the California Prison Industry Authority.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 73; Value: 71 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->73<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr.
Ritter&#8217;s experience as an entrepreneur and chairman of a publicly traded development-phase therapeutics company contributed to
our board of directors&#8217; conclusion that he should serve as a director of our company. Mr. Ritter continued his service on our board
of directors, by agreement in connection with the Reverse Recapitalization Transaction, as the designated legacy member from the pre-Reverse
Recapitalization Transaction public-company board of directors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Committees
of the Board of Directors</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
board of directors has established an Audit Committee, a Compensation Committee and a Nominating and Corporate Governance Committee.
Each committee operates under a charter. Copies of each committee&#8217;s charter are posted on the Investor Relations section of our
website, which is located at <i>www.qualigeninc.com</i>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Audit
Committee</i></b>. The current members of our Audit Committee are Mr. Kruger (Chair), Mr. Emery, and Mr. Korenberg, each of whom was
determined by our board of directors to be independent under Rule 10A-3 under the Exchange Act and the continued listing requirements
of Nasdaq, and to satisfy the other continued listing requirements of Nasdaq for audit committee membership. The Company has identified
Matthew Korenberg as an &#8220;audit committee financial expert&#8221; as such term is defined in Item 407(d)(5) of SEC Regulation S-K,
and has determined that he has the requisite level of financial sophistication required by the continued listing requirements of Nasdaq;
this identification does not constitute a determination that other members of the Audit Committee would not also be able to qualify as
an &#8220;audit committee financial expert.&#8221;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>EXECUTIVE
<span style="text-transform: uppercase">OFFICERS</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table sets forth information about our current executive officers.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Name</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Age</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Position
    with the Company</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Michael
    Poirier</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">67</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chairman
    and Chief Executive Officer</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amy
    Broidrick</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">64</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">President
    and Chief Strategy Officer</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Christopher
    Lotz</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">58</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Financial Officer, Vice President of Finance</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tariq
    Arshad</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">53</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Medical Officer and Senior Vice President</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Officers
serve at the discretion of the board of directors. There are no family relationships among any of our directors or executive officers.
There is no arrangement or understanding between any executive officer and any other person pursuant to which the executive officer was
selected.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 74; Value: 71 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->74<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the biographies of Mr. Poirier and Ms. Broidrick, please see &#8220;Board of Directors - The Board of Directors in General&#8221;.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Christopher
L. Lotz</b> | Chief Financial Officer, Vice President of Finance. Mr. Lotz joined Qualigen as Director of Finance in 2002 and was
promoted to his current role of Chief Financial Officer, Vice President of Finance in 2003. Before joining
Qualigen, Mr. Lotz spent the previous 15 years serving in financial leadership positions with Bexcom, an Asian-based software
developer, California Furniture Collections, Inc., a custom furniture manufacturer, and Group Publishing, Inc., an educational media
publisher. Mr. Lotz holds a B.S. in Business Administration from Colorado State University.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><b>Tariq Arshad, MD, MBA </b>|
Chief Medical Officer and Senior Vice President. <span style="background-color: white">Dr. Arshad brings more than 20 years of biotech
and pharmaceutical experience to Qualigen. He is an oncologist with expertise in both early and late-stage clinical development at several
leading and emergent biopharmaceutical companies. Prior to joining Qualigen in May 2021, </span>Dr. Arshad was Global Head of Medical
Affairs and Clinical Research with Becton Dickinson Biosciences <span style="background-color: white">in San Jose, California from 2019-2021,
where he led a team of MDs and PHDs driving scientific strategy for a cutting-edge immuno-oncology focused portfolio. From 2018-2019,
Dr. Arshad served as</span> Head of Medical Affairs, Immunology, Global Markets for Sanofi Genyzyme, and Chief Medical Officer, Head of
Clinical Research and Medical Affairs for Humanigen, Inc. from 2016-2018. Prior to that, he held leadership positions with XOMA Corporation,
Genentech, Inc., Merck &amp; Co., Inc., and Pfizer Inc. Dr. Arshad <span style="background-color: white">holds a M.B.B.S (Bachelor of
Medicine, Bachelor of Surgery) from University of Punjab, MD from Educational Commission for Foreign Medical Graduates (ECFMG), and a
M.B.A. degree from George Washington University.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><b>Delinquent
Section 16(a) Reports</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
16(a) of the Exchange Act requires the Company&#8217;s officers and directors, and persons who own more than 10% of our common stock,
to file reports of securities ownership and changes in such ownership with the SEC. Officers, directors, and greater than 10% stockholders
also are required by SEC rules to furnish the Company with copies of all Section 16(a) forms they file.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
solely on the Company&#8217;s review of Forms 3, 4 and 5 filed by such persons and information provided by the Company&#8217;s directors
and officers, the Company believes that during the year ended December 31, 2022, all Section 16(a) filing requirements applicable to
such persons were met in a timely manner, except as described below.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
of Michael Poirier, Amy Broidrick, Christopher Lotz, Shishir Sinha, Wajdi Abdul-Ahad, Tariq Arshad, Richard David, Sidney Emery, Jr.,
Matthew Korenberg, Kurt Kruger and Ira Ritter filed one late Form 4 report with respect to a grant of stock options that each of them
received on July 11, 2022 as follows: Michael Poirier (37,000 options), Amy Broidrick (130,000 options), Christopher Lotz (100,000 options),
Shishir Sinha (100,000 options), Wajdi Abdul-Ahad (80,000 options), Tariq Arshad (102,000 options), Richard David (40,000 options), Sidney
Emery (40,000 options), Jr., Matthew Korenberg (40,000 options), Kurt Kruger (40,000 options) and Ira Ritter (40,000 options).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="ax_001"></span>Item
11. Executive Compensation.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 58.5pt; text-align: justify; text-indent: -58.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>EXECUTIVE
AND DIRECTOR COMPENSATION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Summary
Compensation Table (2022 and 2021)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table sets forth the compensation paid to or earned by our named executive officers for the periods presented.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid">Name and Principal Position</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">&#8220;Year&#8221;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Salary <br /> ($)</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Bonus <br /> ($)</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Option Awards<sup>(1)</sup><br /> ($)</span></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All Other Compensation<sup>(2)</sup><br /> ($)</span></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Total <br /> ($)</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; text-align: left">Michael Poirier, Chairman and Chief Executive Officer</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 6%; text-align: right">2022</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 6%; text-align: right">575,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 6%; text-align: right">&#8212;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 6%; text-align: right">145,274</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 6%; text-align: right">8,180</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 6%; text-align: right">728,454</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2021</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">517,788</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">218,740</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,751</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">742,279</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Amy Broidrick, President and Chief Strategy Officer</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2022</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">450,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">50,359</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7,642</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">508,001</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2021</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">403,077</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">155,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">296,170</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,055</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">858,302</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tariq Arshad, Chief Medical Officer and Senior Vice President <sup>(3)</sup></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2022</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">400,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">39,512</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">138</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">439,650</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2021</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">253,846</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">80,212</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">430,569</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">69</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">764,696</td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.35in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            amounts reported in this column reflect the aggregate grant date fair value of the option
                                            awards granted during 2022 and 2021, computed in accordance with Financial Accounting Standard
                                            Board Accounting Standards Codification Topic 718 for stock-based compensation transactions
                                            (&#8220;ASC 718&#8221;). Such grant date fair values do not take into account any estimated
                                            forfeitures related to service-based vesting conditions. Assumptions used in the calculation
                                            of these amounts are included in the notes to our consolidated financial statements included
                                            in this Annual Report. These amounts do not reflect the actual economic value that may be
                                            realized by the executive officers upon the exercise of the stock options or the sale of
                                            the common stock underlying such stock options.</span></td></tr></table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<p style="margin-top: 0; margin-bottom: 0"></p>

<!-- Field: Page; Sequence: 75; Value: 71 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->75<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="margin-top: 0; margin-bottom: 0"></p>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.35in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>
                                                                                <p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></p></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Represents
                                            life insurance premiums paid by us for each named executive officer in addition to 401(k)
                                            matching contributions paid by us for Mr. Poirier and Ms. Broidrick.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.35in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr.
                                            Arshad joined Qualigen in May 2021.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Executive
Employment Agreements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Employment
Agreement with Michael Poirier</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr.
Poirier, is party to an Executive Employment Agreement with Qualigen dated February 1, 2017, as amended January 9, 2018 (the
&#8220;Poirier Employment Agreement&#8221;). The Poirier Employment Agreement had an initial three-year term and is now
automatically renewed for successive one-year periods unless either party gives notice of nonrenewal at least 90 days before the end
of such a one-year period.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the terms of the Poirier Employment Agreement, Mr. Poirier is entitled to an annual base salary of at least $315,000, is eligible to
participate in the Company&#8217;s bonus plans, benefit programs and medical benefits, is eligible for certain event-based bonuses
(including for &#8220;Liquidity Event&#8221; acquisition transactions), and is entitled to four weeks of vacation per year. If Mr.
Poirier&#8217;s employment is terminated without Cause or he resigns for Good Reason (as such terms are defined in the Poirier
Employment Agreement), and he provides a general release to the Company, he will be entitled to one year of salary continuation plus the
cost of COBRA coverage continuation for such one year period. In May 2021, our board of directors and its compensation committee
increased Mr. Poirier&#8217;s annual base salary to $575,000. On January 13, 2023, the Company&#8217;s board of directors, as part
of certain cost-cutting measures, approved a temporary 20% reduction to the base salaries of all executive officers of the Company.
Accordingly, on January 16, 2023, Mr. Poirier&#8217;s base salary was reduced to $460,000.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Employment
Agreement with Amy Broidrick</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon
her promotion to the position of President and Chief Strategy Officer in December 2021, Ms. Broidrick is party to an Executive
Employment Agreement with Qualigen dated December 10, 2021 (the &#8220;Broidrick Employment Agreement&#8221;). The Broidrick
Employment Agreement had an initial term expiring on April 30, 2022 and is now automatically renewed for successive one-year periods
unless either party gives notice of nonrenewal at least 90 days before the end of such a one-year period.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the terms of The Broidrick Employment Agreement, Ms. Broidrick is entitled to an annual base salary of at least $450,000, is
eligible to participate in the Company&#8217;s bonus plans, benefit programs and medical benefits, is eligible for certain
event-based bonuses, and is entitled to four weeks of vacation per year. If Ms. Broidrick&#8217;s employment is terminated without
Cause or she resigns for Good Reason (as such terms are defined in the Broidrick Employment Agreement), and she provides a general
release to the Company, she will be entitled to one year of salary continuation plus the cost of COBRA coverage continuation for
such one year period. On January 13, 2023, the Company&#8217;s board of directors, as part of certain cost-cutting measures,
approved a temporary 20% reduction to the base salaries of all executive officers of the Company. Accordingly, on January 16, 2023,
Ms. Broidrick&#8217;s base salary was reduced to $360,000.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following definitions are used in each of the Employment Agreements described above:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;Cause&#8221;
means any of the following: (i) a material breach by the employee of any of the trade secret/proprietary information, confidential information
of intellectual property ownership sections of the Employment Agreement; (ii) a material breach by the employee of any other provision
of the Employment Agreement, if such material breach (if susceptible to cure) has continued uncured for a period of at least 15 days
following delivery by Qualigen to the employee of written notice of such material breach; (iii) fraud, dishonesty or other breach of
trust whereby the employee obtains personal gain or benefit at the expense of or to the detriment of Qualigen or any of Qualigen&#8217;s
subsidiaries or affiliates; (iv) a conviction of or plea of nolo contendere or similar plea by the employee of any felony; (v) a conviction
of or plea of nolo contendere or similar plea by of any other crime involving theft, misappropriation of property, dishonesty or moral
turpitude; (vi) a willful and material violation of applicable law by the employee in connection with the performance of his/her duties
under the Employment Agreement; (vii) chronic or repeated substance abuse by the employee, or any other use by the employee of alcohol,
drugs or illegal substances in such a manner as to interfere with the performance of his/her material duties hereunder; or (viii) failure
to comply with the lawful directions of Qualigen&#8217;s board of directors which are otherwise consistent with the terms of this Agreement,
which failure has continued for a period of at least 10 days after delivery by Qualigen to the employee of written demand by Qualigen&#8217;s
board of directors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 76; Value: 71 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->76<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;Good
Reason&#8221; means the occurrence of any of the following circumstances, without the employee&#8217;s express consent: the employee
resigns due to (i) a material reduction of the employee&#8217;s title or authority, (ii) a material reduction in the employee&#8217;s
salary or benefits (other than a reduction that generally applies to the officers at the employee&#8217;s level in Qualigen or, as applicable,
after a transaction in which Qualigen or substantially all its assets is acquired, in the successor entity at that time), (iii) any material
breach of this Agreement by Qualigen which is not cured within 30 days after written notice by the employee; or (iv) a change of the
principal non-temporary location in which the employee is required to perform the employee&#8217;s services to any location exceeding
35 miles from Carlsbad, California. In no event shall a resignation be considered to be with Good Reason unless the resignation occurs
after but within 30 days after the initiation of the item of Good Reason.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
foregoing description of the employment agreements does not purport to be complete and is qualified in its entirety by reference to the
employment agreements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>
Offer Letter with Tariq Arshad</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">Under the terms of his offer letter
with the Company, dated May 17, 2021, Dr. Arshad is entitled to an annual base salary of at least $400,000. He received a cash signing
bonus of $25,000 when he joined the Company, is eligible to receive annual cash bonuses equal to an amount up to 40% of his annualized
base salary, and is entitled to four weeks of vacation per year.  Under the terms of his offer letter, if Dr. Arshad&#8217;s employment is terminated without Cause or he resigns for Good
Reason, and he provides a general release to the Company, he will be entitled to 180
days of salary continuation plus the cost of COBRA coverage continuation for such 180 day period. On January 13, 2023, the Company&#8217;s
board of directors, as part of certain cost-cutting measures, approved a temporary 20% reduction to the base salaries of all executive
officers of the Company. Accordingly, on January 16, 2023, Mr. Arshad&#8217;s annual base salary was reduced to $320,000.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Stock
Incentive Plan</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
material terms of our 2020 Stock Equity Incentive Plan (as amended, the &#8220;2020 Plan&#8221;) are outlined below. This summary is
qualified in its entirety by reference to the complete text of the 2020 Plan, which is filed as an exhibit to the Original Report and
incorporated herein by reference.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Authorized
Shares</i>. We have reserved an aggregate of 755,702 shares of our common stock for issuance under the 2020 Plan. The number of shares
is subject to adjustment in the event of any recapitalization, stock split, reclassification, stock dividend or other change in our capitalization.
In addition, the following shares of our common stock will be available for grant and issuance under the 2020 Plan:</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 6pt; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.35in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.35in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares
                                            subject to stock options or stock appreciation rights (&#8220;SARs&#8221;), granted under
                                            the 2020 Plan that cease to be subject to the stock option or SAR for any reason other than
                                            exercise of the stock option or SAR;</span></td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 6pt; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.35in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.35in">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares
                                            subject to awards granted under the 2020 Plan that are subsequently forfeited or repurchased
                                            by us at the original issue price;</span></td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 6pt; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.35in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.35in">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares
                                            subject to awards granted under the 2020 Plan that otherwise terminate without shares being
                                            issued;</span></td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 6pt; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.35in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.35in">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares
                                            surrendered, canceled, or exchanged for cash or a different award (or combination thereof);
                                            and</span></td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 6pt; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.35in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.35in">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares
                                            subject to awards under the 2020 Plan that are used to pay the exercise price of an award
                                            or withheld to satisfy the tax withholding obligations related to any award.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 77; Value: 71 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->77<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Plan
Administration</i>. The 2020 Plan will be administered by our Compensation Committee or by our board of directors acting in place of
our Compensation Committee. Our Compensation Committee will have the authority to construe and interpret the 2020 Plan, grant awards
and make all other determinations necessary or advisable for the administration of the 2020 Plan.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Awards
and Eligible Participants</i>. The 2020 Plan authorizes the award of stock options, stock appreciation rights, restricted stock unit,
performance awards and stock bonuses. The 2020 Plan provides for the grant of awards to our employees, directors, consultants and independent
contractor service providers, subject to certain exceptions. No non-employee director may be granted awards under the 2020 Plan in any
calendar year that, taken together with any cash fees paid by us to such non-employee director during such calendar year, exceed $5,000,000
(calculating the value of any award based on the grant date fair value determined in accordance with GAAP). No more than 98,000,000 shares
of our common stock will be issued under the 2020 Plan pursuant to the exercise of incentive stock options.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Stock
Options</i>. The 2020 Plan permits us to grant incentive stock options and non-qualified stock options. The exercise price of stock options
will be determined by our Compensation Committee, and may not be less than 100% of the fair market value of our common stock on the date
of grant. Our Compensation Committee has the authority to reprice any outstanding stock option (by reducing the exercise price, or canceling
the stock option in exchange for cash or another equity award) under the 2020 Plan without the approval of our stockholders. Stock options
may vest based on the passage of time or the achievement of performance conditions in the discretion of our compensation committee. Our
Compensation Committee may provide for stock options to be exercised only as they vest or to be immediately exercisable with any shares
issued on exercise being subject to our right of repurchase that lapses as the shares vest. The maximum term of stock options granted
under the 2020 Plan is 10 years.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Stock
Appreciation Rights</i>. SARs provide for a payment to the holder, in cash or shares of our common stock, based upon the difference between
the fair market value of our common stock on the date of exercise and the stated exercise price on the date of grant, up to a maximum
amount of cash or number of shares. SARs may vest based on the passage of time or the achievement of performance conditions in the discretion
of our Compensation Committee. Our Compensation Committee has the authority to reprice any outstanding SAR (by reducing the exercise
price, or canceling the SAR in exchange for cash or another equity award) under the 2020 Plan without the approval of our stockholders.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Restricted
Stock Awards</i>. A restricted stock award represents the issuance to the holder of shares of our common stock, subject to the forfeiture
of those shares in the event of failure to achieve certain performance conditions or termination of employment. The purchase price, if
any, for the shares will be determined by our Compensation Committee. Unless otherwise determined by the administrator at the time of
award, vesting will cease on the date the holder no longer provides services to us and unvested shares will be forfeited to us or can
be repurchased by us.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Restricted
Stock Units</i>. Restricted stock units (&#8220;RSUs&#8221;) represent the right on the part of the holder to receive shares of our common
stock at a specified date in the future, subject to forfeiture of that right in the event of failure to achieve certain performance conditions
or termination of employment. If a RSU has not been forfeited, then, on the specified date, we will deliver to the holder of the RSU
shares of our common stock, cash or a combination of cash and shares of our common stock, as previously determined by the Compensation
Committee at the time of the award.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Performance
Awards</i>. Performance awards cover a number of shares of our common stock that may be settled upon achievement of performance conditions
as provided in the 2020 Plan in cash or by issuance of the underlying common stock. These awards are subject to forfeiture before settlement
in the event of failure to achieve certain performance conditions or termination of employment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Stock
Bonuses</i>. Stock bonuses may be granted as additional compensation for past or future service or performance and, therefore, no payment
will be required from a participant for any shares awarded under a stock bonus. Unless otherwise determined by our Compensation Committee
at the time of award, vesting will cease on the date the holder no longer provides services to us and unvested shares will be forfeited
to us.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 78; Value: 71 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->78<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Change-in-Control</i>.
If we are party to a merger or consolidation, sale of all or substantially all our assets or similar change-in-control transaction, outstanding
awards, including any vesting provisions, may be assumed or substituted by the successor company. In the alternative, the successor company
may issue, in place of outstanding shares held by a 2020 Plan participant, substantially similar shares or other property subject to
repurchase obligations no less favorable to the participant. Outstanding awards that are not assumed, substituted or cashed out will
accelerate in full and expire immediately before the transaction, and awards will be exercisable for a period of time determined by the
administrator.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Amendment;
Termination</i>. The 2020 Plan will terminate 10 years from April 8, 2020, unless it is terminated earlier by our board of directors.
Our board of directors may amend, suspend or terminate the 2020 Plan at any time, subject to compliance with applicable law.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Federal
Income Tax Summary</i>. The following is a brief summary of the principal federal income tax consequences to us and to an eligible person
(who is a citizen or resident of the United States for U.S. federal income tax purposes) (a &#8220;Participant&#8221;) of awards that
may be granted under the 2020 Plan. The summary is not intended to be exhaustive and, among other things, does not describe state, local
or foreign tax consequences. The federal income tax consequences of an eligible person&#8217;s award under the 2020 Plan are complex,
are subject to change and differ from person to person. Each person should consult with his or her own tax adviser as to his or her own
particular situation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 58.5pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
discussion is based on the Code, Treasury Regulations promulgated under the Code, Internal Revenue Service rulings, judicial decisions
and administrative rulings as of the date of this proxy statement, all of which are subject to change or differing interpretations, including
changes and interpretations with retroactive effect. No assurance can be given that the tax treatment described herein will remain unchanged
at the time that awards under the 2020 Plan are made.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
Participant will not recognize income upon the grant of an option or at any time prior to the exercise of the option. At the time the
participant exercises a non-qualified option, he or she will recognize compensation taxable as ordinary income in an amount equal to
the excess of the fair market value of the common stock on the date the option is exercised over the price paid for the common stock,
and we will then be entitled to a corresponding deduction.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
Participant who exercises an incentive stock option will not be taxed at the time he or she exercises his or her options or a portion
thereof. Instead, he or she will be taxed at the time he or she sells the common stock purchased pursuant to the option. The Participant
will be taxed on the excess of the amount for which he or she sells the stock over the price he or she had paid for the stock. If the
Participant does not sell the stock prior to two years from the date of grant of the option and one year from the date the stock is transferred
to him or her upon exercise, the gain will be capital gain and we will not get a corresponding deduction. If the Participant sells the
stock at a gain prior to that time, the difference between the amount the Participant paid for the stock and the lesser of the fair market
value on the date of the exercise or the amount for which the stock is sold, will be taxed as ordinary income and we will be entitled
to a corresponding deduction. If the Participant sells the stock for less than the amount he or she paid for the stock prior to the one
or two year periods indicated, no amount will be taxed as ordinary income and the loss will be taxed as a capital loss.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
Participant generally will not recognize income upon the grant of a stock appreciation right or a restricted stock unit. At the time
a Participant receives shares or cash payment under any such award, he or she generally will recognize compensation taxable as ordinary
income in an amount equal to the cash or the fair market value of the common stock received, less any amount paid for the stock, and
we will then be entitled to a corresponding deduction. Upon a subsequent sale of the shares received under the stock appreciation right
or restricted stock unit, if any, the difference between the amount realized on the sale and the Participant&#8217;s tax basis (the amount
previously included in income) is generally taxable as a capital gain or loss, which will be short-term or long-term depending on the
Participant&#8217;s holding time of such shares.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 79; Value: 71 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->79<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
taxation of restricted stock is dependent on the actions taken by the Participant. Generally, absent an election to be taxed currently
under Section 83(b) of the Code, or an 83(b) election, there will be no federal income tax consequences to the Participant upon the grant
of a restricted stock award. At the lapse of the restrictions or satisfaction of the conditions on the restricted stock, the Participant
will recognize ordinary income equal to the fair market value of our common stock at that time. If the Participant makes an 83(b) election
within 30 days of the date of grant, he or she will recognize ordinary income equal to the fair market value of our common stock at the
time of grant, determined without regard to the applicable restrictions. If an 83(b) election is made, no additional income will be recognized
by the Participant upon the lapse of the restrictions or satisfaction of the conditions on the restricted stock award. We generally should
be entitled to a deduction equal to the amount of ordinary income recognized by the Participant, at the same time as the ordinary income
is recognized by the Participant. Upon a subsequent sale of the formerly restricted stock, the difference between the amount realized
on the sale and the Participant&#8217;s tax basis (the amount previously included in income) is generally taxable as a capital gain or
loss, which will be short-term or long-term depending on the Participant&#8217;s holding time of such shares.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
tax consequences to Participants who receive performance-based awards depend on the particular type of award issued. Our ability to take
a deduction for such awards similarly depends on the terms of the awards and the limitations of Section 162(m) of the Code, if applicable<b>.
</b>Section 162(m) of the Code currently imposes a $1 million limit on the amount that a public company may deduct for compensation paid
to an employee who is chief executive officer, chief financial officer, or another &#8220;covered employee&#8221; (as defined by Section
162(m)), or was such an employee beginning in any year after 2017. The Compensation Committee retains the discretion to establish the
compensation paid or intended to be paid or awarded to the executive officers as the Compensation Committee may determine is in the best
interest of us and our stockholders, and without regard to any limitation provided in Section 162(m). This discretion is an important
feature of the Compensation Committee&#8217;s compensation practices because it provides the Compensation Committee with sufficient flexibility
to respond to specific circumstances facing us.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Outstanding
Equity Awards at December 31, 2022</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table presents the outstanding stock options and compensatory warrants held by each of the named executive officers as of December
31, 2022. There were no direct stock awards, restricted stock units or stock appreciation rights outstanding at December 31, 2022. All
pre-2020 &#8220;option&#8221; awards shown were initially issued as Qualigen, Inc. Series C Warrants, and became warrants exercisable
instead for our common stock (at an adjusted exercise price) upon the Reverse Recapitalization Transaction. The share numbers and exercise
prices in the table below reflect the reverse stock split, which was effected by the Company on November 23, 2022 (the &#8220;Reverse
Stock Split&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="15" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Equity Awards</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold">Name</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Grant<br /> Date</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of<br /> Securities<br /> Underlying<br /> Unexercised<br /> Awards<br /> (#)<br /> Exercisable</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of<br /> Securities<br /> Underlying<br /> Unexercised<br /> Awards<br /> (#)<br /> Unexercisable</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Exercise<br /> Price<br /> ($)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Expiration<br /> Date</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 22%; text-align: left">Michael Poirier</td><td style="width: 2%">&#160;</td>
    <td style="width: 14%; text-align: right">7/11/2022</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right">&#8212;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right">37,500</td><td style="width: 1%; text-align: left">(1)</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 11%; text-align: right">5.14</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 13%; text-align: right">7/11/2032</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: right">6/5/2020</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">66,667</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">33,333</td><td style="text-align: left">(1)</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">51.30</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: right">6/5/2030</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: right">9/22/2016</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,443</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">25.41</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: right">9/22/2026</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: right">3/3/2015</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,214</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">25.41</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: right">3/2/2025</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: right"><p style="margin: 0">8/2/2014</p></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><p style="margin: 0">770</p></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><p style="margin: 0">&#8212;</p></td><td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><p style="margin: 0">20.66</p></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: right"><p style="margin: 0">8/2/2024</p></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: right">8/2/2014</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,214</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">20.66</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: right">8/2/2024</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: right">1/31/2014</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,214</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">20.66</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: right">1/31/2024</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: right">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: right">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Amy Broidrick</td><td>&#160;</td>
    <td style="text-align: right">7/11/2022</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">13,000</td><td style="text-align: left">(1)</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5.14</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: right">7/11/2032</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: right">12/8/2021</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">10,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">20,000</td><td style="text-align: left">(1)</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">12.40</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: right">12/8/2031</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: right">12/7/2020</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">10,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,000</td><td style="text-align: left">(1)</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">35.20</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: right">12/7/2030</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: right">8/27/2020</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,333</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,666</td><td style="text-align: left">(1)</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">47.00</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: right">8/27/2030</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Tariq Arshad</td><td>&#160;</td>
    <td style="text-align: right">7/11/2022</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">10,200</td><td style="text-align: left">(1)</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5.14</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: right">7/11/2032</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: right">12/8/2021</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><p style="margin: 0">10,000</p></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">20,000</td><td style="text-align: left">(2)</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">12.40</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: right">5/17/2031</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: right">5/17/2021</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,333</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6,666</td><td style="text-align: left">(1)</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">18.00</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: right">5/17/2031</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.35in"></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.35in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shares
                                            underlying the stock option vest over three years in three equal annual installments from
                                            the date of grant.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shares
                                            underlying the stock option vest over three years in three equal annual installments from
                                            the vesting commencement date of May 17, 2021.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>

<!-- Field: Page; Sequence: 80; Value: 71 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->80<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Pay
Versus Performance (PVP)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
accordance with the SEC&#8217;s disclosure requirements regarding pay versus performance, or PVP, this section presents the SEC-defined
&#8220;Compensation Actually Paid,&#8221; or CAP of our PEO and NEOs for each of the fiscal years ended December 31, 2022 and 2021, and
our financial performance. Also as required by the SEC, this section compares CAP to various measures used to gauge performance at the
Company for each such fiscal year.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Pay
versus Performance Table - Compensation Definitions</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Salary,
Bonus, Stock Awards, and All Other Compensation are each calculated in the same manner for purposes of both CAP and Summary Compensation
Table, or SCT values. The primary difference between the calculation of CAP and SCT total compensation is the calculation of the value
of &#8220;Stock Awards,&#8221; with the table below describing the differences in how these awards are valued for purposes of SCT total
and CAP:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 6%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 2%">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 30%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SCT
    Total</b></span></td>
    <td style="width: 2%">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 60%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CAP</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CFF0FC">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock
    Awards</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Grant
    date fair value of stock awards granted during the year</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fair
    value of stock awards that are unvested as of the end of the year, or vested during the year</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Pa</i></b><span style="font-weight: normal">y
</span><b><i>Versus Performance Table</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
accordance with the SEC&#8217;s new PVP rules, the following table sets forth information concerning the compensation of our NEOs for
each of the fiscal years ended December 31, 2022 and 2021, and our financial performance for each such fiscal year:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Year</td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Summary Compensation Table Total for PEO</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Compensation Actually Paid to PEO</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Average Summary Compensation Table Total for non-PEO named Executive Officers</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Average Compensation Actually Paid to non-PEO Named Executive Officers</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><b>Value of Initial Fixed $100 Investment Based On Total Shareholder Return</b></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Net Loss Attributable to Qualigen
    Therapeutics, Inc. (millions)</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%; text-align: right">2022</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right">728,454</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 11%; text-align: right">262,274</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 11%; text-align: right">473,826</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 11%; text-align: right">121,235</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="text-align: right; width: 11%"><p style="margin: 0">4.29</p></td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 11%; text-align: right">(18.6</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td style="text-align: right">2021</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">742,279</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(753,431</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">811,499</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">609,691</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">38.21</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(17.9</td><td style="text-align: left">)</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 81; Value: 71 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->81<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The principal executive officer
(&#8220;PEO&#8221;) in 2022 and 2021 is Michael Poirier, our Chairman and Chief Executive Officer. The Non-PEO NEOs in 2022 and 2021 are
Amy Broidrick, our President, Chief Strategy and Operating Officer and Tariq Arshad, our Chief Medical Officer and Senior Vice President.
The CAP was calculated beginning with the NEOs SCT total. The following amounts were deducted from and added to the applicable SCT total
compensation:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">SCT Total</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Stock awards deducted from SCT</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Increase for fair value of awards granted during the year that remain unvested as of year end</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Decrease in fair value from prior year-end to current year-end for awards granted in prior years and unvested as of year end</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Decrease in fair value from prior year-end to current year vesting date for awards granted in prior years</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="text-align: center"><b>Total CAP</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">(A)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">(B)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">(C )</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">(D)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">(E )</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><b>A -B+C+D+E</b></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-style: italic">PEO</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 40%">2022</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 6%; text-align: right">728,454</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 6%; text-align: right"><p style="margin: 0">(145,274</p></td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 6%; text-align: right"><p style="margin: 0">31,387</p></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 6%; text-align: right"><p style="margin: 0">(218,695</p></td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 6%; text-align: right"><p style="margin: 0">(133,598</p></td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="text-align: right; width: 6%">262,274</td>
    <td style="width: 1%">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>2021</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">742,279</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><p style="margin: 0">-</p></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><p style="margin: 0">-</p></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><p style="margin: 0">(1,236,534</p></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><p style="margin: 0">(259,176</p></td><td style="text-align: left">)</td><td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">(753,431</td>
    <td>)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-style: italic">Average Non-PEO NEO</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>2022</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">473,826</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><p style="margin: 0">(44,936</p></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><p style="margin: 0">9,709</p></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><p style="margin: 0">(218,541</p></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><p style="margin: 0">(98,823</p></td><td style="text-align: left">)</td><td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">121,235</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>2021</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">811,499</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><p style="margin: 0">(363,370</p></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><p style="margin: 0">314,858</p></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><p style="margin: 0">(104,300</p></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><p style="margin: 0">(48,997</p></td><td style="text-align: left">)</td><td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">609,691</td>
    <td>&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
fair value of stock options reported for CAP purposes in columns (B), (C), (D) and (E) above was estimated using a Black-Scholes option
pricing model for the purposes of this PVP calculation in accordance with SEC rules. This model uses both historical data and current
market data to estimate the fair value of options and requires several assumptions. The assumptions used in estimating fair value for
awards granted during 2022 were as follows: volatility 103%, expected life 5.99 years, expected dividend yield 0%, risk-free rate 3.04%.
The assumptions used in estimating fair value for awards granted during 2021 and prior were as follows: volatility 102%, expected life
5.99 years, expected dividend yield 0%, risk-free rate 0.42% - 1.43%.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Analysis
of Information Presented in the Pay versus Performance Table</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s executive compensation program reflects a variable pay-for-performance philosophy. While the Company utilizes several
performance measures to align executive compensation with Company performance, all of those Company measures are not presented in the
Pay versus Performance table. Moreover, the Company generally seeks to incentivize long-term performance, and therefore does not specifically
align the Company&#8217;s performance measures with compensation that is actually paid (as computed in accordance with SEC rules) for
a particular year. In accordance with SEC rules, the Company is providing the following narrative disclosure regarding the relationships
between information presented in the Pay versus Performance table.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">Compensation
Actually Paid and Cumulative Total Stockholder Return</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
2021 and 2022, compensation actually paid to our PEO increased from ($753,431) in 2021 to $262,274 in 2022 for Mr. Poirier, and average
compensation actually paid to our named executive officers other than our PEO decreased from $609,691 in 2021 to $121,235 in 2022. Over
the same period, the value of an investment of $100 in our common stock on the last trading day of 2020 decreased by $61.79 to $38.21
during 2021, and further decreased by $34.12 to $4.09 during 2022, for a total decrease over 2021 and 2022 of $95.91.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">Compensation
Actually Paid and Net Loss</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
2021 and 2022, compensation actually paid to our PEO increased from ($753,431) in 2021 to $262,274 in 2022 for Mr. Poirier, and average
compensation actually paid to our named executive officers other than our PEO decreased from $609,691 in 2021 to $121,235 in 2022. Over
the same period, our net loss decreased by $1.6 million during 2021 (from a net loss in 2020 of $19.5 million to a net loss in 2021 of
$17.9 million), and increased by $0.7 million during 2022 (from a net loss in 2021 of $17.9 million to a net loss in 2022 of $18.6 million).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Compensation
of Directors</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
2022<span style="text-transform: uppercase">, </span>our non-employee directors received $35,000 in cash for their services. The Audit
Committee chair received additional cash compensation of $15,000 and the other Board committee chairs received additional cash compensation
of $10,000. Each non-chair member of each Board committee received additional cash compensation of $7,500 (Audit Committee) and $5,000
(other Committees). Non-employee directors each received a grant of 4,000 stock options (adjusted for the Reverse Stock Split) during
2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">On January 13, 2023, the Company&#8217;s
board of directors, as part of certain cost-cutting measures, approved a temporary 20% reduction to the compensation of all directors
of the Company effective January 1, 2023.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Compensation
paid to Mr. Poirier and to Ms. Broidrick is presented as part of the &#8220;Summary Compensation Table&#8221; above, rather than here.
Our employee directors do not receive compensation for their service as directors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid">Name of Director</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Fees Earned and<br /> Paid in Cash<br /> ($)</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Option<br /> Awards<sup>(1)</sup><br /> ($)</span></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All other compensation<sup>(2)</sup><br /> ($)</span></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Total<br /> ($)</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; text-align: left">Richard David</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 11%; text-align: right">54,167</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 11%; text-align: right">15,496</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 11%; text-align: right">&#8212;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 11%; text-align: right">69,663</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Sidney Emery, Jr.</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">62,292</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">15,496</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">77,788</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Matthew Korenberg</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">56,875</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">15,496</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">72,371</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Kurt Kruger</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">54,167</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">15,496</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">69,663</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Ira Ritter</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">15,496</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">80,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">95,496</td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 6pt; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.35in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.35in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            amounts reported in this column reflects the aggregate grant date fair value of the option
                                            awards granted during the year ending December 31, 2022, computed in accordance with ASC
                                            718. Such grant date fair values do not take into account any estimated forfeitures related
                                            to service-based vesting conditions. Assumptions used in the calculation of these amounts
                                            are included in the notes to our consolidated financial statements included in our Annual
                                            Report on Form 10-K filed with the Securities and Exchange Commission on April 17, 2023.
                                            These amounts do not reflect the actual economic value that may be realized by the directors
                                            upon the exercise of the stock options or the sale of the common stock underlying such stock
                                            options.</span></td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 6pt; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.35in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.35in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Represents
                                            amounts paid for consulting services.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 82; Value: 71 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->82<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Hedging
or Offsetting Against Compensatory Securities</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have adopted a policy that our employees (including officers) and directors shall not purchase securities or other financial instruments,
or otherwise engage in transactions, that hedge or offset, or are designed to hedge or offset, any decrease in the market value of equity
securities granted as compensation to, or held directly or indirectly by, those persons.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
also intend to adopt a formal claw-back policy for the recovery of incentive-based executive compensation erroneously awarded to executive
officers based on misstated financial reporting measures once Nasdaq&#8217;s listing standards become effective.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="ax_002"></span>Item
12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: -58.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table sets forth certain information regarding the beneficial ownership of our common stock as of April 28, 2023 by:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 48.95pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
our named executive officers;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 48.95pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
our directors;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 48.95pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
all of our current directors and executive officers as a group; and</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 48.95pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
each stockholder known by us to own beneficially more than 5% of our common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Beneficial
ownership is determined in accordance with the rules of the SEC and includes voting or investment power with respect to the securities.
Shares of common stock that may be acquired by an individual or group within 60 days after April 28, 2023, pursuant to the exercise of
options or warrants, are deemed to be outstanding for the purpose of computing the percentage ownership of such individual or group,
but are not deemed to be outstanding for the purpose of computing the percentage ownership of any other person shown in the table. The
percentage of beneficial ownership of our common stock is calculated based on an aggregate of 5,052,463 shares outstanding as of April
28, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Except
as indicated in the footnotes to this table, we believe that the stockholders named in this table have sole voting and investment
power with respect to all shares of common stock shown to be beneficially owned by them, based on information provided to us by such
stockholders. Unless otherwise indicated, the address for each director and executive officer listed is: c/o Qualigen Therapeutics,
Inc., 2042 Corte Del Nogal, Carlsbad, California 92011 USA.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 83; Value: 71 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->83<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Beneficial Owner</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of Shares <br /> Beneficially Owned</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Percentage of <br /> Common Stock <br /> Beneficially Owned</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; font-style: italic; text-align: left">Five Percent Stockholders</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; width: 64%; text-align: left">Alpha Capital Anstalt (1)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right">555,155</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right">9.99</td><td style="width: 1%; text-align: left">%</td>
    </tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; font-style: italic; text-align: left">Executive Officers, Directors and Director Nominees</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Michael Poirier (2)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">96,543</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1.9</td><td style="text-align: left">%</td>
    </tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Amy Broidrick (3)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">26,784</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*%</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Tariq Arshad (4)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">13,334</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*%</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Richard David (5)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,219</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*%</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Sidney Emery, Jr. (6)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,302</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*%</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Matthew Korenberg (7)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,334</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*%</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Kurt Kruger (8)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6,019</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*%</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Ira Ritter (9)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,738</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*%</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">All current executive officers and directors as a group (9 persons)(10)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">208,293</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4.0</td><td style="text-align: left">%</td>
    </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*
Represents beneficial ownership of less than 1% of the shares of common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 24.45pt"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Includes
                                            shares of common stock issuable upon the exercise of warrants; Alpha Capital Anstalt would
                                            not be permitted to convert or exercise all or any portion of its warrants to the extent
                                            that such conversion or exercise would result in Alpha Capital Anstalt (and its affiliates)
                                            beneficially owning more than 9.99% of the number of shares of Qualigen common stock outstanding
                                            immediately after giving effect to the issuance of shares of common stock issuable upon conversion/exercise.
                                            Konrad Ackermann has voting and investment power over the shares held by Alpha Capital Anstalt.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Includes
                                            66,667 shares of common stock exercisable within 60 days under outstanding stock options
                                            and 8,855 shares of common stock exercisable within 60 days under outstanding warrants.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Includes
                                            23,334 shares of common stock exercisable within 60 days under outstanding stock options.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Includes
                                            13,334 shares of common stock exercisable within 60 days under outstanding stock options.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Includes
                                            3,334 shares of common stock exercisable within 60 days under outstanding stock options and
                                            885 shares of common stock exercisable within 60 days under outstanding warrants.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(6)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Includes
                                            3,334 shares of common stock exercisable within 60 days under outstanding stock options.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(7)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Includes
                                            3,334 shares of common stock exercisable within 60 days under outstanding stock options.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(8)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Includes
                                            3,334 shares of common stock exercisable within 60 days under outstanding stock options and
                                            885 shares of common stock exercisable within 60 days under outstanding warrants.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(9)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Includes
                                            3,334 shares of common stock exercisable within 60 days under outstanding stock options.
                                            Also includes shares of common stock held in a retirement plan trust of which Ira Ritter
                                            and his spouse are trustees; and also includes shares beneficially owned by Stonehenge Partners.
                                            As a managing partner of Stonehenge Partners, Ira Ritter may be deemed the beneficial owner
                                            of these shares.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(10)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Includes
                                            160,005 shares of common stock exercisable within 60 days under outstanding stock options
                                            and 18,391 shares of common stock exercisable within 60 days under outstanding warrants.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Equity
Compensation Plan Information</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table presents information regarding securities authorized for issuance under equity compensation plans as of December 31,
2022:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold">Plan Category</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of Securities <br /> to be Issued upon <br /> Exercise of <br /> Outstanding <br /> Options, Warrants and Rights</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted-Average <br /> Exercise Price of Outstanding <br /> Options, Warrants and Rights</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of Securities <br /> Remaining Available <br /> for Future Issuance <br /> Under Equity <br /> Compensation Plans <br /> (excluding securities <br /> reflected in <br /> column (a))</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold; text-align: center"><b>(a)</b></td><td style="font-weight: bold; text-align: center">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold; text-align: center"><b>(b)</b></td><td style="font-weight: bold; text-align: center">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold; text-align: center"><b>(c)</b></td><td style="font-weight: bold; text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 46%; text-align: left">Equity compensation plans approved by stockholders</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right">608,012</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">35.02</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right">147,690</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Equity compensation plans not approved by stockholders (1)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">179,046</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">9.12</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">787,058</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">29.13</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,809,157</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 24.45pt"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consists
                                            of shares of common stock issuable upon the exercise of compensatory warrants granted to
                                            service providers.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>

<!-- Field: Page; Sequence: 84; Value: 71 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->84<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="ax_003"></span>Item
13. Certain Relationships and Related Transactions, and Director Independence.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: -58.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Certain
Relationships and Related Party Transactions</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Audit Committee is responsible for reviewing, approving and overseeing any transaction between the Company and its directors, director
nominees, executive officers, greater than 5% beneficial owners, and each of their respective immediate family members, where the amount
involved exceeds the lesser of (i) $120,000 and (ii) 1% of the average of our total assets at year-end for the prior two fiscal years.
Since January 1, 2021, there have been no such transactions except as described below.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
May 26, 2022, the Company acquired 2,232,861 shares of Series A-1 Preferred Stock of NanoSynex, Ltd. (&#8220;NanoSynex&#8221;) from Alpha
Capital Anstalt (&#8220;Alpha Capital&#8221;), a related party, in exchange for 350,000 reverse split adjusted shares of the Company&#8217;s
common stock and a prefunded warrant to purchase 331,464 reverse split adjusted shares of the Company&#8217;s common stock at an exercise
price of $0.001 per share. These warrants were subsequently exercised on September 13, 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 22, 2022, the Company issued to Alpha Capital, an 8% Senior Convertible Debenture (the &#8220;Debenture&#8221;) in the
aggregate principal amount of $3,300,000 for a purchase price of $3,000,000 pursuant to the terms of a Securities Purchase
Agreement, dated December 21, 2022. The Debenture is convertible, at any time, and from time to time, at Alpha&#8217;s option, into
shares of common stock of the Company, at a price equal to $1.32 per share, subject to adjustment as described in the Debenture and
other terms and conditions described in the Debenture, including the Company&#8217;s receipt of the requisite stockholder approvals.
Additionally, on December 22, 2022, the Company issued to Alpha Capital a liability classified warrant to purchase 2,500,000 shares
of the Company&#8217;s common stock (see Note 10-Warrant Liabilities to the consolidated financial statements included in Part II, Item 8 of this Annual Report on Form 10-K). The exercise price of the warrant is $1.65 (equal to 125% of
the conversion price of the Debenture on the closing date). The warrant may be exercised by Alpha Capital, in whole or in part, at
any time on or after June 22, 2023 and before June 22, 2028, subject to certain terms conditions described in the warrant, including
the Company&#8217;s receipt of the necessary stockholder approvals.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Director
Independence</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
Nasdaq&#8217;s continued listing requirements, a majority of a listed company&#8217;s board of directors must be comprised of independent
directors, subject to certain exceptions. In addition, Nasdaq&#8217;s continued listing requirements require that, subject to certain
exceptions, each member of a listed company&#8217;s audit, compensation and governance and nominating committees must be independent.
Audit Committee members must also satisfy the independence criteria set forth in Rule 10A-3 under the Exchange Act. Under Nasdaq&#8217;s
continued listing requirements, a director will only qualify as an &#8220;independent director&#8221; if, in the opinion of that company&#8217;s
board of directors, such person does not have a relationship that would interfere with the exercise of independent judgment in carrying
out the responsibilities of a director.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
upon information requested from and provided by each director concerning their background, employment and affiliations, including family
relationships, our board of directors determined that each of Messrs. David, Emery, Korenberg and Kruger are independent under the applicable
rules and regulations of Nasdaq. In making such determinations, the board of directors considered the relationships that each such non-employee
director has with our company and all other facts and circumstances the board of directors deemed relevant in determining their independence.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="ax_004"></span>Item
14. Principal Accounting Fees and Services.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: -58.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Baker
Tilly US, LLP (&#8220;Baker Tilly&#8221;) serves as the Company&#8217;s independent registered public accounting firm and has served
in that capacity since June 2018.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Audit Committee considered the independence of Baker Tilly and whether the audit services Baker Tilly provided to the Company are compatible
with maintaining that independence. The Audit Committee has adopted procedures by which the Audit Committee must approve in advance all
services provided by and fees paid to the Company&#8217;s independent registered public accounting firm. The advance approval requirement
was not waived in any instance during 2022 or 2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 85; Value: 71 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->85<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Fees
and Services of Baker Tilly US, LLP</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table sets forth the aggregate fees billed to the Company by Baker Tilly for the years ended December 31, 2022 and 2021:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%">Audit Fees(1)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">411,362</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">267,020</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Audit-Related Fees</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Tax Fees (2)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">35,050</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">25,175</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">All Other Fees</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Total</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">446,412</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">292,195</td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 6pt; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.35in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.35in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Audit
                                            fees consisted of fees for audit work performed in the audit of financial statements, as
                                            well as fees for quarterly reviews and registration statements.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
                                            fees were incurred for professional services rendered in connection with tax compliance,
                                            tax advice, and tax planning. These services included income tax compliance and related tax
                                            services.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Audit Committee has adopted a formal policy on auditor independence requiring the advance approval by the Audit Committee of all audit
and non-audit services provided by our independent registered public accounting firm. In determining whether to approve any services
by our independent registered public accounting firm, the Audit Committee reviews the services and the estimated fees, and considers
whether approval of the proposed services will have a detrimental impact on the auditor&#8217;s independence. On an annual basis, our
management reports to the Audit Committee all audit services performed during the previous 12 months and all fees billed by our independent
registered public accounting firm for such services.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the years ended December 31, 2022 and 2021, all audit services and the corresponding fees were approved by our Audit Committee.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>


<!-- Field: Page; Sequence: 86; Value: 71 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->86<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="psi_011"></span>PART
IV</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="psi_012"></span>Item
15. Exhibits and Financial Statement Schedules</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
The following documents are filed as part of this Annual Report:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 45pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.
<i>Financial Statements.</i> The following documents are included in Part II, Item 8 of this Annual Report and are incorporated by reference
herein:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Page</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#sj_001">Report of Independent Registered Public Accounting Firm</a> (PCAOB ID 23)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">38</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial
    Statements:</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#sj_002">Consolidated Balance Sheets as of December 31, 2022 and December 31, 2021</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">41</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#sj_003">Consolidated Statements of Operations and Comprehensive Loss for the Year Ended December 31, 2022 and Year Ended December 31, 2021</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">42</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#sj_004">Consolidated Statements of Changes in Stockholders&#8217; Equity (Deficit) for the Year Ended December 31, 2022 and Year Ended December 31, 2021</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">43</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#sj_005">Consolidated Statements of Cash Flows for the Year Ended December 31, 2022 and Year Ended December 31, 2021</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">44</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#sj_006">Notes to Consolidated Financial Statements</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">45</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 45pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.
<i>Financial Statement Schedules.</i> Financial statement schedules have been omitted because they are not required or are not applicable,
or the required information is shown in the consolidated financial statements or notes thereto.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 45pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.
<i>Exhibits. </i>See EXHIBIT INDEX</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 87; Value: 71 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->87<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>EXHIBIT
INDEX</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exhibit
    No.</b></span></td>
    <td style="border-bottom: white 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 0.1in; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Description</b></span></td>
    <td style="border-bottom: white 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 0.1in; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Form</b></span></td>
    <td style="border-bottom: white 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 0.1in; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 1in; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>File
    No.</b></span></td>
    <td style="border-bottom: white 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 0.1in; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exhibit</b></span></td>
    <td style="border-bottom: white 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 0.1in; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 0.7in; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Filing
    Date</b></span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">2.1</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1460702/000149315220010166/ex2-4.htm" style="-sec-extract: exhibit">Contingent Value Rights Agreement, dated May 22, 2020, among the Company, John Beck in the capacity of CVR Holders&#8217; Representative and Andrew J. Ritter in his capacity as a consultant to the Company.</a></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">8-K</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">001-37428</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">2.4</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">5/29/2020</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1460702/000157104915005411/t1501532_ex3-1.htm" style="-sec-extract: exhibit">Amended
    and Restated Certificate of Incorporation of Ritter Pharmaceuticals, Inc.</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-37428</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7/1/2015</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.2</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1460702/000149315217010647/ex3-1.htm" style="-sec-extract: exhibit">Certificate
    of Amendment to the Amended and Restated Certificate of Incorporation</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-37428</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">9/15/2017</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.3</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1460702/000149315218003738/ex3-1.htm" style="-sec-extract: exhibit">Certificate
    of Amendment to the Amended and Restated Certificate of Incorporation</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-37428</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3/22/2018</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.4</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1460702/000149315220010166/ex3-1.htm" style="-sec-extract: exhibit">Certificate
    of Designation of Preferences, Rights and Limitations of Series Alpha Preferred Stock of the Company, filed with the Delaware Secretary
    of State on May 29, 2020</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-37428</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5/29/2020</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.5</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1460702/000149315220010166/ex3-2.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certificate
    of Amendment to the Certificate of Incorporation of the Company, filed with the Delaware Secretary of State on May 22, 2020 [reverse stock split]</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-37428</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.2</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5/29/2020</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.6</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1460702/000149315220010166/ex3-3.htm" style="-sec-extract: exhibit">Certificate of Merger, filed with the Delaware Secretary of State on May 22, 2020</a></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-37428</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.3</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5/29/2020</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">3.7</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1460702/000149315220010166/ex3-4.htm" style="-sec-extract: exhibit">Certificate of Amendment to the Certificate of Incorporation of the Company, filed with the Delaware Secretary of State on May 22, 2020</a></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">8-K</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">001-37428</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">3.4</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">5/29/2020</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.8</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1460702/000149315221019709/ex3-1.htm" style="-sec-extract: exhibit">Amended
    and Restated Bylaws of the Company, as of August 10, 2021</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-37428</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8/13/2021</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">3.9</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1460702/000149315222033252/ex3-1.htm" style="-sec-extract: exhibit">Certificate of Amendment to the Amended and Restated Certificate of Incorporation, as amended.</a></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">8-K</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">001-37428</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">3.1</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">11/22/2022</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">4.1</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1460702/000149315220010166/ex10-13.htm" style="-sec-extract: exhibit">Warrant, issued by the Company in favor of Alpha Capital Anstalt, dated May 22, 2020</a></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">8-K</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">001-37428</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">10.13</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">5/29/2020</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">4.2</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1460702/000149315220010166/ex10-10.htm" style="-sec-extract: exhibit">Form of Warrant, issued by the Company in favor of GreenBlock Capital LLC and its designees, dated May 22, 2020 [post-Merger]</a></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">8-K</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">001-37428</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">10.10</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">5/29/2020</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">4.3</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1460702/000149315220013097/ex10-2.htm" style="-sec-extract: exhibit">Common Stock Purchase Warrant in favor of Alpha Capital Anstalt, dated July 10, 2020</a></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">8-K</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">001-37428</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">10.2</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">7/10/2020</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.4</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1460702/000149315220014596/ex10-3.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Common Stock Purchase Warrant in favor of Alpha Capital Anstalt, dated August 4, 2020</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;001-37428</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.3</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8/4/2020</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">4.5</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1460702/000149315220023916/ex10-3.htm" style="-sec-extract: exhibit">&#8220;Two-Year&#8221; Common Stock Purchase Warrant for 1,348,314 shares in favor of Alpha Capital Anstalt, dated December 18, 2020</a></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">8-K</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">001-37428</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">10.3</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">12/18/2020</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">4.6</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1460702/000149315220023916/ex10-4.htm" style="-sec-extract: exhibit">&#8220;Deferred&#8221; Common Stock Purchase Warrant in favor of Alpha Capital Anstalt, dated December 18, 2020</a></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">8-K</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">001-37428</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">10.4</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">12/18/2020</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.7</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1460702/000149315221007476/ex4-13.htm" style="-sec-extract: exhibit">Form
    of liability classified Warrant to Purchase Common Stock </a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;10-K</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;001-37428</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.13</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3/31/2021</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.8</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1460702/000149315221007476/ex4-14.htm" style="-sec-extract: exhibit">Form
    of &#8220;service provider&#8221; compensatory equity classified Warrant</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10-K</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-37428</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.14</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3/31/2021</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">4.9</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1460702/000149315220005503/ex4-7.htm" style="-sec-extract: exhibit">Description of Common Stock</a></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">10-K</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">001-37428</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">4.7</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">3/31/2020</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">4.10</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1460702/000149315222013149/ex4-15.htm" style="-sec-extract: exhibit">Amended and Restated Common Stock Purchase Warrant to GreenBlock Capital LLC, dated April 25, 2022</a></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">10-Q</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">001-37428</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">4.15</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">5/13/2022</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.11</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1460702/000149315222013149/ex4-16.htm" style="-sec-extract: exhibit">Amended
    and Restated Common Stock Purchase Warrant to Christopher Nelson, dated April 25, 2022</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10-Q</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-37428</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.16</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5/13/2022</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.12</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1460702/000149315222036302/ex4-1.htm" style="-sec-extract: exhibit">Common
    Stock Purchase Warrant for 2,500,000 shares in favor of Alpha Capital Anstalt, dated December 22, 2022</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-37428</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">12/22/2022</span></td></tr>


<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1+</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1460702/000149315220010166/ex10-1.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Executive Employment Agreement, by and between Qualigen, Inc. and Michael Poirier, dated as of February 1, 2017 and as amended on January 9, 2018</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-37428</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.7in; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5/29/2020</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.2+</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1460702/000149315220010166/ex10-2.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Executive Employment Agreement, by and between Qualigen, Inc. and Christopher Lotz, dated as of February 1, 2017 and as amended on January 9, 2018</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-37428</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.2</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5/29/2020</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.1in">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.1in">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 0.5in">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.1in">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 1in">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.1in">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 0.5in">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.1in">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 0.7in">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.3+</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1460702/000149315222008431/ex10-53.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Executive Employment Agreement dated December 10, 2021 with Amy Broidrick</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10-K</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-37428</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.53</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3/31/2022</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 88; Value: 71 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->88<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.4+</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1460702/000149315220010166/ex10-20.htm" style="-sec-extract: exhibit">2020
    Stock Equity Incentive Plan</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-37428</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.20</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 0.7in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5/29/2020</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.5+</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1460702/000149315220010979/ex10-1.htm" style="-sec-extract: exhibit">Standard
    template of Stock Option Agreement for use under 2020 Stock Incentive Plan</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-37428</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6/11/2020</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.6+</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1460702/000149315220010166/ex10-21.htm" style="-sec-extract: exhibit">Form
    of Indemnification Agreement &#8211; Qualigen, Inc.</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-37428</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.21</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5/29/2020</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.7</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1460702/000149315220003943/ex10-58.htm" style="-sec-extract: exhibit">Exclusive
    Agreement (QN-24), by and between Qualigen, Inc. and University of Louisville Research Foundation, Inc. dated as of June 8,
    2018</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-4/A</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-37428</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.58</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3/13/2020</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.8*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="ex10-8.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amendment 1 to the Exclusive License Agreement (QN-247), by and between Qualigen, Inc. and University of Louisville Research Foundation, Inc., dated March 16, 2021</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.9*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="ex10-9.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amendment 2 to the Exclusive License Agreement (QN-247), by and between Qualigen, Inc. and University of Louisville Research Foundation, Inc., dated January 17, 2023</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">10.10*</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="ex10-10.htm">Exclusive License Agreement between the Company and University of Louisville Research Foundation (RAS), Inc., dated as of July 17, 2020</a></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">10.11*</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="ex10-11.htm">Amendment 1 to the Exclusive License Agreement (RAS), by and between Qualigen, Inc. and University of Louisville Research Foundation, Inc., dated March 16, 2021</a></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.12</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1460702/000149315220003943/ex10-59.htm" style="-sec-extract: exhibit">License
    Agreement between Qualigen, Inc. and Advanced Cancer Therapeutics, LLC dated December 17, 2018</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-4/A</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-37428</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.59</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3/13/2020</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.13</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1460702/000149315221007476/ex10-31.htm" style="-sec-extract: exhibit">Novation
    Agreement among the Company, Qualigen, Inc. and Advanced Cancer Therapeutics, LLC dated July 29, 2020</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10-K</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-37428</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.31</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3/31/2021</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.14</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1460702/000149315220019228/ex10-1.htm" style="-sec-extract: exhibit">Technology
    Transfer Agreement dated as of October 7, 2020 between Qualigen, Inc. and Yi Xin Zhen Duan Jishu (Suzhou) Ltd.</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-37428</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10/9/2020</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.15</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1460702/000149315221011439/ex10-1.htm" style="-sec-extract: exhibit">Novation
    Agreement among the Company, Qualigen, Inc. and University of Louisville Research Foundation, Inc. dated January 30, 2021 </a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10-Q</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-37428</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5/14/2021</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.16</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1460702/000149315221011439/ex10-2.htm" style="-sec-extract: exhibit">Novation
    Agreement among the Company, Qualigen, Inc. and University of Louisville Research Foundation, Inc. dated March 1, 2021</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10-Q</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-37428</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.2</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5/14/2021</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>

  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.17+</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1460702/000149315221020170/ex10-1.htm" style="-sec-extract: exhibit">Hire
    offer letter from the Company to Tariq Arshad, dated April 22, 2021</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10-Q</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-37428</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8/16/2021</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.18</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1460702/000149315221028354/ex10-2.htm" style="-sec-extract: exhibit">Amendment
    to Technology Transfer Agreement between Yi Xin Zhen Duan Jishu (Suzhou) Ltd. and Qualigen, Inc., dated August 5, 2021</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10-Q</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-37428</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.2</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">11/15/2021</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.19</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1460702/000149315221028354/ex10-3.htm" style="-sec-extract: exhibit">Amendment
    to 2020 Stock Incentive Plan (approved by the Board of Directors on April 27, 2021 and by the Stockholders on August 9, 2021)</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10-Q</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-37428</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.3</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">11/15/2021</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.20</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1460702/000149315222008431/ex10-54.htm" style="-sec-extract: exhibit">Second
    Amendment to Lease with Bond Ranch LP dated December 15, 2021</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10-K</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-37428</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.54</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3/31/2022</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.21*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="ex10-21.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">First Deed of Variation to License Agreement with UCL Business Limited dated March 30, 2022</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.22</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1460702/000149315222013149/ex10-1.htm" style="-sec-extract: exhibit">Series
    B Preferred Share Purchase Agreement between the Company and NanoSynex Ltd. dated April 29, 2022</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10-Q</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-37428</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5/13/2022</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.23</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1460702/000149315222013149/ex10-2.htm" style="-sec-extract: exhibit">Share
    Purchase Agreement between the Company and Alpha Capital Anstalt dated April 29, 2022</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10-Q</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-37428</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.2</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5/13/2022</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.24</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1460702/000149315222015663/ex10-1.htm" style="-sec-extract: exhibit">Master
    Agreement for the Operational and Technological Funding of NanoSynex between Qualigen Therapeutics, Inc. and NanoSynex Ltd., dated
    May 26, 2022</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-37428</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6/2/2022</span></td></tr>
  </table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>


<!-- Field: Page; Sequence: 89; Value: 71 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->89<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.25+</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1460702/000149315222032189/ex10-1.htm" style="-sec-extract: exhibit">Qualigen
    Therapeutics, Inc. 2022 Employee Stock Purchase Plan</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10-Q</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-37428</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 0.7in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">11/14/2022</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.26+</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1460702/000149315222033252/ex10-1.htm" style="-sec-extract: exhibit">Amendment
    No. 2 to the 2020 Stock Incentive Plan of Qualigen Therapeutics, Inc.</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-37428</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">11/22/2022</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.27+</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1460702/000149315222033252/ex10-2.htm" style="-sec-extract: exhibit">Amendment
    No. 1 to the 2022 Employee Stock Purchase Plan of Qualigen Therapeutics, Inc.</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-37428</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.2</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">11/22/2022</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.28</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1460702/000149315222036302/ex10-1.htm" style="-sec-extract: exhibit">Securities
    Purchase Agreement, dated December 21, 2022, by and between Qualigen Therapeutics, Inc. and Alpha Capital Anstalt</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-37428</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">12/22/2022</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.29</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1460702/000149315222036302/ex10-2.htm" style="-sec-extract: exhibit">8%
    Senior Convertible Debenture Due December 22, 2025</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-37428</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.2</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">12/22/2022</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.30</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1460702/000149315222036302/ex10-3.htm" style="-sec-extract: exhibit">Registration
    Rights Agreement, dated December 22, 2022, by and between Qualigen Therapeutics, Inc. and Alpha Capital Anstalt</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-37428</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.3</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">12/22/2022</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.31+*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex10-31.htm">Letter to Michael P. Poirier, dated January 13, 2023, regarding compensatory changes</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.32+*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex10-32.htm">Letter to Amy Broidrick, dated January 13, 2023, regarding compensatory changes</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.33+*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex10-33.htm">Letter to Tariq Arshad, dated January 13, 2023, regarding compensatory changes</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">14.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1460702/000149315220010166/ex14-1.htm" style="-sec-extract: exhibit">Code
    of Business Conduct and Ethics</a></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-37428</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">14.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5/29/2020</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">21.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex21-1.htm">Subsidiaries
    of the Registrant</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">23.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex23-1.htm">Consent
    of Baker Tilly US, LLP, independent registered public accounting firm</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">24.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#paa_001">Power
    of Attorney (included on signature page)</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">31.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex31-1.htm">Certificate
    of principal executive officer pursuant to Rule 13a-14(a)/15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act
    of 2002.</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">31.2</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex31-2.htm">Certificate
    of principal financial officer pursuant to Rule 13a-14(a)/15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act
    of 2002.</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">32.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex32-1.htm">Certificate
    of principal executive officer and principal financial officer pursuant to 18 U.S.C. &#167; 1350, as adopted pursuant to Section
    906 of the Sarbanes-Oxley Act of 2002.</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.INS#</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline
    XBRL Instance Document.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.SCH#</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline
    XBRL Taxonomy Extension Schema Document.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.CAL#</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline
    XBRL Taxonomy Extension Calculation Linkbase Document.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.DEF#</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline
    XBRL Taxonomy Extension Definition Linkbase Document.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.LAB#</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline
    XBRL Taxonomy Extension Label Linkbase Document.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.PRE#</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline
    XBRL Taxonomy Extension Presentation Linkbase Document.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">104</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cover
    Page Interactive Data File (embedded within the Inline XBRL document)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*
Filed or furnished herewith.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">**
Schedules have been omitted pursuant to Item 601(b)(2) of Regulation S-K. A copy of any omitted schedules will be furnished to the SEC
upon request.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">+
Indicates management contract or compensatory plan or arrangement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">#
XBRL (Extensible Business Reporting Language) information is furnished and not filed herewith, is not a part of a registration statement
or Prospectus for purposes of sections 11 or 12 of the Securities Act of 1933, is deemed not filed for purposes of section 18 of the
Securities Exchange Act of 1934, and otherwise is not subject to liability under these sections.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="sj_008"></span>Item
16. Form 10-K Summary</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
applicable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>


<!-- Field: Page; Sequence: 90; Value: 71 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->90<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="sj_007"></span>SIGNATURES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this Annual Report
to be signed on its behalf by the undersigned, thereunto duly authorized.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 45pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Qualigen
    Therapeutics, Inc.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 50%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 3%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 47%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    Michael S. Poirier</i></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Michael
    S. Poirier</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chairman
    of the Board, Chief Executive Officer </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
    May 2, 2023</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="paa_001"></span>POWER
OF ATTORNEY</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 45pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">KNOW
ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below hereby constitutes and appoints Michael S. Poirier and
Christopher L. Lotz, and each of them individually, his true and lawful attorneys-in-fact and agents, with full power of substitution
and resubstitution, for him and in his name, place, and stead, in any and all capacities, to sign any and all amendments to this Annual
Report, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange
Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every
act and thing requisite and necessary to be done in connection therewith, as fully to all intents and purposes as he might or could do
in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or any of them, or his substitute or substitutes,
may lawfully do or cause to be done by virtue hereof.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the requirements of the Securities Exchange Act of 1934, this Annual Report has been signed below by the following persons on behalf
of the Registrant and in the capacities and on the dates indicated.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 45pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 24%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Signature</b></span></td>
    <td style="border-bottom: white 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 56%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Title</b></span></td>
    <td style="border-bottom: white 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 18%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Date</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    Michael S. Poirier</i></span></td>
    <td style="border-bottom: white 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chairman
    of the Board, Chief Executive Officer </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">May 2, 2023</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Michael
    S. Poirier</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Principal
    Executive Officer)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    Christopher L. Lotz</i></span></td>
    <td style="border-bottom: white 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Vice
    President of Finance, Chief Financial Officer</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">May 2, 2023</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Christopher
    L. Lotz</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Principal
    Financial and Accounting Officer)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    Amy S. Broidrick</i></span></td>
    <td style="border-bottom: white 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">President, Chief Strategy and Operating Officer</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">May 2, 2023</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amy
    S. Broidrick</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    Richard A. David</i></span></td>
    <td style="border-bottom: white 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">May 2, 2023</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Richard
    A. David</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    Sidney W. Emery, Jr.</i></span></td>
    <td style="border-bottom: white 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">May 2, 2023</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sidney
    W. Emery, Jr.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    Matthew E. Korenberg</i></span></td>
    <td style="border-bottom: white 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">May 2, 2023</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Matthew
    E. Korenberg</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    Kurt H. Kruger</i></span></td>
    <td style="border-bottom: white 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">May 2, 2023</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Kurt
    H. Kruger</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    Ira E. Ritter</i></span></td>
    <td style="border-bottom: white 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">May 2, 2023</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ira
    E. Ritter</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></p>

<!-- Field: Page; Sequence: 91; Options: Last -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->91<!-- Field: /Sequence --></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
</body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.8
<SEQUENCE>2
<FILENAME>ex10-8.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="text-align: right; margin-top: 0; margin-bottom: 0"><B>Exhibit 10.8</B></P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0"><IMG SRC="ex10-8_001.jpg" ALT="">&nbsp;</P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="text-align: center; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="text-align: center; break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0"><IMG SRC="ex10-8_002.jpg" ALT="">&nbsp;</P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.9
<SEQUENCE>3
<FILENAME>ex10-9.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="text-align: right; margin-top: 0; margin-bottom: 0"><B>Exhibit 10.9</B></P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0"><IMG SRC="ex10-9_001.jpg" ALT="">&nbsp;</P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="text-align: center; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="text-align: center; break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0"><IMG SRC="ex10-9_002.jpg" ALT="">&nbsp;</P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="text-align: center; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="text-align: center; break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0"><IMG SRC="ex10-9_003.jpg" ALT="">&nbsp;</P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="text-align: center; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="text-align: center; break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0"><IMG SRC="ex10-9_004.jpg" ALT="">&nbsp;</P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 4; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.10
<SEQUENCE>4
<FILENAME>ex10-10.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="text-align: right; margin-top: 0; margin-bottom: 0"><B>Exhibit 10.10</B></P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0"><IMG SRC="ex10-10_001.jpg" ALT="">&nbsp;</P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="text-align: center; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="text-align: center; break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0"><IMG SRC="ex10-10_002.jpg" ALT="">&nbsp;</P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.11
<SEQUENCE>5
<FILENAME>ex10-11.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="text-align: right; margin-top: 0; margin-bottom: 0"><B>Exhibit 10.11</B></P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0"><IMG SRC="ex10-11_001.jpg" ALT="">&nbsp;</P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="text-align: center; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="text-align: center; break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0"><IMG SRC="ex10-11_002.jpg" ALT="">&nbsp;</P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="text-align: center; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.21
<SEQUENCE>6
<FILENAME>ex10-21.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: right; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exhibit
10.21</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: right; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Certain
identified information has been excluded from this exhibit because it is both not material and is the type that the registrant treats
as private or confidential. Information that was omitted has been noted in this document with a placeholder identified by the mark &ldquo;[***]&rdquo;.</I></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">First
Deed of Variation</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>THIS
DEED OF VARIATION is made as of the 30<SUP>th</SUP> day of March 2022 BETWEEN</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>UCL
                                            Business Limited</B>, a company incorporated in England and Wales under company registration
                                            number 02776963 whose registered office is at University College London, Gower Street London
                                            WC1E 6BT (<B>&ldquo;UCLB&rdquo;</B>); and</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Qualigen
                                            Therapeutics, Inc.</B>, a Delaware (USA) corporation whose principal place of business is
                                            at 2042 Corte del Nogal, Carlsbad, California 92011 USA (the &ldquo;<B>Licensee</B>&rdquo;)
                                            (each a &ldquo;<B>Party</B>&rdquo; and together the &ldquo;<B>Parties</B>&rdquo;).</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">WHEREAS</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(A)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            Parties entered into a licence agreement with an effective date of 13 January 2022, (the
                                            &ldquo;<B>Agreement</B>&rdquo;).</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(B)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            Parties wish to make certain further changes to the Agreement as set out in this deed (the
                                            &ldquo;<B>First Deed of Variation</B>&rdquo;).</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">THIS
DEED OF VARIATION WITNESSES AS FOLLOWS:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>1.</B></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>INTERPRETATION</B></FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.1</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
                                            the purposes of this First Deed of Variation, &ldquo;<B>Appendix</B>&rdquo; means the appendix
                                            to this First Deed of Variation and &ldquo;<B>First Amendment Date</B>&rdquo; means March
                                            30th 2022.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.2</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
                                            the event of any conflict between the terms of the Agreement (excluding this First Deed of
                                            Variation) and the terms of this First Deed of Variation, then the terms of this First Deed
                                            of Variation shall prevail and be applied.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>2.</B></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>AMENDMENTS
                                            TO THE AGREEMENT</B></FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.1</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            Parties hereby agree that with effect from the First Amendment Date, the terms of the Agreement
                                            shall be amended in accordance with the revisions shown to the Agreement in the Appendix
                                            and the Agreement will thereafter be read and construed in accordance with that amended form.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>3.</B></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CONTINUING
                                            FORCE AND EFFECT</B></FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Save
                                            as varied by this First Deed of Variation, the Agreement shall continue and remain in full
                                            force and effect. If the Agreement terminates for any reason, this First Deed of Variation
                                            will automatically terminate at the same time.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>4.</B></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>MISCELLANEOUS</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
                                            First Deed of Variation may be executed in one or more counterparts, each of which when executed
                                            shall be deemed to be an original but all of which taken together shall constitute one and
                                            the same deed. Delivery of an executed counterpart by email shall be as effective as delivery
                                            of the original.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            Agreement and this First Deed of Variation constitute the entire agreement between the Parties
                                            relating to their subject matter and supersedes any previous agreement between the Parties
                                            relating to such matter.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.3</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Neither
                                            Party has relied upon any promise, condition, representation or warranty, express or implied,
                                            to enter into this First Deed of Variation, other than those warranties and representations
                                            set out in the Agreement as amended hereunder.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.4</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nothing
                                            in this First Deed of Variation, nor the amendment of the Agreement, waives, discharges,
                                            releases or in any other way excuses or excludes any Party&rsquo;s obligations or liabilities
                                            in respect of any accrued liabilities or breaches under the Agreement.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.5</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">None
                                            of the provisions of this First Deed of Variation may be changed, modified, waived or cancelled
                                            orally or otherwise, except by writing, in the manner provided in the Agreement, specifying
                                            such change, modification, waiver or cancellation of such terms or conditions, or of any
                                            proceeding or succeeding breach thereof.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>5.</B></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>GOVERNING
                                            LAW</B></FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.1</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
                                            First Deed of Variation shall be governed by, interpreted and construed in accordance with
                                            English Law and any dispute, controversy or claim arising out of or in relation to this First
                                            Deed of Variation shall be subject to the exclusive jurisdiction of the English courts.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="ex10-21_001.jpg" ALT=""></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">APPENDIX</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>LICENCE
AGREEMENT</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">between</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">UCL
Business Limited</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Qualigen
Therapeutics, Inc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Dated:
13/01/2022</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ref:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">INDEX</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Definitions</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Grant
                                            of Rights</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Know-how
                                            and other Confidential Information</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">15</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Payments</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">18</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Commercialisation</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">24</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Access
                                            to Medicines and Ethical Licensing</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">28</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Compliance
                                            with Laws</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">29</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Intellectual
                                            Property</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">31</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Warranties
                                            and Liability</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">34</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Duration
                                            and Termination</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">38</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">General</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">43</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -36.05pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Schedule 1 Licensed Technology</FONT></TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">48</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Schedule 2 Appointment of
  Expert</FONT></TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">51</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Schedule 3 Development Plan</FONT></TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">52</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Schedule 4 List of Countries
  and Territories for Patents</FONT></TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">53</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Schedule 5 Royalty Statement</FONT></TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">54</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>*The
schedules and exhibits to this agreement have not been filed pursuant to Regulation S-K 601(a)(5). The registrant agrees to provide any
omitted schedule or exhibit to the Securities and Exchange Commission upon request</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>THIS
AGREEMENT <STRIKE>is</STRIKE><U>was</U> made the 13<SUP>th</SUP> day of January 2022 <U>and is hereby amended and restated as of the
30<SUP>th</SUP> day of March 2022 (the &ldquo;First Amendment Date&rdquo;)</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">BETWEEN:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>UCL
                                            BUSINESS LIMITED</B>, a company incorporated in England and Wales under company registration
                                            number 02776963 whose registered office is at University College London, Gower Street London
                                            WC1E 6BT (&ldquo;UCLB&rdquo;);</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Qualigen
                                            Therapeutics, Inc.</B>, a Delaware (USA) corporation whose principal place of business is
                                            at 2042 Corte del Nogal, Carlsbad, California 92011 USA (the &ldquo;Licensee&rdquo;).</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">WHEREAS:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.35pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">University
                                            College London (&ldquo;UCL&rdquo;), through the Principal Investigator, has developed certain
                                            technology and owns certain intellectual property rights relating to G-Quadruplex binding
                                            molecules, including the Patents<U>, </U><STRIKE>and </STRIKE>the Know-how <U>and the Materials</U>.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">B.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">UCLB
                                            hereby represents and warrants to the Licensee that UCL has assigned to UCLB all of its right,
                                            title and interest in and to such property.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">C.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            Licensee wishes to acquire rights under the Patents and to use the Know-how <U>and the Materials
                                            </U>for the development and commercialisation of Licensed Products in the Field and in the
                                            Territory, all in accordance with the provisions of this Agreement.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.35pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">D.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            Licensee acknowledges that UCLB and UCL are committed to implementing effective technology
                                            transfer strategies that promote the availability of health-related technologies in developing
                                            countries for essential medical care, as set out in UCL&rsquo;s Statement of Principles and
                                            Strategies for the Equitable Dissemination of Medical Technologies, and has agreed to work
                                            with UCLB and UCL to achieve this commitment with respect to the Patents<U>,</U> <STRIKE>and
                                            </STRIKE>the Know- how <U>and the Materials</U>.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">E.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            Licensee also acknowledges that it is UCL&rsquo;s and UCLB&rsquo;s policy neither to support
                                            Tobacco Companies nor to accept funds from Tobacco Companies. Accordingly, UCLB is required
                                            to place certain restrictions on the Licensee in this Agreement in order to support this
                                            policy.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOW
IT IS AGREED as follows:</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">1.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>DEFINITIONS</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
this Agreement:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Affiliate
</B>in relation to a Party, means any entity or person that Controls, is Controlled by, or is under common Control with that Party.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>At-Cost
Markets </B>means those markets in Developing Countries where individual poverty and insufficient public funding prevent access to healthcare
at developed country prices.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Claims
</B>means all demands, claims, and liability (whether criminal or civil, in contract, tort or otherwise) for losses, damages, costs and
expenses of any nature whatsoever and all costs and expenses (including legal costs) incurred in connection therewith, in each case which
are payable to third parties, incurred by Indemnitees in connection with any and all suits, actions, investigations, claims or demands
of a third party.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Commencement
Date</B> means the date specified above.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Confidential
Information <FONT STYLE="font-weight: normal">means:</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            existence, subject matter and terms of this Agreement;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            Know-how <U>and the Materials (including any technical information subsisting in or relating
                                            to the Materials)</U>;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -42.6pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
                                            and all information that would qualify as a trade secret pursuant to the EU Trade Secrets
                                            Directive or equivalent law of the United States or of the applicable constituent State of
                                            the United States;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -42.6pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">d)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
                                            and all information which reasonably ought to have been understood (by a reasonable business
                                            person) to be confidential and/or non-public information at the time disclosed to the Receiving
                                            Party;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -42.6pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">e)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
                                            and all information which is identified as being confidential or otherwise designated to
                                            show expressly that it is imparted in confidence including information relating to:</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -42.6pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">i)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            business, affairs, customers, clients, suppliers, or plans, intentions, or market opportunities
                                            of the Disclosing Party; or</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -35.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ii)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            operations, specifications, research, inventions, processes, initiatives, product information,
                                            technology, know-how, designs, trade secrets or software of the Disclosing Party,</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -35.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">in
each case which is disclosed orally, visually (for example, in electronic form) or in writing by or on behalf of one Party to the other
Party, and shall include any information, analyses, compilations, studies, minutes of meetings, or other documents or physical materials
prepared by or on behalf of the Receiving Party which include or otherwise derive from information received (directly or indirectly)
from the Disclosing Party.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 6; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Control
</B>means:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">holding
                                            the right by contract to require that the person under Control conducts its affairs in accordance
                                            with the wishes of the person who holds that right; or</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -42.6pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">in
                                            relation to a body corporate, the direct or indirect beneficial ownership of more than 50%
                                            (fifty percent) (or outside of a Party&rsquo;s home territory, such lesser percentage as
                                            is the maximum permitted level of foreign investment) of the issued shares or securities
                                            of the other entity or the legal power to direct or cause the direction of the general management
                                            of the other entity in question, or its holding company or parent undertaking; and</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -42.6pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">in
                                            relation to a partnership, the right to a share of more than half the assets, or of more
                                            than half the income, of the partnership;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -42.6pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Cost-Based
Price </B>means, in respect of each Licensed Product, a price not exceeding that which fairly reflects the direct cost of manufacture
of the Licensed Product plus a typical margin for a generic pharmaceutical product for the respective market.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Developing
Country </B>or <B>Developing Countries </B>refers to those countries that are at the relevant time:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -0.6pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">eligible
                                            for support from the Global Alliance for Vaccines and Immunization; and</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">to
                                            the extent not included in a);</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">i)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">defined
                                            as of the relevant time by the World Bank as Low-Income and Lower- Middle-Income Countries,
                                            as such definitions may be amended from time to time by the World Bank; and</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ii)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">all
                                            other countries that may be mutually agreed to by UCLB and the Licensee from time to time.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Diligent
Efforts </B>means exerting such efforts and employing such resources at least commensurate to the level of efforts and resources that
a reasonable third party entity would devote to a product of similar market potential at a similar stage of its product life, when utilizing
sound and reasonable scientific, medical and business practice and judgment in order to develop the product in a timely manner and maximize
the economic return to the Parties from its commercialisation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Disclosing
Party</B> has the meaning given in Clause 3.3.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 7; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Field
</B>means development, manufacture, marketing and sale of human pharmaceuticals.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>First
Commercial Sale </B>means the first sale to a third party of a Licensed Product in a given regulatory jurisdiction after all regulatory
and marketing approvals have been obtained for such Licensed Product in such jurisdiction. A sale shall not be deemed to have occurred
if a Licensed Product is provided pursuant to an early access or compassionate use.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>First
Indication </B>means the first Indication in cancer for which a Licensed Product has been approved by a Regulatory Authority.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Historic
Patent Costs</B> has the meaning given in Clause 4.2.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Indemnitees
</B>has the meaning given in Clause 9.6.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Indication
</B>means a separate, distinct and well-categorized class of human disease, syndrome or medical condition. For clarity, different stages
of the same disease or condition will not be different Indications, varying manifestations of the same disease or condition will not
be different Indications, different lines of treatment of the same disease or condition will not be different Indications, and the treatment
or prevention of the same disease or condition in different demographic groups (e.g., adult and pediatric) will not be different Indications.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Insolvency
Event</B> in relation to a Party means:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
                                            notice is issued to convene a meeting for the purpose of a passing a resolution to wind it
                                            up, or such a resolution is passed other than a resolution for its solvent reconstruction
                                            or reorganisation;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -42.6pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
                                            resolution is passed by its directors to seek a winding up or a petition for a winding up
                                            order is presented against it, or such an order is made;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -42.6pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
                                            receiver, administrative receiver, receiver and manager, interim receiver, custodian, sequestrator,
                                            administrator or similar officer is appointed in respect of that Party or over a substantial
                                            part of its assets, or a notice of intention to appoint an administrator is filed in respect
                                            of that Party, or an encumbrancer enforces its security, or any distress, attachment, sequestration
                                            or execution or other similar process affects any of its assets and is not discharged within
                                            60 days;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -42.6pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
                                            proposal for a voluntary arrangement is made in relation to it under Part I of the Insolvency
                                            Act 1986;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -42.6pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -42.6pt"></P>

<!-- Field: Page; Sequence: 8; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -42.6pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
                                            step or event is taken or arises outside the United Kingdom which is similar or analogous
                                            to any of the steps or events listed at (a) to (d) above including the case the Licensee
                                            files, in any court or agency pursuant to any applicable law, a petition in bankruptcy or
                                            insolvency or for reorganization or for an arrangement or for the appointment of a receiver
                                            or trustee of the Licensee or of its assets, or if the Licensee is served with an involuntary
                                            petition against it, filed in any proceeding of such sort, and such petition is not dismissed
                                            within 60 days after the filing thereof, or if the Licensee overtly proposes to dissolve
                                            or liquidate, or if the Licensee makes an assignment for the benefit of its creditors;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">it
                                            proposes or makes any general assignment, composition or arrangement with or for the benefit
                                            of all or some of its creditors (other than for the sole purpose of a solvent amalgamation
                                            or solvent reconstruction), or it suspends making payments to all or some of its creditors.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Know-how
means:</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">all
technical information and know-how developed in any UCL laboratory of the Principal Investigator relating directly to the inventions
claimed in the Patents (but which information/ know-how is not the subject of a Patent and is not in the public domain); and described
in the Part B of Schedule 1.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Laboratory
</B>means any laboratory of the Principal Investigator at UCL.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Licensed
Products </B>means any and all products that are developed, manufactured, used, or sold by or on behalf of the Licensee or its Affiliates
and which (a) are within (or are manufactured using a process described in a Valid Claim of) the Patents in the country where sold and/or
(b) incorporate, or their development or manufacture makes use of, any of the Know-how <U>and/or the Materials</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Licensed
Technology</B> means the Patents<U>,</U> <STRIKE>and</STRIKE> the Know-how <U>and the Materials</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Licensee
Improvements</B> means all improvements, modifications, adaptations and new uses of the Patents<U>,</U> <STRIKE>and</STRIKE> the Know-how
(and all intellectual property rights therein) <U>and the Materials</U> generated by the Licensee, its Affiliates and its Sub-licensees
during the period of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Materials
</U></B><U>means any and all of the materials referred to in Part C of Schedule 1.</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Marketing
Authorisation </B>means those Regulatory Approval(s) required by applicable laws and regulations in a particular country or territory
in order to sell or commercially supply a medicinal product and/or device in that country or territory.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in"></P>

<!-- Field: Page; Sequence: 9; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Net
Receipts </B>means the amount of any cash consideration (excluding value added or other sales tax), and if there is any tangible non-cash
consideration, the relevant open market price for such non-cash consideration in the relevant country or territory or if the relevant
open market price is not ascertainable, a reasonable price, assessed on an arm&rsquo;s length basis, received by or due to the Licensee
or its Affiliates, in relation to the development or sub-licensing (including the grant of any option over a sub-licence) of any of the
Patents<U>,</U> <STRIKE>and</STRIKE> the Know-how <U>and/or the Materials</U>, or the grant of any right (including an option to acquire
a licence) to develop, manufacture, market, or sell Licensed Products, and including any or all of the following (but all only where
in relation to the development or sub-licensing (including the grant of any option over a sub-licence) of any of the Patents<U>,</U>
<STRIKE>and </STRIKE>the Know-how <U>and/or the Materials</U>, or the grant of any right (including an option to acquire a licence) to
develop, manufacture, market, or sell Licensed Products):</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">up-front,
                                            milestone (whether at the stage of development, marketing or otherwise), success, bonus,
                                            maintenance and periodic (including annual) payments, royalty and minimum royalty payments
                                            due under any sub-licence agreement;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">payments
                                            in respect of the funding of research or development activities related to the Patents<U>,
                                            </U><STRIKE>and </STRIKE>the Know-how <U>and/or the Materials </U>or any Licensed Product,
                                            to the extent that such payments exceed reimbursement of the actual costs and expenses incurred
                                            by the Licensee or its Affiliates in performing the relevant research or development activities
                                            without any mark-up being applied to those costs and expenses and without any overhead charges
                                            being applied;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">where
                                            any sub-licence is to be granted under cross-licensing arrangements, the value of any third
                                            party licence obtained under such arrangements;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">d)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
                                            premium paid over the fair market value of shares, options or other securities in respect
                                            of any of the share capital of the Licensee or its Affiliates issued as a component of such
                                            a transaction (such fair market value to be determined on the assumption that UCLB had not
                                            granted, nor agreed to grant, any rights to the Licensee in respect of any of the Patents<U>,
                                            </U><STRIKE>and</STRIKE> the Know-how <U>and the Materials</U>);</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">e)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            extra benefit (above normal market terms) of any loan, guarantee or other financial benefit
                                            made or given other than on normal market terms, occurring as a component of such a transaction;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">f)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
                                            shares, options or other securities obtained from a third party in consideration for the
                                            grant of the relevant rights; and</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">g)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
                                            other payments in respect of the Patents, including payments awarded by a court or arbitrator
                                            or other authorised body but excluding any damages awarded as compensation for lost sales
                                            which will be treated as Net Sales Value.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 10; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Net
Sales Value</B> means:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            gross invoiced price of Licensed Products sold by or on behalf of the Licensee or its Affiliates
                                            in arm&rsquo;s length transactions for a cash consideration; and/ or</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">where
                                            the sale is not at arm&rsquo;s length and/ or is for or includes a non-cash consideration,
                                            or if Licensed Products are disposed of for free by the Licensee or its Affiliates (except
                                            in the context of or subject to Clause 5.9), the relevant open market price for the Licensed
                                            Product in the country or territory in which the sale, use or disposal takes place or if
                                            the relevant open market price is not ascertainable, a reasonable price, assessed on an arm&rsquo;s
                                            length basis therefor,</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">after
deduction of all documented:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">i)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">normal
                                            trade rebates and discounts (but excluding early payment discounts) actually granted and
                                            any credits actually given for rejected or returned Licensed Products;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ii)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">amounts
                                            invoiced for Licensed Product sales but actually written off in good faith as uncollectible
                                            bad debt (net of any recoveries on written-off debt);</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">iii)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">costs
                                            of packaging, insurance, carriage and freight, provided in each case that the amounts are
                                            separately charged to the purchaser on the relevant invoice;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">iv)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">value
                                            added tax or other sales tax; and</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">v)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">import
                                            and export duties or similar applicable government levies charged to the purchaser on the
                                            relevant invoice,</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">provided
that such deductions do not exceed reasonable and customary amounts in the markets in which such sales occurred. Sales of Licensed Products
between the Licensee and its Affiliates shall not be taken into account for the purposes of calculating &ldquo;Net Sales Value&rdquo;
unless there is subsequent sale to a third party in an arm&rsquo;s length transaction for a cash consideration.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Parties
</B>means UCLB and the Licensee, and &ldquo;<B>Party</B>&rdquo; shall mean either of them.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Patents
</B>means any and all of the patents and patent applications referred to in Part A of Schedule 1, including any continuations, continuations
in part, extensions, reissues, divisions, and any patents, supplementary protection certificates and similar rights that are based on
or derive priority from the foregoing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"></P>

<!-- Field: Page; Sequence: 11; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Person
</B>means any individual, partnership, limited liability company, firm, corporation, association, trust, unincorporated organization
or other entity.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Phase
I Study </B>means a human clinical trial of a product in any country, the principal purpose of which is a preliminary determination of
safety in healthy individuals or patients, that would satisfy the requirements of 21 C.F.R. 312.21(a), or a similar clinical study prescribed
by the relevant regulatory authority in a country other than the United States.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Phase
II Study</B> means a clinical study of an investigational product in patients with the primary objective of characterizing its activity
in a specific disease state as well as generating more detailed safety, tolerability, and pharmacokinetics information. The investigational
product can be administered to patients as a single agent or in combination with other investigational or marketed agents and shall be
deemed commenced when the first patient in such study has received his or her initial dose of a product. A &ldquo;Phase II Study&rdquo;
shall include any clinical trial that would satisfy the requirements of 21 C.F.R. &sect; 312.21(b), or a comparable clinical study prescribed
by the relevant regulatory authority in a country other than the United States.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Phase
III Study</B> means a clinical study of an investigational product in patients that incorporates accepted endpoints for confirmation
of statistical significance of efficacy and safety with the aim to obtain regulatory approval in any country as described in 21 C.F.R.
&sect; 312.21(c), or a comparable clinical study prescribed by the relevant regulatory authority in a country other than the United States.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Principal
Investigator </B>means [****], who was an employee of UCL, when the Patents and the Know-how were developed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Receiving
Party</B> has the meaning given in Clause 3.3.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0pt 0pt 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Registration
</B>means any approvals required for the marketing and sale of products based on or which utilise the Patents<U>,</U> <STRIKE>and/or
</STRIKE><U>the </U>Know-how <U>and/or the Materials </U>in a country of the Territory.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Regulatory
Approval </B>means any and all approvals (including any applicable supplements, amendments, pre and post approvals, and approvals of
applications for regulatory exclusivity), licenses, registrations, or authorisations of any federal, national, multinational, state,
provincial or local regulatory agency, department, bureau, commission, council or other governmental entity necessary for the manufacture,
distribution, use, testing, development, storage, import, export, transport, promotion, marketing and sale of a medicinal product and/or
device in a country or countries.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 12; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Regulatory
Authority</B> means any regulatory authority or competent body in any jurisdiction as relevant to a Licensed Product and/or the manufacture,
approval, Registration and sale thereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Second
Indication </B>means the second Indication in cancer for which a Licensed Product has been approved by a Regulatory Authority.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Sub-licensee
</B>means any third party (other than an Affiliate) to whom the Licensee grants a sub-licence of its rights under this Agreement in accordance
with Clause 2.3.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Subsequent
Indication </B>means any Indication in cancer subsequent to the Second Indication for which a Licensed Product has been approved by a
Regulatory Authority.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Territory
</B>means worldwide.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Third
Party</B> has the meaning as given in Clause 11.12.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Tobacco
Company </B>means: (i) any person who develops, sells or manufactures tobacco products; and/ or (ii) any person which makes the majority
of its profits from the importation, marketing, sale or disposal of tobacco products. Furthermore, Tobacco Company shall include any
person that is Controlled by or under common Control with any of the persons referred to in (i) and/or (ii); and for the purposes of
this definition, &ldquo;Control&rdquo; means the possession (directly or indirectly) of fifty per cent (50%) or more of the voting stock
or other equity interest of a subject entity with the power to vote, or the power in fact to control the management decisions of such
entity through the ownership of securities or by contract or otherwise; and &ldquo;Controlling&rdquo; and &ldquo;Controlled by&rdquo;
shall be construed accordingly.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>UCL
</B>means University College London, having its principal place of business at Gower Street London WC1E 6BT.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0pt 0pt 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>UCLB
Improvements</B> means all improvements, modifications, adaptations and new uses of the Patents, <STRIKE>and</STRIKE> the Know-how (and
all intellectual property rights therein) <U>and/or the Materials</U> which are:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">in
                                            the Field;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">generated
                                            by the Principal Investigator in any UCL laboratory and/or any other employees of UCL under
                                            the Principal Investigator&rsquo;s supervision in any UCL laboratory during the period of
                                            twenty four (24) months following the Commencement Date;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -42.6pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 13; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">free
                                            (as of the time of creation, discovery or acquisition of the improvement, modification, adaptation
                                            or new use) from any ownership rights of or other obligations to third parties which would
                                            prevent UCLB from granting a licence thereof to the Licensee pursuant to Clause 2.5.2.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
clarity, any employee of UCL who is in good faith named as a principal investigator with the Principal Investigator on any grant application
will not for the purposes of any research conducted pursuant to such grant be regarded as being under the supervision of the Principal
Investigator.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Valid
Claim </B>means a claim of a patent or patent application that has not been abandoned or allowed to lapse or expired or been rejected
or revoked without a right of appeal in the relevant country or territory or been held invalid or unenforceable by a court of competent
jurisdiction in a final and non-appealable judgment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>GRANT
                                            OF RIGHTS</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">2.1</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Licences.</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">UCLB
hereby grants to the Licensee and its Affiliates, and the Licensee hereby accepts on its own behalf and on behalf of its Affiliates,
subject to the provisions of this Agreement:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.1.1</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">an
                                            exclusive licence under the Patents <U>and the Materials</U>, with the right to sub-license,
                                            subject to Clause 2.3, to develop, have developed, manufacture, have manufactured, import,
                                            use, sell and have sold Licensed Products only in the Field and in the Territory; and</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.1.2</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
                                            non-exclusive licence to use the Know-how, with the right to sub-license, subject to Clause
                                            2.3, to develop, have developed, manufacture, have manufactured, import, use, sell and have
                                            sold Licensed Products only in the Field and in the Territory.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">2.2</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Formal
                                            Licences <U>and Supply/Use of the Materials</U>.</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.2.1</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">UCLB
                                            shall at the Licensee&rsquo;s request and cost execute such formal licences as may be necessary
                                            or appropriate to enable the Licensee to register the licences granted to it under this Agreement
                                            with the patent offices in the Territory. If there is a conflict in meaning between any formal
                                            licence and this Agreement, this Agreement shall prevail wherever possible. The Licensee
                                            shall use its best endeavours to ensure that this Agreement shall not form part of any public
                                            record.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"></P>

<!-- Field: Page; Sequence: 14; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -42.6pt"></P>




<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.2.2</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>On
                                            or within (15) fifteen business days of the Frist Amendment Date, UCLB shall procure that
                                            UCL sends the Materials to the Licensee in such form and by such methods as the Parties may
                                            agree.</U></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.2.3</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>The
                                            Licensee shall be responsible for any reasonable shipping and related packing or transportation
                                            costs which may be incurred in preparing and sending the Materials to the Licensee. The Licensee
                                            shall also bear all risks of loss of the Materials in transit.</U></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -42.6pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.2.4</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>The
                                            Licensee, its Affiliates and its Sub-licensees (where applicable) shall use the Materials
                                            for the purposes of this Agreement only. The Licensee shall (and shall ensure that its Affiliates
                                            and Sub-licensees) use the Materials in accordance with good laboratory practice and the
                                            highest standards of skill and care and shall ensure compliance with any applicable laws
                                            and regulations governing the transportation, keeping or use of the Materials.</U></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">2.3</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Sub-Licensing.</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Licensee shall be entitled to grant sub-licences of its rights under this Agreement to any third party, provided that:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.3.1</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            Licensee receives UCLB&rsquo;s permission (which shall not be unreasonably withheld, conditioned
                                            or delayed) prior to the grant of the sub-licence;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.3.2</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            Licensee notifies UCLB promptly of the grant of the sub-licence and shall enter into a written
                                            sub-licence agreement with such third party;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.3.3</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">such
                                            sub-licence agreement shall include obligations on the Sub-licensee which are consistent
                                            with the obligations on the Licensee under this Agreement (but it is understood that the
                                            Sub-licensee shall not be required to make payments to UCLB corresponding to the Licensee&rsquo;s
                                            payment obligations under Clause 4);</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.3.4</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">such
                                            sub-licence agreement shall prohibit the Sub-licensee from granting further sub- licences
                                            of its rights under the Patents and to use the Know-how <U>and/or the Materials</U>;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.3.5</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            proposed sub-licensee is not a Tobacco Company or an Affiliate of such a company or a Person
                                            involved as its primary business in arms dealing, gambling operations, or the promotion of
                                            violence or an Affiliate of such Person, or if the proposed sub-licensee is a Person regularly
                                            involved in child labour or an Affiliate of such Person;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 15; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.3.6</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">each
                                            sub-licence shall terminate automatically upon termination of this Agreement for any reason
                                            (but not expiry of this Agreement under Clause 10.1) except where:</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"></P>




<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            Sub-licensee was not implicated in or at fault in any circumstances which led to the termination
                                            of this Agreement;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            benefit (but not the burden) of the sub-licence agreement is validly assigned to UCLB in
                                            writing by the Licensee within seven (7) days following the date of termination of this Agreement;
                                            and</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">following
                                            such assignment, the Sub-licensee observes in full the terms of the sub-licence agreement
                                            including paying all sums due to the Licensee under the sub-licence agreement directly to
                                            UCLB in a timely manner,</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">in
which case the Sub-licensee&rsquo;s rights to use (to the full extent of and with the full benefit of whatever exclusivity which UCLB
herein grants to the Licensee, had been afforded by the Licensee to the Sub-licensee in the sub-license) the Patents and the Know-how
<U>and/or the Materials</U> shall continue in full force and effect in accordance with the terms of the relevant sub-licence agreement;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.3.7</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            Licensee shall provide a certified true copy of each sub-licence agreement and of any subsequent
                                            amendments to it to UCLB within thirty (30) days following execution; and</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.3.8</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            Licensee shall ensure that each Sub-licensee complies fully with the terms of the relevant
                                            sub-licence agreement. The Licensee shall be responsible for any breach of or non-compliance
                                            with a sub-licence agreement by its Sub-licensees as if the breach or non-compliance had
                                            been a breach of or non-compliance with this Agreement by the Licensee, and the Licensee
                                            shall indemnify each of the Indemnitees against any Claims which are awarded against or suffered
                                            by any of the Indemnitees as a result of any such breach or non-compliance by its Sub-licensees.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Licensee acknowledges that a breach of Clauses 2.3.1 to 2.3.5 (inclusive) shall be considered a material breach of this Agreement for
the purpose of Clause 10.2.1.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">2.4</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Reservation
                                            of Rights.</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.4.1</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">UCLB
                                            reserves for itself and its non-commercial Affiliates the non-exclusive, irrevocable, worldwide,
                                            royalty-free right to (but only to):</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">use
                                            the Patents <U>and the Materials</U> in the Field for its or their own internal non- commercially
                                            funded research (including conducting clinical trials), academic purposes, publication and
                                            teaching;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"></P>

<!-- Field: Page; Sequence: 16; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"></P>




<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">license
                                            other academic institutions to use the Patents <U>and the Materials</U> in the Field solely
                                            for their own internal non-commercially funded research (including conducting clinical trials),
                                            academic purposes, publication and teaching; and</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">grant
                                            licences to use the Patents <U>and the Materials </U>in the Field to post graduate students
                                            of UCL for the sole purpose of conducting a wholly non- commercial programme of post graduate
                                            academic research.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.4.2</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Except
                                            for the licences expressly granted by this Clause 2, UCLB grants no rights to the Licensee
                                            and its Affiliates to or under any intellectual property or know-how other than the Patents<U>,
                                            </U><STRIKE>and</STRIKE> the Know-how <U>and the Materials</U>, and UCLB hereby expressly
                                            reserves all rights under the Patents<U>,</U> <STRIKE>and</STRIKE> the Know-how <U>and the
                                            Materials </U>outside the Field.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">2.5</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Access
                                            to Improvements</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.5.1</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Licensee
                                            Improvements</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            Licensee shall notify UCLB of each Licensee Improvement, in sufficient detail to allow UCLB
                                            to make use thereof, as soon as reasonably practicable following the creation, discovery
                                            or acquisition of the relevant Licensee Improvement.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -35.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            Licensee hereby grants to UCLB and its wholly non-commercial Affiliates, and UCLB hereby
                                            accepts on its own behalf and on behalf of its wholly non- commercial Affiliates, subject
                                            to the provisions of this Agreement a non- exclusive, transferable, sub-licensable, royalty-free,
                                            irrevocable and perpetual licence under the Licensee Improvements:</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -35.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">to
                                            use the Licensee Improvements solely for its or their own internal non-commercially funded
                                            research (including conducting clinical trials), academic purposes, publication and teaching;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">to
                                            license other academic institutions to use the Licensee Improvements solely for their own
                                            internal non-commercially funded research (including conducting clinical trials), academic
                                            purposes, publication and teaching; and</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">to
                                            grant licences of the Licensee Improvements to post graduate students of UCL for the sole
                                            purpose of conducting a wholly non- commercial programme of post graduate academic research.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -35.45pt"></P>

<!-- Field: Page; Sequence: 17; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -35.45pt"></P>




<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.5.2</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">UCLB
                                            Improvements</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">UCLB
                                            shall notify the Licensee of each UCLB Improvement, in sufficient detail to allow the Licensee
                                            to make use thereof, as soon as reasonably practicable following the creation, discovery
                                            or acquisition of the relevant UCLB Improvement being brought to UCLB&rsquo;s knowledge.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -35.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">UCLB
                                            hereby grants to the Licensee an exclusive option to obtain a licence of any UCLB Improvements,
                                            such licence to be on commercial terms to be negotiated between the Parties.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -35.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            Licensee shall have a period of three (3) months from the date of UCLB&rsquo;s notification
                                            to review and evaluate each UCLB Improvement (the &ldquo;<B>Evaluation Period</B>&rdquo;).
                                            The Licensee may exercise its option over each UCLB Improvement at any time during the relevant
                                            Evaluation Period by serving a written notice upon UCLB.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -35.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
                                            the Licensee exercises its option over any UCLB Improvement in accordance with sub-clause
                                            (c) above, the Licensee and UCLB will use their reasonable endeavours to negotiate in good
                                            faith and agree the terms of a licence for the relevant UCLB Improvement within a period
                                            of twelve (12) months from the date of UCLB&rsquo;s receipt of the Licensee&rsquo;s written
                                            notice (the &ldquo;<B>Negotiation Period</B>&rdquo;), provided that neither Party will be
                                            obliged to enter into such a licence.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -35.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">UCLB
                                            shall not enter into a licence agreement (whether exclusive or non- exclusive) with a third
                                            party in respect of any UCLB Improvement during the relevant Evaluation Period and if the
                                            Licensee exercises its option in accordance with sub-clause (c) above, during the relevant
                                            Negotiation Period. If the Licensee does not exercise its option in relation to any UCLB
                                            Improvement within the relevant Evaluation Period or if the Licensee does exercise its option,
                                            but the Parties cannot agree upon the licence terms within the relevant Negotiation Period,
                                            UCLB shall be at liberty to use the relevant UCLB Improvement for any purpose whatsoever
                                            and to enter into any licence or other agreements or arrangements with any third party or
                                            parties to exploit the UCLB Improvement at its sole discretion.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -35.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">2.6</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Affiliates.</B></FONT></TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Licensee shall:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.6.1</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ensure
                                            that its Affiliates comply fully with the terms of this Agreement;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -42.65pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -42.65pt"></P>

<!-- Field: Page; Sequence: 18; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -42.65pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -42.65pt"></P>




<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.6.2</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">be
                                            responsible for any breach of or non-compliance with this Agreement by its Affiliates as
                                            if the breach or non-compliance had been a breach of or non-compliance with this Agreement
                                            by the Licensee;</FONT></P>
</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.6.3</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">indemnify
                                            each of the Indemnitees against any Claims which are awarded against or suffered by any of
                                            the Indemnitees as a result of any breach of or non-compliance with this Agreement by its
                                            Affiliates; and</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.6.4</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ensure
                                            that if any Affiliate ceases to be an Affiliate as a result of a change of Control or otherwise,
                                            that former Affiliate immediately upon such cessation:</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ceases
                                            developing, manufacturing, having manufactured, importing, using, selling and/ or having
                                            sold Licensed Products and ceases all, use or exploitation of each Valid Claim of an issued
                                            Patent within the Licensed Technology, for as long as the applicable patent claim continues
                                            to be a Valid Claim of an issued Patent within the Licensed Technology, <STRIKE>and </STRIKE>ceases
                                            all use or exploitation of each item of Know-how within the Licensed Technology, for as long
                                            as the applicable item of Know-how remains <STRIKE>confidentia</STRIKE><U>confidential, and
                                            ceases all use or exploitation of the Materials</U>l;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">returns
                                            to the Licensee or destroys any documents or other materials in the former Affiliate&rsquo;s
                                            possession or under its control and that contain UCLB&rsquo;s Confidential Information or
                                            any confidential information of the Licensee relating to the Licensed Technology and/ or
                                            Licensed Products;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">delivers
                                            to the Licensee a copy of all technical and clinical data relating to Licensed Products generated
                                            by the former Affiliate;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">discloses
                                            to the Licensee full details of all and any Licensee Improvements generated by the former
                                            Affiliate; and</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">to
                                            the extent possible, takes all action necessary to have any former Affiliate&rsquo;s product
                                            licences, marketing authorisations, pricing and/ or reimbursement approvals (and any applications
                                            for any of the foregoing) which relate to Licensed Products transferred into the name of
                                            the Licensee.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">3.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>KNOW-HOW
                                            AND OTHER CONFIDENTIAL INFORMATION</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">3.1</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Provision
                                            of Know-how.</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Within
thirty (30) days following the Commencement Date, UCLB shall deliver to the Licensee (electronically or on other appropriate media) a
copy of the Know-how. UCLB shall instruct the Principal Investigator to answer all reasonable queries received from the Licensee regarding
the Know-how, provided that if in order to answer any such queries the Principal Investigator is required to:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1.1</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">work
                                            more than in aggregate two (2) man days of seven and a half (7.5) hours each, the Licensee
                                            shall pay the Principal Investigator a fee for providing such assistance, such fee to be
                                            agreed between the Licensee and the Principal Investigator; and/ or</FONT></TD></TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1.2</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">attend
                                            the Licensee&rsquo;s premises, the Licensee shall reimburse the Principal Investigator promptly
                                            on demand for all travel (at business class rates), accommodation and subsistence costs incurred
                                            in so doing.</FONT></TD></TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 19; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT>&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">3.2</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Confidentiality
                                            of Know-how <U>and the Materials</U>.</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Licensee undertakes that for so long as the Know-how <U>and/or the Materials </U>remains confidential, it shall (and shall ensure that
its Affiliates and Sub-licensees) take all reasonable precautions to prevent unauthorised access to the Know-how <U>and the Materials
</U>and protect the Know-how <U>and the Materials </U>in the same manner as it (or they) protect(s) its (or their) own proprietary information,
and shall not (and shall ensure that its Affiliates and Sub-licensees do not) use the Know-how <U>and/or the Materials </U>for any purpose,
except as expressly licensed hereby and in accordance with the provisions of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">3.3</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Confidentiality
                                            Obligations.</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
Party (&ldquo;<B>Receiving Party</B>&rdquo;) undertakes:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.3.1</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">to
                                            maintain as secret and confidential all Confidential Information obtained from the other
                                            Party (&ldquo;<B>Disclosing Party</B>&rdquo;) in the course of or in anticipation of this
                                            Agreement and to respect the Disclosing Party&rsquo;s rights therein;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.3.2</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">to
                                            use such Confidential Information only for the purposes of or as permitted by this Agreement;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.3.3</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">not
                                            to engage in any conduct which would be regarded as infringing conduct under the EU Trade
                                            Secrets Directive; and</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.3.4</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">to
                                            disclose such Confidential Information only to those of its employees, contractors, Affiliates,
                                            and Sub-licensees (if any) to whom, and to the extent that, such disclosure is reasonably
                                            necessary for the purposes of this Agreement, provided however that the Licensee shall have
                                            the right to disclose Confidential Information received from UCLB to potential or actual
                                            customers of Licensed Products to the extent reasonably necessary to promote the sale or
                                            use of Licensed Products and provided that such customer has agreed to confidentiality provisions
                                            at least as restrictive as those set forth herein.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<!-- Field: Page; Sequence: 20; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -42.6pt"></P>




<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">3.4</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exceptions
                                            to Obligations.</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
provisions of Clause 3.3 shall not apply to Confidential Information which the Receiving Party can demonstrate by reasonable written
evidence:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.4.1</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">was,
                                            prior to its receipt by the Receiving Party from the Disclosing Party, in the possession
                                            of the Receiving Party and at its free disposal; or</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.4.2</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">is
                                            subsequently disclosed to the Receiving Party by a third party without any obligations of
                                            confidence; or</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.4.3</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">is
                                            or becomes generally available to the public through no act or default of the Receiving Party
                                            or its agents, employees, Affiliates or Sub-licensees;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.4.4</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">is
                                            rightfully received by the Receiving Party on a non-confidential basis from a Third Party
                                            who is entitled to disclose it without breaching any confidentiality obligation (directly
                                            or indirectly) to the Disclosing Party and who, to the Receiving Party&rsquo;s best knowledge,
                                            did not obtain such information, directly or indirectly, from the Disclosing Party;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -42.6pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.4.5</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">is
                                            independently developed by or for the Receiving Party, in either case solely by personnel
                                            without any access to or use of the Confidential Information provided by the Disclosing Party;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -42.6pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.4.6</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            Receiving Party is required to disclose to patent offices in furtherance of the Patents;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -42.6pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.4.7</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            Receiving Party is required to disclose by or to the courts of any competent jurisdiction,
                                            or to any government regulatory agency or financial authority, provided that the Receiving
                                            Party shall:</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">inform
                                            the Disclosing Party as soon as is reasonably practicable of such requirement; and</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">at
                                            the Disclosing Party&rsquo;s request and cost seek to persuade the court, agency or authority
                                            to have the information treated in a confidential manner, where this is possible under the
                                            court, agency or authority&rsquo;s procedures; or</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.4.8</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">which
                                            a Party is advised in good faith by its information officer that it is required to disclose
                                            under the Freedom of Information Act 2000 or the Environmental Information Regulations 2004
                                            or equivalent laws of the United States or of another country.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<!-- Field: Page; Sequence: 21; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>




<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">3.5</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Disclosure
                                            to Employees and others.</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Receiving Party shall procure that all of its employees, contractors, Affiliates and Sub- licensees who have access to any of the Disclosing
Party&rsquo;s Confidential Information to which Clause 3.3 applies, shall be made aware of the obligations of confidence and enter into
written undertakings of confidentiality at least as restrictive as those set forth herein.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">4.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>PAYMENTS</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">4.1</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Initial
                                            Payment.</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
or before or within seven (7) days after the Commencement Date, the Licensee shall pay to UCLB a non-refundable, non-deductible licensing
fee of $150,000 (one fifty thousand US dollars).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">4.2</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Historic
                                            Patent Costs.</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
or before or within thirty (30) days after the Commencement Date, the Licensee shall reimburse all of the costs and expenses incurred
by UCLB in respect of drafting, applying for and prosecuting the Patents prior to the Commencement Date, which are estimated to be in
the region of $160,384.22 (one hundred sixty thousand three hundred and eighty-four point twenty-two US dollars) (&ldquo;<B>Historic
Patent Costs</B>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">4.3</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Milestone
                                            Payments.</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.3.1</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Within
                                            15 days following achievement of each of the following milestone events by the Licensee or
                                            any of its Affiliates or Sub-licensees, the Licensee shall notify UCLB in writing that the
                                            relevant milestone event has been achieved and, subject to Clause<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.3.2</FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">below, pay to UCLB the amount(s) set out next to such milestone event in the table below within 30 days after receipt of UCLB&rsquo;s invoice therefor:</FONT></FONT></TD></TR>
                                                                                                                              </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Milestone
    Event</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Amount to be paid</B></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>First
                                            Indication</B></FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Second
                                            Indication and each Subsequent Indication</B></FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 64%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">First patient
    dosed in Phase I Study, for a Licensed Product which has a first patient dosed in a Phase I Study</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[****]</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[****]</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">First patient dosed in Phase
    II Study, for a Licensed Product which has a first patient dosed in a Phase II Study</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[****]</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[****]</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">First patient dosed in Phase
    III Study, for a Licensed Product which has a first patient dosed in a Phase III Study</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[****]</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[****]</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Approval of a New Drug Application
    (NDA) in the United States by the Food and Drug Administration (FDA), for a Licensed Product which has a NDA (or, as the case may
    be, for a Second or Subsequent Indication) approved by the FDA in the United States</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[****]</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[****]</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Approval of Marketing Authorization
    Application in the European Union or in the United Kingdom, for aLicensed Product which has a Marketing Authorization Application
    (or, as the case may be, for a Second or Subsequent Indication) approved in the European Union or in the United Kingdom</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[****]</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[****]</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net Sales Value hitting a
    target figure of $[****] ([****] US dollars) or above during a calendar year</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[****]</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[****]</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 22; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If,
for any reason, any of the milestones set out above are achieved without all or any of the preceding milestones having been achieved
by the Licensee or its Affiliates or Sub-licensees, then upon achievement of the relevant milestone, the milestone payments for the preceding
milestones which have not been achieved shall also be due and payable. By way of example only, if the second milestone is achieved without
the Licensee or its Affiliates or Sub-licensees having achieved the first milestone, then upon achievement of the second milestone, the
payment for the first milestone which has not been achieved shall also be due and payable. (Provided, however, that this rule shall not
apply to deem the milestone of FDA approval of a NDA to have been achieved upon approval of a MAA, and this rule shall not apply to deem
the milestone of FDA approval of a NDA or the milestone of approval of a MAA to have been achieved upon Net Sales Value hitting a target
figure of $[****] during a calendar year.)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notwithstnding
anything stated in Clause 4.3.1 to the contrary, where the Licensee has already paid against a milestone event (for an Indication, as
stated above) in respect of a Licensed Product, it shall not be required to pay again against the same milestone event (for the same
Indication, as stated above) with respect to a subsequent Licensed Product.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.3.2</FONT></TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Licensee shall be entitled
  to deduct (without duplicative deducting) an amount equal to the cumulative Minimum Royalty(ies) paid by it pursuant to Clause 4.8
  from any milestone payment due against a milestone event stated in Clause 4.3.1 that immediately follows such Minimum Royalty(ies)
  payment.</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -42.6pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">4.4</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Royalties
                                            on Net Sales Value.</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Licensee shall pay to UCLB a royalty being a percentage of the Net Sales Value of all Licensed Products or any part thereof used, sold
or disposed of by or on behalf of the Licensee or its Affiliates as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.4.1</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[****]%
                                            ([****] percent) in case cumulative Net Sales Value is equal to or less than $[****] ([****]
                                            US dollars); and</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.4.2</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[****]%
                                            ([****] percent) in case cumulative Net Sales Value is above $[****] ([****] US dollars).</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">4.5</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Royalties
                                            on Net Receipts.</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Licensee shall pay to UCLB a royalty of [****]% ([****] percent) of Net Receipts.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 23; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">4.6</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Combination
                                            Products.</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
any Licensed Products are incorporated in or bundled with any other product (&ldquo;<B>Combination Product</B>&rdquo;) sold by the Licensee
or its Affiliates and the Licensed Product is not priced separately from the Combination Product, the Net Sales Value of such Licensed
Product shall be deemed to be the fair market value of the Licensed Product in the country of sale when sold separately or if not sold
separately in the country of sale, in comparable countries and territories or if neither of the foregoing apply, a reasonable amount
which fairly reflects the value of the Licensed Product within the Combination Product assuming the Licensed Product is not being sold
as a loss leader. For avoidance of doubt, a single medical product which incorporates both a Licensed Product and a non-Licensed Product
active pharmaceutical ingredient would be an instance of a Combination Product. Notwithstanding the foregoing, in no event shall the
Net Sales Value of such Licensed Product be less than [****]% ([****] percent) of the Net Sales Value of the Combination Product (where
the Net Sales Value of the Combination Product is calculated mutatis mutandis with the references to the Licensed Products (in the definition
of &ldquo;Net Sales Value&rdquo;) and such references to Licensed Products treated as if they were references to the Combination Product).<I></I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">4.7</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Valuation
                                            of Non-Monetary Consideration; Referral to Expert.</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
at any time a dispute arises or the Parties are unable to reach agreement in relation to the open market value of any non-cash consideration
received by the Licensee for a Licensed Product or the value of any non-cash consideration which forms part of Net Receipts or the reasonable
value for a Licensed Product when incorporated within a Combination Product and the Parties are not able to resolve such dispute within
thirty (30) days following the dispute first arising, such disagreement shall be referred to an independent expert who shall be appointed
and act in accordance with the provisions of Schedule 2 and whose decision shall be final and binding on the Parties.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">4.8</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Minimum
                                            Royalties.</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
the royalties payable under Clause 4.4 to Clause 4.5 (inclusive) are less than the amounts described in the Table below (&ldquo;<B>Minimum
Royalty</B>&rdquo;) with respect to the corresponding calendar year (i.e., 1 January to 31 December) indicated in the Table below, the
Licensee shall for the avoidance of doubt in addition to the royalties payable pursuant to Clause 4.4 to 4.5, pay to UCLB the amount
by which such royalties are less than the Minimum Royalty within thirty (30) days following the end of the relevant calendar year, failing
which UCLB shall be entitled to terminate this Agreement and all licences granted under this Agreement by notice in writing to the Licensee
given at any time after the expiry of the said thirty (30) day period. If this Agreement ends on any day other than the last day of a
calendar year, the Minimum Royalty due for that year shall be reduced pro-rata calculated on the basis of the number of days of the final
calendar year during which this Agreement was in force.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 75%; margin-left: 0.5in">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; width: 74%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Calendar
    Year</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; width: 22%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Minimum
                                            Royalty</B></FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2025</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[****]</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2026</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[****]</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2027</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[****]</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2028
    and any subsequent calendar year</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[****]</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 24; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the avoidance of doubt, where no royalties under Clauses 4.4 and/or 4.5 are generated by the Licensee, its Affiliates or Sub-licensees
for a calendar year (as stated in the Table above), the Minimum Royalty set out in the above Table shall be payable in its entirety in
respect of the relevant calendar year.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">4.9</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Royalties
                                            to Third Parties.</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If,
during the term of this Agreement, the Licensee has taken appropriate professional advice from its patent agents and is advised in a
written opinion by its patent agents that it is necessary to obtain a licence from any third party (&ldquo;<B>Third Party Licence</B>&rdquo;)
in order to avoid infringing such third party&rsquo;s patent(s) in the course of manufacture or sale of Licensed Products and provided
that the Licensee has, acting reasonably, consulted with UCLB, and has taken into account any representations made to it by UCLB, in
relation to the necessity of obtaining such Third Party Licence, the royalties payable under this Agreement shall be reduced by [****]%
([****] percent) of the amount of royalties paid by the Licensee under the Third Party Licence. Notwithstanding the foregoing, the amount
of royalty payable by the Licensee to UCLB in any quarterly period in respect of each country and territory within the Territory shall
not be reduced by more than [****]% ([****] percent) of the amount which would have otherwise been payable in the absence of this Clause.
The reduction referred to in this Clause shall only be made where the infringement of the third party patent arises from the use of the
inventions claimed in the Patents in accordance with the provisions of this Agreement, and not from the use of any other intellectual
property that the Licensee chooses to use in the manufacture or sale of any Licensed Product. The Licensee shall use its commercially
reasonable efforts to avoid having to pay royalties, and to minimise the amount of any such royalties which it agrees to pay, to any
Third Party. W here the Parties disagree as to the necessity of a Third Party Licence, and the Parties are not able to resolve such dispute
within thirty (30) days following the dispute first arising, then such dispute shall be referred to an expert who shall be appointed
in accordance with the provisions of Schedule 2 and whose decision shall be final and binding on the Parties.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">4.10</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Payment
                                            Frequency.</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Royalties
due under this Agreement shall be paid within thirty (30) days following the end of each calendar quarter ending on 31 March, 30 June,
30 September and 31 December in each year, in respect of sales of Licensed Products made and Net Receipts generated during such quarter
and within thirty (30) days following the termination of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 25; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">4.11</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Payment
                                            terms.</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
sums due under this Agreement:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.11.1</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">are
                                            exclusive of Value Added Tax which where applicable will be paid by the Licensee to UCLB
                                            in addition;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.11.2</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">shall
                                            be paid in US dollars in cash by transferring an amount in aggregate to the following account
                                            number: [****], and in the case of income or amounts received by the Licensee or its Affiliates
                                            in a currency other than US dollars, the royalty shall be calculated in the other currency
                                            and then converted into equivalent US dollars at the relevant daily spot rate for that currency
                                            as quoted in the Financial Times newspaper on the last business day of the period in relation
                                            to which the royalties are payable;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.11.3</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">will
                                            be made without any set-off, deduction or withholding except as may be required by law. If
                                            the Licensee is required by law to make any deduction or to withhold any part of any amount
                                            due to UCLB under this Agreement, the Licensee will give to UCLB proper evidence of the amount
                                            deducted or withheld and payment of that amount to the relevant taxation authority, and will
                                            do all things in its power to enable or assist UCLB to claim exemption from or, if that is
                                            not possible, to obtain a credit for the amount deducted or withheld under any applicable
                                            double taxation or similar agreement from time to time in force; and</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.11.4</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">shall
                                            be made by the due date, failing which UCLB may charge interest on any outstanding amount
                                            on a daily basis until such payment is made at a rate equivalent to 3% above the Barclays
                                            Bank plc base lending rate then in force in London.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">4.12</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Royalty
                                            Statements.</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Licensee shall send to UCLB at the same time as each royalty payment is made in accordance with Clauses 4.4 to 4.5 (inclusive) a statement
setting out for the relevant calendar quarter the detail included at Schedule 5.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">4.13</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Records.</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.13.1</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            Licensee shall keep at its normal place of business detailed and up to date records and accounts
                                            showing the quantity, description and invoiced price or non- cash consideration for all Licensed
                                            Products sold by it or its Affiliates or on its or its Affiliates&rsquo; behalf, and the
                                            amount of Net Receipts, broken down in each case on a country by country basis, and being
                                            sufficient to ascertain the payments due to UCLB under this Agreement.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 26; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.13.2</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            Licensee shall make such records and accounts available, on reasonable notice, for inspection
                                            during business hours by an independent chartered accountant nominated by UCLB for the purpose
                                            of verifying the accuracy of any statement or report given by the Licensee to UCLB under
                                            Clause 4.13.1. The Licensee shall co- operate reasonably with any such accountant, and shall
                                            promptly provide all information and assistance reasonably requested by such accountant.
                                            The accountant shall be required to keep confidential all information learnt during any such
                                            inspection, and to disclose to UCLB only such details as may be necessary to report on the
                                            accuracy of the Licensee&rsquo;s statement or report. UCLB shall be responsible for the accountant&rsquo;s
                                            charges unless the accountant certifies that there is an inaccuracy of more than 5% (five
                                            percent) in any royalty statement, in which case the Licensee shall pay his charges in respect
                                            of that inspection.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.13.3</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Such
                                            records and accounts, and the accountant&rsquo;s reports, shall be deemed to be Confidential
                                            Information of the Licensee.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.13.4</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            Licensee shall ensure that UCLB has the same rights as those set out in this Clause 4.13
                                            in respect of the Licensee&rsquo;s Affiliates.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Licensee shall co-operate with UCLB in good faith to resolve any discrepancies identified during any such inspection and shall pay any
shortfall in the amounts paid to UCLB under this Agreement, together with interest on late payment as specified in Clause 4.11.4, within
thirty (30) days following receipt of a copy of the independent chartered accountant&rsquo;s report.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">4.14</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Accounting
                                            Standards.</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Where
this Agreement requires a financial calculation to be made or an action to be taken, such calculation or action will be made or taken
in accordance with the generally accepted accounting principles (consistently applied) from time to time approved by the United Kingdom&rsquo;s
Accounting Standards Board, or any successor body, applicable as at the date on which such calculation or action is made or taken.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">5.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>COMMERCIALISATION</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">5.1</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>General
                                            Diligence.</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Licensee shall use Diligent Efforts to develop and commercialise Licensed Products in the Territory (including obtaining regulatory approvals
which may be required to market and sell the Licensed Products) and to maximise sales for the benefit of both Parties.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 27; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></P>




<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">5.2</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>[reserved.]</B></FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.3</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Development
                                            Plan.</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Licensee&rsquo;s initial plan for developing and commercialising Licensed Products is set out in Schedule 3 (the &ldquo;<B>Development
Plan</B>&rdquo;). The Licensee shall provide to UCLB on each anniversary of the Commencement Date a written update to the Development
Plan that shall:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.3.1</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">report
                                            on all activities conducted under this Agreement by the Licensee and its Affiliates and Sub-licensees
                                            since the Commencement Date or the date of the previous update (as appropriate);</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.3.2</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">set
                                            out the milestone events achieved since the Commencement Date or the date of the previous
                                            update (as appropriate) and the Licensee&rsquo;s best estimate of the dates for achieving
                                            any future milestone events;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.3.3</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">set
                                            out the current and projected activities being taken or planned to be taken by the Licensee
                                            and its Affiliates and Sub-licensees to bring Licensed Products to market, and to maximise
                                            the sale of Licensed Products in the Territory and in the Field; and</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.3.4</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">set
                                            out the Licensee&rsquo;s and its Affiliates&rsquo; and Sub-licensees&rsquo; projected sales
                                            of Licensed Products (based on the Licensee&rsquo;s current forecasts) for each of the next
                                            three (3) years following the date of the report.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">UCLB&rsquo;s
receipt or approval of any update to the Development Plan shall not be taken to waive or qualify the Licensee&rsquo;s obligations under
Clause 5.1. The Development Plan shall be deemed to be Confidential Information of the Licensee.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">5.4</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Annual
                                            Meeting.</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Licensee will on UCLB&rsquo;s request meet with UCLB at least once per calendar year, following the submission of the update to the Development
Plan pursuant to Clause 5.3, to discuss progress with regard to the development and commercialisation of the Licensed Technology and
the Licensee&rsquo;s efforts to maximise sales of Licensed Products in the Territory and in the Field.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">5.5</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Reporting
                                            of First Commercial Sale.</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Licensee will promptly notify UCLB in writing of the First Commercial Sale of each Licensed Product in each country within the Territory.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 28; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></P>




<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">5.6</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Reporting
                                            for Impact Purposes.</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.6.1</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            Licensee acknowledges that part of UCLB&rsquo;s purpose in licensing the Patents, <STRIKE>the
                                            and </STRIKE>the Know-how <U>and the Materials </U>to the Licensee pursuant this Agreement
                                            is to ensure that the Patents<U>,</U> <STRIKE>and</STRIKE> the Know-how <U>and the Materials
                                            </U>are made available for use and commercial exploitation with the intention of benefitting
                                            society and the economy. In order to enable UCLB and UCL to monitor the benefit that they
                                            are providing, and to enable UCL to demonstrate the impact of its research activities, to
                                            society and the economy, the Licensee will provide to UCLB on each anniversary of the Commencement
                                            Date during the period of this Agreement and for a period of three (3) years thereafter a
                                            written report describing in reasonable detail how it has used the Patents<U>,</U> <STRIKE>and
                                            </STRIKE>the Know-how <U>and the Materials</U> and the societal and economic benefits generated
                                            therefrom.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.6.2</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Such
                                            reports shall be deemed to be Confidential Information of Licensee. The Licensee acknowledges
                                            that UCLB and UCL shall be entitled to make use of any written reports received from the
                                            Licensee (and the information contained therein) pursuant to Clause 5.6.1 in confidential
                                            applications for research or other grant related funding and in confidential submissions
                                            to Higher Education funding bodies such as HEFCE and/ or HEIF (or any replacements for either
                                            of those entities) and like entities, and to use the Licensee&rsquo;s name and the fact that
                                            the Licensed Technology have been provided to the Licensee hereunder in their general publicity
                                            materials.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -42.6pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">5.7</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Quality.</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Licensee shall ensure that all of the Licensed Products marketed by it and its Affiliates are of satisfactory quality and comply with
all applicable laws and regulations in each part of the Territory, and shall use commercially reasonable efforts to ensure that all of
the Licensed Products marketed by its Sub-licensees are of satisfactory quality and comply with all applicable laws and regulations in
each part of the Territory.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">5.8</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Marking
                                            of Licensed Products.</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
the extent permitted under the laws of any country, the Licensee shall mark and cause its Affiliates and Sub-licensees to mark each Licensed
Product with the number of each issued Patent in the applicable country which applies to the Licensed Product and a statement that such
Licensed Products are sold under licence from UCL Business Ltd.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">5.9</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Disposals
                                            of Licensed Products for Free.</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notwithstanding
the terms of Clause 5.1, the Licensee shall be entitled to supply a reasonable number of Licensed Products to third parties free of charge:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"></P>

<!-- Field: Page; Sequence: 29; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></P>




<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.9.1</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">for
                                            use in clinical trials;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.9.2</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">for
                                            use in an early access scheme, patient access scheme or market access scheme approved by
                                            regulatory authorities in the relevant territories;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.9.3</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">as
                                            promotional items for the purpose of establishing a market for the Licensed Products in the
                                            relevant country or territory; and/or</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -42.6pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.9.4</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">for
                                            evaluation and testing purposes,</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -42.65pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">provided
that in the case of sub-clause 5.9.3 and 5.9.4, the Licensee shall be entitled to supply Licensed Products free of charge for a maximum
of [****] ([****]) years following the grant of the first marketing authorisation for the Licensed Product and that the quantity of Licensed
Products supplied for free in each country in each twelve (12) month period is no more than [****] percent ([****]%) of the total sales
volume of Licensed Products in such country during the same period, and in all cases, the quantity of Licensed Products supplied for
free in each country or territory is not excessive and is in line with normal industry practice in such country or territory. Any Licensed
Products disposed of to third parties free of charge in accordance with this Clause 5.9 shall not be taken into account for the purposes
of calculating Net Sales Value. For the avoidance of doubt, Licensed Products disposed of to third parties free of charge, in each country,
in excess of [****] percent ([****]%) of the total sales volume for that country, in each twelve (12) month period, shall be taken into
account for the purposes of calculating Net Sales Value.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">5.10</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Referral
                                            to Expert.</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
UCLB considers at any time during the period of this Agreement that the Licensee has without legitimate reason failed to comply with
its obligations under Clause 5.1, UCLB shall be entitled to refer to an independent expert the following questions:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.10.1</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">whether
                                            the Licensee has complied with its obligations under Clause 5.1; and if not</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.10.2</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">what
                                            specific action the Licensee should have taken (&ldquo;<B>Specific Action</B>&rdquo;) in
                                            order to have so complied.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
independent expert shall be appointed in accordance with the provisions of Schedule 2 and his decision shall be final and binding on
the Parties.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">5.11</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Consequences
                                            of Expert&rsquo;s Decision.</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
the expert determines that the Licensee has failed to comply with its obligations under Clause 5.1, and if the Licensee fails to take
the Specific Action within six (6) months after the expert giving his decision in accordance with Schedule 2, UCLB shall be entitled,
by giving, at any time within four (4) months after the end of that six (6) month period, not less than three (3) months&rsquo; notice,
to terminate this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 30; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></P>




<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">6.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ACCESS
                                            TO MEDICINES AND ETHICAL LICENSING</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">6.1</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Acknowledgements</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.1.1</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            Licensee acknowledges that UCLB and UCL are committed to implementing effective technology
                                            transfer strategies that promote the availability of health-related technologies in developing
                                            countries for essential medical care, as set out in UCL&rsquo;s Statement of Principles and
                                            Strategies for the Equitable Dissemination of Medical Technologies.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.1.2</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">UCLB
                                            recognises the early stage nature of the Licensed Technology and acknowledges that a substantial
                                            investment will be required by the Licensee to develop Licensed Products and to bring those
                                            Licensed Products to market in Developing Countries.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">6.2</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>General
                                            Diligence.</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Licensee agrees to use Diligent Efforts to ensure effective and affordable access to Licensed Products in Developing Countries.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">6.3</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Supply
                                            to Developing Countries.</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Licensee shall use Diligent Efforts to supply or to procure the supply of the Licensed Products to customers in At-Cost Markets at a
Cost-Based Price and to meet market demand for the Licensed Products in those markets. UCLB shall waive its entitlement to royalties
on all Licensed Products sold in to customers in At-Cost Markets at a Cost-Based Price and such sales shall not count toward the $[****]
milestone.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">6.4</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Reporting
                                            and Consultation.</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.4.1</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            Licensee shall keep UCLB regularly updated regarding the Licensee&rsquo;s efforts to supply
                                            the Licensed Products in accordance with the requirements outlined in Clauses 6.2 and 6.3.
                                            Such updates shall be deemed to be Confidential Information of Licensee.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.4.2</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            Licensee shall consult with UCLB prior to filing any patent application which claims priority
                                            from or is based on any of the Patents or in relation to Licensed Products in any Developing
                                            Countries, and shall take into account any comments received from UCLB with respect to the
                                            potential effect of such patent applications on facilitating access to healthcare related
                                            technologies in such countries and territories. Where such patent applications are filed
                                            in Developing Countries, the Licensee shall reasonably consider any request from UCLB not
                                            to assert such patents and patent applications in such countries.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"></P>

<!-- Field: Page; Sequence: 31; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"></P>




<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.4.3</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            Licensee shall consider in good faith all reasonable requests received from UCLB to negotiate
                                            and agree from time to time such amendments to this Agreement as UCLB, acting reasonably,
                                            may deem necessary or appropriate to ensure effective and affordable access to Licensed Products
                                            in Developing Countries.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">6.5</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Step
                                            In Rights.</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.5.1</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
                                            at any time UCLB acting reasonably considers that the Licensee is not meeting its obligations
                                            under Clauses 6.2 and 6.3., UCLB may by written notice require the Licensee:</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">to
                                            seek one or more third parties to develop, commercialise and supply the Licensed Products
                                            to customers in At-Cost Markets; or</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -35.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">to
                                            negotiate with UCLB in respect of reasonable global access terms.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.5.2</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
                                            the Licensee following a written requirement from UCLB refuses to grant a sublicense to or
                                            is unable to identify a third party to develop, commercialise and supply the Licensed Products
                                            to customers in At-Cost Markets or the parties are unable to negotiate reasonable global
                                            access terms, then UCLB notwithstanding the rights granted to the Licensee under this Agreement
                                            shall have the right to seek a third party to, and/ or to grant to a third party a licence
                                            to, manufacture, have manufactured, use, sell, offer for sale and import the Licensed Products
                                            for supply in (but only in and for) the At-Cost Market on such terms as UCLB may in its sole
                                            discretion determine as being appropriate to ensure effective and affordable access to Licensed
                                            Products in Developing Countries.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">7.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>COMPLIANCE
                                            WITH LAWS</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">7.1</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>General
                                            Compliance with Laws.</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Licensee will at all times comply (and will ensure its Affiliates comply) in all material respects with all legislation, rules, regulations
and statutory requirements applying to and obtain any consents necessary for its use of the Patents<U>,</U> <STRIKE>and</STRIKE> the Know-how
<U>and the Materials</U>, the development, manufacture, and sale of Licensed Products in any country or territory, and the Licensee will
at all times use commercially reasonable efforts to ensure its Sub-licensees comply in all material respects with all legislation, rules,
regulations and statutory requirements applying to and obtain any consents necessary for its use of the Patents<U>,</U> <STRIKE>and</STRIKE>
the Know-how <U>and the Materials</U>, the development, manufacture, and sale of Licensed Products in any country or territory.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 32; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></P>




<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">7.2</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Bribery
                                            Act.</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Licensee shall (and shall procure that any persons associated with it engaged in the performance of this Agreement including its Affiliates
shall), and the Licensee shall use commercially reasonable efforts to procure that its Sub-licensees shall:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.2.1</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">comply
                                            with all applicable laws and codes of practice relating to anti-bribery and anti- corruption
                                            including the Bribery Act 2010 and without prejudice to the foregoing generality, shall not
                                            engage in any activity, practice or conduct which would constitute an offence under sections
                                            1, 2 or 6 of the Bribery Act 2010 or do or omit to do any act that will cause or lead UCLB
                                            to be in breach of the Bribery Act 2010;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.2.2</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">comply
                                            with UCLB&rsquo;s ethics, anti-bribery and anti-corruption policies as available on UCL&rsquo;s
                                            website from time to time and maintain in place and enforce throughout the term of this Agreement
                                            adequate procedures to ensure compliance with Clause 7.2.1; and</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.2.3</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">promptly
                                            report to UCLB any request or demand for any undue financial or other advantage of any kind
                                            received in connection with the performance of this Agreement.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the purpose of this Clause 7.2, the meaning of adequate procedures and whether a person is associated with another person shall be determined
in accordance with the Bribery Act 2010 (and any guidance issued under section 9 of that Act). Breach of this Clause 7.2 shall be deemed
a material breach of this Agreement entitling UCLB to terminate under Clause 10.2.1.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">7.3</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Modern
                                            Slavery Act</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Licensee shall (and shall procure that any persons associated with it engaged in the performance of this Agreement including its Affiliates
shall), and the Licensee shall use commercially reasonable efforts to procure that its Sub-licensees shall, comply with all applicable
laws and codes of practice relating to anti-slavery including the Modern Slavery Act 2015. Such compliance shall include ensuring that
all reasonable steps are taken to ensure that all parties associated with the development, manufacture and commercialisation of the Licensed
Products comply with all applicable laws and codes of practice relating to anti-slavery including the Modern Slavery Act 2015.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">7.4</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Export
                                            Control Regulations.</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0pt 0pt 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Licensee shall ensure that, in using the Patents<U>,</U> <STRIKE>or</STRIKE> the Know-how <U>or the Materials </U>and in selling Licensed
Products, it and its Affiliates, employees, sub-contractors and Sub-licensees shall comply fully with any United Nations trade sanctions
or UK legislation or regulation, from time to time in force (as applicable), which impose arms embargoes or control the export of goods,
technology or software, including weapons of mass destruction and arms, military, paramilitary and security equipment and dual-use items
(items designed for civil use but which can be used for military purposes &ndash; but excluding drugs) and certain drugs and chemicals.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 33; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">7.5</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Tobacco
                                            Companies and Restricted Enterprises</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Licensee shall notify UCLB immediately in writing if:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.5.1</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
                                            Tobacco Company or an Affiliate of such a company or a Person involved as its primary business
                                            in arms dealing, gambling operations, or the promotion of violence or an Affiliate of such
                                            Person, or a Person regularly involved in child labour or an Affiliate of such Person, acquires
                                            ownership or Control of the Licensee; or</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -42.6pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.5.2</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            Licensee acquires ownership or Control of a Tobacco Company or an Affiliate of such a company
                                            or a Person involved as its primary business in arms dealing, gambling operations, or the
                                            promotion of violence or an Affiliate of such Person, or a Person regularly involved in child
                                            labour or an Affiliate of such Person<B>.</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">8.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>INTELLECTUAL
                                            PROPERTY</B></FONT></TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">8.1</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Obtain
                                            and Maintain the Patents.</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.1.1</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            Licensee shall be responsible for the drafting, filing, prosecution and maintenance of the
                                            Patents at its own cost and expense.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.1.2</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            Patents will be filed, prosecuted and maintained in the countries and territories set out
                                            in Schedule 4. The Licensee shall consult with UCLB in making any material decisions relating
                                            to the Patents such as which (if any) additional countries to file and maintain Patents in,
                                            and whether to elect to reject or submit to the competence of the Unitary Patent Court in
                                            respect of any Patent pursuant to Article 83(3) of the Agreement on a Unified Patent Court
                                            (2013/C 175/01) or to validate any of the Patents as a patent that has unitary effect by
                                            virtue of Regulation (EU) No 1257/2012, although the Licensee shall have the final decision.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.1.3</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            Licensee will obtain prior written approval of UCLB (which shall not be unreasonably withheld,
                                            conditioned or delayed) in relation to all changes to patent claims or specifications that
                                            would have the effect of reducing or limiting the extent of the patent coverage.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -42.6pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.1.4</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            Licensee will ensure that UCLB receives copies of all material correspondence to and from
                                            patent offices in respect of the Patents, including copies of all documents generated in
                                            or with such correspondence, and where practicable shall be given reasonable notice of and
                                            the opportunity to participate in any material conference calls or meetings with the Licensee&rsquo;s
                                            patent attorneys in relation to the drafting, filing, prosecution and maintenance of the
                                            Patents, so that UCLB may be continuously informed of progress with the drafting, filing,
                                            prosecution and maintenance of the Patents.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></P>

<!-- Field: Page; Sequence: 34; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.1.5</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            Licensee shall promptly notify UCLB of the grant of each patent comprised within the Patents.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.1.6</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
                                            the Licensee wishes to abandon any application contained with the Patents or not to maintain
                                            any Patent, it shall give three (3) months&rsquo; prior written notice to UCLB and on the
                                            expiry of such notice period the licence of such Patent granted to the Licensee under this
                                            Agreement shall cease.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">8.2</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Infringement
                                            of the Patents<U>,</U> <STRIKE>and</STRIKE> the Know-how <U>and/or the Materials</U>.</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.2.1</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
                                            Party shall inform the other Party promptly if it becomes aware of any infringement or potential
                                            infringement of any of the Patents in the Field or any unauthorised use of the Know-how <U>or
                                            the Materials</U> or any challenge to the validity or ownership of the Patents<U>,</U> <STRIKE>or
                                            </STRIKE>the Know-how <U>or the Materials </U>and the Parties shall consult with each other
                                            to decide the best way to respond to such infringement, unauthorised use or challenge.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.2.2</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            Licensee shall have the primary right to take action against any third party alleged to be
                                            infringing the Patents or making unauthorised use of the Know-how <U>or the Materials </U>in
                                            the Field and to defend the Patents against challenges to validity or ownership at its expense,
                                            provided that:</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">UCLB
                                            shall on the Licensee&rsquo;s request cooperate with the Licensee in such action and the
                                            Licensee shall reimburse UCLB for any reasonable expenses incurred by UCLB in relation to
                                            such cooperation; and</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">subject
                                            to Clauses 8.2.3 and 8.2.5, the Licensee shall be solely responsible for the conduct of the
                                            action or for settlement thereof and shall be entitled to all damages received from such
                                            action, subject to Clause 8.2.4.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.2.3</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Before
                                            starting or defending or settling any legal action under Clause 8.2.2, the Licensee shall
                                            consult with UCLB as to the advisability of the action or defence or settlement, its effect
                                            on the good name of UCLB, the public interest, and how the action or defence should be conducted.
                                            If the alleged infringement or unauthorised use is both within and outside the Field or if
                                            there is a challenge to the validity or ownership of the Licensed Technology, the Parties
                                            shall also co-operate with UCLB&rsquo;s other licensees (if any) in relation to any such
                                            action or defence.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<!-- Field: Page; Sequence: 35; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>




<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.2.4</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            Licensee shall reimburse UCLB for any reasonable expenses incurred in assisting it in such
                                            action or defence. The Licensee shall pay to UCLB royalties, in accordance with Clause 4,
                                            on any damages received from such action as if the amount of such damages after deduction
                                            of both Parties&rsquo; reasonable expenses in relation to the action were Net Sales Value.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.2.5</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">UCLB
                                            shall if reasonably requested by the Licensee agree to be joined in any suit to enforce such
                                            rights or take such action in its own name (subject to being indemnified and secured by the
                                            Licensee in a reasonable manner as to any costs (including internal costs), damages, expenses
                                            or other liability which may be incurred as a result of so doing) and shall have the right
                                            to be separately represented by its own counsel at its own expense, except where such separate
                                            counsel is necessary because Licensee&rsquo;s counsel declines or is unable to act for or
                                            represent UCLB due to conflict of interest (such conflict to be determined by Licensee&rsquo;s
                                            counsel acting reasonably) or any other reason, in which case Licensee shall pay the reasonable
                                            costs for UCLB to be separately represented.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.2.6</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notwithstanding
                                            the foregoing, UCLB shall not be obliged to join any suit or to take any action in its own
                                            name if UCLB has reasonable grounds to believe that the action is inadvisable or is likely
                                            to damage the good name of UCLB, provided that where UCLB notifies the Licensee that it declines
                                            to join any suit or take any action in its own name on the foregoing grounds and the Licensee
                                            considers that it cannot effectively enforce such rights or obtain effective relief in the
                                            relevant jurisdiction without the joinder of UCLB, then the Parties will work together in
                                            good faith to try to identify a way for the Licensee to enforce such rights or obtain such
                                            relief in another manner.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.2.7</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If,
                                            within six (6) months of the Licensee first becoming aware of any potential infringement
                                            of the Patents, the Licensee is unsuccessful in persuading the alleged infringer to desist
                                            or fails to initiate an infringement action, UCLB shall have the right, at its sole discretion,
                                            to prosecute such infringement under its sole control and at its sole expense, and any damages
                                            or other payments recovered shall belong solely to UCLB.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">8.3</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Infringement
                                            of Third Party Rights.</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.3.1</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
                                            any warning letter or other notice of infringement is received by a Party, or legal suit
                                            or other action is brought against a Party, alleging infringement of third party rights in
                                            the manufacture, use or sale of any Licensed Product or use of any Patents<U>,</U> <STRIKE>and/or
                                            </STRIKE>the Know-how <U>and/or the Materials</U>, that Party shall promptly provide full
                                            details to the other Party, and the Parties shall discuss the best way to respond.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></P>

<!-- Field: Page; Sequence: 36; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></P>




<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">9.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>WARRANTIES
                                            AND LIABILITY</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">9.1</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Warranties
                                            by UCLB.</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">UCLB
warrants and undertakes to the Licensee as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.1.1</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">it
                                            is the registered proprietor of, or applicant for, the Patents<U>,</U> <STRIKE>and Know-how
                                            </STRIKE>and has caused all of UCL&rsquo;s employees who are named as inventors on such Patents
                                            to execute such assignments of the Patents as may be necessary to pass all of their right,
                                            title and interest in and to the Patents to UCLB;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.1.2</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">it
                                            has the full power and authority to grant the licences contained in this Agreement;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.1.3</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">so
                                            far as it is aware (having made no enquiry of any third parties or conducted any freedom
                                            to operate searches), the use and exploitation of the Licensed Technology will not infringe
                                            the intellectual property rights of any third party.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">9.2</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Warranties
                                            by the Licensee.</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Licensee warrants and undertakes to UCLB that:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.2.1</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">it
                                            has the right to enter into this Agreement;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.2.2</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">is
                                            duly organised and existing under laws of Delaware (USA) and has all necessary authority,
                                            power and capacity to perform its obligations under this Agreement;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.2.3</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">it
                                            is not, and each of its Affiliates and Sub-licensees is not, at the Commencement Date, a
                                            Tobacco Company or an Affiliate of such a company or a Person involved as its primary business
                                            in arms dealing, gambling operations, or the promotion of violence or an Affiliate of such
                                            Person, or a Person regularly involved in child labour or an Affiliate of such Person;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -42.6pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.2.4</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            Licensed Technology shall not at any time be used by the Licensee or its Affiliates or Sub-licensees
                                            in connection with any activities that are known by the Licensee to be privately funded for
                                            the purpose by a Tobacco Company or an Affiliate of such a company or a Person involved as
                                            its primary business in arms dealing, gambling operations, or the promotion of violence or
                                            an Affiliate of such Person, or a Person regularly involved in child labour or an Affiliate
                                            of such Person; and</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.2.5</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">so
                                            far as it is aware (having made no enquiry of any third parties or conducted any freedom
                                            to operate searches), use and exploitation of the Patents will not infringe the intellectual
                                            property rights of any third party.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"></P>

<!-- Field: Page; Sequence: 37; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"></P>




<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">9.3</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Acknowledgements.</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Licensee acknowledges that:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.3.1</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            inventions claimed in the Patents<U>,</U> <STRIKE>and</STRIKE> the Know-how <U>and the Materials
                                            </U>are at an early stage of development. Accordingly, specific results cannot be guaranteed
                                            and any results, materials, information or other items (together &ldquo;Delivered Items&rdquo;)
                                            provided under this Agreement are provided &ldquo;as is&rdquo; and without any express or
                                            implied warranties, representations or undertakings. As examples, but without limiting the
                                            foregoing, UCLB does not give any warranty that Delivered Items are of merchantable or satisfactory
                                            quality, are fit for any particular purpose, comply with any sample or description, or are
                                            viable, uncontaminated, safe or non-toxic.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.3.2</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">UCLB
                                            has not performed any searches or investigations into the existence of any third party rights
                                            that may affect any of the Patents<U>,</U> <STRIKE>or </STRIKE>the Know-how <U>or the Materials
                                            </U>or the use and exploitation of any of the Patents<U>,</U> <STRIKE>or</STRIKE> the Know-how
                                            <U>or the Materials</U>.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">9.4</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>No
                                            Other Warranties.</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.4.1</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
                                            of the Parties acknowledges that, in entering into this Agreement, it does not do so in reliance
                                            on any representation, warranty or other provision except as expressly provided in this Agreement,
                                            and any conditions, warranties or other terms implied by statute or common law are excluded
                                            from this Agreement to the fullest extent permitted by law.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.4.2</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Without
                                            limiting the scope of Clause 9.4.1, UCLB does not make any representation nor give any warranty
                                            or undertaking:</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; width: 1in"></TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">as
                                            to the efficacy or usefulness of the Patents<U>,</U> <STRIKE>or</STRIKE> the Know-how <U>or
                                            the Materials</U>; or</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">as
                                            to the scope of any of the Patents or that any of the Patents is or will be valid or (in
                                            the case of an application) will proceed to grant; or</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">that
                                            the use of any of the Patents<U>,</U> <STRIKE>or</STRIKE> the Know-how <U>or the Materials</U>,
                                            the manufacture, sale or use of the Licensed Products, or the exercise of any of the rights
                                            granted under this Agreement will not infringe any intellectual property or other rights
                                            of any other person; or</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">that
                                            the <U>Materials and</U> Know-how or any other information communicated by UCLB to the Licensee
                                            under or in connection with this Agreement will produce Licensed Products of satisfactory
                                            quality or fit for the purpose for which the Licensee intended or that any product will not
                                            have any defect, latent or otherwise, and whether or not discoverable by inspection; or</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<!-- Field: Page; Sequence: 38; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">as
                                            imposing any obligation on UCLB to bring or prosecute actions or proceedings against third
                                            parties for infringement or to defend any action or proceedings for revocation of any of
                                            the Patents; or</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">as
                                            imposing any liability on UCLB in the event that any third party (which is not authorized
                                            by or under UCLB or UCL) supplies Licensed Products (i.e., products which would be Licensed
                                            Products if sold by the Licensee or its Affiliates) to customers located in the Territory;
                                            or</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(g)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">that
                                            there will be no similar or competitive products manufactured, used, sold or supplied by
                                            any third party in the Territory.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">9.5</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Responsibility
                                            for Development of Licensed Products.</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Licensee shall be exclusively responsible for its and its Affiliates&rsquo; and Sub-licensees&rsquo; use of the Patents<U>,</U> <STRIKE>and
</STRIKE>the Know-how <U>and the Materials</U>, the technical and commercial development and manufacture of Licensed Products and for
incorporating any modifications or developments thereto that may be necessary or desirable, for all Licensed Products sold or supplied,
notwithstanding any consultancy services or other contributions that UCLB may provide in connection with such activities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">9.6</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Indemnity.</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Licensee shall indemnify each of UCLB and UCL, and each of their respective officers, directors, Council members, employees and representatives,
including the Principal Investigator (together, the &ldquo;Indemnitees&rdquo;) against all Claims that may be asserted against or suffered
by any of the Indemnitees and which relate to:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.6.1</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            use by the Licensee or any of its Affiliates or Sub-licensees of any of the Patents or <U>the
                                            </U>Know-how <U>or the Materials</U>; or</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.6.2</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            development, manufacture, use, marketing or sale of, or any other dealing in, any of the
                                            Licensed Products, by or on behalf of the Licensee or any of its Affiliates or Sub-licensees,
                                            or subsequently by any customer or any other person, including claims based on product liability
                                            laws.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
indemnity given by the Licensee to each Indemnitee under this Clause 9.6 will not apply to any Claim to the extent that it is attributable
to the negligent act or omission, reckless misconduct or intentional misconduct of UCLB or UCL or of that Indemnitee.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 39; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></P>




<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">9.7</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Limitations
                                            of Liability.</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.7.1</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
                                            the extent that any Indemnitee has any liability to the Licensee or its Affiliates in contract,
                                            tort, or otherwise under or in connection with this Agreement, including any liability for
                                            breach of warranty, their liability shall be limited in accordance with the following provisions
                                            of this Clause 9.7.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.7.2</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            aggregate liability of the Indemnitees shall be limited to [****] pounds (&pound;[****])
                                            sterling.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.7.3</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
                                            no circumstances shall either Party or any Indemnitee be liable for:</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
                                            loss of profits (whether direct or indirect);</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
                                            loss of revenue (other than revenue due under this Agreement), business opportunity or goodwill;
                                            or</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -35.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
                                            loss, damage, cost or expense of any nature that is of an indirect, special or consequential
                                            nature,</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -35.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">in
each case, which arises directly or indirectly from that Party&rsquo;s breach or non- performance of this Agreement, or negligence in
the performance of this Agreement or from any liability arising in any other way out of the subject matter of this Agreement even if
the Party bringing the claim has advised the other Party or the relevant Indemnitee of the possibility of those losses arising, or if
such losses were within the contemplation of the Parties or the Indemnitee.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.7.4</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            relevant Indemnitee shall provide prompt written notice to the Licensee of the initiation
                                            of any action or proceeding that may reasonably lead to a claim for indemnification. Upon
                                            such notice and subject to confirming that the indemnity will apply, the Licensee shall have
                                            the right to assume the defence and settlement of such action or proceeding, provided that
                                            it shall not settle any action or proceeding without the Indemnitee&rsquo;s written consent
                                            (which shall not be unreasonably withheld, conditioned or delayed) unless (a) there is no
                                            finding or admission of any violation of applicable law or any violation of the rights of
                                            any Person by an Indemnitee, no requirement that the Indemnitee admit fault or culpability,
                                            and no adverse effect on any other claims that may be made by or against the Indemnitee and
                                            (B) the sole relief provided is monetary damages that are paid in full by the Licensee and
                                            such settlement does not require the Indemnitee to take (or refrain from taking) any action.
                                            The Indemnitee shall co-operate with the Licensee in the defence of such claim.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<!-- Field: Page; Sequence: 40; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>




<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.7.5</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nothing
                                            in this Agreement excludes either Party&rsquo;s liability to the extent that it may not be
                                            so excluded under applicable law, including any such liability for death or personal injury
                                            caused by that Party&rsquo;s negligence, or liability for fraud or fraudulent misrepresentation.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">9.8</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Insurance.</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.8.1</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            Licensee shall take out with a reputable insurance company and maintain at all times during
                                            the term of this Agreement and for a further six (6) years after the end of the term of this
                                            Agreement, public and product liability and professional indemnity insurance including against
                                            all loss of and damage to property (whether real, personal or intellectual) and injury to
                                            persons including death arising out of or in connection with this Agreement and the Licensee&rsquo;s
                                            and its Affiliates&rsquo; and Sub-licensees&rsquo; use of the Patents<U>,</U> <STRIKE>or
                                            </STRIKE>the Know-how <U>or the Materials </U>and use, sale of or any other dealing in any
                                            of the Licensed Products. Such insurances may be limited in respect of one claim provided
                                            that such limit must be at least:</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">one
                                            million pounds (&pound;1,000,000) in respect of any one claim and in aggregate at all times
                                            before commencement of clinical trials for any Licensed Product;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -35.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">three
                                            million pounds (&pound;3,000,000) in respect of any one claim and in aggregate at all times
                                            following the commencement of the first clinical trial for any Licensed Product; and</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -35.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">five
                                            million pounds (&pound;5,000,000) in respect of any one claim and in aggregate at all times
                                            following the first commercial sale of the first Licensed Product.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.8.2</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            Licensee will produce to UCLB at all times upon demand proof that the insurance cover required
                                            pursuant to Clause 9.8.1 is in force and evidence that all premiums have been paid up to
                                            date. If UCLB becomes aware that the Licensee has failed to maintain the insurance required
                                            pursuant to Clause 9.8.1 UCLB may effect such insurance and the Licensee will reimburse UCLB
                                            for the reasonable cost of effecting and maintaining such insurance on demand.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">10.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>DURATION
                                            AND TERMINATION</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">10.1</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Commencement
                                            and Termination by Expiry.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Agreement, and the licences granted hereunder, shall come into effect on the Commencement Date and, unless terminated earlier in accordance
with this Clause 10 or Clause 11.1.2, the licences granted hereunder shall continue in force on a country by country basis until the
later of:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 41; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></P>




<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1.1</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            date on which all the Patents have been abandoned or allowed to lapse or expired or been
                                            rejected or revoked without a right of further appeal in the relevant country or territory
                                            or been held invalid or unenforceable by a court of competent jurisdiction in a final and
                                            non-appealable judgment; and</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1.2</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            tenth (10th) anniversary of the First Commercial Sale of Licensed Products in the relevant
                                            country;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">upon
which the licences granted hereunder shall terminate automatically by expiry in such country or territory.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Agreement shall terminate when all of the licences granted hereunder have terminated in all countries and territories within the Territory.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">10.2</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Early
                                            Termination.</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.2.1</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
                                            Party may terminate this Agreement at any time by notice in writing to the other Party (&ldquo;<B>Other
                                            Party</B>&rdquo;), such notice to take effect as specified in the notice, if the Other Party
                                            is in material breach of this Agreement and, in the case of a breach capable of remedy within
                                            thirty (30) days, the breach is not remedied within thirty (30) days of the Other Party receiving
                                            notice specifying the breach and requiring its remedy, or where the breach relates to non-payment
                                            of a sum due under this Agreement, the sum is not paid in full within fourteen (14) days
                                            following the Other Party receiving notice specifying the non-payment and requiring payment
                                            in full.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.2.2</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">UCLB
                                            may terminate this Agreement by giving written notice to the Licensee, such termination to
                                            take effect forthwith or as otherwise stated in the notice:</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">in
                                            accordance with the provisions of Clause 2.3; or</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">in
                                            accordance with the provisions of Clause 5.11; or</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">if
                                            UCLB receives notification from the Licensee pursuant to Clause 7.5, or is otherwise made
                                            aware that there has been an acquisition of the type referred to in Clause 7.5;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -35.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">if
                                            UCLB is made aware that the Licensee has breached either of the warranties in Clause 9.2.3
                                            or Clause 9.2.4, or</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 42; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            Licensee is in persistent breach of this Agreement and where the Parties have failed to agree
                                            a mechanism to remedy the persistent nature of such breaches within a reasonable period following
                                            UCLB notifying the Licensee of the persistent breach and requesting that the Licensee enters
                                            into discussions with UCLB as to mechanisms for remedying the persistent breaches or if the
                                            Parties have agreed a mechanism to remedy the persistent breach but that mechanism if not
                                            fully complied with by the Licensee; or</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">if
                                            the Licensee suffers an Insolvency Event.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.2.3</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            Licensee may terminate this Agreement at any time by giving written notice to UCLB, such
                                            termination to take effect within 45 (forty-five) days of the receipt of the notice by UCLB.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.2.4</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
                                            Party&rsquo;s right of termination under this Agreement, and the exercise of any such right,
                                            shall be without prejudice to any other right or remedy (including any right to claim damages)
                                            that such Party may have in the event of a breach of contract or other default by the other
                                            Party.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">10.3</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Consequences
                                            of Termination.</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.3.1</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon
                                            expiry of the term of this Agreement in accordance with Clause 10.1, and subject to all royalties
                                            and any other sums due to UCLB under this Agreement having been duly paid, the Licensee shall
                                            have a fully paid up licence to the Patents<U>,</U> <STRIKE>and</STRIKE> the Know-how <U>and
                                            to the Materials </U>of the same scope as set forth in Clause 2.1.1 and 2.1.2 without any
                                            further obligation to pay any further sums to UCLB under Clause 4. Notwithstanding the foregoing
                                            the Licensee acknowledges that once each Patent expires or is abandoned or withdrawn or allowed
                                            to lapse in any country or territory, third parties in that country or territory will be
                                            entitled to use the inventions claimed in the Patent and that accordingly the licence granted
                                            to the Licensee under Clause 2.1 will no longer be exclusive in that country or territory.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.3.2</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon
                                            termination of this Agreement for any reason other than as set forth in Clause 10.1:</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            Licensee and its Affiliates and Sub-licensees shall be entitled to sell, use or otherwise
                                            dispose of (subject to payment of royalties under Clause 4) any unsold or unused stocks of
                                            the Licensed Products for a period of six (6) months following the date of termination;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">subject
                                            to paragraph (a) above, any licence that has not become fully paid- up in accordance with
                                            Clause 10.3.1 shall terminate and the Licensee and its Affiliates (and subject to Clause
                                            2.3.6, its Sub-licensees) shall no longer be licensed to use or otherwise exploit the Patents<U>,
                                            </U><STRIKE>and/or</STRIKE> the Know-how <U>and/or the Materials, in so far and for as long
                                            as any of the Patents remain in force and the Know-how remains confidential;</U></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></P>

<!-- Field: Page; Sequence: 43; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            Licensee shall consent to the cancellation of any formal licence granted to it, or of any
                                            registration of it in any register, in relation to any of the Patents;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            Licensee will, promptly on UCLB&rsquo;s request, provide (and will ensure that its patent
                                            agents provide) to UCLB all information, documentation and assistance (including executing
                                            documents) which UCLB may reasonably require to enable it to take over with the drafting,
                                            filing, prosecution and maintenance of the Patents;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">except
                                            as set out in Clause 2.3.6, all sub-licences of the Patents<U>,</U> <STRIKE>and/ or</STRIKE>
                                            the Know-how <U>and/or the Materials</U> granted by the Licensee pursuant to this Agreement
                                            will automatically terminate;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">each
                                            Party shall upon the written request of the other Party, return or destroy any documents
                                            or other materials that are in its or its Affiliates or (where applicable) its Sub-licensees&rsquo;
                                            possession or under its or their control and that contain the other Party&rsquo;s Confidential
                                            Information;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><STRIKE>(f)</STRIKE><U>(g)</U></FONT></TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>the Licensee shall upon
  the written request of UCLB, return or destroy any unused Materials that are in its or its Affiliates or (where applicable) its Sub-
  licensees&rsquo; possession or under its or their control;</U></FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><STRIKE>(g)</STRIKE><U>(h)</U></FONT></TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">in order that UCLB may have
  the opportunity to exercise an option to continue either itself or through an appropriate third party to develop, manufacture and commercialise
  Licensed Products:</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            Licensee shall promptly on UCLB&rsquo;s request:</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(A)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">deliver
                                            to UCLB (as the Licensee&rsquo;s Confidential Information and solely for the purpose of evaluation
                                            by UCLB) a copy of all technical and clinical data relating to Licensed Products generated
                                            by it or its Affiliates and/or Sub-licensees; and</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(B)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">disclose
                                            to UCLB (as the Licensee&rsquo;s Confidential Information and solely for the purpose of evaluation
                                            by UCLB) full details of all and any improvements, modifications, adaptations and new uses
                                            of the Licensed Technology generated by it or its Affiliates and Sub-licensees; and</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<!-- Field: Page; Sequence: 44; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>




<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(C)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">to
                                            the extent possible, and subject to the prior execution and delivery of the agreement contemplated
                                            by Clause 10.3.2(ii) below) take all action necessary to have its right, title and interest
                                            in and to any clinical trial authorisations, product licences, marketing authorisations,
                                            pricing and/ or reimbursement approvals (and any applications for any of the foregoing) which
                                            relate to Licensed Products transferred into the name of UCLB or its nominee;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">UCLB
                                            shall have the option to acquire an exclusive, worldwide licence, with the rights to grant
                                            sub-licences, to use and commercialise any technical and clinical data, and any Licensee
                                            Improvements relating, and any product names and trademarks which have been applied, to Licensed
                                            Products which are owned or controlled by the Licensee or its Affiliates or Sub-licensees
                                            for the purpose of developing, manufacturing and commercialising Licensed Products on terms
                                            to be negotiated between the parties acting reasonably;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">subject
                                            to the prior execution and delivery of the agreement contemplated by Clause 10.3.2(ii) above,
                                            the Licensee hereby appoints (and will ensure that each of its Affiliates and Sub-licensees
                                            appoints) UCLB as its attorney to execute such documents and do such things in its name as
                                            may be necessary to effect the transfer to UCLB or UCLB&rsquo;s nominee of its right, title
                                            and interest in and to all regulatory approvals, and in the case of applications for regulatory
                                            approvals the status of applicant under such applications, for Licensed Products obtained
                                            or submitted by the Licensee or its Affiliates or Sub-licensees if the Licensee or any of
                                            its Affiliates or Sub-licensees (as the case may be) does not execute such documents and/
                                            or do such acts within a period of seven (7) days following UCLB&rsquo;s written request
                                            pursuant to this paragraph,</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">provided
however that all of the foregoing obligations will only apply in relation to Sub-licensees whose rights are terminating under paragraph
(e) above.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.3.3</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon
                                            termination of this Agreement for any reason the provisions of Clauses 1, 2.3.8, 2.5, 3.2
                                            to 3.5, 4 (in respect of amounts paid and payable to UCLB in respect of the period up to
                                            and including the date of termination), 5.6, 7, 9.6, 9.7, 9.8, 10.3 and 11 shall remain in
                                            force.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<!-- Field: Page; Sequence: 45; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>




<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">11.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>GENERAL</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">11.1</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Force
                                            Majeure.</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.1.1</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
                                            delays in or failure of performance by either Party under this Agreement will not be considered
                                            a breach of this Agreement if and to the extent that such delay or failure is caused by occurrences
                                            beyond the reasonable control of that Party and could not have been avoided or mitigated
                                            by contingency planning including acts of God; acts, regulations and laws of any government;
                                            strikes or other concerted acts of workers; epidemics; fire; floods; explosions; riots; wars;
                                            rebellion; and sabotage; and any time for performance hereunder will be extended by the actual
                                            time of delay caused by any such occurrence.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.1.2</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
                                            either Party is prevented from carrying out its obligations under this Agreement for a continuous
                                            period of six (6) months the other Party may terminate this Agreement on giving thirty (30)
                                            days&rsquo; prior written notice provided always that at the date upon which termination
                                            becomes effective the Party which was prevented from carrying out its obligations under this
                                            Agreement remains so prevented.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">11.2</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Amendment.</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Agreement may only be amended in writing signed by duly authorised representatives of UCLB and the Licensee.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">11.3</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Assignment
                                            and Third Party Rights.</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.3.1</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subject
                                            to Clause 11.3.2, neither Party shall assign, mortgage, charge or otherwise transfer or deal
                                            with any rights or obligations under this Agreement, nor any of the Patents<U>,</U> <STRIKE>or
                                            </STRIKE>the Know-how <U>or the Materials</U>, without the prior written consent of the other
                                            Party.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.3.2</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
                                            Party may, subject to obtaining the consent of the other Party which shall not be unreasonably
                                            withheld, delayed or conditioned, transfer all its rights and obligations under this Agreement
                                            together with its rights in the Patents<U>,</U> <STRIKE>and</STRIKE> the Know- how <U>and
                                            the Materials </U>to any company to which it transfers all or substantially all of its assets
                                            or business in the Field, provided that the assignee undertakes to the other Party to be
                                            bound by and perform the obligations of the assignor under this Agreement. However a Party
                                            shall not have such a right to transfer this Agreement if it is insolvent or any other circumstance
                                            described in Clause 10.2.2(f) applies to it or if the proposed assignee is a Tobacco Company
                                            or an Affiliate of such a company or a Person involved as its primary business in arms dealing,
                                            gambling operations, or the promotion of violence or an Affiliate of such Person, or if the
                                            proposed assignee is a Person regularly involved in child labour or an Affiliate of such
                                            Person.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 46; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">11.4</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Waiver.</B></FONT></TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
waiver given under or in relation to this Agreement shall be in writing and signed by or on behalf of the relevant Party. No failure
or delay on the part of either Party to exercise any right or remedy under this Agreement shall be construed or operate as a waiver thereof
or of any other provision hereof, nor shall any single or partial exercise of any right or remedy preclude the further exercise of such
right or remedy or of any other right or remedy.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">11.5</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Invalid
                                            Clauses.</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
any provision or part of this Agreement is held to be invalid, amendments to this Agreement may be made (by the mutual agreement of the
parties if possible, but if not then by a court or arbitrator who shall be appointed with mutual consent of the Parties) by the addition
or deletion of wording as appropriate to remove the invalid part or provision but otherwise retain the provision and the other provisions
of this Agreement to the maximum extent permissible under applicable law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">11.6</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>No
                                            Agency.</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Neither
Party shall act or describe itself as the agent of the other, nor shall it make or represent that it has authority to make any commitments
on the other&rsquo;s behalf.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">11.7</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Interpretation.</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
this Agreement:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.7.1</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            headings are used for convenience only and shall not affect its interpretation;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.7.2</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">references
                                            to persons shall include incorporated and unincorporated persons; references to the singular
                                            include the plural and vice versa; and references to the masculine include the feminine;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.7.3</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">references
                                            to Clauses and Schedules mean clauses of, and schedules to, this Agreement;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.7.4</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">references
                                            in this Agreement to termination shall include termination by expiry;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.7.5</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">where
                                            the word &ldquo;including&rdquo; is used it shall be understood as meaning &ldquo;including
                                            without limitation&rdquo;;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<!-- Field: Page; Sequence: 47; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>




<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.7.6</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
                                            reference to any English law term for any action, remedy, method or judicial proceeding,
                                            legal document, legal status, court, official or any legal concept or thing shall in respect
                                            of any jurisdiction other than England be deemed to include what most nearly approximates
                                            in that jurisdiction to the English law term;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.7.7</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">time
                                            shall be of the essence in relation to the performance of the Licensee&rsquo;s obligations
                                            under this Agreement; and</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.7.8</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
                                            reference to the sale of a Licensed Product by the Licensee or its Affiliates or Sub-licensees
                                            will be taken to include any supply or other disposal of Licensed Products, and the term
                                            sold shall be construed accordingly.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">11.8</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Notices;
                                            Addresses for Service.</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.8.1</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
                                            notice to be given under this Agreement shall be in English, in writing and shall be delivered
                                            by Royal Mail signed for first class mail (if sent to an inland address) or by international
                                            courier, or by email (confirmed by Royal Mail signed for first class mail or international
                                            courier, as appropriate) to the address of the relevant Party set out at the head of this
                                            Agreement or to the address of the Licensee specified for service within the jurisdiction
                                            of the courts of England and Wales, or to the relevant email address set out below, or such
                                            other address or email address as that Party may from time to time notify to the other Party
                                            in accordance with this Clause 11.8. The email addresses of the Parties are as follows:</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">UCLB
&ndash;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Licensee
&ndash;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.8.2</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notices
                                            sent as above shall be deemed to have been received three (3) working days after the day
                                            of posting in the case of delivery inland by Royal Mail signed for first class mail, or three
                                            (3) working days after the date of collection by the international courier, or in the case
                                            of email notifications, at the time the email is sent provided that, within twenty-four (24)
                                            hours of sending the email, a hard copy of the email and any attachments thereto are sent
                                            by Royal Mail signed for first class mail or international courier, as appropriate, or delivered
                                            by hand, to the address of the relevant Party set out at the head of this Agreement.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.8.3</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Either
                                            Party may, by notice given pursuant to this Cause 11.8, change its address- for-notice.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"></P>

<!-- Field: Page; Sequence: 48; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"></P>




<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">11.9</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Dispute
                                            Resolution</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.9.1</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
                                            a dispute (a &ldquo;<B>Dispute</B>&rdquo;) arises out of or in connection with this Agreement
                                            (including in relation to any non-contractual obligations) each Party may during the term
                                            of this Agreement serve a written notice (a &ldquo;<B>Referral Notice</B>&rdquo;) on the
                                            other Party. Each Party will procure that its representatives referred to in Clauses 11.9.2
                                            and 11.9.3 will comply with the provisions of this Clause 11.9.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -42.6pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.9.2</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Following
                                            service of a Referral Notice in relation to a Dispute, that Dispute will be referred for
                                            resolution to the Chief Executive Officer for the time being on behalf of UCLB and the Chief
                                            Executive Officer or other senior manager for the time being on behalf of the Licensee. Those
                                            representatives will meet at the earliest convenient time and in any event within forty-five
                                            (45) days of the date of service of the relevant Referral Notice and will attempt to resolve
                                            the Dispute.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -42.6pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.9.3</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subject
                                            to Clause 11.9.4, the procedures set out in Clauses 11.9.1 to 11.9.3 (inclusive) will be
                                            followed prior to the commencement of any proceedings by each party in relation to a Dispute.
                                            However, if a Dispute is not resolved within forty-five (45) days of the meeting of the representatives
                                            in accordance with Clause 11.9.2 each Party may commence proceedings in accordance with Clause
                                            11.10.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -42.6pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.9.4</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nothing
                                            in this Clause 11.9 will prevent or delay either party from:</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">seeking
                                            orders for specific performance, interim or final injunctive relief;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">exercising
                                            any rights it has to terminate this Agreement; and/or</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">commencing
                                            any proceedings where this is necessary to avoid any loss of a claim due to the rules on
                                            limitation of actions.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -35.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">11.10</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Law
                                            and Jurisdiction.</B></FONT></TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
validity, construction and performance of this Agreement, and any contractual and non- contractual claims arising hereunder, shall be
governed by English law and shall be subject to the exclusive jurisdiction of the English courts to which the parties hereby submit.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">11.11</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Entire
                                            Agreement.</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Agreement, including its Schedules, sets out the entire agreement between the Parties relating to its subject matter and supersedes all
prior oral or written agreements, arrangements or understandings between them relating to such subject matter; provided that any prior
written nondisclosure/non-use provisions are not superseded and shall remain in force. Subject to Clause 9.7.5, the Parties acknowledge
that they are not relying on any representation, agreement, term or condition which is not set out in this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">11.12</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Third
                                            Parties.</B></FONT></TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Except
for the rights of UCL as provided in Clause 2.4, all rights expressly provided herein to Affiliates of a Party, the rights of the Indemnitees
as provided in Clause 9.6 and the limitations of liability afforded to the Indemnitees pursuant to Clause 9.7, who may in their own right
enforce and rely on the provisions of those Clauses, this Agreement does not create any right enforceable by any person who is not a
party to it (&ldquo;Third Party&rdquo;) under the Contracts (Rights of Third Parties) Act 1999, but this Clause does not affect any right
or remedy of a Third Party which exists or is available apart from that Act. The Parties may amend, renew, terminate or otherwise vary
all or any of the provisions of this Agreement, including Clauses 2.4, 9.6 and 9.7, without the consent of UCL and/ or the Indemnitees
and/or any such Affiliate.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">11.13</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Non-use
                                            of Names; Announcements.</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.13.1</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            Licensee shall not use, and shall ensure that its Affiliates and Sub-licensees do not use,
                                            the name, any adaptation of the name, any logo, trademark or other device of UCLB, nor of
                                            the inventors named on the Patents nor the Principal Investigator, in any advertising, promotional
                                            or sales materials without prior, express written consent obtained from UCLB in each case,
                                            except that the Licensee may state that it is licensed by UCLB under the Patents.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -42.6pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.13.2</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Except
                                            as permitted under Clause 5.6 or Clause 11.3.1, neither Party shall make any press or other
                                            public announcement concerning any aspect of this Agreement, or make any use of the name
                                            or trademarks of the other Party in connection with or in consequence of this Agreement,
                                            without the prior, express written consent of the other Party (which shall not be unreasonably
                                            refused, if required by applicable law).</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 49; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">EXECUTED
AND DELIVERED on the date set out at the head of this Licence Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
    and on behalf of</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
    and on behalf of</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>UCL
    Business Limited</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Qualigen
    Therapeutics, Inc.</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">signed</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">signed</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">print
    name</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">print
    name</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">t<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">itle</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">title</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">date</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">date</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></P>

<!-- Field: Page; Sequence: 50; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.31
<SEQUENCE>7
<FILENAME>ex10-31.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
10.31</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Amendment
to Executive Employment Agreement with Michael P. Poirier, dated January 13, 2023</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">January
13, 2023</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dear
Mr. Poirier:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
you know, on January 13, 2023, the board of directors of Qualigen Therapeutics, Inc. (the &ldquo;Company&rdquo;), as part of certain
cost-cutting measures across the Company, approved a temporary 20% reduction to the base salaries of all executive officers of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
that end, effective as of January 16, 2023, your annual base salary will be reduced to $460,000.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
truly appreciate your loyalty, hard work and commitment to the Company. With your help and cooperation, I am confident that we will emerge
stronger and hopeful the changes will allow us to effectively position the Company for future success.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sincerely,</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Christopher
Lotz</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">VP
and CFO of Qualigen Therapeutics, Inc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.32
<SEQUENCE>8
<FILENAME>ex10-32.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
10.32</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Amendment
to Executive Employment Agreement with Amy Broidrick, dated January 13, 2023</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">January
13, 2023</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dear
Ms. Broidrick:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
you know, on January 13, 2023, the board of directors of Qualigen Therapeutics, Inc. (the &ldquo;Company&rdquo;), as part of certain
cost-cutting measures across the Company, approved a temporary 20% reduction to the base salaries of all executive officers of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
that end, effective as of January 16, 2023, your annual base salary will be reduced to $360,000.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
truly appreciate your loyalty, hard work and commitment to the Company. With your help and cooperation, I am confident that we will emerge
stronger and hopeful the changes will allow us to effectively position the Company for future success.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sincerely,</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Michael
Poirier</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chairman
and CEO of Qualigen Therapeutics, Inc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><BR STYLE="clear: both"></FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.33
<SEQUENCE>9
<FILENAME>ex10-33.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
10.33</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Amendment
to Executive Employment Agreement with Tariq Arshad, dated January 13, 2023</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">January
13, 2023</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dear
Dr. Arshad:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
you may know, on January 13, 2023, the board of directors of Qualigen Therapeutics, Inc. (the &ldquo;Company&rdquo;), as part of certain
cost-cutting measures across the Company, approved a temporary 20% reduction to the base salaries of all executive officers of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
that end, effective as of January 16, 2023, your annual base salary will be reduced to $320,000.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
truly appreciate your loyalty, hard work and commitment to the Company. With your help and cooperation, I am confident that we will emerge
stronger and hopeful the changes will allow us to effectively position the Company for future success.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sincerely,</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Michael
Poirier</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chairman
and CEO of Qualigen Therapeutics, Inc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><BR STYLE="clear: both"></FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21.1
<SEQUENCE>10
<FILENAME>ex21-1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
21.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SUBSIDIARIES
OF THE REGISTRANT</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Qualigen,
Inc. &ndash; a Delaware corporation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NanoSynex
Ltd. &ndash; a company incorporated under the laws of the State of Israel</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin: 0pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>11
<FILENAME>ex23-1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
23.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U></U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B><U>CONSENT OF BAKER TILLY US, LLP, INDEPENDENT REGISTERED
PUBLIC ACCOUNTING FIRM</U></B></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U></U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We consent to the incorporation by reference in the
Registration Statements on Form S-3 (File No. 333-266430 and 333-269088) and Form S-8 (File No. 333-220907, 333-249280, 333-249281 and
333-262090) of Qualigen Therapeutics, Inc. of our report dated May 2, 2023, relating to the consolidated financial statements, which includes
an explanatory paragraph relating to the Company&rsquo;s ability to continue as a going concern and appears on page 38 of this annual
report on Form 10-K for the year ended December 31, 2022.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%"><B><I>/s/ BAKER TILLY US, LLP</I></B></TD>
    <TD STYLE="width: 50%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><B>&nbsp;</B></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>San Diego, CA</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>May 2, 2023</TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>12
<FILENAME>ex31-1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
31.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">C<B>ERTIFICATION
OF PRINCIPAL EXECUTIVE OFFICER PURSUANT TO</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SECTION
302 OF THE SARBANES-OXLEY ACT OF 2002</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I,
Michael S. Poirier, certify that:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I
                                            have reviewed this Annual Report on Form 10-K of Qualigen Therapeutics, Inc., a Delaware
                                            corporation;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
                                            on my knowledge, this report does not contain any untrue statement of a material fact or
                                            omit to state a material fact necessary to make the statements made, in light of the circumstances
                                            under which such statements were made, not misleading with respect to the period covered
                                            by this report;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
                                            on my knowledge, the condensed consolidated financial statements, and other financial information
                                            included in this report, fairly present in all material respects the financial condition,
                                            results of operations and cash flows of the registrant as of, and for, the periods presented
                                            in this report;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            registrant&rsquo;s other certifying officer and I are responsible for establishing and maintaining
                                            disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e))
                                            and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f)
                                            and 15d-15(f)) for the registrant and have:</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Designed
                                            such disclosure controls and procedures, or caused such disclosure controls and procedures
                                            to be designed under our supervision, to ensure that material information relating to the
                                            registrant is made known to us by others within those entities, particularly during the period
                                            in which this report is being prepared;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Designed
                                            such control over financial reporting, or caused such internal control over financial reporting
                                            to be designed under our supervision, to provide reasonable assurance regarding the reliability
                                            of financial reporting and the preparation of condensed consolidated financial statements
                                            for external purposes with generally accepted accounting principles;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Evaluated
                                            the effectiveness of the registrant&rsquo;s disclosure controls and procedures and presented
                                            in this report our conclusions about the effectiveness of the disclosure controls and procedures,
                                            as of the end of the period covered by this report based on such evaluation; and</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">d)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Disclosed
                                            in this report any change in the registrant&rsquo;s internal control over financial reporting
                                            that occurred during the registrant&rsquo;s most recent fiscal quarter (the registrant&rsquo;s
                                            fourth fiscal quarter in the case of an annual report) that has materially affected, or is
                                            reasonably likely to materially affect, the registrant&rsquo;s internal control over financial
                                            reporting; and</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            registrant&rsquo;s other certifying officer(s) and I have disclosed, based on our most recent
                                            evaluation of internal control over financial reporting, to the registrant&rsquo;s auditors
                                            and the audit committee of the registrant&rsquo;s board of directors (or persons performing
                                            the equivalent functions):</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
                                            significant deficiencies and material weaknesses in the design or operation of internal control
                                            over financial reporting which are reasonably likely to adversely affect the registrant&rsquo;s
                                            ability to record, process, summarize and report financial information; and</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
                                            fraud, whether or not material, that involves management or other employees who have a significant
                                            role in the registrant&rsquo;s internal control over financial reporting.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">May 2, 2023</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 45%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Michael S. Poirier</I></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Michael
    S. Poirier</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Executive Officer</FONT></TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>13
<FILENAME>ex31-2.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
31.2</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CERTIFICATION
OF PRINCIPAL FINANCIAL OFFICER PURSUANT TO</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SECTION
302 OF THE SARBANES-OXLEY ACT OF 2002</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I,
Christopher L. Lotz, certify that:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I
                                            have reviewed this Annual report on Form 10-K of Qualigen Therapeutics, Inc., a Delaware
                                            corporation;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
                                            on my knowledge, this report does not contain any untrue statement of a material fact or
                                            omit to state a material fact necessary to make the statements made, in light of the circumstances
                                            under which such statements were made, not misleading with respect to the period covered
                                            by this report;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
                                            on my knowledge, the condensed consolidated financial statements, and other financial information
                                            included in this report, fairly present in all material respects the financial condition,
                                            results of operations and cash flows of the registrant as of, and for, the periods presented
                                            in this report;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            registrant&rsquo;s other certifying officer and I are responsible for establishing and maintaining
                                            disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e))
                                            and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f)
                                            and 15d-15(f)) for the registrant and have:</FONT></TD></TR>
                                                                                                        </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Designed
                                            such disclosure controls and procedures, or caused such disclosure controls and procedures
                                            to be designed under our supervision, to ensure that material information relating to the
                                            registrant is made known to us by others within those entities, particularly during the period
                                            in which this report is being prepared;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Designed
                                            such control over financial reporting, or caused such internal control over financial reporting
                                            to be designed under our supervision, to provide reasonable assurance regarding the reliability
                                            of financial reporting and the preparation of condensed consolidated financial statements
                                            for external purposes with generally accepted accounting principles;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Evaluated
                                            the effectiveness of the registrant&rsquo;s disclosure controls and procedures and presented
                                            in this report our conclusions about the effectiveness of the disclosure controls and procedures,
                                            as of the end of the period covered by this report based on such evaluation; and</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">d)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Disclosed
                                            in this report any change in the registrant&rsquo;s internal control over financial reporting
                                            that occurred during the registrant&rsquo;s most recent fiscal quarter (the registrant&rsquo;s
                                            fourth fiscal quarter in the case of an annual report) that has materially affected, or is
                                            reasonably likely to materially affect, the registrant&rsquo;s internal control over financial
                                            reporting; and</FONT></TD></TR>
                                                                           </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            registrant&rsquo;s other certifying officer and I have disclosed, based on our most recent
                                            evaluation of internal control over financial reporting, to the registrant&rsquo;s auditors
                                            and the audit committee of the registrant&rsquo;s board of directors (or persons performing
                                            the equivalent functions):</FONT></TD></TR>
                                                                                       </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
                                            significant deficiencies and material weaknesses in the design or operation of internal control
                                            over financial reporting which are reasonably likely to adversely affect the registrant&rsquo;s
                                            ability to record, process, summarize and report financial information; and</FONT></TD></TR><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
                                            fraud, whether or not material, that involves management or other employees who have a significant
                                            role in the registrant&rsquo;s internal control over financial reporting.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">May
    2, 2023</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 45%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Christopher L. Lotz</I></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Christopher
    L. Lotz</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Financial Officer (Principal Financial Officer)</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>14
<FILENAME>ex32-1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
32.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CERTIFICATIONS
PURSUANT TO 18 U.S.C. SECTION 1350 AS ADOPTED PURSUANT TO</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SECTION
906 OF THE SARBANES-OXLEY ACT OF 2002</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
of the undersigned, Michael S. Poirier, Chief Executive Officer of Qualigen Therapeutics, Inc., a Delaware corporation (the
&ldquo;Company&rdquo;), and Christopher L. Lotz, Chief Financial Officer of the Company, do hereby certify, pursuant to 18 U.S.C.
Section 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to his knowledge (1) the Annual Report on
Form 10-K of the Company for the year ended December 31, 2022, as filed with the Securities and Exchange Commission on the date
hereof (the &ldquo;Report&rdquo;), fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of
1934, as amended, and (2) the information contained in the Report fairly presents, in all material respects, the financial condition
and results of operations of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">May
2, 2023</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0pt; width: 45%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Michael S. Poirier</I></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Michael
    S. Poirier</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Executive Officer (Principal Executive Officer)</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">May
2, 2023</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0pt; width: 45%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Christopher L. Lotz</I></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Christopher
    L. Lotz</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Financial Officer (Principal Financial Officer)</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>These
certifications accompanying and being &ldquo;furnished&rdquo; with this Report, shall not be deemed &ldquo;filed&rdquo; by the Company
for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to liability under that Section and
shall not be deemed to be incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the
Securities Exchange Act of 1934, as amended, whether made before or after the date of this Report, irrespective of any general incorporation
language contained in such filing.</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>form10-k_001.jpg
<TEXT>
begin 644 form10-k_001.jpg
M_]C_X  02D9)1@ ! 0$ > !X  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" #G X0# 2(  A$! Q$!_\0
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MBD3B[T_7O$$>IR2H%DVL\2*!;G*#"]>.N*GZLW?78?UV/NW7Q'Z1JX[9H\T
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MXO"\RW D\,64\5WJ<B_=-Q)(Q&,\D <Y(Z&O8O\ ADOP9_T$_%__ (4][_\
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M#/\ H)^+_P#PI[W_ ..4?\,E^#/^@GXN_P#"GO?_ (Y3NOYG]Q'+_<7W_P#
M.XU3X/\ @O7-1U&_U'PIHM[>:E$(;VXGL(WDN$!!VNQ&2.!U]!741V,=O!'!
M BQ0QJ$6-5^4*!@#'I@5X_\ \,E^#/\ H)^+_P#PI[W_ ..4?\,E^#/^@GXO
M_P#"GO?_ (Y2]W^;\/\ @E>\M5!??_P#N=-^$/@S1=<.LZ=X4T6PU8L7^W6^
MGQI*&/4A@O!]QZUY9=?LKP^(/VD/%7C_ ,2#2-=\,:QI<-DFBW=J9'26,1XD
M;<-O\!QCGFMK_ADOP9_T$_%W_A3WO_QRC_ADOP9_T$_%_P#X4][_ /'*N-3E
MO:3UTV(E3YK)P6]]_P#@'HFN?#?PQXFT6UT?5_#VF:EI5J5-O97%HC0P[1A=
MBD87 XXJ)?A=X3CO/M:>&]+2Z^P_V:)TM%#BUV[?(! XCV\;>F*X#_ADOP9_
MT$_%_P#X4][_ /'*/^&2_!G_ $$_%_\ X4][_P#'*BZM;F?W?\$NS_D7W_\
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M/Q?_ .%/>_\ QRC_ (9+\&?]!/Q?_P"%/>__ !REIMS/[O\ @C][^1??_P
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M/J^H+&D0N;RT61PBC"KDCH!TKKM,TRWT>SAL[.WAM+.%!'%;V\0C2-1T 4<
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHI* %HI*6@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M^_\ X![+N/I1N/I7C7_#(OPS_P"@3J?_ (4&H?\ Q^C_ (9%^&?_ $"=3_\
M"@U#_P"/T<L?YOP_X(<U;^5??_P#V7<?2C<?2O&O^&1?AG_T"=3_ /"@U#_X
M_1_PR+\,_P#H$ZG_ .%!J'_Q^CEC_-^'_!#FK?RK[_\ @'LNX^E&X^E>-?\
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M.I_^%!J'_P ?HY8_S?A_P0YJW\J^_P#X![+N/I1N/I7C7_#(OPS_ .@3J?\
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ME7W_ / /9=Q]*-Q]*\:_X9%^&?\ T"=3_P#"@U#_ ./T?\,B_#/_ *!.I_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0NO^B3_$7_P3I_\ ':]EVGUHVGUHO'L'+/\ F_ \:_X:0NO^B3_$7_P3I_\
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M?6C:?6B\>P<L_P";\#QK_AI"Z_Z)/\1?_!.G_P =H_X:0NO^B3_$7_P3I_\
M':]EVGUHVGUHO'L'+/\ F_ \:_X:0NO^B3_$7_P3I_\ ':/^&D+K_HD_Q%_\
M$Z?_ !VO9=I]:-I]:+Q[!RS_ )OP/&O^&D+K_HD_Q%_\$Z?_ !VC_AI"Z_Z)
M/\1?_!.G_P =KV7:?6C:?6B\>P<L_P";\#QK_AI"Z_Z)/\1?_!.G_P =I/\
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MD+K_ *)/\1?_  3I_P#':]FVGUHVGUHO'L'+/^;\#QK_ (:0NO\ HD_Q%_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !7"?&;X5V'QI^'^K>#]5O+JPT_41
M&'GLBHE38ZN,;@1U4=J[NL7Q9KG_  CVAWM]L\QXH_W<8!)>0\*H ZY) XJH
MWNK&=1Q4'S['B^N?LA>&M8_X5[<6FMZQHNM^"+>.UT_6+%HO.EC3[JRAD*L
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M?+^M077C?6VOVCL[*Q:W_M%-/!FE</EXU<2<#H"<8[^HI<K#ZY36^_\ P_\
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M^%/>_P#QRO:_+H\NM.>7<X_8T^QXI_PR?X+_ .@CXN_\*>]_^.4?\,G^"_\
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M+V<^P_;4_P"9?>>R9%&17C?_  UY\)O^AI?_ ,%5[_\ &:/^&O/A-_T-+_\
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M1[.?8/;4_P"9?>>R9%&17C?_  UY\)O^AI?_ ,%5[_\ &:/^&O/A-_T-+_\
M@JO?_C-'LY]@]M3_ )E]Y[)D49%>-_\ #7GPF_Z&E_\ P57O_P 9H_X:\^$W
M_0TO_P""J]_^,T>SGV#VU/\ F7WGLF11D5XW_P ->?";_H:7_P#!5>__ !FC
M_AKSX3?]#2__ (*KW_XS1[.?8/;4_P"9?>>R9%&17C?_  UY\)O^AI?_ ,%5
M[_\ &:/^&O/A-_T-+_\ @JO?_C-'LY]@]M3_ )E]Y[)D49%>-_\ #7GPF_Z&
ME_\ P57O_P 9H_X:\^$W_0TO_P""J]_^,T>SGV#VU/\ F7WGLF11D5XW_P -
M>?";_H:7_P#!5>__ !FC_AKSX3?]#2__ (*KW_XS1[.?8/;4_P"9?>>R9%&1
M7C?_  UY\)O^AI?_ ,%5[_\ &:/^&O/A-_T-+_\ @JO?_C-'LY]@]M3_ )E]
MY[)D49%>-_\ #7GPF_Z&E_\ P57O_P 9H_X:\^$W_0TO_P""J]_^,T>SGV#V
MU/\ F7WGLF11D5XW_P ->?";_H:7_P#!5>__ !FC_AKSX3?]#2__ (*KW_XS
M1[.?8/;4_P"9?>>R9%&17C?_  UY\)O^AI?_ ,%5[_\ &:/^&O/A-_T-+_\
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M1[.?8/;4_P"9?>>R9%&17C?_  UY\)O^AI?_ ,%5[_\ &:/^&O/A-_T-+_\
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M1[.?8/;4_P"9?>>R9%&17C?_  UY\)O^AI?_ ,%5[_\ &:/^&O/A-_T-+_\
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M .T4?\)O\;O^B6Z!_P"%5_\ :*]HHQ1S_P!U![-_S,\7_P"$W^-W_1+= _\
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M);H'_A5?_:*/^$W^-W_1+= _\*K_ .T5[1BC%'.OY4/V;_F9XO\ \)O\;O\
MHEN@?^%5_P#:*/\ A-_C=_T2W0/_  JO_M%>T8HQ1S_W4+V;_F9XO_PF_P ;
MO^B6Z!_X57_VBC_A-_C=_P!$MT#_ ,*K_P"T5[1BC%'.OY4/V;_F9XO_ ,)O
M\;O^B6Z!_P"%5_\ :*/^$W^-W_1+= _\*K_[17M&*,4<Z_E0O9O^9GB__";_
M !N_Z);H'_A5?_:*/^$W^-W_ $2W0/\ PJO_ +17M&*,4<Z_E0>S?\S/%_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "N<\:>*#X4LH+H6CWHDN$B:-& 95
M()9AZD!2<=\8KHZQ]<T?^UIK%BY06ERMR% R'PK#'_CU5&U]3*HI2@U#<HV7
MC2RNM2DM>!&S0+;S*VY9C*A<8XX&%-/?QOIC3"")IKF=I)(1%;PL[;D8*Y(
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M<@D#&*V=/\36VJ:?-=VWF;(2Z.DR&-E=1RK \@]/SK'M_A[%:K; W<C^2+4
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MK"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *8R9
M;.<4^B@!NVEVBBEH 9Y=.Q2T4 -*;B#FF^4/6I**!6&&//&:7;3J*8QGECJ>
M:/+I]%(!GE^]+LIU% #/+P<@TI7/>G44 -V4;:=10 T)COFC;3J*!#=M&VG4
M4#&>6*<.*6B@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ I"?SI:X[XK:#J7B3P'K>GZ/J.H:5J<D.^WN=*E2*Y$B$.JQ
MN_RJ6(VDMQ@FC2]F3)V5S<T'Q-I?B:.YETK4K74HK>9K:9[259!'*IPT;$'A
MAW'45JU\7?LL_#SXA_!=O%/B+XE:CJ>GZ-9VLVM-:K<PM93S3KYER95 W&="
M@^8?+R<=:N_LP?'>[UW7/$-C+X@;Q?J^MZ.WBBUTWSR3976YQ)IR%A\H"F#
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
64444 %%%% !1110 4444 %%%% '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>ex10-8_001.jpg
<TEXT>
begin 644 ex10-8_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" /+ NX# 2(  A$! Q$!_\0
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MH4 %%%% !111_GU_E0 44@(89&>I'(QR#@_K2T %%%% !1110 4444 %%%%
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M1$O_ !7;:IJ_BWXA>$-'TG3KN*\U._TD _ 7XL_%K]M/_A _BW^SE^T3\?\
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M>'M9\:3Z)XB\.67[4?B:U\,^'O ]M^S]H^G_ %CX1_;P^%OCKX$?!'X[>&?
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M88\)?&CXJ?$3X9>&+GX,V/@FRT7Q1\>_%'C3X,Z;XMU2[^!G@3P!\5_@=>>
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MX_7OQE^'GCKQC<_L)^,_#GPA^&?[5GP%\3>)/V@/CMX1^+V@:M\*O"C?M?\
MB#X'>'O#AO? FGZU\=_#'B?P]?P?$/7OBUK:_K_\(/@!X)^"FL_%3Q!X6U+Q
M]KNJ_%WQAHOBSQ#J'Q(^('BGXH:UI,/A[P'X4\!:/X0\-^*?'6HZYXOLO .G
M1^&;[Q=IWA*_U_4]/TKQOX\^(FOZ6MB/%=W91^Y44 ?SZZO^P_\ M!?"[]G;
M3?BUX:^&'@C7?V@OB5^TU^T'\7?VJO!^B:3\!-(\?:/^RM^TOXQ^*?Q#OOV=
M?A3X@\5Z[X%^#$UW\//'DO[+/C3X[V_Q"^+E_P##WXV:=\"/'5AX]UK]H?P4
MWA?X*^.^G_9 ^!_A[P/\;+'XT? 3]G7P3\8_ WPF^$G[$_['WPN^(FA>//AU
MK,>B:;XOM_&7QH_:S_:,^$GQGUKPOX7M?BE\)K'P3\=O@SX>L[CX<:-X%7QO
M<_#'QA\-?!7PV\(:1X5TGP_%^\=9>C:)HWAS3+31?#VDZ9H6C6"-%8:1HUA:
MZ9IEC$TCRM%9V%C%!:6T;2R22LD,2*9)'<@N[$@'PG^W1^S+XA_:,_X5?>^&
M-#T._P!>^#=E\<?B%X8O?$/@WX(^-K"_\<:K\&?$GPZ\#>!%LOC%X+\81:6W
MBCQ+XUL_$%UK5I';^&8=+\":CI_BR*34-3\'ZIHG3>*/AM\1?V4_V$O$WPM_
M8X\$7?Q*^+/PL^"/B;PC^SKX2MHOA#X&CU/X@MI&I6GP[N=>.M3?#KX8Z;H>
MD>);W3=7\8:C=(+_ %#1['5]4DT[Q?XLO'L];^VJ* /Q _:._8=^)_B7]F?X
M'?LH?#WX<>+/$/P!^%7[&.@?"?X,>#M/^(G@'P'\1/@W^UU\.[#X8Z/^S/\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M5I'52 34444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %?AS_P %YO@W\+1_P3:_;B^+7_"
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MHK]LO_@EA;^%OCYH-S\-?B/KG_!4F/XP_#7P_P# _P"('PANX_%W[*OBK2_
M7@GPA\8/AY\8;[3_ (U?#7XP^!?AS\16\,_$;P-XCEC\&VOQ8CU;XA:!X?\
M%'A6Y^%]]HW]#!. 2>@YX!/Z#)/X5\P7O[%G[*FIZC\(=:U3X%^ M5\0_ GQ
M3XK\<_"[Q1JFFRZEXM\/^-/'XMI/B)XMOO%E]<3^(_%GB7XDZC9:?XA^).N>
M,=4\0:E\0_%VFZ7XR\9W.N>*],L-9M_IN>%+F":WD,JQSQ20NT$\]K.J2H49
MH;FVDAN;>4!B8Y[>6*>%PLD4B2*K  _G_P#V_?C%IO@KXU?"'_@H#%=?$.UT
M#]@7]IBP^%WBFXTWX>_&VY^&>J_LA_%M4^ 7[<_BO7O'GA+PC<?#ZZ'PY^(G
MB3PA\5O$.@^*;_7H-&N/V$M*.B?V!K/B_4KVTZK]MK]O_P#;"^ 'BO\ X*;3
M_#./]G%_ G[ O[+W[*G[6GAJP\:_#SXD^(/%7Q"\._$F/]IN#XG?";7]2T7X
MN>%-*TC6?$%[\"+:Y\%?$_3=-GL_A[8SMI^L_#3XF76LMJWAG]3Q^R;\!/\
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M_P"(_@;5_"VMZ9I7_"03ZUX3N];NK[5-,\2:=XF/B74-4E-O=F2^N_HS6?\
M@JS\>_ GP8^"_P 4_B%X"^'&F>%/$'QB_;V^$WQI^.UOX ^*DOP0^%>J?LN?
MMB^,/V9?@[<?%"Q\,^*_'?B[]GGP+\7/#OA'Q#XK\0?';Q]=^,?A#X$\=>%;
M3P%XWU?P+X>^(EK\1O GZ<^*?V!OV0/'6M_$KQ%XX^!WAGQKK/Q?^(_PY^+_
M ,0KSQAJ'B;Q.-=^*/PA%C!\,/'T-MKFNW]IH7BGP)I.EZ=X8\,ZOX=@TF[T
MOP58VO@:WD7P=!'H:UM'_P"">O[$/AKP[%X0\(_LO?![P/X46_\ 'MY>>&?
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MQ_$'X6_#:\_X+@?LQ>-M0^'?@N\\6C_@FY^V-KMOXPO?"6B7/B+_ (2/P?\
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M%;Q!)I6F:=:6H!]CJP894Y'T(_G@TM( !T^OU/J?6EH **** "BBB@ HHHH
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MB?P#_P %*/V2_P!@;7M U7XN:Q8:[;>'OVM-#_9%UG0OBS<V-S\%XY-/\=^
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M>E>&KNXU"XB\/V8TS2-7?4;A?$=IK,5OIL=@ ?"FB_\ !73Q1??$?0='U?\
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M$1"#PJQ,F?WAU4R?/76_![_@F7\ O@+XQ^)_B;X5^,_V@_"_ASQWJ?Q'\2>
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MCXK6&J:9I_Q*_9$T#PQ:^"O^"AO@7_@F]^TCK/@[]I*+QUIW@CXN_&T_!T_
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M"?$.[\4^&+_08O C:9\+_AO;:/X?^&V@?#C^SKCPG)JYN[C7?&WQ+U3QM?\
M /\ P3!_9N\#?"#X$_!G4-0^)?CW0/V;?VG?%/[6WPB\0>+_ !)HEAXM\/?%
M;QOXR^)/CKQG;7>H_#WPKX$TS7/ WBK5_B_\3++Q!X,UG1KW2M5\/>+KSPY=
MB72-/T.TTH P_P#AXEX@M]<L?"]S^R7\>-6\4>"Y?@?H'[2OASX=>%?&_P 5
M[_X+?$7XXZ#X!\6-\.-"UGX?_#S6_ WQ#\0? SP-\3/!GQ/_ &A;C5?&/PVT
MS1/AIX@TW5/@S=?';Q@=1\":9W'_  4#_;TT3_@G[\+_ /A<?C#X5^)OB!X
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MHWQ#^&_BOX?_  R^)7PHU+7O%;^-8=4 .@N_^"V/A76/AO\ #GXJ_#/]C?\
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M6D:9$P!X/K'PY_;WDUN;1+#7O@MJGPUNOVM?"]UJ+W7QP^-_A;QKJ'[$5QX
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M%-A\>?%,'CKXL^-;SQ_\$_&?Q/T!?#OCCXL_$WPWX'\ :SX,\;^._!,_P'^
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MCX9>'OV=_#?@O7OBI_P4'^%O[)_BGQ-XZ\=>()_ /C'P7XR^"'B[]H2Q\3_
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M^'WB_P ,>.OAMXC\*>-/#6O>%O%N@Z5K6F:CH>OV,\=Q:*CO) \D3_/OA/\
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MJGQ)LOB1:^.I/#WPF\2:!IGCGP5X-M]?M_"%A\3!JWQ2NM$O/B-XG\4^*-:
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MTW5[6+Q)K&@?\(_XC\1^"^-/^"DD>M>,/V1?BMKO[$/BKQ_\7P?^"RNC^ M
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MI-I%IOA/QYX2FT3QA9^+_!.IZ3XT\!Z18ZC-X<AUWPAX@\4Z;J-ZFA>#:/\
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M2?AYX=UGQ?\ LG7W[9?PB^+>E>/X?@CJVM>)?"'C/X/KIG_"4^'W^'V@^*_
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M\0Z[;W6O7OF>G?L6^$_%/PR_9N\&?'?5M=^)'Q!_9%U/1;KX)_M!Z+XS\:>
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MG^S#XS^.ND_LX^/OCQXW^#WA6[UH^,?A/^T9J_P%^/\ ^S+\//#E_#XT\?\
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M^*+31?'?Q=^#/Q#U;5?CIXE\+:Q)\&O ][\))+OX)?%;Q%\3-9TOX<U_A/\
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MD_\ !.?XB?&J5O&OB+]G7X9:;X.TGQ)XN\*_'KQIHL]]X7\1:-HGCR2V\!_
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MT%XBU#_A ;GX$^'?V5_^"*7AWX+?L^>'="7X?>$_A1XD_;5^)GQW^%MUK/\
MPF/BSXO:9X%AMO#NM>7=ZM+-I7P^T_QKX*\,?!_X3P7G@;5?!^I?$SQG^F>M
M_P#!*_\ X)Y>([_Q#JFK?LH?"V?5O$^G_'72M1U:WLM7TW5K/1_VF_LZ?'W2
M/#6J:;JMG?\ @W1_BI;KK%AXKTKPA<:'I]WIGC?XHZ5#;0:;\6OB=:^+>TUC
M_@GG^Q=XE&KQ^+?V?_!OC:T\1?!#PE^SGXGTWQY/X@\=:-XL^$/@"]U*_P#
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M!^(U_P#"W_@JE^W+^R/X.\4W&OZIX/\ $?AO7_V;OV+/VA/BG\/OB%\/=/\
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MXJ\:Z)XM\(V>M>!-0T#PU??"^SO[.?55_1'2?V4?V>=&\!?%CX7VGPOT.X\
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MHO6_@A\'O%_B7Q+\,/@EXP^,VD^)O%?AWQ1XV^&WA/P]XLT3PUXN\5:#\/\
M5_!FG>(-2AG /C?XR_\ !5?]HO58Y/AS\-_@AX=^#/Q?\*_M8_\ !'_3->;Q
M;\5-%\;^'_%/[,/_  44^-&A:)86=IK.C_##7H/#'Q4U&\\'_$CX,_%/0/\
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M;_M2_';79](\._ P?$Q?@M;WVB>)O&VM^$_%-C\,XOB_\0[;0O"OC#P]X@\
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M+O@=XW\"Z_XO^%VN>)/#6A>()/#6LW]P^C:U8/J/A>^T&ZU/69-1 /C#4/\
M@I=^U1K/Q&_;K\,?"K]A?2_'NB_L+^!/AKXZUOP]!\>-8O?CO\8C\8/V9]=^
M/G@GP-\-_A5X+^!GC/2[CXFZ?K:>%? WC#PC;>.-<L)+?5M0U;X8>*/BCXAM
M;+P3?<3X\_;\^'_QQ\$?L9?$=_A3\"_VBO OCG_@J%\%_P!GSX5?$+PI\9?%
MM@WP\\<WWPWNO$6A_''6_A5J?PWT[QUX#^+'@37+GQ_X'\8_LP?%N\\'^+/
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M/$NI>-IO"^L_#SP7X5^(WC+X:_'/0FT#P]'9ZK9?#GXC> O%/ASQ3X-U#7=
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MX7?$;X7?L\^,/AMX4\._$.+Q)\"/AU\4_'GP\L?C!/\ &[X--)HWC3P&NO\
MPEB\1>+KO6=-\:#PIX6M?B7YOH/[0OQ4\1_'?]K#7/AO^Q?X;\/_ +5NB_\
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MXA^+S>&O WQI\9> _A7X^\(^+_#C^'OAI8Z!\7?!>O\ CW^U/AGKVBZ]\2O
M4ALH=2\5Z7J\6FMX?\2_JSXN_;K\5^!?VQO"G[(WBKP5X(\+:SXIA^%)\$Z[
M\1?$_B/X;6/[0EEXECN'^,FN?LS^(M4\+:M\-O'_ (I^!<XTJ+7/V>=4\?:)
M\9M>\-WWB;X@Z?:0Z+X0\,Z9\6,CQ?\ \$AOV1?B!X;C\(>-XOBEXC\-1?L;
M^'?V#8=*F^(=UI2P?LY>#O$6C^,/!WAV*^\.Z9HNJCQ+X9\6^'/#OB&Q\<M?
MGQ5?7>BVUCKVI:SHEWJVDZC[^_[#'P.O-4L]1\02_$GQI;Q?$7X.?&+5=&\>
M_%#QCXWTKQ#\8/V?(O B_!CXI:E_PDVI:GJ>G^,O!%W\//#^JO=>%]2\/:=X
MUU*&)_B1IOC*VT?PQ;:  ?8U%%% !1110 4444 %%%% !1110 4444 %%%%
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M\$H/B=\3_B[^QZGC#XQ>(_B9XG\>1?M-_MT>#+V_^,Q^'J_%2QT7X:_MM?M
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M7.D_V8-(U0:\ <]J_P#P5B_9I\/:=\1[K7M.\7Z=>?#?QO\ L[^"[RW@\2_
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M\"Z%^S_XL\7:IX1_9)\26Z:_XC^#'P@EG^&?B:Y^*VD7=U=2@'O7C[_@IK\
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MC?PEI$WA;X>^$/"?A?X>^$/"4U[X'\,Z3I6AV_AI?#/*?"__ ()7^(OA-/\
M"JY\%?M:>.O"EW\/OV!OV;?V!-=U'PQ\*_AW_:/B[P/^RGXW\5^)OAAXUA3Q
MTWQ!T/1];U;1O'?BS0/B3X;U'0_%'A'QK/=:5<'2M(\.6FL^#O$(!^D?P:^+
MD7QDT#5?$=KX$\;>!]/L-:M].TJ7Q@W@J^T_QOHVH^%/"WC+1?'OP]\3_#OQ
MIX^\&^-/A_KVD^+;.'2_$NB>([B-]7T[7='O+:SU'1[N!?ST_:Z^(/Q:\;?M
MH_"/]C?0I_VA/ _PM^)G[&O[7WQ5UGQ_^SYXM^&O@OXB:=\1_ OQ&_9)\ >
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M>J?+>N_\$?\ 5M;T&#2!^UYX_LWL_A#^P5\.M+B?X8>!]=T3P[KG_!/KXO\
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MKQUX6USX567Q6\(7VN3>+_!>@>#?%6E74VO?"[QC\0/#ZVNJWGYW_'O_ (*
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M\*_BM:?%/P1JVH2ZWX(\*ZKX1\4Q>1#X:\2:!I.N3^'-:@@N-)N@#Y^\,_\
M!4K4?@K^TK_P4'^+?QOTK]J_Q?\ LM>$/"/_  2X\8Z%X+O_ (;^"-!US]C+
MP1^U/\/O'5YXGU_XC?#O7+_X9>,+6#2?&NK>&+3XH^#=!M_C1^T5HNJ!H/\
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M'\1_!7@GP;KWPB^(GPWU7XHW_P -7^&5A\3?#A\)ZEXNLI]:\-7&M^,^-O\
M@J]\%?AIX5\?^*_B/\%_VE_!-KX6_8X\4?MV^ [#7/!7P]:^^/O[/_P\L;#5
M/BQ>?""?3/BIJ6BQ^/?A'I7B+P'J_P 1/AG\5M8^%OC;1]'^(OA/6+/1]3TM
M/$UYX<;X8_X)E:?H/C;]HC0]5_:3^-GC#]C3]I/Q+\>_B!\0/V'-<L?ATGPV
MU#QW^U)-XRN_CXEQ\5;'PE:_'!OAAXSU7QQX@\4:;\*=+\=:'H^A^,-6U34I
M]3U?1KN'0+#D?&7_  2QN/B%\$_$/P<\>?M&>)/'MUI7[#GQH_X)\_ _XD^-
M/AWH>H>-?AS\#_VA-,\'>%_B[XR\<3Z)XB\.V/Q9^//BKP;\-?AIH:_$);?P
M#X9TZY\%QZO;?#EI?%OCZT\5@'F?[7'_  6+/P>_9S_;&\;?"[]FGXM)\:/V
M>?V3/AA^UKX'\.?&X_#CPCX,\=?!SXXW_COPUX'^+OG>$/B;XU\4Z;H?A7Q-
M\/?$UEXN^%/CG0_AS\9K_5K#3]#M/"VEZ-K%WXW\/?3VJ_\ !3/X7^'/C3\?
MO@QXE^"G[0OAN/\ 90^'WPM^+'[37Q7UK2O@];?"7X)?##XJ?#7XL?$ZR\=^
M*-;7XTS>)]>\/>$=-^#?BW0/&4_P^\(^-+JV\1OIR:!:^(M".JZ]I7A_QN_X
M)+M^T%I/[0N@^/OCZUCI?[0?_!._X3_L!:H?!OPI72-0\-Z=\'/$/C[QOX9^
M)^GW6N?$OQ3;7MUJ'C/XG^+Y_$'A"YT^-+KPM%X<T#3/$ND:QI>H^*_$'LWA
MK_@GA;W_ ,2_VV_''QX^)UM\:_#W[>_[-WPD_9M^.7@FW\ 7'PU2X\,?#+P?
M\5_!E_<Z%KWA_P ?ZE=:7;^,-(^-_P 0K.\L+:QAU/2=/3P?'8^)'U?0M;US
MQ6 >>_M'?M[_ -K?!?\ :U^'?A;PW^T%^RW^T-X9_P""??Q;_;%^!/B?QWX4
M^%SKXT\&>%O"%^+WQE\-M7TO7_C1X&?7_A5XVU#P'HOQ,\ _$G2M"\;>&QX_
M\':I'X3O-%U^QUZ.]^QS_P % ?#_ (X\'_L[? Z]T#XM?%OXY67[,O[%/C/X
MW^*='7X?WLNAWG[17PRT34K7XC>)?#VO?$/0?BQK_@R/4W@O?'?Q0\'?#;Q-
M\/\ 1M4\1'2CXENO$'AKXB:3X,Z'7?\ @G1JWC'P/XQ\/?$+]H7Q%\1/&;?L
M8?%']@WX2?$[Q3X#TO\ X2+P7\%?C+_PB\?Q,\7?$&RT'Q+H6F?%KXY^.X/A
M[\+Y/$_CE8O '@V+4?AYIE]X-^&'@N/Q+\0;/QCR_AK_ ()7:#%??LM:A\0/
MB_>>-M7_ &1[OX"ZC\&O'.F?#C0_ _Q;^&B_ GP3\.? M[X)^%?Q6TG7KWQ5
MX2^#/[1.C^!M4L?VI_@_XIE^(GA?XIZ-XW\1Z9X?;X?W$D6J, ?K11110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 5P'Q7\6:=X"^&'Q%\;ZQK.L>'-(\'^!O%GB?5/$7AWPAK/Q U_0-.T+0-0
MU.\UO1? GAW1?$>O^,]5TF"U>_L/"VB^'M<U37[JWBTNQTG4+BZCM9>_KSWX
MM>&=8\:_"SXC^#?#TNF0:[XM\">+?#&CSZU-=6^D6^H^(- U#2+2YU*6QM;V
M]6RMIKQ9[D6EK+</%&R1 ,P90#\T/#'_  5F_8]^&/P3\!3?$?X[_%KXQ^*/
M"_[#GP&_;'^(/Q#TS]E3XQ)XF\9_LZ_$/PUIX'[6>M>!OAE\*Y/#7A[P7JDM
MEK_B[XEQ>"K1O#'P?N+36/#6O6WAR\L]+T2Y]L\!?M]^$_&G[3O[3WP,N/!/
MB;0O 7[./P:_9;^*UI\9II=$UW0_BJG[36H?&N+P[%\/]#\(:MXC\1:YIFIP
M_#+0-%^'T5OI0\9>/_&VL:[X=TKP<D$'@W5/&OY[Z3_P2#^-=A\*?'7PQE^*
M7PN9/%O_  0W^&O_  1PAU:./Q:QMM2^'&D_%#PW!^T1-9-HT:FRU?3/BMJ6
MJ2?"M;B2XT^^\/6>E)\1;RWUNXU;1^V^(G_!)'XJ_%2V^.^B:A^T#X)^'^C_
M !\_9+_80^%%UK'A_P"&FH>-_%GPQ_:$_P"">GC?QO\ $[X%?%+PNOB7Q+HO
MA+QCX E^)GB?0_%GC3P)XP\-+<>)=#\+2> 5U'2HO$-QXLT\ ]7_ &I_V^;Z
M^\(> Q^S3X_G^'WQ&^'?_!3O]@O]DW]JCX;?$#X:1CXD^&_"?QV_:%^$/AGQ
M5X+ET?Q7(-/T+3_B=\+_ (CZ;XC\%?&+PW9^-_#GBCP3JES>?#+Q#;ZY)#XL
M\*^B_LC?M0_$?Q!XI_X*':?\<_%T7CH_!G_@HMXG_9U^ OAWP=X&T[0=7?P1
M)^S'^R_\4_"/PTT+1=/O+W4?%6O66J_$3QOKGB'QEXFUNY6*Q7Q)XRU_4? _
MPS\.&P\&^:Z]^P=^TMXW^!OP[\(>.O&'[(]C\2?"O[9'[+'[36HZ7^SW\$/%
MO[._P0@\*?LJ_&7PK\:=(\&Z5X;O_&?QJ\7ZGX]^).L>$O["\4_$G6?$,6DZ
M%HVLZ8='^'M[/X*F_P"$[XGXD_\ !++XJ>/]/_:(UC2_BQ\+O"?Q-\2_\%*]
M&_X*0_L_:QXC^']]\6_AGI^N:9^SQX0_98USX(?'KX6ZM=^#9O&O@'XB?!OP
MYXNT7Q/K/A3QKX>U_1KWXK3ZCX9%IJ?PTTC4_&(!]GV7_!1O]EW6_A?<?%3P
MOXA\8>+;+2-(^.6N>,_ ?A_X?^*I_C/\/-/_ &8]>MO"?[14?CCX,7NGV'Q*
MT;7/@YXNU#1_"WBOPG'X:O/%UYK>O^';?PKH7B.+7=*GN_G8_P#!8/X":7XQ
M_:^O/%7AGX@:/^SU^R/\-/V1/B)JWQ_TW1M/\8Z#X_T?]K9M?OO!GBKP9X?\
M$:WXC\4ZCX"N]#N/ -SHVIR:%:>)+N:^\976I^&-,T#0M'UO7\:']@W]M/P7
M\2?@Y^T9\%OVG/V7/AS\>;;X/>(?@+^T1X+;]DCQ_-^R+XK^'^H?$BV^)?@#
M4?A+\$?"/[47@3QKX/\ %_P7U*[\;66DZKXL^+_B^3X@R_$KQIJE[<>!+*]M
M?#5IQ7[0_P#P26^)/QNUK_@H?86W[1OA^R\$?MW? C]E;P1-?^*?AEJ&O_$G
MPA\5/V3K>_A\)>)];UC1?&_A;PKXF\*>,;U[36/&]AIOA?PQK$YN]1TGP_<^
M'Q!9ZLX!]]ZW^WE^SEX;\7_M > -=\0>)M-\9?LU^-_V<?AQ\1=!;P1XGO+F
MY\:_M=:YHGA?]G#0/!MQING7MAXNNOBCXG\2:#H&GR:1=RVWAS4-3C/C:;PQ
M9VU]=VGS;\4?VUM8\;>,/^"='BG]F[X@Q6?PK^-7[?OQ;_9&_:"\(>)?AO<6
M'CDZU\*_@5^UUJGC'P'J,GBY+;4_ &L?#CXR_LWWVA^(%T[0;BX\5;+'4_#7
MB^/P@RS>,/)]5_X)P_M@ZIXV_:P^,]E^V#\-/!GQ/_:S\5?L.>*O&WAKP?\
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M#X(_!_Q1\.OB=I/BBS^)W@SXJ>"+;X-KJ'QC;Q=J/Q)^'GBG5?B%XR\/^&?
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MX_UO2],N=-\.^'?&WQ;L=1\':?=R7$]Q9MI.O>(]8M--\'>'/$/B+2^%O/\
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M6][>1^*+/QM\.-#\1Z9\1?A7\5?#GAG]BUR -W)[GW]O;TSSCJ2>:_$#5O\
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M7?[1_P /_#L7Q&\6?L]:%\>?!VH_!7PA+IMNOQ9_X*#? ']GPWGPLUH7%N?
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M]H?X7_M)?'GPYK&F^*#\6/#_ (P\(6?PAM?BYH_@KQM8^)4LM<T7]HA/@7X
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M/#UW/XG>\BBT#X]:S%<>$$U^"7Q#K'P\T[4XM=\(V7Q&N]&^&_O.A_ ;PO\
M&/\ ;3^ OC3P_K_C+0?&_P"R%\(A\ ?VT=#M?AKXXT+X3_&8^#T^$GQM_9G\
M'GQ9\2O"GA)_%\GPE^,>H2_'CX/?$+X2'6[#3+&Y^*'@3Q9KL&G^/M5\.:N
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M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5\L?MR_&;QO\
MLX_L8?M8?M#?#;3O"NK^//@+^SG\9_C1X5TCQQ;:O>>$=5UCX6_#SQ#XYMM-
M\06F@:EHVM7.FWYT)K6:'3-6TR[D\U5CO[3)G3ZGKY9_;D^#WC;]H?\ 8O\
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MCZ[TVQDNKCQKI^K67A/6'N[FXM_#-KXOO9D6Y /V/^'7[:?[*WQ8^(UM\(_
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M>$E\6>-/ \'PW\0?M%?!+X*? WX+?\(1\0/"OP?UCQC\4O">F^'O@;I_BO\
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MXB?\)%X7TFZ^%>DZMXQUC2_".FZ[\4K/P5I-YXDU/2]%2Z35-1M;)_PF\?\
M_!*__@H#\2_#WQ3M?%FI_L>R^-OBG^P3_P %0/V,?$'B[P[\1?B_X0\&MJ_[
M8'Q*^''Q&^"GCOP?\%;#X%7WA?X5^#-&A^&]KX2\;?#3P]KVN:SH<VN:K\5?
M$/Q._:'^)E]XHO?&/UO\8OV._P!LGXH_'23XJ:I\*?V$_B/\._V@/V4_A9\
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M>E^']:UO1_AEXGN=?NKGZBU?]G/7_C%\0_BOJ'Q^TW5KKP98^!](^$_P<E\
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M8SRD\.R53C:XQ6A10 @&!@?J2>ON<F@@'K_,C^5+10 =**** "BBB@ HHHH
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M;_#+7+J]UG7;9#X?\-^-M:\2:#;1"Y\8Z3X935?#@UOZ)K^9S_@GG\&?CO\
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M'B;5KZ\N8+6QT;PWH>JZO?7$J0V=C/*P0_C;^PL]U\)?V0?V'? OQJ\:?\%
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MI_Q7\/\ Q8\0^$%\"?&?XD_$?Q7\._B5\'?&.HZ5)J>F_"OT2QFT[QQ\>/\
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M4NK6_P"T7\4OVE/ ^@?"[XD? .*9AH%MJUIJWA74 #^F4,&&5((Y&1Z@X(_
MTM,3&"00068@CD8)R"#@9!!SW'8$KBGT %%%% !1110 4444 %%%% !1110
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M !)XDDT\ZAID,MEX?TG4KU[S4]+L8+:6^U.PM[GSG]GGX_\ PH_:I^"_P_\
MVA?@=XBN/%WPF^*6BR>(? GB>ZT+Q#X7FUS0EU"\TV+4CH'BO3-%\2:4ES/I
M\[PVVLZ3IU^(/+>>UA,FP?S*?\$UOCMH7Q0^+W_!'C]I+]I/X_\ B#Q%\3/B
M;_P3'_;L\#2^//%7QM\6Z=9_$7XE_"C]IK]C:VM_#TWAG2?%FF>!/$/C+3OA
M1H?B?Q]\6M.M?##7WB/1O!U_\7OB[;:HGP[L_%/AF']AOQ!XR^#/_!(O_@D3
M^WK\-?$_QG\=> OV6_#">%OVK?@!\(O'_P 1M;\/_$3X _$;Q/XN\!>+/&*?
M!/P+)JVD>./B[^S1XVUWPG\7(+&]TFWOK_X;Z#\3_#.J_P!H:HW@O^P0#^MC
M:N=V!N/?'/IU^E! )!QR.A],]?S_ /K5XI^SSX \5?#GX3>&-#\>>(M>\3>/
MM0E\0>-?'MYKGC3Q/X^@TSQQ\1?$FK>/?%OA+P=X@\8W^I^(8OA;X&U[Q%?^
M#/A)X>OKZYD\+?#30?"OAU[J]DTQKR?^=3_@I5\??'W@GXB_\%J]:\+_ +;'
MQ;\ >(/V0_V&_P!AS]I3]GGX?^$_C5X>\'>'_AE\<H?$7[4OVQ'\%:/9:>?&
M6A>+K_1_A5IOQ!^&'Q13QKX7^)\7Q2\-Z1XZT'Q';_\ "B[7P, ?U+X_S_GM
M[=*:44C! (SG!YY]><\XX^A/J:_G2_:U_:=^,\FL_MLCX<?%SQ=X;_:]^%_Q
M-_9]\8?\$K/@WI/B;6]/^%'[6OPB\6_"GX)7]I9:)X*L-7\,^!/VK?"WQ<^,
MFO\ [0/PU^.6MW.I>)[K]GGP9;^$/'-IKGP8N_#_ (1^)U][IX4\/_%K0/V\
MOC/^P]XE\:_M'ZQ\-O'OCSX/_P#!1#X+_%X?'#X^R3>#?@=X82#P?\7_ -EJ
M#Q[J6N1V36.D_M,> O!U_K7PK;Q#XCT[Q5^SY^UEJ.D'1-)C^'FC7^D@'[<,
M0@!VECG [MSZ9.3ZXSZFJ&C:SI'B/1]*\0^']5TW7=!UW3;'6=$UO1KZUU32
M-8TC5+6*^TW5=*U.QEGLM1TW4+*>&[L;ZSFFM;NUFBN+>62*1'/\DGC/]K=O
MVA]8^,/@C2?CU\9]8\*?M"?L9_\ !:/P-J?PC\8?$?XE>"?C?=_M$?LN?&GX
M7Q?"3X:7/P=\+-X'M_V?OBK\/OAQXF^)MI8_ CX4:%I?Q=\1_LW:+:?%3]JF
MY\:G5KF[\,YG@W]K/2K7]F;]A7]GOPO^V=XC_98^'_B[_@G!^R#K?['/[1O@
MGP?\?/VB?^%E_MQZ+XA\;^&_C;\"?!>J>"_C+H'@#XX?$+X7>*M!^!'AFS_9
M"^(-A\4O#'B6U\1^./@TG@2RTW1=8\,:8 ?U)?'G]H3X6?LT^$_#WCCXNZGK
M^B^&/$WQ+^&GPBTS5=#\$>-O&T%OXY^+_C'2_A_\/++7V\%Z!KX\):-K_C/7
M=&\-1^+_ !8=$\(66MZSHVD7VNVVIZUI%I?>U;E"EL$[21C)/(8J<9[G)Y R
M0<<GBOY._P!NOX^R^*]5_;+\%_M._%#XC?#[XX_ S_@H]_P2YUS]GK]F;3O%
M/BZQ\/\ BS]A^S_:2_8.GLOC)X>^#?@D:IH7QSTCQ/\ &;QC\:[WQCXSL+?X
MC^+/ OQ0T#X??!^\U[1+_P ,^"O".J?U;:A86^L:7J&EW4E]#::I9W=C<2Z=
MJ.IZ'J<=O?0O#*]AJ^DW6GZSH]^D<S&UU'3+VQU33KD)=65U;7<,4R $>DZW
MH^OV\MYHFIZ?J]G;ZCK&D37FEWUKJ%K#J_AW6+_P[XATJ2XLIIHH]3T'7],U
M/0M:L'=;K2]8T^_TR]BAO+2>%-7 Z\_F?\?_ -7:OY(/^";7Q2M_ '[.G[''
MP5UCXD>-?!7[+]Y^UC_P5C^''[;GQ$7XW_$?0=?^#_[1&F?M.?%+4?V5_@?\
M6_C1>^/X/'G[/+?$[PMK6O>.M0AM?$_@+Q;XS^*C? M?%'B.35_VA[+1?C5^
M]O\ P35\3_%SQ;^R3X0U'XP^,M:^)M_IWCSXX>$_AI\7?$]G9V?BOXV_L\>!
MOC;\0?!O[-OQS\4RZ9:Z?I&M:Y\9_@9H7@+XF7'BW1]*TC2O&MOXHM/%UAIM
MM;:W&& /HSXP?'_X3? G_A"8/B3XCO+#6?B7XJB\%_#CP?X9\*^,OB-\1/'_
M (G-G<ZM?Z=X(^&GPW\/^+?B!XJ3PYX>L=4\8>-=1T'PU?Z7X$\#:)X@\=^,
M[W0?!_A_6=;L;7PG^./PR^-Z^//^%<ZSJFIW7PQ\;)\-OB)I.O>$/&O@3Q#X
M.\<R^!?!/Q+B\,Z_X9\?>'O#'B&PU&3P'\2/ _B9!-I@A?3_ !)8E9FG%S#!
M^07[4OBI_P!E#_@L?\&/VVOVE_$EGX'_ &&O$'_!/OQ9^R'X;^+VORS#X;_
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MJ,FF7MTV@:E>:EJ6C:3K/]GZKK/ACQAI-K=^&=5_.WXY?MF?MO?L[?M/:I\
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M ?\ :;_;N\$WU_\ "N_\!?#/4_\ @C=\//A1X_U#P -)TGX9:=^WM\<_B?\
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MZ5;6WP]MOB)%XHA\3_$?QM=7E]>_$:_TN]M]=:TET7R=+T1=,_GF^$W_  4
M_:$\6?$;]EK]N'XC^+O'?B2SM_\ @WH_:H_;K\7?LK?#N+P5H'PQ\9?%3P?X
M[_9;NM7T3PM9W/@'7O'MO=?$=K2RDT:?7?&'B[6_"FH_V=IG@6^T?PYKOCS0
MO'?VCXR_;M_:(^%?PB\:?&&X^._[+GQ0^#7QPO/V)(?V?OC)H^I+KC? "/\
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M:'3-<M;6>6?2-1ETR_L-2BLM0CM[I[&]M+Q(S!<PR/\ B;\&_P!FO]C70O\
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MVH8?VBQH$OQE^(/@S1?BQH6N>,?BQX.\'?$CX6:]#X['@;4O$%CXTUVQ\2:
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M#*02#D#@_H?Y$'\:_+S]HZ#4/V8/V$O$_P"SS\/OVH;_ $GXP?$*/XD?L\?
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M7XS/\&X!\5_"/@#QY^TC\1?VFO\ @H+\-?@QX+\!7GQQN/"'B7P?^R!^T_\
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M\1/#:3W6F7%M=B"T\5^$]#OY[82_9[^&VDL+V*>RN)X)/E&3_@JE^S:/V<O
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MQE9K:ZIXLU36O&.@^%?%6@>._M.?MX>-=;_:#_8)\/\ [.FH_&'P]\)_%/\
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MZ)X]TO4-0\8Z,_@/P7%XA\1_&JV^%VF^#_%TVA_'_P"UG^WOKOB[P)\ M5^
M/C+XG_ /XC>!?^"NG[$7[(O[4OP8\8^%_AQ:?$'3]!^)?QY\$>&O%_PV^(-G
MJ&G_ !)T]/!7Q0^&7C+0/B-X!^(OP8\;V]OXQ\(ZYX<U/P_\0;S1;OQ/X=N
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M1A\$_#?Q6_@7Q$-/3X(?\%0O@GX2^"7[%FD?''XB_P#"2_$SXG_#?]C[P?\
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M<K>,O$NF>/X/%/C&/X?>,)/A]JR^ 9?!.N>)/#^N_"*_\5Z-\>/#OB+X5:2
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MO#7B7P#X5O\ XT^ =,UKQ?\ !C_A/]$T'7+O3O%-&_X+(?LOZA\/M&^+.O\
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M^*GPV^%?[/'[-7[7?CWXH?#_ .#&I0>!=$_97_:@T_QMK?A'X\6M_P#$+5_
M6I^)?"OA#PYX'U'Q#X\\,^$M(U[XH16!U>T\%> ?&^M_#KXP:3\. #N_@?\
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MM>,KGI?^"7_Q_P#BA^T]X"_98\=>+/VG_C;XT^(!_86_9@^/7[37PO\ B/\
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M?#7BOP[XLT?4M"T[5=+U"TU-;J[NOU&KX@_:E_;O^'O[*_Q#^$_P@U7X5_M
M_&3XM?''PE\:/&7PO^'GP'^&:>,-6\3Z;\!/"EIXU^(.GPZ[XC\0>#/ UIXC
M3P]="X\.^&K[Q9;:UXFU$6GA_1K.Z\0Z[X9TO7 #QSPU_P $I/@WH"_!&YU3
MXZ_M;_$?Q-\!OC[X4_:'\)>/_C)\:H/C'\0M5\3> /!WCOP!\/\ P=XE\7_$
MGPAXEU:X^&/@KPE\5/BC8:%X.T2;08SJGQ'\7^,-6O\ 5?&^HQ>);;5\._\
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MG]AOPYH7B7QO\-]$\-6NJ^,O"(U_PIXDGEU&6UL=;D/B346N]'T+6]2L.O\
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MJ:IX9\?>/+#PSXF\)Z[=>%?%/A&?XJ?\$Q?$/Q,M+_Q'_P +S\+:+\9/&_\
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M:O#:W]M%=6\6JZ!K]CI>NZ'J4<,J)?:/K>FZ?J^F72RV6I6-I>0301_($?\
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MX4_L.W/Q/U?]B[PMXK^&E[>>)_A[K7C7X7>/?@SX#MOC+XXTSXHZ6/C9X/\
M@O\ "_XL?$;X?>#] T7PW\(==UWPK>>$[CQMXR\0^/O"UQX_U_QGP5_P2J^+
M7@GP+^Q?X#T_]JCX>O8?LC?L*^.OV&KN]N/V4?[8?XI^$_'_ (O_ &<]8U[Q
M%JV@^,?V@_%O@W3;+6/!W[,G@[P!XG\#ZWX9\<:3KNG^,OB;?)J&F)K?A?3O
M!7Z*_M&?M@?L]?LGZ8-6^.WC?4O"UL/ GQ$^*4UOH/P_^)/Q+U>R^&'PA_X1
M7_A:OQ)U30/A=X0\::]I/P^^&Z^.?!\OCGQKJ>FVGAGPO!XCTJ?6=4LX;D./
MHVPOK+5+&SU/3;NUU#3M1M;>^L+^QN(;NROK*[B2XM;RSN[=Y;>YM;F"2.>W
MN())(9H722-V1E8@'Y*?#;_@DYX-^"L_PI\9?!SXA6GP[^)WP,_:"^,?QL^#
M>F:1X+\277[-'PI\*?M&^ /#7PY^//[.GPT_9XU#XMW.I> ?V?\ QZ?#B?&?
M3? ?A7XNZ5:^ OVD+VZ\>^#&TCX;S7WP6O[?PY_X)?R_#+]H;]E/X_Z%\9-(
MEO\ X%:[^WG\1_BQH=Q\)KI9?C;\8?\ @HAX\T'XG?&[Q9H6LP?%>*+X5>%O
M#GBW0+33OA=X,O=%^*&I:!X&ALO#WB;QMXRUJT?Q9<_0/B'_ (*4?L8^%OB#
MXX^&.M?%C5X?%GPO^-OPW_9W^*1M/A!\;M6\*_"SXL_&)/"/_"JM$^)_Q!TC
MX;WWP_\ AUH/Q#O/'?A71?"'Q!\:>)]#^'6N^)M3;PKI_BR?Q)I^J:59>E_$
M3]L7X ?"KQ-!X1\;>)/&%CK.H6WCO_A'VT?X.?&CQ?H?C/Q#\-O"FK^./%GP
MU^'WBKP;\/M?\*_$7XUP>%?#GBK5M%^!'@76?$/QF\7)X-\;VOA'P)KM]X*\
M56ND 'QSIW_!,[Q?%XD_::^&VN?M;?$#7_V!/VH]2_:/\8^-/V.G\#>'K#Q+
MI7CK]JZZ\5:Q\:[#0_VE[76AXTTOX,:_XR^(/CWXDZ?\+=!\(:'KUCX\UNW%
MS\3=0\ _\)+X!\62?LO_ /!.GXN? _X[? CXV?$S]KF;XSM^S=^RO\1/V-/A
MWX?L/@5X?^&U]XF^"?BCQ=\(?%7A.]^+GB:3Q]X]D\5?%/PW)\(=#M_$WC+P
M3I'PP\.^-9;71;RQ\">#&@\76WCGZ/T'_@H/^R=XFD^#JZ+\0/%-S;_'_P#9
MFU_]L+X/ZK/\%/CKIV@>-_V=O"ND^&]=\2>/+#Q)J?PUL] LKS0]&\9^#-2U
M/P'J^I:=\1[6T\9>$9)/"(_X2C01J'UIX7\1:?XO\,^'?%FDV^N6FE>*-"TG
MQ%IEKXG\,>)?!/B6VT_6["WU*R@\0^#/&>DZ!XP\(ZY#;7,<>K>&/%>A:+XE
MT"_6XTK7=)TW5+2ZLX0#=KXF^._[)GB'XQ_M;?L4_M.:?\3M'\*Z=^Q_>_'2
M]E\ 7GPZO?$E[\13\<_AQ_PK358H_&</Q&\-V_@X:'I7^GZ>[^#/%OVC4.;E
M5MOW!Y+X/_'7X]^+_P#@H=^V%^S?XIU[X4W/P2^ GP6_9;^*/@6UT'X8^+-#
M^*%UJ7[26J_'W2KG2?%WCV_^,/B+POK5AX.;X W=U97&C?"_PK=:PGC:"TNO
MLC^%'U#Q/X+^T1^TK^V9\(_A/I7C#PU\1OV<-1\1^(_^"D?P2_9*T\Z[^S9\
M1Y-%TCX1_'+]I'P'^SO9W=WI^G_M7V-[K'Q*\%MXX'C2;QA%J^C^%?%3:2?#
M8^&?AI=1&O:> =7H'_!/GX\?#CXK?'C4/@M^W;\1OAI^S=\;_&/Q9^.4'[/C
M?#/P[XMUWX:?M-?%W^VO$'B'QUX#^-FM>*DU[3?@U+\7-57XY:G^SPOA2/0O
M$?Q#&M:3K'BZ7X7>-_'7PZ\1>0WO_!&_3-(\/^+=5^"?Q^O_ -F'XRM\:OA'
M^TC\(=>_9[^&W_"$_L]_";]H#X5> /BA\*-;^*\'[*-Y\1]<\!7^L?M%?"SX
MN^*/AQ^U7X<\(Z_\-O /QF\,:7X3OSX0\,>.[/Q/XU\7_>7[>OQA^*7[.?[#
MW[57[0WPEO/ Q^)?[/?[/'Q;^..B0_$/PEKOBOP3XBO/@_X!U[X@7?AS6= \
M.>.O 6N06?BN#PY/HD>H:?XN@GT"348]4$&LK8MIM[\K_L\_MA_';Q[^V7/^
MRQKOC;]G[XT^&KS]B3PU^T3KOQ/^!_PX^(GA6Z_9[^,6H>(O!^@Z=\-?C+8Z
ME\2_BM\/+W3OC7H?C.[^)7P3\-:;\3-"^*.G^&?AIXX3Q3H&O>&-0\,?$:_
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MAWX;:/\ &GPOI<*_%'XK7'P_\,>)=!^!?PEU?QA9>.Y+3Q[\3;[PAX TS0/
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M\7>-6UKPM8^%='U?4?%_A:TU@ ^E:*** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "O-_C'X2USQ]\)?B;X'\,:_
M?^%/$WC#P!XP\,>'/%.E:]XB\+:CX;\0:YX>U'3=%UZR\2>$+S3O%.@W&D:G
M<VM_'JWAV_M-9L6MQ<:=<1W21-7I%9>MZQI_A[2-1US59S:Z9I5I/?W]R(+B
MY,%I;(99Y1;VD4]U.4C5B(K:"6:0X6.-F(% 'YI?$+_@E7^SE\9_A'^TW\ ?
MB./B5-\)/C]\.?#/P5TC2['XY?&3Q'?> /A=X-\.^'KKP3'X9TSXF^+/''@C
M2O$7PT^*=KK_ ([^&27'A37]!\+7%PJ_V?=Z?XA\4Z#>T_C+^QQ\>?VQ?V?_
M  A^R5^V#XM^#FN_"&W\5_";5?V@O&OP_P!-\33>*OVK/#OP;\7Z3X^TCP_)
M\.?%6DIX<_9XM?B-X]\%^!-<^)L5MX]^/SOX0'C?X<>&+S1[OQ%I/Q&\-]+X
M=_;NUSX@0B'X,^"=(^,OBF_^&'Q;^(WA;PAIH\7^![?7X-8^.'AWX?\ ['=W
MJ_C#5M!U]?"'@3XN>!+SQ-XX^(?C:/PIXLO_  7X=\*>(/&,?@Y;?16\):EX
M!:?\%//CK\.=1^-?P*_:5_9H^&_@_P#:W\!?%3]CSX0_!S2/AG\=]7\9_LX_
MM%^(/VY]7\4Z'\(]1\/_ !+U_P"$WA3XI^!K/X87GP^^)^K?M#Z-K/P1USQ/
MX3^'WPXU/XB> ])^(EEXAT+1" 8?Q'_8%_:K\9I_P6QTZQE_9ZM=,_X*B>!;
M+P)\,KBZ^)GQ)2_^&2P?LJ:)^R!<ZYX\BB^!UQ;ZH9?"NCQ_%:WT3P]*X@\0
M[_AI)KEQITP^)5M]>0_#?]L![72[.R\.?LU>#+30_@3KO@/75T?XB>+?%'B/
MXW^,])\.P^&/A!H'CKQWJG[-^AZKX!^$'@E_%/Q/\<ZI;>&-,\5^,[[QIJ'A
M*VT;4M"\+_\ "P-)\<^:ZY_P43UZP\0^*OV?=$^'7A_Q!^UIH?[;O@;]AK2/
M"I\4)8>!=5U/QK^S=HG[8O\ PT;J\-HVN>+_  O\+](_9<D\<?$.7P1<V^H:
MWJ7Q&^'6M?!+3_&[Q74?Q6M;/Q _X*"^.?"O[%?[=G[17AGX.^#/$WQA_P""
M?VO_ +1?AWXN_"+Q'\5[WP=X8UJ+]G;0H_BC<^(=!\=>&_A_\4KRPN_B9^SM
MK'@CXS>"/ VI^&GN=.U;QUI/PL\:>+O#MUIVM>-[( S_ (I?\$]]4^+]Y^PW
M\<6UGPM\&OVMOV5M<^!>C>/_ !IX!N_$/BGPC\8OV=_!7C_P7XS^*W[-7BZ7
M4-.\$7'C/P)K^M>#=)^*/PHU#Q?X1FU7X3_&7PWH/B+PL-+@U7QK+XF]N\5?
M SXPZO\ \%"?A#^U)IEI\-3\+/AY^R_\=/V=-4L[_P <^*K3X@7L_P ;?B9^
MSC\36\6V'AVV^&%]X;$7A:Z^ +>'TT>X\<PMKT'BU=9;4]#ET!M&UE_C7]K'
MQ1+\:O@S^S7\(?"?@SQ+\9_B)^SUXW_:H\96?B[Q9J.B>'_ OPH\$7G@KPIH
M^F Z/H>LZK?>+OC!\5?'VC^!O!-QJ5OH?AO0/"/AGXP?$^^U#Q+K7PTT+X0?
M$_V;]E']HGPA^UQ^S3\"OVF_ 4,EEX4^.GPM\&?$O3-&N;_3]2U+PQ+XHT.T
MU'5?!NNWFE37&G/XE\%ZS+J'A/Q-#:3/%::_HVI6N0T+*H!\V7'[#>B_%O\
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M_P"$B\<ZPUSXO\!6MAHOA+3O"7C.P\/1>(=6_9A/VZ_V,)_!GB#XC6?[57P
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M'O&/B'X73ZU9Q:#;>-O$WZ^44 ?@9KO_  3R_;)\8>!_V<[[Q#H7_!/+P?\
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M;9-;LO"7C[0_V6HH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "O//B[IWCG6/A5\2M*^&&L2>'_ (E:CX"\
M7V7P]UV*32HGT;QQ<>']0B\)ZF)-<TCQ!HJ+9:^VGW#MJ^@ZWI@2-OM^DZA:
M^;:R^AT4 ?G_ .#O@!\2OV;;+XQ>,_A0/&7QHU[PW\,_AW\(_P!GCX/>-OB;
MX0\,>&O$?@KX6^#(Q\/]!\7>-U^'KZCX6M-#\>^-/B*M_P"+;NW\:>*AX<N+
MG4[G3_&MY!X6\-67YV^!/V0/V[_BS\-;;4/C_P#L_P#P"^%OQ\^%G[9G[/\
M^WW8>*+']IKQ/\6+7]IO]H#PUXRL-)^*5OKFLZ3\'O <GP2\!>#/V9=%F_9Z
M_9^\&:QH'QNF\/\ AY_@S!XA\;:A'\&M;U/XA_T)44 ?BY!^PG\:$^,7BO\
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M./A'6=.6?0_B+\1_B+XYT/2O@'I'PW\'?!7PQX(\9Z1\1=*\?>(_\$C?V?\
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MVG>!KKX@:!XJ^'.H^.]!\"_$$?&3PW@?!+_@GW\<_A!^VU\&?VI]0^'J:_H
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ML=7^!K>)[;P.?B7HGC+7_$^A>#=0T9?&UR?"K:2-=B\6KK%M>0GPX;>TGNE
M/N2BOFCP[^UG\&]<_9B\0?M>:EJ/BGP+\%O!_@?XF?$+QS??$;P!XS\$>,_
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M/J.I_P!A^%-*UO7[RUTZU62]U![#2[K[#I\%UJ%T(;*UN9X@#LZ*^9$_;"^
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MS^/WCS3OC5^T?9^(O!?_  <'_L]^%_A[<K\?OC3/I7AW]DGXM^'_ -D#P_\
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MATGQ-XU^(_BSEY?VD/V@? /PM^(TWCCP!XM\5?M&?!?]L3X1_"?_ (*>Z_\
M#KX8_&7XP?#?Q=^RE;_#[Q9X-\&?M/\ [+_PJ^$WC'P_>:[\*7\26WPC^(7[
M3_P;^#6HWWQ"^'DNG_M&^ ?BUX)U:RL[.UUS^G(C ) ).#CGD]>,D]_<^GI7
MG/PE^*G@[XV_#[0/B;X!_P"$K/A+Q(VKKI)\;?#SXA_"GQ/G0]=U/PY?G4O
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MOBWXTZ'K-K^PG?>$=9_8Z\6^/-<T>Y\6:9XBU?QMX7\7>*O'\/PKU71_ZO\
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M5/"^J6.G6<<UU-;VL,EU>3PP)+<W$$$;2!YIHXPSCTFB@#\3OV)/B)X*U?\
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M[2OC7]HOXE7>I? G]H/PG^VC\5O%O[//PL^,/QF\2_$35O%GP)UKXU_#&_\
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M7U#2].U: VFJ6%GJ5HS*[6M_:V]Y;,Z_==H+F.6)G7HKE"R@D*1N;(!_//\
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MDY>")EM6]A96AB-K:6UOY-LEG"(+>&'RK2-MT5K$8XU,=M$Q)C@0B)"<J@-
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MUJ'0?"'A3QS\6O#OCGX3: ?$?PL\8?#OXEZOJ'P\^)OPO\<Z9_9NOZ+XOO\
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M\;=7FUWXGZ1I&N>&X=+U?1].\5:I=7=W+::9>VL&E&ZNH="33+>ZN(I#5_\
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M-OB=<36NMPS>)/B)XWO?%?C2;QIXX\4R:UXI\6CX@?$J'Q%JNIV_Q(\<1:Z
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M_KNLZQ=>(9;_ %2]GG /P1_X)I?&SXO_  =^.7PV_9 TF^\ 6/@?X]_MC?\
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MK.*'QMJT5OKWCNUN8[FV\<>([.P\1^+8M9URPM-0B /RD\/?M3_MEZ)\=O\
M@JEXT\(>(9/CYJ_PSUS_ ()A>'/AO\%O#&H?#:;3]%^'?QM\%>#/B7\;=._9
MHN/&W_"D]%^*'Q+T;PK\1_BQK/P-T?XCZQX=UKXL>*O^$*TGQ3_;DL6@>"#^
MR/[%?QXN/VD/V>]!^*E[XIT;Q9J>H^./C1X8U&YTKX7?$7X)ZAX>N? 'QG\?
M> [?P'X\^$?Q9FN/B%\._BS\/]/\/6'@OXN^'-?D,4/Q+T/Q5=^'U'A>ZT4G
M4\3_ +&7[*OC/XC>+?C!XH_9]^$^L?%CQU!X!C\6?$NY\'Z7'XYU>]^%-_:Z
MK\+_ !$WBBV@@UFR\9?#;5=.T75/ 'CG3[RU\8^#M1\.>%;[P[KFFW7A7PY-
MI>;%^QS\%;/XP_!;XPZ5X,\+Z+KGP#TSXI1?#R\TO1[N#Q7;:W\:I]:N?BMJ
MNM>,)=9GNO$-O\1-2\0:KXO\>V^KZ;<ZWX[^)LMM\2O&?B;7O$NGV$UL ?FU
M^WA^VS^VI\$?BI_P4 \(_!7Q'^SIHWA7]D;_ ()E^$O^"A_@VZ^(/P:^('CC
MQ#KVJ:3XE_:3L_%WP;\5#1?CIX&TS4=+\<VO[.=Q'IGQ"T<>%[[X?6WBC[+_
M ,(3X\OK9-=MKOBO_@I!\</V=?$O[:^K_M 6?PZ\<?#WX0?L)?LS_MU?#;3?
MA7X%\1>']<^'%K\=_'/Q]^&&M_"_X@>(O$GQ'U.R^*WA3P/JOP<TGQKJGQ;T
M_P ._!W4HO#&H>+YW^'9:STG3[/]-_'G[)7[/OQ/\1_$OQ;\0/AQ8>*?$'QC
M^%=O\"_BC?ZCK7BH+XX^"]O?7>HK\*-?LK;7H-.N_AW+>:IX@FO/!HM(] U
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MK]NKQ!\(?C3\7OAK>?LP^!+'X=_\$3_V8?\ @KCHFA^*?A!\3/B%=CQ+X_\
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M:[>>.OB3=:W;ZA/\3?'[^(Z'C3_@F[^P=\2=5N]=^)/[(_P"^(VN:KX0\$>
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M_$2Z\266I/\ $'4?"Q\,:+9:+KGC,ZYK5GHMI)X>2_.A7^HZ== 'V4/;U/\
M,Y_6EI%!  )R>Y'&3Z]3_G\J6@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **0D
M @'OP.#_ $_SP3T!I: "BBB@ HHI"P4$L0 ,9)X R<<GMSWH 6B@$$9'0T4
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M)M@0_GA\1OV,/&,WC+Q[^TOX:^,/C*X_:^G^ 2_LM?"'XP>$O!'P+\.:_P"
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MKVVO_'O@+Q/K/AN72+;QCX4N]9\4>'^F\ ?MN_M"^._C/^V%\.OBU^RGXO\
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M%E::A97,-W97UK!>6EW ZR075K<Q)/;W,,BY5X9HG26-U.UD8,.#7XL?$/\
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MH?Q$\$^._A)XC^#NAZ9X>\2^"O%_A2YE\0W=WXEN=5UBYTS5]/T300#5M_\
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M\9O&MO:W;Z++=Z-XA70==B%W%IEQI>H^)^$O^";_ ,*?"&N?#G2+3Q)K&H_
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MXQ_:CUCP-9GQ3K4&@WW@#]I3Q)IVN:9\$O$7ANUU&+P]J_PC^ EGX,^#FE?
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MI:'I/PX^%/@;XI-KOQ#^!OP<UWX4@'ZV^ _^"EO[&?Q-\!+\4?!GQ4UR_P#
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !2%5)!(!(Z'N.O0^HR<'J,\4M% #2JG.1G/7))_F?:G
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MEK]D;X@?LS>)/V5;+6_C3\*OBW^V=X]\9?$SX-^(?#/PU\+_  XMO$&D^/\
MP'\!;_X=>._B'XF^)?C?QMJ.LRZG\(?$>O\ @'P_X.7P=!;7?Q.;P'XNOI/"
M.F@'T%I/_!6SX@ZE\2/^"H_P3D_8\N+3XT?\$RO!'A/XFWOP]'QUTV[OOVC_
M (>>+M$\6>.=,\1_".YM_ABTD'VCX<>'-,UFVL-:L5E7Q=XR\,^ M6DT:^EO
M]4L?H+]D+_@H7/\ MH? 7]B'X_?"7X8>%[OP_P#M>1>/-=\1Z*WQ8U*36?@M
MX'^'2^(],\6^(KN*?X4V+>.K[PI\0-*T#X2>,--LH?#FCZ/\1?&GAZSTGQ5X
MD\-W*^)Y/!?VH/\ @GQ\4O'O_!6O]C7]N#X0W&E:!\.)_@3\8_V9_P!O:636
M+"WU/QW\$]$UGP_\8_@-X(L/"U]:W-KXDT_Q;\7["\\-?%"4*MU>?#I8-!OF
MN=,-O#9XO_!+7_@G?\2O^"=*?MV:'9Z99^)/A3%^TK\:/&/[ ?PKMM9T+3XO
M"OP1^*GAGX>?$76O!&F:\+N];PUI?B/XGZ3IOP[:R\76J7NC3?"B/QBD)TKQ
M8\]^ ?N#7PK^VC^UK\3/V4?"/Q!^)'AO]GB3XK_#/X._LO?M%?M/_%?QSJ'Q
M&D^'FD:!IWP#TOPYKUI\+_#PA^'_ ([D\3?$SXFZ#?>,-8\*V=T?#OAW3;/P
M#JI\1^(=-;5=%%WW7[#_ .T7XR_:P_9B^'/QW^(7P<D^ /C?Q;=^/](\4?"<
M_$7PM\7K'POK/P^^)7C#X;WLF@_%+P1#!X1^(7A77YO"+>)?"?C'PW%_8OB#
MPUK&E:GILMU9W,-U/Q__  4K\"_$;XJ?\$_/VT_@]\'OAWK_ ,4_BG\;?V7O
MCM\%? '@OP[J_@C0;O4/%WQ;^&/B?X?:!=7VL_$7Q=X(\)Z5H.E:GXAM=3\0
MZA?^((;BUT:UO9=-L=6U%;73+H ^5;3_ (*=_&5OV+O'/[<.I?L;067PFT/]
MA7X7?M]^"+NV^/4E[8^.?AOXQ\#^*?B3X^^&%UK$WP6L!X5^.'PN\$Z'H>K3
M^&I].U?P;XPE\9:1;:%X_C2QUNYT[SCXA?\ !8OQWX"^%?\ P2U^*)_9,T+5
M[7_@JMXG^#?@WX3Z9'^T5-9-\,=>^/VF>'_%/PT;XE7DOP+F:32/^$*\2V&K
M>,;[PG8Z_>^']9L]7\/Z1I/BF*#3-9UA]Q\"/VD9?^#?%?V-Q^SO\0/^&I%_
MX)EV_P"QC_PI@>*_@<=8'Q:@_9TC^!;:L?&A^,*?"7_A7Y\21#Q(/$0^(;:F
M?!C?:QX>?Q+CPF?S9^)/_!/C]K)_@E_P;R:7X'_8I^+US\1_V#_BC^R=X]_;
M%M?^%M_L]2P^#-._9Z\&>!? GCN+0AXA_:83P]XMU'Q-J_AZ_P#$W@FS^'$>
MK0WGA6U0:Q/X7UJXLO#-Z ?K/+_P5*\>W7[;?[7/[#^B?LZ?#J'QI^RGX'^&
M_P 1'\<^.OVG9/ O@GXEZ'\:+GP_8?"70M#O)O@5K3>'/'GBC6?%?A_PQ?:#
MXCDM]"TSQ1>MI^F^+?$-A]CU>^O?$O\ X*=_$SX:_&S_ ()F_ '6?V3%T/XC
M?\%+_AMXT\4^%- \>_&:_P#"&J? GQ]\*OA/X5^*_P 5OAC\9-.L/@OXKGM[
MOPS;>,=,\*:3K7AEM;GUGQ18:]!K'A[PG8V%G>ZG^?OB/]@?XS_$+_@L#^WA
M^U!\6_V5_CA?_LY_$#P7^Q:_P)\=^!/'OP!36_%/Q8_8Y^)OPA^+6G7T/@ZZ
M^/.G:U9>%-4\:?"O3!8M\1-!T*'5M)CNQ<6^C-<V=W+J?MK_ +-G[<_[9?[9
M7_!(+XY>,/V4OC+\/_!WP#U'_@H$_P"T/K'P.^/OP<\$?$3X"^"_VI])MOA=
M^SP=$\6Z7^T/X>\3:M\9? ?@?PSX7\9?'&Y^$E]XV\#:-XDFU>P\"ZA\4M!D
MC\.Z@ ?6]Y_P69T:/]EG_@H#\=+/]GS5&^*?_!,KXL>./A?^U'\#-3^)MA96
MEQ;^!V-W+XW^#GQ2T_P9K6F^.O#OB;0F.H^&+'Q7X5^&WB5[W3-?TKQ'HGAH
MVN@WGB;Z8_9E_;<^*_[1C? G5+?]G;PKHW@OX^?LL>'/VE]-\2>'?CS-XWOO
MA5+\1?#/A;Q=\(?AW\<_#+?![POJ/@N_^)^BZMXO;0_%GAR;QSX:@O\ X8^+
M=-EFEO+OPM'X@_#_ ,&?L3?\%'OA3_P2C_X*?_\ !-#QO^RW_P +S^*GCO6/
MC-)\ /VN_A;XI_9X\.7G[<S_ !WU'1YC\5OVE+OX@?&WPIXWB_:'T![F2#XJ
M?$7XH6-M?>(?!7A;1M$TO7OB9XH\*66O?$+]"?\ @G?\!OC/^QYX;_9H\,>'
M/V2/BMH/BOXJ? K]ESPC^W;XL\:>/O@UJ_@;X:^(_P!E#]C.\^%L-W\/DTGX
MZ^(?%7BKQK\0?&GA_P"%7PJT'1O!WAV^^%MCX?\ #GBGQ]J^M:!=W-BWB\ W
M?V<?^"L_Q:_:8\!?&_QWX&_8]T!KC]GW]M;XA?L/^-/AW'^TE-??$WQA\0?@
MYI_AOQ/\6O$'P8T"/X#6^B?$33/"_P /=5\2>/M&\/7?B?PKXS\8Z/X"\1Z?
MHV@#7I]#TO5?:?A5_P %+Y/VJO%'[4EI^Q#\"+_]HKX<_L@?$+5/@[\1?BUK
M'Q&TOX6^%OBQ\8_#6E:3KWC7X9?LNK+X9\:_\+/UGP18:A_9FM^(_B+>?!+X
M>:KXDU+P>?!'C3Q?X"\4GXA:3^?7_!'[_@G'\4/AK\3?VA/CC^U1\ ?B1\"?
MBGI7_!4']MO]L/\ 9TO-=\?_  D\5:=XF^!G[8OPM\-_#>?PKXCTKX1_%[XF
MZ#I/BNTD\-VNO>)+;4;:WU31;[1/#UGX>\2ZKH^K>(K5NJ_X)F_LB?M+?\$=
M/!W[<'[.OA#]F[QA^U1\,/'W[1_Q#_:M_99\>?"OXC?!SP^_B"V^(WAKP'X&
MM/@)\7+#XP_$'X?:M\/?&?@J/X>Z%J=]X_T^S\:^!/$?AO4]8U6SU*T\3:;9
M^"M5 /3O'O\ P7;^"LO[,'[$G[7'[.OPZ?XW?"S]M#]JKX>?L7P:/XD\=S?"
M?XE_ []H'XCKKWV7PE\6O!R> _B%:V$?@NX\*>(+7Q]=:5K]]-'&_A?Q!\.[
M/XD>"_%VF>*5^CO"'_!2B]\1_&G]N#]D_5?@A:>'_P!J[]BWX9>#_C5)X*_X
M6F=5^$/QG^%OCGPK%XET?7O _P 7X?AW:^(O#^K:3<"7PWXL\/\ CGX0:#+I
M^MWF@S:!>^*= OM8USP[_/7JO_!$+]K']F+_ ()N?\$[_P!E_P"'GPF\1?M)
M_&OPA_P5R^&7_!2?]L6X^#7Q1^'?@KPCX4T+PKH?B;PAXF\,_"SQ/\5_B9\!
MO%$NNVW@:3X=:/X8CT348-2O_%FC^,O$D7B?PM;2Z&5_1C]D7]EC]M[]B7XT
M?\%-_A]XH^!OC7]K?X*?M6Z!=_&+X"_MD'QQ\&M<_:VU/4X_ASXA\+>&?V/_
M -J/Q7\7_C)X4^(OQ%?X4V!T[PA\!_%.J7NL?#[P;9ZAK+WOCCP[X?\ &K^'
M?AB ?7O[#_\ P5.\=_MP?"+]C_X_>"_V7-*T7X7_ +66N?$BW?3+7X]P^)OC
M)\(/ _PT\7>.OAKK'Q:\:?#$?"70=.UGX=K\3_"WACP7J&I>$?'>L:CH#_$[
MP?KFL:9;:/;>*;CP_P#L8#D ^H!XZ5_+;_P2$_8J_:@_8#_97_8UM]<_8S^*
M$'[:.C^$;_\ 93^.C:E\4_@1K'P5\$_ ;QU^W9XU^.U[\4=<U;2_C_>R:E-\
M*?AAXP\:Z]HF@?"#1?$'BOQMXQ\;Z)X5U[1VL=+OM<\'?T1_L\_&6[^/'PVM
M_B!J'PP\>?!W4'\1>+_#.H_#[XCZC\--;\3Z+?\ @_Q-JGAJZ:?Q#\&_B#\5
M?A=KMO>R::;J.[\&_$'Q-96,LD^AZG=6?B+2=9TNQ .N\9^*O$?A[Q'\+=+T
M;1?"6I:3XU\;WWAGQ7J'B/QZ/!^K^'](@\ >-_%5GJ/@?P^?#.N#XF^)KK7O
M#.DZ1<^#$U7PC)8^%=1\2>.O[<NH_!TOA_6=&Q^(GP_U3Q%'X0TSQSX.U'Q9
M+I_B#5HO"]AXFT6\\12:7X3\2-X-\4ZE'HEO>R:D^G^&O%Z-X5\07JVQMM&\
M2*VAZC);:FIM1\-_MC_!OQ9X]_:D_P""8/Q4\'?!FX\?-^SW^U%\4?%WQ#^)
M&F1_#6WU?X4?";XA_LD?'SX,:HJZEXO\4^'?&%QH?BCXG_$#X1:EXD\+_#^T
M\0SZIIW@C_A)M7T>XN/!.@12_FE^S%^PQ\0/A!KO_!.37]+_ &(!\,M4^!'_
M  4F_P""E7Q3^(&J:)8_LU:1??#']E_]H[3?VY-(^!RZ?<>$_B;=SP^![G3?
MVB?@)9W?PN^'9U.;PM'X%U]=4\(69\"Z-)J8!_2 64 $G /0^O!/\@3].:Y'
M0OB'X \4>(?%7A'PSXX\'^(O%?@6:PM_&_AC0O$NC:OXA\&SZJ+IM+@\5Z+I
M][<:EX=FU);&^-A'J]M9O=BSNC;K(+>;9T%]!=75A/!8W9L+R>SN(K34/L\5
MV;&ZEMW2VO1:W&(KDVLS).+>;]W*4$<F$8X_G)\+?L@_MK_';]@_6/V=?B+^
MS1;?LQ?MI_"'_@GE\0_V)=(_;)U[XV?#WXEZ'^T-?:]X@^%S^(%\&^(/AWXG
MU7XEV_P\_:BB^"MGXX^,'C'XY?##P;\4/@_XF^(C#P'I/Q&U9?'FK:P ?T%:
M1\4_ACX@T'Q%XIT#XC>!-<\,>$-2U;1O%OB/1_%WA_4]!\+ZOH$<,VNZ5XCU
MBRU"?3]$U+18KBWEU:QU.XM;K3HYX7O(H5E0M _Q>^$\>A>(?%$GQ/\ AY'X
M9\(^+9_ /BOQ$_C7PVFA>&/'5KKMGX7N?!7B'5VU,:?HOBVV\2ZA8>'9_#FI
M7%MK$.N7UGI,EFM_=06[_P W'_!07]@?]H?]JGP1^VI\3OA1^R7XD\ W/QM_
M94_8E^#&B_LFW^K_ +.6E^(O'_QZ^#G[0"?$KQ!\;-5U70/C3)\%](OO@-\%
M)-$^!7@7XA7?C"+QUXAM-(U_P]X5EL/ /@OX8:AXYZSQM^PW^T&/VQOVM/'_
M ,*?@!\8/@9X+\8?M'?LF_%O]FOXZ? O7OV4-+F^$OB7X:_\$^_VE/@C\0_B
MZWP"\<>(-<\._%WP]J'BGQKH_P"SK\2OA)XRT+P#XC\9^#?BW<^//!7BJ&/X
M<6VNZ< ?T#'QYXDF^+'A?PEI^D> ;[X<>)_A9XH\<V?C:/XG*/'=YXAT+Q-X
M&TNUTGP_\*(_"4UOXD\ S:!XR76-<^*%G\0H(_#FLOX5\-2^$K]/&5GK>G_,
MNC?MT>'/$W_!06V_89\*>'_#/BO3U_9?^*?Q[UWXP^&OBAH6N_\ ",^._A'\
M;/A7\'O%OP-UWX>Z-I.H7&D^(M+'Q5TGQ#J^JZSXNTK4=*EMTT-_!]S]J?5K
M/\OM/_8I_;&O_BU\)_$OA;X._#K]EGXGC_@@O\=OV$7^.GP2N/"&A_#+X"?M
M*^*/%7P9U;]GOPGX<M;+QEKOQCA\&?!Z'P'XFU[0K?1[/Q[X2^'5_=KH7ACQ
MWXIN=6FUW4OF7Q-^QM_P4&\;>(O@_P"/?@U^P^_[,/BSX-_\$C/#'[&M_H?C
MCXN?LWOX3^(?C3X*_M2_LE_&R7]F2'Q1\%_C%XB\:7?[/OQT^%/P@^-/P0\'
M^-=8T[PI-X?TOXIZKJ7BKP?\-TUC4VN #^HW2_BS\*]<\&6/Q'T7XE_#_6/A
MYJ<EW#IOCS2_&7AS4/!FH3:?>WVFW\5CXIM-2FT.[EL=1TS4M/O([>^D>VO=
M/O;68)/:SQQME^+GPHAN]"T^;XG?#V*_\4>%+GQYX9L9/&GAM+SQ%X&LK,:C
M>^,]"MFU(3:OX3L]/(O[KQ'IZ7&CV]D?M4UXD'[ROYW?BW^PIXU^-.H_LN?%
M'3?^"=7Q#\!:G=?\%6OV>OVJ/VB/ ?QD^-7P7^,OCFV\,_#7X(^(?AK\0OCG
MXA8?M#>-_A%86_B&>S^#?A^?PM\(+_4?B1\2K'X76OC?XF:)KNK-I^EZ'K_%
M[]C7]HG3?VM/A]K?P1_8E3X??!CX)_\ !3S]CWXW:%>? 7Q)^S'X5^&?CW]E
M[X:?L(:S^RZWC;^SO%'Q1\&_%70_'WP?O=8C^%NL?!/2/"?P[^#/AOX(>']'
MU#X3>$_BG\0-4\;^*/%X!^OWPS_;3^&W[2/@GP#\3_V2O%?P<^.GPUUW]H'Q
M3\%?&WBZ3XQ6'A:R\/Z3X&\2?$CP+XD\6^ 3I'AGQW;?%35]3\9>!=.;X;>%
M8[WP?H_Q-^'_ (FM_B5X<\=_V#'I,/B'ZDM/'?@>_P#%^K?#ZQ\9>%+WQ[H.
MF6>MZ[X(M/$6D7/B_1=&U%HUT_5]6\-0WCZSIVF7S2Q+9W]Y90VMTTD8@E<N
MH/\ .KX=_9!_:FM_"O[ ?A;7?V4/%0\5_LE_\%K/VI?VB?%GQ!F\7?L]:G#>
M?LP_''XH?MS?$&W^)_@;5(/BY<^)F\'ZRG[0/P0/B+P3JECX>^*-UKWAC6Y[
MOX93VW@O1]4U/T7X1?L.?M%6WAW]A/X9_%GX>7^I_$#]CC]H[]K;Q_\ M!?M
M2WUQ\*-2\/\ [8/P(^,?A[X[-XX\(Z'H>D^/+OQ]JGB#]M+XA?%#X*_$#XN?
M"_XJ>#?#?@?1O$WP7^(-_P",/%6NW7@SX%:G\: #]X-&^(?@#Q%K<OAKP_XY
M\'Z[XC@T.V\3S^']&\3:+J>MP^&KW4]1T2S\0RZ597L]_'H=WK.D:MI%MJSP
M"PGU/2]1L(KA[JRN8HNO+!1EB .F3P*_F'_X)O?L#_M&_LW:_P#\$5=3\6?L
MN:E\-=;_ &=_V0OVUO@U^V/XKT_Q%\$;J[T;QQ\3=;^"-Y\)=/\ %^K>$_B7
MJVL?$O0KR3X8^*[[0[GPNOC73/!\&H^'HKR#PY]KEMM,_I;\3Z?J^L>&M?TO
MP]KK^%M>U/1=5L-$\3QZ=:ZO)X<U>]T^YMM,UY-(OV6QU1]'O98-173;TBUO
M6MA;7&V.1R #SGQG^T-\#?A_H7Q:\1>+/BS\/M*T_P"!.B6OB#XQ(WBO1+C4
MOAOIFI65U?Z*_C#1[6]EU30KGQ%;V5S_ ,(S8ZC:6][XCFC-MHD%]<,L9^;?
MV&OVQ_&G[:'@SPY\8+;X->%?"7P(^)?P.^"7QD^%/Q)\*?'?PU\5;^[UGXI:
M1K'B#Q?\$_BOX'L_"WA+6_A9\6_A+HDG@.^\0VEC-X_\':I)XSNM-L_%]KJG
MA>]LK[\D?#/[#7[55K\/OV,([GX$^)?A[\8_V)OV"?VIOV5OCMXL\$^.OAAJ
M]I^W'X@^)WPSTGX6^&M(\+ZY;_$GPIJ/B_P5\1/C-I4O[;6K^(_VBO#O@W7/
M!?BHV0U'1HOB9XR\>W&B_LE_P3A^'OQ ^$'_  3^_8F^#GQ8\'ZEX!^)_P &
M_P!E']GWX0?$/PCJNH^&]8N-$\:_"[X3^$_ GBBUAU?PAKOB7PWJVG'6] OI
M=+U/2=:O;74-.DMKM&3SC&@!W_Q._:Z_9W^#_P ;?@A^SG\0?BMX.\/?&G]H
M?4=5L/A;\.K[7M(M_$^M6^CZ)KNKSZ[/I5UJ%M=VGA^]OM#/@_1=3>%EUSQS
MJVC>%M(CO=1NITM>#_8M_;#T?]K/X5Z1XNUW0?#?PF^*%]XQ_:6\-W_P17XE
M:-X]\4:?H_[-O[4/Q._9AUGQG;7-MI/AB_U;PWK/B'X=P:C-JEIX;71M$U'Q
M':^&1K&KS6\&J:EXA^U]\(OC7K_[>G_!,;X_?#CX5Z]\3/AU\!];_:NT#XQW
M/ASQ1\-M#OO EI\=/A/X7\$>#?&&IZ;\0?''@NZUOPIIFJZ=J%QXF7P3%XM\
M86-A!YFC^#]=NKB"SD_+SPU^P/\ M.CPS^QAJ7A3]G;5O@K\?O!'[:7_  5_
M^('B[X]RO^S_ *GXT^"OP]_;%\,_MZZ9^SS\1K[7=$^)NLZ]XCTK^W?VE/@+
MKVL^ _!EWXGU/2KOP-KTOB70+2;P=IDM^ ?TK^&_'7@CQE<>([7PAXQ\+>*[
MKP?XAO?"/BZW\-^(-)UV?PMXKTT1MJ/ACQ'%I=W=2:'XAL%EB-[HNIK:ZE:B
M2,SVR!USM:KJ^E:#IFI:UKFIV&C:-HVGWFK:QJ^JWEOIVEZ3I6GV\MW?ZGJ6
MH7DD-I8Z?8VD,US>7MU-%;6UO%+--(D<;L/R(_X)N_!3XK:)XKA^+'QZ_8Z\
M<_LQ?';0/V9?AA^S=\2_%^O?M,V'Q>\!_&!/A[KVHZMX<A^"_@WP3\;_ (D:
M19_"_P $7][XUUGPSX@^-OA#PI\9?#VG?$RW\$^')#H<?C87OIW_  6D\/:!
MXG_X)+?\%'--\2:#HWB2PMOV-OCUXBM].U[2;#6K"WUWPCX UKQ7X5U^"RU*
MWNK:'6_"GBC1='\4>&]7CB74/#_B'2-+UW2KFTU33K.ZA /T)M/B%X!O[;Q7
M>6'CCPA>V?@36;OP[XXN[3Q+HUS;>#?$&GVME?7^A>*YX;UXO#NLV5EJ6G7E
MWI>L/9WMM:W]E<30)%=0/)E'XO\ PE$7A.8_%'X=B'Q]KM_X7\"RGQMX:\KQ
MKXFTJ_N-+U3P[X2D_M/;XCUW3=3L[O3K_2-&-[J%G?VMQ9W%O'<0R1K_ #._
MM[?\$N?'_P 9/!?[;.M?LW_L8:;X(\$_%/\ 9M_8 _9T\#_LIZ7IG[./@V[^
M)WCO]G3]IO6/B?XG^-]]9V/Q/L_A/X6TOX5? ;Q-'\%O &KZWXLM_B%KD-MX
MY\.Z5IFD>#]%\ ZC\0OK/]IO]C_XC7WQW\?_  S\,?L,R_&C]B']H_X(?"NT
MT#0?@[\:O '[+OA;]FO]I7PM\=?B;\5/%_BKXT_#_0_B3\*?$>M^$O&WC/XC
M>$_CYKGQU^ )\;_M!^&?B+\,+^71/"/BOQ)+X%U33P#]P6^(WP]3Q1IW@A_'
MG@Q/&FL7&OV>D>$&\4:&OBC5+OPIIVC:QXHM=.T WPU6^N/#>D^(_#VJ:_!;
M6DLNCZ=KVC7NHK;6VJ6,L_GGB3XO7M_H/PC\8_!+_A4/Q7\#_$+XD^%_#NN^
M,K[XTVGA7P[IWP\UM=:L]1\8_#?6-!\'?$32?BQXTM?$-GHVB:!\-(]0\&VO
MB=]3U&7_ (3S1[G18[#5OYPH/^"<?QM&H6U\?V(WBGF_X.'?$W[7]_>17G[.
M4-P?V'M?TGQ%8WWB_P Z#XII.O@O7SKEQ#XA^#]L5\:Z[!JWB%=<^&E]%K6L
MC4.G\._L)?M+Z-)\)4M?V2=9TFU^&G_!Q'\5OVSO#L5KK7[/5O#X'_8M\;6W
MQ%:+Q]X5BM/BGMT/0-6U/Q-X=OM5^&>@);_$66XM;B[OOA_)/9J\H!_3#H_C
MKP7K^M:UX9T3Q?X6UGQ-X:NI+'Q+X=TG7])U'7/#U[%:Z5?2V>N:39WD]_I-
MU#9:[HEW+;W\%O+';:QI=PZ+%J%HTW/V?QH^#NH^&;3QKI_Q8^&E_P"#;_Q'
M!X.L?%MGX[\+W7AF]\77.J+HEMX5M->@U5]*N?$EQK+II$.APW;ZG+J;+8):
MM=,(C_/]JG[$G[<]O:_M8Z5\#/"EOX!TWXC? ;]O"+X36'[0&H_"SQ7XS^$?
MQF^,W[6&A_&Z/X5?"#]HCX0^(_#/CSQ'^RY^VO:R>+?%WQ%\-_%S1/\ A9W[
M-NNQ^$4\(?%R*>*Z\,:?H>)/V1?C=\9)5^-V@?LB?M2?L7_'[QA\4-*\<^*?
M%^N?M$?LW_M9:YI7Q-\+?LD_$K]GF?Q?\1O@'XW^-'Q-_9M^-WP#\=?#WXI6
MG[.][;>&]:^#G[1'BK1?!EGXG\77W@'1O _PRUJP /Z,[*]L]1M+6_T^[MKZ
MQO;:"\LKVSGBN;2\L[J)9[6[M;F%GAN+:XA=)H)X7>*6)U>-V5@3S_B+QSX*
M\(7GAO3_ !9XP\+>%[_QEK4'AOPA8^(O$&DZ)>>*O$5R-UMH'ANVU*[MIM<U
MJX',&EZ8EU?2CF.!A7F'[+/AKQMX-_9E_9V\(_$KP9X"^''Q%\+? GX1>&_'
MWP]^%;WS_##P)XTT+P!X?TOQ1X-^'#:IJNO:D? ?AC6[6]T7PB=0UW6[W_A'
M[+3Q=:OJ<XDOKC\6/^"P?[)7[4'[2VL_'K2O@A^R_>>.+GQ/^R]^S;HGP_\
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M8[:[D>UG6/I?&.E:)K7A#Q-HGB7PM:^./#^K>&];TK7/!5[INE:S9>,-&O\
M2[FTU3PM=Z/KLD6AZM:^(;&6?2+C3-9DCTG4(KQK34G2SFF-?S9?L9?\$ZO&
M_P +;?\ X))1?&+]ABTE7X ?\$Y_VJ?@?^U_#>P?LZ^+%O?BUXFO/V;KKX;>
M#O%RP_$O4X_BY9ZS)\&OBG+X2N[4^,/"'AB;Q?X4DU*Z\)MK=XVA@']%FJ?&
M3X0Z'>:UI^M?%3X<:/?^&_"L'COQ%8ZIXX\,Z?>:#X(N9HK>V\9:U;7>J0S:
M7X4N+B>""#Q%?)!H\TTT,<=XSRHK>$:%^WQ^QUXC^*OQC^#ND_M&_!^X\7_
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M@/\ "[Q++X=_96_;7^&W[<G_  2S_9VUSP+XB\(>)9KOX3_#;X=:U^VA\(O
MOP^\;>#[?XI?"OX9?MA?%2U^.O@[PC\.AH>A:++\2GTC]H#X8^"[KPMKW@'Q
M!XR /Z;:*_GH_;,^$FN?#'2/@T?%G[-GQT^(G[*7[14W[8?C7]N+P'^R5^SO
M\*?CU\1M(_:)^/FI?!SQ%\$O$'CKX.W7PU^)'B#XAZ-X+^'.A?%SX!:I\4/
MG@:?Q3IU\W@GQ9XCU?1(KIKJ/Y*_:<_9<\::AIG[?'A[7OA3^W)\7_%?A/\
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M8-9T/4[+4K0W%O!<""Y3S88Y-R#YL_9F_:[LOVHT\&^*O!GP8^*FC_!7XL?
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MSX(>*=6;5QJGPP\=:Y\._$GBKPV+#6M1TJQ;5-:^%'C/X@^ KT:[IEC9>(K
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M\%OV9OC!%X4\8?&#PE>(_P <_#GQ\\6_ OXBVU]XL:Z^*6C?%?X4ZU8>"M+
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M,^V<_P Z0JK=0#CUIU% #2B'JH/;I_GTQ]..G%*%4'( !]>_K_/G\3ZFEHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M_P"$9_:Y_P"BV_LY_P#B+/Q+_P#HQ:^CJ* /G'_A&?VN?^BV_LY_^(L_$O\
M^C%H_P"$9_:Y_P"BV_LY_P#B+/Q+_P#HQ:^CJ* /G'_A&?VN?^BV_LY_^(L_
M$O\ ^C%H_P"$9_:Y_P"BV_LY_P#B+/Q+_P#HQ:^CJ* /G'_A&?VN?^BV_LY_
M^(L_$O\ ^C%H_P"$9_:Y_P"BV_LY_P#B+/Q+_P#HQ:^CJ* /G'_A&?VN?^BV
M_LY_^(L_$O\ ^C%H_P"$9_:Y_P"BV_LY_P#B+/Q+_P#HQ:^CJ* /G'_A&?VN
M?^BV_LY_^(L_$O\ ^C%H_P"$9_:Y_P"BV_LY_P#B+/Q+_P#HQ:^CJ* /G'_A
M&?VN?^BV_LY_^(L_$O\ ^C%H_P"$9_:Y_P"BV_LY_P#B+/Q+_P#HQ:^CJ* /
MG'_A&?VN?^BV_LY_^(L_$O\ ^C%H_P"$9_:Y_P"BV_LY_P#B+/Q+_P#HQ:^C
MJ* /G'_A&?VN?^BV_LY_^(L_$O\ ^C%H_P"$9_:Y_P"BV_LY_P#B+/Q+_P#H
MQ:^CJ* /G'_A&?VN?^BV_LY_^(L_$O\ ^C%H_P"$9_:Y_P"BV_LY_P#B+/Q+
M_P#HQ:^CJ* /G'_A&?VN?^BV_LY_^(L_$O\ ^C%H_P"$9_:Y_P"BV_LY_P#B
M+/Q+_P#HQ:^CJ* /G'_A&?VN?^BV_LY_^(L_$O\ ^C%H_P"$9_:Y_P"BV_LY
M_P#B+/Q+_P#HQ:^CJ* /G'_A&?VN?^BV_LY_^(L_$O\ ^C%KV?P=;>,K/P]8
MVWC_ %SPUXD\5QM>G4]:\(>%-4\#^'KU)-0NI=.6P\+ZSXT^(6I:8UII3V-E
M>M<>+]6&H:A;W>IP)IEM>PZ18=/10 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M#P'KEU\*M+^(H!^Z(8,,CD?_ %@?ZTM?C=\*/^"B&D_#?]F_]F6WO_#GQ/\
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ML>LZ9JNH> /AAK6C_!/P[=>)#J%EX?\ "OA:S\3_ !S;XP^)?"'A+PCH.A>
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M5LKG3? VCW,4D&J^+;R*'0+"9&ANM0CD5E !Z;17S#\+/VR_V9OC#^SYX/\
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M(M9\/2R>$+32O$ !^Q=%?G3JO[<GQ!U/P9\1]&^#7[*OC?XS_M2?"CXX:Q\
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MW6D>()M"\8Z'K.C:KH_BCPMH.J64MF #MZ*** "BBB@ HHHH **** "BBB@
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M$GQ4'ASXP^$_!OP\\&^*_AA^S9X1U?6OBS_2 /%&C-XG?P<)KS^WX] B\3M
M=)U<6']CS:C-I23+KAL1H;W?VV"1'TE-2;5HH=EY+8I9RQ7#[P=3C!SD9XR>
M.?\  _B,4 ?A?\!_V/O%OQ4\3?\ !3[X4_MD?LT^-O#?[/7[>OA_]F._@UGQ
MIXU^ >LV\MM9_L+?LY_L]>-? 5TG@'XP?$?Q3X=^.G@+XK>"M??3O$5AH-YX
M'M-=\.Z+XN^&WQ6\5W1T*XG^OO\ @FYX<^.TGP-M/B)^U'K6@>-/CM?Z;IWP
M1OOB9X>E%Q:?%SX8?LTZYXQ^'/P[^-7VE+6UM9K?]HG5)O'7[3FCQ:<LNEZ9
MH/QPTK1+&XNXM+-[<_:'Q5^$WPI^.G@+7_A7\;/AKX!^+_PR\5+IR>)_AU\3
M_!^@>/? _B$:-J^G^(='_MOPGXIT[5=#U1M(U_2-*U[2FO+"9].UG2].U6S:
M"^LK6XCZ"\U[PEX5N/"F@ZCK7A[P[=>*]6?PCX&T6]U#3=(G\2:YIWA?7_%[
M^&/">G32VTFL:K8>"_"/BCQ,^BZ1#<W=KX7\+Z[K)MH]*T74+FV /R+_ &>-
M!^(?PO\ %?\ P6A^%NM^'O%/Q-^+?C_]I/6_VGOACX*T#6?"Z>*?B+\$/CU^
MRI\%_A;\(YO">I_$[QCX(\+VMOI7C;X%?$_X-QQ>+?%WA3P]H.I?"R\L+?4[
M3PVFAW,_ _L]?\$N/#OCC_@E7X8_9T^,OPX\4_ 3]JGQ[_P33\+?L%?$[XB^
M.O$^D?'CQ[\*+;3_ (5:+X*\3:7\.-0L?BO\2?!FC_!W4OB#H-E\0T^&OPR\
M:>!_#OBZUTGPI)XATKPYXBT72U\,_MI>^%_"^H>(]#\8W^@:+=^+/#&GZ]I'
MASQ/<Z79RZ_H>D^*9-'E\3Z3I&LR0-J-AI7B*;PYX>N-=TVTN8['5;CP]H5W
M?P3SZ-ILMMY5<_'[P[:_M,:%^R[)X:\6OXNU_P""'C'X\6OBV'_A#Y_ ]GX8
M\%^.? /P_N]#U81>,'\>:7XGUK5_B#:WGA<7G@.+POKNF>&?&9M/%']I>'IM
M-G /CO\ 9!^(G[;GA_X7_"+]G+XV_L3:W\._B1\,/!&@_#+Q;^T7HGQ?^!'C
M/]C_ ,2_\*[L+3PFOQ(^'%GI_P 78_VM+[3_ !SI.F1>,/"WPW\>?L\>!-2T
MV^U ^!/%_P 0M#ALG^(-UH_&GP5\9]9_X*=?L1?%;PY\"?'WB3X*?"G]GC]L
MGX<?$3XQ:9XE^"5GX4\*>*?V@O$?[+>M>";>\\,>(_BYH/Q:U6RL+7X >*8/
M$M[X7^&OB"/3[WQ%X.CL%U6UN?$][X5^N?CG\??!W[/>G>!-?^(-EKL/A3QS
M\5/AG\'?^$LTV/0Y]&\*^,?C%X\\-_##X:KXIAOM>TW7(]+\3_$#Q=X=\,)J
M/A[1_$2Z1<:DNI^((=*T&VO-6MKEU\7TM_C9I7P/'@#X@WM[JO@74O'\WC_3
M[3PG=?#G0]&TW4+717M/$NI1>,3XH\/:WJFKWL%CX5TS4_"-M+XT-OXEU#P>
M^N:/\/?B3J/@\ ^0/$UM-\0O^"L?P9U#P>DDEG^R[^P]^T1IGQPUB%[>&RMK
M_P#:^^,'[-=]\"/!#3P7)N=5U>XL_P!DOXQ>,M9T:>W$7A;2X?!>LW>P^-]!
M>?VCXJ>#OB7\5_CYX"\.647Q<^$_P\^%'AW5OBAI7QR\'C]GG5=%\4?%3Q)9
M:K\-[/P)9Z7\0;KXC^-M,NO"OP_USQQ?ZW<W?P0L- UH>,]#70OB1:WF@:[X
M?UKZ7T#PCX4\*S:]/X9\.:)X>G\5>(;WQ;XHFT;2+'2YO$WBK4+6RT^_\2:_
M+9VT$FL:]=V&EZ98SZM?M/?R:?IFG61G-E8VL,71[UXYZ].#S]..<XX]>V<B
M@#^1#]H+]G;Q_P#!C]E+X,?L@_'O]E_Q!XV^"7P'_P""Y7['%S^R-XS^)&G?
MLI^(=*^,?[.'QJ_;%T77[3X9Z%X'\(_%'7;+X=ZSX1M_B+\1?@/#H'B;P1\&
MOAIJGP.'@C3]-L?".A^(?$OPK\!=K^T3^QSIOP\^,?[-WQ*\?_LL^&+#PO\
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M?NX#G_./YUX#J/[2OPPTK]I7PO\ LGWTOC*V^+_C'X3>-/C9X>AN?AOX]LO
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MVG[;OP!O_BM%\*K'Q)?74MY\<-3_ &7=,\?0:6;CX9ZM^U!H/PS\3_&/Q-\
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M?0;?Q//86FI/+X6U35]/\:6UWX;@[.S_ &T_V=)/C+J/PMM-9NO[33XUZ?\
MLPZG\2H= "?#2Y_:;3X:7_Q<M?V>W\:(Z37WC[3OAO;7.HSZF-/N/AOI/BZX
MM_@M<^.[;XZZA:?#&8 Y3XI>'_C1\>/BIXET/5O _P <_@]\'/V>?^$<^('P
M\U_PUK/[*'B63]K7XN6O]M:KID.A^#_'-Y\4;7POX7^#5UI/AG6O -W\7]+^
M&NH>(?C1X@TOQC'!X*A^"?A'QEXL^#/A[^QG^T1\9/A)_P $D?@_^T?\-_&'
MACP7^R_\,?B7XT_:ZD\:^-OAMXA\>>/OBEIG[/'_  S?X9^#%[XE^&/Q7\1+
MK7AWXUQ?'SXO>/?'>MZ;?:MX3UO2OA,?#WC+_A']0\6^&,_O53=R\C/3KP3C
MZ\4 ?S[?LK_LM?M-_"+5?V'/%GCG]EOQ/,?A/\&/^"E'[2?Q.^'OA7QK\ ?#
M_ASP-^W3^V+\8+'XGZ)X#TK2M"^.MGX5\5R>'O!GBOX[_ CX4ZNECJ/P\\/^
M"OB-97WB/X@>$);>>UL?M3]CS]F/]I'X9?L[_L5:!?\ QAO_ ((:IX$^%'@#
M6/VGO@C!\-OA#XOA^(/QT\3WS_$;]H:]O?&.F:EXET_P7/XU^(_B7QBUWIOP
MF\07_@7PQ)?R0_#Z[;0K32B/TV# C(.1R<X...O/X5\W_'7]J'P!^S[XT_9J
M\#>--)\;:AJG[4_QMB^ ?PZO?"_AZ'4]"TSQQ+X"\;?$E)?&NM7NIZ59Z!I,
MGAKX?>(WM?L[:IK>HW5LZZ9H=Y;6>J76G 'TC1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %075S!9V\]W<R"*WMH99YY6!*QPP1M++(VT$[8XT=S@$D*0H+$ ST
M8!ZCIR/8^M 'XK_%?7?&MSIMI_P42_9]\!^-?B_\1/A/^U/\3O!EM\)M$\.:
M]IGCCXC_ +-WC_3? 7[)_C_X?:3I.HZ/]NLO!^I_$KX4? G]MNW\2VFE:YJ?
MBSP5\(- O_"6H)X>\:?V#)\Z?M=+^T)^S7X_^*5_\"XOVC/%>H_LO?\ !(V+
MX8> _$6@:7\=_$WP_P#%WQM_:.^),WA#2OC1+\,? MOXD\*>+O%_[.$O[/,O
MQ(^($/@CPEXY^.GBY_VE-*CU_4+KP-X&T_7_ (:?T9X&<X&1T/>O#OC)^T;\
M'/V?]5^#6B?%CQ1=>%]0_:!^+WA[X$_"6*#PGXQ\1P>*/BOXKL=6U30?"T]]
MX5\/ZW8>&6O].T+6;U=:\6W6@^'XHM/N!-JT<H6-@#\C+VUT/XH_%3XK_LC_
M !&TG]N73/"WA;X8_ OX!?L,0_#7P%\=/"]_X5^#WQ+^ W@&P\<_MZ:U\<_&
MFBZ=\+-._:1^$GCWQ=XNT9M9^/\ J=Q\4OV>;S]F31]5^#'P\/QK^.>L^&OC
M!XY\5_BY^T%X8NOC#\3]+^&WQI\(>$_VF?\ @J/XN^%'QN\:^'_!/[14?C7X
M9_LR?LZ?!'QI\ _@_INE7?P3^$GCGXV>$OA[\;OC-^SMX;^)=U\2_ASX>O-%
MT[P%^U%-8Z#\6_A1XO\ B:OCKX0?TB-M5>5!&1P #D]!QTR3@#WP,CK5/2M3
MTS6]-T[6]%O[#5M(U>PL]3TG5M+N[>_TW4],O[>.[L+_ $Z_M))K6]L+RUFB
MN;2[MI9;>Y@ECFAD>-U8@'\__@?1_%?@3Q-\)O#?QVMOVBK?]D;3O OQ[_:1
M;P%H_P "OBIX:3]I']H[QQ^T'KNB>&/@E9_L_?#<?$K5?A1\ ?AC\)KK2O'/
MP,_8I^)OB+2_&_Q7T;XM:#XI^+_@?Q9\3OV>_P!H%/!?'_!:]_:,^"-[\3?&
MO[1?PC^.GC#XA?L=_P#!,WX[^,/A[X(\.3?$WQYXAMH_VN_C[\:_C_J?[+FE
M_'J"]U0?%7XC? 7X3_LP_L7?LU:!XG^&WQ6\:^-=>\='Q+K6FZUXFTW3KOQW
MIG[L?'/]H#X3?LV>$=&\=_&3Q#>^%/"?B#XA?#KX5Z=J]EX1\9>+HCXY^+/B
M_2?A_P##W2-0MO!/A[Q%>Z/:^(_&6NZ+X=B\0:S;6'AO3]0U2QCU?6-/2ZA=
M_9@JC    S@  8SUQZ9[T ?S?>-/!'[2/@30OATVH:A^U%XX\ ?L(?\ !'&/
MQ]\;M1\(>+_CSH7C/]M#]J7QG=Z!XH\.?#;PAI^K:5X<\<0_%'4Y?V;/B<OQ
M5\5Z1I?@#XSZ%X;_ &D= ^'>IVNEGQK&OP__ &A_9(\%:M\!OV-/V:/A]\2/
M&^H>,O$7PB_9H^$'A3X@?$CQ)%XNL=3\4ZYX%^&/A[3/%WC;6K7X@0VWCG39
M]9U'3-1UR\T[Q?:6GB32_M#V.L65G?VT]K%]0X Z #_Z_7\Z\]\ ?$SPQ\2W
M\<1^&K/QG:GX=_$'Q!\,O$'_  F7PW^(?PY6Y\3^&8-.GU.[\(M\0?"_AA/'
MW@N6/5;0:+\2? C>(_AYXDE6^M_#WBC4Y]+U*.U /QB_:K\=^-?CG\-? O[3
M=G;W4OP0\:_M(_LC?!GX??"/QQ\(?B$OCIOV?]1_;H^ D7[6OCOXH?"+7K2;
M3]$7XC?!OP%X_P!=UD_%OP$?%WP;_9S\->2;/X/>._B!\;/#MQXU_P %#M:L
M_'W[4GQU^$5[^UK\+?A#=_%SX!_LU_"'X _%KXJ?%_X\_"CP9^Q5\3=>\9_$
MWQ9\2/&GPCB\':/HOP<\5_MXZGX/USX3?%+X7:)J/Q_^%'QCU/PA!\.=#UK2
MO#7P9U&35/C3_2$X&USR"5.2.&Z'H?4=O0U\!VG[//[-WBZP^/'P_P#[0^*6
MB_!CQ#\<?%&G_'CX&>+V\6^#?@G\4OBM\7=1\+_$3QM9V4OQ#\.:;KOC3X:_
M&3Q5\1]&'C7PI\)/'3_L^?%WQ3KWC_X9>*/#OB=_%OQI\&^(@#\[/AK;_&/X
MF_M->*OAM\6;+]H?P?=_ ;]K+P1HOPVL-$T#]I3XCZ[I7[+?[/'BBRUCX)ZC
M#^TK\3(-$^ _AG0OCWX6\-V?Q>_:N^*T_P 7/C_^U#^U+X0^*'Q#_9&\7S6]
MYX"\-_#WPYYE^SWX-_:/B\>?\$]/BU\7I_VK!JWCWQ/^WU^WKXL^%^JZK^T'
MXU\/?#KX%W'A3XU6WP&_98^).F:#IVJQWWQXUOPY^U]\'YVA^-L>J7^E0?LM
M2_!+P1/>>);*5/B=_2VH!49PW).2.^3G /3!R!T('I3L 9.!ZGC\<\=^OO0!
M^+W_  3!^'/[0'P?_8W_ &)]'^%'PK^"VD>#O'7@;3?BK^UC??%)/BY\$/C#
MIGQK^+'CG7_B+^T / WPLD^!T%KK&B:3XM\4^*+7X82^+-6\)Z=JWAJU\.)H
MUT_@F71->O/1_P!@#QRW[/7[*/P\_9]^,7A_XF3_ +57PYU'QSH_Q<\,Q> -
M?EUSX[_'7Q1\3/%WBCXC?&[X9ZTO@_P5X$\6_#O]HCXA^(?$'QBTCXB)J%AX
M.\&Z1XRO8?C+XL\)>(_!'Q)F\/?>?[/O[07PD_:D^%6B_&OX'>)KCQA\-?$6
MN>/?#FE:]=^&O%?@^ZN-:^&7Q!\4_"SQQ8W'ASQOH?AOQ/ITNB>.O!7B70G_
M +3T:T%X=--]8FYTVYL[NX]GVKC&!CTP,=<].G7GZT ?A9^T]>_%?XD>,?VZ
M_!>M^"OC!XR^+^@R^%O@7_P34^$/A#3_ (P>!?AEHK_$?]GSP'K<7[9WB'XG
M^!-4\&:/I&H^#_C_ .,/'^A^//C]%X^MO%?[,WPX^!&D>%?V?;'PK\<OBKK&
MD_M _-O[0OP?_:3^(=W^TSXD\;?$3]J>6R\9_M*_L(_L,?!W4/AL_P"T7X/C
M\<CPA?\ PIT?]HS]MO6/AS\%]3M/$'@3PY\-M=^)'[65Y\-]"\+:]X._9RUS
MQ)X5L?B!\3?#OC-]!^!OQ(\&?TR[5QC:,=<8&,^N.G8?E7"_$CP'#\2/"=QX
M4E\5>.?!)EU?PKKMKXE^''BK4/!OBS3=2\&^+-#\9:1]FUC3]Z7>D7FJ>'[/
M3O%?A76K35O"7CKPG=ZWX(\;:%X@\(>(=;T2_ /P>^(FF>,OBKX3\3^-/"-[
M^T');_M)?\%M/#N@V=Y\/?B9\<9YOAG\)/V"_')\"_$_0=3O?AEX@MKSPKX%
M^./B+]B+XU^!/!NEZ[J]A\-M ^(?[47P[O?$.H>$E\/^%;SP%YYXO^.6K'X/
M> OC+\</$?C[P#=^.O\ @I_^TG\0_P!IC]G;XH67[5WPG\,>)O@S\$/!'Q)^
M"GPYT*;5O#_P@\1Z_9_L=?"+POX._9/^)G[0/CW4O!0_92^*/C&V\5:3\3-:
MTZ^^*-]\&O$/]%?P[^'G@SX4>!_"_P -_AYX<TOPEX'\%Z-9^'_#'AS1X6BL
M-)TFQB6."VC,KRW%Q*Y#W%Y?7DUQ?ZC>37%_J-U=7US<7$OG7CG]GSPKXP^)
M.G?&32?$/C7X<?%K3_!LGPX;Q]X!UFP@O]5^'KZO+XD3P?K_ (:\6:-XM\ Z
M[867B:5M>T;4]3\(W'B;P_=S:G:Z#KNFZ1XC\4Z9K@!^(/P4N-5\!:7\$?A_
MXV\9?$W]JS]GGQ_X0_:%_:YN-0_9>UO]HO\ :N^"?Q^^-?BSXSWFE?##]B+X
M9^/)3X\\%_#K]D[]C_X60:5\.=-\!>-_%?P*^$_QNU.#P=\0/$7@GPKI?A;]
MH[P[>^$^#_#O[0L&@_LX_%]_@9\0_C-^U7^S)_P18_:,_:G^$;?&_P"&G[1?
MCW4?$_[?7[7'C73?BIIGPJCUOXD>%8_$"7O[.^N_!OQ1\/O#'@7XD?%?2OB[
M;>#/C7X+T#0=.6^U-_$J_P!+7PH^'_PU^#_A_P#X5/\ #6UL]&T[0[K7/&M_
MH#ZY?:_XCEU;XI^-_&'C;Q/X[\4ZCKNHZIXGUK6_B3\1;SQYXIUOQ=XBO;W4
M/%GBR?Q1J=UJ-]J:ZF\?J6!Z#KGH.N<Y^N><]<T ?S7:/K_Q9LOAEXG^.OPR
M\7?M:)#\2=9_9Q^!WQ#^-&G? _\ :*@\5^$_A;X_^-6I:[^T%\=]0\-?%7X*
M:-\:OVBOVFM-\+VR?#_PEXVT/]D;X=_L]?L<:+\1O!W@[X/> O"/PQ^%?Q?\
M+:-]V_\ !.OPP-5^//[<GQD;X3_$SX-:-)KO[._[.OP=\)?%/P3\0O#'B74O
M@+\*/@]#\;M&^(.K:O\ $>6_U;Q'XP^(?QG_ &K/CIK'CR:/57UBSURTBA^*
M&F6OQF?XB:GK?V[\4?VJ/@A\&?BO\&?@G\0M?\3:7\3?VA-5U30_@YH&D_"S
MXK^,;?QOK&@Z==ZWX@TZT\2>"_ _B'PMIMUX<\.:?J/BOQ'%KNMZ6WA_P=IF
MI^+]9%CX8TZ]U:"/QU^U3\&?AMXI\?>#?%EY\0;;7/AA\,(_C)XW.B_ [XX^
M+=%TGX<27-]:1:[;>*O"'PXUWPMKMR]QI>LJOAWP]K6J^)=NBZ]*-'\G1-6>
MS /#/VH?!?PI_:S^(^F?L8?$ZRU/7/ .M_!OX^>*/B5:Z3;^(=(DMI_%'@C2
MO@7X>T)?&<6GC0['5-4\!?'CXJ>+M'MM-U-?%^CZ_P"#?#/BO3/L<>C227'Q
MM<_$O]KSPS^QM\2?CE\0_"_C_P /?M):CX]_9_\ V-/C%\2_ GPH\4ZMXI\.
M_"/X0?&+3O@3^TE^V1\%O@SX?\%^,M7UG35\3>.OVI/VD?V:M3N?AQXK\.S?
M#K6?@UX]^)/@6^^'.A^*/#$?ZU_"#XX_#?X]?"3PA\<_A5JFK^)OA;\0/#5K
MXS\%>([CP7XX\,W'BGPGJ-K_ &AHWB30O#/BWPWH7BS4]$\1Z:T&K>%=1M="
MDMO%>D7NG:OX<DU33-2L;NX\ ^'?_!1/]D#XH:MX/T?PQ\3-:TZX\?\ Q-\8
M?!/P1?\ Q"^$'QL^$/A[Q1\:/ %SK%CXN^#FB^+/BQ\./!7A>]^+&BW_ (<\
M4:;/\-XM8/C.?4O"?B[3;/1;F]\*>(H-, /Q\\4>'?C]\3OC)\5O!7[/'@O]
MI;X/^"/'?[9O_!/'X+?#*_\ '-[^TMX<TS0OA'\-OA]??MW_ +6_[6/CS2OB
M9;-:7S_M%>$M0F_9C^)'@_Q7JMWXA^(7Q.\(_#[PU\>-"^'WQ:U^ZUTW/AIH
MWQHT?7-<T+QMXR_:H\+?L?\ Q7_X*$?M3:K\:/''BN;]IC7_ (R7?@7]D/X-
M_"GX"?![X2W7C.'P_?\ B7PK\._VU?BQ\%?B#^U%J/Q'^%C>$OA1XL\.WFE?
MLJ>'_$&D^*OC)HWP@U;]@?%'_!0+]EKP?XP^.O@#6?$WQ'E\6?LS^']*\5_'
M;1] _9Q_:3\7-\.O">O:/XE\0>'_ !5JUYX3^$6MZ=>>&/$6C^#_ !7?^'?$
M.CWFI:-K\?A[64T>]O9=/N8T^OM$UC2_$6CZ3XAT2\AU'1]>TRPUG2=1M]WD
M7^F:G:0WMA>0ET1S#=6DT,T1=$?8Z[E4Y  /YNF'C2W^+G[/'@OXL^*?VA/V
M;OA'\0/VG_VROV\OAS\"/!_B;]H&T^(6A?L0_"+X,_"W]GCP/^SE?>"/A5K6
MO>.=*\5_&C]I'XZ>$_VM? G[/UOH%QKWP<T#5M6^"W@BP^#_ ,1/!FC?#*UR
M=!U[XX_ #PC\6/AM\;?@Q^U=\4/ '@']FS]HO]L+]DK]E;1?"GQX^)-GX[UK
MQM\>?VD_B%\/OV>?BW\:O#D/C73-.\8_LB_ KX6?L]:-X;^%_BCXRMIFE_%#
M]I37M#\#Z!\2=9\#_LP/X7_?S2O@%X7TC]H3QC^TK%X@\9W7CSQK\,/"7P?U
M+2+W6;.7P38>!_ NO:_XJ\,VFB^'8M)A>PU.S\1^,/&VK7>M_P!H3:KK#^++
MNPUJZU'1]!\%:9X6Y+3?VQOV>M7^,>C? K2?&.HZGXZ\0^,OB+\.-$O-.\#>
M.[[X>ZE\3OA)X9M_&7Q+^&</Q8M/#4WPR3XA^#O#,EYJ6J^$9_%D6LR2^'/'
M&D6%M>Z[\._'VF>&@#\L_P!GS]D'XD_%SXI_#CPE\</B5^TK=_#/]GO_ ()M
M?LW? WXI>+++XL?M:_"#Q%^TS^T]\6M>B^,/QN\3:AXHN_&7PT\8:<_AQ/A[
M\-/$WC[5-+\,>&/B+X[U;XO:A\)_BGKMGX1\&^+_ (1ZOXY^R)X3O[G6/V2A
MI/PN^,OPJ\7_ +5__!2/]O#]L_\ :CN=.^&?[0OPSTJU^&GPZU/XR>)?@+\)
M/BGJL?PG\!:/--X<U#QQ^Q_HUC:?%2QTOP)KVJ?#?XT:)X9\0:KXQCU+2]4_
MHK\7^*] \"^&-;\7^)[MK'0?#]A/J.HSQ6=YJ-T8H@-EMI^EZ;;WFJ:OJM_<
M-%9:5HVE6=[JVL:G<6NFZ797>H75O;R_-/[1'[=O[)W[*'@GQ!\1/VA?C!H_
MPT\(^'/'\'PLO=1U/0_%VKW>I>/I?!EG\0IO#OA?0O#/A[7/$'C2?2_!EY)X
M@UZZ\(Z5K>G^'-/TGQ++KMUIQ\+>(UTL _)SPI\8_%.M_#OXL?M0>./A9^V]
MXI_;C_9PU+]K_P#:"U?X6:?\-/C7X.^%OAB3X,>%/C/X)^#W['GAMO$FDV_@
M3XC_  U^(/A#QCX$DM)?V<9-=UC]IGXE^&/#O[0GC*6RL/"]CIWA'F?$EO\
M&GX/V/[)G[&4^A^.7^"/@/\ 8;^'>F^ O%D/[/WQY^.D/QV_:CAN?'WP\^*_
MC#XA_#7X8_#Z/PAXXU?P9X9T'P+\4_A_X%_:C\<? ;X3/XF_:/U7X\?$;P3X
MV\9? K0_^%%?M%KG[:/[+&@>"_AS\19OC7X)UOP)\6?#GB#QM\.?%7@>ZN_B
M-HOBCX?^#].M-6\:_$RQO/ %EXE2W^%O@/3M1TJY\??$[4!9^ ? JZOH\?BW
MQ'HTNK::EUTGQ)_:A^ ?PAD\.I\1OB3H7AR#Q1X,\7?$RQU$PZIK&BZ=\*?
M%OH-WX^^,'B[7M!T_5-#\!_!OP1!XJ\,2>,?B[XWU'P_\-O#(\1:&-;\4V+:
MM8"X /S!^"VG:MHO[7OP_OY_$'[8WBOX,?!K]F;Q#I^K#XT:3\3+;XD?"3XD
M?L:)K/[/%XGQ)\3Z=9W:_M0^!_VT_#7QD\4?&#2(7NO&;_$+XS_LJZ!\<_AW
M?_$G3GTVZ^%OZX_"'XM>!/CE\//#OQ0^&M_J^H^#?$RZJNF3>(?"'C#P!XAM
MKK0=;U'PUKND^(? WQ"T'PMXY\(Z_H7B'1]4T36_#OBSPYHNNZ1JFGW=CJ.G
M6UQ"\8Y;XB?'7X'>$OB-\+OV>/'/Q+T+PY\6OVBAXUT7X2_#J'7M0TWQ[XWC
M\'^"O$7C3QG?>&X_#TT6NZ-9^'/"7AO7-4F\6+=Z-;:;>6=M:6.L0:_=:5;W
M&+8?'[]G/P/X^TW]G/3?&/A[0/%V@S>%_!=GX3LM-U:'P_H'B#Q#X<NO$W@W
MX<7WBR'2V\#Z)\1/$7@_3IO%?AWX:ZIXCM?'NN>%3:^)].\/WFCZA9W]R ?D
MG\*O '@*+_@HS_P6Z\677@O5?"FG>+/V?_V8X_"WQ*\+Z%XV^&^M:K?^'OA-
M\>_#WQZU#X3_ !<\$V_AGQ5#XR\.>(/$?ARV\9^(OA1XMM_&GAWQ9J7AZ^_M
M/3_$_P#9-VGRCX'UK]JNQ\!_L*^-?A3X=^(?B+]K3PC_ ,&U'[1/@W1IO''A
MOQ5<:])^V7Y7[#VJ:#\-O&FK^+[."VA^-7B#QM\%OBHZ>&O&>I1:W?:WX&\4
M7VMVDMEIFJ2G^J?TXQCH/3_/3B@@$$$9!X(/0CT- '\R&L>-/'>N?L\_$/XT
M_LY^'_VYK/X1_$']HW]@;4/VP_@AXU_9A_:/^$?Q ^&'P;TKQPFG_MAZ!\$/
M@QXBAUOXQ>(_B?JGP[B\":%^UOK/P&O?'?P]\;Z%:>-?%_PNOO$'QLUKXJ>.
M-<^]_P#@EO8^%M*^)_\ P4U/@'P#\7?!/PU\>_MG^!OC1\*[GXE_##X\> =$
M\3?#[X@_L1_LFZ.E_P##N_\ CAX=T:>X\,Z3X[\#>/O#EA\/_#,Z:3\(-!TG
MPYX0T?PKX(\!-\/M%/Z[D G) )'0D#(_&EP,YQSTSWQZ4 ?CQ_P4^^#7@7XX
M?%#]EG0-;UCX_?LX_%'P/X8_:%^+'[//_!1+X#Z#XJU1OV5?B[X9U#X#>&-.
M^&?Q,N-,\(^(? E[\+OVEM#\=:T/&GP[^+FK>&/!'Q=\/_!O4_ ":@/$&K:/
M>:;\2^(OB_\ M-M^S;^Q%IO[:WP?^*EM\&/C'X0_;F\%?M6>.OV=_P!CS]H3
M4=1T[XL+\4O#:_LK?M,_$7]GWX*2>%?VIO@)<_M,_"^U^-/Q->?0O!D7B_X/
M_M)?%OX?ZUXBT#X5_$#0M"UKP#_3#28 .0 #ZX&>N>OUY^M '\GG[0'P^U74
M?BQ^T[\+_%/QG_X*(>*?B);?\$5?V2_&_P "?#%C\?OVA?"?Q9\0?MA:A\0?
MVL_ ?P\^((\!?"CQ5X:^%'A7]I#6M?\ A!\'+VYT(Z-X>\$#QK9>,_%WBO0M
M02;XF>)VWOAYIO[3_P"S';_\%:_$>B_L\>.?$W[8-]XU_P""<_QB^(O_  S]
M^SUXMMX/CS\,_P#AGG]AO2/V_P"Y_9E\=V?AWX:^!?&_CKQMJ>E_M5OX+\+^
M _B!X?\ BAJOQ9L=2UC1;'2O&EBNHVG]%FD_L[^"M(_:2\9_M30:GXIE^)?C
MKX2^"O@AK=K/J6GGPF/AS\.O$OBWQGX+TBTT2#2()HKS0_%?Q#^(^N1ZS-J-
MSJU[-X[UC3M2O+W1-,\)Z7X;]YP,8P,9SC QG.<X]<\_6@#^8O1_"/A[QE\?
M?^"?W_"L_&W[:.H?LS?%#]L?]L._\>>%_%/AG]K/]E;X2^$O OCC]@_XB>&M
M>\/:!\'/'4GA#QEX#^#.L?M$'PNWP^N_B?%%I'A'XO\ Q!\=^#_V7#\/_A]K
MTGAB\X3]B6Q^+?AGQO\ \$;O%]]J_P"TTNNWO[0G_!3GX ?'"3QYXT_:(UW3
M[+]E7PC-^U0?V1O"?Q:T+Q_KNIZ+9>&WGL/V8KKX2>+_ (B:?_PE_B>[O/!,
M^C^*-6E\179U/^K#^O6CKUH _CH_8A^!W[9?PV_9I_X)\:I^Q'HWQQ\"_M/^
M"O\ @GA^V=\._P!K3X>_&[4/BSI?PFT[XJ>"/A%)H'[*/@#QW\+_ ([N_A/P
M7\8]!_:QC\#WWP\M/#6C^$+:X^!EM\;[V\O;_P"'^H>'8]1Z/X]ZWXL^)?[$
M?[2_QD_9QUK_ (*7_!GXA>-K7]AO2OB%\%'^&7[7'[->K?#7XRI^T?X'L_BO
M=Z!I_B^UN?'/Q=^/+? SQ+\2-&_:I\=_";Q/XJ^#/C7P_P##WPI\1_B[I?B_
MQW+;^/9_Z\RJG&0#CID X^E+@9SCGIGOCTH \S^$/PQ\$_"#P)IO@;X>-XD;
MPE::AX@US33XK^(/C_XH:N9?%^OZEXMU)AXP^)GBCQAXKNM-DU/6[R71]+FU
MV72/#VE/9Z!X=LM*T'3=.TRT^$_C%J5NO_!6#]B2^$&J2Z=X>_9 _;T\'Z]K
M$&AZY<Z!H?BOXG?$[]@?6/AWX;UCQ#!I\F@Z5K?C;2?AI\0]0\-Z;?ZC;W>K
M6G@OQ%-;1.NFRD?IQ@#H.O)]SZT4 ?SDZ;\+/B?>>!/@+^Q%-X5^,&G_ !F\
M!?\ !;7XD?M.>+O'#?#WQ1+X!O/V?- _;8^*G_!1>P^,NJ_$B"YE\-I\/OBS
M\+/'?@_X&:5J<_B&_P!3U/\ :(U_Q;\(ETC6;SX9_$ZY\-?NS\%OCG\-_P!H
M'PE=^-/ACJ/B*]T;3O$&I^%=5M/&'P^^(?PK\6:+K^DI:W%QI^N^ OBIX5\%
M>.M#:[TW4-*U_1+C5O#EE:>(_"VMZ#XK\/7&J>&M=TC5;WUS:I&"H(ZXP,9]
M<5SOA3PIH7@G0K+PUX;L5T_1[ W<L4+7%[?WEU?:E?76JZQK&KZMJ=S>ZMKW
MB#7]7OK[7/$GB/6[[4->\1Z_J&I:[KNHZAJVHWEY, ?E!_P5'_:*^&WAW0KG
M]CCQ%X;^-FGV7[6/@+5?#?Q^^,'PH_97_:7^/%C\/?V;M;>Z\&?$/2;'4_V>
MO@W\49I?CM\3?"-UXO\  WP9M=<6WT+X:3SZM\8_&K7UGX4\'_"_XS?"_P <
M?A]XJTOP#_P5FB\'?!#XV06O_!27_@F=^S5X*_8U^"VG_!G76O?"/BS6OV;O
MC7^SA:?LJ:A!X-N/%G@;X<^(_A/XC\5>#?'GQ)T_4-8\.?#[X>^ _'_BGQZ-
M3O?!OPX^*GC30_Z:J3 YX'/7@<]>OKU/YF@#\$OBW\=OAS8_&']F_P#8,\3^
M&?VDOB'X7_9M\0_ KQ[\2?$?@_\ 9"_:*UGP_P#M5?M7>#?$/A_Q)\"/ _AC
MXT0> ]1^"'A'3]"^.FFZ1^TE^T%\6OB=\=/ GA'1O'VE?#'P1KOQ&\8>']8_
M:8'P]XE/AW\05\+Z1^Q:OP[^*T7Q>/\ P7+U3]J>\\1Q?#S6C\-I/V>M/_;K
M/_!3,?&6_P#B5%(WAM/AQJ7PDU+2_@%I^MW>IG5;_P#:9CU#X+66A7=SX;UV
M]TS^B2FE1@@ <Y/0?>/?IU]3CF@#R7X-_'/X;?'S0=?\1_#34?$5[8>%?&.L
M> O$=IXM^'WQ#^&'B+1O%.AVVG7]W87_ (1^*'A7P=XKAM;O2=9T;7M!UDZ+
M_8GBCPWK6C>)?#6HZMH.JZ?J-S^"G_!<K6OCC<0?%_0O@-H?[8$7Q6\$_L51
M?%_X,>)_A7X-^.OC;X8_\+-\+_M"Z!JAE^$MI\&O#$OA_P )?M+^#=-\+Z?=
M>.OB1\4_&*7.F?!#Q?8_#'X<_#SQKH7QB^-5]X9_HE\+>%="\&:-#H7AZQ^P
MZ?%<7MXX>ZO=0O+W4-2NYM0U35=5U75+F]U;6=9U;4+BYU#5M9U>^OM5U2_N
M)[R_O+BYFDE;H<#T'8].XZ'\.U '\K7QSM?'MSXV_P""AGQB\*^,?VR8]0^&
MO_!2_P#X)>_$3]EBSE\<?M4V5MX>^&GCRW_8Y_X:Q?P5\-]9U"W/B'X?VN@Z
ME^U?H/Q2^%_B#P]XA\!?";1_#_Q#\,KX&\!P:#K5BL.HW7COQU\>?V,=2^+G
MPC_:CU7]KCX1_P#!;WXIZK\<O$MC\#/VGM5^$<?[,OB[PG^W'X"_9=\;^!O$
M.E>%=2^">L_ 'PW\'[?X#Z%X<\4Z=>3/\+K[4/BKXR\97'AKQ'\3/C?XN\;?
MU64F >"!CKT'7.<_GS]>>M  "&&0<C)'!!Z>XR/\X.#D4M  '0 ?3BB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** /Y8/!_P"U?\7O#/PH_P""D/[7^K_M>?&[
MXMZ)^R[_ ,%+OBM^RQXGT33&T'XE_#CX-_L<Z_\ &W]E+1O''Q5U7X+_  %\
M'>'/'>MZ[^SK\,;?XF^)/"_B7P#J_A[QMH'AG7/B)KFJ3>*GTU6MI/C)\4/"
M.H?#?_@F[KD?[:WAW]K+X9:Y_P %[/@M>?!+XO7*G2?#</@&;X9?$B>_^&/@
M/XF^*/B5\1]<_:"\,?##XCZYXH\)6GQ1U;Q=J^N6%],/A#KMWJ6N?#FYU?5?
MZF"@."6;(! (;&,]^,<CUZD9!R#BC8,DEF.>O/!&<@8QC ],<C(.03D _DN\
M7_MJS?'GQC\4? >@?M-?$#6O#'QY_9+_ ."U'AR?X=ZM\2_%GPD^.K_'+]D/
MXO?"H?!CP/#\$_"5YX0U_P#9M^)?PN^&OB/XBZ7HWPO^'-QI?QB^*/[/N@6/
MQN_:KT>X\7:OK]CX3Q?A?^USX=LOV8?V#/V;O#_[;S?LB^#M?_X)C_LC^/\
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M =4^'\'A"W\#^(=5T,:;IUYX"UW7_#VH:SX$URQ_MG1=NJ>(?B!<>-_ZZP@
MP&8 =!GH.F!QG ' YXP".>:7;Z,W3'7M^7X9^]CO0!_)[\/?^"@_B#P%X!\5
M_##XS?M0:M!^RSX/_P""H_[<_P"QYXP_; \;^-?%/B_6_@OX,^'<%AXA_9<^
M'?QH^-'PS^*/PJ^*GA+1?&^L:CXHT?3OCIJ?CEM>36?"/@#P-XWU35/"GC#7
M+E\OXC?M#?'.;QG>_"/QC_P4P^)'BK1/#O\ P0B_:)_::L?B9\/[;X??LJ7O
MQ%^*GPS^.NAQ_!G]IJT\,65WXP\5^';WQUX TK1?%,TMYXXOO!WC_0(+V^L/
M!O@_P!XZ^(/PVU?^M7RQ_>?H1G<>^,_RX(P1U'.,+MZ_,V"2?O'J3G@]0!V
M. .,4 ?QJ_LW?'SQ%XE\3_\ !0CXR1?M::/\*?VK?VC/^"4__!(/XK?#KXD_
M$KQ[\3_%/@*[\7_%+PI\3K#XF^+=/^&WA;Q)JS>#/@K9_'/Q_P"'_ 6O^-_A
M%X0@\,?LMZS\5-3UCP5IWASQ#XAU32?$_P"OW[*7[1G@SQ/I?PV\2_M&_'WX
MA_LW^,O#/[<?C/X'?#3X7>-/VI_AG\3?A%^T3XW\4? '1/#O@/X0_"SXYV^E
MV-W^V'\&)-*\?Z?X[^%NJZEI_@7XV6OQ]T5_!WQ?TN]^+?@;Q=8>(_VKV9_B
M?_OK'Z]?7C./;@8Y/Q1X'T'QE+X=;Q#'=W]IX9\1Z9XLLM)-Y-'H]YK^@SQW
M_AR^UG3HRL&L?\(UK<%EXET"VOQ-:Z9XHTS2/$-O NK:/I=U: 'YA_\ !1"9
M? W[5_\ P2:_:!\6G_A'_@A\%OVH_CI:_&#XIZFRV_@CX6K\8OV+OV@/A%\,
M=5^(>MLQM_!_AKQ=\4O%7A?X>V/B[7OL/A:U\7^*?#'A_5-9L-3\3:#;:EZ=
M\5OBS\+]4T7]LSXR:?\ $OX?W/P?T#]CO1_#NM_%>#QIX;?X8Z3XBTF;]H34
MM9T6_P#'XU/_ (1.SU70=-\0^&[_ %VQN=5BN=%LO$WANZU)+:#7=+>Z_1LH
M"P;)# 8R,<CK@Y!XS2!!G.6)]SUX].WK@84'D $# !^.O_!,O]K;]G3P?_P3
M?_X)8?#RZ^+WP_UCXD^*OV0/V+OAII/PU\-^,?"VM^/W\41_LW>#M5\21W?A
M6VUD:KIUEX \)>&_%WCOQ]=W\$ \,^#?!OB;5;J-I-.%K-^1'PJ^+GPZ\76G
MP1\7_%_XZ_#3Q'_P3:\,?\%F/V^/B1XI^(/P7U7PU+/\%OVN-%_X*+?&/XT_
ML,>(?VK/BPOC3Q]I%E^RA\6Y;N35M%\1^'?#'P@?_A8/BW]FV/Q3XTUKX1^/
M=7O?$/\ 8&5SCEA@YX.,_7U'MT_(8;L&0=S<9[\<XR/H<=.@[8P, '\^OPR\
M10?&K_@K_P#\%'_#7P!_:I\$>$/%6G_#'_@CGXQUJQ\):IX ^(%]XW^'/PJ^
M+7Q_\??&SP!+I:WM]J^FP^*OA7KMIX"UC5M):VN?"UE\;/"?B.^1H]7\.?;O
MJC_@K)\5/%/P0^#?[*$WP_\ CSK'[.)\7_\ !0_]@WX1>(-2\(ZA\./#\GB3
MX6^._P!H#P;X7^(7@J2?QYX5\21VOA^U\$7.J>(]0M_"ZZ)<+IOAQX/$=UJ7
MP[?QGX9U_P#60+CNQQZGZ]<8]?ITP!@8:8QECE@6QDAB#QTZ=AZ=/:@#^<W7
M?C)XM\$_M92_L2>)_P!N?XJ_!CXO?LZ_$3]F@_LE67Q7\*^+?B7\2_V^/V??
M$W@#X?:U\36U<V/Q"^%OPQ_:!U7Q-XIN?VA/@%\2O&][X)_X2/\ 9ST_X?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MAU&W\,>*KM?AOXQ\))XG_LF#5M3ABT/Q:NN^&YHK^Z2ZT>=9Y WFFI_\$_\
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MY^'_ ,4/A'XK\#?$CP)XIT_3];US2/[:\(>+-&O[G0M=UK0KZ:XT?6-1L;D
M_!_]D'X\_%K]E7]COXC>'OAQX/\ @=8>/_$7_!1;_@KWI9TQQXKUKPWHVN?"
MS]H3]HOQ;9>&OA)\%_"H\.>-_B3X>U/7_#5EX3NM4O/%GPT\,?!KX9G4_BEX
M]\1+I_A2'PKXA^G_ (<_\%-?C=XQE^&'B+Q1X$^%W@/PW^VE_P $U_ W[9?[
M!GA18]7\2Z[XL^/.K^"?A]JGQ _9>\;>-+KQ]X0'B_Q;X.\2?%?X67?@BW\)
M?"[P?/\ %OP7XU\0W]O?>"K_ .$OB)?$/V-'_P $R?V'(9-+G@^#5W;:AI'Q
M;^/7QOAUFW^*OQJMO$-]X]_:EE2X_:+7Q!XCA^(<>O>*/ GQHDAL)/B'\(O$
MVHZM\)?$?]D:#]N\$2+X>T4:?A>"/V+?#WA;6?V?/A!9_"+X8:#^R=^PYXF\
M&?$']D>YU#XL?%#XU?%O_A)-%^#/Q!^$5EH'BK2OBYX6O;GP-H_PKT[Q_=K\
M-=?M?C3\4=0ET+1?".AV.B> [#PW96* ''>$_P!MCXKV?[;>D?L??%O2/AYX
M#U;5?$L^D>"[GQ1X/^)GP]C_ &C/ /A/]FO3_B3XZ^,O[,_CW4]3\6?"GX@:
MUI_QJU:7P#XB_9<M_%5W\8_A-\-O"/B;XK^)M9\3Z%(CZ9E_\%>+_P"(]O\
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M]H3X4_%M/B9\0-4\5_"'P=IO@+Q9X)U#X%6__!23]M'_ (*3^$?BGK'B/5?
M&J^%/B#J?B7]M;P=X(O/@AJ/PAMO"WC+0='T7X2^'IYOB3;_ !.N[OQIXCL+
M+P1H>@ZM]8_&O]C7]GW]H7QK:?$/XL>'?&NM^*K+X,_%C]GNTN]"^-7QO^'^
MFP_"+XZ1Z+%\6?"J^&_AW\1?"GAIIO&W_"->%I=4\3/I#>+8;GPGX2N]/UZR
MN?"OA^;30#\G_!G_  4J_;K^)-C<>&_ _P $_@#KGQ>^)?\ P23^'7_!3K]G
M?P;H9^(FO'6/$UQ!HND>*_V9O%T%]XE\)1ZCK/Q(\4:WI+?#3XB:'K>C6/@/
M^U9O#?BGPKX^&AQ>,O$GT#>_\%,WG^&?@#X__#N^^'WQ:^"_QYU+_@GW\&?@
M1-IOA3QEX-U>\_:(_;C\8^%-)D_X6-K$OBCQE'X2\%?#?P%\1/AW\2]9\*R>
M%$\51_\ "0W7@*X\1#Q/I]M)JOV%\*/V#_V7_@E\1?AI\6/AIX*\7:'XY^$'
M[.&B?LC_  \U/4?C5\<_%FG:#^SUX<U2QUG1/A[-X7\9?$C7_"NN+I^IZ9IU
MW%XI\1:'JWC5GL+)9?$<D=K B;EA^Q3^RSI?[.FM_LEZ?\&O#5G^SKKVN^-_
M%$_PM@N-;31=)\2?$#XM:[\=]:U_PC?#5?[>\"ZSH_QA\0WOQ$^'FI>"]6T"
M[^$OB6S\.WOPKF\&?\(EX531@#\P_C/^W?\ $./2?VE_@/\ &O\ 9V^"'Q:\
M>_LG_MP?\$W?AUXYU75)]8T[X*^/_A'^V'^T-\'G_9_^.GP_\!:M!\0_$>E_
M&OX/^,=<T9==^%_BSQ3:Z/X?\9> ;7XN>%/BGK5E>:!X%K[$\-_M??$?QU-J
M_P 8_!6E_#6Y_9C^''[1_P"TA^SE\:M,U^74=,^,/@F']FGQ!\6/AMXR^+NE
MZQ9>)=2T+Q$VH_&/X9V?AGPU\#+;P%'XLU_P!XRT7XDVOCJ'45;X?2^L>)OV
M#_V8?&'PWUSX3^)/"7CO4_"WB?XP>"/C]XLOV^._[0-O\1/&'Q<^&FM>%->^
M'/C+QC\8++XGV_Q;\7W'@'4? /P_'@W2O$GCC5-!\+Z=\/\ P#HVBZ58Z-X+
M\+V&E.\&_L$_LF_#_P#:+\6?M7>!_A4WA?XU>.M=UCQ=XJU31_'?Q+L_ >K>
M//$'AVV\(^(?B:_P27QC_P *1M/BQX@\,VQT+7OBO8_#JU^(^LZ9>ZQ:ZGXG
MNH]=UD7X!Y-^R-^U;^T1^T'XT\*:_P"*_@7HWAW]F7XY?LS>#/VC_@7\6[+Q
MI\+!K=O?>([[P_<WWPIUOPEX9^-WQ2U[XAV)\%>._!/B_P ._'+PUH?@KPE>
MNNO^'O$O@[PCJ5UX)D\6_-W_  40M_B%XT_X*#?\$E/@VOB+X?W/P8^)?CG]
MKS4/&GPM^('PQO?B%X5\8ZWX%_92^(/EWGC/3C\0O#>D^)M*A\-^+=7T_P +
M:%>Z0MMX>\27DWBK4YO$WE:;H>F_<G[+O[ '[)?[&%YXGN_V:OA;=_#B'Q0E
M];#0Y/B/\5?&WA'P7I6K>)M4\9:UX;^#_@CXA^./%G@_X&>#]?\ %&K2:YXB
M\&?!C0_ 7A3Q#?:9X9DUO1K]?"'A5-&[OXD_LG_ _P"+GQI^!_[0GCS0O%^H
M_%C]G&\\07_P;UW2?B[\8/"&C>$KOQ9IESH?BB>?P'X-\>>'_A]XI;Q'H5Y/
MH.NCQCX6\0+J^A,FBWZW&F0PVL8!^3_P7_;XU7X=? _]A/6_V>O@CX _X8V^
M/7Q?^(O_  3\_9G^&&K^,_B-I/Q4^&OB?X22_&+P%^S3XG\>>/?$%MX_^U?"
M7QM;_LW>(-%^)6A1>#-0^)'P)TKQ)X4U33YOC3/X>\1Z$_W1_P $X/VB/VE/
MVLOV<_AE^TM\=/!7P0\!^$OCY\%_@=\8?A-X=^%/B?QWXC\2:-;>/O L6M^,
MM&^(DGBWP]I&E"2'4IM*UGPK=>&[NZ\C3M?O_".LV]U=^#(/&WCKUJQ_8G_9
MMTKQGK/CS2?!.OZ/KVL>+/BA\0XK;1_BK\7M)\)>%?B;\:/#]]X8^*7Q9^&O
MP_T[QY;> OA/\7_&FCZYXP35OBU\,?#7A'XCC4/B3\7-;M/$]MK?Q@^)^H^+
M?4O@7\#_ (:?LV?"#X=? ;X-Z)J7AKX5_";PMIW@GX?>&]5\7>,O'5UX<\)Z
M.AAT;0(O%'Q \0>*?%U_INC6?E:;HUOJVO7ZZ3I%K8:/I_V;2]/L;2W /ST^
M,W_!0;XB?"C]L'X7?! ^"/AYJOPU\=?MF?#/]C:YGT;5?$WB?QK!J'Q1_9$\
M7_M-6GQ(\1>+M+M;7X<_"OQ)X:UGPW;^#Y/V:/$L/B3XJ>)/AUJ_AS]H"?6?
M!O@;Q_\ #O3_ !/^/_PG\'^%-)G_ &.VTSPYHNGMX7_X.I/^"B/AGPX;/3;2
MW.A^'9K+_@HJ9=$TKRH5^PZ7(?"OAK?90;(#_8&D_*/L%KY7[_>(O^";_P"Q
MSXK^)FM_%S4_AIXF@\:>(/V@/ ?[56I_\(_\;OCWX1\'M^T1\._ 4OPMT7XM
M6/PU\*?$[1?AMI'BW7?AQ/-X'^)MUI'A.Q@^,OAB5]'^+UMXXLF\JC2?^";W
M[(.B-X/;3/ /CJ ^ OVJ_&G[;?A0O^T)^T;=?V9^T_\ $1?$B>-_B<XN_BS.
M-2/B5?&?C)=2\&ZJ+[X?2#QCXMV>%(_^$FUS[> ?<H(/(((]0<TM( !P.Y)[
M#K],?YY.3DTM !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%%  3@$^@SZ?KVK\K?VE_^"@OQB^$W
M[2/Q*_9?^!_[(=Y\>O'_ ,.?V+;K]M--5U_X[>%?A!X9\8^&=*\?ZOX(U+X;
M>%_)\'?$WQ+_ ,+ U-M$O8O!<NM^&M'\)ZSXJ:VT7Q-XC\#>&YU\<1_JD>A[
MU^-?QC_9$^,OQI_X*D^*OB7<0_&CX7_LU>+_ /@FTG[+^O\ QH^$WCSX,>&]
M4UOQ9J7QV\1^.?$7@.U&JW_B+XT^#X[SP9K:QV'Q&\ ^$?"'B;P_K@>Z\*^/
M=!U&VL]64 Z_QM_P5.\.:-X6_9R^*O@WX3W_ (D^"_[16@?L-^+_  WXF\3^
M/]'\(?$&]\)_MY_$G1OA;\/M3\)?";0=!^(&KZB/A;X@\8_#J[^-.J_$?6_A
M!X)TG3_'&EZ1\._&GQ)\?H? ]QRO[//_  4)^+5[\)/%WB[]H;PAX+D^)/B[
M_@H1^U[^QO\  CP/\*+KXK^-=(UC4_V<_&W[1%LWAW4E\&? 7Q)\0;6VT;X7
M_LS^.?%5SXSM/!?C:]\9ZG;WFL3^'?AMIVKV/@KPKZ5X\_X)*?LW^*=5\77G
M@OQG\;O@9H?BSP;^QIX5'@'X/>+_  I8?#OPI?\ [ 'Q"L_B%^RIXK\$>$O'
MG@+Q_8>&KWX:7%C;>'F\$6I?X->*-'@MM5\5_"_6?'-E8>,;237O^"4/P'\0
M?#3XA_#.;XK_ +2NEV?B?]JOQA^V?\+O&/ASXGZ/X<^(G[+_ ,?_ !WXI\>^
M-/$WBSX ^,-%\%6=];KJGB#XJ_$Z348?BXGQ;N=8T7QUK/A#7+W4_!EMH?A[
M2 #Y^UG_ (*T?'(ZK;_#[PU_P3_\;Z;\9(?V*?VD/VM]:\(_'#XOM\"/#<=]
M^RO\>_!_P3^(W@W0=3\0_!_7OBC?>"?&UKK6J>//@-\6/%'P3\$S_$?0-9^$
M4OB#X=?#W2/'7C_Q#\%O2?V6OV^?BM^U9^VAX4\+^%/"'A;PY^R=X^_X)G?L
MM?MT?#Y=<UNZ@^-4\'[5WBOXE1Z%-\0M&LO#&N>%K77/#6G?#*T\-#P/X3\>
MC0M!_M?Q)XKOO'7Q/N-;\.^'/AQZ5:_\$O?A9:>+]+\?GXY_M-:IXTM/V1?B
MW^QYK?BCQ1XS^'7C/Q!XW\(_'3Q%X<\9?%'XE^,]=\8_"?7]8U;XM>(?&'A'
MPUKUE?6]]8?#[PI;Z-I_@_P;\.?#WP\L[?P?'TO[/?\ P3A^%/[-'C_X(_$+
MX>_%'XY7%Y\#_P!CSX5?L/V6A>(==^'=QX=\?_!3X%:GXLU/X.2?$2+1_ACH
M>L7?B[X?MXX\3VUEJGA#6O!FD>(H-0BF\<Z!XKU'3=+O[( ^C/C]\?-!^!EA
M\-K*YM;;5_'7QM^*_A[X'?!OPOJ&M)X9TSQ9\3?$F@^*?%MOINK>*);#5H?#
MNBZ3X,\#>-/%^MZBND:UJTND^&+W3/"OAOQ9XQU#P[X6UKYJT_\ ;#^.=YXC
M\(? S4OV6=/\&?M9^-X?VH?$GASX;>-?CQIT'P5U3X3_ +-'C'X=^#_^%S67
MQU\&_#7QQXN?P3\4KCXT_!B3P=I-]\ M/^(FG7/BGQ78^)_!6D?\(!J5UJ'M
M_P"US^R'\*/VT?A5#\+/BI<>,- ;0?&/AKXG?#+XF_#'Q))X*^+OP4^+W@B2
MYF\$?%WX1>-H;6_?PKX_\*O?:A#IVH3:?J>F7NFZGJV@Z]I&L>']8U;2KWS2
M+_@GY\+['3_@MJNB_$SX\:3\;_@5>^/-2\+?M2W'CW2_&'[0/B2]^+.EZ'H?
MQ:7XH:U\1?"OC+P!\4='^(>B^%O!NDW?A/QM\.M8\&^"+#X>_"R'X3>'OA[_
M ,*D^%[>#P#Y7\/_ /!8/P1XVO\ ]F_2?"WPGO/#.M?M#^&O%4FB:%\?/B%9
M_!*ZUCXO_#K]H&__ &;_ (N_LQ_!SQ/=>%/%GPN^,/[0_P 'O'OA?QC=^+_A
MO)\1? NK>*_"X\$>(_@<OQATKQ-XFNOA_P"0^!?^"JWQC^'NG?ME>-/VH_"'
MPCT7P-\+O^"JK?L,^"O'-CX_\8>&_@=\!? ;? ?X8>,;7QI^TK\5S\$M;OO
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MCXA:1XL /D/]H_Q1XQ\-?\%4_P!I_P .6F@?MK?&[X>67_!+_P"!?QP3X(_
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MK7,'B3PWXQ\,7GAD>&(?A]\2?B9S/[57[3/[1/PL_;R_X)J_L[?#C1?AG/\
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MU?X=^"_%WBCP5X5\1^*_!.LZIHUM, #]'**** "BBB@ HHHH **** "BBB@
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M^'<+_M):@/A3X9\(?"37;749)[FW^(<FO_&)?$OQ"^QZ-X=\4#X<:-XU:_\
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MZ#_@F#I5W\'/^":OPW\2_%@7OBG_ ()Z>'/#7PUU#QYX>^'R>'[7]H+X%Q?
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MPG^U)K'[5_B?7?V<1\*/"^@?%/PUK7[9]MXXOOC9X?LOVD-,\1[+[X8R^/\
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M=S^TG<:CX4CU'Q=?^+=3\6^/]8^)/C/6-2/CG7[2#2+33M/\'V?A?E?VQ_\
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M?#;]I'PCXL\=6GB.VD2^.1\1/VXOCI^R#^WG\1/A_P#';Q3\5/VBO@Q\-?\
M@F#\-/VG?B+X6^!7P&\"6EIX6^(,_P ?_B]X6^,?QET#1#>Q^.M*^&VA^#?
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M+'[!_P '/VV/B9=V'POTSQG\._"-]\2O#!A\0ZG?^ _CC=ZS:?#3QU\ =)T
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MM[?%']KCP%^V+XJ_:2^#W[5VK?#S1M>\!^,/ ?@KXL>$/V-?@IX2O/B=\)/
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MCGXQ?M&_M$?"/]DK]GKPIX@UJZ\->#-3^-?QKU#4;;PY?_$'Q+IVFZWJ^A^
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M;;PYIWA#QQX(^''B;X,>*?' O]5N_"O]KV/[4RV-K\3/'&K_  E\<076@ZP
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M\$_?C9\)O#7[#OPUUKQ)\,/&?@S_ ()E6OQ5?]FOQE!K7B'PO\0/C5_:_P
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M[XDZG%K/_#-OBGPIIGPVT#P;\0/#/G&O_P#!,_\ :LOY_B7+8ZA^SVR^+_\
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M^M_#_P"!GQ+AO?V1_P!F[2OA;H?Q"U[QWK^K>&++Q-\0/B5^TSX_U3PQ;_\
M"5Z;X_\  OPI\0^-_A)[]^W#XU\0:#_P5Y_X)3Z;\/!\,M?^(TG[./\ P4UC
MTWP3\1?B?>_#+3]776[7]CU]'@GUK0_ _P 3-=M9-4G\+ZY+I26_@;6/[1C\
M-Z_):QL^BWC6X!]NZW_P4>_8FT#P!\-_BE>?'WPU?> OBQ\*4^/'@[Q#X;T;
MQCXOB7X&)K/A'P]K'QK\86/A/PWK6J_#3X0^#]9\=^%[#XA_$WXDV/A+P1\-
M9[^Y_P"$_P!=\-QZ/K4FG3?!O]N3X:?%SQ3^UIX='ACXF>"+;]DKXU:;\$?$
MFK>-OAO\1=#7QKX@U+X8_"+XAV$_@NQO_!]M)K&H:_=_&'0?"_@KP/I,^K_$
M/QO,VB:]H'A:XT+QUX$NO$'Y*?%?_@CA^TM+^RA>?L7?"/XX?!K6_@AXK_8H
M_:D^%7B70?B!H/Q!\!:7X=_;%^/_ ,9=<^/E]\=_#_ASP7-XQMO&OPOU3Q3X
MW\6^"O WPW^(&J2ZO^RUI-AH/Q"\):_\;?$VH>(]!O??/B'_ ,$]?VK/BGX6
M_;O\.ZCXM_9N\%W/[1?[4_[-'[<?P>OY[7Q[\8/#%O\ &'X)> ?V1M(O_@=\
M<OAYK/ACX<VFO_! :[^R?'H.H>,?#_B6Z\3?$[P_\3;CQ+-\/OA+?^!8_"'C
M, ^T)/\ @IU^P_'J7AKPX?C6\GCSQ?XE^.7@GP_\(X/AG\8;GXZ7?CO]G+PT
M/&7Q8^']Q\!K?X?2_&72_B#I7A.XT?Q'X6\":MX&L?%OQ/T7Q9X$U'X6Z-XT
MMOB!X)DU_(\"_P#!2S]G?XN_&/\ 9:^&?P6F\8_%CPK^UI\"OB?^T#\-_C1X
M2\!_$"Z^%@\'_#+7?A7X7U+2K[7E\(2167BN#Q!\5=,TOQEHVN-H!^$6JZ5?
M>&OBQ<>$/&NJ>&/"NN?'_P /?V OVH](^/\ ^Q'^T+K?@?\ 80^&NI? _P")
MG[5?Q0^-7PT_9JM/&/PO\"WFK?'']GOPM^SQX/M?!]W#\%QJ?Q1\06.C^!=$
M\2^,/B/\2K3PEK_V>[MOA[HNE3^&? _AJ]NJG[%/_!._]JK]EV3_ ()SR:YJ
M_P"S[K<O[+GPU_;Q^#7QFDTOQO\ $J\^U>$?VM/CY\%_CSX>\7?#&"\^$FA-
MXG\3:,?A!+X#UKPOXKN/ FF::/%*^.;'Q-XE/AT^!O$ !^TGCSXA>$/AGX;E
M\6>-=6_LC1DOM*TFW,5AJ>L:IJNMZ_J-MH^@>'O#_A_0K+4_$'B7Q)X@U>]L
M]*T'PYX>TO5-<UK4[JWL-+T^ZNIDB/RZ/^"A_P"R++\-[SXJ6'Q-UG6_#VEW
M'QOMM;\/^&OA+\:?%'Q:\-R_LU>(X?"'Q_\ ^$K^ _AWX=ZI\;_"<7P>\4WN
MB:!\09_$GP\TN#PUJOBOP19ZC)%+XZ\'+KF-^WO^SC\:/C_X"^#/B7]FOXD>
M%_AO^T3^S%\?O#/[27P:F^(]EK-]\)O'/B;0O /Q*^%NO?"_XPQ^%HV\76?P
M[\??#OXM>-M"U76?!X?Q%X=U.;2->L;+5H],N-%U'P_2_P!E+]KSPY\?_AW^
MVXWC#X!>._VD[G]GWXG?L^_&OX.D^._A3^SN/#WBOQMX9^*'PSU'X/\ C&S\
M,_%3XCZ;K/PW\4^%)M#\?:QX\\+>(K_XZ0_$#Q#XPA;X/Z9X,^'_ ,*=, /K
M?4?VU_V8++6?">AVOQ5T[Q2?&_A_X'^+/#>O?#WP_P",?B;X&N_"_P"TOXR;
MP!^SQXCO?B-\._#GBCP!H>B?&WQ?')H_PNU37?$NFV?C5X)[SP_-?:?;S7<?
MAGP8_P""G'[/7Q<T/Q%X@GTWXL>!([#]HCX]?L[>$_#'B'X+_&:_\>^--5_9
MSUWQ3X;^(WC&S\$:!\.]2UO3O"NCZEX'\23Z[?30W=O\/K2Y\&Z+\5+OP#\1
MO%UO\/;/XS^&G_!(KQK\!4_9!\-_!3XB^&?"5Q^R9\)/V:OA-HW[2?AOQ%\4
MOA]\8_&_A7X=?%'7_B3^T5\/_C3\&=*N_$GP-_:"^"_QH;6)U^$GP[\?W.EZ
MI^R[XM\4^-_'_@SQKX@US4[&WLJUY_P3#^.WB+PS\0?ASXTC^"FH^$3^VM^W
M#^U1\'?B#\//C?\ 'WX&_M-> +W]J[XF>-/B/X*\=_#;XZ?#SX?PZO\  7XH
M_#&+XG^*_!_B+PY8Z9\9_AU\4?#VG16OBQ;C2_%MSH/A$ _;K1?B#X3\2?#[
M1OBIX;O;OQ!X(\1>#=/\?Z#JFAZ'KNJW^M^%=6T2+Q'I=]I'ANQTR?Q1J=YJ
M>D7$-QI^AV6C3:_>SS16%OIDFHR1VC?D[^Q#^W]XT_:-^'?@7]J[X@>+K+P;
M\(?BMXV_:5^%FE_L_P!S\#/BM)\2YO'7P\^.?Q#T/X%V'P!OM-\.-XI^,FK2
M?L_?"?XA>,_VE- T?0/B)<Z9XBT#6?&?AY?A-X'\#>-?"EE^GGPQ\.?$SX??
M GX=>$/&/C#2OC1\9/!7PF\(^&O%/Q OM%LOA1H?Q7^)OASP=I^EZWXQO/#O
MA/2O$6G?#72O'?BJSN=:N-%\-:)KMEX.LM5DL=&TK5(--MK.?\>?V</^"9W[
M1OP3^"/[!2WGBKX--^T!^P/^T=^U)\3-"T6Q\7?$+6O@Q\:?A5^UA?\ QHB\
M=^$M>\17'PX\,>*?AMX\\/:1\:8[[P?XQL? ?Q'L++6/ARNGW>EW.B?$W6XO
M"0!]R>+O^"HW["?@CP7\(O'>M_'BUNM)^._A+XI>-OA5HOA3X??%GQ[\1/%.
MA_ [2[_5_C9 ?A+X%\!^(_BGH7B;X.6^C>([3XJ^!_$W@W1O&OP[UOPEXT\.
M>+_#^C^(/!?BO3-'[;]NG]L[P5^PO^R+\6/VN?%?A'QO\2/#?PT\)-XBL_"O
MP[T/5-8U;Q'>WL:QZ!:W>HV>G7]EX-\-W=[/:#7/''B2.'0O#>G227=P+V_;
M3]'U+\__ (8_\$R?BS\+/VG_ -DW]H'0M6^%D]MX3_:3_P""AO[6?[3NEMXM
M\96<[?$7]O;2C82>#?@_9Q?#"6S\6>'?A'86^AZ%_P )9XRO_A[J?Q*ET.Z\
M93^%/ ]YXCE\-:)]Q_\ !2K]EWQ?^VO^P;^U!^RQX \1>&_"7CGXU_"W5?"?
MA+7_ !BFJ'PG8>(EN['5])7Q)+HEIJ&L66BWU[I<.GZCJFF:7K%]I5M=R:E:
MZ+K4UJFEW@!\[^+_ /@HYHOP%_;#_:!\%?M&^/M#\,?LS>%OV2?V3/VD_AS<
MZ?\  GXR0?$WP!IOQH^(W[1_PW^(^N?'6RTUO&_B32_A[X-U'X*Z!K7BOXJ^
M)?AM\'/A]\%[#QUH7A7XK7&F:NMKXH\4_<7C#]K+]G[P!\2?A_\ "GQA\08=
M#\5_%#Q9I?P^\%7MQX<\83^ -3^(^O>&KOQEX;^&-]\6[/P]<_"?P[\4?%?A
M2T'B#P?\-/$GC72/'/B[2M0T.[\-:!JD?B+03J7YM_M)_L6_MB_M!77_  4)
MUA[#]FOP]J7[9O\ P2S\#_L.^%K*/XR?%2;3O!7Q-M-7_:GO_$>M^(;D_LZM
M<:KX&\/V/[5^KZ?H?B#3K6#Q#XWF^%UCJ5_X$^'</Q0N=+^&%/X>_P#!/3]H
MOPI^UGKGQ!U_2OV&?&_P(^)WQI^'O[5/B#Q-X_\ A+>_$/\ :^^ /Q?\-^%?
M $/B7X2_!3XD:[X+L/!7C;X4W7C7X=VNI?#?XJ^)-$^&_P 5_A1X;\5^(;+0
M]#U#7=+\&:WH(!^W=%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7EWCWXX?!?X5ZIX>T3
MXG_%SX9?#K6?%MYI>G>%M)\=>._"_A/4O$5_K?B+1O!^BV>B66O:I87.IW&L
M>+_$?AWPEI45G',^H^*/$.@^'K,3:QK.FV5UZC7X%?\ !77]AW]J_P#:_;XY
M^&_@I\)?@SKNA^-_V._!GA#P=X^E^(FF?"+XE:S\4_A[^T;:_$W7/A3\7_$%
MO\.=>\8_$#X<:EX'>*Y_9S\")X^\-? G1_B1K?QMUG]H#P_J6KZO\$_&_P .
M0#[J_;K_ &ZO#W[)VD_#?2?"_B+X%>(?BUXW_:/_ &1/A!J'PG\>?%JT\*?$
M*/P+^TS\>M ^#\WC'P-X!TZRU/Q'XZ\2:?97/BGQ'HGAVYD\)Z3=^&O _P 1
M/&7_  D=];_#G4_#.M0?M#?MV>'OA-^T]^QU^S7X$\0?!#QUXI_: _:.\1?
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MJ'B#1GL/ACX1\3^'-22_\+_??[,/PA_:]U3]O7Q-^UE\<_@+\*O@3X)\5_\
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M/&5G\4/V<?B/IOQ.\7^-/&.O? RSTKP1\)/BQ\/?#>CQ^'/A7K/P%F^'_@L
M_HJ\">/O ?Q.\-VOC+X:^-O"WQ"\(WM_K^DV?BCP7XBTGQ5X<NM4\*>(-4\(
M^*-.MM9T.ZO=-FU#PWXIT+6_#6O6<5R;C2=?TG5-(U"*#4+"YMX?ESPG^T?\
M5-=_;R^+W[).I_#OX>V'@#X8_L[?!S]H6R^)MC\0/$E]XT\0Z?\ &WQU\9_A
MUX=\*W/P[G^'EAH&C7>A:[\!/'5[KNLQ_$;5HI]*U/PA_9VER7=]K<>@[O@?
MQEXD^'/QX\"_LB^&OA9>:Q\'/!W[+ND>+?\ A?%U\4="UGQ)HOB;1?%D?@#P
MWX!\=_#4Z8GBJ%_&WA[1M:\6:7\6-1U>'3_&.O\ A[Q;H>E:)?7GA_Q3J&B^
M>>+?A;\6_AE^W!XJ_:V\&>!+GXS>!_BU^RW\)/V<?&'@;P?KWA#PU\3_  #X
MA^!/Q3^/WQ/\(>,M%M_B1XD\'> ?&W@WQU:?M!>)?#OBJ*X\=>$_%'@'6/!O
M@^ZT70/B-I7COQ+=?#$ \P_:*_;3_:1^ OPR^-GQ 3X*_ OQ5=_"_P#;$_9V
M_9CT'1)/C7\0M!M?$?AC]I7Q3^SWX(\'?$37=93X%ZU/X9U[0?$G[2?@Z7Q/
MX$TS1?%FGIX?\.>([_2O'6HZI=Z=H:?67[6?QK\5?LT_LD_M _M&:+X5\/>.
M/$GP#^"7Q!^--YX+U7Q'J?A;0_%%O\+_  GJ7C?Q/X?M_$]KX?\ %&HZ-+JF
MDZ'JMGH6HR>'-52'49=/:_LC:FX*?&O[9?[/OQ\^)/[-GB/PUX1^&Q\:_%;X
MQ_MH_LC?M#^-- \*^,?!5CX9^'_@_P#9R_:#_9E^(-YIUMK?Q UKP++KNK7G
MPA_9KTS18H[2*XCU?XM>(+N3S/#?@66._P!&V_VQ[?\ :\_:3_9S_:]^"G@#
M]FO4?"GACXG_ +%'[0'PD\-:?\1/&OP@@^)/C3]H#XV:&?AY\.FT&\\'_&+Q
M5X"\(_"+X;:!>^+_ !)\7]8\7ZG+XPUTZ]X23X:>']1O?"NNZ'XJ +/P)_;R
M^)?CSX\? #X!?%+X/> O"FM_M.?L2W?[8OPW\1_#?XIZ[\1K7PY+X<OOA9IG
MCCX;_$OPQJ7PT\&^(?"VCZ;=_%_PM_P@GQ?O1:>'/B9<V7B;P_%X?\*>*=&A
MT;4E^ O[87[3WQK\+:-XLA^"G[/NG30?MB?&?]EGQCX'3]H/Q+:^)WT+]G?]
MHGX@? +XP?%;X97WB+X0:'8?$&YT"S^'6N_%BQ^&]U9^%M1U#P1::G8+XE7Q
M)I]KINK_ #O^QE^RE\?_ -C3XI>!/B9X5_9_L-2^'_[17[-?P$^'/[5'PUMO
M$OPG?XO?L^_M#?LY>#-/^'&C^.OAWXWO?%UAX>^('[//Q/\ "ENO_"0?#6S\
M76M]X'\3^&[#XH>#_"47BCXJ_%;PS'[)_P $[OV0H_AW_P +'^*'QR_9<\-?
M"S]H:7]K3]N/XP>"OB0;OX8Z]XXU'X7_ +7/[0_Q%^,>G>'-2\;?#;7M7U._
M73O"?BGPKX7\:^$O%%U=^'D\3^"]$U+P_)K=OX?\-ZSIX!]R_&']JW]ES]GB
MZCL?C_\ M)? /X&WLWAZ7Q;#9_&'XQ?#SX9W4OA2'Q!I'A.;Q-';^-?$6B2O
MX>B\4^(= \-2ZTJ'38_$&N:1HSW(U'4K*VGT]0_:.^ &F>*/&'@6[^-OPHA\
M=_#_ ,*WGCGQOX&;XA>$_P#A,_"O@S3M0M=(O_%>O>%CJPUO2O#MGK%]9:-<
MZW?6,&EV^L7EIID]U'>SQP-\K?&?X"^+?'7_  4A_8W^.T?PDM/$OPP^#O[-
MW[9'PT\;?$'4)/AU.FC>*/V@-9_9WNO!5G9:1K/B&'QM>6MEX?\ @U\2=#\2
M7VE>';B&RA^)VAZ;8'5=+U_Q_+X6^*OV1?V2/VLO@W\2=*;]H[X ^%/C9JW[
M*5O\>U^!_P"V?8_M8?$SXG_%GXY^&_C1JVKPV>A>"/V;OC!K?A#X??LZ_$C7
M_"-WX2?]H'Q;K7Q3U7PEK'BOP%=Z?X-TKQ'9>-M.\;_#D ^U/V!OVK/C#^V7
MX&\!?M%-I7P%7]F[XU? ?X<?%#PA9^"O&?BC4/C5\'OB?XNM8O$VL_!'XIZ5
M/I>I>"_&*Z5X"\1^#]6F\?Z-KGP[U72O%":UX:N?A7J6D7>D^,1]#?&[]H[P
M'\&?%/P=\%^(?&G@#PSK?Q9^(4/A>-_&GB?2]&&D>'K#P1\1/B'J^NC3KS4M
M,N;Y-2L/AEJO@W1[I+F*ST_Q-X@TK4KM=2M]/ET/5?FG]@'P=^T=^SU^R=_P
M3[_9F\<? U+&7X5?LV>%/@U\>_&FH?%#P2S> /%/P6^%G@KPSX=O?!WAWPW+
MXO7XD^%OB7XAL]<L]*OSXA\':QX6TG2[35/$'AR*?4ETFS] _:F^!/QQ^*VN
M7&L?";XN^,?AJVD_LY_';P/HEGX?M_@_<:=J/Q4^(MWX$C\$:O=GXB?"[X@:
MG:6>E6/AS7HO$U]9W>G>5IU]IMOH-M+=3ZV)P#Y*^,O_  4O^/\ \//V;KS]
MLWX7?LH^"?V@OV6OAU\)-#^._P ;O&FC?M"Q?#7QW;_#_6)+CQ;XPTW]G[P=
MXB^&OB#P3\<O$'P ^$$UAXC^)^J:U\7/A)X=\7^-;'7_ (9_#>>_^(.C^(O"
M/A?U_P"-G_!0[4?A5XH_:KU32/A%#XH^!7["UK\'&_:A^)-]XWA\-:]I&H?$
MJP\,?$3Q]9> O"][H,VBZ_%^SY^SKXS\*_'?X@/JWC'1M5\2VGB#2OA_X*T.
M_P#$<[WJ>'_ME^'/V^;;Q#\&/@Q\%/V0X?VR?V9?A7;Z)\2/&FN?$G]J[X+?
MLW>)OC1\5?!_BF/Q#\(?AMXDTG0?@IX@TIO@?\*9]/TKQ1KEG8^#_!_B#XE>
M.?#WPXTS6=1D^'WA+XF:/\>X?C]^PY^T?X^\/_\ !0'X'Z1%X UWP9_P5 F^
M#4_Q&^*T&J77AZV^ =T/@+\,OV7OVJ+A_!NI7NI>(-?M;GX/_!KPGXO_ &7=
M/\/7'BJ77OB]XJ\3^$OC3J?PS\ >&=&\=^* #W+QS_P4BTKPCK_QW\4V_@CP
MWJ'[-?[-'[57P"_8U^+?QBN?B;I^EZO:?%KXT:[\%_#_ (O\4:1X<N-!;PHO
MPG_9^UC]H7X6:#\2]?UKXBZ;XEE\06'QQT[_ (1/0/\ A3>CO\6?:/"G[5GB
MK6OV^OC!^Q/K?PMT+1M)^'O[,WPD_:9\(?%73?B-?:[J/C+P_P#%+XA?$?X8
M/X?\0_#VX^'F@VW@;5?#_BGX4^+)8YM/\>^/+;6?#]SX>U-WT?4;W4M"TGX(
M^*?_  3O^+'B33OVKOV8-#\)>%M1_9V_;,_X*%?!C]M#Q9\4[KXEWNE:QX!^
M'6A>(OV:OB1^T)\.K[PH/#]WXAU7XG^-?B'\ M9TKX03^'+L>!]/\'?%.?6O
M%?BCPGJ_PJTSPG\5/J/P[\(?C'9_\%8OBG^TG=_#+6K?X)>+/V(/@E^S5H_C
MIO$/PZDBD\<_#+XT_M _&#7-4G\-P>.)O&<'A2^T?XM^'O#.BW[>'#J]QXLT
M[7AJ.A:7X:M]-\2:J 4_@#_P4,O_ (R:M^S'XCUGX26_A#X'?MO>(_C9H/[*
M_P 0+?QO#K'B+7XOACX?\1_$3X<:KX^\'7>AZ&^A6W[17P5^'OQ3^,O@0^%]
M2\7V'A+PSX1T+1_%^K?\)'XZL;'1_J'X@_'32?A[\;O#WA7Q/\6_V;/!'P[T
MSX!_&7XQ?%+0_B%\2+;PO\;M+TOP3XC^&5CX=^)_AWP_J%]::'#\ O#&DZA\
M2K;XR^/?$3VMOX;\1W'PRM;&]6VO]>,7Y]_LU_L/?'+X>+_P3@^"/C2U\+6'
MPF_X)?W/Q0U#0/BCI^MK?:E\?G/P?^+G[+/[.5CX?\+QRRZGX;-M^S_\7-<\
M=?M(77B^'PZGAWXY:3X=\#_!Z#XI?#B_UGXA:7J?\% OV:/C-\:/CQ#XK^&G
MP;NO&NAW/_!-+_@H3^RUJ7B:/7/A5H]M<_$C]I[4/V?=3^$NA:A%XM\;Z%XC
MNO#NB3?!/Q>_B/4&T2[TW0+WQQX4ET6+65U+QK<>$ #]&?AU^TK^SG\8-5\5
M:#\)?C[\%?BCKG@70?!WBGQOHWPZ^*?@;QMJO@[PO\1- 7Q7\/\ Q)XJT_PS
MKNIW?A[0/'/A=E\2>#]9U>&STWQ-H+#5]%N;W3R+BL6W_:W_ &5;I-/>W_:5
M^ DJZM\3_"OP2TPK\7O  ^W_ !G\=Z7I>N>!OA':!O$ ,_Q.\:Z)K>BZUX0\
M!1AO%7B?2-9TG4]#TJ^LM2LYYOY^-;_X)A?MD^-/#GA;P/X.\)^&?@?K-C_P
M0@^'G_!/FV\=^(=7^&NO^ M._:+\!>/_  EX^O/!GC?PMX;U;Q7J7B/]GSX@
M0>%M0\#>.+B/P9XNT_5O"OC#6++5_AUXBTN]U;1;SZG^/O[-?[:'[3GPF\'_
M !W\2?L?_LT?!']I_P #_MA_L+?M!:]\)/AU\9-,\=?$7XW>!/V+OC-J?C*?
M0O'/[25_\,/ACX9DU/4](U[7A\$? NM:9K7A_P !:=+?7VN_$BUU;XCZOX/^
M'(!^I&M?MM?L9>&M+UC6_$G[6_[,GAW1_#OCCQO\,?$&JZ]\>?A9HVG:%\2O
MAGX8'C;XC_#S6KW4O%5M;Z5XY^'_ (,9?%WC;PE?20:_X5\+LNOZ[I]AI+"[
M+?"?[;G[&'CW6M \-^!OVN_V8/&?B+Q58ZSJ?A?0/"?Q]^%/B+6O$FF^'? F
MA?%'Q!J&@:5H_BR\OM8L="^&7BCPS\1=9N].@N(-,\">(M"\77LD'A_5]/U"
MX_&7P[^P'^UII?QJ\*^,_'_P5^'7BG0KG_@N?XQ_X*.W%[X.^(OA;Q4?!WP<
MUO\ 9#\3?L]Z9#J>G_$73?A]='Q9H7Q#U+P1XWT(>%3X@O+W1O#&N>))K'P=
MXMT/P=X2\2>X>*OV&/V@_%_A+_@KAH7P@T#P]^S?\3/VC_VF_@S\;OV6?B9K
MM]HVE>%_$EA\%/@?^S)X$L/"WC74?@1XQN_BKX/\"^/?&_P"^)&B>+TLH=*\
M2Z?\(/CG-KFDZ?=>-==\=>!]# /U9TW]IK]G#6?!6J_$C2/C[\&-4^'NA>-E
M^&FN>-]/^)W@N\\*:+\2'U73="3X>:OK]OK4FEZ;X[;7-8TC15\'WMU!XB;5
MM4T[31IIO+VVAE\5_P""?/[5>K_MF_LWQ_'76K'X9V4UU\:?VFOAMI\OP<\<
M7GQ.^&&MZ!\#_P!HOXH?!?PYXJ\$?$6\T;PY+X[\/>+]"\!Z?XGTSQ;%X;\.
MVGB&VU:/5+'0-&M+J'3K?\N+#]D7]LFW\;_L[?MR>&_V/OAK\,_C/\,_VG]:
M^)OQS_9'N?VV_&_QR\<_'WPSJ_[+?Q"_9-TKXR:M^U+\2_",7A'4_C3\*/"?
MCBTL_A%\+]=T+2_#4/PJTSQ1I6H_'7P[KGCVV\(>!OT'_8I_9S^-WPY_9=^/
M/P6^,46@_"+Q5\0_VDOV]?&_@SQ'\%/B9J/C+5M \"?M-_M&_&#XP>"O%VG:
MW?\ PZ^'B^$_&_AJ#XGO#I&F6=AKD5O#X?T#Q/>ZAHNM:[JG@#P8 ?5]M^TK
M^SI>2?$6*T^/?P8N)/A!X;N/&7Q82'XH>"9&^&7@ZTO?$VF7?B[Q^%UL_P#"
M'^%[74_!7C/2[GQ#X@_L_1[?4_!_BO3I;Q+WPYK,%E)\,OVC_P!GGXUZYXC\
M,_!KX\_!GXM^)/!^B>"?$WBWP_\ #+XH>"/'FM^%_#?Q+T&+Q3\.?$/B'2O"
MVN:K?:+H?C_PS/#XB\$ZOJ,%MI_BK0Y8]6T*XO[!UN#^&ES_ ,$[?VH/$?P)
M_9>^&_BGP%HNA>+?V"_^":_[3W[%&FW'@3X@^%M5\*?M8>)OB_\ !'X=_ #X
M<)X?;7F\+ZIH/PF@T3X9Z?\ %_XC:!\7-/\ "-[X0^*3^#/#O@VV^*.E^$;C
MXA7GK7[#G[&_[0/P2_:?_8X^('C/X.P>$/!7P:_X(U?"W]A?QOK-AXF^&-['
MI?QM\$^/?!/B[6+73],\/>*;S5=1\%7$'A;53INO6>G,9=2U2Q-SI-E'/J5U
M8 '[ ^,_CQ\$/AQXH\,>!_B%\8OA=X$\9^-M4\-:'X.\)^,O'WA7PQXD\5:U
MXTUBZ\.^#='\.Z)K6JV6I:SJGB[Q!8WV@^%M/TZVN+OQ#K5E=Z5I$-Y?VTUN
MG,V/[5O[+FI_%:U^!&G?M)? ._\ CA>^(/%7A*S^#5E\8?AY=?%:[\5^!?#-
MEXU\;^&;;X=P>(G\7S^(?!W@W4]-\6^*M%BT=M2\/>&=0LM>U>VL]*NH+N3\
MQ_VJOV&/CQ\4KG_@IE\*=/\ #G@OXH?"[_@IAX+^%>D^#O'_ (BUBPM[_P#9
M$\=^$OA+X9^"&M:YXG\*>)9YY?%'@[X<GPCX?_:>^ H^%2OXJU'X^7GC;PQX
MAM/A7;W>B_&EOIK]D+]GWQ;\,_VHO^"C?Q/\8?"F/PIHOQ\_:,^$GQ&^%/C3
M4)_ASJFM>+O"_@#]D[X/_L^:GJ.H3^%O$&M>(=+U*X\:_#WXC^++&U\0VFES
MOX9^)MMJ4BV?B?Q)XZ\-:  ?96M?'#X+^&_'^@?"CQ#\7/AEH/Q1\5W5I8>%
M_AQK/COPOIGCKQ'?ZAI/B+7]/L-#\)WNJ0:[JM]J&@^#_%VN:?9V-A/<WVC>
M$_$^J6L4UCX>UB>S_)&3_@L7X"N/'/C7Q5:^*O@=IG[/GPS_ &\-,_8$\2:1
MK/B35+SXR^*]?\0VOPR\.:/^T%X'U;PM=Z]X(M/AS!\9?B=9>"[_ ,,>--)T
M'P^?AEHFJ?%^3XZ:=XJGTOX$WWGG[9O[$?[8/QE_:L?XG_#WX,? N;P=X$_;
MH_X)Q_M+^#O$ND?%:U^$NH_%/X=? VTAT;XL?\+KT#1?A/JGB'XE_'?P+XBB
MFDTCQ+\2_&?BGP#X<_9QT+X6Z-^S[X8\._&'3?BYI'Q7P])_9!_:]A^!?[8M
MC#\";ZV\;^-/^"QOP3_X*/?#'P7K/Q,^$]C<>/OA#X)_::_9G^,FK> H/$&B
M>-?$^@>&/BE:>'O@1X@MI['Q/=:?X+74=>\+C2_&>L!]<.B '[C7GQS^"-GX
M_P##OPIOOC%\,;'XH>,-+O\ 6/"7PZNO'_A:T\<^*=(TK1CXDU74O#?A6;5$
MUW6[+2_#O_$_U*YTNQN8K'0RFKWC16!CN:YWX6_M3?LQ_'#^WU^"?[1WP'^,
M+>%=%L_$WB@?"_XO_#[X@GPWX<U"^US3;#7]?_X1+Q#JQT;1+[4?"_B;3K+5
MM1^SV%Q?>'M<M89Y9](OXH/R?\%?LA?M::?^UGKW_"\_@7\-?V@O@O!^U!K'
M[;OP=_:*U?\ :Y^-&IZG\"==U31EOHO@?X?_ &1M?L_#O@+Q;\5/ FO:IX_^
M$_PC^-L?BSX>>![/X)>*?#'BCQ1H$.N>&-=^#GBOZJ_X)'?LV_$+]E/]A/X0
M_!'XP?#W2_A_\4/ NL_&5-=L=*O_  AK-K<:9XX^//Q.^+&AS6.M>#]0U*RN
M;*6P\?QRWMM<R6US!XB;7':UE22'5-0 /+O&O_!6CX>ZIX6_9#^)OP"@\'>-
MOA'^T'^WQXI_8L^(OB_QMXBU'P=K/PNMO 8_: 'B/QX?"4NE%HM-OQ^SSXJU
M33I_&VM>#9M+\+ZEH'B*\T748-0N;;3/T'L?VJ/V8]3^#5C^T7IG[17P,U/]
MGW4XM9FT[XZ:7\6/ FH_!Z_A\.7NM:;XCFLOB79Z]-X,NH?#VH>&_$=GKTT&
MM/'HUQX>UV+4FM7T?41;?BD_[%/[74O@S]C;X8:Y\"M"U;2/V8?^"V'QK_;8
MUKQ39?$WX?:M:>*/@AX_^,W[:?Q<T'QMI7A_7[O0KK3]9T67]J'X=1:1H=U-
M+XJ_M_P+\1-1FTW0$T;X?W?Q!\]T#]B;_@HA\*1K/QD^&?PL3Q5J.D_\%!?^
M"E/QJ\3_ +*E_P#M8:[^S3=_'/X$_MR?%/1O'_PP\:>%_CI\"_$OBC3?"/Q@
M^!]_X<\/R:QX6^(FE7GAO6?".O?%KPUHFLKJ]WX7U;4P#^A3QMX\OH/@[XC^
M)OPED\&>/IT^']]X[\!3ZAXIN+7P#XPMTT)O$&B3/XT\+Z3XON+?PWXAL1!+
M;>)-#T'Q*J6=Y#J=CIFKQ%+:?X\_9B_:]^+'QX^%7[+/QZ\1^!/@CX1^%W[0
M?[.WP[_:,^(%E8_&ZZ?Q]^SYX.^+?PEC^)/@35_$NC>)/!WAS3?&/@Z;6[?5
MOAOJ_BNRO_#EQ;:W!9:YI_A[4-$A\62>#_2OA]\'M5^ W[$6G_!GX>_!;PEH
M6J^$_@]KGAKPK\ O@QXJDN?!OAG4-<M-4?3OAQX0^(/Q:OO"\OB#1_"EQK*:
M-<_$;Q/:>"I/%\>F7GC"W^'W@LZM:?#W2/BC]A'X"?%C]D3X&?LD^ _"'[#F
MF^!?BYX*_9F_9X^"?[9'Q5MM<^!-LGQ0T;]FSX(^+H[73/A?;^#/C)%<?$#X
MA^*_CEX@O++P;XE^+]A\.M%TKP?X\\=^,O%WB.WU;3=)\%:\ >1_#[_@L-XL
M^(G@K]D+XS64_P"RQX5^"G[?GB2U\ _":7Q-\0M8_P"%L?LO^,8?"WQ;^*4U
MQ^T%X)@U.#PU\4/#&I_"/X;6]UJ-[X4\>?!N^\ ?%G7_  Q\-IK/QUX6\70?
M%?0/UJ^"?QKU#4;;P9\(_P!H;Q?^SKX;_;$?PMJ^L>.O@U\'OBO)XOM[B+PQ
M=Z3!JWC#P5HOC#2/"'Q(/A6YTCQ1X"\4:KI^J^%;B3X>M\0?#_AG4_$OBB&?
M1?&/BC\@?V=_V2?VK_A1^R1_P15^"?B3X"^)[GQG^P1\;M%\9_'>;1O'OP1N
MM';PYX=_97_::^!,EQX*OKOXKZ=/XA;5/%'Q\\-ZCIMI<VFDW \+>&_&-SJ<
M&GZK!X:T+Q3WWPZ_8U_:^3]H+X@^!?BOX#\':]\*]-^.O[8_[1?[//[;L'[6
MWQZUGQC\(8?VG-3^.K^$/!?A+]D'59H?!/AOXX?"G1_VA?%_@#3?B?H7B30_
M ]E\*M/AET>V;QI<O:2@'WW^TG_P42_9%_9=^$/Q\^+OCSXS>"M=@_9Q\&/X
MR^(O@#P#XBT7QI\4+.&ZU77O#7AS2T\":'?W>O6EUXK\8>&/$'A+2-2U:UTW
MP[;:MX?\3S:WK.E:5X2\4ZCHVGK/[6OPU\%?%/XHW/Q"_:0_8\\)_L^_#SX&
M_"'X@:GJ.K_&C0M$^*?@G7_'_C#X@V%QXS^*46LZU;>"_"GP'\7^&K;X<V_P
MC\7W5]:W?B;Q>GQ"MI9I=,M-"DF_'GQ!^PK^WS\;/^"7_P 7_P!D;XM_LU?L
M8_#[X^?#'_@GYJ?["WP5^+_P\^),7BC7_CL-,T+X6QG4/"UY;_ SX3Z;^S7\
M#/&D_P ,-(NW^%=V-7CUOQXNA2ZGH?PJ\*_#31M5\;_<VE?LS>/?C;^VI^TQ
M\0OVA/V>!H/[/O[3_P#P3?\ @S^RCX]T*Z\?>"]?MM:U;2/B/^TSXC^)G@G7
M;CP=XGL?%QBU'X;?M"Z!X/;Q!I>EQ6D?B/PQXXT_1]=F\/:7X'\8>- #]%#\
M=?@FNLZUX<;XN_#-/$/AOX>Z7\6_$6@R>.?#,>LZ#\*]<EO(-%^).M:6^IK?
M:7X#U>?3=2M]+\77T$&@W]QIVH06E_++9721;O@+XD_#_P"+7@ZT\??"7QYX
M*^)?@O5+C7[#2/&/@7Q-H_C#PEJ&I^%]=U7PKXCL+;7_  Y>ZCIMS=^'/%6B
M:SX:\0V=O=/=Z-KVD:KHVH16VIZ?=VT/XPZ]^P]^WI<?L#>&_!NH_%+PA\2O
MVUOA=\1?V;'M]3NOB5\1_A-X.^._P+_8L^,T-W\// /C+XJ>"K?4O'7AKQM\
M:OA_9>)?C+XF\>)HM[JV@_M ?$^709]1@\#>#?#.H^'?O']@_P"$7BCX4?"3
MQ[KGCC]GSP=^SE\1/C3\6/%'QG\=?"SP;\:/%W[1.N-XHU7PSX/\&2Z_\1OC
MKX].FS?$OXF>*=/\":;J.JZQI^EZ!X?T;2IO#_A!7U^^\-ZIXY\4 'RWX0_X
M*!_M:>+?V>OCO^T5X;_9(^'GQ&L_V:/VC_VE/@=\3O@_\//C?XGD^*?BCPQ^
MRK\3_&?PQ^)?CSX+MK_P<T_P_P"-_&6IS>#KCQ-X&^#OB*X\#OXEL+@Z"OQ%
ML_$BV%EJGV]\._VXOV1OB?X-^!7CCPQ^T1\)(]*_:6\+_#[Q;\$=/\1>./#_
M (2\5>/M.^*:7X\!6&D>#O$VH:7XH/B7Q#?:1KNA6GA2;2X_$0\3>&_$WAI]
M-77/#NLV%E^;7P5^%'[>?PS_ &9?VL?@E\._V==.\)?&+]IG]K']N[XO>!OB
M1\9?B=\*U^#/PD\#_M5?&/XH?$SPAXD\>VGPQ\5_%7XB>+/&G@GP_P"*M*@O
M/AKX6\"7/ASQ+XY6+PY<_$_P_P"#I;_X@Z?\V:__ ,$P?VJO@[X'\(?L[?!7
MX>_#/XG?!S]GWPS_ ,$EF^$?Q#L_B58_!;XC?%EOV(?VI-)^-GQNTOX\VB^%
MM9UCQ_XFU>:/Q9JWP/\ !GB_QUJ/[/OPPTOQMJ6J^%])T7XI6=Y?^)0#]H/@
M7^WA^S'^T-9?M$:W\._B;H,GA;]F7XX:K\ ?B-XJUZ]M_#.C+XUT73?"KWM[
MICZ]+I]W<>%+WQ/XEN? _A3Q3-:6^A^/]=\.:K?^ +[Q/X9N]"UW5OISP5XV
M\&?$GPEX<\?_  Z\7>&/'W@3QCHVG^(_"/C7P7K^E>*?"7BKP]JUNEWI>N^&
M_$FAW=]HVN:-J5I+'<Z?JFEWMU8WEO(DUO/)&RL?Y\;[]B?_ (*$>"H_VA=:
M^&_@7P)JFKZ3_P %9OB/_P % /!OA6T_:E^(7P>T[]IOX(_&;]F_Q3\&/$WP
M3L_B3\,M)T7QQ\)_'/A:?QK-XDTO6O&-@/!MQX_\%>&5N=.UOPG=W6JVWZF_
MLF^$OC!\'O!WP>^'>H?LT>!/A3X<\>6O[0/QA^,\?A#X_>(/BDOP6^*_CCXD
M:'\0]*\%W_B#Q]H2^+_C]XN^+.L?$;XI>+/B1\5K2X\*:'H'C/PMJ$%GI&OZ
M9XLT75HP#[HHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@#SKXG_  ?^$OQM\-IX-^,_PN^'7Q=\(1:E;:S'X5^)
M_@GPUX^\-QZO9PW-O9ZJFA^*],U;3$U*UM[V\@MKY;474$-W<Q12HD\JOIP_
M#KX?6^L>$_$4'@3P;!X@\!>'-4\'>!M=A\,:)%K'@OPCK8T-=:\+>$]32Q6]
M\.>'-77PSX;74]$T>>STR_'A_0Q=6LHTFP^S]E10 @ '3CM@=/RZ4M%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M1\'?$UZ-4\ ?#7P1XY^*/C#P_P"&M:^'^N_'WQC\6XO"7C7Q%%I]\FG?I+0
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>ex10-8_002.jpg
<TEXT>
begin 644 ex10-8_002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" /+ NX# 2(  A$! Q$!_\0
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MVHW<-JY$\MK87&HZ=!>7"(8K:;4+"*9T>\MUD -"BBB@ HHJ.65(4,DC;47
M)P3RQ"J  "22Q   ))( !) H DHK.TK6-)UVR74=$U/3]8T]KF^LUOM+O;;4
M+,W>EW]SI>IVHN;26: W.G:G9WFG7\ ?S;._M;FSN$CN()8TT: "BBB@ HHH
M_P ^O\J "BHH)X[B,2Q,60D@$JRY(.#PP!X/'(Z@BI: "BBB@ HHHH ****
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M?O WPX\;V_CGY=\0?MZ?MB>(?V0YOA_IOQ,^-^B_M8R?L4_LU_$CX<W5_P#
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M:$M_B#\;+'Q5X\^(FEZ9^P-\//B5XR^-_A?P]\*-!T_XE_M,>$O!7[)5I?\
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M$[X6_!GPUKNB>// 7[-OAZ[^)7C+Q!JCZQX4\6>,/B!_:'P2^%_@G1_"NA>
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M^*O"7P&^%W](V!DG R< G R0,X!/?&3C/3)I-JGJJGY@W0?>  #=/O   'J
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M06,%U?16=CI=K%>744"W-U!;Z;806]Q-+;PV=O'$D2=)2  = !GK@8S@ #]
M!] !VI: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M5>3<0\BQJ% )+MG:.2  2,9) !(R0.: )Z*JF[C#;/+N"Q!('V>49"YR5W*
MPZ9*YV[T#;68"C[4A4D17#'!(00.'R"0JE6"E"^,J9-B@$,[(.: +5%4_ML>
M\H(KDL A8"!R5$CL@9E^^%RN=VW:REBA;RI_*\^\+>,/&.K^,OB1HGB'X;:Y
MX0\*^%M=\/Z9\/O&VH:_X2U>P^+VE:MX-\/>(M7\2:!H>@:I>^)/"5GX5\2Z
MKKG@*_TSQWIVB:QJFH>%[KQ!HEG?>&;_ $W5+L ]-HKY)_9?_:QT+]IK6/VH
M]$TKP)XV\"W_ .RY^U)XS_99\16?C-_"4]YXI\1>"OA[\+/B)<>-= '@SQ1X
MNTRV\(>(-*^*^C/X<AU76+?Q*+&W^T>)]$\+ZU<7GAK1_JM;R)BP"3_+Y8)$
M$CX:3 V,(U=HWC)'FI*(S&I$C 1$/0!;HKF/%'C3PIX'\,>(?&WC;Q#HW@[P
M7X1T'6/%7BWQAXKU.Q\.^%/"WA?P]IUSK&O^)?$GB/6)[/1M#\/Z'I-E>:IJ
M^LZG>VVG:=IMI<7]W<Q6D3S#RSPS\7]7\<>)_ <_@[P-KFL_!;X@_".3XHZ5
M\=6U/PUI7AZRU34KOPA<>"?AS?> =9U"P^*<>O>,?!GB;4_',&N2>%8?#>B6
MGA:[\/:_?Z?XFU32-+NP#WJBJWVD9 \F?<3PI0*V/DR1N8!@N_+;"Q 5^,@;
MDCNXY#&%63$J[XV*$(Z?WU;)&WE??$B'&TY !:HJ.218EW,&.650J(TCDL<?
M*B!F; RS8!VHK.V%5B/F[]HS]I3PS^S[8_"FUU#3K_7/&WQY^,OA7]GOX-^$
M8F72[?Q1\5_&VA^*_$VE6NO^([F"[M_"7@_P_P"%/ WC/QMXT\2KINOZK8^%
MO"NK1^$?"7CKQG=>&_!/B, ^E:*\@^"GQ"\5_$WX8:)XW\<_"KQM\#_%=]+K
MUAKWPQ^(5YX3U#Q/X:U'PSXBU;PU=3/JG@G6O$7AC5O#WB%]'/BCP5KUCJ4<
MNN^!]:\.ZQJVC>%]8O-1\.:3J?#KQAXN\3Z;X@N/&WPTU_X::CIGCWQWX<T7
M2M7USPKXGN?$W@OP_P"*]7T?P3\2[6;P=J>K6VCZ-\2O#FGV?C#2?#>OO8>+
M_#-IJ<>A>,-*TOQ#:W5F #TNBH6G"QI(8YOG Q&L3/(K%2VUU3<%(P5+$^6&
MP"^""?DO0?VKM(UO]LGXB_L8GP3XWTSQE\._@!X"_:/F\;:E'X3;P1XH\#?$
MKQSXN^'?A^W\*V^D^)]7\8OJ&F^)OA]XWL?$,'BGP[X5N+6?1HGTJUUK2]3T
MO5[L ^NJ*H27@9"J+.DC@B)O(+@L S$QE=T<A$:F1&#-$^40,S-Y=?"_A#]M
M+5_B1\6?VDO@U\.?@'\4?$'C']E/]H3X$?!+XK6FJ>(OA%X>A_X1SXU>%_!7
MQ(O?C7X:N9?'%[#JWP]\"_"?QOI7Q N/#DLMI\6?$<4=]X5T[P+;>+(X]((!
M][T526\0*-R7&0&8LT+A=BX)D9V5%1<;MN_8TGEL(U?*%Y([J.6-)$2;:^,;
MH70J-VQB^\*%"<EMQ'RJ2N[@$ LT5SGBOQAX6\">'O$'B_QKXBT7PCX0\):'
MJ_BCQ9XL\3:I8Z#X8\*^&- TV[UC7O$GB37]5GM-*T/0=$TJQN]2U?5]2N[:
MPTVQMYKR\GAMHI94^3_#'[:O@KQG^U'\*OV</"_A/QEJVG?&?]CGQ+^VEX ^
M+[)X;T_P+K7P_P!!\??!WP&OA:UT"ZU\?%&T\82?\+B\.^*+]O%/@3PMH%KH
MMW8V&D:MXAU^/Q/IGA, ^TZ*I)?12%@L<^4D$3CRF.Q^I#[=VP*,$NV$P>&)
MR!<8A5+'HH)..3@#)H 6BJ4E]'$I=XKD(H7+>0^ 6.-O."2/ER0"K%@J,[!E
M5ZWD;8PDY#*&#""1E8,I8;&1660;0"7C+1Y= '+-B@"U157[7%^[RLR^<Q2/
M=#(-S ;@!\O.Y T@(R!&DC.5"-BR2%!)X &2>  .Y).  .I)X YH 6BO-?A;
M\8?AI\;? ^A_$SX2>+])^(?P[\4_VQ)X6\;>%I7U7PQXIL=#U[4_#EWK7AG6
M($-EX@\-W>HZ1>2:#XFTB6\\/>*-)>QU_P -:GJVA:IIFHW??B]A(R$N" [(
MQ^SS 1E" QD)0!0H.XD\;02,\9 +=%?)G[+/[6/AS]J2U^/MYH?@KQWX%_X4
M!^TK\2_V7_$>F>.X_"9U34/%_P *+3PY-XB\16!\$^)_&.BIX9U.Y\21Q>'Y
M9]>.I75A:0WFJ:;H>H7=QHUC]4/>(@W-#<A1U;R'*CG'.,D\$," 0P.U2T@9
M  6Z*Y+QAXBO_#_A3Q/K^C^&M=\6ZMH/AW5]=T_PEH3^&K'Q!XLN]*T^:_@\
M,>';SQQXE\%>"K?7==FBBTC2[GQ;XS\*>%K:_O()]>\3:+I45WJ=MY?^R_\
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M)C[[K/[:FJV'[0GQA_9E\.?LL?M*_$7XD?!_X1_#SXVW-QX0U+]E.P\,^._
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M^-/$MW]CTC0M&L5&^:5E62XN[NZG>#3]*TK3X+O5M;U:[L='T>QOM4OK.SG
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M?Z%;Z9X2\*^&/!NEV'@GP5J>O7W@7X96%]X4\#^!-*\46_PS\,^$E\=0> ?
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M\%_&OC'3=;N=&\">!?!M[\=O .O6OQM\6OI/PXU7PEI_C^[@UA=9\/Z7X?\
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MQQ8?$%O"%]HOB6^_3JS_ &D?V>-9^&NL_&2P^-_P>U+X->'(4N]=^+EE\4/
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MXA_#?71X2MO#OC/PKJH\=:3JGB'P+%HOBO1KX>,O#VBMI7]M>(O"0T_59?\
MA)="TIM>T1M6U?1/M]C82:SIHOYX9M0MUE[MQ'#&[L)&4#Y@&EE9@21@(69I
M&.\@(H:1\)&BL5C0 '\B7[*G[3GBGX]_#W_@F9JO[3G_  4D^+WPR^%7Q0_8
M)_X*/6OQP\9Z#\=_A+\%+'Q?X]_9M_:,_9^^&/P\\:^)?BO9>$])\46WQ:T'
MP'\0;CQ+K7B/1?'&CZYJ=SX)T?4WAC\-^)_C/HOQ7Y']IC]MS]MCX>_L/_"C
M6OBK\<?BM\%OVXO G_!.;X1_M/WWA&^M['X2:7X@\5^'OVCK&RU+XK7WPLT[
M0[[QC\:OBS-\,/ UL?VMO@/XZUGPM\ /V7?!/C[7O'OQ6^%E_-XCA\*^%/Z-
M/!/AGX(_M6_&KX(_M_?!']H/5/B1X<\ ?"W]H/X#> 9?A3XF^%WB?X"^.?#?
MCWXB^"X/BQ?77B:V\ ^(/$_B36--^)'P!\'6.DZIX/\ BGIWARSE\"LMI::E
MIFO>)1KWW-';JJ*'+,^(S(^]P9)$1%\QMK %OD7!QQM&,8% '\K_ ,;_ -JO
M7]"\9_\ !0/XK:#^WQXQFTK]FS_@J?\ \$Q?!WP0T"#XS?#G1_A?I?PB_:8T
MC]B:T^,OP]UWPSH6F:+H'C7X;7'A+XE_M!6^GZ=XVCUJ+PQ-\.=<\>PWR?$+
MPCX[\:7GW=\%M#^-G@[]K;XO?L(>+O&/[1'C#P"OQ@\(?M]?!;]H#Q'\6OC=
MK]Q>?LK:@K17G[,=Q\5)];O-.NM=^&G[3OAK3? NI_"?Q3J>H6'Q,_8Y\<Q:
MSKJZ[X_C\0>*W_;1XLJQ0MO^8J3++C<<G!PX.PD\J"%X7&-BE?#OA5\&)OA=
MJGBKQ!JGQ'^)'Q;\1>+-1NC+XF^)EWX1N]?T'PD/$GBSQ-X5^%^@CP-X-\":
M0_@GP+J/CCQ';^'+_P 1:7K?C^?3;RUM?&GQ \6P:'H3:0 >IZYH4&O^'[O0
M+_\ M:&SU6QOM-U"71-?U?PWKMO:ZE8W=G=SZ7XF\.WVE:_HFL)'<N]CKGA_
M4M,UC2]1,&IZ1J.G7EM;WL'\MGA3XD_MP_"*#]G;6]>O/VD?BQK'[$G[2?QI
M_P"";?[5&E^(?B7\6-/T3]JWQ9^T7K6MZ+^P[^T3>-??$N"*]OM$NO&?[)M]
MXY^(5]I$>@6MO^UAXCM_#\WAVR^!.@Z9X7_ID^&WQL^%?Q@\!VWQ0^&7C?0_
M&?P\N]2\9:1!XQT:Z$F@MJ/P\\6>(? WCJU>_F$,4+^$_%OA/Q)H>LM,8TM[
MW1;Y%:1(MYC^#_Q=^$'[0/@'2/BK\$/'_A+XL_##Q!<^(K+PU\0O 7B.Q\5>
M#/$Y\+^)=;\%:_+X>\1:5>7>EZ]IECXE\.ZYI*ZG87%SI5]-9W%SIMW>6DZW
M4P!_.'^W;\3-;^&R_P#!7;]E7Q/^TSXF\>^ /AW_ ,&[LFOZ+X3^)OC_ $/4
M=1MOBWXATK]K7X2^(?%,XNY4\4:SXU^).G>'_A5JVKW_ (QU7Q3XGN=8\>:'
M96>JP:-XA\*:)%]E?L@>/_ ?B7_@J5XDM/#GC?P?XANKW_@BW_P3LN[*VT+Q
M/H>KSWMG%\</VP==EO+.'3[ZYDN[2/1/&/A#69+JW62W32O%?AG46D%GKVE3
M7?Z^_"/XK?"_XY^ M(^)WP=\7Z+X]^'FO7GB&RT3Q9X<N7N=&U*\\*^)-9\'
M^)(K.8K$S2:1XGT/6]#O3Y:%;W3KF-2\:([>B2>7!B0B4Y+ *CR,I9C(_P!P
MOY>7=BJD@?,T: @! H!^77_!93Q]\2/A;^PIXC\?_"KXX>-/V>?%6C?'S]C7
M0[CXE^!KKP/8:IIGA/XF?M@_ SX1^-XK[4/B#X4\7^'K/2$\)>/]8U*XENM,
M2T>[TVQAU\ZGX3E\0^'=<_.?6?VBO''PBO?VJ[1_VFOBUXO_ &(=2_;Q_8W^
M&?[/?[25U\3H[K3/[>^)OAF/5/VL?@IXV_;+UJ+QN_PZ_9;T'XA:3H?A"]^-
M?@^TM=>^&?Q*^(?C#]E;X4>+/#_Q+T32-(\$?N+^UM^S#X;_ &Q_@PGP8\6^
M.?B+\//#MU\0O@]\39]<^&DO@6U\5G6/@I\4/"'QH\#VAD^(?@/XC^'UTR+X
M@>!/">IZQ;?\(]]LU"STR721?V]C?W\=Q],QP*FUF9I)@H#RL<-(VU%9F5 D
M8W^6I94C1,@80    _EM_9B_:,^/^A? C]D#]N/Q!\3OCM^TO:?!O]H/]J_]
M@;]KWX)Z5XD^(>H:BVC:M^UG\8_@A^Q]\2=9^%,WC#2AJ/Q\^&.M:7\!?AOX
MU7XD>%?&GQ5\1_"/X[2_&/XIMJ_B_P &>%/' _I ^!'@+5_A?\'?AUX!\1>+
M/$'COQ1X8\+Z?8>+O&GB?Q1XL\8ZQXI\8LK7/B[7I=>\;ZMK?B22RU/Q+<:I
M=Z/IEUJ#V7A[1Y;#P]H=KIVA:7ING6G#?%;P#X97QC:?&/XE?&3QAX=^$_PY
M\*Z9JOB+X8Z_XB^''A_X!+J_@7Q9%\0?#WQD\::QKW@^'QW8^)_ >IZ59W%I
M<)\6M%\ O:V=K?>)/".JZAI%AJEIZ=;?%;X82_$.#X.0?$#P2?BQ)X/O/B"G
MPM'B_P .O\1AX#L-2TC1]0\:OX(75'\4GPG9:SXB\/Z3>>)QI;:)!JFOZ+8S
M:@MWJMC%. ?S3^,OB-JO[.?[<7_!:_Q!\-?%7Q#B^)TGQ)_X)D^,-?T71_&/
MC[XJ?%#PS^QQXJMO@QIO[9/QV^%OP3U?4/'DVM:9\'OA_KWQ&D\'>)-%^'NN
M:#\*-9#^%O!VGQ6K3^!-9_5/]@[XA>+?%'Q[_;-\,^ _BI<?'_\ 8H\/:A\
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MJX,5NHE=;IP&"GRI9WV^8R*&9/-&X;@BC 9QN8JNUI29O)B/ED;P$ V;995
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M-LQ_+0!_(YJ?[9'C)?&OQ,^-FA?M[^-_$5AX#_X.+OV>/V:/ &EK\9/A]/\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 $X!/IS7\^?_!5C]H7Q+XDO?V_/V3F^/5O^SYX?
M\#?\$?OBK^T;X8T.UTKX82^)/VB]?\90?M#>%O'&D7&I?%3PKXL=_A_\&_#W
MPD\+:1XPTGX86GA_Q?<C]H.YO[WQSX8O/#WA"YF_H,KRWXD_!'X0?&&;PY/\
M5OA=\-_B7)X0GU:[\*M\0O /A+QPWAN\UW2;C0=:NO#[^*='U9M#N-7T2\NM
M(U:?2C9SZGIDSZ=>RS6#S6TH!_.KX6_;A^-UM^RK\8[+X,?%;2/A+>_L(?\
M!);]B/\ ;!^ .BVFA_#SXC^%_P!KBWN_@Q\0/&GC,^+3KFCZ[XD\0?!'Q#XI
M^#NE?LP2K\"O%7@'X@^%_$&I>.=8MOB!-XI\4_#-/"GB_P"TQXA\1>*?A%_P
M=!^)O$WAF]\#>)O$/[%/[).M^(?!-WJ$FIWG@W6M:_8 O=0USPI=:BUIISW\
M^@WMW=Z3=WC:?8&\>VEGDLK;S6@3^I3Q!\%?A1XKE\%7'B;X;^ ?$%S\-;RU
MO_AM>:WX+\-ZO>_#J\L+K0[[3[GP#<ZEIMV_@NXL;SPUH%U:7'AK^R[BTNM#
MT2ZLY;:XTBPE@Y;6?V7?V<O$<GQ"E\1_ ;X*>(9/BZ;#_A;DFM_"3X>:I+\5
M5TF[AOM)3XCR7GAN8^-ETN[MK>YT\>)!J1L[B&*YMC%<Q0RQ 'XX?M9_M]_%
MWX2?MH^ O#W@3]HOP)<?"71?^"B7[)G[(GQ9^%NH^#_ ?AK0_#6A_'?]G?Q-
M\0O'WAKQ;XD\4:EKGQB\>?$G1K36/"7QHTCXC_#^Y^"'P2\"^')_ O@*2?XY
M>)/#?[1/A3PKR?@SXT_\%%-0^#6F_%E?VHS\6/&OB/\ ;^_:K_9(L_V?=+\)
M?LH_L]^+_B!X _9V_:P_:>T&-/V8/%?Q7\!>*?!M[^U!_P *R^!M]+=^$_C=
MXAC^%GC7X'^$_%GA.RU+X9_'2-/VF+O]P[C]FG]GV[O3J5S\#_@W/J1MOAE9
M?VE/\*? ,^H"R^"FK-K_ ,&+,7DWA^27[)\(=>;^V_A?;9\GP#JSS:CX532K
MR1)XH=-_9A_9VT;PC=_#_1O@3\%M'\ ZAXCU'Q?J'@32_A/X L/!.H>*]8L9
M-+U?Q/?>%;;P_'HEWXDU/2IIM-O=?FLVU:ZL)9+.ZNY[266"0 _,;X^_MG_$
M>T_X(8?'/]LOX)^+O'WBGXO^'?V5/BOK6C>-?B!\)8OA-\5/!_Q+\)R^(? O
MB_6?'?PB@TR31O!7Q$^"/BC2O$$OBS0[2RU'P19>)O NHW-G>ZSX.,6J7G#_
M +=O[+MCX'3]CG1_V,?C+X9^#'[4/[*?A3P?X'_9Z^"OQ'TQ_$_PC^./P&UK
M]J+]B[P[XJT+XRZ58V4?Q!M?">@?'#P?^S/XE\8?%[X5:]IWC[P[>2>;KND^
M,K+QQ8:4W[;:Q\/?!'B'P#JGPMU[PGX<U?X<:YX4U'P)K/@6^T339O"&J>"M
M6T>X\/ZEX1O/#GV<:3-X:O="NI]&N-%:U^P2:7(]B8?(.ROF[0OV-?A/JOPJ
M^'WP;^/?A_PS^U%H7P;N=-A^&/B7X\> _#GC7QEI.C>&I]./@_\ MG7]9M;\
M>(/%VEZ3I6D:)XB\:V]OHUYX[M])CN_%NG:CJ.IZ_=:J ?B_\??BCX$_:*_8
M._X);?';PO\ !33O@LWB/_@L1^P]?3>!8;OP]XKTSPAX]G_X*(7'AWXT:A\-
M?'FB1?8/%GPR^(GQ)T3Q1XU\ >/=%BT:R^(_PZ\2>%_%2Z!X?M-9A\.:7^@7
M_!63Q?X:\1?L6_'SPI8>*])OK#P1\0/V0)_VH?#FC>)X)]1\&_LQZU^U-\%M
M8_:&N/BEI&D72Z]X2\ ZM^S!:?%C6O%]YJ4=A#J/PLM/%>H)++I]O<20_?GC
M3]GGX%?$G2?"N@?$?X,_"3X@:%X'-O\ \(9HOC;X:>#/%>D>$!;6FGV4(\*:
M9K^C:C9>&Q%;:5IEO"NC062PVVGV4$:A+6W,>=X3_9Q^%7@SXJ_&7XTZ+X8T
M.#XC?'G3_ NB?$CQ)#X6\&Z5J6O^'/AMX7'A7P9X>UF_\/\ AO1K_P 8V.AV
MESK5S8WWQ$N_&?B&R77;CPYIVMV7@/2/"_A#00#\%OVFWU*]_P""HNI7>DBZ
M/[->F?MS?\$@M,_:-O\ 25FM_ </[05I\(OV\+SP?9?$34-/\I)?',7Q-U[_
M ()5P017T[R'4-4_9LTN^5M.N=/M7J:+<Z\_[>/P^UJQOM/M?V0)_P#@NU^T
MUIU@TAL;/P/J7QEMO^"4.G>%M+FT:XGM($O'M_VY-%_:D\,:L;?4&T74?VIY
M;W3;NRO_ (F+X?DMOZ'M%^#GPM\.>";SX:>'OAUX!T#X<Z@-76]\ Z'X)\,:
M3X*O!X@O)-0U\7OA*RTN'PW>?VY?3W5WK!N-*D;4;FZGN+DO<2R2O+_PJ/X:
M'P':_"P^ ? O_"L;'2;30+3X;#P;X</P^M]!TXJ=.T2#P4VG-X:M])L&BMVM
M+"VTV"WMS;IY,<8"A0#^<#Q)XN\:^$?^"5G_  43_:?\(7]EJ3?LZ_\ !1W]
MM[]KK]A3Q%H::9=VKR_#+]K[7/$,UKH=_I]@+_4_ WQI^+%S^T3\-O'*:5J/
M]J_$;X-_%[QSX5\->)K+PYXSTF:S_5O]M#]I+Q5\*/CI^PA^S]I_C*^^#?@_
M]KWXY?$CX=>*?V@([+PK>2>$=0^'OPF\5_$GP#\(?"VH_$[PQXL^&FD_$7]H
M'QGHVD>%] /B[P]XEN]7\&^&_B1X5^'NBV_Q$\1>$_&W@/Z3^*?[-GA'XGV_
MP<\%:D\.D_!KX5>-_ WQ$D^$WA_0++3]!\5>(?@WKGA_Q9\ ]&OKRWVQ>'OA
MU\)OB!X:\._$NV\%^%;#0YO$/B_P)\-K34?$,7PZT/QI\.?B7ZK\0OA/\-_B
MYX3U/P!\5_ 7@GXH> ];DLI-:\$_$?PCH'CGPCJS:;>0ZAIYU#PUXGL=3T.[
M;3[ZVMKNP>YL)FM+FV@GA*RPQ-& ?S)?L&?M0^,?A_XB_P""=WP8T;]K'2]1
M^&OQG_:8_P""_7A']H76)$_9_!\6^/?A1^U+\<OC'\/O&]_JR^#+D>#/'$VD
M^,C\6$\,>$]1T7P1J7A+6-/UJ7P/J'@UX+@\=^SI_P %9/VCOC;^S-\&-'N_
MVP?V<OAO^T'>?L>Z-^TUHWQP^/\ X^^%WPN^''QX\=V7[5'[2GPM\:_#?Q;X
M.\+?LU>/]&\2^'OAYI_P2^%GAOXK>"O@-XA^!7QD@T/XVW4GAOQ!I'C-O#OB
MGPM_4+?? 7X+ZKI?AK1-6^$_PQU31O!GQ$MOB]X/TG4/AYX.NM,\*?%>RUK5
M?$=C\3_#6GS:,]IH'Q%LO$.N:QX@M?'&CPV/BB'7M4U+5DU1;N_N7DIW7[.W
MP*OK'X<:9?\ P;^$E_IGP:US3_$_P=TN]^&/@:ZTOX2^(]*G2YT[7OAI8RZ$
MT/@76;*YAM[NTU7PM_9.H6EY!'<6MS"RJJ@'QW_P4;^)WQV^#W[*L?[37P;\
M=^*?!T/[-OC'X4?M#?M >$O#GA'P)J=S\5?V4? 7BW0=6_:L^'LT?Q?\&ZMJ
MOA>>S^!=SX^\;:)>^%/^$3^)\/B'P7I'AK2[Z/4=6O[2#Y7_ &8_VCOVE/BK
M^UW\4/V>-?\ C+\1;O0-:\>^!?VX/V>O$VK^#O@0FE>)?^":'Q!^'GCCPEX3
M\)I/H/P6\-2/>W_[3OA'2KWQ!H^OBR^.VD?!'XB> +0>/]$\<Z7\0;VQ_<?4
M]-T_6=.U#1]6L;/4]*U6RNM-U/3=1M;>^T_4=/OH)+6]L;ZRNXYK6\L[NVEE
MM[JUN89;>X@D>*:-XW93CS^%-%N9Y;JYT[3+BZGTEM!N+F?2[&>>71'F>=M%
M>6:&1Y-%\R1Y!I,YFLC*1*\3NH- '\LGP-_: _:&^/WQ"_X(/_%[XZ_M->-9
M=?\ %G[8'_!6WPW\2K;0K#X;_#KX9^+[/]G'3_VW_ _@G4M:\$6/A"73%:Q^
M''A#3?AXDVIZGJ5WH7A:ZUC6M&U:Q^)VLZO\1M1/^"6WQC_:"^%NE_\ !)KP
M!X>^+%O/\&_VMOB5_P %=_A9XU^"^M?#WPG<>&_#NL_!7X\_M0?&OP/\5_#W
MBZTATWXM'XD'Q%H=_P"#_%^G:GX_NOA5K_P[OK:UTKX7>$O'VFW7Q"U?^C^S
M_93_ &:=.\/>%O".F_L^_ S3?"?@;QP/B;X(\+Z=\'OAQ:>'/!GQ*$5Y$?B+
MX3T-/#1TSP[X\>/4+Y'\7:3:VFNM'=3Q_;0DTZRP:5^R1^R[H(\*#0?V<_@+
MH@\!7>MZAX#72?@S\--.7P3J'B?>/%%_X22S\,0KX<O/$R,J>(+K1A8W&L)&
MBZA+<@'(!^$G[&G[47[=_P"U9:_\$\O"GBC]KC4?!$G[4/[.?_!4CQ%\5O&_
M@'X%_ U?'</C[]D[]L#X4?"[X7>,_!9\:>#?&?P\\-&P\)?$*S\,OX?U7X<^
M*-#O- L=?.OV_B'QQXAT'Q]X'^D/B-\=/C1\??\ @W1\;_M2Z[\1O$'P^^.W
MC3_@D_XT_:&UGQW\)X]/\&:I%X^_X9;UOX@7<_A]Y['6)/"=KK.KQ%;B[\+2
M:/KFE6UW/+X.UGPO>QZ=>6'ZB:3^Q]^RIX?FTJXT#]FG]GO0YM!T/Q/X7T*;
M2/@A\,--FT7POXWCOXO&OAK2I;/PO ^GZ!XRAU;5X/%FD69AL/$$.KZHFIP3
M_;96/I/AWX1?"[PA\.8_A!X2^'7@+PK\*HM+U;0D^&OAKP7X:T+X?)H6O/?2
M:[HB>"-,TRV\+KI&MOJ>I'5M-.E-9:B=0O7O()Y+J9W /PQ^-_[9_C_X6W_A
MC]F#X7_M3? CX'^+?!7[#_P4_:)^$WQA_:9^*7PW\!_#SXW^+!\0_BYX*\=_
M"SQ5H]A^S-XUT;QEX+^&-Q\)/AMX8^*/ACX%>(O@?\8K/PE\:+J3PWX@TWQE
M!X?\7>'?)9?VV/VWM'\?>-?']_\ M#0:GX4^'?\ P7T^"?\ P3ZA^#I^"'PX
M\/\ @KQ/^S;^TMX,_9+TJ^T7Q7?7V@3?&+3_ !=\)KSXPZSXM^%GB;1_'OA3
M7U\7SZY;_&.S^)G@V[\+_#[X?_O]<_LT_L^7FC?"OPW<_ [X.S^'/@7JFBZY
M\$= F^%W@671O@WK?AK[/_PC>L_"?37T$V?PWU7P^;.R;1-1\&0Z)>Z4]G;O
MI\]L\43)CWG[(_[+NH?VH+_]G+X"7HUSQI!\2];^U?!?X9W)UGXE6B3I9?$3
M5OM'A>5=1\<V7VJZ:T\5W:RZY US.$OA'-+&X!\B?M>^)-7\1?M]_P#!,3]G
M?5M.:\^$/C/6?VH?VC/&,;Q!].UKXE?LJ>!_A]-\"O#7B!;FWN=.U#1]*\7?
M&'4OC=HVE.MOK-I\4?@7\,O&NB7]K'X)U:VU#F_&&EZ99?\ !<'X$ZO::9I]
MKJ&J_P#!+']KQM8U2VM(+:_U---_:V_8-@MCJ-_;P?:[_P#LZS9XK1+F246T
M+-#$8(Y7:ON;XZ? ;2OC#I'@>]3Q%JWA'X@_![XB:3\8/@_X^TNQMM9O/!OQ
M$TCPYXH\$W5Q>>'[W_0O$_A?QM\./'?Q#^%/Q#\.SRV.IZU\._B)XOMO#7B;
MP9XU?PUX[\,=!)\!_@]J7C_3_C%JOPJ^&=W\8K'3_P"S[3XK3_#WPA+\2K"T
M:T%B;.P\=7>C3^++.QCLDAM+>V75$9;2"&"Z\W$B$ _G$^$FL?$=?@S_ ,$X
MO"<_B'2;K]LG_A_G^UM?_&2Q@N_#MUXMFN-"^*G_  4#'[2]_J6E06MQ:Z?I
M$/['GB5X;&]ATS2]&M_AMXX^&L?@M](M_%'P^$_ZL_LLZQJGA/\ X*!?\%)/
MV?=%:1/A3I%K^R'^TUH&E+!#';>&?BC^T]X<^-7AGXXZ7X?73+6QLM-\/>*M
M5_9X\*_&+6=+G@N=8NOBY\5OBS\0-5UR[?Q_9V.E_H-;?##P!9>-+SXCVO@S
MPC#\0=2T:W\.ZGX\C\*Z!#XVU#P_:O82PZ'>>+;73[?7[G1UFTRQG&F7-_-8
M)+9V9BMHTM($3SOX"_ K2_@];?$[6;K5KKQ?\3/CG\1KSXM_&KXB7FFQZ#+X
MU\<W7A7POX T9-)\.VTT]IX4\&^ /A=X$^'OPK^'_AJ*YU+5;#P9X&T6]\;^
M)_'GQ+U/QM\0?%8!^/7P<_X*/#XH>!;[]IB__;C^&WPGO?AWX3_;UN?VF?V'
M_B%\(M&^).N_L\V?[/4_CYM+\5>*_!_PKNM(_:M\ ZQ^SZOPKT6Y^*>J?$;6
MM9\'_'2P^)VJZ5X2\(_#7QI\3/@'HWAKX"^-_P"US\;_ (V? 7]MGX$_%_XJ
MZ7\6=/\ A?XM_P"#>CXX^ ==N=,^$VA^.(+O]I[]L7X(:M\0-)U#0O@C-?\
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M>^"NA>)K2^^$FO>"OA+\2/B]J_P<T?X0^#_%WPCB^,7CO1/ /A1](TG1-/\
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MQX/\,ZIXP\/"U>]DMET/Q-?:5/K.E+;/J-^;=;*\A6W^W7OD"-KJ1J /D_\
M;2^/'C;X1^./V)_A[H6O1_#GPA^T[^T])\"?B+\9_)\+3WWP\2X^!GQD^(?P
MUT'PJOC;3]<\&V?C7XT?&7P#\/O@YX>O?%GAOQ/I5S'XQU+PUHNCQ_$'Q)X&
MUK1_QW^)/CG]H?X\>)/V$?#OQ5^)'C32M4^ 7_!>KXK?LI^ ?C=X4T'X16M[
M\??!/PN_8V_:[30_V@-6T?4?A'J7@/3OBOX?U0>,?@C\2K'P5X?TWX0W?Q'\
M%_$_5]'^&W@^>?P]X6^'7]*WB_P5X4\?Z#?^%/&_AS0_%_A76+9['6_#'BG2
M;#Q#X<URQD*,]EK6A:O!=Z5JUHSQQRFVU&SN8/.BAG\OS88G3S/6?V9/V>?$
M5CX"TSQ#\"_@UX@TSX50VMK\+=,U_P"%7@/6--^&EE8V\=G8V/P^L;[0);?P
M7:V5G#':6D'AM-,BM[:..&)%CC10 ?GC_P %'=/U+PG\4/\ @ES%H'Q@\6_!
MGP1JG_!0Z'0/'.B^$+GX?^'/ FMZ:_[)'[8?Q=?6_%]EXG\'ZYI^I7%GXR\
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M?BG(T$<A!D6+_@FI^WU&\IB##>L,5Q(CR%2L<<[JS*LQ#?E%^UU\<].^ O\
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M-S9^'M?\>1Z<?%NL:#9W&FV$]GI&HZS<V5M+9VCI&3:VXC /3Z*** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M_#GARY\&_&SPCX>^/&MV/@SPEX.TK2+3P5X$\#^-&T_^W/'7Q5\(!-/FU_\
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ML\_MF>)/B/XG^*&O?&7P_=?&']EW6?V1/BIIOPW^)%WX7T+QU\)I_%M_X_\
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M?#!/$A&N:1-#I^D?$'PKKAN?$/A#QWH'B'4=4U6^ /2?A%^WE\6_C?\ M?\
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MO5-"U]&\->-/AM\3_''A#79=)ATCQ=I=KK0UKP3XK\(^*]-TKQ!8@'S)X?\
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M]$^-NH^/?A(-2\;7W@SP1\3+,? J7]+_ -D?]I;2_P!K#X6W'Q=\,S?"O6/
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M+0M(_3_XS_L/_"/XU^//&7Q$U37OB7X)U[XK_""V_9Z^.L'PZ\6PZ#H_QV^
MUIJWB#5;7X8_$73-0TC6X;9-/7QI\0=)\/\ Q+^'Y\"_'#P=HGQ#\9:=X+^*
M/AV/5(VM4^#_ .Q/\.?@E\>_CA^T!X/\8_$&36/CUX4^%?@CQ3\/[V#X867P
MO\/>%O@9!K>G?!S1? WA_P ,?#/P[K'AZQ^'GA_Q-X@\-:1 _B._CU+1]4)\
M4+K^J:=HVIZ: >1_M^_M%?'SX$^//V"?"OP7T/X=ZCI?[2O[:'A#X!?$*_\
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M+X)\._!_QO\ "&YUCX-^$?VAOA%XB_: TCQ)^T-X#N_ ?A9?BEJ.@CQMXB\
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MM4WOCS]M7X</\%+7Q5\9O'OPRDUO]A/XYZ%^SU\8O$>G?&3X/_LN?$KX@/\
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MJOQ1T+Q58>#?!OQ _([QY^W'\6?V+_VP_P#@K1^T?K/PF\;?%CX<?"GX#_\
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M%!"L">6I9ADDLV"QSTR0%!(4!<XW,%W,6<LQEH **** "BBB@ HHHH ****
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M_P $]?$GQ'^+/P*_:*^'7[6/Q8_9A_:)^%OP9'[.?C[XE? _P3\&M=TGXP_
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 445Q'Q)^(?@KX2^ _%GQ,^)'C#PY\/\ X?\ @70]
M0\3^,_&WB[5+/1/#7A?PWI%N]YJVLZSJ^H30V>GV5E:122O<7#E P5 DCNJD
M 32OB-X)UCQUXO\ AGI_BSP[?>/O FA>#O%'C#P=9ZI:3>)/"_ASXB7_ (NT
MWP'J_B#24F:[TNR\77G@+QE!X>N+F../5CX<U5K3<+5P/&OB;^V)^SG\*/BC
MX9^!OBGXIZ)-\</&7AR^\7>&/@GX.TKQ-\4?C)J_A2PBO9;CQ?!\*/A=H_B_
MXA1>#H!INH(_BJZ\-P>'YI[.ZMK;4Y;JTN8(_P"9+XP_%OQ)^Q'_ ,%7/V'?
M^"F/Q$AUWX:?L]?\%&]!UO\ 8S_:Q\2^._'GP0O_ (?PZYXNU/7?BC^R3XX\
M/3^#OC1XCLT\._"O1V\'?#/Q+\6-;TGP9IUA\+?ACJ?BN_T/2/%'Q.U^WOO9
M_P#@GSK.I_ O_@O=_P %E='_ &QM>M/"7Q-_:;B^ 'CK]CCQKXWN++PUX;^*
MO[,GPXTWQE%JWA7X3>)=5M/#VD>*Y/ WAG7/A#I'C/0_"UOJ^H66K>!?%,NO
M:C>76@ZYK5^ ?MQ\3O\ @I7^P_\ !WPW;>,OB)^T?\/]"\(S_$]O@C-XFMD\
M1^(]#TSXT_\ "'Z#X_@^#?B#4O"VB:U:>%OBS>^"_$VC^)=.^''B272_&6J:
M9+?OIFBWDFA:ZNG>OZU^U'\)?#?Q#\"?"36]8\2VWQ-^)_@76OB7X"\%Q?"G
MXNWNM:_X(\+-80>+=:^SZ;X(U :7-X2O=7T+3_%NAZP]AK_A'4_%/@O2?$VF
M:7JGC3PO9ZI_.%_P<2>*OV<K']E/]F+XD_"GQW\+]-M_BS_P62_9/^(/CSXD
M0Z_9ZOX5\8^,?A3\/M4^#_BOQU/J,OBC1-+\5:=\-?!_PN\!^!_&]YX9\4:7
MI.B2>![C0M<UW0O$.G:Y<VWTU_P3"_X**:YI_P"UG^TK_P $Y?\ @H[XN^&'
MAO\ X*.>#?%O_"7^$_B9HLL?AWX??MH? +6+&;QS\+->^#DEU,VBZ3=_#?P'
MX@ABD^#EA?KJT7A]]:\:VFGZ[XOTG]H'6M& /U6\#?\ !0[]D#XF_"7XQ?'7
MX<_&_P .>.OA7^S]K.H^'_C=K_A30O&FMZI\*-7T*SLK_P 1VWCOP78>'9_'
M.@P>&M/OAJOB74+KPRNG^&-)T_Q!J?B&YTW3O#'B.\TKTKQO^U9\$/AO<?"[
M1_&_CF'P_P"-?C5:76H?"CX5W'A?QO<_&_XA6.D:;8ZUXGG\+? 6P\.W?QGU
M(>$-)U&UOO&ZQ>!G?P#%-$/&R:$[LB?RE_MC? /QK^S=\++/_@L/_P $XIK7
MXI^#_CG^S]K_ ,"_^"HGP=^&GBGP]XC^'GQB^!S>!]:\ 6_[4N@W>E3:[9>'
MOB7^SA>6-M=_$+5_!=C?75W9:??^,/$UOHNC?\-":GX_^SO 6C>+?@7_ ,',
M_P"US\6?VF)KOPM\+?VH/V*?A=\/_P!AWXG^-KJ*'P%JD?@6+X.R_%?X"^!?
M&NLS0:)X<^(;^/\ PM\0_B?=_".ROK?Q!JVC3S?$4Z>MIK.G7]\ ?LMXL_X*
M+_L8^!_@1>?M->)/VB_AO:_ ?1_&=O\ #GQ3\3+*;6=<\/> /B!<1L6\!?%1
M= TW5=4^$OC;3KN;3M#\0^%?B5IWA?7/"WBW5-*\%>(;#3O%>M:-I%]>B_X*
M"?LF2_&#X2_L_K\7]/3XV?'KP3H'Q*^#/PQG\'_$.V\6?$3X>^)="OO$>F>-
M_#UC/X407'A6'1M)UK4=?UV9[?3O!\.B:];^,)]"O/#VMPV7\]W[,'[)^F_\
M%"OVVO\ @X4\0:5+/%_P3B_;9\*?"3]GKP+XST[0"? ?Q3_:!\!_"?2?!?Q(
M^/OP;6YM[#0?'R_!SXM^'O%FL)\2M O3X=\:>+=8TG5=(U;Q!]GO+K2/@+3[
M+]MZX_X)U?\ !-__ (*.?$#X?^,(OVF_^"*W[67@[]DF7X;Z3I.SQU\>O@[X
M1^/^M?L;?M'^'/![G3M6F\8>(_B-;S_ OX%2WOB*YM[G1?%OPC_:"\2Z0]IJ
MOC5@P!_7O\6/^"D7[&WP(\.ZAXP^,WQGM?AIX1T[XQ^*/V?;CQ3XP\!_%'1_
M#<?QH\(6MM?:Q\.8O$,O@N31M1U^>TN7N?#;:=>W%AXVBTOQ*_@F[\0IX3\2
MMI7T=XT^,W@OX<_"W7/C1XYO-5\.?#?PMX63QKXIUR]\&>-SJ'AKPNEG%J&H
M:QXB\(P>'Y_&6@V^AZ?,-2\41ZEH$5UX.TZUU6^\6V^BVNC:K-:?S4_\'#&B
M1_";_@G/^Q5X-\<^(O"UK\0-5_X*/?LL^*_%3P:W;6MAXF^(^O\ BCXD_$3X
MR:]X5M]472+V[\/MXT\4^(-=AB.D6K:1H=W:R7UI90P[+?\ 87]KS]K;X$2>
M /VK?@1IGQ"\):MKVB?L+?M'_&[XE:UIOBOPI=>&_A-X7T[0;7P;X;'Q'U%M
M=0>%;[XCWFO^(;SP/%J$$-EJUA\,_B!>75]9MIMNNH@'K'PQ_P""@_[)WQGN
M/@]#\+_BDWBRT_:#O/%&G_ KQ#!\/_BII?@GXP7_ ()\.>*/%_B^Q^''Q UW
MP-I7@?QA>^'?#'@GQ?K&I6FA^(;VYBM_#>KQ+$]U:20#C](_X*D_L':S-KRK
M^T?X/\/V/@[XGW?P2\>^(_'VA^//AKX*^'/QGLH=1>;X0_$WQW\0O"GA?P7\
M,OBD;C2[O3H/A_X]U_0/%MUK<<?AZST:YUZ[L]/G_!G_ ((2?$#2_A/^PY_P
M3D^(/QG^/'@'Q)\*O'?PA^'W[//[.GP"TZVT*Z^(OA3]JOQG^V3\:_"NO>+]
M'\(2ZWJ>N>,==UWX:?$B&+Q-XOT73;6X^$?P5^%GQ3\3:AIND^&KSQWJFK?%
M/@CXI? .+]B3_@ZRT+Q_X@\+>)_^%T_\%!/VQ?AW\$/"6F74/BKQ%\3OC?\
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MZ^%&KW/A;QW+J^HZ[?RZU!\?['XKZS96BZO<:5!X=OO#=SI7V:ZN-9@8 V_
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M"?\ :%_X* >.9_AS\:_#1TR]U0_#WQ%\$_#7QDG_ .$M\+W6C^-OA_XO\/\
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M)?!7AOQ%_P $+_VLO$'B#P_I6J>(/ ?_  _=U7PIJ.I:?'<ZMX?U;6OVF?\
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M\MOJG]A^*4U_PCX?\#^$7[+'C_Q!^P7X+_;:\=W?P\\+6'AK_@W/G_90\'>
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MO[%/PQ\*76MWD$4%SKDWA_P39Z)I4NK7<$%M'/J#VOVF:.WABED:.-$7IO\
M@M9\.?AQ\0?#O_!.^W^(/@#P/XZAC_X*Q?L(:###XT\):!XICAT3QE\2I=)\
M5:1"FN:=J"V^F>*=-M8=+\062".TUNPACL-0CN80L=>4Z5_P4_\ VN(OB+;W
M/B#P)^SHGPHT3_@LYJ7_  2O\4>$]$'Q*N?B+JG@_P 7^$O"S_#OXN^'OB-?
MZK9>%]%\6?#[Q3K+:IXX\,ZE\*]?T/XK>']37P_X?O\ X-:GX2;Q#XZ .B^'
M?_!*/]L?X0ZA'JWPG_X*.?#'X8ZI#9:AIL&I?#W_ ()0_L0>"M0AL-5NA>ZG
M8Q7OAK3=+N4LM0NQ]JOK5)%@O+DFXNDFE 8.TK_@E+^V/H5YXQU#1?\ @HU\
M+M'O/B+\1O"GQ@^(5SI7_!*']B/3KCQY\6O GB'3/%W@KXH>,[BTL8KGQ/\
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MM_@XW[.UO\#OA!;_ +/CZ/+X<?X#6_PP\"0_!9_#EQ?OJESX=?X6)X?'@9]
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M7WC+]GQ--^-'QWM/&7P;UK4M$UCPWJ47PZ^*D?Q*/Q7\+>&=1\-Z[JGAN_\
M 6E^.+?P%>Z!?W&EWOAJYLUMH(+-W_P3J_9;U#3OCAHM[X8^)\^A?M)>*O$?
MC'X[Z W[47[5(\/?%C6_%OA?0/ WB27QMX?7XRKHVKZ9K?@7PMX=\":CX:EL
M_P#A')O ^BZ=X..FGPW FEK^$?[,'Q\^--C^P?\ \$>/VA-4\??M>^'?B-\6
M/B7^RAHOQY_:9^-?QT\5^/OV7_%?@7XF:]'X?^)OAWXW^$O$GC?XO6FF/\9]
M!DD\%? ?QE:?#3X5S>'/VC-6^$UOK7QF\ :;XCUCP_X\_:'X*_MT?$'XK?\
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M'\9KXX_X2/XX>"Y?$OA;1O%$?AOXY:A\1](M/$::AJUE:6]WK6KS7O*>&?\
M@GY^RKX+^+'B7XT>$?A<_AOQ;XQ\?W/Q9\5>']!^(_Q8T?X+^(OBS=W&FZG<
M_%K6_P!G"Q\:Q?L]:I\59==TC3=?_P"%E7OPPF\=CQ-8VOC%_$4OBJ-M4?[5
MHH ^2_"O[%7P'\%?$7]HGXL^%=(^(6@?$7]JN/38?CGXMT[]H']H>+4O%_\
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M9;:5XVT;2=;VC41H?B^VTS09/$^A37;Z'K6H^&?"VMWNFR:OX5\.7>E^F44
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M"OARPL/$*:FEC]GT %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M7-2U75?!NA>'++P]I7BW7[KQSJOQ(\+?&'QI\+XOAM:Z/X=O;CXEVWQ;\+_
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M,^IV-C:^)XO 'Q)T*_\  _CV3PW/JR>"?$TFDZ1XI;2;OQ!H$>I^]T %%%%
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MW@'XDZ5=^"M0E\0PZ_?:7;:'97\GB#PYX<O(=6AMK2\LK\ ^F**_FC_X)*_
M_P".WQT\7_M/_$OXL?\ !1__ (*%^-T_9!_X*?\ [5O[-/@WX=ZW\6_A?/\
M#7XB_##]G#QUIFA^#K#XO:)%\$H-9\2WOB+3[R1/'$F@>(_"=GJLF'TBQT!-
ML:_TKSJ7@F4 $M%(H#!BI)0@!@GSD'/(3YB.%YQ0!+17\QFB?M]_'K_AZROQ
M:O/B_=Q?\$[O$7[</C+_ ((U:7\/=4L9K/PA;_M$^&OV?_#7Q/\ #WQ5TN%=
M%M[Z_P#&/B/]K+3?B-^S2/%W]IZCH.IZ;=:9H2QV$V@17E[]I?$7XG_$>/\
MX+??#;X5V?Q"\=67PKU#_@DU^T#\2;_X9V7C'Q';?#Z]^(N@_M-_"OPWHOC^
MY\&Q7\'AV;QOI&A:CJ.CZ7XLFTEM?T_2KVYTVUOHK25XR ?M#17\\W_!,O\
MX*&^$_@__P $C?\ @G%\0OVHOB/\9/C9^T'^T=\//&-CX#\(Z-HGQ5_:=_:N
M_:.\9>#+[XA^,/$\?A?PEX=L_&?Q&\9CPUX.T*.?Q+XX\1/I_@7X?:5)H1\;
M>,O#^G7VC^?]KZW_ ,%?OV*?"O[.D7[3_C/QIXH\!?#G2OCGX4_9K^*FF?$'
MP+XA\"?$']GKXU>)[RVL[SP9^T%X!\56^E^(OAK)X/2]L=5\4:G=6NH:9+X>
MO++Q)X4N?$_A_4](U34@#]0J*^ _V:O^"C_[/_[3_P :O&7[._AC1/CG\,/C
M3X1\%3?%BT^&_P"T9\ ?BQ^SWXP\?? X>)X/!5A\=_AUX?\ BGX8\/:IKOPO
MU3Q=<1>'4N=0M=$\6:/JS1V/B7PGHMQ/&E? O_!?#]HG]H[X,?"K]D[1?V1O
MB9XF\ ?M Z_^TIXZ^)6E^%_#-G=W1^-'PZ_9>_9"_::_:!\8_!S7$EL7TB_T
M+XC^*/!OPR\(7'AVZN6U'6[CQ!:RZ-INL_V7J$$(!^^U%?S9?\%A?^"D7B#5
M/^":GP9\6?L3?&.;X3_&;]MKX(?$C]IGX(>/M-EO+;QAX4^ ?[,_[+/BK]N#
MXU:Y:!=%OVTO6KGPWX$\)? >_MKJ.TN=.\3_ !CTZ*\?2FM+^33_ -!=#_X*
M2_!3X;?LF_L7?%+QTWQ7\=?$K]K']GSX;_$WX1?!#X8?#7Q)\;_VF/B])?\
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M?%3X'_"3]IGQU>^,=<N+K2_BM^SU\*/^$7\,ZO>7%AXG^%GSKK/PK_;W\*>
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MQ>7=GX5AO-73>-;N-3:>Y>?Z1CC6)%C7[J#"C &!G@8  &!QP /84 /HHHH
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M !2TW3DU87'@>[UB\U9%T74VMI]3@L+B^/[L>3%L*;!L+AR"2<N&#[N3G=O
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M]M9ZEXM\03Z[8O;V^E:2T^G:/<W@GO4FE>/;=ZO9V/F11-.P>;3UFDNHT:W
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M(K3Q3%\5+76O@_\ $C1/!OA+7I;Z6#XBR?0/AX_L)^*]$N/AKKM[\&M;T/\
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MX=T*30]!\/1:9H^GOI5DUO8H8$(M:Q^S'\ /$&OV/BK6OA/X/U/Q)IOCR_\
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M[38[=/!=G\3]5TS6OB OA^!#Y&GW'BS4=)M)M8OH8Q?7$3W]F+E;+5M5M[T
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MQC^-.L?$;]J+QU;?#/Q;\??C%X@\*ZAJ_P 5_CYXY\9Q_$/1O@O\+?AM\.O
MNF:GJ.K7NH6/PY^+%M^SQ^R3\!M \5ZKX-\,^&_%>O#PYJ7BCQGXE\=?$:K\
M1=$\2?'+3U^+O[<FLZ!^S%^QMX!O/^$AM?V;_B5XT\&Z&GQ%6W%FFF>+_P!M
MSXAVOB67X9IX4M=1?4Y/#?[*_AGQ-XJ^'EQ%:>'_ !E\<?'/C_5]4C^#'PN
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MG2">OSK_ ."H'_!/W5/CU^P;^UK^T)^W+XA\)?$KXU_!+]D']H[XD?!+X?\
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MVMM?:;>VVH65Y$L]I>64T=U:7<#@E)[:YA9X9X' RDT3O&X*E6(9<_SPP?\
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M8:?86-I'#:V=E96D$-K:6MO%'!;6T,4$,:11HH^?_P#ACO\ 9+_Z-=_9R_\
M#'?#/_YFJ3_ACK]DK_HUS]G'_P ,=\,O_F:H#[ODOZVZ=D?2%%?-_P#PQU^R
M5_T:Y^SC_P"&.^&7_P S5'_#'7[)7_1KG[./_ACOAE_\S5 'TA17S?\ \,=?
MLE?]&N?LX_\ ACOAE_\ ,U1_PQU^R5_T:Y^SC_X8[X9?_,U0!](45\W_ /#'
M7[)7_1KG[./_ (8[X9?_ #-4?\,=?LE?]&N?LX_^&.^&7_S-4 ?2%%?-_P#P
MQU^R5_T:Y^SC_P"&.^&7_P S5'_#'7[)7_1KG[./_ACOAE_\S5 'TA17S?\
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MB'X,_M=_"S]G_P""_@G]D[]KBR^(^@?''X+?#OPS\%?&NC3_ +.OQI\;Z/\
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M1T^V\2> /B/X,\,>+-)M]=T77_#>I7>E1Z=XFT#7?#]UJ>BZAB?\,=?LE?\
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MT)R40D9 .T9P1@C.,\@D'U!YI_3I7S?_ ,,=?LE?]&N?LX_^&.^&7_S-4?\
M#'7[)7_1KG[./_ACOAE_\S5 'TA17S?_ ,,=?LE?]&N?LX_^&.^&7_S-4?\
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M9@Q+,<@;1RQ(&,M]T87KSC-.HHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBO./B]\3]$^"_PS\:?%/Q'I'B[Q!HW@C0[K7+
MOP_X!\,:GXU\<Z^T!2.UT+P=X/T6.;6/%/B?6;R6WTS0O#^E0S:CJ^J75K86
M<4EQ/&A /1Z*_/W2?^"A_@35/B3\3?A2?@9^T9:>+O@?X\^ 7P[^-MM%X:^&
MGB*#X6:Y^TS=^&(?A+>ZZW@OXL>)[GQ!X;U#3_%VD>(_%?B3X>VOC32/AQX6
M35O$/Q"N?#.F:'K$]E^@5 !17AU[^T?\'-._:/\ #_[)=YXM\CX]^*/@UXE^
M/^B>"7T77ECO?A7X2\9^'/ &M^((O$K:8/"K7=OXH\4Z79IX<36F\22V@O-6
M721I-E/>K\@?'K_@JO\ LY_L[/\ MT)XW\'_ !XU)O\ @GWX%^ /C_XT#PM\
M-(]0'B/2?VCY?&</@2/X7G4O$&CCQ%%IK^!M6'B_Q-KO_"*^ M$,L*0^+]0D
MLM>310#],**** "BOEOXN?M>?"KX'?'C]G3]GWXCVWBW1?$O[5.M>*_"?P:\
M5IH]E=^ -;\=>#?"FL>-M7\"ZMKD&K-J'AOQ)<>'-'>[T(:UHMGHWB.YO+;2
MM"UC4-6M]5L=-C^,7[8?PA^"GQL_9A_9V\2_\)3J_P 7_P!KW7?B/I'P6\*>
M&=%AO%U.P^#OA;3O&_Q8\5:]KFJZCHWA[P[X;\!>$]4M=:U234-576=6##2_
M"FC>(M<EMM+G /JBBD!! (Z$ CD'@C/4$@_4$CT)I: "BO.-#^(-YK/Q,\?_
M  YG^'/Q#T&S\#Z+X$UFP^).N6'AN'X<?$1O&J>*&OM(^'^H6'BC4?$M]K'P
M^?PW:Q>/H/$/A7PS:Z=)XN\)'0[SQ#%?W\FE^CT %%?&GQP_;8\#_ SXN?"W
MX(:E\,?C-X_^(/QJ\#_%3Q[\,-+^&>A>"M>3Q=I?P0M-+U+XL:7I[ZMX_P##
MTZ>)/"&D^(?"VI1Z%=6T%YXQC\26-C\/1XNUC3_$6F:)S'[//_!2']EW]JSX
MNZ#\)?@#X@\4_$$>*/V:--_:K\/_ !&M_".IZ#\.=3^'.I?%#6_@\^BQWOBG
M^P_%=M\0]$\=^&O$.B>+_!E]X0M;[P3J>B:KX?\ %TNB^*K"YT", ^\J*\?_
M &@/C5X8_9P^"GQ0^/GCC2_$FJ^!/@[X)\0_$CQZGA*ST[4M>TWP)X.TVXU_
MQIXCM-*U+5M&&KQ>%O#%AJOB2^TG3+FZ\1:I8:5<V/AC1M>\03Z;HM_\]>'O
M^"@7P7N?$WP0\*_$7P[\4/@7=_M.0Z'_ ,,XZY\5O#.CKX#^,NK>(?#FI^+M
M)\'>'OB7\._$WQ"^'GACXD:GX:TQ]8\/_"[XF^*/ ?Q&\9VTQ3P-X6\3W&FZ
M]!I !]RT4A(4$GH 2< DX R< 9)^@!)[5\M?LP?M??"G]K+2/BW?_#>T\9:-
MK'P&^/'C_P#9G^+_ (/\=:!#H/B3P1\:OAG:>'[[Q=X1N&LM2UCP[X@MK6R\
M4:%=Z9XL\'^(/$7@SQ!:ZC;W.@^(=1@D21@#ZFHKY>_9G_:Y^%7[6A^,]W\'
MK;QA>^&_@A\;?'_[/?B'QCX@T&/P_P"'?$OQ-^%>KS:%\1=/\"_:]0;6_$6A
M^%M72WL)_%C:+8^&=7NKP6_AO5-:GT[78])\JNO^"@7@:V\0_M'Z#%\$/VC=
M73]D;Q1IOAC]H?4_#/@[P/XM?P$^L>!/#/Q6TK5M.\'^%_B3K'Q,^)6GW_PI
M\8^&?B';6/PD\#>/?$SZ-JJZ,?#Z^-;+4_"MD ?>U%<7X ^(?@SXJ> ?!WQ1
M^'6OV7B_X??$+P?X:\?^!O%>CL\ND>*O!OC'0[+Q)X7\0Z-<2I#]IT[6]#U&
MQU&RF*IN@N8_,$;[E7A-#_:-^#?B/X_>./V7](\:Z?<_'3X<_#;P+\7/%W@!
MDN(=3T[X??$76_%WA_PSX@AFFB2SU*)M4\&7\.LVNF7%W>^&DU;PE-XAM],C
M\7^'&U$ ]OHHHH **** "BBB@ HHHH **** "BBB@ HHHH **^6/VF?VO_A3
M^R5+\&+CXQ6?C.P\,?&_XW> _P!GG0/'.AZ!#K7A7PO\3_BCJEIHWPZT[Q[)
M#J46M^'= \5ZG/=64'C./1-0\(Z+=Z=/9^*=:T&\O]!M]8;^U#^V%\)_V2])
M^#U]\2+3QGK6L_M ?'CP+^S1\&O!W@?P]'K'B;QU\9OB/:^(K[PKX6M_[5U'
M0?#_ (=LKBS\+:U<ZEXK\9Z_X:\'Z#!:B;7->T^.5&(!]4T5YMX3^(=[XJ\<
M_$_P;+\-OB-X6L/AQ?>$['3?B!XIT_PW:>!?BH/$WABU\17EY\,;O3/%.K^(
MM0M/!MU<MX3\8-XL\->#[BS\5VEY9:3;ZUIT(U5_,?B9^U7\./A5^T;^S/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M:-J5T);:QO;BX@FBCW/A-\8?A[\;/ 6C_$SX;^(X_$?@G7[GQ!:Z/KITK6]
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0\*QSW-S'X9\+^&M&\/^'DN+V3S;R==%TFRM--$UW+^]N9/LV^>7$DI9P&H
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MJ!BU'398H0#\=?A!_P %%?BA\4?CMXU@\(_&/X4:C\4O@C\0_P!O+X3?$/\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%<]XIU^/POH5]KLVGZ[JD&GK%)-9>&
MM"U'Q-K<L;S1Q'[#H6CP76J:BX,BEXK&UN)DCWSLBP12S1 '0T5\]?\ #1?A
M[_HG_P ??P_9Y^+Y'X$^%D)'N40GKM7H#_AHOP]_T3[X^_\ B/'Q?_\ F8H
M^A:*^>O^&B_#W_1/OC[_ .(\?%__ .9BC_AHOP]_T3[X^_\ B/'Q?_\ F8H
M^A:*^>O^&B_#W_1/OC[_ .(\?%__ .9BC_AHOP]_T3[X^_\ B/'Q?_\ F8H
M^A:*^>O^&B_#W_1/OC[_ .(\?%__ .9BC_AHOP]_T3[X^_\ B/'Q?_\ F8H
M^A:*^>O^&B_#W_1/OC[_ .(\?%__ .9BC_AHOP]_T3[X^_\ B/'Q?_\ F8H
M^A:*^>O^&B_#W_1/OC[_ .(\?%__ .9BC_AHOP]_T3[X^_\ B/'Q?_\ F8H
M^A:*^>O^&B_#W_1/OC[_ .(\?%__ .9BC_AHOP]_T3[X^_\ B/'Q?_\ F8H
M^A:*^>O^&B_#W_1/OC[_ .(\?%__ .9BC_AHOP]_T3[X^_\ B/'Q?_\ F8H
M^A:*^>O^&B_#W_1/OC[_ .(\?%__ .9BC_AHOP]_T3[X^_\ B/'Q?_\ F8H
M^A:*^>O^&B_#W_1/OC[_ .(\?%__ .9BC_AHOP]_T3[X^_\ B/'Q?_\ F8H
M^A:*^>O^&B_#W_1/OC[_ .(\?%__ .9BC_AHOP]_T3[X^_\ B/'Q?_\ F8H
M^A:*^>O^&B_#W_1/OC[_ .(\?%__ .9BC_AHOP]_T3[X^_\ B/'Q?_\ F8H
M^A:*^>O^&B_#W_1/OC[_ .(\?%__ .9BC_AHOP]_T3[X^_\ B/'Q?_\ F8H
M^A:*^>O^&B_#W_1/OC[_ .(\?%__ .9BO4/ WC2V\<Z9=:M9Z-XOT2WM[Y[
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MK=ZI\7]._P"%CZ!\=?@S\2K']D#1?$_P)_:*L/!LFB_&OP;^SOKGQK\0>*O
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MXXU34_$>@>%OBM+X\\!_'GX0?!CX ?M)^+_VB/$GB[QM\:Y?AI\#/VB?B?\
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1** "BBB@ HHHH **** /_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>ex10-9_001.jpg
<TEXT>
begin 644 ex10-9_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" /+ NX# 2(  A$! Q$!_\0
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M?%CPMX)^)OPW\27?AGQ7X2\6:;H?COPCX>U/5/!_B[PGXNTVUNO#7B?0M4U
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MMOR >S45\-Z)_P %&?V5O$NF^-;[P]K'QLUS4O FD>'/%&I>!M*_9%_:[O\
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M[0/@]^V1\&?&WQ+^&GP=\&?LS^-?@-\7/VC-;^.M[\8/C+\1/B /B%X+\/\
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M)M\4J+)&X! =&&589 .U@05.,$$$<$&@"2BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH S=6U?3]#L+K5-5NK>QT^QM;J^OKZ\NK6RL[*
MQL;>2[O;V]O+V>VM+2SL[6&6YNKFXGBA@@CDEE=(T9A^&'QR^,EO\<OVE/\
M@FEXU\3:E\)1^SKX[_;*U#7?V?\ 7Y/BVS>/KGPU\-_V3_VI?%47QUE^'?\
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MWG_$M_M)_C#]HW1O!W[1WPC_ &9!\-_B1XA\6?%_X;_$GXJ^'_%OAV/X>?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M_A?K\'A?QU\2?&/A_7KSXX_"_P#9BLK*Y_9W_::N(KK]HWXR_#7PM\8/AO\
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MMIP 7J*** "BBL+Q!XH\,^$[2RO_ !5XBT+PU8ZEKOA_POIUYX@U:PT:UO\
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MLS;%G$0;>82_R"7;LW_+NW<4 3T44Q)(W+!'5BAVN%()5N>&QT/'0\XYZ$4
M/HHHH **8LD;LZHZ,R':ZJP)5A@D, >",C(/(R,U#)>V<5U;V,MU;1WMW%<S
MVMF\\2W5S!9M;I=S6]NS"::&U>[M%N9(T9(&NK<2LAFCW %FBBFAU)8!@2C!
M6 Y*L0&"MC.#M96P<85@3P0: '44T.I9D#*63&Y002NX9&X=B1R ><$'H12L
MRJK,S!54%F9B JJ!DLQ.   "22< <F@!:*K17EI-+/!#<P2SVTH@N88Y8WEM
MYVMX+P03QJQ>&8VEU;77E2!9/L]S;S;?+FB9K- !15:VO+2]222SNK>[CBN+
MFTEDMIXYTCN[*XEM+RUD>)G5+BTNH9K:Z@8B6WN(I(9521&46: "BC_/K_*J
M\]W:VR2R7-S!;QP123323RI$D,,2-)+-*\C*L<4<:/))(Y")&K.S!030!8HJ
M"WN;>[BCGM9X;F"6.*:*:"1)H989D$D,L4L99)(I8V#QR(S(Z$,I(.:GH **
M** "BD)"@LQ 4 DDD   9))/  '))X J,30MLVRH1(Q6,A@0[*'+*ISAF412
M9 R1L;(&#0!+1110 4444 %%%,>2.(;I'2-?5V"C\V('<9]* 'T4Q)8Y!N21
M'4':2K @-G&TD'ALD#:><\8S389X+A#);S13QK+/ SPR)*BSVL\EM<PED+*)
M;>YAEMYXR=\,\4D4@61&4 $M%,>2./:)'1"Q(4,P!8@%CM!.3A02<= ,GBGT
M %%%% !113=Z;=^Y=O\ >R-O)P,-T//'!Z\=: '44T,K ,IW*0"K#)5@1D$$
M<$$<@@D'M34EBDR8Y%DQUV$/C(R,[<XR.@[]N: )**;O7<4W#>%WE,_-MR5W
M;>N"00#C!(XH9T3&]@N6506. 6=MJJ">"S-@ #G)''- #J*** "BJC7]BD\=
MLUY:K<RQW$T5N;B(3RPV<UM;W<L<1?S'CM9[VSAN752L$MW:QRE'N(@]N@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH \U\<?"'X7_$;7? /BCQ]X&\-^,-<^%WB"_\ %'P]O?$FGPZJOA+Q
M-K7AO5_!%_X@T>TO/-L8-;E\)>)/$/AV#4VMGOK32M?UJRLIK>+5K];C^0_1
MO@=\(+__ (-W?V3?B^_PF^&NH?&SX;?''X!:3\.?&FHZ#I>G>(?"NG_$+_@L
MM\%;7Q7INE^);30=8U+P[IGBM/#NC:;K-YIVE:E+_9EF\$&GWULUQI]W_91K
M.DVNO:/JVAWTNI066LZ;?:3>3Z-K.L>'-8AM=1M9;.XETGQ#X>OM+U_0=2CB
MF=['6=#U/3M8TNZ$5]IE]:7L$%Q'\C:1_P $^OV0?#_[/]A^ROH/P@BT7]GG
M2/&EA\0=&^$^E>./B5I_A71/%>D^)K;QSI5]HEO:>,8KK1K/2_B%9VOQ,TW0
MM,NK30+#XHP1_$VTTN'QZO\ PD- 'YA_&_\ ;1_:.T3P-^V_X*^*7AK]E/XR
M:W^QY_P4=_X)W_!6QU#5_@9XWL?A_P"./A9^U/XL_8I\8:!>S_"_7?CAX[GT
M;XS?!'Q)^T'9:YX-^) \<:SH%YXD^'?AOQ5;?#CP[K$4(B^I_P!G_P#;<^+/
MC3]MCQC^S-\:;?PO\+P=2_:L?X3>%;[X8^*FLOC?X+^#7Q<\!^$OA]XY^ O[
M3F@?$#Q?\%?B+?Z!\/M0\2W_ .U+\#_$>E> ?V@/A1\3]5T_1+7P##X#\!>(
M/%OBGZI\3_L+?LN^,O\ A:?_  DWP[U35?\ A=GQ#^'WQ8^*IE^)OQ9A;QM\
M1_A/_9?_  K#QAJ[6OCF!O[9^'W_  COA ^#KBU-LOAT^ /AH=*CM3\-/ 1\
M.^E>#_V</@?X!\77/CKPC\.- T;Q1/JGC;7;;48A>W46AZ_\3_$VI^-/BIXA
M\*:9?7=UI/@WQ!\6?%NK7GB7XLZ[X4L=&U;XHZVMCJ7CZ\\176E:7+9@'QC_
M ,%5/@IKW[0W[/\ X1^$G@3XN>!?A;\7=<_:!^$/B[X)Z)\8M&\1^)OV??CQ
M\5/@S=:K\<?#W[.W[17AWPSY6J:I\%OBI:?#35;3Q9;03O+'<Z3H]]I&E^(_
M$UMHOA/Q#^?G[/'[>/A[X+>&_C_=>-?V4O$?[)G[<GQ4_;?_ &<_@3^T[\#-
M.E\"^,_A)HO[0/QL^#?A7P_\)/C1\-OB-=^/OAU\,/&/@#XT_"[X<>&;71[%
M/''AC7-/^+=U9^&O&>ER7FLIX[\=?O3\6_@=\(OCSH&E^&/C'\/?#/Q$T+0O
M$NF>-= L?$VGI>CP[XVT&WO[?PWXV\.W&Y+O0/&?A1]2N=1\(>+='GLO$/A+
M75L_$7AO4M+U[3=.U*U\[U?]C3]EOQ+\(?B;\!_&'P/\">//A5\:]9?Q+\9/
M#'Q$TV3XAR_%GQ81X>6T\9_$OQ#XVN->\4>.O&^C1^#_  7!X:\:>*-:U3Q3
MX6MO _@:V\.:OI=OX+\+QZ2 ?#'@K]LC]J"7XD_!O]D'XVQ?!#X,_M/?&34_
MVQ]3\*^-((X/&^BZKX"_9GMO@?XG\%V-[\$_"WQ3U]_"_P ;/'GP]_:+\%^-
MO%?PUC^.OB[2-'\(?#OXB>*-$\7&'Q9X-TS0O$O%?_!1_P#:TT'X8_MM^(H]
M*_9ANOBG_P $P?V<_@+\;OVF/!FA+X_USX:?M&ZIJ'P=\2_'OX^0_L]?$27Q
M%IWBWX>?"W6_!W@[Q1\-?@1\0?&OPU\<76C_ !R\.>,=)\;:+XRT;P%K%CJG
MZ'Z__P $UOV _%?P"^'W[+?B;]D'X!^(/V??A1J\?B#X;_"O6?AWH6H^&?!F
MO_VQ/KU_KN@1W=M+>6.L^(=4O-1N/&&J)>?;O&T>L:[9^+KC6[+7=8M[[TKQ
M%^QU^R[XIUGP?KVK? SX>+J7@3PEX.^'OAPZ/H<7ANRC^&WPZU^'Q9\._A?K
M.D^'&TK2?%7PM^'WBRWA\6>!?AGXJLM:\">#O%,4?B/PYX?TW6E%]0!^.7Q>
M_P""G?[97@GQ!^VUXIT70?@!IGPT_8U_;!_X)O\ PK7P#XQ^%GQ/B^*OQ&^$
MG[<FG?LO2>*?"OB/7X/C38Z+\*OBS\-9?VD?M%CXY@\'_$'P]J5]X7.A:E\*
M+%(9]7UCR#]L[]H#QI^V+_PK'QG;V_PIT?X5?LI_\'$W[$_[*^B>#=7\#3>*
MOC%;>)?@O^U'\(?!?C#XES^/H/'"Z3\,=:\9^+/%&LGPOX>MO!VJ7&H? '5/
M#U[JVJ6FM?$B]TKPU^XGB[]@_P#94\>3_%VX\6_#"XUF7X]^._A_\3?C"9OB
M#\3X$\?^/?A0^FO\+_$VNPV?C2VADU#X=-H/A?\ X0@6R6]OX6'@KP$NB062
M^ O!HT.EXT_X)Y?L.?$?XD:[\7?B#^RO\%?&_P 1?%5SX!U+Q;XE\5^"-*U^
M;QAKWPMED?X>^+?&%AJD5UI/BOQQX2@D_LO1_'7B&PU+QA!H,5MX=;6WT&TM
M=.A /KN]O;2RM)I[ZXMK>".VGFGGNI5MK5(886EGEGN'RD$$4*R33RL2L%O'
M+.Y\J)V'X#67QBG^''_!1C]E_P#:LU;_ (6UI/@_]OG1/%7[%?Q-TCQ;X0^*
MO@?X:^"M4TA]:^-?_!.[58;CQ9X'L/!GB#Q3<:3H7QU^''B.+PEKNLV7_"W/
MVG=8F\/^+-5\#6WAQ9_W-^)GPU\%?&'P#XP^%_Q&T9O$7@/Q_P"'=4\(^,?#
M_P#:FL:1#K_AC7;=K+7-!OKS0M0TO4CI6M:>\VF:Q9PWL4.J:5<WFEWRW&GW
MEU;3><?%S]ESX(?'KP!X7^%_QA\*ZMX_\$>#]1\+:SHVCZ]X_P#B-+-)KW@B
M:QO/"'B/7M:M_%MOKWBWQ-X:U;3-/\0Z-XD\5ZGK6NV'BJSM_%EOJ">)(UU4
M 'XMW/\ P4L_;?LO&GB"^>P_9>O/ _AO_@M9-_P2[;PC%X!^*-CXBUGX=?$+
M0/AVWPZ^)[^.YOBS>6.A^,OAKJOC"YU'QCH\7@+Q!HWQ=MX5TK19/@X7748>
MT^&'_!3GX_ZNES^SYX^T3P?KW[3MU^WG^UA^Q3X.^(GPF^'FE>'?AWXW3]FK
MX9:7\7+?Q9;?"OXT_M*^&D\/>,O%'AWQ#96%MX"D^/GB.WU"V\,>+_$NEZZ'
M73_#-?I%!_P3W_9%M[1K-?A9?312_'32/VG;F6]^)WQ<U"^OOVB=!M+*RTCX
MV:CJ5_X\N=1U+XFV-MIFEK'XQO[JYUMI-+TN>6[DGTVRE@S_ !E_P3;_ &&?
MB1\/_B+\+/B1^S9\/_B/\/\ XK?%RZ^/OCGPS\0EUKQS9:G\<+^RN=+O_B[I
MTWBK5]6O?#'Q(O\ 1[V[T._\9>%;K1=?O= N)M!NK^71Y&LB ?F?K_[?'_!1
MF/QWI/P:U'2_V//AC\4=/_X)??M+_M8_$%[;PSX^^.?AW1/VB/V5OVD?!'P>
M\5:%ILOA3XX^#["Z\!>/-#U/589/ARGB>^\9_!/QGJ5UI'B'XE_$V;P*]EXS
M\ _:Q_;?^(G[?G_!.7]N7PCI_A;X6?#+1- _X(6_#+]N#XI:)XZ\(:C\6)O%
M_BS]KG]G_P",_P 3]-\)?#!E\8>!8_"^C_!+2_@UK$>C?$_6--\1:U)\6?&7
MP_\ $R>%])TSX5W^@_%W]VI?V%OV43J&BZE8_!_2_#TOAKX!ZA^RUX:M/!WB
M#QEX)T;PW^SMJT%C!JGP=\.^'_"'B/1-"T+P-J']E:+<WNC:3IUG#<ZCH'AW
M59B^I>'M$N[#CO$/_!-']@SQ;H_@/0O%'[+OPN\0V7PS^"NL?LW^"9]:TN]U
M+6-&_9\UK1-:\/2_!%_$-W?R^(-6^%.D:9X@U-?"/@'6M3U'PQX&OWM-8\%Z
M9H.L:7I=_9 'Y+^)O^"C/[:/PD\/?M1S^#]/_9CO/AS^PS^T?_P3$^!&G>$/
M$_@'XHP^+?C#\,OVSO"'[)%KKFB:OX_T;XK7&E?"KQQX O/VC?MNF?%#2_AK
M\4]"UJ'08[&?X)6;6\EWKGT(?^"D_P 9_A=\3OCM^SI\<%^'GB[XB:#_ ,%"
M/A!^Q1\&?B?\(O %C\-]!U.3X_?L1Z7^V3X#L/$_P[^-O[2TVAMXU6]CU;X$
M>'-53XZ:98>-_'7B;X?ZA9^!H;M[KPAKWW@__!.;]BX>&_&W@RR^!NDZ'X-^
M(FO?"?Q+XN\'^%_%7C_PEX3U'5_@-I^AZ3\#WM?#7AGQ9I.B:)8_![2O"G@G
M2_A?HV@V.F:-X#T[X>_#6Q\+V&EVOPW\"Q>'^B\6_L(_LC_$+1_C[X=^(WP0
M\+_$KP]^U%J6B:Y\>M ^)5YXA^(6A_$7Q!X8TNPT/PIXEU+2/&>LZYIVF^*/
M".B:/X=T;PAXF\/VVD:]X4TGPEX+T[P]J.FV?@OPI#HX!^<P_;"_X*)#X_?L
M<?LG>(X_V4?AS\3_ -H'PU^WM8?$#QE?^ _%/Q('A#7?V8['X4^(/@QX[7X:
M^ OVE?[*T&Y^(G@KXO>%M=^(WP!O_C)X@O/!VI33G0?CUX@TJ#3H/$/D?["/
M[:?[2'[9/[2G_!.#XS^+O%VB^#?"_P"T!_P21_:"^.WC_P"!GA/0;D_#BV^)
M_AO]HW]CCP/K_C#0KJ^U:;Q3]NU@:WJ(\-Q^*=6\6I\/?"$M]X4TE]3U77?$
MOC;6_P!;O"O[!/[(O@%?@DGP]^"NA_#B']F_P7XW^'WP*M?AQK?B_P"']E\+
MO"_Q-+R?$JV\)V7@[Q%HEI8:I\1;TQ:QX]\3&&7Q/XQ\0V6E^)/$>L:EKVD:
M7J-H_P "_L%?L@_#2?X(W/@GX%>$=%N/V;]&\1^&_@=/Y^O:E+\-_#'BK5=*
MU_5?"F@2:MK%^P\)P^(="T+Q'H/A>^-YH'A/Q)H>C>(?"VG:-K.E6%];@'@?
M_!4+Q3\9_"W[/_PGUOX0?$^]^&.I:G^VQ^P)X"UZ^TWP_IVLW7BCPC\6OVS_
M (&?"O7_  U>/<W=M=Z=HNH:3XON)->@T::QU?6[83^&_P"T].TF_P!1:Y\!
M^)/_  4>^-_A;PI^T3\<?"G@WPOK?PT_9%_X* ?##]B#XA_!6^\$>(H_C5\6
MM/\ &FL?L^_##6O'_@+Q!IGCJ\TSP?XFN?B)^T;X7\>_"?P=JW@3Q)8>//A-
MX=L[.]U;2-2^+FA>*_AS^L'QF^!_PG_:%^'.K?"7XS^!]'\?_#S6KOP_J-]X
M;U?[7% NJ>$]?TSQ5X6UC3[[3;FQU31]:\-^)-&TG7=!UG2+ZQU32-5TZSO=
M/N[>>"-QQ*_LC?LT1?$+3/BE9?!7P)I/C;2W\$SIJ.@Z2/#^G:G>_##1;CPY
M\*]4\3>&=$DL/"WB_6OA/H%W<Z/\)]<\5:+K.K_"_3KB6T\!7OAZ&1D(!H_M
M4>+/''@+]F3]H?QW\,]8T;P_\1/!'P1^*?C#P/K?B'0)/%6AZ5XJ\,>"-;US
M0K_5O#<6L^'WURQMM2L+>6XTO^VM.2\C4PR7*QLZM_*3X'_:M^/G[)FEZ[^W
MOIVE_"SXU?$_0O\ @@+_ ,$B_P!I+]HK4/','B_POXJ^/6F7WQO_ &EK#Q<+
MSQ+I-]XGOC\:=;^%,=OH\OQH\93>+;%?%GA'P]<S_#:;PEJK:!X._L=UO1-&
M\2Z-J_ASQ'I&F:_X>U_3+_1->T'6["UU71M;T;5;66QU32-7TN_BGL=2TS4K
M&>>SO["\@FM;RUFEM[B*2&1T;X:L/^"7W[!^F>#/$WPZL?V>M"M_ 7C+X0^%
M_@#XH\&+XK^(C>&=9^"_@KQ&WB[PE\-+O17\8-I__")>'?$=QJNJ:3I<4$<5
MG+XE\9118MO&WBV'6@#YV^,O[>7QI\._ME>%?V</AI/\!M7\"_$'XB?%C]G*
MU\76>D?$?XB^)?A#\:_!O["OCO\ ;$T77?BU/%J?PO\  CZI!/X/MM$U#]F?
MP9K7B/Q/>_#S7O#GQ2\2_'?X6:CXLT/X:#Z&_P""6_C'XG?$/_@G-^Q#\2_C
M)XV/Q$^)'Q*_9*_9X^)7B?QC<:?J^GZGK>H>._A'X4\575]XBDU?Q-XIDU?Q
M/<W>J75SXA\164NC:7K>HS37NG>%_#MHT6D6O;V'_!/S]BW3_BK_ ,+R7]F_
MX9W_ ,83XST?XC/\2=>T>3Q-XPF^(&A_#J_^%%IXVN-:\17.J7ESXKO/ NHS
MZ5K_ (@GDDU3Q3>PZ=XC\376K^)M(TG6;+V3X&_ #X,_LU?#O3?A-\"/AWX=
M^&7PZTB:YGT[PKX;MYHM/MWNA'$%WW<]U=RP65A;V.B:/:SW,EMH7AK2=#\+
MZ+%8>'="T?2[$ _,?XC_ /!2/XJ^"/A5\<OVO-!\*?!+QA^RU^SIXW_;Q^$'
MQ<\"ZCX\/@7X]^$O'O['&H?$SPAX:U\^*M0U36OA[J=K\8OB;\)+CP]9?"FZ
M\,>'?%_A[X<_&/X6_&"/Q;K\.B^*/ ][P_Q8_P""B_[7WPNU#X6:+_PK/]G+
M5[;XV?M/?L-?"3P+XQU7QYHUGJT/PN_;%U_XL^%6^(<WP>^$'QC_ &A7U71-
M&U7X80WWPT\?ZC\8?!/ASXQ6>K>+].TK0-"O_A7JLOB3]%[[]@7]B?4_C_XA
M_:FU/]E?X%ZC^T)XN\':SX"\5_%6_P#AQX:O/$WBCPSXCT:Y\,>(;?Q%)<6$
MEEK>J:]X0O+SP/K/B34[.Z\2ZIX!N[KP'>ZO/X0N)M%?@?!__!+O]@#X=>'+
M'PA\-_V7OAU\-/#6F?&71/VA+'2/AJ-?^'MK;?&;PLJIX/\ 'R#P;K6B2'5_
M Z IX#A>1M-\#)+<)X2L=&6YN!( ?#'P(_:<_:X\ W/[>5_^T=\</V;]3\?^
M%OVZ?V9/V:_!6B-X*^-6G?#/PQXE^)/[*G[#GBSQAX4^!/A;2/%WQ*^)GQ4>
M&;XI^/O$'P[^$6G:%X8\4_%7XA0ZEXE\5>/_ (4^$/%6H0?#+R+X8_\ !3'X
MN_&/0?V0?CSXG_92_9V;XL>*OV'O^"IGQ5T3Q!J?B/7(?%?A#XE_L7_%_P"&
M7PJ^(7PZ\+>(+;P?XVU#X9?";XY74'@;Q1XJCT7Q)\4K^6?2M/\ #<[^(5^'
MN@>-/&?Z\?$'_@G[^Q;\5?%/CSQO\1/V;_AEXN\7_$OQA\-?B%XR\1ZOHTDN
MK:EX]^$,>E6_P^\;6=Y'<QRZ!XMT2RT'0=+N?$7ATZ3J_B#1M!T/1/$MYK&D
MZ/IME:Y>G_\ !.?]BK0H=%L_"?P$\-^ =*\-^&_C#X/\.^'_ (::UXR^&7A;
M0O"_[0.MS^(OC7H6C^%/ 'B3PWX;TW3OB=J[Z?<^,+>STN%=7C\,>!+.?-C\
M/? UMX> /EC_ ()U_M^?'7]J;QWX8\$_&_P)\*/#$_Q%_P""=_[$W_!0#P;>
M?"B]\730:-HO[4B?$OPWKOPZ\4KXP>>75-2TCQ-\+[WQ3I&L:.FE6VFZ'XFM
M/!E[#XBOO#4WCCQ3Y#_P4-^''A;Q?_P53_X)+7+_  @^$_Q2\0:_X/\ ^"@/
MAC6[#XEVVEV.DZWX>\,_"#X>>)M T;Q+K+^ ?B!?:AI?AK6]5U77/#6BW?A[
M4K73]:UJ^U>Q^Q2W5U<3_J;\*/V1_P!GGX'>(_#WBOX4_#R/P=KOA3X,^$?V
M>/#US9>)_&EY;:7\$/A]J>K:O\/_ (80:7JWB/4-*;PEX"OM>UQ_ ^FS64J>
M$+?6M6L?#K:;8ZC>6TTGQ0_9/^!7QC^)G@7XR>/O"VOWOQ1^&&B>(_#WPW\<
M:!\2_BEX%U[P%I?C)8XO&B>#KKP)XT\-#PW>^-;2VT_3?&>K:1'::MXMT?1M
M T;Q%?:EI7A[1+/3P#\N/'?QV^,W_!/_ /9M^!/C7P)\%/@%\+/@Z^H_%.]_
M;#^"VGZG?>.O%W[*GQO_ &@+7QI\?I/%GAN^@^)7P\\-:_\ L]_##XP?$>X\
M>?M$VUOIFBZM\-/V9VUCXO\ AC3]&^&NAZI/X#^C+3]JC]HG5?%7Q)^'&AZQ
M^R_K_C+]DS2_V9-9_:C;6/\ A(OAMH/C[PI\:+!/%OQ*^)OPHU#5OB;XG3X,
M_"WX>_#-=<\1_#_Q7\0Y/BQ%\5_&_@#XA_#;4X/AO9:!;_$'4OJ;PW^QK^SM
MX0GN[SPSX*UK1=2U'1OBWHFK:S9?$WXK1Z_KL7QVU73M;^+6L>(=?;QNVL^(
M?&/C75-$\.76H>/=;OK_ ,;VI\)^#8M+\06$'@WPO%I'EP_X)@?\$^7U;]G_
M ,07_P"R1\&==\1?LL:1I?AW]GWQ'XI\,)XM\1_##PSX>U[4?%'A'PIH.O\
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MMK%E\3OAY\/-4T+X&Z7JV@:GI5[:_$+0OV>/%_B/PW\2='N?#FDW>E_$C3=
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MGQ$OM0\%_#+1O&?C[PMI6K_&GXJ2WVKVOQ#O/TF^.'[.OAG]H#]F3XB?LO\
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MJ7@VQT/XU>)?JVP_X)H_!#1_VD->_:7T#XA?M">'-9\<>(?#GQ'^*?PA\/\
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MQ: <QX)_:KL?V9_%WQ7^&=G\./VK/C1HO@']HOPSX?\ V@M<?Q=\>?VJ-/\
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MK;X6ZG^T1^QI\+K[6/@;\=/AWHWBKP7XM^-?QN^#\?A?2/B-KW@SXDZ)X[\
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M%%;CPUXZ\"?'O]IO]H#]KK]G?0_A/I'PJ\5^(=*^'WPG^(7Q(^).D_"GX?\
MC7Q%JGB2Q\#R:[;VWC+Q1\3G^&FGV7B6R]_\0_\ !4:T\&_%O3?@7XQ^#2:#
M\1?#_P"UG\&?V1?C7)_PL2\U#P1\._%7[3GPWB^(_P"S'\1O#'BBT^&S7WCS
MX6_&*Z,WPBM]1UCPY\._%WA?XX?8O"6M>#1X2U*V^(-=/J__  2D_9:\16GQ
M=T#7M8^+FL^!?C+\!/@7\ ]<\#WGC2QV:+I?[-7Q$\4_%WX2?$W0/B);^&;?
MXX7GQU\/?&KQUXX^+VN?%+QA\4_%WB7QE\3O%M_XF\<'7[ZU\/KI'?\ C?\
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M;FVT9S/J_A#_ (6U\8O!'C+2]3U"VD\1>&_%/@+4]/U*UG^%,6A^*P#\E_\
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M7\2OB9H?P]TKP?HGC[Q1IVI?H70 4444 %%%% !1110 4444 %%%% !1110
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M77;>^U7P-\,/AC<ZWXO^(/C[XF^*1\.?@M8^(-.^%/@1?%7Q&\0>)?$3^%_
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MHT61_'W@?X9:W%-X?\+>)O _V<_^"J/QS_:.^''[,?C30_V0?".C:_\ MA_
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M-M_PM[Q%\'=,_9/M_P!ICQUXW^!?A33_ (?S_![]I;PI\-/%$7B;]GCQ=>?
MC]HKQSX@T?XE^!O%>LZOX<LO %MIWBO4O4=4_;J_:<T#3!=>(?V,- T&X\30
M?!>7X7ZGKG[5'@RQ\'>-+[X@>)-4TOXE>'%D/PV'Q8U;Q1\*O#MIX>\2Z!X=
M^#7P8^.&H_&N\\=^'?"G@%H]=BU:#3/HW3/V$_V:M(\0Z9KEA\-K,:=H,[WG
MAGX>7WB'Q7JWP:\(W_\ PS_IO[*,%YX0^">IZO=?"GPJ+?\ 9MTUO@];:;X>
M\):7H5MX1UGQ="FD/J?CKQKJOB#P?P;_ ,$@/V%_A_;^!+?P?\.?B1H;_"SX
M@?#'XB_"[58/VHOVI[KQ'\,;SX/:+\4_#WP]\#_#KQ)??&*YUWP5\&O#NA?&
M_P"+VB0_!+P[J.G_  GOM-^(WBA-3\'7<]Y%+  ?.OPA_P""P?BCXRW/[+%Y
MH'[-.CZ#X0^/7_!/23_@HUX]\3>+?CM?6TOPJ^%G@_XP?"/X=_&/PEHGA_PY
M\!_$VK?$_P 3^!O!GQ.O/B-X7E8?#RT^(E[X=M_!,!\-RZV_B'2//?VSOCU^
MT%\8/A'^RQXXU7X'WOPS^'GB#]L'_@C5\9?@K\4OAW^U8=>\,?%(_&/]M3X<
M:1XK^!WQ:\,^$- \ WQN?#?A35/#.N7EGJ>B?&CX$^)%\:6'B?PQXID\:_#S
M3H4_1[X(?\$Y_P!EG]G+Q)\)O%7P>\$^(O"^H? WX">(_P!F#X66.H?%CXL^
M-="\+? ?Q7XLTWQWKWP\;2/'WC'Q3:Z[8:AXNT'PWJC:MX@34M?LXO#>@:3I
M6IZ=X=TN'0W\Q\+?\$A?V&_!.A:3X8\)?#OX@:'X>\+>,_AWXZ^'^BG]H_\
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M)>IZWK/@'QMK5O>^*/#.D:WK_A'3KR/P5JE]H! /COPW^US\2==^&/[-6O\
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M/ 'Q)\+V^KZ=H7C?P3XX\!ZQX?\ %GAS7;/1O$7B70;B33M7AM=9\.^(M?\
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M07P:\=ZG=^&M;T?X;:VUIJ%P/$?Q(L?"7B>'Q]IOQ?\ A+<>"[OX"_%OX/\
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MYG7Q?HVJ>$O!5]9ZU9/:7:S> ?AX6=U^'_@Q=#]K^'O[./P0^$7Q%^*GQ:\
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M!SXQ_ #]GGXW>!-2\67OA'Q3X7\/?$K]F?X/_%.T\<?"R_B;_A#]&A\#Z_\
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M'IG[+7Q)\>?%#X51>(?BKX4\+^"/B1I'B_XA> O&7A[PAXQ\)^--$AU3X?\
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M>,?"OCKQ#\/?A!JFB_%?QKJGQ2^-7PWC\0VNJ6^BZ7XF\3^.9=;LM.^58/\
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MKL_@6;PLVG>#AX4 /S[^&G_!7'XZ^"/V3/@?XQ^,/P=\+?%#XF7?_!#/6?\
M@K%XJ\::1\7X_!\?Q+O?@SX5^!UW\0O!VI>&K#]G@Z)\/M<^(MG\4W\8Z;<^
M&H]=\-^&_$$%YX(M]*_L%;'Q8GW]X'_;1\>_&W4/#T/PP_9W\1>//ABGQ5\
M_ [X_P#BCP_\5M,\,_$/X.:K\3?V>O 7QM?QSH?@V^\.^'_^$W^&/@?_ (7%
M\,_!_C/Q3HGQ'\%_$_2[R]\5^-/"'PTU_0?"5E+XAXS6O^"./[&7B'X5_#SX
M/:K9_&]_"GPQ_9U^(_[)7AV^T[]I/XW:!XIOOV:OBEH7ACP]XA^!7BK7] \8
M:9-XI^%.FV/@3P')X<\#:Q#<>'+"Z\*6\MUIE['KGB^'Q)Z!I/\ P2\_9:\.
M?%+P]\8/"4/QJ\(^*-#T_P"%MMJ>B:5^TQ^T!J?PZ^)6M? OPEX6\$? _P ?
M_&OX;>*OB#X@\$?&OXF_"30O!'@]_!_C[XJ:%XO\22ZUX6\-Z_XIU#Q+J^A:
M7=VH!^;O_!)#]L#X^^-?^">VBV7P;T#P]^UQ\2_@-H?[14WQBD^,7[5WC31_
MC#J?Q?O/C1\5/&OPF^%,UYK7P@^/7C+Q/J'C#X;WGA^_G^)7C[Q+HVGVZ:OX
M5TKPQ_PL/4+3XB0_#S]2?V*_VQ]1_;*\'_#'XH^&? OAW2/A;\0OV7/@;\<+
MWQ%:?$;4/$NL>&/BO\7D\27GB'X S:,GPP\/:3?:A\*-*\/6USXN\3W7BO1/
M$:WOB;0+6Y^%FDZ?J%IK$OE'A+_@GUX*_8S\'6?C_P#8\\/^-?%'Q7^$'PF\
M;^!? /PX\5?&VS\ ^'?C-X8U[XF>(OC?%\*/BI\0;SX7^/FN=/M/BCXO\<Z]
M\-_%_B'PUK.L_"R^^(/C?1O"6N>$?!WCKQG!>:WA']@\^&?@?HWP[^'_ (AU
MWX"Z_P"*/VOOB)^V!\1=;^"7Q0\=^![C1_%GQ1^*_C[XO>(_#<,V@6NEV_QB
M\,V<WB/0/AP_@3QW8:#\)O%.F:'IGBSQ1X'UKP]X?@^$GB( ^HOVJ/VD_AY^
MRC\']8^+WQ*\4>"?#.CVNIZ%X4T ?$#Q_P"$OAAX:\0^._&FKV?AOP7X:U'Q
MSXUO;+0?#=AJ&LW\4^MZW<F[.A^'+/6=>_L[4(M+EM9/YTOV&_VT/&W[3/QC
M^#?[)-S^U3J7QT\(_$3]NG_@L/KGQ@^)_P */C)J6E>,]2^$'[.'C"YT']E_
MX?Z%XJ^$WC"/Q%\'O@YX[LOB?I7Q6^'X^'_B[PLVHZ/\)/#/A[PEJ>L?#76_
M&MCK']6%W96E_ ;>^M;6\A;!:&ZMXKF L,$,8IE9#M8 C(R,#D'FOB_2OV!/
M@!X<L;6'PCI?B'P;K.F_M2?&']LG0/&.@^)+R3Q?X3^/WQ]/Q"M/B[XG\.:G
MK$&IV$6E>,_#?Q8^(_@J\\+ZGI&I:#8>&/%5P-%LM+UK2?#>L:( ?EGX*\4^
M*_VE?^"76F?M!?&[X_?M2>'?BIX)\/?'K]G;X8+^S[\8M4^!?CCX@_M,?!+]
MHOXZ?LI?!SXGFV\!>)_A9I?Q@^/7[0OBWPI\.Y1\'/C'XAU[]EZ^^(^I+"/A
MEHWA_5==O#Y)XU_:#_;1^%?[/7[4?Q\^,WQ4U_7_ -I?_@GQ\:O^"7'[/]_X
M3^'^NWGA;X'_ !$\5^*?A%^PMXO_ &P9-<\ ^&K/1?!'CFX^/^O_ +7OQA\&
M:9K7B#X?W4'PRT+1OA)XS^#_ (9\$>/_  ;9:N_Z_P#B3_@G#\#M5T/]G7PI
MX3\2_&KX.>#OV4? J?#WX!>$?@Q\7?$O@;1/AWI*>'%\%?VY8G9JNKZQX^/@
M;[3X''Q#\0ZMJ7C2'PCK7C+0K76X+3XC_$@>+NGT[]@/X :=K6@:_-8>,/$N
MHZ3!\ +KQ#-XS\?^*/%=S\5?&O[+7B6\\9? 'XJ_&#5]9O+OQ#\0/BG\./%V
MHZAXIA\8ZIK*W7B[6CH%SX^M_%+_  \^&,O@P ^6==^$OQ$\ ?M\_LL0?!O]
MHG]I;Q_XHU&[^+7Q!_;M\*?$/XP7'COX)S?LTZOX$\:>'OA'K%]\$-6U*7X<
M_L[>.[_]H?1O NA?LY2_L\?#?X27WQ+\$^ /VD[[QOJ_Q!D^'WCS4)_M;]J?
MXW^/O@K9?"M? /A3PQXDO_B9\1;_ .'UQJ'BSQ)+IUAX3:'X5_$[XAZ3J6G^
M!_#FG:_\5OC)KGB+Q#X T?P%:?#SX/>&/$'C#2=-\6:S\5]4LF\$_#3Q3'-Y
MWX,_X)_?#7P/\5=;^+>G_%S]J/5=7\5_&/4/CQXS\,:Y^T/X\F\ >-?B5=V>
MG:=IVJ>+?"&GSZ=8:]HGA;3-!\(Z'X,\%7DA\&^$O"W@+P%X+T+0[/P9X0T/
MP_9>N?'7]E/X2?M#^+O@MX\\?V_C"S\9_L_^*/$'BOX7^+? /Q&\>?##Q1H%
MUXP\,WO@SQII)\0?#[Q!X=U:\\.>+_"]_+IGB#1;B[:"[^S:?<P/:W5G'. #
M\U? W_!7FX\<0_L*:C?_  Q\-?"73/VYO@G^R+\3_AS>_&#QWKGACP9XP\;?
MM%?$&XT#XH_ CX5?&5OAHGPOU[XV?L^?#VQ7XE:1\+O%NJ>%_'W[2Z>+O!?A
M+X4^&=(U4>(K_3/HG_@KW\>OC5^S1_P3;_:<^/G[/^N^$_#_ ,3OA[X BU72
M/$/BO0M4\0VFDV>L:OIGAO4M7T'3--US0(QXOTRTUUM1\':CK,FJZ!H_B"UT
M_5]:\,>*+*RET#4=KP?_ ,$N/V5/ W@/PS\*=$T;X@7WPK\-^!O@C\-)?AUX
MO^+/COQYX8\2?#_]FGXE>+/C!^SWX.UM/&FI:]JEEI'PA^(OC#4-9\-2^$M4
M\,:AK.FV&B^#O'USXS\!:<OA*7ZF_:/_ &=_AI^U;\"?B/\ LY_&C2KW7_AC
M\6/#$_A/QIINEZYJ_AK4Y]/GEM[N*ZTO7M%NK;5M-U'3=1L[/4]/GAN=ANK2
M%+Y+RS:YM;@ _GY^(/[57Q,_85_;._X+,?M&:5X$TKXO>'/A=X2_X)2^)?CA
MH.O?%3Q=X9:Q\+^*O"_Q;\)>*5^ ^GZQI/Q)M(=;74-7MM:TKP5K-Q\/_ :P
MPSH^O0ZQJ^IZO;?J==?MV^)]>^-[^ O@Q\(_$GQM^'W@O]IJ+]EKXY^(O#&A
M>,]#\0_"SQ')X>TR_P!;^)1U;Q/X0TWX2ZUX)^'?BKQ3X0\.>-/!DOC[2OB/
M?>$;O6?B9\/++Q\+/PKX(\>-\:_\$JOV;/B+HW[2GA_QGK?QIU_3OVN?"'P0
M\$?'RXU;XIZCK&N>-M"_9YFFG^&*MXEUC3-0\3Z5?Z9+>:HVJ:MI6N6FI:\N
MK7,6K7-U%::0FF]_H_\ P3K_ &==$_:4UC]JJPB^*5G\2_&.L>&O%WQ,\/:9
M\;_BKH7P.^+'Q+\'>&=$\+>%/B]\3/V<M \2Z5\"?%_Q/\,V'AGP]=:%XBO/
MA_#;Z9XFT;2/'EAIMIXXT31]>L@#UC]I#XW^)/@IX"\+^)O#'A/3?%]WXD^*
M7P_^'>IWNM>)]'\,:7X+TGQWXB709O&/]CWEQ'XE^*&M:9<S6>D^#?@G\,+/
M6?BK\7O&^J^&_ GA*SM;K6;K7M(_-GP%_P %9?%7Q._9^_9"^)-A\-?AQ\(O
M&G[5%O\ M>:*^O\ Q[^(FN^#/V9/A_\ %#]CK5O&_A#6?AGK?Q=/@B'Q+:^)
M/C9XI\&:SXC^&6CZWX&T;Q7I?P5\#?&OXD:MX6U3Q)\(;OX9>*OTS^/W[,/P
MR_:3M_AI!\1QXRM+CX/?%_PM\<OAMX@^'GQ'\>_"KQ9X4^(7A71?$GA5+ZR\
M2_#OQ!X<UB?3?$/@GQMXZ\ ^+="O+R?1O$'@SQGK^EWEB;N6RU&Q_*OXL_\
M!.G5O@I'\ ?"G[(GP[^,/B3X._"^[_:FU"^\,>#?^"@'Q6^$7Q2T+QG^TK\0
M?!OQ(UZ;3I/B5:>,/!_COX:C5O"7B!!IFO\ C/3?%'A/Q/XBB\1>';76]4U_
MX@>)(P#T#1O^"GOQ=\?_  8\$^(OAM^RWK=S^TQK'[*GP5_;%U_]DS7)OBUJ
MGBJ3X??';Q+\0=$\!?#71O'WAGX!-H7ACXEZ[!\(/B?"?$'Q3T7P;\/O#'B_
M3_ F@>(]07PIX_U;XC?#;-N/^"H'QQMO%OBJ6^_9K\"Z7\,OA[_P4U^"/_!/
M/QIJ-Q\=-0NO'O\ 9_[2_A[]EV[^$GQ/\.^';'X.W/AS4_%&AZQ^TWH,_P 6
MO EYXMTOPQX?TK2-0T_P!\2/BA<^3KA]"\-_\$P/#'Q3\/?!WQW^U=X_^+'B
M+]J/X9Z/\0? S_'#X)_M&_&SX1^/=3_9\\<?%6\^)VA?LF_$KXN?":^^"?BK
M]I#X3^![!/!WAB]\6?$/PGX6\2^/-7\'3?$271?"'BCQKXNM[CVG4O\ @F_\
M#]2L?&VGC7_B7IEKX]_:P^%/[:VKVVD:_P"%[2UT_P#: ^"<'P_L_AAXBT*U
M?P+/;6/AWPC:?!_X-6]CX#D@N/!UY#\+O#T.J:/>+J_CH^,0#B/^"9?QX^/'
M[0FG?MD^(OCMK7@O6+_X:?MZ_M.?L\^#X_ VAZSX=T?2O"?P$\56GPTL+6+3
M-:UWQ!<I#?1Z##K[-)J5Y/+X@UGQ3J#W$%KJ5CI=CF?M#?\ !0[Q)\(X?VV?
M&'@3X4V/Q,^'/_!.BW^'>M?M36DWBP^$_B+?>'->^&.@_'[XJ/\ !C3]9T6W
M\%Z_K7PH_9T\6>%?B1H.F^)_&.E1?%WQEJ6K?"A+[X9SZ-8>,?$/US\ _P!E
M#X3?LU^)/C;XC^%,7C+21^T!\6O&/QQ\?>'=7^(OC;Q5X/M_B9\0]3?7_'FO
M^#_"GB/6=0T7P<?%WB6ZU#Q#K5OH=K;1R7]Y]EM/LFB6>F:38<=\2?V%O@'\
M4OB'\0?B/XDT37+;4?C1X.\#?#G]H+P]H'BG6=#\#?M&_#SX;ZQJ6M^#?!OQ
MR\%VTTF@^.-'L&U?5_"VNO\ 9M,U3XA?"G7-<^!WQ-U/QG\$=4OOAU<@'YP_
M"7PG<?M7?\%2/V_O#?QU'A[XB?#?]G72?^"='B_]GDP7/C+PIXO^#<^HZ1\5
M_C)H.M_"KQ5X9U?0-?\ !^N^,/$]O;W/QIO['4K:Y^*/AVWM/AOXREU_X9VM
MMX*M_IG]IOXL_&O2O^"C'[!W[+WAS7?"^F? G]HKX4?MD^,OB=IT5OXOTWQ]
MJ<WP.\/?";0H=.T[QIH7BK3FT;3+FP^/EWJ>D0:-I^EZII?BGPSH^O-X@G2Q
ML--M_JKX<?LI^"?AC^T#\<OVE="\1^-[WXC?M'6_@.Q^*\.MZMHUWX8U.P^%
M=KJ6G?"^WT71+/PUIK^'SX$T/6M=\.Z;+IM]!/KVFZU=WWCN;Q?X@MM*U?3Y
M?C)^R;\,?C;\7?@9\=_$=WX[T#XK_LXP_$FT^%'C#P)\0/$W@ZXTK3?BU9^$
M(/'6AZ]HVEW0\.>-/#^M7WP^\":U/H7C#2-;T>>^\)6-AJ%AJ/AG5_%/A_70
M#\"/^"97_!1?Q1^S)^PG_P $^/#?[0G@&VM_@;XI_P""7/[1/[6=O\;-'^(.
MI>._C H_8NM/ /BOXU#QS\+)_!=EHYL/%OA/XIV6M?#O4M ^+'BSQ7J-]HUS
M;>,?#>@W^L/;Z'^V'[/G[27Q?^*?Q0\>^"O'7P<N?#?@"P\&>"O'OPQ^-^@0
M^.M/\"^-XO$<UY9>+OAS=Z-\6_A_\,/';^+OAY?6^D:C:^//#'AW5_AE\1/
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M-GX>T;X@_#_Q5HGP6^(>NWGA_P =?!+XD:W%\8?$?ACXB?#K6M&TCP]X=O?
MGAKP)\,OAQXDTOPIIWBSXA^!O&WQ1UCQ+X[U#[U_:F\1?!WX,?&GPM^U#\4]
M.NT\._LY_L5?MM_&;Q7J>E+J]W>6?A;X5:K^SCXCUS58?"UC>V^F>*_$'AOP
MKK/CR/P6=2L;V^T.;Q;XGL?#-YHX\7>(#J/UA\=_@)\+OVD?A]/\-/BYX9;Q
M'X:.O>&?%NESV&O^)?!OBKPCXS\%:W9>)O!GCSX?^/O!&K^'O'7P\^('@[Q#
MIUCK7A+QUX(\1:!XI\-ZK;17VE:K;RJRR5?#WP)\+V=SX@U+QUJ>N_&76O$O
MA;4? NIZO\6&\/\ B%$\"ZX8'\1^"-,\+Z1X<\-^ =$\-^*IK2QF\;P:+X1T
M^\^(1TGPU%X[N_$-MX.\(0:$ ?FW\0/V^OCSI&@7'@G7/A_X4^%?Q&^.O[ /
MQ;_;"_9<\>>'O$(^)/A?2=6^#GA?P?JGQ?\ AM\3-*\0>'?">IP^,OAU;_%O
MX0>(? GBJQ\,ZEX%^)JZWXQT[7?#W@R7P+;6'C?\]OV>/V>O <WAK_@WF^/N
MOZ-/_P +9_:>LO@W8_'OQ)X=\>_%71=,^/NF>'_^"6?[3_[0WA_Q-\>O \'C
M:/P'\5?BU=_&+1]#\>>,/BKXQ\-:YX]\7:KX?T&PU[Q/J6@:5::/%^U/@_\
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MBK]F/Q@GA:]_9Q_; \*6/P-^(%G\)/BEXMN]9T70'Q?M>^%/B-X+_:#^'_\
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MZYXPNO$GW;0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M?^('C;XD>+M.\?>._$%_J<^UX4_X)Z^-_AE^T'<?&#X4?MH?M+^$OASX^O\
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M7R)XQ\7K8_&NV-OJ7A:3X+?#,RZ/HQMK37T@\?HM[X>/B[PW+\/_ #_X:_\
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MC ZY'X$\!P^.?A1X)\4^.)O#&F1ZKXA30=0^,WQ#^%G@&"/2K>ZTV&ZN]?\
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M;?M@_M%?M:^ ]%\<_#OX9^,[2.X_:4^ ^I_!;Q/\+?'GB:"#PW\0/'G@_P
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M4'Q)\3_#?QE\(/!7P^\;>*_CMX1^&6D>'[N<?G/\$OVS_%!MOVB[W]ICQO\
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M6'4]3\/W'B"/4O!OASXC^%?&?AK3-2M;OQ)\,?B)X)\5JFD^+?AG\3=)BN_
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M$7PD^(>A_#CXGZOX[UCP]I7A;PIX@M-4348N*_8R^./QH^)O_!2'_@HY\/\
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MQ?\ $/[!G[)W[1/QQET_Q9\-)_B7;>%_BIX)M(]0^+VH>"/&WC[P'XQ^(O\
M;.L^%_BOXBE\+_!'PI\1_B#K$'P[\4Z1X8\&^)/&=]X)\+>,/O/QG^VCH6E:
MQJ.B>!/@G\?OCAIFB_&+PO\ L_\ B[QK\(?!N@ZMX4\%?%3Q?X=T37M,TWQ
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M^&?[57Q.^/O@?XN:#>>$- U[5+BP^#7[.OCO]H/P[>^$?$FH6QNO"UWK^I>
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MOJWP\\0:SIDEG:>)+*P-YIEV9(DED@:XTK5M$\0:9'<MJOAK7-$\1V&E:M9
M'S]JG_!3?]DCPWK5GX3\8>)?B+X/\<W?[04/[++>!-:^"/Q@N/%-G\>=2^#V
MD?'_ ,,?#N]M- \%:W91:SX^^#NO:3XU^&VS4)8/B+'/>>'?!<NM^,-#\0^'
M=)V/#'_!0W]F[XA?#;X;^._ 6N>-]8U;XO\ Q'^)GP8\ _"Z?X7^-M$^-LOQ
M>^"D_C.#XS> /$?P<\6:;X7\:^$M:^$A^'GC*;X@+XLM?#>G:=!H]M!::S-?
M>*O!47B#\_\ PU_P2A^.WA?X_>%/BW;_ !3_ &<[;PK9?MV_ O\ ;G\0>"/
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M&O\ P!^/7@[PA!\?O@C'XKOO'_P*\6^+_&WP\T#P_P##WXLV^G> /'&JZ'X
M\>7WAOQ!KVE^$=4N-&L;B)]+74/F3X9_L1_M,ZY^T$_[6MSKOP&^$.B_M6)^
MSE\;?VH/V9_BG\!O!_QX^-7[,/QO^'WP ^$WPO\ &W@7]F+]JKPIXQ\)^'6L
M=>TKX8>"/!'BK5_%WP[\=:%HFJ^"K_X@?"RVTVY\87-G:Z'@_P#X)V_&OP\W
MP+:\\8_"V7_A5/\ P5<_::_X*0ZFEO>>+9?M_A_]HV/]I6.3X1V#S>&X0VL^
M$/\ AJOQ8T?C6:.RL=</PV\.Y\+Z0WC[4Y/ @!^GWQGT?XM^)/AY?:3\"_&W
MAKX=?$/4-:\#K9>-?%GAB3QCI6A^%5\=>&+CXCSVOAC[780ZGXGNOAI%XNL/
M!/\ :-P-'LO&5UH-]KD%UI%M?6LWYX_!CQ7^V3\9O'/[8WACPA^T=H>EW7[+
M'[<GA[X!:%%\0?A'X*\0Z%XP^"]Q^S5^S%\;?%=]XJC\&6'@'6_^%I6>H_'G
MQ+_PB^K^'M6\/>$;FR\*>&_#>L^%4GU75_&MO^L4:A$1-P;8JH3A5R5 7.U0
M%7./NJ !T  %?!_[,7[/WQT^!WCW]M_QQXFU;X3>)H_VGOVA+O\ :-\%:%X>
MO/&6CMX5UJ+X%_"'X#Z7X"\6:UJ>E:NFHZ9<:%\#O"/B#4O&FC:%:W4.L:_X
MCMK/P9+866DHP!\R_P#!.'_@IWX"^-_[,G[*B?M ^/M?C_:)\??L*Z+^UK\0
M/&6M?!_QEX$^%7C?1O"6D>$%^.VN> /B';^#-)^#GB?4OA7K?C7PNGQ%\&>
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M_P :/#/@CP=X)\4^*-38Z5^S3H;R?##1='U_687\<ZV+/7]8'@:R7QQ]!_\
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M_&?]ECX?Z+J&K?$7]L?P!XQ_9>\-RV&C7FI:7X*T?XW:!J'P_P#B1\9_&EW
MUGI.@^!_@G\/O$7B+XDZS=^)-;\/P>,-9T;PY\(_!EYK?Q;^)?PZ\&>)^_\
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M$?$T]N/"OC/Q7\*M7U73['XG^#_"^N:MXK^',]Y;Q>-='T9W)'SI^WS^S?\
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MO@+J/CK2-/\ BOXMM==E\*>%M0M-7L8O%5]X6T>T\3^)_#7ACQ-<V2>$]?\
M'WAWP??V?C;6OAGI.MWGQ TOP-*WCF_\/6W@^*76T^)?AK_P4%L?C%_P4?\
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M/X!>#K[1?!/@*P\0VUQ^T!J7[3O#_"7_ ()Y?&_3=$_8H^!OQ/U_P+I?P/\
M^"?GPV^-O@3X2?$;X0>.?B)X:^.GCF_\2?"KQE^R?\!O$L>+#3K+X2ZQX"_9
M1\?^+KSXCZWIOBKQKJ6M?M :EHVO?#R'P?X7\(PR^(@#V&S_ ."ANN>*OVT_
MB/\ LQ_#7X31>.O"G@7]CCQ[^T)X<\5V?B":RU_XK_%/P1\>KOX%ZA\-?"=A
M<Z?_ &;I'@_3_%&C:MX:D^(&KS7":WXHBU:ZTS2[;P7X<T_Q1XXL_LI_M3_M
MA>(OVI_BS^R-^V%\#?@OX8\7>$/@QX"_:0\'_%O]F#X@?$3XC?""Z\ _$GX@
M>/OAKI'PP\<2?$SX<_#OQ'X<^*VF:Y\,_%6KZ3JT%K<^'OB5X5T_6=4TC1?"
MUSX5UBQ?Y[^'/_!,CXL_L]_MS:5^T[\*OBIXX^)?PO\ AC^P'JO[.GPT^%_Q
MB^/5[:ZCXC^(^G>.->UGP5\.O&5]I/P1U^RT3]G[3?#UWI4]GX@L?^$F\7>'
M/&MEIVKCP1XEL=(^S:A[O^PS\*?V]/!/Q&\?^,_VOO ?[).G:U\4-/O_ !/\
M4/B?\&OC/\6OB[XW\=?$73[WPQHGPI\&>#_#WCCX!_ [0/@9^SI\%OAI#XZ\
M->$OAO8:G\4=8UCQ!XF;XA>)O%&H_%/Q3\:OB-\8 #O'_:N^(GQD_:X^.G[)
MG[-\?P^\/2_LEZ%\*-5_:/\ BU\4_#/C'QY9VOB[XZ^$/$'B_P"&/PE^&7PX
M\'>)?A^/$&KV_A73;#QY\3/'?B'XH>';7P5I6M>"O"^A^!?'=[XYU;Q+\,^N
MT#]K>Z^'GPGO?&'[9VA>'/V=_'ND^.?C7H5UX*\/ZCXK^*5OXE\%?#'Q3XEO
MM)^)'PQ71O"%GXX^('@R[^"UMX4^*'C/7;+P%8K\/K._\3MXTT[PW:>$M5D@
M^?M:_9=_:F_9X_;5_:._:U_9"T?X'_&'PM^VCX<^%,G[0GP:^/WQ2\:?!#6O
M!_Q;^ O@RW^&WP\^)GP;^+/@;X,?'NWU'PIXK^&<=OX5^(7PF\;_  UMIK#Q
M-X;T'QUX/^)-I:ZKXD\'7'6^.OV>_P!JD?M,? ;]L_PY=_"WQO\ $'P5\$/C
MW\!_B3^SWKWC?Q5X/^&&F>%/C?XF^"7Q0TW5_@W\2K7P#XEU>Y\8>"O'_P"S
MYX,\-^,-=\=_#/3T^+'A/Q+JWBNPLOAA<^"O"GPTOP#UKXF_\%%OV(/A-?>%
M-)\8?M3?!:UUGQW\.?"GQ>\$Z+HOB^T\<:]XN^&'C[Q?X1\"> /'_AKP_P"!
M#XBUG7?"'C_Q7XX\-Z+X&U_3+2XT_P 83WMW<^&9=7LM#U^?3>3^"G_!2/\
M9Z^,?[+2?M@2W'C3X=_!Z7Q!\7-,AN/'?PT^).E^)Y- ^$7B_P 5Z#KGC4>#
M5\)/XKE\,P>&_"TWC?Q5JMEHU[I7PYTUM:TKQMJ>F:KX+\81Z/\ &O[#_P#P
M3$^*/[&'[1G[+/B+2-1\"Z_\%/@1^P+\?/V;/$%S9:_>Z5XI?XN?'[]JWP)^
MU+K9\ ^ 8/!5IX<TOX*^%+WPSK7@?P?!>^,;7Q+8^'[CPO87.B3)H][J5YX?
M\'_^";?[?'P'^%G['^DZ#H/[%_Q5US]E6Y_;=^%GB;X3_$GXN?&71_AS\;O@
MI^U?\8_!OQT\,_$O2?B-H?P U;6/@U\:OAOXU^'GA;1CX7D^$_Q3\/ZEX'U#
MQQI]M\0+*]\30#2 #]GOVCOC3KO@O]D+XP?M$_ _6/A[XEU/P?\  KQ?\;?A
MYJ^M)<^-/AKXQTSPMX*OOB#IC?;/!GBC1)M2\.^-=#TW[+I'B70?$,\%C%K%
MCXC@M?$%K:'1M2_/76O^"C?QV^ '[,?[*'[<G[27@_X2>*OV2OCUX;_9OU#X
MZ>*OA99>*OAYX\_9$D_:7TSPM9^!_'%[X9\9^,?B)I'Q^^%-A\2?B!X+\!_$
M"^T/Q!\*?'O@?2KV3QUH'@?XGQO>>%M$^SOBI^S_ .-6_P""??C[]E[X2>%_
MA'IWCG5_V8_$WP+\&^%=#B;X/? [P]JWBCX>WW@&VM=$M/#OA?Q5<^"?AMX3
M.K/<Z3INE>%-<U2W\/Z5;:?%8WFHREV^"O&W[ /[4'[1W['7[(__  3R^-^F
M?!+P)^S)\,/!/[+&A_M4^)?"'Q1\:>-OB9\:K;]F&V\$>)+'X8?"O3'^%'@&
MP\ >$_&WQ/\ ACX+U/7?BKJ7C&/QI8^#XM3T;1O ECJM^-6L@#]3[W]H?X97
M?Q*D^ ^E>._#D'QFUOPYXVU7P1X8UVQ\1Z;8>+IO 3Z18>-?^$6UV:PM=$\?
M)\.M6\3>%K3XGZ3X#UK6/$'@+^W;&/Q59:#<7$ ;YW_X)S?M)_%K]L__ ()T
M?LZ?M.>)(?AOX+^,?QU^$:^,KB/P[X5\5:C\+_#GBC4KS5;+3GM_"6J>/5\6
MZEX>L3:V<E[ITGQ#M;_4 MR+77=/CG@>V^>?V8OV,OVF/@]\;-7U+XJ?#W]C
M[XH^"/AM\;OVI/CC\ _VD7U3Q1>_M;:QI?Q^U;XG:WH?PJ\:^%=;^$4/@?X<
M^--%;XP>*/#'C+]HOP!\6]8U#QKX!T#2_"NH_#":X\?>-O$.G?0?_!,C]F[X
MO_L9?\$[_P!FW]F+XH0^!M:^+'P'^&/_  A&IMX&\3ZMJO@CQ)J&D:CJEUIU
MQI7B'7?"OAK5[6SU:"XMEEFO_"\<^FR22LUG=K"$D /E[X#?\%,?BS\<OV6/
MVFKG5/!GPZ^"O[=?[+WPIN_C%XB^%GC"PU[Q?\*_B#\*M=\'77Q4^!?QO^';
M:'XUT+Q'JGPC^/?P\MAIHN1XEG\4_!?XF6_BSP/X_P!$O]=\%II/BG]&?$?[
M3GPB^%_B;P7\+/BM\7? .F_%/7[_ , >$KR*VLM5TG0D\:_$6ZN="^']GKP:
M_P#$UA\)IOC1XHTO6M%^!_ASXD>,+;4/B9XBT[4/!'P]U?Q]XCTF_8?G#\9/
M^"</Q?\ CC^R_P#LTW5GJO@[X _MU_LT?!*Z^!V@^+O!WC_Q)X^^#7C;X5>+
M?".B_#+XY? 7XFW]YX"\#:SXX^$GQI\&:%9>(M$U2^^&UIXQ^"GQ8T?P5\1O
M!7G7WAO6M+\7W?VEO^"=_P :/C/I7_!1/X!VNH?"KQ'^SG_P4F\6_#GQSXL\
M7^,-7U[3_BU^S]XBM?A=\$_@)\4F\.>&9?"'C7P=\3[.R^&_[/WP^\=_ FXG
MU7X>ZEX3^*;ZEHOB-I_#=GH?B>P /T$UC]LK]FCPW\3[;X/^)_C5X#\,^.[G
MQ:WP^AT_Q!?7.C:)=?$E?"^C>-3\)M/\<:C!;>!;[XQCP=XAT+QD?A%;^(G^
M))\&ZO9^*QX5&@LM_+(_[3?PM\=>(/''PI^#_P 3?A_XA^,>B^$/B7K/AK1M
M4;7)?#&L:M\+_$9^'7C>YL-;T^&UT_X@>'_A#\6KC3OAW\>K/X;:WKNM?"KQ
ME/'X"\;Q>'?&.H6NCM_.9I/BSX?:-^US\3-4TJP^ OQK\&>'O^"K7BCXW>'_
M -C?X5_MT:<G[1NB?M)67C!?V9_%'QQL_P!C'Q+^R4_Q=N_'FE)K'B;X]^+?
M VJ_M>>&_P!GVX\-6LOQPT30M#T:\BU+4_OSX*_L6?MU>!_VE?A3^T+\1-+_
M &5/%^J>!?!'_!1WX=>+]2^'OQ9^*?@'3?&&B_M/_&GX/?&7X):_X#^"-U\!
MM2^'_P *'T^U^$S> OB+X.TWQ?JM_+KOB74/CKXQ^+GQ\^(VH>*QXN /TB_8
M+^.7B[]IS]B/]D;]H[Q]IWAO1_&_QY_9O^#'Q?\ %VD^#K/5=/\ ">F>(_B+
M\/M \6ZQI_AJQUS6?$6LVFAV=_JT]OIEOJFO:Q?Q6<<*76I7DP>=_)O&G[6G
MQ#\7?MD7O[$O[.NC^!F\5?#3X,^&_CQ^T=\9_']MJOB_P=\)M"^(GBG7O"GP
M>^%VC_#?P;XH\+^(O%OQ9^)9\(>,?%]W;>(?&WPZT3P3\.M&T?Q793?$*?Q?
M8:)I_%?L">&OVD/V9_AE^Q[^PU\1O 7PEU/1?@3^PO\ #CPG\0OBO\.OBMXS
M\37^F?%?X67&E_"S2],7P7K_ ,$_!VBM\-OB+X:T"\\5>%?%ES\0['QW)KVE
M>+/"DWPL72O"UWXUN,KXF_LK?M*?"G]M3Q5^W%^QS8?![QWJ_P =_A)X!^#7
M[3_P$^//Q,\6_"30/%4?P;U+Q1?_  7^+WPR^+OA#X._'_6/"'C+PMIWBW7O
M!GC'X<W'P\'@/QQX=U*RUV'5= \8Z ^H^( #W;3_ -K.Y^%7AWXB7G[8MIX8
M^#>J^$_B_P")OA[\/[GPW%XL\3VGQ]\&:!\*?#?Q@B^)7P@\&V^EWGQ/\3K9
M>!;_ ,6:Y\5_"NC>$];?X+WWPS^,%A?^(/&GPY^%=Y\;?$]_5O\ @H3^Q=I'
MC'P)\/Y?VI/@'>^-OBCHOPN\2?#OPQI'Q*T'Q#J'BSPS\<-:T3PQ\%_%VFMX
M5N/$,)\&_%7Q+XJ\)Z3X(\62F/0==D\2:,^E:AJ"ZKIOVOY^_:1^ /[;GQ_'
MP+O;BW_9ITS3[+6OC!%\:?AQ!XV^(.DW?ASPYXU^%>H^#? -O\-OVA],^%;^
M/O%FEZ/XEN[G7_B_X/C^'OP3B^,]G/X7\%7GB7P]\/O"WCCP[\9/ OV!/V#?
MVK?V:?C1^SO\0?BSH_P,N=%^"O\ P2&_9I_X)ZZ@_P .?BOXQ\4ZSJGQ,_9[
M\<ZWKUSXJTJT\3_!?X?06O@3QUH5WI#W$DVJQZSHFNVTVES:)XCTRPL=?NP#
MUO\ 8F_X*5>'/B/^R1\+_C;^UQXR^$?PI^*'CKQ!^U;'K^E>#M.\9:=X$T?P
MA^SK^U'\3O@3'XSN(=>U+Q=JGA/PS/!X=\$Z/J'BSQMXBTG1]>^)OC#1_"OA
M](/$'B_PGX)38^"7_!2'P'#\?OVC_P!G3]IOXE_!7X9>/O"W[>$W[*W[.6CZ
M>?%.DR>/_#VM_LZ_LX?&/X=:5XS\0>(]4U;0;;XM>,O$'QD\2>#O"D$D_@K3
M/B5K?AL^$OAGX9U[7]&U66[_ #U\"?\ !(_]KOP_^SG\+? UIK7PC^$?[2/P
MD\+?M<Z3\-_VD/@W\:/B$FL>&=3_ &E/VM/'_P"T5#X#^+'@?Q-\&[GX2?M5
M_LJ:EHVJ?#[3_B?\"_C!\+FDD\5>'-?F^'FJ^';CQ%%XYTGZS^*'_!.[XW?%
MU_VV_@]XCN_A_HGP0_:Z_;Y_9H_;&@^*&@>.M>N?BKX.\'?!+PW^Q8OB?X?V
MWPZO_AS;^&[+XAZ]XB_9#DT?PKXQ@^(FKZ%X?T#XAKXNN[*\U;P@? WBP _2
M/2?VM/V=O$?QB_X4)X9^,7@77/BP+GQWIR>#].U-[N>_UWX6GPV?BCX0TC6H
MH_\ A&M6\?\ PQ@\7^&+WXC_  ]TW6+OQKX$TSQ)H&K^+-#T;2M5M;U_E'PA
M^WQI/Q0_X*$?"+]FOX1>+?A9X\^#_CW]DK]HKXZ:]KNGZ/X['CU?%'PA^,OP
M&^&GA77O!GB:]O-,^'_BOX%^-;;XE>-=/T/QEX3TGQCH_BGQ?\.O$L.A>-+=
M/#^IVFH?&WBO_@FQ^V'\1?VI/AQ\7?%^M_ _0_#'@KXQ_P#!1"WN_%7PW^+/
MQ"\(>+8?@?\ MG_#[6O!W@+QG\//A/9_ P?#_P"'/QK^&=OJ%G+\0[>+QAXD
MU+XX_$&UF^*WBSXS6][-:>'-,U_@+^RU^WO^SG<?L9>-/'_AS]B\>'_^"?'[
M '[3O[(-E-HWQ]^,^GZ5\5=/N_"?[*.H_!KXC7EO>?LQSGX06&L:E^RS:Z1\
M6-#@;XH-\//#^IZCXF\*7GQ)NH;+PP@!^J'[9O[5_P -_P!A[]F3XO?M3_%F
M/5[OP+\'_#":]J.D>'+>UO/$OB?5M3UG2?"WA'P7X8L[V]TZTN?$WCCQEX@\
M/^#_  ['=WMK9G6M<L!=W$,!=QYWI7Q _;>\+W_P1U;XF_#?X+>*/#?Q ^(,
M&@?'#PY\')?'EUK_ .S7X<\2^'_%TGA74=)\4^)KM(OVA]*T3Q[=?#/P;\1O
M&<7P_P#@3-X?\-R^+/BG#\/)/#T5[I?@WE/VGOV8KS_@I9_P3W\2?L\?'K3=
M3^!'B']H'X7> -8\26OAB_?Q?<?!OXM>'=<\&_%/PI=V+^(='\"7GCC0_ GQ
M1\*:#J-UHWB7PSX&U7Q?H&E7NB:[I?@^_P!5N;#3^O\ @5=_\%"-530/#?[3
M'@?]E/P1'H5EHK^,/BM\"?B[\2OB'>?%76-*N%35H]"^#/Q!^ OP]L_@YH?C
M-8!J5Z;[XP_%_5?"5E>7GA'2'UR^>R^(VD@&?^U!^V@W[.?QD_9@\ MX)3Q)
MX$^+OQL\ _"/XS_$"'4KH3_!%/CW9>/_  1^S+K4V@6^GR-KUK\7_P!HWPMI
MGPCDNXM0AMO!ZW-QJVN)'%?Z4[?=4$AFACE*[2Z!BN0P&?1AE6'HZ%D<89&=
M"K'\>?VC/V!OB+^US^R3^UUX2^+.C#P?^T=\?9?&5UX(TOP!^UC\<4^#/A+7
M_",NAV7[*_BF1-/\/>$-#M[OX?P^ _AEXW\<6][\'?%:W7Q"TGQ=<:6-9TC5
M].MT_3'X)WGQLOOAIX*G_:%\/_#KPS\87\.VB?$?2OA'XEUSQ;\,HO%T 6'5
M+OP1K?BOPUX2\53>'-5G674M*LM?T.'5-'M)TTO4+[6+JV?5;L _.'X_?\%(
MO&7PFM?VW_BYX8\#>#/%'P._X)Q^/_A]X'_:/\&7NIWEE\;_ !=HVM_#+X9?
M&?XI_$KX9WD>J_\ "+:)HGPR^%_QB\-ZQX'\,^*M#U"^^.OB[P+\3/ D>O\
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M>(KCP_\ %/2;/7?#=CH<VG>'=9L]1TJP\1^++*VMO$>H_;E?FY\#O@C^TO\
M"+XX?\%*_C(/"'PFU.;]I[XB>!?BS\!M%G^*OB*U@NM<^&7[)_P<_9[T?PC\
M6;Z#X3WTO@73/$_BOX1OXDOO$OA"Q^)5SH7A7Q#;B+0=6URPN-*E_0+PG/XH
MN?#6@W/C;3=%T;Q?<:-I$_BC1_#>L7?B+P[I/B*;3;237=,T#Q%J.B>&=2\0
M:)8:NU[:Z3K>I>&?#>H:II\5O>WF@Z5<326<0!T-%%% !1110 4444 %%%%
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MNZF@TW7/&6FVGBBU^)7A3PWJ'VI_%7B'X>:9X>T&WB\77WARY0 ^O]&_:P\
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M_AC3I+^26&R74-?\.:GI5B;N>"*>>"V%W=0F>6&VN94B#F*WE?:M 'S3X?\
MVU-"\7?LF_#']L3PE\'_ (T>)/A[\8O#_P +?&'@#P=IFD_#%?B;JO@SXU7V
M@V_PT\53:3??%ZR\+65AXAL_%'AO5Y=,N_&,/B?1--URW;Q!H&DWVG:YI^F;
MGP]_:XT?XC?M)_&G]ERP^%?Q5\/^/?@)X0^&/CGQ_K_B>U^','@6'P]\99?%
MT?PQFT34]#^)VO\ B'7[CQ:WP]\?P016'A4QZ'=>#M3A\53:$]_X>36OA[]C
MR[\26W_!.K]B[]D;7OAQ\6O"?Q^^"WPG_8[^!_Q-\"^+?A5X^T/3?"?C#]FF
M\^%GA_XL:K-\2)_#[?"O6/ =I%\./%'B+P?X]\/>.=8\,?$SP]_PCT_PSO\
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MG^)G@WP/\'="M_A)\+_#?AWX>PV">#YO#'[.\NB?M&:/\3-3_:X^'GQZ\$>
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MM^$O[.^I>._"?QZ_:;^!'PV_X2?4KGXCWGQC_:*A\(>,=.\8V6@ZU\8_BO\
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M;:#\%/!G[..F?!;7;#XZ>"_%'B_Q+I?Q;\%>(/A5I'QN\7:> ?T?F[M1G-Q
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7&>(_B)X&\(^(O
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MO_"0_$G3)3<)'^@BQ6\T>3%&R3 EU8(ZMNV[@V"R/DJH8@LKE%.6 4U_+/\
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M^,_B!%=>"=0O_BAH?@^X^*/QBLO&%CX"/B#0O/OV2?B_H7Q^^*__  ;V>/\
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M'E*00 01N! *MDALY.Y58L<L6 8DGF@V\).XQ@MD')SDX)*@G.65"2R*<JC
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MQ#XBN[&&ZO+:75]1ATMM+T*P^T^(?$E[I7A_2]4U>Q]P^R6V,?9X< @@&-2
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M-(\3^&?$GC[5+GQ/HO@_X+:=X)U/X;ZU0^"O[;O[06L_LV_$?XA_%'X[>!_
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M?QUIO[-=_P"*/%5I\2/V+OV@OAM\!M ^(W@[3]=^-$/@_1HO' ^(GA[Q-?\
M@O4_"VO:+H-W8>,K!+G6K+Q3X5D^&H!_1[Y1\XS>;,0451#N A!7?\X4*&+L
M)"&W.5;"$KF-"L+V:.Q82SQ[I?-*QN%4MA <C8<@^6"#]Y6+.K*Y##^5KXL?
M\%@_VPH?^"?G@']J_P -WWPG\(_&'PE^PQH7[77Q*^#>A^![W7M+\4ZM;?M
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M:TFNV-AK&CH=7\,ZX\<UL@!_5 D>PD^9(V<_*[ @%CN)'R@C!R  =J@[0
M*[V4<C!VDEW+MP2RMC9()(SAT8$QL&,;,"RERP.Y8V3\3?VG_P!J+]O32OVE
MOCS\(?V;O"ES=:U\+G_8\E_9[\):=\*;[XN_";XXZ5\9/%VJ:;^TM>?M*_%'
MP_I]JG[-NM_"OPO=0^(OAWH/B?XC?"B[O-(\,0?$"-?C;I'CA_!?A+H?A/\
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M\"^(/&FF0^$='L_'LDB:MHFL^$]#U)=,U  _I%^QC:X^TW6]XS&9A(@FV_O
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M0\!^./!OB:WT_7K3YM_:2_;&_:-^'-E_P4>T_P"&GC(>'KO_ ()<?LO?!_\
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MH4>W'91"-!!<31P_NVC6%XA&8U*LB+B(@PE5C0*#CRDV*0LDWF_C_P#\%0/
MGQ6_:L\ _$OX&?!#P-\3O%'C+X1>"M(^,OPD\:?#76?@[I5MX&_;C\):KI?Q
M1_9;N=<U3XE?%GX<1I=_"_4O!>E>-/%/@F6S\3:=K'AOXO> M=\0V%KIL.DK
MJ^+XV_;^^)7QA^%?_!-WXE_!>+Q7\.OA;^V9X1\>^*/C9XU^$7@=/VDOCG\
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MP:KX*\)>-OB#X<U;7/'5KXUN)]-[[_@G=^UQ\7O!?[!W[&/PNN;O0?B7\?\
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M6EF_V=10!X!KO[*7[+_BSX;0?!WQ=^SC\"?%7PHM_%1\>Q_#+Q/\)O ?B/P
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M5;&^A^!'PNCO++XG^#]#7PSX2^(UI<IX66:V\=^%_#:KX?\ #OBZ%TU_1=%
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MR%D4CUVB@#YY\._LV?#CPY\??B-^TG8^&_"MC\5/B7X9T#P9XB\3Z#X1\/\
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M^K>#KWPYJ-]ID_Z$44 ?"'PT_P"":/[&GP=\1? KQ3\,_AIXM\(:K^S/I/Q
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M*\M=(\%^%;+1^P_94_8B_9@_8D\/^)_"W[,?PQ7X;Z'XOU.PU'6K6;QCX_\
M'<ZV^CVTUIX>\,:'J?Q(\5>+]5\*_#WPG#>:H?!GPQ\+7NC?#KP;<:[XCN_"
M_A;2+OQ'KD^H?5E% #)$$D;QL7"R(R$QN\4@#J5)26-EDC< Y5XV5T;#*P8
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MT'Q=X2^&WA;PCX,O= TS1/#']AGP_P"'=#T^Q^R:* /S;TG_ ()$?\$[-%^
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MPY\;_#_[0TND_##P_P".O >MR>)[.RT*?Q'^T#]O^%]SH/Q@TWX.>(1XOO\
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M3Q/K^J:DK1:AXAU6^U^ZU*ZF^LJ "BBB@ HHHH **** "BBB@ HHHH ****
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M3OV-]:\5_%?X@_%;]K']M3XV_MZ? /\ :#^"W[./B+PAH'[)WQQU3]HCP?\
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M3^,OCU;_ /!4+P]H/[16B^ ?!W_!3GPO\*++Q9I^J_ Z?QQKWPJ\6_#+X5>
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M/])T44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!7X]6'P*_P""EUU^W-<_'GQ%XS_8FM?@=9:^W@/PAIUE8_'+Q1\:/AM^S9-X
MC\)^+?&G@OP5%J%MX8^%H^)?QSU;P+X<?XI^-M;TC4I-+L;;P_I'A.YM+3P)
MI#:K^PM% 'XW_"K_ ()X>._A7:?LM?"^#Q1\+]?_ &>OV!?BY\>OCU^S;X1B
MT_6?#?C#Q=XG\>Z#\=_!/[//PU^)-]'I?B#0?A[X _9I^&WQ_P#&OA6_\9>&
M;'X@^*/C-KVC_#SXA2>'_ARWA77O _Q)Z/\ 8>^!_P#P4=^&7QJ^)OCO]K[Q
MG^Q;XJT;XK2ZUXQ\>^*/V?M!^-UO\6/%7CFUNM%\-_![P#-+\4KV\\%>#OV>
M_@_\,9->\.^&O!_@G2=,\3:CXKL-%^(/BWQ#XA\>^/OCQXU^)OZVT4 ?G=_P
M3]_9P^,/[.EU^V#<?%AOAC.G[1O[7_Q-_:K\-_\ "M_&/BOQ5_PC\/Q;TKPM
M8:CX%UP^*/AM\/\ S9/"_P#PAVGSZ?XET\7">)EUJ]2YT'PP=%@;6^2_:2_X
M)M^!/VC/C_XM\?\ C?Q1=+\%OCO^R?XA_9G_ &JO@M;Z=I;6'QRF\+^*+S6O
MV:/&]_?:A87UOI>O? 6#XF?'F^TC54A&IZAX@U[X=W=Q-=6W@6PMH/T^HH _
M&;Q3^P1^T'JGP-_X)K?#V3XK>$/BK\3/V2/VJ/@_^U-^T/\ &+XDZOXH\-ZK
M\=?%/@;P5\0_#7C&\T>#1_"WCBZ?5O%VJ?$&ZU*UOO$]];G2].\-Z7IUZ;^X
MU*>]TCSVW_X)W?M.VOA_]ESP(WB[X#7GA+]F/_@K)\8_V^=&U$:K\1]'\3^+
M/A9\4_B+^UA\2YO"^IV7_"%:U8:=\08+O]K'4= ?1+5YO#NFP?"ZRO6\9:]<
M_$^XTKX8_NW10!^??[ O[,_Q1_9D\&_M,>'/B'JG@.YU;XS_ +97[5?[47AR
M_P# NL:_XELM#TC]I/XI:W\3=.\-:RGB+PCX,EFU7P:^LC1;BXL8[JQUU+$:
MBK:2;H:;;_C?\8?^",_[;7Q9\.>.+KQ#\=/V9_$_Q7^+W[%>F_LK?&+XAZGI
M?Q;T'5_'7C#P%^UOI_[0/A[XYWNNFT\9M _CS0;<Z???!_1]&\-_#[]GRWT_
M3_@Y\%+*_P#A#HW@S_A!_P"I2B@#\[_V=_V;?BM\._VUOVY?VCO&E[\/1X1_
M:PT[]F;_ (1;0?"GBGQ7K'B7PG>_ 'X<:KX%U>+6AJO@7PII=U9>)9?$$NH6
M-_I.J-/9I8K:365PUQ<7&G?)6L?\$_\ ]KN^_;.^$'[5NO\ QA^ _P 2;W]G
MG]K[]J+XO>!4\3>'?B/H?C'7/V</VB/V>_%7PN\#_ Y]2TF3Q#X7^%L_P1U'
M5[3PA##X%\*ZEX9^+$,%[^TSX]LD^-FM_$+P_P#$;]Q:* /PV_90_8 _:4_9
MR_X=A1:IJ7P.\4M^P#^Q1^TK^S+XI-A\1/B'8+\1?%GQ=F^!DOA+7-":?X*W
M2Z/X7L?^&>_#:^(CJ37&J:8OC[5Y=,TW7(_ .G_\)_\ /WPZ_P""1W[47PF\
M'?LF6WA3Q'^PQX^\0_#O]C?X'?L(_M&>"?VG?@5KO[0WPEU3P+\!?%_Q4U[P
MA\>O@7,L7PT\:67Q0M;#XR_$;3_$/PH\4W.D_#[QG8Z_I>AZMXQL;CPOI_BJ
M]_I*HH _ ;XO?\$SOVCO'&G?\%!M*\+^*?@J+7]K/]IO_@G;\;/A_?>)/%?B
M;3;GPYX:_88MOV98=6LO&NE^%?@9#X7M?$WQ'C_9FTJ6UT_P;I7_  BWAR3Q
MWJ%K!;SV/@>UM/%&DO\ P39_:NM_$GP*\'VOQP^ C? C]GG_ (*@^+?^"B_P
MXU+5O ?Q'N_BZWA_XMZQ^U;X^^+'P%\4:;8^*])\)ZY?Z5XX_:3URP\!?%^'
M6M)%_P"'[Y-:\1_#%+GP/#X<\=_O/10!^&_P3_X)_P#[2?PWN_V GUJ^^!EX
M?V2/VT_V^/VF_&2Z9\1_B#='Q/X8_;//[4\ND>&_#+W?P4L#+XD\!+^U?J)U
M.75TTO3->7X>Z6]I=:=_PG]RO@3P3P[_ ,$I/VK? 7@C]GOQ'X/\2?L1>*?B
MY\&/$G[>'A_Q%\./VCO /CSX[?LY^/OA9^VI^UG<?M3V.N:?<PZ/\-_&/@KX
MM?!WQ&+3PM;7-EH.LZ3XTT1=4:?6/"MOK#V5I_2'10!^$OQO_P"";WQY\<>
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M@>$=2UG0C=>'_M@N#^V=% 'X(:K_ ,$__P!KWQ7X=_98UW7]'_X)\^$/B?\
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MV&214 +5%4FO550WD7'S;]N8]@.T@#+.RJOF%E6,,1O9@!QD@:]4.T8@N'9
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M''@;]J3X&P?&:31OA9JWB?5O$E_XHT#[+X-\2_"Z^^#NL>/M0U[4->D\/?\
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ME'\4OQ9_9&_:D^*WP\_:"FL_V!OCIX&\2_'K_@F/_P %+_AKXS^%NO:7X?\
MB1'8?MA']K/PQ\2_A#I?B3XU^+/'WCKXA?M >-M.\,ZU\6]8^$/[0OC'Q9<^
M"_&\WCSQ+)^R;X9^&&@^+O$7PA\*?U^>)OCY\/\ PQJOB[1[F]U2^OO!&L?#
MSPQK\&C^&O$&KA/&/Q4U'1]-\$^"["ZL+&6RU+Q3>'Q!X9U+7=+M;ASX(\-^
M,?"'C#QY-X7\(:]I^NW/!?"']KGX=?&;X^_M"_LW^%]#^(-I\0_V8)/!<7Q<
MGU[PA+I'@[3)?B7H_P#PD_PV'AOQC+J,VE^.4\<^#UF\6Z<WA1=1/A_28EL_
M'B>$/$EYI^@78![%\)=1T'5/AYX2O/"G@#5?AAX5N-"L+CPWX'USPI!X"U?P
M]H=P))=)LM0\!Q)#/X*N)-.-IJ!\*:K::7XA\/I?II/B;0O#_B.SU;0]/_/3
MXT^ ?'OPS_X*A_!/]LB;P%XQ\;? F7]B#XU_LI^,=3^&/AG5OB!XK^&WCWQ)
M\:OA%\9?!WB+Q1\./#%IJ'C[7/ 'BC3/A[X@\(1:S\-_#7CO5/#OC"ZT,^+]
M T#P?J=WXOTS[[A^)E[<?%K5?A8OP^^(-M::5\/-"\>GXHW6@Z<OPHU.[USQ
M/XH\,O\ #W2O$T?B)M4N/B1H$?AJ+Q1XB\/R^&X--L?"7B'PWJ</B"YN=1N+
M&P]1%Q 2%$BEFW;5&2SA5+%D4#+KA6^9 RE@5!+#% 'XY?M5?#3]H3QQ\/K_
M .(WPN\ >)_$/@CQ+_P4%_9U_:"^,/P&N+"PT+XE?&G]C3P#\/?@U\,OB7X2
M;PQXI-F(=7_X2#X?V'QP?X.:Q=Z1XG^*'P\\!'X1ZYHMMXJ\>:A\/W_/+XV_
MLEZS%X/OXO"W[.?C_4OV<-<_X+0_L:_M%_LU? "']G3Q]XHN?@9^S1X#\7?L
MT:[^VOXOL?ATG@_7=8^!_P /?B]\6/#GQS^+:?!:XT?PA)XMT[6]2\1Z)X"D
MUKXB:OH"_P!30N(&#$2J I(;<=N-NXDG=C  1R3T 1N?E.&_:K?"D2JX<93R
M\R>9P6Q$$#&5MHWE8]S!,.1L(8@'Y*^%O$</PZ_X*6_M*?$&\^$?QQT7X23_
M +%7[$?P/\%>)O"_[,_QU\0^#=2\:_"GXL?MH^-_%OACPDW@;X9:S')I'A7P
ME\8_A["=5MK*U\/>?JLVB:;<W%[I&J6=E^C?P0^(/BGXJ?#/0/B#XO\ AIK_
M ,(=2\3WGB>^TSP'XLFG/BW3O!<?BS7+3X=ZOXNTR[TG1;[PGXM\8> +;PSX
MR\4?#[4;)]3^&VOZ_J/@#5-1UC4/#5SJ]]Z<UU!L9DFB8XG"88."\#>7,,*<
ML(9<138/[N3,;E7X'S9IG[57P\U3]K/6OV,X+/Q<GQ<\/_ G2OVC-2NKOPI>
M:?X&;X<ZUXXN?AWIPTGQ;>W<,7B#7;CQ'9WK2VVAZ?J&G:=9V<\.JZE9:FT%
ME* ? WQC^#47B7_@L!\+/BEI?P>U"*/3?V ?VC/AK'\>[S]G?Q!XL\'^$OVB
M?$/QC_9=\:?!34=4\=2^#I/#5]K7A_P9X!\?:AH>KW'B5+#0?[*O?!L^M:)K
MGB/3=(U7\HOCA^QU^TKXP_8L\*^'/#?P*^+/@O\ :<^'O_!,;]LG]GW_ (*&
M7EKX"U'6_$7[:_QV\1?LZW/PX^ ,%Q\1_"<&KG]JOQ5\3?VN+R?]K;P-\7K7
M5_&VL?";0=5^)R_&_P 3_!GQ=\7O'?@+Q=_0O^TA^WE\(_V7+3XJ:U\2O#/Q
M;E\'_!;1OA9J_P 2O'OACX=W>M>#?#C?&?Q9/X)\ :-:ZM/J>EOXP\37_B%+
M"'7O#/@:U\2:SX'TSQ!X6\0^.+;P]X=\4:%JM][U\+OC%IWQ.OOB!H__  BG
MCSP-XA^&7BZT\%^*O#_Q \-)H=T-4U/PEX9\<Z7?>'=7T[5->\*^,_#EYX?\
M6Z7"GB?P?K^MZ&/$-IX@\,37MOXC\->(='TL \2_8'^ GPI_9]_9I^'OAWX6
M?"/3?@[)XO\ "_@3QU\3]%A\)ZMX.\2^)/B[/\,O _A#QEXS^)&G^(;2R\3:
ME\2]:3P;I4/C'Q-XKAD\5^*=1L/[?\27VJ:QJ%WJEY\W?M__  L\+_$7]J/_
M ()EZYKWP*O_ (K:/\-/VF_B'XC^*&NQ? 'Q-\6=&\,?#'Q)^QS^U3\.- ;Q
M-KND>!/%6G66@S?&WQM\,H9-%NKSS=+U6YTCQY?Z9:Z)X<N_$ND?JL;J)D8P
MO&[X<(K,R*SJ#@L0CNL1X8S"-D$9$B[E()^<OV:?VJOAG^U1HOQ9U[X;0>+[
M*Q^#GQ]^*/[./BM?&_A6\\%ZC)\0?A%J-GI7BUM.T75;A]8_L07UX(M-O-8L
MM&U"]2&6X;2+:W,$LX!_./;?LO?';PMX[\$?#P?L;?&&[7X3_P#!Q?\ &']L
M?5?&'ACP1X-/@:R_8^^.?@G]H/Q-H?Q,\ ^+X_%-C%K>B0:1XA\.6WC?PEX+
M,GQ#\,>*/#T'@F[\(2^/]2^&7AKQMYM\"?\ @G;;_#G]B#_@D%\0[S]@GQ'J
M?Q[^%'[=7@+7/VQ[.?X$-J?QXN?A3I&A_MKZ-H5QXU@\>6EMXI\8^!_#OBGX
MS_#6.QW7^I^'/!WAR;0)8#I'@_X>6Z^%O[$#=0*F\R +D<E6[Y.<;<[0H9V;
M&U(TDD8A(W9>7\;^,++P-X3\1^,;^TUC4=,\+>']=\2ZG9>'= UGQ/XBNM.T
M#2[S5+J#0?#>@VEYK&OZO<QV;P:9HNFVTU_JUU)%;6$<T[I&X!_*WXD_9E^(
MX^*?Q,^-EE^S=\;%^+.B?\'&OPA^/OPT^(NG_!CXL-XS\/?L9:_X/_9E\(_M
M#^,? VOVGALWVD?"SX@>'OAI\0O"_P 7M*T"ZM[3XI:#X>T+1_$.F>+-+G^'
M5K?<[\5OV</VC/B=X8_;.L/C;^RQ^VIK?[9/@[X)_P#!37P+8_&_PEIOP/M/
MV=?VBOAM\??#/Q5T#]G?PSX7\9_!SPO=?'GX_6OB?4+_ /9ZN?!_[/'Q1U&V
MT7]G?5_ -IXPU^3P';?![PSX;U/^H_\ 9]^-_A3]HWX%?!C]H/P5;ZQI_@CX
M[_"/X=_&KP3:>)K.STOQ';^#?B9X.T7QOX?7Q!IUAJFM6.GZO;Z/K]A'JUK:
M:OJ5I:7WG6\-_=I&)W]@6XA9BBR!G7;N1<LZ[\["ZJ"R!]K%&8 .%8J2 2 #
MXD_X)Y?L\?#3]G;]E?X1:'\/OA-8?!_6/%/PW^%_B/XNZ&GA?6/"WB?Q%\8;
M'X6^"/!/C'QA\1H_$D$'BG7?B+J2^#].LO%/BWQ6MQXI\5WFG?V[XBU36M3O
M9=3G^?/^"AO@KQGK?[0W[#'C'Q7^S]XM_:D_8Y\):A\?M"_:"^$/A+P]I?Q)
M.C_%#XD^'_AWX0_9X^,WBSX)ZD<_%7P+\/[";XU^%?$,$=IK\7@&;XG:9\2;
MCPW<-X6@\0^&/U?\^':KB12CE0CJ=R,7954!URI+,ZA1GYL\9P<?(.N?MK_"
MGPYXQUWP+K'A_P".=GKWA[XV?"?X%ZFZ_LT?'R]T2#7/C4M_!X ^(*^([3P&
M^@3? '4-=T7Q#X-U3]H0ZE!\(O#GC+0KO0=<\56=Q=:0VI '\QOP+_9=_:H^
M'?[-O[/W[.W[1_[$O[9GB/\ 9S\4_!WQ5\+OA]X%_9ZTC]CCQ/\ &/\ 9M_:
M1N?VS/VH_B)9?$?5KGXM3>)[_P" >F>.OA9\4?@)XA\#?M-^"?BSX*U[X,^/
M?@#9:WXB7PIJ/_"(^*%_6?XE?L+^(+7]LR67PU\"_!'BO]GG_@HA\!O!?P[_
M ."C-YJ>D>%/&6B>'O'_ .R=XHT[QEX1\4^(F\40Z!J'Q-N/VL?AUXZ^)?[.
M'C#7;7P+X>\1:=J/@[X6_%V%].U;07TR\_7SX4_&'P/\8_"]SXJ\&:L;NST[
MQ%K_ (0U[3M0TW5?#_B+PIXN\+7[:7XC\)>+_#6OV>G:[X9\2Z-?+MNM+U:Q
MM99[*>QUC3S>:)J>F:E>>F&XB"ABVU3G!977(499QN49C ()D^X 02V"* /Y
M[_AK\)/C7JG_  4$F3]H3]GO]IV\^*'P@_:=^-/Q=^ 7[7'PYA_9K\-?LMZA
M^QWXVU7Q&/!'PX^(GQHT3P;9?M/37GAGX9^)=/\ @[K?[(%X/&>E>.?B1\+O
MA7\2;Q='\!I:_$[X:>:_LP_!+XAZ?X$_9J'[1O[-GC_XG?LEZ+\0O^"P7A[X
M]_ CQ_\  WQ5XMN/"WC#]IS]M_6_C+^S%\?]?_9J\2^$=1\6_&;PGX@^!&M>
M/?A7%?>"/ GC;7?AO_PT-J<>OZ1IWAD?&._\#_TM&X@"[_-39A&W!@5V2'"/
MN&1Y;8.'SL^5SNPC8^</BQ^U!\/OA/\ &G]E_P" >O6'C&_\9_M;^,/B5X(^
M&VH:'X9NK_P9IFH_"OX0^-_C/XKD\;>,WGMM'\-M)X3\!ZS:>'M+B;5_$>OZ
MX\<=GH:Z#IOB?Q%X= /Y1=!_8ZTU?CWK/[._[;'P*^('[4WC/5/^"(_CGP]X
M-^$-[::]\;/'>C)XN_;A_:"G_9@^&VLZ\FN:OX4\)_&CX1_"*;X7?"/3?VC_
M !%XML-"^'/CKP=JWBB3]H'1;>\;QQXA]@^/?[#GQ@U/X4?\%!=$^+7PA^)?
M[1'[5=M_P2,_X)P^#OAM\7M-^'GQI^(NE_$+_@H;\ /!7[2OA#QA\6/@WXQO
M_#;Z"?C-X5\4?$_X3:QX8^*VA1Z+XF\+:5XR\<:IIVKZ'%!\?)=/_ISMOV=O
M@K;?M 3?M3VV@:F/CGJGPWM?A++XV7QOX]FM;OX8VFLS>);/PFO@X^)7\!'1
M;;Q!>7>OV\D7AA9H=:U&^UB.[74M2NKJX]V^T0@XWC=E5VX;=N==Z@+C<24R
MV ,A0Q. IP ?S5?%CX(_&_P%\6O^"D=_^Q#\ /BCIOA;XK> _P#@EQ\9X_"F
MC?#F^^'J?M)7G@SXZ?%CQ9^WUI5MKW[0'A)?ACXJ_:6^*_[/7BWP%X;^)=U\
M8%U'Q-\6-8O1X3^)4?B_6_"_CS1]*R] _9:\)^,KO_@GWJ-O^RC^UMX:^$NK
M_P#!2?X_?%CQ3\+OVA_AU902_#OX.?%3]B3XP?!SXEQ^+_@I^SEX6LO@I^SY
M\#OBY^T7XA\(76N_"3Q!9G3?B/<^/?B;\7O&]A)X'^(WQ?CLOZ;$D20 HP8,
MJN".A1QE'![JP^ZW1L-@G:<1_:K?_GJO4#@,>H)';IM#.3T5$D<X2-RH!_,?
M^Q?^SSJ/PV_:%_8(\7WG[('Q%MO"7PS\3_\ !9_X.:1?S_L\:IX97X->$?BI
M^W;\'_C!^Q-<W:?$'0_"^H_#_P"$VA?LR:7XJO/AAJ=OLT[P1IMMJOP<\.VU
MG\0[T_#RY_I@NVN)].1H2UC<2J CK UY]CE9'$4K6X:W:X$,OELT)VK*1Y;(
MZL4:_P#:K;G%Q"<% 0)%)S(ADC& 229(QYB #YX_G7*\TIN8 GF&0"/H9"&$
M8.]HR&?&U2KHRL"04888#(R ?SJ?LW_LQ?$;1/$7[!?BCXF? OQ9X*^.W[.?
MPG^/G@'_ (*K_$*X\%:]XST7]L+P7JOPA\3:(EO?^*?#/AW5K;]M#5?CK^T5
M>>$OVK/AWI-AIOCKQ=\+M)B^)7A+QU#\*_BKXLUCX7^.?L'_ ((;?![4O@5_
MP3._9L^&?B_X0:Q\&/BMX4\,WND_%OPOXE^&NH_#?Q-+XUAUG4;D7^L1ZIH6
MBR>*Y#X=O-"M8?%5E)K.F7$=N=)M]8EN-(O+2S_6PSP@J"X4NVQ58%6+9 VA
M2 V1D9XX#*3@,,M-S &5/,&]]VU<$L2GWEP!D,I^4J<-N^7&[B@#\B/^"@7P
M9U'Q!^VW_P $GOV@+/X":Q\6?#/P1_:&^-D7Q3\1^$OAYI_CKQ%X/TGQG^R?
M\;/#'PEOM7@2"76[3PI8_&/6=!NX?$4HC\)^!/$<VG^(]=U7P_<2:??S?D=^
MR1^RU\<OAQK'_!+/Q]X0^ GQ:^%GQ^T+XT_\%>/!WQS^*>N?!?XJZ3>^&?A!
M\;?%/[6OCO\ 98\-_&35Y_"4OV[X#W_Q7^)GP>^*>@>!-7BU#P?X8\<ZAJ?C
MR70]&\2:9\0-2M_ZZ/M,!)'FID%@5)PP*AR<J<,!B-SD@ A202!FG&:,=6ZG
M;D D;MQ4#(!&2P( SDD'&<&@#\!/^"4'PG^(]C\2KGXJ?&']F[]L#]G_ /:0
MTO\ 9K\&?!7]K7Q'\9KG]GKPW\'?C5\8=%\3Z#KZ>*_!#?L\Z26_:IU^SU@?
M%K7M*_:7^(VNZGXC\(^'OB)J?AF'5?$FJ?%+Q;_PC/\ 0!7S#+^U7\/H/VMM
M#_8QDTWQJWQ<\0?L\>,/VF[*_P#^$1OK7X>K\.?!GQ)^'WPMU&R7QOJ-S9V.
MJ>,9/$?Q'T68>'-"M-4?3-(M[J^\3W?AV>]\.V&O?3U !1110 4444 %%%%
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MZ/\ "CXD:-HAO?&7A"V^).H-_7.88BNPQH4R&V%04W*P=6VXVAE<!PP&0X#
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M\7/V@?@/I?QM_; \8VFKW?BO]O/X0_%33O%GBG]L+X#^*/V]=4\>_$SQO<_
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M:/<6.HZ7J=I:ZEI^I:=/;WNFZII^H017-CJ-C>VKR6UY:7MKY%Q;W,$DD-Q
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MQZ7\2/A;K4OA?Q]X=@M_%F@Z!=7I\/:Y#<:7)K.CPWWA_4)(I3I6K7T<<K(
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MQ7X,\9_#OQ$^F:BLC6K:SX&^(GA_PIXY\+7O[MO.TCQ1X<T?5K?C[18Q%@*
M/SO_ &8I->;_ (*-?\%3H--:^/PCDM_V&I[E(9)?[#;]JJ7X#^)8?C((WD<2
MQ>,5_9[7]B!_$$-F\>DV_A^7X=7D*1:O>:M<3_F-\7O&_P 7/ OC[]IGX<V/
MAW]KN\\6>#?^"ZW[#W[07@ZR\ _#?]I3QG8Z;^Q%XKM/V*W^+&O>"-9\':%K
M&C>*?@[KU]X=_:/T[QA\+O -[XF9]2?QVFJ> 8;=]8NK;]O_ !/XL_9D_P""
M>'P6O_%OQ#UR;X?_  [U'XF:2WB;QSK,'COXE^*_&7Q=^.GCK3?#.FZIXGO]
M+TSQAX\\4>)_%_C+6](T.+4KFTETS0]+71M$TU?#G@KP_I>D:']?QI')%@PJ
MHW-NB.U@K@D,#M)0G.<XR"<GOD@'\EOPT\1?%;PY\1?@'\38?C9^TWJ_B"V_
MX.$_VL?@I=)XM^./QL\9>&%_8 \4:%^T!IWAK3-9\$>(?%&K>$_$?P+NM0L/
M@A<^"OBSXYT3Q%)HMUJO@A_!OQ#T?2+_ ,)V-OP6F>)_VD?&?BC]@KQ[<?"_
M]I#6/^"GWP9_:6_X*1:/^T1I'CKX1?M/7?P5\'?&OXD_LG_MC^"_V<9-1DM]
M*N/V?9OV9+SQ+XI^!OACX%_%33/$E_X<\,_ 36UN;KXC:39R_%_5U_JK^-O[
M0WP<_9WLOAQ>_&+QA#X0M_B_\8OAM^S]\.1)H_B/7)?%'Q>^,'B&#PI\.O!T
M-OX;T?6I[ ^(=?NH;&37=8BT_P ,Z''(U]X@UG2M.26Z3VA4CV!1&H0C(0J
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M\)^&+_XI?&SX??##XGV/Q$\(_%?QCXVU?0Y+W4=#^'GAGX=ZE^Z=A\5_V?\
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MVKWMIINGP7%Y<10N ?R:_M$_M!>$/VE?^"8?_!3'XB^%_P!N[3OCU\)_%?\
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MH@!_/QXG^+G[2/B?X/\ _!4CXO\ @/\ : ^+'Q1\4_\ !/+_ (*@77Q$\-^
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MIXAT?Q?\!OVC[_P[XWCN=*^('C2U^(6CZEX#\2?&/2;FULO$_P"POK'AK5O
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MC+&*U@CMHXA%;P[B((8]L<()6)4#,#J4 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !7XGIXF\;_ !"_:7M;&X\2_&+5_"7C/]KO
M1=.N($^ ^F:=HU[\&OV.;2&\GO)?%46@6M];:;\/OVW[C_A!M7U^=[37O$'@
M]U\46<>L_#* >(YOVPK@=*^&_A+0]4L]8TG0=*L-0T^?QW+9WEG;?9KB#_A9
M_BZQ\>?$'RWC_P!7_P );XOTVP\0Z\D81=4U6TBNYRI>X2< _"#_ ()'^!O
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M%=(NM4TWX;Z7X9O[#2]'_P""BW@#P7HVEZIKPN/A9X1/_",_M6^#_ &ERO\
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MZS\2/VG)]!^/G[(,UQ(/#7[,/Q,_9H\$R>$?&WQ8\7^,KV'0?"7C'QM^U/\
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M%#3? /[//[2?_#,?C[4UMM<\,_"2^_8C_:.U'1_V??BI\2?%^MS0ZAX;UM-
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M<'U! (/J" 0>" :6@ HHJ!KF%7,99MRD!L1R,J94,"[JA1%(/WF8+D,,Y5@
M">BFHRNJNIRKJK*2""58 @D, 1D$<$ CH0#3J "BFLRHI9CA5!)."3@>@ ))
M/0  DG@ DXH5@ZAER0>F05/7!!# $$$8((!!X(S0 ZBBB@ HHHH **B>:.-D
M5VVE_N\,0?GCCZ@$#+RQJ 2,EAC.#B6@ HHHH **BDGBB9$D?:TAP@PQ+'.
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MI8_$#3[3X>V3:/XZL/\ A#?'VL>'-2NM3M=#35/$FE8&E_\ !27X8_#?X%?
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M^$+_ $.'3]5LK7XI:%X7^(OPBT_PWJ7A<_"K6?!OAOPM976N?"B\\>?#CQV
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MPK\&ZOK>C_#GP%I]^8+[6+WXA^-;F.?1? ^CS:+;:I;^&/V7\7?M"_"OP+\
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M\$_#Z3PQX'\$7.D>-=3^(WZ)^#O^"4<OPZ^$?QK_ &<_!_[8O[0=U^S1\0/
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M>&_$=C\2/&NB>)_"=V^J^(_#EQ\']7\&^,KC]HJW^#6@^%?$&M:9PW_!,O\
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MJ6O?$8>!;'PMXS?PW\;_ +2?[?.NZWXQ_8HM_P!GSQOK_P ,]9U+_@JK\/\
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MX#\,GXLV]YX$TW3_ (6"SU;Q'\0=9UCQQ?Z_\39_$GB&#PMI'@_5O#GP_P#
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@=+3Q5X_TOQMI_Q1T*X_9D\?>)DL?$7A30? &I^ L:IH_P 0K[QJ-+^'OB$
M_>N;XD?#NW\4V'@>?QYX,A\:ZK>:QI^E^#Y?$^B1^*=2O_#VB:+XF\065AX?
M>^&K7EWH/AOQ'X>\0ZU;6]I)-I6A:]HVKWZ6^GZI8W$_R?\ 'G]M32/@Y^T!
M^RI\ M%T+P?X^UK]HGX[ZG\$?&AM?BKHFD>+_@A(WP%^+?QX\(>*-;^&T.D:
M[XA\16/C+2?A!KNEV,5W<>#;"U6[M-4;6[E9;2QOOQ!_X8'^/&C^(?%OBW0_
MV-+K1_$3_P#!Q3X*_;D\-Z]HL_[.>F:_:_LA6>G^!(/%_P 3]+U*#XEVU]I-
MAK<^F>.)-=\ P2VGQ+UP>)=7GU/P1-)XFUBXF[3PW^R;^VI87_[+7@?Q-^S5
MJU]\8OV;?^"G'[6OQS\2_M[IXB_9?O-%\:?![]KCP/\ MUZ-IGQO\*:)J7Q8
M;XNPW_@+4_BQ^SU:_$;X)>)/ NE.\?PI\#^'O!J>./"WA313X8 /Z,K;XI_#
M*\A\=7-G\1? MW;_  NFOK?XF3VOB[0+B'X=7&EV4FHZG!X[EAU!X_",VG:=
M#-J%_'X@;3WL[&&:[N%CMXI)%Z+1O$?A[Q'8W&I^'==T?7].M-6UW0+J_P!$
MU.RU:SMM=\+ZW?\ AKQ-HL]S837$,.K>'?$>E:GH&NZ=(ZWFD:UIM_I>H0V]
M]9W$$?\ *-\2/V%/VH_C[_P3R_:3^'?Q'_X)[>--&_;1E_X)]^'/V+FUOQ5^
MU%\./B[\//C_ .,_!?CW1/$GPP\0_ _0M5^/FM>%=!^'_@7QEH?BKXSV'C7]
MI+0_AY\6O@CK_P 1K3P]\*M3\27FJ_%6[D_I_P#A;\-?AC\.?!\ND_"CX5>#
M_@]HGB/5KKQGK7A#P9X-\,^ H3XK\1?9+K7=6UW2O"%M::7/XMNS%;IK6M)+
M>W=]<VL4O]J7J1V]P0#X \??\%7?@<?#?ACQ9^SA=^#/VG/#]Y^W]^SE^P7X
M[UCP?\3-"TO2_ NM_'SXD>$_AC=?$BQN;*R\5S^-=$\&>(?%#V-CIME9Z+9^
M.]6T#Q+9:1XFTW1M&/B>[_0=_C1\(8?AXWQ;NOBI\-[;X61%DN/B9-XX\,1_
M#R":/7AX4EAE\;MJG_",))'XJSX:9#JNX:^K:/@Z@K6X_GCU7]D+]K!_AC\5
M_A'JO[+GC3Q EW_P<!>%/VX[351XS_9[U#PCX[_96NOVUO#GQ]USQ=H]G=_&
M*/7@N@_"_P -W=IXA\&>+O#/AKQ??^)=2L/#WASPYXIA?6M1TK!\/_LF_MD?
M _XV?'?XA?#G]D?Q3XJ_9OU[_@HM^U5\3M1_9C^&?Q&^!GPA\7_$'X2?'_\
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M[U*:TM)P#[_TSXC?#[6[#Q5JNC>.O!VKZ7X$UCQ!X>\<:II?B71K_3?!NO\
MA)!)XKT/Q7?6E[-:^'=8\,1E7\1:9J\UG>Z(CQMJ<%J)$+9:_&/X1-HGA/Q*
MOQ4^'#>'/'K7"^!M?'CCPR=$\:-:6-YJ=VOA/51JGV#Q&;73=/O]0N!H\]X8
M+&QO+N7;!:SR)_/[\5?V5/VA-%^.W_!23QG\(_V%[;Q=\*OV@O&/_!(7Q;X
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MOAUX=U_PO9?$&/PC-X:\":AXCN=1T75(M;C>S.;\2OV>OVU/B3\0/VHOC=\
M/V&)?V6]<^)G[$'_  3\\.:+\+O'WQ8_9Q\%V?Q*^)7[&O[9?Q3\>?%+]F'Q
M-KW[.?Q1^(4=IX?^-_[+]]X?^"?A/XCW,VG>&;7X;:IHWAK7[GPG%ID_AWPZ
M ?T&6OQE^$-_\/S\6+#XJ_#B\^%@ANY_^%FVOC;PU=?#U8+#5IM O;AO&<&J
M-X;%O9:];W&AW<QU18H-9@FTJ61+^-X%^?OV'OVM)_VQ_AE\1_B%<^ +#X<S
M_#O]I3]HS]G672=+\>P?$?3M9F_9\^*WB+X6W'C&P\2VOAGPM:M8^+;GP]-K
M5EI]M97T%A9W4$46M:LI%V_Y>:Q^S_\ '?1A\#OVD_A3^PQ\5M$MM&_;\M/V
MH/VF/V*?&GQZ^!?BWXU_'&:/]EKQM^S_ *5\?SK?B#X]:W^RW:_$#X:_$2\^
M&7Q6\->!M/\ BEX<E\>:K\+M$^,?BWQ9I_QP31(=$^T/^"6/P-^*?[/WPD_:
M%\%_$7X/?\*1L?$/[>_[;7Q7^&/@\:W\-]5MV^"OQ?\ CWXL^(WPMO[*P^&'
MB3Q5X<\+6:^%?$%GI:>$SJ,&HZ)/8&";3[2S%N) #]$M3\>^!M%\4^'O VL>
M,_"FE>-O%UOJEWX4\':EXATBQ\5>)[71+66^UJY\.^';J\BU?6[?2+*":\U.
M;3+.ZCL+6&6XNFBBC=Q\8_%W]NG1?AQ^V7^R?^Q]H'AOPKX]UG]HOQ'\:O#7
MCOQ#IGQ4T.#7_@->_#+X#^)/CIX07Q%\-;'2=;US6KCXFZ5X:O;+3K;6-3\
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MUCQQXD\$:_9?%/2[/5].\4>&? 7Q2T'7H+BWU/X;S:2EYX@L0#]H?V)_VUO
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M]LW2?@E\+_"_Q4^&>A>$?C]H6I_M3_LX_LR>+7\,_%70M*L_ MW\?/CKX!^
MU]XBO=3TW2?&2ZIK?P^\2?$;P_=ZG\/H[2PU?4(IQ'=ZGX?M1-J5O^9OQ*^
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M'(BC!SNX11R&9\C X.YW8GNS,QY)-?+7[+'[4W@[]JZQ^.>I>%? OCOP'/\
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MI<V-Y"))83+:W<+V]Q$)8'CFB,D,CH)(9(Y4SNC=' 8<'\+O@_\ "SX)>!=
M^&'P@^'WA'X:?#GPI#+;>%_ W@G0[#P[X5\.6DUY<Z@]EH6AZ9#;Z=I-B+V\
MNKF*RL+>"TAEN)6AACWD5_/;\3O!OQD^&/Q,_P""B%S^QK\#/VDVT;QY\ /^
M"6'QON_#6C?"[XF>'I?CMK?AOX_?%'4/V]X/!7B+]I7PHGPI\8?M9^._V0KW
MX=>%O'NC>,K[5?B-\0=?.A^&_'FE^(?&OAKQ9I^D4=/LO%OP<^$WP6^+'PR_
M9@_;P^*G["'B3]M;XK_$/]HG]EKXI_ 326^/FF^&/'WP%UCP1X>\5?#G]@?P
MG\./AI/HW[-?A;]JP3_%3QA\&KCP1+XOO_BAKVI?M5>#O FNZ%-X;\13 '],
M#6UNRE6AC93U5E# \J>C9[JI/K@4X00@@B-,@J0<#.5+%>>OREW*Y/REV(P6
M.?Y6?BY\#?&>GZEX-_9PU;]FO_@I5X9_9Q\1_ _X6_\ #OG4O@!#X#^+/CS]
MF/XQZ!^T!\8?%$'@;XF_M _$;PC\;OB-^Q)XCT+1=9_9OO?!'Q"N-8TKX/?#
MSX,>#K'X1^+O&&JGX(-H^J^M>+_A5\;-+^,?[86OZ;\-_P!J/XD?#?XM:#_P
M4:DUKQKX.^&/B?X/_P#!0#]GB2Y^&^O^$_"3?L]_'6&2V^ 7[9'PY^(>H>!;
M*Q_85\.>(KNU_:-_9NA^(_P@\/:=JVL?!OPQX[TOX< '])K0Q.XD:-"X0QAR
MHWA&(+)NZ[20"1G!_$TS[-;XQY,>/38.N"N>G4JQ4GJ5.TDCBOYKO!'P[^,/
M@OX4>'_A7\4/V<==\;^ [S_@H#\'Y/$_QF^ W[/_ .TY\(/@_P"//!-K^RM!
M\/X_BG\6/^":>E7P\?0> H?$'@3X=?#3X@?"+PS)??L@CXK^)-*_:PUZUOO#
M_@'XC_#6]\ _8:_96\3_ !8U/_@F/\)?VT_@/^UMJ=I\,_V$/VW/@[\6M(^,
MGA?]J+3OA]X?^(/P[_:T_9V\3_LSZ'XN\3>'OL/P6M]8T#PIX \?ZG\)/$,>
MI6MIK?\ PK?P%XH\"ZIK>GZ+^SCK9 /ZTC!"PP8U()R01P3ZD=_Q]_4Y\M^.
M7QA\"_LX_!+XN_'WXD7%Y8?#GX(_#3QU\6O'-QI5BVHZG#X3^'WAK4_%GB%M
M*TR-XGU'4SI>E72:=IT<D;WMX;>TC=&E4C\F_P!F']DP_!W]J#XC_LG+\)O"
M<G[)?P1^-FG?\%'OV;=:M](\"W,'A/Q)^T9I'Q.\!VOP)U+PS%X9TB[M;OX1
M?&?3OCU\6?ACXRB35[SP5\.)/@-X"TKQ381> _[.MOH'_@L9X'F^)G_!-']M
MWP!IOPO\1?%[QAXL_9H^+V@?"_P5X2^%GB?XP^*=1^*NL> ?$NG^!3X8\)>$
MO"WBS6K3Q"FLS0QZ3XCM]/@30;Z>WNI=5T?S$NW /L?X3_%#Q/\ $;6?B1X?
M\:? [Q_\)+[P-J_ARRL]0\72>&-8\+_$+1O$_A33/%-EK7@OQ'X7UG5K74'\
M/S7MUX.\;Z5?PZ?=^'_&6AZA;:>^O^%[KP[XKUWVXPQ$@F-<C)!QR-S%S^;$
ML?<YK\#_ -I#X86.J^-?BEX>U[]FSXT>+OV6OB)^PKX3T+]B73?@A\$/B!HS
M_ ']K;0?&_QS\3?$B[M/ASX<T'0_&'[,OQX^(=WXP^ 'C'X6?M$^,O!_@#P[
MX(U#X7:[#>_$_P"'.N>;%XQP?V/?V7_'/B3]N[QYXQ_;2\%?%+XC?'/X8_L9
M?\$J_$1^->JZ9\=]-^!.K_MD_"/P;^U%X8_:2\8?!3Q&-,\'_ NZU2WG^(7A
MF&ZT/X?V%MHXT/XE^-TM_"]K!XN^+UC< '[I?$#XB^ ?A9I>F:[X_P!?TGPM
MI&M>+_ 7P\TG4-6F,$.H^./BGXUT'X<?#OPK9HD<DMUJ_B_QOXC\/^&]&M+:
M*:674=1M_,2*W66XC\4^"'[4W@KXY?&O]K'X!Z+X%\<>$_%/['GCSX?_  Z\
M?7?BV'P@FC>);[XE_"_0OBYX7UKP+/X5\6^)[BZ\-WO@7Q5X=OA)XCM_#.O6
MUWJ$NG:AX>L+NQN(Q\H_\%?/A;I'Q%_9Z^#VN:E\$M2^.,7PB_;>_8.^*_B'
M1/#/P3UWX]^.- ^%7@[]KWX-ZO\ &S7O"?P]\&^$O&WQ \01Q_"NS\41^+]"
M\#>&]:UW7?!(U_3I-(U'2I-1MV_&[]JGX'^/-7^(7_!5KXQ^$_V9_P!IN+XB
M6'[=O_!'KXB?LHZYX6^ 7[06HZOH^B_#7PI^Q_X%^//C/X%1>"O"NJ:)++X+
M\ ^%?C=X!^(OCKX7'4!+X.M]4\*W7B34O#NKZ#97X!_7(UM;N&#0QL'!#AE#
M!@2I(.<Y5BB;@>#L3(.U<"VUNO"PQKR[<* =TO\ K"3U)<X+D\LP#'+#-?S[
M_LR^%?B9XO\ V\SX@^.'PD_;F\%?M)?!WXS?MDWE[\4H? ?PT\&?L;_%#]D?
MXCZYX_'P+L-0^/\ H?PVA\2?'3PG;>#_ !+\ (_!W[./BWXH-\7/A/\ %CX:
MV_BO5_"7ASPA\+O$$^H?I;_P427XZ)^R/\0+W]G/PGXG\?\ Q)T/7?@[XGN_
MAWX+U&ST7Q?\2/A3X3^./PR\3?M!_#7PG?7]_I<%OXL^(O[/ND?%'P1X:@75
M=*OK[6=>M-+TO5+'5;VRN$ /MXPQ'&8T. 0.!T9=C9]=RC:<YRO!XI$@AC8L
MD2*S-N9E4!F;##<3U+8=AD\X8\\U_/EIO@R/Q!XS_9[^,7PQ_8^^//PL_P""
M>_Q ^-WQ<US]J3]EKXD_!3Q=I.OZAX\\5_L^>%_A=\$_BY)^PYHECXAUW0?@
M+HGC30M=T/XA> 1X#ANM:^-OBZP_:Q\4_#&V\.^#(/CDOS/\,OV8OB#-\?O^
M"?G@C]H3X8?M*_$;]E>S\ _\%?\ 2&\!^,O G[1_Q \ ^#OV0?%_Q:\ WO\
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MGX:Z?<']H"']H;XK?&_X/^.OB_\ L>_&?4OBJOPY\4:_^T/XGM="^&OC_P
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MO[?0]-U2^M=8\*--]#^"O!6H^'_V7_VJOB[?_L:_'C2OVI?VJ-(^%_C7Q_\
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MPTR/Q':? ?P3^$6N>'OB?^RA\9M,^ ?[2OA[XH:I_P %TO\ @I9>>-O&NI_
M+]IO2]6TK]C'XYZU^V[XLT1_%G]N>!X[7P/^SA\2?&'CC]FCQA#%JUIX?^&F
MK>-YX_&=R@\3^'O'^M:4 ?U(K&B%BJ@%B"Q'<CIGZ4^OY]?^"7_A'XN:M\8M
M"\:_'WX7?MM?#/\ :_\ AI\%M1^$'[:_B/XC^#?A1\._V2?CUXS36]+ET#Q]
MX-\?^"_A+X;OOVNM8_X2[1/%'C;X":_IOBGQ(/V?_AS\3/BSX7\8^,_#^L>+
M]"\(?$'^@J@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MS5^V/^Q5K'B[XI:1X]^,/Q>\'Z;X(^*OP&^*GBG7='U/6?B;X+^#?A'P/\/
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M\<O$5[#X+_;!_9Y^&G[./@+X$6/P:\%7VKW.C_ OXH:3:'XI_#VY\)_!S1?
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M_%#_ (-TO!_[3GQ#N8_VN/BQH_B.']N#X/:3X1TKP9XJ\->*+#Q?IWB_X/\
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M'Q!I?BCX=6/P^^+&C_!YM:^)_AR]\ Z'XY\2>)[#X=2>$]7^%VK:\\%IX_\
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M]G\/OAAX.^%&B^+-5\2^,?#^EX6^)/QKM/"'_!5W]I+PE\5?VN?CAXL^ /\
MP4HG\#^&?AIX4^+'Q)\7/H?[$OC:^_82O/CO_P *N^ &GW\GAR/7_ 7PNC_:
M3N_@[J^B>"F\6?#_ ,:>'_'%KX,B7QB_BJRNP#]__B3^U!\+/A1\;_V<_@!X
MOO/$</Q _:F\0?$;PU\(X=+\%^*M7\-7NH_"CX7>*OB[XX7Q/XZM-)/@CP?-
M8^$O"EX^CZ+K7B&'Q5XGNY9#X>\/:CI>C^)=5T+Z%,\0C24OA) "AVMELH7
M";=^[:K$J5##!! (Q7\MGCC7/V?_ (W?M7_\$P]:^$WQ\_:G\3?L_P#Q=_:Z
M_;$\0:9XS^+GQ#^./@S6_"GA7Q?_ ,$U/B3\,_$NE_LZ_%3XPCPY^TEX9^%7
MB/QY<6MCHOQ!L_%5K+X0^,/Q)USP[^SUX]\,:II7A[3/!?WC_P $T?C]\1?%
M'_!)>#XG>/O&/QG^./Q#^%MI^VEH/]J>%++3_C#^TAXI\/\ P1^-_P <] ^"
M^EZ#I_B"&Z7XJ_&/5O@QX>^&,O@:;Q^NI:G\8=0U7POXH\67OB6X\97NM:F
M?L\][:1[O,GC38I=MQQA5#,S'(^ZH1MQZ*0 V"0"XW"/#))"ROLW+EB8TW@
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M-T'QEJ/A7\Y/^"2$_A32_%7_  4]MO!VI?$S7O _B#_@HEJ?Q*\ >/?B1/\
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M[XLT/5X?$^B^'9_%]CJ<WA&"]\87::MX!UG6O#?C#0+/2/"MKK6M:MXE\/\
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M;QK^U9XT3Q!X%U#_ ()O?!_P;_P3A^*EM#X9\-_ _P"&?Q7/P:^'7@C]M?\
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M70;2P\":=XZBUZU\0_%3XD:C>7VK_$#6;74&\:7]E<V#Z;H?A*TT'Z7HH 0
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MQ)\+-'\/_ GX>_!#X<V7@'XA>)/"7A6Z^+^DCP/)>?'#2/"OA/P9\9]2\?\
M@;PAX0\,^'_LZB@!J JJJ3DA5!//)  )^9F;D\_,S'U8GDNHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MC#XN:9JUWIO@O6KO2O!/Q<^*$M]XJ\<:?'X?UJVUJYN4UG7M!\0ZQ90%N_\
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M:G%:W=UH^JZ=J<$,EE>6\\F]7\^_Q2_;I^/GP0^-W[0NB> _A%^RG8Z_=?\
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MYI]U:W^DZII=]9I>Z?J^EZC:2W%CJ.EWEK+%=6=_:S36=[:O'=6LLUK-#-(
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MW@^WM=;^)OQ&C\,>!5U/P_8^(+OQ1H8!].4R21(P&<G!. %5G8G!. J*S$D
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M7/B;XG '[_45^ O[1_[</_!13X%_&+]IWX'6VI_L5ZEJ_P $_P#@FO\ &/\
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M(:'XUUNT@NOV0_B%\*/!::+J/Q%\8ZXO@GXU'Q#X2^(^K>&_CUX)\,?!W2_
M_P -OBF^K?"[2?C-\1O$'PP^)_AVT /V0TC6=(\0:=:ZQH.JZ;K>D7R/)9:I
MI%]:ZEIUXD<KPN]K?64LUM<(DT<D3M%*X66-XR0R, W6-;T;P]87.JZ_JVF:
M'I=G&)KS4]7OK73=.M(C+# )+F]O98;6W0SW$$*M+*BM+-'&"6=0?Y;_ /@F
M;^V!\=-!_P""=W[#W[)_[(?@3PWX^_::\&_\$T/A!^U18^#_ ![;>"F\-?$+
MPAXC^(OQ,^'VF>$K"[U?]H[X#>(O",-QXB^&=QX6\9?%K2-"^,.G?"JY^(WP
MX\1ZS\./%#7T?A7Q/;_X*G_M"_$#]K3]D']L>/1(O@7I/PF_96_:A_X)J>$+
M_P /:GH6I_&#XH>*_''Q!\<?L>_'76O'OPY^)/A[QSX=\#>!O!D6A_M%>"/!
MGP^\3VG@+XC7/CNT\%_%^>+5M*T'Q[H$WA, _J6D=8D>1SM2-6=S@G"J"2<*
M"3@#H 2>P-*CI(NY&#J<@,I!!P<'!'!Y[CBOS$_X*D^._CIX$^%/[/&J? SX
MHV/PNO=?_;]_8"^&7BZXNO"%UXHF\4>%_B=^U_\ ![P+JOAF[DM/%WA.XT[P
MEJ-KK<J^-=/TVZ35_&OAMKSP?!KGA2RU34M0N/G[QC_P4F^-.C:)\6_C=X,\
M*?#W7_@C^S/_ ,%%_!7[ 7QA^$%[X5\8_P##0_C5?%WQ'^"W[/VH?%+X;>*K
M#X@WOA#PEK5A\7/C]X1^('@/X2>+OAUXE_X69\#M%L9!\2O!VO?$O3-5\'@'
M[<RS1P*&D+!2P4%8Y)#N() (C5B-V-JY #.509=U4Y^CZ[HOB"VGO-!U;3M:
ML[74]8T6XO-*O+>_M(=8\.ZO?>'_ !#I4ES:R2PKJ6@Z_I>IZ%K=D7^TZ5K6
MFZAI-_%;ZA8W5O%^9O[9OC+X^^'/VQ?^"5WA+X=?%K2_"7P[^+/[2_QH\*?$
MOP7>>";S7K7Q_I_AO]B']J/XBP0^(]3LO&WAFXET:QF\(P3>'O#<%M%9:?XX
M71/'.O3^)X?"^E^%6_-'_@G'^T!\3_V6OA[^Q#\'M \-?!FP_90^/G[6O_!8
M+X,:7X(\*>"M>T?XJ?#75?@7^T1_P4*_:*T3Q;X7\06?BJR^&$7@.30OA/=?
M"?3_ ((V_P *;6YT7=IGCFR^+LME>2?#?0@#^G6BORR_8E_;#_:(_:G\1_#7
MX@:W\./!6@?LN?M'?LO:7^T7\%/%,6L>!-$^)7AK69->\$277P[U3P[H?[0'
MQIU7XRZ%<^$/BGH8UCXH1> OV?D^&?BSP//HWBWP+>:E\6_#>C_#[Y$_:<_X
M*/?MO_"'QU_P5(UCP)X;_94O?A%_P3&M/V7_ (J:GX1\7:#\7+OXE_'3X/\
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M?1_"F@?!73?V4?B-_P %B_\ @K7^S=J/PQ\.^!O$%G\2_"FD^#OB/^WU\?\
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MQ=^"5YHUQ>W7P_\ &6E:1K/P\\2?">36K%S*VC^+M-\0Q:;?:IX/N-)EU+4
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MM\/M1TC1-7\"P>'=6T/2+ZR_,O\ X*&_'3]H&\^/G[8?[, \2>'M"^ &E?\
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M.?V?)OA9\9/"$_Q6T6/X6^*O%.KZ-X9\;:GX!FU<>"_&&@>*M6\#VWCWPO\
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M6]1\2:[K6H7FK:EJ<]].\M?"NJ_M=_M.W-U\;OA?X._9\^#GC7]I?]FSX?\
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M?"7PT\>Z[\1/AW\0OA5X_P# ;?L^>$? FI?$CXV^.C\.O#/PBCO?^%B#4O#
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MC?Q#I?PJ_9B^)LFFS?$#X+?"S7;C68_&_A3PMXGFT'PE%+J!\57_ (LT31?
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M,6OWEW!=0Z[>:O8:KJ]G?_C]\2/VS?C%^R9^T[^VS\9/B+X.^,GQS\ _"_\
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M OXI_!FZ\=37OBNZT;1-?\::;:^+?A9HG@+P'8>$C\+M"^$_PKA^&C>&M/\
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M7<0V_@SX:>#_  GX.\"_"CPKX%\#>$_#_AO3O+O!?_!)W]DKP#H7[/\ X?\
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M?C!IG[2GQSL/C#\6?A3\4I[K6?B/\._C_P#$Z/QRWBOXU^&/%?BV:+QVMO\
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MQXRU/6]!\->#)?V;?'O[&\OB#6_B5\,=(:[L+KXL?!E_%WQ8\#^(-3$OB?\
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M@R?P)8ZU=ZCKGB[68/"T'Q:\<ZIXAU6?7/B:]DGAZPT'[9_:+^.'A?\ 9J^
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M-GH>N^%?"%KK&O:Y?V^HQ^"M/\4VVFZS>Z. >B?LQ?LLZ1^RX/C98^&OB?\
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MS6]=\)?L&_&G]H[P+X2\&6^IV<NOW%P_B;P]\/;G3!\)_"_BUOB]>:]X?LO
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MMXU]'^CMH,0+_O2>G02,!TQT %?AK\</V[_'EA^TU^WAX7U+X@^+OV8O@?\
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M']QXWN_"\'Q+^'[>(@#R/Q]_P2T^ 'Q&\0?%235]4\4:#\.OB5^R?\"/V/\
M1_A1X#CT#P1X<^#WP_\ V8O''B?XG? #Q=\&]9T32(O%7@OXF?"7XB>,M:\6
M^!_$@UF_L?#^I:5X'DTW1+:3PC%+J/F7[8G['?B]/@'\?_$/AW4/CQ^TE\>O
MCMIW[,GPE^*?BGP=8_LJ:;\8-<_99^#'Q4M/$7B7X4^#OAU\5_"G@_\ 94\;
M^'=;T#QE\>=;^)OP^^)_AR]L?C.GQI^(W@?4QK'@.V^%?P=\*_KO"SO&K. &
M.[( ( PQ&,$D@@#Y@3D-D5\#_P#!0_\ :4^+/[.G[/WC'QM^SEX%T+XO?&SP
M;X9\4_&*W^&6L_VS);>(/A)\!'T+Q[\>8[1/#K'7)/%&K>"0GPM^&W]CVNK7
M%K\9_B?\-;C5-%U7PS;>)+)P#X!\ ? KXU:A^S=\>/V5O&7[.GQ<^(7[+?[3
MG@_7_@IX(^'_ ,2/AC^PW^S]X\^$7COXBZ)\9;GXR?$[XMZ9^RCK'@#X>^$_
MV;=<OKKX6W7@GQ9X(\$?$;]J"T^+C_$CQC?^$+GPS=_"_5=4_;+X/?#W2_A/
M\+?A]\,]&U/6]=T[P!X0T#PA;>(O%&H7NL^+/$K>'],M],NO$_BW7-4:75==
M\6>);VWN=>\4:]JMS>:IKNOZCJ6KZA>WEY>S7$GD?B/]K[X+:)X3^!WC'3?%
MEKXTL?VF6TH?L]Z1X!MI_&7B?XS1ZU\.M1^+UI=_#W1=&>8ZYIEC\*]+U'XA
MZSK9NK70M.\,:=/>3ZG&UWIJW7S6G_!7;]B:]TSX1W^@^,OB[XNO?C[I'Q;U
M7X->%_!/[)/[6?B_QOX^'P"UNP\-_'/3M"\$Z-\&9O$]]XF^$&N7_P#9?Q!\
M$PZ9_P )=X=O-.UJWOM*BFT358[, ^G/CO\ LS:=\>/&_P"S-XVU3Q[XH\*7
M'[+_ ,>O^&A?"NE>';'PW/I_BOQ</AG\0_@^ND>+GU[2-6O#X;/@'XL_$&QE
M@\/7.@ZJ^K:II.KQZM"VA0VMUYW^S9^PIX"_9O\ 'VM_%FS\?_$?XH?%CQ-\
M%O@_\!?&/Q0^)5UX9G\>?$[PA\$;34[7P=XR^-.N^$O#?A1_C%\;KF+5KBUU
MSXN>.8-3UV32H+?2M"M?#]K=^(!KW=77[9?P TCXNZ7\%_%/C5?!OB?Q-8_%
M6]\#:UXOTO4?#/P]^(%Q\"TCF^-7A[P9\1M7BM_!VM^,/A7:)JVJ^+_"$>K1
M>(H?#OA;QUXIT[3;_P -_#KQ_JGAKQOXD?\ !3S]DSX.1?%>3XO^,?%OPGF^
M#-E\)-=\;:3\0?@]\8=&\06G@CX\^)9? _P?^)MEH5MX(U#4;_X7>,?'<4_@
M>^\=B"WT3X=^-K'4_!?Q4E\#^*;&XTJ, ]N_:G_9FT[]J7PEX!\(ZOX^\5>
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M,ZQ\6/%&CZYX2^'ECXD\3Z%K&D6(!^?7PG_8PB_8J^&7[&WQ3_:9^(]GXB\
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M[GP%+I$?CR7Q!\3K"[TG5/A7X9M/#-SXA^)VD>)_!.L> M+\0Z5X]\%7NO\
M*:C^V)^S7_PJ?PA\7/#WQ8\"W_A/XHS>)=#^%'B#3CJ.OVOBKQ9X3T_Q7J?B
MO1H="\,:9J_BQ+WX9?\ "#>.]1^,&F3:!'JWPAL/ 'CW4/B-8^%T\)>('T\
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M6&EW/Q)\")<6>LRZ;K!7Q9X>FBTV2#6+"2?VN@ HHHH **** "BBB@ HHHH
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M\/:%8ZM+JNM>"[BWU&QFMO%6FVUSH4T=]92QWTD=S!YOR_\ LN?MO^&/C#\
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M/VF*R_X2/X@^*]!\&: ;V>.>:&R&L^([_3=-:[DAM;F9+47)G:*"641[$+
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ML^G1 'Y>?#C]B?\ :N\#?"+]FB_ME^%>F_&?]D__ (*$?M:_MB>'? =YX_\
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M>$W\5? #P)<:+8:O_P ,X:A8^++/48([CP?9?$O18K#4_&9TCQ';+Y9\)?\
M@FS^VC\(/AY^S/X*N/ O[&GQY\)Z=_P3K^!W[!7[3'P@^-/Q!^+-KX+T'7_V
M?-;^+-OH7QS^%U_H'P?\4:?\9? 7Q&\"_';XC:/\4/@3X[\%_#2Y\96EGX$T
M"?Q[96UEKZI^GG[4/[<UA\'?C?\ "K]E?X9_\*B\2_M$_&OX9?&OXA^!-"^*
M7Q>TGX:^$DU+X43_  RT/PE\/]>O+:R\1^*+;Q3\<?'7Q;\*>$OA^MEX:NUC
MTS3?'WBVWM?$MWX.MO!?B7Z@\+_&70?$4UAX$N]8\ :%^T/_ ,*_TWQQXI^
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M&GWW@;P!\$_B+^SUH_\ P2Z^,W[ [^"/C]\0_B%:)XTU+XJ_%;X"^*L^+I?
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MX?\ %/@S3[WQ/X!\1&QF^TV7BSX9^(-.M8=34^*/AOX]T6RU+PGK_P">&O\
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MKIVG0/+/#"DUY<PQO-+'$C-(ZJ0#^='X;_\ !'CXV^+_ -F']B;]F_XZ^,?
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M?GOCI^PK^W5\1/CU/\6++PK^Q1\0;/PG^UC^T%\6/AWI'C;Q9\6/ OP^\4?
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M:<VDZ[XBLYO!NBVDEQK&J:%<Z9X=\0ZLVL>&M \116NC:-X@U>UL;VWTJ^1
M#\;_ (%?\$]?VL/AA\;/@=X^\6Q_ _5O#GP\_P""KW_!1O\ ;I\1W7A/QYXY
MBU63X/\ [8OPS^/G@+P%I-EH6N_"^RLYOB'HNJ_',ZSXIT)?$BZ+IN@^%VBL
M_$^N:WJR0P^!^/\ _@EY^W[\2_#WQ2T_Q4/V1$\:?%/]@K_@J'^QMKOB?PI\
M2?BOX0\$#6OVO_B;\-_B9\%O'O@GX'Z?\"[_ ,.?"KP'HJ?#BQ\)>,OAUH6N
M:[XHTF[\1:C\3_&7Q&^//Q+OO$FN>./U[_X)^_MX>#_VW?@#\'OB?J2^ ?AG
M\7?BG\-=1^+E_P#LZ:9\3M.\=^.?!W@!/B3XM^'6D>+)X9M'\(>*M6\':IJ?
MAA[.U\:77@'PYHUUK)N]+BCCNK5X%^^V8*I9B J@DD] !R30!^0WC7]G#]K+
M6/B-\5/C!8>!O@)KLG[6/[#/@W]E+X\? WQK\3?&FJ^%/A3XM^$^M_'75/AK
MKG@SXCR?!N&P^+7PJUS3/VF/B9HWQ?\ #NL?"/P5KHU'1/#.L^#!K.G:_P")
M=%M?._V'/V,+G_@F_P"(/VN_$_QC\8_"[3?V6#\ OV%OA9X1^*OCSQMINCWR
M_#+]B;]EW3?V?O%OB/X]V6N^'=#\$^!M(\00:7?^+ MOXN\2:#8:7?WTNKOH
M<LK0-^P<?Q1^&DOCJ3X71?$/P1+\38O#4_C27X<Q^*]"D\>Q>#;6\TC3[KQ;
M+X/2_/B*/PQ:WVOZ%9W6OOIRZ3;W.M:5#-=I)J%HLV!HOQ>^!_Q+U>\\"^%O
MBI\,/'GB!?"=EXQU+P;X9\;>$_%>MOX#\13WFBZ?XEOO#FEZCJ.H/X0UZZBO
MM*LM9FLO[(U.ZAN;*VNIIXI(U /A7_@EK^S[?? OX3^,-(3XB1?%+X3:#XLU
M?X3?L<^(U;7YY=,_8:^'?BKQ=JW[/O@R\U3Q!K6N-XR/@.3QSXS\ >$OBEID
MUOIOQ1^#/@_X0>*+,:EI[:?K>I_J)7YU>%/VY_#GB;_@H/:?L.> ;?X9>-/#
M$7[*_P 5OCGK'Q/\#?%;3?%.K^$/'OP?^.OPG^#6N?!7Q1\-?#_AV33?"E_8
MVOQ3LM9N-4NO'<NK175E-H]_X)T-++^T=2_16@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH *_F:G_8Z_:2U3]J?X;_%7Q[^R)HW
MACX8>%_'7_!9C1_C1I'A_P 2_L[ZA\%M6\#?MFR^%];^''Q8T'PZGC:?XO\
MQ1TCXU>&?!<=Q^T"WQA\.3_$P?'W6;W0_"?PN\#?LY2>'[?P)_3+7R7^T_\
MM _"+X.ZQ^S[\)/BY\./$?C_ $G]L[XQS?LNZ#:Z?X3\*>)_ T?B'Q/\.?'O
MC>]L/BK#XJUW2;5/!VN>#? WB^WN[6ST[Q3>ZL(9[$^'[NUDN9(P#^4+QG^R
M._CK_@C;\$?VA-(_9[\/?![X5?L[_P#!N+\=_"OC'5-1TKX1I/\ M,?$+]H#
MX%? /XR^"M6TGP]\.]=\4W]QX>^%_P 3_A?XZ_:<U?Q+\8;7P;XML?C5\0O
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M43:+XJ\+66L>+K&]A(TRQ$1NKJW /RBU+]C']I_3?BUX[^(_@?\ 91\-Z/\
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MVP@%<YVD C!% '\MG[17[-GQK\&?M&_M8^-O"_[.?C+PLOQR_;T_X)B_%/\
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MH _F9\0_L<_M9-\+_BQ\']1_99\2^-(+_P#X+[>$?VZ+?4%^(/[-EWX1\?\
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MG_%74?%OQ4\9S_%?XT:=XYM_%J^'O%O@+Q OQ&^(-K_:7VSPW?V6E^(]2O\
M0?#+:S_59I.AZ)H.DZ7H&AZ/I>C:%HFFV6C:+HNDZ?::=I.D:1IMK%9:=I6E
MZ;9PPV>GZ;864$%I96-I##:VMK#%;P11Q1H@O&VMSN)MX26 #$Q1_,%=I5#?
M+R!(S2 '(#LSCYB30!_,+^U=^S;\2?#OCG_@JAXLM_V>/%?P\^'_ .UU9?\
M!'GX??LR3>!O&?[)OAK7O'/QT^"GQ<ETN;0]$\%:[\7]/\-^)M8\"W_B;P%<
M3?#7XIWWP[\!_&[P3\/O$WPM'Q0\&>$-3LO'>G_HC_P3LU#2++XU_MIZ3\0O
M@O\ &'X+?M5?%#QG\)_VH/CKH?Q!\*? WPSX"O+#QSX'?X"?#"_^%.G_ +/7
M[3?[7?A+PVM]H/[,=[J7C_P]XY^-FJ_%+Q#\0[SQ-\2YM(TCP'XT\$Z!X?\
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M=/M_&/\ 0'4(MK<.9!!")&(+.(D#L05();;DD%5(R>JKZ#$U !1110 4444
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M^T9^RU^TR/VX_ASX?_X*#^"/C;J&I_"3QKI'[,7[1/P^\?#XG'X0++X[\1^
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M7OB?Q%'\*+2]\9:-X,3Q7X_\(^'/%7B"W6#1=)L/$32^*;VS\,OJUS'^OE%
M'\PC?LU?'/X0_LP^-/VIM,T/XGZZ?V /V_OCW^U'^Q5\(/B3JNJZAX]\6_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 45X3\<OVGOV=/V9=+T77OVC/CQ\%O@%X?\1ZI+HF@:_\ &[XL
M> ?A)HNNZQ!9G4+C2=$U/X@>(/#UGK&IP67^FS6.G37,\=FLT[J!"RFM8_M5
M?LUZK\8I_P!G;2OC_P#!'4?VA;:R;5+GX!VGQ:\ 3?&NWTA-,BUJ35KCX5IK
MY\=0:=%HT\.LO>RZ$EL-&DCU196LI8II #W^BOD/Q#^W_P#L->$K;P??>*_V
MS/V3/"]C\0=9\1>'O M]XC_:2^#6B6?C37?!WB&3P?XQT7P?<:CXRMX_$^L^
M$O%\9\*^)-+T9KN\T3Q%G1=4BM-31[0;:?MK_LB2?$;Q=\'$_:A_9Q?XP?#[
M2=>UWX@_">/X\?"A_B9X!T3PIIB:UXKUKQMX$_X2T>*?"VC>&-&<:QXAU+6=
M*M+;1-*!U#5FLK3$I /J&BOD3PY^W]^PUXT@\'W/@G]LO]DWQE;_ !!\:Z1\
M-O 4WA7]I#X.^((O'/Q%UVYFM-%^'W@Q])\87B^*?'6LW5O<6FB^$=%-WKNK
M7D$MM9V4CQRF.77?V]_V(/"_B/X@>#/$W[8O[*?AOQG\)8;NX^+'A#Q#^T9\
M'=%\3_"^WTZ>WM]0G^(F@ZCXQ@U;P5%92W,,=R_B6STQ;:66*&[-M)*BD ^M
MJ*^</'O[8'[+'PG'P[/Q8_:2_9^^%_\ PN"&RN/A$?B#\;?AEX-7XK1:D--.
MGR_#5O$OB;2O^$YAU#^V-+-A/X9&IPWBZE8&%V>]MTDZGX;?M"_!#XRW'BVT
M^$/Q@^$WQ6N? 5_IND^-[?X:?$SP7X\G\&:MK%@-5TK2O%\/A?6=4?PSJ6H:
M7NU2RLM7%M<WVF 7UC'=0;VC /9J*Y'POXZ\)^-1J\GA+Q)X=\3P^'_$NO>#
MM>G\-Z]I6OQ:%XM\+7CZ;XD\*ZU+I-S=PZ7XG\/ZE')8:YX?NY8]5TB[4VVH
M6UO<+)%'PZ?M#? V;Q)J?@ZT^,7PGN_%VBZM'H.K^%;?XE^"YO$^EZW/XITW
MP-;Z1J'A^#69M6M-4N/&VMZ%X/@TR:T74Y?%.M:5X>CLWUG4+.QN #V:BC/&
M3QQD@XX^N"1Q[$CWHH **3(/0CMW]>GY]O6C(]1^?^?4?G0 M%)D9QD9P3C(
MS@=3CT'>ER.F>?3\O\1^8H **3(]1TSU[>OTH9@H+,0 H+$D@  #)))(  '4
MD@#N10 M%>1V7QV^$FH_%W4/@%8?$/P9?_&O1O!EM\1M=^%>G^)=+O\ QWH'
M@"]U2RT33_&6O^&[.>;4=#\/:KJU_;V>BW^KQ6*ZTPN'TM+M;*^-MZYD'H<T
M %%&1ZCCK[=?\#^1II95#,S*JJ"68D * "26).   22>  2>E #J*Y[Q;XM\
M,> _"OB;QQXT\0Z%X2\'>#- UCQ5XM\5>*-9TWP[X9\,>&?#VG7&KZ]XB\1^
M(-9NK+2-"T'1-*L[O4]8UG5;RTT[2].M;F^OKF"V@ED7A/AA\<OAC\8Y_&%G
M\/?$L6LZI\._$4'A+X@^'[S3=<\->+/ WB2\T#2O%FF:5XN\'>+-*T'Q7X=E
MUWPEX@\.^+O#4VKZ-9VWB?PGX@T7Q/X?FU+0=3LM0G /7**3(XY'/3GK]*\F
MLOCI\(]0^+=[\!;'XB^"[[XU:9X&B^)NJ_"K3_$NEZAX^T;X>7.KZ?H5AXTU
MWPO93SZKH?AW5-7U.UT_2-1U6"T@UJY6]71FU"+3=1EM0#UJBC(]?;\?2C(]
M10 449'K_GG_  /Y&OEC4?VXOV-=%U#XBZ/KG[6/[,F@ZW\(+C4++XKZ'K?[
M0'PDTW5_A??:597FHZG9_$>PG\7BX\#7.G6&GW][?P>)4TV>RM+&]N;J*&"U
MF=0#ZGHJJ;H"WEG,97RBX:-GC#91MI!;?Y:[OO(&<$JR[]CED7R_X7?'7X1?
M&NX^(EO\)?B+X,^)'_"I?B3X@^#GQ+N/ _B+3?$]CX*^*WA+2_#VL>*OAYKU
M_I,US96OB[PQ9>*M"7Q)HHN)+SP_J-X^B:Q'9:W8ZCIUH >M45\S2_MC_LPP
M>,4^'TWQQ^&<'CB?XUW_ .SC8^#KKQ9IMCXIU7XZ:3X1\->/=6^%^BZ!?/;:
MCK?BK2O!?C/PEXGU2UT>&_M]*T;7K*_U.ZL[=UD;U+QW\6_AW\,M6^&NB>._
M%6D^&=1^+_Q M?A7\.+?5)WAD\6_$2_\+>+/&MAX1T@)%()=8O/"O@7Q?KD,
M4S6\+67A^^Q.;DVMO<@'H]%)N7^\O4CJ.H)4CZA@01V((/(KYW\??M;_ +,'
MPK\0>+/"?Q,_:+^ 7PZ\4>!=#TSQ1XS\.^/OC5\-?!VN^$_#&MPZA<Z'XD\3
MZ/K_ (DL=2\.Z!K%OI&K7&FZOK-K96%]!I>HRV<]P+*X$8!]$T4P./+$C_NU
MV!V\SY=@V[COSC;M&=V<8P<]*=D>H_/\/Y\4 +14,\PACWD!N5&-RK]Y@N<L
M0.K#ZD@#DBO*_A7\=?A'\;I?B+%\)/B)X-^(Z_"3XD:[\'?B5=>"/$-AXFL/
M!?Q8\+:9H&L>*OAUKM_IDDUI9^+_  O8>*- _P"$CT-YC?Z#J-[-H>L06.N:
M9JFG68!ZU129!Z$''7FJ]Y=PV-I<7MP\<5O:Q///++(D,,,$0WS3S32LL<,$
M,8:6:61@D<2.[$*IH LT5SGA#Q=X7\?^$_#/COP3XBT#Q=X+\9^']'\6>$?%
MOA;6M-\1^&/%/A;Q#I]OJ_A_Q)X<\0Z-<WNCZ]H&NZ1=VFJZ-K.E7EWIFJ:;
M=6U]875Q:3Q3/T61ZC\Z %HHR.>1QU]OK^8I,C.,C/IGGT_GQ0 M%%)D>H_,
M>_\ @?R/I0 M%&1ZCIG\/7Z4@93T(/)'!!Y4D$?4$$$=B"#R* %HKR35OCI\
M)=#^+/AGX$ZI\0_!=E\9/&7AK7/&WA;X7S^)--3Q[KG@GPS<+9^(?&-EX5$K
M:N/"^D7K&PNM?N;:WTAM04Z?;7MQ?![9/65<,JMP,J&(R#C(!QGCH3C- #J*
M3(]1Z=1U]*,CU'KU'3KG\N: %HHR/6DW+G&X9QG&1G'KCTH 6BC(]:3(]1^?
M^?4?G0 M%%)D>H_.@!:*,CU'_P"HX/Z\?6C(]1V_7I^?:@ HI,CU'YCW_P #
M^1]*,CU'KU[>M "T4F1TR,]<9[>OZBEH **3<N2-PR "1D9 )(!([ E6 ]2#
MZ&EH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBJ\%U;7+3+;S1S-;2>3<"-@WD3A5<P38SY=PB,CO ^V6-)(G=%66,L 6***C
MDECA7?(VU><G!., L2< D!55F8GA54LQ !- $E%5;>]M+J2XBMYXYI;21(KJ
M-#E[6:2&*Y2&Y7&Z"=[:XM[E890DK6UQ!<!##-$[6J /S5_X*[?L1C_@H-_P
M3S_:=_9GTVUBNO'OBSX?S^(_@X);JWTU8?C7\/;F+QM\+4?5KFYM;?2;36O%
MFBZ?X7UC4IYDAM/#^O:P]R)X"81_,_/^T3^U'XMD_P""(?\ P7E\+?#77=2\
M;?$6\\!_\$S?C_\ #B/2M4L]6^+_ (/^,5I/X!M/B'KUG96VH:W8^&W_ &P;
M7XH:S\/[?6/$MQ;:A!/\ -1L-,GO/%NM07O]P\B"1"C%@#CE6*L,$,"K#E3D
M#!4AAU!!P:PQX5\-+I&GZ F@Z-'HFDSZ?=:5I,>EV$6G:9=:1=Q:AI-UIUE'
M;K:Z?<Z5J$%OJ&F7%G%!-I]];P75F\,\,;J ?S&_\%P?!E]\.KK_ (-_OAQH
M?BRVOO$7A[_@KS^QIH5KXI\26CZLFK>*]*=-,F\9>(/#UAK.@7&K_P!I>()3
MKOB2PT_6M$EOKO5;NWBU33;K4UO1TG['Q\86O_!R]_P44TWQWXI\+>*?%4'_
M  3[_9Q-_?>#O"VJ>"-&:)?$'@">WBA\,:UX]^(VI6DMK:7]N;J:;Q).LSW:
MSK;6D=RBR_O[\2_V9OV=/C3J6CZU\9/@-\&OBYK/AVVFL_#VL?%#X7>!?B#J
MF@V5Q<17=Q9Z)?\ B[0-8NM)M+B[ACNY[;3Y;>"6['VET:<+(,:3]D+]E*7Q
M=XD^(#?LS_L_'QYXQLO$NF^+O&Y^"_PT;Q?XJL/&>FS:+XOL_$GB9_"[:WKM
MIXJT6YN-'\2VNJWUW;:_I5Q/I^KQ7MI-+$X!_)7_ ,&^4WB7P=_P3;_9K^-/
MQY\7_#^;]@/X;6/[9_B+7_!^J:&+77[;]K?0OVXOV8?&O[*FN6DEYXOUR^^*
M'CNYU7PA\3=/^">@^!? _A?5=.\=:A%X4F7QYK_Q!\*PZ=#^U7\6_P!HCX+_
M /!5G_@X'\=_LS?!KPK^T9\0-#_X)U?LQ6NL?"W6=?UJPUA?".K?#CPEHWBO
MQEH'AO2=/O9OB'<?#O1-;G\;:U\-AKO@[5?&'AVVNM+\-^+(/$UWI6EZS_6'
MI_[%7[&F@-H,^C_LG?LT:,_A77=-\3>%Y=*^ GPIL)/#GB?2-1BU71?$6@/9
M>$8I-'U[1]3ACO\ 2M7TTVU_87JK>P7$=U'',G0^&?V<_P!F30OB9JWQ@\'?
M [X)Z#\9M1GU:\UWXK>&_A?X#T?XHWM[XJCAO-?N=7\>Z;X?MO%MQ?>)8KB"
MZUN2^U9[G68KF.?4/M$<Z,P!_)-\<-.^!FC_ /!+G_@V@\*_L<?&?5?BY\*-
M._X+&_\ !.^#X;_$[XE6\&M^(6\176I?''4M?T[Q[X.T3Q9"='OOA]X[UG5/
M"NM?#*P\8V@\'VVCIX$TSQ-';:9:ZW)^Z_PA^+&K?LW>!OB_IGQWUCX=_$__
M (*)WESXWU?QQHWP]N]-\-0_$ZY\??M3_'#PS_P3T\ 7D^K^(M?TKX7P?%S2
M/%GAWP)\"- ^)GB^^U[P[X%T/6['QIXUU/0O@_XA\16'VM%^PG^Q+;V.DZ5;
M_L??LM6^E:%K5YXCT;3(/V>O@_%I^D^(-1@TBUU+7-,LU\&"#3]8U&U\/>'K
M6^U2R2"_NK?P_HD,UPT>F6BQ32_L9_L8*)]*NOV6/V9W77==\->+KW3I_@7\
M*3'KGBGP#8:SI/A'Q;>V0\)+%J7B+P5IGBO7M-\.Z]+#+J'A?3_$FKV6E7.G
M6FNZA%>@'X&_\$P_$?CW]AC_ (*U_MM?\$^?C$GB_0? _P"W01_P4@_9/USX
MQ:I\,I/%?Q(^+NK:5I'AS]L+1X=4\$^+_%MGJGBC6O$'AB]\7:%\.M.\0^(-
M:\%?"KX6-XSO[&WT[4Y-1U3Y=_9QE_::_9T\0_L-:OX*\;?!+_@IM_P1T_:;
M_;H^'VJ_LMW_ (T0Z;^W1^PI\8/C/\1?B'XKT^]L]>MM5_M/Q=KGP=U[QIX\
MLOCY<R:]\0O&DWPX\-_&3P[XH\+?"'X677C72;K^KKQS\%?V8[_QIIGQL^)G
MPI^"=_\ $3P3)I$^C_&3QWX \"7?C/PE/IMVI\/2Z9\2M?T636M N=,U"_C;
M1&L];LYK*^O8OL1CFNHQ)V>E?!KX1Z+XFL?'.A_#+X?Z-XUT[PS;>"],\9Z1
MX+\-:3XMT[P79QV,-IX/T_Q)8:5:ZU9>%K:WTS3[:WT"WO8M+AMK*S@BM4CM
M;=8@#>T#QWX&\7^&+CQ?X3\8>&/%7A&WG\2:?<>)O"VNZ9X@T&*]\'ZOJGAS
MQ;8?VMH]S>V!OO"_B#1-:T#7[)9FNM'UO2=2TG4(;>_L;FWB_E]\%?\ !2#]
MJ[Q7XI^)'AKP1^U;\!_'EO\ %K_@G/\ !+]IK]GGQQ\0M+^$_P "_#=Q\2/B
M/^UIXM^">EO\+K&TT'XA3_!32?CCX GT^'X.>%OVLKK]I?Q7\.?%UK\+_$OQ
MU\'>$=1TSXZ_ J;^D+X"_ /X<?L[>![KP#\,O#.D>%]#U#7]4\5:M%H?AWP=
MX/AU?Q-KR6W]LZ]<:#\.O#O@[P9IE_>+:VD$Z^&O"^@V<OV..[>UDOY[N\N'
M6'[-?[.^E&V.E? ?X,Z6UG;^++.U;3OA9X#LS;V7CSQKI7Q*\<64!@\/IY%I
MXR^(V@Z!X_\ %<$/EIXB\;:%HWBK6!>ZYIMK?1 'S-^PA\:O$7QV^&/Q*D\9
M7/Q=TSXF?#+XZ>/?A'\0OA_^T)\.?AWX'^*OP>\8:%HWA/7++X?^*&^"RP?!
MSXHZ$OACQEH'C[P1\6OA3KFH^$_B)\._'7A35K'5+366U*ST7\5/@;^V#_P4
M)UCX"?LD?M ZU^UQH?Q/\1_M&>,_^"H/P5\:_!G4_P!G[X)Z5HG@C0/V8[;]
ML?7?A?\ M4>#+;PAI?AOQXFH_"+Q9^S[\./A7\1+/Q9XN\1_"GQ9H?QA\ >$
M;SPSHGQ8O+'Q]XY_IWT;P9X9\ >&K'PS\/?#OASP7H>EQS6OA_P_X=\/V&C^
M%]$^TSRW[+9>&_#\>D6<=M)?L;JYM+(6SW<KRL)HKB=[D?!_["/_  3V^%?[
M+/[/5U\%?%=I\(OCQJ6L:M\:V\6_$^7X'>%_"U_\0_!_QH^,?C#XQ:UX \86
ME_XG^)L_B;PUH>N^+KK0(;'4O$MWIMUHVC:!:W>DQ7VF37=Z ?F1X$_;._:%
M\-_LY_\ !.&3XY?MCZ3X?\2?\%(/V,8/V@8?VB?BA<?LX_LX>&?@O\8=!_9\
M_9<UZ\^$?@SQ'<?LB?&+X0:A??%-_BO\6?C;I&E_%3P*U]-J?PS\0Z#X:UP>
M%#:> X/6+#]LW]I:T^,7P N?B9\6/"VL?!_QUHO[ '@#QM\0OV.M!^&WC_X(
M>!OCW\=O'<.AZC9?&/X=?&7P]!^UIX?^!?[:NL>)]!\!?LJ_M%_#CQ%KOP_T
M2/4/#LOBK1])DTGQ'X_\8?L]JW[-W[/>O_##3_@CKWP-^#VM_!?2$L$TGX0:
MO\,/ NI?"W2QI=W-J&F?V=\/;S0)O"-D=/U">6_L3;:/']DO'>XM_+DDE9^I
MO/A;\,;CQ9I_Q"O?A_X*N/'6D2W+Z3XVG\)Z#<>,-+EU+3;+0;IM,\3/ILFO
M6,EWI-AIVDSM9W\3SZ;966GRL]E:6\$0!_.CX4_X**_M'?&SP-\5OCK\+_VE
M/@)X'O=*_9M_;D_X3_\ 8Z\0W^E?%#]HC]FGXW_L]Z!XLN/">M7GPCLOV>?A
MG\0_AG/\,/%GA?5/!OQ?/[2WQ)^(?PI\<7?BOX7S^ CX>O\ QCX4T/X@_"'[
M<?[5G[96O_L=_%+P=XX_:M\9ZMH?QO\ ^"'_ .RA^W1K3>%/!7PF^%FJ^$?B
MGK_Q8^'7PB^*'A'P1XF\!^#-+UZ#X0?'#0?'EQKOQ0\(^+-2\7:V_B6QDTGP
M'XR\$_"7Q!X@^%-]_7M<?L__ +/VM:K\1O$MS\&OA!JVM_%[3+;PM\7=>N/A
MUX'U'5?BEHWA\2Z9:>'?B5J\^B3WWCG3=&,4MC!I/BJYU6UTYHGMX[>$HR#'
M7]D_]EY0RI^SC\!E1_A[=_"61%^#OPY"R?"S4+>>TO\ X:N/^$:RWP_O;6YN
M+:[\%D_\(S<V\TUO-I;PRR1L ?CQ\8?"7Q/^)7_!5/XJ^ ?V??VCM4^&/QAU
M'_@B?9:3\-?VB;?0OA5X^DT+XG:+^V?XFM[#Q)XL\(>(O 7B3X7Z_I6I>)](
M?1OB1H-CX&TV1=!O?%&E^"I/ OB*/1-:\/\ V)_P3O\ VB/'?[77A[PY\8];
MU[QQX8A^'7PTTW]G;X[_  0UVQ^&L2^&/V[?A[XAU_3/VJ[3QAJ.D?##P[XK
MU#Q#\*M>T+2/!_AO6/!OB3PY\&O&-AXR\2Z[I_PW-W8^'-2T7Z<\??LQ^&!H
MFMZQ^SWX?^#GP&^/</PXM/AK\,_CO!\!/A[XTU3X=>'=(2SM_#_A>30"OA#4
M->^&VDZ7I]OH"?#ZQ\9^&+!-";[%I%_HEU;V.I67L7PR^'UI\.O"MMH$=W<Z
ME>OK7B[Q5K6K7 2)]7\5_$#Q7KOCKQEJR6L3/'I]GJ7BGQ-K%U9:-%+-::/9
M-9Z9;22V^G6LM 'X<?$G]OC]H[X*_'#]H6]\3P>-?BMX7L-0_;5N/V4_#OP6
M\,_"[XC_ +/'QX\9?LO?LY>,/B79?L8^(M=\&^$)OVHOV=/VPM)N/A?XR\6Z
MMI7Q/NO&?PZ^,!\,_$"]^$WBFPAOO"'P=\-?$G[8_P"U?\4OC;^P=^TKXX^'
MG[?/PT^(_P '?&FC_L(^./#\O[._Q(\'^+_BU\/-,^+O[6OPO^$OQ)^'?Q:\
M0^%OV7?@MI'PS^"WQA^'_B>PET?X2?&*TO/CAX@\8^$_COX/\2>,/'_P>T;Q
MU\-_"G]5.E_"OX::'XIU/QSH?@#P7H?C;6K:[L]8\8Z+X6T'2/%>JV=_J\NO
M7UGJ7B33M/MM:OK2\UN>?5[NVNKZ6"ZU2>;4;A);V1ISQL/[.7[.VF>%O'_@
M.U^!WP>L? WQ@UK5]?\ BIX(LOA=X(MO"/Q0\0Z_%9Q:[KOQ%\.6GA]-(\:Z
MOJ]OINGPZMJOBBTU.ZU""QM(K^>>.WB50#\U?^"X5F][_P $9_V[;K0_B5X@
MO$M/V:?&$MUXCT>?P3<3>-;6RL4T[5['6IK?PM<:.NG^([AY&\1#PG8^'+B.
M4S6.@W?AZQ=K(:GQT^(WQ>L?VE_B'^R=X:_:.O\ ]FZ]T7]@[4?VJ?"7[4?B
M3X=_ O6]9^+GQ'TCXF>,O GB]/'T'B[X7Z?\+]6^&_[,OA31?A9J/Q1T#P79
M>"_&M]X1^-OAAI?&_@3[+INO:Q^EWC'X/?!/QEX,M_AS\0?AA\-_&'PZL+6P
M@L_ ?C/P5X;\2^!M/L=$L[JWTFWM?#&N:7?>'[*ST33?MEII5O#910:5IQN+
M:R2WMVD0LU;X)?!'QCX5\+^$]?\ A5\-/%/@?PC-8WW@CPKKO@;POKGA+PG<
M:=87&EZ7>>$O#NJ:3=Z+X?FT_3;R[L=/N-&LK1[:QNKBTMW6TGDB8 _FGTO]
MJ+]N?]J_X??\% /%'B3]I#X@_LF6/P=_X)@?L9?M<Z9\%_@U\./A9X2\1^#?
M&_[2/['/[3?Q$^*WPSU'XE_$7P+XU^,?ATV'Q!\&Z!KNF^)M \1^#OB1X*N-
M$CL-!U'PO?IJ-[=>#:%XD^+?A.?PAX_^#'[1OB;P5\2/A/\ \&L/A;XR:+\5
M--\*_!SQQXIL_%?P_P#'T?Q.\->%+C2_%?@#7?A4?#$4^GV?@SQ+::E\.;_Q
MCJ_@3'V'Q9X?\=L/B _];VG?!?X2:1XM\7>/M*^&?P_TSQU\0;%-+\?^--.\
M$^%;#Q;XZTR.%;>/3?&?B2STB#6O%%@EO'!"EGK=]?6ZQVUNHC'E UYW:_LB
M_LD:%81:98_LR?L\Z7ID?@J]^&T-A8_!'X:6>GP_#N_U"XU6]\ I;6GA2.VB
M\%76IW=U?W'A78N@W=]<W%W<:?/=3RRN ?)WQJ_;"^*_PT_X)'ZU^W'X:\#:
M!XK^+=K^QWX'^/5]X;T_3-<D\$:%K/BCX=^%O$?C#Q;-X=MM3O\ Q1>_#OX7
M66LZU\0-9\*V>O3>(M4\&^$[[0+'7XM3NH-3B_.#]NS]M']L?]FWP_\ MN^'
M/@5\>;+XH^#_  7^SK^PA^TS\(OVH?%?P\^#/B[4?AW>_M)_M077[/NN? ^7
M3?A[X1\%?"'XC^#_ ![X"\$S?&/X<^+-1\+OXR\+1^(O&EMJ^K>*/#6O?"Z7
MP%_1QX/\-^#?!_AZQ\%^ M$\.^%?"_A2"VT32_"GA+3-+T#0_"UK#:6UU::-
MI^@:-;V>GZ%!%975K=0:;;V=K&EM=0S) (YT9_,KS]FC]FL>!-8^'5Y\!?@F
M/AEK&O1>+]?\ S?"GP#)X#U7Q/:VNGV47BK6/"<GAU_#][KUMI^DZ=9C7KS3
MY-0AL-/LH3=K!IUG]F /C7]B7XO_ !LUS]L3_@IQ^SC\5/B=<?%OPK^SC\5/
MV>M4^$WB77O!O@/PGXO\/>'OC_\ L_>'?B?XB^&]W/\ #;PYX.\/Z]X+\%>*
MCJ"_#J_UWP_J'Q)M=!U673O'WQ"^(E]:6&LP?$WPW\.?$OQ1_P %"?\ @M19
M^&_&OP7T#X4CX[?\$ZT_:%T#XQ_#Z[\4:5XN^! _8_\ @S/\<_#P\67WC6T\
M%>$+'6?@ZWC#3;YO%WPW\8Z?<Q7;P2ZEX8DU&Q\4^&OW ^'?PW^!_A_5]=^(
MGPK\!_"[1M;^(%GIC>(_'O@'PCX1TO4?&]EI:R6FDG6?%GAO3+:X\3V^GI"]
MO8"]U"_CLHXQ';"%, \#K'[%_P"R!XAOO%FJ:_\ LL?LXZYJ?CR]U34O'.I:
MS\#/A9JNH^--1UL3KK.H>+;[4/"=Q=>);_5EN;A=4O-:EOKG41//]MEG,TI<
M _,C]K']J#XJ_#SXJ?"CXK^%?VF_%GA']AS]I?X,>!]&^(7C6'X9?#32M>_X
M)_:G\3?$6F7GP6_;$UX?$SX!>)M5L_AU\;_,UCX-^)=#_:92Q\+_  4\4PGX
MF:_X?O?!?AGXG1?#7Y!\/_$SX^? 'XQ?M5?$OX<?&;4K/P]?_P#!PY^S/^S-
M\2_AEK'@/X=:YX?^,_A#]I;X#_\ !.+X'>-O$7C[Q!>^&1XQ\/>*/".C^(+3
MQ=\+9O@YK?PLT+2/&,>MIX\T3XF>#M7T+PIX1_HB\6_L[_L\>+E\=W7CGX(_
M!WQ0OQ(M- @^)]SXL^&O@C7_ /A/K+P="D7A2/Q]/K>AWI\56?A"VACC\.Q^
M(GO[7P_;PHNGI:PP($XS3_V4?V-C9WGA+3?V;/V:Q82:]X;^(M]X:M?@O\+H
M[.3Q+HMO>:=X-\=W6C0^&$MY-;TBT^WZ?X6\536S7]E;)>VFE:@D:W4= '\]
M'Q_^*7QV^/7Q6^'G@3XA?&BYTW4?A#_P<V:?^SG\%O'/A3P+\/=#U7X2?"S_
M (=<^.?''A73/"FBZYHGB3PKXA\6^%O$7Q6\5:EH'B7XHZ1\18M5\27MA)XF
MT#Q'X1LK#P##[UX/_:O_ &VM-N_V?/AYX@^--UJ^D2_\%N/C_P#\$\;_ ..#
M_#?X0)XO_:6_9R\+? ;X]?$7P]XNOUT/P'I7PH\+^/\ X4?%'X?ZO\#O'6H_
M#;X:^&]*USQW\%];ENM(\/E_%'A2^_<B?]F+]F^ZT[QGH]W\ ?@I=:/\1O%6
MG^.OB%I%S\*? $VE^//&VDZM'KVD^,/&EA)X>:U\5>*M+UN-=8TWQ'KL5_K5
MCJ@_M"UOHKS$PW-<^!'P4\3P^ +?Q-\(_AEXDA^$][::G\*X]>\ ^$M63X8Z
MG80V]O8ZE\.X[[1YH_ ^H65O:6EO:7GA=-*GMH;2V2%T$$>T _,;_@B%?ZIK
M'[!^B7'BCXL>+/BOXM;]I;]NB]U2[\=ZQX:\0>+;;3S^WQ^T[X?L+K5=0TW1
M-(UF]B\13>&=4\3/J.O27UQ<Z[)K,&A7-CX:T_3_  UI7S7_ ,$==?\ AU)_
MP3N^+_P/_;?U/X7:;^TS:_%K]K"U_P""I?PY^,'B#0+#6)O'WQD^+7Q)@%]\
M8]/\7:G#%KO@+XK?L_2>!+3X<>,KZ[U#P1XN^$%EX?L?"NN:GI6DM#9_O;X.
M^&GP\^';^)G^'_@;PAX%/C7QAKWQ"\9CP=X;T;PPOC#Q[XI-NWB7QQXJ31+*
MQ7Q%XQ\0R6=I)K?BG6!>Z_JKVT!O]1N!$@'*>)?V>?@+XS^)7AGXS>,/@K\)
M?%GQ?\%16D'@KXJ>)OAOX+U[XD>#8;*XOKFUA\*>.M5T.[\5>'88)M2OY((=
M(U:TBMY;V\GMDAGN[J68 _*3_@LEJ/B'PO\ \$EO%-[\.?B?\8OAW#I>J?L<
M^&O^$@EU&^T'XD^,?ASXY_:3^!'PT\2>%_B??_$[PQ-XUC_X2OP=XJN8?B;H
MOB"ST/7?$-W+>^%?B7:7WAS6/&7@W7?.?V@_VS/VB_"GA7_@H!XY^%?Q4EU3
MXE_\$]_BY^S1X>^&7[.,_AWX1:Q#^V;\-OBG\,?@C?Z#K/Q%U"#P#<>-E\3_
M +5WQ1^)'QE^#OP9UW]GW6?AIX>T;XK?![PSHVF>#?%MUX<^)OPY\:_N-X[\
M-?#?Q_X8U'P+\3]!\)^,O!GB^"7PIK7@WQ_HVD:[X7\7P:AAI/#^K>'?$=G<
MZ5X@@OA:%_[*N;.Z@O5@<_9YDC.VC-\&?A'<:OX&\0W'PQ^']SXB^&&G2:1\
M,_$-QX,\-3ZY\.=*FLX]/ETWP%JLNEO>^#=/>PBBLC8^&YM,M!9Q16BP+;Q1
MQ( ?F;_P5[L=?3X1?LH7_AGXJ>//A@T__!3/_@G+X<U:X\#WOA:P37M)\0_M
MF?"#36@\2R>)/#'B0:SIWA^=G\4:;HEPZ^&;S7[.RNO%NB^)-,L%TNOS>\*?
M%_XV_!3XO?M1?&+X2?&8V_@KQ7_P<4?L]?L\>./AG+X,^'GB?P3\9OAU^U;\
M"_\ @G?\(?$/B3Q+XMO-$NO'.D:SX+\.^)-,\7?!K4OA'XM^'>D6GB2+5)/B
M1IOQ9\+:SH_ASPM_31X\^&OP\^*G@W5?AW\4/ W@_P")/@'7A9+KG@GQ_P"&
M-#\9^$M933=2M-8TU-6\-^)+#4]%U%-.U73[#4K%;RQF^R:A8V=[!LNK:&9/
M-+O]D[]EN^&K"\_9N^ ET/$'C>S^)>O_ &GX._#FY_M[XC:='=PV'C_6C<>&
MY3JGC:SAO[Z&T\67IG\06T5Y=I!J,:W,XD /R9_9:_;=^+O[2?[6/@N71_C_
M /L]^&O"5I\?OVT/V>_C=^Q-K7C71O$GQT\*-\#=5^)VA>!/%?A_P!X6^ _A
MWXI?"[X@Z9=?"GPGXE\=Z_\ &'X[>./@YXL\#_%?Q*WASPUHOC#Q'\%-%T']
M0/VG_&>J6^E^%OA)X8\,>(/'7B+XLZC+'KOA'P3J?@BS\9-\&/"\^G3_ !=U
MJT@\?^,_A[H0TC4HM6\*?".^UE/&.C:IX8U3XO:%XBT8ZEJVFV6BZC[!9_"3
MX5:/X_USXP6'PY\"Z?\ %;Q#H5OX<\3?%*P\'^'K/XC>(O#6GO:3VGA_7?&M
MEID/B;6-"LY=.LIK31;W4;C3K:6SLWMK2-[.T,%#6_ ?P6U+Q_H?Q<\0>#_A
MO<_%+P=I\G@WPU\3M7\->%Y?B#X3TOQ5,(9?#&B>-;_3V\2Z!IOB6?44CDT2
MQU2TLM<;441[2[%^!, ?S^?!#XU_&G]DK_@GY_P4&_9=^'.GZ+\/OCM_P3C\
M9:SH7[//A[XX>)O 46OK^RE\>-9TOXK?LMW)N+3Q-KWPLUOQKI/@CQKXU_9P
M^#-O/XDN/AEXR^+_ ,"-!\*>,+K3(;KQAI.DR_%[XY_\%"O /B7P;+HO[2WC
MC0_@5\;?^"HO['?[,?P8\7?$KX)?L^6/QZO_ ($?&+X:R:C\?+76? ;? KP3
MI/@+7?"?Q7?Q/X*^$WC/QKX(O-4U;1/#%OJ6I^!/%7AU-+^(OQB_7']HC]A3
MX*?&_P %_%(>"?!7P=^%?QA^+%IHEOXA^-Z?L_?"7Q]KWBVQT3Q?X9\977@W
MXMZ9XH\/PW/Q;^%7CV;PCIOA+XJ> M9\1:1<^,/ MYJVDZ?XG\-:Q)IWB'3?
M$OV=/^"7/P!^$OB_7?BC\5/A/^R7XI^)6M:;X1T6RT_X%_L>> _V=?@5X?@^
M'VN^*?$GA;Q5H?P:E\6?&G6KWXLPW7B^^M;CXF>,/B;XLU/2;'3X=,^&>F?#
M2PUSQS;^.P#Y'TS]K3X]-^U"O[,R_M<_!#1/B!^RS^TS^R[\!?BAX.^.NK_#
MWPKX_P#VR?A?\4OA1\'M2\7?%K3/@!X)_9KE\9Q^//'UU\5/B%>?"KQ%\%OC
M-\-_@UX5\<_"?0XO'O@F;X7:-\2[/Q+Y3X+_ ."AG[1'QOT3XD_%_P"&O[27
M[/O@*[TCX+?MV:-X_P#V-?$=_H_Q-_:"_9M^-'[/FD^,1X-UZ]^$=A^S_P##
M?XB?#+6/AOXA\#3Z!\99OVC?BGX]^$_CRY\9>!+CP$VA7/B[P)I/C7^@?4/A
MS\%-?^)7AWXBZKX&^'&M?&+P7HU_8^$?'FH^&/#FH?$[PCX<\3B\LM3L_#?B
MNZL)?%GA_0-?4ZC9:C;Z7J%IIFJJ]]:WB7"O/&:E[^SQ\!-2UKX@^)-1^"OP
MHU#Q'\6M'M?#OQ7\0W_P[\(7NN_%#P[8VRV=CX?^(^KW6CS:AXZT*QLXXK2R
MT?Q3<:KI]I;P6\5O;QK;P[ #^;+1?VM/V_/$?@ZVL9/VR-8TW6_BK_P;_P#@
M;_@I?:^*-)^ '[.;>(/A5^T5\/-(\(6^IV7PM@U3X::GX7G^&?QHO-=.J_&;
MPC\6_"WQ1U@:F=27X">*?@1I%]8:/X9]?^%7_!33XR?'GQ!X!TX_&?\ 9M_9
MY^*GA+3?V!/'NN?!?XB>,D\/6'[4WPY_:H_9^_9_^+?Q&U3X7_"#4?V>_B1\
M9?B%<ZOXI^+7QI^$OP)T_P" W[1.GZQH_P >/@_X"TWQ_IGBK0]3\2^$O'W[
MH)^R?^RY'Y97]F_X"AHO!$GPRB=?@[\.D>+X<3-*\_P_C*>&U$?@BXEGN)I_
M"2!?#\LMQ.SZ<1-(&W-._9V^ 6D:I\-]=TGX)?"/2M=^#>DZIH7P?US3/AMX
M*T[6?A/HVN:?>:3K>E?#+5++0X+[P%IVL:9J-]IVJ6/A6?2;2^LKRZM;F&2"
MYN(Y #\"_AK^UG^VGJGBCX%Z[XL_:2O=4T_QQ_P6\_;<_P"";NM^"M%^#OP2
M\/\ @ZZ^!WP_T7]L)O ?C));GP%KWCN'XM_#S6/@5X=F\(^(;'QW:^#KW1[B
M[T?XG^ _B;??;-=O_JW_ ((H^/\ 1K;]BSX=Z-\1?V@[OQS\3_'?[3W_  4&
MC\-Z=\4/&O@B]^)'BEM _;9_:H-]#I*0:;H?B?Q=/=:-X1USX@:W-/'K5];R
M+XAO-/FTGP9I5GH6C_I)!^RM^ROICZ+':?LX_ BQDT'QM>_$_P -FR^#/P^M
MO[ ^(]ZEG%??$#0Y;3PPBZ1X[NX[&PBG\5V30>)+I+.S1]0E^RVXCYN3]DK]
MFW7OB!X ^+&D_"?X86&I>#?'WCKXU>'M9\*_#SX8:<^K?%CXJV'A^'Q3\7;K
MQ59^$&\:W'C3Q#9^'=.76O$>B>+-*B\>6LEA+X[C\:)H_AM]  /@#]N7PCXF
M^(7_  5)_P""9OA#P7\9?&7P)US6OV:/^"F\,'Q,^&NC_"WQ!X]T5+#6/V M
M4N;3PQ8_&?P)\4_AE]JU6.Q.FZO)XH^&OC,)X;N=:31['1?$$FD^+O#OP)X
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M]IRU^!O[-7B3X$_&/X _$62Z\ ?LW>(?$]C\"_VK?V09OB#)\,O$>M6OP_\
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M]\)_AI:?$[PYK^FZQXJ\%>.>$\%?M5?MR:_K?P.U;6/VHY5B\>?\%P?VTO\
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M'_A3:ZNGB"U^%VBZ[I&E6>J:7\.+;7HTUJ#P/97</AF'54COH],6YC21?5:
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K^7O\
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M^,W^+#^(?#WQ)N6^-_Q\^&'[4'Q+>S_:/_:;T*77?CQ\%SX07X3^/+"7P_\
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M5?>)+6PL/%NDZ9XY^%OC#P9XKG\%>.M,TK3-,^(GPZU'5[[P%\1--TW3=/\
M&_AOQ!I^F:=:VGS!J?\ P2$_X)VZGX#^ /PRG_9Q\/6G@S]E_0=0\(_!C3=(
M\;_%CP[J&A>"M=U"WU7Q+X \7>)?#OQ"TCQ3\7/AUXQU:)M3\9^ /C%K7CWP
MCXSU"ZN[GQ1H^L-=W(F /)/$?[;O[2>F_&[XE_ N)/@GH/B/XO?LZ_!CXV_\
M$[];UOP#XW\3^'?B'KGC[X@0_"[XL^"/BGKG@GXSWGA/Q];_ +._B/Q=\$/$
MOQ)\2?!KQ-I<[_"CXQ6GQ1\,>'M;T3PQ-8>(^JT']M/XS_%SXL#3_A;\&?#/
MQ3_9A\+_ +5/CS]BS]I'Q!K/B/X1>#]9\ >+/"&J:Q\/_$OQ$:7Q+^T1/J^H
M:4?BC!X<\%:?^SGJ'P-_X3KQQX%^(WA/XG^$O'>N1:AI_A#7_P! O&?P)^$W
MQ"^)WP@^-/BOP-X=UWXH_ 5_'DOP=\=7MK.^O^ U^*?AI/!_Q%AT2[M[NWC-
MEXS\-0V6FZS8WD-W97(T_3KPP?;M.TZZL_!H?^">?[)=G^TGKW[76F_"J'1_
MV@O%-LZ>(_'&A^-/B;H&G:UK#^&+KP4/'.H?#O0?'&E_"Z;XJQ>$[V[\.V_Q
M>7P3%\3[/1KB2PLO%EM#C !^1/\ P2)^-_C#P?\ L*_\$UOV1O@I;^ _"OQ
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MCE)XP\"^)9[?]H_X%>#_ -F+XO:)X>^,WQY\#>$=?_9_\ SZ[+X1^%>B^"O
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M^%_[2GA/2? _QAM/%&N>&-#\<^"?B5IFG>&_B9\6OAC)!XV^&WC+0OB#\/\
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MG@7X(ZMXP\*^-O@_I/Q=^'FHW:_%9/"WC-_!^OZ/J6E^*_A;X.\3P^]>+/\
M@G;^RSXX;XROXF\*>/[U_C_\;OA/^T9\6#9_M#?M+:$/$OQC^!7_  BW_"HO
M%]HF@?&/3(_"@\"_\(!\.?[)\.>#$\.^$'/P[\"&Z\/3_P#"&>%!HH!Q?PQ_
M:<^+WQK\30>./AB/A!_PH#PQ^UQ\?/V2?BOX:\97FJ:'\8/#=Y\!_&GQ,^#N
MJ_$K0_&P\67O@W4M2UWXT^!-'T_P_P#!>Y^'<.LZ[\-?'.E^-HOB)IVM6(\%
MWGY ?M/?\%3/VN_$7[,W[=VE^#[[X.?"GQWX*_X)9>&_V\?A;\6/A?IGCCQ]
MI?ABS\>>,OC;\.-:\&_#_P <:YXF\'Z+\:8H+?X?:'XI^#7[8?@KPWH'PH\3
M/J$OBWP3\-OB/X-3P_XAUC]O]%_X)X_L=^'?C[XX_:<T7X'^&;'XR?$EM9N/
M'.L+J?BZX\'^(]9\3>&Y?!GBKQC>?"&^\27?P=C^(WB[P;<7OA+QA\3;;P%#
M\0?%GAO5-:T7Q!XEU'3]:U2"Z\VL/^"3G["NG>$M6\"Q_"#6;_PGKG[-.L_L
M<ZEHOB#XW?M%^*;:7]F+6-3U;5K?X.P/XE^,&K7-CX:\$S^(-?L_@_/IT]GK
M/P.T+6]6\-?!W4_ _A[4KW3)P#Y>_:"_;A3]DC]I7]M?Q+\4_@5\(O%NL_LK
M?\$K/AW^U/>?&7X;>'+KP_\ &?XP:%)\6OC_ *18?!6]U35+3Q+J'@#X;:?X
MW^'_ (BU+P_X;NO$OQ'T;P[?>+]1^(-[J@GO]8T6RXS]LK_@I_\ M1_L2>,?
MB'\)O%_PG^#OQ4\?1_#W]FCXW_"[Q?X;O_&7@#X7Q?#[XP?M<_![]C3XG?#O
MQ]8ZCJWQ \:W'Q*^'_Q#^+?A+QCX!\9Z0=#\(_$SX?>(?$;ZAX6\"^)?A0^C
M?%7]*-#_ &#?V8="\;>(/B$?!&J^*_%?C/\ 9ZTS]E7QU<?%#XH?&#XQ:5\0
M_@/H^H^(-27P+\1/"OQ8^(?C7PA\0SJ6K^,_&FJ>+?%7C;P_X@\<>-]:\:>+
M-6\:>)M=U3Q1XAN]5XK5O^"9'[&NO_"_6_@_KOPY\3:OX$UZX^#_ /:-O?\
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MWP;??L:?LPIX4^+WBSQYJUE\.M3\.?$76OVF/A]XW;Q];1?#72_@?IFC>--
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M2:Y<WW"_%;_@G!^R3\:/$OQE\5^/O GC&\U3]H'Q%\'/&/Q>M_#_ ,>?VB_
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M['XI6NO?!3Q=X:\":9;_  ];4?@MJ'P^_MOX<M<_#W7X]3\%WU_H5U0\*?\
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M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K^>/]HO]JWXB?M%?&?\
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M^"OAYX\\*^$_'VGV'Q.^&'@;Q$O_  E^AZS));Z5=^&YW/A;Q)XIT'6?1O\
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M/(2P^)?CRRUJ/7?$>OV?B6P\2ZA::]8W,5MH4>C_ !YI/_!&K]GKP[\(-3^
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M.^'?ABU\"RP_!E[[PK#I?PZ\#Z)X(S/?ZU<76D1SZS>W5[XWNY/%,(!8U_\
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M\\7:YX)\96%Q8_"KP[\1K;QSX/\ VE_%ECX@LOBEXQ/PSAU^[\/V2>"=-O?
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MGP^\GP_G\8:C\/K;Q-X[TKPW8^--<^F: "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH) !)(  R2>
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M44A(4$L0H'4D@ ?4G@4 +10"",@@@]".0?QHH **** "BBFLZ(0&=5+$!0S
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M_%4_B+4M:U+PW;:-/%?W_AVUTNQN[C4HY]2N(HK!N1_X+$?L*?M*_P#!2_\
MX)^ZW^R5X"OO@C\,/'7Q-\1?#/Q'X^UWQAXY\<:YX0\$/X#\2:1XUN--\&7N
MB_"2WUKQ[_:&MZ/!HL6I:]H'P^6'2"=6;2VOI'TJ, \N\0?\%)/CRW_!6?\
M8S_80^&7Q7_8\^+7P7^.'P#\=_%+XN^-O!'PX\6>(/'.B^*_A)I6KW'B;0O"
MNN>'_P!JO6?"GA'3_'USI]M>^'+3Q5X6\6ZEX'L;G['?WOCZ69=1M?FOX!?\
M%9/VU/CS\1?VU_V9]/\ B5^POX:_:O\ A1^W'\??V,OV0? &K? #XPOIOQNU
M3X#?"_XF?&B]\5?$K28OVR_^$G\%^%_$?@WX2>*/#]SXWTHW'AGP;XKU7PPU
MTGB.?5+3PS??:'Q/_8;_ &L_B;_P5E_8R_X*'2+^SQX?\ ?L[_ /Q=\&_&_P
MX7XI_$S7/%^I7_Q;T[Q /'/B#PGJ[_ S1M#O;7P/J.NQ0>%+#5K;0I_'UAI+
M3ZS=_#^75HK/0_$/V6?^";O[:/[,/B/]M_XL6GA/]BWXB_&;]H?]N#XW?MV?
ML[WOC/XQ?'0^"OV=/BC\5_AU\0OA7ID.O:;HGP!TG6/B9!HW@?XI^-_#?B"X
MT[4/ $WB;0];U&RL?^$:OKBRUC20#UKXF?MV_M0>&_\ @K9\0/V H/B9^R3\
M+_@K;?\ !-G5OVZO"?Q<^*?P6^(6I:_X-US3_C8GP=F\*>/+T?M8_#KPKXL\
M):/96&N_$36-8T^S^&U^ND6[Z))_9T>D7GBN]^$_BE_P6R_;=\._\$5OV7?^
M"EUC\)O@1\)_B[\2OC5X7^%7Q*\#?%GX;?$WQ!\,O$OASQ-\1O%7@#3_ (J_
M"V*Q^.?PV\8>#O".L:9H6G>/= ?QGJWC#[?IVH7.D6\][HJ:1\0]9]^^-W_!
M&CXB_M3_ +;FN?%G]J2;X.?&C]FSQQ_P3&T;_@F[\0DU7QIXALOC]K=_I/Q2
MT_XXQ?M8:/;+\#9OAYX?^+-C\1].M[CP]X4L=2BT?0;V"T\66OBDI;?\(7)Y
M1\7_ /@DO_P4R^-G_!,?X4_\$[/BG\>/V7OBAK?P'_:%^''B;X>_M(Z]K?Q4
M\.^*O%/[/?P3U26^^%GA3XB^"K#X6:]8W/Q2M-.^Q^%M3\46/B>ZL7\-Z;I4
MFM2>,?&,6N>,O$H!^H_P]_:2_:"^)O@K]LSXC_#WXN_LP_$CX6_#+P]X@\,_
ML^_%'PS\%/B-:6=I\>?@M/\ $[1?VBO#GQ+\)S_M)Z@GQ7\ >'_$N@>!M,\&
M>(_ ?C3X2W.I:DWQ%T:X^UZ;H?AGQMXF_-S]@C_@LG\:_P!IC]DGX$_M7_%7
MXE?LB:;)HOP3_:)_:O\ VY/@I\,_A!\3;CQE\)/V9/@EXX^*/@.R\2^#=3/[
M3GCC7-%\;>(KOP9I_B'PUX<\6?#?Q-;?$'0] ^)4.BWGA[4](T*VU;])+OX!
M?M=#7/CJ/!7A3]E_X2_"_P"(?P5^-]OI_P 'O"_Q0^)&O:?\1/VJ_CYXG\*7
MGB7XW_$WQ?>_ /06\&:-X;\/^&M6GL/#_P /O!^I7'C+QG\1_B-XG\9RW>L:
MSIVKZ1XC_P $S?\ @E='^RU^P#X _9 _:F\,?!SXG>,_!_P;_:!_9E\4?$#X
M>:KXFU72_BE^SU\?/B;XF^)WB#P=XETWQ;X2\(R6T$=SXKN]"M] U2W\8V6E
M1P:WK7A_7=&7QYXE\/T >"?"_P#X*9?MT_''_@EE\5/^"M7@?PS^S!X3^&OA
M_P +?'CX^_#?]FCQ5X!^)OB7QWK?[//[/FK?$BR\0:+XW^/&B_'30?#/A_XL
M^,-*^'VH:_I&I:)\&-?\+^&!;6VB:AH?B&_\1>?X6@E_X+#_ !1^,GQ[_P""
M,*?LUZA\%_#G[,?_  5@^'?[4_B'5+CXT_"#QYJ?Q:^#?B[]F3X6V_B_5- M
M_$&E_M ?#KP=K_\ :OCN_/P]N(I/"*V$<F@W.O>&?$_B[3O$NC_8.N\"_P#!
M+']J_P"#7_!-SXF?\$D_A;\</@[>_L]>,M)^+OPA\#?M,^.-#U\_&[X;?LT?
M'C7?$^L^/?!'B;X$Z%X?C^'_ ,7?BGI.C^+_ !?X'\/_ !1T_P",_P &]&U"
M'Q38^.+OX<:1J?@E/#/C#G/BQ_P1;NI/BU_P2E\,_!WP1^S_ *_^Q7_P3<^$
MO[3'P8\1_";XX^+_ !))XQ_:!\(?M:_!S3?@Q\4KGQ78>%_@GJO@FVU^.VM-
M4^(6K7_F2VOQ(\9^)]9BGL?A_:^1>@ X<_\ !7+]L*Y_X)H_\%-?VKM,\-?L
M]WGQ*_8&_:,^-?PS^%_Q=M/A?X]U#]EG]KKX7_";Q/H>DVWC?P%X3M/VD&\:
M:-<ZM'JEYH>LZMI7QB\=>$-$UZQM[G1]2\77+:[X2\.?=/[ 7[9_QM_:YU'P
M!XI7XF?LQ?$KX;6O[-GPQU[]HC1OA1\,?'_A#Q7\*OVHOC!X#^$OQ?\ !?@7
MP]XRUCX]_%+PQXK\'VOPS\7>+[KQMH<_AK3O$?A#51\/!_PE>M2ZYXHT?PI\
M!67_  1\_;A^'G_!._\ ;=_X)9> _C9\#/B1^S#\4)=2\/\ [$OC+XP>(OB'
MHWQA_9Z^$OC3Q7%XI\5?"[XHGPS\,O$FB_$O2_"=R+B;X=ZAINHZ/J,6I:GX
MA&HW-KX5O_"_A#P)]D_#[]F_]LW]FGP'\'8_ASH'[+'@.3X/?LZVNE?'#Q!X
M>\1?'KXL>(_VL/B'^S[^R9K?P3_9UTSQ)X(\,? 70=9T3P=IWBV\T7QGXQN/
M!2^-OC7XATOP!\// 7A)M5MM%33+P _9VZDBBM;B6=HT@C@EDF>61(8DA1&:
M5I)9,1Q1J@8O(Y"(H+,0H)'Y<_!S_@I!^S1H_P (_@1JOCG]J_3?CKK?[1?C
MC]K'2O@EXL\"?LY?%[PYK7QA;]GKQG\9M7\9> _!'P6\(^'/'7B^X\2?"WPK
M\/;[X8:&RVW]J?M">,O!UO=_"[2->\3?$CPMX7OOOGX.:O\ %#7/A%\/=9^+
M^A>&?#OQEU'P!X4U#XF>$?"^JW&H^#_#?Q,N=!LYO&7AOP]KTUM->7WAK2O%
M!U#3])U*XM[N_;3(()K@WEQN>3\;_@#_ ,$VOVHOA++_ ,$X)=;U7X$:E_PQ
M9^U7_P %!?V@?'":9\1OB$X\8:'^V@W[2S>'M$\,FZ^"EH!K7@4_M*7RZO<:
MLMA9ZJ/ \!L7MO\ A,)E\* '[#? ?X\?";]ICX3>"/C?\$?&VE_$#X9_$'2[
MG5/#/B72[?5-.%R-.U2^T#7--U+0]?L=)\2^&O$7AGQ)I6K^%_%GA/Q1H^C^
M*?"/BG1]8\,>)]'TG7])U'3K;S'_ (;1_9S'Q5T'X-2_$W3;+QOXJN_B[I?A
M)M3\/^,=*\">,?$/P"8M\:_!W@[XQ:CX?MO@_P"*O'?PKBL_$7_"=>!= \=:
MCXQ\./X'^)2:KH-F_P +/B0OA;S#_@FI^S'\3_V0/V5?#GP(^+-_X&U;Q3H/
MQ,_:-\;'5?AYKNO:]X=N].^-_P"T5\4/CUI]N9_$OA'P7J=OJ6AK\4)O"U[&
MFDS6EZ?#\>MP7-J-6&C:7\L?"7_@G1^TSI'PD^.?[#WQG_:"^''C;]@SQ1H/
M[3/@SX87WASP/XGLOVO]3^'G[4J_%RUU'P-\4?B%XL\3>*/AMHT?P0T?XO:O
MHW@?Q;\,O!6EZW\0(/#W@C^U+3X;^'M(\6^#/B  ?55W_P %+_V--.T?XK:_
MJ_QGC\/:1\&?@3I?[3OC2Z\4?#+XP^%Y+S]GC5Y=0MK+XU_#>P\0^!=+U'XU
M_#.2\L#83^+_ (,6OC[1--U"\T.PU._M+[Q3X9M=3T--_P""C?[(^J7?B6PM
MOBCJAU+PXOP,O(=%NO@W\<]+U_QMH?[2OB&[\(_ OQ1\'=$U'X=0:O\ 'GP5
M\2O$VE:[I6A>/?@K8>._!T$V@Z[_ &GJ]G%H.MSV'PW\9?\ @FY^TS\=O@7K
M'@+XB^-O@=J?Q-^'_P#P32_:B_X)W_!?QGH5WXV\*^&_'FI?M8>&_AAX!^('
M[0GQ7T!/".N3?#F?1_"_P6\#:QX7^#'@N3XCZ5;ZYKOCW2[SXE2V4WA;5=#?
M\5?^";WQR^,'Q4\3>)?'7AG]F+QG\,O&W[&?[&/[,_C+X?\ C#X@_&":^U?5
MOV8/B;\9?B_X@U3PUXM\&_#KP/XJ^&GB#6/$_P 7H+3X3?&WPAK\?C?X0>(_
M .@?%BW\&^(]0OG\ :4 ?8K_ +67PQ\:_'[]E;P=X)_:*T_PY)\8[;]J-;#X
M":Y\$/'<?C;XX77P0NCX7\8RQ^(O$VG^'-4^ _\ PHWQ=H?B&+7['QAH%O-\
M1=4G?0].:#^SX+W4OG#Q)_P4GTWQ+^WG^Q?\&?A)X[\,:M^S9\9/A?\ ML>-
M_B7X[USX1?$GPOHE_-^S!%H&EVGB'X;?M">,Y-#^$GCSX?6^MZIK,GB6Z^&T
M7BBUCT[1O#WC&3QL? GCKPV^J)H/_!/[]I#3OB]_P3Q\9^+/B[I'Q8T']D/0
M_P!N'PYXY\3?$7X@>,M;^,>N>%/VKKR*P^&WA33_ !=J?@+5YOBCK'P"^'.F
M>&? .I_%GXC:GX<\6_''4?#[>/\ Q7I'AS7]9U*"7Y/D_P""-_[5_C[X>_LR
M?L[_ !<_:)^!,/P;_90_8]_;?_8,\)?$7P'\._'1^+?Q!^!/[2W[.WP\_9\^
M%/BW6/".I^)=,\&^ OBI\,M"\&VLWBN6Q\4>//#OBU="$ME;Z9<>-KI/!8!^
MK?C3_@I!^QY\,O#GC?7_ (H_&"3X8CX;^/?A#\-_'.F_$7X6_&3P%XH\.^(O
MCU?0:7\']2NO 7C#P%HOCB7P!\0-7&KZ+X<^*UKH<_PNNM9\'_$'2YO&5MJ/
MPW^(-GX8?8?\%%OV4K^?PG:/X_\ %>AZCXMU?X;Z$-&\7? /]HGP7K7@;5?C
M+\4_&7P2^$-I\:])\8_"W0-5_9]?XF_%KX?^+/AYX#?XYZ=\/(/%WBJQM-,T
M*>\EUC0QJOP(W_!/;]L;6_V>?%/@KQ;I7_!/71OC#J_QW_8F\6KK'[.WPR\1
M_LX^$?&/@+]C?]I?P)^TM)XO^)7B#3_ OQ!\8:I\3/B?K'A+4/"VE?#W3=,3
MX:?""'Q%K'BC1->\4W]Y>Z1?^E?MD_L*_M>?M%_%?QWXET/XI_!#7/AG'XM_
M81^+GP&\"_$ZR^(%I+\'_B%^R7^TAH7QK^)/AVV_X1=+[0;Z'X\Z?X?L;2X^
M-]UHNH_$/PAICZC\*;;PAJ?@W4XO$6C@&[IO_!37X8?&KP_\4+C2?&7C3]E2
MV^%/_!1[X/\ [#NE^*OBU^S]\0?$UU\7?%VI>/\ X4Z?J'@#2?")TK3%\,7G
MQRN=;\9?"W0];OM3NM;^"^BZAX3^,GQ-T'PI-J%MX.M_LK4_VU?V==%^*'AG
MX/:I\1X+3QEXT^(VK?!KPI>S>#OB#%\--<^-&A:%<>)-3^#5E\;W\+_\*6;X
MN1:/8:Q/;_#%_'R>.[^]\/>*-$T[P]>ZSX6\0VFG?FU=?\$Z/VK]%\-?M(^"
M_#OB7]G[Q/H?Q9_X*L_ W_@HYX5U#6/$WQ&\!ZK)H_@+XU? 'X\>,/AWXFLK
M+X=_$BRT+4%UKX!6_@CPU<Z9=>+;35+#QPWC;5+S1+GP.O@GQS[)#_P3S^(Z
M%O@W?^.O"&K_ +-<?_!1*#_@HYH7B(PWVF?&_P +>)A^TK-^V1-\ H]"BT.\
M\%>(/#+?M)RW>LM\8K[Q99:^OP;U_4OA'%\,_P#A*=*TWXS70!]"_"3_ (*2
M?L<_''QK\.O 7PP^+\GBO6_BOXD^+'@KP!?VWPP^,NF>"O$/C[X'ZEXZT_XH
M_#.#XEZ]\/M*^'-E\4O"]K\./%OBP?#/5?%.G^/=<^&NF6WQ5\.^&]6^&NO^
M'O%>I?5OQ+^)W@GX1^%SXO\ 'VOP>']%?6O#WAJSD:QU36-2UCQ+XNUJQ\->
M%/#'ASP]H-GJ/B'Q/XI\2^(=3T[1O#WAKP]IFIZWKFJ7EOI^G6,UQ,NW\G?A
M5^PM^U%X.NOV,[C7V^!L@_9Y_P""C7[<_P"V5XX_LOXL_$/4Y-2\!_M?K^U]
M_9?A?PNVI? ;3EU3Q?X*?]L?7_[4_M9?#FD:Z/A;ITEIJFE3_$V]D^&_VA^V
M;^R[X@_:9\&_!.\\)>,;/P7\6OV:OVC_ (6?M2?"C4-;L[C5O!&O>,_AE_PD
M&CZAX%^(>G:>]G?/X1^(?P^\9>-O!5SKFE)<ZKX!UK7M&^)&C:-XDU/P;9^'
M-7 /D7]I3_@J)X LO#/[-MG^S]KGB3Q%=?'_ /;C/[$WC[Q/I_P2^,%[X^_9
M]UCPUX*^)GC3XM6^I?!S6_AO>>*-$^.^F:1\/;6S^'/PX^*/@N.ZU#2_'7A[
MXWQ> OB?\(=,N=/\3?27Q9_:!^(7["O[#/Q*_: _:5EG_:$\5_ +X9_$CQYX
MPU?X*_"K6O"-Q\0=*\&Q>(];\+7<_@A-9\76G@74I/ VGZ%)\4O%%[K.G?#_
M $GQ);^+/$6EZ;X.\*R:+X3TWXO^(W_!.+]H3Q7\:? O[1>E3?!%?B1J?_!2
M7X=?M\?&#0K[XE?$*Q\-6&@?!']CK5OV+/A?\&O .KQ_!O6[SQ#>:CX,N;/X
MB^,OB%KOAWP<8O%MQK?AW2_"=WHDVC:GHOZ5?MM? ;6OVIOV.?VJ?V:?#>O:
M7X7\0_'_ /9Y^,7P<T+Q'KEO=W6BZ%K/Q(\ :_X2TS5=7M[ -?2Z98WNK07-
M\+-);H6L<K6\$\H2%P#\^OB/_P %.;7X$?MK>/O#?QVUY/"O[)GA'_@G/X2_
M;&<Z/^SG\>]:^,GA/4]0^-7B7X<>/?$'C?PIH.B>*?BI<_#[P%X=\(7'B+Q#
MK0^"O@?2_AUH.LOJ_P 2;VUTZWL]8'W_ /$3]L;]G_X51>!]0\<?$:STOPWX
M_P!3^'^E:'XZTSPMXW\9?#"TF^+>IV6@?"F\\:_%KP3X?\0?#+X7Z#\2?$>H
MZ=HG@?Q/\1_%?ASP[XHU;5]$TG0]2O\ 4-:TR&Y_-[X\?L!?M>_'GQY^TQ\1
MM8U7]G30M8_:+_X))>*?^"?#:/I?CCXFMH_@SXD^,?$WQ(\22^,HI;OX57EY
MXA\%^%H?B;<>'X=0?^P]?\9GPE;^)9O#'@?_ (2U_"G@SDO#7_!+7]HSP=\7
M?!_B?2]9_8Q\9?#3XE_#/]FGP=^TAH?QT^"2?&7XD?!3QE^S?\-/"WPE/Q&_
M8H\=ZKX:T;0Y;KXE>"_!_A:Y;PK\<O!&I>$OAI\2_"6D_$;3=&\;Z?JWBCP!
MK !^I?@K]LGX ?$6]O[7P=XYO-2M['0/&?BJWUV\^'7Q1T+PCXH\,> /&MK\
M/O$WB7X>^-M?\'Z5X0^)F@1^++_3-)T35/ASK?BRR\6IK.B:QX4N=:T+5].U
M"Z[?X,?M$_"CX]'Q];?#KQ%J-]KGPL\:R_#_ .)'A#Q/X(\??#+Q]X#\5?V1
MIGB*PT[Q;\._BAX8\'^.M!MO$/AG6M'\6^#M;U'P];Z%XX\&:SHWC'PAJ6M>
M&M5L-3G_ !XUG_@C]\4O&/@CX[^#+;XV>&/V>;#XV^#M.\0>)O"'P@L=>^)W
M[/\ KO[77A/X_?";]I+X<?M3Z#^SK\9(W\*? 3[#XO\ AYXC\)?M"?!CX6:]
M?_#K]KS2/'%OXQ\;6OP^\4^#]*ANOT-_8?\ @%\8O@[X.\2ZK\>O#/[(7@KX
MI^-]8TNXU[PI^Q-\);GX8_!:UT_PQ9S:9HVL7M_XLMI_B5X]\?ZU;W4YU?6O
M$5]8>'?#WA_3O!_@[PAX6T^\T+Q=XY^)@!WWC[]M;]FOX;?&"Q^!'BOXI:;8
M?$^\\1?"+PE>:%9>'/&OB+3O"7B3X^W_ (GT?X&Z)\2_&'AKPYJW@GX4:E\8
MM>\':]X;^&=M\3/$7A1_&OB-=&T#PTNJZYXG\-:9K'F'A+_@IG^QIXY\=>$O
MAYX5^,R:SK?CCX[_ !'_ &7O#FJ0?##XRVG@&?\ :,^$VE:YK/C7X*:M\5]1
M\ VOPL\,_$<:5X9U[5/"'A7Q)XQTK5_B39Z9=M\-K/Q>85\[Y5_:\_8 _:U_
M:&^/NO\ Q%T[XP_!7Q#\-O#'[0'_  3S_:-_9W\'?$;1_B!IFJ?"+4?V3/B[
MHOCOXQ_#&T@\,7.I^$0WQB.C2>+H_C\FA7?Q,OUU:/X$>*?#\WP\\&> /&/A
MOS7P]_P3/_:CTQ_A:U_KGP%F_P"$&_X+4_&G_@J%J9@\>_$.07/PX^*UK\:X
M+7X8Z7'<?!T;/&>C2_&R\EGO[F1-"NAX5A%O<6C>)"_AD ]]^*W_  4#&H_M
MS_\ !/W]GWX&^,M*UWX??&3X]?M8?"/X[37'P/\ BK>:7X@U'X"?LR_&GQW)
MIOPG_:1OAI'P2U.;X9_&+X<KX+^+7ACP8OC_ ,3KXNL;WPC=Z]X&OO GQ%\+
MZU^E?Q*^+/@+X36&A7?C?7QI=SXM\1VG@WP7H>GZ1KOBKQ=XV\77NEZUK\?A
MOP3X'\):;K?C+QGK5KX8\,^*O&6JZ9X7T/5KS1? _A'QAXWU>*Q\)^$O$>LZ
M9^,7[/W_  3$_:J^"7B7]A/P(_QH^"'B+X!?\$[?VC?C=\1?@]XKUCPMXXU#
MXY?%'X+?'#X1?&SX>R> ?B7HFGZAX:\!>&_B+\.HOC5K/AK3?B!X?USQ!HWC
MRSTOP_\ $#6/!WAC4]-UGP'XL_1']K+]FGQ?\9?&W[*_QH^&&O>&](^+'[(G
MQIU?XM>#-(\<?VZO@3X@:)XY^$GQ&^!/Q1^'7B6_\/RW&I^$[OQ%\._B?K-U
MX/\ B+8>'?%]QX$\8:1I&IW/@WQ=HEQK7AW40#R37_\ @IY\%?\ A;7[%7PI
M^'NE>/?B(O[:WQ(^+GPTT#QQI/PS^(5EH/PE\0?!SX8_$WQ=XO\ #GQ8T+5_
M#^F^,?"GQ3\/>-?A[+X!\>?!CQ-HGACQU\)GL_&FN_&&W^'EAX0(U7Q'_@FA
M_P %--#_ &B/AK\"? O[1'Q)\(0_MB?&[7?VPWT'0/#'PJ^(?@#X6>.;+]GG
M]IWXT> +OPQ\,_%6K/XK^'4_CKP9\,?!_AOQ5XB^"P^,/C3XUZ-X#>W^)'B2
MQO\ POJC^-;WFK#_ ()>?%3P-\9OV;OVE?AOXG^%!^*WAK]O?]K+]MS]H'PC
MXDN_&-KX$N+_ /:__9Z\5_L]ZKX?^&7B#2M NM8UVZ^#'A"?P!9VMSXA\+^"
M(?CAJWAKQ#XQOV^"LGBE/"NC^6_"#_@E#^T;X4\*?\$__ 7CCQ1\'SX;_98^
M*G_!1WQ-\4=0\%?$?QY'X@\1>"_V[X/CS8:9!\/3JWP6@LX?%?PWLOCM<R/+
MX@-GINIWWA"TDMY;6+Q!*FA 'Z/>./\ @IE^Q7\,-%^,FN_$?XWVO@S3O@9\
M*]*^.7C2]\0?#CXNZ7%J7P7U_P 37'@_1?BQ\++:[\#)=?'SX<W7B5=/T23Q
MG\"!\1?#T.I:]X7MI]0MO^$O\*/K7T]\*_C+X(^-'A74O%_P^O=:O-&TOQ7K
MG@ZXN/$W@7Q]\/;B35O#NI)IU_+9Z1\1/#/A36M1T.^WQ7OAWQ;IFGWWA+Q3
MI%Y8Z_X5UO7]!O+/4KG\#5_X)%_M=W?[#G[17[(WB/6_^"?UQXJ\3?LJ7W['
MOPA^./PJ^ VL_ [QU\2?!^K7'A.WN?BQ^TYKT&D?$?Q!8>+K#2?!&D7;?#3X
M7ZE=^!?%GBS5]?UWQ+K FM?![>%?Z,-+DU(:/97'B&TT_3-5DM[*YU:RTK5+
MO6M+T_4IHK>;4;:QUF\TK0;K4M-L]0>YBM=2N=$T:2[L(HKRZTK37DEM(0#X
M2^$?_!4?]A[XX>,_#/@?X:_'*/Q)J?C/6_B]X2\*:D_PM^-/ASP9KWCCX$2>
M()/BO\/=/^)'BKX?:-\.I?B5X.T;PKKOC&Z^&O\ PE1\=ZI\.+:U^*&A>']1
M^'FIZ7XEOM#X._\ !2G]D?\ :$\%ZC\0?@E\0_%OQ&\'6]KH5SHOB'P]^SW^
MTC<6OCZ3Q'JOQ!T>UL/A%9S?"FVOOC=JV@ZA\*?B19^.=%^#T?C?6OA\? OB
M^[^(&G^$K?P]?[?R\_80^".M?M;?!O\ 9Z\0V^M_"34OA'^R3_P5!_X*1_M5
M>&CX;\?ZKK?C+XA_%NR_:P_;DT?X/>$/$HTGPS<^&OAUX!;2_P!H2'XOW/C'
M2];^(&M>+/#,7PZ72?!Z^'O%UWJS=GX;_P""57[3/A7]@[]A+X(:5XQ_9@U?
M]H+]A+XD^,_'&DZ/\6O"OB_XQ_LM?'70?'&B_%WPAK?@[XA:/<Z1X&\9^&+@
M>'_BU_;?AKQ1I.D>)I/"7BOP=82)HNM6FKE]' /O.^_X*I?L.6ND^#]4L_CA
M)XFE\?? [Q?^T5X1\/\ @'X0?'/XF^.M7^%?P^\>:+\+_B)JB_#?X>_#KQ%X
M^M/%OPQ\>ZO<:!\4OA-?^';7XM?#9_"WQ$OO'7@KPUIWPJ^)]WX/Z#2?^"AG
M[)7Q-C\=>'OA_P#'G17O]!_9XN/VE['QG)X"^(;>!=9^!KZ9IMQ)\:?A=XLU
MGPQI/@3X^>$?!.H^(/#NE>/K?X0^*O&,O@OQAJ%M\._'#^&?&=S%HS_-_A+]
MAW]H?P=\6?@U\1;*P_9?MK#P/^PW^V/^S_XH\-?#9=;^!_@^S^+G[6?QB^%7
MQYD?X;> ?"WPF\1:/H_PO\%>*/A-:>#3XBUG5KOXC>+M-\5W_P 2?%EEK'C?
M1]1L?'7GOP5_X)Y_M/\ PL@_8]BOKSX$ZJ?V:/\ @D!\0?\ @G!K1LOB7\0K
M8>)?B'K@^ *>'OB)H_G?!!_[/\(7"_LX: VM6]WYNMZ4?B#JJV-EK@\ V3>/
M@#Z\^"G[='P,U#X;?L\:5J?Q\D^-WC'QU\$_V1_&-_\ %+PK^S_\7/"WAWQU
M_P -5)IWA7X)_$KQ)H6D>&/$7AS]GB+]H7QG#?WGA/X;_$CQ+I&I>$8-5M++
M59X;.R2XNO2_%W[=/[,/P_\ 'VJ_#CQ]\6='\ ^(-(\!_%KXEOJ?CSP[XW\&
M_#O6/!WP$MH=0^-VH>$/C!XB\.:=\*/'6H?"#37FU'XF^&O!'C'Q'XJ\#Z=9
M:QJ?B;0M)LO#FORV'YP_!7_@EU\=?A[IW[#]W=^,OA7\/OBG^R=^S_\ L7?
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M<_8^'P,USQ+K&A_M:_M0W7[/>M^/O#?P0^+7BWQO\(+/PA\+/CW\0/B79?\
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M,^(?^%XW>FZ7JX\1?VQ<IX$MM>N_#NBR>.I?#G@3]2J "BBB@ HHHH ****
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MOQ/#>>!?.A:PU76M*O$UM9M1U'1C9W < ^D/A_\ MQ?L>_%FPUG4_A5^T]\
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M[Q?IWCZ&XN5D\#W?A/Q1%XM313X;US^S^:\=?MN_L??"_5->T3XD_M1?L]^
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M_%:XE;3=3@M[B6-)2B/''<-'^&O[7'[ O[7GQ(TS_@N-X,^'OP_\ >(?#?\
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M\7?'/P5^PSH/@KPQ\6]2^/O@/P[\'O&5_P"-?BW:ZYX*U#6O!^L?$?XJ>/O
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MKP[X8\=^$?%FA^-8OVD=*T2S\0^#OB=?6GA?6/"&M7&NVK^']0T?6+F3P?\
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M:UB7PG<6W@'5[.WTB[UW5;?1[F2UO[8VD%CKEM866HWG=? C]AS]MSX?^+O
MW@3XB_![X2_%W]G3QVG[%/C'4)_'O[5_QN\-WG[)/Q$_92_9_P#V;OA9XIM;
MG]FWP;%XL^"/[2&F:M\0_P!F[PS\:/V?]7TO7_ VH>&/B)J^H:[\2+BS%CH\
M]B ?M)\+OVO?V6/C;XWO?AI\'OVC_@1\5?B%IOA_7/%>H>"?AO\ %WP!XY\4
M6OACPQXN;P!XE\12Z%X:U_4=570_#GCD1^#M?U-K1;31O$UU9Z)J,EOJ%W#
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M7WB7P%9Z)<ZUXKEUS2_"MGXQCU'3[3Q!:Z-8 'HU%%% !1110 4444 %%%%
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M7]GKXG_M<_$O]I?X$_M<?"WP1^Q9\//"_P *;[XJ_"Z^_P"%A?LH?LM?'/\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
C %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>ex10-9_002.jpg
<TEXT>
begin 644 ex10-9_002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" /+ NX# 2(  A$! Q$!_\0
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M^UWK?Q]M_@GX%_;,_:+^#WBOX=66I?L0_LF?LJ>'/B)\*OV\/A!\"OAY\9O
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MC[4/@!X]^&OP,\1_#;XV_$/XU>.]'^,'Q$BM;+_A:4'Q5\3_ +.WPFTOX?\
M@;X;IIFE^(=+\"R?!WXC:O\ %KQ;:Z#=Z_K'PMT[P/%9>-?G']NG_@FGXO\
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M=ZCK1;6M1N?%6OV%_K<VHZR6U>_DO6N]39KZ:<U[A10 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%9VI:QI.C16T^L:II^E0WFH:=I%I-
MJ5[;6,5UJNL7L&FZ1IEO)=2Q)-J.J:C<V]AIME&S7-]>3PVMK%+/(D; &C11
M10 445Q'@WXE_#OXBW7C:Q\ ^.?"7C6\^&OC.[^'/Q"MO"OB'2M?E\$?$#3]
M$T'Q)J'@GQ4NE75T="\56&@^*/#NK7V@ZC]GU.SL=;TV>YMHDNX2P!V]%%%
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M/FU;Q+XP\9:]I?ACPMX>TNWQY^I:YX@UNZL=)TG3X-R^=>7]W;V\>X;Y%R*
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M+S5OV.OV/O@!X_\ #WQ:\5^++#0?@Y-X]7X=^(?VEO@[$/V?H_"GB>U^(_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MH ^CJ*^<?^&6?AI_T-'[1G_B87[7/_S\*/\ AEGX:?\ 0T?M&?\ B87[7/\
M\_"@#Z.HKYQ_X99^&G_0T?M&?^)A?M<__/PH_P"&6?AI_P!#1^T9_P")A?M<
M_P#S\* /HZBOG'_AEGX:?]#1^T9_XF%^US_\_"C_ (99^&G_ $-'[1G_ (F%
M^US_ //PH ^CJ*^<?^&6?AI_T-'[1G_B87[7/_S\*/\ AEGX:?\ 0T?M&?\
MB87[7/\ \_"@#Z.HKYQ_X99^&G_0T?M&?^)A?M<__/PH_P"&6?AI_P!#1^T9
M_P")A?M<_P#S\* /HZBOG'_AEGX:?]#1^T9_XF%^US_\_"C_ (99^&G_ $-'
M[1G_ (F%^US_ //PH ^CJ*^<?^&6?AI_T-'[1G_B87[7/_S\*/\ AEGX:?\
M0T?M&?\ B87[7/\ \_"@#Z.HKYQ_X99^&G_0T?M&?^)A?M<__/PH_P"&6?AI
M_P!#1^T9_P")A?M<_P#S\* /HZBOG'_AEGX:?]#1^T9_XF%^US_\_"C_ (99
M^&G_ $-'[1G_ (F%^US_ //PH ^CJ*^<?^&6?AI_T-'[1G_B87[7/_S\*/\
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MW01IEK<7\>HVS2V\]G&;B!Y8F1V /3Z*Y'P!X\\'?%3P)X*^)WP[\0Z;XN\
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M.A -+0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MM3\-_$7X5>./A[JGPKOM'\/W!U_7=]/VW/VT/!W@O4/!5[\?_P#A,]7^"_\
MP<)_L]_\$ZM;^*GBKX4?"BV^)/QB_9;^)^L_L\>*-4\/>/+;P=X6\)?"31/&
MQL/CAJ_@>Z\=_#7X3>![FZ\*>'M!N-)TKP]XUGU?QC?_ +L:K^R)^REKNO>(
M?%6N_LR_L]ZUXH\7>*="\<>*_$NK_!;X:ZCK_B?QKX7;4&\,^,/$6L7?AB;4
M=;\5>'3J^KG0O$.I7-SJVDG5=2:PN[=KVY,DUW^R;^RU?G4VOOV;/@#>G6O'
MT'Q5UDW?P:^'%R=6^)]KY_V7XCZF9O#3F_\ 'MM]JN!!XPNO.\0PB>81ZBIF
MD9@#^?7]FKX@_M'?!'6_#_COX0_%/Q%XM\)_&;_@X)_;U_99^(/[)LOA?X5'
MP-KGPX\<?M6_M@>*OB)\7]'\3+\/-0^/$/Q;^$>A>'I_C'J3:?\ %;3OA?+\
M(OA;K6E:C\,+>_?6?B!=YVB?&W]H+XH_M>_\$N=8^-/[3OC-(O"O_!3O_@M'
M\&]?M?#VG_#;X<_#+Q#X,_90\+?MA>"? >I>(?"#>$]1M;N:Q\!>%5\%R:KK
MVN:SJ>A>&]3UW4])UJP\>:C>>.I?Z5M ^#WPG\*^-/$_Q(\,?#+X>^'/B+XV
M<R>,_'V@>"?#.C^-O%TK6^DVCR>)_%>GZ9;Z]K\CVF@Z):L^K7]X[6^CZ5"S
M&/3K18>,TO\ 97_9DT/3= T;1?V=?@3I&C^%?B=#\;/"^E:7\(/AYI^F^&_C
M-;1206_Q<T"QM/#L5KH_Q.MXI9(X/'NGPV_BJ*-VC35@CLK %/\ :6\;>)O"
MOPX&A_#^+6;SXH_$S5[/X>?#_3O"USX5MO& O-5@NM2\8^)/"+^/-2T;P._B
M/X=_#32/&_Q'T6U\9:QIGAW5=4\)V6A7]T\FK6]G=?F[_P $Q-07]GSX[_ME
M?\$\[[X>>*?@WX8\&^,;3]M/]D_P)\0/%OPPU7Q'+^SE^UGKOB74?B?X<T'2
MOAOXQ\:6!T'X._M;>'?C+9/,NN7]QHO@[XI?".PUIUU+4H+[5_UH\4_"CX7^
M./%/@/QQXS^''@+Q=XU^%MWJVH?#/QAXH\'>'?$'BGX=W^O0V-OKE[X%\0ZO
MIMYJ_A&[UF#3--AU:Y\/WFG3ZC#864=Y),EI;B/#E^ /P+N/BO:?'FY^#'PG
MN/CC8V!TFR^,T_PX\&R_%>TTHZ=-HYTNV^(LFC-XPM]._LFXN-,^QPZRD!TZ
MXFLBAM97B(!_/C\<_P!I#XN_LE?MF?\ !:SXU>'/B7XU\=W7PS_9V_X)<)X4
M\&>.I- U[P#\+/"WQ.^(/[3UK\1OB3I_A30O">G>(9/!/[,/PX?Q]\?]<\.:
M/K6FR>)O#7ASQ[J7Q+\0:F9+7Q5X6_5?]F?XB_&VS_;$_:L_9Q\:?%:X_:)^
M$?@KX5_LU_'GX8_%K6_#GP[\/^,? VI?'2\^,GACQ'^S]XHU#X2^&O!G@'QI
M#HMM\%]&^,7A'6T\'>'_ !II7A/XQ:7I?BVX\4Z=/X1\177VR_PO^&S_ !#G
M^+C?#_P0?BO<^"1\-+CXG'PEX?/Q#G^'*ZRWB,?#^;QJVG'Q)+X('B)WU\>%
M)-2;0AK3OJGV'[:QFI/A]\+OAM\)M%E\-_"SX?>!_AKX<N+Y]4N/#_P_\)>'
M_!FB3ZI)9V&FOJ4VE>&]/TVPEOVTW2],T]KQX&N&LM.L;4R&"TMXXP#^5[QG
M<>-)/V=?^"NVE:U\;_%WQ$\4VG_!?/\ 8@\-^#H/BQ+X:\4+IECX6_:&_P""
M0XMM4@T/PEIWPZUVZ\/:/+XHT#PS=^%M"U_P]X8TKP_H_AK2- B\*ZWJ&JZ]
MK7U;X[_;V^.7P ^+'QD_9@^)?[1VEG03_P %#=(_9>\!?M:_'+5?@C\"M0^'
MWA[QC_P3L^&'[:WASP1XB\?Z-^SGXH_9]L_&7B#XA^*]:^'7PQOO%O[/M]-X
MF\(:7>>%[R36/B-J&D>--._;?Q5^RU^S/XZO_&FJ^-_V>/@7XRU/XDZSX+\1
M_$74O%?PB^'OB+4/'WB'X;Z9<:+\/-?\:WFK^';RX\4ZUX#T:[NM(\&:IKLE
M_>^%M+NKFPT*:PMIY(S+?_LP_LVZK9?%+3-4_9]^!^I:;\<M0L]6^-FGW_PE
M\ 7=E\8=4TZZ>]L-2^*=I<>'Y;?X@ZA8WDDEW9WOBR/5[FUN7>>"6.9V<@'F
M'[$WQ ^(WB/]D7X9^-?V@/B]\'?B[X[TW3/&NG^-?CC\(3>:5\)O'VG>!/&_
MBWPSI_Q&T^^UCP_X-TR5M:\*>'M-UWQCXB\,>'/#WPOUCQ/+X@\0?"[3[+X8
M7OA5%_*7XP>//$WP@_:[_9*_X*7^)O@_\3?!_@[X@?$[7OV-/CI\4?%T'PFB
M\#Z9^QG^UMXC\*:/^R9KLR#XN7'Q6^&MOX+_ &BO ?[/7B76=/\ '7@/2['P
MEJ/[2/[1\NNV&@:EJ5G!8?O1?_#CX?:I\/KCX3:IX&\':E\+;SPHW@.\^&VH
M>%]#O/ %WX%?2_["?P7<^#;FQE\.3>$WT/\ XDK>')--;1SI/_$N^Q?8P(1Q
M/BW]F[]GKQ_\-]#^#GCSX$_!KQM\(?#!TP^&OA5XN^%W@?Q)\-O#QT6RN=-T
M@Z'X%UG0KWPOI!TO3KV]L--.G:7;&QLKRZM;4Q03RQN ?D_\4/C9^VO\1_VK
MOBW\)?@M\4?&O@D_"?\ ;*_9>^&%AIGP^\"? GQC\!-5_97\8_"OX9^._P!H
MW4_BC\3/B!X!\9^,_ /[77@;3?B/XV\6^'_!=SXE\*:'?V\/[(UAX5^%GQ"T
M?QA\7]8\3?-6F_MT?M8?#[X7_MF_M4?&']IW3[[X??"3_@I5\5/^"?>F^#[[
MP!\'_A%\#?@M\-==_:N^!_PF\(?M'>,?BC<?#KXE>/M U[X-^&?$_CO2IO%'
MC?5?&?PIFA\3>#=5\??#+Q#>^"=:U+QW]=_$O_@CYX)^+/Q2^(6J>-KK]EWQ
M+\(_B9XDT[6[Z^UW]A'X5K^VO\._#VD:3X9T;P]\,/@E^VCX4\9^$;7X9^!?
M NC>$=%\(?"[Q&/V>]?^//PJ\$QK#X"^-^A_$#0? ?Q)\%_JAX<^!GP6\':-
MXW\.>$/A%\+O"GAWXF7VL:G\1] \-_#[PCH>B_$#4O$-M+9>(-0\;Z7IFD6M
MCXLO==LYIK76+K7X-0GU.WEDAO7GC=E(!^#MY^W[\<OAWH'@'X0?%/\ :[_9
MZU;3?CS^TC^TE\+_ (9_MU^"_BEX'\.^#/ 6F^$/A7\,?B_\,?@G\0?COXA_
M8O\ $?[)VK?M#:I+XZ^)^D^$=9T_]GK1_AWXI\'_  ;TSP'=V^K?'U_&TD_F
M7C?]K7_@H=:?#']LWQC=_ME_#>75?V6_^"1'P;_;Q\*:[^SG\$/ ^K?";XI?
M%_PYXA_;GTKQ#=Z7XJ^-'@K7-:\6?L]?M V'[-.@Z_J>H>&-%\/W&L>'-<\+
M^(OV>?B1X/\ "]E?>)?BS_0M<_LU?L[7GPAA_9\O/@+\%KOX!VT44-M\#[GX
M5^!9_@_;Q0:T?$D$<'PSET%_!<20^)&;Q#$L>B*J:VQU10+T^<*.O?LK_LR^
M*K[Q;J?B?]G;X$^(]2\?^$]&\!>.]0U[X0?#W6+[QKX%\.7&D7?A[P7XMN]1
M\.W-QXC\)Z!=>']!N-$\.:Q+>:-I4VAZ/+8V4$FF630 'Y-?$[]L_P#:2_8_
MUW_@H;JOQ"\<:K^T;X7^!/[&O['O[87A^TU#X9:%X3M/A#=_'[XI?M._#?XR
M6VBV/P@\$ZIXSU#]GKX/^'?@?;_%JTTSQPGQA^+VA>%M&\8V'B+XK^-6MX=5
MB\;M?VK/VQ=1^)G[.?A+P-^WK\ /C!\(OCQ^W_X"^$-E\0?@=#\*_P!HSQ=H
MGP>^)?[%7[2_Q?UWP!XD^+_AGX$_!K]G^;QEX7\;?!/3?'?PLN/"OPTO?&/A
M[PAXS\!7_P :].\=^$YM-@^+G[T^%_@%\#/!'BF\\<>"O@S\*/"'C74?!VB_
M#K4/&'A?X<^#M \4WWP^\-V>FZ=X=\"7OB#2=&L]7NO!F@Z=HNCZ?HOA>>\?
M0]*L=)TRTL;&""PM8XN8T;]DS]EGPYI_@72/#_[-?P T+2?A?XNO?B#\--,T
M;X-?#C2].^'GC[4IX;O4O''@6RL?#<%KX1\8:C=VUM=7WB7P_%I^LW=Q;02W
M%[))#&R@'\\F@?&CX]?$;]J[_@E!)\7_ -J+XD7EM\.O^"CW_!8W]G_Q#JC0
M_"/P-H7Q.\)_L=^#?VP?A_X(^(7Q9\-^'_AQHG@/4?'NK^ _"<?AKQ9K/A_0
M/"7A31=/U7Q%JWP\\+?#_P 3ZG<>(A^U/[77Q1^,'PW^/?\ P3:T/X?^-H/#
M_@'XW?M=^,?@S\:O"1\(:'K5YXY\+G]C;]J7XS>'8+?Q1K"7EYX1MM \8?!?
M2=1O5\/6-MK6N"6W@;Q#IND6.K:1XC]ZTS]EC]F71-.T'1]&_9U^!.D:1X6^
M)\7QM\,:5I?P@^'MAIWAOXSV\4D-O\7=!LK7P[%:Z1\3X(I9$A\?:?%;^*HT
M=T3551V4]OXR^$?PJ^(NN^!?$_Q ^&?P^\<^)?A?K3^)?AKXB\8^"_#?BC7?
MA[XC=K-WU_P-J^N:;?ZAX2UMGT^P=]5T"XL+]WL;-FN";:$H ?EK_P $Q?VF
MOCY\7?$/BCP/^U%XYU[7OBI/^SU\!_C-H<&AZ/\ !;Q-^S-\1O"'CGQE\;+*
M3]I?]D#X]?!O2?#^K>,/@%\:],M_ B^#?A7\?O#'A_X[?"'1?"FER>)KOQT_
MC2[\:ZCX3J?[6G[7'PO\-_\ !6_]J7Q7\:[SXB_#_P#X)^?M'?&OP/X&_9\T
MWX,^"=)\&7OPTC_92_91^+VA:UX^\4>&_#?B'XSWND_ O4OB5XH\;ZMJWAWQ
M%#JGB#PY_P +"?Q%%J.G77@'2OAA^XG@?X5?#/X8V^HVGPT^'O@;X=VNKW-O
M>:M;>!?"'AWPE;ZI=VELEE:W6HP>']-T^*^N+:RC2SMY[I998+5%@C=8U55@
M\&_!_P"%'PYU+QKK/P^^&7P]\":Q\2M<?Q-\1M6\&>"O#7A;4OB!XCD%RKZ_
MXWOM"TRPNO%>ML+NZ#:KKTM_?,+B<-.?.EW@'\YOBG]LG]LN'QY^SMX6^&O_
M  4#_9T^*?PF_:+_ ."B?[,7P;TGXC_!R/X2_M)^.?"7P<^-'[./[2/C?QU\
M/=6^*7ASX$? _P#9[GUN?Q!\#]!\7_!N]TCX;:_\0?"</CFTU'XKP>./!4O@
M[0_'D>N_%/X[_$;6_P!AGPM\=?%UY\6+G]G[_@X[\?\ [/'PQ^/>H:!X/\.:
MO\=OA5\.?V2_VO[C2O%?B33_ (;>%_!/PS?QI\.O%6O>,_V=_B'??#WPAX7\
M-W?CSX)^)II?#F@:]_;FCV/ZF_M'_P#!-?X6?&#3OV6/"/PMT3X)_ ;X8?LY
M_M>Z3^UQXD^%VA_L[>'-7\#_ !>\067P[^(_PVU3P_K'ASPYXI^'/A_26\2:
M1\3M;OM<\27VB>+;^]U;2_#LL]A/:6-U:ZC]H:C^S]\"-9T_X;:3K'P5^$NK
M:7\&KRPU#X/Z9J?PW\&7^G_"B_TJ""VTN]^&ME=:)+:^!;S3;:UM;>PNO"T6
ME36D-K;10/&D,:@ _G@T?_@K#\:]+O/BG\7/ GQF\*_M2?"[6/\ @FC_ ,%%
M_P!LWX0Z,G@7P)X1\/:MXS_9*_:9\*_#WX2'X=?#GP3J-]\9M+^'7B#PKXZU
MWP?XDC^+WQN\4?$#XIW_ ,,$\1Z5X-_9NU^T\8>%=7^F?BE_P4%T7X+?#CQC
M\7?AO^WCX!_:L^"7C_QY^QEX''Q5UC4/@UH/AK]BO3_VA]9\=^$M5^*WQ,^-
M?P<^"^K?#70OAAXVGTSX<VG@[_A;WPO\0WOPE^(/B?4?%?Q-UW7/A9XD\+>$
MM _8K1O@'\#?#GB6S\:>'O@U\)]!\8Z=XF^(7C33O%FC?#CP;I?B:P\8_%R2
MTE^*_BRRUVRT:#5+7Q+\3I+&RD^(6NP72:KXT>TM7\27>IM;PE)-"^!'P3\+
M^!?$GPN\,_!_X6^'?AEXRG\37/B_X<Z%\/?".D> _%=SXT,I\8W'B7P?IVCV
MWA[7I_%AGF/B6;5-/NI-=,TQU-KKS7R ?AM\(/VP?VB/%/Q[^!'[(WQ6_;C^
M$%EX?^(/A?\ ;K^)GA+]KOX%GX/>)-2^-:?!3Q3\!]!^%7P$TKX@_$CX+Z#^
MSKX[^)OPN\%?'+Q]XZ_:"U3X'_ ;3++4M:^#GA"UL8? -OH7QO\ !VK>J?\
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M"5V\/ZK=:?8W%]I\\UG;21 '\SO[3'[4%S\?O''[)?Q,\;?M.>']/T_X4_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MQ'^+7Q+-Y\ [S3/%>O\ B+Q'KM[I0T&#3-(\ Z1X5$&BZ%X/TS8]S( ?#O\
MP32^*?Q2_P""D_[>_P#P5C\?_'[XW?&73_A_^QK^U1J_[('[-_[-WPD^,_Q=
M^ GP_P# 'A+P#J?C_P ,^(_B+X]T/X-_$CP=<?%GQS\4+K1;;5O[7^*L7B8^
M#-<L_$=MX'N;#15\/:%X*\V_X*X^'/CW^RIXV_X)JS>&/VI_VN?%-O\ '?\
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M/_!57]DGQ!\4?^"@NK>!O%G_  46T']E'X5_&[P?^W#^T[80_L0>&/$OP?\
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MCXJZ1X=\-?#CX.6'B>S\"?#7PWX3TS0-/TCPQX?M6>U?4=6U^ZU/]>_VF_\
M@FM\)OVJ=._9&3QQ\4/C/X.\4?L5>.-#^)7P8^(OPG;X,> _'$'C?P_HNG:%
M8:IJM[9_!B[T:QT2>QTY4UOX=^"-"\&_"[Q*DD%IXC\$ZKIVA^&++0KG[4W_
M  3F^&O[6OQX_94_:)\=?%_X[^$/'G[&NNZGXM^"5K\.=3^%&F>&[#QAX@ET
MN/Q1XG\1Z;XI^$7B^\\27WB;1]$TGPYJ.FWNI#PU9:/9LWA_0M%U:^U+5+T
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH *_%[X@^-OVQ/AQ^VM^PA^S+XL_:KU>_T_\ :Q\-
M?MU>.?B9J'@;X3_!/0;?P2/@4OPP\4_";PE\*3XM^'/C34(M,TG0?B8_A3QU
MK_CZ?Q?JOC^\\/VWBS1;3X;KJEQX<MOVAKX$^.7[*OQ/^*'[<_[%7[6'AWQQ
MX!T3P9^RAX5_:'\+:YX!UOPQXCU/Q5\0(/VD-&\%Z#X@N]&\5V'B33='\(3>
M#8/AWX:U31TO_#/BR+Q&][KNCWO_  CH>PURS /C#]G+]O7Q[\"_BQ^TY\$/
MV]_C%JOQ6\1_#C]K3]DW]F/P[\3OA;^S7XCT+X3>"O$/Q]_9%_9.\2Z%<>.[
MKP%HGBJ#X9^$?B?^TE\8M6\*>$_$GQ1\7:@J^(_%.F:6NH:'X6LFAT#]']3_
M &R_@?HWQI\!_ _4]7U>WUGXG^*O&'PW\ >-X]'EO?A7XD^,7@#2=6\0>+?@
MK#X[L)KJPTWXF:;H7AOQA>6>D:Y!I6E^(M4\ ?$SP7X8UG6O'_PP^(?A/PQ\
M8?%?_@GK\8_B%+^V=)IOQ0^&FE+^U/\ MN?L4_M=:+'J'A7Q9>_\(78?L:G]
MEPV?@;5#;:Y:C7;SXB']D'P%]JUZS72(_"Z^/_%PATSQ%_PB^B'7^W_9]_87
M^-7[/W[0'Q*\0Z7\?/ACXJ_9F\=?'WXV_M*:'X$UG]G"QM?VEO WBSX^>,-;
M^*'CGX1Z9^TCIWQ#M]$U/X&#XQ>,/'?Q,T^VU+X-GXEQ0>)O^%=7'CRX\*:?
M$TX!V?[=O[1OQ8^#/B;]C3X;?##PIXUNF_:>_:@_X4QXJ\9^!K;X37WBKPYH
M&E?L\_M"?'!],\!0?%SQ)9>$;?QQKVK?!C2+"74?&/A;7O"%O\/9_'0M[O2_
M',W@VYC9\+?VP? 7PMM/A-\%?CY\>IOBWXTU?XM:S^R?#^UFWPD@^$_P8^*_
M[3GAR746M?@]>ZEHNKZMX#TCXVWMA9CP/X@O/"_]A?!KQC^TCX?\=_!+X>KX
M-^-&GWG[./@ST?\ :@_9\^(GQM^(O['OC+P?XD\%^'M._9:_:*D_:$O=/\3:
M7KVH7GC6\D^!/QT^ /\ PB=I<Z1=6EOH%J-#^.^K^*EUR6'5Y!JWAC3=&;1V
MLM7NM2T[P'3/^">'B.SO]6^&MY\7=.U7]EJY_;PL?^"@OA_P9=>"7L_B[X4^
M(L'QJB_:NO?A3:?$'2_$%GX?UKX?7O[7D3?%ZW\3>(_"&I>+-/\ ASJ&L_ <
MVU]$_ASXH^%0#XNTW]LK]K_3/@M^P+K^K_&C2-=\4?%3_@MK^T%^Q/\ &G7X
M_A/X&T9_'?P/\!?M+_ML_#WPQX:T/2H8+W3/ -O9>&/@9X,TN74K"+6?'-W:
M6@DN_'4^NS:MX@UC]4;']NOX!ZEXU\'>"=-U'Q-=I\3O$WQ=^'GPA\;R>&KG
M3?AK\7?BY\#-0U?3OB1\'? ?CK6)].T*Z^(UA/X>\2R>%]-URXT'1OB;8^#_
M ![J?PNUWQGIOPZ\?77AKXL3_@FM\9+CX;?LP>"+[XL?#%-2_9[_ ."H_P 4
M?^"C6H:E9^#_ !;]@\6Z;\4/BM^T-\7+WX0V5K/XB^T:'?Z3K/[27B70+3QU
M/<ZM;7.D^"]!U&?P?]K\1ZC::)V/PK_X)@V7P[L/V7_@_J/CC1->_9@_8K_:
MB^(W[5G[.7@RP\-^)M"^)FG^(O$FG_%FS^&/PV^(7C=_'>K:;XP\(?!:^^._
MQ-U>Q\2VNBZ'XE^(]OIOP=T3QO:M/X'^)NO_ !W /8_A3_P4M_9Z^,W_  RA
M)X'TCXK3V?[:%_\ &[1/@EJ&M>"(?#MK-XI_9WNO&4/Q9\#^-AK6N65SX"\?
M^&K7P#XKU0>!/$MM9>+-2L/#_B9-.TBXU'P5X[L/"_DWC+_@I%^S_P##KQ[X
MM^*WCWXR_'KP]X#\$?L":%^UGXN_9O@_9HUWQ?I_AOX2:S\0[.WTW]I!/&OP
M[^&_B[Q7XCUFYL-73PSXG\*>%?B1XC\!_#7PCX>\0>.?B=HO@9-"USQ)!R/C
MK_@D+X5\6Z9\6K#3OC;XR\.3Z[^VYX?_ &Q/V=;ZUTIFN?V3HO$7B'P;XL_:
MB^&'PJNK'7],U&WT;]J?7K[]HEOB)<V&I>'](DT3XYIH>H>%M=_X12^O?%\O
M[9/_  31^(/[3'Q4_:;\:^$OB=\/OA_X9_:#_P""8_BO_@G%IWA[4/!6O:M=
M^![7QEX\U[Q3?_%6.72M?T?3M3M]#TCQ3J6CZ-\/8+/28KBZT[3+Z?Q?:VDU
MSI< !]/G_@H_^RE86/[3&J>+_%WB_P"&FF?LF^&?A_X\^*M_\4/A5\3/ -MJ
M/P[^+C>);'X2^/OA:_B+PM9GXP>'?BCXH\%>,O 7@&+X;KXDU_Q-\0/#ESX,
MT_1)-<U/P[:ZUZK\$_VK_A7\=?'WQ>^$?AN#QOX;^+_P U+0M(^-7PS\<>"-
M>T+6OA]?>+-,CU_P<;KQ-;V^I_#3Q38>,?#,UOXD\,ZO\/\ QWXOTG5-*EN
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MC=HUY\-?VE?!?[)GQ-\:ZQ^S)^T+HOPH^''QD^)EKX=?X9V/C3XHZS\-]/\
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M*:7K.O:=\CS_ /!3O]EJ-?@U8VES\6-;\9_'KQ7^TI\//AS\-_#OP3^)^O\
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MJ"^)=?\ ')FL[^V\1?IQ\"OV6O'7PO\ VSOVSOVJ_$/B[PIJVD?M8>$/V7]
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M%X-\$^"/%'B/2?"7Q?T^RU6WTF/Q3IWA_P 8:!XQTF?X2^,?"/ASXRZCX?\
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M(1?SM:@'Z/\ [/W[7OP?_:9-I<?"IO&.I:!KGA:\\>^"/&NH>#=:T_P#\1_
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M+QW^Q9<>"9_@]\1O$GB#0/VH?AYX4;QYK7P>UN^\ :!XR\')XFU?P,;;Q?X
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MX?)XBT[5=9?3)/%%U9:,+K5_TZH **** "BBB@ HHHH **** "BBB@ HHHH
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M6WFUJ+P'IE[XQEL$\.0/J0_G7\-?\$K?VA_A!^SO^UG^SWX?\%K\3]>\>_\
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M:Q\4$F\4_P#",_#_ -T^.W[&_P"TSXK_ &Q/B>]Q\*OA/^U-^QG^TWKO[/\
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M2T4 %%%% !@=<<^M&!Z"BB@ P/3W_'UHP/0444 &!Z>_X^M&!Z"BB@ HHHH
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M\,+>?$3XS_#N[TWQ9I-EXS\'W.GVNK:?8Z-KR^([6'1=<OKK3?$%OHWVL#D
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M!]+O?&/P#\'ZU?7N@:WJ,7BR8 _HE+@9R'X[[3C&<=>G'4\] 32>8,9PPS@
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MO%OBG]2/^"/_ (<\7^ ?A3^U9\,=>\$_%KX=>"OA_P#\%!OVP-)^ '@_XH^
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MG_X1;0=$\5?&F3P[KFKV-HFK>-[X _17QS\=[WP)J'[/ND7?P4^+FN:K\?\
MQG!X$CL- N?@](_PFUS_ (0#Q%\2M3;XIW6K_%S1].-AH7AGP?XM;4;SX87G
MQ-6XU'P_/IVB)K%QJGAT:UXYX&_;]^#GQ)O/!E_X&\,?%3Q+\,/B3\>?%W[-
MOPZ^.FE>&-&O/A5XS^*GP_O/B'HWCFUL)X/%$GCC1?"7AWQ3\)_B)X-3XB^+
M_ _AOP#XH\4^';;3? WB/Q2GBSP-<>)]*/XC:?\ M#>-?V:=;\!>#?C'HMCX
M%^(6I?%;Q>_Q7^!/QG^!\NB>&M:_9[^-'P_L+)T^+_@+P4NH>*AXH^)/ARTO
M/"VDOJ&KZ9 FL7VHP6UKI<SO^*WP*^%?Q;^'O[3O[/\ \7OV.?AG^T=\&-+_
M &F/VA[F_P#^"A'[ GQP^!'QCL/V-/ATEGIOB/Q-X^_;$^ GQ%^(/@/1/!GP
M8^*E[J\'AW5O#V@_#GQ;JX^,NO>,O#/AG6/"NAZC\-O&[>&@#]8?A/\ \%/O
MV>OBO^TGI7[, \(_M ?#3Q;\0K+Q?J_[.?CKXO\ P6\4> ?A#^UMH7P[LIM5
M^(.O_LU^/K_S[3QSH_A/0ELO%,EUK%GX5;Q1X*UG1/'?@&+Q=X+U*#7SZM\$
M_P!N+X(?'GQ1X)\,^#I/%%C'\7O"'Q4^)7[/_B;7],TR'PK^T+\*O@MXO\#>
M"/B%\4?A5JFCZWK<LW@NQUGXG?#R]\-W7C6S\%ZK\1/"/B_2OB!\-](\6^ X
M]2\26'YC6?QGT#]MK]KF/P[JO[-?[<OPHL?!W@3]H;]F7]DOQ/XZ_8(_:)^%
MOP[^'[?$WX;7:_%C]LCXC?%/XM>!/A[X,\&P:KX?\!:1\'?V9_ /ACQ%H/Q
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MKH/@VSD\4Q>??LL^,[W]I?3?VD+_ %/]G']IOP%\=/VR/'/P5L_VC?$GQO\
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MR/\ M5:OJ^G3:)J]Y\>?@=^T'\:+7P3XB_:/\/63VWQG\0?&7PGXC\5^(Y/
M&MQ:Y^U3XB\7>)W\6>%M"\3>)/AA^>VF2?$F_P#C-?:_I7B[XF?"G]HOX<?M
M ?\ !2G0O@M^TA\:?V>_VS/ 'A_]LOXC?&OQ3\3/!/[#/P<_:5^,6J? /PY^
MPYJGPK\#_%S5?ACI7[*^H3_M-_%RP\2>%OA'^S9\+OA#\._AOXB^,6N?!7P&
M ?UN^8./E?D\#:<]"<XZD<<XR1D9 S7*>-O'_@WX;Z%%XF\>>(M,\*:!/XC\
M&>$+?5-9N!:6USXJ^(OC'0?AYX"\.6I8%[G6_&/CKQ3X<\(^'-,@22\U?Q#K
M>F:790RW=Y!&_P#)-\<_!GQ,^(?[!O[7'Q"^#OPD_P""MOPT^./CGX:?LO>%
MOC+\"_$GPI\;>$FO?V@_#_[0OA74/&/BOX9Z'^S]^SUX%\>?M,>.I_ EY\2=
M'^-W[3GA[5=>^&_Q4^&^C_#)OB"/'&KQ:;+X%[OX]?L_23?$O_@H_I;_ ++G
MQW\>_ ?P9_P4'_X(V_M0?"O1=?\ V6/VAOC+I5UI_P#PM[]GW4?VZOBG\"]!
MUWX:>--?^(OB;7- T_QE=?M&0?!FP\5>,O%E@_C&7QKI6K'6?$C:@ ?UFT5\
MC?!G2OVPH_BOXKU7XF>,/V9W_9;O-!OW^#7PW^'_ ,#OBO\ #OX]^#1<ZKH-
MQX+TWXF^+O$WQR\9> =430/!JZWHWB;2/#7PJ\%RW?B1](OM-?0=,TZ]T*_^
MN: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH *\D^+'QS^%GP2M?#-S\2O%]CH%UXX\26O@WP%X=MK/
M5_$GCCXA>+[JWN+Y?"_P[^'WA33M<\<^/_$%MH]EJ/B+4M(\'>'M;O\ 2/"N
MCZ]XKU6"R\.:#J^J6?K9Z''7M7X4_'?XAZ)^R[_P6O\ AG^T+^U/XKA^%/[+
MOQ4_X)X:Q^R_\ ?C;X_UV'0O@1X7_:7;]H _&#XL?"GQ=XON]0M_"?PN^(/Q
M:^&?A+X=Z_X!U#XB?V-9?%2+X6ZQX/\  GB34/$_AR[\*W8!^OWPG^.7PG^.
M=AXGU/X3>//#_CBV\#>+KOX>>/;?2+F1=8^'_P 1M,T/0/$6M?#CQ_H%]%::
M[X(^(GAK2O%.@/XM\!^*M-TCQ;X1O]071_$VC:5K$%U8P>K;T_O+^8K\<OCU
M^T7\-=(\>?LY^-/V?M>T;3_V9?VP/VL](^'O[9/[9WPJ\6V#>!KT6/[./Q#\
M(_!WP_HWQ.TJ34]%T[4?BG\6_!7P-_9GUCX\^"M2TR?PG?/HGP8T3Q_X=^,N
MH>%+_P !_ ?P_P#VB?VP/%'QW_8)_9Z\:?M6?$:S^#WQ/_;=_P""G7[.'A'X
MJ^'7^"FF^.?VK_V5_@3^S3\0M?\ @;\9_$7BJW\&ZW>7/CSP;\0=-U?P%;?$
M/P+%X$\,_$2?PE:?%"\\#W?B#7O!WBRQ /Z0_%7Q7\&^#?'?PO\ AOKDWB)/
M%?QBOO%FG^!HM+\">._$6A3W/@CPQ<^,/$(\3^,O#OAO5?!GP\ACT*SGDTFZ
M^(FO^%;3Q-J8B\/>&9]8\0W%OI4OHVY0"=RX'4Y%?R_?L<_M@_M)?&[2_P#@
MB3I/C/\ :-\:>,O#W[1OQ&_X*F?!GX^G2I? FC7GQCT/]FK0?VC/"GP<\4^)
M_&O@/PGX?\8Z/X\T#2/ _AO69]=^'/B?P+INM>)I9/&%_H,^M1Z#?:*?L8_\
M% O''Q(MO^"5!E_:O\)^(?BK\6O^"8'[9]_^T)'\1/&AU7X=W?[6_P"S]I'[
M)_B;0K7XO^'M!U'3['PY\1OA5'XU^-.M_%KPKX:;PK\2K'P6]VWC:&&QT3P;
M-I8!_4"749RP&.O/3MSZ<\9/<$=C56\U'3].A2XU"^L[""2[L+".:]N8;6*2
M^U6_MM+TNR22=XT:[U+4[VSTZPME)FO+^[MK2W22XGBC?^2_X-_\% _B_K/P
M)\9_M"7G[?T/A'P1X2_X)Q_#/Q1\;8]!\=_L;_M4_$2__;?\>_$;P[X!UC]I
M?X/?"G3O%OC*^^"7P'U.'7;369?#_P"T#>_LY_ KX.2?$/X1:WX]^"WPLT#P
M9^T!X0T/S+QK^TI#\0O$7P=L/C5^U''<>!OV=?\ @XI\%_!G3-7T[]J_Q4OA
M/PE^RY\1OV$M5^.O@+2?&'Q6M]<^'&I?%#PS#\;VUBQ^$?QG^+5K?^-+B;0I
M_"?A+Q8]FFHZ== ']D^]/[R\8SR.^<=_8UX[<?'_ .$EM\?](_9<E\96H^.^
MN_!_Q'\>],^'Z:7KTUW-\)/"7C/PE\/=?\8SZY#I;^%[""T\7^./#6CVVDW^
MMVVOZL][<WFDZ5?:=I&LWEA^&GPS_;V^*OQ9^*OQ9U[X:_%WPU>?M1? 3Q+_
M ,%!?A[\4O\ @F!<7FO>(_B5X[_X4U9_$:^_9INCX)O)-,O?A)X6E?PC\(+C
MP]^U-X'T[4/AM\73\<]0^'7B^RU+XB>*?AQ;?";@/V!/C]\-/C+_ ,%!?^"?
M'Q*M_P!KZQ_:"^(WQ=_X(]_M%R?%+3KGXC^#]9M-(_:4U7XS_L'_ !#^*V@Z
M'X#M8E\1_"'QM<+9^)HO$G[/BW>GZ)\,_#?PHB@T7X:>"M8TCXDZSXJ /Z [
M/]HCX-WOQVU3]F8>-[*Q^.FE^"5^)*_#?6=,U[P_KFN?#X7>FZ==>-O!TVNZ
M5INE^//"VDZOJVGZ'K^N>"-0\0Z=X=U^Y30=>N--UB.:QCUO 'QI^'WQ.\3_
M !3\'^#M1UR]U_X+>+K?P)\2+75? _COPK;:!XNN](M/$=KH=OJOBSPUHFD>
M(;JY\+ZIH/BV"3PO?ZU;3>$/%7@OQ;'.?#GC;PGJ>L_F9^VI^SQX>_:C_:3U
M+3?A9\4O WPP_;R_9E^"OPF_:"_8\\=S:_I\/C'X?^,V\7?M!>&]=T;QIH>E
M-=^.M4_9?^.5A/IGPU_:.\*6>EW&A>-O"CZ1(\,_B[PIX+N],^8-*_;@U[Q!
M\$==\>_%'5?%'[$/Q6^)?_!3+X8?LR_'#X5>+]2\,>#[32/BSX<_9,^$>G?%
M#X$ZA^T=K5U<:!\,/@_\0+[X>ZGX@^'7[4OPWFUKQMX\^&FJ^!(O@381?&3X
MK>"].TL _HEWH<893GI\PY^G/--9D8%2Z\@=2IX/J#D8/3D8.<=37\I/[$G[
M5G[1/[6%I_P3H^'GCS]O[Q[H:_&K]F/_ (*F^$_V@M0^'ES\ -%\91^-?V0/
MVDOA5X"^%7Q#AU^_^&%]KO@[XO7'PE\<7.I>++S68;O1[_1-"A\6Z9X"\+Z[
M?^(O%%[)\,?V]/VB_CQ^R58>(OB[^T[K_P  /B)9?\$>OV9?VR/V8_BUX3B^
M'^CVO[2/[5]O:?$Z7]H[Q/JOAQO#<?A+XGQ?#?Q[HGP&^$OCG]EFQ>PT.2U^
M.VI:MJ/@Z#7?'WP,\2?#  _H_P#AO^SA\(?A-\4/CK\9? FBZSIWQ#_:6\1^
M%?%WQGU?4/'7CKQ+I_BSQ'X'\(Z9X!\*ZI:>&/$OB75_"WA*71_ ^AZ#X5BB
M\%:-X=MKK1]#TB+4(;N:P@G5GP$_9M^#G[,NE_$+1?@WH>L^'M-^*?Q:\?\
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M (+/_$GX@_%+X?>#/A]X/_X*E?$GQ!XJ\>>+O&WAS0?!_AGP[!^R#^Q1I?\
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M7P7XZT#XA12_#GQ%X"\4P:3XT\/?$6"Z\ ZUH-CXPM9]%C_FTT[QS^RQ\?\
MXM>%OVXO /Q,^"GC&;XD?\%4?V$OCK^UWX?^&/C71OC+X:^!OP*TCX&_'?\
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M '])&],XW+GG@D \=>/U^G->*?&3]HSX,?L_W/PELOBYXYLO"%[\=?B]X1^
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M%:G\5KS2_"&EZ[XI^-VEWOPP^%P\/?$;3=6\+(NE_P!F61\+W]]XH\4ZSXT
M/Z*_C5^TY\%_V>M5^&FB_%OQ5J'A;4OC'XOM_AY\,((/ _Q!\4+XU^(%[;W%
M[IW@31+GP=X5\06DWC+5=.L=3U32/"\D\6NZMI&B>(=7TW3[O3/#VMW5A?\
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M=^/=$\5:7I.J_"JV\;>)-"U[PMX2G^*%IX/C\1>+- U[PKI!O/$6BZGIEK]
M:3X]\'ZUXN\6> M-\2:+=^-O ECX9U3QAX1BOX?^$D\.Z1XTBU63PAKFI:,[
M+?Q>'_%#Z!XCL_#WB!8&T;6-4\+>+-(L+Z;5?"OB"RT[^?7]N/XI_$+]J?\
MX))WEMKVH_ ?X1?MI:Q^SA^SG^U!^T[^P%XR\+76O?$#XT:_<1^%_&&A_L?>
M(?A1_P )SX=^//@]?VFO&7@^[^ /@WP\MO?_ !9UC7=5L?A9X>U<>)K:_-W]
MD?MFZM>Z1^U'_P $X?%#^*;[X%^+/BMI7[9'P0^-GB;1=>\'R:W\-_V?]<_8
M\\=_'CQOXD'B'Q#HVL^&K!/A)^T%\#/V?M3TGXHZGI5QX7\-:O-'HU_#-I/Q
M)O=)U@ _7+K7Q/\ "W_@GI^RQ\'/$7A[7_ _AGXG_8?!FK)KOP_^'?C+]I3]
MICXG? [X8ZM;?V@-)O/A5^SY\3/B_P"+O@;\+F\,1:K?6G@J+P#\/?#L'@2P
MDBT[P9%H5A:VUM#] ? GQ'X)\5_!KX7ZW\.OC!;_ +0/@JX\#>'+;P]\;[?Q
M3X2\;GXKV6EZ9;Z4WCR]\7> K+3/!/B#5_$ES93ZEK>I>%=+TK0IM8GOO[-T
MK3+81V%OZQ0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MRPJMW;P72K&R@7$$,X EB1EFTW0M$T43C1]'TO21=2"6Y&F6%K8"YE52BRW
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M_P#PCVL>(?$7@'PGK>N:MH!1(SH>I:MJ>D7-_?:.8XT0Z9=7$MEL1$\C:J@
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MQ,U34?B<_A/Q=^QIXJ\)^'? VMZAX6_X1WQK9Z+XHGE^(_C+PQH/[BZ#XO\
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MN_ _XI_"OPWX,C^&_P"UK\05/Q@U#X__ !*C\%_&#0_$GB;4/V<O#GBOX?\
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M444 %%%% !1110 4444 (> ?H:_$_P"(/B&77O\ @O+\$_AC\;[J)_A/H_\
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MX>:KX/\ ''Q-O_ .CCXN>+O'NF:_\0]-\:^O0_LK?LW6MSX3N;#X%?"?3/\
MA!O"'PZ^'OA.UTGP'X>TC3=%^'_P=O\ 5-7^#W@*#2=,LK32I_!/PCUS6]6\
M1?"SPG>65QH'PZ\2WTGB3P=I^BZZJ:@/1/B;X$TGXG?#3XA?#/7]+\*Z_H7Q
M#\#>+? VMZ)X\\-MXS\$:WI/B[0-0T#4M*\9^$%U;06\5>%=1L]1FM/$7AM=
M<T8ZYI$UYI:ZKIWVH7<(!W" A5!Z@ <^W';(_+CTK\8_VR]*\1:M_P %=/\
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MC?K'P:TBQT;4?"^E^*_K#X_?M??MX?";PMH*>$O'/[-LUK\2?VS/^"=/P_\
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M?'OPTU_38M6\<3^*_@C]%_\ !.WXF?MF?';3O'OQ4_:#^+?P&\0> _#GQ?\
MVNOV==.^'OPN_9Y\9?#;6KKQ9^S7^V%\6?@GH_Q9_P"$S\2?M!_$U=(TCQ-X
M3\ W=CJOPGN/#_BJ:SN!X:UBT^*GVVP\367BCZSU_P#9(_9>\5_'/PQ^T[XG
M_9Y^"NO_ +1O@JS%AX3^.VK?#+P=??%K0+-+.YTZWM]-\?7&D2>)88K&POM0
MLM,!U%CI=MJ.HP:<UK%?W:3=U\)_@S\+_@7X<U#PC\)/!>C> _#6J^*/$/C7
M4=&T*.XBLKWQ=XNO3JOBSQ)<)<7%PTFM^*=:DN=?\2:B7^TZ]XBO]4\0ZJ]W
MK6K:E?W8!V/BGPMX9\<>&?$7@KQKX<T+QAX-\8:%J_A?Q;X2\4Z1I_B#PSXH
M\,^(-/N-)U[P[XBT'5K>[TK6]"UO2KN[TS5](U.TNM/U+3[JXLKVWFMIY8V_
ME/\ V7]+U74?^"-/_!%?X?+HVE3_  .\=?M_?!WP5^T;I%^=/TWPK/\ "5?V
M@/C]KG@'POKMM<75AI]UX=\7_M,:!^SWX"D\(R6^H:?XU;Q+:^ [S1=1TWQ'
M<VK?U>ZOI=IK>E:EHVH+*]AJ]A>:9?);W5Y8SO9W]M+:720WVGW%I?V<K03.
ML=W975O=VSE9K:>&=(Y%\+\)_LH_LX>!O@_)^SYX3^"WP[T;X%O?)J4/PBA\
M-V4_P\L+^+6+'Q)!=Z3X4NUN-(T:6T\4:;8^*]/.D6MB-.\6VR^*K$6_B%Y=
M2D /E#]@FXN[7X__ /!5?POH"6I^#_AK]O72)_A^-.U(W^DZ;XR\<_L:?LG?
M$C]H;2='A75+RWTR.;X\>+_'/C+Q;I]CI^GVR?%7QG\1Y[R2X\03Z[;:;^F$
MAPC'K@9QC.<'IC(SGZU\F:A^Q3^S[<>)/V?-8TGX8_#KPQIW[-?BWXA?$7X;
M0^'?!&EZ9XIT3X@_$B_BU7Q9X@T7QS;RIK/A]?'FMW?B#Q+\9I]*BB\5_&O7
M[^W3Q[XPO_"NH_$GPI\3/K4C(X..G/7H<T ?@A\6OV0_V;]!_;,^$'Q5_9J^
M%GPS\$_M _LM>//B3\9_VC?VL_)\'^#_ !9\7OC;^TE\+O&?PZ^$'['/QB^)
M5O+X-7XA_$S]H[XH_'OP%\9-1\!:GKWE_"WX?>'/A=X2TKPU\/O#7[2?P-FO
MOGK]E+1-5\1^%O\ @WM/P\U;6'\0_'G]@?\ :RD_:M^(7AKQS?K\5[C0OCA^
MSO\ !SXP_M)_%G4O%$WB(^(KGXGZU^WW>?";Q%XY^(MS%X@\7Z#\8?&EU)?O
MINI^*-<NF_:3PM_P3G_80\$?&QOVE/"7[(W[/V@?M"OXN\3^/9OC=IWPQ\,P
M_%*X\:^-&UA_%OBRZ\<&R;Q%=^(O$K>(-:?7-8N=1FO=3DU6_DNY96N9"?5]
M$_9<_9V\,ZQXU\0^&O@M\-?#FO\ Q$\/>)_"7C+7- \(Z1HVL:SX6\;>)-:\
M:^,O#8U/3;>UO=,T#Q=X\\3>*/B'XHT?2)["P\0_$7Q1XE^(&KP7?C+Q!K.N
M7P!_.1^TI\%?A/\  /P3_P %2_VO_P#@F[X/\$_LC:=X7_X)K?'O]F+X9Z)^
MSN?#OP#\/_M)?%;X:+KGQ<^,7[3?PT\$?#2[\%:5K_B']D+09IOAS\+OCWX<
MGG^(]U\1[WXZ^&1IJ>&? 'PWU3XA_IM\'O#ND_#O_@JKI7@']GSP[X5T?]FV
MV_X)'_!?2/$-KX(O+.;PYX?M/AE^T1XR\-_L8Z3IEC9ZU+;6'AVZ^'/B']IR
MT\&:GI^CS6WB+2?"UY:2:Y);^%M+LU^M?@-_P3U_89_9;\6:QX[_ &;_ -DG
M]GOX'>,_$/A2_P# NN^*/AA\*?"'@_7-8\&:KJ>CZSJ?A;4M1T73+2XO-!U#
M5?#^AZC>:7.SVES>:1I\\T3O:P[?9/A/^S[\$/@2FLQ_!GX4?#[X7IXBA\-6
MFN?\(-X4T?PX^J:9X)T*+PMX$T*ZETVV@E?PY\/_  I;6GA'X?>&@XT#P%X0
MLK'PIX0TW1?#]E:Z?$ ?-?\ P5&_:3\:_L@?\$]/VN_VDOAM;6<_Q$^%7P5\
M5ZSX"FU#R'L=)\9ZE#%X<\,>)+RSNK'4;;5[?PKK6M67B67P_<V\=OXC323H
M,]]ID6HOJ5I\O_$*]N/A]\3_  M_P2M^ J:!\-? NF?\$^OV@/VD/%'Q!^(W
M@BP^,A^*FK1>/?#WPNCT'Q;H/B?7-*N?BS+XW\>_$'Q?\7_VPO%&M^(=-^)/
MQ'U?Q1X?S\1=%\5?%CQ%X[TS]8_B-\/?!GQ<^'WCKX5?$?P_8^+/AY\3/!WB
MCX?>//"NIB8Z;XF\&>--#O\ PWXI\/Z@+>:"?[%K.AZG?:;=^3-%+]GN9/*D
MC?:Z_-%E^QI\,/'_ (!^#?A+]K/P?\+_ -K/Q;^SQ<ZA9_"WXN?%?X7^&-5\
M<_V6(H-'TWQ'K:ZA:ZEI^F_$CQ#X3TW0M'^,^J>#3H/@7XK>)M&OO&5C\/\
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MS]GK0/''_!.;6U\!> ]6&E_&+P7\1+?P)^TOX1\<:=+>6>M?$32_A38?$KX
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M-YX+291K$OAF]N[C1KGQ/N\6W-G-XI=]9;W\C((Z9'7T]_PH _&/]H/]J?\
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MLOAGH3:[IGAG6=7\5?#SP]XQ\L;_ (*K_!^3Q-XGTK3O@Q^T?K/@SP/^U?\
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M4 ,2,'@'\_Y8)/H 32>8@ZG'..01S^7^>/45^"'_  2=_P""D7B'XD_LS?\
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M/"FGV6E:W<:?X(O- ^%=I>WZ75Y)X"\%^%M"EF&GZ596=K]XT4 ?F?\ "?\
MX)SV_P )/^%#BU^,$_Q"/[&GP7\<? K]BJ?XH_#W3-6O/A+X.^(-CX5\.:G=
M_$J\\&^(? 4WQA\2>&?AOX(\,_"#P)X@TH_"O4;3X<0ZV?'<WQ%^(7B;6?B%
M<?1O[)W[/.M_LK?LJ?!K]F33O'NE>,1\!OA-X2^#O@+QK=^"KW11=^'/A[X4
MTWPEX,U'QAX:B\;ZI_;&N)9Z5:7?BF?1=?\ "]AKMVUR-(T[PK!)#%;?4=%
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M/>W/B?6;M[#Q%XKU+6U_(?XN?L>?&;]G?P'^PE^SEXD\=?'+X[?"G]E;X/\
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MRWN-&U*XU#3M0T7[-HH _-'X/_\ !-#X?_"#4/@?X4LO'^N>)_V=?V6OC?\
M%']HG]F+X&>(_#GA^X;X1?$CXG:;\3-#M-(B\>P+#J'B7X6?!S0_C3\5M+^!
M'@O4M"AUOP1!XFT?^WO&_C0?#_X?+X:^@/$/[->J:U^VI\,OVO8/'VG647PZ
M_9W^+'[.Q^'<O@JYO)M:T'XP>._A=\1_$'B#_A,D\9V<>G:KIOB3X*?#N+1+
M?_A$KZTAT1_&]C?+?W_B+0=6\&?5U% 'Y*_";_@EKX@^$7PI^+7[-F@_MZ?M
M>']EG6?A-XX^$'[-/P@L]4^&F@>)/V2- ^(&C:YH]S>>"?COH_@&W^-'Q&NO
MAA9:]=:'^S[IWQ/\7:]X?^%7A2#2=-O-(\:>(/"G@7Q;X3\JM/\ @BW9Z7XE
MUWXD^'?VOOBQX*^+(US]E#XH?#7Q+\/_ (5_ 7P1X-^$WQS_ &5OV>_&'[+^
MD>(/#'PL\/> K+PG<?!GQ;\%?&.K^ ;SX!7@&C:+X;USQ19V?BR[O;KPCJ?@
M7]OZ* /CG]CG]D"R_9#TSX\V]O\ %CQU\5]3_:%_:.^)O[37C"^\9:1X"T2R
MT3QQ\4[C3Y-?TOPCIO@GPIX?FM/#XBTG3BL/B'4_$VH?;([B:VO[.SG33H/B
M+X6?\$?=1^$_C/X=>/-!_;I_:/G\5_#WX#?%O]G-?%EUX-_9\E\8^)_!/Q,_
M:<\*_M+'QAXPURX^%%S:>-/C/JVM^'[Z'XV_$CQUHWBS_AH'Q;KNJ>/_ !MX
M?M;K7?'.A>-OVCHH ^/_ -E+]D/PM^R%\/OB7X,^%=QX8\.Q?$SXD:[\7!X1
M\'^!_P#A"_@-\,?&7B#P/X)\(:GH_P %O@QI_B6]G^'GPPUC6/ X^)WB#P%%
MX_U5]2^)_CKXG>(['Q#H]IXJLM(T'Y]^'7_!-L>!_A)\*?!%S\91<_$;]G?]
MJKXT?M>_L_\ Q=\-_#F/PY?^$OB%\??&_P ;O&_Q3\%^-O#6K^-O&-OX]^$G
MC>W_ &B?BM\,O$OA;3M8\#^(;CX3ZUIEMHOC+0/BSX:\/_&+3OU"HH _,'4?
M^":NBRZE\"_$FC?$NTTKQC\/OV\->_X*)_&#Q)+\/!=2?&_X_>)_AMXR^#NH
M6<6GV7C31[3P!X!T+X6>.KSP'X*TD'QCXFTW0_ _PJN/%?C#QOX@T'QUKGQ,
MYKP#_P $O%\ :EX2^)&D?'*:S^/_ ,,_VKOVN/VI/AQ\3-'^';:?X:C@_;?\
M3ZUXP_:%^ _Q(^'-_P"/];/C[X,>)O$6L:?JVEVNE^,/ WCO0-2^'?PIU2P\
M;C5O"VMW_BW]8Z* /SC\1_\ !,SX(>,O@%\-/@5XIUSQG>MX"_:<NOVO-:^(
MFE7MEX8\8?$/XV>.OB1X[^(/[0NI^)?^$>L[#3;+PW^T3I_Q?^-/PQ\>>%-
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M ?@OI]EXQ^'NH67CKQ'X+\<?#?X@:)\1I],^(G@72?"+:Y9ZIX7O=1NC>^'
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M::L_Q^^'WBJ[OO"7BPZ#IO@?4- U37/%GAV3XJ?!IO'8!^GM%?G3_P $_/\
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M^&M[^S?)X?\  GC/P;8:+>7.L^!KSXM>+]%U2]^SV5E\1[:*X:\L_4_V8?\
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M6T6XDBU+1&\7068MI7Z)_P $G_VOM/\ @A\2_A?<WG[-$FM^+O\ @WT^#?\
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MP_I*>"++X2'PPUQJ'AA_#FMGQ!J'Q)B\:);:3J8TKPQ-X8FDUNWU:  ^5?\
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M%N;RRNTBN;6#6-+FGBCCU"T:;<H **** "BBB@ HHHH **** "BBB@ HHHH
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M1_&<FFI^V7^S3\:M(\#^&="LT6YL/VCS\(VUS3X?&/PSM;73_P!DOVP?VJ?
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M:QX4T3Q3XV\->/=)\<2?LU_%F;PMIEW::RT%U:^"KOQ%H?AO6_$_@IKCYT^
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MU)=+6RU2>TAT[5M)N;[MJ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MK_XE_#+XW?LO?\* ^&WQ+^)'PGT32/"GPQ^+_P 74_9?\3_&'PO\?/B"=2^
M?PJ^+_P_C^*FBVD'B3P#??!GQYXPOY/U9_X)*R^"M/\ @3\3/!OA[XG^-/&'
MB?PS\?/B=JGBKX7_ !!\)?'_ .'?B#]EO0OB1K+_ !-^#W[-&C> /VH/ /PH
M^->F?#/X3?!OQ;X'\-?"SQ'XE^&/@;2_&_@^RL]>\*^'-!\.R6'AW1/:[73_
M -F3_@IG\%/A_P#$S3[CXO/X,\-_%/XDW?P]\6^'O$?[1?[(7QK\"_$KX2>+
M?B;^SI\18H;WPUK'P:^.G@*[AU'3OB-X#\3^$_$2Z(=8TBZOM/\ $GAYXI5M
MX_HKX/?!7X<? GPW=^&?A]8ZZJZMJ4>M>*/%'C7QKXU^*'Q)\>>(8](TKP[;
M^(_B+\5?B9K_ (M^)'Q%\0VGAK0/#WA33=9\9^*M=O\ 2?"'AOPUX1TJ>R\,
M^'-#TJP .(N?@1^R_P#!C1M#^).C_L[_  QT#_AGC2OC%XT^'US\+?V>=+\0
M>._AY'\28KKQ)\;I/@OX3^&'@?6?B#_PE7Q=FMYKGQAX;^%6AW?B_P"+FNR0
M6%QI/BC7+ZTM9_QO_:&\&?'[P+:_L9?\%*;3PSX@\?\ CWP/^UE8_$WQW\(?
MAA^Q]^U!K'[3=O\ LY_ME:9:?!SXY_"'7?#WAS6?%.N^)Y/V?_A#;?!S7+S4
M/$W[.WPRU#Q/=_LA>$+N.R\&^+O$MOX9U;^B'>O W+DG &1DGV'?\.H((X(I
M/,3LP/TY_EGKU'J,D< F@#^8;XD_#_Q3<^/?VLOC5X=\ ?MQ7_BSPM_P6>_X
M)[?%7]G?6;SX?_MX:MJ.C? GQ;X?_84TW]J_Q%\.?#>L>'[RYG^#MUX3T;]J
M[P1\4?#]EI-[\./#W@W2E^'"Z!HOA]OA;X>N?'+3X5?&>R^(FF_$B3X9?MM:
MMXVT7_@XN\9Z?I7B'Q-\._VQ/%UQ8?L#?$7PC9^&/B!<1KXET+5K6Y_93\::
M5IVF:+XC\2W\-[\*=1L-%\-Z<^K#3O"7A.VT/^F7Q'^TG\*O"O[0?PV_9>UK
M5M<M/C)\7? 7C[XF_#W1CX'\;2>&]?\ !WPPN] L/'=[!\0ET$?#X:KX;N_%
M7AA-2\*CQ0?%=I!XDT#4;K1;?2]9TR^N_9)M?T.WUG3_  Y<:SI<'B+5M+U?
M6]+T&6_M8]:U/1O#UWH=AK^L:?I3RB^O=*T2_P#$_AJRU?4+:"6TTV[\0Z%;
M7DT,VKZ>EP ?RA?L9>$_VD_A[XP_X)"Z!KO[,O[7<GC3]EKXD?\ !7'X=_M(
M/<_"+QQX=T2Q@U1?BQK_ ,!?"UQ\5?'A\,?"SQQ\./'$6O\ A9?@IX_TGQUK
MWP#GU6XM=-TSQ[I.I:1=VMA\R_&70/VA_B!^QG^VSX*\+_LY?MR*_P"TE_P1
MH_9<DT?X6^)/V4_VQ-;\<ZM^UOX?^/\ ^T!H7Q@\,?%WQAXI^%B7?QB_:\T3
MPUK7PJT+XK?''6M-\(Z_^T3H=AI'Q=\+>$K#X/Z191>#?[:O,3&=P/;@Y)Z=
M .3U'0="#T.:^</VFOVM?@5^R+\(?BI\;OC7XMN]*\%?!;PGH?CCXCP>%/"_
MBCXC^+_#GA3Q1K6I>'/#7B"^\#> -(\1^+;70-;UW1M;T^W\37NDVGA>R&@^
M(]2UG6M+T7PUXAU/2P#/_:^UQF_8[_:*U32-%\<ZY=ZW\ /B59>']!\&_#OX
M@^-?B!J>J^*O ^J:3X?T[2/AMX,\,:]\1M1UFXU/5;&&71]/\+W&KZ<6FDO[
M*UCL[Q[?\.OB/\(?C+X&^!7_  4W_94\+?!;XW:K^RE_PK_]H#]M?]E36_#_
M ,(O%NOR^-M6_;D^&_Q2O="_8]T?X)^'O 2>.K7Q?\'?VR/$OQ6^-MOX4T_P
M9_PE/P;T0?L_7/C32_#$TUIX@U3^F7< /F90>X![@X.,\]>/J0*4,#G!!QU(
MZ<C/7ITY]@1ZB@#^<?X;>'_B /''[&-W/X*_;*\.^%K?_@@+\=_@]X[CTOP#
M^V?X!L? _P 9=-UK]DY_"_A:RTG1-#\.R_"/]H^^T_X>_&0:!=>$++P?^T!X
MBM?#GAN&SO=16W^$L=?#ME\&?C]X'_9S\!_\(+\+_P!NSPQ\4?B/_P &QWQ,
M\%_&3_A%_"/[:6F^(-;_ &]OA?X3_9ZTC]GGPIXK73+*..P_:*\*ZKIOQS\.
M>!]&"V/C9?!>H:[X8\B;X>>)=&TW4_ZI_CW^T7\,/V:_"_A;QG\5[_Q%IGAK
MQC\4OA?\&M'U/P_X$\;^.8+?Q[\8_&&F^ ?A]:>))O!F@ZW;^"M UWQAK.C^
M&U\:>-)O#_@RSU[5]$T*\U^+7/$&@Z9J7N.\ ?.R@\Y ST!(!QR<$C /0D@#
M)(% '\CO[1?P<^-OQ(M_VGE/PV_;<U^UB_X-VOA%>?!O0[;P5^U[;Z!!_P %
M /!T_P 7+[PWI?@SP_#H]KI6D_M%^%M8LO@;KR^!],M-.\467B6*W\5:OX<D
M\0Z7KNK:=6_:9^!7[0OBGP5_P4(\)_";X1_M6^)K_P".O_!$?]FWXG*NO_#K
MX^2GX@?MY^$?%GQDO?&NJZ5JOC_0+;3;;]J?2?AX?A5;2>#-!N=)^)I73O#7
MAO0_"[ZSX=@TG2_ZZ_,3^\/PY[9SD=@.2>@')(KR;XF_'GX/_!WP%\1_B9\1
M?B!X?\/^#/A(]M:_$34TFFUR[\,:OJ-EX>U#1O#-WH'AZ#5O$5UXR\16WB_P
M@?"W@G3=*O/%OBJ;Q=X4M/#FBZG=^)-$@O@#^9S]HVP^*?Q1_;(^/'Q*^'WP
M2_;KT#X/?$O]H_\ X("_$?PAK_ACX$?M@?".S\:>'?A3^TI\6KK]JO7/%'A+
MPSX8\*^,;2V\$_##7]*N_B5H/QE\*Z'?:+=^%/"/BR[T&#6O#7PC\2.[4O@-
MXX^'&J>.M2^'?PE_;(T:?X"?\'!/[.^I_LVIX=\(_MEZA8> OV+_ !^G[,-Q
M^U=>?"O2X+.^TQOV7O&MU=_M5#XI-HMI>?!WQ$FIZQ!<K=6^I^"8Y_Z6/@[\
M;_#'QJL?';Z#HGCGPMKOPO\ B-K/PH^(/A3XB>#=7\'ZYX>\;:'I7A_Q%<6=
MI/>1S>'?&6@ZAX9\5^&O$&@^.OAYK_B_P%KVGZS"-*\37=]9:M9:?\Y0?\%)
M?V4+OPEH_CBR\6>.[KPYK?[96B_L"VMTWP1^,]A=6'[3^M^/--^&,?@GQ5IN
MJ^!;'4O &BV'CK4D\-7WCOX@6GA?P2=9BCTFPUV_U35_#EEK0!]B1> O!44^
MC747A'PM%<^'?$'B/Q9X>N(_#NCI<:!XH\8G7#XO\1Z+.MH)-+U_Q6WB?Q,?
M$NLV+0:CKO\ PD>O'5+FZ.KZ@;C\K_VQ?"7B'7?^"I/_  3+\3IX%^,&L?#?
MP;\!?^"DNA?$KX@?#[P#\7-2\/>!)?B=X+_9ZMO!UEK7Q,^'&ASV_@+Q)XJ3
MP/XNB\'L/$>B>)+G5=(CC\/2+K-QHRW/Z^J<J">X!_,4M '\?G@+P%^V+/\
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M8:U'X8?M4GXA>$-=^!7A7]HOX[:#XW^%DOQ$U;P9XSO](UOX3_M!_&KQ];>
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M_9 M/^"/?PY^#R^!/!7[-'[16B?$CX._M\?#FT2#]I_Q;XA^$?@OX<VGQ?\
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M:+\X?\%"#\<;O]M#3/&7@3X._MBP-\"?VK?^"8/C"U^(O@;X<?'SXN:+XF^
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M@=/2EQ_G)_S_ (]Z /Y:_B+^U[\5?V=OCK_P52\&?#SX\_%+XN? KX?>*/\
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M.%IPGE"21$+[G4&U0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M;5IM!UE;;3+F_P!-GO=(TJZLP#\CO '_  4__:I^.7PK\&?#?X._ WX<W_\
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M'/P]^(FI>+O"_CJT@\._$Z'Q58QZ:_@NZTOQ3\X?L/?MQ_M ?M,^,?&OPO\
M%T_P43XD?![XW_M#Z;\0-%T/X=^,O!%MXH_9[TWP9\+O'G['?CS0TO\ XX_%
M#6_AOJ?Q\^'?[0/P8^+-]J_B?2?&$<6E)\2_AK!X&T#QKX(U+5;3]/OB]\'_
M (7_ !\^&WB_X/?&?P'X8^)OPP\>Z7_8OC'P-XQTN#6/#GB'35N;>]BMM1L+
MA623[-?6EI?V<Z%+BQO[6UOK26&[MH94KV?P:^&^F_$#XC?%72O"MAHWQ(^+
MO@[P+X"^)/C71)K_ $7Q%XM\+?#*;Q[/X L=0U'2KNSGBO/"3_$WQL-&UVQ>
MUU^VAUE+;^TVMM(T.+30#^=7]B?XX?$?]I&P_8+\*CP;^S/\&/V3_P!H7_@G
M+_P4H\:_$;]B3X4_ 5+;X#SWOPZ_:3_9^^%6HZ;!83^--.\/ZII_B#0?BOXC
M5+/7/AW+X51M?^(L_B'P5XGU#Q_I=Y\/?2?^":?[1'[1G@_]FO\ 8&_9S\1^
M&/V?O%GP_P#B/_P0R\*?M(?!/2HH_'^D:WX?US]G?X?_ +*OPUO?!GQK\87S
M>)=%\<>%_C%;?'WPQXLEN_!_PL\(7WPD_LGQ/X#DLOC7%_9?C_4?U!\'_P#!
M-3]CGX?Z'\%_#G@GX;^*_"FE_L]>'?B]X1^$7]@?'G]H?3-1\*^%/CKJ.BZ]
M\2_#4^MVOQ636_$^A:MXJ\->&/&^BZ3XNU#7K'P-\0?"WA7XA> H/#'C;PSH
M6O6&OX/_ .">G[*W@%/A(G@_PA\0-"3X$_LZ>,/V3/A*MK^T1^TBX\&?L]^.
MCHQ\1_#JQ^T_%N?[9;R_\(QX/71_$.J_VAXN\*KX#^'J^%M?T=/A_P""TT(
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M8,_9I^+VAZ[X>^(?AOXB>(=/\0_';P!^TO>3K^T-^T;HVMZ=\;_A98^'M/\
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MOP:_9[^ OC'X7Z(=.T'4]-^/G[&WQ(_;-\.Z'X\\#?%KXY>!=.UGQ;X$\/\
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MUCQC9P:";634_%D>F>$K:#4-$C\.:/PW_P""4GB3X?>./V=-5A_:P\0#X?\
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M4=<UFXN+Z5;G5Y[:*SM[7],8HHH8HX8(DAACC2***)%BCBBC4)''&B!5C2-
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MZKXMUW5O">F1^$+#7/$=M8R^%/"-]H7A"ZU!-7G?Q)=:#-XFN+?3KG6)M-M
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MT+P+>>.[#PAXC_:,^-5R6U'5/AIX9\6_#?PCJX\&?4GB#]O_ .!GP;_:9_;
M\*^)?&?[2GB?Q/\ #SQ3^PC\*;OX5>*-&^%GA7X-:#XY_:>N/B!H7PP@_9]\
M4>,3\,97F\=2Z7?ZE\6_$WQ9^),W@JYUC0/#'AOX4ZE-XJO)O"&K^0_'C_@D
MI\3_ -H;1_\ @H5!XW_:N\%V>O\ _!0WX ?LO?!'QUJ^@?LTZQ9Z=\/KG]G&
M[\=W\_B?PCHEY^T=J$U[8^+)_B7XKM=*\.:QK$]WX4TNU\)PZIXH\<:II6O:
MQXK]6\5_\$UO&/C/X[?M7?&7Q#\<OACK^A_M:Z7^RUHOQ%^#?C#]EK1_B!\+
M=>\/?LS>$OB7X>/@KQYX:\>_%;Q)IGCKP'\2]0^)E[J_B+1Q8>'->T--!\/1
M^&O%5AK=D?$K@'Z1_#/X@1?$SP99^,4\)^-/ YN=4\4Z/<^%OB#I%KH?BS2K
M[PCXKUOPAJ*ZA866I:O8&UN[_0KF_P!%U"PU2^T_6-"NM-UBQNI;2^A:O@#]
MJ+]J;XP?!W]J7]F#4?#\]C%^R!#\:M%_97_:TNI_"LNN:AIOQ5_:C\)1/^S-
MXHLM:MH[;4O!6F> /B[;_!3X8^)M1EEU+PEXFC_;(TEM2CL=1^',E]I_U=^R
MA^SAH_[)?[/'@3]GCPCXHU[Q)X>^'<7BRV\*W?B:]UG5H?#.A>(O&?B7Q=H'
MP[\+1:]KVO>(=-^%/PETWQ#:?#'X/>$M8\7>(]8\(?"3PAX,\(7WB[Q!>:-+
MK]]\7_&C_@E[X>_:&_8^^+7P1^+.K? '6_VG_B_8^(;K6?VR-+_9FOM.\2Z!
MX_U?Q:OBKP]\3_"WAR_^.6M_$72O%'PSN+;1W^&%I_POR;P]X/N?"O@_3K/1
MY/ /AZ#P!* >T?M/?\%$O@Y^RM<_%F'Q1X-^+GQ%M/V=?A5X%^.'[2NJ_"G0
M?"&M6_P#^$?Q*\3^+/#/@GQUXVT_Q3XZ\&>(/$MCK"?#?XK^)KO2/A'HGQ*\
M4>&_"?PQ\0ZSXLT#0!KGP\M_&W)-_P %0?@M;?&7XU?!_5_A7^T3X=M_V8AH
MC?M2?%SQ#X \.:5\&_V=XO$G[/NN_M&:#>>._%4_CK^U?$FEZIX6\-ZKX2AU
MOX0^'/B9HD'Q F\,:/>ZC:Z-\0OASXA\6_F5^U;\,_V@)_VIYM2^)R7OQ$^(
MMA^S/\#/@MI.N1?\$D_VIOVC/@9^U+K.@>-O'?Q0UNXTO7OV7/VW_A]\,/A1
MX/UWXB:WX.\->+?@Q_P43^(O_"LO"?BCP,OQ+\,:[X1^%/C7Q9XCO_N#PK_P
M3>\2_%;1/V_=7_:C^(&GZ1JG_!3KX4_!#2OC+\._@GI^IZ+J'[.WCSP#^SWH
MGP?U,?"KXT:WXDUH>/\ _A'M5T__ (2#PKXFUWX6>&(KS6-*LK_5O#%SHUW<
M>&Z /1?"?_!67]E/Q5<_%?P_+J.H>%_B#\)?&?P^\$W_ ,/_ !1XX_9_MF\7
MWGQ4\!^.?B3\/]3\"_%?2OC;J_[.NK:=XA\*_";XR7 L]2^-&B^)-'O_ (2>
M,=)\0:!I.I3^$K;Q1C^&O^"MOP)^(FF?!]O@_P#!S]J#XR>+_CA\$?C]\:/
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M7FEW_P -EG\;?" ?$GR[PG_P2.O(OAG^S3\$/B7\?-!\:_"3X)_\$Q_V@/\
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M'4_*^/UZ?# \$/JQ6R%J=9.N1P!9VTQI"Z6OV6O^"5_Q*_9=MOV8++1?VF?
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M)N_%WB/Q/I'Q#BO_ (D>%O%^H_!GXT?'&T^'OP[\0?&SXN:/HOAKQEX>\!^
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MMZ?M!?'KX[?&;P#X;^%L>ISCQ-)8?#/X9_"E[;PKX8^&VH_%?6O&_P 4=/\
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M[S6=!^*5BGC5_'/B#X=W7B?X)>*IOA)_P37^*/P3TKXV?"SP/^VAXSF_9?\
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M:/XBT']H_7?$5MX&LKK4;[2]4\ :;X4D\4WMGX[O/%_@;HOVG/\ @E%^T?\
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M0\=?!/X&^ HOA=^SW\1O ?[,>F?#[]L+QYX&\BWTW1=&_:9^*<>L77A*]C\
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M]BSX)^+]#^)D^B2:?XT^)Z?$%=3^'OA/P3XWTC0/ (![3_P2Y_:S^(/[3?\
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MM/!/Q';2]"OF^&7Q!7PS^>/QP_X)N_%'XK?%?_@H^;'XE>!-,^#7_!3?X+_
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M8^*/ 'P\^+/@WX0:WI^D?%3X>ZJ/B]X0C^(LDV@-H>N^#+#Q%K@!^G?P*_:
M^$_[27@W4_'OP<\5-XI\.Z'X\^(GPM\1)>^'_%'@[Q'X5^(_PF\9ZS\/_B)X
M(\7^"_&^C>'/&/A+Q+X7\5Z!J5A=Z5XBT+3;BZM!8:YIHO= UC2-3OO9J_+7
M]B+]CO\ :/\ V,%\9> M$\8_LXZ[\&_B/^W'^T[^T3XHT_1?A[XZ\&^(]#^$
M7QXL_'/Q"T#P=\.]*M?%NI>%/#7B?PA\:]<\&^&AI^H1:[X9C^#7A?7;JRO6
M\7^*-+L/!OZE4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 444?Y_S^8H **** "BBB@ I" >OU^A]
M1Z4M% "  >O8<DGI]2?6EHHH **** $(!QD XZ>HR,'!ZC()!QV)'2EHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@! H!) P3R?<CC)]\<9],>@I:** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@!" 3GOTR"0<9SC(QQGM2XQ^I_,YHHH **** "BBB@ H
MHHH **** "BBC^O2@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ K\N?\ @IS\(_ ?Q_NOV!_@7\5M.UG7?A9\5/VY
MK;0?'_AG1?&OCCP!-XCTG0OV.OVQ?'>D6%SXD^'7B3PEXLMK6R\8>$O#.O\
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MEN[7PI" ?HQ_PX?_ ."6O7_AG[QT.@Y_:Q_;('7&.OQ_]P/KQU!H_P"'#_\
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M8_\ ]$!1_P .'O\ @EM_T;]XZ_\ $L?VQ_\ Z("OU[!##(Z'^G!'U!X/O2T
M?D'_ ,.'O^"6W_1OWCK_ ,2Q_;'_ /H@*/\ AP]_P2V_Z-^\=?\ B6/[8_\
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MQ_;'_P#H@*/^'#W_  2V_P"C?O'7_B6/[8__ -$!7Z^44 ?D'_PX>_X);?\
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M!_\ #A[_ ();?]&_>.O_ !+']L?_ .B H_X</?\ !+;_ *-^\=?^)8_MC_\
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MZ?J%CJ4)66*ZBNK:W_6[]KSXO^(/@]\'-0N_!>C?$G5?B%\0-7TKX3_#>_\
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MI_\ A.?&7BWQI^T9^T)KG@_P]\$/"7A+X7ZIXRD\(?LG)XH\&Z3?^#](U_\
M9U\&?$  ^FKGX+>)-2\=:E\$&_X+;_M@#XJO91Q:C\,=/7_@DOI_Q0L;76-
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MVBO^DL7[?_\ X;G_ ()9?_2TZ/\ AC?]HK_I+%^W_P#^&Y_X)9?_ $M.OO\
MHH ^ /\ AC?]HK_I+%^W_P#^&Y_X)9?_ $M.C_AC?]HK_I+%^W__ .&Y_P""
M67_TM.OO^B@#X _X8W_:*_Z2Q?M__P#AN?\ @EE_]+3H_P"&-_VBO^DL7[?_
M /X;G_@EE_\ 2TZ^_P"B@#X _P"&-_VBO^DL7[?_ /X;G_@EE_\ 2TZ/^&-_
MVBO^DL7[?_\ X;G_ ()9?_2TZ^_Z* /@#_AC?]HK_I+%^W__ .&Y_P""67_T
MM.C_ (8W_:*_Z2Q?M_\ _AN?^"67_P!+3K[_ ** /@#_ (8W_:*_Z2Q?M_\
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MO_I:='_#&_[17_26+]O_ /\ #<_\$LO_ *6G7W_10!\ ?\,;_M%?])8OV_\
M_P -S_P2R_\ I:='_#&_[17_ $EB_;__ /#<_P#!++_Z6G7W_10!\ ?\,;_M
M%?\ 26+]O_\ \-S_ ,$LO_I:='_#&_[17_26+]O_ /\ #<_\$LO_ *6G7W_1
M0!^?Y_8U_:))R?\ @K#^W\3ZGX<?\$L2>_\ UC3]S^9]:0?L:?M#CI_P5?\
MV_1]/AO_ ,$L1_\  TJ_0&B@#\_A^QI^T0.!_P %8/V_0.F!\-_^"6(X]/\
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M^T1G/_#V#]OW/K_PK?\ X)8YZY_Z1I^H!^HS1_PQI^T1_P!)8/V_?3_DF_\
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M]+DT_P ,:J)];BTVSODM--N+S4+3],Z^ OVU/^2R?\$QO^S_ &]_]8-_;GH
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M_P#0L4?\)#_P5,_Z)#^P#_XD;^T5_P#0L5]_44 ? /\ PD/_  5,_P"B0_L
M_P#B1O[17_T+%'_"0_\ !4S_ *)#^P#_ .)&_M%?_0L5]_44 ? /_"0_\%3/
M^B0_L _^)&_M%?\ T+%'_"0_\%3/^B0_L _^)&_M%?\ T+%??U% 'P#_ ,)#
M_P %3/\ HD/[ /\ XD;^T5_]"Q1_PD/_  5,_P"B0_L _P#B1O[17_T+%??U
M% 'P#_PD/_!4S_HD/[ /_B1O[17_ -"Q1_PD/_!4S_HD/[ /_B1O[17_ -"Q
M7W]10!\ _P#"0_\ !4S_ *)#^P#_ .)&_M%?_0L4?\)#_P %3/\ HD/[ /\
MXD;^T5_]"Q7W]10!\ _\)#_P5,_Z)#^P#_XD;^T5_P#0L4?\)#_P5,_Z)#^P
M#_XD;^T5_P#0L5]_44 ? /\ PD/_  5,_P"B0_L _P#B1O[17_T+%'_"0_\
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M0NFS6\FO^#KO7=%TUO%/@W4))/#OC71XKKPKXML=8\*ZMK6C:B ?*G_"1?\
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MF^,FH^-]<U33?'OBG1OA1X F\'?!;PQXN^(GQ#MOBQ\#0#Z0'_!0?XV@8/\
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MP3X_^F T?\/"/C;_ -(CO^"FO_?K_@GQ_P#3 :_36B@#\RO^'A'QM_Z1'?\
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M9N](*>)?VY?#>L1:MX9O;^X\,^((YM)CLO[=TC47T2^UK07TS7-2_H%;H/\
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M?#O_ (2"?XV>'O$7PW^'T&A_$36M'^)&N>']=O\ PKKEYX7T+6O$.G\M<?\
M!8/]F&^TCXB^*OA_H/Q.^*W@/P+_ ,$\4_X*:Z5X\\$Z;X.M] ^(/[.L>K>+
MM'U'2/"]EXR\;>$_%6E?%C2[KP-XE34/!'C[PYX-MK*XLO[+U#7['61=:;:
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M'X>:9\0M?B\&Z?XDUC4/"WQ(D\#>.>)_^"POP#\&7OQ[TOQ1\(?VC]"U_P"
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MQ\&?\$<?^"JVF0^&OB%\6OB_X"\#7/BO]AK6?AE\,?B]\=H=5M?BW\3OAGX
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MCW7/%OC^Q\*V'BOPC\*[KQKHL'AWPQ\39(M=NO@Y>^)? \^O"_.F:M\1[?\
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MZ@WA^+PL/VB/BF_@+6+&*\N].GA^'DNM6^O'PMXB7QWX;<_L]?\ !/B3X?\
MCOP.O_!4CQMJLGQ)_8.\7_\ !/[QGK'BGX Z=?SZ_P##+Q#\6O&?Q(L_B+J\
MGACX:^#-<UGXV2K\2_B#JOQ"^(FL^(]1U/XM_&/6+#XN^,DN($\5^!/&?Z*?
MLY_\%*/VF?BI<_\ !,"'QMX.^!5A'^V/^U1_P4G_ &?OC:_A2P^(2R>'[']C
MF3]KY?AC>?"F/5_%-PMI<ZZO[.F@'Q[K7C"374U5M3U8>'?"?A;^TK1O#GZ%
MW/\ P4-_8>L?!OQ$^(NH_M1_!S2?A]\*_!OAKXC>,_'6L^,K#1O!T/PZ\:>)
MM4\#^"OB#X<\3:J]GHOCSP)XU\?:'K/P[\&^,? =[XE\.>+/B-I6H_#_ ,/:
MEJ/C&RN-$C /R\_::^)/_!//]KO5O!^H?&K]LK0-3M_#$/P,UG3(="^"OC;2
MM;^$_P 6O@CXV\4?$:+XZ?LG>.;O1]4\=?LW_%+Q]XCUCPWX=\;^((_$/Q&>
M]^%O@70?!5G]EU2:_P#%\W3_ +7W[9O[%GC+XD_LB_M2?#KXPZ7XX^)W[&?Q
M9\8^+[?X?VND^.M&O_B+\)OC)\*/%_P5^,WA3P]=ZYX=L/#,'C?1]&\5:'\5
M_ \>LR6B^*?$?PNL_A?_ ,)!X1T[XBZMXHTK]*O"W[?'[&GCB]EL?!7[17PW
M\7M9^,D^'NLWGAC6)M>T;PMXUOOB)%\)/"_ASQMK^EVUUH?@74?B3\39X/ W
MP<3QCJ.AQ_&KQ)/!IGPED\:3S1JW:?M,_'VT_9[\#:!K%IH47C;XB?$GXC>!
M?@I\%/AM)XB@\+?\+#^+WQ,UE=(\-Z3?:_)I^NW^A^#?"^FQ:[\3/BWXHT#P
MKXX\2>!_@OX$^(_CS0OA_P".]1\,6_A35@#\6_VE?BQ^Q]^U"WQ@\-:I_P %
M(M;\/_ ']I/PKXA\-?$7X>:C\%?'6K_$/P%X0^)'P6T'X(_$OP;\ ?&>O>&[
M'1OA;X;^(7@SP]::KKWA_P"(_P (_BKK7A?XC^)_B1XT\-ZGX?UGQ%I5GX2X
MK0_&?P+T;]JY_P!HB/\ X+&>*K/P#)XC\&0?\,_^'?V6?#>CZ-9?!;X;:S8:
MWX(_9ZT#XM7_ ,.=?^,GA7X:?;-(TRZ\?6GASQ=II^)U_+KUQXP@O;36SI]E
M]JM^WY\>?%/[:GQB_9&^&OA+X47'Q3_9N\"ZUXPUSX#?$.^USP#XX_:B\#/X
M7_96UO1/C?\ !7Q]=:EJ6A?#_P #ZCXG^+7QN^'/A73;GPO\8M&O?&?P77P]
M\4?B!\)9_',.J^!M"]_X*"_$G5O^"K&@?L%Z'-\#/AGX#C\)7_B"YM?V@/#7
M[2O@'X_?'^+PUX+U#Q9XQ\1?L;WFI_#G0_V=?C3X3\-ZCJ_A3PQK]IIOQ5O?
M&VA6OA'XU^/T\,:[X3\%VBW(!\W?#WQ__P $X_AUXR^%.HV7[:^LZY\+?V=/
MC!^T%^T'^SS\%]0^'NO1:1X%^+O[1Z?%JS\2WFM>)K?X?V6L>+_!?PM\/?''
MXK^$/V>? JR>%K#P!X<^(&NVGC75OB9>Z!\*]4^&'+^#OCW\"]<\.?"'XH?$
MW_@ICJND?MD^#OA)\>_@/XJ^/&A_ 3P[8ZCXL^#WQN^*&C^-= 7Q5\,] ^'&
MJ?"+3OCG\'-!\&> 9_ 7BOPO-XE^%_A?XHV_CC4-2\*?%_X=>+]:\->(?M'X
M2?\ !2#4_B'>_LR_$W4O"_@JQ_9E_;9_::^+_P"S%^SEXET[Q'=2^.;34?AI
MX5^._B7P!\3/',]TX\-:IX>_:-C_ &=?'P\%^$O#5M::SX!@USX6)KNL>*M6
M\:>)='^&_P!#?&;]I;QY8_M.>!_V1?@-HO@+6_BQJ/P+\=_M->/-0^(VJ:S;
MZ!X:^&/A+Q5H'P^\&>&+/3_#S)JTOBSXT_$/7;O0=#\37$O_  COP_\ #7@?
MQ_XPU72_&&JZ;X;\ ^+0#\L-6UC_ ()H:#X&\._#_P#9[_;A\8?LY:/:_L<>
M#/V O%=]X/\ "WC/Q%K^O_LT?#J/5T^'5]HNI^)/ <\?A?\ :#^%R>*_B/!\
M-?C)=67B72M)B^,/Q3N_%WPV\=:_?>!-<^'C_%U__P $KM6L_'/P[\$?M83_
M  N_9P^-EG^S]I7[0'[/OACP/X[N?#7Q!\/_ +-?AOPUX \'^&?#6NZEX0FU
M#P#H/Q1^$7@;X<_ ?]HRT%KXFNOB)\%/AKX*\,>!;WX1>)U\6^./%WU!X-_X
M*>>*_P!I#P#X9\=_LD_";1?%,5E_P3P\$_\ !1+XA:;\0?%FGV=M(OQ:M?B'
M9?!/]D;0M<T;58!X<^)?COQ9\&OC?I'C[XVZOI7B3P9\$8OAKHPG^&7Q0F^)
MD+>!,S5?^"L47B#X<?'3]JGX1?#V'7_V//V5OAU^S'\2?BUXJ\477]D_$/XA
M:!^T3\+OA9^TEXUNOAGIMMK,EEX77]FW]DSXR_#?XT7L'B73O%,WQ_\ &_B6
M^^!OAG_A5MSX5N/B9K8!P9_;C_8R^)_[=7A_]I/Q;\9M.\,^!/V8?@I\4?@3
M\$GU#PS\1[36OB5XV_:#\4?"KQ3\=_B%)H=KX5FFLOASX-T?X(?"[P!\+]0U
M^2RU+QMXHUCXUZ\?",/@C0/A!\0OB#Z_X2_:A^ _[2O_  5*_9@D^"'Q"L?'
MJ>"OV O^"AZ>*&LM(\1Z5_9+>)?VB?\ @EL=#$H\0:-I!G^WCP_K!0V@N!%]
MB?[08?,@\W[L\,_'6X'[1_C3]F?Q[HEGH7BF/X?P?&OX-^(=-U.2XTGXN?"&
M'7K3P?X[>+2[Z"UU/0?B#\$/&^K^$_#_ ,3M&MY?$7A>X\,_$_X(>/M#\5QZ
MQ\1_%?PP^%'B'Q&_Y2F_L;_]F ?\%+/_ %HK_@D[0!]_T444 %%%% !1110
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MWP2_X* _MQ^#/VR/#OQ-^'/B+0_@'XLA_P"%T?#T>&=/\!?$;P;K?ABU\/\
MCS3_  _I2:+X_P!,BT[3;MO;OA5^P;\=],_X(L^&/^"=GBWX@>#/AY^T!HG[
M'LO[/$/Q%^&NK:]XL^'NF^,-#\.77A_PCKDL_B;P?X;UCQ%X/UA;/1#\1/#5
M_P"$8;?5-&U'Q1X4ACU/39H;^\][_P"'4?\ P3"_Z1X_L4_^(Q_!K_YCJ/\
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M^#7_ ,QU'_#J'_@F#_TCP_8H_P#$8O@U_P#,=0!]_P!%? '_  ZA_P""8/\
MTCP_8H_\1B^#7_S'4?\ #J'_ ()@_P#2/#]BC_Q&+X-?_,=0!]^MT_X$OZ,,
MU\#?\$RXI(?V1](BFC>*5/CW^VBKQRHT<B-_PVE^T#PR, RGV(!I@_X)1?\
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MO^D>/[%/_B,?P:_^8Z@#\]V_X)\?MRV7B7]GGX<P+^S'K_P2_9J_X*^>/O\
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M,\'^.+_P=\9=)^R3WNL?#'3] \6>Z?\ #J/_ ()ACI_P3R_8I_\ $8_@W_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
2**** "BBB@ HHHH **** /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>ex10-9_003.jpg
<TEXT>
begin 644 ex10-9_003.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" /+ NX# 2(  A$! Q$!_\0
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M^UWK?Q]M_@GX%_;,_:+^#WBOX=66I?L0_LF?LJ>'/B)\*OV\/A!\"OAY\9O
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MC[4/@!X]^&OP,\1_#;XV_$/XU>.]'^,'Q$BM;+_A:4'Q5\3_ +.WPFTOX?\
M@;X;IIFE^(=+\"R?!WXC:O\ %KQ;:Z#=Z_K'PMT[P/%9>-?G']NG_@FGXO\
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M=ZCK1;6M1N?%6OV%_K<VHZR6U>_DO6N]39KZ:<U[A10 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%9VI:QI.C16T^L:II^E0WFH:=I%I-
MJ5[;6,5UJNL7L&FZ1IEO)=2Q)-J.J:C<V]AIME&S7-]>3PVMK%+/(D; &C11
M10 445Q'@WXE_#OXBW7C:Q\ ^.?"7C6\^&OC.[^'/Q"MO"OB'2M?E\$?$#3]
M$T'Q)J'@GQ4NE75T="\56&@^*/#NK7V@ZC]GU.SL=;TV>YMHDNX2P!V]%%%
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M/FU;Q+XP\9:]I?ACPMX>TNWQY^I:YX@UNZL=)TG3X-R^=>7]W;V\>X;Y%R*
M.EHKB_"_Q(^'GC?PCH7C_P %^//!GB_P)XH>UC\->-?"_BC0_$'A/Q%)?:F-
M$LDT+Q'I-_>:/J[WFLD:3:)I][<-<ZF180A[L^37:4 %%%% !1169#K>C7&L
M7_AZ#5M-FU_2]-TK6=3T.*^M9-8T[1]>NM:L=#U:^TQ93>VFF:U>^&_$5GI-
M_<01VNHW6@ZU;V<LTVEWR0 &G1110 4444 %%!X!/IZ=:0$$ CH>G!'\^: %
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** *6HZE8:/87
MNJ:K>VFFZ9IMI=:AJ.HW]S!9V&GV%E"]S>7U]>7,D5O:6=K;QR3W-U<2QP6\
M,;RRND:LP_##X[?&6W^.G[2__!-'QIXCN_A)#^SKX^_;,U#7?V?-;E^+CS>/
M[GPQ\-OV3?VHO%$'QU?X>'PI8^%_#4?Q$^,NA^!?A9H/BJX^('C+4M(^%'Q'
M\-> IM"^'OQ+_:'\:>$?#/[N5\P^#OVH-+\=?&_]H+X$^'_A+\7I-?\ V<=-
M\*77BWQ;>V7P\L? /B;5_'7AJU\7>$/"7@/6I_B,-1U?Q-K7A^Y_M"6'5M$T
M#2/#J+;KXOUCP\VK:#_:H!_.L?VN_P#@J!JOPB\1_$>3XU_&3P7+XO\ V*=-
M^,'A/2)/@E^S3?:Q\./B%^WO^V3:_#__ ()B>']1M)OA+KE[K/Q@\,^%=,\>
M2?M:Z1'H6M^%O OP&N_A]\,M!^%7C#]HR%_VGO&'U3\8/VTOVN_'-[^U_<_"
M+Q#XZ^'7COX-:K\5?V6_ ?[/&@>#?##^-]0^.?Q._:>T#]F;]C;XNZSXB^*7
MP7\6_#_X>> ?$>F7/AO]I6U\5^+_ !#XGO\ XA_!SXI^(M6T;X$#X=_"#0OB
MG\6OT\^!_P"W1X6^/'Q+\&_"[P[\#OC[X:U;Q;^SI\./VI;G7O&.E_"FW\*>
M#/A3\8-3\=Z/\,)O&&J>&OBYXHNK3Q3XTU'X=>)H-,\)Z-IVNZS:QVKWFLP:
M98V6L76F1^!_V]OASXO\<6O@[4_AC\:?A]I^J_M$?$']E+PWX^\8Z'X$O/!'
MB+X[_#C3O$&L:IX,M7^'_P 1?'7BO1++5])\'^,;KPYXT\8^%/#/@/4+SPV_
MAN?Q-9>+?$/@O0/$X!^=5O\ MI?'7P/\;_B7\-?B9\8OB+<^#O'G[;\?[/7A
M;QM8? O1O$^@^&?^$#_9*\&?%CXA_"S]G+6O '@+2YK?Q=\4/CUXSN/@Y\'=
M&^.D'Q8UW2] ^#OQ=\1Z[X^O/&6M^"="K\Y?V?/CA_P4FU6P\9>+_A5\0_B3
MX;UOXX_&7]D#6;O1_%_P]^$UWJWBO]I+]IW]I+Q[=ZGX.^(OB1OV=H[*?PA^
MS9_P2J\'?LRW'[3FI?"/P9X:LM3U/P+?>(_A)JUE%XSUWXE7?]'/@C]M9/B&
M_B&Z\)_LO_M.:MX;\*?M!:C^S?XB\66>F_ V^TS2_&6@_%73O@_XJ\1R:)IW
MQVO?'-S\/?!WB:^NM3\4^*[#PC=QZ3X1T+Q!XH>S?3-+ED;[<ZT ?S:Z+^VI
M^U[XWTCPW\#]$^+WC_PWXQ_:1\??MA6W[/W[2?BWX1>#9I]-L?!'[45]\ ?A
M4/!6A>"/@SKOA+XSGX>?#/3KO]K9?A!/\/-%G\=>!]?\,:!\6?VEOAI\*?A%
M\=_BUK/J5Y^UE^T];_'3P=XU\1_$KXK>!/V>?$?_  4 _:]T;P_X,/@GX.^,
M+S5OV.OV/O@!X_\ #WQ:\5^++#0?@Y-X]7X=^(?VEO@[$/V?H_"GB>U^(_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MUV]6#3+&_P#%/B/PYX7TZ>Z2^\2>(="T2WO]6LP#I**_/7X0_MB?&WQWXO\
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M$'VSP_?W/_"/1[=O^T%\!KW3_ >JV/QN^$-YIGQ5UJ^\-?"[4;;XE>#9]/\
MB1XDTS5SH&H^'_ 5Y%K+V_C#6]/UY6T2^TKP])J-_::NITV>".\!AH ]>HKX
MD^&7_!1O]B3XM:9X_P#$'A3]I?X,Q^%OAU\<;O\ 9TU/Q9X@^)'@OPUX=U[X
ML6>CKJK>'_!^HZUKUFOB)+V:U\2Z1H%W:QK'XLOO _C&^\)KK?AW28M=O/J>
M#XD?#NZU?QSX?MO'O@NXU[X86^EW?Q+T2#Q3H<VK_#RTUS1Y?$.BW7CG38[Y
MKSPE;ZOH$,VN:7-K\.GQZAH\4NIVC364;3@ [2BOE7X)?MM?LM?M!?!?7/VA
MOAK\;?AUJGP7\-^,_B)X'UKXBWGC#PWIOA33M3^&OQ(\2?"_5=2O-=N=6_LJ
MT\.Z_KGAF?5O!&N7=Y;V7B[PCJWASQ1I#3:9KVGR2_2FDZ_H6OZ%IGBC0M:T
MG6O#6M:39:]H_B+2=2L]2T+5M#U*SBU'3M:TS5[.:;3[_2;_ $^>&^LM1M;B
M6SNK.:*Z@FD@D1R :U%>(M^TQ^S@G@_Q'\0W_:!^"*> /!T?AN;Q=XY;XK>!
M%\'^%H?&/A;0O'/A&7Q'XF.O#1=#C\5>"?%'AGQAX;?4[VU77/"WB+0O$&F&
MZTG5]/N[CNO%/Q)^'7@>_P#"FE>-?'W@KP?JGCS6K;PWX'TWQ3XIT/P_?^,_
M$5Y-;6UIH'A2SU:_M+CQ%K5U<7MG!;:7I$=Y?3S7=M%% SSQ*X!VE%?#7[8W
M[;'AO]E>\^!WAS3H_AQXX^(/Q:_:4_94^#&J_#36/BYI/@CX@^'OAS^TQ\=]
M ^ R_&/PWX-&A^)M?\<VOA3Q+KR3+H0L_#FDZQ;Z9XB<^,M.FT">TNOKKQMX
M\\#_  T\-:GXT^(WC/PIX \':+''+K/BSQMXBTCPKX:TF*:5((I=3UW7;RPT
MNPCEGDCAC>ZNHE>5TC4EV4$ ZNBO/KCXM?"JT\1:+X1NOB9\/K;Q9XDT;2_$
M?AWPQ<>,_#D/B+7O#VN:FFB:)KVBZ+)J2ZEJFC:QK,D>D:7JEC;3V.H:G(EA
M:3S7;+$?F?\ ;/\ VW?AI^QS;_ ?2?%^L^#K'QC^TE\<O#/P+^'<7C7QEI/@
M[PSHMWJ^B^)/%GB;XA^,]3O9)+VT\$>"/"7A'6KFYFLK)XM8\87W@KP/=:MX
M8'C&/Q-I(!]LT5\X_!SXYWNO:3X#\'_'Z'X4_!G]IKQ3IWBG4;KX"Z!\:O#7
MQ'U#4-)\,>(-?TR#QGX!O/L/A7Q)XN\$^)O#FCV?CG3KZ7P9I&J:%H^M1Z1X
MITW2]=TG5;6#\Y+G_@K%XYM)M>BN/V;O"Z#P]_P6<\%?\$H=3:'XX:G<&'PQ
MXTL_AS=Z;^T-9JWP:MO[3UMQ\0+1+OX/2'2K/3=DC+\4M5%FPO0#]J:*X)_B
MI\,(_&U_\-)/B/X"3XCZ5X7O/&^J?#]_&'AY?&VF^"].FTBVU#Q??^%&U$:[
M9^%[&XU_0;>\U^XL(])M9M;TB*>[234K-9N+T']IW]FOQ4/AVWAC]H7X'>(U
M^+TFJP_"=M!^+/@+6!\3Y="OYM*UR+X=G3]?N!XUDT;4[>XT[54\-?VFVG7\
M$UG=B&XB>-0#W&BO(]'_ &@/@/XBN?#5GX?^-GPCUV[\9Z?'JW@^UT?XD>#=
M3N?%>E3>(9O",.I^&H++69Y==T^7Q7;W'AB.\TM;JV?Q#!-HJR'4HGME[GPW
MXQ\(^,4UF3PCXJ\-^*H_#GB/6?!WB&3PWKFF:XF@^+O#EP+/Q#X6UEM,NKI=
M+\1Z#=D6NLZ'?&#4]+N"(+ZU@E(6@#HZ*** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH *XKXD:_XI\*^ /&?B?P1X#U/XI^,?#OAC6];\+_#31=<\->&-8\?Z
M]I>G7%YI?@W2O$?C/4='\(:%J7B.\AATFQU;Q1J^D^'[&ZNXKC5]4TZPCGO(
M>UHH _*7]EG]F^[^"'[5O[7G[7UOX/UC]D+]G7X\?"7X2>(_B!^SYX\\:^")
MK"?]IGP;=?$6]^-G[4WB+2?A_P#$WXH?!7X91ZI\(6^"O@'7-:\%^,M/N?B#
MK_@+QSXO^(V@P/I'AGQQX\]+_P""6^@:YIG[(MAXMU?2-6\.:;\=?CU^UW^U
M/X \,^(+,Z3XA\/?"/\ :O\ VK_C/^T;\(-.\2>'S/<?\(KXGE^&GQ.\+ZGX
MH\(LXN/"OB'4-3T"_!U+3[UV^\?$WA;PQXUT._\ #'C+PYH7BWPWJBPIJ?A[
MQ-I&GZ]H>HI;7,-[;I?Z3JEO=6%XMO>6UM=PK<6\@BNK>"XC"RQ1NNZ%"Y(_
MB.3R3S^)./H.* /R]_X+!_!KXO\ [1/[$7B/X(_!3X-Z_P#&WQAXT^-G[*&L
MW7AC1/$/PJ\-6]AX.^$W[4GP>^-GC[6-=O\ XM_$/X<Z'-IW_"&_#;6](L=-
MTK4-7UO4_$.K:-9?V3%I,VIZSI7/>*_A+J%_\-?VH?@CX4_X)UZ]'\"/CSX;
MU2\^(/PU\9^*?V?A;?$_XH?'*X\+?"?7+CPUH7A#]INRTOPG\./A9\/_  ?>
M?$SXQI+XK\#>,M>FU[PX_P !)-7\?66OZ;;_ *R44 ?S8_$#]E7]M35O@5\/
MOV4/$_[-_P 4?V@8/V=/^"I7[$_Q:MOVH/''Q*_9PUCQ#^V+^RE\)_BGX%\<
M^)?BY\9CX[_:%?QWK/QK\!?#_P '/\'?'NG^,M!TD_$>Q\.?#G7?AUX<T;PS
MKVL?#7X0<!XE_8(_:>DN?B;-I7[&^ISY_P"#C[X&_P#!1#X;O:>*/V6K1K']
MFSPM8_ "W^)?Q=\/>?\ &>T/AO6M<G^''Q%DO?#1_LOXE>)5\6VSZCX<:3Q!
MXD&F_P!1M% '\[?P_P#^"?'QUU7Q;X0\.ZK\(+OX/:[\*_\ @M]^TE_P403]
MIJW\4?#!;3Q;\ _'OQ1^-GQ#TSPOX-3X??$#5/BSKVM?&7P)\3?#7P$^(7@_
MXH>$O 6A:3X7F^(6IZC<>(;+P7\/M'^(G"_!C]C3]K#X5_$C]AGQ[HG[(WB'
MPYX.^ ?_  5-_P""JGQ4U[X9:3X^_9LT.7P9^SW^VC#^T5I7P#^).GV.A?&*
M[\(Q?#OP9IOQ=\)Q>//"7A34-4^+'A'3-(UZU\%_"+QK)9:19ZS_ $O44 ?E
M=^W_ /LP_&7Q9^T!^PO^W?\ L]>%K+XN?%;]@W7?C_;S?L[:CXJT3X?GXU?"
MS]ISX=Z)\//B58^#/'7B01>&?#_Q9\(+X7\-^)/AW:>-=5\.^ ?$DD.N>'/%
M7BCPNFHV'B/2?M/X.?$3XN_%**X\1^//@#XS_9OT"VAN--M? GQ>\0?"/Q1\
M6=7UH7-O(NORM^S_ /%KXS_"OP[X-M-/66#38Q\0_$WBSQ/J>H7+ZEH7P]L_
M"UFWQ ]^HH _ WXE?L-_M,>+X?V@?@A?>'=5\2:W\6/^"IOP5_;Q^#O[;46N
M_#G3['X+?#7PYXW^"OB?Q%X>U6UN?'-I\=-#^,/PP^"'P<\?_LB_#M_A]\/_
M !/X:\6^ _'7P9TW5_'7A;P7XC^- ^#_ -@_\$]OAI\:?AS\2/\ @HWK7Q:^
M#?C#X6Z1\>OV[O$7Q^^%&H^)O$WPB\0IXJ^'6L?LY_LU_"FVN?L_PS^)WC^^
MT/4H/$WPB\4/+I?B2TT>=='N-$NXB\]U=V5A^F-% '\VGQ>_9!_:WU'X9_\
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MO$_@DZ-X3M_AM\3?&=A\/]!;]IOXOVESXF\#_!'2-=O/%EGX;C^(WA?]V:*
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M?LF_&SX2?M$?L]_M%^'_ -A;Q6/@K\05_;?\/_&?]D[Q'^T5\//C+\5/V?\
MXG?MB^//@!XH\1?M6^+O%WQL^.'BKX;>/HOB OP@^(&E_%[P)\$_B?>7/@WP
MO\6;R_\  ?A'XC^*O&7Q>TW6OH/]EW]F3XV>"O\ @A[X _9$^,WP,M+OXXZ#
M^PGKOP(\3? A?$_PR\<VVN>+$^'.M>#=.\,W?B#5-<L/A)J#:]-)8SW:WOBN
M7PGIS7DME-XFU"UMI-0G_8^B@#^53P?_ ,$[OVD(8/@9/XS_ &))=:U;P?\
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M_9K^/^A:E^S_ "?%G]O3]IO]JK]EW]I>;QS\/+VTT'Q7XR^)'_"\OV:OC?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MC/'#-]EU/2KZTOK?SH8I?)N$$D2/E:Z>@ HHHH **** "BBB@ HHHH ****
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M? ?]JC]E7]G_ ,"?L4_&WQG;^&_"?P7@L_A?X4^&NA>-?V8O!?C[4KZT\/\
M@7QH=4\!:QXST[X'6$^D:AXI\+^"+OX@+H'V'3M)O;K^H# /K^9'IZ'V_GZF
MFA%' &/H2/Y$?E0!_(;^R];Z#X7_ &P?^"R?_!1G7O%7A#X,_P#!/[]I']KK
M_@GGX)^#'Q$^)%YX6^%OP?\ VAM?^%'Q3^&L7Q.^.G@/Q#XDU32/"7C;X5ZQ
MJM[XAO/"7QDT:;5_!OQLA\7>*/$.A^(]3N-'\11I] ?LV_LE?&'_ ()F_P#!
M2KX)?LR_!FSO_%__  2=_::^*7Q)_:._9[BNK]+V']CK]HO3OV9/VA;;XD?
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH ***R!X@T%M5?05UO2&UR-5:31EU*S.K(KP?:E9].$QO%#6O\
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MVGS[O(O],O+>_LYMC%'\JZM9)8)-C@JVQSM8%3@@BK] !1110 4444 %%%%
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MQA^$?B?PQHQ\.OXB^!6E:A;^![GQ/+J-_8^'/AC-XB'BV#6_"&N:G;>)K?\
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M]\7>)?%FKZ[XC\1>*M=L] T:WU/6=7U6[O;M-.M?-E9DR?9Z "BBB@ HHHH
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M/B6'XL6UOXZ\0:E\)M2^+'A:P^-OB7Q!XO\ B)9>']<M_A#8^$Y4U;Q1XO\
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M;P!+X;\):QX2FTCQ+X5T'6[  ^Y><>AQ]<'^M?B)^P3/XJ_X*#Z#^UO^T?\
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M_".B?$"UO]3\(>"?!NDZ#9V]@UOJ$=Q\\^(OVT?VD_@Q_P $T/VXOVP?@/\
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M ($L_%7P1T7P]HOPF^$'@3P5/\35O_ GP1LKC1=0\8_$#2AXP\0?$;QYX_\
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M _B?QAX;T[QS\;]+N?!MZ7\17>J:;XC\0:?["WQH^,GQ2O\ ]MK]E/\ :?\
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M1[0^&-5M=;N?$@\>Z5K$>AZ< ?&'PWD^/ME_P4_UK]D;QS^U9\:?'G@3P?\
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M"^!7BGQYX'^%O[6?P>_:B\7:+^T#^P1X^\ +X2\1>"OV+;7QIX_T7X4?%OX
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MCXZL_B0EOIOAWP9X9\*Z-X/4 \$\/_MB?$#XN_L<_MQ?M1?LL_MC?#G]H?\
M9Z^'O[)]M\5/V4OC]X>\#^!!\6=$^._@3PG\9_B7\8?A5^TMX(%II'ARXN=.
MT_3/@0W_  C<_P #_P!GSQEI'PV^(5UX8GL8_B)I<OQ<U'VS_@G_ /'WQ/\
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M/#/C;4/$GA;4=1EU74#X@T>:X\:)K>@7D6BZ;]$^+/VG?B+H/[;W[97[-WQ
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M#T#XX7&DZ?IOC2XT'X8^"[-_AWI?_"%^ -2L_B+ /"6KZEX(U37EGM-,\71
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M+X:V6GCPK=>!->T?P;K^JQ^-_&=[<0+XWM?H3]L;XN_M,_L>>//@Q^U-XO\
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M06W^(DFJ7<5M\/IOM+^ KGQ-$+^;Z 3]DWXXZW^V++^V[XM^(/P=MO'O@?\
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MO0-=\%Z]I^J_#2/P=IMUX<_X2'P[?:#XM?4]>UFUUO34T[Y"\._L!?%K0O\
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M/XS?M$_L"?!+X\^#O#WQ'^#?PYG\(^&/VH_&G@#PO\2W\,"[\,^%](F/[/\
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M?A1\4=:\:Q>,X_$<6@64VCZ[\&?"6BZ1X:;PA=)<:5J7B34+[Q%]KN-*L=*
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M5^,=6U+5[L_#[P/XL\>:+\,/AUH^C:7:>'-<\7:MXY\1>,_&^KVW@S3_  *
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M\31X#_:R_P"&E/A9\-63X9?$&PUK0_A8=;\%?'*X\/\ PW^*>A1>&O&_P>\
M> ?#'B'0-1^%'Q*TVY\2:5?6.I7>B:Q-H(LM6GGN]<T[1OMROFWPUX._:"N/
MB_IWC3QCXN^&'AWX9V'A7Q3:ZQ\-/AWX6U>YUWX@?$35[SPC:>$O''B[XCZ[
M=Z?=VVD?#SP?HGBCP_8>#=/\-W,?B/4_&5CX@U/7;%/ FAZ5=_25 !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5^)GQK_X*7_M#
M?"#P'_P5+U5O@C\&=8^)/_!-?6O _CUO 4OQ0\7:)I'Q;_9-\?\ @4_$O1?C
M8/&&M^!=.;PQXGC\(V?CVRNOA]HWA_QW%=_$KX)>/_AKX8\1^*+C7_"_B./]
MLZ_,K]H3]AK6_C%^VY\(OCLNJZ+=? C7?@7JWP7_ &O_ (6ZWK6OV"?%72_A
M3\5_#7QY_9'NM+TS1K<V6KS_  [^*U[\3XO$NFZY>V&CZW\/OB%XO\+:H=7T
M?7M3\.:V >K>-/VA/BTOC#Q3HWPETGX1^.O"GA;]C_\ X:(N/&NK:UXNTK3+
M[QIXBUC5[7X2>'=/ET72O$6GWWP_^*.D>"?B?JUUXKTK4M5\0> (O".C--X6
M\96_C6PGTWY6_9S_ ."D_P 4_B+XS_X)LZ-\6?@QX&T+PM_P4^_94U[]HCX3
MZU\,?B%J_B3Q+\(_%GA3X7^"?C=K'PZ^)_@WQ%X3T:?6? MS\-?'FEVUK\=/
M#6I6NE:7\4+:Q^''B/P1I+^.O ?B+6NM_9#_ &4_C5^R?^PAX]^"OB26Y^./
MQ.\.Z/\ $SX-?"*UM]3\,Z+J^J?L_P#PTNO$7P=_9"\.:UXHUO5K70[2^7X)
MZ3X.\<>.KRZGA?1?%7B_QO9V>EZI>VEO::E\G_L$_L+?'W]@_6/V4/B;X.^!
M6D:G<>*/V(O@%^QI^WM\-K+XC> D\6>'/B9^RSX)M=$^%W[3?[/=_JU_/X.U
MSP/X[U&7QQH?QE^&K>._A1J7B.QUSX;_ !C;PI??$_PWX]T'Q> ?;WPN_:6_
M:\^+GQ?_ &D/ACX<^%_[/]GH_P"SE^UMI?[.OB;QI=>._'EW<'P3J?[+O@_]
MI:#XHGPC+X5TAKK6);CXO?!WX7)\/].\37"1ZMJ/CWQA-XP30_"VCZ?XI\P_
M9@_;2_;>_:P_9G^%7[1_PL_9X_9^U"T^*/B;XH>#+_PIJ_QE\7>&Y_AI?_#/
M]J$? RY\5ZCJ]WX$OU\>>$[OX?\ A3XJ?$_4++1=,\.^*M*\0Z+X(^'.E:3X
MJM?%FL^._"'L'[)O@KXV?#+XO_\ !1OQY\0/@GKNC:!\>/VD].^/WPACTWQQ
M\+]?UCQ5X?\ #?[+?[//[/J>%;RQ@\86ECX9\::WKOP$O_$NDQ:UJT/A2+0_
M&&A6^L>+=)U.PUJ"TSO^"1WP+^,O[,O["OPX^!?[0'@>T\"_$_P)XY^/.I:S
MI^D>+?#WCGPY?V'Q.^.WQ'^,>@ZAX;\2:#.L][8VNB?$2Q\/ZFNNZ)X8U:'Q
M1H?B"*WT>Z\/KH?B'70"G\+_ -J#]KOXO>+/VB_"_@?X7_ C59/V9_VQ])_9
M4\<->^+O&>A7>J^&=3^"?P-^,&I_'#PW#=:==V5U+X,@^/.C1:K\(-0U+3KO
MQ#H?@WQ1J&@?$K_A(;_P]X3O<;]A?]MKX]?M?_!_]E'XX:CX"^!OA'2OVA9_
MBUJ7C'X9Z9\0=>OO'GPY^'WPJO?B+X)U7XA^%K[7--T-OBKIEK\6=,^#/A/7
M=/M?"'A%M%TOXRP:Q>:C'/X=L].\5=-^QKX"^./PC\<_\%%O&?Q&^"?B'1K'
MX[_M::S^TO\ "/2])\:_"SQ!K7BOPI%^S;^S_P#!+3_!URD'C>STKPY\0M5U
MCX#:AK<=IKNK6?@BRTOQAX<AO/'JW5KKXTKXQ_X)O_L@_'']D3X&?LJ>"7_8
MQ^&G@W]JKPC>>*OA_P#';]IS4/$7PKU+P19_ +XD_'W_ (7A\7-'T+5OA]XS
MM?B]\5O&/B#P]X4\'>"OA^/%_P /?#NE^&/B%+9^,]4O?^$1T'7/#_C( ^P/
MV9OV[_''Q@^,7[0'[)_Q6^'G@[X0_M.?#:+XA^*_@F^G>)M>\9?"+]H[X)^"
M_&U]\(;KXR^&-3N/#OACQ%X<E\%?&[2M7^&WQ?\ A9J,%YXE\'2)X6\4Z/KG
MB?PGX_\ #NL'[,_9N^('C+XM?L__  ;^*OC[2?#'AWQ?\3?AIX.^(6L>'_!F
MIZKK?ACP_-XUT.S\2VVA:1KFNZ7HFK:[#H]EJ=KILNMW^A:#+K%U:SZDN@Z+
M%=1Z9:_GW\0/V.O'W[2WP+NKB\\*:K^R_P#M??L\?M'_ +1'[0/[$/QUN?$_
M@WQ)J'@7QM\0_B1\2?&?A2\U]_ 6K>*X=7^$OQ.\%>/!\*OVF/@OXBM-0TGQ
M1X6OM?M-(.I:[H?@#X@Z/^@_[-W@_P 3_#S]GGX$?#_QK;:/9>,_ GP9^%O@
MWQ=8^'K^ZU3P]9>*/"_@;0=$U^TT+4[Z"WO=1T:#5K&[BTR_N[:WNKRQ6"YG
M@BDE9  ?$/P=_;B^/'[6'PL^-W[1O[(OP-^&WQ'^!G@CQ!\5O!7[.<7C;XMZ
MOX*\:?M@^)?@QK'B?P+XRUGP]J>G^ /$O@_X,?#O6OBAX6U7PI\+/$VO7/Q%
MU/QM8Z;/KOB[P]\*;:\@CM^]\!_MMWW[1/[0/Q'_ &>OV;O",8O_ (#_  P^
M#OCS]H7Q]\9M)\8>$;/X;^,OVA?#EIX^^$/P1T?P#'I%IJOC+XB_\*RAU;QS
M\7VG\5>%=.^#\6L?"_PW_P 5UXE\:^*]/^&'RY^PO^S7^V%_P35^'T_["_PF
M^#/PE^.W[*G@;XC_ !'\2?LN?&_6?CUJ7PQ\7>"_A;\6?'?BKXN:I\-?VC?
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M@YKEK?:;XA\/W'B"VT3^UM9\._#WXAZ?B?MT?LN?M%?%G_@D#8_L=_##X?\
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M^&'C[2_A7^T?X,TPW.JZ%K>EW7B/P;#XOU+X:_"OQ[KH!ZI:_M=_M#7/Q?\
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MM"^'$'[._@_5I/!'P\\9Z9XB\0WWQ)\:_$+PQ/!HOQ5@U?PQ-H-MX8\/^$/
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MVBOV5OAG^TK\?/"GPH^%OB?X(_LV_LJ>(_C]-J?BGQ[K^G>,_B9X_P#!\7Q
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MP-XOM_VEOVL_AQ^RKK,WC#6?$&DS^";KXIZ5XFU31/'VEVVB:;?Q^)K?0/\
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MO%NK^/\ [CH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MA_!.EZEK=[X4^&7PK\"?#*#0K"Z\82>'?%OCKQWXUU*^TKP[;^!O!>A^)_B
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M7P['IMOXZ\$ZU%H_BO0;OQKHOB;2=(T?Q(?"[1=3^$HUH_#;]FC]HZ[E\<?
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MC?#G[0G[0O[5_P#P2]^-?BO]E'X]>"? GP3^(7[<WBOXJV_A'QIH$/BSX;^
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M\0/+\3/#7Q,T#Q+X+\6>$M+\0^%K:X\+^.=$\>WW@>_3P$?B" >G?%G_ (*
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MG^&?[$WB7]J'1/C?\)?A)H%WXT^+J^$_VH_A-H7PTTOXR^ /A[93#5/B//\
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M?W;Z1XI\$?$WP?KNDV>@V_B'PGXYO]%TS4 #[\\,?M^_"KQ_\6?V8OAI\,O
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MOPS_ ."C'ASXM:]XNT+P=^S%^U/>)\/OVDO&W[)WCW6_[&^!=UHG@SXU>!_
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M?Q(^+&NQ^'?AA^W9^S=\5/'^N7>B_#3PMXKU2QTKPO\ #_P9XG\2ZA?7EI!
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M_M(?M%?%'XO_ +,WBG]L?4/AIHVF^ _$/Q;^#OQ&T3P1!\7_ (-?';X:>-_
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4A(&,]^!P>OITI:_
MD>_;=^ /CC_@GC^U9^U;_P %D?V,/AY)XH\$>#?BG:?#+_@IO^QKX;T31/\
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M'_A6+5;S0@#^SRBOY/G_ ."^W[4>K?\ !.?]C?\ ;]3]G3P7\/OAO\=?A?\
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M[\'Z_P##?7OBYXD^!VA-X8\=>./$GB'3-2\&_!OX?>+="U686D%U8JVM0ZH
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MZ?)#IOB.:YL;.'P_J$J7!2RUN6[U/3;6/2KEH[][G4;&!;<RW=NLGXW?'/\
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M5<^?%OA4>*5\#GQ-X?'C5]"/BE/!YUG3AXI?PPM__93>(T\/FY_M9M!74_\
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M?%/0?@W\:KCX4?%O1K7QEXDCN&FU?7-!\7#PA\4I_ GA?LOV9OC ?V>_C_\
MMK?"#X4^%_ ?A?Q)^UG_ ,%UOB1\*/#^O:MX?:W^'7@?7[K_ ();_ +]J;X@
M>.?$7ACPO>^$Y_%WB;QS)\*/%>GVND6WB;PQJOBWXD^/D\5ZSX@NFMM<CU,
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M?%#34\.R> V\$^"/["TKPFNA:'"/!/@M9M,G7PCX>&G?-OB?]N7XZ>)O&O\
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M?]FWQ]XR_:0^&-A\</ 'BG3-<USPGX^_9NUSX@^&-3N?B%\+]0TK0QI/PO\
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M /#.X_X1CXO_ +.2_""/X;:!X/.K_L\:M)#\.XE^ 7P7&MZ1XE;Q1XGU?_A
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M^'>B:!XI^$7A+XA:A8_VUIGC'Q)H.A?"_P 3^"/'OBKZ,_:F_;%\$?LI:G\
M?#_B?X=_&OXD>)OVF/B^_P "_A5H'P;\ Q>,+F]^([^ _&'Q!TS2O$>J:IKG
MAKPSX.TW5M(\$ZU&GB/Q-KNF>']#MK?4O%WB_4O#?PX\*>.O&_A0 \8\5?\
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M?C[X">/[WXG7UW\1=06Z^"GQO\%:KK>O? _P3--X=\9_$?X7^&YOB3:RZ?\
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MDA\27-M/X GUS3M1\*&SM]>GT[Q 8-$]E^,7QJ\.>"_VI?V//@Y>_':7X?\
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MEX:^(S7^L:E\(]+^/?@UO^$1\;PZ1\6/@SK?BBP\%Z-\1_@?XAE\.+H7QO\
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M&J6T^HWG@7PJ_P""@NE^"OVB_P!L?X,?M0?$>W?_ (1#]O;X9?LU? &]\%?
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MCSP+X2^.$EK;?"/2?'WA._T30] \6Z+;7WB7Q$FJMXS\)Z6^C>,?A;\2M,T
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MM]$^-/A/X%?#ZY\,>#?@#>WWP]\.^,/AY)X$\/>(;3Q3<:A?^+(?$>3\7O\
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M Z!XY^%_A_Q#^S]X.U'QEX,\5P2>*_C)I7@GP]IGACP[K/Q&U;4K'X;:9?\
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M\&>#_$>@ZAX^?Q3XM\8:OXVT"Z^&72_#?]AC]JO3/&O[%7Q+^(P_8<T?Q-\
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M>)-=\7^$]$T"V\-MJ4VL:OXH\/:;IR7%YK6FPW./JG[3?[-^A^-M*^&FM?M
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M>&?BK\&_''@B#6=(U+PEJ?[2GP\U:>S_ .$D\7Z+:?K13/+7T..PW-@>P&<
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M'O"7QUGN+RS^-'Q,\4>-_@G\6=/\'Z[\<!XZTO5[OXW>#]1\-1?$[XL_NYM
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MBA^T)XCT"[\2Z3\'II=(AB^*?B:?PKKGB >$F\;^'/ 7@_4KW1OA[I'[#44
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M)_ 77SJ_CGQCXH_:7^!^J_M(_!WX/?#WP%KGB_XS>)O@GX:^&T?Q;\7^/9_
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M^-M>_;4\?_%CX0?#3]MK^U/&/[./]OR?\$_HO&'Q'M;_ .+7Q-LOVNKF[L]
MDO-$TWQ)XVU7PY^R+JFM^'M,U#6?%6G6FI>)M'TO7IM"M;/Z._X*-RR7'[<O
M_!(U[;Q!XW\&6/@/XU?M4>/?'GQ(\'>$EUVS^%W@_4/V)_CMX"TC7?%?B'7O
M WC?X=>%+;Q?XW\2Z'X \/Q>,[-;OQ/JNM3:?X1MKK5[*6ZTS]F-ZX)W#"Y)
M/H!G)/TP?R/I7D/C7X^_!SX=_%#X,_!7QI\1?#/A_P"+'[0NI^,](^"WP]O+
MQG\5?$*Z^'/@K6/B'X\GT/2;:.>X_LGPEX0T*^U/7==OEL]$L)YM)TB?45UK
M7M"T[4P#\G_BMH^F?&+]D?X1? #X5_$OX^K\>OV?_C%\ ?@U^R?^UI\2O#/C
M_1X_B]^T/\ O '@;Q[J/QI^(6I1Z79Z+\2/V<O%%GH_B?PC\=-1\:BR^'GQD
M\:VOB_X6?#._O/C1J/P;O-0^'M3^.U[XH\(_!+P_XO\ @3^U!\$/V>OC-X*_
M:K\+_M2:W\*?@%^TU^T?\2/@?_P44F\4_"^5_$&FZ[^SGHD/BG5/ 6J^'-7\
M677[%/[2_P !-&D^&FFP1Z*W@[1M&TY-$L/AG_4_O0]&!_\ K].?ISGTYI/,
M3CYUYR1SZ=: /Y[-2\2_$O4_CKXO_9Z_:^\*?MT77CN_\)?L.>(_V#_CY\*?
MAAK.IZU>7OAGP?X.U+XVZ9XV^,7[/OPF\5?L]? 'XN:A^TKX=\9Q?M=ZAXZU
M+P7\$?&WP$\6?#;08] ;X;Z';_;_ )*GT[XTZ?XZ\-_!;6/AO^T[J6J>%_\
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MJYO->\8:GJGB#4-4_1+]N:U\2Z[\>/CSX*^.-G^T79? SQ9^PYHLW[%OC_\
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M<^,-6U2W^''BF_U/P_XP?Q+&^E>$?$1!OM.NOD?Q'XH^*NO?'?XU>%_B[/\
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M*/$8TWQ7'X&UG5_AY9?$;69=>^)FG?#[7O%_@RP\96WA_P"(7Q$L?%GV.!@
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M6SMH D*6J /Y%_VCO@3<? V7_@X=\'?"/X8?M%>!_'7C/]E?]E/5/V7?B/\
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MGXTW7Q(CD_X1RW^&VA?"&U;X"66OWVJVE_??M-:)'\$M)T=M1B@N8OZ***
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M:>"?"-KI'A#5AKWA/2K;PWHT&F^%]= U%1K7AVQBLDMM$U8+J^K :CID5M>
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MII-C<:C-<RVFFVMM8V[QVL$42 '\YEU^VM\>O$GP]M/'_P"S_P#M^_ WXU^
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M/C?XO_"G2?#OP/\ COX7\9_"/XN_"GP%#XATFQM6\9>#?BI\W_$C]KBQ^/\
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M/B]^S!\.]2M?CY\8_P!CCXA3_$[X<Z/\3OB3KW@KPC\*?@[J?PV\.?!CX?\
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M/\_Y[T %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MD+*" 2 6.U03RS8+8'J=JEB!R%!8\ F@D*,D@#U) 'YF@!:*.M-+*" 6 +'
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M\0:#J<<,SO8:UH>IZ=K&E70BOM,OK2]@@GC^(M+_ .":G['VC?LM:9^Q;8^
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M'O@-K>+PI/H=EK$W@KPG<^(;;5[CP_I4EH ?)/Q)_P""D?QMT/\ :>UCX&>
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M5O\ QAQWA;_@G-^R%X/M/A+I>E?#/7;[0/@A^S=XV_9!^'/A/Q=\9/CEX_\
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M5++P]J'BC7%6^DL SLG[4?\ P5#_ &M?$'[(?[:6I_#N]^%OPB\>?"KX0?\
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M=>#KSQ)_PNWX>WW['GQO_;3_ &I=1UO3M'O;9/ _B;PEXA^'_P -?%_P^L/
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MD'QN\6:UI^L2_!6QUK]J+Q/\>$_:(^$'_!2K]O#4X=1\,:G^T!_PMF;PI?\
M_!,WQ9X7B_8TAUCQ_P##5KCX*>-QJWCCQ;X.T_4-2U+XR1>'O%>KI;^!YP#]
MS0<@'KD Y/7\:6@   #H!@?044 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 <=\0_'7A7X7^
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MB)KWQ3O?"4OQ ^*FL^)_B_K6N3Z'K'P]\-^'-!^&/T?^R3\!;;]E[]FGX*?
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MX+U[XU?%63PPVJ^!O@YX5D.H>%_V>_@IX9\(>'/"_A3X4_!/1O$MQJ_C:_\
M#VC:3<^)_'WCO6[SQA\5O&?Q UVQ\/7NB\?\1_V#;+5/VA_%'[4GP#_:!^,G
M[*'Q=^*>@^$_#'Q^G^$FC?!3Q3X,_:"TWX?:?<:1\/-8^)O@KXT_"CXF:8OC
M_P  :+<-X<\+_$3P;+X4\4/X22#PCXENO$GA[2_#^GZ, ?'/Q1U#]HWX"?M.
M_P#!'KP/\7OVH_&OBZVU[]IK_@H;I/Q9UR/6](\$^$_C'\)-)_9C_:W^*GP-
MU7X\Z'X6\,> ?!^L>+O '@G0_AMJ7B:UT;P_X7^$.B_$O1-<\2>"/ VAZ7I_
MA'^P?J'PI_P4A\)^,(/B#JWA?X'?&_XD>'M"_9IE_:J^%NH?!3PG<?%*^^-'
M@B*98$^&.B:=!'H%OX1_:.U%=3\':KX?^$?C'5--MO$WA[QUI6J:!XQU&;PC
M\7K#X9]OX]_89\+_ !$^(7[)/Q%\1?$;Q[K>K_LI^+_BMX[/_"56_A;Q%<_&
MWQ3\:OA#XM^!_P 0M3^*]T-&TNWC@OO ?CWQ;#H/AOX>Z?X(\&^#[FY\/Z/X
M5\,:5\//"/A_P#9_.GA3_@D=X3\,_LL_$/\ 8WO?VO\ ]L_QA\!]<^#M_P#
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M_$WX=?#[5[*/X)?%_P",7@OQE??#[PM\;-4L?"_A?5?'>AZ7XU\4>$*6E_\
M!,JUT[XX:)\<KS]J/X[^+=8T_P#:V\+_ +:6L>'_ !?X;^ KZ-X@^-'A[]DF
M+]B>\N9;CP;\)/!.LZ=X=\0? IKK3[O0+#4%L=+\41Z3XBT)-,-GJEIK];XS
M?\$L?"/Q@^,WB/XU']I3]HOP3JFK_M-_L[?M=Z%X5T*#X#^(/#W@OXR?L\^
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M\5O"/W7^SY\&_%OP<\,:GI_Q!^/GQ6_:5\<ZWJ2WFK_%+XOV'PPT+Q!-I]E
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M*?".F>!=%M_#>J6$J^%]7T*RU?Q-J6NZ[HD8TG681HT&J:AI]U:-^6'[#?\
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MK/QU\7?$2:Z\&#5_A)HE]?\ BJZT7QS<167A'4],T/3K1?"J3WOC6XO/%_\
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M.?P9C^$?[1_[67[1O[2GP]^#_P 2=8\7I_PD/QW_ &6]=_9N\.:I9_$KQ/\
M"SX:Z[^T)\4=8N;O2/&7Q(^(7C?PI\.;O2-'\[P+HL_C>#PKHVN>(P#]$E_;
MD_9%?P1\/_B7#^T1\*;OX=_%+P;J?Q$\"^.;#Q79:AX3UCP'H^H:5HFH^,;C
M7K$W.FZ%X;M?%.O^'O <FK^(KC2;)_B5XF\+?#.*9_'WB70_#NH>FZE\?/A!
MI'Q5T#X):GX^T#3OB?XK?4K/PMX7U"6ZLW\2Z]HOAAO'>M>#/#^KW%K'X?UG
MXAZ1\/E'Q'U/X;Z=JUSX]L/AL1\0[SPY!X+9==;^?/X:?\$H_P!KSPW^SA\*
M/!L0^'GPI_:4^$?@K]KG1?AW\>OAE\9/$,IM-?\ VE?VI_BO\>C\-OV@OA[X
MC^'6M_"7]J;]CK7_  ]KWPY3XF?#'XA_#F;QIH'CS1?$S?"B73I?%!^)>@_5
M-O\ \$_OVC=0^-GQM\#?$#0O@1\2OV<_B!^T1\3?VFO@Q^T_XD^)WQ#D_:?_
M &8M=^)>A>(=23P_\//@=?\ PRUKX;W?Q*^&7Q \8^+]&^"?QWT_XQ^#M>^&
M'PNUNUETK2[C7?#UAX;N@#]9_ ?QT^%7Q-\2^+/!O@7QKH^O^+/!%CX>UGQ)
MX<B^V6.LV?AKQ?/KMMX.\:VEAJEK8W&M_#_QG<^%_%%IX,^(6A1ZEX(\6WOA
M?Q-:>'O$&I7'A_5H[3P_X>?MU? WXA?$W]KKX=K=^)O MC^Q-+H]I\=?B%\5
MO!_BKX6?#[P]<77@2V^)VO:A)XL\>Z)X?\/VGA3PWX!UCPYXJ;Q7J6K6>FZ[
MX>U.Y\6:"M]X%L[/Q9JOS+_P3I_93_:%^#4WA/6OVJOA'^R?I'Q7^$'P"TK]
MFS1OC_\ !3QMX\^)?Q ^.?A2VU?P[JMWJVH6OQ"^%7P\G_9R\%-/X)T/7]0^
M#O@_Q-\2O#/B_P =:_?Z[N\#6?@/P[9^)_(OC#_P3X_:=^)7C/\ X*KV/A[6
M?A#X1\-?M=_$_P#8]_:4_9P^(U]XX\;ZIJ=A\6_V3/AY^S!8:%\,?C7\+=)^
M'VAR6'PO\6?$+]FM[;QWXF\&?%K5]?O?AEXS^Q:)H-OX@-X=- /UV^&GQB^&
M_P 7K;Q1<?#[Q39Z[-X&\4S>"/'&D26NIZ)XE\$>,8=(T?Q%_P (SXS\*>(;
M'2?$WA36KGPUXC\->*M-T_Q!I&G7.J^$_$OAOQ1IL=WH&OZ1J-YSNI?M%?!6
MR^)EI\%Y/B3X37XH:GKMQX.TWPM/J,T0N/B%;^ (_BR/AG-K<5I<:)9_$V3X
M4RP_%=/AM-?'X@R?"MQ\2;7PM=^#"-9/@_P'^ OCZR_:A_:!_:]^)/AKPC\,
M_%7QN^#7[-7P.E^&7@CQ(OCBVEM_V?[[XS^+[_XG>+?'!\(^!GU?Q'KWB/X]
MZY\.O#&D'0[R33OAA\*/!?BO5=>MM8^(-]\*OA+\CR_L!?&^[M?B7\ ]8NOA
M[K?P6\8?\%-_ _\ P4/\!_'BZ\0ZQ<?%SX<:-I'[1?@_]L7Q=\+YOA[J/AJ[
MTV^\;GXN>#=0^!/PZ\8>&_'7AOP_I'[.?Q'D\3Z]9R^,OA7-\._C@ =#^P!_
MP52^'O[1?P9\)+\>O''PD\,_M7ZSJG[7M]>_ 7X/6GCKQ+K>J^#OV:/VE?C!
M\)B?AUX(\OQ9\0?B!XLM?A_X%\+^*_$'A7P[9ZAXWU1=;7Q;I_@'0?#6NZ+I
MMM]"?"O_ (*3_LM?$G]EWX9_M<ZKXUF^%_PK^,.F^)]?^'%M\2-$U_P_XT\5
M^&?#&E:]XQU+7/#W@N327\1^*K/1OA=X>U/XI^,[WP9IOB;0_!'@71/&'B?7
M-<7POX)\2^(+#XP_9=_X)S_'3P-H7[%?PZ^+,_PTT+2/V)/VT/VS/VNK?XC>
M!-=U/Q/KOQ53]HCQ1^UK-\/OAGX;L=5\+>&K[P-H">'OVK;G5_C/?:U-?EM=
M^%?AOPEX3TSQ5IWC&Z\>?#_R7X5_\$]OV[?"?[$'["7[)_B'PK^RB9_V=_A#
M\=/@'\6M6TKXT_$6'7-5T[7/A4G@KX6?$;X?_%JT_9PL?'7A[P=K6NKK5]\7
M/@9X?TOPCJGC73Y/AQIFN_%[4?!FD_$;X<^, #]/;[]L_P"!^A?$KXC:OK_[
M77[']G\ _AY^SK\,OB_XCMSX\TB/Q[X&3Q[XBU:?1_BWX]^(#?$.;P!IGP0^
M(W@W5?A]#\)[>;PMINK^(]<EU;6=,\6>(M$UK1+"Q]N^$W[3W[/GQV\3^/?!
M?P<^,?PZ^)7BOX7?\(R_Q#\/>#_$^GZSK'A"W\9Z9/JOA2]UC3[:1KB'3=?M
M[/4H=+U5(WTVZU+1?$&C+=#6?#VM6%C^!_A3_@E[^V?8? /XI_"K7]!^#5OX
MB\7_ /!O9\'_ /@DMH5_H?Q7UC5]#_X7O\--%^.?A4^-]4N-1^&_AW4+/X9:
MGI?QETC6;V^MM,U#Q%I-_P"&_$VB6'A_Q#;G0-=UW](_V;_V7?C'\./VSU^.
M/B7PMX.\/_#63_@FQ^R;^R7%9Z)XI@O]7T?XF? ?XA_&CQWXFAM-$M-"T^P;
MP'<6/QBLM#\.:S;WMI?37WA+5/M7A;3-,N](NIP#['UW]J3]G[PY\2E^#^J_
M%?PE'\36UJV\+'P7:W<^J:S%XVU#P)J'Q2T;X=W46E6][%:?$WQ+\,M'UCXB
M^$OAE<RQ>/\ Q?X$TG5/%_A?PWJ_A_3KN_BYC]D?]K/X?_MG_".]^,OPMT/Q
M_HGA>'XD_&KX:V=M\2O /C/X;ZU?WOP8^,7C[X.W^KKI'C/P_HNJVMGKNI>
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MOPF\=:AJ7Q!^&FFZ=X;O)-%\>6=E]2+)^TAHOQBB_;U^+G[*WB'P5JW[,W[
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MB!I-QX9URSN=.U7Q$GABR[KP+\0/ GQ1\+:;XY^&?C3PE\1/!.LOJ,>C^,/
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M#'Q9/<7D7B'6=:MK_1M?^&GC_P =^$KO2[^WU:"WLFN_$-AJ"7-M<#4-.T^
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MV.B7/B.'Q-XTU"T2:W\(>!=)\0^,=;:WT70[^ZC_ )J/$7[!_P"W-JW[,O\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MX,";P38^%_$%D ?W-T5_+#\,?&?Q<_:$_P""P7_!93X%Z3_P4._: ^$/PO\
MV3-?_8!^.?PH\">!OB)H'C_P_86>G> -)^(W[2WAN/P=XWM?%>M7G@/5/%#:
MQX)\>>#?"VIZ1X2\/ZCXRTK0/$>@7UMHO@_PI:^N_P#!#[]JS]HSXP?$_P"-
MGP>^/_BRX^.TO@KX!? GQ[X=_:G^%'QLU+XJ_LW?&FS\4>+OBOI,/CK6?AKX
M^B/Q<_8__:=\:Z?I5C8_%;]F_P 0ZCI?A/2]4^'&O:AX.^!O[/=C9O;_ !3
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MOP+^+7P^TG3/AM\;K:]UC4_^"BMG!IJRGQ+?> +[X8>/?$?P3L+OX97GQ?\
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M=-\2?M&Z5J?Q$^"6IZGX* /Z:AR ?6BOQ,_;M\76MG^WG\%_AG\5OVY_BO\
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MJZZ^(WP.\>?#_P 1_#?4W\2>!M*L? /C8 _H:JA8ZII^IV9U#3;VUU&R$MY
M+G3KB*_@>>PN9K*]@CEM'F22>UO;:XL[B!&:6&[@FM942>-XU_D5_8;_ &HO
MB1\5-;_X(^M\1?VY?BS\3Y_VWM:_X*L_ 7X_Z3>?'G2M @\>^#OA%XQ^,7B+
MX+ZIX8L_A:? \_P\^*'AG5='\,P^&_BG\'Y/!'CF3P_XB@\$0ZN_@6'P#X8\
M+_JK_P $8O$?PTOO^"*_[)5SX/\ C1#HNDZ#^R-X0TOQ]\4=(^)6B>,A\&O&
MVB_"S3!XZD37/B1/\0/ G@K5?A3>K)<ZCX*\0Z3<^"/AYK.E7>B>(?!-I::?
MK&@J ?KOX!\:Z1\1_!'A/Q_H%GXGT[1/&?A[2?$VDV'C3P?XJ^'WBZST_6;*
M&_M+;Q+X&\<:/X?\8^$=;AAG2/4O#WB?0])US2KI9;/4;"VNHI(EP?C'\7?
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M$GP%N?VL+*+X/_M:?#\6J:YJOAKP!H_AV/P_]#?#']LKQ1\9/VE/@[\+-?\
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M4 1B,C^-\<<%B>!TY.6SZG/S=6!.32>5_MR8X.-W?.<Y '4]?4U+10!'Y?\
MMN1[G/<9SV(.,$8Z9P1DTXK\I&6Y(.2<GC'Y=.V.Y!!YIU% # F/XW/U;/\
MG^O?H,((P/XGSC&2<GZYQG.,CKT)Q@DFI** (O*&<[GSZ[N?S !YXSSV &*<
M4R<[G^F>G7IQD=>O7MG&07T4 ,"$ C>YX'4\CU.1@\_7O], 3&?F;!).,]SU
M_ ^AXSSW.7T4 ,9,G(9@< <' X)(SZ]?Z="05VX7:"?KWY.3TP?USZDFG44
M,*9S\S#G/!^GU],?3WYHV?[;],9W'/;GG(]>W?BGT4 1^7ZNY_X$1T]Q] ?7
M.>QP#R^^]R0,9W>N,_F1D^O'8#$E% $?EG_GH_?N.,_ASCMG/ON& ',N>Y'!
M'!P>>_ID=1D&G44 1^7SG>W<'D\CJ!U[$G'IGC XI=G&-[^W/L!Z>WTY.>U/
MHH 9L_VG[]3GKC/UZ?ADA<"E5=HQDD# &3G']?\  8 X IU% !1110 4444
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MM+I9=#\216-C!KVD2*VGZS#:VT&H6]S'#&BZ'_!3W]AOXPS?M2:S_P %)O\
M@G;8P>&/V_/V)_A/\%_$FE_#[2-#6;PC^V=\#]7U?XSZ?\5OV;/B-X>L7MTU
M+7]9\&^'DA^&_B?3K2X\6+?:?8>#--N=-UP_##QY\(@#^BI/&GA*1%DC\3^'
M)(W>6-)$U[261I((K>>= PNRI:""[M)IE4EHX;JVD90D\9;:T[4M/U>SAU'2
M[ZRU*PN0YM[W3[J"]LYQ%*\,AANK9Y()1'-')$^QVV2(\;896 _AV_X*4^/?
M@)^U9_P;L_!_]JCX9_!;PWX"T/XW_P#!1>Z^,]MX;U7P)X2TSQ'X5\8>.?VS
MOC=X<\<)JDVEZ<D4_BA(5U+P1KGBJW,-YXIT2V,=VPT^_DT]?T&UB;Q=^SU_
MP=(_!OX1?LGZ5%X<^#7[4_["_B3XM_M\?#CP/86J^!4UGP5<?&W2_AS\=_%G
MA?1S:Z;X4^(%YXTT;X/?#W_A/[RT?4M:T_Q<=";=)XNN[RX /Z@]1U+3])M)
M+_5+ZSTZQAQYUY?W5O96D(8X4RW%S)%"@9L*-SC)( S5+_A(M#$.GW+:QI*V
M^K(DFE7!U.Q$&IQRHDD4FG3&<)>QRQNLD;VQE5U((."*_E[\<M<?M*?\'1=M
M^SS^UIX;T[Q/\ _V;_\ @GZOQ_\ V,?A=X_L-/UKX<^)_C%J?C7X=:;K7QOL
M/"&NVNHZ-K_COP])JGQ>\/Z%XA>S_M3PQ<_"FTU+0I["]T*6>XXC_@XX_9;^
M#?PS^#_PS^.'@;0M-T'Q9\7OVYO^":?@'Q9X8TJQT>P\,6=E\(/'7[7GB/PY
MXGTS1+&QA.EZ]XFO/V@_'MCXEU&-A;ZU!IMHX@6^;6[G40#^M6BOP#^!'_!3
MW]K[]H[]H7]J&W^%O[//P^US]F[]E?\ X*%?'']A_P"*5QK/BKP#X"UCX?\
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M=:_:D_;&\+:O'XBL=7TR\M=;35?#.F:9X;U--2ANEU#0M-T_2+Q9K"RMK>(
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M?!'XH? 'P%IEI#HO@/XO?"S3]8\*>)/^%]:':7FE27^DZOI7V'5O$L6NWO\
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M!J7@:\\CQ7HVC7OCS]F/4O'T>B+-JNG6J:W%X>U+4(4L-0N=+LYKB;3[>_\
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MTUKG7M,NO"/B>WO;"";0=52T^$-)_:E^+'QA^*GQKTKX/^(?V>/"'A#]EO\
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MBC4D\.WVEQ7'B[6==\6M'_PDNNZOJM[YA_PP?^R__P (!%\+V\$>*Y/ UO\
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M_B#[%HH ^._"O[ W[*7@AOA*_A7X;:KH[_ CQ[\2/BA\(7A^*/Q>F;P'X_\
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MV719-6NKV\N?KBB@! ,#UY))XY)^@ _3]:6BB@ HHHH **** "BBB@ HHHH
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MB+XA^)EE\(7\-ZWI/Q+T'P=X.T?Q#\0O#WCG5?BA:>(? &J>$]!UKPWKJ:>
M?K+17X1ZU_P<"_LJVT_P\3PC\#/VJ_B9:?%']@O7O^"BWA._\'^&/@MID"?
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M1?\ "OO&.@ZAI=SX>N_"_A3P=XET%O$5_4U[_@F->7/A_P#:#\)^$/BYX/\
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M=?UOXF'1?&0^%_A[1=#U;3_A)\7/^$DO[+PO]/6/[8G[*5WX1^('CB3]I?\
M9\B\*_"'1O"^O_%[Q0OQE\!GPI\,=&\:V\EQX1UWQIXDNM9LM/\ #GAKQ<EO
M=2>#?$>NG2M+\5V]M-<:+-=+'*L8!])45XYX1_:)^ /Q \&>/?B+X!^-OPG\
M=> ?A9KGBWPQ\3/&?@OX@^%/%7ACX?>)? -K%?>./#OC36]!U74-.\,Z]X1L
M9[>^\2:/K-Q9ZCHUE<VUWJ%M;V]S!))EVO[4?[--Z+%K3]H'X+SQ:G\#9/VG
M=-N$^)O@PVFH_LW01Z;-<?'ZPNSK(MKSX,6L.LZ/->?$VWED\&6D.KZ7+<ZS
M%'J-FTP![O17@M_^U/\ LT:7X#\3?%'4?C_\&['X<^"M6O\ 0/&GC>Z^)'A&
M#PSX.U_2?#$/C?6="\6ZO)JRV?AK6]#\%3Q>,=>TC6Y;'4=#\*%O$>K6UGHT
M<EZG<>-_'.DZ%\+/%OQ'TWQA\/='T;2? .N>--.\>>-_$%MIWPKTS3K/P_<Z
MU8^+/%OBF"[BM++P#:P)#JVN:]!?1P0>'TNK^&Z5$64 'H5%?$GA[]O#]EOP
MK\*O WB/X]?MB_L6^&O%\OPK^"7C;XA:QX?_ &@/ .D?#(W'QF\.VU[X0\7>
M"[WQEXKMM93X5?%'4X=8OO@UK_B!TD\8^&;:.\L[J_EM[Z2/[;H **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ (R"#T/!KX9^)?_!.#]D'XO?MJ_!3_ (*#^/OA
MC/K?[4O[/_@JZ\ _#;QP?%OBVUT?3]!>?Q7<:4^I^"+768O!VL:KX:F\>^.9
M= U:^T62^MYO$TMQ>RW]SX?\&S>&ON:B@ HHHH ^2/$OPC\<^._VSOAG\5?$
MEEI\7P?^ 'P0\;)\.HVU&"[NO$/Q^^-_B2S\.^)O$\^BJOVC1KOX/_!WX?W?
MACPYK32K#KFG_M,>/M-2*>31'DM?S1_X+M>'/A/^T)\&/ 7[*OA#]H#X:_!_
M_@I%8>-_ W[6_P#P3JL/%&LS6/BV?XY? +XA>&H-*N?"UM;V=_#+J_BNU\3Z
MSX$\,66L6UU:7>KZG>>+(M&UC2_AMXHN=#_0;]D+]M/1_P!J6]_:"TG4O!:_
M"3Q'\$_VLOCM^R]I/A/Q!XY\/>(?$WQ 7X$P^#9];\?Z?8:3#;6]E;WB>,[&
M:\\/Z3>>*D\.VAL9-2\0/=:B;.T^@!J_P'\;^)?AAXU6_P#A+XO\8&S\:CX,
M>+4N_!GB#Q,;&XM["S^(J_"_7EFN]5:UGM;33+7QH/"=T89(+2P@UW,<%LJ@
M'XB_MU?\$ROV@OB1^UI^P'\>OAY;Z?\ M$_!7X,?"C]I3]G_ /:=^"6L?'CX
MB_LU>*_%$'[4.B2V7CWXX_#_ ,6> [X6=EJ?C+Q#J5]K'QAT./5M+O\ 4=#\
M/^'?#OAVR\1&]M;WP+^?O[2/_!&G]O3Q?XH_X03X&_ W]DSX;_LT_ O]MO\
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M#H5EJNGW>LZ#)J-E;ZGIZ:UI=O<R7VE-?:;>6FH6:WT$#7-E=6UW"'@GBD8
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M_P# DV/AV#4-'O?WMHH _,G]CKX'_&+X<?LQ_M6^!_B#\*=/T_QA\4?VG_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MXB^$/"?Q$\-?#S5_AUKVM_"KXA^(+?PY\7[73?%=S_PJ.72/&.H_$IO"VC^
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M#]QI>G3:')IO]D2Z)-8VDFD/I/D&U_LY],D@:Q?3A;$6WV-H#:B "%H_+RI
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M'+]@WX&>-OVMOB!X(^'7Q]^'O_!6/P?-\2?AYH/P-T+Q%^T5\*_V1OB]\-O
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M>*?!&F^/O!VB6WQPU"TUP0>+_#OC'XH^(=,-UI6EZ'X>T#P[^ WP9^)'BGX
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MV%U!%<V5PJB:UGCCF@>.1%8 '\E/PX^,?Q&^"GQ:^*WQ'^&?QVUSPQ9^.?\
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MQ9>7OC'X8M8^/-(UW1-4\$^(KS4M0\&:S8W?A?4-9U2^TV6^NG^%?V)_V-/
MG@:U^%_@C]DC]F3P;\-++QW<_%*R^'GA7X"_"OP]X&M/B;>>%Y/ ]W\1;7PE
MI'A2ST"W\=W7@N:;PA<^+HM/3Q!/X7EDT"74&TEVM#Z;H7P3^#7A;Q?I7Q!\
M,_"3X8^'?'VA?#:Q^#6B>-]"\!>%=(\7Z/\ "#2]77Q!IGPITKQ+I^E6^M:?
M\-M.UY5UNQ\#6E[#X8M-75=2M]+CO0)J /3J*** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MTA='MO\ A'/#&C27NLRZH ?S]?L5_$/XP?'#QS^U7^S!XC^,_P"WO%XBU?\
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M]I.PUSX^?\%,?^";WP]U+1="_:#^,/@KP9X)^#WQ ^-?[.OP'^(GPF\#^"O
M_C7P[X5TKPWX[T>P\8>*/$FKMH\OC&\\4_$KQ5>)XBBM[7PY!HWJEKXBTG]F
M7]K?1_@C;:3^UC\:-6\1_LS?MC_M4?#35O%?[1,WB_PVGAWPGXY_9;T3QQ^S
MKH.A?%#XPVK>+_&D'BSQ-X:UWX9>.?CJWA[P[\*O#OCG4? _@?XHIX;UGXAV
M'ACZ5_:]_9'TG]L'PK\-?".N_&/XP_!ZR^%_QO\ A1^T!HVH?!R/X.-JFK>/
MO@CXRT?XB_#0:\_QB^#WQAL#HOA_QWX>T3Q))8:%I^A3ZS+IR:3KM[J7AV\U
M/1KZ3XC?LFZ5\1?V@/ W[1K_ !A^+GA'QE\/OV?/C;^SGH6A^%H?@U-X1D\-
M?'K5/ &O>-?%VH6GC#X.^+=?N?'%GXB^%'PSUSP_+'XCM_!UC=>#;:QO?!NI
M:'KWC'2?$@!\*?#[_@JO\3_BKHGPEO/ O[$/C*]UK]H[]@6+]OC]GK3=8^/'
MPKT33?%'@WPW#\)5^)W@OXB:N]O=7?PSU;2+KXW_  U7X<ZY;:%XWTWXA6WB
M);GQ%;?#"32]?L]'K>*/^"F_PJM;[X5_M*Z3\$/VD->T+Q7_ ,$=?C+_ ,%)
M/"OD_$WPIH.@7WP9T;6?V9_&&O\ PQU+X-R_%EO M_\ '30])^(/AC6+_P"(
M_B73;6#PCX?_ +9\(?"SQSXY_P"$Q\;Z)I'O_P ,_P#@F9X"^$T7[.4/A3]H
M/]H[9^R[^Q'X\_8)^&O]IO\ L\7AN?@YX\/P[+Z_XIV_L\0+J_Q&\,_\*=^$
M8\.:Q;#3O#4G_"OM.;Q/X1\2OXB\?-XOX&?_ ()"_!Z;X<?#;X6']H+]IN/P
MO\+_ /@G5\3?^"8>@;+_ /9Y.I7W[.7Q6L_ FE>(=3UJ\E_9TD%U\3;+1?A=
M\.-(T3Q'9PZ?H-K;>$+:ZO?">H:MK?BW4?$(!S^D?\%>/!NDV7QSUOXQ? 7X
MF_#?0/A#_P $]/ __!3'1O["UKPI\1_$WCO]G?Q+HWBMM;TH:!IUQH5GX1^)
M>B^+/!&NZ+I6@:QK]SX>U;P]<Z+XL\0^+O!DDWB#P_X8^I?V=_VM_%'QB^//
MQP_9R\;?!^W\ >.O@7\/_@=\5-6\6^$/BGH'Q8^$WC/P1^T/9^,9/AO=>"?$
M\>A>!_%UQJ?]I_#'XH:5XFL/$7P[\.0::/#.C:SH^H^)-"\8Z1J(^4_C#_P3
MBO\ X;^"?B;\4_@%\1?VG_B/\<5_X)S>&?\ @G=X3\*:1\2/V?/A=XAO_A1X
M2U/5+C3_ !WX#\<2_!GPEI_AC]IC0X?%?BSQ-X(U_5_&'@[X5ZGXW70M)UVU
M\%:"8_$7AW1_X)M? OX[_ [7O$&@)X,^-'PB_9IG\&%I?AA^TQ\/O^"9'@#X
MA1?%S3I_!GAOP5KGPGT7_@E?X-\)_"G2_A_I_P +/#>J^%_B"_QAU/Q;XPUF
MXT[X-:5\-[#P%X<\!^,!XV .OB_X*9:5KGC[]KGX=^"OA;;ZUXE_9!7XNP_$
M+PEXB^)^F^"/BCH#_"GP'8^.=$\2_$7X2ZMX3G\<>$_A-^T#IVHP:I^SA\9O
M!6G?%;X>_$#PPAU/Q#J_@3Q%=:9X+U+\Q_\ @I-_P5"\2?%/_@GU\5-%^&6@
M_$SX#>+_ (V?\$;] _X*>?"KXN?#WXRZOX8\>?#VTO\ QK\$]/;X;7M_X/TS
MPUK.F:[9W/Q0TR"XU_P[XIN]*\3Z-9:]IFH:=I=MJ"6US^Q^L_\ !._X+^-?
MB5IOQ.^*WBSXJ?&+5O#=_P#M&R^";/Q_KOA0W/@30/VI+/QMH_Q1^'?AOX@^
M$?!/A3XSO\*E\.>/M:\.>$OAEK_Q.UWP3X4L]+\#:IINB?\ "4?#7X>Z_P"&
M/DB?_@A;^S5K?PUL/A?XZ^//[6WQ#T72/V!-:_X)LZ+J'B3QQ\(-+U'2/V:K
MWQ+X3\3>&K>VT_P)\#/!GA.Y\>^ )O WA73?#GC35/#.H76N:=H]H_Q)M/'V
MJH-4H Y_]L/_ (*1Z9X!^"__  4:\"?M)_LO_'WPAKW[*7PM^&'QG?PW\#OV
MB+'P;XB^+_[.'QH\6:_X9^'OQ5\ ?'CP'XO^%/C#X5:YH/CKX=^./"_QD\*Z
M5=S>)O"Y\,7T7PYU'XUZ;KEJM_\ 9/BS]N^+2_CIH/PL\"? _P"+OQC\&1?M
M!:'^S/\ %/XF?"[P'\4?%EM\(?B#X@\*:?XEA\6>(X]'^%]]\/+OX,^%-2U_
MPOX*^*GCJ/XN67B+X8>)M7U&Z\1^ O\ A#_"?B3Q;I_QY_P4$_8*\=_%GX(_
MM&_!#X9Z!\7OCG\<OV\OA!X3^ _CW]L/XG>*?@7I_A7X%>!O@_XMTW6?AWX=
M\;^"?#][\&KBU\""Y^)'QK^(-I#\!/@IXO\ $.M>,;WQ'!XXGCBU#P$FF?8M
MG_P3O^'>B?M2^.?VFO"'QI_:+\#:3\6/'W@GXN?&+]F'PIXX\(6'[+_Q3^,O
MP[\,:3X7\+?%OQ%X0NOA[??$+P_XW,'A+X=ZKXLD^''Q1\#:!\2M8^&OA"3X
MFZ!XQT]/$&F^( #Q'XQ?\%&_BIIO[-7CK]J+]GK]G/3OBI\%+[]F7]H?]H3X
M'?&G6/B1?Z;X)U2S^!?AN#Q1I-Q\9?#&E^ [GQ+X#\-?&?PS:^*?%_P-NO"V
MI>.+GQCI_A[3/#OQ*F^!GB+QA:IHK_C/^UW^TY\+?^",WB/]MS1_#OPIUS]H
MOPQ^P]_POV^MM>\5Z[:_#]=<C^$A\93^,(AI/PS6[US4(D,'BB+X8C0?"&A:
MIK,LO@%OB-X=T54\>Q]+\._^"3'P%^&GP_\ C'\$]&^*G[1VI_LY?$_P+\:/
MAWX+_9OU[X@>%[SX/_LV^'OC]I_B;2?B,O[/>GVOP^L/%V@7<FE>,/$FD^$9
M?B#XQ^)<'P^T76]8T#P-;>']"UK6M.U'W6__ &'O GB+]A+Q/^P!XW^)?Q?\
M=?#/Q=\!/$7[.6K_ !&UW4/AUIGQ='@#7/"-UX#L)K"Z\&?#3PI\,-.U[PGX
M4EL-,\/W%G\+(=*N9-&LM4\5:/XFUF^\0ZCK8!XU\:?^"BJ_!?3/VCI_^%2G
MXDZC^PU\-/AC\7OVW;/P+\2=.(^%_@7Q[I?B3QEK8^%\WB;P?X6N/B_XU^'O
MPA\):M\:?%/A76]*^$-IJG@J_P##.G>"M:\1>.=:D\':;];_ !0^/^B^"/@E
MI7QP\+Z->_$#PQXAC^'MWH=W:7]AX3T&Q\.?$G6- TVQ^)?C[Q'XI-DO@7X2
M^"-(\0IX^^*?BJ?3-7U_PI\/]&U_5-'\&^*O$EGI_A35/FWQC_P3;^&/CX?$
MA_%'Q=^.5]<_M#_!#PU^S[^V'>6D_P %]%G_ &R/A[X;&M:6I^-2:)\%-/M/
M"OBS5? OC+XB_"W4/&O[.%M\!/$UK\._'<NB^']1T.]^'?P4U7X7^V_M,?LF
M>!OVF/A?X$^%U]XN^(GP<M?A;\5/@W\9/AGXF^"&K>'/#6K^"_&_P(\6Z3XQ
M^'9@\->*_"?CCX5^+/"^FZCH]K#)X%^(OPZ\9>#5\K3]9L-#T_Q7X=\*>(=!
M /ESX<_\%'K+XZ>&?@9X=^&/PFU#5?C?\?\ Q/\ MA>#K+X?ZM\0)O"?@SPI
MI_[#OQ*U+X+?M#?$/4/B[:^#-3UAO!$/Q*E\$>&?A=<Z7\-T^(GBR]^*?@?5
M=:\ >!=$TSXC:O\ #[\V/^";/[5.MW7P"_X) >'?B;9?M'_%S]HGXV>$O^"C
M6K^ ?B1\1/VI?'MKX$N=8^$_B/XEWFL>%_VDDT_QUXYU#XS:T-&M/"OAWPCX
MA\8?#GXL:/\ "^--0\3^ -475[.VTG6?TDTC_@E1\./"EYX"\4>#?VE?VL?!
M_P 3/A/\?OVI?CK\,OBOHOBCX*7'C#PGIW[9WC2Z^)/[1?P+O-'U_P" NM?#
M7XB_!CQ]\1+L>-C%\7_ /Q#^*>A>(M.\.7F@_%338O"'A*#0_FKX#_\ !.?Q
M!\&_VC_V%? /PW\)?&#1/V9_^"=<7[;;VGQ7^/WQ"^%WCGQ!\>Y/VL_"OA!]
M)MO (^''B"'Q-I%IH/BKQ1\1[?6_^$^^'GP\N=*MO ]JEC9^(?\ A*]-\1R@
M'N?AK_@JC9ZW\./@%\5Y?@!XRO?"_P >O^"77Q?_ ."E^B>'/ WB6'QM\4X+
M/X*:3\!]>\3_  (TCP0?"N@Z=XJ\6^(K#]H#PG9> =?T_P 66G_"0>(-.UG2
M-1\,>'X?[+U/4?,/B#_P4P^,GBS2/V(O$O[.7@_]GOQ3\.OVGOV\O!G[+U]\
M6] _:%7XE_#WQQX5E_9[\0_M!:GK?P/\6>%/A9J'VC1;OQ#X%\?_  )\<ZU\
M1/"'A+QSX'\6_#_Q7HFG_#"2;Q+HGQ(\#^M^ ?\ @D=\,?ASI/PQTKPY^U-^
MVM;-\$?V6_CY^QK\%M6T_P"+'P_\+:S\+/@%\==$^&VC6GA[PE>^!/@_X3 \
M4?!:7X4^$->^#_Q)UJ+6/B-%XBTS2=3^)_BGXGGPAX B\(];XA_X)9?!?6]1
MLO%>F_%#XT^#/B=;_MF>%_V[;[XI>#8_@3I6OZ[\=?"_P5UW]G];G6/!MW\"
MM2^#4FC^(OAMXDUFR\77EE\+K'QQXBUVZB\4WWC1O$-AI^HVP!X_H'_!6O4_
M$>O?#>WL?V0/BO9>&/B7^VK^T5_P3\TO5=8^(OPGB\1Z?^TK\"4^+5Q9Z;J'
MAK1]<UO27^'WB:W^!WQ&CUWQW8>,+R+P=?Z=IL&GZ1XUL=2?4[/OO!G_  4X
MC^(/PKT>?PU\"O$;_M0ZGXQ_:R^'TO[-KZSXJ\2V=KXH_8G^,6F_ GX^W_\
MPM+X5?"GXF2R^ =+^(_B7P+H'A?QM+\.K6+5[KXA>$;C7]*\*:3_ ,)+JGAS
M?\.?\$M_AAX:D^&DEM\=OVB[[_A5O[?WQ:_X*.:*FH7?P%9-5^-_QK3XG1^.
MO"VOFR^ -B\_PLN$^,_Q0&F:+I;Z3XPTS_A+)#!XZ)T+PM_87(WG_!(;X2_V
M?X<U#PW^TA^UEX ^+O@;]I#]I[]I;X>_M#>!?%7P3T+XM^!]>_;'\3WOC/\
M:)^&VGP-\!+SX5>(_A#\0?%5W!KESX5^(/PP\9:KIM]HWAQ])\262>'M(2T
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M:OAEXKT?Q1H=G:0+-KWP]\?Z!)XH\/O83/X2\2Q:KHEKJOB:RM+37M1\(_:
M_P""5/PF_:*\8?M/^,_%7QR_:+\,7?[5P_8[7QYI?@N^^!$&C^&8_P!AOXG7
MGQ@^!\7@5?%/P#\5:G:JOCW4M2U7Q>WBW5/&$OB&VO7TF.33M+@LK2T^G?@I
M^REX6^"'QQ_:J^/.B_$+XE>*_$W[7?C/X>>._B'X>\8R_#R3PGX:U[X9_"[P
MQ\'/#_\ P@4/A3X=>$_$EA93>!?!OAG3]3M?%/B;Q<)[S2AJ=J]E>W^J2WP!
M^$GQ/_;4_:Q^-?P/\+?$KQBQ^%>O_##_ (.'?@)^R=I'A7]F[XQ>+K2/Q?\
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MSPX+[1M2\%:UX8\0^%O#6M:76_9U_P""6WPC_9B\9_LZ^*_A]\9_VAM3TO\
M9>T3]K#PQ\,/ OC/6?A!KOAD^&/VQOB7X=^+?Q3T/Q/J\7P7T_XC:^FG>-?"
M'A>^\(:W/X]A\56L&C+;>)-?\4KJNOMJP!^<?P)_:^_:_P#B_P",/^"5'[2L
MWA/4/'_Q3_:G_P""87[9/Q@U[]G/X=?'37? 7[//C'Q9X?\ %?["OB[X=^(M
M;T;QG:V_A7X?ZSH%E\8?B!X.TK79_#?Q4\5:):ZUH?AZ_P#&OBK3CJ?BRS_=
M[]F/X]>&/VIOV<O@3^TKX+TK7-"\(_'SX2?#[XP>&]$\31V,7B+1M%^(?A;3
M/%6GZ5KD>F7FHZ:NK:=;:I'9W_\ 9]_>V1N89#:75Q 8Y6^,O@/_ ,$N_!G[
M/:_LO+X/_:@_:CUK_AD#]G3XP_LN_!;_ (2P?LO7HTWX8_&&W^&4%Y_;<6C?
MLP:#!K/B/P4WP6^$]QX.U:2*".YNO!<<_CZQ\<MXG\=+XK^P?V6?V>?#7[)G
M[.GP6_9G\%^*?&GC/P7\"/AWX<^%W@WQ#\0YO"MSXTN_"7A"QCTCPQ;>(+OP
M1X2\"^&;Z\T?0K:PT9-0LO"NFW5_;6$-YJ\FHZS/J&J7H![]1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110!X5\=?C[X3^ ]C\/DUW1?%OC+Q5\7?B9H'PA^%7PZ^'^F:?J
M_C;Q_P".M;TW7/$][INC6^M:QX>\/V.G>$_A]X0\<_$WQKXA\2>(M T+PUX
M\#^*-<O-1\RQM[2[_$O]E7]N#QCXE\*>%(_VH/C!^U=HWCCQ-_P6^_:+_9(^
M%&G^'O"?P'M]6U#3?AG-\1=+\$?L^_M)ZAX-\(7WPGT_X<:7X6\-ZKJ'BV_^
M%>J67BWQ;XM\(V&L^"O&GB/2O[>N=5_6+]L/]ECQ!^TIIOP9\0_#GXPZM\!/
MCE^S;\8;/XY? _XGVWA+2OB+X;L/%K> _'GPI\3^&?B/\-=6U3PZ/'?PY\=?
M#'XG>-_"7B;1=&\8^ /%<*:I;:GX9\=>'=0LO-G^(-#_ ."2?BC1'^'=R/VI
M6U>Z\(?\%6OB%_P51UF+6?@AI0TO4/%_Q$L?B/INI?!WPI:Z%\1]"U/PUX4M
MX/BEXEO4\3^*-;^(^O2:K#I$L=M:Z597&BWX!]2?"S_@H_\  ?XM?#&?XV^&
M]&^(MM\%M0L=!NOAO\5;W2_".I>$?C'>^+_B_<_ CP3X-\ 2>$O'/B?6+#XL
M>*?BE_8?@\_!+XEZ3\//C+X,\3>+/#_@_P")W@/P-XV;5_#6DFH_\%"O!WAK
MQ_\ #+X9_$#X _M+?#7Q9\4?VJ+/]D72H/&7A+X;KHVF?$+7/@9XA_:'\(>*
MIO%/AWXL^(?#/B_X9^+OAYX4\10V7BGX5:O\0[SPWXRT;4_!'Q"T3P9XFTZ]
MTVW^7-1_X(W^$O%GA_XOGQ?\<O$>B_%+XR?#7X3^'/&_Q?\ @3X#\/\ P+U7
MXD?&OX'?%[P;^T!\*_VP/CC\/M'UKQ)\)?B=^U%X.^,'@:RUJR^(ND>!_AX-
M:\)>)O&/@#QGIWBKP[<>$8O!?J?CG]@/]H+XF?"_X"3?$7]MO4_'G[5?[//[
M37@']J'P7\;_ !'\!/"-I\&YO$?@GP1X^^%=W\/;W]F/P5XT\&BW^'/B?X<_
M%7XD+J-SI7QEL/BFOQ \0:5XIG^)M[X4\(^&OAUIH!?\/?\ !5SX+>*KJZT'
MP_\ "#]H35?'VFZE^V3I^J_#"RT/X27/Q!A3]A;XN67P4^.%YH>C0?&:2T^(
M1_X32^C/A/0OA;J?CGQ=JNB[-4U3PYH27FFQ7_M_A#]N'X9_$3XC_$SX>^"?
M!7Q5\6V?PD^)/Q#^$7C3QWX8\/>'/$OAG2_B9\+/ \'CKQ?X,U/PWH'C+4_B
M[X<UDVLSZ3X1M_&?PQ\,K\2[^.SU?X;2>+/!7B+PGXLU[X'UG_@BW;^*OAW\
M0_A;XZ_:6O\ XA>%_'OQ\_:?_:)T/6/%?P%^%\'Q-^ OQ5_:+^.6M?&C2OC-
M^S-\5?!EWX.\;?!O]HGX0W6LSVOA'XH6&IZUX3U76+W6]1\0?">Z\)/X3^'G
M@[ZFL_\ @GTT'[5]C^V//\3](7XU>&K_ .-?_".^./#GPMA\#>,_&7@+XJZ1
MKNB^%OV?OVF-?\%>/- T[]I?]GCX-&Y\$^*?AKX2\9^&=*^(OAKQW\+/!6O^
M&OBWX;TV;Q7X>\2 '/\ [.W[=/PMU#]F7]E&]^%C?M/_ +6/CGXW?LQ>(OV@
MOA?X/\36GP8B_:F^)GP>^&O_  AFE^)_B/\ $2[O_$_P8^!&E>(Y?$?Q+^&_
MA86:^)_#$OB'Q'XTTY= T6ZT[1/&FI^&^0US_@M1^R-_PCWC[QE\+/#_ ,<?
MV@O!/PT_9/\ "W[;WB_QI\(_ &BP^&--_9LUOQ#\0?#?BCQH=5^*GC3X81MX
MA^%-]\+?'<'Q-^%I5/BQH^L^$_%?@G0_!'B3XC>#/&O@WPW7^ '_  2[\4_L
MT> ?V*7^%O[0N@6O[0/[&'[-?CK]D:P^)^O? A=7^&OQE^!7C?5/!/B)O#WQ
M*^$D7Q>L/&=GK7ASQ?\ ##X?^,?#>O>!_CQX5^S:W:>*;6^T^^\.>+;C0-.\
MPD_X(MZ=X9\(_M(?#3X2_'BR\&_#KX]_\$UY_P#@G5:VGBCX/3^-?&/AZWUW
MQM\>_B%X]^/?B'Q+I/Q=\!:!XN\=^/?%W[2_Q;\1ZKX;T;P-\/\ PIIVMWWA
MQ]&M['1=$O="UP ^^/!G[=?PC^)7Q]U[]G[X9Z#\0/B%K/@G5_AMX>^)OC/P
MOI?AB7PG\)];^+OP+UK]HSX=1_$K0M3\8:9\7?"_AKQ9\,=/T630OB7/\+9O
MA1K/C;QAH_PNTCQU?_$K0?B'X4\$8_QS^._@7P%^V1^Q[\(]<\=?M#:)XR^*
M'A#]J#Q/X7^'OP[\)Z#JOP1^)6D_#?P1X7U?Q1/\8M2U'PCJWC*\\2^![:>T
MO?A-X:^$_B+3M=O->UV^D\5Z)K6BW>F_9O*;?_@G"=8^-WP/^.OQ"^*/AO7_
M !W\ M6^'-_\/O'W@KX-VOPQ^,WA[PIX)^#.@_#7Q#\ -,^+ND?$+5=6U7]E
MGXE^,4^(?Q7\8_!;XF:/\3)6\0_%37[73?&=G<:#X-UO0/8?CC^R5XJ^+7[6
MW[(O[4^A_%+0O![_ +)WAO\ :*T33? NK_#2_P#%Z^-;S]H3PEX;\*:CJ-]X
MFL_B?X0;1;;PU'X3TB\LM/AT'4IM1DDU.&XU*V6ZM9=/ /*/V:?^"K/[/_[4
M?BO]F7PYX+\ _'OPCI'[87PH^+WQ5_9W\=_$OP'X?\.>%O'\?P%\2Z3X?^+'
M@IM/T[QOKWCWPOXM\,66OZ%XLMK[QCX*\/\ P\\5>'-4CC\&>/?$7B6QU?PY
MIV?\<OC3X_\ AW_P4;\+>$;[XF?$Z/X#7W_!+S]L7XS^)OA1X,\,>%O$+V/Q
M ^"_QW_92TG2/B9X%L=+\!W_ ,2-?^)3^#_BKXJ\/6GA[4O$7BGPI<?9-"7P
MWX'TG6;SQ/?^*/*_V8/^"3_BG]G#4O\ @FU/_P -':%XRT[_ ()W?#O]J#X<
M6%H?@7?>';SXL:5^TY?>';K5K^\U!?CCKL/@O4O"D/A;2(+!H-+\3VFI2MJM
MQ<6MJEW96^G?6'QF_9%\;_$O]JC0OVD_#WQ;\*>%;70?V.?VB/V3[?P/K7PD
MUCQ=//-\?_%GPK\:W'C^Y\56/QA\&1F#PMKWP9\$K!X0@\+PRZOI%QXLLI/%
MNG7NKZ+JGAD ^;_#/_!4C]G_ .&W[-GP2\2VEG^TW\=(+3_@G)\+?V_O'VK:
MUIWP=NOC=X-_9,U+PSH*Q?';]H2.3QU\-O!6L^/M9L;3QMXG\6^%O@;#XOU?
M6M8^'GQ(A\#^"[F5O!6A^)_$-0_X*87'P'_:=_;;^*/Q//[17Q2_9,\,?LJ_
M\$YOVBM+\.>$/"/P>\2Z-^RA\-_C%>_M::5\7_BYJ=_X8U'PG<>)/  LO 'P
MZ\:^*]%T?QK^T#\<]6:[U[4?A3X5\3?#WPAJNB?#_P":OBY^RK\1/@/K?[)7
M[.7B+6==\8^"_P!GS_@GG\-/V.O"_P 2Y?\ @EE^UQ^UQ\)/C[H::ROA/XG>
M O&VE_L2_M/^%?$WP]\.>)?!_P ,_@;'\9_A5^V#XG\6?LV?%>&>WU7P=H5A
M9:#\2H9/K7Q#_P $Z/VE_P!JWX._M=:W^T!\4_A=\#?BS_P41_8._9I_9D^+
MWP]\&_!K5/&ND_ 7Q3\);3XL7GB/7=!UJ']HYM+\63:M/\>OB/9CPC9:K>Z%
MX+O[7PA8:=\3?BOI/A35/%/Q+ /LS]G7]L;QC\<?VR/V[/V:-0^"VK^ O"G[
M'FM?!;PEIGCS4M>\'ZS+X]USXD_#FU^*%WKE]::'XOOM0\/Z9KGA_P 5>&G\
M#:"OAZ\FL]'T#6];\;^)="\2^)K/X;>$;?Q _P""BOP%^'/B6\M=9L/'U]\+
MO#/[0_AC]E+XH_M%Z'H_A[4?@;\&/CYXSMO#</AGP1\3=9?Q9:^-]/TV\\6^
M.OAU\,M8^(WAWP#XE^%?@?XG>.]+\&?$#QOX5U+P_P"/AX/L? S]D+QE\&_V
MLOVJ?VE[CXQ:3XDTK]K:R^!FM>/OAQ:?"YM DT;XG_!CX1:#\&#KWAOQG=?$
M3Q))#\/?$7AO0+76(?A]?>&KSQ-HGB5Y;B;XJ:YHI_L-_)_$7_!,GPGK.I_&
M'P9:?$&6R_9A_:&_:T^&_P"VQ\8?@5J'@Y-:UJZ^./@#QK\._BIJMI\/OB?)
MXKLHO!WPP^*7Q;^#GPT^(/Q+\&:[\/\ QUJUY>W?Q:TWPCXO\'67Q%T4?#X
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MV7B?Q!XD\<>"O%'@SQ7X1N-!\ 0>,D\4>(=$DA^'U[XQT_4M#U'5?ASXE_\
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MUEXY^(OQKO?@YX&^*'@+XU:C^W-\4O#7QJ_:0TKQ7\#-;UG0K;2="'Q'\$>
M[[X*Q:-\0HM:^&?A[P/X;\/>)M=^*#)K.I:SW6F_\$Q-.U+Q1_P4!_X6O\;?
M$OQ/^&__  4!_9L^$/[,WC[29?#$/AWXK:'X9^%?PH\??".;Q?=?%6+Q1JN@
M^)O'7C+2/B/XBUW6[VW^%7A;1+7Q$--FTW18-*MKC2;P ]^U3]N+P#X,B^)A
M^,?P[^*OP#F^'=K\*KK3#\8H/AGX<T/XI-\:M2\1^'?AWIWPW\>:5\4-?^&C
MZ_J?BWPEX@\,Z_X7\=^-? OB7X?-96_BWXBZ3X5^'.L:)XUU+YKTG_@H]^SW
M\?I?V4M7\%:_^TGX1U7QI^V[\2/V:CX/\%Z%\/+K2[KXV?"3X*?&'Q/XD^#G
MQ]\9PZAX[^&&I_"_7/"5BWQ-\%Z[\'/B9JH\=ZOH_P /_$7A#QKJ'A/2_'%O
M;IKO_!.3X]_$K]GFX^&OQO\ ^"A'QA^('QX\&^.OA9\2?V<?VE?#OPM^&/PX
MN_@5XW^!>NW>M?#;Q9=?"325U3P3\7/$'B6#4=1\-?'Z/X@W%UX2^+?A*^O-
M"T7PA\-8I8YH>XU7]B#X\^,8?V--9^*'[6]I\3?B/^S1^U9-^U5\0_&FO_ Q
M=-TWXJZT?@K\3?@!8^ _A]X'\-?%W1-"^ O@O2? 'Q3UR[MK:VE^)=Q>^-+.
MS\8ZTVJZEJGBV+Q* =S\)_\ @H#X'^+OA?PCXDT/X/\ QET-M8_:9^-?[*/C
MG0O%%_\  *TUGX(?$7]GO_A8W_"T=8^+DVD?'?6_#]EX*T6/X6^)KJSU;P/K
MGCO5M9TR?P]K6E:!<Z+XET74+SS#0_\ @L#^Q7K.L?%73;[QEJN@Z5\-?@7I
MG[2>F^*S%X6\<:%\5O@SK'BZQ\!Z?KOPSMOA)XN^(WB9_&=[XQ\0^ _#&G?!
M'Q_X<\ ?'K5]?^)G@#1]'^%^HZCKDMK8^U^&_P!A;X8Z)^T#^U?\;;W5O$>M
MZ)^UMX1T#1/&?PFNK^\T[P;X<\377@;1_A9\8_&WAQM#U#39HM:^./PV^&WP
M \->*KF:W_M?19_@U:ZMX=UVSG\8^(H'^.M%_P""2OCGQ'^RS\0/V-/VCOVZ
MOC;\??@=!\/O!/PN_9K:+P7X$^%/Q'^!WA[X5>-O!'Q"^$?C#QQXQ\%EM*_:
M"^,/PU\2_"KX5_V!\0?%/A'PO9ZAIGAGQ#9^)?">M7'Q%\;7^K '8?L7?M$_
M&_XM?\%&O^"DGPT^)5I\:/ _@+X5?";]@#Q)\-?@A\9;'X'I/\*]4^*VD_M1
MR?$"7PAKGP,U3Q=H?BG0?&DO@;PMJM[J^O?$GXB:]:^(++5?#XUK2M+T73_"
M^A_KE7Y[?LK_ +&?Q1^"W[0?QN_:@^,_[1\'QO\ BO\ M!?"']GKX5_$*S\)
M_!G0O@O\-C<?LZ/\3H_#/C/1/#+^,_BAXKT[5]<L_B=K4NM:9+\0;W15UK4-
M=O;.U@T6?PGX:\$?H30 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?/WQZ_:E^!/[,<G
MPGA^-_C>7P9-\<_BGHGP3^%$,7A/QKXJF\9?%7Q+IVK:IX=\$V,/@OPYXBEL
M]7UVUT344T?^UDT^TU*_BATFSN9M5O+*RN.(\!?MR_LV_%+X17/QK^'/BCQO
MXR\)V/C+XC?#G5/#>B?!#XY3_&C1?B%\(M8UG0OB9X"U_P#9TF^'$'[0'A_Q
MOX,U'0=0CUGPEK7PSL/$*0MI=U;Z;<6NOZ!-J?G_ .W+^S+\2OVDM<_8KU'X
M>ZEX&TJV_9H_;2^&/[4OB[_A,=8\0:9<>(="^'OA'XB>$I/"'AU-#\*^(D_M
M35D^(MUJ2ZCJ<UG9V1T**P:WNEUJ2^T;\S+_ /X)(_M-62:O\4?!WC?]D^Z^
M.?A[]N;]M[]IWP3X"^.?P_\ %7QY_9E^(?PF_;IU_1]:\:?"7XLZ VD_#KQO
MX;\:?#75/#7@GQ7X"^)_@/4;QI]=\%R:5JWAR/PSXUUFSTL _4S4O^"D'[%.
MF_"_0/C6OQVT+6?A)KWP[^'?Q=F^(?A/0/&GC/PQX.^%/Q7\57_@CP#\2OBE
M?^$_#>L_\*A\"ZYXKT3Q7HTWBKXHQ^$-%T&7P!\3KKQ)>:/I_P +_B%=^&?5
MO$G[5OP(\&_$;PI\+_%OC*\\,Z_XZUCQ5X9\'Z[KG@WQSIGPN\1>,/!&@:EX
MJ\5>!=-^--UX;C^#\GC_ $?PYH7BC6'\"/XYC\6WUGX)^(;:7H]])\./'L?A
MO\_/"'[!_P"V1\%/CS-\0OV?_P!IG]GWP;\-?CU\+/A#X)_:J\!:E^S;KR:5
MX \9_"*S\?V__"POV'_ GASXLZ1\./AG!XPT/QOI_P /K#PE\8=&^*R^#M+\
M">"/&OC_ ,1_M":IINL>%_$&7\*?^"=/QZ^#'[2?Q9\3^%?'G[).O_L_>./B
M_P#'[]I[P5XD\<_LL:;JW[:GPW^+/Q]\8>+?B-X@^$.C?&B'6D\$W/P1M?B1
MX\\8>)K;QIK?@37OBQ:>!?$FL?!O3FLXSH'Q'\- 'V9H/_!0G]E#Q+X<T3Q1
MI'COQ9+IWBNQ^!FI^![2[^"OQQTG7_B)I_[2LGBL?!"]^&WAC5OAS8^(OB':
M^.;3P+XSUD3>#=,UM/"_ASPKXB\2>-CX:T+1-4U"T\G^)G[>'PD\/_$+X2^)
M-!^,_CRXT*^_9\_:[^+9_9CT/]F3XAW_ ,2/CY:? S7/ /A[7]2T;Q1XOT#P
MJ_PH\7? [Q':>(/"NH_#GQA+X<NO%^H?$>TO_$$FB:+X/.K'Y9\.?\$H_%.B
M_"'QO\%KW_A16N? SQGJOPEU+5_V2KJ]^-T'[.NE>)?AY;_&_7/B1\3_ -EV
M\D\37OCW]@+5_CE\0?'GPG\6>"OA]\![KQ5X9_9%UKX0?\)5X!\2_%C5?&&M
M63=D/^"=O[1%UXZ_9#O/%_Q[L?BOHW[/?[.7[?GP!\1?$OXHZ_XH\1?&;5-$
M_;(\0>!;CX;V]W</X:V?%2__ &=O 7PK\"_#C5_B)XT\8>&O&G[0%P-2^(_B
MR/P=XG:]L_$ !]0_LH_\%#?@[^TSX>_9-LY-.\>> _C!^UG^R)X7_;"\(_#G
M7?A;\7X?#4/@&]T?P+/XZM]&^,VJ_#S1?A1XHN?A]XA^(GA'1-5L--\4)XCN
M-.\5^"?%T?A]?"WCCPOJVI[W[07[:GAKX;_\$^_C7^W=\,M \2>-O#_@;]F3
MXH?M!_#S0?%/P_\ B?X'O_%J^#OAWXB\:^%;;Q/X4U_PAI7Q$\%>'?$5QH]D
M-1UOQ!X7TJ/1O#NH#Q)>M;:0!?5^;<?[+&J:;\"O^"<?[!7B#XNV/A7]OK]B
M_P #? 2^^&WQ*^ G@KQM!+I?[+WAOP[9_L>_M(>(;#XG^-/#=OI=HGC_ . 4
MGCN76;2QU;P]J'P_^-&M_ +48] U?6_#_P ,=>\:?J+^V9\ ->^-O[$?[1W[
M*'P>LO GA.\^-'[.7Q-_9T\*MK<]]X6\#_#[0OB7\.-<^%\&K6FG^%?"WB&5
MK'P/H^LC4-'\(Z=I6FV>K#3+?P^NL>'+:Z75+0 ^;OAS^U_!\#? OB+XL?M6
M_M&ZWX\\%^+_ (.^'OVC-#\':;^R#\5M+^+/P$\$>&= M-)^.^N^-]'^%OAO
MQ!K=U\!8O%[6>N?"W7/&/PNT+Q+H.C?\)F-7^*7QFT.UL]<\)^[W/_!13]D)
M?C+X?^ 6D?$S7O&_Q0\4:!\%/&.AZ5\+?@]\;OBYX<N_A]^T1JE_HOP@^*<O
MQ$^%_P ./%WPXL/A!XIU73WL+SXO:CXMM/AGX1N;W1(_&OBKPXWB'0?[2\6A
M_9+_ &A/"'Q3\*_M'_"WQ-\(M,^+.K?L9>$_V,_BY\-O'EQXL\4_"B:P^%WB
MKQKXP^"_Q@\'>,=#\,>$/'=YJO@37OB/\1T\:_"^_P!"\-Z=\6="\9:9I-G\
M0/A?J?@&S\4>*D_8^_83\2_LC_'73M0\/:OH&N? ;P+_ ,$\OV.?V%O %QJ7
MB75;OXL:J?V2-?\ C+K=MX\\9Z'!X$TCP=;3^.%^.&KV-Y9Z)XFECT:;P;::
MI:6L\'C:70O P!]3_M"?MC_L[?LM#'QL\=7_ (<GB^&WC[XRZC8Z#X$^(GQ&
MU30O@_\ "O4O!FD?$OXK>)-)^&OA3Q=J?ASX<^ ;[X@^#U\7>,];M+'P_H-K
MK!U/4;^#2]-U>]T_@?\ @HI\;_B?^SE^PI^U+^TK\$M4\%VWC[X#? WXA?&S
MPS'X[\*ZCXY\%^)!\./"VI>,)?#FKZ1H/C+P-J9L/%-II;:5%K6F^)[6XT22
M\BUA+/5H[5]*OOG;_@H[^PO^T+^VG;>.O 7A/XW?#C0O@7\2_P!C?]HG]GO6
M/A7\3?!'BCQ+HWA?XS?%.#38?!'[1&D6?ACQ-H6F^+O$OA;3K:Y\/:';^-[:
M\3X3WCQ?$+X?"ZU^]US1M6]J_;$^ 'QP_:5_X)\_&K]EG2=2^$^G?%SX\? 3
MQ/\ !+Q#XGU"Y\9Z)\-/";?$+PC?>$_$7B'0K6VTGQ;XJUU/#5IJ,LF@Z;J(
MT<^)+FVBFU*]\.1W#V,0!^;?QV_X*3_M#?#CXL_&3X9^#_B[^SMX_P#AO\&_
MB=_P2ZUCQ)^T-X1^&MU=^'?"_@K]K3]K_P )?L[_ !O_ &<?B=XD/QDUOX?>
M$_C98^$?$6C_ !T\%^,;2UO4TWX+:[=Z;KGPZL=:G\-?%EOU0T;_ (*"?LG:
MWX3O_%L/Q%UW1H=-^/NC_LLW'A+QK\)?C+\.OBJ?VA?$6BZ)XF\._":#X,_$
M'X?^&/BU<^*O$'A+Q%HOC31(H/!<ECJG@:]'CBSOI?"5O=ZU!R?[5WP%^,OQ
M^_9I^&OPX\,Z)\(/"WQ)T+X^?LD?&WQ7I[^-O%FF?#NS?]FO]HGX8_M%:OHO
MA;Q%IWPGU+7]1?QCJ7PJLO!&GWNI^"="_L&S\4W7BVYCU>?PQ%X6\3_/NN_L
M7_M77/C;]I/7O"'Q&^#G@_PQ\>?^"AWP=_:F\3^$=2O?B)XKTOXL_L\>#?V=
M/A/^S9XR^ WQ'FT'1_AIK_A*?4I/@MX*^.OE>&?$WBCP;\1[J&__ &7OBWI6
MO_ _7_B!JGQ" /IK3_\ @H]^QQK7@OP=\0?#OQ6U+Q7X5\;?##QE\9["[\'_
M  K^,/BW4_#_ ,,OAYXMM? /CKQ5\2/#'ASP!J?BGX31>$?'4]YX-\0Z3\3]
M%\(Z_I/B3PUX\TJ]TF&Y^''Q 7PSZMXL_:Q^ W@7XI^ /@YXP\8W_AWQC\4_
M&-[\-_A]?:GX)\>0?#SQ/\3;#PWJ'B]_AA9_%\>&6^$UO\3+WPWI&KZIHGP_
MU'QK9>+O$2:-K=IX?T?4]0T+6;2P_&#X:_\ !&[X[>!/V??A-\&$^-/P;T/X
M@_L]GX^V_P"S3^U#\&/#'Q0^"GQG_9W\1?&#XZ_%SXHZ=\2- .B>,=;TWXH_
M#>?1/%_@S0_BQ^P]\1[N?X+?%.#2K31[_P")&EQ^"8O$'C[ZC^$?_!.SXP?!
MS]L7XB^/=(\7_LK>+?V8/B)\>?'G[5=KJ/C?]FBSUG]N#X:?$OXCZR?%WBSX
M/_#[XYOKA\"1_!N_^(D^N>,;#QCXB\ :Q\5/#?A'QOXN^$WAF?2[FU\%?%;P
M> ?1'[5?QJ^.GPX_:7_X)\?#/X7^*?A]HW@7]I_X\?$7X3_%.S\7_#?5_%_B
M.WT7P%^S7\:_VCXM5\"^(=-^)'@^Q\.:OJ8^"TO@:Z77?#7C*QB@\5KXCM[>
M*Y\/?V7KWYM?&/\ X*&_MJ_#3]D7_@KS\>M.\7? +4?&/[ /[7LOP,^#UE?_
M  +\7GPWXE\":3X/_9\\=7TOQ+TRU^/=MJ>M>+-3T[]H5/#\>M^%M?\ !>DV
M.H>!K3Q(OAB>UU^^\+6?Z:?M/_ ;XV?%/]HW]A/XJ_#H?"M?!W[*?QG\>_%O
MQG:>-?%/B[1?$_BE/'_[/WQ@_9SN-#\,6V@^ O$VDVIT/P_\9=6\;0W^K:BO
M]M:UX>TSPHUKHECJ5SXFL_SN^+W_  34_:Z^)_[*'_!4O]GRWUW]FW0?$G_!
M0S]JQOC[X9\4S^-/BEK.A?##PQJOA'X&>"]4\-Z]HD?PHTO4?%.O:7I?[/7A
MZYL=1T_5-%TW6M0\?ZT\]IX?M/ UC:>.0#]PM=\8Z-\*O !\5?%;QAI5I9>'
M-)T>+Q/XNEL6T>PU/6KA[#1HCI>@0W.K7JZEXJ\1WEMIWACPCI<^MZQJ>L:K
MIGAK15U?5;JSANOS=^-/[>\^I?&3]COPC^SQXSL8=%\2?\%"E_8T_:N\!?$3
MX-_$+P;\4O#M[JG['OQ?_:<\-V-A:_$F'P5J?A2TO-'\(^"_$-IKL?@;Q+I?
MC_PUXQTC4_!WC'3;'3-2BUWZ;_:\_9W\>?M:_LL:S\)--^(%I\ _B]>:Y\"?
MBKX4\?>'[%OBAH/PY^-'P"^,GPU_:$\$7-O::Q9^ ;OQWX/L/B3\,M%T[4?M
M-CX+U37_  S)=SQ6WAS4KF)+3YD\4_LP?MQ?%VZ_8>\9_'SXC_LS^+/B#^SU
M^V)IO[37Q#L?A;X<^(WPH^'&E^%=,^ /QA^ ]O\ #WX8Z;XD/QC\9^,->G'Q
MOU_Q]JOC7QSXP\+V%[<^%]&\'Z3X/\.V6N7OB/1 #I? ?_!1;]FCPMK'CS2O
MB%^U5>_$W4/$O[;/QK_9?^&VDZ1^S5\7= N_"?Q5^&7P[TKQ_K'[+6DIX;\#
M:U-\3_%7AK0+#5]5\+^/H$$/Q?U;7(?!G@-_$7B>RL]&G[>;]MCX)_%;5?V,
M-5^%'[1>H>#-)^.G[1/Q<^&^E^#->_9Z^)H\1_&O7O@K\-OCII?Q1_9X\56/
MCCPEX8\4?LP^.?A[XY\(2>/-=U+XE:+X6\0FX^#NK?#R/2I1XMN9K?X^\ _\
M$Z_VC_"7Q>T7QS>ZU\$[KP_#_P %@?BS_P %*M26U\;^/H]9MO WQ,_9A\<?
MLR1_#&RLYOA+]AU#Q3HUC\0=2\>R:O<:II6CZE/H%GX-6*RBUVX\7Z%UWP\_
M87_:/\-2_LR2:W+\$A_PI[_@J1^V%^W[XQ32?B1X^OOM7@_]J:/]K2&S\!>&
MUN_@GIAU'Q+X)_X;'\3F?4=4_L/2]?\ ^%2:&L+:1_PM;4#\*@#[4O\ ]OS]
MDK2=9U?1];^+46@P:3\'?B]^T#%XMU_P=X_T3X:^)/@S\ KO0[/XS_$'P)\5
M=3\*VOPV^(6B_#AO$N@7GB5/ _BK7]1MM%U>P\10V-QX>NH=4?Y)_:>_X*'V
MEWX4^'%[^R7\2-(A\1>&/^"D_P"P!^RC^TIX5^(WP;^(&B>.]$\#?M-_%3X*
M?VMH6D>'/B2GP[U/PE>>-_A7\7/#7B3PM\4IO"7CSPSJ?AV_U[2/"L-KXP@?
MQ1X%YWX _L1?\%#/@9^RIXQ_8]TC]M[X3Z?X$^%OP U_X"?L3?%;PY^SYJ\?
MQU\,6EOX:B\/?"7QA\?=7\1?$G7O &M7OP=T2.W\(Z7HOPS\!^&$\5)H^B^-
M-3UJTFBNO!=QX"?^"4?[3.E^)?BCXHT?QM^SK=I\6?VRO^":7[:>L^&DNOC/
MHK:3XT_8GL?@])\2/"T_C[Q/'\6O%?CR;XE:K\$K&Z/Q0\907'CGQAXB^)GB
MCXC^.Q'K7ATZ%X_ /U+_ &M_VS?"O[)NJ_LP>'->\%^/O%VL_M2_M(^"_P!G
M7PC/X3\+:SKNB^'=5UW1_$GC37=;\57>C6>HZA$MEX%\#^+KSP]HFB:7K>N^
M(-?MK"W?3K#PO!XG\4^'/EKXU?\ !5G]D'6_@S^T;J'PS_:N\5?!Z]^!E_XG
M\)^/_C\_['/[1WQ2\ _"+QY\./C+X&^$?CWP7>QWOPIL/ WC3XBZ;XL\9^'M
M#N/AEI?B2\\:Q^&?%EA\4[#0[KP#;?\ "2U[]^W;^RS\2/VEX_V0/$'PH\7>
M!O"OC#]E;]LSX;?M10V_Q$TKQ!J7AKQ9I7AGX<?%[X6ZWX:E;PQ>6NJV&I1Z
M7\7KKQ/I$JF6UU+4O#=OX<O9M(M=<E\0Z/\ #'C3_@F9^T-XQ_X)Z_MY_L?_
M /"5_!O3/&_[7O[7/[0/[0WAKQ1_PD_CF_\ "O@SPS\>OVCX_P!H&70=8!^&
M]CJ^H:UX3+3^$T&GV$>G^(F"Z^]WH1G;18@#]*_&7[<7[+/P]^,%M\!O%WQ:
MT_3?B?/X]^%/PNO=(B\/^,=5T7PQ\2/COIGB#5_@KX#\<^.-'\.ZAX'\ >*?
MBI8^&;]/ FC^-?$6@WGB34;[PKHVG)-K7COP-8^(_.O^"=WQR^+OQ\^$GQ@U
M_P"->M>%M?\ &?P[_;-_;4^ ":IX,\*3>"?#MWX9_9^_:4^(OP@\)3Z?X;NM
M?\5W^G>?H/A"SN;B/4_%'B'4?M$\@NM9U"1?M+_(?[5__!//]K']IKXXZ7\5
MKKXW_ N/P]\/OVG?V"?VFO@5X7\;^ OB'XIU/X,P?LWZU:ZA\;_@KX;U/2?%
M_A3PPVB?$'Q FK?%*#XS6/@;1OBK\3;K7;'X'?%$V7PX^%_P:U_X?>F_ ?X0
M_MB?LIZ!H_@?PSI?P)\42?&G_@HM^TO\?_BY"+GXP^)XM(_9_P#VEOC+XZ^-
M/B+3/"'BZR\#^"_#?A#XF?#&Y^()%IJGQ'2;PM\1-,\!7&A^'=+@\7_$;3+'
MP0 ?3WQ6_; T'X=?M9_LZ_L?1^#?'%YXT_:)\$?&GQ]I'CR'P?K^K_#[PUHO
MP:B\#:?J=OJ%YI$#SW^IW'B/XH>"%O-LNF^'-!T.74+GQ)XKT#4;OP[9:O\
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M'O"TMSXXO?#EOX'B\3:EJG@[Q,C> SXC/CJPL=)EU?4O#EGH]Q9W]S\"> _
M=A^QSX6_X**?%G]LS5?A9?\ P+_:-_:.MOC7XBO=%T?QSX^T.V\'>-O@C\ /
MV4]9\-_$GX=W'P^U-K+PQJC_  HTKQ1KQ2^\<>'/#WAWQ]KVC^+]5_X1GX>:
MCX_\4>H_\$Z/V:M5_9E_9ZT?P;XB\3^+_&FH6M[J?A3P%K/Q%TZWL?'7AO\
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M8_[87B_X[Z-\>]?_ &AOV>O'7COPSI7_  4A^&FE>)/BM\'_ !MX_.M_!_\
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MS1+'QY>V'Q5\,^#KC6=?U>+P!JEU:>)M(C^(FH^"['2/$WB$ _2#P/\ M&>
M;?X3?L]^+/C+\8OV;O#WBSXY^%OAE_PCE]X(^,>B:K\)OB?X_P#B!;>$].LM
M._9Y\8^*CX9U/XK>%O%/B_QAH.D?#+4;+18-:\8V_B7PF(='BU/7[*PD\V^!
M?[5_B;XM_MA_MO?LOZU\/-!\+:9^R1;_ +-4^A>,-*\9:CXEU#XB6OQ^\$>,
M_&TNHZUHM[X0\,6W@JXT&/P_9:1'H6GZGXTBG;[3JC^)3]L72=*_G_\ C/\
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MRN:\%_M*_LY_$CQE:_#KX=_'[X*>/?B#?>#M<^(EEX$\%_%3P+XI\97GP_\
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M2$^'+^ M/\;W]QX^@\>Z3X?^'7BX _7/X8_M*?!CXE>%?%.M:7\6OA/>ZO\
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MXQT>[N/$_P .-1^#6L^&_P!G_7?#I\=^#-:\%>+_  ?:_&"2PT[P[XN\->(
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M^.7@"S\:?LHVGP\?XY76N^*?#OA[PUX0U;XD7]YINF^&VUS6M6LH;W6= O\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
<@ HHHH **** "BBB@ HHHH **** "BBB@#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>ex10-9_004.jpg
<TEXT>
begin 644 ex10-9_004.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" /+ NX# 2(  A$! Q$!_\0
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M^UWK?Q]M_@GX%_;,_:+^#WBOX=66I?L0_LF?LJ>'/B)\*OV\/A!\"OAY\9O
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MC[4/@!X]^&OP,\1_#;XV_$/XU>.]'^,'Q$BM;+_A:4'Q5\3_ +.WPFTOX?\
M@;X;IIFE^(=+\"R?!WXC:O\ %KQ;:Z#=Z_K'PMT[P/%9>-?G']NG_@FGXO\
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M=ZCK1;6M1N?%6OV%_K<VHZR6U>_DO6N]39KZ:<U[A10 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%9VI:QI.C16T^L:II^E0WFH:=I%I-
MJ5[;6,5UJNL7L&FZ1IEO)=2Q)-J.J:C<V]AIME&S7-]>3PVMK%+/(D; &C11
M10 445Q'@WXE_#OXBW7C:Q\ ^.?"7C6\^&OC.[^'/Q"MO"OB'2M?E\$?$#3]
M$T'Q)J'@GQ4NE75T="\56&@^*/#NK7V@ZC]GU.SL=;TV>YMHDNX2P!V]%%%
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M/FU;Q+XP\9:]I?ACPMX>TNWQY^I:YX@UNZL=)TG3X-R^=>7]W;V\>X;Y%R*
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M+S5OV.OV/O@!X_\ #WQ:\5^++#0?@Y-X]7X=^(?VEO@[$/V?H_"GB>U^(_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *_+O0_@U\=O"
MR_MM_#'2OA7K=YK?[7_Q_P#%7Q!O?VB;CXI>#H_AYIO@'XA> ?A=\$8=6.EW
M-_=_%C0/B1\%_@%\-](\->%/AUI?PFU?P'XR\9>!_!UO=_%/POH?C?Q3XL\!
M_J)10!^4/@N[_:7^&'QK_;8^,R?L1?&#QKK'Q*^(OP4^&7P%M]"\>_LF:/:#
M]F3X-?#3P;H6C3:W#JW[3&BQ6(TSXV_$3]JKXG:1I4\%MXGU;P%XA\+:)J;:
M)K<EOX>\.?-?[-W[*?[0WP.US]AC]H'XB?LW>/OBY\0X_A/^UKXR_:K^%ME\
M8?AQK:? G]NK]I?X@>&_C9XP^.'P!\ ?$;X]V?P"\.:/XW\1>)OVIOA9>^)?
MAOXK3QUI/@?XL>#M&TNP\->%/%?QRM+O]\J* /S _8!_8TO_ (:_#3]G;XP?
M'+2?B%X7_:IM/AS\8O$/QR\ ZG\4KKQC\*=._:-_:M^(>B_&G]I?QUX1\"V/
MC7X@?#/POJ=W\6(?&X\ Z_\ #._T,V_P^^)'C#1]8LS+XEO-,TGB_CC^Q;\6
MOC%\=/VVOV@='T#X4Z3\2(/V:?A3\'/V#+SXE>'/!>O>&-/_ &@?A%8_$KXX
M^ /VFO'UQ#X?\=>(Y+'X?_M"?$[P-HW@>SUJQCOO"&I?!;Q#XTTGX;7T][X)
M\7ZW^N=!&00>A&#VZ^XY'X4 ?S7?#_\ 9LT+XB>//A#IM]^S7H/C+XC:5^T/
M\;_VOOVG?A+XW\8_ ?XDSZ5XA^!?[+UM\'/A'\$?BG=>"=7^*'PQ^&/Q>\??
M%SXS_";XF>%;'Q9\4?C/\2?'WA+X5/\ &;XT?M#>*_&^@:CX9TS]D_VA?AGX
ML_:D_8U\2_"WQ5X#B\%^,OCA\.O"7A_QCX&U>;X;_$6'X8:OXSN/#P\71:E<
M^(M,U[X?^-T^%,EYJFI7-WI-E+-XA_X1A[GX?WNF^(KKPYJEG]4V6A:+IM_J
MVJZ?I.FV.J:]-:7.NZE:6-K;7^MW%A90Z98W&KWD$27&ISV6FVUOI]G+>R3R
M6MC;PVD#1V\21C5H ^,?V0/V9;3]G+3OC+JQTVPM?$OQ6^+'C/Q/J]GHW@SX
M.^#8+GP_X8U_7/!7PCGMX_A3X*\"Z5+/J'P;T/P!/?VFJ^:++7Y=7OY(=)UK
M6?$HN?D[P=\'_P!JC5O@=\=O$.J?"C7_ (?_ !*_:5_;U\4?%C]H;X;ZIXI^
M#=YX^\;_ +)VBZSX1^$'@SP7\/M<\.>.O&GPAT7QCXZ_8]^#'P+^%_CF/5?%
MGA:_T^"7XN'PSXR\.?$1_!?Q=E_7^B@#\*OAO\)?VH_V3_V;]+_9>^#?[&_Q
M;U[X?_$GQ)\=?$)U'X/_ !Q_9N^&OCO]GCX0>)/%<VD_L\?L\:[\2]=^,'@7
MQA-X[\%_!J'PM\.?$WQQ^&TGQ8\1? ?P+X-\/^%?A!XP^._B3PMX6^(-O[Y\
M6_V:=>^,7Q;^"O@+1/V0_"/PB\ _L-?%3X._$+]G#]INP\?^ M)U&Z^'W@'P
M/HNJM\'/@=H'@[3=7^(OPVTOQ?XCTN7]G7XZ>"_'V@:#\.+[X!76H^(O".K^
M./$NIZ3X?\&_JS10!^3GP:_9L^,_BSXJ?'?]L/2_AEH7_!/;XY_M%? CX%?#
M/Q%X/5OA_P#&S6=0^('PT\:>.?$_BSXG_'K1OAOXCMOA)\4?$6FZ9XI_X5I\
M$O%^F>,Y?&=O\.+K6]7\?W=E<ZKX<^&'PTS/#EM^V/\ ##]H[]I#XW>*?V9O
MB9^TCKVD_LU_ 7X _ [6O!^O_LM_"30_BUK_ ,-KWXQ?$+XF^.+RQ\2_M)RZ
MA\.-$^*GQ!^)?A70X+77/#]]J/A#PY\.[6]L= O;N]U&/Q!^NU% 'Y#>-_A'
M^TY\0?CK^P_\<O%'P[^*FO6K_M.ZSXS^/'PIU34OV7H? ?[/GP2\,? ;]H/P
M/\)M,N-.C^(&H:]XH\16OQR\9_!#X^:ZO@3Q[\9+B/QQX3\0^)[34V'PW^!'
M@G0NR^.'[.'[2NNV'[/GB?XA^,3^UQ;? 7]LK0/VD[[X7> O O@GX$>(O%/A
M+PO\%OC3X-^&W@_23XD^+.E>!/$.J?#O]H'QS\)?CK>:EXT\<>%;2?1/AGJ:
MV&F:_P"([;0O"VO_ *CT4 ?B1\*/@W^TOX8N]*_9N^*O[*?Q$\;_  W^*/QN
M\0_M/?M+?&GPO\<_@[;_  7\:?%7X\_%S7/C?XY^$VM)KWQ6L/VC-=_9G_9M
MT;5M!^#GAKPS8_ VPN/VK/\ A7?A/P'\2O"?PU_9WO/B+IWQ2_;55V@\DY)/
M( Z^F /KSDY)YQ@!U% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 445A^)O$%EX4\/:UXFU*WUJ[T[0-,O=7OK;PWX:\1^,O$$]II]O
M)=3Q:+X2\'Z3KOBOQ+JCQQLMCH?AS1=5UK4[@QVFG6%U=2QQ, ;E%?&_PC_;
MW_9C^.EE\$=6^&/B[QMK?A_]I&2>'X%^+-5^ _[0/@SP5\2I[?P#XP^*+V_A
M[QOXY^%WAKPB\\O@#P!XR\3V4-YK5I+J%AX>U!+&.XNTBMI?L?<O7<N/7(]C
M_(@_B* %HI-R]=PQZY'U_ES1N7^\/S'U_ES0 M%49=4TR"_LM+GU&PAU/4H+
MVYT[3I;NWCO]0MM-^R_VC<65H\@N+J"P^VV7VV6".2.U^UVOGM']HBWW20.I
M [\D#CUH 6BDW+_>''7D<49''(Y.!R.3Z#U/M0 M%-W+_>7MW'?IW[X./I1N
M7^\OYCT!]?0@_0CUH =13=RYQN7. <9&<'@'KT)X'K1O3^\O/3YAS@9/?TY^
ME #J*\)^"/[2/PB_:'N_C38_"KQ!J6MW/[/GQO\ %'[.GQ5@U;PAXQ\&3^'_
M (M^#/#OA#Q5XC\/VUMXTT+P_=:[I]KHGCKPS?6/BK0H-1\*:[;ZBMUX?UK5
M;(+=OUOQA^+?@+X"_"KXB_&OXI:O>Z!\-?A/X-\0_$#Q_K^G>&O%'C"ZT#P=
MX4TVXUGQ'KG_  C7@G1O$7BK5;?1])M+K4KV#1-$U&\CLK:XN!;F*&1E /2:
M*\&\6?M+?!WP-^S9JG[7'BGQ)J6G? /0_A$OQWUKQE;>#?&VOWVE_"@>%X_&
MMSXLN/!?AOP[K'CIX-.\*R'6M5L+;PW<:II=E!=S7UE EE=&+U+P7XPT#X@>
M#O"?CSPO>/?>&?&_AG0?%_AR^FM+O3IKW0?$NEVFLZ/=RZ?J$-M?V,ESI][;
M3/9WMO!=VSN8+F&*9'10#IZ*:64=64=^2.GKUI"XQ\I4ME1C(_B. 3STQD^I
M . 2,4 /HKQ?X _'_P"&'[3?PQTOXQ?!W6=4U[P!K'B+XC>$[+4=<\(^+_ 6
ML1^(?A1\1_%GPF\>:5J?A'Q]H?AKQ?H=YH/CWP1XFT.>UUO0].N9'TYKF.$V
MTL$DGLV]/[R_]]#_ !H =102!R3@>IKQG]H7X_?"[]EOX*?$?]H7XTZUJGAW
MX4?";PY<>+?'GB#1?"/B_P =WVB^'K2:""\U3_A&/ >A^)/%%]9V'VA+G5+J
MQT>XMM&TN.\UO69M/T33M1U&T /9J*\7\(?M ?"_QS\;/C+^SSX=UK4[GXK_
M  "\._"7Q7\3_#][X1\7Z)8Z1H'QPM_&US\-=3T;Q/KFAZ=X7\:VFN)\._&,
M%U<^"=7\0VNA:GHE[HFO3Z=K<$^G0^S[E_O#CKR.* %HKY\_:0_:C^"7[)OP
MD^)_QP^.'B^3PY\//@WX6TCQI\1[O0O#GBCQ]XB\->%]>UFZT#1=>O/!7@'1
MO$OC Z-J6KV.HVD.L)HATBV32-=U#4+ZSTO0=:OK#Z 5LCDJ&&00"#T+#/K@
M[21GI@CJ#0 ^BF[ESC<N<9QD9QTSUZ9XJEJ.JZ9H]C>ZIJVHV&EZ;IMM+>ZC
MJ.HWEO96-A9P(9)KN]N[F2*WM;:%%+RSSR1Q1H"SN ": +]%-WIS\R\<'YAP
M?0\\?C2[E_O#CKR./\Y'YT +12;EY^8<<GD<#GD^G0_D?2C(]1STY'/3_$?F
M* %HI"RC.6 QR<D# QG)]..?IS1N7^\OYC_/<?G0 M%>'?%W]HWX1_ OQ+\$
M/"/Q,\0ZGH.N?M&?%&V^"_P@CM?!OC7Q#IGB;XF7GAS7O%]IX7OO$/AOP_JW
MAWPC=77ACPMXEUNSN?&6JZ!9:A9:!J_]G7%W/8SPI[@2!P2 ?0D?Y['\J %H
MI-R],C)Z#(YI-R_WE_,?X^X_.@!U%>(?M'_M$_"G]D[X(_$3]HKXX:YJGAKX
M2?"K0CXD\=>(=&\(^+_'5[H^C"]M+ WP\->!-$\1^)KRVAN;ZW:^N[329K+1
M['[3K&M7.G:-87^H6W2_\+7\*0>)?B/X;U9?$/AN/X4^&/#7C#QEXQ\6^$?%
M7A+X8Q:!XFM?%%\EWH'Q2\1Z/IGP^\62>'+'PCJEYX\M?#7B/4[CX?6USHDW
MC./15\0:+]N /2J*XJW\>:5<?$75OADNF>+TUO1_!?A_QW<:U/X'\76_@"XT
MGQ'KGB7P_9Z7IOQ*FT=/ >J^,;*]\*W]UKO@;3_$%QXMT#1+_P .Z_K&CV>C
M^)-#O;[M-R_WEZ9ZCISS].#^1]* %HI-R]=PQTSD=?3]#0"",@@CU!!'YT +
M14,T\<,3S/)$D<2-+(\DB1QI$BEGD>1B$2-%!=W8[5122>]?-GP,_:[^!W[1
MFJMI7PKU[7]6-W\+?AQ\</#.I:OX&\9^%M!\>?!OXMOKD?P\^)G@#Q!XCT/3
M=&\7^&?$<GAS50/[(O9M8T>'^R+W7]*TO3_%'A:[UD ^F:*\)\=?M)_!WX<_
M$?X*_"GQ1XINH?&O[07CSQ?\,?A?9Z3X7\6>)-'U3Q]X$\ :[\4?$WA77_%O
MAW1-3\(^!=;M/ GAC7_$%CIOCG7/#M[KUMH^IIX?@U6?3M0BM?=-R_WEZ9ZC
MIZ]>GO0 ZB@$'D'(]17EK_&GX6I\9(?V>F\=>&U^-T_PSN?C-#\,6OU'BR?X
M46?BJU\#W7CZ+3BNY_#MMXNO;/P_<7BLRPZE=VT$@4S1[@#U*BFET R64#&<
MEAC')SG/3 )S['THW+G&Y<GH,C)QUXSVH =13=RY W+DC(&1D@8R0,\@9'3U
M%&]./G7GI\PY^G/- #J*;N7^\O4CJ.H.".O4'@CUXI=R_P!Y?S'J!_,@?4@=
MZ %HK.O=8TC3KG2+/4-4TZPN]?U&72-!M;V^MK6YUO5H-*U37I]+TB">5)=2
MU&'0]$UK69;*S6:YCTK2-4U%XA9V%W-%H,< G(![9.!GL.U "T5XMX6_:!^%
M_C+XW?%K]G?0=8U:7XL_ _PI\+O&_P 2/#]_X/\ &.B:=I?A7XS#QJ/AUK6B
M^+-;T'3_  EXULM:F^'GC&RN;CP5K7B"#1-5T'4M%UR;3M9LKFPB]F9\ [=K
M-D +N Y/8GL<9(]?IS0 ^BOA.W_X*2_L@W4EK%#\0_$ZO??MHR?\$^+47/P:
M^-5B#^UG;Q6DUQ\-;YK[X?6RZ)IZ1W>^V^(>O'3/AOJRVT_]B>+-4#V;77W6
M648R0,\#) R?09ZT +13=R_WE_,=^G?O2[E_O+^8] ?Y$'Z$'O0 M%)N7.-R
MYYXR,\=>/;OZ5QMSXYTJV\?Z/\.&T[Q8^LZUX/\ $7C>WUF#P7XJN/ =KI7A
MG6_"N@WNF:K\1H-)?P-H_BZ_N_%^G77A[P5J>O6WBOQ)HVG>)M<T/2+[2/"O
MB"\TX [.BDW+G&X9],C/?_ _D?2N'F^(&D0?$C3OA=)I?C,Z[J?@C6_'T&MQ
M> O&4OP\@T?0=?T#PY=:7J/Q0CT5_A]IOC.[O?$=E=Z-X"OO$<'C+6]#L]<\
M1:5HEUHF@ZQ>V0!W-%-WH02'4@'!.X8!Z8//!SVIU !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 445X???M)_ O3?B=8?!R^^)?
MANW^(VI>*1X"M- :XF: _$>3P%%\5[;X67/B".!_#5A\6K_X3SQ?%?2_A1J&
ML6OQ&U3X7./B+IWABY\&@ZT #W"L/Q/XG\->"?#NN>,/&7B'0_"7A+PQI5_K
MWB7Q1XFU:PT'P[X>T/2K:2]U36==UO5;BTTS2-)TVSAFN[_4=0NK>SL[:*2>
MXFCB1F'&?%/XU_"+X'Z;X8U?XP_$GP5\---\;^._"OPN\%W7C7Q%IGAY/%_Q
M)\<7KV'@_P  ^%DU*Y@F\0^,/$=Q#<G2?#NCQWNJW5M8ZA>I:_8M/O;B!/AU
M\:OA#\7]1^(^D_"SXD^"OB)?_![X@:K\*?BC!X+\1Z7XC_X0'XG:%96%]K_P
M_P#$\^D7-U!I/C'P_;:K8KK_ (=N94U70KJ<Z?JUK9W\4]M& ?SV?\$9_C%\
M,?"/[#W_  3&L?$/[7>B^.KCQ?\ LL^&/@SX=_96TC7_ (5'QMX7^)^NBU\2
MZIXYT2'P>?#/C?2[?X8_!OPG\3]6\>ZKXQU'4M;\&>!-"\3ZQH.H0:IJ&M:7
MKF/\+_VEO'7PQU+XI_#K1?VB_%?[3?Q:L_V9?VUOVE_^"+8U+XX>*_$L7[>?
M@J5O&GBZP\&?&'2-%^.7B'2OVBOBQ\%_%=I8^$/@K9RZ/H,7BK]EO5],^*FF
MZ?J/Q"\,?$S3?V>OW_\ %/[4'[/G@GXD^&_A%XK^+/A'0OB'XM\7:9\/-#\/
MWVI.BS?$;7O#%[XU\+_#>_UE8WT#0_B/XS\&Z=J?BOP+\/\ 7=4TWQCXZ\.:
M7JFM>$M%UK3M,O;BW][VCGKR<GD\G\_3 ], #H!0!_-OJ/[>'P[7]F'XF?M>
M_LE?M+_M"?&?X8V.F_LD^'_VN8?%OACXQ_&*Q_98@UGXSV%C^TG\5KCPGI][
MX=^+OAGXJZ1\)?%WB&3XV_ C]G76/#EG\#/"'P^T[XFZ-X-^&>LS>&;KQYX-
MIWQWU/4/CA^PAX0N/^"K7Q$\>_L/_'WXI_\ !2C[7\8/"GB.#X"> _%'PU\&
M_!?X5>(_#/PY\._M'^.?'?Q-^,'Q'T3X2?%'Q7\3_!_AOXVV/QLT3QWX>U72
M+[P#I^K0>)OA2OC&_P#ZP=H..O'3DY'&.N<YQWZU\I?%7]DKPK\6OVFOV8/V
MI=6^(/Q.T#Q?^RC:?&.R\"^#?#-S\/D^'WBJ#XX^&M'\*>-!X^M_$/P\\1>-
M+MXM+T+33HI\)>-O!JV%S TTZWWFRK( ?A=^Q?XBUV;]KO\ X)4^//VL?BU\
M2-0^+'Q(_8?_ ."E?P^^%/BOXE_$?XD?#S7OVA?#G@+]M']D>U_9C\3/\'CX
MKT7PWJGQ&^*W[)VGZ#\</BMX:M/ UIK7BR""Y^(OQ9\,K+\,]+N/!'Z.?\%0
M_C?#\.KG]FKX4O\ $[XF_"RZ_: \2_&GPMH^I>$]<\1_#'P1XF\1>&O@;XPU
MOPUX2\6?&[P3IC?$G0_'DGB"?3?%/P-^"GPA\4>#?B?^T7\0/"J>#[36'\ :
M/\1H:_6 (,<YR>2-S8)(P<C)!&.QR.AZ@&G$ G/.<8X)'7U (!Z<9Z<XQDY
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MXU^!GBD:W\5?V8O!Z:9X7^!U]\)IO'[Z5\._#'QBU[1/B9Z1XX_;(^(_P/\
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MB;X<:MXP\0W5C9^#=%T;Q#_1Y@>_K]YO\?TZ4@50, 8'/&3W.3W[DDGU))-
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M-(^"GP*T3P?XFT2Q\7ZW_3:5!YY_!F'MT!P/P[\]:-H]^?\ :;_'CIV]_4T
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MV4K[1/C-;V'A&X\!Z7HEEX!U*_BN/!?POG\!>-+_ ,,7/B'P+?:S9R_#B_\
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MW#P/?\S_ (T8'OSSU/KGUX]\=: /YG_^"77[2'Q UW]I?_@GIX5\3_M7^/\
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MFG2]=L]'\4:9JFG6VLZ<9YS8ZI#;)?69ED^SSQ[WW 'XJ_L5Z!\3/B_^WO\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M;^'"^'?'FLZOK.IZ;\./#O@WPU\4?#NO:'?^//#6IV=Y%H.F^;:I^U)^T/\
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M-*\+>+]:^V>%--^)<7Q[\,Z#X6O;C4=.-QJW@>YN?'4'AC2WT;4(?SF\._L
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M^";?PU^+_P '_P!G_P 3?#WXV_#1_ASXKD_:5_:\^+-A;)XP\(>-=.U+PO\
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MV:?'LL6K7/C?5([ZS\0>"[*+3(KJ;6[K3,_]FKX _'SX5_L9?"__ ()X>+?
MVF3:-\*?A!H/[-FK?M(:9XNT > ?'GP.\*Z-8?#^W\<>#O"#7]]\3O#OQU\8
M?#K[/?S_  Z\6>"Y?A?\.?'C>(H8OB]\5/#/ACPZ_P 3<[XA_##]LB7]L?\
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M_A+X=\;^&/%&FP1>*M2\;_M0?M70:O/!IGB2=_$ !X#\2?\ @HY\=/ &J_\
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MA^S;XOU3]O?]K']IKXJ?L.WOQG\%^.?!/["VF?L[3KXF_9ROO&?A;XD?L?\
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M@C4=6L=%T?3-6NM!\,7-A)<:KK&KS7.GV/S!\</V_/VL?@A^Q='^VCKGP/\
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MCZO)X5?0?"6M0:)XKUG4[_2+:?P']D;X"?MD?\$\M \6?LE_"3X,?";]H?\
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M U72_&7@_P 5:7)93VMG::A>_B9!\$/VRKCX)_\ !*+P-^T7X3_:-^-_BO\
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M+PO>^'[_ ,73W7P5^-GPZ\>^$/''PS\=MIGGZ[X:U.>]@T*2:PFMF^2/ /\
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M>+_%FB>)=7B\)W7@[4?$'@'QQX<^(%W@?LO_  9^+/[#?[1_[>6F2_#7Q?\
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MHH **** # ]!1@>E%% !1@>@HHH ,#THHHH ,#T'^1C^7'THP/2BB@ P/2C
M]!110 8'I1110 4F!TP,>F*6B@ P/0?YS_B?S-%%% !1@>@HHH *,#THHH *
M,#THHH *,#THHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MH? G]E_0;_XQ?"CP_J/Q0\;:1X7\2-X)U6#_ ()L?LJ^$=3\0V^O:W\0=/\
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MM_BI\</&.GFT\>?MN^$/C+'J?@X_!#X<^*?"?@WX+Z7^Q!X[\0>*]6^).D>
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M9X6TNR33K=;"YN=.BU"33D_X)L_L521O$?@E;['!!4>//B@JX(F 4;/&RE4
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M$?\ 8U^$7[(1^(GPST71/A7^T7^T_P#M VY?]F?PSXA^$:']J#0/VR_#^I^
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M ]UHK$\-^(-.\5^']#\3Z0+\:1XCT;2M>THZKI&L>'M4.G:S8P:C8_VEX?\
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MZC+'J6G2164XCN9$O[)TB*W4!D -&BBB@ HHHH **** "BBB@ HHHH ****
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MUNU\1Z7#XXO?$]QX8\/3Z8 ?5/V;_@J7_P!!;]@+_P )_P#:+_\ FHH^S?\
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M-?[,WCIO#GQ+UUOA3X]^&_Q+\4ZS\-O'=QI/C?Q'X)^']]XVU?Q7K)\<R^(
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MG_VB_P#YJ*/LW_!4O_H+?L!?^$_^T7_\U%??]% 'P!]F_P""I?\ T%OV O\
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M[]F;X=?"_P 5ZK\'O@SIWQ4T3XRVV@_!_6/ 7AWQG<W>DW7]H>-9K[ZOU_\
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M!]%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M\(Z[XE\0?!?QM>Z'J7P@U;PCX+\%I\0/#GA;X@:1XJT737\6^!O%?SC\9?\
M@DK\:O%GAC_@H1X!^&?B/X/>&/!?[67B;_@GM+\)K;7O%?Q O;_X;>#?V$[?
MX4Z9;Z7XK=/ %_+K>J>.=)^$VG16\]EJ,O\ 8$^NW#WEYX@;1A/K?]!-% 'X
M:?$S_@G1^TOXO^-W[57Q;T?5?@:EM^T'^VM_P35_:QT/0M2\>>/[*;P[I?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M3_\ ,)0!]Z?\))X=_P"@_HO_ (-+'_X_1_PDGAW_ *#^B_\ @TL?_C]?!?\
MPZ,_X)5?](U_V#__ !$OX$__ #"4?\.C/^"57_2-?]@__P 1+^!/_P PE 'W
MI_PDGAW_ *#^B_\ @TL?_C]'_"2>'?\ H/Z+_P"#2Q_^/U\%_P##HS_@E5_T
MC7_8/_\ $2_@3_\ ,)1_PZ,_X)5?](U_V#__ !$OX$__ #"4 ?>G_"2>'?\
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M (-+'_X_7P7_ ,.C/^"57_2-?]@__P 1+^!/_P PE'_#HS_@E5_TC7_8/_\
M$2_@3_\ ,)0!]Z?\))X=_P"@_HO_ (-+'_X_1_PDGAW_ *#^B_\ @TL?_C]?
M!?\ PZ,_X)5?](U_V#__ !$OX$__ #"4?\.C/^"57_2-?]@__P 1+^!/_P P
ME 'WI_PDGAW_ *#^B_\ @TL?_C]'_"2>'?\ H/Z+_P"#2Q_^/U\%_P##HS_@
ME5_TC7_8/_\ $2_@3_\ ,)1_PZ,_X)5?](U_V#__ !$OX$__ #"4 ?>G_"2>
M'?\ H/Z+_P"#2Q_^/T?\))X=_P"@_HO_ (-+'_X_7P7_ ,.C/^"57_2-?]@_
M_P 1+^!/_P PE'_#HS_@E5_TC7_8/_\ $2_@3_\ ,)0!]Z?\))X=_P"@_HO_
M (-+'_X_1_PDGAW_ *#^B_\ @TL?_C]?!?\ PZ,_X)5?](U_V#__ !$OX$__
M #"4?\.C/^"57_2-?]@__P 1+^!/_P PE 'WI_PDGAW_ *#^B_\ @TL?_C]'
M_"2>'?\ H/Z+_P"#2Q_^/U\%_P##HS_@E5_TC7_8/_\ $2_@3_\ ,)1_PZ,_
MX)5?](U_V#__ !$OX$__ #"4 ?H1!<6]U&DUM/%<0RHLD4T$BRPR1OG:\<L9
M:-T;!PRL0<'!XJ:N.^'_ ,// /PG\&>&_AQ\+O!7A3X<_#[P;I<&A^$O _@;
MP_I7A7PCX8T:V+&WTKP_X=T.UL=(TC3H"[&*SL+2WMXRS%8P6.>QH *^4OV[
M+;6=0_8L_:PT/PWX8\5>-?%'BG]G?XP^#/"G@_P1X=U3Q5XJ\3^+/&O@+7?"
M?A;0=&T72()[B2?5-?UG3K2;4+LV>B:):2W&N>)-5T;P]IVJ:O8_5M(0",$9
M'I]>/Y&@#^;#XU? 7X[?MI_\$O\ ]CG_ ()8>$/@3\6/",WB;X;_ +#?@K]L
M'X[?%'PI>?"?P'^R]X,_9SF^%GQ*^($.BV'Q'M=&\5_'SXK>)_%'P:'PU^'_
M (9^#OA/QI\.TU#7?^$F^)?Q,^'WA5=&U'7^&MOV=/VD/$G[>_PX^*L_[%'Q
M+\!>"-7\3_\ !6SX*?&&TMKGP%XI\">(;'XYZY\-/B'\"?B)XZ^(OC3XM:[X
M^^*_@CXJ3>"KGXE1G5[#PS\$O@AJ=GX _9Z^%'PE\/\ C/X>#4_'7]1 4#H*
M;Y:<?*.,XZ\9QGOWQS[Y/4G(!_(UHGP!_:-7]EK]AKX&?&C]AK]KCXB_LKZM
M_P $YO@7^R#\1/@[\ O!O['%E\<?@]^VA\-K?3=#^)7Q-US2_P!HJ_T6]\">
M /BS&]M/X7_:<\%?$KP5XF^'WCO]GOPYX\+Z/IOCKX?_ !"O/Z3_ (-Z'H/A
MWXD>+]'F^#GB30/B;I?P._9PTGX@?M ZK!I_B72?C/:Z4/BO8>'? ME\9[U]
M-\?_ !6U_P"#&HP>+M7\2W?C7P=X6^P1?&+0M=TV*XOO&?B"PT7Z6\M#_".>
MOOP!S]0 #Z@ 'BE"JI)  )Z^_P#G% &2_B'0(Y)(I-<T>.6&1XIHI-2LDEBE
MB8I)%+&TP>.2-U9)(W"NCJRL P(IO_"2>'?^@_HO_@TL?_C]?%GB[_@ES_P3
M4\?^+/%'CSQU_P $_/V+?&?C?QMXBUOQ?XR\8>*OV8O@QX@\3^*_%?B74[K6
MO$7B7Q'KVJ^#+O5-:UW7=7O;S5-7U74;JXOM0O[JXN[J>6>9W;GO^'1G_!*K
M_I&O^P?_ .(E_ G_ .82@#[T_P"$D\._]!_1?_!I8_\ Q^C_ (23P[_T']%_
M\&EC_P#'Z^"_^'1G_!*K_I&O^P?_ .(E_ G_ .82C_AT9_P2J_Z1K_L'_P#B
M)?P)_P#F$H ^]/\ A)/#O_0?T7_P:6/_ ,?H_P"$D\._]!_1?_!I8_\ Q^O@
MO_AT9_P2J_Z1K_L'_P#B)?P)_P#F$H_X=&?\$JO^D:_[!_\ XB7\"?\ YA*
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
7!1110 4444 %%%% !1110 4444 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>ex10-10_001.jpg
<TEXT>
begin 644 ex10-10_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" /+ NX# 2(  A$! Q$!_\0
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **SGUC28
M]6MM!DU/3X]<O=/O]6L]&DO;9-6N]*TJYTZRU/4[73FE%W<:=IUYJ^DVE_>P
MPO;6=SJFG6]Q+'+>VR2:- !116=K&L:3X>TG5-?U_5-.T30M$TZ]U?6M:U>]
MMM-TG1])TRVEO=2U35-2O98++3].T^S@FN[V^NYX;6UMH99YY8XD9@ :-%<M
MX(\<>#OB7X.\+?$+X>>*-!\;^ _&_A_1_%G@WQEX5U6RUWPSXJ\,>(+&'4]#
M\0^']:TV:XT_5M&U?3KBWOM.U&RGFM;RTGBG@EDBD5CU- !12$X&?Y5QOQ ^
M(_P]^$W@S7_B/\5/'?@WX9_#WPI9'4O%/COXA>)]$\%^#?#6G++' ;_Q!XG\
M27VF:)HUD)I8H3=:E?6T EECC+AW52 =G132P7&<\G XSSV''KV[>].H **\
M)^('[4G[,OPF\37/@OXI_M%? GX:>,;+PU)XSO/"?Q ^+OP_\&^)K3P?%+Y$
MGBNYT'Q'XATW5(/#4<X,+Z[+:II:2@QM=!_EKU_P_P"(-!\6Z#HGBKPKK>D>
M)O"_B;2--\0>&_$GA_4K/6=!\0:#K-G#J.CZWHFL:=-<Z?JND:KI]S;W^FZE
M87%Q97]E<075K/+!+'(P!KT5P?CKXI?#;X8)X:D^(_C[P?X$3QGXO\+?#[P>
M?%OB/2?#[>*O'7C?7]-\*^$/!_AU-4N[:36O$OB7Q'K.E:+HVBZ:MSJ%_J&H
M6MM;P/)*H/>4 %%4SJ%@+]=+-[:#4WM)+]-.-S"+Y[&*:.VEO5M"_P!H:TCN
M)HH)+E8S DTL<3.)'53<H **\Q^)GQL^#/P5M]!O/C'\6_AE\);/Q5JZ^'_#
M%W\3/'OA7P':^)-?>)ITT/0;CQ3JVE1:QK#0(\ZZ9IS7-Z85:00[ 6KT%M1L
M$OK?2WO;6/4[RTO;^TTZ2XA2_NK'39K&WU&]M[-G%Q-:6%QJFF07MS'&T%K-
MJ-A%/(DEW;K( 7:*** "BBD) &3[?J<=/\GTH 6BL_2]7TK7+,:AHNIZ?K%@
M;F_LA?:7>VVH69O-*O[G2M4M!<VDLT)N=-U2RO--OX-_FV=_:7-G<)'<02QI
MH4 %%%% !111_GU_E0 44@(89&>I'(QR#@_K2T %%%% !1110 4444 %%%%
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M1$O_ !7;:IJ_BWXA>$-'TG3KN*\U._TD _ 7XL_%K]M/_A _BW^SE^T3\?\
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MU"/3M9TRSUJTA\96'A;4K+7+#20#Y(_X*6ZK<ZI\+_@7\#+/Q=XR\"2_M/\
M[6'P0^#^L>)/!K7$$O\ PKW0;[6?CU\9?!^M7UGHWB*\ATSXK?!KX*^/_@_I
MFE0:#JL7C7QE\0/"GP]U."VT;Q=J6HV/AW[-'[27[07QR^-_P2-KXO\ $\MS
MJM_\?/%W[5OP7U#P+H]E\-?V9_A!H)\1?#WX(_![7_%5OX.@\6:=^VE>?$?3
M_ 7B+Q%X>UGQI/HGB+PY9?M1^)K7PSX>\#VW[/VCZ?\ 4O@_]O[X3>+_  %'
MXD'@7XT>&/B._P ?]3_96_X9N\7^"+#1?CW_ ,-"Z7X7N?B++\-X=%/B.Y\
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MQ_X)3_!CX'_'OX9_LMWO[1G["$6J>&[]M5^$'@WP%\(?VO?',WP:@\,^&?B
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M@_V@_BMX<^(WC/\ 9'_X)S_ CXGV_P /="^'"V?PQ_:._;2^.6H?"/XL>+_
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MXDZA\0_V@O"YT;]NKQP/B+^RDG@^SF_:?^+&C^+_ /@H;>_#NVD_:BL-;O\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !2$@=?\_X#U/0#
MDTM(0",'_#ISU'- '\>W_!7[XUS_ !!^'WPZ_P""TW[)7B_P1\2]._X)G_M<
M>&;OX8?$7P!\?? $OP\^)W[.FG74/PH_:D^#EI+I7B/79X_'_P ;/'/BK5;#
M5;_2X'TSQI^SCX6\#W/A^QOM=U>SMM?^O?\ @J?X3_9Y_P""PGP'^%_P@_9Z
M^._PNU[XK?&']B_XY?M6_L0SV'C;POI_Q!N/BO\ #_XB?LS^,_A1XD\(Z/J.
MM:7XL\)ZAKR>$?B=\(O$WBF"R@U7P!I6I?%.UU&&'4_#6N:9#_27M')YR1@G
M<V< DCG/;)QW&3ZT%%.<Y(/4$L1^1./TH _A=_:Q_:DUKXTZ%_P;E?M9?M::
MAX7^"WQJ^,_[=O['OQ&\4^#OB'J_AGX?>*/#_P '/A7H]GH>K_%76O#-U?Z?
M:Z-\.?''Q8\3?$_XN>'_ !9'9V>EV7PZ^*OPST#Q%<:?JFF6^E6GT%X ^(G@
M7Q+_ ,%C?^"Y/C/PO^W/\'O@)X-\&_M,?\$1OB3XYU77?BE\*="^'_Q;^&7[
M,O@F37OVCOA]J'CK5IY=6TB[\"6?@KQ'I7B>+PCXATE++Q)IU[\.?BC%_8&L
MZW:6?]D&T=,MZ?>8_J3G\>M+M&<\Y_WFQ^6<?I[=* /YW/CM\&?V)?\ @L;X
M;\2? ;PG\5-#^$_BG6?V4?V1_P!I7]B76O"6MZ+X:^-'P-NO"'C+]JE/@?\
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M7$K6]O/J^HV>FPSSI!-=/##)>30I+*MK;7%RT:,SK!!-,5$<3LH!K45Y]?\
MQ:^%6EZ!>>*]3^)OP^T[POI^I:!HU_XDO_&?ARST"QUCQ7KEAX9\+:5>:Q<:
ME'IUMJ7B7Q)JFF>'] L9KE+K6=<U&PTG3HKF_O+>WD]!H **3('!/7_$#^9
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M)50R1,)$W(0:L4 %%%% !1129&0,C)Z#N>O^!_(^AH 6B@$$9'(-% !1110
M4444 %%)D XR,\<?4X'Z\?7 ZD5%-<06\4TUQ-%!#;Q//<332+%%!!&K/)--
M(Y5(HD16=Y'94558E@%. ":BC_/Y4W>G]X<G YZD=OK_ )[4 .HHHH ***.G
M6@ HI-P(R"".>1R.,YY]L&@$'I_(T +130RG.#G'7&3C//:ER.G?Z']?0<<$
M\&@!:*3(! )Y/3W[\>IQSCKCFEH ***AGN;>V19+F>&WC:6WMU>>5(D:>[N(
M[2T@#2,JF:ZNIH;:WB!WSW$L<,2M(ZJ0":BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K
M\.?^"\WP;^%H_P"";7[<7Q:_X0#PO=_$[Q7\.?@!X,U_QK?:3:ZCX@U#PCX#
M_:#\-:GX0\.->WR7#VVC:!J/CGQEJ5AI]D+:V6_\1ZQ>/')<W<DA_<:O$/VA
M?V;_ (*?M6_#/4_@U^T'X%M?B9\*]<U#2M2\0> ]6U;Q#IWAOQ+-H=V-1T>W
M\3Z?H&KZ1'XETK3M6BM-<M-#UTZAHT7B#2]%U];#^V=#T>^L0#\=/VLO@5IO
M@K_@L+_P3\\4_LP^%O@C\&?CC\;?V=O^"E]UXS^+&M_"Z?Q-8:KKOA#P;^Q#
MX9\'>)O'?@KP=XF^&.M?%2;PWHUI9>&=,T.?XF>!#9:/<7%[!XC/]FC0M;\^
M\ ?\%(_C]\8O!_\ P34^/=M\$_V5M3^)O[37_!+O]NG]I6VM_$UCJ/A2]\)?
M'#X'^$?V>M2G\(>#/CCXL\;26?P@^ ?QE\4>--!?X@6/B.QUR^\.Z-X2T*XU
M_P ?Z['X?&IG]N/$'[+?P4\5>-?AE\2?$&@>)]4^(?P;\!^*/AK\-/'-Q\4O
MBLOB[PIX1\<:58Z+XUMK/Q%%XVCU:ZUGQC9:1H4GBOQ;J=W>^+O$>I>&O"NM
M:QKM[K/A;P]?Z9Y9I_\ P3I_8OTW0/A[X1A^!FC7/@[X4_"OXF? [X?>"M6\
M3>.]<\%>&_@W\9K233_BM\+K?P?K7BK4/#5WX#\?Z;]ATOQ1X7U+2[W2-4TO
MP_X1TRXM6L?!GA.WT8 X_P#8 _:N\1?M-Z)\9M/\?ZFFF_$SX0>/_#'A'Q=\
M(_%7P-\<?LY_'+X0OK'PK\#>)'T?XR_#;Q?XX^).A:I-XB\4WOC+Q#\./BA\
M'?'?C3X*>.?AO<>'[/PAXR\6ZWX7\7:_?_.7_!>[2K/5/^":'Q(:;1=%UV_T
M[]H']@N[T.TUQ(A:1ZI=?M[?LUZ.<WK:7K5QI*:AI^IW^BWVHV>EW]RFD:GJ
M4"V&H0SSV-Q^IW@#X2_#SX7G7IO!/AN#2M1\57L&H>*-?N[W5-?\5>))[));
M?2(_$'BWQ'?:MXFUFQ\-Z=*-#\):7J6K7.F^$/#5O8^&/#%II/A[3[#3+;EO
MV@/V<O@S^U+\/IOA3\>_!B_$+X<7>L:)KVI>#+S7_%&C:#K.I^&M1AUKPY-K
M]EX:UO15\00:!K]IIWB71;#6C?Z?I?BG1]!\465K!X@T'1M2L0#\HOVPM3^(
M'[,W[/W[1_[3^O\ [*?['/ASXF>)?VG/V#/@S=:)=:3K7QM^'_Q4_9['[1GP
M8\$?#GQ/XAD"?!B>;XI?##XI?M&?%SQGX)UC6? FBOX.\0Z%H^GKIGC;2M"\
M,^.=5JW7[:?[?^JZ?_P4'\:^!-%^ ?C30OV.OVV[O]EOP=\'_"?PNUMOC%\3
M?!>OZ3^Q[XLTKQ%X=\5_$7]J;X=_#S6?C%X'\$_'?Q_+HGPRF@T:T_:*^(]A
MX+^'7A?4OAK?:K;W&K_K3\6?V=OA%\=/AG8?!_XM>&]2\;_#S3]2\&ZRFB:K
MXT\=1W-]K'P\U/3]>\$ZOKGB&P\2V?B;Q'JGAOQ+H^B^+=-U'7]8U.\B\9:)
MHGC%IG\3Z/IFK6O)Z/\ L>?LXZ'IOQ1TBS^'*W.G_&CXG>%OC7\2[?7/%?CC
MQ*?$OQB\#ZMX6UWP=\5?.\1^)M5N-'^(GA?5_ ?@"^T'QGH$NE>(=+F^'OP^
M^QZA"G@3PDFC@'X_>!_VT/C3^T5^V7_P2PM_"WQ\T&Y^&OQ'US_@J3'\8?AK
MX?\ @?\ $#X0W<?B[]E7Q5I?@+P3X0^,'P\^,-]I_P :OAK\8? OPY^(K>&?
MB-X&\1RQ^#;7XL1ZM\0M \/^*/"MS\+[[1OZ&"< D]!SP"?T&2?PKY@O?V+/
MV5-3U'X0ZUJGP+\!:KXA^!/BGQ7XY^%WBC5--EU+Q;X?\:>/Q;2?$3Q;?>++
MZXG\1^+/$OQ)U&RT_P 0_$G7/&.J>(-2^(?B[3=+\9>,[G7/%>F6&LV_TW/"
MES!-;R&58YXI(7:">>UG5)4*,T-S;20W-O* Q,<]O+%/"X62*1)%5@ ?S_\
M[?OQBTWP5\:OA#_P4!BNOB':Z!^P+^TQ8?"[Q3<:;\/?C;<_#/5?V0_BVJ?
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M7XJ?#3P[XO\ &GP5UG7?$'PE\8W:7ECXL^'FK^)]*CT;Q#=^$_$ND7>GZUI
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MB\0P6L4<$]_&GD1P0*(1Y)HG_!/#]A/P[\1_CQ\6](_9&_9]M_B'^T_H.O\
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M?B%XJAUCQO;:'!8:*WB"32M,TZTM0#['5@PRIR/H1_/!I:0 #I]?J?4^M+0
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M^IV,5IJ7Q!LIQX.N_M7B#PUJLGB'4+VTG^\X/^"6WP+T_P"*OA+XQ>'?B?\
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MXLU'0/A]X8\$?#_1M0N]%\-^'--O%\(^"_#D&N7&DOXL\31:[X]\0^+/%GB
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MGQEKGQ>\/>,-6U3PY^P%\37^,'[-EIJ'AGQI\._$7PQ-WX7\>1:)K&K:U9^
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MPI\8&\9:]^UA)KD^M^(_CBNK?"OXZ_"_PSX1\!_%(W[:;X@\-?#[P1X1\?\
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M>(/^">/[+?B[0+K1/%WA7QSXFU&[^.G@K]I0_$/4_C;\:D^,-C\:OAWX4L/
M/@SQKX?^,6G>/K'XE>$9] \ :?\ \(-9:3X0\3Z#H!\*:MXHTF;29%\7^*IM
M: /SXU3_ (*&V7Q,MO\ @GK\;O%?[&/BKQAX_P#$_P"T-_P4[\$>!?#GPH^/
M6M:]KG@#XG_L6_"C]MGP)J%MX)\-/X2^&6F?M!:M^T/X1^!?CGPKX.\,?$+0
M_!^@>!-:\?:+K,EW<>)O#FC:E/V_PZ_X*X:]\3/AO\(OC9X3^"GPG\5?!CQ7
M^VS\-?V+_C1XW\'?M)>+K[5_V>]<^*FD_"SP]X=\4^-?AGXO_9?\!_$W1=:T
M[]HCXDQ_L\^*?A5\5_"GP:\=>'M9NOA]\2;NU;X7>/KGQ+X2^G$_X)6?L3P^
M"?A_\-[7X<>-+7P+\,/%?[1'C?P5X;'QZ^/EW;Z3XG_:O\,>.?!GQ_U/^TM3
M^)-_KERWQ \,?%#XE:8]O/JCVGA>?QYXHUWP7;^'/$FJ2:PGL&I_L0?LS>(?
MAC^T'\(?%OPZF\:^"_VJ;@77Q]7QIXT\>>*/%'Q&N+;P+X2^&>B7FH>/]7\2
MW/CO2]4\)^!_ 7@O2/!NM^'_ !'I.N>%-0\-Z?XNT34K/QO)?>);P _.#X_?
MM'Q_$3XT_!WPOXW^ MQX;U[XO_LM_P#!5K5_V</VAOA=^UA\5=$U70?@K\,H
M_@]H\/C:PT#P1X2^%\]KXM^/OA?5OA=\2_"7B+3/$UUK/P6L(K"[^&OQ*U?5
M-:UJ^C_/K]G3]IJ;]F_Q!_P2C^-/C#5_B+XXM]4_X-RO@YIL/@2\^)'BR7PQ
MXP^-'Q3^/_\ P3.^#?PONYM'U[6=3\"^"]>\7?$/XL:+H'CKXN6_AI-?_P"$
M;O(]3\8WOB+2O!VB:?8?T4_%']C'X"?%SQM\.?B'XM\-Z_:>)OA'\+/BI\%?
MAO)X)\=^-/ &D^$?AK\;-$T'P]\3?#>F^'?!FMZ)H)B\1:1X2\(6MO>W.G7&
MH^'&\*>'[KPM=:'=V N'\5D_X)A_L-ZEX>\#>%]9^%]QXJ\$^#/V1-5_85\(
M>$_%7Q-^(/B;PFO[*>K3>'=4NOA<^E:KXLN[361:S>"/ VH:;X]NQ>?$C2)O
M ?A2^T_QA;3Z)%,P!]"_L^_&#XL?$^^^*6C?%[X"7/P,U3P-XFT2T\(R?\+&
MT#Q_I7Q.\"^(/"VF:I:>.-+@ATKPEXW\)M8^+$\9> ]4T3QKX%T6&XU/P;<:
MOX2UWQ9H>H"[LOQ"_;P^-6B_ +]O_P#:KO/B'I?[4_CCX)#]@3]C7QAJ&F?#
M#]JGXH_!?X9? SXF_%O]J3]J+X-W/QZ\:Z_X>^-7A+7O@1\-X;#P1\-(/C%\
M7_@WX#\:ZK\/? OA/5_'FK>#M46TU.'7OW"_9N_99^#'[*OACQ)X8^#>C^++
M6+QAX@M?$_BWQ)\0_BG\4?C7\0?%FLZ=X7T#P5HMQXB^)GQE\8>/?'VL67A[
MP=X6\.>%?"^DWOB.;1_#?AW1K'2]"L+"S0QOSNK?L5_ #Q#\<OB7^T-XE\-^
M(O%/Q!^,7P93]GCXFZ=XJ^(GC_Q+\+O&?P0@?Q!/:?#36_@MK/B*\^$UQX;M
M;WQ=XQU&%4\'1:B+SQGXP+:@\'B?6X;X ^4;7]IK]IG]GSP1\%OV6;KX>VG[
M;W[<'@C]B+P]\8_C=J.B>/++X2>'O'_C71+;3OA_;W7AO6KWX?:I:W,OQ@^*
M>C^-8;/6;GPUX6\.^$;+3+36?&0\-1^)=$TR7R?3_P#@L_X-_MW]I30O%?PA
MC\ >(/V<_ OBSQ=JGPC\7_%2PT?]HG4G'Q)^&7PJ^"6HW/P[OO ]K\/M7^$'
M[1/B+XB0ZOX+_:.^!_QG^/?P.\)^$7\)WGQ)\8^$/$_C./PEH?T-K?\ P2-_
M8@\2>!/A/\/->\&_&+4]$^!FA>-?!GPHUE_VM/VL++XC^$?AE\1-+TC1/&?P
M:7XOZ7\9[+XK:]\%=;T;0],T=_A/XI\9ZYX&L-'M(=)TO1++3(H;.+UB/_@G
MC^R*;'Q=HM_\)DUWPMXR^'OQ]^%%_P""O$WC7X@>)_!.C_#C]J3QUI?Q*_:
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M1O#WP[\6V-MX1\<Z7>:'XQ\'_%+X,Z[HMK;:5X2\?_#R[\9ZOJ4^C^%_U/\
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MTBT_9]U?6K^Y^*WCWX;_ !"\4Z&NB>)0#[&HI ".IR<_YP.WTR?K2T %%%%
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M;+_A+].TKPGHWC#3_!?V/QJFEZ+!XWM[KP[<Q>-+7P_X;L_%*ZO:^'-#AT\
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M)T\8>'[2ZM_#?CT_!KXD27?Q'^";^.-(\0O\&/B%J>L^./A<WA+Q1K6K:K>
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MM%\ 1>%_!'P_\0>-/''C^:S\">!=#OO$?B'18I/D;X\_\$V;_P#X3SX7ZO\
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M6OC[]D;PCXU\#Z-^S9X]\%^*OAEIL_[+_P 4O!GP,\)?$%/#RZ#\//'.H_\
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MV@/C=^TEK_\ P44\8?%?X@>%_%_A;PK^WA?^ O@YH/A73&_LKP'\.K3]E?\
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M#QUX- /OC(/0YHIJX(RIR"2<_4_YQ[4Z@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KR_P"-UMXQO?@S\6K+X=_$
M/0_A%\0+SX9^/;7P+\6/$^BZ;XC\-_"_QE/X4U:/PO\ $7Q#X>UJ:VT?7=#\
M$:XUAXFU;1]5N+?3=3L-+N+*^GBMIY7'J%>=?%_X5>!_CM\)OBA\$/B;I$FO
M_#;XQ_#SQK\*_B#H4.I:EHTVM>!_B'X:U/PAXMTF+5]%N[#6-*EU+0-8U"RC
MU+2KZSU*Q><75C=6]U%%,@!_/3X?_; ^)'[$7PV^/7CGXU:!\?;7]JW]C7]@
MO6_'_P 4_P!C7XZ?M1^,OB+\'OVF_#_P[\8>$K'5OVROV7OVBM:3XT:AJ&C:
M^]K?^%O%.A^*?!>C^-/!.N^*? GAWQM\-?A%+KUSXI^)7UG\<_\ @H#I6H?%
M?XR_ ?QS^SCXC\0VW[-'_!1K_@F!^S]#XD\%_M":OX.MK^__ &LO&GP7\:?#
M+XS>(5T?1_ _B Z%\,O$/C;PQ;>+/@G;R?$71/B??1_\(OXHE;X<ZIXFUC2O
ML3Q%_P $\OV</'^G_%+3?B]IWCGXW1?%C]GS4?V3M8OOBU\0_%'BOQ#H'[-V
MKS2W>K_"WPCXM%Y8^+-)?Q#J TG5O&_Q.N=;U+XV_$W7O"'@#Q)\4/B;XT\0
M> /!NI:'Y?IG_!)[]E_13XTU#3=?_:(F\7_$?XN_LT_'7Q_X_P#%_P"T5\4O
MBUXO\6?%#]D-?#MW\ _$VJ3?&;6_B+HL=SX/\2>$O#7BJ\33-$T^/Q-=Z%I/
MA;Q,FK?#33-.\"6@!\I_LY?\%._CGXA\6?M >!/BA\._"_C'XDS_ +>?[8OP
M,^ O@_X?77Q2U/0M ^#_ .R0G@SP[XQU'QE?> /V<_'OC.&VTS4_$7@2>/7(
M?#7CG7_&7C?XM:ILT;P#\/?""1Z/^PWP(^(_B+XN?!_X??$?Q?\ ##Q9\%O%
MOBSP[:ZAXH^$_CBXTJ\\4^ /$<;RV>M^&=5OM$N+G3-0.G:G;745GJ-N;9M1
MT_[)>W&FZ3=3S:79_#GC3_@D1^QOXTO/&^KM9_'+PAXE\8?M&^*OVLM(\8_#
M;]IGX\_#CQC\*?CU\0-"U7PY\2O&WP8\2>#_ !YI.I_#A/B9I7B#Q#;^//#^
MBSCPYKZ:P(9M)CMM"\*P:#]^?"GX6^!O@G\.?!WPH^&FB'P]X&\":):Z!X>T
MR74]8U[4/LMMN>?4=<\2>([_ %;Q-XL\3ZU>RW6M>*O&'BK6-9\5^+_$>H:I
MXE\4:SJ^OZKJ.I70!^5G_!0S4M7^"_QS_95^-]KXE_;O\,6/B']I_P#9P^'_
M (L^+_PH^(6C^(_V0/A'\-=?^)6@^#M7^$O[0'[+5Y\7/!V@>(/#7[05[XFU
M3PA=?M$7WP8\=_$/X->(?'>D^.+?XRV.D_#+X:_!C6_F;P'^U5\:;6#]CG]K
M?4_$?Q*UWQ+^TI_P4Z_;\_8_^(?P6O/'_B!OA7IOP,^&4G[>VA?"_P .>&_A
MZMA/X0\/>,OAQ<_L1_!_79OB7IG@ZR\=^(+[5/B];ZSK$.E?$O5[2Q_:+4_V
M9_!NN?$?Q7X_U_Q9\4_$VE>-=8\ ^)M?^$/BSXAZYXN^"*>*?AA;6,/@G7_"
M_P ./%+:SIOP^DTR\TS3/$NHZ%\.[CPIX0\5^.=.LOB!XP\-:_XVM8=>7 \+
M?L8_ +P?\67^,NC^$YE\46OQ"^(OQ>\*Z5<ZG=S>#? 'Q=^,OAV+PK\9_B?X
M'\* QZ;HOC7XKZ+%+#XNU:1;U8;S7?B#J_ABV\.ZO\8?C)?>/P#\K?V(OV@_
MC%_PLS_@DEK7BWQ[\1/B1=?\%-O^";WQ@_:5_:#L?%7C/7-7\%^%OB]X0TO]
MD[XU>$?$?PM\%:BNJ^'_ (5^&=$B_::^*7PJ'A+P%'X/TCQ!X5E^&;^+;CQ%
MK?PW\/RW?[^5^>VI_P#!.[X,^&_ GB_0O@W:>*_ 7BG4? GBKX2?#7Q+X=^+
M?Q%^&VK_  '^$_Q&^*>D_%GQS\/?@GXM^'5UI_B[X:>#;CQQ81>*AHGA'4-)
MU[4;'0O!WPIL/''@_P"&W@;X96/PX^Z/".B7?AGPIX8\-ZAXAUCQ;?\ A_P]
MHNB7OBOQ$]I)X@\3W>DZ;;6%QXAUU["UL;%]9UJ:W?4M3:RLK2T:]N9S;6L$
M)2) #\VOV =$NK;]H+_@J>;WQU\9?%MKX-_;FTCX<^"='^)?Q[^.'Q:\-^!O
M!-Q^QE^R)\9I_#O@3PO\4?B'XP\.^"-.F^)7QB^(WB$Q>$]+T8I;:]:^&(6B
M\(>&?"6@:#1UK_@IM:P^,-?O/"?P?/C#X ^%_P!N/PA_P3JUWXOQ_$%O#_BJ
MP_:3\9WWAKP+9ZD?A+K?@""74/@AI'QW\>>!_@=K/C_1?'&J>-&UR\\2^/=!
M^%.O_";P]8>.?$?M(_8&\ 1V7[1&CV_Q?_:%LM!_:Q\:>(/'O[0FE:=X_P!"
MTNY\?Z_XH\ ^$?A1K+6?BW3O!=MX_P#AS:/\+O 7@WP#ID'PG\7> V\.:'X>
ML+GPU+I&O-<ZS/TFD_L(?LYZ%\2==^(NA^$[_1;7Q/\ &3P]^TAXA^&&E:[J
M%C\'-:_:-\)>!="^&OA?XX:E\/+9HM+NO&.A^$/"WA3[#HKR#X<IX\\)>$?C
M7)X'D^.OA+PU\3=+ /C_ /9D_P""HOBC]INP_9CNK;]FA-'MOVH?V6OVTOCS
MH6CZ'\;K/6O%6E>,/V-_CA\./@KKOPK@C\0?#GX<>%[RS^)!^*.@ZSX3^)&I
M>./"46C7D.I:3XC\+:796L'B:X\L_9)_X*A>$/%<W[$7[+WPI^"FF^ M7^.G
M[&?P/^,?P8\'?'3]IOQ9%XGU/PMXO_9D^(OQ<TNR\&^.?B#\./%_B#]I#PU\
M.-4\!^#?A%\6O'>@>*O%_P ==!\1^+=;^('B;X+7G@CP?=^*O$?V#\,?^"6G
M[*OP6\9^#O'_ ,)S\</ WB+X9^&?VA/!_P *;73?VC?C9J7@3X7>'/VFO$%M
MXK^)FB^#OA#XD\::W\'UT1O%%EIWB/0_#FO^ M>\-V.NZ#X-U>\TC4M0^'GP
M[N/"FS\+/^":O[-7PCTOX*:!H$7Q%UKPQ^S]K7PX\2_#+PGXR^(.L>)O"NB>
M)/@M\*YO@C\%?$4?A^[2/3;77_A?\*KJY\'Z7K&DP:9J/C.--%U_XM7'Q%\6
M>#? NO>& #Y8N_\ @HAXH^+G[#GC#XN^-/V6Y;4Z5\"?V^=0_;#^!/@S]IO6
M=(^)GP.NOV4==\>?!GQE\+O"GQ4\-?#OP+'J'Q$\5>.O#>N:-I_BRU\6_!9O
M#NCZ!XR^(/PD\4?$>Z\(:+%X@_*O]LCXI>)M;T3]JS5_AYX]_:!^&/@2\_X-
MC/#'[3_PY\":3^U#\?KJ;X8?$:R\:^(M5\*>(M$\60>/M+UJ7Q?9Z3X)\%^'
M?'GBZ(Z??_&;2]%OK'XKP>+-)\3>)=+U3^D+5OV'OV=;[P]^U]X>T?P9)X,3
M]NLZD_[3&J>$-3NM,U3QS/K7PUTWX1ZW<V9NAJ.F^%;S6? VG26FIWOAC3=*
MNKO7]:\1>-WE'C?6[_Q%-X/XG_X)3?LT>,-+UK1M=UCXN7.G>(_V+=$_X)[Z
M[;1^-M.MQJ?[*&A:A-J$/P[FDA\+K+%J5\UWJ=KJ/CRT>W\?S6>KWL4/B:WD
MBT^6S .MU;]MK6W^.?BSX.?##X$>-OBEI/P?^-WPL^ 7QL\3:3'XWLK_ ,'>
M(/B+\/?A+\4=0\6Z#M^%FK_"C7O!7PV^'OQS^''C/Q]/XN^./PX\7?V%;>/%
M\'>$/&&O:#X4T'X@_H&,X&<$X&<=,^WM7YY>*/\ @F5^S+XD^.+_ +35W8_$
MZX^-FI0?"W4?B+?:=\;?B3X'\!?M">.?@'IFFVWP%^(/[0OPF\%ZII_P;^(W
MCGX1ZIHND:_X!\3ZM\,;IO"VN:=I.HV6DW$7AWP[I^F_37[-GPCUGX%_!?P5
M\+M>^('CSXG:GX9C\0//XN^)OQ \5_%7QK/'K_BO7/$]GH6J_$CQU<77C+QQ
M;>#;'6K;P7H?B?Q5,?$&K:!X>TN[U5(;V6>", _$O]NK]IB[_9._X*Z?!_QC
MKWC3X\V'P8U/]@#XG>*_B!%9_%3XRZY^S%\$_%$/[27P(^$NB?M1?'3]G[1O
MBMH7@^^^'7PU\)^/_$VB>)]6\.>!]0>WUGQ?X>\7?$&]\'^&/#FJ?&;X8?H'
M>?$SP-^Q%X7^ 7P"^%$_QG_:/\:?&BU\<^*_ ^L_%SXR?M(?M%:]XA\+^ /#
MOA?4/'OQ+\5?%M_"_P"TI\0(= FO?%7@*PT7P]X+\(7/AK^V/'5O=>&O#7AS
MPC:^(-3TCW;6_P!CSX8>)/VI]/\ VOM<U;QSJ7Q0T[X*^(?V=8]$N]=T^Y^&
M<_P4\7ZQIGBCQ9X"OO -SH<^E7]KXD\8Z%H'BS6=?NGD\77E_H6DZ*?$">#;
M*+PO7ROIW_!';]D[3/@G\._@);>(OVDK?P;\$O'7_"Q_V>->T;]H[XF^#OBG
M^S=XHN?#.O>"M<A^!/Q<\!ZMX6^(OP_\$>)O!_B34_#FK?">R\0W/PFM-.>W
M/ASP/H-Y;QW= 'SK??\ !9_Q]H'B+XCZ7XW_ &$/B)\-;#X$3?\ !.P?'RW\
M??&;X?VGCGP?;_\ !0+XJ>(/@AHR^#_!GA;1/%MKXPU?P!\2M.TD+I'B3Q1\
M.3XI\$/XK\2ZI=> =;T3PMX-\?1?"_\ X*8_M%:#^T+\6_A]\8/AKX \8^!?
M%W_!9R]_X)P_"74O"GQ)O-%U;X2>%D_8A\"_'_PWJ5YX>G^"5N?']KJ=SX>\
M5^)_%E[K'CBSUS3?&7Q+U/POX?FN_ O@KPS+=_54_P#P20_9(_L?XJ>'-*M_
MB;H/A_XP:)^ROH7BW3+'X@W>HS&']BWQ^OQ4_9WU.V\0>)M.U_Q9>>)O"OQ&
MEU?QKXI\5^(-?USQ)\6/$GB;Q'J_Q<U3QS>ZCY\?3^*/^"7'[*GB[Q7X[\::
MI;_&"RU_Q]^TMX&_:_N[OPM\>?BUX('AG]HKP5X*TKX:3_$WP(O@SQ5H)\&Z
M[XX^&^EGP!X\DT9H8]8\'ZEJVA:?'H]E>F.( \=^%'_!3'XB?';X2^'=0^$G
M[,6C^+?VE/$GA+]NCQO8?L_W'Q[B\.^%M7T3]B#]J+5/V4]4TGP[\:=;^$-I
M'?>,/B]XY_X1N]\":?KWPZ\*^%-"LM4UB/X@>-?"T>DZ'>^,/(OV0?VC_&"?
MMH?\% /@+X#M+_Q1\3/$'[4OPN^,:_ W]IK]HOQEHGB_X$_L^^*_V#/V+?B!
M\5+_ ,*QW.D?M#M=Q>$?CS\:+?PW!\&OAW<V'PL\%ZIXWDT[3?%G@?PG:^"M
M/\0_3$W_  2'_8T@\&?#_P '^%K?]HGX=W7PK\:?&3QS\/?B+\.?VQ?VK/"'
MQC\+:A^T-XJTSQM\<]%TWXN:9\7U\>KX,^*_BG2;/Q#XR\%RZW)X:U#Q+]K\
M7Q:;!XRU/4_$-YL)_P $M/V:=,\5Z3X\\,:A\3_ WC#PC\;?!OQ]^&_B'P5X
MHT70[[X7>-_ _P"SQ;_LE:-I7@>.+PI+9P?#Z_\ V;]%\#?"+Q?\.=>MM?\
M!WQ!\-_#GPA=^.](\1^(?^$CUKQ$ 4/@5^W7\5OB_P#$CXD?!;6OV?/!7@?X
MO?!O]M;7OV;/B=X-B^/FK>*&T;X&V/P#TOX^>&?VJ-,GC^ FB:GJ.B^.]%\4
M^!?#WAKP7J>@>'=#'B'QCI^F:I\5K#5HUTFX_3('@$^@)_+GU_K7YR^"?V;O
M&OC?XC_M0?M-?$[X4>$?@Y^T%\9/@)#^R9H5G\,?CQXHO]4D^&_PG\??M ZK
MX)^(EG\>/#_PW\'^(?AYKOQ1A^*?AK7$N-%^&^K>-/A7%X3\,ROJ?B36-&M-
M#T?[*^"OP[U+X2_"?P!\,]7\=^+?B=?^"/"VE^&[CQYX\UC5O$7B_P 3-IL/
MDKJ&O:_XAU/7?$NN7OE".V_MCQ7XB\3^+M4AMXKWQ9XI\3^(I]3U[40#\-/^
M"F/_  4J^'OP_P#VF?V3/@WX5_:\^%_P9L?A?_P4&_9@\'?M.:&OQV^''@[Q
M7XD\+^,/!'Q#\>>+_#?Q!TBY\8Z=XN\+_!OP#H4/PRU#QQJ.L:/#X0\>^(OB
M;X<\-2>(;7_A /%_AGQ+GM^T1^T!#<_LN_M!GXF_$RT\9?M0?\%@?VQ_^"?O
MB?P-;^(;Z?X;^!?V?_"GB7]M7X#?#RW\+?"GQ%9^(?AS;>-_A?XB_9-^%/QR
MNOB->>"/^$X\0>+(OB=X/U7Q!IGPR^)'B3PQ#^UOQN_9E^$7[0E]\']0^)GA
M^?4[OX&_''P3^T3\/Y].U.]T1[7XH_#S2?$VB^%M3UDZ;) ?$&E66G^+=9AF
MT+56N-,NFFADF@+VL)'(Z;^QC\"]&^)^H_%S1]"U/2_%D_Q'\9?&O0;:UU:1
MO#'@;XY_$?X8R?!OXB_&CP7X7NH;G1M+^('C?X<R2Z'KEQ=VNI:!]KU7QGXD
MTS0--\4_%'XL:YXZ /Q6_:[UOX\?L>^.?V@]2_98_:+_ &D/%'PU/P;^ /P!
M_:%U;XR?&74?V@-'^%7[9O[8/[:7[,?PD^%OQ,^#<_Q/U;QGJ?PN^/'@O]G'
MXU_%WXO>,_@7X+L_ /[-_AK3?$?[(WB9O@A/H'C/2K:OI_P2S>,OVC/^"C/[
M)7Q;^//QV\"_LK?LC:E^SO\ M Z?XO@_:6^)WPY\76W@3X[_  +\9>(/B!\.
M/'/[5)\56/[0.A?"CX:?$3X::[\=[#7-!^.OA/7]'?QC_P *QU?Q!;_LZ>$=
M+^%U[](^$/\ @EA^S=X;\%^*/AAXC\6?M(_%OX2^-/!GQ8\%^)_A1\7OVD/B
MKXQ\!ZXOQPNM3O\ XH^,M6TQ==TV]U;XI>*]2\0>*]<O?BGJNHWWCV/Q7XP\
M4>.+?7HO&^K2^(U[;XA_\$\O@G\3?!VM>$O$'BKXU:?=>,_CEX%_:1^)WC7P
ME\4=6\'>-?BS\9/ACX,\$^!/A[XI^(6H>&[33M*U33_!VA?#+X:RZ!X)TS1=
M&\!6&O\ P_\ !_BN/PP?$VA66JQ@%?\ X)HV?QWM/V2O"C?'WQ+\1/%>I7WC
MKXPZE\(-5^,[VUQ\<G_9=OOBKXNF_99'QROX4AN]1^+MQ\!#X!U'QU<>([>V
M\=P:Q?2Z?\2($^(5CXH+>=_\%&OV^/'G[#/AC7O&^@?!G1?B1X6\#?LZ?&K]
MI#Q/<ZEX^&FZWK]C\#_$OPFL-<^&WA/P)X0T'QO\1[,:GX5^(FM>)-;^/VN>
M#S\#OA-K>B_#[P-\1-6L[_XU>']6\-_;/P1^"NB? OPKJ?AC1O&7Q6\?2:UX
MDO?%6L>*/C'\3/%?Q3\87^IWFG:3HZ1#7?%=]=R:;I%AI&AZ58:?H6BP:;H]
MO]FGU%K*36M4UG4]0^?/VE_^"=?[,7[6?BOQ9XS^,&@^.Y==\?\ [/'B?]E?
MQ_+X&^+OQ.^&EGX\^"'B;6[GQ*O@[QGIO@3Q1H-AXDM_#FOZGXAU/PQ)JL%S
M_9[^*O$]G<QWVF:S=6# '"?"_P#;JUSQ[^V5X_\ V3-<\$>%/AYXB\$^)?&4
M*>#_ (@>*M<\&_&CQ)\)M T*"Z\%?M%?"WPKKWA"U\%?'OX-_$CQ(-8\.Z[J
MWPE\<ZMJOP)O++PCIGQ%TV]U[QSX@TOX5?6'[3/C/QY\./V>/CG\0_AC)X2B
M^('@+X2?$'QIX/D\>Z/K'B#P8NO^%O"^J:[IY\3Z'X>\0>%-<UC1O-L +S3-
M)\3>'KV]C)MX=:TUI!>0^7>!?V'?@;X \4?#[Q;9I\0?%>I?"?QW\3OBM\,C
M\3/B;XT^)D_@7XJ?&O3O'.A_%OQ_H&O>-=5UGQ;'J7COP_\ $7Q3H=_X<O?$
M5[\/]%M-1NKSPCX.\.:WJ.L:MJ7U#XO\*:!X[\)^)_ _BJP&J^%_&7AW6O"G
MB32S=7MB-2T#Q%IMSI&L6!O=-N+/4;,7FG7EQ;_:K"[M;VW\SS;6X@G2.50#
M^4SX6_M)_M)6'QO_ &1?VOTMO#?QF^.VN_\ !M"W[2?Q TCX@?$CQG\//AGX
MGU"V^*_[-/Q&\5ZPEIH?AWXAV7A;QIX@TB[U"">X\)?#RTL-;\0SQ-K-S8Z+
MIFDVD/ZGVW_!5.[^(_@[P?XL_9R^ GC3XS^(XO@9^R/^T5\4O@EI.F>+!\1-
M'\!_M9:$OC?3?#/A7QI;>%I?@S:_$'P7\-;;6O&-H_Q,\=^ _AK\0=9L+;P'
M;_$/P==#Q/XE\)>I>#?^"4/[,O@&S\/6/AG7?C?%;^%OV.?$_P"P7H7]M?%7
M4?%LVG?LQ^++G1KK4O =G<^+M-UVXLI+9_#/A>+0]8L9+;4?#EIX=L;#0IK"
MRO-;M]5?:?\ !)G]D*QUSX*^([.R^,FEZQ\$_@K\-?V;K5_"_P"T!\7O 6C_
M !:_9_\ @]_:8^&?P=_:+\(?#[Q7X5\%?'WP'X9M]7O]-N-(^)WASQ WC#1+
MFYT+Q_<>+-&OM0L+L _2_H.><#FOR@T+_@I+XC?]M'PA^REXK^#%G!#\1H_V
MW(_"VJ> O'-K\1?$&CW/[&OB3P#:V">*9M%TQ?AW)K_QQ\$>.[7QO8_#'1O'
M$_Q-^"0N/!OAOXM^'K+6_&MS#X1_5_G'7G'7ISZXYK\Q;K_@EM^SUX$\16?Q
MD^!VD^.]%^-WPQ\2?M2?%+X!V'B3]I#]HRP^#O@[XB_M4PR^(OBGX5E\&^'/
M'<EEX<^#7Q$^+%MI7Q'\9^%?"&BPO;:\M]<Z'#'I\\F@W !\Y?#W_@L%J.I:
M*_Q2^(7PH\#V?P%TS]A;Q]^W3\4_%WP^^)7B+Q?\0/V9H/A_XBE\+:S^R]\>
M/A_;?#6XTG1/VB(O$7]I>%$TC4?''A%I/&7PA_:<\/W?AW2[GX%7G_"4=O\
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M1ZO<6%YHG@_Q%I]A#<>(_P!R_CM^RY\+?VB/$?P.\7^/&\:Z=XJ_9W^(U_\
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M_P#::ZSXD/C?3/%/BC2/B!#XCU#58OB+IOBCQ/IGCN+Q%8^)-<M]0^=O"?\
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M3OB+\,_C9\(/B7XD\1>%M<_96^,)\'^)M$M='T[Q;KOB:6TU_3=$N?T1M/V
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M_L^?&+XA0:1X]N/$7@/7]1@BG\3_  Q\/WMW>_#^]\!ZS+'<:Q8C4TTS4I[
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M_P!)_:'\,6]A_P $W?B'\,?B+\/_ !+?? C5;ZY^(U_\%/A%XF^"_P --/\
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M_$KXMZ7X\NM!U72O$'@+PE\0?AEX'O?BQ8W_ /9_PLD\8^)=,UW0=)K>-/\
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MWXJ_&7Q!XR^('PG\.V0^*6O_ !5^!_BK]GBY\/:+X2^'GBKP+X)^#W@KPO\
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MX(/C9:?$WP9K%Q;_ !BO9?#]CH%G^T/\3;?PGJNGB^NX1%X*DU6#4SH&N?\
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M,M!TN.4Z=I$5]-KVN:%I6I_)FG?\%6_V?[_PE^R+\0)O 'QTT3P#^VC;^.-
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MXT\+_$OPCXLU'3?"GQG^Z?C#^P+X>^./[0?@/X]^.?'M[<:K\*?BU\/?B_\
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M"T7P]?VL?QV\&>!_@WIUUJW@WQ#\'O!WBBW +\W_  5?^"5K\1]6\!7WP?\
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MU30)O# OX=4TG3_#VGZ^NL:I=:U<:!HOT/I7_!/WQQ\0OB5_P4%\0?M+^,/
M_B'P9_P4)_9&^#'[+?Q%TWX/6_B;P5JWA?3_ (=^#?C[X.\7:CX:3Q6WC)(A
MXJTS]HSQ%;:->7FL7D_AZX\$:3J]Q8:O_P )==:1X/ .J^,W[?7@C6O@E^U'
MIWP)\9W?@#]I#X=?L8>-OVLOA7H/QC^%?BK0-1\1?#7_ (0[Q'>>#?C)X8\
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M\3/"?P^T_1?BQ\4;OXQ^*8=5\2W=KXZU?P'X:^'/B>\\)ZGXCU34_!&C>-M
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ME>&8O&]QXK\.Z+I_B?5M:\+Z9H/BD2ZE?_(OQ:_X)*?M"?%WX8_\%!_ NO\
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M7WQ-\6W$7A'X8VWCC7?#LOQ&\5LWAKP2FO:W')8)[;7Y >#OV6/VT?!'Q_\
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MGQU2_'_PY<?"O_@HM^R3^USKKP1_"G6O@-\?OV'?&FNRB6VLOAOXX^-GQ#^
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M'P[':^+-4^%$&MQ^)="TKXK'P9K\<7@A[-[C2?$.I:=JUYI\T%I=@'[TZ_\
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M-[\/V_96TWQ)\)_^"//P._8$#^+/%_B/Q1H%Q\9?AE\9OA#X]\6:GH>DZM\
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M(\,?LZ^!_#_AGQ"?A7/KNL@'[OP2I/#%/&P>.:-)8W7(5XY%#HX!PP#*0P!
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MH']E7X!_LT:9\6?C/I_Q+\6>,K/X[?%7XFZ9\%_AWHG@7XE:[X)T;P3H^O>
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M!?&?PYXC^'NMZQXM^&'[3/[.7Q(U:Z\#^%?C'\,-#OM+A^(7@GQ>/BQHNO\
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M@  _IC_9A\?Z#\8_V>O@A\<_#_@G3?A];?'3X/\ PN^,$GA33GLKK^PS\1/
MN@^+(=%N=6LM*T2/6YM$M]6CTH:JVE:?]M2T6=+&R21;:+S/Q7^UE!=_M%ZE
M^RC\#?! ^,/QB\#^"= ^)'QPN+GQAI_@;X:?L_>$/'2>)(_A1'\3O%O]E^+/
M$T_C/XPWOA'Q1_P@7@?X?_#_ ,<:I::'X;U/Q9\1IOA]X;U3P)J'C;R7]@+X
MA^(?!OPA_97_ &/_ !Y\%?C)X$^(/PL_81_9[U3Q+XL\4Z'X7MOAV?$7A#P7
MX*^''C7X=6^IZ=XPU3Q3:^-O"OB9#'-_;?@_2/"?BBQBU'4/A[XK\96^@^(F
MTCYQC^'?QS_8A_X*._MD?M1Z)\ /B=^U'^S_ /\ !0[PU^SWKFN:G\!Y? MS
M\3_V;_C+^RW\*W^$4/A3QM\-?'?C7P5)XU^%OQC\#KIWB+PG\2/A_K6L:WX0
M\>:+XA\&^._ UAX?UGPIXTG /TD^"G[1OAOXN?#[4?'&O>%_%GP-U'0?B?X]
M^$?BGX?_ !IG\&:%XS\*^,O!/CC5/!]G8ZM)X8\6^+/!UY%XZTZUT3QYX!O/
M#7BS7].\4>!_&7A36M,O;A=52)/8/$'B:VT>VO(K1(]7\21V%Q=:/X/MM5T+
M3]>\2WXTS7-2TW1-*77-2TVPCO\ 6H_#NL+I\VHWEEIZKI>I7EW=P6&EZE<6
MWX3?\%2?A)^U)^U7X%T_P_X1_8H\6:KK/Q,_8Q_X*"_"WPWKND^-_@=KWC_X
M*>/_ (R?"'X?:9\/OA3\3]$\<?&32_@+X=7XOWWAG5=-\6_&[P2_QSUCX>0^
M&8?AA\-_%/A*W^*?B#XB:A%^Q5^RAHNI_M7>/?VB_P!I_P#8SO;#Q-:?L3?\
M$R]9\+>,OC-\'O#'C_QM8?M._LSZ#^T1IWQ4\9:;K6@-\1FN_COX5\*>./@E
MIV@>,](UC4?B%>::I\&>&-6EU3P-XU\.^' #]3?V-/VM/#/[7'[,'[-?[1PT
MFT^&EQ^TO\+=)^*'ACX<:SXKT[6==L;'4+*#4+S3;6\-IH<GB*71;6\LY-5N
M].T:&"U^TQ&6...2%Y<+]D#]L?1OVJH?CND_@2\^%.M?!3]JGX\_LR6WA;Q+
MXN\.:]XC\72_ C4-"TO6_'%I:Z"S6%G9:E<ZTDK:1INH^(TT:W%NVH:V;J[D
MM+3\%?V</V,OVO\ P)\!?V"/[&^ 6O6/Q?\ @=^RK^PA\+_B5\(OCOX?\&>,
M/@7\8_$'P&_:0^*GQ#\0^"_[9LM5TOX@?LI?&+]EK4=-TG]H'X>_M+>'_%NM
M_"[XP7'B7P3X*F^'/Q?\1>"_"/AV'U+P+_P3W^(^I_%OQK?WO[-Q\"?M"Z3_
M ,%V_$7[:G@G]J&[BT/1)M%_8Q?QEX=^(7BF_P!,^+7@S4[S5O%&A_'3X9V_
MC/\ 9LNOV?KV^N/$">)/B-+KGQ$^'6A^!O#EYXZTX _I6M?$&AWVIZMHMCJ^
MF7NLZ#]@.N:/::A9W&JZ*-5A>YTLZMI\,[W>FC4K:-[FP-Y##]L@1I;;S4!-
M?(&D?MF:1KG[>^H?L/:5X(N+X:;^R_K7[1=S\8;7QCX;U#P_)J6@?&'1OA'K
M'PN@\*Z2VHZS:^(-"O-774?$-_X@O-!DT^06FFVFB:F+JXU&Q_#NQ_9H_;JU
M+XA:QXJ^%_[+'Q*_99^+7C7]E[_@MO\ !'2O&.A?$#X1ZC\-?A)\??VL?V@O
MAQ\<?V=OBA%\9?\ A9VO?M'>-?#'BGQ?H/C#XJZ_X\\2Z+<V7AKQ]K%M;_"#
MX)_"SP_</X(T/K_@U9?%S]FK]I30?VWKG_@EK^T3\'/A3\%O^"3V@_LO?$GX
M<>"M2_8YU7QXGQ+^'/[0WA+9HGA_4(/VF-#L/B7X)\)?#[P[KOBO0OB3JFLZ
M=ITWPYTL:M<IHVL:S9>&[L _?7]IG]H_X4_LC_ SXB?M$?&S6KW0OAM\--)M
M-1URYTK2KS7=<U&^UG6=,\+^%?"_AK0M/22]USQ9XT\7ZYH/@_PGHEJOG:MX
MDUW2M/5X1<F9/+=&_:;^(>F^./V?/!OQ@_9O\:?"A_VEO$/BWPOX+O!X\^'?
MQ"'P^\3^%?A?XU^+L?@'XWQ^#-5N[/PSX^\0^"_A]XPOM&E^&>J?&/X1K=>%
M?$&E:K\8M-UN[^'^E?$#RK_@IK^S%\0OVQ_V3;+P]\$[W3M-^,OPW^+'P%_:
MC^#>B>/'U'PYX2\7>/?@#\2/#7Q3T3X<_$=TLO\ A(?#FC>-K;1[WPQ<ZA:+
M8:EX5UV^TS6;WSK32;_2;_T;X4?M/?%OXHA#KO[$W[2'P'/A_3]<UGXB7'QH
MF^"]U#I4OA^VE63PG\-+?X/?%_XI:C\6O&/BO462#PC=Z#;:5X#/AF+7?$6N
M>-+#Q/;>$OAOX^ .J\8_M:_"CPE^UE\*OV-O$UIX@3Q_\;_AC\3O'G@[79-+
MLIOA[J-W\-6\.7&K_"V]UAK]KD?$G6_!FL^(/B)I'AN32C:W/@3P'XLU:YU"
M!H=/M=0^K000".A (^AK\$OVE?@M^TMXR_9Y^"_[8W@'P[\3M0_:<^&_[6/P
MJ_;<\/\ [,UI\/M,\'_%V37[W43\+_B]^R]XH^(4&K7VA1VEE^R'XC\9_LU7
M/CHOI/PU\>-X1\)>-I]6ET77!>:G^Y_A?7T\4>'M$\0QZ5KNA)K6E66I#1?$
M^EW&A^(]):[@25]-US1[H>;I^IV3,;>\M_,EC6>-S#-/ 8IY #\__$'_  4F
M^%?AW5_B!K\_A?Q#>_L^_"/]J7PA^Q=\6/V@(=6\.:=H7P]_: \8:]X2\'EM
M>\*:_?Z/K#?!KPG\0_'W@3X4>-OBC87-WJ.A_$/Q;:7=OX%U+X2:%XV^+7A2
MCXL_X*1:=\/?VD/A3\'_ (A_LP_M$>#/@Q\=?C3??LU?![]KC4HOA5?_  A\
M:_'VQM?'$L'@Z7P3H?Q*U3X]>%/"_B34/ 'B/P[X*^)'BSX5:-X7\6ZO:VNN
M:6Q^&>I:9\1K_P"9OC[^PJWQZ^-GB;X+?"#X5^,_@U^RK\8?VE?AG^U;^WSX
MVUO5-+\._#+XU_%+X%>-/A'XWTCPC\#OA1%<+\3XOB)\;]9^%WP_'QO^./A^
MZ^&?PA;PQX9UOQ%IG_"W?CGXNU[6/"_3^-OB_P#M!_%#]OGX;V.O_L"?M4ZK
M\'?V?/BJ^C?!#X@:@OP+\-? J\\;^,8/^%6_$W]L7QYXKE^--]\8K>T^&7P3
M\5?&GP3\!?A7I?P2U'3/&$/CK7/%/CG5;+7/%_P\U?X! 'U9X#_;[^'OCSQ[
MX T6T\%^,-/^&GQJ_:!^-/[+GP)^,=Q<:!=^&_B=\8OV>/#WQ5\0?%&WCT33
M]3N=<\*^";B3X'_&3P[\,_%GB"&WN?B)KOPF\:7D7A_1/!FM?!KQC\7NP^ G
M[1W@W]HOXO\ [4OP[E^#7C'X?^//V._B[H/P@\37GQ*M_AG?WNO7?B7X<>%_
MB[X4\8>!-1^'_C/Q_%!X-\3> OB!X8\3:$NL:IH7B^SAUUK#Q9X1\)^)K35]
M"LORK^"7["_Q;\/^#?\ @FU^QWJWPR\>:/X&_P""?_[?/QT_:6\3_&S5-<^'
MH\*>*?A'X1M/VM[3]E^7PW<6.H76I^(?&?QDOOC[\/K[Q?X0TWP;ILOPQL/A
M_P#&"R\87W@Z6]^"&J_%3[C_ &.?"'C?PS^V?_P5(\9>)? OC7P[X1^.?Q\^
M!'CSX4>*/$'AC6='T3QKX9^'_P"QQ^SQ\#O%][IUW?6<3VT^E_$KX>^+='M[
M'58=/N]<TW38?%GAZ+5O"&I:;KUT >Z_LB_M>:/^UJO[1T6G?"WXC_"+5_V:
M/VE/$W[,7C3PO\4+OX<WOB&Y\8>$_AO\*_B/J&MV<_PK\=_$GPB=!O;'XJZ9
M;:7Y'BZ^U!TL99M4M-(O99=)LOKX@$8(!'O7X_?L):=\3/@0O_!6'XC^*_@7
M\9M1;X@_MX_%_P#:@^$'@72_"5II?CGXR_"[4OV=/V?/!_AL_#^W\<:SX.\,
M#Q7XI\6?"?QGH.E^%/&'BGPCJVG3VNE:AXKB\.:+XAT/4]0_7Z&1I8HY&B>%
MG1',4NSS8BRAC')Y;R1^9&24<1R2)N4[9'7#$ 9#:VUNTSP6\,+W$K3W#11)
M&T\[)'&T\S* 99GCAB1Y7+2,D42LQ6- 'R0Q3*%FC255>.55D57420R)-#(
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4A&01DC((R.HSW'O2T4 ?)OAS]A/]
MCWPC\6]7^.GAG]G3X5:)\4]=\7ZO\1=3\3Z=X6L[>.7XEZ_/#=:]\4;;PZG_
M !2VG?%37;F*2YUKXFZ=HEKX[U:XO]8N-0\07,VN:R]_]8@8&,DX[DY/MD]\
M=,]Z6B@#,M-$T?3]0U75K'2M-L]5UU[.36]2M;&TM]0UB33K5;'3WU6]AA2Y
MU%["R1;.S:\EF:UM56WA*1*$&G110 4444 %%%% !67J^B:/X@M8K'7-*TW6
M;*WU/1=:@M-5L+74;6'6/#>L6'B+P]JL5O>0S0QZEH/B#2],UW1KY$6ZTO6=
M.L-4L)K>^L[:>+4HH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "OC[QI^WG^RW\._VKOA?^Q#XS\?>(-"_:;^-7A[6O%7PH^'DWPC^,
M]UI_CW0?#?AWQ/XL\1WWASXCZ?\ #V[^%E\?#V@>#O$%]KUHOC87VC/:6UCJ
M5K;:AJND6M]]@U^ 7_!>WX._$;1O O[(?_!1G]GCP9XA\>?M'?\ !-[]JCX8
M_$71?A_X)TF]U3QI\8_@C\9/&7A?X1?'#X):%'IFDZQ>6K^.++6_"]QJFM-8
MWD&@^$M'\6W26Z7-S%?68!^AOPJ_X*6?L>_&[X<_M$_%;X5^.OB'XP\&?LH>
M+==\ _'R6S_9O_:9LO$G@7QWX63S/%7@B+P%JWP>L/'OB_QAX5C,3^)_"_@7
MPUXGUWPZEU9/K5A8I?6C3;%O_P %#?V5;K]I[5_V,[?Q3\3)?VF-"^&5Y\9M
M3^%J_LU_M-?;X?A596L,TOC^#7S\'AX0OO"\VH7-MX5L-4L/$-S!JGC^YM_A
MQIIN_'T\7AM_Q8^!7[''[0W[.7_!:WXS>$TTV?Q!^S3_ ,%&?V=/A5^VE^T=
MXGT.!-/\)>#?VL/V5_BYX27QGX>\,RWM[]LF\._$/Q7XOTZZU'0I[>WN_%/@
MOXGWVG7FE:W9?#G5=:L.2U?Q_P##G5O^#J'XHZ99_M,:%\*KW1?^".7_  AN
ML:YX5\8?!B?6+3QGX9_:2\*_$?Q%\,]9M_B7X?\ 'FBZ;X@T[X=6=Y\3-=\.
MR:-9>,=,\%:.WBYI;+PO'?7=R ?K)I__  6=_P""=6I_LX_$S]KFU^,OQ '[
M.7P:^(6F?"KXH?%.[_98_:YT[1?!?C[5)X;)- U>PU'X$VNOJ=*U2[TW0?%.
MIP:1/H_@SQ)K?A[PUXMU#1=?\1Z%INH?1_@_]N3]G7QUXZB^&?AW5_BB?'=[
M\"M=_:5T/PUKO[.'[2/A&^\7?!CPSK7ASP]KWBOP&WB[X2Z';?$"_P!+UGQC
MX/L+GP7X(G\0>.Q+XL\,LGAEX=?TF6[_ (4O#7Q8^%4G_!KC_P %=?#4/Q=^
M'^M>(M8_X*!^,8=(LQXW\%S:]XEE\8?M#? 3Q7X1NK+3-(N[6._N/&WA;P5X
MQ\7>'4T73(;/7M \,^)-;T"U?1=%OI;3^IS]@_\ : ^!WP@URU^'_C/]J_P5
M^T9\0OCS]G^-WP]GL?&7PS\3>(?V8_V7?AU^PW^R]X8^*EW\6;[PA9^%_"?P
MA^$6G?&;X(WEC%-::=IEKXB\3>//!5]K$7B#Q)9^/_%6E@'TW\.O^"P/_!/3
MXJ>$? GQ#\(_''Q OPX^)'Q@'P \*_$KQ;\ OVDOAS\-6^,[M/%#\.O$7Q"^
M(OP@\*^#/!'B2ZO;=](L[7QMKGAY+W7Y+;P[:2SZY>6FGS^M>(_^"@_[+GA;
M]I37OV/]4\1?%.Y_:1\.?#)?C1J'PN\._LS?M/>,-3N?A*VMV7AC_A8WA_6/
M"/P<USPQXL\&CQ3?P^%6U_PKKFLZ<OBB*^\.-.-:TS4K&T_@.^!_Q#DN?^"5
M'P[@^,M_X&^+G_!)>P_X*R^.]1_X*/\ ACX,6]Q-^TA\+_"^L_$;2=5^!GC;
MQ/XOT_6?B587/[.'C?Q?=Z'J_B[2O"OPP^'7Q6U]/#GA/PC\.OBA=6_Q3O;S
M1OV<_;:\;^!/VF_^"WWQ@T/]GC]NGX3_  <U3XD_\&Z.O_#WP#\?/"WQ6^$-
M[X('C;XC?M37_B[P3X4U3QKJ$7BF/2]/\<^!O&/AKQI!J?P[O]!^*=IX$UW1
M?B%\/_$%E:RV5[? ']4O@3]JKX#?$C]G2/\ :S\)^/$G_9]/@?Q7\1[CX@ZW
MX<\7>#UTOP;X&&MGQCJ^N^%O&.@:#XU\//X:/AO7$UC2M<\-Z?K-E+IEU!)I
MXG58W['_ (7A\(A\%H?VBV^(?A5/@7<?#BT^+]O\5'U6!/!D_P ,-0\.0^+K
M#QQ#K#$02>'[SPU<0:S:WBY$]G-$T2NTB*WY3?$;]K/]D#]O+PUI?[&WP)\6
M?#3XI>#OVF-8^.UQXN\%^#_BEX#\$:U\>OV;_AMK_B;PS\</'_P7DMM;:?Q'
MX0^(7[2T>M_"[6_%-[H1TKXP>#O!G[3?B3P9JNHV.E:=XZD_&_\ 80^-?PI^
M('_!)K]M[_@CQ^WMK7B;XQ>._P!A;XG:?^Q1XXTCX#ZQJGQ4^,?B?]F_Q_\
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M#P[:>/\ P-HGPNU+QO\ "."XNIHK/4-2^+/A[P3IF@WLB6>O7FF7++$?"_\
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M'A_QOXB^$WB;Q#\6K'5?%4_A:SURS /ZYJ*_EBT_QSXZ^*OQ\_X)B_LTV_\
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M9?M(?LI3?LNZ3'K?[.'Q@^'MBOB_X"&_^+'Q1\9>,O@=X8\#Z5XOL/"_P&^
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH ***0D#&>YP/K_G\AR:  $$D @D=0""1R1S^((^H([&EK\!O#OQ?^(GP
MU_X*-_!7]K/7? 7Q!\,_LU?\%%-%U;]D37_'GB?7OA+#\/8=>\$:[XL^)O\
MP3,^(&BZ=8^-]?\ B?H.F_&7P)JGQY\,2>'O%OA#X<:K;_%;]H?X;>#?%NE2
M>,DT?1;?;\<_M\_MYO\ $+QO;?#+X4?# >"? VK_ /!2#2_B+:^*OA#\5M=M
M?@EHW[(FCV<O[-/CKQ;\9-+^*OA#P%XYT?\ :JO86O#HW@O1EUOP]J'BO6OA
MIH=OKGBK]EC]HS6;4 _=ZBOPD^&'_!0']K3QC\.O^">FF^*/%7['7AKXR_\
M!0[]D[Q3^UCX"U37/#/COX=> O#R^$/@E^R-XKU+X#Z%X<\1_&WQ3K?Q,^(\
MGBOX]?$KXGKJVG^+/#0;X$?"K6]/'A&VUS1M7\>A_P #?^"D_P ?/CIKRIHG
MCK_@GSI-A\._C[^RM\#_ (OZ/<_$SXF74WBS3?VBO@]\'?%.E?$OX ZM_9-E
MK7BWP[\7O&WQ4N]8_8^U'5? T'A#XY?#3PHD>K>+O"&H^(-;\5?#8 _=B@C(
MQDCW'7^M?R]_#'_@JM_P49^(_P"S?\/OC4(OV+-%U_XH_P#!-_\ ;?\ VY-,
MT;_A27QWU/1_!^O?L0?%#X>^ [_P=?2?\-+Z9?>,M)^-%I\4?#EW:20R>"KS
MX0W.F:OYM]\7HY;"*?ZLM?\ @IU\<_BE+?S?"R/]D;X0ZCX)^ '[$'[0/BGP
M-^U'\1/''AFX\5^&?VG-.\/^,/&E_P"#O%'A?1+S59_!-IIVNR?!+X8>,M#^
M'7C'5+[]H?2KW1_$'@J\L[C1_#VK '[J!%C&<D*N6//!R",GUP#_ %.3S3BN
M?XF'T.*_E(\;?\%6OV^-5_9OUGQ!KNK_ +/O@W5/C-^QA_P7,\8^!]?^$GPJ
M\>>'O&_P2^+G_!+GXL:G\.?!GCFWUOXA?&7XF^%?&NC^//#SQ/<^$-1\ ^'[
MCPOXQL;?Q4/%>O:+/)X!B_6W5/VG/%_[+'_!*;X;?M$>*=2T;QSXS\)? ']F
M^'6O%?BL:_8^%=%U+XF/\,O! ^*7Q=FDU[Q/XJ3P1\+[/QS;_$WXU:R-?;6;
M_P (>%_%VO6USI,MY;BQ /TI\5^*?"W@7P[J_B_QOXHT+P;X3\/64FI:_P"*
M/%.M:=X>\.Z)I\)7S;_6-;U:XL],TVRB+*)+F]NH+=-PWN,BLBP^)'PWU?Q/
M8^"M*^(7@O4_&>J>$(?B#IGA'3_%NA7OB;4/ 4]W;V-OXXL= M[^75+OPA/?
M7MG9Q>);>TDT:6ZNK6W6]:6:)&_";XT?$S]J#XJ?M%_L)>$O%'Q9_9,O[?PM
M_P %+M#M?"TGP1M?&GQ.E30_$O\ P2]_;!^*OARW^/&A3>+M#\-:5XHTK4](
MUKQ=X7T7PWXOU1M;\#>)_@Y\6+RR\#W5AIMIXT^2/V4?$F@_LG^$OC'XF;P!
M^RU!KFD_\%S?VDOV5/V=/B'XT^$%IX$\ ?LE)XG\'V?P_EU#PYXD@\1ZK<_#
M/P!XK^%7PS\/?LM_"SPCX7G\-Z1INN^*_A;X(US7=9\%VT6B0@']8^P9SN?T
M^]VSZ]1QQG.<=\\USWB'Q7X4\'P:;=>+/%.@^%[76?$&@^$M'N?$>MZ=HMOJ
MWBKQ5JD&B>%_#.F3ZG<6L5_XA\1ZS=VVCZ#HMHTNI:QJ=Q;V%A;7-W-%$WXQ
M:#^WM^TSXB\7_&SX!GXL?\$Z/"_[0GP$^%UQ\<+;5=:\9>.[[X&?&WP1'^TG
M\>OAOKWA>Y\6?\)5H&O_  3\4_ KP'\#+3P?^U!K^@:)^T7X<^$GQI^+'AC4
M[JWGTOPEJ/PN\6?+$/[3_P =/#/B/]J'6?%6N?"?]I3PI=_\'&?[(G[.'@[1
M_CCX$O/%UG\*O@]\3?"?["FE>']4^!T6C>,-.\->%/$OPIE^(F@^)/A9XFM=
M",=C\0K?Q'\6/$@\6>-/'5])& ?TR>6"/O.>^<]>F,C&#C P2":/+']^3M_&
M3CY=N1GH2.21WYK\2=*_;X_:G\+W'[6GPN^(MC\'O%_[0G[%'Q5^*?Q1^(O@
MKX6_"GX@64OQ9_8(\*_L]6'QH^$?BCX9>'_$'QBU2^T[XN?&SQ/XF\-?!BV\
M22ZSXJ\)Z+\4?#GQGT;0_ /B[3_AI=ZC<?27[%?[4/QD^.WBBP/CGXB?L9_$
M3X?>/OV;?A?\=/AS??LX^-?&6J>/8+SQ'K_B+1O$VIZYX9U:V\0:&_P9\1A=
M%M/A=XMU+Q1X6\8R^*/"OQ+\-7OA3Q*FB:CJ_A< _0KQ%X<L?$^C7NAZC=Z[
M:6>H)#'/<^'O$>O>$]:CCAN8;G;8>(O"^HZ1K^EM,T"PSS:7J5G<2VSS6[3>
M5-(K:&EZ7IFAZ9IVBZ+IUCI&C:/86FEZ3I.EVEOI^F:7IFGV\=I8:=IUA:1P
MVME8V5K#%;6EI;116]M;Q1PPQI&BJ/P(C_X*>_M2>(OC=\=/ ?P@L_V6?C7X
M8N?V3?\ @H#\:_V5KS0_[:\#Z#XF^*/[(_[8'A+]D_X?^!/$GQ8^(/QFT&Q\
M6V?B_P 0^*Y=%\=7EW\-?@AX!_X61X>N[#X1_&WXC_#+6++XFV7U_P#!;]O[
M5_$_["_[2G[6GC'P;XIUSQC^S+I'QY\0>./@,WP>\:? /XV^'M0^$GPVC^+V
ME_!/X@_"WQWX@^(4GAWXRWW@O5/#,4^I>%?&/C;X<^+T\2>'_&W@'6+OPQXB
ML+.W /U#8*6 +%6P<8.#CJ<_EQ^/IQP.C_%;X6>(/!6K?$;0?B7X"USX=Z%'
MXDFUSQ]I'C+P[J?@S1HO!DU[;^+Y-5\566H3:%IR>$Y],U&#Q*]W?0C0I=/O
M4U4VKVLXC_F!_P""A_[9O[57Q$_8!_:V^%?BK6O@SXO\,?&S_@BQ)^VQI7QP
M^ /P_P#'VA^%_#^F^.+Z#P/X^^"^KG5?BUX\TV^T3XL^%/'.FZS\$_'\7BF&
MXUSPOX'^-5OK?@;7+.QL]1MOZ5M!TSX;_!#3M6UKQ1>?"/P'X@^+'Q/T6^\;
M>+=(T/1/A+I7Q2^,OCI_"_PR\&3W]OJ&NZE<^(?B-XHT_1?A]\-="_M/Q#K_
M (I\42:+X:T'3GN/+TO2[< Z;X;_ !5^%?QDT&;Q9\(?B;X"^*OABWU*YT2X
M\2?#?QIX=\<Z!!K-G!:W5WI,VL>&-1U338]3M+;4+*XN;![A;FW@O;2:6%([
MF!GM7'Q"^'T7CVT^$DOQ"\)6OQ5U;P=JOQ TOX<-XHT%/B'>> ]'U?3?#FK^
M/--\%SW3:_>^$='\0ZWHVB:AXD32;C0+'6M5TO3+RY2[O[:WF_FL_P""1_Q7
M^(/PN_9V_P""=7P.M_',OPQ^$?Q0_P""?W_!3/XTZ[:W.A?#_18_!OB;X,?M
M=?"<_#WXL>%=9\6>$;G^SDN?!_[0_BO7M4/BQ_$_PVUO2]*\(>((O#4=I!KM
M[XE]=_9^^('Q:_:W^)W_  2[^.%G\1= \$?M'?M%?\$%/VHO%^H?&O0O WA?
MQ+IGAOXN>*?B+_P3"\0W.M7/@FX\O0]<T'PUX^U_5Y-0^'T]_I<$$%YK>AV&
MH^&]3N_[2M #]DOV2?V6?"_['WP9A^"/@[Q[\1_B'X=@^(7Q?^),6N?%";P%
M+XG37?C=\4_%WQE\;V@D^''@'X;^'O[(;Q]XZ\4ZGI%L?#OVK3K34ETL7LVG
MV.GP6GT!J7B'P[HVH^'](U?Q!I.E:MXMU*YT7PKI>I:M96.H>)M7LM%U;Q+>
M:3X>LKJ>*YUK4K3PYH.N:]=66FQW-W!HFB:MJLT:V6G7MQ#^8G_!//\ :8^+
M_P"U-I'@2X\<>+]2T?QW^SKX&\=?!3]N3X;3Z/\ #BY5OVV- ^(">!]=T>/6
MO#&D(?#_ (>\'0?#GQQX_P#!NFZ&^F?\)U\)?C=\"_'&IK##<)'K_"_MS^$/
M"G_#TC_@B/X^'A7PX?' ^-W[97A!O&_]@Z6WB]?"G_# '[2&M+X47Q.;0ZVG
MAQ]7#:NV@+?+I4NJ(NHO:->1),H!]@_M)_&[]FRREA^&OCC]O'P;^RIX[\)>
M)O"7C/68])^.'P$\#?$)M)L=FL_\(MXHT'XP:7XNM8O!7CC1;GR=8#>&;#69
M]'NH=2\,>(="U&'3]8MOK'PKX7T'P1X9\/>#O"VG1:/X9\)Z%H_AGPYI%NTK
MV^DZ!H&GV^E:/IENT[RSO!8:?:V]K$T\LT[)$IEEDD+.?R'_ &XOV//V3?BE
M\7?V>/A!:_LQ? /QA\;?VG_VCM)^,_QE^*GC+X:^$_%_Q5M?V>_V8M9\)?%W
MXR^*-<\:^*M#U;Q;XG\)>*=8TGX!_L5CPO)XI@M/"G@/]H?PIH7AO2U^''@1
M?#-E^Q]M=V]Y$\MI/!=1QS7-L\EO+'-&+JRN9K*]MB\3.%GL[VWN+2ZA8B2W
MN8)8)566-U !Q_A_XF_#;Q?XE\:>"?"GQ"\$>)_&7PYN=+LOB'X3\.>+-!UK
MQ/X"O-<AN+G1;7QGH.F7]UJOA:YU>WM+JXTN'7+2QEOX;6XFM%EC@E9;>@^.
M/ WBG4_%&C>&/&GACQ)K'@?5$T7QII.@^)-*UC4O"&LR0F>/2/%%AIUY<76@
M:D]NK3K8:M%:730JTPBV*6'X+:E^S/\ LZZ1^V7X<^+7[#G@_P"%'PR^*O[(
MWP6_:W^"J?$+PQ=_#GP'XB_;._;:^,'@&RU;0?@#XVUJX_L:[_:?U[X3Q> _
M'GQJ_:#\1_$#5@GA?XU^)/#;Z=XOU[QEX>_:CTKX:>*_LR^#-"^)^@_\$$_!
MV@V.C>+O GQO_P""57[4=W^V.KZO87-SXY^%7Q%^'7[&WCKXU:S\2)]2U--1
M\27GQ'_:OUOPS8?%34[U-7\8:EK_ ,1OB&-3DM'\0^-M6MP#^D?P'\2?AQ\4
MM!D\5?#'XA^#/B/X8BU'4='F\2>!/%F@^,-!AU?29%BU72I-8\/WVHZ?%J.F
M2[8]0L6N5N;.0A+F*-C@Z'@SQMX*^(GA^T\7?#[QCX8\>>%=2DNHM/\ $W@[
MQ!I'BCP_?26-U-97L5EK6AW5[IUR]G>P7%G=)#<R-;74,MO*$EC=!_+)^T%\
M*OV?;+X%?\%&_CU^RKHOPP^ /P(_:>\&?L4?"BX^&GP@U?PK\(O#_P ;?V+_
M (%_M0:!H?[:G[;\^@>"KSPA-X:^$7CCX ?M$^-/A=IOQ&T>*QM]2^ OP\\.
M_&OP]XSU'PY\;/ \MC^QWP/DT?PY_P %.?V[= \#R:/IGPVB_9F_X)\7?CG3
M=%U&VB\.:/\ M):AXA_:O\(7%C?:7%??V;H7Q&U?]GC0/V8=,U'2XK"TU6Z^
M'NF?!*2>!=.O?"TFH@'Z8S2P11RO/*D,44;332R.L<<4,8+O)+(Y"1QHJEG9
MR%" EB!DUDR:YX?CT:#Q#+KVEIX?O(+"ZM==?5+-='N+;5&MTTNYM]4:;[#+
M!J+W-JEA-'.T=X]U ENTAGC#?G'^WWXID\2?&?\ X)V_LE:UI1U'X3?M<?M/
M>-]&^.%J\Q6T\5> OV?/V9OC9^TQI'PNUJS^Q2)J7A#XA_$OX7> +?XBZ)<W
MZ:1XV^&VC>,?A;XKT7Q%X-\?^)M.2M_P4F^%5U^V%\._%G[#;> _B5XN\ ?$
MWX5>*M:^,'B#X977PL@UCP%>ZO!J6@?LYWSVGQ5^)/PG&HS6?Q7TK6OCCH][
MX(\2:I>Z7K_[->D^%/'&E0^%_B9:IJ@!^G^W/.YN>>N/TQQ]*:8P1@L_;^+T
MYZ8QU]OY#'X0_#[_ (* ?M#_ !._9>_X)P^(]=L/$?P\\8_&CXI?$']FC]O3
MQ)\//!%E\1?C[\#?V@/@!\/?C!X5^(/A[X:? #2/ GQ0;6O[:_:A^$DEAXYU
MJV^'7C_1/A=\$KC6/%]_H^C>$+YOC1\-^>\(?'W_ (*P?$3Q7^P-\%?'/Q!^
M W[,OQ4_:A_9A_;'^+GQ"DN_V6?%'BO7/!NO_LZ?%+]GW3?A;K-YX*\1?M!V
M9TB/XG_#SXS^%M4\?_"C5[G1?%'PYO\ 4?''A*;Q1#XK&@7O@( _H ,><_/(
M,C'#GT[>AXSGU^IRY5"@*.@Z5^ ?AW_@IE\=M6^%OB[]N/PW)\(_&'[/'AWX
M._MP^(_B!^RWKOC.]T;]HCP1\4_V4/#7C/Q5X4^&W@'P[HGP7.LZ9XV@3X9>
M*_!/[1FB?&'Q;J^@?V_KWAGX@?!OQ-I_A_\ L;X>>.LSXX?MJ?MK?"CX ?$;
MXZ_#;X^_LC?&7P+XO\7?L ^*O@9KEA8W_P 1?$MKX&_:E_::\"_L^^/[&>'P
M%I_PT\(VGPE\1Z9XZ\,_$']GGQMXE;Q#\2K<V/Q5\ >*].^(CZ)H_P 2-  /
MZ#F7=CEEQ_=.#SCOC...G3UHV]?F;G'.X]OTY[\8K^=SXC?MF_MV?";6?VQ4
MO/C'\,/&&D_L5?\ !1;]A+X(>3+\#;?1+WXU?"7]N&Y_8_77? WB&:S\9W,/
M@N?X0P?M5ZH/ ?B_PNMUXAUV;P9X8/C9=51M?'B3Z2^'W[7_ .T+^T!\<=5U
M3X-?$G]G[PEX!^&_[6?[1O[%?QD^!7Q5U"_U?QKH^J?"[5/B+X2\#_$+PCX;
M\*^#=&^(.J?%O7=7\+> /CU!X7OO'<7PB\5_LG_$36+2:[^'?C+P9+\7+L _
M9!@ IRS ?WLG(R>,'GIT],=>]44O],?4+O28]1M&U6SL[#4KW2X[N!M0M-/U
M*?4+33;^XLE<W5O9ZC<Z3JEM974D:07EQIE_#;O))97*1_R)^(/^"EG[?7CW
M]B'X%_%S7_C5X>\&:M^V?_P2)_X*0_M20R_!WX;:#X.U_P""'Q:_8R\,> /'
MW@SQ+X&\4>+9?B!)?0?$+3OB'<>$/&.G:QI9D\/:/IND:E\/]:\/^-;2X\;:
MI^GGC5M>^$O[%?\ P2Y_:'T3Q+J^O_%[X4_$S_@GO\*[CQ9K\.D1>(?%OPH_
M;4^(?P1_9J^,GPC\<WO@W2O"8U#P1+X?^+OAKXAZ7X<NK%]*NOBY\$/@'\2?
M%.F>)O%GP_TC5B ?N 2 !D\$@ ^I/ Z<<G '8D@=2*0KDYW,.,?*<>O^?_UG
M/Y"_M8>(OB=X3_X*=?L03Z/\3?C=?_#?_ADS_@H%\5=9_9Y\!6O@#4/#7C+Q
M?\#;_P#90L?#LUCH>H>!;GQ#K?C'Q=I'Q@\3>#+274?%K7>DF[L=/^'5]X$D
M\3^/9/&GG?[*?[<?[2/Q+^(?_!,;Q;K^I>$OBE\)_P#@IW^R+XT^./B[P=X1
M\-0:6?V/_B!\._AW\/OB>\_A?Q3HBZO>^+OA7>O\2[/X#_$&T^*=\_B32/C+
M:>"]=\/^)]$M/&%]\*]/ /V\$8  #/@?[1SQC'/;@8P,#&<\DF@Q D$LY*YP
M=W()&#SCOU(Z=@ .*_)C]HG]JOXG:M\>_P!JW]G;X2?'#X>?LR_$O]E?]F[X
M"?M+> KKXU>'M,UWP)\=+7Q[XL^+Q\>-XZ\/3Z:WCO5/V?M!LOA7X<^&6J>-
MO@9XET#XA>#O'GCCQ1-J5OJ%QI/@'1O%7DOC3]O3]HK^P_C+^T'X3L8M/\.?
MLV_\%2? G[ OBK]E?5O"-HVN_$+X9>/_ (M? _\ 9OTKQR_B@17GC;1/BUXL
M\9?'OP?^TQ\(]4L!8^ =?_9\U/PAX#OOAKKFN>*[;XU4 ?N#Y8Y^=^3D_-P>
M #D8P00,8Z>F#S1Y0P!N<@= 2#WZ'CGCCZ>_-?S>^$OV\OV^==\1?!G5=1^)
MOP0_LWQW_P %D/VO/^"7FK^%=,^!NJ6.B3>!_AII_P"TD_@[XS0W5[\2=:\3
M6/C#PG=_L\6L]AX0C\07?A_7;;Q1KMKXGUJ\D?1KWPSL?##]N+]M[Q]XQ_8Q
M^!EU\6OAIINI?$3_ (*!_P#!5']ACXN?%>+X&V]SXN\::5^QEX&_:@E^$GQ3
M\/Z2WCNW\!>!O$%W<_"'2];\8^&8O"/B/1==\5+I=WIUUH'@_3?$7@+QF ?T
M6!<?Q,?J<TZOYK/V9_\ @HO^VMJ]S_P3+\:_%?QAX*^*7AW]I_Q=_P %)/V;
M/B_\-? 'P+7POKWB+Q7^PC9_M-:CX-^-?P]OE^(6MZAI/Q.^*,_[-!TWQ)\.
M)'U'X;2Q_$&:R\,:/X;O_#MIK&II\0O^"C/[8[_L'?'7]N7X,_&C]E+6_ WC
M'_@G#K'[7'P/TN>6[^+?C3X=?%_P%J_ABX^)_AW1O"GAGPC\'=/U#X6:?X;\
M<6_@*XM?B]XJU+XH_!+XZ>&K>7QAH_QF\/:MXC^'WA$ _I0V  G>XXY);I@<
MMSP/?C;WP.,<9H/Q#^'GBKQ3X[\"^%_'WA#Q'XV^%][H.F?$SP?H/BG1-8\5
M?#K4?%?AZT\5^%]/\=>']/O;G5_"-[XC\*ZC8>)O#]IX@L]/N-8T"^M-:TZ.
MYTZYAN7_ !\\:_M$?M1:)\5?VOOV8;S]L3X)> OCS^SA\!_ O[8WPD\8_$/X
M-Z-X&^&GQ3\&?%/XD_'5[OP!\1OAI-XI\??$+Q+^SU\&+#X4^$_A-XD^,/P5
M\<>%OBE;W_Q$:3Q#;W'B_0/#U_\ $K!\0?MV_%[PS\>_^"@GP>UOQW\'?!FH
M?#O]MK]AG]E[]GVXTOX>26OQ$^(-I^TM\$OAA\5M<\"^!M-UGQ/K>B^.?VFY
M/"'B[Q1I/PZ\7?$"\L/@AX-F\(Q?%3XL^%-)^#GA'QUI! /VCUSXA?#WPIXI
M\"^!_$WCSP?X=\:?$^^UW2OAGX/U_P 4:)I'B?XB:GX5\/WOBSQ/IW@3P_J%
M[;:MXMO_  WX4TW4?$NO6GA^TU"XTCP_87NLZC';Z=:3W,=OP9XZ\$?$?04\
M4_#SQCX5\>>&)-6\2Z#'XC\&>(=(\4:"^N>#?$FK>#/&&BIK&AWE]I[:MX4\
M8:!KOA3Q)IRW!O-"\2Z+JVA:I#:ZIIMY:P_@'\.OC9X__:2\5?\ !$SXJ_%\
M^&]2^*>B?\%&_P#@IG\&=6\0:)IFE6C:CI/P*^ '_!4CX :#K=V-(N;O28-8
M\::!\&- \1>,F\*R:7X,UOQ?'JFH^%M!T+P_#H^AZ/O>'?VQOVD;C]AKX7?%
M6X\?7>M_M1>/_P!IK]N#]F#X5? +]FCX5?#7X?/^TU\=?"'[:_QE^%'PPGL8
MOBOHW[0:?!KX._"OX7_"3QI\4_C]XCO$\9:EX5^&]CXN^*'C'XA:U>^"KJV\
M; '] @C   >3 &!\W0?ECZ9SCMBN ^(_Q8^%7P9T&#Q5\7OB;X!^%7A>YU.W
MT2V\1_$GQIX=\#Z!<:S>6]Y>6FDPZSXHU+2]/EU2YL]/O[FWL$N6NY[:QO+B
M.%X[:>1/R#^+?[4_[37AOQ1JG[)WPY_:7_9T;]J/]GC]D+X,_M/>-OBK\:+W
MPM\._A?^T'JL_P 4/B_\-_CF^K?#?0/"7C3Q)X7^"'@KQ%\$[GPGXZN?A?XC
ML_B!\(-:^+O@1=3USQ1J/AZ31_'?8_\ !>>%=7_X)*?M2Q/IMIJ,UT/@!,-+
MOXYFL9[A?VE_@M<P6]U]HTRXGBMUN%C#SR:1+=6P1Y_[.:XA-M0!^JG@3XE?
M#;XKZ1=:_P###XA>"?B/H6G:K-HE]K?@#Q9H/B_2;'6[6TL[ZYT>[U+P]?ZC
M9VVJ6]CJ>G7D^GS3)=Q6E_97$D*PW4#R=N4S_$_0CAB.I'IWXZ]1DXZU_/7\
M.OB5K7@G]H/_ (+2?MO_ !*U#X4_LD?M#? K]G_P=\)?$7P3\66WB/Q1\$E\
M#?!?P]\<?B5^S+^W/\;_ (@?#M+'QK^T=X=^.VC^)Y] \*#P+X!\#_$CX5>!
M_AOXW_9N.E>)_BIX9OSI638_MV_MX2>(/VO_ (/:7HE]X^\7_L^_M,_L?^%+
M3P[;0_L[?#3]L'Q=\)OC9^RIIG[0/QO\'? WP;XK\4:S^S/XN^._@>[L/$GQ
M ^'?PR\4^(M6U.Y_9[L?$^C:WXF\2_%70=.\07@!_15L_P!I^3G[WT]N<X'7
MIC P"04\L9SND_[[/8DCWXS_ (U^:K?M1_%7QM_P3,\6?M)_ ;Q;\+_B-\>3
M\-_B+;^ M1^(_AW5OV7/ ^M_''PMXP\1?#I?A_XH\$_&36;C4O@MXPL?B1H]
MS\,KCP'\3?%E[;^&/B79+X5\6>-M0TZ&]\4W'QUX3_;>_:A^)WCW]F#X:^!?
MB/?^ +KQ_P#MW?M ?L??'3PA^T9^RD_@_P#:3^$4O@7_ ()W^,OVGO!&D>+?
M[$^(,7P2UCQI97/A?3OB@/'OPAT[Q[\$OCAX;^)GPT\2?#_7_"'@W1_%'P]\
M1@'[W^7VWN !@ $=,8]/_P!7;%<_XM\5^%/ /AG7_&WCKQ3H/@OP;X4TB_\
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MI[>WT/QO;VLGAK5;B:&&PU.>25$;U%4VD'<YP,?,V<].O'MGTSR1P,?SI_\
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M_&VE>/?A3XBN%N/"'PPU@ _0N7]A?]BB?P7XH^&]Q^R%^S'<?#KQN/"2>,_
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M2/V;_P#@L9^Q-X\T#X%OX&\"?M&>$OVK_A1XG_::^&7Q!BUOXD_M'?M(ZO\
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M^$]\+VUC9WGA'7-"U[2]!UO1OE/]CWQY\:K?XT?M%_LD^%-?\,^(OAA^Q/\
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M2:RMGCX32/V%/V)/#_@'Q%\*?#_['O[+GA_X7^,/%NE>/O%WPWT'X _"K1?
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M:YJUE+XT@UM[;4=:U>]A*7&IWLD_U)10!X1XQ_9;_9E^(OBCX7>./B%^SO\
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MS7H/%5YK7PQ;4?#%RW@/5[SQ3;6_B6[U/PL=*OKKQ!!#K4\\FI1I<CT/XO\
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M\-?MC_\ !,K]H7]I#QO^QG\)/#GPB\2?\)/\4_ ^G?L;>,_"7B+X>>*==O\
M2KK1(]1T+X^>.8-$7XM_'[P?X3OM$LO NC7^A^&OBUJ<^B>)OJKQY_P6/_8F
M^'WP@^%OQWU7QIJEY\,?B3\+_@S\;]2U:V_X0[2_$/PO^#?QYU/^R? 'Q*\=
M_#GQ9XV\-?$O5M $]KK]]XGL?A+X/^*'B?PEH?A77?$&OZ!8Z&='U'5P#]4Z
M*^5_VWOVH-"_8L_9"_:+_:O\1^'Y?%FG_ 3X3>,/B-!X.BU*XT5O&>NZ'I<[
M>%_!C:_::)XEE\.Q>+?$\FD>'9O$K>']:M_#L&I2:W>:9=VEC/ W@/@CX?\
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M%OPY?1?'7P^\$>,/#/BOPAJ.O@'WK17SO^T-^TU\.?V:M/\ A1)X\:^NM?\
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MQGXG^(^H^ FTOP=H]TT&K>/--T_3]6\;^%O#</BC7W\)7FF_#'XMS> ?D_\
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MM?$DVK_$;4=4^R64,?A^R\':KX,T_P#MB^\8VOC2PT?C?&GC'XT6_P#P5A^
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M  4>^ 5[XD^,OAKQIIWQ#^#,WP?\!_!7XL1:I\9M!T+P)H_Q,^%'[1?B77?
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MFL>&]%\(Z=\4_$_@V\\0>)O&7@+PKID-SXD\?>#-*UT ^9/ W[&/[0]YX]\
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MCXHU[03?_#FV\8S^.IO#&O:)X\T_P]=^!-8T[Q)<_8815Y  /^?U]^N !VH
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MVM?"'PW\,]6^*O@CXI_#C3_"GB"P\2_"[QUX-\-?$&U\5:<_@>/PU-XTGM=
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M7=3FL=2O]:^=OVRO^";'Q&_:J^(/Q:\7:=^U#;^%/#_Q#\&?LK67@[P5X_\
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M/AS<_'7P<?A9H&L>&?%'BF7Q3\.M(@MO"7C?X>>++>2Y\.?$3P/JGB#J)/\
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MU#XEW6L^&/A]HFLZMKVHZ#X:U2?Q'=:Q>7#W45[!;V7E4O\ P50_9]UWXO\
M[$7PN^%^B_%;XD6'[:WBWXY^&-"\=V?PE^*/AK0/AK=?L^Z7XSL/'OA_XAZ+
MXI\&Z3XV\-?$;2?B9X8'@?Q/X"\0>%-%O?AEIEAXM\8_%N_\ Z5I/AR+Q?\
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MZA\._B]I_AC6OA_XO\$?'CP;<IIVDZKHOB/1]=L_$EYY/S?X9_8T^(7[./\
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MB%X,^"WB _M$P^$;OPV/#WPKUOX_:AXB^(;_  ^U:'X+Z7%IOA]_!'PO\/\
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MIWB?2M,\2:I\-;"#Q?=^,7_!.3XS_$9M>^)>FZG\(K/XU?%?_@IM^QS^WO\
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MT'X7V.H>(O$HT#2(;_4CK6N1>&O"NE$:'I':?&K_ (*=?L9?!KX!?%;]H?\
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MU?X,^,_B-\7_ -N+]EG]E[XF^#?%7C&_A\5^"/"/QZ\2Z5#K6H>&_#>A1_\
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M?B=IWP4^(/BKP]XIT_6M \(_&#5O$V@>#=/^%VMZKILES9V?Q N/%7BOPMH
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MWP[I_A_6+/1YHM)/@C66^(^GZE>^([*]?7]*_L:\TN#PQJ@U*'5]/Y;]@O\
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MPTC^,WP\?QQ9^(?A!X;L_&/Q6T"[\-+XA.K6NN?#?PE?0^)_'.D3VL>H^%M
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M;3P?X?U_QA-H%B9]:3PEH.M^)S8?V%I.H:A; 'IU%%% !1110 4444 %%%%
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M%KK]QX3T#2?@'XHT7Q->C3$UN/Q#KWA6/0_#VNZ)/KNNZ!R6H_\ !4SX /\
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ML^@_LT? /P&;;X?^&=:T]8+;0M*U6_\ CM\2?VH/BQ$NE-J5^_AWXL>'=/\
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MQA?^/?B,OA_Q1<^&_#.B:2CZ)X?BL?#'BW5+WQYX^\/6D>A:;X7O/&OCCP@
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MO-#\2:0;+7=!O]0T?4;*]G /P?\ ''_!/S]O)_$FM_#+P]X7_9R\;?#/3_\
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MUKX*_!3X[>!-,_X)V_!'_@G)^TC^RAXS_;B^.'P1^',5Q\"+34/#FD?M#?\
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MCW2Y([;X;>(H/C-XDU/X/?T,44 ?R-?M&^ ?A1\-OB[^V?\ !N\;0?C+\(O
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M(_C!\%_%]IHWQPM?C;?^*-&N/C-\-OB)XY\;_P#"3>$M$T.WU/5OA'93ZO\
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M>D:WK>BP>$/%NFZ3=ZQX6=VL;V?29_7/VM-/^$^K?M0?M1_$']I7X;?$V;X
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M)7@?P;\1?"DFJR^%O'WA7P[XT\-2Z[X<\1^#M;E\/^*=(L]=T:76/"/C'2=
M\7^%=5DTZ_MFU#PWXKT+1/$FAW9FTS7-(T[4[6ZLX>LH **\3G_:*^#EO^T-
MI_[*<OC*(?'_ %3X.:[^T!9?#Y-&\12S2?"+PWXU\-?#O6/%\WB./2&\(6:V
MWC'QAX=TB+0KOQ!!XFOAJ#:C8:+=:59:A?6G;>._B%X8^&^G:+JOBJ36X[+Q
M!XU\#?#[36T'PEXM\97!\3_$;Q7I7@KPI%?6/@[0]>OM'T2?Q!K6GPZWXNUB
MWL/"/A#3'N?$7B_7="\.Z?J&JVH!VU%4K34K"_FU"WL[VSNKG2+Q-.U:VMKJ
M"XGTO4)-/L=6CL=0BA=WLKR32M4TS4X[:Y6*9]/U&QO50VUY;RR7: "BBD)V
M@DYX&>.M "T5YGJWQ?\  >C>*_AQX,N-1U>_UKXK>(?&WA7P?-X<\(>,O%WA
MP>(/AUHNNZ]XPT[Q;XS\*^']9\&_#I])M?#6MZ>D_P 1->\*VNJ>)[%O!FCS
M:AXOGMM$G],H **** "BBL#Q7XHT/P3X9\1>,?$]\-+\-^$]"U?Q-XAU-H+F
MY73=#T'3[C5=7OVMK*&YO;E;/3[2XN6@L[:XNIA$8[>"69DC8 WZ*\\^$?Q6
M\!_';X5_#7XV?"O7#XH^&/Q?\!>$/B?\.O$QTK6M#_X2+P-X\T"P\4>%-<&B
M^)-.T?Q#I(U70M4L;\:;KND:9J]D+@6^H6%I=QRP1^AT %%4+_5=,TPV:ZCJ
M%A8-J%S+:6"WMY;VC7MU;Z??:O<6UH)Y(S<W$&DZ7J6J30P!Y8M.TZ^O746U
MI<21^1?L\?M%?!W]JWX2^'?CI\ _%X\>_"KQ;J/C/2?#OBQ= \4>&8]3OOA]
MXZ\2?#;Q;%'H_C+1/#OB&"/3/&?A#Q#I$5U=:3!::I'IXU71Y]0T6]T[4;L
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MSPW2QVZBYBF4E9HYO,2525D5E)% '^;/\!?B#;:I_P $IOA9X=^.5YH_C_\
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M'A/Q'X1E\::_XC\0>--,\>>(/$')WO[4'[27AKQ)IGP<TS]OSXL:#X2\&?\
M!PUJO["VI?$'7[O]G3Q3XWE_9I\6?L7+^TC'X$\5^-/&OPCU6"ZO?#7QBM/$
M_A#P1KNIP'5K+0[JY\%>(3XNN_#&@)HW],4_Q%^ $:ZN;GQ]\'XUTS6DT+73
M/XH\$JNG>(KEO$*1Z/JWF7H6UUJ>33/%:QZ?>[+Z1[#Q$JPL;74A'\^?M/\
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M_P"%@_#OQI<>-;GQ/??$&W\*1:_I7A6]^'/A30OZG/"OCCX9^+K.[F\#^,?
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MOAO/K_PXN/@7J/B'0OAM\;K[0)/Z>Y=,T^XC>&XLK2>&687,D4]K;RQR7*X
MN)$DB827&%4><X:3"KA@1D\GX@U#X:>%I=$T_P 5:AX'\.3>.=7@\%>'+'Q!
M=>']'E\8Z]>65Q>VWA'1+;46MV\0ZM=:?H]W>0:#8)>7L]GI=Q<1VKP6,C1
M'\Y'CW]O_4O'5I\$OA#K'[7_ (Y_8Q\5^,OV'?V;?C]^RS\:/C]X,&D_$W]H
MOXZ6GQ)^(G@3XU^'-6\"^!KG0_V>?V@/B=)J/A+X-:?J'[+O@W4=2T_XL>%/
MCWJWC/\ 9_M/L%YX,\?_  __ *4=?\/V7B_PMJ_AC6)M=LK#Q'HMYI&IS^&?
M$OB3P/XCM;?4[1[:[DT/Q9X+UO1_%?A75H4FD-AK?AGQ#IVM:1=+'=Z7JMO=
MP0W*[;V\4I0RHLACD$T9D1',<RJ466,LI,<JJS*LB;6 9@#@FG[!MVY.,]L<
M#.0!QQMXVD888!SGF@#^,K_@GA=^ /B_X3_X((^$_#'[3^L^&=7U_P#X)Q?\
M%+-,^*?CWX?_ !HT;Q5\3_"'C>X7]A:^\:Z%IGB?QKJ/CY?A?XOTM])U/6M2
MT:UTNTO/"/\ 9'B2XLM&T&\34=2L?7/A!_P4L^*OQR^"G[)OA'XK_MH>'/V9
M?VA/B'^P/^QU^TA\ /BYJNBSZU#^U7\=-6\<>,O#?[0'@GPE\+O"'B/P1\./
MCY\2M1\3>%/!'P>\3_LDS0VOCZX3XCW7BGX-0>&O%>L:;XB^'7]8\VA:-<.T
MEQI6FSR,D\;O-I]G*[QW)NS<1LSP,Q2<ZA?F9,[9C?7AE#_:IM]F#3[&V1([
M>TMH(XII+F*.&W@BCBN)C(TT\:1QJL<TQEE,LJ /(992[%G8D YWQQ$)/ WC
M.'_A--0^&HD\+>)(_P#A8FE/X2BU3P#OTF\7_A-=,D\?:#XJ\"I?^%L_V[92
M>-?#'B3PFMQ81MXDT'5]'%YIUQ_,#^S_ /MJ_M3>&?A%^R%\9M'_ &B/%_[4
M?QG_ &B_^"#O[4O[5U_^S_XIN?A[KOA[QO\ M5?LV>&OV8M9^#\7@#P5X$\+
MZ-X[TSQ?XLUKXD?&CP;X]TO1=>OG^(,^B7AN="MM;\ "31OZI[B"&Z@FM;F*
M*>WN8I(+B":-)H9H9D,<L,T4JO'+%+&S))'(C(Z,592I(JA%H>CP317,&EZ=
M!<P%S!<0V-I%/ 96O7D,,R0K)"9'U'47<QLI9[^]<Y:ZG,@!_,UKOQZ\9_%+
M]F7]H+]LC]BW_@H-XR_:E\!? B[_ &9/VTI_A%\,_$&L)>:;X6^&>O3^-OVM
M/V??'7BW5Y=2\6:9XA_:$_9KTS6K^']C[6=+\-Z_\$_CCHNC7.@ZM\*O OQ!
ML/ 5G]1?LS>//C7XN_;?\=?!?Q3K/QI/PQ^(^J_#O_@I%\!/$OBKXG_&!8M*
M_9,UOPIXX^$:_LZWL=W!X6@L?&%A^T%8>#?CAKWP<\1:/J]EI/PA^-=OX!^(
M6O:CKOPQ\#6=S^UEEXG\%S^*M8\#:=XE\-2^-]&TK2?%>O\ @VRUC27\5:3H
M?B6\U:QT3Q)K'AV"<ZO8Z3XAO]!URSTO6+ZSCM-7N]%U6WM+FXFTVZ2#IQ&H
M)()R2#T7HO1<[<[1S@$G;D[=O& "2BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KQS]HG2;?7OV?_ (YZ%=:5
M#KMMK?P=^)ND7&AW&GIJUOK,&H^"=<M)M*GTJ6&XBU*'48Y6M)=/EMYX[U)C
M;/#*)3&WL=! /4 X.1GL?7ZT ?C!^R9X>\+:M_P1#_X)O^'M:\/^'M6T+5OV
M6/\ @EXEQH.L:/IFI:+JVK:G+^S==6\<VD7]M/8:AJ>H>)+B&YMT>VFN[S7I
MH98A)J,D;'N?V==$T:V_X+#_ /!4+6+;1M+M]4O_ -E7_@F#/=ZI;:=9P:C?
MO<ZO^W5I]S-=7T4*7-W)/8^'=!L)9IYI'DL] T6T=S;Z381V_P!Y^%OV;/@C
MX'\2#Q/X/^'FB>'+N'Q+XD\:Z=I&ERZI;^"O#_CCQG/J]UXS\>^%/AT-0/P_
M\(>/_&5WXC\4WWB[QUX7\,:1XM\37_C+QQ?ZYK-_=^-_%<VK\Y)^R+\!C\1/
MB!\6['PKK_A[XG?%:7PW+\2_'?@[XG_%CP1XF\=KX,M=0LO!5IXJU3PAXXT2
MYUO3/ ]EK&L67@?2;YY=,\&V.L:K9>&;32K;4KZ.X /P?_X*!?%6/P=_P4L\
M:?'+X6?LS_#K]N&T\._\$4_VI_"?Q)^%5[K?A](O&_PX\(_MN_"GP/\ &KPS
M<I?^"O'-I\2;3X?6-S\13XO^#;V[ZSXMT^Q\<>"/"FEZ]XYUW3_"7B'J_CG\
M%]&^!W_!*;_@D1\,O 'Q2T?]JO3OA=^V_P#\$A;CX-_&77'&D>&_'6BW_P"U
M'\*Y/AWK'A/5;>'Q]J7@SX=R>#?$5EX.\$7UI+XUUW0_A9)I^EW>H>,;HWTV
MK_M)X$_8H_9;^&'Q#\#?%?X=?!CPGX)^(7PS^%.E? GP!XC\-/K&E2^#_@CH
MMLEOIGP?T#3[35(])T_X86=Q''KT7@.*P'A9_&,<?CB;2I?&"#6ARQ_X)Y_L
M:+\._"OPAM/@%X.T?X2^ OB/-\7OAY\+/#MWXF\,_#;X;?$V36[_ ,30>-?A
MIX#\/Z]IOA;X=:[I?B;5=6\3^'KGP5I6A#PSXEUG6?$'A]=-UC5M1O;H [+]
MG_X=>*M(TKXC_$'XB?#;X3?"7]H'XM>,_&B_$2_^#DTVMZ)XD\,>!/&?C+P/
M^SAXJU_6=2T7PY)XR\<Z?^SS9?#'3/$&OZWX<TS57.E67@^2VM/"_A/PQHFB
M?BU^QG^V5\=-*^ /[-?P(U?XH^/?B3^TA^UO\:?^"O5U\/?C!XE\*?!_Q%J5
MQJ_[)_[:?Q5T2#P9%X7\2_$7X!>"M1U35= \20?$&V\'>']5L;/2_A!\(_B9
MX.\ :%X-TVR\.^)? ?\ 1_%$L44<2ERL<:1AGDDED(10H+S2N\TKD#+2RR/*
M[9=W9R6/Q/XN_P"";G[!GC_X?>+?A5XV_9%^ /BKX=>-_B?=_&GQ)X0UWX<:
M!J6D77Q8O[S6[Z]\?6*7-J\N@^([BX\3^*RU]H$FF$1>,/&=L$%MXN\1Q:D
M?'VG?MD?M5?$F#X@_ V#Q1^R9^S_ /ME_ W]ASX5_M4^*K/Q)XHUGXD_L]_$
M'X@>)O'WQ[^'7C_1C/;)X>^(/A[]G#X;^)_V?FT7X@_$7PE>^+_%_@W5OB[H
MMI.+M_A_IJ_&CYKL?B;\9/V8/VA?^"AGQ ^"+?!CP[\,M2_X+5_L)?#+XK>
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M\+/V5K#1M0_9BU75O"WC*?XW:3X]U+X1^(?A/XY\3_$CXB>-OB)X]EUR#2M
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M:1X:LM3\"V?VQ^P3^U!K?[3?A3XXKXJU/6M,\<?"3XO6GPWUWX8_$;X+Z_\
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MXC\KPI_8FA+H4=@FAZ2MF ?DY\2/V_\ ]NOP+XM_:R^">E>)?V9==^(_[/\
M_P %'O\ @F_^S?X;^(NL_!#XBZ9X1\2?![_@H#=?!:&30M3^'^F_'^ZU/2/&
M'PLU3XOQ0P^/8?'6LV?BSPSH<]C+X%T+Q#J,/B?3_5_#O[:W[76G^./CM^S=
MXXUCX/:W\5/A%^WQ\._V;/#_ ,2_"OPJ\>^%KKXY?"_XK?LCZ%^UU#X2^ WP
MNO/%GQ#\/:O^T_\ #C0/%%EI?C:[\??$7PO\#? GPNL-2^/7Q,UG1/#F@7ND
M:S]"_M;_ /!/3PS\5M U"]^"?@[X?Z-\2?B#^U%^QW^T'\=/$OCSQAX[LV^+
M6G_L@_%;P)\3?#OA[Q+JUOI/CZ^U#5M9T+X<Z/\ !_1M<N=.67P-X.U=M1LE
MUJQ\+:?X'UGZC\0_L;_LN>,/!?A[X=^-?@3\-O'7@_PK\5[3X[Z%IGCSP[:^
M.+FT^-MGK%]K@^+D^M>*QK&N:E\1[V^U35UUKQCJFI7NO^(-.UK7-%UV_P!1
MT;6M3L+H _'G]F7_ (*!?MW?M:>&/V(8/#^O?LW_  CUS]JG]A?]LOXN^+M;
MU?X*>/?'D_@+XT?LE?M!_!/X/MXLT3P[;?'GPWIOB/P9X]TSXJ)<+\*KK7M(
MN_!NIP:CJ7_"X/'5E%I>AR=9\,_^"C7[1\GA_P#8Y^+_ ,9YOA[I?PX_X*+_
M /!/_P '_$/]F[1/!GA#5-*3P]_P4%U'X2^"?B+)^S9?^(_$FIZY8ZS!\:](
MUK7O$G[-]AK&NZ)J5U>>!/B7X(\0W?BG41X)OKC],?!'[ G['GPONM)N_A5\
M O _PH/A_0_BKX:\/6OPK76/AIIGA_0_C?J#:K\6-/T'1_ NJ^'])T6+QSJ,
M6C7NM/I=E:3-/X*^&C6TMO\ \*N^'7_"+\[X8_9'F\/^.?A9X/AL_@OI?['W
M[,S^"O&O[+WP@T#X?>)Y/'_@/XGZ1X1^*O@#4;37_%_C'Q[XO\)2_#/P=X>\
M>V>I_!W1? G@?P+KW@K5+;3M$M-6L_#'@VPL_$@!\R?\%A_%_P ?/@Y_P28^
M/?BOPA\:M2\)?&?PI\/OACHOB;XI> ?"VA:'/XGN?$?C/P1\/_B,^A:%KZ^+
M_P#A [+QG:^(]:DLI-$U:X\5^#[>[A'AKQ=8ZW96FOP\?^TK^W7^T+\,_#?_
M  4/\;_"2[^%VN3_ /!+(?!_5/B)\)/'VD7P\2?M-^#;SX">!/VD?B_X@C\4
M^$[^2_\ A)J'C;P)X[O_ (>_ "_T[X<^(?#.A?&3X6^,M4\9#XB>$=>D\'_#
M3]:_BQ\)?AE\=OASXO\ A#\9? ?A;XF_##Q[I$NA>,? OC71K/7O#7B'2Y9(
MKA;?4=,OXI8)'MKNWMK^PND5+O3=2M+/4]/GMK^SMKF+S:3]DC]FN37/!?B4
M?!/X>0:Y\/\ 0_!'AGPQ?6F@V]CY'A[X7^+W^(OPMT/6;:S\FT\6:1\+/B3)
M-\3/ACIWBVWUNU^'?Q,GG^(O@V/1/&MQ/KD@!Y/_ ,% OCC\9_V>O@W\-_'_
M ,$)?AP_B+6?VM/V./@YXDTWXF^'/$FN:3K/@3]HC]I?X9? +Q'9Z/?>&?%/
MAV[\(>)+/_A95EKMAXLO-,\<V%E:Z/J&FGP1J%[JUEJFC?GW=?MG?MT^"=9^
M(</BGQW^S=XLT7]GC_@K+^RM^PKXWFTGX">/O"^I_&;X7_M>/^QG);:CIMK/
M^T#XAM/A'XP^#-K^UZ?[/\2QWOQ-TWXFS^!K%-5\&>"(KV]EU#]D_BY\%/AI
M\=O#&F>#OBMX:3Q9X=TCQ9X9\=Z=ILFKZ_H\=IXR\%:DFN^#?$L4_A[5=)O/
M[6\)>)+>P\5>%[M[AI/#WB[1]!\6Z2;3Q)X>T34[#RW6_P!BS]FOQ$_CA]8^
M&L5U)\2/B]X4^/WC:1/%OCVT;7OC9X#^R#P-\49C9>*K8VGC;P6-)\,CPEKV
MG-:7OAO_ (03X9C1Y+,?"[X>#PT ?G7#^VY\9_%?[<_P6_9C\8Z'\%?BC^S3
M^T[\4?\ @H)\ =6G\-^%M>U?P1;Z-^S-X.BU'2="/B[QO/I4WQ'^(UM=:/X^
M^'O[3N@Z9\/=;^!6D>*=97X6>#OB!>^._@O\4K;Q1\>?\$XOV_)?@W_P24\%
M?$75['Q+X=TC]@?_ ()U?LN:]XN^!NJ^#[*;QAX^TGXA?!+1]5^''[0K>*4U
M :%#\ _$5UIOBF/2=2\$>(O$6IVNG?#;XD0^.X_"7Q.\(>*OA#X<_;:Y_P""
M>W[$-QX[N_BE'^RK\"]-^)]Y\4/%_P ;#\2]"^'VA>'/B'9_%_Q_X77PCXU^
M)FD>-] MM-\3Z%XV\3:9'#J&L>(M$U33]3O/%T%MX^DN3XZM+?Q%'IZ;^PK^
MR7I.F^!-$L?@;X.BT+X:?"WQ=\"O!F@.VM7&@:9\#/'EW;7GC+X)W6AW6JSZ
M5KOP>\226&EP:M\+/$%GJG@2ZTW0_#ND/H/]E^'=#M+  P?V5/B7^T%XO\6?
M&3PY\:[3P-<^%-+A^&/CWX$>*M(UKP9;_$KQ'\-?B1HFNP7B_$GX?_#OQG\3
M_!&G:;I_C3P3XEF^&OQ,\-_$)K3XD^$]4_L.^\"^'==^&FK^+/B+\B_\%9M(
MU"Z^)7_!(C5?"]KX5A\>6W_!4[P5HOAGQ'XITJYU.U\/P:[^R#^V/-JDL\&F
M3Z=K6I:4)]&TC6K_ ,*6&N^'(O%=[X>TC3+OQ#X>(M_$&D?1DG_!,C]C'1_A
MCX.^"GPP_9Z^#'P?^%/AC]H/PS^TK+X7^'GPZTOPY,OQ4\(VEPNA^._"VIZ)
M<Z0?"?Q&M+J#0=,M/B";36];T#P7I]YH/@Q/"VO_ /"*>,_!?U3\3/@?\+OC
M#JOPUUKXD>$[;Q5J7P=\<V?Q-^&4][J.MVJ^#?B)IUE>:7I_C72+?3-2LK5?
M$ECH^J:UH=GJUQ!/>6V@^(?$^@P2QZ1XH\06>I 'XO>#O^"@'[67B[X*Z%X6
MD\9?L_2?M'Z/^U5_P4C_ &<O$=SX7\"Z_:>-?C!X:_85U#XV>%M$^*WP8^ W
MB3Q_J?@_PCI7_"5^&OA'JW[0.J?%KX\Z5\/O#GAK6K[X<>!_&4'QG^-?P0TR
MPW_#7_!1#X^VNC_\$YOCS\6!H&D_ +_@HC^PA9^)M"T+X>^$M/\ ^$A\'?\
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MNU.W^*?_  4&\,PW(CFFEALU30O#6A6'V;3X[6S9=/CN6@:\GNKFX]6\%_\
M!+#]BCX>?!?XN_L\^$/A]\0--^#?QM^']]\(_&7@6^_:'_:*\3:5I'PBUB34
MV\0?"?X5-XL^*NNW?P,^''B:#6=2L?$O@_X*W'@'1M>L)K2TU.VN(]&T(:9M
M?%3]@CX9>,K/XM:QX3UWXP>%?BG\8O@Y\&_@!XA^).C_ +2O[1W@CQ#IWPX^
M"GBV;Q)\/;K2-9^'7Q*\-:_IWB/P+J7B'QYXI@NM U;PWJ7Q)U7QGXQ\*_$?
MQ)>^$_'?B-: /0_VO/VH]._99\#_  YULZ#'XI\6_&?]H7X#?LR?"_0KJ^O-
M)T>\^(WQ]^(FC^!=&U'Q)K=CI.MRZ1X9\*Z;>ZSXRUN9-.FNM1L?#LFA:4#K
M.L::#^1O[7'[6/QU^*GP]^//[+NOS_#SP#\6OV:?^"BG_!,#X-?%S7O#GA7Q
M7XM^%7QY^!G[5O[6G[->M?#F\TS0KCXF>$/$WA+3_%OP_P#$VI>"?VDO@GXJ
MU+QQH^OZ9:>,_AYI'CO6?!_CFS\9V?[F?%;X+?#OXZ_#'6_A'\7="E\9^"?$
M46A'5;.?5=5T'5QJOA;6M)\4>%O%>B^)_"-[X>\1^$?&_A3Q=H.A^,_!_C3P
M;JGA[Q/X-\8Z+H_BGPGJ>B:YI6GWMKXEXF_82_9W\7^#;[P1X@TKX@7NG:S\
M;/!W[1GB?6$^,/Q5L_&?C+XU_#C6_ GB+X;>/?&/CBR\7V_BSQ)??#K4_A;\
M,E\#:5JFKW'ASPSHWP^\'>%M+T:W\*:#8Z)$ ?A9K?P:^!O[/G[3_P#P4ROO
MCOX<^%&N_LT?L@?LY?L0?M@:'\./"/@WXE?#R#X:_%_Q+\7OVVOCAJGB_P#9
MH\0S?M ZW'^RMXC\9_'WP)X<\;^/O$'@5])\+:^EMX?MO$=IHECX<UKQ/K7W
M1\:?^"A'[:7P+\4^ ?A]X@_93^'.I7WQA_;+_9U_9G^%?Q-\3?$MOAGX?UOP
MM^T#X1\>ZY?>+K[X4Z-+\9O'>GZY\(O$GPL\:^&M=M=7\0Z%X9^(F@W/@WQE
MX!\03:UJ'C?X;?#K[\N_V)/V=]6\9?'SQSXD\+:_XPU?]J+X5:-\$/C[I_C'
MQ]XY\4>%?B5\*/#NF^.M(\/^"-8\&ZSX@N_"UEI&D:?\3_B);VW]AZ3I5W./
M&6M/J%U>2R6KVOC_ (9_X)6?L6^#_"WPD\':%X*^*!T;X%?%GX<_&GX4R^(O
MVEOVE/'?B#P?XR^#WA[5O"GPETRP\7^/_BSXI\6S?#'X9^'O$/B;3_!'P4O-
M;N/@WX??Q7XLU.Q\"1ZSXGUW4;\ ^>/^"P7Q"_:5\ ?\$7?VL?'J^)?!/PD^
M/VE?LO:D?B7J/PPF\4^-/#FEZGKVAV_AOXAZ5\'_ !AK0^&?BK1S/<:S>Q>#
M_B!K7AN+7M#T\"]3PU#X@%IJ.F^?7WQ?M?V-?$'_  4-\'?L>_ SX%R^._V6
M?A9\'OVYOVR=#L(O'_P7^&OQJ\1^/_!WCW29/ WP-^'R>(/&_@SX+?$2_P#V
M>_V78-5U+XDI<:_X)\1_$*7P7IOC'P[>ZEX@\>>// GZP_M*?LT_"+]K?X-^
M,?@!\==%UKQ-\)?B%9KI?CGPKHOC+Q?X&;Q1HP8R2Z)J6N^!M;\.^)!I%U*(
MI+NRL]7M8[EK>W$I9(]AXCXF?L3?L\?&#5T\0_$+PSXEUGQ#=_"B+X$>,=<L
M_B1\1/#E_P#%;X+QZT_B(_"[XS'PQXGT:V^+G@M]8N]=N$T?X@6WB"*SM?&G
MQ(T;3FLM#^*'Q&TSQ2 ?&O[-G_!0KXZ?M=?M3^.OAU\'/@S\']'_ &=_ACX#
M_8N^,NO^.OB#\5/&]I\7O%7P@_;(^!OQ:^*&AWF@>!=!^%6H^$_#WQ(\(Z]X
M>\ Z;J7@K5_&FK^%[W06\37EM\21JVI:?IOAWT#XE?MV^-?AM^W'X<_98\5>
M"O"WPY\*^.=0^%.D_"'QE\5QXR\+Z%^T1%XRCU2]^(EU\#_C%8Z7JOP?U/XO
M_"B[T=?"]Q^R+XVU'P9\7O'&AZK=?&?P9K^J:#X?TCP#X_\ KGP!^S!\'?AA
M\;OC5^T/X,T37--^*?[0FE?#?1/BMJUSXT\8ZMHFNZ7\(=,U71?AM9Z9X,U;
M7+WP?X1B\*Z5KFM65K_PB&AZ$U]'JEU)K#:C.8I8LK7?V1/@+XE\>Z]\1==\
M*:QJFM^*?B1\,OC#XETJ\\=^/9_ ^N?%3X+6W@:V^$OC^^^'<GB5O H\2_#Y
MOAKX&O\ P]>6OA^V1-:\,:'K]_#?:YH^E:C9 'YG3?MW>._CW\1/C[^R;\0_
MA;X)TSP5\0/V(OVV_BKH>N>!?&OB'Q ?"LO[.7Q?T']F_P 6_#G5?B)IUE:^
M"OB[JWC'3OB?X:\9^(==^%E]X<T_X">-]/\ &?[/>MS?$KQ5X6U3QS:^3?L9
M?ME?%KP5_P $]_V(?A=^S'\'K/XZ?$7]GO\ X)D?\$R/BU\6O .IZIHWA'_A
M(_ _QD^$2:9%X?\ #OQ"\2^,_"WAWX<>)[#P7\)?B!XMT+Q9XST?Q'\._$7B
M"ST7P)K&J^"[>Y\3^-?!_P"BO@C_ ()9?L4?#2[T*^^'WP[\=^#I_"GPQ^,O
MP5\(Q:'^T'^T/;:7X1^$'QYUC3-?^(7PN\+: _Q3E\/Z#\//[;T71M7\&>"M
M,TJW\,_#;5=(TO5?A[I?AG4M/M+N&LW_  2D_88-]\"M4B^%7BJPU3]G3X(^
M&_V9?ASJ&A?'3X^>%[G4/V;/!^KV>M^&OV??BR/"_P 3M&A^/WP7TN_T^SS\
M-_CK#\1O"VIVBWEAK6FZE9:QKEOJ0![K^U5\:_&'P2\(^ [_ ,$:/X.U'5O'
MWQ8\)_#&?5?&6JZJUMX/T[Q-8:_>7/BW0OAQX6M+OQ_\=_%=A)HL%EX?^"/P
MZ?2O%7C6\U+SY/$WA'PSHWB3Q5HWY?? '_@J'^U;^U)X;_8WMOA?^SM\"/"7
MC+]K?]E3]L#XK6NI_$/XQ>.[KP[X#^,O['OQM^&WP3\9^'M;\.>&OA?)JMW\
M,==U#XAZ-KOAW5](\3ZEXPNCJ=]HFJ:%H47A >(/&GZX?&[]G3X4?M#P?#A/
MB?I/B.ZO?A%\2M)^+OPU\0>#?B'\1/A9XN\'>/M)T+Q'X4&KZ/XR^%WBGP=X
MJAM=6\(>,/%G@_Q-H3ZQ)H'BGPKXEUK0/$.F:EIM]+;GY^^%G_!-?]DSX(WO
MPXOOA+X7^(W@9_A!X2^/?@7X6VVF?'GXY7NG> ?"O[3/B+3O%_QET;PSINN?
M$+5;+3K/Q+XJT#PKXBTV)(&3P?K'A#PW?>#5T":P=IP#\VOC)^WQXQ_;>_8<
M^('ACX<_#/PMX&O/B=_P1A3]OCXT6?CKQ+XBUG3M%\*_M'>!/B3X?^'_ ,#O
M &O^#X_#NL3ZYJ=Y\-_C)>>(OB]JFA26/@NR\(>!K.+X0^/I?B?J_P#PK3W"
M7QY%\)?^#?;PS\2%^$GP_P#CEH/PZ_X)-> ?%OBGX,?$[7;_ ,)> ?B'\._#
M?[*_AW4OB!X1U^^T7PAXYN3#J7@&U\0PZ?X>30DL/$^IK8^%=1\0^#M*U>[\
M8:%]$7O_  2:_85O?"WPJ\(_\*N\::9IGP;_ &?_ !%^RAX-OO"_[0'[0W@K
MQ->_LP^)P?MW[/WQ"\7>#/BGH'BCXN?".R9;>;0?!/Q5U;QGHWAVZM8;W1;>
MQO7NKBX^B-6_9$^ NL?LI3_L2W'A;7+?]FJY^#T'[/\ <> K'X@_$.UU&;X-
MQ:!%X2F\!R_$%/%)^),FF7_A*-_"^I7LGBYM:OM#N;NRGU1EN)&(!^3?[2'_
M  5@^/'P"U/]N=_"/[._P=U3X<?\$^-(_85\7^*XM0^*7BR#Q7\6/AU^U+%J
MT6MZ)X+T^U^']AH'P\\<>&8UTN+P[#KNH>+/"2)HH34M;O?^$SN7^&?3_$[_
M (*??M3_  LUK]L/X>M^SG\ O'7Q/_9?_:D_8"^%%G;6_P =?B#X%\%>)?AG
M_P %"/''A'P-X E?7+GX(^-]8'Q#^'GBCQ?I'A_Q;>/H&E^%=8T"ZO\ XD:1
M:VNI:##\(O$?V9XX_P""7O['OQ)TS]H72?'/A/XC^(K7]JOPU\#_  C\?'NO
MCU\<+:\\?Z%^SE'#'\'[>2_T[X@65[X:N?#7E-)?:EX/G\/ZEXMFN;R;QC=Z
M_+=3,_C'[9O_  3NTWQMX4^+WB?]GCPKJE[\=OVCOCY^P!\0?CAXC\5?'?XC
M^';/7?!O[$?[0/PK^+>FOH,LU_X@T_P-XNB\"?#?5_ WA._^'VB>%KVZ\3^*
M]/U[Q'J\26%SK5H <UX;_P""EOQ1L_B_\1/V0_B=\*_A_HW[4NA?MF?"?]EC
MP;K_ (,\3>)/$7P'U3PG\?/V;O''[7/@CXNZS+JVCZ#X^AU;P/\ !SX6?%C0
M/$WPNBL+6+QM\5O!?A32-.^(W@+P1\4;CQS\,\/Q!_P4:_:J3Q!X'^"GA']G
MSX)ZA\<Y?V\_BK_P3U^)>M>,OBYXK\+?#:Q^(6C_ +&VO?MI?!7XR^ ]'\-^
M _B#KVL_#/X@_!U/#GB7Q_X2\1^)O#WCKX9^+6U+X0Z.WQ&CN$^+NE??>N?L
M/_LT^*O ?B?P!XH\!ZAXAL_&/QB\-_M#:_XMU;QOXZF^*LOQW\%2^%/^$$^+
MFG?%V+Q)%\2M \>^ -/\!^"/#/@/7O#WBG3+CP=X(\(^'O 7AS^SO!6EVV@H
MC_L1?L]/J?PGUPZ!XO&O?!KXX^)/VE/"FO#XI?$LZYJWQT\7>&==\#:_\1?B
M%JS>*S??$_5+CX>>*?$GPSTW3OB!/XB\/>&_AIJX^'_A?1]%\(Z/X<TC1@#Y
MP_X)R_%/]J[XE>-OV^=/_:C\<_"WQ)J_PA_:Y\/?"31/"/PH\%^)]#\(_#MD
M_8R_9 ^)WB#PMX-\4>*O&6KZWXO\&V'BOXG>(C;:]XD\,>'?$OB[Q'/XB\?3
M:9X%T/Q5HGP?^&_S'X2_X*J_M,:EXD/B_P 8?LQ_"/1?V?\ PY_P51U3_@EY
MXWOO!WQM\1^-/BG#XDU[XG:#\"OA]\:=(TOQ#\,_AMX;3P7I_P 8-;T+2_&/
MAZ2\U+Q7J/AOQ;<:WHMCIB_#]E^(/ZR_#O\ 9H^$7PH^+'QM^-7@+2/$VB^.
M?VA]>T7Q9\6(Y?B/\2-8\$Z]XNT+PEX6\"0>+]+^&&M>+-1^&W@_Q5J/@_P/
MX+\/^(O$/@OPGX?U?Q/I_A/P_'X@N]1?38)%^!?V(?\ @GU??#?Q)\=_'/[2
M?A73M6\3:O\ \%%_VI?VSO@/IFF_%+Q?XR\#^&;/XW:KJP\$>*]3\!W?]C^"
M]*^+GA7PIX@U[1KEH= UO3O#VJ:I=:[X9\07^MSOKL8!Y3\+?^"FW[4'B+P;
M\'?'OQ0^!?[.O@S1?VF?VN?'_P"P?\%M-\&?&;XI>/-7TC]H+X9?M-_M'_#/
MQMXE\82ZM\#_  )8:S\)-+^"G[/7C?QYX:N;63P=XM\:>/?!VF>$=1TGP!I'
MQ?37?@WZEIW_  45^(=U\2?^&0[_ ,&>!=)_:^_X;7U']CR/7I4\1WOP*NM#
MLOV6;_\ ;HM_C]:Z5::FWC 6][^RS#I+O\%[OQ-::I9?'K78/AK_ ,+.O/ &
MGZC\9X?KC1_V#_V9M&^ ][^S9'X.\2W_ ,)[KXIZM\;[73]6^*'Q0U'Q=X=^
M+^M?%>;X\7GQ*\%_$Z?Q@?B9X'\9V_QJNK_XI:+X@\(^+=%U+PUXRU&]U+PW
M<:3'*MO'0\?_ /!/S]ECXG^ !\/_ !MX)\5:BB_&N+]I%/B'I?Q>^,'A'XZ0
M_'^TTF7PUI?Q?M/V@?!GCOP]\:K#QMH'@EK7X9^%KZP\=VMIX3^#VC^&O@OX
M9L=)^$WA;PYX+TH _%C_ ()?_M$?%/X0?%'PW^QU8^%?AAI</[2_[9?_  7@
M\0ZSK-HGB[Q'9_#'XA_LN?M7:9#80Z!-=:KX7O/'_P /M6G^*UKI<=CK%KX.
M\3KIGA%+E]?@N=>%EH'U]^RO_P %-OC/^VE\#/@S/\%_ /PGT3]JKQK^PCHG
M[='B+X:^-=0UV3X?ZWI_C3QCX_\ AM\+?A'X0UN/7]"\0Z(?B!XX^''BRW\4
M_%Z\LO&FE?!33M.\.-K'P\\>3_$/1SH_U[HO_!,/]B[PYK/A+Q+H/PU\6Z3X
MI\$_'CXS?M(Z#XLL_CG\>T\5CXG_ +16I:9JWQY&K^)G^)KZYXB^'OQBU#1-
M&NOB1\'=?O\ 4OA'XQGTNSFU[P3?31M(_*VO_!(W]@;3?!/P"\ :%\(?%WA3
M0_V9?!OBGX;_  AO_!/[0/[1O@;QGI?PR\;Z[!XG\6_"_P 4_$3P?\6=$\??
M$CX8:]X@MH-3O/AS\1O$GBKP6DD9MK70[>PEGM)0#X=\-?MV?MD:-\;_ /@I
MIXAU/2M,^*_@S]G[4O\ @GWX<\!_"/X5_"'QC\1=9^$?@;]I/P]X6\>_$'XK
MOI/PO^(_C/Q#^T)<_ SP3\3?%7BSXB:'\+M&L]=^/EG\-M"B^']]\,](%O:6
M_P"N7[(GQ_LOVH?V??!?QUTG7?A;XGT3QSJ'CZ3PYXB^#?C2X\>^ =<\+^'_
M (C>+O"OA75K76+[2M#U72O$>H^'-#TJ\\?> ==TJR\1_"[Q]/XF^&GB)9-;
M\)W\TGG_ (B_X)Z?LI>)?BC\0/C+<^!_%ND_$#XG:C\%->\7W_A+XS_&OP9H
M%YXH_9TET%_@KXOLO 7A7XA:1\/](\6> K?PQH.D:=X@TOPO::C?>'+&;PMK
M<VI^&]6US2M3TO#'['7@3X??$[X4>,/AK?>-? ?ASX:7OQM\4ZMX=T/XN_%O
M^QOBMXW^/^O>)?%7Q&U7XK^ ;CQ:_P -O'MUK?C?Q;K'Q/O?&7C#PYXC^(47
MCNU\-+X6\0^#_#6D:SHWBD ^*_VS?^"B_P"T9^SS\3?VT_ _PY^!/P:\4Z'^
MQ[^P5X2_X*"2^)?&GQ9\9:9>_$#X<Q^(/CC9^/OAZV@:+\,[G_A$O'ES:_ #
MQGI/@B\BU7Q;X9BDO]!\5^(]0C\^Y\#PZNH_\%.O$GPA\2?M9+^TK\-_ ?A#
MP7\$_P!DK]GG]L[X=:OX-\>ZEJ%UJ'@']H;Q?\7/A=X?^&WQ5U#Q'X=T?P[X
M6\::3\0_A#<-JWCK2-0OOAUIOAOQA:7NJ7%C9^$]5US5_L3XK?L*_LX?&OQ7
M\<O&?Q&\,^*]:US]I#]G.']DOXQFT^)WQ(T#3/%G[/4.I>)]6'PZCT7P_P"*
M=+TGP_!)>^.O'S2^)?#5GI'C-H/'7BFT7Q&MKJ*PP1W?[!W[,NK:Q\0M9\3>
M"]<\:2?%C]F3PS^QW\2--\:_$'Q_XI\/>,OV=_!T7B5/#W@/6_#FL>);K1)Y
M[&?QMXZOW\7I8Q>-[W4/&WB:[O\ Q'<R:B/) /S-_:5_:Z_X* :%\8?V4/A)
M)H/A'X%^'/B!_P %#_@?\%+CXE:AX(L=4/Q]^%'CWX%?&OXW6S:;X"TC]HW4
M?'_P;D\ ?$+]G_Q-\,_B5HVO76K:/\9?#FJ^%/%?@#XD:5IC_$_X3V'A_P"P
M/^T;\0OV7]:M_ASI/PR\#:C\ OVB_P#@NM_P4[_90N=8?QAKD7Q.\.^,KOXJ
M?M/?%/P)XIT/1/["N/#MUX%T'2/@AK'@SQ%9:YXC/BG5+K6M+U72C86/A\VO
MB;]6=*_X)9_L8:-\/_ /PVL_!WQ;FT7X6?%WP1\;_AQX@U7]JO\ :MUWXG^"
M/'7PV\&Z_P##OP';^&/C'K?QKU#XLZ-X!\)>!?%OC#POH/PFL/&D'PMTW3_&
M7C"XM?!T>J>*M?U#4.ETG_@G)^RIH?\ PA_]G>%?',1\"?M9>-OVXO#!D^,G
MQ<N#8?M0?$A/%$?CGXERFX\:2F_C\2)X[\>K?>";\W/P]4>-_$YM?"ENVH@P
M@'S!\-O^"H=[XP\._L7_ +16K^"_#]G^R-^WGXL^*G@/X5:OI;:]/\5OAEJ?
MA3PA\7/BW\)?%?Q&T^\$6G^)O#WQ@^"WP+^(_B3QAH?A;1-+UOX%^/(_"W@&
MQN_CCI&NZAX_\/\ Y[_$+]IOXY^.OVH_^"<__!0+P_\  7PY\1]5^)/_  2N
M_P""D?[3/[-/P%^&VH>)[CXL^+/#FJZ!^Q]\2OA;\'/&ESJ-K?:-J/Q$OO"G
MBOPO=7^J> =-*_\ "9^-?&?PX\/Z#XKM?!GA;QM\2?WK\!_L9?LZ_#3QE8^-
M?!_@>^L+G0_&WQ2^)GA#PM?>-O'>O?#+X>?$KXV2:D_Q6^(?PT^%&O\ B74_
MAO\ #KQKXSC\0>,[6\\1^#/"^BZEI=A\3OC/I_AV?1K+XX_&.#QU\UZ9_P $
M>O\ @G]H]EX6TC3_ (3>/HO#O@'2?C#X<^&_A-_VF/VH[CPC\+O"OQZC\&+\
M4?!WPM\+W'QFET/X;>#-<N/ 'A;4M*\(^";'0O#G@S6-.76/!.F^'=28W0 /
M:OV(?VJ-._:W^'/CSQWH_BOX8^--+\%_%C6_A5!KOPZ3QIX:U5]0\)>$O!%Y
MXGL?BU\%_B=INE_%+]FWXLZ7XOUSQ!I^O_ ;XDI?>+?"6A6WAG5[G6M<T[Q+
MIFK7G$_M_P#[5OQ4_9<\%Z-J7PH\&?#WQ1KFM>$?C;XH6Y\<Z]KEU=0W_P (
M_AIJ'C_0_"WASX5>"[.3QQX\D\?ZE8IX=\2^,K75O#7@KX#^$FUKXM>/M5U6
MPT+3?!7B[M-4_8P\#0>+/!OB?P1K?Q'\%ZM9_'73OVA/B3XQT;XV_&33O%7Q
M1\:Z#X'\$_#:QL?'^F:=XQM?"7Q0T37/AW\/O"'PSU?3/BKI?C#PWX?^'.BW
M>E^#?"FD^+]7TWQWX3[KX\_LA_ +]I?7O OB;XQ>$M;U[7/AWH'Q/\'^';_0
M/B-\2_AY)/X'^-&C:-H7Q5\ ^)T^'/B_PI%XV\ ^/++PUX7E\1^"O&*:YX9O
M]1\+^'=4DTO^T-'L;F$ _)#QG_P5[_:)NOAM\5?BM\+OV:/@['X7^&G_  2A
M_9Q_X*T10>//C=XPFU77/A=\5/#_ ,6/&'COX/W,7A_X26\.B?$73K'X,>,O
M#/@G7+9_$7A6ZGDT/QEXBEL!J-SX"T[S/_@I;^T7XD_:O_9S^-L7@OPKX#@^
M"_[+?_!0[_@F1\&?%UUXIN?%2_$[4_BWK7[0O[$7Q=\4Z]X1ALK9/"D7A?P?
MI/Q]\!_"W^R-<@O9_&VH:C\3_%EEK?AK3/ O@JR^*OZBZ;_P2W_8UTGP9XO^
M'MEX+^(1\'>//V2/#/["GBK1;_X]_'76%U/]E'P?-XDE\._"%=0UCXB7^K6.
MFZ7#XV\<Z;9^(=/O[3QE:Z'XSU_0+7Q'!HLME86,'CK_ ()5_L3_ !*U'QGJ
MGC+P#\1]0N/B7HWP3TGXH6FF?M(?M)^%-!^)]W^SEJ?PYU7X*>,OB%X4\'_%
MK0/"OBWXF^ )OA/X#L])^*FKZ+<?$:;1]#BT/4?$][I$T]E( =#^WK^UUXB_
M8Y\(?"_Q_'X+DNOAAKGQ!U;1?C5\9]2\)_$+QO\ #_\ 9Z\#Z)\-?'7CNS\:
M?%+1_A/H_B+QUX9\">,/%'A+0_A9J?Q??0M1\"_!2;QM;?$CX@VVIZ%H8\-Z
M_P#.T_\ P47^*OC.V5_V>?A%X+_: \3?"'P3^RKXY_:0\#_#?XC^ =3T35-$
M_:3\(^'_ (AZQJOP8^.?B;XD^!?AS#X3\!?"W5KWXF_#_P"(GBG3]6^&_P"T
M+'I>J>!-+\7?##4-'O\ Q2?T9^)OP*^'WQ9USP%XH\51^*K3Q1\,+KQ%=^!?
M$?@_QYXU\"ZQH4GBW2%T#Q+&;GPAKVC+JUKJ^B@V$]EKD6IVENQBU*PAM-8L
M[#4;7YKO/^"9'[$]QXV^$_C^P^$>J>%->^#'PO\ AG\$?"5K\/OBU\:/AQX3
MUGX.?!JZCO/A=\+/BIX$\!_$/P[X)^.'@#P7-$L>E>$_C-X?\>:+)8O<:5J%
MG>Z5=W5E, ?%X_;V_P""A'Q.\*_\%"O'/P#_ &:OV<-4T_\ 8;^+_P"U!\%=
M%\!W_P 2?BUX]^*7QP\9? CP)\$OB'X(L/"6B:'\-_ ^D6ES\4M'\9>/M(O+
M&XU=M0\)^,!X*T31;3X@Z8FI>(]5R?VSOVT=,\7?L4_&/]H*/X7_ +.'[:'[
M&4NG_L(7GA+P_P",],\8>#[;QQXG^.7Q$^%/B"/Q5JFE:W:?$#3M:T3X>/\
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M'6G^!_ASX;N/#_PO\+^%_%_B/3?B3X#L?M"?L"?LI_M3>*+[QI\;/AQJNO\
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MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BC('4XHH **** "BBB@
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M.OV'-7\9_M6>!OB=X#_8)_9_^.7[*GPN\.Z1^S7??#[QCXQ^!'Q-T#]G'2/
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M^$[#P%X\^'^H?"GX^? #PW_85YX5UG4/V+?VAO![0_# ^,M.UG6=0O[[XP>
M/BK\.OC+X ^.(TFW3PUX9\566AZ+I=[J5M<VFHWMGP__ ,%4/V4M=O=(S/\
M%NR\,^./@[\4_P!H/X+^/+/X+_$'QQX2^/WP3^"%\]C\6/B%\'Y/A9I/CW7]
M<LO"!N?#.H0^']=T#PUXU\9Z'X_\ >(?AYX8\7Z%XIT_46H>+/V#SX._;/\
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M:>,?%'C+2_!^A>([K2]!\4:[HNL:OI=A>>F_LQ_";XZ_"[0/$S?M"?'/PO\
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M[JW[>'[%7Q/\ _M-G]K7X9?M(?M@?"VW^$/C/5M9^$7C7P[\!_V48_B!\/\
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MZ!I&CZ!X$N- ^''Q&^,7C?XD:7I7@4 _9BBBB@ HHHH **** "BBB@ HHHH
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M^$-<N_A7'I_B[50#[[TW_@L/\(=3\0?\%'/!47[-?[6L/Q"_X)@>'_#OB_\
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M;PSI\@U'1M.?XO\ AOXL&2'1]+U!-7U$ _H"KXL_:T_;:\-?LAZ;XGUWQ/\
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M%U?PGX,\1_C!_P $0?V4?&E]\5OVI_C7\0=!_:W^ ^M^!O\ @K_^W?\ M-^
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M$\?C#\!_%5S\%_VS_%WBOPS\'=<\-_L(Z)^UIXK^#JR^%?$#6WPQOO"?A/\
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MJ*:I)'(P<D8X/3N,$\'\_4 Y =0 4444 %%%% !1110 4444 %%%% !1110
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M=^'+?Q+\._B0EO=:"U[!JEM;S-X+\8R^$/'^I^&=8T'Q_P"'O"FM?#W6=/\
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M?\:Z#>Z3X]U[6]<N?$DFOZE^,GP-^-W[07[-'P2_8D3]EOQK\8/C-XM\=?\
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MLK?\+]TCP?\  'P[\1O!GA_XOZ_X<N=4^/\ =_!WPQXLU#4M4T[X\_"272?
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MOH"M\-/CUIOA'7+OX>S?LW_&SQN=/\4>.?@]\1U^('@G1["/QSXXL--_3>@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HP#U'3D>Q]:**  @'J <=,TF
MU<[L#<!@-@9 ],]<>U+10 @ &< #/)P.I]32_P"?SZT44 %'7K110 4  #
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M_*BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M.7_B4OQ-_P#H.Z/^$J_:V_Z(C^SE_P")2_$W_P"@[KZ/HH ^</\ A*OVMO\
MHB/[.7_B4OQ-_P#H.Z/^$J_:V_Z(C^SE_P")2_$W_P"@[KZ/HH ^</\ A*OV
MMO\ HB/[.7_B4OQ-_P#H.Z/^$J_:V_Z(C^SE_P")2_$W_P"@[KZ/HH ^</\
MA*OVMO\ HB/[.7_B4OQ-_P#H.Z/^$J_:V_Z(C^SE_P")2_$W_P"@[KZ/HH ^
M</\ A*OVMO\ HB/[.7_B4OQ-_P#H.Z/^$J_:V_Z(C^SE_P")2_$W_P"@[KZ/
MHH ^</\ A*OVMO\ HB/[.7_B4OQ-_P#H.Z/^$J_:V_Z(C^SE_P")2_$W_P"@
M[KZ/HH ^</\ A*OVMO\ HB/[.7_B4OQ-_P#H.Z/^$J_:V_Z(C^SE_P")2_$W
M_P"@[KZ/HH ^</\ A*OVMO\ HB/[.7_B4OQ-_P#H.Z/^$J_:V_Z(C^SE_P")
M2_$W_P"@[KZ/HH ^</\ A*OVMO\ HB/[.7_B4OQ-_P#H.Z/^$J_:V_Z(C^SE
M_P")2_$W_P"@[KZ/HH ^</\ A*OVMO\ HB/[.7_B4OQ-_P#H.Z/^$J_:V_Z(
MC^SE_P")2_$W_P"@[KZ/HH ^</\ A*OVMO\ HB/[.7_B4OQ-_P#H.Z/^$J_:
MV_Z(C^SE_P")2_$W_P"@[KZ/HH ^</\ A*OVMO\ HB/[.7_B4OQ-_P#H.Z/^
M$J_:V_Z(C^SE_P")2_$W_P"@[KZ/HH ^</\ A*OVMO\ HB/[.7_B4OQ-_P#H
M.Z/^$J_:V_Z(C^SE_P")2_$W_P"@[KZ/HH ^</\ A*OVMO\ HB/[.7_B4OQ-
M_P#H.Z/^$J_:V_Z(C^SE_P")2_$W_P"@[KZ/HH ^</\ A*OVMO\ HB/[.7_B
M4OQ-_P#H.Z/^$J_:V_Z(C^SE_P")2_$W_P"@[KZ/HH ^</\ A*OVMO\ HB/[
M.7_B4OQ-_P#H.Z/^$J_:V_Z(C^SE_P")2_$W_P"@[KZ/HH ^</\ A*OVMO\
MHB/[.7_B4OQ-_P#H.Z/^$J_:V_Z(C^SE_P")2_$W_P"@[KZ/HH ^</\ A*OV
MMO\ HB/[.7_B4OQ-_P#H.Z/^$J_:V_Z(C^SE_P")2_$W_P"@[KZ/HH ^</\
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MT^#]D+XXW^FZCX!E\ _MP^$_V;?#.N>,O&GBFR^!OB[6/A3J_P 6M!\-:/\
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M+\+M4^%O@GPG\4+C_A"&,:Z':R>&?%T^L?#G_A7^K:OXO\':6][<GPQJ.O\
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M^W:MXK\3^(-8^VZ* /D[XJ?LH:1\4/VGOV>?VJG^(/B[PUXU_9K\ ?'WX?\
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M^+7B";0?!FA:#I^I:582ZZNM?K=10!^;?B/]GB?XV?M/_LYZKX\\%_&Q+O\
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MB_QMKWPKMM"_:#_X*[>#?VS]"^)-]\,OVC?B%I_P#M-(_9UT/X:>&XM=\>?
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M\2/#WB#Q/X#^*?A_Q;I?AC1/!OB35XM#AU>]UL:#\2KG4[7X5:MIGAB/3?\
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M &7Q?X/?\%$_&O[17@3]O;QU\+OA1\(O WA_]C_]H;7/V>/ 7B_]HK]HF_\
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MNHZ9JFFW4%]IVHZ??01W5E?V%[;/+;7EE>6TL5S:W5O+)!<02QS0R/&ZL;M
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M\,_MP^!O^"A/[)3?"OQS\0[O]G^;]DO]H#X!?'?Q;XD^&O@[X@?!JQ\;:O\
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M$-1\<:?J/Q>\1S:SXZ\3?'/Q59:AXLU3XA^&?#\?A3P5X3_HDHH _G;\;?\
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M9'AMOB!H7A^[\8VP^%WQ4U+2[&75-6L-0T^\\U\:?L$_M*?$RX_9;\?W_P
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% &3K^HWFCZ'K&K:?H>J>)[[2],O\
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M=Y^SSXB\1V\?C/4/".MV'A[5O!ESH$5UXGEUWP]X:_J/V)_=7C&/E';&.W;
MQ]!2[5_NCTZ#H>"/RXH _GD\<?L&>)O&>@_\%W];;]A;P_\ \)U^UI_;.L?L
MF7FMV7[*EQXB\>^(?%'_  3[\(?L\ZI?Z-KL7Q,U&+X?ZS-\9V^+6K:_J/Q
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M9TJ&YEBDU&S68 T:*9YL8ZN!]>_T]>AZ9Z'T->#_ !#_ &EOA#\+_C3^S_\
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M^PWHA^"7QKTWP?\ "W5M9_:O^!?BCX[W'@#6K/1OC=X:U;P5\*=*\5Z#X2\
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M@ZQ_:'@3QIH4$T>MZ;XC\(:DZ7O]*?\ 7K10!_-O^U!^TQXUN=*_;8M/AO\
M'_QIX)LO '[(OP2^-W_!&GQ'\./C/JWB>/\ ;,^)ECI7Q"U:\B\):EK6L^*/
M^&U?$OQ/_: M?A%\ =>^"_B6?XL1>(_AQXS^#>I> O#FG:G^T/HGC'QC]>_\
M%=/CG\8_@1_P3!O_ (O?\+2/[/GQLLO%W['EAXHUCP3KVA:)9IK7CC]H/X,>
M$_BSX+T?6O$/]MW,/A^;PWX@\;L;K0]:M_$$6BZ2]ZGB,Z;!JK7?[%_UZT8'
MITX'T]/T'Y4 ?R0?MB?M>_%#P7\0_P#@K-XYT+]MWQ]I+_L>?MT?\$G+#X >
M%['XL>%-!\!^$_"OQTD_9LT[XV>%M=\(^'+71-,^(/@'4/#_ ,1_C!8ZOX8^
M(<?B;0H9?#UQXIU6"X\:>"QXGT[]$OV9?VKO!GQH_:=O_#OCCX^_&KP#^UK\
M"OVG/VS_  ]\:OV:0OCVW^&%_P#LE:+XA^,]G^SEX[\;^!O%=K9?"SPM\(=0
M^#\/[./Q7\$?M4>!K.SNO&_Q#F_X0>W\<:W#\0O&GAU_W-HH _D"_P""8?Q\
M\*?#OX#_ /!+RU\3_&_Q#X1^#OQE_8,_X*8_"BZTO0OBCX_T_P (^._VC-$_
M:T^"VK?!OP1X%T'P3KXBN?VH)O!7B3XWR_#*P^&VGP_'OQ-ITNKZ?X4;5Y]'
MT2ST_E_%O[7UQ\5_V _ /A#]IK]HCXQ>#]$^)W_!NSX:^(WP(\0ZOXH^(?PU
M3]JO]MZ[^%_Q3T+]I[2/$7CK48-.N?C]\7_!5MX'^$%[X/\ @IJ6H^(+'XA^
M'?C#\1O'%QX!^+&BZWX=UWPI_9+_ )_S^9HH _DWT#]K3QY<:)^RO^S?J7[2
M_BC]B/QW:?LE_P#!/7QU^P2?^%'?%OQU-^UI)<^!? I^,O@[PQX/T_X[?"?P
M!\4_%VI^*--O?@;X[^$'QR\'73?#OP#XC\%?&KP'J_A>?7]3\=:'^F?_  5<
ML?ASIGQ6_P""3OQ#^)GC'5O _AWP]_P4ETKP[J6O2?&'QQ\,?"EE;^*?V-OV
MRH=&2\30?&7A?09O%.N>-++PIX4\):G<6\OBW4KKQ%/\-_#=W<6'Q#USPUXC
M_97^O6D"JO10/H /Y?04 ?RL?LQ_&+1/ _Q'_9:\<>!?VJ+VWM_CI_P7G_X*
MR_L[^*/AE8?%_P +2?"3QI\)?&/Q _;W^+VG6,OPZLYDT77/%4GQ.T'X ^)?
M!_Q%O8]0^(MJGQ0\/>%=#\2GP5\1/"OAFX^I_P#@EQ^T]XV_:>^+VB^,O$_[
M3GB.Y^-MA\#=2\.?MZ?L$7GP:^+&C6O[.GQ]TK7]$CTW5O$.J?%/XS>,-#^!
M>H^%?%5M\4_ 7@'P[\,O"OA.W_:>^'WB+3O'>J^$=>A^#8\8>#_Z :,#T% '
M\[GQF\2W/AG_ (*N_P#!0/Q+^SAKT'CK]K7P?_P1Q^&/B?X"_"&\^,_BF^T_
MQC^T;X?\??MZ7OA7X<ZM\+O^%EZ-H6M:43/X%U*[\ ZC9VFA^%SXE@\=V5OX
M8USQ+-XIO/G#]J;X]'7_ -DK]LR^^&G[2?BWXR? KXH?\$*/VO\ Q3^U)I_Q
M7\97'B&]^"?[7=MX'T7X?_!O3]7M-?NK&X_9Y^,?[0E_X\^.O@?QO^S%:Z%X
M(T#2O&?[/\&D^%/A-X \5:3XLLO$']65& <$@9'0^G;CTXXH _ED_:H^.?Q1
M\(_MK_$GQQ^Q?=:!\3_VDM*_X-XKKQ/\#?#'A"YT#Q_XCU_7)/VA]$\2:=K?
M@+P7;G6D^)/B2R\'O=>.? ?@ZUTO6[?XB7VGZ-HMKI^KVFMQP7/LGC+2?CS^
MU)J_[<WPJ_8&_:V^*?CC]GOQ1^Q)\)_C;\$?C=H'[0GC75M4^%/_  41AUSQ
M9?>%?@[X>^.NGZ_J'C31OAW\7_ACX,^&7B7]HS]GNY_M27X;:%XSTCQ?X=T?
MX87'QQTH^(OZ-_\ /Y=*0@'J <=,@''3_ ?D* /YV_@;\8?CA^T'^TK\._&T
M.G_M1>#OV=/^"I/[.OP*_:(^"VB>)/BC\9?#UQ^RS?\ [+_C7X>>,OVE? OB
M70].UJWMOAJ/VH? _P 1/#6F_#_4? >N6>D>(--\)7\]BLFA^//$"Z+\T>!O
MVJ_B5XW^.&@?#[5?V]/B(-/U[_@X:_:?_90O-$TWXI?"W2=0\3?LY?\ #$7C
M7Q1X4^&]I)IGAJSU+1O#WA7XG:'X7\)^!U\#2^'+FU\4>-EOI)]4^+]YX/\
M%VD?U>8'H.<9_#I^7:B@#^5#3?VW#X,_9W_9=NOB+^VBGBC]G3PS_P %-?\
M@HI^RQ\6=>US]J;PS\)_C'\6?@I\&_&'[4/AO]F2QE_;*\0?%;X/Z-IVM^!O
M#VA_!WXB^(I?%/QF\"?$/X[>%(]$U;3?%7C.74+KP=\2?T?^!?C_ .(VD?\
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MSPYX$T&\^('Q[\%7OC[6]=TKX??$FRT[]FS3O%.L^#/ WCOX4^&OZ7Z3 SG
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M&?LP76GIXKTGQF-*\(?L<_$#QA\,_P!HK6K[]GGPI\0=;\2:Y_4$  ,   =
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M*<"#T.><?C0 M%%(2!Z]SP">GT!]: %HHII95ZG'X$]P,G X&2,D\#DDX!P
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MCK6OC/\ '/6-*^"OQ6MM(;XAR^ M"\1:UX;\/W7Q%^*GA'_A/#KNE>F>(_\
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MC:?\/_$7CSP9\.(_!5CX<?X6ZMIWC?0/CAI>CZ9K/Q9MM$'B'7;#0OL[3O\
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M#>,OC3KO_!2W_@KAX=^,L=]H,_A+2/V [CP[\/M-^.WC[XY_##PC:^)OA?\
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MQ+\!?V6OBSXI^%5GX"^(WQ\^'?@.RNI?AEXK/B?P_P"*O#7CB[@\+ZG<>*?
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M_3#X _ 7P+^SA\.K?X;> /[;N["7Q-X\\?>)O$GBK57USQCX\^)7Q5\;:_\
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M;2+7P_J_PYN/%5AXCUO3-,\07/BCQ#XF^&.B:SXB\.?!O6/ASX=\7>,=*\0
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M\,8/AOX=\9_$+1?%P!\V?&C_ (*!VVJ:K-\,/CA^R_XA'CWX&?\ !6/]@_\
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ML$U2#Q+HFIV>M_#GQ2/#'Q;\#+!:O\1_A_X-?6="AU/COC!_P4)_9X^!VO\
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M![C]H?Q187?[._PB^/6B_#3Q?'=:GJ.FR>/_ (>?"S_A:7@#P#KWA^VL=?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MTBUO]/L[S5_B'::YK7BRZQ?:7X4\,Z#!K/C, X[]@[]I+XC_ +5_P.U'XO\
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MYO"W_"6^)_"_PMUSXA>!_$TOC"_\"^G_ +)GP>^*O@#]K7_@I=\4_'/@._\
M"O@O]I'XZ_!+X@?";6+S7/!.IR:]X<^'?[*/P7^ 6MM?6'AKQ1KNJZ)>2>+?
MA5K>MZ=::Q96@F\*ZYX=NY7MM=GUWP_H7PA^U7^Q7^UEXM\9?\%MK;P#\,-!
M\;>%/^"B/[$_PE^$OP3\16'Q*\,:+?:1\2/"GP9^+WP3U'PYXO\ #GBHZ$=-
MMK;6OB'I'C34-=MM6NM+3X?V6JW&D2Z]X[AL?A_J !^DOQ8_;$^%MK\(OC+X
M@^#W[3'[%]O\0_@IXD\(^"/B/>_&'XY>'-,^%?P?\=ZWXJTG1[SP5\;M5\*Z
M]=ZU\//%FH6K:UI7A;PYKBZ=K&H>+ETS39+1XFN]M_XX?\%"_P!AW]G&W^(H
M^,O[5_P%\%>(/A1HNNZ[X[^'US\3/">J_%C2;;PWX(O?B3JNG6WPDT+5-2^)
M.M>)%\!Z?=^++'PMH?A;4O$6J:'#_:&F:7=VSI(?R-_;I_8?_:5^/>F_MV:+
M\(_V:[O2M+_:#_9-_P""8/PM^$6FZGXI^ GAG2- \7?LE?M"_%[XP_$30-6L
MM+^)M_#X<A\.^#_C!HGA;PI=Z-9ZEHM[XA\$^+]-TV]M_#%MX*\0>,?4/'?[
M"'QT^*/BC_@O-/:_"CP[X)G_ ."B/[-'@_X8_LZ^,?%FN> #Y_B_0OV,_B%^
MS]-'XYN/!NJ^+/$OABTM?&OCW4KFTO1I^K1KX;U;Q%?0^7?:E<Z3>@'ZH_!K
M]L#]G3XXVGA:U\%_&#X977CWQ%\(/"?QQO\ X2P?$?P-J_Q/\)?#WQ=I=IJ-
MEX@\4>$="U_4M4TW1K>:Z;29]?:!M!EU6UNK2TU*X>(BO:M ^('@3Q9X$T?X
MH^%?&OA+Q)\-/$7A:R\<^'_B'H7B+2-7\#:YX*U/2X]<TWQCI'BRPO)]!U+P
MK?Z)-%K-EX@LM0FTF\TJ6/4+>\DLY$F/XA>-_@O\0/%]Y_P3WA\(>*?A]\#/
MVW/AIX \.?LI_M2_"O1_B;HGBOXAR_L,?'CX>:Q:?%"WOM>\!Z5=:UX8\=>%
M=>^!EE\<_P!FCQ_=@^!=&^*/P[\1^$K75]>TKQOXOM;_ /4G]L7X"ZE^T%^Q
M9^U1^S#X"N?#WA+6/CC^R]\;_@-X,O=3AGL_"GAG5/B7\)_$WP[\.76H6VCV
M=S<VGA[1;K6;*6[@TK3YYK?3;:1+*SE=(X6 /!+[]L/X_>,OV7-(_:E^!7[/
MOPFU3P-XN^'_ (K^._A#6/V@/VF$^ OA6/\ 9]TS0- \5^ /&'CGQ!:?"7XE
M3>!O%_Q:\(ZCJ7C33/#6KZ4OA'X;>$+ W7Q:^(_A+Q5'+X,,'A?]O3Q1\4K[
M]D3P)\*_@E#;_&W]IK]D>_\ VUO%OPN^+GCN7P#?_ ;X2:;I7PQM+;PUXW.D
M^$/&&N2_$KQE\3_BUX=^''A/2;_PYX9T,:=X1^-'C?4=<35OA=:_#3QOQNA^
M*H_VJOV1/V>O VL_L::3^TG\$?BM\%M0\!_M)?#KQ]XT^&VF^*/@1\8? ND>
M$O"=_P#"+XE?#;Q[':6-_K/A+QW;_$?P=\4]:\.^+(_'7PA\8_#RW?PYX(\:
M7>L1W.@^%_L_?L"?M$?L22_L=?%#P4FG_M4_%3X)?\$_?B'^Q1\4=+\4?%_6
M/"\NJ:QJ_P 1_AU\8/@O>^#_ !EXVT#6G_X4]\,/%>B^-_ACXBOM9L)?B/I_
MP>U'P9XE\,>$?'/B;P2?AKXE /LKX._\% O ?Q@\/_L2_$2Q\/#1OA-^WMX$
MTVZ^#?B^7Q3HNKZGH'QT;X:^*OB_KG[.OQ'T+2!<66A^+M/\!> _B*UEXAT;
MQ#XBT5O&GPM^(?P_\2P^%/$$7@%?B%]J^-O'G@CX;>'Y_%GQ#\8>&/ OA>VO
M]"TJ?Q%XPUW3/#FB1:KXHUW3O"_AG2FU35[FSLO[4\2>)=8TGPYX?TX3&]UK
M7]5TW1]-@NM1OK6VE_"KQ#^QS=?"C]F[_@CQ_P $T?!WBC3=;^*OP7_:*_98
M_:'^*.LZ3-JMWI-CX%_9!\0M\>_C_P#%*:SN8UUG2_A[X^^,=OH7P:^'\5^J
M2VGBOXT^ ]/GCGTC1O$5QIWW%^WU\%_VA?&?C?\ 8D^/W[//A3PU\6M9_9 _
M:-\3?%OQ;\ O%?Q"'PR@^*7A/QU^SK\:O@!>ZEX.\4:AX>\2>%8_BK\.&^+0
M\5>!M-\:1^&_#>K0+XBT^X\=^%;FYMI+X SOV1?^"C?PZ^-'[-7BS]I/X\^.
M_P!GCX)^"]&_:/\ VI/@KHOB^R^-.C:C\'_$?A_]GKXE?$CPO9^,/"OQ7\6Q
M^#M-\8:/KW@/X:ZY\3&\16FDZ+82^#K+4O%(TO3-"TZ]FM?KVR_:?_9KU+6?
MB3X=TW]H+X)ZCK_P:\%Z5\2/B_HEA\4_ ][JWPJ^'FO>&H/&F@^.OB1IUMKD
MMWX'\'Z[X.N8/%FB>)?$\6EZ-J_AF1=>TZ\N=*S=C\/M,_86_;QL=*T7P[?_
M  4_9EO]%\0?MQ?\%;OC!K>OZ=\;-2TWXR> O!_[8>K?%GQ'^S]XN\)?&(_
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M>^'WA[XO?M<^(?BCI_AWQ?\ $J:/4O!7PO\ #7PK^%'B_P"(=UXI\3^"]/\
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M0G1M#G\<:> ?TZTC':"<9QV'4^@_$U_)K^W9^S+XY\9?#C]M_P 2_LE_ O\
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MG@]<=L\<4^@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% "8
M')P,G@G'4#H#ZXR?SHP"02!D=#CD=.GY#\A2T4 '^?\ /YFBBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M[?Q*^NR?$30?VC/B#X)^!N@:%\5]%^%5O\5/&.OG6O@UJ/Q#^'/A_P 6>.M
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(4 %%%% '_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>ex10-10_002.jpg
<TEXT>
begin 644 ex10-10_002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" /+ NX# 2(  A$! Q$!_\0
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MVHW<-JY$\MK87&HZ=!>7"(8K:;4+"*9T>\MUD -"BBB@ HHJ.65(4,DC;47
M)P3RQ"J  "22Q   ))( !) H DHK.TK6-)UVR74=$U/3]8T]KF^LUOM+O;;4
M+,W>EW]SI>IVHN;26: W.G:G9WFG7\ ?S;._M;FSN$CN()8TT: "BBB@ HHH
M_P ^O\J "BHH)X[B,2Q,60D@$JRY(.#PP!X/'(Z@BI: "BBB@ HHHH ****
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M?O WPX\;V_CGY=\0?MZ?MB>(?V0YOA_IOQ,^-^B_M8R?L4_LU_$CX<W5_P#
M[PMIWQ*\0?%?]LGQAK?A_1/BO\6M57X(:Y\'=5_9^_94L-<\!^ OBA<?#/X2
M>'O$GQ5^(FD_$F+P[X6TB_U7X46_B7]M-&_;_P#AGJG@CXA>+=<^%GQK\$ZO
M\.OV<-%_:ZG^'OB[P_X$'B[Q3\ ];TO7=0L/&W@[5/#OQ$\1_#2]U.UN?"_B
M#2-;\#:Q\0M"^(/AF^L+&Y\0^&-+T;Q9X&U7Q1ZW\)/VBM1^+.J>!;67]G?X
M]_#K1/B%\,[[XJ>'/&WCVR^$=SX0BTNT/@86_A[6[_X=_%[X@ZAX<\::S:^/
M[.]T+P_K.EV,FK6&@^,I[6X=?#>H* #^;/PM^T%^W1\&?@S)<_#?XK_$SP]\
M /A?^R__ ,% OB#\&/A]'X!^$5OK7AW]E_X(_%C1_@/_ ,$R_"UEJ'BSX >)
M=5U/]H?]HO3-/TC_ (5=?>--=U'PM-\.M"\5>+_%'A_XG^-M4?2M'^\5_;2_
M:$M_B#\;+'Q5X\^(FEZ9^P-\//B5XR^-_A?P]\*-!T_XE_M,>$O!7[)5I?\
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M$[X6_!GPUKNB>// 7[-OAZ[^)7C+Q!JCZQX4\6>,/B!_:'P2^%_@G1_"NA>
MM5_3_P#X*-ZSX$U3X$?!;]D7Q7XBTN_N/VNOV@_V>?V=M0TKQS=^'[.3Q]\*
M-/\ B1X1\9?M):=X@@%C9V]G%XP^!7@_QQ\/'OM(TO07A^(/Q)\">'/#5WX<
M\3>*?"$J_H7XS\;V'@;1M-U>]TN_O_[3\9^"/ ]G9Z5';&8:AX^\::'X.LK^
M66^FL+>+2-.N=;CUK6)Q*]RVDV-W_95GJVKOI^EWO(V?QN\-W_P7M/CKI?AW
MQOK'A36/"\7C+PYHGA[PO=^(_'GBSP[JJ/<^#[KP]X.\/MJ6K75YXXL)]+U3
M0M'ODT_6-.L]:MD\86/A>_L==LM) /D3_@IAJD^K_"_X#? ^S\8^-? LO[4/
M[5GP4^#^K^)O XO;>=_AUH5WK'Q\^,_A'5[W3]#\2ZC;Z=\5O@U\$_'OPCTO
M2+?1=23QGXN\?>&/ .J10Z)XIU34++Q/]FS]I7]H#XV_&_X*&U\8>)KFZU/4
M?CYXJ_:M^"U[X,T&S^''[-/PE\/GQ/\ #[X(?![7?%$7@^T\66'[:&I_$G3O
M GB#Q#X>U?QK+H?B#P_8?M.^([/PSX=\!VWP$TK3_J3PC^W]\*O%_@F'Q"/
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M$?AR/QA\4_A%X.\1'4QK'B[QM\._#-OXGF\8W7AWPUJ7@?0?%?PY^*_PLO\
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M]K3P=^REJ7Q"\>?#35-?\5?#O]HS1O$_BWP;X%US4-6^"_C3X_\ QG\=^/\
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M^&.I_M??#J[U_P"'/A2;XR?L^?M'_#3XL>.OCG\!_@MX!UB/Q'^J?[0GQSU
M^(-6^"GPT\2_#RV\3>&_"2?$W]H36/&WQED^#.G_  <^ \IO84U&;QSI/A+Q
M]XC\/>-O'NH6<VF>'+^/0-!L_"_@73_B!\0;GQYX2\3Z+\+-/\=_<>!SP/F^
M]P/FX Y]> !SV '2@      8     '0 =!C QCICB@#^67X=_M#?$CX;?L9?
M\$J_@U\#_CS\-/V7;O\ :'_82M=5\-WLNJ_"/P=\/_A%^UWXZF^#\?A?PO\
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M/?PK\5>$O@-\+OZ1L#).!DX!.!D@9P">^,G&>F32;5/55/S!N@^\  &Z?>
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MVTJT@L8+J^BL['2[6*\NHH%N;J"WTVP@M[B:6WAL[>.)(DZ2D  Z #/7 QG
M 'Z #Z #M2T %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M&DUVV\)_ K]G/4OAWX;T67Q$/'-QJ/BWQ1\7?V@/$-G^T?J]W+\/9X=#\?\
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M7^B@#\=O@!KG[;/P.^"-_ID/[#_Q)\0_'+XS?M$?M'_%_P")&L:E\0OV5H/
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MXH_:MU'6+_0?A7\%_#WA#X.?%+Q#\'?VL0?VJ_!.OZ_\#]0\&? ;0OB5XO\
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M"Z>8,L!@ )@DD@995!+';0!_-EXN_8X_;1^+'[+W[4O[)'Q8_9%\!^-OB?\
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MQXTL?"6LS:U/<16OAT:/:V.MZS]5)=Q/C:LQ#.$#")V 9MF-^T,8N'!/FA"
M#N XR 6J*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M:U8_\%!;;P+^R7\5M4A\9?\ !$OX(:G\)X8?V>OCM<1^,_\ @I#X=C_:9MM
M^)-K;:QX-=?%G[:_@V+Q9^SW /C5XF34?C]X#LUU&"Z\9Z+:>'OBHNE?1OBS
MPI\<_B+^UCH.@?&'X)?ML^*8O$'BO]E;XS_L+?M"?"/P3\&]%\-?!S3O!/P8
M^$+_ !A^'G[1?QK^+7P=O_CY^R;*_P 5_"7QJU+XRV-SK4NN?'OX'?'7Q?\
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MO7?BS9^./&^GW7A7]F>'PK#K'BSQ=\5]$N)/!'C;XI^!M-_X4?:>%/BAJB^
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M1#HGQ7LO&_Q*^(>N>,_%T"ZWJ'A7^KGR4XYE&&9N)YARQ+'($@R,DX!R!T
M %'D1XQA]OEF/9YDFP(1C 3?L! X# ;E'"D"@#^5'X8?ML?M/_$OX%?M(?M
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MX!*R#=\P .<Y7*'*$K0!_(!\>O'DOP_B_P""B?C3PQ^W'\:HOBO^S#_P0_\
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MCSXT?%KX?:%I'PL^!GAY_#VBZMX"NM9O?B+X<TG6? 'P)M]!\7?2'[:_Q.\
M1_\ !1?_ ((4_P!H^)]%\*7^L?&3]JOQ)'X9\6ZC;>%/%-CI/C?]@CXZ>&?!
MXU?PQK\NG:UI=UJWB*]L?!]C9ZC91W4GBLGPO!YVL1/;']P5AC0*J!D500JJ
M\BJ <9^4,!VX)&5R<8W-D6")!M52HW,Y 9\,S[][.-V'+EV9M^[<Y#G+JK
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M8%<;%VXQL*@IM(H _EPTW]L.ST*3X&^,K7_@H!J'QA_X)<_&']L8Z?\ %O\
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M2&02[Q\WRN)0)%9<%7^92&))<8D,9B8%T/!5V9]P)R0Q<LS#/&&)&/EQMXH
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MPLG_  4"U30OC/\ "6R$7[,O[.'[2'ACQ#J'QJ^*EG^SMI?PL^-%[\*?V_\
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M\2/C;H/PY\ 3_&;4/&?@2[U/P?<:C<7&OZOX<^&ZQ^&?WF_8-^+OA.T^"7P
M^&OB7]JS_AI?QA\3]$^-/B_X#_%3Q1X/NOA]XL^/GP*^&WCS3HM.\9:/INI^
M)O%VL^/M$\!>#?B+\+O"G_"Y==UF;7_C7I4NA?&/4I]:E\=R>(M4_0<6\2K&
MJAE6( 1A995" !0%7#C"@(%V]-I9<8=PQ]FA)!*DX='.7D(9X^49P6(D*MAA
MO#8<*_WU#  GHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M?&_PM\*_ @67PU\ Z]\2?B#J_B3PEXLLO'_B'0? DW@S65;X9^$=4N/!>O\
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M(OC+XP_%#7?A-\79].M?%DGA3PI!J?A_3I/'7Q'\,67BNUUFV_0?X2_\$_\
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M'!'K^K>#O%'@(:C<Q2VTYO3:^'?&_B.WL8&<6/GZD;JZM[N2UM#;_&_[2/\
MP3X\"_M#_"KX"_!^Y_: _:>^"/@;]GFX\(WWA&#X%?$3PGX-U#Q!KGP_T[0]
M,^&FO>.M7\0?#WQ=>:_JOPYN]&A\2^"1;R:7IVC>.Y;/Q\NGS>,_"W@77/"H
M!^=_Q]F_;$^&O_!&_P#9@\4?'[XU?%7PY^U[X2^*O_!.Z7XI^,?!7BZ_^&WB
MW5[OXH?MI_ /X8^)? GQ.N?AY<:';>(+B'X4_$C4? GQ-TJVG;PQXI\76.HZ
MS(=96&TO!T'[6'Q>^*_C#XM?\%<K?0/B%\4_A')_P3O_ .">O@3Q_P#LZR>
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M5OW\9>"_'/B?PU8ZEJ5A^A_PX\6ZUX_^&W@7QSJG@OQ)\-M8\9>%?#_BB_\
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M+#4[S5_%MS;>"_%6NQ_7_P"SK^U#X._:"U;XT>";71O$O@7XL_L[_$1/AO\
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M;FSU'PMK&KOX[L_%G_"17.M>*9=.UCPMJ?@;0["X\):E]U !0%4!54 *H
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M9\0-)UI8-<D\+?%NP^&OV]\/O",O@/P7X;\(W/BSQ;X]OM"TR&TU/QQX\O\
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M;<7FAW?P(\#^(( #W;Q__P %3?A]\/OB'\:O VK_  )_:3FTK]G/]J/]G?\
M99^.'Q(T[P]\&SX&\!^(/VJ(?A&GP5^(,"WWQKM_%WCCP!XBU+XX_#6PU2R\
M >%/$OQ/\)1ZQ=:IXI^'.DZ8NG7%[\]?M%_ML>,/B'\=_P#@G=<_L^:G\6=(
M^"'BG_@J#XT_97\??%'1I?ASHWPE^.D'PM^"_P"TM:?$CP5)IMWK5S\9=4T7
MPM\<?A1KWA?PIXAL=!T?P!XLU;X4_%#5;R;5/#-Q\%O%?CSV3QW_ ,$P_$OC
MJU_:HAO_ -I!'O?VK/VC/V/_ -I'Q9KE_P#!^VFU71O%7[%\7P+3X>Z?9Q:+
M\0_#NBW,'C&;]FKX1WGQ"N+?2-(@N;B7XE)X1TSPC:^+O"=M\-J6D_\ !)JW
MT#Q?\-IM%_:T^.&F_"+X+_MRZ_\ M\?"+X-0^$_@?=V'@3XF?$*+]H6^^+7P
M\L/&FM_#+6?$VH_"'QSXF_:(\7ZEI^CZRVH>-/!>DZCXDT[1/'<GB'4_"GC+
MP" ?KW14,"2)&%E?S'R3NSDX)^4$X4$J,*65(PQ&[8I8@34 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %?FK_P %'?VP_P#AGKX$?M)Z9\)M<U:;]I+P'^R)\8/VB/#T/A?X
M?R?%8?"CP]X1TK5])\+?%7XD^%H;VSMK?PIJGCN)]%\-:9>'5=6\7/X9\?\
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M4M;T_P ':+:^&O 'ARSCU&QT^Z^,7Q@^$>G:_>6OAK4-<N[3S&;XX_&[0_\
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M/_%6F?LX_M.:KJOA]?V>/VK?^"COQ&_8B\%_#:W\+ZG;ZYX0^'7A;Q-^T?\
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M+IOC/K#3:/XV\0>/-:UCQYJNK>(-0\>ZMXJO[W1#HGBD _7?Q[^V1\$/A?\
M$_PO\*?&FMSZ'?\ BOXE>'?@EIGBF:&V;P+IOQK\:>%8_&?P]^$7B768;I[[
MPWXS^(7AZYTI_!(U#1U\-Z]K_BCP)X!L_$)^(OQ#\"^$?$/A?PM_X*I?LG_%
M_P 0?!S0_#&H?%+1[/X^7G[0.C_"[QC\1/@?\7OAAX%UKQ7^S#JWQ%T[XQ>
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MHWQ'X9TWXO>!?$'P.\$^(_$]EH6@VWA#Q$\GB?3/">G?#V;4/#^M^&^(TO\
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M?"_PQXUUCXK/'X(;S;XK_L6S?%O]IS]E_P#:KU/Q99^$_%OPE\!>+OAO\=/
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M.([FW?YX9E>-LE2:_ ?]GS]CG]J/1;W]@'P7XW\-:[X8^-_[(/[6O[4GQ/\
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MJOAO7EM'T/Q!INMZ9?:)K*7[F*P;2M5M;J6PU%;V16CM&L[B87+J4A+L"*_
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M\.?@#^SB+(^ K*/]FSXU?#WQ1\8-4O\ 1M<'B+Q3H7B+PMIWQ!\??$?X3?M
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MX**_L]_!"X_9:\ _&O4_C#K7P-_9W^'/A[XH>.M ^-&N^%_A;^TPECHGPO\
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M@'](=%0P&5HP9E"OEN!_=S\N0"0&"X#8)4L"RX4A1-0 4444 %%%% !1110
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M1/'DG[9/P7T[X^6^N>)O@YX]^"WA_3/A/K?QT\$^(?%?PQUSQMXB_9LTS0O
MMKXJ\5_$#Q;#HVD:;XB^+LDP!_72;U%S^YN"0I=55$9Y$"LX9$$A?#A2(PP5
MG?\ =@;\J.#\3^*_$6B^)_ VBZ;X&\5>)=+\7:UKNF:_XIT>Z\)6VA?"_3],
M\&>(?$=EXD\;6VM>)=)\0WVAZ[K6BV7@C2QX)T?Q;K,7BGQ)I%SJ>E:=X3BU
M/Q%I?\[7Q%\,^+OA9\;?^"IVE?#7X'?ML7WP!^+(_P""4OQ"T2T\ >"/VR;7
M0=0\:^(/BYXGL/VQOB[I>GZ3I1^('Q=N[+X;#X/ZQ^V/\(/@#*?C)^T7\/\
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M)I]U\0)(O'<6KIXNTCXDZS;?=?\ P4)T;Q_=?M\?L6:IX?\ #G[4.K?#2/\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MCO=^'H0#^@>BOYFO^"O?QZ_X*+?L2?!?P%XU\/\ [8^L>#5^(O\ P5!_9\^
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MG9\'OCQXFC_;2_X)M>"? 7[3O[-/[1WAGX5? CQ)XF_:/^#?B3X5^'?B;=_
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M2UDP:=.FHM;W<-I)X?U?PYJNM 'TE1110 4444 %%%% !1110 4444 %%%%
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M5Q>9'[0G[3G[7_P?^%G[.GB?0/BI\)=0\1?&3_@JKIW[%NNW6J_ :\;3M/\
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M[_%OPEHW[1OP@\+?##X9Q_!"#P#I6G_"KX@:S^TEXY^+EM\([?X0?%37-?\
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M$'P;X;^(GB74=0;XI?"WX>?#;X?VEO=_##QM\'M3U_XI:CXW\-W_ (AL/A<
M?N?15:TV"!1&<QJTBIPPPBR.JC#X8;0 .@7CY $VU9H **** "BBB@ HHHH
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M[^T]_P %$/AQX*^ MYXIUC0M;\,_"_\ 9M_9V\ 6&LP>$/AIX%.CZ9XE\?\
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M7_AUIGC/Q5\-?!OQQ^&_QMD^ &@:SK/P=U[XJ>!_'7PP\9:Q8?!75O%7PO\
M&7A*ZTOQ'X-NVU3PJWB8 ]9_8H_9(U/]B']F^_\ @MX7\57'Q5O/#&M>+4^%
MC>,KR7PM;6/PT\,6]MX)_9H^$VNZ_I6D^*-1CM/AC\$?!WPN^%_B3QU%X=UK
M5/$.H^'M<\=/X=U*\U8:;+^<?PU_X)D?M:> OV5O^"<W[/\ ?:_^SMK_ (B_
M83_;0U7]J[5_$=GXQ^)OA_0_B?IUM<?'+4O#O@O3+"?X4^(M0\&7^HW_ .T-
MKNGZ[K5Y<>*;?1[/X;:1JFGZ;K4WQ*O=*^%_UYX:_P""@/C_ .(/CS]G_P"
M/PY^"/AGQ)^TO\3?V9?!W[7_ ,9/"MW\6_&>A? K]GKX&>.-9L_#'A:?5OC^
MW[.6K:GXZ^)?CWQ,^N:?\,OAKIGP=\,ZEK-CX!^(?B'QE?\ P^\/:7X9U3Q=
M]:?L\?&'XC?%.Y^,.B_$_P"%$_PC\5?"'XQ7_P +);"#Q1>^./#'CK28_AI\
M,_B9HGQ&\#^+[OP!\/4UGPQKNE_$ZQT[;!HHET?7]"U[P[J\UMXDTC7=!T4
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MS4_A_P#"+P5\77^/O[4?P7_9:>V\7?&;7O@W_P (=KOQQUU?#'A3Q5#=:/\
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M*%G^TC^RX_P4^-_C?XE?\%&-+O/&CZO\%;_XC:]\"OVX_P!HWXC_ !=;3/\
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M'\(6^(>M>%=#^'OB_2O%6L^"_'/PRT[6_B/JFO\ PT\6Z);:9=ZAX,\?Z?\
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MX@\,6OA3PG^S;\;/BKXP_:B\/^*_A?I<QA\467Q<^"_C'4?@IHNGKIFMVGQ
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M\0:AJNLZ==Z[^TSH'[0?C;5[/5-0NM0U;7/%>I^,KR66?Q4T\OUK10 4444
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M:7G_  K'2=?^)FK:^ ?T)45\/_L7_';]IOX^>&#XW^/O[.'P]^ /AKQ-X/\
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M OC;XF^&/B+HK_#WX;ZMXLT?QYXQU^'4_!OA_P *3^!M/M]9\5W^M:CXRL-
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M9>&+:VODG@CL]->P^ O[,W[1UW?SS(US>#R;JQTXVT*17.I">?[/!B:1H_\
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MHT^Z@O3&4>VUZU_9WC\-RO#%*D]U;C61=6\1R\&\B,T;C_@HIJ=[=2P^!_\
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MS@;B""%Z99B%Z\X'/)QP*\"75OVITZ?#SX =,<_&/XC$\%CU'P&4_P 6.<\
M=\DN_MG]JC_HGG[/_P#X>/XC_P#SB*J$8TU:&BW;=VVWJW=MO5Z[]NQS8O$3
MQE>=>JDG+EA&G&_LJ5*FE"C2IQ;;5.E34804G*;2DYRG*3;^4?VL/CSXN\-_
M$[X!^!9/'7BG]EKX6^,?''QNTWXD?'?Q#IW@*WLF7X9_LV_$WXH^#M(\,:GX
MVMO%7@_3-*>_\-ZY\7=4UOQ)ID7V[1_@CJOA+4]*OO"?BCQ#%7P1\"_VL?VU
M?VLOB7^RM\.?%VL?$W]B_P 9_M"?\$Y/CSXVUG1-0_9Z\5O;^'?V@/ .H?\
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MXAL/#<?B7Q9XIUG6@#]&RJGDJ"<YR0.O S]< #\!Z4  9( !)R2!U/ R?4X
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M2YT[X;^"X98K@A7=H;E?#]O,VR;YXY'CC9BJN\:ME1Z!X>\(>&/"-B^F>$M
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M\5/$>C_%'_@LUI5]X^_;SU_5_P!F3XA?#W4?V:K#X!:Y\;O'>K^ $\6?L1_
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M@/C_ .*VUZ[\&>%;;P'HW[,6K:5HGQ/^$<GBN\\07G@_Q/\ M&>)KV?Q9<_
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M4_V8=2^"GQY_X*"ZS\0?B[X.\2_ OQM^S7^T9X9_9Y\+^!]5^$?Q#_9R\?\
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M\(/VA/C;\3?@A\,?!7Q]U*\^#_Q(^*WP=^(7Q*U?X'^.O#?PA\._%+X0:/\
M"GQ!K_@F_P#&NNZ?8?9-1\0Z+\6M,U7X?ZC=Z9;>'O'>E^'/$>J^'=9O-+N/
M!]YXL\*^*/\ P3?\1_$>^_:VL8/CWI>A> /^"@WP]\ >"_VT?"$GPBN]7O\
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MPM^-L_PZOOB7X*\-^%_!FF>.[SPG]F_MT_LB_$?]K;3OV>;'P#\9?!'P>E^
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M ;POX-^!?B#]M?1OBS^S%\,M'A\'> ++6?V=YO"W[7#?#GPXL5A\/?!'CO\
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M-_AUX&TJ[O8="\'>$-*DUK5O$OC"]\3>+O$0!]6T444 %%%% !1110 4444
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MCY/C;\&/@)\<?%?@JQNOB;XD\<W&FGPU\0OBA\-/!/B8>-/BS\#]/^&_P_\
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M-NOVN]6T^'XD:#\)/V.?A'X+^-GC3XX>+/AGXV\,^!?B1\//%4/QPN-2\:?
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M_P ,M_#O_H9?VAO_ !,3]KK_ .?71_PRW\._^AE_:&_\3%_:Z_\ GUU])44
M?-O_  RW\._^AE_:&_\ $Q?VNO\ Y]='_#+?P[_Z&7]H;_Q,7]KK_P"?77TE
M10!\V_\ #+?P[_Z&7]H;_P 3%_:Z_P#GUT?\,M_#O_H9?VAO_$Q?VNO_ )]=
M?25% 'S;_P ,M_#O_H9?VAO_ !,7]KK_ .?71_PRW\._^AE_:&_\3%_:Z_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M%?&#3_V8OB9J'CSP]\=_#_AGXI:%XZ\#>*_BCI?QF^"6G^ V\2^#O"%GX_\
M@]ILS?"SQ+XAF^&OQY^*WA^7QRL=KX$E\,@'IL?_  45^ TO[.NG_M01_P#"
M:GX;:]\??&W[./A:P/A)1XX\4^/_  -^TCXY_9DU.YTCPLVMAT\,R>)OAWXI
M^(0U/6+_ $C4-*^$VE7OBKQ5HWAF^T[5="L/H#PG\=](\4?'KXO_ +/(\/\
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MXS\?_M ^'OV5]>E\7_"3QYX,^,OA#Q!H?[3%_P"$?$?@77K>PTKQ1>?$/S/
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
,B@ HHHH **** /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>24
<FILENAME>ex10-11_001.jpg
<TEXT>
begin 644 ex10-11_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" /+ NX# 2(  A$! Q$!_\0
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MH4 %%%% !111_GU_E0 44@(89&>I'(QR#@_K2T %%%% !1110 4444 %%%%
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M1$O_ !7;:IJ_BWXA>$-'TG3KN*\U._TD _ 7XL_%K]M/_A _BW^SE^T3\?\
MXK6/C7QA^SG_ ,$QOV=/B;_PKW0?AR]CX&^/O[77QBUOP-^TUK?PS^)WPJ^"
MWAO6M(^(/P[_ &;?#=[\2_%NN:E/JGA/QGXR^("7WP1^&?P^TKPYX;\!ZI^H
MW_!2+4O UW\#/@I^R+XO\0Z1J=Q^U[^T%^SM^SU?Z/XXN= MS\0OA'8?$GP?
MXS_:3TWQ%&UA:VMK;>-/@)X/\=_#PZMHVFZ+)%\0_B3X$\.^&+_PUXM\4^$9
MH_T(\:^-M/\  NE:9JVHV&J:A'JOC+P-X)MK;2(;26YCU#Q[XTT3P5IU_<&^
MO-/M8-*TRZUR+5=8F:Y-V-*L[N/2;/5M9DT[2+_CK'XU>'M2^"UO\==+\.>.
MM8\*:IX67QGX;T/0/"E[XB\>>+/#>HJ;CPC=^'_!N@-J6K37GC;3)M*U;0]%
MU"/3M9TRSUJTA\96'A;4K+7+#20#Y(_X*6ZK<ZI\+_@7\#+/Q=XR\"2_M/\
M[6'P0^#^L>)/!K7$$O\ PKW0;[6?CU\9?!^M7UGHWB*\ATSXK?!KX*^/_@_I
MFE0:#JL7C7QE\0/"GP]U."VT;Q=J6HV/AW[-'[27[07QR^-_P2-KXO\ $\MS
MJM_\?/%W[5OP7U#P+H]E\-?V9_A!H)\1?#WX(_![7_%5OX.@\6:=^VE>?$?3
M_ 7B+Q%X>UGQI/HGB+PY9?M1^)K7PSX>\#VW[/VCZ?\ 4O@_]O[X3>+_  %'
MXD'@7XT>&/B._P ?]3_96_X9N\7^"+#1?CW_ ,-"Z7X7N?B++\-X=%/B.Y\
MWZS_  @MI/CC!\0-+^(M]\*%^"BS_$V[\>VOA;3]4OK'L[C]M?X 6GPD_9\^
M-$_B6^/A/]I_Q-\%O!WP?L;/1[O5/%.N>(/CIXI\*>$/"]C>^'M*6]NM(B\.
MZQXNT\?$74+QTTOP+;6>J2ZY>PO:Q17 !^9?BWX\Z'XG_;Q_:8^)>A_M.?!3
MX5>$_A1XC_9+_8R\2^#M9T+3?BM\8/C'H?P^U.__ &C?C%H7[/WA+0O$&J7?
MB2]^-/BS]H_P-^QWXBT8?#7Q_P"*=+\4_#GXGV7P\E\(_$S08A?\%X4_;4^*
MVB>"?VD?&7PX^-/Q*^)/A_\ 9L^'OB'XV_LF>!D_9AT[P]\//VB/V2OC5X>\
M--\,/C;\;M)\'_!32?B%:?#G]F+XCZ_\0/AA\._ _P #Y/@1\1?B=\*/V6_&
MGQ"FT?XSOXOMM3\+_KUI7[8OP?UKXMCX3Z?)X@E2Y\6_$7X9Z-\3GL+"/X4>
M*OC#\(O#J^+?BE\(/!OB1M5_M7Q=XT^'OAZU\4-XPOO#WAW4? N@>*OAO\6?
MA=J7C.W^+?PI^(/@/PXS]F?]L7X4_M4I=#P!8>--"N_^%5?!;X^Z#IWCC1;#
M2KSQ9^S_ /M'6WC:?X$?&;1#HVL^(;.S\-_$N7X9_$>QL/"OBF[\-_%?PM>^
M"]2B^(7PZ\'QZEX:FUT _-3QY\3].\7?&W]C;0;K]HGXJ_'7X0^+_%7[07[;
MOA'Q)J/PHT/1;B\\+?LD_ /1_AIIN@^ ]2\(_#OPY#XPT;QK\9?CAI?[3?PH
MUO6O#6G>!/'NB_#;78_"7Q \0?#A?"?A#XC_ #I\"_VVOVN_&_P-TO3O&?[2
MZ> _BKHO[!/['_BJT^)OQH^&W@?P1\+?B-^UW\>--^+7[2_Q8T'XB_$/PY\+
MY/ OPD\'^'_@C\%])^"7P[^+[Z=X;\(VMY\3=?\ BA%\+/B[J=Q\'['6_P!U
M?A+^TCI'Q@^*O[0_PIT3X;_$SP_=_LT?$33?A9X\\8^*8? 4/@O5O&>L_#7X
M;_&+2--\'S^'_'WB+Q+JD=_\,/BW\/\ Q@+K4_#&B6]A:Z^FD:N^G>)K.^T.
MVZ-/V@_A?/\ M"M^R]:ZQ>WGQ?M_A1?_ !GU+2+?1=5;1M(\$67B?P]X2C-_
MXH>T3P^?$5[JGB2PN(O"MGJ%WX@L-%:VUW7+#2=*UWPM=:^ ?A(OQY_;)\5_
M"O\ :R_:-^&'CKX^0^.?V=O"?["7COPY\)/CI^SM\(]'^.S6_C>Z'[8?[2G[
M*&M6WPT_9>UKQ'J*>*/V;_CA\$_V=6\(>&9[WXTZ+^T+\$+[6YSX,@\3Q:W\
M0?I*[^/?[5EQ^UIX*_90U#X@^._AEJWB'Q;\-OVBM(\2^+?!/@?Q!J&K?!CQ
MI\?_ (S^//B%^S[IVE^!OA9KOA[Q^GP[^"'P]^''[-_BCQ+!KWP^TO\ 9VNO
MB_JOQ1\>?M ?&_XAP?L^:9\6_P!M*3 ]!^7^?0?E0!^6/[7_ ,5_@W>?MM?L
M&_"'XE_$3X:^#=%^$MY\<_VU/%%_X[\5>%-&TVPU[X>?#N#]G3X0^$-7;Q!?
MVB:-K?C'5OVK/%OQ/\ S32V]UJI_9\\57&D)=IHFHS67S+\2OVW_ !1/\5/V
M@/CM\+/&E[<_ KP1X1_85^%/ACQMXX^$7AZY\/? C2OVK/B];:O^T7^T;IGB
MG3/AK!XYM?A98_LYS? +XM:7I_Q"\>:UX2F\4K:>+/B?X0\!_"WP@^NO^]-'
M^?\ /Y"@#\,O$?[17Q__ .&@?A5^S3X+_: ^)&E>'OBO;?"3]HOX6_'GXM?!
M*/0M=\:_#/Q/\4_'S_%GX):;X+L/@I"_BK4_A1\/OA;X?/BB7Q%X>^$@\!^!
M/VH?#'Q3^*/Q-\'W/P^\ >#?C/XU\+_VKOVOO$VK? G7?B1^T-\0O@3H'QY_
M9<_:P^.6B0^._A#\'_B9I'PB\,_&[]HGX:?#W_@G+KO[0&A_#_X4>#];L/B-
MI&C_ !S@UOQG]D\<^!_A)X.\#_!"[\%_%==;\47WCSXW'^C*@ #H ,G)QW/K
M]: /YS?#G[9?[7OQ @^#'P/@\;_$7X/_ !+_ &B=+O\ Q/X%^+?C'P9X-\?^
M&I]?\*_%2^_9]\>Z/^SEK7@;X"_8/VD?A+X6L_ACJO[8_P /;OQ%\.O"\WQE
M_9\_:,^&7Q;^(/QT_9^^!W@+7+?Q5^J_[1/QVN4U[5?@I\,O$OPVM_$_AKPK
M%\4/VA]<\;?&I_@S8?![X"N-0@_M)_&FC>$O'>O^'_&7CS4+1M/\/ZA%H&BV
M/A;P+I_COQ_=^/\ P;XJTGX8:;X[^V\#GCKU]_K1@>E '\LOP\_:&^(WPW_8
MQ_X)3_!CX'_'OX9_LMWO[1G["$6J>&[]M5^$'@WP%\(?VO?',WP:@\,^&?B
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M@_V@_BMX<^(WC/\ 9'_X)S_ CXGV_P /="^'"V?PQ_:._;2^.6H?"/XL>+_
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MXDZA\0_V@O"YT;]NKQP/B+^RDG@^SF_:?^+&C^+_ /@H;>_#NVD_:BL-;O\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M;\2? ;PG\5-#^$_BG6?V4?V1_P!I7]B76O"6MZ+X:^-'P-NO"'C+]JE/@?\
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M7$K6]O/J^HV>FPSSI!-=/##)>30I+*MK;7%RT:,SK!!-,5$<3LH!K45Y]?\
MQ:^%6EZ!>>*]3^)OP^T[POI^I:!HU_XDO_&?ARST"QUCQ7KEAX9\+:5>:Q<:
ME'IUMJ7B7Q)JFF>'] L9KE+K6=<U&PTG3HKF_O+>WD]!H **3('!/7_$#^9
M_&EH **89(U;:SH&*LP4L Q52@9@"<D*9(PQ PID0'!=<OH **** "BC('4X
M[?CZ5B>'?$WAOQAI%MX@\)>(-$\4:#>O=QV>M^'=5L-;TB[DT^^N=,OTM=2T
MVXN;*X>QU*SO-/O%BF<VU]:7-I,$N()8T -NBBB@ HI"0 23@#DD] /4^@'<
M]NII: "B@'(R.AY%% !12$@8R<9.!]3VID4T4REX98Y4626)FB=9%$L$KP3Q
M%D) DAGBDAE0G='+&\;A75@ "2BBC/7V_P#UT %%)D9QWZX]O7_/OZ&EZ4 %
M%1+/"\CQ)+&TL:QO)$KJ9(TFW^4[H#N1)?*D\MF 5_+?:3M;$M !15>"\M+I
MKE+6ZM[E[*X-I>)!/%,UI=K%#.UK<K&S&"X6"XMYC#*$D$4\,A79*A:Q0 44
MA( R2 !W-+0 457BO+2>>YMH+JWFN;)HEO+>*:.2>T:>(30+<Q(QD@,T++-$
M)50R1,)$W(0:L4 %%%% !1129&0,C)Z#N>O^!_(^AH 6B@$$9'(-% !1110
M4444 %%)D XR,\<?4X'Z\?7 ZD5%-<06\4TUQ-%!#;Q//<332+%%!!&K/)--
M(Y5(HD16=Y'94558E@%. ":BC_/Y4W>G]X<G YZD=OK_ )[4 .HHHH ***.G
M6@ HI-P(R"".>1R.,YY]L&@$'I_(T +130RG.#G'7&3C//:ER.G?Z']?0<<$
M\&@!:*3(! )Y/3W[\>IQSCKCFEH ***AGN;>V19+F>&WC:6WMU>>5(D:>[N(
M[2T@#2,JF:ZNIH;:WB!WSW$L<,2M(ZJ0":BBB@ HHHH **** "BBB@ HHHH
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MES!-;R&58YXI(7:">>UG5)4*,T-S;20W-O* Q,<]O+%/"X62*1)%5@ ?S_\
M[?OQBTWP5\:OA#_P4!BNOB':Z!^P+^TQ8?"[Q3<:;\/?C;<_#/5?V0_BVJ?
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M7XJ?#3P[XO\ &GP5UG7?$'PE\8W:7ECXL^'FK^)]*CT;Q#=^$_$ND7>GZUI
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MB\0P6L4<$]_&GD1P0*(1Y)HG_!/#]A/P[\1_CQ\6](_9&_9]M_B'^T_H.O\
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M?B%XJAUCQO;:'!8:*WB"32M,TZTM0#['5@PRIR/H1_/!I:0 #I]?J?4^M+0
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M^IV,5IJ7Q!LIQX.N_M7B#PUJLGB'4+VTG^\X/^"6WP+T_P"*OA+XQ>'?B?\
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MXLU'0/A]X8\$?#_1M0N]%\-^'--O%\(^"_#D&N7&DOXL\31:[X]\0^+/%GB
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MGQEKGQ>\/>,-6U3PY^P%\37^,'[-EIJ'AGQI\._$7PQ-WX7\>1:)K&K:U9^
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MPI\8&\9:]^UA)KD^M^(_CBNK?"OXZ_"_PSX1\!_%(W[:;X@\-?#[P1X1\?\
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M>(/^">/[+?B[0+K1/%WA7QSXFU&[^.G@K]I0_$/4_C;\:D^,-C\:OAWX4L/
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MC^R*;'Q=HM_\)DUWPMXR^'OQ]^%%_P""O$WC7X@>)_!.C_#C]J3QUI?Q*_:
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M1O#WP[\6V-MX1\<Z7>:'XQ\'_%+X,Z[HMK;:5X2\?_#R[\9ZOJ4^C^%_U/\
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MTBT_9]U?6K^Y^*WCWX;_ !"\4Z&NB>)0#[&HI ".IR<_YP.WTR?K2T %%%%
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M;+_A+].TKPGHWC#3_!?V/QJFEZ+!XWM[KP[<Q>-+7P_X;L_%*ZO:^'-#AT\
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M)T\8>'[2ZM_#?CT_!KXD27?Q'^";^.-(\0O\&/B%J>L^./A<WA+Q1K6K:K>
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MM%\ 1>%_!'P_\0>-/''C^:S\">!=#OO$?B'18I/D;X\_\$V;_P#X3SX7ZO\
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M6OC[]D;PCXU\#Z-^S9X]\%^*OAEIL_[+_P 4O!GP,\)?$%/#RZ#\//'.H_\
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MV@/C=^TEK_\ P44\8?%?X@>%_%_A;PK^WA?^ O@YH/A73&_LKP'\.K3]E?\
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M#QUX- /OC(/0YHIJX(RIR"2<_4_YQ[4Z@ HHHH **** "BBB@ HHHH ****
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MHT70[[X7>-_ _P"SQ;_LE:-I7@>.+PI+9P?#Z_\ V;]%\#?"+Q?\.=>MM?\
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M/A_;?#6XTG1/VB(O$7]I>%$TC4?''A%I/&7PA_:<\/W?AW2[GX%7G_"4=O\
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M1ZO<6%YHG@_Q%I]A#<>(_P!R_CM^RY\+?VB/$?P.\7^/&\:Z=XJ_9W^(U_\
M$[X7>(_ 7C_Q9\/=;T;7M;\$>)_AMXFLKC4_">IZ9>7FB>*? OC+Q'X9URR:
M5)Y-.U.;[!>Z?<$SMX/H_P#P3=^!6B)X'CM_$'Q2N$\ ?M?_ !(_;KT5;SQ)
MX=D6?]I'XN0^.(/B)XKU)(O!L,=QH7B6#XJ?%F*X\$0+:^#[)/B1KHTO1;+^
MR/!'_") !^R9^V=XP_:@\4^'-3TWX-:_:?L__%?]GWPK^T+\'_CC#I7C30]'
M:T\2WFBSV_PR\9V'C_PKX3BU7Q3J?@SQAX.\<^$/&?PDU'XB_#_7K6/XB:+J
M^I>%G\)>"M9^*[_^"KIDMO\ @F+_ ,%"=:L[F]T[6_"/[%G[3GCSPGK>EWMY
MI>L^&O&O@+X,>,_&'@SQ5H.K:=/;:AI&O^%_%&BZ3KVB:K87-O>:?J>GVUU;
MS))&IKI/V3O^"?'[-O[%-UJ9^ FG_$W2M$ETF[\-^#_!7C;XX_&+XJ^ ?@YX
M0U/5;;7]=\$_ KP7\3/&OBK0?@_X1\2>(;#2];\2Z-X'L])AUZ^T7P\NJ-=6
MGAKP];:9]@>)_#'AKQMX;\0>#?&7A[0_%OA#Q9H>K>&?%7A7Q/I-AKWAOQ-X
M;UZPN-*UWP_X@T/5;>[TS6=#UK2[NZTW5M)U&UN;#4;"YN+.\MYK>:2-@#\W
M=>^&7@/5_P!@?]D+PWK&@"[TO1_%7_!/2^@AN=4US[5<7WB'XV_ S1O%#ZUJ
M_P#::ZSXD/C?3/%/BC2/B!#XCU#58OB+IOBCQ/IGCN+Q%8^)-<M]0^=O"?\
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M3OB+\,_C9\(/B7XD\1>%M<_96^,)\'^)M$M='T[Q;KOB:6TU_3=$N?T1M/V
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M_L^?&+XA0:1X]N/$7@/7]1@BG\3_  Q\/WMW>_#^]\!ZS+'<:Q8C4TTS4I[
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M_P!)_:'\,6]A_P $W?B'\,?B+\/_ !+?? C5;ZY^(U_\%/A%XF^"_P --/\
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M_$KXMZ7X\NM!U72O$'@+PE\0?AEX'O?BQ8W_ /9_PLD\8^)=,UW0=)K>-/\
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MWXJ_&7Q!XR^('PG\.V0^*6O_ !5^!_BK]GBY\/:+X2^'GBKP+X)^#W@KPO\
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MX(/C9:?$WP9K%Q;_ !BO9?#]CH%G^T/\3;?PGJNGB^NX1%X*DU6#4SH&N?\
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M,M!TN.4Z=I$5]-KVN:%I6I_)FG?\%6_V?[_PE^R+\0)O 'QTT3P#^VC;^.-
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MXT\+_$OPCXLU'3?"GQG^Z?C#^P+X>^./[0?@/X]^.?'M[<:K\*?BU\/?B_\
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M"T7P]?VL?QV\&>!_@WIUUJW@WQ#\'O!WBBW +\W_  5?^"5K\1]6\!7WP?\
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MU30)O# OX=4TG3_#VGZ^NL:I=:U<:!HOT/I7_!/WQQ\0OB5_P4%\0?M+^,/
M_B'P9_P4)_9&^#'[+?Q%TWX/6_B;P5JWA?3_ (=^#?C[X.\7:CX:3Q6WC)(A
MXJTS]HSQ%;:->7FL7D_AZX\$:3J]Q8:O_P )==:1X/ .J^,W[?7@C6O@E^U'
MIWP)\9W?@#]I#X=?L8>-OVLOA7H/QC^%?BK0-1\1?#7_ (0[Q'>>#?C)X8\
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M\3/"?P^T_1?BQ\4;OXQ^*8=5\2W=KXZU?P'X:^'/B>\\)ZGXCU34_!&C>-M
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ME>&8O&]QXK\.Z+I_B?5M:\+Z9H/BD2ZE?_(OQ:_X)*?M"?%WX8_\%!_ NO\
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M7WQ-\6W$7A'X8VWCC7?#LOQ&\5LWAKP2FO:W')8)[;7Y >#OV6/VT?!'Q_\
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MGQU2_'_PY<?"O_@HM^R3^USKKP1_"G6O@-\?OV'?&FNRB6VLOAOXX^-GQ#^
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M'P[':^+-4^%$&MQ^)="TKXK'P9K\<7@A[-[C2?$.I:=JUYI\T%I=@'[TZ_\
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M-[\/V_96TWQ)\)_^"//P._8$#^+/%_B/Q1H%Q\9?AE\9OA#X]\6:GH>DZM\
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M(\,?LZ^!_#_AGQ"?A7/KNL@'[OP2I/#%/&P>.:-)8W7(5XY%#HX!PP#*0P!
M(!Y .17YM_!_]M7Q%J7[5?\ P4C^$OQNO?A+X$^$G['GC/\ 97\/?#KQ=:?V
MWH^M:O;?M#?"72/&@M/'>K:]XCO=)UKQ1J7C3Q!H_A'P3H?A/P_H=S?7U_8:
M':6_B77-7LA7Z >!M-\2Z/X)\'Z1XTUG3/$?C'2_"^@:=XL\0Z)HH\-Z+KWB
M6QTJTMM=UK2/#HO-1&@:7JFJ175]I^B#4+X:5:3PV N[G[/YS_B5\4/^";?[
M27C[]I?]L_X_:1KGPRT,^-OVK_\ @GG^UM^S5H4_Q*\8VVD>/-=_8@\#Z/X1
MU[X7_M'VFG?"F\F\%^$OB,;/4KKPSXB\%3?%6[\%^(#X0^(%_P"%O$-SX/E\
M!^(@#]7?#'[4?P+\;?#S5_BCX0\?6?B+PKX?\9^(OAKKL&E:+XHN_&>C?%#P
MEK,_AWQ'\*M3^&46B-\2[+XJ:1KMM+I5Y\,[CPC'X[CO/)B7P\YN+?S>.U/]
MN?\ 9-T?X?>&?BI?_'3P/'X$\6Z-\1/$NE:Q!-J=]<VGA;X-ZS;^&_CAXM\3
MZ#8:;<^(O!/A+X!^)+RT\.?M ^*?&>D^'_#WP(\07,&A_%S4_!FJ3):'\Z?'
MW_!/[]K"+XM>-/VTO@MJWP,T[]IKQ!^WY\)?VL+?X%_$[Q=XXF^ VJ?"?X7_
M +%/BW]@?4_AQJGQ1\'_  \/C#0OBMX]^&/C_P 9_%B+XC0?"[Q=X9\#>/)/
M G@)_"/CS0? ^H^.O&E7]KS]AK]N3]HWX6:K\/\ 0M._8R\):=\6_P!C#_@H
MA\(/B9X5\+^+/B5\+E^'/[1W[8_]GZGX4\:^'OBKX0^!NJ^+?CU\(+6\AU"S
M^,W@KQ3X4^"EI\5_'=W%^T)X[\+^//&&A?#?P3\,@#[]\"_MW?!GQ_\ M-?M
M+_LQZ;;^-=(US]E7X7_"+XH?$WQ_XL\!>-_"/PS33?BU<_%1K2VTCQIXE\-Z
M3X;U2QT?0_AM;^(H?%EAJ]UX1\86'B*ZA\$:QK]YX#^($'AWN-._;&_9PU;X
M>ZU\3K+XGZ9)X7\.?$U/@GXALI-&\5VGC[0_C5/K.E:#9?!G5OA->:#;_%73
M_B]JVH:]X?70OAE=>#(O&^O6?B/PWJNC:#?Z3XATB^N_R+\;?\$V/VV?%WB3
M]K3Q1X<\0?LW_#GQ!^T3^SC_ ,$RKCP7JMQXZ^(7Q$TKX=_M/?\ !-WXE:Y\
M6-%^'GB[PO-\&/!4/Q-_9X^+?B&_T[PSXO\ 'B:IX/\ %5KX,36[;_A36KS:
MPMI9>N:]^QC^UU-%\ ?VB/A_\(/V(?A-^T]\$/VK(OCKKOP+\(?$WXG0_ OX
MU>$)_P!ECXI_LC:NOQ%_:,MOV=]-^*>H_&"P^'?Q3O;CX7^+M8^!GB+PW\.-
M"\,>'/AFFA:UI$NK^)KD ^JO^":W[6GC3]LOX+?%?XG>-%^'3MX._:W_ &J?
M@7X1U/X7Z;XDTSPQXB^'GP0^,?B3X>>!_%)C\5>(?$>IW>K>)= T6UUK5;])
MM+L;FXO<V>@Z1"@M5^C_ (U?M0? +]G4:<WQK^*GA/X=IJ.F:EXBSKMU<,=(
M\%:#J?A_1?%'Q,\5KI]M>MX+^$7@O6O%OA'2/'GQ?\7C0_AAX$U/QAX0T_QA
MXMT6[\4Z##?_ #Y_P3Q_9P^,7[-'@/\ :+T'XT2?#5M8^+7[</[7O[2WA2#X
M9>)O$WBO3M-\!_M%?&7Q!\5O#VC>(=5\4>"/ -R?%FB'Q)>:3JT.G:+-I)CL
M[.XM=1GDN)X;;YF_X*C?L0_M8?MF0?$_P+\)M3_9Z3X4?$K]AK]H+]G^WA\?
M>(OB!\,?B!X6^.WQ+NM+;PKXVU[Q?\/_ (??$#5/BG\'H-*T^&Q/P@O-0\"^
M$_#?BI;KXG>)M#^-/B.P^&NG_#  ^VO@]^V?\,_C=^TY^TS^RWX0T'XCVWC#
M]E:T^'4?Q#U_Q-\-O'_A/PK=Z_X_MM;U1-%\/ZWXD\+Z7H^IV]EH-KX<UO1]
M:MM4FL/'NF^(KG5O W]N>'_#FJZW7L_QL\1_%3PQ\.-<O_@CX%\/_$7XL7<F
MFZ-X&\->,?$NH^#/ PUG6-1M=/\ [=\>>+-(\.^+-7T/P7X6LI[OQ)XBGT?P
MUK>N7VGZ5)H^@:;=ZYJ6G0O\5?LR_LX_M&_"_P#;>_;2_:*^(&D_!BU^'?[7
MGA;]EOQ&]IX-^)WC7Q5XR\!_$CX*?!>R^&/BKP'%HVM_!KP/HOB7P9<ZL^I:
MOH7Q0D\3Z#K.HZ;9Z=:WWPFT2[U>[ET'[)_: O/C[8_!OQ]/^RYX?^$OB;]H
M!]"DM/A=IOQW\4>+?"'P?A\3WUQ;V<.M_$'5_ ?A;QCXRN?#WAJVGNO$-SX;
M\-Z/:ZGXRDTR'PC!XG\$#6W\9Z  ?E1X5_X*:?M$^%O#'QG^$W[0WP(^%>B?
MMA?#3]LS]GS]A?P+<_#+QYXRU+]EWXS_ !2_:?\ AY\./C%X*\4Z#XJ\9^#_
M  ]X\\.V7PK^$GQ%E\?_ !K^',FD^(_%%CH?A-3X4UW5]0\<Z%IVF_9'PN_;
M3TN]N/VG/ GQ8M]*M/BM^RA\?O /[//BG3? D<\L?Q6\1?&+X8_!WXH_!+7O
M 'A35-5OM1\-'XH:?\:= \,Q^&O$WB?4K/PAXLT'Q>NL^.+OPCH,_C&3XR\*
M_L+_ +5GC#X/>$]%^,?@W]FKPE\4?@5^U?\  /\ ;.^%.L^&_CQ\7?C'K7QE
M_:"\+_$;Q7XB_:5^(_[0OQ4O?@#\ --TRY^-?PW\8ZQ\-/ASX+\#? *^\ ?L
M_P SV-YX,T&Z^&OA3X9?!SX=>G>"O^";&K>,OBA\:OVE?C7\2?'?PC^.WQB_
M:6OOCA8V/[+/Q<\2Z;X8\%^%_#_[._PO_93^&GA?6[_Q;X:@TKQ[XNM/A9\,
MM4\1ZUXO3X>>&KSPYK_QE^)?@3PO?ZGX02/6?$ !A_!3]M']O+]L3]B/]G+]
MH']E7X!_LT:9\6?C/I_Q+\6>,K/X[?%7XFZ9\%_AWHG@7XE:[X)T;P3H^O>
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M!?&?PYXC^'NMZQXM^&'[3/[.7Q(U:Z\#^%?C'\,-#OM+A^(7@GQ>/BQHNO\
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M@  _IC_9A\?Z#\8_V>O@A\<_#_@G3?A];?'3X/\ PN^,$GA33GLKK^PS\1/
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M&T\[)'&T\S* 99GCAB1Y7+2,D42LQ6- 'R0Q3*%FC255>.55D57420R)-#(
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M('_!)K]M[_@CQ^WMK7B;XQ>._P!A;XG:?^Q1XXTCX#ZQJGQ4^,?B?]F_Q_\
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M#P[:>/\ P-HGPNU+QO\ "."XNIHK/4-2^+/A[P3IF@WLB6>O7FF7++$?"_\
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M'A_QOXB^$WB;Q#\6K'5?%4_A:SURS /ZYJ*_EBT_QSXZ^*OQ\_X)B_LTV_\
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M9?M(?LI3?LNZ3'K?[.'Q@^'MBOB_X"&_^+'Q1\9>,O@=X8\#Z5XOL/"_P&^
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH ***0D#&>YP/K_G\AR:  $$D @D=0""1R1S^((^H([&EK\!O#OQ?^(GP
MU_X*-_!7]K/7? 7Q!\,_LU?\%%-%U;]D37_'GB?7OA+#\/8=>\$:[XL^)O\
MP3,^(&BZ=8^-]?\ B?H.F_&7P)JGQY\,2>'O%OA#X<:K;_%;]H?X;>#?%NE2
M>,DT?1;?;\<_M\_MYO\ $+QO;?#+X4?# >"? VK_ /!2#2_B+:^*OA#\5M=M
M?@EHW[(FCV<O[-/CKQ;\9-+^*OA#P%XYT?\ :JO86O#HW@O1EUOP]J'BO6OA
MIH=OKGBK]EC]HS6;4 _=ZBOPD^&'_!0']K3QC\.O^">FF^*/%7['7AKXR_\
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M1@'[W^7VWN !@ $=,8]/_P!7;%<_XM\5^%/ /AG7_&WCKQ3H/@OP;X4TB_\
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MI[>WT/QO;VLGAK5;B:&&PU.>25$;U%4VD'<YP,?,V<].O'MGTSR1P,?SI_\
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M_&VE>/?A3XBN%N/"'PPU@ _0N7]A?]BB?P7XH^&]Q^R%^S'<?#KQN/"2>,_
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M2/V;_P#@L9^Q-X\T#X%OX&\"?M&>$OVK_A1XG_::^&7Q!BUOXD_M'?M(ZO\
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M^$]\+VUC9WGA'7-"U[2]!UO1OE/]CWQY\:K?XT?M%_LD^%-?\,^(OAA^Q/\
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M2:RMGCX32/V%/V)/#_@'Q%\*?#_['O[+GA_X7^,/%NE>/O%WPWT'X _"K1?
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M:YJUE+XT@UM[;4=:U>]A*7&IWLD_U)10!X1XQ_9;_9E^(OBCX7>./B%^SO\
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MS7H/%5YK7PQ;4?#%RW@/5[SQ3;6_B6[U/PL=*OKKQ!!#K4\\FI1I<CT/XO\
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M\-?MC_\ !,K]H7]I#QO^QG\)/#GPB\2?\)/\4_ ^G?L;>,_"7B+X>>*==O\
M2KK1(]1T+X^>.8-$7XM_'[P?X3OM$LO NC7^A^&OBUJ<^B>)OJKQY_P6/_8F
M^'WP@^%OQWU7QIJEY\,?B3\+_@S\;]2U:V_X0[2_$/PO^#?QYU/^R? 'Q*\=
M_#GQ9XV\-?$O5M $]KK]]XGL?A+X/^*'B?PEH?A77?$&OZ!8Z&='U'5P#]4Z
M*^5_VWOVH-"_8L_9"_:+_:O\1^'Y?%FG_ 3X3>,/B-!X.BU*XT5O&>NZ'I<[
M>%_!C:_::)XEE\.Q>+?$\FD>'9O$K>']:M_#L&I2:W>:9=VEC/ W@/@CX?\
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M%OPY?1?'7P^\$>,/#/BOPAJ.O@'WK17SO^T-^TU\.?V:M/\ A1)X\:^NM?\
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MQGXG^(^H^ FTOP=H]TT&K>/--T_3]6\;^%O#</BC7W\)7FF_#'XMS> ?D_\
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MM?$DVK_$;4=4^R64,?A^R\':KX,T_P#MB^\8VOC2PT?C?&GC'XT6_P#P5A^
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M  4>^ 5[XD^,OAKQIIWQ#^#,WP?\!_!7XL1:I\9M!T+P)H_Q,^%'[1?B77?
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MFL>&]%\(Z=\4_$_@V\\0>)O&7@+PKID-SXD\?>#-*UT ^9/ W[&/[0]YX]\
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MCXHU[03?_#FV\8S^.IO#&O:)X\T_P]=^!-8T[Q)<_8815Y  /^?U]^N !VH
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MVM?"'PW\,]6^*O@CXI_#C3_"GB"P\2_"[QUX-\-?$&U\5:<_@>/PU-XTGM=
MG /C_P#X<WZ=9^"?BPO@O]H"Z^"OQJ\;^,_V<?C=X(^)O[/WPBT#X3_#_P !
M_M4_LWW7C&YA_:CU3]G&R\7:Q\)O%WQ._:"L/&4W@O\ :NT;3K/P3\-_C9\/
M=&T+0Y?!?AO7K ^+)?7?'G_!/KX[?%S0O@/)\6OVV=?\;>.O 'B#XPZG\8;V
M?X*>&[?X4_$ZT^+WPW3X96>J_#CX+7/C;4M&^"7Q(^".D:?I^I_ 3QG>^(_B
MQH/A;Q!KOQ1UWQSX"^)6K_$BZOM&^R[7]J_X$W7CGX>?#QO%6N:=X@^++ZC9
M?#:]U[X;_$[PUX)\9^)-)\/S>*]2^'^A_$SQ#X-TSX;W7Q7L_#=AXAUJ?X1'
MQ8GQ/73_  1\2)QX2*_#/X@?\(W\-6'_  4)?XJ?\%!_V0?@E\!O%VG^,?V:
M?CI\ /VO?B+K/BF7X)_%30-/\7^(_@)XL^$GACPGXH^$7Q\\6VVC_#+XO?#+
MQ$/'6N7ME>?"&P\2:;/I&G^%_'L7CK7? WQ0\!3W !E?LI?\$L-9^ 7B?P;?
M?$CXX^%OC-X+\/?\$OO@+_P3!UWP;I/P6\1_"N[\5> /@)JOQ!GTGX@2^*8?
MC[XXNM%UCQ7HGQ#U/1_$NAZ;II\JYM+75M \0Z,2]D//-0_X))_'C7OV"_C#
M^P)XQ_X*">)_'_PZU_X%O^RY\ =<\6_L]^#[:;X/_ >&3PO8Z)#\2-%\!>/_
M  )%^T!\8/#'A+PAHWA#0?BO?ZG\/+:#3([^_O? NH:[XB\5ZEK_ .Y Z#/7
MO7S/^T/^V!^SY^RM??#'2?CAXTU;PUK?QHUSQ3X8^%'A[P]\.OB;\3?$OQ \
M4>#O!>L_$#6O#'ACPU\+?!OC37M2\22>&=!U"70- BT[^UO%^M'3O"7A&SUS
MQ;K.CZ'? 'F_P5_9/\9_#']LC]J;]K/Q%\5O#/BR/]I[X5_LP_#O4/A_HWPK
MU7P@_A#4/V;+'XGPVGB&T\6WWQ9\:+K%IXNO/BWXIGN-!E\+Z;-HMK:^'K2/
M7=3FL=2O]:^=OVRO^";'Q&_:J^(/Q:\7:=^U#;^%/#_Q#\&?LK67@[P5X_\
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M/AS<_'7P<?A9H&L>&?%'BF7Q3\.M(@MO"7C?X>>++>2Y\.?$3P/JGB#J)/\
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MU#XEW6L^&/A]HFLZMKVHZ#X:U2?Q'=:Q>7#W45[!;V7E4O\ P50_9]UWXO\
M[$7PN^%^B_%;XD6'[:WBWXY^&-"\=V?PE^*/AK0/AK=?L^Z7XSL/'OA_XAZ+
MXI\&Z3XV\-?$;2?B9X8'@?Q/X"\0>%-%O?AEIEAXM\8_%N_\ Z5I/AR+Q?\
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MZA\._B]I_AC6OA_XO\$?'CP;<IIVDZKHOB/1]=L_$EYY/S?X9_8T^(7[./\
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MB%X,^"WB _M$P^$;OPV/#WPKUOX_:AXB^(;_  ^U:'X+Z7%IOA]_!'PO\/\
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MIWB?2M,\2:I\-;"#Q?=^,7_!.3XS_$9M>^)>FZG\(K/XU?%?_@IM^QS^WO\
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MT'X7V.H>(O$HT#2(;_4CK6N1>&O"NE$:'I':?&K_ (*=?L9?!KX!?%;]H?\
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MU?X,^,_B-\7_ -N+]EG]E[XF^#?%7C&_A\5^"/"/QZ\2Z5#K6H>&_#>A1_\
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M?B=IWP4^(/BKP]XIT_6M \(_&#5O$V@>#=/^%VMZKILES9V?Q N/%7BOPMH
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MWP[I_A_6+/1YHM)/@C66^(^GZE>^([*]?7]*_L:\TN#PQJ@U*'5]/Y;]@O\
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MPTC^,WP\?QQ9^(?A!X;L_&/Q6T"[\-+XA.K6NN?#?PE?0^)_'.D3VL>H^%M
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M;3P?X?U_QA-H%B9]:3PEH.M^)S8?V%I.H:A; 'IU%%% !1110 4444 %%%%
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M%KK]QX3T#2?@'XHT7Q->C3$UN/Q#KWA6/0_#VNZ)/KNNZ!R6H_\ !4SX /\
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ML^@_LT? /P&;;X?^&=:T]8+;0M*U6_\ CM\2?VH/BQ$NE-J5^_AWXL>'=/\
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MQA?^/?B,OA_Q1<^&_#.B:2CZ)X?BL?#'BW5+WQYX^\/6D>A:;X7O/&OCCP@
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MO-#\2:0;+7=!O]0T?4;*]G /P?\ ''_!/S]O)_$FM_#+P]X7_9R\;?#/3_\
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MUKX*_!3X[>!-,_X)V_!'_@G)^TC^RAXS_;B^.'P1^',5Q\"+34/#FD?M#?\
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MCW2Y([;X;>(H/C-XDU/X/?T,44 ?R-?M&^ ?A1\-OB[^V?\ !N\;0?C+\(O
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M(_C!\%_%]IHWQPM?C;?^*-&N/C-\-OB)XY\;_P#"3>$M$T.WU/5OA'93ZO\
M#.R\#>"/[#L_"5Y];?MW_L_^*A_P44UOX[>'_P!FWQ7XZT#Q[_P2%_;0^ ND
M_$WX>?"R+QO>6?[0>N^,/A;<^%])\2:CX?LKWQ'H6N:C\*K#Q+H?AC5=4AAD
M\1:5)J?@7PC/K&HW%UX??^@*B@#^0'X4?LM?M??"O3?A]+^R5\#/BM\)OCMX
MO_X-Z/AG\'?B/K%WX0\4_"^Q^(7[</P=U'X1Z;X9^'OQ.^(_C31(O!*_'/1_
MA=X;^*'PL^$GQ4^(U[<V7PWT75-,TC1?&.@^$9]$AD_8_P#X)7?#30_#?_#1
MGQ2\*?L\_M7?LQ:+\9_%'P]U/Q!\,_VH-'^!_P +&O/BAX-\,:CX9\9>,_A_
M^SU^SKH6D?"_P18:IH">!/#OB+XKV[1^(/CCJ7A.UGU#2DT;P'X<\4^,?UOH
MH _D2^,W[)6O>(_V$O\ @NKX*^'_ .R1\2[;Q_\ '[]N6V\<_L^^'=#_ &:_
MB)X-\0_$CX/:CX=_8\&A/X8@7P+H4][X.M_''PE^*&J:KX7OGBL-*U'2QXB\
M2Z+:0>*/#VH:W[K^UQ\#OB9\4XO^#C*#3O@7\;/$FG_M0?LC_LQ^&_V<H[?X
M0?%BW;XL_$;P9\ _'OA6UTCP@EOX:M+V^U'PW\3_ !+X*M=7MKH0:?I\+WVI
M^(@GA+1/%5[I_P#3Q10!_(?^VC^RWXZ^)_B[_@KY\7? O[,WQV\2^/\ Q[\2
M/^"37Q@_8S\;Q_!+XT6_C*R\=?!=/!?_  L?XA_!6;6?#-EKOPP\>_#S1I?%
M>D:WK>BP>$/%NFZ3=ZQX6=VL;V?29_7/VM-/^$^K?M0?M1_$']I7X;?$V;X
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M)7@?P;\1?"DFJR^%O'WA7P[XT\-2Z[X<\1^#M;E\/^*=(L]=T:76/"/C'2=
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MXZ\2?#;Q;%'H_C+1/#OB&"/3/&?A#Q#I$5U=:3!::I'IXU71Y]0T6]T[4;L
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MSPW2QVZBYBF4E9HYO,2525D5E)% '^;/\!?B#;:I_P $IOA9X=^.5YH_C_\
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M'A/Q'X1E\::_XC\0>--,\>>(/$')WO[4'[27AKQ)IGP<TS]OSXL:#X2\&?\
M!PUJO["VI?$'7[O]G3Q3XWE_9I\6?L7+^TC'X$\5^-/&OPCU6"ZO?#7QBM/$
M_A#P1KNIP'5K+0[JY\%>(3XNN_#&@)HW],4_Q%^ $:ZN;GQ]\'XUTS6DT+73
M/XH\$JNG>(KEO$*1Z/JWF7H6UUJ>33/%:QZ?>[+Z1[#Q$JPL;74A'\^?M/\
M[/OP?_: M_V8?BSK_P 5=(^'_@[]G/\ :%\%?M3>&/$VCR>!_P#A$/'WB9/!
M_CGX8>&=*\4>)-<672+[P1XGT#XU>++*./2KNTU/5]=US0+O2==@:"6QU@ _
MGM^)7[:?[2'@/X"_&3P!K/[8/CZ.7PQ-_P %>[O]A?XIZ]JWA'X<:Q^U;\,/
MV6?!_P )]1^"/Q%O?C ;+4?$?QM^*WP!^+'B?XF> OA_\'/ASX7L;#]LSPCX
M#D^+?Q.>?X3:!<W?Q*W_ (P?MJ_'?QK\#OV\OCKX/_X* ^+O#VK_  :_X)"?
M\$_?V\/A+I'PQU[]G(>$/#W[1GB#0/VH[SQEI>FVJ_#?6T\3_#;QOXV^&WPX
M_P"%@_#OQI<>-;GQ/??$&W\*1:_I7A6]^'/A30OZG/"OCCX9^+K.[F\#^,?
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MOAO/K_PXN/@7J/B'0OAM\;K[0)/Z>Y=,T^XC>&XLK2>&687,D4]K;RQR7*X
MN)$DB827&%4><X:3"KA@1D\GX@U#X:>%I=$T_P 5:AX'\.3>.=7@\%>'+'Q!
M=>']'E\8Z]>65Q>VWA'1+;46MV\0ZM=:?H]W>0:#8)>7L]GI=Q<1VKP6,C1
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M)()R2#T7HO1<[<[1S@$G;D[=O& "2BBB@ HHHH **** "BBB@ HHHH ****
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M!J6D77Q8O[S6[Z]\?6*7-J\N@^([BX\3^*RU]H$FF$1>,/&=L$%MXN\1Q:D
M?'VG?MD?M5?$F#X@_ V#Q1^R9^S_ /ME_ W]ASX5_M4^*K/Q)XHUGXD_L]_$
M'X@>)O'WQ[^'7C_1C/;)X>^(/A[]G#X;^)_V?FT7X@_$7PE>^+_%_@W5OB[H
MMI.+M_A_IJ_&CYKL?B;\9/V8/VA?^"AGQ ^"+?!CP[\,M2_X+5_L)?#+XK>
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M\+/V5K#1M0_9BU75O"WC*?XW:3X]U+X1^(?A/XY\3_$CXB>-OB)X]EUR#2M
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M:1X:LM3\"V?VQ^P3^U!K?[3?A3XXKXJU/6M,\<?"3XO6GPWUWX8_$;X+Z_\
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MXC\KPI_8FA+H4=@FAZ2MF ?DY\2/V_\ ]NOP+XM_:R^">E>)?V9==^(_[/\
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MPW_#7_!1#X^VNC_\$YOCS\6!H&D_ +_@HC^PA9^)M"T+X>^$M/\ ^$A\'?\
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MNU.W^*?_  4&\,PW(CFFEALU30O#6A6'V;3X[6S9=/CN6@:\GNKFX]6\%_\
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M&4NG_L(7GA+P_P",],\8>#[;QQXG^.7Q$^%/B"/Q5JFE:W:?$#3M:T3X>/\
M$/X!?%;P1X=NM+\)ZY+K>J:]X7U_7?#FL?#BTUOQE^KOP-_9E^$7[.=Y\8[_
M .%&D:_I%U\?/C#XC^/GQ2?6O&_C/QDOB#XL>+M/T?2?$?BBSC\7Z[KD?AM-
M3TOP[H-BWA_PRFD>&;2#2+/^S]&M)!-)+Y%JW_!.K]D#4_V3K?\ 8<M/A5-X
M6_9:L_$<?BFP^%/@?QW\1?!5CIFJ0?%R;X[6D6D>(/#7BO3?%VCZ+8?%:5/%
M.F>'-+U^S\/Z7'9Z=X<T[3;7PGI]GH,(!Q7AC]K/XJ_%[QSX@USX#>%_AGXN
M^"OPH_;)UC]CCXV:1XK\0?\ "'?$K1[CPC#;^'_'_P 7_#'B*Y\0W'A^27PK
M\5==T+P=I/P*U[P58>)_B%X/L[OXD^%/B%))XI\&^"+_ .>]+_X*(_M1^+_@
M[XD_:;^$7[(&J_&WX#>/OV-+_P#:F_9IB\(ZGI^E?%?6O%46D:#XL\+?!37/
M ;^*?$6L_%+Q'\1?AQXF_P"$WTB;X4Z5:>(O#?B?P-XZ^#FI>"-6UZ\^'_BW
MQE]H:'^P3^RWX;_:'U[]J30_ GB+2OB_XMU72O$GC">P^+'Q>LOAOXR\;:'X
M7M_!ND_$CQ?\"K3QW#\#/$_Q/T[PY:6EC9?$?6_AS?>-+2>TM=4MM;BU>WAO
MT\\\ ?\ !+3]B#X6:#X_\(_#[X5^*?"W@CXB37TUYX!TWXZ?'Y?A_P"!QJ_Q
M,L/C)KEO\$? \WQ0E\+?L]6?B#XH:5I7C37;/X%Z5\/+;5=7TK26NXI+;2=-
MM[4 [W]B/]JC3?VN/ACXL^(>C>*?ACXRTCPS\3M?^&EMX@^&TWBW2)[FZ\)>
M'_"4FN0_$KX4_$?3-'^)_P"SU\5+7Q+JVLVWBOX!?$JRF\8_#F&/2K2[USQ=
MIU[I?C#7_'/^"BG[;GQ"_8T\#>)/&W@CP)X-\:6O@+]F[]H[]IW7M.UG5M7U
M+Q-XKTO]FVU\!:SJGPUT/P3X.2X\4^$/#_B_P_XKUR?Q%^U1KUEKGPG^!7B'
M2/ /A#QAX0\6:_\ &SP;:67K]]^QKX*LO'/@3QAX'UWXD>"]2T?XQW/QV^(O
MBG2?C9\9HO$'Q7\:Q^ O 'PP@M?B)X=A\:0^ ?BE9:W\//AUX0^'M]<_%S0/
M'6G^!_ASX;N/#_PO\+^%_%_B/3?B3X#L?M"?L"?LI_M3>*+[QI\;/AQJNO\
MBC6?@9\1/V:/$NK^&?B=\6/A?<^,O@'\5")?&?PI\=#X5^.?!D7CGP?<7WFZ
MQH>F^+DUH>#]?NK[Q!X0DT/6KZ\OYP#\W?VG?^"M'QV^"?B?]N^\\+? +X2Z
MM\-?V!8/V'/&OB^Y\0?%/Q=_PFOQ:^''[5\NLKKUEX:L-,^'MOHO@+X@>&XF
MTV328-5OO&?A8MHLB7.L:D?&LA^&GGO[?_Q[\2_M5^#/'MIX'\,_#R7X+?L<
M_P#!8/\ X)L_LZ>*-2\477C:Q^)NK_%;0_VJ_P!CCQ'XX\=^!XK"$>%FT#P[
MJ7QLT'X.0>"_%NE3)XHM)?B)\3['QEI/_"->!?#'CG]&/%/_  2P_8T\;Z!\
M??#/BWPG\5/$>E?M0>%O@?X,^.KZY^TE^T7J^M^/_#_[.*1I\'[>^\5:E\4K
MKQ5IU_X:*/)J.NZ)K6F:]XQFN;N;QMJ?B*6YE=M7XD_\$Q?V-OBUXP^('C?Q
MQX$^(-WK'Q8U7X5^)OBAI_A[]H;]HKP'X-^('CGX)ZW\/-?^%WQ,\4_#SP#\
M5?#'@'4?BIX2O_A5X$AL_B;_ ,(U'XXNM*T*'1-2UV]T>:XL90#[]HH_S_GZ
M?_KHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBC(]10 449'J.N/Q]/K1D>M !129'J/S]>E+0 449'J/\Y_P/Y&DR/4
M>O7MZT +111D>HH **** "BC(]:* "BBB@ HHHH **** "BBB@ HHHH ****
M "BC(/0T9'K0 4444 %%%% !1110 4449'3//I0 4449!Z&@ HHHH **,CUH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BC('4XHH **** "BBB@
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M.OV'-7\9_M6>!OB=X#_8)_9_^.7[*GPN\.Z1^S7??#[QCXQ^!'Q-T#]G'2/
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M^$[#P%X\^'^H?"GX^? #PW_85YX5UG4/V+?VAO![0_# ^,M.UG6=0O[[XP>
M/BK\.OC+X ^.(TFW3PUX9\566AZ+I=[J5M<VFHWMGP__ ,%4/V4M=O=(S/\
M%NR\,^./@[\4_P!H/X+^/+/X+_$'QQX2^/WP3^"%\]C\6/B%\'Y/A9I/CW7]
M<LO"!N?#.H0^']=T#PUXU\9Z'X_\ >(?AYX8\7Z%XIT_46H>+/V#SX._;/\
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M:>,?%'C+2_!^A>([K2]!\4:[HNL:OI=A>>F_LQ_";XZ_"[0/$S?M"?'/PO\
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M[JW[>'[%7Q/\ _M-G]K7X9?M(?M@?"VW^$/C/5M9^$7C7P[\!_V48_B!\/\
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MZ!I&CZ!X$N- ^''Q&^,7C?XD:7I7@4 _9BBBB@ HHHH **** "BBB@ HHHH
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M^$-<N_A7'I_B[50#[[TW_@L/\(=3\0?\%'/!47[-?[6L/Q"_X)@>'_#OB_\
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M;PSI\@U'1M.?XO\ AOXL&2'1]+U!-7U$ _H"KXL_:T_;:\-?LAZ;XGUWQ/\
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M%U?PGX,\1_C!_P $0?V4?&E]\5OVI_C7\0=!_:W^ ^M^!O\ @K_^W?\ M-^
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M$\?C#\!_%5S\%_VS_%WBOPS\'=<\-_L(Z)^UIXK^#JR^%?$#6WPQOO"?A/\
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MJ*:I)'(P<D8X/3N,$\'\_4 Y =0 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4A(49/3Z$_RS2U\M_MO^*?CAX(_8
MY_:B\8_LSZ)K/B3]H3PO\!/BKKWP8T/PYH^G^(O$FI?$C2O!>L7OA.#PUX=U
M;2M>TOQ!XE&KPVTOA[0=1\/^(K+6=:CL=,N?#NOQ73:/>@'U%O3^\/\ /'Z'
M@^AX/-)YB'HP/TR<?7TZ5_.SXA_:/T_Q-\'_ !3\?_V%?'7[<7C?]G[Q!^T%
M^PUH'[5K_$RR_:EUW4O@S\$K#XG>(?#G[5^J_LZ-\9;:]^/NB^.M$\$_\(9H
M?[5UI\-KN]\-_"?P/I>N_$7X:CPS\=;;XB>*(^-\>Q_M467@']K?]HGX)_%O
MX]_%/]G?]@G]M'X;?M)?LG:?H?QY^+OB37OVJ?V:_#'PZ^&GQ#_X*!_LYWOB
MY/&-\?VFOA[9>*=6^-6A?LTM\2V^(<OAKXM^#V^"VBZ_;_"_PW::!IH!_2QY
MB#^(>OTQQSZ?C2[U)QG]#_AZ<GT')XK^>_\ ;"^*GBG]FK2?@S-\8?B%\>/@
M_P#LQ_M6W/[87Q)^.?QHN#^W+\5-9^ /Q9\;:_\ !>\_93^%EWJOP._:'\%?
M%C]G+0A\%M4^*_@RW\+?#K7[3X-:=\;_  U:ZAH?@O2_$6LV?B ?)/[2_CSX
MMV-K^WS%XI_;1_:FE\?_  /_ ."%?[/?Q[\"01?%'Q/^RMKK_MM>''_:JT_2
M_B-J'P)^%7BWP_/X$^)GC[5=/^ .L>./V>+N[N?#GB#4/B[X+\%_%+X=^(4U
M#X8>'_#H!_6+YB?WA^&3WQQCJ<\$#D=Z!(AXW#(QUR.IP.N,Y) &.N1C.17\
MP7Q:_:X\>7O[9_[.OC7P)\8_VBK7PWX5_;^_92^%_P 9-,N=>\?:A\)O%'P/
M^/W[ OCF_BUGP=\+/A]X?LO@CJG[.'Q'^+5WX/D^'OQ5\=P_$WXH_$7]I76/
M&.E_#'4?A7X6^%7@&#QQYW^R%\4/&M]XH_X)=:MXF_:^_:!^(%[^T%^UY_P5
MC_98^.]GXN_:B\<:UH?B?X%>$O$G[;'BC]GVUNO#5AXIL/#?ASQC:>([7X W
M7PN^.'A?2= ^+9\/^-/AU\-O"?CY?A-JWPS\!Z> ?U6:-XAT+Q%9RZAH&L:;
MK5A!JFN:)->:5>V]_:Q:SX8US4?#/B/2Y)[626-+_0?$6D:IH>KVC,)].U;3
MKW3[M(KJVEB36+J "3@$X!]Z_BA_9/\ &GQ"^&7_  36_8&L_AIXU^.6J7WP
ML_9&^-WA7X_?LIZ!\7?VG_@%\6=8^(-QXGT+2]4'[*WQ&TBSUSP#XI_;A^#N
MI>"?[)^%_P"PA\3M)71?B0?$?C.W^'NG^$]4LOB//JG]*O\ P49^)1^'7PZ^
M =M+XN^,G@#2_B1^UO\  WX8ZUXQ^%>HWOA?PUHNG^(KS7K^.V^/7Q \-^$/
M%WC[P#\&O$FIZ+IW@T77PW;P3XJ\??%CQ#\*?@M=_%GX1>#_ (H>*_B5X8 /
MT(\Q/[PZX[]?\_IS7$_$KXB^$_A/\/?''Q0\;WFJ67@SX=^$]?\ &WBV]T/P
MSXH\9ZQ8^&_#&F7.LZY>Z=X2\%:-XA\7>([NTTVTN+B'1O#6A:OK5^T?V?3]
M.NKATB;^5G]C+XP?$;XW:W_P38^''[3G[6'[37AZSN/V?/\ @K]\/?VG/#6J
M_&SXR?LR>)KY_P!FK]J+X=>&O@+JOQ/U5O$?@WXX>'OB!X1^$VF^,)(/B1K/
MQ B^,]W;?#?QNGC7XC:_J6G?'0^)..T+]I;XI_&3]D_]FGP]^UO\7/VBK?X>
M?%S_ ((FW5W\+?B%\/?%?Q0\+)\:_P#@HN-.\>Z;\8OAO\7O&?P=OK;Q!XR^
M./A/P+X'\ O\//@Q\0%.C?$'5_%?QLM?$'A'XG^-;6VL?"@!_51^SEXS^%GQ
M%_9^^"7Q)^".B67AKX-?$GX4?#_XC?"S0M/\.67@^TTOX?\ CWPKI?B[PE:I
MX5TZ*&Q\.NFAZQ9&?1[:-8K"<RVXSL+'V7S$SMW#=QQR#SP/UX^M?SA?M!>,
M_B9\+_\ @V&\'^(/A[XP^+?P%^-'@K_@F_\ LS:)X8U+PM+XK^#WQAT'XD>&
M_AW\,O#\WAG0A?Z?HOCK0];OM8TZ^T6"+1;?3];U;3Y6?0+UK6_MKR9/VR/B
M1K'P+^+MI^SQ!^TO^T[\(_@S\9?@SX'^)O[&?[3FC>&_VP_VP/$OBS]L+Q[\
M:/C-JWB_X7>&_%?PQ^.NDZ+XVNM+TY/V:/$GP6_9[^./ACXC_ [Q?X)O?&/@
M&'09?AO?>)?!^K@']'^],D;AD'!]B??I2"1#T8'OQ^77Z\8ZYXZU_*G\;/$G
MQ[U+XU_\%.],^$G[3O[2%[^V5\-/VU/V";']AK]G.]_:!\=V?@>RU'QK\"/V
M-/B=\7/"-Q\ / WB^U\'?$'X(ZK:^/\ XD7?[0.F^+Q\1?AE\'_A/HOB'XL6
M$_P_O=,\7?%#7^J^#GC3XQ^&OV4/VZ/VQ_ 7QK_:L_:3^*7PV_;U_:2^!D?A
M&3XN?&/X^^&M#_8A@_X*-^"(/$^M?#?]G7P1\0?!^E:EXT\#_LC:?XZ\<_![
MX@^"KC0?C%+X6\376D^"/B+'X#'PY\/^$P#^H+S$/\0['\S@?F>![@^AHWH>
MC _SYZ#'7/MU]J_D^^(WQ;^*?BSX+:3X]_9O_;)^+O[0/PBUBY_;=^(/@_P)
MXBU[]L+]A>_^+GAN3X>_ +P=)X'_ &2_VO\ QWXZ^*GQ:UGX_P#PD^//BWQG
M=_LS?#S]I6T^*?P<^)_B/XR_$[X8>$]'\+>'_P!D_P"'>N_"7ZA\2?M0_$_X
MA_M]:=\+/'/Q'_:+_9>\>VOQ^_9D\>?LG?"+3_V>OVB=:?X__LN^(_@S\'/%
M/QO\(>,IM%^+]A^R1?\ ]B^(O$G[3'P^^/6N_%#X>>*/%?[/S:=HGCWP=XK/
MB[P'\*I]  /Z(/,3^\.@//'!.!UZY. ,=21CJ*R=%\1Z!XDLY]1\/:UI>N6%
MMJ_B'0+B]TB^MM1M(-<\):_J?A7Q3H\MQ:22Q1ZGX<\3:+J_A_7+%W%SI6M:
M9?Z9?1P7EK-"G\PG[/\ \0[Z;Q/^Q1K]]^VC\=_B'>_%/_@K)_P4X_9'\5_\
M))^UUXNU+0?%?[*E@_[>^I?!W1AX3\/>+M#\)O>)KEI^RYJ_PH^,MCH"?$_0
ME^(_PJ\(_#/Q_HGPY\7?"3P1:?)G[-7C*[^'7_!,C]E7]FWX<^-_VN/A?\3[
MZT_X*N:+J7AKX?ZM^T#I/AC2/CE\-9?BS>> O@IXAN_A[I<WQZ@_:*_LV]T;
MQE\ ?V7_ (9?$[X#Z+XG%I\5?C/XMU+Q-XV\&^"/AW\6P#^P_P 7_$#P_P"$
M+#Q%-,UYKNN>'?!6O>/V\"^$[-_$GQ"USP]X>A=KIO"_@O3G?7-?OKV]$.C:
M19V-M(^IZ[=V>DVS&[N8TK1\&>*8/&O@WPEXSAT;Q+X;@\7^&=!\3P>'O&F@
M7_A7QCH,6OZ7::K%HOBSPQJ:1ZEX;\3:6EVMCKN@ZC''?:1JL%UIUVBW%O(H
M_DV^'WQ:N]>O?BS^TCXD^+GQ:\-?M!_M ?\ !MS^RY\3=)^*%CXI^(7@W4?$
MW[0/AG3OVT/^%Q>)?#NBVT>G?#;P_J7A'Q1J'@2>SATSPGH_AGP)XL\=>$]3
M^'=AX>\0_$K1[KQ#]/\ AWXK>,_'WP8_9^T/]H[X^?M)_"SX-^-_^".O[._B
M_P"#?[17PO\ BI\3/"7B?7/VZ[/3_%0^/VG:]\2/!>NW/B/XG_M*Z3IVF_ [
MQ'\,O@=\3=.\;GXN7Z_&VQA^'OQ-DT[XF:%8@'])WF)Z_D"?7T'MQZ]J4.I.
M <D^Q]^^,<X./7'&:_BI^+G[0/[9ME\*O^"C/Q)^+G[37[0'P[_:N_9]^!/_
M  18^+GA7X<^"OC5J?A3P1\-OVK-4\$V=I^U1X2\-?"GP/JS?#OQIX2N_%FK
M:]HWQ@^#6N:;\0/A1XGGO--U#QIX5UO5M%\%ZSHW["?!7XH_%2[_ ."C=[I]
MWXR^)7QT^#OQ)^.'QJ?PCXF\"_%'XK>&[[X#1^#_ (0^)M"T[P'^T1^R5XFE
ME^#FK?L@:W_P@.I_\*"_;3^!;:;IOBCXZO\ #[P5\1-#U/XF?$;Q-XY\0@'[
MH,R'&6QM?T!^89XY4^O48.>AK$\,^'/#7@[0],\,>$=$TCPUX<TBV6ST?0=!
MTZTTK2--M5=I!!8:?8PP6MM$TDSRNL4:AY)))6S(\CG\7/VJO'?Q5\-_\%#/
M!,>@^-_B3X[^&VHZA^QAX,U_X%^ _BG\:/@M\2?AMK-]^T+?:A<?&+X0>$-%
MTS5?@1^V9\)-?T'7)=/_ &[?AYXBMM,^)OP'^ OA&W^(4WB:W\+Z_P"%-/D^
M&O#WQ ^*W[7?C'X]> _BE\6?VFO#7[2WACX5?MU?#3]JG]@?PI\'OVI_#?PZ
MO/!DMEXWL_@?XB?QIXE^,>K?!&/PC>S^'/A;/\"_B%^RCX=L/B+^T!X7^(EQ
MX<\8IXZ\*:]\6]2\/@']1GA[Q'H/C#P[H?BWPEK6E>)O"_BC1M+\1>&O$>@Z
MA::MH?B#0-;L;?4]&UO1=5LIIK'4])U73;JVO].U"SN)K2]M)X;BWEDBD1C\
MS_ ?]LKX5?M&>)K31?AMH_Q1N_#?B3X3Z#\</AC\6-4^&GB6P^#?QB^%NOZY
M=^'+?Q+\._B0EO=:"U[!JEM;S-X+\8R^$/'^I^&=8T'Q_P"'O"FM?#W6=/\
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M?\:Z#>Z3X]U[6]<N?$DFOZE^,GP-^-W[07[-'P2_8D3]EOQK\8/C-XM\=?\
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MLK?\+]TCP?\  'P[\1O!GA_XOZ_X<N=4^/\ =_!WPQXLU#4M4T[X\_"272?
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MOH"M\-/CUIOA'7+OX>S?LW_&SQN=/\4>.?@]\1U^('@G1["/QSXXL--_3>@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HP#U'3D>Q]:**  @'J <=,TF
MU<[L#<!@-@9 ],]<>U+10 @ &< #/)P.I]32_P"?SZT44 %'7K110 4  #
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M_*BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M.7_B4OQ-_P#H.Z/^$J_:V_Z(C^SE_P")2_$W_P"@[KZ/HH ^</\ A*OVMO\
MHB/[.7_B4OQ-_P#H.Z/^$J_:V_Z(C^SE_P")2_$W_P"@[KZ/HH ^</\ A*OV
MMO\ HB/[.7_B4OQ-_P#H.Z/^$J_:V_Z(C^SE_P")2_$W_P"@[KZ/HH ^</\
MA*OVMO\ HB/[.7_B4OQ-_P#H.Z/^$J_:V_Z(C^SE_P")2_$W_P"@[KZ/HH ^
M</\ A*OVMO\ HB/[.7_B4OQ-_P#H.Z/^$J_:V_Z(C^SE_P")2_$W_P"@[KZ/
MHH ^</\ A*OVMO\ HB/[.7_B4OQ-_P#H.Z/^$J_:V_Z(C^SE_P")2_$W_P"@
M[KZ/HH ^</\ A*OVMO\ HB/[.7_B4OQ-_P#H.Z/^$J_:V_Z(C^SE_P")2_$W
M_P"@[KZ/HH ^</\ A*OVMO\ HB/[.7_B4OQ-_P#H.Z/^$J_:V_Z(C^SE_P")
M2_$W_P"@[KZ/HH ^</\ A*OVMO\ HB/[.7_B4OQ-_P#H.Z/^$J_:V_Z(C^SE
M_P")2_$W_P"@[KZ/HH ^</\ A*OVMO\ HB/[.7_B4OQ-_P#H.Z/^$J_:V_Z(
MC^SE_P")2_$W_P"@[KZ/HH ^</\ A*OVMO\ HB/[.7_B4OQ-_P#H.Z/^$J_:
MV_Z(C^SE_P")2_$W_P"@[KZ/HH ^</\ A*OVMO\ HB/[.7_B4OQ-_P#H.Z/^
M$J_:V_Z(C^SE_P")2_$W_P"@[KZ/HH ^</\ A*OVMO\ HB/[.7_B4OQ-_P#H
M.Z/^$J_:V_Z(C^SE_P")2_$W_P"@[KZ/HH ^</\ A*OVMO\ HB/[.7_B4OQ-
M_P#H.Z/^$J_:V_Z(C^SE_P")2_$W_P"@[KZ/HH ^</\ A*OVMO\ HB/[.7_B
M4OQ-_P#H.Z/^$J_:V_Z(C^SE_P")2_$W_P"@[KZ/HH ^</\ A*OVMO\ HB/[
M.7_B4OQ-_P#H.Z/^$J_:V_Z(C^SE_P")2_$W_P"@[KZ/HH ^</\ A*OVMO\
MHB/[.7_B4OQ-_P#H.Z/^$J_:V_Z(C^SE_P")2_$W_P"@[KZ/HH ^</\ A*OV
MMO\ HB/[.7_B4OQ-_P#H.Z/^$J_:V_Z(C^SE_P")2_$W_P"@[KZ/HH ^</\
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MT^#]D+XXW^FZCX!E\ _MP^$_V;?#.N>,O&GBFR^!OB[6/A3J_P 6M!\-:/\
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M+\+M4^%O@GPG\4+C_A"&,:Z':R>&?%T^L?#G_A7^K:OXO\':6][<GPQJ.O\
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M^W:MXK\3^(-8^VZ* /D[XJ?LH:1\4/VGOV>?VJG^(/B[PUXU_9K\ ?'WX?\
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M^+7B";0?!FA:#I^I:582ZZNM?K=10!^;?B/]GB?XV?M/_LYZKX\\%_&Q+O\
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MB_QMKWPKMM"_:#_X*[>#?VS]"^)-]\,OVC?B%I_P#M-(_9UT/X:>&XM=\>?
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M\2/#WB#Q/X#^*?A_Q;I?AC1/!OB35XM#AU>]UL:#\2KG4[7X5:MIGAB/3?\
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M &7Q?X/?\%$_&O[17@3]O;QU\+OA1\(O WA_]C_]H;7/V>/ 7B_]HK]HF_\
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MNHZ9JFFW4%]IVHZ??01W5E?V%[;/+;7EE>6TL5S:W5O+)!<02QS0R/&ZL;M
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M\,_MP^!O^"A/[)3?"OQS\0[O]G^;]DO]H#X!?'?Q;XD^&O@[X@?!JQ\;:O\
M%/X=>.OA=\7_  9\/?BIK?PU^*WPU^(FKZM%K.BZ_P##CQQX(^*G@'Q1?:1*
M_P /O%?AO0O%5]^H=% 'Y-?M:_L[_M??M2>!OV2=0U'0/@GX9\;_  H_;K_9
M1_:>\=_#;2_BCXEU?P9X,^'?[/\ XSN_$_BG1O"GQ/U#X.Z!K_Q3^(WBZ.>-
MK+^U?A_\+O!]@W]GZ"CV_P#9&H^-O&OR!\:_^"=?[<GQ!_:1\)?'&PTW]EZ_
M@^%O[1G[=/B_PA!:?%WXC?#R#7O@W^U+^S-\2_@K\/W/P]T3]G_5O"/@GXK>
M$-1\<:?J/Q>\1S:SXZ\3?'/Q59:AXLU3XA^&?#\?A3P5X3_HDHH _G;\;?\
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M9'AMOB!H7A^[\8VP^%WQ4U+2[&75-6L-0T^\\U\:?L$_M*?$RX_9;\?W_P
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% &3K^HWFCZ'K&K:?H>J>)[[2],O\
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M=Y^SSXB\1V\?C/4/".MV'A[5O!ESH$5UXGEUWP]X:_J/V)_=7C&/E';&.W;
MQ]!2[5_NCTZ#H>"/RXH _GD\<?L&>)O&>@_\%W];;]A;P_\ \)U^UI_;.L?L
MF7FMV7[*EQXB\>^(?%'_  3[\(?L\ZI?Z-KL7Q,U&+X?ZS-\9V^+6K:_J/Q
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M9TJ&YEBDU&S68 T:*9YL8ZN!]>_T]>AZ9Z'T->#_ !#_ &EOA#\+_C3^S_\
ML^>,=?UC3?BI^T_=_$JR^#.C6_@GQKJNB>))_A'X&O?B-X]BU+QQI>@7?@;P
ME<Z3X3L9M0LM/\6^(]%U/Q$1)%X;LM6:RU(V0![W13/,3.-PR>@YYZ]/7D$<
M=Q2>;'_?'Z^F<?7')'4 @D8(R 245XEH'[0OPM\2_'SXA_LSZ5K.M-\8OA=\
M/_ /Q2\8>&]0\$>-M$TRW\!?$[4_%.C>"?$FA>,=:\/Z?X.\9Z?J^L>"/%VD
M32^#-=U]=(UGPYK.C:T=.U;3KNQA]J\Q/[PZ@<9/)[<#V/Y$] : 'T4SS8^N
M\8X.<\') &#WY(Z>H]11YB$9##''/..?\_G@=2* 'T4@((!'0_YZ'D'U!Y!X
M-+0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!\=_M
MM_M:_LR?L/?!YOVD/VF_%/A;PMH_A/6[?P_\-X]<U;PYI'B'QA\4O&=C>Z)X
M=\ ?#V?Q1JFBZ/%XL\5V<NIVE[K&JZOHGA?P9X+@\6>//B+XF\'_  O\+>-/
M%NB?CC:^(OV>-9_X(=_\%!OBI\"_BG\//B7XX6?]K']KGQ+\7?@]?^+6^&2_
M\%(-:U:/]L?P#=?L^>+?%FD^'+SQY:?![]HO7?@]X+^"^N:;I4=]XA\4_#W0
M- \1:-_PLV+QAX=A_I2KQWXL?!'PG\:;CX?1>.[O7;_PU\/?B#X5^*5MX'MK
MVUM/"?BKQQ\/=<T[Q=\,M6\:VR:>^K:U!\-O'FC:)\0O">D6^LZ=HP\;:%H&
MNZYI^MS:%I"60!Z5X>N=4N_#^AW>NVL=CK=UH^F7.L642&.*SU2:R@EU"UCC
M:>Y9([>[::)$:YN"JH%,\I'F-^%7_!0WQYX#TO\ X*S?\$K= U3]HGP[\ -<
MTK]GO_@I1JVI^*9?$7PGL]=\)V'B[P[^S5I'@_5=1TOXK:7XC\/VFE>)=8\,
M^(K?1+C5="":]>>$]<T_2[MFTW5UA_>P<  \D <\_P!23^9)]S2@ #   '0#
M@#\* /P$^.WQK\47_P '?V;-?_9%_:5L/BO^U%^SCKWC_35\-W/Q8C\+_ __
M (*">&/@;\'(=%_;?\07&AZ'\</A]HGB^+P9XH\5:F/"GQ/U'7(K#X<_MH>&
M_#/A#XB:SH?PYU+QIXNB^)O$OQ._9@^.WQY^ GBCX!_MG?%*[^&&O_\ !!O]
MN?XB>%OCA;_M2ZU9?M$7&IVWQ_\ V6_&27GC7XN:EXCN_B%X,\<>&/%?@SQ/
MK/B_PE9ZEX:L_"^L_#+Q?\,]7\.6OPT\->-?AS)_6I10!_'+\4?VL?C5^TI\
M ]!\-^(?V@]=^*NN?M._\&D_[5_QJ\9?!CP_=>!8M'\:?M9:_P" ?@?8:IXV
MTCX<?#[P[H]_>?$_7[G5OBEH-MH$4=]IWA^VTCQ3H?P_\,>%(X?&EOJ/J/C+
MXP_%_P"%O[/O[:'Q"_9?_:Z^('B7]FC2_P#@AU>?M WWQB7XLV?Q1T7X,?M\
M:!HNJ3?"#PS\"OB1XAO/$?P]\(GXS^#+77AXZ^!GPLTRTTWX?KHWPJUSP9H?
MPHN_B?X$NO$_]9-&!UQR.A],]: /Y\/^">GB'P')_P %7_VT]1OOB3KVO^.O
MC9^P5_P3#^*WP_L=9^+_ ([\90_$3PC/HG[31^)?Q#\%^%]5\7:SX=U#X;^&
M_%%_X3TR7Q%X;TB/X?\ @#Q;X[CT;1)_#_B/XL:A:>+/N#]J.[\&_M<_$7QO
M^PWHA^"7QKTWP?\ "W5M9_:O^!?BCX[W'@#6K/1OC=X:U;P5\*=*\5Z#X2\
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M@ZQ_:'@3QIH4$T>MZ;XC\(:DZ7O]*?\ 7K10!_-O^U!^TQXUN=*_;8M/AO\
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M7Q1X4^&]I)IGAJSU+1O#WA7XG:'X7\)^!U\#2^'+FU\4>-EOI)]4^+]YX/\
M%VD?U>8'H.<9_#I^7:B@#^5#3?VW#X,_9W_9=NOB+^VBGBC]G3PS_P %-?\
M@HI^RQ\6=>US]J;PS\)_C'\6?@I\&_&'[4/AO]F2QE_;*\0?%;X/Z-IVM^!O
M#VA_!WXB^(I?%/QF\"?$/X[>%(]$U;3?%7C.74+KP=\2?T?^!?C_ .(VD?\
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MSPYX$T&\^('Q[\%7OC[6]=TKX??$FRT[]FS3O%.L^#/ WCOX4^&OZ7Z3 SG
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M&?LP76GIXKTGQF-*\(?L<_$#QA\,_P!HK6K[]GGPI\0=;\2:Y_4$  ,   =
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M*<"#T.><?C0 M%%(2!Z]SP">GT!]: %HHII95ZG'X$]P,G X&2,D\#DDX!P
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MCK6OC/\ '/6-*^"OQ6MM(;XAR^ M"\1:UX;\/W7Q%^*GA'_A/#KNE>F>(_\
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MC:?\/_$7CSP9\.(_!5CX<?X6ZMIWC?0/CAI>CZ9K/Q9MM$'B'7;#0OL[3O\
M@J!X0O9O@?\ $-?AQ>R?LK_M$?M3_$O]B?X8?&G2/%4VM>-IOVAO!?Q0\>_!
MCP@?%/P?M/!HTW0/@S\6_B=\(?B5X1\&_$^U^*FLZKH][?\ P?U/QU\/_"WA
MCQYXVUWX278?^"47P5LOACX(^#VF_&3]HW3_  %\,/VUQ^W1\,M&7Q1\+]1;
MP)\1(/C3XJ_:&TSX?Z5=ZY\(=5N=7^%^F_&#QSXQ\6B7Q?)XD^+&M1ZX/#?B
MKXK>(/">@>$]!\/^N>&_^"?'P1\*>,;77-)UGXC/X#T/XZ>//VH_ _P(U;7M
M#U[X-_#C]I;XD3>)+_Q/\9?!&EZWX7U#QKINI?\ "0^.?B)XVT/X=7_CK5/@
M=X8^(GCW6OB)X>^%6F^-=*\&Z[X6 /C_ /9;_P""N7B#]H7QQ^Q;I?B7]E36
M?A5\//VXM6_;,^'7PX\7/\9_"OCGQ=X1^,O[&7C7XI6?BOPYX]\!Z5X5TC2;
M?X=^,_AS\+-=UOP]\1O#'Q"\3:]8_$NVO_AWJ?PTC\%QZ!\9O%-__@H/XN^,
MWA/_ (*%_P#!)>U^"<U[K_B+Q=K/[<UC-\*_$WQP^(/PC^!_Q!OO#?[*FNZY
MX;/Q47PMX>^)>D(OA^^EO;GP_P"+O^%*_$KQ9X?U&\6TT>PLM)U77+ZV]8^$
M'_!*3X+_  5N/V/Y_#'Q@_:"U-/V)_B9^TK\5?A+;>(=5^#MQ!K'B+]K"X\=
M7'Q<L_'ATCX*Z+<:KHMTWQ+\<)X?M- N?#%YH<>N8AU"5]+T5],^G/C[^R;X
M*^/OQ(_9Y^,=[XU^(WPW^*O[,'B3X@>(_A/XX^'%]X.-Y8CXI?#_ %/X:^/=
M%UOP_P#$3P3\0_!6O:/KOAG4@ U[X8.LZ3J%A97FAZQIA:^CO0#\S?'?_!:P
M_#_]E/P]^U3XE_9+\<>'M%T#P)\5_%/[0O@OQ)\7?AM9^*OASXO_ &;?VCK'
M]FW]ICX-_"/1/#L?BWQ?\?OB'\-O$>G^/?%.D>)%\&_#+X$WWA#0O!UY\4/C
M-\&;SXC:9:Z1].C_ (*4>#K+]ICXZ?L_^*?#_A'P7!^SM-XI\0?$V7Q9\5DT
M+XRZ3\"_"/P,A^+6H?M0Z7\!=1\"VE]XU_9]O?%$]O\ "G3_ !S\-_'/CA[?
MQ/=VR^([#P]JD6I^'=,X[XJ_\$8/V2?BGX0\5^ SXE_: \!^%OB+^S)\0?V6
M?BII_@GXM7$UU\4_"OC[XK^)/CY)\0_'6M^/-$\<Z]J/QFT3X[^.?B%\6Y?'
MVGZII3?$GQ)\0/%FB_'72OBSX#OK;P?9?0<W_!/OX,^(?'7A;QU\5?$?Q(^/
M$O@GQ5\3_'/A3PS\:]4\(^-?"^@^*OC7\)/$_P #?BU-I< \$Z9K5AX,^(/P
MU\:>+-&\1_!6TUV#X"W&IZW)XLA^%T'BW3M%UO3 #YOU'_@JC>^$] ^+?C/Q
M[^R;\=]%\ ^'OA[\&_'/P+\<V'AGXAZ=X7^.'B7X^?%C0O@=\,/@-JGB'XP_
M"KX+>'?AO\=M7^)GC;X<VNIZ99:S\0OA%I?@_P ;6_CE?C-=Z-X;\6KHG+?L
M#>,OC3KO_!2W_@KAX=^,L=]H,_A+2/V [CP[\/M-^.WC[XY_##PC:^)OA?\
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MQ+\!?V6OBSXI^%5GX"^(WQ\^'?@.RNI?AEXK/B?P_P"*O#7CB[@\+ZG<>*?
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M_3#X _ 7P+^SA\.K?X;> /[;N["7Q-X\\?>)O$GBK57USQCX\^)7Q5\;:_\
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M;2+7P_J_PYN/%5AXCUO3-,\07/BCQ#XF^&.B:SXB\.?!O6/ASX=\7>,=*\0
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M\,8/AOX=\9_$+1?%P!\V?&C_ (*!VVJ:K-\,/CA^R_XA'CWX&?\ !6/]@_\
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ML$U2#Q+HFIV>M_#GQ2/#'Q;\#+!:O\1_A_X-?6="AU/COC!_P4)_9X^!VO\
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M![C]H?Q187?[._PB^/6B_#3Q?'=:GJ.FR>/_ (>?"S_A:7@#P#KWA^VL=?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MTBUO]/L[S5_B'::YK7BRZQ?:7X4\,Z#!K/C, X[]@[]I+XC_ +5_P.U'XO\
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MYO"W_"6^)_"_PMUSXA>!_$TOC"_\"^G_ +)GP>^*O@#]K7_@I=\4_'/@._\
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M  4_9EO]%\0?MQ?\%;OC!K>OZ=\;-2TWXR> O!_[8>K?%GQ'^S]XN\)?&(_
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M>^'WA[XO?M<^(?BCI_AWQ?\ $J:/4O!7PO\ #7PK^%'B_P"(=UXI\3^"]/\
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M0G1M#G\<:> ?TZTC':"<9QV'4^@_$U_)K^W9^S+XY\9?#C]M_P 2_LE_ O\
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MG@]<=L\<4^@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% "8
M')P,G@G'4#H#ZXR?SHP"02!D=#CD=.GY#\A2T4 '^?\ /YFBBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M[?Q*^NR?$30?VC/B#X)^!N@:%\5]%^%5O\5/&.OG6O@UJ/Q#^'/A_P 6>.M
MK>)O^"BWPE\*>$K+Q'J7P\^.DVNV4GQ^O_B;\,]-\#Z#J/Q*^"?@3]E;6=%T
M3]H?XG?$+0K?QD=.UCPG\/&\6_#[6=(TGX2:W\4/B+\9?#/Q*\!^)?V?? ?Q
M:T7Q##>Q?-/C/_@FG\2O%>HWT">+/A)::/\ "#XL?M"_M&_LS7][9?$/4+_7
M_CC\<OV_/@S_ ,%(/#;_ !FT6RUG1(O#7@7X4_&CX//\/M=T[PAXD\:WWQF\
M"^-O^$DL/^%'ZKX*C\+^,7^./^"=/QD\2P>-?'NC>)_@UI7QL^/WA;]O7X7_
M !F>^_X6+J'@'P+X)_;K;]G_ $:'Q7\/A"]EJOQ#\5? /P5^RI\#-(N_"VN:
M=\*])_:#UBS\;ZU:^*_V;T\2VMAI !^QUI=6][:VU[:7$%W:7<$5S:W=K-'<
M6UU;3HLMO<V\\+/%-!<0LDL,L;LDD;JZ,5(-6*Q/#7A_3/"?AS0/"NBQ20:/
MX9T72O#^DPS3R7,T.F:-8P:=812W,Q::>5+2VB62:5FDE<%W9F8D[= !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
(4 %%%% '_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>25
<FILENAME>ex10-11_002.jpg
<TEXT>
begin 644 ex10-11_002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" /+ NX# 2(  A$! Q$!_\0
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MVHW<-JY$\MK87&HZ=!>7"(8K:;4+"*9T>\MUD -"BBB@ HHJ.65(4,DC;47
M)P3RQ"J  "22Q   ))( !) H DHK.TK6-)UVR74=$U/3]8T]KF^LUOM+O;;4
M+,W>EW]SI>IVHN;26: W.G:G9WFG7\ ?S;._M;FSN$CN()8TT: "BBB@ HHH
M_P ^O\J "BHH)X[B,2Q,60D@$JRY(.#PP!X/'(Z@BI: "BBB@ HHHH ****
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M?O WPX\;V_CGY=\0?MZ?MB>(?V0YOA_IOQ,^-^B_M8R?L4_LU_$CX<W5_P#
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M:$M_B#\;+'Q5X\^(FEZ9^P-\//B5XR^-_A?P]\*-!T_XE_M,>$O!7[)5I?\
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M$[X6_!GPUKNB>// 7[-OAZ[^)7C+Q!JCZQX4\6>,/B!_:'P2^%_@G1_"NA>
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M GB#Q#X>U?QK+H?B#P_8?M.^([/PSX=\!VWP$TK3_J3PC^W]\*O%_@F'Q"/
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M$?AR/QA\4_A%X.\1'4QK'B[QM\._#-OXGF\8W7AWPUJ7@?0?%?PY^*_PLO\
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M]K3P=^REJ7Q"\>?#35-?\5?#O]HS1O$_BWP;X%US4-6^"_C3X_\ QG\=^/\
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M^&.I_M??#J[U_P"'/A2;XR?L^?M'_#3XL>.OCG\!_@MX!UB/Q'^J?[0GQSU
M^(-6^"GPT\2_#RV\3>&_"2?$W]H36/&WQED^#.G_  <^ \IO84U&;QSI/A+Q
M]XC\/>-O'NH6<VF>'+^/0-!L_"_@73_B!\0;GQYX2\3Z+\+-/\=_<>!SP/F^
M]P/FX Y]> !SV '2@      8     '0 =!C QCICB@#^67X=_M#?$CX;?L9?
M\$J_@U\#_CS\-/V7;O\ :'_82M=5\-WLNJ_"/P=\/_A%^UWXZF^#\?A?PO\
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M/?PK\5>$O@-\+OZ1L#).!DX!.!D@9P">^,G&>F32;5/55/S!N@^\  &Z?>
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MVTJT@L8+J^BL['2[6*\NHH%N;J"WTVP@M[B:6WAL[>.)(DZ2D  Z #/7 QG
M 'Z #Z #M2T %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M&DUVV\)_ K]G/4OAWX;T67Q$/'-QJ/BWQ1\7?V@/$-G^T?J]W+\/9X=#\?\
MAVV\5WWC33[[X-? 3PX/W-HH _GQ\$?L)_M?:'X&^ >D>'K;4?ASXD_8TTSX
MGV=GXCN_'_AS7/$G[2_QE_:O_:2\*>(_VS_VJ?AI;IKOB;POX \;P?LY2?M'
M0_LOW'QRE:[U_P"-W[6VM6WQ(\%?!+P7\'K?Q%\5/H_]E7]D#X[?L^^#?'ND
M_!2ZTG]EKX3W_P"TUXQ^*?@;]GBY^%_PI^+'Q&A^!'_" _!WP[8?!S7?B3IG
MQ TCPYIFMWOC?P'\5-4^%5]>_$'XI6?PH^#/CSX/?!BTU[P_X*^#/AWP)X5_
M7^B@#\=O@!KG[;/P.^"-_ID/[#_Q)\0_'+XS?M$?M'_%_P")&L:E\0OV5H/
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MXH_:MU'6+_0?A7\%_#WA#X.?%+Q#\'?VL0?VJ_!.OZ_\#]0\&? ;0OB5XO\
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M"Z>8,L!@ )@DD@995!+';0!_-EXN_8X_;1^+'[+W[4O[)'Q8_9%\!^-OB?\
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MQXTL?"6LS:U/<16OAT:/:V.MZS]5)=Q/C:LQ#.$#")V 9MF-^T,8N'!/FA"
M#N XR 6J*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M:U8_\%!;;P+^R7\5M4A\9?\ !$OX(:G\)X8?V>OCM<1^,_\ @I#X=C_:9MM
M^)-K;:QX-=?%G[:_@V+Q9^SW /C5XF34?C]X#LUU&"Z\9Z+:>'OBHNE?1OBS
MPI\<_B+^UCH.@?&'X)?ML^*8O$'BO]E;XS_L+?M"?"/P3\&]%\-?!S3O!/P8
M^$+_ !A^'G[1?QK^+7P=O_CY^R;*_P 5_"7QJU+XRV-SK4NN?'OX'?'7Q?\
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MO7?BS9^./&^GW7A7]F>'PK#K'BSQ=\5]$N)/!'C;XI^!M-_X4?:>%/BAJB^
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M1#HGQ7LO&_Q*^(>N>,_%T"ZWJ'A7^KGR4XYE&&9N)YARQ+'($@R,DX!R!T
M %'D1XQA]OEF/9YDFP(1C 3?L! X# ;E'"D"@#^5'X8?ML?M/_$OX%?M(?M
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MX!*R#=\P .<Y7*'*$K0!_(!\>O'DOP_B_P""B?C3PQ^W'\:HOBO^S#_P0_\
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MCSXT?%KX?:%I'PL^!GAY_#VBZMX"NM9O?B+X<TG6? 'P)M]!\7?2'[:_Q.\
M1_\ !1?_ ((4_P!H^)]%\*7^L?&3]JOQ)'X9\6ZC;>%/%-CI/C?]@CXZ>&?!
MXU?PQK\NG:UI=UJWB*]L?!]C9ZC91W4GBLGPO!YVL1/;']P5AC0*J!D500JJ
M\BJ <9^4,!VX)&5R<8W-D6")!M52HW,Y 9\,S[][.-V'+EV9M^[<Y#G+JK
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M8%<;%VXQL*@IM(H _EPTW]L.ST*3X&^,K7_@H!J'QA_X)<_&']L8Z?\ %O\
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M2&02[Q\WRN)0)%9<%7^92&))<8D,9B8%T/!5V9]P)R0Q<LS#/&&)&/EQMXH
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MPLG_  4"U30OC/\ "6R$7[,O[.'[2'ACQ#J'QJ^*EG^SMI?PL^-%[\*?V_\
MXY:;\&?#WQ*T3QIK$?@3XA-XK^%'B;QQX3CT#XZV/@CX1>(/CIX<U9H-1M[W
M4OT>_P"":'BZ/Q=\!O'OBO3/VKV_;'^%NH?&WXC:E\&_CA_PA_B#P]H"_"^\
MAT35AX \*>.O%_Q+^*_BCXW^$?A5XUO?''@33OB[XG\7W6OO+H-]\.=:DU34
M/AO<>)=>_1'[) '\W8WF?/\ /YDNX%U*D@[\@A&*(PP8TPB%5  E6*-?, 4G
MS3F3<S/N.Q8^=Y;C8JJ0, @<C))H _F*_9N_:\_9 \-_\$_O^"C^G^,_'G@/
MXU1_&+]N[_@K5X<\ _ #X:7^@?&?XH?M-P_&;]I#XYP>"OA[\)_A!X3O-:\2
M?%.?XMZ#?O/HL6D:;/H%UX,GU+QKKFJZ9\/-+U[Q+I_RWX?^/WQC_8@^!G[)
M_P"S)\8/CUXE^"G[0'[%/PG_ .",VE_&;P3\0OB5!X-^&OACX9?%_P#:CTKX
M/?'>]\*6VGQV7@/]HWX;:/\ !G7#\)/VA?C;\2/%7C'X!?L[^(/ASX3T/X*Z
MY8_$S6_$?C+2?[&#"C$$F3C''G3!3@%<%!)M8$'Y@P.X\MD@&A84087>!\Q_
MULAR6(+$Y<Y.0,'JO(7 8@@'\B'PF_:%\-?LCZ;^W;I=C\4/$G@;POJ/_!;O
MXF>$?VN/'7C+Q1^T5\8/$G[-7[+_ ,0_@-K&H?!+XS_$W3],^+OA[XI?"'PC
M\2/C;H/PY\ 3_&;4/&?@2[U/P?<:C<7&OZOX<^&ZQ^&?WF_8-^+OA.T^"7P
M^&OB7]JS_AI?QA\3]$^-/B_X#_%3Q1X/NOA]XL^/GP*^&WCS3HM.\9:/INI^
M)O%VL^/M$\!>#?B+\+O"G_"Y==UF;7_C7I4NA?&/4I]:E\=R>(M4_0<6\2K&
MJAE6( 1A995" !0%7#C"@(%V]-I9<8=PQ]FA)!*DX='.7D(9X^49P6(D*MAA
MO#8<*_WU#  GHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M?&_PM\*_ @67PU\ Z]\2?B#J_B3PEXLLO'_B'0? DW@S65;X9^$=4N/!>O\
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M(OC+XP_%#7?A-\79].M?%DGA3PI!J?A_3I/'7Q'\,67BNUUFV_0?X2_\$_\
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M'!'K^K>#O%'@(:C<Q2VTYO3:^'?&_B.WL8&<6/GZD;JZM[N2UM#;_&_[2/\
MP3X\"_M#_"KX"_!^Y_: _:>^"/@;]GFX\(WWA&#X%?$3PGX-U#Q!KGP_T[0]
M,^&FO>.M7\0?#WQ=>:_JOPYN]&A\2^"1;R:7IVC>.Y;/Q\NGS>,_"W@77/"H
M!^=_Q]F_;$^&O_!&_P#9@\4?'[XU?%7PY^U[X2^*O_!.Z7XI^,?!7BZ_^&WB
MW5[OXH?MI_ /X8^)? GQ.N?AY<:';>(+B'X4_$C4? GQ-TJVG;PQXI\76.HZ
MS(=96&TO!T'[6'Q>^*_C#XM?\%<K?0/B%\4_A')_P3O_ .">O@3Q_P#LZR>
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M5OW\9>"_'/B?PU8ZEJ5A^A_PX\6ZUX_^&W@7QSJG@OQ)\-M8\9>%?#_BB_\
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M+#4[S5_%MS;>"_%6NQ_7_P"SK^U#X._:"U;XT>";71O$O@7XL_L[_$1/AO\
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M;FSU'PMK&KOX[L_%G_"17.M>*9=.UCPMJ?@;0["X\):E]U !0%4!54 *H
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M9\0-)UI8-<D\+?%NP^&OV]\/O",O@/P7X;\(W/BSQ;X]OM"TR&TU/QQX\O\
M3M1\9>,M68M/J_BGQ+-HFD>'O#EOJ^OZG-=ZK>:9X3\-^%_!NBR79T?P=X6\
M,^&+'2="T_X:^*O_  3L\%?%#7OVC[*X\<:YIOP8_;4U+P'J_P"UY\$[JQ@U
MO0_B5JG@#P]X/\"SZE\/M=DN=/O/@_J/QD^%OP]\"_"7]H&ZL=/\5KXL\"^%
M-#U#X70?!;XLP:K\6-; /#OV9M6^-/[4?[4O[6NM>._&GQY^$VF_L>_MW6W@
M/X>:-X"^(W@>U^&WB'X8:?\ L:?LU^)[[X%?%CX:R6OB_P .>/-/\8^+/CCX
MO^+^I>.WT*W^)'AO6&\*Z)X&^*O@_3O"UKX9A]<_X*P?'[XP?LV?L7^._B3\
M&HY8/&5]\4/V8_A;I^O6S:)%=^%]'^./[3/P=^"WBK6M.?6KQ88O$3>'/B#K
M.G^$=6%I>Q^'O%5UHNNZAI5WI6F7KR>W?LV_LT>*?@)XZ_:<\9ZI\2]!\:Q_
MM/?'1/V@O$6EZ;\.]0\'GPSXT/PF^%7P4N-.T>]N?B+XO%YX7D\$?!?P//#I
M]_9G5(/%5SXMUE];N=+U71/#OAB+]MO]E?4/VR/@C=_ QOB)!\.=!U/XC?!;
MXA:MK(\(/XPU.6;X&?%SP/\ ''PKI>EV_P#PE'A:TTQ=1\??#GPO!XBO;TZX
M;WPA+KVBZ9::)K%_8>)]( /@JS^/VA?L5_$K]N>[U&#_ (*(?'+6?@!^RE\+
M/VM?%/P:^)?Q8^$WQ3\(^#_@5XO\5_M!^)-3TC]FBZUKQEI/BOQGXR\)>(/!
M7Q@T_P 87/QB\8:]XZUG2O"/@[X;^!/&OB7P/X4^%_AS2/LWQ-^W5\-O!L%S
MK_B,V>F_#V;X;_ 7QSX3^*%SX]^$L7P]^(FM_M&ZOXATGX=?#KP;KUQXZLGF
M\1S1^&[SQ+JWB/5+6Q^'^F^!+O3/&$?B74=*76Y]&ZKPA^S)XET3]K;Q_P#M
M7^(?B)X=UW4_B+^SC\'OV==:\$Z9\.]1T/3+?2_@YXR^)_Q%TOQ+8:O?_$3Q
M)<)=:[XP^-OQ/;5=*N]/O+:#PU+X"T.TNQJ7A/Q!XD\??-J_\$G_ (1:3^Q?
MH/[&7@?XI_&CP#IWP^^*OA/XR_!SXXZ-XDT+5_C1\*/&WPG\>:/XH^ IT34_
M%GA?7_"^M^'O@UX$\*>"/V?M!\/>)/#6I6FJ? _PCIWAR_EBUJ0^((0#ZT_9
M/_:F\$?M:_#[Q+X[\%Z/XM\.OX+^)WC;X3>+-"\76.CE[+Q3X)N;3?>^&?%O
MA#6/%'PY^)/@KQ/X>U3P]XQ\*>/?AOXR\5^&M1TKQ%#I&I7F@^.-$\7^"?"O
MR1^U'^U3\9M"_:SU;]D+PIX;N?!O@_Q!_P $ZOVK_P!IG3?CMH6N>#[_ ,<^
M'_B%\+/&?P+\%>&M2\.^%?%6@>(= T_3O!9^)-_="?Q%H_C"3Q1XGUC2L^$[
M'0/"5[>^(/N3]GKX5>.?A!\.K;PU\3OCO\0?VD_B+>ZE<ZWXQ^+WQ&TOP5X8
MU3Q'JDUK8Z;;0Z1X$^&?ASPA\-_ 'AW2M'TK2]-T_P -^"_#.EV=S<6]]XH\
M03:[XW\1^*?$VM^ _M!?L4WGQG_:"\)_M%^&/C)K7PS\5^'OV:OCS^RWJ^A#
MP?X=\:>%_%WP\^..N?#;QE=MJ%OJ<FEZQI-]I/C+X6>&I[V;1=;MKS6/#1U'
M1--U#PMJ5XGB*U /A7]AC_@J9X!\-?LH_LU:5^US<?%WP9X@\.?\$BO@E^WE
MXW_:*^*%OHWBCPU\8/AWX)^%/P?T_P#:#^(VER>$_$_B_P"+NH^+M"^(/Q T
M6&^TCQG\/] \3?$S4_$"ZG\,+'QS9W"7MQ[E\;_^"L?P[_9MO_'?AKXY? WX
M\_#[X@>"_#'P/^(]E\/;J/X.Z_KGCGX2_''XT^ _V<8O'_@CQ!X3^*VO?#W5
MF^$OQO\ B5X2\!_&[P=>^,='\5^#[G4].\1^';'QOX&\1^"_$_BSF?#_ /P2
M!\"'1?@WX#^)GQ(M_BA\*?A;_P $R_%G_!*_6? ]UX"N_#%_X_\ @-XL_P"%
M=17/BR^\6:?X_P!0N/#7Q0M+7X/?#?[)X@T#2(["RU&'QEJ^D:3I5]KWA:3P
M#T?QQ_X)2^'_ -I?P1\0=*^.GQZ\<^,OBMK'P5^&_P  _A?\?;'PAX#T'X@?
M#OP;\)/C7X*_:+\,^*O$.EC2-3\&_$7XH^/?C1\,_AIXO^/6J/H/A/X8>/K;
MX>>&=!^'OP@^#%I<^+;CQ0 =5X[_ ."I/P5^'?Q*^-OPF\6Z#XR\-^*/@G^T
MS\#?V5-1UCQ'=?#OPU\/M?\ B+^T1\&+7X^?#K4H/'^O>-K+P[X5\)2^ +N&
MQN-5^(%SX2O[_P"(5WHGPT\*:-XM\:>)?"VE>(%_:._X*?\ P_\ V5OA;H_Q
M@^-/P/\ VE/ _@^7X<Z#\4O'<OB/P#X4T(?"S2-;\>:+X%F\ :UK^J^.K?P3
MXV^.ND?VIK'C:Z^"OPF\5_$#QKJOPX\"^+?$OA2U\13W'@33_'F#9_\ !,.Z
M7QG^TC\0_$7[2/BGXB:]^U9XY^$?CSXW^!/B3\)O@UXJ_9W^)H^%G[*5[^RW
M<_#OXA_!>/PCI6I>+OA1X\M;K3?'_BKPA<_$NTD@UKP-\.K7PYJ>AZAI'C'Q
M-\0/&?B=_P $/OASX\^#LWP%T#]J7]HKP3\*9?V+_$7[&%KX-D3X6_$#3_#/
MA&_^,(^,N@ZY\/K[X@_#_7]?^&UI::C_ &;X \9>#O ^LZ)I/CWX3?#3]G[P
M;<7FAW?P(\#^(( #W;Q__P %3?A]\/OB'\:O VK_  )_:3FTK]G/]J/]G?\
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M?R?%8?"CP]X1TK5])\+?%7XD^%H;VSMK?PIJGCN)]%\-:9>'5=6\7/X9\?\
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M4M;T_P ':+:^&O 'ARSCU&QT^Z^,7Q@^$>G:_>6OAK4-<N[3S&;XX_&[0_\
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M/_%6F?LX_M.:KJOA]?V>/VK?^"COQ&_8B\%_#:W\+ZG;ZYX0^'7A;Q-^T?\
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M+IOC/K#3:/XV\0>/-:UCQYJNK>(-0\>ZMXJO[W1#HGBD _7?Q[^V1\$/A?\
M$_PO\*?&FMSZ'?\ BOXE>'?@EIGBF:&V;P+IOQK\:>%8_&?P]^$7B768;I[[
MPWXS^(7AZYTI_!(U#1U\-Z]K_BCP)X!L_$)^(OQ#\"^$?$/A?PM_X*I?LG_%
M_P 0?!S0_#&H?%+1[/X^7G[0.C_"[QC\1/@?\7OAAX%UKQ7^S#JWQ%T[XQ>
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MHWQ'X9TWXO>!?$'P.\$^(_$]EH6@VWA#Q$\GB?3/">G?#V;4/#^M^&^(TO\
MX)(_'S1-0^-&NZ?\;?V>+>[^./Q6_P"";'QV\3>'/#/P#^*7@WPYH'Q(_P""
M?OCGP-\0[^V\/WVK_M!?$OQ%K'A_XQ:W\-=&M=6UKQ==ZOX_AO?&?BSQKK_B
M3Q+JFC6&DZ\ ?JU+^US\+K#]G!?VH?&6E_$[X7_#=]/@DGT#XM_"3XD?#;XQ
M6NNZAXP3X>:)X";X*>*O#%A\2K_XA^-/'=UI?@[X8^#M'\.ZGJ_Q7\1>(O"=
MK\.;?Q)9^+O#5_JOY\_L]?M]>+E_:+_X*3Z/\?M4\6V?@+X&?M-_L@_ ']GS
MX57OPST7P[X\T3Q;^T?\*OAR^B?# 2:%<ZA'XNUGQS\9/'VFZ+8?$S7O'=_\
M)H_#MQI_C\>,O"GPJAUKQ!9?>G[;7[-6L?M6_ J?X8^%OB%+\(_'NA_$?X*_
M&GX5_%%/"=AX]M_ ?Q<_9^^,7@3XU_#77-8\":GJ^A6/C/PV/%7@6PL/$_AN
M;6=+.JZ!>:A;VNIZ=>M;7]M^?UG_ ,$W_P!K^3QI^U)\5-0_;#^%VE>/_P!J
M[XY_L5_&3XD>'/ O[-7C#1/A)K^D_LP_"CP=\*_B9\&/&.EZ[^TAK?CGQ'\(
M?CE8>$M/O+[PYHGC/PC?O;:5)X.\?^)?B-\+_''C+X?7H!]C^$_^"B7P'\=:
MM^S3I/A72_BAJ!_:L\8_'#X9?#/5KWX?ZKH/A[2?BS^S9?>-M,^-_P */B+K
M>N26%KX+^('@F]^&?Q*^Q:#.+Y_B-IWP]\9ZY\))_'^C>']1OK?8TO\ ;W^"
M^K^,KOP):Z)\5/\ A(=*U[PEHFNVP^'NJ7XT"S^)?[2/C?\ 9/\ A)XSU2'1
M9M6U*3X=?%3XS_#'XE6/A?QWHVG:QX<TOP1X*OOBEXYOO"'PWUSP;XH\2_FY
MXY_8MO/AK^R=8_L)7_Q+EO?C_P"-OVI/C7^U9^P?\4_@K^RKXWT70/V>?C.?
MVFM1_:M\,>*_'>LZC?\ Q@^$'A#0OA3XK^+=UHGB73?$7B7P3<_$K]G2S\<?
M#WX>>%/''B0^([/5?I_XW?\ !. ?%#XL?!+XB^#_ !M9?#BX^ &A?LY^'?@U
M\1?"OAJZ\,_M&_"S3OA%\1/%?BGXPZ3:_&#PQKF@W'Q8^&_[47@'5O#OPG^(
MWP1^+MAKOPD\/Q:5K?Q-MO#7CCQ-XDN?#, !^@WQ7^,G@_X/6'A&;Q/)?WFM
M_$3QA9_#KX:^#/#]A/J_B[XC_$/4="U_Q/9^#/".EQB**2_3PSX4\4^+-<UK
M7+O0_!O@CP/X5\6?$+XA^)_"'@#PGXG\4:/^7GQY_P""D=MXS\*?L>:E^R?;
M>-_$EM^TA^VY+^Q[\4KO2-%^'FB_&+X#>,/ 7PT^.GQ$^*'PCUKX>?'+4M.L
M? OQ]TG7_@ROA#Q!H7Q*\+7OA?2_!U]KOB2UOQJ&H?#?6-3^U?VK?V8M4^.V
MO?LW_$_P)XQB^'_QG_93^,5Q\8/A9K^JZ(_BGP9K,'B7X=^-O@U\5/AMX[\-
M0ZKHE^^@?$3X2_$GQAH6F^*_#VIV7BKX=>,5\+>.M)C\16.@ZUX$\8?'4W_!
M-CQW9Z[\'O&WA_QUX$@\>:#_ ,%'O%G_  4M^.&HZCHWC Z%\0OB?XG^"7Q%
M_9QB^'?@K2?^$BU2;P3X5\._";QCX5TW3/$$U[JMSJ^J_#6WUO4O"=G>^/-9
MCT( ]>^(?[1GQ>_9"TO]B#X+?$W1_%_[6OQ"_:(^/[?L]ZC\=?#?ASX7_!NV
M2:+P1\7?B]HNJ^./AX/B)I=C/\1]6^&/PMO['Q#<>!=+\/?"77?%FD^+_&UI
MH_PKTN_\&_!>[\1_8<_X*#_VI=VWP4_:8\<>+?&7QJ\:?MR?\%!_V:/AW\1-
M*^!'B'PS\(M9U+]G#X^_'RT\$_"R]\:>#/"US\.?"OQ%N?@7\'M7\7:!X5\2
M^);KQ3X@\/>%M2OM5\0:YXBO=,;7?K_]KS]FOXB_M!ZG^RIXJ^''C_P=\._&
M'[,/[5>A?M'V4OCGX?:[\1_#'BO3K3X+?''X%Z[X2FTC0/B+\+]5L-2ET#XX
M7WB30M9/B(6<6M^'+*QU+2[C3=0NI;3Y;\%_\$]OC)X8?]G^2]^)GPVO8_@S
M_P %-_VJ?^"B6KQ6OA;Q8C:_9_M-1?M.+<?"/2GFUO-C>^#O^&MO'GV;QK<6
M]Q;:ZW@/PC)-X5TMO$NMPZ( ?97@G]L[X)_$;XQV/P'T'5=6B\8>+?A]J_Q2
M^&.KWFF/'X(^,OPY\.ZWIGAOQAXL^$?C.SEO=&\61>#-2\1^$;G7-)EFTK7Y
M_"GCCP)\2] TO6OA;XT\,^-M3_/C]J_]KSQ!\ /^"@6O_"[XH_M8W_P&_90T
MO_@G)\5/VR]>N=+\(_!*;QGHOC'X-_%?P5X*US2?#&M>._AIX[N_%.@Z[X$U
MO6O$3>!QX=UCQO>>+]/=O#?B%]%N4\*Z;[9^P1^PK\;/V+]+\._"KQ)\<_AI
M\7_@5\&/",WP]^ 4FC_L[VGPJ_: F\#6%_':_#_P[^T)\6-,^(VN>'/BH?A-
MX MM(^'GA2^\(_#7X:-XMM-)7Q=\07O_ !($MYNJ^(?[)7QD\2_M\+^V/HWB
M'X.ZIX.M/V-_%'[(,'P>\:^&O%TESJUEXZ^+?@GXJ^*_&GB3Q5:7^HZ-?:?)
M_P (=;>#[#P%%X):V>QO=1UW5O&&HQ3IX:M #Q7XR_%3]L+3?C7^S-^P_8>-
M?&^A_$?XH?LB_M/?$CQM^U-\%_AG^SS>75[\5/@WKW[,OP[\)>*_#WP\^.GB
M#7/!^E_#S1KSXY:YXV^)?@6^\.#Q!?\ B2'X>Z%X!\4W7AU/&7]H<A^Q=^U!
M^TC\7O ?A?\ :K^.?Q0U;PUX?N/B=^U_^S[J_P"S+8?!GX,Z;X.^,GC7X9_M
M*?%+X/?">^_9[US3OBCK?Q:^&_CWP3X9_9_\0ZO\9=.^,GQ1^)WPK:P\5_$?
MQI+JW@OX8>!++XF^"_ICPO\ LM?M-Q?M'? ']I#X@_%_X6_$+Q7\(O@K^UA\
M+/$*IX!\1^"X/$K?M5?&'X/_ !>M8_#EI:Z_K/\ PC'A;X)6'P1\'_"KPAIF
MLS^*_$GBSPS/>^*O%GB=?%$<L6I?/S?\$Q_C"?V4_AK\%]-^.?@'PK\:/@!^
MVG\7_P!M?X*_%(_"B]^('PQOO$_QP^+G[1GCOQ]\*OB[\'M?\7:'?>*_AOX@
M^&W[5'Q7^!NJS:#X^\/>(1I=U8?$72M2T/Q#8VNA( ?6&F_\%'_V<O$7PQN/
MBAX,F\;^.H-"T#XR^*/B!\.O"WA&[F^-7PLT3]G'Q)_PA/[03?$#X1ZQ/HWC
M*RU[X2>.'@\(:UX%\/V'B3X@>*]:N;<?#'PIX[TZ4:BOR5\1/^"I/@_Q)I'_
M  4>MK7_ (6]\!?A;^Q[^SK\&_B);_M<^"/A_P"#/C[JMM%\?_!GB+QMX0^+
M7@+X0^'9?BGJ'B'PG9^#[KP=XYT2?Q]\.(-$TC1=+\>:W\:X?AQX6T2*[N^P
MF_87_;#\-_%'X9?M'_"?]JKX(_#_ ./?_"G=<^ ?[0FD7/[*GB?6OV:?'/P]
M/Q&OOB3\.KOX3?!'0?VDO"'B'X:>*_@SK.O^-++P7J?B3XK_ ! B\4V?CWQ/
MJ7C*-+F[ETT\=\;?^"7?Q<^(MU_P4RL/"O[0'A6V\(?\%'?V9/A1\ M<_P"%
M@_##6O$7Q"^'_B/X;?"G6?@K/\0[GQ?X?^)/A_0_%]OJ7A/7]7\47'AY? FB
MW>J>-'L[$:YHWA^*:YN #[?US]MSX:>%O%G[3OP]NO WQ@O/%?[(?PT^'WQ7
M^)FB:9X0T_4=0U_P#\4)/',/P^U?X61)XD\WXF7_ (K_ .%8_$"/3/#?AU9_
M%4VK^%[KPE)HJ>.-3T#PSK&KXH_;;^!G@;XI> /A/XWUJ[\*:M\3?B-;?!+P
MGXGU==._X0*7X^WWA.Z\<:7\"-5\4V&I7T.C_$C7/#MA?#PVUY;#P/XJ\6VS
M?"_PQXUUCXK/'X(;S;XK_L6S?%O]IS]E_P#:KU/Q99^$_%OPE\!>+OAO\=/
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M.([FW?YX9E>-LE2:_ ?]GS]CG]J/1;W]@'P7XW\-:[X8^-_[(/[6O[4GQ/\
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MJOAO7EM'T/Q!INMZ9?:)K*7[F*P;2M5M;J6PU%;V16CM&L[B87+J4A+L"*_
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M\.?@#^SB+(^ K*/]FSXU?#WQ1\8-4O\ 1M<'B+Q3H7B+PMIWQ!\??$?X3?M
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MX**_L]_!"X_9:\ _&O4_C#K7P-_9W^'/A[XH>.M ^-&N^%_A;^TPECHGPO\
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M@'](=%0P&5HP9E"OEN!_=S\N0"0&"X#8)4L"RX4A1-0 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5')(L04L&)=@
MBJBEF+$$@ #G& 23]U0"S%4#,)*^'O\ @IEI?C#6_P#@GA^V]HWPZL/B9JGQ
M(U3]E;X[V/PTTSX-Q?$&X^*&I?$NX^&GB1/AUI_@NU^%F?'E[K%[XU.A6R6.
MA1S+>P2SVNKP3:%-J:$ ^UQ= R>5Y%QOQ&V"B@!)"X+Y+XQ&4Q* 2ZED(5@P
M-(+Q6QMAG;/]U%." I8, ^4*;UW*X5LG"AB#C^7GXG?!.R^%/PH_98\"^*O@
M3^W=JW[(7[2'[+WBF;]H6^_9S^$/Q,_:+_:-^''[;VI_"CX!>&-.^*GQ9^%G
MQ.^&7QB^./PO\2Z[\./ GBK3/!_QE^&_A?PSXT^'?QTA\5^*/&2:;XI^+MUX
MYF\:_:]^ 'QKU+PW_P %6;N+X=?M\^/OC3X4_P""?'_!,G4/V7O&FH:;^TY\
M1/'DG[9/P7T[X^6^N>)O@YX]^"WA_3/A/K?QT\$^(?%?PQUSQMXB_9LTS0O
MMKXJ\5_$#Q;#HVD:;XB^+LDP!_72;U%S^YN"0I=55$9Y$"LX9$$A?#A2(PP5
MG?\ =@;\J.#\3^*_$6B^)_ VBZ;X&\5>)=+\7:UKNF:_XIT>Z\)6VA?"_3],
M\&>(?$=EXD\;6VM>)=)\0WVAZ[K6BV7@C2QX)T?Q;K,7BGQ)I%SJ>E:=X3BU
M/Q%I?\[7Q%\,^+OA9\;?^"IVE?#7X'?ML7WP!^+(_P""4OQ"T2T\ >"/VR;7
M0=0\:^(/BYXGL/VQOB[I>GZ3I1^('Q=N[+X;#X/ZQ^V/\(/@#*?C)^T7\/\
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M)I]U\0)(O'<6KIXNTCXDZS;?=?\ P4)T;Q_=?M\?L6:IX?\ #G[4.K?#2/\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MCO=^'H0#^@>BOYFO^"O?QZ_X*+?L2?!?P%XU\/\ [8^L>#5^(O\ P5!_9\^
M'@#Q1X4^%O[-FHZI??LF_%GX$^ =.\3P_$/3OB)\"?'^AVWQ8\/?&?P'\8O$
MFG>*_"^F:+HE[%XK-Y/X3A\+MX7^'W@G]&/V3/VA-,_X*(2>&_VF_P!E_P#;
M0\;WO[,/@O\ X3KX07'@;PEH'P0?6/B?\1_"6HR:%JOC7X_Z!\0_V<)OBG\"
M/%UE!/:^,?!_PTT3Q#X+D\7^$==^'WCW7_"?A#2-6N_!.L 'ZFT5_)I9?\%"
M?VW/V3_%?Q;_ &7?VXOVGM?U'1OVNO@U\2_C?_P2O_;SM/A[^SAX.\90>-_A
MWX(TW7/$G[(?Q)\):1\&;CX%3_$+0]66TM?#WC3Q/\+XM.^)8U>9=&@TKQ'\
M0/ _@+X=?:/A[]L_]HC]H;_@L+\8?^"9'@'XN^*O@_\ "C]@S]FOX<_$GXT_
M%K3/"WP9U[XV_M,?%7XBZ%\)M?\ #NG3R^+OA5XL^%O@;X=VOA+XD1ZAXP;P
M7\-_"GB;4?'=E>6_AF7P[X2O+.TTH _?JBOY._B5^W#_ ,%(?$6L_P#!8G_@
MG9\'OCQXFC_;2_X)M>"? 7[3O[-/[1WAGX5? CQ)XF_:/^#?B3X5^'?B;=_
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M2UDP:=.FHM;W<-I)X?U?PYJNM 'TE1110 4444 %%%% !1110 4444 %%%%
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M5Q>9'[0G[3G[7_P?^%G[.GB?0/BI\)=0\1?&3_@JKIW[%NNW6J_ :\;3M/\
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M[_%OPEHW[1OP@\+?##X9Q_!"#P#I6G_"KX@:S^TEXY^+EM\([?X0?%37-?\
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M$'P;X;^(GB74=0;XI?"WX>?#;X?VEO=_##QM\'M3U_XI:CXW\-W_ (AL/A<
M?N?15:TV"!1&<QJTBIPPPBR.JC#X8;0 .@7CY $VU9H **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBN=\6S>*+;PSKMQX*TS1-
M:\70Z7>2>&]'\2>(;[PCH&J:VL#G3-/UGQ3IOA3QUJ'AW3+N\\F"^UFR\%^*
M;K3[9Y;F#0M2E1+9P#X&_9Z_9H^//PD_;2_X*!_M'>)9?A+J7@3]KC5/@IK/
M@'P]X?\ $_C$^+O"5S\!/A=:?"/1K/QG<ZGX$M]$O;7XB:5:KXNU2[T B?X<
M7ZGPE:6?Q,@G'BZU^3O&/_!/C]K+QO\ \$V?VR?V']1\0_L_Z5XV_:I^*O[6
M7B[3/'6G^)OB7>>#_!7A;]KWX[^/_CUXLMM0TJ;X>VFNZUX@^'NK?$+5?!WA
MN&VN-*T?Q?I<=OXEUB?P]<P3^'-1Z']F/_@JG\2_C1I?_!.'QC\4/V:/"7PM
M^'__  4PT#QI+\)]:\ ?M)#XR>*/A_X[\._#/Q?\9= \)_$?X=^)/@1\#]=F
M\,>)/AIX(\0SZC\1? %UXTT3P5X[M]+\)^++?3- \2:!X]O_ &7PA^V?^U#X
MXU']K;1?#7[,_P #-0UK]EG]I.^_9SM-&N?VQ?$6CZQ\8=87X*_!CX]Z--X+
M&L_LA:7HUAXLUOP+\:-+T^U\':OJ\6FQ>.M!U;1F\8R^%/)\94 9GC']EK]I
M?Q9^W+IW[76K^"_V:?%'@Y_V&/$G[('B/X'^(_BA\0OL.NW7Q(^*/@CXJ^._
M$&J>)KC]G[7](UKPC;R>$IO .G^#[_P%%/XCT2]N?$FNZGIG]HMX+L/NWX1^
M%?BOIGPPL]-^.OBOP_XX^)^MWOC34O&&I^#-)70O"ND67BWQ/XAUK0_!/A..
M>TMM3U'1/AKX7U71_A[HOB?6[:W\1^,[;PW#XK\3VMGK.M7\%I\ _%'_ (*3
M>*=)^-7[<GP*^!?P3T#XQ?$']@KX)>%_B]\0/ _BCXY0?"GXE_%F7Q9\-A\5
MM)TOX"^ M.^$7Q1E\:>%O^$=N=&\,:C\0_$NN^"M)M?BMK4?@"+3;F*VD\1O
MZ?K?[7WQRL?VM_CG^S#I7P7^"!T/X-?LY?"3]I6/XO\ CC]J#Q=X&TS6? WQ
M1\8_&KP#Y?BCP]:_LK>+;'P%J/AKQ!\!O&M[K4Z>,?%.B+X6O-#UM-62ZDU7
M2]$ (/@7^RE\9?A/^SI\,?V)=6U[X=Z_^S]\'?!'@WX/Z!\4K67Q'9?%SQY\
M"?AW;Z3HOA3X=^+_ (:'2(_"'A?QO?\ @73K7P-X\^,OAKXIZM:^(KW3=3\?
M>$/A)\,KOQKI_A[X6][XU_9GNOC_ *_^U/\ #_\ :<^&?PB^(7[+W[0G@#P1
M\.7\&)XB\6ZEXJUW1?#$'B9-1;QC87/A3PU8>&]1N+WQ*NN^%O$7@3QC'XB\
M"Z]X=T;4]$U:36A:Z[HWJGBCXS^-? W[,]C\9?&WPN?1/BLWPP\.:Y>_ 6P\
M:Z7K5Z_QL\5:3H]CH'P$T;XA+I%EI>M:MKOQ5US2OA1H/BZ'P[;:?JVL:IIV
MK_V1:V5PUHGRAXN_X*&W$_\ P2RNO^"GGP8^'.B?$7P]:_LKC]JZ7X3^+_BI
M)\/+F#PSH_@%O'WQ"\ W/C[PW\+?BS;Q_$;P:NG>(/",&FKX071M0\9:2^E:
MOKOAFQ>;6+4 ^?/&/_!./]I^U_9;_8B_9X\._&SPM\<O$W[)W[<'A7]K/Q7\
M9OVA-8\5Z#XY^+_AWX6_M#>/?C%X#\'^(=0\(^$/&;ZA\4/%_AWQ9I?AWXH_
M&C64N1/XJT+5/&X\$>+;SQG<6VA?9W[8_P"Q+I7[5GB+]F3QY;^*#X)\:_L\
M_%C5-?N-2;15UN#QW\"/BIX*UKX8?M+?L_:S8/?:>(M ^-/P[UB& ZMYS7GA
MKQGX6\%>*;6&0:)/IE]QW@W]N?Q7I7[4WBS]E/\ :3^&O@#X0^)]&_9"7]M'
M0?'?PV^.<GQJ\ 7OPI\->,=+^'OQ9M_&T?B7X0? ?Q[\.M:\$>+M6TZ;PU<W
MG@;6O#7Q*\%W&I:WHGB32O%7A3QGX%\.<OX+_;R^.7Q'_9OTO]LKP/\ LIV^
MJ_LW>++GPKXX^'T=Y\9?$%E^T3XH_9?UKQ?HFGZC^T-=_ RT_9YU32+(K\,K
MC7/C[X2^%.A_%?Q5XZ\9_"JU\/V,8T/XJ^)Y/AOH(!Z]^UA\#_CK\7_BI^QE
MXZ^&EM\+#H_[+7Q]UWX_:WI_CGQGXN\*:OXUU74/V>/CQ^SY8^$=*NO#_P -
M_'UEH.E1VGQTU+Q;?Z_>0ZM=7$GAVS\/0Z):IJDNO6?@/[0_[*G[7_QM\$:!
MH6G3_LW>$4\+_ME_LL_M*>#_ (;V6O>,+?P%X&\"?LM?%'X<_'9O"$7BS2O@
MQ8^)?&WQ&^.7Q=\,^-;[QKXZU'P[X9\/^!_"?B#PII>@^!?%?B+P_P")?%/C
MKUGX0?M=?'/XM_M)?M]?LYZ?\"?AAI5]^QM??#71/!?BO4/VB?%<UO\ &+7/
MB]\-++XJ^!4\3:3:_LPQO\(]&'AK4].MO%FJZ5??&*YT3Q%_:.FZ/HOB;3K2
M#6+STC]A#]I?QS^V/^QI\$_VJ=?^&GA?X6:Q\>OAUI?Q1\+?#O1OBCJOQ,T[
M1O#OBRP36/"%CKWCJ^^$?PNNH]:DT^XM8_$MKI_@74K'0KW[3;Z3K/BRW@AU
M*\ /F7P+^Q)^T)\#? ?[7O[//[.OQ'^'/PF_9Z^/'AGXQ^*_V8+K0;/Q/IGQ
M)_8(^.'QV\,^+KGQ]IOPVTC3M.7P9\1_@C8_'/5[3XZ?"_0;>[^"^M_#'4O$
MGC;PA9PZ]X4L_ UAX9Z;X?\ [%GC?PK^VAX\_;SE\*_ ;P?\8/$/[-6J? CQ
M1X6^#M_\0O"'A_\ :D\:Q>*_"WB7PG\:_P!HC7[[2[[3]#U'PGI_@Y/ OP^T
M:S^&GQ<\>_#;PCXU\:6FL_&KXPZ78_#SPUX1R_@?^W/^T/\ %;X6>&/C'XB^
M /[//@3P@G[0'QP^#GQ/BE_;.UNYU?P=X/\ V;OVA/B?^SU\9OC%X6B\7_LC
M_#70O'7AWP???#'4OB??:/JWB/X=W,?PP-_J=YJ.F^(M.A\*ZM4M?^"C'Q!\
M4_LEZE^WQ\.?V9[_ ,5_LH66B>)_BS8S7?Q0O/"O[1_B[]F?P==:O-J7QS\"
M_ ?7?A OAW4W\2>"-"N_BS\-OAGXD^,_A#Q;XV^'-WI;2-H7C_5;;P%0!Y!\
M.?\ @GA^TIX(_P"",/BG_@F-=^)?@?J7Q.UWX#?&G]FNU^*=KJOQ L_AZ/!_
MQEC\76EUX_GT"7P9=>)[3Q1X;L/&U_;6W@I+J]T75[O1;/5I/&NG6^L3:'H_
MZ^>$Q\0K+X:Z2GB'1?!X^)6G^&+>"[T/1?$VN2>!KCQ-8Z<D,-K:>+=0\(VW
MB&#P_?7L,9FU2;P3<ZCIEK/-LT?69;-%O_BKX%_ML^*_C]^U)XJ^#_@?P1\+
MM6^ $7[*W[.G[7GPW_:,T'XT^+M:\0?$?X:?M2:W\5-%^%0M/@SJ?[//A/3-
M#\]_@KXSU'7)YOC1J;Z9H6K^";JQ36M7U;Q'I'@WS[]HK]N3]I_]G?X9?&_X
MOW/[(WA+XL^%_@'^T'X0^&GB[P;\&/VBO&7BWXR^(_A!XKL?A5J#_$GX9?#[
M5OV1_#^G>,OBUH6C_%6UUV^^ \_C71]*U%/#>KV/A_XQZUJ$^EZ5?@'J_P#P
M36_9F^+'[(?[,6A_ CXOZGX!\1>(M ^)?[0?CN+Q1\.=3\27>AZU;?'CX]_$
M;]H":&?2O%'AK0=1T"[\-ZK\4-4\'QVHO?$46K:?X>L/$CZEIUUK5SX<T=OQ
M$_9'\5:;^V9IW[=WP*U3P_#\4]4^!LW[-?QG^%WQ!U7Q)H_P\^,GPMTWQ=<>
M.OAOKNG>*O#-GXDN?A?\6/A1XMO=9O=&\83_  Y^*&D^*O GB+Q3\.-4\-:#
MJ^L^'?B1X$[/3?VF/%/Q'\9?L\/\ /#OPM^*OP1_:&^ 7CG]H/PW\7]5^+WB
M[P)?7'AO1(?A=+X&C\.^ K;X#>.TUW1_'$OQ?\%/>ZQK/C?P3K'A;2)/$%X?
M"_B#4M)LM+U?X1\!?\%5?CIKW[$&E_\ !07Q=^Q[X4L_V?\ PUK?QQ'Q\TWX
M9_M/:S\1_B]\+?A_\ OC3X^^#?Q(^*GA;P3XB_9@^%6@_%+PQX4M_AUXF^)F
MO:4GCGP5XKM? ]B7T70O$FO*VA$ K?M._P#!+WXL_'SX1_\ !1*]_P"$Y^%M
M[^T]_P %$/AQX*^ MYXIUC0M;\,_"_\ 9M_9V\ 6&LP>$/AIX%.CZ9XE\?\
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M7_AUIGC/Q5\-?!OQQ^&_QMD^ &@:SK/P=U[XJ>!_'7PP\9:Q8?!75O%7PO\
M&7A*ZTOQ'X-NVU3PJWB8 ]9_8H_9(U/]B']F^_\ @MX7\57'Q5O/#&M>+4^%
MC>,KR7PM;6/PT\,6]MX)_9H^$VNZ_I6D^*-1CM/AC\$?!WPN^%_B3QU%X=UK
M5/$.H^'M<\=/X=U*\U8:;+^<?PU_X)D?M:> OV5O^"<W[/\ ?:_^SMK_ (B_
M83_;0U7]J[5_$=GXQ^)OA_0_B?IUM<?'+4O#O@O3+"?X4^(M0\&7^HW_ .T-
MKNGZ[K5Y<>*;?1[/X;:1JFGZ;K4WQ*O=*^%_UYX:_P""@/C_ .(/CS]G_P"
M/PY^"/AGQ)^TO\3?V9?!W[7_ ,9/"MW\6_&>A? K]GKX&>.-9L_#'A:?5OC^
MW[.6K:GXZ^)?CWQ,^N:?\,OAKIGP=\,ZEK-CX!^(?B'QE?\ P^\/:7X9U3Q=
M]:?L\?&'XC?%.Y^,.B_$_P"%$_PC\5?"'XQ7_P +);"#Q1>^./#'CK28_AI\
M,_B9HGQ&\#^+[OP!\/4UGPQKNE_$ZQT[;!HHET?7]"U[P[J\UMXDTC7=!T4
M^+_VNOV9/VU?VL_AOXR\ :GJ_P"S[X'\/ZQ\1/V0O%GA/P'9^,?''B+3?#<G
M[-_[2_AW]IGQYXMUCXCO\$= \0>*=?\ BU<_#_X??"[0O"$/A30/#GPRT?3=
M=\<RZWX[UC68O"UIZ1^TG\'_ -M?]H[X7_M!_#;[;^S]\-?#/Q,_94^,_P !
MO#7@>U\9^-O'FG:O\2_C=:Z7X5C^+WCGQ_<?!?P1XFT/1/@YX*3Q&_AOX:^#
M=!NH_B9K/B[4[?Q5XS\)+H_AO6-(_1^B@#\^/V<_@A^TU\-(/V8_!7B%_@AX
M(\"_ WX0>%/AI\3O$_@#5]:^(?Q(_:,MOAA\-;WX??"[PIK=QXQ^#O@1/AC\
M.]"UWQ1XJ^,%S!H?B/Q1XGA\:VFB>&=)U>T\+:_\1_\ A+OT'HHH **** "B
MBB@ HHHH _&G_@JIX2^'M]XQ_9;^,^A^,/B7\+?VR?V7?%'Q ^(_[+/Q-\,_
ML:?M0?MC?"Q],\<>%K/X>?''X-_'SP=^SQX \1_9_AG\:_ ][:^']19/&7@#
MXGZ+JNFZ#XX^'FLW</A77/#OB3YD^-GQA^%'[<G[-/Q8^ '[:6M_M&^%M,^)
M.FZ5:Z'IG[+O_!.+_@I]I4GPZ\7>$O&OASXA^ OB]:?$OQ_^RM/XG\2_$#P9
MXU\&^'?$'AJSL?#O@;PK;6D_B/PSXPT[XAVFHZ?JFD?IE^WA^UG\2OV2+#]G
MS4_A_P#"+P5\77^/O[4?P7_9:>V\7?&;7O@W_P (=KOQQUU?#'A3Q5#=:/\
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M*%G^TC^RX_P4^-_C?XE?\%&-+O/&CZO\%;_XC:]\"OVX_P!HWXC_ !=;3/\
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M'\(6^(>M>%=#^'OB_2O%6L^"_'/PRT[6_B/JFO\ PT\6Z);:9=ZAX,\?Z?\
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MX@\,6OA3PG^S;\;/BKXP_:B\/^*_A?I<QA\467Q<^"_C'4?@IHNGKIFMVGQ
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M\0:AJNLZ==Z[^TSH'[0?C;5[/5-0NM0U;7/%>I^,KR66?Q4T\OUK10 4444
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M:7G_  K'2=?^)FK:^ ?T)45\/_L7_';]IOX^>&#XW^/O[.'P]^ /AKQ-X/\
MAYX]^$FI_#7]J[PG^U;HGQ \.>.]'U/5;N"]\2>$/AG\/M T?4_"]G!X;OY+
M_P *ZI\2? OBZW\7P7O@CX@Z]I>F7DJ?<% !1110 444UFVXX)R<$C''&<G.
M/3ZD]J-P_K5I?FU_7W%>\NH+2WFN+AQ'%;PR3R2$<)'$A=V/;A5Z'[W0<XKR
M/3-"F\6:+X@UBY>XLKKQ#>I<Z1,I,=S8QZ7,[Z7+'+O62(B[7:XB*)-'$L\;
ML)EE.K\0-8AE.G^&(YS;RZM.O]I3;2YM]*BW22HJ1"226ZNF14MK>)'ED*L0
MNU21L)JMY';Q6FA^&]1FBMXX88)+]X]&LA!'&L<;JUP[W14*@.QK.-N^ PP>
M62A5K23D^6E%::.U63WC[K2Y(V=W]J6C>R]S#QKX+ TJ]!<F*Q]6G6A4FX4U
M2P6!KQG%U'5<+0Q6+A"33C453"8>I"=&=.K)5/AVT^(G[ ^I>*O''P8^(7A/
MX-Z7XXE\;>,_V9/BII?C7X+_ -E>#/%_Q(_:E\-_##XH?$+X)WGQ!\2> K+X
M<?$#Q)^TOH.L?"3Q?X[^&UMXJ\0:A\6[B^\&IXLTC7]=MK"TM?I7QO\ #']E
MU]9UVY^(WPX^"S^(_P!H>PO/@IXIN?&7@CP;)KWQTT?Q-X6N/[4^$OB2;6=)
M;4/B?HNM^"/"%Z=8\!:LVN:;=^$?"MZ=1TEM$\.SFQ^$M?\ V(/CS\0?B)^T
M1IOB74OA#X;^#7QV_;K_ &=?VNI_%GA[QEXZU_XIVOA3]GSX?_L1QQ?"]?!E
MS\/O#'AO2=6\8?$W]CZ*"[\9VWQ,UB+0/!7B8ZC8:#>Z^ATVW^6_#W_!-K]J
M#3O&_A'Q[\8XOV<_BN_@3]HO]G/XX1^%=.,UE\//%OB/X>_##X^_"/X]?%'2
MO %A^SSIOA;X%>,_BW!\4O /Q-T[P7X=\-_%2Y&M?##2? ?B_P".6M/I_ASX
MIZ/ISNFDG>4;**D_B=OM/O=6;:BM6]$KG*\+3Q59^PJX>G4J<U2>'A-.C3JR
MJ5FZ6&K3E3C5I./+*FY.+@I*FW)J+/V[U'X._!74=4NM;U;X5_#S4=:U/QN_
MQ.O]8U'P#X;OM5U+XD?\*R3X(GXA7FHW>C37M_XX_P"%,(GP@7Q9/--KW_"K
M-GP_%^?"#II+>0^'_CG^QY\"++4/A3X9UGX>_!O2_">I:])I?P_T;P1-\.-)
M\0ZWK'Q;T#P'XI'PC\,V'AG0].^+&N:K^T%\5_"7P^\0P?"*R\7ZE>?'3XI^
M%? NHQ/\1?'NB:/JWPY^QK^QG\5/V=[[X7?\)CXUB^,_C:UG^%GA_P"*OCCQ
M7\6?&?A2[\62?"_X3_M >$=:_:6C^'?A']GWP-9^,OVA/C)XH^.+)\:-*^/G
MQ!^+NJ^,-";0/%^M_'7Q-X]^#/@*36_0/BE^R#^TA\<_C#X@^,OQ!;X+Z5X@
M^&/Q'^#VM?LHV.F?$'Q;XGT3P]\,?@O\>O"'Q8\3^#_&MK?_  /\-:[X9\;_
M +6T'A6PO_C#XZ\)>*?$7A+X9W_@3]F_PQH/PG^*L?P)\5^.?CW<)J=VE9)V
MW3_%:>NO7H<E?#U,/*,:B:<H*2O&4;])6YDE)*5U>+E'323/M>W_ &K_ -GJ
M[M_!E_:?$W2+K1O'U_X<T?P_XFMK#7KCPA#X@\8^/)OA3X1\+>*?&$.DOX7\
M!^+_ !7\6;:Z^$WAKPAXZU?PYXFU[XJVMU\-=*TF[\;V\VA)J>"/VE?@9\0_
M OC;XF^&/B+HK_#WX;ZMXLT?QYXQU^'4_!OA_P *3^!M/M]9\5W^M:CXRL-
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M9>&+:VODG@CL]->P^ O[,W[1UW?SS(US>#R;JQTXVT*17.I">?[/!B:1H_\
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MHT^Z@O3&4>VUZU_9WC\-RO#%*D]U;C61=6\1R\&\B,T;C_@HIJ=[=2P^!_\
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MS@;B""%Z99B%Z\X'/)QP*\"75OVITZ?#SX =,<_&/XC$\%CU'P&4_P 6.<\
M=\DN_MG]JC_HGG[/_P#X>/XC_P#SB*J$8TU:&BW;=VVWJW=MO5Z[]NQS8O$3
MQE>=>JDG+EA&G&_LJ5*FE"C2IQ;;5.E34804G*;2DYRG*3;^4?VL/CSXN\-_
M$[X!^!9/'7BG]EKX6^,?''QNTWXD?'?Q#IW@*WLF7X9_LV_$WXH^#M(\,:GX
MVMO%7@_3-*>_\-ZY\7=4UOQ)ID7V[1_@CJOA+4]*OO"?BCQ#%7P1\"_VL?VU
M?VLOB7^RM\.?%VL?$W]B_P 9_M"?\$Y/CSXVUG1-0_9Z\5O;^'?V@/ .H?\
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MXAL/#<?B7Q9XIUG6@#]&RJGDJ"<YR0.O S]< #\!Z4  9( !)R2!U/ R?4X
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M2YT[X;^"X98K@A7=H;E?#]O,VR;YXY'CC9BJN\:ME1Z!X>\(>&/"-B^F>$M
MT3PKISS2W#V'AO1M)T2R:YN)3-<7+6NFV5M;FXGD9VFE,9>1I'D8F0AP ?G3
M9?\ !8/]A#6_L\G@WQY\8?B?9W88V.H?!O\ 8\_;3^,VGZO$I4->>']3^%W[
M.WBS2O$.F1_O&DU/1K^\LE2&0K*[)(B27W_!5?X)6]W):Z=^S?\ \%,=>3*B
MUO--_P""6?[?UI9WP<*5DMY?$/[/FAO!%ET5IM1BL8DW!W=8LR5^F0C .=TA
M/O(Q&.W&<<#OC)ZDDDDO"A<X&,G)]SW/U/?UH _+>3_@J(+W3="U3PA_P3O_
M ."I/C2'7/$%CX9-O%^R+)\.=2T;4]3M%O+&XUW2OCCX^^%6H6'AYT\V*^\7
M+;W'A/0KJ%K3Q%K>D7,UI'<^F6/[:/QKU*RM;RU_X)B?M[1/>6R7$-EJ>K_L
M%:3>*\C(8[6ZCU#]N6!;&X\DRR3?;7@@MWA^SRS">:W27[]HH ^$M"_:P_:,
MUS4-/MIO^"9_[6_A?3KZZMX)=;\6?%']@:VM--@GF2+[9J&G^'?VR_$^O*D:
MN97MK72+J^90(XK:29Q'7W'8SS75E:7-Q9S:=<7%K;SSZ?<R6LUQ8S31))+9
MSS6,]U92S6SLT$LEG=7-J[HS6\\T121K5% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M A (P?YX_P _RH"@<BEHH#_A_F%%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M7G'Q>\":Q\3OAGXT^'V@?$/Q=\)M6\7Z%=Z#:?$KX?R:;!XZ\%C4-L%SKW@V
M[UBRU/2]/\3VEFUQ_8>IZAIFJ6FF:B]O?SZ9J,=NUE/Z/10!^'?P"\%^.OBC
M^W7_ ,%)?@M'^T1^TEX6\)?LL_%G]@36_@E!!\<?B9XKA\.:)X@^%'@?XT_%
M?P3KEAXZ\4>([+Q_X7^,.HZ5JWA7Q:GC^/Q-J.C>&?%&LP>!-0\)W\>GWEG^
MW[31B-Y5='5$:0[74@A=_<$@ E&7)X!5AU4X^,_@O^R1)\%/VG_VL_VF[7XJ
M>,/&>I?M>:G\-M4\8^ ==T#P38>%?!EQ\'O"2> / 2^!-3T+1]/\4QQ_\(3#
M%IOB9/&.L>*4UO6(+;6M+;PJ&O[*^]X\*>"?'.B?!^U\ ZQ\7O%OBWQ_;>"I
M_#LGQN\1>&?AW:^,M2\22Z9<6D/CS4/"'A;PIH/PNBUJUOI8M2.@Z5X+T_PA
M+-:QVQT3[#--;$ _,#XI?MM^*O '_!0S]E^.3XJ>$F_90^,WQ#^+G[ ^L?#5
M-3\"76K:;^U5;^'$^(_PN^-=T]G!/\3[*TU7QI\*/CG^R&?!^HQ:?X:LO%=M
MI/C;SM1L?&6AWEE^<_\ P4>^.'[0O@F;_@X=E\$?M(_'KP<OP8_9$_X)M?$3
MX,)X4^(MYH*?![6O'%W^T7;>.HOA2VFV5O+X C\>)X7T1_&FN^&FT_QOK[V=
MN9O%L*6&C)I7[)_%_P#X)^:%\7OV3?!_[,FI_%+QGX>\0>#-=^#_ (RT[]I3
MPKX3\ 6OQ^/Q$^!GC[P[\4_!WQ4M=7U#0+KPK8?%._\ B#X.T3Q'XK\6MX?N
MK;Q3=W7B..]T>*W\1R^5Y-\;O^"4WA_X^Z=^W/!X]^.OQ(^W?M\_!G]G+X*_
M&/4O#_A;X?Z9<Z)H/[-LGBJ?PSJOPXM[C3+[3],USQ))X\\7R^+'\06?B#3I
MWO\ 3X?#MEX<325$H!]#?%7]N[PG\.?BJGPUT#P)XD^+*^%OC!\.?@E\:9?A
MQ<1:SXU^%7BSXM:3X&U_PE>V_P +UM/^$G^(/ASPOX<^*WPE\8?&'4/";R:C
MX \ _$G2/'&C:+XYT7PG\5V^'/AGP&_X*L:'\;_&_P"RMX<N/V8_C9\,_#/[
M7/Q$_:S^"_@'QGXR\1_!+4D\,_&?]D/Q%\:K7QWX \;Z#X$^*'B^]$6J^%/@
M%\1->TSQMX'N?''@:/7;*P\)_P!OW4>I6GB*7U*\_8)>']IOQG^TMX*_:4_:
M(^&7_"Z)_A5J_P"TW\"_!M_\.+GX&?M!^+?@UX5L_!/A#Q=J6E>-/ /C#Q_\
M*]6UGPEHGA/P=\1S\&_B1X('Q'\">#/!_A?Q5)<?V//J%UPOPJ_X)F^'_A;=
M?L>W-E\8_'FMC]C[]HC]JS]HSP>-5\->#('\6^+/VP3\9Y?BAIGC;^SK:U5=
M"TQOV@OBI_P@R>&5T2[T8WOA1->/B4^';LZL >9?\%1OB]\6OV:/B3^S9^T]
MX \9>/X/AA\![/QY\4?VNOA+H>H:IJOA7XG_ +*>D>-O@A\)_BEX@N/!IDN-
M*LO%'[/VA_'[5?VDK/Q98VVFZC>Z)\(]6\*ZUJ9L+[1;[P]B_M6?&SXIZK_P
M4U_X)A?!/P1\3=?\.? KQ+\5/VC/#/QV\->"_$5UH\'Q?\>Z%^QUXN_:0^'.
MB:[K6A2Z7XBMO"GPOAT'P1XNN-"L-:DT'XDCXK?V9XKLVT3P_+IWB?\ 1OXL
M? !OBI\3/#/C'6O&-\? ^D_"KXN_!_QC\'7\+>%]4\)_%/P;\;&\$GQ?9>*]
M=U*PN/%FFO OP^T&#2(O"6L>'[1;>XUQ/$-OKXU#2_[&^-O ?_!+#P;\*W_X
M)YIX ^.?QJM=&_X)OV?C-?AAI?BT>#/'6M?%C4_B-\/]7^$_C#6/C-XMUGP[
M'K.IW;_#CQ!JOAWPC8>#)O VA>"FN;?[+I^HZ-H'AK1=% .OL?\ @IO\,M0U
MGX-:W8> _%.J_L^_M!?'KXG_ +*?P?\ V@M$U?PIJF@^*OVB?AGXK\9^";+P
MI<^$H-776]#\!?%[Q9\,_B9X4^#'Q9N;JX\+:_XC\$RIXQ3P'X8\:?"WQ7X]
M^<?#7_!:NT\5?#C]GSXP:9^P;^UDGPR_:K^.^D_LT_ KQ1<^)_V4]^K?&:^^
M*OQK^&-_X3\:^'K3]HN[\3>$+71_^%+ZAXCG\6Z?H_BOP1<Z;K$<EMXF;3M.
MEU>Y^H?"G_!.3X6^#==\'V6D>(_%%W\&/A=^T-X]_:S^#7[/FNZ%X%O_ (;?
M"GX\^/W\7WTFJ^%;JV\-V'BH^!/!GC+XB_$7XJ?#OX;ZGK5S9>"/B-XWN[W0
M]?MO"GA#X:>%/ /F7@__ ()5^$?!OP"_8X_9\T_XT?$JZ\/?L9?M6S_M>^!/
M$6H>'O K^)/%_C?_ (2_XH^,[;PEXZ^RZ7;:*WA%]5^,OCB*6/PWIGAW7CI:
M>'+;^WK6\TK4-0UP \FU#_@I?\-_@I\4OVOO&?QB^%W[1/P/\;?#GPK_ ,$S
M-&^*_AC]H+X[?#_4?V<?AEJ_[7_B;XF^ O 6O:?K/@/XF_%SX5? ?X?>!/$O
M]IV/[3WQICM='_X29O#&DZK9>&O&]OHW@6\\4_K7\&?BA<?%SP!HOCR\\$^(
M?AU_;L_B7[)X;\67_A?4=7&F:'XKUSP]I6OPZGX+U[Q1X1UGP_XRTG2+/QMX
M3USPYXDUG2]5\)^(-%U*&[:*[C>3Y%U_]@FWU3]H']H/]HK2OC?\3/"_BK]H
MVQ_9PTKQCX;T32/"4W@L^'OV8;7XG6GA#P1JND:II=Y_PE_P[\?P?%_QI8_&
M;PMXGGOKGQ?HUUIUMX1U7P!JVD6FJ12_ G]C_P 2?LOZS\'?AM\!_'?B'P?^
MS%\-M-^-NN>*?@^/"GP3LOAIXE\3?&OXG_$3XK16'@;2="^'MEX]^'2_#SQI
MXXN&\"^'?#/B3PQ\*/ 7PLTG0/AOI_A'QOJ>KW7B'P  ?*7_  4)\=ZMX&_;
MU_8%\ WOQ2_:?\*?"/XT_!']O:3XL^%OV<KSX[Z_XFUR^^#?A/X/:]\+O$_A
M_P"'_P "M)\5^+Y?%?@K5OB%XJN[:Y\+>$YT\6/>Z3HOCJR\6V6E^&='@_/7
MX&?ML_M]_L[?&*7XC_MO>%OCQ\4_&GPY_P""/6H_M*_%[]GC2-;^$/P]M- T
MGP+^V3\9=,N/COXF\$V7B_1O@MX:^.NO_LP>$_!6N^/_  QHFNZEK<_Q!U+7
M?A_X.T[PQX5LM?@\*?O=\6OV2)?BO^UO^RY^UC-\4_%_AG6?V5=!^,'AWPI\
M.]&\.>#;OP3XQTKXZ6.A:)\2$\:ZAK>F7?BT7=SI7@[P@?"L_A/6_#A\/:KI
M,MY>CQ#I6JZEH\GF/[0O_!//0/V@_BS^T%\7=:^*GCCPSJ7[0O["WBK_ ()_
M^(_#^@:%X4N])\/_  D\6ZYXI\2ZIXO\.SZM8SZ@_P 3HK_QMXAM],U+5KV\
M\'16@TU;KP5>7-G+)J(!J?MS_&*36?\ @EG^U/\ M&?!_P 7^+/!NJVW[#GQ
M=_:+^$'C'0=6U7P9XO\ #NN^'_@9KOQ=^&NO!M.O;>Y@N=-U.PT'4-6\.:FU
M]H>L6D=YX>\3Z9K&@7^I:;=_!'[17Q8^,?[$W[('[(O[?O@/XR?$[Q9X?EU'
M]C?0_P!K7X$?%3QGK/Q8\*_&3P-^T;K/@WX:>(/%/@K7OB3>>(/&_P %_BYX
M+\8_%33_ !MX6OO 'COP9\,-<L]'G\-_$'P+XGBA\*W?AO\ 0CQ9^Q)JOB[]
ME'XC?LAZG\??B0/ACX^_90\)?LFQQ6WA7X5)JG@_PIIO@CQ3\-?'?CCPI?+X
M0CO9_B'\4/ ?B2RT?Q!)XJU'Q!X.\/:KX3T?6_ ?A/PJ-0\066LX5M_P3PT#
MQ5K'[-:_&[XQ_$GXM_#C]D6;X?ZY\&_@G>Z3X#\(?"V]^)7PNT8Z-\/?C#\3
M['0- F\6?$3QYX$A2UO_  ;8W'B[1/AKH/B6U3Q9'\.;GQ-;:5K6G 'Z,2,&
MCE"D,RHP*JRY!VD@'<0JD]MY [D@<U^'/[&'[2?C;X+_ !>_;I_9]_:-^)/C
MCXE^'_ OB'XY_M??LN^)_%>J:GXK\;2?LD>#_C1\1?V?_'/P!TK4M6LUUKQW
MXE_9U^*/P?L;I]6UGQ=XQ\6ZEX5_:1^#D'B/6K/6=1CBN_V.\#>&O$WAK1-9
ML/$OCS7OB+JE_P")_&>N6.M^)M+\(Z-?Z5HGB/Q)JVN>'? ]O#X&\/\ A73+
MC0/A_I.HVG@[P]JEY9W'BK5-$T>SU'Q=KWB'Q3<ZKK^H_#<?_!.OP-K_ (M_
M9X^(7Q4^(/Q#^)7Q#_9G^._QY^.WPX\60IH/PYBO#^T-XBOOB%XO^%?CKP]X
M%TW1],\5_##0_BTG@CXJ>&M+G$'B&;Q1\(/A;%XK\0>)X-*\4'Q> >6?\$C?
M'GQ>^)7A']M/Q;\>?B)K_CKX@:#_ ,%%/VO_ (/06VH^)-0U'P=X \%?"7XE
MS>'/!_PX^&>AR?8='T/PIX4M[BYTZ#4H-&MO$?BI%LKSQ/>W7V+1[#2/D+Q5
M\5/$>C_%'_@LUI5]X^_;SU_5_P!F3XA?#W4?V:K#X!:Y\;O'>K^ $\6?L1_
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M@/C_ .*VUZ[\&>%;;P'HW[,6K:5HGQ/^$<GBN\\07G@_Q/\ M&>)KV?Q9<_
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M4_V8=2^"GQY_X*"ZS\0?B[X.\2_ OQM^S7^T9X9_9Y\+^!]5^$?Q#_9R\?\
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M\(/VA/C;\3?@A\,?!7Q]U*\^#_Q(^*WP=^(7Q*U?X'^.O#?PA\._%+X0:/\
M"GQ!K_@F_P#&NNZ?8?9-1\0Z+\6M,U7X?ZC=Z9;>'O'>E^'/$>J^'=9O-+N/
M!]YXL\*^*/\ P3?\1_$>^_:VL8/CWI>A> /^"@WP]\ >"_VT?"$GPBN]7O\
MQ-K'A[X::-\!/'?C7X ^)Q\5]+E^">J?$K]G_2+'X>7&D^,=)^.FA>%-9\,^
M!_'N@V(UJQ\>6WQ)]M_8^_9%\2_LN^(OVM]=UWXJ:'\2(OVH?VM_&O[4]K8Z
M-\-M0^'Q\ /XR\!?#?X>OX$GN;_XD_$-?%T6F:5\,-!O(?$45MX3:YOKK52^
MAQ1W%J+$ ^XJ*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@#\I?^"J7QW^+7[//AS]D+Q=\-OCK?\ P0T+QU^WG^S+\ _BWJ?]
MA_"'4]#U'X1_&[Q0_ACQC<:AJ?Q5\$^+H/"^J>&+6U_MGP]XDTZZTRVM+J:[
MBU[3M=LFM4LO&?@9_P %-M9^'/ACQ19_M*6/QE^-6F>+?VV_B_\ LP_L.?%?
MX8_LV^)5UC]KWP1X3^$5M\9?"?B/9X7T[3?A3<:O<W&G_$CX5>'OB;X>N/ '
MPM^-L_PZOOB7X*\-^%_!FF>.[SPG]F_MT_LB_$?]K;3OV>;'P#\9?!'P>E^
M_P"U-\&/VHI+GQA\&O$/Q@7Q9J_P/UQ?$?A;PG#;:'\;_@P/#NGZEJCW47B'
M4I9_$5Q=Z9-';:?::5=P?VA)U_[2/[,GB_X[?$+]C[QKH?Q/\/>";']EC]II
MOVC-1T76_AQJWCF\^(C_ /"DOB]\"XO"%AK5C\3? D7@B-/#?QJ\6ZO_ &Y<
MZ-XW9M;L?#9DTF33[#5;/70#RCQ#_P %4OV0O!GB7X:>'?'GB[5O *_$R[T_
MPS!J/C&TT71;SP/\5M3^&6H?%ZV^"7Q/^'LWB!_C#X#^)R^"=*U-;NUUKX;Q
M^$['QQ92?"6\\70?%J6V\#S\#\6_^"B7P9UO]E^[^-$?B_\ :7^ '@G6(_V2
M/$OAOXI^"/A%X/\ '6N:IX:_:;^)6CP_!C4?!FHWWA[XT_!W6O!WQBLH+3PG
MXH\3WTES9>"M'\=VNC3ZKX,^+4MG;^'M/0?V#_VBOAO\7/CKK'P4_;?U+X=?
ML\?'+XB^.OCO-\#]2^"5GXW\8?#GX\^/M'DO=?USX<_&C4OB?IJZ1\(M>^+4
M&G?&#Q;\%M1^&FJV?B#6KCQCX>B\7Z3H'CG6X:^=/$W_  1<MYOV?_VB/@9\
M+_C7X#^"6E_M$>/?V1/B-K'A;X=_ +Q%I/[.G@_QE^RO\8='^,&L^._ G[-%
ME^T)8^$O 7Q"_:&OO#/@WPU\:-4^&?B'P#X'UO1O OA75(?ANOC"/7?$VN@'
M3?\ !3_]O3QK\)OA1\1M(_9CUSXF:3\3/@W^TO\ L1_##XH?%+PG\/?A]XN^
M&/@>\^/OQY^".C^(/@SXVU3XAV6M)'XG\0? _P")]MXDN)?!WA74[_P4?'?P
MEGUCQ1X2U7QUX<L]6^L]9_X*3_LM:!\;[7X"WWB76[_Q9JUK\=8?#5YX/TFV
M^)$7BGQC^S7I.LZ]\9OA=H_@_P"&VI>+OBU%\3?#&C>%O&M]I/A76OAOI$OC
M]_ GB_3?AO=>+]7TAM/F^5OC]_P2H^)GQ8?]K'POX#_:O\._#+X0?M@?'']F
MG]J7QWX*U?\ 9S/Q%\5^!OVCOV??&7[,^N:MXQ^&'Q E^-OA&"Q\#_%;P[^R
M]X'TKQ#\-_'W@WXB1^&_$<\WB3POXFL]&2]\&:M[/\%_V'/VB_@?XJ^*VA^'
M/VTH]=_9G\1>.?VCOBQ\'?@9XJ_9_P!,G\4?"WQY^T7JGBGQ7J/A+Q?\9?#_
M ,4/#E]\7OV?/!/Q"^(?Q \<>%?AG<^"?!7Q&BO;_P ':)-\=/\ A&_ >FZ5
M>@'$7W_!8'X(:K\)O$?Q3^'/PD_:'\5M'^PAK?\ P4-^%7A[7O >F?#*S^.G
MP&\*67@^X\>77@KQCX\U_3O#FF:K\+KSX@>!(/B!I_B2?2[^ZTCQ7I_B/X5V
M'Q4TNXL)[JSXV_;\\5^$_P!C3X2?M<>,/".K>$&TW]D;XA?MU?&WX=6H\.R3
M:K\-_A7\$%UZ]^'7AK7=,U#X@VNC:I\0?BM\1/A=J/@.YN+J65OASHOC!?%6
MK:-XCTN^\.:AY[X?_P""3/CJP^&G[/WPGU[]IOP?JOA;X*?\$HOCC_P2RU6Z
MTC]GG7-#\0^,O#?QDT3X/^'H?C#8WU]^T/XCTOPIK7AC3?@+\-GD\'S:)XGL
MM=OY_'<X\0:/:^(?#ECX'^I_@K^PK;^'OV=]4_9\_:6\9>%?VCM!\3?LU> O
MV2?%MII'P\USX0^"]8^"/@3PAXD\%?V#:>%)/BC\3/$&CZKXMTOQ7J]YXP\0
MVWQ EU2^U1K&329M$LM%\.66B 'F7PDC_;\\?_LX? +]HR+X\>'M4^*WQ8U'
MX ?&;XD? =_ 'PXTWX'>%_@QX^\4> O%?Q.^"WPFU^#09_BK%XU\'_"&]UO0
M?#OQ7\>_$WQSI_C_ ,<6FNZT?!/P[TGQIX3TKX2_)&N_M,_'R_\ VL/^"F/[
M/-[^VM\5?A9-\.OB/^R9\)_V/;W2O@-\"_'GAWP7\1_VS/A/HEQX,M?B)*WP
M%U&;Q/X)\)_&#Q?I/V6+Q%XQ\+^(+KP1ICZ5J/B;6=:E&O:C]S?LW_LB?M7?
M ;POX-^!?B#]M?1OBS^S%\,M'A\'> ++6?V=YO"W[7#?#GPXL5A\/?!'CO\
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M-_AUX&TJ[O8="\'>$-*DUK5O$OC"]\3>+O$0!]6T444 %%%% !1110 4444
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MCY/C;\&/@)\<?%?@JQNOB;XD\<W&FGPU\0OBA\-/!/B8>-/BS\#]/^&_P_\
M#?@FV/C"T\.?'GXG7'PMTV/XR_40_:J^ )^* ^#8^+O@+_A8\MEX_O+/PU+K
M"6K:D_PI?2/^%IZ7I&M7&SPYK/B'X76_B+PY>_$OPOI>KW?B7X?Z=XAT75?&
M6D:#I>I6=Y<?*W[)_AS_ (*-?"WP%\-/V;?C/X3_ &9M:\._"+PYI'PW_P"&
MNO OQ0\7#Q'\3O ?@.SM-$\*>,A^RE??!C1]#\ _%CQOX8L+"U\7^&T^.^O?
M#7P!XOGU?Q9X<OO'?AO3]+^&VL?-W@;_ ()R_&CP_H/[,7P#\3ZGHNM_"']C
M[]O[XN?MU>!?C9;^/9M2^,OQ5T[Q#XB^/?Q)^'_PZ\:^']:\!VVGZ#\3-5\>
M?M%^)?#'QJ\=V'B.\\/>*_A]X,GUG0WTK7_C/JWAGX1@'V]I?_!2C]A+6AG1
M/VM/@)XAA?P'XD^)NGWGASX@:1KMCXE\!^#/$$WA;Q3XD\%WFE3WMIXVBT[7
M8H+%-+\(7&NZO=IJ_AO4+"TO=+\4>&[W5M#6?^"BG[#N@:'H_B75/VLO@!#H
MOB'X)W?[2&A36_Q*\-ZC>:S\!;36+7PX_P 6]+TO3-0O=6OO!,GB.Z'A^WU6
M#3VCO-:M=7TRS\^]\/ZY;V/Y8?LF_P#!.;]JWX(R?\$D9/&GA/X87C?L+^)/
M^"AOB#XPKH'Q$6\CO[S]K*?QY-X U'X>+?>"].&O:G8Q>-;BV\:W^K#P5=60
MNM:.EOKT&H3VUSL_L1?L#?M:_LWP?L(GX@^!?AIKUQ^RI^R9_P %#OA+XJ/A
MWXH)?/>?$O\ :L^/'PN^,7@"]\%3:QX+TTOIB:!\('\(^+]<O5\.7^FZIX\L
MOL5IKF@Z;K<X /UV^&G[8G[+7QA\>7_PP^&'[0GP<^('Q T_X8>'OC8WA7P=
M\0/#GB#4;[X/>*OL9T'XI:&VFZA<VGB3X?WBZKH@F\6^'KK5-"TR3Q!X<BU2
M_LY/$>AI?<C?_M]?L=:+I'B'6O$W[2WP:\&:?X2^(7@GX5>))OB!XSTWX<3:
M7\0?B;I%OXF^&?AN;3?'<^@:DTGQ+\)7=MXR^'.J0VTVC>.?!/VCQOX8O]4\
M)VMSJ\/Y,>%O^"8G[3MU\"/V4_V?M5'@;X:K\-/^"*?[4_\ P32\??$OPCXZ
MN-9/A'XW_'71/V>]#T;XN^#/#EMX;\,7GB?P?;W7[.E[XCUF>YU'PQXKN+CX
MD^&X&L&O=&\2ZC8]KXZ_8M_;+^,O[-_B[2OB?^SI^QQX)_:0\5?$W]@B;QQJ
MWP>^-/Q'\=>'/BMX6_9(_:J\&_M1_$+Q)=^-?B[\)M!\8>#/!WBO4=$\;:)\
M%_@!=V?CRW\#ZUX^U+5O%OQ(U2/7-:O]- /TVL?V\/V3=3\"^#?BAIGQX^'^
MJ?#'QY?:5IN@_$S2+O4-9^'=M>ZY\29_@WHEMXN\:Z=93^&_AS+K_P 7K/4O
MA3H'_"QM3\*#6_B/HVN>#-)^W>(=$U?3+'#^'7[5GP^CTKXU>+?'O[0_[-WC
M;PWX4_:>\4_ GPM??!0ZC-)X>\2"U\'Q^&OV=?%L">-?B!>?$C]JZ+Q!K<^B
M:QX2^&UG8:KK^M:EHGA+1?AKI_BC2M2L;SYP\??LR_M;6G[7'[0WC#P/X6_9
MH^,G[,7[:7@KX&Z!\4-*_:$\0ZS!XU_9\UOX2Z3KW@[5Y?"/P]@^$'Q)\'_M
M _#K6/#NHVOC/P[\)?%'COX5Z+9?%FZ\6ZG-KVB6/C'7M9U'PKPO^Q%^V/X5
MT;X^Q:/X3^!U[<_%K_@KWXB_;0-CX@^*&L>'M?'[-/C/P+H/@RZMO WQ6T?X
M2^.]=^"7Q^TG5=!L+O5-9\'>&+W4V^&-SXS\&_#_ .*/@_QEXLT_QKX6 /K"
M3]N2'QK^U?\ L7> _A/XC^#GC[]E?]JC]F3]K3XWQ_&#0M6U75-<DU3]G?Q!
M^S[I5I_PCVN6.MV?A+2?"TUI\9;K_A)(]7L=:URUUO0KS1KZ/PM=:)>IJ&Y\
M)OV\O@U:? G1/B/\4OVB_@?\4HX?"GQ*^*'C'XP?LQ>"?B;KW[/>E_"7P9\0
M_B'X6?XC-K.CWWQAL_!W@#P[9^ ]9TGQ+\0_%OQ!/@S6?$'@WQOXAT+5;+PU
M%%9Z5\&_L,?\$]_VLOV9/&G[!3_$#PU\)=2\-?LC^"O^"I'@KQ'JO@7XK:WK
MUUXC@_;-_:,^'WQM^%&I:'IOBGX=^$;F-]*L?AQ>^'_%]AJE_))I@\1>&=4L
M]8U^Y_X26PT##^!'[!G[8WA;]G7]D']D;XZ_#+X5^-OV=?@IXQ^,'QY^//A#
MPE\7[RZU/X_?&*;]J/QE\:/V;_AGK*:_X>\/Z4GP!\#)XGL?B[\6+34)=3U;
MXC_%KP5\/?AM<Z)<_!^P^(!^) !^OFN_MF_LU^%]<\#^%O$7QA\&Z7XG^(EM
MX N?"N@SR:B=5NV^+-OK=U\(].U33TLWO/"GB/XQ+X7\6Z=\&?"/BZ'0_%'Q
M?\1>#_%GA?X::3XJ\1^&M=TG3OFC0?\ @HE\-OC;\&_A5\7?AQ\0_!?P&T?X
M@_MLV_[*_A^/]K?X??$;P#K7Q5U+PM^TEXP^!/BKX?\ P@\(>([WX9^(;SXU
M?$B#P#XAO?AIITEIXGN_AOJ$DZ_&7X=V=YX.\<^&-'^/_P!I+]BO]O\ _:!^
M)VD_%#4/ _[*-C<:)\8/^"7?[0^B:%H'QG^(?@*.V\4?LM?%'PO\4?VAOA]X
M[O-&^!.MW7QHU>[U_3==T;X3?&+Q_J$^D>$OABGA+P]X%^"W@'Q7/\4_$?Q)
MD7]A+]LBW_9=^%W[/]UX6^#DU]\'/^"N6E?MK:7KNA?%_7[N#QQ\#+7_ (*(
M>._VYM5BO]/UGX8>'!X6\?G1?%=E\/=$\*'4/%>C7WB737UO5?%F@:5-%+;@
M'ZZ-^U'\"(OBU8_ J3XK>!T^*^IOXDL=+\&2:L([S5/$/@W0M.\8>,/!6FZJ
MZG0;_P"(GA'P'K.B_$'Q5\-;;5)?B#X<^'FL:3\0M;\-6'@K5+'79N"^%G[?
M7[&GQK\8> / /PF_:>^!_P 2O%?Q6T;Q[X@^%VF>"O'^A:VOQ+T7X6>)-6\)
M?$75/A_?65Y<:9XRA\*:YH6KC4K?PU?ZM<)I&GW'B: 7/AA1K)_/ZQ_X)R?&
MN\TSX3?L^^.K[P1XJ^#7P!_X*=>)_P#@HY\-?V@(?$EXWQFU#3]4^.OQ._:P
MTSX;^(?!NO>$]4L['XJ7?QB^+_B_X.>.?'N@>,=/\/>+?V=VU'Q-#+H'C+QK
MJ_PUT;@_V=?V /VJ_AI<_P#!,F;Q7X=\ QM^R;^V9_P4@_:#^,LFE_$?^T_M
MOA3]LA?VKA\.!X2:7PM8MXG\1>&4_:9TB'QLFKQ>'(K+_A"O$J^'YO$45]H7
MV\ ^X_VKOVF_CM\)?VLOV&/V>_AK#\)[?PQ^V+XL^.?P_O\ Q3X[\(>,?%.N
M^ -=^#7P"\<?'VWU[3M)\/\ Q#\#Z=XKTCQ58^#+CP;-HEWJ'AF]\.WK+XDB
MUKQ';W!T"S\?^-W[9_[3WPL^&W[''C+0Y/V9O&]G^U1^V;\-/V<-&\?^&])\
M<>(/ 'B?X-_M!_VOJ_P4_:)\!VFG_$N"[BN(/"VF6-[XH^&FI^(]5T_7;C79
M+KP_\3M-TS1+.;Q7T_[;W[,/QB^//[5O_!/;XI:#\+?AQ\2OA'^RKXW_ &B?
MB)\5=%\:^*]+TW4_$EY\3?V=O'GP4\ >'?"/@_7/"GB;P[K\VE^)/%]MXR\0
M:UXGUKPY;:%8Z+:'0]/\3ZO<&VT_PC]IG]C[]J#XT?"?]E+X4^&_V<_V;=#^
M$?[,O[=?[//Q6\"? E?B5+;^'_"W[&_[-/@73/">C_#O4Y[SX;:WH'B?XJ>*
M]5NO$]QH7@VQL=)^&OAOP/%X9\,:OX^O-2T[4M3UP ?J7_!2_P#:!U7X2^-=
M5\)>#/@9IWQ3^"'_  5-^%O_  2_^+4E[=>+?'7PS\4Z[\5_B-\!/AYI/QG^
M'EQH7B+PMKGAZ+0$_:#\,:]XM^$GB>XUO5M#\0:#XP^&<OCJ6ZT:U\:ZM^E7
M[57[5WPN_8J_9?\ BY^U1\>]4FM/ 'P3\$W?BOQ/'H%OIRZYXDOXKBQT70O"
MO@[2=:U^QT^7Q7X]\8:KH7@[P9HNK^);&SN/$_B/1=*O]>MH;AM3'S3^VM^R
MSXUUOX#? 'X,_L>_!SX3:3H?PI_:U_9,^/1\$)KFC_!'X?>&?!/[-7[1?@+]
MH77O#WA+2?"G@37M/@UKQS<^"[G0=(T^TT+3-%M=9\17GB+6-3MH[:6VU/S+
M]JK_ ()#> ?VN/A/^V)\.?B%^TQ^V1=:;^U]X1ETJ3P1XT^.FM_$+X,? [Q5
M9?$;P3\7O WB;X3_  ;NY=-\.:);_#_Q]X \,K:Z#8ZO9Q:KX-B\0>#UU6PM
MO$EUJ,0!],^&?B=^VUHEM\$_$_Q8^#?PIU+2?B=XVT'0OBYX#^$&I>/=9\6?
MLOZ'XPL?$%OX;U1?%?B#3[2T_:0L-*\9WGP^\-_%'Q!I?@/X#Q?#KP[=^,/B
M1#H/BWPYH%W;V':^+/VX_P!D_P  #XJ'X@?M!_"GX?Q_!3POIOCGXG7GCWQ+
M;^!].\+^!]<\6:A\/]#\9Q7WBQM'M/$W@_5OB+H^L?#73?%7A6?5]$U#XE:9
M>?#VUNG\8P3Z+#P'P1O_ /@H;XBTKPYX,_:9^''[-7@&ZT33]&B\>?&/X'?&
MWQQXZ;XC:KI1C36KSX??"/Q?\"? 4OPRM?'4EM->NOB'XI>+;_X<6VJMIFCW
M?C74;.V\2VWY<>&/^"<W[; _86^.W[+/Q+^&7[(.N?&32_\ @GW\;/V!O@K^
MT_X/^+7Q7U/Q3\9]!^+/A/P_\+_#/C#QUX>^(7PSDG_9OTO2?!/@OP%XG^._
MA3P1XO\ B[:?%CXC: +_ ,*V_A30O#WAW1;T _1_XZ?\%2_V0?@E\'/VC_B]
M;_$[2OBZO[+<GAG2_BQX&^#%MJOQ'\:^%_$_Q 5XOAII/B?1_"EAK%SX-\/^
M.]3BN-'TGXD^*(=-^'<5[::G'/XC^T:+J]G9_4&M_M*_!GPGXK^&?@OQIX\T
MKP9XD^,-WHFD?#S1_%NG>(?"UYK?B7Q1I>NZYX4\&WW_  D6DZ7#X6\?^*]'
M\+^)KSPQ\._%CZ+XV\1R^%_%UCH6AZE<^$M=%I^.O[8W_!/3]J3]I;1?VV]#
M\%^%OA;X+M_C[^P+^PE^S[\+H?$_Q'N(])TGXD_LJ_''XO\ QM\7>'==M_#'
M@74QX?\ "6LVOQG7P?X2\1Z/IVM>7K/@W5]3OO#^EZ-JND&;UK_AD3]KK5?V
MJ_BGXU^(?PD_9,^*/[/O[1_Q1_9R_:"U&'QA\9/BUK7CK]E'XF_"3X7_  3\
M%^//#7A7X<:K\)KCX4_M&>']0UW]GCX;>._@IXDU&Y^!VH_#WXHW?B+QMX@T
M?78K'PYI\ !^@GP:_;;_ &1?VA_'5_\ #;X%?M*_!+XQ^-M.\/>(?%UQX<^&
M7Q#\.>,[]/"_A3Q;9^!/$FN1-H-_?6U]IN@>+M0TW0];O+*:6'2]0UK0H+OR
MTUG2I[_ZFKX)_P""?GP'^)G[/OP^^-_A_P"*/A[PUH6M?$C]LW]LS]HG2SX7
M\0Q>((+OPE^TA^T)XR^-/@Z'7KE-+TED\7>'_#WC*T\(^(X!%J%E;:CX<E71
MM;U719;"Z?[VH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "OB^__;4\%Z;^W?9?L$7WA+Q5:^.M6_9NT;]HS1?B,W]CR_#K4(M;
M^('Q'\$V/PM=_P"U8O$MK\1+S2_A9XV\?:;"-"N=!O\ PGX2\62-J]I?Z-%;
M7_VA7XM_MP?L8?M3_$;X[?&/]IK]F&\\#:)\:_#?P?\ V)]/_96UWQCJA.A:
M5\7/AIXJ_P""EWPR^.>J>,]&@%G=OI&D_LX_M\:MJ?@];75K&37/&L<5C+=V
M4&FW!O0#Z.^"G_!3W]EWXJ?"7XO?'CQEXV\._L^_!WX7?M(^(_V<-,^('QS\
M8^#_  )X;^(VIZ?I/A7Q#X)\;^#M5U36X;&Y\.?%_P ,>,M"\4_#33+B:+Q-
MJ_AZ]M;VYTFTNIIM/L_>8?VU_P!CRYT[X)ZO;?M2?L_76F?M)ZM=Z#^SY?6O
MQ<\"W-O\;=<T[Q9H/@/5-&^%DD.N2#QUJVD>./%'ASP=K.G>&_[1O-'\4:WI
MN@ZG#:ZI=Q6K?E]J'[!7[1OP/^%VL_#C]FW1HT^'7AC]LOX?^*O#'A/P;\7-
M#^&?QHU+]DGX?_\ !.KX8?LC>$M'^&?QC\0> _$T'PL^)6C?$OP#X7U/Q/)I
MD_@O4/$_PB\.^-_#%MXS@L_'%YX+\3TOV9?^"<_[1/A"U\$:%\1CH_PS-I\!
M_P#@L7\,M=\3>$?CI\0OVA_$/@KQ!_P4+_:K_9=^._P?UCPY\8?BW8^%_C%\
M8O$'@?P5X*\<Z7X[^)?Q'L_!_BW7?B3X5N+];:31O$FC:Y, ?>'Q"_X*9?L9
M^$_A?XV^+'@_]H/X)_%SPO\ "OXM?LT_"OXP7GPZ^,7PWUVR^$$?[37[0?@K
M]GWPUXZ^)6J6WB233?"'@KP_JWBG6?%>K:UKEU86-[H'@#QM'I=U/>Z%?QVO
MT[\%?C]\$/VC?"4WCKX"?%WX;_&;PA9ZS>>&]0\2_#'QCH7C/1=.\2:=::=?
MZAH&HWN@W]_%INM6FGZQH^I3Z3?M!J$>FZOI.H/;BSU.RGG_ "*U?]C_ /:D
M^,?PY^"_@KXB_LQ_LD?"JY_9YG_X)Z?#V#5O">N:9\1_$WQ!\%?L^_MX?LE?
M'WXTV7P_\<W7P]^']_\ #G]F_3?A=^SM=W_A7X0:[X>EUOXK>.M8TB#7_#/P
MV3X8:%>?$?\ 2'X+?!_QIX&_:2_;#^*&O0:7%X5^-NM_ S4_!4UIJ+7.I72^
M O@]I/@CQ)+K6G[%BTZ=-8L/(LV62XDO;**&6241QPQ1@'BWPT_X*?\ [.'Q
M-NOVN]6T^'XD:#\)/V.?A'X+^-GC3XX>+/AGXV\,^!?B1\//%4/QPN-2\:?
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M_P ,M_#O_H9?VAO_ !,3]KK_ .?71_PRW\._^AE_:&_\3%_:Z_\ GUU])44
M?-O_  RW\._^AE_:&_\ $Q?VNO\ Y]='_#+?P[_Z&7]H;_Q,7]KK_P"?77TE
M10!\V_\ #+?P[_Z&7]H;_P 3%_:Z_P#GUT?\,M_#O_H9?VAO_$Q?VNO_ )]=
M?25% 'S;_P ,M_#O_H9?VAO_ !,7]KK_ .?71_PRW\._^AE_:&_\3%_:Z_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M%?&#3_V8OB9J'CSP]\=_#_AGXI:%XZ\#>*_BCI?QF^"6G^ V\2^#O"%GX_\
M@]ILS?"SQ+XAF^&OQY^*WA^7QRL=KX$E\,@'IL?_  45^ TO[.NG_M01_P#"
M:GX;:]\??&W[./A:P/A)1XX\4^/_  -^TCXY_9DU.YTCPLVMAT\,R>)OAWXI
M^(0U/6+_ $C4-*^$VE7OBKQ5HWAF^T[5="L/H#PG\=](\4?'KXO_ +/(\/\
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MXS\?_M ^'OV5]>E\7_"3QYX,^,OA#Q!H?[3%_P"$?$?@77K>PTKQ1>?$/S/
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
,B@ HHHH **** /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>26
<FILENAME>ex10-21_001.jpg
<TEXT>
begin 644 ex10-21_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" )X F@# 2(  A$! Q$!_\0
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M;R18G$D5RS()4<-N!!"A>#ZC'KFK-MHZVT!0WES-,\RS2W$VQGD88P"-NT#
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M** "BBB@ HHHH **** "BBB@ HHHH **** "BBLVRUNUO]5OM/MP[O9%5FD
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MZO*/B3XIBN_$FF^"X//FBEE234X[==SM'P5B'^]P3[8KNO%WB2#PKX;NM3E
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M6.FG6@_[8+_A0!+8ZA::G;"XLKF*XA)*B2)MPR.O-6:BAAAMXQ'#&D:#HJ*
M!^ J7- !1110 4444 %%%% '-ZYX"\,^)=0%]J^F_:;D((P_GR)\HS@85@.Y
MJ;3O!GA_2FL39V'E_82YM@TTCB,O]X@,Q&3ZGFN;^)NBZ6^GVE\^GVSW<VI6
ML;S/$&<IN VY/\..W2J?B>W@\+^+-.N=$L[.U:#3+Z=8Q%B/*A6QM4CCKP".
MI-).W]>5QM7?]=TCK-0\"^&]42Z2\T[>EU.+F9%GD16E (W85@ <$YQU[T:)
MX%\->'99Y-+TQ86N(_*EW2R2!T]"'8BN=O\ 3+K4Q:>,-#MXH=;6SAN)(5&%
MNT<'?$Y[D@  GT'X#^(8]$\'VEYH%IIU@;M+B[%K+;D,0@+$;$*C(  +%N,#
M / IM<MT_3^O+02]ZUNIT>D^!?#.A:D^HZ;I$,%VV?W@9FVYZ[020OX8J.Y^
M'_A2[UDZO/HL#WI?>SDMM9O4IG:3]15#3?$NMZOKL-K;II\=O+IMM?D2(Y=0
M[8=<AL'@-@X'.,@U-J&N7=SXUT+3],O[1K"XCGDF*KYF\QX4KN5A@\GZ$<@]
M*=FFEU_X?_(5U9O^NG^9T-YI-C?W=E=7,&^:RD,ENV]AL8C!. <'CUS1JVDV
M.N:9-IVI0>?:38\R/>RYP01RI!Z@=ZX?5O#>G:7XF\#P?9HI889IHO.G0,2=
MC.@)/HV2!V/2I]?DET.5'T%+&SEU/7(;>:86V=P*@G.TKGY@V>>[<@TDKJW?
M_-%;/Y?Y_P"7XFC8_#+PAILLDMII'EO)$\+'[3,<HX*L.7[@FI]&^'OA70+]
M;[3=(CBN4'RR-*\A7Z;V.#[BN0_X2'6(7O(;1K&VN9?$R6,LZ02$2#:OS%3(
M<9V@$ C(].M=7HOB'5Y=;UBVUW3XM/L+:=(K.Z<E!<;C@8+'#$\8QZXZTUW7
M];?YB:MH_P"NGZ'27=K%>VLEM-YGER+M;RY&C;'LRD$?@:YX_#WPT;"WL?LE
MU]DMI/-AA_M"XVQOZJ/,X/\ +)]361\2;"SNKKPLUQ:03,VL0PL9(PQ*$'*G
M(^Z<#(Z4V#QGJR>(A820V)M!K+:8!'$ZOL\O>K9W$9'0\<^U)?U\K?Y@]/Z]
M?\COHXQ%$D:EBJ *"S%CQZD\D^YJBNBV2ZV^L 3_ &UX_*+&YD*;/3R]VP>O
M3KS6-X:\1WNL03:G>-I]OI9>2-$)9)H620KAR25.1S_#C(&#UKI8YXIF=8Y4
M=HVVN%8':>N#Z&CS#R(M0T^UU73KC3[V+S;6XC,<J;BNY2,$9!!'X5@:#\._
M"?AF_P#MVDZ/'!=8P)6D>1E^F]CC\*R+[Q)>Q:S92VFJ7$]M/JHLFC-M%';A
M=Q5E!;]XS@@_,"1QT K<\'SZC?:0^HZAJ,MR\TDJI$8XU2)5D91C:H). ,Y)
M_"A;<W]?UJ#_ )7_ %_5C,N_A'X&OKR>[N-#WSSR-+(_VN<;F)R3@/CJ:EU+
MX5^"]7OY+Z^T;S;F0*'?[5,N< *. X'0"LS2K_Q!>VOAIY=?G#ZLTIF*V\'[
MM51B GR<'@')SSVQQ4FFZ[K&J7-KITVJFT,<=V[W:0Q[IS#-Y8!# J./F; '
MMBBUEZ ]R[J_PW\#W5M:-JNFQB"RA6U@:2\E0(F?E7.\9Y;OSS73Z7I5AHFG
M16&FVL=K:Q#"11C 'K]3[FN+OM1N=2^$5K?WEU&UQ+]G>2X90%SYZ?,0,#'T
MJS<:WJ>G:EJ$?]HF[M-.DMKB:1HXP?*D+!T)4 ?*,.#P<=2>[UNU_7]:@]DR
M]/\ #GPC<ZLVJ3Z)#+>M<&Y:5W<[I#W(S@CCIC'M3;SPS<:IX_T_7;R*TCM=
M+BD6VV2,\LK. ,N"H"A>< %NN>*T="U&6[TFXU6[GS;2RR2P9  2 '"G('.0
MN[G/WJY+P9XCOKKQ*[7\U\UOK,;W%K%<6\L:0%2=J(74*<QE6^4D9!]:([I+
MI_E_PX/9MGHSHLB,CJ&5A@J1D$5P9\"7&F>*K;4=*\BZTJ, II=]=RK%9R9_
MUD  =0?]G:,=B*A^(^J33V>K:"D5MY,>DO>RO/&7+X;:H3D $$9SSVX[U)X>
MO;Z^UVUT:62V?2H]"@DDMW@+>9O&T@G=CMW!XR,=Z2[K^M'_ )?\,$G;1_UM
M_F;]QX(\/W.H_;Y+%Q<_:A>!H[F5 )@,;PJL "1UXY[YH'@K0Q?WU\(KS[3?
M(8[E_P"T+C]XI!&"-^, $XQT[8KC] UR3PU\-()K.U$DDFIRVL2A1MC+3L 2
M"RC ]-RCIR*Z8:CXBFLX'OK)]/C*$7$EHJW$R,"1P@+!1@ \>8><'IDEM/ZZ
MI ]]?ZLR"Z^'6C0Z?,ND036]Y]C:R@D>_N"$B)SL&7.!Z<'!P<'&*K:#X%O$
MTZ^L?$6J:E?6ET%4VTVKRW&,9S^\"1, 0<%<$<=ZU+QH;VRN[%I[&]TYM/:3
MRIG,D[/D_,RGC;QZ<$8[5P.@P)_9O@#3YK>)-&ODF>[0*%2XG"G8).S9QT/7
M'?%"U;7]=?\ (&[)/^NG^9Z&?!&@F.P0P79&GJRVN=0N,Q!A@@'?G&..>@X%
M:6C:-8:!I<6FZ;"T-I#GRXVE>3;DYP"Q)Q[9KR_7GO-,'C:QT.1+;2+>UA;8
MBG9#*V-Z1@$!"0<D#@>G->FZ#IEOI&BVUG;)&D:KN(B!";FY8J"3@9)P,G%-
M:J_]=1-6=OZZ?YFE1112&%%%% !7(6OPYT>UDC0/<R6,=PUU'8R2!H5D/?!&
M?PS77T4 ><^*_AL^LWELNE3IIMO#8W%N&B8@DRMD@_[)Y_.M_2O VD:7HC::
ML(;S;!+&>0<&1 "/P)W,?QKIZ* .=O?!>CW[W#30,?M'V<2 -P1"V4'T]:Y?
MQ9X*FOX)-+T2VFAENM3759=0:10D4G0X[YXXX[UZ510!YUH'P?T72E1[ZXN=
M1F$QN"97(4R$8+8ZD^^:ZK3_  II.E/;-96XA6V:1XT4\;G !)]>.!]:VZ*
M$ (ZG-+110 5YKK&F01_$Z^LYI/)C\3Z0ULLHZK)&,$ =SM.?PKTJO%?$^I7
MOB'XHZ5>VD 32/#FJ0VDUSG.^65E##Z#A?J?>@#T?PEX*TKP?8^181[I64+)
M._WGQ_+Z5O\ V>'S%D\F/>N=K;1D9ZXJ0=*R[;Q#IMWX@O-#AG#:A9QI+-'@
M_*K=.?R_,4 :F*XGXGZQ<:?X873]/G,>IZM.EE;;1EOF/S$>F%SSVR*ZG5]5
MM=$TFZU.^?9;6L9ED8=<#T]ZX31[NT\??$;^V[63S=*T*W$=LV.))Y1EFP?0
M #ZT =IX>T*T\.:'::59*!# FW/=V[L?<GFM2BJ][>0:=8SWERXC@@C:21S_
M  J!DF@#S[XS+LT30;P.RFVUJV8;1GJ3S7?:A?Q:;9/<S)*ZKP%AC+LQ[  5
MYMXZU*+QC\*;#7K2&:*W%Y!=>7(N7VK(5/3ZYKTN\>X73YI+*));D1DQ(YPK
M-C@$]J ..'CK5QJ]C93>$[Z-;QG:,^:F\HHY)4].J]373Z%K<&O64ES!%-%Y
M4SP21S+M974X((KR'2H?&NO?%^^DFO[2WN=)LQ [)$6A02*&PJD\G)SDGM7?
M^'"_A&&UT/5"\DEU<2&._P Y6XE<LY#=U8\\>W6@#LJ*XOQUJ%S_ &CX>T&S
MU"6REU2[*RO 0)/*12S;3VYQS3_![W2:[XAL3J%U?6%I+%'#+<OO82;,R*&[
MX...U '8T4A.!67K/B32/#\:OJ=ZEN&Q@$%CC.,X )Q[]* -6BD5@RAAR",B
MLK3?$5EJVL:GIUH6D?3F1)Y!]S>P)V ]R,<^F: -:BN9\6^+[;PC)IDMZ@^R
M7=QY$D@/,?&0V.X]:Z.*1)8DDC8.C ,K*<@@]Z 'T5@>++ZWTZP@GNM=;2(/
M-"M(B*S2G!P@R#]>!GBJ]YK-_IGBS2M.+Q7=MJ9<!=NV2 (F2Q(^\"?8<F@#
MIZ**Y[_A)UE\<GPU;VQE:*T^TW-P'XAR<(N,<D]?I0!T-%8'B[Q%_P (WHOV
MB&#[5?3R+;V=KG!FE8X"_3J3["JOA/5M<N[F^T_Q#!:1WUL(Y?\ 12=FUP2%
MY)Y&",T 6/&6M1>&/"6H:H !+%&P@&>LK<*/^^C5CPG!>6_A/2H]0FDFO!;(
M9GE)+%B,G.>_-<#\5I7UGQ9X2\))REU<_:K@8_@4XS^6_P#*MB;QYJ&M:I/I
M_@S3(]02W;RY]1G<K;H_HN.7Q[$?C0!W]%8VDP^(1M;5[W3G.>4M;=QG_@3/
M_2MF@ HHHH **** *6H:-I>K>7_:6FV=[Y>=GVF!9-N>N-P..@J"[TK0;BZM
MX[RPTV6X,31P+-"C/Y8&&501G;@\@<<UAZW]L'B?,_\ ;?V40Q&R&F;MIEWG
MS/,Q\G3;_K/EQG'-6[B3^T/&&C75K',\%NMY#-)Y3 (XV#!R.,D''KVS0NG]
M=QFM8Z%I&F3F>PTJQM)6789(+=(V*^F0.G X]JEGTVPNC&;BRMIO++%/,B5M
MI;[V,CC.3GUK,\5?:_L-M]G^V?9OM*_;/L6[SO)P<[=OS==N=OS8SBJWAV^D
MM89(;QKX0S7,G]G"[21IC"J _,6&X'._&_YB,4;[_P!?U_F+;^OZ_JQJ)IFB
M:5.EXEEI]G+M6W698DC;!("H&P.,X 'TJ"RTO0;.QCN8HK%H;=Y+A;DK'A&.
M=[A@ %[Y(QTK/U>_2^BM9=(FO7N)I+*8B+SE!MS,,G;T'&[=QG'WN,5S\>FZ
MMIVAPR67]K+<36]\LL0>0A#AVCVIT1LXP0 3GO0[H.J1W5XNDZE93QWHLKJT
MCP9EF".BX 8;@>!P0>?7-5[E_#JZ/MNFTL:9;N$Q*8_)C=3P.?E!![=JY76_
M._MNW_UGV7RK'^TLYQ_KOEW>_7/MUXK9U"QBTGQ!9ZF+"::Q59S(+>)IFBGD
M93YFQ<L<@,,@'&?0FG_7W?UH).YHV>D^';NR>2RT_2IK6Y<2LT,,;)*P.0Q(
M&&(/>C5=6T2WF%GJ;1LZ&*41R0EPI:39&W0C._IZ=>*K>'X7?5-7U!+26TL[
MMXS%'+&8VD8+AI"AY7/ P0#\O2FM8&?QW<2SVADM3IL(#O'E-ZRLP&3QN'!]
M1P:.J'W+36?A_P 3QK=3V%EJ"PN\*O<VH<HRL58#>,CY@?RJ0>&]"$OFC1=.
M$GF^=N%JF?,_O9Q][WZUQ=AX?EM1I]_!ILL6I-KER99_*(<0,TV-QQGRS\I]
M.0>]0^%M(U6WU2P:3=!J,:R?;91I,B^:2I_UL[2[9AN((V@GC^$9H7]?@#_K
M\3O3I^E0W<B#38!+>Y:9UM,B7;C_ %C!<9YXW'GM5V."*%G:.)$:1MSE5 W'
MID^IKCM9M=;CU6QN+B%=4>*TO>+&![8'*)M0L7<JQ(.#D>PXJCX1M9(/&+3V
M^DM86,NG8;R["6W0RAQ]\O@L^"?F(!//7K26H/34[,Z#H[7;W;:38FY=U=YC
M;IO9@<@EL9)!Z&GZ?/I[&YL[ 1H+27RYHXX]@1R Y'0 Y# Y'K7%^*DNX9/%
M<*:=?7#:EI\:6IM[9Y5=E5PP)4$*1D<'&>V:K77A^1AKNHC3)CJ*ZE:M:3"%
MO,"!8 QC.,X^\"1Z'/2G%70,]"CT^RB6W6.TMT%OGR L8'E9&#MXXX]*Q]9\
M-?V@D$=HVG00QL[F"YTY+B,NQSY@&5*OG)SG')R#6%96$4>O7S:CI&I3ZN][
M*\%];QL MN5^3][D+M XV$GYN=O>H_!5FVE:I*L6G3BU%I^]N9+"6UFWJW"R
M+DI.YR3O0=NIR*2UW_K^OS!Z'7:?H5E8Z!;:,\:W5K!&J8N$#;\'.2,8Z\UB
MQ3Z+J<&H^&?#_EZ?,F5NT&E2(D8;@]55=Q'0DG/7!%=8K!T5AG!&1D$'\CTK
MRRY:_%]\0)K2SUB*:[BB-C+%9W$;2.B;?D8*.=V._(YY&:&]7?\ K8:Z6/3!
M8VHT\6#01O:",1>2Z@J4QC:0>",4K65H_P!GWVL+?9SN@S&#Y1QC*_W>..*\
MQBN/%"66N1P+K<B;;*1/-CF\PH57[0(BP!#=?E!R#G !KOM(=+6UM+2/^U;B
M.4.Z3WJ,709R%<L PZX&X9XYJFM?Z\R%LOZ[%N]TK3M2*&_T^UNB@(7SX5?:
M",$#(XR*8=$TDJJG2[(JD)MU'V=,+$>J#C[OMTJAXTL9M1\'ZI;V[7/FFVD*
MI;_>E.TX3H203C@<GI6=>Z/)<^(O#\LJ74MM]EFAGB(/E1@Q <X'!/3)/TJ?
MZ_!E/37^NAO0^']%MK.:S@TBPBM9_P#6PI;(J2?[R@8/XU+-=6.DI9V[E+=)
MI!;V\:(=N[!(4 # X4^W%8%OHK:?X\LY;=;HV2:5) @8EHH</$%0''!(!/))
M/X<6O%%M/<7&@&&&241:HDDA12VQ?+D&XXZ#)'/O0]KK^MP7]?=<OQPZ/K]D
MM[]EMKRWNX0N^6 'S(\Y (89QGG![TZ+0M'AL'L(M*L8[*0[GMUMT$;'U*XP
M:X#2]!ET;3-*N;30[@W4FCW0O8XPT,DTF$*([C!#?>"YY'.*T/ ]K);^)]2E
MATLV&G36<)C1+"6UC,@9PQ(?!9^F6(!(QUQDNVMAR5CL&T+2'TY=.?2K%K%3
MN%L;=#&#Z[<8JW!!%;01P01)%#&H5(XU"JH'0 #H*DHI""BBB@ HHHH *B-U
M;AF4SQ H0&&\?*3TS1<3+;6TL[_=C0N?H!FO&/"/AR^\6?#C4S)9VXE\0:C+
M<O=R-@Q(&4J0,9."'P,CK0![9D>M&1ZU\_V'B7Q)::!H>H7NJS:E:#5C;K:>
M2NZ:&$$[BV,D_+GGT%7[3QKXKD72]1N[X_9]0L=2N_LJPJ!%'&I,9R!G(('Y
M^] 'N&X$9R,5%'=VTT*S17$3Q,<!U<%2<XQGZUYCI8F\(_L^M,99'N&L&E1C
MG<&F/R?EO%<F-*O- U+1_AP!++;S7\.K)=,<;(E&Z1,?[RL?_P!= 'T!FC->
M/Z1X_P!7O?$L6H_:&DT:[M+Z>.U^SA1&D!^1@W5B<<\]ZK0>(/&;K!)=:Z(E
M?P[+JLX6U3]UDGRP..30![3FBOGJX^(WCNYM I=+*ZLQ:@1);;C=O(?XB>@(
MYP,5Z7XQ\=SZ+]GT;2+/[=XEO$'EVR\K#G^-_;/;O0!#\3?&LN@Z<-(T;]]X
M@OU*P1QG+0J>LA'\O?Z5QE]HWB#3O@;=6$NFPV0@5;F>9IR9I6$H<MC'!X'4
M]J[_ ,$>"!H'FZKJTPOO$5[\]U=MSM)_@3T Z?AZ5?\ B  WP[\1*.IT^?\
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M\2M?U6[C673M'_XEME'(-R>9UE?!XSD8^A%7O!MQ+I_C7Q+X764RV5GY5S;
MG_4K("3&/8=JI^%+'5_!O@_3M.L](-_J=^TMS/(9 D<;L0<R,>>A'Y&M[P7X
M5?P]%?7=]="]U?49?.O+D# )[*OHHZ"@#CO%>K7EU\:-+TNRTR/4GL;!I8XY
MGVQQ2N?]8W!SA0/SKOM$T 6%Q/J5],MUJUS_ *ZXQ@(O:.,'[J#]>IK-\.>&
M7MO%GB#Q%?1*+J\G$5N>I6!  /IN(S^%;5[X?LM2F+WPFN(R,"%Y6$8_X",
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M'SF75O$;FTOH$N+X3Q-<V<L(=/+1<C>H[J>.M=;3[!U84444@"BBB@ HHHH
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M% "8&<XY]:6BB@!"BL02 2#D>U(Z*X =0P!!P?4'(IU% "%%((*@@]:-HSG
MSZTM% "8%(B+&NU%"CT IU% "  =!2T44 %%%% !2%02"0"1TI:* &B*,%<(
MHV]..E.HHH **** "BBB@ HHHH **** "F211S+ME177(.&&1D'(/YT^B@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M62^:5KS5)AB2Y=0.O)"CMDUV5%% !1110 4444 %%%% !1110 4444 %%%%
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MT_488='\)_VM:L@+W']HQP;&R01M89/&#GWKHQTY&*;=]1)6T"BBBD,****
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MY0,#A1U[ I:V\[?\$;Z_,[&B@<"B@ HHHH *BGN;>U56N)XH59@JF1PH)/
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MU<0I;?.JKA5!<DYW,V> I 6NMKDO"H;4_$7B'7F.8WN!86W/'EPY!(^LC/\
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M))J>BBD 4444 %%%% !1110 44A(%&0: %HHHH **** "BBB@ HHHH ****
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M:PL]%71X(-E@L1A$6]C\A&",DY[^M7J*'KN!332K&-[-H[=5^Q(8[<+D+&"
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MXA'!$NU5')^I/4GW-6JMVN[$J]M0HHHJ1A1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% #)(HYMOF1H^U@R[E!P1
MT(]Z?110 4444 %%%% !1110 4444 %0QVT<<SS8+3/PSMUQV'L!Z?UJ:B@
MHHHH *9+%'/&8YHTDC;JKJ"#^!I]% !3)88IU"RQI(H(8!U!&0<@_4&GT4 %
M%%% !1110 5!>6S7=LT*W,]ON(S) 0&QGD D'&>GKSP0>:GHH H:3HUAHELT
M%A;B-7<R2.6+/*YZL[')9CZDU?HHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **Y7X@>(-2\+^&)-6T[[(S0R(KQW,3
M.&#,!P5=<8SGO4NFWNLZIIT]Q8ZUH=\"NV&6&TD$:R#!(.)FW#!QD$8/KTHZ
M-]@[>9TM%>?^'O%7B+Q!$]B#IUKK=I=-'?PR6<ACAC'0C][R3VYY]!C-+!XS
MU&W\;:IHNIW6F""T$8@$=NR2W$D@RB+NE(R._K[=@#OZ*X3Q3KOBOPOX3EUB
M>?1YIXY$4PK92 89@.OG=1G/^<UT#R:XLVGHMYIQ\R-C,#9N-S@9&T^;\HZ=
M=U']?J!MT5P9USQ4/'"^&?MFC;C8?;/M']GRXSNV[=OG_KG\*@D\7:U;^-+C
MP_>ZKH-EL@CECEEM)"9'<@>6H\X9//;KZ"CMY@]#T.BN4U?Q)J&G:CHV@0QV
MLVM:B&+2E6$$2J,L^W.X^RY_&G6?B2[M?&"^&=9^S/<3V_VFVNK:-HTD )!4
MHS,01@G[QS[4+7^NP/0ZFBD)PI(!..P[UQ-E\4-(O!:,UAJ=O%<Z@=-$LT<>
MU)Q_"VUR<'U&1ZXH6KL@>BN=O1110 45R_BOQ]HO@Z\TZUU3[29+]RL?DQ[@
MH! +-R.,D=,GVKJ.M'2X=;!117GL?B3Q;<^+_$.BVLFC.-)BCFC#VDJF<.-P
M0MYI"G'&[!]<=J5QV/0J*\NU3XG7LG@S1/$FDFPMHKR\6SNHKZ)I/(8D@MN#
MH,+@GD<@CD5T4VL:S'X1U/6K;5]$U!(8&FMI[>SD$;[-V]2/..X'& P;\#3>
MB;?0$KM)=?\ ACKZ*XCP1XEU7Q396E\=7T*<-$LEW:6MJXDMRP.%+^<PSD="
MH./2LNV\7>+99O%&#HTZ^'Y,-$MK)$URNTL<,96"' [AJ'H[,2UV/2Z*S/#N
MN6WB3P_9:Q:!EANHPX5NJGH0?H0163X\\17WAC1K6_L5MF+WL4$JSQLV4<X.
M-K#!'X_2FU9V8D[JZ.IHKGKGQQX?L[">]GO)DAMYQ;SC[),7BD/0,@3<N>,$
MC!R,=16M:ZE;7EU<6T/G>9;[?,WP.B_,,C#, &XZX)QWQ2&6Z*R?$VJ3Z+X;
MOM1MEC::"/<JR E2<@<X(J+7=8N-+N]$B@2)EO[];:7>"2%*.V5P1SE1US0M
M0-NBN8AU37=:^UW.C'3H;2VGD@1;J%Y'N6C.UN5=1&-P8 X?UQVJ:RUV_G\3
M6VEW5DEJ)-,^URQ,P=XY-X4KN4[2.:%_7Y@]#H:**S=>U&;2=(FU"*-94ML2
M3(0<F('Y]ON!D_A0!I44U'62-70AE8 @CN*=0 445SW]OZE>7=XFDZ5!<0V4
MY@G-Q>&&0L "=B>6P/!XW,N?IS0!T-%8J>([;?&;@+:)]B%W.MT2DL )PH9=
MN.NX?>SD< ]0ZW\4Z/<SB!;F1)O*>8Q36\D3JB8RS*Z@J.1@GKVS0] -BBLJ
MQ\2:5J,B);7#G?#YZ/)!)&CQ\9*LR@-C(R <C/.*CM_%6CW4XABGF+.I:)FM
M9568 9/E,5 DX&?D)H>@&S16#HWBW3]9L+:\1;B!+NX:"V6:"1#*0"0P!49!
M52V>GOG(JQ<^)M'LYY(9[T))'.MLPV,?WK)O5!@<DKSQ[>M &M16+/XKTBV*
M"66Y5F02,OV.8F%3T,H"?NA_O[:V$=9$5T8,C#*L#D$>M #J*** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@#E?B!H&I>)_#+Z3IOV17ED1GDN960*%8-P%5LYQCM5B
M/_A*D1RFGZ+$1'PHO9&$DG !8^2, #/0$G &16%\9;6"X^&U_)+!%+)#)$T3
M.H)0F102#VR"1QV-8-A"^@?$V.'^SK/09KS3)!:0:</-M;EU!8M+@1G*^FT?
M[U"V?]=+_D-K9_UNO\S>G\*>(8/$.G^(M+.GIJ9C9-46:[D,=R"> ,1=NQP,
M8 P<9JI>> =4UC7]>O=3M-,:WU.%%B$=Y)YEO)&OR,K&'N0,^@/?H6Z!X^UG
M5KWP=%=0Z?Y&NP7+7"1PN&1HMWW27(P>."#WYYXN?"2*.'0M:BB18XTUJZ5$
M48"@$  #L*KEZ=K_ )I?\,3S;>=OR;_0EN?"_B/7_ D_A_Q!<V'VH*GE7MO*
M[^8RL"-ZE%QT )!.<]*Z738=5D:&758K*%X4*!+69I0Y('S99%V]#Q@]>M<#
M<?$/Q%:V.KW31:7(-.UM=-VB&1?-0D#/WSM(R#WSZ"I]5\4:_+X<\=64T]G%
M?:-& EW:P.@='CW<*9"5;K@[CCK@XJ7+1R^?X+]&AVLU%^GX_P# -QM UL_$
MM?$8BT_[$+3['L^U/YFW=NWX\O&?]G/XU = \10^/-1U^*STB>WN;=;98);V
M16PI!#']R1GCISCUKG-%;4-&UCP=I6E2V-I'J]JU]>[+9RLKK$O\/F<9!'0C
MYAN(/2NL\)^(/$^K>(-;M-:T'^S[*TEVVD^UAYHR1U)P_&#E< =*IQL[=K_G
M9D\W,K][?\ 74?#6J7][H^O>;:1Z[IQDS&&8P2H^08]V-PP",-M]>#4UEX<O
M+GQ>OB;5VMX[B&V^S6]K;2-(D8))+%V522<_W1CWK,^,<:2?"[5RZ*Q3RF4D
M9VGS%Y'OR:I1>)M4L_&%S;O<1?V3IF@)>O (26DR.?FW<-\HY(/&1CG-2GOY
M7_*[+:V\_P#-)?F>CG.TX )QP":\CB^&_B=-+LK8G2-]OKYU=C]KEP5Z[!^Z
MZ]>:L:3<W6I_$CPKK-[%9)-J&D3SC[-$4(0[2J,226*@]>.IX%>JTTG%WZ_Y
M/_,FZ>G]:H**BN+>"[MY+>YACF@E4K)%(H97!Z@@\$5P'PIM+9O#>NV9MXC:
MG6+N+R"@V;,@;=O3&.,4EK?^NM@;M;^NAW5WIMA?O ]Y96UP\#[X6FB5S&WJ
MN1P?<5:KS;X9V$!L?&6GQ1K!;G6KF%4B&P(NU1A0.F!Z56U+P_-HT_A73M3M
MIM1\-6=C);W>R%ID6;:-LCH,G:,<'&%Z\4/3\']ZN4UJUV_K]3U*O/H/#?BN
MU\8^(-:@BT95U6*.%-UY*Q@"#:'*^4 Q[[<CTSWK1^%\NH3> -/DU&6:5V+^
M3)-]]H=Q\LG_ (#C\,5DW)U&VUSQSJ%AJ26K6BP3A/*5_,*09P^[/R$<?+@^
M_:B22>O9_I_F$;M67=?G_P  K:C\-M1M?"&A:!H;V4OV"]2^GN+R9XC)(I)(
M"JC<'/KQ@=:Z/4K+Q/JFAZK8M8Z-:_:;9X8HX[V1U+/D,[-Y((P#D  Y).2.
MM9C>*=466[TV2;9?Z@MM-I9*+E$FPK#&,-Y9#,<YX(S78ZO>+IVBWEW)=I:K
M#"SFXDC,@CP/O%006^@ZTY+1W_KI^EA0>J:_K6_ZW.;\*Z5XGT32-*TF>TT9
M8K2-89KN&\D>21%S@!#" ,GU;C)K(M/"/BR*?Q3D:/ OB!\M*MU)*UL"I4X4
MQ*'//JOXUI:#K&J?\)HNE7-WJ%S9SZ<;I6O[:*%U<.H^4(%.W#=&&?<\UJ^(
M;R^.KZ/H]E=O9?;FE:6ZCC1W58U!VJ'!7))')!X!XHEJ[OK_ $_R_JXHZ;=+
M/_+\R_X=T.V\-^'[+1[0LT-K&$#-U8]23]22:H>,_#D_B?1X+*">.!H[N*X+
M2 D'8<XX]3@?YQ7)^&;W4--U6TT_[:LRW6OWZ73K&O[T+&6';Y3D#IBK<7B/
M6+VYBTU+\PO=Z[=V8NEC0M%#$K,%4%2I;Y<98'OUHUDT^KU_+^OD"22:_KK_
M %\R>30K.PM_$-]XIFMX#XBDCMY(H7>2*+Y-B*&*J22><E1R0.U=/X<L9]-\
M/V-I>3F>\2%1-*1@NP &?Y#\*YV6Y\3/JVG^'9=5BMKLV=Q<R7MO$C&78ZK&
M-KKM&0P+ #V!%96J7NKZ'KNIZO<W8>^MO#\<CVZ!3;^9O93@E0^T-\W4'GTP
M >7]:?\ !':_]=[?H=UK^E?VYH%[IGG&$W,119 N=A[''?G'%91TK6]6U+2Y
M=8CT^"#39_M"FUG>5IWV,@R&1=@^8G&6],USWB?6]?\ "UK<0IK)O99],FNH
MYI8(@T$D;1CY0J@%#OZ,"1CJ:[W3;>XMK)$NKZ:]E/S-+*J*>>P"*HP.W&?<
MT)6U_J^HG_7H84&E:_HC7EMHXTZ>SN;B2XC:ZE>-[9I#N8;51A(-Q8CE.N,]
MZKG1/$-AKMEJ5J]GJCQZ;]CG>\N6MV=]X8N-D3C''3BI+V[U74O$NIZ=9ZH=
M-BTZUBF4QQ1N97?>?GW@_(-N,+@]>17/^'R_B7QYI.MWLA+_ -A17<<!CC:.
M)V8JVPE-R@]<@Y[9QQ273^NC_P ARV?]:Z?YGHMHUT]K&U[###<$?/'#*9$'
MT8JI/Y"LSQ9*R^&+^&)/,N+J(VT$>,[GD&T#]<GV!K:KG?&SM9^'7U6)BL^F
MR)=1D=2 <,O_  )2R_C0TGHQIM:HV[&V^QV%M:[MWDQ+'D]\ "IZ0'*@^HI:
M;=W=DI)*R ]..M<;>0:M>121R^'9(]9>$Q#5+.YCABR,[3NW^;MSSM*-UQR,
MUV5%(JYP.IZ3J'VZ>^NQ%+<M>V8M[=IT0WJ0IO(0$X#%VD8*2/N#.!S5:[M]
M1\4ZUK3Q:=]G(@M],;?*A>.-WWS[BI*Y"$# )KO[VPL]2M6M;^T@NK=OO13Q
MAT/U!XIUI9VMA;);6=M#;6Z#"10H$5?H!P*:8O0YC5])UFXU6ZNM.6*W-EIQ
M@TPL5VF5S\[8YQA511D=SVK)NM(UW4=5L;V+3=0@^R6=UL-_?HY-PR;8R41V
M0#YF^8<^N._H=%2]5;^NO^8T[?UZ?Y'%66FZC:W'AEAH]P;6PL6A$/F0@PS$
M*NY_GQC:&&4+'YCQ3M*T+46U'2;O4K0*_FW.H71\Q6$<[X2-.#\VU"1G&/EK
MLZ*OFUO_ %W_ *^1*6ECCC9ZU8_VW8VVE_:9=2N))8[]I4$*!U"@2 MORH&,
M*I! '([;VG0MI&CPV$-I<RI8Q1P1G<F9@% R,M^>['3O6G14K:W]:#>]PHHH
MH **** "BBB@ HHHH ****  G )QGVJO'<2OY&ZRG3S 2^XI^ZQV;#'K_LYJ
MQ10!'!(\T*N\$D#'K'(5+#Z[21^M2444 %%%% !1110 4444 %1F1Q,4\F0J
M%W>9E<$_W>N<_ACWJ2B@"%9I&$.;69?,^\"4_=_[WS?RS2&>38S?9)B0^T+E
M,D?WA\V,?K[5/10!%YK[Y%\B3"#*ME</[#G/YXI%GD)A!M9E\P$L24_=^S?-
M_+-344 1PR/*K%X)(2&( <J21Z\$\'\ZDHHH **** "BBB@ HHHH Y_Q?:>'
MK[2X;7Q*Y%G-.D:1BXDC\V0GY5Q&06YYP<@8SVJ:P\)Z-IU^;^&UDEO"GE_:
M+JXDN)%3^Z&D9B!["J7CW_D7(O\ L(6G_H]*R$\;ZE)XWUS0YHK/3K*P@$D=
M_=(Q1#E?F?+*"IR<8(Z=30O\_P D#_K[S9M? /AJQNK*YM;"2*6R:1K8K=S8
MBW_>"C?@*>?EZ<GCFGV?@;P[8+$MO92 17?VU-]U,^)R,%_F<Y)SSV-5M,\0
M&[U&& >,/#-Z7)'V>TAQ*_'13]H;_P!!-=%I_P!N^P0_VE]G^V;?WOV;=Y>?
M]G=SCZT]1'/2_#GPQ-%<QR6=TR7-P+J9?[0N,/*.CG]YUY_0>@J>3P)X?F&I
MB2VNF_M3'VW-_<?OL=,_/^'';CIQ6KK5]-IFB7M];VS74UO"TB0KU<@9 KFO
MAOXOU+QCH<][J6GI;/'+L22($1RCV!)/'0\TEK=+H-]V;*>$]%C.EL+1R^EJ
MRV;M/(S1J1@J26RPQQALBMJBBG<5C/UO0]/\1:7)INJ0-/9R$%XUE>/=@Y&2
MI!QGM4$7AC1X;Z.]6SS<I;"T\QY78M$.BMDG?]6R?>M>BD,YN+P)X>MI89K:
MR>.:WBDA@)NIF6-'&&3;OQL_V>@[8K3T'1K;P]HMMI=H7\BW!";F+8R2<#))
MP,\#)P*T:P]6\2PZ+J9AOD2.S%C)=M<^9R-C*"NW'?>,'/7C%%PM<U[FW2ZM
MI()&D5)%*L8I6C8#V92"#[@@UCZ3X0T;0H+N#38KN".[W&8?;IVRQZL"7.UC
M_>&#[U=@US2[F2&*#4+26>>+SHH4G0O(F.H&>1[]*CTK4KJ]N;VWN[)+=[9U
M :.?S5<,,]=HPP[CG&1R<T6"Y#H?A/1_#D]Q-I<-Q$]RQ>;S+R:4.QZL0[D;
MCC[W7WJU?:+I^ISI+?0&X"+M$4DC&(\YR8\["?<C--U?4+RPC1K/37OB5<E5
M?;@@9 Z'J>*L:?<SW=J9;FU-K()9$\LMNRJN5#=!U !_&C?Y 6@   !@#H!6
M'=^#]#OK^XO;FS9Y[DK]HQ<2*DP484.@;:R@#H01[5N44>8&#<:&U]XOLM5N
M;>V6'389%M75R9&:0 -D;0%  (&"<Y[5KWEG;:A936=W"LUO,A22-QPP/:IZ
MXNP^)NC:AJT5@+/58!+<O:+=36N(#,I(V;P2,G&1^N*-_=#;4V]/\*Z1I>H+
MJ%M!-]L6$P">:ZEF<QD@[278DC(&,].V*MZGI%CK$,<=[$S>4_F1O'(T<D;8
MQE70AE."1P1P:R?#/C2R\57-U%8V&I1);,R-/<0!8F96*E58$@GC/T(J.Q\=
MV&H^(YM'M-.U>5896@DOTLF-JLB]4,@Z$>I&/>C>P;7+2^#-!CT];&.S>.%;
MAKI3'<RK(DIZNL@;>"<GH>YIZ^$=#33C8QV1C@^T&Y'ES2*Z2GJZN&W*WN".
MI]:S++XBZ-?:K+8QP:@@ D\BZEMRL%T8P2XB<GYB,'TJ/0/B7HGB&]M[:&VU
M*U^T6[7$$MY;>7'*J_?"MD@E>^./<T?U_7W ]/Z_KN:S^#]#>S@M1:/&D!<Q
MR0W$L<H+_?S(K!SN[Y)SWS4O_"+Z*'A9;!%$5L;18U9EC:$_P,@.UQR?O XS
M61I7Q'T+59+@;+ZSBB@>ZCGO+8Q1W$*_>DC/\2C(]#4_ASQSIGB6]>S@M=1L
MYQ'YT27UL8?M$6<>9'D_,O(]^>E/<+EE?!F@BUN;9K-Y([F+R9/.N99&\O.=
MBLS$HN?X5(%;H   '05C7OBO1["\DM)[E_.C(5MEO(ZAR,A"ZJ5#D8PN=QR,
M#FH/!VOS^(="@O[E=LEPOFJBVDL*HA/"[GR'(_O# /4 "A:@U8N:GX;TK5[@
M3WENYEV>6SQ3R1%TSG8^QAO7_9;(]JGAT>PMK];Z"V6.X6W6U5E) $0.0H7H
M #[5>HI %96O:7)K-I#9;U2U:='N>>613NVCCN0 ?8FM6JFJ37-MI=S/9QI)
M<11ETC?.'(YV_CTS1>VHTKZ%NBJVG7T&J:;:W]LVZ"YB66,_[+#(_G5FFU9V
M9*=U<***\I@NIM:TN_NK23Q(VNW-U.;%HVO$M8U$A$1).("@ !/7/(Y/%):N
MP^ESU:BN&&O:S?(C/]D2TGU7[! JK(LDBH_SR;PZXXCDXQSQGC(,1\7ZVEA;
MZA,-/CM;Q+MX56%V=(XU=TE8[P""%4%0!]X'<.E#T5QI:V.^HKC'FU:R^%ZF
M]OR^JW%ND:W$8*,))B%7JQ.07'((Z< =*IVVL7,"Z?IES?LD^E75P+V:><KY
MD4,1*M(WH1)"23GG--JS:["6J374[^BO/W\;:G:-J*2_8KUXM,>^A-O:S1(K
M[@JQ[G)\T$G[R[?NG@9IUWXE\4V3:F)8]*;^SK>&YEV0R'<SY_<+\_WN/O\
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MSE8_G!SA3A>@[8P>.2:LT4 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MN"-@)YQE"1Z9QVH VZ*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MU#;@))+$JE5' 7(Y/XDT 8&J_$O^R[J_D;P_J$ND6$YMY]1C9=HD! ("D@D
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **1V5$+L0JJ,DDX %4M,UBPUFS^UZ=<I<6^XIO3ID=10
M!>HI@E0H6# J.X-$<T<J[HW5U]5.10 ^BBD+ 4 +12 YI: "H;JZM[*W>XN[
MB*W@09>65PBJ/<G@5-69KFDV>K6&R\T]+\0'SHK:1L))( <!AT(Y_B!'>DQH
MO6UU;WMNEQ:3Q3P.,I)$X96'L1P:EKS+P];M%HNLP_;3X4O;;4/M4EN-A@M0
MR#:O7:\9 ).,<^F*ZGPGX@O-<AN!<V\;QPD"._MU98+H>J!P&X]LKZ,:JW8D
MZ2J']N:1]N>Q_M6Q^UH"6@^T)YB@<G*YR*QOB+JMUHW@34[RS=DG"+&LB]4W
M,%+#Z U%K-MHV@> &MYM*FO-)C@Q,MLL98+CF0[V&3GG(R<G-+S*MLNYOQ:Q
MI\^KS:5%=QO?01B26%>2BG&,]AU'%7JX*/5[:U\=76K7JRVEM'X?CFD$H#/&
MOFL>0A;)^F:DN_'Z:@FES>%Y+2]MKN_%C--.LJ&-RN[A2HSQDYSZ#Z.VW]=6
MOT)OU_K9,Z?_ (2'1/[0_L_^V-/^V[_+^S?:4\S=Z;<YS[5I5Q6E"\_X67(=
M1^S_ &S^PXO--OGR]WG-]W/./K6YK&J7,&HZ?I5AY"WE[YC"2="Z1H@!+%00
M6.2HQD=<]J71>?\ P?\ (?5_UV_S-FBN%D\;7L$#0WHM+&XMK\V=Y>21.]NG
MR;E? 8%0^0.6^4GG/>[%KFM)XATRWO9-,33[^UDE1HHV<B1 #M#[]I!!W XZ
M CWH_K\+@=;52'5-/N;Z:Q@O[66[A&98$F5I(_\ >4'(Z]ZY:VUWQ'?&2RM/
M[,?4+>T2[E+P.J.)"WEQA?,RIPN2Q) R.#57Q+INIW>M6&LZ;&+?7+*Q\[R-
MP(E&X;X6(ZC!(!]>:-M_Z_JP>AV"ZUI3ZD=-34[-K]>MJ)U,HXS]S.>G/2KU
M<'#XOL9C>>);>,NB:2A,).'602./+;T.[BIM6U[7M-DFTZZDLEGNK":YM+J"
M!L1O&,LC*7.3@\-D?[M)NRO_ %U_1#6KM_73]6=)>^(=%TRY%M?ZQI]I.0&\
MJ>Y2-L'H<$YK2SD9%>::;]J>7X<27DT<TC1RLK)&5PIML@'+')]3QGT%>EU;
MC;3S?X$WN%%%%2,***X1K74_$OC/7K9=9O['2K18(,6DNQFDV[V"MSM^\,D#
M)X&11UL'2YW=%>?6&LW^G>%+W3TN);G5QJ<^G61GD:1RQ8E"Q;)(5#NY[+6G
M!XR\-Z%>6WABZUJ:;5(O+@82QRR/)(P&,OM().1WXS36NW]=0V.NHKS'Q6=0
M@\3W$^LZOK^EZ3E!8WFF2 6T7 SYZ@$_>[GC'I7HU@LR:?;K<72W4PC4/.J;
M!*<?>QDXSUZTEJK@]'8L445Q/Q(L&U.VT"S2XDMI)=6C"31GYHV"2%6'T(%
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MH4D0]P:YE_"&IOH3^'WU\2Z0\?D?O;/-R(\8VB0.%_$H:Z^B@#G;;PW=VWC
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M:SIVI0S+:R".5S\JAB<#!.,Y/'%/MO%_AZ\2[:VUFSF%HA>?9*#Y:CJ3[<4
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
4% !1110 4444 %%%% !1110!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>27
<FILENAME>qlgn-20221231.xsd
<DESCRIPTION>INLINE XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.18a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: 96Mps7xRiXgen8uDanwsWa2D2bP9z5Z86ekhvWBwbcnqfykq2NPHNidrg4Y2MVkC -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:us-gaap="http://fasb.org/srt-sup/2022q3" xmlns:srt="http://fasb.org/srt/2022" xmlns:srt-types="http://fasb.org/srt-types/2022" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:QLGN="http://qualigeninc.com/20221231" elementFormDefault="qualified" targetNamespace="http://qualigeninc.com/20221231">
    <annotation>
      <appinfo>
	<link:roleType roleURI="http://qualigeninc.com/role/Cover" id="Cover">
	  <link:definition>00000001 - Document - Cover</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://qualigeninc.com/role/BalanceSheets" id="BalanceSheets">
	  <link:definition>00000002 - Statement - Consolidated Balance Sheets</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://qualigeninc.com/role/BalanceSheetsParenthetical" id="BalanceSheetsParenthetical">
	  <link:definition>00000003 - Statement - Consolidated Balance Sheets (Parenthetical)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://qualigeninc.com/role/StatementsOfOperationsAndComprehensiveLoss" id="StatementsOfOperationsAndComprehensiveLoss">
	  <link:definition>00000004 - Statement - Consolidated Statements of Operations and Comprehensive Loss</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://qualigeninc.com/role/StatementsOfChangesInStockholdersEquity" id="StatementsOfChangesInStockholdersEquity">
	  <link:definition>00000005 - Statement - Consolidated Statements of Changes in Stockholders' Equity</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://qualigeninc.com/role/StatementsOfCashFlows" id="StatementsOfCashFlows">
	  <link:definition>00000006 - Statement - Consolidated Statements of Cash Flows</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://qualigeninc.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesAndEstimates" id="OrganizationAndSummaryOfSignificantAccountingPoliciesAndEstimates">
	  <link:definition>00000007 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND ESTIMATES</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://qualigeninc.com/role/LiquidityAndGoingConcern" id="LiquidityAndGoingConcern">
	  <link:definition>00000008 - Disclosure - LIQUIDITY AND GOING CONCERN</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://qualigeninc.com/role/Acquisition" id="Acquisition">
	  <link:definition>00000009 - Disclosure - ACQUISITION</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://qualigeninc.com/role/InventoryNet" id="InventoryNet">
	  <link:definition>00000010 - Disclosure - INVENTORY, NET</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://qualigeninc.com/role/PrepaidExpensesAndOtherCurrentAssets" id="PrepaidExpensesAndOtherCurrentAssets">
	  <link:definition>00000011 - Disclosure - PREPAID EXPENSES AND OTHER CURRENT ASSETS</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://qualigeninc.com/role/PropertyAndEquipmentNet" id="PropertyAndEquipmentNet">
	  <link:definition>00000012 - Disclosure - PROPERTY AND EQUIPMENT, NET</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://qualigeninc.com/role/GoodwillIprdAndOtherIntangibles" id="GoodwillIprdAndOtherIntangibles">
	  <link:definition>00000013 - Disclosure - GOODWILL, IPR&amp;D AND OTHER INTANGIBLES</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://qualigeninc.com/role/AccruedExpensesAndOtherCurrentLiabilities" id="AccruedExpensesAndOtherCurrentLiabilities">
	  <link:definition>00000014 - Disclosure - ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://qualigeninc.com/role/ShortTermDebt-RelatedParty" id="ShortTermDebt-RelatedParty">
	  <link:definition>00000015 - Disclosure - SHORT TERM DEBT - RELATED PARTY</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://qualigeninc.com/role/WarrantLiabilities" id="WarrantLiabilities">
	  <link:definition>00000016 - Disclosure - WARRANT LIABILITIES</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://qualigeninc.com/role/ConvertibleDebt-RelatedParty" id="ConvertibleDebt-RelatedParty">
	  <link:definition>00000017 - Disclosure - CONVERTIBLE DEBT - RELATED PARTY</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://qualigeninc.com/role/EarningsLossPerShare" id="EarningsLossPerShare">
	  <link:definition>00000018 - Disclosure - EARNINGS (LOSS) PER SHARE</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://qualigeninc.com/role/CommitmentsAndContingencies" id="CommitmentsAndContingencies">
	  <link:definition>00000019 - Disclosure - COMMITMENTS AND CONTINGENCIES</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://qualigeninc.com/role/ResearchAndLicenseAgreements" id="ResearchAndLicenseAgreements">
	  <link:definition>00000020 - Disclosure - RESEARCH AND LICENSE AGREEMENTS</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://qualigeninc.com/role/StockholdersEquity" id="StockholdersEquity">
	  <link:definition>00000021 - Disclosure - STOCKHOLDERS&#8217; EQUITY</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://qualigeninc.com/role/RelatedPartyTransactions" id="RelatedPartyTransactions">
	  <link:definition>00000022 - Disclosure - RELATED PARTY TRANSACTIONS</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://qualigeninc.com/role/IncomeTaxes" id="IncomeTaxes">
	  <link:definition>00000023 - Disclosure - INCOME TAXES</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://qualigeninc.com/role/SubsequentEvents" id="SubsequentEvents">
	  <link:definition>00000024 - Disclosure - SUBSEQUENT EVENTS</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://qualigeninc.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesAndEstimatesPolicies" id="OrganizationAndSummaryOfSignificantAccountingPoliciesAndEstimatesPolicies">
	  <link:definition>00000025 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND ESTIMATES (Policies)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://qualigeninc.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesAndEstimatesTables" id="OrganizationAndSummaryOfSignificantAccountingPoliciesAndEstimatesTables">
	  <link:definition>00000026 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND ESTIMATES (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://qualigeninc.com/role/AcquisitionTables" id="AcquisitionTables">
	  <link:definition>00000027 - Disclosure - ACQUISITION (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://qualigeninc.com/role/InventoryNetTables" id="InventoryNetTables">
	  <link:definition>00000028 - Disclosure - INVENTORY, NET (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://qualigeninc.com/role/PrepaidExpensesAndOtherCurrentAssetsTables" id="PrepaidExpensesAndOtherCurrentAssetsTables">
	  <link:definition>00000029 - Disclosure - PREPAID EXPENSES AND OTHER CURRENT ASSETS (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://qualigeninc.com/role/PropertyAndEquipmentNetTables" id="PropertyAndEquipmentNetTables">
	  <link:definition>00000030 - Disclosure - PROPERTY AND EQUIPMENT, NET (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://qualigeninc.com/role/GoodwillIprdAndOtherIntangiblesTables" id="GoodwillIprdAndOtherIntangiblesTables">
	  <link:definition>00000031 - Disclosure - GOODWILL, IPR&amp;D AND OTHER INTANGIBLES (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://qualigeninc.com/role/AccruedExpensesAndOtherCurrentLiabilitiesTables" id="AccruedExpensesAndOtherCurrentLiabilitiesTables">
	  <link:definition>00000032 - Disclosure - ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://qualigeninc.com/role/WarrantLiabilitiesTables" id="WarrantLiabilitiesTables">
	  <link:definition>00000033 - Disclosure - WARRANT LIABILITIES (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://qualigeninc.com/role/ConvertibleDebt-RelatedPartyTables" id="ConvertibleDebt-RelatedPartyTables">
	  <link:definition>00000034 - Disclosure - CONVERTIBLE DEBT - RELATED PARTY (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://qualigeninc.com/role/EarningsLossPerShareTables" id="EarningsLossPerShareTables">
	  <link:definition>00000035 - Disclosure - EARNINGS (LOSS) PER SHARE (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://qualigeninc.com/role/CommitmentsAndContingenciesTables" id="CommitmentsAndContingenciesTables">
	  <link:definition>00000036 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://qualigeninc.com/role/StockholdersEquityTables" id="StockholdersEquityTables">
	  <link:definition>00000037 - Disclosure - STOCKHOLDERS&#8217; EQUITY (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://qualigeninc.com/role/IncomeTaxesTables" id="IncomeTaxesTables">
	  <link:definition>00000038 - Disclosure - INCOME TAXES (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://qualigeninc.com/role/ScheduleOfAccountsReceivableDetails" id="ScheduleOfAccountsReceivableDetails">
	  <link:definition>00000039 - Disclosure - SCHEDULE OF ACCOUNTS RECEIVABLE (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://qualigeninc.com/role/ScheduleOfUsefulLivesOfPropertyAndEquipmentDetails" id="ScheduleOfUsefulLivesOfPropertyAndEquipmentDetails">
	  <link:definition>00000040 - Disclosure - SCHEDULE OF USEFUL LIVES OF PROPERTY AND EQUIPMENT (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://qualigeninc.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesAndEstimatesDetailsNarrative" id="OrganizationAndSummaryOfSignificantAccountingPoliciesAndEstimatesDetailsNarrative">
	  <link:definition>00000041 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND ESTIMATES (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://qualigeninc.com/role/LiquidityAndGoingConcernDetailsNarrative" id="LiquidityAndGoingConcernDetailsNarrative">
	  <link:definition>00000042 - Disclosure - LIQUIDITY AND GOING CONCERN (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://qualigeninc.com/role/ScheduleOfConsiderationTransferredDetails" id="ScheduleOfConsiderationTransferredDetails">
	  <link:definition>00000043 - Disclosure - SCHEDULE OF CONSIDERATION TRANSFERRED (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://qualigeninc.com/role/ScheduleOfConsiderationTransferredDetailsParenthetical" id="ScheduleOfConsiderationTransferredDetailsParenthetical">
	  <link:definition>00000044 - Disclosure - SCHEDULE OF CONSIDERATION TRANSFERRED (Details) (Parenthetical)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://qualigeninc.com/role/ScheduleOfAssetsAcquiredAndLiabilitiesDetails" id="ScheduleOfAssetsAcquiredAndLiabilitiesDetails">
	  <link:definition>00000045 - Disclosure - SCHEDULE OF ASSETS ACQUIRED AND LIABILITIES (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://qualigeninc.com/role/ScheduleOfProFormaInformationDetails" id="ScheduleOfProFormaInformationDetails">
	  <link:definition>00000046 - Disclosure - SCHEDULE OF PRO FORMA INFORMATION (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://qualigeninc.com/role/AcquisitionDetailsNarrative" id="AcquisitionDetailsNarrative">
	  <link:definition>00000047 - Disclosure - ACQUISITION (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://qualigeninc.com/role/ScheduleOfInventoryDetails" id="ScheduleOfInventoryDetails">
	  <link:definition>00000048 - Disclosure - SCHEDULE OF INVENTORY (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://qualigeninc.com/role/ScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails" id="ScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails">
	  <link:definition>00000049 - Disclosure - SCHEDULE OF PREPAID EXPENSES AND OTHER CURRENT ASSETS (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://qualigeninc.com/role/ScheduleOfPropertyAndEquipmentDetails" id="ScheduleOfPropertyAndEquipmentDetails">
	  <link:definition>00000050 - Disclosure - SCHEDULE OF PROPERTY AND EQUIPMENT (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://qualigeninc.com/role/PropertyAndEquipmentNetDetailsNarrative" id="PropertyAndEquipmentNetDetailsNarrative">
	  <link:definition>00000051 - Disclosure - PROPERTY AND EQUIPMENT, NET (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://qualigeninc.com/role/ScheduleOfGoodwillAndOtherIntangibleDetails" id="ScheduleOfGoodwillAndOtherIntangibleDetails">
	  <link:definition>00000052 - Disclosure - SCHEDULE OF GOODWILL AND OTHER INTANGIBLE (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://qualigeninc.com/role/GoodwillIprdAndOtherIntangiblesDetailsNarrative" id="GoodwillIprdAndOtherIntangiblesDetailsNarrative">
	  <link:definition>00000053 - Disclosure - GOODWILL, IPR&amp;D AND OTHER INTANGIBLES (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://qualigeninc.com/role/ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails" id="ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails">
	  <link:definition>00000054 - Disclosure - SCHEDULE OF ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://qualigeninc.com/role/ShortTermDebt-RelatedPartyDetailsNarrative" id="ShortTermDebt-RelatedPartyDetailsNarrative">
	  <link:definition>00000055 - Disclosure - SHORT TERM DEBT - RELATED PARTY (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://qualigeninc.com/role/ScheduleOfWarrantsActivityDetails" id="ScheduleOfWarrantsActivityDetails">
	  <link:definition>00000056 - Disclosure - SCHEDULE OF WARRANTS ACTIVITY (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://qualigeninc.com/role/ScheduleOfFairValueHierarchyForWarrantLiabilitiesDetails" id="ScheduleOfFairValueHierarchyForWarrantLiabilitiesDetails">
	  <link:definition>00000057 - Disclosure - SCHEDULE OF FAIR VALUE HIERARCHY FOR WARRANT LIABILITIES (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://qualigeninc.com/role/ScheduleOfAssumptionsOfWarrantLiabilitiesDetails" id="ScheduleOfAssumptionsOfWarrantLiabilitiesDetails">
	  <link:definition>00000058 - Disclosure - SCHEDULE OF ASSUMPTIONS OF WARRANT LIABILITIES (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://qualigeninc.com/role/WarrantLiabilitiesDetailsNarrative" id="WarrantLiabilitiesDetailsNarrative">
	  <link:definition>00000059 - Disclosure - WARRANT LIABILITIES (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://qualigeninc.com/role/ScheduleOfSeniorSecuredConvertibleDebtDetails" id="ScheduleOfSeniorSecuredConvertibleDebtDetails">
	  <link:definition>00000060 - Disclosure - SCHEDULE OF SENIOR SECURED CONVERTIBLE DEBT (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://qualigeninc.com/role/ConvertibleDebt-RelatedPartyDetailsNarrative" id="ConvertibleDebt-RelatedPartyDetailsNarrative">
	  <link:definition>00000061 - Disclosure - CONVERTIBLE DEBT - RELATED PARTY (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://qualigeninc.com/role/ScheduleOfEarningsPerShareBasicAndDilutedDetails" id="ScheduleOfEarningsPerShareBasicAndDilutedDetails">
	  <link:definition>00000062 - Disclosure - SCHEDULE OF EARNINGS PER SHARE BASIC AND DILUTED (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://qualigeninc.com/role/ScheduleOfDilutiveSecuritiesExcludedFromDilutedNetLossPerShareDetails" id="ScheduleOfDilutiveSecuritiesExcludedFromDilutedNetLossPerShareDetails">
	  <link:definition>00000063 - Disclosure - SCHEDULE OF DILUTIVE SECURITIES EXCLUDED FROM DILUTED NET LOSS PER SHARE (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://qualigeninc.com/role/ScheduleOfOperatingLeaseRightOfUseAssetsAndOperatingLeaseLiabilitiesDetails" id="ScheduleOfOperatingLeaseRightOfUseAssetsAndOperatingLeaseLiabilitiesDetails">
	  <link:definition>00000064 - Disclosure - SCHEDULE OF OPERATING LEASE RIGHT OF USE ASSETS AND OPERATING LEASE LIABILITIES (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://qualigeninc.com/role/ScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails" id="ScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails">
	  <link:definition>00000065 - Disclosure - SCHEDULE OF MATURITIES OF OPERATING LEASE LIABILITIES (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://qualigeninc.com/role/CommitmentsAndContingenciesDetailsNarrative" id="CommitmentsAndContingenciesDetailsNarrative">
	  <link:definition>00000066 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://qualigeninc.com/role/ResearchAndLicenseAgreementsDetailsNarrative" id="ResearchAndLicenseAgreementsDetailsNarrative">
	  <link:definition>00000067 - Disclosure - RESEARCH AND LICENSE AGREEMENTS (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://qualigeninc.com/role/ScheduleOfReservedSharesDetails" id="ScheduleOfReservedSharesDetails">
	  <link:definition>00000068 - Disclosure - SCHEDULE OF RESERVED SHARES (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://qualigeninc.com/role/ScheduleOfStockOptionActivityDetails" id="ScheduleOfStockOptionActivityDetails">
	  <link:definition>00000069 - Disclosure - SCHEDULE OF STOCK OPTION ACTIVITY (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://qualigeninc.com/role/ScheduleOfAssumptionUsedInBlack-scholesOption-pricingMethodDetails" id="ScheduleOfAssumptionUsedInBlack-scholesOption-pricingMethodDetails">
	  <link:definition>00000070 - Disclosure - SCHEDULE OF ASSUMPTION USED IN BLACK-SCHOLES OPTION-PRICING METHOD (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://qualigeninc.com/role/ScheduleOfShare-basedCompensationExpenseDetails" id="ScheduleOfShare-basedCompensationExpenseDetails">
	  <link:definition>00000071 - Disclosure - SCHEDULE OF SHARE-BASED COMPENSATION EXPENSE (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://qualigeninc.com/role/ScheduleOfWarrantActivityDetails" id="ScheduleOfWarrantActivityDetails">
	  <link:definition>00000072 - Disclosure - SCHEDULE OF WARRANT ACTIVITY (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://qualigeninc.com/role/StockholdersEquityDetailsNarrative" id="StockholdersEquityDetailsNarrative">
	  <link:definition>00000073 - Disclosure - STOCKHOLDERS&#8217; EQUITY (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://qualigeninc.com/role/RelatedPartyTransactionsDetailsNarrative" id="RelatedPartyTransactionsDetailsNarrative">
	  <link:definition>00000074 - Disclosure - RELATED PARTY TRANSACTIONS (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://qualigeninc.com/role/ScheduleOfDomesticAndForeignComponentsDetails" id="ScheduleOfDomesticAndForeignComponentsDetails">
	  <link:definition>00000075 - Disclosure - SCHEDULE OF DOMESTIC AND FOREIGN COMPONENTS (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://qualigeninc.com/role/ScheduleOfReconciliationsOfStatutoryIncomeTaxRateDetails" id="ScheduleOfReconciliationsOfStatutoryIncomeTaxRateDetails">
	  <link:definition>00000076 - Disclosure - SCHEDULE OF RECONCILIATIONS OF STATUTORY INCOME TAX RATE (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://qualigeninc.com/role/ScheduleOfProvisionForIncomeTaxesDetails" id="ScheduleOfProvisionForIncomeTaxesDetails">
	  <link:definition>00000077 - Disclosure - SCHEDULE OF PROVISION FOR INCOME TAXES (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://qualigeninc.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" id="ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails">
	  <link:definition>00000078 - Disclosure - SCHEDULE OF DEFERRED TAX ASSETS AND LIABILITIES (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://qualigeninc.com/role/IncomeTaxesDetailsNarrative" id="IncomeTaxesDetailsNarrative">
	  <link:definition>00000079 - Disclosure - INCOME TAXES (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://qualigeninc.com/role/SubsequentEventsDetailsNarrative" id="SubsequentEventsDetailsNarrative">
	  <link:definition>00000080 - Disclosure - SUBSEQUENT EVENTS (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:linkbaseRef xlink:type="simple" xlink:href="qlgn-20221231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="qlgn-20221231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="qlgn-20221231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Calculation Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="qlgn-20221231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Definition Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2022" schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd" />
    <import namespace="http://fasb.org/us-gaap/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd" />
    <import namespace="http://fasb.org/us-gaap-sup/2022q3" schemaLocation="https://xbrl.fasb.org/us-gaap/2022q3/us-gaap-sup-2022q3.xsd" />
    <import namespace="http://fasb.org/srt-sup/2022q3" schemaLocation="https://xbrl.fasb.org/srt/2022q3/srt-sup-2022q3.xsd" />
    <import namespace="http://fasb.org/us-types/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2022" schemaLocation="https://xbrl.sec.gov/country/2022/country-2022.xsd" />
    <import namespace="http://fasb.org/srt/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd" />
    <import namespace="http://fasb.org/srt-types/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd" />
    <element id="QLGN_NetProductSalesMember" name="NetProductSalesMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_LicenseRevenueMember" name="LicenseRevenueMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_SeriesAlphaConvertiblePreferredStockMember" name="SeriesAlphaConvertiblePreferredStockMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_NanoSynexLtdMember" name="NanoSynexLtdMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_SeriesAOnePreferredStockMember" name="SeriesAOnePreferredStockMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_PrefundedWarrantMember" name="PrefundedWarrantMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_GeneralAdministrativeResearchAndDevelopmentExpensesMember" name="GeneralAdministrativeResearchAndDevelopmentExpensesMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_LicenseRevenuesMember" name="LicenseRevenuesMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_PatentsAndLicensesMember" name="PatentsAndLicensesMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_MoldsAndToolingMember" name="MoldsAndToolingMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_NanoSynexMember" name="NanoSynexMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_AlphaCapitalAnstaltMember" name="AlphaCapitalAnstaltMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_SekisuiDistributionAgreementMember" name="SekisuiDistributionAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_DevelopedProductTechnologyRightsMember" name="DevelopedProductTechnologyRightsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_LicensingRightsMember" name="LicensingRightsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_NotesPayableMember" name="NotesPayableMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_SeriesCWarrantsMember" name="SeriesCWarrantsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_AlphaCapitalMember" name="AlphaCapitalMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_CommonStockWarrantsMember" name="CommonStockWarrantsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_SeniorConvertibleDebentureMember" name="SeniorConvertibleDebentureMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_AlphaCapitalOtherThirdPartiesMember" name="AlphaCapitalOtherThirdPartiesMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_SeniorSecuredConvertibleDebtMember" name="SeniorSecuredConvertibleDebtMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_SharesOfCommonStockSubjectToOutstandingOptionsMember" name="SharesOfCommonStockSubjectToOutstandingOptionsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_SharesOfCommonStockSubjectToOutstandingWarrantsMember" name="SharesOfCommonStockSubjectToOutstandingWarrantsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_FirstTwelveMonthsMember" name="FirstTwelveMonthsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_LongtermOperatingLeaseAgreementMember" name="LongtermOperatingLeaseAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_SponsoredResearchAgreementAndLicenseMember" name="SponsoredResearchAgreementAndLicenseMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_UniversityOfLouisvilleResearchFoundationMember" name="UniversityOfLouisvilleResearchFoundationMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_LicenseAndSponsoredResearchAgreementsMember" name="LicenseAndSponsoredResearchAgreementsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_PhaseOneClinicalTrialMember" name="PhaseOneClinicalTrialMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_PhaseTwoClinicalTrialMember" name="PhaseTwoClinicalTrialMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_PhaseThreeClinicalTrialMember" name="PhaseThreeClinicalTrialMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_LicensedProductSalesMember" name="LicensedProductSalesMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_LicenseAgreementMember" name="LicenseAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_PhaseClinicalTrialMember" name="PhaseClinicalTrialMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_AdvancedCancerTherapeuticsLLCMember" name="AdvancedCancerTherapeuticsLLCMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_CEMarkMember" name="CEMarkMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_YiXinZhenDuanJishuLtdMember" name="YiXinZhenDuanJishuLtdMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_STAPharmaceuticalCoLtdMember" name="STAPharmaceuticalCoLtdMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_UpfrontPaymentMember" name="UpfrontPaymentMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_SecuritiesPurchaseAgreementMember" name="SecuritiesPurchaseAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_TwoThousandTwentyStockIncentivePlanMember" name="TwoThousandTwentyStockIncentivePlanMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_EmployeesAndNonemployeeServiceProviderMember" name="EmployeesAndNonemployeeServiceProviderMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_CompensatoryWarrantsMember" name="CompensatoryWarrantsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_WarrantOneMember" name="WarrantOneMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_CompensatoryWarrantActivityMember" name="CompensatoryWarrantActivityMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_NoncompensatoryEquityClassifiedWarrantsMember" name="NoncompensatoryEquityClassifiedWarrantsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_NonCompensatoryWarrantActivityMember" name="NonCompensatoryWarrantActivityMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_AccruedVacation" name="AccruedVacation" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_ResearchAndDevelopmentGrantLiability" name="ResearchAndDevelopmentGrantLiability" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_WarrantLiabilitiesRelatedParty" name="WarrantLiabilitiesRelatedParty" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_CostOfProductSales" name="CostOfProductSales" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_StockIssuedUponCashExerciseOfWarrants" name="StockIssuedUponCashExerciseOfWarrants" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_StockIssuedUponCashExerciseOfWarrantsShares" name="StockIssuedUponCashExerciseOfWarrantsShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_CommonStockAndPrefundedWarrantsIssuedForBusinessAcquisition" name="CommonStockAndPrefundedWarrantsIssuedForBusinessAcquisition" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_CommonStockAndPrefundedWarrantsIssuedSharesForBusinessAcquisition" name="CommonStockAndPrefundedWarrantsIssuedSharesForBusinessAcquisition" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_NoncontrollingInterestAdjustmentsRelatingToStockbasedCompensationAndOther" name="NoncontrollingInterestAdjustmentsRelatingToStockbasedCompensationAndOther" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_FairValueOfWarrantModificationForProfessionalServices" name="FairValueOfWarrantModificationForProfessionalServices" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_FairValueOfWarrantModificationForBusinessAcquisition" name="FairValueOfWarrantModificationForBusinessAcquisition" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_StockIssuedDuringPeriodValuesReverseStockSplits" name="StockIssuedDuringPeriodValuesReverseStockSplits" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_StockIssuedUponNetexerciseOfWarrants" name="StockIssuedUponNetexerciseOfWarrants" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_StockIssuedUponNetexerciseOfWarrantsShares" name="StockIssuedUponNetexerciseOfWarrantsShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_IssuanceOfCommonStockForConversionOfPreferredStock" name="IssuanceOfCommonStockForConversionOfPreferredStock" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_IssuanceOfCommonStockSharesForConversionOfPreferredStock" name="IssuanceOfCommonStockSharesForConversionOfPreferredStock" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_FairValueOfWarrantsIssuedForProfessionalServices" name="FairValueOfWarrantsIssuedForProfessionalServices" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_SharesIssuedPursuantToSecuritiesPurchaseAgreements" name="SharesIssuedPursuantToSecuritiesPurchaseAgreements" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_SharesIssuedPursuantToSecuritiesPurchaseShareAgreements" name="SharesIssuedPursuantToSecuritiesPurchaseShareAgreements" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_CommissionAndOfferingCostsOfSecuritiesPurchaseAgreements" name="CommissionAndOfferingCostsOfSecuritiesPurchaseAgreements" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_FairValueOfWarrantModificationsPursuantToSecuritiesPurchaseAgreements" name="FairValueOfWarrantModificationsPursuantToSecuritiesPurchaseAgreements" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_IncreaseDecreaseInInventoryAndEquipmentHeldForLeases" name="IncreaseDecreaseInInventoryAndEquipmentHeldForLeases" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_IncreaseDecreaseInResearchAndDevelopmentGrantLiability" name="IncreaseDecreaseInResearchAndDevelopmentGrantLiability" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_PurchasesOfEquipmentHeldForLease" name="PurchasesOfEquipmentHeldForLease" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_ProceedsFromIssuanceOfSharesAndWarrantsPursuantToSecuritiesPurchaseAgreements" name="ProceedsFromIssuanceOfSharesAndWarrantsPursuantToSecuritiesPurchaseAgreements" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_ProceedsFromIssuanceOfConvertibleDebt" name="ProceedsFromIssuanceOfConvertibleDebt" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_FractionalSharePaymentsRelatedToReverseStockSplit" name="FractionalSharePaymentsRelatedToReverseStockSplit" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_CashPaidForAbstract" name="CashPaidForAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_IssuanceOfCommonStockForConversionOfPreferredStockBeforeClosingOfReverseRecapitalization" name="IssuanceOfCommonStockForConversionOfPreferredStockBeforeClosingOfReverseRecapitalization" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_RightofuseAssetsObtainedInExchangeForOperatingLeaseLiabilities" name="RightofuseAssetsObtainedInExchangeForOperatingLeaseLiabilities" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_SharesIssuedForCashlessWarrantsAmount" name="SharesIssuedForCashlessWarrantsAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_TransfersOfInventoryFromEquipmentHeldForLease" name="TransfersOfInventoryFromEquipmentHeldForLease" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_FairValueOfWarrantLiabilitiesOnDateOfExercise" name="FairValueOfWarrantLiabilitiesOnDateOfExercise" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_FairValueOfWarrantModificationsForBusinessAcquisition" name="FairValueOfWarrantModificationsForBusinessAcquisition" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_FairValueOfWarrantsRepricedDueToAcquisition" name="FairValueOfWarrantsRepricedDueToAcquisition" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_FairValueOfQualigenPrefundedWarrantIssuedInExchangeForNanosynexStock" name="FairValueOfQualigenPrefundedWarrantIssuedInExchangeForNanosynexStock" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_DisclosurePrepaidExpensesAndOtherCurrentAssetsAbstract" name="DisclosurePrepaidExpensesAndOtherCurrentAssetsAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_PrepaidExpensesAndOtherCurrentAssetsTextBlock" name="PrepaidExpensesAndOtherCurrentAssetsTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_DisclosureWarrantLiabilitiesAbstract" name="DisclosureWarrantLiabilitiesAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_WarrantLiabilitiesTextBlock" name="WarrantLiabilitiesTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_DisclosureResearchAndLicenseAgreementsAbstract" name="DisclosureResearchAndLicenseAgreementsAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_ResearchAndLicenseAgreementsTextBlock" name="ResearchAndLicenseAgreementsTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_OrganizationPolicyTextBlock" name="OrganizationPolicyTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_ResearchAndDevelopmentGrantsPolicyTextBlock" name="ResearchAndDevelopmentGrantsPolicyTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_PatentCostsPolicyTextBlock" name="PatentCostsPolicyTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_ShippingAndHandlingCostsPolicyTextBlock" name="ShippingAndHandlingCostsPolicyTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_DeferredRevenuePolicyTextBlock" name="DeferredRevenuePolicyTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_DerivativeFinancialInstrumentsAndWarrantLiabilitiesPolicyTextBlock" name="DerivativeFinancialInstrumentsAndWarrantLiabilitiesPolicyTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_SalesAndExciseTaxesPolicyTextBlock" name="SalesAndExciseTaxesPolicyTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_WarrantyReservePolicyTextBlock" name="WarrantyReservePolicyTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_GlobalEconomicConditionsPolicyTextBlock" name="GlobalEconomicConditionsPolicyTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_ScheduleOfUsefulLivesOfPropertyAndEquipmentTableTextBlock" name="ScheduleOfUsefulLivesOfPropertyAndEquipmentTableTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_ScheduleOfFairValueHierarchyForWarrantLiabilitiesTableTextBlock" name="ScheduleOfFairValueHierarchyForWarrantLiabilitiesTableTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_ScheduleOfAssumptionsOfWarrantLiabilitiesTableTextBlock" name="ScheduleOfAssumptionsOfWarrantLiabilitiesTableTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_ScheduleOfOperatingLeaseRightOfUseAssetsAndLiabilitiesTableTextBlock" name="ScheduleOfOperatingLeaseRightOfUseAssetsAndLiabilitiesTableTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_ScheduleOfReservedSharesTableTextBlock" name="ScheduleOfReservedSharesTableTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_SummaryOfWarrantActivityTableTextBlock" name="SummaryOfWarrantActivityTableTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_AllowancesForSalesReturn" name="AllowancesForSalesReturn" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_PaymentsToAcquireBusinesses" name="PaymentsToAcquireBusinesses" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_PrefundedWarrantsIssuedForBusinessAcquisition" name="PrefundedWarrantsIssuedForBusinessAcquisition" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedResearchAndDevelopmentExpense" name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedResearchAndDevelopmentExpense" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpensesAndOtherPayables" name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpensesAndOtherPayables" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedResearchAndDevelopmentGrantLiability" name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedResearchAndDevelopmentGrantLiability" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesShortTermDebt" name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesShortTermDebt" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_PrepaidManufacturingExpenses" name="PrepaidManufacturingExpenses" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_FixedAssetImpairments" name="FixedAssetImpairments" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_AccruedCompensation" name="AccruedCompensation" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_AccruedEquipmentHeldForLease" name="AccruedEquipmentHeldForLease" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_AccruedFranchiseSalesAndUseTaxes" name="AccruedFranchiseSalesAndUseTaxes" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_AccruedResearchAndDevelopmentCurrent" name="AccruedResearchAndDevelopmentCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_AccruedLicenseFees" name="AccruedLicenseFees" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice" nillable="true" xbrli:periodType="instant" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_RangeOfExercisePrice" name="RangeOfExercisePrice" nillable="true" xbrli:periodType="instant" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAveragRemainingContractualTerm1" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAveragRemainingContractualTerm1" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedInPeriodWeightedAverageExercisePrice" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedInPeriodWeightedAverageExercisePrice" nillable="true" xbrli:periodType="duration" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedInPeriodWeightedAverageExercisePrice" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedInPeriodWeightedAverageExercisePrice" nillable="true" xbrli:periodType="duration" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInPeriodWeightedAverageExercisePrice" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInPeriodWeightedAverageExercisePrice" nillable="true" xbrli:periodType="duration" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice" nillable="true" xbrli:periodType="duration" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber" nillable="true" xbrli:periodType="instant" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageVestedExercisePrice" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageVestedExercisePrice" nillable="true" xbrli:periodType="instant" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_RangeOfExercisePriceExercisableVested" name="RangeOfExercisePriceExercisableVested" nillable="true" xbrli:periodType="instant" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNonExercisableWeightedAverageRemainingContractualTerm1" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNonExercisableWeightedAverageRemainingContractualTerm1" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_FairValueAdjustmentOfWarrant" name="FairValueAdjustmentOfWarrant" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_FairValueOfWarrantLiabilitiesIssuanceOfAlphaWarrants" name="FairValueOfWarrantLiabilitiesIssuanceOfAlphaWarrants" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_ChangeInFairValueOfWarrantLiabilities" name="ChangeInFairValueOfWarrantLiabilities" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_ConversionPricePercentage" name="ConversionPricePercentage" nillable="true" xbrli:periodType="duration" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_PurchasePrice" name="PurchasePrice" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_PrincipalAmountPercentage" name="PrincipalAmountPercentage" nillable="true" xbrli:periodType="duration" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_FeesAndCostsPaid" name="FeesAndCostsPaid" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_DilutivePotentialSharesIssuableFromStockOptionsAndWarrants" name="DilutivePotentialSharesIssuableFromStockOptionsAndWarrants" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_TenantImprovementAllowance" name="TenantImprovementAllowance" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_DevelopmentFund" name="DevelopmentFund" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_ReimbursementOfResearchExpenses" name="ReimbursementOfResearchExpenses" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_AgreementTermPaymentDescription" name="AgreementTermPaymentDescription" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_MilestonePayment" name="MilestonePayment" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_RegulatoryMarketingApprovalExpenses" name="RegulatoryMarketingApprovalExpenses" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_CumulativeSales" name="CumulativeSales" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_UpfrontLicenseFee" name="UpfrontLicenseFee" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_LicenseCost" name="LicenseCost" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_PatentCosts" name="PatentCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_RegulatoryMarketingApprovalExpensesOne" name="RegulatoryMarketingApprovalExpensesOne" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_ShortfallPayments" name="ShortfallPayments" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_AgreementDescription" name="AgreementDescription" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_MilestonePaymentForCumulativeMarketingExpenses" name="MilestonePaymentForCumulativeMarketingExpenses" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_MilestoneMethodRevenueRecognized" name="MilestoneMethodRevenueRecognized" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_ReimbursementOfPatent" name="ReimbursementOfPatent" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm3" name="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm3" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionGrantedWeightedAverageExercisePrice" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionGrantedWeightedAverageExercisePrice" nillable="true" xbrli:periodType="duration" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm2" name="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm2" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExpirationsInPeriodWeightedAverageExercisePrice" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExpirationsInPeriodWeightedAverageExercisePrice" nillable="true" xbrli:periodType="duration" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToNonVestExercisableWeightedAverageExercisePrice" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToNonVestExercisableWeightedAverageExercisePrice" nillable="true" xbrli:periodType="instant" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_WeightedAverageRemainingContractualLifeInYearsOptionsNonexercisableNonvested" name="WeightedAverageRemainingContractualLifeInYearsOptionsNonexercisableNonvested" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_RangeOfExercisePriceOutstanding" name="RangeOfExercisePriceOutstanding" nillable="true" xbrli:periodType="instant" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAveragRemainingContractualTerm1" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAveragRemainingContractualTerm1" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNonVestedNumber" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNonVestedNumber" nillable="true" xbrli:periodType="instant" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageNonVestedExercise" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageNonVestedExercise" nillable="true" xbrli:periodType="instant" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_RangeOfExercisePriceNonexercisableNonvested" name="RangeOfExercisePriceNonexercisableNonvested" nillable="true" xbrli:periodType="instant" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsRangeOfExercisePrice" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsRangeOfExercisePrice" nillable="true" xbrli:periodType="instant" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_RangeOfExercisePriceGranted" name="RangeOfExercisePriceGranted" nillable="true" xbrli:periodType="duration" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_RangeOfExercisePriceExpired" name="RangeOfExercisePriceExpired" nillable="true" xbrli:periodType="duration" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInRangeOfExercisePrice" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInRangeOfExercisePrice" nillable="true" xbrli:periodType="duration" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedInRangeOfExercisePrice" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedInRangeOfExercisePrice" nillable="true" xbrli:periodType="duration" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsNonExercisableNumber" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsNonExercisableNumber" nillable="true" xbrli:periodType="instant" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageVestedNonExercisePrice" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageVestedNonExercisePrice" nillable="true" xbrli:periodType="instant" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_RangeOfExercisePriceNonExercisableVested" name="RangeOfExercisePriceNonExercisableVested" nillable="true" xbrli:periodType="instant" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_FairValueOfIssuanceCost" name="FairValueOfIssuanceCost" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_WarrantsExtendedDateDescription" name="WarrantsExtendedDateDescription" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_WarrantsExercised" name="WarrantsExercised" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_ModifiedToExercisePrice" name="ModifiedToExercisePrice" nillable="true" xbrli:periodType="instant" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_EffectiveIncomeTaxRateReconciliationNonOperatingLossExpiration" name="EffectiveIncomeTaxRateReconciliationNonOperatingLossExpiration" nillable="true" xbrli:periodType="duration" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_EffectiveIncomeTaxRateReconciliationFairValueOfWarrant" name="EffectiveIncomeTaxRateReconciliationFairValueOfWarrant" nillable="true" xbrli:periodType="duration" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_DefferdTaxAssetsAccruedExpenses" name="DefferdTaxAssetsAccruedExpenses" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_DeferredTaxAssetsResearchAndDevelopmentExpenses" name="DeferredTaxAssetsResearchAndDevelopmentExpenses" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_BaseSalaryPercentage" name="BaseSalaryPercentage" nillable="true" xbrli:periodType="duration" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_AnnualCashCompensation" name="AnnualCashCompensation" nillable="true" xbrli:periodType="duration" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_FixedAssetImpairment" name="FixedAssetImpairment" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_ForeignCurrencyTranslationAdjustment" name="ForeignCurrencyTranslationAdjustment" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_StockIssuedForProfessionalServices" name="StockIssuedForProfessionalServices" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_WarrantModificationsPursuantToSecuritiesPurchaseAgreementsValue" name="WarrantModificationsPursuantToSecuritiesPurchaseAgreementsValue" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_TotalCashAndRestrictedCash" name="TotalCashAndRestrictedCash" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_ProceedsFromIssuanceOrSaleOfEquityAndDebt" name="ProceedsFromIssuanceOrSaleOfEquityAndDebt" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_RegulatoryMarketingApprovalMember" name="RegulatoryMarketingApprovalMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_DebentureAccruesInterestRate" name="DebentureAccruesInterestRate" nillable="true" xbrli:periodType="duration" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_WarrantTwoMember" name="WarrantTwoMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_AccruedExpensesAndOtherCurrentLiabilities" name="AccruedExpensesAndOtherCurrentLiabilities" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_GoodwillImpairmentLosses" name="GoodwillImpairmentLosses" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_UpfrontPaymenetMember" name="UpfrontPaymenetMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>28
<FILENAME>qlgn-20221231_cal.xml
<DESCRIPTION>INLINE XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.18a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://qualigeninc.com/role/Cover" xlink:href="qlgn-20221231.xsd#Cover" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigeninc.com/role/BalanceSheets" xlink:href="qlgn-20221231.xsd#BalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigeninc.com/role/BalanceSheetsParenthetical" xlink:href="qlgn-20221231.xsd#BalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigeninc.com/role/StatementsOfOperationsAndComprehensiveLoss" xlink:href="qlgn-20221231.xsd#StatementsOfOperationsAndComprehensiveLoss" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigeninc.com/role/StatementsOfChangesInStockholdersEquity" xlink:href="qlgn-20221231.xsd#StatementsOfChangesInStockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigeninc.com/role/StatementsOfCashFlows" xlink:href="qlgn-20221231.xsd#StatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigeninc.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesAndEstimates" xlink:href="qlgn-20221231.xsd#OrganizationAndSummaryOfSignificantAccountingPoliciesAndEstimates" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigeninc.com/role/LiquidityAndGoingConcern" xlink:href="qlgn-20221231.xsd#LiquidityAndGoingConcern" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigeninc.com/role/Acquisition" xlink:href="qlgn-20221231.xsd#Acquisition" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigeninc.com/role/InventoryNet" xlink:href="qlgn-20221231.xsd#InventoryNet" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigeninc.com/role/PrepaidExpensesAndOtherCurrentAssets" xlink:href="qlgn-20221231.xsd#PrepaidExpensesAndOtherCurrentAssets" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigeninc.com/role/PropertyAndEquipmentNet" xlink:href="qlgn-20221231.xsd#PropertyAndEquipmentNet" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigeninc.com/role/GoodwillIprdAndOtherIntangibles" xlink:href="qlgn-20221231.xsd#GoodwillIprdAndOtherIntangibles" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigeninc.com/role/AccruedExpensesAndOtherCurrentLiabilities" xlink:href="qlgn-20221231.xsd#AccruedExpensesAndOtherCurrentLiabilities" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigeninc.com/role/ShortTermDebt-RelatedParty" xlink:href="qlgn-20221231.xsd#ShortTermDebt-RelatedParty" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigeninc.com/role/WarrantLiabilities" xlink:href="qlgn-20221231.xsd#WarrantLiabilities" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigeninc.com/role/ConvertibleDebt-RelatedParty" xlink:href="qlgn-20221231.xsd#ConvertibleDebt-RelatedParty" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigeninc.com/role/EarningsLossPerShare" xlink:href="qlgn-20221231.xsd#EarningsLossPerShare" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigeninc.com/role/CommitmentsAndContingencies" xlink:href="qlgn-20221231.xsd#CommitmentsAndContingencies" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigeninc.com/role/ResearchAndLicenseAgreements" xlink:href="qlgn-20221231.xsd#ResearchAndLicenseAgreements" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigeninc.com/role/StockholdersEquity" xlink:href="qlgn-20221231.xsd#StockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigeninc.com/role/RelatedPartyTransactions" xlink:href="qlgn-20221231.xsd#RelatedPartyTransactions" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigeninc.com/role/IncomeTaxes" xlink:href="qlgn-20221231.xsd#IncomeTaxes" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigeninc.com/role/SubsequentEvents" xlink:href="qlgn-20221231.xsd#SubsequentEvents" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigeninc.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesAndEstimatesPolicies" xlink:href="qlgn-20221231.xsd#OrganizationAndSummaryOfSignificantAccountingPoliciesAndEstimatesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigeninc.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesAndEstimatesTables" xlink:href="qlgn-20221231.xsd#OrganizationAndSummaryOfSignificantAccountingPoliciesAndEstimatesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigeninc.com/role/AcquisitionTables" xlink:href="qlgn-20221231.xsd#AcquisitionTables" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigeninc.com/role/InventoryNetTables" xlink:href="qlgn-20221231.xsd#InventoryNetTables" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigeninc.com/role/PrepaidExpensesAndOtherCurrentAssetsTables" xlink:href="qlgn-20221231.xsd#PrepaidExpensesAndOtherCurrentAssetsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigeninc.com/role/PropertyAndEquipmentNetTables" xlink:href="qlgn-20221231.xsd#PropertyAndEquipmentNetTables" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigeninc.com/role/GoodwillIprdAndOtherIntangiblesTables" xlink:href="qlgn-20221231.xsd#GoodwillIprdAndOtherIntangiblesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigeninc.com/role/AccruedExpensesAndOtherCurrentLiabilitiesTables" xlink:href="qlgn-20221231.xsd#AccruedExpensesAndOtherCurrentLiabilitiesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigeninc.com/role/WarrantLiabilitiesTables" xlink:href="qlgn-20221231.xsd#WarrantLiabilitiesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigeninc.com/role/ConvertibleDebt-RelatedPartyTables" xlink:href="qlgn-20221231.xsd#ConvertibleDebt-RelatedPartyTables" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigeninc.com/role/EarningsLossPerShareTables" xlink:href="qlgn-20221231.xsd#EarningsLossPerShareTables" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigeninc.com/role/CommitmentsAndContingenciesTables" xlink:href="qlgn-20221231.xsd#CommitmentsAndContingenciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigeninc.com/role/StockholdersEquityTables" xlink:href="qlgn-20221231.xsd#StockholdersEquityTables" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigeninc.com/role/IncomeTaxesTables" xlink:href="qlgn-20221231.xsd#IncomeTaxesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigeninc.com/role/ScheduleOfAccountsReceivableDetails" xlink:href="qlgn-20221231.xsd#ScheduleOfAccountsReceivableDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigeninc.com/role/ScheduleOfUsefulLivesOfPropertyAndEquipmentDetails" xlink:href="qlgn-20221231.xsd#ScheduleOfUsefulLivesOfPropertyAndEquipmentDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigeninc.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesAndEstimatesDetailsNarrative" xlink:href="qlgn-20221231.xsd#OrganizationAndSummaryOfSignificantAccountingPoliciesAndEstimatesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigeninc.com/role/LiquidityAndGoingConcernDetailsNarrative" xlink:href="qlgn-20221231.xsd#LiquidityAndGoingConcernDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigeninc.com/role/ScheduleOfConsiderationTransferredDetails" xlink:href="qlgn-20221231.xsd#ScheduleOfConsiderationTransferredDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigeninc.com/role/ScheduleOfConsiderationTransferredDetailsParenthetical" xlink:href="qlgn-20221231.xsd#ScheduleOfConsiderationTransferredDetailsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigeninc.com/role/ScheduleOfAssetsAcquiredAndLiabilitiesDetails" xlink:href="qlgn-20221231.xsd#ScheduleOfAssetsAcquiredAndLiabilitiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigeninc.com/role/ScheduleOfProFormaInformationDetails" xlink:href="qlgn-20221231.xsd#ScheduleOfProFormaInformationDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigeninc.com/role/AcquisitionDetailsNarrative" xlink:href="qlgn-20221231.xsd#AcquisitionDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigeninc.com/role/ScheduleOfInventoryDetails" xlink:href="qlgn-20221231.xsd#ScheduleOfInventoryDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigeninc.com/role/ScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails" xlink:href="qlgn-20221231.xsd#ScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigeninc.com/role/ScheduleOfPropertyAndEquipmentDetails" xlink:href="qlgn-20221231.xsd#ScheduleOfPropertyAndEquipmentDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigeninc.com/role/PropertyAndEquipmentNetDetailsNarrative" xlink:href="qlgn-20221231.xsd#PropertyAndEquipmentNetDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigeninc.com/role/ScheduleOfGoodwillAndOtherIntangibleDetails" xlink:href="qlgn-20221231.xsd#ScheduleOfGoodwillAndOtherIntangibleDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigeninc.com/role/GoodwillIprdAndOtherIntangiblesDetailsNarrative" xlink:href="qlgn-20221231.xsd#GoodwillIprdAndOtherIntangiblesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigeninc.com/role/ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails" xlink:href="qlgn-20221231.xsd#ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigeninc.com/role/ShortTermDebt-RelatedPartyDetailsNarrative" xlink:href="qlgn-20221231.xsd#ShortTermDebt-RelatedPartyDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigeninc.com/role/ScheduleOfWarrantsActivityDetails" xlink:href="qlgn-20221231.xsd#ScheduleOfWarrantsActivityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigeninc.com/role/ScheduleOfFairValueHierarchyForWarrantLiabilitiesDetails" xlink:href="qlgn-20221231.xsd#ScheduleOfFairValueHierarchyForWarrantLiabilitiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigeninc.com/role/ScheduleOfAssumptionsOfWarrantLiabilitiesDetails" xlink:href="qlgn-20221231.xsd#ScheduleOfAssumptionsOfWarrantLiabilitiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigeninc.com/role/WarrantLiabilitiesDetailsNarrative" xlink:href="qlgn-20221231.xsd#WarrantLiabilitiesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigeninc.com/role/ScheduleOfSeniorSecuredConvertibleDebtDetails" xlink:href="qlgn-20221231.xsd#ScheduleOfSeniorSecuredConvertibleDebtDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigeninc.com/role/ConvertibleDebt-RelatedPartyDetailsNarrative" xlink:href="qlgn-20221231.xsd#ConvertibleDebt-RelatedPartyDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigeninc.com/role/ScheduleOfEarningsPerShareBasicAndDilutedDetails" xlink:href="qlgn-20221231.xsd#ScheduleOfEarningsPerShareBasicAndDilutedDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigeninc.com/role/ScheduleOfDilutiveSecuritiesExcludedFromDilutedNetLossPerShareDetails" xlink:href="qlgn-20221231.xsd#ScheduleOfDilutiveSecuritiesExcludedFromDilutedNetLossPerShareDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigeninc.com/role/ScheduleOfOperatingLeaseRightOfUseAssetsAndOperatingLeaseLiabilitiesDetails" xlink:href="qlgn-20221231.xsd#ScheduleOfOperatingLeaseRightOfUseAssetsAndOperatingLeaseLiabilitiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigeninc.com/role/ScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails" xlink:href="qlgn-20221231.xsd#ScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigeninc.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:href="qlgn-20221231.xsd#CommitmentsAndContingenciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigeninc.com/role/ResearchAndLicenseAgreementsDetailsNarrative" xlink:href="qlgn-20221231.xsd#ResearchAndLicenseAgreementsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigeninc.com/role/ScheduleOfReservedSharesDetails" xlink:href="qlgn-20221231.xsd#ScheduleOfReservedSharesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigeninc.com/role/ScheduleOfStockOptionActivityDetails" xlink:href="qlgn-20221231.xsd#ScheduleOfStockOptionActivityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigeninc.com/role/ScheduleOfAssumptionUsedInBlack-scholesOption-pricingMethodDetails" xlink:href="qlgn-20221231.xsd#ScheduleOfAssumptionUsedInBlack-scholesOption-pricingMethodDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigeninc.com/role/ScheduleOfShare-basedCompensationExpenseDetails" xlink:href="qlgn-20221231.xsd#ScheduleOfShare-basedCompensationExpenseDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigeninc.com/role/ScheduleOfWarrantActivityDetails" xlink:href="qlgn-20221231.xsd#ScheduleOfWarrantActivityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigeninc.com/role/StockholdersEquityDetailsNarrative" xlink:href="qlgn-20221231.xsd#StockholdersEquityDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigeninc.com/role/RelatedPartyTransactionsDetailsNarrative" xlink:href="qlgn-20221231.xsd#RelatedPartyTransactionsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigeninc.com/role/ScheduleOfDomesticAndForeignComponentsDetails" xlink:href="qlgn-20221231.xsd#ScheduleOfDomesticAndForeignComponentsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigeninc.com/role/ScheduleOfReconciliationsOfStatutoryIncomeTaxRateDetails" xlink:href="qlgn-20221231.xsd#ScheduleOfReconciliationsOfStatutoryIncomeTaxRateDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigeninc.com/role/ScheduleOfProvisionForIncomeTaxesDetails" xlink:href="qlgn-20221231.xsd#ScheduleOfProvisionForIncomeTaxesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigeninc.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:href="qlgn-20221231.xsd#ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigeninc.com/role/IncomeTaxesDetailsNarrative" xlink:href="qlgn-20221231.xsd#IncomeTaxesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigeninc.com/role/SubsequentEventsDetailsNarrative" xlink:href="qlgn-20221231.xsd#SubsequentEventsDetailsNarrative" xlink:type="simple" />
    <link:calculationLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/Cover" xlink:title="00000001 - Document - Cover" />
    <link:calculationLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/BalanceSheets" xlink:title="00000002 - Statement - Consolidated Balance Sheets">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Cash" xlink:label="loc_us-gaapCash" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapCash" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaapAccountsReceivableNetCurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapAccountsReceivableNetCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaapInventoryNet" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapInventoryNet" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapAssetsCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalents" xlink:label="loc_us-gaapRestrictedCashAndCashEquivalents" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapRestrictedCashAndCashEquivalents" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaapIntangibleAssetsNetExcludingGoodwill" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapIntangibleAssetsNetExcludingGoodwill" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaapGoodwill" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapGoodwill" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaapOtherAssetsNoncurrent" />
      <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapOtherAssetsNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaapAccountsPayableCurrent" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapAccountsPayableCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_AccruedVacation" xlink:label="loc_QLGNAccruedVacation" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_QLGNAccruedVacation" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:label="loc_us-gaapAccruedLiabilitiesAndOtherLiabilities" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapAccruedLiabilitiesAndOtherLiabilities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_ResearchAndDevelopmentGrantLiability" xlink:label="loc_QLGNResearchAndDevelopmentGrantLiability" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_QLGNResearchAndDevelopmentGrantLiability" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeCurrent" xlink:label="loc_us-gaapDeferredIncomeCurrent" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapDeferredIncomeCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityCurrent" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapOperatingLeaseLiabilityCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermBorrowings" xlink:label="loc_us-gaapShortTermBorrowings" />
      <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapShortTermBorrowings" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingLiabilitiesCurrent" xlink:label="loc_us-gaapHedgingLiabilitiesCurrent" />
      <link:calculationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapHedgingLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_WarrantLiabilitiesRelatedParty" xlink:label="loc_QLGNWarrantLiabilitiesRelatedParty" />
      <link:calculationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_QLGNWarrantLiabilitiesRelatedParty" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleDebt" xlink:label="loc_us-gaapConvertibleDebt" />
      <link:calculationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapConvertibleDebt" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityNoncurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapOperatingLeaseLiabilityNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:label="loc_us-gaapDeferredRevenueNoncurrent" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapDeferredRevenueNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:label="loc_us-gaapDeferredIncomeTaxLiabilitiesNet" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapDeferredIncomeTaxLiabilitiesNet" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaapAdditionalPaidInCapital" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapAdditionalPaidInCapital" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossNetOfTax" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaapStockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterest" xlink:label="loc_us-gaapMinorityInterest" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="loc_us-gaapMinorityInterest" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapLiabilities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaapCommitmentsAndContingencies" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapCommitmentsAndContingencies" xlink:type="arc" weight="1" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapStockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/BalanceSheetsParenthetical" xlink:title="00000003 - Statement - Consolidated Balance Sheets (Parenthetical)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/StatementsOfOperationsAndComprehensiveLoss" xlink:title="00000004 - Statement - Consolidated Statements of Operations and Comprehensive Loss">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaapOperatingExpenses" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_CostOfProductSales" xlink:label="loc_QLGNCostOfProductSales" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_QLGNCostOfProductSales" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapGeneralAndAdministrativeExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketingAndAdvertisingExpense" xlink:label="loc_us-gaapMarketingAndAdvertisingExpense" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapMarketingAndAdvertisingExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillImpairmentLoss" xlink:label="loc_us-gaapGoodwillImpairmentLoss" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapGoodwillImpairmentLoss" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingIncomeLoss" xlink:to="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingIncomeLoss" xlink:to="loc_us-gaapOperatingExpenses" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaapNonoperatingIncomeExpense" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeGainLossOnDerivativeNet" xlink:label="loc_us-gaapDerivativeGainLossOnDerivativeNet" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapDerivativeGainLossOnDerivativeNet" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestIncomeExpenseNet" xlink:label="loc_us-gaapInterestIncomeExpenseNet" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapInterestIncomeExpenseNet" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaapOtherNonoperatingIncomeExpense" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapOtherNonoperatingIncomeExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="loc_us-gaapOperatingIncomeLoss" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="loc_us-gaapNonoperatingIncomeExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaapProfitLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapProfitLoss" xlink:to="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaapIncomeTaxExpenseBenefit" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapProfitLoss" xlink:to="loc_us-gaapIncomeTaxExpenseBenefit" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapProfitLoss" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="loc_us-gaapNetIncomeLossAttributableToNoncontrollingInterest" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapNetIncomeLossAttributableToNoncontrollingInterest" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaapComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:to="loc_us-gaapProfitLoss" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="loc_us-gaapOtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:to="loc_us-gaapOtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaapComprehensiveIncomeNetOfTax" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapComprehensiveIncomeNetOfTax" xlink:to="loc_us-gaapComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:label="loc_us-gaapComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapComprehensiveIncomeNetOfTax" xlink:to="loc_us-gaapComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:type="arc" weight="-1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/StatementsOfChangesInStockholdersEquity" xlink:title="00000005 - Statement - Consolidated Statements of Changes in Stockholders&apos; Equity" />
    <link:calculationLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/StatementsOfCashFlows" xlink:title="00000006 - Statement - Consolidated Statements of Cash Flows">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaapProfitLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapProfitLoss" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaapDepreciationDepletionAndAmortization" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapDepreciationDepletionAndAmortization" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAssetAmortizationExpense" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAssetAmortizationExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProvisionForDoubtfulAccounts" xlink:label="loc_us-gaapProvisionForDoubtfulAccounts" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapProvisionForDoubtfulAccounts" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryWriteDown" xlink:label="loc_us-gaapInventoryWriteDown" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapInventoryWriteDown" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:label="loc_us-gaapIssuanceOfStockAndWarrantsForServicesOrClaims" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIssuanceOfStockAndWarrantsForServicesOrClaims" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_FairValueOfWarrantsIssuedForProfessionalServices" xlink:label="loc_QLGNFairValueOfWarrantsIssuedForProfessionalServices" />
      <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_QLGNFairValueOfWarrantsIssuedForProfessionalServices" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:calculationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_FairValueOfWarrantModificationForProfessionalServices" xlink:label="loc_QLGNFairValueOfWarrantModificationForProfessionalServices" />
      <link:calculationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_QLGNFairValueOfWarrantModificationForProfessionalServices" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillImpairmentLoss" xlink:label="loc_us-gaapGoodwillImpairmentLoss" />
      <link:calculationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapGoodwillImpairmentLoss" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaapFairValueAdjustmentOfWarrants" />
      <link:calculationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapFairValueAdjustmentOfWarrants" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsReceivable" />
      <link:calculationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsReceivable" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_IncreaseDecreaseInInventoryAndEquipmentHeldForLeases" xlink:label="loc_QLGNIncreaseDecreaseInInventoryAndEquipmentHeldForLeases" />
      <link:calculationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_QLGNIncreaseDecreaseInInventoryAndEquipmentHeldForLeases" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaapIncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
      <link:calculationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsPayable" />
      <link:calculationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsPayable" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" />
      <link:calculationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_IncreaseDecreaseInResearchAndDevelopmentGrantLiability" xlink:label="loc_QLGNIncreaseDecreaseInResearchAndDevelopmentGrantLiability" />
      <link:calculationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_QLGNIncreaseDecreaseInResearchAndDevelopmentGrantLiability" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="loc_us-gaapIncreaseDecreaseInOperatingLeaseLiability" />
      <link:calculationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInOperatingLeaseLiability" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="loc_us-gaapIncreaseDecreaseInContractWithCustomerLiability" />
      <link:calculationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInContractWithCustomerLiability" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInDeferredLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInDeferredLiabilities" />
      <link:calculationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInDeferredLiabilities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_PurchasesOfEquipmentHeldForLease" xlink:label="loc_QLGNPurchasesOfEquipmentHeldForLease" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:to="loc_QLGNPurchasesOfEquipmentHeldForLease" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="loc_us-gaapPaymentsToAcquireIntangibleAssets" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaapPaymentsToAcquireIntangibleAssets" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAcquiredFromAcquisition" xlink:label="loc_us-gaapCashAcquiredFromAcquisition" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaapCashAcquiredFromAcquisition" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaapProceedsFromWarrantExercises" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromWarrantExercises" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_ProceedsFromIssuanceOfSharesAndWarrantsPursuantToSecuritiesPurchaseAgreements" xlink:label="loc_QLGNProceedsFromIssuanceOfSharesAndWarrantsPursuantToSecuritiesPurchaseAgreements" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_QLGNProceedsFromIssuanceOfSharesAndWarrantsPursuantToSecuritiesPurchaseAgreements" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_ProceedsFromIssuanceOfConvertibleDebt" xlink:label="loc_QLGNProceedsFromIssuanceOfConvertibleDebt" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_QLGNProceedsFromIssuanceOfConvertibleDebt" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaapPaymentsOfStockIssuanceCosts" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapPaymentsOfStockIssuanceCosts" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfNotesPayable" xlink:label="loc_us-gaapRepaymentsOfNotesPayable" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapRepaymentsOfNotesPayable" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_FractionalSharePaymentsRelatedToReverseStockSplit" xlink:label="loc_QLGNFractionalSharePaymentsRelatedToReverseStockSplit" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_QLGNFractionalSharePaymentsRelatedToReverseStockSplit" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:type="arc" weight="1" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesAndEstimates" xlink:title="00000007 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND ESTIMATES" />
    <link:calculationLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/LiquidityAndGoingConcern" xlink:title="00000008 - Disclosure - LIQUIDITY AND GOING CONCERN" />
    <link:calculationLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/Acquisition" xlink:title="00000009 - Disclosure - ACQUISITION" />
    <link:calculationLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/InventoryNet" xlink:title="00000010 - Disclosure - INVENTORY, NET" />
    <link:calculationLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/PrepaidExpensesAndOtherCurrentAssets" xlink:title="00000011 - Disclosure - PREPAID EXPENSES AND OTHER CURRENT ASSETS" />
    <link:calculationLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/PropertyAndEquipmentNet" xlink:title="00000012 - Disclosure - PROPERTY AND EQUIPMENT, NET" />
    <link:calculationLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/GoodwillIprdAndOtherIntangibles" xlink:title="00000013 - Disclosure - GOODWILL, IPR&amp;D AND OTHER INTANGIBLES" />
    <link:calculationLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/AccruedExpensesAndOtherCurrentLiabilities" xlink:title="00000014 - Disclosure - ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES" />
    <link:calculationLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/ShortTermDebt-RelatedParty" xlink:title="00000015 - Disclosure - SHORT TERM DEBT - RELATED PARTY" />
    <link:calculationLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/WarrantLiabilities" xlink:title="00000016 - Disclosure - WARRANT LIABILITIES" />
    <link:calculationLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/ConvertibleDebt-RelatedParty" xlink:title="00000017 - Disclosure - CONVERTIBLE DEBT - RELATED PARTY" />
    <link:calculationLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/EarningsLossPerShare" xlink:title="00000018 - Disclosure - EARNINGS (LOSS) PER SHARE" />
    <link:calculationLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/CommitmentsAndContingencies" xlink:title="00000019 - Disclosure - COMMITMENTS AND CONTINGENCIES" />
    <link:calculationLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/ResearchAndLicenseAgreements" xlink:title="00000020 - Disclosure - RESEARCH AND LICENSE AGREEMENTS" />
    <link:calculationLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/StockholdersEquity" xlink:title="00000021 - Disclosure - STOCKHOLDERS&#8217; EQUITY" />
    <link:calculationLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/RelatedPartyTransactions" xlink:title="00000022 - Disclosure - RELATED PARTY TRANSACTIONS" />
    <link:calculationLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/IncomeTaxes" xlink:title="00000023 - Disclosure - INCOME TAXES" />
    <link:calculationLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/SubsequentEvents" xlink:title="00000024 - Disclosure - SUBSEQUENT EVENTS" />
    <link:calculationLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesAndEstimatesPolicies" xlink:title="00000025 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND ESTIMATES (Policies)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesAndEstimatesTables" xlink:title="00000026 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND ESTIMATES (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/AcquisitionTables" xlink:title="00000027 - Disclosure - ACQUISITION (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/InventoryNetTables" xlink:title="00000028 - Disclosure - INVENTORY, NET (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/PrepaidExpensesAndOtherCurrentAssetsTables" xlink:title="00000029 - Disclosure - PREPAID EXPENSES AND OTHER CURRENT ASSETS (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/PropertyAndEquipmentNetTables" xlink:title="00000030 - Disclosure - PROPERTY AND EQUIPMENT, NET (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/GoodwillIprdAndOtherIntangiblesTables" xlink:title="00000031 - Disclosure - GOODWILL, IPR&amp;D AND OTHER INTANGIBLES (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/AccruedExpensesAndOtherCurrentLiabilitiesTables" xlink:title="00000032 - Disclosure - ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/WarrantLiabilitiesTables" xlink:title="00000033 - Disclosure - WARRANT LIABILITIES (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/ConvertibleDebt-RelatedPartyTables" xlink:title="00000034 - Disclosure - CONVERTIBLE DEBT - RELATED PARTY (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/EarningsLossPerShareTables" xlink:title="00000035 - Disclosure - EARNINGS (LOSS) PER SHARE (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/CommitmentsAndContingenciesTables" xlink:title="00000036 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/StockholdersEquityTables" xlink:title="00000037 - Disclosure - STOCKHOLDERS&#8217; EQUITY (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/IncomeTaxesTables" xlink:title="00000038 - Disclosure - INCOME TAXES (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/ScheduleOfAccountsReceivableDetails" xlink:title="00000039 - Disclosure - SCHEDULE OF ACCOUNTS RECEIVABLE (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaapAccountsReceivableNetCurrent" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableGrossCurrent" xlink:label="loc_us-gaapAccountsReceivableGrossCurrent" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAccountsReceivableNetCurrent" xlink:to="loc_us-gaapAccountsReceivableGrossCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:label="loc_us-gaapAllowanceForDoubtfulAccountsReceivableCurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAccountsReceivableNetCurrent" xlink:to="loc_us-gaapAllowanceForDoubtfulAccountsReceivableCurrent" xlink:type="arc" weight="-1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/ScheduleOfUsefulLivesOfPropertyAndEquipmentDetails" xlink:title="00000040 - Disclosure - SCHEDULE OF USEFUL LIVES OF PROPERTY AND EQUIPMENT (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesAndEstimatesDetailsNarrative" xlink:title="00000041 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND ESTIMATES (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/LiquidityAndGoingConcernDetailsNarrative" xlink:title="00000042 - Disclosure - LIQUIDITY AND GOING CONCERN (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/ScheduleOfConsiderationTransferredDetails" xlink:title="00000043 - Disclosure - SCHEDULE OF CONSIDERATION TRANSFERRED (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/ScheduleOfConsiderationTransferredDetailsParenthetical" xlink:title="00000044 - Disclosure - SCHEDULE OF CONSIDERATION TRANSFERRED (Details) (Parenthetical)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/ScheduleOfAssetsAcquiredAndLiabilitiesDetails" xlink:title="00000045 - Disclosure - SCHEDULE OF ASSETS ACQUIRED AND LIABILITIES (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/ScheduleOfProFormaInformationDetails" xlink:title="00000046 - Disclosure - SCHEDULE OF PRO FORMA INFORMATION (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/AcquisitionDetailsNarrative" xlink:title="00000047 - Disclosure - ACQUISITION (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/ScheduleOfInventoryDetails" xlink:title="00000048 - Disclosure - SCHEDULE OF INVENTORY (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaapInventoryNet" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryRawMaterials" xlink:label="loc_us-gaapInventoryRawMaterials" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapInventoryNet" xlink:to="loc_us-gaapInventoryRawMaterials" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryWorkInProcess" xlink:label="loc_us-gaapInventoryWorkInProcess" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapInventoryNet" xlink:to="loc_us-gaapInventoryWorkInProcess" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryFinishedGoods" xlink:label="loc_us-gaapInventoryFinishedGoods" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapInventoryNet" xlink:to="loc_us-gaapInventoryFinishedGoods" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/ScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails" xlink:title="00000049 - Disclosure - SCHEDULE OF PREPAID EXPENSES AND OTHER CURRENT ASSETS (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidInsurance" xlink:label="loc_us-gaapPrepaidInsurance" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:to="loc_us-gaapPrepaidInsurance" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_PrepaidManufacturingExpenses" xlink:label="loc_QLGNPrepaidManufacturingExpenses" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:to="loc_QLGNPrepaidManufacturingExpenses" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherPrepaidExpenseCurrent" xlink:label="loc_us-gaapOtherPrepaidExpenseCurrent" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:to="loc_us-gaapOtherPrepaidExpenseCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsCurrent" xlink:label="loc_us-gaapOtherAssetsCurrent" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:to="loc_us-gaapOtherAssetsCurrent" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/ScheduleOfPropertyAndEquipmentDetails" xlink:title="00000050 - Disclosure - SCHEDULE OF PROPERTY AND EQUIPMENT (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/PropertyAndEquipmentNetDetailsNarrative" xlink:title="00000051 - Disclosure - PROPERTY AND EQUIPMENT, NET (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/ScheduleOfGoodwillAndOtherIntangibleDetails" xlink:title="00000052 - Disclosure - SCHEDULE OF GOODWILL AND OTHER INTANGIBLE (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/GoodwillIprdAndOtherIntangiblesDetailsNarrative" xlink:title="00000053 - Disclosure - GOODWILL, IPR&amp;D AND OTHER INTANGIBLES (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails" xlink:title="00000054 - Disclosure - SCHEDULE OF ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccruedLiabilitiesCurrent" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_AccruedCompensation" xlink:label="loc_QLGNAccruedCompensation" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAccruedLiabilitiesCurrent" xlink:to="loc_QLGNAccruedCompensation" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_AccruedEquipmentHeldForLease" xlink:label="loc_QLGNAccruedEquipmentHeldForLease" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAccruedLiabilitiesCurrent" xlink:to="loc_QLGNAccruedEquipmentHeldForLease" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_AccruedFranchiseSalesAndUseTaxes" xlink:label="loc_QLGNAccruedFranchiseSalesAndUseTaxes" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAccruedLiabilitiesCurrent" xlink:to="loc_QLGNAccruedFranchiseSalesAndUseTaxes" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedIncomeTaxesCurrent" xlink:label="loc_us-gaapAccruedIncomeTaxesCurrent" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAccruedLiabilitiesCurrent" xlink:to="loc_us-gaapAccruedIncomeTaxesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPayableCurrent" xlink:label="loc_us-gaapInterestPayableCurrent" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAccruedLiabilitiesCurrent" xlink:to="loc_us-gaapInterestPayableCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedPayrollTaxesCurrent" xlink:label="loc_us-gaapAccruedPayrollTaxesCurrent" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAccruedLiabilitiesCurrent" xlink:to="loc_us-gaapAccruedPayrollTaxesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="loc_us-gaapAccruedProfessionalFeesCurrent" />
      <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAccruedLiabilitiesCurrent" xlink:to="loc_us-gaapAccruedProfessionalFeesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_AccruedResearchAndDevelopmentCurrent" xlink:label="loc_QLGNAccruedResearchAndDevelopmentCurrent" />
      <link:calculationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAccruedLiabilitiesCurrent" xlink:to="loc_QLGNAccruedResearchAndDevelopmentCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedRoyaltiesCurrent" xlink:label="loc_us-gaapAccruedRoyaltiesCurrent" />
      <link:calculationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAccruedLiabilitiesCurrent" xlink:to="loc_us-gaapAccruedRoyaltiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductWarrantyAccrual" xlink:label="loc_us-gaapProductWarrantyAccrual" />
      <link:calculationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAccruedLiabilitiesCurrent" xlink:to="loc_us-gaapProductWarrantyAccrual" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_AccruedLicenseFees" xlink:label="loc_QLGNAccruedLicenseFees" />
      <link:calculationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAccruedLiabilitiesCurrent" xlink:to="loc_QLGNAccruedLicenseFees" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaapOtherAccruedLiabilitiesCurrent" />
      <link:calculationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAccruedLiabilitiesCurrent" xlink:to="loc_us-gaapOtherAccruedLiabilitiesCurrent" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/ShortTermDebt-RelatedPartyDetailsNarrative" xlink:title="00000055 - Disclosure - SHORT TERM DEBT - RELATED PARTY (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/ScheduleOfWarrantsActivityDetails" xlink:title="00000056 - Disclosure - SCHEDULE OF WARRANTS ACTIVITY (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/ScheduleOfFairValueHierarchyForWarrantLiabilitiesDetails" xlink:title="00000057 - Disclosure - SCHEDULE OF FAIR VALUE HIERARCHY FOR WARRANT LIABILITIES (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/ScheduleOfAssumptionsOfWarrantLiabilitiesDetails" xlink:title="00000058 - Disclosure - SCHEDULE OF ASSUMPTIONS OF WARRANT LIABILITIES (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/WarrantLiabilitiesDetailsNarrative" xlink:title="00000059 - Disclosure - WARRANT LIABILITIES (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/ScheduleOfSeniorSecuredConvertibleDebtDetails" xlink:title="00000060 - Disclosure - SCHEDULE OF SENIOR SECURED CONVERTIBLE DEBT (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/ConvertibleDebt-RelatedPartyDetailsNarrative" xlink:title="00000061 - Disclosure - CONVERTIBLE DEBT - RELATED PARTY (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/ScheduleOfEarningsPerShareBasicAndDilutedDetails" xlink:title="00000062 - Disclosure - SCHEDULE OF EARNINGS PER SHARE BASIC AND DILUTED (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/ScheduleOfDilutiveSecuritiesExcludedFromDilutedNetLossPerShareDetails" xlink:title="00000063 - Disclosure - SCHEDULE OF DILUTIVE SECURITIES EXCLUDED FROM DILUTED NET LOSS PER SHARE (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/ScheduleOfOperatingLeaseRightOfUseAssetsAndOperatingLeaseLiabilitiesDetails" xlink:title="00000064 - Disclosure - SCHEDULE OF OPERATING LEASE RIGHT OF USE ASSETS AND OPERATING LEASE LIABILITIES (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/ScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails" xlink:title="00000065 - Disclosure - SCHEDULE OF MATURITIES OF OPERATING LEASE LIABILITIES (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearThree" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearFour" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearFive" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:title="00000066 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/ResearchAndLicenseAgreementsDetailsNarrative" xlink:title="00000067 - Disclosure - RESEARCH AND LICENSE AGREEMENTS (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/ScheduleOfReservedSharesDetails" xlink:title="00000068 - Disclosure - SCHEDULE OF RESERVED SHARES (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/ScheduleOfStockOptionActivityDetails" xlink:title="00000069 - Disclosure - SCHEDULE OF STOCK OPTION ACTIVITY (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/ScheduleOfAssumptionUsedInBlack-scholesOption-pricingMethodDetails" xlink:title="00000070 - Disclosure - SCHEDULE OF ASSUMPTION USED IN BLACK-SCHOLES OPTION-PRICING METHOD (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/ScheduleOfShare-basedCompensationExpenseDetails" xlink:title="00000071 - Disclosure - SCHEDULE OF SHARE-BASED COMPENSATION EXPENSE (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/ScheduleOfWarrantActivityDetails" xlink:title="00000072 - Disclosure - SCHEDULE OF WARRANT ACTIVITY (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/StockholdersEquityDetailsNarrative" xlink:title="00000073 - Disclosure - STOCKHOLDERS&#8217; EQUITY (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/RelatedPartyTransactionsDetailsNarrative" xlink:title="00000074 - Disclosure - RELATED PARTY TRANSACTIONS (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/ScheduleOfDomesticAndForeignComponentsDetails" xlink:title="00000075 - Disclosure - SCHEDULE OF DOMESTIC AND FOREIGN COMPONENTS (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/ScheduleOfReconciliationsOfStatutoryIncomeTaxRateDetails" xlink:title="00000076 - Disclosure - SCHEDULE OF RECONCILIATIONS OF STATUTORY INCOME TAX RATE (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/ScheduleOfProvisionForIncomeTaxesDetails" xlink:title="00000077 - Disclosure - SCHEDULE OF PROVISION FOR INCOME TAXES (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="loc_us-gaapCurrentIncomeTaxExpenseBenefit" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:label="loc_us-gaapCurrentFederalTaxExpenseBenefit" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCurrentIncomeTaxExpenseBenefit" xlink:to="loc_us-gaapCurrentFederalTaxExpenseBenefit" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="loc_us-gaapCurrentStateAndLocalTaxExpenseBenefit" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCurrentIncomeTaxExpenseBenefit" xlink:to="loc_us-gaapCurrentStateAndLocalTaxExpenseBenefit" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentForeignTaxExpenseBenefit" xlink:label="loc_us-gaapCurrentForeignTaxExpenseBenefit" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCurrentIncomeTaxExpenseBenefit" xlink:to="loc_us-gaapCurrentForeignTaxExpenseBenefit" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="loc_us-gaapDeferredIncomeTaxExpenseBenefit" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:label="loc_us-gaapDeferredFederalIncomeTaxExpenseBenefit" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredIncomeTaxExpenseBenefit" xlink:to="loc_us-gaapDeferredFederalIncomeTaxExpenseBenefit" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:label="loc_us-gaapDeferredStateAndLocalIncomeTaxExpenseBenefit" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredIncomeTaxExpenseBenefit" xlink:to="loc_us-gaapDeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:label="loc_us-gaapDeferredForeignIncomeTaxExpenseBenefit" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredIncomeTaxExpenseBenefit" xlink:to="loc_us-gaapDeferredForeignIncomeTaxExpenseBenefit" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaapIncomeTaxExpenseBenefit" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeTaxExpenseBenefit" xlink:to="loc_us-gaapDeferredIncomeTaxExpenseBenefit" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="loc_us-gaapValuationAllowanceDeferredTaxAssetChangeInAmount" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeTaxExpenseBenefit" xlink:to="loc_us-gaapValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:type="arc" weight="-1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:title="00000078 - Disclosure - SCHEDULE OF DEFERRED TAX ASSETS AND LIABILITIES (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpense" xlink:label="loc_us-gaapDeferredTaxAssetsTaxDeferredExpense" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwards" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsTaxDeferredExpense" xlink:to="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwards" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="loc_us-gaapDeferredTaxAssetsInProcessResearchAndDevelopment" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsTaxDeferredExpense" xlink:to="loc_us-gaapDeferredTaxAssetsInProcessResearchAndDevelopment" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_DefferdTaxAssetsAccruedExpenses" xlink:label="loc_QLGNDefferdTaxAssetsAccruedExpenses" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsTaxDeferredExpense" xlink:to="loc_QLGNDefferdTaxAssetsAccruedExpenses" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:label="loc_us-gaapDeferredTaxAssetsGoodwillAndIntangibleAssets" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsTaxDeferredExpense" xlink:to="loc_us-gaapDeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsTaxDeferredExpense" xlink:to="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_DeferredTaxAssetsResearchAndDevelopmentExpenses" xlink:label="loc_QLGNDeferredTaxAssetsResearchAndDevelopmentExpenses" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsTaxDeferredExpense" xlink:to="loc_QLGNDeferredTaxAssetsResearchAndDevelopmentExpenses" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:label="loc_us-gaapDeferredTaxAssetsPropertyPlantAndEquipment" />
      <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsTaxDeferredExpense" xlink:to="loc_us-gaapDeferredTaxAssetsPropertyPlantAndEquipment" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="loc_us-gaapDeferredIncomeTaxLiabilities" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:label="loc_us-gaapDeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredIncomeTaxLiabilities" xlink:to="loc_us-gaapDeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:label="loc_us-gaapDeferredTaxLiabilitiesLeasingArrangements" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredIncomeTaxLiabilities" xlink:to="loc_us-gaapDeferredTaxLiabilitiesLeasingArrangements" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaapDeferredTaxAssetsGross" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsGross" xlink:to="loc_us-gaapDeferredTaxAssetsTaxDeferredExpense" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsGross" xlink:to="loc_us-gaapDeferredIncomeTaxLiabilities" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="loc_us-gaapDeferredTaxAssetsLiabilitiesNet" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsLiabilitiesNet" xlink:to="loc_us-gaapDeferredTaxAssetsGross" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapDeferredTaxAssetsValuationAllowance" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsLiabilitiesNet" xlink:to="loc_us-gaapDeferredTaxAssetsValuationAllowance" xlink:type="arc" weight="-1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/IncomeTaxesDetailsNarrative" xlink:title="00000079 - Disclosure - INCOME TAXES (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/SubsequentEventsDetailsNarrative" xlink:title="00000080 - Disclosure - SUBSEQUENT EVENTS (Details Narrative)" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>29
<FILENAME>qlgn-20221231_def.xml
<DESCRIPTION>INLINE XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.18a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://qualigeninc.com/role/Cover" xlink:href="qlgn-20221231.xsd#Cover" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigeninc.com/role/BalanceSheets" xlink:href="qlgn-20221231.xsd#BalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigeninc.com/role/BalanceSheetsParenthetical" xlink:href="qlgn-20221231.xsd#BalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigeninc.com/role/StatementsOfOperationsAndComprehensiveLoss" xlink:href="qlgn-20221231.xsd#StatementsOfOperationsAndComprehensiveLoss" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigeninc.com/role/StatementsOfChangesInStockholdersEquity" xlink:href="qlgn-20221231.xsd#StatementsOfChangesInStockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigeninc.com/role/StatementsOfCashFlows" xlink:href="qlgn-20221231.xsd#StatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigeninc.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesAndEstimates" xlink:href="qlgn-20221231.xsd#OrganizationAndSummaryOfSignificantAccountingPoliciesAndEstimates" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigeninc.com/role/LiquidityAndGoingConcern" xlink:href="qlgn-20221231.xsd#LiquidityAndGoingConcern" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigeninc.com/role/Acquisition" xlink:href="qlgn-20221231.xsd#Acquisition" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigeninc.com/role/InventoryNet" xlink:href="qlgn-20221231.xsd#InventoryNet" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigeninc.com/role/PrepaidExpensesAndOtherCurrentAssets" xlink:href="qlgn-20221231.xsd#PrepaidExpensesAndOtherCurrentAssets" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigeninc.com/role/PropertyAndEquipmentNet" xlink:href="qlgn-20221231.xsd#PropertyAndEquipmentNet" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigeninc.com/role/GoodwillIprdAndOtherIntangibles" xlink:href="qlgn-20221231.xsd#GoodwillIprdAndOtherIntangibles" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigeninc.com/role/AccruedExpensesAndOtherCurrentLiabilities" xlink:href="qlgn-20221231.xsd#AccruedExpensesAndOtherCurrentLiabilities" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigeninc.com/role/ShortTermDebt-RelatedParty" xlink:href="qlgn-20221231.xsd#ShortTermDebt-RelatedParty" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigeninc.com/role/WarrantLiabilities" xlink:href="qlgn-20221231.xsd#WarrantLiabilities" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigeninc.com/role/ConvertibleDebt-RelatedParty" xlink:href="qlgn-20221231.xsd#ConvertibleDebt-RelatedParty" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigeninc.com/role/EarningsLossPerShare" xlink:href="qlgn-20221231.xsd#EarningsLossPerShare" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigeninc.com/role/CommitmentsAndContingencies" xlink:href="qlgn-20221231.xsd#CommitmentsAndContingencies" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigeninc.com/role/ResearchAndLicenseAgreements" xlink:href="qlgn-20221231.xsd#ResearchAndLicenseAgreements" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigeninc.com/role/StockholdersEquity" xlink:href="qlgn-20221231.xsd#StockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigeninc.com/role/RelatedPartyTransactions" xlink:href="qlgn-20221231.xsd#RelatedPartyTransactions" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigeninc.com/role/IncomeTaxes" xlink:href="qlgn-20221231.xsd#IncomeTaxes" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigeninc.com/role/SubsequentEvents" xlink:href="qlgn-20221231.xsd#SubsequentEvents" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigeninc.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesAndEstimatesPolicies" xlink:href="qlgn-20221231.xsd#OrganizationAndSummaryOfSignificantAccountingPoliciesAndEstimatesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigeninc.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesAndEstimatesTables" xlink:href="qlgn-20221231.xsd#OrganizationAndSummaryOfSignificantAccountingPoliciesAndEstimatesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigeninc.com/role/AcquisitionTables" xlink:href="qlgn-20221231.xsd#AcquisitionTables" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigeninc.com/role/InventoryNetTables" xlink:href="qlgn-20221231.xsd#InventoryNetTables" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigeninc.com/role/PrepaidExpensesAndOtherCurrentAssetsTables" xlink:href="qlgn-20221231.xsd#PrepaidExpensesAndOtherCurrentAssetsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigeninc.com/role/PropertyAndEquipmentNetTables" xlink:href="qlgn-20221231.xsd#PropertyAndEquipmentNetTables" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigeninc.com/role/GoodwillIprdAndOtherIntangiblesTables" xlink:href="qlgn-20221231.xsd#GoodwillIprdAndOtherIntangiblesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigeninc.com/role/AccruedExpensesAndOtherCurrentLiabilitiesTables" xlink:href="qlgn-20221231.xsd#AccruedExpensesAndOtherCurrentLiabilitiesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigeninc.com/role/WarrantLiabilitiesTables" xlink:href="qlgn-20221231.xsd#WarrantLiabilitiesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigeninc.com/role/ConvertibleDebt-RelatedPartyTables" xlink:href="qlgn-20221231.xsd#ConvertibleDebt-RelatedPartyTables" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigeninc.com/role/EarningsLossPerShareTables" xlink:href="qlgn-20221231.xsd#EarningsLossPerShareTables" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigeninc.com/role/CommitmentsAndContingenciesTables" xlink:href="qlgn-20221231.xsd#CommitmentsAndContingenciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigeninc.com/role/StockholdersEquityTables" xlink:href="qlgn-20221231.xsd#StockholdersEquityTables" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigeninc.com/role/IncomeTaxesTables" xlink:href="qlgn-20221231.xsd#IncomeTaxesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigeninc.com/role/ScheduleOfAccountsReceivableDetails" xlink:href="qlgn-20221231.xsd#ScheduleOfAccountsReceivableDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigeninc.com/role/ScheduleOfUsefulLivesOfPropertyAndEquipmentDetails" xlink:href="qlgn-20221231.xsd#ScheduleOfUsefulLivesOfPropertyAndEquipmentDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigeninc.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesAndEstimatesDetailsNarrative" xlink:href="qlgn-20221231.xsd#OrganizationAndSummaryOfSignificantAccountingPoliciesAndEstimatesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigeninc.com/role/LiquidityAndGoingConcernDetailsNarrative" xlink:href="qlgn-20221231.xsd#LiquidityAndGoingConcernDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigeninc.com/role/ScheduleOfConsiderationTransferredDetails" xlink:href="qlgn-20221231.xsd#ScheduleOfConsiderationTransferredDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigeninc.com/role/ScheduleOfConsiderationTransferredDetailsParenthetical" xlink:href="qlgn-20221231.xsd#ScheduleOfConsiderationTransferredDetailsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigeninc.com/role/ScheduleOfAssetsAcquiredAndLiabilitiesDetails" xlink:href="qlgn-20221231.xsd#ScheduleOfAssetsAcquiredAndLiabilitiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigeninc.com/role/ScheduleOfProFormaInformationDetails" xlink:href="qlgn-20221231.xsd#ScheduleOfProFormaInformationDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigeninc.com/role/AcquisitionDetailsNarrative" xlink:href="qlgn-20221231.xsd#AcquisitionDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigeninc.com/role/ScheduleOfInventoryDetails" xlink:href="qlgn-20221231.xsd#ScheduleOfInventoryDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigeninc.com/role/ScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails" xlink:href="qlgn-20221231.xsd#ScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigeninc.com/role/ScheduleOfPropertyAndEquipmentDetails" xlink:href="qlgn-20221231.xsd#ScheduleOfPropertyAndEquipmentDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigeninc.com/role/PropertyAndEquipmentNetDetailsNarrative" xlink:href="qlgn-20221231.xsd#PropertyAndEquipmentNetDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigeninc.com/role/ScheduleOfGoodwillAndOtherIntangibleDetails" xlink:href="qlgn-20221231.xsd#ScheduleOfGoodwillAndOtherIntangibleDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigeninc.com/role/GoodwillIprdAndOtherIntangiblesDetailsNarrative" xlink:href="qlgn-20221231.xsd#GoodwillIprdAndOtherIntangiblesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigeninc.com/role/ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails" xlink:href="qlgn-20221231.xsd#ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigeninc.com/role/ShortTermDebt-RelatedPartyDetailsNarrative" xlink:href="qlgn-20221231.xsd#ShortTermDebt-RelatedPartyDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigeninc.com/role/ScheduleOfWarrantsActivityDetails" xlink:href="qlgn-20221231.xsd#ScheduleOfWarrantsActivityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigeninc.com/role/ScheduleOfFairValueHierarchyForWarrantLiabilitiesDetails" xlink:href="qlgn-20221231.xsd#ScheduleOfFairValueHierarchyForWarrantLiabilitiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigeninc.com/role/ScheduleOfAssumptionsOfWarrantLiabilitiesDetails" xlink:href="qlgn-20221231.xsd#ScheduleOfAssumptionsOfWarrantLiabilitiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigeninc.com/role/WarrantLiabilitiesDetailsNarrative" xlink:href="qlgn-20221231.xsd#WarrantLiabilitiesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigeninc.com/role/ScheduleOfSeniorSecuredConvertibleDebtDetails" xlink:href="qlgn-20221231.xsd#ScheduleOfSeniorSecuredConvertibleDebtDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigeninc.com/role/ConvertibleDebt-RelatedPartyDetailsNarrative" xlink:href="qlgn-20221231.xsd#ConvertibleDebt-RelatedPartyDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigeninc.com/role/ScheduleOfEarningsPerShareBasicAndDilutedDetails" xlink:href="qlgn-20221231.xsd#ScheduleOfEarningsPerShareBasicAndDilutedDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigeninc.com/role/ScheduleOfDilutiveSecuritiesExcludedFromDilutedNetLossPerShareDetails" xlink:href="qlgn-20221231.xsd#ScheduleOfDilutiveSecuritiesExcludedFromDilutedNetLossPerShareDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigeninc.com/role/ScheduleOfOperatingLeaseRightOfUseAssetsAndOperatingLeaseLiabilitiesDetails" xlink:href="qlgn-20221231.xsd#ScheduleOfOperatingLeaseRightOfUseAssetsAndOperatingLeaseLiabilitiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigeninc.com/role/ScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails" xlink:href="qlgn-20221231.xsd#ScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigeninc.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:href="qlgn-20221231.xsd#CommitmentsAndContingenciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigeninc.com/role/ResearchAndLicenseAgreementsDetailsNarrative" xlink:href="qlgn-20221231.xsd#ResearchAndLicenseAgreementsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigeninc.com/role/ScheduleOfReservedSharesDetails" xlink:href="qlgn-20221231.xsd#ScheduleOfReservedSharesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigeninc.com/role/ScheduleOfStockOptionActivityDetails" xlink:href="qlgn-20221231.xsd#ScheduleOfStockOptionActivityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigeninc.com/role/ScheduleOfAssumptionUsedInBlack-scholesOption-pricingMethodDetails" xlink:href="qlgn-20221231.xsd#ScheduleOfAssumptionUsedInBlack-scholesOption-pricingMethodDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigeninc.com/role/ScheduleOfShare-basedCompensationExpenseDetails" xlink:href="qlgn-20221231.xsd#ScheduleOfShare-basedCompensationExpenseDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigeninc.com/role/ScheduleOfWarrantActivityDetails" xlink:href="qlgn-20221231.xsd#ScheduleOfWarrantActivityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigeninc.com/role/StockholdersEquityDetailsNarrative" xlink:href="qlgn-20221231.xsd#StockholdersEquityDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigeninc.com/role/RelatedPartyTransactionsDetailsNarrative" xlink:href="qlgn-20221231.xsd#RelatedPartyTransactionsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigeninc.com/role/ScheduleOfDomesticAndForeignComponentsDetails" xlink:href="qlgn-20221231.xsd#ScheduleOfDomesticAndForeignComponentsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigeninc.com/role/ScheduleOfReconciliationsOfStatutoryIncomeTaxRateDetails" xlink:href="qlgn-20221231.xsd#ScheduleOfReconciliationsOfStatutoryIncomeTaxRateDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigeninc.com/role/ScheduleOfProvisionForIncomeTaxesDetails" xlink:href="qlgn-20221231.xsd#ScheduleOfProvisionForIncomeTaxesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigeninc.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:href="qlgn-20221231.xsd#ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigeninc.com/role/IncomeTaxesDetailsNarrative" xlink:href="qlgn-20221231.xsd#IncomeTaxesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigeninc.com/role/SubsequentEventsDetailsNarrative" xlink:href="qlgn-20221231.xsd#SubsequentEventsDetailsNarrative" xlink:type="simple" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll" arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" />
    <link:definitionLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/Cover" xlink:title="00000001 - Document - Cover" />
    <link:definitionLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/BalanceSheets" xlink:title="00000002 - Statement - Consolidated Balance Sheets" />
    <link:definitionLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/BalanceSheetsParenthetical" xlink:title="00000003 - Statement - Consolidated Balance Sheets (Parenthetical)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/StatementsOfOperationsAndComprehensiveLoss" xlink:title="00000004 - Statement - Consolidated Statements of Operations and Comprehensive Loss">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srtProductOrServiceAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtProductOrServiceAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srtProductsAndServicesDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtProductOrServiceAxis" xlink:to="loc_srtProductsAndServicesDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srtProductsAndServicesDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtProductOrServiceAxis" xlink:to="loc_srtProductsAndServicesDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_NetProductSalesMember" xlink:label="loc_QLGNNetProductSalesMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_QLGNNetProductSalesMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_LicenseRevenueMember" xlink:label="loc_QLGNLicenseRevenueMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_QLGNLicenseRevenueMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenuesAbstract" xlink:label="loc_us-gaapRevenuesAbstract_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapRevenuesAbstract_70" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRevenuesAbstract_70" xlink:to="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax_70" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingCostsAndExpensesAbstract" xlink:label="loc_us-gaapOperatingCostsAndExpensesAbstract_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOperatingCostsAndExpensesAbstract_70" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_CostOfProductSales" xlink:label="loc_QLGNCostOfProductSales_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOperatingCostsAndExpensesAbstract_70" xlink:to="loc_QLGNCostOfProductSales_70" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOperatingCostsAndExpensesAbstract_70" xlink:to="loc_us-gaapGeneralAndAdministrativeExpense_70" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOperatingCostsAndExpensesAbstract_70" xlink:to="loc_us-gaapResearchAndDevelopmentExpense_70" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketingAndAdvertisingExpense" xlink:label="loc_us-gaapMarketingAndAdvertisingExpense_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOperatingCostsAndExpensesAbstract_70" xlink:to="loc_us-gaapMarketingAndAdvertisingExpense_70" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillImpairmentLoss" xlink:label="loc_us-gaapGoodwillImpairmentLoss_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOperatingCostsAndExpensesAbstract_70" xlink:to="loc_us-gaapGoodwillImpairmentLoss_70" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaapOperatingExpenses_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOperatingCostsAndExpensesAbstract_70" xlink:to="loc_us-gaapOperatingExpenses_70" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOperatingIncomeLoss_70" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaapNonoperatingIncomeExpenseAbstract_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNonoperatingIncomeExpenseAbstract_70" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeGainLossOnDerivativeNet" xlink:label="loc_us-gaapDerivativeGainLossOnDerivativeNet_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract_70" xlink:to="loc_us-gaapDerivativeGainLossOnDerivativeNet_70" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestIncomeExpenseNet" xlink:label="loc_us-gaapInterestIncomeExpenseNet_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract_70" xlink:to="loc_us-gaapInterestIncomeExpenseNet_70" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaapOtherNonoperatingIncomeExpense_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract_70" xlink:to="loc_us-gaapOtherNonoperatingIncomeExpense_70" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaapNonoperatingIncomeExpense_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract_70" xlink:to="loc_us-gaapNonoperatingIncomeExpense_70" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_70" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaapIncomeTaxExpenseBenefit_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapIncomeTaxExpenseBenefit_70" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaapProfitLoss_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapProfitLoss_70" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="loc_us-gaapNetIncomeLossAttributableToNoncontrollingInterest_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLossAttributableToNoncontrollingInterest_70" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLoss_70" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaapEarningsPerShareBasic_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapEarningsPerShareBasic_70" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic_70" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:label="loc_us-gaapOtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_70" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="loc_us-gaapOtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_70" xlink:to="loc_us-gaapOtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_70" xlink:type="arc" order="23" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaapComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_70" xlink:to="loc_us-gaapComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_70" xlink:type="arc" order="24" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:label="loc_us-gaapComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_70" xlink:to="loc_us-gaapComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_70" xlink:type="arc" order="25" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaapComprehensiveIncomeNetOfTax_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_70" xlink:to="loc_us-gaapComprehensiveIncomeNetOfTax_70" xlink:type="arc" order="26" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/StatementsOfChangesInStockholdersEquity" xlink:title="00000005 - Statement - Consolidated Statements of Changes in Stockholders&apos; Equity">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockMember" xlink:label="loc_us-gaapPreferredStockMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapPreferredStockMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaapAdditionalPaidInCapitalMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapAdditionalPaidInCapitalMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaapRetainedEarningsMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapRetainedEarningsMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ParentMember" xlink:label="loc_us-gaapParentMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapParentMember_50" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncontrollingInterestMember" xlink:label="loc_us-gaapNoncontrollingInterestMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapNoncontrollingInterestMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_SeriesAlphaConvertiblePreferredStockMember" xlink:label="loc_QLGNSeriesAlphaConvertiblePreferredStockMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_QLGNSeriesAlphaConvertiblePreferredStockMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaapStockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_90" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding_90" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_StockIssuedUponCashExerciseOfWarrants" xlink:label="loc_QLGNStockIssuedUponCashExerciseOfWarrants_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_QLGNStockIssuedUponCashExerciseOfWarrants_90" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_StockIssuedUponCashExerciseOfWarrantsShares" xlink:label="loc_QLGNStockIssuedUponCashExerciseOfWarrantsShares_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_QLGNStockIssuedUponCashExerciseOfWarrantsShares_90" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions_90" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_CommonStockAndPrefundedWarrantsIssuedForBusinessAcquisition" xlink:label="loc_QLGNCommonStockAndPrefundedWarrantsIssuedForBusinessAcquisition_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_QLGNCommonStockAndPrefundedWarrantsIssuedForBusinessAcquisition_90" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_CommonStockAndPrefundedWarrantsIssuedSharesForBusinessAcquisition" xlink:label="loc_QLGNCommonStockAndPrefundedWarrantsIssuedSharesForBusinessAcquisition_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_QLGNCommonStockAndPrefundedWarrantsIssuedSharesForBusinessAcquisition_90" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_NoncontrollingInterestAdjustmentsRelatingToStockbasedCompensationAndOther" xlink:label="loc_QLGNNoncontrollingInterestAdjustmentsRelatingToStockbasedCompensationAndOther_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_QLGNNoncontrollingInterestAdjustmentsRelatingToStockbasedCompensationAndOther_90" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="loc_us-gaapOtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_90" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_FairValueOfWarrantModificationForProfessionalServices" xlink:label="loc_QLGNFairValueOfWarrantModificationForProfessionalServices_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_QLGNFairValueOfWarrantModificationForProfessionalServices_90" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_FairValueOfWarrantModificationForBusinessAcquisition" xlink:label="loc_QLGNFairValueOfWarrantModificationForBusinessAcquisition_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_QLGNFairValueOfWarrantModificationForBusinessAcquisition_90" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_StockIssuedDuringPeriodValuesReverseStockSplits" xlink:label="loc_QLGNStockIssuedDuringPeriodValuesReverseStockSplits_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_QLGNStockIssuedDuringPeriodValuesReverseStockSplits_90" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesReverseStockSplits_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesReverseStockSplits_90" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaapProfitLoss_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapProfitLoss_90" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_StockIssuedUponNetexerciseOfWarrants" xlink:label="loc_QLGNStockIssuedUponNetexerciseOfWarrants_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_QLGNStockIssuedUponNetexerciseOfWarrants_90" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_StockIssuedUponNetexerciseOfWarrantsShares" xlink:label="loc_QLGNStockIssuedUponNetexerciseOfWarrantsShares_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_QLGNStockIssuedUponNetexerciseOfWarrantsShares_90" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_IssuanceOfCommonStockForConversionOfPreferredStock" xlink:label="loc_QLGNIssuanceOfCommonStockForConversionOfPreferredStock_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_QLGNIssuanceOfCommonStockForConversionOfPreferredStock_90" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_IssuanceOfCommonStockSharesForConversionOfPreferredStock" xlink:label="loc_QLGNIssuanceOfCommonStockSharesForConversionOfPreferredStock_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_QLGNIssuanceOfCommonStockSharesForConversionOfPreferredStock_90" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_FairValueOfWarrantsIssuedForProfessionalServices" xlink:label="loc_QLGNFairValueOfWarrantsIssuedForProfessionalServices_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_QLGNFairValueOfWarrantsIssuedForProfessionalServices_90" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_SharesIssuedPursuantToSecuritiesPurchaseAgreements" xlink:label="loc_QLGNSharesIssuedPursuantToSecuritiesPurchaseAgreements_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_QLGNSharesIssuedPursuantToSecuritiesPurchaseAgreements_90" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_SharesIssuedPursuantToSecuritiesPurchaseShareAgreements" xlink:label="loc_QLGNSharesIssuedPursuantToSecuritiesPurchaseShareAgreements_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_QLGNSharesIssuedPursuantToSecuritiesPurchaseShareAgreements_90" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_CommissionAndOfferingCostsOfSecuritiesPurchaseAgreements" xlink:label="loc_QLGNCommissionAndOfferingCostsOfSecuritiesPurchaseAgreements_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_QLGNCommissionAndOfferingCostsOfSecuritiesPurchaseAgreements_90" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_FairValueOfWarrantModificationsPursuantToSecuritiesPurchaseAgreements" xlink:label="loc_QLGNFairValueOfWarrantModificationsPursuantToSecuritiesPurchaseAgreements_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_QLGNFairValueOfWarrantModificationsPursuantToSecuritiesPurchaseAgreements_90" xlink:type="arc" order="23" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueIssuedForServices_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueIssuedForServices_90" xlink:type="arc" order="24" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesIssuedForServices_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesIssuedForServices_90" xlink:type="arc" order="25" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_90" xlink:type="arc" order="26" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/StatementsOfCashFlows" xlink:title="00000006 - Statement - Consolidated Statements of Cash Flows" />
    <link:definitionLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesAndEstimates" xlink:title="00000007 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND ESTIMATES" />
    <link:definitionLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/LiquidityAndGoingConcern" xlink:title="00000008 - Disclosure - LIQUIDITY AND GOING CONCERN" />
    <link:definitionLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/Acquisition" xlink:title="00000009 - Disclosure - ACQUISITION" />
    <link:definitionLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/InventoryNet" xlink:title="00000010 - Disclosure - INVENTORY, NET" />
    <link:definitionLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/PrepaidExpensesAndOtherCurrentAssets" xlink:title="00000011 - Disclosure - PREPAID EXPENSES AND OTHER CURRENT ASSETS" />
    <link:definitionLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/PropertyAndEquipmentNet" xlink:title="00000012 - Disclosure - PROPERTY AND EQUIPMENT, NET" />
    <link:definitionLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/GoodwillIprdAndOtherIntangibles" xlink:title="00000013 - Disclosure - GOODWILL, IPR&amp;D AND OTHER INTANGIBLES" />
    <link:definitionLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/AccruedExpensesAndOtherCurrentLiabilities" xlink:title="00000014 - Disclosure - ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES" />
    <link:definitionLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/ShortTermDebt-RelatedParty" xlink:title="00000015 - Disclosure - SHORT TERM DEBT - RELATED PARTY" />
    <link:definitionLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/WarrantLiabilities" xlink:title="00000016 - Disclosure - WARRANT LIABILITIES" />
    <link:definitionLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/ConvertibleDebt-RelatedParty" xlink:title="00000017 - Disclosure - CONVERTIBLE DEBT - RELATED PARTY" />
    <link:definitionLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/EarningsLossPerShare" xlink:title="00000018 - Disclosure - EARNINGS (LOSS) PER SHARE" />
    <link:definitionLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/CommitmentsAndContingencies" xlink:title="00000019 - Disclosure - COMMITMENTS AND CONTINGENCIES" />
    <link:definitionLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/ResearchAndLicenseAgreements" xlink:title="00000020 - Disclosure - RESEARCH AND LICENSE AGREEMENTS" />
    <link:definitionLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/StockholdersEquity" xlink:title="00000021 - Disclosure - STOCKHOLDERS&#8217; EQUITY" />
    <link:definitionLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/RelatedPartyTransactions" xlink:title="00000022 - Disclosure - RELATED PARTY TRANSACTIONS" />
    <link:definitionLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/IncomeTaxes" xlink:title="00000023 - Disclosure - INCOME TAXES" />
    <link:definitionLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/SubsequentEvents" xlink:title="00000024 - Disclosure - SUBSEQUENT EVENTS" />
    <link:definitionLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesAndEstimatesPolicies" xlink:title="00000025 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND ESTIMATES (Policies)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesAndEstimatesTables" xlink:title="00000026 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND ESTIMATES (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/AcquisitionTables" xlink:title="00000027 - Disclosure - ACQUISITION (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/InventoryNetTables" xlink:title="00000028 - Disclosure - INVENTORY, NET (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/PrepaidExpensesAndOtherCurrentAssetsTables" xlink:title="00000029 - Disclosure - PREPAID EXPENSES AND OTHER CURRENT ASSETS (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/PropertyAndEquipmentNetTables" xlink:title="00000030 - Disclosure - PROPERTY AND EQUIPMENT, NET (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/GoodwillIprdAndOtherIntangiblesTables" xlink:title="00000031 - Disclosure - GOODWILL, IPR&amp;D AND OTHER INTANGIBLES (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/AccruedExpensesAndOtherCurrentLiabilitiesTables" xlink:title="00000032 - Disclosure - ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/WarrantLiabilitiesTables" xlink:title="00000033 - Disclosure - WARRANT LIABILITIES (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/ConvertibleDebt-RelatedPartyTables" xlink:title="00000034 - Disclosure - CONVERTIBLE DEBT - RELATED PARTY (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/EarningsLossPerShareTables" xlink:title="00000035 - Disclosure - EARNINGS (LOSS) PER SHARE (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/CommitmentsAndContingenciesTables" xlink:title="00000036 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/StockholdersEquityTables" xlink:title="00000037 - Disclosure - STOCKHOLDERS&#8217; EQUITY (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_CompensatoryWarrantActivityMember" xlink:label="loc_QLGNCompensatoryWarrantActivityMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_QLGNCompensatoryWarrantActivityMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_NonCompensatoryWarrantActivityMember" xlink:label="loc_QLGNNonCompensatoryWarrantActivityMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_QLGNNonCompensatoryWarrantActivityMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_ScheduleOfReservedSharesTableTextBlock" xlink:label="loc_QLGNScheduleOfReservedSharesTableTextBlock_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_QLGNScheduleOfReservedSharesTableTextBlock_40" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_40" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_40" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:label="loc_us-gaapScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_40" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_SummaryOfWarrantActivityTableTextBlock" xlink:label="loc_QLGNSummaryOfWarrantActivityTableTextBlock_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_QLGNSummaryOfWarrantActivityTableTextBlock_40" xlink:type="arc" order="4" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/IncomeTaxesTables" xlink:title="00000038 - Disclosure - INCOME TAXES (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/ScheduleOfAccountsReceivableDetails" xlink:title="00000039 - Disclosure - SCHEDULE OF ACCOUNTS RECEIVABLE (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/ScheduleOfUsefulLivesOfPropertyAndEquipmentDetails" xlink:title="00000040 - Disclosure - SCHEDULE OF USEFUL LIVES OF PROPERTY AND EQUIPMENT (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaapPropertyPlantAndEquipmentLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MachineryAndEquipmentMember" xlink:label="loc_us-gaapMachineryAndEquipmentMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapMachineryAndEquipmentMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComputerEquipmentMember" xlink:label="loc_us-gaapComputerEquipmentMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapComputerEquipmentMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_MoldsAndToolingMember" xlink:label="loc_QLGNMoldsAndToolingMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_QLGNMoldsAndToolingMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaapFurnitureAndFixturesMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapFurnitureAndFixturesMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaapPropertyPlantAndEquipmentUsefulLife_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentUsefulLife_50" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesAndEstimatesDetailsNarrative" xlink:title="00000041 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND ESTIMATES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaapBusinessAcquisitionAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapBusinessAcquisitionAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaapBusinessAcquisitionAcquireeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapBusinessAcquisitionAxis" xlink:to="loc_us-gaapBusinessAcquisitionAcquireeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaapBusinessAcquisitionAcquireeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapBusinessAcquisitionAxis" xlink:to="loc_us-gaapBusinessAcquisitionAcquireeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_NanoSynexLtdMember" xlink:label="loc_QLGNNanoSynexLtdMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessAcquisitionAcquireeDomain" xlink:to="loc_QLGNNanoSynexLtdMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_SeriesAOnePreferredStockMember" xlink:label="loc_QLGNSeriesAOnePreferredStockMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_QLGNSeriesAOnePreferredStockMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="loc_us-gaapSeriesBPreferredStockMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesBPreferredStockMember_40" xlink:type="arc" order="42" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_PrefundedWarrantMember" xlink:label="loc_QLGNPrefundedWarrantMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_QLGNPrefundedWarrantMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapWarrantMember_160" xlink:type="arc" order="161" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srtProductOrServiceAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtProductOrServiceAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srtProductsAndServicesDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtProductOrServiceAxis" xlink:to="loc_srtProductsAndServicesDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srtProductsAndServicesDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtProductOrServiceAxis" xlink:to="loc_srtProductsAndServicesDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShippingAndHandlingMember" xlink:label="loc_us-gaapShippingAndHandlingMember_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_us-gaapShippingAndHandlingMember_70" xlink:type="arc" order="71" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_LicenseRevenuesMember" xlink:label="loc_QLGNLicenseRevenuesMember_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_QLGNLicenseRevenuesMember_110" xlink:type="arc" order="111" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaapIncomeStatementLocationAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapIncomeStatementLocationAxis" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_GeneralAdministrativeResearchAndDevelopmentExpensesMember" xlink:label="loc_QLGNGeneralAdministrativeResearchAndDevelopmentExpensesMember_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_QLGNGeneralAdministrativeResearchAndDevelopmentExpensesMember_90" xlink:type="arc" order="91" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember_140" xlink:type="arc" order="141" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember_150" xlink:type="arc" order="151" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_PatentsAndLicensesMember" xlink:label="loc_QLGNPatentsAndLicensesMember_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_QLGNPatentsAndLicensesMember_140" xlink:type="arc" order="142" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesAcquisitions_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesAcquisitions_210" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_210" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_210" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="loc_us-gaapStockholdersEquityReverseStockSplit_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquityReverseStockSplit_210" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueAcquisitions_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueAcquisitions_210" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:label="loc_us-gaapBusinessAcquisitionPercentageOfVotingInterestsAcquired_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapBusinessAcquisitionPercentageOfVotingInterestsAcquired_210" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetImpairmentCharges" xlink:label="loc_us-gaapAssetImpairmentCharges_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAssetImpairmentCharges_210" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="loc_us-gaapCostOfGoodsAndServicesSold_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCostOfGoodsAndServicesSold_210" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax_210" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_AllowancesForSalesReturn" xlink:label="loc_QLGNAllowancesForSalesReturn_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_QLGNAllowancesForSalesReturn_210" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillImpairmentLoss" xlink:label="loc_us-gaapGoodwillImpairmentLoss_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapGoodwillImpairmentLoss_210" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetUsefulLife_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetUsefulLife_210" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdvertisingExpense" xlink:label="loc_us-gaapAdvertisingExpense_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdvertisingExpense_210" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductWarrantyAccrual" xlink:label="loc_us-gaapProductWarrantyAccrual_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapProductWarrantyAccrual_210" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductWarrantyExpense" xlink:label="loc_us-gaapProductWarrantyExpense_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapProductWarrantyExpense_210" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="loc_us-gaapOtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_210" xlink:type="arc" order="15" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/LiquidityAndGoingConcernDetailsNarrative" xlink:title="00000042 - Disclosure - LIQUIDITY AND GOING CONCERN (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostAndReserveLineItems" xlink:label="loc_us-gaapRestructuringCostAndReserveLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:label="loc_us-gaapScheduleOfRestructuringAndRelatedCostsTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRestructuringCostAndReserveLineItems" xlink:to="loc_us-gaapScheduleOfRestructuringAndRelatedCostsTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaapBusinessAcquisitionAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfRestructuringAndRelatedCostsTable" xlink:to="loc_us-gaapBusinessAcquisitionAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaapBusinessAcquisitionAcquireeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapBusinessAcquisitionAxis" xlink:to="loc_us-gaapBusinessAcquisitionAcquireeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaapBusinessAcquisitionAcquireeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapBusinessAcquisitionAxis" xlink:to="loc_us-gaapBusinessAcquisitionAcquireeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_NanoSynexLtdMember" xlink:label="loc_QLGNNanoSynexLtdMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessAcquisitionAcquireeDomain" xlink:to="loc_QLGNNanoSynexLtdMember_50" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Cash" xlink:label="loc_us-gaapCash_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRestructuringCostAndReserveLineItems" xlink:to="loc_us-gaapCash_70" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRestructuringCostAndReserveLineItems" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit_70" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRestructuringCostAndReserveLineItems" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities_70" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRestructuringCostAndReserveLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock_70" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="loc_us-gaapProceedsFromConvertibleDebt_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRestructuringCostAndReserveLineItems" xlink:to="loc_us-gaapProceedsFromConvertibleDebt_70" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueAcquisitions_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRestructuringCostAndReserveLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueAcquisitions_70" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteStockSplit" xlink:label="loc_us-gaapStockholdersEquityNoteStockSplit_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRestructuringCostAndReserveLineItems" xlink:to="loc_us-gaapStockholdersEquityNoteStockSplit_70" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRestructuringCostAndReserveLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_70" xlink:type="arc" order="7" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/ScheduleOfConsiderationTransferredDetails" xlink:title="00000043 - Disclosure - SCHEDULE OF CONSIDERATION TRANSFERRED (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaapBusinessAcquisitionLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaapBusinessAcquisitionAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="loc_us-gaapBusinessAcquisitionAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaapBusinessAcquisitionAcquireeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapBusinessAcquisitionAxis" xlink:to="loc_us-gaapBusinessAcquisitionAcquireeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaapBusinessAcquisitionAcquireeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapBusinessAcquisitionAxis" xlink:to="loc_us-gaapBusinessAcquisitionAcquireeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_NanoSynexLtdMember" xlink:label="loc_QLGNNanoSynexLtdMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessAcquisitionAcquireeDomain" xlink:to="loc_QLGNNanoSynexLtdMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_PaymentsToAcquireBusinesses" xlink:label="loc_QLGNPaymentsToAcquireBusinesses_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_QLGNPaymentsToAcquireBusinesses_20" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueAcquisitions_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueAcquisitions_20" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_PrefundedWarrantsIssuedForBusinessAcquisition" xlink:label="loc_QLGNPrefundedWarrantsIssuedForBusinessAcquisition_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_QLGNPrefundedWarrantsIssuedForBusinessAcquisition_20" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationConsiderationTransferred1" xlink:label="loc_us-gaapBusinessCombinationConsiderationTransferred1_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_us-gaapBusinessCombinationConsiderationTransferred1_20" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_FairValueOfWarrantModificationForBusinessAcquisition" xlink:label="loc_QLGNFairValueOfWarrantModificationForBusinessAcquisition_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_QLGNFairValueOfWarrantModificationForBusinessAcquisition_20" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAcquiredFromAcquisition" xlink:label="loc_us-gaapCashAcquiredFromAcquisition_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_us-gaapCashAcquiredFromAcquisition_20" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:label="loc_us-gaapPaymentsToAcquireBusinessesNetOfCashAcquired_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_us-gaapPaymentsToAcquireBusinessesNetOfCashAcquired_20" xlink:type="arc" order="6" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/ScheduleOfConsiderationTransferredDetailsParenthetical" xlink:title="00000044 - Disclosure - SCHEDULE OF CONSIDERATION TRANSFERRED (Details) (Parenthetical)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaapBusinessAcquisitionLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaapBusinessAcquisitionAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="loc_us-gaapBusinessAcquisitionAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaapBusinessAcquisitionAcquireeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapBusinessAcquisitionAxis" xlink:to="loc_us-gaapBusinessAcquisitionAcquireeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaapBusinessAcquisitionAcquireeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapBusinessAcquisitionAxis" xlink:to="loc_us-gaapBusinessAcquisitionAcquireeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_NanoSynexLtdMember" xlink:label="loc_QLGNNanoSynexLtdMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessAcquisitionAcquireeDomain" xlink:to="loc_QLGNNanoSynexLtdMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_AlphaCapitalAnstaltMember" xlink:label="loc_QLGNAlphaCapitalAnstaltMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessAcquisitionAcquireeDomain" xlink:to="loc_QLGNAlphaCapitalAnstaltMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesAcquisitions_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesAcquisitions_40" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/ScheduleOfAssetsAcquiredAndLiabilitiesDetails" xlink:title="00000045 - Disclosure - SCHEDULE OF ASSETS ACQUIRED AND LIABILITIES (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/ScheduleOfProFormaInformationDetails" xlink:title="00000046 - Disclosure - SCHEDULE OF PRO FORMA INFORMATION (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/AcquisitionDetailsNarrative" xlink:title="00000047 - Disclosure - ACQUISITION (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaapBusinessAcquisitionLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaapBusinessAcquisitionAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="loc_us-gaapBusinessAcquisitionAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaapBusinessAcquisitionAcquireeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapBusinessAcquisitionAxis" xlink:to="loc_us-gaapBusinessAcquisitionAcquireeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaapBusinessAcquisitionAcquireeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapBusinessAcquisitionAxis" xlink:to="loc_us-gaapBusinessAcquisitionAcquireeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_NanoSynexLtdMember" xlink:label="loc_QLGNNanoSynexLtdMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessAcquisitionAcquireeDomain" xlink:to="loc_QLGNNanoSynexLtdMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_SeriesAOnePreferredStockMember" xlink:label="loc_QLGNSeriesAOnePreferredStockMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_QLGNSeriesAOnePreferredStockMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="loc_us-gaapSeriesBPreferredStockMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesBPreferredStockMember_50" xlink:type="arc" order="52" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_PrefundedWarrantMember" xlink:label="loc_QLGNPrefundedWarrantMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_QLGNPrefundedWarrantMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="loc_deiLegalEntityAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_NanoSynexMember" xlink:label="loc_QLGNNanoSynexMember_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_QLGNNanoSynexMember_70" xlink:type="arc" order="71" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:label="loc_us-gaapBusinessAcquisitionPercentageOfVotingInterestsAcquired_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_us-gaapBusinessAcquisitionPercentageOfVotingInterestsAcquired_110" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesAcquisitions_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesAcquisitions_110" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_110" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_110" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="loc_us-gaapStockholdersEquityReverseStockSplit_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_us-gaapStockholdersEquityReverseStockSplit_110" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueAcquisitions_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueAcquisitions_110" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterestDecreaseFromRedemptions" xlink:label="loc_us-gaapMinorityInterestDecreaseFromRedemptions_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_us-gaapMinorityInterestDecreaseFromRedemptions_110" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillPeriodIncreaseDecrease" xlink:label="loc_us-gaapGoodwillPeriodIncreaseDecrease_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_us-gaapGoodwillPeriodIncreaseDecrease_110" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossTax" xlink:label="loc_us-gaapOtherComprehensiveIncomeLossTax_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_us-gaapOtherComprehensiveIncomeLossTax_110" xlink:type="arc" order="8" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/ScheduleOfInventoryDetails" xlink:title="00000048 - Disclosure - SCHEDULE OF INVENTORY (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/ScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails" xlink:title="00000049 - Disclosure - SCHEDULE OF PREPAID EXPENSES AND OTHER CURRENT ASSETS (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/ScheduleOfPropertyAndEquipmentDetails" xlink:title="00000050 - Disclosure - SCHEDULE OF PROPERTY AND EQUIPMENT (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaapPropertyPlantAndEquipmentLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MachineryAndEquipmentMember" xlink:label="loc_us-gaapMachineryAndEquipmentMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapMachineryAndEquipmentMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComputerEquipmentMember" xlink:label="loc_us-gaapComputerEquipmentMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapComputerEquipmentMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaapLeaseholdImprovementsMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapLeaseholdImprovementsMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_MoldsAndToolingMember" xlink:label="loc_QLGNMoldsAndToolingMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_QLGNMoldsAndToolingMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaapFurnitureAndFixturesMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapFurnitureAndFixturesMember_80" xlink:type="arc" order="81" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquipmentMember" xlink:label="loc_us-gaapEquipmentMember_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapEquipmentMember_100" xlink:type="arc" order="101" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaapPropertyPlantAndEquipmentGross_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentGross_150" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_150" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_FixedAssetImpairments" xlink:label="loc_QLGNFixedAssetImpairments_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_QLGNFixedAssetImpairments_150" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet_150" xlink:type="arc" order="3" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/PropertyAndEquipmentNetDetailsNarrative" xlink:title="00000051 - Disclosure - PROPERTY AND EQUIPMENT, NET (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_SekisuiDistributionAgreementMember" xlink:label="loc_QLGNSekisuiDistributionAgreementMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_QLGNSekisuiDistributionAgreementMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaapDepreciation_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapDepreciation_40" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment_40" xlink:type="arc" order="1" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/ScheduleOfGoodwillAndOtherIntangibleDetails" xlink:title="00000052 - Disclosure - SCHEDULE OF GOODWILL AND OTHER INTANGIBLE (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_DevelopedProductTechnologyRightsMember" xlink:label="loc_QLGNDevelopedProductTechnologyRightsMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_QLGNDevelopedProductTechnologyRightsMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_LicensingRightsMember" xlink:label="loc_QLGNLicensingRightsMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_QLGNLicensingRightsMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember_40" xlink:type="arc" order="42" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember_50" xlink:type="arc" order="52" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaapIndefiniteLivedIntangibleAssetsByMajorClassAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="loc_us-gaapIndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaapIndefiniteLivedIntangibleAssetsMajorClassNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapIndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="loc_us-gaapIndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaapIndefiniteLivedIntangibleAssetsMajorClassNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapIndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="loc_us-gaapIndefiniteLivedIntangibleAssetsMajorClassNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InProcessResearchAndDevelopmentMember" xlink:label="loc_us-gaapInProcessResearchAndDevelopmentMember_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_us-gaapInProcessResearchAndDevelopmentMember_90" xlink:type="arc" order="91" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaapGoodwill_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapGoodwill_120" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsGross_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsGross_120" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetUsefulLife_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetUsefulLife_120" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAccumulatedAmortization_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAccumulatedAmortization_120" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsNet_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsNet_120" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaapIntangibleAssetsNetExcludingGoodwill_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapIntangibleAssetsNetExcludingGoodwill_120" xlink:type="arc" order="5" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/GoodwillIprdAndOtherIntangiblesDetailsNarrative" xlink:title="00000053 - Disclosure - GOODWILL, IPR&amp;D AND OTHER INTANGIBLES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PatentsMember" xlink:label="loc_us-gaapPatentsMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_us-gaapPatentsMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LicenseMember" xlink:label="loc_us-gaapLicenseMember_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_us-gaapLicenseMember_70" xlink:type="arc" order="71" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillImpairmentLoss" xlink:label="loc_us-gaapGoodwillImpairmentLoss_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapGoodwillImpairmentLoss_120" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:label="loc_us-gaapImpairmentOfIntangibleAssetsFinitelived_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapImpairmentOfIntangibleAssetsFinitelived_120" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsGross_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsGross_120" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAccumulatedAmortization_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAccumulatedAmortization_120" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaapAmortizationOfIntangibleAssets_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapAmortizationOfIntangibleAssets_120" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_120" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_120" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearThree_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearThree_120" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearFour_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearFour_120" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearFive_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearFive_120" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_120" xlink:type="arc" order="10" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails" xlink:title="00000054 - Disclosure - SCHEDULE OF ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/ShortTermDebt-RelatedPartyDetailsNarrative" xlink:title="00000055 - Disclosure - SHORT TERM DEBT - RELATED PARTY (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtLineItems" xlink:label="loc_us-gaapShortTermDebtLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShortTermDebtTable" xlink:label="loc_us-gaapScheduleOfShortTermDebtTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapScheduleOfShortTermDebtTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="loc_us-gaapShortTermDebtTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_us-gaapShortTermDebtTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaapShortTermDebtTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapShortTermDebtTypeAxis" xlink:to="loc_us-gaapShortTermDebtTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaapShortTermDebtTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShortTermDebtTypeAxis" xlink:to="loc_us-gaapShortTermDebtTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_NotesPayableMember" xlink:label="loc_QLGNNotesPayableMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtTypeDomain" xlink:to="loc_QLGNNotesPayableMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_NanoSynexMember" xlink:label="loc_QLGNNanoSynexMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_QLGNNanoSynexMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaapDebtInstrumentFaceAmount_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentFaceAmount_40" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPayableCurrent" xlink:label="loc_us-gaapInterestPayableCurrent_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapInterestPayableCurrent_40" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermBorrowings" xlink:label="loc_us-gaapShortTermBorrowings_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapShortTermBorrowings_40" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaapDebtInstrumentInterestRateStatedPercentage_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentInterestRateStatedPercentage_40" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromRelatedPartyDebt" xlink:label="loc_us-gaapProceedsFromRelatedPartyDebt_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapProceedsFromRelatedPartyDebt_40" xlink:type="arc" order="4" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/ScheduleOfWarrantsActivityDetails" xlink:title="00000056 - Disclosure - SCHEDULE OF WARRANTS ACTIVITY (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_SeriesCWarrantsMember" xlink:label="loc_QLGNSeriesCWarrantsMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_QLGNSeriesCWarrantsMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_CommonStockWarrantsMember" xlink:label="loc_QLGNCommonStockWarrantsMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_QLGNCommonStockWarrantsMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember_40" xlink:type="arc" order="43" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember_50" xlink:type="arc" order="53" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_80" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice" xlink:label="loc_QLGNShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_QLGNShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_80" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_RangeOfExercisePrice" xlink:label="loc_QLGNRangeOfExercisePrice_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_QLGNRangeOfExercisePrice_80" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAveragRemainingContractualTerm1" xlink:label="loc_QLGNShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAveragRemainingContractualTerm1_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_QLGNShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAveragRemainingContractualTerm1_80" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_80" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedInPeriodWeightedAverageExercisePrice" xlink:label="loc_QLGNShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedInPeriodWeightedAverageExercisePrice_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_QLGNShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedInPeriodWeightedAverageExercisePrice_80" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_80" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedInPeriodWeightedAverageExercisePrice" xlink:label="loc_QLGNShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedInPeriodWeightedAverageExercisePrice_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_QLGNShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedInPeriodWeightedAverageExercisePrice_80" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_80" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInPeriodWeightedAverageExercisePrice" xlink:label="loc_QLGNShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInPeriodWeightedAverageExercisePrice_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_QLGNShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInPeriodWeightedAverageExercisePrice_80" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_80" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_QLGNShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_QLGNShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice_80" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber" xlink:label="loc_QLGNShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_QLGNShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_80" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageVestedExercisePrice" xlink:label="loc_QLGNShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageVestedExercisePrice_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_QLGNShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageVestedExercisePrice_80" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_RangeOfExercisePriceExercisableVested" xlink:label="loc_QLGNRangeOfExercisePriceExercisableVested_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_QLGNRangeOfExercisePriceExercisableVested_80" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNonExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_QLGNShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNonExercisableWeightedAverageRemainingContractualTerm1_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_QLGNShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNonExercisableWeightedAverageRemainingContractualTerm1_80" xlink:type="arc" order="18" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/ScheduleOfFairValueHierarchyForWarrantLiabilitiesDetails" xlink:title="00000057 - Disclosure - SCHEDULE OF FAIR VALUE HIERARCHY FOR WARRANT LIABILITIES (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:label="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:label="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:to="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:to="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaapFairValueInputsLevel1Member_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel1Member_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaapFairValueInputsLevel2Member_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel2Member_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaapFairValueInputsLevel3Member_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel3Member_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_FairValueAdjustmentOfWarrant" xlink:label="loc_QLGNFairValueAdjustmentOfWarrant_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_QLGNFairValueAdjustmentOfWarrant_210" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_FairValueOfWarrantLiabilitiesOnDateOfExercise" xlink:label="loc_QLGNFairValueOfWarrantLiabilitiesOnDateOfExercise_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_QLGNFairValueOfWarrantLiabilitiesOnDateOfExercise_210" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_FairValueOfWarrantLiabilitiesIssuanceOfAlphaWarrants" xlink:label="loc_QLGNFairValueOfWarrantLiabilitiesIssuanceOfAlphaWarrants_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_QLGNFairValueOfWarrantLiabilitiesIssuanceOfAlphaWarrants_210" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_ChangeInFairValueOfWarrantLiabilities" xlink:label="loc_QLGNChangeInFairValueOfWarrantLiabilities_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_QLGNChangeInFairValueOfWarrantLiabilities_210" xlink:type="arc" order="3" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/ScheduleOfAssumptionsOfWarrantLiabilitiesDetails" xlink:title="00000058 - Disclosure - SCHEDULE OF ASSUMPTIONS OF WARRANT LIABILITIES (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_WeightedAverageMember" xlink:label="loc_srtWeightedAverageMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtWeightedAverageMember_20" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="loc_us-gaapMeasurementInputTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapMeasurementInputTypeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaapMeasurementInputTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapMeasurementInputTypeAxis" xlink:to="loc_us-gaapMeasurementInputTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaapMeasurementInputTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapMeasurementInputTypeAxis" xlink:to="loc_us-gaapMeasurementInputTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="loc_us-gaapMeasurementInputRiskFreeInterestRateMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputRiskFreeInterestRateMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="loc_us-gaapMeasurementInputPriceVolatilityMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputPriceVolatilityMember_60" xlink:type="arc" order="62" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="loc_us-gaapMeasurementInputExpectedTermMember_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputExpectedTermMember_120" xlink:type="arc" order="122" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputExpectedDividendRateMember" xlink:label="loc_us-gaapMeasurementInputExpectedDividendRateMember_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputExpectedDividendRateMember_180" xlink:type="arc" order="181" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:label="loc_us-gaapWarrantsAndRightsOutstandingMeasurementInput_230" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstandingMeasurementInput_230" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="loc_us-gaapWarrantsAndRightsOutstandingTerm_230" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstandingTerm_230" xlink:type="arc" order="1" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/WarrantLiabilitiesDetailsNarrative" xlink:title="00000059 - Disclosure - WARRANT LIABILITIES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_SeriesCWarrantsMember" xlink:label="loc_QLGNSeriesCWarrantsMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_QLGNSeriesCWarrantsMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_SeriesCWarrantsMember" xlink:label="loc_QLGNSeriesCWarrantsMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_QLGNSeriesCWarrantsMember_50" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtTitleOfIndividualAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_AlphaCapitalMember" xlink:label="loc_QLGNAlphaCapitalMember_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_QLGNAlphaCapitalMember_120" xlink:type="arc" order="122" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_150" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="loc_us-gaapWarrantsAndRightsOutstandingTerm_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstandingTerm_150" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_150" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_150" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_ConversionPricePercentage" xlink:label="loc_QLGNConversionPricePercentage_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_QLGNConversionPricePercentage_150" xlink:type="arc" order="4" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/ScheduleOfSeniorSecuredConvertibleDebtDetails" xlink:title="00000060 - Disclosure - SCHEDULE OF SENIOR SECURED CONVERTIBLE DEBT (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtLineItems" xlink:label="loc_us-gaapShortTermDebtLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShortTermDebtTable" xlink:label="loc_us-gaapScheduleOfShortTermDebtTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapScheduleOfShortTermDebtTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaapDebtInstrumentAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_us-gaapDebtInstrumentAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaapDebtInstrumentNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapDebtInstrumentAxis" xlink:to="loc_us-gaapDebtInstrumentNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaapDebtInstrumentNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapDebtInstrumentAxis" xlink:to="loc_us-gaapDebtInstrumentNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_SeniorSecuredConvertibleDebtMember" xlink:label="loc_QLGNSeniorSecuredConvertibleDebtMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_QLGNSeniorSecuredConvertibleDebtMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SecuredDebt" xlink:label="loc_us-gaapSecuredDebt_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapSecuredDebt_30" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="loc_us-gaapDebtInstrumentUnamortizedDiscount_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentUnamortizedDiscount_30" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleDebt" xlink:label="loc_us-gaapConvertibleDebt_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapConvertibleDebt_30" xlink:type="arc" order="2" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/ConvertibleDebt-RelatedPartyDetailsNarrative" xlink:title="00000061 - Disclosure - CONVERTIBLE DEBT - RELATED PARTY (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtLineItems" xlink:label="loc_us-gaapShortTermDebtLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShortTermDebtTable" xlink:label="loc_us-gaapScheduleOfShortTermDebtTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapScheduleOfShortTermDebtTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_srtTitleOfIndividualAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_AlphaCapitalMember" xlink:label="loc_QLGNAlphaCapitalMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_QLGNAlphaCapitalMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_AlphaCapitalOtherThirdPartiesMember" xlink:label="loc_QLGNAlphaCapitalOtherThirdPartiesMember_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_QLGNAlphaCapitalOtherThirdPartiesMember_70" xlink:type="arc" order="71" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaapDebtInstrumentAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_us-gaapDebtInstrumentAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaapDebtInstrumentNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapDebtInstrumentAxis" xlink:to="loc_us-gaapDebtInstrumentNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaapDebtInstrumentNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapDebtInstrumentAxis" xlink:to="loc_us-gaapDebtInstrumentNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_SeniorConvertibleDebentureMember" xlink:label="loc_QLGNSeniorConvertibleDebentureMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_QLGNSeniorConvertibleDebentureMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_SeriesCWarrantsMember" xlink:label="loc_QLGNSeriesCWarrantsMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_QLGNSeriesCWarrantsMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtInterestRateIncrease" xlink:label="loc_us-gaapShortTermDebtInterestRateIncrease_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapShortTermDebtInterestRateIncrease_100" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SecuredDebt" xlink:label="loc_us-gaapSecuredDebt_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapSecuredDebt_100" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_PurchasePrice" xlink:label="loc_QLGNPurchasePrice_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_QLGNPurchasePrice_100" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="loc_us-gaapDebtInstrumentConvertibleConversionPrice1_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentConvertibleConversionPrice1_100" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_100" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_100" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_ConversionPricePercentage" xlink:label="loc_QLGNConversionPricePercentage_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_QLGNConversionPricePercentage_100" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentIncreaseAccruedInterest" xlink:label="loc_us-gaapDebtInstrumentIncreaseAccruedInterest_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentIncreaseAccruedInterest_100" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtConversionConvertedInstrumentRate" xlink:label="loc_us-gaapDebtConversionConvertedInstrumentRate_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtConversionConvertedInstrumentRate_100" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_PrincipalAmountPercentage" xlink:label="loc_QLGNPrincipalAmountPercentage_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_QLGNPrincipalAmountPercentage_100" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaapDebtInstrumentInterestRateStatedPercentage_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentInterestRateStatedPercentage_100" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapCommonStockSharesIssued_100" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="loc_us-gaapAmortizationOfDebtDiscountPremium_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapAmortizationOfDebtDiscountPremium_100" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaapFairValueAdjustmentOfWarrants_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapFairValueAdjustmentOfWarrants_100" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeNet" xlink:label="loc_us-gaapEmbeddedDerivativeFairValueOfEmbeddedDerivativeNet_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapEmbeddedDerivativeFairValueOfEmbeddedDerivativeNet_100" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_FeesAndCostsPaid" xlink:label="loc_QLGNFeesAndCostsPaid_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_QLGNFeesAndCostsPaid_100" xlink:type="arc" order="15" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/ScheduleOfEarningsPerShareBasicAndDilutedDetails" xlink:title="00000062 - Disclosure - SCHEDULE OF EARNINGS PER SHARE BASIC AND DILUTED (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/ScheduleOfDilutiveSecuritiesExcludedFromDilutedNetLossPerShareDetails" xlink:title="00000063 - Disclosure - SCHEDULE OF DILUTIVE SECURITIES EXCLUDED FROM DILUTED NET LOSS PER SHARE (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaapAntidilutiveSecuritiesNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaapAntidilutiveSecuritiesNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="loc_us-gaapAntidilutiveSecuritiesNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_SharesOfCommonStockSubjectToOutstandingOptionsMember" xlink:label="loc_QLGNSharesOfCommonStockSubjectToOutstandingOptionsMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_QLGNSharesOfCommonStockSubjectToOutstandingOptionsMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_SharesOfCommonStockSubjectToOutstandingWarrantsMember" xlink:label="loc_QLGNSharesOfCommonStockSubjectToOutstandingWarrantsMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_QLGNSharesOfCommonStockSubjectToOutstandingWarrantsMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_70" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/ScheduleOfOperatingLeaseRightOfUseAssetsAndOperatingLeaseLiabilitiesDetails" xlink:title="00000064 - Disclosure - SCHEDULE OF OPERATING LEASE RIGHT OF USE ASSETS AND OPERATING LEASE LIABILITIES (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_LongtermOperatingLeaseAgreementMember" xlink:label="loc_QLGNLongtermOperatingLeaseAgreementMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_QLGNLongtermOperatingLeaseAgreementMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset_40" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAssetAmortizationExpense_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAssetAmortizationExpense_40" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaapOperatingLeaseLiability_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapOperatingLeaseLiability_40" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasePayments" xlink:label="loc_us-gaapOperatingLeasePayments_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapOperatingLeasePayments_40" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityNoncurrent_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapOperatingLeaseLiabilityNoncurrent_40" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityCurrent_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapOperatingLeaseLiabilityCurrent_40" xlink:type="arc" order="7" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/ScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails" xlink:title="00000065 - Disclosure - SCHEDULE OF MATURITIES OF OPERATING LEASE LIABILITIES (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:title="00000066 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_FirstTwelveMonthsMember" xlink:label="loc_QLGNFirstTwelveMonthsMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_QLGNFirstTwelveMonthsMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_srtTitleOfIndividualAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_SekisuiDistributionAgreementMember" xlink:label="loc_QLGNSekisuiDistributionAgreementMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_QLGNSekisuiDistributionAgreementMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_NanoSynexMember" xlink:label="loc_QLGNNanoSynexMember_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_QLGNNanoSynexMember_70" xlink:type="arc" order="71" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventTypeDomain" xlink:to="loc_us-gaapSubsequentEventMember_90" xlink:type="arc" order="92" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AreaOfLand" xlink:label="loc_us-gaapAreaOfLand_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapAreaOfLand_120" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="loc_us-gaapLesseeOperatingLeaseTermOfContract_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapLesseeOperatingLeaseTermOfContract_120" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseDescription" xlink:label="loc_us-gaapLesseeOperatingLeaseDescription_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapLesseeOperatingLeaseDescription_120" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRent" xlink:label="loc_us-gaapPaymentsForRent_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapPaymentsForRent_120" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_TenantImprovementAllowance" xlink:label="loc_QLGNTenantImprovementAllowance_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_QLGNTenantImprovementAllowance_120" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="loc_us-gaapOperatingLeaseWeightedAverageRemainingLeaseTerm1_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapOperatingLeaseWeightedAverageRemainingLeaseTerm1_120" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="loc_us-gaapOperatingLeaseWeightedAverageDiscountRatePercent_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapOperatingLeaseWeightedAverageDiscountRatePercent_120" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseExpense" xlink:label="loc_us-gaapOperatingLeaseExpense_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapOperatingLeaseExpense_120" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:label="loc_us-gaapAccruedLiabilitiesAndOtherLiabilities_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapAccruedLiabilitiesAndOtherLiabilities_120" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="loc_us-gaapLineOfCreditFacilityMaximumBorrowingCapacity_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapLineOfCreditFacilityMaximumBorrowingCapacity_120" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_DevelopmentFund" xlink:label="loc_QLGNDevelopmentFund_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_QLGNDevelopmentFund_120" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity" xlink:label="loc_us-gaapLineOfCreditFacilityCurrentBorrowingCapacity_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapLineOfCreditFacilityCurrentBorrowingCapacity_120" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationSettlementAmountAwardedToOtherParty" xlink:label="loc_us-gaapLitigationSettlementAmountAwardedToOtherParty_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapLitigationSettlementAmountAwardedToOtherParty_120" xlink:type="arc" order="12" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/ResearchAndLicenseAgreementsDetailsNarrative" xlink:title="00000067 - Disclosure - RESEARCH AND LICENSE AGREEMENTS (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_SponsoredResearchAgreementAndLicenseMember" xlink:label="loc_QLGNSponsoredResearchAgreementAndLicenseMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_QLGNSponsoredResearchAgreementAndLicenseMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_LicenseAndSponsoredResearchAgreementsMember" xlink:label="loc_QLGNLicenseAndSponsoredResearchAgreementsMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_QLGNLicenseAndSponsoredResearchAgreementsMember_20" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_LicenseAgreementMember" xlink:label="loc_QLGNLicenseAgreementMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_QLGNLicenseAgreementMember_80" xlink:type="arc" order="82" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_deiLegalEntityAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_UniversityOfLouisvilleResearchFoundationMember" xlink:label="loc_QLGNUniversityOfLouisvilleResearchFoundationMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_QLGNUniversityOfLouisvilleResearchFoundationMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_AdvancedCancerTherapeuticsLLCMember" xlink:label="loc_QLGNAdvancedCancerTherapeuticsLLCMember_310" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_QLGNAdvancedCancerTherapeuticsLLCMember_310" xlink:type="arc" order="312" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_YiXinZhenDuanJishuLtdMember" xlink:label="loc_QLGNYiXinZhenDuanJishuLtdMember_350" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_QLGNYiXinZhenDuanJishuLtdMember_350" xlink:type="arc" order="351" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_STAPharmaceuticalCoLtdMember" xlink:label="loc_QLGNSTAPharmaceuticalCoLtdMember_380" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_QLGNSTAPharmaceuticalCoLtdMember_380" xlink:type="arc" order="381" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_PhaseOneClinicalTrialMember" xlink:label="loc_QLGNPhaseOneClinicalTrialMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_QLGNPhaseOneClinicalTrialMember_40" xlink:type="arc" order="43" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_PhaseTwoClinicalTrialMember" xlink:label="loc_QLGNPhaseTwoClinicalTrialMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_QLGNPhaseTwoClinicalTrialMember_50" xlink:type="arc" order="53" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_PhaseThreeClinicalTrialMember" xlink:label="loc_QLGNPhaseThreeClinicalTrialMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_QLGNPhaseThreeClinicalTrialMember_60" xlink:type="arc" order="63" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_PhaseClinicalTrialMember" xlink:label="loc_QLGNPhaseClinicalTrialMember_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_QLGNPhaseClinicalTrialMember_200" xlink:type="arc" order="201" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_UpfrontPaymentMember" xlink:label="loc_QLGNUpfrontPaymentMember_410" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_QLGNUpfrontPaymentMember_410" xlink:type="arc" order="411" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srtProductOrServiceAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtProductOrServiceAxis" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srtProductsAndServicesDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtProductOrServiceAxis" xlink:to="loc_srtProductsAndServicesDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srtProductsAndServicesDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtProductOrServiceAxis" xlink:to="loc_srtProductsAndServicesDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_LicensedProductSalesMember" xlink:label="loc_QLGNLicensedProductSalesMember_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_QLGNLicensedProductSalesMember_70" xlink:type="arc" order="71" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_LicenseRevenueMember" xlink:label="loc_QLGNLicenseRevenueMember_360" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_QLGNLicenseRevenueMember_360" xlink:type="arc" order="361" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtTitleOfIndividualAxis" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_CEMarkMember" xlink:label="loc_QLGNCEMarkMember_320" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_QLGNCEMarkMember_320" xlink:type="arc" order="321" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_ReimbursementOfResearchExpenses" xlink:label="loc_QLGNReimbursementOfResearchExpenses_460" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_QLGNReimbursementOfResearchExpenses_460" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_AgreementTermPaymentDescription" xlink:label="loc_QLGNAgreementTermPaymentDescription_460" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_QLGNAgreementTermPaymentDescription_460" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_MilestonePayment" xlink:label="loc_QLGNMilestonePayment_460" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_QLGNMilestonePayment_460" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_RegulatoryMarketingApprovalExpenses" xlink:label="loc_QLGNRegulatoryMarketingApprovalExpenses_460" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_QLGNRegulatoryMarketingApprovalExpenses_460" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_CumulativeSales" xlink:label="loc_QLGNCumulativeSales_460" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_QLGNCumulativeSales_460" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:label="loc_us-gaapRevenueFromContractWithCustomerIncludingAssessedTax_460" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapRevenueFromContractWithCustomerIncludingAssessedTax_460" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_UpfrontLicenseFee" xlink:label="loc_QLGNUpfrontLicenseFee_460" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_QLGNUpfrontLicenseFee_460" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense_460" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapResearchAndDevelopmentExpense_460" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_LicenseCost" xlink:label="loc_QLGNLicenseCost_460" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_QLGNLicenseCost_460" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="loc_us-gaapProceedsFromConvertibleDebt_460" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapProceedsFromConvertibleDebt_460" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_PatentCosts" xlink:label="loc_QLGNPatentCosts_460" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_QLGNPatentCosts_460" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_RegulatoryMarketingApprovalExpensesOne" xlink:label="loc_QLGNRegulatoryMarketingApprovalExpensesOne_460" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_QLGNRegulatoryMarketingApprovalExpensesOne_460" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_ShortfallPayments" xlink:label="loc_QLGNShortfallPayments_460" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_QLGNShortfallPayments_460" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RoyaltyExpense" xlink:label="loc_us-gaapRoyaltyExpense_460" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapRoyaltyExpense_460" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_AgreementDescription" xlink:label="loc_QLGNAgreementDescription_460" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_QLGNAgreementDescription_460" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_MilestonePaymentForCumulativeMarketingExpenses" xlink:label="loc_QLGNMilestonePaymentForCumulativeMarketingExpenses_460" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_QLGNMilestonePaymentForCumulativeMarketingExpenses_460" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_MilestoneMethodRevenueRecognized" xlink:label="loc_QLGNMilestoneMethodRevenueRecognized_460" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_QLGNMilestoneMethodRevenueRecognized_460" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredRevenue" xlink:label="loc_us-gaapDeferredRevenue_460" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDeferredRevenue_460" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax_460" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax_460" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepositAssets" xlink:label="loc_us-gaapDepositAssets_460" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDepositAssets_460" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_ReimbursementOfPatent" xlink:label="loc_QLGNReimbursementOfPatent_460" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_QLGNReimbursementOfPatent_460" xlink:type="arc" order="20" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/ScheduleOfReservedSharesDetails" xlink:title="00000068 - Disclosure - SCHEDULE OF RESERVED SHARES (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockOptionMember" xlink:label="loc_us-gaapStockOptionMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapStockOptionMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapWarrantMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaapCommonStockCapitalSharesReservedForFutureIssuance_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapCommonStockCapitalSharesReservedForFutureIssuance_40" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/ScheduleOfStockOptionActivityDetails" xlink:title="00000069 - Disclosure - SCHEDULE OF STOCK OPTION ACTIVITY (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems" xlink:label="loc_us-gaapDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable" xlink:label="loc_us-gaapScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems" xlink:to="loc_us-gaapScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable" xlink:to="loc_srtTitleOfIndividualAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_EmployeesAndNonemployeeServiceProviderMember" xlink:label="loc_QLGNEmployeesAndNonemployeeServiceProviderMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_QLGNEmployeesAndNonemployeeServiceProviderMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember_10" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember_20" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_100" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_100" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm3" xlink:label="loc_QLGNSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm3_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems" xlink:to="loc_QLGNSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm3_100" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_100" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_100" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionGrantedWeightedAverageExercisePrice" xlink:label="loc_QLGNShareBasedCompensationArrangementByShareBasedPaymentAwardOptionGrantedWeightedAverageExercisePrice_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems" xlink:to="loc_QLGNShareBasedCompensationArrangementByShareBasedPaymentAwardOptionGrantedWeightedAverageExercisePrice_100" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm2" xlink:label="loc_QLGNSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm2_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems" xlink:to="loc_QLGNSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm2_100" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_100" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_100" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="loc_QLGNShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExpirationsInPeriodWeightedAverageExercisePrice_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems" xlink:to="loc_QLGNShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExpirationsInPeriodWeightedAverageExercisePrice_100" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_100" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_100" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_100" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_100" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_100" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_100" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_100" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_100" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToNonVestExercisableWeightedAverageExercisePrice" xlink:label="loc_QLGNShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToNonVestExercisableWeightedAverageExercisePrice_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems" xlink:to="loc_QLGNShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToNonVestExercisableWeightedAverageExercisePrice_100" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_100" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_WeightedAverageRemainingContractualLifeInYearsOptionsNonexercisableNonvested" xlink:label="loc_QLGNWeightedAverageRemainingContractualLifeInYearsOptionsNonexercisableNonvested_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems" xlink:to="loc_QLGNWeightedAverageRemainingContractualLifeInYearsOptionsNonexercisableNonvested_100" xlink:type="arc" order="22" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/ScheduleOfAssumptionUsedInBlack-scholesOption-pricingMethodDetails" xlink:title="00000070 - Disclosure - SCHEDULE OF ASSUMPTION USED IN BLACK-SCHOLES OPTION-PRICING METHOD (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_70" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_70" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_70" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_70" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_70" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaapSharePrice_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharePrice_70" xlink:type="arc" order="5" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/ScheduleOfShare-basedCompensationExpenseDetails" xlink:title="00000071 - Disclosure - SCHEDULE OF SHARE-BASED COMPENSATION EXPENSE (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaapIncomeStatementLocationAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapIncomeStatementLocationAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaapGeneralAndAdministrativeExpenseMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapGeneralAndAdministrativeExpenseMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaapResearchAndDevelopmentExpenseMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapResearchAndDevelopmentExpenseMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaapAllocatedShareBasedCompensationExpense_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAllocatedShareBasedCompensationExpense_70" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/ScheduleOfWarrantActivityDetails" xlink:title="00000072 - Disclosure - SCHEDULE OF WARRANT ACTIVITY (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_CompensatoryWarrantActivityMember" xlink:label="loc_QLGNCompensatoryWarrantActivityMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_QLGNCompensatoryWarrantActivityMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember_10" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember_20" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_CompensatoryWarrantActivityMember" xlink:label="loc_QLGNCompensatoryWarrantActivityMember_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_QLGNCompensatoryWarrantActivityMember_70" xlink:type="arc" order="71" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_NonCompensatoryWarrantActivityMember" xlink:label="loc_QLGNNonCompensatoryWarrantActivityMember_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_QLGNNonCompensatoryWarrantActivityMember_120" xlink:type="arc" order="121" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_220" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice" xlink:label="loc_QLGNShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_QLGNShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_220" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_RangeOfExercisePriceOutstanding" xlink:label="loc_QLGNRangeOfExercisePriceOutstanding_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_QLGNRangeOfExercisePriceOutstanding_220" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAveragRemainingContractualTerm1" xlink:label="loc_QLGNShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAveragRemainingContractualTerm1_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_QLGNShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAveragRemainingContractualTerm1_220" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_220" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_QLGNShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_QLGNShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice_220" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_220" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedInPeriodWeightedAverageExercisePrice" xlink:label="loc_QLGNShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedInPeriodWeightedAverageExercisePrice_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_QLGNShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedInPeriodWeightedAverageExercisePrice_220" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_220" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInPeriodWeightedAverageExercisePrice" xlink:label="loc_QLGNShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInPeriodWeightedAverageExercisePrice_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_QLGNShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInPeriodWeightedAverageExercisePrice_220" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_220" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedInPeriodWeightedAverageExercisePrice" xlink:label="loc_QLGNShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedInPeriodWeightedAverageExercisePrice_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_QLGNShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedInPeriodWeightedAverageExercisePrice_220" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAveragRemainingContractualTerm1" xlink:label="loc_QLGNShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAveragRemainingContractualTerm1_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_QLGNShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAveragRemainingContractualTerm1_220" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber" xlink:label="loc_QLGNShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_QLGNShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_220" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageVestedExercisePrice" xlink:label="loc_QLGNShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageVestedExercisePrice_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_QLGNShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageVestedExercisePrice_220" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_RangeOfExercisePriceExercisableVested" xlink:label="loc_QLGNRangeOfExercisePriceExercisableVested_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_QLGNRangeOfExercisePriceExercisableVested_220" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNonVestedNumber" xlink:label="loc_QLGNShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNonVestedNumber_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_QLGNShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNonVestedNumber_220" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageNonVestedExercise" xlink:label="loc_QLGNShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageNonVestedExercise_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_QLGNShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageNonVestedExercise_220" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_RangeOfExercisePriceNonexercisableNonvested" xlink:label="loc_QLGNRangeOfExercisePriceNonexercisableNonvested_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_QLGNRangeOfExercisePriceNonexercisableNonvested_220" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsRangeOfExercisePrice" xlink:label="loc_QLGNShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsRangeOfExercisePrice_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_QLGNShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsRangeOfExercisePrice_220" xlink:type="arc" order="23" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_RangeOfExercisePriceGranted" xlink:label="loc_QLGNRangeOfExercisePriceGranted_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_QLGNRangeOfExercisePriceGranted_220" xlink:type="arc" order="24" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_RangeOfExercisePriceExpired" xlink:label="loc_QLGNRangeOfExercisePriceExpired_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_QLGNRangeOfExercisePriceExpired_220" xlink:type="arc" order="25" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInRangeOfExercisePrice" xlink:label="loc_QLGNShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInRangeOfExercisePrice_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_QLGNShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInRangeOfExercisePrice_220" xlink:type="arc" order="26" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedInRangeOfExercisePrice" xlink:label="loc_QLGNShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedInRangeOfExercisePrice_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_QLGNShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedInRangeOfExercisePrice_220" xlink:type="arc" order="27" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsNonExercisableNumber" xlink:label="loc_QLGNShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsNonExercisableNumber_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_QLGNShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsNonExercisableNumber_220" xlink:type="arc" order="29" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageVestedNonExercisePrice" xlink:label="loc_QLGNShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageVestedNonExercisePrice_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_QLGNShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageVestedNonExercisePrice_220" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_RangeOfExercisePriceNonExercisableVested" xlink:label="loc_QLGNRangeOfExercisePriceNonExercisableVested_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_QLGNRangeOfExercisePriceNonExercisableVested_220" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNonExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_QLGNShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNonExercisableWeightedAverageRemainingContractualTerm1_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_QLGNShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNonExercisableWeightedAverageRemainingContractualTerm1_220" xlink:type="arc" order="32" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/StockholdersEquityDetailsNarrative" xlink:title="00000073 - Disclosure - STOCKHOLDERS&#8217; EQUITY (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaapClassOfStockLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaapScheduleOfStockByClassTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapScheduleOfStockByClassTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_SecuritiesPurchaseAgreementMember" xlink:label="loc_QLGNSecuritiesPurchaseAgreementMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_QLGNSecuritiesPurchaseAgreementMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapCommonStockMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_SeriesCWarrantsMember" xlink:label="loc_QLGNSeriesCWarrantsMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_QLGNSeriesCWarrantsMember_50" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_SeriesAlphaConvertiblePreferredStockMember" xlink:label="loc_QLGNSeriesAlphaConvertiblePreferredStockMember_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_QLGNSeriesAlphaConvertiblePreferredStockMember_70" xlink:type="arc" order="71" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_srtTitleOfIndividualAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_AlphaCapitalMember" xlink:label="loc_QLGNAlphaCapitalMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_QLGNAlphaCapitalMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_EmployeesAndNonemployeeServiceProviderMember" xlink:label="loc_QLGNEmployeesAndNonemployeeServiceProviderMember_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_QLGNEmployeesAndNonemployeeServiceProviderMember_110" xlink:type="arc" order="111" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaapDebtInstrumentAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapDebtInstrumentAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaapDebtInstrumentNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapDebtInstrumentAxis" xlink:to="loc_us-gaapDebtInstrumentNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaapDebtInstrumentNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapDebtInstrumentAxis" xlink:to="loc_us-gaapDebtInstrumentNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_SeniorConvertibleDebentureMember" xlink:label="loc_QLGNSeniorConvertibleDebentureMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_QLGNSeniorConvertibleDebentureMember_30" xlink:type="arc" order="32" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockOptionMember" xlink:label="loc_us-gaapStockOptionMember_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapStockOptionMember_90" xlink:type="arc" order="91" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaapEmployeeStockOptionMember_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapEmployeeStockOptionMember_200" xlink:type="arc" order="201" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_CompensatoryWarrantsMember" xlink:label="loc_QLGNCompensatoryWarrantsMember_260" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_QLGNCompensatoryWarrantsMember_260" xlink:type="arc" order="261" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_NoncompensatoryEquityClassifiedWarrantsMember" xlink:label="loc_QLGNNoncompensatoryEquityClassifiedWarrantsMember_450" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_QLGNNoncompensatoryEquityClassifiedWarrantsMember_450" xlink:type="arc" order="451" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapPlanNameAxis" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_TwoThousandTwentyStockIncentivePlanMember" xlink:label="loc_QLGNTwoThousandTwentyStockIncentivePlanMember_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_QLGNTwoThousandTwentyStockIncentivePlanMember_90" xlink:type="arc" order="92" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember_120" xlink:type="arc" order="122" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember_130" xlink:type="arc" order="132" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember_310" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapWarrantMember_310" xlink:type="arc" order="311" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_WarrantOneMember" xlink:label="loc_QLGNWarrantOneMember_380" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_QLGNWarrantOneMember_380" xlink:type="arc" order="382" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_CompensatoryWarrantActivityMember" xlink:label="loc_QLGNCompensatoryWarrantActivityMember_430" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_QLGNCompensatoryWarrantActivityMember_430" xlink:type="arc" order="431" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaapIncomeStatementLocationAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapIncomeStatementLocationAxis" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaapGeneralAndAdministrativeExpenseMember_340" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapGeneralAndAdministrativeExpenseMember_340" xlink:type="arc" order="341" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaapBusinessAcquisitionAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapBusinessAcquisitionAxis" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaapBusinessAcquisitionAcquireeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapBusinessAcquisitionAxis" xlink:to="loc_us-gaapBusinessAcquisitionAcquireeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaapBusinessAcquisitionAcquireeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapBusinessAcquisitionAxis" xlink:to="loc_us-gaapBusinessAcquisitionAcquireeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_NanoSynexMember" xlink:label="loc_QLGNNanoSynexMember_570" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessAcquisitionAcquireeDomain" xlink:to="loc_QLGNNanoSynexMember_570" xlink:type="arc" order="571" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_650" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_650" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaapSharePrice_650" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapSharePrice_650" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock_650" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock_650" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtInterestRateIncrease" xlink:label="loc_us-gaapShortTermDebtInterestRateIncrease_650" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapShortTermDebtInterestRateIncrease_650" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SecuredDebt" xlink:label="loc_us-gaapSecuredDebt_650" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapSecuredDebt_650" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_PurchasePrice" xlink:label="loc_QLGNPurchasePrice_650" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_QLGNPurchasePrice_650" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="loc_us-gaapDebtInstrumentConvertibleConversionPrice1_650" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapDebtInstrumentConvertibleConversionPrice1_650" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_650" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_650" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaapCommonStockCapitalSharesReservedForFutureIssuance_650" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapCommonStockCapitalSharesReservedForFutureIssuance_650" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="loc_us-gaapConvertiblePreferredStockSharesIssuedUponConversion_650" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapConvertiblePreferredStockSharesIssuedUponConversion_650" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesOther_650" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesOther_650" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_650" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_650" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_650" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_650" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm3" xlink:label="loc_QLGNSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm3_650" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_QLGNSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm3_650" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_650" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_650" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_650" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_650" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionGrantedWeightedAverageExercisePrice" xlink:label="loc_QLGNShareBasedCompensationArrangementByShareBasedPaymentAwardOptionGrantedWeightedAverageExercisePrice_650" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_QLGNShareBasedCompensationArrangementByShareBasedPaymentAwardOptionGrantedWeightedAverageExercisePrice_650" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm2" xlink:label="loc_QLGNSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm2_650" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_QLGNSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm2_650" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_650" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_650" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_650" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_650" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="loc_QLGNShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExpirationsInPeriodWeightedAverageExercisePrice_650" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_QLGNShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExpirationsInPeriodWeightedAverageExercisePrice_650" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_650" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_650" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_650" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_650" xlink:type="arc" order="23" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_650" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_650" xlink:type="arc" order="24" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_650" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_650" xlink:type="arc" order="27" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_650" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_650" xlink:type="arc" order="28" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_650" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_650" xlink:type="arc" order="29" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_650" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_650" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_650" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_650" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToNonVestExercisableWeightedAverageExercisePrice" xlink:label="loc_QLGNShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToNonVestExercisableWeightedAverageExercisePrice_650" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_QLGNShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToNonVestExercisableWeightedAverageExercisePrice_650" xlink:type="arc" order="32" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_650" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_650" xlink:type="arc" order="33" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_WeightedAverageRemainingContractualLifeInYearsOptionsNonexercisableNonvested" xlink:label="loc_QLGNWeightedAverageRemainingContractualLifeInYearsOptionsNonexercisableNonvested_650" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_QLGNWeightedAverageRemainingContractualLifeInYearsOptionsNonexercisableNonvested_650" xlink:type="arc" order="34" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation_650" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapShareBasedCompensation_650" xlink:type="arc" order="35" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_650" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_650" xlink:type="arc" order="36" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_650" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_650" xlink:type="arc" order="37" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_650" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_650" xlink:type="arc" order="38" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="loc_us-gaapProceedsFromIssuanceOrSaleOfEquity_650" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOrSaleOfEquity_650" xlink:type="arc" order="39" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_650" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_650" xlink:type="arc" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_650" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_650" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_FairValueOfIssuanceCost" xlink:label="loc_QLGNFairValueOfIssuanceCost_650" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_QLGNFairValueOfIssuanceCost_650" xlink:type="arc" order="42" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_WarrantsExtendedDateDescription" xlink:label="loc_QLGNWarrantsExtendedDateDescription_650" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_QLGNWarrantsExtendedDateDescription_650" xlink:type="arc" order="43" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaapFairValueAdjustmentOfWarrants_650" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapFairValueAdjustmentOfWarrants_650" xlink:type="arc" order="44" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaapAllocatedShareBasedCompensationExpense_650" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapAllocatedShareBasedCompensationExpense_650" xlink:type="arc" order="45" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_WarrantsExercised" xlink:label="loc_QLGNWarrantsExercised_650" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_QLGNWarrantsExercised_650" xlink:type="arc" order="46" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaapClassOfWarrantOrRightOutstanding_650" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightOutstanding_650" xlink:type="arc" order="47" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_ModifiedToExercisePrice" xlink:label="loc_QLGNModifiedToExercisePrice_650" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_QLGNModifiedToExercisePrice_650" xlink:type="arc" order="48" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/RelatedPartyTransactionsDetailsNarrative" xlink:title="00000074 - Disclosure - RELATED PARTY TRANSACTIONS (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaapRelatedPartyTransactionLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_srtTitleOfIndividualAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_AlphaCapitalMember" xlink:label="loc_QLGNAlphaCapitalMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_QLGNAlphaCapitalMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaapDebtInstrumentAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapDebtInstrumentAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaapDebtInstrumentNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapDebtInstrumentAxis" xlink:to="loc_us-gaapDebtInstrumentNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaapDebtInstrumentNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapDebtInstrumentAxis" xlink:to="loc_us-gaapDebtInstrumentNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_SeniorConvertibleDebentureMember" xlink:label="loc_QLGNSeniorConvertibleDebentureMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_QLGNSeniorConvertibleDebentureMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="loc_us-gaapShortTermDebtTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapShortTermDebtTypeAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaapShortTermDebtTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapShortTermDebtTypeAxis" xlink:to="loc_us-gaapShortTermDebtTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaapShortTermDebtTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShortTermDebtTypeAxis" xlink:to="loc_us-gaapShortTermDebtTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_NotesPayableMember" xlink:label="loc_QLGNNotesPayableMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtTypeDomain" xlink:to="loc_QLGNNotesPayableMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_NanoSynexMember" xlink:label="loc_QLGNNanoSynexMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_QLGNNanoSynexMember_20" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaapBusinessAcquisitionAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapBusinessAcquisitionAxis" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaapBusinessAcquisitionAcquireeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapBusinessAcquisitionAxis" xlink:to="loc_us-gaapBusinessAcquisitionAcquireeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaapBusinessAcquisitionAcquireeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapBusinessAcquisitionAxis" xlink:to="loc_us-gaapBusinessAcquisitionAcquireeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_NanoSynexLtdMember" xlink:label="loc_QLGNNanoSynexLtdMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessAcquisitionAcquireeDomain" xlink:to="loc_QLGNNanoSynexLtdMember_50" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_SeriesAOnePreferredStockMember" xlink:label="loc_QLGNSeriesAOnePreferredStockMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_QLGNSeriesAOnePreferredStockMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="loc_us-gaapSeriesBPreferredStockMember_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesBPreferredStockMember_100" xlink:type="arc" order="102" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_PrefundedWarrantMember" xlink:label="loc_QLGNPrefundedWarrantMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_QLGNPrefundedWarrantMember_80" xlink:type="arc" order="81" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtInterestRateIncrease" xlink:label="loc_us-gaapShortTermDebtInterestRateIncrease_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapShortTermDebtInterestRateIncrease_120" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SecuredDebt" xlink:label="loc_us-gaapSecuredDebt_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapSecuredDebt_120" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_PurchasePrice" xlink:label="loc_QLGNPurchasePrice_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_QLGNPurchasePrice_120" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="loc_us-gaapDebtInstrumentConvertibleConversionPrice1_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapDebtInstrumentConvertibleConversionPrice1_120" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaapDebtInstrumentFaceAmount_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapDebtInstrumentFaceAmount_120" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPayableCurrent" xlink:label="loc_us-gaapInterestPayableCurrent_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapInterestPayableCurrent_120" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermBorrowings" xlink:label="loc_us-gaapShortTermBorrowings_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapShortTermBorrowings_120" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaapDebtInstrumentInterestRateStatedPercentage_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapDebtInstrumentInterestRateStatedPercentage_120" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromRelatedPartyDebt" xlink:label="loc_us-gaapProceedsFromRelatedPartyDebt_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapProceedsFromRelatedPartyDebt_120" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:label="loc_us-gaapBusinessAcquisitionPercentageOfVotingInterestsAcquired_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapBusinessAcquisitionPercentageOfVotingInterestsAcquired_120" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesAcquisitions_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesAcquisitions_120" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_120" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_120" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="loc_us-gaapStockholdersEquityReverseStockSplit_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapStockholdersEquityReverseStockSplit_120" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueAcquisitions_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueAcquisitions_120" xlink:type="arc" order="14" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/ScheduleOfDomesticAndForeignComponentsDetails" xlink:title="00000075 - Disclosure - SCHEDULE OF DOMESTIC AND FOREIGN COMPONENTS (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/ScheduleOfReconciliationsOfStatutoryIncomeTaxRateDetails" xlink:title="00000076 - Disclosure - SCHEDULE OF RECONCILIATIONS OF STATUTORY INCOME TAX RATE (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/ScheduleOfProvisionForIncomeTaxesDetails" xlink:title="00000077 - Disclosure - SCHEDULE OF PROVISION FOR INCOME TAXES (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:title="00000078 - Disclosure - SCHEDULE OF DEFERRED TAX ASSETS AND LIABILITIES (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/IncomeTaxesDetailsNarrative" xlink:title="00000079 - Disclosure - INCOME TAXES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="loc_us-gaapOperatingLossCarryforwardsLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="loc_us-gaapOperatingLossCarryforwardsTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapOperatingLossCarryforwardsTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaapIncomeTaxAuthorityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapOperatingLossCarryforwardsTable" xlink:to="loc_us-gaapIncomeTaxAuthorityAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaapIncomeTaxAuthorityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapIncomeTaxAuthorityAxis" xlink:to="loc_us-gaapIncomeTaxAuthorityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaapIncomeTaxAuthorityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapIncomeTaxAuthorityAxis" xlink:to="loc_us-gaapIncomeTaxAuthorityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCountryMember" xlink:label="loc_us-gaapForeignCountryMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeTaxAuthorityDomain" xlink:to="loc_us-gaapForeignCountryMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DomesticCountryMember" xlink:label="loc_us-gaapDomesticCountryMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeTaxAuthorityDomain" xlink:to="loc_us-gaapDomesticCountryMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="loc_us-gaapStateAndLocalJurisdictionMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeTaxAuthorityDomain" xlink:to="loc_us-gaapStateAndLocalJurisdictionMember_50" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:label="loc_us-gaapDeferredForeignIncomeTaxExpenseBenefit_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapDeferredForeignIncomeTaxExpenseBenefit_70" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:label="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_70" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaapOperatingLossCarryforwards_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapOperatingLossCarryforwards_70" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="loc_us-gaapDeferredTaxAssetsTaxCreditCarryforwardsResearch_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapDeferredTaxAssetsTaxCreditCarryforwardsResearch_70" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardLimitationsOnUse" xlink:label="loc_us-gaapTaxCreditCarryforwardLimitationsOnUse_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapTaxCreditCarryforwardLimitationsOnUse_70" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="loc_us-gaapUnrecognizedTaxBenefits_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapUnrecognizedTaxBenefits_70" xlink:type="arc" order="5" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/SubsequentEventsDetailsNarrative" xlink:title="00000080 - Disclosure - SUBSEQUENT EVENTS (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaapSubsequentEventLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaapSubsequentEventTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapSubsequentEventTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventTypeDomain" xlink:to="loc_us-gaapSubsequentEventMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaapDebtInstrumentFaceAmount_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapDebtInstrumentFaceAmount_40" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockDividendsShares" xlink:label="loc_us-gaapCommonStockDividendsShares_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapCommonStockDividendsShares_40" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="loc_us-gaapDebtInstrumentConvertibleConversionPrice1_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapDebtInstrumentConvertibleConversionPrice1_40" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_BaseSalaryPercentage" xlink:label="loc_QLGNBaseSalaryPercentage_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_QLGNBaseSalaryPercentage_40" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_AnnualCashCompensation" xlink:label="loc_QLGNAnnualCashCompensation_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_QLGNAnnualCashCompensation_40" xlink:type="arc" order="4" />
    </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>30
<FILENAME>qlgn-20221231_lab.xml
<DESCRIPTION>INLINE XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.18a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductOrServiceAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ProductOrServiceAxis_lbl" xml:lang="en-US">Product and Service [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_NetProductSalesMember" xlink:label="QLGN_NetProductSalesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_NetProductSalesMember" xlink:to="QLGN_NetProductSalesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_NetProductSalesMember_lbl" xml:lang="en-US">Net Product Sales [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_LicenseRevenueMember" xlink:label="QLGN_LicenseRevenueMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_LicenseRevenueMember" xlink:to="QLGN_LicenseRevenueMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_LicenseRevenueMember_lbl" xml:lang="en-US">License Revenue [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US">Equity Components [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockMember" xlink:label="us-gaap_PreferredStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockMember" xlink:to="us-gaap_PreferredStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockMember_lbl" xml:lang="en-US">Preferred Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xml:lang="en-US">Class of Stock [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_SeriesAlphaConvertiblePreferredStockMember" xlink:label="QLGN_SeriesAlphaConvertiblePreferredStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_SeriesAlphaConvertiblePreferredStockMember" xlink:to="QLGN_SeriesAlphaConvertiblePreferredStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_SeriesAlphaConvertiblePreferredStockMember_lbl" xml:lang="en-US">Series Alpha Convertible Preferred Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US">Common Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US">Retained Earnings [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ParentMember" xlink:label="us-gaap_ParentMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ParentMember" xlink:to="us-gaap_ParentMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ParentMember_lbl" xml:lang="en-US">Parent [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncontrollingInterestMember" xlink:label="us-gaap_NoncontrollingInterestMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncontrollingInterestMember" xlink:to="us-gaap_NoncontrollingInterestMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NoncontrollingInterestMember_lbl" xml:lang="en-US">Noncontrolling Interest [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessAcquisitionAxis_lbl" xml:lang="en-US">Business Acquisition [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_NanoSynexLtdMember" xlink:label="QLGN_NanoSynexLtdMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_NanoSynexLtdMember" xlink:to="QLGN_NanoSynexLtdMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_NanoSynexLtdMember_lbl" xml:lang="en-US">Nano Synex Ltd [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_SeriesAOnePreferredStockMember" xlink:label="QLGN_SeriesAOnePreferredStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_SeriesAOnePreferredStockMember" xlink:to="QLGN_SeriesAOnePreferredStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_SeriesAOnePreferredStockMember_lbl" xml:lang="en-US">Series A-1 Preferred Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_PrefundedWarrantMember" xlink:label="QLGN_PrefundedWarrantMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_PrefundedWarrantMember" xlink:to="QLGN_PrefundedWarrantMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_PrefundedWarrantMember_lbl" xml:lang="en-US">Pre-funded Warrant [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="us-gaap_SeriesBPreferredStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesBPreferredStockMember" xlink:to="us-gaap_SeriesBPreferredStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SeriesBPreferredStockMember_lbl" xml:lang="en-US">Series B Preferred Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShippingAndHandlingMember" xlink:label="us-gaap_ShippingAndHandlingMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShippingAndHandlingMember" xlink:to="us-gaap_ShippingAndHandlingMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShippingAndHandlingMember_lbl" xml:lang="en-US">Shipping and Handling [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xml:lang="en-US">Income Statement Location [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_GeneralAdministrativeResearchAndDevelopmentExpensesMember" xlink:label="QLGN_GeneralAdministrativeResearchAndDevelopmentExpensesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_GeneralAdministrativeResearchAndDevelopmentExpensesMember" xlink:to="QLGN_GeneralAdministrativeResearchAndDevelopmentExpensesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_GeneralAdministrativeResearchAndDevelopmentExpensesMember_lbl" xml:lang="en-US">General Administrative Research and Development Expenses [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_LicenseRevenuesMember" xlink:label="QLGN_LicenseRevenuesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_LicenseRevenuesMember" xlink:to="QLGN_LicenseRevenuesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_LicenseRevenuesMember_lbl" xml:lang="en-US">License Revenues [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeAxis_lbl" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MinimumMember_lbl" xml:lang="en-US">Minimum [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_PatentsAndLicensesMember" xlink:label="QLGN_PatentsAndLicensesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_PatentsAndLicensesMember" xlink:to="QLGN_PatentsAndLicensesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_PatentsAndLicensesMember_lbl" xml:lang="en-US">Patents and Licenses [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MaximumMember_lbl" xml:lang="en-US">Maximum [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantMember_lbl" xml:lang="en-US">Warrant [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MachineryAndEquipmentMember" xlink:label="us-gaap_MachineryAndEquipmentMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MachineryAndEquipmentMember" xlink:to="us-gaap_MachineryAndEquipmentMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MachineryAndEquipmentMember_lbl" xml:lang="en-US">Machinery and Equipment [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComputerEquipmentMember" xlink:to="us-gaap_ComputerEquipmentMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComputerEquipmentMember_lbl" xml:lang="en-US">Computer Equipment [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_MoldsAndToolingMember" xlink:label="QLGN_MoldsAndToolingMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_MoldsAndToolingMember" xlink:to="QLGN_MoldsAndToolingMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_MoldsAndToolingMember_lbl" xml:lang="en-US">Molds and Tooling [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FurnitureAndFixturesMember" xlink:to="us-gaap_FurnitureAndFixturesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xml:lang="en-US">Furniture and Fixtures [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LegalEntityAxis" xlink:to="dei_LegalEntityAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LegalEntityAxis_lbl" xml:lang="en-US">Legal Entity [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_NanoSynexMember" xlink:label="QLGN_NanoSynexMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_NanoSynexMember" xlink:to="QLGN_NanoSynexMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="QLGN_NanoSynexMember_lbl" xml:lang="en-US">Nano Synex Ltd [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_AlphaCapitalAnstaltMember" xlink:label="QLGN_AlphaCapitalAnstaltMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_AlphaCapitalAnstaltMember" xlink:to="QLGN_AlphaCapitalAnstaltMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_AlphaCapitalAnstaltMember_lbl" xml:lang="en-US">Alpha Capital Anstalt [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdImprovementsMember" xlink:to="us-gaap_LeaseholdImprovementsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xml:lang="en-US">Leasehold Improvements [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquipmentMember" xlink:label="us-gaap_EquipmentMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquipmentMember" xlink:to="us-gaap_EquipmentMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquipmentMember_lbl" xml:lang="en-US">Equipment [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_SekisuiDistributionAgreementMember" xlink:label="QLGN_SekisuiDistributionAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_SekisuiDistributionAgreementMember" xlink:to="QLGN_SekisuiDistributionAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_SekisuiDistributionAgreementMember_lbl" xml:lang="en-US">Sekisui Distribution Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_DevelopedProductTechnologyRightsMember" xlink:label="QLGN_DevelopedProductTechnologyRightsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_DevelopedProductTechnologyRightsMember" xlink:to="QLGN_DevelopedProductTechnologyRightsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_DevelopedProductTechnologyRightsMember_lbl" xml:lang="en-US">Developed-Product-Technology Rights [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_LicensingRightsMember" xlink:label="QLGN_LicensingRightsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_LicensingRightsMember" xlink:to="QLGN_LicensingRightsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_LicensingRightsMember_lbl" xml:lang="en-US">Licensing Rights [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xml:lang="en-US">Indefinite-Lived Intangible Assets [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InProcessResearchAndDevelopmentMember" xlink:label="us-gaap_InProcessResearchAndDevelopmentMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InProcessResearchAndDevelopmentMember" xlink:to="us-gaap_InProcessResearchAndDevelopmentMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InProcessResearchAndDevelopmentMember_lbl" xml:lang="en-US">In Process Research and Development [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PatentsMember" xlink:label="us-gaap_PatentsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PatentsMember" xlink:to="us-gaap_PatentsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PatentsMember_lbl" xml:lang="en-US">Patents [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LicenseMember" xlink:label="us-gaap_LicenseMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LicenseMember" xlink:to="us-gaap_LicenseMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LicenseMember_lbl" xml:lang="en-US">License [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="us-gaap_ShortTermDebtTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_ShortTermDebtTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShortTermDebtTypeAxis_lbl" xml:lang="en-US">Short-Term Debt, Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_NotesPayableMember" xlink:label="QLGN_NotesPayableMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_NotesPayableMember" xlink:to="QLGN_NotesPayableMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_NotesPayableMember_lbl" xml:lang="en-US">Notes Payable [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xml:lang="en-US">Related Party [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_SeriesCWarrantsMember" xlink:label="QLGN_SeriesCWarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_SeriesCWarrantsMember" xlink:to="QLGN_SeriesCWarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_SeriesCWarrantsMember_lbl" xml:lang="en-US">Series C Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_TitleOfIndividualAxis_lbl" xml:lang="en-US">Title of Individual [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_AlphaCapitalMember" xlink:label="QLGN_AlphaCapitalMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_AlphaCapitalMember" xlink:to="QLGN_AlphaCapitalMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_AlphaCapitalMember_lbl" xml:lang="en-US">Alpha Capital [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_CommonStockWarrantsMember" xlink:label="QLGN_CommonStockWarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_CommonStockWarrantsMember" xlink:to="QLGN_CommonStockWarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_CommonStockWarrantsMember_lbl" xml:lang="en-US">Common Stock Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel2Member" xlink:to="us-gaap_FairValueInputsLevel2Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel3Member" xlink:to="us-gaap_FairValueInputsLevel3Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputTypeAxis_lbl" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:to="us-gaap_MeasurementInputRiskFreeInterestRateMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember_lbl" xml:lang="en-US">Measurement Input, Risk Free Interest Rate [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_WeightedAverageMember" xlink:label="srt_WeightedAverageMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_WeightedAverageMember" xlink:to="srt_WeightedAverageMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_WeightedAverageMember_lbl" xml:lang="en-US">Weighted Average [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputPriceVolatilityMember" xlink:to="us-gaap_MeasurementInputPriceVolatilityMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember_lbl" xml:lang="en-US">Measurement Input, Price Volatility [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="us-gaap_MeasurementInputExpectedTermMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputExpectedTermMember" xlink:to="us-gaap_MeasurementInputExpectedTermMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputExpectedTermMember_lbl" xml:lang="en-US">Measurement Input, Expected Term [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputExpectedDividendRateMember" xlink:label="us-gaap_MeasurementInputExpectedDividendRateMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputExpectedDividendRateMember" xlink:to="us-gaap_MeasurementInputExpectedDividendRateMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputExpectedDividendRateMember_lbl" xml:lang="en-US">Measurement Input, Expected Dividend Rate [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentAxis_lbl" xml:lang="en-US">Debt Instrument [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_SeniorConvertibleDebentureMember" xlink:label="QLGN_SeniorConvertibleDebentureMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_SeniorConvertibleDebentureMember" xlink:to="QLGN_SeniorConvertibleDebentureMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_SeniorConvertibleDebentureMember_lbl" xml:lang="en-US">Senior Convertible Debenture [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_AlphaCapitalOtherThirdPartiesMember" xlink:label="QLGN_AlphaCapitalOtherThirdPartiesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_AlphaCapitalOtherThirdPartiesMember" xlink:to="QLGN_AlphaCapitalOtherThirdPartiesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_AlphaCapitalOtherThirdPartiesMember_lbl" xml:lang="en-US">Alpha Capital Other Third Parties [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_SeniorSecuredConvertibleDebtMember" xlink:label="QLGN_SeniorSecuredConvertibleDebtMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_SeniorSecuredConvertibleDebtMember" xlink:to="QLGN_SeniorSecuredConvertibleDebtMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_SeniorSecuredConvertibleDebtMember_lbl" xml:lang="en-US">Senior Secured Convertible Debt [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_SharesOfCommonStockSubjectToOutstandingOptionsMember" xlink:label="QLGN_SharesOfCommonStockSubjectToOutstandingOptionsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_SharesOfCommonStockSubjectToOutstandingOptionsMember" xlink:to="QLGN_SharesOfCommonStockSubjectToOutstandingOptionsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_SharesOfCommonStockSubjectToOutstandingOptionsMember_lbl" xml:lang="en-US">Shares of Common Stock Subject to Outstanding Options [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_SharesOfCommonStockSubjectToOutstandingWarrantsMember" xlink:label="QLGN_SharesOfCommonStockSubjectToOutstandingWarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_SharesOfCommonStockSubjectToOutstandingWarrantsMember" xlink:to="QLGN_SharesOfCommonStockSubjectToOutstandingWarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_SharesOfCommonStockSubjectToOutstandingWarrantsMember_lbl" xml:lang="en-US">Shares of Common Stock Subject to Outstanding Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AwardTypeAxis_lbl" xml:lang="en-US">Award Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_FirstTwelveMonthsMember" xlink:label="QLGN_FirstTwelveMonthsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_FirstTwelveMonthsMember" xlink:to="QLGN_FirstTwelveMonthsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_FirstTwelveMonthsMember_lbl" xml:lang="en-US">First 12 Months [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventMember_lbl" xml:lang="en-US">Subsequent Event [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_LongtermOperatingLeaseAgreementMember" xlink:label="QLGN_LongtermOperatingLeaseAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_LongtermOperatingLeaseAgreementMember" xlink:to="QLGN_LongtermOperatingLeaseAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_LongtermOperatingLeaseAgreementMember_lbl" xml:lang="en-US">Long term Operating Lease Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_SponsoredResearchAgreementAndLicenseMember" xlink:label="QLGN_SponsoredResearchAgreementAndLicenseMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_SponsoredResearchAgreementAndLicenseMember" xlink:to="QLGN_SponsoredResearchAgreementAndLicenseMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_SponsoredResearchAgreementAndLicenseMember_lbl" xml:lang="en-US">Sponsored Research and License Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_UniversityOfLouisvilleResearchFoundationMember" xlink:label="QLGN_UniversityOfLouisvilleResearchFoundationMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_UniversityOfLouisvilleResearchFoundationMember" xlink:to="QLGN_UniversityOfLouisvilleResearchFoundationMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_UniversityOfLouisvilleResearchFoundationMember_lbl" xml:lang="en-US">University of Louisville Research Foundation [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_LicenseAndSponsoredResearchAgreementsMember" xlink:label="QLGN_LicenseAndSponsoredResearchAgreementsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_LicenseAndSponsoredResearchAgreementsMember" xlink:to="QLGN_LicenseAndSponsoredResearchAgreementsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_LicenseAndSponsoredResearchAgreementsMember_lbl" xml:lang="en-US">License and Sponsored Research Agreements [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_PhaseOneClinicalTrialMember" xlink:label="QLGN_PhaseOneClinicalTrialMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_PhaseOneClinicalTrialMember" xlink:to="QLGN_PhaseOneClinicalTrialMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_PhaseOneClinicalTrialMember_lbl" xml:lang="en-US">Phase 1 Clinical Trial [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_PhaseTwoClinicalTrialMember" xlink:label="QLGN_PhaseTwoClinicalTrialMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_PhaseTwoClinicalTrialMember" xlink:to="QLGN_PhaseTwoClinicalTrialMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_PhaseTwoClinicalTrialMember_lbl" xml:lang="en-US">Phase 2 Clinical Trial [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_PhaseThreeClinicalTrialMember" xlink:label="QLGN_PhaseThreeClinicalTrialMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_PhaseThreeClinicalTrialMember" xlink:to="QLGN_PhaseThreeClinicalTrialMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_PhaseThreeClinicalTrialMember_lbl" xml:lang="en-US">Phase 3 Clinical Trial [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_LicensedProductSalesMember" xlink:label="QLGN_LicensedProductSalesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_LicensedProductSalesMember" xlink:to="QLGN_LicensedProductSalesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_LicensedProductSalesMember_lbl" xml:lang="en-US">Licensed Product Sales [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_LicenseAgreementMember" xlink:label="QLGN_LicenseAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_LicenseAgreementMember" xlink:to="QLGN_LicenseAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_LicenseAgreementMember_lbl" xml:lang="en-US">License Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_PhaseClinicalTrialMember" xlink:label="QLGN_PhaseClinicalTrialMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_PhaseClinicalTrialMember" xlink:to="QLGN_PhaseClinicalTrialMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_PhaseClinicalTrialMember_lbl" xml:lang="en-US">Phase Clinical Trial [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_AdvancedCancerTherapeuticsLLCMember" xlink:label="QLGN_AdvancedCancerTherapeuticsLLCMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_AdvancedCancerTherapeuticsLLCMember" xlink:to="QLGN_AdvancedCancerTherapeuticsLLCMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_AdvancedCancerTherapeuticsLLCMember_lbl" xml:lang="en-US">Advanced Cancer Therapeutics, LLC [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_CEMarkMember" xlink:label="QLGN_CEMarkMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_CEMarkMember" xlink:to="QLGN_CEMarkMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_CEMarkMember_lbl" xml:lang="en-US">CE Mark [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_YiXinZhenDuanJishuLtdMember" xlink:label="QLGN_YiXinZhenDuanJishuLtdMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_YiXinZhenDuanJishuLtdMember" xlink:to="QLGN_YiXinZhenDuanJishuLtdMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_YiXinZhenDuanJishuLtdMember_lbl" xml:lang="en-US">Yi Xin Zhen Duan Jishu Ltd [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_STAPharmaceuticalCoLtdMember" xlink:label="QLGN_STAPharmaceuticalCoLtdMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_STAPharmaceuticalCoLtdMember" xlink:to="QLGN_STAPharmaceuticalCoLtdMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_STAPharmaceuticalCoLtdMember_lbl" xml:lang="en-US">STA Pharmaceutical Co Ltd [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_UpfrontPaymentMember" xlink:label="QLGN_UpfrontPaymentMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_UpfrontPaymentMember" xlink:to="QLGN_UpfrontPaymentMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_UpfrontPaymentMember_lbl" xml:lang="en-US">Upfront Payment [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_SecuritiesPurchaseAgreementMember" xlink:label="QLGN_SecuritiesPurchaseAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_SecuritiesPurchaseAgreementMember" xlink:to="QLGN_SecuritiesPurchaseAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_SecuritiesPurchaseAgreementMember_lbl" xml:lang="en-US">Securities Purchase Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockOptionMember" xlink:label="us-gaap_StockOptionMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockOptionMember" xlink:to="us-gaap_StockOptionMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockOptionMember_lbl" xml:lang="en-US">Equity Option [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameAxis_lbl" xml:lang="en-US">Plan Name [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_TwoThousandTwentyStockIncentivePlanMember" xlink:label="QLGN_TwoThousandTwentyStockIncentivePlanMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_TwoThousandTwentyStockIncentivePlanMember" xlink:to="QLGN_TwoThousandTwentyStockIncentivePlanMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_TwoThousandTwentyStockIncentivePlanMember_lbl" xml:lang="en-US">2020 Stock Incentive Plan [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_EmployeesAndNonemployeeServiceProviderMember" xlink:label="QLGN_EmployeesAndNonemployeeServiceProviderMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_EmployeesAndNonemployeeServiceProviderMember" xlink:to="QLGN_EmployeesAndNonemployeeServiceProviderMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_EmployeesAndNonemployeeServiceProviderMember_lbl" xml:lang="en-US">Employees and Non-employee Service Provider [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xml:lang="en-US">Share-Based Payment Arrangement, Option [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_CompensatoryWarrantsMember" xlink:label="QLGN_CompensatoryWarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_CompensatoryWarrantsMember" xlink:to="QLGN_CompensatoryWarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_CompensatoryWarrantsMember_lbl" xml:lang="en-US">Compensatory Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xml:lang="en-US">General and Administrative Expense [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_WarrantOneMember" xlink:label="QLGN_WarrantOneMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_WarrantOneMember" xlink:to="QLGN_WarrantOneMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_WarrantOneMember_lbl" xml:lang="en-US">Warrant One [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_CompensatoryWarrantActivityMember" xlink:label="QLGN_CompensatoryWarrantActivityMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_CompensatoryWarrantActivityMember" xlink:to="QLGN_CompensatoryWarrantActivityMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_CompensatoryWarrantActivityMember_lbl" xml:lang="en-US">Compensatory Warrant Activity [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_NoncompensatoryEquityClassifiedWarrantsMember" xlink:label="QLGN_NoncompensatoryEquityClassifiedWarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_NoncompensatoryEquityClassifiedWarrantsMember" xlink:to="QLGN_NoncompensatoryEquityClassifiedWarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_NoncompensatoryEquityClassifiedWarrantsMember_lbl" xml:lang="en-US">Noncompensatory Equity Classified Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_NonCompensatoryWarrantActivityMember" xlink:label="QLGN_NonCompensatoryWarrantActivityMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_NonCompensatoryWarrantActivityMember" xlink:to="QLGN_NonCompensatoryWarrantActivityMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_NonCompensatoryWarrantActivityMember_lbl" xml:lang="en-US">Non Compensatory Warrant Activity [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xml:lang="en-US">Research and Development Expense [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxAuthorityAxis_lbl" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCountryMember" xlink:label="us-gaap_ForeignCountryMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCountryMember" xlink:to="us-gaap_ForeignCountryMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ForeignCountryMember_lbl" xml:lang="en-US">Foreign Tax Authority [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DomesticCountryMember" xlink:to="us-gaap_DomesticCountryMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DomesticCountryMember_lbl" xml:lang="en-US">Domestic Tax Authority [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StateAndLocalJurisdictionMember" xlink:to="us-gaap_StateAndLocalJurisdictionMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StateAndLocalJurisdictionMember_lbl" xml:lang="en-US">State and Local Jurisdiction [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Cover [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_IcfrAuditorAttestationFlag" xlink:to="dei_IcfrAuditorAttestationFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_IcfrAuditorAttestationFlag_lbl" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorFirmId" xlink:to="dei_AuditorFirmId_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorFirmId_lbl" xml:lang="en-US">Auditor Firm ID</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorName" xlink:label="dei_AuditorName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorName" xlink:to="dei_AuditorName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorName_lbl" xml:lang="en-US">Auditor Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorLocation" xlink:to="dei_AuditorLocation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorLocation_lbl" xml:lang="en-US">Auditor Location</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US">ASSETS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US">Current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Cash" xlink:label="us-gaap_Cash" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Cash" xlink:to="us-gaap_Cash_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Cash_lbl" xml:lang="en-US">Cash</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableNetCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xml:lang="en-US">Accounts receivable, net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryNet_lbl" xml:lang="en-US">Inventory, net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US">Total current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalents" xlink:label="us-gaap_RestrictedCashAndCashEquivalents" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashAndCashEquivalents" xlink:to="us-gaap_RestrictedCashAndCashEquivalents_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedCashAndCashEquivalents_lbl" xml:lang="en-US">Restricted cash</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US">Right-of-use assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US">Property and equipment, net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl" xml:lang="en-US">Intangible assets, net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill" xlink:label="us-gaap_Goodwill" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Goodwill" xlink:to="us-gaap_Goodwill_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Goodwill_lbl" xml:lang="en-US">Goodwill</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xml:lang="en-US">Other assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">Total Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US">Current liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US">Accounts payable</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_AccruedVacation" xlink:label="QLGN_AccruedVacation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_AccruedVacation" xlink:to="QLGN_AccruedVacation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_AccruedVacation_lbl" xml:lang="en-US">Accrued vacation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:to="us-gaap_AccruedLiabilitiesAndOtherLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities_lbl" xml:lang="en-US">Accrued expenses and other current liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_ResearchAndDevelopmentGrantLiability" xlink:label="QLGN_ResearchAndDevelopmentGrantLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_ResearchAndDevelopmentGrantLiability" xlink:to="QLGN_ResearchAndDevelopmentGrantLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_ResearchAndDevelopmentGrantLiability_lbl" xml:lang="en-US">R&amp;D grant liability</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeCurrent" xlink:label="us-gaap_DeferredIncomeCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeCurrent" xlink:to="us-gaap_DeferredIncomeCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredIncomeCurrent_lbl" xml:lang="en-US">Deferred revenue, current portion</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xml:lang="en-US">Operating lease liability, current portion</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermBorrowings" xlink:label="us-gaap_ShortTermBorrowings" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermBorrowings" xlink:to="us-gaap_ShortTermBorrowings_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShortTermBorrowings_lbl" xml:lang="en-US">Short term debt - related party</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingLiabilitiesCurrent" xlink:label="us-gaap_HedgingLiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_HedgingLiabilitiesCurrent" xlink:to="us-gaap_HedgingLiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_HedgingLiabilitiesCurrent_lbl" xml:lang="en-US">Warrant liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_WarrantLiabilitiesRelatedParty" xlink:label="QLGN_WarrantLiabilitiesRelatedParty" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_WarrantLiabilitiesRelatedParty" xlink:to="QLGN_WarrantLiabilitiesRelatedParty_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_WarrantLiabilitiesRelatedParty_lbl" xml:lang="en-US">Warrant liabilities - related party</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleDebt" xlink:label="us-gaap_ConvertibleDebt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleDebt" xlink:to="us-gaap_ConvertibleDebt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertibleDebt_lbl" xml:lang="en-US">Convertible debt - related party</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">Total current liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xml:lang="en-US">Operating lease liability, net of current portion</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:label="us-gaap_DeferredRevenueNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenueNoncurrent" xlink:to="us-gaap_DeferredRevenueNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredRevenueNoncurrent_lbl" xml:lang="en-US">Deferred revenue, net of current portion</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:label="us-gaap_DeferredIncomeTaxLiabilitiesNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:to="us-gaap_DeferredIncomeTaxLiabilitiesNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredIncomeTaxLiabilitiesNet_lbl" xml:lang="en-US">Deferred tax liability</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US">Total liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US">Commitments and Contingencies (Note 13)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_lbl" xml:lang="en-US">Stockholders&#8217; equity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US">Qualigen Therapeutics, Inc. stockholders&#8217; equity:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US">Common stock, $0.001 par value; 225,000,000 shares authorized; 4,210,737 and 3,529,018 shares issued and outstanding as of December 31, 2022 and December 31, 2021, respectively</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xml:lang="en-US">Additional paid-in capital</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xml:lang="en-US">Accumulated other comprehensive income</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US">Accumulated deficit</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Total Qualigen Therapeutics, Inc. stockholders&#8217; equity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterest" xlink:label="us-gaap_MinorityInterest" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MinorityInterest" xlink:to="us-gaap_MinorityInterest_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MinorityInterest_lbl" xml:lang="en-US">Noncontrolling interest</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl" xml:lang="en-US">Total Stockholders&#8217; Equity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">Total Liabilities &amp; Stockholders&#8217; Equity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Common stock, par value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US">Common stock, shares authorized</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US">Common stock, shares issued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US">Common stock, shares outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US">Statement [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US">Statement [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenuesAbstract" xlink:label="us-gaap_RevenuesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_RevenuesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenuesAbstract_lbl" xml:lang="en-US">REVENUES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xml:lang="en-US">Total revenues</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingCostsAndExpensesAbstract" xlink:label="us-gaap_OperatingCostsAndExpensesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingCostsAndExpensesAbstract" xlink:to="us-gaap_OperatingCostsAndExpensesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingCostsAndExpensesAbstract_lbl" xml:lang="en-US">EXPENSES</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_CostOfProductSales" xlink:label="QLGN_CostOfProductSales" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_CostOfProductSales" xlink:to="QLGN_CostOfProductSales_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_CostOfProductSales_lbl" xml:lang="en-US">Cost of product sales</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US">General and administrative</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Research and development</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketingAndAdvertisingExpense" xlink:label="us-gaap_MarketingAndAdvertisingExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketingAndAdvertisingExpense" xlink:to="us-gaap_MarketingAndAdvertisingExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MarketingAndAdvertisingExpense_lbl" xml:lang="en-US">Sales and marketing</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillImpairmentLoss" xlink:label="us-gaap_GoodwillImpairmentLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillImpairmentLoss" xlink:to="us-gaap_GoodwillImpairmentLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GoodwillImpairmentLoss_lbl" xml:lang="en-US">Goodwill and fixed asset impairment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US">Total expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US">LOSS FROM OPERATIONS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xml:lang="en-US">OTHER EXPENSE (INCOME), NET</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeGainLossOnDerivativeNet" xlink:label="us-gaap_DerivativeGainLossOnDerivativeNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeGainLossOnDerivativeNet" xlink:to="us-gaap_DerivativeGainLossOnDerivativeNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DerivativeGainLossOnDerivativeNet_lbl" xml:lang="en-US">Gain on change in fair value of warrant liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestIncomeExpenseNet" xlink:label="us-gaap_InterestIncomeExpenseNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestIncomeExpenseNet" xlink:to="us-gaap_InterestIncomeExpenseNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_InterestIncomeExpenseNet_lbl" xml:lang="en-US">Interest (income) expense, net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xml:lang="en-US">Other income, net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xml:lang="en-US">Total other expense (income), net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xml:lang="en-US">LOSS BEFORE (BENEFIT) PROVISION FOR INCOME TAXES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US">(BENEFIT) PROVISION FOR INCOME TAXES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_ProfitLoss_lbl" xml:lang="en-US">Net loss</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:to="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_lbl" xml:lang="en-US">Net loss attributable to noncontrolling interest</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Net loss attributable to Qualigen Therapeutics, Inc.</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US">Net loss per common share, basic and diluted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US">Weighted&#8212;average number of shares outstanding, basic and diluted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_lbl" xml:lang="en-US">Other comprehensive loss, net of tax</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_lbl" xml:lang="en-US">Foreign currency translation adjustment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_lbl" xml:lang="en-US">Other comprehensive loss</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:to="us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_lbl" xml:lang="en-US">Comprehensive loss attributable to noncontrolling interest</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xml:lang="en-US">Comprehensive loss attributable to Qualigen Therapeutics, Inc.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_2_lbl" xml:lang="en-US">Balance. value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US">Balance, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_StockIssuedUponCashExerciseOfWarrants" xlink:label="QLGN_StockIssuedUponCashExerciseOfWarrants" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_StockIssuedUponCashExerciseOfWarrants" xlink:to="QLGN_StockIssuedUponCashExerciseOfWarrants_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_StockIssuedUponCashExerciseOfWarrants_lbl" xml:lang="en-US">Stock issued upon cash-exercise of warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_StockIssuedUponCashExerciseOfWarrantsShares" xlink:label="QLGN_StockIssuedUponCashExerciseOfWarrantsShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_StockIssuedUponCashExerciseOfWarrantsShares" xlink:to="QLGN_StockIssuedUponCashExerciseOfWarrantsShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_StockIssuedUponCashExerciseOfWarrantsShares_lbl" xml:lang="en-US">Stock issued upon cash exercise of warrants, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions_lbl" xml:lang="en-US">Stock-based compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_CommonStockAndPrefundedWarrantsIssuedForBusinessAcquisition" xlink:label="QLGN_CommonStockAndPrefundedWarrantsIssuedForBusinessAcquisition" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_CommonStockAndPrefundedWarrantsIssuedForBusinessAcquisition" xlink:to="QLGN_CommonStockAndPrefundedWarrantsIssuedForBusinessAcquisition_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_CommonStockAndPrefundedWarrantsIssuedForBusinessAcquisition_lbl" xml:lang="en-US">Common stock and prefunded warrants issued for business acquisition</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_CommonStockAndPrefundedWarrantsIssuedSharesForBusinessAcquisition" xlink:label="QLGN_CommonStockAndPrefundedWarrantsIssuedSharesForBusinessAcquisition" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_CommonStockAndPrefundedWarrantsIssuedSharesForBusinessAcquisition" xlink:to="QLGN_CommonStockAndPrefundedWarrantsIssuedSharesForBusinessAcquisition_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_CommonStockAndPrefundedWarrantsIssuedSharesForBusinessAcquisition_lbl" xml:lang="en-US">Balance, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_NoncontrollingInterestAdjustmentsRelatingToStockbasedCompensationAndOther" xlink:label="QLGN_NoncontrollingInterestAdjustmentsRelatingToStockbasedCompensationAndOther" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_NoncontrollingInterestAdjustmentsRelatingToStockbasedCompensationAndOther" xlink:to="QLGN_NoncontrollingInterestAdjustmentsRelatingToStockbasedCompensationAndOther_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_NoncontrollingInterestAdjustmentsRelatingToStockbasedCompensationAndOther_lbl" xml:lang="en-US">&#160;Noncontrolling interest adjustments relating to Stock-based compensation and other</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_FairValueOfWarrantModificationForProfessionalServices" xlink:label="QLGN_FairValueOfWarrantModificationForProfessionalServices" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_FairValueOfWarrantModificationForProfessionalServices" xlink:to="QLGN_FairValueOfWarrantModificationForProfessionalServices_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_FairValueOfWarrantModificationForProfessionalServices_lbl" xml:lang="en-US">Fair value of warrant modification for professional services</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_FairValueOfWarrantModificationForBusinessAcquisition" xlink:label="QLGN_FairValueOfWarrantModificationForBusinessAcquisition" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_FairValueOfWarrantModificationForBusinessAcquisition" xlink:to="QLGN_FairValueOfWarrantModificationForBusinessAcquisition_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_FairValueOfWarrantModificationForBusinessAcquisition_lbl" xml:lang="en-US">Fair value of warrant modification for business acquisition</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_StockIssuedDuringPeriodValuesReverseStockSplits" xlink:label="QLGN_StockIssuedDuringPeriodValuesReverseStockSplits" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_StockIssuedDuringPeriodValuesReverseStockSplits" xlink:to="QLGN_StockIssuedDuringPeriodValuesReverseStockSplits_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_StockIssuedDuringPeriodValuesReverseStockSplits_lbl" xml:lang="en-US">Issuance of rounded shares as a result of the reverse stock split</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits" xlink:label="us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits" xlink:to="us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits_lbl" xml:lang="en-US">Balance, shares</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProfitLoss_2_lbl" xml:lang="en-US">Net Loss</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_StockIssuedUponNetexerciseOfWarrants" xlink:label="QLGN_StockIssuedUponNetexerciseOfWarrants" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_StockIssuedUponNetexerciseOfWarrants" xlink:to="QLGN_StockIssuedUponNetexerciseOfWarrants_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_StockIssuedUponNetexerciseOfWarrants_lbl" xml:lang="en-US">Stock issued upon net-exercise of warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_StockIssuedUponNetexerciseOfWarrantsShares" xlink:label="QLGN_StockIssuedUponNetexerciseOfWarrantsShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_StockIssuedUponNetexerciseOfWarrantsShares" xlink:to="QLGN_StockIssuedUponNetexerciseOfWarrantsShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_StockIssuedUponNetexerciseOfWarrantsShares_lbl" xml:lang="en-US">Stock issued upon net-exercise of warrants, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_IssuanceOfCommonStockForConversionOfPreferredStock" xlink:label="QLGN_IssuanceOfCommonStockForConversionOfPreferredStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_IssuanceOfCommonStockForConversionOfPreferredStock" xlink:to="QLGN_IssuanceOfCommonStockForConversionOfPreferredStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_IssuanceOfCommonStockForConversionOfPreferredStock_lbl" xml:lang="en-US">Issuance of common stock for conversion of preferred stock</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_IssuanceOfCommonStockSharesForConversionOfPreferredStock" xlink:label="QLGN_IssuanceOfCommonStockSharesForConversionOfPreferredStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_IssuanceOfCommonStockSharesForConversionOfPreferredStock" xlink:to="QLGN_IssuanceOfCommonStockSharesForConversionOfPreferredStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_IssuanceOfCommonStockSharesForConversionOfPreferredStock_lbl" xml:lang="en-US">Issuance of common stock for conversion of preferred stock, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_FairValueOfWarrantsIssuedForProfessionalServices" xlink:label="QLGN_FairValueOfWarrantsIssuedForProfessionalServices" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_FairValueOfWarrantsIssuedForProfessionalServices" xlink:to="QLGN_FairValueOfWarrantsIssuedForProfessionalServices_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_FairValueOfWarrantsIssuedForProfessionalServices_lbl" xml:lang="en-US">Fair value of warrants issued for professional services</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_SharesIssuedPursuantToSecuritiesPurchaseAgreements" xlink:label="QLGN_SharesIssuedPursuantToSecuritiesPurchaseAgreements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_SharesIssuedPursuantToSecuritiesPurchaseAgreements" xlink:to="QLGN_SharesIssuedPursuantToSecuritiesPurchaseAgreements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_SharesIssuedPursuantToSecuritiesPurchaseAgreements_lbl" xml:lang="en-US">Shares issued pursuant to Securities Purchase Agreements</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_SharesIssuedPursuantToSecuritiesPurchaseShareAgreements" xlink:label="QLGN_SharesIssuedPursuantToSecuritiesPurchaseShareAgreements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_SharesIssuedPursuantToSecuritiesPurchaseShareAgreements" xlink:to="QLGN_SharesIssuedPursuantToSecuritiesPurchaseShareAgreements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_SharesIssuedPursuantToSecuritiesPurchaseShareAgreements_lbl" xml:lang="en-US">Shares issued pursuant to Securities Purchase Agreements, Shares</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_CommissionAndOfferingCostsOfSecuritiesPurchaseAgreements" xlink:label="QLGN_CommissionAndOfferingCostsOfSecuritiesPurchaseAgreements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_CommissionAndOfferingCostsOfSecuritiesPurchaseAgreements" xlink:to="QLGN_CommissionAndOfferingCostsOfSecuritiesPurchaseAgreements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_CommissionAndOfferingCostsOfSecuritiesPurchaseAgreements_lbl" xml:lang="en-US">Commission and offering costs of Securities Purchase Agreements</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_FairValueOfWarrantModificationsPursuantToSecuritiesPurchaseAgreements" xlink:label="QLGN_FairValueOfWarrantModificationsPursuantToSecuritiesPurchaseAgreements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_FairValueOfWarrantModificationsPursuantToSecuritiesPurchaseAgreements" xlink:to="QLGN_FairValueOfWarrantModificationsPursuantToSecuritiesPurchaseAgreements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_FairValueOfWarrantModificationsPursuantToSecuritiesPurchaseAgreements_lbl" xml:lang="en-US">Fair value of warrant modifications pursuant to Securities Purchase Agreements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_lbl" xml:lang="en-US">Stock issued for professional services</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl" xml:lang="en-US">Stock issued for professional services, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_lbl" xml:lang="en-US">Stock-based compensation</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_3_lbl" xml:lang="en-US">Balance, value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharesOutstanding_2_lbl" xml:lang="en-US">Balance, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">CASH FLOWS FROM OPERATING ACTIVITIES</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProfitLoss_3_lbl" xml:lang="en-US">Net loss</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationDepletionAndAmortization" xlink:to="us-gaap_DepreciationDepletionAndAmortization_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xml:lang="en-US">Depreciation and amortization</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_lbl" xml:lang="en-US">Amortization of right-of-use assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProvisionForDoubtfulAccounts" xlink:label="us-gaap_ProvisionForDoubtfulAccounts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProvisionForDoubtfulAccounts" xlink:to="us-gaap_ProvisionForDoubtfulAccounts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProvisionForDoubtfulAccounts_lbl" xml:lang="en-US">Accounts receivable reserves and allowances</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryWriteDown" xlink:label="us-gaap_InventoryWriteDown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryWriteDown" xlink:to="us-gaap_InventoryWriteDown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryWriteDown_lbl" xml:lang="en-US">Inventory reserves</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:label="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:to="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_lbl" xml:lang="en-US">Common stock issued for professional services</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US">Stock-based compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAdjustmentOfWarrants" xlink:to="us-gaap_FairValueAdjustmentOfWarrants_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_lbl" xml:lang="en-US">Change in fair value of warrant liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xml:lang="en-US">Accounts receivable</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_IncreaseDecreaseInInventoryAndEquipmentHeldForLeases" xlink:label="QLGN_IncreaseDecreaseInInventoryAndEquipmentHeldForLeases" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_IncreaseDecreaseInInventoryAndEquipmentHeldForLeases" xlink:to="QLGN_IncreaseDecreaseInInventoryAndEquipmentHeldForLeases_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="QLGN_IncreaseDecreaseInInventoryAndEquipmentHeldForLeases_lbl" xml:lang="en-US">Inventory and equipment held for lease</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xml:lang="en-US">Prepaid expenses and other assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xml:lang="en-US">Accounts payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities_lbl" xml:lang="en-US">Accrued expenses and other current liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_IncreaseDecreaseInResearchAndDevelopmentGrantLiability" xlink:label="QLGN_IncreaseDecreaseInResearchAndDevelopmentGrantLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_IncreaseDecreaseInResearchAndDevelopmentGrantLiability" xlink:to="QLGN_IncreaseDecreaseInResearchAndDevelopmentGrantLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="QLGN_IncreaseDecreaseInResearchAndDevelopmentGrantLiability_lbl" xml:lang="en-US">R&amp;D grant liability</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl" xml:lang="en-US">Operating lease liability</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_lbl" xml:lang="en-US">Deferred revenue</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInDeferredLiabilities" xlink:label="us-gaap_IncreaseDecreaseInDeferredLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDeferredLiabilities" xlink:to="us-gaap_IncreaseDecreaseInDeferredLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInDeferredLiabilities_lbl" xml:lang="en-US">Deferred tax liability</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">Net cash used in operating activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US">CASH FLOWS FROM INVESTING ACTIVITIES:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US">Purchases of property and equipment</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_PurchasesOfEquipmentHeldForLease" xlink:label="QLGN_PurchasesOfEquipmentHeldForLease" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_PurchasesOfEquipmentHeldForLease" xlink:to="QLGN_PurchasesOfEquipmentHeldForLease_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="QLGN_PurchasesOfEquipmentHeldForLease_lbl" xml:lang="en-US">Purchases of equipment held for lease</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireIntangibleAssets" xlink:to="us-gaap_PaymentsToAcquireIntangibleAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets_lbl" xml:lang="en-US">Payments for patents and licenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAcquiredFromAcquisition" xlink:label="us-gaap_CashAcquiredFromAcquisition" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAcquiredFromAcquisition" xlink:to="us-gaap_CashAcquiredFromAcquisition_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAcquiredFromAcquisition_lbl" xml:lang="en-US">Net cash acquired in business combination</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US">Net cash used in investing activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US">CASH FLOWS FROM FINANCING ACTIVITIES:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromWarrantExercises" xlink:to="us-gaap_ProceedsFromWarrantExercises_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromWarrantExercises_lbl" xml:lang="en-US">Net proceeds from warrant exercises</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_ProceedsFromIssuanceOfSharesAndWarrantsPursuantToSecuritiesPurchaseAgreements" xlink:label="QLGN_ProceedsFromIssuanceOfSharesAndWarrantsPursuantToSecuritiesPurchaseAgreements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_ProceedsFromIssuanceOfSharesAndWarrantsPursuantToSecuritiesPurchaseAgreements" xlink:to="QLGN_ProceedsFromIssuanceOfSharesAndWarrantsPursuantToSecuritiesPurchaseAgreements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_ProceedsFromIssuanceOfSharesAndWarrantsPursuantToSecuritiesPurchaseAgreements_lbl" xml:lang="en-US">Proceeds from issuance of shares and warrants pursuant to Securities Purchase Agreements</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_ProceedsFromIssuanceOfConvertibleDebt" xlink:label="QLGN_ProceedsFromIssuanceOfConvertibleDebt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_ProceedsFromIssuanceOfConvertibleDebt" xlink:to="QLGN_ProceedsFromIssuanceOfConvertibleDebt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_ProceedsFromIssuanceOfConvertibleDebt_lbl" xml:lang="en-US">Proceeds from issuance of convertible debt - related party</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xml:lang="en-US">Offering costs of Securities Purchase Agreements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfNotesPayable" xlink:label="us-gaap_RepaymentsOfNotesPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfNotesPayable" xlink:to="us-gaap_RepaymentsOfNotesPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_RepaymentsOfNotesPayable_lbl" xml:lang="en-US">Principal payments on notes payable</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_FractionalSharePaymentsRelatedToReverseStockSplit" xlink:label="QLGN_FractionalSharePaymentsRelatedToReverseStockSplit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_FractionalSharePaymentsRelatedToReverseStockSplit" xlink:to="QLGN_FractionalSharePaymentsRelatedToReverseStockSplit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="QLGN_FractionalSharePaymentsRelatedToReverseStockSplit_lbl" xml:lang="en-US">Fractional share payments related to the reverse stock split</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">Net cash provided by financing activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xml:lang="en-US">Net change in cash and restricted cash</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xml:lang="en-US">Effect of exchange rate changes on cash and restricted cash</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xml:lang="en-US">Cash and restricted cash - beginning of period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_2_lbl" xml:lang="en-US">Cash and restricted cash - end of period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US">SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_CashPaidForAbstract" xlink:label="QLGN_CashPaidForAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_CashPaidForAbstract" xlink:to="QLGN_CashPaidForAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_CashPaidForAbstract_lbl" xml:lang="en-US">Cash paid during the year for:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaidNet" xlink:to="us-gaap_InterestPaidNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestPaidNet_lbl" xml:lang="en-US">Interest</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxesPaidNet" xlink:label="us-gaap_IncomeTaxesPaidNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxesPaidNet" xlink:to="us-gaap_IncomeTaxesPaidNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxesPaidNet_lbl" xml:lang="en-US">Taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xml:lang="en-US">NONCASH FINANCING AND INVESTING ACTIVITIES:</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_IssuanceOfCommonStockForConversionOfPreferredStockBeforeClosingOfReverseRecapitalization" xlink:label="QLGN_IssuanceOfCommonStockForConversionOfPreferredStockBeforeClosingOfReverseRecapitalization" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_IssuanceOfCommonStockForConversionOfPreferredStockBeforeClosingOfReverseRecapitalization" xlink:to="QLGN_IssuanceOfCommonStockForConversionOfPreferredStockBeforeClosingOfReverseRecapitalization_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_IssuanceOfCommonStockForConversionOfPreferredStockBeforeClosingOfReverseRecapitalization_lbl" xml:lang="en-US">Issuance of common stock for conversion of preferred stock after closing of reverse recapitalization</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_RightofuseAssetsObtainedInExchangeForOperatingLeaseLiabilities" xlink:label="QLGN_RightofuseAssetsObtainedInExchangeForOperatingLeaseLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_RightofuseAssetsObtainedInExchangeForOperatingLeaseLiabilities" xlink:to="QLGN_RightofuseAssetsObtainedInExchangeForOperatingLeaseLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_RightofuseAssetsObtainedInExchangeForOperatingLeaseLiabilities_lbl" xml:lang="en-US">Right-of-use assets obtained in exchange for operating lease liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_SharesIssuedForCashlessWarrantsAmount" xlink:label="QLGN_SharesIssuedForCashlessWarrantsAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_SharesIssuedForCashlessWarrantsAmount" xlink:to="QLGN_SharesIssuedForCashlessWarrantsAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_SharesIssuedForCashlessWarrantsAmount_lbl" xml:lang="en-US">Fair value of shares issued for cashless warrant exercises</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_TransfersOfInventoryFromEquipmentHeldForLease" xlink:label="QLGN_TransfersOfInventoryFromEquipmentHeldForLease" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_TransfersOfInventoryFromEquipmentHeldForLease" xlink:to="QLGN_TransfersOfInventoryFromEquipmentHeldForLease_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_TransfersOfInventoryFromEquipmentHeldForLease_lbl" xml:lang="en-US">Net transfers to inventory from equipment held for lease</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_FairValueOfWarrantLiabilitiesOnDateOfExercise" xlink:label="QLGN_FairValueOfWarrantLiabilitiesOnDateOfExercise" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_FairValueOfWarrantLiabilitiesOnDateOfExercise" xlink:to="QLGN_FairValueOfWarrantLiabilitiesOnDateOfExercise_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_FairValueOfWarrantLiabilitiesOnDateOfExercise_lbl" xml:lang="en-US">Fair value of warrant liabilities on date of exercise</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_FairValueOfWarrantModificationsForBusinessAcquisition" xlink:label="QLGN_FairValueOfWarrantModificationsForBusinessAcquisition" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_FairValueOfWarrantModificationsForBusinessAcquisition" xlink:to="QLGN_FairValueOfWarrantModificationsForBusinessAcquisition_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_FairValueOfWarrantModificationsForBusinessAcquisition_lbl" xml:lang="en-US">Fair value of warrant modifications for business acquisition</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" xml:lang="en-US">ACQUISITION:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueOfAssetsAcquired" xlink:label="us-gaap_FairValueOfAssetsAcquired" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueOfAssetsAcquired" xlink:to="us-gaap_FairValueOfAssetsAcquired_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_FairValueOfAssetsAcquired_lbl" xml:lang="en-US">Fair value of assets acquired</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAssumed1" xlink:label="us-gaap_LiabilitiesAssumed1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAssumed1" xlink:to="us-gaap_LiabilitiesAssumed1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAssumed1_lbl" xml:lang="en-US">Fair value of liabilities assumed, net of goodwill</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_FairValueOfWarrantsRepricedDueToAcquisition" xlink:label="QLGN_FairValueOfWarrantsRepricedDueToAcquisition" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_FairValueOfWarrantsRepricedDueToAcquisition" xlink:to="QLGN_FairValueOfWarrantsRepricedDueToAcquisition_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_FairValueOfWarrantsRepricedDueToAcquisition_lbl" xml:lang="en-US">Fair value of Alpha Capital/Qualigen warrants repriced due to acquisition</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_FairValueOfQualigenPrefundedWarrantIssuedInExchangeForNanosynexStock" xlink:label="QLGN_FairValueOfQualigenPrefundedWarrantIssuedInExchangeForNanosynexStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_FairValueOfQualigenPrefundedWarrantIssuedInExchangeForNanosynexStock" xlink:to="QLGN_FairValueOfQualigenPrefundedWarrantIssuedInExchangeForNanosynexStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_FairValueOfQualigenPrefundedWarrantIssuedInExchangeForNanosynexStock_lbl" xml:lang="en-US">Fair value of Qualigen prefunded warrant issued in exchange for NanoSynex stock</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssued1" xlink:label="us-gaap_StockIssued1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssued1" xlink:to="us-gaap_StockIssued1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssued1_lbl" xml:lang="en-US">Fair value of Qualigen common stock issued in exchange for NanoSynex stock</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationConsiderationTransferred1" xlink:label="us-gaap_BusinessCombinationConsiderationTransferred1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationConsiderationTransferred1" xlink:to="us-gaap_BusinessCombinationConsiderationTransferred1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationConsiderationTransferred1_lbl" xml:lang="en-US">Net cash acquired in business combination (Note 3)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US">ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND ESTIMATES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" xlink:label="us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" xlink:to="us-gaap_SubstantialDoubtAboutGoingConcernTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubstantialDoubtAboutGoingConcernTextBlock_lbl" xml:lang="en-US">LIQUIDITY AND GOING CONCERN</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:label="us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:to="us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_lbl" xml:lang="en-US">Business Combination and Asset Acquisition [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationDisclosureTextBlock" xlink:label="us-gaap_BusinessCombinationDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationDisclosureTextBlock" xlink:to="us-gaap_BusinessCombinationDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationDisclosureTextBlock_lbl" xml:lang="en-US">ACQUISITION</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="us-gaap_InventoryDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryDisclosureAbstract" xlink:to="us-gaap_InventoryDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryDisclosureAbstract_lbl" xml:lang="en-US">Inventory Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureTextBlock" xlink:label="us-gaap_InventoryDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryDisclosureTextBlock" xlink:to="us-gaap_InventoryDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryDisclosureTextBlock_lbl" xml:lang="en-US">INVENTORY, NET</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_DisclosurePrepaidExpensesAndOtherCurrentAssetsAbstract" xlink:label="QLGN_DisclosurePrepaidExpensesAndOtherCurrentAssetsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_DisclosurePrepaidExpensesAndOtherCurrentAssetsAbstract" xlink:to="QLGN_DisclosurePrepaidExpensesAndOtherCurrentAssetsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_DisclosurePrepaidExpensesAndOtherCurrentAssetsAbstract_lbl" xml:lang="en-US">Prepaid Expenses And Other Current Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_PrepaidExpensesAndOtherCurrentAssetsTextBlock" xlink:label="QLGN_PrepaidExpensesAndOtherCurrentAssetsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_PrepaidExpensesAndOtherCurrentAssetsTextBlock" xlink:to="QLGN_PrepaidExpensesAndOtherCurrentAssetsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_PrepaidExpensesAndOtherCurrentAssetsTextBlock_lbl" xml:lang="en-US">PREPAID EXPENSES AND OTHER CURRENT ASSETS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xml:lang="en-US">PROPERTY AND EQUIPMENT, NET</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_lbl" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:to="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_lbl" xml:lang="en-US">GOODWILL, IPR&amp;D AND OTHER INTANGIBLES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_PayablesAndAccrualsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PayablesAndAccrualsAbstract_lbl" xml:lang="en-US">Payables and Accruals [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:to="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_lbl" xml:lang="en-US">ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtDisclosureAbstract_lbl" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtTextBlock" xlink:label="us-gaap_ShortTermDebtTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermDebtTextBlock" xlink:to="us-gaap_ShortTermDebtTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShortTermDebtTextBlock_lbl" xml:lang="en-US">SHORT TERM DEBT - RELATED PARTY</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_DisclosureWarrantLiabilitiesAbstract" xlink:label="QLGN_DisclosureWarrantLiabilitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_DisclosureWarrantLiabilitiesAbstract" xlink:to="QLGN_DisclosureWarrantLiabilitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_DisclosureWarrantLiabilitiesAbstract_lbl" xml:lang="en-US">Warrant Liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_WarrantLiabilitiesTextBlock" xlink:label="QLGN_WarrantLiabilitiesTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_WarrantLiabilitiesTextBlock" xlink:to="QLGN_WarrantLiabilitiesTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_WarrantLiabilitiesTextBlock_lbl" xml:lang="en-US">WARRANT LIABILITIES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="us-gaap_DebtDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureTextBlock" xlink:to="us-gaap_DebtDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl" xml:lang="en-US">CONVERTIBLE DEBT - RELATED PARTY</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareTextBlock" xlink:to="us-gaap_EarningsPerShareTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xml:lang="en-US">EARNINGS (LOSS) PER SHARE</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US">COMMITMENTS AND CONTINGENCIES</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_DisclosureResearchAndLicenseAgreementsAbstract" xlink:label="QLGN_DisclosureResearchAndLicenseAgreementsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_DisclosureResearchAndLicenseAgreementsAbstract" xlink:to="QLGN_DisclosureResearchAndLicenseAgreementsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_DisclosureResearchAndLicenseAgreementsAbstract_lbl" xml:lang="en-US">Research And License Agreements</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_ResearchAndLicenseAgreementsTextBlock" xlink:label="QLGN_ResearchAndLicenseAgreementsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_ResearchAndLicenseAgreementsTextBlock" xlink:to="QLGN_ResearchAndLicenseAgreementsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_ResearchAndLicenseAgreementsTextBlock_lbl" xml:lang="en-US">RESEARCH AND LICENSE AGREEMENTS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_EquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityAbstract_lbl" xml:lang="en-US">Equity [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US">STOCKHOLDERS&#8217; EQUITY</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsAbstract_lbl" xml:lang="en-US">Related Party Transactions [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xml:lang="en-US">RELATED PARTY TRANSACTIONS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US">INCOME TAXES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US">SUBSEQUENT EVENTS</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_OrganizationPolicyTextBlock" xlink:label="QLGN_OrganizationPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_OrganizationPolicyTextBlock" xlink:to="QLGN_OrganizationPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_OrganizationPolicyTextBlock_lbl" xml:lang="en-US">Organization</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xml:lang="en-US">Basis of Presentation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="us-gaap_ConsolidationPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConsolidationPolicyTextBlock" xlink:to="us-gaap_ConsolidationPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConsolidationPolicyTextBlock_lbl" xml:lang="en-US">Principles of Consolidation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US">Accounting Estimates</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="us-gaap_StockholdersEquityReverseStockSplit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityReverseStockSplit" xlink:to="us-gaap_StockholdersEquityReverseStockSplit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityReverseStockSplit_lbl" xml:lang="en-US">Reverse Stock Split</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xml:lang="en-US">Cash</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryPolicyTextBlock" xlink:label="us-gaap_InventoryPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryPolicyTextBlock" xlink:to="us-gaap_InventoryPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryPolicyTextBlock_lbl" xml:lang="en-US">Inventory, Net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xml:lang="en-US">Impairment of Long-Lived Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xml:lang="en-US">Segment Reporting</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:label="us-gaap_TradeAndOtherAccountsReceivablePolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:to="us-gaap_TradeAndOtherAccountsReceivablePolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TradeAndOtherAccountsReceivablePolicy_lbl" xml:lang="en-US">Accounts Receivable, Net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xml:lang="en-US">Research and Development</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_ResearchAndDevelopmentGrantsPolicyTextBlock" xlink:label="QLGN_ResearchAndDevelopmentGrantsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_ResearchAndDevelopmentGrantsPolicyTextBlock" xlink:to="QLGN_ResearchAndDevelopmentGrantsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_ResearchAndDevelopmentGrantsPolicyTextBlock_lbl" xml:lang="en-US">R&amp;D Grants</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_PatentCostsPolicyTextBlock" xlink:label="QLGN_PatentCostsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_PatentCostsPolicyTextBlock" xlink:to="QLGN_PatentCostsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_PatentCostsPolicyTextBlock_lbl" xml:lang="en-US">Patent Costs</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_ShippingAndHandlingCostsPolicyTextBlock" xlink:label="QLGN_ShippingAndHandlingCostsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_ShippingAndHandlingCostsPolicyTextBlock" xlink:to="QLGN_ShippingAndHandlingCostsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_ShippingAndHandlingCostsPolicyTextBlock_lbl" xml:lang="en-US">Shipping and Handling Costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" xml:lang="en-US">Revenue from Contracts with Customers</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_DeferredRevenuePolicyTextBlock" xlink:label="QLGN_DeferredRevenuePolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_DeferredRevenuePolicyTextBlock" xlink:to="QLGN_DeferredRevenuePolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_DeferredRevenuePolicyTextBlock_lbl" xml:lang="en-US">Deferred Revenue</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xml:lang="en-US">Operating Leases</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xml:lang="en-US">Property and Equipment, Net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationsPolicy" xlink:label="us-gaap_BusinessCombinationsPolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationsPolicy" xlink:to="us-gaap_BusinessCombinationsPolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationsPolicy_lbl" xml:lang="en-US">Business Combinations</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:label="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:to="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_lbl" xml:lang="en-US">Goodwill</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:label="us-gaap_IntangibleAssetsFiniteLivedPolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:to="us-gaap_IntangibleAssetsFiniteLivedPolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IntangibleAssetsFiniteLivedPolicy_lbl" xml:lang="en-US">Intangible Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_DerivativeFinancialInstrumentsAndWarrantLiabilitiesPolicyTextBlock" xlink:label="QLGN_DerivativeFinancialInstrumentsAndWarrantLiabilitiesPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_DerivativeFinancialInstrumentsAndWarrantLiabilitiesPolicyTextBlock" xlink:to="QLGN_DerivativeFinancialInstrumentsAndWarrantLiabilitiesPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_DerivativeFinancialInstrumentsAndWarrantLiabilitiesPolicyTextBlock_lbl" xml:lang="en-US">Derivative Financial Instruments and Warrant Liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xml:lang="en-US">Fair Value of Financial Instruments</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdvertisingCostsPolicyTextBlock" xlink:label="us-gaap_AdvertisingCostsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdvertisingCostsPolicyTextBlock" xlink:to="us-gaap_AdvertisingCostsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdvertisingCostsPolicyTextBlock_lbl" xml:lang="en-US">Advertising</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl" xml:lang="en-US">Comprehensive Loss</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:to="us-gaap_CompensationRelatedCostsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock_lbl" xml:lang="en-US">Stock-Based Compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xml:lang="en-US">Income Taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_SalesAndExciseTaxesPolicyTextBlock" xlink:label="QLGN_SalesAndExciseTaxesPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_SalesAndExciseTaxesPolicyTextBlock" xlink:to="QLGN_SalesAndExciseTaxesPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_SalesAndExciseTaxesPolicyTextBlock_lbl" xml:lang="en-US">Sales and Excise Taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_WarrantyReservePolicyTextBlock" xlink:label="QLGN_WarrantyReservePolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_WarrantyReservePolicyTextBlock" xlink:to="QLGN_WarrantyReservePolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_WarrantyReservePolicyTextBlock_lbl" xml:lang="en-US">Warranty Costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:to="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl" xml:lang="en-US">Foreign Currency Translation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US">Recent Accounting Pronouncements</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_GlobalEconomicConditionsPolicyTextBlock" xlink:label="QLGN_GlobalEconomicConditionsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_GlobalEconomicConditionsPolicyTextBlock" xlink:to="QLGN_GlobalEconomicConditionsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_GlobalEconomicConditionsPolicyTextBlock_lbl" xml:lang="en-US">Global Economic Conditions</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:label="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:to="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF ACCOUNTS RECEIVABLE</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_ScheduleOfUsefulLivesOfPropertyAndEquipmentTableTextBlock" xlink:label="QLGN_ScheduleOfUsefulLivesOfPropertyAndEquipmentTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_ScheduleOfUsefulLivesOfPropertyAndEquipmentTableTextBlock" xlink:to="QLGN_ScheduleOfUsefulLivesOfPropertyAndEquipmentTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_ScheduleOfUsefulLivesOfPropertyAndEquipmentTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF USEFUL LIVES OF PROPERTY AND EQUIPMENT</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" xlink:to="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_lbl" xml:lang="en-US">SCHEDULE OF CONSIDERATION TRANSFERRED</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:label="us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:to="us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF ASSETS ACQUIRED AND LIABILITIES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionProFormaInformationTextBlock" xlink:label="us-gaap_BusinessAcquisitionProFormaInformationTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionProFormaInformationTextBlock" xlink:to="us-gaap_BusinessAcquisitionProFormaInformationTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessAcquisitionProFormaInformationTextBlock_lbl" xml:lang="en-US">SCHEDULE OF PRO FORMA INFORMATION</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF INVENTORY</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:to="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_lbl" xml:lang="en-US">SCHEDULE OF PREPAID EXPENSES AND OTHER CURRENT ASSETS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xml:lang="en-US">SCHEDULE OF PROPERTY AND EQUIPMENT</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:label="us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:to="us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF GOODWILL AND OTHER INTANGIBLE</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl" xml:lang="en-US">SCHEDULE OF WARRANTS ACTIVITY</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_ScheduleOfFairValueHierarchyForWarrantLiabilitiesTableTextBlock" xlink:label="QLGN_ScheduleOfFairValueHierarchyForWarrantLiabilitiesTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_ScheduleOfFairValueHierarchyForWarrantLiabilitiesTableTextBlock" xlink:to="QLGN_ScheduleOfFairValueHierarchyForWarrantLiabilitiesTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_ScheduleOfFairValueHierarchyForWarrantLiabilitiesTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF FAIR VALUE HIERARCHY FOR WARRANT LIABILITIES</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_ScheduleOfAssumptionsOfWarrantLiabilitiesTableTextBlock" xlink:label="QLGN_ScheduleOfAssumptionsOfWarrantLiabilitiesTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_ScheduleOfAssumptionsOfWarrantLiabilitiesTableTextBlock" xlink:to="QLGN_ScheduleOfAssumptionsOfWarrantLiabilitiesTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_ScheduleOfAssumptionsOfWarrantLiabilitiesTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF ASSUMPTIONS OF WARRANT LIABILITIES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleDebtTableTextBlock" xlink:label="us-gaap_ConvertibleDebtTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleDebtTableTextBlock" xlink:to="us-gaap_ConvertibleDebtTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertibleDebtTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF SENIOR SECURED CONVERTIBLE DEBT</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF EARNINGS PER SHARE BASIC AND DILUTED</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xml:lang="en-US">SCHEDULE OF DILUTIVE SECURITIES EXCLUDED FROM DILUTED NET LOSS PER SHARE</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_ScheduleOfOperatingLeaseRightOfUseAssetsAndLiabilitiesTableTextBlock" xlink:label="QLGN_ScheduleOfOperatingLeaseRightOfUseAssetsAndLiabilitiesTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_ScheduleOfOperatingLeaseRightOfUseAssetsAndLiabilitiesTableTextBlock" xlink:to="QLGN_ScheduleOfOperatingLeaseRightOfUseAssetsAndLiabilitiesTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_ScheduleOfOperatingLeaseRightOfUseAssetsAndLiabilitiesTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF OPERATING LEASE RIGHT OF USE ASSETS AND OPERATING LEASE LIABILITIES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF MATURITIES OF OPERATING LEASE LIABILITIES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_lbl" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_lbl" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_ScheduleOfReservedSharesTableTextBlock" xlink:label="QLGN_ScheduleOfReservedSharesTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_ScheduleOfReservedSharesTableTextBlock" xlink:to="QLGN_ScheduleOfReservedSharesTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_ScheduleOfReservedSharesTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF RESERVED SHARES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF STOCK OPTION ACTIVITY</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF ASSUMPTION USED IN BLACK-SCHOLES OPTION-PRICING METHOD</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:label="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:to="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF SHARE-BASED COMPENSATION EXPENSE</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_SummaryOfWarrantActivityTableTextBlock" xlink:label="QLGN_SummaryOfWarrantActivityTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_SummaryOfWarrantActivityTableTextBlock" xlink:to="QLGN_SummaryOfWarrantActivityTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_SummaryOfWarrantActivityTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF WARRANT ACTIVITY</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:label="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:to="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF DOMESTIC AND FOREIGN COMPONENTS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF RECONCILIATIONS OF STATUTORY INCOME TAX RATE</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:to="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF PROVISION FOR INCOME TAXES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF DEFERRED TAX ASSETS AND LIABILITIES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableGrossCurrent" xlink:label="us-gaap_AccountsReceivableGrossCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableGrossCurrent" xlink:to="us-gaap_AccountsReceivableGrossCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsReceivableGrossCurrent_lbl" xml:lang="en-US">Accounts Receivable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:to="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_lbl" xml:lang="en-US">Less Reserves and Allowances</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableNetCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AccountsReceivableNetCurrent_2_lbl" xml:lang="en-US">Accounts receivable, net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xml:lang="en-US">Property and equipment, useful life</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:label="us-gaap_StockIssuedDuringPeriodSharesAcquisitions" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:to="us-gaap_StockIssuedDuringPeriodSharesAcquisitions_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesAcquisitions_lbl" xml:lang="en-US">Stock issued during period shares acquisitions</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_lbl" xml:lang="en-US">Warrants to purchase common stock</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityReverseStockSplit" xlink:to="us-gaap_StockholdersEquityReverseStockSplit_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockholdersEquityReverseStockSplit_2_lbl" xml:lang="en-US">Reverse split, description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:label="us-gaap_StockIssuedDuringPeriodValueAcquisitions" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:to="us-gaap_StockIssuedDuringPeriodValueAcquisitions_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueAcquisitions_lbl" xml:lang="en-US">Stock issued during period, value, acquisitions</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:label="us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:to="us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_lbl" xml:lang="en-US">Voting interests acquired</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetImpairmentCharges" xlink:label="us-gaap_AssetImpairmentCharges" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetImpairmentCharges" xlink:to="us-gaap_AssetImpairmentCharges_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetImpairmentCharges_lbl" xml:lang="en-US">Impairment losses on construction-in-progress</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="us-gaap_CostOfGoodsAndServicesSold" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfGoodsAndServicesSold" xlink:to="us-gaap_CostOfGoodsAndServicesSold_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostOfGoodsAndServicesSold_lbl" xml:lang="en-US">Other shipping and handling costs</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_2_lbl" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_AllowancesForSalesReturn" xlink:label="QLGN_AllowancesForSalesReturn" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_AllowancesForSalesReturn" xlink:to="QLGN_AllowancesForSalesReturn_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_AllowancesForSalesReturn_lbl" xml:lang="en-US">Allowance for estimated returns</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillImpairmentLoss" xlink:to="us-gaap_GoodwillImpairmentLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_GoodwillImpairmentLoss_2_lbl" xml:lang="en-US">Goodwill impairment charges</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:to="us-gaap_FiniteLivedIntangibleAssetUsefulLife_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife_lbl" xml:lang="en-US">Estimated useful lives</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdvertisingExpense" xlink:label="us-gaap_AdvertisingExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdvertisingExpense" xlink:to="us-gaap_AdvertisingExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdvertisingExpense_lbl" xml:lang="en-US">Advertising expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductWarrantyAccrual" xlink:label="us-gaap_ProductWarrantyAccrual" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProductWarrantyAccrual" xlink:to="us-gaap_ProductWarrantyAccrual_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProductWarrantyAccrual_lbl" xml:lang="en-US">Accrued warranty liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductWarrantyExpense" xlink:label="us-gaap_ProductWarrantyExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProductWarrantyExpense" xlink:to="us-gaap_ProductWarrantyExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProductWarrantyExpense_lbl" xml:lang="en-US">Warranty costs</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_2_lbl" xml:lang="en-US">Adjustment net of tax</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:label="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:to="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_lbl" xml:lang="en-US">Schedule of Restructuring and Related Costs [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostAndReserveLineItems" xlink:label="us-gaap_RestructuringCostAndReserveLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="us-gaap_RestructuringCostAndReserveLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestructuringCostAndReserveLineItems_lbl" xml:lang="en-US">Restructuring Cost and Reserve [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_2_lbl" xml:lang="en-US">Accumulated deficit</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_2_lbl" xml:lang="en-US">Net cash used in operating activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US">Proceeds from issuance of common stock</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="us-gaap_ProceedsFromConvertibleDebt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromConvertibleDebt" xlink:to="us-gaap_ProceedsFromConvertibleDebt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromConvertibleDebt_lbl" xml:lang="en-US">Proceeds from issuance of debt</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:to="us-gaap_StockIssuedDuringPeriodValueAcquisitions_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueAcquisitions_2_lbl" xml:lang="en-US">Stock issued during period value acquisitions</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteStockSplit" xlink:label="us-gaap_StockholdersEquityNoteStockSplit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteStockSplit" xlink:to="us-gaap_StockholdersEquityNoteStockSplit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteStockSplit_lbl" xml:lang="en-US">Stockholders equity note stock split</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US">Stock issued during period value new issues</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_lbl" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="us-gaap_BusinessAcquisitionLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessAcquisitionLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessAcquisitionLineItems_lbl" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_PaymentsToAcquireBusinesses" xlink:label="QLGN_PaymentsToAcquireBusinesses" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_PaymentsToAcquireBusinesses" xlink:to="QLGN_PaymentsToAcquireBusinesses_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_PaymentsToAcquireBusinesses_lbl" xml:lang="en-US">Cash paid for NanoSynex preferred stock:</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:to="us-gaap_StockIssuedDuringPeriodValueAcquisitions_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueAcquisitions_3_lbl" xml:lang="en-US">FMV of 3,500,000 shares of Qualigen stock issued to Alpha Capital Anstalt</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_PrefundedWarrantsIssuedForBusinessAcquisition" xlink:label="QLGN_PrefundedWarrantsIssuedForBusinessAcquisition" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_PrefundedWarrantsIssuedForBusinessAcquisition" xlink:to="QLGN_PrefundedWarrantsIssuedForBusinessAcquisition_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_PrefundedWarrantsIssuedForBusinessAcquisition_lbl" xml:lang="en-US">FMV of 3,314,641 shares of Qualigen stock related to prefunded warrant issued to Alpha Capital Anstalt</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationConsiderationTransferred1" xlink:to="us-gaap_BusinessCombinationConsiderationTransferred1_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_BusinessCombinationConsiderationTransferred1_2_lbl" xml:lang="en-US">Total consideration paid for NanoSynex common stock</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_FairValueOfWarrantModificationForBusinessAcquisition" xlink:to="QLGN_FairValueOfWarrantModificationForBusinessAcquisition_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="QLGN_FairValueOfWarrantModificationForBusinessAcquisition_2_lbl" xml:lang="en-US">FMV of consideration related to related to repricing of 70,478 shares of Alpha Capital/Qualigen warrants *</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAcquiredFromAcquisition" xlink:to="us-gaap_CashAcquiredFromAcquisition_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_CashAcquiredFromAcquisition_2_lbl" xml:lang="en-US">NanoSynex cash acquired</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:label="us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:to="us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_lbl" xml:lang="en-US">Total consideration transferred, net of cash acquired</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:to="us-gaap_StockIssuedDuringPeriodSharesAcquisitions_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesAcquisitions_2_lbl" xml:lang="en-US">Common stock issued for business acquisition</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_lbl" xml:lang="en-US">Accounts receivable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_lbl" xml:lang="en-US">Property and equipment</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedResearchAndDevelopmentExpense" xlink:label="QLGN_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedResearchAndDevelopmentExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedResearchAndDevelopmentExpense" xlink:to="QLGN_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedResearchAndDevelopmentExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedResearchAndDevelopmentExpense_lbl" xml:lang="en-US">In process R&amp;D</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_lbl" xml:lang="en-US">Accounts payable</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpensesAndOtherPayables" xlink:label="QLGN_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpensesAndOtherPayables" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpensesAndOtherPayables" xlink:to="QLGN_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpensesAndOtherPayables_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpensesAndOtherPayables_lbl" xml:lang="en-US">Accrued expenses and other payables</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedResearchAndDevelopmentGrantLiability" xlink:label="QLGN_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedResearchAndDevelopmentGrantLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedResearchAndDevelopmentGrantLiability" xlink:to="QLGN_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedResearchAndDevelopmentGrantLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="QLGN_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedResearchAndDevelopmentGrantLiability_lbl" xml:lang="en-US">R&amp;D grant liability</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesShortTermDebt" xlink:label="QLGN_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesShortTermDebt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesShortTermDebt" xlink:to="QLGN_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesShortTermDebt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesShortTermDebt_lbl" xml:lang="en-US">Short term debt</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_lbl" xml:lang="en-US">Deferred tax liability</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedLessNoncontrollingInterest" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedLessNoncontrollingInterest" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedLessNoncontrollingInterest" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedLessNoncontrollingInterest_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedLessNoncontrollingInterest_lbl" xml:lang="en-US">Noncontrolling interest assumed</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_lbl" xml:lang="en-US">Identifiable net assets acquired</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_lbl" xml:lang="en-US">Total consideration transferred, net of cash acquired</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionsProFormaRevenue" xlink:label="us-gaap_BusinessAcquisitionsProFormaRevenue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionsProFormaRevenue" xlink:to="us-gaap_BusinessAcquisitionsProFormaRevenue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessAcquisitionsProFormaRevenue_lbl" xml:lang="en-US">Business acquisitions pro forma revenue</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" xlink:label="us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" xlink:to="us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_lbl" xml:lang="en-US">Business acquisitions pro forma net income loss</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:to="us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_2_lbl" xml:lang="en-US">Business acquisition, voting equity rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xml:lang="en-US">Warrants to purchase shares</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_2_lbl" xml:lang="en-US">Warrants or rights</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterestDecreaseFromRedemptions" xlink:label="us-gaap_MinorityInterestDecreaseFromRedemptions" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MinorityInterestDecreaseFromRedemptions" xlink:to="us-gaap_MinorityInterestDecreaseFromRedemptions_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MinorityInterestDecreaseFromRedemptions_lbl" xml:lang="en-US">Decrease to noncontrolling interest</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillPeriodIncreaseDecrease" xlink:label="us-gaap_GoodwillPeriodIncreaseDecrease" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillPeriodIncreaseDecrease" xlink:to="us-gaap_GoodwillPeriodIncreaseDecrease_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GoodwillPeriodIncreaseDecrease_lbl" xml:lang="en-US">Decrease in good will</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossTax" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossTax_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherComprehensiveIncomeLossTax_lbl" xml:lang="en-US">Other comprehensive income loss tax</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryRawMaterials" xlink:label="us-gaap_InventoryRawMaterials" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryRawMaterials" xlink:to="us-gaap_InventoryRawMaterials_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryRawMaterials_lbl" xml:lang="en-US">Raw materials</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryWorkInProcess" xlink:label="us-gaap_InventoryWorkInProcess" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryWorkInProcess" xlink:to="us-gaap_InventoryWorkInProcess_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryWorkInProcess_lbl" xml:lang="en-US">Work in process</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryFinishedGoods" xlink:label="us-gaap_InventoryFinishedGoods" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryFinishedGoods" xlink:to="us-gaap_InventoryFinishedGoods_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryFinishedGoods_lbl" xml:lang="en-US">Finished goods</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryNet_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_InventoryNet_2_lbl" xml:lang="en-US">Total inventory</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_DisclosurePrepaidExpensesAndOtherCurrentAssetsAbstract" xlink:to="QLGN_DisclosurePrepaidExpensesAndOtherCurrentAssetsAbstract_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="QLGN_DisclosurePrepaidExpensesAndOtherCurrentAssetsAbstract_2_lbl" xml:lang="en-US">Schedule Of Prepaid Expenses And Other Current Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidInsurance" xlink:label="us-gaap_PrepaidInsurance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidInsurance" xlink:to="us-gaap_PrepaidInsurance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidInsurance_lbl" xml:lang="en-US">Prepaid insurance</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_PrepaidManufacturingExpenses" xlink:label="QLGN_PrepaidManufacturingExpenses" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_PrepaidManufacturingExpenses" xlink:to="QLGN_PrepaidManufacturingExpenses_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_PrepaidManufacturingExpenses_lbl" xml:lang="en-US">Prepaid manufacturing expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherPrepaidExpenseCurrent" xlink:label="us-gaap_OtherPrepaidExpenseCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherPrepaidExpenseCurrent" xlink:to="us-gaap_OtherPrepaidExpenseCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherPrepaidExpenseCurrent_lbl" xml:lang="en-US">Other prepaid expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsCurrent" xlink:label="us-gaap_OtherAssetsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsCurrent" xlink:to="us-gaap_OtherAssetsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAssetsCurrent_lbl" xml:lang="en-US">Other current assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_2_lbl" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xml:lang="en-US">Property and equipment, gross</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xml:lang="en-US">Accumulated depreciation</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_FixedAssetImpairments" xlink:label="QLGN_FixedAssetImpairments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_FixedAssetImpairments" xlink:to="QLGN_FixedAssetImpairments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_FixedAssetImpairments_lbl" xml:lang="en-US">Fixed asset impairment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Depreciation_lbl" xml:lang="en-US">Depreciation expense</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_2_lbl" xml:lang="en-US">Payments to acquire assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_lbl" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems_lbl" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsGross" xlink:to="us-gaap_FiniteLivedIntangibleAssetsGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross_lbl" xml:lang="en-US">Licensing rights</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:to="us-gaap_FiniteLivedIntangibleAssetUsefulLife_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife_2_lbl" xml:lang="en-US">Finite lived intangible asset useful life</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl" xml:lang="en-US">Less: Accumulated amortization</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xml:lang="en-US">Total finite-lived intangible assets, net</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill_2_lbl" xml:lang="en-US">Total other intangible assets, net</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillImpairmentLoss" xlink:to="us-gaap_GoodwillImpairmentLoss_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GoodwillImpairmentLoss_3_lbl" xml:lang="en-US">Goodwill, Impairment Loss</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsFinitelived" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:to="us-gaap_ImpairmentOfIntangibleAssetsFinitelived_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsFinitelived_lbl" xml:lang="en-US">Impairment of Intangible Assets, Finite-Lived</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsGross" xlink:to="us-gaap_FiniteLivedIntangibleAssetsGross_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross_2_lbl" xml:lang="en-US">Finite lived intangible assets gross</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_2_lbl" xml:lang="en-US">Accumulated amortization</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="us-gaap_AmortizationOfIntangibleAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfIntangibleAssets" xlink:to="us-gaap_AmortizationOfIntangibleAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AmortizationOfIntangibleAssets_lbl" xml:lang="en-US">Licenses charged</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_lbl" xml:lang="en-US">Future estimated amortization of license costs 2023</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_lbl" xml:lang="en-US">Future estimated amortization of patent costs Year 2024</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_lbl" xml:lang="en-US">Future estimated amortization of patent costs Year 2025</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_lbl" xml:lang="en-US">Future estimated amortization of patent costs Year 2026</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_lbl" xml:lang="en-US">Future estimated amortization of patent costs Year 2027</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_lbl" xml:lang="en-US">Future estimated amortization of patent costs thereafter</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_AccruedCompensation" xlink:label="QLGN_AccruedCompensation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_AccruedCompensation" xlink:to="QLGN_AccruedCompensation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_AccruedCompensation_lbl" xml:lang="en-US">Board compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_AccruedEquipmentHeldForLease" xlink:label="QLGN_AccruedEquipmentHeldForLease" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_AccruedEquipmentHeldForLease" xlink:to="QLGN_AccruedEquipmentHeldForLease_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_AccruedEquipmentHeldForLease_lbl" xml:lang="en-US">Equipment held for lease</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_AccruedFranchiseSalesAndUseTaxes" xlink:label="QLGN_AccruedFranchiseSalesAndUseTaxes" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_AccruedFranchiseSalesAndUseTaxes" xlink:to="QLGN_AccruedFranchiseSalesAndUseTaxes_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_AccruedFranchiseSalesAndUseTaxes_lbl" xml:lang="en-US">Franchise, sales and use taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedIncomeTaxesCurrent" xlink:label="us-gaap_AccruedIncomeTaxesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedIncomeTaxesCurrent" xlink:to="us-gaap_AccruedIncomeTaxesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedIncomeTaxesCurrent_lbl" xml:lang="en-US">Income taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPayableCurrent" xlink:label="us-gaap_InterestPayableCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPayableCurrent" xlink:to="us-gaap_InterestPayableCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestPayableCurrent_lbl" xml:lang="en-US">Interest (Convertible debt - related party)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedPayrollTaxesCurrent" xlink:label="us-gaap_AccruedPayrollTaxesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedPayrollTaxesCurrent" xlink:to="us-gaap_AccruedPayrollTaxesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedPayrollTaxesCurrent_lbl" xml:lang="en-US">Payroll</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedProfessionalFeesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xml:lang="en-US">Professional fees</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_AccruedResearchAndDevelopmentCurrent" xlink:label="QLGN_AccruedResearchAndDevelopmentCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_AccruedResearchAndDevelopmentCurrent" xlink:to="QLGN_AccruedResearchAndDevelopmentCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="QLGN_AccruedResearchAndDevelopmentCurrent_lbl" xml:lang="en-US">Research and development</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedRoyaltiesCurrent" xlink:label="us-gaap_AccruedRoyaltiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedRoyaltiesCurrent" xlink:to="us-gaap_AccruedRoyaltiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedRoyaltiesCurrent_lbl" xml:lang="en-US">Royalties</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProductWarrantyAccrual" xlink:to="us-gaap_ProductWarrantyAccrual_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProductWarrantyAccrual_2_lbl" xml:lang="en-US">Warranty liability</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_AccruedLicenseFees" xlink:label="QLGN_AccruedLicenseFees" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_AccruedLicenseFees" xlink:to="QLGN_AccruedLicenseFees_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_AccruedLicenseFees_lbl" xml:lang="en-US">License fees</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Other</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Accrued liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShortTermDebtTable" xlink:label="us-gaap_ScheduleOfShortTermDebtTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShortTermDebtTable" xlink:to="us-gaap_ScheduleOfShortTermDebtTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShortTermDebtTable_lbl" xml:lang="en-US">Schedule of Short-Term Debt [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtLineItems" xlink:label="us-gaap_ShortTermDebtLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermDebtLineItems" xlink:to="us-gaap_ShortTermDebtLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShortTermDebtLineItems_lbl" xml:lang="en-US">Short-Term Debt [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentFaceAmount" xlink:to="us-gaap_DebtInstrumentFaceAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentFaceAmount_lbl" xml:lang="en-US">Short term debt principal outstanding</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPayableCurrent" xlink:to="us-gaap_InterestPayableCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_InterestPayableCurrent_2_lbl" xml:lang="en-US">Accrued interest</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermBorrowings" xlink:to="us-gaap_ShortTermBorrowings_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShortTermBorrowings_2_lbl" xml:lang="en-US">Short term debt outstanding balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xml:lang="en-US">Accrued interest rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromRelatedPartyDebt" xlink:label="us-gaap_ProceedsFromRelatedPartyDebt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromRelatedPartyDebt" xlink:to="us-gaap_ProceedsFromRelatedPartyDebt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromRelatedPartyDebt_lbl" xml:lang="en-US">Proceeds from related party debt</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_lbl" xml:lang="en-US">Number of Shares, Warrants Outstanding Beginning</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice" xlink:label="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice" xlink:to="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price Per Share Warrants Outstanding Beginning</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_RangeOfExercisePrice" xlink:label="QLGN_RangeOfExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_RangeOfExercisePrice" xlink:to="QLGN_RangeOfExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="QLGN_RangeOfExercisePrice_lbl" xml:lang="en-US">Range of Exercise Beginning</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAveragRemainingContractualTerm1" xlink:label="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAveragRemainingContractualTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAveragRemainingContractualTerm1" xlink:to="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAveragRemainingContractualTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAveragRemainingContractualTerm1_lbl" xml:lang="en-US">Weighted Averag Remaining Contractual Term</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_lbl" xml:lang="en-US">Number of Shares, Warrants Exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedInPeriodWeightedAverageExercisePrice" xlink:label="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedInPeriodWeightedAverageExercisePrice" xlink:to="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price Per Share Warrants Exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_lbl" xml:lang="en-US">Number of Shares, Warrants Forfeited</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedInPeriodWeightedAverageExercisePrice" xlink:label="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedInPeriodWeightedAverageExercisePrice" xlink:to="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price Per Share Warrants Forfeited</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_lbl" xml:lang="en-US">Number of Shares, Warrants Expired</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInPeriodWeightedAverageExercisePrice" xlink:label="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInPeriodWeightedAverageExercisePrice" xlink:to="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price Per Share Warrants Expired</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_lbl" xml:lang="en-US">Number of Shares, Warrants Granted</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price Per Share Warrants Granted</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_2_lbl" xml:lang="en-US">Number of Shares, Warrants Outstanding Ending</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice" xlink:to="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_2_lbl" xml:lang="en-US">Weighted Average Exercise Price Per Share Warrants Outstanding Ending</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_RangeOfExercisePrice" xlink:to="QLGN_RangeOfExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="QLGN_RangeOfExercisePrice_2_lbl" xml:lang="en-US">Range of Exercise Ending</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber" xlink:label="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber" xlink:to="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_lbl" xml:lang="en-US">Number of Shares, Warrants Exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageVestedExercisePrice" xlink:label="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageVestedExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageVestedExercisePrice" xlink:to="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageVestedExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageVestedExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price Per Share Exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_RangeOfExercisePriceExercisableVested" xlink:label="QLGN_RangeOfExercisePriceExercisableVested" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_RangeOfExercisePriceExercisableVested" xlink:to="QLGN_RangeOfExercisePriceExercisableVested_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="QLGN_RangeOfExercisePriceExercisableVested_lbl" xml:lang="en-US">Range of Exercise Price, Exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNonExercisableWeightedAverageRemainingContractualTerm1" xlink:label="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNonExercisableWeightedAverageRemainingContractualTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNonExercisableWeightedAverageRemainingContractualTerm1" xlink:to="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNonExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNonExercisableWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US">Exercisable Weighted Averag Remaining Contractual Term</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_RangeOfExercisePriceExercisableVested" xlink:to="QLGN_RangeOfExercisePriceExercisableVested_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_RangeOfExercisePriceExercisableVested_2_lbl" xml:lang="en-US">Range of Exercise Price, Exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:label="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_lbl" xml:lang="en-US">Schedule of Defined Benefit Plans Disclosures [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:label="us-gaap_DefinedBenefitPlanDisclosureLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:to="us-gaap_DefinedBenefitPlanDisclosureLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedBenefitPlanDisclosureLineItems_lbl" xml:lang="en-US">Defined Benefit Plan Disclosure [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_FairValueAdjustmentOfWarrant" xlink:label="QLGN_FairValueAdjustmentOfWarrant" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_FairValueAdjustmentOfWarrant" xlink:to="QLGN_FairValueAdjustmentOfWarrant_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="QLGN_FairValueAdjustmentOfWarrant_lbl" xml:lang="en-US">Fair value for warrant liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_FairValueOfWarrantLiabilitiesOnDateOfExercise" xlink:to="QLGN_FairValueOfWarrantLiabilitiesOnDateOfExercise_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="QLGN_FairValueOfWarrantLiabilitiesOnDateOfExercise_2_lbl" xml:lang="en-US">Common Stock Warrant liabilities, Exercises</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_FairValueOfWarrantLiabilitiesIssuanceOfAlphaWarrants" xlink:label="QLGN_FairValueOfWarrantLiabilitiesIssuanceOfAlphaWarrants" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_FairValueOfWarrantLiabilitiesIssuanceOfAlphaWarrants" xlink:to="QLGN_FairValueOfWarrantLiabilitiesIssuanceOfAlphaWarrants_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="QLGN_FairValueOfWarrantLiabilitiesIssuanceOfAlphaWarrants_lbl" xml:lang="en-US">Issuance of Alpha warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_ChangeInFairValueOfWarrantLiabilities" xlink:label="QLGN_ChangeInFairValueOfWarrantLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_ChangeInFairValueOfWarrantLiabilities" xlink:to="QLGN_ChangeInFairValueOfWarrantLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="QLGN_ChangeInFairValueOfWarrantLiabilities_lbl" xml:lang="en-US">Change in fair value of warrant liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_FairValueAdjustmentOfWarrant" xlink:to="QLGN_FairValueAdjustmentOfWarrant_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="QLGN_FairValueAdjustmentOfWarrant_2_lbl" xml:lang="en-US">Fair value for warrant liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:label="us-gaap_WarrantsAndRightsOutstandingMeasurementInput" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:to="us-gaap_WarrantsAndRightsOutstandingMeasurementInput_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantsAndRightsOutstandingMeasurementInput_lbl" xml:lang="en-US">Fair value assumptions, measurement input, percentages</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstandingTerm" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm_lbl" xml:lang="en-US">Fair value assumptions, measurement input, term</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_3_lbl" xml:lang="en-US">Exercise price of warrant</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstandingTerm" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm_2_lbl" xml:lang="en-US">Warrants and Rights Outstanding, Term</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_2_lbl" xml:lang="en-US">Warrant to purchase shares</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_ConversionPricePercentage" xlink:label="QLGN_ConversionPricePercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_ConversionPricePercentage" xlink:to="QLGN_ConversionPricePercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_ConversionPricePercentage_lbl" xml:lang="en-US">Conversion price percentage</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SecuredDebt" xlink:label="us-gaap_SecuredDebt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SecuredDebt" xlink:to="us-gaap_SecuredDebt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SecuredDebt_lbl" xml:lang="en-US">Senior secured convertible debenture</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentUnamortizedDiscount" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount_lbl" xml:lang="en-US">Discount on convertible debenture</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleDebt" xlink:to="us-gaap_ConvertibleDebt_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ConvertibleDebt_2_lbl" xml:lang="en-US">Total convertible debt - related party</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtInterestRateIncrease" xlink:label="us-gaap_ShortTermDebtInterestRateIncrease" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermDebtInterestRateIncrease" xlink:to="us-gaap_ShortTermDebtInterestRateIncrease_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShortTermDebtInterestRateIncrease_lbl" xml:lang="en-US">Senior convertible debenture rate</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SecuredDebt" xlink:to="us-gaap_SecuredDebt_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SecuredDebt_2_lbl" xml:lang="en-US">Principal amount</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_PurchasePrice" xlink:label="QLGN_PurchasePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_PurchasePrice" xlink:to="QLGN_PurchasePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_PurchasePrice_lbl" xml:lang="en-US">Purchase Price</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:to="us-gaap_DebtInstrumentConvertibleConversionPrice1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1_lbl" xml:lang="en-US">Conversion price</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentIncreaseAccruedInterest" xlink:label="us-gaap_DebtInstrumentIncreaseAccruedInterest" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentIncreaseAccruedInterest" xlink:to="us-gaap_DebtInstrumentIncreaseAccruedInterest_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentIncreaseAccruedInterest_lbl" xml:lang="en-US">Unpaid interest</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtConversionConvertedInstrumentRate" xlink:label="us-gaap_DebtConversionConvertedInstrumentRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtConversionConvertedInstrumentRate" xlink:to="us-gaap_DebtConversionConvertedInstrumentRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtConversionConvertedInstrumentRate_lbl" xml:lang="en-US">Conversion rate</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_PrincipalAmountPercentage" xlink:label="QLGN_PrincipalAmountPercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_PrincipalAmountPercentage" xlink:to="QLGN_PrincipalAmountPercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_PrincipalAmountPercentage_lbl" xml:lang="en-US">Principal amount percentage</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_2_lbl" xml:lang="en-US">Debenture accrues interest rate</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockSharesIssued_2_lbl" xml:lang="en-US">Shares of Common stock, issued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfDebtDiscountPremium" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium_lbl" xml:lang="en-US">Debt discount</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAdjustmentOfWarrants" xlink:to="us-gaap_FairValueAdjustmentOfWarrants_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_2_lbl" xml:lang="en-US">Fair value of warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeNet" xlink:label="us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeNet" xlink:to="us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeNet_lbl" xml:lang="en-US">Fair value of embedded derivative features</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_FeesAndCostsPaid" xlink:label="QLGN_FeesAndCostsPaid" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_FeesAndCostsPaid" xlink:to="QLGN_FeesAndCostsPaid_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_FeesAndCostsPaid_lbl" xml:lang="en-US">Fees and costs paid</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLoss_2_lbl" xml:lang="en-US">Net loss used for basic earnings per share</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_2_lbl" xml:lang="en-US">Basic weighted-average common shares outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_DilutivePotentialSharesIssuableFromStockOptionsAndWarrants" xlink:label="QLGN_DilutivePotentialSharesIssuableFromStockOptionsAndWarrants" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_DilutivePotentialSharesIssuableFromStockOptionsAndWarrants" xlink:to="QLGN_DilutivePotentialSharesIssuableFromStockOptionsAndWarrants_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_DilutivePotentialSharesIssuableFromStockOptionsAndWarrants_lbl" xml:lang="en-US">Dilutive potential shares issuable from stock options and warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:label="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:to="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_lbl" xml:lang="en-US">Diluted weighted-average common shares outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US">Total common stock equivalents</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_2_lbl" xml:lang="en-US">Operating lease right-of-use assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_2_lbl" xml:lang="en-US">Less amortization of operating lease right-of-use assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_3_lbl" xml:lang="en-US">Operating lease right-of-use assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xml:lang="en-US">Lease liabilities at December 31, 2021</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasePayments" xlink:to="us-gaap_OperatingLeasePayments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_OperatingLeasePayments_lbl" xml:lang="en-US">Less principal payments on operating lease liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_OperatingLeaseLiability_2_lbl" xml:lang="en-US">Lease liabilities at December 31, 2022</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_2_lbl" xml:lang="en-US">Less non-current portion</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_2_lbl" xml:lang="en-US">Current portion at Decebmer 31, 2022</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xml:lang="en-US">2023</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xml:lang="en-US">2024</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xml:lang="en-US">2025</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xml:lang="en-US">2026</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl" xml:lang="en-US">2027</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xml:lang="en-US">Total</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xml:lang="en-US">Less present value discount</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiability_3_lbl" xml:lang="en-US">Operating lease liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xml:lang="en-US">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AreaOfLand" xlink:label="us-gaap_AreaOfLand" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AreaOfLand" xlink:to="us-gaap_AreaOfLand_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AreaOfLand_lbl" xml:lang="en-US">Area of land</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseTermOfContract" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract_lbl" xml:lang="en-US">Operating lease term</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseDescription" xlink:label="us-gaap_LesseeOperatingLeaseDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseDescription" xlink:to="us-gaap_LesseeOperatingLeaseDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseDescription_lbl" xml:lang="en-US">Operating lease term description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRent" xlink:label="us-gaap_PaymentsForRent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForRent" xlink:to="us-gaap_PaymentsForRent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsForRent_lbl" xml:lang="en-US">Payments for Rent</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_TenantImprovementAllowance" xlink:label="QLGN_TenantImprovementAllowance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_TenantImprovementAllowance" xlink:to="QLGN_TenantImprovementAllowance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_TenantImprovementAllowance_lbl" xml:lang="en-US">Tenant improvement allowance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xml:lang="en-US">Weighted-average remaining lease term</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xml:lang="en-US">Weighted-average discount rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseExpense" xlink:label="us-gaap_OperatingLeaseExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseExpense" xlink:to="us-gaap_OperatingLeaseExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseExpense_lbl" xml:lang="en-US">Operating Lease, Expense</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:to="us-gaap_AccruedLiabilitiesAndOtherLiabilities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities_2_lbl" xml:lang="en-US">Accrued expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:to="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_lbl" xml:lang="en-US">Maximum future funding amount</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_DevelopmentFund" xlink:label="QLGN_DevelopmentFund" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_DevelopmentFund" xlink:to="QLGN_DevelopmentFund_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_DevelopmentFund_lbl" xml:lang="en-US">Development fund</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity" xlink:label="us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity" xlink:to="us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity_lbl" xml:lang="en-US">Additional funding amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationSettlementAmountAwardedToOtherParty" xlink:label="us-gaap_LitigationSettlementAmountAwardedToOtherParty" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LitigationSettlementAmountAwardedToOtherParty" xlink:to="us-gaap_LitigationSettlementAmountAwardedToOtherParty_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LitigationSettlementAmountAwardedToOtherParty_lbl" xml:lang="en-US">Litigation settlement amount</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_ReimbursementOfResearchExpenses" xlink:label="QLGN_ReimbursementOfResearchExpenses" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_ReimbursementOfResearchExpenses" xlink:to="QLGN_ReimbursementOfResearchExpenses_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_ReimbursementOfResearchExpenses_lbl" xml:lang="en-US">Reimbursement of research expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_AgreementTermPaymentDescription" xlink:label="QLGN_AgreementTermPaymentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_AgreementTermPaymentDescription" xlink:to="QLGN_AgreementTermPaymentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_AgreementTermPaymentDescription_lbl" xml:lang="en-US">Agreement term payment, description</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_MilestonePayment" xlink:label="QLGN_MilestonePayment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_MilestonePayment" xlink:to="QLGN_MilestonePayment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_MilestonePayment_lbl" xml:lang="en-US">Milestone payment</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_RegulatoryMarketingApprovalExpenses" xlink:label="QLGN_RegulatoryMarketingApprovalExpenses" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_RegulatoryMarketingApprovalExpenses" xlink:to="QLGN_RegulatoryMarketingApprovalExpenses_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_RegulatoryMarketingApprovalExpenses_lbl" xml:lang="en-US">Regulatory marketing approval, expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_CumulativeSales" xlink:label="QLGN_CumulativeSales" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_CumulativeSales" xlink:to="QLGN_CumulativeSales_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_CumulativeSales_lbl" xml:lang="en-US">Cumulative sales</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:to="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_lbl" xml:lang="en-US">Licensed product net sale</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_UpfrontLicenseFee" xlink:label="QLGN_UpfrontLicenseFee" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_UpfrontLicenseFee" xlink:to="QLGN_UpfrontLicenseFee_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_UpfrontLicenseFee_lbl" xml:lang="en-US">Upfront license fee</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_LicenseCost" xlink:label="QLGN_LicenseCost" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_LicenseCost" xlink:to="QLGN_LicenseCost_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_LicenseCost_lbl" xml:lang="en-US">License cost</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromConvertibleDebt" xlink:to="us-gaap_ProceedsFromConvertibleDebt_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromConvertibleDebt_2_lbl" xml:lang="en-US">Proceeds from convertible debt</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_PatentCosts" xlink:label="QLGN_PatentCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_PatentCosts" xlink:to="QLGN_PatentCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_PatentCosts_lbl" xml:lang="en-US">Patent costs</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_RegulatoryMarketingApprovalExpensesOne" xlink:label="QLGN_RegulatoryMarketingApprovalExpensesOne" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_RegulatoryMarketingApprovalExpensesOne" xlink:to="QLGN_RegulatoryMarketingApprovalExpensesOne_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="QLGN_RegulatoryMarketingApprovalExpensesOne_lbl" xml:lang="en-US">Regulatory marketing approval, expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_ShortfallPayments" xlink:label="QLGN_ShortfallPayments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_ShortfallPayments" xlink:to="QLGN_ShortfallPayments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_ShortfallPayments_lbl" xml:lang="en-US">Shortfall payments</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RoyaltyExpense" xlink:label="us-gaap_RoyaltyExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RoyaltyExpense" xlink:to="us-gaap_RoyaltyExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RoyaltyExpense_lbl" xml:lang="en-US">Minimum annual royalties</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_AgreementDescription" xlink:label="QLGN_AgreementDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_AgreementDescription" xlink:to="QLGN_AgreementDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_AgreementDescription_lbl" xml:lang="en-US">Agreement description</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_MilestonePaymentForCumulativeMarketingExpenses" xlink:label="QLGN_MilestonePaymentForCumulativeMarketingExpenses" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_MilestonePaymentForCumulativeMarketingExpenses" xlink:to="QLGN_MilestonePaymentForCumulativeMarketingExpenses_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_MilestonePaymentForCumulativeMarketingExpenses_lbl" xml:lang="en-US">Milestone payment for cumulative marketing expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_MilestoneMethodRevenueRecognized" xlink:label="QLGN_MilestoneMethodRevenueRecognized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_MilestoneMethodRevenueRecognized" xlink:to="QLGN_MilestoneMethodRevenueRecognized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_MilestoneMethodRevenueRecognized_lbl" xml:lang="en-US">Milestone method revenue recognized</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredRevenue" xlink:label="us-gaap_DeferredRevenue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenue" xlink:to="us-gaap_DeferredRevenue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DeferredRevenue_lbl" xml:lang="en-US">Deferred revenue</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_3_lbl" xml:lang="en-US">Product sales</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepositAssets" xlink:label="us-gaap_DepositAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepositAssets" xlink:to="us-gaap_DepositAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepositAssets_lbl" xml:lang="en-US">Upfront deposit</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_ReimbursementOfPatent" xlink:label="QLGN_ReimbursementOfPatent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_ReimbursementOfPatent" xlink:to="QLGN_ReimbursementOfPatent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_ReimbursementOfPatent_lbl" xml:lang="en-US">Reimbursement of patent</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xml:lang="en-US">Total</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable" xlink:label="us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable" xlink:to="us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable_lbl" xml:lang="en-US">Schedule of Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits, by Title of Individual and by Type of Deferred Compensation [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems" xlink:to="us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems_lbl" xml:lang="en-US">Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US">Number of shares, options outstanding, beginning</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Range of Exercise price, Options Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm3" xlink:label="QLGN_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm3" xlink:to="QLGN_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm3_lbl" xml:lang="en-US">Weighted- Average Remaining Contractual Life (in Years), Outstanding, Beginning</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_lbl" xml:lang="en-US">Number of shares, options granted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average exercise price, options granted</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionGrantedWeightedAverageExercisePrice" xlink:label="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionGrantedWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionGrantedWeightedAverageExercisePrice" xlink:to="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionGrantedWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionGrantedWeightedAverageExercisePrice_lbl" xml:lang="en-US">Range of Exercise price, Options Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm2" xlink:label="QLGN_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm2" xlink:to="QLGN_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US">Weighted- Average Remaining Contractual Life (in Years), Options Granted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_lbl" xml:lang="en-US">Number of shares, options expired</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average exercise price, options expired</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExpirationsInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExpirationsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExpirationsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Range of exercise price, options expired</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xml:lang="en-US">Number of shares, options forfeited</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average exercise price, options forfeited</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Range of Exercise price, Options Forfeited</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2_lbl" xml:lang="en-US">Number of Shares, Options Outstanding at Ending</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2_lbl" xml:lang="en-US">Range of Exercise price, Options Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US">Weighted- Average Remaining Contractual Life (in Years), Outstanding at Ending</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_lbl" xml:lang="en-US">Number of shares, options exercisable (vested)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US">Range of exercise price, options exercisable (vested)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US">Weighted- Average Remaining Contractual Life (in Years), Options Exercisable (vested)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_lbl" xml:lang="en-US">Number of shares, options non-exercisable (non-vested)</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToNonVestExercisableWeightedAverageExercisePrice" xlink:label="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToNonVestExercisableWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToNonVestExercisableWeightedAverageExercisePrice" xlink:to="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToNonVestExercisableWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToNonVestExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average exercise price, options non-exercisable (non-vested)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Range of exercise price, options non-exercisable (non-vested)</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_WeightedAverageRemainingContractualLifeInYearsOptionsNonexercisableNonvested" xlink:label="QLGN_WeightedAverageRemainingContractualLifeInYearsOptionsNonexercisableNonvested" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_WeightedAverageRemainingContractualLifeInYearsOptionsNonexercisableNonvested" xlink:to="QLGN_WeightedAverageRemainingContractualLifeInYearsOptionsNonexercisableNonvested_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_WeightedAverageRemainingContractualLifeInYearsOptionsNonexercisableNonvested_lbl" xml:lang="en-US">Weighted- Average Remaining Contractual Life (in Years), Options Non-exercisable (non-vested)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US">Expected dividend yield</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xml:lang="en-US">Expected stock-price volatility</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl" xml:lang="en-US">Risk-free interest rate, minimum</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl" xml:lang="en-US">Risk-free interest rate, maximum</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US">Expected average term of options (in years)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharePrice" xlink:to="us-gaap_SharePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharePrice_lbl" xml:lang="en-US">Share price</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US">Total</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_RangeOfExercisePriceOutstanding" xlink:label="QLGN_RangeOfExercisePriceOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_RangeOfExercisePriceOutstanding" xlink:to="QLGN_RangeOfExercisePriceOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="QLGN_RangeOfExercisePriceOutstanding_lbl" xml:lang="en-US">Range of exercise price - beginning</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAveragRemainingContractualTerm1" xlink:label="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAveragRemainingContractualTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAveragRemainingContractualTerm1" xlink:to="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAveragRemainingContractualTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAveragRemainingContractualTerm1_lbl" xml:lang="en-US">Weighted Average Remaining Life (Years) - outstanding</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_2_lbl" xml:lang="en-US">Number of shares, warrants granted</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice_2_lbl" xml:lang="en-US">Weighted average exercise price per share warrants granted</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedInPeriodWeightedAverageExercisePrice" xlink:to="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedInPeriodWeightedAverageExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedInPeriodWeightedAverageExercisePrice_2_lbl" xml:lang="en-US">Weighted average exercise price per share warrants exercised</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInPeriodWeightedAverageExercisePrice" xlink:to="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInPeriodWeightedAverageExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInPeriodWeightedAverageExercisePrice_2_lbl" xml:lang="en-US">Weighted average exercise price per share warrants expired</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedInPeriodWeightedAverageExercisePrice" xlink:to="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedInPeriodWeightedAverageExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedInPeriodWeightedAverageExercisePrice_2_lbl" xml:lang="en-US">Weighted average exercise price per share warrants forfeited</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_RangeOfExercisePriceOutstanding" xlink:to="QLGN_RangeOfExercisePriceOutstanding_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="QLGN_RangeOfExercisePriceOutstanding_2_lbl" xml:lang="en-US">Range of exercise price - ending</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAveragRemainingContractualTerm1" xlink:to="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAveragRemainingContractualTerm1_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAveragRemainingContractualTerm1_2_lbl" xml:lang="en-US">Weighted average remaining life (Years) exercisable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber" xlink:to="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_2_lbl" xml:lang="en-US">Number of Shares, Warrants Exercisable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageVestedExercisePrice" xlink:to="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageVestedExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageVestedExercisePrice_2_lbl" xml:lang="en-US">Weighted Average Exercise Price Per Share Exercisable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_RangeOfExercisePriceExercisableVested" xlink:to="QLGN_RangeOfExercisePriceExercisableVested_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="QLGN_RangeOfExercisePriceExercisableVested_3_lbl" xml:lang="en-US">Range of exercise price - Exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNonVestedNumber" xlink:label="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNonVestedNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNonVestedNumber" xlink:to="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNonVestedNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNonVestedNumber_lbl" xml:lang="en-US">Number of shares, warrants non-exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageNonVestedExercise" xlink:label="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageNonVestedExercise" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageNonVestedExercise" xlink:to="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageNonVestedExercise_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageNonVestedExercise_lbl" xml:lang="en-US">Weighted Average Exercise Price Per Share Non-Exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_RangeOfExercisePriceNonexercisableNonvested" xlink:label="QLGN_RangeOfExercisePriceNonexercisableNonvested" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_RangeOfExercisePriceNonexercisableNonvested" xlink:to="QLGN_RangeOfExercisePriceNonexercisableNonvested_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_RangeOfExercisePriceNonexercisableNonvested_lbl" xml:lang="en-US">Range of Exercise Price, Non-Exercisable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_2_lbl" xml:lang="en-US">Number of Shares, Warrants Expired</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsRangeOfExercisePrice" xlink:label="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsRangeOfExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsRangeOfExercisePrice" xlink:to="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsRangeOfExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsRangeOfExercisePrice_lbl" xml:lang="en-US">Range of exercise price</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_RangeOfExercisePriceGranted" xlink:label="QLGN_RangeOfExercisePriceGranted" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_RangeOfExercisePriceGranted" xlink:to="QLGN_RangeOfExercisePriceGranted_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_RangeOfExercisePriceGranted_lbl" xml:lang="en-US">Range of exercise price - granted</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_RangeOfExercisePriceExpired" xlink:label="QLGN_RangeOfExercisePriceExpired" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_RangeOfExercisePriceExpired" xlink:to="QLGN_RangeOfExercisePriceExpired_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_RangeOfExercisePriceExpired_lbl" xml:lang="en-US">Range of exercise price - Expired</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInRangeOfExercisePrice" xlink:label="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInRangeOfExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInRangeOfExercisePrice" xlink:to="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInRangeOfExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInRangeOfExercisePrice_lbl" xml:lang="en-US">Weighted average exercise price per share warrants expired</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedInRangeOfExercisePrice" xlink:label="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedInRangeOfExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedInRangeOfExercisePrice" xlink:to="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedInRangeOfExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedInRangeOfExercisePrice_lbl" xml:lang="en-US">Weighted average exercise price per share warrants forfeited</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsRangeOfExercisePrice" xlink:to="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsRangeOfExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsRangeOfExercisePrice_2_lbl" xml:lang="en-US">Range of exercise price</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsNonExercisableNumber" xlink:label="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsNonExercisableNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsNonExercisableNumber" xlink:to="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsNonExercisableNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsNonExercisableNumber_lbl" xml:lang="en-US">Number of Shares, Warrants Exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageVestedNonExercisePrice" xlink:label="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageVestedNonExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageVestedNonExercisePrice" xlink:to="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageVestedNonExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageVestedNonExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price Per Share Exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_RangeOfExercisePriceNonExercisableVested" xlink:label="QLGN_RangeOfExercisePriceNonExercisableVested" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_RangeOfExercisePriceNonExercisableVested" xlink:to="QLGN_RangeOfExercisePriceNonExercisableVested_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_RangeOfExercisePriceNonExercisableVested_lbl" xml:lang="en-US">Range of exercise price - Exercisable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNonExercisableWeightedAverageRemainingContractualTerm1" xlink:to="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNonExercisableWeightedAverageRemainingContractualTerm1_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNonExercisableWeightedAverageRemainingContractualTerm1_2_lbl" xml:lang="en-US">Weighted average remaining life (Years) non-exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ScheduleOfStockByClassTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfStockByClassTable_lbl" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfStockLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfStockLineItems_lbl" xml:lang="en-US">Class of Stock [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_2_lbl" xml:lang="en-US">Shares issued, shares</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharePrice" xlink:to="us-gaap_SharePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharePrice_2_lbl" xml:lang="en-US">Share Price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_2_lbl" xml:lang="en-US">Plan shares available</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:to="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_lbl" xml:lang="en-US">Convertible preferred stock, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:to="us-gaap_StockIssuedDuringPeriodSharesOther_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther_lbl" xml:lang="en-US">Shares issued during conversion, shares</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3_lbl" xml:lang="en-US">Options outstanding</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_2_lbl" xml:lang="en-US">Stock option granted exercise price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExpirationsInPeriodWeightedAverageExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExpirationsInPeriodWeightedAverageExercisePrice_2_lbl" xml:lang="en-US">Range of Exercise price, Options Expired</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_2_lbl" xml:lang="en-US">Cost is expected to be recognized over a weighted average period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_2_lbl" xml:lang="en-US">Compensation cost</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xml:lang="en-US">Unrecognized compensation cost</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US">Stock options exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_lbl" xml:lang="en-US">Stock options description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl" xml:lang="en-US">Proceeds from Issuance or Sale of Equity</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_2_lbl" xml:lang="en-US">Purchase of warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_FairValueOfIssuanceCost" xlink:label="QLGN_FairValueOfIssuanceCost" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_FairValueOfIssuanceCost" xlink:to="QLGN_FairValueOfIssuanceCost_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_FairValueOfIssuanceCost_lbl" xml:lang="en-US">Fair value of issuance cost</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_WarrantsExtendedDateDescription" xlink:label="QLGN_WarrantsExtendedDateDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_WarrantsExtendedDateDescription" xlink:to="QLGN_WarrantsExtendedDateDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_WarrantsExtendedDateDescription_lbl" xml:lang="en-US">Warrants extended date description</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAdjustmentOfWarrants" xlink:to="us-gaap_FairValueAdjustmentOfWarrants_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_3_lbl" xml:lang="en-US">Fair value adjustment of warrants</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_2_lbl" xml:lang="en-US">Compensation cost</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_WarrantsExercised" xlink:label="QLGN_WarrantsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_WarrantsExercised" xlink:to="QLGN_WarrantsExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_WarrantsExercised_lbl" xml:lang="en-US">Warrants exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xml:lang="en-US">Number of outstanding warrants to purchase, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_ModifiedToExercisePrice" xlink:label="QLGN_ModifiedToExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_ModifiedToExercisePrice" xlink:to="QLGN_ModifiedToExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_ModifiedToExercisePrice_lbl" xml:lang="en-US">Modified to exercise price</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionLineItems_lbl" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_lbl" xml:lang="en-US">Domestic</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_lbl" xml:lang="en-US">Foreign</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2_lbl" xml:lang="en-US">Loss before provision for income taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US">Statutory federal income tax rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xml:lang="en-US">State taxes, net of federal tax benefit</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepletion" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepletion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepletion" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepletion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepletion_lbl" xml:lang="en-US">Non-deductible expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_EffectiveIncomeTaxRateReconciliationNonOperatingLossExpiration" xlink:label="QLGN_EffectiveIncomeTaxRateReconciliationNonOperatingLossExpiration" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_EffectiveIncomeTaxRateReconciliationNonOperatingLossExpiration" xlink:to="QLGN_EffectiveIncomeTaxRateReconciliationNonOperatingLossExpiration_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_EffectiveIncomeTaxRateReconciliationNonOperatingLossExpiration_lbl" xml:lang="en-US">NOL expiration</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_lbl" xml:lang="en-US">Tax credit</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses_lbl" xml:lang="en-US">Goodwill impairment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlementsForeign" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlementsForeign" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlementsForeign" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlementsForeign_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlementsForeign_lbl" xml:lang="en-US">Foreign rate differential</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_EffectiveIncomeTaxRateReconciliationFairValueOfWarrant" xlink:label="QLGN_EffectiveIncomeTaxRateReconciliationFairValueOfWarrant" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_EffectiveIncomeTaxRateReconciliationFairValueOfWarrant" xlink:to="QLGN_EffectiveIncomeTaxRateReconciliationFairValueOfWarrant_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_EffectiveIncomeTaxRateReconciliationFairValueOfWarrant_lbl" xml:lang="en-US">Change in FV of warrant liability</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsOther" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsOther" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsOther" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsOther_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsOther_lbl" xml:lang="en-US">True-up</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Change in valuation allowance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xml:lang="en-US">Income taxes provision (benefit)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentFederalTaxExpenseBenefit" xlink:to="us-gaap_CurrentFederalTaxExpenseBenefit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit_lbl" xml:lang="en-US">US Federal</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:to="us-gaap_CurrentStateAndLocalTaxExpenseBenefit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit_lbl" xml:lang="en-US">US State</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentForeignTaxExpenseBenefit" xlink:label="us-gaap_CurrentForeignTaxExpenseBenefit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentForeignTaxExpenseBenefit" xlink:to="us-gaap_CurrentForeignTaxExpenseBenefit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CurrentForeignTaxExpenseBenefit_lbl" xml:lang="en-US">Foreign</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Total current provision</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_lbl" xml:lang="en-US">US Federal</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_lbl" xml:lang="en-US">US State</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredForeignIncomeTaxExpenseBenefit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredForeignIncomeTaxExpenseBenefit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DeferredForeignIncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Foreign</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Total deferred benefit</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xml:lang="en-US">Change in valuation allowance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_IncomeTaxExpenseBenefit_2_lbl" xml:lang="en-US">Total provision (benefit) for income taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xml:lang="en-US">Net operating loss</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl" xml:lang="en-US">Research and development credits</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_DefferdTaxAssetsAccruedExpenses" xlink:label="QLGN_DefferdTaxAssetsAccruedExpenses" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_DefferdTaxAssetsAccruedExpenses" xlink:to="QLGN_DefferdTaxAssetsAccruedExpenses_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_DefferdTaxAssetsAccruedExpenses_lbl" xml:lang="en-US">Accrued expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:label="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:to="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_lbl" xml:lang="en-US">Patent</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xml:lang="en-US">Stock compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_DeferredTaxAssetsResearchAndDevelopmentExpenses" xlink:label="QLGN_DeferredTaxAssetsResearchAndDevelopmentExpenses" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_DeferredTaxAssetsResearchAndDevelopmentExpenses" xlink:to="QLGN_DeferredTaxAssetsResearchAndDevelopmentExpenses_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_DeferredTaxAssetsResearchAndDevelopmentExpenses_lbl" xml:lang="en-US">Research and development expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:label="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:to="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_lbl" xml:lang="en-US">Fixed assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpense" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpense" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpense_lbl" xml:lang="en-US">Total deferred income tax assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:label="us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:to="us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_lbl" xml:lang="en-US">Intangible assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:label="us-gaap_DeferredTaxLiabilitiesLeasingArrangements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:to="us-gaap_DeferredTaxLiabilitiesLeasingArrangements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredTaxLiabilitiesLeasingArrangements_lbl" xml:lang="en-US">Right-of-use asset</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="us-gaap_DeferredIncomeTaxLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxLiabilities" xlink:to="us-gaap_DeferredIncomeTaxLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_lbl" xml:lang="en-US">Total deferred income tax liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xml:lang="en-US">Net deferred income tax assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Valuation allowance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xml:lang="en-US">Deferred tax asset, net of allowance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="us-gaap_OperatingLossCarryforwardsTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="us-gaap_OperatingLossCarryforwardsTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLossCarryforwardsTable_lbl" xml:lang="en-US">Operating Loss Carryforwards [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_OperatingLossCarryforwardsLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems_lbl" xml:lang="en-US">Operating Loss Carryforwards [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredForeignIncomeTaxExpenseBenefit_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredForeignIncomeTaxExpenseBenefit_2_lbl" xml:lang="en-US">Foreign deferred tax benefit</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_lbl" xml:lang="en-US">Operating loss carryforwards</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwards" xlink:to="us-gaap_OperatingLossCarryforwards_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xml:lang="en-US">Net operating loss carryforwards</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xml:lang="en-US">Research and development credit carryforwards</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardLimitationsOnUse" xlink:label="us-gaap_TaxCreditCarryforwardLimitationsOnUse" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardLimitationsOnUse" xlink:to="us-gaap_TaxCreditCarryforwardLimitationsOnUse_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TaxCreditCarryforwardLimitationsOnUse_lbl" xml:lang="en-US">Tax credit carryforward, limitations on use</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefits" xlink:to="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xml:lang="en-US">Unrecognized tax benefits</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTable_lbl" xml:lang="en-US">Subsequent Event [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventLineItems_lbl" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentFaceAmount" xlink:to="us-gaap_DebtInstrumentFaceAmount_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DebtInstrumentFaceAmount_2_lbl" xml:lang="en-US">Debenture voluntarily converted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockDividendsShares" xlink:label="us-gaap_CommonStockDividendsShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockDividendsShares" xlink:to="us-gaap_CommonStockDividendsShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockDividendsShares_lbl" xml:lang="en-US">Shares of common stock</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_BaseSalaryPercentage" xlink:label="QLGN_BaseSalaryPercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_BaseSalaryPercentage" xlink:to="QLGN_BaseSalaryPercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_BaseSalaryPercentage_lbl" xml:lang="en-US">Base salary percentage</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_AnnualCashCompensation" xlink:label="QLGN_AnnualCashCompensation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_AnnualCashCompensation" xlink:to="QLGN_AnnualCashCompensation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_AnnualCashCompensation_lbl" xml:lang="en-US">Annual cash compensation</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_AccruedVacation" xlink:to="QLGN_AccruedVacation_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_AccruedVacation_doc" xml:lang="en-US">Accrued vacation.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_ResearchAndDevelopmentGrantLiability" xlink:to="QLGN_ResearchAndDevelopmentGrantLiability_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_ResearchAndDevelopmentGrantLiability_doc" xml:lang="en-US">Research and development grant liability</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_CostOfProductSales" xlink:to="QLGN_CostOfProductSales_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_CostOfProductSales_doc" xml:lang="en-US">Cost of product sales.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_SeriesAlphaConvertiblePreferredStockMember" xlink:to="QLGN_SeriesAlphaConvertiblePreferredStockMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_SeriesAlphaConvertiblePreferredStockMember_doc" xml:lang="en-US">Series Alpha Convertible Preferred Stock [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_StockIssuedUponCashExerciseOfWarrants" xlink:to="QLGN_StockIssuedUponCashExerciseOfWarrants_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_StockIssuedUponCashExerciseOfWarrants_doc" xml:lang="en-US">Stock issued upon cash exercise of warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_FixedAssetImpairment" xlink:label="QLGN_FixedAssetImpairment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_FixedAssetImpairment" xlink:to="QLGN_FixedAssetImpairment_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_FixedAssetImpairment_doc" xml:lang="en-US">Fixed asset impairment.</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_ForeignCurrencyTranslationAdjustment" xlink:label="QLGN_ForeignCurrencyTranslationAdjustment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_ForeignCurrencyTranslationAdjustment" xlink:to="QLGN_ForeignCurrencyTranslationAdjustment_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_ForeignCurrencyTranslationAdjustment_doc" xml:lang="en-US">Foreign currency translation adjustment</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_NoncontrollingInterestAdjustmentsRelatingToStockbasedCompensationAndOther" xlink:to="QLGN_NoncontrollingInterestAdjustmentsRelatingToStockbasedCompensationAndOther_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_NoncontrollingInterestAdjustmentsRelatingToStockbasedCompensationAndOther_doc" xml:lang="en-US">Noncontrolling interest adjustments relating to stockbased compensation and other.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_FairValueOfWarrantModificationForProfessionalServices" xlink:to="QLGN_FairValueOfWarrantModificationForProfessionalServices_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_FairValueOfWarrantModificationForProfessionalServices_doc" xml:lang="en-US">Fair value of warrant modification for professional services.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_FairValueOfWarrantModificationForBusinessAcquisition" xlink:to="QLGN_FairValueOfWarrantModificationForBusinessAcquisition_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_FairValueOfWarrantModificationForBusinessAcquisition_doc" xml:lang="en-US">Fair value of warrant modification for business acquisition.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_StockIssuedDuringPeriodValuesReverseStockSplits" xlink:to="QLGN_StockIssuedDuringPeriodValuesReverseStockSplits_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_StockIssuedDuringPeriodValuesReverseStockSplits_doc" xml:lang="en-US">Stock issued during period values reverse stock splits.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_CommonStockAndPrefundedWarrantsIssuedForBusinessAcquisition" xlink:to="QLGN_CommonStockAndPrefundedWarrantsIssuedForBusinessAcquisition_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_CommonStockAndPrefundedWarrantsIssuedForBusinessAcquisition_doc" xml:lang="en-US">Common stock and prefunded warrants issued for business acquisition.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_DevelopedProductTechnologyRightsMember" xlink:to="QLGN_DevelopedProductTechnologyRightsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_DevelopedProductTechnologyRightsMember_doc" xml:lang="en-US">Developed-Product-Technology Rights [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_LicensingRightsMember" xlink:to="QLGN_LicensingRightsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_LicensingRightsMember_doc" xml:lang="en-US">Licensing Rights [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_IssuanceOfCommonStockForConversionOfPreferredStock" xlink:to="QLGN_IssuanceOfCommonStockForConversionOfPreferredStock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_IssuanceOfCommonStockForConversionOfPreferredStock_doc" xml:lang="en-US">Issuance of common stock for conversion of preferred stock.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_IssuanceOfCommonStockSharesForConversionOfPreferredStock" xlink:to="QLGN_IssuanceOfCommonStockSharesForConversionOfPreferredStock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_IssuanceOfCommonStockSharesForConversionOfPreferredStock_doc" xml:lang="en-US">Issuance of common stock shares for conversion of preferred stock.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_FairValueOfWarrantsIssuedForProfessionalServices" xlink:to="QLGN_FairValueOfWarrantsIssuedForProfessionalServices_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_FairValueOfWarrantsIssuedForProfessionalServices_doc" xml:lang="en-US">Fair value of warrants issued for professional services.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_SharesIssuedPursuantToSecuritiesPurchaseAgreements" xlink:to="QLGN_SharesIssuedPursuantToSecuritiesPurchaseAgreements_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_SharesIssuedPursuantToSecuritiesPurchaseAgreements_doc" xml:lang="en-US">Shares issued pursuant to securitie purchase agreements.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_CommissionAndOfferingCostsOfSecuritiesPurchaseAgreements" xlink:to="QLGN_CommissionAndOfferingCostsOfSecuritiesPurchaseAgreements_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_CommissionAndOfferingCostsOfSecuritiesPurchaseAgreements_doc" xml:lang="en-US">Commission and offering costs of securities purchase agreements.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_FairValueOfWarrantModificationsPursuantToSecuritiesPurchaseAgreements" xlink:to="QLGN_FairValueOfWarrantModificationsPursuantToSecuritiesPurchaseAgreements_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_FairValueOfWarrantModificationsPursuantToSecuritiesPurchaseAgreements_doc" xml:lang="en-US">Fair value of warrant modifications pursuant to securities purchase agreements.</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_StockIssuedForProfessionalServices" xlink:label="QLGN_StockIssuedForProfessionalServices" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_StockIssuedForProfessionalServices" xlink:to="QLGN_StockIssuedForProfessionalServices_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_StockIssuedForProfessionalServices_doc" xml:lang="en-US">Stock issued for professional services.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_StockIssuedUponNetexerciseOfWarrantsShares" xlink:to="QLGN_StockIssuedUponNetexerciseOfWarrantsShares_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_StockIssuedUponNetexerciseOfWarrantsShares_doc" xml:lang="en-US">Stock issued upon net exercise of warrants shares</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_SharesIssuedPursuantToSecuritiesPurchaseShareAgreements" xlink:to="QLGN_SharesIssuedPursuantToSecuritiesPurchaseShareAgreements_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_SharesIssuedPursuantToSecuritiesPurchaseShareAgreements_doc" xml:lang="en-US">Shares issued pursuant to securities purchase share agreements.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_IncreaseDecreaseInInventoryAndEquipmentHeldForLeases" xlink:to="QLGN_IncreaseDecreaseInInventoryAndEquipmentHeldForLeases_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_IncreaseDecreaseInInventoryAndEquipmentHeldForLeases_doc" xml:lang="en-US">Increase decrease in inventoryaAnd equipment held for leases.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_ProceedsFromIssuanceOfSharesAndWarrantsPursuantToSecuritiesPurchaseAgreements" xlink:to="QLGN_ProceedsFromIssuanceOfSharesAndWarrantsPursuantToSecuritiesPurchaseAgreements_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_ProceedsFromIssuanceOfSharesAndWarrantsPursuantToSecuritiesPurchaseAgreements_doc" xml:lang="en-US">Proceeds from issuance of shares and warrants pursuant to securities purchase agreements.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_CashPaidForAbstract" xlink:to="QLGN_CashPaidForAbstract_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_CashPaidForAbstract_doc" xml:lang="en-US">Cash paid for abstract.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_TransfersOfInventoryFromEquipmentHeldForLease" xlink:to="QLGN_TransfersOfInventoryFromEquipmentHeldForLease_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_TransfersOfInventoryFromEquipmentHeldForLease_doc" xml:lang="en-US">Transfers of inventory from equipment held for lease.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_FairValueOfWarrantLiabilitiesOnDateOfExercise" xlink:to="QLGN_FairValueOfWarrantLiabilitiesOnDateOfExercise_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_FairValueOfWarrantLiabilitiesOnDateOfExercise_doc" xml:lang="en-US">Fair value of warrant liabilities on date of exercise.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_IssuanceOfCommonStockForConversionOfPreferredStockBeforeClosingOfReverseRecapitalization" xlink:to="QLGN_IssuanceOfCommonStockForConversionOfPreferredStockBeforeClosingOfReverseRecapitalization_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_IssuanceOfCommonStockForConversionOfPreferredStockBeforeClosingOfReverseRecapitalization_doc" xml:lang="en-US">Issuance of common stock for conversion of preferred stock before closing of reverse recapitalization.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_RightofuseAssetsObtainedInExchangeForOperatingLeaseLiabilities" xlink:to="QLGN_RightofuseAssetsObtainedInExchangeForOperatingLeaseLiabilities_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_RightofuseAssetsObtainedInExchangeForOperatingLeaseLiabilities_doc" xml:lang="en-US">Rightofuse assets obtained in exchange for operating lease liabilities.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_SharesIssuedForCashlessWarrantsAmount" xlink:to="QLGN_SharesIssuedForCashlessWarrantsAmount_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_SharesIssuedForCashlessWarrantsAmount_doc" xml:lang="en-US">Shares issued for cashless warrants amount.</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_WarrantModificationsPursuantToSecuritiesPurchaseAgreementsValue" xlink:label="QLGN_WarrantModificationsPursuantToSecuritiesPurchaseAgreementsValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_WarrantModificationsPursuantToSecuritiesPurchaseAgreementsValue" xlink:to="QLGN_WarrantModificationsPursuantToSecuritiesPurchaseAgreementsValue_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_WarrantModificationsPursuantToSecuritiesPurchaseAgreementsValue_doc" xml:lang="en-US">Warrant modifications pursuant to securities purchase agreements value.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_FairValueOfWarrantsRepricedDueToAcquisition" xlink:to="QLGN_FairValueOfWarrantsRepricedDueToAcquisition_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_FairValueOfWarrantsRepricedDueToAcquisition_doc" xml:lang="en-US">Fair value of warrants repriced due to acquisition</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_FairValueOfQualigenPrefundedWarrantIssuedInExchangeForNanosynexStock" xlink:to="QLGN_FairValueOfQualigenPrefundedWarrantIssuedInExchangeForNanosynexStock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_FairValueOfQualigenPrefundedWarrantIssuedInExchangeForNanosynexStock_doc" xml:lang="en-US">Fair value of qualigen prefunded warrant issued in exchange for nanosynex stock</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_TotalCashAndRestrictedCash" xlink:label="QLGN_TotalCashAndRestrictedCash" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_TotalCashAndRestrictedCash" xlink:to="QLGN_TotalCashAndRestrictedCash_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_TotalCashAndRestrictedCash_doc" xml:lang="en-US">Total cash and restricted cash.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_AccruedCompensation" xlink:to="QLGN_AccruedCompensation_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_AccruedCompensation_doc" xml:lang="en-US">Accrued compensation.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_AccruedResearchAndDevelopmentCurrent" xlink:to="QLGN_AccruedResearchAndDevelopmentCurrent_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_AccruedResearchAndDevelopmentCurrent_doc" xml:lang="en-US">Research and development.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_NotesPayableMember" xlink:to="QLGN_NotesPayableMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_NotesPayableMember_doc" xml:lang="en-US">Notes Payable [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_NanoSynexMember" xlink:to="QLGN_NanoSynexMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_NanoSynexMember_doc" xml:lang="en-US">Nano Synex Ltd [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_WarrantLiabilitiesTextBlock" xlink:to="QLGN_WarrantLiabilitiesTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_WarrantLiabilitiesTextBlock_doc" xml:lang="en-US">Warrant Liabilities [Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_SeriesCWarrantsMember" xlink:to="QLGN_SeriesCWarrantsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_SeriesCWarrantsMember_doc" xml:lang="en-US">Series C Warrants [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_CommonStockWarrantsMember" xlink:to="QLGN_CommonStockWarrantsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_CommonStockWarrantsMember_doc" xml:lang="en-US">Common Stock Warrants [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber" xlink:to="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_doc" xml:lang="en-US">The number of shares into which fully or partially vestednon-option equity outstanding as of the balance sheet date can be currently converted under the non-option equity plan.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice" xlink:to="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_doc" xml:lang="en-US">Weighted average price at which grantees can acquire the shares reserved for issuance under the stock non-option equity plan.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedInPeriodWeightedAverageExercisePrice" xlink:to="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedInPeriodWeightedAverageExercisePrice_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedInPeriodWeightedAverageExercisePrice_doc" xml:lang="en-US">Weighted average exercise price per share warrants exercised.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedInPeriodWeightedAverageExercisePrice" xlink:to="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedInPeriodWeightedAverageExercisePrice_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedInPeriodWeightedAverageExercisePrice_doc" xml:lang="en-US">Weighted average exercise price per share warrants forfeited.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInPeriodWeightedAverageExercisePrice" xlink:to="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInPeriodWeightedAverageExercisePrice_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInPeriodWeightedAverageExercisePrice_doc" xml:lang="en-US">Share based compensation arrangement by share based payment award non option equity instruments expired in period weighted average exercise price.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice_doc" xml:lang="en-US">Share based compensation arrangement by share based payment award non option equity instruments exercised in period weighted average common stock warrants reverse recapitalization.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageVestedExercisePrice" xlink:to="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageVestedExercisePrice_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageVestedExercisePrice_doc" xml:lang="en-US">Weighted average exercise price per share exercisable (vested).</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_RangeOfExercisePriceExercisableVested" xlink:to="QLGN_RangeOfExercisePriceExercisableVested_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_RangeOfExercisePriceExercisableVested_doc" xml:lang="en-US">Range of exercise price, exercisable (vested).</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAveragRemainingContractualTerm1" xlink:to="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAveragRemainingContractualTerm1_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAveragRemainingContractualTerm1_doc" xml:lang="en-US">Weighted average remaining contractual term for vested portions of non-option equity outstanding and currently vested exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNonExercisableWeightedAverageRemainingContractualTerm1" xlink:to="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNonExercisableWeightedAverageRemainingContractualTerm1_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNonExercisableWeightedAverageRemainingContractualTerm1_doc" xml:lang="en-US">Weighted average remaining contractual term for vested portions of non-option equity outstanding and currently nonvested exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_ScheduleOfFairValueHierarchyForWarrantLiabilitiesTableTextBlock" xlink:to="QLGN_ScheduleOfFairValueHierarchyForWarrantLiabilitiesTableTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_ScheduleOfFairValueHierarchyForWarrantLiabilitiesTableTextBlock_doc" xml:lang="en-US">Schedule Of Fair Value Hierarchy For Warrant Liabilities [Table Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_FairValueAdjustmentOfWarrant" xlink:to="QLGN_FairValueAdjustmentOfWarrant_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_FairValueAdjustmentOfWarrant_doc" xml:lang="en-US">Amount of expense (income) related to adjustment to fair value of warrant liability.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_ChangeInFairValueOfWarrantLiabilities" xlink:to="QLGN_ChangeInFairValueOfWarrantLiabilities_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_ChangeInFairValueOfWarrantLiabilities_doc" xml:lang="en-US">Change in fair value of warrant liabilities.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_SecuritiesPurchaseAgreementMember" xlink:to="QLGN_SecuritiesPurchaseAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_SecuritiesPurchaseAgreementMember_doc" xml:lang="en-US">Securities Purchase Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_ScheduleOfReservedSharesTableTextBlock" xlink:to="QLGN_ScheduleOfReservedSharesTableTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_ScheduleOfReservedSharesTableTextBlock_doc" xml:lang="en-US">Schedule of reserved shares [Table Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_NanoSynexLtdMember" xlink:to="QLGN_NanoSynexLtdMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_NanoSynexLtdMember_doc" xml:lang="en-US">Nano Synex Ltd [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_SeriesAOnePreferredStockMember" xlink:to="QLGN_SeriesAOnePreferredStockMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_SeriesAOnePreferredStockMember_doc" xml:lang="en-US">Series A-1 Preferred Stock [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_PrefundedWarrantMember" xlink:to="QLGN_PrefundedWarrantMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_PrefundedWarrantMember_doc" xml:lang="en-US">Pre-funded Warrant [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_PrepaidExpensesAndOtherCurrentAssetsTextBlock" xlink:to="QLGN_PrepaidExpensesAndOtherCurrentAssetsTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_PrepaidExpensesAndOtherCurrentAssetsTextBlock_doc" xml:lang="en-US">Prepaid Expenses and Other Current Assets [Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_TwoThousandTwentyStockIncentivePlanMember" xlink:to="QLGN_TwoThousandTwentyStockIncentivePlanMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_TwoThousandTwentyStockIncentivePlanMember_doc" xml:lang="en-US">2020 Stock Incentive Plan [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_PrepaidManufacturingExpenses" xlink:to="QLGN_PrepaidManufacturingExpenses_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_PrepaidManufacturingExpenses_doc" xml:lang="en-US">Prepaid manufacturing expenses.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_ScheduleOfAssumptionsOfWarrantLiabilitiesTableTextBlock" xlink:to="QLGN_ScheduleOfAssumptionsOfWarrantLiabilitiesTableTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_ScheduleOfAssumptionsOfWarrantLiabilitiesTableTextBlock_doc" xml:lang="en-US">Schedule Of Assumptions Of Warrant Liabilities [Table Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_PaymentsToAcquireBusinesses" xlink:to="QLGN_PaymentsToAcquireBusinesses_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_PaymentsToAcquireBusinesses_doc" xml:lang="en-US">Payments to acquire businesses.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_PrefundedWarrantsIssuedForBusinessAcquisition" xlink:to="QLGN_PrefundedWarrantsIssuedForBusinessAcquisition_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_PrefundedWarrantsIssuedForBusinessAcquisition_doc" xml:lang="en-US">Prefunded warrants issued for business acquisition.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_AlphaCapitalAnstaltMember" xlink:to="QLGN_AlphaCapitalAnstaltMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_AlphaCapitalAnstaltMember_doc" xml:lang="en-US">Alpha Capital Anstalt [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_EmployeesAndNonemployeeServiceProviderMember" xlink:to="QLGN_EmployeesAndNonemployeeServiceProviderMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_EmployeesAndNonemployeeServiceProviderMember_doc" xml:lang="en-US">Employees and Non-employee Service Provider [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToNonVestExercisableWeightedAverageExercisePrice" xlink:to="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToNonVestExercisableWeightedAverageExercisePrice_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToNonVestExercisableWeightedAverageExercisePrice_doc" xml:lang="en-US">Weighted average exercise price, options non-exercisable (non-vested).</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm3" xlink:to="QLGN_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm3_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm3_doc" xml:lang="en-US">Share based compensation arrangement by share based payment award non option equity instruments legacy ritter weighted average exercise price one.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm2" xlink:to="QLGN_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm2_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm2_doc" xml:lang="en-US">Weighted- Average Remaining Contractual Life (in Years), Options Granted.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_WeightedAverageRemainingContractualLifeInYearsOptionsNonexercisableNonvested" xlink:to="QLGN_WeightedAverageRemainingContractualLifeInYearsOptionsNonexercisableNonvested_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_WeightedAverageRemainingContractualLifeInYearsOptionsNonexercisableNonvested_doc" xml:lang="en-US">Weighted- average remaining contractual life (in years), options non-exercisable (non-vested).</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionGrantedWeightedAverageExercisePrice" xlink:to="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionGrantedWeightedAverageExercisePrice_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionGrantedWeightedAverageExercisePrice_doc" xml:lang="en-US">Share based compensation arrangement by share based payment award option granted weighted average exercise price.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExpirationsInPeriodWeightedAverageExercisePrice_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExpirationsInPeriodWeightedAverageExercisePrice_doc" xml:lang="en-US">Share-based compensation arrangement by share-based payment award option expirations in period weighted average exercise price.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedResearchAndDevelopmentExpense" xlink:to="QLGN_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedResearchAndDevelopmentExpense_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedResearchAndDevelopmentExpense_doc" xml:lang="en-US">Business combination recognized identifiable assets acquired and liabilities assumed research and development expense.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpensesAndOtherPayables" xlink:to="QLGN_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpensesAndOtherPayables_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpensesAndOtherPayables_doc" xml:lang="en-US">Business combination recognized identifiable assets acquired and liabilities assumed current liabilities accrued expenses and other payables.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedResearchAndDevelopmentGrantLiability" xlink:to="QLGN_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedResearchAndDevelopmentGrantLiability_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedResearchAndDevelopmentGrantLiability_doc" xml:lang="en-US">Business combination recognized identifiable assets acquired and liabilities assumed research and development grant liability.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesShortTermDebt" xlink:to="QLGN_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesShortTermDebt_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesShortTermDebt_doc" xml:lang="en-US">Business combination recognized identifiable assets acquired and liabilities assumed current liabilities short term debt.</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_ProceedsFromIssuanceOrSaleOfEquityAndDebt" xlink:label="QLGN_ProceedsFromIssuanceOrSaleOfEquityAndDebt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_ProceedsFromIssuanceOrSaleOfEquityAndDebt" xlink:to="QLGN_ProceedsFromIssuanceOrSaleOfEquityAndDebt_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_ProceedsFromIssuanceOrSaleOfEquityAndDebt_doc" xml:lang="en-US">Proceeds From Issuance or sale of equity and debt.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_DilutivePotentialSharesIssuableFromStockOptionsAndWarrants" xlink:to="QLGN_DilutivePotentialSharesIssuableFromStockOptionsAndWarrants_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_DilutivePotentialSharesIssuableFromStockOptionsAndWarrants_doc" xml:lang="en-US">Dilutive potential shares issuable from stock options and warrants.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_SharesOfCommonStockSubjectToOutstandingOptionsMember" xlink:to="QLGN_SharesOfCommonStockSubjectToOutstandingOptionsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_SharesOfCommonStockSubjectToOutstandingOptionsMember_doc" xml:lang="en-US">Shares of Common Stock Subject to Outstanding Options [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_SharesOfCommonStockSubjectToOutstandingWarrantsMember" xlink:to="QLGN_SharesOfCommonStockSubjectToOutstandingWarrantsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_SharesOfCommonStockSubjectToOutstandingWarrantsMember_doc" xml:lang="en-US">Shares of Common Stock Subject to Outstanding Warrants [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_CompensatoryWarrantsMember" xlink:to="QLGN_CompensatoryWarrantsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_CompensatoryWarrantsMember_doc" xml:lang="en-US">Compensatory Warrants [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_WarrantsExtendedDateDescription" xlink:to="QLGN_WarrantsExtendedDateDescription_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_WarrantsExtendedDateDescription_doc" xml:lang="en-US">Warrants extended date, description.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_WarrantOneMember" xlink:to="QLGN_WarrantOneMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_WarrantOneMember_doc" xml:lang="en-US">Warrant One [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_FirstTwelveMonthsMember" xlink:to="QLGN_FirstTwelveMonthsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_FirstTwelveMonthsMember_doc" xml:lang="en-US">First 12 Months [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_TenantImprovementAllowance" xlink:to="QLGN_TenantImprovementAllowance_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_TenantImprovementAllowance_doc" xml:lang="en-US">Tenant improvement allowance.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_SummaryOfWarrantActivityTableTextBlock" xlink:to="QLGN_SummaryOfWarrantActivityTableTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_SummaryOfWarrantActivityTableTextBlock_doc" xml:lang="en-US">Summary Of Warrant Activity [Table Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_ScheduleOfOperatingLeaseRightOfUseAssetsAndLiabilitiesTableTextBlock" xlink:to="QLGN_ScheduleOfOperatingLeaseRightOfUseAssetsAndLiabilitiesTableTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_ScheduleOfOperatingLeaseRightOfUseAssetsAndLiabilitiesTableTextBlock_doc" xml:lang="en-US">Schedule Of Operating Lease Right Of Use Assets And Liabilities [Table Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_LongtermOperatingLeaseAgreementMember" xlink:to="QLGN_LongtermOperatingLeaseAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_LongtermOperatingLeaseAgreementMember_doc" xml:lang="en-US">Longterm Operating Lease Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_CompensatoryWarrantActivityMember" xlink:to="QLGN_CompensatoryWarrantActivityMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_CompensatoryWarrantActivityMember_doc" xml:lang="en-US">Compensatory Warrant Activity [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_RangeOfExercisePriceOutstanding" xlink:to="QLGN_RangeOfExercisePriceOutstanding_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_RangeOfExercisePriceOutstanding_doc" xml:lang="en-US">Range Of Exercise Price Outstanding.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAveragRemainingContractualTerm1" xlink:to="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAveragRemainingContractualTerm1_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAveragRemainingContractualTerm1_doc" xml:lang="en-US">Share based compensation arrangement by share based payment award non option equity instruments legacy ritter weighted average exercise price one.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNonVestedNumber" xlink:to="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNonVestedNumber_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNonVestedNumber_doc" xml:lang="en-US">Number of shares, warrants non-exercisable (non-vested).</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageNonVestedExercise" xlink:to="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageNonVestedExercise_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageNonVestedExercise_doc" xml:lang="en-US">Weighted average exercise price per share non-exercisable (non-vested).</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_RangeOfExercisePriceNonexercisableNonvested" xlink:to="QLGN_RangeOfExercisePriceNonexercisableNonvested_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_RangeOfExercisePriceNonexercisableNonvested_doc" xml:lang="en-US">Range of exercise price, non-exercisable (non-vested).</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_GeneralAdministrativeResearchAndDevelopmentExpensesMember" xlink:to="QLGN_GeneralAdministrativeResearchAndDevelopmentExpensesMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_GeneralAdministrativeResearchAndDevelopmentExpensesMember_doc" xml:lang="en-US">General Administrative Research and Development Expenses [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_LicenseRevenueMember" xlink:to="QLGN_LicenseRevenueMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_LicenseRevenueMember_doc" xml:lang="en-US">License Revenue [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_AllowancesForSalesReturn" xlink:to="QLGN_AllowancesForSalesReturn_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_AllowancesForSalesReturn_doc" xml:lang="en-US">Allowances for sales return.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_ResearchAndLicenseAgreementsTextBlock" xlink:to="QLGN_ResearchAndLicenseAgreementsTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_ResearchAndLicenseAgreementsTextBlock_doc" xml:lang="en-US">Research And License Agreements [Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_MoldsAndToolingMember" xlink:to="QLGN_MoldsAndToolingMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_MoldsAndToolingMember_doc" xml:lang="en-US">Molds and Tooling [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_NoncompensatoryEquityClassifiedWarrantsMember" xlink:to="QLGN_NoncompensatoryEquityClassifiedWarrantsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_NoncompensatoryEquityClassifiedWarrantsMember_doc" xml:lang="en-US">Noncompensatory Equity Classified Warrants [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_WarrantsExercised" xlink:to="QLGN_WarrantsExercised_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_WarrantsExercised_doc" xml:lang="en-US">Warrants exercised.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_ModifiedToExercisePrice" xlink:to="QLGN_ModifiedToExercisePrice_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_ModifiedToExercisePrice_doc" xml:lang="en-US">Modified to exercise price.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_PatentsAndLicensesMember" xlink:to="QLGN_PatentsAndLicensesMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_PatentsAndLicensesMember_doc" xml:lang="en-US">Patents and Licenses [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_LicenseAndSponsoredResearchAgreementsMember" xlink:to="QLGN_LicenseAndSponsoredResearchAgreementsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_LicenseAndSponsoredResearchAgreementsMember_doc" xml:lang="en-US">License and Sponsored Research Agreements [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_UniversityOfLouisvilleResearchFoundationMember" xlink:to="QLGN_UniversityOfLouisvilleResearchFoundationMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_UniversityOfLouisvilleResearchFoundationMember_doc" xml:lang="en-US">University of Louisville Research Foundation [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_ReimbursementOfResearchExpenses" xlink:to="QLGN_ReimbursementOfResearchExpenses_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_ReimbursementOfResearchExpenses_doc" xml:lang="en-US">Reimbursement of research expenses.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_PatentCosts" xlink:to="QLGN_PatentCosts_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_PatentCosts_doc" xml:lang="en-US">Patent costs.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_AgreementTermPaymentDescription" xlink:to="QLGN_AgreementTermPaymentDescription_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_AgreementTermPaymentDescription_doc" xml:lang="en-US">Agreement term payment, description.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_MilestonePayment" xlink:to="QLGN_MilestonePayment_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_MilestonePayment_doc" xml:lang="en-US">Milestone payment.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_NonCompensatoryWarrantActivityMember" xlink:to="QLGN_NonCompensatoryWarrantActivityMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_NonCompensatoryWarrantActivityMember_doc" xml:lang="en-US">Non Compensatory Warrant Activity [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_PhaseTwoClinicalTrialMember" xlink:to="QLGN_PhaseTwoClinicalTrialMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_PhaseTwoClinicalTrialMember_doc" xml:lang="en-US">Phase 2 Clinical Trial [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_PhaseOneClinicalTrialMember" xlink:to="QLGN_PhaseOneClinicalTrialMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_PhaseOneClinicalTrialMember_doc" xml:lang="en-US">Phase 1 Clinical Trial [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_PhaseThreeClinicalTrialMember" xlink:to="QLGN_PhaseThreeClinicalTrialMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_PhaseThreeClinicalTrialMember_doc" xml:lang="en-US">Phase 3 Clinical Trial [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_RegulatoryMarketingApprovalExpenses" xlink:to="QLGN_RegulatoryMarketingApprovalExpenses_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_RegulatoryMarketingApprovalExpenses_doc" xml:lang="en-US">Regulatory marketing approval, expenses.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_LicensedProductSalesMember" xlink:to="QLGN_LicensedProductSalesMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_LicensedProductSalesMember_doc" xml:lang="en-US">Licensed Product Sales [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_CumulativeSales" xlink:to="QLGN_CumulativeSales_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_CumulativeSales_doc" xml:lang="en-US">Cumulative sales.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_SponsoredResearchAgreementAndLicenseMember" xlink:to="QLGN_SponsoredResearchAgreementAndLicenseMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_SponsoredResearchAgreementAndLicenseMember_doc" xml:lang="en-US">Sponsored Research and License Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_RegulatoryMarketingApprovalExpensesOne" xlink:to="QLGN_RegulatoryMarketingApprovalExpensesOne_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_RegulatoryMarketingApprovalExpensesOne_doc" xml:lang="en-US">Regulatory marketing approval expenses one.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_ShortfallPayments" xlink:to="QLGN_ShortfallPayments_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_ShortfallPayments_doc" xml:lang="en-US">Shortfall payments.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_SalesAndExciseTaxesPolicyTextBlock" xlink:to="QLGN_SalesAndExciseTaxesPolicyTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_SalesAndExciseTaxesPolicyTextBlock_doc" xml:lang="en-US">Sales And Excise Taxes [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_LicenseCost" xlink:to="QLGN_LicenseCost_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_LicenseCost_doc" xml:lang="en-US">License costs.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_UpfrontLicenseFee" xlink:to="QLGN_UpfrontLicenseFee_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_UpfrontLicenseFee_doc" xml:lang="en-US">Upfront license fee.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_LicenseAgreementMember" xlink:to="QLGN_LicenseAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_LicenseAgreementMember_doc" xml:lang="en-US">License Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_RangeOfExercisePriceGranted" xlink:to="QLGN_RangeOfExercisePriceGranted_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_RangeOfExercisePriceGranted_doc" xml:lang="en-US">Range of exercise price granted.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_RangeOfExercisePriceExpired" xlink:to="QLGN_RangeOfExercisePriceExpired_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_RangeOfExercisePriceExpired_doc" xml:lang="en-US">Range of exercise price expired</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_RegulatoryMarketingApprovalMember" xlink:label="QLGN_RegulatoryMarketingApprovalMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_RegulatoryMarketingApprovalMember" xlink:to="QLGN_RegulatoryMarketingApprovalMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_RegulatoryMarketingApprovalMember_doc" xml:lang="en-US">Regulatory Marketing Approval [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_DefferdTaxAssetsAccruedExpenses" xlink:to="QLGN_DefferdTaxAssetsAccruedExpenses_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_DefferdTaxAssetsAccruedExpenses_doc" xml:lang="en-US">Defferd tax assets accrued expenses.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_AgreementDescription" xlink:to="QLGN_AgreementDescription_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_AgreementDescription_doc" xml:lang="en-US">Agreement description.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_AdvancedCancerTherapeuticsLLCMember" xlink:to="QLGN_AdvancedCancerTherapeuticsLLCMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_AdvancedCancerTherapeuticsLLCMember_doc" xml:lang="en-US">Advanced Cancer Therapeutics, LLC [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_MilestonePaymentForCumulativeMarketingExpenses" xlink:to="QLGN_MilestonePaymentForCumulativeMarketingExpenses_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_MilestonePaymentForCumulativeMarketingExpenses_doc" xml:lang="en-US">Milestone payment for cumulative marketing expenses.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_MilestoneMethodRevenueRecognized" xlink:to="QLGN_MilestoneMethodRevenueRecognized_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_MilestoneMethodRevenueRecognized_doc" xml:lang="en-US">Milestone method revenue recognized.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_CEMarkMember" xlink:to="QLGN_CEMarkMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_CEMarkMember_doc" xml:lang="en-US">CE Mark [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_DeferredTaxAssetsResearchAndDevelopmentExpenses" xlink:to="QLGN_DeferredTaxAssetsResearchAndDevelopmentExpenses_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_DeferredTaxAssetsResearchAndDevelopmentExpenses_doc" xml:lang="en-US">Research and development expenses.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_EffectiveIncomeTaxRateReconciliationNonOperatingLossExpiration" xlink:to="QLGN_EffectiveIncomeTaxRateReconciliationNonOperatingLossExpiration_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_EffectiveIncomeTaxRateReconciliationNonOperatingLossExpiration_doc" xml:lang="en-US">Effective income tax rate reconciliation non operating loss expiration.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_EffectiveIncomeTaxRateReconciliationFairValueOfWarrant" xlink:to="QLGN_EffectiveIncomeTaxRateReconciliationFairValueOfWarrant_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_EffectiveIncomeTaxRateReconciliationFairValueOfWarrant_doc" xml:lang="en-US">Effective income tax rate reconciliation fair value of warrant.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_YiXinZhenDuanJishuLtdMember" xlink:to="QLGN_YiXinZhenDuanJishuLtdMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_YiXinZhenDuanJishuLtdMember_doc" xml:lang="en-US">Yi Xin Zhen Duan Jishu Ltd [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_STAPharmaceuticalCoLtdMember" xlink:to="QLGN_STAPharmaceuticalCoLtdMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_STAPharmaceuticalCoLtdMember_doc" xml:lang="en-US">STA Pharmaceutical Co Ltd [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_SeniorSecuredConvertibleDebtMember" xlink:to="QLGN_SeniorSecuredConvertibleDebtMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_SeniorSecuredConvertibleDebtMember_doc" xml:lang="en-US">Senior Secured Convertible Debt [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_SekisuiDistributionAgreementMember" xlink:to="QLGN_SekisuiDistributionAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_SekisuiDistributionAgreementMember_doc" xml:lang="en-US">Sekisui Distribution Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_StockIssuedUponCashExerciseOfWarrantsShares" xlink:to="QLGN_StockIssuedUponCashExerciseOfWarrantsShares_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_StockIssuedUponCashExerciseOfWarrantsShares_doc" xml:lang="en-US">Stock issued upon cash exercise of warrants shares.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_CommonStockAndPrefundedWarrantsIssuedSharesForBusinessAcquisition" xlink:to="QLGN_CommonStockAndPrefundedWarrantsIssuedSharesForBusinessAcquisition_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_CommonStockAndPrefundedWarrantsIssuedSharesForBusinessAcquisition_doc" xml:lang="en-US">Common stock and prefunded warrants issued shares for business acquisition.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_StockIssuedUponNetexerciseOfWarrants" xlink:to="QLGN_StockIssuedUponNetexerciseOfWarrants_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_StockIssuedUponNetexerciseOfWarrants_doc" xml:lang="en-US">Stock issued upon net exercise of warrants.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_IncreaseDecreaseInResearchAndDevelopmentGrantLiability" xlink:to="QLGN_IncreaseDecreaseInResearchAndDevelopmentGrantLiability_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_IncreaseDecreaseInResearchAndDevelopmentGrantLiability_doc" xml:lang="en-US">Research and development grant liability.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_PurchasesOfEquipmentHeldForLease" xlink:to="QLGN_PurchasesOfEquipmentHeldForLease_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_PurchasesOfEquipmentHeldForLease_doc" xml:lang="en-US">Purchases of equipment held for lease.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_FractionalSharePaymentsRelatedToReverseStockSplit" xlink:to="QLGN_FractionalSharePaymentsRelatedToReverseStockSplit_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_FractionalSharePaymentsRelatedToReverseStockSplit_doc" xml:lang="en-US">Fractional share payments related to reverse stock split.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_ProceedsFromIssuanceOfConvertibleDebt" xlink:to="QLGN_ProceedsFromIssuanceOfConvertibleDebt_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_ProceedsFromIssuanceOfConvertibleDebt_doc" xml:lang="en-US">Proceeds from issuance of convertible debt.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_FairValueOfWarrantModificationsForBusinessAcquisition" xlink:to="QLGN_FairValueOfWarrantModificationsForBusinessAcquisition_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_FairValueOfWarrantModificationsForBusinessAcquisition_doc" xml:lang="en-US">Fair value of warrant modifications for business acquisition.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_AccruedFranchiseSalesAndUseTaxes" xlink:to="QLGN_AccruedFranchiseSalesAndUseTaxes_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_AccruedFranchiseSalesAndUseTaxes_doc" xml:lang="en-US">Accrued franchise sales and use taxes.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_AccruedEquipmentHeldForLease" xlink:to="QLGN_AccruedEquipmentHeldForLease_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_AccruedEquipmentHeldForLease_doc" xml:lang="en-US">Accrued equipment held for lease.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_AccruedLicenseFees" xlink:to="QLGN_AccruedLicenseFees_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_AccruedLicenseFees_doc" xml:lang="en-US">Accrued license fees.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_AlphaCapitalMember" xlink:to="QLGN_AlphaCapitalMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_AlphaCapitalMember_doc" xml:lang="en-US">Alpha Capital [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_ConversionPricePercentage" xlink:to="QLGN_ConversionPricePercentage_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_ConversionPricePercentage_doc" xml:lang="en-US">Conversion price percentage.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_FairValueOfWarrantLiabilitiesIssuanceOfAlphaWarrants" xlink:to="QLGN_FairValueOfWarrantLiabilitiesIssuanceOfAlphaWarrants_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_FairValueOfWarrantLiabilitiesIssuanceOfAlphaWarrants_doc" xml:lang="en-US">Fair value of warrant liabilities issuance of alpha warrants.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_OrganizationPolicyTextBlock" xlink:to="QLGN_OrganizationPolicyTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_OrganizationPolicyTextBlock_doc" xml:lang="en-US">Organization Policy [TextBlock]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_FixedAssetImpairments" xlink:to="QLGN_FixedAssetImpairments_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_FixedAssetImpairments_doc" xml:lang="en-US">Fixed asset lmpairments.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_ResearchAndDevelopmentGrantsPolicyTextBlock" xlink:to="QLGN_ResearchAndDevelopmentGrantsPolicyTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_ResearchAndDevelopmentGrantsPolicyTextBlock_doc" xml:lang="en-US">Research And Development Grants Policy [TextBlock]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_PatentCostsPolicyTextBlock" xlink:to="QLGN_PatentCostsPolicyTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_PatentCostsPolicyTextBlock_doc" xml:lang="en-US">Patent Costs Policy [TextBlock]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_ShippingAndHandlingCostsPolicyTextBlock" xlink:to="QLGN_ShippingAndHandlingCostsPolicyTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_ShippingAndHandlingCostsPolicyTextBlock_doc" xml:lang="en-US">Shipping And Handling Costs Policy [TextBlock]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_DeferredRevenuePolicyTextBlock" xlink:to="QLGN_DeferredRevenuePolicyTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_DeferredRevenuePolicyTextBlock_doc" xml:lang="en-US">Deferred Revenue Policy [TextBlock]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_DevelopmentFund" xlink:to="QLGN_DevelopmentFund_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_DevelopmentFund_doc" xml:lang="en-US">Development fund.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_ScheduleOfUsefulLivesOfPropertyAndEquipmentTableTextBlock" xlink:to="QLGN_ScheduleOfUsefulLivesOfPropertyAndEquipmentTableTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_ScheduleOfUsefulLivesOfPropertyAndEquipmentTableTextBlock_doc" xml:lang="en-US">Schedule Of Useful Lives Of Property And Equipment [Table TextBlock]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_DerivativeFinancialInstrumentsAndWarrantLiabilitiesPolicyTextBlock" xlink:to="QLGN_DerivativeFinancialInstrumentsAndWarrantLiabilitiesPolicyTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_DerivativeFinancialInstrumentsAndWarrantLiabilitiesPolicyTextBlock_doc" xml:lang="en-US">Derivative Financial Instruments And Warrant Liabilities [Policy TextBlock]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_WarrantyReservePolicyTextBlock" xlink:to="QLGN_WarrantyReservePolicyTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_WarrantyReservePolicyTextBlock_doc" xml:lang="en-US">Warranty Reserve [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_GlobalEconomicConditionsPolicyTextBlock" xlink:to="QLGN_GlobalEconomicConditionsPolicyTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_GlobalEconomicConditionsPolicyTextBlock_doc" xml:lang="en-US">Global Economic Conditions [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_SeniorConvertibleDebentureMember" xlink:to="QLGN_SeniorConvertibleDebentureMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_SeniorConvertibleDebentureMember_doc" xml:lang="en-US">Senior Convertible Debenture [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_PurchasePrice" xlink:to="QLGN_PurchasePrice_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_PurchasePrice_doc" xml:lang="en-US">Purchase price.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_PrincipalAmountPercentage" xlink:to="QLGN_PrincipalAmountPercentage_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_PrincipalAmountPercentage_doc" xml:lang="en-US">Principal amount percentage.</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_DebentureAccruesInterestRate" xlink:label="QLGN_DebentureAccruesInterestRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_DebentureAccruesInterestRate" xlink:to="QLGN_DebentureAccruesInterestRate_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_DebentureAccruesInterestRate_doc" xml:lang="en-US">Debenture accrues interest rate.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_AlphaCapitalOtherThirdPartiesMember" xlink:to="QLGN_AlphaCapitalOtherThirdPartiesMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_AlphaCapitalOtherThirdPartiesMember_doc" xml:lang="en-US">Alpha Capital Other Third Parties [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_FeesAndCostsPaid" xlink:to="QLGN_FeesAndCostsPaid_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_FeesAndCostsPaid_doc" xml:lang="en-US">Fees and costs paid.</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_WarrantTwoMember" xlink:label="QLGN_WarrantTwoMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_WarrantTwoMember" xlink:to="QLGN_WarrantTwoMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_WarrantTwoMember_doc" xml:lang="en-US">Warrant Two [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_BaseSalaryPercentage" xlink:to="QLGN_BaseSalaryPercentage_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_BaseSalaryPercentage_doc" xml:lang="en-US">Base salary percentage.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_AnnualCashCompensation" xlink:to="QLGN_AnnualCashCompensation_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_AnnualCashCompensation_doc" xml:lang="en-US">Annual cash compensation.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsRangeOfExercisePrice" xlink:to="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsRangeOfExercisePrice_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsRangeOfExercisePrice_doc" xml:lang="en-US">Share based compensation arrangement by share based payment award non option equity instruments range of exercise price.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInRangeOfExercisePrice" xlink:to="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInRangeOfExercisePrice_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInRangeOfExercisePrice_doc" xml:lang="en-US">Share based compensation arrangement by share based payment award non option equity instruments expired in range of exercise price.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedInRangeOfExercisePrice" xlink:to="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedInRangeOfExercisePrice_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedInRangeOfExercisePrice_doc" xml:lang="en-US">Share based compensation arrangement by share based payment award non option equity instruments forfeited in range of exercise price.</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_AccruedExpensesAndOtherCurrentLiabilities" xlink:label="QLGN_AccruedExpensesAndOtherCurrentLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_AccruedExpensesAndOtherCurrentLiabilities" xlink:to="QLGN_AccruedExpensesAndOtherCurrentLiabilities_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_AccruedExpensesAndOtherCurrentLiabilities_doc" xml:lang="en-US">Accrued expenses and other current liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_FairValueOfIssuanceCost" xlink:to="QLGN_FairValueOfIssuanceCost_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_FairValueOfIssuanceCost_doc" xml:lang="en-US">Fair value of Issuance cost.</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_GoodwillImpairmentLosses" xlink:label="QLGN_GoodwillImpairmentLosses" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_GoodwillImpairmentLosses" xlink:to="QLGN_GoodwillImpairmentLosses_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_GoodwillImpairmentLosses_doc" xml:lang="en-US">Goodwill impairment losses.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_NetProductSalesMember" xlink:to="QLGN_NetProductSalesMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_NetProductSalesMember_doc" xml:lang="en-US">Net Product Sales [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_RangeOfExercisePrice" xlink:to="QLGN_RangeOfExercisePrice_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_RangeOfExercisePrice_doc" xml:lang="en-US">Range of exercise price.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_PhaseClinicalTrialMember" xlink:to="QLGN_PhaseClinicalTrialMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_PhaseClinicalTrialMember_doc" xml:lang="en-US">Phase Clinical Trial [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_LicenseRevenuesMember" xlink:to="QLGN_LicenseRevenuesMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_LicenseRevenuesMember_doc" xml:lang="en-US">License Revenues [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_ReimbursementOfPatent" xlink:to="QLGN_ReimbursementOfPatent_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_ReimbursementOfPatent_doc" xml:lang="en-US">Reimbursement of patent.</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_UpfrontPaymenetMember" xlink:label="QLGN_UpfrontPaymenetMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_UpfrontPaymenetMember" xlink:to="QLGN_UpfrontPaymenetMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_UpfrontPaymenetMember_doc" xml:lang="en-US">Upfront Paymenet [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_UpfrontPaymentMember" xlink:to="QLGN_UpfrontPaymentMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_UpfrontPaymentMember_doc" xml:lang="en-US">Upfront Payment [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_RangeOfExercisePriceNonExercisableVested" xlink:to="QLGN_RangeOfExercisePriceNonExercisableVested_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_RangeOfExercisePriceNonExercisableVested_doc" xml:lang="en-US">Range of exercise price non exercisable vested</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageVestedNonExercisePrice" xlink:to="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageVestedNonExercisePrice_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageVestedNonExercisePrice_doc" xml:lang="en-US">Share based compensation arrangement by share based payment award non option equity instruments exercisable weighted average vested non exercise price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsNonExercisableNumber" xlink:to="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsNonExercisableNumber_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsNonExercisableNumber_doc" xml:lang="en-US">Share based compensation arrangement by share based payment award non option equity instruments non exercisable number</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_NanoSynexMember" xlink:to="QLGN_NanoSynexMember_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_NanoSynexMember_3_lbl" xml:lang="en-US">Nano Synex Ltd [Member] [Default Label]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_2_lbl" xml:lang="en-US">Assets, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_2_lbl" xml:lang="en-US">Assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_2_lbl" xml:lang="en-US">Liabilities, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Liabilities_2_lbl" xml:lang="en-US">Liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_2_lbl" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_4_lbl" xml:lang="en-US">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_2_lbl" xml:lang="en-US">Liabilities and Equity</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpenses_2_lbl" xml:lang="en-US">Operating Expenses</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_2_lbl" xml:lang="en-US">Operating Income (Loss)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeGainLossOnDerivativeNet" xlink:to="us-gaap_DerivativeGainLossOnDerivativeNet_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeGainLossOnDerivativeNet_2_lbl" xml:lang="en-US">Derivative, Gain (Loss) on Derivative, Net</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestIncomeExpenseNet" xlink:to="us-gaap_InterestIncomeExpenseNet_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestIncomeExpenseNet_2_lbl" xml:lang="en-US">Interest Income (Expense), Net</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_2_lbl" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpense_2_lbl" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_2_lbl" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_2_lbl" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesOutstanding_3_lbl" xml:lang="en-US">Shares, Outstanding</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits" xlink:to="us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits_2_lbl" xml:lang="en-US">Stock Issued During Period, Shares, Reverse Stock Splits</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_2_lbl" xml:lang="en-US">APIC, Share-Based Payment Arrangement, Option, Increase for Cost Recognition</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_2_lbl" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_IncreaseDecreaseInInventoryAndEquipmentHeldForLeases" xlink:to="QLGN_IncreaseDecreaseInInventoryAndEquipmentHeldForLeases_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_IncreaseDecreaseInInventoryAndEquipmentHeldForLeases_3_lbl" xml:lang="en-US">IncreaseDecreaseInInventoryAndEquipmentHeldForLeases</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_2_lbl" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_2_lbl" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities_2_lbl" xml:lang="en-US">Increase (Decrease) in Other Accounts Payable and Accrued Liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_IncreaseDecreaseInResearchAndDevelopmentGrantLiability" xlink:to="QLGN_IncreaseDecreaseInResearchAndDevelopmentGrantLiability_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_IncreaseDecreaseInResearchAndDevelopmentGrantLiability_3_lbl" xml:lang="en-US">IncreaseDecreaseInResearchAndDevelopmentGrantLiability</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDeferredLiabilities" xlink:to="us-gaap_IncreaseDecreaseInDeferredLiabilities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInDeferredLiabilities_2_lbl" xml:lang="en-US">Increase (Decrease) in Deferred Liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_3_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_PurchasesOfEquipmentHeldForLease" xlink:to="QLGN_PurchasesOfEquipmentHeldForLease_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_PurchasesOfEquipmentHeldForLease_3_lbl" xml:lang="en-US">PurchasesOfEquipmentHeldForLease</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireIntangibleAssets" xlink:to="us-gaap_PaymentsToAcquireIntangibleAssets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets_2_lbl" xml:lang="en-US">Payments to Acquire Intangible Assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_2_lbl" xml:lang="en-US">Payments of Stock Issuance Costs</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfNotesPayable" xlink:to="us-gaap_RepaymentsOfNotesPayable_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RepaymentsOfNotesPayable_2_lbl" xml:lang="en-US">Repayments of Notes Payable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_FractionalSharePaymentsRelatedToReverseStockSplit" xlink:to="QLGN_FractionalSharePaymentsRelatedToReverseStockSplit_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_FractionalSharePaymentsRelatedToReverseStockSplit_3_lbl" xml:lang="en-US">FractionalSharePaymentsRelatedToReverseStockSplit</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_2_lbl" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_3_lbl" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueOfAssetsAcquired" xlink:to="us-gaap_FairValueOfAssetsAcquired_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueOfAssetsAcquired_2_lbl" xml:lang="en-US">Fair Value of Assets Acquired</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_2_lbl" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:to="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_2_lbl" xml:lang="en-US">Goodwill and Intangible Assets, Policy [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:to="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_2_lbl" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_2_lbl" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accounts Payable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedResearchAndDevelopmentGrantLiability" xlink:to="QLGN_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedResearchAndDevelopmentGrantLiability_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedResearchAndDevelopmentGrantLiability_3_lbl" xml:lang="en-US">BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedResearchAndDevelopmentGrantLiability</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_2_lbl" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_2_lbl" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_2_lbl" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_2_lbl" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_AccruedResearchAndDevelopmentCurrent" xlink:to="QLGN_AccruedResearchAndDevelopmentCurrent_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_AccruedResearchAndDevelopmentCurrent_3_lbl" xml:lang="en-US">AccruedResearchAndDevelopmentCurrent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedLiabilitiesCurrent_2_lbl" xml:lang="en-US">Accrued Liabilities, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_3_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding, Number</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice" xlink:to="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_4_lbl" xml:lang="en-US">ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_RangeOfExercisePrice" xlink:to="QLGN_RangeOfExercisePrice_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_RangeOfExercisePrice_4_lbl" xml:lang="en-US">RangeOfExercisePrice</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_2_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Exercised</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_2_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Forfeitures</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_FairValueAdjustmentOfWarrant" xlink:to="QLGN_FairValueAdjustmentOfWarrant_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_FairValueAdjustmentOfWarrant_4_lbl" xml:lang="en-US">FairValueAdjustmentOfWarrant</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_FairValueOfWarrantLiabilitiesIssuanceOfAlphaWarrants" xlink:to="QLGN_FairValueOfWarrantLiabilitiesIssuanceOfAlphaWarrants_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_FairValueOfWarrantLiabilitiesIssuanceOfAlphaWarrants_3_lbl" xml:lang="en-US">FairValueOfWarrantLiabilitiesIssuanceOfAlphaWarrants</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_ChangeInFairValueOfWarrantLiabilities" xlink:to="QLGN_ChangeInFairValueOfWarrantLiabilities_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_ChangeInFairValueOfWarrantLiabilities_3_lbl" xml:lang="en-US">ChangeInFairValueOfWarrantLiabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentUnamortizedDiscount" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscount_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount_2_lbl" xml:lang="en-US">Debt Instrument, Unamortized Discount</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasePayments" xlink:to="us-gaap_OperatingLeasePayments_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasePayments_2_lbl" xml:lang="en-US">Operating Lease, Payments</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_2_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_2_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_RegulatoryMarketingApprovalExpensesOne" xlink:to="QLGN_RegulatoryMarketingApprovalExpensesOne_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_RegulatoryMarketingApprovalExpensesOne_3_lbl" xml:lang="en-US">RegulatoryMarketingApprovalExpensesOne</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenue" xlink:to="us-gaap_DeferredRevenue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredRevenue_2_lbl" xml:lang="en-US">Deferred Revenue [Default Label]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_2_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_2_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_3_lbl" xml:lang="en-US">Share-Based Payment Arrangement, Expense</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_RangeOfExercisePriceOutstanding" xlink:to="QLGN_RangeOfExercisePriceOutstanding_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_RangeOfExercisePriceOutstanding_4_lbl" xml:lang="en-US">RangeOfExercisePriceOutstanding</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsRangeOfExercisePrice" xlink:to="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsRangeOfExercisePrice_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsRangeOfExercisePrice_4_lbl" xml:lang="en-US">ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsRangeOfExercisePrice</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsNonExercisableNumber" xlink:to="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsNonExercisableNumber_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsNonExercisableNumber_3_lbl" xml:lang="en-US">ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsNonExercisableNumber</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageVestedNonExercisePrice" xlink:to="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageVestedNonExercisePrice_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageVestedNonExercisePrice_3_lbl" xml:lang="en-US">ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageVestedNonExercisePrice</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentForeignTaxExpenseBenefit" xlink:to="us-gaap_CurrentForeignTaxExpenseBenefit_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CurrentForeignTaxExpenseBenefit_2_lbl" xml:lang="en-US">Current Foreign Tax Expense (Benefit)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit_2_lbl" xml:lang="en-US">Current Income Tax Expense (Benefit)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_2_lbl" xml:lang="en-US">Deferred Federal Income Tax Expense (Benefit)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_2_lbl" xml:lang="en-US">Deferred State and Local Income Tax Expense (Benefit)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredForeignIncomeTaxExpenseBenefit_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredForeignIncomeTaxExpenseBenefit_3_lbl" xml:lang="en-US">Deferred Foreign Income Tax Expense (Benefit)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit_2_lbl" xml:lang="en-US">Deferred Income Tax Expense (Benefit)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_2_lbl" xml:lang="en-US">Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpense" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpense_2_lbl" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:to="us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_2_lbl" xml:lang="en-US">Deferred Tax Liabilities, Intangible Assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:to="us-gaap_DeferredTaxLiabilitiesLeasingArrangements_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxLiabilitiesLeasingArrangements_2_lbl" xml:lang="en-US">Deferred Tax Liabilities, Leasing Arrangements</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxLiabilities" xlink:to="us-gaap_DeferredIncomeTaxLiabilities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_2_lbl" xml:lang="en-US">Deferred Tax Liabilities, Gross</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsGross_2_lbl" xml:lang="en-US">Deferred Tax Assets, Gross</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_2_lbl" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_2_lbl" xml:lang="en-US">Deferred Tax Assets, Net</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>31
<FILENAME>qlgn-20221231_pre.xml
<DESCRIPTION>INLINE XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.18a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://qualigeninc.com/role/Cover" xlink:href="qlgn-20221231.xsd#Cover" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigeninc.com/role/BalanceSheets" xlink:href="qlgn-20221231.xsd#BalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigeninc.com/role/BalanceSheetsParenthetical" xlink:href="qlgn-20221231.xsd#BalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigeninc.com/role/StatementsOfOperationsAndComprehensiveLoss" xlink:href="qlgn-20221231.xsd#StatementsOfOperationsAndComprehensiveLoss" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigeninc.com/role/StatementsOfChangesInStockholdersEquity" xlink:href="qlgn-20221231.xsd#StatementsOfChangesInStockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigeninc.com/role/StatementsOfCashFlows" xlink:href="qlgn-20221231.xsd#StatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigeninc.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesAndEstimates" xlink:href="qlgn-20221231.xsd#OrganizationAndSummaryOfSignificantAccountingPoliciesAndEstimates" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigeninc.com/role/LiquidityAndGoingConcern" xlink:href="qlgn-20221231.xsd#LiquidityAndGoingConcern" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigeninc.com/role/Acquisition" xlink:href="qlgn-20221231.xsd#Acquisition" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigeninc.com/role/InventoryNet" xlink:href="qlgn-20221231.xsd#InventoryNet" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigeninc.com/role/PrepaidExpensesAndOtherCurrentAssets" xlink:href="qlgn-20221231.xsd#PrepaidExpensesAndOtherCurrentAssets" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigeninc.com/role/PropertyAndEquipmentNet" xlink:href="qlgn-20221231.xsd#PropertyAndEquipmentNet" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigeninc.com/role/GoodwillIprdAndOtherIntangibles" xlink:href="qlgn-20221231.xsd#GoodwillIprdAndOtherIntangibles" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigeninc.com/role/AccruedExpensesAndOtherCurrentLiabilities" xlink:href="qlgn-20221231.xsd#AccruedExpensesAndOtherCurrentLiabilities" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigeninc.com/role/ShortTermDebt-RelatedParty" xlink:href="qlgn-20221231.xsd#ShortTermDebt-RelatedParty" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigeninc.com/role/WarrantLiabilities" xlink:href="qlgn-20221231.xsd#WarrantLiabilities" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigeninc.com/role/ConvertibleDebt-RelatedParty" xlink:href="qlgn-20221231.xsd#ConvertibleDebt-RelatedParty" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigeninc.com/role/EarningsLossPerShare" xlink:href="qlgn-20221231.xsd#EarningsLossPerShare" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigeninc.com/role/CommitmentsAndContingencies" xlink:href="qlgn-20221231.xsd#CommitmentsAndContingencies" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigeninc.com/role/ResearchAndLicenseAgreements" xlink:href="qlgn-20221231.xsd#ResearchAndLicenseAgreements" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigeninc.com/role/StockholdersEquity" xlink:href="qlgn-20221231.xsd#StockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigeninc.com/role/RelatedPartyTransactions" xlink:href="qlgn-20221231.xsd#RelatedPartyTransactions" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigeninc.com/role/IncomeTaxes" xlink:href="qlgn-20221231.xsd#IncomeTaxes" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigeninc.com/role/SubsequentEvents" xlink:href="qlgn-20221231.xsd#SubsequentEvents" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigeninc.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesAndEstimatesPolicies" xlink:href="qlgn-20221231.xsd#OrganizationAndSummaryOfSignificantAccountingPoliciesAndEstimatesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigeninc.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesAndEstimatesTables" xlink:href="qlgn-20221231.xsd#OrganizationAndSummaryOfSignificantAccountingPoliciesAndEstimatesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigeninc.com/role/AcquisitionTables" xlink:href="qlgn-20221231.xsd#AcquisitionTables" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigeninc.com/role/InventoryNetTables" xlink:href="qlgn-20221231.xsd#InventoryNetTables" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigeninc.com/role/PrepaidExpensesAndOtherCurrentAssetsTables" xlink:href="qlgn-20221231.xsd#PrepaidExpensesAndOtherCurrentAssetsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigeninc.com/role/PropertyAndEquipmentNetTables" xlink:href="qlgn-20221231.xsd#PropertyAndEquipmentNetTables" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigeninc.com/role/GoodwillIprdAndOtherIntangiblesTables" xlink:href="qlgn-20221231.xsd#GoodwillIprdAndOtherIntangiblesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigeninc.com/role/AccruedExpensesAndOtherCurrentLiabilitiesTables" xlink:href="qlgn-20221231.xsd#AccruedExpensesAndOtherCurrentLiabilitiesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigeninc.com/role/WarrantLiabilitiesTables" xlink:href="qlgn-20221231.xsd#WarrantLiabilitiesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigeninc.com/role/ConvertibleDebt-RelatedPartyTables" xlink:href="qlgn-20221231.xsd#ConvertibleDebt-RelatedPartyTables" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigeninc.com/role/EarningsLossPerShareTables" xlink:href="qlgn-20221231.xsd#EarningsLossPerShareTables" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigeninc.com/role/CommitmentsAndContingenciesTables" xlink:href="qlgn-20221231.xsd#CommitmentsAndContingenciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigeninc.com/role/StockholdersEquityTables" xlink:href="qlgn-20221231.xsd#StockholdersEquityTables" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigeninc.com/role/IncomeTaxesTables" xlink:href="qlgn-20221231.xsd#IncomeTaxesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigeninc.com/role/ScheduleOfAccountsReceivableDetails" xlink:href="qlgn-20221231.xsd#ScheduleOfAccountsReceivableDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigeninc.com/role/ScheduleOfUsefulLivesOfPropertyAndEquipmentDetails" xlink:href="qlgn-20221231.xsd#ScheduleOfUsefulLivesOfPropertyAndEquipmentDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigeninc.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesAndEstimatesDetailsNarrative" xlink:href="qlgn-20221231.xsd#OrganizationAndSummaryOfSignificantAccountingPoliciesAndEstimatesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigeninc.com/role/LiquidityAndGoingConcernDetailsNarrative" xlink:href="qlgn-20221231.xsd#LiquidityAndGoingConcernDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigeninc.com/role/ScheduleOfConsiderationTransferredDetails" xlink:href="qlgn-20221231.xsd#ScheduleOfConsiderationTransferredDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigeninc.com/role/ScheduleOfConsiderationTransferredDetailsParenthetical" xlink:href="qlgn-20221231.xsd#ScheduleOfConsiderationTransferredDetailsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigeninc.com/role/ScheduleOfAssetsAcquiredAndLiabilitiesDetails" xlink:href="qlgn-20221231.xsd#ScheduleOfAssetsAcquiredAndLiabilitiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigeninc.com/role/ScheduleOfProFormaInformationDetails" xlink:href="qlgn-20221231.xsd#ScheduleOfProFormaInformationDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigeninc.com/role/AcquisitionDetailsNarrative" xlink:href="qlgn-20221231.xsd#AcquisitionDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigeninc.com/role/ScheduleOfInventoryDetails" xlink:href="qlgn-20221231.xsd#ScheduleOfInventoryDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigeninc.com/role/ScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails" xlink:href="qlgn-20221231.xsd#ScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigeninc.com/role/ScheduleOfPropertyAndEquipmentDetails" xlink:href="qlgn-20221231.xsd#ScheduleOfPropertyAndEquipmentDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigeninc.com/role/PropertyAndEquipmentNetDetailsNarrative" xlink:href="qlgn-20221231.xsd#PropertyAndEquipmentNetDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigeninc.com/role/ScheduleOfGoodwillAndOtherIntangibleDetails" xlink:href="qlgn-20221231.xsd#ScheduleOfGoodwillAndOtherIntangibleDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigeninc.com/role/GoodwillIprdAndOtherIntangiblesDetailsNarrative" xlink:href="qlgn-20221231.xsd#GoodwillIprdAndOtherIntangiblesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigeninc.com/role/ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails" xlink:href="qlgn-20221231.xsd#ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigeninc.com/role/ShortTermDebt-RelatedPartyDetailsNarrative" xlink:href="qlgn-20221231.xsd#ShortTermDebt-RelatedPartyDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigeninc.com/role/ScheduleOfWarrantsActivityDetails" xlink:href="qlgn-20221231.xsd#ScheduleOfWarrantsActivityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigeninc.com/role/ScheduleOfFairValueHierarchyForWarrantLiabilitiesDetails" xlink:href="qlgn-20221231.xsd#ScheduleOfFairValueHierarchyForWarrantLiabilitiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigeninc.com/role/ScheduleOfAssumptionsOfWarrantLiabilitiesDetails" xlink:href="qlgn-20221231.xsd#ScheduleOfAssumptionsOfWarrantLiabilitiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigeninc.com/role/WarrantLiabilitiesDetailsNarrative" xlink:href="qlgn-20221231.xsd#WarrantLiabilitiesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigeninc.com/role/ScheduleOfSeniorSecuredConvertibleDebtDetails" xlink:href="qlgn-20221231.xsd#ScheduleOfSeniorSecuredConvertibleDebtDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigeninc.com/role/ConvertibleDebt-RelatedPartyDetailsNarrative" xlink:href="qlgn-20221231.xsd#ConvertibleDebt-RelatedPartyDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigeninc.com/role/ScheduleOfEarningsPerShareBasicAndDilutedDetails" xlink:href="qlgn-20221231.xsd#ScheduleOfEarningsPerShareBasicAndDilutedDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigeninc.com/role/ScheduleOfDilutiveSecuritiesExcludedFromDilutedNetLossPerShareDetails" xlink:href="qlgn-20221231.xsd#ScheduleOfDilutiveSecuritiesExcludedFromDilutedNetLossPerShareDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigeninc.com/role/ScheduleOfOperatingLeaseRightOfUseAssetsAndOperatingLeaseLiabilitiesDetails" xlink:href="qlgn-20221231.xsd#ScheduleOfOperatingLeaseRightOfUseAssetsAndOperatingLeaseLiabilitiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigeninc.com/role/ScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails" xlink:href="qlgn-20221231.xsd#ScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigeninc.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:href="qlgn-20221231.xsd#CommitmentsAndContingenciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigeninc.com/role/ResearchAndLicenseAgreementsDetailsNarrative" xlink:href="qlgn-20221231.xsd#ResearchAndLicenseAgreementsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigeninc.com/role/ScheduleOfReservedSharesDetails" xlink:href="qlgn-20221231.xsd#ScheduleOfReservedSharesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigeninc.com/role/ScheduleOfStockOptionActivityDetails" xlink:href="qlgn-20221231.xsd#ScheduleOfStockOptionActivityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigeninc.com/role/ScheduleOfAssumptionUsedInBlack-scholesOption-pricingMethodDetails" xlink:href="qlgn-20221231.xsd#ScheduleOfAssumptionUsedInBlack-scholesOption-pricingMethodDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigeninc.com/role/ScheduleOfShare-basedCompensationExpenseDetails" xlink:href="qlgn-20221231.xsd#ScheduleOfShare-basedCompensationExpenseDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigeninc.com/role/ScheduleOfWarrantActivityDetails" xlink:href="qlgn-20221231.xsd#ScheduleOfWarrantActivityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigeninc.com/role/StockholdersEquityDetailsNarrative" xlink:href="qlgn-20221231.xsd#StockholdersEquityDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigeninc.com/role/RelatedPartyTransactionsDetailsNarrative" xlink:href="qlgn-20221231.xsd#RelatedPartyTransactionsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigeninc.com/role/ScheduleOfDomesticAndForeignComponentsDetails" xlink:href="qlgn-20221231.xsd#ScheduleOfDomesticAndForeignComponentsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigeninc.com/role/ScheduleOfReconciliationsOfStatutoryIncomeTaxRateDetails" xlink:href="qlgn-20221231.xsd#ScheduleOfReconciliationsOfStatutoryIncomeTaxRateDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigeninc.com/role/ScheduleOfProvisionForIncomeTaxesDetails" xlink:href="qlgn-20221231.xsd#ScheduleOfProvisionForIncomeTaxesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigeninc.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:href="qlgn-20221231.xsd#ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigeninc.com/role/IncomeTaxesDetailsNarrative" xlink:href="qlgn-20221231.xsd#IncomeTaxesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigeninc.com/role/SubsequentEventsDetailsNarrative" xlink:href="qlgn-20221231.xsd#SubsequentEventsDetailsNarrative" xlink:type="simple" />
    <link:presentationLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="loc_deiIcfrAuditorAttestationFlag" />
      <link:presentationArc order="580" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiIcfrAuditorAttestationFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorFirmId" xlink:label="loc_deiAuditorFirmId" />
      <link:presentationArc order="590" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditorFirmId" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorName" xlink:label="loc_deiAuditorName" />
      <link:presentationArc order="600" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditorName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorLocation" xlink:label="loc_deiAuditorLocation" />
      <link:presentationArc order="610" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditorLocation" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/BalanceSheets" xlink:title="00000002 - Statement - Consolidated Balance Sheets">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaapStatementOfFinancialPositionAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaapAssetsAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapAssetsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaapAssetsCurrentAbstract" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapAssetsCurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Cash" xlink:label="loc_us-gaapCash" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapCash" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaapAccountsReceivableNetCurrent" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapAccountsReceivableNetCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaapInventoryNet" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapInventoryNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapAssetsCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalents" xlink:label="loc_us-gaapRestrictedCashAndCashEquivalents" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapRestrictedCashAndCashEquivalents" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaapIntangibleAssetsNetExcludingGoodwill" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapIntangibleAssetsNetExcludingGoodwill" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaapGoodwill" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapGoodwill" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaapOtherAssetsNoncurrent" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapOtherAssetsNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaapLiabilitiesCurrentAbstract" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilitiesCurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaapAccountsPayableCurrent" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapAccountsPayableCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_AccruedVacation" xlink:label="loc_QLGNAccruedVacation" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_QLGNAccruedVacation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:label="loc_us-gaapAccruedLiabilitiesAndOtherLiabilities" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapAccruedLiabilitiesAndOtherLiabilities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_ResearchAndDevelopmentGrantLiability" xlink:label="loc_QLGNResearchAndDevelopmentGrantLiability" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_QLGNResearchAndDevelopmentGrantLiability" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeCurrent" xlink:label="loc_us-gaapDeferredIncomeCurrent" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapDeferredIncomeCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityCurrent" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapOperatingLeaseLiabilityCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermBorrowings" xlink:label="loc_us-gaapShortTermBorrowings" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapShortTermBorrowings" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingLiabilitiesCurrent" xlink:label="loc_us-gaapHedgingLiabilitiesCurrent" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapHedgingLiabilitiesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_WarrantLiabilitiesRelatedParty" xlink:label="loc_QLGNWarrantLiabilitiesRelatedParty" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_QLGNWarrantLiabilitiesRelatedParty" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleDebt" xlink:label="loc_us-gaapConvertibleDebt" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapConvertibleDebt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapLiabilitiesCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityNoncurrent" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapOperatingLeaseLiabilityNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:label="loc_us-gaapDeferredRevenueNoncurrent" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapDeferredRevenueNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:label="loc_us-gaapDeferredIncomeTaxLiabilitiesNet" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapDeferredIncomeTaxLiabilitiesNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaapCommitmentsAndContingencies" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapCommitmentsAndContingencies" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:label="loc_us-gaapStockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapStockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaapStockholdersEquityAbstract" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapStockholdersEquityAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaapAdditionalPaidInCapital" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapAdditionalPaidInCapital" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossNetOfTax" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterest" xlink:label="loc_us-gaapMinorityInterest" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapMinorityInterest" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaapStockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapStockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/BalanceSheetsParenthetical" xlink:title="00000003 - Statement - Consolidated Balance Sheets (Parenthetical)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaapStatementOfFinancialPositionAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockSharesOutstanding" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/StatementsOfOperationsAndComprehensiveLoss" xlink:title="00000004 - Statement - Consolidated Statements of Operations and Comprehensive Loss">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaapIncomeStatementAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srtProductOrServiceAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtProductOrServiceAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srtProductsAndServicesDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtProductOrServiceAxis" xlink:to="loc_srtProductsAndServicesDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_NetProductSalesMember" xlink:label="loc_QLGNNetProductSalesMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_QLGNNetProductSalesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_LicenseRevenueMember" xlink:label="loc_QLGNLicenseRevenueMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_QLGNLicenseRevenueMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenuesAbstract" xlink:label="loc_us-gaapRevenuesAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapRevenuesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRevenuesAbstract" xlink:to="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingCostsAndExpensesAbstract" xlink:label="loc_us-gaapOperatingCostsAndExpensesAbstract" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOperatingCostsAndExpensesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_CostOfProductSales" xlink:label="loc_QLGNCostOfProductSales" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingCostsAndExpensesAbstract" xlink:to="loc_QLGNCostOfProductSales" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingCostsAndExpensesAbstract" xlink:to="loc_us-gaapGeneralAndAdministrativeExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingCostsAndExpensesAbstract" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketingAndAdvertisingExpense" xlink:label="loc_us-gaapMarketingAndAdvertisingExpense" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingCostsAndExpensesAbstract" xlink:to="loc_us-gaapMarketingAndAdvertisingExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillImpairmentLoss" xlink:label="loc_us-gaapGoodwillImpairmentLoss" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingCostsAndExpensesAbstract" xlink:to="loc_us-gaapGoodwillImpairmentLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaapOperatingExpenses" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingCostsAndExpensesAbstract" xlink:to="loc_us-gaapOperatingExpenses" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOperatingIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaapNonoperatingIncomeExpenseAbstract" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeGainLossOnDerivativeNet" xlink:label="loc_us-gaapDerivativeGainLossOnDerivativeNet" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapDerivativeGainLossOnDerivativeNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestIncomeExpenseNet" xlink:label="loc_us-gaapInterestIncomeExpenseNet" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapInterestIncomeExpenseNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaapOtherNonoperatingIncomeExpense" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapOtherNonoperatingIncomeExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaapNonoperatingIncomeExpense" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapNonoperatingIncomeExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaapIncomeTaxExpenseBenefit" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapIncomeTaxExpenseBenefit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaapProfitLoss" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapProfitLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="loc_us-gaapNetIncomeLossAttributableToNoncontrollingInterest" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLossAttributableToNoncontrollingInterest" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaapEarningsPerShareBasic" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapEarningsPerShareBasic" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:label="loc_us-gaapOtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="loc_us-gaapOtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="loc_us-gaapOtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaapComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="loc_us-gaapComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:label="loc_us-gaapComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="loc_us-gaapComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaapComprehensiveIncomeNetOfTax" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="loc_us-gaapComprehensiveIncomeNetOfTax" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/StatementsOfChangesInStockholdersEquity" xlink:title="00000005 - Statement - Consolidated Statements of Changes in Stockholders&apos; Equity">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaapStatementOfStockholdersEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfStockholdersEquityAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="80" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockMember" xlink:label="loc_us-gaapPreferredStockMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaapAdditionalPaidInCapitalMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapAdditionalPaidInCapitalMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaapRetainedEarningsMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapRetainedEarningsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ParentMember" xlink:label="loc_us-gaapParentMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapParentMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncontrollingInterestMember" xlink:label="loc_us-gaapNoncontrollingInterestMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapNoncontrollingInterestMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="80" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_SeriesAlphaConvertiblePreferredStockMember" xlink:label="loc_QLGNSeriesAlphaConvertiblePreferredStockMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_QLGNSeriesAlphaConvertiblePreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaapStockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_StockIssuedUponCashExerciseOfWarrants" xlink:label="loc_QLGNStockIssuedUponCashExerciseOfWarrants" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_QLGNStockIssuedUponCashExerciseOfWarrants" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_StockIssuedUponCashExerciseOfWarrantsShares" xlink:label="loc_QLGNStockIssuedUponCashExerciseOfWarrantsShares" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_QLGNStockIssuedUponCashExerciseOfWarrantsShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_CommonStockAndPrefundedWarrantsIssuedForBusinessAcquisition" xlink:label="loc_QLGNCommonStockAndPrefundedWarrantsIssuedForBusinessAcquisition" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_QLGNCommonStockAndPrefundedWarrantsIssuedForBusinessAcquisition" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_CommonStockAndPrefundedWarrantsIssuedSharesForBusinessAcquisition" xlink:label="loc_QLGNCommonStockAndPrefundedWarrantsIssuedSharesForBusinessAcquisition" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_QLGNCommonStockAndPrefundedWarrantsIssuedSharesForBusinessAcquisition" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_NoncontrollingInterestAdjustmentsRelatingToStockbasedCompensationAndOther" xlink:label="loc_QLGNNoncontrollingInterestAdjustmentsRelatingToStockbasedCompensationAndOther" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_QLGNNoncontrollingInterestAdjustmentsRelatingToStockbasedCompensationAndOther" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="loc_us-gaapOtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_FairValueOfWarrantModificationForProfessionalServices" xlink:label="loc_QLGNFairValueOfWarrantModificationForProfessionalServices" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_QLGNFairValueOfWarrantModificationForProfessionalServices" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_FairValueOfWarrantModificationForBusinessAcquisition" xlink:label="loc_QLGNFairValueOfWarrantModificationForBusinessAcquisition" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_QLGNFairValueOfWarrantModificationForBusinessAcquisition" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_StockIssuedDuringPeriodValuesReverseStockSplits" xlink:label="loc_QLGNStockIssuedDuringPeriodValuesReverseStockSplits" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_QLGNStockIssuedDuringPeriodValuesReverseStockSplits" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesReverseStockSplits" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesReverseStockSplits" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaapProfitLoss" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapProfitLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_StockIssuedUponNetexerciseOfWarrants" xlink:label="loc_QLGNStockIssuedUponNetexerciseOfWarrants" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_QLGNStockIssuedUponNetexerciseOfWarrants" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_StockIssuedUponNetexerciseOfWarrantsShares" xlink:label="loc_QLGNStockIssuedUponNetexerciseOfWarrantsShares" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_QLGNStockIssuedUponNetexerciseOfWarrantsShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_IssuanceOfCommonStockForConversionOfPreferredStock" xlink:label="loc_QLGNIssuanceOfCommonStockForConversionOfPreferredStock" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_QLGNIssuanceOfCommonStockForConversionOfPreferredStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_IssuanceOfCommonStockSharesForConversionOfPreferredStock" xlink:label="loc_QLGNIssuanceOfCommonStockSharesForConversionOfPreferredStock" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_QLGNIssuanceOfCommonStockSharesForConversionOfPreferredStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_FairValueOfWarrantsIssuedForProfessionalServices" xlink:label="loc_QLGNFairValueOfWarrantsIssuedForProfessionalServices" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_QLGNFairValueOfWarrantsIssuedForProfessionalServices" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_SharesIssuedPursuantToSecuritiesPurchaseAgreements" xlink:label="loc_QLGNSharesIssuedPursuantToSecuritiesPurchaseAgreements" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_QLGNSharesIssuedPursuantToSecuritiesPurchaseAgreements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_SharesIssuedPursuantToSecuritiesPurchaseShareAgreements" xlink:label="loc_QLGNSharesIssuedPursuantToSecuritiesPurchaseShareAgreements" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_QLGNSharesIssuedPursuantToSecuritiesPurchaseShareAgreements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_CommissionAndOfferingCostsOfSecuritiesPurchaseAgreements" xlink:label="loc_QLGNCommissionAndOfferingCostsOfSecuritiesPurchaseAgreements" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_QLGNCommissionAndOfferingCostsOfSecuritiesPurchaseAgreements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_FairValueOfWarrantModificationsPursuantToSecuritiesPurchaseAgreements" xlink:label="loc_QLGNFairValueOfWarrantModificationsPursuantToSecuritiesPurchaseAgreements" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_QLGNFairValueOfWarrantModificationsPursuantToSecuritiesPurchaseAgreements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueIssuedForServices" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueIssuedForServices" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesIssuedForServices" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesIssuedForServices" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaapStockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_2" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding_2" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/StatementsOfCashFlows" xlink:title="00000006 - Statement - Consolidated Statements of Cash Flows">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaapStatementOfCashFlowsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaapProfitLoss" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapProfitLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaapDepreciationDepletionAndAmortization" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapDepreciationDepletionAndAmortization" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAssetAmortizationExpense" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAssetAmortizationExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProvisionForDoubtfulAccounts" xlink:label="loc_us-gaapProvisionForDoubtfulAccounts" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapProvisionForDoubtfulAccounts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryWriteDown" xlink:label="loc_us-gaapInventoryWriteDown" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapInventoryWriteDown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:label="loc_us-gaapIssuanceOfStockAndWarrantsForServicesOrClaims" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapIssuanceOfStockAndWarrantsForServicesOrClaims" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_FairValueOfWarrantsIssuedForProfessionalServices" xlink:label="loc_QLGNFairValueOfWarrantsIssuedForProfessionalServices" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_QLGNFairValueOfWarrantsIssuedForProfessionalServices" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_FairValueOfWarrantModificationForProfessionalServices" xlink:label="loc_QLGNFairValueOfWarrantModificationForProfessionalServices" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_QLGNFairValueOfWarrantModificationForProfessionalServices" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillImpairmentLoss" xlink:label="loc_us-gaapGoodwillImpairmentLoss" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapGoodwillImpairmentLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaapFairValueAdjustmentOfWarrants" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapFairValueAdjustmentOfWarrants" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsReceivable" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsReceivable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_IncreaseDecreaseInInventoryAndEquipmentHeldForLeases" xlink:label="loc_QLGNIncreaseDecreaseInInventoryAndEquipmentHeldForLeases" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_QLGNIncreaseDecreaseInInventoryAndEquipmentHeldForLeases" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaapIncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsPayable" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsPayable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_IncreaseDecreaseInResearchAndDevelopmentGrantLiability" xlink:label="loc_QLGNIncreaseDecreaseInResearchAndDevelopmentGrantLiability" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_QLGNIncreaseDecreaseInResearchAndDevelopmentGrantLiability" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="loc_us-gaapIncreaseDecreaseInOperatingLeaseLiability" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOperatingLeaseLiability" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="loc_us-gaapIncreaseDecreaseInContractWithCustomerLiability" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInContractWithCustomerLiability" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInDeferredLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInDeferredLiabilities" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInDeferredLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_PurchasesOfEquipmentHeldForLease" xlink:label="loc_QLGNPurchasesOfEquipmentHeldForLease" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_QLGNPurchasesOfEquipmentHeldForLease" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="loc_us-gaapPaymentsToAcquireIntangibleAssets" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_us-gaapPaymentsToAcquireIntangibleAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAcquiredFromAcquisition" xlink:label="loc_us-gaapCashAcquiredFromAcquisition" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_us-gaapCashAcquiredFromAcquisition" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaapProceedsFromWarrantExercises" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromWarrantExercises" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_ProceedsFromIssuanceOfSharesAndWarrantsPursuantToSecuritiesPurchaseAgreements" xlink:label="loc_QLGNProceedsFromIssuanceOfSharesAndWarrantsPursuantToSecuritiesPurchaseAgreements" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_QLGNProceedsFromIssuanceOfSharesAndWarrantsPursuantToSecuritiesPurchaseAgreements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_ProceedsFromIssuanceOfConvertibleDebt" xlink:label="loc_QLGNProceedsFromIssuanceOfConvertibleDebt" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_QLGNProceedsFromIssuanceOfConvertibleDebt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaapPaymentsOfStockIssuanceCosts" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapPaymentsOfStockIssuanceCosts" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfNotesPayable" xlink:label="loc_us-gaapRepaymentsOfNotesPayable" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapRepaymentsOfNotesPayable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_FractionalSharePaymentsRelatedToReverseStockSplit" xlink:label="loc_QLGNFractionalSharePaymentsRelatedToReverseStockSplit" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_QLGNFractionalSharePaymentsRelatedToReverseStockSplit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="loc_us-gaapEffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapEffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_2" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaapSupplementalCashFlowInformationAbstract" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_CashPaidForAbstract" xlink:label="loc_QLGNCashPaidForAbstract" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_QLGNCashPaidForAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPaidNet" xlink:label="loc_us-gaapInterestPaidNet" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_QLGNCashPaidForAbstract" xlink:to="loc_us-gaapInterestPaidNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxesPaidNet" xlink:label="loc_us-gaapIncomeTaxesPaidNet" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_QLGNCashPaidForAbstract" xlink:to="loc_us-gaapIncomeTaxesPaidNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="loc_us-gaapCashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_IssuanceOfCommonStockForConversionOfPreferredStockBeforeClosingOfReverseRecapitalization" xlink:label="loc_QLGNIssuanceOfCommonStockForConversionOfPreferredStockBeforeClosingOfReverseRecapitalization" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="loc_QLGNIssuanceOfCommonStockForConversionOfPreferredStockBeforeClosingOfReverseRecapitalization" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_RightofuseAssetsObtainedInExchangeForOperatingLeaseLiabilities" xlink:label="loc_QLGNRightofuseAssetsObtainedInExchangeForOperatingLeaseLiabilities" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="loc_QLGNRightofuseAssetsObtainedInExchangeForOperatingLeaseLiabilities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_SharesIssuedForCashlessWarrantsAmount" xlink:label="loc_QLGNSharesIssuedForCashlessWarrantsAmount" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="loc_QLGNSharesIssuedForCashlessWarrantsAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_TransfersOfInventoryFromEquipmentHeldForLease" xlink:label="loc_QLGNTransfersOfInventoryFromEquipmentHeldForLease" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="loc_QLGNTransfersOfInventoryFromEquipmentHeldForLease" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_FairValueOfWarrantModificationsPursuantToSecuritiesPurchaseAgreements" xlink:label="loc_QLGNFairValueOfWarrantModificationsPursuantToSecuritiesPurchaseAgreements" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="loc_QLGNFairValueOfWarrantModificationsPursuantToSecuritiesPurchaseAgreements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_FairValueOfWarrantLiabilitiesOnDateOfExercise" xlink:label="loc_QLGNFairValueOfWarrantLiabilitiesOnDateOfExercise" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="loc_QLGNFairValueOfWarrantLiabilitiesOnDateOfExercise" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_FairValueOfWarrantModificationsForBusinessAcquisition" xlink:label="loc_QLGNFairValueOfWarrantModificationsForBusinessAcquisition" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="loc_QLGNFairValueOfWarrantModificationsForBusinessAcquisition" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueOfAssetsAcquired" xlink:label="loc_us-gaapFairValueOfAssetsAcquired" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" xlink:to="loc_us-gaapFairValueOfAssetsAcquired" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAssumed1" xlink:label="loc_us-gaapLiabilitiesAssumed1" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" xlink:to="loc_us-gaapLiabilitiesAssumed1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_FairValueOfWarrantsRepricedDueToAcquisition" xlink:label="loc_QLGNFairValueOfWarrantsRepricedDueToAcquisition" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" xlink:to="loc_QLGNFairValueOfWarrantsRepricedDueToAcquisition" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_FairValueOfQualigenPrefundedWarrantIssuedInExchangeForNanosynexStock" xlink:label="loc_QLGNFairValueOfQualigenPrefundedWarrantIssuedInExchangeForNanosynexStock" />
      <link:presentationArc order="580" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" xlink:to="loc_QLGNFairValueOfQualigenPrefundedWarrantIssuedInExchangeForNanosynexStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssued1" xlink:label="loc_us-gaapStockIssued1" />
      <link:presentationArc order="590" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" xlink:to="loc_us-gaapStockIssued1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationConsiderationTransferred1" xlink:label="loc_us-gaapBusinessCombinationConsiderationTransferred1" />
      <link:presentationArc order="600" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" xlink:to="loc_us-gaapBusinessCombinationConsiderationTransferred1" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesAndEstimates" xlink:title="00000007 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND ESTIMATES">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/LiquidityAndGoingConcern" xlink:title="00000008 - Disclosure - LIQUIDITY AND GOING CONCERN">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" xlink:label="loc_us-gaapSubstantialDoubtAboutGoingConcernTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapSubstantialDoubtAboutGoingConcernTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/Acquisition" xlink:title="00000009 - Disclosure - ACQUISITION">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:label="loc_us-gaapBusinessCombinationAndAssetAcquisitionAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationDisclosureTextBlock" xlink:label="loc_us-gaapBusinessCombinationDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessCombinationAndAssetAcquisitionAbstract" xlink:to="loc_us-gaapBusinessCombinationDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/InventoryNet" xlink:title="00000010 - Disclosure - INVENTORY, NET">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaapInventoryDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureTextBlock" xlink:label="loc_us-gaapInventoryDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInventoryDisclosureAbstract" xlink:to="loc_us-gaapInventoryDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/PrepaidExpensesAndOtherCurrentAssets" xlink:title="00000011 - Disclosure - PREPAID EXPENSES AND OTHER CURRENT ASSETS">
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_DisclosurePrepaidExpensesAndOtherCurrentAssetsAbstract" xlink:label="loc_QLGNDisclosurePrepaidExpensesAndOtherCurrentAssetsAbstract" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_PrepaidExpensesAndOtherCurrentAssetsTextBlock" xlink:label="loc_QLGNPrepaidExpensesAndOtherCurrentAssetsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_QLGNDisclosurePrepaidExpensesAndOtherCurrentAssetsAbstract" xlink:to="loc_QLGNPrepaidExpensesAndOtherCurrentAssetsTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/PropertyAndEquipmentNet" xlink:title="00000012 - Disclosure - PROPERTY AND EQUIPMENT, NET">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaapPropertyPlantAndEquipmentAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="loc_us-gaapPropertyPlantAndEquipmentDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/GoodwillIprdAndOtherIntangibles" xlink:title="00000013 - Disclosure - GOODWILL, IPR&amp;D AND OTHER INTANGIBLES">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:label="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/AccruedExpensesAndOtherCurrentLiabilities" xlink:title="00000014 - Disclosure - ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaapPayablesAndAccrualsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:label="loc_us-gaapAccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapAccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/ShortTermDebt-RelatedParty" xlink:title="00000015 - Disclosure - SHORT TERM DEBT - RELATED PARTY">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaapDebtDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtTextBlock" xlink:label="loc_us-gaapShortTermDebtTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapShortTermDebtTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/WarrantLiabilities" xlink:title="00000016 - Disclosure - WARRANT LIABILITIES">
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_DisclosureWarrantLiabilitiesAbstract" xlink:label="loc_QLGNDisclosureWarrantLiabilitiesAbstract" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_WarrantLiabilitiesTextBlock" xlink:label="loc_QLGNWarrantLiabilitiesTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_QLGNDisclosureWarrantLiabilitiesAbstract" xlink:to="loc_QLGNWarrantLiabilitiesTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/ConvertibleDebt-RelatedParty" xlink:title="00000017 - Disclosure - CONVERTIBLE DEBT - RELATED PARTY">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaapDebtDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="loc_us-gaapDebtDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapDebtDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/EarningsLossPerShare" xlink:title="00000018 - Disclosure - EARNINGS (LOSS) PER SHARE">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaapEarningsPerShareAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="loc_us-gaapEarningsPerShareTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareAbstract" xlink:to="loc_us-gaapEarningsPerShareTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/CommitmentsAndContingencies" xlink:title="00000019 - Disclosure - COMMITMENTS AND CONTINGENCIES">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapCommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/ResearchAndLicenseAgreements" xlink:title="00000020 - Disclosure - RESEARCH AND LICENSE AGREEMENTS">
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_DisclosureResearchAndLicenseAgreementsAbstract" xlink:label="loc_QLGNDisclosureResearchAndLicenseAgreementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_ResearchAndLicenseAgreementsTextBlock" xlink:label="loc_QLGNResearchAndLicenseAgreementsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_QLGNDisclosureResearchAndLicenseAgreementsAbstract" xlink:to="loc_QLGNResearchAndLicenseAgreementsTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/StockholdersEquity" xlink:title="00000021 - Disclosure - STOCKHOLDERS&#8217; EQUITY">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaapStockholdersEquityNoteDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapStockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/RelatedPartyTransactions" xlink:title="00000022 - Disclosure - RELATED PARTY TRANSACTIONS">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaapRelatedPartyTransactionsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="loc_us-gaapRelatedPartyTransactionsDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsAbstract" xlink:to="loc_us-gaapRelatedPartyTransactionsDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/IncomeTaxes" xlink:title="00000023 - Disclosure - INCOME TAXES">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaapIncomeTaxDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeTaxDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/SubsequentEvents" xlink:title="00000024 - Disclosure - SUBSEQUENT EVENTS">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaapSubsequentEventsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaapSubsequentEventsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventsAbstract" xlink:to="loc_us-gaapSubsequentEventsTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesAndEstimatesPolicies" xlink:title="00000025 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND ESTIMATES (Policies)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_OrganizationPolicyTextBlock" xlink:label="loc_QLGNOrganizationPolicyTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_QLGNOrganizationPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="loc_us-gaapBasisOfAccountingPolicyPolicyTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapBasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="loc_us-gaapConsolidationPolicyTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapConsolidationPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaapUseOfEstimates" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapUseOfEstimates" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="loc_us-gaapStockholdersEquityReverseStockSplit" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapStockholdersEquityReverseStockSplit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="loc_us-gaapCashAndCashEquivalentsPolicyTextBlock" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsPolicyTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryPolicyTextBlock" xlink:label="loc_us-gaapInventoryPolicyTextBlock" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapInventoryPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="loc_us-gaapImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="loc_us-gaapSegmentReportingPolicyPolicyTextBlock" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapSegmentReportingPolicyPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:label="loc_us-gaapTradeAndOtherAccountsReceivablePolicy" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapTradeAndOtherAccountsReceivablePolicy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="loc_us-gaapResearchAndDevelopmentExpensePolicy" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapResearchAndDevelopmentExpensePolicy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_ResearchAndDevelopmentGrantsPolicyTextBlock" xlink:label="loc_QLGNResearchAndDevelopmentGrantsPolicyTextBlock" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_QLGNResearchAndDevelopmentGrantsPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_PatentCostsPolicyTextBlock" xlink:label="loc_QLGNPatentCostsPolicyTextBlock" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_QLGNPatentCostsPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_ShippingAndHandlingCostsPolicyTextBlock" xlink:label="loc_QLGNShippingAndHandlingCostsPolicyTextBlock" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_QLGNShippingAndHandlingCostsPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="loc_us-gaapRevenueRecognitionPolicyTextBlock" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapRevenueRecognitionPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_DeferredRevenuePolicyTextBlock" xlink:label="loc_QLGNDeferredRevenuePolicyTextBlock" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_QLGNDeferredRevenuePolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="loc_us-gaapLesseeLeasesPolicyTextBlock" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapLesseeLeasesPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="loc_us-gaapPropertyPlantAndEquipmentPolicyTextBlock" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationsPolicy" xlink:label="loc_us-gaapBusinessCombinationsPolicy" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapBusinessCombinationsPolicy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:label="loc_us-gaapGoodwillAndIntangibleAssetsPolicyTextBlock" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapGoodwillAndIntangibleAssetsPolicyTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:label="loc_us-gaapIntangibleAssetsFiniteLivedPolicy" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapIntangibleAssetsFiniteLivedPolicy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_DerivativeFinancialInstrumentsAndWarrantLiabilitiesPolicyTextBlock" xlink:label="loc_QLGNDerivativeFinancialInstrumentsAndWarrantLiabilitiesPolicyTextBlock" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_QLGNDerivativeFinancialInstrumentsAndWarrantLiabilitiesPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="loc_us-gaapFairValueOfFinancialInstrumentsPolicy" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapFairValueOfFinancialInstrumentsPolicy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdvertisingCostsPolicyTextBlock" xlink:label="loc_us-gaapAdvertisingCostsPolicyTextBlock" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapAdvertisingCostsPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="loc_us-gaapComprehensiveIncomePolicyPolicyTextBlock" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapComprehensiveIncomePolicyPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:label="loc_us-gaapCompensationRelatedCostsPolicyTextBlock" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapCompensationRelatedCostsPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="loc_us-gaapIncomeTaxPolicyTextBlock" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapIncomeTaxPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_SalesAndExciseTaxesPolicyTextBlock" xlink:label="loc_QLGNSalesAndExciseTaxesPolicyTextBlock" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_QLGNSalesAndExciseTaxesPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_WarrantyReservePolicyTextBlock" xlink:label="loc_QLGNWarrantyReservePolicyTextBlock" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_QLGNWarrantyReservePolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:label="loc_us-gaapForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaapNewAccountingPronouncementsPolicyPolicyTextBlock" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapNewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_GlobalEconomicConditionsPolicyTextBlock" xlink:label="loc_QLGNGlobalEconomicConditionsPolicyTextBlock" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_QLGNGlobalEconomicConditionsPolicyTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesAndEstimatesTables" xlink:title="00000026 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND ESTIMATES (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:label="loc_us-gaapScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_ScheduleOfUsefulLivesOfPropertyAndEquipmentTableTextBlock" xlink:label="loc_QLGNScheduleOfUsefulLivesOfPropertyAndEquipmentTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_QLGNScheduleOfUsefulLivesOfPropertyAndEquipmentTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/AcquisitionTables" xlink:title="00000027 - Disclosure - ACQUISITION (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:label="loc_us-gaapBusinessCombinationAndAssetAcquisitionAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" xlink:label="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessCombinationAndAssetAcquisitionAbstract" xlink:to="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:label="loc_us-gaapScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessCombinationAndAssetAcquisitionAbstract" xlink:to="loc_us-gaapScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionProFormaInformationTextBlock" xlink:label="loc_us-gaapBusinessAcquisitionProFormaInformationTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessCombinationAndAssetAcquisitionAbstract" xlink:to="loc_us-gaapBusinessAcquisitionProFormaInformationTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/InventoryNetTables" xlink:title="00000028 - Disclosure - INVENTORY, NET (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaapInventoryDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:label="loc_us-gaapScheduleOfInventoryCurrentTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInventoryDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfInventoryCurrentTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/PrepaidExpensesAndOtherCurrentAssetsTables" xlink:title="00000029 - Disclosure - PREPAID EXPENSES AND OTHER CURRENT ASSETS (Tables)">
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_DisclosurePrepaidExpensesAndOtherCurrentAssetsAbstract" xlink:label="loc_QLGNDisclosurePrepaidExpensesAndOtherCurrentAssetsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:label="loc_us-gaapDeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_QLGNDisclosurePrepaidExpensesAndOtherCurrentAssetsAbstract" xlink:to="loc_us-gaapDeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/PropertyAndEquipmentNetTables" xlink:title="00000030 - Disclosure - PROPERTY AND EQUIPMENT, NET (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaapPropertyPlantAndEquipmentAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/GoodwillIprdAndOtherIntangiblesTables" xlink:title="00000031 - Disclosure - GOODWILL, IPR&amp;D AND OTHER INTANGIBLES (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:label="loc_us-gaapScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/AccruedExpensesAndOtherCurrentLiabilitiesTables" xlink:title="00000032 - Disclosure - ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaapPayablesAndAccrualsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:label="loc_us-gaapScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/WarrantLiabilitiesTables" xlink:title="00000033 - Disclosure - WARRANT LIABILITIES (Tables)">
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_DisclosureWarrantLiabilitiesAbstract" xlink:label="loc_QLGNDisclosureWarrantLiabilitiesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="loc_us-gaapScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_QLGNDisclosureWarrantLiabilitiesAbstract" xlink:to="loc_us-gaapScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_ScheduleOfFairValueHierarchyForWarrantLiabilitiesTableTextBlock" xlink:label="loc_QLGNScheduleOfFairValueHierarchyForWarrantLiabilitiesTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_QLGNDisclosureWarrantLiabilitiesAbstract" xlink:to="loc_QLGNScheduleOfFairValueHierarchyForWarrantLiabilitiesTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_ScheduleOfAssumptionsOfWarrantLiabilitiesTableTextBlock" xlink:label="loc_QLGNScheduleOfAssumptionsOfWarrantLiabilitiesTableTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_QLGNDisclosureWarrantLiabilitiesAbstract" xlink:to="loc_QLGNScheduleOfAssumptionsOfWarrantLiabilitiesTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/ConvertibleDebt-RelatedPartyTables" xlink:title="00000034 - Disclosure - CONVERTIBLE DEBT - RELATED PARTY (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaapDebtDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleDebtTableTextBlock" xlink:label="loc_us-gaapConvertibleDebtTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapConvertibleDebtTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/EarningsLossPerShareTables" xlink:title="00000035 - Disclosure - EARNINGS (LOSS) PER SHARE (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaapEarningsPerShareAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="loc_us-gaapScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareAbstract" xlink:to="loc_us-gaapScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareAbstract" xlink:to="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/CommitmentsAndContingenciesTables" xlink:title="00000036 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_ScheduleOfOperatingLeaseRightOfUseAssetsAndLiabilitiesTableTextBlock" xlink:label="loc_QLGNScheduleOfOperatingLeaseRightOfUseAssetsAndLiabilitiesTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_QLGNScheduleOfOperatingLeaseRightOfUseAssetsAndLiabilitiesTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityMaturityTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/StockholdersEquityTables" xlink:title="00000037 - Disclosure - STOCKHOLDERS&#8217; EQUITY (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_CompensatoryWarrantActivityMember" xlink:label="loc_QLGNCompensatoryWarrantActivityMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_QLGNCompensatoryWarrantActivityMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_NonCompensatoryWarrantActivityMember" xlink:label="loc_QLGNNonCompensatoryWarrantActivityMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_QLGNNonCompensatoryWarrantActivityMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_ScheduleOfReservedSharesTableTextBlock" xlink:label="loc_QLGNScheduleOfReservedSharesTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_QLGNScheduleOfReservedSharesTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:label="loc_us-gaapScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_SummaryOfWarrantActivityTableTextBlock" xlink:label="loc_QLGNSummaryOfWarrantActivityTableTextBlock" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_QLGNSummaryOfWarrantActivityTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/IncomeTaxesTables" xlink:title="00000038 - Disclosure - INCOME TAXES (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:label="loc_us-gaapScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="loc_us-gaapScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="loc_us-gaapScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="loc_us-gaapScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/ScheduleOfAccountsReceivableDetails" xlink:title="00000039 - Disclosure - SCHEDULE OF ACCOUNTS RECEIVABLE (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableGrossCurrent" xlink:label="loc_us-gaapAccountsReceivableGrossCurrent" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapAccountsReceivableGrossCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:label="loc_us-gaapAllowanceForDoubtfulAccountsReceivableCurrent" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapAllowanceForDoubtfulAccountsReceivableCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaapAccountsReceivableNetCurrent" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapAccountsReceivableNetCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/ScheduleOfUsefulLivesOfPropertyAndEquipmentDetails" xlink:title="00000040 - Disclosure - SCHEDULE OF USEFUL LIVES OF PROPERTY AND EQUIPMENT (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaapPropertyPlantAndEquipmentLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MachineryAndEquipmentMember" xlink:label="loc_us-gaapMachineryAndEquipmentMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapMachineryAndEquipmentMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComputerEquipmentMember" xlink:label="loc_us-gaapComputerEquipmentMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapComputerEquipmentMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_MoldsAndToolingMember" xlink:label="loc_QLGNMoldsAndToolingMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_QLGNMoldsAndToolingMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaapFurnitureAndFixturesMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapFurnitureAndFixturesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaapPropertyPlantAndEquipmentUsefulLife" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentUsefulLife" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesAndEstimatesDetailsNarrative" xlink:title="00000041 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND ESTIMATES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaapBusinessAcquisitionAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapBusinessAcquisitionAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaapBusinessAcquisitionAcquireeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionAxis" xlink:to="loc_us-gaapBusinessAcquisitionAcquireeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_NanoSynexLtdMember" xlink:label="loc_QLGNNanoSynexLtdMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionAcquireeDomain" xlink:to="loc_QLGNNanoSynexLtdMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_SeriesAOnePreferredStockMember" xlink:label="loc_QLGNSeriesAOnePreferredStockMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_QLGNSeriesAOnePreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="loc_us-gaapSeriesBPreferredStockMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesBPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_PrefundedWarrantMember" xlink:label="loc_QLGNPrefundedWarrantMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_QLGNPrefundedWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srtProductOrServiceAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtProductOrServiceAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srtProductsAndServicesDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtProductOrServiceAxis" xlink:to="loc_srtProductsAndServicesDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShippingAndHandlingMember" xlink:label="loc_us-gaapShippingAndHandlingMember" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_us-gaapShippingAndHandlingMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_LicenseRevenuesMember" xlink:label="loc_QLGNLicenseRevenuesMember" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_QLGNLicenseRevenuesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaapIncomeStatementLocationAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapIncomeStatementLocationAxis" order="50" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_GeneralAdministrativeResearchAndDevelopmentExpensesMember" xlink:label="loc_QLGNGeneralAdministrativeResearchAndDevelopmentExpensesMember" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_QLGNGeneralAdministrativeResearchAndDevelopmentExpensesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtRangeAxis" order="60" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" order="70" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_PatentsAndLicensesMember" xlink:label="loc_QLGNPatentsAndLicensesMember" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_QLGNPatentsAndLicensesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesAcquisitions" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesAcquisitions" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="loc_us-gaapStockholdersEquityReverseStockSplit" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquityReverseStockSplit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueAcquisitions" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueAcquisitions" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:label="loc_us-gaapBusinessAcquisitionPercentageOfVotingInterestsAcquired" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapBusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetImpairmentCharges" xlink:label="loc_us-gaapAssetImpairmentCharges" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAssetImpairmentCharges" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="loc_us-gaapCostOfGoodsAndServicesSold" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCostOfGoodsAndServicesSold" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_AllowancesForSalesReturn" xlink:label="loc_QLGNAllowancesForSalesReturn" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_QLGNAllowancesForSalesReturn" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillImpairmentLoss" xlink:label="loc_us-gaapGoodwillImpairmentLoss" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapGoodwillImpairmentLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetUsefulLife" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetUsefulLife" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdvertisingExpense" xlink:label="loc_us-gaapAdvertisingExpense" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdvertisingExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductWarrantyAccrual" xlink:label="loc_us-gaapProductWarrantyAccrual" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapProductWarrantyAccrual" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductWarrantyExpense" xlink:label="loc_us-gaapProductWarrantyExpense" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapProductWarrantyExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="loc_us-gaapOtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/LiquidityAndGoingConcernDetailsNarrative" xlink:title="00000042 - Disclosure - LIQUIDITY AND GOING CONCERN (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:label="loc_us-gaapScheduleOfRestructuringAndRelatedCostsTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapScheduleOfRestructuringAndRelatedCostsTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostAndReserveLineItems" xlink:label="loc_us-gaapRestructuringCostAndReserveLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfRestructuringAndRelatedCostsTable" xlink:to="loc_us-gaapRestructuringCostAndReserveLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaapBusinessAcquisitionAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfRestructuringAndRelatedCostsTable" xlink:to="loc_us-gaapBusinessAcquisitionAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaapBusinessAcquisitionAcquireeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionAxis" xlink:to="loc_us-gaapBusinessAcquisitionAcquireeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_NanoSynexLtdMember" xlink:label="loc_QLGNNanoSynexLtdMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionAcquireeDomain" xlink:to="loc_QLGNNanoSynexLtdMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Cash" xlink:label="loc_us-gaapCash" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRestructuringCostAndReserveLineItems" xlink:to="loc_us-gaapCash" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRestructuringCostAndReserveLineItems" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRestructuringCostAndReserveLineItems" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRestructuringCostAndReserveLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="loc_us-gaapProceedsFromConvertibleDebt" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRestructuringCostAndReserveLineItems" xlink:to="loc_us-gaapProceedsFromConvertibleDebt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueAcquisitions" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRestructuringCostAndReserveLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueAcquisitions" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteStockSplit" xlink:label="loc_us-gaapStockholdersEquityNoteStockSplit" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRestructuringCostAndReserveLineItems" xlink:to="loc_us-gaapStockholdersEquityNoteStockSplit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRestructuringCostAndReserveLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/ScheduleOfConsiderationTransferredDetails" xlink:title="00000043 - Disclosure - SCHEDULE OF CONSIDERATION TRANSFERRED (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:label="loc_us-gaapBusinessCombinationAndAssetAcquisitionAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessCombinationAndAssetAcquisitionAbstract" xlink:to="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaapBusinessAcquisitionLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="loc_us-gaapBusinessAcquisitionLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaapBusinessAcquisitionAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="loc_us-gaapBusinessAcquisitionAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaapBusinessAcquisitionAcquireeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionAxis" xlink:to="loc_us-gaapBusinessAcquisitionAcquireeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_NanoSynexLtdMember" xlink:label="loc_QLGNNanoSynexLtdMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionAcquireeDomain" xlink:to="loc_QLGNNanoSynexLtdMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_PaymentsToAcquireBusinesses" xlink:label="loc_QLGNPaymentsToAcquireBusinesses" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_QLGNPaymentsToAcquireBusinesses" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueAcquisitions" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueAcquisitions" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_PrefundedWarrantsIssuedForBusinessAcquisition" xlink:label="loc_QLGNPrefundedWarrantsIssuedForBusinessAcquisition" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_QLGNPrefundedWarrantsIssuedForBusinessAcquisition" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationConsiderationTransferred1" xlink:label="loc_us-gaapBusinessCombinationConsiderationTransferred1" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_us-gaapBusinessCombinationConsiderationTransferred1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_FairValueOfWarrantModificationForBusinessAcquisition" xlink:label="loc_QLGNFairValueOfWarrantModificationForBusinessAcquisition" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_QLGNFairValueOfWarrantModificationForBusinessAcquisition" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAcquiredFromAcquisition" xlink:label="loc_us-gaapCashAcquiredFromAcquisition" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_us-gaapCashAcquiredFromAcquisition" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:label="loc_us-gaapPaymentsToAcquireBusinessesNetOfCashAcquired" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_us-gaapPaymentsToAcquireBusinessesNetOfCashAcquired" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/ScheduleOfConsiderationTransferredDetailsParenthetical" xlink:title="00000044 - Disclosure - SCHEDULE OF CONSIDERATION TRANSFERRED (Details) (Parenthetical)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:label="loc_us-gaapBusinessCombinationAndAssetAcquisitionAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessCombinationAndAssetAcquisitionAbstract" xlink:to="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaapBusinessAcquisitionLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="loc_us-gaapBusinessAcquisitionLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaapBusinessAcquisitionAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="loc_us-gaapBusinessAcquisitionAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaapBusinessAcquisitionAcquireeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionAxis" xlink:to="loc_us-gaapBusinessAcquisitionAcquireeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_NanoSynexLtdMember" xlink:label="loc_QLGNNanoSynexLtdMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionAcquireeDomain" xlink:to="loc_QLGNNanoSynexLtdMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_AlphaCapitalAnstaltMember" xlink:label="loc_QLGNAlphaCapitalAnstaltMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionAcquireeDomain" xlink:to="loc_QLGNAlphaCapitalAnstaltMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesAcquisitions" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesAcquisitions" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/ScheduleOfAssetsAcquiredAndLiabilitiesDetails" xlink:title="00000045 - Disclosure - SCHEDULE OF ASSETS ACQUIRED AND LIABILITIES (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:label="loc_us-gaapBusinessCombinationAndAssetAcquisitionAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:label="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessCombinationAndAssetAcquisitionAbstract" xlink:to="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:label="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessCombinationAndAssetAcquisitionAbstract" xlink:to="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedResearchAndDevelopmentExpense" xlink:label="loc_QLGNBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedResearchAndDevelopmentExpense" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessCombinationAndAssetAcquisitionAbstract" xlink:to="loc_QLGNBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedResearchAndDevelopmentExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:label="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessCombinationAndAssetAcquisitionAbstract" xlink:to="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpensesAndOtherPayables" xlink:label="loc_QLGNBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpensesAndOtherPayables" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessCombinationAndAssetAcquisitionAbstract" xlink:to="loc_QLGNBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpensesAndOtherPayables" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedResearchAndDevelopmentGrantLiability" xlink:label="loc_QLGNBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedResearchAndDevelopmentGrantLiability" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessCombinationAndAssetAcquisitionAbstract" xlink:to="loc_QLGNBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedResearchAndDevelopmentGrantLiability" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesShortTermDebt" xlink:label="loc_QLGNBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesShortTermDebt" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessCombinationAndAssetAcquisitionAbstract" xlink:to="loc_QLGNBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesShortTermDebt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:label="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessCombinationAndAssetAcquisitionAbstract" xlink:to="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedLessNoncontrollingInterest" xlink:label="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedLessNoncontrollingInterest" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessCombinationAndAssetAcquisitionAbstract" xlink:to="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedLessNoncontrollingInterest" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:label="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessCombinationAndAssetAcquisitionAbstract" xlink:to="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaapGoodwill" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessCombinationAndAssetAcquisitionAbstract" xlink:to="loc_us-gaapGoodwill" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:label="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessCombinationAndAssetAcquisitionAbstract" xlink:to="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/ScheduleOfProFormaInformationDetails" xlink:title="00000046 - Disclosure - SCHEDULE OF PRO FORMA INFORMATION (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:label="loc_us-gaapBusinessCombinationAndAssetAcquisitionAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionsProFormaRevenue" xlink:label="loc_us-gaapBusinessAcquisitionsProFormaRevenue" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessCombinationAndAssetAcquisitionAbstract" xlink:to="loc_us-gaapBusinessAcquisitionsProFormaRevenue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" xlink:label="loc_us-gaapBusinessAcquisitionsProFormaNetIncomeLoss" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessCombinationAndAssetAcquisitionAbstract" xlink:to="loc_us-gaapBusinessAcquisitionsProFormaNetIncomeLoss" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/AcquisitionDetailsNarrative" xlink:title="00000047 - Disclosure - ACQUISITION (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:label="loc_us-gaapBusinessCombinationAndAssetAcquisitionAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessCombinationAndAssetAcquisitionAbstract" xlink:to="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaapBusinessAcquisitionLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="loc_us-gaapBusinessAcquisitionLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaapBusinessAcquisitionAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="loc_us-gaapBusinessAcquisitionAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaapBusinessAcquisitionAcquireeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionAxis" xlink:to="loc_us-gaapBusinessAcquisitionAcquireeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_NanoSynexLtdMember" xlink:label="loc_QLGNNanoSynexLtdMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionAcquireeDomain" xlink:to="loc_QLGNNanoSynexLtdMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_SeriesAOnePreferredStockMember" xlink:label="loc_QLGNSeriesAOnePreferredStockMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_QLGNSeriesAOnePreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="loc_us-gaapSeriesBPreferredStockMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesBPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_PrefundedWarrantMember" xlink:label="loc_QLGNPrefundedWarrantMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_QLGNPrefundedWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="loc_deiLegalEntityAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_NanoSynexMember" xlink:label="loc_QLGNNanoSynexMember" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_QLGNNanoSynexMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:label="loc_us-gaapBusinessAcquisitionPercentageOfVotingInterestsAcquired" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_us-gaapBusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesAcquisitions" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesAcquisitions" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="loc_us-gaapStockholdersEquityReverseStockSplit" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_us-gaapStockholdersEquityReverseStockSplit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueAcquisitions" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueAcquisitions" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterestDecreaseFromRedemptions" xlink:label="loc_us-gaapMinorityInterestDecreaseFromRedemptions" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_us-gaapMinorityInterestDecreaseFromRedemptions" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillPeriodIncreaseDecrease" xlink:label="loc_us-gaapGoodwillPeriodIncreaseDecrease" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_us-gaapGoodwillPeriodIncreaseDecrease" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossTax" xlink:label="loc_us-gaapOtherComprehensiveIncomeLossTax" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_us-gaapOtherComprehensiveIncomeLossTax" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/ScheduleOfInventoryDetails" xlink:title="00000048 - Disclosure - SCHEDULE OF INVENTORY (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaapInventoryDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryRawMaterials" xlink:label="loc_us-gaapInventoryRawMaterials" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInventoryDisclosureAbstract" xlink:to="loc_us-gaapInventoryRawMaterials" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryWorkInProcess" xlink:label="loc_us-gaapInventoryWorkInProcess" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInventoryDisclosureAbstract" xlink:to="loc_us-gaapInventoryWorkInProcess" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryFinishedGoods" xlink:label="loc_us-gaapInventoryFinishedGoods" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInventoryDisclosureAbstract" xlink:to="loc_us-gaapInventoryFinishedGoods" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaapInventoryNet" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInventoryDisclosureAbstract" xlink:to="loc_us-gaapInventoryNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/ScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails" xlink:title="00000049 - Disclosure - SCHEDULE OF PREPAID EXPENSES AND OTHER CURRENT ASSETS (Details)">
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_DisclosurePrepaidExpensesAndOtherCurrentAssetsAbstract" xlink:label="loc_QLGNDisclosurePrepaidExpensesAndOtherCurrentAssetsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidInsurance" xlink:label="loc_us-gaapPrepaidInsurance" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_QLGNDisclosurePrepaidExpensesAndOtherCurrentAssetsAbstract" xlink:to="loc_us-gaapPrepaidInsurance" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_PrepaidManufacturingExpenses" xlink:label="loc_QLGNPrepaidManufacturingExpenses" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_QLGNDisclosurePrepaidExpensesAndOtherCurrentAssetsAbstract" xlink:to="loc_QLGNPrepaidManufacturingExpenses" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherPrepaidExpenseCurrent" xlink:label="loc_us-gaapOtherPrepaidExpenseCurrent" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_QLGNDisclosurePrepaidExpensesAndOtherCurrentAssetsAbstract" xlink:to="loc_us-gaapOtherPrepaidExpenseCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsCurrent" xlink:label="loc_us-gaapOtherAssetsCurrent" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_QLGNDisclosurePrepaidExpensesAndOtherCurrentAssetsAbstract" xlink:to="loc_us-gaapOtherAssetsCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_QLGNDisclosurePrepaidExpensesAndOtherCurrentAssetsAbstract" xlink:to="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/ScheduleOfPropertyAndEquipmentDetails" xlink:title="00000050 - Disclosure - SCHEDULE OF PROPERTY AND EQUIPMENT (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaapPropertyPlantAndEquipmentAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract" xlink:to="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaapPropertyPlantAndEquipmentLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MachineryAndEquipmentMember" xlink:label="loc_us-gaapMachineryAndEquipmentMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapMachineryAndEquipmentMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComputerEquipmentMember" xlink:label="loc_us-gaapComputerEquipmentMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapComputerEquipmentMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaapLeaseholdImprovementsMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapLeaseholdImprovementsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_MoldsAndToolingMember" xlink:label="loc_QLGNMoldsAndToolingMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_QLGNMoldsAndToolingMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaapFurnitureAndFixturesMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapFurnitureAndFixturesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquipmentMember" xlink:label="loc_us-gaapEquipmentMember" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapEquipmentMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaapPropertyPlantAndEquipmentGross" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_FixedAssetImpairments" xlink:label="loc_QLGNFixedAssetImpairments" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_QLGNFixedAssetImpairments" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/PropertyAndEquipmentNetDetailsNarrative" xlink:title="00000051 - Disclosure - PROPERTY AND EQUIPMENT, NET (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaapPropertyPlantAndEquipmentAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract" xlink:to="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_SekisuiDistributionAgreementMember" xlink:label="loc_QLGNSekisuiDistributionAgreementMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_QLGNSekisuiDistributionAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaapDepreciation" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapDepreciation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/ScheduleOfGoodwillAndOtherIntangibleDetails" xlink:title="00000052 - Disclosure - SCHEDULE OF GOODWILL AND OTHER INTANGIBLE (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_DevelopedProductTechnologyRightsMember" xlink:label="loc_QLGNDevelopedProductTechnologyRightsMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_QLGNDevelopedProductTechnologyRightsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_LicensingRightsMember" xlink:label="loc_QLGNLicensingRightsMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_QLGNLicensingRightsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="loc_srtRangeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaapIndefiniteLivedIntangibleAssetsByMajorClassAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="loc_us-gaapIndefiniteLivedIntangibleAssetsByMajorClassAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaapIndefiniteLivedIntangibleAssetsMajorClassNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="loc_us-gaapIndefiniteLivedIntangibleAssetsMajorClassNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InProcessResearchAndDevelopmentMember" xlink:label="loc_us-gaapInProcessResearchAndDevelopmentMember" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_us-gaapInProcessResearchAndDevelopmentMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaapGoodwill" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapGoodwill" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsGross" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetUsefulLife" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetUsefulLife" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAccumulatedAmortization" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsNet" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaapIntangibleAssetsNetExcludingGoodwill" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapIntangibleAssetsNetExcludingGoodwill" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/GoodwillIprdAndOtherIntangiblesDetailsNarrative" xlink:title="00000053 - Disclosure - GOODWILL, IPR&amp;D AND OTHER INTANGIBLES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PatentsMember" xlink:label="loc_us-gaapPatentsMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_us-gaapPatentsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LicenseMember" xlink:label="loc_us-gaapLicenseMember" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_us-gaapLicenseMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillImpairmentLoss" xlink:label="loc_us-gaapGoodwillImpairmentLoss" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapGoodwillImpairmentLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:label="loc_us-gaapImpairmentOfIntangibleAssetsFinitelived" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapImpairmentOfIntangibleAssetsFinitelived" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsGross" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsGross" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAccumulatedAmortization" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaapAmortizationOfIntangibleAssets" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapAmortizationOfIntangibleAssets" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearThree" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearFour" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearFive" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails" xlink:title="00000054 - Disclosure - SCHEDULE OF ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaapPayablesAndAccrualsAbstract" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_AccruedCompensation" xlink:label="loc_QLGNAccruedCompensation" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_QLGNAccruedCompensation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_AccruedEquipmentHeldForLease" xlink:label="loc_QLGNAccruedEquipmentHeldForLease" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_QLGNAccruedEquipmentHeldForLease" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_AccruedFranchiseSalesAndUseTaxes" xlink:label="loc_QLGNAccruedFranchiseSalesAndUseTaxes" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_QLGNAccruedFranchiseSalesAndUseTaxes" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedIncomeTaxesCurrent" xlink:label="loc_us-gaapAccruedIncomeTaxesCurrent" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapAccruedIncomeTaxesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPayableCurrent" xlink:label="loc_us-gaapInterestPayableCurrent" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapInterestPayableCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedPayrollTaxesCurrent" xlink:label="loc_us-gaapAccruedPayrollTaxesCurrent" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapAccruedPayrollTaxesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="loc_us-gaapAccruedProfessionalFeesCurrent" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapAccruedProfessionalFeesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_AccruedResearchAndDevelopmentCurrent" xlink:label="loc_QLGNAccruedResearchAndDevelopmentCurrent" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_QLGNAccruedResearchAndDevelopmentCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedRoyaltiesCurrent" xlink:label="loc_us-gaapAccruedRoyaltiesCurrent" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapAccruedRoyaltiesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductWarrantyAccrual" xlink:label="loc_us-gaapProductWarrantyAccrual" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapProductWarrantyAccrual" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_AccruedLicenseFees" xlink:label="loc_QLGNAccruedLicenseFees" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_QLGNAccruedLicenseFees" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaapOtherAccruedLiabilitiesCurrent" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapOtherAccruedLiabilitiesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccruedLiabilitiesCurrent" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapAccruedLiabilitiesCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/ShortTermDebt-RelatedPartyDetailsNarrative" xlink:title="00000055 - Disclosure - SHORT TERM DEBT - RELATED PARTY (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaapDebtDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShortTermDebtTable" xlink:label="loc_us-gaapScheduleOfShortTermDebtTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfShortTermDebtTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtLineItems" xlink:label="loc_us-gaapShortTermDebtLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_us-gaapShortTermDebtLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="loc_us-gaapShortTermDebtTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_us-gaapShortTermDebtTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaapShortTermDebtTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtTypeAxis" xlink:to="loc_us-gaapShortTermDebtTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_NotesPayableMember" xlink:label="loc_QLGNNotesPayableMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtTypeDomain" xlink:to="loc_QLGNNotesPayableMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_NanoSynexMember" xlink:label="loc_QLGNNanoSynexMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_QLGNNanoSynexMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaapDebtInstrumentFaceAmount" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentFaceAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPayableCurrent" xlink:label="loc_us-gaapInterestPayableCurrent" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapInterestPayableCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermBorrowings" xlink:label="loc_us-gaapShortTermBorrowings" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapShortTermBorrowings" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaapDebtInstrumentInterestRateStatedPercentage" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentInterestRateStatedPercentage" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromRelatedPartyDebt" xlink:label="loc_us-gaapProceedsFromRelatedPartyDebt" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapProceedsFromRelatedPartyDebt" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/ScheduleOfWarrantsActivityDetails" xlink:title="00000056 - Disclosure - SCHEDULE OF WARRANTS ACTIVITY (Details)">
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_DisclosureWarrantLiabilitiesAbstract" xlink:label="loc_QLGNDisclosureWarrantLiabilitiesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_QLGNDisclosureWarrantLiabilitiesAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_SeriesCWarrantsMember" xlink:label="loc_QLGNSeriesCWarrantsMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_QLGNSeriesCWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_CommonStockWarrantsMember" xlink:label="loc_QLGNCommonStockWarrantsMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_QLGNCommonStockWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtRangeAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice" xlink:label="loc_QLGNShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_QLGNShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_RangeOfExercisePrice" xlink:label="loc_QLGNRangeOfExercisePrice" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_QLGNRangeOfExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAveragRemainingContractualTerm1" xlink:label="loc_QLGNShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAveragRemainingContractualTerm1" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_QLGNShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAveragRemainingContractualTerm1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedInPeriodWeightedAverageExercisePrice" xlink:label="loc_QLGNShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_QLGNShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedInPeriodWeightedAverageExercisePrice" xlink:label="loc_QLGNShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_QLGNShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInPeriodWeightedAverageExercisePrice" xlink:label="loc_QLGNShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_QLGNShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_QLGNShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_QLGNShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_2" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice" xlink:label="loc_QLGNShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_2" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_QLGNShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_RangeOfExercisePrice" xlink:label="loc_QLGNRangeOfExercisePrice_2" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_QLGNRangeOfExercisePrice_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber" xlink:label="loc_QLGNShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_QLGNShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageVestedExercisePrice" xlink:label="loc_QLGNShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageVestedExercisePrice" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_QLGNShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageVestedExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_RangeOfExercisePriceExercisableVested" xlink:label="loc_QLGNRangeOfExercisePriceExercisableVested" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_QLGNRangeOfExercisePriceExercisableVested" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNonExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_QLGNShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNonExercisableWeightedAverageRemainingContractualTerm1" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_QLGNShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNonExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_RangeOfExercisePriceExercisableVested" xlink:label="loc_QLGNRangeOfExercisePriceExercisableVested_2" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_QLGNRangeOfExercisePriceExercisableVested_2" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/ScheduleOfFairValueHierarchyForWarrantLiabilitiesDetails" xlink:title="00000057 - Disclosure - SCHEDULE OF FAIR VALUE HIERARCHY FOR WARRANT LIABILITIES (Details)">
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_DisclosureWarrantLiabilitiesAbstract" xlink:label="loc_QLGNDisclosureWarrantLiabilitiesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:label="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_QLGNDisclosureWarrantLiabilitiesAbstract" xlink:to="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:label="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:to="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaapFairValueInputsLevel1Member" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel1Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaapFairValueInputsLevel2Member" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel2Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaapFairValueInputsLevel3Member" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel3Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_FairValueAdjustmentOfWarrant" xlink:label="loc_QLGNFairValueAdjustmentOfWarrant" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_QLGNFairValueAdjustmentOfWarrant" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_FairValueOfWarrantLiabilitiesOnDateOfExercise" xlink:label="loc_QLGNFairValueOfWarrantLiabilitiesOnDateOfExercise" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_QLGNFairValueOfWarrantLiabilitiesOnDateOfExercise" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_FairValueOfWarrantLiabilitiesIssuanceOfAlphaWarrants" xlink:label="loc_QLGNFairValueOfWarrantLiabilitiesIssuanceOfAlphaWarrants" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_QLGNFairValueOfWarrantLiabilitiesIssuanceOfAlphaWarrants" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_ChangeInFairValueOfWarrantLiabilities" xlink:label="loc_QLGNChangeInFairValueOfWarrantLiabilities" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_QLGNChangeInFairValueOfWarrantLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_FairValueAdjustmentOfWarrant" xlink:label="loc_QLGNFairValueAdjustmentOfWarrant_2" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_QLGNFairValueAdjustmentOfWarrant_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/ScheduleOfAssumptionsOfWarrantLiabilitiesDetails" xlink:title="00000058 - Disclosure - SCHEDULE OF ASSUMPTIONS OF WARRANT LIABILITIES (Details)">
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_DisclosureWarrantLiabilitiesAbstract" xlink:label="loc_QLGNDisclosureWarrantLiabilitiesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_QLGNDisclosureWarrantLiabilitiesAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtRangeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_WeightedAverageMember" xlink:label="loc_srtWeightedAverageMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtWeightedAverageMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="loc_us-gaapMeasurementInputTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapMeasurementInputTypeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaapMeasurementInputTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMeasurementInputTypeAxis" xlink:to="loc_us-gaapMeasurementInputTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="loc_us-gaapMeasurementInputRiskFreeInterestRateMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputRiskFreeInterestRateMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="loc_us-gaapMeasurementInputPriceVolatilityMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputPriceVolatilityMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="loc_us-gaapMeasurementInputExpectedTermMember" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputExpectedTermMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputExpectedDividendRateMember" xlink:label="loc_us-gaapMeasurementInputExpectedDividendRateMember" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputExpectedDividendRateMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:label="loc_us-gaapWarrantsAndRightsOutstandingMeasurementInput" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstandingMeasurementInput" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="loc_us-gaapWarrantsAndRightsOutstandingTerm" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstandingTerm" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/WarrantLiabilitiesDetailsNarrative" xlink:title="00000059 - Disclosure - WARRANT LIABILITIES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_DisclosureWarrantLiabilitiesAbstract" xlink:label="loc_QLGNDisclosureWarrantLiabilitiesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_QLGNDisclosureWarrantLiabilitiesAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_SeriesCWarrantsMember" xlink:label="loc_QLGNSeriesCWarrantsMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_QLGNSeriesCWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtRangeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_SeriesCWarrantsMember" xlink:label="loc_QLGNSeriesCWarrantsMember_2" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_QLGNSeriesCWarrantsMember_2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtTitleOfIndividualAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_AlphaCapitalMember" xlink:label="loc_QLGNAlphaCapitalMember" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_QLGNAlphaCapitalMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="loc_us-gaapWarrantsAndRightsOutstandingTerm" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstandingTerm" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_ConversionPricePercentage" xlink:label="loc_QLGNConversionPricePercentage" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_QLGNConversionPricePercentage" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/ScheduleOfSeniorSecuredConvertibleDebtDetails" xlink:title="00000060 - Disclosure - SCHEDULE OF SENIOR SECURED CONVERTIBLE DEBT (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaapDebtDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShortTermDebtTable" xlink:label="loc_us-gaapScheduleOfShortTermDebtTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfShortTermDebtTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtLineItems" xlink:label="loc_us-gaapShortTermDebtLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_us-gaapShortTermDebtLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaapDebtInstrumentAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_us-gaapDebtInstrumentAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaapDebtInstrumentNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentAxis" xlink:to="loc_us-gaapDebtInstrumentNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_SeniorSecuredConvertibleDebtMember" xlink:label="loc_QLGNSeniorSecuredConvertibleDebtMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_QLGNSeniorSecuredConvertibleDebtMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SecuredDebt" xlink:label="loc_us-gaapSecuredDebt" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapSecuredDebt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="loc_us-gaapDebtInstrumentUnamortizedDiscount" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentUnamortizedDiscount" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleDebt" xlink:label="loc_us-gaapConvertibleDebt" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapConvertibleDebt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/ConvertibleDebt-RelatedPartyDetailsNarrative" xlink:title="00000061 - Disclosure - CONVERTIBLE DEBT - RELATED PARTY (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaapDebtDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShortTermDebtTable" xlink:label="loc_us-gaapScheduleOfShortTermDebtTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfShortTermDebtTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtLineItems" xlink:label="loc_us-gaapShortTermDebtLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_us-gaapShortTermDebtLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_srtTitleOfIndividualAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_AlphaCapitalMember" xlink:label="loc_QLGNAlphaCapitalMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_QLGNAlphaCapitalMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_AlphaCapitalOtherThirdPartiesMember" xlink:label="loc_QLGNAlphaCapitalOtherThirdPartiesMember" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_QLGNAlphaCapitalOtherThirdPartiesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaapDebtInstrumentAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_us-gaapDebtInstrumentAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaapDebtInstrumentNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentAxis" xlink:to="loc_us-gaapDebtInstrumentNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_SeniorConvertibleDebentureMember" xlink:label="loc_QLGNSeniorConvertibleDebentureMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_QLGNSeniorConvertibleDebentureMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_SeriesCWarrantsMember" xlink:label="loc_QLGNSeriesCWarrantsMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_QLGNSeriesCWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtInterestRateIncrease" xlink:label="loc_us-gaapShortTermDebtInterestRateIncrease" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapShortTermDebtInterestRateIncrease" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SecuredDebt" xlink:label="loc_us-gaapSecuredDebt" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapSecuredDebt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_PurchasePrice" xlink:label="loc_QLGNPurchasePrice" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_QLGNPurchasePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="loc_us-gaapDebtInstrumentConvertibleConversionPrice1" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentConvertibleConversionPrice1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_ConversionPricePercentage" xlink:label="loc_QLGNConversionPricePercentage" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_QLGNConversionPricePercentage" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentIncreaseAccruedInterest" xlink:label="loc_us-gaapDebtInstrumentIncreaseAccruedInterest" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentIncreaseAccruedInterest" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtConversionConvertedInstrumentRate" xlink:label="loc_us-gaapDebtConversionConvertedInstrumentRate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtConversionConvertedInstrumentRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_PrincipalAmountPercentage" xlink:label="loc_QLGNPrincipalAmountPercentage" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_QLGNPrincipalAmountPercentage" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaapDebtInstrumentInterestRateStatedPercentage" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentInterestRateStatedPercentage" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapCommonStockSharesIssued" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="loc_us-gaapAmortizationOfDebtDiscountPremium" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapAmortizationOfDebtDiscountPremium" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaapFairValueAdjustmentOfWarrants" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapFairValueAdjustmentOfWarrants" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeNet" xlink:label="loc_us-gaapEmbeddedDerivativeFairValueOfEmbeddedDerivativeNet" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapEmbeddedDerivativeFairValueOfEmbeddedDerivativeNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_FeesAndCostsPaid" xlink:label="loc_QLGNFeesAndCostsPaid" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_QLGNFeesAndCostsPaid" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/ScheduleOfEarningsPerShareBasicAndDilutedDetails" xlink:title="00000062 - Disclosure - SCHEDULE OF EARNINGS PER SHARE BASIC AND DILUTED (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaapEarningsPerShareAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareAbstract" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareAbstract" xlink:to="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_DilutivePotentialSharesIssuableFromStockOptionsAndWarrants" xlink:label="loc_QLGNDilutivePotentialSharesIssuableFromStockOptionsAndWarrants" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareAbstract" xlink:to="loc_QLGNDilutivePotentialSharesIssuableFromStockOptionsAndWarrants" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:label="loc_us-gaapWeightedAverageNumberDilutedSharesOutstandingAdjustment" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareAbstract" xlink:to="loc_us-gaapWeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/ScheduleOfDilutiveSecuritiesExcludedFromDilutedNetLossPerShareDetails" xlink:title="00000063 - Disclosure - SCHEDULE OF DILUTIVE SECURITIES EXCLUDED FROM DILUTED NET LOSS PER SHARE (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaapEarningsPerShareAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareAbstract" xlink:to="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaapAntidilutiveSecuritiesNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="loc_us-gaapAntidilutiveSecuritiesNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_SharesOfCommonStockSubjectToOutstandingOptionsMember" xlink:label="loc_QLGNSharesOfCommonStockSubjectToOutstandingOptionsMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_QLGNSharesOfCommonStockSubjectToOutstandingOptionsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_SharesOfCommonStockSubjectToOutstandingWarrantsMember" xlink:label="loc_QLGNSharesOfCommonStockSubjectToOutstandingWarrantsMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_QLGNSharesOfCommonStockSubjectToOutstandingWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/ScheduleOfOperatingLeaseRightOfUseAssetsAndOperatingLeaseLiabilitiesDetails" xlink:title="00000064 - Disclosure - SCHEDULE OF OPERATING LEASE RIGHT OF USE ASSETS AND OPERATING LEASE LIABILITIES (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_LongtermOperatingLeaseAgreementMember" xlink:label="loc_QLGNLongtermOperatingLeaseAgreementMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_QLGNLongtermOperatingLeaseAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAssetAmortizationExpense" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAssetAmortizationExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset_2" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaapOperatingLeaseLiability" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapOperatingLeaseLiability" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasePayments" xlink:label="loc_us-gaapOperatingLeasePayments" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapOperatingLeasePayments" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaapOperatingLeaseLiability_2" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapOperatingLeaseLiability_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityNoncurrent" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapOperatingLeaseLiabilityNoncurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityCurrent" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapOperatingLeaseLiabilityCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/ScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails" xlink:title="00000065 - Disclosure - SCHEDULE OF MATURITIES OF OPERATING LEASE LIABILITIES (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearThree" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearFour" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearFive" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaapOperatingLeaseLiability" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapOperatingLeaseLiability" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:title="00000066 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_FirstTwelveMonthsMember" xlink:label="loc_QLGNFirstTwelveMonthsMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_QLGNFirstTwelveMonthsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_srtTitleOfIndividualAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_SekisuiDistributionAgreementMember" xlink:label="loc_QLGNSekisuiDistributionAgreementMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_QLGNSekisuiDistributionAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_NanoSynexMember" xlink:label="loc_QLGNNanoSynexMember" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_QLGNNanoSynexMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeDomain" xlink:to="loc_us-gaapSubsequentEventMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AreaOfLand" xlink:label="loc_us-gaapAreaOfLand" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapAreaOfLand" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="loc_us-gaapLesseeOperatingLeaseTermOfContract" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapLesseeOperatingLeaseTermOfContract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseDescription" xlink:label="loc_us-gaapLesseeOperatingLeaseDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapLesseeOperatingLeaseDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRent" xlink:label="loc_us-gaapPaymentsForRent" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapPaymentsForRent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_TenantImprovementAllowance" xlink:label="loc_QLGNTenantImprovementAllowance" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_QLGNTenantImprovementAllowance" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="loc_us-gaapOperatingLeaseWeightedAverageRemainingLeaseTerm1" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapOperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="loc_us-gaapOperatingLeaseWeightedAverageDiscountRatePercent" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapOperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseExpense" xlink:label="loc_us-gaapOperatingLeaseExpense" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapOperatingLeaseExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:label="loc_us-gaapAccruedLiabilitiesAndOtherLiabilities" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapAccruedLiabilitiesAndOtherLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="loc_us-gaapLineOfCreditFacilityMaximumBorrowingCapacity" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapLineOfCreditFacilityMaximumBorrowingCapacity" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_DevelopmentFund" xlink:label="loc_QLGNDevelopmentFund" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_QLGNDevelopmentFund" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity" xlink:label="loc_us-gaapLineOfCreditFacilityCurrentBorrowingCapacity" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapLineOfCreditFacilityCurrentBorrowingCapacity" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationSettlementAmountAwardedToOtherParty" xlink:label="loc_us-gaapLitigationSettlementAmountAwardedToOtherParty" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapLitigationSettlementAmountAwardedToOtherParty" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/ResearchAndLicenseAgreementsDetailsNarrative" xlink:title="00000067 - Disclosure - RESEARCH AND LICENSE AGREEMENTS (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_DisclosureResearchAndLicenseAgreementsAbstract" xlink:label="loc_QLGNDisclosureResearchAndLicenseAgreementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_QLGNDisclosureResearchAndLicenseAgreementsAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_SponsoredResearchAgreementAndLicenseMember" xlink:label="loc_QLGNSponsoredResearchAgreementAndLicenseMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_QLGNSponsoredResearchAgreementAndLicenseMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_LicenseAndSponsoredResearchAgreementsMember" xlink:label="loc_QLGNLicenseAndSponsoredResearchAgreementsMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_QLGNLicenseAndSponsoredResearchAgreementsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_LicenseAgreementMember" xlink:label="loc_QLGNLicenseAgreementMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_QLGNLicenseAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_deiLegalEntityAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_UniversityOfLouisvilleResearchFoundationMember" xlink:label="loc_QLGNUniversityOfLouisvilleResearchFoundationMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_QLGNUniversityOfLouisvilleResearchFoundationMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_AdvancedCancerTherapeuticsLLCMember" xlink:label="loc_QLGNAdvancedCancerTherapeuticsLLCMember" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_QLGNAdvancedCancerTherapeuticsLLCMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_YiXinZhenDuanJishuLtdMember" xlink:label="loc_QLGNYiXinZhenDuanJishuLtdMember" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_QLGNYiXinZhenDuanJishuLtdMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_STAPharmaceuticalCoLtdMember" xlink:label="loc_QLGNSTAPharmaceuticalCoLtdMember" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_QLGNSTAPharmaceuticalCoLtdMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtRangeAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapAwardTypeAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_PhaseOneClinicalTrialMember" xlink:label="loc_QLGNPhaseOneClinicalTrialMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_QLGNPhaseOneClinicalTrialMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_PhaseTwoClinicalTrialMember" xlink:label="loc_QLGNPhaseTwoClinicalTrialMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_QLGNPhaseTwoClinicalTrialMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_PhaseThreeClinicalTrialMember" xlink:label="loc_QLGNPhaseThreeClinicalTrialMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_QLGNPhaseThreeClinicalTrialMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_PhaseClinicalTrialMember" xlink:label="loc_QLGNPhaseClinicalTrialMember" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_QLGNPhaseClinicalTrialMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_UpfrontPaymentMember" xlink:label="loc_QLGNUpfrontPaymentMember" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_QLGNUpfrontPaymentMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srtProductOrServiceAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtProductOrServiceAxis" order="50" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srtProductsAndServicesDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtProductOrServiceAxis" xlink:to="loc_srtProductsAndServicesDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_LicensedProductSalesMember" xlink:label="loc_QLGNLicensedProductSalesMember" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_QLGNLicensedProductSalesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_LicenseRevenueMember" xlink:label="loc_QLGNLicenseRevenueMember" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_QLGNLicenseRevenueMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtTitleOfIndividualAxis" order="60" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_CEMarkMember" xlink:label="loc_QLGNCEMarkMember" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_QLGNCEMarkMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_ReimbursementOfResearchExpenses" xlink:label="loc_QLGNReimbursementOfResearchExpenses" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_QLGNReimbursementOfResearchExpenses" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_AgreementTermPaymentDescription" xlink:label="loc_QLGNAgreementTermPaymentDescription" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_QLGNAgreementTermPaymentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_MilestonePayment" xlink:label="loc_QLGNMilestonePayment" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_QLGNMilestonePayment" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_RegulatoryMarketingApprovalExpenses" xlink:label="loc_QLGNRegulatoryMarketingApprovalExpenses" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_QLGNRegulatoryMarketingApprovalExpenses" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_CumulativeSales" xlink:label="loc_QLGNCumulativeSales" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_QLGNCumulativeSales" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:label="loc_us-gaapRevenueFromContractWithCustomerIncludingAssessedTax" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapRevenueFromContractWithCustomerIncludingAssessedTax" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_UpfrontLicenseFee" xlink:label="loc_QLGNUpfrontLicenseFee" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_QLGNUpfrontLicenseFee" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_LicenseCost" xlink:label="loc_QLGNLicenseCost" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_QLGNLicenseCost" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="loc_us-gaapProceedsFromConvertibleDebt" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapProceedsFromConvertibleDebt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_PatentCosts" xlink:label="loc_QLGNPatentCosts" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_QLGNPatentCosts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_RegulatoryMarketingApprovalExpensesOne" xlink:label="loc_QLGNRegulatoryMarketingApprovalExpensesOne" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_QLGNRegulatoryMarketingApprovalExpensesOne" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_ShortfallPayments" xlink:label="loc_QLGNShortfallPayments" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_QLGNShortfallPayments" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RoyaltyExpense" xlink:label="loc_us-gaapRoyaltyExpense" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapRoyaltyExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_AgreementDescription" xlink:label="loc_QLGNAgreementDescription" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_QLGNAgreementDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_MilestonePaymentForCumulativeMarketingExpenses" xlink:label="loc_QLGNMilestonePaymentForCumulativeMarketingExpenses" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_QLGNMilestonePaymentForCumulativeMarketingExpenses" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_MilestoneMethodRevenueRecognized" xlink:label="loc_QLGNMilestoneMethodRevenueRecognized" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_QLGNMilestoneMethodRevenueRecognized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredRevenue" xlink:label="loc_us-gaapDeferredRevenue" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDeferredRevenue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepositAssets" xlink:label="loc_us-gaapDepositAssets" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDepositAssets" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_ReimbursementOfPatent" xlink:label="loc_QLGNReimbursementOfPatent" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_QLGNReimbursementOfPatent" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/ScheduleOfReservedSharesDetails" xlink:title="00000068 - Disclosure - SCHEDULE OF RESERVED SHARES (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockOptionMember" xlink:label="loc_us-gaapStockOptionMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapStockOptionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaapCommonStockCapitalSharesReservedForFutureIssuance" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapCommonStockCapitalSharesReservedForFutureIssuance" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/ScheduleOfStockOptionActivityDetails" xlink:title="00000069 - Disclosure - SCHEDULE OF STOCK OPTION ACTIVITY (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable" xlink:label="loc_us-gaapScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems" xlink:label="loc_us-gaapDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable" xlink:to="loc_us-gaapDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable" xlink:to="loc_srtTitleOfIndividualAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_EmployeesAndNonemployeeServiceProviderMember" xlink:label="loc_QLGNEmployeesAndNonemployeeServiceProviderMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_QLGNEmployeesAndNonemployeeServiceProviderMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable" xlink:to="loc_srtRangeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm3" xlink:label="loc_QLGNSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm3" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems" xlink:to="loc_QLGNSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionGrantedWeightedAverageExercisePrice" xlink:label="loc_QLGNShareBasedCompensationArrangementByShareBasedPaymentAwardOptionGrantedWeightedAverageExercisePrice" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems" xlink:to="loc_QLGNShareBasedCompensationArrangementByShareBasedPaymentAwardOptionGrantedWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm2" xlink:label="loc_QLGNSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm2" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems" xlink:to="loc_QLGNSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="loc_QLGNShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExpirationsInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems" xlink:to="loc_QLGNShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToNonVestExercisableWeightedAverageExercisePrice" xlink:label="loc_QLGNShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToNonVestExercisableWeightedAverageExercisePrice" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems" xlink:to="loc_QLGNShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToNonVestExercisableWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_WeightedAverageRemainingContractualLifeInYearsOptionsNonexercisableNonvested" xlink:label="loc_QLGNWeightedAverageRemainingContractualLifeInYearsOptionsNonexercisableNonvested" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems" xlink:to="loc_QLGNWeightedAverageRemainingContractualLifeInYearsOptionsNonexercisableNonvested" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/ScheduleOfAssumptionUsedInBlack-scholesOption-pricingMethodDetails" xlink:title="00000070 - Disclosure - SCHEDULE OF ASSUMPTION USED IN BLACK-SCHOLES OPTION-PRICING METHOD (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtRangeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaapSharePrice" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharePrice" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/ScheduleOfShare-basedCompensationExpenseDetails" xlink:title="00000071 - Disclosure - SCHEDULE OF SHARE-BASED COMPENSATION EXPENSE (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaapIncomeStatementLocationAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapIncomeStatementLocationAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaapGeneralAndAdministrativeExpenseMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapGeneralAndAdministrativeExpenseMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaapResearchAndDevelopmentExpenseMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapResearchAndDevelopmentExpenseMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaapAllocatedShareBasedCompensationExpense" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAllocatedShareBasedCompensationExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/ScheduleOfWarrantActivityDetails" xlink:title="00000072 - Disclosure - SCHEDULE OF WARRANT ACTIVITY (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_CompensatoryWarrantActivityMember" xlink:label="loc_QLGNCompensatoryWarrantActivityMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_QLGNCompensatoryWarrantActivityMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_srtRangeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapAwardTypeAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_CompensatoryWarrantActivityMember" xlink:label="loc_QLGNCompensatoryWarrantActivityMember_2" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_QLGNCompensatoryWarrantActivityMember_2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_NonCompensatoryWarrantActivityMember" xlink:label="loc_QLGNNonCompensatoryWarrantActivityMember" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_QLGNNonCompensatoryWarrantActivityMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice" xlink:label="loc_QLGNShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_QLGNShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_RangeOfExercisePriceOutstanding" xlink:label="loc_QLGNRangeOfExercisePriceOutstanding" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_QLGNRangeOfExercisePriceOutstanding" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAveragRemainingContractualTerm1" xlink:label="loc_QLGNShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAveragRemainingContractualTerm1" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_QLGNShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAveragRemainingContractualTerm1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_QLGNShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_QLGNShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedInPeriodWeightedAverageExercisePrice" xlink:label="loc_QLGNShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_QLGNShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedInPeriodWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInPeriodWeightedAverageExercisePrice" xlink:label="loc_QLGNShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_QLGNShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInPeriodWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedInPeriodWeightedAverageExercisePrice" xlink:label="loc_QLGNShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_QLGNShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedInPeriodWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_2" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice" xlink:label="loc_QLGNShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_2" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_QLGNShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_RangeOfExercisePriceOutstanding" xlink:label="loc_QLGNRangeOfExercisePriceOutstanding_2" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_QLGNRangeOfExercisePriceOutstanding_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAveragRemainingContractualTerm1" xlink:label="loc_QLGNShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAveragRemainingContractualTerm1" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_QLGNShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAveragRemainingContractualTerm1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber" xlink:label="loc_QLGNShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_QLGNShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageVestedExercisePrice" xlink:label="loc_QLGNShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageVestedExercisePrice" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_QLGNShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageVestedExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_RangeOfExercisePriceExercisableVested" xlink:label="loc_QLGNRangeOfExercisePriceExercisableVested" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_QLGNRangeOfExercisePriceExercisableVested" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNonVestedNumber" xlink:label="loc_QLGNShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNonVestedNumber" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_QLGNShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNonVestedNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageNonVestedExercise" xlink:label="loc_QLGNShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageNonVestedExercise" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_QLGNShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageNonVestedExercise" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_RangeOfExercisePriceNonexercisableNonvested" xlink:label="loc_QLGNRangeOfExercisePriceNonexercisableNonvested" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_QLGNRangeOfExercisePriceNonexercisableNonvested" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_2" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsRangeOfExercisePrice" xlink:label="loc_QLGNShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsRangeOfExercisePrice" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_QLGNShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsRangeOfExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_RangeOfExercisePriceGranted" xlink:label="loc_QLGNRangeOfExercisePriceGranted" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_QLGNRangeOfExercisePriceGranted" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_RangeOfExercisePriceExpired" xlink:label="loc_QLGNRangeOfExercisePriceExpired" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_QLGNRangeOfExercisePriceExpired" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInRangeOfExercisePrice" xlink:label="loc_QLGNShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInRangeOfExercisePrice" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_QLGNShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInRangeOfExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedInRangeOfExercisePrice" xlink:label="loc_QLGNShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedInRangeOfExercisePrice" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_QLGNShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedInRangeOfExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsRangeOfExercisePrice" xlink:label="loc_QLGNShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsRangeOfExercisePrice_2" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_QLGNShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsRangeOfExercisePrice_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsNonExercisableNumber" xlink:label="loc_QLGNShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsNonExercisableNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_QLGNShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsNonExercisableNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageVestedNonExercisePrice" xlink:label="loc_QLGNShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageVestedNonExercisePrice" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_QLGNShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageVestedNonExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_RangeOfExercisePriceNonExercisableVested" xlink:label="loc_QLGNRangeOfExercisePriceNonExercisableVested" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_QLGNRangeOfExercisePriceNonExercisableVested" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNonExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_QLGNShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNonExercisableWeightedAverageRemainingContractualTerm1" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_QLGNShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNonExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/StockholdersEquityDetailsNarrative" xlink:title="00000073 - Disclosure - STOCKHOLDERS&#8217; EQUITY (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaapScheduleOfStockByClassTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapScheduleOfStockByClassTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaapClassOfStockLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapClassOfStockLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_SecuritiesPurchaseAgreementMember" xlink:label="loc_QLGNSecuritiesPurchaseAgreementMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_QLGNSecuritiesPurchaseAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_SeriesCWarrantsMember" xlink:label="loc_QLGNSeriesCWarrantsMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_QLGNSeriesCWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_SeriesAlphaConvertiblePreferredStockMember" xlink:label="loc_QLGNSeriesAlphaConvertiblePreferredStockMember" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_QLGNSeriesAlphaConvertiblePreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_srtTitleOfIndividualAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_AlphaCapitalMember" xlink:label="loc_QLGNAlphaCapitalMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_QLGNAlphaCapitalMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_EmployeesAndNonemployeeServiceProviderMember" xlink:label="loc_QLGNEmployeesAndNonemployeeServiceProviderMember" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_QLGNEmployeesAndNonemployeeServiceProviderMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaapDebtInstrumentAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapDebtInstrumentAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaapDebtInstrumentNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentAxis" xlink:to="loc_us-gaapDebtInstrumentNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_SeniorConvertibleDebentureMember" xlink:label="loc_QLGNSeniorConvertibleDebentureMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_QLGNSeniorConvertibleDebentureMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapAwardTypeAxis" order="50" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockOptionMember" xlink:label="loc_us-gaapStockOptionMember" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapStockOptionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaapEmployeeStockOptionMember" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapEmployeeStockOptionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_CompensatoryWarrantsMember" xlink:label="loc_QLGNCompensatoryWarrantsMember" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_QLGNCompensatoryWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_NoncompensatoryEquityClassifiedWarrantsMember" xlink:label="loc_QLGNNoncompensatoryEquityClassifiedWarrantsMember" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_QLGNNoncompensatoryEquityClassifiedWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapPlanNameAxis" order="60" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_TwoThousandTwentyStockIncentivePlanMember" xlink:label="loc_QLGNTwoThousandTwentyStockIncentivePlanMember" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_QLGNTwoThousandTwentyStockIncentivePlanMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_srtRangeAxis" order="70" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="80" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_WarrantOneMember" xlink:label="loc_QLGNWarrantOneMember" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_QLGNWarrantOneMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_CompensatoryWarrantActivityMember" xlink:label="loc_QLGNCompensatoryWarrantActivityMember" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_QLGNCompensatoryWarrantActivityMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaapIncomeStatementLocationAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapIncomeStatementLocationAxis" order="90" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaapGeneralAndAdministrativeExpenseMember" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapGeneralAndAdministrativeExpenseMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaapBusinessAcquisitionAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapBusinessAcquisitionAxis" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaapBusinessAcquisitionAcquireeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionAxis" xlink:to="loc_us-gaapBusinessAcquisitionAcquireeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_NanoSynexMember" xlink:label="loc_QLGNNanoSynexMember" />
      <link:presentationArc order="580" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionAcquireeDomain" xlink:to="loc_QLGNNanoSynexMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaapSharePrice" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapSharePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtInterestRateIncrease" xlink:label="loc_us-gaapShortTermDebtInterestRateIncrease" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapShortTermDebtInterestRateIncrease" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SecuredDebt" xlink:label="loc_us-gaapSecuredDebt" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapSecuredDebt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_PurchasePrice" xlink:label="loc_QLGNPurchasePrice" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_QLGNPurchasePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="loc_us-gaapDebtInstrumentConvertibleConversionPrice1" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapDebtInstrumentConvertibleConversionPrice1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaapCommonStockCapitalSharesReservedForFutureIssuance" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapCommonStockCapitalSharesReservedForFutureIssuance" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="loc_us-gaapConvertiblePreferredStockSharesIssuedUponConversion" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapConvertiblePreferredStockSharesIssuedUponConversion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesOther" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesOther" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm3" xlink:label="loc_QLGNSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm3" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_QLGNSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionGrantedWeightedAverageExercisePrice" xlink:label="loc_QLGNShareBasedCompensationArrangementByShareBasedPaymentAwardOptionGrantedWeightedAverageExercisePrice" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_QLGNShareBasedCompensationArrangementByShareBasedPaymentAwardOptionGrantedWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm2" xlink:label="loc_QLGNSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm2" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_QLGNSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="loc_QLGNShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExpirationsInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_QLGNShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToNonVestExercisableWeightedAverageExercisePrice" xlink:label="loc_QLGNShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToNonVestExercisableWeightedAverageExercisePrice" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_QLGNShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToNonVestExercisableWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_WeightedAverageRemainingContractualLifeInYearsOptionsNonexercisableNonvested" xlink:label="loc_QLGNWeightedAverageRemainingContractualLifeInYearsOptionsNonexercisableNonvested" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_QLGNWeightedAverageRemainingContractualLifeInYearsOptionsNonexercisableNonvested" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="loc_us-gaapProceedsFromIssuanceOrSaleOfEquity" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOrSaleOfEquity" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_FairValueOfIssuanceCost" xlink:label="loc_QLGNFairValueOfIssuanceCost" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_QLGNFairValueOfIssuanceCost" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_WarrantsExtendedDateDescription" xlink:label="loc_QLGNWarrantsExtendedDateDescription" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_QLGNWarrantsExtendedDateDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaapFairValueAdjustmentOfWarrants" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapFairValueAdjustmentOfWarrants" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaapAllocatedShareBasedCompensationExpense" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapAllocatedShareBasedCompensationExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_WarrantsExercised" xlink:label="loc_QLGNWarrantsExercised" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_QLGNWarrantsExercised" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaapClassOfWarrantOrRightOutstanding" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_ModifiedToExercisePrice" xlink:label="loc_QLGNModifiedToExercisePrice" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_QLGNModifiedToExercisePrice" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/RelatedPartyTransactionsDetailsNarrative" xlink:title="00000074 - Disclosure - RELATED PARTY TRANSACTIONS (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaapRelatedPartyTransactionsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsAbstract" xlink:to="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaapRelatedPartyTransactionLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapRelatedPartyTransactionLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_srtTitleOfIndividualAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_AlphaCapitalMember" xlink:label="loc_QLGNAlphaCapitalMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_QLGNAlphaCapitalMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaapDebtInstrumentAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapDebtInstrumentAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaapDebtInstrumentNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentAxis" xlink:to="loc_us-gaapDebtInstrumentNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_SeniorConvertibleDebentureMember" xlink:label="loc_QLGNSeniorConvertibleDebentureMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_QLGNSeniorConvertibleDebentureMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="loc_us-gaapShortTermDebtTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapShortTermDebtTypeAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaapShortTermDebtTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtTypeAxis" xlink:to="loc_us-gaapShortTermDebtTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_NotesPayableMember" xlink:label="loc_QLGNNotesPayableMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtTypeDomain" xlink:to="loc_QLGNNotesPayableMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_NanoSynexMember" xlink:label="loc_QLGNNanoSynexMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_QLGNNanoSynexMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaapBusinessAcquisitionAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapBusinessAcquisitionAxis" order="50" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaapBusinessAcquisitionAcquireeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionAxis" xlink:to="loc_us-gaapBusinessAcquisitionAcquireeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_NanoSynexLtdMember" xlink:label="loc_QLGNNanoSynexLtdMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionAcquireeDomain" xlink:to="loc_QLGNNanoSynexLtdMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="60" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_SeriesAOnePreferredStockMember" xlink:label="loc_QLGNSeriesAOnePreferredStockMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_QLGNSeriesAOnePreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="loc_us-gaapSeriesBPreferredStockMember" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesBPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="70" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_PrefundedWarrantMember" xlink:label="loc_QLGNPrefundedWarrantMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_QLGNPrefundedWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtInterestRateIncrease" xlink:label="loc_us-gaapShortTermDebtInterestRateIncrease" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapShortTermDebtInterestRateIncrease" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SecuredDebt" xlink:label="loc_us-gaapSecuredDebt" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapSecuredDebt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_PurchasePrice" xlink:label="loc_QLGNPurchasePrice" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_QLGNPurchasePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="loc_us-gaapDebtInstrumentConvertibleConversionPrice1" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapDebtInstrumentConvertibleConversionPrice1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaapDebtInstrumentFaceAmount" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapDebtInstrumentFaceAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPayableCurrent" xlink:label="loc_us-gaapInterestPayableCurrent" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapInterestPayableCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermBorrowings" xlink:label="loc_us-gaapShortTermBorrowings" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapShortTermBorrowings" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaapDebtInstrumentInterestRateStatedPercentage" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapDebtInstrumentInterestRateStatedPercentage" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromRelatedPartyDebt" xlink:label="loc_us-gaapProceedsFromRelatedPartyDebt" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapProceedsFromRelatedPartyDebt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:label="loc_us-gaapBusinessAcquisitionPercentageOfVotingInterestsAcquired" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapBusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesAcquisitions" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesAcquisitions" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="loc_us-gaapStockholdersEquityReverseStockSplit" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapStockholdersEquityReverseStockSplit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueAcquisitions" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueAcquisitions" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/ScheduleOfDomesticAndForeignComponentsDetails" xlink:title="00000075 - Disclosure - SCHEDULE OF DOMESTIC AND FOREIGN COMPONENTS (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:label="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:label="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/ScheduleOfReconciliationsOfStatutoryIncomeTaxRateDetails" xlink:title="00000076 - Disclosure - SCHEDULE OF RECONCILIATIONS OF STATUTORY INCOME TAX RATE (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepletion" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepletion" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepletion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_EffectiveIncomeTaxRateReconciliationNonOperatingLossExpiration" xlink:label="loc_QLGNEffectiveIncomeTaxRateReconciliationNonOperatingLossExpiration" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_QLGNEffectiveIncomeTaxRateReconciliationNonOperatingLossExpiration" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationTaxCredits" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationTaxCredits" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlementsForeign" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationTaxSettlementsForeign" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationTaxSettlementsForeign" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_EffectiveIncomeTaxRateReconciliationFairValueOfWarrant" xlink:label="loc_QLGNEffectiveIncomeTaxRateReconciliationFairValueOfWarrant" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_QLGNEffectiveIncomeTaxRateReconciliationFairValueOfWarrant" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsOther" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationTaxCreditsOther" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationTaxCreditsOther" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/ScheduleOfProvisionForIncomeTaxesDetails" xlink:title="00000077 - Disclosure - SCHEDULE OF PROVISION FOR INCOME TAXES (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:label="loc_us-gaapCurrentFederalTaxExpenseBenefit" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapCurrentFederalTaxExpenseBenefit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="loc_us-gaapCurrentStateAndLocalTaxExpenseBenefit" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapCurrentStateAndLocalTaxExpenseBenefit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentForeignTaxExpenseBenefit" xlink:label="loc_us-gaapCurrentForeignTaxExpenseBenefit" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapCurrentForeignTaxExpenseBenefit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="loc_us-gaapCurrentIncomeTaxExpenseBenefit" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapCurrentIncomeTaxExpenseBenefit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:label="loc_us-gaapDeferredFederalIncomeTaxExpenseBenefit" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredFederalIncomeTaxExpenseBenefit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:label="loc_us-gaapDeferredStateAndLocalIncomeTaxExpenseBenefit" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:label="loc_us-gaapDeferredForeignIncomeTaxExpenseBenefit" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredForeignIncomeTaxExpenseBenefit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="loc_us-gaapDeferredIncomeTaxExpenseBenefit" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredIncomeTaxExpenseBenefit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="loc_us-gaapValuationAllowanceDeferredTaxAssetChangeInAmount" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaapIncomeTaxExpenseBenefit" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeTaxExpenseBenefit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:title="00000078 - Disclosure - SCHEDULE OF DEFERRED TAX ASSETS AND LIABILITIES (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwards" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwards" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="loc_us-gaapDeferredTaxAssetsInProcessResearchAndDevelopment" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsInProcessResearchAndDevelopment" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_DefferdTaxAssetsAccruedExpenses" xlink:label="loc_QLGNDefferdTaxAssetsAccruedExpenses" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_QLGNDefferdTaxAssetsAccruedExpenses" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:label="loc_us-gaapDeferredTaxAssetsGoodwillAndIntangibleAssets" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_DeferredTaxAssetsResearchAndDevelopmentExpenses" xlink:label="loc_QLGNDeferredTaxAssetsResearchAndDevelopmentExpenses" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_QLGNDeferredTaxAssetsResearchAndDevelopmentExpenses" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:label="loc_us-gaapDeferredTaxAssetsPropertyPlantAndEquipment" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsPropertyPlantAndEquipment" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpense" xlink:label="loc_us-gaapDeferredTaxAssetsTaxDeferredExpense" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsTaxDeferredExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:label="loc_us-gaapDeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:label="loc_us-gaapDeferredTaxLiabilitiesLeasingArrangements" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxLiabilitiesLeasingArrangements" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="loc_us-gaapDeferredIncomeTaxLiabilities" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredIncomeTaxLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaapDeferredTaxAssetsGross" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsGross" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapDeferredTaxAssetsValuationAllowance" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsValuationAllowance" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="loc_us-gaapDeferredTaxAssetsLiabilitiesNet" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsLiabilitiesNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/IncomeTaxesDetailsNarrative" xlink:title="00000079 - Disclosure - INCOME TAXES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="loc_us-gaapOperatingLossCarryforwardsTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapOperatingLossCarryforwardsTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="loc_us-gaapOperatingLossCarryforwardsLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingLossCarryforwardsTable" xlink:to="loc_us-gaapOperatingLossCarryforwardsLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaapIncomeTaxAuthorityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingLossCarryforwardsTable" xlink:to="loc_us-gaapIncomeTaxAuthorityAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaapIncomeTaxAuthorityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxAuthorityAxis" xlink:to="loc_us-gaapIncomeTaxAuthorityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCountryMember" xlink:label="loc_us-gaapForeignCountryMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxAuthorityDomain" xlink:to="loc_us-gaapForeignCountryMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DomesticCountryMember" xlink:label="loc_us-gaapDomesticCountryMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxAuthorityDomain" xlink:to="loc_us-gaapDomesticCountryMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="loc_us-gaapStateAndLocalJurisdictionMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxAuthorityDomain" xlink:to="loc_us-gaapStateAndLocalJurisdictionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:label="loc_us-gaapDeferredForeignIncomeTaxExpenseBenefit" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapDeferredForeignIncomeTaxExpenseBenefit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:label="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaapOperatingLossCarryforwards" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapOperatingLossCarryforwards" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="loc_us-gaapDeferredTaxAssetsTaxCreditCarryforwardsResearch" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapDeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardLimitationsOnUse" xlink:label="loc_us-gaapTaxCreditCarryforwardLimitationsOnUse" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapTaxCreditCarryforwardLimitationsOnUse" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="loc_us-gaapUnrecognizedTaxBenefits" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapUnrecognizedTaxBenefits" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/SubsequentEventsDetailsNarrative" xlink:title="00000080 - Disclosure - SUBSEQUENT EVENTS (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaapSubsequentEventsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaapSubsequentEventTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventsAbstract" xlink:to="loc_us-gaapSubsequentEventTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaapSubsequentEventLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapSubsequentEventLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeDomain" xlink:to="loc_us-gaapSubsequentEventMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaapDebtInstrumentFaceAmount" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapDebtInstrumentFaceAmount" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockDividendsShares" xlink:label="loc_us-gaapCommonStockDividendsShares" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapCommonStockDividendsShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="loc_us-gaapDebtInstrumentConvertibleConversionPrice1" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapDebtInstrumentConvertibleConversionPrice1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_BaseSalaryPercentage" xlink:label="loc_QLGNBaseSalaryPercentage" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_QLGNBaseSalaryPercentage" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20221231.xsd#QLGN_AnnualCashCompensation" xlink:label="loc_QLGNAnnualCashCompensation" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_QLGNAnnualCashCompensation" xlink:type="arc" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140569892342896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Apr. 11, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-37428<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Qualigen
Therapeutics, Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001460702<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">26-3474527<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">2042
Corte Del Nogal<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Carlsbad<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">92011<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(760)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">918-9165<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common
    Stock, par value $0.001 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">QLGN<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21,943,148<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,052,463<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentsIncorporatedByReferenceTextBlock', window );">Documents Incorporated by Reference [Text Block]</a></td>
<td class="text">None.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">23<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">BAKER TILLY US, LLP<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">San
Diego, California<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentsIncorporatedByReferenceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Documents incorporated by reference.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentsIncorporatedByReferenceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140569893027824">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Cash', window );">Cash</a></td>
<td class="nump">$ 7,034,434<span></span>
</td>
<td class="nump">$ 17,538,272<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net</a></td>
<td class="nump">538,587<span></span>
</td>
<td class="nump">822,351<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory, net</a></td>
<td class="nump">1,586,297<span></span>
</td>
<td class="nump">1,055,878<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">1,661,220<span></span>
</td>
<td class="nump">1,379,896<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">10,820,538<span></span>
</td>
<td class="nump">20,796,397<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalents', window );">Restricted cash</a></td>
<td class="nump">5,690<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use assets</a></td>
<td class="nump">1,422,538<span></span>
</td>
<td class="nump">1,645,568<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">345,087<span></span>
</td>
<td class="nump">204,217<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net</a></td>
<td class="nump">5,845,702<span></span>
</td>
<td class="nump">171,190<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">625,602<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">18,334<span></span>
</td>
<td class="nump">18,334<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total Assets</a></td>
<td class="nump">19,083,491<span></span>
</td>
<td class="nump">22,835,705<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">857,311<span></span>
</td>
<td class="nump">886,224<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_AccruedVacation', window );">Accrued vacation</a></td>
<td class="nump">467,948<span></span>
</td>
<td class="nump">282,910<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities', window );">Accrued expenses and other current liabilities</a></td>
<td class="nump">1,511,856<span></span>
</td>
<td class="nump">1,510,990<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_ResearchAndDevelopmentGrantLiability', window );">R&amp;D grant liability</a></td>
<td class="nump">780,682<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeCurrent', window );">Deferred revenue, current portion</a></td>
<td class="nump">116,161<span></span>
</td>
<td class="nump">135,063<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liability, current portion</a></td>
<td class="nump">240,645<span></span>
</td>
<td class="nump">134,091<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermBorrowings', window );">Short term debt - related party</a></td>
<td class="nump">950,722<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HedgingLiabilitiesCurrent', window );">Warrant liabilities</a></td>
<td class="nump">788,100<span></span>
</td>
<td class="nump">1,686,200<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_WarrantLiabilitiesRelatedParty', window );">Warrant liabilities - related party</a></td>
<td class="nump">2,834,547<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleDebt', window );">Convertible debt - related party</a></td>
<td class="nump">60,197<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">8,608,169<span></span>
</td>
<td class="nump">4,635,479<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liability, net of current portion</a></td>
<td class="nump">1,301,919<span></span>
</td>
<td class="nump">1,542,564<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredRevenueNoncurrent', window );">Deferred revenue, net of current portion</a></td>
<td class="nump">49,056<span></span>
</td>
<td class="nump">92,928<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilitiesNet', window );">Deferred tax liability</a></td>
<td class="nump">357,757<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">10,316,901<span></span>
</td>
<td class="nump">6,270,971<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and Contingencies (Note 13)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Qualigen Therapeutics, Inc. stockholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.001 par value; 225,000,000 shares authorized; 4,210,737 and 3,529,018 shares issued and outstanding as of December 31, 2022 and December 31, 2021, respectively</a></td>
<td class="nump">42,110<span></span>
</td>
<td class="nump">35,290<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">110,528,050<span></span>
</td>
<td class="nump">101,274,073<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income</a></td>
<td class="nump">50,721<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(103,385,172)<span></span>
</td>
<td class="num">(84,744,629)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total Qualigen Therapeutics, Inc. stockholders&#8217; equity</a></td>
<td class="nump">7,235,709<span></span>
</td>
<td class="nump">16,564,734<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Noncontrolling interest</a></td>
<td class="nump">1,530,881<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Total Stockholders&#8217; Equity</a></td>
<td class="nump">8,766,590<span></span>
</td>
<td class="nump">16,564,734<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total Liabilities &amp; Stockholders&#8217; Equity</a></td>
<td class="nump">$ 19,083,491<span></span>
</td>
<td class="nump">$ 22,835,705<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_AccruedVacation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued vacation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_AccruedVacation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_ResearchAndDevelopmentGrantLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Research and development grant liability</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_ResearchAndDevelopmentGrantLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_WarrantLiabilitiesRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_WarrantLiabilitiesRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesAndOtherLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Cash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=118262064&amp;loc=SL116631418-115840<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section 45<br> -Paragraph 21<br> -URI https://asc.fasb.org/extlink&amp;oid=118262064&amp;loc=SL116631419-115840<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Cash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, carrying amount of debt identified as being convertible into another form of financial instrument (typically the entity's common stock) as of the balance sheet date, which originally required full repayment more than twelve months after issuance or greater than the normal operating cycle of the company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income excluding obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 25<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=28183603&amp;loc=d3e692-112598<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31917-109318<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(c))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of the liability arising from a financial instrument or a contract used to mitigate a specified risk (hedge), and which are expected to be converted into cash or otherwise disposed of within a year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6904-107765<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.31)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reflects the total carrying amount as of the balance sheet date of debt having initial terms less than one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(13))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21914-107793<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4568740-111683<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21711-107793<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL125981372-237846<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 25: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4568447-111683<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140569888465136">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">225,000,000<span></span>
</td>
<td class="nump">225,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">4,210,737<span></span>
</td>
<td class="nump">3,529,018<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">4,210,737<span></span>
</td>
<td class="nump">3,529,018<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140569889492336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations and Comprehensive Loss - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>REVENUES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 4,983,556<span></span>
</td>
<td class="nump">$ 5,653,725<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingCostsAndExpensesAbstract', window );"><strong>EXPENSES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_CostOfProductSales', window );">Cost of product sales</a></td>
<td class="nump">4,302,755<span></span>
</td>
<td class="nump">4,332,485<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">10,835,647<span></span>
</td>
<td class="nump">11,724,964<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">6,837,133<span></span>
</td>
<td class="nump">11,716,718<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketingAndAdvertisingExpense', window );">Sales and marketing</a></td>
<td class="nump">950,420<span></span>
</td>
<td class="nump">542,594<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Goodwill and fixed asset impairment</a></td>
<td class="nump">4,239,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total expenses</a></td>
<td class="nump">27,164,955<span></span>
</td>
<td class="nump">28,316,761<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">LOSS FROM OPERATIONS</a></td>
<td class="num">(22,181,399)<span></span>
</td>
<td class="num">(22,663,036)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>OTHER EXPENSE (INCOME), NET</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeGainLossOnDerivativeNet', window );">Gain on change in fair value of warrant liabilities</a></td>
<td class="num">(907,203)<span></span>
</td>
<td class="num">(4,723,187)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestIncomeExpenseNet', window );">Interest (income) expense, net</a></td>
<td class="nump">26,646<span></span>
</td>
<td class="num">(42,693)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income, net</a></td>
<td class="num">(1,125)<span></span>
</td>
<td class="num">(5,446)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other expense (income), net</a></td>
<td class="num">(881,682)<span></span>
</td>
<td class="num">(4,771,326)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">LOSS BEFORE (BENEFIT) PROVISION FOR INCOME TAXES</a></td>
<td class="num">(21,299,717)<span></span>
</td>
<td class="num">(17,891,710)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">(BENEFIT) PROVISION FOR INCOME TAXES</a></td>
<td class="num">(265,074)<span></span>
</td>
<td class="nump">5,427<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">(21,034,643)<span></span>
</td>
<td class="num">(17,897,137)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Net loss attributable to noncontrolling interest</a></td>
<td class="num">(2,394,100)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss attributable to Qualigen Therapeutics, Inc.</a></td>
<td class="num">$ (18,640,543)<span></span>
</td>
<td class="num">$ (17,897,137)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per common share, basic and diluted</a></td>
<td class="num">$ (4.85)<span></span>
</td>
<td class="num">$ (6.10)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted&#8212;average number of shares outstanding, basic and diluted</a></td>
<td class="nump">3,840,340<span></span>
</td>
<td class="nump">2,933,487<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract', window );"><strong>Other comprehensive loss, net of tax</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation adjustment</a></td>
<td class="nump">$ 50,721<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest', window );">Other comprehensive loss</a></td>
<td class="num">(20,983,922)<span></span>
</td>
<td class="num">(17,897,137)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest', window );">Comprehensive loss attributable to noncontrolling interest</a></td>
<td class="num">(2,394,100)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss attributable to Qualigen Therapeutics, Inc.</a></td>
<td class="num">(18,589,822)<span></span>
</td>
<td class="num">(17,897,137)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=QLGN_NetProductSalesMember', window );">Net Product Sales [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>REVENUES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">4,983,556<span></span>
</td>
<td class="nump">5,021,721<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=QLGN_LicenseRevenueMember', window );">License Revenue [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>REVENUES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 632,004<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_CostOfProductSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cost of product sales.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_CostOfProductSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income (loss) and other comprehensive income (loss), attributable to noncontrolling interests. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(21))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 21<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4613674-111683<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569643-111683<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeGainLossOnDerivativeNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the fair value of derivatives recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5618551-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeGainLossOnDerivativeNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13854-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13777-109266<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126941158&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net amount of operating interest income (expense).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.10)<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketingAndAdvertisingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total expense recognized in the period for promotion, public relations, and brand or product advertising.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketingAndAdvertisingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingCostsAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingCostsAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=QLGN_NetProductSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=QLGN_NetProductSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=QLGN_LicenseRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=QLGN_LicenseRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140569888991616">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Changes in Stockholders' Equity - USD ($)<br></strong></div></th>
<th class="th">
<div>Preferred Stock [Member] </div>
<div>Series Alpha Convertible Preferred Stock [Member]</div>
</th>
<th class="th"><div>Common Stock [Member]</div></th>
<th class="th"><div>Additional Paid-in Capital [Member]</div></th>
<th class="th"><div>AOCI Attributable to Parent [Member]</div></th>
<th class="th"><div>Retained Earnings [Member]</div></th>
<th class="th"><div>Parent [Member]</div></th>
<th class="th"><div>Noncontrolling Interest [Member]</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance. value at Dec. 31, 2020</a></td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">$ 27,296<span></span>
</td>
<td class="nump">$ 85,114,755<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (66,847,492)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18,294,560<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Dec. 31, 2020</a></td>
<td class="nump">18<span></span>
</td>
<td class="nump">2,729,606<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_StockIssuedUponCashExerciseOfWarrants', window );">Stock issued upon cash-exercise of warrants</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 1,619<span></span>
</td>
<td class="nump">2,358,570<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,360,189<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_StockIssuedUponCashExerciseOfWarrantsShares', window );">Stock issued upon cash exercise of warrants, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">161,830<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_FairValueOfWarrantModificationForProfessionalServices', window );">Fair value of warrant modification for professional services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net Loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(17,897,137)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(17,897,137)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_StockIssuedUponNetexerciseOfWarrants', window );">Stock issued upon net-exercise of warrants</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 227<span></span>
</td>
<td class="num">(227)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_StockIssuedUponNetexerciseOfWarrantsShares', window );">Stock issued upon net-exercise of warrants, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,740<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_IssuanceOfCommonStockForConversionOfPreferredStock', window );">Issuance of common stock for conversion of preferred stock</a></td>
<td class="num">$ (1)<span></span>
</td>
<td class="nump">$ 243<span></span>
</td>
<td class="num">(243)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_IssuanceOfCommonStockSharesForConversionOfPreferredStock', window );">Issuance of common stock for conversion of preferred stock, shares</a></td>
<td class="num">(18)<span></span>
</td>
<td class="nump">24,342<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_FairValueOfWarrantsIssuedForProfessionalServices', window );">Fair value of warrants issued for professional services</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">298,651<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">298,651<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_SharesIssuedPursuantToSecuritiesPurchaseAgreements', window );">Shares issued pursuant to Securities Purchase Agreements</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 5,880<span></span>
</td>
<td class="nump">8,814,120<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,820,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_SharesIssuedPursuantToSecuritiesPurchaseShareAgreements', window );">Shares issued pursuant to Securities Purchase Agreements, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">588,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_CommissionAndOfferingCostsOfSecuritiesPurchaseAgreements', window );">Commission and offering costs of Securities Purchase Agreements</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(2,960,465)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,960,465)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_FairValueOfWarrantModificationsPursuantToSecuritiesPurchaseAgreements', window );">Fair value of warrant modifications pursuant to Securities Purchase Agreements</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">2,253,536<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,253,536<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Stock issued for professional services</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 25<span></span>
</td>
<td class="nump">101,725<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">101,750<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Stock issued for professional services, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition', window );">Stock-based compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">5,293,651<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,293,651<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance, value at Dec. 31, 2021</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 35,290<span></span>
</td>
<td class="nump">101,274,073<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(84,744,629)<span></span>
</td>
<td class="nump">$ 16,564,734<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">16,564,734<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Dec. 31, 2021</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">3,529,018<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_StockIssuedUponCashExerciseOfWarrants', window );">Stock issued upon cash-exercise of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,320<span></span>
</td>
<td class="nump">4,711<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">8,031<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">8,031<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_StockIssuedUponCashExerciseOfWarrantsShares', window );">Stock issued upon cash exercise of warrants, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">332,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions', window );">Stock-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">5,484,044<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">5,484,044<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">5,484,044<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_CommonStockAndPrefundedWarrantsIssuedForBusinessAcquisition', window );">Common stock and prefunded warrants issued for business acquisition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,500<span></span>
</td>
<td class="nump">3,740,417<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">3,743,917<span></span>
</td>
<td class="nump">3,882,225<span></span>
</td>
<td class="nump">7,626,142<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_CommonStockAndPrefundedWarrantsIssuedSharesForBusinessAcquisition', window );">Balance, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">350,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_NoncontrollingInterestAdjustmentsRelatingToStockbasedCompensationAndOther', window );">&#160;Noncontrolling interest adjustments relating to Stock-based compensation and other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(42,756)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(42,756)<span></span>
</td>
<td class="nump">42,756<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">50,721<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">50,721<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">50,721<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_FairValueOfWarrantModificationForProfessionalServices', window );">Fair value of warrant modification for professional services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">67,370<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">67,370<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">67,370<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_FairValueOfWarrantModificationForBusinessAcquisition', window );">Fair value of warrant modification for business acquisition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">696<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">696<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">696<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_StockIssuedDuringPeriodValuesReverseStockSplits', window );">Issuance of rounded shares as a result of the reverse stock split</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(505)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(505)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(505)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits', window );">Balance, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(281)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net Loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(18,640,543)<span></span>
</td>
<td class="num">(18,640,543)<span></span>
</td>
<td class="num">(2,394,100)<span></span>
</td>
<td class="num">(21,034,643)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_FairValueOfWarrantsIssuedForProfessionalServices', window );">Fair value of warrants issued for professional services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_FairValueOfWarrantModificationsPursuantToSecuritiesPurchaseAgreements', window );">Fair value of warrant modifications pursuant to Securities Purchase Agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,439<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance, value at Dec. 31, 2022</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 42,110<span></span>
</td>
<td class="nump">$ 110,528,050<span></span>
</td>
<td class="nump">$ 50,721<span></span>
</td>
<td class="num">$ (103,385,172)<span></span>
</td>
<td class="nump">$ 7,235,709<span></span>
</td>
<td class="nump">$ 1,530,881<span></span>
</td>
<td class="nump">$ 8,766,590<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Dec. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,210,737<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_CommissionAndOfferingCostsOfSecuritiesPurchaseAgreements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission and offering costs of securities purchase agreements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_CommissionAndOfferingCostsOfSecuritiesPurchaseAgreements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_CommonStockAndPrefundedWarrantsIssuedForBusinessAcquisition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common stock and prefunded warrants issued for business acquisition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_CommonStockAndPrefundedWarrantsIssuedForBusinessAcquisition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_CommonStockAndPrefundedWarrantsIssuedSharesForBusinessAcquisition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common stock and prefunded warrants issued shares for business acquisition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_CommonStockAndPrefundedWarrantsIssuedSharesForBusinessAcquisition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_FairValueOfWarrantModificationForBusinessAcquisition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of warrant modification for business acquisition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_FairValueOfWarrantModificationForBusinessAcquisition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_FairValueOfWarrantModificationForProfessionalServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of warrant modification for professional services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_FairValueOfWarrantModificationForProfessionalServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_FairValueOfWarrantModificationsPursuantToSecuritiesPurchaseAgreements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of warrant modifications pursuant to securities purchase agreements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_FairValueOfWarrantModificationsPursuantToSecuritiesPurchaseAgreements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_FairValueOfWarrantsIssuedForProfessionalServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of warrants issued for professional services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_FairValueOfWarrantsIssuedForProfessionalServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_IssuanceOfCommonStockForConversionOfPreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance of common stock for conversion of preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_IssuanceOfCommonStockForConversionOfPreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_IssuanceOfCommonStockSharesForConversionOfPreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance of common stock shares for conversion of preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_IssuanceOfCommonStockSharesForConversionOfPreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_NoncontrollingInterestAdjustmentsRelatingToStockbasedCompensationAndOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Noncontrolling interest adjustments relating to stockbased compensation and other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_NoncontrollingInterestAdjustmentsRelatingToStockbasedCompensationAndOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_SharesIssuedPursuantToSecuritiesPurchaseAgreements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Shares issued pursuant to securitie purchase agreements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_SharesIssuedPursuantToSecuritiesPurchaseAgreements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_SharesIssuedPursuantToSecuritiesPurchaseShareAgreements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Shares issued pursuant to securities purchase share agreements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_SharesIssuedPursuantToSecuritiesPurchaseShareAgreements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_StockIssuedDuringPeriodValuesReverseStockSplits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period values reverse stock splits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_StockIssuedDuringPeriodValuesReverseStockSplits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_StockIssuedUponCashExerciseOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued upon cash exercise of warrants</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_StockIssuedUponCashExerciseOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_StockIssuedUponCashExerciseOfWarrantsShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued upon cash exercise of warrants shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_StockIssuedUponCashExerciseOfWarrantsShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_StockIssuedUponNetexerciseOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued upon net exercise of warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_StockIssuedUponNetexerciseOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_StockIssuedUponNetexerciseOfWarrantsShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued upon net exercise of warrants shares</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_StockIssuedUponNetexerciseOfWarrantsShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) to additional paid-in capital (APIC) for recognition and exercise of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reduction in the number of shares during the period as a result of a reverse stock split.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21914-107793<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4568740-111683<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21711-107793<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL125981372-237846<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 25: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4568447-111683<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140569894206080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>CASH FLOWS FROM OPERATING ACTIVITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (21,034,643)<span></span>
</td>
<td class="num">$ (17,897,137)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">152,573<span></span>
</td>
<td class="nump">113,218<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense', window );">Amortization of right-of-use assets</a></td>
<td class="nump">223,030<span></span>
</td>
<td class="nump">225,059<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProvisionForDoubtfulAccounts', window );">Accounts receivable reserves and allowances</a></td>
<td class="num">(59,982)<span></span>
</td>
<td class="num">(247,845)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryWriteDown', window );">Inventory reserves</a></td>
<td class="nump">18,943<span></span>
</td>
<td class="num">(108,138)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims', window );">Common stock issued for professional services</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">101,750<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_FairValueOfWarrantsIssuedForProfessionalServices', window );">Fair value of warrants issued for professional services</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">298,651<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">5,484,044<span></span>
</td>
<td class="nump">5,293,651<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_FairValueOfWarrantModificationForProfessionalServices', window );">Fair value of warrant modification for professional services</a></td>
<td class="nump">67,370<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Goodwill and fixed asset impairment</a></td>
<td class="nump">4,239,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Change in fair value of warrant liabilities</a></td>
<td class="num">(906,345)<span></span>
</td>
<td class="num">(4,723,187)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="nump">417,708<span></span>
</td>
<td class="nump">41,250<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_IncreaseDecreaseInInventoryAndEquipmentHeldForLeases', window );">Inventory and equipment held for lease</a></td>
<td class="num">(637,410)<span></span>
</td>
<td class="nump">111,422<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other assets</a></td>
<td class="num">(99,251)<span></span>
</td>
<td class="nump">1,298,998<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="num">(33,397)<span></span>
</td>
<td class="nump">385,455<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities', window );">Accrued expenses and other current liabilities</a></td>
<td class="num">(76,266)<span></span>
</td>
<td class="nump">1,047,163<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_IncreaseDecreaseInResearchAndDevelopmentGrantLiability', window );">R&amp;D grant liability</a></td>
<td class="num">(534,426)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability', window );">Operating lease liability</a></td>
<td class="num">(134,091)<span></span>
</td>
<td class="num">(254,740)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="num">(62,775)<span></span>
</td>
<td class="num">(416,312)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDeferredLiabilities', window );">Deferred tax liability</a></td>
<td class="num">(271,622)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(13,247,540)<span></span>
</td>
<td class="num">(14,730,742)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>CASH FLOWS FROM INVESTING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(164,684)<span></span>
</td>
<td class="num">(134,471)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_PurchasesOfEquipmentHeldForLease', window );">Purchases of equipment held for lease</a></td>
<td class="num">(154,433)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireIntangibleAssets', window );">Payments for patents and licenses</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(6,893)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAcquiredFromAcquisition', window );">Net cash acquired in business combination</a></td>
<td class="nump">135,354<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(183,763)<span></span>
</td>
<td class="num">(141,364)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>CASH FLOWS FROM FINANCING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Net proceeds from warrant exercises</a></td>
<td class="nump">7,173<span></span>
</td>
<td class="nump">459,476<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_ProceedsFromIssuanceOfSharesAndWarrantsPursuantToSecuritiesPurchaseAgreements', window );">Proceeds from issuance of shares and warrants pursuant to Securities Purchase Agreements</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">8,820,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_ProceedsFromIssuanceOfConvertibleDebt', window );">Proceeds from issuance of convertible debt - related party</a></td>
<td class="nump">2,903,847<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Offering costs of Securities Purchase Agreements</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(706,929)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfNotesPayable', window );">Principal payments on notes payable</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(138,739)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_FractionalSharePaymentsRelatedToReverseStockSplit', window );">Fractional share payments related to the reverse stock split</a></td>
<td class="num">(505)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">2,910,515<span></span>
</td>
<td class="nump">8,433,808<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net change in cash and restricted cash</a></td>
<td class="num">(10,520,787)<span></span>
</td>
<td class="num">(6,438,298)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Effect of exchange rate changes on cash and restricted cash</a></td>
<td class="nump">22,639<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash and restricted cash - beginning of period</a></td>
<td class="nump">17,538,272<span></span>
</td>
<td class="nump">23,976,570<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash and restricted cash - end of period</a></td>
<td class="nump">7,040,123<span></span>
</td>
<td class="nump">17,538,272<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_CashPaidForAbstract', window );"><strong>Cash paid during the year for:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Interest</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">1,233<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaidNet', window );">Taxes</a></td>
<td class="nump">5,571<span></span>
</td>
<td class="nump">5,133<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>NONCASH FINANCING AND INVESTING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_IssuanceOfCommonStockForConversionOfPreferredStockBeforeClosingOfReverseRecapitalization', window );">Issuance of common stock for conversion of preferred stock after closing of reverse recapitalization</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">243<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_RightofuseAssetsObtainedInExchangeForOperatingLeaseLiabilities', window );">Right-of-use assets obtained in exchange for operating lease liabilities</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">1,439,830<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_SharesIssuedForCashlessWarrantsAmount', window );">Fair value of shares issued for cashless warrant exercises</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">764,657<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_TransfersOfInventoryFromEquipmentHeldForLease', window );">Net transfers to inventory from equipment held for lease</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">1,304<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_FairValueOfWarrantModificationsPursuantToSecuritiesPurchaseAgreements', window );">Fair value of warrant modifications pursuant to Securities Purchase Agreements</a></td>
<td class="nump">9,439<span></span>
</td>
<td class="nump">2,253,536<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_FairValueOfWarrantLiabilitiesOnDateOfExercise', window );">Fair value of warrant liabilities on date of exercise</a></td>
<td class="nump">858<span></span>
</td>
<td class="nump">1,900,713<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_FairValueOfWarrantModificationsForBusinessAcquisition', window );">Fair value of warrant modifications for business acquisition</a></td>
<td class="nump">33,543<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>ACQUISITION:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOfAssetsAcquired', window );">Fair value of assets acquired</a></td>
<td class="num">(5,896,278)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAssumed1', window );">Fair value of liabilities assumed, net of goodwill</a></td>
<td class="nump">2,321,845<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_FairValueOfWarrantsRepricedDueToAcquisition', window );">Fair value of Alpha Capital/Qualigen warrants repriced due to acquisition</a></td>
<td class="nump">696<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_FairValueOfQualigenPrefundedWarrantIssuedInExchangeForNanosynexStock', window );">Fair value of Qualigen prefunded warrant issued in exchange for NanoSynex stock</a></td>
<td class="nump">1,804,102<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssued1', window );">Fair value of Qualigen common stock issued in exchange for NanoSynex stock</a></td>
<td class="nump">1,904,989<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Net cash acquired in business combination (Note 3)</a></td>
<td class="nump">$ 135,354<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_CashPaidForAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash paid for abstract.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_CashPaidForAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_FairValueOfQualigenPrefundedWarrantIssuedInExchangeForNanosynexStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of qualigen prefunded warrant issued in exchange for nanosynex stock</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_FairValueOfQualigenPrefundedWarrantIssuedInExchangeForNanosynexStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_FairValueOfWarrantLiabilitiesOnDateOfExercise">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of warrant liabilities on date of exercise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_FairValueOfWarrantLiabilitiesOnDateOfExercise</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_FairValueOfWarrantModificationForProfessionalServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of warrant modification for professional services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_FairValueOfWarrantModificationForProfessionalServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_FairValueOfWarrantModificationsForBusinessAcquisition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of warrant modifications for business acquisition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_FairValueOfWarrantModificationsForBusinessAcquisition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_FairValueOfWarrantModificationsPursuantToSecuritiesPurchaseAgreements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of warrant modifications pursuant to securities purchase agreements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_FairValueOfWarrantModificationsPursuantToSecuritiesPurchaseAgreements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_FairValueOfWarrantsIssuedForProfessionalServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of warrants issued for professional services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_FairValueOfWarrantsIssuedForProfessionalServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_FairValueOfWarrantsRepricedDueToAcquisition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of warrants repriced due to acquisition</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_FairValueOfWarrantsRepricedDueToAcquisition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_FractionalSharePaymentsRelatedToReverseStockSplit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fractional share payments related to reverse stock split.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_FractionalSharePaymentsRelatedToReverseStockSplit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_IncreaseDecreaseInInventoryAndEquipmentHeldForLeases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase decrease in inventoryaAnd equipment held for leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_IncreaseDecreaseInInventoryAndEquipmentHeldForLeases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_IncreaseDecreaseInResearchAndDevelopmentGrantLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Research and development grant liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_IncreaseDecreaseInResearchAndDevelopmentGrantLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_IssuanceOfCommonStockForConversionOfPreferredStockBeforeClosingOfReverseRecapitalization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance of common stock for conversion of preferred stock before closing of reverse recapitalization.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_IssuanceOfCommonStockForConversionOfPreferredStockBeforeClosingOfReverseRecapitalization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_ProceedsFromIssuanceOfConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from issuance of convertible debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_ProceedsFromIssuanceOfConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_ProceedsFromIssuanceOfSharesAndWarrantsPursuantToSecuritiesPurchaseAgreements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from issuance of shares and warrants pursuant to securities purchase agreements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_ProceedsFromIssuanceOfSharesAndWarrantsPursuantToSecuritiesPurchaseAgreements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_PurchasesOfEquipmentHeldForLease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Purchases of equipment held for lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_PurchasesOfEquipmentHeldForLease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_RightofuseAssetsObtainedInExchangeForOperatingLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Rightofuse assets obtained in exchange for operating lease liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_RightofuseAssetsObtainedInExchangeForOperatingLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_SharesIssuedForCashlessWarrantsAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Shares issued for cashless warrants amount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_SharesIssuedForCashlessWarrantsAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_TransfersOfInventoryFromEquipmentHeldForLease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Transfers of inventory from equipment held for lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_TransfersOfInventoryFromEquipmentHeldForLease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferred1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126966197&amp;loc=d3e6613-128477<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126975305&amp;loc=d3e6927-128479<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126966197&amp;loc=d3e6578-128477<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferred1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAcquiredFromAcquisition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the acquisition of business during the period (for example, cash that was held by the acquired business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAcquiredFromAcquisition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section 25<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=109262497&amp;loc=d3e20148-110875<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfAssetsAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The fair value of assets acquired in noncash investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4313-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4332-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfAssetsAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13854-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13777-109266<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4297-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 310<br> -Section 45<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126938201&amp;loc=d3e55415-109406<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDeferredLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Change during the period in carrying value for all deferred liabilities due within one year or operating cycle.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDeferredLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in other obligations or expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3367-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWriteDown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4542-108314<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWriteDown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of share-based compensation granted to nonemployees as payment for services rendered or acknowledged claims.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAssumed1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The fair value of liabilities assumed in noncash investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4304-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4332-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4313-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAssumed1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashInvestingAndFinancingItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for right-of-use asset from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProvisionForDoubtfulAccounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (reversal of expense) for expected credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919249-210447<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProvisionForDoubtfulAccounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for a borrowing supported by a written promise to pay an obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The fair value of stock issued in noncash financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4304-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4332-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4313-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140569898322432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND ESTIMATES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock', window );">ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND ESTIMATES</a></td>
<td class="text"><p id="xdx_80D_eus-gaap--OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_zFtXKJBIDe11" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
1 &#8212; <span id="xdx_829_zkOtCUiAh3ch">ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND ESTIMATES</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_84C_ecustom--OrganizationPolicyTextBlock_zeWI3RRbueC4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86A_z2jwwuWoT1kg">Organization</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Qualigen,
Inc., now a subsidiary of Qualigen Therapeutics, Inc., was incorporated in Minnesota in 1996 to design, develop, manufacture and sell
Physician Office Laboratory (&#8220;POL&#8221;) market quantitative immunoassay diagnostic products for use in physician offices and
other point-of-care settings worldwide, and was reincorporated in Delaware in 1999. In May 2020, Qualigen, Inc. completed a reverse recapitalization
transaction with Ritter Pharmaceuticals, Inc. (&#8220;Ritter&#8221;) and Ritter was renamed Qualigen Therapeutics, Inc. All shares of
Qualigen, Inc.&#8217;s capital stock were exchanged for Qualigen Therapeutics, Inc.&#8217;s capital stock in the merger. Ritter/Qualigen
Therapeutics common stock, which was previously traded on the Nasdaq Capital Market under the ticker symbol &#8220;RTTR,&#8221; commenced
trading on the Nasdaq Capital Market, on a post-reverse-stock-split adjusted basis, under the trading symbol &#8220;QLGN&#8221; on May
26, 2020. Qualigen Therapeutics, Inc. (the &#8220;Company&#8221;) operates in one business segment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">On
May 26, 2022, the Company acquired <span id="xdx_903_eus-gaap--StockIssuedDuringPeriodSharesAcquisitions_c20220524__20220526__us-gaap--BusinessAcquisitionAxis__custom--NanoSynexLtdMember__us-gaap--StatementClassOfStockAxis__custom--SeriesAOnePreferredStockMember_zfMeIdzOzlJa" title="Number of common stock acquired shares">2,232,861</span> shares of Series A-1 Preferred Stock of NanoSynex, Ltd. (&#8220;NanoSynex&#8221;) from Alpha
Capital Anstalt (&#8220;Alpha Capital&#8221;), a related party, in exchange for <span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodSharesAcquisitions_c20220524__20220526__us-gaap--BusinessAcquisitionAxis__custom--NanoSynexLtdMember_zks2Cx6r38pd" title="Number of common stock acquired shares">350,000</span> reverse split adjusted shares of the Company&#8217;s common stock and a prefunded warrant
to purchase <span id="xdx_904_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_c20220526__us-gaap--StatementEquityComponentsAxis__custom--PrefundedWarrantMember_zrdIBprn3PV4" title="Warrants to purchase common stock">331,464 reverse split adjusted shares of the Company&#8217;s common stock at an exercise price of $<span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20220526__us-gaap--StatementEquityComponentsAxis__custom--PrefundedWarrantMember_zHeVCJY9m9L4" title="Class of Warrant or Right, Exercise Price of Warrants or Rights">0.001</span> per share. <span id="xdx_901_eus-gaap--StockholdersEquityReverseStockSplit_c20220525__20220526_zPIU0Z15PR81" title="Reverse split, description">These warrants were subsequently exercised on September 13, 2022</span>. Concurrently with this transaction,
the Company also purchased <span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodSharesAcquisitions_c20220524__20220526__us-gaap--BusinessAcquisitionAxis__custom--NanoSynexLtdMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zotzw9HT11Zf" title="Stock issued during period shares acquisitions">381,786</span> shares of Series B preferred stock from NanoSynex for a total purchase price of $<span id="xdx_909_eus-gaap--StockIssuedDuringPeriodValueAcquisitions_pp0p0_c20220524__20220526__us-gaap--BusinessAcquisitionAxis__custom--NanoSynexLtdMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zdCN0AghKGfa" title="Stock issued during period, value, acquisitions">600,000</span>. The transactions
resulted in the Company acquiring a <span id="xdx_902_eus-gaap--BusinessAcquisitionPercentageOfVotingInterestsAcquired_iI_pid_dp_uPure_c20220526__us-gaap--BusinessAcquisitionAxis__custom--NanoSynexLtdMember_zxyij6GwHYRj" title="Voting interests acquired">52.8</span>% interest in NanoSynex. The Company envisions future synergies from the integration of its own
proprietary results-proven FastPack diagnostics platform with the innovative NanoSynex technology. NanoSynex is a micro-biologics diagnostics
company domiciled in Israel.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_845_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_z1Pi6ADgTcDe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86C_zG5TuUfpYqN8">Basis
of Presentation</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying consolidated financial statements of the Company have been prepared in conformity with accounting principles generally accepted
in the United States of America (&#8220;U.S. GAAP&#8221;), Regulation S-X and rules and regulations of the Securities and Exchange Commission
(&#8220;SEC&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_844_eus-gaap--ConsolidationPolicyTextBlock_zc9xiQDmxLdj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_865_zMvhOGZXViX">Principles
of Consolidation</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying consolidated financial statements include the accounts of the Company and its majority owned subsidiaries. All intercompany
balances and transactions have been eliminated in consolidation. Any reference in these notes to applicable guidance is meant to refer
to U.S. GAAP. The Company views its operations and manages its business in one operating segment. In general, the functional currency
of the Company and its subsidiaries is the U.S. dollar, however for NanoSynex, the functional currency is the local currency, New Israeli
Shekels (NIS). As such, assets and liabilities for NanoSynex are translated into U.S. dollars and the effects of foreign currency translation
adjustments are reflected as a component of accumulated other comprehensive income within the Company&#8217;s consolidated statements
of changes in stockholders&#8217; equity.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_84F_eus-gaap--UseOfEstimates_zp75wf8bIeGk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_868_zng6SGdCYpk5">Accounting
Estimates</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management
uses estimates and assumptions in preparing its consolidated financial statements in accordance with U.S. GAAP. Those estimates and assumptions
affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities, and the reported revenues
and expenses. The most significant estimates relate to the estimated fair value of in-process research and development, goodwill, warrant
liabilities, stock-based compensation, amortization and depreciation, inventory reserves, allowances for doubtful accounts and returns,
and warranty costs. Actual results could vary from the estimates that were used.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_844_eus-gaap--StockholdersEquityReverseStockSplit_zDVn316Ow2Cb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86B_zyCSoAvlK6Ie">Reverse
Stock Split</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
November 23, 2022, the Company effected a 1-for-10, as determined by the Company&#8217;s board of directors, reverse stock split of its
outstanding shares of common stock (the &#8220;Reverse Stock Split&#8221;). The Reverse Stock Split reduced the Company&#8217;s shares
of outstanding common stock, stock options, and warrants to purchase shares of our common stock. Fractional shares of common stock that
would have otherwise resulted from the Reverse Stock Split were rounded down to the nearest whole share and cash in lieu of payments
were made to stockholders. All share and per share data for all periods presented in the accompanying financial statements and the related
disclosures have been adjusted retrospectively to reflect the Reverse Stock Split. The number of authorized shares of common stock and
the par value per share remains unchanged.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p id="xdx_84F_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_z37X8m4Hmt6e" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86C_zpPLvuZmDhz6">Cash</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company considers all highly liquid investments purchased with an initial maturity of 90 days or less and money market funds to be cash
equivalents. Restricted cash includes cash that is restricted due to Israeli banking regulations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company maintains the majority of its cash in accounts at banking institutions in the U.S. that are of high quality.
Cash held in these accounts often exceed the FDIC insurance limits. If such banking institutions were to fail, the Company could lose
all or a portion of amounts held in excess of such insurance limitations. The FDIC recently took control of two such banking institutions,
Silicon Valley Bank on March 10, 2023 and Signature Bank on March 12, 2023. While the Company did not have an account at either of these two banks, in
the event of failure of any of the financial institutions where the Company maintains its cash and cash equivalents, there can be no
assurance that the Company would be able to access uninsured funds in a timely manner or at all. Any inability to access or delay in
accessing these funds could adversely affect our business and financial position.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_847_eus-gaap--InventoryPolicyTextBlock_zGf7dL4h9BTf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_866_z33yerdHlCCf">Inventory,
Net</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inventory
is recorded at the lower of cost or net realizable value. Cost is determined using the first-in, first-out method. The Company reviews
the components of its inventory on a periodic basis for excess or obsolete inventory, and records reserves for inventory components identified
as excess or obsolete.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_848_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_zk9MLFjdKX3c" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_864_zQs6GPn4XfVb">Impairment
of Long-Lived Assets</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company assesses potential impairments to its long-lived assets when there is evidence that events or changes in circumstances indicate
that assets may not be recoverable. An impairment loss would be recognized when the sum of the expected future undiscounted cash flows
is less than the carrying amount of the assets. The amount of impairment loss, if any, will generally be measured as the difference between
the net book value of the assets and their estimated fair values. During the fiscal year ending December 31, 2022 the Company recorded
an impairment loss of $<span id="xdx_907_eus-gaap--AssetImpairmentCharges_c20220101__20221231_z1ZrkrruzaJd" title="Impairment losses on construction-in-progress">4,239,000</span> related to the NanoSynex acquisition.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_84C_eus-gaap--SegmentReportingPolicyPolicyTextBlock_zZfhfcFxJmJ6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_860_zxtDXJfGGB1e">Segment
Reporting</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating
segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation
by the chief operating decision-maker in making decisions regarding resource allocation and assessing performance. To date, the Company
has viewed its operations and managed its business as one segment operating primarily within the United States and Israel.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_840_eus-gaap--TradeAndOtherAccountsReceivablePolicy_zsaXR112070d" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_865_zY0FbtBxe95i">Accounts
Receivable, Net</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company grants credit to domestic physicians, clinics, and distributors. The Company performs ongoing credit evaluations of its customers
and generally requires no collateral. Customers can purchase certain products through a financing agreement that the Company has with
an outside leasing company. Under the agreement, the leasing company evaluates the credit worthiness of the customer. Upon acceptance
of the product by the customer, the leasing company remits payment to the Company at a discount. This financing arrangement is without
recourse to the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company records an allowance for doubtful accounts and returns equal to the estimated uncollectible amounts or expected returns. The
Company&#8217;s estimates are based on historical collections and returns and a review of the current status of trade accounts receivable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_893_eus-gaap--ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_zQIpz9BhMTj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accounts
receivable is comprised of the following at:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span id="xdx_8B0_zE01wFmfI8La" style="display: none">SCHEDULE
OF ACCOUNTS RECEIVABLE</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_49C_20221231_zvfQMHAuvDj7" style="font-weight: bold; text-align: center">December 31,</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_492_20211231_zxut4lxKKfY1" style="font-weight: bold; text-align: center">December 31,</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--AccountsReceivableGrossCurrent_iI_pp0p0_maARNCz1PU_maARNCzMpq_zouIgJCiaAvj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Accounts Receivable</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">726,449</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">958,448</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--AllowanceForDoubtfulAccountsReceivableCurrent_iNI_pp0p0_di_msARNCz1PU_msARNCzMpq_zKWim65hnST7" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Less Reserves and Allowances</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(187,862</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(136,097</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_40C_eus-gaap--AccountsReceivableNetCurrent_iTI_pp0p0_mtARNCzMpq_zJsnp5ZYOKe2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Accounts receivable,
    net</span></td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">538,587</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">822,351</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A7_zNcz49UOgnh7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_84E_eus-gaap--ResearchAndDevelopmentExpensePolicy_ztMuZpwk3j0d" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86F_z19JFpz1Rujl">Research
and Development</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Except
for acquired in process research and development (IPR&amp;D), the Company expenses research and development costs as incurred including
therapeutics license costs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p id="xdx_844_ecustom--ResearchAndDevelopmentGrantsPolicyTextBlock_zxQP3l4NISq8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86A_zkHH9mEzbZCg">R&amp;D
Grants</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NanoSynex
has received R&amp;D grants from Israel Innovation Authority (IIA) and from the European Commission. These grants may provide cash funding
to NanoSynex from time to time in advance of the applicable costs being incurred. When such cash funding is received from these grants
in advance, the proceeds are recorded as a current or non-current R&amp;D grant liability based on the time from the consolidated balance
sheets date to the expected future date of recognition as a reduction to research and development expenses.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_841_ecustom--PatentCostsPolicyTextBlock_zBCruCgfuRp3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_868_z37jRTIWlBl4">Patent
Costs</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company expenses all costs as incurred in connection with patent applications (including direct application fees, and the legal and consulting
expenses related to making such applications) and such costs are included in general and administrative expenses in the consolidated
statement of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_841_ecustom--ShippingAndHandlingCostsPolicyTextBlock_zwI40cOosWhg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_868_zOB31OSRUN04">Shipping
and Handling Costs</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company includes shipping and handling fees billed to customers in net sales. Shipping and handling costs associated with inbound and
outbound freight are generally recorded in cost of sales; such shipping and handling costs totaled approximately $<span id="xdx_904_eus-gaap--CostOfGoodsAndServicesSold_c20220101__20221231__srt--ProductOrServiceAxis__us-gaap--ShippingAndHandlingMember_zdk8CCBRyhze" title="Cost of Goods and Services Sold">267,000</span> and $<span id="xdx_904_eus-gaap--CostOfGoodsAndServicesSold_c20210101__20211231__srt--ProductOrServiceAxis__us-gaap--ShippingAndHandlingMember_zCWJOmSRtr47" title="Cost of Goods and Services Sold">113,000</span>,
respectively, for the years December 31, 2022 and 2021. Other shipping and handling costs included in general and administrative, research
and development, and sales and marketing expenses totaled approximately $<span id="xdx_901_eus-gaap--CostOfGoodsAndServicesSold_c20220101__20221231__us-gaap--IncomeStatementLocationAxis__custom--GeneralAdministrativeResearchAndDevelopmentExpensesMember_zNAiaPKLGGPg" title="Other shipping and handling costs">14,000</span> and $<span id="xdx_908_eus-gaap--CostOfGoodsAndServicesSold_c20210101__20211231__us-gaap--IncomeStatementLocationAxis__custom--GeneralAdministrativeResearchAndDevelopmentExpensesMember_z9cn1bTADg3d" title="Other shipping and handling costs">12,000</span> for the years ended December 31, 2022 and
2021, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_84E_eus-gaap--RevenueRecognitionPolicyTextBlock_zABQ76nng5rl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86B_zk6ye9FRqsz3">Revenue
from Contracts with Customers</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company applies the following five-step model in accordance with ASC 606, Revenue from Contracts with Customers, in order to determine
revenue: (i) identification of the promised goods or services in the contract; (ii) determination of whether the promised goods or services
are performance obligations, including whether they are distinct in the context of the contract; (iii) measurement of the transaction
price, including the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations; and
(v) recognition of revenue when (or as) the Company satisfies each performance obligation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Product
Sales</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company generates revenue from selling FastPack System analyzers, accessories and disposable products used with the FastPack System.
Disposable products include reagent packs, which are diagnostic tests for prostate-specific antigen, testosterone, thyroid disorders,
pregnancy, and Vitamin D.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company provides disposable products and equipment in exchange for consideration, which occurs when a customer submits a purchase order
and the Company provides disposable products and equipment at the agreed upon prices in the invoice. Generally, customers purchase disposable
products using separate purchase orders after the equipment (&#8220;analyzer&#8221;) has been provided to the customer. The initial delivery
of the equipment and reagent packs represents a single performance obligation and is completed upon receipt by the customer. The delivery
of each subsequent individual reagent pack represents a separate performance obligation because the reagent packs are standardized, are
not interrelated in any way, and the customer can benefit from each reagent pack without any other product. There are no significant
discounts, rebates, returns or other forms of variable consideration. Customers are generally required to pay within 30 days.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
performance obligation arising from the delivery of the equipment is satisfied upon the delivery of the equipment to the customer. The
disposable products are shipped Free on Board (&#8220;FOB&#8221;) shipping point. For disposable products that are shipped FOB shipping
point, the customer has the significant risks and rewards of ownership and legal title to the assets when the disposable products leave
the Company&#8217;s shipping facilities, thus the customer obtains control and revenue is recognized at that point in time.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has elected the practical expedient and accounting policy election to account for the shipping and handling as activities to
fulfill the promise to transfer the disposable products and not as a separate performance obligation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s contracts with customers generally have an expected duration of one year or less, and therefore the Company has elected
the practical expedient in ASC 606 to not disclose information about its remaining performance obligations. Any incremental costs to
obtain contracts are recorded as selling, general and administrative expense as incurred due to the short duration of the Company&#8217;s
contracts.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>License
Revenue</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company entered into an out-license agreement with Yi Xin to develop and/or commercialize its products in exchange for nonrefundable
upfront license fees and/or sales-based royalties.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
the license to the Company&#8217;s intellectual property is determined to be distinct from the other performance obligations identified
in the arrangement, the Company recognizes revenue from nonrefundable upfront fees allocated to the license when the license is transferred
to the customer and the customer can benefit from the license. For licenses that are bundled with other performance obligations, management
uses judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is
satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing
revenue from nonrefundable upfront fees. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts
the measure of progress and related revenue recognition. During years ended December 31, 2022 and 2021, the Company recognized license
revenue of approximately $<span id="xdx_90D_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_dxL_c20220101__20221231__srt--ProductOrServiceAxis__custom--LicenseRevenuesMember_zFBg85urxvHl" title="::XDX::-"><span style="-sec-ix-hidden: xdx2ixbrl0752">0</span></span> and $<span id="xdx_90A_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20210101__20211231__srt--ProductOrServiceAxis__custom--LicenseRevenuesMember_zIZj4c0axwf4">632,000</span>, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Contract
Asset and Liability Balances</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
timing of the Company&#8217;s revenue recognition may differ from the timing of payment by the Company&#8217;s customers. The Company
records a receivable when revenue is recognized prior to payment and there is an unconditional right to payment. Alternatively, when
payment precedes the performance of the related services, the Company records deferred revenue until the performance obligations are
satisfied.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Multiple
performance obligations include contracts that combine both the Company&#8217;s analyzer and a customer&#8217;s future reagent purchases
under a single contract. In some sales contracts, the Company provides analyzers at no charge to customers. Title to the analyzer is
maintained by the Company and the analyzer is returned by the customer to the Company at the end of the purchase agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the years December 31, 2022 and 2021, product sales are stated net of an allowance for estimated returns of approximately $<span id="xdx_90F_ecustom--AllowancesForSalesReturn_c20220101__20221231_z3orAMfHfQTa" title="Allowance for estimated returns">96,000</span> and
$<span id="xdx_90C_ecustom--AllowancesForSalesReturn_c20210101__20211231_zplKcwOU6s79" title="Allowance for estimated returns">150,000</span>, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_84E_ecustom--DeferredRevenuePolicyTextBlock_zoQqOxBjcdPg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86C_zN6oYNVEGld1">Deferred
Revenue</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Payments
received in advance from customers pursuant to certain collaborative research license agreements, deposits against future product sales,
multiple element arrangements and extended warranties are recorded as a current or non-current deferred revenue liability based on the
time from the Consolidated Balance Sheet date to the future date of revenue recognition.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_848_eus-gaap--LesseeLeasesPolicyTextBlock_zwgVxRU1aNrj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_860_ztpvsNrpeia6">Operating
Leases</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effective
April 1, 2020, the Company adopted Accounting Standards Update (&#8220;ASU&#8221;) No. 2018-11, <i>Leases (Topic 842) Targeted Improvements
</i>(&#8220;Topic 842&#8221;). In accordance with the guidance in Topic 842, the Company recognizes lease liabilities and corresponding
right-of-use-assets for all leases with terms of greater than 12 months. Leases with a term of 12 months or less will be accounted for
in a manner similar to the guidance for operating leases prior to the adoption of Topic 842. (See Note 13-Commitments and Contingencies).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_84B_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zxkFwQXeVvI3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86E_zUjoRKE3YoLk">Property
and Equipment, Net</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_89A_ecustom--ScheduleOfUsefulLivesOfPropertyAndEquipmentTableTextBlock_zFBqhrfk1vIi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property
and equipment are stated at cost and are presented net of accumulated depreciation. Depreciation is provided for on a straight-line basis
over the estimated useful lives of the related assets as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span id="xdx_8B2_zAPA13MDyEXg" style="display: none">SCHEDULE
OF USEFUL LIVES OF PROPERTY AND EQUIPMENT</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 77%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Machinery
    and equipment</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 23%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_904_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20220101__20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--MachineryAndEquipmentMember_zqufBTavuQy3" title="Property and equipment, useful life">5</span>
    years</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Computer
    equipment</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_908_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20220101__20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember_zawkBQjlOUM3" title="Property and equipment, useful life">3</span>
    years</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Molds
    and tooling</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90A_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20220101__20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--MoldsAndToolingMember_zIvIh9XUZzWi" title="Property and equipment, useful life">5</span>
    years</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Furniture
    and fixtures</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_906_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20220101__20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_z5DGlGqVKWNg" title="Property and equipment, useful life">5</span>
    years</span></td></tr>
  </table>
<p id="xdx_8A6_zffzxAM1cCy5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Leasehold
improvements are amortized on a straight-line basis over the shorter of the lease term or their estimated useful lives. The Company occasionally
designs and builds its own machinery. The costs of these projects, which includes the cost of construction and other direct costs attributable
to the construction, are capitalized as construction in progress. No provision for depreciation is made on construction in progress until
the relevant assets are completed and placed in service.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s policy is to evaluate the remaining lives and recoverability of long-term assets on at least an annual basis or when
conditions are present that indicate impairment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p id="xdx_841_eus-gaap--BusinessCombinationsPolicy_zvdZiwqEUsXg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86F_zfZHqhXQ1spi">Business
Combinations</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounts for business combinations using the acquisition method pursuant to FASB ASC Topic 805. This method requires, among other
things, that results of operations of acquired companies are included in Qualigen&#8217;s financial results beginning on the respective
acquisition dates, and that assets acquired and liabilities assumed and noncontrolling interests are recognized at fair value as of the
acquisition date. Intangible assets acquired in a business combination are recorded at fair value using a discounted cash flow model.
We have third-party valuations completed for intangible assets in a business combination using a discounted cash flow analysis, incorporating
various assumptions. The discounted cash flow model requires assumptions about the timing and amount of future net cash flows, the cost
of capital and terminal values from the perspective of a market participant. Each of these factors can significantly affect the value
of the intangible asset. Any excess of the fair value of consideration transferred (the &#8220;Purchase Price&#8221;) over the fair values
of the net assets acquired is recognized as goodwill. The fair value of assets acquired and liabilities assumed in certain cases may
be subject to revision based on the final determination of fair value during a period of time not to exceed 12 months from the acquisition
date. Legal costs, due diligence costs, business valuation costs and all other acquisition-related costs are expensed when incurred.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p id="xdx_845_eus-gaap--GoodwillAndIntangibleAssetsPolicyTextBlock_zbYKJt4uxjJi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_862_zcL6YjOj8s15">Goodwill</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Goodwill
represents the difference between the purchase price and the fair value of the identifiable tangible and intangible net assets
acquired, when accounted for using the purchase method of accounting. Goodwill has an indefinite useful life and is not amortized
but is reviewed for impairment annually and whenever events or changes in circumstances indicate that the carrying value of the
goodwill may not be recoverable. In testing for impairment, the fair value of the reporting unit is compared to the carrying value.
If the net assets assigned to the reporting unit exceed the fair value of the reporting unit, an impairment loss equal to the
difference is recorded. As a result of the annual goodwill impairment analysis, the Company recognized a $<span id="xdx_905_eus-gaap--GoodwillImpairmentLoss_c20220101__20221231_zPKuBPchBib5" title="Goodwill impairment charges">4,239,000</span>
non-cash goodwill and fixed asset impairment charge in the valuation of its business acquisition of NanoSynex for the year ended
December 30, 2022. For more information, refer to Note 1 - Organization and Summary of Significant Accounting Policies and Estimates
and Note 7 - Goodwill, IPR&amp;D and other Intangibles.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_844_eus-gaap--IntangibleAssetsFiniteLivedPolicy_zwDMssJ6GRgf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86C_zQvb0w9eUW4c">Intangible
Assets</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>In
Process R&amp;D</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Acquired
in process R&amp;D (IPR&amp;D) represents the fair value assigned to the research and development assets that have not reached technological
feasibility. The value assigned to IPR&amp;D is determined by estimating the costs to develop the acquired technology into commercially
viable products, estimating the resulting revenue from the projects, and discounting the net cash flow to present value. The revenue
and cost projections used to value acquired IPR&amp;D are, as applicable, reduced based on the probability of success of developing the
new product. Additionally, projections consider relevant market sizes and growth factors, expected trends in technology and the nature
and expected timing of new product introductions. The rates utilized to discount the net cash flow to its present value are commensurate
with the stage of development of the project and uncertainties in the economic estimates used in the projections. Upon the acquisition
of acquired IPR&amp;D, an assessment is completed as to whether the acquisition constitutes an acquisition of a single asset or a group
of assets. Multiple factors are considered in this assessment, including the nature of the technology acquired, the presence or absence
of separate cash flows, the development process and stage of completion, quantitative significance, and the Company&#8217;s rationale
for entering into the transaction.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
a business is acquired, as defined under the applicable accounting standards, then the acquired IPR&amp;D is capitalized as an intangible
asset. If an asset or group of assets is acquired that do not meet the definition under the applicable accounting standards, then the
acquired IPR&amp;D is expensed on its acquisition date. Future costs to develop these assets are recorded to research and development
expense in the Company&#8217;s consolidated statements of operations and comprehensive loss as they are incurred.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">IPR&amp;D
is evaluated for impairment annually using the same methodology as described above for calculating fair value. If the carrying value
of the acquired IPR&amp;D exceeds the fair value, then the intangible asset is written down to its fair value, with the resulting adjustment
recorded as a charge to operations. Changes in estimates and assumptions used in determining the fair value of acquired IPR&amp;D could
result in an impairment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Other
Intangible Assets, Net</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
intangible assets consist of patent-related costs and costs for license agreements. Management reviews the carrying value of other intangible
assets that are being amortized on an annual basis or sooner when there is evidence that events or changes in circumstances may indicate
that impairment exists. The Company considers relevant cash flow and profitability information, including estimated future operating
results, trends and other available information, in assessing whether the carrying value of intangible assets being amortized can be
recovered.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
the Company determines that the carrying value of other intangible assets will not be recovered from the undiscounted future cash flows
expected to result from the use and eventual disposition of the underlying assets, the Company considers the carrying value of such intangible
assets as impaired and reduces them by a charge to operations in the amount of the impairment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Costs
related to acquiring patents and licenses are capitalized and amortized over their estimated useful lives, which is generally<span id="xdx_90C_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dtY_c20220101__20221231__srt--RangeAxis__srt--MinimumMember__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PatentsAndLicensesMember_zkxYMMM8Ak3f" title="Estimated useful lives"> 5</span> to <span id="xdx_902_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dtY_c20220101__20221231__srt--RangeAxis__srt--MaximumMember__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PatentsAndLicensesMember_zWMNAhPGgml7" title="Estimated useful lives">17</span>
years, using the straight-line method. Amortization of patents and licenses commences once final approval of the patent or license has
been obtained. Patent and license costs are charged to operations if it is determined that the patent or license will not be obtained.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_84A_ecustom--DerivativeFinancialInstrumentsAndWarrantLiabilitiesPolicyTextBlock_zYk7vHQpnWp7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86A_zNtcOzvKQ3g7">Derivative
Financial Instruments and Warrant Liabilities</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company does not use derivative instruments to hedge exposures to cash flow, market, or foreign currency risks. The Company evaluates
all of its financial instruments, including issued stock purchase warrants, to determine if such instruments are derivatives or contain
features that qualify as embedded derivatives. For derivative financial instruments that are accounted for as liabilities, the derivative
instrument is initially recorded at its fair value and is then re-valued at each reporting date, with changes in the fair value reported
in the consolidated statements of operations and comprehensive loss. Depending on the features of the derivative financial instrument,
the Company uses either the Black-Scholes option-pricing model or a Monte-Carlo simulation to value the derivative instruments at inception
and subsequent valuation dates. The classification of derivative instruments, including whether such instruments should be recorded as
liabilities or as equity, is re-assessed at the end of each reporting period (See Note 10-Warrant Liabilities and Note 11- Convertible
Debt - Related Party).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Fair
Value Measurements</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company determines the fair value measurements of applicable assets and liabilities based on a three-tier fair value hierarchy established
by accounting guidance and prioritizes the inputs used in measuring fair value. The Company discloses and recognizes the fair value of
its assets and liabilities using a hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy
gives the highest priority to valuations based upon unadjusted quoted prices in active markets for identical assets or liabilities (Level
1 measurements) and the lowest priority to valuations based upon unobservable inputs that are significant to the valuation (Level 3 measurements).
The guidance establishes three levels of the fair value hierarchy as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
                                            1 - Inputs that reflect unadjusted quoted prices in active markets for identical assets or
                                            liabilities that the Company has the ability to access at the measurement date;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
                                            2 - Inputs other than quoted prices that are observable for the assets or liability either
                                            directly or indirectly, including inputs in markets that are not considered to be active;
                                            and</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
                                            3 - Inputs that are unobservable.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_84D_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zP6ZVVYW4Vx8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_861_z3ymfQ7hS3v4">Fair
Value of Financial Instruments</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash,
accounts receivable, prepaids, accounts payable, and accrued liabilities are carried at cost, which management believes approximates
fair value due to the short-term nature of these instruments.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_840_eus-gaap--AdvertisingCostsPolicyTextBlock_zYVNkMB16xgf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_867_zXo6xMwPUfAi">Advertising</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Advertising
expense consists primarily of print and digital media promotional materials for a distributor. Advertising costs are expensed as incurred.
Advertising expense for the years ended December 31, 2022 and 2021 amounted to $<span id="xdx_90B_eus-gaap--AdvertisingExpense_c20220101__20221231_zbt2JY0VnqH" title="Advertising expense">50,000</span> and $<span id="xdx_90C_eus-gaap--AdvertisingExpense_c20210101__20211231_zSf9jmc2eJw7" title="Advertising expense">0</span>, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p id="xdx_845_eus-gaap--ComprehensiveIncomePolicyPolicyTextBlock_zaraFTgm9v08" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_862_zP4m4XVUM4R">Comprehensive
Loss</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Comprehensive
loss consists of net income and foreign currency translation adjustments. Comprehensive gains (losses) have been reflected in the statements
of operations and comprehensive loss and as a separate component in the statements of stockholders&#8217; equity for all periods presented.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p id="xdx_84B_eus-gaap--CompensationRelatedCostsPolicyTextBlock_zuMCtZNK0dV" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86B_z93HuhI6ZM32">Stock-Based
Compensation</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock-based
compensation cost for equity awards granted to employees and non-employees is measured at the grant date based on the calculated fair
value of the award using the Black-Scholes option-pricing model, and is recognized as an expense, under the straight-line method, over
the requisite service period (generally the vesting period of the equity grant). If the Company determines that other methods are more
reasonable, or other methods for calculating these assumptions are prescribed by regulators, the fair value calculated for the Company&#8217;s
stock options could change significantly. Higher volatility, lower risk-free interest rates, and longer expected lives would result in
an increase to stock-based compensation expense to employees and non-employees determined at the date of grant.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_84C_eus-gaap--IncomeTaxPolicyTextBlock_z0GYTOjzvE98" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86B_zajN575xWrPk">Income
Taxes</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deferred
income taxes are recognized for temporary differences in the basis of assets and liabilities for financial statement and income tax reporting
that arise due to net operating loss carry forwards, research and development credit carry forwards and from using different methods
and periods to calculate depreciation and amortization, allowance for doubtful accounts, accrued vacation, research and development expenses,
and state taxes. A provision has been made for income taxes due on taxable income and for the deferred taxes on the temporary differences.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deferred
tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion or all
of the deferred tax assets will not be realized. Deferred tax assets and liabilities are adjusted for the effects of changes in tax laws
and rates on the date of enactment. Realization of the deferred income tax asset is dependent on generating sufficient taxable income
in future years. For more information, refer to Note 17-Income Taxes.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_841_ecustom--SalesAndExciseTaxesPolicyTextBlock_zFjBkSfE43Z" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86C_zJc7M9MEsVh2">Sales
and Excise Taxes</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sales
and other taxes collected from customers and subsequently remitted to government authorities are recorded as accounts receivable with
corresponding tax payable. These balances are removed from the consolidated balance sheet as cash is collected from customers and remitted
to the tax authority.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_84B_ecustom--WarrantyReservePolicyTextBlock_zuXhILNGtyr7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86F_zZFzrwafMcV7">Warranty
Costs</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s warranty policy generally provides for one year of coverage against defects and nonperformance within published specifications
for sold analyzers and for the term of the contract for equipment held for lease. The Company accrues for estimated warranty costs in
the period in which the revenue is recognized based on historical data and the Company&#8217;s best estimates of analyzer failure rates
and costs to repair.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accrued
warranty liabilities were approximately $<span id="xdx_901_eus-gaap--ProductWarrantyAccrual_iI_c20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zYMTyRdVoxbf" title="Accrued warranty liabilities">138,000</span> and $<span id="xdx_90E_eus-gaap--ProductWarrantyAccrual_iI_c20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z5rpvRsY2Bhe" title="Accrued warranty liabilities">60,000</span>, respectively, at December 31, 2022 and December 31, 2021 and are included
in accrued expenses and other current liabilities on the Consolidated Balance Sheets. Warranty costs were approximately $<span id="xdx_908_eus-gaap--ProductWarrantyExpense_c20220101__20221231_zjAeybIH7LRb" title="Warranty costs">69,000</span> and $<span id="xdx_90C_eus-gaap--ProductWarrantyExpense_c20210101__20211231_zgQ7NMp3UHI6" title="Warranty costs">57,000</span>
for the years ended December 31, 2022 and 2021, respectively, and are included in cost of product sales in the Consolidated Statements
of Operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_84D_eus-gaap--ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_zQ6eZKfREUnf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_861_zr4gZVO6OLT1">Foreign
Currency Translation</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
functional currency for the Company is the U.S. dollar. The functional currency for NanoSynex, the Company&#8217;s newly acquired majority
owned subsidiary, is the New Israeli Shekel (NIS). The financial statements of NanoSynex are translated into U.S. dollars using exchange
rates in effect at each period end for assets and liabilities; using exchange rates in effect during the period for results of operations;
and using historical exchange rates for certain equity accounts. The adjustment resulting from translating the financial statements of
NanoSynex is reflected as a separate component of other comprehensive income (loss).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
comprehensive loss related to the effects of foreign currency translation adjustments attributable to NanoSynex was $<span id="xdx_901_eus-gaap--OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_c20220101__20221231__us-gaap--BusinessAcquisitionAxis__custom--NanoSynexLtdMember_zdomOdXwjkPi" title="Adjustment net of tax">50,721</span> and $<span id="xdx_900_eus-gaap--OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_c20210101__20211231__us-gaap--BusinessAcquisitionAxis__custom--NanoSynexLtdMember_znsm1pjH0QU7" title="Adjustment net of tax">0</span> at
December 31, 2022 and 2021, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p id="xdx_844_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zIJBrwoB7uI3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86E_zP8oTscRYrR2">Recent
Accounting Pronouncements</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
June 2016, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued ASU No. 2016-13, <i>Measurement of Credit Losses on Financial
Instruments</i>, which supersedes current guidance by requiring recognition of credit losses when it is probable that a loss has been
incurred. The new standard requires the establishment of an allowance for estimated credit losses on financial assets including trade
and other receivables at each reporting date. The new standard will result in earlier recognition of allowances for losses on trade and
other receivables and other contractual rights to receive cash. In November 2019, the FASB issued ASU No. 2019-10, <i>Financial Instruments
&#8211; Credit Losses (Topic 326), Derivatives and Hedging (Topic 815) </i>and <i>Leases (Topic 842)</i>, which extended the effective
date of Topic 326 for certain companies until fiscal years beginning after December 15, 2022. The new standard will be effective for
the Company in the first quarter of fiscal year beginning January 1, 2023, and early adoption is permitted. The Company adopted ASU 2016-13
on January 1, 2023. Adoption did not have a material impact on the Company&#8217;s consolidated financial statements and related disclosures.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_84A_ecustom--GlobalEconomicConditionsPolicyTextBlock_z9Nrhk6J8AMl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86D_zY9GyuybJgi8">Global
Economic Conditions</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>War
in Ukraine</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
February 2022, Russia invaded Ukraine. While the Company has no direct exposure in Russia and Ukraine, the Company continues to monitor
any broader impact to the global economy, including with respect to inflation, supply chains and fuel prices. The full impact of the
conflict on the Company&#8217;s business and financial results remains uncertain and will depend on the severity and duration of the
conflict and its impact on regional and global economic conditions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Inflationary
Cost Environment</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year ended 2022 and continuing into the current fiscal year, global commodity and labor markets experienced significant inflationary
pressures attributable to ongoing economic recovery and supply chain issues. The Company is subject to inflationary pressures with respect
to raw materials, labor and transportation. Accordingly, the Company continues to take actions with its customers and suppliers to mitigate
the impact of these inflationary pressures in the future. Actions to mitigate inflationary pressures with suppliers include aggregation
of purchase requirements to achieve optimal volume benefits, negotiation of cost-reductions and identification of more cost competitive
suppliers. While these actions are designed to offset the impact of inflationary pressures, the Company cannot provide assurance that
it will be successful in fully offsetting increased costs resulting from inflationary pressure.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Impact of
COVID-19 Pandemic</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
COVID-19 pandemic has had a dramatic impact on businesses globally and on the Company&#8217;s business as well. Sales of diagnostic products
fell significantly during 2020 and the Company&#8217;s net loss increased significantly, as deferral of patients&#8217; non-emergency
visits to physician offices, clinics and small hospitals sharply reduced demand for FastPack tests. Since then we have experienced some recovery in demand.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
accounting standard updates are either not applicable to the Company or are not expected to have a material impact on the Company&#8217;s
consolidated financial statements.</span></p>

<p id="xdx_853_zHs18ScsZ2f5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows. Describes procedure if disclosures are provided in more than one note to the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI https://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI https://asc.fasb.org/topic&amp;trid=2197479<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI https://asc.fasb.org/topic&amp;trid=2122369<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI https://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140569898950080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LIQUIDITY AND GOING CONCERN<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubstantialDoubtAboutGoingConcernTextBlock', window );">LIQUIDITY AND GOING CONCERN</a></td>
<td class="text"><p id="xdx_804_eus-gaap--SubstantialDoubtAboutGoingConcernTextBlock_z3ue2rwHlAt3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
2 &#8212; <span id="xdx_822_zeUG5Zah2X08">LIQUIDITY AND GOING CONCERN</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2022, the Company had approximately $<span id="xdx_903_eus-gaap--Cash_iI_pn5n6_c20221231_zQqdfCVC1aJ1" title="Cash">7.0</span> million in cash and an accumulated deficit of $<span id="xdx_90F_eus-gaap--RetainedEarningsAccumulatedDeficit_iNI_pn5n6_di_c20221231_zPnOkApQF176" title="Accumulated deficit">103.4</span> million. For the years
ended December 31, 2022 and 2021, the Company used cash of $<span id="xdx_90C_eus-gaap--NetCashProvidedByUsedInOperatingActivities_iN_pn5n6_di_c20220101__20221231_zWTPslDhDkGe" title="Net cash used in operating activities">13.2</span> million and $<span id="xdx_903_eus-gaap--NetCashProvidedByUsedInOperatingActivities_iN_pn5n6_di_c20210101__20211231_znn9cGD4qqT7" title="Net cash used in operating activities">14.7</span> million, respectively, in operations. The Company&#8217;s
cash balances are expected to fund operations into the third quarter of 2023. As a pre-clinical development-stage therapeutics biotechnology
company, the Company expects to continue to have net losses and negative cash flow from operations, which over time will challenge its
liquidity. These factors raise substantial doubt about the Company&#8217;s ability to continue as a going concern for the one-year period
following the date that these financial statements were issued.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
is no assurance that profitable operations will ever be achieved, or, if achieved, could be sustained on a continuing basis. In order
to fully execute its business plan, the Company will require significant additional financing for planned research and development activities,
capital expenditures, clinical and pre-clinical testing for its QN-302 clinical trials, preclinical development of RAS and QN-247, and
funding for NanoSynex operations (See Note 3-Acquisition), as well as commercialization activities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Historically,
the Company&#8217;s principal sources of cash have included proceeds from the issuance of common and preferred equity and proceeds
from the issuance of debt. In December 2021, the Company raised $<span id="xdx_907_eus-gaap--ProceedsFromIssuanceOfCommonStock_pn5n6_c20211201__20211231_zHtwcTNjb6t9" title="Proceeds from issuance of common stock">8.8</span>
million from the issuance of common stock to several institutional investors, and in December 2022 the Company raised $<span id="xdx_904_eus-gaap--ProceedsFromConvertibleDebt_pn5n6_c20221201__20221231_z3gJr5eZpxk3" title="Proceeds from issuance of debt">3.0</span>
million from the sale of a convertible debt - related party (see Note 11-Convertible Debt - Related Party).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
can be no assurance that further financing can be obtained on favorable terms, or at all. If we are unable to obtain funding, we could
be required to delay, reduce or eliminate research and development programs, product portfolio expansion or future commercialization
efforts, which could adversely affect our business prospects.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a condition to the NanoSynex closing, the Company agreed to provide NanoSynex with up to $<span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodValueAcquisitions_pn5n6_c20220101__20221231__us-gaap--BusinessAcquisitionAxis__custom--NanoSynexLtdMember_zwXw0OgDeosj" title="Stock issued during period value acquisitions">10.4</span> million of future funding based on NanoSynex&#8217;s
achievement of certain future development milestones and subject to other terms and conditions described in the Master Agreement for
the Operational and Technological Funding of NanoSynex (the &#8220;Funding Agreement&#8221;) entered into with NanoSynex. These funding
commitments are in the form of convertible promissory notes to be issued to <span id="xdx_908_eus-gaap--StockholdersEquityNoteStockSplit_c20220101__20221231_zUODpnZ8KXKj" title="Stockholders equity note stock split">the Company with a face value equal to the amount paid by
the Company to NanoSynex upon satisfaction of the applicable performance milestone, bearing interest at the rate of 9% per annum on the
principal balance from time to time outstanding under the particular promissory note, convertible at the option of the Company into additional
shares of NanoSynex in order for the Company to maintain at least a 50.1% controlling ownership interest in NanoSynex, should NanoSynex
issue additional shares. The principal of the convertible notes are due and payable upon the sooner to occur of: i) five years from the
date of issuance of the particular promissory note; ii) the acquisition by any person or entity of all or substantially all of the share
capital of NanoSynex, through share purchase, issuance or shares or merger of NanoSynex, or the purchase of all or substantially all
of the assets of NanoSynex; or iii) the initial public offering of NanoSynex.</span> The Company provided funding to NanoSynex of $<span id="xdx_905_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pn5n6_c20220101__20221231__us-gaap--BusinessAcquisitionAxis__custom--NanoSynexLtdMember_zJ4TP8Nrzlh4" title="Stock issued during period value new issues">2.4</span> million
during 2022 pursuant to this agreement. The Company may terminate the Funding Agreement upon 120 days&#8217; notice, but would still
be liable for any payments due for milestones achieved prior to termination.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
the extent that the Company raises additional capital through the sale of equity or convertible debt securities, the ownership interests
of its common stockholders will be diluted, and the terms of these securities may include liquidation or other preferences that adversely
affect the rights of our common stockholders. Debt financing, if available, may involve agreements that include covenants limiting or
restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends.
If the Company raises additional funds through government or other third-party funding, commercialization, marketing and distribution
arrangements or other collaborations, strategic alliances or licensing arrangements with third parties, it may have to relinquish valuable
rights to its technologies, future revenue streams, research programs or product candidates or grant licenses on terms that may not be
favorable to the Company. Additional funding may not be available to the Company on acceptable terms, or at all. In addition, any future
financing (depending on the terms and conditions) may be subject to the approval of Alpha Capital, the holder of the Company&#8217;s
8% Senior Convertible Debenture (the &#8220;Debenture&#8221;), or trigger certain adjustments to the Debenture or warrants held by Alpha
Capital.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying financial statements have been prepared assuming that the Company will continue as a going concern. The financial statements
do not include any adjustments that would be necessary should the Company be unable to continue as a going concern, and therefore, be
required to liquidate its assets and discharge its liabilities in other than the normal course of business and at amounts that may differ
from those reflected in the accompanying financial statements</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubstantialDoubtAboutGoingConcernTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure when substantial doubt is raised about the ability to continue as a going concern. Includes, but is not limited to, principal conditions or events that raised substantial doubt about the ability to continue as a going concern, management's evaluation of the significance of those conditions or events in relation to the ability to meet its obligations, and management's plans that alleviated or are intended to mitigate the conditions or events that raise substantial doubt about the ability to continue as a going concern.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 40<br> -URI https://asc.fasb.org/subtopic&amp;trid=51888271<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubstantialDoubtAboutGoingConcernTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140569900213776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ACQUISITION<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract', window );"><strong>Business Combination and Asset Acquisition [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationDisclosureTextBlock', window );">ACQUISITION</a></td>
<td class="text"><p id="xdx_803_eus-gaap--BusinessCombinationDisclosureTextBlock_z9GfJCFJd2Zc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
3 &#8212; <span id="xdx_822_z7BJAxPkbEQb">ACQUISITION</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Business
Combination</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">The Company acquired a <span id="xdx_903_eus-gaap--BusinessAcquisitionPercentageOfVotingInterestsAcquired_iI_pid_dp_uPure_c20220526__us-gaap--BusinessAcquisitionAxis__custom--NanoSynexLtdMember_ziE1aWhduCsh" title="Business acquisition, voting equity rate">52.8</span>%
voting equity interest in NanoSynex on May 26, 2022 (the &#8220;NanoSynex Acquisition Date&#8221;) through: (1) the purchase of <span id="xdx_901_eus-gaap--StockIssuedDuringPeriodSharesAcquisitions_c20220524__20220526__us-gaap--StatementClassOfStockAxis__custom--SeriesAOnePreferredStockMember_z2KnsEtsvxT5" title="Number of shares of stock issued">2,232,861</span>
shares Preferred A-1 Stock of NanoSynex from Alpha Capital (a related party) for <span id="xdx_903_eus-gaap--StockIssuedDuringPeriodSharesAcquisitions_c20220524__20220526__us-gaap--BusinessAcquisitionAxis__custom--NanoSynexLtdMember_z5ZdbQdIRa37" title="Stock issued during period shares acquisitions">350,000</span>
reverse split adjusted shares of the Company&#8217;s common stock and a prefunded warrant to purchase <span id="xdx_901_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20220526__us-gaap--StatementEquityComponentsAxis__custom--PrefundedWarrantMember_zia7g6kOVve5" title="Warrants to purchase shares">331,464
reverse split adjusted shares of the Company&#8217;s common stock at a purchase price of $<span id="xdx_909_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20220526__us-gaap--BusinessAcquisitionAxis__custom--NanoSynexLtdMember__us-gaap--StatementEquityComponentsAxis__custom--PrefundedWarrantMember_z8HidDJfpUx4" title="Warrants or rights">0.001</span>
per share (<span id="xdx_90B_eus-gaap--StockholdersEquityReverseStockSplit_c20220524__20220526__us-gaap--BusinessAcquisitionAxis__custom--NanoSynexLtdMember_zfcy0ZSHZbZh" title="Reverse split, description">these warrants were subsequently exercised on September 13, 2022)</span>, and (2) the purchase of <span id="xdx_902_eus-gaap--StockIssuedDuringPeriodSharesAcquisitions_c20220524__20220526__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember__us-gaap--BusinessAcquisitionAxis__custom--NanoSynexLtdMember_zyVm1ZSvx9G5" title="Stock issued during period shares acquisitions">381,786</span>
shares of Series B preferred stock of NanoSynex from NanoSynex in exchange for $<span id="xdx_901_eus-gaap--StockIssuedDuringPeriodValueAcquisitions_c20220524__20220526__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember__us-gaap--BusinessAcquisitionAxis__custom--NanoSynexLtdMember_zAhUPKw0qxh2" title="Stock issued during period value acquisitions">600,000</span></span>
(collectively, the &#8220;NanoSynex Acquisition&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
acquisition of the majority interest of NanoSynex was accounted for as a business combination using the acquisition method, in accordance
with FASB ASC Topic 805. Identifiable assets acquired, liabilities assumed and any noncontrolling interest in the acquiree are recognized
and measured as of the acquisition date at fair value. Determining the fair value of assets acquired, liabilities assumed and noncontrolling
interest requires management&#8217;s judgment and often involves the use of significant estimates and assumptions, including assumptions
with respect to future cash flows, discount rates and asset lives among other items. The Company uses third-party valuations for intangible
assets in a business combination using a discounted cash flow analysis, incorporating various assumptions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_890_eus-gaap--ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_zOsbLs4POgyk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
summary of the consideration transferred and fair value of assets acquired and liabilities assumed in the NanoSynex Acquisition is as
follows (all shares shown post 1 for 10 reverse split on November 23, 2022):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B8_zhGesOfCesRi" style="display: none">SCHEDULE
OF CONSIDERATION TRANSFERRED</span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Consideration transferred, net of cash acquired</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 80%; text-align: left; padding-bottom: 1.5pt">Cash paid for NanoSynex preferred stock:</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td id="xdx_986_ecustom--PaymentsToAcquireBusinesses_pp0p0_c20220524__20220526__us-gaap--BusinessAcquisitionAxis__custom--NanoSynexLtdMember_zs1OfV4i1qV1" style="border-bottom: Black 1.5pt solid; width: 16%; text-align: right" title="Cash paid for NanoSynex preferred stock:">600,000</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">FMV of <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIENPTlNJREVSQVRJT04gVFJBTlNGRVJSRUQgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_905_eus-gaap--StockIssuedDuringPeriodSharesAcquisitions_c20220524__20220526__us-gaap--BusinessAcquisitionAxis__custom--NanoSynexLtdMember_zkEfDIX9oqbc" title="Common stock issued for business acquisition">350,000</span> shares of Qualigen stock issued to Alpha Capital Anstalt</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_987_eus-gaap--StockIssuedDuringPeriodValueAcquisitions_pp0p0_c20220524__20220526__us-gaap--BusinessAcquisitionAxis__custom--NanoSynexLtdMember_zxs0bN5NF5Ui" style="text-align: right" title="FMV of 3,500,000 shares of Qualigen stock issued to Alpha Capital Anstalt">1,904,989</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">FMV of <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIENPTlNJREVSQVRJT04gVFJBTlNGRVJSRUQgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90F_eus-gaap--StockIssuedDuringPeriodSharesAcquisitions_c20220524__20220526__us-gaap--BusinessAcquisitionAxis__custom--AlphaCapitalAnstaltMember_zdIwRg5Vz5Jl" title="Common stock issued for business acquisition">331,464</span>
    shares of Qualigen stock related to prefunded warrant issued to Alpha Capital Anstalt (See Note 15)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td id="xdx_986_ecustom--PrefundedWarrantsIssuedForBusinessAcquisition_pp0p0_c20220524__20220526__us-gaap--BusinessAcquisitionAxis__custom--NanoSynexLtdMember_zjG0dIRqPrIe" style="border-bottom: Black 1.5pt solid; text-align: right" title="FMV of 3,314,641 shares of Qualigen stock related to prefunded warrant issued to Alpha Capital Anstalt">1,804,102</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Total consideration paid for NanoSynex preferred stock</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td id="xdx_982_eus-gaap--BusinessCombinationConsiderationTransferred1_pp0p0_c20220524__20220526__us-gaap--BusinessAcquisitionAxis__custom--NanoSynexLtdMember_zf0PuKozuuF2" style="border-bottom: Black 1.5pt solid; text-align: right" title="Total consideration paid for NanoSynex common stock">3,709,091</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td id="xdx_F47_zewy4rTtnOag" style="text-align: left; padding-bottom: 1.5pt">FMV of consideration related to related to repricing of <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIENPTlNJREVSQVRJT04gVFJBTlNGRVJSRUQgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesAcquisitions_c20220524__20220526_zZyBkxTCAyp7" title="Common stock issued for business acquisition">7,048</span> shares of Alpha Capital/Qualigen warrants *</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td id="xdx_98E_ecustom--FairValueOfWarrantModificationForBusinessAcquisition_pp0p0_c20220524__20220526__us-gaap--BusinessAcquisitionAxis__custom--NanoSynexLtdMember_fKg_____zeuMe7mz3ow5" style="border-bottom: Black 1.5pt solid; text-align: right" title="FMV of consideration related to related to repricing of 70,478 shares of Alpha Capital/Qualigen warrants *">696</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">NanoSynex cash acquired</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--CashAcquiredFromAcquisition_iN_pp0p0_di_c20220524__20220526__us-gaap--BusinessAcquisitionAxis__custom--NanoSynexLtdMember_zdeO6GLj5Olf" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right" title="NanoSynex cash acquired">(735,354</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Total consideration transferred, net of cash acquired</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td id="xdx_98B_eus-gaap--PaymentsToAcquireBusinessesNetOfCashAcquired_pp0p0_c20220524__20220526__us-gaap--BusinessAcquisitionAxis__custom--NanoSynexLtdMember_z9onq8HthZe4" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right" title="Total consideration transferred, net of cash acquired">3,574,433</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td id="xdx_F01_zHAnwfOGCQR6" style="width: 15pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="text-align: justify"><span id="xdx_F19_z5NxVo6luna4" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">See disclosure
under <i>Noncompensatory Equity Classified Warrants</i> regarding May 26, 2022 transaction-Note 15-Stockholders&#8217; Equity</span></td>
</tr></table>


<p id="xdx_8A6_zhome0atFQBl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_892_eus-gaap--ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_zZYSY9jhcOy9" style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B2_zP1gRBl98nNb" style="display: none">SCHEDULE
OF ASSETS ACQUIRED AND LIABILITIES</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_497_20220526_zyjYIFjvvDcl" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Purchase Price Allocation</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_iI_ziI0KgaE9ZF" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; width: 80%; text-align: left">Accounts receivable</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">75,336</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_iI_z9T12KJnysSj" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Property and equipment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">120,942</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_ecustom--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedResearchAndDevelopmentExpense_iI_zHDGLPvjxUth" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">In process R&amp;D</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,700,000</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_iNI_di_zDPdWepmReW9" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Accounts payable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(4,588</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40A_ecustom--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpensesAndOtherPayables_iI_zTQOiTkoF3m4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Accrued expenses and other payables</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(291,093</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_409_ecustom--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedResearchAndDevelopmentGrantLiability_iI_z3fOD7mPKuek" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">R&amp;D grant liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,362,264</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40E_ecustom--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesShortTermDebt_iI_zYMnPbk7tEMk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Short term debt</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(941,898</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40A_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_iNI_di_zuieaCdeGej4" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Deferred tax liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(629,379</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40B_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedLessNoncontrollingInterest_iI_zGNbjPAzXf98" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Noncontrolling interest assumed</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(3,882,225</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_40F_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_iNI_di_z8X9huu3FFX4" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left">Identifiable net assets acquired</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,215,169</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40E_eus-gaap--Goodwill_iI_zm5gS7WIrxP2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; padding-bottom: 1.5pt">Goodwill</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">4,789,602</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_iI_zQUA13f31O1e" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Total consideration transferred, net of cash acquired</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">3,574,433</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A7_zaHtMPVNz2O" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year ended December 31, 2022, the Company made measurement period adjustments to the preliminary purchase price allocation which
included: (i) a decrease to noncontrolling interest of $<span id="xdx_90B_eus-gaap--MinorityInterestDecreaseFromRedemptions_c20220101__20221231_zWO1JSzS0fM9" title="Decrease to noncontrolling interest">117,775</span>, (ii) a decrease to goodwill of $<span id="xdx_908_eus-gaap--GoodwillPeriodIncreaseDecrease_c20220101__20221231_z528J6raPBXh" title="Decrease in good will">106,621</span>. The measurement period adjustments
were made to reflect facts and circumstances that existed as of the acquisition date and is reflected in the table above.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Company
transaction costs, which were immaterial, have been expensed as incurred and charged to the Company&#8217;s consolidated statements of
operations and comprehensive loss. There was no provision for reimbursement of transaction costs from the Company to NanoSynex.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Goodwill
represents the excess of the purchase price over the fair value of the net assets acquired as of the acquisition date. Goodwill represents
the value of the future technology to be developed in excess of the identifiable assets as well as the operational synergies of the combined
companies to be recognized. Goodwill has an indefinite useful life and is not amortized. None of the Goodwill is expected to be deductible
for tax purposes.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a condition to the closing, the Company agreed to provide NanoSynex with up to $<span id="xdx_904_eus-gaap--StockIssuedDuringPeriodValueAcquisitions_pn5n6_c20220101__20221231__dei--LegalEntityAxis__custom--NanoSynexMember_zH9nhBrzmzDb" title="Stock issued during period value acquisitions">10.4</span> million of future funding based on NanoSynex&#8217;s
achievement of certain future development milestones and subject to other terms and conditions described in the Funding Agreement entered
into with NanoSynex. (See Note 2-Liquidity for further details regarding the terms and conditions of the Funding Agreement).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">The
Company&#8217;s consolidated statements of operations and comprehensive loss for the years ended December 31, 2022 and 2021 include
approximately $<span id="xdx_90A_eus-gaap--OtherComprehensiveIncomeLossTax_pn5n6_c20220101__20221231__us-gaap--BusinessAcquisitionAxis__custom--NanoSynexLtdMember_z2dz503bU9c" title="Other comprehensive income loss tax">5.1 million and $<span id="xdx_908_eus-gaap--OtherComprehensiveIncomeLossTax_c20210101__20211231__us-gaap--BusinessAcquisitionAxis__custom--NanoSynexLtdMember_zvxypw86ddQj" title="Other comprehensive income loss tax">0</span>, respectively, of net loss associated with the results of operations of NanoSynex from the NanoSynex
Acquisition Date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following proforma information has been prepared as if the NanoSynex Acquisition occurred on January 1, 2021. The following unaudited
supplemental proforma consolidated results do not purport to reflect what the combined Company&#8217;s results of operations would have
been, nor do they project the future results of operations of the combined Company. The unaudited supplemental proforma consolidated
results reflect the historical financial information of the Company and NanoSynex, adjusted to give effect to the NanoSynex Acquisition
as if it had occurred on January 1, 2021, as well as to record NanoSynex stock compensation expense and to record the net loss related
to the non-controlling interest, in accordance with generally accepted accounting principles:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"/><p id="xdx_89D_eus-gaap--BusinessAcquisitionProFormaInformationTextBlock_zXMOHqz5Mwlb" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BD_zFvG4O9lWCI5" style="display: none">SCHEDULE
OF PRO FORMA INFORMATION</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center">Consolidated Pro Forma Financial</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center">Results for the Years Ending</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Net revenue</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98B_eus-gaap--BusinessAcquisitionsProFormaRevenue_c20220101__20221231_zzNPb9cAfb91" style="width: 16%; text-align: right" title="Business acquisitions pro forma revenue">4,983,556</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_986_eus-gaap--BusinessAcquisitionsProFormaRevenue_c20210101__20211231_znICUMbVL3Gd" style="width: 16%; text-align: right" title="Business acquisitions pro forma revenue">5,653,725</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Net loss attributable to Qualigen Therapeutics, Inc.</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98F_eus-gaap--BusinessAcquisitionsProFormaNetIncomeLoss_c20220101__20221231_z8b3BcgWawu2" style="text-align: right" title="Business acquisitions pro forma net income loss">(19,538,959</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_986_eus-gaap--BusinessAcquisitionsProFormaNetIncomeLoss_c20210101__20211231_zqf918hBz2tg" style="text-align: right" title="Business acquisitions pro forma net income loss">(17,897,137</td><td style="text-align: left">)</td></tr>
  </table>

<p id="xdx_8AA_z9jgqHEF2Haa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationAndAssetAcquisitionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -URI https://asc.fasb.org/topic&amp;trid=2303972<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4946-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140569897073648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INVENTORY, NET<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureTextBlock', window );">INVENTORY, NET</a></td>
<td class="text"><p id="xdx_807_eus-gaap--InventoryDisclosureTextBlock_zM22F3ZlaLD3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
4 &#8212; <span id="xdx_820_zmgcWUUon9si">INVENTORY, NET</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_89A_eus-gaap--ScheduleOfInventoryCurrentTableTextBlock_zBA3nzCi8nXf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inventory,
net consisted of the following at December 31, 2022 and December 31, 2021:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B4_zl936wY2g2zk" style="display: none">SCHEDULE OF INVENTORY</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49D_20221231_zPIw4EdGbJF5" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31,<br/>
 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_492_20211231_zBFmkgZkZj17" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31,<br/>
 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--InventoryRawMaterials_iI_maIFGz0my_ztIAItWFXVpe" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Raw materials</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">949,796</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">823,315</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--InventoryWorkInProcess_iI_maIFGz0my_zqzR4p4q4kz6" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Work in process</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">200,318</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">188,135</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--InventoryFinishedGoods_iI_maIFGz0my_zOgIAUswNtX7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Finished goods</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">436,183</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">44,428</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--InventoryNet_iTI_mtIFGz0my_zzqttACnIBTg" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Total inventory</span></td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,586,297</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,055,878</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A7_z4ocf0uz3Wv6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI https://asc.fasb.org/topic&amp;trid=2126998<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140569897077440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PREPAID EXPENSES AND OTHER CURRENT ASSETS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_DisclosurePrepaidExpensesAndOtherCurrentAssetsAbstract', window );"><strong>Prepaid Expenses And Other Current Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_PrepaidExpensesAndOtherCurrentAssetsTextBlock', window );">PREPAID EXPENSES AND OTHER CURRENT ASSETS</a></td>
<td class="text"><p id="xdx_80D_ecustom--PrepaidExpensesAndOtherCurrentAssetsTextBlock_z8Ubvmm1KKsa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
5 &#8212; <span id="xdx_82D_zGnIs5Onxrlf">PREPAID EXPENSES AND OTHER CURRENT ASSETS</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_896_eus-gaap--DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_zbCZypHtjnw1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prepaid
expenses and other current assets consisted of the following at December 31, 2022 and December 31, 2021:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B4_z8X22FW3VM7h" style="display: none">SCHEDULE OF PREPAID EXPENSES AND OTHER CURRENT ASSETS</span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_493_20221231_zz71PbAaF8C8" style="font-weight: bold; text-align: center">December 31,</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_49B_20211231_zTidS1QDTV7a" style="font-weight: bold; text-align: center">December 31,</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--PrepaidInsurance_iI_pp0p0_maPECzoJ5_zBmCuDbCnSld" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Prepaid insurance</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">1,377,323</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">1,197,726</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_ecustom--PrepaidManufacturingExpenses_iI_maPECzoJ5_zOVYhOPv484d" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Prepaid manufacturing expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">43,820</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">67,410</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--OtherPrepaidExpenseCurrent_iI_pp0p0_maPECzoJ5_zuORQtWfNO6h" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Other prepaid expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">227,451</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">111,183</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--OtherAssetsCurrent_iI_pp0p0_maPECzoJ5_zYtyYb3022Ri" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Other current assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">12,626</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">3,577</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_iTI_pp0p0_mtPECzoJ5_znJgfhRZQd8f" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Prepaid expenses and
    other current assets</span></td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,661,220</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,379,896</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_DisclosurePrepaidExpensesAndOtherCurrentAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_DisclosurePrepaidExpensesAndOtherCurrentAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_PrepaidExpensesAndOtherCurrentAssetsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Prepaid Expenses and Other Current Assets [Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_PrepaidExpensesAndOtherCurrentAssetsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140569897187520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PROPERTY AND EQUIPMENT, NET<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">PROPERTY AND EQUIPMENT, NET</a></td>
<td class="text"><p id="xdx_80D_eus-gaap--PropertyPlantAndEquipmentDisclosureTextBlock_zyIuG3aX4Hy6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
6 &#8212; <span id="xdx_82A_zj9JWUvK6HB2">PROPERTY AND EQUIPMENT, NET</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_896_eus-gaap--PropertyPlantAndEquipmentTextBlock_zwUq8vngJ0o6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property
and equipment, net consisted of the following at December 31, 2022 and December 31, 2021:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span id="xdx_8B7_zwHYaspSTkb4" style="display: none">SCHEDULE OF PROPERTY AND EQUIPMENT</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_49F_20221231_zJU1p80YDKNl" style="font-weight: bold; text-align: center">December 31,</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_497_20211231_zgVH9Cax4sOc" style="font-weight: bold; text-align: center">December 31,</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--PropertyPlantAndEquipmentGross_iI_pp0p0_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--MachineryAndEquipmentMember_zpueYdQY8YF8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Machinery and equipment</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">2,510,148</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">2,482,841</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--PropertyPlantAndEquipmentGross_iI_pp0p0_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember_zSOYXrFAcKA9" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Computer equipment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">395,836</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">345,117</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--PropertyPlantAndEquipmentGross_iI_pp0p0_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zOCk7Ja6f9A1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Leasehold improvements</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">333,271</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">333,271</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--PropertyPlantAndEquipmentGross_iI_pp0p0_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--MoldsAndToolingMember_zT1y1bTnjWfh" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Molds and tooling</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">260,002</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">260,002</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--PropertyPlantAndEquipmentGross_iI_pp0p0_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_zd9DJwDk3yI4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Furniture and fixtures</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">144,832</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">143,013</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--PropertyPlantAndEquipmentGross_iI_pp0p0_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--EquipmentMember_zP3Rohjc16D" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Equipment held for lease</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,399,444</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,181,211</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--PropertyPlantAndEquipmentGross_iI_ze0HrC0A1zqf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Property and equipment, gross</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,043,533</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,745,455</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_di_msPPAENzZdO_zYseZPs8KDK7" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Accumulated depreciation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(4,623,446</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(4,541,238</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_402_ecustom--FixedAssetImpairments_iI_msPPAENzZdO_zA9FKaxLJSac" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Fixed asset impairment</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(75,000</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0996">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--PropertyPlantAndEquipmentNet_iI_zsy8xKqFo83a" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Property and equipment,
    net</span></td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">345,087</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">204,217</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A4_ztzrh9YppC0j" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Depreciation
expense relating to property and equipment was approximately $<span id="xdx_90F_eus-gaap--Depreciation_pp0p0_c20220101__20221231_zGvndBEQgQVb" title="Depreciation expense">92,000</span> and $<span id="xdx_909_eus-gaap--Depreciation_pp0p0_c20210101__20211231_zElf27B7nkce" title="Depreciation expense">73,000</span> for the years ended December 31, 2022 and 2021, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon
termination of the Sekisui Distribution Agreement on March 31, 2022, the Company had a commitment to purchase leased FastPack rental
systems back from Sekisui at Sekisui&#8217;s net book value, which was determined to be approximately $<span id="xdx_90D_eus-gaap--PaymentsToAcquirePropertyPlantAndEquipment_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--SekisuiDistributionAgreementMember_zr2s6Wg1tnW7" title="Payments to acquire assets">154,000</span>. This amount is included
in equipment held for lease in the table above and in accrued expenses at December 31, 2022. An assignment agreement is to be executed
by both parties to legally transfer title to this equipment from Sekisui to Qualigen.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99893-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI https://asc.fasb.org/topic&amp;trid=2155823<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=SL120174063-112916<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99779-112916<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140569897142016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>GOODWILL, IPR&amp;D AND OTHER INTANGIBLES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock', window );">GOODWILL, IPR&amp;D AND OTHER INTANGIBLES</a></td>
<td class="text"><p id="xdx_80A_eus-gaap--GoodwillAndIntangibleAssetsDisclosureTextBlock_zs0p0XkWM4ji" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
7 &#8212; <span id="xdx_826_zwBe5NfUt4D2">GOODWILL, IPR&amp;D AND OTHER INTANGIBLES</span></b></span></p>

<p id="xdx_890_eus-gaap--ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_zb1Z4BLWS9rd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span id="xdx_8BC_zBUOXlS71fsg" style="display: none">SCHEDULE
OF GOODWILL AND OTHER INTANGIBLE</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_496_20221231_zdHCMRDRg7f7" style="font-weight: bold; text-align: center">December 31,</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_495_20211231_z5dz6BcG59Sg" style="font-weight: bold; text-align: center">December 31,</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">2022</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">2021</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Estimated Useful Lives</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Gross carrying amounts</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Gross carrying amounts</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--Goodwill_iI_zXcKA7UVsgHf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 48%; padding-bottom: 2.5pt">Goodwill</td><td style="width: 2%; padding-bottom: 2.5pt">&#160;</td>
    <td style="width: 14%; padding-bottom: 2.5pt">&#160;</td><td style="width: 2%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 14%; text-align: right">625,602</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 14%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1012">&#8212;</span></td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: center">&#160;</td><td>&#160;</td>
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Finite-lived intangible assets:</td><td>&#160;</td>
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_hus-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--DevelopedProductTechnologyRightsMember_zWed598pIel5" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Developed-product-technology rights</td><td>&#160;</td>
    <td style="text-align: center"><span id="xdx_906_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dtY_c20220101__20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--DevelopedProductTechnologyRightsMember__srt--RangeAxis__srt--MinimumMember_zaqWF5dt3oFl" title="Finite lived intangible asset useful life">8</span> - <span id="xdx_909_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dtY_c20220101__20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--DevelopedProductTechnologyRightsMember__srt--RangeAxis__srt--MaximumMember_z6JFgJEVb2zg" title="Finite lived intangible asset useful life">17</span> years</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">479,103</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">479,103</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_hus-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LicensingRightsMember_z4iPpECocP7a" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Licensing rights</td><td>&#160;</td>
    <td style="text-align: center"><span id="xdx_905_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dtY_c20220101__20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LicensingRightsMember_z4fGm9PcNJgb" title="Finite lived intangible asset useful life">10</span> years</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">418,836</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">418,836</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iNI_di_zCWaIq8XEbjl" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Less: Accumulated amortization</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(752,237</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(726,749</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_403_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_zKjOgTu1Ams7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Total finite-lived intangible assets, net</td><td>&#160;</td>
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">145,702</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">171,190</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Indefinite-lived intangible assets:</td><td>&#160;</td>
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_hus-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--InProcessResearchAndDevelopmentMember_zkdNsPD4tnbi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; text-align: left; padding-bottom: 1.5pt">In-process research and development</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">5,700,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1033">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_zQnV9t4KQpJi" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Total other intangible assets, net</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">5,845,702</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">171,190</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8AA_zMiu2tkjPu0g" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company periodically reviews goodwill for impairment in accordance with relevant accounting standards. Goodwill is attributable to
the NanoSynex Acquisition. Goodwill and intangible assets are recognized at fair value during the period in which an acquisition is
completed, from updated estimates during the measurement period, or when they are considered to be impaired. These non-recurring
fair value measurements, primarily for goodwill and intangible assets acquired, were based on Level 3 inputs. The Company estimates
the fair value of long-lived assets on a non-recurring basis based on a market valuation approach, engaging independent valuation
experts to assist in the determination of fair value. In the fourth quarter of fiscal 2022, in conjunction with the annual
impairment assessment, the Company determined that the fair value of the reporting unit was less than the carrying value. In
addition to continued losses in the reporting unit, the Company considered macroeconomic conditions including a deterioration in the
equity markets evidenced by sustained declines in the Company&#8217;s stock price, peer companies, and major market indices since
the acquisition date. The Company engaged independent valuation experts to assist in determining the fair value of the reporting
unit. As a result of this analysis, the Company recorded a $<span id="xdx_906_eus-gaap--GoodwillImpairmentLoss_c20220101__20221231_zA2nmoahhgj8">4,239,000 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">goodwill and fixed asset impairment charge associated with the reporting unit.</span> There were <span id="xdx_90B_eus-gaap--ImpairmentOfIntangibleAssetsFinitelived_do_c20210101__20211231_zA7G4J7NFlJh">no </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">impairments
to intangible assets and goodwill during the year ended December 31, 2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
carrying value of the patents of approximately $<span id="xdx_901_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_c20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zL2k9bRE9po8" title="Assets gross">140,000</span> and $<span id="xdx_909_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_c20211231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zNKyGi9WYK89" title="Assets gross">159,000</span> at December 31, 2022 and December 31, 2021, respectively, are stated
net of accumulated amortization of approximately $<span id="xdx_908_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_c20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_z1eUTIF91ZRe" title="Accumulated amortization">339,000</span> and $<span id="xdx_902_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_c20211231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_z8I9qIoO5ria" title="Accumulated amortization">320,000</span>, respectively. Amortization of patents charged to operations for
the year ended December 31, 2022 and December 31, 2021 were approximately $<span id="xdx_903_eus-gaap--AmortizationOfIntangibleAssets_c20220101__20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zleS6mV8cZGf" title="Amortization of intangible assets">18,000</span> and $<span id="xdx_900_eus-gaap--AmortizationOfIntangibleAssets_c20210101__20211231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zROdRa2puvGh" title="Amortization of intangible assets">17,000</span>, respectively. Total future estimated amortization
of patent costs for the five succeeding years is approximately $<span id="xdx_90A_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_iI_c20221231_zOobvQzNfBcl" title="Future estimated amortization of patent costs Year 2023">18,000</span> for the year ending December 31, 2023, approximately $<span id="xdx_90B_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_iI_c20221231_zyssy5GjxBhc" title="Future estimated amortization of patent costs Year 2024">15,000</span> for
the year ending December 31, 2024, approximately $<span id="xdx_905_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_iI_c20221231_zX83EZKGhb5j" title="Future estimated amortization of patent costs Year 2025"><span id="xdx_904_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_iI_c20221231_zUhPFiV1BBQk" title="Future estimated amortization of patent costs Year 2026"><span id="xdx_905_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_iI_c20221231_zgZ1rdjuARUb" title="Future estimated amortization of patent costs Year 2027">14,000</span></span></span> for years 2025, 2026 and 2027, and approximately $<span id="xdx_90E_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_iI_c20221231_zgBXLNEi5rz5" title="Future estimated amortization of patent costs thereafter">65,000</span> thereafter.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
carrying value of the licenses of approximately $<span id="xdx_904_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_c20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicenseMember_zokqiRXfUkk5" title="Finite lived intangible assets gross">5,000</span> and $<span id="xdx_90E_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_c20211231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicenseMember_z9113trqX9Hh" title="Finite lived intangible assets gross">12,000</span> at December 31, 2022 and December 31, 2021 are stated net of accumulated
amortization of approximately $<span id="xdx_90E_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_c20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicenseMember_zf73ANwZ6VV3" title="Accumulated amortization">414,000</span> and $<span id="xdx_90F_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_c20211231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicenseMember_zojlMSaT70Tg" title="Accumulated amortization">407,000</span>, respectively. Amortization of licenses charged to operations for the year ended
December 31, 2022 and December 31, 2021 was approximately $<span id="xdx_903_eus-gaap--AmortizationOfIntangibleAssets_c20220101__20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicenseMember_zHeLVHwO1lwj" title="Licenses charged">7,000</span> and $<span id="xdx_904_eus-gaap--AmortizationOfIntangibleAssets_c20210101__20211231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicenseMember_zwQVdoDKyGCb" title="Licenses charged">7,000</span>, respectively. Total future estimated amortization of license
costs for the five succeeding years is approximately $<span id="xdx_903_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_iI_c20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicenseMember_z1mo1wC09943" title="Future estimated amortization of license costs 2023">5,000</span> for the year ending December 31, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -URI https://asc.fasb.org/topic&amp;trid=2144416<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140569892288784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock', window );">ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES</a></td>
<td class="text"><p id="xdx_80D_eus-gaap--AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_zgaL5IHNqmMd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
8 &#8212; <span id="xdx_824_zYcXxQ8gw5Bi">ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p id="xdx_899_eus-gaap--ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_zDIhix1BX3Tf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accrued
expenses and other current liabilities consisted of the following at December 31, 2022 and December 31, 2021:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span id="xdx_8B9_zKHaUW9L91Hh" style="display: none">SCHEDULE OF ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_49D_20221231_zBbMkbGrB9md" style="font-weight: bold; text-align: center">December 31,</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_494_20211231_ztpKeTIDF99j" style="font-weight: bold; text-align: center">December 31,</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_402_ecustom--AccruedCompensation_iI_pp0p0_maALCzkYM_zOLE87lWqRI5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Board compensation</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">70,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">17,500</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_ecustom--AccruedEquipmentHeldForLease_iI_pp0p0_maALCzkYM_zYeN16y7xf98" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Equipment held for lease</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">154,433</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1086">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_ecustom--AccruedFranchiseSalesAndUseTaxes_iI_pp0p0_maALCzkYM_zhmSlBQL4EWg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Franchise, sales and use taxes</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">27,531</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">14,090</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--AccruedIncomeTaxesCurrent_iI_pp0p0_maALCzkYM_zP28APwIULVa" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Income taxes</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,663</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,620</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--InterestPayableCurrent_iI_pp0p0_maALCzkYM_zOzKyyIb5kF4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Interest (Convertible debt - related party)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,829</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1095">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--AccruedPayrollTaxesCurrent_iI_pp0p0_maALCzkYM_zJNRO73693I4" style="vertical-align: bottom; background-color: White">
    <td>Payroll</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">209,303</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">682,036</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--AccruedProfessionalFeesCurrent_iI_pp0p0_maALCzkYM_zrpYF7asHehb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Professional fees</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">238,211</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">225,308</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_ecustom--AccruedResearchAndDevelopmentCurrent_iI_pp0p0_maALCzkYM_zk7F9NtWCfb4" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Research and development</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">322,987</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">232,712</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--AccruedRoyaltiesCurrent_iI_pp0p0_maALCzkYM_zB4ANgfhV2xe" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Royalties</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">13,158</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">10,152</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--ProductWarrantyAccrual_iI_pp0p0_maALCzkYM_zMzNOQPLAo4j" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Warranty liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">137,568</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">60,281</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_ecustom--AccruedLicenseFees_iI_pp0p0_maALCzkYM_zPQndZ4yZ6yh" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">License fees</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">150,130</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1113">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--OtherAccruedLiabilitiesCurrent_iI_pp0p0_maALCzkYM_zNkSVNMli169" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Other</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">181,043</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">265,292</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--AccruedLiabilitiesCurrent_iTI_mtALCzkYM_zAYI6VOc0MWe" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Accrued liabilities</span></td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,511,856</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,510,990</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A8_zueUm56vJTLa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140569897409712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHORT TERM DEBT - RELATED PARTY<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtTextBlock', window );">SHORT TERM DEBT - RELATED PARTY</a></td>
<td class="text"><p id="xdx_803_eus-gaap--ShortTermDebtTextBlock_zDQGZEWRdpE3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
9 &#8211; <span id="xdx_82F_zfilWLp0PCqg">SHORT TERM DEBT - RELATED PARTY</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NanoSynex
has four separate Notes Payable (the &#8220;Notes&#8221;) outstanding to Alpha Capital, dated between March 26, 2020 and September 2,
2021, aggregating to a total principal outstanding balance of $<span id="xdx_900_eus-gaap--DebtInstrumentFaceAmount_iI_c20210902__us-gaap--ShortTermDebtTypeAxis__custom--NotesPayableMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NanoSynexMember_zQrNlMRSVo13" title="Short term debt principal outstanding">905,000</span>, and aggregate accrued interest of $<span id="xdx_90C_eus-gaap--InterestPayableCurrent_iI_pp0p0_c20221231__us-gaap--ShortTermDebtTypeAxis__custom--NotesPayableMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NanoSynexMember_zsHnjDV8n9W9" title="Accrued interest">45,722</span> for a total outstanding
balance of $<span id="xdx_90C_eus-gaap--ShortTermBorrowings_iI_pp0p0_c20221231__us-gaap--ShortTermDebtTypeAxis__custom--NotesPayableMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NanoSynexMember_zk1r2mvHgOzf" title="Short term debt outstanding balance">950,722</span> as of December 31, 2022. The Notes all accrue interest at <span id="xdx_90A_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20210902__us-gaap--ShortTermDebtTypeAxis__custom--NotesPayableMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NanoSynexMember_z3fZvCpt3kw5" title="Accrued interest rate">2.62%</span> per annum, accrued daily, and provide that the full
amount of principal and interest under each Note shall be due immediately prior to a Liquidation Event (the Maturity Date) unless due
earlier in accordance with the terms of the Notes. &#8220;Liquidation Event&#8221; means either i) the merger or consolidation of NanoSynex
into any other entity, other than one in control or under control of NanoSynex or NanoSynex&#8217;s majority shareholder; ii) a transaction
or series of transactions resulting in the transfer of all or substantially all of NanoSynex&#8217;s assets or issued and outstanding
share capital (other than to a company under the control of NanoSynex or NanoSynex&#8217;s majority shareholders; or iii) an underwritten
public offering by NanoSynex of its ordinary shares. Notwithstanding the above, if NanoSynex receives subsequent debt, convertible debt,
or equity funding with gross proceeds of USD $<span id="xdx_90C_eus-gaap--ProceedsFromRelatedPartyDebt_pp0p0_c20210326__20210902__us-gaap--ShortTermDebtTypeAxis__custom--NotesPayableMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NanoSynexMember_zDc0R3RsSkVj" title="Proceeds from related party debt">3,000,000</span> or more, then these Notes shall be due and payable upon the actual receipt of
such funding.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b/></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b/></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"/>

<p style="margin: 0"/>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b/></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b/></span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for short-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI https://asc.fasb.org/topic&amp;trid=2208564<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140569897262368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>WARRANT LIABILITIES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_DisclosureWarrantLiabilitiesAbstract', window );"><strong>Warrant Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_WarrantLiabilitiesTextBlock', window );">WARRANT LIABILITIES</a></td>
<td class="text"><p id="xdx_800_ecustom--WarrantLiabilitiesTextBlock_zTNKi3pAAyR" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
10 &#8211; <span id="xdx_823_zr13o4sFvmg6">WARRANT LIABILITIES</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
2004, the Company issued warrants to various investors and brokers for the purchase of Series C preferred stock in connection with a
private placement (the &#8220;Series C Warrants&#8221;). The Series C Warrants were subsequently extended and, upon closing of the reverse
recapitalization transaction with Ritter, exchanged for warrants to purchase common stock of the Company, pursuant to the Series C Warrant
terms as adjusted.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
exchange for the Series C Warrants, upon closing of the merger with Ritter, the holders received warrants to purchase shares of the Company&#8217;s
common stock at $<span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20221231__us-gaap--StatementEquityComponentsAxis__custom--SeriesCWarrantsMember_z2NoJyddELoi">7.195
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per share, subject to adjustment. As of December
31, 2022, the warrants have remaining terms ranging from <span id="xdx_90E_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20221231__srt--RangeAxis__srt--MinimumMember__us-gaap--StatementEquityComponentsAxis__custom--SeriesCWarrantsMember_z6gB9ujWHnN3">0.90
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">to <span id="xdx_90C_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20221231__srt--RangeAxis__srt--MaximumMember__us-gaap--StatementEquityComponentsAxis__custom--SeriesCWarrantsMember_zI59ZOuW8Nra">1.49
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">years. The warrants were determined to be liability-classified
pursuant to the guidance in ASC 480 and ASC 815-40, resulting from inclusion of a leveraged ratchet provision for subsequent dilutive
issuances. On April 25, 2022 the warrants were repriced from $<span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20220425__srt--RangeAxis__srt--MaximumMember_zjDFXDHgRwOh">7.195
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">to $<span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20220425__srt--RangeAxis__srt--MinimumMember_zGbBu03voTtl">6.00
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">with an additional <span id="xdx_903_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20220423__20220425__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember_zc1BDoKqkEFl">49,318
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ratchet shares issued, and on May 26 2022 the
warrants were repriced from $<span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20220526__srt--RangeAxis__srt--MaximumMember_zTC0bcXzw7Ef">6.00
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">to $<span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20220526__srt--RangeAxis__srt--MinimumMember_zwTvwWquk3k3">5.136
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">with an additional <span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20220523__20220526__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember_zPaScz4ZUk0f">49,952
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ratchet shares issued. On December 22, 2022 the
warrants were repriced again from $<span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20221222__srt--RangeAxis__srt--MaximumMember_zl0Lk6bDRGG2">5.136
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">to $<span id="xdx_901_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20221222__srt--RangeAxis__srt--MinimumMember_z1GvwYAJ8Eh2">1.32
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">with an additional <span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20221219__20221222__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember_zcgnKiHGAeNk">1,002,717
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ratchet shares issued.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additionally,
on December 22, 2022, in conjunction with the issuance of Convertible Debt - Related Party (Note 11), the Company issued to
Alpha Capital a warrant to purchase <span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20221222__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember_z5ojSDPH9vd1" title="Warrant to purchase shares">2,500,000</span>
shares of the Company&#8217;s common stock. The exercise price of the warrant is $<span id="xdx_905_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20221222__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember_zyiFGSys0NIj" title="Exercise price of warrant">1.65</span>
(equal to <span id="xdx_90A_ecustom--ConversionPricePercentage_dp_uPure_c20221219__20221222__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember_zlZOsLU6OjP7" title="Conversion price percentage">125%</span>
of the conversion price of the Debenture on the closing date). The warrant may be exercised by Alpha, in whole or in part, at any
time on or after June 22, 2023 and before June 22, 2028, subject to certain terms conditions described in the warrant, including the
Company&#8217;s receipt of the necessary stockholder approvals.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>





<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_892_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zi4R4vr76wV6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes the activity in liability classified warrants for the year ended December 31, 2022:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span id="xdx_8B9_zlbDiViAHMLj" style="display: none">SCHEDULE OF WARRANTS ACTIVITY</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Common Stock Warrants</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Shares</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted&#8211;<br/> Average<br/> Exercise<br/>
    Price</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Range of Exercise<br/> Price</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted&#8211;<br/> Average<br/> Remaining
    Life (Years)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%">Total outstanding &#8211; December 31, 2021</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20220101__20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zgRZ9lBrrAU4" style="width: 11%; text-align: right" title="Number of Shares, Warrants Outstanding Beginning">248,162</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iS_c20220101__20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zdHaBnbdKIxk" style="width: 11%; text-align: right" title="Weighted Average Exercise Price Per Share Warrants Outstanding Beginning">7.20</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right"><span id="xdx_90B_ecustom--RangeOfExercisePrice_iS_c20220101__20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zDEOdKz4r8sd" title="Range of Exercise Beginning">7.20</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 11%; text-align: right"><span id="xdx_907_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAveragRemainingContractualTerm1_dtY_c20210101__20211231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zEg9rAw2F3tg" title="Weighted Averag Remaining Contractual Term">2.00</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt">Exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_di_c20220101__20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_z4v1hFTq5Sdf" style="text-align: right" title="Number of Shares, Warrants Exercised">(536</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedInPeriodWeightedAverageExercisePrice_c20220101__20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zNez6fhlXGcj" style="text-align: right" title="Weighted Average Exercise Price Per Share Warrants Exercised">7.20</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt">Forfeited</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_iN_di_c20220101__20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zwKh1cVFEL3e" style="text-align: right" title="Number of Shares, Warrants Forfeited">(247,625</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedInPeriodWeightedAverageExercisePrice_c20220101__20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zMKKnE0lOn3l" style="text-align: right" title="Weighted Average Exercise Price Per Share Warrants Forfeited">7.20</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt">Expired</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_c20220101__20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zly3pspvqndi" style="text-align: right" title="Number of Shares, Warrants Expired"><span style="-sec-ix-hidden: xdx2ixbrl1171">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInPeriodWeightedAverageExercisePrice_c20220101__20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zN1SodGJJ9H4" style="text-align: right" title="Weighted Average Exercise Price Per Share Warrants Expired"><span style="-sec-ix-hidden: xdx2ixbrl1173">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; padding-bottom: 1.5pt">Granted</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20220101__20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zIovgXO5mrPg" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Shares, Warrants Granted">3,849,570</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice_c20220101__20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zBUeAcTQIYuj" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Exercise Price Per Share Warrants Granted">1.53</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Total outstanding &#8211; December 31, 2022</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_c20220101__20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zFsS5v1SLk0h" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Shares, Warrants Outstanding Ending">3,849,571</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_982_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iE_c20220101__20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zP8I6u5b9Rfg" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price Per Share Warrants Outstanding Ending">1.53</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right"><span id="xdx_90F_ecustom--RangeOfExercisePrice_iE_c20220101__20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember__srt--RangeAxis__srt--MinimumMember_ziMXfIKHccal" title="Range of Exercise Ending">1.32</span> - <span id="xdx_900_ecustom--RangeOfExercisePrice_iE_c20220101__20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember__srt--RangeAxis__srt--MaximumMember_ztM5JNlu8qog" title="Range of Exercise Ending">1.65</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right"><span id="xdx_909_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAveragRemainingContractualTerm1_dtY_c20220101__20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_z5ISRz135JAi" title="Weighted Averag Remaining Contractual Term">3.9</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Exercisable</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_iE_c20220101__20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zQgOSvu364ug" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Shares, Warrants Exercisable">1,349,571</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageVestedExercisePrice_iE_c20220101__20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_z51QXKjozQH9" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price Per Share Exercisable">1.32</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_987_ecustom--RangeOfExercisePriceExercisableVested_iE_c20220101__20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zwFbKLcsDzlc" style="border-bottom: Black 2.5pt double; text-align: right" title="Range of Exercise Price, Exercisable">1.32</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNonExercisableWeightedAverageRemainingContractualTerm1_dtY_c20220101__20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zqzXgGiB5XWk" title="Exercisable Weighted Average Remaining Contractual Term">1.00</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes the activity in the Common Stock Warrants received in exchange for the Series C Warrants for the year ended
December 31, 2021:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Common Stock Warrants</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Shares</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted&#8211; Average<br/> Exercise<br/>
    Price</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Range of Exercise<br/> Price</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted&#8211;<br/> Average<br/> Remaining<br/>
    Life (Years)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; text-align: left">Total outstanding &#8211;December 31, 2020</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_pid_c20210101__20211231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zH77yzJp8ctc" style="width: 11%; text-align: right" title="Number of Shares, Warrants Outstanding Beginning">337,860</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iS_c20210101__20211231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zImbi4AYEEEh" style="width: 11%; text-align: right" title="Weighted Average Exercise Price Per Share Warrants Outstanding Beginning">7.20</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 11%; text-align: right">&#160;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 11%; text-align: right">&#160;</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt">Exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_pid_di_c20210101__20211231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zfpK04P8y6g3" style="text-align: right" title="Number of Shares, Warrants Exercised">(80,731</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedInPeriodWeightedAverageExercisePrice_c20210101__20211231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zD3Kkx3xf4s2" style="text-align: right" title="Weighted Average Exercise Price Per Share Warrants Exercised">7.20</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt">Forfeited</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_iN_pid_di_c20210101__20211231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zobya8eIBZu4" style="text-align: right" title="Number of Shares, Warrants Forfeited">(8,967</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedInPeriodWeightedAverageExercisePrice_c20210101__20211231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zDjLjuPENNR6" style="text-align: right" title="Weighted Average Exercise Price Per Share Warrants Forfeited">7.20</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt">Expired</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_pid_c20210101__20211231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zFC5SgAGzsEf" style="text-align: right" title="Number of Shares, Warrants Expired"><span style="-sec-ix-hidden: xdx2ixbrl1209">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInPeriodWeightedAverageExercisePrice_c20210101__20211231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_z7nycVmTb8B" style="text-align: right" title="Weighted Average Exercise Price Per Share Warrants Expired"><span style="-sec-ix-hidden: xdx2ixbrl1211">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; padding-bottom: 1.5pt">Granted</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pid_c20210101__20211231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zHOeD4mc3zk8" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Shares, Warrants Granted"><span style="-sec-ix-hidden: xdx2ixbrl1213">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice_c20210101__20211231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_z8XNUGVPEb2" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Exercise Price Per Share Warrants Granted"><span style="-sec-ix-hidden: xdx2ixbrl1215">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Total outstanding &#8211; December 31, 2021</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_pid_c20210101__20211231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zvGIKed08Dji" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Shares, Warrants Outstanding Ending">248,162</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iE_c20210101__20211231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zCk65p5rvzGj" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price Per Share Warrants Outstanding Ending">7.20</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Exercisable</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_iE_c20210101__20211231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zBkvGyDabBh5" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Shares, Warrants Exercisable">248,162</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_984_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageVestedExercisePrice_iE_c20210101__20211231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_ztQSbDCkta6l" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price Per Share Exercisable">7.20</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_985_ecustom--RangeOfExercisePriceExercisableVested_iI_c20211231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zEu6lMmQ7Yj" style="border-bottom: Black 2.5pt double; text-align: right" title="Range of Exercise Price, Exercisable">7.20</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_901_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNonExercisableWeightedAverageRemainingContractualTerm1_dtY_c20210101__20211231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zoFCBLkRSPC9" title="Exercisable Weighted Averag Remaining Contractual Term">2.00</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A0_zIsFfauJIwP7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_891_ecustom--ScheduleOfFairValueHierarchyForWarrantLiabilitiesTableTextBlock_ztNQLBf0mxnf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table presents the Company&#8217;s fair value hierarchy for its Common Stock Warrant liabilities measured at fair value on
a recurring basis as of December 31, 2022:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span id="xdx_8BC_zcaqBHalynh3" style="display: none">SCHEDULE OF FAIR VALUE HIERARCHY FOR WARRANT LIABILITIES</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Quoted</td><td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Market</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Significant</td><td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Prices for</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Other</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Significant</td><td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Identical</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Observable</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Unobservable</td><td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Assets</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Inputs</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Inputs</td><td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Common Stock Warrant liabilities</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">(Level 1)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">(Level 2)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">(Level 3)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%">Balance as of December 31, 2021</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_986_ecustom--FairValueAdjustmentOfWarrant_iS_pp0p0_c20220101__20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zA7XDLaSeJp7" style="width: 11%; text-align: right" title="Fair value for warrant liabilities"><span style="-sec-ix-hidden: xdx2ixbrl1231">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_987_ecustom--FairValueAdjustmentOfWarrant_iS_pp0p0_c20220101__20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_z9ZvtjE2OlEl" style="width: 11%; text-align: right" title="Fair value for warrant liabilities"><span style="-sec-ix-hidden: xdx2ixbrl1233">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">$</td><td id="xdx_98C_ecustom--FairValueAdjustmentOfWarrant_iS_pp0p0_c20220101__20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z4eVzr78nfqg" style="width: 11%; font-weight: bold; text-align: right" title="Fair value for warrant liabilities">1,686,200</td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 2%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">$</td><td id="xdx_98E_ecustom--FairValueAdjustmentOfWarrant_iS_pp0p0_c20220101__20221231_zQW5z8Rhuhi8" style="width: 11%; font-weight: bold; text-align: right" title="Fair value for warrant liabilities, beginning balance">1,686,200</td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Exercises</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_ecustom--FairValueOfWarrantLiabilitiesOnDateOfExercise_iN_pp0p0_di_c20220101__20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zGCennZ52Y2b" style="text-align: right" title="Common Stock Warrant liabilities, Exercises"><span style="-sec-ix-hidden: xdx2ixbrl1239">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_ecustom--FairValueOfWarrantLiabilitiesOnDateOfExercise_iN_pp0p0_di_c20220101__20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zdSg6uJAd9a2" style="text-align: right" title="Common Stock Warrant liabilities, Exercises"><span style="-sec-ix-hidden: xdx2ixbrl1241">&#8212;</span></td><td style="text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td id="xdx_981_ecustom--FairValueOfWarrantLiabilitiesOnDateOfExercise_iN_pp0p0_di_c20220101__20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zeARMJfHa1kf" style="font-weight: bold; text-align: right" title="Common Stock Warrant liabilities, Exercises">(858</td><td style="font-weight: bold; text-align: left">)</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td id="xdx_987_ecustom--FairValueOfWarrantLiabilitiesOnDateOfExercise_iN_pp0p0_di_c20220101__20221231_zuK1t4bnPMHi" style="font-weight: bold; text-align: right" title="Common Stock Warrant liabilities, Exercises">(858</td><td style="font-weight: bold; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Issuance of Alpha warrants</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td id="xdx_980_ecustom--FairValueOfWarrantLiabilitiesIssuanceOfAlphaWarrants_iN_pp0p0_di_c20220101__20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_z3KPQHnVEkj6" style="font-weight: bold; text-align: right" title="Issuance of Alpha warrants"><span style="-sec-ix-hidden: xdx2ixbrl1247">&#8212;</span></td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td id="xdx_984_ecustom--FairValueOfWarrantLiabilitiesIssuanceOfAlphaWarrants_iN_pp0p0_di_c20220101__20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_ziP3TcxufO4b" style="font-weight: bold; text-align: right" title="Issuance of Alpha warrants"><span style="-sec-ix-hidden: xdx2ixbrl1249">&#8212;</span></td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td id="xdx_985_ecustom--FairValueOfWarrantLiabilitiesIssuanceOfAlphaWarrants_iN_pp0p0_di_c20220101__20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zC4IQi7vMGL9" style="font-weight: bold; text-align: right" title="Issuance of Alpha warrants">2,834,547</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td id="xdx_98D_ecustom--FairValueOfWarrantLiabilitiesIssuanceOfAlphaWarrants_iN_pp0p0_di_c20220101__20221231_zkJjn6nyDGFc" style="font-weight: bold; text-align: right" title="Issuance of Alpha warrants">2,834,547</td><td style="font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Gain on change in fair value of warrant liabilities</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td id="xdx_984_ecustom--ChangeInFairValueOfWarrantLiabilities_pdp0_c20220101__20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_z4oIucfXRdvj" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right" title="Change in fair value of warrant liabilities"><span style="-sec-ix-hidden: xdx2ixbrl1255">&#8212;</span></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td id="xdx_98E_ecustom--ChangeInFairValueOfWarrantLiabilities_pdp0_c20220101__20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zSDM0xe7XeJ1" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right" title="Change in fair value of warrant liabilities"><span style="-sec-ix-hidden: xdx2ixbrl1257">&#8212;</span></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td id="xdx_98D_ecustom--ChangeInFairValueOfWarrantLiabilities_pp0p0_c20220101__20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zF5xzgPb65c7" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right" title="Change in fair value of warrant liabilities">(897,242</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td id="xdx_983_ecustom--ChangeInFairValueOfWarrantLiabilities_pp0p0_c20220101__20221231_zE61mt7RQZUg" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right" title="Change in fair value of warrant liabilities">(897,242</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Balance as of December 31, 2022</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td id="xdx_980_ecustom--FairValueAdjustmentOfWarrant_iE_pp0p0_c20220101__20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zch8P99usN7j" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right" title="Fair value for warrant liabilities"><span style="-sec-ix-hidden: xdx2ixbrl1263">&#8212;</span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td id="xdx_981_ecustom--FairValueAdjustmentOfWarrant_iE_pp0p0_c20220101__20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zh60I5eW81yc" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right" title="Fair value for warrant liabilities"><span style="-sec-ix-hidden: xdx2ixbrl1265">&#8212;</span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td id="xdx_980_ecustom--FairValueAdjustmentOfWarrant_iE_pp0p0_c20220101__20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zUga1nycgLLh" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right" title="Fair value for warrant liabilities">3,622,647</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td id="xdx_98B_ecustom--FairValueAdjustmentOfWarrant_iE_pp0p0_c20220101__20221231_zP2mygjPKjpa" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right" title="Fair value for warrant liabilities, ending balance">3,622,647</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table presents the Company&#8217;s fair value hierarchy for its Common Stock Warrant liabilities (all of which arose under
the warrants received in exchange for the Series C Warrants) measured at fair value on a recurring basis as of December 31, 2021:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Quoted</td><td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Market</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Significant</td><td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Prices for</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Other</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Significant</td><td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Identical</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Observable</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Unobservable</td><td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Assets</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Inputs</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Inputs</td><td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Common Stock Warrant liabilities</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">(Level 1)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">(Level 2)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">(Level 3)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%">Balance as of December 31, 2020</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_982_ecustom--FairValueAdjustmentOfWarrant_iS_pdp0_c20210101__20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zM0g0w5THkD8" style="width: 11%; text-align: right" title="Fair value for warrant liabilities"><span style="-sec-ix-hidden: xdx2ixbrl1271">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_981_ecustom--FairValueAdjustmentOfWarrant_iS_pdp0_c20210101__20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zA6XmeoqnPg5" style="width: 11%; text-align: right" title="Fair value for warrant liabilities"><span style="-sec-ix-hidden: xdx2ixbrl1273">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">$</td><td id="xdx_985_ecustom--FairValueAdjustmentOfWarrant_iS_pdp0_c20210101__20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zwEyPxSvBSel" style="width: 11%; font-weight: bold; text-align: right" title="Fair value for warrant liabilities">8,310,100</td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 2%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">$</td><td id="xdx_982_ecustom--FairValueAdjustmentOfWarrant_iS_pdp0_c20210101__20211231_zcqAWIAU3JA" style="width: 11%; font-weight: bold; text-align: right" title="Fair value for warrant liabilities">8,310,100</td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Exercises</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_ecustom--FairValueOfWarrantLiabilitiesOnDateOfExercise_iN_di_c20210101__20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_z46tU59ZOJMh" style="text-align: right" title="Common Stock Warrant liabilities, Exercises"><span style="-sec-ix-hidden: xdx2ixbrl1279">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_ecustom--FairValueOfWarrantLiabilitiesOnDateOfExercise_iN_di_c20210101__20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_ztEJ6mZBI9fl" style="text-align: right" title="Common Stock Warrant liabilities, Exercises"><span style="-sec-ix-hidden: xdx2ixbrl1281">&#8212;</span></td><td style="text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td id="xdx_983_ecustom--FairValueOfWarrantLiabilitiesOnDateOfExercise_iN_pp0p0_di_c20210101__20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zSMlhmnylCFk" style="font-weight: bold; text-align: right" title="Common Stock Warrant liabilities, Exercises">(1,900,713</td><td style="font-weight: bold; text-align: left">)</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td id="xdx_98A_ecustom--FairValueOfWarrantLiabilitiesOnDateOfExercise_iN_pdp0_di_c20210101__20211231_z4iQ5tt73t8j" style="font-weight: bold; text-align: right" title="Common Stock Warrant liabilities, Exercises">(1,900,713</td><td style="font-weight: bold; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Gain on change in fair value of warrant liabilities</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td id="xdx_986_ecustom--ChangeInFairValueOfWarrantLiabilities_pdp0_c20210101__20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_z5WZCTIomEEe" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right" title="Change in fair value of warrant liabilities"><span style="-sec-ix-hidden: xdx2ixbrl1287">&#8212;</span></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td id="xdx_98B_ecustom--ChangeInFairValueOfWarrantLiabilities_pdp0_c20210101__20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zxU6GLyUYMXf" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right" title="Change in fair value of warrant liabilities"><span style="-sec-ix-hidden: xdx2ixbrl1289">&#8212;</span></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td id="xdx_98D_ecustom--ChangeInFairValueOfWarrantLiabilities_pp0p0_c20210101__20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zr8rKFav1sw3" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right" title="Change in fair value of warrant liabilities">(4,723,187</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td id="xdx_988_ecustom--ChangeInFairValueOfWarrantLiabilities_pp0p0_c20210101__20211231_zwTo0iwheP79" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right" title="Change in fair value of warrant liabilities">(4,723,187</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Balance as of December 31, 2021</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td id="xdx_989_ecustom--FairValueAdjustmentOfWarrant_iE_pdp0_c20210101__20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zWuKHKzFgNV1" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right" title="Fair value for warrant liabilities"><span style="-sec-ix-hidden: xdx2ixbrl1295">&#8212;</span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td id="xdx_980_ecustom--FairValueAdjustmentOfWarrant_iE_pdp0_c20210101__20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zi58ZANZKaEf" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right" title="Fair value for warrant liabilities"><span style="-sec-ix-hidden: xdx2ixbrl1297">&#8212;</span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td id="xdx_989_ecustom--FairValueAdjustmentOfWarrant_iE_pdp0_c20210101__20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zKOUQjYDEWL9" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right" title="Fair value for warrant liabilities">1,686,200</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td id="xdx_986_ecustom--FairValueAdjustmentOfWarrant_iE_pdp0_c20210101__20211231_z9XQoM1ibaw7" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right" title="Fair value for warrant liabilities">1,686,200</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8AB_zzS6BEzkcisd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
were no transfers of financial assets or liabilities between category levels for the year ended December 31, 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
value of the warrant liabilities was based on a valuation received from an independent valuation firm determined using a Monte-Carlo
simulation. For volatility, the Company considers comparable public companies as a basis for its expected volatility to calculate the
fair value of common stock warrants and transitions to its own volatility as the Company develops sufficient appropriate history as a
public company. The risk-free interest rate is based on U.S. Treasury notes with a term approximating the expected term of the common
stock warrant. The Company uses an expected dividend yield of zero based on the fact that the Company has never paid cash dividends and
does not expect to pay cash dividends in the foreseeable future. Any significant changes in the inputs may result in significantly higher
or lower fair value measurements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_893_ecustom--ScheduleOfAssumptionsOfWarrantLiabilitiesTableTextBlock_zUrjGat2pOm7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following are the weighted average and the range of assumptions used in estimating the fair value of warrant liabilities (weighted average
calculated based on the number of outstanding warrants on each issuance) as of December 31, 2022 and December 31, 2021:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span id="xdx_8B8_zXu2zfSuQhk8" style="display: none">SCHEDULE
OF ASSUMPTIONS OF WARRANT LIABILITIES</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"/>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"/>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="font-size: 11pt; text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">December 31, 2022</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">December 31, 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 11pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Range</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Weighted<br/> Average</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Range</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Weighted<br/> Average</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 11pt; text-align: center">&#160;</td><td style="font-size: 11pt; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-size: 11pt">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 11pt">&#160;</td><td style="font-size: 11pt; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-size: 11pt">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 11pt">&#160;</td><td style="font-size: 11pt; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-size: 11pt">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 11pt">&#160;</td><td style="font-size: 11pt; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-size: 11pt">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 11pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 38%; text-align: left">Risk-free interest rate</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 13%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90F_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20221231__srt--RangeAxis__srt--MinimumMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zSh0YEfZ8bD2" title="Fair value assumptions, measurement input, percentages"><span style="-sec-ix-hidden: xdx2ixbrl1305">3.906%</span></span>
                                            &#8212; <span id="xdx_909_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20221231__srt--RangeAxis__srt--MaximumMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_z2M90k7YyeQa" title="Fair value assumptions, measurement input, percentages">4.628</span>&#160;</span></td><td style="width: 1%; text-align: left">%</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 11%; text-align: right"><span id="xdx_907_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20221231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--WeightedAverageMember_znbc0RjerXb7" title="Fair value assumptions, measurement input, percentages">4.15</span></td><td style="width: 1%; text-align: left">%</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 11%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_905_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20211231__srt--RangeAxis__srt--MinimumMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zJI6idtaQfU5" title="Fair value assumptions, measurement input, percentages">0.69%</span>
                                            &#8212; <span id="xdx_902_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20211231__srt--RangeAxis__srt--MaximumMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zSmNpTAFL4Gg" title="Fair value assumptions, measurement input, percentages">0.84</span></span></td><td style="width: 1%; text-align: left">&#160;%</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 11%; text-align: right"><span id="xdx_90C_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20211231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--WeightedAverageMember_z6QdufRA9ndh" title="Fair value assumptions, measurement input, percentages">0.72</span></td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Expected volatility (peer group)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_908_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20221231__srt--RangeAxis__srt--MinimumMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zit3kgSqXrtb" title="Expected volatility"><span style="-sec-ix-hidden: xdx2ixbrl1317">88%</span></span>
                                            &#8212; <span id="xdx_908_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20221231__srt--RangeAxis__srt--MaximumMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zLsHapTdV8Z6" title="Expected volatility">103</span></span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_903_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20221231__srt--RangeAxis__srt--WeightedAverageMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zF6rWT0z5K69" title="Expected volatility">98</span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_909_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20211231__srt--RangeAxis__srt--MinimumMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zoHjfNGTL03i" title="Expected volatility"><span style="-sec-ix-hidden: xdx2ixbrl1323">84%</span></span>
                                            &#8212; <span id="xdx_90A_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20211231__srt--RangeAxis__srt--MaximumMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_z9PatBOSI5Tc" title="Expected volatility">87</span></span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90D_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20211231__srt--RangeAxis__srt--WeightedAverageMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zahxBsQHA2Kk" title="Expected volatility">85</span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Term of warrants (in years)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90D_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20221231__srt--RangeAxis__srt--MinimumMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_z0eLWOuKRvbc" title="Fair value assumptions, measurement input, term">.90</span>
                                            &#8212; <span id="xdx_905_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20221231__srt--RangeAxis__srt--MaximumMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_zR6KYxzz12Jb" title="Fair value assumptions, measurement input, term">5.48</span></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_906_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20221231__srt--RangeAxis__srt--WeightedAverageMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_zDr2I1FtDGdj" title="Fair value assumptions, measurement input, term">3.9</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90E_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20211231__srt--RangeAxis__srt--MinimumMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_zDR8E7tt1go8" title="Fair value assumptions, measurement input, term">1.90</span>
                                            &#8212; <span id="xdx_902_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20211231__srt--RangeAxis__srt--MaximumMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_zZURLdhnmmP7" title="Fair value assumptions, measurement input, term">2.50</span></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90A_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20211231__srt--RangeAxis__srt--WeightedAverageMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_zP51RGjPTRe7" title="Fair value assumptions, measurement input, term">2.01</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Expected dividend yield</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_902_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20221231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zK2qdLEmQqJ7" title="Fair value assumptions, measurement input, percentages">0.00</span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_901_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20221231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember__srt--RangeAxis__srt--WeightedAverageMember_zwosA5i5B0sc" title="Fair value assumptions, measurement input, percentages">0.00</span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_902_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20211231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zZTTgQ114pN1" title="Fair value assumptions, measurement input, percentages">0.00</span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_900_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20211231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember__srt--RangeAxis__srt--WeightedAverageMember_zW3iPjqQxj3f" title="Fair value assumptions, measurement input, percentages">0.00</span></td><td style="text-align: left">%</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"/>

<p id="xdx_8AD_z4Tsxf65hVLh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
value of the warrant liabilities is based on a valuation received from an independent valuation firm determined using a Monte-Carlo simulation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_DisclosureWarrantLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_DisclosureWarrantLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_WarrantLiabilitiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrant Liabilities [Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_WarrantLiabilitiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140569897092528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONVERTIBLE DEBT - RELATED PARTY<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">CONVERTIBLE DEBT - RELATED PARTY</a></td>
<td class="text"><p id="xdx_80B_eus-gaap--DebtDisclosureTextBlock_z9OmxLFhk9A1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
11 &#8212; <span id="xdx_828_zn2ByDMuxcoh">CONVERTIBLE DEBT - RELATED PARTY</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 22, 2022, the Company issued to Alpha Capital, an <span id="xdx_902_eus-gaap--ShortTermDebtInterestRateIncrease_pid_dp_uPure_c20221222__20221222__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember__us-gaap--DebtInstrumentAxis__custom--SeniorConvertibleDebentureMember_zuFRI2SmP6aj" title="Senior convertible debenture rate">8%</span> Senior Convertible Debenture in the aggregate principal amount of $<span id="xdx_902_eus-gaap--SecuredDebt_iI_c20221222__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember__us-gaap--DebtInstrumentAxis__custom--SeniorConvertibleDebentureMember_zFjlBePNcWbg" title="Principal amount">3,300,000</span>
for a purchase price of $<span id="xdx_90C_ecustom--PurchasePrice_iI_c20221222__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember__us-gaap--DebtInstrumentAxis__custom--SeniorConvertibleDebentureMember_zdLia0UcJPnd" title="Purchase Price">3,000,000</span> pursuant to the terms of a Securities Purchase Agreement, dated December 21, 2022 (the &#8220;Alpha
Purchase Agreement&#8221;). The Debenture is convertible, at any time, and from time to time, at Alpha&#8217;s option, into shares of
common stock of the Company (the &#8220;Conversion Shares&#8221;), at a price equal to $<span id="xdx_904_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pid_c20221222__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember__us-gaap--DebtInstrumentAxis__custom--SeniorConvertibleDebentureMember_zKupsPjE5LY4" title="Conversion price">1.32</span> per share, subject to adjustment as described
in the Debenture (the &#8220;Conversion Price&#8221;) and other terms and conditions described in the Debenture, including the Company&#8217;s
receipt of the requisite stockholder approvals. Additionally, on December 22, 2022, the Company issued to Alpha Capital a liability classified warrant to purchase
<span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20221222__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember_zvrBJUvRVqJ5" title="Warrant to purchase shares">2,500,000</span> shares of the Company&#8217;s common stock (see Note 10-Warrant Liabilities). The exercise price of the warrant is $<span id="xdx_905_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20221222__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember_zIBuKGkTrdF9" title="Exercise price of warrant">1.65</span> (equal to <span id="xdx_904_ecustom--ConversionPricePercentage_dp_uPure_c20221219__20221222__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember_zOPPXckyWKaj" title="Conversion price percentage">125</span>% of the conversion
price of the Debenture on the closing date). The warrant may be exercised by Alpha Capital, in whole or in part, at any time on or after
June 22, 2023 and before June 22, 2028, subject to certain terms conditions described in the warrant, including the Company&#8217;s receipt
of the necessary stockholder approvals.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
proceeds from the transaction will be dedicated to the Company&#8217;s efforts of advancing its QN-302 Investigative New Drug candidate
towards clinical trials and other working capital purposes.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Commencing
June 1, 2023 and continuing on the first day of each month thereafter until the earlier of (i) December 22, 2025 and (ii) the full redemption
of the Debenture (each such date, a &#8220;Monthly Redemption Date&#8221;), the Company will redeem $<span id="xdx_903_eus-gaap--DebtInstrumentIncreaseAccruedInterest_c20221222__20221222__us-gaap--DebtInstrumentAxis__custom--SeniorConvertibleDebentureMember_z2DarAAqVvs7" title="Unpaid interest">110,000</span> plus accrued but unpaid
interest, liquidated damages and any amounts then owing under the Debenture (the &#8220;Monthly Redemption Amount&#8221;). The Monthly
Redemption Amount will be paid in cash; provided that after the first two monthly redemptions, the Company may elect to pay all or a
portion of a Monthly Redemption Amount in shares of common stock of the Company, based on a conversion price equal to the lesser of (i)
the then Conversion Price of the Debenture and (ii) <span id="xdx_908_eus-gaap--DebtConversionConvertedInstrumentRate_pid_dp_uPure_c20221222__20221222__us-gaap--DebtInstrumentAxis__custom--SeniorConvertibleDebentureMember_zzSyfBCM6PRa" title="Conversion rate">85%</span> of the average of the VWAPs (as defined in the Debenture) for the five consecutive
trading days ending on the trading day that is immediately prior to the applicable Monthly Redemption Date. The Company may also redeem
some or all of the then outstanding principal amount of the Debenture at any time for cash in an amount equal to <span id="xdx_90F_ecustom--PrincipalAmountPercentage_pid_dp_uPure_c20221222__20221222__us-gaap--DebtInstrumentAxis__custom--SeniorConvertibleDebentureMember_zuo1xCjerRd4" title="Principal amount percentage">105%</span> of the then outstanding
principal amount of the Debenture being redeemed plus accrued but unpaid interest, liquidated damages and any amounts then owing under
the Debenture. These monthly redemption and optional redemptions are subject to the satisfaction of the Equity Conditions (as defined
in the Debenture), which includes a condition that we have obtained stockholder approval for such share issuances.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Debenture accrues interest at the rate of <span id="xdx_908_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_dp_uPure_c20221222_zqktQaiukE0e" title="Debenture accrues interest rate">8%</span> per annum, which does not begin accruing until December 1, 2023, and will be payable on
a quarterly basis. Interest may be paid in cash or shares of common stock of the Company or a combination thereof at the option of the
Company; provided that interest may only be paid in shares if the Equity Conditions have been satisfied, including the stockholder approval
condition as described above.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Both
the Debenture and the Alpha Warrant provide for adjustments to the Conversion Price and Exercise Price, respectively, in connection with
stock dividends and splits, subsequent equity sales and rights offerings, pro rata distributions, and certain fundamental transactions.
Both the Debenture and the Alpha Warrant include a beneficial ownership blocker of 9.99%, which may only be waived by Alpha Capital upon
61 days&#8217; notice to the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"/>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company filed a registration statement on Form S-3 (No. 333-269088) with the Securities and Exchange Commission on December 30, 2022
registering the resale by Alpha Capital of an aggregate of <span id="xdx_90D_eus-gaap--CommonStockSharesIssued_iI_c20221230__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember_z8Hbnh4pDkBb" title="Shares of Common stock, issued">5,157,087</span> shares of our common stock, which may be issuable to the selling
stockholder pursuant to the terms of the Debenture and Alpha Warrant.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company evaluated the Debenture and Alpha Warrants (&#8220;Warrants&#8221;) and determined that the Warrants are freestanding financial
instruments. The Warrants are not considered indexed to an entity&#8217;s own stock, because the settlement amount would not equal the
difference between the fair value of a fixed number of the entity&#8217;s equity shares and a fixed strike price and all of the adjustment
features in Section 3(b) of the warrant agreement are not down round provisions, as defined in ASU 2017-11. Accordingly, the warrants
are classified as a liability and recognized at fair value, with subsequent changes in fair value recognized in earnings.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
proceeds were allocated to the initial fair value of the Warrants, with the residual balance allocated to the initial carrying value
of the Debenture. The Company has not elected the fair value option for the Debenture. The Debenture was recognized at proceeds received
after allocating the proceeds to the Warrants, and then allocating remaining proceeds to a suite of bifurcated embedded derivative features
(conversion option, contingent acceleration upon an Event of Default, and contingent interest upon an Event of Default), with the resulting
difference, if any, allocated to the loan host instrument. The suite of derivative features was measured and determined to have no fair
value.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
original issue discount ($<span id="xdx_90F_eus-gaap--AmortizationOfDebtDiscountPremium_pn5n6_c20220101__20221231__srt--TitleOfIndividualAxis__custom--AlphaCapitalOtherThirdPartiesMember_zp4lvSqRUHC6" title="Debt discount">0.3</span> million), the initial fair value of the Warrant ($<span id="xdx_90D_eus-gaap--FairValueAdjustmentOfWarrants_pn5n6_c20220101__20221231__srt--TitleOfIndividualAxis__custom--AlphaCapitalOtherThirdPartiesMember_zO2owtL4DxRk" title="Fair value of warrants">2.8</span> million), the initial fair value of the suite of
bifurcated embedded derivative features ($<span id="xdx_909_eus-gaap--EmbeddedDerivativeFairValueOfEmbeddedDerivativeNet_iI_c20221231__srt--TitleOfIndividualAxis__custom--AlphaCapitalOtherThirdPartiesMember_zI0TkalCerC5" title="Fair value of embedded derivative features">0</span>), and the fees and costs paid to Alpha Capital and other third parties ($<span id="xdx_90D_ecustom--FeesAndCostsPaid_pn5n6_c20220101__20221231__srt--TitleOfIndividualAxis__custom--AlphaCapitalOtherThirdPartiesMember_zScSabRjudtg" title="Fees and costs paid">0.1</span> million) comprise
the debt discount.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
debt discount shall be amortized to interest expense over the expected term of the Debenture using the effective interest method, in
accordance with ASC 835-30. The debt host instrument of the Debenture will subsequently be measured at amortized cost using the effective
interest method to accrete interest over its term to bring the Debenture&#8217;s initial carrying value to the principal balance at maturity.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_893_eus-gaap--ConvertibleDebtTableTextBlock_ztEJAzIDLiAf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
senior secured convertible debt comprises the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span id="xdx_8BC_z1WPDg8CZWAc" style="display: none">SCHEDULE OF SENIOR SECURED CONVERTIBLE DEBT</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49B_20221231__us-gaap--DebtInstrumentAxis__custom--SeniorSecuredConvertibleDebtMember_zeAxq957M6G" style="border-bottom: Black 1.5pt solid; text-align: center">December 31, 2022</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49A_20211231__us-gaap--DebtInstrumentAxis__custom--SeniorSecuredConvertibleDebtMember_zH6RVIUHly2d" style="border-bottom: Black 1.5pt solid; text-align: center">December 31, 2021</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--SecuredDebt_iI_zAbA2kDFz948" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Senior secured convertible debenture</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">3,300,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1386">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--DebtInstrumentUnamortizedDiscount_iNI_di_zxkB9aHFk1al" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Discount on convertible debenture</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(3,239,803</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1389">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--ConvertibleDebt_iI_zRqBAw6xB991" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt">Total convertible debt - related party</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">60,197</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1392">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A8_zt7yx6G1i148" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2022, there were no events of default or violation of any covenants under our financing obligations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI https://asc.fasb.org/topic&amp;trid=2208564<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140569897205408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>EARNINGS (LOSS) PER SHARE<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">EARNINGS (LOSS) PER SHARE</a></td>
<td class="text"><p id="xdx_805_eus-gaap--EarningsPerShareTextBlock_zHY7egubaLke" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
12 &#8212; <span id="xdx_82F_zPGZC2l028Hh">EARNINGS (LOSS) PER SHARE</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basic
earnings (loss) per share (&#8220;EPS&#8221;) is computed by dividing net income (loss) by the weighted-average number of common
shares outstanding. Diluted EPS is computed based on the sum of the weighted-average number of common shares and potentially
dilutive common shares outstanding during the period. Potentially dilutive common shares consist of shares issuable from stock
options and warrants as shown below.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_89B_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_zaoyhmNBTzl3" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table reconciles net loss and the weighted-average shares used in computing basic and diluted EPS in the respective periods:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span id="xdx_8BD_z7LQ3fmEIrCi" style="display: none">SCHEDULE OF EARNINGS PER SHARE BASIC AND DILUTED</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_497_20220101__20221231_z6dwpAP8J93c" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49A_20210101__20211231_z9KIausBOqgc" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">For the Years Ended<br/> December
    31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--NetIncomeLoss_zJ7l70jhJT83" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left; padding-bottom: 1.5pt">Net loss used for basic earnings per share</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt double; width: 16%; text-align: right">(18,640,543</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">)</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt double; width: 16%; text-align: right">(17,897,137</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_zu7PiFAlXhde" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Basic weighted-average common shares outstanding</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,840,340</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,933,487</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_ecustom--DilutivePotentialSharesIssuableFromStockOptionsAndWarrants_zAYVlK9dICj5" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Dilutive potential shares issuable from stock options and warrants</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1404">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1405">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--WeightedAverageNumberDilutedSharesOutstandingAdjustment_zGRAE7ZM1bQi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Diluted weighted-average common shares outstanding</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">3,840,340</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,933,487</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>


<p id="xdx_8A6_zuXyI6L94J1a" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_892_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zBltfnfiJ6zd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span id="xdx_8B1_zEGCJvcq8ezb" style="display: none">SCHEDULE
OF DILUTIVE SECURITIES EXCLUDED FROM DILUTED NET LOSS PER SHARE</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">As of December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Shares of common stock subject to outstanding options</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20220101__20221231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--SharesOfCommonStockSubjectToOutstandingOptionsMember_ztotXvbX597a" style="width: 16%; text-align: right" title="Total common stock equivalents">608,012</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20210101__20211231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--SharesOfCommonStockSubjectToOutstandingOptionsMember_zlSKky8vBqE7" style="width: 16%; text-align: right" title="Total common stock equivalents">484,186</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Shares of common stock subject to outstanding warrants</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20220101__20221231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--SharesOfCommonStockSubjectToOutstandingWarrantsMember_zpZnNV69Vlba" style="border-bottom: Black 1.5pt solid; text-align: right" title="Total common stock equivalents">4,575,617</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20210101__20211231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--SharesOfCommonStockSubjectToOutstandingWarrantsMember_zYNSh0cCai5j" style="border-bottom: Black 1.5pt solid; text-align: right" title="Total common stock equivalents">982,140</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Total common stock equivalents</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20220101__20221231_z4StuYQKGSP5" style="border-bottom: Black 2.5pt double; text-align: right" title="Total common stock equivalents">5,183,629</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20210101__20211231_zZ2vqFx77pi6" style="border-bottom: Black 2.5pt double; text-align: right" title="Total common stock equivalents">1,466,326</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>



<p id="xdx_8A9_zvcqruAJdDuf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"/>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Potentially
dilutive common shares excluded from the calculation above represent stock options and warrants because their effect would be anti-dilutive.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI https://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140569897205408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">COMMITMENTS AND CONTINGENCIES</a></td>
<td class="text"><p id="xdx_806_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_z9iGw5PtcN4f" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
13 &#8212; <span id="xdx_821_zjEMbMiCADH3">COMMITMENTS AND CONTINGENCIES</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Leases</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company leases its facilities under a long-term operating lease agreement. On December 15, 2021, our wholly-owned subsidiary Qualigen,
Inc. entered into a Second Amendment to Lease with Bond Ranch LP. This Amendment extended the Company&#8217;s triple-net leasehold on
the Company&#8217;s existing <span id="xdx_907_eus-gaap--AreaOfLand_iI_pid_uSqft_c20211215_zaAbtsgHCJIi" title="Area of land">22,624</span>-square-feet headquarters/manufacturing facility at 2042 Corte del Nogal, Carlsbad, California for
the <span id="xdx_907_eus-gaap--LesseeOperatingLeaseTermOfContract_iI_dtM_c20211215_zmFD2xTsFte8" title="Lessee operating lease term of contract">61</span>-month period of <span id="xdx_90F_eus-gaap--LesseeOperatingLeaseDescription_c20211214__20211215_z6AeFyO5EqWc" title="Operating lease term description">November 1, 2022 to November 30, 2027</span>. Over the <span id="xdx_907_eus-gaap--LesseeOperatingLeaseTermOfContract_iI_dtM_c20211215_zVIwr4pGAJNi" title="Operating lease term">61</span> months, the base rent payable by Qualigen, Inc. will total
$<span id="xdx_908_eus-gaap--PaymentsForRent_pp0p0_c20211214__20211215_zD87jiSScl8l" title="Payments for Rent">1,950,710</span>; however, the base rent for the first 12 months of the <span id="xdx_907_eus-gaap--LesseeOperatingLeaseTermOfContract_iI_dtM_c20211215_zvVNz8xyQE5h" title="Operating lease term">61</span>-month period is only $<span id="xdx_906_eus-gaap--PaymentsForRent_pp0p0_c20211214__20211215__us-gaap--AwardTypeAxis__custom--FirstTwelveMonthsMember_zRstPgwarKb1" title="Payments for Rent">335,966</span>. Additionally, under the Second Amendment
to Lease Qualigen, Inc. is entitled to a $<span id="xdx_90D_ecustom--TenantImprovementAllowance_pp0p0_c20211214__20211215_z109P4LxiNbe" title="Tenant improvement allowance">339,360</span> tenant improvement allowance.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_899_ecustom--ScheduleOfOperatingLeaseRightOfUseAssetsAndLiabilitiesTableTextBlock_z0ulwQjfH8U4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
tables below show the operating lease right-of-use assets and operating lease liabilities and the balances as of December 31, 2022 and 2021,
including the changes during the periods:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span id="xdx_8BA_ziFz6VW0TG05" style="display: none">SCHEDULE OF OPERATING LEASE RIGHT OF USE ASSETS AND OPERATING LEASE LIABILITIES</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"/>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"/>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="font-size: 11pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Operating lease<br/>
 right-of-use assets</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Net right-of-use assets at December 31, 2021</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_980_eus-gaap--OperatingLeaseRightOfUseAsset_iS_pp0p0_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--LongtermOperatingLeaseAgreementMember_zoWJJfQiX20c" style="width: 20%; text-align: right" title="Operating lease right-of-use assets">1,645,568</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Less amortization of operating lease right-of-use assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--OperatingLeaseRightOfUseAssetAmortizationExpense_iN_pp0p0_di_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--LongtermOperatingLeaseAgreementMember_zRBGziJpQXff" style="border-bottom: Black 1.5pt solid; text-align: right" title="Less amortization of operating lease right-of-use assets">(223,030</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Operating lease right-of-use assets at December 31, 2022</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98E_eus-gaap--OperatingLeaseRightOfUseAsset_iE_pp0p0_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--LongtermOperatingLeaseAgreementMember_z9nu3gT7HO9i" style="border-bottom: Black 2.5pt double; text-align: right" title="Operating lease right-of-use assets">1,422,538</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"/>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"/>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="font-size: 11pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Operating lease <br/>
liabilities</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify">Lease liabilities at December 31, 2021</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--OperatingLeaseLiability_iS_pp0p0_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--LongtermOperatingLeaseAgreementMember_z3PIOEpBaz6c" style="width: 20%; text-align: right" title="Lease liabilities at December 31, 2021">1,676,655</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Less principal payments on operating lease liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--OperatingLeasePayments_iN_pp0p0_di_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--LongtermOperatingLeaseAgreementMember_z7BsWNkVCFb3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Less principal payments on operating lease liabilities">(134,091</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Lease liabilities at December 31, 2022</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--OperatingLeaseLiability_iE_pp0p0_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--LongtermOperatingLeaseAgreementMember_z2BlWDvHWsEe" style="text-align: right" title="Lease liabilities at December 31, 2022">1,542,564</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Less non-current portion</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--OperatingLeaseLiabilityNoncurrent_iNI_pp0p0_di_c20221231__us-gaap--TypeOfArrangementAxis__custom--LongtermOperatingLeaseAgreementMember_zhXkVZb3zUD4" style="border-bottom: Black 1.5pt solid; text-align: right" title="Less non-current portion">(1,301,919</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Current portion at December 31, 2022</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_985_eus-gaap--OperatingLeaseLiabilityCurrent_iI_pp0p0_c20221231__us-gaap--TypeOfArrangementAxis__custom--LongtermOperatingLeaseAgreementMember_zN5pWBRG2zJe" style="border-bottom: Black 2.5pt double; text-align: right" title="Current portion at Decebmer 31, 2022">240,645</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8AE_zes6jdNH188a" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2022, the Company&#8217;s operating leases have a weighted-average remaining lease term of <span id="xdx_900_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20221231_zSqpD6tjQxyi" title="Weighted-average remaining lease term">4.9</span> years and a weighted-average
discount rate of <span id="xdx_908_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pid_dp_uPure_c20221231_zbSLh6l6MEQ2" title="Weighted-average discount rate">8.9%</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_896_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_zSBkOaWTrCPh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2022, the maturities of operating lease liabilities are as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span id="xdx_8BE_z9uHZNcDlUZ4" style="display: none">SCHEDULE OF MATURITIES OF OPERATING LEASE LIABILITIES</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; text-align: left; font-weight: bold">Year Ending December 31,</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49E_20221231_zn3gN7h6B1nl" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Amount</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_pp0p0_maLOLLPzeyI_zIWHtmgJn8Ia" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">2023</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 20%; text-align: right">368,341</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_pp0p0_maLOLLPzeyI_zZMNmVXDq436" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">2024</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">379,392</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_pp0p0_maLOLLPzeyI_zC64ZeHfUxLe" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">2025</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">390,773</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFour_iI_pp0p0_maLOLLPzeyI_z00UeWrsMc3i" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">2026</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">402,497</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFive_iI_pp0p0_maLOLLPzeyI_zTPS48niBBhi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">2027</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">379,164</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_pp0p0_mtLOLLPzeyI_z2xGUrk62F7k" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Total</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,920,168</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_pp0p0_di_zO7AcWnTUBmh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Less present value discount</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(377,604</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_407_eus-gaap--OperatingLeaseLiability_iI_pp0p0_zYZMazngQ4g2" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Operating lease liabilities</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,542,564</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8AA_zvYjPd46qM0g" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
lease expense was approximately $<span id="xdx_900_eus-gaap--OperatingLeaseExpense_c20220101__20221231_zjr6RpIrW6X5">462,000</span> and $<span id="xdx_90D_eus-gaap--OperatingLeaseExpense_c20210101__20211231_zgZOSCr6uhje">342,000</span>, respectively, for the years ended December 31, 2022 and December 31, 2021. Lease
expense was recorded in cost of product sales, general and administrative expenses, research and development and sales and marketing
expenses.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Termination
of Sekisui Distribution Agreement</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sekisui&#8217;s
Distribution Arrangement expired on March 31, 2022. Following the expiration of the Sekisui Distribution Agreement on March 31, 2022,
the Company had a commitment to purchase leased FastPack rental systems back from Sekisui at Sekisui&#8217;s net book value, in the amount
of $<span id="xdx_901_eus-gaap--AccruedLiabilitiesAndOtherLiabilities_iI_c20221231__srt--TitleOfIndividualAxis__custom--SekisuiDistributionAgreementMember_zQ7KZ4Ig9A6b" title="Accrued expenses">154,000</span> which is included in equipment held for lease and accrued expenses on the consolidated balance sheet.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>NanoSynex
Funding Commitment</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a condition to the NanoSynex Acquisition, the Company agreed to provide NanoSynex with up to $<span id="xdx_908_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iI_pn5n6_c20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NanoSynexMember_zMLqrzeE72Ol" title="Maximum future funding amount">10.4</span> million of future funding in the form
of promissory notes to the Company based on NanoSynex&#8217;s achievement of certain future development milestones and subject to other
terms and conditions described in the Funding Agreement entered into with NanoSynex. Of this amount approximately $<span id="xdx_903_ecustom--DevelopmentFund_pn5n6_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NanoSynexMember_zZAk0FaQXX4f" title="Development fund">2.4</span> million was funded
during the year ended December 31, 2022, and an additional $<span id="xdx_906_eus-gaap--LineOfCreditFacilityCurrentBorrowingCapacity_iI_pn5n6_c20230228__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NanoSynexMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zqegjOgAERag" title="Additional funding amount">0.5</span> million was funded in February 2023 (See Note 2-Liquidity for further details regarding the terms and conditions of the Funding Agreement).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"/>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Litigation
and Other Legal Proceedings</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
November 9, 2021, the Company was named as a defendant in an action brought by Mediant Communications Inc. (&#8220;Mediant&#8221;) in
the U.S. District Court for the Southern District of New York. The complaint alleged that Qualigen entered into an implied contract with
Mediant, whereby Qualigen retained Mediant to distribute proxy materials and subsequently conduct shareholder vote tabulations. The Company
filed a Motion to Dismiss with the District Court and on March 14, 2022 a hearing was held during which the presiding judge ruled in
favor of the Motion to Dismiss. The Company and Mediant settled the litigation on April 5, 2022 in the amount of $<span id="xdx_905_eus-gaap--LitigationSettlementAmountAwardedToOtherParty_pp0p0_c20220404__20220405_z40tOhfkOwOk" title="Litigation settlement amount">96,558</span>, at which time
the amount was paid.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI https://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI https://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140569892288784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RESEARCH AND LICENSE AGREEMENTS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_DisclosureResearchAndLicenseAgreementsAbstract', window );"><strong>Research And License Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_ResearchAndLicenseAgreementsTextBlock', window );">RESEARCH AND LICENSE AGREEMENTS</a></td>
<td class="text"><p id="xdx_80A_ecustom--ResearchAndLicenseAgreementsTextBlock_zVAoYUU74L9j" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
14 &#8212; <span id="xdx_829_zwvo1fWa5Cz9">RESEARCH AND LICENSE AGREEMENTS</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>The
University of Louisville Research Foundation</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
March 2019, the Company entered into a sponsored research agreement and an option for a license agreement with ULRF for development of
several small-molecule RAS interaction inhibitor drug candidates. Under the terms of this agreement, the Company was to reimburse ULRF
for sponsored research expenses of up to $<span id="xdx_90A_ecustom--ReimbursementOfResearchExpenses_pp0p0_c20190301__20190331__us-gaap--TypeOfArrangementAxis__custom--SponsoredResearchAgreementAndLicenseMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember_zCLvzpzjMyik">693,000
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">for this program. In February 2021, March 2022,
and October 2022, the Company extended the term of this agreement until September 2023 and increased the amount that the Company will
reimburse ULRF for sponsored research expenses to approximately $<span id="xdx_906_ecustom--ReimbursementOfResearchExpenses_pn5n6_c20210201__20210228__us-gaap--TypeOfArrangementAxis__custom--SponsoredResearchAgreementAndLicenseMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember_zgeRqiu8lyGl">2.7
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million. <span id="xdx_908_ecustom--AgreementTermPaymentDescription_c20190301__20190331__us-gaap--TypeOfArrangementAxis__custom--SponsoredResearchAgreementAndLicenseMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember_zvNNEzQiBlJi">In
July 2020, the Company entered into an exclusive license agreement with ULRF for RAS interaction inhibitor drug candidates. Under the
agreement, the Company will take over development, regulatory approval and commercialization of the candidates from ULRF and is responsible
for maintenance of the related intellectual property portfolio. In return, ULRF received approximately $112,000 for an upfront license
fee and reimbursement of prior patent costs. In addition, the Company has agreed to pay ULRF (i) royalties, on patent-covered net sales
associated with the commercialization, of 4% (on net sales up to a cumulative $250,000,000) or 5% (on net sales above a cumulative $250,000,000),
until expiration of the licensed patent, and 2.5% (on net sales for any sales not covered by Licensed Patents), (ii) 30% to 50% of any
non-royalty sublicensee income received (50% for sublicenses granted in the first two years of the ULRF license agreement, 40% for sublicenses
granted in the third or fourth years of the ULRF license agreement, and 30% for sublicenses granted in the fifth year of the ULRF license
agreement or thereafter), (iii) reimbursements for ongoing costs associated with the preparation, filing, prosecution and maintenance
of licensed patents, incurred prior to July 2020, and (iv) payments ranging from $</span></span><span id="xdx_904_ecustom--MilestonePayment_pp0p0_c20190301__20190331__srt--RangeAxis__srt--MinimumMember__us-gaap--TypeOfArrangementAxis__custom--LicenseAndSponsoredResearchAgreementsMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember_zi75rTkpdRO7" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">50,000
</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">to
$</span><span id="xdx_908_ecustom--MilestonePayment_pp0p0_c20190301__20190331__srt--RangeAxis__srt--MaximumMember__us-gaap--TypeOfArrangementAxis__custom--LicenseAndSponsoredResearchAgreementsMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember_zzisbQOnJ7W" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5,000,000
</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">upon
the achievement of certain regulatory and commercial milestones.</span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Milestone
payments for the first therapeutic indication would be $<span id="xdx_90B_ecustom--MilestonePayment_c20190301__20190331__us-gaap--TypeOfArrangementAxis__custom--LicenseAndSponsoredResearchAgreementsMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember__us-gaap--AwardTypeAxis__custom--PhaseOneClinicalTrialMember_zjG7RTmAlUl6">50,000
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">for first dosing in a Phase 1 clinical trial,
$<span id="xdx_90B_ecustom--MilestonePayment_c20190301__20190331__us-gaap--TypeOfArrangementAxis__custom--LicenseAndSponsoredResearchAgreementsMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember__us-gaap--AwardTypeAxis__custom--PhaseTwoClinicalTrialMember_z1Fq5VC7aWu3">100,000
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">for first dosing in a Phase 2 clinical trial,
$<span id="xdx_90D_ecustom--MilestonePayment_c20190301__20190331__us-gaap--TypeOfArrangementAxis__custom--LicenseAndSponsoredResearchAgreementsMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember__us-gaap--AwardTypeAxis__custom--PhaseThreeClinicalTrialMember_zFC5HQXQnMcg">150,000
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">for first dosing in a Phase 3 clinical trial,
$<span id="xdx_908_ecustom--RegulatoryMarketingApprovalExpenses_pp0p0_c20190301__20190331__us-gaap--TypeOfArrangementAxis__custom--SponsoredResearchAgreementAndLicenseMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember_zXrv7UsytLp9">300,000
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">for regulatory marketing approval and $<span id="xdx_90B_ecustom--CumulativeSales_pp0p0_c20190301__20190331__srt--ProductOrServiceAxis__custom--LicensedProductSalesMember__us-gaap--TypeOfArrangementAxis__custom--LicenseAndSponsoredResearchAgreementsMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember_zsH40GEqRIvh">5,000,000
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">upon achieving a cumulative $<span id="xdx_902_eus-gaap--RevenueFromContractWithCustomerIncludingAssessedTax_pp0p0_c20190301__20190331__us-gaap--TypeOfArrangementAxis__custom--SponsoredResearchAgreementAndLicenseMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember_z8mvC1jWDDeb">500,000,000
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">of Licensed Product sales. The Company also must
pay ULRF shortfall payments if the total amounts actually paid with respect to royalties and non-royalty sublicensee income for any year
is less than the applicable annual minimum (ranging from $<span id="xdx_905_ecustom--UpfrontLicenseFee_iI_pp0p0_c20190331__srt--RangeAxis__srt--MinimumMember__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember_z9Wb1eJfRII2" title="Upfront license fee">20,000
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">to $<span id="xdx_90D_ecustom--UpfrontLicenseFee_iI_pp0p0_c20190331__srt--RangeAxis__srt--MaximumMember__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember_zd4MF4c7bOL8" title="Upfront license fee">100,000</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)
for such year.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sponsored
research expenses related to these agreements for the years ended December 31, 2022 and December 31, 2021 were approximately $<span id="xdx_904_eus-gaap--ResearchAndDevelopmentExpense_pp0p0_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--LicenseAndSponsoredResearchAgreementsMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember_zXcTVKWgpgwc" title="Research and development">758,000</span>
and $<span id="xdx_907_eus-gaap--ResearchAndDevelopmentExpense_pp0p0_c20210101__20211231__us-gaap--TypeOfArrangementAxis__custom--LicenseAndSponsoredResearchAgreementsMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember_ziPv1zw7Wp1g" title="Research and development">646,000</span>, respectively, and are recorded in research and development expenses in the Consolidated Statements of Operations. License
costs related to these agreements for the years ended December 31, 2022 and December 31, 2021 were approximately $<span id="xdx_903_ecustom--LicenseCost_pp0p0_c20220101__20221231_zeBCXcxnnH5b" title="License costs">40,000</span> and $<span id="xdx_90D_ecustom--LicenseCost_pp0p0_c20210101__20211231_zTb5XJrhEAVb" title="License costs">60,000</span>,
respectively, and are included in research and development expenses in the Consolidated Statements of Operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Between
June 2018 and September 2020, the Company entered into license and sponsored research agreements with the University of Louisville
Research Foundation (&#8220;ULRF&#8221;) for QN-247, a novel aptamer-based compound that has shown promise as an anticancer drug.
Under the agreements, the Company took over development, regulatory approval and commercialization of the compound from ULRF and is
responsible for maintenance of the related intellectual property portfolio. In return, ULRF received a $<span id="xdx_90A_eus-gaap--ProceedsFromConvertibleDebt_pp0p0_c20180601__20200930__us-gaap--TypeOfArrangementAxis__custom--LicenseAndSponsoredResearchAgreementsMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember_zyVH2yPJzTV2" title="Proceeds from convertible debt">50,000</span>
convertible promissory note in payment of an upfront license fee, which was subsequently converted into the Company&#8217;s common
stock, and the Company agreed to reimburse ULRF for sponsored research expenses of up to $<span id="xdx_902_ecustom--ReimbursementOfResearchExpenses_pp0p0_c20180601__20200930__us-gaap--TypeOfArrangementAxis__custom--LicenseAndSponsoredResearchAgreementsMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember_z25ifum6bXJ7" title="Reimbursement of research expenses">830,000</span>
and prior patent costs of up to $<span id="xdx_90C_ecustom--PatentCosts_pp0p0_c20180601__20200930__us-gaap--TypeOfArrangementAxis__custom--LicenseAndSponsoredResearchAgreementsMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember_z8nQBpxyEjzj" title="Patent costs">200,000</span>.
The sponsored research agreement ended on August 31, 2022. <span id="xdx_90A_ecustom--AgreementTermPaymentDescription_c20180601__20200930__us-gaap--TypeOfArrangementAxis__custom--LicenseAndSponsoredResearchAgreementsMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember_zOxTiAHB57Di" title="Agreement term payment, description">In
addition, the Company agreed to pay ULRF (i) royalties, on patent-covered net sales associated with the commercialization of
anti-nucleolin agent-conjugated nanoparticles, of 4% (on net sales up to a cumulative $250,000,000) or 5% (on net sales above a
cumulative $250,000,000), until expiration of the last to expire of the licensed patents, (ii) 30% to 50% of any non-royalty
sublicensee income received (50% for sublicenses granted in the first two years of the ULRF license agreement, 40% for sublicenses
granted in the third or fourth years of the ULRF license agreement, and 30% for sublicenses granted in the fifth year of the ULRF
license agreement or thereafter), (iii) reimbursements for ongoing costs associated with the preparation, filing, prosecution and
maintenance of licensed patents, incurred prior to June 2018, and (iv) payments ranging from $<span id="xdx_900_ecustom--MilestonePayment_pp0p0_c20180601__20180630__srt--RangeAxis__srt--MinimumMember__us-gaap--TypeOfArrangementAxis__custom--LicenseAndSponsoredResearchAgreementsMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember_z6JELV5a6zL6" title="Milestone payment">100,000</span>
to $<span id="xdx_909_ecustom--MilestonePayment_pp0p0_c20180601__20180630__srt--RangeAxis__srt--MaximumMember__us-gaap--TypeOfArrangementAxis__custom--LicenseAndSponsoredResearchAgreementsMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember_zQeDmNDDTMa6" title="Milestone payment">5,000,000</span>
upon the achievement of certain regulatory and commercial milestones.</span> Milestone payments for the first therapeutic indication
would be $<span id="xdx_90C_ecustom--MilestonePayment_pp0p0_c20180601__20180630__us-gaap--AwardTypeAxis__custom--PhaseOneClinicalTrialMember__us-gaap--TypeOfArrangementAxis__custom--LicenseAndSponsoredResearchAgreementsMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember_zI2d4t7SZST" title="Milestone payment">100,000</span>
for first dosing in a Phase 1 clinical trial, $<span id="xdx_909_ecustom--MilestonePayment_pp0p0_c20180601__20180630__us-gaap--AwardTypeAxis__custom--PhaseTwoClinicalTrialMember__us-gaap--TypeOfArrangementAxis__custom--LicenseAndSponsoredResearchAgreementsMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember_zNL8atpu6O93" title="Milestone payment">200,000</span>
for first dosing in a Phase 2 clinical trial, $<span id="xdx_90E_ecustom--MilestonePayment_pp0p0_c20180601__20180630__us-gaap--AwardTypeAxis__custom--PhaseThreeClinicalTrialMember__us-gaap--TypeOfArrangementAxis__custom--LicenseAndSponsoredResearchAgreementsMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember_z29VWeREQaqa" title="Milestone payment">350,000</span>
for first dosing in a Phase 3 clinical trial, $<span id="xdx_909_ecustom--MilestonePayment_c20180601__20180630__us-gaap--AwardTypeAxis__custom--PhaseClinicalTrialMember__us-gaap--TypeOfArrangementAxis__custom--LicenseAndSponsoredResearchAgreementsMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember_zVcVfqTkcXXj" title="Milestone payment">500,000</span>
for regulatory marketing approval and $<span id="xdx_90A_ecustom--RegulatoryMarketingApprovalExpenses_pp0p0_c20180601__20180630__srt--ProductOrServiceAxis__custom--LicensedProductSalesMember__us-gaap--TypeOfArrangementAxis__custom--LicenseAndSponsoredResearchAgreementsMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember_zE3AIOiJE55k" title="Regulatory marketing approval, expenses">5,000,000</span>
upon achieving a cumulative $<span id="xdx_903_ecustom--CumulativeSales_pp0p0_c20180601__20180630__us-gaap--TypeOfArrangementAxis__custom--SponsoredResearchAgreementAndLicenseMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember_zZwARTQp1OPd" title="Cumulative sales">500,000,000</span>
of Licensed Product sales; the Company would also pay another $<span id="xdx_905_ecustom--RegulatoryMarketingApprovalExpensesOne_pp0p0_c20180601__20180630__srt--ProductOrServiceAxis__custom--LicensedProductSalesMember__us-gaap--TypeOfArrangementAxis__custom--LicenseAndSponsoredResearchAgreementsMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember_zecFxuofTmj7" title="Regulatory marketing approval, expenses">500,000</span>
milestone payment for any additional regulatory marketing approval for each additional therapeutic (or diagnostic) indication. The
Company also must pay ULRF shortfall payments if the total amounts actually paid with respect to royalties and non-royalty
sublicensee income for any year is less than the applicable annual minimum (ranging from $<span id="xdx_901_ecustom--ShortfallPayments_pp0p0_c20180601__20200930__srt--RangeAxis__srt--MinimumMember__us-gaap--TypeOfArrangementAxis__custom--LicenseAndSponsoredResearchAgreementsMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember_zWGKg4JlYkvi" title="Shortfall payments">10,000</span>
to $<span id="xdx_907_ecustom--ShortfallPayments_c20180601__20200930__srt--RangeAxis__srt--MaximumMember__us-gaap--TypeOfArrangementAxis__custom--LicenseAndSponsoredResearchAgreementsMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember_zmPotP7EeEt1" title="Shortfall payments">50,000</span>)
for such year.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sponsored
research expenses related to these agreements for the years ended December 31, 2022 and December 31, 2021 were approximately $<span id="xdx_907_eus-gaap--ResearchAndDevelopmentExpense_pp0p0_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--SponsoredResearchAgreementAndLicenseMember_zDcCfjwJb3Fh" title="Research and development">164,000</span>
and $<span id="xdx_901_eus-gaap--ResearchAndDevelopmentExpense_pp0p0_c20210101__20211231__us-gaap--TypeOfArrangementAxis__custom--SponsoredResearchAgreementAndLicenseMember_zHhXERwipNul" title="Research and development">325,000</span>, respectively, and these amounts are recorded in research and development expenses in the Consolidated Statements of Operations.
Minimum annual royalties of $<span id="xdx_90F_eus-gaap--RoyaltyExpense_pp0p0_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--SponsoredResearchAgreementAndLicenseMember_zZJb9QDsbLfa" title="Minimum annual royalties">0</span> and $<span id="xdx_901_eus-gaap--RoyaltyExpense_c20210101__20211231__us-gaap--TypeOfArrangementAxis__custom--SponsoredResearchAgreementAndLicenseMember_z9GOmSy2etHg" title="Minimum annual royalties">0</span> related to these agreements are included in research and development expenses in the Consolidated
Statements of Operations for the years ended December 31, 2022 and December 31, 2021, respectively. License costs related to these agreements
were approximately $<span id="xdx_90F_ecustom--LicenseCost_pp0p0_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--SponsoredResearchAgreementAndLicenseMember_zhNOCabKEKW6" title="License costs">94,000</span> and $<span id="xdx_908_ecustom--LicenseCost_pp0p0_c20210101__20211231__us-gaap--TypeOfArrangementAxis__custom--SponsoredResearchAgreementAndLicenseMember_zjJi6dMlb7va" title="License costs">118,000</span> for the years ended December 31, 2022 and December 31, 2021, respectively, and are included in
research and development expenses in the Consolidated Statements of Operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>






<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
June 2020, the Company entered into an exclusive license agreement with ULRF for its intellectual property in the use of QN-165 as a
treatment for COVID-19. Under the agreement, the Company took over development, regulatory approval and commercialization of the
compound (for such use) from ULRF and was responsible for maintenance of the related intellectual property portfolio. In return,
ULRF received approximately $<span id="xdx_907_ecustom--UpfrontLicenseFee_iI_pp0p0_c20200630__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember_z8HdOcgnzqd4" title="Upfront license fee">24,000 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">for
an upfront license fee and reimbursement of prior patent costs. In addition, the Company executed a sponsored research agreement
with ULRF (for QN-165 as a treatment for COVID-19) supporting up to $<span id="xdx_90E_eus-gaap--ResearchAndDevelopmentExpense_pp0p0_c20201101__20201130__srt--RangeAxis__srt--MaximumMember__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember_zLZYohcJBbf6">430,000</span>. </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This sponsored research agreement expired in November 2021 and effective October 31, 2022 the license agreement for
QN-165 was terminated.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sponsored
research expenses related to these agreements for the years ended December 31, 2022 and December 31, 2021 were approximately $<span id="xdx_90D_eus-gaap--ResearchAndDevelopmentExpense_pp0p0_c20220101__20221231__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember_zDkvbJNgCrMk" title="Research and Development Expense">14,000</span> and $<span id="xdx_906_eus-gaap--ResearchAndDevelopmentExpense_pp0p0_c20210101__20211231__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember_z8y24e1EHbXj" title="Research and Development Expense">243,000</span>,
respectively, and are recorded in research and development expenses in the Consolidated Statements of Operations. License costs related
to these agreements for the years ended December 31, 2022 and December 31, 2021 were approximately $<span id="xdx_904_ecustom--LicenseCost_pp0p0_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--LicenseAndSponsoredResearchAgreementsMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember_zomdtHB2ueha" title="License cost">2,000</span> and $<span id="xdx_90B_ecustom--LicenseCost_pp0p0_c20210101__20211231__us-gaap--TypeOfArrangementAxis__custom--LicenseAndSponsoredResearchAgreementsMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember_ze91Ty8znN8l" title="License cost">28,000</span>, respectively,
and are included in research and development expenses in the Consolidated Statements of Operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Advanced
Cancer Therapeutics</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
December 2018, <span id="xdx_90E_ecustom--AgreementDescription_c20181201__20181231__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember__dei--LegalEntityAxis__custom--AdvancedCancerTherapeuticsLLCMember_zW2Af8FERock" title="Agreement description">the Company entered into a license agreement with Advanced Cancer Therapeutics, LLC (&#8220;ACT&#8221;), granting the
Company exclusive rights to develop and commercialize QN-165, an aptamer-based drug candidate</span>. In return, ACT received a $<span id="xdx_902_eus-gaap--ProceedsFromConvertibleDebt_pp0p0_c20181201__20181231__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember__dei--LegalEntityAxis__custom--AdvancedCancerTherapeuticsLLCMember_z8Q75pH4KISg" title="Proceeds from convertible debt">25,000</span> convertible
promissory note in payment of an upfront license fee, which was subsequently converted into the Company&#8217;s common stock. In addition,
the Company agreed to pay ACT (i) royalties, on net sales associated with the commercialization of QN-165, of 2% (only if patent-covered
and only on net sales above a cumulative $<span id="xdx_90F_ecustom--CumulativeSales_pp0p0_c20181201__20181231__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember__dei--LegalEntityAxis__custom--AdvancedCancerTherapeuticsLLCMember_zqXDrko20eDc" title="Cumulative sales">3,000,000</span>) or 1% (if not patent-covered, but only on net sales above a cumulative $<span id="xdx_90A_ecustom--CumulativeSales_pp0p0_c20181201__20181231__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember__dei--LegalEntityAxis__custom--AdvancedCancerTherapeuticsLLCMember_zUD4zsAXDgRd" title="Cumulative sales">3,000,000</span>),
until the 15th anniversary of the ACT license agreement and (ii) milestone payments of $<span id="xdx_90C_ecustom--MilestonePaymentForCumulativeMarketingExpenses_pp0p0_c20181201__20181231__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember__dei--LegalEntityAxis__custom--AdvancedCancerTherapeuticsLLCMember_zZeQymAmRl8" title="Milestone payment for cumulative marketing expenses">100,000</span> for the Company raising a cumulative
total of $<span id="xdx_901_eus-gaap--RevenueFromContractWithCustomerIncludingAssessedTax_pp0p0_c20181201__20181231__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember__dei--LegalEntityAxis__custom--AdvancedCancerTherapeuticsLLCMember_zqd072Tcu4rk" title="Cumulative amount">2,000,000</span> in new equity financing after the date of the ACT license agreement, $<span id="xdx_90A_ecustom--MilestoneMethodRevenueRecognized_pp0p0_c20181201__20181231__srt--TitleOfIndividualAxis__custom--CEMarkMember__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember__dei--LegalEntityAxis__custom--AdvancedCancerTherapeuticsLLCMember_zD10HCcn3qKd" title="Milestone method revenue recognized">100,000</span> upon any first QN-165-based licensed
product receiving the CE Mark or similar FDA status, and $<span id="xdx_90B_ecustom--CumulativeSales_pp0p0_c20181201__20181231__srt--TitleOfIndividualAxis__custom--CEMarkMember__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember__dei--LegalEntityAxis__custom--AdvancedCancerTherapeuticsLLCMember_zKE7WypjOpJ3" title="Cumulative sales">500,000</span> upon cumulative worldwide QN-165-based licensed product net sales reaching
$<span id="xdx_90B_eus-gaap--RevenueFromContractWithCustomerIncludingAssessedTax_pp0p0_c20181201__20181231__srt--TitleOfIndividualAxis__custom--CEMarkMember__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember__dei--LegalEntityAxis__custom--AdvancedCancerTherapeuticsLLCMember_zzAk2tbZUUAc" title="Licensed product net sale">3,000,000</span>. For the years ended December 31, 2022 and December 31, 2021, there were approximately $<span id="xdx_902_ecustom--LicenseCost_pp0p0_do_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember__dei--LegalEntityAxis__custom--AdvancedCancerTherapeuticsLLCMember_zLBc8V231CYd" title="License cost">0</span> and $<span id="xdx_90C_ecustom--LicenseCost_pp0p0_do_c20210101__20211231__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember__dei--LegalEntityAxis__custom--AdvancedCancerTherapeuticsLLCMember_z6ZbkeVYPWpc" title="License cost">2,000</span>, respectively in costs
related to this agreement which are included in research and development expenses in the Consolidated Statements of Operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Yi
Xin</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In October 2020, through our wholly-owned diagnostics subsidiary Qualigen, Inc. we entered into a Technology Transfer
Agreement with Yi Xin Zhen Duan Jishu (Suzhou) Ltd. (&#8220;Yi Xin&#8221;), of Suzhou, China, for Yi Xin to develop, manufacture and sell
new generations of diagnostic test systems based on the Company&#8217;s core FastPack technology. In addition, the Technology Transfer Agreement
authorized Yi Xin to manufacture and sell the Company&#8217;s current generations of FastPack System diagnostic products (1.0, IP and PRO) in
China.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company will receive low- to mid-single-digit royalties on any future new-generations and current-generations
product sales by Yi Xin. We received total net cash payments of approximately $<span id="xdx_908_eus-gaap--DeferredRevenue_iI_pp0p0_c20211231__dei--LegalEntityAxis__custom--YiXinZhenDuanJishuLtdMember_zCeceoVHCbg6" title="Deferred revenue">670,000</span>, of which approximately $<span id="xdx_906_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20210101__20211231__srt--ProductOrServiceAxis__custom--LicenseRevenueMember__dei--LegalEntityAxis__custom--YiXinZhenDuanJishuLtdMember_zCb5e3Vm5vL5" title="Product sales">632,000</span>
is classified as license revenue, and approximately $<span id="xdx_90C_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20210101__20211231__dei--LegalEntityAxis__custom--YiXinZhenDuanJishuLtdMember_zq6MARk7I1S3" title="Product sales">38,000</span> is classified as product sales on the Consolidated Statements of Operations for the fiscal year ended December&#160;31,
2021. The Company provided technology transfer and patent/know-how license rights to facilitate Yi Xin&#8217;s development and commercialization.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"/>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company gave Yi Xin the exclusive rights for China &#8211; which is
a market we have not otherwise entered &#8211; both for Yi Xin&#8217;s new generations of FastPack-based products and for Yi Xin-manufactured
versions of our existing FastPack product lines. Yi Xin also has the right to sell its new generations of FastPack-based diagnostic test
systems throughout the world (but not to or toward current customers of our existing generations of FastPack products). After March 31,
2022, Yi Xin has the right to sell Yi Xin-manufactured versions of existing FastPack 1.0, IP and PRO product lines worldwide (other than
in the United States and other than to or toward current non-US customers of those products), as well as the right to buy Qualigen-manufactured
FastPack 1.0, IP and PRO products from us at distributor prices for resale in and for the United States (but not to or toward current
U.S. customers of those products). The Company did not license Yi Xin to sell in the U.S. market any Yi Xin-manufactured versions of those
legacy FastPack 1.0, IP and PRO product lines. In the Technology Transfer Agreement the Company also confirmed that after March 31, 2022
it would not seek new FastPack customers outside the U.S.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>STA
Pharmaceutical</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
November 2020, the Company entered into a contract with STA Pharmaceutical Co., Ltd., a subsidiary of WuXi AppTec, for GMP production
of QN-165, which was the Company&#8217;s lead drug candidate for the treatment of COVID-19 and other viral diseases. In connection with
this agreement, the Company paid an upfront deposit of approximately $<span id="xdx_907_eus-gaap--DepositAssets_iI_pn5n6_c20201231__dei--LegalEntityAxis__custom--STAPharmaceuticalCoLtdMember_zSeIjxwRVih6" title="Upfront deposit">1.1</span> million which was classified as a prepaid expense on the December
31, 2020 Consolidated Balance Sheet date, and all of which was included in research and development expenses in the statement of operations
for the year ended December 31, 2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and development expenses related to this agreement for the years ended December 31, 2022 and December 31, 2021 were approximately $<span id="xdx_90F_eus-gaap--ResearchAndDevelopmentExpense_c20220101__20221231__dei--LegalEntityAxis__custom--STAPharmaceuticalCoLtdMember_ziJaZGX2iDce" title="Research and development">9,000</span>
and $<span id="xdx_902_eus-gaap--ResearchAndDevelopmentExpense_pn5n6_c20210101__20211231__dei--LegalEntityAxis__custom--STAPharmaceuticalCoLtdMember_zUJAjf06Gs4g" title="Research and development">3.2</span> million, respectively, and are recorded in research and development expenses in the Consolidated Statements of Operations.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>UCL Business Limited</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In January 2022, the Company entered into a License
Agreement with UCL Business Limited to obtain an exclusive worldwide in-license of a genomic quadruplex (G4)-selective transcription inhibitor
drug development program which had been developed at University College London, including lead and back-up compounds, preclinical data
and a patent estate. (UCL Business Limited is the commercialization company for University College London.) The program&#8217;s lead compound
is now being developed at Qualigen under the name QN-302 as a candidate for treatment for pancreatic ductal adenocarcinoma (PDAC), which
represents the vast majority of pancreatic cancers. The License Agreement required a $<span id="xdx_907_ecustom--ReimbursementOfPatent_c20220101__20220131__us-gaap--AwardTypeAxis__custom--UpfrontPaymentMember__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember_ztgkoq21V9V6" title="Reimbursement of patent">150,000</span> upfront payment, reimbursement of past patent
prosecution expenses (approximately $<span id="xdx_907_ecustom--ReimbursementOfPatent_c20220101__20220131__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember_zNYvUJX1HZGf" title="Reimbursement of patent">160,000</span>), and (if and when applicable) tiered royalty payments in the low to mid-single digits, clinical/regulatory/sales
milestone payments and a percentage of any non-royalty sublicensing consideration paid to Qualigen.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="margin: 0">For the years ended December 31, 2022 and 2021 there were license costs of approximately $<span id="xdx_905_ecustom--LicenseCost_pp0p0_do_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember_zBjRqmr4W2Id" title="License cost">338,000</span> and $<span id="xdx_900_ecustom--LicenseCost_pp0p0_do_c20210101__20211231__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember_z0WdYlIwavA7" title="License cost">0</span>, respectively,
related to this agreement which are included in research and development expenses in the Consolidated Statements of Operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_DisclosureResearchAndLicenseAgreementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_DisclosureResearchAndLicenseAgreementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_ResearchAndLicenseAgreementsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Research And License Agreements [Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_ResearchAndLicenseAgreementsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140569888958096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS&#8217; EQUITY<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">STOCKHOLDERS&#8217; EQUITY</a></td>
<td class="text"><p id="xdx_809_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zjzuQwYLCyBa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
15 &#8212; <span id="xdx_82A_zV1ZI9B4TKI5">STOCKHOLDERS&#8217; EQUITY</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2022, and 2021 the Company had two classes of capital stock: common stock and preferred stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Common
Stock</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Holders
of common stock generally vote as a class with the holders of the preferred stock and are entitled to one vote for each share held. Subject
to the rights of the holders of the preferred stock to receive preferential dividends, the holders of common stock are entitled to receive
dividends when and if declared by the Board of Directors. Following payment of the liquidation preference of the preferred stock, any
remaining assets will be distributed ratably among the holders of the common stock and, on an as-if-converted basis, the holders of any
preferred stock upon liquidation, dissolution or winding up of the affairs of the Company. The holders of common stock have no preemptive,
subscription or conversion rights and there are no redemption or sinking fund provisions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 1, 2021, the Company closed a Securities Purchase Agreement (dated November 29, 2021) with several institutional investors
for the purchase and sale of <span id="xdx_905_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20211201__20211201__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_zXvFBZ25PmQh" title="Shares issued, shares">588,000</span>
reverse split adjusted shares of Company common stock at a reverse split adjusted exercise price of $<span id="xdx_90D_eus-gaap--SharePrice_iI_pid_c20211201__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zB5FISyNOSJh" title="Share Price">15.00</span>
per share, for aggregate gross proceeds of $<span id="xdx_90A_eus-gaap--ProceedsFromIssuanceOfCommonStock_pn4n6_c20211201__20211201__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zYELsj42bDth" title="Proceeds from issuance of common stock">8.82</span>
million.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 22, 2022, the Company issued to Alpha Capital, an <span id="xdx_900_eus-gaap--ShortTermDebtInterestRateIncrease_pid_dp_uPure_c20221222__20221222__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember__us-gaap--DebtInstrumentAxis__custom--SeniorConvertibleDebentureMember_zCLUosOzRfQg" title="Senior convertible debenture rate">8</span>%
Senior Convertible Debenture in the aggregate principal amount of $<span id="xdx_902_eus-gaap--SecuredDebt_iI_c20221222__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember__us-gaap--DebtInstrumentAxis__custom--SeniorConvertibleDebentureMember_zgyBCJ3DxKt" title="Principal amount">3,300,000</span>
for a purchase price of $<span id="xdx_90C_ecustom--PurchasePrice_iI_c20221222__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember__us-gaap--DebtInstrumentAxis__custom--SeniorConvertibleDebentureMember_z0YPpYvHvrr3" title="Purchase Price">3,000,000</span>
pursuant to the terms of a Securities Purchase Agreement, dated December 21, 2022. The Debenture is convertible, at any time, and
from time to time, at Alpha&#8217;s option, into shares of common stock of the Company, at a price equal to $<span id="xdx_904_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pid_c20221222__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember__us-gaap--DebtInstrumentAxis__custom--SeniorConvertibleDebentureMember_z4dEgdCRWaza" title="Conversion price">1.32</span>
per share, and other terms and conditions described in the Debenture (see Note 11 -Convertible Debt - Related Party). As part of
this transaction, the Company issued to Alpha Capital a warrant to purchase <span id="xdx_907_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20221222__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember_zze5nSNHwkmb" title="Warrant to purchase shares">2,500,000</span>
shares of the Company&#8217;s common stock (see Note 10-Warrant Liabilities).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
December 31, 2022, the Company has reserved <span id="xdx_904_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_c20221231_zb8yzrO0mbvc" title="Common stock, shares reserved for future issuance">5,183,629</span> shares of authorized but unissued common stock for possible future issuance. At
December 31, 2022, <span id="xdx_909_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_c20221231_zUzMHDYiHo81" title="Common stock, shares reserved for future issuance">5,183,629</span> shares were reserved as follows:</span></p>

<p id="xdx_89B_ecustom--ScheduleOfReservedSharesTableTextBlock_zimAAIToJ9Ea" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B7_zax3uzRUfCia" style="display: none">SCHEDULE
OF RESERVED SHARES</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
  <tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_49C_20221231_zNuw65UoxOj9" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_hus-gaap--AwardTypeAxis__us-gaap--StockOptionMember_z3ZC73O4yVG8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 78%; text-align: left">Exercise of issued and future grants of stock options</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 18%; text-align: right">608,012</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_hus-gaap--AwardTypeAxis__us-gaap--WarrantMember_zkBEyoRIIQza" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">Exercise of stock warrants</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">4,575,617</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_zDujkcYLn797" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt; padding-left: 10pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">5,183,629</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8AF_z9Le9WWtUHcb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"/>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Preferred
Stock</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
December 31, 2022 and 2021, there were no shares of preferred stock outstanding. All shares of Series A, B, C, D, D-1 convertible preferred
stock were converted into common stock at the time of the May 2020 reverse recapitalization transaction.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year ended December 31, 2021, the holder of Series Alpha convertible preferred stock converted <span id="xdx_903_eus-gaap--ConvertiblePreferredStockSharesIssuedUponConversion_iI_pid_c20211231__us-gaap--StatementClassOfStockAxis__custom--SeriesAlphaConvertiblePreferredStockMember_z4p1JV3satYc" title="Convertible preferred stock, shares">180</span> of its shares of Series Alpha
convertible preferred stock into an aggregate of <span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodSharesOther_pid_c20210101__20211231__us-gaap--StatementClassOfStockAxis__custom--SeriesAlphaConvertiblePreferredStockMember_zKqE7rP9O0mj" title="Shares issued during conversion, shares">243,416</span> shares of the Company&#8217;s common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Stock
Options and Equity Classified Warrants</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Stock
Options</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company recognizes all compensatory stock-based payments as compensation expense over the service period, which is generally the vesting
period.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
April 2020, the Company adopted the 2020 Stock Incentive Plan (the &#8220;2020 Plan&#8221;) which provides for the grant of incentive
or non-statutory common stock options, restricted stock, stock bonus awards, stock appreciation rights, restricted stock units and performance
awards to qualified employees, officers, directors, consultants and other service providers. At December 31, 2022 and December 31, 2021
there were <span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20221231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--PlanNameAxis__custom--TwoThousandTwentyStockIncentivePlanMember_zHfLhUpRqNWk" title="Options outstanding">608,012</span> and <span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20211231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--PlanNameAxis__custom--TwoThousandTwentyStockIncentivePlanMember_z8NOvTtLyl0h" title="Options outstanding">484,186</span> outstanding stock options, respectively, under the 2020 Plan and there were <span id="xdx_908_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_pid_c20221231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--PlanNameAxis__custom--TwoThousandTwentyStockIncentivePlanMember_zYMFBxZIt9ok" title="Plan shares available">147,690</span> and <span id="xdx_901_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_pid_c20211231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--PlanNameAxis__custom--TwoThousandTwentyStockIncentivePlanMember_zJoKk2UrZhn1" title="Plan shares available">280,916</span> of Plan
shares available, respectively, for future grant.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_892_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_z2FB81mZIsEk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following represents a summary of the options granted to employees and non-employee service providers that were outstanding at December
31, 2022, and changes during the twelve months then ended:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B8_zD3cw60EzoEa" style="display: none">SCHEDULE
OF STOCK OPTION ACTIVITY</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Shares</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted&#8211;<br/> Average<br/> Exercise<br/>
    Price</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Range of<br/> Exercise<br/> Price</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted&#8211;<br/> Average<br/> Remaining<br/>
    Life (Years)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 32%">Total outstanding &#8211; December 31, 2021</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20220101__20221231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zqnBPyfdF0z1" style="width: 12%; text-align: right" title="Number of shares, options outstanding, beginning">484,186</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20220101__20221231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zSo8odCfMjb9" style="width: 12%; text-align: right" title="Weighted Average Exercise Price, Outstanding, Beginning">60.70</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$<span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20220101__20221231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember__srt--RangeAxis__srt--MinimumMember_zNVJxn68qcaf" title="Range of Exercise price, Options Outstanding">12.40</span>
                                            &#8212; $<span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20220101__20221231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember__srt--RangeAxis__srt--MaximumMember_zwIjOyKur9uj" title="Range of Exercise price, Options Outstanding">14,657.50</span></span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right"><span id="xdx_90E_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm3_dtY_c20220101__20221231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zj7EqTYG69L9" title="Weighted- Average Remaining Contractual Life (in Years), Outstanding, Beginning">8.52</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt">Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20220101__20221231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_z1RPE2CQS8d2" style="text-align: right" title="Number of shares, options granted">134,469</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20220101__20221231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zkvwQJ0CQG36" style="text-align: right" title="Weighted average exercise price, options granted">5.24</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_908_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionGrantedWeightedAverageExercisePrice_c20220101__20221231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember__srt--RangeAxis__srt--MinimumMember_zmSEZ3YUzaA2" title="Range of Exercise price, Options Outstanding">5.14</span>
                                            &#8212; <span id="xdx_907_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionGrantedWeightedAverageExercisePrice_c20220101__20221231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember__srt--RangeAxis__srt--MaximumMember_zdkGibkxK343" title="Range of Exercise price, Options Outstanding">10.50</span></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_904_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm2_dtY_c20220101__20221231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_ztVfDUW1dy94" title="Weighted- Average Remaining Contractual Life (in Years), Options Granted">5.99</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt">Expired</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_iN_di_c20220101__20221231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zKuj5b6rQuu" style="text-align: right" title="Number of shares, options expired">(9,379</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_c20220101__20221231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_z30ZbFDj4F7i" style="text-align: right" title="Weighted average exercise price, options expired">932.75</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_906_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExpirationsInPeriodWeightedAverageExercisePrice_c20220101__20221231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember__srt--RangeAxis__srt--MinimumMember_zQRRIzsHx5N4" title="Range of Exercise price, Options Expired">57.50</span>
                                            - <span id="xdx_908_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExpirationsInPeriodWeightedAverageExercisePrice_pid_c20220101__20221231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember__srt--RangeAxis__srt--MaximumMember_zDNvdUlW7dcc" title="Range of exercise price, options expired">14,657.50</span></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; padding-left: 10pt">Forfeited</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_di_c20220101__20221231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zRDjr5XQ9nlb" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of shares, options forfeited">(1,264</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20220101__20221231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zTrLEmJH9Gnf" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted average exercise price, options forfeited">22.64</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_c20220101__20221231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember__srt--RangeAxis__srt--MinimumMember_zhh9NAU4Ppec" title="Range of Exercise price, Options Forfeited">5.14</span>
                                            - <span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_c20220101__20221231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember__srt--RangeAxis__srt--MaximumMember_zuki1SvKVugj" title="Range of Exercise price, Options Forfeited">49.70</span></span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Total outstanding &#8211; December 31, 2022</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20220101__20221231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zHQHex6Q7moe" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Shares, Options Outstanding at Ending">608,012</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20220101__20221231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zkOS9mXytQXa" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price, Outstanding at Ending">35.02</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$<span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20220101__20221231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember__srt--RangeAxis__srt--MinimumMember_zDgugfq7l8k9" title="Range of Exercise price, Options Outstanding">5.14</span>
                                            &#8212; $<span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20220101__20221231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember__srt--RangeAxis__srt--MaximumMember_znYSLY54sQRk" title="Range of Exercise price, Options Outstanding">51.30</span></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20220101__20221231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_z48fHiVCqQ4b" title="Weighted- Average Remaining Contractual Life (in Years), Outstanding at Ending">8.09</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Exercisable (vested)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_iI_c20221231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_z7oIvggtyFlh" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of shares, options exercisable (vested)">288,704</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_c20221231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zAkadtWfXRtk" style="border-bottom: Black 2.5pt double; text-align: right" title="Range of exercise price, options exercisable (vested)">46.32</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$<span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_c20221231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember__srt--RangeAxis__srt--MinimumMember_zFQiWU7oOUwe" title="Range of exercise price, options exercisable (vested)">12.40</span>
                                            &#8212; $<span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_c20221231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember__srt--RangeAxis__srt--MaximumMember_zk4vMa0xUGHe" title="Range of exercise price, options exercisable (vested)">51.30</span></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_906_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_dtY_c20220101__20221231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zbxpgyXpO7sc" title="Weighted- Average Remaining Contractual Life (in Years), Options Exercisable (vested)">7.59</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Non-Exercisable (non-vested)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iI_c20221231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zvZPeCoYNwCe" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of shares, options non-exercisable (non-vested)">319,308</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToNonVestExercisableWeightedAverageExercisePrice_iI_c20221231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zFFoxY8BCaj9" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price, options non-exercisable (non-vested)">24.80</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">$<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_iI_c20221231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember__srt--RangeAxis__srt--MinimumMember_zqbVRgVjO6ad" title="Range of exercise price, options non-exercisable (non-vested)">5.14</span>
                                            &#8212; $<span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_iI_c20221231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember__srt--RangeAxis__srt--MaximumMember_zDcdUCBXQ7x2" title="Range of exercise price, options non-exercisable (non-vested)">10.50</span></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_908_ecustom--WeightedAverageRemainingContractualLifeInYearsOptionsNonexercisableNonvested_dtY_c20220101__20221231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_z5KM8vgvprkf" title="Weighted- Average Remaining Contractual Life (in Years), Options Non-exercisable (non-vested)">8.59</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8AA_zseIMDhlGu28" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following represents a summary of the options granted (under the 2020 Plan and otherwise) to employees and non-employee service providers
that were outstanding at December 31, 2021, and changes during the twelve months then ended:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"/>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"/>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Shares</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Weighted&#8211;<br/>
    Average<br/> Exercise<br/> Price</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font: bold 10pt Times New Roman, Times, Serif">Range
    of<br/> Exercise<br/> Price</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Weighted&#8211;<br/>
    Average<br/> Remaining<br/> Life (Years)</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 32%">Total outstanding &#8211; December 31, 2020</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20210101__20211231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zlnTNVLyRFpg" style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right" title="Number of shares, options outstanding, beginning">401,136</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20210101__20211231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zHaziYuPldph" style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right" title="Weighted Average Exercise Price, Outstanding, Beginning">70.50</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$<span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20210101__20211231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember__srt--RangeAxis__srt--MinimumMember_zKwvVnwVjRL1" title="Range of Exercise price, Options Outstanding">35.20</span>
                                            &#8212; $<span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20210101__20211231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember__srt--RangeAxis__srt--MaximumMember_zhxpaEnRRPRg" title="Range of Exercise price, Options Outstanding">14,657.50</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"><span id="xdx_903_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm3_dtY_c20210101__20211231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zZFjNkCETqXl" title="Weighted- Average Remaining Contractual Life (in Years), Outstanding, Beginning">9.29</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt">Granted</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20210101__20211231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_z2MqQeJ1z484" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of shares, options granted">83,500</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20210101__20211231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zxyPRlmnsw6g" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price, options granted">13.70</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_905_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionGrantedWeightedAverageExercisePrice_c20210101__20211231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember__srt--RangeAxis__srt--MinimumMember_zOLEWJPrpGV5" title="Range of Exercise price, Options Outstanding">12.40</span>
                                            &#8212; <span id="xdx_907_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionGrantedWeightedAverageExercisePrice_c20210101__20211231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember__srt--RangeAxis__srt--MaximumMember_zIgleUIHQg02" title="Range of Exercise price, Options Outstanding">32.90</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_909_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm2_dtY_c20210101__20211231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zBlmxS6bsdGb" title="Weighted- Average Remaining Contractual Life (in Years), Options Granted">9.79</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt">Expired</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_iN_di_c20210101__20211231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zI7xBpgmoeFi" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of shares, options expired"><span style="-sec-ix-hidden: xdx2ixbrl1744">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_c20210101__20211231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zYXSPv8ok47k" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price, options expired"><span style="-sec-ix-hidden: xdx2ixbrl1746">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_905_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExpirationsInPeriodWeightedAverageExercisePrice_pid_c20210101__20211231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zXSx1gzCejZ4" title="Range of Exercise price, Options Expired"><span style="-sec-ix-hidden: xdx2ixbrl1748">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#8212;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; padding-left: 10pt">Forfeited</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_di_c20210101__20211231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zwHpz37AiXV4" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of shares, options forfeited">(450</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20210101__20211231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zoua4IVotl38" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price, options forfeited">36.80</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_c20210101__20211231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember__srt--RangeAxis__srt--MinimumMember_z7pjlwC3o4sh" title="Range of Exercise price, Options Forfeited">35.20</span>
                                            &#8212; <span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_c20210101__20211231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember__srt--RangeAxis__srt--MaximumMember_zffNW6BQTM0k" title="Range of Exercise price, Options Forfeited">49.70</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">&#8212;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">Total outstanding &#8211; December 31, 2021</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20210101__20211231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zIFAVcwX0f04" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Shares, Options Outstanding at Ending">484,186</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20210101__20211231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zBJouRvbgPqb" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price, Outstanding at Ending">60.70</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$<span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20210101__20211231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember__srt--RangeAxis__srt--MinimumMember_z8hAg45JY5Kb" title="Range of Exercise price, Options Outstanding">12.40</span>
                                            &#8212; $<span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20210101__20211231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember__srt--RangeAxis__srt--MaximumMember_zkyaelHb6GU8" title="Range of Exercise price, Options Outstanding">14,657.50</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20210101__20211231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zeZsbAxIcF7d" title="Weighted- Average Remaining Contractual Life (in Years), Outstanding at Ending">8.52</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Exercisable (vested)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_iI_c20211231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zsdgVzadx08k" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of shares, options exercisable (vested)">140,820</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_c20211231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zuUPP8744Yk7" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Range of exercise price, options exercisable (vested)">108.80</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">$<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_c20211231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember__srt--RangeAxis__srt--MinimumMember_zClFjuotgPLc" title="Range of exercise price, options exercisable (vested)">35.20</span>
                                            &#8212; $<span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_c20211231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember__srt--RangeAxis__srt--MaximumMember_zNlHtSLqUBrk" title="Range of exercise price, options exercisable (vested)">14,657.50</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_dtY_c20210101__20211231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zr0KmYVSOCN9" title="Weighted- Average Remaining Contractual Life (in Years), Options Exercisable (vested)">7.94</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Non-Exercisable (non-vested)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iI_c20211231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zmWVhhGC6U12" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of shares, options non-exercisable (non-vested)">343,366</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToNonVestExercisableWeightedAverageExercisePrice_iI_c20211231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zBywnFXAAj8f" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price, options non-exercisable (non-vested)">41.00</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">$<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_iI_c20211231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember__srt--RangeAxis__srt--MinimumMember_zk9HGnKXZZsd" title="Range of exercise price, options non-exercisable (non-vested)">12.40</span>
                                            &#8212; $<span id="xdx_906_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_iI_c20211231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember__srt--RangeAxis__srt--MaximumMember_zFQLWXItfD7c" title="Range of exercise price, options non-exercisable (non-vested)">51.30</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_908_ecustom--WeightedAverageRemainingContractualLifeInYearsOptionsNonexercisableNonvested_dtY_c20210101__20211231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zkdl0OaBs8Hl" title="Weighted- Average Remaining Contractual Life (in Years), Options Non-exercisable (non-vested)">8.81</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"/>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
was approximately $<span id="xdx_90D_eus-gaap--ShareBasedCompensation_pn5n6_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zuWnPueaqHp5" title="Compensation cost">5.4</span> million and $<span id="xdx_90C_eus-gaap--ShareBasedCompensation_pn5n6_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zykv4IKU9abf" title="Compensation cost">5.3</span> million of compensation costs related to outstanding options for the year ended December 31,
2022 and December 31, 2021, respectively. As of December 31, 2022, there was approximately $<span id="xdx_901_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_iI_pn5n6_c20221231_zlXSZYNG6LK8" title="Unrecognized compensation cost">3.3</span> million of total unrecognized compensation
cost related to unvested stock-based compensation arrangements. This cost is expected to be recognized over a weighted average period
of <span id="xdx_906_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20220101__20221231_zmlZSvswkSAa" title="Cost is expected to be recognized over a weighted average period">0.93</span> years.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_906_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_do_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zoAYorNYuci3" title="Stock options exercised"><span id="xdx_904_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_do_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zQBCDmXkTzf1" title="Stock options exercised">No</span></span>
stock options were exercised during the year ended December 31, 2022 or 2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--PlanNameAxis__custom--TwoThousandTwentyStockIncentivePlanMember_zVADe2p1sLcl" title="Stock options description">The
exercise price for an option issued under the 2020 Plan is determined by the Board of Directors, but will be (i) in the case of an incentive
stock option (A) granted to an employee who, at the time of grant of such option, is a 10% stockholder, no less than 110% of the fair
market value per share on the date of grant; or (B) granted to any other employee, no less than 100% of the fair market value per share
on the date of grant; and (ii) in the case of a non-statutory stock option, no less than 100% of the fair market value per share on the
date of grant.</span> The options awarded under the 2020 Plan will vest as determined by the Board of Directors but will not exceed a 10-year
period. The weighted average grant date fair value per share of the shares underlying options granted during the year ended December
31, 2022 was $<span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zY5vuAG3Uoe7" title="Stock option granted exercise price">3.96</span> and during the year ended December 31, 2021 was $<span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zAGRhIfrlSy4" title="Stock option granted exercise price">11.00</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"/>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Fair
Value of Equity Awards</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company utilizes the Black-Scholes option pricing model to value awards under the 2020 Plan, and for equity classified compensatory warrants.
Key valuation assumptions include:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Expected
    dividend yield.</i> The expected dividend is assumed to be zero, as the Company has never paid dividends and has no current plans
    to pay any dividends on the Company&#8217;s common stock.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Expected
    stock-price volatility.</i> The Company&#8217;s expected volatility is derived from the average historical volatilities of publicly
    traded companies within the Company&#8217;s industry that the Company considers to be comparable to the Company&#8217;s business
    over a period approximately equal to the expected term.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Risk-free
    interest rate. </i>The risk-free interest rate is based on the U.S. Treasury yield in effect at the time of grant for zero coupon
    U.S. Treasury notes with maturities approximately equal to the expected term.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Expected
    term.</i> The expected term represents the period that the stock-based awards are expected to be outstanding. The Company&#8217;s
    historical share option exercise experience does not provide a reasonable basis upon which to estimate an expected term because of
    a lack of sufficient data. Therefore, the Company estimates the expected term by using the simplified method provided by the SEC.
    The simplified method calculates the expected term as the average of the time-to-vesting and the contractual life of the options.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_898_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zXJHUhXRyRX8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
material factors incorporated in the Black-Scholes model in estimating the fair value of the options granted for the periods presented
were as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8BA_z7qII3f5qwu3" style="display: none">SCHEDULE
OF ASSUMPTION USED IN BLACK-SCHOLES OPTION-PRICING METHOD</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">For the Years Ended<br/> December
    31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Expected dividend yield</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20220101__20221231_zhag32jN4YRf" style="width: 16%; text-align: right" title="Expected dividend yield">0.00</td><td style="width: 1%; text-align: left">%</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20210101__20211231_zTIEJPQ084o4" style="width: 16%; text-align: right" title="Expected dividend yield">0.00</td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Expected stock-price volatility</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20220101__20221231_zKtIwKVsS3U" style="text-align: right" title="Expected stock-price volatility">103</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20210101__20211231_zuEHSOgSMVc6" style="text-align: right" title="Expected stock-price volatility">102</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Risk-free interest rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_pid_dp_uPure_c20220101__20221231_zLvLnQPVePo9" title="Risk-free interest rate, minimum">1.58</span>%
                                            &#8212; <span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_pid_dp_uPure_c20220101__20221231_zjt5MWct8SE7" title="Risk-free interest rate, maximum">3.77</span>%</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_pid_dp_uPure_c20210101__20211231_zJBi7nhkA5E" title="Risk-free interest rate, minimum">0.84</span>%
                                            &#8212; <span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_pid_dp_uPure_c20210101__20211231_z829pG31GkU2" title="Risk-free interest rate, maximum">1.51</span>%</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Expected average term of options (in years)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20220101__20221231_zKzJtlwDIcD8" title="Expected average term of options (in years)">5.99</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20210101__20211231_z7gMe5DCjO56" title="Expected average term of options (in years)">6.27</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Stock price</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_900_eus-gaap--SharePrice_iI_c20221231__srt--RangeAxis__srt--MinimumMember_zGc28BFmmRvg" title="Share price">5.14</span>
                                            - <span id="xdx_902_eus-gaap--SharePrice_iI_c20221231__srt--RangeAxis__srt--MaximumMember_zgkx93Yfjlue" title="Share price">10.50</span></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_903_eus-gaap--SharePrice_iI_c20211231__srt--RangeAxis__srt--MinimumMember_z5tPoCaiZ4C2" title="Share price">12.40</span>
                                            &#8212; <span id="xdx_904_eus-gaap--SharePrice_iI_c20211231__srt--RangeAxis__srt--MaximumMember_ztiGNvk1kf9k" title="Share price">32.90</span></span></td><td style="text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A1_zGLJGlfc0sjj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_89C_eus-gaap--ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_zh066EzBM4zd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company recorded stock-based compensation expense and classified it in the Consolidated Statements of Operations as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B7_zhN52oK5Tr13" style="display: none">SCHEDULE
OF SHARE-BASED COMPENSATION EXPENSE</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_491_20220101__20221231_zWbgOUKJSTsa" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_497_20210101__20211231_zC4rKQvO8pf5" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">For the Years Ended<br/> December
    31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--AllocatedShareBasedCompensationExpense_hus-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_z6NjOKdlH8xk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">General and administrative</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">4,649,649</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">4,465,911</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--AllocatedShareBasedCompensationExpense_hus-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zQQRXIbMtjSl" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Research and development</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">834,395</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">827,740</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--AllocatedShareBasedCompensationExpense_z8koch4cNqm9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt; padding-left: 10pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">5,484,044</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">5,293,651</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A5_zV04WYauZgVl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Equity
Classified Compensatory Warrants</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with the $<span id="xdx_907_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_pn5n6_c20220101__20221231__us-gaap--AwardTypeAxis__custom--CompensatoryWarrantsMember_zwMsTE61gQFk">4.0 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million
equity capital raise as part of the May 2020 reverse recapitalization transaction, the Company issued common stock warrants to an
advisor and its designees for the purchase of <span id="xdx_901_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_c20221231__us-gaap--AwardTypeAxis__custom--CompensatoryWarrantsMember_zjgTNrzmiqZ4">81,143
reverse split adjusted </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of the
Company&#8217;s common stock at a reverse split adjusted exercise price of $<span id="xdx_900_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20221231__us-gaap--AwardTypeAxis__custom--CompensatoryWarrantsMember_zNjdEUO6etbc">11.1<span style="background-color: white">0 </span></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per
share. The issuance cost of these warrants was charged to additional paid-in capital, and did not result in expense in the
Company&#8217;s consolidated <span style="background-color: white">statements of operations and comprehensive
loss.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, various service providers hold equity classified compensatory warrants issued in 2017 and earlier (originally exercisable to
purchase Series C convertible preferred stock, and now instead exercisable to purchase common stock) for the purchase of <span id="xdx_900_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_c20171231__us-gaap--AwardTypeAxis__custom--CompensatoryWarrantsMember_zReF2tUb7Ixg" title="Purchase of warrants">66,802 reverse split adjusted s</span>hares
of Company common stock at a weighted average exercise price of $<span id="xdx_901_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20171231__us-gaap--AwardTypeAxis__custom--CompensatoryWarrantsMember_zdZ90OV21Emd" title="Exercise price of warrants">23.40</span> per share. These are to be differentiated from the Series C Warrants
described in Note 10- Warrant Liabilities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year ended December 31, 2021, the Company issued equity classified compensatory warrants to a service provider for the purchase of
<span id="xdx_906_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20211231_zAW9cFKMDrj5">60,000</span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reverse split adjusted shares of Company common stock at a
reverse split adjusted exercise price of $<span id="xdx_907_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20211231_zInLCdDgEsGh">13.20</span>
per share. The fair value issuance cost of approximately $</span><span id="xdx_900_ecustom--FairValueOfIssuanceCost_pn5n6_c20210101__20211231_zJDERWaiZi3c" style="font-family: Times New Roman, Times, Serif; font-size: 10pt" title="Fair value of issuance cost">0.3
</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million
using the Black-Scholes options pricing model for these warrants was charged to general and administrative expenses in the Company&#8217;s
consolidated statements of operations and comprehensive loss. On April 25, 2022, </span><span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20220425__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zVEDdVaiyjOc" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">60,000
</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">warrants
were repriced from $</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_909_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20220424__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zsFyZ1STGzv1">13.20</span>
to </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
reverse split adjusted exercise price of $6.00</span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">and
extended from </span><span id="xdx_905_ecustom--WarrantsExtendedDateDescription_c20220423__20220425__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zNBBNOSezz4e" style="font-family: Times New Roman, Times, Serif; font-size: 10pt" title="Warrants extended date description">June
3, 2023 to September 14, 2023</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.
The increase in fair value of $</span><span id="xdx_90C_eus-gaap--FairValueAdjustmentOfWarrants_c20220423__20220425__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zzNzyneGvfi6" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">67,370
</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">using
a Monte Carlo pricing model for the modification of these warrants was charged to general and administrative expenses in the Company&#8217;s
consolidated statements of operations and comprehensive loss. On April 25, 2022 and May 26, 2022 an additional </span><span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_c20220526__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z4jnGGNLlJVb" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">67,619 reverse split adjusted
</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">warrants
were repriced from reverse split adjusted $11</span><span id="xdx_902_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20220526__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MinimumMember_zFUMTHnRFl4a" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.10
</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">to
$</span><span id="xdx_907_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20220526__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MaximumMember_z7pL3aTTTANk" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.136</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.
The increase in fair value of $</span><span id="xdx_90A_eus-gaap--FairValueAdjustmentOfWarrants_c20220523__20220526__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember__us-gaap--StatementEquityComponentsAxis__custom--WarrantOneMember_zk9GJs6d5TX7" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">31,010
</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">using
a Monte Carlo pricing model for the modification of these warrants was charged to additional paid-in capital and did not result in expense
on the Company&#8217;s consolidated statements of operations and comprehensive loss. On December 22, 2022 </span><span id="xdx_902_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_c20221222__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zmS18vwC5u43" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">67,620
</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">warrants
were repriced from $</span><span id="xdx_903_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20221222__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MinimumMember_zLYsaYYaalN4" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.136
</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">to
$</span><span id="xdx_902_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20221222__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MaximumMember_z9Mt5Rbq8Aih" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.32</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.
The increase in fair value of $</span><span id="xdx_906_eus-gaap--FairValueAdjustmentOfWarrants_c20221220__20221222__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zvWYdjs2ZGS" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8,548
</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">using
a Monte Carlo pricing model for the modification of these warrants was charged to additional paid-in capital and did not result in expense
on the Company&#8217;s consolidated statements of operations and comprehensive loss.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"/>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">No
new compensatory warrants were issued during the year ended December 31, 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_890_ecustom--SummaryOfWarrantActivityTableTextBlock_hus-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zm91MkMsDeuf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes the equity classified compensatory warrant activity for the year ended December 31, 2022:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B3_zXMa6WS7uYJ2" style="display: none">SCHEDULE
OF WARRANT ACTIVITY</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Common Stock</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Shares</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted&#8211; Average<br/> Exercise<br/>
    Price</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Range of<br/> Exercise Price</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted&#8211;<br/> Average<br/> Remaining<br/>
    Life (Years)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 32%">Total outstanding &#8211; December 31, 2021</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zc6X8p6TnZK2" style="width: 12%; text-align: right" title="Number of Shares, Warrants Outstanding Beginning">179,046</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iS_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_z6ZXiyP4CFQg" style="width: 12%; text-align: right" title="Weighted Average Exercise Price Per Share Warrants Outstanding Beginning">15.20</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="width: 16%; text-align: right"><span id="xdx_901_ecustom--RangeOfExercisePriceOutstanding_iS_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember__srt--RangeAxis__srt--MinimumMember_zfDlRJ4MFaAl" title="Range of exercise price - beginning">11.10</span>
                                            &#8212; $<span id="xdx_905_ecustom--RangeOfExercisePriceOutstanding_iS_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember__srt--RangeAxis__srt--MaximumMember_zUOo2hZXtozc">25.40</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right"><span id="xdx_90C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAveragRemainingContractualTerm1_dtY_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zIwhEPjpTkIj" title="Weighted Average Remaining Life (Years) - outstanding">2.64</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt">Granted to advisor and its designees</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_z6ayF8s7k1u5" style="text-align: right" title="Number of shares, warrants granted"><span style="-sec-ix-hidden: xdx2ixbrl1882">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zTsDqkiT7ug2" style="text-align: right" title="Weighted average exercise price per share warrants granted"><span style="-sec-ix-hidden: xdx2ixbrl1884">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt">Exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_di_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zsXfVyH9frHj" style="text-align: right" title="Number of Shares, Warrants Exercised"><span style="-sec-ix-hidden: xdx2ixbrl1886">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedInPeriodWeightedAverageExercisePrice_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zpp0ZfLX7rS1" style="text-align: right" title="Weighted average exercise price per share warrants exercised"><span style="-sec-ix-hidden: xdx2ixbrl1888">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt">Expired</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zmAmgvhiTLmc" style="text-align: right" title="Number of Shares, Warrants Expired"><span style="-sec-ix-hidden: xdx2ixbrl1890">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInPeriodWeightedAverageExercisePrice_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zIxcQeJ9pkNe" style="text-align: right" title="Weighted average exercise price per share warrants expired"><span style="-sec-ix-hidden: xdx2ixbrl1892">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; padding-left: 10pt">Forfeited</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_iN_di_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_z5uADim7WDt3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Shares, Warrants Forfeited"><span style="-sec-ix-hidden: xdx2ixbrl1894">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedInPeriodWeightedAverageExercisePrice_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zpEak3XxjT87" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted average exercise price per share warrants forfeited"><span style="-sec-ix-hidden: xdx2ixbrl1896">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Total outstanding &#8211; December 31, 2022</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zmok0BDWJap7" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Shares, Warrants Outstanding Ending">179,046</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iE_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_ztctxxBQvZl7" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price Per Share Warrants Outstanding Ending">9.12</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="padding-bottom: 2.5pt; text-align: right"><span id="xdx_906_ecustom--RangeOfExercisePriceOutstanding_iE_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember__srt--RangeAxis__srt--MinimumMember_zBdMA35yQnne" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.32
</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212; $<span id="xdx_902_ecustom--RangeOfExercisePriceOutstanding_iE_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember__srt--RangeAxis__srt--MaximumMember_zD11N8oa9I98">25.40</span></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right"><span id="xdx_90C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAveragRemainingContractualTerm1_dtY_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zHI1aNvl8JV7" title="Weighted Average Remaining Life (Years) - outstanding">1.73</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Exercisable</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_iI_c20221231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zlw5vYR1cbVd" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Shares, Warrants Exercisable">179,046</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_981_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageVestedExercisePrice_iI_c20221231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zGkDkIc0xBt7" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price Per Share Exercisable">9.12</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_903_ecustom--RangeOfExercisePriceExercisableVested_iI_c20221231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember__srt--RangeAxis__srt--MinimumMember_zs7o9GJr1DMb">1.32</span>-
                                            $<span id="xdx_90B_ecustom--RangeOfExercisePriceExercisableVested_iI_c20221231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember__srt--RangeAxis__srt--MaximumMember_zlcUR6iJK9dd" title="Range of exercise price - ending">25.40</span></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAveragRemainingContractualTerm1_dtY_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zq2PDHCWcnYa" title="Weighted Average Remaining Life (Years) Exercisable">1.73</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Non-Exercisable</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNonVestedNumber_iI_c20221231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_z9JCQxPvZMe3" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of shares, warrants non-exercisable"><span style="-sec-ix-hidden: xdx2ixbrl1915">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_984_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageNonVestedExercise_iI_c20221231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zIQo5bxFh7l8" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price Per Share Non-Exercisable"><span style="-sec-ix-hidden: xdx2ixbrl1917">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98E_ecustom--RangeOfExercisePriceNonexercisableNonvested_iI_c20221231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_z3PBkLPWv78e" style="border-bottom: Black 2.5pt double; text-align: right" title="Range of Exercise Price, Non-Exercisable"><span style="-sec-ix-hidden: xdx2ixbrl1919">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">&#8212;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes the equity classified compensatory warrant activity for the year ended December 31, 2021:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Common Stock</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Shares</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted&#8211; Average<br/> Exercise<br/>
    Price</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Range of<br/> Exercise Price</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted&#8211;<br/> Average<br/> Remaining<br/>
    Life (Years)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 32%">Total outstanding &#8211; December 31, 2020</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20210101__20211231__us-gaap--AwardTypeAxis__custom--CompensatoryWarrantActivityMember_zXEEiX2Ns9ij" style="width: 12%; text-align: right" title="Number of shares, warrants outstanding beginning">129,403</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iS_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zsAprVVc6pza" style="width: 12%; text-align: right" title="Weighted Average Exercise Price Per Share Warrants Outstanding Beginning">16.60</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right">&#160;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right">&#160;</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt">Granted to advisor and its designees</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20210101__20211231__us-gaap--AwardTypeAxis__custom--CompensatoryWarrantActivityMember_zPTolTwgpNl1" style="text-align: right" title="Number of shares, warrants outstanding beginning">60,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zpjy7tjjG7lg" style="text-align: right" title="Weighted average exercise price per share warrants granted">13.20</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt">Exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_di_c20210101__20211231__us-gaap--AwardTypeAxis__custom--CompensatoryWarrantActivityMember_zY5fckfJX907" style="text-align: right" title="Number of shares, warrants outstanding beginning">(3,839</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedInPeriodWeightedAverageExercisePrice_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zwvyAfJJtXIb" style="text-align: right" title="Weighted average exercise price per share warrants exercised">20.90</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt">Expired</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_iN_di_c20210101__20211231__us-gaap--AwardTypeAxis__custom--CompensatoryWarrantActivityMember_zqkBZSUcrDc8" style="text-align: right" title="Number of shares, warrants outstanding beginning"><span style="-sec-ix-hidden: xdx2ixbrl1933">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInPeriodWeightedAverageExercisePrice_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_z4fOBs5hLglk" style="text-align: right" title="Weighted average exercise price per share warrants expired"><span style="-sec-ix-hidden: xdx2ixbrl1935">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; padding-left: 10pt">Forfeited</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_iN_di_c20210101__20211231__us-gaap--AwardTypeAxis__custom--CompensatoryWarrantActivityMember_zJXVwXTfBsLf" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of shares, warrants outstanding beginning">(6,518</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedInPeriodWeightedAverageExercisePrice_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zbskeWqjnywl" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted average exercise price per share warrants forfeited">20.70</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Total outstanding &#8211; December 31, 2021</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_c20210101__20211231__us-gaap--AwardTypeAxis__custom--CompensatoryWarrantActivityMember_zc65SVAw9uPg" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of shares, warrants outstanding beginning">179,046</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iE_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zKVVPYIXz5lh" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price Per Share Warrants Outstanding Ending">15.20</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 2.5pt; text-align: right">$<span id="xdx_907_ecustom--RangeOfExercisePriceOutstanding_iE_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember__srt--RangeAxis__srt--MinimumMember_zFtZ5QShHcE2">11.10</span>
                                            &#8212; $<span id="xdx_90E_ecustom--RangeOfExercisePriceOutstanding_iE_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember__srt--RangeAxis__srt--MaximumMember_zqDqBD5TT456" title="Range of exercise price - ending">25.40</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right"><span id="xdx_90A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAveragRemainingContractualTerm1_dtY_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zJmgIMArS5u7" title="Weighted Average Remaining Life (Years) - outstanding">2.64</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Exercisable</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_iI_c20211231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zYINqjRAnRv3" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Shares, Warrants Exercisable">179,046</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_982_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageVestedExercisePrice_iI_c20211231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zRAneQeqjhv7" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price Per Share Exercisable">15.20</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 2.5pt double; text-align: right">$<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90A_ecustom--RangeOfExercisePriceExercisableVested_iI_c20211231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember__srt--RangeAxis__srt--MinimumMember_z4MNabjtCaf5">11.10</span>
                                            &#8212; $<span id="xdx_900_ecustom--RangeOfExercisePriceExercisableVested_iI_c20211231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember__srt--RangeAxis__srt--MaximumMember_zNvjGiy4ITMk" title="Range of exercise price - ending">25.40</span></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAveragRemainingContractualTerm1_dtY_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zR4QFPoIUOA7" title="Weighted Average Remaining Life (Years) Exercisable">2.64</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Non-Exercisable</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNonVestedNumber_iI_c20211231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_z7ZZNsmCWqp8" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of shares, warrants non-exercisable"><span style="-sec-ix-hidden: xdx2ixbrl1959">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageNonVestedExercise_iI_c20211231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_ziPEgq6dUs4b" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price Per Share Non-Exercisable"><span style="-sec-ix-hidden: xdx2ixbrl1961">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_980_ecustom--RangeOfExercisePriceNonexercisableNonvested_iI_c20211231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zJ0O7U0xHvIh" style="border-bottom: Black 2.5pt double; text-align: right" title="Range of Exercise Price, Non-Exercisable"><span style="-sec-ix-hidden: xdx2ixbrl1963">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">&#8212;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8AA_zlgfXByNtr9k" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
were $<span id="xdx_902_eus-gaap--AllocatedShareBasedCompensationExpense_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zGO8KZPVkVLj" title="Compensation cost">67,370</span> in compensation costs related to outstanding warrants for the year ended December 31, 2022 and $<span id="xdx_902_eus-gaap--AllocatedShareBasedCompensationExpense_pn5n6_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zh0Q6NAeRwe2" title="Compensation cost">0.3</span> million for the year
ended December 31, 2021. As of December 31, 2022 and December 31, 2021, there was no unrecognized compensation cost related to nonvested
warrants.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Noncompensatory
Equity Classified Warrants</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
May 2020, as a commitment fee, the Company issued noncompensatory equity classified warrants to Alpha Capital (a related party) for the purchase of <span id="xdx_906_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_c20200531__us-gaap--AwardTypeAxis__custom--NoncompensatoryEquityClassifiedWarrantsMember_z2MZLezvuRn3">27,048
reverse split adjusted shares of Company common stock at a reverse split adjusted exercise price of $</span></span><span id="xdx_909_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20200531__us-gaap--AwardTypeAxis__custom--NoncompensatoryEquityClassifiedWarrantsMember_zvbebgmQQKb4" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.10 </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per
share (of which warrants for </span><span id="xdx_903_ecustom--WarrantsExercised_c20201201__20201231__us-gaap--AwardTypeAxis__custom--NoncompensatoryEquityClassifiedWarrantsMember_z8LpI3z0Zar2" style="font-family: Times New Roman, Times, Serif; font-size: 10pt" title="Warrants exercised">20,000 </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares
were subsequently exercised in December 2020). In July 2020 the Company issued noncompensatory equity classified warrants to Alpha Capital for the purchase of </span><span id="xdx_909_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_c20200731__us-gaap--AwardTypeAxis__custom--NoncompensatoryEquityClassifiedWarrantsMember__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember_zijiCBZozBs5" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">78,019
reverse split adjusted</span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares
of Company common stock at a reverse split adjusted exercise price of $</span><span id="xdx_904_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20200731__us-gaap--AwardTypeAxis__custom--NoncompensatoryEquityClassifiedWarrantsMember__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember_zQfcjhzOozug" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.01 </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per
share (which were subsequently exercised in July 2020), and <span id="xdx_905_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_c20200731__us-gaap--AwardTypeAxis__custom--NoncompensatoryEquityClassifiedWarrantsMember_zHh7kJ5Uuas3">192,068</span> reverse split adjusted shares of Company common stock at a
reverse split adjusted exercise price of $</span><span id="xdx_900_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20200731__us-gaap--AwardTypeAxis__custom--NoncompensatoryEquityClassifiedWarrantsMember_z8lt0Jmnzu26" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">52.50 </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per
share. In August 2020, the Company issued noncompensatory equity classified warrants to Alpha Capital for the purchase of </span><span id="xdx_903_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_c20200831__us-gaap--AwardTypeAxis__custom--NoncompensatoryEquityClassifiedWarrantsMember__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zgU8GMM1UD52" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">128,783
reverse split adjusted shares of Company common stock at a reverse split adjusted exercise price of $</span><span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20200831__us-gaap--AwardTypeAxis__custom--NoncompensatoryEquityClassifiedWarrantsMember__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zmF05Pr6KTR3" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">60.00 </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per
share. In December 2020, the Company issued noncompensatory equity classified warrants to Alpha Capital for the purchase of </span><span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_c20201231__us-gaap--AwardTypeAxis__custom--NoncompensatoryEquityClassifiedWarrantsMember__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember_zOoKzGlJGis4" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">100,000 </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reverse
split adjusted shares of Company common stock at a reverse split adjusted exercise price of $</span><span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20201231__us-gaap--AwardTypeAxis__custom--NoncompensatoryEquityClassifiedWarrantsMember__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember_zwreAXqRa7ye" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.10 </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per
share (which were exercised in February 2021) and </span><span id="xdx_909_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_c20201231_zEfuGpcs7FA3" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">219,101
reverse split adjusted</span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares
of Company common stock at a reverse split adjusted exercise price of $</span><span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20201231_z3QyJ92TdD9e" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">40.70 </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per
share. In May 2022, the Company issued noncompensatory equity classified warrants to Alpha Capital for the purchase of </span><span id="xdx_901_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_c20220531__us-gaap--AwardTypeAxis__custom--NoncompensatoryEquityClassifiedWarrantsMember_z5LoGPTOrvE1" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">331,464
reverse split adjusted</span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares
of Company common stock at a reverse split adjusted exercise price of $</span><span id="xdx_900_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20220531__us-gaap--AwardTypeAxis__custom--NoncompensatoryEquityClassifiedWarrantsMember_zzERc0VKrLB2" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.01 </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per
share (See Note 3 -Acquisition).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"/>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">On
November 29, 2021, with the exception of the warrants to purchase <span id="xdx_903_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_c20211129__us-gaap--AwardTypeAxis__custom--NoncompensatoryEquityClassifiedWarrantsMember_zeIeAtZFYJkb" title="Number of securities called by Each warrant or right">27,048
reverse split adjusted shares of the Company&#8217;s common stock at a reverse split adjusted exercise price of $<span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20211129__us-gaap--AwardTypeAxis__custom--NoncompensatoryEquityClassifiedWarrantsMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z0wnOdvdTm5i" title="Exercise price of warrants">11.10</span>
per share, the exercise prices of all outstanding warrants to purchase a total of <span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20211129__us-gaap--AwardTypeAxis__custom--NoncompensatoryEquityClassifiedWarrantsMember_zZIlHOnBCSWa" title="Number of outstanding warrants to purchase, shares">539,951
reverse split adjusted</span> shares of the Company&#8217;s common stock were modified to a reverse split adjusted exercise price of
$<span id="xdx_908_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20211129__us-gaap--AwardTypeAxis__custom--NoncompensatoryEquityClassifiedWarrantsMember_zEcNBEAtthCg" title="Exercise price of warrants">20.00</span>
per share and each of their remaining terms extended by six months. The fair value of the modification cost of these warrant
modifications of approximately $<span id="xdx_907_eus-gaap--FairValueAdjustmentOfWarrants_pn5n6_c20220101__20221231__us-gaap--AwardTypeAxis__custom--NoncompensatoryEquityClassifiedWarrantsMember_zUHKcymBIuIg" title="Fair value of warrants">2.3</span>
million was charged to additional paid-in capital and did not result in expense on the Company&#8217;s consolidated statements of
operations and comprehensive loss. In May 2022, pre-funded warrants to purchase <span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_c20220930__us-gaap--AwardTypeAxis__custom--NoncompensatoryEquityClassifiedWarrantsMember_zAa5DJ8XHQrh" title="Purchase of warrants">331,464
reverse split adjusted</span> shares of the Company&#8217;s common stock at a reverse split adjusted exercise price of $<span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20220930__us-gaap--AwardTypeAxis__custom--NoncompensatoryEquityClassifiedWarrantsMember_z9sDvAuGwgH1" title=" Exercise price of warrants or rights">0.01</span>
per share with no expiration date were issued. These warrants were subsequently exercised during the period ended September 30,
2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">In
conjunction with the NanoSynex Acquisition (See Note 3-Acquisition), on April 25, 2022 the exercise price of <span id="xdx_907_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_c20220425__us-gaap--BusinessAcquisitionAxis__custom--NanoSynexMember_z9yALRVQV102" title="Purchase of warrants">7,048
reverse split adjusted outstanding warrants at $<span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20211231__us-gaap--AwardTypeAxis__custom--NoncompensatoryEquityClassifiedWarrantsMember_zT420ek5Kjpf" title="Exercise price of warrants">11.10</span>
was modified to a reverse split adjusted exercise price of $<span id="xdx_900_ecustom--ModifiedToExercisePrice_iI_c20220425__us-gaap--BusinessAcquisitionAxis__custom--NanoSynexMember_zN4BuVTwIfSe" title="Modified to exercise price">6.00</span>.
The increase in fair value of $<span id="xdx_90D_eus-gaap--FairValueAdjustmentOfWarrants_c20220423__20220425__us-gaap--BusinessAcquisitionAxis__custom--NanoSynexMember_zJEIpQn8FNp3" title="Fair value of warrants">2,533</span>,
using a Monte Carlo pricing model for the modification of these warrants, was charged to additional paid-in capital and did not
result in expense on the Company&#8217;s consolidated statements of operations and comprehensive loss. On May 26, 2022, the
reverse split adjusted exercise price of these warrants was modified again to $<span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20220526__us-gaap--BusinessAcquisitionAxis__custom--NanoSynexMember_zurAVj0Qtuxa" title="Class of warrant or right, exercise">5.136</span>,
and the increase in fair value of $<span id="xdx_90A_eus-gaap--FairValueAdjustmentOfWarrants_c20220523__20220526__us-gaap--BusinessAcquisitionAxis__custom--NanoSynexMember_zK1wcBgwQFU8" title="Fair value adjustment of warrants">696</span>,
using a Monte Carlo pricing model for the modification of these warrants, was included in consideration transferred in the NanoSynex
Acquisition. On December 22, 2022 the exercise price of these warrants was modified again to $<span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20221222__us-gaap--BusinessAcquisitionAxis__custom--NanoSynexMember_zo7wHeVdlDSa" title="Class of warrant or right, exercise">1.32</span>.
The increase in fair value of $<span id="xdx_90D_eus-gaap--FairValueAdjustmentOfWarrants_c20221220__20221222__us-gaap--BusinessAcquisitionAxis__custom--NanoSynexMember_zIdwFZZ7rdOk" title="Fair value adjustment of warrants">891</span>,
using a Monte Carlo pricing model for the modification of those warrants, was charged to additional paid-in capital and did not
result in expense on the Company&#8217;s consolidated statements of operations and comprehensive loss.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_896_ecustom--SummaryOfWarrantActivityTableTextBlock_hus-gaap--StatementEquityComponentsAxis__custom--NonCompensatoryWarrantActivityMember_z3Ezp2e9l6U5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes the noncompensatory equity classified warrant activity for the year ended December 31, 2022:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8BD_z7kPo6hRT5N9" style="display: none">SCHEDULE
OF WARRANT ACTIVITY</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"/>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"/>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Common
    Stock</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif">Shares</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Weighted&#8211;<br/>
    Average<br/> Exercise<br/> Price</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Range
    of<br/> Exercise Price</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Weighted&#8211;<br/>
    Average<br/> Remaining<br/> Life (Years)</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 32%; padding-bottom: 2.5pt">Total outstanding &#8211; December 31, 2021</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 2.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; width: 1%; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20220101__20221231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zwjFSRJNVUW9" style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; width: 12%; text-align: right" title="Number of shares, warrants outstanding beginning">554,914</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 2.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; width: 1%; text-align: left">$</td><td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iS_c20220101__20221231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zVikSZesbGu9" style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; width: 12%; text-align: right" title="Weighted Average exercise price per share warrants outstanding beginning">20.10</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 2.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_903_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsRangeOfExercisePrice_iS_c20220101__20221231__srt--RangeAxis__srt--MinimumMember__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zMUMmCqTfd85" title="Range of exercise price">11.10</span>&#8212;
                                            <span id="xdx_909_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsRangeOfExercisePrice_iS_c20220101__20221231__srt--RangeAxis__srt--MaximumMember__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_z7eX7LOBnGI3" title="Range of exercise price">37.78</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 2.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; width: 12%; text-align: right"><span id="xdx_90D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAveragRemainingContractualTerm1_dtY_c20210101__20211231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zL0eZezEfLbh" title="Weighted average remaining life (Years) exercisable">1.32</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt">Granted</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20220101__20221231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zleoRD6BR5kc" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of shares, warrants granted">331,464</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_981_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice_c20220101__20221231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zzuzx14V31M9" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price per share warrants granted">0.01</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_980_ecustom--RangeOfExercisePriceGranted_c20220101__20221231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zVOw8zcBTcrc" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Range of exercise price - granted">0.01</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt">Exercised</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_di_c20220101__20221231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zCes61SgT65l" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Shares, Warrants Exercised">(331,464</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedInPeriodWeightedAverageExercisePrice_c20220101__20221231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zTuzD7PPoiFa" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price per share warrants exercised">0.01</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_989_ecustom--RangeOfExercisePriceExpired_c20220101__20221231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zfa6QtYaCcGe" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Range of exercise price - Expired">0.01</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt">Expired</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_iN_di_c20220101__20221231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zT83qno96T8k" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Shares, Warrants Expired">(7,911</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInPeriodWeightedAverageExercisePrice_c20220101__20221231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zCWvJvJpGnle" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price per share warrants expired">37.78</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInRangeOfExercisePrice_c20220101__20221231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zreaXubl0vi3" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price per share warrants expired">37.78</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; padding-left: 10pt">Forfeited</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_iN_di_c20220101__20221231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zUfyKeYAqJh7" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Shares, Warrants Forfeited"><span style="-sec-ix-hidden: xdx2ixbrl2045">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedInPeriodWeightedAverageExercisePrice_c20220101__20221231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_z18TDDCOaWL5" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price per share warrants forfeited"><span style="-sec-ix-hidden: xdx2ixbrl2047">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedInRangeOfExercisePrice_c20220101__20221231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zOYk6TDl4qP3" style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right" title="Weighted average exercise price per share warrants forfeited"><span style="-sec-ix-hidden: xdx2ixbrl2049">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">Total outstanding &#8211; December 31, 2022</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_c20220101__20221231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zubz5owdsLu7" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of shares, warrants outstanding ending">547,003</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iE_c20220101__20221231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zmgV7gzBuov4" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">19.76</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_907_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsRangeOfExercisePrice_iE_c20220101__20221231__srt--RangeAxis__srt--MinimumMember__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zFFcgD4S67i5" title="Range of exercise price">1.32</span>
                                            - <span id="xdx_90A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsRangeOfExercisePrice_iE_c20220101__20221231__srt--RangeAxis__srt--MaximumMember__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zKF9YJmyPbOh" title="Range of exercise price">20.00</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right"><p style="margin: 0"><span id="xdx_903_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAveragRemainingContractualTerm1_dtY_c20220101__20221231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_z3ZFJGZrIQ3j" title="Weighted average remaining life (Years) exercisable">0.33</span></p></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">Exercisable</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_iI_c20221231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zlrYJwXik0Lk" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Shares, Warrants Exercisable">547,003</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"/><td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageVestedExercisePrice_iI_c20221231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zdNu49nlWmh8" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price Per Share Exercisable">19.76</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90C_ecustom--RangeOfExercisePriceExercisableVested_iI_c20221231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember__srt--RangeAxis__srt--MinimumMember_z75s4PgkKA08">1.32</span>
                                            - <span id="xdx_908_ecustom--RangeOfExercisePriceExercisableVested_iI_c20221231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember__srt--RangeAxis__srt--MaximumMember_z53sjGNxbes" title="Range of exercise price - Exercisable">20.00</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_902_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAveragRemainingContractualTerm1_dtY_c20220101__20221231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zY5i18pnUj9g" title="Weighted average remaining life (Years) exercisable">0.33</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">Non-Exercisable</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><p id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsNonExercisableNumber_iI_c20221231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_z9QB1DrWVd54" style="margin: 0" title="Number of Shares, Warrants Exercisable"><span style="-sec-ix-hidden: xdx2ixbrl2069">&#8212;</span></p></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageVestedNonExercisePrice_iI_c20221231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zRUYi3jgb2T" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price Per Share Exercisable"><p style="margin: 0"><span style="-sec-ix-hidden: xdx2ixbrl2071">&#8212;</span></p></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><p style="margin: 0"><span id="xdx_905_ecustom--RangeOfExercisePriceNonExercisableVested_iI_c20221231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zS6McpAPGdJ8" title="Range of exercise price - Exercisable"><span style="-sec-ix-hidden: xdx2ixbrl2073">&#8212;</span></span></p></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><p style="margin: 0">&#8212;</p></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"/>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes the noncompensatory equity classified warrant activity for the year ended December 31, 2021:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"/>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt"/>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Common
    Stock</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Shares</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Weighted&#8211;<br/>
    Average<br/> Exercise<br/> Price</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Range
    of<br/> Exercise Price</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Weighted&#8211;<br/>
    Average<br/> Remaining<br/> Life (Years)</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 32%">Total outstanding &#8211; December 31, 2020</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20210101__20211231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zrgu3znl8ir8" style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right" title="Number of shares, warrants outstanding beginning">654,978</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iS_c20210101__20211231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zuq0DGS0fNgc" style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right" title="Weighted Average exercise price per share warrants outstanding beginning">43.60</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right">&#160;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right">&#160;</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt">Granted</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20210101__20211231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zseVSSaR3om2" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of shares, warrants granted"><span style="-sec-ix-hidden: xdx2ixbrl2079">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice_c20210101__20211231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zd7XDgXX7v0e" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price per share warrants granted"><span style="-sec-ix-hidden: xdx2ixbrl2081">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt">Exercised</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_di_c20210101__20211231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_z4VTL9fYAHg7" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Shares, Warrants Exercised">(100,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_984_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedInPeriodWeightedAverageExercisePrice_c20210101__20211231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zk9RebS1SFOa" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price per share warrants exercised">0.01</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt">Expired</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_iN_di_c20210101__20211231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zMrt5FX6PAk7" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Shares, Warrants Expired">(64</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInPeriodWeightedAverageExercisePrice_c20210101__20211231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_z4PGH6tMj7L" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price per share warrants expired">23,250.00</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; padding-left: 10pt">Forfeited</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_iN_di_c20210101__20211231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zWrrkA6OrSX4" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Shares, Warrants Forfeited"><span style="-sec-ix-hidden: xdx2ixbrl2091">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_984_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedInPeriodWeightedAverageExercisePrice_c20210101__20211231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zHFgSqFaYdF" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price per share warrants forfeited"><span style="-sec-ix-hidden: xdx2ixbrl2093">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">Total outstanding &#8211; December 31, 2021</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_c20210101__20211231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zzvbBfvHzVw9" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of shares, warrants outstanding ending">554,914</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iE_c20210101__20211231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_z5YMpRUmKmxb" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price per share warrants outstanding ending">20.10</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">Exercisable</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_iI_c20211231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zRtonYIo0gr" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Shares, Warrants Exercisable">554,914</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageVestedExercisePrice_iI_c20211231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_z4XqDAu7DU09" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price Per Share Exercisable">20.10</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90A_ecustom--RangeOfExercisePriceExercisableVested_iI_c20211231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember__srt--RangeAxis__srt--MinimumMember_z2Cgb5GcUwU1">11.10</span>&#8212;
                                            <span id="xdx_90E_ecustom--RangeOfExercisePriceExercisableVested_iI_c20211231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember__srt--RangeAxis__srt--MaximumMember_zT9QG9krjKff" title="Range of exercise price - Exercisable">37.78</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_909_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAveragRemainingContractualTerm1_dtY_c20210101__20211231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zhxtRGlF0sia" title="Weighted average remaining life (Years) exercisable">1.32</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">Non-Exercisable</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNonVestedNumber_iI_c20211231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zsRMNxUJolef" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of shares, warrants non-exercisable"><span style="-sec-ix-hidden: xdx2ixbrl2108">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageNonVestedExercise_iI_c20211231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_z6BDf9VNYLpb" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price Per Share Non-Exercisable"><span style="-sec-ix-hidden: xdx2ixbrl2110">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_98A_ecustom--RangeOfExercisePriceNonexercisableNonvested_iI_c20211231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zh4z4Kxg5TPh" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Range of Exercise Price, Non-Exercisable"><span style="-sec-ix-hidden: xdx2ixbrl2112">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNonExercisableWeightedAverageRemainingContractualTerm1_dtY_c20210101__20211231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zxT9GOV6SKZb" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average remaining life (Years) non-exercisable"><span style="-sec-ix-hidden: xdx2ixbrl2114">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A7_zsJm35GUamO2" style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI https://asc.fasb.org/topic&amp;trid=2208762<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496180-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126731327&amp;loc=SL126733271-114008<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140569897133840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RELATED PARTY TRANSACTIONS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">RELATED PARTY TRANSACTIONS</a></td>
<td class="text"><p id="xdx_806_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_zw8BAxRq9xI3" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>NOTE 16 &#8212; <span id="xdx_829_ztv8nxMGTeY9">RELATED PARTY TRANSACTIONS</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Convertible Debt </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">On December 22, 2022, the Company issued to Alpha
Capital, an <span id="xdx_902_eus-gaap--ShortTermDebtInterestRateIncrease_pid_dp_uPure_c20221222__20221222__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember__us-gaap--DebtInstrumentAxis__custom--SeniorConvertibleDebentureMember_zCYtEOlEyKWg" title="Senior convertible debenture rate">8</span>% Senior Convertible Debenture in the aggregate principal amount of $<span id="xdx_902_eus-gaap--SecuredDebt_iI_c20221222__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember__us-gaap--DebtInstrumentAxis__custom--SeniorConvertibleDebentureMember_zKrKJCk27pOc" title="Principal amount">3,300,000</span> for a purchase price of $<span id="xdx_902_ecustom--PurchasePrice_iI_c20221222__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember__us-gaap--DebtInstrumentAxis__custom--SeniorConvertibleDebentureMember_zs7z0yaWDZV9" title="Purchase Price">3,000,000</span> pursuant
to the terms of a Securities Purchase Agreement, dated December 21, 2022 (the &#8220;Alpha Purchase Agreement&#8221;). The Debenture is
convertible, at any time, and from time to time, at Alpha&#8217;s option, into shares of common stock of the Company (the &#8220;Conversion
Shares&#8221;), at a price equal to $<span id="xdx_904_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pid_c20221222__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember__us-gaap--DebtInstrumentAxis__custom--SeniorConvertibleDebentureMember_zeDshKsge7zf" title="Conversion price">1.32 </span>per share, subject to adjustment as described in the Debenture (the &#8220;Conversion Price&#8221;)
and other terms and conditions described in the Debenture, including the Company&#8217;s receipt of the requisite stockholder approvals
(See Note 11 -Convertible Debt - Related Party).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Short-Term Debt</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">NanoSynex has four separate notes payable (the &#8220;Notes&#8221;) outstanding to Alpha Capital, dated between March
26, 2020 and September 2, 2021, aggregating to a total principal outstanding balance of $<span id="xdx_90B_eus-gaap--DebtInstrumentFaceAmount_iI_c20210902__us-gaap--ShortTermDebtTypeAxis__custom--NotesPayableMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NanoSynexMember_zq1GyqxWFFfd" title="Short term debt principal outstanding">905,000</span>, and aggregate accrued interest of $<span id="xdx_90C_eus-gaap--InterestPayableCurrent_iI_pp0p0_c20221231__us-gaap--ShortTermDebtTypeAxis__custom--NotesPayableMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NanoSynexMember_zL0FRomOK44d" title="Accrued interest">45,722</span>
for a total outstanding balance of $<span id="xdx_90B_eus-gaap--ShortTermBorrowings_iI_pp0p0_c20221231__us-gaap--ShortTermDebtTypeAxis__custom--NotesPayableMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NanoSynexMember_zffaPZB0t9r6" title="Short term debt outstanding balance">950,722</span> as of December&#160;31, 2022. The Notes all accrue interest at<span id="xdx_90A_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20210902__us-gaap--ShortTermDebtTypeAxis__custom--NotesPayableMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NanoSynexMember_z2M0M949Qbed" title="Accrued interest rate"> 2.62</span>% per annum, accrued daily,
and provide that the full amount of principal and interest under each Note shall be due immediately prior to a Liquidation Event (the
Maturity Date) unless due earlier in accordance with the terms of the Notes. &#8220;Liquidation Event&#8221; means either i) the merger
or consolidation of NanoSynex into any other entity, other than one in control or under control of NanoSynex or NanoSynex&#8217;s majority shareholder;
ii) a transaction or series of transactions resulting in the transfer of all or substantially all of NanoSynex&#8217;s assets or issued and
outstanding share capital (other than to a company under the control of NanoSynex or NanoSynex&#8217;s majority shareholders; or iii) an underwritten
public offering by NanoSynex of its ordinary shares. Notwithstanding the above, if NanoSynex receives subsequent debt, convertible debt,
or equity funding with gross proceeds of USD $<span id="xdx_901_eus-gaap--ProceedsFromRelatedPartyDebt_pp0p0_c20210326__20210902__us-gaap--ShortTermDebtTypeAxis__custom--NotesPayableMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NanoSynexMember_zNJI6se0a2Tg" title="Proceeds from related party debt">3,000,000</span> or more, then these Notes shall be due and payable upon the actual receipt of
such funding (See Note 9 -Short-term Debt - Related Party).</p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Nanosynex Acquisition</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company acquired a <span id="xdx_903_eus-gaap--BusinessAcquisitionPercentageOfVotingInterestsAcquired_iI_pid_dp_uPure_c20220526__us-gaap--BusinessAcquisitionAxis__custom--NanoSynexLtdMember_z3qyVFVo5SJg" title="Business acquisition, voting equity rate">52.8</span>% voting equity interest
in NanoSynex on May 26, 2022 (the &#8220;NanoSynex Acquisition Date&#8221;) through: (1) the purchase of <span id="xdx_901_eus-gaap--StockIssuedDuringPeriodSharesAcquisitions_c20220524__20220526__us-gaap--StatementClassOfStockAxis__custom--SeriesAOnePreferredStockMember_z5BJO4JXkBvh" title="Number of shares of stock issued">2,232,861</span> shares Preferred A-1
Stock of NanoSynex from Alpha Capital (a related party) for <span id="xdx_900_eus-gaap--StockIssuedDuringPeriodSharesAcquisitions_c20220524__20220526__us-gaap--BusinessAcquisitionAxis__custom--NanoSynexLtdMember_zcfpx0LwPU74" title="Stock issued during period shares acquisitions">350,000</span> reverse split adjusted shares of the Company&#8217;s common stock and a
prefunded warrant to purchase <span id="xdx_901_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20220526__us-gaap--StatementEquityComponentsAxis__custom--PrefundedWarrantMember_zmIDxCjjYZr8" title="Warrants to purchase shares">331,464 reverse split adjusted shares of the Company&#8217;s common stock at a purchase price of $<span id="xdx_909_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20220526__us-gaap--BusinessAcquisitionAxis__custom--NanoSynexLtdMember__us-gaap--StatementEquityComponentsAxis__custom--PrefundedWarrantMember_zV0i1KkZvyZe" title="Warrants or rights">0.001</span> per share
(<span id="xdx_90B_eus-gaap--StockholdersEquityReverseStockSplit_c20220524__20220526__us-gaap--BusinessAcquisitionAxis__custom--NanoSynexLtdMember_zHFGo44DRS7k" title="Reverse split, description">these warrants were subsequently exercised on September 13, 2022)</span>, and (2) the purchase of <span id="xdx_902_eus-gaap--StockIssuedDuringPeriodSharesAcquisitions_c20220524__20220526__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember__us-gaap--BusinessAcquisitionAxis__custom--NanoSynexLtdMember_zL544l13VBX8" title="Stock issued during period shares acquisitions">381,786</span> shares of Series B preferred stock
of NanoSynex from NanoSynex in exchange for $<span id="xdx_901_eus-gaap--StockIssuedDuringPeriodValueAcquisitions_c20220524__20220526__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember__us-gaap--BusinessAcquisitionAxis__custom--NanoSynexLtdMember_zPey05GwWsja" title="Stock issued during period value acquisitions">600,000</span></span> (See Note 3 - Acquisition).</p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -URI https://asc.fasb.org/topic&amp;trid=2122745<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39691-107864<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140569897201552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">INCOME TAXES</a></td>
<td class="text"><p id="xdx_806_eus-gaap--IncomeTaxDisclosureTextBlock_zXkjUdIAk7a8" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
17 &#8212; <span id="xdx_824_zCH2Y3cvJuEi">INCOME TAXES</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p id="xdx_89D_eus-gaap--ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_zC5WzqnHGoG" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table presents domestic and foreign components of consolidated loss before income taxes for the periods presented:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span><span id="xdx_8BE_zZJmOpqAkPFh" style="display: none">SCHEDULE
OF DOMESTIC AND FOREIGN COMPONENTS</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_498_20220101__20221231_zCIo0y8ZD4Cc" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_494_20210101__20211231_zA5yjKw0koBj" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_z37fmY4jBFv4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%">Domestic</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">(15,954,750</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">(17,891,710</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr id="xdx_401_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_zifcygSnRYn6" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">Foreign</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(5,344,967</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2160">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_zbeeiP0iNXBh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Loss before provision for income taxes</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(21,299,717</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(17,891,710</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  </table>

<p id="xdx_8A2_z2FlujSNayk7" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_89D_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zno2KvHtuSh3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
reconciliation of the statutory income tax rates and the Company&#8217;s effective tax rate is as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8BB_zJ7HCURHx36a" style="display: none">SCHEDULE
OF RECONCILIATIONS OF STATUTORY INCOME TAX RATE</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_498_20220101__20221231_zXdooMsJEywk" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_492_20210101__20211231_zLf6HVlYXzf2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_uPure_zIeBXIwCOqH" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Statutory federal income tax rate</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right">21.00</td><td style="width: 1%; text-align: left">%</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right">21.00</td><td style="width: 1%; text-align: left">%</td></tr>
  <tr id="xdx_400_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_pid_dp_uPure_zJIAGKaGcMX" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">State taxes, net of federal tax benefit</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5.46</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6.63</td><td style="text-align: left">%</td></tr>
  <tr id="xdx_40B_eus-gaap--EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepletion_pid_dp_uPure_zR0JUoqHu6o1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Non-deductible expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-1.36</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-1.19</td><td style="text-align: left">%</td></tr>
  <tr id="xdx_408_ecustom--EffectiveIncomeTaxRateReconciliationNonOperatingLossExpiration_pid_dp_uPure_z2f8h7JF900b" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">NOL expiration</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-12.96</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-2.71</td><td style="text-align: left">%</td></tr>
  <tr id="xdx_40E_eus-gaap--EffectiveIncomeTaxRateReconciliationTaxCredits_pid_dp_uPure_zfEWJloNJUJd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Tax credit</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2.42</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.86</td><td style="text-align: left">%</td></tr>
  <tr id="xdx_400_eus-gaap--EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses_pid_dp_uPure_zRgn6HftpuW6" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Goodwill impairment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-4.50</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.00</td><td style="text-align: left">%</td></tr>
  <tr id="xdx_406_eus-gaap--EffectiveIncomeTaxRateReconciliationTaxSettlementsForeign_pid_dp_uPure_zTFGuDKMxGJ" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Foreign rate differential</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.50</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.00</td><td style="text-align: left">%</td></tr>
  <tr id="xdx_40B_ecustom--EffectiveIncomeTaxRateReconciliationFairValueOfWarrant_pid_dp_uPure_zQoQFFPXWgm2" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Change in FV of warrant liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.89</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5.54</td><td style="text-align: left">%</td></tr>
  <tr id="xdx_40C_eus-gaap--EffectiveIncomeTaxRateReconciliationTaxCreditsOther_pid_dp_uPure_zDHCM6gQLox8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>True-up</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1.47</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-2.72</td><td style="text-align: left">%</td></tr>
  <tr id="xdx_404_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_pid_dp_uPure_zL6RGqQhU227" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Change in valuation allowance</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-11.68</td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-27.44</td><td style="padding-bottom: 1.5pt; text-align: left">%</td></tr>
  <tr id="xdx_401_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_pid_dp_uPure_zhMdntHmS9rd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Income taxes provision (benefit)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">1.24</td><td style="padding-bottom: 2.5pt; text-align: left">%</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">-0.03</td><td style="padding-bottom: 2.5pt; text-align: left">%</td></tr>
  </table>

<p id="xdx_8A9_z98hbu2gEOFh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_891_eus-gaap--ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_zz2iHIEA3rO1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Income
tax expense for the year ended December 31, 2022 and 2021 consisted of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B5_zrvQuSeeDsud" style="display: none">SCHEDULE
OF PROVISION FOR INCOME TAXES</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49E_20220101__20221231_zfGOltlCv5L8" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_495_20210101__20211231_zRwty91B7ob" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">For the Years Ended</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Current</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--CurrentFederalTaxExpenseBenefit_maCITEBz1MC_zWa9bmB5ez1a" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">US Federal</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2202">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2203">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--CurrentStateAndLocalTaxExpenseBenefit_maCITEBz1MC_zs53W0Vutu4a" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">US State</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right">7,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right">5,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--CurrentForeignTaxExpenseBenefit_maCITEBz1MC_zmIFaJ38JYcc" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">Foreign</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2208">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2209">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--CurrentIncomeTaxExpenseBenefit_iT_mtCITEBz1MC_zmsyTOrYMKqf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10pt">Total current provision</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Deferred</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--DeferredFederalIncomeTaxExpenseBenefit_maDITEBzCKf_zEjGPYIO4jae" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">US Federal</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(236,000</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,268,000</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_402_eus-gaap--DeferredStateAndLocalIncomeTaxExpenseBenefit_maDITEBzCKf_z9jvGGv8uVSc" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">US State</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(2,252,000</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(3,641,000</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_400_eus-gaap--DeferredForeignIncomeTaxExpenseBenefit_maDITEBzCKf_zaz4C0dB2JDh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Foreign</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(272,000</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2221">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--DeferredIncomeTaxExpenseBenefit_iT_mtDITEBzCKf_maITEBzWbu_zpUmzlIz4zlg" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt">Total deferred benefit</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(2,760,000</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(4,909,000</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_409_eus-gaap--ValuationAllowanceDeferredTaxAssetChangeInAmount_iN_di_msITEBzWbu_zqClhg5UPcqe" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt">Change in valuation allowance</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,488,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">4,909,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--IncomeTaxExpenseBenefit_iT_pn3d_mtITEBzWbu_zQCM7qvLFCth" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 10pt">Total provision (benefit) for income taxes</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(265,000</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">5,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A6_zTO9prVN39h5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_896_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zeTmu6uRlQPe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
components of deferred tax assets and liabilities are as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8BF_z3dFPzGVRSH2" style="display: none">SCHEDULE
OF DEFERRED TAX ASSETS AND LIABILITIES</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_496_20221231_zZGWMXRDemS6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_491_20211231_zBm7PHs84ebh" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Deferred tax assets:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_maDTATDzYdX_znrofrP5Xlre" style="vertical-align: bottom; background-color: White">
    <td style="width: 60%; text-align: left; padding-left: 10pt">Net operating loss</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">33,540,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">33,362,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--DeferredTaxAssetsInProcessResearchAndDevelopment_iI_maDTATDzYdX_z2tuGmtJmegd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10pt">Research and development credits</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7,857,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6,185,000</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_ecustom--DefferdTaxAssetsAccruedExpenses_iI_maDTATDzYdX_z6JoyJ0i7os9" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt">Accrued expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,020,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">757,000</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--DeferredTaxAssetsGoodwillAndIntangibleAssets_iI_maDTATDzYdX_zDuKcQEhBRof" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt">Patent</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2243">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">262,000</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_iI_maDTATDzYdX_zzxLy03Czow" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt">Stock compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,069,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,747,000</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_ecustom--DeferredTaxAssetsResearchAndDevelopmentExpenses_iI_maDTATDzYdX_zxSJdg5AvK3a" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10pt">Research and development expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,196,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2250">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--DeferredTaxAssetsPropertyPlantAndEquipment_iI_maDTATDzYdX_zJIaj0YTTjCb" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt">Fixed assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">280,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">282,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--DeferredTaxAssetsTaxDeferredExpense_iTI_mtDTATDzYdX_maDTAGzJfc_z7vYln7SyRlk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 20pt">Total deferred income tax assets</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">46,962,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">43,595,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Deferred tax liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_iNI_di_maDITLzOxa_zNVXxDQARH21" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt">Intangible assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,324,000</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(34,000</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_401_eus-gaap--DeferredTaxLiabilitiesLeasingArrangements_iNI_di_maDITLzOxa_zYhrq6gYXyog" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt">Right-of-use asset</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(382,000</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(436,000</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_40B_eus-gaap--DeferredIncomeTaxLiabilities_iNTI_di_mtDITLzOxa_msDTAGzJfc_zyOXhtPGufhj" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 10pt">Total deferred income tax liabilities</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">(1,706,000</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">(470,000</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--DeferredTaxAssetsGross_iTI_mtDTAGzJfc_maDTALNzbeu_zuHVng7UZHZj" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Net deferred income tax assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">45,256,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">43,125,000</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_di_msDTALNzbeu_zpSSzdtVNXlf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Valuation allowance</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(45,614,000</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(43,125,000</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_402_eus-gaap--DeferredTaxAssetsLiabilitiesNet_iNTI_di_mtDTALNzbeu_zPeqin1vXMda" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Deferred tax asset, net of allowance</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(358,000</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2274">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8AB_zDZsKxpqeVi9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
on the available objective evidence, including the Company&#8217;s history of cumulative losses, management believes it is likely that
the Company&#8217;s U.S. federal and state net deferred tax assets will not be realizable. Accordingly, the Company provided for a full
valuation allowance against its U.S. federal and state net deferred tax assets at December 31, 2022 and December 31, 2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"/>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Due
to the full valuation allowance already in place on the Company&#8217;s U.S. federal and state net deferred tax assets, the Company does
not anticipate significant changes in the Company&#8217;s effective tax rate. However, there is no valuation allowance recorded against
the Company&#8217;s foreign net operating loss deferred tax assets, as the Company&#8217;s foreign IPR&amp;D deferred tax liabilities
and foreign net operating loss deferred tax assets are both indefinite-lived and thus they may be netted to arrive at a net foreign deferred
tax liability. This results in $<span id="xdx_906_eus-gaap--DeferredForeignIncomeTaxExpenseBenefit_iN_di_c20220101__20221231_z4J4CGvC0Ix3" title="Foreign deferred tax benefit">272,000</span> of foreign deferred tax benefit recorded to the income statement in 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Tax Cuts and Jobs Act resulted in significant changes to the treatment of research or experimental (&#8220;R&amp;E&#8221;) expenditures
under Section 174. For tax years beginning after December 31, 2021, taxpayers are required to capitalize and amortize all R&amp;E expenditures
that are paid or incurred in connection with their trade or business which represent costs in the experimental or laboratory sense. Specifically,
costs for U.S. based R&amp;E activities must be amortized over five years and costs for foreign R&amp;E activities must be amortized
over 15 years; both using a midyear convention. The Company has incorporated the impact of this new tax legislation into its 2022 consolidated
financial statements, noting that the impact on the Company&#8217;s consolidated financial statements was immaterial.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
December 31, 2022, the Company has U.S. federal and state net operating loss carryforwards of approximately $<span id="xdx_90B_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_iI_c20221231_zNp7gpV8pwxc" title="Operating loss carryforwards">119,254,000</span> and $<span id="xdx_90B_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_iI_c20211231_zkiPkHs24gWd" title="Operating loss carryforwards">110,227,000</span>,
respectively, which are available to offset future taxable income. U.S. federal and state net operating loss carryovers began to expire
in 2020. As a result of the May 2020 reverse recapitalization, an ownership change has occurred. The Company has not completed an Internal
Revenue Code Section 382 analysis. As a result, there could be substantial limitations on the Company&#8217;s ability to utilize its
pre-ownership change net operating loss and tax credit carryforwards. These substantial limitations may result in both a permanent loss
of certain tax benefits related to net operating loss carryforwards and federal research and development credits, and an annual utilization
limitation. At December 31, 2022, the Company has foreign net operating loss carryforwards of approximately $<span id="xdx_90E_eus-gaap--OperatingLossCarryforwards_iI_c20221231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--ForeignCountryMember_zchcYg8podU9" title="Net operating loss carryforwards">953,000</span>, which are available
to offset future taxable income. Foreign net operating loss carryovers are indefinite lived and do not expire.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company also has research and development credit carryforwards for federal and state tax purposes of approximately $<span id="xdx_90F_eus-gaap--DeferredTaxAssetsTaxCreditCarryforwardsResearch_iI_c20221231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--DomesticCountryMember_zIkejkX2Nh1b" title="Research and development credit carryforwards">5,484,000</span> and $<span id="xdx_90D_eus-gaap--DeferredTaxAssetsTaxCreditCarryforwardsResearch_iI_c20221231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--StateAndLocalJurisdictionMember_z2NHT4EcUhvf" title="Research and development credit carryforwards">2,373,000</span>,
respectively. <span id="xdx_907_eus-gaap--TaxCreditCarryforwardLimitationsOnUse_c20220101__20221231_zfQmsPXr41Me" title="Tax credit carryforward, limitations on use">The research and development credit carryforwards began to expire in 2020 for federal tax purposes and have an indefinite
life for state tax purposes</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">U.S.
income tax has not been recognized on the excess of the amount for financial reporting over the tax basis of investments in foreign subsidiaries
that is indefinitely reinvested outside the United States. This amount becomes taxable upon a repatriation of assets from the subsidiary
or a sale or liquidation of the subsidiary. Determination of the amount of any unrecognized deferred income tax liability on this temporary
difference is not practicable because of the complexities of the hypothetical calculation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company files income tax returns in the U.S. federal jurisdiction and in various states. The Company&#8217;s U.S. federal income tax
returns remain subject to examination by the Internal Revenue Service. The Company&#8217;s California income tax returns remain subject
to examination by the California Franchise Tax Board. Due to net operating losses, research and development credits and other tax credit
carryforwards that may be utilized in future years, all U.S. federal and state tax years are open to examination.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Generally
accepted accounting principles clarify the accounting for uncertainty in income taxes recognized in the Company&#8217;s financial statements
and prescribe thresholds for financial statement recognition and measurement of a tax position taken or expected to be taken in a tax
return, and also provide guidance on de-recognition and measurement of a tax position taken or expected to be taken in a tax return.
The Company adopted these provisions effective April 1, 2009.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company did <span id="xdx_900_eus-gaap--UnrecognizedTaxBenefits_iI_do_c20221231_zM8VQdjlj4b" title="Unrecognized tax benefits"><span id="xdx_90A_eus-gaap--UnrecognizedTaxBenefits_iI_do_c20211231_zIDyRoiZlTKd" title="Unrecognized tax benefits">no</span></span>t have any unrecognized tax benefits as of December 31, 2022 and December 31, 2021 and does not expect this to change significantly
over the next 12 months. In accordance with generally accepted accounting principles, the Company will recognize interest and penalties
accrued on any unrecognized tax benefits as a component of income tax expense. As of December 31, 2022, the Company has not accrued any
interest or penalties related to uncertain tax positions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI https://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140569897327280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUBSEQUENT EVENTS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">SUBSEQUENT EVENTS</a></td>
<td class="text"><p id="xdx_80B_eus-gaap--SubsequentEventsTextBlock_zmFV7KP8YqY9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
18 &#8212; <span id="xdx_82D_z1nZVeCrSx02">SUBSEQUENT EVENTS</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Between
January 9 and 12, 2023 Alpha Capital voluntarily converted $<span id="xdx_906_eus-gaap--DebtInstrumentFaceAmount_iI_c20230112__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zZExaEB2DUH3" title="Debenture voluntarily converted">1,111,078</span>
of its outstanding Senior Convertible Debenture principal into <span id="xdx_90B_eus-gaap--CommonStockDividendsShares_c20230109__20230112__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zmGQ3orIfXSi" title="Shares of common stock">841,726</span>
shares of common stock at a conversion price of $<span id="xdx_90D_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pid_c20230112__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zTTmQBPGRwbe" title="Conversion price">1.32</span>
per share.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 13, 2023, the Company&#8217;s board of directors, as part of certain cost-cutting measures, approved a temporary <span id="xdx_902_ecustom--BaseSalaryPercentage_dp_uPure_c20230113__20230113__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zOqPQRfD2kKa" title="Base salary percentage">20</span>% reduction
to the base salaries of all executive officers of the Company and a <span id="xdx_906_ecustom--AnnualCashCompensation_dp_uPure_c20230113__20230113__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zfYg1rIIZu1j" title="Annual cash compensation">20</span>% reduction to the non-employee directors&#8217; annual cash compensation.
The Company also terminated the employment of certain employees, including its Senior Vice President/Chief Operating Officer and Vice President/Chief Scientific
Officer.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company filed a Notification of Late Filing on Form 12b-25 on March 31, 2023, indicating that the filing of this Annual Report would
be delayed on account of the Company and its registered public accounting firm requiring additional time to complete the
accounting and disclosures related to the Company&#8217;s acquisition of a majority interest in NanoSynex, Ltd., which accounting and disclosures have been included in this
Annual Report. On April 20, 2023, the Company received a notification
letter from the Listing Qualifications Department of Nasdaq indicating that, as a result of the Company&#8217;s delay in filing this
Annual Report, the Company was not in compliance with the timely filing requirements for continued listing under Nasdaq Listing Rule
5250(c)(1). The notification letter has no immediate effect on the listing or trading of the Company&#8217;s common stock on the
Nasdaq Capital Market. The notification letter stated that, under Nasdaq rules, the Company has 60 calendar days, or until June 20,
2023, to submit a plan to regain compliance with Nasdaq&#8217;s continued listing requirements. The Company may also regain
compliance with Nasdaq&#8217;s continued listing requirements at any time before June 20, 2023, by filing this Annual Report with
the SEC, as well as any subsequent periodic financial reports that may become due, and continuing to comply with Nasdaq&#8217;s
other continued listing requirements. The filing of this Annual Report was the Company&#8217;s action to regain
compliance.</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI https://asc.fasb.org/topic&amp;trid=2122774<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6842918&amp;loc=SL6314017-165662<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140569888942608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND ESTIMATES (Policies)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>May 26, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_OrganizationPolicyTextBlock', window );">Organization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p id="xdx_84C_ecustom--OrganizationPolicyTextBlock_zeWI3RRbueC4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86A_z2jwwuWoT1kg">Organization</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Qualigen,
Inc., now a subsidiary of Qualigen Therapeutics, Inc., was incorporated in Minnesota in 1996 to design, develop, manufacture and sell
Physician Office Laboratory (&#8220;POL&#8221;) market quantitative immunoassay diagnostic products for use in physician offices and
other point-of-care settings worldwide, and was reincorporated in Delaware in 1999. In May 2020, Qualigen, Inc. completed a reverse recapitalization
transaction with Ritter Pharmaceuticals, Inc. (&#8220;Ritter&#8221;) and Ritter was renamed Qualigen Therapeutics, Inc. All shares of
Qualigen, Inc.&#8217;s capital stock were exchanged for Qualigen Therapeutics, Inc.&#8217;s capital stock in the merger. Ritter/Qualigen
Therapeutics common stock, which was previously traded on the Nasdaq Capital Market under the ticker symbol &#8220;RTTR,&#8221; commenced
trading on the Nasdaq Capital Market, on a post-reverse-stock-split adjusted basis, under the trading symbol &#8220;QLGN&#8221; on May
26, 2020. Qualigen Therapeutics, Inc. (the &#8220;Company&#8221;) operates in one business segment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">On
May 26, 2022, the Company acquired <span id="xdx_903_eus-gaap--StockIssuedDuringPeriodSharesAcquisitions_c20220524__20220526__us-gaap--BusinessAcquisitionAxis__custom--NanoSynexLtdMember__us-gaap--StatementClassOfStockAxis__custom--SeriesAOnePreferredStockMember_zfMeIdzOzlJa" title="Number of common stock acquired shares">2,232,861</span> shares of Series A-1 Preferred Stock of NanoSynex, Ltd. (&#8220;NanoSynex&#8221;) from Alpha
Capital Anstalt (&#8220;Alpha Capital&#8221;), a related party, in exchange for <span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodSharesAcquisitions_c20220524__20220526__us-gaap--BusinessAcquisitionAxis__custom--NanoSynexLtdMember_zks2Cx6r38pd" title="Number of common stock acquired shares">350,000</span> reverse split adjusted shares of the Company&#8217;s common stock and a prefunded warrant
to purchase <span id="xdx_904_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_c20220526__us-gaap--StatementEquityComponentsAxis__custom--PrefundedWarrantMember_zrdIBprn3PV4" title="Warrants to purchase common stock">331,464 reverse split adjusted shares of the Company&#8217;s common stock at an exercise price of $<span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20220526__us-gaap--StatementEquityComponentsAxis__custom--PrefundedWarrantMember_zHeVCJY9m9L4" title="Class of Warrant or Right, Exercise Price of Warrants or Rights">0.001</span> per share. <span id="xdx_901_eus-gaap--StockholdersEquityReverseStockSplit_c20220525__20220526_zPIU0Z15PR81" title="Reverse split, description">These warrants were subsequently exercised on September 13, 2022</span>. Concurrently with this transaction,
the Company also purchased <span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodSharesAcquisitions_c20220524__20220526__us-gaap--BusinessAcquisitionAxis__custom--NanoSynexLtdMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zotzw9HT11Zf" title="Stock issued during period shares acquisitions">381,786</span> shares of Series B preferred stock from NanoSynex for a total purchase price of $<span id="xdx_909_eus-gaap--StockIssuedDuringPeriodValueAcquisitions_pp0p0_c20220524__20220526__us-gaap--BusinessAcquisitionAxis__custom--NanoSynexLtdMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zdCN0AghKGfa" title="Stock issued during period, value, acquisitions">600,000</span>. The transactions
resulted in the Company acquiring a <span id="xdx_902_eus-gaap--BusinessAcquisitionPercentageOfVotingInterestsAcquired_iI_pid_dp_uPure_c20220526__us-gaap--BusinessAcquisitionAxis__custom--NanoSynexLtdMember_zxyij6GwHYRj" title="Voting interests acquired">52.8</span>% interest in NanoSynex. The Company envisions future synergies from the integration of its own
proprietary results-proven FastPack diagnostics platform with the innovative NanoSynex technology. NanoSynex is a micro-biologics diagnostics
company domiciled in Israel.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p id="xdx_845_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_z1Pi6ADgTcDe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86C_zG5TuUfpYqN8">Basis
of Presentation</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying consolidated financial statements of the Company have been prepared in conformity with accounting principles generally accepted
in the United States of America (&#8220;U.S. GAAP&#8221;), Regulation S-X and rules and regulations of the Securities and Exchange Commission
(&#8220;SEC&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Principles of Consolidation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p id="xdx_844_eus-gaap--ConsolidationPolicyTextBlock_zc9xiQDmxLdj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_865_zMvhOGZXViX">Principles
of Consolidation</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying consolidated financial statements include the accounts of the Company and its majority owned subsidiaries. All intercompany
balances and transactions have been eliminated in consolidation. Any reference in these notes to applicable guidance is meant to refer
to U.S. GAAP. The Company views its operations and manages its business in one operating segment. In general, the functional currency
of the Company and its subsidiaries is the U.S. dollar, however for NanoSynex, the functional currency is the local currency, New Israeli
Shekels (NIS). As such, assets and liabilities for NanoSynex are translated into U.S. dollars and the effects of foreign currency translation
adjustments are reflected as a component of accumulated other comprehensive income within the Company&#8217;s consolidated statements
of changes in stockholders&#8217; equity.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Accounting Estimates</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p id="xdx_84F_eus-gaap--UseOfEstimates_zp75wf8bIeGk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_868_zng6SGdCYpk5">Accounting
Estimates</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management
uses estimates and assumptions in preparing its consolidated financial statements in accordance with U.S. GAAP. Those estimates and assumptions
affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities, and the reported revenues
and expenses. The most significant estimates relate to the estimated fair value of in-process research and development, goodwill, warrant
liabilities, stock-based compensation, amortization and depreciation, inventory reserves, allowances for doubtful accounts and returns,
and warranty costs. Actual results could vary from the estimates that were used.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityReverseStockSplit', window );">Reverse Stock Split</a></td>
<td class="text">These warrants were subsequently exercised on September 13, 2022<span></span>
</td>
<td class="text">Reverse
Stock Split

&#160;

On
November 23, 2022, the Company effected a 1-for-10, as determined by the Company&#8217;s board of directors, reverse stock split of its
outstanding shares of common stock (the &#8220;Reverse Stock Split&#8221;). The Reverse Stock Split reduced the Company&#8217;s shares
of outstanding common stock, stock options, and warrants to purchase shares of our common stock. Fractional shares of common stock that
would have otherwise resulted from the Reverse Stock Split were rounded down to the nearest whole share and cash in lieu of payments
were made to stockholders. All share and per share data for all periods presented in the accompanying financial statements and the related
disclosures have been adjusted retrospectively to reflect the Reverse Stock Split. The number of authorized shares of common stock and
the par value per share remains unchanged.

&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p id="xdx_84F_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_z37X8m4Hmt6e" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86C_zpPLvuZmDhz6">Cash</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company considers all highly liquid investments purchased with an initial maturity of 90 days or less and money market funds to be cash
equivalents. Restricted cash includes cash that is restricted due to Israeli banking regulations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company maintains the majority of its cash in accounts at banking institutions in the U.S. that are of high quality.
Cash held in these accounts often exceed the FDIC insurance limits. If such banking institutions were to fail, the Company could lose
all or a portion of amounts held in excess of such insurance limitations. The FDIC recently took control of two such banking institutions,
Silicon Valley Bank on March 10, 2023 and Signature Bank on March 12, 2023. While the Company did not have an account at either of these two banks, in
the event of failure of any of the financial institutions where the Company maintains its cash and cash equivalents, there can be no
assurance that the Company would be able to access uninsured funds in a timely manner or at all. Any inability to access or delay in
accessing these funds could adversely affect our business and financial position.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryPolicyTextBlock', window );">Inventory, Net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p id="xdx_847_eus-gaap--InventoryPolicyTextBlock_zGf7dL4h9BTf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_866_z33yerdHlCCf">Inventory,
Net</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inventory
is recorded at the lower of cost or net realizable value. Cost is determined using the first-in, first-out method. The Company reviews
the components of its inventory on a periodic basis for excess or obsolete inventory, and records reserves for inventory components identified
as excess or obsolete.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Impairment of Long-Lived Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p id="xdx_848_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_zk9MLFjdKX3c" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_864_zQs6GPn4XfVb">Impairment
of Long-Lived Assets</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company assesses potential impairments to its long-lived assets when there is evidence that events or changes in circumstances indicate
that assets may not be recoverable. An impairment loss would be recognized when the sum of the expected future undiscounted cash flows
is less than the carrying amount of the assets. The amount of impairment loss, if any, will generally be measured as the difference between
the net book value of the assets and their estimated fair values. During the fiscal year ending December 31, 2022 the Company recorded
an impairment loss of $<span id="xdx_907_eus-gaap--AssetImpairmentCharges_c20220101__20221231_z1ZrkrruzaJd" title="Impairment losses on construction-in-progress">4,239,000</span> related to the NanoSynex acquisition.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment Reporting</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p id="xdx_84C_eus-gaap--SegmentReportingPolicyPolicyTextBlock_zZfhfcFxJmJ6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_860_zxtDXJfGGB1e">Segment
Reporting</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating
segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation
by the chief operating decision-maker in making decisions regarding resource allocation and assessing performance. To date, the Company
has viewed its operations and managed its business as one segment operating primarily within the United States and Israel.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TradeAndOtherAccountsReceivablePolicy', window );">Accounts Receivable, Net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p id="xdx_840_eus-gaap--TradeAndOtherAccountsReceivablePolicy_zsaXR112070d" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_865_zY0FbtBxe95i">Accounts
Receivable, Net</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company grants credit to domestic physicians, clinics, and distributors. The Company performs ongoing credit evaluations of its customers
and generally requires no collateral. Customers can purchase certain products through a financing agreement that the Company has with
an outside leasing company. Under the agreement, the leasing company evaluates the credit worthiness of the customer. Upon acceptance
of the product by the customer, the leasing company remits payment to the Company at a discount. This financing arrangement is without
recourse to the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company records an allowance for doubtful accounts and returns equal to the estimated uncollectible amounts or expected returns. The
Company&#8217;s estimates are based on historical collections and returns and a review of the current status of trade accounts receivable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_893_eus-gaap--ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_zQIpz9BhMTj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accounts
receivable is comprised of the following at:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span id="xdx_8B0_zE01wFmfI8La" style="display: none">SCHEDULE
OF ACCOUNTS RECEIVABLE</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_49C_20221231_zvfQMHAuvDj7" style="font-weight: bold; text-align: center">December 31,</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_492_20211231_zxut4lxKKfY1" style="font-weight: bold; text-align: center">December 31,</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--AccountsReceivableGrossCurrent_iI_pp0p0_maARNCz1PU_maARNCzMpq_zouIgJCiaAvj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Accounts Receivable</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">726,449</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">958,448</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--AllowanceForDoubtfulAccountsReceivableCurrent_iNI_pp0p0_di_msARNCz1PU_msARNCzMpq_zKWim65hnST7" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Less Reserves and Allowances</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(187,862</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(136,097</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_40C_eus-gaap--AccountsReceivableNetCurrent_iTI_pp0p0_mtARNCzMpq_zJsnp5ZYOKe2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Accounts receivable,
    net</span></td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">538,587</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">822,351</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A7_zNcz49UOgnh7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p id="xdx_84E_eus-gaap--ResearchAndDevelopmentExpensePolicy_ztMuZpwk3j0d" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86F_z19JFpz1Rujl">Research
and Development</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Except
for acquired in process research and development (IPR&amp;D), the Company expenses research and development costs as incurred including
therapeutics license costs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_ResearchAndDevelopmentGrantsPolicyTextBlock', window );">R&amp;D Grants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p id="xdx_844_ecustom--ResearchAndDevelopmentGrantsPolicyTextBlock_zxQP3l4NISq8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86A_zkHH9mEzbZCg">R&amp;D
Grants</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NanoSynex
has received R&amp;D grants from Israel Innovation Authority (IIA) and from the European Commission. These grants may provide cash funding
to NanoSynex from time to time in advance of the applicable costs being incurred. When such cash funding is received from these grants
in advance, the proceeds are recorded as a current or non-current R&amp;D grant liability based on the time from the consolidated balance
sheets date to the expected future date of recognition as a reduction to research and development expenses.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_PatentCostsPolicyTextBlock', window );">Patent Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p id="xdx_841_ecustom--PatentCostsPolicyTextBlock_zBCruCgfuRp3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_868_z37jRTIWlBl4">Patent
Costs</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company expenses all costs as incurred in connection with patent applications (including direct application fees, and the legal and consulting
expenses related to making such applications) and such costs are included in general and administrative expenses in the consolidated
statement of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_ShippingAndHandlingCostsPolicyTextBlock', window );">Shipping and Handling Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p id="xdx_841_ecustom--ShippingAndHandlingCostsPolicyTextBlock_zwI40cOosWhg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_868_zOB31OSRUN04">Shipping
and Handling Costs</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company includes shipping and handling fees billed to customers in net sales. Shipping and handling costs associated with inbound and
outbound freight are generally recorded in cost of sales; such shipping and handling costs totaled approximately $<span id="xdx_904_eus-gaap--CostOfGoodsAndServicesSold_c20220101__20221231__srt--ProductOrServiceAxis__us-gaap--ShippingAndHandlingMember_zdk8CCBRyhze" title="Cost of Goods and Services Sold">267,000</span> and $<span id="xdx_904_eus-gaap--CostOfGoodsAndServicesSold_c20210101__20211231__srt--ProductOrServiceAxis__us-gaap--ShippingAndHandlingMember_zCWJOmSRtr47" title="Cost of Goods and Services Sold">113,000</span>,
respectively, for the years December 31, 2022 and 2021. Other shipping and handling costs included in general and administrative, research
and development, and sales and marketing expenses totaled approximately $<span id="xdx_901_eus-gaap--CostOfGoodsAndServicesSold_c20220101__20221231__us-gaap--IncomeStatementLocationAxis__custom--GeneralAdministrativeResearchAndDevelopmentExpensesMember_zNAiaPKLGGPg" title="Other shipping and handling costs">14,000</span> and $<span id="xdx_908_eus-gaap--CostOfGoodsAndServicesSold_c20210101__20211231__us-gaap--IncomeStatementLocationAxis__custom--GeneralAdministrativeResearchAndDevelopmentExpensesMember_z9cn1bTADg3d" title="Other shipping and handling costs">12,000</span> for the years ended December 31, 2022 and
2021, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Revenue from Contracts with Customers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p id="xdx_84E_eus-gaap--RevenueRecognitionPolicyTextBlock_zABQ76nng5rl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86B_zk6ye9FRqsz3">Revenue
from Contracts with Customers</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company applies the following five-step model in accordance with ASC 606, Revenue from Contracts with Customers, in order to determine
revenue: (i) identification of the promised goods or services in the contract; (ii) determination of whether the promised goods or services
are performance obligations, including whether they are distinct in the context of the contract; (iii) measurement of the transaction
price, including the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations; and
(v) recognition of revenue when (or as) the Company satisfies each performance obligation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Product
Sales</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company generates revenue from selling FastPack System analyzers, accessories and disposable products used with the FastPack System.
Disposable products include reagent packs, which are diagnostic tests for prostate-specific antigen, testosterone, thyroid disorders,
pregnancy, and Vitamin D.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company provides disposable products and equipment in exchange for consideration, which occurs when a customer submits a purchase order
and the Company provides disposable products and equipment at the agreed upon prices in the invoice. Generally, customers purchase disposable
products using separate purchase orders after the equipment (&#8220;analyzer&#8221;) has been provided to the customer. The initial delivery
of the equipment and reagent packs represents a single performance obligation and is completed upon receipt by the customer. The delivery
of each subsequent individual reagent pack represents a separate performance obligation because the reagent packs are standardized, are
not interrelated in any way, and the customer can benefit from each reagent pack without any other product. There are no significant
discounts, rebates, returns or other forms of variable consideration. Customers are generally required to pay within 30 days.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
performance obligation arising from the delivery of the equipment is satisfied upon the delivery of the equipment to the customer. The
disposable products are shipped Free on Board (&#8220;FOB&#8221;) shipping point. For disposable products that are shipped FOB shipping
point, the customer has the significant risks and rewards of ownership and legal title to the assets when the disposable products leave
the Company&#8217;s shipping facilities, thus the customer obtains control and revenue is recognized at that point in time.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has elected the practical expedient and accounting policy election to account for the shipping and handling as activities to
fulfill the promise to transfer the disposable products and not as a separate performance obligation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s contracts with customers generally have an expected duration of one year or less, and therefore the Company has elected
the practical expedient in ASC 606 to not disclose information about its remaining performance obligations. Any incremental costs to
obtain contracts are recorded as selling, general and administrative expense as incurred due to the short duration of the Company&#8217;s
contracts.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>License
Revenue</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company entered into an out-license agreement with Yi Xin to develop and/or commercialize its products in exchange for nonrefundable
upfront license fees and/or sales-based royalties.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
the license to the Company&#8217;s intellectual property is determined to be distinct from the other performance obligations identified
in the arrangement, the Company recognizes revenue from nonrefundable upfront fees allocated to the license when the license is transferred
to the customer and the customer can benefit from the license. For licenses that are bundled with other performance obligations, management
uses judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is
satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing
revenue from nonrefundable upfront fees. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts
the measure of progress and related revenue recognition. During years ended December 31, 2022 and 2021, the Company recognized license
revenue of approximately $<span id="xdx_90D_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_dxL_c20220101__20221231__srt--ProductOrServiceAxis__custom--LicenseRevenuesMember_zFBg85urxvHl" title="::XDX::-"><span style="-sec-ix-hidden: xdx2ixbrl0752">0</span></span> and $<span id="xdx_90A_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20210101__20211231__srt--ProductOrServiceAxis__custom--LicenseRevenuesMember_zIZj4c0axwf4">632,000</span>, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Contract
Asset and Liability Balances</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
timing of the Company&#8217;s revenue recognition may differ from the timing of payment by the Company&#8217;s customers. The Company
records a receivable when revenue is recognized prior to payment and there is an unconditional right to payment. Alternatively, when
payment precedes the performance of the related services, the Company records deferred revenue until the performance obligations are
satisfied.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Multiple
performance obligations include contracts that combine both the Company&#8217;s analyzer and a customer&#8217;s future reagent purchases
under a single contract. In some sales contracts, the Company provides analyzers at no charge to customers. Title to the analyzer is
maintained by the Company and the analyzer is returned by the customer to the Company at the end of the purchase agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the years December 31, 2022 and 2021, product sales are stated net of an allowance for estimated returns of approximately $<span id="xdx_90F_ecustom--AllowancesForSalesReturn_c20220101__20221231_z3orAMfHfQTa" title="Allowance for estimated returns">96,000</span> and
$<span id="xdx_90C_ecustom--AllowancesForSalesReturn_c20210101__20211231_zplKcwOU6s79" title="Allowance for estimated returns">150,000</span>, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_DeferredRevenuePolicyTextBlock', window );">Deferred Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p id="xdx_84E_ecustom--DeferredRevenuePolicyTextBlock_zoQqOxBjcdPg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86C_zN6oYNVEGld1">Deferred
Revenue</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Payments
received in advance from customers pursuant to certain collaborative research license agreements, deposits against future product sales,
multiple element arrangements and extended warranties are recorded as a current or non-current deferred revenue liability based on the
time from the Consolidated Balance Sheet date to the future date of revenue recognition.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Operating Leases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p id="xdx_848_eus-gaap--LesseeLeasesPolicyTextBlock_zwgVxRU1aNrj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_860_ztpvsNrpeia6">Operating
Leases</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effective
April 1, 2020, the Company adopted Accounting Standards Update (&#8220;ASU&#8221;) No. 2018-11, <i>Leases (Topic 842) Targeted Improvements
</i>(&#8220;Topic 842&#8221;). In accordance with the guidance in Topic 842, the Company recognizes lease liabilities and corresponding
right-of-use-assets for all leases with terms of greater than 12 months. Leases with a term of 12 months or less will be accounted for
in a manner similar to the guidance for operating leases prior to the adoption of Topic 842. (See Note 13-Commitments and Contingencies).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment, Net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p id="xdx_84B_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zxkFwQXeVvI3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86E_zUjoRKE3YoLk">Property
and Equipment, Net</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_89A_ecustom--ScheduleOfUsefulLivesOfPropertyAndEquipmentTableTextBlock_zFBqhrfk1vIi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property
and equipment are stated at cost and are presented net of accumulated depreciation. Depreciation is provided for on a straight-line basis
over the estimated useful lives of the related assets as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span id="xdx_8B2_zAPA13MDyEXg" style="display: none">SCHEDULE
OF USEFUL LIVES OF PROPERTY AND EQUIPMENT</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 77%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Machinery
    and equipment</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 23%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_904_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20220101__20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--MachineryAndEquipmentMember_zqufBTavuQy3" title="Property and equipment, useful life">5</span>
    years</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Computer
    equipment</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_908_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20220101__20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember_zawkBQjlOUM3" title="Property and equipment, useful life">3</span>
    years</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Molds
    and tooling</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90A_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20220101__20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--MoldsAndToolingMember_zIvIh9XUZzWi" title="Property and equipment, useful life">5</span>
    years</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Furniture
    and fixtures</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_906_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20220101__20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_z5DGlGqVKWNg" title="Property and equipment, useful life">5</span>
    years</span></td></tr>
  </table>
<p id="xdx_8A6_zffzxAM1cCy5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Leasehold
improvements are amortized on a straight-line basis over the shorter of the lease term or their estimated useful lives. The Company occasionally
designs and builds its own machinery. The costs of these projects, which includes the cost of construction and other direct costs attributable
to the construction, are capitalized as construction in progress. No provision for depreciation is made on construction in progress until
the relevant assets are completed and placed in service.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s policy is to evaluate the remaining lives and recoverability of long-term assets on at least an annual basis or when
conditions are present that indicate impairment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationsPolicy', window );">Business Combinations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p id="xdx_841_eus-gaap--BusinessCombinationsPolicy_zvdZiwqEUsXg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86F_zfZHqhXQ1spi">Business
Combinations</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounts for business combinations using the acquisition method pursuant to FASB ASC Topic 805. This method requires, among other
things, that results of operations of acquired companies are included in Qualigen&#8217;s financial results beginning on the respective
acquisition dates, and that assets acquired and liabilities assumed and noncontrolling interests are recognized at fair value as of the
acquisition date. Intangible assets acquired in a business combination are recorded at fair value using a discounted cash flow model.
We have third-party valuations completed for intangible assets in a business combination using a discounted cash flow analysis, incorporating
various assumptions. The discounted cash flow model requires assumptions about the timing and amount of future net cash flows, the cost
of capital and terminal values from the perspective of a market participant. Each of these factors can significantly affect the value
of the intangible asset. Any excess of the fair value of consideration transferred (the &#8220;Purchase Price&#8221;) over the fair values
of the net assets acquired is recognized as goodwill. The fair value of assets acquired and liabilities assumed in certain cases may
be subject to revision based on the final determination of fair value during a period of time not to exceed 12 months from the acquisition
date. Legal costs, due diligence costs, business valuation costs and all other acquisition-related costs are expensed when incurred.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p id="xdx_845_eus-gaap--GoodwillAndIntangibleAssetsPolicyTextBlock_zbYKJt4uxjJi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_862_zcL6YjOj8s15">Goodwill</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Goodwill
represents the difference between the purchase price and the fair value of the identifiable tangible and intangible net assets
acquired, when accounted for using the purchase method of accounting. Goodwill has an indefinite useful life and is not amortized
but is reviewed for impairment annually and whenever events or changes in circumstances indicate that the carrying value of the
goodwill may not be recoverable. In testing for impairment, the fair value of the reporting unit is compared to the carrying value.
If the net assets assigned to the reporting unit exceed the fair value of the reporting unit, an impairment loss equal to the
difference is recorded. As a result of the annual goodwill impairment analysis, the Company recognized a $<span id="xdx_905_eus-gaap--GoodwillImpairmentLoss_c20220101__20221231_zPKuBPchBib5" title="Goodwill impairment charges">4,239,000</span>
non-cash goodwill and fixed asset impairment charge in the valuation of its business acquisition of NanoSynex for the year ended
December 30, 2022. For more information, refer to Note 1 - Organization and Summary of Significant Accounting Policies and Estimates
and Note 7 - Goodwill, IPR&amp;D and other Intangibles.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsFiniteLivedPolicy', window );">Intangible Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p id="xdx_844_eus-gaap--IntangibleAssetsFiniteLivedPolicy_zwDMssJ6GRgf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86C_zQvb0w9eUW4c">Intangible
Assets</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>In
Process R&amp;D</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Acquired
in process R&amp;D (IPR&amp;D) represents the fair value assigned to the research and development assets that have not reached technological
feasibility. The value assigned to IPR&amp;D is determined by estimating the costs to develop the acquired technology into commercially
viable products, estimating the resulting revenue from the projects, and discounting the net cash flow to present value. The revenue
and cost projections used to value acquired IPR&amp;D are, as applicable, reduced based on the probability of success of developing the
new product. Additionally, projections consider relevant market sizes and growth factors, expected trends in technology and the nature
and expected timing of new product introductions. The rates utilized to discount the net cash flow to its present value are commensurate
with the stage of development of the project and uncertainties in the economic estimates used in the projections. Upon the acquisition
of acquired IPR&amp;D, an assessment is completed as to whether the acquisition constitutes an acquisition of a single asset or a group
of assets. Multiple factors are considered in this assessment, including the nature of the technology acquired, the presence or absence
of separate cash flows, the development process and stage of completion, quantitative significance, and the Company&#8217;s rationale
for entering into the transaction.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
a business is acquired, as defined under the applicable accounting standards, then the acquired IPR&amp;D is capitalized as an intangible
asset. If an asset or group of assets is acquired that do not meet the definition under the applicable accounting standards, then the
acquired IPR&amp;D is expensed on its acquisition date. Future costs to develop these assets are recorded to research and development
expense in the Company&#8217;s consolidated statements of operations and comprehensive loss as they are incurred.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">IPR&amp;D
is evaluated for impairment annually using the same methodology as described above for calculating fair value. If the carrying value
of the acquired IPR&amp;D exceeds the fair value, then the intangible asset is written down to its fair value, with the resulting adjustment
recorded as a charge to operations. Changes in estimates and assumptions used in determining the fair value of acquired IPR&amp;D could
result in an impairment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Other
Intangible Assets, Net</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
intangible assets consist of patent-related costs and costs for license agreements. Management reviews the carrying value of other intangible
assets that are being amortized on an annual basis or sooner when there is evidence that events or changes in circumstances may indicate
that impairment exists. The Company considers relevant cash flow and profitability information, including estimated future operating
results, trends and other available information, in assessing whether the carrying value of intangible assets being amortized can be
recovered.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
the Company determines that the carrying value of other intangible assets will not be recovered from the undiscounted future cash flows
expected to result from the use and eventual disposition of the underlying assets, the Company considers the carrying value of such intangible
assets as impaired and reduces them by a charge to operations in the amount of the impairment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Costs
related to acquiring patents and licenses are capitalized and amortized over their estimated useful lives, which is generally<span id="xdx_90C_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dtY_c20220101__20221231__srt--RangeAxis__srt--MinimumMember__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PatentsAndLicensesMember_zkxYMMM8Ak3f" title="Estimated useful lives"> 5</span> to <span id="xdx_902_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dtY_c20220101__20221231__srt--RangeAxis__srt--MaximumMember__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PatentsAndLicensesMember_zWMNAhPGgml7" title="Estimated useful lives">17</span>
years, using the straight-line method. Amortization of patents and licenses commences once final approval of the patent or license has
been obtained. Patent and license costs are charged to operations if it is determined that the patent or license will not be obtained.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_DerivativeFinancialInstrumentsAndWarrantLiabilitiesPolicyTextBlock', window );">Derivative Financial Instruments and Warrant Liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p id="xdx_84A_ecustom--DerivativeFinancialInstrumentsAndWarrantLiabilitiesPolicyTextBlock_zYk7vHQpnWp7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86A_zNtcOzvKQ3g7">Derivative
Financial Instruments and Warrant Liabilities</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company does not use derivative instruments to hedge exposures to cash flow, market, or foreign currency risks. The Company evaluates
all of its financial instruments, including issued stock purchase warrants, to determine if such instruments are derivatives or contain
features that qualify as embedded derivatives. For derivative financial instruments that are accounted for as liabilities, the derivative
instrument is initially recorded at its fair value and is then re-valued at each reporting date, with changes in the fair value reported
in the consolidated statements of operations and comprehensive loss. Depending on the features of the derivative financial instrument,
the Company uses either the Black-Scholes option-pricing model or a Monte-Carlo simulation to value the derivative instruments at inception
and subsequent valuation dates. The classification of derivative instruments, including whether such instruments should be recorded as
liabilities or as equity, is re-assessed at the end of each reporting period (See Note 10-Warrant Liabilities and Note 11- Convertible
Debt - Related Party).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Fair
Value Measurements</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company determines the fair value measurements of applicable assets and liabilities based on a three-tier fair value hierarchy established
by accounting guidance and prioritizes the inputs used in measuring fair value. The Company discloses and recognizes the fair value of
its assets and liabilities using a hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy
gives the highest priority to valuations based upon unadjusted quoted prices in active markets for identical assets or liabilities (Level
1 measurements) and the lowest priority to valuations based upon unobservable inputs that are significant to the valuation (Level 3 measurements).
The guidance establishes three levels of the fair value hierarchy as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
                                            1 - Inputs that reflect unadjusted quoted prices in active markets for identical assets or
                                            liabilities that the Company has the ability to access at the measurement date;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
                                            2 - Inputs other than quoted prices that are observable for the assets or liability either
                                            directly or indirectly, including inputs in markets that are not considered to be active;
                                            and</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
                                            3 - Inputs that are unobservable.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value of Financial Instruments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p id="xdx_84D_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zP6ZVVYW4Vx8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_861_z3ymfQ7hS3v4">Fair
Value of Financial Instruments</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash,
accounts receivable, prepaids, accounts payable, and accrued liabilities are carried at cost, which management believes approximates
fair value due to the short-term nature of these instruments.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdvertisingCostsPolicyTextBlock', window );">Advertising</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p id="xdx_840_eus-gaap--AdvertisingCostsPolicyTextBlock_zYVNkMB16xgf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_867_zXo6xMwPUfAi">Advertising</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Advertising
expense consists primarily of print and digital media promotional materials for a distributor. Advertising costs are expensed as incurred.
Advertising expense for the years ended December 31, 2022 and 2021 amounted to $<span id="xdx_90B_eus-gaap--AdvertisingExpense_c20220101__20221231_zbt2JY0VnqH" title="Advertising expense">50,000</span> and $<span id="xdx_90C_eus-gaap--AdvertisingExpense_c20210101__20211231_zSf9jmc2eJw7" title="Advertising expense">0</span>, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock', window );">Comprehensive Loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p id="xdx_845_eus-gaap--ComprehensiveIncomePolicyPolicyTextBlock_zaraFTgm9v08" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_862_zP4m4XVUM4R">Comprehensive
Loss</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Comprehensive
loss consists of net income and foreign currency translation adjustments. Comprehensive gains (losses) have been reflected in the statements
of operations and comprehensive loss and as a separate component in the statements of stockholders&#8217; equity for all periods presented.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationRelatedCostsPolicyTextBlock', window );">Stock-Based Compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p id="xdx_84B_eus-gaap--CompensationRelatedCostsPolicyTextBlock_zuMCtZNK0dV" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86B_z93HuhI6ZM32">Stock-Based
Compensation</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock-based
compensation cost for equity awards granted to employees and non-employees is measured at the grant date based on the calculated fair
value of the award using the Black-Scholes option-pricing model, and is recognized as an expense, under the straight-line method, over
the requisite service period (generally the vesting period of the equity grant). If the Company determines that other methods are more
reasonable, or other methods for calculating these assumptions are prescribed by regulators, the fair value calculated for the Company&#8217;s
stock options could change significantly. Higher volatility, lower risk-free interest rates, and longer expected lives would result in
an increase to stock-based compensation expense to employees and non-employees determined at the date of grant.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p id="xdx_84C_eus-gaap--IncomeTaxPolicyTextBlock_z0GYTOjzvE98" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86B_zajN575xWrPk">Income
Taxes</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deferred
income taxes are recognized for temporary differences in the basis of assets and liabilities for financial statement and income tax reporting
that arise due to net operating loss carry forwards, research and development credit carry forwards and from using different methods
and periods to calculate depreciation and amortization, allowance for doubtful accounts, accrued vacation, research and development expenses,
and state taxes. A provision has been made for income taxes due on taxable income and for the deferred taxes on the temporary differences.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deferred
tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion or all
of the deferred tax assets will not be realized. Deferred tax assets and liabilities are adjusted for the effects of changes in tax laws
and rates on the date of enactment. Realization of the deferred income tax asset is dependent on generating sufficient taxable income
in future years. For more information, refer to Note 17-Income Taxes.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_SalesAndExciseTaxesPolicyTextBlock', window );">Sales and Excise Taxes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p id="xdx_841_ecustom--SalesAndExciseTaxesPolicyTextBlock_zFjBkSfE43Z" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86C_zJc7M9MEsVh2">Sales
and Excise Taxes</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sales
and other taxes collected from customers and subsequently remitted to government authorities are recorded as accounts receivable with
corresponding tax payable. These balances are removed from the consolidated balance sheet as cash is collected from customers and remitted
to the tax authority.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_WarrantyReservePolicyTextBlock', window );">Warranty Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p id="xdx_84B_ecustom--WarrantyReservePolicyTextBlock_zuXhILNGtyr7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86F_zZFzrwafMcV7">Warranty
Costs</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s warranty policy generally provides for one year of coverage against defects and nonperformance within published specifications
for sold analyzers and for the term of the contract for equipment held for lease. The Company accrues for estimated warranty costs in
the period in which the revenue is recognized based on historical data and the Company&#8217;s best estimates of analyzer failure rates
and costs to repair.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accrued
warranty liabilities were approximately $<span id="xdx_901_eus-gaap--ProductWarrantyAccrual_iI_c20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zYMTyRdVoxbf" title="Accrued warranty liabilities">138,000</span> and $<span id="xdx_90E_eus-gaap--ProductWarrantyAccrual_iI_c20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z5rpvRsY2Bhe" title="Accrued warranty liabilities">60,000</span>, respectively, at December 31, 2022 and December 31, 2021 and are included
in accrued expenses and other current liabilities on the Consolidated Balance Sheets. Warranty costs were approximately $<span id="xdx_908_eus-gaap--ProductWarrantyExpense_c20220101__20221231_zjAeybIH7LRb" title="Warranty costs">69,000</span> and $<span id="xdx_90C_eus-gaap--ProductWarrantyExpense_c20210101__20211231_zgQ7NMp3UHI6" title="Warranty costs">57,000</span>
for the years ended December 31, 2022 and 2021, respectively, and are included in cost of product sales in the Consolidated Statements
of Operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock', window );">Foreign Currency Translation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p id="xdx_84D_eus-gaap--ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_zQ6eZKfREUnf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_861_zr4gZVO6OLT1">Foreign
Currency Translation</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
functional currency for the Company is the U.S. dollar. The functional currency for NanoSynex, the Company&#8217;s newly acquired majority
owned subsidiary, is the New Israeli Shekel (NIS). The financial statements of NanoSynex are translated into U.S. dollars using exchange
rates in effect at each period end for assets and liabilities; using exchange rates in effect during the period for results of operations;
and using historical exchange rates for certain equity accounts. The adjustment resulting from translating the financial statements of
NanoSynex is reflected as a separate component of other comprehensive income (loss).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
comprehensive loss related to the effects of foreign currency translation adjustments attributable to NanoSynex was $<span id="xdx_901_eus-gaap--OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_c20220101__20221231__us-gaap--BusinessAcquisitionAxis__custom--NanoSynexLtdMember_zdomOdXwjkPi" title="Adjustment net of tax">50,721</span> and $<span id="xdx_900_eus-gaap--OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_c20210101__20211231__us-gaap--BusinessAcquisitionAxis__custom--NanoSynexLtdMember_znsm1pjH0QU7" title="Adjustment net of tax">0</span> at
December 31, 2022 and 2021, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p id="xdx_844_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zIJBrwoB7uI3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86E_zP8oTscRYrR2">Recent
Accounting Pronouncements</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
June 2016, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued ASU No. 2016-13, <i>Measurement of Credit Losses on Financial
Instruments</i>, which supersedes current guidance by requiring recognition of credit losses when it is probable that a loss has been
incurred. The new standard requires the establishment of an allowance for estimated credit losses on financial assets including trade
and other receivables at each reporting date. The new standard will result in earlier recognition of allowances for losses on trade and
other receivables and other contractual rights to receive cash. In November 2019, the FASB issued ASU No. 2019-10, <i>Financial Instruments
&#8211; Credit Losses (Topic 326), Derivatives and Hedging (Topic 815) </i>and <i>Leases (Topic 842)</i>, which extended the effective
date of Topic 326 for certain companies until fiscal years beginning after December 15, 2022. The new standard will be effective for
the Company in the first quarter of fiscal year beginning January 1, 2023, and early adoption is permitted. The Company adopted ASU 2016-13
on January 1, 2023. Adoption did not have a material impact on the Company&#8217;s consolidated financial statements and related disclosures.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_GlobalEconomicConditionsPolicyTextBlock', window );">Global Economic Conditions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p id="xdx_84A_ecustom--GlobalEconomicConditionsPolicyTextBlock_z9Nrhk6J8AMl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86D_zY9GyuybJgi8">Global
Economic Conditions</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>War
in Ukraine</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
February 2022, Russia invaded Ukraine. While the Company has no direct exposure in Russia and Ukraine, the Company continues to monitor
any broader impact to the global economy, including with respect to inflation, supply chains and fuel prices. The full impact of the
conflict on the Company&#8217;s business and financial results remains uncertain and will depend on the severity and duration of the
conflict and its impact on regional and global economic conditions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Inflationary
Cost Environment</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year ended 2022 and continuing into the current fiscal year, global commodity and labor markets experienced significant inflationary
pressures attributable to ongoing economic recovery and supply chain issues. The Company is subject to inflationary pressures with respect
to raw materials, labor and transportation. Accordingly, the Company continues to take actions with its customers and suppliers to mitigate
the impact of these inflationary pressures in the future. Actions to mitigate inflationary pressures with suppliers include aggregation
of purchase requirements to achieve optimal volume benefits, negotiation of cost-reductions and identification of more cost competitive
suppliers. While these actions are designed to offset the impact of inflationary pressures, the Company cannot provide assurance that
it will be successful in fully offsetting increased costs resulting from inflationary pressure.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Impact of
COVID-19 Pandemic</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
COVID-19 pandemic has had a dramatic impact on businesses globally and on the Company&#8217;s business as well. Sales of diagnostic products
fell significantly during 2020 and the Company&#8217;s net loss increased significantly, as deferral of patients&#8217; non-emergency
visits to physician offices, clinics and small hospitals sharply reduced demand for FastPack tests. Since then we have experienced some recovery in demand.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
accounting standard updates are either not applicable to the Company or are not expected to have a material impact on the Company&#8217;s
consolidated financial statements.</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_DeferredRevenuePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Revenue Policy [TextBlock]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_DeferredRevenuePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_DerivativeFinancialInstrumentsAndWarrantLiabilitiesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Derivative Financial Instruments And Warrant Liabilities [Policy TextBlock]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_DerivativeFinancialInstrumentsAndWarrantLiabilitiesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_GlobalEconomicConditionsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Global Economic Conditions [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_GlobalEconomicConditionsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_OrganizationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Organization Policy [TextBlock]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_OrganizationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_PatentCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Patent Costs Policy [TextBlock]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_PatentCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_ResearchAndDevelopmentGrantsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Research And Development Grants Policy [TextBlock]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_ResearchAndDevelopmentGrantsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_SalesAndExciseTaxesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sales And Excise Taxes [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_SalesAndExciseTaxesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_ShippingAndHandlingCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Shipping And Handling Costs Policy [TextBlock]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_ShippingAndHandlingCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_WarrantyReservePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warranty Reserve [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_WarrantyReservePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdvertisingCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for advertising cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 720<br> -SubTopic 35<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6420018&amp;loc=d3e36677-107848<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdvertisingCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -Subparagraph (a)-(d)<br> -URI https://asc.fasb.org/extlink&amp;oid=6909625&amp;loc=d3e227-128457<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4273-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationRelatedCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationRelatedCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomePolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=d3e5614-111684<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 60<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=7493716&amp;loc=d3e21868-110260<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13279-108611<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -URI https://asc.fasb.org/topic&amp;trid=2175825<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for goodwill and intangible assets. This accounting policy also may address how an entity assesses and measures impairment of goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=109226317&amp;loc=d3e202-110218<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -URI https://asc.fasb.org/extlink&amp;oid=27011434&amp;loc=d3e125687-122742<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32247-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32847-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32840-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL116659661-227067<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32280-109318<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsFiniteLivedPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for finite-lived intangible assets. This accounting policy also might address: (1) the amortization method used; (2) the useful lives of such assets; and (3) how the entity assesses and measures impairment of such assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 920<br> -SubTopic 350<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=120155617&amp;loc=SL120155638-234783<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 920<br> -SubTopic 350<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=120155617&amp;loc=SL120155628-234783<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 920<br> -SubTopic 350<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=120155617&amp;loc=SL120155628-234783<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsFiniteLivedPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4556-108314<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI https://asc.fasb.org/topic&amp;trid=2126998<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 330<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6471895&amp;loc=d3e55923-109411<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4492-108314<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126900757&amp;loc=d3e543-108305<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918666-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99779-112916<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99893-112916<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityReverseStockSplit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB Topic 4.C)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187143-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityReverseStockSplit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TradeAndOtherAccountsReceivablePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e4975-111524<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5212-111524<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=SL6953423-111524<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5093-111524<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5033-111524<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=84159169&amp;loc=d3e10133-111534<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TradeAndOtherAccountsReceivablePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140569897272320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND ESTIMATES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock', window );">SCHEDULE OF ACCOUNTS RECEIVABLE</a></td>
<td class="text"><p id="xdx_893_eus-gaap--ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_zQIpz9BhMTj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accounts
receivable is comprised of the following at:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span id="xdx_8B0_zE01wFmfI8La" style="display: none">SCHEDULE
OF ACCOUNTS RECEIVABLE</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_49C_20221231_zvfQMHAuvDj7" style="font-weight: bold; text-align: center">December 31,</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_492_20211231_zxut4lxKKfY1" style="font-weight: bold; text-align: center">December 31,</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--AccountsReceivableGrossCurrent_iI_pp0p0_maARNCz1PU_maARNCzMpq_zouIgJCiaAvj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Accounts Receivable</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">726,449</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">958,448</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--AllowanceForDoubtfulAccountsReceivableCurrent_iNI_pp0p0_di_msARNCz1PU_msARNCzMpq_zKWim65hnST7" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Less Reserves and Allowances</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(187,862</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(136,097</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_40C_eus-gaap--AccountsReceivableNetCurrent_iTI_pp0p0_mtARNCzMpq_zJsnp5ZYOKe2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Accounts receivable,
    net</span></td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">538,587</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">822,351</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_ScheduleOfUsefulLivesOfPropertyAndEquipmentTableTextBlock', window );">SCHEDULE OF USEFUL LIVES OF PROPERTY AND EQUIPMENT</a></td>
<td class="text"><p id="xdx_89A_ecustom--ScheduleOfUsefulLivesOfPropertyAndEquipmentTableTextBlock_zFBqhrfk1vIi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property
and equipment are stated at cost and are presented net of accumulated depreciation. Depreciation is provided for on a straight-line basis
over the estimated useful lives of the related assets as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span id="xdx_8B2_zAPA13MDyEXg" style="display: none">SCHEDULE
OF USEFUL LIVES OF PROPERTY AND EQUIPMENT</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 77%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Machinery
    and equipment</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 23%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_904_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20220101__20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--MachineryAndEquipmentMember_zqufBTavuQy3" title="Property and equipment, useful life">5</span>
    years</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Computer
    equipment</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_908_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20220101__20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember_zawkBQjlOUM3" title="Property and equipment, useful life">3</span>
    years</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Molds
    and tooling</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90A_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20220101__20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--MoldsAndToolingMember_zIvIh9XUZzWi" title="Property and equipment, useful life">5</span>
    years</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Furniture
    and fixtures</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_906_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20220101__20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_z5DGlGqVKWNg" title="Property and equipment, useful life">5</span>
    years</span></td></tr>
  </table>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_ScheduleOfUsefulLivesOfPropertyAndEquipmentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule Of Useful Lives Of Property And Equipment [Table TextBlock]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_ScheduleOfUsefulLivesOfPropertyAndEquipmentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the various types of trade accounts and notes receivable and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.3,4)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140569892275664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ACQUISITION (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract', window );"><strong>Business Combination and Asset Acquisition [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock', window );">SCHEDULE OF CONSIDERATION TRANSFERRED</a></td>
<td class="text"><p id="xdx_890_eus-gaap--ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_zOsbLs4POgyk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
summary of the consideration transferred and fair value of assets acquired and liabilities assumed in the NanoSynex Acquisition is as
follows (all shares shown post 1 for 10 reverse split on November 23, 2022):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B8_zhGesOfCesRi" style="display: none">SCHEDULE
OF CONSIDERATION TRANSFERRED</span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Consideration transferred, net of cash acquired</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 80%; text-align: left; padding-bottom: 1.5pt">Cash paid for NanoSynex preferred stock:</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td id="xdx_986_ecustom--PaymentsToAcquireBusinesses_pp0p0_c20220524__20220526__us-gaap--BusinessAcquisitionAxis__custom--NanoSynexLtdMember_zs1OfV4i1qV1" style="border-bottom: Black 1.5pt solid; width: 16%; text-align: right" title="Cash paid for NanoSynex preferred stock:">600,000</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">FMV of <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIENPTlNJREVSQVRJT04gVFJBTlNGRVJSRUQgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_905_eus-gaap--StockIssuedDuringPeriodSharesAcquisitions_c20220524__20220526__us-gaap--BusinessAcquisitionAxis__custom--NanoSynexLtdMember_zkEfDIX9oqbc" title="Common stock issued for business acquisition">350,000</span> shares of Qualigen stock issued to Alpha Capital Anstalt</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_987_eus-gaap--StockIssuedDuringPeriodValueAcquisitions_pp0p0_c20220524__20220526__us-gaap--BusinessAcquisitionAxis__custom--NanoSynexLtdMember_zxs0bN5NF5Ui" style="text-align: right" title="FMV of 3,500,000 shares of Qualigen stock issued to Alpha Capital Anstalt">1,904,989</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">FMV of <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIENPTlNJREVSQVRJT04gVFJBTlNGRVJSRUQgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90F_eus-gaap--StockIssuedDuringPeriodSharesAcquisitions_c20220524__20220526__us-gaap--BusinessAcquisitionAxis__custom--AlphaCapitalAnstaltMember_zdIwRg5Vz5Jl" title="Common stock issued for business acquisition">331,464</span>
    shares of Qualigen stock related to prefunded warrant issued to Alpha Capital Anstalt (See Note 15)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td id="xdx_986_ecustom--PrefundedWarrantsIssuedForBusinessAcquisition_pp0p0_c20220524__20220526__us-gaap--BusinessAcquisitionAxis__custom--NanoSynexLtdMember_zjG0dIRqPrIe" style="border-bottom: Black 1.5pt solid; text-align: right" title="FMV of 3,314,641 shares of Qualigen stock related to prefunded warrant issued to Alpha Capital Anstalt">1,804,102</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Total consideration paid for NanoSynex preferred stock</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td id="xdx_982_eus-gaap--BusinessCombinationConsiderationTransferred1_pp0p0_c20220524__20220526__us-gaap--BusinessAcquisitionAxis__custom--NanoSynexLtdMember_zf0PuKozuuF2" style="border-bottom: Black 1.5pt solid; text-align: right" title="Total consideration paid for NanoSynex common stock">3,709,091</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td id="xdx_F47_zewy4rTtnOag" style="text-align: left; padding-bottom: 1.5pt">FMV of consideration related to related to repricing of <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIENPTlNJREVSQVRJT04gVFJBTlNGRVJSRUQgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesAcquisitions_c20220524__20220526_zZyBkxTCAyp7" title="Common stock issued for business acquisition">7,048</span> shares of Alpha Capital/Qualigen warrants *</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td id="xdx_98E_ecustom--FairValueOfWarrantModificationForBusinessAcquisition_pp0p0_c20220524__20220526__us-gaap--BusinessAcquisitionAxis__custom--NanoSynexLtdMember_fKg_____zeuMe7mz3ow5" style="border-bottom: Black 1.5pt solid; text-align: right" title="FMV of consideration related to related to repricing of 70,478 shares of Alpha Capital/Qualigen warrants *">696</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">NanoSynex cash acquired</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--CashAcquiredFromAcquisition_iN_pp0p0_di_c20220524__20220526__us-gaap--BusinessAcquisitionAxis__custom--NanoSynexLtdMember_zdeO6GLj5Olf" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right" title="NanoSynex cash acquired">(735,354</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Total consideration transferred, net of cash acquired</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td id="xdx_98B_eus-gaap--PaymentsToAcquireBusinessesNetOfCashAcquired_pp0p0_c20220524__20220526__us-gaap--BusinessAcquisitionAxis__custom--NanoSynexLtdMember_z9onq8HthZe4" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right" title="Total consideration transferred, net of cash acquired">3,574,433</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td id="xdx_F01_zHAnwfOGCQR6" style="width: 15pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="text-align: justify"><span id="xdx_F19_z5NxVo6luna4" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">See disclosure
under <i>Noncompensatory Equity Classified Warrants</i> regarding May 26, 2022 transaction-Note 15-Stockholders&#8217; Equity</span></td>
</tr></table>


<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock', window );">SCHEDULE OF ASSETS ACQUIRED AND LIABILITIES</a></td>
<td class="text"><p id="xdx_892_eus-gaap--ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_zZYSY9jhcOy9" style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B2_zP1gRBl98nNb" style="display: none">SCHEDULE
OF ASSETS ACQUIRED AND LIABILITIES</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_497_20220526_zyjYIFjvvDcl" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Purchase Price Allocation</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_iI_ziI0KgaE9ZF" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; width: 80%; text-align: left">Accounts receivable</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">75,336</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_iI_z9T12KJnysSj" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Property and equipment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">120,942</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_ecustom--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedResearchAndDevelopmentExpense_iI_zHDGLPvjxUth" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">In process R&amp;D</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,700,000</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_iNI_di_zDPdWepmReW9" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Accounts payable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(4,588</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40A_ecustom--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpensesAndOtherPayables_iI_zTQOiTkoF3m4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Accrued expenses and other payables</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(291,093</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_409_ecustom--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedResearchAndDevelopmentGrantLiability_iI_z3fOD7mPKuek" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">R&amp;D grant liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,362,264</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40E_ecustom--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesShortTermDebt_iI_zYMnPbk7tEMk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Short term debt</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(941,898</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40A_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_iNI_di_zuieaCdeGej4" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Deferred tax liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(629,379</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40B_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedLessNoncontrollingInterest_iI_zGNbjPAzXf98" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Noncontrolling interest assumed</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(3,882,225</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_40F_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_iNI_di_z8X9huu3FFX4" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left">Identifiable net assets acquired</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,215,169</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40E_eus-gaap--Goodwill_iI_zm5gS7WIrxP2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; padding-bottom: 1.5pt">Goodwill</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">4,789,602</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_iI_zQUA13f31O1e" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Total consideration transferred, net of cash acquired</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">3,574,433</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionProFormaInformationTextBlock', window );">SCHEDULE OF PRO FORMA INFORMATION</a></td>
<td class="text"><p id="xdx_89D_eus-gaap--BusinessAcquisitionProFormaInformationTextBlock_zXMOHqz5Mwlb" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BD_zFvG4O9lWCI5" style="display: none">SCHEDULE
OF PRO FORMA INFORMATION</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center">Consolidated Pro Forma Financial</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center">Results for the Years Ending</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Net revenue</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98B_eus-gaap--BusinessAcquisitionsProFormaRevenue_c20220101__20221231_zzNPb9cAfb91" style="width: 16%; text-align: right" title="Business acquisitions pro forma revenue">4,983,556</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_986_eus-gaap--BusinessAcquisitionsProFormaRevenue_c20210101__20211231_znICUMbVL3Gd" style="width: 16%; text-align: right" title="Business acquisitions pro forma revenue">5,653,725</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Net loss attributable to Qualigen Therapeutics, Inc.</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98F_eus-gaap--BusinessAcquisitionsProFormaNetIncomeLoss_c20220101__20221231_z8b3BcgWawu2" style="text-align: right" title="Business acquisitions pro forma net income loss">(19,538,959</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_986_eus-gaap--BusinessAcquisitionsProFormaNetIncomeLoss_c20210101__20211231_zqf918hBz2tg" style="text-align: right" title="Business acquisitions pro forma net income loss">(17,897,137</td><td style="text-align: left">)</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionProFormaInformationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of pro forma results of operations for a material business acquisition or series of individually immaterial business acquisitions that are material in the aggregate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionProFormaInformationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationAndAssetAcquisitionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of a material business combination completed during the period, including background, timing, and recognized assets and liabilities. This table does not include leveraged buyouts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1486-128463<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140569897409712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INVENTORY, NET (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">SCHEDULE OF INVENTORY</a></td>
<td class="text"><p id="xdx_89A_eus-gaap--ScheduleOfInventoryCurrentTableTextBlock_zBA3nzCi8nXf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inventory,
net consisted of the following at December 31, 2022 and December 31, 2021:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B4_zl936wY2g2zk" style="display: none">SCHEDULE OF INVENTORY</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49D_20221231_zPIw4EdGbJF5" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31,<br/>
 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_492_20211231_zBFmkgZkZj17" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31,<br/>
 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--InventoryRawMaterials_iI_maIFGz0my_ztIAItWFXVpe" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Raw materials</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">949,796</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">823,315</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--InventoryWorkInProcess_iI_maIFGz0my_zqzR4p4q4kz6" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Work in process</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">200,318</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">188,135</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--InventoryFinishedGoods_iI_maIFGz0my_zOgIAUswNtX7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Finished goods</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">436,183</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">44,428</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--InventoryNet_iTI_mtIFGz0my_zzqttACnIBTg" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Total inventory</span></td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,586,297</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,055,878</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140569897315408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PREPAID EXPENSES AND OTHER CURRENT ASSETS (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_DisclosurePrepaidExpensesAndOtherCurrentAssetsAbstract', window );"><strong>Prepaid Expenses And Other Current Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock', window );">SCHEDULE OF PREPAID EXPENSES AND OTHER CURRENT ASSETS</a></td>
<td class="text"><p id="xdx_896_eus-gaap--DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_zbCZypHtjnw1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prepaid
expenses and other current assets consisted of the following at December 31, 2022 and December 31, 2021:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B4_z8X22FW3VM7h" style="display: none">SCHEDULE OF PREPAID EXPENSES AND OTHER CURRENT ASSETS</span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_493_20221231_zz71PbAaF8C8" style="font-weight: bold; text-align: center">December 31,</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_49B_20211231_zTidS1QDTV7a" style="font-weight: bold; text-align: center">December 31,</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--PrepaidInsurance_iI_pp0p0_maPECzoJ5_zBmCuDbCnSld" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Prepaid insurance</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">1,377,323</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">1,197,726</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_ecustom--PrepaidManufacturingExpenses_iI_maPECzoJ5_zOVYhOPv484d" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Prepaid manufacturing expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">43,820</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">67,410</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--OtherPrepaidExpenseCurrent_iI_pp0p0_maPECzoJ5_zuORQtWfNO6h" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Other prepaid expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">227,451</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">111,183</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--OtherAssetsCurrent_iI_pp0p0_maPECzoJ5_zYtyYb3022Ri" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Other current assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">12,626</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">3,577</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_iTI_pp0p0_mtPECzoJ5_znJgfhRZQd8f" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Prepaid expenses and
    other current assets</span></td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,661,220</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,379,896</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_DisclosurePrepaidExpensesAndOtherCurrentAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_DisclosurePrepaidExpensesAndOtherCurrentAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140569892288784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PROPERTY AND EQUIPMENT, NET (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">SCHEDULE OF PROPERTY AND EQUIPMENT</a></td>
<td class="text"><p id="xdx_896_eus-gaap--PropertyPlantAndEquipmentTextBlock_zwUq8vngJ0o6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property
and equipment, net consisted of the following at December 31, 2022 and December 31, 2021:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span id="xdx_8B7_zwHYaspSTkb4" style="display: none">SCHEDULE OF PROPERTY AND EQUIPMENT</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_49F_20221231_zJU1p80YDKNl" style="font-weight: bold; text-align: center">December 31,</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_497_20211231_zgVH9Cax4sOc" style="font-weight: bold; text-align: center">December 31,</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--PropertyPlantAndEquipmentGross_iI_pp0p0_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--MachineryAndEquipmentMember_zpueYdQY8YF8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Machinery and equipment</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">2,510,148</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">2,482,841</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--PropertyPlantAndEquipmentGross_iI_pp0p0_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember_zSOYXrFAcKA9" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Computer equipment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">395,836</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">345,117</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--PropertyPlantAndEquipmentGross_iI_pp0p0_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zOCk7Ja6f9A1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Leasehold improvements</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">333,271</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">333,271</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--PropertyPlantAndEquipmentGross_iI_pp0p0_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--MoldsAndToolingMember_zT1y1bTnjWfh" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Molds and tooling</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">260,002</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">260,002</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--PropertyPlantAndEquipmentGross_iI_pp0p0_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_zd9DJwDk3yI4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Furniture and fixtures</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">144,832</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">143,013</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--PropertyPlantAndEquipmentGross_iI_pp0p0_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--EquipmentMember_zP3Rohjc16D" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Equipment held for lease</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,399,444</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,181,211</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--PropertyPlantAndEquipmentGross_iI_ze0HrC0A1zqf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Property and equipment, gross</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,043,533</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,745,455</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_di_msPPAENzZdO_zYseZPs8KDK7" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Accumulated depreciation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(4,623,446</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(4,541,238</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_402_ecustom--FixedAssetImpairments_iI_msPPAENzZdO_zA9FKaxLJSac" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Fixed asset impairment</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(75,000</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0996">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--PropertyPlantAndEquipmentNet_iI_zsy8xKqFo83a" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Property and equipment,
    net</span></td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">345,087</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">204,217</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140569887673776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>GOODWILL, IPR&amp;D AND OTHER INTANGIBLES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock', window );">SCHEDULE OF GOODWILL AND OTHER INTANGIBLE</a></td>
<td class="text"><p id="xdx_890_eus-gaap--ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_zb1Z4BLWS9rd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span id="xdx_8BC_zBUOXlS71fsg" style="display: none">SCHEDULE
OF GOODWILL AND OTHER INTANGIBLE</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_496_20221231_zdHCMRDRg7f7" style="font-weight: bold; text-align: center">December 31,</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_495_20211231_z5dz6BcG59Sg" style="font-weight: bold; text-align: center">December 31,</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">2022</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">2021</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Estimated Useful Lives</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Gross carrying amounts</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Gross carrying amounts</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--Goodwill_iI_zXcKA7UVsgHf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 48%; padding-bottom: 2.5pt">Goodwill</td><td style="width: 2%; padding-bottom: 2.5pt">&#160;</td>
    <td style="width: 14%; padding-bottom: 2.5pt">&#160;</td><td style="width: 2%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 14%; text-align: right">625,602</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 14%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1012">&#8212;</span></td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: center">&#160;</td><td>&#160;</td>
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Finite-lived intangible assets:</td><td>&#160;</td>
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_hus-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--DevelopedProductTechnologyRightsMember_zWed598pIel5" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Developed-product-technology rights</td><td>&#160;</td>
    <td style="text-align: center"><span id="xdx_906_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dtY_c20220101__20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--DevelopedProductTechnologyRightsMember__srt--RangeAxis__srt--MinimumMember_zaqWF5dt3oFl" title="Finite lived intangible asset useful life">8</span> - <span id="xdx_909_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dtY_c20220101__20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--DevelopedProductTechnologyRightsMember__srt--RangeAxis__srt--MaximumMember_z6JFgJEVb2zg" title="Finite lived intangible asset useful life">17</span> years</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">479,103</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">479,103</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_hus-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LicensingRightsMember_z4iPpECocP7a" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Licensing rights</td><td>&#160;</td>
    <td style="text-align: center"><span id="xdx_905_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dtY_c20220101__20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LicensingRightsMember_z4fGm9PcNJgb" title="Finite lived intangible asset useful life">10</span> years</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">418,836</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">418,836</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iNI_di_zCWaIq8XEbjl" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Less: Accumulated amortization</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(752,237</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(726,749</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_403_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_zKjOgTu1Ams7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Total finite-lived intangible assets, net</td><td>&#160;</td>
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">145,702</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">171,190</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Indefinite-lived intangible assets:</td><td>&#160;</td>
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_hus-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--InProcessResearchAndDevelopmentMember_zkdNsPD4tnbi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; text-align: left; padding-bottom: 1.5pt">In-process research and development</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">5,700,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1033">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_zQnV9t4KQpJi" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Total other intangible assets, net</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">5,845,702</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">171,190</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of goodwill and intangible assets, which may be broken down by segment or major class.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140569898289568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock', window );">SCHEDULE OF ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES</a></td>
<td class="text"><p id="xdx_899_eus-gaap--ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_zDIhix1BX3Tf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accrued
expenses and other current liabilities consisted of the following at December 31, 2022 and December 31, 2021:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span id="xdx_8B9_zKHaUW9L91Hh" style="display: none">SCHEDULE OF ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_49D_20221231_zBbMkbGrB9md" style="font-weight: bold; text-align: center">December 31,</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_494_20211231_ztpKeTIDF99j" style="font-weight: bold; text-align: center">December 31,</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_402_ecustom--AccruedCompensation_iI_pp0p0_maALCzkYM_zOLE87lWqRI5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Board compensation</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">70,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">17,500</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_ecustom--AccruedEquipmentHeldForLease_iI_pp0p0_maALCzkYM_zYeN16y7xf98" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Equipment held for lease</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">154,433</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1086">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_ecustom--AccruedFranchiseSalesAndUseTaxes_iI_pp0p0_maALCzkYM_zhmSlBQL4EWg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Franchise, sales and use taxes</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">27,531</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">14,090</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--AccruedIncomeTaxesCurrent_iI_pp0p0_maALCzkYM_zP28APwIULVa" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Income taxes</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,663</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,620</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--InterestPayableCurrent_iI_pp0p0_maALCzkYM_zOzKyyIb5kF4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Interest (Convertible debt - related party)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,829</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1095">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--AccruedPayrollTaxesCurrent_iI_pp0p0_maALCzkYM_zJNRO73693I4" style="vertical-align: bottom; background-color: White">
    <td>Payroll</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">209,303</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">682,036</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--AccruedProfessionalFeesCurrent_iI_pp0p0_maALCzkYM_zrpYF7asHehb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Professional fees</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">238,211</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">225,308</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_ecustom--AccruedResearchAndDevelopmentCurrent_iI_pp0p0_maALCzkYM_zk7F9NtWCfb4" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Research and development</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">322,987</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">232,712</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--AccruedRoyaltiesCurrent_iI_pp0p0_maALCzkYM_zB4ANgfhV2xe" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Royalties</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">13,158</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">10,152</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--ProductWarrantyAccrual_iI_pp0p0_maALCzkYM_zMzNOQPLAo4j" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Warranty liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">137,568</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">60,281</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_ecustom--AccruedLicenseFees_iI_pp0p0_maALCzkYM_zPQndZ4yZ6yh" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">License fees</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">150,130</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1113">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--OtherAccruedLiabilitiesCurrent_iI_pp0p0_maALCzkYM_zNkSVNMli169" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Other</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">181,043</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">265,292</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--AccruedLiabilitiesCurrent_iTI_mtALCzkYM_zAYI6VOc0MWe" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Accrued liabilities</span></td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,511,856</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,510,990</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140569894227456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>WARRANT LIABILITIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_DisclosureWarrantLiabilitiesAbstract', window );"><strong>Warrant Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock', window );">SCHEDULE OF WARRANTS ACTIVITY</a></td>
<td class="text"><p id="xdx_892_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zi4R4vr76wV6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes the activity in liability classified warrants for the year ended December 31, 2022:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span id="xdx_8B9_zlbDiViAHMLj" style="display: none">SCHEDULE OF WARRANTS ACTIVITY</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Common Stock Warrants</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Shares</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted&#8211;<br/> Average<br/> Exercise<br/>
    Price</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Range of Exercise<br/> Price</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted&#8211;<br/> Average<br/> Remaining
    Life (Years)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%">Total outstanding &#8211; December 31, 2021</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20220101__20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zgRZ9lBrrAU4" style="width: 11%; text-align: right" title="Number of Shares, Warrants Outstanding Beginning">248,162</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iS_c20220101__20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zdHaBnbdKIxk" style="width: 11%; text-align: right" title="Weighted Average Exercise Price Per Share Warrants Outstanding Beginning">7.20</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right"><span id="xdx_90B_ecustom--RangeOfExercisePrice_iS_c20220101__20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zDEOdKz4r8sd" title="Range of Exercise Beginning">7.20</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 11%; text-align: right"><span id="xdx_907_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAveragRemainingContractualTerm1_dtY_c20210101__20211231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zEg9rAw2F3tg" title="Weighted Averag Remaining Contractual Term">2.00</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt">Exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_di_c20220101__20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_z4v1hFTq5Sdf" style="text-align: right" title="Number of Shares, Warrants Exercised">(536</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedInPeriodWeightedAverageExercisePrice_c20220101__20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zNez6fhlXGcj" style="text-align: right" title="Weighted Average Exercise Price Per Share Warrants Exercised">7.20</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt">Forfeited</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_iN_di_c20220101__20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zwKh1cVFEL3e" style="text-align: right" title="Number of Shares, Warrants Forfeited">(247,625</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedInPeriodWeightedAverageExercisePrice_c20220101__20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zMKKnE0lOn3l" style="text-align: right" title="Weighted Average Exercise Price Per Share Warrants Forfeited">7.20</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt">Expired</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_c20220101__20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zly3pspvqndi" style="text-align: right" title="Number of Shares, Warrants Expired"><span style="-sec-ix-hidden: xdx2ixbrl1171">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInPeriodWeightedAverageExercisePrice_c20220101__20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zN1SodGJJ9H4" style="text-align: right" title="Weighted Average Exercise Price Per Share Warrants Expired"><span style="-sec-ix-hidden: xdx2ixbrl1173">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; padding-bottom: 1.5pt">Granted</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20220101__20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zIovgXO5mrPg" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Shares, Warrants Granted">3,849,570</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice_c20220101__20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zBUeAcTQIYuj" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Exercise Price Per Share Warrants Granted">1.53</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Total outstanding &#8211; December 31, 2022</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_c20220101__20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zFsS5v1SLk0h" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Shares, Warrants Outstanding Ending">3,849,571</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_982_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iE_c20220101__20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zP8I6u5b9Rfg" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price Per Share Warrants Outstanding Ending">1.53</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right"><span id="xdx_90F_ecustom--RangeOfExercisePrice_iE_c20220101__20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember__srt--RangeAxis__srt--MinimumMember_ziMXfIKHccal" title="Range of Exercise Ending">1.32</span> - <span id="xdx_900_ecustom--RangeOfExercisePrice_iE_c20220101__20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember__srt--RangeAxis__srt--MaximumMember_ztM5JNlu8qog" title="Range of Exercise Ending">1.65</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right"><span id="xdx_909_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAveragRemainingContractualTerm1_dtY_c20220101__20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_z5ISRz135JAi" title="Weighted Averag Remaining Contractual Term">3.9</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Exercisable</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_iE_c20220101__20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zQgOSvu364ug" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Shares, Warrants Exercisable">1,349,571</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageVestedExercisePrice_iE_c20220101__20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_z51QXKjozQH9" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price Per Share Exercisable">1.32</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_987_ecustom--RangeOfExercisePriceExercisableVested_iE_c20220101__20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zwFbKLcsDzlc" style="border-bottom: Black 2.5pt double; text-align: right" title="Range of Exercise Price, Exercisable">1.32</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNonExercisableWeightedAverageRemainingContractualTerm1_dtY_c20220101__20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zqzXgGiB5XWk" title="Exercisable Weighted Average Remaining Contractual Term">1.00</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes the activity in the Common Stock Warrants received in exchange for the Series C Warrants for the year ended
December 31, 2021:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Common Stock Warrants</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Shares</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted&#8211; Average<br/> Exercise<br/>
    Price</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Range of Exercise<br/> Price</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted&#8211;<br/> Average<br/> Remaining<br/>
    Life (Years)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; text-align: left">Total outstanding &#8211;December 31, 2020</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_pid_c20210101__20211231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zH77yzJp8ctc" style="width: 11%; text-align: right" title="Number of Shares, Warrants Outstanding Beginning">337,860</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iS_c20210101__20211231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zImbi4AYEEEh" style="width: 11%; text-align: right" title="Weighted Average Exercise Price Per Share Warrants Outstanding Beginning">7.20</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 11%; text-align: right">&#160;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 11%; text-align: right">&#160;</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt">Exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_pid_di_c20210101__20211231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zfpK04P8y6g3" style="text-align: right" title="Number of Shares, Warrants Exercised">(80,731</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedInPeriodWeightedAverageExercisePrice_c20210101__20211231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zD3Kkx3xf4s2" style="text-align: right" title="Weighted Average Exercise Price Per Share Warrants Exercised">7.20</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt">Forfeited</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_iN_pid_di_c20210101__20211231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zobya8eIBZu4" style="text-align: right" title="Number of Shares, Warrants Forfeited">(8,967</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedInPeriodWeightedAverageExercisePrice_c20210101__20211231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zDjLjuPENNR6" style="text-align: right" title="Weighted Average Exercise Price Per Share Warrants Forfeited">7.20</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt">Expired</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_pid_c20210101__20211231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zFC5SgAGzsEf" style="text-align: right" title="Number of Shares, Warrants Expired"><span style="-sec-ix-hidden: xdx2ixbrl1209">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInPeriodWeightedAverageExercisePrice_c20210101__20211231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_z7nycVmTb8B" style="text-align: right" title="Weighted Average Exercise Price Per Share Warrants Expired"><span style="-sec-ix-hidden: xdx2ixbrl1211">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; padding-bottom: 1.5pt">Granted</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pid_c20210101__20211231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zHOeD4mc3zk8" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Shares, Warrants Granted"><span style="-sec-ix-hidden: xdx2ixbrl1213">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice_c20210101__20211231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_z8XNUGVPEb2" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Exercise Price Per Share Warrants Granted"><span style="-sec-ix-hidden: xdx2ixbrl1215">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Total outstanding &#8211; December 31, 2021</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_pid_c20210101__20211231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zvGIKed08Dji" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Shares, Warrants Outstanding Ending">248,162</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iE_c20210101__20211231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zCk65p5rvzGj" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price Per Share Warrants Outstanding Ending">7.20</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Exercisable</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_iE_c20210101__20211231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zBkvGyDabBh5" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Shares, Warrants Exercisable">248,162</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_984_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageVestedExercisePrice_iE_c20210101__20211231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_ztQSbDCkta6l" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price Per Share Exercisable">7.20</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_985_ecustom--RangeOfExercisePriceExercisableVested_iI_c20211231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zEu6lMmQ7Yj" style="border-bottom: Black 2.5pt double; text-align: right" title="Range of Exercise Price, Exercisable">7.20</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_901_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNonExercisableWeightedAverageRemainingContractualTerm1_dtY_c20210101__20211231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zoFCBLkRSPC9" title="Exercisable Weighted Averag Remaining Contractual Term">2.00</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_ScheduleOfFairValueHierarchyForWarrantLiabilitiesTableTextBlock', window );">SCHEDULE OF FAIR VALUE HIERARCHY FOR WARRANT LIABILITIES</a></td>
<td class="text"><p id="xdx_891_ecustom--ScheduleOfFairValueHierarchyForWarrantLiabilitiesTableTextBlock_ztNQLBf0mxnf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table presents the Company&#8217;s fair value hierarchy for its Common Stock Warrant liabilities measured at fair value on
a recurring basis as of December 31, 2022:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span id="xdx_8BC_zcaqBHalynh3" style="display: none">SCHEDULE OF FAIR VALUE HIERARCHY FOR WARRANT LIABILITIES</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Quoted</td><td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Market</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Significant</td><td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Prices for</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Other</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Significant</td><td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Identical</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Observable</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Unobservable</td><td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Assets</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Inputs</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Inputs</td><td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Common Stock Warrant liabilities</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">(Level 1)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">(Level 2)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">(Level 3)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%">Balance as of December 31, 2021</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_986_ecustom--FairValueAdjustmentOfWarrant_iS_pp0p0_c20220101__20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zA7XDLaSeJp7" style="width: 11%; text-align: right" title="Fair value for warrant liabilities"><span style="-sec-ix-hidden: xdx2ixbrl1231">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_987_ecustom--FairValueAdjustmentOfWarrant_iS_pp0p0_c20220101__20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_z9ZvtjE2OlEl" style="width: 11%; text-align: right" title="Fair value for warrant liabilities"><span style="-sec-ix-hidden: xdx2ixbrl1233">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">$</td><td id="xdx_98C_ecustom--FairValueAdjustmentOfWarrant_iS_pp0p0_c20220101__20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z4eVzr78nfqg" style="width: 11%; font-weight: bold; text-align: right" title="Fair value for warrant liabilities">1,686,200</td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 2%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">$</td><td id="xdx_98E_ecustom--FairValueAdjustmentOfWarrant_iS_pp0p0_c20220101__20221231_zQW5z8Rhuhi8" style="width: 11%; font-weight: bold; text-align: right" title="Fair value for warrant liabilities, beginning balance">1,686,200</td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Exercises</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_ecustom--FairValueOfWarrantLiabilitiesOnDateOfExercise_iN_pp0p0_di_c20220101__20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zGCennZ52Y2b" style="text-align: right" title="Common Stock Warrant liabilities, Exercises"><span style="-sec-ix-hidden: xdx2ixbrl1239">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_ecustom--FairValueOfWarrantLiabilitiesOnDateOfExercise_iN_pp0p0_di_c20220101__20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zdSg6uJAd9a2" style="text-align: right" title="Common Stock Warrant liabilities, Exercises"><span style="-sec-ix-hidden: xdx2ixbrl1241">&#8212;</span></td><td style="text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td id="xdx_981_ecustom--FairValueOfWarrantLiabilitiesOnDateOfExercise_iN_pp0p0_di_c20220101__20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zeARMJfHa1kf" style="font-weight: bold; text-align: right" title="Common Stock Warrant liabilities, Exercises">(858</td><td style="font-weight: bold; text-align: left">)</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td id="xdx_987_ecustom--FairValueOfWarrantLiabilitiesOnDateOfExercise_iN_pp0p0_di_c20220101__20221231_zuK1t4bnPMHi" style="font-weight: bold; text-align: right" title="Common Stock Warrant liabilities, Exercises">(858</td><td style="font-weight: bold; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Issuance of Alpha warrants</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td id="xdx_980_ecustom--FairValueOfWarrantLiabilitiesIssuanceOfAlphaWarrants_iN_pp0p0_di_c20220101__20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_z3KPQHnVEkj6" style="font-weight: bold; text-align: right" title="Issuance of Alpha warrants"><span style="-sec-ix-hidden: xdx2ixbrl1247">&#8212;</span></td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td id="xdx_984_ecustom--FairValueOfWarrantLiabilitiesIssuanceOfAlphaWarrants_iN_pp0p0_di_c20220101__20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_ziP3TcxufO4b" style="font-weight: bold; text-align: right" title="Issuance of Alpha warrants"><span style="-sec-ix-hidden: xdx2ixbrl1249">&#8212;</span></td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td id="xdx_985_ecustom--FairValueOfWarrantLiabilitiesIssuanceOfAlphaWarrants_iN_pp0p0_di_c20220101__20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zC4IQi7vMGL9" style="font-weight: bold; text-align: right" title="Issuance of Alpha warrants">2,834,547</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td id="xdx_98D_ecustom--FairValueOfWarrantLiabilitiesIssuanceOfAlphaWarrants_iN_pp0p0_di_c20220101__20221231_zkJjn6nyDGFc" style="font-weight: bold; text-align: right" title="Issuance of Alpha warrants">2,834,547</td><td style="font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Gain on change in fair value of warrant liabilities</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td id="xdx_984_ecustom--ChangeInFairValueOfWarrantLiabilities_pdp0_c20220101__20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_z4oIucfXRdvj" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right" title="Change in fair value of warrant liabilities"><span style="-sec-ix-hidden: xdx2ixbrl1255">&#8212;</span></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td id="xdx_98E_ecustom--ChangeInFairValueOfWarrantLiabilities_pdp0_c20220101__20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zSDM0xe7XeJ1" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right" title="Change in fair value of warrant liabilities"><span style="-sec-ix-hidden: xdx2ixbrl1257">&#8212;</span></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td id="xdx_98D_ecustom--ChangeInFairValueOfWarrantLiabilities_pp0p0_c20220101__20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zF5xzgPb65c7" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right" title="Change in fair value of warrant liabilities">(897,242</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td id="xdx_983_ecustom--ChangeInFairValueOfWarrantLiabilities_pp0p0_c20220101__20221231_zE61mt7RQZUg" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right" title="Change in fair value of warrant liabilities">(897,242</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Balance as of December 31, 2022</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td id="xdx_980_ecustom--FairValueAdjustmentOfWarrant_iE_pp0p0_c20220101__20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zch8P99usN7j" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right" title="Fair value for warrant liabilities"><span style="-sec-ix-hidden: xdx2ixbrl1263">&#8212;</span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td id="xdx_981_ecustom--FairValueAdjustmentOfWarrant_iE_pp0p0_c20220101__20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zh60I5eW81yc" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right" title="Fair value for warrant liabilities"><span style="-sec-ix-hidden: xdx2ixbrl1265">&#8212;</span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td id="xdx_980_ecustom--FairValueAdjustmentOfWarrant_iE_pp0p0_c20220101__20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zUga1nycgLLh" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right" title="Fair value for warrant liabilities">3,622,647</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td id="xdx_98B_ecustom--FairValueAdjustmentOfWarrant_iE_pp0p0_c20220101__20221231_zP2mygjPKjpa" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right" title="Fair value for warrant liabilities, ending balance">3,622,647</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table presents the Company&#8217;s fair value hierarchy for its Common Stock Warrant liabilities (all of which arose under
the warrants received in exchange for the Series C Warrants) measured at fair value on a recurring basis as of December 31, 2021:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Quoted</td><td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Market</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Significant</td><td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Prices for</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Other</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Significant</td><td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Identical</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Observable</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Unobservable</td><td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Assets</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Inputs</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Inputs</td><td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Common Stock Warrant liabilities</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">(Level 1)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">(Level 2)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">(Level 3)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%">Balance as of December 31, 2020</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_982_ecustom--FairValueAdjustmentOfWarrant_iS_pdp0_c20210101__20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zM0g0w5THkD8" style="width: 11%; text-align: right" title="Fair value for warrant liabilities"><span style="-sec-ix-hidden: xdx2ixbrl1271">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_981_ecustom--FairValueAdjustmentOfWarrant_iS_pdp0_c20210101__20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zA6XmeoqnPg5" style="width: 11%; text-align: right" title="Fair value for warrant liabilities"><span style="-sec-ix-hidden: xdx2ixbrl1273">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">$</td><td id="xdx_985_ecustom--FairValueAdjustmentOfWarrant_iS_pdp0_c20210101__20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zwEyPxSvBSel" style="width: 11%; font-weight: bold; text-align: right" title="Fair value for warrant liabilities">8,310,100</td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 2%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">$</td><td id="xdx_982_ecustom--FairValueAdjustmentOfWarrant_iS_pdp0_c20210101__20211231_zcqAWIAU3JA" style="width: 11%; font-weight: bold; text-align: right" title="Fair value for warrant liabilities">8,310,100</td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Exercises</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_ecustom--FairValueOfWarrantLiabilitiesOnDateOfExercise_iN_di_c20210101__20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_z46tU59ZOJMh" style="text-align: right" title="Common Stock Warrant liabilities, Exercises"><span style="-sec-ix-hidden: xdx2ixbrl1279">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_ecustom--FairValueOfWarrantLiabilitiesOnDateOfExercise_iN_di_c20210101__20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_ztEJ6mZBI9fl" style="text-align: right" title="Common Stock Warrant liabilities, Exercises"><span style="-sec-ix-hidden: xdx2ixbrl1281">&#8212;</span></td><td style="text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td id="xdx_983_ecustom--FairValueOfWarrantLiabilitiesOnDateOfExercise_iN_pp0p0_di_c20210101__20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zSMlhmnylCFk" style="font-weight: bold; text-align: right" title="Common Stock Warrant liabilities, Exercises">(1,900,713</td><td style="font-weight: bold; text-align: left">)</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td id="xdx_98A_ecustom--FairValueOfWarrantLiabilitiesOnDateOfExercise_iN_pdp0_di_c20210101__20211231_z4iQ5tt73t8j" style="font-weight: bold; text-align: right" title="Common Stock Warrant liabilities, Exercises">(1,900,713</td><td style="font-weight: bold; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Gain on change in fair value of warrant liabilities</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td id="xdx_986_ecustom--ChangeInFairValueOfWarrantLiabilities_pdp0_c20210101__20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_z5WZCTIomEEe" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right" title="Change in fair value of warrant liabilities"><span style="-sec-ix-hidden: xdx2ixbrl1287">&#8212;</span></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td id="xdx_98B_ecustom--ChangeInFairValueOfWarrantLiabilities_pdp0_c20210101__20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zxU6GLyUYMXf" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right" title="Change in fair value of warrant liabilities"><span style="-sec-ix-hidden: xdx2ixbrl1289">&#8212;</span></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td id="xdx_98D_ecustom--ChangeInFairValueOfWarrantLiabilities_pp0p0_c20210101__20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zr8rKFav1sw3" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right" title="Change in fair value of warrant liabilities">(4,723,187</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td id="xdx_988_ecustom--ChangeInFairValueOfWarrantLiabilities_pp0p0_c20210101__20211231_zwTo0iwheP79" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right" title="Change in fair value of warrant liabilities">(4,723,187</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Balance as of December 31, 2021</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td id="xdx_989_ecustom--FairValueAdjustmentOfWarrant_iE_pdp0_c20210101__20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zWuKHKzFgNV1" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right" title="Fair value for warrant liabilities"><span style="-sec-ix-hidden: xdx2ixbrl1295">&#8212;</span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td id="xdx_980_ecustom--FairValueAdjustmentOfWarrant_iE_pdp0_c20210101__20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zi58ZANZKaEf" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right" title="Fair value for warrant liabilities"><span style="-sec-ix-hidden: xdx2ixbrl1297">&#8212;</span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td id="xdx_989_ecustom--FairValueAdjustmentOfWarrant_iE_pdp0_c20210101__20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zKOUQjYDEWL9" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right" title="Fair value for warrant liabilities">1,686,200</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td id="xdx_986_ecustom--FairValueAdjustmentOfWarrant_iE_pdp0_c20210101__20211231_z9XQoM1ibaw7" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right" title="Fair value for warrant liabilities">1,686,200</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_ScheduleOfAssumptionsOfWarrantLiabilitiesTableTextBlock', window );">SCHEDULE OF ASSUMPTIONS OF WARRANT LIABILITIES</a></td>
<td class="text"><p id="xdx_893_ecustom--ScheduleOfAssumptionsOfWarrantLiabilitiesTableTextBlock_zUrjGat2pOm7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following are the weighted average and the range of assumptions used in estimating the fair value of warrant liabilities (weighted average
calculated based on the number of outstanding warrants on each issuance) as of December 31, 2022 and December 31, 2021:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span id="xdx_8B8_zXu2zfSuQhk8" style="display: none">SCHEDULE
OF ASSUMPTIONS OF WARRANT LIABILITIES</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"/>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"/>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="font-size: 11pt; text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">December 31, 2022</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">December 31, 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 11pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Range</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Weighted<br/> Average</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Range</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Weighted<br/> Average</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 11pt; text-align: center">&#160;</td><td style="font-size: 11pt; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-size: 11pt">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 11pt">&#160;</td><td style="font-size: 11pt; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-size: 11pt">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 11pt">&#160;</td><td style="font-size: 11pt; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-size: 11pt">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 11pt">&#160;</td><td style="font-size: 11pt; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-size: 11pt">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 11pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 38%; text-align: left">Risk-free interest rate</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 13%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90F_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20221231__srt--RangeAxis__srt--MinimumMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zSh0YEfZ8bD2" title="Fair value assumptions, measurement input, percentages"><span style="-sec-ix-hidden: xdx2ixbrl1305">3.906%</span></span>
                                            &#8212; <span id="xdx_909_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20221231__srt--RangeAxis__srt--MaximumMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_z2M90k7YyeQa" title="Fair value assumptions, measurement input, percentages">4.628</span>&#160;</span></td><td style="width: 1%; text-align: left">%</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 11%; text-align: right"><span id="xdx_907_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20221231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--WeightedAverageMember_znbc0RjerXb7" title="Fair value assumptions, measurement input, percentages">4.15</span></td><td style="width: 1%; text-align: left">%</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 11%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_905_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20211231__srt--RangeAxis__srt--MinimumMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zJI6idtaQfU5" title="Fair value assumptions, measurement input, percentages">0.69%</span>
                                            &#8212; <span id="xdx_902_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20211231__srt--RangeAxis__srt--MaximumMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zSmNpTAFL4Gg" title="Fair value assumptions, measurement input, percentages">0.84</span></span></td><td style="width: 1%; text-align: left">&#160;%</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 11%; text-align: right"><span id="xdx_90C_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20211231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--WeightedAverageMember_z6QdufRA9ndh" title="Fair value assumptions, measurement input, percentages">0.72</span></td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Expected volatility (peer group)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_908_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20221231__srt--RangeAxis__srt--MinimumMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zit3kgSqXrtb" title="Expected volatility"><span style="-sec-ix-hidden: xdx2ixbrl1317">88%</span></span>
                                            &#8212; <span id="xdx_908_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20221231__srt--RangeAxis__srt--MaximumMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zLsHapTdV8Z6" title="Expected volatility">103</span></span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_903_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20221231__srt--RangeAxis__srt--WeightedAverageMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zF6rWT0z5K69" title="Expected volatility">98</span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_909_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20211231__srt--RangeAxis__srt--MinimumMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zoHjfNGTL03i" title="Expected volatility"><span style="-sec-ix-hidden: xdx2ixbrl1323">84%</span></span>
                                            &#8212; <span id="xdx_90A_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20211231__srt--RangeAxis__srt--MaximumMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_z9PatBOSI5Tc" title="Expected volatility">87</span></span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90D_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20211231__srt--RangeAxis__srt--WeightedAverageMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zahxBsQHA2Kk" title="Expected volatility">85</span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Term of warrants (in years)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90D_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20221231__srt--RangeAxis__srt--MinimumMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_z0eLWOuKRvbc" title="Fair value assumptions, measurement input, term">.90</span>
                                            &#8212; <span id="xdx_905_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20221231__srt--RangeAxis__srt--MaximumMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_zR6KYxzz12Jb" title="Fair value assumptions, measurement input, term">5.48</span></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_906_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20221231__srt--RangeAxis__srt--WeightedAverageMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_zDr2I1FtDGdj" title="Fair value assumptions, measurement input, term">3.9</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90E_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20211231__srt--RangeAxis__srt--MinimumMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_zDR8E7tt1go8" title="Fair value assumptions, measurement input, term">1.90</span>
                                            &#8212; <span id="xdx_902_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20211231__srt--RangeAxis__srt--MaximumMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_zZURLdhnmmP7" title="Fair value assumptions, measurement input, term">2.50</span></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90A_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20211231__srt--RangeAxis__srt--WeightedAverageMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_zP51RGjPTRe7" title="Fair value assumptions, measurement input, term">2.01</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Expected dividend yield</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_902_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20221231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zK2qdLEmQqJ7" title="Fair value assumptions, measurement input, percentages">0.00</span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_901_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20221231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember__srt--RangeAxis__srt--WeightedAverageMember_zwosA5i5B0sc" title="Fair value assumptions, measurement input, percentages">0.00</span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_902_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20211231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zZTTgQ114pN1" title="Fair value assumptions, measurement input, percentages">0.00</span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_900_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20211231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember__srt--RangeAxis__srt--WeightedAverageMember_zW3iPjqQxj3f" title="Fair value assumptions, measurement input, percentages">0.00</span></td><td style="text-align: left">%</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"/>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_DisclosureWarrantLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_DisclosureWarrantLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_ScheduleOfAssumptionsOfWarrantLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule Of Assumptions Of Warrant Liabilities [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_ScheduleOfAssumptionsOfWarrantLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_ScheduleOfFairValueHierarchyForWarrantLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule Of Fair Value Hierarchy For Warrant Liabilities [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_ScheduleOfFairValueHierarchyForWarrantLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 50<br> -Section S99<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6784392&amp;loc=d3e188667-122775<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140570005236480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONVERTIBLE DEBT - RELATED PARTY (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleDebtTableTextBlock', window );">SCHEDULE OF SENIOR SECURED CONVERTIBLE DEBT</a></td>
<td class="text"><p id="xdx_893_eus-gaap--ConvertibleDebtTableTextBlock_ztEJAzIDLiAf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
senior secured convertible debt comprises the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span id="xdx_8BC_z1WPDg8CZWAc" style="display: none">SCHEDULE OF SENIOR SECURED CONVERTIBLE DEBT</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49B_20221231__us-gaap--DebtInstrumentAxis__custom--SeniorSecuredConvertibleDebtMember_zeAxq957M6G" style="border-bottom: Black 1.5pt solid; text-align: center">December 31, 2022</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49A_20211231__us-gaap--DebtInstrumentAxis__custom--SeniorSecuredConvertibleDebtMember_zH6RVIUHly2d" style="border-bottom: Black 1.5pt solid; text-align: center">December 31, 2021</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--SecuredDebt_iI_zAbA2kDFz948" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Senior secured convertible debenture</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">3,300,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1386">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--DebtInstrumentUnamortizedDiscount_iNI_di_zxkB9aHFk1al" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Discount on convertible debenture</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(3,239,803</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1389">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--ConvertibleDebt_iI_zRqBAw6xB991" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt">Total convertible debt - related party</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">60,197</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1392">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of convertible debt instrument. Includes, but is not limited to, principal amount and amortized premium or discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140569898237024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>EARNINGS (LOSS) PER SHARE (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">SCHEDULE OF EARNINGS PER SHARE BASIC AND DILUTED</a></td>
<td class="text"><p id="xdx_89B_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_zaoyhmNBTzl3" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table reconciles net loss and the weighted-average shares used in computing basic and diluted EPS in the respective periods:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span id="xdx_8BD_z7LQ3fmEIrCi" style="display: none">SCHEDULE OF EARNINGS PER SHARE BASIC AND DILUTED</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_497_20220101__20221231_z6dwpAP8J93c" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49A_20210101__20211231_z9KIausBOqgc" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">For the Years Ended<br/> December
    31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--NetIncomeLoss_zJ7l70jhJT83" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left; padding-bottom: 1.5pt">Net loss used for basic earnings per share</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt double; width: 16%; text-align: right">(18,640,543</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">)</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt double; width: 16%; text-align: right">(17,897,137</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_zu7PiFAlXhde" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Basic weighted-average common shares outstanding</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,840,340</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,933,487</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_ecustom--DilutivePotentialSharesIssuableFromStockOptionsAndWarrants_zAYVlK9dICj5" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Dilutive potential shares issuable from stock options and warrants</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1404">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1405">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--WeightedAverageNumberDilutedSharesOutstandingAdjustment_zGRAE7ZM1bQi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Diluted weighted-average common shares outstanding</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">3,840,340</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,933,487</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>


<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">SCHEDULE OF DILUTIVE SECURITIES EXCLUDED FROM DILUTED NET LOSS PER SHARE</a></td>
<td class="text"><p id="xdx_892_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zBltfnfiJ6zd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span id="xdx_8B1_zEGCJvcq8ezb" style="display: none">SCHEDULE
OF DILUTIVE SECURITIES EXCLUDED FROM DILUTED NET LOSS PER SHARE</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">As of December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Shares of common stock subject to outstanding options</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20220101__20221231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--SharesOfCommonStockSubjectToOutstandingOptionsMember_ztotXvbX597a" style="width: 16%; text-align: right" title="Total common stock equivalents">608,012</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20210101__20211231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--SharesOfCommonStockSubjectToOutstandingOptionsMember_zlSKky8vBqE7" style="width: 16%; text-align: right" title="Total common stock equivalents">484,186</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Shares of common stock subject to outstanding warrants</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20220101__20221231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--SharesOfCommonStockSubjectToOutstandingWarrantsMember_zpZnNV69Vlba" style="border-bottom: Black 1.5pt solid; text-align: right" title="Total common stock equivalents">4,575,617</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20210101__20211231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--SharesOfCommonStockSubjectToOutstandingWarrantsMember_zYNSh0cCai5j" style="border-bottom: Black 1.5pt solid; text-align: right" title="Total common stock equivalents">982,140</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Total common stock equivalents</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20220101__20221231_z4StuYQKGSP5" style="border-bottom: Black 2.5pt double; text-align: right" title="Total common stock equivalents">5,183,629</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20210101__20211231_zZ2vqFx77pi6" style="border-bottom: Black 2.5pt double; text-align: right" title="Total common stock equivalents">1,466,326</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>



<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140569896115808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_ScheduleOfOperatingLeaseRightOfUseAssetsAndLiabilitiesTableTextBlock', window );">SCHEDULE OF OPERATING LEASE RIGHT OF USE ASSETS AND OPERATING LEASE LIABILITIES</a></td>
<td class="text"><p id="xdx_899_ecustom--ScheduleOfOperatingLeaseRightOfUseAssetsAndLiabilitiesTableTextBlock_z0ulwQjfH8U4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
tables below show the operating lease right-of-use assets and operating lease liabilities and the balances as of December 31, 2022 and 2021,
including the changes during the periods:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span id="xdx_8BA_ziFz6VW0TG05" style="display: none">SCHEDULE OF OPERATING LEASE RIGHT OF USE ASSETS AND OPERATING LEASE LIABILITIES</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"/>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"/>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="font-size: 11pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Operating lease<br/>
 right-of-use assets</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Net right-of-use assets at December 31, 2021</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_980_eus-gaap--OperatingLeaseRightOfUseAsset_iS_pp0p0_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--LongtermOperatingLeaseAgreementMember_zoWJJfQiX20c" style="width: 20%; text-align: right" title="Operating lease right-of-use assets">1,645,568</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Less amortization of operating lease right-of-use assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--OperatingLeaseRightOfUseAssetAmortizationExpense_iN_pp0p0_di_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--LongtermOperatingLeaseAgreementMember_zRBGziJpQXff" style="border-bottom: Black 1.5pt solid; text-align: right" title="Less amortization of operating lease right-of-use assets">(223,030</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Operating lease right-of-use assets at December 31, 2022</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98E_eus-gaap--OperatingLeaseRightOfUseAsset_iE_pp0p0_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--LongtermOperatingLeaseAgreementMember_z9nu3gT7HO9i" style="border-bottom: Black 2.5pt double; text-align: right" title="Operating lease right-of-use assets">1,422,538</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"/>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"/>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="font-size: 11pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Operating lease <br/>
liabilities</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify">Lease liabilities at December 31, 2021</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--OperatingLeaseLiability_iS_pp0p0_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--LongtermOperatingLeaseAgreementMember_z3PIOEpBaz6c" style="width: 20%; text-align: right" title="Lease liabilities at December 31, 2021">1,676,655</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Less principal payments on operating lease liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--OperatingLeasePayments_iN_pp0p0_di_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--LongtermOperatingLeaseAgreementMember_z7BsWNkVCFb3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Less principal payments on operating lease liabilities">(134,091</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Lease liabilities at December 31, 2022</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--OperatingLeaseLiability_iE_pp0p0_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--LongtermOperatingLeaseAgreementMember_z2BlWDvHWsEe" style="text-align: right" title="Lease liabilities at December 31, 2022">1,542,564</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Less non-current portion</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--OperatingLeaseLiabilityNoncurrent_iNI_pp0p0_di_c20221231__us-gaap--TypeOfArrangementAxis__custom--LongtermOperatingLeaseAgreementMember_zhXkVZb3zUD4" style="border-bottom: Black 1.5pt solid; text-align: right" title="Less non-current portion">(1,301,919</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Current portion at December 31, 2022</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_985_eus-gaap--OperatingLeaseLiabilityCurrent_iI_pp0p0_c20221231__us-gaap--TypeOfArrangementAxis__custom--LongtermOperatingLeaseAgreementMember_zN5pWBRG2zJe" style="border-bottom: Black 2.5pt double; text-align: right" title="Current portion at Decebmer 31, 2022">240,645</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">SCHEDULE OF MATURITIES OF OPERATING LEASE LIABILITIES</a></td>
<td class="text"><p id="xdx_896_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_zSBkOaWTrCPh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2022, the maturities of operating lease liabilities are as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span id="xdx_8BE_z9uHZNcDlUZ4" style="display: none">SCHEDULE OF MATURITIES OF OPERATING LEASE LIABILITIES</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; text-align: left; font-weight: bold">Year Ending December 31,</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49E_20221231_zn3gN7h6B1nl" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Amount</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_pp0p0_maLOLLPzeyI_zIWHtmgJn8Ia" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">2023</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 20%; text-align: right">368,341</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_pp0p0_maLOLLPzeyI_zZMNmVXDq436" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">2024</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">379,392</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_pp0p0_maLOLLPzeyI_zC64ZeHfUxLe" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">2025</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">390,773</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFour_iI_pp0p0_maLOLLPzeyI_z00UeWrsMc3i" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">2026</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">402,497</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFive_iI_pp0p0_maLOLLPzeyI_zTPS48niBBhi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">2027</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">379,164</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_pp0p0_mtLOLLPzeyI_z2xGUrk62F7k" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Total</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,920,168</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_pp0p0_di_zO7AcWnTUBmh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Less present value discount</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(377,604</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_407_eus-gaap--OperatingLeaseLiability_iI_pp0p0_zYZMazngQ4g2" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Operating lease liabilities</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,542,564</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_ScheduleOfOperatingLeaseRightOfUseAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule Of Operating Lease Right Of Use Assets And Liabilities [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_ScheduleOfOperatingLeaseRightOfUseAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140569888589904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS&#8217; EQUITY (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_ScheduleOfReservedSharesTableTextBlock', window );">SCHEDULE OF RESERVED SHARES</a></td>
<td class="text"><p id="xdx_89B_ecustom--ScheduleOfReservedSharesTableTextBlock_zimAAIToJ9Ea" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B7_zax3uzRUfCia" style="display: none">SCHEDULE
OF RESERVED SHARES</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
  <tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_49C_20221231_zNuw65UoxOj9" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_hus-gaap--AwardTypeAxis__us-gaap--StockOptionMember_z3ZC73O4yVG8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 78%; text-align: left">Exercise of issued and future grants of stock options</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 18%; text-align: right">608,012</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_hus-gaap--AwardTypeAxis__us-gaap--WarrantMember_zkBEyoRIIQza" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">Exercise of stock warrants</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">4,575,617</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_zDujkcYLn797" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt; padding-left: 10pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">5,183,629</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">SCHEDULE OF STOCK OPTION ACTIVITY</a></td>
<td class="text"><p id="xdx_892_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_z2FB81mZIsEk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following represents a summary of the options granted to employees and non-employee service providers that were outstanding at December
31, 2022, and changes during the twelve months then ended:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B8_zD3cw60EzoEa" style="display: none">SCHEDULE
OF STOCK OPTION ACTIVITY</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Shares</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted&#8211;<br/> Average<br/> Exercise<br/>
    Price</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Range of<br/> Exercise<br/> Price</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted&#8211;<br/> Average<br/> Remaining<br/>
    Life (Years)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 32%">Total outstanding &#8211; December 31, 2021</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20220101__20221231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zqnBPyfdF0z1" style="width: 12%; text-align: right" title="Number of shares, options outstanding, beginning">484,186</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20220101__20221231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zSo8odCfMjb9" style="width: 12%; text-align: right" title="Weighted Average Exercise Price, Outstanding, Beginning">60.70</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$<span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20220101__20221231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember__srt--RangeAxis__srt--MinimumMember_zNVJxn68qcaf" title="Range of Exercise price, Options Outstanding">12.40</span>
                                            &#8212; $<span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20220101__20221231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember__srt--RangeAxis__srt--MaximumMember_zwIjOyKur9uj" title="Range of Exercise price, Options Outstanding">14,657.50</span></span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right"><span id="xdx_90E_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm3_dtY_c20220101__20221231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zj7EqTYG69L9" title="Weighted- Average Remaining Contractual Life (in Years), Outstanding, Beginning">8.52</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt">Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20220101__20221231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_z1RPE2CQS8d2" style="text-align: right" title="Number of shares, options granted">134,469</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20220101__20221231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zkvwQJ0CQG36" style="text-align: right" title="Weighted average exercise price, options granted">5.24</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_908_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionGrantedWeightedAverageExercisePrice_c20220101__20221231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember__srt--RangeAxis__srt--MinimumMember_zmSEZ3YUzaA2" title="Range of Exercise price, Options Outstanding">5.14</span>
                                            &#8212; <span id="xdx_907_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionGrantedWeightedAverageExercisePrice_c20220101__20221231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember__srt--RangeAxis__srt--MaximumMember_zdkGibkxK343" title="Range of Exercise price, Options Outstanding">10.50</span></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_904_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm2_dtY_c20220101__20221231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_ztVfDUW1dy94" title="Weighted- Average Remaining Contractual Life (in Years), Options Granted">5.99</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt">Expired</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_iN_di_c20220101__20221231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zKuj5b6rQuu" style="text-align: right" title="Number of shares, options expired">(9,379</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_c20220101__20221231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_z30ZbFDj4F7i" style="text-align: right" title="Weighted average exercise price, options expired">932.75</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_906_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExpirationsInPeriodWeightedAverageExercisePrice_c20220101__20221231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember__srt--RangeAxis__srt--MinimumMember_zQRRIzsHx5N4" title="Range of Exercise price, Options Expired">57.50</span>
                                            - <span id="xdx_908_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExpirationsInPeriodWeightedAverageExercisePrice_pid_c20220101__20221231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember__srt--RangeAxis__srt--MaximumMember_zDNvdUlW7dcc" title="Range of exercise price, options expired">14,657.50</span></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; padding-left: 10pt">Forfeited</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_di_c20220101__20221231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zRDjr5XQ9nlb" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of shares, options forfeited">(1,264</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20220101__20221231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zTrLEmJH9Gnf" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted average exercise price, options forfeited">22.64</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_c20220101__20221231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember__srt--RangeAxis__srt--MinimumMember_zhh9NAU4Ppec" title="Range of Exercise price, Options Forfeited">5.14</span>
                                            - <span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_c20220101__20221231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember__srt--RangeAxis__srt--MaximumMember_zuki1SvKVugj" title="Range of Exercise price, Options Forfeited">49.70</span></span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Total outstanding &#8211; December 31, 2022</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20220101__20221231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zHQHex6Q7moe" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Shares, Options Outstanding at Ending">608,012</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20220101__20221231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zkOS9mXytQXa" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price, Outstanding at Ending">35.02</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$<span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20220101__20221231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember__srt--RangeAxis__srt--MinimumMember_zDgugfq7l8k9" title="Range of Exercise price, Options Outstanding">5.14</span>
                                            &#8212; $<span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20220101__20221231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember__srt--RangeAxis__srt--MaximumMember_znYSLY54sQRk" title="Range of Exercise price, Options Outstanding">51.30</span></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20220101__20221231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_z48fHiVCqQ4b" title="Weighted- Average Remaining Contractual Life (in Years), Outstanding at Ending">8.09</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Exercisable (vested)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_iI_c20221231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_z7oIvggtyFlh" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of shares, options exercisable (vested)">288,704</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_c20221231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zAkadtWfXRtk" style="border-bottom: Black 2.5pt double; text-align: right" title="Range of exercise price, options exercisable (vested)">46.32</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$<span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_c20221231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember__srt--RangeAxis__srt--MinimumMember_zFQiWU7oOUwe" title="Range of exercise price, options exercisable (vested)">12.40</span>
                                            &#8212; $<span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_c20221231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember__srt--RangeAxis__srt--MaximumMember_zk4vMa0xUGHe" title="Range of exercise price, options exercisable (vested)">51.30</span></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_906_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_dtY_c20220101__20221231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zbxpgyXpO7sc" title="Weighted- Average Remaining Contractual Life (in Years), Options Exercisable (vested)">7.59</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Non-Exercisable (non-vested)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iI_c20221231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zvZPeCoYNwCe" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of shares, options non-exercisable (non-vested)">319,308</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToNonVestExercisableWeightedAverageExercisePrice_iI_c20221231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zFFoxY8BCaj9" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price, options non-exercisable (non-vested)">24.80</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">$<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_iI_c20221231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember__srt--RangeAxis__srt--MinimumMember_zqbVRgVjO6ad" title="Range of exercise price, options non-exercisable (non-vested)">5.14</span>
                                            &#8212; $<span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_iI_c20221231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember__srt--RangeAxis__srt--MaximumMember_zDcdUCBXQ7x2" title="Range of exercise price, options non-exercisable (non-vested)">10.50</span></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_908_ecustom--WeightedAverageRemainingContractualLifeInYearsOptionsNonexercisableNonvested_dtY_c20220101__20221231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_z5KM8vgvprkf" title="Weighted- Average Remaining Contractual Life (in Years), Options Non-exercisable (non-vested)">8.59</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">SCHEDULE OF ASSUMPTION USED IN BLACK-SCHOLES OPTION-PRICING METHOD</a></td>
<td class="text"><p id="xdx_898_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zXJHUhXRyRX8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
material factors incorporated in the Black-Scholes model in estimating the fair value of the options granted for the periods presented
were as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8BA_z7qII3f5qwu3" style="display: none">SCHEDULE
OF ASSUMPTION USED IN BLACK-SCHOLES OPTION-PRICING METHOD</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">For the Years Ended<br/> December
    31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Expected dividend yield</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20220101__20221231_zhag32jN4YRf" style="width: 16%; text-align: right" title="Expected dividend yield">0.00</td><td style="width: 1%; text-align: left">%</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20210101__20211231_zTIEJPQ084o4" style="width: 16%; text-align: right" title="Expected dividend yield">0.00</td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Expected stock-price volatility</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20220101__20221231_zKtIwKVsS3U" style="text-align: right" title="Expected stock-price volatility">103</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20210101__20211231_zuEHSOgSMVc6" style="text-align: right" title="Expected stock-price volatility">102</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Risk-free interest rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_pid_dp_uPure_c20220101__20221231_zLvLnQPVePo9" title="Risk-free interest rate, minimum">1.58</span>%
                                            &#8212; <span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_pid_dp_uPure_c20220101__20221231_zjt5MWct8SE7" title="Risk-free interest rate, maximum">3.77</span>%</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_pid_dp_uPure_c20210101__20211231_zJBi7nhkA5E" title="Risk-free interest rate, minimum">0.84</span>%
                                            &#8212; <span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_pid_dp_uPure_c20210101__20211231_z829pG31GkU2" title="Risk-free interest rate, maximum">1.51</span>%</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Expected average term of options (in years)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20220101__20221231_zKzJtlwDIcD8" title="Expected average term of options (in years)">5.99</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20210101__20211231_z7gMe5DCjO56" title="Expected average term of options (in years)">6.27</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Stock price</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_900_eus-gaap--SharePrice_iI_c20221231__srt--RangeAxis__srt--MinimumMember_zGc28BFmmRvg" title="Share price">5.14</span>
                                            - <span id="xdx_902_eus-gaap--SharePrice_iI_c20221231__srt--RangeAxis__srt--MaximumMember_zgkx93Yfjlue" title="Share price">10.50</span></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_903_eus-gaap--SharePrice_iI_c20211231__srt--RangeAxis__srt--MinimumMember_z5tPoCaiZ4C2" title="Share price">12.40</span>
                                            &#8212; <span id="xdx_904_eus-gaap--SharePrice_iI_c20211231__srt--RangeAxis__srt--MaximumMember_ztiGNvk1kf9k" title="Share price">32.90</span></span></td><td style="text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock', window );">SCHEDULE OF SHARE-BASED COMPENSATION EXPENSE</a></td>
<td class="text"><p id="xdx_89C_eus-gaap--ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_zh066EzBM4zd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company recorded stock-based compensation expense and classified it in the Consolidated Statements of Operations as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B7_zhN52oK5Tr13" style="display: none">SCHEDULE
OF SHARE-BASED COMPENSATION EXPENSE</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_491_20220101__20221231_zWbgOUKJSTsa" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_497_20210101__20211231_zC4rKQvO8pf5" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">For the Years Ended<br/> December
    31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--AllocatedShareBasedCompensationExpense_hus-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_z6NjOKdlH8xk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">General and administrative</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">4,649,649</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">4,465,911</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--AllocatedShareBasedCompensationExpense_hus-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zQQRXIbMtjSl" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Research and development</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">834,395</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">827,740</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--AllocatedShareBasedCompensationExpense_z8koch4cNqm9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt; padding-left: 10pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">5,484,044</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">5,293,651</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=QLGN_CompensatoryWarrantActivityMember', window );">Compensatory Warrant Activity [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_SummaryOfWarrantActivityTableTextBlock', window );">SCHEDULE OF WARRANT ACTIVITY</a></td>
<td class="text"><p id="xdx_890_ecustom--SummaryOfWarrantActivityTableTextBlock_hus-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zm91MkMsDeuf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes the equity classified compensatory warrant activity for the year ended December 31, 2022:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B3_zXMa6WS7uYJ2" style="display: none">SCHEDULE
OF WARRANT ACTIVITY</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Common Stock</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Shares</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted&#8211; Average<br/> Exercise<br/>
    Price</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Range of<br/> Exercise Price</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted&#8211;<br/> Average<br/> Remaining<br/>
    Life (Years)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 32%">Total outstanding &#8211; December 31, 2021</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zc6X8p6TnZK2" style="width: 12%; text-align: right" title="Number of Shares, Warrants Outstanding Beginning">179,046</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iS_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_z6ZXiyP4CFQg" style="width: 12%; text-align: right" title="Weighted Average Exercise Price Per Share Warrants Outstanding Beginning">15.20</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="width: 16%; text-align: right"><span id="xdx_901_ecustom--RangeOfExercisePriceOutstanding_iS_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember__srt--RangeAxis__srt--MinimumMember_zfDlRJ4MFaAl" title="Range of exercise price - beginning">11.10</span>
                                            &#8212; $<span id="xdx_905_ecustom--RangeOfExercisePriceOutstanding_iS_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember__srt--RangeAxis__srt--MaximumMember_zUOo2hZXtozc">25.40</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right"><span id="xdx_90C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAveragRemainingContractualTerm1_dtY_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zIwhEPjpTkIj" title="Weighted Average Remaining Life (Years) - outstanding">2.64</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt">Granted to advisor and its designees</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_z6ayF8s7k1u5" style="text-align: right" title="Number of shares, warrants granted"><span style="-sec-ix-hidden: xdx2ixbrl1882">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zTsDqkiT7ug2" style="text-align: right" title="Weighted average exercise price per share warrants granted"><span style="-sec-ix-hidden: xdx2ixbrl1884">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt">Exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_di_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zsXfVyH9frHj" style="text-align: right" title="Number of Shares, Warrants Exercised"><span style="-sec-ix-hidden: xdx2ixbrl1886">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedInPeriodWeightedAverageExercisePrice_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zpp0ZfLX7rS1" style="text-align: right" title="Weighted average exercise price per share warrants exercised"><span style="-sec-ix-hidden: xdx2ixbrl1888">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt">Expired</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zmAmgvhiTLmc" style="text-align: right" title="Number of Shares, Warrants Expired"><span style="-sec-ix-hidden: xdx2ixbrl1890">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInPeriodWeightedAverageExercisePrice_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zIxcQeJ9pkNe" style="text-align: right" title="Weighted average exercise price per share warrants expired"><span style="-sec-ix-hidden: xdx2ixbrl1892">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; padding-left: 10pt">Forfeited</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_iN_di_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_z5uADim7WDt3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Shares, Warrants Forfeited"><span style="-sec-ix-hidden: xdx2ixbrl1894">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedInPeriodWeightedAverageExercisePrice_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zpEak3XxjT87" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted average exercise price per share warrants forfeited"><span style="-sec-ix-hidden: xdx2ixbrl1896">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Total outstanding &#8211; December 31, 2022</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zmok0BDWJap7" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Shares, Warrants Outstanding Ending">179,046</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iE_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_ztctxxBQvZl7" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price Per Share Warrants Outstanding Ending">9.12</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="padding-bottom: 2.5pt; text-align: right"><span id="xdx_906_ecustom--RangeOfExercisePriceOutstanding_iE_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember__srt--RangeAxis__srt--MinimumMember_zBdMA35yQnne" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.32
</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212; $<span id="xdx_902_ecustom--RangeOfExercisePriceOutstanding_iE_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember__srt--RangeAxis__srt--MaximumMember_zD11N8oa9I98">25.40</span></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right"><span id="xdx_90C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAveragRemainingContractualTerm1_dtY_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zHI1aNvl8JV7" title="Weighted Average Remaining Life (Years) - outstanding">1.73</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Exercisable</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_iI_c20221231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zlw5vYR1cbVd" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Shares, Warrants Exercisable">179,046</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_981_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageVestedExercisePrice_iI_c20221231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zGkDkIc0xBt7" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price Per Share Exercisable">9.12</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_903_ecustom--RangeOfExercisePriceExercisableVested_iI_c20221231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember__srt--RangeAxis__srt--MinimumMember_zs7o9GJr1DMb">1.32</span>-
                                            $<span id="xdx_90B_ecustom--RangeOfExercisePriceExercisableVested_iI_c20221231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember__srt--RangeAxis__srt--MaximumMember_zlcUR6iJK9dd" title="Range of exercise price - ending">25.40</span></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAveragRemainingContractualTerm1_dtY_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zq2PDHCWcnYa" title="Weighted Average Remaining Life (Years) Exercisable">1.73</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Non-Exercisable</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNonVestedNumber_iI_c20221231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_z9JCQxPvZMe3" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of shares, warrants non-exercisable"><span style="-sec-ix-hidden: xdx2ixbrl1915">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_984_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageNonVestedExercise_iI_c20221231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zIQo5bxFh7l8" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price Per Share Non-Exercisable"><span style="-sec-ix-hidden: xdx2ixbrl1917">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98E_ecustom--RangeOfExercisePriceNonexercisableNonvested_iI_c20221231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_z3PBkLPWv78e" style="border-bottom: Black 2.5pt double; text-align: right" title="Range of Exercise Price, Non-Exercisable"><span style="-sec-ix-hidden: xdx2ixbrl1919">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">&#8212;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes the equity classified compensatory warrant activity for the year ended December 31, 2021:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Common Stock</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Shares</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted&#8211; Average<br/> Exercise<br/>
    Price</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Range of<br/> Exercise Price</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted&#8211;<br/> Average<br/> Remaining<br/>
    Life (Years)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 32%">Total outstanding &#8211; December 31, 2020</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20210101__20211231__us-gaap--AwardTypeAxis__custom--CompensatoryWarrantActivityMember_zXEEiX2Ns9ij" style="width: 12%; text-align: right" title="Number of shares, warrants outstanding beginning">129,403</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iS_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zsAprVVc6pza" style="width: 12%; text-align: right" title="Weighted Average Exercise Price Per Share Warrants Outstanding Beginning">16.60</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right">&#160;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right">&#160;</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt">Granted to advisor and its designees</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20210101__20211231__us-gaap--AwardTypeAxis__custom--CompensatoryWarrantActivityMember_zPTolTwgpNl1" style="text-align: right" title="Number of shares, warrants outstanding beginning">60,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zpjy7tjjG7lg" style="text-align: right" title="Weighted average exercise price per share warrants granted">13.20</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt">Exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_di_c20210101__20211231__us-gaap--AwardTypeAxis__custom--CompensatoryWarrantActivityMember_zY5fckfJX907" style="text-align: right" title="Number of shares, warrants outstanding beginning">(3,839</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedInPeriodWeightedAverageExercisePrice_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zwvyAfJJtXIb" style="text-align: right" title="Weighted average exercise price per share warrants exercised">20.90</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt">Expired</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_iN_di_c20210101__20211231__us-gaap--AwardTypeAxis__custom--CompensatoryWarrantActivityMember_zqkBZSUcrDc8" style="text-align: right" title="Number of shares, warrants outstanding beginning"><span style="-sec-ix-hidden: xdx2ixbrl1933">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInPeriodWeightedAverageExercisePrice_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_z4fOBs5hLglk" style="text-align: right" title="Weighted average exercise price per share warrants expired"><span style="-sec-ix-hidden: xdx2ixbrl1935">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; padding-left: 10pt">Forfeited</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_iN_di_c20210101__20211231__us-gaap--AwardTypeAxis__custom--CompensatoryWarrantActivityMember_zJXVwXTfBsLf" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of shares, warrants outstanding beginning">(6,518</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedInPeriodWeightedAverageExercisePrice_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zbskeWqjnywl" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted average exercise price per share warrants forfeited">20.70</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Total outstanding &#8211; December 31, 2021</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_c20210101__20211231__us-gaap--AwardTypeAxis__custom--CompensatoryWarrantActivityMember_zc65SVAw9uPg" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of shares, warrants outstanding beginning">179,046</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iE_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zKVVPYIXz5lh" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price Per Share Warrants Outstanding Ending">15.20</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 2.5pt; text-align: right">$<span id="xdx_907_ecustom--RangeOfExercisePriceOutstanding_iE_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember__srt--RangeAxis__srt--MinimumMember_zFtZ5QShHcE2">11.10</span>
                                            &#8212; $<span id="xdx_90E_ecustom--RangeOfExercisePriceOutstanding_iE_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember__srt--RangeAxis__srt--MaximumMember_zqDqBD5TT456" title="Range of exercise price - ending">25.40</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right"><span id="xdx_90A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAveragRemainingContractualTerm1_dtY_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zJmgIMArS5u7" title="Weighted Average Remaining Life (Years) - outstanding">2.64</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Exercisable</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_iI_c20211231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zYINqjRAnRv3" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Shares, Warrants Exercisable">179,046</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_982_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageVestedExercisePrice_iI_c20211231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zRAneQeqjhv7" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price Per Share Exercisable">15.20</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 2.5pt double; text-align: right">$<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90A_ecustom--RangeOfExercisePriceExercisableVested_iI_c20211231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember__srt--RangeAxis__srt--MinimumMember_z4MNabjtCaf5">11.10</span>
                                            &#8212; $<span id="xdx_900_ecustom--RangeOfExercisePriceExercisableVested_iI_c20211231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember__srt--RangeAxis__srt--MaximumMember_zNvjGiy4ITMk" title="Range of exercise price - ending">25.40</span></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAveragRemainingContractualTerm1_dtY_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zR4QFPoIUOA7" title="Weighted Average Remaining Life (Years) Exercisable">2.64</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Non-Exercisable</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNonVestedNumber_iI_c20211231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_z7ZZNsmCWqp8" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of shares, warrants non-exercisable"><span style="-sec-ix-hidden: xdx2ixbrl1959">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageNonVestedExercise_iI_c20211231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_ziPEgq6dUs4b" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price Per Share Non-Exercisable"><span style="-sec-ix-hidden: xdx2ixbrl1961">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_980_ecustom--RangeOfExercisePriceNonexercisableNonvested_iI_c20211231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zJ0O7U0xHvIh" style="border-bottom: Black 2.5pt double; text-align: right" title="Range of Exercise Price, Non-Exercisable"><span style="-sec-ix-hidden: xdx2ixbrl1963">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">&#8212;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=QLGN_NonCompensatoryWarrantActivityMember', window );">Non Compensatory Warrant Activity [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_SummaryOfWarrantActivityTableTextBlock', window );">SCHEDULE OF WARRANT ACTIVITY</a></td>
<td class="text"><p id="xdx_896_ecustom--SummaryOfWarrantActivityTableTextBlock_hus-gaap--StatementEquityComponentsAxis__custom--NonCompensatoryWarrantActivityMember_z3Ezp2e9l6U5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes the noncompensatory equity classified warrant activity for the year ended December 31, 2022:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8BD_z7kPo6hRT5N9" style="display: none">SCHEDULE
OF WARRANT ACTIVITY</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"/>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"/>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Common
    Stock</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif">Shares</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Weighted&#8211;<br/>
    Average<br/> Exercise<br/> Price</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Range
    of<br/> Exercise Price</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Weighted&#8211;<br/>
    Average<br/> Remaining<br/> Life (Years)</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 32%; padding-bottom: 2.5pt">Total outstanding &#8211; December 31, 2021</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 2.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; width: 1%; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20220101__20221231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zwjFSRJNVUW9" style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; width: 12%; text-align: right" title="Number of shares, warrants outstanding beginning">554,914</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 2.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; width: 1%; text-align: left">$</td><td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iS_c20220101__20221231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zVikSZesbGu9" style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; width: 12%; text-align: right" title="Weighted Average exercise price per share warrants outstanding beginning">20.10</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 2.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_903_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsRangeOfExercisePrice_iS_c20220101__20221231__srt--RangeAxis__srt--MinimumMember__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zMUMmCqTfd85" title="Range of exercise price">11.10</span>&#8212;
                                            <span id="xdx_909_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsRangeOfExercisePrice_iS_c20220101__20221231__srt--RangeAxis__srt--MaximumMember__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_z7eX7LOBnGI3" title="Range of exercise price">37.78</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 2.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; width: 12%; text-align: right"><span id="xdx_90D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAveragRemainingContractualTerm1_dtY_c20210101__20211231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zL0eZezEfLbh" title="Weighted average remaining life (Years) exercisable">1.32</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt">Granted</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20220101__20221231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zleoRD6BR5kc" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of shares, warrants granted">331,464</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_981_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice_c20220101__20221231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zzuzx14V31M9" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price per share warrants granted">0.01</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_980_ecustom--RangeOfExercisePriceGranted_c20220101__20221231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zVOw8zcBTcrc" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Range of exercise price - granted">0.01</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt">Exercised</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_di_c20220101__20221231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zCes61SgT65l" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Shares, Warrants Exercised">(331,464</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedInPeriodWeightedAverageExercisePrice_c20220101__20221231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zTuzD7PPoiFa" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price per share warrants exercised">0.01</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_989_ecustom--RangeOfExercisePriceExpired_c20220101__20221231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zfa6QtYaCcGe" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Range of exercise price - Expired">0.01</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt">Expired</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_iN_di_c20220101__20221231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zT83qno96T8k" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Shares, Warrants Expired">(7,911</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInPeriodWeightedAverageExercisePrice_c20220101__20221231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zCWvJvJpGnle" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price per share warrants expired">37.78</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInRangeOfExercisePrice_c20220101__20221231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zreaXubl0vi3" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price per share warrants expired">37.78</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; padding-left: 10pt">Forfeited</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_iN_di_c20220101__20221231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zUfyKeYAqJh7" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Shares, Warrants Forfeited"><span style="-sec-ix-hidden: xdx2ixbrl2045">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedInPeriodWeightedAverageExercisePrice_c20220101__20221231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_z18TDDCOaWL5" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price per share warrants forfeited"><span style="-sec-ix-hidden: xdx2ixbrl2047">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedInRangeOfExercisePrice_c20220101__20221231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zOYk6TDl4qP3" style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right" title="Weighted average exercise price per share warrants forfeited"><span style="-sec-ix-hidden: xdx2ixbrl2049">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">Total outstanding &#8211; December 31, 2022</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_c20220101__20221231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zubz5owdsLu7" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of shares, warrants outstanding ending">547,003</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iE_c20220101__20221231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zmgV7gzBuov4" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">19.76</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_907_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsRangeOfExercisePrice_iE_c20220101__20221231__srt--RangeAxis__srt--MinimumMember__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zFFcgD4S67i5" title="Range of exercise price">1.32</span>
                                            - <span id="xdx_90A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsRangeOfExercisePrice_iE_c20220101__20221231__srt--RangeAxis__srt--MaximumMember__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zKF9YJmyPbOh" title="Range of exercise price">20.00</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right"><p style="margin: 0"><span id="xdx_903_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAveragRemainingContractualTerm1_dtY_c20220101__20221231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_z3ZFJGZrIQ3j" title="Weighted average remaining life (Years) exercisable">0.33</span></p></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">Exercisable</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_iI_c20221231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zlrYJwXik0Lk" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Shares, Warrants Exercisable">547,003</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"/><td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageVestedExercisePrice_iI_c20221231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zdNu49nlWmh8" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price Per Share Exercisable">19.76</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90C_ecustom--RangeOfExercisePriceExercisableVested_iI_c20221231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember__srt--RangeAxis__srt--MinimumMember_z75s4PgkKA08">1.32</span>
                                            - <span id="xdx_908_ecustom--RangeOfExercisePriceExercisableVested_iI_c20221231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember__srt--RangeAxis__srt--MaximumMember_z53sjGNxbes" title="Range of exercise price - Exercisable">20.00</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_902_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAveragRemainingContractualTerm1_dtY_c20220101__20221231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zY5i18pnUj9g" title="Weighted average remaining life (Years) exercisable">0.33</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">Non-Exercisable</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><p id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsNonExercisableNumber_iI_c20221231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_z9QB1DrWVd54" style="margin: 0" title="Number of Shares, Warrants Exercisable"><span style="-sec-ix-hidden: xdx2ixbrl2069">&#8212;</span></p></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageVestedNonExercisePrice_iI_c20221231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zRUYi3jgb2T" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price Per Share Exercisable"><p style="margin: 0"><span style="-sec-ix-hidden: xdx2ixbrl2071">&#8212;</span></p></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><p style="margin: 0"><span id="xdx_905_ecustom--RangeOfExercisePriceNonExercisableVested_iI_c20221231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zS6McpAPGdJ8" title="Range of exercise price - Exercisable"><span style="-sec-ix-hidden: xdx2ixbrl2073">&#8212;</span></span></p></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><p style="margin: 0">&#8212;</p></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"/>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes the noncompensatory equity classified warrant activity for the year ended December 31, 2021:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"/>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt"/>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Common
    Stock</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Shares</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Weighted&#8211;<br/>
    Average<br/> Exercise<br/> Price</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Range
    of<br/> Exercise Price</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Weighted&#8211;<br/>
    Average<br/> Remaining<br/> Life (Years)</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 32%">Total outstanding &#8211; December 31, 2020</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20210101__20211231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zrgu3znl8ir8" style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right" title="Number of shares, warrants outstanding beginning">654,978</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iS_c20210101__20211231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zuq0DGS0fNgc" style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right" title="Weighted Average exercise price per share warrants outstanding beginning">43.60</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right">&#160;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right">&#160;</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt">Granted</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20210101__20211231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zseVSSaR3om2" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of shares, warrants granted"><span style="-sec-ix-hidden: xdx2ixbrl2079">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice_c20210101__20211231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zd7XDgXX7v0e" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price per share warrants granted"><span style="-sec-ix-hidden: xdx2ixbrl2081">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt">Exercised</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_di_c20210101__20211231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_z4VTL9fYAHg7" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Shares, Warrants Exercised">(100,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_984_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedInPeriodWeightedAverageExercisePrice_c20210101__20211231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zk9RebS1SFOa" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price per share warrants exercised">0.01</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt">Expired</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_iN_di_c20210101__20211231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zMrt5FX6PAk7" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Shares, Warrants Expired">(64</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInPeriodWeightedAverageExercisePrice_c20210101__20211231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_z4PGH6tMj7L" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price per share warrants expired">23,250.00</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; padding-left: 10pt">Forfeited</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_iN_di_c20210101__20211231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zWrrkA6OrSX4" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Shares, Warrants Forfeited"><span style="-sec-ix-hidden: xdx2ixbrl2091">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_984_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedInPeriodWeightedAverageExercisePrice_c20210101__20211231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zHFgSqFaYdF" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price per share warrants forfeited"><span style="-sec-ix-hidden: xdx2ixbrl2093">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">Total outstanding &#8211; December 31, 2021</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_c20210101__20211231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zzvbBfvHzVw9" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of shares, warrants outstanding ending">554,914</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iE_c20210101__20211231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_z5YMpRUmKmxb" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price per share warrants outstanding ending">20.10</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">Exercisable</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_iI_c20211231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zRtonYIo0gr" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Shares, Warrants Exercisable">554,914</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageVestedExercisePrice_iI_c20211231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_z4XqDAu7DU09" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price Per Share Exercisable">20.10</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90A_ecustom--RangeOfExercisePriceExercisableVested_iI_c20211231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember__srt--RangeAxis__srt--MinimumMember_z2Cgb5GcUwU1">11.10</span>&#8212;
                                            <span id="xdx_90E_ecustom--RangeOfExercisePriceExercisableVested_iI_c20211231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember__srt--RangeAxis__srt--MaximumMember_zT9QG9krjKff" title="Range of exercise price - Exercisable">37.78</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_909_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAveragRemainingContractualTerm1_dtY_c20210101__20211231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zhxtRGlF0sia" title="Weighted average remaining life (Years) exercisable">1.32</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">Non-Exercisable</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNonVestedNumber_iI_c20211231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zsRMNxUJolef" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of shares, warrants non-exercisable"><span style="-sec-ix-hidden: xdx2ixbrl2108">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageNonVestedExercise_iI_c20211231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_z6BDf9VNYLpb" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price Per Share Non-Exercisable"><span style="-sec-ix-hidden: xdx2ixbrl2110">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_98A_ecustom--RangeOfExercisePriceNonexercisableNonvested_iI_c20211231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zh4z4Kxg5TPh" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Range of Exercise Price, Non-Exercisable"><span style="-sec-ix-hidden: xdx2ixbrl2112">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNonExercisableWeightedAverageRemainingContractualTerm1_dtY_c20210101__20211231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zxT9GOV6SKZb" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average remaining life (Years) non-exercisable"><span style="-sec-ix-hidden: xdx2ixbrl2114">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_ScheduleOfReservedSharesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of reserved shares [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_ScheduleOfReservedSharesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_SummaryOfWarrantActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Summary Of Warrant Activity [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_SummaryOfWarrantActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=QLGN_CompensatoryWarrantActivityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=QLGN_CompensatoryWarrantActivityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=QLGN_NonCompensatoryWarrantActivityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=QLGN_NonCompensatoryWarrantActivityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140569892242784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock', window );">SCHEDULE OF DOMESTIC AND FOREIGN COMPONENTS</a></td>
<td class="text"><p id="xdx_89D_eus-gaap--ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_zC5WzqnHGoG" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table presents domestic and foreign components of consolidated loss before income taxes for the periods presented:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span><span id="xdx_8BE_zZJmOpqAkPFh" style="display: none">SCHEDULE
OF DOMESTIC AND FOREIGN COMPONENTS</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_498_20220101__20221231_zCIo0y8ZD4Cc" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_494_20210101__20211231_zA5yjKw0koBj" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_z37fmY4jBFv4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%">Domestic</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">(15,954,750</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">(17,891,710</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr id="xdx_401_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_zifcygSnRYn6" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">Foreign</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(5,344,967</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2160">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_zbeeiP0iNXBh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Loss before provision for income taxes</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(21,299,717</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(17,891,710</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">SCHEDULE OF RECONCILIATIONS OF STATUTORY INCOME TAX RATE</a></td>
<td class="text"><p id="xdx_89D_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zno2KvHtuSh3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
reconciliation of the statutory income tax rates and the Company&#8217;s effective tax rate is as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8BB_zJ7HCURHx36a" style="display: none">SCHEDULE
OF RECONCILIATIONS OF STATUTORY INCOME TAX RATE</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_498_20220101__20221231_zXdooMsJEywk" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_492_20210101__20211231_zLf6HVlYXzf2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_uPure_zIeBXIwCOqH" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Statutory federal income tax rate</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right">21.00</td><td style="width: 1%; text-align: left">%</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right">21.00</td><td style="width: 1%; text-align: left">%</td></tr>
  <tr id="xdx_400_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_pid_dp_uPure_zJIAGKaGcMX" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">State taxes, net of federal tax benefit</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5.46</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6.63</td><td style="text-align: left">%</td></tr>
  <tr id="xdx_40B_eus-gaap--EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepletion_pid_dp_uPure_zR0JUoqHu6o1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Non-deductible expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-1.36</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-1.19</td><td style="text-align: left">%</td></tr>
  <tr id="xdx_408_ecustom--EffectiveIncomeTaxRateReconciliationNonOperatingLossExpiration_pid_dp_uPure_z2f8h7JF900b" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">NOL expiration</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-12.96</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-2.71</td><td style="text-align: left">%</td></tr>
  <tr id="xdx_40E_eus-gaap--EffectiveIncomeTaxRateReconciliationTaxCredits_pid_dp_uPure_zfEWJloNJUJd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Tax credit</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2.42</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.86</td><td style="text-align: left">%</td></tr>
  <tr id="xdx_400_eus-gaap--EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses_pid_dp_uPure_zRgn6HftpuW6" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Goodwill impairment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-4.50</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.00</td><td style="text-align: left">%</td></tr>
  <tr id="xdx_406_eus-gaap--EffectiveIncomeTaxRateReconciliationTaxSettlementsForeign_pid_dp_uPure_zTFGuDKMxGJ" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Foreign rate differential</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.50</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.00</td><td style="text-align: left">%</td></tr>
  <tr id="xdx_40B_ecustom--EffectiveIncomeTaxRateReconciliationFairValueOfWarrant_pid_dp_uPure_zQoQFFPXWgm2" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Change in FV of warrant liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.89</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5.54</td><td style="text-align: left">%</td></tr>
  <tr id="xdx_40C_eus-gaap--EffectiveIncomeTaxRateReconciliationTaxCreditsOther_pid_dp_uPure_zDHCM6gQLox8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>True-up</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1.47</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-2.72</td><td style="text-align: left">%</td></tr>
  <tr id="xdx_404_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_pid_dp_uPure_zL6RGqQhU227" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Change in valuation allowance</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-11.68</td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-27.44</td><td style="padding-bottom: 1.5pt; text-align: left">%</td></tr>
  <tr id="xdx_401_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_pid_dp_uPure_zhMdntHmS9rd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Income taxes provision (benefit)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">1.24</td><td style="padding-bottom: 2.5pt; text-align: left">%</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">-0.03</td><td style="padding-bottom: 2.5pt; text-align: left">%</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock', window );">SCHEDULE OF PROVISION FOR INCOME TAXES</a></td>
<td class="text"><p id="xdx_891_eus-gaap--ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_zz2iHIEA3rO1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Income
tax expense for the year ended December 31, 2022 and 2021 consisted of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B5_zrvQuSeeDsud" style="display: none">SCHEDULE
OF PROVISION FOR INCOME TAXES</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49E_20220101__20221231_zfGOltlCv5L8" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_495_20210101__20211231_zRwty91B7ob" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">For the Years Ended</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Current</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--CurrentFederalTaxExpenseBenefit_maCITEBz1MC_zWa9bmB5ez1a" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">US Federal</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2202">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2203">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--CurrentStateAndLocalTaxExpenseBenefit_maCITEBz1MC_zs53W0Vutu4a" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">US State</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right">7,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right">5,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--CurrentForeignTaxExpenseBenefit_maCITEBz1MC_zmIFaJ38JYcc" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">Foreign</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2208">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2209">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--CurrentIncomeTaxExpenseBenefit_iT_mtCITEBz1MC_zmsyTOrYMKqf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10pt">Total current provision</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Deferred</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--DeferredFederalIncomeTaxExpenseBenefit_maDITEBzCKf_zEjGPYIO4jae" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">US Federal</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(236,000</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,268,000</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_402_eus-gaap--DeferredStateAndLocalIncomeTaxExpenseBenefit_maDITEBzCKf_z9jvGGv8uVSc" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">US State</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(2,252,000</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(3,641,000</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_400_eus-gaap--DeferredForeignIncomeTaxExpenseBenefit_maDITEBzCKf_zaz4C0dB2JDh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Foreign</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(272,000</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2221">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--DeferredIncomeTaxExpenseBenefit_iT_mtDITEBzCKf_maITEBzWbu_zpUmzlIz4zlg" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt">Total deferred benefit</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(2,760,000</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(4,909,000</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_409_eus-gaap--ValuationAllowanceDeferredTaxAssetChangeInAmount_iN_di_msITEBzWbu_zqClhg5UPcqe" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt">Change in valuation allowance</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,488,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">4,909,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--IncomeTaxExpenseBenefit_iT_pn3d_mtITEBzWbu_zQCM7qvLFCth" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 10pt">Total provision (benefit) for income taxes</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(265,000</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">5,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">SCHEDULE OF DEFERRED TAX ASSETS AND LIABILITIES</a></td>
<td class="text"><p id="xdx_896_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zeTmu6uRlQPe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
components of deferred tax assets and liabilities are as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8BF_z3dFPzGVRSH2" style="display: none">SCHEDULE
OF DEFERRED TAX ASSETS AND LIABILITIES</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_496_20221231_zZGWMXRDemS6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_491_20211231_zBm7PHs84ebh" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Deferred tax assets:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_maDTATDzYdX_znrofrP5Xlre" style="vertical-align: bottom; background-color: White">
    <td style="width: 60%; text-align: left; padding-left: 10pt">Net operating loss</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">33,540,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">33,362,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--DeferredTaxAssetsInProcessResearchAndDevelopment_iI_maDTATDzYdX_z2tuGmtJmegd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10pt">Research and development credits</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7,857,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6,185,000</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_ecustom--DefferdTaxAssetsAccruedExpenses_iI_maDTATDzYdX_z6JoyJ0i7os9" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt">Accrued expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,020,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">757,000</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--DeferredTaxAssetsGoodwillAndIntangibleAssets_iI_maDTATDzYdX_zDuKcQEhBRof" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt">Patent</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2243">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">262,000</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_iI_maDTATDzYdX_zzxLy03Czow" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt">Stock compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,069,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,747,000</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_ecustom--DeferredTaxAssetsResearchAndDevelopmentExpenses_iI_maDTATDzYdX_zxSJdg5AvK3a" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10pt">Research and development expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,196,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2250">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--DeferredTaxAssetsPropertyPlantAndEquipment_iI_maDTATDzYdX_zJIaj0YTTjCb" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt">Fixed assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">280,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">282,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--DeferredTaxAssetsTaxDeferredExpense_iTI_mtDTATDzYdX_maDTAGzJfc_z7vYln7SyRlk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 20pt">Total deferred income tax assets</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">46,962,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">43,595,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Deferred tax liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_iNI_di_maDITLzOxa_zNVXxDQARH21" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt">Intangible assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,324,000</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(34,000</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_401_eus-gaap--DeferredTaxLiabilitiesLeasingArrangements_iNI_di_maDITLzOxa_zYhrq6gYXyog" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt">Right-of-use asset</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(382,000</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(436,000</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_40B_eus-gaap--DeferredIncomeTaxLiabilities_iNTI_di_mtDITLzOxa_msDTAGzJfc_zyOXhtPGufhj" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 10pt">Total deferred income tax liabilities</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">(1,706,000</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">(470,000</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--DeferredTaxAssetsGross_iTI_mtDTAGzJfc_maDTALNzbeu_zuHVng7UZHZj" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Net deferred income tax assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">45,256,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">43,125,000</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_di_msDTALNzbeu_zpSSzdtVNXlf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Valuation allowance</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(45,614,000</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(43,125,000</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_402_eus-gaap--DeferredTaxAssetsLiabilitiesNet_iNTI_di_mtDTALNzbeu_zPeqin1vXMda" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Deferred tax asset, net of allowance</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(358,000</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2274">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of income before income tax between domestic and foreign jurisdictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140569888930608">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SCHEDULE OF ACCOUNTS RECEIVABLE (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableGrossCurrent', window );">Accounts Receivable</a></td>
<td class="nump">$ 726,449<span></span>
</td>
<td class="nump">$ 958,448<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent', window );">Less Reserves and Allowances</a></td>
<td class="num">(187,862)<span></span>
</td>
<td class="num">(136,097)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net</a></td>
<td class="nump">$ 538,587<span></span>
</td>
<td class="nump">$ 822,351<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableGrossCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableGrossCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on accounts receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5074-111524<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124255206&amp;loc=SL82895884-210446<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140569888591536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE OF USEFUL LIVES OF PROPERTY AND EQUIPMENT (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember', window );">Machinery and Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment, useful life</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment, useful life</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=QLGN_MoldsAndToolingMember', window );">Molds and Tooling [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment, useful life</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and Fixtures [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment, useful life</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=QLGN_MoldsAndToolingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=QLGN_MoldsAndToolingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140569887385056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND ESTIMATES (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="2"></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>May 26, 2022</div></th>
<th class="th"><div>May 26, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 22, 2022</div></th>
<th class="th"><div>Apr. 25, 2022</div></th>
<th class="th"><div>Apr. 24, 2022</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions', window );">Stock issued during period shares acquisitions</a></td>
<td class="nump">7,048<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Warrants to purchase common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">219,101<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of Warrant or Right, Exercise Price of Warrants or Rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13.20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40.70<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityReverseStockSplit', window );">Reverse split, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">These warrants were subsequently exercised on September 13, 2022<span></span>
</td>
<td class="text">Reverse
Stock Split

&#160;

On
November 23, 2022, the Company effected a 1-for-10, as determined by the Company&#8217;s board of directors, reverse stock split of its
outstanding shares of common stock (the &#8220;Reverse Stock Split&#8221;). The Reverse Stock Split reduced the Company&#8217;s shares
of outstanding common stock, stock options, and warrants to purchase shares of our common stock. Fractional shares of common stock that
would have otherwise resulted from the Reverse Stock Split were rounded down to the nearest whole share and cash in lieu of payments
were made to stockholders. All share and per share data for all periods presented in the accompanying financial statements and the related
disclosures have been adjusted retrospectively to reflect the Reverse Stock Split. The number of authorized shares of common stock and
the par value per share remains unchanged.

&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Impairment losses on construction-in-progress</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,239,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue from Contract with Customer, Excluding Assessed Tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,983,556<span></span>
</td>
<td class="nump">$ 5,653,725<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_AllowancesForSalesReturn', window );">Allowance for estimated returns</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">96,000<span></span>
</td>
<td class="nump">150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Goodwill impairment charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,239,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdvertisingExpense', window );">Advertising expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductWarrantyAccrual', window );">Accrued warranty liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">137,568<span></span>
</td>
<td class="nump">60,281<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductWarrantyExpense', window );">Warranty costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">69,000<span></span>
</td>
<td class="nump">57,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Adjustment net of tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,721<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of Warrant or Right, Exercise Price of Warrants or Rights</a></td>
<td class="nump">$ 5.136<span></span>
</td>
<td class="nump">$ 5.136<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.32<span></span>
</td>
<td class="nump">$ 6.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member] | Patents and Licenses [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of Warrant or Right, Exercise Price of Warrants or Rights</a></td>
<td class="nump">$ 6.00<span></span>
</td>
<td class="nump">$ 6.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.136<span></span>
</td>
<td class="nump">$ 7.195<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | Patents and Licenses [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">17 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=QLGN_GeneralAdministrativeResearchAndDevelopmentExpensesMember', window );">General Administrative Research and Development Expenses [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Other shipping and handling costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,000<span></span>
</td>
<td class="nump">12,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ShippingAndHandlingMember', window );">Shipping and Handling [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Other shipping and handling costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">267,000<span></span>
</td>
<td class="nump">113,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=QLGN_LicenseRevenuesMember', window );">License Revenues [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue from Contract with Customer, Excluding Assessed Tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">632,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=QLGN_PrefundedWarrantMember', window );">Pre-funded Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Warrants to purchase common stock</a></td>
<td class="nump">331,464<span></span>
</td>
<td class="nump">331,464<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of Warrant or Right, Exercise Price of Warrants or Rights</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember', window );">Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Warrants to purchase common stock</a></td>
<td class="nump">67,619<span></span>
</td>
<td class="nump">67,619<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">67,620<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of Warrant or Right, Exercise Price of Warrants or Rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13.20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductWarrantyAccrual', window );">Accrued warranty liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">138,000<span></span>
</td>
<td class="nump">60,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember', window );">Warrant [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of Warrant or Right, Exercise Price of Warrants or Rights</a></td>
<td class="nump">$ 0.10<span></span>
</td>
<td class="nump">$ 0.10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.136<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember', window );">Warrant [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of Warrant or Right, Exercise Price of Warrants or Rights</a></td>
<td class="nump">$ 5.136<span></span>
</td>
<td class="nump">$ 5.136<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.32<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=QLGN_SeriesAOnePreferredStockMember', window );">Series A-1 Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions', window );">Stock issued during period shares acquisitions</a></td>
<td class="nump">2,232,861<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=QLGN_NanoSynexLtdMember', window );">Nano Synex Ltd [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions', window );">Stock issued during period shares acquisitions</a></td>
<td class="nump">350,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityReverseStockSplit', window );">Reverse split, description</a></td>
<td class="text">these warrants were subsequently exercised on September 13, 2022)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions', window );">Stock issued during period, value, acquisitions</a></td>
<td class="nump">$ 1,904,989<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired', window );">Voting interests acquired</a></td>
<td class="nump">52.80%<span></span>
</td>
<td class="nump">52.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Adjustment net of tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,721<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=QLGN_NanoSynexLtdMember', window );">Nano Synex Ltd [Member] | Pre-funded Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of Warrant or Right, Exercise Price of Warrants or Rights</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=QLGN_NanoSynexLtdMember', window );">Nano Synex Ltd [Member] | Series A-1 Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions', window );">Stock issued during period shares acquisitions</a></td>
<td class="nump">2,232,861<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=QLGN_NanoSynexLtdMember', window );">Nano Synex Ltd [Member] | Series B Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions', window );">Stock issued during period shares acquisitions</a></td>
<td class="nump">381,786<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions', window );">Stock issued during period, value, acquisitions</a></td>
<td class="nump">$ 600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_AllowancesForSalesReturn">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Allowances for sales return.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_AllowancesForSalesReturn</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdvertisingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount charged to advertising expense for the period, which are expenses incurred with the objective of increasing revenue for a specified brand, product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 720<br> -SubTopic 35<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6420018&amp;loc=d3e36677-107848<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdvertisingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126905981&amp;loc=d3e2420-110228<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of voting equity interests acquired at the acquisition date in the business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13854-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13777-109266<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductWarrantyAccrual">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for estimated claims under standard and extended warranty protection rights granted to customers.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 460<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126907703&amp;loc=d3e12565-110249<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 460<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (c)(5)<br> -URI https://asc.fasb.org/extlink&amp;oid=126907703&amp;loc=d3e12565-110249<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductWarrantyAccrual</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductWarrantyExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The expense charged against earnings for the period pertaining to standard and extended warranties on the entity's goods and services granted to customers.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 460<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph ((c)(3,4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126907703&amp;loc=d3e12565-110249<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductWarrantyExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued during the period pursuant to acquisitions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued pursuant to acquisitions during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityReverseStockSplit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB Topic 4.C)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187143-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityReverseStockSplit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=QLGN_PatentsAndLicensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=QLGN_PatentsAndLicensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=QLGN_GeneralAdministrativeResearchAndDevelopmentExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=QLGN_GeneralAdministrativeResearchAndDevelopmentExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ShippingAndHandlingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ShippingAndHandlingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=QLGN_LicenseRevenuesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=QLGN_LicenseRevenuesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=QLGN_PrefundedWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=QLGN_PrefundedWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=QLGN_SeriesAOnePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=QLGN_SeriesAOnePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=QLGN_NanoSynexLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=QLGN_NanoSynexLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140569888553296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LIQUIDITY AND GOING CONCERN (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>May 26, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Cash', window );">Cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,034,434<span></span>
</td>
<td class="nump">$ 17,538,272<span></span>
</td>
<td class="nump">$ 7,034,434<span></span>
</td>
<td class="nump">$ 17,538,272<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">103,385,172<span></span>
</td>
<td class="nump">84,744,629<span></span>
</td>
<td class="nump">103,385,172<span></span>
</td>
<td class="nump">84,744,629<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,247,540<span></span>
</td>
<td class="nump">$ 14,730,742<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromConvertibleDebt', window );">Proceeds from issuance of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteStockSplit', window );">Stockholders equity note stock split</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">the Company with a face value equal to the amount paid by
the Company to NanoSynex upon satisfaction of the applicable performance milestone, bearing interest at the rate of 9% per annum on the
principal balance from time to time outstanding under the particular promissory note, convertible at the option of the Company into additional
shares of NanoSynex in order for the Company to maintain at least a 50.1% controlling ownership interest in NanoSynex, should NanoSynex
issue additional shares. The principal of the convertible notes are due and payable upon the sooner to occur of: i) five years from the
date of issuance of the particular promissory note; ii) the acquisition by any person or entity of all or substantially all of the share
capital of NanoSynex, through share purchase, issuance or shares or merger of NanoSynex, or the purchase of all or substantially all
of the assets of NanoSynex; or iii) the initial public offering of NanoSynex.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=QLGN_NanoSynexLtdMember', window );">Nano Synex Ltd [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions', window );">Stock issued during period value acquisitions</a></td>
<td class="nump">$ 1,904,989<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Stock issued during period value new issues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Cash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=118262064&amp;loc=SL116631418-115840<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section 45<br> -Paragraph 21<br> -URI https://asc.fasb.org/extlink&amp;oid=118262064&amp;loc=SL116631419-115840<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Cash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued pursuant to acquisitions during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteStockSplit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of the stock split arrangement. Also provide the retroactive effect given by a stock split that occurs after the balance date but before the release of financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB Topic 4.C)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187143-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteStockSplit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=QLGN_NanoSynexLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=QLGN_NanoSynexLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140569892169552">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE OF CONSIDERATION TRANSFERRED (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>May 26, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Total consideration paid for NanoSynex common stock</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 135,354<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_FairValueOfWarrantModificationForBusinessAcquisition', window );">FMV of consideration related to related to repricing of 70,478 shares of Alpha Capital/Qualigen warrants *</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">696<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAcquiredFromAcquisition', window );">NanoSynex cash acquired</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(135,354)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=QLGN_NanoSynexLtdMember', window );">Nano Synex Ltd [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_PaymentsToAcquireBusinesses', window );">Cash paid for NanoSynex preferred stock:</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions', window );">FMV of 3,500,000 shares of Qualigen stock issued to Alpha Capital Anstalt</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,904,989<span></span>
</td>
<td class="nump">$ 10,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_PrefundedWarrantsIssuedForBusinessAcquisition', window );">FMV of 3,314,641 shares of Qualigen stock related to prefunded warrant issued to Alpha Capital Anstalt</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,804,102<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Total consideration paid for NanoSynex common stock</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">3,709,091<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_FairValueOfWarrantModificationForBusinessAcquisition', window );">FMV of consideration related to related to repricing of 70,478 shares of Alpha Capital/Qualigen warrants *</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">696<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAcquiredFromAcquisition', window );">NanoSynex cash acquired</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(735,354)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired', window );">Total consideration transferred, net of cash acquired</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 3,574,433<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="4"></td></tr>
<tr><td colspan="4"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">See disclosure
under <i>Noncompensatory Equity Classified Warrants</i> regarding May 26, 2022 transaction-Note 15-Stockholders&#8217; Equity</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_FairValueOfWarrantModificationForBusinessAcquisition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of warrant modification for business acquisition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_FairValueOfWarrantModificationForBusinessAcquisition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_PaymentsToAcquireBusinesses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payments to acquire businesses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_PaymentsToAcquireBusinesses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_PrefundedWarrantsIssuedForBusinessAcquisition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Prefunded warrants issued for business acquisition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_PrefundedWarrantsIssuedForBusinessAcquisition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferred1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126966197&amp;loc=d3e6613-128477<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126975305&amp;loc=d3e6927-128479<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126966197&amp;loc=d3e6578-128477<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferred1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAcquiredFromAcquisition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the acquisition of business during the period (for example, cash that was held by the acquired business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAcquiredFromAcquisition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued pursuant to acquisitions during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=QLGN_NanoSynexLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=QLGN_NanoSynexLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140569896269456">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SCHEDULE OF CONSIDERATION TRANSFERRED (Details) (Parenthetical)<br></strong></div></th>
<th class="th">
<div>May 26, 2022 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions', window );">Common stock issued for business acquisition</a></td>
<td class="nump">7,048<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=QLGN_NanoSynexLtdMember', window );">Nano Synex Ltd [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions', window );">Common stock issued for business acquisition</a></td>
<td class="nump">350,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=QLGN_AlphaCapitalAnstaltMember', window );">Alpha Capital Anstalt [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions', window );">Common stock issued for business acquisition</a></td>
<td class="nump">331,464<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued during the period pursuant to acquisitions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=QLGN_NanoSynexLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=QLGN_NanoSynexLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=QLGN_AlphaCapitalAnstaltMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=QLGN_AlphaCapitalAnstaltMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140569892650416">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SCHEDULE OF ASSETS ACQUIRED AND LIABILITIES (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>May 26, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract', window );"><strong>Business Combination and Asset Acquisition [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables', window );">Accounts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75,336<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment', window );">Property and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">120,942<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedResearchAndDevelopmentExpense', window );">In process R&amp;D</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable', window );">Accounts payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,588)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpensesAndOtherPayables', window );">Accrued expenses and other payables</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(291,093)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedResearchAndDevelopmentGrantLiability', window );">R&amp;D grant liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,362,264)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesShortTermDebt', window );">Short term debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(941,898)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities', window );">Deferred tax liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(629,379)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedLessNoncontrollingInterest', window );">Noncontrolling interest assumed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,882,225)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets', window );">Identifiable net assets acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,215,169)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">$ 625,602<span></span>
</td>
<td class="nump">4,789,602<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet', window );">Total consideration transferred, net of cash acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,574,433<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpensesAndOtherPayables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business combination recognized identifiable assets acquired and liabilities assumed current liabilities accrued expenses and other payables.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpensesAndOtherPayables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesShortTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business combination recognized identifiable assets acquired and liabilities assumed current liabilities short term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesShortTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business combination recognized identifiable assets acquired and liabilities assumed research and development expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedResearchAndDevelopmentGrantLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business combination recognized identifiable assets acquired and liabilities assumed research and development grant liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedResearchAndDevelopmentGrantLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationAndAssetAcquisitionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of assets acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount due from customers or clients for goods or services, including trade receivables, that have been delivered or sold in the normal course of business, and amounts due from others, including related parties expected to be converted to cash, sold or exchanged within one year or the normal operating cycle, if longer, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities incurred for goods and services received that are used in an entity's business and related party payables, assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount recognized as of the acquisition date for the identifiable assets acquired in excess of (less than) the aggregate liabilities assumed.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -URI https://asc.fasb.org/extlink&amp;oid=123455525&amp;loc=d3e2207-128464<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of property, plant, and equipment recognized as of the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -URI https://asc.fasb.org/extlink&amp;oid=123455525&amp;loc=d3e2207-128464<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedLessNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount recognized as of the acquisition date for the assets, including goodwill, in excess of (less than) the aggregate liabilities assumed, less the noncontrolling interest in the acquiree.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedLessNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140569888528112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE OF PRO FORMA INFORMATION (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract', window );"><strong>Business Combination and Asset Acquisition [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionsProFormaRevenue', window );">Business acquisitions pro forma revenue</a></td>
<td class="nump">$ 4,983,556<span></span>
</td>
<td class="nump">$ 5,653,725<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss', window );">Business acquisitions pro forma net income loss</a></td>
<td class="num">$ (19,538,959)<span></span>
</td>
<td class="num">$ (17,897,137)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The pro forma net Income or Loss for the period as if the business combination or combinations had been completed at the beginning of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionsProFormaRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The pro forma revenue for a period as if the business combination or combinations had been completed at the beginning of the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionsProFormaRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationAndAssetAcquisitionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140569888711344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ACQUISITION (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="2"></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>May 26, 2022</div></th>
<th class="th"><div>May 26, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions', window );">Stock issued during period shares acquisitions</a></td>
<td class="nump">7,048<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants or rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13.20<span></span>
</td>
<td class="nump">$ 40.70<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityReverseStockSplit', window );">Reverse split, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">These warrants were subsequently exercised on September 13, 2022<span></span>
</td>
<td class="text">Reverse
Stock Split

&#160;

On
November 23, 2022, the Company effected a 1-for-10, as determined by the Company&#8217;s board of directors, reverse stock split of its
outstanding shares of common stock (the &#8220;Reverse Stock Split&#8221;). The Reverse Stock Split reduced the Company&#8217;s shares
of outstanding common stock, stock options, and warrants to purchase shares of our common stock. Fractional shares of common stock that
would have otherwise resulted from the Reverse Stock Split were rounded down to the nearest whole share and cash in lieu of payments
were made to stockholders. All share and per share data for all periods presented in the accompanying financial statements and the related
disclosures have been adjusted retrospectively to reflect the Reverse Stock Split. The number of authorized shares of common stock and
the par value per share remains unchanged.

&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestDecreaseFromRedemptions', window );">Decrease to noncontrolling interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 117,775<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillPeriodIncreaseDecrease', window );">Decrease in good will</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">106,621<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=QLGN_NanoSynexMember', window );">Nano Synex Ltd [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions', window );">Stock issued during period value acquisitions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=QLGN_PrefundedWarrantMember', window );">Pre-funded Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase shares</a></td>
<td class="nump">331,464<span></span>
</td>
<td class="nump">331,464<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants or rights</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=QLGN_SeriesAOnePreferredStockMember', window );">Series A-1 Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions', window );">Stock issued during period shares acquisitions</a></td>
<td class="nump">2,232,861<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=QLGN_NanoSynexLtdMember', window );">Nano Synex Ltd [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired', window );">Business acquisition, voting equity rate</a></td>
<td class="nump">52.80%<span></span>
</td>
<td class="nump">52.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions', window );">Stock issued during period shares acquisitions</a></td>
<td class="nump">350,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityReverseStockSplit', window );">Reverse split, description</a></td>
<td class="text">these warrants were subsequently exercised on September 13, 2022)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions', window );">Stock issued during period value acquisitions</a></td>
<td class="nump">$ 1,904,989<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossTax', window );">Other comprehensive income loss tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,100,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=QLGN_NanoSynexLtdMember', window );">Nano Synex Ltd [Member] | Pre-funded Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants or rights</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=QLGN_NanoSynexLtdMember', window );">Nano Synex Ltd [Member] | Series A-1 Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions', window );">Stock issued during period shares acquisitions</a></td>
<td class="nump">2,232,861<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=QLGN_NanoSynexLtdMember', window );">Nano Synex Ltd [Member] | Series B Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions', window );">Stock issued during period shares acquisitions</a></td>
<td class="nump">381,786<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions', window );">Stock issued during period value acquisitions</a></td>
<td class="nump">$ 600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of voting equity interests acquired at the acquisition date in the business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestDecreaseFromRedemptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Decrease in noncontrolling interest (for example, but not limited to, redeeming or purchasing the interests of noncontrolling shareholders, issuance of shares (interests) by the non-wholly owned subsidiary to the parent entity for other than cash, and a buyback of shares (interest) by the non-wholly owned subsidiary from the noncontrolling interests).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569655-111683<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4616395-111683<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestDecreaseFromRedemptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of tax expense (benefit) allocated to other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e39076-109324<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442407-227067<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e640-108580<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued during the period pursuant to acquisitions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued pursuant to acquisitions during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityReverseStockSplit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB Topic 4.C)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187143-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityReverseStockSplit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=QLGN_NanoSynexMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=QLGN_NanoSynexMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=QLGN_PrefundedWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=QLGN_PrefundedWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=QLGN_SeriesAOnePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=QLGN_SeriesAOnePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=QLGN_NanoSynexLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=QLGN_NanoSynexLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140569892275984">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SCHEDULE OF INVENTORY (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryRawMaterials', window );">Raw materials</a></td>
<td class="nump">$ 949,796<span></span>
</td>
<td class="nump">$ 823,315<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcess', window );">Work in process</a></td>
<td class="nump">200,318<span></span>
</td>
<td class="nump">188,135<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoods', window );">Finished goods</a></td>
<td class="nump">436,183<span></span>
</td>
<td class="nump">44,428<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Total inventory</a></td>
<td class="nump">$ 1,586,297<span></span>
</td>
<td class="nump">$ 1,055,878<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoods">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoods</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterials">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterials</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWorkInProcess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140569888872448">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SCHEDULE OF PREPAID EXPENSES AND OTHER CURRENT ASSETS (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_DisclosurePrepaidExpensesAndOtherCurrentAssetsAbstract', window );"><strong>Prepaid Expenses And Other Current Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidInsurance', window );">Prepaid insurance</a></td>
<td class="nump">$ 1,377,323<span></span>
</td>
<td class="nump">$ 1,197,726<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_PrepaidManufacturingExpenses', window );">Prepaid manufacturing expenses</a></td>
<td class="nump">43,820<span></span>
</td>
<td class="nump">67,410<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherPrepaidExpenseCurrent', window );">Other prepaid expenses</a></td>
<td class="nump">227,451<span></span>
</td>
<td class="nump">111,183<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other current assets</a></td>
<td class="nump">12,626<span></span>
</td>
<td class="nump">3,577<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">$ 1,661,220<span></span>
</td>
<td class="nump">$ 1,379,896<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_DisclosurePrepaidExpensesAndOtherCurrentAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_DisclosurePrepaidExpensesAndOtherCurrentAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_PrepaidManufacturingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Prepaid manufacturing expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_PrepaidManufacturingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherPrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6387103&amp;loc=d3e6435-108320<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherPrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidInsurance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6387103&amp;loc=d3e6435-108320<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126905020&amp;loc=d3e5879-108316<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidInsurance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140569893117744">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SCHEDULE OF PROPERTY AND EQUIPMENT (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 5,043,533<span></span>
</td>
<td class="nump">$ 4,745,455<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated depreciation</a></td>
<td class="num">(4,623,446)<span></span>
</td>
<td class="num">(4,541,238)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_FixedAssetImpairments', window );">Fixed asset impairment</a></td>
<td class="num">(75,000)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">345,087<span></span>
</td>
<td class="nump">204,217<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember', window );">Machinery and Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">2,510,148<span></span>
</td>
<td class="nump">2,482,841<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">395,836<span></span>
</td>
<td class="nump">345,117<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold Improvements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">333,271<span></span>
</td>
<td class="nump">333,271<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=QLGN_MoldsAndToolingMember', window );">Molds and Tooling [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">260,002<span></span>
</td>
<td class="nump">260,002<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and Fixtures [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">144,832<span></span>
</td>
<td class="nump">143,013<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember', window );">Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 1,399,444<span></span>
</td>
<td class="nump">$ 1,181,211<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_FixedAssetImpairments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fixed asset lmpairments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_FixedAssetImpairments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=QLGN_MoldsAndToolingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=QLGN_MoldsAndToolingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140569888528320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PROPERTY AND EQUIPMENT, NET (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="nump">$ 92,000<span></span>
</td>
<td class="nump">$ 73,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Payments to acquire assets</a></td>
<td class="nump">164,684<span></span>
</td>
<td class="nump">$ 134,471<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=QLGN_SekisuiDistributionAgreementMember', window );">Sekisui Distribution Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Payments to acquire assets</a></td>
<td class="nump">$ 154,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=QLGN_SekisuiDistributionAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=QLGN_SekisuiDistributionAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140569892201792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE OF GOODWILL AND OTHER INTANGIBLE (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>May 26, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">$ 625,602<span></span>
</td>
<td class="nump">$ 4,789,602<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Less: Accumulated amortization</a></td>
<td class="num">(752,237)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(726,749)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Total finite-lived intangible assets, net</a></td>
<td class="nump">145,702<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">171,190<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Total other intangible assets, net</a></td>
<td class="nump">5,845,702<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">171,190<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember', window );">In Process Research and Development [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Total other intangible assets, net</a></td>
<td class="nump">5,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=QLGN_DevelopedProductTechnologyRightsMember', window );">Developed-Product-Technology Rights [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Licensing rights</a></td>
<td class="nump">$ 479,103<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">479,103<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=QLGN_DevelopedProductTechnologyRightsMember', window );">Developed-Product-Technology Rights [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Finite lived intangible asset useful life</a></td>
<td class="text">8 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=QLGN_DevelopedProductTechnologyRightsMember', window );">Developed-Product-Technology Rights [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Finite lived intangible asset useful life</a></td>
<td class="text">17 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=QLGN_LicensingRightsMember', window );">Licensing Rights [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Licensing rights</a></td>
<td class="nump">$ 418,836<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 418,836<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Finite lived intangible asset useful life</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 928<br> -SubTopic 340<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6473545&amp;loc=d3e61844-108004<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=QLGN_DevelopedProductTechnologyRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=QLGN_DevelopedProductTechnologyRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=QLGN_LicensingRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=QLGN_LicensingRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140569893028192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>GOODWILL, IPR&amp;D AND OTHER INTANGIBLES (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Goodwill, Impairment Loss</a></td>
<td class="nump">$ 4,239,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsFinitelived', window );">Impairment of Intangible Assets, Finite-Lived</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated amortization</a></td>
<td class="nump">752,237<span></span>
</td>
<td class="nump">726,749<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths', window );">Future estimated amortization of license costs 2023</a></td>
<td class="nump">18,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo', window );">Future estimated amortization of patent costs Year 2024</a></td>
<td class="nump">15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree', window );">Future estimated amortization of patent costs Year 2025</a></td>
<td class="nump">14,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour', window );">Future estimated amortization of patent costs Year 2026</a></td>
<td class="nump">14,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive', window );">Future estimated amortization of patent costs Year 2027</a></td>
<td class="nump">14,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive', window );">Future estimated amortization of patent costs thereafter</a></td>
<td class="nump">65,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember', window );">Patents [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Finite lived intangible assets gross</a></td>
<td class="nump">140,000<span></span>
</td>
<td class="nump">159,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated amortization</a></td>
<td class="nump">339,000<span></span>
</td>
<td class="nump">320,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Licenses charged</a></td>
<td class="nump">18,000<span></span>
</td>
<td class="nump">17,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicenseMember', window );">License [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Finite lived intangible assets gross</a></td>
<td class="nump">5,000<span></span>
</td>
<td class="nump">12,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated amortization</a></td>
<td class="nump">414,000<span></span>
</td>
<td class="nump">407,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Licenses charged</a></td>
<td class="nump">7,000<span></span>
</td>
<td class="nump">$ 7,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths', window );">Future estimated amortization of license costs 2023</a></td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for asset, excluding financial asset and goodwill, lacking physical substance with finite life expected to be recognized after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 928<br> -SubTopic 340<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6473545&amp;loc=d3e61844-108004<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13854-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13777-109266<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsFinitelived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of a finite-lived intangible asset to fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16373-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsFinitelived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140569889618320">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SCHEDULE OF ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_AccruedCompensation', window );">Board compensation</a></td>
<td class="nump">$ 70,000<span></span>
</td>
<td class="nump">$ 17,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_AccruedEquipmentHeldForLease', window );">Equipment held for lease</a></td>
<td class="nump">154,433<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_AccruedFranchiseSalesAndUseTaxes', window );">Franchise, sales and use taxes</a></td>
<td class="nump">27,531<span></span>
</td>
<td class="nump">14,090<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedIncomeTaxesCurrent', window );">Income taxes</a></td>
<td class="nump">4,663<span></span>
</td>
<td class="nump">3,620<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPayableCurrent', window );">Interest (Convertible debt - related party)</a></td>
<td class="nump">2,829<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedPayrollTaxesCurrent', window );">Payroll</a></td>
<td class="nump">209,303<span></span>
</td>
<td class="nump">682,036<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Professional fees</a></td>
<td class="nump">238,211<span></span>
</td>
<td class="nump">225,308<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_AccruedResearchAndDevelopmentCurrent', window );">Research and development</a></td>
<td class="nump">322,987<span></span>
</td>
<td class="nump">232,712<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedRoyaltiesCurrent', window );">Royalties</a></td>
<td class="nump">13,158<span></span>
</td>
<td class="nump">10,152<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductWarrantyAccrual', window );">Warranty liability</a></td>
<td class="nump">137,568<span></span>
</td>
<td class="nump">60,281<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_AccruedLicenseFees', window );">License fees</a></td>
<td class="nump">150,130<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other</a></td>
<td class="nump">181,043<span></span>
</td>
<td class="nump">265,292<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued liabilities</a></td>
<td class="nump">$ 1,511,856<span></span>
</td>
<td class="nump">$ 1,510,990<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_AccruedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_AccruedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_AccruedEquipmentHeldForLease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued equipment held for lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_AccruedEquipmentHeldForLease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_AccruedFranchiseSalesAndUseTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued franchise sales and use taxes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_AccruedFranchiseSalesAndUseTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_AccruedLicenseFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued license fees.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_AccruedLicenseFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_AccruedResearchAndDevelopmentCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Research and development.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_AccruedResearchAndDevelopmentCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedIncomeTaxesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(15)(b)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedIncomeTaxesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedPayrollTaxesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable for statutory payroll taxes incurred through that date and withheld from employees pertaining to services received from them, including entity's matching share of the employees FICA taxes and contributions to the state and federal unemployment insurance programs. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedPayrollTaxesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedRoyaltiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedRoyaltiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductWarrantyAccrual">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for estimated claims under standard and extended warranty protection rights granted to customers.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 460<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126907703&amp;loc=d3e12565-110249<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 460<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (c)(5)<br> -URI https://asc.fasb.org/extlink&amp;oid=126907703&amp;loc=d3e12565-110249<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductWarrantyAccrual</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140569888670832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHORT TERM DEBT - RELATED PARTY (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">5 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 02, 2021</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 22, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPayableCurrent', window );">Accrued interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,829<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermBorrowings', window );">Short term debt outstanding balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">950,722<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Accrued interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=QLGN_NotesPayableMember', window );">Notes Payable [Member] | Nano Synex Ltd [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Short term debt principal outstanding</a></td>
<td class="nump">$ 905,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPayableCurrent', window );">Accrued interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45,722<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermBorrowings', window );">Short term debt outstanding balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 950,722<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Accrued interest rate</a></td>
<td class="nump">2.62%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromRelatedPartyDebt', window );">Proceeds from related party debt</a></td>
<td class="nump">$ 3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromRelatedPartyDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a long-term borrowing made from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Proceeds from Advances from Affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromRelatedPartyDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reflects the total carrying amount as of the balance sheet date of debt having initial terms less than one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(13))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTypeAxis=QLGN_NotesPayableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTypeAxis=QLGN_NotesPayableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=QLGN_NanoSynexMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=QLGN_NanoSynexMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140569893383056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE OF WARRANTS ACTIVITY (Details) - Series C Warrants [Member] - Common Stock Warrants [Member] - $ / shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber', window );">Number of Shares, Warrants Outstanding Beginning</a></td>
<td class="nump">248,162<span></span>
</td>
<td class="nump">337,860<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Per Share Warrants Outstanding Beginning</a></td>
<td class="nump">$ 7.20<span></span>
</td>
<td class="nump">$ 7.20<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_RangeOfExercisePrice', window );">Range of Exercise Beginning</a></td>
<td class="nump">$ 7.20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAveragRemainingContractualTerm1', window );">Weighted Averag Remaining Contractual Term</a></td>
<td class="text">3 years 10 months 24 days<span></span>
</td>
<td class="text">2 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised', window );">Number of Shares, Warrants Exercised</a></td>
<td class="num">(536)<span></span>
</td>
<td class="num">(80,731)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Per Share Warrants Exercised</a></td>
<td class="nump">$ 7.20<span></span>
</td>
<td class="nump">$ 7.20<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures', window );">Number of Shares, Warrants Forfeited</a></td>
<td class="num">(247,625)<span></span>
</td>
<td class="num">(8,967)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Per Share Warrants Forfeited</a></td>
<td class="nump">$ 7.20<span></span>
</td>
<td class="nump">$ 7.20<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations', window );">Number of Shares, Warrants Expired</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Per Share Warrants Expired</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted', window );">Number of Shares, Warrants Granted</a></td>
<td class="nump">3,849,570<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Per Share Warrants Granted</a></td>
<td class="nump">$ 1.53<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber', window );">Number of Shares, Warrants Outstanding Ending</a></td>
<td class="nump">3,849,571<span></span>
</td>
<td class="nump">248,162<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Per Share Warrants Outstanding Ending</a></td>
<td class="nump">$ 1.53<span></span>
</td>
<td class="nump">$ 7.20<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_RangeOfExercisePrice', window );">Range of Exercise Ending</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.20<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber', window );">Number of Shares, Warrants Exercisable</a></td>
<td class="nump">1,349,571<span></span>
</td>
<td class="nump">248,162<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageVestedExercisePrice', window );">Weighted Average Exercise Price Per Share Exercisable</a></td>
<td class="nump">$ 1.32<span></span>
</td>
<td class="nump">$ 7.20<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_RangeOfExercisePriceExercisableVested', window );">Range of Exercise Price, Exercisable</a></td>
<td class="nump">$ 1.32<span></span>
</td>
<td class="nump">$ 7.20<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNonExercisableWeightedAverageRemainingContractualTerm1', window );">Exercisable Weighted Averag Remaining Contractual Term</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">2 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_RangeOfExercisePriceExercisableVested', window );">Range of Exercise Price, Exercisable</a></td>
<td class="nump">$ 1.32<span></span>
</td>
<td class="nump">$ 7.20<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=QLGN_SeriesCWarrantsMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_RangeOfExercisePrice', window );">Range of Exercise Ending</a></td>
<td class="nump">1.32<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=QLGN_SeriesCWarrantsMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_RangeOfExercisePrice', window );">Range of Exercise Ending</a></td>
<td class="nump">$ 1.65<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_RangeOfExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Range of exercise price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_RangeOfExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_RangeOfExercisePriceExercisableVested">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Range of exercise price, exercisable (vested).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_RangeOfExercisePriceExercisableVested</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vestednon-option equity outstanding as of the balance sheet date can be currently converted under the non-option equity plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageVestedExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average exercise price per share exercisable (vested).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageVestedExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average exercise price per share warrants exercised.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award non option equity instruments expired in period weighted average exercise price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average exercise price per share warrants forfeited.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award non option equity instruments exercised in period weighted average common stock warrants reverse recapitalization.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAveragRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of non-option equity outstanding and currently vested exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAveragRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNonExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of non-option equity outstanding and currently nonvested exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNonExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock non-option equity plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of non-option equity instruments exercised by participants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares under non-option equity instrument agreements for which rights to exercise lapsed.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares under non-option equity instrument agreements that were cancelled as a result of occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net number of non-option equity instruments granted to participants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of equity instruments other than options outstanding, including both vested and non-vested instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=QLGN_SeriesCWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=QLGN_SeriesCWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=QLGN_CommonStockWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=QLGN_CommonStockWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140569893036736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE OF FAIR VALUE HIERARCHY FOR WARRANT LIABILITIES (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_FairValueAdjustmentOfWarrant', window );">Fair value for warrant liabilities</a></td>
<td class="nump">$ 1,686,200<span></span>
</td>
<td class="nump">$ 8,310,100<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_FairValueOfWarrantLiabilitiesOnDateOfExercise', window );">Common Stock Warrant liabilities, Exercises</a></td>
<td class="num">(858)<span></span>
</td>
<td class="num">(1,900,713)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_FairValueOfWarrantLiabilitiesIssuanceOfAlphaWarrants', window );">Issuance of Alpha warrants</a></td>
<td class="nump">2,834,547<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_ChangeInFairValueOfWarrantLiabilities', window );">Change in fair value of warrant liabilities</a></td>
<td class="num">(897,242)<span></span>
</td>
<td class="num">(4,723,187)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_FairValueAdjustmentOfWarrant', window );">Fair value for warrant liabilities</a></td>
<td class="nump">3,622,647<span></span>
</td>
<td class="nump">1,686,200<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Fair Value, Inputs, Level 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_FairValueAdjustmentOfWarrant', window );">Fair value for warrant liabilities</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_FairValueOfWarrantLiabilitiesOnDateOfExercise', window );">Common Stock Warrant liabilities, Exercises</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_FairValueOfWarrantLiabilitiesIssuanceOfAlphaWarrants', window );">Issuance of Alpha warrants</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_ChangeInFairValueOfWarrantLiabilities', window );">Change in fair value of warrant liabilities</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_FairValueAdjustmentOfWarrant', window );">Fair value for warrant liabilities</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Fair Value, Inputs, Level 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_FairValueAdjustmentOfWarrant', window );">Fair value for warrant liabilities</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_FairValueOfWarrantLiabilitiesOnDateOfExercise', window );">Common Stock Warrant liabilities, Exercises</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_FairValueOfWarrantLiabilitiesIssuanceOfAlphaWarrants', window );">Issuance of Alpha warrants</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_ChangeInFairValueOfWarrantLiabilities', window );">Change in fair value of warrant liabilities</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_FairValueAdjustmentOfWarrant', window );">Fair value for warrant liabilities</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Fair Value, Inputs, Level 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_FairValueAdjustmentOfWarrant', window );">Fair value for warrant liabilities</a></td>
<td class="nump">1,686,200<span></span>
</td>
<td class="nump">8,310,100<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_FairValueOfWarrantLiabilitiesOnDateOfExercise', window );">Common Stock Warrant liabilities, Exercises</a></td>
<td class="num">(858)<span></span>
</td>
<td class="num">(1,900,713)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_FairValueOfWarrantLiabilitiesIssuanceOfAlphaWarrants', window );">Issuance of Alpha warrants</a></td>
<td class="nump">2,834,547<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_ChangeInFairValueOfWarrantLiabilities', window );">Change in fair value of warrant liabilities</a></td>
<td class="num">(897,242)<span></span>
</td>
<td class="num">(4,723,187)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_FairValueAdjustmentOfWarrant', window );">Fair value for warrant liabilities</a></td>
<td class="nump">$ 3,622,647<span></span>
</td>
<td class="nump">$ 1,686,200<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_ChangeInFairValueOfWarrantLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Change in fair value of warrant liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_ChangeInFairValueOfWarrantLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_FairValueAdjustmentOfWarrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_FairValueAdjustmentOfWarrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_FairValueOfWarrantLiabilitiesIssuanceOfAlphaWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of warrant liabilities issuance of alpha warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_FairValueOfWarrantLiabilitiesIssuanceOfAlphaWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_FairValueOfWarrantLiabilitiesOnDateOfExercise">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of warrant liabilities on date of exercise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_FairValueOfWarrantLiabilitiesOnDateOfExercise</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140569892132112">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SCHEDULE OF ASSUMPTIONS OF WARRANT LIABILITIES (Details)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember', window );">Measurement Input, Expected Dividend Rate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Fair value assumptions, measurement input, percentages</a></td>
<td class="nump">0.00<span></span>
</td>
<td class="nump">0.00<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member] | Measurement Input, Risk Free Interest Rate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Fair value assumptions, measurement input, percentages</a></td>
<td class="nump">3.906<span></span>
</td>
<td class="nump">0.69<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member] | Measurement Input, Price Volatility [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Fair value assumptions, measurement input, percentages</a></td>
<td class="nump">88<span></span>
</td>
<td class="nump">84<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member] | Measurement Input, Expected Term [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Fair value assumptions, measurement input, term</a></td>
<td class="text">10 months 24 days<span></span>
</td>
<td class="text">1 year 10 months 24 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | Measurement Input, Risk Free Interest Rate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Fair value assumptions, measurement input, percentages</a></td>
<td class="nump">4.628<span></span>
</td>
<td class="nump">0.84<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | Measurement Input, Price Volatility [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Fair value assumptions, measurement input, percentages</a></td>
<td class="nump">103<span></span>
</td>
<td class="nump">87<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | Measurement Input, Expected Term [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Fair value assumptions, measurement input, term</a></td>
<td class="text">5 years 5 months 23 days<span></span>
</td>
<td class="text">2 years 6 months<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_WeightedAverageMember', window );">Weighted Average [Member] | Measurement Input, Risk Free Interest Rate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Fair value assumptions, measurement input, percentages</a></td>
<td class="nump">4.15<span></span>
</td>
<td class="nump">0.72<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_WeightedAverageMember', window );">Weighted Average [Member] | Measurement Input, Price Volatility [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Fair value assumptions, measurement input, percentages</a></td>
<td class="nump">98<span></span>
</td>
<td class="nump">85<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_WeightedAverageMember', window );">Weighted Average [Member] | Measurement Input, Expected Term [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Fair value assumptions, measurement input, term</a></td>
<td class="text">3 years 10 months 24 days<span></span>
</td>
<td class="text">2 years 3 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_WeightedAverageMember', window );">Weighted Average [Member] | Measurement Input, Expected Dividend Rate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Fair value assumptions, measurement input, percentages</a></td>
<td class="nump">0.00<span></span>
</td>
<td class="nump">0.00<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_WeightedAverageMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_WeightedAverageMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140569893386896">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>WARRANT LIABILITIES (Details Narrative) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 22, 2022</div></th>
<th class="th"><div>May 26, 2022</div></th>
<th class="th"><div>Apr. 25, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13.20<span></span>
</td>
<td class="nump">$ 40.70<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrant to purchase shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=QLGN_SeriesCWarrantsMember', window );">Series C Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock Issued During Period, Shares, New Issues</a></td>
<td class="nump">1,002,717<span></span>
</td>
<td class="nump">49,952<span></span>
</td>
<td class="nump">49,318<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=QLGN_SeriesCWarrantsMember', window );">Series C Warrants [Member] | Alpha Capital [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrant</a></td>
<td class="nump">$ 1.65<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrant to purchase shares</a></td>
<td class="nump">2,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_ConversionPricePercentage', window );">Conversion price percentage</a></td>
<td class="nump">125.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrant</a></td>
<td class="nump">$ 1.32<span></span>
</td>
<td class="nump">$ 5.136<span></span>
</td>
<td class="nump">$ 6.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrant</a></td>
<td class="nump">$ 5.136<span></span>
</td>
<td class="nump">$ 6.00<span></span>
</td>
<td class="nump">$ 7.195<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=QLGN_SeriesCWarrantsMember', window );">Series C Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.195<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=QLGN_SeriesCWarrantsMember', window );">Series C Warrants [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrants and Rights Outstanding, Term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=QLGN_SeriesCWarrantsMember', window );">Series C Warrants [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrants and Rights Outstanding, Term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year 5 months 26 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_ConversionPricePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Conversion price percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_ConversionPricePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=QLGN_SeriesCWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=QLGN_SeriesCWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=QLGN_AlphaCapitalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=QLGN_AlphaCapitalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=QLGN_SeriesCWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=QLGN_SeriesCWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140569889479664">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SCHEDULE OF SENIOR SECURED CONVERTIBLE DEBT (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleDebt', window );">Total convertible debt - related party</a></td>
<td class="nump">$ 60,197<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=QLGN_SeniorSecuredConvertibleDebtMember', window );">Senior Secured Convertible Debt [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SecuredDebt', window );">Senior secured convertible debenture</a></td>
<td class="nump">3,300,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Discount on convertible debenture</a></td>
<td class="num">(3,239,803)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleDebt', window );">Total convertible debt - related party</a></td>
<td class="nump">$ 60,197<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, carrying amount of debt identified as being convertible into another form of financial instrument (typically the entity's common stock) as of the balance sheet date, which originally required full repayment more than twelve months after issuance or greater than the normal operating cycle of the company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28541-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SecuredDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date, including the current and noncurrent portions, of collateralized debt obligations (with maturities initially due after one year or beyond the operating cycle, if longer). Such obligations include mortgage loans, chattel loans, and any other borrowings secured by assets of the borrower.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SecuredDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=QLGN_SeniorSecuredConvertibleDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=QLGN_SeniorSecuredConvertibleDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140569889551872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONVERTIBLE DEBT - RELATED PARTY (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="2"></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 22, 2022</div></th>
<th class="th"><div>Dec. 22, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrant to purchase shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13.20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40.70<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debenture accrues interest rate</a></td>
<td class="nump">8.00%<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Shares of Common stock, issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,210,737<span></span>
</td>
<td class="nump">3,529,018<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Fair value of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (906,345)<span></span>
</td>
<td class="num">$ (4,723,187)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=QLGN_SeniorConvertibleDebentureMember', window );">Senior Convertible Debenture [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentIncreaseAccruedInterest', window );">Unpaid interest</a></td>
<td class="nump">$ 110,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentRate', window );">Conversion rate</a></td>
<td class="nump">85.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_PrincipalAmountPercentage', window );">Principal amount percentage</a></td>
<td class="nump">105.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=QLGN_AlphaCapitalMember', window );">Alpha Capital [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Shares of Common stock, issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,157,087<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=QLGN_AlphaCapitalMember', window );">Alpha Capital [Member] | Series C Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrant to purchase shares</a></td>
<td class="nump">2,500,000<span></span>
</td>
<td class="nump">2,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrant</a></td>
<td class="nump">$ 1.65<span></span>
</td>
<td class="nump">$ 1.65<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_ConversionPricePercentage', window );">Conversion price percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">125.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=QLGN_AlphaCapitalMember', window );">Alpha Capital [Member] | Senior Convertible Debenture [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtInterestRateIncrease', window );">Senior convertible debenture rate</a></td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SecuredDebt', window );">Principal amount</a></td>
<td class="nump">$ 3,300,000<span></span>
</td>
<td class="nump">$ 3,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_PurchasePrice', window );">Purchase Price</a></td>
<td class="nump">$ 3,000,000<span></span>
</td>
<td class="nump">$ 3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Conversion price</a></td>
<td class="nump">$ 1.32<span></span>
</td>
<td class="nump">$ 1.32<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=QLGN_AlphaCapitalOtherThirdPartiesMember', window );">Alpha Capital Other Third Parties [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Debt discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Fair value of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeNet', window );">Fair value of embedded derivative features</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_FeesAndCostsPaid', window );">Fees and costs paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_ConversionPricePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Conversion price percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_ConversionPricePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_FeesAndCostsPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fees and costs paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_FeesAndCostsPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_PrincipalAmountPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Principal amount percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_PrincipalAmountPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_PurchasePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Purchase price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_PurchasePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfDebtDiscountPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28541-108399<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfDebtDiscountPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Dividend or interest rate associated with the financial instrument issued in exchange for the original debt being converted in a noncash or part noncash transaction. Noncash are transactions that affect recognized assets or liabilities but that do not result in cash receipts or cash payments. Part noncash refers to that portion of the transaction not resulting in cash receipts or cash payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4304-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionPrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The price per share of the conversion feature embedded in the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031898-161870<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionPrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentIncreaseAccruedInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase for accrued, but unpaid interest on the debt instrument for the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentIncreaseAccruedInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net fair value as of the balance sheet date of the embedded derivative or group of embedded derivatives classified as assets, net of those classified as liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126966630&amp;loc=d3e41228-113958<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section 25<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=109262497&amp;loc=d3e20148-110875<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SecuredDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date, including the current and noncurrent portions, of collateralized debt obligations (with maturities initially due after one year or beyond the operating cycle, if longer). Such obligations include mortgage loans, chattel loans, and any other borrowings secured by assets of the borrower.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SecuredDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtInterestRateIncrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage increase in the stated interest rate on a short-term debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtInterestRateIncrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=QLGN_SeniorConvertibleDebentureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=QLGN_SeniorConvertibleDebentureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=QLGN_AlphaCapitalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=QLGN_AlphaCapitalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=QLGN_SeriesCWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=QLGN_SeriesCWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=QLGN_AlphaCapitalOtherThirdPartiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=QLGN_AlphaCapitalOtherThirdPartiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140569888930608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE OF EARNINGS PER SHARE BASIC AND DILUTED (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss used for basic earnings per share</a></td>
<td class="num">$ (18,640,543)<span></span>
</td>
<td class="num">$ (17,897,137)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic weighted-average common shares outstanding</a></td>
<td class="nump">3,840,340<span></span>
</td>
<td class="nump">2,933,487<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_DilutivePotentialSharesIssuableFromStockOptionsAndWarrants', window );">Dilutive potential shares issuable from stock options and warrants</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment', window );">Diluted weighted-average common shares outstanding</a></td>
<td class="nump">3,840,340<span></span>
</td>
<td class="nump">2,933,487<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_DilutivePotentialSharesIssuableFromStockOptionsAndWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Dilutive potential shares issuable from stock options and warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_DilutivePotentialSharesIssuableFromStockOptionsAndWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140569887630512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE OF DILUTIVE SECURITIES EXCLUDED FROM DILUTED NET LOSS PER SHARE (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total common stock equivalents</a></td>
<td class="nump">5,183,629<span></span>
</td>
<td class="nump">1,466,326<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=QLGN_SharesOfCommonStockSubjectToOutstandingOptionsMember', window );">Shares of Common Stock Subject to Outstanding Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total common stock equivalents</a></td>
<td class="nump">608,012<span></span>
</td>
<td class="nump">484,186<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=QLGN_SharesOfCommonStockSubjectToOutstandingWarrantsMember', window );">Shares of Common Stock Subject to Outstanding Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total common stock equivalents</a></td>
<td class="nump">4,575,617<span></span>
</td>
<td class="nump">982,140<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=QLGN_SharesOfCommonStockSubjectToOutstandingOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=QLGN_SharesOfCommonStockSubjectToOutstandingOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=QLGN_SharesOfCommonStockSubjectToOutstandingWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=QLGN_SharesOfCommonStockSubjectToOutstandingWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140569892227232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE OF OPERATING LEASE RIGHT OF USE ASSETS AND OPERATING LEASE LIABILITIES (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">$ 1,645,568<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense', window );">Less amortization of operating lease right-of-use assets</a></td>
<td class="num">(223,030)<span></span>
</td>
<td class="num">$ (225,059)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">1,422,538<span></span>
</td>
<td class="nump">1,645,568<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Lease liabilities at December 31, 2022</a></td>
<td class="nump">1,542,564<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Less non-current portion</a></td>
<td class="num">(1,301,919)<span></span>
</td>
<td class="num">(1,542,564)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current portion at Decebmer 31, 2022</a></td>
<td class="nump">240,645<span></span>
</td>
<td class="nump">134,091<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=QLGN_LongtermOperatingLeaseAgreementMember', window );">Long term Operating Lease Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">1,645,568<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense', window );">Less amortization of operating lease right-of-use assets</a></td>
<td class="num">(223,030)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">1,422,538<span></span>
</td>
<td class="nump">1,645,568<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Lease liabilities at December 31, 2021</a></td>
<td class="nump">1,676,655<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Less principal payments on operating lease liabilities</a></td>
<td class="num">(134,091)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Lease liabilities at December 31, 2022</a></td>
<td class="nump">1,542,564<span></span>
</td>
<td class="nump">$ 1,676,655<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Less non-current portion</a></td>
<td class="num">(1,301,919)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current portion at Decebmer 31, 2022</a></td>
<td class="nump">$ 240,645<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for right-of-use asset from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=QLGN_LongtermOperatingLeaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=QLGN_LongtermOperatingLeaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140569898295280">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SCHEDULE OF MATURITIES OF OPERATING LEASE LIABILITIES (Details)<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2023</a></td>
<td class="nump">$ 368,341<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2024</a></td>
<td class="nump">379,392<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2025</a></td>
<td class="nump">390,773<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2026</a></td>
<td class="nump">402,497<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive', window );">2027</a></td>
<td class="nump">379,164<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total</a></td>
<td class="nump">1,920,168<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less present value discount</a></td>
<td class="num">(377,604)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating lease liabilities</a></td>
<td class="nump">$ 1,542,564<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140569893688864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES (Details Narrative)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Apr. 05, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 15, 2021 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Feb. 28, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AreaOfLand', window );">Area of land | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,624<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Operating lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">61 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseDescription', window );">Operating lease term description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">November 1, 2022 to November 30, 2027<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRent', window );">Payments for Rent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,950,710<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_TenantImprovementAllowance', window );">Tenant improvement allowance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">339,360<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted-average remaining lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years 10 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted-average discount rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseExpense', window );">Operating Lease, Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 462,000<span></span>
</td>
<td class="nump">$ 342,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities', window );">Accrued expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,511,856<span></span>
</td>
<td class="nump">$ 1,510,990<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LitigationSettlementAmountAwardedToOtherParty', window );">Litigation settlement amount</a></td>
<td class="nump">$ 96,558<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=QLGN_NanoSynexMember', window );">Nano Synex Ltd [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Maximum future funding amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_DevelopmentFund', window );">Development fund</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=QLGN_NanoSynexMember', window );">Nano Synex Ltd [Member] | Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity', window );">Additional funding amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=QLGN_SekisuiDistributionAgreementMember', window );">Sekisui Distribution Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities', window );">Accrued expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 154,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=QLGN_FirstTwelveMonthsMember', window );">First 12 Months [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRent', window );">Payments for Rent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 335,966<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_DevelopmentFund">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Development fund.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_DevelopmentFund</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_TenantImprovementAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tenant improvement allowance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_TenantImprovementAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesAndOtherLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AreaOfLand">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area of land held.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AreaOfLand</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of lessee's operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current borrowing capacity under the credit facility considering any current restrictions on the amount that could be borrowed (for example, borrowings may be limited by the amount of current assets), but without considering any amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationSettlementAmountAwardedToOtherParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount awarded to other party in judgment or settlement of litigation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationSettlementAmountAwardedToOtherParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating lease expense. Excludes sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918638-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash payments to lessor's for use of assets under operating leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=QLGN_NanoSynexMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=QLGN_NanoSynexMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=QLGN_SekisuiDistributionAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=QLGN_SekisuiDistributionAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=QLGN_FirstTwelveMonthsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=QLGN_FirstTwelveMonthsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140569885563584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RESEARCH AND LICENSE AGREEMENTS (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="7">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1">28 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Jan. 31, 2022</div></th>
<th class="th"><div>Feb. 28, 2021</div></th>
<th class="th"><div>Nov. 30, 2020</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,837,133<span></span>
</td>
<td class="nump">$ 11,716,718<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_LicenseCost', window );">License cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40,000<span></span>
</td>
<td class="nump">60,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromConvertibleDebt', window );">Proceeds from convertible debt</a></td>
<td class="nump">$ 3,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Product sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,983,556<span></span>
</td>
<td class="nump">5,653,725<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=QLGN_LicenseRevenueMember', window );">License Revenue [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Product sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">632,004<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=QLGN_UniversityOfLouisvilleResearchFoundationMember', window );">University of Louisville Research Foundation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,000<span></span>
</td>
<td class="nump">243,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=QLGN_YiXinZhenDuanJishuLtdMember', window );">Yi Xin Zhen Duan Jishu Ltd [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredRevenue', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">670,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Product sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">38,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=QLGN_YiXinZhenDuanJishuLtdMember', window );">Yi Xin Zhen Duan Jishu Ltd [Member] | License Revenue [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Product sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">632,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=QLGN_STAPharmaceuticalCoLtdMember', window );">STA Pharmaceutical Co Ltd [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,000<span></span>
</td>
<td class="nump">3,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepositAssets', window );">Upfront deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=QLGN_SponsoredResearchAgreementAndLicenseMember', window );">Sponsored Research and License Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">164,000<span></span>
</td>
<td class="nump">325,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_LicenseCost', window );">License cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">94,000<span></span>
</td>
<td class="nump">118,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RoyaltyExpense', window );">Minimum annual royalties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=QLGN_SponsoredResearchAgreementAndLicenseMember', window );">Sponsored Research and License Agreement [Member] | University of Louisville Research Foundation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_ReimbursementOfResearchExpenses', window );">Reimbursement of research expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 693,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_AgreementTermPaymentDescription', window );">Agreement term payment, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">In
July 2020, the Company entered into an exclusive license agreement with ULRF for RAS interaction inhibitor drug candidates. Under the
agreement, the Company will take over development, regulatory approval and commercialization of the candidates from ULRF and is responsible
for maintenance of the related intellectual property portfolio. In return, ULRF received approximately $112,000 for an upfront license
fee and reimbursement of prior patent costs. In addition, the Company has agreed to pay ULRF (i) royalties, on patent-covered net sales
associated with the commercialization, of 4% (on net sales up to a cumulative $250,000,000) or 5% (on net sales above a cumulative $250,000,000),
until expiration of the licensed patent, and 2.5% (on net sales for any sales not covered by Licensed Patents), (ii) 30% to 50% of any
non-royalty sublicensee income received (50% for sublicenses granted in the first two years of the ULRF license agreement, 40% for sublicenses
granted in the third or fourth years of the ULRF license agreement, and 30% for sublicenses granted in the fifth year of the ULRF license
agreement or thereafter), (iii) reimbursements for ongoing costs associated with the preparation, filing, prosecution and maintenance
of licensed patents, incurred prior to July 2020, and (iv) payments ranging from $<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_RegulatoryMarketingApprovalExpenses', window );">Regulatory marketing approval, expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_CumulativeSales', window );">Cumulative sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Licensed product net sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=QLGN_LicenseAndSponsoredResearchAgreementsMember', window );">License and Sponsored Research Agreements [Member] | University of Louisville Research Foundation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_ReimbursementOfResearchExpenses', window );">Reimbursement of research expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 830,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_AgreementTermPaymentDescription', window );">Agreement term payment, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">In
addition, the Company agreed to pay ULRF (i) royalties, on patent-covered net sales associated with the commercialization of
anti-nucleolin agent-conjugated nanoparticles, of 4% (on net sales up to a cumulative $250,000,000) or 5% (on net sales above a
cumulative $250,000,000), until expiration of the last to expire of the licensed patents, (ii) 30% to 50% of any non-royalty
sublicensee income received (50% for sublicenses granted in the first two years of the ULRF license agreement, 40% for sublicenses
granted in the third or fourth years of the ULRF license agreement, and 30% for sublicenses granted in the fifth year of the ULRF
license agreement or thereafter), (iii) reimbursements for ongoing costs associated with the preparation, filing, prosecution and
maintenance of licensed patents, incurred prior to June 2018, and (iv) payments ranging from $100,000
to $5,000,000
upon the achievement of certain regulatory and commercial milestones.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">758,000<span></span>
</td>
<td class="nump">646,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_LicenseCost', window );">License cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000<span></span>
</td>
<td class="nump">28,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromConvertibleDebt', window );">Proceeds from convertible debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_PatentCosts', window );">Patent costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=QLGN_LicenseAndSponsoredResearchAgreementsMember', window );">License and Sponsored Research Agreements [Member] | University of Louisville Research Foundation [Member] | Licensed Product Sales [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_RegulatoryMarketingApprovalExpenses', window );">Regulatory marketing approval, expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_CumulativeSales', window );">Cumulative sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_RegulatoryMarketingApprovalExpensesOne', window );">Regulatory marketing approval, expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=QLGN_LicenseAndSponsoredResearchAgreementsMember', window );">License and Sponsored Research Agreements [Member] | University of Louisville Research Foundation [Member] | Phase 1 Clinical Trial [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_MilestonePayment', window );">Milestone payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=QLGN_LicenseAndSponsoredResearchAgreementsMember', window );">License and Sponsored Research Agreements [Member] | University of Louisville Research Foundation [Member] | Phase 2 Clinical Trial [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_MilestonePayment', window );">Milestone payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=QLGN_LicenseAndSponsoredResearchAgreementsMember', window );">License and Sponsored Research Agreements [Member] | University of Louisville Research Foundation [Member] | Phase 3 Clinical Trial [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_MilestonePayment', window );">Milestone payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">350,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=QLGN_LicenseAndSponsoredResearchAgreementsMember', window );">License and Sponsored Research Agreements [Member] | University of Louisville Research Foundation [Member] | Phase Clinical Trial [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_MilestonePayment', window );">Milestone payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=QLGN_LicenseAndSponsoredResearchAgreementsMember', window );">License and Sponsored Research Agreements [Member] | University of Louisville Research Foundation [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_MilestonePayment', window );">Milestone payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_ShortfallPayments', window );">Shortfall payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=QLGN_LicenseAndSponsoredResearchAgreementsMember', window );">License and Sponsored Research Agreements [Member] | University of Louisville Research Foundation [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_MilestonePayment', window );">Milestone payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_ShortfallPayments', window );">Shortfall payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=QLGN_LicenseAgreementMember', window );">License Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_LicenseCost', window );">License cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">338,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_ReimbursementOfPatent', window );">Reimbursement of patent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 160,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=QLGN_LicenseAgreementMember', window );">License Agreement [Member] | Upfront Payment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_ReimbursementOfPatent', window );">Reimbursement of patent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=QLGN_LicenseAgreementMember', window );">License Agreement [Member] | University of Louisville Research Foundation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_UpfrontLicenseFee', window );">Upfront license fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 24,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=QLGN_LicenseAgreementMember', window );">License Agreement [Member] | University of Louisville Research Foundation [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_UpfrontLicenseFee', window );">Upfront license fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=QLGN_LicenseAgreementMember', window );">License Agreement [Member] | University of Louisville Research Foundation [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_UpfrontLicenseFee', window );">Upfront license fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 430,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=QLGN_LicenseAgreementMember', window );">License Agreement [Member] | Advanced Cancer Therapeutics, LLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_CumulativeSales', window );">Cumulative sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Licensed product net sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_LicenseCost', window );">License cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromConvertibleDebt', window );">Proceeds from convertible debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_AgreementDescription', window );">Agreement description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">the Company entered into a license agreement with Advanced Cancer Therapeutics, LLC (&#8220;ACT&#8221;), granting the
Company exclusive rights to develop and commercialize QN-165, an aptamer-based drug candidate<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_MilestonePaymentForCumulativeMarketingExpenses', window );">Milestone payment for cumulative marketing expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=QLGN_LicenseAgreementMember', window );">License Agreement [Member] | Advanced Cancer Therapeutics, LLC [Member] | CE Mark [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_CumulativeSales', window );">Cumulative sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Licensed product net sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_MilestoneMethodRevenueRecognized', window );">Milestone method revenue recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_AgreementDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Agreement description.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_AgreementDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_AgreementTermPaymentDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Agreement term payment, description.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_AgreementTermPaymentDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_CumulativeSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cumulative sales.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_CumulativeSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_LicenseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>License costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_LicenseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_MilestoneMethodRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Milestone method revenue recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_MilestoneMethodRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_MilestonePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Milestone payment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_MilestonePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_MilestonePaymentForCumulativeMarketingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Milestone payment for cumulative marketing expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_MilestonePaymentForCumulativeMarketingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_PatentCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Patent costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_PatentCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_RegulatoryMarketingApprovalExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Regulatory marketing approval, expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_RegulatoryMarketingApprovalExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_RegulatoryMarketingApprovalExpensesOne">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Regulatory marketing approval expenses one.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_RegulatoryMarketingApprovalExpensesOne</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_ReimbursementOfPatent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reimbursement of patent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_ReimbursementOfPatent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_ReimbursementOfResearchExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reimbursement of research expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_ReimbursementOfResearchExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_ShortfallPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Shortfall payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_ShortfallPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_UpfrontLicenseFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Upfront license fee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_UpfrontLicenseFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(c))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepositAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The carrying amount of the asset transferred to a third party to serve as a deposit, which typically serves as security against failure by the transferor to perform under terms of an agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepositAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RoyaltyExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RoyaltyExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=QLGN_LicenseRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=QLGN_LicenseRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=QLGN_UniversityOfLouisvilleResearchFoundationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=QLGN_UniversityOfLouisvilleResearchFoundationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=QLGN_YiXinZhenDuanJishuLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=QLGN_YiXinZhenDuanJishuLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=QLGN_STAPharmaceuticalCoLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=QLGN_STAPharmaceuticalCoLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=QLGN_SponsoredResearchAgreementAndLicenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=QLGN_SponsoredResearchAgreementAndLicenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=QLGN_LicenseAndSponsoredResearchAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=QLGN_LicenseAndSponsoredResearchAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=QLGN_LicensedProductSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=QLGN_LicensedProductSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=QLGN_PhaseOneClinicalTrialMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=QLGN_PhaseOneClinicalTrialMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=QLGN_PhaseTwoClinicalTrialMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=QLGN_PhaseTwoClinicalTrialMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=QLGN_PhaseThreeClinicalTrialMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=QLGN_PhaseThreeClinicalTrialMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=QLGN_PhaseClinicalTrialMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=QLGN_PhaseClinicalTrialMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=QLGN_LicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=QLGN_LicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=QLGN_UpfrontPaymentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=QLGN_UpfrontPaymentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=QLGN_AdvancedCancerTherapeuticsLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=QLGN_AdvancedCancerTherapeuticsLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=QLGN_CEMarkMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=QLGN_CEMarkMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>99
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140569898285280">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SCHEDULE OF RESERVED SHARES (Details)<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Total</a></td>
<td class="nump">5,183,629<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_StockOptionMember', window );">Equity Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Total</a></td>
<td class="nump">608,012<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_WarrantMember', window );">Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Total</a></td>
<td class="nump">4,575,617<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_StockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_StockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>100
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140569893281040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE OF STOCK OPTION ACTIVITY (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems', window );"><strong>Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted- Average Remaining Contractual Life (in Years), Outstanding at Ending</a></td>
<td class="text">11 months 4 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=QLGN_EmployeesAndNonemployeeServiceProviderMember', window );">Employees and Non-employee Service Provider [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems', window );"><strong>Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of shares, options outstanding, beginning</a></td>
<td class="nump">484,186<span></span>
</td>
<td class="nump">401,136<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Range of Exercise price, Options Outstanding</a></td>
<td class="nump">$ 60.70<span></span>
</td>
<td class="nump">$ 70.50<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm3', window );">Weighted- Average Remaining Contractual Life (in Years), Outstanding, Beginning</a></td>
<td class="text">8 years 6 months 7 days<span></span>
</td>
<td class="text">9 years 3 months 14 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod', window );">Number of shares, options granted</a></td>
<td class="nump">134,469<span></span>
</td>
<td class="nump">83,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, options granted</a></td>
<td class="nump">$ 5.24<span></span>
</td>
<td class="nump">$ 13.70<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm2', window );">Weighted- Average Remaining Contractual Life (in Years), Options Granted</a></td>
<td class="text">5 years 11 months 26 days<span></span>
</td>
<td class="text">9 years 9 months 14 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod', window );">Number of shares, options expired</a></td>
<td class="num">(9,379)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, options expired</a></td>
<td class="nump">$ 932.75<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExpirationsInPeriodWeightedAverageExercisePrice', window );">Range of exercise price, options expired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Number of shares, options forfeited</a></td>
<td class="num">(1,264)<span></span>
</td>
<td class="num">(450)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, options forfeited</a></td>
<td class="nump">$ 22.64<span></span>
</td>
<td class="nump">$ 36.80<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Shares, Options Outstanding at Ending</a></td>
<td class="nump">608,012<span></span>
</td>
<td class="nump">484,186<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Range of Exercise price, Options Outstanding</a></td>
<td class="nump">$ 35.02<span></span>
</td>
<td class="nump">$ 60.70<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted- Average Remaining Contractual Life (in Years), Outstanding at Ending</a></td>
<td class="text">8 years 1 month 2 days<span></span>
</td>
<td class="text">8 years 6 months 7 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber', window );">Number of shares, options exercisable (vested)</a></td>
<td class="nump">288,704<span></span>
</td>
<td class="nump">140,820<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice', window );">Range of exercise price, options exercisable (vested)</a></td>
<td class="nump">$ 46.32<span></span>
</td>
<td class="nump">$ 108.80<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted- Average Remaining Contractual Life (in Years), Options Exercisable (vested)</a></td>
<td class="text">7 years 7 months 2 days<span></span>
</td>
<td class="text">7 years 11 months 8 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares', window );">Number of shares, options non-exercisable (non-vested)</a></td>
<td class="nump">319,308<span></span>
</td>
<td class="nump">343,366<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToNonVestExercisableWeightedAverageExercisePrice', window );">Weighted average exercise price, options non-exercisable (non-vested)</a></td>
<td class="nump">$ 24.80<span></span>
</td>
<td class="nump">$ 41.00<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_WeightedAverageRemainingContractualLifeInYearsOptionsNonexercisableNonvested', window );">Weighted- Average Remaining Contractual Life (in Years), Options Non-exercisable (non-vested)</a></td>
<td class="text">8 years 7 months 2 days<span></span>
</td>
<td class="text">8 years 9 months 21 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=QLGN_EmployeesAndNonemployeeServiceProviderMember', window );">Employees and Non-employee Service Provider [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems', window );"><strong>Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Range of Exercise price, Options Outstanding</a></td>
<td class="nump">$ 12.40<span></span>
</td>
<td class="nump">$ 35.20<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionGrantedWeightedAverageExercisePrice', window );">Range of Exercise price, Options Outstanding</a></td>
<td class="nump">5.14<span></span>
</td>
<td class="nump">12.40<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExpirationsInPeriodWeightedAverageExercisePrice', window );">Range of exercise price, options expired</a></td>
<td class="nump">57.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice', window );">Range of Exercise price, Options Forfeited</a></td>
<td class="nump">5.14<span></span>
</td>
<td class="nump">35.20<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Range of Exercise price, Options Outstanding</a></td>
<td class="nump">5.14<span></span>
</td>
<td class="nump">12.40<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice', window );">Range of exercise price, options exercisable (vested)</a></td>
<td class="nump">12.40<span></span>
</td>
<td class="nump">35.20<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Range of exercise price, options non-exercisable (non-vested)</a></td>
<td class="nump">5.14<span></span>
</td>
<td class="nump">12.40<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=QLGN_EmployeesAndNonemployeeServiceProviderMember', window );">Employees and Non-employee Service Provider [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems', window );"><strong>Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Range of Exercise price, Options Outstanding</a></td>
<td class="nump">14,657.50<span></span>
</td>
<td class="nump">14,657.50<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionGrantedWeightedAverageExercisePrice', window );">Range of Exercise price, Options Outstanding</a></td>
<td class="nump">10.50<span></span>
</td>
<td class="nump">32.90<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExpirationsInPeriodWeightedAverageExercisePrice', window );">Range of exercise price, options expired</a></td>
<td class="nump">14,657.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice', window );">Range of Exercise price, Options Forfeited</a></td>
<td class="nump">49.70<span></span>
</td>
<td class="nump">49.70<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Range of Exercise price, Options Outstanding</a></td>
<td class="nump">51.30<span></span>
</td>
<td class="nump">14,657.50<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice', window );">Range of exercise price, options exercisable (vested)</a></td>
<td class="nump">51.30<span></span>
</td>
<td class="nump">14,657.50<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Range of exercise price, options non-exercisable (non-vested)</a></td>
<td class="nump">$ 10.50<span></span>
</td>
<td class="nump">$ 51.30<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-based compensation arrangement by share-based payment award option expirations in period weighted average exercise price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionGrantedWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award option granted weighted average exercise price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionGrantedWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToNonVestExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average exercise price, options non-exercisable (non-vested).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToNonVestExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted- Average Remaining Contractual Life (in Years), Options Granted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm3">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award non option equity instruments legacy ritter weighted average exercise price one.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm3</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_WeightedAverageRemainingContractualLifeInYearsOptionsNonexercisableNonvested">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted- average remaining contractual life (in years), options non-exercisable (non-vested).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_WeightedAverageRemainingContractualLifeInYearsOptionsNonexercisableNonvested</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price of options that were either forfeited or expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of non-vested options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average grant-date fair value of non-vested options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=QLGN_EmployeesAndNonemployeeServiceProviderMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=QLGN_EmployeesAndNonemployeeServiceProviderMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>101
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140569895849696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE OF ASSUMPTION USED IN BLACK-SCHOLES OPTION-PRICING METHOD (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected stock-price volatility</a></td>
<td class="nump">103.00%<span></span>
</td>
<td class="nump">102.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum', window );">Risk-free interest rate, minimum</a></td>
<td class="nump">1.58%<span></span>
</td>
<td class="nump">0.84%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum', window );">Risk-free interest rate, maximum</a></td>
<td class="nump">3.77%<span></span>
</td>
<td class="nump">1.51%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected average term of options (in years)</a></td>
<td class="text">5 years 11 months 26 days<span></span>
</td>
<td class="text">6 years 3 months 7 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price</a></td>
<td class="nump">$ 5.14<span></span>
</td>
<td class="nump">$ 12.40<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price</a></td>
<td class="nump">$ 10.50<span></span>
</td>
<td class="nump">$ 32.90<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>102
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140569894206000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE OF SHARE-BASED COMPENSATION EXPENSE (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total</a></td>
<td class="nump">$ 5,484,044<span></span>
</td>
<td class="nump">$ 5,293,651<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and Administrative Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total</a></td>
<td class="nump">4,649,649<span></span>
</td>
<td class="nump">4,465,911<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total</a></td>
<td class="nump">$ 834,395<span></span>
</td>
<td class="nump">$ 827,740<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>103
<FILENAME>R72.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140569887497184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE OF WARRANT ACTIVITY (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=QLGN_CompensatoryWarrantActivityMember', window );">Compensatory Warrant Activity [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber', window );">Number of Shares, Warrants Outstanding Beginning</a></td>
<td class="nump">179,046<span></span>
</td>
<td class="nump">129,403<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted', window );">Number of shares, warrants granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised', window );">Number of Shares, Warrants Exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,839)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations', window );">Number of Shares, Warrants Expired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures', window );">Number of Shares, Warrants Forfeited</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6,518)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber', window );">Number of Shares, Warrants Outstanding Ending</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">179,046<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations', window );">Number of Shares, Warrants Expired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=QLGN_NonCompensatoryWarrantActivityMember', window );">Non Compensatory Warrant Activity [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber', window );">Number of Shares, Warrants Outstanding Beginning</a></td>
<td class="nump">554,914<span></span>
</td>
<td class="nump">654,978<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Per Share Warrants Outstanding Beginning</a></td>
<td class="nump">$ 20.10<span></span>
</td>
<td class="nump">$ 43.60<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted', window );">Number of shares, warrants granted</a></td>
<td class="nump">331,464<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price per share warrants granted</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised', window );">Number of Shares, Warrants Exercised</a></td>
<td class="num">(331,464)<span></span>
</td>
<td class="num">(100,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price per share warrants exercised</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations', window );">Number of Shares, Warrants Expired</a></td>
<td class="nump">7,911<span></span>
</td>
<td class="nump">64<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price per share warrants expired</a></td>
<td class="nump">$ 37.78<span></span>
</td>
<td class="nump">$ 23,250.00<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures', window );">Number of Shares, Warrants Forfeited</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price per share warrants forfeited</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber', window );">Number of Shares, Warrants Outstanding Ending</a></td>
<td class="nump">547,003<span></span>
</td>
<td class="nump">554,914<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Per Share Warrants Outstanding Ending</a></td>
<td class="nump">$ 19.76<span></span>
</td>
<td class="nump">$ 20.10<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAveragRemainingContractualTerm1', window );">Weighted average remaining life (Years) exercisable</a></td>
<td class="text">3 months 29 days<span></span>
</td>
<td class="text">1 year 3 months 25 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber', window );">Number of Shares, Warrants Exercisable</a></td>
<td class="nump">547,003<span></span>
</td>
<td class="nump">554,914<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageVestedExercisePrice', window );">Weighted Average Exercise Price Per Share Exercisable</a></td>
<td class="nump">$ 19.76<span></span>
</td>
<td class="nump">$ 20.10<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNonVestedNumber', window );">Number of shares, warrants non-exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageNonVestedExercise', window );">Weighted Average Exercise Price Per Share Non-Exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_RangeOfExercisePriceNonexercisableNonvested', window );">Range of Exercise Price, Non-Exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations', window );">Number of Shares, Warrants Expired</a></td>
<td class="num">(7,911)<span></span>
</td>
<td class="num">(64)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_RangeOfExercisePriceGranted', window );">Range of exercise price - granted</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_RangeOfExercisePriceExpired', window );">Range of exercise price - Expired</a></td>
<td class="nump">0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInRangeOfExercisePrice', window );">Weighted average exercise price per share warrants expired</a></td>
<td class="nump">37.78<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedInRangeOfExercisePrice', window );">Weighted average exercise price per share warrants forfeited</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsNonExercisableNumber', window );">Number of Shares, Warrants Exercisable</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageVestedNonExercisePrice', window );">Weighted Average Exercise Price Per Share Exercisable</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_RangeOfExercisePriceNonExercisableVested', window );">Range of exercise price - Exercisable</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNonExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted average remaining life (Years) non-exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member] | Non Compensatory Warrant Activity [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_RangeOfExercisePriceExercisableVested', window );">Range of exercise price - Exercisable</a></td>
<td class="nump">1.32<span></span>
</td>
<td class="nump">$ 11.10<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsRangeOfExercisePrice', window );">Range of exercise price</a></td>
<td class="nump">11.10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsRangeOfExercisePrice', window );">Range of exercise price</a></td>
<td class="nump">1.32<span></span>
</td>
<td class="nump">11.10<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | Non Compensatory Warrant Activity [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_RangeOfExercisePriceExercisableVested', window );">Range of exercise price - Exercisable</a></td>
<td class="nump">20.00<span></span>
</td>
<td class="nump">37.78<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsRangeOfExercisePrice', window );">Range of exercise price</a></td>
<td class="nump">37.78<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsRangeOfExercisePrice', window );">Range of exercise price</a></td>
<td class="nump">$ 20.00<span></span>
</td>
<td class="nump">37.78<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=QLGN_CompensatoryWarrantActivityMember', window );">Compensatory Warrant Activity [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber', window );">Number of Shares, Warrants Outstanding Beginning</a></td>
<td class="nump">179,046<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Per Share Warrants Outstanding Beginning</a></td>
<td class="nump">$ 15.20<span></span>
</td>
<td class="nump">16.60<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAveragRemainingContractualTerm1', window );">Weighted Average Remaining Life (Years) - outstanding</a></td>
<td class="text">2 years 7 months 20 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted', window );">Number of shares, warrants granted</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price per share warrants granted</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">13.20<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised', window );">Number of Shares, Warrants Exercised</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price per share warrants exercised</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">20.90<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations', window );">Number of Shares, Warrants Expired</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price per share warrants expired</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures', window );">Number of Shares, Warrants Forfeited</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price per share warrants forfeited</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 20.70<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber', window );">Number of Shares, Warrants Outstanding Ending</a></td>
<td class="nump">179,046<span></span>
</td>
<td class="nump">179,046<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Per Share Warrants Outstanding Ending</a></td>
<td class="nump">$ 9.12<span></span>
</td>
<td class="nump">$ 15.20<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAveragRemainingContractualTerm1', window );">Weighted average remaining life (Years) exercisable</a></td>
<td class="text">1 year 8 months 23 days<span></span>
</td>
<td class="text">2 years 7 months 20 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber', window );">Number of Shares, Warrants Exercisable</a></td>
<td class="nump">179,046<span></span>
</td>
<td class="nump">179,046<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageVestedExercisePrice', window );">Weighted Average Exercise Price Per Share Exercisable</a></td>
<td class="nump">$ 9.12<span></span>
</td>
<td class="nump">$ 15.20<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNonVestedNumber', window );">Number of shares, warrants non-exercisable</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageNonVestedExercise', window );">Weighted Average Exercise Price Per Share Non-Exercisable</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_RangeOfExercisePriceNonexercisableNonvested', window );">Range of Exercise Price, Non-Exercisable</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations', window );">Number of Shares, Warrants Expired</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=QLGN_CompensatoryWarrantActivityMember', window );">Compensatory Warrant Activity [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_RangeOfExercisePriceOutstanding', window );">Range of exercise price - beginning</a></td>
<td class="nump">$ 11.10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_RangeOfExercisePriceOutstanding', window );">Range of exercise price - ending</a></td>
<td class="nump">1.32<span></span>
</td>
<td class="nump">11.10<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_RangeOfExercisePriceExercisableVested', window );">Range of exercise price - Exercisable</a></td>
<td class="nump">1.32<span></span>
</td>
<td class="nump">11.10<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=QLGN_CompensatoryWarrantActivityMember', window );">Compensatory Warrant Activity [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_RangeOfExercisePriceOutstanding', window );">Range of exercise price - beginning</a></td>
<td class="nump">25.40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_RangeOfExercisePriceOutstanding', window );">Range of exercise price - ending</a></td>
<td class="nump">25.40<span></span>
</td>
<td class="nump">25.40<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_RangeOfExercisePriceExercisableVested', window );">Range of exercise price - Exercisable</a></td>
<td class="nump">$ 25.40<span></span>
</td>
<td class="nump">$ 25.40<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_RangeOfExercisePriceExercisableVested">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Range of exercise price, exercisable (vested).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_RangeOfExercisePriceExercisableVested</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_RangeOfExercisePriceExpired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Range of exercise price expired</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_RangeOfExercisePriceExpired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_RangeOfExercisePriceGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Range of exercise price granted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_RangeOfExercisePriceGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_RangeOfExercisePriceNonExercisableVested">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Range of exercise price non exercisable vested</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_RangeOfExercisePriceNonExercisableVested</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_RangeOfExercisePriceNonexercisableNonvested">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Range of exercise price, non-exercisable (non-vested).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_RangeOfExercisePriceNonexercisableNonvested</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_RangeOfExercisePriceOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Range Of Exercise Price Outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_RangeOfExercisePriceOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNonVestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares, warrants non-exercisable (non-vested).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNonVestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vestednon-option equity outstanding as of the balance sheet date can be currently converted under the non-option equity plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageNonVestedExercise">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average exercise price per share non-exercisable (non-vested).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageNonVestedExercise</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageVestedExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average exercise price per share exercisable (vested).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageVestedExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageVestedNonExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award non option equity instruments exercisable weighted average vested non exercise price</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageVestedNonExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average exercise price per share warrants exercised.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award non option equity instruments expired in period weighted average exercise price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInRangeOfExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award non option equity instruments expired in range of exercise price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInRangeOfExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average exercise price per share warrants forfeited.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedInRangeOfExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award non option equity instruments forfeited in range of exercise price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedInRangeOfExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award non option equity instruments exercised in period weighted average common stock warrants reverse recapitalization.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsNonExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award non option equity instruments non exercisable number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsNonExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAveragRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of non-option equity outstanding and currently vested exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAveragRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNonExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of non-option equity outstanding and currently nonvested exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNonExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAveragRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award non option equity instruments legacy ritter weighted average exercise price one.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAveragRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock non-option equity plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsRangeOfExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award non option equity instruments range of exercise price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsRangeOfExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of non-option equity instruments exercised by participants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares under non-option equity instrument agreements for which rights to exercise lapsed.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares under non-option equity instrument agreements that were cancelled as a result of occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net number of non-option equity instruments granted to participants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of equity instruments other than options outstanding, including both vested and non-vested instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=QLGN_CompensatoryWarrantActivityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=QLGN_CompensatoryWarrantActivityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=QLGN_NonCompensatoryWarrantActivityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=QLGN_NonCompensatoryWarrantActivityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=QLGN_CompensatoryWarrantActivityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=QLGN_CompensatoryWarrantActivityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>104
<FILENAME>R73.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140569875870048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS&#8217; EQUITY (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="3"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 22, 2022</div></th>
<th class="th"><div>Dec. 22, 2022</div></th>
<th class="th"><div>Dec. 22, 2022</div></th>
<th class="th"><div>May 26, 2022</div></th>
<th class="th"><div>Apr. 25, 2022</div></th>
<th class="th"><div>Dec. 01, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>May 31, 2022</div></th>
<th class="th"><div>Apr. 24, 2022</div></th>
<th class="th"><div>Nov. 29, 2021</div></th>
<th class="th"><div>Aug. 31, 2020</div></th>
<th class="th"><div>Jul. 31, 2020</div></th>
<th class="th"><div>May 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrant to purchase shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Plan shares available</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,183,629<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Cost is expected to be recognized over a weighted average period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">11 months 4 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Compensation cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,484,044<span></span>
</td>
<td class="nump">$ 5,293,651<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized compensation cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Purchase of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">219,101<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of Warrant or Right, Exercise Price of Warrants or Rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13.20<span></span>
</td>
<td class="nump">$ 40.70<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13.20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_FairValueOfIssuanceCost', window );">Fair value of issuance cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Fair value adjustment of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(906,345)<span></span>
</td>
<td class="num">(4,723,187)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Compensation cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,484,044<span></span>
</td>
<td class="nump">5,293,651<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=QLGN_NanoSynexMember', window );">Nano Synex Ltd [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Purchase of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,048<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of Warrant or Right, Exercise Price of Warrants or Rights</a></td>
<td class="nump">$ 1.32<span></span>
</td>
<td class="nump">$ 1.32<span></span>
</td>
<td class="nump">$ 1.32<span></span>
</td>
<td class="nump">$ 5.136<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Fair value adjustment of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 891<span></span>
</td>
<td class="nump">$ 696<span></span>
</td>
<td class="nump">$ 2,533<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_ModifiedToExercisePrice', window );">Modified to exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and Administrative Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Compensation cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,649,649<span></span>
</td>
<td class="nump">4,465,911<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember', window );">Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrant to purchase shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Purchase of warrants</a></td>
<td class="nump">67,620<span></span>
</td>
<td class="nump">67,620<span></span>
</td>
<td class="nump">67,620<span></span>
</td>
<td class="nump">67,619<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of Warrant or Right, Exercise Price of Warrants or Rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13.20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_WarrantsExtendedDateDescription', window );">Warrants extended date description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">June
3, 2023 to September 14, 2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Fair value adjustment of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,548<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember', window );">Warrant [Member] | General and Administrative Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Fair value adjustment of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 67,370<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=QLGN_WarrantOneMember', window );">Warrant One [Member] | General and Administrative Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Fair value adjustment of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 31,010<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=QLGN_CompensatoryWarrantActivityMember', window );">Compensatory Warrant Activity [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Compensation cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 67,370<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share Price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.14<span></span>
</td>
<td class="nump">$ 12.40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of Warrant or Right, Exercise Price of Warrants or Rights</a></td>
<td class="nump">$ 1.32<span></span>
</td>
<td class="nump">$ 1.32<span></span>
</td>
<td class="nump">$ 1.32<span></span>
</td>
<td class="nump">$ 5.136<span></span>
</td>
<td class="nump">$ 6.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member] | Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of Warrant or Right, Exercise Price of Warrants or Rights</a></td>
<td class="nump">5.136<span></span>
</td>
<td class="nump">5.136<span></span>
</td>
<td class="nump">5.136<span></span>
</td>
<td class="nump">0.10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share Price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 32.90<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.50<span></span>
</td>
<td class="nump">32.90<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of Warrant or Right, Exercise Price of Warrants or Rights</a></td>
<td class="nump">5.136<span></span>
</td>
<td class="nump">5.136<span></span>
</td>
<td class="nump">5.136<span></span>
</td>
<td class="nump">6.00<span></span>
</td>
<td class="nump">$ 7.195<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of Warrant or Right, Exercise Price of Warrants or Rights</a></td>
<td class="nump">$ 1.32<span></span>
</td>
<td class="nump">$ 1.32<span></span>
</td>
<td class="nump">$ 1.32<span></span>
</td>
<td class="nump">$ 5.136<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_StockOptionMember', window );">Equity Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Plan shares available</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">608,012<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Stock option granted exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.96<span></span>
</td>
<td class="nump">$ 11.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Stock options exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_StockOptionMember', window );">Equity Option [Member] | 2020 Stock Incentive Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Plan shares available</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">280,916<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">147,690<span></span>
</td>
<td class="nump">280,916<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">484,186<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">608,012<span></span>
</td>
<td class="nump">484,186<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of shares, options outstanding, beginning</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">484,186<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Shares, Options Outstanding at Ending</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">484,186<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">608,012<span></span>
</td>
<td class="nump">484,186<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription', window );">Stock options description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The
exercise price for an option issued under the 2020 Plan is determined by the Board of Directors, but will be (i) in the case of an incentive
stock option (A) granted to an employee who, at the time of grant of such option, is a 10% stockholder, no less than 110% of the fair
market value per share on the date of grant; or (B) granted to any other employee, no less than 100% of the fair market value per share
on the date of grant; and (ii) in the case of a non-statutory stock option, no less than 100% of the fair market value per share on the
date of grant.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Share-Based Payment Arrangement, Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Compensation cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,400,000<span></span>
</td>
<td class="nump">$ 5,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=QLGN_CompensatoryWarrantsMember', window );">Compensatory Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity', window );">Proceeds from Issuance or Sale of Equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Purchase of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">81,143<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">66,802<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of Warrant or Right, Exercise Price of Warrants or Rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 23.40<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=QLGN_NoncompensatoryEquityClassifiedWarrantsMember', window );">Noncompensatory Equity Classified Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Purchase of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">331,464<span></span>
</td>
<td class="nump">331,464<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,048<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">192,068<span></span>
</td>
<td class="nump">27,048<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of Warrant or Right, Exercise Price of Warrants or Rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11.10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11.10<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 52.50<span></span>
</td>
<td class="nump">$ 11.10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Fair value adjustment of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_WarrantsExercised', window );">Warrants exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of outstanding warrants to purchase, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">539,951<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=QLGN_NoncompensatoryEquityClassifiedWarrantsMember', window );">Noncompensatory Equity Classified Warrants [Member] | Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of Warrant or Right, Exercise Price of Warrants or Rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11.10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=QLGN_AlphaCapitalMember', window );">Alpha Capital [Member] | Noncompensatory Equity Classified Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Purchase of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">78,019<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of Warrant or Right, Exercise Price of Warrants or Rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=QLGN_AlphaCapitalMember', window );">Alpha Capital [Member] | Noncompensatory Equity Classified Warrants [Member] | Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Purchase of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">128,783<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of Warrant or Right, Exercise Price of Warrants or Rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 60.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=QLGN_AlphaCapitalMember', window );">Alpha Capital [Member] | Senior Convertible Debenture [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtInterestRateIncrease', window );">Senior convertible debenture rate</a></td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SecuredDebt', window );">Principal amount</a></td>
<td class="nump">$ 3,300,000<span></span>
</td>
<td class="nump">$ 3,300,000<span></span>
</td>
<td class="nump">$ 3,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_PurchasePrice', window );">Purchase Price</a></td>
<td class="nump">$ 3,000,000<span></span>
</td>
<td class="nump">$ 3,000,000<span></span>
</td>
<td class="nump">$ 3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Conversion price</a></td>
<td class="nump">$ 1.32<span></span>
</td>
<td class="nump">$ 1.32<span></span>
</td>
<td class="nump">$ 1.32<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=QLGN_EmployeesAndNonemployeeServiceProviderMember', window );">Employees and Non-employee Service Provider [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">484,186<span></span>
</td>
<td class="nump">401,136<span></span>
</td>
<td class="nump">608,012<span></span>
</td>
<td class="nump">484,186<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of shares, options outstanding, beginning</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">484,186<span></span>
</td>
<td class="nump">401,136<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Range of Exercise price, Options Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 60.70<span></span>
</td>
<td class="nump">$ 70.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm3', window );">Weighted- Average Remaining Contractual Life (in Years), Outstanding, Beginning</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">8 years 6 months 7 days<span></span>
</td>
<td class="text">9 years 3 months 14 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod', window );">Number of shares, options granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">134,469<span></span>
</td>
<td class="nump">83,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Stock option granted exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.24<span></span>
</td>
<td class="nump">$ 13.70<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm2', window );">Weighted- Average Remaining Contractual Life (in Years), Options Granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years 11 months 26 days<span></span>
</td>
<td class="text">9 years 9 months 14 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod', window );">Number of shares, options expired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(9,379)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, options expired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 932.75<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExpirationsInPeriodWeightedAverageExercisePrice', window );">Range of Exercise price, Options Expired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Number of shares, options forfeited</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,264)<span></span>
</td>
<td class="num">(450)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, options forfeited</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22.64<span></span>
</td>
<td class="nump">$ 36.80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Shares, Options Outstanding at Ending</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">484,186<span></span>
</td>
<td class="nump">401,136<span></span>
</td>
<td class="nump">608,012<span></span>
</td>
<td class="nump">484,186<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Range of Exercise price, Options Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 60.70<span></span>
</td>
<td class="nump">$ 70.50<span></span>
</td>
<td class="nump">$ 35.02<span></span>
</td>
<td class="nump">$ 60.70<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Cost is expected to be recognized over a weighted average period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">8 years 1 month 2 days<span></span>
</td>
<td class="text">8 years 6 months 7 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber', window );">Number of shares, options exercisable (vested)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">140,820<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">288,704<span></span>
</td>
<td class="nump">140,820<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice', window );">Range of exercise price, options exercisable (vested)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 108.80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 46.32<span></span>
</td>
<td class="nump">$ 108.80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted- Average Remaining Contractual Life (in Years), Options Exercisable (vested)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years 7 months 2 days<span></span>
</td>
<td class="text">7 years 11 months 8 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares', window );">Number of shares, options non-exercisable (non-vested)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">343,366<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">319,308<span></span>
</td>
<td class="nump">343,366<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToNonVestExercisableWeightedAverageExercisePrice', window );">Weighted average exercise price, options non-exercisable (non-vested)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 41.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 24.80<span></span>
</td>
<td class="nump">$ 41.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_WeightedAverageRemainingContractualLifeInYearsOptionsNonexercisableNonvested', window );">Weighted- Average Remaining Contractual Life (in Years), Options Non-exercisable (non-vested)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">8 years 7 months 2 days<span></span>
</td>
<td class="text">8 years 9 months 21 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=QLGN_EmployeesAndNonemployeeServiceProviderMember', window );">Employees and Non-employee Service Provider [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Range of Exercise price, Options Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12.40<span></span>
</td>
<td class="nump">$ 35.20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionGrantedWeightedAverageExercisePrice', window );">Range of Exercise price, Options Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.14<span></span>
</td>
<td class="nump">12.40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExpirationsInPeriodWeightedAverageExercisePrice', window );">Range of Exercise price, Options Expired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">57.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice', window );">Range of Exercise price, Options Forfeited</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.14<span></span>
</td>
<td class="nump">35.20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Range of Exercise price, Options Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.40<span></span>
</td>
<td class="nump">35.20<span></span>
</td>
<td class="nump">5.14<span></span>
</td>
<td class="nump">12.40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice', window );">Range of exercise price, options exercisable (vested)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35.20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.40<span></span>
</td>
<td class="nump">35.20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Range of exercise price, options non-exercisable (non-vested)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.14<span></span>
</td>
<td class="nump">12.40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=QLGN_EmployeesAndNonemployeeServiceProviderMember', window );">Employees and Non-employee Service Provider [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Range of Exercise price, Options Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,657.50<span></span>
</td>
<td class="nump">14,657.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionGrantedWeightedAverageExercisePrice', window );">Range of Exercise price, Options Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.50<span></span>
</td>
<td class="nump">32.90<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExpirationsInPeriodWeightedAverageExercisePrice', window );">Range of Exercise price, Options Expired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,657.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice', window );">Range of Exercise price, Options Forfeited</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49.70<span></span>
</td>
<td class="nump">49.70<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Range of Exercise price, Options Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,657.50<span></span>
</td>
<td class="nump">$ 14,657.50<span></span>
</td>
<td class="nump">51.30<span></span>
</td>
<td class="nump">14,657.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice', window );">Range of exercise price, options exercisable (vested)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,657.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">51.30<span></span>
</td>
<td class="nump">14,657.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Range of exercise price, options non-exercisable (non-vested)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 51.30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.50<span></span>
</td>
<td class="nump">$ 51.30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=QLGN_SeriesCWarrantsMember', window );">Series C Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,002,717<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49,952<span></span>
</td>
<td class="nump">49,318<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=QLGN_SeriesCWarrantsMember', window );">Series C Warrants [Member] | Alpha Capital [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrant to purchase shares</a></td>
<td class="nump">2,500,000<span></span>
</td>
<td class="nump">2,500,000<span></span>
</td>
<td class="nump">2,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of Warrant or Right, Exercise Price of Warrants or Rights</a></td>
<td class="nump">$ 1.65<span></span>
</td>
<td class="nump">$ 1.65<span></span>
</td>
<td class="nump">$ 1.65<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=QLGN_SeriesAlphaConvertiblePreferredStockMember', window );">Series Alpha Convertible Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion', window );">Convertible preferred stock, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">180<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">180<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesOther', window );">Shares issued during conversion, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">243,416<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=QLGN_SecuritiesPurchaseAgreementMember', window );">Securities Purchase Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share Price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,820,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=QLGN_SecuritiesPurchaseAgreementMember', window );">Securities Purchase Agreement [Member] | Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">588,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_FairValueOfIssuanceCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of Issuance cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_FairValueOfIssuanceCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_ModifiedToExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Modified to exercise price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_ModifiedToExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_PurchasePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Purchase price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_PurchasePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-based compensation arrangement by share-based payment award option expirations in period weighted average exercise price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionGrantedWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award option granted weighted average exercise price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionGrantedWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToNonVestExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average exercise price, options non-exercisable (non-vested).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToNonVestExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted- Average Remaining Contractual Life (in Years), Options Granted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm3">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award non option equity instruments legacy ritter weighted average exercise price one.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm3</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_WarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrants exercised.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_WarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_WarrantsExtendedDateDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrants extended date, description.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_WarrantsExtendedDateDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_WeightedAverageRemainingContractualLifeInYearsOptionsNonexercisableNonvested">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted- average remaining contractual life (in years), options non-exercisable (non-vested).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_WeightedAverageRemainingContractualLifeInYearsOptionsNonexercisableNonvested</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for each share of convertible preferred stock that is converted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496180-112644<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21506-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionPrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The price per share of the conversion feature embedded in the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031898-161870<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionPrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section 25<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=109262497&amp;loc=d3e20148-110875<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOrSaleOfEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SecuredDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date, including the current and noncurrent portions, of collateralized debt obligations (with maturities initially due after one year or beyond the operating cycle, if longer). Such obligations include mortgage loans, chattel loans, and any other borrowings secured by assets of the borrower.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SecuredDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of terms of share-based payment arrangement. Includes, but is not limited to, type of award or grantee and reason for issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price of options that were either forfeited or expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of non-vested options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average grant-date fair value of non-vested options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtInterestRateIncrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage increase in the stated interest rate on a short-term debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtInterestRateIncrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued attributable to transactions classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=QLGN_NanoSynexMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=QLGN_NanoSynexMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=QLGN_WarrantOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=QLGN_WarrantOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=QLGN_CompensatoryWarrantActivityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=QLGN_CompensatoryWarrantActivityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_StockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_StockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=QLGN_TwoThousandTwentyStockIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=QLGN_TwoThousandTwentyStockIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=QLGN_CompensatoryWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=QLGN_CompensatoryWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=QLGN_NoncompensatoryEquityClassifiedWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=QLGN_NoncompensatoryEquityClassifiedWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=QLGN_AlphaCapitalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=QLGN_AlphaCapitalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=QLGN_SeniorConvertibleDebentureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=QLGN_SeniorConvertibleDebentureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=QLGN_EmployeesAndNonemployeeServiceProviderMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=QLGN_EmployeesAndNonemployeeServiceProviderMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=QLGN_SeriesCWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=QLGN_SeriesCWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=QLGN_SeriesAlphaConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=QLGN_SeriesAlphaConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=QLGN_SecuritiesPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=QLGN_SecuritiesPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>105
<FILENAME>R74.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140569887465808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RELATED PARTY TRANSACTIONS (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2"></th>
<th class="th" colspan="1">5 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 22, 2022</div></th>
<th class="th"><div>May 26, 2022</div></th>
<th class="th"><div>May 26, 2022</div></th>
<th class="th"><div>Sep. 02, 2021</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPayableCurrent', window );">Accrued interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,829<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermBorrowings', window );">Short term debt outstanding balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 950,722<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Accrued interest rate</a></td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions', window );">Stock issued during period shares acquisitions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,048<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants or rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13.20<span></span>
</td>
<td class="nump">$ 40.70<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityReverseStockSplit', window );">Reverse split, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">These warrants were subsequently exercised on September 13, 2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Reverse
Stock Split

&#160;

On
November 23, 2022, the Company effected a 1-for-10, as determined by the Company&#8217;s board of directors, reverse stock split of its
outstanding shares of common stock (the &#8220;Reverse Stock Split&#8221;). The Reverse Stock Split reduced the Company&#8217;s shares
of outstanding common stock, stock options, and warrants to purchase shares of our common stock. Fractional shares of common stock that
would have otherwise resulted from the Reverse Stock Split were rounded down to the nearest whole share and cash in lieu of payments
were made to stockholders. All share and per share data for all periods presented in the accompanying financial statements and the related
disclosures have been adjusted retrospectively to reflect the Reverse Stock Split. The number of authorized shares of common stock and
the par value per share remains unchanged.

&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=QLGN_PrefundedWarrantMember', window );">Pre-funded Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">331,464<span></span>
</td>
<td class="nump">331,464<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants or rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=QLGN_SeriesAOnePreferredStockMember', window );">Series A-1 Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions', window );">Stock issued during period shares acquisitions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,232,861<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=QLGN_NanoSynexLtdMember', window );">Nano Synex Ltd [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired', window );">Business acquisition, voting equity rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">52.80%<span></span>
</td>
<td class="nump">52.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions', window );">Stock issued during period shares acquisitions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">350,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityReverseStockSplit', window );">Reverse split, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">these warrants were subsequently exercised on September 13, 2022)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions', window );">Stock issued during period value acquisitions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,904,989<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=QLGN_NanoSynexLtdMember', window );">Nano Synex Ltd [Member] | Pre-funded Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants or rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=QLGN_NanoSynexLtdMember', window );">Nano Synex Ltd [Member] | Series A-1 Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions', window );">Stock issued during period shares acquisitions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,232,861<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=QLGN_NanoSynexLtdMember', window );">Nano Synex Ltd [Member] | Series B Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions', window );">Stock issued during period shares acquisitions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">381,786<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions', window );">Stock issued during period value acquisitions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=QLGN_NotesPayableMember', window );">Notes Payable [Member] | Nano Synex Ltd [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Short term debt principal outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 905,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPayableCurrent', window );">Accrued interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45,722<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermBorrowings', window );">Short term debt outstanding balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 950,722<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Accrued interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.62%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromRelatedPartyDebt', window );">Proceeds from related party debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=QLGN_AlphaCapitalMember', window );">Alpha Capital [Member] | Senior Convertible Debenture [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtInterestRateIncrease', window );">Senior convertible debenture rate</a></td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SecuredDebt', window );">Principal amount</a></td>
<td class="nump">$ 3,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_PurchasePrice', window );">Purchase Price</a></td>
<td class="nump">$ 3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Conversion price</a></td>
<td class="nump">$ 1.32<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_PurchasePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Purchase price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_PurchasePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of voting equity interests acquired at the acquisition date in the business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionPrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The price per share of the conversion feature embedded in the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031898-161870<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionPrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromRelatedPartyDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a long-term borrowing made from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Proceeds from Advances from Affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromRelatedPartyDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SecuredDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date, including the current and noncurrent portions, of collateralized debt obligations (with maturities initially due after one year or beyond the operating cycle, if longer). Such obligations include mortgage loans, chattel loans, and any other borrowings secured by assets of the borrower.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SecuredDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reflects the total carrying amount as of the balance sheet date of debt having initial terms less than one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(13))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtInterestRateIncrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage increase in the stated interest rate on a short-term debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtInterestRateIncrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued during the period pursuant to acquisitions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued pursuant to acquisitions during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityReverseStockSplit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB Topic 4.C)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187143-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityReverseStockSplit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=QLGN_PrefundedWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=QLGN_PrefundedWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=QLGN_SeriesAOnePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=QLGN_SeriesAOnePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=QLGN_NanoSynexLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=QLGN_NanoSynexLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTypeAxis=QLGN_NotesPayableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTypeAxis=QLGN_NotesPayableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=QLGN_NanoSynexMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=QLGN_NanoSynexMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=QLGN_AlphaCapitalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=QLGN_AlphaCapitalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=QLGN_SeniorConvertibleDebentureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=QLGN_SeniorConvertibleDebentureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>106
<FILENAME>R75.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140569898240848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE OF DOMESTIC AND FOREIGN COMPONENTS (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic', window );">Domestic</a></td>
<td class="num">$ (15,954,750)<span></span>
</td>
<td class="num">$ (17,891,710)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign', window );">Foreign</a></td>
<td class="num">(5,344,967)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before provision for income taxes</a></td>
<td class="num">$ (21,299,717)<span></span>
</td>
<td class="num">$ (17,891,710)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.3)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126941158&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.3)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>107
<FILENAME>R76.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140569888541120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE OF RECONCILIATIONS OF STATUTORY INCOME TAX RATE (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Statutory federal income tax rate</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State taxes, net of federal tax benefit</a></td>
<td class="nump">5.46%<span></span>
</td>
<td class="nump">6.63%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepletion', window );">Non-deductible expenses</a></td>
<td class="num">(1.36%)<span></span>
</td>
<td class="num">(1.19%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_EffectiveIncomeTaxRateReconciliationNonOperatingLossExpiration', window );">NOL expiration</a></td>
<td class="num">(12.96%)<span></span>
</td>
<td class="num">(2.71%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits', window );">Tax credit</a></td>
<td class="nump">2.42%<span></span>
</td>
<td class="nump">0.86%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses', window );">Goodwill impairment</a></td>
<td class="num">(4.50%)<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlementsForeign', window );">Foreign rate differential</a></td>
<td class="nump">0.50%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_EffectiveIncomeTaxRateReconciliationFairValueOfWarrant', window );">Change in FV of warrant liability</a></td>
<td class="nump">0.89%<span></span>
</td>
<td class="nump">5.54%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsOther', window );">True-up</a></td>
<td class="nump">1.47%<span></span>
</td>
<td class="num">(2.72%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="num">(11.68%)<span></span>
</td>
<td class="num">(27.44%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Income taxes provision (benefit)</a></td>
<td class="nump">1.24%<span></span>
</td>
<td class="num">(0.03%)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_EffectiveIncomeTaxRateReconciliationFairValueOfWarrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective income tax rate reconciliation fair value of warrant.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_EffectiveIncomeTaxRateReconciliationFairValueOfWarrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_EffectiveIncomeTaxRateReconciliationNonOperatingLossExpiration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective income tax rate reconciliation non operating loss expiration.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_EffectiveIncomeTaxRateReconciliationNonOperatingLossExpiration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepletion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to depletion.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepletion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to impairment loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other tax credits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlementsForeign">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to foreign income tax settlement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlementsForeign</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>108
<FILENAME>R77.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140569888512160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE OF PROVISION FOR INCOME TAXES (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentFederalTaxExpenseBenefit', window );">US Federal</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit', window );">US State</a></td>
<td class="nump">7,000<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentForeignTaxExpenseBenefit', window );">Foreign</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefit', window );">Total current provision</a></td>
<td class="nump">7,000<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit', window );">US Federal</a></td>
<td class="num">(236,000)<span></span>
</td>
<td class="num">(1,268,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit', window );">US State</a></td>
<td class="num">(2,252,000)<span></span>
</td>
<td class="num">(3,641,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredForeignIncomeTaxExpenseBenefit', window );">Foreign</a></td>
<td class="num">(272,000)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Total deferred benefit</a></td>
<td class="num">(2,760,000)<span></span>
</td>
<td class="num">(4,909,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Change in valuation allowance</a></td>
<td class="nump">2,488,000<span></span>
</td>
<td class="nump">4,909,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Total provision (benefit) for income taxes</a></td>
<td class="num">$ (265,074)<span></span>
</td>
<td class="nump">$ 5,427<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentFederalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentFederalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentForeignTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentForeignTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentStateAndLocalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFederalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredForeignIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredForeignIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.1)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>109
<FILENAME>R78.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140569888699536">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SCHEDULE OF DEFERRED TAX ASSETS AND LIABILITIES (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss</a></td>
<td class="nump">$ 33,540,000<span></span>
</td>
<td class="nump">$ 33,362,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment', window );">Research and development credits</a></td>
<td class="nump">7,857,000<span></span>
</td>
<td class="nump">6,185,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_DefferdTaxAssetsAccruedExpenses', window );">Accrued expenses</a></td>
<td class="nump">1,020,000<span></span>
</td>
<td class="nump">757,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets', window );">Patent</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">262,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Stock compensation</a></td>
<td class="nump">3,069,000<span></span>
</td>
<td class="nump">2,747,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_DeferredTaxAssetsResearchAndDevelopmentExpenses', window );">Research and development expenses</a></td>
<td class="nump">1,196,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment', window );">Fixed assets</a></td>
<td class="nump">280,000<span></span>
</td>
<td class="nump">282,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpense', window );">Total deferred income tax assets</a></td>
<td class="nump">46,962,000<span></span>
</td>
<td class="nump">43,595,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets', window );">Intangible assets</a></td>
<td class="num">(1,324,000)<span></span>
</td>
<td class="num">(34,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesLeasingArrangements', window );">Right-of-use asset</a></td>
<td class="num">(382,000)<span></span>
</td>
<td class="num">(436,000)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilities', window );">Total deferred income tax liabilities</a></td>
<td class="num">(1,706,000)<span></span>
</td>
<td class="num">(470,000)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Net deferred income tax assets</a></td>
<td class="nump">45,256,000<span></span>
</td>
<td class="nump">43,125,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">(45,614,000)<span></span>
</td>
<td class="num">(43,125,000)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNet', window );">Deferred tax asset, net of allowance</a></td>
<td class="num">$ (358,000)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_DeferredTaxAssetsResearchAndDevelopmentExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Research and development expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_DeferredTaxAssetsResearchAndDevelopmentExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_DefferdTaxAssetsAccruedExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Defferd tax assets accrued expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_DefferdTaxAssetsAccruedExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(15)(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from intangible assets including goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from in-process research and development costs expensed in connection with a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from property, plant, and equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowances, of deferred tax asset attributable to deductible differences from reserves and accruals, compensation and benefit costs, and other provisions, reserves, and allowances.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from intangible assets other than goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesLeasingArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from leasing arrangements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesLeasingArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>110
<FILENAME>R79.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140569888562976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredForeignIncomeTaxExpenseBenefit', window );">Foreign deferred tax benefit</a></td>
<td class="nump">$ 272,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal', window );">Operating loss carryforwards</a></td>
<td class="nump">$ 119,254,000<span></span>
</td>
<td class="nump">110,227,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLimitationsOnUse', window );">Tax credit carryforward, limitations on use</a></td>
<td class="text">The research and development credit carryforwards began to expire in 2020 for federal tax purposes and have an indefinite
life for state tax purposes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Unrecognized tax benefits</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember', window );">Foreign Tax Authority [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">953,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Domestic Tax Authority [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Research and development credit carryforwards</a></td>
<td class="nump">5,484,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State and Local Jurisdiction [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Research and development credit carryforwards</a></td>
<td class="nump">$ 2,373,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredForeignIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredForeignIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible state and local operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwardsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwardsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardLimitationsOnUse">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of the limitation related to use of the tax credit carryforward.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardLimitationsOnUse</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10B<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=SL37586934-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>111
<FILENAME>R80.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140569894198416">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SUBSEQUENT EVENTS (Details Narrative) - Subsequent Event [Member] - USD ($)<br></strong></div></th>
<th class="th"><div>Jan. 13, 2023</div></th>
<th class="th"><div>Jan. 12, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debenture voluntarily converted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,111,078<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockDividendsShares', window );">Shares of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">841,726<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Conversion price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.32<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_BaseSalaryPercentage', window );">Base salary percentage</a></td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_AnnualCashCompensation', window );">Annual cash compensation</a></td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_AnnualCashCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Annual cash compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_AnnualCashCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_BaseSalaryPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Base salary percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_BaseSalaryPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockDividendsShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock issued as dividends during the period. Excludes stock splits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockDividendsShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionPrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The price per share of the conversion feature embedded in the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031898-161870<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionPrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>112
<FILENAME>form10-k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:QLGN="http://qualigeninc.com/20221231"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2022"
  xmlns:us-gaap="http://fasb.org/us-gaap/2022"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xhtml="http://www.w3.org/1999/xhtml"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="qlgn-20221231.xsd" xlink:type="simple"/>
    <context id="From2022-01-01to2022-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="AsOf2023-04-11">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
        </entity>
        <period>
            <instant>2023-04-11</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="From2021-01-012021-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_NetProductSalesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">QLGN:NetProductSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_custom_NetProductSalesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">QLGN:NetProductSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_LicenseRevenueMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">QLGN:LicenseRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_custom_LicenseRevenueMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">QLGN:LicenseRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_PreferredStockMember_custom_SeriesAlphaConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">QLGN:SeriesAlphaConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_ParentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_NoncontrollingInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_us-gaap_PreferredStockMember_custom_SeriesAlphaConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">QLGN:SeriesAlphaConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_PreferredStockMember_custom_SeriesAlphaConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">QLGN:SeriesAlphaConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_ParentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_NoncontrollingInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_us-gaap_PreferredStockMember_custom_SeriesAlphaConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">QLGN:SeriesAlphaConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_PreferredStockMember_custom_SeriesAlphaConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">QLGN:SeriesAlphaConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_ParentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_NoncontrollingInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="From2022-05-242022-05-26_custom_NanoSynexLtdMember_custom_SeriesAOnePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">QLGN:NanoSynexLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">QLGN:SeriesAOnePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-24</startDate>
            <endDate>2022-05-26</endDate>
        </period>
    </context>
    <context id="From2022-05-242022-05-26_custom_NanoSynexLtdMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">QLGN:NanoSynexLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-24</startDate>
            <endDate>2022-05-26</endDate>
        </period>
    </context>
    <context id="AsOf2022-05-26_custom_PrefundedWarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">QLGN:PrefundedWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-26</instant>
        </period>
    </context>
    <context id="From2022-05-252022-05-26">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
        </entity>
        <period>
            <startDate>2022-05-25</startDate>
            <endDate>2022-05-26</endDate>
        </period>
    </context>
    <context id="From2022-05-242022-05-26_custom_NanoSynexLtdMember_us-gaap_SeriesBPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">QLGN:NanoSynexLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-24</startDate>
            <endDate>2022-05-26</endDate>
        </period>
    </context>
    <context id="AsOf2022-05-26_custom_NanoSynexLtdMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">QLGN:NanoSynexLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-26</instant>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_ShippingAndHandlingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ShippingAndHandlingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_us-gaap_ShippingAndHandlingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ShippingAndHandlingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_GeneralAdministrativeResearchAndDevelopmentExpensesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">QLGN:GeneralAdministrativeResearchAndDevelopmentExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_custom_GeneralAdministrativeResearchAndDevelopmentExpensesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">QLGN:GeneralAdministrativeResearchAndDevelopmentExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_LicenseRevenuesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">QLGN:LicenseRevenuesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_custom_LicenseRevenuesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">QLGN:LicenseRevenuesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_srt_MinimumMember_custom_PatentsAndLicensesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">QLGN:PatentsAndLicensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_srt_MaximumMember_custom_PatentsAndLicensesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">QLGN:PatentsAndLicensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_NanoSynexLtdMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">QLGN:NanoSynexLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_custom_NanoSynexLtdMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">QLGN:NanoSynexLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_MachineryAndEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_ComputerEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_MoldsAndToolingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">QLGN:MoldsAndToolingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_FurnitureAndFixturesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2021-12-012021-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
        </entity>
        <period>
            <startDate>2021-12-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2022-12-012022-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
        </entity>
        <period>
            <startDate>2022-12-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-05-242022-05-26_custom_SeriesAOnePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">QLGN:SeriesAOnePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-24</startDate>
            <endDate>2022-05-26</endDate>
        </period>
    </context>
    <context id="AsOf2022-05-26_custom_NanoSynexLtdMember_custom_PrefundedWarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">QLGN:NanoSynexLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">QLGN:PrefundedWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-26</instant>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_NanoSynexMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">QLGN:NanoSynexMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-05-242022-05-26_custom_AlphaCapitalAnstaltMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">QLGN:AlphaCapitalAnstaltMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-24</startDate>
            <endDate>2022-05-26</endDate>
        </period>
    </context>
    <context id="From2022-05-242022-05-26">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
        </entity>
        <period>
            <startDate>2022-05-24</startDate>
            <endDate>2022-05-26</endDate>
        </period>
    </context>
    <context id="AsOf2022-05-26">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
        </entity>
        <period>
            <instant>2022-05-26</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_MachineryAndEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_MachineryAndEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_ComputerEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_ComputerEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_LeaseholdImprovementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_LeaseholdImprovementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_MoldsAndToolingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">QLGN:MoldsAndToolingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_custom_MoldsAndToolingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">QLGN:MoldsAndToolingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_FurnitureAndFixturesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_FurnitureAndFixturesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_EquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_EquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_SekisuiDistributionAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">QLGN:SekisuiDistributionAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_DevelopedProductTechnologyRightsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">QLGN:DevelopedProductTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_custom_DevelopedProductTechnologyRightsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">QLGN:DevelopedProductTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_DevelopedProductTechnologyRightsMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">QLGN:DevelopedProductTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_DevelopedProductTechnologyRightsMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">QLGN:DevelopedProductTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_LicensingRightsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">QLGN:LicensingRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_custom_LicensingRightsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">QLGN:LicensingRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_LicensingRightsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">QLGN:LicensingRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_InProcessResearchAndDevelopmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_InProcessResearchAndDevelopmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_PatentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_PatentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_PatentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_us-gaap_PatentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_LicenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_LicenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_LicenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_us-gaap_LicenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2021-09-02_custom_NotesPayableMember_custom_NanoSynexMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">QLGN:NanoSynexMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">QLGN:NotesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-02</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_NotesPayableMember_custom_NanoSynexMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">QLGN:NanoSynexMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">QLGN:NotesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="From2021-03-262021-09-02_custom_NotesPayableMember_custom_NanoSynexMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">QLGN:NanoSynexMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">QLGN:NotesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-26</startDate>
            <endDate>2021-09-02</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_SeriesCWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">QLGN:SeriesCWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_srt_MinimumMember_custom_SeriesCWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">QLGN:SeriesCWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_srt_MaximumMember_custom_SeriesCWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">QLGN:SeriesCWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-04-25_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-25</instant>
        </period>
    </context>
    <context id="AsOf2022-04-25_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-25</instant>
        </period>
    </context>
    <context id="From2022-04-232022-04-25_custom_SeriesCWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">QLGN:SeriesCWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-23</startDate>
            <endDate>2022-04-25</endDate>
        </period>
    </context>
    <context id="AsOf2022-05-26_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-26</instant>
        </period>
    </context>
    <context id="AsOf2022-05-26_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-26</instant>
        </period>
    </context>
    <context id="From2022-05-232022-05-26_custom_SeriesCWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">QLGN:SeriesCWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-23</startDate>
            <endDate>2022-05-26</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-22_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-22</instant>
        </period>
    </context>
    <context id="AsOf2022-12-22_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-22</instant>
        </period>
    </context>
    <context id="From2022-12-192022-12-22_custom_SeriesCWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">QLGN:SeriesCWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-19</startDate>
            <endDate>2022-12-22</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-22_custom_SeriesCWarrantsMember_custom_AlphaCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">QLGN:AlphaCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">QLGN:SeriesCWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-22</instant>
        </period>
    </context>
    <context id="From2022-12-192022-12-22_custom_SeriesCWarrantsMember_custom_AlphaCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">QLGN:AlphaCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">QLGN:SeriesCWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-19</startDate>
            <endDate>2022-12-22</endDate>
        </period>
    </context>
    <context id="AsOf2021-12-31_custom_SeriesCWarrantsMember_custom_CommonStockWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">QLGN:SeriesCWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">QLGN:CommonStockWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_custom_SeriesCWarrantsMember_custom_CommonStockWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">QLGN:SeriesCWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">QLGN:CommonStockWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_SeriesCWarrantsMember_custom_CommonStockWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">QLGN:SeriesCWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">QLGN:CommonStockWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_SeriesCWarrantsMember_custom_CommonStockWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">QLGN:SeriesCWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">QLGN:CommonStockWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_SeriesCWarrantsMember_custom_CommonStockWarrantsMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">QLGN:SeriesCWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">QLGN:CommonStockWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_SeriesCWarrantsMember_custom_CommonStockWarrantsMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">QLGN:SeriesCWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">QLGN:CommonStockWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_custom_SeriesCWarrantsMember_custom_CommonStockWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">QLGN:SeriesCWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">QLGN:CommonStockWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_FairValueInputsLevel1Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_FairValueInputsLevel2Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_FairValueInputsLevel3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_FairValueInputsLevel1Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_FairValueInputsLevel2Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_FairValueInputsLevel3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_FairValueInputsLevel1Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_FairValueInputsLevel2Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_FairValueInputsLevel3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_us-gaap_FairValueInputsLevel1Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_us-gaap_FairValueInputsLevel2Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_us-gaap_FairValueInputsLevel3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_us-gaap_FairValueInputsLevel1Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_us-gaap_FairValueInputsLevel2Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_us-gaap_FairValueInputsLevel3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-31_srt_MinimumMember_us-gaap_MeasurementInputRiskFreeInterestRateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_srt_MaximumMember_us-gaap_MeasurementInputRiskFreeInterestRateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_MeasurementInputRiskFreeInterestRateMember_srt_WeightedAverageMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_srt_MinimumMember_us-gaap_MeasurementInputRiskFreeInterestRateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_srt_MaximumMember_us-gaap_MeasurementInputRiskFreeInterestRateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_MeasurementInputRiskFreeInterestRateMember_srt_WeightedAverageMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_srt_MinimumMember_us-gaap_MeasurementInputPriceVolatilityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_srt_MaximumMember_us-gaap_MeasurementInputPriceVolatilityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_srt_WeightedAverageMember_us-gaap_MeasurementInputPriceVolatilityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_srt_MinimumMember_us-gaap_MeasurementInputPriceVolatilityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_srt_MaximumMember_us-gaap_MeasurementInputPriceVolatilityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_srt_WeightedAverageMember_us-gaap_MeasurementInputPriceVolatilityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_srt_MinimumMember_us-gaap_MeasurementInputExpectedTermMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_srt_MaximumMember_us-gaap_MeasurementInputExpectedTermMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_srt_WeightedAverageMember_us-gaap_MeasurementInputExpectedTermMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_srt_MinimumMember_us-gaap_MeasurementInputExpectedTermMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_srt_MaximumMember_us-gaap_MeasurementInputExpectedTermMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_srt_WeightedAverageMember_us-gaap_MeasurementInputExpectedTermMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_MeasurementInputExpectedDividendRateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_MeasurementInputExpectedDividendRateMember_srt_WeightedAverageMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_MeasurementInputExpectedDividendRateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_MeasurementInputExpectedDividendRateMember_srt_WeightedAverageMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="From2022-12-222022-12-22_custom_AlphaCapitalMember_custom_SeniorConvertibleDebentureMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">QLGN:AlphaCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">QLGN:SeniorConvertibleDebentureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-22</startDate>
            <endDate>2022-12-22</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-22_custom_AlphaCapitalMember_custom_SeniorConvertibleDebentureMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">QLGN:AlphaCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">QLGN:SeniorConvertibleDebentureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-22</instant>
        </period>
    </context>
    <context id="From2022-12-222022-12-22_custom_SeniorConvertibleDebentureMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">QLGN:SeniorConvertibleDebentureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-22</startDate>
            <endDate>2022-12-22</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-22">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
        </entity>
        <period>
            <instant>2022-12-22</instant>
        </period>
    </context>
    <context id="AsOf2022-12-30_custom_AlphaCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">QLGN:AlphaCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-30</instant>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_AlphaCapitalOtherThirdPartiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">QLGN:AlphaCapitalOtherThirdPartiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_AlphaCapitalOtherThirdPartiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">QLGN:AlphaCapitalOtherThirdPartiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_SeniorSecuredConvertibleDebtMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">QLGN:SeniorSecuredConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_custom_SeniorSecuredConvertibleDebtMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">QLGN:SeniorSecuredConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_SharesOfCommonStockSubjectToOutstandingOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">QLGN:SharesOfCommonStockSubjectToOutstandingOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_custom_SharesOfCommonStockSubjectToOutstandingOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">QLGN:SharesOfCommonStockSubjectToOutstandingOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_SharesOfCommonStockSubjectToOutstandingWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">QLGN:SharesOfCommonStockSubjectToOutstandingWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_custom_SharesOfCommonStockSubjectToOutstandingWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">QLGN:SharesOfCommonStockSubjectToOutstandingWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2021-12-15">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
        </entity>
        <period>
            <instant>2021-12-15</instant>
        </period>
    </context>
    <context id="From2021-12-142021-12-15">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
        </entity>
        <period>
            <startDate>2021-12-14</startDate>
            <endDate>2021-12-15</endDate>
        </period>
    </context>
    <context id="From2021-12-142021-12-15_custom_FirstTwelveMonthsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">QLGN:FirstTwelveMonthsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-12-14</startDate>
            <endDate>2021-12-15</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_SekisuiDistributionAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">QLGN:SekisuiDistributionAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_NanoSynexMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">QLGN:NanoSynexMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_NanoSynexMember72014625">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">QLGN:NanoSynexMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-02-28_custom_NanoSynexMember_us-gaap_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">QLGN:NanoSynexMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-02-28</instant>
        </period>
    </context>
    <context id="From2022-04-042022-04-05">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
        </entity>
        <period>
            <startDate>2022-04-04</startDate>
            <endDate>2022-04-05</endDate>
        </period>
    </context>
    <context id="AsOf2021-12-31_custom_LongtermOperatingLeaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">QLGN:LongtermOperatingLeaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_LongtermOperatingLeaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">QLGN:LongtermOperatingLeaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_LongtermOperatingLeaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">QLGN:LongtermOperatingLeaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="From2019-03-012019-03-31_custom_SponsoredResearchAgreementAndLicenseMember_custom_UniversityOfLouisvilleResearchFoundationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">QLGN:SponsoredResearchAgreementAndLicenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">QLGN:UniversityOfLouisvilleResearchFoundationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-03-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="From2021-02-012021-02-28_custom_SponsoredResearchAgreementAndLicenseMember_custom_UniversityOfLouisvilleResearchFoundationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">QLGN:SponsoredResearchAgreementAndLicenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">QLGN:UniversityOfLouisvilleResearchFoundationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-01</startDate>
            <endDate>2021-02-28</endDate>
        </period>
    </context>
    <context id="From2019-03-012019-03-31_srt_MinimumMember_custom_LicenseAndSponsoredResearchAgreementsMember_custom_UniversityOfLouisvilleResearchFoundationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">QLGN:LicenseAndSponsoredResearchAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">QLGN:UniversityOfLouisvilleResearchFoundationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-03-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="From2019-03-012019-03-31_srt_MaximumMember_custom_LicenseAndSponsoredResearchAgreementsMember_custom_UniversityOfLouisvilleResearchFoundationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">QLGN:LicenseAndSponsoredResearchAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">QLGN:UniversityOfLouisvilleResearchFoundationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-03-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="From2019-03-012019-03-31_custom_LicenseAndSponsoredResearchAgreementsMember_custom_UniversityOfLouisvilleResearchFoundationMember_custom_PhaseOneClinicalTrialMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">QLGN:PhaseOneClinicalTrialMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">QLGN:LicenseAndSponsoredResearchAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">QLGN:UniversityOfLouisvilleResearchFoundationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-03-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="From2019-03-012019-03-31_custom_LicenseAndSponsoredResearchAgreementsMember_custom_UniversityOfLouisvilleResearchFoundationMember_custom_PhaseTwoClinicalTrialMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">QLGN:PhaseTwoClinicalTrialMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">QLGN:LicenseAndSponsoredResearchAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">QLGN:UniversityOfLouisvilleResearchFoundationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-03-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="From2019-03-012019-03-31_custom_LicenseAndSponsoredResearchAgreementsMember_custom_UniversityOfLouisvilleResearchFoundationMember_custom_PhaseThreeClinicalTrialMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">QLGN:PhaseThreeClinicalTrialMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">QLGN:LicenseAndSponsoredResearchAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">QLGN:UniversityOfLouisvilleResearchFoundationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-03-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="From2019-03-012019-03-31_custom_LicensedProductSalesMember_custom_LicenseAndSponsoredResearchAgreementsMember_custom_UniversityOfLouisvilleResearchFoundationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">QLGN:LicensedProductSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">QLGN:LicenseAndSponsoredResearchAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">QLGN:UniversityOfLouisvilleResearchFoundationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-03-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2019-03-31_srt_MinimumMember_custom_LicenseAgreementMember_custom_UniversityOfLouisvilleResearchFoundationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">QLGN:LicenseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">QLGN:UniversityOfLouisvilleResearchFoundationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="AsOf2019-03-31_srt_MaximumMember_custom_LicenseAgreementMember_custom_UniversityOfLouisvilleResearchFoundationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">QLGN:LicenseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">QLGN:UniversityOfLouisvilleResearchFoundationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_LicenseAndSponsoredResearchAgreementsMember_custom_UniversityOfLouisvilleResearchFoundationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">QLGN:LicenseAndSponsoredResearchAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">QLGN:UniversityOfLouisvilleResearchFoundationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_custom_LicenseAndSponsoredResearchAgreementsMember_custom_UniversityOfLouisvilleResearchFoundationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">QLGN:LicenseAndSponsoredResearchAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">QLGN:UniversityOfLouisvilleResearchFoundationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2018-06-012020-09-30_custom_LicenseAndSponsoredResearchAgreementsMember_custom_UniversityOfLouisvilleResearchFoundationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">QLGN:LicenseAndSponsoredResearchAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">QLGN:UniversityOfLouisvilleResearchFoundationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-06-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="From2018-06-012018-06-30_srt_MinimumMember_custom_LicenseAndSponsoredResearchAgreementsMember_custom_UniversityOfLouisvilleResearchFoundationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">QLGN:LicenseAndSponsoredResearchAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">QLGN:UniversityOfLouisvilleResearchFoundationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-06-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="From2018-06-012018-06-30_srt_MaximumMember_custom_LicenseAndSponsoredResearchAgreementsMember_custom_UniversityOfLouisvilleResearchFoundationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">QLGN:LicenseAndSponsoredResearchAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">QLGN:UniversityOfLouisvilleResearchFoundationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-06-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="From2018-06-012018-06-30_custom_PhaseOneClinicalTrialMember_custom_LicenseAndSponsoredResearchAgreementsMember_custom_UniversityOfLouisvilleResearchFoundationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">QLGN:PhaseOneClinicalTrialMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">QLGN:LicenseAndSponsoredResearchAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">QLGN:UniversityOfLouisvilleResearchFoundationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-06-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="From2018-06-012018-06-30_custom_PhaseTwoClinicalTrialMember_custom_LicenseAndSponsoredResearchAgreementsMember_custom_UniversityOfLouisvilleResearchFoundationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">QLGN:PhaseTwoClinicalTrialMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">QLGN:LicenseAndSponsoredResearchAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">QLGN:UniversityOfLouisvilleResearchFoundationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-06-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="From2018-06-012018-06-30_custom_PhaseThreeClinicalTrialMember_custom_LicenseAndSponsoredResearchAgreementsMember_custom_UniversityOfLouisvilleResearchFoundationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">QLGN:PhaseThreeClinicalTrialMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">QLGN:LicenseAndSponsoredResearchAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">QLGN:UniversityOfLouisvilleResearchFoundationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-06-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="From2018-06-012018-06-30_custom_PhaseClinicalTrialMember_custom_LicenseAndSponsoredResearchAgreementsMember_custom_UniversityOfLouisvilleResearchFoundationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">QLGN:PhaseClinicalTrialMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">QLGN:LicenseAndSponsoredResearchAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">QLGN:UniversityOfLouisvilleResearchFoundationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-06-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="From2018-06-012018-06-30_custom_LicensedProductSalesMember_custom_LicenseAndSponsoredResearchAgreementsMember_custom_UniversityOfLouisvilleResearchFoundationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">QLGN:LicensedProductSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">QLGN:LicenseAndSponsoredResearchAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">QLGN:UniversityOfLouisvilleResearchFoundationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-06-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="From2018-06-012018-06-30_custom_SponsoredResearchAgreementAndLicenseMember_custom_UniversityOfLouisvilleResearchFoundationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">QLGN:SponsoredResearchAgreementAndLicenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">QLGN:UniversityOfLouisvilleResearchFoundationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-06-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="From2018-06-012020-09-30_srt_MinimumMember_custom_LicenseAndSponsoredResearchAgreementsMember_custom_UniversityOfLouisvilleResearchFoundationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">QLGN:LicenseAndSponsoredResearchAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">QLGN:UniversityOfLouisvilleResearchFoundationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-06-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="From2018-06-012020-09-30_srt_MaximumMember_custom_LicenseAndSponsoredResearchAgreementsMember_custom_UniversityOfLouisvilleResearchFoundationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">QLGN:LicenseAndSponsoredResearchAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">QLGN:UniversityOfLouisvilleResearchFoundationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-06-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_SponsoredResearchAgreementAndLicenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">QLGN:SponsoredResearchAgreementAndLicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_custom_SponsoredResearchAgreementAndLicenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">QLGN:SponsoredResearchAgreementAndLicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2020-06-30_custom_LicenseAgreementMember_custom_UniversityOfLouisvilleResearchFoundationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">QLGN:LicenseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">QLGN:UniversityOfLouisvilleResearchFoundationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="From2020-11-012020-11-30_srt_MaximumMember_custom_LicenseAgreementMember_custom_UniversityOfLouisvilleResearchFoundationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">QLGN:LicenseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">QLGN:UniversityOfLouisvilleResearchFoundationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-11-01</startDate>
            <endDate>2020-11-30</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_UniversityOfLouisvilleResearchFoundationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">QLGN:UniversityOfLouisvilleResearchFoundationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_custom_UniversityOfLouisvilleResearchFoundationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">QLGN:UniversityOfLouisvilleResearchFoundationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2018-12-012018-12-31_custom_LicenseAgreementMember_custom_AdvancedCancerTherapeuticsLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">QLGN:LicenseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">QLGN:AdvancedCancerTherapeuticsLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="From2018-12-012018-12-31_custom_CEMarkMember_custom_LicenseAgreementMember_custom_AdvancedCancerTherapeuticsLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">QLGN:CEMarkMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">QLGN:LicenseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">QLGN:AdvancedCancerTherapeuticsLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_LicenseAgreementMember_custom_AdvancedCancerTherapeuticsLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">QLGN:LicenseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">QLGN:AdvancedCancerTherapeuticsLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_custom_LicenseAgreementMember_custom_AdvancedCancerTherapeuticsLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">QLGN:LicenseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">QLGN:AdvancedCancerTherapeuticsLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2021-12-31_custom_YiXinZhenDuanJishuLtdMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">QLGN:YiXinZhenDuanJishuLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_custom_LicenseRevenueMember_custom_YiXinZhenDuanJishuLtdMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">QLGN:LicenseRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">QLGN:YiXinZhenDuanJishuLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_custom_YiXinZhenDuanJishuLtdMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">QLGN:YiXinZhenDuanJishuLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2020-12-31_custom_STAPharmaceuticalCoLtdMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">QLGN:STAPharmaceuticalCoLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_STAPharmaceuticalCoLtdMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">QLGN:STAPharmaceuticalCoLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_custom_STAPharmaceuticalCoLtdMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">QLGN:STAPharmaceuticalCoLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-01-31_custom_UpfrontPaymentMember_custom_LicenseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">QLGN:UpfrontPaymentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">QLGN:LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-01-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-01-31_custom_LicenseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">QLGN:LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-01-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_LicenseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">QLGN:LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_custom_LicenseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">QLGN:LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2021-12-012021-12-01_custom_SecuritiesPurchaseAgreementMember_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">QLGN:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-12-01</startDate>
            <endDate>2021-12-01</endDate>
        </period>
    </context>
    <context id="AsOf2021-12-01_custom_SecuritiesPurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">QLGN:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-01</instant>
        </period>
    </context>
    <context id="From2021-12-012021-12-01_custom_SecuritiesPurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">QLGN:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-12-01</startDate>
            <endDate>2021-12-01</endDate>
        </period>
    </context>
    <context id="AsOf2021-12-31_custom_SeriesAlphaConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">QLGN:SeriesAlphaConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_custom_SeriesAlphaConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">QLGN:SeriesAlphaConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_StockOptionMember_custom_TwoThousandTwentyStockIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">QLGN:TwoThousandTwentyStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_StockOptionMember_custom_TwoThousandTwentyStockIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">QLGN:TwoThousandTwentyStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_custom_EmployeesAndNonemployeeServiceProviderMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">QLGN:EmployeesAndNonemployeeServiceProviderMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_custom_EmployeesAndNonemployeeServiceProviderMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">QLGN:EmployeesAndNonemployeeServiceProviderMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_custom_EmployeesAndNonemployeeServiceProviderMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">QLGN:EmployeesAndNonemployeeServiceProviderMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_custom_EmployeesAndNonemployeeServiceProviderMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">QLGN:EmployeesAndNonemployeeServiceProviderMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_custom_EmployeesAndNonemployeeServiceProviderMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">QLGN:EmployeesAndNonemployeeServiceProviderMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_custom_EmployeesAndNonemployeeServiceProviderMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">QLGN:EmployeesAndNonemployeeServiceProviderMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2021-12-31_custom_EmployeesAndNonemployeeServiceProviderMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">QLGN:EmployeesAndNonemployeeServiceProviderMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_custom_EmployeesAndNonemployeeServiceProviderMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">QLGN:EmployeesAndNonemployeeServiceProviderMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_custom_EmployeesAndNonemployeeServiceProviderMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">QLGN:EmployeesAndNonemployeeServiceProviderMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_us-gaap_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_StockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_us-gaap_StockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_StockOptionMember_custom_TwoThousandTwentyStockIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">QLGN:TwoThousandTwentyStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_CompensatoryWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">QLGN:CompensatoryWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_CompensatoryWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">QLGN:CompensatoryWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2017-12-31_custom_CompensatoryWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">QLGN:CompensatoryWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-04-25_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-25</instant>
        </period>
    </context>
    <context id="AsOf2022-04-24_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-24</instant>
        </period>
    </context>
    <context id="From2022-04-232022-04-25_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-23</startDate>
            <endDate>2022-04-25</endDate>
        </period>
    </context>
    <context id="From2022-04-232022-04-25_us-gaap_GeneralAndAdministrativeExpenseMember_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-23</startDate>
            <endDate>2022-04-25</endDate>
        </period>
    </context>
    <context id="AsOf2022-05-26_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-26</instant>
        </period>
    </context>
    <context id="AsOf2022-05-26_us-gaap_WarrantMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-26</instant>
        </period>
    </context>
    <context id="AsOf2022-05-26_us-gaap_WarrantMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-26</instant>
        </period>
    </context>
    <context id="From2022-05-232022-05-26_us-gaap_GeneralAndAdministrativeExpenseMember_custom_WarrantOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">QLGN:WarrantOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-23</startDate>
            <endDate>2022-05-26</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-22_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-22</instant>
        </period>
    </context>
    <context id="AsOf2022-12-22_us-gaap_WarrantMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-22</instant>
        </period>
    </context>
    <context id="AsOf2022-12-22_us-gaap_WarrantMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-22</instant>
        </period>
    </context>
    <context id="From2022-12-202022-12-22_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-20</startDate>
            <endDate>2022-12-22</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_CompensatoryWarrantActivityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">QLGN:CompensatoryWarrantActivityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_custom_CompensatoryWarrantActivityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">QLGN:CompensatoryWarrantActivityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2020-05-31_custom_NoncompensatoryEquityClassifiedWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">QLGN:NoncompensatoryEquityClassifiedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-05-31</instant>
        </period>
    </context>
    <context id="From2020-12-012020-12-31_custom_NoncompensatoryEquityClassifiedWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">QLGN:NoncompensatoryEquityClassifiedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2020-07-31_custom_NoncompensatoryEquityClassifiedWarrantsMember_custom_AlphaCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">QLGN:AlphaCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">QLGN:NoncompensatoryEquityClassifiedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-07-31</instant>
        </period>
    </context>
    <context id="AsOf2020-07-31_custom_NoncompensatoryEquityClassifiedWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">QLGN:NoncompensatoryEquityClassifiedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-07-31</instant>
        </period>
    </context>
    <context id="AsOf2020-08-31_custom_NoncompensatoryEquityClassifiedWarrantsMember_custom_AlphaCapitalMember_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">QLGN:AlphaCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">QLGN:NoncompensatoryEquityClassifiedWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-08-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_custom_NoncompensatoryEquityClassifiedWarrantsMember_custom_AlphaCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">QLGN:AlphaCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">QLGN:NoncompensatoryEquityClassifiedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-05-31_custom_NoncompensatoryEquityClassifiedWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">QLGN:NoncompensatoryEquityClassifiedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-31</instant>
        </period>
    </context>
    <context id="AsOf2021-11-29_custom_NoncompensatoryEquityClassifiedWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">QLGN:NoncompensatoryEquityClassifiedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-11-29</instant>
        </period>
    </context>
    <context id="AsOf2021-11-29_custom_NoncompensatoryEquityClassifiedWarrantsMember_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">QLGN:NoncompensatoryEquityClassifiedWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-11-29</instant>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_NoncompensatoryEquityClassifiedWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">QLGN:NoncompensatoryEquityClassifiedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-09-30_custom_NoncompensatoryEquityClassifiedWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">QLGN:NoncompensatoryEquityClassifiedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="AsOf2022-04-25_custom_NanoSynexMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">QLGN:NanoSynexMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-25</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_custom_NoncompensatoryEquityClassifiedWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">QLGN:NoncompensatoryEquityClassifiedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="From2022-04-232022-04-25_custom_NanoSynexMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">QLGN:NanoSynexMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-23</startDate>
            <endDate>2022-04-25</endDate>
        </period>
    </context>
    <context id="AsOf2022-05-26_custom_NanoSynexMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">QLGN:NanoSynexMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-26</instant>
        </period>
    </context>
    <context id="From2022-05-232022-05-26_custom_NanoSynexMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">QLGN:NanoSynexMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-23</startDate>
            <endDate>2022-05-26</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-22_custom_NanoSynexMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">QLGN:NanoSynexMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-22</instant>
        </period>
    </context>
    <context id="From2022-12-202022-12-22_custom_NanoSynexMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">QLGN:NanoSynexMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-20</startDate>
            <endDate>2022-12-22</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_NonCompensatoryWarrantActivityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">QLGN:NonCompensatoryWarrantActivityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_StockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_WarrantMember72029296">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_EmployeesAndNonemployeeServiceProviderMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">QLGN:EmployeesAndNonemployeeServiceProviderMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_EmployeesAndNonemployeeServiceProviderMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">QLGN:EmployeesAndNonemployeeServiceProviderMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_EmployeesAndNonemployeeServiceProviderMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">QLGN:EmployeesAndNonemployeeServiceProviderMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_EmployeesAndNonemployeeServiceProviderMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">QLGN:EmployeesAndNonemployeeServiceProviderMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_EmployeesAndNonemployeeServiceProviderMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">QLGN:EmployeesAndNonemployeeServiceProviderMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_EmployeesAndNonemployeeServiceProviderMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">QLGN:EmployeesAndNonemployeeServiceProviderMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_GeneralAndAdministrativeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_us-gaap_GeneralAndAdministrativeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_us-gaap_ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2021-12-31_custom_CompensatoryWarrantActivityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">QLGN:CompensatoryWarrantActivityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_custom_CompensatoryWarrantActivityMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">QLGN:CompensatoryWarrantActivityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_custom_CompensatoryWarrantActivityMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">QLGN:CompensatoryWarrantActivityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_CompensatoryWarrantActivityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">QLGN:CompensatoryWarrantActivityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_CompensatoryWarrantActivityMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">QLGN:CompensatoryWarrantActivityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_CompensatoryWarrantActivityMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">QLGN:CompensatoryWarrantActivityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_custom_CompensatoryWarrantActivityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">QLGN:CompensatoryWarrantActivityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_custom_CompensatoryWarrantActivityMember72031578">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">QLGN:CompensatoryWarrantActivityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_custom_CompensatoryWarrantActivityMember72031656">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">QLGN:CompensatoryWarrantActivityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2021-12-31_custom_CompensatoryWarrantActivityMember72031921">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">QLGN:CompensatoryWarrantActivityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_custom_NonCompensatoryWarrantActivityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">QLGN:NonCompensatoryWarrantActivityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_srt_MinimumMember_custom_NonCompensatoryWarrantActivityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">QLGN:NonCompensatoryWarrantActivityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_srt_MaximumMember_custom_NonCompensatoryWarrantActivityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">QLGN:NonCompensatoryWarrantActivityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_custom_NonCompensatoryWarrantActivityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">QLGN:NonCompensatoryWarrantActivityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_NonCompensatoryWarrantActivityMember72032375">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">QLGN:NonCompensatoryWarrantActivityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_NonCompensatoryWarrantActivityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">QLGN:NonCompensatoryWarrantActivityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_srt_MinimumMember_custom_NonCompensatoryWarrantActivityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">QLGN:NonCompensatoryWarrantActivityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_srt_MaximumMember_custom_NonCompensatoryWarrantActivityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">QLGN:NonCompensatoryWarrantActivityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_custom_NonCompensatoryWarrantActivityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">QLGN:NonCompensatoryWarrantActivityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_ForeignCountryMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_DomesticCountryMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_StateAndLocalJurisdictionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-01-12_us-gaap_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-12</instant>
        </period>
    </context>
    <context id="From2023-01-092023-01-12_us-gaap_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-09</startDate>
            <endDate>2023-01-12</endDate>
        </period>
    </context>
    <context id="From2023-01-132023-01-13_us-gaap_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-13</startDate>
            <endDate>2023-01-13</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="Pure">
        <measure>pure</measure>
    </unit>
    <unit id="Sqft">
        <measure>utr:sqft</measure>
    </unit>
    <dei:EntityCentralIndexKey contextRef="From2022-01-01to2022-12-31">0001460702</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="From2022-01-01to2022-12-31">false</dei:AmendmentFlag>
    <dei:DocumentFiscalPeriodFocus contextRef="From2022-01-01to2022-12-31">FY</dei:DocumentFiscalPeriodFocus>
    <us-gaap:RestrictedCashAndCashEquivalents
      contextRef="AsOf2021-12-31"
      id="xdx2ixbrl0070"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:Goodwill
      contextRef="AsOf2021-12-31"
      id="xdx2ixbrl0082"
      unitRef="USD"
      xsi:nil="true"/>
    <QLGN:ResearchAndDevelopmentGrantLiability
      contextRef="AsOf2021-12-31"
      id="xdx2ixbrl0106"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ShortTermBorrowings
      contextRef="AsOf2021-12-31"
      id="xdx2ixbrl0115"
      unitRef="USD"
      xsi:nil="true"/>
    <QLGN:WarrantLiabilitiesRelatedParty
      contextRef="AsOf2021-12-31"
      id="xdx2ixbrl0121"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ConvertibleDebt
      contextRef="AsOf2021-12-31"
      id="xdx2ixbrl0124"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="AsOf2021-12-31"
      id="xdx2ixbrl0136"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="AsOf2022-12-31"
      id="xdx2ixbrl0141"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="AsOf2021-12-31"
      id="xdx2ixbrl0142"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="AsOf2021-12-31"
      id="xdx2ixbrl0173"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:MinorityInterest
      contextRef="AsOf2021-12-31"
      id="xdx2ixbrl0182"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2022-01-012022-12-31_custom_LicenseRevenueMember"
      id="xdx2ixbrl0196"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="From2021-01-012021-12-31"
      id="xdx2ixbrl0218"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="From2021-01-012021-12-31"
      id="xdx2ixbrl0251"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="From2021-01-012021-12-31"
      id="xdx2ixbrl0269"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
      contextRef="From2021-01-012021-12-31"
      id="xdx2ixbrl0275"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2021-12-31_us-gaap_PreferredStockMember_custom_SeriesAlphaConvertiblePreferredStockMember"
      id="xdx2ixbrl0280"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2021-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0283"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2021-12-31_us-gaap_NoncontrollingInterestMember"
      id="xdx2ixbrl0286"
      unitRef="USD"
      xsi:nil="true"/>
    <QLGN:StockIssuedUponCashExerciseOfWarrants
      contextRef="From2022-01-012022-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0294"
      unitRef="USD"
      xsi:nil="true"/>
    <QLGN:StockIssuedUponCashExerciseOfWarrants
      contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0295"
      unitRef="USD"
      xsi:nil="true"/>
    <QLGN:StockIssuedUponCashExerciseOfWarrants
      contextRef="From2022-01-012022-12-31_us-gaap_NoncontrollingInterestMember"
      id="xdx2ixbrl0297"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions
      contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0303"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions
      contextRef="From2022-01-012022-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0305"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions
      contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0306"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions
      contextRef="From2022-01-012022-12-31_us-gaap_NoncontrollingInterestMember"
      id="xdx2ixbrl0308"
      unitRef="USD"
      xsi:nil="true"/>
    <QLGN:CommonStockAndPrefundedWarrantsIssuedForBusinessAcquisition
      contextRef="From2022-01-012022-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0314"
      unitRef="USD"
      xsi:nil="true"/>
    <QLGN:CommonStockAndPrefundedWarrantsIssuedForBusinessAcquisition
      contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0315"
      unitRef="USD"
      xsi:nil="true"/>
    <QLGN:NoncontrollingInterestAdjustmentsRelatingToStockbasedCompensationAndOther
      contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0323"
      unitRef="USD"
      xsi:nil="true"/>
    <QLGN:NoncontrollingInterestAdjustmentsRelatingToStockbasedCompensationAndOther
      contextRef="From2022-01-012022-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0325"
      unitRef="USD"
      xsi:nil="true"/>
    <QLGN:NoncontrollingInterestAdjustmentsRelatingToStockbasedCompensationAndOther
      contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0326"
      unitRef="USD"
      xsi:nil="true"/>
    <QLGN:NoncontrollingInterestAdjustmentsRelatingToStockbasedCompensationAndOther
      contextRef="From2022-01-01to2022-12-31"
      id="xdx2ixbrl0329"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0332"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0333"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0335"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="From2022-01-012022-12-31_us-gaap_NoncontrollingInterestMember"
      id="xdx2ixbrl0337"
      unitRef="USD"
      xsi:nil="true"/>
    <QLGN:FairValueOfWarrantModificationForProfessionalServices
      contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0341"
      unitRef="USD"
      xsi:nil="true"/>
    <QLGN:FairValueOfWarrantModificationForProfessionalServices
      contextRef="From2022-01-012022-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0343"
      unitRef="USD"
      xsi:nil="true"/>
    <QLGN:FairValueOfWarrantModificationForProfessionalServices
      contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0344"
      unitRef="USD"
      xsi:nil="true"/>
    <QLGN:FairValueOfWarrantModificationForProfessionalServices
      contextRef="From2022-01-012022-12-31_us-gaap_NoncontrollingInterestMember"
      id="xdx2ixbrl0346"
      unitRef="USD"
      xsi:nil="true"/>
    <QLGN:FairValueOfWarrantModificationForBusinessAcquisition
      contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0350"
      unitRef="USD"
      xsi:nil="true"/>
    <QLGN:FairValueOfWarrantModificationForBusinessAcquisition
      contextRef="From2022-01-012022-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0352"
      unitRef="USD"
      xsi:nil="true"/>
    <QLGN:FairValueOfWarrantModificationForBusinessAcquisition
      contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0353"
      unitRef="USD"
      xsi:nil="true"/>
    <QLGN:FairValueOfWarrantModificationForBusinessAcquisition
      contextRef="From2022-01-012022-12-31_us-gaap_NoncontrollingInterestMember"
      id="xdx2ixbrl0355"
      unitRef="USD"
      xsi:nil="true"/>
    <QLGN:StockIssuedDuringPeriodValuesReverseStockSplits
      contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0359"
      unitRef="USD"
      xsi:nil="true"/>
    <QLGN:StockIssuedDuringPeriodValuesReverseStockSplits
      contextRef="From2022-01-012022-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0361"
      unitRef="USD"
      xsi:nil="true"/>
    <QLGN:StockIssuedDuringPeriodValuesReverseStockSplits
      contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0362"
      unitRef="USD"
      xsi:nil="true"/>
    <QLGN:StockIssuedDuringPeriodValuesReverseStockSplits
      contextRef="From2022-01-012022-12-31_us-gaap_NoncontrollingInterestMember"
      id="xdx2ixbrl0364"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="From2022-01-012022-12-31_us-gaap_PreferredStockMember_custom_SeriesAlphaConvertiblePreferredStockMember"
      id="xdx2ixbrl0369"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0370"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0371"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="From2022-01-012022-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0372"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2022-12-31_us-gaap_PreferredStockMember_custom_SeriesAlphaConvertiblePreferredStockMember"
      id="xdx2ixbrl0378"
      unitRef="USD"
      xsi:nil="true"/>
    <QLGN:StockIssuedUponCashExerciseOfWarrants
      contextRef="From2021-01-012021-12-31_us-gaap_PreferredStockMember_custom_SeriesAlphaConvertiblePreferredStockMember"
      id="xdx2ixbrl0409"
      unitRef="USD"
      xsi:nil="true"/>
    <QLGN:StockIssuedUponCashExerciseOfWarrants
      contextRef="From2021-01-012021-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0412"
      unitRef="USD"
      xsi:nil="true"/>
    <QLGN:StockIssuedUponNetexerciseOfWarrants
      contextRef="From2021-01-012021-12-31_us-gaap_PreferredStockMember_custom_SeriesAlphaConvertiblePreferredStockMember"
      id="xdx2ixbrl0417"
      unitRef="USD"
      xsi:nil="true"/>
    <QLGN:StockIssuedUponNetexerciseOfWarrants
      contextRef="From2021-01-012021-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0420"
      unitRef="USD"
      xsi:nil="true"/>
    <QLGN:StockIssuedUponNetexerciseOfWarrants
      contextRef="From2021-01-012021-12-31"
      id="xdx2ixbrl0421"
      unitRef="USD"
      xsi:nil="true"/>
    <QLGN:IssuanceOfCommonStockForConversionOfPreferredStock
      contextRef="From2021-01-012021-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0428"
      unitRef="USD"
      xsi:nil="true"/>
    <QLGN:FairValueOfWarrantsIssuedForProfessionalServices
      contextRef="From2021-01-012021-12-31_us-gaap_PreferredStockMember_custom_SeriesAlphaConvertiblePreferredStockMember"
      id="xdx2ixbrl0435"
      unitRef="USD"
      xsi:nil="true"/>
    <QLGN:FairValueOfWarrantsIssuedForProfessionalServices
      contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0436"
      unitRef="USD"
      xsi:nil="true"/>
    <QLGN:FairValueOfWarrantsIssuedForProfessionalServices
      contextRef="From2021-01-012021-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0438"
      unitRef="USD"
      xsi:nil="true"/>
    <QLGN:SharesIssuedPursuantToSecuritiesPurchaseAgreements
      contextRef="From2021-01-012021-12-31_us-gaap_PreferredStockMember_custom_SeriesAlphaConvertiblePreferredStockMember"
      id="xdx2ixbrl0441"
      unitRef="USD"
      xsi:nil="true"/>
    <QLGN:SharesIssuedPursuantToSecuritiesPurchaseAgreements
      contextRef="From2021-01-012021-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0444"
      unitRef="USD"
      xsi:nil="true"/>
    <QLGN:CommissionAndOfferingCostsOfSecuritiesPurchaseAgreements
      contextRef="From2021-01-012021-12-31_us-gaap_PreferredStockMember_custom_SeriesAlphaConvertiblePreferredStockMember"
      id="xdx2ixbrl0449"
      unitRef="USD"
      xsi:nil="true"/>
    <QLGN:CommissionAndOfferingCostsOfSecuritiesPurchaseAgreements
      contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0450"
      unitRef="USD"
      xsi:nil="true"/>
    <QLGN:CommissionAndOfferingCostsOfSecuritiesPurchaseAgreements
      contextRef="From2021-01-012021-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0452"
      unitRef="USD"
      xsi:nil="true"/>
    <QLGN:FairValueOfWarrantModificationsPursuantToSecuritiesPurchaseAgreements
      contextRef="From2021-01-012021-12-31_us-gaap_PreferredStockMember_custom_SeriesAlphaConvertiblePreferredStockMember"
      id="xdx2ixbrl0455"
      unitRef="USD"
      xsi:nil="true"/>
    <QLGN:FairValueOfWarrantModificationsPursuantToSecuritiesPurchaseAgreements
      contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0456"
      unitRef="USD"
      xsi:nil="true"/>
    <QLGN:FairValueOfWarrantModificationsPursuantToSecuritiesPurchaseAgreements
      contextRef="From2021-01-012021-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0458"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2021-01-012021-12-31_us-gaap_PreferredStockMember_custom_SeriesAlphaConvertiblePreferredStockMember"
      id="xdx2ixbrl0461"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2021-01-012021-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0464"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="From2021-01-012021-12-31_us-gaap_PreferredStockMember_custom_SeriesAlphaConvertiblePreferredStockMember"
      id="xdx2ixbrl0469"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0470"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="From2021-01-012021-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0472"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="From2021-01-012021-12-31_us-gaap_PreferredStockMember_custom_SeriesAlphaConvertiblePreferredStockMember"
      id="xdx2ixbrl0475"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0476"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="From2021-01-012021-12-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0477"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2021-12-31_us-gaap_PreferredStockMember_custom_SeriesAlphaConvertiblePreferredStockMember"
      id="xdx2ixbrl0481"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2021-12-31_us-gaap_PreferredStockMember_custom_SeriesAlphaConvertiblePreferredStockMember"
      id="xdx2ixbrl0487"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2021-12-31_us-gaap_PreferredStockMember_custom_SeriesAlphaConvertiblePreferredStockMember"
      id="xdx2ixbrl0491"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2021-12-31_us-gaap_PreferredStockMember_custom_SeriesAlphaConvertiblePreferredStockMember"
      id="xdx2ixbrl0497"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims
      contextRef="From2022-01-01to2022-12-31"
      id="xdx2ixbrl0522"
      unitRef="USD"
      xsi:nil="true"/>
    <QLGN:FairValueOfWarrantsIssuedForProfessionalServices
      contextRef="From2022-01-01to2022-12-31"
      id="xdx2ixbrl0525"
      unitRef="USD"
      xsi:nil="true"/>
    <QLGN:FairValueOfWarrantModificationForProfessionalServices
      contextRef="From2021-01-012021-12-31"
      id="xdx2ixbrl0532"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="From2021-01-012021-12-31"
      id="xdx2ixbrl0535"
      unitRef="USD"
      xsi:nil="true"/>
    <QLGN:IncreaseDecreaseInResearchAndDevelopmentGrantLiability
      contextRef="From2021-01-012021-12-31"
      id="xdx2ixbrl0559"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncreaseDecreaseInDeferredLiabilities
      contextRef="From2021-01-012021-12-31"
      id="xdx2ixbrl0568"
      unitRef="USD"
      xsi:nil="true"/>
    <QLGN:PurchasesOfEquipmentHeldForLease
      contextRef="From2021-01-012021-12-31"
      id="xdx2ixbrl0580"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="From2022-01-01to2022-12-31"
      id="xdx2ixbrl0582"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CashAcquiredFromAcquisition
      contextRef="From2021-01-012021-12-31"
      id="xdx2ixbrl0586"
      unitRef="USD"
      xsi:nil="true"/>
    <QLGN:ProceedsFromIssuanceOfSharesAndWarrantsPursuantToSecuritiesPurchaseAgreements
      contextRef="From2022-01-01to2022-12-31"
      id="xdx2ixbrl0597"
      unitRef="USD"
      xsi:nil="true"/>
    <QLGN:ProceedsFromIssuanceOfConvertibleDebt
      contextRef="From2021-01-012021-12-31"
      id="xdx2ixbrl0601"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="From2022-01-01to2022-12-31"
      id="xdx2ixbrl0603"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:RepaymentsOfNotesPayable
      contextRef="From2022-01-01to2022-12-31"
      id="xdx2ixbrl0606"
      unitRef="USD"
      xsi:nil="true"/>
    <QLGN:FractionalSharePaymentsRelatedToReverseStockSplit
      contextRef="From2021-01-012021-12-31"
      id="xdx2ixbrl0610"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="From2021-01-012021-12-31"
      id="xdx2ixbrl0619"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:InterestPaidNet
      contextRef="From2022-01-01to2022-12-31"
      id="xdx2ixbrl0633"
      unitRef="USD"
      xsi:nil="true"/>
    <QLGN:IssuanceOfCommonStockForConversionOfPreferredStockBeforeClosingOfReverseRecapitalization
      contextRef="From2022-01-01to2022-12-31"
      id="xdx2ixbrl0642"
      unitRef="USD"
      xsi:nil="true"/>
    <QLGN:RightofuseAssetsObtainedInExchangeForOperatingLeaseLiabilities
      contextRef="From2022-01-01to2022-12-31"
      id="xdx2ixbrl0645"
      unitRef="USD"
      xsi:nil="true"/>
    <QLGN:SharesIssuedForCashlessWarrantsAmount
      contextRef="From2022-01-01to2022-12-31"
      id="xdx2ixbrl0648"
      unitRef="USD"
      xsi:nil="true"/>
    <QLGN:TransfersOfInventoryFromEquipmentHeldForLease
      contextRef="From2022-01-01to2022-12-31"
      id="xdx2ixbrl0651"
      unitRef="USD"
      xsi:nil="true"/>
    <QLGN:FairValueOfWarrantModificationsForBusinessAcquisition
      contextRef="From2021-01-012021-12-31"
      id="xdx2ixbrl0661"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:FairValueOfAssetsAcquired
      contextRef="From2021-01-012021-12-31"
      id="xdx2ixbrl0667"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:LiabilitiesAssumed1
      contextRef="From2021-01-012021-12-31"
      id="xdx2ixbrl0670"
      unitRef="USD"
      xsi:nil="true"/>
    <QLGN:FairValueOfWarrantsRepricedDueToAcquisition
      contextRef="From2021-01-012021-12-31"
      id="xdx2ixbrl0673"
      unitRef="USD"
      xsi:nil="true"/>
    <QLGN:FairValueOfQualigenPrefundedWarrantIssuedInExchangeForNanosynexStock
      contextRef="From2021-01-012021-12-31"
      id="xdx2ixbrl0676"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssued1
      contextRef="From2021-01-012021-12-31"
      id="xdx2ixbrl0679"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:BusinessCombinationConsiderationTransferred1
      contextRef="From2021-01-012021-12-31"
      id="xdx2ixbrl0682"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2022-01-012022-12-31_custom_LicenseRevenuesMember"
      id="xdx2ixbrl0752"
      unitRef="USD"
      xsi:nil="true"/>
    <QLGN:FixedAssetImpairments
      contextRef="AsOf2021-12-31"
      id="xdx2ixbrl0996"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:Goodwill
      contextRef="AsOf2021-12-31"
      id="xdx2ixbrl1012"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="AsOf2021-12-31_us-gaap_InProcessResearchAndDevelopmentMember"
      id="xdx2ixbrl1033"
      unitRef="USD"
      xsi:nil="true"/>
    <QLGN:AccruedEquipmentHeldForLease
      contextRef="AsOf2021-12-31"
      id="xdx2ixbrl1086"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:InterestPayableCurrent
      contextRef="AsOf2021-12-31"
      id="xdx2ixbrl1095"
      unitRef="USD"
      xsi:nil="true"/>
    <QLGN:AccruedLicenseFees
      contextRef="AsOf2021-12-31"
      id="xdx2ixbrl1113"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations
      contextRef="From2022-01-012022-12-31_custom_SeriesCWarrantsMember_custom_CommonStockWarrantsMember"
      id="xdx2ixbrl1171"
      unitRef="Shares"
      xsi:nil="true"/>
    <QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInPeriodWeightedAverageExercisePrice
      contextRef="From2022-01-012022-12-31_custom_SeriesCWarrantsMember_custom_CommonStockWarrantsMember"
      id="xdx2ixbrl1173"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations
      contextRef="From2021-01-012021-12-31_custom_SeriesCWarrantsMember_custom_CommonStockWarrantsMember"
      id="xdx2ixbrl1209"
      unitRef="Shares"
      xsi:nil="true"/>
    <QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInPeriodWeightedAverageExercisePrice
      contextRef="From2021-01-012021-12-31_custom_SeriesCWarrantsMember_custom_CommonStockWarrantsMember"
      id="xdx2ixbrl1211"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted
      contextRef="From2021-01-012021-12-31_custom_SeriesCWarrantsMember_custom_CommonStockWarrantsMember"
      id="xdx2ixbrl1213"
      unitRef="Shares"
      xsi:nil="true"/>
    <QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="From2021-01-012021-12-31_custom_SeriesCWarrantsMember_custom_CommonStockWarrantsMember"
      id="xdx2ixbrl1215"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <QLGN:FairValueAdjustmentOfWarrant
      contextRef="AsOf2021-12-31_us-gaap_FairValueInputsLevel1Member"
      id="xdx2ixbrl1231"
      unitRef="USD"
      xsi:nil="true"/>
    <QLGN:FairValueAdjustmentOfWarrant
      contextRef="AsOf2021-12-31_us-gaap_FairValueInputsLevel2Member"
      id="xdx2ixbrl1233"
      unitRef="USD"
      xsi:nil="true"/>
    <QLGN:FairValueOfWarrantLiabilitiesOnDateOfExercise
      contextRef="From2022-01-012022-12-31_us-gaap_FairValueInputsLevel1Member"
      id="xdx2ixbrl1239"
      unitRef="USD"
      xsi:nil="true"/>
    <QLGN:FairValueOfWarrantLiabilitiesOnDateOfExercise
      contextRef="From2022-01-012022-12-31_us-gaap_FairValueInputsLevel2Member"
      id="xdx2ixbrl1241"
      unitRef="USD"
      xsi:nil="true"/>
    <QLGN:FairValueOfWarrantLiabilitiesIssuanceOfAlphaWarrants
      contextRef="From2022-01-012022-12-31_us-gaap_FairValueInputsLevel1Member"
      id="xdx2ixbrl1247"
      unitRef="USD"
      xsi:nil="true"/>
    <QLGN:FairValueOfWarrantLiabilitiesIssuanceOfAlphaWarrants
      contextRef="From2022-01-012022-12-31_us-gaap_FairValueInputsLevel2Member"
      id="xdx2ixbrl1249"
      unitRef="USD"
      xsi:nil="true"/>
    <QLGN:ChangeInFairValueOfWarrantLiabilities
      contextRef="From2022-01-012022-12-31_us-gaap_FairValueInputsLevel1Member"
      id="xdx2ixbrl1255"
      unitRef="USD"
      xsi:nil="true"/>
    <QLGN:ChangeInFairValueOfWarrantLiabilities
      contextRef="From2022-01-012022-12-31_us-gaap_FairValueInputsLevel2Member"
      id="xdx2ixbrl1257"
      unitRef="USD"
      xsi:nil="true"/>
    <QLGN:FairValueAdjustmentOfWarrant
      contextRef="AsOf2022-12-31_us-gaap_FairValueInputsLevel1Member"
      id="xdx2ixbrl1263"
      unitRef="USD"
      xsi:nil="true"/>
    <QLGN:FairValueAdjustmentOfWarrant
      contextRef="AsOf2022-12-31_us-gaap_FairValueInputsLevel2Member"
      id="xdx2ixbrl1265"
      unitRef="USD"
      xsi:nil="true"/>
    <QLGN:FairValueAdjustmentOfWarrant
      contextRef="AsOf2020-12-31_us-gaap_FairValueInputsLevel1Member"
      id="xdx2ixbrl1271"
      unitRef="USD"
      xsi:nil="true"/>
    <QLGN:FairValueAdjustmentOfWarrant
      contextRef="AsOf2020-12-31_us-gaap_FairValueInputsLevel2Member"
      id="xdx2ixbrl1273"
      unitRef="USD"
      xsi:nil="true"/>
    <QLGN:FairValueOfWarrantLiabilitiesOnDateOfExercise
      contextRef="From2021-01-012021-12-31_us-gaap_FairValueInputsLevel1Member"
      id="xdx2ixbrl1279"
      unitRef="USD"
      xsi:nil="true"/>
    <QLGN:FairValueOfWarrantLiabilitiesOnDateOfExercise
      contextRef="From2021-01-012021-12-31_us-gaap_FairValueInputsLevel2Member"
      id="xdx2ixbrl1281"
      unitRef="USD"
      xsi:nil="true"/>
    <QLGN:ChangeInFairValueOfWarrantLiabilities
      contextRef="From2021-01-012021-12-31_us-gaap_FairValueInputsLevel1Member"
      id="xdx2ixbrl1287"
      unitRef="USD"
      xsi:nil="true"/>
    <QLGN:ChangeInFairValueOfWarrantLiabilities
      contextRef="From2021-01-012021-12-31_us-gaap_FairValueInputsLevel2Member"
      id="xdx2ixbrl1289"
      unitRef="USD"
      xsi:nil="true"/>
    <QLGN:FairValueAdjustmentOfWarrant
      contextRef="AsOf2021-12-31_us-gaap_FairValueInputsLevel1Member"
      id="xdx2ixbrl1295"
      unitRef="USD"
      xsi:nil="true"/>
    <QLGN:FairValueAdjustmentOfWarrant
      contextRef="AsOf2021-12-31_us-gaap_FairValueInputsLevel2Member"
      id="xdx2ixbrl1297"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2022-12-31_srt_MinimumMember_us-gaap_MeasurementInputRiskFreeInterestRateMember"
      decimals="INF"
      id="xdx2ixbrl1305"
      unitRef="Pure">3.906</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2022-12-31_srt_MinimumMember_us-gaap_MeasurementInputPriceVolatilityMember"
      decimals="INF"
      id="xdx2ixbrl1317"
      unitRef="Pure">88</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2021-12-31_srt_MinimumMember_us-gaap_MeasurementInputPriceVolatilityMember"
      decimals="INF"
      id="xdx2ixbrl1323"
      unitRef="Pure">84</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:SecuredDebt
      contextRef="AsOf2021-12-31_custom_SeniorSecuredConvertibleDebtMember"
      id="xdx2ixbrl1386"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DebtInstrumentUnamortizedDiscount
      contextRef="AsOf2021-12-31_custom_SeniorSecuredConvertibleDebtMember"
      id="xdx2ixbrl1389"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ConvertibleDebt
      contextRef="AsOf2021-12-31_custom_SeniorSecuredConvertibleDebtMember"
      id="xdx2ixbrl1392"
      unitRef="USD"
      xsi:nil="true"/>
    <QLGN:DilutivePotentialSharesIssuableFromStockOptionsAndWarrants
      contextRef="From2022-01-01to2022-12-31"
      id="xdx2ixbrl1404"
      unitRef="Shares"
      xsi:nil="true"/>
    <QLGN:DilutivePotentialSharesIssuableFromStockOptionsAndWarrants
      contextRef="From2021-01-012021-12-31"
      id="xdx2ixbrl1405"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
      contextRef="From2021-01-012021-12-31_custom_EmployeesAndNonemployeeServiceProviderMember"
      id="xdx2ixbrl1744"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="From2021-01-012021-12-31_custom_EmployeesAndNonemployeeServiceProviderMember"
      id="xdx2ixbrl1746"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="From2021-01-012021-12-31_custom_EmployeesAndNonemployeeServiceProviderMember"
      id="xdx2ixbrl1748"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted
      contextRef="From2022-01-012022-12-31_custom_CompensatoryWarrantActivityMember"
      id="xdx2ixbrl1882"
      unitRef="Shares"
      xsi:nil="true"/>
    <QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="From2022-01-012022-12-31_custom_CompensatoryWarrantActivityMember"
      id="xdx2ixbrl1884"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised
      contextRef="From2022-01-012022-12-31_custom_CompensatoryWarrantActivityMember"
      id="xdx2ixbrl1886"
      unitRef="Shares"
      xsi:nil="true"/>
    <QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedInPeriodWeightedAverageExercisePrice
      contextRef="From2022-01-012022-12-31_custom_CompensatoryWarrantActivityMember"
      id="xdx2ixbrl1888"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations
      contextRef="From2022-01-012022-12-31_custom_CompensatoryWarrantActivityMember"
      id="xdx2ixbrl1890"
      unitRef="Shares"
      xsi:nil="true"/>
    <QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInPeriodWeightedAverageExercisePrice
      contextRef="From2022-01-012022-12-31_custom_CompensatoryWarrantActivityMember"
      id="xdx2ixbrl1892"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures
      contextRef="From2022-01-012022-12-31_custom_CompensatoryWarrantActivityMember"
      id="xdx2ixbrl1894"
      unitRef="Shares"
      xsi:nil="true"/>
    <QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedInPeriodWeightedAverageExercisePrice
      contextRef="From2022-01-012022-12-31_custom_CompensatoryWarrantActivityMember"
      id="xdx2ixbrl1896"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNonVestedNumber
      contextRef="AsOf2022-12-31_custom_CompensatoryWarrantActivityMember"
      id="xdx2ixbrl1915"
      unitRef="Shares"
      xsi:nil="true"/>
    <QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageNonVestedExercise
      contextRef="AsOf2022-12-31_custom_CompensatoryWarrantActivityMember"
      id="xdx2ixbrl1917"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <QLGN:RangeOfExercisePriceNonexercisableNonvested
      contextRef="AsOf2022-12-31_custom_CompensatoryWarrantActivityMember"
      id="xdx2ixbrl1919"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations
      contextRef="From2021-01-012021-12-31_custom_CompensatoryWarrantActivityMember72031656"
      id="xdx2ixbrl1933"
      unitRef="Shares"
      xsi:nil="true"/>
    <QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInPeriodWeightedAverageExercisePrice
      contextRef="From2021-01-012021-12-31_custom_CompensatoryWarrantActivityMember"
      id="xdx2ixbrl1935"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNonVestedNumber
      contextRef="AsOf2021-12-31_custom_CompensatoryWarrantActivityMember"
      id="xdx2ixbrl1959"
      unitRef="Shares"
      xsi:nil="true"/>
    <QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageNonVestedExercise
      contextRef="AsOf2021-12-31_custom_CompensatoryWarrantActivityMember"
      id="xdx2ixbrl1961"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <QLGN:RangeOfExercisePriceNonexercisableNonvested
      contextRef="AsOf2021-12-31_custom_CompensatoryWarrantActivityMember"
      id="xdx2ixbrl1963"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures
      contextRef="From2022-01-012022-12-31_custom_NonCompensatoryWarrantActivityMember72032375"
      id="xdx2ixbrl2045"
      unitRef="Shares"
      xsi:nil="true"/>
    <QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedInPeriodWeightedAverageExercisePrice
      contextRef="From2022-01-012022-12-31_custom_NonCompensatoryWarrantActivityMember72032375"
      id="xdx2ixbrl2047"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedInRangeOfExercisePrice
      contextRef="From2022-01-012022-12-31_custom_NonCompensatoryWarrantActivityMember72032375"
      id="xdx2ixbrl2049"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsNonExercisableNumber
      contextRef="AsOf2022-12-31_custom_NonCompensatoryWarrantActivityMember"
      id="xdx2ixbrl2069"
      unitRef="Shares"
      xsi:nil="true"/>
    <QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageVestedNonExercisePrice
      contextRef="AsOf2022-12-31_custom_NonCompensatoryWarrantActivityMember"
      id="xdx2ixbrl2071"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <QLGN:RangeOfExercisePriceNonExercisableVested
      contextRef="AsOf2022-12-31_custom_NonCompensatoryWarrantActivityMember"
      id="xdx2ixbrl2073"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted
      contextRef="From2021-01-012021-12-31_custom_NonCompensatoryWarrantActivityMember"
      id="xdx2ixbrl2079"
      unitRef="Shares"
      xsi:nil="true"/>
    <QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="From2021-01-012021-12-31_custom_NonCompensatoryWarrantActivityMember"
      id="xdx2ixbrl2081"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures
      contextRef="From2021-01-012021-12-31_custom_NonCompensatoryWarrantActivityMember"
      id="xdx2ixbrl2091"
      unitRef="Shares"
      xsi:nil="true"/>
    <QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedInPeriodWeightedAverageExercisePrice
      contextRef="From2021-01-012021-12-31_custom_NonCompensatoryWarrantActivityMember"
      id="xdx2ixbrl2093"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNonVestedNumber
      contextRef="AsOf2021-12-31_custom_NonCompensatoryWarrantActivityMember"
      id="xdx2ixbrl2108"
      unitRef="Shares"
      xsi:nil="true"/>
    <QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageNonVestedExercise
      contextRef="AsOf2021-12-31_custom_NonCompensatoryWarrantActivityMember"
      id="xdx2ixbrl2110"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <QLGN:RangeOfExercisePriceNonexercisableNonvested
      contextRef="AsOf2021-12-31_custom_NonCompensatoryWarrantActivityMember"
      id="xdx2ixbrl2112"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNonExercisableWeightedAverageRemainingContractualTerm1
      contextRef="From2021-01-012021-12-31_custom_NonCompensatoryWarrantActivityMember"
      id="xdx2ixbrl2114"
      xsi:nil="true"/>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="From2021-01-012021-12-31"
      id="xdx2ixbrl2160"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="From2022-01-01to2022-12-31"
      id="xdx2ixbrl2202"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="From2021-01-012021-12-31"
      id="xdx2ixbrl2203"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CurrentForeignTaxExpenseBenefit
      contextRef="From2022-01-01to2022-12-31"
      id="xdx2ixbrl2208"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CurrentForeignTaxExpenseBenefit
      contextRef="From2021-01-012021-12-31"
      id="xdx2ixbrl2209"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DeferredForeignIncomeTaxExpenseBenefit
      contextRef="From2021-01-012021-12-31"
      id="xdx2ixbrl2221"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets
      contextRef="AsOf2022-12-31"
      id="xdx2ixbrl2243"
      unitRef="USD"
      xsi:nil="true"/>
    <QLGN:DeferredTaxAssetsResearchAndDevelopmentExpenses
      contextRef="AsOf2021-12-31"
      id="xdx2ixbrl2250"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="AsOf2021-12-31"
      id="xdx2ixbrl2274"
      unitRef="USD"
      xsi:nil="true"/>
    <dei:DocumentType contextRef="From2022-01-01to2022-12-31">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport contextRef="From2022-01-01to2022-12-31">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate contextRef="From2022-01-01to2022-12-31">2022-12-31</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate contextRef="From2022-01-01to2022-12-31">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus contextRef="From2022-01-01to2022-12-31">2022</dei:DocumentFiscalYearFocus>
    <dei:DocumentTransitionReport contextRef="From2022-01-01to2022-12-31">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="From2022-01-01to2022-12-31">001-37428</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="From2022-01-01to2022-12-31">Qualigen Therapeutics, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="From2022-01-01to2022-12-31">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="From2022-01-01to2022-12-31">26-3474527</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="From2022-01-01to2022-12-31">2042 Corte Del Nogal</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="From2022-01-01to2022-12-31">Carlsbad</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="From2022-01-01to2022-12-31">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="From2022-01-01to2022-12-31">92011</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="From2022-01-01to2022-12-31">(760)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="From2022-01-01to2022-12-31">918-9165</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="From2022-01-01to2022-12-31">Common     Stock, par value $0.001 per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="From2022-01-01to2022-12-31">QLGN</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="From2022-01-01to2022-12-31">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer contextRef="From2022-01-01to2022-12-31">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers contextRef="From2022-01-01to2022-12-31">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus contextRef="From2022-01-01to2022-12-31">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="From2022-01-01to2022-12-31">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="From2022-01-01to2022-12-31">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="From2022-01-01to2022-12-31">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="From2022-01-01to2022-12-31">false</dei:EntityEmergingGrowthCompany>
    <dei:IcfrAuditorAttestationFlag contextRef="From2022-01-01to2022-12-31">false</dei:IcfrAuditorAttestationFlag>
    <dei:EntityShellCompany contextRef="From2022-01-01to2022-12-31">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat contextRef="AsOf2022-06-30" decimals="0" unitRef="USD">21943148</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding contextRef="AsOf2023-04-11" decimals="INF" unitRef="Shares">5052463</dei:EntityCommonStockSharesOutstanding>
    <dei:DocumentsIncorporatedByReferenceTextBlock contextRef="From2022-01-01to2022-12-31">None.</dei:DocumentsIncorporatedByReferenceTextBlock>
    <dei:AuditorFirmId contextRef="From2022-01-01to2022-12-31">23</dei:AuditorFirmId>
    <dei:AuditorFirmId contextRef="From2022-01-01to2022-12-31">23</dei:AuditorFirmId>
    <dei:AuditorName contextRef="From2022-01-01to2022-12-31">BAKER TILLY US, LLP</dei:AuditorName>
    <dei:AuditorLocation contextRef="From2022-01-01to2022-12-31">San Diego, California</dei:AuditorLocation>
    <us-gaap:Cash contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">7034434</us-gaap:Cash>
    <us-gaap:Cash contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">17538272</us-gaap:Cash>
    <us-gaap:AccountsReceivableNetCurrent contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">538587</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">822351</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:InventoryNet contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">1586297</us-gaap:InventoryNet>
    <us-gaap:InventoryNet contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">1055878</us-gaap:InventoryNet>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">1661220</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">1379896</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">10820538</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">20796397</us-gaap:AssetsCurrent>
    <us-gaap:RestrictedCashAndCashEquivalents contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">5690</us-gaap:RestrictedCashAndCashEquivalents>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">1422538</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">1645568</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">345087</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">204217</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">5845702</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">171190</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:Goodwill contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">625602</us-gaap:Goodwill>
    <us-gaap:OtherAssetsNoncurrent contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">18334</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">18334</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">19083491</us-gaap:Assets>
    <us-gaap:Assets contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">22835705</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">857311</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">886224</us-gaap:AccountsPayableCurrent>
    <QLGN:AccruedVacation contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">467948</QLGN:AccruedVacation>
    <QLGN:AccruedVacation contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">282910</QLGN:AccruedVacation>
    <us-gaap:AccruedLiabilitiesAndOtherLiabilities contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">1511856</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
    <us-gaap:AccruedLiabilitiesAndOtherLiabilities contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">1510990</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
    <QLGN:ResearchAndDevelopmentGrantLiability contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">780682</QLGN:ResearchAndDevelopmentGrantLiability>
    <us-gaap:DeferredIncomeCurrent contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">116161</us-gaap:DeferredIncomeCurrent>
    <us-gaap:DeferredIncomeCurrent contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">135063</us-gaap:DeferredIncomeCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">240645</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">134091</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:ShortTermBorrowings contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">950722</us-gaap:ShortTermBorrowings>
    <us-gaap:HedgingLiabilitiesCurrent contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">788100</us-gaap:HedgingLiabilitiesCurrent>
    <us-gaap:HedgingLiabilitiesCurrent contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">1686200</us-gaap:HedgingLiabilitiesCurrent>
    <QLGN:WarrantLiabilitiesRelatedParty contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">2834547</QLGN:WarrantLiabilitiesRelatedParty>
    <us-gaap:ConvertibleDebt contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">60197</us-gaap:ConvertibleDebt>
    <us-gaap:LiabilitiesCurrent contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">8608169</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">4635479</us-gaap:LiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">1301919</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">1542564</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:DeferredRevenueNoncurrent contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">49056</us-gaap:DeferredRevenueNoncurrent>
    <us-gaap:DeferredRevenueNoncurrent contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">92928</us-gaap:DeferredRevenueNoncurrent>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">357757</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:Liabilities contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">10316901</us-gaap:Liabilities>
    <us-gaap:Liabilities contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">6270971</us-gaap:Liabilities>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2022-12-31"
      decimals="INF"
      unitRef="USDPShares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2021-12-31"
      decimals="INF"
      unitRef="USDPShares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized contextRef="AsOf2022-12-31" decimals="INF" unitRef="Shares">225000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized contextRef="AsOf2021-12-31" decimals="INF" unitRef="Shares">225000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued contextRef="AsOf2022-12-31" decimals="INF" unitRef="Shares">4210737</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="AsOf2022-12-31" decimals="INF" unitRef="Shares">4210737</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued contextRef="AsOf2021-12-31" decimals="INF" unitRef="Shares">3529018</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="AsOf2021-12-31" decimals="INF" unitRef="Shares">3529018</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">42110</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">35290</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">110528050</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">101274073</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">50721</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">-103385172</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">-84744629</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">7235709</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">16564734</us-gaap:StockholdersEquity>
    <us-gaap:MinorityInterest contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">1530881</us-gaap:MinorityInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">8766590</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">16564734</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">19083491</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">22835705</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2022-01-012022-12-31_custom_NetProductSalesMember"
      decimals="0"
      unitRef="USD">4983556</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2021-01-012021-12-31_custom_NetProductSalesMember"
      decimals="0"
      unitRef="USD">5021721</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2021-01-012021-12-31_custom_LicenseRevenueMember"
      decimals="0"
      unitRef="USD">632004</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">4983556</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">5653725</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <QLGN:CostOfProductSales
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">4302755</QLGN:CostOfProductSales>
    <QLGN:CostOfProductSales
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">4332485</QLGN:CostOfProductSales>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">10835647</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">11724964</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">6837133</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">11716718</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:MarketingAndAdvertisingExpense
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">950420</us-gaap:MarketingAndAdvertisingExpense>
    <us-gaap:MarketingAndAdvertisingExpense
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">542594</us-gaap:MarketingAndAdvertisingExpense>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">4239000</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:OperatingExpenses
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">27164955</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">28316761</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">-22181399</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">-22663036</us-gaap:OperatingIncomeLoss>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">907203</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">4723187</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:InterestIncomeExpenseNet
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">-26646</us-gaap:InterestIncomeExpenseNet>
    <us-gaap:InterestIncomeExpenseNet
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">42693</us-gaap:InterestIncomeExpenseNet>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">1125</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">5446</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">881682</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">4771326</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">-21299717</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">-17891710</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">-265074</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">5427</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ProfitLoss
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">-21034643</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">-17897137</us-gaap:ProfitLoss>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">-2394100</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">-18640543</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">-17897137</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2022-01-01to2022-12-31"
      decimals="INF"
      unitRef="USDPShares">-4.85</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2021-01-012021-12-31"
      decimals="INF"
      unitRef="USDPShares">-6.10</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2022-01-01to2022-12-31"
      decimals="INF"
      unitRef="Shares">3840340</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2021-01-012021-12-31"
      decimals="INF"
      unitRef="Shares">2933487</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:ProfitLoss
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">-21034643</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">-17897137</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">50721</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">-20983922</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">-17897137</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">-2394100</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">-18589822</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">-17897137</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2021-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">3529018</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2021-12-31_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">35290</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2021-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">101274073</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2021-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-84744629</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2021-12-31_us-gaap_ParentMember"
      decimals="0"
      unitRef="USD">16564734</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">16564734</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <QLGN:StockIssuedUponCashExerciseOfWarrantsShares
      contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">332000</QLGN:StockIssuedUponCashExerciseOfWarrantsShares>
    <QLGN:StockIssuedUponCashExerciseOfWarrants
      contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">3320</QLGN:StockIssuedUponCashExerciseOfWarrants>
    <QLGN:StockIssuedUponCashExerciseOfWarrants
      contextRef="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">4711</QLGN:StockIssuedUponCashExerciseOfWarrants>
    <QLGN:StockIssuedUponCashExerciseOfWarrants
      contextRef="From2022-01-012022-12-31_us-gaap_ParentMember"
      decimals="0"
      unitRef="USD">8031</QLGN:StockIssuedUponCashExerciseOfWarrants>
    <QLGN:StockIssuedUponCashExerciseOfWarrants
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">8031</QLGN:StockIssuedUponCashExerciseOfWarrants>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions
      contextRef="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">5484044</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions
      contextRef="From2022-01-012022-12-31_us-gaap_ParentMember"
      decimals="0"
      unitRef="USD">5484044</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">5484044</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions>
    <QLGN:CommonStockAndPrefundedWarrantsIssuedSharesForBusinessAcquisition
      contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">350000</QLGN:CommonStockAndPrefundedWarrantsIssuedSharesForBusinessAcquisition>
    <QLGN:CommonStockAndPrefundedWarrantsIssuedForBusinessAcquisition
      contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">3500</QLGN:CommonStockAndPrefundedWarrantsIssuedForBusinessAcquisition>
    <QLGN:CommonStockAndPrefundedWarrantsIssuedForBusinessAcquisition
      contextRef="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">3740417</QLGN:CommonStockAndPrefundedWarrantsIssuedForBusinessAcquisition>
    <QLGN:CommonStockAndPrefundedWarrantsIssuedForBusinessAcquisition
      contextRef="From2022-01-012022-12-31_us-gaap_ParentMember"
      decimals="0"
      unitRef="USD">3743917</QLGN:CommonStockAndPrefundedWarrantsIssuedForBusinessAcquisition>
    <QLGN:CommonStockAndPrefundedWarrantsIssuedForBusinessAcquisition
      contextRef="From2022-01-012022-12-31_us-gaap_NoncontrollingInterestMember"
      decimals="0"
      unitRef="USD">3882225</QLGN:CommonStockAndPrefundedWarrantsIssuedForBusinessAcquisition>
    <QLGN:CommonStockAndPrefundedWarrantsIssuedForBusinessAcquisition
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">7626142</QLGN:CommonStockAndPrefundedWarrantsIssuedForBusinessAcquisition>
    <QLGN:NoncontrollingInterestAdjustmentsRelatingToStockbasedCompensationAndOther
      contextRef="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">-42756</QLGN:NoncontrollingInterestAdjustmentsRelatingToStockbasedCompensationAndOther>
    <QLGN:NoncontrollingInterestAdjustmentsRelatingToStockbasedCompensationAndOther
      contextRef="From2022-01-012022-12-31_us-gaap_ParentMember"
      decimals="0"
      unitRef="USD">-42756</QLGN:NoncontrollingInterestAdjustmentsRelatingToStockbasedCompensationAndOther>
    <QLGN:NoncontrollingInterestAdjustmentsRelatingToStockbasedCompensationAndOther
      contextRef="From2022-01-012022-12-31_us-gaap_NoncontrollingInterestMember"
      decimals="0"
      unitRef="USD">42756</QLGN:NoncontrollingInterestAdjustmentsRelatingToStockbasedCompensationAndOther>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="From2022-01-012022-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="0"
      unitRef="USD">50721</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="From2022-01-012022-12-31_us-gaap_ParentMember"
      decimals="0"
      unitRef="USD">50721</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">50721</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <QLGN:FairValueOfWarrantModificationForProfessionalServices
      contextRef="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">67370</QLGN:FairValueOfWarrantModificationForProfessionalServices>
    <QLGN:FairValueOfWarrantModificationForProfessionalServices
      contextRef="From2022-01-012022-12-31_us-gaap_ParentMember"
      decimals="0"
      unitRef="USD">67370</QLGN:FairValueOfWarrantModificationForProfessionalServices>
    <QLGN:FairValueOfWarrantModificationForProfessionalServices
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">67370</QLGN:FairValueOfWarrantModificationForProfessionalServices>
    <QLGN:FairValueOfWarrantModificationForBusinessAcquisition
      contextRef="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">696</QLGN:FairValueOfWarrantModificationForBusinessAcquisition>
    <QLGN:FairValueOfWarrantModificationForBusinessAcquisition
      contextRef="From2022-01-012022-12-31_us-gaap_ParentMember"
      decimals="0"
      unitRef="USD">696</QLGN:FairValueOfWarrantModificationForBusinessAcquisition>
    <QLGN:FairValueOfWarrantModificationForBusinessAcquisition
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">696</QLGN:FairValueOfWarrantModificationForBusinessAcquisition>
    <us-gaap:StockIssuedDuringPeriodSharesReverseStockSplits
      contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">-281</us-gaap:StockIssuedDuringPeriodSharesReverseStockSplits>
    <QLGN:StockIssuedDuringPeriodValuesReverseStockSplits
      contextRef="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">-505</QLGN:StockIssuedDuringPeriodValuesReverseStockSplits>
    <QLGN:StockIssuedDuringPeriodValuesReverseStockSplits
      contextRef="From2022-01-012022-12-31_us-gaap_ParentMember"
      decimals="0"
      unitRef="USD">-505</QLGN:StockIssuedDuringPeriodValuesReverseStockSplits>
    <QLGN:StockIssuedDuringPeriodValuesReverseStockSplits
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">-505</QLGN:StockIssuedDuringPeriodValuesReverseStockSplits>
    <us-gaap:ProfitLoss
      contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-18640543</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="From2022-01-012022-12-31_us-gaap_ParentMember"
      decimals="0"
      unitRef="USD">-18640543</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="From2022-01-012022-12-31_us-gaap_NoncontrollingInterestMember"
      decimals="0"
      unitRef="USD">-2394100</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">-21034643</us-gaap:ProfitLoss>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2022-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">4210737</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2022-12-31_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">42110</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2022-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">110528050</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2022-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="0"
      unitRef="USD">50721</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2022-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-103385172</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2022-12-31_us-gaap_ParentMember"
      decimals="0"
      unitRef="USD">7235709</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2022-12-31_us-gaap_NoncontrollingInterestMember"
      decimals="0"
      unitRef="USD">1530881</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">8766590</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2020-12-31_us-gaap_PreferredStockMember_custom_SeriesAlphaConvertiblePreferredStockMember"
      decimals="INF"
      unitRef="Shares">18</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2020-12-31_us-gaap_PreferredStockMember_custom_SeriesAlphaConvertiblePreferredStockMember"
      decimals="0"
      unitRef="USD">1</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2020-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">2729606</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2020-12-31_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">27296</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2020-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">85114755</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2020-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-66847492</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">18294560</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2020-12-31_us-gaap_PreferredStockMember_custom_SeriesAlphaConvertiblePreferredStockMember"
      decimals="INF"
      unitRef="Shares">18</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2020-12-31_us-gaap_PreferredStockMember_custom_SeriesAlphaConvertiblePreferredStockMember"
      decimals="0"
      unitRef="USD">1</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2020-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">2729606</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2020-12-31_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">27296</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2020-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">85114755</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2020-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-66847492</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">18294560</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <QLGN:StockIssuedUponCashExerciseOfWarrantsShares
      contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">161830</QLGN:StockIssuedUponCashExerciseOfWarrantsShares>
    <QLGN:StockIssuedUponCashExerciseOfWarrants
      contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">1619</QLGN:StockIssuedUponCashExerciseOfWarrants>
    <QLGN:StockIssuedUponCashExerciseOfWarrants
      contextRef="From2021-01-012021-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">2358570</QLGN:StockIssuedUponCashExerciseOfWarrants>
    <QLGN:StockIssuedUponCashExerciseOfWarrants
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">2360189</QLGN:StockIssuedUponCashExerciseOfWarrants>
    <QLGN:StockIssuedUponNetexerciseOfWarrantsShares
      contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">22740</QLGN:StockIssuedUponNetexerciseOfWarrantsShares>
    <QLGN:StockIssuedUponNetexerciseOfWarrants
      contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">227</QLGN:StockIssuedUponNetexerciseOfWarrants>
    <QLGN:StockIssuedUponNetexerciseOfWarrants
      contextRef="From2021-01-012021-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">-227</QLGN:StockIssuedUponNetexerciseOfWarrants>
    <QLGN:IssuanceOfCommonStockSharesForConversionOfPreferredStock
      contextRef="From2021-01-012021-12-31_us-gaap_PreferredStockMember_custom_SeriesAlphaConvertiblePreferredStockMember"
      decimals="INF"
      unitRef="Shares">-18</QLGN:IssuanceOfCommonStockSharesForConversionOfPreferredStock>
    <QLGN:IssuanceOfCommonStockForConversionOfPreferredStock
      contextRef="From2021-01-012021-12-31_us-gaap_PreferredStockMember_custom_SeriesAlphaConvertiblePreferredStockMember"
      decimals="0"
      unitRef="USD">-1</QLGN:IssuanceOfCommonStockForConversionOfPreferredStock>
    <QLGN:IssuanceOfCommonStockSharesForConversionOfPreferredStock
      contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">24342</QLGN:IssuanceOfCommonStockSharesForConversionOfPreferredStock>
    <QLGN:IssuanceOfCommonStockForConversionOfPreferredStock
      contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">243</QLGN:IssuanceOfCommonStockForConversionOfPreferredStock>
    <QLGN:IssuanceOfCommonStockForConversionOfPreferredStock
      contextRef="From2021-01-012021-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">-243</QLGN:IssuanceOfCommonStockForConversionOfPreferredStock>
    <QLGN:IssuanceOfCommonStockForConversionOfPreferredStock
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">-1</QLGN:IssuanceOfCommonStockForConversionOfPreferredStock>
    <QLGN:FairValueOfWarrantsIssuedForProfessionalServices
      contextRef="From2021-01-012021-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">298651</QLGN:FairValueOfWarrantsIssuedForProfessionalServices>
    <QLGN:FairValueOfWarrantsIssuedForProfessionalServices
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">298651</QLGN:FairValueOfWarrantsIssuedForProfessionalServices>
    <QLGN:SharesIssuedPursuantToSecuritiesPurchaseShareAgreements
      contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">588000</QLGN:SharesIssuedPursuantToSecuritiesPurchaseShareAgreements>
    <QLGN:SharesIssuedPursuantToSecuritiesPurchaseAgreements
      contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">5880</QLGN:SharesIssuedPursuantToSecuritiesPurchaseAgreements>
    <QLGN:SharesIssuedPursuantToSecuritiesPurchaseAgreements
      contextRef="From2021-01-012021-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">8814120</QLGN:SharesIssuedPursuantToSecuritiesPurchaseAgreements>
    <QLGN:SharesIssuedPursuantToSecuritiesPurchaseAgreements
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">8820000</QLGN:SharesIssuedPursuantToSecuritiesPurchaseAgreements>
    <QLGN:CommissionAndOfferingCostsOfSecuritiesPurchaseAgreements
      contextRef="From2021-01-012021-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">-2960465</QLGN:CommissionAndOfferingCostsOfSecuritiesPurchaseAgreements>
    <QLGN:CommissionAndOfferingCostsOfSecuritiesPurchaseAgreements
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">-2960465</QLGN:CommissionAndOfferingCostsOfSecuritiesPurchaseAgreements>
    <QLGN:FairValueOfWarrantModificationsPursuantToSecuritiesPurchaseAgreements
      contextRef="From2021-01-012021-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">2253536</QLGN:FairValueOfWarrantModificationsPursuantToSecuritiesPurchaseAgreements>
    <QLGN:FairValueOfWarrantModificationsPursuantToSecuritiesPurchaseAgreements
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">2253536</QLGN:FairValueOfWarrantModificationsPursuantToSecuritiesPurchaseAgreements>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">2500</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">25</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2021-01-012021-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">101725</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">101750</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="From2021-01-012021-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">5293651</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">5293651</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:ProfitLoss
      contextRef="From2021-01-012021-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-17897137</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">-17897137</us-gaap:ProfitLoss>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2021-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">3529018</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2021-12-31_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">35290</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2021-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">101274073</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2021-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-84744629</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">16564734</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2021-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">3529018</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2021-12-31_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">35290</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2021-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">101274073</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2021-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-84744629</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">16564734</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">-21034643</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">-17897137</us-gaap:ProfitLoss>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">152573</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">113218</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">223030</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">225059</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:ProvisionForDoubtfulAccounts
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">-59982</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:ProvisionForDoubtfulAccounts
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">-247845</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:InventoryWriteDown
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">18943</us-gaap:InventoryWriteDown>
    <us-gaap:InventoryWriteDown
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">-108138</us-gaap:InventoryWriteDown>
    <us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">101750</us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims>
    <QLGN:FairValueOfWarrantsIssuedForProfessionalServices
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">298651</QLGN:FairValueOfWarrantsIssuedForProfessionalServices>
    <us-gaap:ShareBasedCompensation
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">5484044</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">5293651</us-gaap:ShareBasedCompensation>
    <QLGN:FairValueOfWarrantModificationForProfessionalServices
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">67370</QLGN:FairValueOfWarrantModificationForProfessionalServices>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">4239000</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">-906345</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">-4723187</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">-417708</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">-41250</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <QLGN:IncreaseDecreaseInInventoryAndEquipmentHeldForLeases
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">637410</QLGN:IncreaseDecreaseInInventoryAndEquipmentHeldForLeases>
    <QLGN:IncreaseDecreaseInInventoryAndEquipmentHeldForLeases
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">-111422</QLGN:IncreaseDecreaseInInventoryAndEquipmentHeldForLeases>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">99251</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">-1298998</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">-33397</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">385455</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">-76266</us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">1047163</us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities>
    <QLGN:IncreaseDecreaseInResearchAndDevelopmentGrantLiability
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">-534426</QLGN:IncreaseDecreaseInResearchAndDevelopmentGrantLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">-134091</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">-254740</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">-62775</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">-416312</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInDeferredLiabilities
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">-271622</us-gaap:IncreaseDecreaseInDeferredLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">-13247540</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">-14730742</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">164684</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">134471</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <QLGN:PurchasesOfEquipmentHeldForLease
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">154433</QLGN:PurchasesOfEquipmentHeldForLease>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">6893</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:CashAcquiredFromAcquisition
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">135354</us-gaap:CashAcquiredFromAcquisition>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">-183763</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">-141364</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">7173</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">459476</us-gaap:ProceedsFromWarrantExercises>
    <QLGN:ProceedsFromIssuanceOfSharesAndWarrantsPursuantToSecuritiesPurchaseAgreements
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">8820000</QLGN:ProceedsFromIssuanceOfSharesAndWarrantsPursuantToSecuritiesPurchaseAgreements>
    <QLGN:ProceedsFromIssuanceOfConvertibleDebt
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">2903847</QLGN:ProceedsFromIssuanceOfConvertibleDebt>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">706929</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:RepaymentsOfNotesPayable
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">138739</us-gaap:RepaymentsOfNotesPayable>
    <QLGN:FractionalSharePaymentsRelatedToReverseStockSplit
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">505</QLGN:FractionalSharePaymentsRelatedToReverseStockSplit>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">2910515</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">8433808</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">-10520787</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">-6438298</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">22639</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">17538272</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">23976570</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">7040123</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">17538272</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:InterestPaidNet
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">1233</us-gaap:InterestPaidNet>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">5571</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">5133</us-gaap:IncomeTaxesPaidNet>
    <QLGN:IssuanceOfCommonStockForConversionOfPreferredStockBeforeClosingOfReverseRecapitalization
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">243</QLGN:IssuanceOfCommonStockForConversionOfPreferredStockBeforeClosingOfReverseRecapitalization>
    <QLGN:RightofuseAssetsObtainedInExchangeForOperatingLeaseLiabilities
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">1439830</QLGN:RightofuseAssetsObtainedInExchangeForOperatingLeaseLiabilities>
    <QLGN:SharesIssuedForCashlessWarrantsAmount
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">764657</QLGN:SharesIssuedForCashlessWarrantsAmount>
    <QLGN:TransfersOfInventoryFromEquipmentHeldForLease
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">1304</QLGN:TransfersOfInventoryFromEquipmentHeldForLease>
    <QLGN:FairValueOfWarrantModificationsPursuantToSecuritiesPurchaseAgreements
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">9439</QLGN:FairValueOfWarrantModificationsPursuantToSecuritiesPurchaseAgreements>
    <QLGN:FairValueOfWarrantModificationsPursuantToSecuritiesPurchaseAgreements
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">2253536</QLGN:FairValueOfWarrantModificationsPursuantToSecuritiesPurchaseAgreements>
    <QLGN:FairValueOfWarrantLiabilitiesOnDateOfExercise
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">858</QLGN:FairValueOfWarrantLiabilitiesOnDateOfExercise>
    <QLGN:FairValueOfWarrantLiabilitiesOnDateOfExercise
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">1900713</QLGN:FairValueOfWarrantLiabilitiesOnDateOfExercise>
    <QLGN:FairValueOfWarrantModificationsForBusinessAcquisition
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">33543</QLGN:FairValueOfWarrantModificationsForBusinessAcquisition>
    <us-gaap:FairValueOfAssetsAcquired
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">5896278</us-gaap:FairValueOfAssetsAcquired>
    <us-gaap:LiabilitiesAssumed1
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">2321845</us-gaap:LiabilitiesAssumed1>
    <QLGN:FairValueOfWarrantsRepricedDueToAcquisition
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">696</QLGN:FairValueOfWarrantsRepricedDueToAcquisition>
    <QLGN:FairValueOfQualigenPrefundedWarrantIssuedInExchangeForNanosynexStock
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">1804102</QLGN:FairValueOfQualigenPrefundedWarrantIssuedInExchangeForNanosynexStock>
    <us-gaap:StockIssued1
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">1904989</us-gaap:StockIssued1>
    <us-gaap:BusinessCombinationConsiderationTransferred1
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">135354</us-gaap:BusinessCombinationConsiderationTransferred1>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_80D_eus-gaap--OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_zFtXKJBIDe11" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
1 &#x2014; &lt;span id="xdx_829_zkOtCUiAh3ch"&gt;ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND ESTIMATES&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84C_ecustom--OrganizationPolicyTextBlock_zeWI3RRbueC4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86A_z2jwwuWoT1kg"&gt;Organization&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Qualigen,
Inc., now a subsidiary of Qualigen Therapeutics, Inc., was incorporated in Minnesota in 1996 to design, develop, manufacture and sell
Physician Office Laboratory (&#x201c;POL&#x201d;) market quantitative immunoassay diagnostic products for use in physician offices and
other point-of-care settings worldwide, and was reincorporated in Delaware in 1999. In May 2020, Qualigen, Inc. completed a reverse recapitalization
transaction with Ritter Pharmaceuticals, Inc. (&#x201c;Ritter&#x201d;) and Ritter was renamed Qualigen Therapeutics, Inc. All shares of
Qualigen, Inc.&#x2019;s capital stock were exchanged for Qualigen Therapeutics, Inc.&#x2019;s capital stock in the merger. Ritter/Qualigen
Therapeutics common stock, which was previously traded on the Nasdaq Capital Market under the ticker symbol &#x201c;RTTR,&#x201d; commenced
trading on the Nasdaq Capital Market, on a post-reverse-stock-split adjusted basis, under the trading symbol &#x201c;QLGN&#x201d; on May
26, 2020. Qualigen Therapeutics, Inc. (the &#x201c;Company&#x201d;) operates in one business segment.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;On
May 26, 2022, the Company acquired &lt;span id="xdx_903_eus-gaap--StockIssuedDuringPeriodSharesAcquisitions_c20220524__20220526__us-gaap--BusinessAcquisitionAxis__custom--NanoSynexLtdMember__us-gaap--StatementClassOfStockAxis__custom--SeriesAOnePreferredStockMember_zfMeIdzOzlJa" title="Number of common stock acquired shares"&gt;2,232,861&lt;/span&gt; shares of Series A-1 Preferred Stock of NanoSynex, Ltd. (&#x201c;NanoSynex&#x201d;) from Alpha
Capital Anstalt (&#x201c;Alpha Capital&#x201d;), a related party, in exchange for &lt;span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodSharesAcquisitions_c20220524__20220526__us-gaap--BusinessAcquisitionAxis__custom--NanoSynexLtdMember_zks2Cx6r38pd" title="Number of common stock acquired shares"&gt;350,000&lt;/span&gt; reverse split adjusted shares of the Company&#x2019;s common stock and a prefunded warrant
to purchase &lt;span id="xdx_904_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_c20220526__us-gaap--StatementEquityComponentsAxis__custom--PrefundedWarrantMember_zrdIBprn3PV4" title="Warrants to purchase common stock"&gt;331,464 reverse split adjusted shares of the Company&#x2019;s common stock at an exercise price of $&lt;span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20220526__us-gaap--StatementEquityComponentsAxis__custom--PrefundedWarrantMember_zHeVCJY9m9L4" title="Class of Warrant or Right, Exercise Price of Warrants or Rights"&gt;0.001&lt;/span&gt; per share. &lt;span id="xdx_901_eus-gaap--StockholdersEquityReverseStockSplit_c20220525__20220526_zPIU0Z15PR81" title="Reverse split, description"&gt;These warrants were subsequently exercised on September 13, 2022&lt;/span&gt;. Concurrently with this transaction,
the Company also purchased &lt;span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodSharesAcquisitions_c20220524__20220526__us-gaap--BusinessAcquisitionAxis__custom--NanoSynexLtdMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zotzw9HT11Zf" title="Stock issued during period shares acquisitions"&gt;381,786&lt;/span&gt; shares of Series B preferred stock from NanoSynex for a total purchase price of $&lt;span id="xdx_909_eus-gaap--StockIssuedDuringPeriodValueAcquisitions_pp0p0_c20220524__20220526__us-gaap--BusinessAcquisitionAxis__custom--NanoSynexLtdMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zdCN0AghKGfa" title="Stock issued during period, value, acquisitions"&gt;600,000&lt;/span&gt;. The transactions
resulted in the Company acquiring a &lt;span id="xdx_902_eus-gaap--BusinessAcquisitionPercentageOfVotingInterestsAcquired_iI_pid_dp_uPure_c20220526__us-gaap--BusinessAcquisitionAxis__custom--NanoSynexLtdMember_zxyij6GwHYRj" title="Voting interests acquired"&gt;52.8&lt;/span&gt;% interest in NanoSynex. The Company envisions future synergies from the integration of its own
proprietary results-proven FastPack diagnostics platform with the innovative NanoSynex technology. NanoSynex is a micro-biologics diagnostics
company domiciled in Israel.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_845_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_z1Pi6ADgTcDe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86C_zG5TuUfpYqN8"&gt;Basis
of Presentation&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
accompanying consolidated financial statements of the Company have been prepared in conformity with accounting principles generally accepted
in the United States of America (&#x201c;U.S. GAAP&#x201d;), Regulation S-X and rules and regulations of the Securities and Exchange Commission
(&#x201c;SEC&#x201d;).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_844_eus-gaap--ConsolidationPolicyTextBlock_zc9xiQDmxLdj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_865_zMvhOGZXViX"&gt;Principles
of Consolidation&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
accompanying consolidated financial statements include the accounts of the Company and its majority owned subsidiaries. All intercompany
balances and transactions have been eliminated in consolidation. Any reference in these notes to applicable guidance is meant to refer
to U.S. GAAP. The Company views its operations and manages its business in one operating segment. In general, the functional currency
of the Company and its subsidiaries is the U.S. dollar, however for NanoSynex, the functional currency is the local currency, New Israeli
Shekels (NIS). As such, assets and liabilities for NanoSynex are translated into U.S. dollars and the effects of foreign currency translation
adjustments are reflected as a component of accumulated other comprehensive income within the Company&#x2019;s consolidated statements
of changes in stockholders&#x2019; equity.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84F_eus-gaap--UseOfEstimates_zp75wf8bIeGk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_868_zng6SGdCYpk5"&gt;Accounting
Estimates&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Management
uses estimates and assumptions in preparing its consolidated financial statements in accordance with U.S. GAAP. Those estimates and assumptions
affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities, and the reported revenues
and expenses. The most significant estimates relate to the estimated fair value of in-process research and development, goodwill, warrant
liabilities, stock-based compensation, amortization and depreciation, inventory reserves, allowances for doubtful accounts and returns,
and warranty costs. Actual results could vary from the estimates that were used.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_844_eus-gaap--StockholdersEquityReverseStockSplit_zDVn316Ow2Cb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86B_zyCSoAvlK6Ie"&gt;Reverse
Stock Split&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
November 23, 2022, the Company effected a 1-for-10, as determined by the Company&#x2019;s board of directors, reverse stock split of its
outstanding shares of common stock (the &#x201c;Reverse Stock Split&#x201d;). The Reverse Stock Split reduced the Company&#x2019;s shares
of outstanding common stock, stock options, and warrants to purchase shares of our common stock. Fractional shares of common stock that
would have otherwise resulted from the Reverse Stock Split were rounded down to the nearest whole share and cash in lieu of payments
were made to stockholders. All share and per share data for all periods presented in the accompanying financial statements and the related
disclosures have been adjusted retrospectively to reflect the Reverse Stock Split. The number of authorized shares of common stock and
the par value per share remains unchanged.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84F_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_z37X8m4Hmt6e" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86C_zpPLvuZmDhz6"&gt;Cash&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company considers all highly liquid investments purchased with an initial maturity of 90 days or less and money market funds to be cash
equivalents. Restricted cash includes cash that is restricted due to Israeli banking regulations.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company maintains the majority of its cash in accounts at banking institutions in the U.S. that are of high quality.
Cash held in these accounts often exceed the FDIC insurance limits. If such banking institutions were to fail, the Company could lose
all or a portion of amounts held in excess of such insurance limitations. The FDIC recently took control of two such banking institutions,
Silicon Valley Bank on March 10, 2023 and Signature Bank on March 12, 2023. While the Company did not have an account at either of these two banks, in
the event of failure of any of the financial institutions where the Company maintains its cash and cash equivalents, there can be no
assurance that the Company would be able to access uninsured funds in a timely manner or at all. Any inability to access or delay in
accessing these funds could adversely affect our business and financial position.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_847_eus-gaap--InventoryPolicyTextBlock_zGf7dL4h9BTf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_866_z33yerdHlCCf"&gt;Inventory,
Net&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Inventory
is recorded at the lower of cost or net realizable value. Cost is determined using the first-in, first-out method. The Company reviews
the components of its inventory on a periodic basis for excess or obsolete inventory, and records reserves for inventory components identified
as excess or obsolete.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_848_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_zk9MLFjdKX3c" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_864_zQs6GPn4XfVb"&gt;Impairment
of Long-Lived Assets&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company assesses potential impairments to its long-lived assets when there is evidence that events or changes in circumstances indicate
that assets may not be recoverable. An impairment loss would be recognized when the sum of the expected future undiscounted cash flows
is less than the carrying amount of the assets. The amount of impairment loss, if any, will generally be measured as the difference between
the net book value of the assets and their estimated fair values. During the fiscal year ending December 31, 2022 the Company recorded
an impairment loss of $&lt;span id="xdx_907_eus-gaap--AssetImpairmentCharges_c20220101__20221231_z1ZrkrruzaJd" title="Impairment losses on construction-in-progress"&gt;4,239,000&lt;/span&gt; related to the NanoSynex acquisition.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84C_eus-gaap--SegmentReportingPolicyPolicyTextBlock_zZfhfcFxJmJ6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_860_zxtDXJfGGB1e"&gt;Segment
Reporting&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Operating
segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation
by the chief operating decision-maker in making decisions regarding resource allocation and assessing performance. To date, the Company
has viewed its operations and managed its business as one segment operating primarily within the United States and Israel.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_840_eus-gaap--TradeAndOtherAccountsReceivablePolicy_zsaXR112070d" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_865_zY0FbtBxe95i"&gt;Accounts
Receivable, Net&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company grants credit to domestic physicians, clinics, and distributors. The Company performs ongoing credit evaluations of its customers
and generally requires no collateral. Customers can purchase certain products through a financing agreement that the Company has with
an outside leasing company. Under the agreement, the leasing company evaluates the credit worthiness of the customer. Upon acceptance
of the product by the customer, the leasing company remits payment to the Company at a discount. This financing arrangement is without
recourse to the Company.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company records an allowance for doubtful accounts and returns equal to the estimated uncollectible amounts or expected returns. The
Company&#x2019;s estimates are based on historical collections and returns and a review of the current status of trade accounts receivable.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_893_eus-gaap--ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_zQIpz9BhMTj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Accounts
receivable is comprised of the following at:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span id="xdx_8B0_zE01wFmfI8La" style="display: none"&gt;SCHEDULE
OF ACCOUNTS RECEIVABLE&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49C_20221231_zvfQMHAuvDj7" style="font-weight: bold; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_492_20211231_zxut4lxKKfY1" style="font-weight: bold; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--AccountsReceivableGrossCurrent_iI_pp0p0_maARNCz1PU_maARNCzMpq_zouIgJCiaAvj" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;Accounts Receivable&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;726,449&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;958,448&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--AllowanceForDoubtfulAccountsReceivableCurrent_iNI_pp0p0_di_msARNCz1PU_msARNCzMpq_zKWim65hnST7" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Less Reserves and Allowances&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(187,862&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(136,097&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--AccountsReceivableNetCurrent_iTI_pp0p0_mtARNCzMpq_zJsnp5ZYOKe2" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Accounts receivable,
    net&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;538,587&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;822,351&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A7_zNcz49UOgnh7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84E_eus-gaap--ResearchAndDevelopmentExpensePolicy_ztMuZpwk3j0d" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86F_z19JFpz1Rujl"&gt;Research
and Development&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Except
for acquired in process research and development (IPR&amp;amp;D), the Company expenses research and development costs as incurred including
therapeutics license costs.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_844_ecustom--ResearchAndDevelopmentGrantsPolicyTextBlock_zxQP3l4NISq8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86A_zkHH9mEzbZCg"&gt;R&amp;amp;D
Grants&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;NanoSynex
has received R&amp;amp;D grants from Israel Innovation Authority (IIA) and from the European Commission. These grants may provide cash funding
to NanoSynex from time to time in advance of the applicable costs being incurred. When such cash funding is received from these grants
in advance, the proceeds are recorded as a current or non-current R&amp;amp;D grant liability based on the time from the consolidated balance
sheets date to the expected future date of recognition as a reduction to research and development expenses.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_841_ecustom--PatentCostsPolicyTextBlock_zBCruCgfuRp3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_868_z37jRTIWlBl4"&gt;Patent
Costs&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company expenses all costs as incurred in connection with patent applications (including direct application fees, and the legal and consulting
expenses related to making such applications) and such costs are included in general and administrative expenses in the consolidated
statement of operations.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_841_ecustom--ShippingAndHandlingCostsPolicyTextBlock_zwI40cOosWhg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_868_zOB31OSRUN04"&gt;Shipping
and Handling Costs&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company includes shipping and handling fees billed to customers in net sales. Shipping and handling costs associated with inbound and
outbound freight are generally recorded in cost of sales; such shipping and handling costs totaled approximately $&lt;span id="xdx_904_eus-gaap--CostOfGoodsAndServicesSold_c20220101__20221231__srt--ProductOrServiceAxis__us-gaap--ShippingAndHandlingMember_zdk8CCBRyhze" title="Cost of Goods and Services Sold"&gt;267,000&lt;/span&gt; and $&lt;span id="xdx_904_eus-gaap--CostOfGoodsAndServicesSold_c20210101__20211231__srt--ProductOrServiceAxis__us-gaap--ShippingAndHandlingMember_zCWJOmSRtr47" title="Cost of Goods and Services Sold"&gt;113,000&lt;/span&gt;,
respectively, for the years December 31, 2022 and 2021. Other shipping and handling costs included in general and administrative, research
and development, and sales and marketing expenses totaled approximately $&lt;span id="xdx_901_eus-gaap--CostOfGoodsAndServicesSold_c20220101__20221231__us-gaap--IncomeStatementLocationAxis__custom--GeneralAdministrativeResearchAndDevelopmentExpensesMember_zNAiaPKLGGPg" title="Other shipping and handling costs"&gt;14,000&lt;/span&gt; and $&lt;span id="xdx_908_eus-gaap--CostOfGoodsAndServicesSold_c20210101__20211231__us-gaap--IncomeStatementLocationAxis__custom--GeneralAdministrativeResearchAndDevelopmentExpensesMember_z9cn1bTADg3d" title="Other shipping and handling costs"&gt;12,000&lt;/span&gt; for the years ended December 31, 2022 and
2021, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84E_eus-gaap--RevenueRecognitionPolicyTextBlock_zABQ76nng5rl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86B_zk6ye9FRqsz3"&gt;Revenue
from Contracts with Customers&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company applies the following five-step model in accordance with ASC 606, Revenue from Contracts with Customers, in order to determine
revenue: (i) identification of the promised goods or services in the contract; (ii) determination of whether the promised goods or services
are performance obligations, including whether they are distinct in the context of the contract; (iii) measurement of the transaction
price, including the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations; and
(v) recognition of revenue when (or as) the Company satisfies each performance obligation.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Product
Sales&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company generates revenue from selling FastPack System analyzers, accessories and disposable products used with the FastPack System.
Disposable products include reagent packs, which are diagnostic tests for prostate-specific antigen, testosterone, thyroid disorders,
pregnancy, and Vitamin D.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company provides disposable products and equipment in exchange for consideration, which occurs when a customer submits a purchase order
and the Company provides disposable products and equipment at the agreed upon prices in the invoice. Generally, customers purchase disposable
products using separate purchase orders after the equipment (&#x201c;analyzer&#x201d;) has been provided to the customer. The initial delivery
of the equipment and reagent packs represents a single performance obligation and is completed upon receipt by the customer. The delivery
of each subsequent individual reagent pack represents a separate performance obligation because the reagent packs are standardized, are
not interrelated in any way, and the customer can benefit from each reagent pack without any other product. There are no significant
discounts, rebates, returns or other forms of variable consideration. Customers are generally required to pay within 30 days.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
performance obligation arising from the delivery of the equipment is satisfied upon the delivery of the equipment to the customer. The
disposable products are shipped Free on Board (&#x201c;FOB&#x201d;) shipping point. For disposable products that are shipped FOB shipping
point, the customer has the significant risks and rewards of ownership and legal title to the assets when the disposable products leave
the Company&#x2019;s shipping facilities, thus the customer obtains control and revenue is recognized at that point in time.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company has elected the practical expedient and accounting policy election to account for the shipping and handling as activities to
fulfill the promise to transfer the disposable products and not as a separate performance obligation.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s contracts with customers generally have an expected duration of one year or less, and therefore the Company has elected
the practical expedient in ASC 606 to not disclose information about its remaining performance obligations. Any incremental costs to
obtain contracts are recorded as selling, general and administrative expense as incurred due to the short duration of the Company&#x2019;s
contracts.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;License
Revenue&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company entered into an out-license agreement with Yi Xin to develop and/or commercialize its products in exchange for nonrefundable
upfront license fees and/or sales-based royalties.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;If
the license to the Company&#x2019;s intellectual property is determined to be distinct from the other performance obligations identified
in the arrangement, the Company recognizes revenue from nonrefundable upfront fees allocated to the license when the license is transferred
to the customer and the customer can benefit from the license. For licenses that are bundled with other performance obligations, management
uses judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is
satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing
revenue from nonrefundable upfront fees. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts
the measure of progress and related revenue recognition. During years ended December 31, 2022 and 2021, the Company recognized license
revenue of approximately $&lt;span id="xdx_90D_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_dxL_c20220101__20221231__srt--ProductOrServiceAxis__custom--LicenseRevenuesMember_zFBg85urxvHl" title="::XDX::-"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0752"&gt;0&lt;/span&gt;&lt;/span&gt; and $&lt;span id="xdx_90A_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20210101__20211231__srt--ProductOrServiceAxis__custom--LicenseRevenuesMember_zIZj4c0axwf4"&gt;632,000&lt;/span&gt;, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Contract
Asset and Liability Balances&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
timing of the Company&#x2019;s revenue recognition may differ from the timing of payment by the Company&#x2019;s customers. The Company
records a receivable when revenue is recognized prior to payment and there is an unconditional right to payment. Alternatively, when
payment precedes the performance of the related services, the Company records deferred revenue until the performance obligations are
satisfied.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Multiple
performance obligations include contracts that combine both the Company&#x2019;s analyzer and a customer&#x2019;s future reagent purchases
under a single contract. In some sales contracts, the Company provides analyzers at no charge to customers. Title to the analyzer is
maintained by the Company and the analyzer is returned by the customer to the Company at the end of the purchase agreement.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
the years December 31, 2022 and 2021, product sales are stated net of an allowance for estimated returns of approximately $&lt;span id="xdx_90F_ecustom--AllowancesForSalesReturn_c20220101__20221231_z3orAMfHfQTa" title="Allowance for estimated returns"&gt;96,000&lt;/span&gt; and
$&lt;span id="xdx_90C_ecustom--AllowancesForSalesReturn_c20210101__20211231_zplKcwOU6s79" title="Allowance for estimated returns"&gt;150,000&lt;/span&gt;, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84E_ecustom--DeferredRevenuePolicyTextBlock_zoQqOxBjcdPg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86C_zN6oYNVEGld1"&gt;Deferred
Revenue&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Payments
received in advance from customers pursuant to certain collaborative research license agreements, deposits against future product sales,
multiple element arrangements and extended warranties are recorded as a current or non-current deferred revenue liability based on the
time from the Consolidated Balance Sheet date to the future date of revenue recognition.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_848_eus-gaap--LesseeLeasesPolicyTextBlock_zwgVxRU1aNrj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_860_ztpvsNrpeia6"&gt;Operating
Leases&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Effective
April 1, 2020, the Company adopted Accounting Standards Update (&#x201c;ASU&#x201d;) No. 2018-11, &lt;i&gt;Leases (Topic 842) Targeted Improvements
&lt;/i&gt;(&#x201c;Topic 842&#x201d;). In accordance with the guidance in Topic 842, the Company recognizes lease liabilities and corresponding
right-of-use-assets for all leases with terms of greater than 12 months. Leases with a term of 12 months or less will be accounted for
in a manner similar to the guidance for operating leases prior to the adoption of Topic 842. (See Note 13-Commitments and Contingencies).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84B_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zxkFwQXeVvI3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86E_zUjoRKE3YoLk"&gt;Property
and Equipment, Net&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89A_ecustom--ScheduleOfUsefulLivesOfPropertyAndEquipmentTableTextBlock_zFBqhrfk1vIi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Property
and equipment are stated at cost and are presented net of accumulated depreciation. Depreciation is provided for on a straight-line basis
over the estimated useful lives of the related assets as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span id="xdx_8B2_zAPA13MDyEXg" style="display: none"&gt;SCHEDULE
OF USEFUL LIVES OF PROPERTY AND EQUIPMENT&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 77%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Machinery
    and equipment&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 23%; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_904_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20220101__20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--MachineryAndEquipmentMember_zqufBTavuQy3" title="Property and equipment, useful life"&gt;5&lt;/span&gt;
    years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Computer
    equipment&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_908_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20220101__20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember_zawkBQjlOUM3" title="Property and equipment, useful life"&gt;3&lt;/span&gt;
    years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Molds
    and tooling&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90A_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20220101__20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--MoldsAndToolingMember_zIvIh9XUZzWi" title="Property and equipment, useful life"&gt;5&lt;/span&gt;
    years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Furniture
    and fixtures&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_906_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20220101__20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_z5DGlGqVKWNg" title="Property and equipment, useful life"&gt;5&lt;/span&gt;
    years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p id="xdx_8A6_zffzxAM1cCy5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Leasehold
improvements are amortized on a straight-line basis over the shorter of the lease term or their estimated useful lives. The Company occasionally
designs and builds its own machinery. The costs of these projects, which includes the cost of construction and other direct costs attributable
to the construction, are capitalized as construction in progress. No provision for depreciation is made on construction in progress until
the relevant assets are completed and placed in service.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s policy is to evaluate the remaining lives and recoverability of long-term assets on at least an annual basis or when
conditions are present that indicate impairment.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_841_eus-gaap--BusinessCombinationsPolicy_zvdZiwqEUsXg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86F_zfZHqhXQ1spi"&gt;Business
Combinations&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company accounts for business combinations using the acquisition method pursuant to FASB ASC Topic 805. This method requires, among other
things, that results of operations of acquired companies are included in Qualigen&#x2019;s financial results beginning on the respective
acquisition dates, and that assets acquired and liabilities assumed and noncontrolling interests are recognized at fair value as of the
acquisition date. Intangible assets acquired in a business combination are recorded at fair value using a discounted cash flow model.
We have third-party valuations completed for intangible assets in a business combination using a discounted cash flow analysis, incorporating
various assumptions. The discounted cash flow model requires assumptions about the timing and amount of future net cash flows, the cost
of capital and terminal values from the perspective of a market participant. Each of these factors can significantly affect the value
of the intangible asset. Any excess of the fair value of consideration transferred (the &#x201c;Purchase Price&#x201d;) over the fair values
of the net assets acquired is recognized as goodwill. The fair value of assets acquired and liabilities assumed in certain cases may
be subject to revision based on the final determination of fair value during a period of time not to exceed 12 months from the acquisition
date. Legal costs, due diligence costs, business valuation costs and all other acquisition-related costs are expensed when incurred.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_845_eus-gaap--GoodwillAndIntangibleAssetsPolicyTextBlock_zbYKJt4uxjJi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_862_zcL6YjOj8s15"&gt;Goodwill&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Goodwill
represents the difference between the purchase price and the fair value of the identifiable tangible and intangible net assets
acquired, when accounted for using the purchase method of accounting. Goodwill has an indefinite useful life and is not amortized
but is reviewed for impairment annually and whenever events or changes in circumstances indicate that the carrying value of the
goodwill may not be recoverable. In testing for impairment, the fair value of the reporting unit is compared to the carrying value.
If the net assets assigned to the reporting unit exceed the fair value of the reporting unit, an impairment loss equal to the
difference is recorded. As a result of the annual goodwill impairment analysis, the Company recognized a $&lt;span id="xdx_905_eus-gaap--GoodwillImpairmentLoss_c20220101__20221231_zPKuBPchBib5" title="Goodwill impairment charges"&gt;4,239,000&lt;/span&gt;
non-cash goodwill and fixed asset impairment charge in the valuation of its business acquisition of NanoSynex for the year ended
December 30, 2022. For more information, refer to Note 1 - Organization and Summary of Significant Accounting Policies and Estimates
and Note 7 - Goodwill, IPR&amp;amp;D and other Intangibles.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_844_eus-gaap--IntangibleAssetsFiniteLivedPolicy_zwDMssJ6GRgf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86C_zQvb0w9eUW4c"&gt;Intangible
Assets&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;In
Process R&amp;amp;D&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Acquired
in process R&amp;amp;D (IPR&amp;amp;D) represents the fair value assigned to the research and development assets that have not reached technological
feasibility. The value assigned to IPR&amp;amp;D is determined by estimating the costs to develop the acquired technology into commercially
viable products, estimating the resulting revenue from the projects, and discounting the net cash flow to present value. The revenue
and cost projections used to value acquired IPR&amp;amp;D are, as applicable, reduced based on the probability of success of developing the
new product. Additionally, projections consider relevant market sizes and growth factors, expected trends in technology and the nature
and expected timing of new product introductions. The rates utilized to discount the net cash flow to its present value are commensurate
with the stage of development of the project and uncertainties in the economic estimates used in the projections. Upon the acquisition
of acquired IPR&amp;amp;D, an assessment is completed as to whether the acquisition constitutes an acquisition of a single asset or a group
of assets. Multiple factors are considered in this assessment, including the nature of the technology acquired, the presence or absence
of separate cash flows, the development process and stage of completion, quantitative significance, and the Company&#x2019;s rationale
for entering into the transaction.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;If
a business is acquired, as defined under the applicable accounting standards, then the acquired IPR&amp;amp;D is capitalized as an intangible
asset. If an asset or group of assets is acquired that do not meet the definition under the applicable accounting standards, then the
acquired IPR&amp;amp;D is expensed on its acquisition date. Future costs to develop these assets are recorded to research and development
expense in the Company&#x2019;s consolidated statements of operations and comprehensive loss as they are incurred.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;IPR&amp;amp;D
is evaluated for impairment annually using the same methodology as described above for calculating fair value. If the carrying value
of the acquired IPR&amp;amp;D exceeds the fair value, then the intangible asset is written down to its fair value, with the resulting adjustment
recorded as a charge to operations. Changes in estimates and assumptions used in determining the fair value of acquired IPR&amp;amp;D could
result in an impairment.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Other
Intangible Assets, Net&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Other
intangible assets consist of patent-related costs and costs for license agreements. Management reviews the carrying value of other intangible
assets that are being amortized on an annual basis or sooner when there is evidence that events or changes in circumstances may indicate
that impairment exists. The Company considers relevant cash flow and profitability information, including estimated future operating
results, trends and other available information, in assessing whether the carrying value of intangible assets being amortized can be
recovered.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;If
the Company determines that the carrying value of other intangible assets will not be recovered from the undiscounted future cash flows
expected to result from the use and eventual disposition of the underlying assets, the Company considers the carrying value of such intangible
assets as impaired and reduces them by a charge to operations in the amount of the impairment.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Costs
related to acquiring patents and licenses are capitalized and amortized over their estimated useful lives, which is generally&lt;span id="xdx_90C_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dtY_c20220101__20221231__srt--RangeAxis__srt--MinimumMember__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PatentsAndLicensesMember_zkxYMMM8Ak3f" title="Estimated useful lives"&gt; 5&lt;/span&gt; to &lt;span id="xdx_902_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dtY_c20220101__20221231__srt--RangeAxis__srt--MaximumMember__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PatentsAndLicensesMember_zWMNAhPGgml7" title="Estimated useful lives"&gt;17&lt;/span&gt;
years, using the straight-line method. Amortization of patents and licenses commences once final approval of the patent or license has
been obtained. Patent and license costs are charged to operations if it is determined that the patent or license will not be obtained.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84A_ecustom--DerivativeFinancialInstrumentsAndWarrantLiabilitiesPolicyTextBlock_zYk7vHQpnWp7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86A_zNtcOzvKQ3g7"&gt;Derivative
Financial Instruments and Warrant Liabilities&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company does not use derivative instruments to hedge exposures to cash flow, market, or foreign currency risks. The Company evaluates
all of its financial instruments, including issued stock purchase warrants, to determine if such instruments are derivatives or contain
features that qualify as embedded derivatives. For derivative financial instruments that are accounted for as liabilities, the derivative
instrument is initially recorded at its fair value and is then re-valued at each reporting date, with changes in the fair value reported
in the consolidated statements of operations and comprehensive loss. Depending on the features of the derivative financial instrument,
the Company uses either the Black-Scholes option-pricing model or a Monte-Carlo simulation to value the derivative instruments at inception
and subsequent valuation dates. The classification of derivative instruments, including whether such instruments should be recorded as
liabilities or as equity, is re-assessed at the end of each reporting period (See Note 10-Warrant Liabilities and Note 11- Convertible
Debt - Related Party).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Fair
Value Measurements&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company determines the fair value measurements of applicable assets and liabilities based on a three-tier fair value hierarchy established
by accounting guidance and prioritizes the inputs used in measuring fair value. The Company discloses and recognizes the fair value of
its assets and liabilities using a hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy
gives the highest priority to valuations based upon unadjusted quoted prices in active markets for identical assets or liabilities (Level
1 measurements) and the lowest priority to valuations based upon unobservable inputs that are significant to the valuation (Level 3 measurements).
The guidance establishes three levels of the fair value hierarchy as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
                                            1 - Inputs that reflect unadjusted quoted prices in active markets for identical assets or
                                            liabilities that the Company has the ability to access at the measurement date;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -24.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
                                            2 - Inputs other than quoted prices that are observable for the assets or liability either
                                            directly or indirectly, including inputs in markets that are not considered to be active;
                                            and&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -24.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&#x25cf;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
                                            3 - Inputs that are unobservable.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -24.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84D_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zP6ZVVYW4Vx8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_861_z3ymfQ7hS3v4"&gt;Fair
Value of Financial Instruments&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Cash,
accounts receivable, prepaids, accounts payable, and accrued liabilities are carried at cost, which management believes approximates
fair value due to the short-term nature of these instruments.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_840_eus-gaap--AdvertisingCostsPolicyTextBlock_zYVNkMB16xgf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_867_zXo6xMwPUfAi"&gt;Advertising&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Advertising
expense consists primarily of print and digital media promotional materials for a distributor. Advertising costs are expensed as incurred.
Advertising expense for the years ended December 31, 2022 and 2021 amounted to $&lt;span id="xdx_90B_eus-gaap--AdvertisingExpense_c20220101__20221231_zbt2JY0VnqH" title="Advertising expense"&gt;50,000&lt;/span&gt; and $&lt;span id="xdx_90C_eus-gaap--AdvertisingExpense_c20210101__20211231_zSf9jmc2eJw7" title="Advertising expense"&gt;0&lt;/span&gt;, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_845_eus-gaap--ComprehensiveIncomePolicyPolicyTextBlock_zaraFTgm9v08" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_862_zP4m4XVUM4R"&gt;Comprehensive
Loss&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Comprehensive
loss consists of net income and foreign currency translation adjustments. Comprehensive gains (losses) have been reflected in the statements
of operations and comprehensive loss and as a separate component in the statements of stockholders&#x2019; equity for all periods presented.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84B_eus-gaap--CompensationRelatedCostsPolicyTextBlock_zuMCtZNK0dV" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86B_z93HuhI6ZM32"&gt;Stock-Based
Compensation&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Stock-based
compensation cost for equity awards granted to employees and non-employees is measured at the grant date based on the calculated fair
value of the award using the Black-Scholes option-pricing model, and is recognized as an expense, under the straight-line method, over
the requisite service period (generally the vesting period of the equity grant). If the Company determines that other methods are more
reasonable, or other methods for calculating these assumptions are prescribed by regulators, the fair value calculated for the Company&#x2019;s
stock options could change significantly. Higher volatility, lower risk-free interest rates, and longer expected lives would result in
an increase to stock-based compensation expense to employees and non-employees determined at the date of grant.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84C_eus-gaap--IncomeTaxPolicyTextBlock_z0GYTOjzvE98" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86B_zajN575xWrPk"&gt;Income
Taxes&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Deferred
income taxes are recognized for temporary differences in the basis of assets and liabilities for financial statement and income tax reporting
that arise due to net operating loss carry forwards, research and development credit carry forwards and from using different methods
and periods to calculate depreciation and amortization, allowance for doubtful accounts, accrued vacation, research and development expenses,
and state taxes. A provision has been made for income taxes due on taxable income and for the deferred taxes on the temporary differences.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Deferred
tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion or all
of the deferred tax assets will not be realized. Deferred tax assets and liabilities are adjusted for the effects of changes in tax laws
and rates on the date of enactment. Realization of the deferred income tax asset is dependent on generating sufficient taxable income
in future years. For more information, refer to Note 17-Income Taxes.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_841_ecustom--SalesAndExciseTaxesPolicyTextBlock_zFjBkSfE43Z" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86C_zJc7M9MEsVh2"&gt;Sales
and Excise Taxes&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Sales
and other taxes collected from customers and subsequently remitted to government authorities are recorded as accounts receivable with
corresponding tax payable. These balances are removed from the consolidated balance sheet as cash is collected from customers and remitted
to the tax authority.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84B_ecustom--WarrantyReservePolicyTextBlock_zuXhILNGtyr7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86F_zZFzrwafMcV7"&gt;Warranty
Costs&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s warranty policy generally provides for one year of coverage against defects and nonperformance within published specifications
for sold analyzers and for the term of the contract for equipment held for lease. The Company accrues for estimated warranty costs in
the period in which the revenue is recognized based on historical data and the Company&#x2019;s best estimates of analyzer failure rates
and costs to repair.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Accrued
warranty liabilities were approximately $&lt;span id="xdx_901_eus-gaap--ProductWarrantyAccrual_iI_c20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zYMTyRdVoxbf" title="Accrued warranty liabilities"&gt;138,000&lt;/span&gt; and $&lt;span id="xdx_90E_eus-gaap--ProductWarrantyAccrual_iI_c20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z5rpvRsY2Bhe" title="Accrued warranty liabilities"&gt;60,000&lt;/span&gt;, respectively, at December 31, 2022 and December 31, 2021 and are included
in accrued expenses and other current liabilities on the Consolidated Balance Sheets. Warranty costs were approximately $&lt;span id="xdx_908_eus-gaap--ProductWarrantyExpense_c20220101__20221231_zjAeybIH7LRb" title="Warranty costs"&gt;69,000&lt;/span&gt; and $&lt;span id="xdx_90C_eus-gaap--ProductWarrantyExpense_c20210101__20211231_zgQ7NMp3UHI6" title="Warranty costs"&gt;57,000&lt;/span&gt;
for the years ended December 31, 2022 and 2021, respectively, and are included in cost of product sales in the Consolidated Statements
of Operations.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84D_eus-gaap--ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_zQ6eZKfREUnf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_861_zr4gZVO6OLT1"&gt;Foreign
Currency Translation&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
functional currency for the Company is the U.S. dollar. The functional currency for NanoSynex, the Company&#x2019;s newly acquired majority
owned subsidiary, is the New Israeli Shekel (NIS). The financial statements of NanoSynex are translated into U.S. dollars using exchange
rates in effect at each period end for assets and liabilities; using exchange rates in effect during the period for results of operations;
and using historical exchange rates for certain equity accounts. The adjustment resulting from translating the financial statements of
NanoSynex is reflected as a separate component of other comprehensive income (loss).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Other
comprehensive loss related to the effects of foreign currency translation adjustments attributable to NanoSynex was $&lt;span id="xdx_901_eus-gaap--OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_c20220101__20221231__us-gaap--BusinessAcquisitionAxis__custom--NanoSynexLtdMember_zdomOdXwjkPi" title="Adjustment net of tax"&gt;50,721&lt;/span&gt; and $&lt;span id="xdx_900_eus-gaap--OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_c20210101__20211231__us-gaap--BusinessAcquisitionAxis__custom--NanoSynexLtdMember_znsm1pjH0QU7" title="Adjustment net of tax"&gt;0&lt;/span&gt; at
December 31, 2022 and 2021, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_844_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zIJBrwoB7uI3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86E_zP8oTscRYrR2"&gt;Recent
Accounting Pronouncements&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
June 2016, the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) issued ASU No. 2016-13, &lt;i&gt;Measurement of Credit Losses on Financial
Instruments&lt;/i&gt;, which supersedes current guidance by requiring recognition of credit losses when it is probable that a loss has been
incurred. The new standard requires the establishment of an allowance for estimated credit losses on financial assets including trade
and other receivables at each reporting date. The new standard will result in earlier recognition of allowances for losses on trade and
other receivables and other contractual rights to receive cash. In November 2019, the FASB issued ASU No. 2019-10, &lt;i&gt;Financial Instruments
&#x2013; Credit Losses (Topic 326), Derivatives and Hedging (Topic 815) &lt;/i&gt;and &lt;i&gt;Leases (Topic 842)&lt;/i&gt;, which extended the effective
date of Topic 326 for certain companies until fiscal years beginning after December 15, 2022. The new standard will be effective for
the Company in the first quarter of fiscal year beginning January 1, 2023, and early adoption is permitted. The Company adopted ASU 2016-13
on January 1, 2023. Adoption did not have a material impact on the Company&#x2019;s consolidated financial statements and related disclosures.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84A_ecustom--GlobalEconomicConditionsPolicyTextBlock_z9Nrhk6J8AMl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86D_zY9GyuybJgi8"&gt;Global
Economic Conditions&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;War
in Ukraine&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
February 2022, Russia invaded Ukraine. While the Company has no direct exposure in Russia and Ukraine, the Company continues to monitor
any broader impact to the global economy, including with respect to inflation, supply chains and fuel prices. The full impact of the
conflict on the Company&#x2019;s business and financial results remains uncertain and will depend on the severity and duration of the
conflict and its impact on regional and global economic conditions.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Inflationary
Cost Environment&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
the year ended 2022 and continuing into the current fiscal year, global commodity and labor markets experienced significant inflationary
pressures attributable to ongoing economic recovery and supply chain issues. The Company is subject to inflationary pressures with respect
to raw materials, labor and transportation. Accordingly, the Company continues to take actions with its customers and suppliers to mitigate
the impact of these inflationary pressures in the future. Actions to mitigate inflationary pressures with suppliers include aggregation
of purchase requirements to achieve optimal volume benefits, negotiation of cost-reductions and identification of more cost competitive
suppliers. While these actions are designed to offset the impact of inflationary pressures, the Company cannot provide assurance that
it will be successful in fully offsetting increased costs resulting from inflationary pressure.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Impact of
COVID-19 Pandemic&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
COVID-19 pandemic has had a dramatic impact on businesses globally and on the Company&#x2019;s business as well. Sales of diagnostic products
fell significantly during 2020 and the Company&#x2019;s net loss increased significantly, as deferral of patients&#x2019; non-emergency
visits to physician offices, clinics and small hospitals sharply reduced demand for FastPack tests. Since then we have experienced some recovery in demand.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Other
accounting standard updates are either not applicable to the Company or are not expected to have a material impact on the Company&#x2019;s
consolidated financial statements.&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_853_zHs18ScsZ2f5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock>
    <QLGN:OrganizationPolicyTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_84C_ecustom--OrganizationPolicyTextBlock_zeWI3RRbueC4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86A_z2jwwuWoT1kg"&gt;Organization&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Qualigen,
Inc., now a subsidiary of Qualigen Therapeutics, Inc., was incorporated in Minnesota in 1996 to design, develop, manufacture and sell
Physician Office Laboratory (&#x201c;POL&#x201d;) market quantitative immunoassay diagnostic products for use in physician offices and
other point-of-care settings worldwide, and was reincorporated in Delaware in 1999. In May 2020, Qualigen, Inc. completed a reverse recapitalization
transaction with Ritter Pharmaceuticals, Inc. (&#x201c;Ritter&#x201d;) and Ritter was renamed Qualigen Therapeutics, Inc. All shares of
Qualigen, Inc.&#x2019;s capital stock were exchanged for Qualigen Therapeutics, Inc.&#x2019;s capital stock in the merger. Ritter/Qualigen
Therapeutics common stock, which was previously traded on the Nasdaq Capital Market under the ticker symbol &#x201c;RTTR,&#x201d; commenced
trading on the Nasdaq Capital Market, on a post-reverse-stock-split adjusted basis, under the trading symbol &#x201c;QLGN&#x201d; on May
26, 2020. Qualigen Therapeutics, Inc. (the &#x201c;Company&#x201d;) operates in one business segment.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;On
May 26, 2022, the Company acquired &lt;span id="xdx_903_eus-gaap--StockIssuedDuringPeriodSharesAcquisitions_c20220524__20220526__us-gaap--BusinessAcquisitionAxis__custom--NanoSynexLtdMember__us-gaap--StatementClassOfStockAxis__custom--SeriesAOnePreferredStockMember_zfMeIdzOzlJa" title="Number of common stock acquired shares"&gt;2,232,861&lt;/span&gt; shares of Series A-1 Preferred Stock of NanoSynex, Ltd. (&#x201c;NanoSynex&#x201d;) from Alpha
Capital Anstalt (&#x201c;Alpha Capital&#x201d;), a related party, in exchange for &lt;span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodSharesAcquisitions_c20220524__20220526__us-gaap--BusinessAcquisitionAxis__custom--NanoSynexLtdMember_zks2Cx6r38pd" title="Number of common stock acquired shares"&gt;350,000&lt;/span&gt; reverse split adjusted shares of the Company&#x2019;s common stock and a prefunded warrant
to purchase &lt;span id="xdx_904_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_c20220526__us-gaap--StatementEquityComponentsAxis__custom--PrefundedWarrantMember_zrdIBprn3PV4" title="Warrants to purchase common stock"&gt;331,464 reverse split adjusted shares of the Company&#x2019;s common stock at an exercise price of $&lt;span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20220526__us-gaap--StatementEquityComponentsAxis__custom--PrefundedWarrantMember_zHeVCJY9m9L4" title="Class of Warrant or Right, Exercise Price of Warrants or Rights"&gt;0.001&lt;/span&gt; per share. &lt;span id="xdx_901_eus-gaap--StockholdersEquityReverseStockSplit_c20220525__20220526_zPIU0Z15PR81" title="Reverse split, description"&gt;These warrants were subsequently exercised on September 13, 2022&lt;/span&gt;. Concurrently with this transaction,
the Company also purchased &lt;span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodSharesAcquisitions_c20220524__20220526__us-gaap--BusinessAcquisitionAxis__custom--NanoSynexLtdMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zotzw9HT11Zf" title="Stock issued during period shares acquisitions"&gt;381,786&lt;/span&gt; shares of Series B preferred stock from NanoSynex for a total purchase price of $&lt;span id="xdx_909_eus-gaap--StockIssuedDuringPeriodValueAcquisitions_pp0p0_c20220524__20220526__us-gaap--BusinessAcquisitionAxis__custom--NanoSynexLtdMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zdCN0AghKGfa" title="Stock issued during period, value, acquisitions"&gt;600,000&lt;/span&gt;. The transactions
resulted in the Company acquiring a &lt;span id="xdx_902_eus-gaap--BusinessAcquisitionPercentageOfVotingInterestsAcquired_iI_pid_dp_uPure_c20220526__us-gaap--BusinessAcquisitionAxis__custom--NanoSynexLtdMember_zxyij6GwHYRj" title="Voting interests acquired"&gt;52.8&lt;/span&gt;% interest in NanoSynex. The Company envisions future synergies from the integration of its own
proprietary results-proven FastPack diagnostics platform with the innovative NanoSynex technology. NanoSynex is a micro-biologics diagnostics
company domiciled in Israel.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</QLGN:OrganizationPolicyTextBlock>
    <us-gaap:StockIssuedDuringPeriodSharesAcquisitions
      contextRef="From2022-05-242022-05-26_custom_NanoSynexLtdMember_custom_SeriesAOnePreferredStockMember"
      decimals="INF"
      unitRef="Shares">2232861</us-gaap:StockIssuedDuringPeriodSharesAcquisitions>
    <us-gaap:StockIssuedDuringPeriodSharesAcquisitions
      contextRef="From2022-05-242022-05-26_custom_NanoSynexLtdMember"
      decimals="INF"
      unitRef="Shares">350000</us-gaap:StockIssuedDuringPeriodSharesAcquisitions>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
      contextRef="AsOf2022-05-26_custom_PrefundedWarrantMember"
      decimals="INF"
      unitRef="Shares">331464</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2022-05-26_custom_PrefundedWarrantMember"
      decimals="INF"
      unitRef="USDPShares">0.001</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:StockholdersEquityReverseStockSplit contextRef="From2022-05-252022-05-26">These warrants were subsequently exercised on September 13, 2022</us-gaap:StockholdersEquityReverseStockSplit>
    <us-gaap:StockIssuedDuringPeriodSharesAcquisitions
      contextRef="From2022-05-242022-05-26_custom_NanoSynexLtdMember_us-gaap_SeriesBPreferredStockMember"
      decimals="INF"
      unitRef="Shares">381786</us-gaap:StockIssuedDuringPeriodSharesAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions
      contextRef="From2022-05-242022-05-26_custom_NanoSynexLtdMember_us-gaap_SeriesBPreferredStockMember"
      decimals="0"
      unitRef="USD">600000</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired
      contextRef="AsOf2022-05-26_custom_NanoSynexLtdMember"
      decimals="INF"
      unitRef="Pure">0.528</us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_845_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_z1Pi6ADgTcDe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86C_zG5TuUfpYqN8"&gt;Basis
of Presentation&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
accompanying consolidated financial statements of the Company have been prepared in conformity with accounting principles generally accepted
in the United States of America (&#x201c;U.S. GAAP&#x201d;), Regulation S-X and rules and regulations of the Securities and Exchange Commission
(&#x201c;SEC&#x201d;).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:ConsolidationPolicyTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_844_eus-gaap--ConsolidationPolicyTextBlock_zc9xiQDmxLdj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_865_zMvhOGZXViX"&gt;Principles
of Consolidation&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
accompanying consolidated financial statements include the accounts of the Company and its majority owned subsidiaries. All intercompany
balances and transactions have been eliminated in consolidation. Any reference in these notes to applicable guidance is meant to refer
to U.S. GAAP. The Company views its operations and manages its business in one operating segment. In general, the functional currency
of the Company and its subsidiaries is the U.S. dollar, however for NanoSynex, the functional currency is the local currency, New Israeli
Shekels (NIS). As such, assets and liabilities for NanoSynex are translated into U.S. dollars and the effects of foreign currency translation
adjustments are reflected as a component of accumulated other comprehensive income within the Company&#x2019;s consolidated statements
of changes in stockholders&#x2019; equity.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:UseOfEstimates contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_84F_eus-gaap--UseOfEstimates_zp75wf8bIeGk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_868_zng6SGdCYpk5"&gt;Accounting
Estimates&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Management
uses estimates and assumptions in preparing its consolidated financial statements in accordance with U.S. GAAP. Those estimates and assumptions
affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities, and the reported revenues
and expenses. The most significant estimates relate to the estimated fair value of in-process research and development, goodwill, warrant
liabilities, stock-based compensation, amortization and depreciation, inventory reserves, allowances for doubtful accounts and returns,
and warranty costs. Actual results could vary from the estimates that were used.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:UseOfEstimates>
    <us-gaap:StockholdersEquityReverseStockSplit contextRef="From2022-01-01to2022-12-31">Reverse
Stock Split

&#160;

On
November 23, 2022, the Company effected a 1-for-10, as determined by the Company&#x2019;s board of directors, reverse stock split of its
outstanding shares of common stock (the &#x201c;Reverse Stock Split&#x201d;). The Reverse Stock Split reduced the Company&#x2019;s shares
of outstanding common stock, stock options, and warrants to purchase shares of our common stock. Fractional shares of common stock that
would have otherwise resulted from the Reverse Stock Split were rounded down to the nearest whole share and cash in lieu of payments
were made to stockholders. All share and per share data for all periods presented in the accompanying financial statements and the related
disclosures have been adjusted retrospectively to reflect the Reverse Stock Split. The number of authorized shares of common stock and
the par value per share remains unchanged.

&#160;</us-gaap:StockholdersEquityReverseStockSplit>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_84F_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_z37X8m4Hmt6e" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86C_zpPLvuZmDhz6"&gt;Cash&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company considers all highly liquid investments purchased with an initial maturity of 90 days or less and money market funds to be cash
equivalents. Restricted cash includes cash that is restricted due to Israeli banking regulations.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company maintains the majority of its cash in accounts at banking institutions in the U.S. that are of high quality.
Cash held in these accounts often exceed the FDIC insurance limits. If such banking institutions were to fail, the Company could lose
all or a portion of amounts held in excess of such insurance limitations. The FDIC recently took control of two such banking institutions,
Silicon Valley Bank on March 10, 2023 and Signature Bank on March 12, 2023. While the Company did not have an account at either of these two banks, in
the event of failure of any of the financial institutions where the Company maintains its cash and cash equivalents, there can be no
assurance that the Company would be able to access uninsured funds in a timely manner or at all. Any inability to access or delay in
accessing these funds could adversely affect our business and financial position.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:InventoryPolicyTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_847_eus-gaap--InventoryPolicyTextBlock_zGf7dL4h9BTf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_866_z33yerdHlCCf"&gt;Inventory,
Net&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Inventory
is recorded at the lower of cost or net realizable value. Cost is determined using the first-in, first-out method. The Company reviews
the components of its inventory on a periodic basis for excess or obsolete inventory, and records reserves for inventory components identified
as excess or obsolete.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:InventoryPolicyTextBlock>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_848_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_zk9MLFjdKX3c" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_864_zQs6GPn4XfVb"&gt;Impairment
of Long-Lived Assets&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company assesses potential impairments to its long-lived assets when there is evidence that events or changes in circumstances indicate
that assets may not be recoverable. An impairment loss would be recognized when the sum of the expected future undiscounted cash flows
is less than the carrying amount of the assets. The amount of impairment loss, if any, will generally be measured as the difference between
the net book value of the assets and their estimated fair values. During the fiscal year ending December 31, 2022 the Company recorded
an impairment loss of $&lt;span id="xdx_907_eus-gaap--AssetImpairmentCharges_c20220101__20221231_z1ZrkrruzaJd" title="Impairment losses on construction-in-progress"&gt;4,239,000&lt;/span&gt; related to the NanoSynex acquisition.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <us-gaap:AssetImpairmentCharges
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">4239000</us-gaap:AssetImpairmentCharges>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_84C_eus-gaap--SegmentReportingPolicyPolicyTextBlock_zZfhfcFxJmJ6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_860_zxtDXJfGGB1e"&gt;Segment
Reporting&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Operating
segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation
by the chief operating decision-maker in making decisions regarding resource allocation and assessing performance. To date, the Company
has viewed its operations and managed its business as one segment operating primarily within the United States and Israel.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:TradeAndOtherAccountsReceivablePolicy contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_840_eus-gaap--TradeAndOtherAccountsReceivablePolicy_zsaXR112070d" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_865_zY0FbtBxe95i"&gt;Accounts
Receivable, Net&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company grants credit to domestic physicians, clinics, and distributors. The Company performs ongoing credit evaluations of its customers
and generally requires no collateral. Customers can purchase certain products through a financing agreement that the Company has with
an outside leasing company. Under the agreement, the leasing company evaluates the credit worthiness of the customer. Upon acceptance
of the product by the customer, the leasing company remits payment to the Company at a discount. This financing arrangement is without
recourse to the Company.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company records an allowance for doubtful accounts and returns equal to the estimated uncollectible amounts or expected returns. The
Company&#x2019;s estimates are based on historical collections and returns and a review of the current status of trade accounts receivable.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_893_eus-gaap--ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_zQIpz9BhMTj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Accounts
receivable is comprised of the following at:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span id="xdx_8B0_zE01wFmfI8La" style="display: none"&gt;SCHEDULE
OF ACCOUNTS RECEIVABLE&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49C_20221231_zvfQMHAuvDj7" style="font-weight: bold; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_492_20211231_zxut4lxKKfY1" style="font-weight: bold; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--AccountsReceivableGrossCurrent_iI_pp0p0_maARNCz1PU_maARNCzMpq_zouIgJCiaAvj" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;Accounts Receivable&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;726,449&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;958,448&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--AllowanceForDoubtfulAccountsReceivableCurrent_iNI_pp0p0_di_msARNCz1PU_msARNCzMpq_zKWim65hnST7" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Less Reserves and Allowances&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(187,862&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(136,097&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--AccountsReceivableNetCurrent_iTI_pp0p0_mtARNCzMpq_zJsnp5ZYOKe2" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Accounts receivable,
    net&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;538,587&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;822,351&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A7_zNcz49UOgnh7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:TradeAndOtherAccountsReceivablePolicy>
    <us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_893_eus-gaap--ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_zQIpz9BhMTj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Accounts
receivable is comprised of the following at:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span id="xdx_8B0_zE01wFmfI8La" style="display: none"&gt;SCHEDULE
OF ACCOUNTS RECEIVABLE&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49C_20221231_zvfQMHAuvDj7" style="font-weight: bold; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_492_20211231_zxut4lxKKfY1" style="font-weight: bold; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--AccountsReceivableGrossCurrent_iI_pp0p0_maARNCz1PU_maARNCzMpq_zouIgJCiaAvj" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;Accounts Receivable&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;726,449&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;958,448&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--AllowanceForDoubtfulAccountsReceivableCurrent_iNI_pp0p0_di_msARNCz1PU_msARNCzMpq_zKWim65hnST7" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Less Reserves and Allowances&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(187,862&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(136,097&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--AccountsReceivableNetCurrent_iTI_pp0p0_mtARNCzMpq_zJsnp5ZYOKe2" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Accounts receivable,
    net&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;538,587&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;822,351&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock>
    <us-gaap:AccountsReceivableGrossCurrent contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">726449</us-gaap:AccountsReceivableGrossCurrent>
    <us-gaap:AccountsReceivableGrossCurrent contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">958448</us-gaap:AccountsReceivableGrossCurrent>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">187862</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">136097</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:AccountsReceivableNetCurrent contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">538587</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">822351</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_84E_eus-gaap--ResearchAndDevelopmentExpensePolicy_ztMuZpwk3j0d" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86F_z19JFpz1Rujl"&gt;Research
and Development&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Except
for acquired in process research and development (IPR&amp;amp;D), the Company expenses research and development costs as incurred including
therapeutics license costs.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <QLGN:ResearchAndDevelopmentGrantsPolicyTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_844_ecustom--ResearchAndDevelopmentGrantsPolicyTextBlock_zxQP3l4NISq8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86A_zkHH9mEzbZCg"&gt;R&amp;amp;D
Grants&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;NanoSynex
has received R&amp;amp;D grants from Israel Innovation Authority (IIA) and from the European Commission. These grants may provide cash funding
to NanoSynex from time to time in advance of the applicable costs being incurred. When such cash funding is received from these grants
in advance, the proceeds are recorded as a current or non-current R&amp;amp;D grant liability based on the time from the consolidated balance
sheets date to the expected future date of recognition as a reduction to research and development expenses.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</QLGN:ResearchAndDevelopmentGrantsPolicyTextBlock>
    <QLGN:PatentCostsPolicyTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_841_ecustom--PatentCostsPolicyTextBlock_zBCruCgfuRp3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_868_z37jRTIWlBl4"&gt;Patent
Costs&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company expenses all costs as incurred in connection with patent applications (including direct application fees, and the legal and consulting
expenses related to making such applications) and such costs are included in general and administrative expenses in the consolidated
statement of operations.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</QLGN:PatentCostsPolicyTextBlock>
    <QLGN:ShippingAndHandlingCostsPolicyTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_841_ecustom--ShippingAndHandlingCostsPolicyTextBlock_zwI40cOosWhg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_868_zOB31OSRUN04"&gt;Shipping
and Handling Costs&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company includes shipping and handling fees billed to customers in net sales. Shipping and handling costs associated with inbound and
outbound freight are generally recorded in cost of sales; such shipping and handling costs totaled approximately $&lt;span id="xdx_904_eus-gaap--CostOfGoodsAndServicesSold_c20220101__20221231__srt--ProductOrServiceAxis__us-gaap--ShippingAndHandlingMember_zdk8CCBRyhze" title="Cost of Goods and Services Sold"&gt;267,000&lt;/span&gt; and $&lt;span id="xdx_904_eus-gaap--CostOfGoodsAndServicesSold_c20210101__20211231__srt--ProductOrServiceAxis__us-gaap--ShippingAndHandlingMember_zCWJOmSRtr47" title="Cost of Goods and Services Sold"&gt;113,000&lt;/span&gt;,
respectively, for the years December 31, 2022 and 2021. Other shipping and handling costs included in general and administrative, research
and development, and sales and marketing expenses totaled approximately $&lt;span id="xdx_901_eus-gaap--CostOfGoodsAndServicesSold_c20220101__20221231__us-gaap--IncomeStatementLocationAxis__custom--GeneralAdministrativeResearchAndDevelopmentExpensesMember_zNAiaPKLGGPg" title="Other shipping and handling costs"&gt;14,000&lt;/span&gt; and $&lt;span id="xdx_908_eus-gaap--CostOfGoodsAndServicesSold_c20210101__20211231__us-gaap--IncomeStatementLocationAxis__custom--GeneralAdministrativeResearchAndDevelopmentExpensesMember_z9cn1bTADg3d" title="Other shipping and handling costs"&gt;12,000&lt;/span&gt; for the years ended December 31, 2022 and
2021, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</QLGN:ShippingAndHandlingCostsPolicyTextBlock>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="From2022-01-012022-12-31_us-gaap_ShippingAndHandlingMember"
      decimals="0"
      unitRef="USD">267000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="From2021-01-012021-12-31_us-gaap_ShippingAndHandlingMember"
      decimals="0"
      unitRef="USD">113000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="From2022-01-012022-12-31_custom_GeneralAdministrativeResearchAndDevelopmentExpensesMember"
      decimals="0"
      unitRef="USD">14000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="From2021-01-012021-12-31_custom_GeneralAdministrativeResearchAndDevelopmentExpensesMember"
      decimals="0"
      unitRef="USD">12000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:RevenueRecognitionPolicyTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_84E_eus-gaap--RevenueRecognitionPolicyTextBlock_zABQ76nng5rl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86B_zk6ye9FRqsz3"&gt;Revenue
from Contracts with Customers&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company applies the following five-step model in accordance with ASC 606, Revenue from Contracts with Customers, in order to determine
revenue: (i) identification of the promised goods or services in the contract; (ii) determination of whether the promised goods or services
are performance obligations, including whether they are distinct in the context of the contract; (iii) measurement of the transaction
price, including the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations; and
(v) recognition of revenue when (or as) the Company satisfies each performance obligation.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Product
Sales&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company generates revenue from selling FastPack System analyzers, accessories and disposable products used with the FastPack System.
Disposable products include reagent packs, which are diagnostic tests for prostate-specific antigen, testosterone, thyroid disorders,
pregnancy, and Vitamin D.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company provides disposable products and equipment in exchange for consideration, which occurs when a customer submits a purchase order
and the Company provides disposable products and equipment at the agreed upon prices in the invoice. Generally, customers purchase disposable
products using separate purchase orders after the equipment (&#x201c;analyzer&#x201d;) has been provided to the customer. The initial delivery
of the equipment and reagent packs represents a single performance obligation and is completed upon receipt by the customer. The delivery
of each subsequent individual reagent pack represents a separate performance obligation because the reagent packs are standardized, are
not interrelated in any way, and the customer can benefit from each reagent pack without any other product. There are no significant
discounts, rebates, returns or other forms of variable consideration. Customers are generally required to pay within 30 days.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
performance obligation arising from the delivery of the equipment is satisfied upon the delivery of the equipment to the customer. The
disposable products are shipped Free on Board (&#x201c;FOB&#x201d;) shipping point. For disposable products that are shipped FOB shipping
point, the customer has the significant risks and rewards of ownership and legal title to the assets when the disposable products leave
the Company&#x2019;s shipping facilities, thus the customer obtains control and revenue is recognized at that point in time.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company has elected the practical expedient and accounting policy election to account for the shipping and handling as activities to
fulfill the promise to transfer the disposable products and not as a separate performance obligation.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s contracts with customers generally have an expected duration of one year or less, and therefore the Company has elected
the practical expedient in ASC 606 to not disclose information about its remaining performance obligations. Any incremental costs to
obtain contracts are recorded as selling, general and administrative expense as incurred due to the short duration of the Company&#x2019;s
contracts.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;License
Revenue&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company entered into an out-license agreement with Yi Xin to develop and/or commercialize its products in exchange for nonrefundable
upfront license fees and/or sales-based royalties.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;If
the license to the Company&#x2019;s intellectual property is determined to be distinct from the other performance obligations identified
in the arrangement, the Company recognizes revenue from nonrefundable upfront fees allocated to the license when the license is transferred
to the customer and the customer can benefit from the license. For licenses that are bundled with other performance obligations, management
uses judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is
satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing
revenue from nonrefundable upfront fees. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts
the measure of progress and related revenue recognition. During years ended December 31, 2022 and 2021, the Company recognized license
revenue of approximately $&lt;span id="xdx_90D_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_dxL_c20220101__20221231__srt--ProductOrServiceAxis__custom--LicenseRevenuesMember_zFBg85urxvHl" title="::XDX::-"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0752"&gt;0&lt;/span&gt;&lt;/span&gt; and $&lt;span id="xdx_90A_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20210101__20211231__srt--ProductOrServiceAxis__custom--LicenseRevenuesMember_zIZj4c0axwf4"&gt;632,000&lt;/span&gt;, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Contract
Asset and Liability Balances&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
timing of the Company&#x2019;s revenue recognition may differ from the timing of payment by the Company&#x2019;s customers. The Company
records a receivable when revenue is recognized prior to payment and there is an unconditional right to payment. Alternatively, when
payment precedes the performance of the related services, the Company records deferred revenue until the performance obligations are
satisfied.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Multiple
performance obligations include contracts that combine both the Company&#x2019;s analyzer and a customer&#x2019;s future reagent purchases
under a single contract. In some sales contracts, the Company provides analyzers at no charge to customers. Title to the analyzer is
maintained by the Company and the analyzer is returned by the customer to the Company at the end of the purchase agreement.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
the years December 31, 2022 and 2021, product sales are stated net of an allowance for estimated returns of approximately $&lt;span id="xdx_90F_ecustom--AllowancesForSalesReturn_c20220101__20221231_z3orAMfHfQTa" title="Allowance for estimated returns"&gt;96,000&lt;/span&gt; and
$&lt;span id="xdx_90C_ecustom--AllowancesForSalesReturn_c20210101__20211231_zplKcwOU6s79" title="Allowance for estimated returns"&gt;150,000&lt;/span&gt;, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:RevenueRecognitionPolicyTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2021-01-012021-12-31_custom_LicenseRevenuesMember"
      decimals="0"
      unitRef="USD">632000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <QLGN:AllowancesForSalesReturn
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">96000</QLGN:AllowancesForSalesReturn>
    <QLGN:AllowancesForSalesReturn
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">150000</QLGN:AllowancesForSalesReturn>
    <QLGN:DeferredRevenuePolicyTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_84E_ecustom--DeferredRevenuePolicyTextBlock_zoQqOxBjcdPg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86C_zN6oYNVEGld1"&gt;Deferred
Revenue&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Payments
received in advance from customers pursuant to certain collaborative research license agreements, deposits against future product sales,
multiple element arrangements and extended warranties are recorded as a current or non-current deferred revenue liability based on the
time from the Consolidated Balance Sheet date to the future date of revenue recognition.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</QLGN:DeferredRevenuePolicyTextBlock>
    <us-gaap:LesseeLeasesPolicyTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_848_eus-gaap--LesseeLeasesPolicyTextBlock_zwgVxRU1aNrj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_860_ztpvsNrpeia6"&gt;Operating
Leases&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Effective
April 1, 2020, the Company adopted Accounting Standards Update (&#x201c;ASU&#x201d;) No. 2018-11, &lt;i&gt;Leases (Topic 842) Targeted Improvements
&lt;/i&gt;(&#x201c;Topic 842&#x201d;). In accordance with the guidance in Topic 842, the Company recognizes lease liabilities and corresponding
right-of-use-assets for all leases with terms of greater than 12 months. Leases with a term of 12 months or less will be accounted for
in a manner similar to the guidance for operating leases prior to the adoption of Topic 842. (See Note 13-Commitments and Contingencies).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_84B_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zxkFwQXeVvI3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86E_zUjoRKE3YoLk"&gt;Property
and Equipment, Net&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89A_ecustom--ScheduleOfUsefulLivesOfPropertyAndEquipmentTableTextBlock_zFBqhrfk1vIi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Property
and equipment are stated at cost and are presented net of accumulated depreciation. Depreciation is provided for on a straight-line basis
over the estimated useful lives of the related assets as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span id="xdx_8B2_zAPA13MDyEXg" style="display: none"&gt;SCHEDULE
OF USEFUL LIVES OF PROPERTY AND EQUIPMENT&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 77%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Machinery
    and equipment&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 23%; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_904_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20220101__20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--MachineryAndEquipmentMember_zqufBTavuQy3" title="Property and equipment, useful life"&gt;5&lt;/span&gt;
    years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Computer
    equipment&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_908_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20220101__20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember_zawkBQjlOUM3" title="Property and equipment, useful life"&gt;3&lt;/span&gt;
    years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Molds
    and tooling&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90A_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20220101__20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--MoldsAndToolingMember_zIvIh9XUZzWi" title="Property and equipment, useful life"&gt;5&lt;/span&gt;
    years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Furniture
    and fixtures&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_906_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20220101__20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_z5DGlGqVKWNg" title="Property and equipment, useful life"&gt;5&lt;/span&gt;
    years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p id="xdx_8A6_zffzxAM1cCy5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Leasehold
improvements are amortized on a straight-line basis over the shorter of the lease term or their estimated useful lives. The Company occasionally
designs and builds its own machinery. The costs of these projects, which includes the cost of construction and other direct costs attributable
to the construction, are capitalized as construction in progress. No provision for depreciation is made on construction in progress until
the relevant assets are completed and placed in service.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s policy is to evaluate the remaining lives and recoverability of long-term assets on at least an annual basis or when
conditions are present that indicate impairment.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <QLGN:ScheduleOfUsefulLivesOfPropertyAndEquipmentTableTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_89A_ecustom--ScheduleOfUsefulLivesOfPropertyAndEquipmentTableTextBlock_zFBqhrfk1vIi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Property
and equipment are stated at cost and are presented net of accumulated depreciation. Depreciation is provided for on a straight-line basis
over the estimated useful lives of the related assets as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span id="xdx_8B2_zAPA13MDyEXg" style="display: none"&gt;SCHEDULE
OF USEFUL LIVES OF PROPERTY AND EQUIPMENT&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 77%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Machinery
    and equipment&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 23%; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_904_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20220101__20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--MachineryAndEquipmentMember_zqufBTavuQy3" title="Property and equipment, useful life"&gt;5&lt;/span&gt;
    years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Computer
    equipment&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_908_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20220101__20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember_zawkBQjlOUM3" title="Property and equipment, useful life"&gt;3&lt;/span&gt;
    years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Molds
    and tooling&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90A_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20220101__20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--MoldsAndToolingMember_zIvIh9XUZzWi" title="Property and equipment, useful life"&gt;5&lt;/span&gt;
    years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Furniture
    and fixtures&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_906_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20220101__20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_z5DGlGqVKWNg" title="Property and equipment, useful life"&gt;5&lt;/span&gt;
    years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
</QLGN:ScheduleOfUsefulLivesOfPropertyAndEquipmentTableTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="From2022-01-012022-12-31_us-gaap_MachineryAndEquipmentMember">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="From2022-01-012022-12-31_us-gaap_ComputerEquipmentMember">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="From2022-01-012022-12-31_custom_MoldsAndToolingMember">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="From2022-01-012022-12-31_us-gaap_FurnitureAndFixturesMember">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:BusinessCombinationsPolicy contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_841_eus-gaap--BusinessCombinationsPolicy_zvdZiwqEUsXg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86F_zfZHqhXQ1spi"&gt;Business
Combinations&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company accounts for business combinations using the acquisition method pursuant to FASB ASC Topic 805. This method requires, among other
things, that results of operations of acquired companies are included in Qualigen&#x2019;s financial results beginning on the respective
acquisition dates, and that assets acquired and liabilities assumed and noncontrolling interests are recognized at fair value as of the
acquisition date. Intangible assets acquired in a business combination are recorded at fair value using a discounted cash flow model.
We have third-party valuations completed for intangible assets in a business combination using a discounted cash flow analysis, incorporating
various assumptions. The discounted cash flow model requires assumptions about the timing and amount of future net cash flows, the cost
of capital and terminal values from the perspective of a market participant. Each of these factors can significantly affect the value
of the intangible asset. Any excess of the fair value of consideration transferred (the &#x201c;Purchase Price&#x201d;) over the fair values
of the net assets acquired is recognized as goodwill. The fair value of assets acquired and liabilities assumed in certain cases may
be subject to revision based on the final determination of fair value during a period of time not to exceed 12 months from the acquisition
date. Legal costs, due diligence costs, business valuation costs and all other acquisition-related costs are expensed when incurred.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:BusinessCombinationsPolicy>
    <us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_845_eus-gaap--GoodwillAndIntangibleAssetsPolicyTextBlock_zbYKJt4uxjJi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_862_zcL6YjOj8s15"&gt;Goodwill&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Goodwill
represents the difference between the purchase price and the fair value of the identifiable tangible and intangible net assets
acquired, when accounted for using the purchase method of accounting. Goodwill has an indefinite useful life and is not amortized
but is reviewed for impairment annually and whenever events or changes in circumstances indicate that the carrying value of the
goodwill may not be recoverable. In testing for impairment, the fair value of the reporting unit is compared to the carrying value.
If the net assets assigned to the reporting unit exceed the fair value of the reporting unit, an impairment loss equal to the
difference is recorded. As a result of the annual goodwill impairment analysis, the Company recognized a $&lt;span id="xdx_905_eus-gaap--GoodwillImpairmentLoss_c20220101__20221231_zPKuBPchBib5" title="Goodwill impairment charges"&gt;4,239,000&lt;/span&gt;
non-cash goodwill and fixed asset impairment charge in the valuation of its business acquisition of NanoSynex for the year ended
December 30, 2022. For more information, refer to Note 1 - Organization and Summary of Significant Accounting Policies and Estimates
and Note 7 - Goodwill, IPR&amp;amp;D and other Intangibles.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">4239000</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:IntangibleAssetsFiniteLivedPolicy contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_844_eus-gaap--IntangibleAssetsFiniteLivedPolicy_zwDMssJ6GRgf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86C_zQvb0w9eUW4c"&gt;Intangible
Assets&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;In
Process R&amp;amp;D&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Acquired
in process R&amp;amp;D (IPR&amp;amp;D) represents the fair value assigned to the research and development assets that have not reached technological
feasibility. The value assigned to IPR&amp;amp;D is determined by estimating the costs to develop the acquired technology into commercially
viable products, estimating the resulting revenue from the projects, and discounting the net cash flow to present value. The revenue
and cost projections used to value acquired IPR&amp;amp;D are, as applicable, reduced based on the probability of success of developing the
new product. Additionally, projections consider relevant market sizes and growth factors, expected trends in technology and the nature
and expected timing of new product introductions. The rates utilized to discount the net cash flow to its present value are commensurate
with the stage of development of the project and uncertainties in the economic estimates used in the projections. Upon the acquisition
of acquired IPR&amp;amp;D, an assessment is completed as to whether the acquisition constitutes an acquisition of a single asset or a group
of assets. Multiple factors are considered in this assessment, including the nature of the technology acquired, the presence or absence
of separate cash flows, the development process and stage of completion, quantitative significance, and the Company&#x2019;s rationale
for entering into the transaction.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;If
a business is acquired, as defined under the applicable accounting standards, then the acquired IPR&amp;amp;D is capitalized as an intangible
asset. If an asset or group of assets is acquired that do not meet the definition under the applicable accounting standards, then the
acquired IPR&amp;amp;D is expensed on its acquisition date. Future costs to develop these assets are recorded to research and development
expense in the Company&#x2019;s consolidated statements of operations and comprehensive loss as they are incurred.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;IPR&amp;amp;D
is evaluated for impairment annually using the same methodology as described above for calculating fair value. If the carrying value
of the acquired IPR&amp;amp;D exceeds the fair value, then the intangible asset is written down to its fair value, with the resulting adjustment
recorded as a charge to operations. Changes in estimates and assumptions used in determining the fair value of acquired IPR&amp;amp;D could
result in an impairment.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Other
Intangible Assets, Net&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Other
intangible assets consist of patent-related costs and costs for license agreements. Management reviews the carrying value of other intangible
assets that are being amortized on an annual basis or sooner when there is evidence that events or changes in circumstances may indicate
that impairment exists. The Company considers relevant cash flow and profitability information, including estimated future operating
results, trends and other available information, in assessing whether the carrying value of intangible assets being amortized can be
recovered.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;If
the Company determines that the carrying value of other intangible assets will not be recovered from the undiscounted future cash flows
expected to result from the use and eventual disposition of the underlying assets, the Company considers the carrying value of such intangible
assets as impaired and reduces them by a charge to operations in the amount of the impairment.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Costs
related to acquiring patents and licenses are capitalized and amortized over their estimated useful lives, which is generally&lt;span id="xdx_90C_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dtY_c20220101__20221231__srt--RangeAxis__srt--MinimumMember__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PatentsAndLicensesMember_zkxYMMM8Ak3f" title="Estimated useful lives"&gt; 5&lt;/span&gt; to &lt;span id="xdx_902_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dtY_c20220101__20221231__srt--RangeAxis__srt--MaximumMember__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PatentsAndLicensesMember_zWMNAhPGgml7" title="Estimated useful lives"&gt;17&lt;/span&gt;
years, using the straight-line method. Amortization of patents and licenses commences once final approval of the patent or license has
been obtained. Patent and license costs are charged to operations if it is determined that the patent or license will not be obtained.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:IntangibleAssetsFiniteLivedPolicy>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="From2022-01-012022-12-31_srt_MinimumMember_custom_PatentsAndLicensesMember">P5Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="From2022-01-012022-12-31_srt_MaximumMember_custom_PatentsAndLicensesMember">P17Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <QLGN:DerivativeFinancialInstrumentsAndWarrantLiabilitiesPolicyTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_84A_ecustom--DerivativeFinancialInstrumentsAndWarrantLiabilitiesPolicyTextBlock_zYk7vHQpnWp7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86A_zNtcOzvKQ3g7"&gt;Derivative
Financial Instruments and Warrant Liabilities&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company does not use derivative instruments to hedge exposures to cash flow, market, or foreign currency risks. The Company evaluates
all of its financial instruments, including issued stock purchase warrants, to determine if such instruments are derivatives or contain
features that qualify as embedded derivatives. For derivative financial instruments that are accounted for as liabilities, the derivative
instrument is initially recorded at its fair value and is then re-valued at each reporting date, with changes in the fair value reported
in the consolidated statements of operations and comprehensive loss. Depending on the features of the derivative financial instrument,
the Company uses either the Black-Scholes option-pricing model or a Monte-Carlo simulation to value the derivative instruments at inception
and subsequent valuation dates. The classification of derivative instruments, including whether such instruments should be recorded as
liabilities or as equity, is re-assessed at the end of each reporting period (See Note 10-Warrant Liabilities and Note 11- Convertible
Debt - Related Party).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Fair
Value Measurements&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company determines the fair value measurements of applicable assets and liabilities based on a three-tier fair value hierarchy established
by accounting guidance and prioritizes the inputs used in measuring fair value. The Company discloses and recognizes the fair value of
its assets and liabilities using a hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy
gives the highest priority to valuations based upon unadjusted quoted prices in active markets for identical assets or liabilities (Level
1 measurements) and the lowest priority to valuations based upon unobservable inputs that are significant to the valuation (Level 3 measurements).
The guidance establishes three levels of the fair value hierarchy as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
                                            1 - Inputs that reflect unadjusted quoted prices in active markets for identical assets or
                                            liabilities that the Company has the ability to access at the measurement date;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -24.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
                                            2 - Inputs other than quoted prices that are observable for the assets or liability either
                                            directly or indirectly, including inputs in markets that are not considered to be active;
                                            and&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -24.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&#x25cf;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
                                            3 - Inputs that are unobservable.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -24.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</QLGN:DerivativeFinancialInstrumentsAndWarrantLiabilitiesPolicyTextBlock>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_84D_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zP6ZVVYW4Vx8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_861_z3ymfQ7hS3v4"&gt;Fair
Value of Financial Instruments&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Cash,
accounts receivable, prepaids, accounts payable, and accrued liabilities are carried at cost, which management believes approximates
fair value due to the short-term nature of these instruments.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:AdvertisingCostsPolicyTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_840_eus-gaap--AdvertisingCostsPolicyTextBlock_zYVNkMB16xgf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_867_zXo6xMwPUfAi"&gt;Advertising&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Advertising
expense consists primarily of print and digital media promotional materials for a distributor. Advertising costs are expensed as incurred.
Advertising expense for the years ended December 31, 2022 and 2021 amounted to $&lt;span id="xdx_90B_eus-gaap--AdvertisingExpense_c20220101__20221231_zbt2JY0VnqH" title="Advertising expense"&gt;50,000&lt;/span&gt; and $&lt;span id="xdx_90C_eus-gaap--AdvertisingExpense_c20210101__20211231_zSf9jmc2eJw7" title="Advertising expense"&gt;0&lt;/span&gt;, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:AdvertisingCostsPolicyTextBlock>
    <us-gaap:AdvertisingExpense
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">50000</us-gaap:AdvertisingExpense>
    <us-gaap:AdvertisingExpense
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">0</us-gaap:AdvertisingExpense>
    <us-gaap:ComprehensiveIncomePolicyPolicyTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_845_eus-gaap--ComprehensiveIncomePolicyPolicyTextBlock_zaraFTgm9v08" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_862_zP4m4XVUM4R"&gt;Comprehensive
Loss&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Comprehensive
loss consists of net income and foreign currency translation adjustments. Comprehensive gains (losses) have been reflected in the statements
of operations and comprehensive loss and as a separate component in the statements of stockholders&#x2019; equity for all periods presented.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:ComprehensiveIncomePolicyPolicyTextBlock>
    <us-gaap:CompensationRelatedCostsPolicyTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_84B_eus-gaap--CompensationRelatedCostsPolicyTextBlock_zuMCtZNK0dV" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86B_z93HuhI6ZM32"&gt;Stock-Based
Compensation&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Stock-based
compensation cost for equity awards granted to employees and non-employees is measured at the grant date based on the calculated fair
value of the award using the Black-Scholes option-pricing model, and is recognized as an expense, under the straight-line method, over
the requisite service period (generally the vesting period of the equity grant). If the Company determines that other methods are more
reasonable, or other methods for calculating these assumptions are prescribed by regulators, the fair value calculated for the Company&#x2019;s
stock options could change significantly. Higher volatility, lower risk-free interest rates, and longer expected lives would result in
an increase to stock-based compensation expense to employees and non-employees determined at the date of grant.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:CompensationRelatedCostsPolicyTextBlock>
    <us-gaap:IncomeTaxPolicyTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_84C_eus-gaap--IncomeTaxPolicyTextBlock_z0GYTOjzvE98" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86B_zajN575xWrPk"&gt;Income
Taxes&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Deferred
income taxes are recognized for temporary differences in the basis of assets and liabilities for financial statement and income tax reporting
that arise due to net operating loss carry forwards, research and development credit carry forwards and from using different methods
and periods to calculate depreciation and amortization, allowance for doubtful accounts, accrued vacation, research and development expenses,
and state taxes. A provision has been made for income taxes due on taxable income and for the deferred taxes on the temporary differences.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Deferred
tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion or all
of the deferred tax assets will not be realized. Deferred tax assets and liabilities are adjusted for the effects of changes in tax laws
and rates on the date of enactment. Realization of the deferred income tax asset is dependent on generating sufficient taxable income
in future years. For more information, refer to Note 17-Income Taxes.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:IncomeTaxPolicyTextBlock>
    <QLGN:SalesAndExciseTaxesPolicyTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_841_ecustom--SalesAndExciseTaxesPolicyTextBlock_zFjBkSfE43Z" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86C_zJc7M9MEsVh2"&gt;Sales
and Excise Taxes&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Sales
and other taxes collected from customers and subsequently remitted to government authorities are recorded as accounts receivable with
corresponding tax payable. These balances are removed from the consolidated balance sheet as cash is collected from customers and remitted
to the tax authority.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</QLGN:SalesAndExciseTaxesPolicyTextBlock>
    <QLGN:WarrantyReservePolicyTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_84B_ecustom--WarrantyReservePolicyTextBlock_zuXhILNGtyr7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86F_zZFzrwafMcV7"&gt;Warranty
Costs&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s warranty policy generally provides for one year of coverage against defects and nonperformance within published specifications
for sold analyzers and for the term of the contract for equipment held for lease. The Company accrues for estimated warranty costs in
the period in which the revenue is recognized based on historical data and the Company&#x2019;s best estimates of analyzer failure rates
and costs to repair.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Accrued
warranty liabilities were approximately $&lt;span id="xdx_901_eus-gaap--ProductWarrantyAccrual_iI_c20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zYMTyRdVoxbf" title="Accrued warranty liabilities"&gt;138,000&lt;/span&gt; and $&lt;span id="xdx_90E_eus-gaap--ProductWarrantyAccrual_iI_c20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z5rpvRsY2Bhe" title="Accrued warranty liabilities"&gt;60,000&lt;/span&gt;, respectively, at December 31, 2022 and December 31, 2021 and are included
in accrued expenses and other current liabilities on the Consolidated Balance Sheets. Warranty costs were approximately $&lt;span id="xdx_908_eus-gaap--ProductWarrantyExpense_c20220101__20221231_zjAeybIH7LRb" title="Warranty costs"&gt;69,000&lt;/span&gt; and $&lt;span id="xdx_90C_eus-gaap--ProductWarrantyExpense_c20210101__20211231_zgQ7NMp3UHI6" title="Warranty costs"&gt;57,000&lt;/span&gt;
for the years ended December 31, 2022 and 2021, respectively, and are included in cost of product sales in the Consolidated Statements
of Operations.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</QLGN:WarrantyReservePolicyTextBlock>
    <us-gaap:ProductWarrantyAccrual
      contextRef="AsOf2022-12-31_us-gaap_WarrantMember"
      decimals="0"
      unitRef="USD">138000</us-gaap:ProductWarrantyAccrual>
    <us-gaap:ProductWarrantyAccrual
      contextRef="AsOf2021-12-31_us-gaap_WarrantMember"
      decimals="0"
      unitRef="USD">60000</us-gaap:ProductWarrantyAccrual>
    <us-gaap:ProductWarrantyExpense
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">69000</us-gaap:ProductWarrantyExpense>
    <us-gaap:ProductWarrantyExpense
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">57000</us-gaap:ProductWarrantyExpense>
    <us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_84D_eus-gaap--ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_zQ6eZKfREUnf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_861_zr4gZVO6OLT1"&gt;Foreign
Currency Translation&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
functional currency for the Company is the U.S. dollar. The functional currency for NanoSynex, the Company&#x2019;s newly acquired majority
owned subsidiary, is the New Israeli Shekel (NIS). The financial statements of NanoSynex are translated into U.S. dollars using exchange
rates in effect at each period end for assets and liabilities; using exchange rates in effect during the period for results of operations;
and using historical exchange rates for certain equity accounts. The adjustment resulting from translating the financial statements of
NanoSynex is reflected as a separate component of other comprehensive income (loss).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Other
comprehensive loss related to the effects of foreign currency translation adjustments attributable to NanoSynex was $&lt;span id="xdx_901_eus-gaap--OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_c20220101__20221231__us-gaap--BusinessAcquisitionAxis__custom--NanoSynexLtdMember_zdomOdXwjkPi" title="Adjustment net of tax"&gt;50,721&lt;/span&gt; and $&lt;span id="xdx_900_eus-gaap--OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_c20210101__20211231__us-gaap--BusinessAcquisitionAxis__custom--NanoSynexLtdMember_znsm1pjH0QU7" title="Adjustment net of tax"&gt;0&lt;/span&gt; at
December 31, 2022 and 2021, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="From2022-01-012022-12-31_custom_NanoSynexLtdMember"
      decimals="0"
      unitRef="USD">50721</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="From2021-01-012021-12-31_custom_NanoSynexLtdMember"
      decimals="0"
      unitRef="USD">0</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_844_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zIJBrwoB7uI3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86E_zP8oTscRYrR2"&gt;Recent
Accounting Pronouncements&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
June 2016, the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) issued ASU No. 2016-13, &lt;i&gt;Measurement of Credit Losses on Financial
Instruments&lt;/i&gt;, which supersedes current guidance by requiring recognition of credit losses when it is probable that a loss has been
incurred. The new standard requires the establishment of an allowance for estimated credit losses on financial assets including trade
and other receivables at each reporting date. The new standard will result in earlier recognition of allowances for losses on trade and
other receivables and other contractual rights to receive cash. In November 2019, the FASB issued ASU No. 2019-10, &lt;i&gt;Financial Instruments
&#x2013; Credit Losses (Topic 326), Derivatives and Hedging (Topic 815) &lt;/i&gt;and &lt;i&gt;Leases (Topic 842)&lt;/i&gt;, which extended the effective
date of Topic 326 for certain companies until fiscal years beginning after December 15, 2022. The new standard will be effective for
the Company in the first quarter of fiscal year beginning January 1, 2023, and early adoption is permitted. The Company adopted ASU 2016-13
on January 1, 2023. Adoption did not have a material impact on the Company&#x2019;s consolidated financial statements and related disclosures.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <QLGN:GlobalEconomicConditionsPolicyTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_84A_ecustom--GlobalEconomicConditionsPolicyTextBlock_z9Nrhk6J8AMl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86D_zY9GyuybJgi8"&gt;Global
Economic Conditions&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;War
in Ukraine&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
February 2022, Russia invaded Ukraine. While the Company has no direct exposure in Russia and Ukraine, the Company continues to monitor
any broader impact to the global economy, including with respect to inflation, supply chains and fuel prices. The full impact of the
conflict on the Company&#x2019;s business and financial results remains uncertain and will depend on the severity and duration of the
conflict and its impact on regional and global economic conditions.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Inflationary
Cost Environment&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
the year ended 2022 and continuing into the current fiscal year, global commodity and labor markets experienced significant inflationary
pressures attributable to ongoing economic recovery and supply chain issues. The Company is subject to inflationary pressures with respect
to raw materials, labor and transportation. Accordingly, the Company continues to take actions with its customers and suppliers to mitigate
the impact of these inflationary pressures in the future. Actions to mitigate inflationary pressures with suppliers include aggregation
of purchase requirements to achieve optimal volume benefits, negotiation of cost-reductions and identification of more cost competitive
suppliers. While these actions are designed to offset the impact of inflationary pressures, the Company cannot provide assurance that
it will be successful in fully offsetting increased costs resulting from inflationary pressure.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Impact of
COVID-19 Pandemic&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
COVID-19 pandemic has had a dramatic impact on businesses globally and on the Company&#x2019;s business as well. Sales of diagnostic products
fell significantly during 2020 and the Company&#x2019;s net loss increased significantly, as deferral of patients&#x2019; non-emergency
visits to physician offices, clinics and small hospitals sharply reduced demand for FastPack tests. Since then we have experienced some recovery in demand.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Other
accounting standard updates are either not applicable to the Company or are not expected to have a material impact on the Company&#x2019;s
consolidated financial statements.&lt;/span&gt;&lt;/p&gt;

</QLGN:GlobalEconomicConditionsPolicyTextBlock>
    <us-gaap:SubstantialDoubtAboutGoingConcernTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_804_eus-gaap--SubstantialDoubtAboutGoingConcernTextBlock_z3ue2rwHlAt3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
2 &#x2014; &lt;span id="xdx_822_zeUG5Zah2X08"&gt;LIQUIDITY AND GOING CONCERN&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of December 31, 2022, the Company had approximately $&lt;span id="xdx_903_eus-gaap--Cash_iI_pn5n6_c20221231_zQqdfCVC1aJ1" title="Cash"&gt;7.0&lt;/span&gt; million in cash and an accumulated deficit of $&lt;span id="xdx_90F_eus-gaap--RetainedEarningsAccumulatedDeficit_iNI_pn5n6_di_c20221231_zPnOkApQF176" title="Accumulated deficit"&gt;103.4&lt;/span&gt; million. For the years
ended December 31, 2022 and 2021, the Company used cash of $&lt;span id="xdx_90C_eus-gaap--NetCashProvidedByUsedInOperatingActivities_iN_pn5n6_di_c20220101__20221231_zWTPslDhDkGe" title="Net cash used in operating activities"&gt;13.2&lt;/span&gt; million and $&lt;span id="xdx_903_eus-gaap--NetCashProvidedByUsedInOperatingActivities_iN_pn5n6_di_c20210101__20211231_znn9cGD4qqT7" title="Net cash used in operating activities"&gt;14.7&lt;/span&gt; million, respectively, in operations. The Company&#x2019;s
cash balances are expected to fund operations into the third quarter of 2023. As a pre-clinical development-stage therapeutics biotechnology
company, the Company expects to continue to have net losses and negative cash flow from operations, which over time will challenge its
liquidity. These factors raise substantial doubt about the Company&#x2019;s ability to continue as a going concern for the one-year period
following the date that these financial statements were issued.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;There
is no assurance that profitable operations will ever be achieved, or, if achieved, could be sustained on a continuing basis. In order
to fully execute its business plan, the Company will require significant additional financing for planned research and development activities,
capital expenditures, clinical and pre-clinical testing for its QN-302 clinical trials, preclinical development of RAS and QN-247, and
funding for NanoSynex operations (See Note 3-Acquisition), as well as commercialization activities.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Historically,
the Company&#x2019;s principal sources of cash have included proceeds from the issuance of common and preferred equity and proceeds
from the issuance of debt. In December 2021, the Company raised $&lt;span id="xdx_907_eus-gaap--ProceedsFromIssuanceOfCommonStock_pn5n6_c20211201__20211231_zHtwcTNjb6t9" title="Proceeds from issuance of common stock"&gt;8.8&lt;/span&gt;
million from the issuance of common stock to several institutional investors, and in December 2022 the Company raised $&lt;span id="xdx_904_eus-gaap--ProceedsFromConvertibleDebt_pn5n6_c20221201__20221231_z3gJr5eZpxk3" title="Proceeds from issuance of debt"&gt;3.0&lt;/span&gt;
million from the sale of a convertible debt - related party (see Note 11-Convertible Debt - Related Party).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;There
can be no assurance that further financing can be obtained on favorable terms, or at all. If we are unable to obtain funding, we could
be required to delay, reduce or eliminate research and development programs, product portfolio expansion or future commercialization
efforts, which could adversely affect our business prospects.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
a condition to the NanoSynex closing, the Company agreed to provide NanoSynex with up to $&lt;span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodValueAcquisitions_pn5n6_c20220101__20221231__us-gaap--BusinessAcquisitionAxis__custom--NanoSynexLtdMember_zwXw0OgDeosj" title="Stock issued during period value acquisitions"&gt;10.4&lt;/span&gt; million of future funding based on NanoSynex&#x2019;s
achievement of certain future development milestones and subject to other terms and conditions described in the Master Agreement for
the Operational and Technological Funding of NanoSynex (the &#x201c;Funding Agreement&#x201d;) entered into with NanoSynex. These funding
commitments are in the form of convertible promissory notes to be issued to &lt;span id="xdx_908_eus-gaap--StockholdersEquityNoteStockSplit_c20220101__20221231_zUODpnZ8KXKj" title="Stockholders equity note stock split"&gt;the Company with a face value equal to the amount paid by
the Company to NanoSynex upon satisfaction of the applicable performance milestone, bearing interest at the rate of 9% per annum on the
principal balance from time to time outstanding under the particular promissory note, convertible at the option of the Company into additional
shares of NanoSynex in order for the Company to maintain at least a 50.1% controlling ownership interest in NanoSynex, should NanoSynex
issue additional shares. The principal of the convertible notes are due and payable upon the sooner to occur of: i) five years from the
date of issuance of the particular promissory note; ii) the acquisition by any person or entity of all or substantially all of the share
capital of NanoSynex, through share purchase, issuance or shares or merger of NanoSynex, or the purchase of all or substantially all
of the assets of NanoSynex; or iii) the initial public offering of NanoSynex.&lt;/span&gt; The Company provided funding to NanoSynex of $&lt;span id="xdx_905_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pn5n6_c20220101__20221231__us-gaap--BusinessAcquisitionAxis__custom--NanoSynexLtdMember_zJ4TP8Nrzlh4" title="Stock issued during period value new issues"&gt;2.4&lt;/span&gt; million
during 2022 pursuant to this agreement. The Company may terminate the Funding Agreement upon 120 days&#x2019; notice, but would still
be liable for any payments due for milestones achieved prior to termination.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;To
the extent that the Company raises additional capital through the sale of equity or convertible debt securities, the ownership interests
of its common stockholders will be diluted, and the terms of these securities may include liquidation or other preferences that adversely
affect the rights of our common stockholders. Debt financing, if available, may involve agreements that include covenants limiting or
restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends.
If the Company raises additional funds through government or other third-party funding, commercialization, marketing and distribution
arrangements or other collaborations, strategic alliances or licensing arrangements with third parties, it may have to relinquish valuable
rights to its technologies, future revenue streams, research programs or product candidates or grant licenses on terms that may not be
favorable to the Company. Additional funding may not be available to the Company on acceptable terms, or at all. In addition, any future
financing (depending on the terms and conditions) may be subject to the approval of Alpha Capital, the holder of the Company&#x2019;s
8% Senior Convertible Debenture (the &#x201c;Debenture&#x201d;), or trigger certain adjustments to the Debenture or warrants held by Alpha
Capital.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
accompanying financial statements have been prepared assuming that the Company will continue as a going concern. The financial statements
do not include any adjustments that would be necessary should the Company be unable to continue as a going concern, and therefore, be
required to liquidate its assets and discharge its liabilities in other than the normal course of business and at amounts that may differ
from those reflected in the accompanying financial statements&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:SubstantialDoubtAboutGoingConcernTextBlock>
    <us-gaap:Cash contextRef="AsOf2022-12-31" decimals="-5" unitRef="USD">7000000.0</us-gaap:Cash>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="AsOf2022-12-31" decimals="-5" unitRef="USD">-103400000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2022-01-01to2022-12-31"
      decimals="-5"
      unitRef="USD">-13200000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2021-01-012021-12-31"
      decimals="-5"
      unitRef="USD">-14700000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2021-12-012021-12-31"
      decimals="-5"
      unitRef="USD">8800000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromConvertibleDebt
      contextRef="From2022-12-012022-12-31"
      decimals="-5"
      unitRef="USD">3000000.0</us-gaap:ProceedsFromConvertibleDebt>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions
      contextRef="From2022-01-012022-12-31_custom_NanoSynexLtdMember"
      decimals="-5"
      unitRef="USD">10400000</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <us-gaap:StockholdersEquityNoteStockSplit contextRef="From2022-01-01to2022-12-31">the Company with a face value equal to the amount paid by
the Company to NanoSynex upon satisfaction of the applicable performance milestone, bearing interest at the rate of 9% per annum on the
principal balance from time to time outstanding under the particular promissory note, convertible at the option of the Company into additional
shares of NanoSynex in order for the Company to maintain at least a 50.1% controlling ownership interest in NanoSynex, should NanoSynex
issue additional shares. The principal of the convertible notes are due and payable upon the sooner to occur of: i) five years from the
date of issuance of the particular promissory note; ii) the acquisition by any person or entity of all or substantially all of the share
capital of NanoSynex, through share purchase, issuance or shares or merger of NanoSynex, or the purchase of all or substantially all
of the assets of NanoSynex; or iii) the initial public offering of NanoSynex.</us-gaap:StockholdersEquityNoteStockSplit>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2022-01-012022-12-31_custom_NanoSynexLtdMember"
      decimals="-5"
      unitRef="USD">2400000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:BusinessCombinationDisclosureTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_803_eus-gaap--BusinessCombinationDisclosureTextBlock_z9GfJCFJd2Zc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
3 &#x2014; &lt;span id="xdx_822_z7BJAxPkbEQb"&gt;ACQUISITION&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Business
Combination&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;The Company acquired a &lt;span id="xdx_903_eus-gaap--BusinessAcquisitionPercentageOfVotingInterestsAcquired_iI_pid_dp_uPure_c20220526__us-gaap--BusinessAcquisitionAxis__custom--NanoSynexLtdMember_ziE1aWhduCsh" title="Business acquisition, voting equity rate"&gt;52.8&lt;/span&gt;%
voting equity interest in NanoSynex on May 26, 2022 (the &#x201c;NanoSynex Acquisition Date&#x201d;) through: (1) the purchase of &lt;span id="xdx_901_eus-gaap--StockIssuedDuringPeriodSharesAcquisitions_c20220524__20220526__us-gaap--StatementClassOfStockAxis__custom--SeriesAOnePreferredStockMember_z2KnsEtsvxT5" title="Number of shares of stock issued"&gt;2,232,861&lt;/span&gt;
shares Preferred A-1 Stock of NanoSynex from Alpha Capital (a related party) for &lt;span id="xdx_903_eus-gaap--StockIssuedDuringPeriodSharesAcquisitions_c20220524__20220526__us-gaap--BusinessAcquisitionAxis__custom--NanoSynexLtdMember_z5ZdbQdIRa37" title="Stock issued during period shares acquisitions"&gt;350,000&lt;/span&gt;
reverse split adjusted shares of the Company&#x2019;s common stock and a prefunded warrant to purchase &lt;span id="xdx_901_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20220526__us-gaap--StatementEquityComponentsAxis__custom--PrefundedWarrantMember_zia7g6kOVve5" title="Warrants to purchase shares"&gt;331,464
reverse split adjusted shares of the Company&#x2019;s common stock at a purchase price of $&lt;span id="xdx_909_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20220526__us-gaap--BusinessAcquisitionAxis__custom--NanoSynexLtdMember__us-gaap--StatementEquityComponentsAxis__custom--PrefundedWarrantMember_z8HidDJfpUx4" title="Warrants or rights"&gt;0.001&lt;/span&gt;
per share (&lt;span id="xdx_90B_eus-gaap--StockholdersEquityReverseStockSplit_c20220524__20220526__us-gaap--BusinessAcquisitionAxis__custom--NanoSynexLtdMember_zfcy0ZSHZbZh" title="Reverse split, description"&gt;these warrants were subsequently exercised on September 13, 2022)&lt;/span&gt;, and (2) the purchase of &lt;span id="xdx_902_eus-gaap--StockIssuedDuringPeriodSharesAcquisitions_c20220524__20220526__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember__us-gaap--BusinessAcquisitionAxis__custom--NanoSynexLtdMember_zyVm1ZSvx9G5" title="Stock issued during period shares acquisitions"&gt;381,786&lt;/span&gt;
shares of Series B preferred stock of NanoSynex from NanoSynex in exchange for $&lt;span id="xdx_901_eus-gaap--StockIssuedDuringPeriodValueAcquisitions_c20220524__20220526__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember__us-gaap--BusinessAcquisitionAxis__custom--NanoSynexLtdMember_zAhUPKw0qxh2" title="Stock issued during period value acquisitions"&gt;600,000&lt;/span&gt;&lt;/span&gt;
(collectively, the &#x201c;NanoSynex Acquisition&#x201d;).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
acquisition of the majority interest of NanoSynex was accounted for as a business combination using the acquisition method, in accordance
with FASB ASC Topic 805. Identifiable assets acquired, liabilities assumed and any noncontrolling interest in the acquiree are recognized
and measured as of the acquisition date at fair value. Determining the fair value of assets acquired, liabilities assumed and noncontrolling
interest requires management&#x2019;s judgment and often involves the use of significant estimates and assumptions, including assumptions
with respect to future cash flows, discount rates and asset lives among other items. The Company uses third-party valuations for intangible
assets in a business combination using a discounted cash flow analysis, incorporating various assumptions.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_890_eus-gaap--ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_zOsbLs4POgyk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;A
summary of the consideration transferred and fair value of assets acquired and liabilities assumed in the NanoSynex Acquisition is as
follows (all shares shown post 1 for 10 reverse split on November 23, 2022):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B8_zhGesOfCesRi" style="display: none"&gt;SCHEDULE
OF CONSIDERATION TRANSFERRED&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;Consideration transferred, net of cash acquired&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 80%; text-align: left; padding-bottom: 1.5pt"&gt;Cash paid for NanoSynex preferred stock:&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_ecustom--PaymentsToAcquireBusinesses_pp0p0_c20220524__20220526__us-gaap--BusinessAcquisitionAxis__custom--NanoSynexLtdMember_zs1OfV4i1qV1" style="border-bottom: Black 1.5pt solid; width: 16%; text-align: right" title="Cash paid for NanoSynex preferred stock:"&gt;600,000&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;FMV of &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIENPTlNJREVSQVRJT04gVFJBTlNGRVJSRUQgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_905_eus-gaap--StockIssuedDuringPeriodSharesAcquisitions_c20220524__20220526__us-gaap--BusinessAcquisitionAxis__custom--NanoSynexLtdMember_zkEfDIX9oqbc" title="Common stock issued for business acquisition"&gt;350,000&lt;/span&gt; shares of Qualigen stock issued to Alpha Capital Anstalt&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--StockIssuedDuringPeriodValueAcquisitions_pp0p0_c20220524__20220526__us-gaap--BusinessAcquisitionAxis__custom--NanoSynexLtdMember_zxs0bN5NF5Ui" style="text-align: right" title="FMV of 3,500,000 shares of Qualigen stock issued to Alpha Capital Anstalt"&gt;1,904,989&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;FMV of &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIENPTlNJREVSQVRJT04gVFJBTlNGRVJSRUQgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90F_eus-gaap--StockIssuedDuringPeriodSharesAcquisitions_c20220524__20220526__us-gaap--BusinessAcquisitionAxis__custom--AlphaCapitalAnstaltMember_zdIwRg5Vz5Jl" title="Common stock issued for business acquisition"&gt;331,464&lt;/span&gt;
    shares of Qualigen stock related to prefunded warrant issued to Alpha Capital Anstalt (See Note 15)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_ecustom--PrefundedWarrantsIssuedForBusinessAcquisition_pp0p0_c20220524__20220526__us-gaap--BusinessAcquisitionAxis__custom--NanoSynexLtdMember_zjG0dIRqPrIe" style="border-bottom: Black 1.5pt solid; text-align: right" title="FMV of 3,314,641 shares of Qualigen stock related to prefunded warrant issued to Alpha Capital Anstalt"&gt;1,804,102&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Total consideration paid for NanoSynex preferred stock&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--BusinessCombinationConsiderationTransferred1_pp0p0_c20220524__20220526__us-gaap--BusinessAcquisitionAxis__custom--NanoSynexLtdMember_zf0PuKozuuF2" style="border-bottom: Black 1.5pt solid; text-align: right" title="Total consideration paid for NanoSynex common stock"&gt;3,709,091&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td id="xdx_F47_zewy4rTtnOag" style="text-align: left; padding-bottom: 1.5pt"&gt;FMV of consideration related to related to repricing of &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIENPTlNJREVSQVRJT04gVFJBTlNGRVJSRUQgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesAcquisitions_c20220524__20220526_zZyBkxTCAyp7" title="Common stock issued for business acquisition"&gt;7,048&lt;/span&gt; shares of Alpha Capital/Qualigen warrants *&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_ecustom--FairValueOfWarrantModificationForBusinessAcquisition_pp0p0_c20220524__20220526__us-gaap--BusinessAcquisitionAxis__custom--NanoSynexLtdMember_fKg_____zeuMe7mz3ow5" style="border-bottom: Black 1.5pt solid; text-align: right" title="FMV of consideration related to related to repricing of 70,478 shares of Alpha Capital/Qualigen warrants *"&gt;696&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;NanoSynex cash acquired&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--CashAcquiredFromAcquisition_iN_pp0p0_di_c20220524__20220526__us-gaap--BusinessAcquisitionAxis__custom--NanoSynexLtdMember_zdeO6GLj5Olf" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right" title="NanoSynex cash acquired"&gt;(735,354&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt"&gt;Total consideration transferred, net of cash acquired&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--PaymentsToAcquireBusinessesNetOfCashAcquired_pp0p0_c20220524__20220526__us-gaap--BusinessAcquisitionAxis__custom--NanoSynexLtdMember_z9onq8HthZe4" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right" title="Total consideration transferred, net of cash acquired"&gt;3,574,433&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td id="xdx_F01_zHAnwfOGCQR6" style="width: 15pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span id="xdx_F19_z5NxVo6luna4" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;See disclosure
under &lt;i&gt;Noncompensatory Equity Classified Warrants&lt;/i&gt; regarding May 26, 2022 transaction-Note 15-Stockholders&#x2019; Equity&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;


&lt;p id="xdx_8A6_zhome0atFQBl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_892_eus-gaap--ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_zZYSY9jhcOy9" style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B2_zP1gRBl98nNb" style="display: none"&gt;SCHEDULE
OF ASSETS ACQUIRED AND LIABILITIES&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_497_20220526_zyjYIFjvvDcl" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Purchase Price Allocation&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_iI_ziI0KgaE9ZF" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; width: 80%; text-align: left"&gt;Accounts receivable&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;75,336&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_iI_z9T12KJnysSj" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Property and equipment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;120,942&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_ecustom--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedResearchAndDevelopmentExpense_iI_zHDGLPvjxUth" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;In process R&amp;amp;D&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5,700,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_iNI_di_zDPdWepmReW9" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Accounts payable&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(4,588&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_ecustom--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpensesAndOtherPayables_iI_zTQOiTkoF3m4" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Accrued expenses and other payables&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(291,093&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_ecustom--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedResearchAndDevelopmentGrantLiability_iI_z3fOD7mPKuek" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;R&amp;amp;D grant liability&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(1,362,264&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_ecustom--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesShortTermDebt_iI_zYMnPbk7tEMk" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Short term debt&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(941,898&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_iNI_di_zuieaCdeGej4" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Deferred tax liability&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(629,379&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedLessNoncontrollingInterest_iI_zGNbjPAzXf98" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt"&gt;Noncontrolling interest assumed&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(3,882,225&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_iNI_di_z8X9huu3FFX4" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 20pt; text-align: left"&gt;Identifiable net assets acquired&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(1,215,169&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--Goodwill_iI_zm5gS7WIrxP2" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; padding-bottom: 1.5pt"&gt;Goodwill&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;4,789,602&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_iI_zQUA13f31O1e" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt"&gt;Total consideration transferred, net of cash acquired&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"&gt;3,574,433&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A7_zaHtMPVNz2O" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
the year ended December 31, 2022, the Company made measurement period adjustments to the preliminary purchase price allocation which
included: (i) a decrease to noncontrolling interest of $&lt;span id="xdx_90B_eus-gaap--MinorityInterestDecreaseFromRedemptions_c20220101__20221231_zWO1JSzS0fM9" title="Decrease to noncontrolling interest"&gt;117,775&lt;/span&gt;, (ii) a decrease to goodwill of $&lt;span id="xdx_908_eus-gaap--GoodwillPeriodIncreaseDecrease_c20220101__20221231_z528J6raPBXh" title="Decrease in good will"&gt;106,621&lt;/span&gt;. The measurement period adjustments
were made to reflect facts and circumstances that existed as of the acquisition date and is reflected in the table above.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Company
transaction costs, which were immaterial, have been expensed as incurred and charged to the Company&#x2019;s consolidated statements of
operations and comprehensive loss. There was no provision for reimbursement of transaction costs from the Company to NanoSynex.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Goodwill
represents the excess of the purchase price over the fair value of the net assets acquired as of the acquisition date. Goodwill represents
the value of the future technology to be developed in excess of the identifiable assets as well as the operational synergies of the combined
companies to be recognized. Goodwill has an indefinite useful life and is not amortized. None of the Goodwill is expected to be deductible
for tax purposes.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
a condition to the closing, the Company agreed to provide NanoSynex with up to $&lt;span id="xdx_904_eus-gaap--StockIssuedDuringPeriodValueAcquisitions_pn5n6_c20220101__20221231__dei--LegalEntityAxis__custom--NanoSynexMember_zH9nhBrzmzDb" title="Stock issued during period value acquisitions"&gt;10.4&lt;/span&gt; million of future funding based on NanoSynex&#x2019;s
achievement of certain future development milestones and subject to other terms and conditions described in the Funding Agreement entered
into with NanoSynex. (See Note 2-Liquidity for further details regarding the terms and conditions of the Funding Agreement).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;The
Company&#x2019;s consolidated statements of operations and comprehensive loss for the years ended December 31, 2022 and 2021 include
approximately $&lt;span id="xdx_90A_eus-gaap--OtherComprehensiveIncomeLossTax_pn5n6_c20220101__20221231__us-gaap--BusinessAcquisitionAxis__custom--NanoSynexLtdMember_z2dz503bU9c" title="Other comprehensive income loss tax"&gt;5.1 million and $&lt;span id="xdx_908_eus-gaap--OtherComprehensiveIncomeLossTax_c20210101__20211231__us-gaap--BusinessAcquisitionAxis__custom--NanoSynexLtdMember_zvxypw86ddQj" title="Other comprehensive income loss tax"&gt;0&lt;/span&gt;, respectively, of net loss associated with the results of operations of NanoSynex from the NanoSynex
Acquisition Date.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following proforma information has been prepared as if the NanoSynex Acquisition occurred on January 1, 2021. The following unaudited
supplemental proforma consolidated results do not purport to reflect what the combined Company&#x2019;s results of operations would have
been, nor do they project the future results of operations of the combined Company. The unaudited supplemental proforma consolidated
results reflect the historical financial information of the Company and NanoSynex, adjusted to give effect to the NanoSynex Acquisition
as if it had occurred on January 1, 2021, as well as to record NanoSynex stock compensation expense and to record the net loss related
to the non-controlling interest, in accordance with generally accepted accounting principles:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"/&gt;&lt;p id="xdx_89D_eus-gaap--BusinessAcquisitionProFormaInformationTextBlock_zXMOHqz5Mwlb" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8BD_zFvG4O9lWCI5" style="display: none"&gt;SCHEDULE
OF PRO FORMA INFORMATION&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center"&gt;Consolidated Pro Forma Financial&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center"&gt;Results for the Years Ending&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;Net revenue&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--BusinessAcquisitionsProFormaRevenue_c20220101__20221231_zzNPb9cAfb91" style="width: 16%; text-align: right" title="Business acquisitions pro forma revenue"&gt;4,983,556&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--BusinessAcquisitionsProFormaRevenue_c20210101__20211231_znICUMbVL3Gd" style="width: 16%; text-align: right" title="Business acquisitions pro forma revenue"&gt;5,653,725&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Net loss attributable to Qualigen Therapeutics, Inc.&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--BusinessAcquisitionsProFormaNetIncomeLoss_c20220101__20221231_z8b3BcgWawu2" style="text-align: right" title="Business acquisitions pro forma net income loss"&gt;(19,538,959&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--BusinessAcquisitionsProFormaNetIncomeLoss_c20210101__20211231_zqf918hBz2tg" style="text-align: right" title="Business acquisitions pro forma net income loss"&gt;(17,897,137&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AA_z9jgqHEF2Haa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:BusinessCombinationDisclosureTextBlock>
    <us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired
      contextRef="AsOf2022-05-26_custom_NanoSynexLtdMember"
      decimals="INF"
      unitRef="Pure">0.528</us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired>
    <us-gaap:StockIssuedDuringPeriodSharesAcquisitions
      contextRef="From2022-05-242022-05-26_custom_SeriesAOnePreferredStockMember"
      decimals="INF"
      unitRef="Shares">2232861</us-gaap:StockIssuedDuringPeriodSharesAcquisitions>
    <us-gaap:StockIssuedDuringPeriodSharesAcquisitions
      contextRef="From2022-05-242022-05-26_custom_NanoSynexLtdMember"
      decimals="INF"
      unitRef="Shares">350000</us-gaap:StockIssuedDuringPeriodSharesAcquisitions>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2022-05-26_custom_PrefundedWarrantMember"
      decimals="INF"
      unitRef="Shares">331464</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2022-05-26_custom_NanoSynexLtdMember_custom_PrefundedWarrantMember"
      decimals="INF"
      unitRef="USDPShares">0.001</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:StockholdersEquityReverseStockSplit contextRef="From2022-05-242022-05-26_custom_NanoSynexLtdMember">these warrants were subsequently exercised on September 13, 2022)</us-gaap:StockholdersEquityReverseStockSplit>
    <us-gaap:StockIssuedDuringPeriodSharesAcquisitions
      contextRef="From2022-05-242022-05-26_custom_NanoSynexLtdMember_us-gaap_SeriesBPreferredStockMember"
      decimals="INF"
      unitRef="Shares">381786</us-gaap:StockIssuedDuringPeriodSharesAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions
      contextRef="From2022-05-242022-05-26_custom_NanoSynexLtdMember_us-gaap_SeriesBPreferredStockMember"
      decimals="0"
      unitRef="USD">600000</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_890_eus-gaap--ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_zOsbLs4POgyk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;A
summary of the consideration transferred and fair value of assets acquired and liabilities assumed in the NanoSynex Acquisition is as
follows (all shares shown post 1 for 10 reverse split on November 23, 2022):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B8_zhGesOfCesRi" style="display: none"&gt;SCHEDULE
OF CONSIDERATION TRANSFERRED&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;Consideration transferred, net of cash acquired&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 80%; text-align: left; padding-bottom: 1.5pt"&gt;Cash paid for NanoSynex preferred stock:&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_ecustom--PaymentsToAcquireBusinesses_pp0p0_c20220524__20220526__us-gaap--BusinessAcquisitionAxis__custom--NanoSynexLtdMember_zs1OfV4i1qV1" style="border-bottom: Black 1.5pt solid; width: 16%; text-align: right" title="Cash paid for NanoSynex preferred stock:"&gt;600,000&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;FMV of &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIENPTlNJREVSQVRJT04gVFJBTlNGRVJSRUQgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_905_eus-gaap--StockIssuedDuringPeriodSharesAcquisitions_c20220524__20220526__us-gaap--BusinessAcquisitionAxis__custom--NanoSynexLtdMember_zkEfDIX9oqbc" title="Common stock issued for business acquisition"&gt;350,000&lt;/span&gt; shares of Qualigen stock issued to Alpha Capital Anstalt&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--StockIssuedDuringPeriodValueAcquisitions_pp0p0_c20220524__20220526__us-gaap--BusinessAcquisitionAxis__custom--NanoSynexLtdMember_zxs0bN5NF5Ui" style="text-align: right" title="FMV of 3,500,000 shares of Qualigen stock issued to Alpha Capital Anstalt"&gt;1,904,989&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;FMV of &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIENPTlNJREVSQVRJT04gVFJBTlNGRVJSRUQgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90F_eus-gaap--StockIssuedDuringPeriodSharesAcquisitions_c20220524__20220526__us-gaap--BusinessAcquisitionAxis__custom--AlphaCapitalAnstaltMember_zdIwRg5Vz5Jl" title="Common stock issued for business acquisition"&gt;331,464&lt;/span&gt;
    shares of Qualigen stock related to prefunded warrant issued to Alpha Capital Anstalt (See Note 15)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_ecustom--PrefundedWarrantsIssuedForBusinessAcquisition_pp0p0_c20220524__20220526__us-gaap--BusinessAcquisitionAxis__custom--NanoSynexLtdMember_zjG0dIRqPrIe" style="border-bottom: Black 1.5pt solid; text-align: right" title="FMV of 3,314,641 shares of Qualigen stock related to prefunded warrant issued to Alpha Capital Anstalt"&gt;1,804,102&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Total consideration paid for NanoSynex preferred stock&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--BusinessCombinationConsiderationTransferred1_pp0p0_c20220524__20220526__us-gaap--BusinessAcquisitionAxis__custom--NanoSynexLtdMember_zf0PuKozuuF2" style="border-bottom: Black 1.5pt solid; text-align: right" title="Total consideration paid for NanoSynex common stock"&gt;3,709,091&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td id="xdx_F47_zewy4rTtnOag" style="text-align: left; padding-bottom: 1.5pt"&gt;FMV of consideration related to related to repricing of &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIENPTlNJREVSQVRJT04gVFJBTlNGRVJSRUQgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesAcquisitions_c20220524__20220526_zZyBkxTCAyp7" title="Common stock issued for business acquisition"&gt;7,048&lt;/span&gt; shares of Alpha Capital/Qualigen warrants *&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_ecustom--FairValueOfWarrantModificationForBusinessAcquisition_pp0p0_c20220524__20220526__us-gaap--BusinessAcquisitionAxis__custom--NanoSynexLtdMember_fKg_____zeuMe7mz3ow5" style="border-bottom: Black 1.5pt solid; text-align: right" title="FMV of consideration related to related to repricing of 70,478 shares of Alpha Capital/Qualigen warrants *"&gt;696&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;NanoSynex cash acquired&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--CashAcquiredFromAcquisition_iN_pp0p0_di_c20220524__20220526__us-gaap--BusinessAcquisitionAxis__custom--NanoSynexLtdMember_zdeO6GLj5Olf" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right" title="NanoSynex cash acquired"&gt;(735,354&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt"&gt;Total consideration transferred, net of cash acquired&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--PaymentsToAcquireBusinessesNetOfCashAcquired_pp0p0_c20220524__20220526__us-gaap--BusinessAcquisitionAxis__custom--NanoSynexLtdMember_z9onq8HthZe4" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right" title="Total consideration transferred, net of cash acquired"&gt;3,574,433&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td id="xdx_F01_zHAnwfOGCQR6" style="width: 15pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span id="xdx_F19_z5NxVo6luna4" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;See disclosure
under &lt;i&gt;Noncompensatory Equity Classified Warrants&lt;/i&gt; regarding May 26, 2022 transaction-Note 15-Stockholders&#x2019; Equity&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;


</us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock>
    <QLGN:PaymentsToAcquireBusinesses
      contextRef="From2022-05-242022-05-26_custom_NanoSynexLtdMember"
      decimals="0"
      unitRef="USD">600000</QLGN:PaymentsToAcquireBusinesses>
    <us-gaap:StockIssuedDuringPeriodSharesAcquisitions
      contextRef="From2022-05-242022-05-26_custom_NanoSynexLtdMember"
      decimals="INF"
      unitRef="Shares">350000</us-gaap:StockIssuedDuringPeriodSharesAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions
      contextRef="From2022-05-242022-05-26_custom_NanoSynexLtdMember"
      decimals="0"
      unitRef="USD">1904989</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <us-gaap:StockIssuedDuringPeriodSharesAcquisitions
      contextRef="From2022-05-242022-05-26_custom_AlphaCapitalAnstaltMember"
      decimals="INF"
      unitRef="Shares">331464</us-gaap:StockIssuedDuringPeriodSharesAcquisitions>
    <QLGN:PrefundedWarrantsIssuedForBusinessAcquisition
      contextRef="From2022-05-242022-05-26_custom_NanoSynexLtdMember"
      decimals="0"
      unitRef="USD">1804102</QLGN:PrefundedWarrantsIssuedForBusinessAcquisition>
    <us-gaap:BusinessCombinationConsiderationTransferred1
      contextRef="From2022-05-242022-05-26_custom_NanoSynexLtdMember"
      decimals="0"
      unitRef="USD">3709091</us-gaap:BusinessCombinationConsiderationTransferred1>
    <us-gaap:StockIssuedDuringPeriodSharesAcquisitions
      contextRef="From2022-05-242022-05-26"
      decimals="INF"
      unitRef="Shares">7048</us-gaap:StockIssuedDuringPeriodSharesAcquisitions>
    <QLGN:FairValueOfWarrantModificationForBusinessAcquisition
      contextRef="From2022-05-242022-05-26_custom_NanoSynexLtdMember"
      decimals="0"
      id="Fact000879"
      unitRef="USD">696</QLGN:FairValueOfWarrantModificationForBusinessAcquisition>
    <us-gaap:CashAcquiredFromAcquisition
      contextRef="From2022-05-242022-05-26_custom_NanoSynexLtdMember"
      decimals="0"
      unitRef="USD">735354</us-gaap:CashAcquiredFromAcquisition>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="From2022-05-242022-05-26_custom_NanoSynexLtdMember"
      decimals="0"
      unitRef="USD">3574433</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_892_eus-gaap--ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_zZYSY9jhcOy9" style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B2_zP1gRBl98nNb" style="display: none"&gt;SCHEDULE
OF ASSETS ACQUIRED AND LIABILITIES&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_497_20220526_zyjYIFjvvDcl" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Purchase Price Allocation&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_iI_ziI0KgaE9ZF" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; width: 80%; text-align: left"&gt;Accounts receivable&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;75,336&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_iI_z9T12KJnysSj" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Property and equipment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;120,942&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_ecustom--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedResearchAndDevelopmentExpense_iI_zHDGLPvjxUth" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;In process R&amp;amp;D&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5,700,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_iNI_di_zDPdWepmReW9" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Accounts payable&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(4,588&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_ecustom--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpensesAndOtherPayables_iI_zTQOiTkoF3m4" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Accrued expenses and other payables&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(291,093&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_ecustom--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedResearchAndDevelopmentGrantLiability_iI_z3fOD7mPKuek" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;R&amp;amp;D grant liability&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(1,362,264&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_ecustom--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesShortTermDebt_iI_zYMnPbk7tEMk" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Short term debt&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(941,898&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_iNI_di_zuieaCdeGej4" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Deferred tax liability&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(629,379&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedLessNoncontrollingInterest_iI_zGNbjPAzXf98" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt"&gt;Noncontrolling interest assumed&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(3,882,225&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_iNI_di_z8X9huu3FFX4" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 20pt; text-align: left"&gt;Identifiable net assets acquired&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(1,215,169&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--Goodwill_iI_zm5gS7WIrxP2" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; padding-bottom: 1.5pt"&gt;Goodwill&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;4,789,602&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_iI_zQUA13f31O1e" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt"&gt;Total consideration transferred, net of cash acquired&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"&gt;3,574,433&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables contextRef="AsOf2022-05-26" decimals="0" unitRef="USD">75336</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment contextRef="AsOf2022-05-26" decimals="0" unitRef="USD">120942</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment>
    <QLGN:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedResearchAndDevelopmentExpense contextRef="AsOf2022-05-26" decimals="0" unitRef="USD">5700000</QLGN:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedResearchAndDevelopmentExpense>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable contextRef="AsOf2022-05-26" decimals="0" unitRef="USD">4588</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable>
    <QLGN:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpensesAndOtherPayables contextRef="AsOf2022-05-26" decimals="0" unitRef="USD">-291093</QLGN:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpensesAndOtherPayables>
    <QLGN:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedResearchAndDevelopmentGrantLiability contextRef="AsOf2022-05-26" decimals="0" unitRef="USD">-1362264</QLGN:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedResearchAndDevelopmentGrantLiability>
    <QLGN:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesShortTermDebt contextRef="AsOf2022-05-26" decimals="0" unitRef="USD">-941898</QLGN:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesShortTermDebt>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities contextRef="AsOf2022-05-26" decimals="0" unitRef="USD">629379</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedLessNoncontrollingInterest contextRef="AsOf2022-05-26" decimals="0" unitRef="USD">-3882225</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedLessNoncontrollingInterest>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets contextRef="AsOf2022-05-26" decimals="0" unitRef="USD">1215169</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets>
    <us-gaap:Goodwill contextRef="AsOf2022-05-26" decimals="0" unitRef="USD">4789602</us-gaap:Goodwill>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet contextRef="AsOf2022-05-26" decimals="0" unitRef="USD">3574433</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet>
    <us-gaap:MinorityInterestDecreaseFromRedemptions
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">117775</us-gaap:MinorityInterestDecreaseFromRedemptions>
    <us-gaap:GoodwillPeriodIncreaseDecrease
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">106621</us-gaap:GoodwillPeriodIncreaseDecrease>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions
      contextRef="From2022-01-012022-12-31_custom_NanoSynexMember"
      decimals="-5"
      unitRef="USD">10400000</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <us-gaap:OtherComprehensiveIncomeLossTax
      contextRef="From2022-01-012022-12-31_custom_NanoSynexLtdMember"
      decimals="-5"
      unitRef="USD">5100000</us-gaap:OtherComprehensiveIncomeLossTax>
    <us-gaap:OtherComprehensiveIncomeLossTax
      contextRef="From2021-01-012021-12-31_custom_NanoSynexLtdMember"
      decimals="0"
      unitRef="USD">0</us-gaap:OtherComprehensiveIncomeLossTax>
    <us-gaap:BusinessAcquisitionProFormaInformationTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_89D_eus-gaap--BusinessAcquisitionProFormaInformationTextBlock_zXMOHqz5Mwlb" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8BD_zFvG4O9lWCI5" style="display: none"&gt;SCHEDULE
OF PRO FORMA INFORMATION&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center"&gt;Consolidated Pro Forma Financial&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center"&gt;Results for the Years Ending&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;Net revenue&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--BusinessAcquisitionsProFormaRevenue_c20220101__20221231_zzNPb9cAfb91" style="width: 16%; text-align: right" title="Business acquisitions pro forma revenue"&gt;4,983,556&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--BusinessAcquisitionsProFormaRevenue_c20210101__20211231_znICUMbVL3Gd" style="width: 16%; text-align: right" title="Business acquisitions pro forma revenue"&gt;5,653,725&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Net loss attributable to Qualigen Therapeutics, Inc.&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--BusinessAcquisitionsProFormaNetIncomeLoss_c20220101__20221231_z8b3BcgWawu2" style="text-align: right" title="Business acquisitions pro forma net income loss"&gt;(19,538,959&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--BusinessAcquisitionsProFormaNetIncomeLoss_c20210101__20211231_zqf918hBz2tg" style="text-align: right" title="Business acquisitions pro forma net income loss"&gt;(17,897,137&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:BusinessAcquisitionProFormaInformationTextBlock>
    <us-gaap:BusinessAcquisitionsProFormaRevenue
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">4983556</us-gaap:BusinessAcquisitionsProFormaRevenue>
    <us-gaap:BusinessAcquisitionsProFormaRevenue
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">5653725</us-gaap:BusinessAcquisitionsProFormaRevenue>
    <us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">-19538959</us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss>
    <us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">-17897137</us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss>
    <us-gaap:InventoryDisclosureTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_807_eus-gaap--InventoryDisclosureTextBlock_zM22F3ZlaLD3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
4 &#x2014; &lt;span id="xdx_820_zmgcWUUon9si"&gt;INVENTORY, NET&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89A_eus-gaap--ScheduleOfInventoryCurrentTableTextBlock_zBA3nzCi8nXf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Inventory,
net consisted of the following at December 31, 2022 and December 31, 2021:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B4_zl936wY2g2zk" style="display: none"&gt;SCHEDULE OF INVENTORY&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49D_20221231_zPIw4EdGbJF5" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31,&lt;br/&gt;
 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_492_20211231_zBFmkgZkZj17" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31,&lt;br/&gt;
 2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--InventoryRawMaterials_iI_maIFGz0my_ztIAItWFXVpe" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;Raw materials&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;949,796&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;823,315&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--InventoryWorkInProcess_iI_maIFGz0my_zqzR4p4q4kz6" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Work in process&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;200,318&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;188,135&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--InventoryFinishedGoods_iI_maIFGz0my_zOgIAUswNtX7" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Finished goods&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;436,183&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;44,428&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--InventoryNet_iTI_mtIFGz0my_zzqttACnIBTg" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Total inventory&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,586,297&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,055,878&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A7_z4ocf0uz3Wv6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:InventoryDisclosureTextBlock>
    <us-gaap:ScheduleOfInventoryCurrentTableTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_89A_eus-gaap--ScheduleOfInventoryCurrentTableTextBlock_zBA3nzCi8nXf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Inventory,
net consisted of the following at December 31, 2022 and December 31, 2021:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B4_zl936wY2g2zk" style="display: none"&gt;SCHEDULE OF INVENTORY&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49D_20221231_zPIw4EdGbJF5" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31,&lt;br/&gt;
 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_492_20211231_zBFmkgZkZj17" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31,&lt;br/&gt;
 2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--InventoryRawMaterials_iI_maIFGz0my_ztIAItWFXVpe" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;Raw materials&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;949,796&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;823,315&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--InventoryWorkInProcess_iI_maIFGz0my_zqzR4p4q4kz6" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Work in process&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;200,318&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;188,135&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--InventoryFinishedGoods_iI_maIFGz0my_zOgIAUswNtX7" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Finished goods&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;436,183&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;44,428&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--InventoryNet_iTI_mtIFGz0my_zzqttACnIBTg" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Total inventory&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,586,297&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,055,878&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
    <us-gaap:InventoryRawMaterials contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">949796</us-gaap:InventoryRawMaterials>
    <us-gaap:InventoryRawMaterials contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">823315</us-gaap:InventoryRawMaterials>
    <us-gaap:InventoryWorkInProcess contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">200318</us-gaap:InventoryWorkInProcess>
    <us-gaap:InventoryWorkInProcess contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">188135</us-gaap:InventoryWorkInProcess>
    <us-gaap:InventoryFinishedGoods contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">436183</us-gaap:InventoryFinishedGoods>
    <us-gaap:InventoryFinishedGoods contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">44428</us-gaap:InventoryFinishedGoods>
    <us-gaap:InventoryNet contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">1586297</us-gaap:InventoryNet>
    <us-gaap:InventoryNet contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">1055878</us-gaap:InventoryNet>
    <QLGN:PrepaidExpensesAndOtherCurrentAssetsTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_80D_ecustom--PrepaidExpensesAndOtherCurrentAssetsTextBlock_z8Ubvmm1KKsa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
5 &#x2014; &lt;span id="xdx_82D_zGnIs5Onxrlf"&gt;PREPAID EXPENSES AND OTHER CURRENT ASSETS&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_896_eus-gaap--DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_zbCZypHtjnw1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Prepaid
expenses and other current assets consisted of the following at December 31, 2022 and December 31, 2021:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B4_z8X22FW3VM7h" style="display: none"&gt;SCHEDULE OF PREPAID EXPENSES AND OTHER CURRENT ASSETS&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_493_20221231_zz71PbAaF8C8" style="font-weight: bold; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49B_20211231_zTidS1QDTV7a" style="font-weight: bold; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--PrepaidInsurance_iI_pp0p0_maPECzoJ5_zBmCuDbCnSld" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;Prepaid insurance&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;1,377,323&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;1,197,726&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_ecustom--PrepaidManufacturingExpenses_iI_maPECzoJ5_zOVYhOPv484d" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Prepaid manufacturing expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;43,820&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;67,410&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--OtherPrepaidExpenseCurrent_iI_pp0p0_maPECzoJ5_zuORQtWfNO6h" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Other prepaid expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;227,451&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;111,183&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--OtherAssetsCurrent_iI_pp0p0_maPECzoJ5_zYtyYb3022Ri" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Other current assets&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;12,626&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;3,577&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_iTI_pp0p0_mtPECzoJ5_znJgfhRZQd8f" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Prepaid expenses and
    other current assets&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,661,220&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,379,896&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</QLGN:PrepaidExpensesAndOtherCurrentAssetsTextBlock>
    <us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_896_eus-gaap--DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_zbCZypHtjnw1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Prepaid
expenses and other current assets consisted of the following at December 31, 2022 and December 31, 2021:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B4_z8X22FW3VM7h" style="display: none"&gt;SCHEDULE OF PREPAID EXPENSES AND OTHER CURRENT ASSETS&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_493_20221231_zz71PbAaF8C8" style="font-weight: bold; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49B_20211231_zTidS1QDTV7a" style="font-weight: bold; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--PrepaidInsurance_iI_pp0p0_maPECzoJ5_zBmCuDbCnSld" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;Prepaid insurance&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;1,377,323&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;1,197,726&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_ecustom--PrepaidManufacturingExpenses_iI_maPECzoJ5_zOVYhOPv484d" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Prepaid manufacturing expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;43,820&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;67,410&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--OtherPrepaidExpenseCurrent_iI_pp0p0_maPECzoJ5_zuORQtWfNO6h" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Other prepaid expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;227,451&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;111,183&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--OtherAssetsCurrent_iI_pp0p0_maPECzoJ5_zYtyYb3022Ri" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Other current assets&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;12,626&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;3,577&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_iTI_pp0p0_mtPECzoJ5_znJgfhRZQd8f" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Prepaid expenses and
    other current assets&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,661,220&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,379,896&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock>
    <us-gaap:PrepaidInsurance contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">1377323</us-gaap:PrepaidInsurance>
    <us-gaap:PrepaidInsurance contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">1197726</us-gaap:PrepaidInsurance>
    <QLGN:PrepaidManufacturingExpenses contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">43820</QLGN:PrepaidManufacturingExpenses>
    <QLGN:PrepaidManufacturingExpenses contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">67410</QLGN:PrepaidManufacturingExpenses>
    <us-gaap:OtherPrepaidExpenseCurrent contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">227451</us-gaap:OtherPrepaidExpenseCurrent>
    <us-gaap:OtherPrepaidExpenseCurrent contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">111183</us-gaap:OtherPrepaidExpenseCurrent>
    <us-gaap:OtherAssetsCurrent contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">12626</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">3577</us-gaap:OtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">1661220</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">1379896</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_80D_eus-gaap--PropertyPlantAndEquipmentDisclosureTextBlock_zyIuG3aX4Hy6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
6 &#x2014; &lt;span id="xdx_82A_zj9JWUvK6HB2"&gt;PROPERTY AND EQUIPMENT, NET&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_896_eus-gaap--PropertyPlantAndEquipmentTextBlock_zwUq8vngJ0o6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Property
and equipment, net consisted of the following at December 31, 2022 and December 31, 2021:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span id="xdx_8B7_zwHYaspSTkb4" style="display: none"&gt;SCHEDULE OF PROPERTY AND EQUIPMENT&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49F_20221231_zJU1p80YDKNl" style="font-weight: bold; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_497_20211231_zgVH9Cax4sOc" style="font-weight: bold; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--PropertyPlantAndEquipmentGross_iI_pp0p0_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--MachineryAndEquipmentMember_zpueYdQY8YF8" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;Machinery and equipment&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;2,510,148&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;2,482,841&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--PropertyPlantAndEquipmentGross_iI_pp0p0_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember_zSOYXrFAcKA9" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Computer equipment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;395,836&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;345,117&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--PropertyPlantAndEquipmentGross_iI_pp0p0_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zOCk7Ja6f9A1" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Leasehold improvements&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;333,271&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;333,271&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--PropertyPlantAndEquipmentGross_iI_pp0p0_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--MoldsAndToolingMember_zT1y1bTnjWfh" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Molds and tooling&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;260,002&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;260,002&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--PropertyPlantAndEquipmentGross_iI_pp0p0_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_zd9DJwDk3yI4" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Furniture and fixtures&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;144,832&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;143,013&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--PropertyPlantAndEquipmentGross_iI_pp0p0_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--EquipmentMember_zP3Rohjc16D" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Equipment held for lease&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,399,444&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,181,211&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--PropertyPlantAndEquipmentGross_iI_ze0HrC0A1zqf" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Property and equipment, gross&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5,043,533&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4,745,455&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_di_msPPAENzZdO_zYseZPs8KDK7" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Accumulated depreciation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(4,623,446&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(4,541,238&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_ecustom--FixedAssetImpairments_iI_msPPAENzZdO_zA9FKaxLJSac" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Fixed asset impairment&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(75,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0996"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--PropertyPlantAndEquipmentNet_iI_zsy8xKqFo83a" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Property and equipment,
    net&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;345,087&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;204,217&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A4_ztzrh9YppC0j" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Depreciation
expense relating to property and equipment was approximately $&lt;span id="xdx_90F_eus-gaap--Depreciation_pp0p0_c20220101__20221231_zGvndBEQgQVb" title="Depreciation expense"&gt;92,000&lt;/span&gt; and $&lt;span id="xdx_909_eus-gaap--Depreciation_pp0p0_c20210101__20211231_zElf27B7nkce" title="Depreciation expense"&gt;73,000&lt;/span&gt; for the years ended December 31, 2022 and 2021, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Upon
termination of the Sekisui Distribution Agreement on March 31, 2022, the Company had a commitment to purchase leased FastPack rental
systems back from Sekisui at Sekisui&#x2019;s net book value, which was determined to be approximately $&lt;span id="xdx_90D_eus-gaap--PaymentsToAcquirePropertyPlantAndEquipment_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--SekisuiDistributionAgreementMember_zr2s6Wg1tnW7" title="Payments to acquire assets"&gt;154,000&lt;/span&gt;. This amount is included
in equipment held for lease in the table above and in accrued expenses at December 31, 2022. An assignment agreement is to be executed
by both parties to legally transfer title to this equipment from Sekisui to Qualigen.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_896_eus-gaap--PropertyPlantAndEquipmentTextBlock_zwUq8vngJ0o6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Property
and equipment, net consisted of the following at December 31, 2022 and December 31, 2021:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span id="xdx_8B7_zwHYaspSTkb4" style="display: none"&gt;SCHEDULE OF PROPERTY AND EQUIPMENT&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49F_20221231_zJU1p80YDKNl" style="font-weight: bold; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_497_20211231_zgVH9Cax4sOc" style="font-weight: bold; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--PropertyPlantAndEquipmentGross_iI_pp0p0_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--MachineryAndEquipmentMember_zpueYdQY8YF8" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;Machinery and equipment&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;2,510,148&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;2,482,841&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--PropertyPlantAndEquipmentGross_iI_pp0p0_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember_zSOYXrFAcKA9" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Computer equipment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;395,836&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;345,117&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--PropertyPlantAndEquipmentGross_iI_pp0p0_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zOCk7Ja6f9A1" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Leasehold improvements&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;333,271&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;333,271&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--PropertyPlantAndEquipmentGross_iI_pp0p0_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--MoldsAndToolingMember_zT1y1bTnjWfh" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Molds and tooling&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;260,002&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;260,002&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--PropertyPlantAndEquipmentGross_iI_pp0p0_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_zd9DJwDk3yI4" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Furniture and fixtures&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;144,832&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;143,013&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--PropertyPlantAndEquipmentGross_iI_pp0p0_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--EquipmentMember_zP3Rohjc16D" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Equipment held for lease&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,399,444&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,181,211&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--PropertyPlantAndEquipmentGross_iI_ze0HrC0A1zqf" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Property and equipment, gross&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5,043,533&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4,745,455&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_di_msPPAENzZdO_zYseZPs8KDK7" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Accumulated depreciation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(4,623,446&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(4,541,238&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_ecustom--FixedAssetImpairments_iI_msPPAENzZdO_zA9FKaxLJSac" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Fixed asset impairment&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(75,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0996"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--PropertyPlantAndEquipmentNet_iI_zsy8xKqFo83a" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Property and equipment,
    net&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;345,087&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;204,217&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2022-12-31_us-gaap_MachineryAndEquipmentMember"
      decimals="0"
      unitRef="USD">2510148</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2021-12-31_us-gaap_MachineryAndEquipmentMember"
      decimals="0"
      unitRef="USD">2482841</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2022-12-31_us-gaap_ComputerEquipmentMember"
      decimals="0"
      unitRef="USD">395836</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2021-12-31_us-gaap_ComputerEquipmentMember"
      decimals="0"
      unitRef="USD">345117</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2022-12-31_us-gaap_LeaseholdImprovementsMember"
      decimals="0"
      unitRef="USD">333271</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2021-12-31_us-gaap_LeaseholdImprovementsMember"
      decimals="0"
      unitRef="USD">333271</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2022-12-31_custom_MoldsAndToolingMember"
      decimals="0"
      unitRef="USD">260002</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2021-12-31_custom_MoldsAndToolingMember"
      decimals="0"
      unitRef="USD">260002</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2022-12-31_us-gaap_FurnitureAndFixturesMember"
      decimals="0"
      unitRef="USD">144832</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2021-12-31_us-gaap_FurnitureAndFixturesMember"
      decimals="0"
      unitRef="USD">143013</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2022-12-31_us-gaap_EquipmentMember"
      decimals="0"
      unitRef="USD">1399444</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2021-12-31_us-gaap_EquipmentMember"
      decimals="0"
      unitRef="USD">1181211</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">5043533</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">4745455</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">4623446</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">4541238</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <QLGN:FixedAssetImpairments contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">-75000</QLGN:FixedAssetImpairments>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">345087</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">204217</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Depreciation
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">92000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">73000</us-gaap:Depreciation>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="From2022-01-012022-12-31_custom_SekisuiDistributionAgreementMember"
      decimals="0"
      unitRef="USD">154000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_80A_eus-gaap--GoodwillAndIntangibleAssetsDisclosureTextBlock_zs0p0XkWM4ji" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
7 &#x2014; &lt;span id="xdx_826_zwBe5NfUt4D2"&gt;GOODWILL, IPR&amp;amp;D AND OTHER INTANGIBLES&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_890_eus-gaap--ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_zb1Z4BLWS9rd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span id="xdx_8BC_zBUOXlS71fsg" style="display: none"&gt;SCHEDULE
OF GOODWILL AND OTHER INTANGIBLE&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_496_20221231_zdHCMRDRg7f7" style="font-weight: bold; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_495_20211231_z5dz6BcG59Sg" style="font-weight: bold; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Estimated Useful Lives&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Gross carrying amounts&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Gross carrying amounts&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--Goodwill_iI_zXcKA7UVsgHf" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 48%; padding-bottom: 2.5pt"&gt;Goodwill&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 14%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; width: 14%; text-align: right"&gt;625,602&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; width: 14%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1012"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Finite-lived intangible assets:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_hus-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--DevelopedProductTechnologyRightsMember_zWed598pIel5" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Developed-product-technology rights&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span id="xdx_906_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dtY_c20220101__20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--DevelopedProductTechnologyRightsMember__srt--RangeAxis__srt--MinimumMember_zaqWF5dt3oFl" title="Finite lived intangible asset useful life"&gt;8&lt;/span&gt; - &lt;span id="xdx_909_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dtY_c20220101__20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--DevelopedProductTechnologyRightsMember__srt--RangeAxis__srt--MaximumMember_z6JFgJEVb2zg" title="Finite lived intangible asset useful life"&gt;17&lt;/span&gt; years&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;479,103&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;479,103&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_hus-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LicensingRightsMember_z4iPpECocP7a" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Licensing rights&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span id="xdx_905_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dtY_c20220101__20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LicensingRightsMember_z4fGm9PcNJgb" title="Finite lived intangible asset useful life"&gt;10&lt;/span&gt; years&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;418,836&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;418,836&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iNI_di_zCWaIq8XEbjl" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Less: Accumulated amortization&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(752,237&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(726,749&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_zKjOgTu1Ams7" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Total finite-lived intangible assets, net&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;145,702&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;171,190&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Indefinite-lived intangible assets:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_hus-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--InProcessResearchAndDevelopmentMember_zkdNsPD4tnbi" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 20pt; text-align: left; padding-bottom: 1.5pt"&gt;In-process research and development&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;5,700,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1033"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_zQnV9t4KQpJi" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Total other intangible assets, net&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;5,845,702&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;171,190&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AA_zMiu2tkjPu0g" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company periodically reviews goodwill for impairment in accordance with relevant accounting standards. Goodwill is attributable to
the NanoSynex Acquisition. Goodwill and intangible assets are recognized at fair value during the period in which an acquisition is
completed, from updated estimates during the measurement period, or when they are considered to be impaired. These non-recurring
fair value measurements, primarily for goodwill and intangible assets acquired, were based on Level 3 inputs. The Company estimates
the fair value of long-lived assets on a non-recurring basis based on a market valuation approach, engaging independent valuation
experts to assist in the determination of fair value. In the fourth quarter of fiscal 2022, in conjunction with the annual
impairment assessment, the Company determined that the fair value of the reporting unit was less than the carrying value. In
addition to continued losses in the reporting unit, the Company considered macroeconomic conditions including a deterioration in the
equity markets evidenced by sustained declines in the Company&#x2019;s stock price, peer companies, and major market indices since
the acquisition date. The Company engaged independent valuation experts to assist in determining the fair value of the reporting
unit. As a result of this analysis, the Company recorded a $&lt;span id="xdx_906_eus-gaap--GoodwillImpairmentLoss_c20220101__20221231_zA2nmoahhgj8"&gt;4,239,000 &lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;goodwill and fixed asset impairment charge associated with the reporting unit.&lt;/span&gt; There were &lt;span id="xdx_90B_eus-gaap--ImpairmentOfIntangibleAssetsFinitelived_do_c20210101__20211231_zA7G4J7NFlJh"&gt;no &lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;impairments
to intangible assets and goodwill during the year ended December 31, 2021.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
carrying value of the patents of approximately $&lt;span id="xdx_901_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_c20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zL2k9bRE9po8" title="Assets gross"&gt;140,000&lt;/span&gt; and $&lt;span id="xdx_909_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_c20211231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zNKyGi9WYK89" title="Assets gross"&gt;159,000&lt;/span&gt; at December 31, 2022 and December 31, 2021, respectively, are stated
net of accumulated amortization of approximately $&lt;span id="xdx_908_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_c20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_z1eUTIF91ZRe" title="Accumulated amortization"&gt;339,000&lt;/span&gt; and $&lt;span id="xdx_902_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_c20211231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_z8I9qIoO5ria" title="Accumulated amortization"&gt;320,000&lt;/span&gt;, respectively. Amortization of patents charged to operations for
the year ended December 31, 2022 and December 31, 2021 were approximately $&lt;span id="xdx_903_eus-gaap--AmortizationOfIntangibleAssets_c20220101__20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zleS6mV8cZGf" title="Amortization of intangible assets"&gt;18,000&lt;/span&gt; and $&lt;span id="xdx_900_eus-gaap--AmortizationOfIntangibleAssets_c20210101__20211231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zROdRa2puvGh" title="Amortization of intangible assets"&gt;17,000&lt;/span&gt;, respectively. Total future estimated amortization
of patent costs for the five succeeding years is approximately $&lt;span id="xdx_90A_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_iI_c20221231_zOobvQzNfBcl" title="Future estimated amortization of patent costs Year 2023"&gt;18,000&lt;/span&gt; for the year ending December 31, 2023, approximately $&lt;span id="xdx_90B_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_iI_c20221231_zyssy5GjxBhc" title="Future estimated amortization of patent costs Year 2024"&gt;15,000&lt;/span&gt; for
the year ending December 31, 2024, approximately $&lt;span id="xdx_905_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_iI_c20221231_zX83EZKGhb5j" title="Future estimated amortization of patent costs Year 2025"&gt;&lt;span id="xdx_904_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_iI_c20221231_zUhPFiV1BBQk" title="Future estimated amortization of patent costs Year 2026"&gt;&lt;span id="xdx_905_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_iI_c20221231_zgZ1rdjuARUb" title="Future estimated amortization of patent costs Year 2027"&gt;14,000&lt;/span&gt;&lt;/span&gt;&lt;/span&gt; for years 2025, 2026 and 2027, and approximately $&lt;span id="xdx_90E_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_iI_c20221231_zgBXLNEi5rz5" title="Future estimated amortization of patent costs thereafter"&gt;65,000&lt;/span&gt; thereafter.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
carrying value of the licenses of approximately $&lt;span id="xdx_904_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_c20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicenseMember_zokqiRXfUkk5" title="Finite lived intangible assets gross"&gt;5,000&lt;/span&gt; and $&lt;span id="xdx_90E_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_c20211231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicenseMember_z9113trqX9Hh" title="Finite lived intangible assets gross"&gt;12,000&lt;/span&gt; at December 31, 2022 and December 31, 2021 are stated net of accumulated
amortization of approximately $&lt;span id="xdx_90E_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_c20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicenseMember_zf73ANwZ6VV3" title="Accumulated amortization"&gt;414,000&lt;/span&gt; and $&lt;span id="xdx_90F_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_c20211231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicenseMember_zojlMSaT70Tg" title="Accumulated amortization"&gt;407,000&lt;/span&gt;, respectively. Amortization of licenses charged to operations for the year ended
December 31, 2022 and December 31, 2021 was approximately $&lt;span id="xdx_903_eus-gaap--AmortizationOfIntangibleAssets_c20220101__20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicenseMember_zHeLVHwO1lwj" title="Licenses charged"&gt;7,000&lt;/span&gt; and $&lt;span id="xdx_904_eus-gaap--AmortizationOfIntangibleAssets_c20210101__20211231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicenseMember_zwQVdoDKyGCb" title="Licenses charged"&gt;7,000&lt;/span&gt;, respectively. Total future estimated amortization of license
costs for the five succeeding years is approximately $&lt;span id="xdx_903_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_iI_c20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicenseMember_z1mo1wC09943" title="Future estimated amortization of license costs 2023"&gt;5,000&lt;/span&gt; for the year ending December 31, 2023.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock>
    <us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_890_eus-gaap--ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_zb1Z4BLWS9rd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span id="xdx_8BC_zBUOXlS71fsg" style="display: none"&gt;SCHEDULE
OF GOODWILL AND OTHER INTANGIBLE&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_496_20221231_zdHCMRDRg7f7" style="font-weight: bold; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_495_20211231_z5dz6BcG59Sg" style="font-weight: bold; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Estimated Useful Lives&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Gross carrying amounts&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Gross carrying amounts&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--Goodwill_iI_zXcKA7UVsgHf" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 48%; padding-bottom: 2.5pt"&gt;Goodwill&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 14%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; width: 14%; text-align: right"&gt;625,602&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; width: 14%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1012"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Finite-lived intangible assets:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_hus-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--DevelopedProductTechnologyRightsMember_zWed598pIel5" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Developed-product-technology rights&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span id="xdx_906_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dtY_c20220101__20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--DevelopedProductTechnologyRightsMember__srt--RangeAxis__srt--MinimumMember_zaqWF5dt3oFl" title="Finite lived intangible asset useful life"&gt;8&lt;/span&gt; - &lt;span id="xdx_909_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dtY_c20220101__20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--DevelopedProductTechnologyRightsMember__srt--RangeAxis__srt--MaximumMember_z6JFgJEVb2zg" title="Finite lived intangible asset useful life"&gt;17&lt;/span&gt; years&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;479,103&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;479,103&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_hus-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LicensingRightsMember_z4iPpECocP7a" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Licensing rights&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span id="xdx_905_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dtY_c20220101__20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LicensingRightsMember_z4fGm9PcNJgb" title="Finite lived intangible asset useful life"&gt;10&lt;/span&gt; years&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;418,836&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;418,836&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iNI_di_zCWaIq8XEbjl" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Less: Accumulated amortization&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(752,237&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(726,749&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_zKjOgTu1Ams7" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Total finite-lived intangible assets, net&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;145,702&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;171,190&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Indefinite-lived intangible assets:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_hus-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--InProcessResearchAndDevelopmentMember_zkdNsPD4tnbi" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 20pt; text-align: left; padding-bottom: 1.5pt"&gt;In-process research and development&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;5,700,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1033"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_zQnV9t4KQpJi" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Total other intangible assets, net&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;5,845,702&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;171,190&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock>
    <us-gaap:Goodwill contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">625602</us-gaap:Goodwill>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="From2022-01-012022-12-31_custom_DevelopedProductTechnologyRightsMember_srt_MinimumMember">P8Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="From2022-01-012022-12-31_custom_DevelopedProductTechnologyRightsMember_srt_MaximumMember">P17Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="AsOf2022-12-31_custom_DevelopedProductTechnologyRightsMember"
      decimals="0"
      unitRef="USD">479103</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="AsOf2021-12-31_custom_DevelopedProductTechnologyRightsMember"
      decimals="0"
      unitRef="USD">479103</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="From2022-01-012022-12-31_custom_LicensingRightsMember">P10Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="AsOf2022-12-31_custom_LicensingRightsMember"
      decimals="0"
      unitRef="USD">418836</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="AsOf2021-12-31_custom_LicensingRightsMember"
      decimals="0"
      unitRef="USD">418836</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">752237</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">726749</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">145702</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">171190</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="AsOf2022-12-31_us-gaap_InProcessResearchAndDevelopmentMember"
      decimals="0"
      unitRef="USD">5700000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">5845702</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">171190</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">4239000</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:ImpairmentOfIntangibleAssetsFinitelived
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">0</us-gaap:ImpairmentOfIntangibleAssetsFinitelived>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="AsOf2022-12-31_us-gaap_PatentsMember"
      decimals="0"
      unitRef="USD">140000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="AsOf2021-12-31_us-gaap_PatentsMember"
      decimals="0"
      unitRef="USD">159000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="AsOf2022-12-31_us-gaap_PatentsMember"
      decimals="0"
      unitRef="USD">339000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="AsOf2021-12-31_us-gaap_PatentsMember"
      decimals="0"
      unitRef="USD">320000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="From2022-01-012022-12-31_us-gaap_PatentsMember"
      decimals="0"
      unitRef="USD">18000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="From2021-01-012021-12-31_us-gaap_PatentsMember"
      decimals="0"
      unitRef="USD">17000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">18000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">15000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">14000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">14000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">14000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">65000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="AsOf2022-12-31_us-gaap_LicenseMember"
      decimals="0"
      unitRef="USD">5000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="AsOf2021-12-31_us-gaap_LicenseMember"
      decimals="0"
      unitRef="USD">12000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="AsOf2022-12-31_us-gaap_LicenseMember"
      decimals="0"
      unitRef="USD">414000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="AsOf2021-12-31_us-gaap_LicenseMember"
      decimals="0"
      unitRef="USD">407000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="From2022-01-012022-12-31_us-gaap_LicenseMember"
      decimals="0"
      unitRef="USD">7000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="From2021-01-012021-12-31_us-gaap_LicenseMember"
      decimals="0"
      unitRef="USD">7000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
      contextRef="AsOf2022-12-31_us-gaap_LicenseMember"
      decimals="0"
      unitRef="USD">5000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>
    <us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_80D_eus-gaap--AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_zgaL5IHNqmMd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
8 &#x2014; &lt;span id="xdx_824_zYcXxQ8gw5Bi"&gt;ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_899_eus-gaap--ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_zDIhix1BX3Tf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Accrued
expenses and other current liabilities consisted of the following at December 31, 2022 and December 31, 2021:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span id="xdx_8B9_zKHaUW9L91Hh" style="display: none"&gt;SCHEDULE OF ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49D_20221231_zBbMkbGrB9md" style="font-weight: bold; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_494_20211231_ztpKeTIDF99j" style="font-weight: bold; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_ecustom--AccruedCompensation_iI_pp0p0_maALCzkYM_zOLE87lWqRI5" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;Board compensation&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;70,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;17,500&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_ecustom--AccruedEquipmentHeldForLease_iI_pp0p0_maALCzkYM_zYeN16y7xf98" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Equipment held for lease&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;154,433&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1086"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_ecustom--AccruedFranchiseSalesAndUseTaxes_iI_pp0p0_maALCzkYM_zhmSlBQL4EWg" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Franchise, sales and use taxes&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;27,531&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;14,090&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--AccruedIncomeTaxesCurrent_iI_pp0p0_maALCzkYM_zP28APwIULVa" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Income taxes&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4,663&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,620&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--InterestPayableCurrent_iI_pp0p0_maALCzkYM_zOzKyyIb5kF4" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Interest (Convertible debt - related party)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,829&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1095"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--AccruedPayrollTaxesCurrent_iI_pp0p0_maALCzkYM_zJNRO73693I4" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Payroll&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;209,303&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;682,036&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--AccruedProfessionalFeesCurrent_iI_pp0p0_maALCzkYM_zrpYF7asHehb" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Professional fees&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;238,211&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;225,308&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_ecustom--AccruedResearchAndDevelopmentCurrent_iI_pp0p0_maALCzkYM_zk7F9NtWCfb4" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Research and development&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;322,987&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;232,712&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--AccruedRoyaltiesCurrent_iI_pp0p0_maALCzkYM_zB4ANgfhV2xe" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Royalties&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;13,158&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;10,152&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--ProductWarrantyAccrual_iI_pp0p0_maALCzkYM_zMzNOQPLAo4j" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Warranty liability&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;137,568&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;60,281&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_ecustom--AccruedLicenseFees_iI_pp0p0_maALCzkYM_zPQndZ4yZ6yh" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;License fees&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;150,130&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1113"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--OtherAccruedLiabilitiesCurrent_iI_pp0p0_maALCzkYM_zNkSVNMli169" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Other&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;181,043&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;265,292&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--AccruedLiabilitiesCurrent_iTI_mtALCzkYM_zAYI6VOc0MWe" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,511,856&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,510,990&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A8_zueUm56vJTLa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock>
    <us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_899_eus-gaap--ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_zDIhix1BX3Tf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Accrued
expenses and other current liabilities consisted of the following at December 31, 2022 and December 31, 2021:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span id="xdx_8B9_zKHaUW9L91Hh" style="display: none"&gt;SCHEDULE OF ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49D_20221231_zBbMkbGrB9md" style="font-weight: bold; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_494_20211231_ztpKeTIDF99j" style="font-weight: bold; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_ecustom--AccruedCompensation_iI_pp0p0_maALCzkYM_zOLE87lWqRI5" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;Board compensation&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;70,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;17,500&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_ecustom--AccruedEquipmentHeldForLease_iI_pp0p0_maALCzkYM_zYeN16y7xf98" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Equipment held for lease&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;154,433&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1086"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_ecustom--AccruedFranchiseSalesAndUseTaxes_iI_pp0p0_maALCzkYM_zhmSlBQL4EWg" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Franchise, sales and use taxes&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;27,531&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;14,090&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--AccruedIncomeTaxesCurrent_iI_pp0p0_maALCzkYM_zP28APwIULVa" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Income taxes&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4,663&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,620&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--InterestPayableCurrent_iI_pp0p0_maALCzkYM_zOzKyyIb5kF4" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Interest (Convertible debt - related party)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,829&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1095"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--AccruedPayrollTaxesCurrent_iI_pp0p0_maALCzkYM_zJNRO73693I4" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Payroll&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;209,303&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;682,036&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--AccruedProfessionalFeesCurrent_iI_pp0p0_maALCzkYM_zrpYF7asHehb" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Professional fees&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;238,211&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;225,308&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_ecustom--AccruedResearchAndDevelopmentCurrent_iI_pp0p0_maALCzkYM_zk7F9NtWCfb4" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Research and development&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;322,987&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;232,712&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--AccruedRoyaltiesCurrent_iI_pp0p0_maALCzkYM_zB4ANgfhV2xe" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Royalties&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;13,158&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;10,152&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--ProductWarrantyAccrual_iI_pp0p0_maALCzkYM_zMzNOQPLAo4j" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Warranty liability&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;137,568&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;60,281&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_ecustom--AccruedLicenseFees_iI_pp0p0_maALCzkYM_zPQndZ4yZ6yh" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;License fees&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;150,130&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1113"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--OtherAccruedLiabilitiesCurrent_iI_pp0p0_maALCzkYM_zNkSVNMli169" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Other&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;181,043&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;265,292&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--AccruedLiabilitiesCurrent_iTI_mtALCzkYM_zAYI6VOc0MWe" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,511,856&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,510,990&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock>
    <QLGN:AccruedCompensation contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">70000</QLGN:AccruedCompensation>
    <QLGN:AccruedCompensation contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">17500</QLGN:AccruedCompensation>
    <QLGN:AccruedEquipmentHeldForLease contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">154433</QLGN:AccruedEquipmentHeldForLease>
    <QLGN:AccruedFranchiseSalesAndUseTaxes contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">27531</QLGN:AccruedFranchiseSalesAndUseTaxes>
    <QLGN:AccruedFranchiseSalesAndUseTaxes contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">14090</QLGN:AccruedFranchiseSalesAndUseTaxes>
    <us-gaap:AccruedIncomeTaxesCurrent contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">4663</us-gaap:AccruedIncomeTaxesCurrent>
    <us-gaap:AccruedIncomeTaxesCurrent contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">3620</us-gaap:AccruedIncomeTaxesCurrent>
    <us-gaap:InterestPayableCurrent contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">2829</us-gaap:InterestPayableCurrent>
    <us-gaap:AccruedPayrollTaxesCurrent contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">209303</us-gaap:AccruedPayrollTaxesCurrent>
    <us-gaap:AccruedPayrollTaxesCurrent contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">682036</us-gaap:AccruedPayrollTaxesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">238211</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">225308</us-gaap:AccruedProfessionalFeesCurrent>
    <QLGN:AccruedResearchAndDevelopmentCurrent contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">322987</QLGN:AccruedResearchAndDevelopmentCurrent>
    <QLGN:AccruedResearchAndDevelopmentCurrent contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">232712</QLGN:AccruedResearchAndDevelopmentCurrent>
    <us-gaap:AccruedRoyaltiesCurrent contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">13158</us-gaap:AccruedRoyaltiesCurrent>
    <us-gaap:AccruedRoyaltiesCurrent contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">10152</us-gaap:AccruedRoyaltiesCurrent>
    <us-gaap:ProductWarrantyAccrual contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">137568</us-gaap:ProductWarrantyAccrual>
    <us-gaap:ProductWarrantyAccrual contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">60281</us-gaap:ProductWarrantyAccrual>
    <QLGN:AccruedLicenseFees contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">150130</QLGN:AccruedLicenseFees>
    <us-gaap:OtherAccruedLiabilitiesCurrent contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">181043</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">265292</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">1511856</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">1510990</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:ShortTermDebtTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_803_eus-gaap--ShortTermDebtTextBlock_zDQGZEWRdpE3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
9 &#x2013; &lt;span id="xdx_82F_zfilWLp0PCqg"&gt;SHORT TERM DEBT - RELATED PARTY&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;NanoSynex
has four separate Notes Payable (the &#x201c;Notes&#x201d;) outstanding to Alpha Capital, dated between March 26, 2020 and September 2,
2021, aggregating to a total principal outstanding balance of $&lt;span id="xdx_900_eus-gaap--DebtInstrumentFaceAmount_iI_c20210902__us-gaap--ShortTermDebtTypeAxis__custom--NotesPayableMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NanoSynexMember_zQrNlMRSVo13" title="Short term debt principal outstanding"&gt;905,000&lt;/span&gt;, and aggregate accrued interest of $&lt;span id="xdx_90C_eus-gaap--InterestPayableCurrent_iI_pp0p0_c20221231__us-gaap--ShortTermDebtTypeAxis__custom--NotesPayableMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NanoSynexMember_zsHnjDV8n9W9" title="Accrued interest"&gt;45,722&lt;/span&gt; for a total outstanding
balance of $&lt;span id="xdx_90C_eus-gaap--ShortTermBorrowings_iI_pp0p0_c20221231__us-gaap--ShortTermDebtTypeAxis__custom--NotesPayableMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NanoSynexMember_zk1r2mvHgOzf" title="Short term debt outstanding balance"&gt;950,722&lt;/span&gt; as of December 31, 2022. The Notes all accrue interest at &lt;span id="xdx_90A_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20210902__us-gaap--ShortTermDebtTypeAxis__custom--NotesPayableMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NanoSynexMember_z3fZvCpt3kw5" title="Accrued interest rate"&gt;2.62%&lt;/span&gt; per annum, accrued daily, and provide that the full
amount of principal and interest under each Note shall be due immediately prior to a Liquidation Event (the Maturity Date) unless due
earlier in accordance with the terms of the Notes. &#x201c;Liquidation Event&#x201d; means either i) the merger or consolidation of NanoSynex
into any other entity, other than one in control or under control of NanoSynex or NanoSynex&#x2019;s majority shareholder; ii) a transaction
or series of transactions resulting in the transfer of all or substantially all of NanoSynex&#x2019;s assets or issued and outstanding
share capital (other than to a company under the control of NanoSynex or NanoSynex&#x2019;s majority shareholders; or iii) an underwritten
public offering by NanoSynex of its ordinary shares. Notwithstanding the above, if NanoSynex receives subsequent debt, convertible debt,
or equity funding with gross proceeds of USD $&lt;span id="xdx_90C_eus-gaap--ProceedsFromRelatedPartyDebt_pp0p0_c20210326__20210902__us-gaap--ShortTermDebtTypeAxis__custom--NotesPayableMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NanoSynexMember_zDc0R3RsSkVj" title="Proceeds from related party debt"&gt;3,000,000&lt;/span&gt; or more, then these Notes shall be due and payable upon the actual receipt of
such funding.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b/&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b/&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"/&gt;

&lt;p style="margin: 0"/&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b/&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b/&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:ShortTermDebtTextBlock>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="AsOf2021-09-02_custom_NotesPayableMember_custom_NanoSynexMember"
      decimals="0"
      unitRef="USD">905000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:InterestPayableCurrent
      contextRef="AsOf2022-12-31_custom_NotesPayableMember_custom_NanoSynexMember"
      decimals="0"
      unitRef="USD">45722</us-gaap:InterestPayableCurrent>
    <us-gaap:ShortTermBorrowings
      contextRef="AsOf2022-12-31_custom_NotesPayableMember_custom_NanoSynexMember"
      decimals="0"
      unitRef="USD">950722</us-gaap:ShortTermBorrowings>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="AsOf2021-09-02_custom_NotesPayableMember_custom_NanoSynexMember"
      decimals="INF"
      unitRef="Pure">0.0262</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:ProceedsFromRelatedPartyDebt
      contextRef="From2021-03-262021-09-02_custom_NotesPayableMember_custom_NanoSynexMember"
      decimals="0"
      unitRef="USD">3000000</us-gaap:ProceedsFromRelatedPartyDebt>
    <QLGN:WarrantLiabilitiesTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_800_ecustom--WarrantLiabilitiesTextBlock_zTNKi3pAAyR" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
10 &#x2013; &lt;span id="xdx_823_zr13o4sFvmg6"&gt;WARRANT LIABILITIES&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
2004, the Company issued warrants to various investors and brokers for the purchase of Series C preferred stock in connection with a
private placement (the &#x201c;Series C Warrants&#x201d;). The Series C Warrants were subsequently extended and, upon closing of the reverse
recapitalization transaction with Ritter, exchanged for warrants to purchase common stock of the Company, pursuant to the Series C Warrant
terms as adjusted.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
exchange for the Series C Warrants, upon closing of the merger with Ritter, the holders received warrants to purchase shares of the Company&#x2019;s
common stock at $&lt;span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20221231__us-gaap--StatementEquityComponentsAxis__custom--SeriesCWarrantsMember_z2NoJyddELoi"&gt;7.195
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;per share, subject to adjustment. As of December
31, 2022, the warrants have remaining terms ranging from &lt;span id="xdx_90E_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20221231__srt--RangeAxis__srt--MinimumMember__us-gaap--StatementEquityComponentsAxis__custom--SeriesCWarrantsMember_z6gB9ujWHnN3"&gt;0.90
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;to &lt;span id="xdx_90C_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20221231__srt--RangeAxis__srt--MaximumMember__us-gaap--StatementEquityComponentsAxis__custom--SeriesCWarrantsMember_zI59ZOuW8Nra"&gt;1.49
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;years. The warrants were determined to be liability-classified
pursuant to the guidance in ASC 480 and ASC 815-40, resulting from inclusion of a leveraged ratchet provision for subsequent dilutive
issuances. On April 25, 2022 the warrants were repriced from $&lt;span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20220425__srt--RangeAxis__srt--MaximumMember_zjDFXDHgRwOh"&gt;7.195
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;to $&lt;span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20220425__srt--RangeAxis__srt--MinimumMember_zGbBu03voTtl"&gt;6.00
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;with an additional &lt;span id="xdx_903_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20220423__20220425__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember_zc1BDoKqkEFl"&gt;49,318
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;ratchet shares issued, and on May 26 2022 the
warrants were repriced from $&lt;span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20220526__srt--RangeAxis__srt--MaximumMember_zTC0bcXzw7Ef"&gt;6.00
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;to $&lt;span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20220526__srt--RangeAxis__srt--MinimumMember_zwTvwWquk3k3"&gt;5.136
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;with an additional &lt;span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20220523__20220526__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember_zPaScz4ZUk0f"&gt;49,952
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;ratchet shares issued. On December 22, 2022 the
warrants were repriced again from $&lt;span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20221222__srt--RangeAxis__srt--MaximumMember_zl0Lk6bDRGG2"&gt;5.136
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;to $&lt;span id="xdx_901_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20221222__srt--RangeAxis__srt--MinimumMember_z1GvwYAJ8Eh2"&gt;1.32
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;with an additional &lt;span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20221219__20221222__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember_zcgnKiHGAeNk"&gt;1,002,717
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;ratchet shares issued.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Additionally,
on December 22, 2022, in conjunction with the issuance of Convertible Debt - Related Party (Note 11), the Company issued to
Alpha Capital a warrant to purchase &lt;span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20221222__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember_z5ojSDPH9vd1" title="Warrant to purchase shares"&gt;2,500,000&lt;/span&gt;
shares of the Company&#x2019;s common stock. The exercise price of the warrant is $&lt;span id="xdx_905_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20221222__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember_zyiFGSys0NIj" title="Exercise price of warrant"&gt;1.65&lt;/span&gt;
(equal to &lt;span id="xdx_90A_ecustom--ConversionPricePercentage_dp_uPure_c20221219__20221222__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember_zlZOsLU6OjP7" title="Conversion price percentage"&gt;125%&lt;/span&gt;
of the conversion price of the Debenture on the closing date). The warrant may be exercised by Alpha, in whole or in part, at any
time on or after June 22, 2023 and before June 22, 2028, subject to certain terms conditions described in the warrant, including the
Company&#x2019;s receipt of the necessary stockholder approvals.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;





&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_892_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zi4R4vr76wV6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table summarizes the activity in liability classified warrants for the year ended December 31, 2022:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span id="xdx_8B9_zlbDiViAHMLj" style="display: none"&gt;SCHEDULE OF WARRANTS ACTIVITY&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Common Stock Warrants&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Shares&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Weighted&#x2013;&lt;br/&gt; Average&lt;br/&gt; Exercise&lt;br/&gt;
    Price&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Range of Exercise&lt;br/&gt; Price&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Weighted&#x2013;&lt;br/&gt; Average&lt;br/&gt; Remaining
    Life (Years)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 40%"&gt;Total outstanding &#x2013; December 31, 2021&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20220101__20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zgRZ9lBrrAU4" style="width: 11%; text-align: right" title="Number of Shares, Warrants Outstanding Beginning"&gt;248,162&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iS_c20220101__20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zdHaBnbdKIxk" style="width: 11%; text-align: right" title="Weighted Average Exercise Price Per Share Warrants Outstanding Beginning"&gt;7.20&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;&lt;span id="xdx_90B_ecustom--RangeOfExercisePrice_iS_c20220101__20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zDEOdKz4r8sd" title="Range of Exercise Beginning"&gt;7.20&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;&lt;span id="xdx_907_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAveragRemainingContractualTerm1_dtY_c20210101__20211231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zEg9rAw2F3tg" title="Weighted Averag Remaining Contractual Term"&gt;2.00&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt"&gt;Exercised&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_di_c20220101__20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_z4v1hFTq5Sdf" style="text-align: right" title="Number of Shares, Warrants Exercised"&gt;(536&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedInPeriodWeightedAverageExercisePrice_c20220101__20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zNez6fhlXGcj" style="text-align: right" title="Weighted Average Exercise Price Per Share Warrants Exercised"&gt;7.20&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt"&gt;Forfeited&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_iN_di_c20220101__20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zwKh1cVFEL3e" style="text-align: right" title="Number of Shares, Warrants Forfeited"&gt;(247,625&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedInPeriodWeightedAverageExercisePrice_c20220101__20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zMKKnE0lOn3l" style="text-align: right" title="Weighted Average Exercise Price Per Share Warrants Forfeited"&gt;7.20&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt"&gt;Expired&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_c20220101__20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zly3pspvqndi" style="text-align: right" title="Number of Shares, Warrants Expired"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1171"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInPeriodWeightedAverageExercisePrice_c20220101__20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zN1SodGJJ9H4" style="text-align: right" title="Weighted Average Exercise Price Per Share Warrants Expired"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1173"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; padding-bottom: 1.5pt"&gt;Granted&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20220101__20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zIovgXO5mrPg" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Shares, Warrants Granted"&gt;3,849,570&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice_c20220101__20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zBUeAcTQIYuj" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Exercise Price Per Share Warrants Granted"&gt;1.53&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Total outstanding &#x2013; December 31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_c20220101__20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zFsS5v1SLk0h" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Shares, Warrants Outstanding Ending"&gt;3,849,571&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iE_c20220101__20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zP8I6u5b9Rfg" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price Per Share Warrants Outstanding Ending"&gt;1.53&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&lt;span id="xdx_90F_ecustom--RangeOfExercisePrice_iE_c20220101__20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember__srt--RangeAxis__srt--MinimumMember_ziMXfIKHccal" title="Range of Exercise Ending"&gt;1.32&lt;/span&gt; - &lt;span id="xdx_900_ecustom--RangeOfExercisePrice_iE_c20220101__20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember__srt--RangeAxis__srt--MaximumMember_ztM5JNlu8qog" title="Range of Exercise Ending"&gt;1.65&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&lt;span id="xdx_909_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAveragRemainingContractualTerm1_dtY_c20220101__20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_z5ISRz135JAi" title="Weighted Averag Remaining Contractual Term"&gt;3.9&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Exercisable&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_iE_c20220101__20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zQgOSvu364ug" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Shares, Warrants Exercisable"&gt;1,349,571&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageVestedExercisePrice_iE_c20220101__20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_z51QXKjozQH9" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price Per Share Exercisable"&gt;1.32&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_ecustom--RangeOfExercisePriceExercisableVested_iE_c20220101__20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zwFbKLcsDzlc" style="border-bottom: Black 2.5pt double; text-align: right" title="Range of Exercise Price, Exercisable"&gt;1.32&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_90F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNonExercisableWeightedAverageRemainingContractualTerm1_dtY_c20220101__20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zqzXgGiB5XWk" title="Exercisable Weighted Average Remaining Contractual Term"&gt;1.00&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table summarizes the activity in the Common Stock Warrants received in exchange for the Series C Warrants for the year ended
December 31, 2021:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Common Stock Warrants&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Shares&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Weighted&#x2013; Average&lt;br/&gt; Exercise&lt;br/&gt;
    Price&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Range of Exercise&lt;br/&gt; Price&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Weighted&#x2013;&lt;br/&gt; Average&lt;br/&gt; Remaining&lt;br/&gt;
    Life (Years)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 40%; text-align: left"&gt;Total outstanding &#x2013;December 31, 2020&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_pid_c20210101__20211231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zH77yzJp8ctc" style="width: 11%; text-align: right" title="Number of Shares, Warrants Outstanding Beginning"&gt;337,860&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iS_c20210101__20211231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zImbi4AYEEEh" style="width: 11%; text-align: right" title="Weighted Average Exercise Price Per Share Warrants Outstanding Beginning"&gt;7.20&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt"&gt;Exercised&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_pid_di_c20210101__20211231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zfpK04P8y6g3" style="text-align: right" title="Number of Shares, Warrants Exercised"&gt;(80,731&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedInPeriodWeightedAverageExercisePrice_c20210101__20211231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zD3Kkx3xf4s2" style="text-align: right" title="Weighted Average Exercise Price Per Share Warrants Exercised"&gt;7.20&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt"&gt;Forfeited&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_iN_pid_di_c20210101__20211231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zobya8eIBZu4" style="text-align: right" title="Number of Shares, Warrants Forfeited"&gt;(8,967&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedInPeriodWeightedAverageExercisePrice_c20210101__20211231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zDjLjuPENNR6" style="text-align: right" title="Weighted Average Exercise Price Per Share Warrants Forfeited"&gt;7.20&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt"&gt;Expired&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_pid_c20210101__20211231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zFC5SgAGzsEf" style="text-align: right" title="Number of Shares, Warrants Expired"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1209"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInPeriodWeightedAverageExercisePrice_c20210101__20211231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_z7nycVmTb8B" style="text-align: right" title="Weighted Average Exercise Price Per Share Warrants Expired"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1211"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; padding-bottom: 1.5pt"&gt;Granted&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pid_c20210101__20211231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zHOeD4mc3zk8" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Shares, Warrants Granted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1213"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice_c20210101__20211231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_z8XNUGVPEb2" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Exercise Price Per Share Warrants Granted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1215"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Total outstanding &#x2013; December 31, 2021&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_pid_c20210101__20211231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zvGIKed08Dji" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Shares, Warrants Outstanding Ending"&gt;248,162&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iE_c20210101__20211231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zCk65p5rvzGj" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price Per Share Warrants Outstanding Ending"&gt;7.20&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Exercisable&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_iE_c20210101__20211231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zBkvGyDabBh5" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Shares, Warrants Exercisable"&gt;248,162&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageVestedExercisePrice_iE_c20210101__20211231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_ztQSbDCkta6l" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price Per Share Exercisable"&gt;7.20&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_ecustom--RangeOfExercisePriceExercisableVested_iI_c20211231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zEu6lMmQ7Yj" style="border-bottom: Black 2.5pt double; text-align: right" title="Range of Exercise Price, Exercisable"&gt;7.20&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_901_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNonExercisableWeightedAverageRemainingContractualTerm1_dtY_c20210101__20211231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zoFCBLkRSPC9" title="Exercisable Weighted Averag Remaining Contractual Term"&gt;2.00&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A0_zIsFfauJIwP7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_891_ecustom--ScheduleOfFairValueHierarchyForWarrantLiabilitiesTableTextBlock_ztNQLBf0mxnf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table presents the Company&#x2019;s fair value hierarchy for its Common Stock Warrant liabilities measured at fair value on
a recurring basis as of December 31, 2022:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span id="xdx_8BC_zcaqBHalynh3" style="display: none"&gt;SCHEDULE OF FAIR VALUE HIERARCHY FOR WARRANT LIABILITIES&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Quoted&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Market&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Significant&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Prices for&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Other&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Significant&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Identical&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Observable&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Unobservable&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Assets&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Inputs&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Inputs&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Common Stock Warrant liabilities&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;(Level 1)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;(Level 2)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;(Level 3)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 40%"&gt;Balance as of December 31, 2021&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_ecustom--FairValueAdjustmentOfWarrant_iS_pp0p0_c20220101__20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zA7XDLaSeJp7" style="width: 11%; text-align: right" title="Fair value for warrant liabilities"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1231"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_ecustom--FairValueAdjustmentOfWarrant_iS_pp0p0_c20220101__20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_z9ZvtjE2OlEl" style="width: 11%; text-align: right" title="Fair value for warrant liabilities"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1233"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_ecustom--FairValueAdjustmentOfWarrant_iS_pp0p0_c20220101__20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z4eVzr78nfqg" style="width: 11%; font-weight: bold; text-align: right" title="Fair value for warrant liabilities"&gt;1,686,200&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_ecustom--FairValueAdjustmentOfWarrant_iS_pp0p0_c20220101__20221231_zQW5z8Rhuhi8" style="width: 11%; font-weight: bold; text-align: right" title="Fair value for warrant liabilities, beginning balance"&gt;1,686,200&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Exercises&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_ecustom--FairValueOfWarrantLiabilitiesOnDateOfExercise_iN_pp0p0_di_c20220101__20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zGCennZ52Y2b" style="text-align: right" title="Common Stock Warrant liabilities, Exercises"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1239"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_ecustom--FairValueOfWarrantLiabilitiesOnDateOfExercise_iN_pp0p0_di_c20220101__20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zdSg6uJAd9a2" style="text-align: right" title="Common Stock Warrant liabilities, Exercises"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1241"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_ecustom--FairValueOfWarrantLiabilitiesOnDateOfExercise_iN_pp0p0_di_c20220101__20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zeARMJfHa1kf" style="font-weight: bold; text-align: right" title="Common Stock Warrant liabilities, Exercises"&gt;(858&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_ecustom--FairValueOfWarrantLiabilitiesOnDateOfExercise_iN_pp0p0_di_c20220101__20221231_zuK1t4bnPMHi" style="font-weight: bold; text-align: right" title="Common Stock Warrant liabilities, Exercises"&gt;(858&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Issuance of Alpha warrants&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_ecustom--FairValueOfWarrantLiabilitiesIssuanceOfAlphaWarrants_iN_pp0p0_di_c20220101__20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_z3KPQHnVEkj6" style="font-weight: bold; text-align: right" title="Issuance of Alpha warrants"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1247"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_ecustom--FairValueOfWarrantLiabilitiesIssuanceOfAlphaWarrants_iN_pp0p0_di_c20220101__20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_ziP3TcxufO4b" style="font-weight: bold; text-align: right" title="Issuance of Alpha warrants"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1249"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_ecustom--FairValueOfWarrantLiabilitiesIssuanceOfAlphaWarrants_iN_pp0p0_di_c20220101__20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zC4IQi7vMGL9" style="font-weight: bold; text-align: right" title="Issuance of Alpha warrants"&gt;2,834,547&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_ecustom--FairValueOfWarrantLiabilitiesIssuanceOfAlphaWarrants_iN_pp0p0_di_c20220101__20221231_zkJjn6nyDGFc" style="font-weight: bold; text-align: right" title="Issuance of Alpha warrants"&gt;2,834,547&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Gain on change in fair value of warrant liabilities&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_ecustom--ChangeInFairValueOfWarrantLiabilities_pdp0_c20220101__20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_z4oIucfXRdvj" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right" title="Change in fair value of warrant liabilities"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1255"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_ecustom--ChangeInFairValueOfWarrantLiabilities_pdp0_c20220101__20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zSDM0xe7XeJ1" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right" title="Change in fair value of warrant liabilities"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1257"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_ecustom--ChangeInFairValueOfWarrantLiabilities_pp0p0_c20220101__20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zF5xzgPb65c7" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right" title="Change in fair value of warrant liabilities"&gt;(897,242&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_ecustom--ChangeInFairValueOfWarrantLiabilities_pp0p0_c20220101__20221231_zE61mt7RQZUg" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right" title="Change in fair value of warrant liabilities"&gt;(897,242&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Balance as of December 31, 2022&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_ecustom--FairValueAdjustmentOfWarrant_iE_pp0p0_c20220101__20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zch8P99usN7j" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right" title="Fair value for warrant liabilities"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1263"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_ecustom--FairValueAdjustmentOfWarrant_iE_pp0p0_c20220101__20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zh60I5eW81yc" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right" title="Fair value for warrant liabilities"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1265"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_ecustom--FairValueAdjustmentOfWarrant_iE_pp0p0_c20220101__20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zUga1nycgLLh" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right" title="Fair value for warrant liabilities"&gt;3,622,647&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_ecustom--FairValueAdjustmentOfWarrant_iE_pp0p0_c20220101__20221231_zP2mygjPKjpa" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right" title="Fair value for warrant liabilities, ending balance"&gt;3,622,647&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table presents the Company&#x2019;s fair value hierarchy for its Common Stock Warrant liabilities (all of which arose under
the warrants received in exchange for the Series C Warrants) measured at fair value on a recurring basis as of December 31, 2021:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Quoted&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Market&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Significant&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Prices for&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Other&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Significant&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Identical&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Observable&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Unobservable&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Assets&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Inputs&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Inputs&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Common Stock Warrant liabilities&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;(Level 1)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;(Level 2)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;(Level 3)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 40%"&gt;Balance as of December 31, 2020&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_ecustom--FairValueAdjustmentOfWarrant_iS_pdp0_c20210101__20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zM0g0w5THkD8" style="width: 11%; text-align: right" title="Fair value for warrant liabilities"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1271"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_ecustom--FairValueAdjustmentOfWarrant_iS_pdp0_c20210101__20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zA6XmeoqnPg5" style="width: 11%; text-align: right" title="Fair value for warrant liabilities"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1273"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_ecustom--FairValueAdjustmentOfWarrant_iS_pdp0_c20210101__20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zwEyPxSvBSel" style="width: 11%; font-weight: bold; text-align: right" title="Fair value for warrant liabilities"&gt;8,310,100&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_ecustom--FairValueAdjustmentOfWarrant_iS_pdp0_c20210101__20211231_zcqAWIAU3JA" style="width: 11%; font-weight: bold; text-align: right" title="Fair value for warrant liabilities"&gt;8,310,100&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Exercises&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_ecustom--FairValueOfWarrantLiabilitiesOnDateOfExercise_iN_di_c20210101__20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_z46tU59ZOJMh" style="text-align: right" title="Common Stock Warrant liabilities, Exercises"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1279"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_ecustom--FairValueOfWarrantLiabilitiesOnDateOfExercise_iN_di_c20210101__20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_ztEJ6mZBI9fl" style="text-align: right" title="Common Stock Warrant liabilities, Exercises"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1281"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_ecustom--FairValueOfWarrantLiabilitiesOnDateOfExercise_iN_pp0p0_di_c20210101__20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zSMlhmnylCFk" style="font-weight: bold; text-align: right" title="Common Stock Warrant liabilities, Exercises"&gt;(1,900,713&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_ecustom--FairValueOfWarrantLiabilitiesOnDateOfExercise_iN_pdp0_di_c20210101__20211231_z4iQ5tt73t8j" style="font-weight: bold; text-align: right" title="Common Stock Warrant liabilities, Exercises"&gt;(1,900,713&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Gain on change in fair value of warrant liabilities&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_ecustom--ChangeInFairValueOfWarrantLiabilities_pdp0_c20210101__20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_z5WZCTIomEEe" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right" title="Change in fair value of warrant liabilities"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1287"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_ecustom--ChangeInFairValueOfWarrantLiabilities_pdp0_c20210101__20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zxU6GLyUYMXf" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right" title="Change in fair value of warrant liabilities"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1289"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_ecustom--ChangeInFairValueOfWarrantLiabilities_pp0p0_c20210101__20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zr8rKFav1sw3" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right" title="Change in fair value of warrant liabilities"&gt;(4,723,187&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_ecustom--ChangeInFairValueOfWarrantLiabilities_pp0p0_c20210101__20211231_zwTo0iwheP79" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right" title="Change in fair value of warrant liabilities"&gt;(4,723,187&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Balance as of December 31, 2021&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_ecustom--FairValueAdjustmentOfWarrant_iE_pdp0_c20210101__20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zWuKHKzFgNV1" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right" title="Fair value for warrant liabilities"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1295"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_ecustom--FairValueAdjustmentOfWarrant_iE_pdp0_c20210101__20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zi58ZANZKaEf" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right" title="Fair value for warrant liabilities"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1297"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_ecustom--FairValueAdjustmentOfWarrant_iE_pdp0_c20210101__20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zKOUQjYDEWL9" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right" title="Fair value for warrant liabilities"&gt;1,686,200&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_ecustom--FairValueAdjustmentOfWarrant_iE_pdp0_c20210101__20211231_z9XQoM1ibaw7" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right" title="Fair value for warrant liabilities"&gt;1,686,200&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AB_zzS6BEzkcisd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;There
were no transfers of financial assets or liabilities between category levels for the year ended December 31, 2022.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
value of the warrant liabilities was based on a valuation received from an independent valuation firm determined using a Monte-Carlo
simulation. For volatility, the Company considers comparable public companies as a basis for its expected volatility to calculate the
fair value of common stock warrants and transitions to its own volatility as the Company develops sufficient appropriate history as a
public company. The risk-free interest rate is based on U.S. Treasury notes with a term approximating the expected term of the common
stock warrant. The Company uses an expected dividend yield of zero based on the fact that the Company has never paid cash dividends and
does not expect to pay cash dividends in the foreseeable future. Any significant changes in the inputs may result in significantly higher
or lower fair value measurements.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_893_ecustom--ScheduleOfAssumptionsOfWarrantLiabilitiesTableTextBlock_zUrjGat2pOm7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following are the weighted average and the range of assumptions used in estimating the fair value of warrant liabilities (weighted average
calculated based on the number of outstanding warrants on each issuance) as of December 31, 2022 and December 31, 2021:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span id="xdx_8B8_zXu2zfSuQhk8" style="display: none"&gt;SCHEDULE
OF ASSUMPTIONS OF WARRANT LIABILITIES&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"/&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"/&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 11pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;December 31, 2022&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;December 31, 2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 11pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Range&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Weighted&lt;br/&gt; Average&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Range&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Weighted&lt;br/&gt; Average&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 11pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-size: 11pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 11pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-size: 11pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 11pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-size: 11pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 11pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-size: 11pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 11pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 38%; text-align: left"&gt;Risk-free interest rate&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90F_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20221231__srt--RangeAxis__srt--MinimumMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zSh0YEfZ8bD2" title="Fair value assumptions, measurement input, percentages"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1305"&gt;3.906%&lt;/span&gt;&lt;/span&gt;
                                            &#x2014; &lt;span id="xdx_909_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20221231__srt--RangeAxis__srt--MaximumMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_z2M90k7YyeQa" title="Fair value assumptions, measurement input, percentages"&gt;4.628&lt;/span&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;&lt;span id="xdx_907_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20221231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--WeightedAverageMember_znbc0RjerXb7" title="Fair value assumptions, measurement input, percentages"&gt;4.15&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_905_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20211231__srt--RangeAxis__srt--MinimumMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zJI6idtaQfU5" title="Fair value assumptions, measurement input, percentages"&gt;0.69%&lt;/span&gt;
                                            &#x2014; &lt;span id="xdx_902_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20211231__srt--RangeAxis__srt--MaximumMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zSmNpTAFL4Gg" title="Fair value assumptions, measurement input, percentages"&gt;0.84&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;%&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;&lt;span id="xdx_90C_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20211231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--WeightedAverageMember_z6QdufRA9ndh" title="Fair value assumptions, measurement input, percentages"&gt;0.72&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Expected volatility (peer group)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_908_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20221231__srt--RangeAxis__srt--MinimumMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zit3kgSqXrtb" title="Expected volatility"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1317"&gt;88%&lt;/span&gt;&lt;/span&gt;
                                            &#x2014; &lt;span id="xdx_908_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20221231__srt--RangeAxis__srt--MaximumMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zLsHapTdV8Z6" title="Expected volatility"&gt;103&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_903_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20221231__srt--RangeAxis__srt--WeightedAverageMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zF6rWT0z5K69" title="Expected volatility"&gt;98&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_909_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20211231__srt--RangeAxis__srt--MinimumMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zoHjfNGTL03i" title="Expected volatility"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1323"&gt;84%&lt;/span&gt;&lt;/span&gt;
                                            &#x2014; &lt;span id="xdx_90A_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20211231__srt--RangeAxis__srt--MaximumMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_z9PatBOSI5Tc" title="Expected volatility"&gt;87&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90D_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20211231__srt--RangeAxis__srt--WeightedAverageMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zahxBsQHA2Kk" title="Expected volatility"&gt;85&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Term of warrants (in years)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90D_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20221231__srt--RangeAxis__srt--MinimumMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_z0eLWOuKRvbc" title="Fair value assumptions, measurement input, term"&gt;.90&lt;/span&gt;
                                            &#x2014; &lt;span id="xdx_905_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20221231__srt--RangeAxis__srt--MaximumMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_zR6KYxzz12Jb" title="Fair value assumptions, measurement input, term"&gt;5.48&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_906_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20221231__srt--RangeAxis__srt--WeightedAverageMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_zDr2I1FtDGdj" title="Fair value assumptions, measurement input, term"&gt;3.9&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90E_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20211231__srt--RangeAxis__srt--MinimumMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_zDR8E7tt1go8" title="Fair value assumptions, measurement input, term"&gt;1.90&lt;/span&gt;
                                            &#x2014; &lt;span id="xdx_902_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20211231__srt--RangeAxis__srt--MaximumMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_zZURLdhnmmP7" title="Fair value assumptions, measurement input, term"&gt;2.50&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90A_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20211231__srt--RangeAxis__srt--WeightedAverageMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_zP51RGjPTRe7" title="Fair value assumptions, measurement input, term"&gt;2.01&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Expected dividend yield&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20221231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zK2qdLEmQqJ7" title="Fair value assumptions, measurement input, percentages"&gt;0.00&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_901_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20221231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember__srt--RangeAxis__srt--WeightedAverageMember_zwosA5i5B0sc" title="Fair value assumptions, measurement input, percentages"&gt;0.00&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20211231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zZTTgQ114pN1" title="Fair value assumptions, measurement input, percentages"&gt;0.00&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_900_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20211231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember__srt--RangeAxis__srt--WeightedAverageMember_zW3iPjqQxj3f" title="Fair value assumptions, measurement input, percentages"&gt;0.00&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"/&gt;

&lt;p id="xdx_8AD_z4Tsxf65hVLh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
value of the warrant liabilities is based on a valuation received from an independent valuation firm determined using a Monte-Carlo simulation.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</QLGN:WarrantLiabilitiesTextBlock>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2022-12-31_custom_SeriesCWarrantsMember"
      decimals="INF"
      unitRef="USDPShares">7.195</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstandingTerm contextRef="AsOf2022-12-31_srt_MinimumMember_custom_SeriesCWarrantsMember">P0Y10M24D</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:WarrantsAndRightsOutstandingTerm contextRef="AsOf2022-12-31_srt_MaximumMember_custom_SeriesCWarrantsMember">P1Y5M26D</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2022-04-25_srt_MaximumMember"
      decimals="INF"
      unitRef="USDPShares">7.195</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2022-04-25_srt_MinimumMember"
      decimals="INF"
      unitRef="USDPShares">6.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2022-04-232022-04-25_custom_SeriesCWarrantsMember"
      decimals="INF"
      unitRef="Shares">49318</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2022-05-26_srt_MaximumMember"
      decimals="INF"
      unitRef="USDPShares">6.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2022-05-26_srt_MinimumMember"
      decimals="INF"
      unitRef="USDPShares">5.136</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2022-05-232022-05-26_custom_SeriesCWarrantsMember"
      decimals="INF"
      unitRef="Shares">49952</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2022-12-22_srt_MaximumMember"
      decimals="INF"
      unitRef="USDPShares">5.136</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2022-12-22_srt_MinimumMember"
      decimals="INF"
      unitRef="USDPShares">1.32</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2022-12-192022-12-22_custom_SeriesCWarrantsMember"
      decimals="INF"
      unitRef="Shares">1002717</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2022-12-22_custom_SeriesCWarrantsMember_custom_AlphaCapitalMember"
      decimals="INF"
      unitRef="Shares">2500000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2022-12-22_custom_SeriesCWarrantsMember_custom_AlphaCapitalMember"
      decimals="INF"
      unitRef="USDPShares">1.65</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <QLGN:ConversionPricePercentage
      contextRef="From2022-12-192022-12-22_custom_SeriesCWarrantsMember_custom_AlphaCapitalMember"
      decimals="INF"
      unitRef="Pure">1.25</QLGN:ConversionPricePercentage>
    <us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_892_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zi4R4vr76wV6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table summarizes the activity in liability classified warrants for the year ended December 31, 2022:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span id="xdx_8B9_zlbDiViAHMLj" style="display: none"&gt;SCHEDULE OF WARRANTS ACTIVITY&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Common Stock Warrants&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Shares&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Weighted&#x2013;&lt;br/&gt; Average&lt;br/&gt; Exercise&lt;br/&gt;
    Price&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Range of Exercise&lt;br/&gt; Price&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Weighted&#x2013;&lt;br/&gt; Average&lt;br/&gt; Remaining
    Life (Years)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 40%"&gt;Total outstanding &#x2013; December 31, 2021&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20220101__20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zgRZ9lBrrAU4" style="width: 11%; text-align: right" title="Number of Shares, Warrants Outstanding Beginning"&gt;248,162&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iS_c20220101__20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zdHaBnbdKIxk" style="width: 11%; text-align: right" title="Weighted Average Exercise Price Per Share Warrants Outstanding Beginning"&gt;7.20&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;&lt;span id="xdx_90B_ecustom--RangeOfExercisePrice_iS_c20220101__20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zDEOdKz4r8sd" title="Range of Exercise Beginning"&gt;7.20&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;&lt;span id="xdx_907_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAveragRemainingContractualTerm1_dtY_c20210101__20211231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zEg9rAw2F3tg" title="Weighted Averag Remaining Contractual Term"&gt;2.00&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt"&gt;Exercised&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_di_c20220101__20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_z4v1hFTq5Sdf" style="text-align: right" title="Number of Shares, Warrants Exercised"&gt;(536&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedInPeriodWeightedAverageExercisePrice_c20220101__20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zNez6fhlXGcj" style="text-align: right" title="Weighted Average Exercise Price Per Share Warrants Exercised"&gt;7.20&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt"&gt;Forfeited&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_iN_di_c20220101__20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zwKh1cVFEL3e" style="text-align: right" title="Number of Shares, Warrants Forfeited"&gt;(247,625&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedInPeriodWeightedAverageExercisePrice_c20220101__20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zMKKnE0lOn3l" style="text-align: right" title="Weighted Average Exercise Price Per Share Warrants Forfeited"&gt;7.20&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt"&gt;Expired&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_c20220101__20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zly3pspvqndi" style="text-align: right" title="Number of Shares, Warrants Expired"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1171"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInPeriodWeightedAverageExercisePrice_c20220101__20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zN1SodGJJ9H4" style="text-align: right" title="Weighted Average Exercise Price Per Share Warrants Expired"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1173"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; padding-bottom: 1.5pt"&gt;Granted&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20220101__20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zIovgXO5mrPg" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Shares, Warrants Granted"&gt;3,849,570&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice_c20220101__20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zBUeAcTQIYuj" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Exercise Price Per Share Warrants Granted"&gt;1.53&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Total outstanding &#x2013; December 31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_c20220101__20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zFsS5v1SLk0h" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Shares, Warrants Outstanding Ending"&gt;3,849,571&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iE_c20220101__20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zP8I6u5b9Rfg" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price Per Share Warrants Outstanding Ending"&gt;1.53&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&lt;span id="xdx_90F_ecustom--RangeOfExercisePrice_iE_c20220101__20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember__srt--RangeAxis__srt--MinimumMember_ziMXfIKHccal" title="Range of Exercise Ending"&gt;1.32&lt;/span&gt; - &lt;span id="xdx_900_ecustom--RangeOfExercisePrice_iE_c20220101__20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember__srt--RangeAxis__srt--MaximumMember_ztM5JNlu8qog" title="Range of Exercise Ending"&gt;1.65&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&lt;span id="xdx_909_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAveragRemainingContractualTerm1_dtY_c20220101__20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_z5ISRz135JAi" title="Weighted Averag Remaining Contractual Term"&gt;3.9&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Exercisable&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_iE_c20220101__20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zQgOSvu364ug" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Shares, Warrants Exercisable"&gt;1,349,571&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageVestedExercisePrice_iE_c20220101__20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_z51QXKjozQH9" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price Per Share Exercisable"&gt;1.32&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_ecustom--RangeOfExercisePriceExercisableVested_iE_c20220101__20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zwFbKLcsDzlc" style="border-bottom: Black 2.5pt double; text-align: right" title="Range of Exercise Price, Exercisable"&gt;1.32&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_90F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNonExercisableWeightedAverageRemainingContractualTerm1_dtY_c20220101__20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zqzXgGiB5XWk" title="Exercisable Weighted Average Remaining Contractual Term"&gt;1.00&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table summarizes the activity in the Common Stock Warrants received in exchange for the Series C Warrants for the year ended
December 31, 2021:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Common Stock Warrants&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Shares&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Weighted&#x2013; Average&lt;br/&gt; Exercise&lt;br/&gt;
    Price&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Range of Exercise&lt;br/&gt; Price&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Weighted&#x2013;&lt;br/&gt; Average&lt;br/&gt; Remaining&lt;br/&gt;
    Life (Years)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 40%; text-align: left"&gt;Total outstanding &#x2013;December 31, 2020&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_pid_c20210101__20211231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zH77yzJp8ctc" style="width: 11%; text-align: right" title="Number of Shares, Warrants Outstanding Beginning"&gt;337,860&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iS_c20210101__20211231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zImbi4AYEEEh" style="width: 11%; text-align: right" title="Weighted Average Exercise Price Per Share Warrants Outstanding Beginning"&gt;7.20&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt"&gt;Exercised&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_pid_di_c20210101__20211231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zfpK04P8y6g3" style="text-align: right" title="Number of Shares, Warrants Exercised"&gt;(80,731&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedInPeriodWeightedAverageExercisePrice_c20210101__20211231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zD3Kkx3xf4s2" style="text-align: right" title="Weighted Average Exercise Price Per Share Warrants Exercised"&gt;7.20&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt"&gt;Forfeited&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_iN_pid_di_c20210101__20211231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zobya8eIBZu4" style="text-align: right" title="Number of Shares, Warrants Forfeited"&gt;(8,967&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedInPeriodWeightedAverageExercisePrice_c20210101__20211231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zDjLjuPENNR6" style="text-align: right" title="Weighted Average Exercise Price Per Share Warrants Forfeited"&gt;7.20&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt"&gt;Expired&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_pid_c20210101__20211231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zFC5SgAGzsEf" style="text-align: right" title="Number of Shares, Warrants Expired"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1209"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInPeriodWeightedAverageExercisePrice_c20210101__20211231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_z7nycVmTb8B" style="text-align: right" title="Weighted Average Exercise Price Per Share Warrants Expired"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1211"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; padding-bottom: 1.5pt"&gt;Granted&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pid_c20210101__20211231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zHOeD4mc3zk8" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Shares, Warrants Granted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1213"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice_c20210101__20211231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_z8XNUGVPEb2" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Exercise Price Per Share Warrants Granted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1215"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Total outstanding &#x2013; December 31, 2021&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_pid_c20210101__20211231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zvGIKed08Dji" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Shares, Warrants Outstanding Ending"&gt;248,162&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iE_c20210101__20211231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zCk65p5rvzGj" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price Per Share Warrants Outstanding Ending"&gt;7.20&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Exercisable&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_iE_c20210101__20211231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zBkvGyDabBh5" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Shares, Warrants Exercisable"&gt;248,162&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageVestedExercisePrice_iE_c20210101__20211231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_ztQSbDCkta6l" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price Per Share Exercisable"&gt;7.20&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_ecustom--RangeOfExercisePriceExercisableVested_iI_c20211231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zEu6lMmQ7Yj" style="border-bottom: Black 2.5pt double; text-align: right" title="Range of Exercise Price, Exercisable"&gt;7.20&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_901_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNonExercisableWeightedAverageRemainingContractualTerm1_dtY_c20210101__20211231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zoFCBLkRSPC9" title="Exercisable Weighted Averag Remaining Contractual Term"&gt;2.00&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="AsOf2021-12-31_custom_SeriesCWarrantsMember_custom_CommonStockWarrantsMember"
      decimals="INF"
      unitRef="Shares">248162</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2021-12-31_custom_SeriesCWarrantsMember_custom_CommonStockWarrantsMember"
      decimals="INF"
      unitRef="USDPShares">7.20</QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice>
    <QLGN:RangeOfExercisePrice
      contextRef="AsOf2021-12-31_custom_SeriesCWarrantsMember_custom_CommonStockWarrantsMember"
      decimals="INF"
      unitRef="USDPShares">7.20</QLGN:RangeOfExercisePrice>
    <QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAveragRemainingContractualTerm1 contextRef="From2021-01-012021-12-31_custom_SeriesCWarrantsMember_custom_CommonStockWarrantsMember">P2Y</QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAveragRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised
      contextRef="From2022-01-012022-12-31_custom_SeriesCWarrantsMember_custom_CommonStockWarrantsMember"
      decimals="INF"
      unitRef="Shares">536</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised>
    <QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedInPeriodWeightedAverageExercisePrice
      contextRef="From2022-01-012022-12-31_custom_SeriesCWarrantsMember_custom_CommonStockWarrantsMember"
      decimals="INF"
      unitRef="USDPShares">7.20</QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures
      contextRef="From2022-01-012022-12-31_custom_SeriesCWarrantsMember_custom_CommonStockWarrantsMember"
      decimals="INF"
      unitRef="Shares">247625</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures>
    <QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedInPeriodWeightedAverageExercisePrice
      contextRef="From2022-01-012022-12-31_custom_SeriesCWarrantsMember_custom_CommonStockWarrantsMember"
      decimals="INF"
      unitRef="USDPShares">7.20</QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted
      contextRef="From2022-01-012022-12-31_custom_SeriesCWarrantsMember_custom_CommonStockWarrantsMember"
      decimals="INF"
      unitRef="Shares">3849570</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted>
    <QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="From2022-01-012022-12-31_custom_SeriesCWarrantsMember_custom_CommonStockWarrantsMember"
      decimals="INF"
      unitRef="USDPShares">1.53</QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="AsOf2022-12-31_custom_SeriesCWarrantsMember_custom_CommonStockWarrantsMember"
      decimals="INF"
      unitRef="Shares">3849571</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2022-12-31_custom_SeriesCWarrantsMember_custom_CommonStockWarrantsMember"
      decimals="INF"
      unitRef="USDPShares">1.53</QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice>
    <QLGN:RangeOfExercisePrice
      contextRef="AsOf2022-12-31_custom_SeriesCWarrantsMember_custom_CommonStockWarrantsMember_srt_MinimumMember"
      decimals="INF"
      unitRef="USDPShares">1.32</QLGN:RangeOfExercisePrice>
    <QLGN:RangeOfExercisePrice
      contextRef="AsOf2022-12-31_custom_SeriesCWarrantsMember_custom_CommonStockWarrantsMember_srt_MaximumMember"
      decimals="INF"
      unitRef="USDPShares">1.65</QLGN:RangeOfExercisePrice>
    <QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAveragRemainingContractualTerm1 contextRef="From2022-01-012022-12-31_custom_SeriesCWarrantsMember_custom_CommonStockWarrantsMember">P3Y10M24D</QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAveragRemainingContractualTerm1>
    <QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber
      contextRef="AsOf2022-12-31_custom_SeriesCWarrantsMember_custom_CommonStockWarrantsMember"
      decimals="INF"
      unitRef="Shares">1349571</QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber>
    <QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageVestedExercisePrice
      contextRef="AsOf2022-12-31_custom_SeriesCWarrantsMember_custom_CommonStockWarrantsMember"
      decimals="INF"
      unitRef="USDPShares">1.32</QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageVestedExercisePrice>
    <QLGN:RangeOfExercisePriceExercisableVested
      contextRef="AsOf2022-12-31_custom_SeriesCWarrantsMember_custom_CommonStockWarrantsMember"
      decimals="INF"
      unitRef="USDPShares">1.32</QLGN:RangeOfExercisePriceExercisableVested>
    <QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNonExercisableWeightedAverageRemainingContractualTerm1 contextRef="From2022-01-012022-12-31_custom_SeriesCWarrantsMember_custom_CommonStockWarrantsMember">P1Y</QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNonExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="AsOf2020-12-31_custom_SeriesCWarrantsMember_custom_CommonStockWarrantsMember"
      decimals="INF"
      unitRef="Shares">337860</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2020-12-31_custom_SeriesCWarrantsMember_custom_CommonStockWarrantsMember"
      decimals="INF"
      unitRef="USDPShares">7.20</QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised
      contextRef="From2021-01-012021-12-31_custom_SeriesCWarrantsMember_custom_CommonStockWarrantsMember"
      decimals="INF"
      unitRef="Shares">80731</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised>
    <QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedInPeriodWeightedAverageExercisePrice
      contextRef="From2021-01-012021-12-31_custom_SeriesCWarrantsMember_custom_CommonStockWarrantsMember"
      decimals="INF"
      unitRef="USDPShares">7.20</QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures
      contextRef="From2021-01-012021-12-31_custom_SeriesCWarrantsMember_custom_CommonStockWarrantsMember"
      decimals="INF"
      unitRef="Shares">8967</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures>
    <QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedInPeriodWeightedAverageExercisePrice
      contextRef="From2021-01-012021-12-31_custom_SeriesCWarrantsMember_custom_CommonStockWarrantsMember"
      decimals="INF"
      unitRef="USDPShares">7.20</QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="AsOf2021-12-31_custom_SeriesCWarrantsMember_custom_CommonStockWarrantsMember"
      decimals="INF"
      unitRef="Shares">248162</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2021-12-31_custom_SeriesCWarrantsMember_custom_CommonStockWarrantsMember"
      decimals="INF"
      unitRef="USDPShares">7.20</QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice>
    <QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber
      contextRef="AsOf2021-12-31_custom_SeriesCWarrantsMember_custom_CommonStockWarrantsMember"
      decimals="INF"
      unitRef="Shares">248162</QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber>
    <QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageVestedExercisePrice
      contextRef="AsOf2021-12-31_custom_SeriesCWarrantsMember_custom_CommonStockWarrantsMember"
      decimals="INF"
      unitRef="USDPShares">7.20</QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageVestedExercisePrice>
    <QLGN:RangeOfExercisePriceExercisableVested
      contextRef="AsOf2021-12-31_custom_SeriesCWarrantsMember_custom_CommonStockWarrantsMember"
      decimals="INF"
      unitRef="USDPShares">7.20</QLGN:RangeOfExercisePriceExercisableVested>
    <QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNonExercisableWeightedAverageRemainingContractualTerm1 contextRef="From2021-01-012021-12-31_custom_SeriesCWarrantsMember_custom_CommonStockWarrantsMember">P2Y</QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNonExercisableWeightedAverageRemainingContractualTerm1>
    <QLGN:ScheduleOfFairValueHierarchyForWarrantLiabilitiesTableTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_891_ecustom--ScheduleOfFairValueHierarchyForWarrantLiabilitiesTableTextBlock_ztNQLBf0mxnf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table presents the Company&#x2019;s fair value hierarchy for its Common Stock Warrant liabilities measured at fair value on
a recurring basis as of December 31, 2022:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span id="xdx_8BC_zcaqBHalynh3" style="display: none"&gt;SCHEDULE OF FAIR VALUE HIERARCHY FOR WARRANT LIABILITIES&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Quoted&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Market&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Significant&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Prices for&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Other&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Significant&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Identical&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Observable&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Unobservable&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Assets&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Inputs&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Inputs&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Common Stock Warrant liabilities&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;(Level 1)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;(Level 2)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;(Level 3)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 40%"&gt;Balance as of December 31, 2021&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_ecustom--FairValueAdjustmentOfWarrant_iS_pp0p0_c20220101__20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zA7XDLaSeJp7" style="width: 11%; text-align: right" title="Fair value for warrant liabilities"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1231"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_ecustom--FairValueAdjustmentOfWarrant_iS_pp0p0_c20220101__20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_z9ZvtjE2OlEl" style="width: 11%; text-align: right" title="Fair value for warrant liabilities"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1233"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_ecustom--FairValueAdjustmentOfWarrant_iS_pp0p0_c20220101__20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z4eVzr78nfqg" style="width: 11%; font-weight: bold; text-align: right" title="Fair value for warrant liabilities"&gt;1,686,200&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_ecustom--FairValueAdjustmentOfWarrant_iS_pp0p0_c20220101__20221231_zQW5z8Rhuhi8" style="width: 11%; font-weight: bold; text-align: right" title="Fair value for warrant liabilities, beginning balance"&gt;1,686,200&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Exercises&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_ecustom--FairValueOfWarrantLiabilitiesOnDateOfExercise_iN_pp0p0_di_c20220101__20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zGCennZ52Y2b" style="text-align: right" title="Common Stock Warrant liabilities, Exercises"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1239"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_ecustom--FairValueOfWarrantLiabilitiesOnDateOfExercise_iN_pp0p0_di_c20220101__20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zdSg6uJAd9a2" style="text-align: right" title="Common Stock Warrant liabilities, Exercises"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1241"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_ecustom--FairValueOfWarrantLiabilitiesOnDateOfExercise_iN_pp0p0_di_c20220101__20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zeARMJfHa1kf" style="font-weight: bold; text-align: right" title="Common Stock Warrant liabilities, Exercises"&gt;(858&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_ecustom--FairValueOfWarrantLiabilitiesOnDateOfExercise_iN_pp0p0_di_c20220101__20221231_zuK1t4bnPMHi" style="font-weight: bold; text-align: right" title="Common Stock Warrant liabilities, Exercises"&gt;(858&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Issuance of Alpha warrants&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_ecustom--FairValueOfWarrantLiabilitiesIssuanceOfAlphaWarrants_iN_pp0p0_di_c20220101__20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_z3KPQHnVEkj6" style="font-weight: bold; text-align: right" title="Issuance of Alpha warrants"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1247"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_ecustom--FairValueOfWarrantLiabilitiesIssuanceOfAlphaWarrants_iN_pp0p0_di_c20220101__20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_ziP3TcxufO4b" style="font-weight: bold; text-align: right" title="Issuance of Alpha warrants"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1249"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_ecustom--FairValueOfWarrantLiabilitiesIssuanceOfAlphaWarrants_iN_pp0p0_di_c20220101__20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zC4IQi7vMGL9" style="font-weight: bold; text-align: right" title="Issuance of Alpha warrants"&gt;2,834,547&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_ecustom--FairValueOfWarrantLiabilitiesIssuanceOfAlphaWarrants_iN_pp0p0_di_c20220101__20221231_zkJjn6nyDGFc" style="font-weight: bold; text-align: right" title="Issuance of Alpha warrants"&gt;2,834,547&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Gain on change in fair value of warrant liabilities&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_ecustom--ChangeInFairValueOfWarrantLiabilities_pdp0_c20220101__20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_z4oIucfXRdvj" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right" title="Change in fair value of warrant liabilities"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1255"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_ecustom--ChangeInFairValueOfWarrantLiabilities_pdp0_c20220101__20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zSDM0xe7XeJ1" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right" title="Change in fair value of warrant liabilities"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1257"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_ecustom--ChangeInFairValueOfWarrantLiabilities_pp0p0_c20220101__20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zF5xzgPb65c7" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right" title="Change in fair value of warrant liabilities"&gt;(897,242&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_ecustom--ChangeInFairValueOfWarrantLiabilities_pp0p0_c20220101__20221231_zE61mt7RQZUg" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right" title="Change in fair value of warrant liabilities"&gt;(897,242&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Balance as of December 31, 2022&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_ecustom--FairValueAdjustmentOfWarrant_iE_pp0p0_c20220101__20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zch8P99usN7j" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right" title="Fair value for warrant liabilities"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1263"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_ecustom--FairValueAdjustmentOfWarrant_iE_pp0p0_c20220101__20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zh60I5eW81yc" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right" title="Fair value for warrant liabilities"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1265"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_ecustom--FairValueAdjustmentOfWarrant_iE_pp0p0_c20220101__20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zUga1nycgLLh" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right" title="Fair value for warrant liabilities"&gt;3,622,647&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_ecustom--FairValueAdjustmentOfWarrant_iE_pp0p0_c20220101__20221231_zP2mygjPKjpa" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right" title="Fair value for warrant liabilities, ending balance"&gt;3,622,647&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table presents the Company&#x2019;s fair value hierarchy for its Common Stock Warrant liabilities (all of which arose under
the warrants received in exchange for the Series C Warrants) measured at fair value on a recurring basis as of December 31, 2021:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Quoted&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Market&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Significant&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Prices for&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Other&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Significant&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Identical&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Observable&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Unobservable&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Assets&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Inputs&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Inputs&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Common Stock Warrant liabilities&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;(Level 1)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;(Level 2)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;(Level 3)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 40%"&gt;Balance as of December 31, 2020&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_ecustom--FairValueAdjustmentOfWarrant_iS_pdp0_c20210101__20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zM0g0w5THkD8" style="width: 11%; text-align: right" title="Fair value for warrant liabilities"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1271"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_ecustom--FairValueAdjustmentOfWarrant_iS_pdp0_c20210101__20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zA6XmeoqnPg5" style="width: 11%; text-align: right" title="Fair value for warrant liabilities"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1273"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_ecustom--FairValueAdjustmentOfWarrant_iS_pdp0_c20210101__20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zwEyPxSvBSel" style="width: 11%; font-weight: bold; text-align: right" title="Fair value for warrant liabilities"&gt;8,310,100&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_ecustom--FairValueAdjustmentOfWarrant_iS_pdp0_c20210101__20211231_zcqAWIAU3JA" style="width: 11%; font-weight: bold; text-align: right" title="Fair value for warrant liabilities"&gt;8,310,100&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Exercises&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_ecustom--FairValueOfWarrantLiabilitiesOnDateOfExercise_iN_di_c20210101__20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_z46tU59ZOJMh" style="text-align: right" title="Common Stock Warrant liabilities, Exercises"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1279"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_ecustom--FairValueOfWarrantLiabilitiesOnDateOfExercise_iN_di_c20210101__20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_ztEJ6mZBI9fl" style="text-align: right" title="Common Stock Warrant liabilities, Exercises"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1281"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_ecustom--FairValueOfWarrantLiabilitiesOnDateOfExercise_iN_pp0p0_di_c20210101__20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zSMlhmnylCFk" style="font-weight: bold; text-align: right" title="Common Stock Warrant liabilities, Exercises"&gt;(1,900,713&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_ecustom--FairValueOfWarrantLiabilitiesOnDateOfExercise_iN_pdp0_di_c20210101__20211231_z4iQ5tt73t8j" style="font-weight: bold; text-align: right" title="Common Stock Warrant liabilities, Exercises"&gt;(1,900,713&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Gain on change in fair value of warrant liabilities&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_ecustom--ChangeInFairValueOfWarrantLiabilities_pdp0_c20210101__20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_z5WZCTIomEEe" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right" title="Change in fair value of warrant liabilities"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1287"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_ecustom--ChangeInFairValueOfWarrantLiabilities_pdp0_c20210101__20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zxU6GLyUYMXf" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right" title="Change in fair value of warrant liabilities"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1289"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_ecustom--ChangeInFairValueOfWarrantLiabilities_pp0p0_c20210101__20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zr8rKFav1sw3" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right" title="Change in fair value of warrant liabilities"&gt;(4,723,187&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_ecustom--ChangeInFairValueOfWarrantLiabilities_pp0p0_c20210101__20211231_zwTo0iwheP79" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right" title="Change in fair value of warrant liabilities"&gt;(4,723,187&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Balance as of December 31, 2021&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_ecustom--FairValueAdjustmentOfWarrant_iE_pdp0_c20210101__20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zWuKHKzFgNV1" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right" title="Fair value for warrant liabilities"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1295"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_ecustom--FairValueAdjustmentOfWarrant_iE_pdp0_c20210101__20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zi58ZANZKaEf" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right" title="Fair value for warrant liabilities"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1297"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_ecustom--FairValueAdjustmentOfWarrant_iE_pdp0_c20210101__20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zKOUQjYDEWL9" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right" title="Fair value for warrant liabilities"&gt;1,686,200&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_ecustom--FairValueAdjustmentOfWarrant_iE_pdp0_c20210101__20211231_z9XQoM1ibaw7" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right" title="Fair value for warrant liabilities"&gt;1,686,200&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</QLGN:ScheduleOfFairValueHierarchyForWarrantLiabilitiesTableTextBlock>
    <QLGN:FairValueAdjustmentOfWarrant
      contextRef="AsOf2021-12-31_us-gaap_FairValueInputsLevel3Member"
      decimals="0"
      unitRef="USD">1686200</QLGN:FairValueAdjustmentOfWarrant>
    <QLGN:FairValueAdjustmentOfWarrant contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">1686200</QLGN:FairValueAdjustmentOfWarrant>
    <QLGN:FairValueOfWarrantLiabilitiesOnDateOfExercise
      contextRef="From2022-01-012022-12-31_us-gaap_FairValueInputsLevel3Member"
      decimals="0"
      unitRef="USD">858</QLGN:FairValueOfWarrantLiabilitiesOnDateOfExercise>
    <QLGN:FairValueOfWarrantLiabilitiesOnDateOfExercise
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">858</QLGN:FairValueOfWarrantLiabilitiesOnDateOfExercise>
    <QLGN:FairValueOfWarrantLiabilitiesIssuanceOfAlphaWarrants
      contextRef="From2022-01-012022-12-31_us-gaap_FairValueInputsLevel3Member"
      decimals="0"
      unitRef="USD">-2834547</QLGN:FairValueOfWarrantLiabilitiesIssuanceOfAlphaWarrants>
    <QLGN:FairValueOfWarrantLiabilitiesIssuanceOfAlphaWarrants
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">-2834547</QLGN:FairValueOfWarrantLiabilitiesIssuanceOfAlphaWarrants>
    <QLGN:ChangeInFairValueOfWarrantLiabilities
      contextRef="From2022-01-012022-12-31_us-gaap_FairValueInputsLevel3Member"
      decimals="0"
      unitRef="USD">-897242</QLGN:ChangeInFairValueOfWarrantLiabilities>
    <QLGN:ChangeInFairValueOfWarrantLiabilities
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">-897242</QLGN:ChangeInFairValueOfWarrantLiabilities>
    <QLGN:FairValueAdjustmentOfWarrant
      contextRef="AsOf2022-12-31_us-gaap_FairValueInputsLevel3Member"
      decimals="0"
      unitRef="USD">3622647</QLGN:FairValueAdjustmentOfWarrant>
    <QLGN:FairValueAdjustmentOfWarrant contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">3622647</QLGN:FairValueAdjustmentOfWarrant>
    <QLGN:FairValueAdjustmentOfWarrant
      contextRef="AsOf2020-12-31_us-gaap_FairValueInputsLevel3Member"
      decimals="0"
      unitRef="USD">8310100</QLGN:FairValueAdjustmentOfWarrant>
    <QLGN:FairValueAdjustmentOfWarrant contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">8310100</QLGN:FairValueAdjustmentOfWarrant>
    <QLGN:FairValueOfWarrantLiabilitiesOnDateOfExercise
      contextRef="From2021-01-012021-12-31_us-gaap_FairValueInputsLevel3Member"
      decimals="0"
      unitRef="USD">1900713</QLGN:FairValueOfWarrantLiabilitiesOnDateOfExercise>
    <QLGN:FairValueOfWarrantLiabilitiesOnDateOfExercise
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">1900713</QLGN:FairValueOfWarrantLiabilitiesOnDateOfExercise>
    <QLGN:ChangeInFairValueOfWarrantLiabilities
      contextRef="From2021-01-012021-12-31_us-gaap_FairValueInputsLevel3Member"
      decimals="0"
      unitRef="USD">-4723187</QLGN:ChangeInFairValueOfWarrantLiabilities>
    <QLGN:ChangeInFairValueOfWarrantLiabilities
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">-4723187</QLGN:ChangeInFairValueOfWarrantLiabilities>
    <QLGN:FairValueAdjustmentOfWarrant
      contextRef="AsOf2021-12-31_us-gaap_FairValueInputsLevel3Member"
      decimals="0"
      unitRef="USD">1686200</QLGN:FairValueAdjustmentOfWarrant>
    <QLGN:FairValueAdjustmentOfWarrant contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">1686200</QLGN:FairValueAdjustmentOfWarrant>
    <QLGN:ScheduleOfAssumptionsOfWarrantLiabilitiesTableTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_893_ecustom--ScheduleOfAssumptionsOfWarrantLiabilitiesTableTextBlock_zUrjGat2pOm7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following are the weighted average and the range of assumptions used in estimating the fair value of warrant liabilities (weighted average
calculated based on the number of outstanding warrants on each issuance) as of December 31, 2022 and December 31, 2021:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span id="xdx_8B8_zXu2zfSuQhk8" style="display: none"&gt;SCHEDULE
OF ASSUMPTIONS OF WARRANT LIABILITIES&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"/&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"/&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 11pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;December 31, 2022&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;December 31, 2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 11pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Range&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Weighted&lt;br/&gt; Average&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Range&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Weighted&lt;br/&gt; Average&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 11pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-size: 11pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 11pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-size: 11pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 11pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-size: 11pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 11pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-size: 11pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 11pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 38%; text-align: left"&gt;Risk-free interest rate&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90F_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20221231__srt--RangeAxis__srt--MinimumMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zSh0YEfZ8bD2" title="Fair value assumptions, measurement input, percentages"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1305"&gt;3.906%&lt;/span&gt;&lt;/span&gt;
                                            &#x2014; &lt;span id="xdx_909_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20221231__srt--RangeAxis__srt--MaximumMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_z2M90k7YyeQa" title="Fair value assumptions, measurement input, percentages"&gt;4.628&lt;/span&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;&lt;span id="xdx_907_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20221231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--WeightedAverageMember_znbc0RjerXb7" title="Fair value assumptions, measurement input, percentages"&gt;4.15&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_905_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20211231__srt--RangeAxis__srt--MinimumMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zJI6idtaQfU5" title="Fair value assumptions, measurement input, percentages"&gt;0.69%&lt;/span&gt;
                                            &#x2014; &lt;span id="xdx_902_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20211231__srt--RangeAxis__srt--MaximumMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zSmNpTAFL4Gg" title="Fair value assumptions, measurement input, percentages"&gt;0.84&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;%&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;&lt;span id="xdx_90C_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20211231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--WeightedAverageMember_z6QdufRA9ndh" title="Fair value assumptions, measurement input, percentages"&gt;0.72&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Expected volatility (peer group)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_908_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20221231__srt--RangeAxis__srt--MinimumMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zit3kgSqXrtb" title="Expected volatility"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1317"&gt;88%&lt;/span&gt;&lt;/span&gt;
                                            &#x2014; &lt;span id="xdx_908_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20221231__srt--RangeAxis__srt--MaximumMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zLsHapTdV8Z6" title="Expected volatility"&gt;103&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_903_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20221231__srt--RangeAxis__srt--WeightedAverageMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zF6rWT0z5K69" title="Expected volatility"&gt;98&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_909_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20211231__srt--RangeAxis__srt--MinimumMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zoHjfNGTL03i" title="Expected volatility"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1323"&gt;84%&lt;/span&gt;&lt;/span&gt;
                                            &#x2014; &lt;span id="xdx_90A_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20211231__srt--RangeAxis__srt--MaximumMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_z9PatBOSI5Tc" title="Expected volatility"&gt;87&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90D_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20211231__srt--RangeAxis__srt--WeightedAverageMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zahxBsQHA2Kk" title="Expected volatility"&gt;85&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Term of warrants (in years)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90D_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20221231__srt--RangeAxis__srt--MinimumMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_z0eLWOuKRvbc" title="Fair value assumptions, measurement input, term"&gt;.90&lt;/span&gt;
                                            &#x2014; &lt;span id="xdx_905_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20221231__srt--RangeAxis__srt--MaximumMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_zR6KYxzz12Jb" title="Fair value assumptions, measurement input, term"&gt;5.48&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_906_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20221231__srt--RangeAxis__srt--WeightedAverageMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_zDr2I1FtDGdj" title="Fair value assumptions, measurement input, term"&gt;3.9&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90E_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20211231__srt--RangeAxis__srt--MinimumMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_zDR8E7tt1go8" title="Fair value assumptions, measurement input, term"&gt;1.90&lt;/span&gt;
                                            &#x2014; &lt;span id="xdx_902_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20211231__srt--RangeAxis__srt--MaximumMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_zZURLdhnmmP7" title="Fair value assumptions, measurement input, term"&gt;2.50&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90A_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20211231__srt--RangeAxis__srt--WeightedAverageMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_zP51RGjPTRe7" title="Fair value assumptions, measurement input, term"&gt;2.01&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Expected dividend yield&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20221231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zK2qdLEmQqJ7" title="Fair value assumptions, measurement input, percentages"&gt;0.00&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_901_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20221231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember__srt--RangeAxis__srt--WeightedAverageMember_zwosA5i5B0sc" title="Fair value assumptions, measurement input, percentages"&gt;0.00&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20211231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zZTTgQ114pN1" title="Fair value assumptions, measurement input, percentages"&gt;0.00&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_900_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20211231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember__srt--RangeAxis__srt--WeightedAverageMember_zW3iPjqQxj3f" title="Fair value assumptions, measurement input, percentages"&gt;0.00&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"/&gt;

</QLGN:ScheduleOfAssumptionsOfWarrantLiabilitiesTableTextBlock>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2022-12-31_srt_MaximumMember_us-gaap_MeasurementInputRiskFreeInterestRateMember"
      decimals="INF"
      unitRef="Pure">4.628</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2022-12-31_us-gaap_MeasurementInputRiskFreeInterestRateMember_srt_WeightedAverageMember"
      decimals="INF"
      unitRef="Pure">4.15</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2021-12-31_srt_MinimumMember_us-gaap_MeasurementInputRiskFreeInterestRateMember"
      decimals="INF"
      unitRef="Pure">0.69</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2021-12-31_srt_MaximumMember_us-gaap_MeasurementInputRiskFreeInterestRateMember"
      decimals="INF"
      unitRef="Pure">0.84</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2021-12-31_us-gaap_MeasurementInputRiskFreeInterestRateMember_srt_WeightedAverageMember"
      decimals="INF"
      unitRef="Pure">0.72</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2022-12-31_srt_MaximumMember_us-gaap_MeasurementInputPriceVolatilityMember"
      decimals="INF"
      unitRef="Pure">103</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2022-12-31_srt_WeightedAverageMember_us-gaap_MeasurementInputPriceVolatilityMember"
      decimals="INF"
      unitRef="Pure">98</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2021-12-31_srt_MaximumMember_us-gaap_MeasurementInputPriceVolatilityMember"
      decimals="INF"
      unitRef="Pure">87</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2021-12-31_srt_WeightedAverageMember_us-gaap_MeasurementInputPriceVolatilityMember"
      decimals="INF"
      unitRef="Pure">85</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingTerm contextRef="AsOf2022-12-31_srt_MinimumMember_us-gaap_MeasurementInputExpectedTermMember">P0Y10M24D</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:WarrantsAndRightsOutstandingTerm contextRef="AsOf2022-12-31_srt_MaximumMember_us-gaap_MeasurementInputExpectedTermMember">P5Y5M23D</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:WarrantsAndRightsOutstandingTerm contextRef="AsOf2022-12-31_srt_WeightedAverageMember_us-gaap_MeasurementInputExpectedTermMember">P3Y10M24D</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:WarrantsAndRightsOutstandingTerm contextRef="AsOf2021-12-31_srt_MinimumMember_us-gaap_MeasurementInputExpectedTermMember">P1Y10M24D</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:WarrantsAndRightsOutstandingTerm contextRef="AsOf2021-12-31_srt_MaximumMember_us-gaap_MeasurementInputExpectedTermMember">P2Y6M</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:WarrantsAndRightsOutstandingTerm contextRef="AsOf2021-12-31_srt_WeightedAverageMember_us-gaap_MeasurementInputExpectedTermMember">P2Y3D</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2022-12-31_us-gaap_MeasurementInputExpectedDividendRateMember"
      decimals="INF"
      unitRef="Pure">0.00</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2022-12-31_us-gaap_MeasurementInputExpectedDividendRateMember_srt_WeightedAverageMember"
      decimals="INF"
      unitRef="Pure">0.00</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2021-12-31_us-gaap_MeasurementInputExpectedDividendRateMember"
      decimals="INF"
      unitRef="Pure">0.00</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2021-12-31_us-gaap_MeasurementInputExpectedDividendRateMember_srt_WeightedAverageMember"
      decimals="INF"
      unitRef="Pure">0.00</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:DebtDisclosureTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_80B_eus-gaap--DebtDisclosureTextBlock_z9OmxLFhk9A1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
11 &#x2014; &lt;span id="xdx_828_zn2ByDMuxcoh"&gt;CONVERTIBLE DEBT - RELATED PARTY&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
December 22, 2022, the Company issued to Alpha Capital, an &lt;span id="xdx_902_eus-gaap--ShortTermDebtInterestRateIncrease_pid_dp_uPure_c20221222__20221222__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember__us-gaap--DebtInstrumentAxis__custom--SeniorConvertibleDebentureMember_zuFRI2SmP6aj" title="Senior convertible debenture rate"&gt;8%&lt;/span&gt; Senior Convertible Debenture in the aggregate principal amount of $&lt;span id="xdx_902_eus-gaap--SecuredDebt_iI_c20221222__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember__us-gaap--DebtInstrumentAxis__custom--SeniorConvertibleDebentureMember_zFjlBePNcWbg" title="Principal amount"&gt;3,300,000&lt;/span&gt;
for a purchase price of $&lt;span id="xdx_90C_ecustom--PurchasePrice_iI_c20221222__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember__us-gaap--DebtInstrumentAxis__custom--SeniorConvertibleDebentureMember_zdLia0UcJPnd" title="Purchase Price"&gt;3,000,000&lt;/span&gt; pursuant to the terms of a Securities Purchase Agreement, dated December 21, 2022 (the &#x201c;Alpha
Purchase Agreement&#x201d;). The Debenture is convertible, at any time, and from time to time, at Alpha&#x2019;s option, into shares of
common stock of the Company (the &#x201c;Conversion Shares&#x201d;), at a price equal to $&lt;span id="xdx_904_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pid_c20221222__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember__us-gaap--DebtInstrumentAxis__custom--SeniorConvertibleDebentureMember_zKupsPjE5LY4" title="Conversion price"&gt;1.32&lt;/span&gt; per share, subject to adjustment as described
in the Debenture (the &#x201c;Conversion Price&#x201d;) and other terms and conditions described in the Debenture, including the Company&#x2019;s
receipt of the requisite stockholder approvals. Additionally, on December 22, 2022, the Company issued to Alpha Capital a liability classified warrant to purchase
&lt;span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20221222__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember_zvrBJUvRVqJ5" title="Warrant to purchase shares"&gt;2,500,000&lt;/span&gt; shares of the Company&#x2019;s common stock (see Note 10-Warrant Liabilities). The exercise price of the warrant is $&lt;span id="xdx_905_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20221222__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember_zIBuKGkTrdF9" title="Exercise price of warrant"&gt;1.65&lt;/span&gt; (equal to &lt;span id="xdx_904_ecustom--ConversionPricePercentage_dp_uPure_c20221219__20221222__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember_zOPPXckyWKaj" title="Conversion price percentage"&gt;125&lt;/span&gt;% of the conversion
price of the Debenture on the closing date). The warrant may be exercised by Alpha Capital, in whole or in part, at any time on or after
June 22, 2023 and before June 22, 2028, subject to certain terms conditions described in the warrant, including the Company&#x2019;s receipt
of the necessary stockholder approvals.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
proceeds from the transaction will be dedicated to the Company&#x2019;s efforts of advancing its QN-302 Investigative New Drug candidate
towards clinical trials and other working capital purposes.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Commencing
June 1, 2023 and continuing on the first day of each month thereafter until the earlier of (i) December 22, 2025 and (ii) the full redemption
of the Debenture (each such date, a &#x201c;Monthly Redemption Date&#x201d;), the Company will redeem $&lt;span id="xdx_903_eus-gaap--DebtInstrumentIncreaseAccruedInterest_c20221222__20221222__us-gaap--DebtInstrumentAxis__custom--SeniorConvertibleDebentureMember_z2DarAAqVvs7" title="Unpaid interest"&gt;110,000&lt;/span&gt; plus accrued but unpaid
interest, liquidated damages and any amounts then owing under the Debenture (the &#x201c;Monthly Redemption Amount&#x201d;). The Monthly
Redemption Amount will be paid in cash; provided that after the first two monthly redemptions, the Company may elect to pay all or a
portion of a Monthly Redemption Amount in shares of common stock of the Company, based on a conversion price equal to the lesser of (i)
the then Conversion Price of the Debenture and (ii) &lt;span id="xdx_908_eus-gaap--DebtConversionConvertedInstrumentRate_pid_dp_uPure_c20221222__20221222__us-gaap--DebtInstrumentAxis__custom--SeniorConvertibleDebentureMember_zzSyfBCM6PRa" title="Conversion rate"&gt;85%&lt;/span&gt; of the average of the VWAPs (as defined in the Debenture) for the five consecutive
trading days ending on the trading day that is immediately prior to the applicable Monthly Redemption Date. The Company may also redeem
some or all of the then outstanding principal amount of the Debenture at any time for cash in an amount equal to &lt;span id="xdx_90F_ecustom--PrincipalAmountPercentage_pid_dp_uPure_c20221222__20221222__us-gaap--DebtInstrumentAxis__custom--SeniorConvertibleDebentureMember_zuo1xCjerRd4" title="Principal amount percentage"&gt;105%&lt;/span&gt; of the then outstanding
principal amount of the Debenture being redeemed plus accrued but unpaid interest, liquidated damages and any amounts then owing under
the Debenture. These monthly redemption and optional redemptions are subject to the satisfaction of the Equity Conditions (as defined
in the Debenture), which includes a condition that we have obtained stockholder approval for such share issuances.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Debenture accrues interest at the rate of &lt;span id="xdx_908_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_dp_uPure_c20221222_zqktQaiukE0e" title="Debenture accrues interest rate"&gt;8%&lt;/span&gt; per annum, which does not begin accruing until December 1, 2023, and will be payable on
a quarterly basis. Interest may be paid in cash or shares of common stock of the Company or a combination thereof at the option of the
Company; provided that interest may only be paid in shares if the Equity Conditions have been satisfied, including the stockholder approval
condition as described above.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Both
the Debenture and the Alpha Warrant provide for adjustments to the Conversion Price and Exercise Price, respectively, in connection with
stock dividends and splits, subsequent equity sales and rights offerings, pro rata distributions, and certain fundamental transactions.
Both the Debenture and the Alpha Warrant include a beneficial ownership blocker of 9.99%, which may only be waived by Alpha Capital upon
61 days&#x2019; notice to the Company.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"/&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company filed a registration statement on Form S-3 (No. 333-269088) with the Securities and Exchange Commission on December 30, 2022
registering the resale by Alpha Capital of an aggregate of &lt;span id="xdx_90D_eus-gaap--CommonStockSharesIssued_iI_c20221230__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember_z8Hbnh4pDkBb" title="Shares of Common stock, issued"&gt;5,157,087&lt;/span&gt; shares of our common stock, which may be issuable to the selling
stockholder pursuant to the terms of the Debenture and Alpha Warrant.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company evaluated the Debenture and Alpha Warrants (&#x201c;Warrants&#x201d;) and determined that the Warrants are freestanding financial
instruments. The Warrants are not considered indexed to an entity&#x2019;s own stock, because the settlement amount would not equal the
difference between the fair value of a fixed number of the entity&#x2019;s equity shares and a fixed strike price and all of the adjustment
features in Section 3(b) of the warrant agreement are not down round provisions, as defined in ASU 2017-11. Accordingly, the warrants
are classified as a liability and recognized at fair value, with subsequent changes in fair value recognized in earnings.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
proceeds were allocated to the initial fair value of the Warrants, with the residual balance allocated to the initial carrying value
of the Debenture. The Company has not elected the fair value option for the Debenture. The Debenture was recognized at proceeds received
after allocating the proceeds to the Warrants, and then allocating remaining proceeds to a suite of bifurcated embedded derivative features
(conversion option, contingent acceleration upon an Event of Default, and contingent interest upon an Event of Default), with the resulting
difference, if any, allocated to the loan host instrument. The suite of derivative features was measured and determined to have no fair
value.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
original issue discount ($&lt;span id="xdx_90F_eus-gaap--AmortizationOfDebtDiscountPremium_pn5n6_c20220101__20221231__srt--TitleOfIndividualAxis__custom--AlphaCapitalOtherThirdPartiesMember_zp4lvSqRUHC6" title="Debt discount"&gt;0.3&lt;/span&gt; million), the initial fair value of the Warrant ($&lt;span id="xdx_90D_eus-gaap--FairValueAdjustmentOfWarrants_pn5n6_c20220101__20221231__srt--TitleOfIndividualAxis__custom--AlphaCapitalOtherThirdPartiesMember_zO2owtL4DxRk" title="Fair value of warrants"&gt;2.8&lt;/span&gt; million), the initial fair value of the suite of
bifurcated embedded derivative features ($&lt;span id="xdx_909_eus-gaap--EmbeddedDerivativeFairValueOfEmbeddedDerivativeNet_iI_c20221231__srt--TitleOfIndividualAxis__custom--AlphaCapitalOtherThirdPartiesMember_zI0TkalCerC5" title="Fair value of embedded derivative features"&gt;0&lt;/span&gt;), and the fees and costs paid to Alpha Capital and other third parties ($&lt;span id="xdx_90D_ecustom--FeesAndCostsPaid_pn5n6_c20220101__20221231__srt--TitleOfIndividualAxis__custom--AlphaCapitalOtherThirdPartiesMember_zScSabRjudtg" title="Fees and costs paid"&gt;0.1&lt;/span&gt; million) comprise
the debt discount.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
debt discount shall be amortized to interest expense over the expected term of the Debenture using the effective interest method, in
accordance with ASC 835-30. The debt host instrument of the Debenture will subsequently be measured at amortized cost using the effective
interest method to accrete interest over its term to bring the Debenture&#x2019;s initial carrying value to the principal balance at maturity.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_893_eus-gaap--ConvertibleDebtTableTextBlock_ztEJAzIDLiAf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
senior secured convertible debt comprises the following:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span id="xdx_8BC_z1WPDg8CZWAc" style="display: none"&gt;SCHEDULE OF SENIOR SECURED CONVERTIBLE DEBT&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49B_20221231__us-gaap--DebtInstrumentAxis__custom--SeniorSecuredConvertibleDebtMember_zeAxq957M6G" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;December 31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49A_20211231__us-gaap--DebtInstrumentAxis__custom--SeniorSecuredConvertibleDebtMember_zH6RVIUHly2d" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;December 31, 2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--SecuredDebt_iI_zAbA2kDFz948" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;Senior secured convertible debenture&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;3,300,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1386"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--DebtInstrumentUnamortizedDiscount_iNI_di_zxkB9aHFk1al" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Discount on convertible debenture&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(3,239,803&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1389"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--ConvertibleDebt_iI_zRqBAw6xB991" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt"&gt;Total convertible debt - related party&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;60,197&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1392"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A8_zt7yx6G1i148" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of December 31, 2022, there were no events of default or violation of any covenants under our financing obligations.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:ShortTermDebtInterestRateIncrease
      contextRef="From2022-12-222022-12-22_custom_AlphaCapitalMember_custom_SeniorConvertibleDebentureMember"
      decimals="INF"
      unitRef="Pure">0.08</us-gaap:ShortTermDebtInterestRateIncrease>
    <us-gaap:SecuredDebt
      contextRef="AsOf2022-12-22_custom_AlphaCapitalMember_custom_SeniorConvertibleDebentureMember"
      decimals="0"
      unitRef="USD">3300000</us-gaap:SecuredDebt>
    <QLGN:PurchasePrice
      contextRef="AsOf2022-12-22_custom_AlphaCapitalMember_custom_SeniorConvertibleDebentureMember"
      decimals="0"
      unitRef="USD">3000000</QLGN:PurchasePrice>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="AsOf2022-12-22_custom_AlphaCapitalMember_custom_SeniorConvertibleDebentureMember"
      decimals="INF"
      unitRef="USDPShares">1.32</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2022-12-22_custom_SeriesCWarrantsMember_custom_AlphaCapitalMember"
      decimals="INF"
      unitRef="Shares">2500000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2022-12-22_custom_SeriesCWarrantsMember_custom_AlphaCapitalMember"
      decimals="INF"
      unitRef="USDPShares">1.65</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <QLGN:ConversionPricePercentage
      contextRef="From2022-12-192022-12-22_custom_SeriesCWarrantsMember_custom_AlphaCapitalMember"
      decimals="INF"
      unitRef="Pure">1.25</QLGN:ConversionPricePercentage>
    <us-gaap:DebtInstrumentIncreaseAccruedInterest
      contextRef="From2022-12-222022-12-22_custom_SeniorConvertibleDebentureMember"
      decimals="0"
      unitRef="USD">110000</us-gaap:DebtInstrumentIncreaseAccruedInterest>
    <us-gaap:DebtConversionConvertedInstrumentRate
      contextRef="From2022-12-222022-12-22_custom_SeniorConvertibleDebentureMember"
      decimals="INF"
      unitRef="Pure">0.85</us-gaap:DebtConversionConvertedInstrumentRate>
    <QLGN:PrincipalAmountPercentage
      contextRef="From2022-12-222022-12-22_custom_SeniorConvertibleDebentureMember"
      decimals="INF"
      unitRef="Pure">1.05</QLGN:PrincipalAmountPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="AsOf2022-12-22" decimals="INF" unitRef="Pure">0.08</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2022-12-30_custom_AlphaCapitalMember"
      decimals="INF"
      unitRef="Shares">5157087</us-gaap:CommonStockSharesIssued>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="From2022-01-012022-12-31_custom_AlphaCapitalOtherThirdPartiesMember"
      decimals="-5"
      unitRef="USD">300000</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="From2022-01-012022-12-31_custom_AlphaCapitalOtherThirdPartiesMember"
      decimals="-5"
      unitRef="USD">2800000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:EmbeddedDerivativeFairValueOfEmbeddedDerivativeNet
      contextRef="AsOf2022-12-31_custom_AlphaCapitalOtherThirdPartiesMember"
      decimals="0"
      unitRef="USD">0</us-gaap:EmbeddedDerivativeFairValueOfEmbeddedDerivativeNet>
    <QLGN:FeesAndCostsPaid
      contextRef="From2022-01-012022-12-31_custom_AlphaCapitalOtherThirdPartiesMember"
      decimals="-5"
      unitRef="USD">100000</QLGN:FeesAndCostsPaid>
    <us-gaap:ConvertibleDebtTableTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_893_eus-gaap--ConvertibleDebtTableTextBlock_ztEJAzIDLiAf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
senior secured convertible debt comprises the following:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span id="xdx_8BC_z1WPDg8CZWAc" style="display: none"&gt;SCHEDULE OF SENIOR SECURED CONVERTIBLE DEBT&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49B_20221231__us-gaap--DebtInstrumentAxis__custom--SeniorSecuredConvertibleDebtMember_zeAxq957M6G" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;December 31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49A_20211231__us-gaap--DebtInstrumentAxis__custom--SeniorSecuredConvertibleDebtMember_zH6RVIUHly2d" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;December 31, 2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--SecuredDebt_iI_zAbA2kDFz948" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;Senior secured convertible debenture&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;3,300,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1386"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--DebtInstrumentUnamortizedDiscount_iNI_di_zxkB9aHFk1al" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Discount on convertible debenture&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(3,239,803&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1389"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--ConvertibleDebt_iI_zRqBAw6xB991" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt"&gt;Total convertible debt - related party&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;60,197&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1392"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ConvertibleDebtTableTextBlock>
    <us-gaap:SecuredDebt
      contextRef="AsOf2022-12-31_custom_SeniorSecuredConvertibleDebtMember"
      decimals="0"
      unitRef="USD">3300000</us-gaap:SecuredDebt>
    <us-gaap:DebtInstrumentUnamortizedDiscount
      contextRef="AsOf2022-12-31_custom_SeniorSecuredConvertibleDebtMember"
      decimals="0"
      unitRef="USD">3239803</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:ConvertibleDebt
      contextRef="AsOf2022-12-31_custom_SeniorSecuredConvertibleDebtMember"
      decimals="0"
      unitRef="USD">60197</us-gaap:ConvertibleDebt>
    <us-gaap:EarningsPerShareTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_805_eus-gaap--EarningsPerShareTextBlock_zHY7egubaLke" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
12 &#x2014; &lt;span id="xdx_82F_zPGZC2l028Hh"&gt;EARNINGS (LOSS) PER SHARE&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Basic
earnings (loss) per share (&#x201c;EPS&#x201d;) is computed by dividing net income (loss) by the weighted-average number of common
shares outstanding. Diluted EPS is computed based on the sum of the weighted-average number of common shares and potentially
dilutive common shares outstanding during the period. Potentially dilutive common shares consist of shares issuable from stock
options and warrants as shown below.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89B_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_zaoyhmNBTzl3" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table reconciles net loss and the weighted-average shares used in computing basic and diluted EPS in the respective periods:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span id="xdx_8BD_z7LQ3fmEIrCi" style="display: none"&gt;SCHEDULE OF EARNINGS PER SHARE BASIC AND DILUTED&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_497_20220101__20221231_z6dwpAP8J93c" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49A_20210101__20211231_z9KIausBOqgc" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;For the Years Ended&lt;br/&gt; December
    31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--NetIncomeLoss_zJ7l70jhJT83" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left; padding-bottom: 1.5pt"&gt;Net loss used for basic earnings per share&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt double; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt double; width: 16%; text-align: right"&gt;(18,640,543&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt double; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt double; width: 16%; text-align: right"&gt;(17,897,137&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_zu7PiFAlXhde" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Basic weighted-average common shares outstanding&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,840,340&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,933,487&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_ecustom--DilutivePotentialSharesIssuableFromStockOptionsAndWarrants_zAYVlK9dICj5" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Dilutive potential shares issuable from stock options and warrants&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1404"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1405"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--WeightedAverageNumberDilutedSharesOutstandingAdjustment_zGRAE7ZM1bQi" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Diluted weighted-average common shares outstanding&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;3,840,340&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;2,933,487&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p id="xdx_8A6_zuXyI6L94J1a" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_892_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zBltfnfiJ6zd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span id="xdx_8B1_zEGCJvcq8ezb" style="display: none"&gt;SCHEDULE
OF DILUTIVE SECURITIES EXCLUDED FROM DILUTED NET LOSS PER SHARE&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;As of December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;Shares of common stock subject to outstanding options&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20220101__20221231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--SharesOfCommonStockSubjectToOutstandingOptionsMember_ztotXvbX597a" style="width: 16%; text-align: right" title="Total common stock equivalents"&gt;608,012&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20210101__20211231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--SharesOfCommonStockSubjectToOutstandingOptionsMember_zlSKky8vBqE7" style="width: 16%; text-align: right" title="Total common stock equivalents"&gt;484,186&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Shares of common stock subject to outstanding warrants&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20220101__20221231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--SharesOfCommonStockSubjectToOutstandingWarrantsMember_zpZnNV69Vlba" style="border-bottom: Black 1.5pt solid; text-align: right" title="Total common stock equivalents"&gt;4,575,617&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20210101__20211231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--SharesOfCommonStockSubjectToOutstandingWarrantsMember_zYNSh0cCai5j" style="border-bottom: Black 1.5pt solid; text-align: right" title="Total common stock equivalents"&gt;982,140&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Total common stock equivalents&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20220101__20221231_z4StuYQKGSP5" style="border-bottom: Black 2.5pt double; text-align: right" title="Total common stock equivalents"&gt;5,183,629&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20210101__20211231_zZ2vqFx77pi6" style="border-bottom: Black 2.5pt double; text-align: right" title="Total common stock equivalents"&gt;1,466,326&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;



&lt;p id="xdx_8A9_zvcqruAJdDuf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"/&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Potentially
dilutive common shares excluded from the calculation above represent stock options and warrants because their effect would be anti-dilutive.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_89B_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_zaoyhmNBTzl3" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table reconciles net loss and the weighted-average shares used in computing basic and diluted EPS in the respective periods:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span id="xdx_8BD_z7LQ3fmEIrCi" style="display: none"&gt;SCHEDULE OF EARNINGS PER SHARE BASIC AND DILUTED&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_497_20220101__20221231_z6dwpAP8J93c" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49A_20210101__20211231_z9KIausBOqgc" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;For the Years Ended&lt;br/&gt; December
    31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--NetIncomeLoss_zJ7l70jhJT83" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left; padding-bottom: 1.5pt"&gt;Net loss used for basic earnings per share&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt double; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt double; width: 16%; text-align: right"&gt;(18,640,543&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt double; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt double; width: 16%; text-align: right"&gt;(17,897,137&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_zu7PiFAlXhde" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Basic weighted-average common shares outstanding&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,840,340&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,933,487&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_ecustom--DilutivePotentialSharesIssuableFromStockOptionsAndWarrants_zAYVlK9dICj5" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Dilutive potential shares issuable from stock options and warrants&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1404"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1405"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--WeightedAverageNumberDilutedSharesOutstandingAdjustment_zGRAE7ZM1bQi" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Diluted weighted-average common shares outstanding&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;3,840,340&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;2,933,487&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">-18640543</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">-17897137</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2022-01-01to2022-12-31"
      decimals="INF"
      unitRef="Shares">3840340</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2021-01-012021-12-31"
      decimals="INF"
      unitRef="Shares">2933487</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="From2022-01-01to2022-12-31"
      decimals="INF"
      unitRef="Shares">3840340</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="From2021-01-012021-12-31"
      decimals="INF"
      unitRef="Shares">2933487</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_892_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zBltfnfiJ6zd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span id="xdx_8B1_zEGCJvcq8ezb" style="display: none"&gt;SCHEDULE
OF DILUTIVE SECURITIES EXCLUDED FROM DILUTED NET LOSS PER SHARE&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;As of December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;Shares of common stock subject to outstanding options&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20220101__20221231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--SharesOfCommonStockSubjectToOutstandingOptionsMember_ztotXvbX597a" style="width: 16%; text-align: right" title="Total common stock equivalents"&gt;608,012&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20210101__20211231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--SharesOfCommonStockSubjectToOutstandingOptionsMember_zlSKky8vBqE7" style="width: 16%; text-align: right" title="Total common stock equivalents"&gt;484,186&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Shares of common stock subject to outstanding warrants&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20220101__20221231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--SharesOfCommonStockSubjectToOutstandingWarrantsMember_zpZnNV69Vlba" style="border-bottom: Black 1.5pt solid; text-align: right" title="Total common stock equivalents"&gt;4,575,617&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20210101__20211231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--SharesOfCommonStockSubjectToOutstandingWarrantsMember_zYNSh0cCai5j" style="border-bottom: Black 1.5pt solid; text-align: right" title="Total common stock equivalents"&gt;982,140&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Total common stock equivalents&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20220101__20221231_z4StuYQKGSP5" style="border-bottom: Black 2.5pt double; text-align: right" title="Total common stock equivalents"&gt;5,183,629&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20210101__20211231_zZ2vqFx77pi6" style="border-bottom: Black 2.5pt double; text-align: right" title="Total common stock equivalents"&gt;1,466,326&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;



</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2022-01-012022-12-31_custom_SharesOfCommonStockSubjectToOutstandingOptionsMember"
      decimals="INF"
      unitRef="Shares">608012</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2021-01-012021-12-31_custom_SharesOfCommonStockSubjectToOutstandingOptionsMember"
      decimals="INF"
      unitRef="Shares">484186</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2022-01-012022-12-31_custom_SharesOfCommonStockSubjectToOutstandingWarrantsMember"
      decimals="INF"
      unitRef="Shares">4575617</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2021-01-012021-12-31_custom_SharesOfCommonStockSubjectToOutstandingWarrantsMember"
      decimals="INF"
      unitRef="Shares">982140</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2022-01-01to2022-12-31"
      decimals="INF"
      unitRef="Shares">5183629</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2021-01-012021-12-31"
      decimals="INF"
      unitRef="Shares">1466326</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_806_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_z9iGw5PtcN4f" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
13 &#x2014; &lt;span id="xdx_821_zjEMbMiCADH3"&gt;COMMITMENTS AND CONTINGENCIES&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Leases&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company leases its facilities under a long-term operating lease agreement. On December 15, 2021, our wholly-owned subsidiary Qualigen,
Inc. entered into a Second Amendment to Lease with Bond Ranch LP. This Amendment extended the Company&#x2019;s triple-net leasehold on
the Company&#x2019;s existing &lt;span id="xdx_907_eus-gaap--AreaOfLand_iI_pid_uSqft_c20211215_zaAbtsgHCJIi" title="Area of land"&gt;22,624&lt;/span&gt;-square-feet headquarters/manufacturing facility at 2042 Corte del Nogal, Carlsbad, California for
the &lt;span id="xdx_907_eus-gaap--LesseeOperatingLeaseTermOfContract_iI_dtM_c20211215_zmFD2xTsFte8" title="Lessee operating lease term of contract"&gt;61&lt;/span&gt;-month period of &lt;span id="xdx_90F_eus-gaap--LesseeOperatingLeaseDescription_c20211214__20211215_z6AeFyO5EqWc" title="Operating lease term description"&gt;November 1, 2022 to November 30, 2027&lt;/span&gt;. Over the &lt;span id="xdx_907_eus-gaap--LesseeOperatingLeaseTermOfContract_iI_dtM_c20211215_zVIwr4pGAJNi" title="Operating lease term"&gt;61&lt;/span&gt; months, the base rent payable by Qualigen, Inc. will total
$&lt;span id="xdx_908_eus-gaap--PaymentsForRent_pp0p0_c20211214__20211215_zD87jiSScl8l" title="Payments for Rent"&gt;1,950,710&lt;/span&gt;; however, the base rent for the first 12 months of the &lt;span id="xdx_907_eus-gaap--LesseeOperatingLeaseTermOfContract_iI_dtM_c20211215_zvVNz8xyQE5h" title="Operating lease term"&gt;61&lt;/span&gt;-month period is only $&lt;span id="xdx_906_eus-gaap--PaymentsForRent_pp0p0_c20211214__20211215__us-gaap--AwardTypeAxis__custom--FirstTwelveMonthsMember_zRstPgwarKb1" title="Payments for Rent"&gt;335,966&lt;/span&gt;. Additionally, under the Second Amendment
to Lease Qualigen, Inc. is entitled to a $&lt;span id="xdx_90D_ecustom--TenantImprovementAllowance_pp0p0_c20211214__20211215_z109P4LxiNbe" title="Tenant improvement allowance"&gt;339,360&lt;/span&gt; tenant improvement allowance.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_899_ecustom--ScheduleOfOperatingLeaseRightOfUseAssetsAndLiabilitiesTableTextBlock_z0ulwQjfH8U4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
tables below show the operating lease right-of-use assets and operating lease liabilities and the balances as of December 31, 2022 and 2021,
including the changes during the periods:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span id="xdx_8BA_ziFz6VW0TG05" style="display: none"&gt;SCHEDULE OF OPERATING LEASE RIGHT OF USE ASSETS AND OPERATING LEASE LIABILITIES&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"/&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"/&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 11pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Operating lease&lt;br/&gt;
 right-of-use assets&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Net right-of-use assets at December 31, 2021&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--OperatingLeaseRightOfUseAsset_iS_pp0p0_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--LongtermOperatingLeaseAgreementMember_zoWJJfQiX20c" style="width: 20%; text-align: right" title="Operating lease right-of-use assets"&gt;1,645,568&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Less amortization of operating lease right-of-use assets&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--OperatingLeaseRightOfUseAssetAmortizationExpense_iN_pp0p0_di_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--LongtermOperatingLeaseAgreementMember_zRBGziJpQXff" style="border-bottom: Black 1.5pt solid; text-align: right" title="Less amortization of operating lease right-of-use assets"&gt;(223,030&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Operating lease right-of-use assets at December 31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--OperatingLeaseRightOfUseAsset_iE_pp0p0_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--LongtermOperatingLeaseAgreementMember_z9nu3gT7HO9i" style="border-bottom: Black 2.5pt double; text-align: right" title="Operating lease right-of-use assets"&gt;1,422,538&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"/&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"/&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 11pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;Operating lease &lt;br/&gt;
liabilities&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: justify"&gt;Lease liabilities at December 31, 2021&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--OperatingLeaseLiability_iS_pp0p0_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--LongtermOperatingLeaseAgreementMember_z3PIOEpBaz6c" style="width: 20%; text-align: right" title="Lease liabilities at December 31, 2021"&gt;1,676,655&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Less principal payments on operating lease liabilities&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--OperatingLeasePayments_iN_pp0p0_di_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--LongtermOperatingLeaseAgreementMember_z7BsWNkVCFb3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Less principal payments on operating lease liabilities"&gt;(134,091&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Lease liabilities at December 31, 2022&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--OperatingLeaseLiability_iE_pp0p0_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--LongtermOperatingLeaseAgreementMember_z2BlWDvHWsEe" style="text-align: right" title="Lease liabilities at December 31, 2022"&gt;1,542,564&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Less non-current portion&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--OperatingLeaseLiabilityNoncurrent_iNI_pp0p0_di_c20221231__us-gaap--TypeOfArrangementAxis__custom--LongtermOperatingLeaseAgreementMember_zhXkVZb3zUD4" style="border-bottom: Black 1.5pt solid; text-align: right" title="Less non-current portion"&gt;(1,301,919&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Current portion at December 31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--OperatingLeaseLiabilityCurrent_iI_pp0p0_c20221231__us-gaap--TypeOfArrangementAxis__custom--LongtermOperatingLeaseAgreementMember_zN5pWBRG2zJe" style="border-bottom: Black 2.5pt double; text-align: right" title="Current portion at Decebmer 31, 2022"&gt;240,645&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AE_zes6jdNH188a" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of December 31, 2022, the Company&#x2019;s operating leases have a weighted-average remaining lease term of &lt;span id="xdx_900_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20221231_zSqpD6tjQxyi" title="Weighted-average remaining lease term"&gt;4.9&lt;/span&gt; years and a weighted-average
discount rate of &lt;span id="xdx_908_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pid_dp_uPure_c20221231_zbSLh6l6MEQ2" title="Weighted-average discount rate"&gt;8.9%&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_896_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_zSBkOaWTrCPh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of December 31, 2022, the maturities of operating lease liabilities are as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span id="xdx_8BE_z9uHZNcDlUZ4" style="display: none"&gt;SCHEDULE OF MATURITIES OF OPERATING LEASE LIABILITIES&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left; font-weight: bold"&gt;Year Ending December 31,&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49E_20221231_zn3gN7h6B1nl" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Amount&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_pp0p0_maLOLLPzeyI_zIWHtmgJn8Ia" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;2023&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 20%; text-align: right"&gt;368,341&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_pp0p0_maLOLLPzeyI_zZMNmVXDq436" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;2024&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;379,392&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_pp0p0_maLOLLPzeyI_zC64ZeHfUxLe" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;2025&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;390,773&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFour_iI_pp0p0_maLOLLPzeyI_z00UeWrsMc3i" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;2026&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;402,497&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFive_iI_pp0p0_maLOLLPzeyI_zTPS48niBBhi" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;2027&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;379,164&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_pp0p0_mtLOLLPzeyI_z2xGUrk62F7k" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Total&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,920,168&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_pp0p0_di_zO7AcWnTUBmh" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Less present value discount&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(377,604&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--OperatingLeaseLiability_iI_pp0p0_zYZMazngQ4g2" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Operating lease liabilities&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,542,564&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AA_zvYjPd46qM0g" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Total
lease expense was approximately $&lt;span id="xdx_900_eus-gaap--OperatingLeaseExpense_c20220101__20221231_zjr6RpIrW6X5"&gt;462,000&lt;/span&gt; and $&lt;span id="xdx_90D_eus-gaap--OperatingLeaseExpense_c20210101__20211231_zgZOSCr6uhje"&gt;342,000&lt;/span&gt;, respectively, for the years ended December 31, 2022 and December 31, 2021. Lease
expense was recorded in cost of product sales, general and administrative expenses, research and development and sales and marketing
expenses.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Termination
of Sekisui Distribution Agreement&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Sekisui&#x2019;s
Distribution Arrangement expired on March 31, 2022. Following the expiration of the Sekisui Distribution Agreement on March 31, 2022,
the Company had a commitment to purchase leased FastPack rental systems back from Sekisui at Sekisui&#x2019;s net book value, in the amount
of $&lt;span id="xdx_901_eus-gaap--AccruedLiabilitiesAndOtherLiabilities_iI_c20221231__srt--TitleOfIndividualAxis__custom--SekisuiDistributionAgreementMember_zQ7KZ4Ig9A6b" title="Accrued expenses"&gt;154,000&lt;/span&gt; which is included in equipment held for lease and accrued expenses on the consolidated balance sheet.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;NanoSynex
Funding Commitment&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
a condition to the NanoSynex Acquisition, the Company agreed to provide NanoSynex with up to $&lt;span id="xdx_908_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iI_pn5n6_c20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NanoSynexMember_zMLqrzeE72Ol" title="Maximum future funding amount"&gt;10.4&lt;/span&gt; million of future funding in the form
of promissory notes to the Company based on NanoSynex&#x2019;s achievement of certain future development milestones and subject to other
terms and conditions described in the Funding Agreement entered into with NanoSynex. Of this amount approximately $&lt;span id="xdx_903_ecustom--DevelopmentFund_pn5n6_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NanoSynexMember_zZAk0FaQXX4f" title="Development fund"&gt;2.4&lt;/span&gt; million was funded
during the year ended December 31, 2022, and an additional $&lt;span id="xdx_906_eus-gaap--LineOfCreditFacilityCurrentBorrowingCapacity_iI_pn5n6_c20230228__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NanoSynexMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zqegjOgAERag" title="Additional funding amount"&gt;0.5&lt;/span&gt; million was funded in February 2023 (See Note 2-Liquidity for further details regarding the terms and conditions of the Funding Agreement).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"/&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Litigation
and Other Legal Proceedings&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
November 9, 2021, the Company was named as a defendant in an action brought by Mediant Communications Inc. (&#x201c;Mediant&#x201d;) in
the U.S. District Court for the Southern District of New York. The complaint alleged that Qualigen entered into an implied contract with
Mediant, whereby Qualigen retained Mediant to distribute proxy materials and subsequently conduct shareholder vote tabulations. The Company
filed a Motion to Dismiss with the District Court and on March 14, 2022 a hearing was held during which the presiding judge ruled in
favor of the Motion to Dismiss. The Company and Mediant settled the litigation on April 5, 2022 in the amount of $&lt;span id="xdx_905_eus-gaap--LitigationSettlementAmountAwardedToOtherParty_pp0p0_c20220404__20220405_z40tOhfkOwOk" title="Litigation settlement amount"&gt;96,558&lt;/span&gt;, at which time
the amount was paid.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:AreaOfLand contextRef="AsOf2021-12-15" decimals="INF" unitRef="Sqft">22624</us-gaap:AreaOfLand>
    <us-gaap:LesseeOperatingLeaseTermOfContract contextRef="AsOf2021-12-15">P61M</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:LesseeOperatingLeaseDescription contextRef="From2021-12-142021-12-15">November 1, 2022 to November 30, 2027</us-gaap:LesseeOperatingLeaseDescription>
    <us-gaap:LesseeOperatingLeaseTermOfContract contextRef="AsOf2021-12-15">P61M</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:PaymentsForRent
      contextRef="From2021-12-142021-12-15"
      decimals="0"
      unitRef="USD">1950710</us-gaap:PaymentsForRent>
    <us-gaap:LesseeOperatingLeaseTermOfContract contextRef="AsOf2021-12-15">P61M</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:PaymentsForRent
      contextRef="From2021-12-142021-12-15_custom_FirstTwelveMonthsMember"
      decimals="0"
      unitRef="USD">335966</us-gaap:PaymentsForRent>
    <QLGN:TenantImprovementAllowance
      contextRef="From2021-12-142021-12-15"
      decimals="0"
      unitRef="USD">339360</QLGN:TenantImprovementAllowance>
    <QLGN:ScheduleOfOperatingLeaseRightOfUseAssetsAndLiabilitiesTableTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_899_ecustom--ScheduleOfOperatingLeaseRightOfUseAssetsAndLiabilitiesTableTextBlock_z0ulwQjfH8U4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
tables below show the operating lease right-of-use assets and operating lease liabilities and the balances as of December 31, 2022 and 2021,
including the changes during the periods:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span id="xdx_8BA_ziFz6VW0TG05" style="display: none"&gt;SCHEDULE OF OPERATING LEASE RIGHT OF USE ASSETS AND OPERATING LEASE LIABILITIES&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"/&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"/&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 11pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Operating lease&lt;br/&gt;
 right-of-use assets&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Net right-of-use assets at December 31, 2021&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--OperatingLeaseRightOfUseAsset_iS_pp0p0_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--LongtermOperatingLeaseAgreementMember_zoWJJfQiX20c" style="width: 20%; text-align: right" title="Operating lease right-of-use assets"&gt;1,645,568&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Less amortization of operating lease right-of-use assets&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--OperatingLeaseRightOfUseAssetAmortizationExpense_iN_pp0p0_di_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--LongtermOperatingLeaseAgreementMember_zRBGziJpQXff" style="border-bottom: Black 1.5pt solid; text-align: right" title="Less amortization of operating lease right-of-use assets"&gt;(223,030&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Operating lease right-of-use assets at December 31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--OperatingLeaseRightOfUseAsset_iE_pp0p0_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--LongtermOperatingLeaseAgreementMember_z9nu3gT7HO9i" style="border-bottom: Black 2.5pt double; text-align: right" title="Operating lease right-of-use assets"&gt;1,422,538&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"/&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"/&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 11pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;Operating lease &lt;br/&gt;
liabilities&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: justify"&gt;Lease liabilities at December 31, 2021&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--OperatingLeaseLiability_iS_pp0p0_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--LongtermOperatingLeaseAgreementMember_z3PIOEpBaz6c" style="width: 20%; text-align: right" title="Lease liabilities at December 31, 2021"&gt;1,676,655&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Less principal payments on operating lease liabilities&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--OperatingLeasePayments_iN_pp0p0_di_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--LongtermOperatingLeaseAgreementMember_z7BsWNkVCFb3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Less principal payments on operating lease liabilities"&gt;(134,091&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Lease liabilities at December 31, 2022&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--OperatingLeaseLiability_iE_pp0p0_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--LongtermOperatingLeaseAgreementMember_z2BlWDvHWsEe" style="text-align: right" title="Lease liabilities at December 31, 2022"&gt;1,542,564&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Less non-current portion&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--OperatingLeaseLiabilityNoncurrent_iNI_pp0p0_di_c20221231__us-gaap--TypeOfArrangementAxis__custom--LongtermOperatingLeaseAgreementMember_zhXkVZb3zUD4" style="border-bottom: Black 1.5pt solid; text-align: right" title="Less non-current portion"&gt;(1,301,919&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Current portion at December 31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--OperatingLeaseLiabilityCurrent_iI_pp0p0_c20221231__us-gaap--TypeOfArrangementAxis__custom--LongtermOperatingLeaseAgreementMember_zN5pWBRG2zJe" style="border-bottom: Black 2.5pt double; text-align: right" title="Current portion at Decebmer 31, 2022"&gt;240,645&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</QLGN:ScheduleOfOperatingLeaseRightOfUseAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="AsOf2021-12-31_custom_LongtermOperatingLeaseAgreementMember"
      decimals="0"
      unitRef="USD">1645568</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="From2022-01-012022-12-31_custom_LongtermOperatingLeaseAgreementMember"
      decimals="0"
      unitRef="USD">223030</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="AsOf2022-12-31_custom_LongtermOperatingLeaseAgreementMember"
      decimals="0"
      unitRef="USD">1422538</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiability
      contextRef="AsOf2021-12-31_custom_LongtermOperatingLeaseAgreementMember"
      decimals="0"
      unitRef="USD">1676655</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeasePayments
      contextRef="From2022-01-012022-12-31_custom_LongtermOperatingLeaseAgreementMember"
      decimals="0"
      unitRef="USD">134091</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeaseLiability
      contextRef="AsOf2022-12-31_custom_LongtermOperatingLeaseAgreementMember"
      decimals="0"
      unitRef="USD">1542564</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="AsOf2022-12-31_custom_LongtermOperatingLeaseAgreementMember"
      decimals="0"
      unitRef="USD">1301919</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="AsOf2022-12-31_custom_LongtermOperatingLeaseAgreementMember"
      decimals="0"
      unitRef="USD">240645</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="AsOf2022-12-31">P4Y10M24D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent contextRef="AsOf2022-12-31" decimals="INF" unitRef="Pure">0.089</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_896_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_zSBkOaWTrCPh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of December 31, 2022, the maturities of operating lease liabilities are as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span id="xdx_8BE_z9uHZNcDlUZ4" style="display: none"&gt;SCHEDULE OF MATURITIES OF OPERATING LEASE LIABILITIES&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left; font-weight: bold"&gt;Year Ending December 31,&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49E_20221231_zn3gN7h6B1nl" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Amount&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_pp0p0_maLOLLPzeyI_zIWHtmgJn8Ia" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;2023&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 20%; text-align: right"&gt;368,341&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_pp0p0_maLOLLPzeyI_zZMNmVXDq436" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;2024&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;379,392&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_pp0p0_maLOLLPzeyI_zC64ZeHfUxLe" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;2025&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;390,773&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFour_iI_pp0p0_maLOLLPzeyI_z00UeWrsMc3i" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;2026&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;402,497&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFive_iI_pp0p0_maLOLLPzeyI_zTPS48niBBhi" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;2027&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;379,164&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_pp0p0_mtLOLLPzeyI_z2xGUrk62F7k" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Total&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,920,168&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_pp0p0_di_zO7AcWnTUBmh" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Less present value discount&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(377,604&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--OperatingLeaseLiability_iI_pp0p0_zYZMazngQ4g2" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Operating lease liabilities&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,542,564&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">368341</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">379392</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">390773</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">402497</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">379164</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">1920168</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">377604</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">1542564</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseExpense
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">462000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">342000</us-gaap:OperatingLeaseExpense>
    <us-gaap:AccruedLiabilitiesAndOtherLiabilities
      contextRef="AsOf2022-12-31_custom_SekisuiDistributionAgreementMember"
      decimals="0"
      unitRef="USD">154000</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="AsOf2022-12-31_custom_NanoSynexMember"
      decimals="-5"
      unitRef="USD">10400000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <QLGN:DevelopmentFund
      contextRef="From2022-01-012022-12-31_custom_NanoSynexMember72014625"
      decimals="-5"
      unitRef="USD">2400000</QLGN:DevelopmentFund>
    <us-gaap:LineOfCreditFacilityCurrentBorrowingCapacity
      contextRef="AsOf2023-02-28_custom_NanoSynexMember_us-gaap_SubsequentEventMember"
      decimals="-5"
      unitRef="USD">500000</us-gaap:LineOfCreditFacilityCurrentBorrowingCapacity>
    <us-gaap:LitigationSettlementAmountAwardedToOtherParty
      contextRef="From2022-04-042022-04-05"
      decimals="0"
      unitRef="USD">96558</us-gaap:LitigationSettlementAmountAwardedToOtherParty>
    <QLGN:ResearchAndLicenseAgreementsTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_80A_ecustom--ResearchAndLicenseAgreementsTextBlock_zVAoYUU74L9j" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
14 &#x2014; &lt;span id="xdx_829_zwvo1fWa5Cz9"&gt;RESEARCH AND LICENSE AGREEMENTS&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;The
University of Louisville Research Foundation&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
March 2019, the Company entered into a sponsored research agreement and an option for a license agreement with ULRF for development of
several small-molecule RAS interaction inhibitor drug candidates. Under the terms of this agreement, the Company was to reimburse ULRF
for sponsored research expenses of up to $&lt;span id="xdx_90A_ecustom--ReimbursementOfResearchExpenses_pp0p0_c20190301__20190331__us-gaap--TypeOfArrangementAxis__custom--SponsoredResearchAgreementAndLicenseMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember_zCLvzpzjMyik"&gt;693,000
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;for this program. In February 2021, March 2022,
and October 2022, the Company extended the term of this agreement until September 2023 and increased the amount that the Company will
reimburse ULRF for sponsored research expenses to approximately $&lt;span id="xdx_906_ecustom--ReimbursementOfResearchExpenses_pn5n6_c20210201__20210228__us-gaap--TypeOfArrangementAxis__custom--SponsoredResearchAgreementAndLicenseMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember_zgeRqiu8lyGl"&gt;2.7
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;million. &lt;span id="xdx_908_ecustom--AgreementTermPaymentDescription_c20190301__20190331__us-gaap--TypeOfArrangementAxis__custom--SponsoredResearchAgreementAndLicenseMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember_zvNNEzQiBlJi"&gt;In
July 2020, the Company entered into an exclusive license agreement with ULRF for RAS interaction inhibitor drug candidates. Under the
agreement, the Company will take over development, regulatory approval and commercialization of the candidates from ULRF and is responsible
for maintenance of the related intellectual property portfolio. In return, ULRF received approximately $112,000 for an upfront license
fee and reimbursement of prior patent costs. In addition, the Company has agreed to pay ULRF (i) royalties, on patent-covered net sales
associated with the commercialization, of 4% (on net sales up to a cumulative $250,000,000) or 5% (on net sales above a cumulative $250,000,000),
until expiration of the licensed patent, and 2.5% (on net sales for any sales not covered by Licensed Patents), (ii) 30% to 50% of any
non-royalty sublicensee income received (50% for sublicenses granted in the first two years of the ULRF license agreement, 40% for sublicenses
granted in the third or fourth years of the ULRF license agreement, and 30% for sublicenses granted in the fifth year of the ULRF license
agreement or thereafter), (iii) reimbursements for ongoing costs associated with the preparation, filing, prosecution and maintenance
of licensed patents, incurred prior to July 2020, and (iv) payments ranging from $&lt;/span&gt;&lt;/span&gt;&lt;span id="xdx_904_ecustom--MilestonePayment_pp0p0_c20190301__20190331__srt--RangeAxis__srt--MinimumMember__us-gaap--TypeOfArrangementAxis__custom--LicenseAndSponsoredResearchAgreementsMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember_zi75rTkpdRO7" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;50,000
&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;to
$&lt;/span&gt;&lt;span id="xdx_908_ecustom--MilestonePayment_pp0p0_c20190301__20190331__srt--RangeAxis__srt--MaximumMember__us-gaap--TypeOfArrangementAxis__custom--LicenseAndSponsoredResearchAgreementsMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember_zzisbQOnJ7W" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;5,000,000
&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;upon
the achievement of certain regulatory and commercial milestones.&lt;/span&gt; &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Milestone
payments for the first therapeutic indication would be $&lt;span id="xdx_90B_ecustom--MilestonePayment_c20190301__20190331__us-gaap--TypeOfArrangementAxis__custom--LicenseAndSponsoredResearchAgreementsMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember__us-gaap--AwardTypeAxis__custom--PhaseOneClinicalTrialMember_zjG7RTmAlUl6"&gt;50,000
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;for first dosing in a Phase 1 clinical trial,
$&lt;span id="xdx_90B_ecustom--MilestonePayment_c20190301__20190331__us-gaap--TypeOfArrangementAxis__custom--LicenseAndSponsoredResearchAgreementsMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember__us-gaap--AwardTypeAxis__custom--PhaseTwoClinicalTrialMember_z1Fq5VC7aWu3"&gt;100,000
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;for first dosing in a Phase 2 clinical trial,
$&lt;span id="xdx_90D_ecustom--MilestonePayment_c20190301__20190331__us-gaap--TypeOfArrangementAxis__custom--LicenseAndSponsoredResearchAgreementsMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember__us-gaap--AwardTypeAxis__custom--PhaseThreeClinicalTrialMember_zFC5HQXQnMcg"&gt;150,000
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;for first dosing in a Phase 3 clinical trial,
$&lt;span id="xdx_908_ecustom--RegulatoryMarketingApprovalExpenses_pp0p0_c20190301__20190331__us-gaap--TypeOfArrangementAxis__custom--SponsoredResearchAgreementAndLicenseMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember_zXrv7UsytLp9"&gt;300,000
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;for regulatory marketing approval and $&lt;span id="xdx_90B_ecustom--CumulativeSales_pp0p0_c20190301__20190331__srt--ProductOrServiceAxis__custom--LicensedProductSalesMember__us-gaap--TypeOfArrangementAxis__custom--LicenseAndSponsoredResearchAgreementsMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember_zsH40GEqRIvh"&gt;5,000,000
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;upon achieving a cumulative $&lt;span id="xdx_902_eus-gaap--RevenueFromContractWithCustomerIncludingAssessedTax_pp0p0_c20190301__20190331__us-gaap--TypeOfArrangementAxis__custom--SponsoredResearchAgreementAndLicenseMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember_z8mvC1jWDDeb"&gt;500,000,000
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;of Licensed Product sales. The Company also must
pay ULRF shortfall payments if the total amounts actually paid with respect to royalties and non-royalty sublicensee income for any year
is less than the applicable annual minimum (ranging from $&lt;span id="xdx_905_ecustom--UpfrontLicenseFee_iI_pp0p0_c20190331__srt--RangeAxis__srt--MinimumMember__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember_z9Wb1eJfRII2" title="Upfront license fee"&gt;20,000
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;to $&lt;span id="xdx_90D_ecustom--UpfrontLicenseFee_iI_pp0p0_c20190331__srt--RangeAxis__srt--MaximumMember__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember_zd4MF4c7bOL8" title="Upfront license fee"&gt;100,000&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)
for such year.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Sponsored
research expenses related to these agreements for the years ended December 31, 2022 and December 31, 2021 were approximately $&lt;span id="xdx_904_eus-gaap--ResearchAndDevelopmentExpense_pp0p0_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--LicenseAndSponsoredResearchAgreementsMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember_zXcTVKWgpgwc" title="Research and development"&gt;758,000&lt;/span&gt;
and $&lt;span id="xdx_907_eus-gaap--ResearchAndDevelopmentExpense_pp0p0_c20210101__20211231__us-gaap--TypeOfArrangementAxis__custom--LicenseAndSponsoredResearchAgreementsMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember_ziPv1zw7Wp1g" title="Research and development"&gt;646,000&lt;/span&gt;, respectively, and are recorded in research and development expenses in the Consolidated Statements of Operations. License
costs related to these agreements for the years ended December 31, 2022 and December 31, 2021 were approximately $&lt;span id="xdx_903_ecustom--LicenseCost_pp0p0_c20220101__20221231_zeBCXcxnnH5b" title="License costs"&gt;40,000&lt;/span&gt; and $&lt;span id="xdx_90D_ecustom--LicenseCost_pp0p0_c20210101__20211231_zTb5XJrhEAVb" title="License costs"&gt;60,000&lt;/span&gt;,
respectively, and are included in research and development expenses in the Consolidated Statements of Operations.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Between
June 2018 and September 2020, the Company entered into license and sponsored research agreements with the University of Louisville
Research Foundation (&#x201c;ULRF&#x201d;) for QN-247, a novel aptamer-based compound that has shown promise as an anticancer drug.
Under the agreements, the Company took over development, regulatory approval and commercialization of the compound from ULRF and is
responsible for maintenance of the related intellectual property portfolio. In return, ULRF received a $&lt;span id="xdx_90A_eus-gaap--ProceedsFromConvertibleDebt_pp0p0_c20180601__20200930__us-gaap--TypeOfArrangementAxis__custom--LicenseAndSponsoredResearchAgreementsMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember_zyVH2yPJzTV2" title="Proceeds from convertible debt"&gt;50,000&lt;/span&gt;
convertible promissory note in payment of an upfront license fee, which was subsequently converted into the Company&#x2019;s common
stock, and the Company agreed to reimburse ULRF for sponsored research expenses of up to $&lt;span id="xdx_902_ecustom--ReimbursementOfResearchExpenses_pp0p0_c20180601__20200930__us-gaap--TypeOfArrangementAxis__custom--LicenseAndSponsoredResearchAgreementsMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember_z25ifum6bXJ7" title="Reimbursement of research expenses"&gt;830,000&lt;/span&gt;
and prior patent costs of up to $&lt;span id="xdx_90C_ecustom--PatentCosts_pp0p0_c20180601__20200930__us-gaap--TypeOfArrangementAxis__custom--LicenseAndSponsoredResearchAgreementsMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember_z8nQBpxyEjzj" title="Patent costs"&gt;200,000&lt;/span&gt;.
The sponsored research agreement ended on August 31, 2022. &lt;span id="xdx_90A_ecustom--AgreementTermPaymentDescription_c20180601__20200930__us-gaap--TypeOfArrangementAxis__custom--LicenseAndSponsoredResearchAgreementsMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember_zOxTiAHB57Di" title="Agreement term payment, description"&gt;In
addition, the Company agreed to pay ULRF (i) royalties, on patent-covered net sales associated with the commercialization of
anti-nucleolin agent-conjugated nanoparticles, of 4% (on net sales up to a cumulative $250,000,000) or 5% (on net sales above a
cumulative $250,000,000), until expiration of the last to expire of the licensed patents, (ii) 30% to 50% of any non-royalty
sublicensee income received (50% for sublicenses granted in the first two years of the ULRF license agreement, 40% for sublicenses
granted in the third or fourth years of the ULRF license agreement, and 30% for sublicenses granted in the fifth year of the ULRF
license agreement or thereafter), (iii) reimbursements for ongoing costs associated with the preparation, filing, prosecution and
maintenance of licensed patents, incurred prior to June 2018, and (iv) payments ranging from $&lt;span id="xdx_900_ecustom--MilestonePayment_pp0p0_c20180601__20180630__srt--RangeAxis__srt--MinimumMember__us-gaap--TypeOfArrangementAxis__custom--LicenseAndSponsoredResearchAgreementsMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember_z6JELV5a6zL6" title="Milestone payment"&gt;100,000&lt;/span&gt;
to $&lt;span id="xdx_909_ecustom--MilestonePayment_pp0p0_c20180601__20180630__srt--RangeAxis__srt--MaximumMember__us-gaap--TypeOfArrangementAxis__custom--LicenseAndSponsoredResearchAgreementsMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember_zQeDmNDDTMa6" title="Milestone payment"&gt;5,000,000&lt;/span&gt;
upon the achievement of certain regulatory and commercial milestones.&lt;/span&gt; Milestone payments for the first therapeutic indication
would be $&lt;span id="xdx_90C_ecustom--MilestonePayment_pp0p0_c20180601__20180630__us-gaap--AwardTypeAxis__custom--PhaseOneClinicalTrialMember__us-gaap--TypeOfArrangementAxis__custom--LicenseAndSponsoredResearchAgreementsMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember_zI2d4t7SZST" title="Milestone payment"&gt;100,000&lt;/span&gt;
for first dosing in a Phase 1 clinical trial, $&lt;span id="xdx_909_ecustom--MilestonePayment_pp0p0_c20180601__20180630__us-gaap--AwardTypeAxis__custom--PhaseTwoClinicalTrialMember__us-gaap--TypeOfArrangementAxis__custom--LicenseAndSponsoredResearchAgreementsMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember_zNL8atpu6O93" title="Milestone payment"&gt;200,000&lt;/span&gt;
for first dosing in a Phase 2 clinical trial, $&lt;span id="xdx_90E_ecustom--MilestonePayment_pp0p0_c20180601__20180630__us-gaap--AwardTypeAxis__custom--PhaseThreeClinicalTrialMember__us-gaap--TypeOfArrangementAxis__custom--LicenseAndSponsoredResearchAgreementsMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember_z29VWeREQaqa" title="Milestone payment"&gt;350,000&lt;/span&gt;
for first dosing in a Phase 3 clinical trial, $&lt;span id="xdx_909_ecustom--MilestonePayment_c20180601__20180630__us-gaap--AwardTypeAxis__custom--PhaseClinicalTrialMember__us-gaap--TypeOfArrangementAxis__custom--LicenseAndSponsoredResearchAgreementsMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember_zVcVfqTkcXXj" title="Milestone payment"&gt;500,000&lt;/span&gt;
for regulatory marketing approval and $&lt;span id="xdx_90A_ecustom--RegulatoryMarketingApprovalExpenses_pp0p0_c20180601__20180630__srt--ProductOrServiceAxis__custom--LicensedProductSalesMember__us-gaap--TypeOfArrangementAxis__custom--LicenseAndSponsoredResearchAgreementsMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember_zE3AIOiJE55k" title="Regulatory marketing approval, expenses"&gt;5,000,000&lt;/span&gt;
upon achieving a cumulative $&lt;span id="xdx_903_ecustom--CumulativeSales_pp0p0_c20180601__20180630__us-gaap--TypeOfArrangementAxis__custom--SponsoredResearchAgreementAndLicenseMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember_zZwARTQp1OPd" title="Cumulative sales"&gt;500,000,000&lt;/span&gt;
of Licensed Product sales; the Company would also pay another $&lt;span id="xdx_905_ecustom--RegulatoryMarketingApprovalExpensesOne_pp0p0_c20180601__20180630__srt--ProductOrServiceAxis__custom--LicensedProductSalesMember__us-gaap--TypeOfArrangementAxis__custom--LicenseAndSponsoredResearchAgreementsMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember_zecFxuofTmj7" title="Regulatory marketing approval, expenses"&gt;500,000&lt;/span&gt;
milestone payment for any additional regulatory marketing approval for each additional therapeutic (or diagnostic) indication. The
Company also must pay ULRF shortfall payments if the total amounts actually paid with respect to royalties and non-royalty
sublicensee income for any year is less than the applicable annual minimum (ranging from $&lt;span id="xdx_901_ecustom--ShortfallPayments_pp0p0_c20180601__20200930__srt--RangeAxis__srt--MinimumMember__us-gaap--TypeOfArrangementAxis__custom--LicenseAndSponsoredResearchAgreementsMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember_zWGKg4JlYkvi" title="Shortfall payments"&gt;10,000&lt;/span&gt;
to $&lt;span id="xdx_907_ecustom--ShortfallPayments_c20180601__20200930__srt--RangeAxis__srt--MaximumMember__us-gaap--TypeOfArrangementAxis__custom--LicenseAndSponsoredResearchAgreementsMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember_zmPotP7EeEt1" title="Shortfall payments"&gt;50,000&lt;/span&gt;)
for such year.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Sponsored
research expenses related to these agreements for the years ended December 31, 2022 and December 31, 2021 were approximately $&lt;span id="xdx_907_eus-gaap--ResearchAndDevelopmentExpense_pp0p0_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--SponsoredResearchAgreementAndLicenseMember_zDcCfjwJb3Fh" title="Research and development"&gt;164,000&lt;/span&gt;
and $&lt;span id="xdx_901_eus-gaap--ResearchAndDevelopmentExpense_pp0p0_c20210101__20211231__us-gaap--TypeOfArrangementAxis__custom--SponsoredResearchAgreementAndLicenseMember_zHhXERwipNul" title="Research and development"&gt;325,000&lt;/span&gt;, respectively, and these amounts are recorded in research and development expenses in the Consolidated Statements of Operations.
Minimum annual royalties of $&lt;span id="xdx_90F_eus-gaap--RoyaltyExpense_pp0p0_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--SponsoredResearchAgreementAndLicenseMember_zZJb9QDsbLfa" title="Minimum annual royalties"&gt;0&lt;/span&gt; and $&lt;span id="xdx_901_eus-gaap--RoyaltyExpense_c20210101__20211231__us-gaap--TypeOfArrangementAxis__custom--SponsoredResearchAgreementAndLicenseMember_z9GOmSy2etHg" title="Minimum annual royalties"&gt;0&lt;/span&gt; related to these agreements are included in research and development expenses in the Consolidated
Statements of Operations for the years ended December 31, 2022 and December 31, 2021, respectively. License costs related to these agreements
were approximately $&lt;span id="xdx_90F_ecustom--LicenseCost_pp0p0_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--SponsoredResearchAgreementAndLicenseMember_zhNOCabKEKW6" title="License costs"&gt;94,000&lt;/span&gt; and $&lt;span id="xdx_908_ecustom--LicenseCost_pp0p0_c20210101__20211231__us-gaap--TypeOfArrangementAxis__custom--SponsoredResearchAgreementAndLicenseMember_zjJi6dMlb7va" title="License costs"&gt;118,000&lt;/span&gt; for the years ended December 31, 2022 and December 31, 2021, respectively, and are included in
research and development expenses in the Consolidated Statements of Operations.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;






&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
June 2020, the Company entered into an exclusive license agreement with ULRF for its intellectual property in the use of QN-165 as a
treatment for COVID-19. Under the agreement, the Company took over development, regulatory approval and commercialization of the
compound (for such use) from ULRF and was responsible for maintenance of the related intellectual property portfolio. In return,
ULRF received approximately $&lt;span id="xdx_907_ecustom--UpfrontLicenseFee_iI_pp0p0_c20200630__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember_z8HdOcgnzqd4" title="Upfront license fee"&gt;24,000 &lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;for
an upfront license fee and reimbursement of prior patent costs. In addition, the Company executed a sponsored research agreement
with ULRF (for QN-165 as a treatment for COVID-19) supporting up to $&lt;span id="xdx_90E_eus-gaap--ResearchAndDevelopmentExpense_pp0p0_c20201101__20201130__srt--RangeAxis__srt--MaximumMember__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember_zLZYohcJBbf6"&gt;430,000&lt;/span&gt;. &lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;This sponsored research agreement expired in November 2021 and effective October 31, 2022 the license agreement for
QN-165 was terminated.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Sponsored
research expenses related to these agreements for the years ended December 31, 2022 and December 31, 2021 were approximately $&lt;span id="xdx_90D_eus-gaap--ResearchAndDevelopmentExpense_pp0p0_c20220101__20221231__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember_zDkvbJNgCrMk" title="Research and Development Expense"&gt;14,000&lt;/span&gt; and $&lt;span id="xdx_906_eus-gaap--ResearchAndDevelopmentExpense_pp0p0_c20210101__20211231__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember_z8y24e1EHbXj" title="Research and Development Expense"&gt;243,000&lt;/span&gt;,
respectively, and are recorded in research and development expenses in the Consolidated Statements of Operations. License costs related
to these agreements for the years ended December 31, 2022 and December 31, 2021 were approximately $&lt;span id="xdx_904_ecustom--LicenseCost_pp0p0_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--LicenseAndSponsoredResearchAgreementsMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember_zomdtHB2ueha" title="License cost"&gt;2,000&lt;/span&gt; and $&lt;span id="xdx_90B_ecustom--LicenseCost_pp0p0_c20210101__20211231__us-gaap--TypeOfArrangementAxis__custom--LicenseAndSponsoredResearchAgreementsMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember_ze91Ty8znN8l" title="License cost"&gt;28,000&lt;/span&gt;, respectively,
and are included in research and development expenses in the Consolidated Statements of Operations.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Advanced
Cancer Therapeutics&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
December 2018, &lt;span id="xdx_90E_ecustom--AgreementDescription_c20181201__20181231__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember__dei--LegalEntityAxis__custom--AdvancedCancerTherapeuticsLLCMember_zW2Af8FERock" title="Agreement description"&gt;the Company entered into a license agreement with Advanced Cancer Therapeutics, LLC (&#x201c;ACT&#x201d;), granting the
Company exclusive rights to develop and commercialize QN-165, an aptamer-based drug candidate&lt;/span&gt;. In return, ACT received a $&lt;span id="xdx_902_eus-gaap--ProceedsFromConvertibleDebt_pp0p0_c20181201__20181231__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember__dei--LegalEntityAxis__custom--AdvancedCancerTherapeuticsLLCMember_z8Q75pH4KISg" title="Proceeds from convertible debt"&gt;25,000&lt;/span&gt; convertible
promissory note in payment of an upfront license fee, which was subsequently converted into the Company&#x2019;s common stock. In addition,
the Company agreed to pay ACT (i) royalties, on net sales associated with the commercialization of QN-165, of 2% (only if patent-covered
and only on net sales above a cumulative $&lt;span id="xdx_90F_ecustom--CumulativeSales_pp0p0_c20181201__20181231__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember__dei--LegalEntityAxis__custom--AdvancedCancerTherapeuticsLLCMember_zqXDrko20eDc" title="Cumulative sales"&gt;3,000,000&lt;/span&gt;) or 1% (if not patent-covered, but only on net sales above a cumulative $&lt;span id="xdx_90A_ecustom--CumulativeSales_pp0p0_c20181201__20181231__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember__dei--LegalEntityAxis__custom--AdvancedCancerTherapeuticsLLCMember_zUD4zsAXDgRd" title="Cumulative sales"&gt;3,000,000&lt;/span&gt;),
until the 15th anniversary of the ACT license agreement and (ii) milestone payments of $&lt;span id="xdx_90C_ecustom--MilestonePaymentForCumulativeMarketingExpenses_pp0p0_c20181201__20181231__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember__dei--LegalEntityAxis__custom--AdvancedCancerTherapeuticsLLCMember_zZeQymAmRl8" title="Milestone payment for cumulative marketing expenses"&gt;100,000&lt;/span&gt; for the Company raising a cumulative
total of $&lt;span id="xdx_901_eus-gaap--RevenueFromContractWithCustomerIncludingAssessedTax_pp0p0_c20181201__20181231__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember__dei--LegalEntityAxis__custom--AdvancedCancerTherapeuticsLLCMember_zqd072Tcu4rk" title="Cumulative amount"&gt;2,000,000&lt;/span&gt; in new equity financing after the date of the ACT license agreement, $&lt;span id="xdx_90A_ecustom--MilestoneMethodRevenueRecognized_pp0p0_c20181201__20181231__srt--TitleOfIndividualAxis__custom--CEMarkMember__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember__dei--LegalEntityAxis__custom--AdvancedCancerTherapeuticsLLCMember_zD10HCcn3qKd" title="Milestone method revenue recognized"&gt;100,000&lt;/span&gt; upon any first QN-165-based licensed
product receiving the CE Mark or similar FDA status, and $&lt;span id="xdx_90B_ecustom--CumulativeSales_pp0p0_c20181201__20181231__srt--TitleOfIndividualAxis__custom--CEMarkMember__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember__dei--LegalEntityAxis__custom--AdvancedCancerTherapeuticsLLCMember_zKE7WypjOpJ3" title="Cumulative sales"&gt;500,000&lt;/span&gt; upon cumulative worldwide QN-165-based licensed product net sales reaching
$&lt;span id="xdx_90B_eus-gaap--RevenueFromContractWithCustomerIncludingAssessedTax_pp0p0_c20181201__20181231__srt--TitleOfIndividualAxis__custom--CEMarkMember__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember__dei--LegalEntityAxis__custom--AdvancedCancerTherapeuticsLLCMember_zzAk2tbZUUAc" title="Licensed product net sale"&gt;3,000,000&lt;/span&gt;. For the years ended December 31, 2022 and December 31, 2021, there were approximately $&lt;span id="xdx_902_ecustom--LicenseCost_pp0p0_do_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember__dei--LegalEntityAxis__custom--AdvancedCancerTherapeuticsLLCMember_zLBc8V231CYd" title="License cost"&gt;0&lt;/span&gt; and $&lt;span id="xdx_90C_ecustom--LicenseCost_pp0p0_do_c20210101__20211231__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember__dei--LegalEntityAxis__custom--AdvancedCancerTherapeuticsLLCMember_z6ZbkeVYPWpc" title="License cost"&gt;2,000&lt;/span&gt;, respectively in costs
related to this agreement which are included in research and development expenses in the Consolidated Statements of Operations.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Yi
Xin&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In October 2020, through our wholly-owned diagnostics subsidiary Qualigen, Inc. we entered into a Technology Transfer
Agreement with Yi Xin Zhen Duan Jishu (Suzhou) Ltd. (&#x201c;Yi Xin&#x201d;), of Suzhou, China, for Yi Xin to develop, manufacture and sell
new generations of diagnostic test systems based on the Company&#x2019;s core FastPack technology. In addition, the Technology Transfer Agreement
authorized Yi Xin to manufacture and sell the Company&#x2019;s current generations of FastPack System diagnostic products (1.0, IP and PRO) in
China.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The Company will receive low- to mid-single-digit royalties on any future new-generations and current-generations
product sales by Yi Xin. We received total net cash payments of approximately $&lt;span id="xdx_908_eus-gaap--DeferredRevenue_iI_pp0p0_c20211231__dei--LegalEntityAxis__custom--YiXinZhenDuanJishuLtdMember_zCeceoVHCbg6" title="Deferred revenue"&gt;670,000&lt;/span&gt;, of which approximately $&lt;span id="xdx_906_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20210101__20211231__srt--ProductOrServiceAxis__custom--LicenseRevenueMember__dei--LegalEntityAxis__custom--YiXinZhenDuanJishuLtdMember_zCb5e3Vm5vL5" title="Product sales"&gt;632,000&lt;/span&gt;
is classified as license revenue, and approximately $&lt;span id="xdx_90C_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20210101__20211231__dei--LegalEntityAxis__custom--YiXinZhenDuanJishuLtdMember_zq6MARk7I1S3" title="Product sales"&gt;38,000&lt;/span&gt; is classified as product sales on the Consolidated Statements of Operations for the fiscal year ended December&#160;31,
2021. The Company provided technology transfer and patent/know-how license rights to facilitate Yi Xin&#x2019;s development and commercialization.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"/&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The Company gave Yi Xin the exclusive rights for China &#x2013; which is
a market we have not otherwise entered &#x2013; both for Yi Xin&#x2019;s new generations of FastPack-based products and for Yi Xin-manufactured
versions of our existing FastPack product lines. Yi Xin also has the right to sell its new generations of FastPack-based diagnostic test
systems throughout the world (but not to or toward current customers of our existing generations of FastPack products). After March 31,
2022, Yi Xin has the right to sell Yi Xin-manufactured versions of existing FastPack 1.0, IP and PRO product lines worldwide (other than
in the United States and other than to or toward current non-US customers of those products), as well as the right to buy Qualigen-manufactured
FastPack 1.0, IP and PRO products from us at distributor prices for resale in and for the United States (but not to or toward current
U.S. customers of those products). The Company did not license Yi Xin to sell in the U.S. market any Yi Xin-manufactured versions of those
legacy FastPack 1.0, IP and PRO product lines. In the Technology Transfer Agreement the Company also confirmed that after March 31, 2022
it would not seek new FastPack customers outside the U.S.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;STA
Pharmaceutical&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
November 2020, the Company entered into a contract with STA Pharmaceutical Co., Ltd., a subsidiary of WuXi AppTec, for GMP production
of QN-165, which was the Company&#x2019;s lead drug candidate for the treatment of COVID-19 and other viral diseases. In connection with
this agreement, the Company paid an upfront deposit of approximately $&lt;span id="xdx_907_eus-gaap--DepositAssets_iI_pn5n6_c20201231__dei--LegalEntityAxis__custom--STAPharmaceuticalCoLtdMember_zSeIjxwRVih6" title="Upfront deposit"&gt;1.1&lt;/span&gt; million which was classified as a prepaid expense on the December
31, 2020 Consolidated Balance Sheet date, and all of which was included in research and development expenses in the statement of operations
for the year ended December 31, 2021.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Research
and development expenses related to this agreement for the years ended December 31, 2022 and December 31, 2021 were approximately $&lt;span id="xdx_90F_eus-gaap--ResearchAndDevelopmentExpense_c20220101__20221231__dei--LegalEntityAxis__custom--STAPharmaceuticalCoLtdMember_ziJaZGX2iDce" title="Research and development"&gt;9,000&lt;/span&gt;
and $&lt;span id="xdx_902_eus-gaap--ResearchAndDevelopmentExpense_pn5n6_c20210101__20211231__dei--LegalEntityAxis__custom--STAPharmaceuticalCoLtdMember_zUJAjf06Gs4g" title="Research and development"&gt;3.2&lt;/span&gt; million, respectively, and are recorded in research and development expenses in the Consolidated Statements of Operations.&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;UCL Business Limited&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In January 2022, the Company entered into a License
Agreement with UCL Business Limited to obtain an exclusive worldwide in-license of a genomic quadruplex (G4)-selective transcription inhibitor
drug development program which had been developed at University College London, including lead and back-up compounds, preclinical data
and a patent estate. (UCL Business Limited is the commercialization company for University College London.) The program&#x2019;s lead compound
is now being developed at Qualigen under the name QN-302 as a candidate for treatment for pancreatic ductal adenocarcinoma (PDAC), which
represents the vast majority of pancreatic cancers. The License Agreement required a $&lt;span id="xdx_907_ecustom--ReimbursementOfPatent_c20220101__20220131__us-gaap--AwardTypeAxis__custom--UpfrontPaymentMember__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember_ztgkoq21V9V6" title="Reimbursement of patent"&gt;150,000&lt;/span&gt; upfront payment, reimbursement of past patent
prosecution expenses (approximately $&lt;span id="xdx_907_ecustom--ReimbursementOfPatent_c20220101__20220131__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember_zNYvUJX1HZGf" title="Reimbursement of patent"&gt;160,000&lt;/span&gt;), and (if and when applicable) tiered royalty payments in the low to mid-single digits, clinical/regulatory/sales
milestone payments and a percentage of any non-royalty sublicensing consideration paid to Qualigen.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0"&gt;For the years ended December 31, 2022 and 2021 there were license costs of approximately $&lt;span id="xdx_905_ecustom--LicenseCost_pp0p0_do_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember_zBjRqmr4W2Id" title="License cost"&gt;338,000&lt;/span&gt; and $&lt;span id="xdx_900_ecustom--LicenseCost_pp0p0_do_c20210101__20211231__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember_z0WdYlIwavA7" title="License cost"&gt;0&lt;/span&gt;, respectively,
related to this agreement which are included in research and development expenses in the Consolidated Statements of Operations.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</QLGN:ResearchAndLicenseAgreementsTextBlock>
    <QLGN:ReimbursementOfResearchExpenses
      contextRef="From2019-03-012019-03-31_custom_SponsoredResearchAgreementAndLicenseMember_custom_UniversityOfLouisvilleResearchFoundationMember"
      decimals="0"
      unitRef="USD">693000</QLGN:ReimbursementOfResearchExpenses>
    <QLGN:ReimbursementOfResearchExpenses
      contextRef="From2021-02-012021-02-28_custom_SponsoredResearchAgreementAndLicenseMember_custom_UniversityOfLouisvilleResearchFoundationMember"
      decimals="-5"
      unitRef="USD">2700000</QLGN:ReimbursementOfResearchExpenses>
    <QLGN:AgreementTermPaymentDescription contextRef="From2019-03-012019-03-31_custom_SponsoredResearchAgreementAndLicenseMember_custom_UniversityOfLouisvilleResearchFoundationMember">In
July 2020, the Company entered into an exclusive license agreement with ULRF for RAS interaction inhibitor drug candidates. Under the
agreement, the Company will take over development, regulatory approval and commercialization of the candidates from ULRF and is responsible
for maintenance of the related intellectual property portfolio. In return, ULRF received approximately $112,000 for an upfront license
fee and reimbursement of prior patent costs. In addition, the Company has agreed to pay ULRF (i) royalties, on patent-covered net sales
associated with the commercialization, of 4% (on net sales up to a cumulative $250,000,000) or 5% (on net sales above a cumulative $250,000,000),
until expiration of the licensed patent, and 2.5% (on net sales for any sales not covered by Licensed Patents), (ii) 30% to 50% of any
non-royalty sublicensee income received (50% for sublicenses granted in the first two years of the ULRF license agreement, 40% for sublicenses
granted in the third or fourth years of the ULRF license agreement, and 30% for sublicenses granted in the fifth year of the ULRF license
agreement or thereafter), (iii) reimbursements for ongoing costs associated with the preparation, filing, prosecution and maintenance
of licensed patents, incurred prior to July 2020, and (iv) payments ranging from $</QLGN:AgreementTermPaymentDescription>
    <QLGN:MilestonePayment
      contextRef="From2019-03-012019-03-31_srt_MinimumMember_custom_LicenseAndSponsoredResearchAgreementsMember_custom_UniversityOfLouisvilleResearchFoundationMember"
      decimals="0"
      unitRef="USD">50000</QLGN:MilestonePayment>
    <QLGN:MilestonePayment
      contextRef="From2019-03-012019-03-31_srt_MaximumMember_custom_LicenseAndSponsoredResearchAgreementsMember_custom_UniversityOfLouisvilleResearchFoundationMember"
      decimals="0"
      unitRef="USD">5000000</QLGN:MilestonePayment>
    <QLGN:MilestonePayment
      contextRef="From2019-03-012019-03-31_custom_LicenseAndSponsoredResearchAgreementsMember_custom_UniversityOfLouisvilleResearchFoundationMember_custom_PhaseOneClinicalTrialMember"
      decimals="0"
      unitRef="USD">50000</QLGN:MilestonePayment>
    <QLGN:MilestonePayment
      contextRef="From2019-03-012019-03-31_custom_LicenseAndSponsoredResearchAgreementsMember_custom_UniversityOfLouisvilleResearchFoundationMember_custom_PhaseTwoClinicalTrialMember"
      decimals="0"
      unitRef="USD">100000</QLGN:MilestonePayment>
    <QLGN:MilestonePayment
      contextRef="From2019-03-012019-03-31_custom_LicenseAndSponsoredResearchAgreementsMember_custom_UniversityOfLouisvilleResearchFoundationMember_custom_PhaseThreeClinicalTrialMember"
      decimals="0"
      unitRef="USD">150000</QLGN:MilestonePayment>
    <QLGN:RegulatoryMarketingApprovalExpenses
      contextRef="From2019-03-012019-03-31_custom_SponsoredResearchAgreementAndLicenseMember_custom_UniversityOfLouisvilleResearchFoundationMember"
      decimals="0"
      unitRef="USD">300000</QLGN:RegulatoryMarketingApprovalExpenses>
    <QLGN:CumulativeSales
      contextRef="From2019-03-012019-03-31_custom_LicensedProductSalesMember_custom_LicenseAndSponsoredResearchAgreementsMember_custom_UniversityOfLouisvilleResearchFoundationMember"
      decimals="0"
      unitRef="USD">5000000</QLGN:CumulativeSales>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="From2019-03-012019-03-31_custom_SponsoredResearchAgreementAndLicenseMember_custom_UniversityOfLouisvilleResearchFoundationMember"
      decimals="0"
      unitRef="USD">500000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <QLGN:UpfrontLicenseFee
      contextRef="AsOf2019-03-31_srt_MinimumMember_custom_LicenseAgreementMember_custom_UniversityOfLouisvilleResearchFoundationMember"
      decimals="0"
      unitRef="USD">20000</QLGN:UpfrontLicenseFee>
    <QLGN:UpfrontLicenseFee
      contextRef="AsOf2019-03-31_srt_MaximumMember_custom_LicenseAgreementMember_custom_UniversityOfLouisvilleResearchFoundationMember"
      decimals="0"
      unitRef="USD">100000</QLGN:UpfrontLicenseFee>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2022-01-012022-12-31_custom_LicenseAndSponsoredResearchAgreementsMember_custom_UniversityOfLouisvilleResearchFoundationMember"
      decimals="0"
      unitRef="USD">758000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2021-01-012021-12-31_custom_LicenseAndSponsoredResearchAgreementsMember_custom_UniversityOfLouisvilleResearchFoundationMember"
      decimals="0"
      unitRef="USD">646000</us-gaap:ResearchAndDevelopmentExpense>
    <QLGN:LicenseCost
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">40000</QLGN:LicenseCost>
    <QLGN:LicenseCost
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">60000</QLGN:LicenseCost>
    <us-gaap:ProceedsFromConvertibleDebt
      contextRef="From2018-06-012020-09-30_custom_LicenseAndSponsoredResearchAgreementsMember_custom_UniversityOfLouisvilleResearchFoundationMember"
      decimals="0"
      unitRef="USD">50000</us-gaap:ProceedsFromConvertibleDebt>
    <QLGN:ReimbursementOfResearchExpenses
      contextRef="From2018-06-012020-09-30_custom_LicenseAndSponsoredResearchAgreementsMember_custom_UniversityOfLouisvilleResearchFoundationMember"
      decimals="0"
      unitRef="USD">830000</QLGN:ReimbursementOfResearchExpenses>
    <QLGN:PatentCosts
      contextRef="From2018-06-012020-09-30_custom_LicenseAndSponsoredResearchAgreementsMember_custom_UniversityOfLouisvilleResearchFoundationMember"
      decimals="0"
      unitRef="USD">200000</QLGN:PatentCosts>
    <QLGN:AgreementTermPaymentDescription contextRef="From2018-06-012020-09-30_custom_LicenseAndSponsoredResearchAgreementsMember_custom_UniversityOfLouisvilleResearchFoundationMember">In
addition, the Company agreed to pay ULRF (i) royalties, on patent-covered net sales associated with the commercialization of
anti-nucleolin agent-conjugated nanoparticles, of 4% (on net sales up to a cumulative $250,000,000) or 5% (on net sales above a
cumulative $250,000,000), until expiration of the last to expire of the licensed patents, (ii) 30% to 50% of any non-royalty
sublicensee income received (50% for sublicenses granted in the first two years of the ULRF license agreement, 40% for sublicenses
granted in the third or fourth years of the ULRF license agreement, and 30% for sublicenses granted in the fifth year of the ULRF
license agreement or thereafter), (iii) reimbursements for ongoing costs associated with the preparation, filing, prosecution and
maintenance of licensed patents, incurred prior to June 2018, and (iv) payments ranging from $100,000
to $5,000,000
upon the achievement of certain regulatory and commercial milestones.</QLGN:AgreementTermPaymentDescription>
    <QLGN:MilestonePayment
      contextRef="From2018-06-012018-06-30_srt_MinimumMember_custom_LicenseAndSponsoredResearchAgreementsMember_custom_UniversityOfLouisvilleResearchFoundationMember"
      decimals="0"
      unitRef="USD">100000</QLGN:MilestonePayment>
    <QLGN:MilestonePayment
      contextRef="From2018-06-012018-06-30_srt_MaximumMember_custom_LicenseAndSponsoredResearchAgreementsMember_custom_UniversityOfLouisvilleResearchFoundationMember"
      decimals="0"
      unitRef="USD">5000000</QLGN:MilestonePayment>
    <QLGN:MilestonePayment
      contextRef="From2018-06-012018-06-30_custom_PhaseOneClinicalTrialMember_custom_LicenseAndSponsoredResearchAgreementsMember_custom_UniversityOfLouisvilleResearchFoundationMember"
      decimals="0"
      unitRef="USD">100000</QLGN:MilestonePayment>
    <QLGN:MilestonePayment
      contextRef="From2018-06-012018-06-30_custom_PhaseTwoClinicalTrialMember_custom_LicenseAndSponsoredResearchAgreementsMember_custom_UniversityOfLouisvilleResearchFoundationMember"
      decimals="0"
      unitRef="USD">200000</QLGN:MilestonePayment>
    <QLGN:MilestonePayment
      contextRef="From2018-06-012018-06-30_custom_PhaseThreeClinicalTrialMember_custom_LicenseAndSponsoredResearchAgreementsMember_custom_UniversityOfLouisvilleResearchFoundationMember"
      decimals="0"
      unitRef="USD">350000</QLGN:MilestonePayment>
    <QLGN:MilestonePayment
      contextRef="From2018-06-012018-06-30_custom_PhaseClinicalTrialMember_custom_LicenseAndSponsoredResearchAgreementsMember_custom_UniversityOfLouisvilleResearchFoundationMember"
      decimals="0"
      unitRef="USD">500000</QLGN:MilestonePayment>
    <QLGN:RegulatoryMarketingApprovalExpenses
      contextRef="From2018-06-012018-06-30_custom_LicensedProductSalesMember_custom_LicenseAndSponsoredResearchAgreementsMember_custom_UniversityOfLouisvilleResearchFoundationMember"
      decimals="0"
      unitRef="USD">5000000</QLGN:RegulatoryMarketingApprovalExpenses>
    <QLGN:CumulativeSales
      contextRef="From2018-06-012018-06-30_custom_SponsoredResearchAgreementAndLicenseMember_custom_UniversityOfLouisvilleResearchFoundationMember"
      decimals="0"
      unitRef="USD">500000000</QLGN:CumulativeSales>
    <QLGN:RegulatoryMarketingApprovalExpensesOne
      contextRef="From2018-06-012018-06-30_custom_LicensedProductSalesMember_custom_LicenseAndSponsoredResearchAgreementsMember_custom_UniversityOfLouisvilleResearchFoundationMember"
      decimals="0"
      unitRef="USD">500000</QLGN:RegulatoryMarketingApprovalExpensesOne>
    <QLGN:ShortfallPayments
      contextRef="From2018-06-012020-09-30_srt_MinimumMember_custom_LicenseAndSponsoredResearchAgreementsMember_custom_UniversityOfLouisvilleResearchFoundationMember"
      decimals="0"
      unitRef="USD">10000</QLGN:ShortfallPayments>
    <QLGN:ShortfallPayments
      contextRef="From2018-06-012020-09-30_srt_MaximumMember_custom_LicenseAndSponsoredResearchAgreementsMember_custom_UniversityOfLouisvilleResearchFoundationMember"
      decimals="0"
      unitRef="USD">50000</QLGN:ShortfallPayments>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2022-01-012022-12-31_custom_SponsoredResearchAgreementAndLicenseMember"
      decimals="0"
      unitRef="USD">164000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2021-01-012021-12-31_custom_SponsoredResearchAgreementAndLicenseMember"
      decimals="0"
      unitRef="USD">325000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:RoyaltyExpense
      contextRef="From2022-01-012022-12-31_custom_SponsoredResearchAgreementAndLicenseMember"
      decimals="0"
      unitRef="USD">0</us-gaap:RoyaltyExpense>
    <us-gaap:RoyaltyExpense
      contextRef="From2021-01-012021-12-31_custom_SponsoredResearchAgreementAndLicenseMember"
      decimals="0"
      unitRef="USD">0</us-gaap:RoyaltyExpense>
    <QLGN:LicenseCost
      contextRef="From2022-01-012022-12-31_custom_SponsoredResearchAgreementAndLicenseMember"
      decimals="0"
      unitRef="USD">94000</QLGN:LicenseCost>
    <QLGN:LicenseCost
      contextRef="From2021-01-012021-12-31_custom_SponsoredResearchAgreementAndLicenseMember"
      decimals="0"
      unitRef="USD">118000</QLGN:LicenseCost>
    <QLGN:UpfrontLicenseFee
      contextRef="AsOf2020-06-30_custom_LicenseAgreementMember_custom_UniversityOfLouisvilleResearchFoundationMember"
      decimals="0"
      unitRef="USD">24000</QLGN:UpfrontLicenseFee>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2020-11-012020-11-30_srt_MaximumMember_custom_LicenseAgreementMember_custom_UniversityOfLouisvilleResearchFoundationMember"
      decimals="0"
      unitRef="USD">430000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2022-01-012022-12-31_custom_UniversityOfLouisvilleResearchFoundationMember"
      decimals="0"
      unitRef="USD">14000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2021-01-012021-12-31_custom_UniversityOfLouisvilleResearchFoundationMember"
      decimals="0"
      unitRef="USD">243000</us-gaap:ResearchAndDevelopmentExpense>
    <QLGN:LicenseCost
      contextRef="From2022-01-012022-12-31_custom_LicenseAndSponsoredResearchAgreementsMember_custom_UniversityOfLouisvilleResearchFoundationMember"
      decimals="0"
      unitRef="USD">2000</QLGN:LicenseCost>
    <QLGN:LicenseCost
      contextRef="From2021-01-012021-12-31_custom_LicenseAndSponsoredResearchAgreementsMember_custom_UniversityOfLouisvilleResearchFoundationMember"
      decimals="0"
      unitRef="USD">28000</QLGN:LicenseCost>
    <QLGN:AgreementDescription contextRef="From2018-12-012018-12-31_custom_LicenseAgreementMember_custom_AdvancedCancerTherapeuticsLLCMember">the Company entered into a license agreement with Advanced Cancer Therapeutics, LLC (&#x201c;ACT&#x201d;), granting the
Company exclusive rights to develop and commercialize QN-165, an aptamer-based drug candidate</QLGN:AgreementDescription>
    <us-gaap:ProceedsFromConvertibleDebt
      contextRef="From2018-12-012018-12-31_custom_LicenseAgreementMember_custom_AdvancedCancerTherapeuticsLLCMember"
      decimals="0"
      unitRef="USD">25000</us-gaap:ProceedsFromConvertibleDebt>
    <QLGN:CumulativeSales
      contextRef="From2018-12-012018-12-31_custom_LicenseAgreementMember_custom_AdvancedCancerTherapeuticsLLCMember"
      decimals="0"
      unitRef="USD">3000000</QLGN:CumulativeSales>
    <QLGN:CumulativeSales
      contextRef="From2018-12-012018-12-31_custom_LicenseAgreementMember_custom_AdvancedCancerTherapeuticsLLCMember"
      decimals="0"
      unitRef="USD">3000000</QLGN:CumulativeSales>
    <QLGN:MilestonePaymentForCumulativeMarketingExpenses
      contextRef="From2018-12-012018-12-31_custom_LicenseAgreementMember_custom_AdvancedCancerTherapeuticsLLCMember"
      decimals="0"
      unitRef="USD">100000</QLGN:MilestonePaymentForCumulativeMarketingExpenses>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="From2018-12-012018-12-31_custom_LicenseAgreementMember_custom_AdvancedCancerTherapeuticsLLCMember"
      decimals="0"
      unitRef="USD">2000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <QLGN:MilestoneMethodRevenueRecognized
      contextRef="From2018-12-012018-12-31_custom_CEMarkMember_custom_LicenseAgreementMember_custom_AdvancedCancerTherapeuticsLLCMember"
      decimals="0"
      unitRef="USD">100000</QLGN:MilestoneMethodRevenueRecognized>
    <QLGN:CumulativeSales
      contextRef="From2018-12-012018-12-31_custom_CEMarkMember_custom_LicenseAgreementMember_custom_AdvancedCancerTherapeuticsLLCMember"
      decimals="0"
      unitRef="USD">500000</QLGN:CumulativeSales>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="From2018-12-012018-12-31_custom_CEMarkMember_custom_LicenseAgreementMember_custom_AdvancedCancerTherapeuticsLLCMember"
      decimals="0"
      unitRef="USD">3000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <QLGN:LicenseCost
      contextRef="From2022-01-012022-12-31_custom_LicenseAgreementMember_custom_AdvancedCancerTherapeuticsLLCMember"
      decimals="0"
      unitRef="USD">0</QLGN:LicenseCost>
    <QLGN:LicenseCost
      contextRef="From2021-01-012021-12-31_custom_LicenseAgreementMember_custom_AdvancedCancerTherapeuticsLLCMember"
      decimals="0"
      unitRef="USD">2000</QLGN:LicenseCost>
    <us-gaap:DeferredRevenue
      contextRef="AsOf2021-12-31_custom_YiXinZhenDuanJishuLtdMember"
      decimals="0"
      unitRef="USD">670000</us-gaap:DeferredRevenue>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2021-01-012021-12-31_custom_LicenseRevenueMember_custom_YiXinZhenDuanJishuLtdMember"
      decimals="0"
      unitRef="USD">632000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2021-01-012021-12-31_custom_YiXinZhenDuanJishuLtdMember"
      decimals="0"
      unitRef="USD">38000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:DepositAssets
      contextRef="AsOf2020-12-31_custom_STAPharmaceuticalCoLtdMember"
      decimals="-5"
      unitRef="USD">1100000</us-gaap:DepositAssets>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2022-01-012022-12-31_custom_STAPharmaceuticalCoLtdMember"
      decimals="0"
      unitRef="USD">9000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2021-01-012021-12-31_custom_STAPharmaceuticalCoLtdMember"
      decimals="-5"
      unitRef="USD">3200000</us-gaap:ResearchAndDevelopmentExpense>
    <QLGN:ReimbursementOfPatent
      contextRef="From2022-01-012022-01-31_custom_UpfrontPaymentMember_custom_LicenseAgreementMember"
      decimals="0"
      unitRef="USD">150000</QLGN:ReimbursementOfPatent>
    <QLGN:ReimbursementOfPatent
      contextRef="From2022-01-012022-01-31_custom_LicenseAgreementMember"
      decimals="0"
      unitRef="USD">160000</QLGN:ReimbursementOfPatent>
    <QLGN:LicenseCost
      contextRef="From2022-01-012022-12-31_custom_LicenseAgreementMember"
      decimals="0"
      unitRef="USD">338000</QLGN:LicenseCost>
    <QLGN:LicenseCost
      contextRef="From2021-01-012021-12-31_custom_LicenseAgreementMember"
      decimals="0"
      unitRef="USD">0</QLGN:LicenseCost>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_809_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zjzuQwYLCyBa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
15 &#x2014; &lt;span id="xdx_82A_zV1ZI9B4TKI5"&gt;STOCKHOLDERS&#x2019; EQUITY&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of December 31, 2022, and 2021 the Company had two classes of capital stock: common stock and preferred stock.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Common
Stock&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Holders
of common stock generally vote as a class with the holders of the preferred stock and are entitled to one vote for each share held. Subject
to the rights of the holders of the preferred stock to receive preferential dividends, the holders of common stock are entitled to receive
dividends when and if declared by the Board of Directors. Following payment of the liquidation preference of the preferred stock, any
remaining assets will be distributed ratably among the holders of the common stock and, on an as-if-converted basis, the holders of any
preferred stock upon liquidation, dissolution or winding up of the affairs of the Company. The holders of common stock have no preemptive,
subscription or conversion rights and there are no redemption or sinking fund provisions.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
December 1, 2021, the Company closed a Securities Purchase Agreement (dated November 29, 2021) with several institutional investors
for the purchase and sale of &lt;span id="xdx_905_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20211201__20211201__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_zXvFBZ25PmQh" title="Shares issued, shares"&gt;588,000&lt;/span&gt;
reverse split adjusted shares of Company common stock at a reverse split adjusted exercise price of $&lt;span id="xdx_90D_eus-gaap--SharePrice_iI_pid_c20211201__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zB5FISyNOSJh" title="Share Price"&gt;15.00&lt;/span&gt;
per share, for aggregate gross proceeds of $&lt;span id="xdx_90A_eus-gaap--ProceedsFromIssuanceOfCommonStock_pn4n6_c20211201__20211201__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zYELsj42bDth" title="Proceeds from issuance of common stock"&gt;8.82&lt;/span&gt;
million.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
December 22, 2022, the Company issued to Alpha Capital, an &lt;span id="xdx_900_eus-gaap--ShortTermDebtInterestRateIncrease_pid_dp_uPure_c20221222__20221222__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember__us-gaap--DebtInstrumentAxis__custom--SeniorConvertibleDebentureMember_zCLUosOzRfQg" title="Senior convertible debenture rate"&gt;8&lt;/span&gt;%
Senior Convertible Debenture in the aggregate principal amount of $&lt;span id="xdx_902_eus-gaap--SecuredDebt_iI_c20221222__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember__us-gaap--DebtInstrumentAxis__custom--SeniorConvertibleDebentureMember_zgyBCJ3DxKt" title="Principal amount"&gt;3,300,000&lt;/span&gt;
for a purchase price of $&lt;span id="xdx_90C_ecustom--PurchasePrice_iI_c20221222__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember__us-gaap--DebtInstrumentAxis__custom--SeniorConvertibleDebentureMember_z0YPpYvHvrr3" title="Purchase Price"&gt;3,000,000&lt;/span&gt;
pursuant to the terms of a Securities Purchase Agreement, dated December 21, 2022. The Debenture is convertible, at any time, and
from time to time, at Alpha&#x2019;s option, into shares of common stock of the Company, at a price equal to $&lt;span id="xdx_904_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pid_c20221222__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember__us-gaap--DebtInstrumentAxis__custom--SeniorConvertibleDebentureMember_z4dEgdCRWaza" title="Conversion price"&gt;1.32&lt;/span&gt;
per share, and other terms and conditions described in the Debenture (see Note 11 -Convertible Debt - Related Party). As part of
this transaction, the Company issued to Alpha Capital a warrant to purchase &lt;span id="xdx_907_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20221222__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember_zze5nSNHwkmb" title="Warrant to purchase shares"&gt;2,500,000&lt;/span&gt;
shares of the Company&#x2019;s common stock (see Note 10-Warrant Liabilities).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;At
December 31, 2022, the Company has reserved &lt;span id="xdx_904_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_c20221231_zb8yzrO0mbvc" title="Common stock, shares reserved for future issuance"&gt;5,183,629&lt;/span&gt; shares of authorized but unissued common stock for possible future issuance. At
December 31, 2022, &lt;span id="xdx_909_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_c20221231_zUzMHDYiHo81" title="Common stock, shares reserved for future issuance"&gt;5,183,629&lt;/span&gt; shares were reserved as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89B_ecustom--ScheduleOfReservedSharesTableTextBlock_zimAAIToJ9Ea" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8B7_zax3uzRUfCia" style="display: none"&gt;SCHEDULE
OF RESERVED SHARES&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"&gt;
  &lt;tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_49C_20221231_zNuw65UoxOj9" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_hus-gaap--AwardTypeAxis__us-gaap--StockOptionMember_z3ZC73O4yVG8" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 78%; text-align: left"&gt;Exercise of issued and future grants of stock options&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 18%; text-align: right"&gt;608,012&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_hus-gaap--AwardTypeAxis__us-gaap--WarrantMember_zkBEyoRIIQza" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Exercise of stock warrants&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;4,575,617&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_zDujkcYLn797" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt; padding-left: 10pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;5,183,629&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AF_z9Le9WWtUHcb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"/&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Preferred
Stock&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;At
December 31, 2022 and 2021, there were no shares of preferred stock outstanding. All shares of Series A, B, C, D, D-1 convertible preferred
stock were converted into common stock at the time of the May 2020 reverse recapitalization transaction.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
the year ended December 31, 2021, the holder of Series Alpha convertible preferred stock converted &lt;span id="xdx_903_eus-gaap--ConvertiblePreferredStockSharesIssuedUponConversion_iI_pid_c20211231__us-gaap--StatementClassOfStockAxis__custom--SeriesAlphaConvertiblePreferredStockMember_z4p1JV3satYc" title="Convertible preferred stock, shares"&gt;180&lt;/span&gt; of its shares of Series Alpha
convertible preferred stock into an aggregate of &lt;span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodSharesOther_pid_c20210101__20211231__us-gaap--StatementClassOfStockAxis__custom--SeriesAlphaConvertiblePreferredStockMember_zKqE7rP9O0mj" title="Shares issued during conversion, shares"&gt;243,416&lt;/span&gt; shares of the Company&#x2019;s common stock.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Stock
Options and Equity Classified Warrants&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Stock
Options&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company recognizes all compensatory stock-based payments as compensation expense over the service period, which is generally the vesting
period.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
April 2020, the Company adopted the 2020 Stock Incentive Plan (the &#x201c;2020 Plan&#x201d;) which provides for the grant of incentive
or non-statutory common stock options, restricted stock, stock bonus awards, stock appreciation rights, restricted stock units and performance
awards to qualified employees, officers, directors, consultants and other service providers. At December 31, 2022 and December 31, 2021
there were &lt;span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20221231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--PlanNameAxis__custom--TwoThousandTwentyStockIncentivePlanMember_zHfLhUpRqNWk" title="Options outstanding"&gt;608,012&lt;/span&gt; and &lt;span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20211231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--PlanNameAxis__custom--TwoThousandTwentyStockIncentivePlanMember_z8NOvTtLyl0h" title="Options outstanding"&gt;484,186&lt;/span&gt; outstanding stock options, respectively, under the 2020 Plan and there were &lt;span id="xdx_908_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_pid_c20221231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--PlanNameAxis__custom--TwoThousandTwentyStockIncentivePlanMember_zYMFBxZIt9ok" title="Plan shares available"&gt;147,690&lt;/span&gt; and &lt;span id="xdx_901_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_pid_c20211231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--PlanNameAxis__custom--TwoThousandTwentyStockIncentivePlanMember_zJoKk2UrZhn1" title="Plan shares available"&gt;280,916&lt;/span&gt; of Plan
shares available, respectively, for future grant.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_892_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_z2FB81mZIsEk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following represents a summary of the options granted to employees and non-employee service providers that were outstanding at December
31, 2022, and changes during the twelve months then ended:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8B8_zD3cw60EzoEa" style="display: none"&gt;SCHEDULE
OF STOCK OPTION ACTIVITY&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Shares&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Weighted&#x2013;&lt;br/&gt; Average&lt;br/&gt; Exercise&lt;br/&gt;
    Price&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Range of&lt;br/&gt; Exercise&lt;br/&gt; Price&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Weighted&#x2013;&lt;br/&gt; Average&lt;br/&gt; Remaining&lt;br/&gt;
    Life (Years)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 32%"&gt;Total outstanding &#x2013; December 31, 2021&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20220101__20221231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zqnBPyfdF0z1" style="width: 12%; text-align: right" title="Number of shares, options outstanding, beginning"&gt;484,186&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20220101__20221231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zSo8odCfMjb9" style="width: 12%; text-align: right" title="Weighted Average Exercise Price, Outstanding, Beginning"&gt;60.70&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20220101__20221231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember__srt--RangeAxis__srt--MinimumMember_zNVJxn68qcaf" title="Range of Exercise price, Options Outstanding"&gt;12.40&lt;/span&gt;
                                            &#x2014; $&lt;span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20220101__20221231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember__srt--RangeAxis__srt--MaximumMember_zwIjOyKur9uj" title="Range of Exercise price, Options Outstanding"&gt;14,657.50&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&lt;span id="xdx_90E_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm3_dtY_c20220101__20221231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zj7EqTYG69L9" title="Weighted- Average Remaining Contractual Life (in Years), Outstanding, Beginning"&gt;8.52&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt"&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20220101__20221231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_z1RPE2CQS8d2" style="text-align: right" title="Number of shares, options granted"&gt;134,469&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20220101__20221231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zkvwQJ0CQG36" style="text-align: right" title="Weighted average exercise price, options granted"&gt;5.24&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_908_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionGrantedWeightedAverageExercisePrice_c20220101__20221231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember__srt--RangeAxis__srt--MinimumMember_zmSEZ3YUzaA2" title="Range of Exercise price, Options Outstanding"&gt;5.14&lt;/span&gt;
                                            &#x2014; &lt;span id="xdx_907_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionGrantedWeightedAverageExercisePrice_c20220101__20221231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember__srt--RangeAxis__srt--MaximumMember_zdkGibkxK343" title="Range of Exercise price, Options Outstanding"&gt;10.50&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_904_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm2_dtY_c20220101__20221231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_ztVfDUW1dy94" title="Weighted- Average Remaining Contractual Life (in Years), Options Granted"&gt;5.99&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt"&gt;Expired&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_iN_di_c20220101__20221231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zKuj5b6rQuu" style="text-align: right" title="Number of shares, options expired"&gt;(9,379&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_c20220101__20221231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_z30ZbFDj4F7i" style="text-align: right" title="Weighted average exercise price, options expired"&gt;932.75&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_906_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExpirationsInPeriodWeightedAverageExercisePrice_c20220101__20221231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember__srt--RangeAxis__srt--MinimumMember_zQRRIzsHx5N4" title="Range of Exercise price, Options Expired"&gt;57.50&lt;/span&gt;
                                            - &lt;span id="xdx_908_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExpirationsInPeriodWeightedAverageExercisePrice_pid_c20220101__20221231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember__srt--RangeAxis__srt--MaximumMember_zDNvdUlW7dcc" title="Range of exercise price, options expired"&gt;14,657.50&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt; padding-left: 10pt"&gt;Forfeited&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_di_c20220101__20221231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zRDjr5XQ9nlb" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of shares, options forfeited"&gt;(1,264&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20220101__20221231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zTrLEmJH9Gnf" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted average exercise price, options forfeited"&gt;22.64&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_c20220101__20221231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember__srt--RangeAxis__srt--MinimumMember_zhh9NAU4Ppec" title="Range of Exercise price, Options Forfeited"&gt;5.14&lt;/span&gt;
                                            - &lt;span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_c20220101__20221231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember__srt--RangeAxis__srt--MaximumMember_zuki1SvKVugj" title="Range of Exercise price, Options Forfeited"&gt;49.70&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Total outstanding &#x2013; December 31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20220101__20221231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zHQHex6Q7moe" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Shares, Options Outstanding at Ending"&gt;608,012&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20220101__20221231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zkOS9mXytQXa" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price, Outstanding at Ending"&gt;35.02&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20220101__20221231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember__srt--RangeAxis__srt--MinimumMember_zDgugfq7l8k9" title="Range of Exercise price, Options Outstanding"&gt;5.14&lt;/span&gt;
                                            &#x2014; $&lt;span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20220101__20221231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember__srt--RangeAxis__srt--MaximumMember_znYSLY54sQRk" title="Range of Exercise price, Options Outstanding"&gt;51.30&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20220101__20221231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_z48fHiVCqQ4b" title="Weighted- Average Remaining Contractual Life (in Years), Outstanding at Ending"&gt;8.09&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Exercisable (vested)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_iI_c20221231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_z7oIvggtyFlh" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of shares, options exercisable (vested)"&gt;288,704&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_c20221231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zAkadtWfXRtk" style="border-bottom: Black 2.5pt double; text-align: right" title="Range of exercise price, options exercisable (vested)"&gt;46.32&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_c20221231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember__srt--RangeAxis__srt--MinimumMember_zFQiWU7oOUwe" title="Range of exercise price, options exercisable (vested)"&gt;12.40&lt;/span&gt;
                                            &#x2014; $&lt;span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_c20221231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember__srt--RangeAxis__srt--MaximumMember_zk4vMa0xUGHe" title="Range of exercise price, options exercisable (vested)"&gt;51.30&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_906_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_dtY_c20220101__20221231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zbxpgyXpO7sc" title="Weighted- Average Remaining Contractual Life (in Years), Options Exercisable (vested)"&gt;7.59&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Non-Exercisable (non-vested)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iI_c20221231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zvZPeCoYNwCe" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of shares, options non-exercisable (non-vested)"&gt;319,308&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToNonVestExercisableWeightedAverageExercisePrice_iI_c20221231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zFFoxY8BCaj9" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price, options non-exercisable (non-vested)"&gt;24.80&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;$&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_iI_c20221231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember__srt--RangeAxis__srt--MinimumMember_zqbVRgVjO6ad" title="Range of exercise price, options non-exercisable (non-vested)"&gt;5.14&lt;/span&gt;
                                            &#x2014; $&lt;span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_iI_c20221231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember__srt--RangeAxis__srt--MaximumMember_zDcdUCBXQ7x2" title="Range of exercise price, options non-exercisable (non-vested)"&gt;10.50&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_908_ecustom--WeightedAverageRemainingContractualLifeInYearsOptionsNonexercisableNonvested_dtY_c20220101__20221231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_z5KM8vgvprkf" title="Weighted- Average Remaining Contractual Life (in Years), Options Non-exercisable (non-vested)"&gt;8.59&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AA_zseIMDhlGu28" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following represents a summary of the options granted (under the 2020 Plan and otherwise) to employees and non-employee service providers
that were outstanding at December 31, 2021, and changes during the twelve months then ended:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"/&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"/&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;Shares&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;Weighted&#x2013;&lt;br/&gt;
    Average&lt;br/&gt; Exercise&lt;br/&gt; Price&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font: bold 10pt Times New Roman, Times, Serif"&gt;Range
    of&lt;br/&gt; Exercise&lt;br/&gt; Price&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;Weighted&#x2013;&lt;br/&gt;
    Average&lt;br/&gt; Remaining&lt;br/&gt; Life (Years)&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 32%"&gt;Total outstanding &#x2013; December 31, 2020&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20210101__20211231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zlnTNVLyRFpg" style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right" title="Number of shares, options outstanding, beginning"&gt;401,136&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20210101__20211231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zHaziYuPldph" style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right" title="Weighted Average Exercise Price, Outstanding, Beginning"&gt;70.50&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20210101__20211231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember__srt--RangeAxis__srt--MinimumMember_zKwvVnwVjRL1" title="Range of Exercise price, Options Outstanding"&gt;35.20&lt;/span&gt;
                                            &#x2014; $&lt;span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20210101__20211231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember__srt--RangeAxis__srt--MaximumMember_zhxpaEnRRPRg" title="Range of Exercise price, Options Outstanding"&gt;14,657.50&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"&gt;&lt;span id="xdx_903_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm3_dtY_c20210101__20211231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zZFjNkCETqXl" title="Weighted- Average Remaining Contractual Life (in Years), Outstanding, Beginning"&gt;9.29&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"&gt;Granted&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20210101__20211231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_z2MqQeJ1z484" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of shares, options granted"&gt;83,500&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20210101__20211231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zxyPRlmnsw6g" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price, options granted"&gt;13.70&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_905_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionGrantedWeightedAverageExercisePrice_c20210101__20211231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember__srt--RangeAxis__srt--MinimumMember_zOLEWJPrpGV5" title="Range of Exercise price, Options Outstanding"&gt;12.40&lt;/span&gt;
                                            &#x2014; &lt;span id="xdx_907_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionGrantedWeightedAverageExercisePrice_c20210101__20211231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember__srt--RangeAxis__srt--MaximumMember_zIgleUIHQg02" title="Range of Exercise price, Options Outstanding"&gt;32.90&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_909_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm2_dtY_c20210101__20211231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zBlmxS6bsdGb" title="Weighted- Average Remaining Contractual Life (in Years), Options Granted"&gt;9.79&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"&gt;Expired&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_iN_di_c20210101__20211231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zI7xBpgmoeFi" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of shares, options expired"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1744"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_c20210101__20211231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zYXSPv8ok47k" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price, options expired"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1746"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_905_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExpirationsInPeriodWeightedAverageExercisePrice_pid_c20210101__20211231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zXSx1gzCejZ4" title="Range of Exercise price, Options Expired"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1748"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; padding-left: 10pt"&gt;Forfeited&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_di_c20210101__20211231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zwHpz37AiXV4" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of shares, options forfeited"&gt;(450&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20210101__20211231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zoua4IVotl38" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price, options forfeited"&gt;36.80&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_c20210101__20211231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember__srt--RangeAxis__srt--MinimumMember_z7pjlwC3o4sh" title="Range of Exercise price, Options Forfeited"&gt;35.20&lt;/span&gt;
                                            &#x2014; &lt;span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_c20210101__20211231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember__srt--RangeAxis__srt--MaximumMember_zffNW6BQTM0k" title="Range of Exercise price, Options Forfeited"&gt;49.70&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;Total outstanding &#x2013; December 31, 2021&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20210101__20211231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zIFAVcwX0f04" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Shares, Options Outstanding at Ending"&gt;484,186&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20210101__20211231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zBJouRvbgPqb" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price, Outstanding at Ending"&gt;60.70&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20210101__20211231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember__srt--RangeAxis__srt--MinimumMember_z8hAg45JY5Kb" title="Range of Exercise price, Options Outstanding"&gt;12.40&lt;/span&gt;
                                            &#x2014; $&lt;span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20210101__20211231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember__srt--RangeAxis__srt--MaximumMember_zkyaelHb6GU8" title="Range of Exercise price, Options Outstanding"&gt;14,657.50&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20210101__20211231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zeZsbAxIcF7d" title="Weighted- Average Remaining Contractual Life (in Years), Outstanding at Ending"&gt;8.52&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"&gt;Exercisable (vested)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_iI_c20211231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zsdgVzadx08k" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of shares, options exercisable (vested)"&gt;140,820&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_c20211231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zuUPP8744Yk7" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Range of exercise price, options exercisable (vested)"&gt;108.80&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;$&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_c20211231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember__srt--RangeAxis__srt--MinimumMember_zClFjuotgPLc" title="Range of exercise price, options exercisable (vested)"&gt;35.20&lt;/span&gt;
                                            &#x2014; $&lt;span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_c20211231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember__srt--RangeAxis__srt--MaximumMember_zNlHtSLqUBrk" title="Range of exercise price, options exercisable (vested)"&gt;14,657.50&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_dtY_c20210101__20211231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zr0KmYVSOCN9" title="Weighted- Average Remaining Contractual Life (in Years), Options Exercisable (vested)"&gt;7.94&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"&gt;Non-Exercisable (non-vested)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iI_c20211231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zmWVhhGC6U12" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of shares, options non-exercisable (non-vested)"&gt;343,366&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToNonVestExercisableWeightedAverageExercisePrice_iI_c20211231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zBywnFXAAj8f" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price, options non-exercisable (non-vested)"&gt;41.00&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;$&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_iI_c20211231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember__srt--RangeAxis__srt--MinimumMember_zk9HGnKXZZsd" title="Range of exercise price, options non-exercisable (non-vested)"&gt;12.40&lt;/span&gt;
                                            &#x2014; $&lt;span id="xdx_906_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_iI_c20211231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember__srt--RangeAxis__srt--MaximumMember_zFQLWXItfD7c" title="Range of exercise price, options non-exercisable (non-vested)"&gt;51.30&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_908_ecustom--WeightedAverageRemainingContractualLifeInYearsOptionsNonexercisableNonvested_dtY_c20210101__20211231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zkdl0OaBs8Hl" title="Weighted- Average Remaining Contractual Life (in Years), Options Non-exercisable (non-vested)"&gt;8.81&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"/&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;There
was approximately $&lt;span id="xdx_90D_eus-gaap--ShareBasedCompensation_pn5n6_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zuWnPueaqHp5" title="Compensation cost"&gt;5.4&lt;/span&gt; million and $&lt;span id="xdx_90C_eus-gaap--ShareBasedCompensation_pn5n6_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zykv4IKU9abf" title="Compensation cost"&gt;5.3&lt;/span&gt; million of compensation costs related to outstanding options for the year ended December 31,
2022 and December 31, 2021, respectively. As of December 31, 2022, there was approximately $&lt;span id="xdx_901_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_iI_pn5n6_c20221231_zlXSZYNG6LK8" title="Unrecognized compensation cost"&gt;3.3&lt;/span&gt; million of total unrecognized compensation
cost related to unvested stock-based compensation arrangements. This cost is expected to be recognized over a weighted average period
of &lt;span id="xdx_906_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20220101__20221231_zmlZSvswkSAa" title="Cost is expected to be recognized over a weighted average period"&gt;0.93&lt;/span&gt; years.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_906_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_do_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zoAYorNYuci3" title="Stock options exercised"&gt;&lt;span id="xdx_904_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_do_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zQBCDmXkTzf1" title="Stock options exercised"&gt;No&lt;/span&gt;&lt;/span&gt;
stock options were exercised during the year ended December 31, 2022 or 2021.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--PlanNameAxis__custom--TwoThousandTwentyStockIncentivePlanMember_zVADe2p1sLcl" title="Stock options description"&gt;The
exercise price for an option issued under the 2020 Plan is determined by the Board of Directors, but will be (i) in the case of an incentive
stock option (A) granted to an employee who, at the time of grant of such option, is a 10% stockholder, no less than 110% of the fair
market value per share on the date of grant; or (B) granted to any other employee, no less than 100% of the fair market value per share
on the date of grant; and (ii) in the case of a non-statutory stock option, no less than 100% of the fair market value per share on the
date of grant.&lt;/span&gt; The options awarded under the 2020 Plan will vest as determined by the Board of Directors but will not exceed a 10-year
period. The weighted average grant date fair value per share of the shares underlying options granted during the year ended December
31, 2022 was $&lt;span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zY5vuAG3Uoe7" title="Stock option granted exercise price"&gt;3.96&lt;/span&gt; and during the year ended December 31, 2021 was $&lt;span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zAGRhIfrlSy4" title="Stock option granted exercise price"&gt;11.00&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"/&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Fair
Value of Equity Awards&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company utilizes the Black-Scholes option pricing model to value awards under the 2020 Plan, and for equity classified compensatory warrants.
Key valuation assumptions include:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Expected
    dividend yield.&lt;/i&gt; The expected dividend is assumed to be zero, as the Company has never paid dividends and has no current plans
    to pay any dividends on the Company&#x2019;s common stock.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Expected
    stock-price volatility.&lt;/i&gt; The Company&#x2019;s expected volatility is derived from the average historical volatilities of publicly
    traded companies within the Company&#x2019;s industry that the Company considers to be comparable to the Company&#x2019;s business
    over a period approximately equal to the expected term.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Risk-free
    interest rate. &lt;/i&gt;The risk-free interest rate is based on the U.S. Treasury yield in effect at the time of grant for zero coupon
    U.S. Treasury notes with maturities approximately equal to the expected term.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Expected
    term.&lt;/i&gt; The expected term represents the period that the stock-based awards are expected to be outstanding. The Company&#x2019;s
    historical share option exercise experience does not provide a reasonable basis upon which to estimate an expected term because of
    a lack of sufficient data. Therefore, the Company estimates the expected term by using the simplified method provided by the SEC.
    The simplified method calculates the expected term as the average of the time-to-vesting and the contractual life of the options.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_898_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zXJHUhXRyRX8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
material factors incorporated in the Black-Scholes model in estimating the fair value of the options granted for the periods presented
were as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8BA_z7qII3f5qwu3" style="display: none"&gt;SCHEDULE
OF ASSUMPTION USED IN BLACK-SCHOLES OPTION-PRICING METHOD&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;For the Years Ended&lt;br/&gt; December
    31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;Expected dividend yield&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20220101__20221231_zhag32jN4YRf" style="width: 16%; text-align: right" title="Expected dividend yield"&gt;0.00&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20210101__20211231_zTIEJPQ084o4" style="width: 16%; text-align: right" title="Expected dividend yield"&gt;0.00&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Expected stock-price volatility&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20220101__20221231_zKtIwKVsS3U" style="text-align: right" title="Expected stock-price volatility"&gt;103&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20210101__20211231_zuEHSOgSMVc6" style="text-align: right" title="Expected stock-price volatility"&gt;102&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Risk-free interest rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_pid_dp_uPure_c20220101__20221231_zLvLnQPVePo9" title="Risk-free interest rate, minimum"&gt;1.58&lt;/span&gt;%
                                            &#x2014; &lt;span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_pid_dp_uPure_c20220101__20221231_zjt5MWct8SE7" title="Risk-free interest rate, maximum"&gt;3.77&lt;/span&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_pid_dp_uPure_c20210101__20211231_zJBi7nhkA5E" title="Risk-free interest rate, minimum"&gt;0.84&lt;/span&gt;%
                                            &#x2014; &lt;span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_pid_dp_uPure_c20210101__20211231_z829pG31GkU2" title="Risk-free interest rate, maximum"&gt;1.51&lt;/span&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Expected average term of options (in years)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20220101__20221231_zKzJtlwDIcD8" title="Expected average term of options (in years)"&gt;5.99&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20210101__20211231_z7gMe5DCjO56" title="Expected average term of options (in years)"&gt;6.27&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Stock price&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_900_eus-gaap--SharePrice_iI_c20221231__srt--RangeAxis__srt--MinimumMember_zGc28BFmmRvg" title="Share price"&gt;5.14&lt;/span&gt;
                                            - &lt;span id="xdx_902_eus-gaap--SharePrice_iI_c20221231__srt--RangeAxis__srt--MaximumMember_zgkx93Yfjlue" title="Share price"&gt;10.50&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_903_eus-gaap--SharePrice_iI_c20211231__srt--RangeAxis__srt--MinimumMember_z5tPoCaiZ4C2" title="Share price"&gt;12.40&lt;/span&gt;
                                            &#x2014; &lt;span id="xdx_904_eus-gaap--SharePrice_iI_c20211231__srt--RangeAxis__srt--MaximumMember_ztiGNvk1kf9k" title="Share price"&gt;32.90&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A1_zGLJGlfc0sjj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89C_eus-gaap--ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_zh066EzBM4zd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company recorded stock-based compensation expense and classified it in the Consolidated Statements of Operations as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8B7_zhN52oK5Tr13" style="display: none"&gt;SCHEDULE
OF SHARE-BASED COMPENSATION EXPENSE&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_491_20220101__20221231_zWbgOUKJSTsa" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_497_20210101__20211231_zC4rKQvO8pf5" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;For the Years Ended&lt;br/&gt; December
    31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--AllocatedShareBasedCompensationExpense_hus-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_z6NjOKdlH8xk" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;General and administrative&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;4,649,649&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;4,465,911&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--AllocatedShareBasedCompensationExpense_hus-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zQQRXIbMtjSl" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Research and development&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;834,395&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;827,740&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--AllocatedShareBasedCompensationExpense_z8koch4cNqm9" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt; padding-left: 10pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;5,484,044&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;5,293,651&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A5_zV04WYauZgVl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Equity
Classified Compensatory Warrants&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
connection with the $&lt;span id="xdx_907_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_pn5n6_c20220101__20221231__us-gaap--AwardTypeAxis__custom--CompensatoryWarrantsMember_zwMsTE61gQFk"&gt;4.0 &lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;million
equity capital raise as part of the May 2020 reverse recapitalization transaction, the Company issued common stock warrants to an
advisor and its designees for the purchase of &lt;span id="xdx_901_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_c20221231__us-gaap--AwardTypeAxis__custom--CompensatoryWarrantsMember_zjgTNrzmiqZ4"&gt;81,143
reverse split adjusted &lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;shares of the
Company&#x2019;s common stock at a reverse split adjusted exercise price of $&lt;span id="xdx_900_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20221231__us-gaap--AwardTypeAxis__custom--CompensatoryWarrantsMember_zNjdEUO6etbc"&gt;11.1&lt;span style="background-color: white"&gt;0 &lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;per
share. The issuance cost of these warrants was charged to additional paid-in capital, and did not result in expense in the
Company&#x2019;s consolidated &lt;span style="background-color: white"&gt;statements of operations and comprehensive
loss.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
addition, various service providers hold equity classified compensatory warrants issued in 2017 and earlier (originally exercisable to
purchase Series C convertible preferred stock, and now instead exercisable to purchase common stock) for the purchase of &lt;span id="xdx_900_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_c20171231__us-gaap--AwardTypeAxis__custom--CompensatoryWarrantsMember_zReF2tUb7Ixg" title="Purchase of warrants"&gt;66,802 reverse split adjusted s&lt;/span&gt;hares
of Company common stock at a weighted average exercise price of $&lt;span id="xdx_901_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20171231__us-gaap--AwardTypeAxis__custom--CompensatoryWarrantsMember_zdZ90OV21Emd" title="Exercise price of warrants"&gt;23.40&lt;/span&gt; per share. These are to be differentiated from the Series C Warrants
described in Note 10- Warrant Liabilities.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
the year ended December 31, 2021, the Company issued equity classified compensatory warrants to a service provider for the purchase of
&lt;span id="xdx_906_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20211231_zAW9cFKMDrj5"&gt;60,000&lt;/span&gt;&lt;/span&gt;
&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;reverse split adjusted shares of Company common stock at a
reverse split adjusted exercise price of $&lt;span id="xdx_907_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20211231_zInLCdDgEsGh"&gt;13.20&lt;/span&gt;
per share. The fair value issuance cost of approximately $&lt;/span&gt;&lt;span id="xdx_900_ecustom--FairValueOfIssuanceCost_pn5n6_c20210101__20211231_zJDERWaiZi3c" style="font-family: Times New Roman, Times, Serif; font-size: 10pt" title="Fair value of issuance cost"&gt;0.3
&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;million
using the Black-Scholes options pricing model for these warrants was charged to general and administrative expenses in the Company&#x2019;s
consolidated statements of operations and comprehensive loss. On April 25, 2022, &lt;/span&gt;&lt;span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20220425__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zVEDdVaiyjOc" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;60,000
&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;warrants
were repriced from $&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_909_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20220424__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zsFyZ1STGzv1"&gt;13.20&lt;/span&gt;
to &lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;a
reverse split adjusted exercise price of $6.00&lt;/span&gt; &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;and
extended from &lt;/span&gt;&lt;span id="xdx_905_ecustom--WarrantsExtendedDateDescription_c20220423__20220425__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zNBBNOSezz4e" style="font-family: Times New Roman, Times, Serif; font-size: 10pt" title="Warrants extended date description"&gt;June
3, 2023 to September 14, 2023&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;.
The increase in fair value of $&lt;/span&gt;&lt;span id="xdx_90C_eus-gaap--FairValueAdjustmentOfWarrants_c20220423__20220425__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zzNzyneGvfi6" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;67,370
&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;using
a Monte Carlo pricing model for the modification of these warrants was charged to general and administrative expenses in the Company&#x2019;s
consolidated statements of operations and comprehensive loss. On April 25, 2022 and May 26, 2022 an additional &lt;/span&gt;&lt;span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_c20220526__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z4jnGGNLlJVb" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;67,619 reverse split adjusted
&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;warrants
were repriced from reverse split adjusted $11&lt;/span&gt;&lt;span id="xdx_902_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20220526__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MinimumMember_zFUMTHnRFl4a" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;.10
&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;to
$&lt;/span&gt;&lt;span id="xdx_907_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20220526__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MaximumMember_z7pL3aTTTANk" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;5.136&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;.
The increase in fair value of $&lt;/span&gt;&lt;span id="xdx_90A_eus-gaap--FairValueAdjustmentOfWarrants_c20220523__20220526__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember__us-gaap--StatementEquityComponentsAxis__custom--WarrantOneMember_zk9GJs6d5TX7" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;31,010
&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;using
a Monte Carlo pricing model for the modification of these warrants was charged to additional paid-in capital and did not result in expense
on the Company&#x2019;s consolidated statements of operations and comprehensive loss. On December 22, 2022 &lt;/span&gt;&lt;span id="xdx_902_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_c20221222__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zmS18vwC5u43" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;67,620
&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;warrants
were repriced from $&lt;/span&gt;&lt;span id="xdx_903_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20221222__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MinimumMember_zLYsaYYaalN4" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;5.136
&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;to
$&lt;/span&gt;&lt;span id="xdx_902_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20221222__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MaximumMember_z9Mt5Rbq8Aih" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1.32&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;.
The increase in fair value of $&lt;/span&gt;&lt;span id="xdx_906_eus-gaap--FairValueAdjustmentOfWarrants_c20221220__20221222__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zvWYdjs2ZGS" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;8,548
&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;using
a Monte Carlo pricing model for the modification of these warrants was charged to additional paid-in capital and did not result in expense
on the Company&#x2019;s consolidated statements of operations and comprehensive loss.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"/&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;No
new compensatory warrants were issued during the year ended December 31, 2022.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_890_ecustom--SummaryOfWarrantActivityTableTextBlock_hus-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zm91MkMsDeuf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table summarizes the equity classified compensatory warrant activity for the year ended December 31, 2022:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8B3_zXMa6WS7uYJ2" style="display: none"&gt;SCHEDULE
OF WARRANT ACTIVITY&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Common Stock&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Shares&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Weighted&#x2013; Average&lt;br/&gt; Exercise&lt;br/&gt;
    Price&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Range of&lt;br/&gt; Exercise Price&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Weighted&#x2013;&lt;br/&gt; Average&lt;br/&gt; Remaining&lt;br/&gt;
    Life (Years)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 32%"&gt;Total outstanding &#x2013; December 31, 2021&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zc6X8p6TnZK2" style="width: 12%; text-align: right" title="Number of Shares, Warrants Outstanding Beginning"&gt;179,046&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iS_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_z6ZXiyP4CFQg" style="width: 12%; text-align: right" title="Weighted Average Exercise Price Per Share Warrants Outstanding Beginning"&gt;15.20&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span id="xdx_901_ecustom--RangeOfExercisePriceOutstanding_iS_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember__srt--RangeAxis__srt--MinimumMember_zfDlRJ4MFaAl" title="Range of exercise price - beginning"&gt;11.10&lt;/span&gt;
                                            &#x2014; $&lt;span id="xdx_905_ecustom--RangeOfExercisePriceOutstanding_iS_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember__srt--RangeAxis__srt--MaximumMember_zUOo2hZXtozc"&gt;25.40&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&lt;span id="xdx_90C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAveragRemainingContractualTerm1_dtY_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zIwhEPjpTkIj" title="Weighted Average Remaining Life (Years) - outstanding"&gt;2.64&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-left: 10pt"&gt;Granted to advisor and its designees&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_z6ayF8s7k1u5" style="text-align: right" title="Number of shares, warrants granted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1882"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zTsDqkiT7ug2" style="text-align: right" title="Weighted average exercise price per share warrants granted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1884"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt"&gt;Exercised&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_di_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zsXfVyH9frHj" style="text-align: right" title="Number of Shares, Warrants Exercised"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1886"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedInPeriodWeightedAverageExercisePrice_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zpp0ZfLX7rS1" style="text-align: right" title="Weighted average exercise price per share warrants exercised"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1888"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt"&gt;Expired&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zmAmgvhiTLmc" style="text-align: right" title="Number of Shares, Warrants Expired"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1890"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInPeriodWeightedAverageExercisePrice_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zIxcQeJ9pkNe" style="text-align: right" title="Weighted average exercise price per share warrants expired"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1892"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt; padding-left: 10pt"&gt;Forfeited&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_iN_di_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_z5uADim7WDt3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Shares, Warrants Forfeited"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1894"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedInPeriodWeightedAverageExercisePrice_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zpEak3XxjT87" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted average exercise price per share warrants forfeited"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1896"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Total outstanding &#x2013; December 31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zmok0BDWJap7" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Shares, Warrants Outstanding Ending"&gt;179,046&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iE_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_ztctxxBQvZl7" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price Per Share Warrants Outstanding Ending"&gt;9.12&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&lt;span id="xdx_906_ecustom--RangeOfExercisePriceOutstanding_iE_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember__srt--RangeAxis__srt--MinimumMember_zBdMA35yQnne" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1.32
&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x2014; $&lt;span id="xdx_902_ecustom--RangeOfExercisePriceOutstanding_iE_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember__srt--RangeAxis__srt--MaximumMember_zD11N8oa9I98"&gt;25.40&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&lt;span id="xdx_90C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAveragRemainingContractualTerm1_dtY_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zHI1aNvl8JV7" title="Weighted Average Remaining Life (Years) - outstanding"&gt;1.73&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Exercisable&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_iI_c20221231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zlw5vYR1cbVd" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Shares, Warrants Exercisable"&gt;179,046&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageVestedExercisePrice_iI_c20221231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zGkDkIc0xBt7" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price Per Share Exercisable"&gt;9.12&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_903_ecustom--RangeOfExercisePriceExercisableVested_iI_c20221231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember__srt--RangeAxis__srt--MinimumMember_zs7o9GJr1DMb"&gt;1.32&lt;/span&gt;-
                                            $&lt;span id="xdx_90B_ecustom--RangeOfExercisePriceExercisableVested_iI_c20221231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember__srt--RangeAxis__srt--MaximumMember_zlcUR6iJK9dd" title="Range of exercise price - ending"&gt;25.40&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_90E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAveragRemainingContractualTerm1_dtY_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zq2PDHCWcnYa" title="Weighted Average Remaining Life (Years) Exercisable"&gt;1.73&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Non-Exercisable&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNonVestedNumber_iI_c20221231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_z9JCQxPvZMe3" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of shares, warrants non-exercisable"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1915"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageNonVestedExercise_iI_c20221231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zIQo5bxFh7l8" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price Per Share Non-Exercisable"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1917"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_ecustom--RangeOfExercisePriceNonexercisableNonvested_iI_c20221231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_z3PBkLPWv78e" style="border-bottom: Black 2.5pt double; text-align: right" title="Range of Exercise Price, Non-Exercisable"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1919"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table summarizes the equity classified compensatory warrant activity for the year ended December 31, 2021:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Common Stock&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Shares&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Weighted&#x2013; Average&lt;br/&gt; Exercise&lt;br/&gt;
    Price&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Range of&lt;br/&gt; Exercise Price&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Weighted&#x2013;&lt;br/&gt; Average&lt;br/&gt; Remaining&lt;br/&gt;
    Life (Years)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 32%"&gt;Total outstanding &#x2013; December 31, 2020&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20210101__20211231__us-gaap--AwardTypeAxis__custom--CompensatoryWarrantActivityMember_zXEEiX2Ns9ij" style="width: 12%; text-align: right" title="Number of shares, warrants outstanding beginning"&gt;129,403&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iS_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zsAprVVc6pza" style="width: 12%; text-align: right" title="Weighted Average Exercise Price Per Share Warrants Outstanding Beginning"&gt;16.60&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-left: 10pt"&gt;Granted to advisor and its designees&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20210101__20211231__us-gaap--AwardTypeAxis__custom--CompensatoryWarrantActivityMember_zPTolTwgpNl1" style="text-align: right" title="Number of shares, warrants outstanding beginning"&gt;60,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zpjy7tjjG7lg" style="text-align: right" title="Weighted average exercise price per share warrants granted"&gt;13.20&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt"&gt;Exercised&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_di_c20210101__20211231__us-gaap--AwardTypeAxis__custom--CompensatoryWarrantActivityMember_zY5fckfJX907" style="text-align: right" title="Number of shares, warrants outstanding beginning"&gt;(3,839&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedInPeriodWeightedAverageExercisePrice_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zwvyAfJJtXIb" style="text-align: right" title="Weighted average exercise price per share warrants exercised"&gt;20.90&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt"&gt;Expired&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_iN_di_c20210101__20211231__us-gaap--AwardTypeAxis__custom--CompensatoryWarrantActivityMember_zqkBZSUcrDc8" style="text-align: right" title="Number of shares, warrants outstanding beginning"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1933"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInPeriodWeightedAverageExercisePrice_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_z4fOBs5hLglk" style="text-align: right" title="Weighted average exercise price per share warrants expired"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1935"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt; padding-left: 10pt"&gt;Forfeited&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_iN_di_c20210101__20211231__us-gaap--AwardTypeAxis__custom--CompensatoryWarrantActivityMember_zJXVwXTfBsLf" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of shares, warrants outstanding beginning"&gt;(6,518&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedInPeriodWeightedAverageExercisePrice_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zbskeWqjnywl" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted average exercise price per share warrants forfeited"&gt;20.70&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Total outstanding &#x2013; December 31, 2021&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_c20210101__20211231__us-gaap--AwardTypeAxis__custom--CompensatoryWarrantActivityMember_zc65SVAw9uPg" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of shares, warrants outstanding beginning"&gt;179,046&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iE_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zKVVPYIXz5lh" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price Per Share Warrants Outstanding Ending"&gt;15.20&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;$&lt;span id="xdx_907_ecustom--RangeOfExercisePriceOutstanding_iE_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember__srt--RangeAxis__srt--MinimumMember_zFtZ5QShHcE2"&gt;11.10&lt;/span&gt;
                                            &#x2014; $&lt;span id="xdx_90E_ecustom--RangeOfExercisePriceOutstanding_iE_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember__srt--RangeAxis__srt--MaximumMember_zqDqBD5TT456" title="Range of exercise price - ending"&gt;25.40&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&lt;span id="xdx_90A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAveragRemainingContractualTerm1_dtY_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zJmgIMArS5u7" title="Weighted Average Remaining Life (Years) - outstanding"&gt;2.64&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Exercisable&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_iI_c20211231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zYINqjRAnRv3" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Shares, Warrants Exercisable"&gt;179,046&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageVestedExercisePrice_iI_c20211231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zRAneQeqjhv7" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price Per Share Exercisable"&gt;15.20&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;$&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90A_ecustom--RangeOfExercisePriceExercisableVested_iI_c20211231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember__srt--RangeAxis__srt--MinimumMember_z4MNabjtCaf5"&gt;11.10&lt;/span&gt;
                                            &#x2014; $&lt;span id="xdx_900_ecustom--RangeOfExercisePriceExercisableVested_iI_c20211231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember__srt--RangeAxis__srt--MaximumMember_zNvjGiy4ITMk" title="Range of exercise price - ending"&gt;25.40&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_90D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAveragRemainingContractualTerm1_dtY_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zR4QFPoIUOA7" title="Weighted Average Remaining Life (Years) Exercisable"&gt;2.64&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Non-Exercisable&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNonVestedNumber_iI_c20211231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_z7ZZNsmCWqp8" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of shares, warrants non-exercisable"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1959"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageNonVestedExercise_iI_c20211231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_ziPEgq6dUs4b" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price Per Share Non-Exercisable"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1961"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_ecustom--RangeOfExercisePriceNonexercisableNonvested_iI_c20211231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zJ0O7U0xHvIh" style="border-bottom: Black 2.5pt double; text-align: right" title="Range of Exercise Price, Non-Exercisable"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1963"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AA_zlgfXByNtr9k" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;There
were $&lt;span id="xdx_902_eus-gaap--AllocatedShareBasedCompensationExpense_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zGO8KZPVkVLj" title="Compensation cost"&gt;67,370&lt;/span&gt; in compensation costs related to outstanding warrants for the year ended December 31, 2022 and $&lt;span id="xdx_902_eus-gaap--AllocatedShareBasedCompensationExpense_pn5n6_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zh0Q6NAeRwe2" title="Compensation cost"&gt;0.3&lt;/span&gt; million for the year
ended December 31, 2021. As of December 31, 2022 and December 31, 2021, there was no unrecognized compensation cost related to nonvested
warrants.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Noncompensatory
Equity Classified Warrants&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
May 2020, as a commitment fee, the Company issued noncompensatory equity classified warrants to Alpha Capital (a related party) for the purchase of &lt;span id="xdx_906_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_c20200531__us-gaap--AwardTypeAxis__custom--NoncompensatoryEquityClassifiedWarrantsMember_z2MZLezvuRn3"&gt;27,048
reverse split adjusted shares of Company common stock at a reverse split adjusted exercise price of $&lt;/span&gt;&lt;/span&gt;&lt;span id="xdx_909_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20200531__us-gaap--AwardTypeAxis__custom--NoncompensatoryEquityClassifiedWarrantsMember_zvbebgmQQKb4" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;11.10 &lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;per
share (of which warrants for &lt;/span&gt;&lt;span id="xdx_903_ecustom--WarrantsExercised_c20201201__20201231__us-gaap--AwardTypeAxis__custom--NoncompensatoryEquityClassifiedWarrantsMember_z8LpI3z0Zar2" style="font-family: Times New Roman, Times, Serif; font-size: 10pt" title="Warrants exercised"&gt;20,000 &lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;shares
were subsequently exercised in December 2020). In July 2020 the Company issued noncompensatory equity classified warrants to Alpha Capital for the purchase of &lt;/span&gt;&lt;span id="xdx_909_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_c20200731__us-gaap--AwardTypeAxis__custom--NoncompensatoryEquityClassifiedWarrantsMember__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember_zijiCBZozBs5" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;78,019
reverse split adjusted&lt;/span&gt; &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;shares
of Company common stock at a reverse split adjusted exercise price of $&lt;/span&gt;&lt;span id="xdx_904_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20200731__us-gaap--AwardTypeAxis__custom--NoncompensatoryEquityClassifiedWarrantsMember__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember_zQfcjhzOozug" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;0.01 &lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;per
share (which were subsequently exercised in July 2020), and &lt;span id="xdx_905_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_c20200731__us-gaap--AwardTypeAxis__custom--NoncompensatoryEquityClassifiedWarrantsMember_zHh7kJ5Uuas3"&gt;192,068&lt;/span&gt; reverse split adjusted shares of Company common stock at a
reverse split adjusted exercise price of $&lt;/span&gt;&lt;span id="xdx_900_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20200731__us-gaap--AwardTypeAxis__custom--NoncompensatoryEquityClassifiedWarrantsMember_z8lt0Jmnzu26" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;52.50 &lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;per
share. In August 2020, the Company issued noncompensatory equity classified warrants to Alpha Capital for the purchase of &lt;/span&gt;&lt;span id="xdx_903_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_c20200831__us-gaap--AwardTypeAxis__custom--NoncompensatoryEquityClassifiedWarrantsMember__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zgU8GMM1UD52" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;128,783
reverse split adjusted shares of Company common stock at a reverse split adjusted exercise price of $&lt;/span&gt;&lt;span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20200831__us-gaap--AwardTypeAxis__custom--NoncompensatoryEquityClassifiedWarrantsMember__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zmF05Pr6KTR3" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;60.00 &lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;per
share. In December 2020, the Company issued noncompensatory equity classified warrants to Alpha Capital for the purchase of &lt;/span&gt;&lt;span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_c20201231__us-gaap--AwardTypeAxis__custom--NoncompensatoryEquityClassifiedWarrantsMember__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember_zOoKzGlJGis4" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;100,000 &lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;reverse
split adjusted shares of Company common stock at a reverse split adjusted exercise price of $&lt;/span&gt;&lt;span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20201231__us-gaap--AwardTypeAxis__custom--NoncompensatoryEquityClassifiedWarrantsMember__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember_zwreAXqRa7ye" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;0.10 &lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;per
share (which were exercised in February 2021) and &lt;/span&gt;&lt;span id="xdx_909_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_c20201231_zEfuGpcs7FA3" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;219,101
reverse split adjusted&lt;/span&gt; &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;shares
of Company common stock at a reverse split adjusted exercise price of $&lt;/span&gt;&lt;span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20201231_z3QyJ92TdD9e" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;40.70 &lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;per
share. In May 2022, the Company issued noncompensatory equity classified warrants to Alpha Capital for the purchase of &lt;/span&gt;&lt;span id="xdx_901_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_c20220531__us-gaap--AwardTypeAxis__custom--NoncompensatoryEquityClassifiedWarrantsMember_z5LoGPTOrvE1" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;331,464
reverse split adjusted&lt;/span&gt; &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;shares
of Company common stock at a reverse split adjusted exercise price of $&lt;/span&gt;&lt;span id="xdx_900_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20220531__us-gaap--AwardTypeAxis__custom--NoncompensatoryEquityClassifiedWarrantsMember_zzERc0VKrLB2" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;0.01 &lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;per
share (See Note 3 -Acquisition).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"/&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;On
November 29, 2021, with the exception of the warrants to purchase &lt;span id="xdx_903_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_c20211129__us-gaap--AwardTypeAxis__custom--NoncompensatoryEquityClassifiedWarrantsMember_zeIeAtZFYJkb" title="Number of securities called by Each warrant or right"&gt;27,048
reverse split adjusted shares of the Company&#x2019;s common stock at a reverse split adjusted exercise price of $&lt;span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20211129__us-gaap--AwardTypeAxis__custom--NoncompensatoryEquityClassifiedWarrantsMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z0wnOdvdTm5i" title="Exercise price of warrants"&gt;11.10&lt;/span&gt;
per share, the exercise prices of all outstanding warrants to purchase a total of &lt;span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20211129__us-gaap--AwardTypeAxis__custom--NoncompensatoryEquityClassifiedWarrantsMember_zZIlHOnBCSWa" title="Number of outstanding warrants to purchase, shares"&gt;539,951
reverse split adjusted&lt;/span&gt; shares of the Company&#x2019;s common stock were modified to a reverse split adjusted exercise price of
$&lt;span id="xdx_908_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20211129__us-gaap--AwardTypeAxis__custom--NoncompensatoryEquityClassifiedWarrantsMember_zEcNBEAtthCg" title="Exercise price of warrants"&gt;20.00&lt;/span&gt;
per share and each of their remaining terms extended by six months. The fair value of the modification cost of these warrant
modifications of approximately $&lt;span id="xdx_907_eus-gaap--FairValueAdjustmentOfWarrants_pn5n6_c20220101__20221231__us-gaap--AwardTypeAxis__custom--NoncompensatoryEquityClassifiedWarrantsMember_zUHKcymBIuIg" title="Fair value of warrants"&gt;2.3&lt;/span&gt;
million was charged to additional paid-in capital and did not result in expense on the Company&#x2019;s consolidated statements of
operations and comprehensive loss. In May 2022, pre-funded warrants to purchase &lt;span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_c20220930__us-gaap--AwardTypeAxis__custom--NoncompensatoryEquityClassifiedWarrantsMember_zAa5DJ8XHQrh" title="Purchase of warrants"&gt;331,464
reverse split adjusted&lt;/span&gt; shares of the Company&#x2019;s common stock at a reverse split adjusted exercise price of $&lt;span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20220930__us-gaap--AwardTypeAxis__custom--NoncompensatoryEquityClassifiedWarrantsMember_z9sDvAuGwgH1" title=" Exercise price of warrants or rights"&gt;0.01&lt;/span&gt;
per share with no expiration date were issued. These warrants were subsequently exercised during the period ended September 30,
2022.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;In
conjunction with the NanoSynex Acquisition (See Note 3-Acquisition), on April 25, 2022 the exercise price of &lt;span id="xdx_907_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_c20220425__us-gaap--BusinessAcquisitionAxis__custom--NanoSynexMember_z9yALRVQV102" title="Purchase of warrants"&gt;7,048
reverse split adjusted outstanding warrants at $&lt;span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20211231__us-gaap--AwardTypeAxis__custom--NoncompensatoryEquityClassifiedWarrantsMember_zT420ek5Kjpf" title="Exercise price of warrants"&gt;11.10&lt;/span&gt;
was modified to a reverse split adjusted exercise price of $&lt;span id="xdx_900_ecustom--ModifiedToExercisePrice_iI_c20220425__us-gaap--BusinessAcquisitionAxis__custom--NanoSynexMember_zN4BuVTwIfSe" title="Modified to exercise price"&gt;6.00&lt;/span&gt;.
The increase in fair value of $&lt;span id="xdx_90D_eus-gaap--FairValueAdjustmentOfWarrants_c20220423__20220425__us-gaap--BusinessAcquisitionAxis__custom--NanoSynexMember_zJEIpQn8FNp3" title="Fair value of warrants"&gt;2,533&lt;/span&gt;,
using a Monte Carlo pricing model for the modification of these warrants, was charged to additional paid-in capital and did not
result in expense on the Company&#x2019;s consolidated statements of operations and comprehensive loss. On May 26, 2022, the
reverse split adjusted exercise price of these warrants was modified again to $&lt;span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20220526__us-gaap--BusinessAcquisitionAxis__custom--NanoSynexMember_zurAVj0Qtuxa" title="Class of warrant or right, exercise"&gt;5.136&lt;/span&gt;,
and the increase in fair value of $&lt;span id="xdx_90A_eus-gaap--FairValueAdjustmentOfWarrants_c20220523__20220526__us-gaap--BusinessAcquisitionAxis__custom--NanoSynexMember_zK1wcBgwQFU8" title="Fair value adjustment of warrants"&gt;696&lt;/span&gt;,
using a Monte Carlo pricing model for the modification of these warrants, was included in consideration transferred in the NanoSynex
Acquisition. On December 22, 2022 the exercise price of these warrants was modified again to $&lt;span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20221222__us-gaap--BusinessAcquisitionAxis__custom--NanoSynexMember_zo7wHeVdlDSa" title="Class of warrant or right, exercise"&gt;1.32&lt;/span&gt;.
The increase in fair value of $&lt;span id="xdx_90D_eus-gaap--FairValueAdjustmentOfWarrants_c20221220__20221222__us-gaap--BusinessAcquisitionAxis__custom--NanoSynexMember_zIdwFZZ7rdOk" title="Fair value adjustment of warrants"&gt;891&lt;/span&gt;,
using a Monte Carlo pricing model for the modification of those warrants, was charged to additional paid-in capital and did not
result in expense on the Company&#x2019;s consolidated statements of operations and comprehensive loss.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_896_ecustom--SummaryOfWarrantActivityTableTextBlock_hus-gaap--StatementEquityComponentsAxis__custom--NonCompensatoryWarrantActivityMember_z3Ezp2e9l6U5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table summarizes the noncompensatory equity classified warrant activity for the year ended December 31, 2022:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8BD_z7kPo6hRT5N9" style="display: none"&gt;SCHEDULE
OF WARRANT ACTIVITY&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"/&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"/&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="14" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;Common
    Stock&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif"&gt;Shares&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;Weighted&#x2013;&lt;br/&gt;
    Average&lt;br/&gt; Exercise&lt;br/&gt; Price&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;Range
    of&lt;br/&gt; Exercise Price&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;Weighted&#x2013;&lt;br/&gt;
    Average&lt;br/&gt; Remaining&lt;br/&gt; Life (Years)&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 32%; padding-bottom: 2.5pt"&gt;Total outstanding &#x2013; December 31, 2021&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20220101__20221231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zwjFSRJNVUW9" style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; width: 12%; text-align: right" title="Number of shares, warrants outstanding beginning"&gt;554,914&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iS_c20220101__20221231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zVikSZesbGu9" style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; width: 12%; text-align: right" title="Weighted Average exercise price per share warrants outstanding beginning"&gt;20.10&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; width: 16%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_903_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsRangeOfExercisePrice_iS_c20220101__20221231__srt--RangeAxis__srt--MinimumMember__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zMUMmCqTfd85" title="Range of exercise price"&gt;11.10&lt;/span&gt;&#x2014;
                                            &lt;span id="xdx_909_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsRangeOfExercisePrice_iS_c20220101__20221231__srt--RangeAxis__srt--MaximumMember__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_z7eX7LOBnGI3" title="Range of exercise price"&gt;37.78&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; width: 12%; text-align: right"&gt;&lt;span id="xdx_90D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAveragRemainingContractualTerm1_dtY_c20210101__20211231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zL0eZezEfLbh" title="Weighted average remaining life (Years) exercisable"&gt;1.32&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"&gt;Granted&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20220101__20221231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zleoRD6BR5kc" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of shares, warrants granted"&gt;331,464&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice_c20220101__20221231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zzuzx14V31M9" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price per share warrants granted"&gt;0.01&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_ecustom--RangeOfExercisePriceGranted_c20220101__20221231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zVOw8zcBTcrc" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Range of exercise price - granted"&gt;0.01&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"&gt;Exercised&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_di_c20220101__20221231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zCes61SgT65l" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Shares, Warrants Exercised"&gt;(331,464&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedInPeriodWeightedAverageExercisePrice_c20220101__20221231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zTuzD7PPoiFa" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price per share warrants exercised"&gt;0.01&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_ecustom--RangeOfExercisePriceExpired_c20220101__20221231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zfa6QtYaCcGe" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Range of exercise price - Expired"&gt;0.01&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"&gt;Expired&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_iN_di_c20220101__20221231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zT83qno96T8k" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Shares, Warrants Expired"&gt;(7,911&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInPeriodWeightedAverageExercisePrice_c20220101__20221231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zCWvJvJpGnle" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price per share warrants expired"&gt;37.78&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInRangeOfExercisePrice_c20220101__20221231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zreaXubl0vi3" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price per share warrants expired"&gt;37.78&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; padding-left: 10pt"&gt;Forfeited&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_iN_di_c20220101__20221231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zUfyKeYAqJh7" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Shares, Warrants Forfeited"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2045"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedInPeriodWeightedAverageExercisePrice_c20220101__20221231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_z18TDDCOaWL5" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price per share warrants forfeited"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2047"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedInRangeOfExercisePrice_c20220101__20221231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zOYk6TDl4qP3" style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right" title="Weighted average exercise price per share warrants forfeited"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2049"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;Total outstanding &#x2013; December 31, 2022&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_c20220101__20221231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zubz5owdsLu7" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of shares, warrants outstanding ending"&gt;547,003&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iE_c20220101__20221231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zmgV7gzBuov4" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;19.76&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_907_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsRangeOfExercisePrice_iE_c20220101__20221231__srt--RangeAxis__srt--MinimumMember__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zFFcgD4S67i5" title="Range of exercise price"&gt;1.32&lt;/span&gt;
                                            - &lt;span id="xdx_90A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsRangeOfExercisePrice_iE_c20220101__20221231__srt--RangeAxis__srt--MaximumMember__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zKF9YJmyPbOh" title="Range of exercise price"&gt;20.00&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&lt;p style="margin: 0"&gt;&lt;span id="xdx_903_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAveragRemainingContractualTerm1_dtY_c20220101__20221231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_z3ZFJGZrIQ3j" title="Weighted average remaining life (Years) exercisable"&gt;0.33&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;Exercisable&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_iI_c20221231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zlrYJwXik0Lk" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Shares, Warrants Exercisable"&gt;547,003&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"/&gt;&lt;td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageVestedExercisePrice_iI_c20221231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zdNu49nlWmh8" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price Per Share Exercisable"&gt;19.76&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90C_ecustom--RangeOfExercisePriceExercisableVested_iI_c20221231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember__srt--RangeAxis__srt--MinimumMember_z75s4PgkKA08"&gt;1.32&lt;/span&gt;
                                            - &lt;span id="xdx_908_ecustom--RangeOfExercisePriceExercisableVested_iI_c20221231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember__srt--RangeAxis__srt--MaximumMember_z53sjGNxbes" title="Range of exercise price - Exercisable"&gt;20.00&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_902_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAveragRemainingContractualTerm1_dtY_c20220101__20221231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zY5i18pnUj9g" title="Weighted average remaining life (Years) exercisable"&gt;0.33&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;Non-Exercisable&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;p id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsNonExercisableNumber_iI_c20221231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_z9QB1DrWVd54" style="margin: 0" title="Number of Shares, Warrants Exercisable"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2069"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageVestedNonExercisePrice_iI_c20221231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zRUYi3jgb2T" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price Per Share Exercisable"&gt;&lt;p style="margin: 0"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2071"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;p style="margin: 0"&gt;&lt;span id="xdx_905_ecustom--RangeOfExercisePriceNonExercisableVested_iI_c20221231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zS6McpAPGdJ8" title="Range of exercise price - Exercisable"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2073"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;p style="margin: 0"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"/&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table summarizes the noncompensatory equity classified warrant activity for the year ended December 31, 2021:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"/&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt"/&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="14" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;Common
    Stock&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;Shares&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;Weighted&#x2013;&lt;br/&gt;
    Average&lt;br/&gt; Exercise&lt;br/&gt; Price&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;Range
    of&lt;br/&gt; Exercise Price&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;Weighted&#x2013;&lt;br/&gt;
    Average&lt;br/&gt; Remaining&lt;br/&gt; Life (Years)&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 32%"&gt;Total outstanding &#x2013; December 31, 2020&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20210101__20211231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zrgu3znl8ir8" style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right" title="Number of shares, warrants outstanding beginning"&gt;654,978&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iS_c20210101__20211231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zuq0DGS0fNgc" style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right" title="Weighted Average exercise price per share warrants outstanding beginning"&gt;43.60&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"&gt;Granted&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20210101__20211231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zseVSSaR3om2" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of shares, warrants granted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2079"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice_c20210101__20211231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zd7XDgXX7v0e" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price per share warrants granted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2081"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"&gt;Exercised&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_di_c20210101__20211231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_z4VTL9fYAHg7" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Shares, Warrants Exercised"&gt;(100,000&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedInPeriodWeightedAverageExercisePrice_c20210101__20211231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zk9RebS1SFOa" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price per share warrants exercised"&gt;0.01&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"&gt;Expired&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_iN_di_c20210101__20211231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zMrt5FX6PAk7" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Shares, Warrants Expired"&gt;(64&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInPeriodWeightedAverageExercisePrice_c20210101__20211231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_z4PGH6tMj7L" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price per share warrants expired"&gt;23,250.00&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; padding-left: 10pt"&gt;Forfeited&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_iN_di_c20210101__20211231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zWrrkA6OrSX4" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Shares, Warrants Forfeited"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2091"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedInPeriodWeightedAverageExercisePrice_c20210101__20211231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zHFgSqFaYdF" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price per share warrants forfeited"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2093"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;Total outstanding &#x2013; December 31, 2021&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_c20210101__20211231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zzvbBfvHzVw9" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of shares, warrants outstanding ending"&gt;554,914&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iE_c20210101__20211231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_z5YMpRUmKmxb" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price per share warrants outstanding ending"&gt;20.10&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;Exercisable&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_iI_c20211231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zRtonYIo0gr" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Shares, Warrants Exercisable"&gt;554,914&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageVestedExercisePrice_iI_c20211231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_z4XqDAu7DU09" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price Per Share Exercisable"&gt;20.10&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90A_ecustom--RangeOfExercisePriceExercisableVested_iI_c20211231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember__srt--RangeAxis__srt--MinimumMember_z2Cgb5GcUwU1"&gt;11.10&lt;/span&gt;&#x2014;
                                            &lt;span id="xdx_90E_ecustom--RangeOfExercisePriceExercisableVested_iI_c20211231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember__srt--RangeAxis__srt--MaximumMember_zT9QG9krjKff" title="Range of exercise price - Exercisable"&gt;37.78&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_909_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAveragRemainingContractualTerm1_dtY_c20210101__20211231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zhxtRGlF0sia" title="Weighted average remaining life (Years) exercisable"&gt;1.32&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;Non-Exercisable&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNonVestedNumber_iI_c20211231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zsRMNxUJolef" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of shares, warrants non-exercisable"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2108"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageNonVestedExercise_iI_c20211231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_z6BDf9VNYLpb" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price Per Share Non-Exercisable"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2110"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_ecustom--RangeOfExercisePriceNonexercisableNonvested_iI_c20211231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zh4z4Kxg5TPh" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Range of Exercise Price, Non-Exercisable"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2112"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNonExercisableWeightedAverageRemainingContractualTerm1_dtY_c20210101__20211231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zxT9GOV6SKZb" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average remaining life (Years) non-exercisable"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2114"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A7_zsJm35GUamO2" style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2021-12-012021-12-01_custom_SecuritiesPurchaseAgreementMember_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">588000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharePrice
      contextRef="AsOf2021-12-01_custom_SecuritiesPurchaseAgreementMember"
      decimals="INF"
      unitRef="USDPShares">15.00</us-gaap:SharePrice>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2021-12-012021-12-01_custom_SecuritiesPurchaseAgreementMember"
      decimals="-4"
      unitRef="USD">8820000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ShortTermDebtInterestRateIncrease
      contextRef="From2022-12-222022-12-22_custom_AlphaCapitalMember_custom_SeniorConvertibleDebentureMember"
      decimals="INF"
      unitRef="Pure">0.08</us-gaap:ShortTermDebtInterestRateIncrease>
    <us-gaap:SecuredDebt
      contextRef="AsOf2022-12-22_custom_AlphaCapitalMember_custom_SeniorConvertibleDebentureMember"
      decimals="0"
      unitRef="USD">3300000</us-gaap:SecuredDebt>
    <QLGN:PurchasePrice
      contextRef="AsOf2022-12-22_custom_AlphaCapitalMember_custom_SeniorConvertibleDebentureMember"
      decimals="0"
      unitRef="USD">3000000</QLGN:PurchasePrice>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="AsOf2022-12-22_custom_AlphaCapitalMember_custom_SeniorConvertibleDebentureMember"
      decimals="INF"
      unitRef="USDPShares">1.32</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2022-12-22_custom_SeriesCWarrantsMember_custom_AlphaCapitalMember"
      decimals="INF"
      unitRef="Shares">2500000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance contextRef="AsOf2022-12-31" decimals="INF" unitRef="Shares">5183629</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance contextRef="AsOf2022-12-31" decimals="INF" unitRef="Shares">5183629</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <QLGN:ScheduleOfReservedSharesTableTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_89B_ecustom--ScheduleOfReservedSharesTableTextBlock_zimAAIToJ9Ea" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8B7_zax3uzRUfCia" style="display: none"&gt;SCHEDULE
OF RESERVED SHARES&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"&gt;
  &lt;tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_49C_20221231_zNuw65UoxOj9" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_hus-gaap--AwardTypeAxis__us-gaap--StockOptionMember_z3ZC73O4yVG8" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 78%; text-align: left"&gt;Exercise of issued and future grants of stock options&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 18%; text-align: right"&gt;608,012&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_hus-gaap--AwardTypeAxis__us-gaap--WarrantMember_zkBEyoRIIQza" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Exercise of stock warrants&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;4,575,617&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_zDujkcYLn797" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt; padding-left: 10pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;5,183,629&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</QLGN:ScheduleOfReservedSharesTableTextBlock>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="AsOf2022-12-31_us-gaap_StockOptionMember"
      decimals="INF"
      unitRef="Shares">608012</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="AsOf2022-12-31_us-gaap_WarrantMember72029296"
      decimals="INF"
      unitRef="Shares">4575617</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance contextRef="AsOf2022-12-31" decimals="INF" unitRef="Shares">5183629</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion
      contextRef="AsOf2021-12-31_custom_SeriesAlphaConvertiblePreferredStockMember"
      decimals="INF"
      unitRef="Shares">180</us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion>
    <us-gaap:StockIssuedDuringPeriodSharesOther
      contextRef="From2021-01-012021-12-31_custom_SeriesAlphaConvertiblePreferredStockMember"
      decimals="INF"
      unitRef="Shares">243416</us-gaap:StockIssuedDuringPeriodSharesOther>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2022-12-31_us-gaap_StockOptionMember_custom_TwoThousandTwentyStockIncentivePlanMember"
      decimals="INF"
      unitRef="Shares">608012</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2021-12-31_us-gaap_StockOptionMember_custom_TwoThousandTwentyStockIncentivePlanMember"
      decimals="INF"
      unitRef="Shares">484186</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="AsOf2022-12-31_us-gaap_StockOptionMember_custom_TwoThousandTwentyStockIncentivePlanMember"
      decimals="INF"
      unitRef="Shares">147690</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="AsOf2021-12-31_us-gaap_StockOptionMember_custom_TwoThousandTwentyStockIncentivePlanMember"
      decimals="INF"
      unitRef="Shares">280916</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_892_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_z2FB81mZIsEk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following represents a summary of the options granted to employees and non-employee service providers that were outstanding at December
31, 2022, and changes during the twelve months then ended:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8B8_zD3cw60EzoEa" style="display: none"&gt;SCHEDULE
OF STOCK OPTION ACTIVITY&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Shares&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Weighted&#x2013;&lt;br/&gt; Average&lt;br/&gt; Exercise&lt;br/&gt;
    Price&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Range of&lt;br/&gt; Exercise&lt;br/&gt; Price&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Weighted&#x2013;&lt;br/&gt; Average&lt;br/&gt; Remaining&lt;br/&gt;
    Life (Years)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 32%"&gt;Total outstanding &#x2013; December 31, 2021&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20220101__20221231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zqnBPyfdF0z1" style="width: 12%; text-align: right" title="Number of shares, options outstanding, beginning"&gt;484,186&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20220101__20221231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zSo8odCfMjb9" style="width: 12%; text-align: right" title="Weighted Average Exercise Price, Outstanding, Beginning"&gt;60.70&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20220101__20221231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember__srt--RangeAxis__srt--MinimumMember_zNVJxn68qcaf" title="Range of Exercise price, Options Outstanding"&gt;12.40&lt;/span&gt;
                                            &#x2014; $&lt;span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20220101__20221231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember__srt--RangeAxis__srt--MaximumMember_zwIjOyKur9uj" title="Range of Exercise price, Options Outstanding"&gt;14,657.50&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&lt;span id="xdx_90E_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm3_dtY_c20220101__20221231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zj7EqTYG69L9" title="Weighted- Average Remaining Contractual Life (in Years), Outstanding, Beginning"&gt;8.52&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt"&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20220101__20221231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_z1RPE2CQS8d2" style="text-align: right" title="Number of shares, options granted"&gt;134,469&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20220101__20221231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zkvwQJ0CQG36" style="text-align: right" title="Weighted average exercise price, options granted"&gt;5.24&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_908_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionGrantedWeightedAverageExercisePrice_c20220101__20221231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember__srt--RangeAxis__srt--MinimumMember_zmSEZ3YUzaA2" title="Range of Exercise price, Options Outstanding"&gt;5.14&lt;/span&gt;
                                            &#x2014; &lt;span id="xdx_907_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionGrantedWeightedAverageExercisePrice_c20220101__20221231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember__srt--RangeAxis__srt--MaximumMember_zdkGibkxK343" title="Range of Exercise price, Options Outstanding"&gt;10.50&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_904_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm2_dtY_c20220101__20221231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_ztVfDUW1dy94" title="Weighted- Average Remaining Contractual Life (in Years), Options Granted"&gt;5.99&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt"&gt;Expired&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_iN_di_c20220101__20221231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zKuj5b6rQuu" style="text-align: right" title="Number of shares, options expired"&gt;(9,379&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_c20220101__20221231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_z30ZbFDj4F7i" style="text-align: right" title="Weighted average exercise price, options expired"&gt;932.75&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_906_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExpirationsInPeriodWeightedAverageExercisePrice_c20220101__20221231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember__srt--RangeAxis__srt--MinimumMember_zQRRIzsHx5N4" title="Range of Exercise price, Options Expired"&gt;57.50&lt;/span&gt;
                                            - &lt;span id="xdx_908_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExpirationsInPeriodWeightedAverageExercisePrice_pid_c20220101__20221231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember__srt--RangeAxis__srt--MaximumMember_zDNvdUlW7dcc" title="Range of exercise price, options expired"&gt;14,657.50&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt; padding-left: 10pt"&gt;Forfeited&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_di_c20220101__20221231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zRDjr5XQ9nlb" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of shares, options forfeited"&gt;(1,264&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20220101__20221231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zTrLEmJH9Gnf" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted average exercise price, options forfeited"&gt;22.64&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_c20220101__20221231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember__srt--RangeAxis__srt--MinimumMember_zhh9NAU4Ppec" title="Range of Exercise price, Options Forfeited"&gt;5.14&lt;/span&gt;
                                            - &lt;span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_c20220101__20221231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember__srt--RangeAxis__srt--MaximumMember_zuki1SvKVugj" title="Range of Exercise price, Options Forfeited"&gt;49.70&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Total outstanding &#x2013; December 31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20220101__20221231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zHQHex6Q7moe" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Shares, Options Outstanding at Ending"&gt;608,012&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20220101__20221231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zkOS9mXytQXa" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price, Outstanding at Ending"&gt;35.02&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20220101__20221231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember__srt--RangeAxis__srt--MinimumMember_zDgugfq7l8k9" title="Range of Exercise price, Options Outstanding"&gt;5.14&lt;/span&gt;
                                            &#x2014; $&lt;span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20220101__20221231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember__srt--RangeAxis__srt--MaximumMember_znYSLY54sQRk" title="Range of Exercise price, Options Outstanding"&gt;51.30&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20220101__20221231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_z48fHiVCqQ4b" title="Weighted- Average Remaining Contractual Life (in Years), Outstanding at Ending"&gt;8.09&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Exercisable (vested)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_iI_c20221231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_z7oIvggtyFlh" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of shares, options exercisable (vested)"&gt;288,704&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_c20221231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zAkadtWfXRtk" style="border-bottom: Black 2.5pt double; text-align: right" title="Range of exercise price, options exercisable (vested)"&gt;46.32&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_c20221231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember__srt--RangeAxis__srt--MinimumMember_zFQiWU7oOUwe" title="Range of exercise price, options exercisable (vested)"&gt;12.40&lt;/span&gt;
                                            &#x2014; $&lt;span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_c20221231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember__srt--RangeAxis__srt--MaximumMember_zk4vMa0xUGHe" title="Range of exercise price, options exercisable (vested)"&gt;51.30&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_906_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_dtY_c20220101__20221231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zbxpgyXpO7sc" title="Weighted- Average Remaining Contractual Life (in Years), Options Exercisable (vested)"&gt;7.59&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Non-Exercisable (non-vested)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iI_c20221231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zvZPeCoYNwCe" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of shares, options non-exercisable (non-vested)"&gt;319,308&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToNonVestExercisableWeightedAverageExercisePrice_iI_c20221231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zFFoxY8BCaj9" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price, options non-exercisable (non-vested)"&gt;24.80&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;$&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_iI_c20221231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember__srt--RangeAxis__srt--MinimumMember_zqbVRgVjO6ad" title="Range of exercise price, options non-exercisable (non-vested)"&gt;5.14&lt;/span&gt;
                                            &#x2014; $&lt;span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_iI_c20221231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember__srt--RangeAxis__srt--MaximumMember_zDcdUCBXQ7x2" title="Range of exercise price, options non-exercisable (non-vested)"&gt;10.50&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_908_ecustom--WeightedAverageRemainingContractualLifeInYearsOptionsNonexercisableNonvested_dtY_c20220101__20221231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_z5KM8vgvprkf" title="Weighted- Average Remaining Contractual Life (in Years), Options Non-exercisable (non-vested)"&gt;8.59&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2021-12-31_custom_EmployeesAndNonemployeeServiceProviderMember"
      decimals="INF"
      unitRef="Shares">484186</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2021-12-31_custom_EmployeesAndNonemployeeServiceProviderMember"
      decimals="INF"
      unitRef="USDPShares">60.70</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2021-12-31_custom_EmployeesAndNonemployeeServiceProviderMember_srt_MinimumMember"
      decimals="INF"
      unitRef="USDPShares">12.40</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2021-12-31_custom_EmployeesAndNonemployeeServiceProviderMember_srt_MaximumMember"
      decimals="INF"
      unitRef="USDPShares">14657.50</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <QLGN:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm3 contextRef="From2022-01-012022-12-31_custom_EmployeesAndNonemployeeServiceProviderMember">P8Y6M7D</QLGN:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm3>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
      contextRef="From2022-01-012022-12-31_custom_EmployeesAndNonemployeeServiceProviderMember"
      decimals="INF"
      unitRef="Shares">134469</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="From2022-01-012022-12-31_custom_EmployeesAndNonemployeeServiceProviderMember"
      decimals="INF"
      unitRef="USDPShares">5.24</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionGrantedWeightedAverageExercisePrice
      contextRef="From2022-01-012022-12-31_custom_EmployeesAndNonemployeeServiceProviderMember_srt_MinimumMember"
      decimals="INF"
      unitRef="USDPShares">5.14</QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionGrantedWeightedAverageExercisePrice>
    <QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionGrantedWeightedAverageExercisePrice
      contextRef="From2022-01-012022-12-31_custom_EmployeesAndNonemployeeServiceProviderMember_srt_MaximumMember"
      decimals="INF"
      unitRef="USDPShares">10.50</QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionGrantedWeightedAverageExercisePrice>
    <QLGN:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm2 contextRef="From2022-01-012022-12-31_custom_EmployeesAndNonemployeeServiceProviderMember">P5Y11M26D</QLGN:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
      contextRef="From2022-01-012022-12-31_custom_EmployeesAndNonemployeeServiceProviderMember"
      decimals="INF"
      unitRef="Shares">9379</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="From2022-01-012022-12-31_custom_EmployeesAndNonemployeeServiceProviderMember"
      decimals="INF"
      unitRef="USDPShares">932.75</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice>
    <QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="From2022-01-012022-12-31_custom_EmployeesAndNonemployeeServiceProviderMember_srt_MinimumMember"
      decimals="INF"
      unitRef="USDPShares">57.50</QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExpirationsInPeriodWeightedAverageExercisePrice>
    <QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="From2022-01-012022-12-31_custom_EmployeesAndNonemployeeServiceProviderMember_srt_MaximumMember"
      decimals="INF"
      unitRef="USDPShares">14657.50</QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="From2022-01-012022-12-31_custom_EmployeesAndNonemployeeServiceProviderMember"
      decimals="INF"
      unitRef="Shares">1264</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="From2022-01-012022-12-31_custom_EmployeesAndNonemployeeServiceProviderMember"
      decimals="INF"
      unitRef="USDPShares">22.64</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="From2022-01-012022-12-31_custom_EmployeesAndNonemployeeServiceProviderMember_srt_MinimumMember"
      decimals="INF"
      unitRef="USDPShares">5.14</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="From2022-01-012022-12-31_custom_EmployeesAndNonemployeeServiceProviderMember_srt_MaximumMember"
      decimals="INF"
      unitRef="USDPShares">49.70</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2022-12-31_custom_EmployeesAndNonemployeeServiceProviderMember"
      decimals="INF"
      unitRef="Shares">608012</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2022-12-31_custom_EmployeesAndNonemployeeServiceProviderMember"
      decimals="INF"
      unitRef="USDPShares">35.02</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2022-12-31_custom_EmployeesAndNonemployeeServiceProviderMember_srt_MinimumMember"
      decimals="INF"
      unitRef="USDPShares">5.14</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2022-12-31_custom_EmployeesAndNonemployeeServiceProviderMember_srt_MaximumMember"
      decimals="INF"
      unitRef="USDPShares">51.30</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="From2022-01-012022-12-31_custom_EmployeesAndNonemployeeServiceProviderMember">P8Y1M2D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber
      contextRef="AsOf2022-12-31_custom_EmployeesAndNonemployeeServiceProviderMember"
      decimals="INF"
      unitRef="Shares">288704</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
      contextRef="AsOf2022-12-31_custom_EmployeesAndNonemployeeServiceProviderMember"
      decimals="INF"
      unitRef="USDPShares">46.32</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
      contextRef="AsOf2022-12-31_custom_EmployeesAndNonemployeeServiceProviderMember_srt_MinimumMember"
      decimals="INF"
      unitRef="USDPShares">12.40</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
      contextRef="AsOf2022-12-31_custom_EmployeesAndNonemployeeServiceProviderMember_srt_MaximumMember"
      decimals="INF"
      unitRef="USDPShares">51.30</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1 contextRef="From2022-01-012022-12-31_custom_EmployeesAndNonemployeeServiceProviderMember">P7Y7M2D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
      contextRef="AsOf2022-12-31_custom_EmployeesAndNonemployeeServiceProviderMember"
      decimals="INF"
      unitRef="Shares">319308</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares>
    <QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToNonVestExercisableWeightedAverageExercisePrice
      contextRef="AsOf2022-12-31_custom_EmployeesAndNonemployeeServiceProviderMember"
      decimals="INF"
      unitRef="USDPShares">24.80</QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToNonVestExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="AsOf2022-12-31_custom_EmployeesAndNonemployeeServiceProviderMember_srt_MinimumMember"
      decimals="INF"
      unitRef="USDPShares">5.14</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="AsOf2022-12-31_custom_EmployeesAndNonemployeeServiceProviderMember_srt_MaximumMember"
      decimals="INF"
      unitRef="USDPShares">10.50</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue>
    <QLGN:WeightedAverageRemainingContractualLifeInYearsOptionsNonexercisableNonvested contextRef="From2022-01-012022-12-31_custom_EmployeesAndNonemployeeServiceProviderMember">P8Y7M2D</QLGN:WeightedAverageRemainingContractualLifeInYearsOptionsNonexercisableNonvested>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2020-12-31_custom_EmployeesAndNonemployeeServiceProviderMember"
      decimals="INF"
      unitRef="Shares">401136</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2020-12-31_custom_EmployeesAndNonemployeeServiceProviderMember"
      decimals="INF"
      unitRef="USDPShares">70.50</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2020-12-31_custom_EmployeesAndNonemployeeServiceProviderMember_srt_MinimumMember"
      decimals="INF"
      unitRef="USDPShares">35.20</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2020-12-31_custom_EmployeesAndNonemployeeServiceProviderMember_srt_MaximumMember"
      decimals="INF"
      unitRef="USDPShares">14657.50</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <QLGN:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm3 contextRef="From2021-01-012021-12-31_custom_EmployeesAndNonemployeeServiceProviderMember">P9Y3M14D</QLGN:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm3>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
      contextRef="From2021-01-012021-12-31_custom_EmployeesAndNonemployeeServiceProviderMember"
      decimals="INF"
      unitRef="Shares">83500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="From2021-01-012021-12-31_custom_EmployeesAndNonemployeeServiceProviderMember"
      decimals="INF"
      unitRef="USDPShares">13.70</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionGrantedWeightedAverageExercisePrice
      contextRef="From2021-01-012021-12-31_custom_EmployeesAndNonemployeeServiceProviderMember_srt_MinimumMember"
      decimals="INF"
      unitRef="USDPShares">12.40</QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionGrantedWeightedAverageExercisePrice>
    <QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionGrantedWeightedAverageExercisePrice
      contextRef="From2021-01-012021-12-31_custom_EmployeesAndNonemployeeServiceProviderMember_srt_MaximumMember"
      decimals="INF"
      unitRef="USDPShares">32.90</QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionGrantedWeightedAverageExercisePrice>
    <QLGN:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm2 contextRef="From2021-01-012021-12-31_custom_EmployeesAndNonemployeeServiceProviderMember">P9Y9M14D</QLGN:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="From2021-01-012021-12-31_custom_EmployeesAndNonemployeeServiceProviderMember"
      decimals="INF"
      unitRef="Shares">450</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="From2021-01-012021-12-31_custom_EmployeesAndNonemployeeServiceProviderMember"
      decimals="INF"
      unitRef="USDPShares">36.80</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="From2021-01-012021-12-31_custom_EmployeesAndNonemployeeServiceProviderMember_srt_MinimumMember"
      decimals="INF"
      unitRef="USDPShares">35.20</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="From2021-01-012021-12-31_custom_EmployeesAndNonemployeeServiceProviderMember_srt_MaximumMember"
      decimals="INF"
      unitRef="USDPShares">49.70</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2021-12-31_custom_EmployeesAndNonemployeeServiceProviderMember"
      decimals="INF"
      unitRef="Shares">484186</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2021-12-31_custom_EmployeesAndNonemployeeServiceProviderMember"
      decimals="INF"
      unitRef="USDPShares">60.70</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2021-12-31_custom_EmployeesAndNonemployeeServiceProviderMember_srt_MinimumMember"
      decimals="INF"
      unitRef="USDPShares">12.40</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2021-12-31_custom_EmployeesAndNonemployeeServiceProviderMember_srt_MaximumMember"
      decimals="INF"
      unitRef="USDPShares">14657.50</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="From2021-01-012021-12-31_custom_EmployeesAndNonemployeeServiceProviderMember">P8Y6M7D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber
      contextRef="AsOf2021-12-31_custom_EmployeesAndNonemployeeServiceProviderMember"
      decimals="INF"
      unitRef="Shares">140820</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
      contextRef="AsOf2021-12-31_custom_EmployeesAndNonemployeeServiceProviderMember"
      decimals="INF"
      unitRef="USDPShares">108.80</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
      contextRef="AsOf2021-12-31_custom_EmployeesAndNonemployeeServiceProviderMember_srt_MinimumMember"
      decimals="INF"
      unitRef="USDPShares">35.20</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
      contextRef="AsOf2021-12-31_custom_EmployeesAndNonemployeeServiceProviderMember_srt_MaximumMember"
      decimals="INF"
      unitRef="USDPShares">14657.50</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1 contextRef="From2021-01-012021-12-31_custom_EmployeesAndNonemployeeServiceProviderMember">P7Y11M8D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
      contextRef="AsOf2021-12-31_custom_EmployeesAndNonemployeeServiceProviderMember"
      decimals="INF"
      unitRef="Shares">343366</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares>
    <QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToNonVestExercisableWeightedAverageExercisePrice
      contextRef="AsOf2021-12-31_custom_EmployeesAndNonemployeeServiceProviderMember"
      decimals="INF"
      unitRef="USDPShares">41.00</QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToNonVestExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="AsOf2021-12-31_custom_EmployeesAndNonemployeeServiceProviderMember_srt_MinimumMember"
      decimals="INF"
      unitRef="USDPShares">12.40</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="AsOf2021-12-31_custom_EmployeesAndNonemployeeServiceProviderMember_srt_MaximumMember"
      decimals="INF"
      unitRef="USDPShares">51.30</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue>
    <QLGN:WeightedAverageRemainingContractualLifeInYearsOptionsNonexercisableNonvested contextRef="From2021-01-012021-12-31_custom_EmployeesAndNonemployeeServiceProviderMember">P8Y9M21D</QLGN:WeightedAverageRemainingContractualLifeInYearsOptionsNonexercisableNonvested>
    <us-gaap:ShareBasedCompensation
      contextRef="From2022-01-012022-12-31_us-gaap_EmployeeStockOptionMember"
      decimals="-5"
      unitRef="USD">5400000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2021-01-012021-12-31_us-gaap_EmployeeStockOptionMember"
      decimals="-5"
      unitRef="USD">5300000</us-gaap:ShareBasedCompensation>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized contextRef="AsOf2022-12-31" decimals="-5" unitRef="USD">3300000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="From2022-01-01to2022-12-31">P0Y11M4D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="From2022-01-012022-12-31_us-gaap_StockOptionMember"
      decimals="INF"
      unitRef="Shares">0</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="From2021-01-012021-12-31_us-gaap_StockOptionMember"
      decimals="INF"
      unitRef="Shares">0</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription contextRef="From2022-01-012022-12-31_us-gaap_StockOptionMember_custom_TwoThousandTwentyStockIncentivePlanMember">The
exercise price for an option issued under the 2020 Plan is determined by the Board of Directors, but will be (i) in the case of an incentive
stock option (A) granted to an employee who, at the time of grant of such option, is a 10% stockholder, no less than 110% of the fair
market value per share on the date of grant; or (B) granted to any other employee, no less than 100% of the fair market value per share
on the date of grant; and (ii) in the case of a non-statutory stock option, no less than 100% of the fair market value per share on the
date of grant.</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="From2022-01-012022-12-31_us-gaap_StockOptionMember"
      decimals="INF"
      unitRef="USDPShares">3.96</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="From2021-01-012021-12-31_us-gaap_StockOptionMember"
      decimals="INF"
      unitRef="USDPShares">11.00</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_898_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zXJHUhXRyRX8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
material factors incorporated in the Black-Scholes model in estimating the fair value of the options granted for the periods presented
were as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8BA_z7qII3f5qwu3" style="display: none"&gt;SCHEDULE
OF ASSUMPTION USED IN BLACK-SCHOLES OPTION-PRICING METHOD&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;For the Years Ended&lt;br/&gt; December
    31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;Expected dividend yield&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20220101__20221231_zhag32jN4YRf" style="width: 16%; text-align: right" title="Expected dividend yield"&gt;0.00&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20210101__20211231_zTIEJPQ084o4" style="width: 16%; text-align: right" title="Expected dividend yield"&gt;0.00&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Expected stock-price volatility&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20220101__20221231_zKtIwKVsS3U" style="text-align: right" title="Expected stock-price volatility"&gt;103&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20210101__20211231_zuEHSOgSMVc6" style="text-align: right" title="Expected stock-price volatility"&gt;102&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Risk-free interest rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_pid_dp_uPure_c20220101__20221231_zLvLnQPVePo9" title="Risk-free interest rate, minimum"&gt;1.58&lt;/span&gt;%
                                            &#x2014; &lt;span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_pid_dp_uPure_c20220101__20221231_zjt5MWct8SE7" title="Risk-free interest rate, maximum"&gt;3.77&lt;/span&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_pid_dp_uPure_c20210101__20211231_zJBi7nhkA5E" title="Risk-free interest rate, minimum"&gt;0.84&lt;/span&gt;%
                                            &#x2014; &lt;span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_pid_dp_uPure_c20210101__20211231_z829pG31GkU2" title="Risk-free interest rate, maximum"&gt;1.51&lt;/span&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Expected average term of options (in years)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20220101__20221231_zKzJtlwDIcD8" title="Expected average term of options (in years)"&gt;5.99&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20210101__20211231_z7gMe5DCjO56" title="Expected average term of options (in years)"&gt;6.27&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Stock price&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_900_eus-gaap--SharePrice_iI_c20221231__srt--RangeAxis__srt--MinimumMember_zGc28BFmmRvg" title="Share price"&gt;5.14&lt;/span&gt;
                                            - &lt;span id="xdx_902_eus-gaap--SharePrice_iI_c20221231__srt--RangeAxis__srt--MaximumMember_zgkx93Yfjlue" title="Share price"&gt;10.50&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_903_eus-gaap--SharePrice_iI_c20211231__srt--RangeAxis__srt--MinimumMember_z5tPoCaiZ4C2" title="Share price"&gt;12.40&lt;/span&gt;
                                            &#x2014; &lt;span id="xdx_904_eus-gaap--SharePrice_iI_c20211231__srt--RangeAxis__srt--MaximumMember_ztiGNvk1kf9k" title="Share price"&gt;32.90&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="From2022-01-01to2022-12-31"
      decimals="INF"
      unitRef="Pure">0.0000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="From2021-01-012021-12-31"
      decimals="INF"
      unitRef="Pure">0.0000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="From2022-01-01to2022-12-31"
      decimals="INF"
      unitRef="Pure">1.03</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="From2021-01-012021-12-31"
      decimals="INF"
      unitRef="Pure">1.02</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="From2022-01-01to2022-12-31"
      decimals="INF"
      unitRef="Pure">0.0158</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="From2022-01-01to2022-12-31"
      decimals="INF"
      unitRef="Pure">0.0377</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="From2021-01-012021-12-31"
      decimals="INF"
      unitRef="Pure">0.0084</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="From2021-01-012021-12-31"
      decimals="INF"
      unitRef="Pure">0.0151</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2022-01-01to2022-12-31">P5Y11M26D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2021-01-012021-12-31">P6Y3M7D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharePrice
      contextRef="AsOf2022-12-31_srt_MinimumMember"
      decimals="INF"
      unitRef="USDPShares">5.14</us-gaap:SharePrice>
    <us-gaap:SharePrice
      contextRef="AsOf2022-12-31_srt_MaximumMember"
      decimals="INF"
      unitRef="USDPShares">10.50</us-gaap:SharePrice>
    <us-gaap:SharePrice
      contextRef="AsOf2021-12-31_srt_MinimumMember"
      decimals="INF"
      unitRef="USDPShares">12.40</us-gaap:SharePrice>
    <us-gaap:SharePrice
      contextRef="AsOf2021-12-31_srt_MaximumMember"
      decimals="INF"
      unitRef="USDPShares">32.90</us-gaap:SharePrice>
    <us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_89C_eus-gaap--ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_zh066EzBM4zd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company recorded stock-based compensation expense and classified it in the Consolidated Statements of Operations as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8B7_zhN52oK5Tr13" style="display: none"&gt;SCHEDULE
OF SHARE-BASED COMPENSATION EXPENSE&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_491_20220101__20221231_zWbgOUKJSTsa" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_497_20210101__20211231_zC4rKQvO8pf5" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;For the Years Ended&lt;br/&gt; December
    31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--AllocatedShareBasedCompensationExpense_hus-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_z6NjOKdlH8xk" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;General and administrative&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;4,649,649&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;4,465,911&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--AllocatedShareBasedCompensationExpense_hus-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zQQRXIbMtjSl" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Research and development&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;834,395&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;827,740&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--AllocatedShareBasedCompensationExpense_z8koch4cNqm9" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt; padding-left: 10pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;5,484,044&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;5,293,651&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2022-01-012022-12-31_us-gaap_GeneralAndAdministrativeExpenseMember"
      decimals="0"
      unitRef="USD">4649649</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2021-01-012021-12-31_us-gaap_GeneralAndAdministrativeExpenseMember"
      decimals="0"
      unitRef="USD">4465911</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2022-01-012022-12-31_us-gaap_ResearchAndDevelopmentExpenseMember"
      decimals="0"
      unitRef="USD">834395</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2021-01-012021-12-31_us-gaap_ResearchAndDevelopmentExpenseMember"
      decimals="0"
      unitRef="USD">827740</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">5484044</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">5293651</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ProceedsFromIssuanceOrSaleOfEquity
      contextRef="From2022-01-012022-12-31_custom_CompensatoryWarrantsMember"
      decimals="-5"
      unitRef="USD">4000000.0</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
      contextRef="AsOf2022-12-31_custom_CompensatoryWarrantsMember"
      decimals="INF"
      unitRef="Shares">81143</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2022-12-31_custom_CompensatoryWarrantsMember"
      decimals="INF"
      unitRef="USDPShares">11.1</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
      contextRef="AsOf2017-12-31_custom_CompensatoryWarrantsMember"
      decimals="INF"
      unitRef="Shares">66802</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2017-12-31_custom_CompensatoryWarrantsMember"
      decimals="INF"
      unitRef="USDPShares">23.40</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="AsOf2021-12-31" decimals="INF" unitRef="Shares">60000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2021-12-31"
      decimals="INF"
      unitRef="USDPShares">13.20</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <QLGN:FairValueOfIssuanceCost
      contextRef="From2021-01-012021-12-31"
      decimals="-5"
      unitRef="USD">300000</QLGN:FairValueOfIssuanceCost>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2022-04-25_us-gaap_WarrantMember"
      decimals="INF"
      unitRef="Shares">60000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2022-04-24_us-gaap_WarrantMember"
      decimals="INF"
      unitRef="USDPShares">13.20</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <QLGN:WarrantsExtendedDateDescription contextRef="From2022-04-232022-04-25_us-gaap_WarrantMember">June
3, 2023 to September 14, 2023</QLGN:WarrantsExtendedDateDescription>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="From2022-04-232022-04-25_us-gaap_GeneralAndAdministrativeExpenseMember_us-gaap_WarrantMember"
      decimals="0"
      unitRef="USD">67370</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
      contextRef="AsOf2022-05-26_us-gaap_WarrantMember"
      decimals="INF"
      unitRef="Shares">67619</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2022-05-26_us-gaap_WarrantMember_srt_MinimumMember"
      decimals="INF"
      unitRef="USDPShares">0.10</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2022-05-26_us-gaap_WarrantMember_srt_MaximumMember"
      decimals="INF"
      unitRef="USDPShares">5.136</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="From2022-05-232022-05-26_us-gaap_GeneralAndAdministrativeExpenseMember_custom_WarrantOneMember"
      decimals="0"
      unitRef="USD">31010</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
      contextRef="AsOf2022-12-22_us-gaap_WarrantMember"
      decimals="INF"
      unitRef="Shares">67620</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2022-12-22_us-gaap_WarrantMember_srt_MinimumMember"
      decimals="INF"
      unitRef="USDPShares">5.136</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2022-12-22_us-gaap_WarrantMember_srt_MaximumMember"
      decimals="INF"
      unitRef="USDPShares">1.32</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="From2022-12-202022-12-22_us-gaap_WarrantMember"
      decimals="0"
      unitRef="USD">8548</us-gaap:FairValueAdjustmentOfWarrants>
    <QLGN:SummaryOfWarrantActivityTableTextBlock contextRef="From2022-01-012022-12-31_custom_CompensatoryWarrantActivityMember">&lt;p id="xdx_890_ecustom--SummaryOfWarrantActivityTableTextBlock_hus-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zm91MkMsDeuf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table summarizes the equity classified compensatory warrant activity for the year ended December 31, 2022:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8B3_zXMa6WS7uYJ2" style="display: none"&gt;SCHEDULE
OF WARRANT ACTIVITY&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Common Stock&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Shares&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Weighted&#x2013; Average&lt;br/&gt; Exercise&lt;br/&gt;
    Price&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Range of&lt;br/&gt; Exercise Price&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Weighted&#x2013;&lt;br/&gt; Average&lt;br/&gt; Remaining&lt;br/&gt;
    Life (Years)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 32%"&gt;Total outstanding &#x2013; December 31, 2021&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zc6X8p6TnZK2" style="width: 12%; text-align: right" title="Number of Shares, Warrants Outstanding Beginning"&gt;179,046&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iS_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_z6ZXiyP4CFQg" style="width: 12%; text-align: right" title="Weighted Average Exercise Price Per Share Warrants Outstanding Beginning"&gt;15.20&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span id="xdx_901_ecustom--RangeOfExercisePriceOutstanding_iS_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember__srt--RangeAxis__srt--MinimumMember_zfDlRJ4MFaAl" title="Range of exercise price - beginning"&gt;11.10&lt;/span&gt;
                                            &#x2014; $&lt;span id="xdx_905_ecustom--RangeOfExercisePriceOutstanding_iS_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember__srt--RangeAxis__srt--MaximumMember_zUOo2hZXtozc"&gt;25.40&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&lt;span id="xdx_90C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAveragRemainingContractualTerm1_dtY_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zIwhEPjpTkIj" title="Weighted Average Remaining Life (Years) - outstanding"&gt;2.64&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-left: 10pt"&gt;Granted to advisor and its designees&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_z6ayF8s7k1u5" style="text-align: right" title="Number of shares, warrants granted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1882"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zTsDqkiT7ug2" style="text-align: right" title="Weighted average exercise price per share warrants granted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1884"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt"&gt;Exercised&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_di_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zsXfVyH9frHj" style="text-align: right" title="Number of Shares, Warrants Exercised"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1886"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedInPeriodWeightedAverageExercisePrice_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zpp0ZfLX7rS1" style="text-align: right" title="Weighted average exercise price per share warrants exercised"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1888"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt"&gt;Expired&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zmAmgvhiTLmc" style="text-align: right" title="Number of Shares, Warrants Expired"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1890"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInPeriodWeightedAverageExercisePrice_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zIxcQeJ9pkNe" style="text-align: right" title="Weighted average exercise price per share warrants expired"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1892"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt; padding-left: 10pt"&gt;Forfeited&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_iN_di_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_z5uADim7WDt3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Shares, Warrants Forfeited"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1894"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedInPeriodWeightedAverageExercisePrice_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zpEak3XxjT87" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted average exercise price per share warrants forfeited"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1896"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Total outstanding &#x2013; December 31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zmok0BDWJap7" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Shares, Warrants Outstanding Ending"&gt;179,046&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iE_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_ztctxxBQvZl7" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price Per Share Warrants Outstanding Ending"&gt;9.12&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&lt;span id="xdx_906_ecustom--RangeOfExercisePriceOutstanding_iE_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember__srt--RangeAxis__srt--MinimumMember_zBdMA35yQnne" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1.32
&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x2014; $&lt;span id="xdx_902_ecustom--RangeOfExercisePriceOutstanding_iE_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember__srt--RangeAxis__srt--MaximumMember_zD11N8oa9I98"&gt;25.40&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&lt;span id="xdx_90C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAveragRemainingContractualTerm1_dtY_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zHI1aNvl8JV7" title="Weighted Average Remaining Life (Years) - outstanding"&gt;1.73&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Exercisable&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_iI_c20221231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zlw5vYR1cbVd" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Shares, Warrants Exercisable"&gt;179,046&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageVestedExercisePrice_iI_c20221231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zGkDkIc0xBt7" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price Per Share Exercisable"&gt;9.12&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_903_ecustom--RangeOfExercisePriceExercisableVested_iI_c20221231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember__srt--RangeAxis__srt--MinimumMember_zs7o9GJr1DMb"&gt;1.32&lt;/span&gt;-
                                            $&lt;span id="xdx_90B_ecustom--RangeOfExercisePriceExercisableVested_iI_c20221231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember__srt--RangeAxis__srt--MaximumMember_zlcUR6iJK9dd" title="Range of exercise price - ending"&gt;25.40&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_90E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAveragRemainingContractualTerm1_dtY_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zq2PDHCWcnYa" title="Weighted Average Remaining Life (Years) Exercisable"&gt;1.73&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Non-Exercisable&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNonVestedNumber_iI_c20221231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_z9JCQxPvZMe3" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of shares, warrants non-exercisable"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1915"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageNonVestedExercise_iI_c20221231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zIQo5bxFh7l8" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price Per Share Non-Exercisable"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1917"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_ecustom--RangeOfExercisePriceNonexercisableNonvested_iI_c20221231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_z3PBkLPWv78e" style="border-bottom: Black 2.5pt double; text-align: right" title="Range of Exercise Price, Non-Exercisable"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1919"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table summarizes the equity classified compensatory warrant activity for the year ended December 31, 2021:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Common Stock&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Shares&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Weighted&#x2013; Average&lt;br/&gt; Exercise&lt;br/&gt;
    Price&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Range of&lt;br/&gt; Exercise Price&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Weighted&#x2013;&lt;br/&gt; Average&lt;br/&gt; Remaining&lt;br/&gt;
    Life (Years)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 32%"&gt;Total outstanding &#x2013; December 31, 2020&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20210101__20211231__us-gaap--AwardTypeAxis__custom--CompensatoryWarrantActivityMember_zXEEiX2Ns9ij" style="width: 12%; text-align: right" title="Number of shares, warrants outstanding beginning"&gt;129,403&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iS_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zsAprVVc6pza" style="width: 12%; text-align: right" title="Weighted Average Exercise Price Per Share Warrants Outstanding Beginning"&gt;16.60&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-left: 10pt"&gt;Granted to advisor and its designees&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20210101__20211231__us-gaap--AwardTypeAxis__custom--CompensatoryWarrantActivityMember_zPTolTwgpNl1" style="text-align: right" title="Number of shares, warrants outstanding beginning"&gt;60,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zpjy7tjjG7lg" style="text-align: right" title="Weighted average exercise price per share warrants granted"&gt;13.20&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt"&gt;Exercised&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_di_c20210101__20211231__us-gaap--AwardTypeAxis__custom--CompensatoryWarrantActivityMember_zY5fckfJX907" style="text-align: right" title="Number of shares, warrants outstanding beginning"&gt;(3,839&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedInPeriodWeightedAverageExercisePrice_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zwvyAfJJtXIb" style="text-align: right" title="Weighted average exercise price per share warrants exercised"&gt;20.90&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt"&gt;Expired&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_iN_di_c20210101__20211231__us-gaap--AwardTypeAxis__custom--CompensatoryWarrantActivityMember_zqkBZSUcrDc8" style="text-align: right" title="Number of shares, warrants outstanding beginning"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1933"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInPeriodWeightedAverageExercisePrice_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_z4fOBs5hLglk" style="text-align: right" title="Weighted average exercise price per share warrants expired"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1935"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt; padding-left: 10pt"&gt;Forfeited&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_iN_di_c20210101__20211231__us-gaap--AwardTypeAxis__custom--CompensatoryWarrantActivityMember_zJXVwXTfBsLf" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of shares, warrants outstanding beginning"&gt;(6,518&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedInPeriodWeightedAverageExercisePrice_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zbskeWqjnywl" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted average exercise price per share warrants forfeited"&gt;20.70&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Total outstanding &#x2013; December 31, 2021&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_c20210101__20211231__us-gaap--AwardTypeAxis__custom--CompensatoryWarrantActivityMember_zc65SVAw9uPg" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of shares, warrants outstanding beginning"&gt;179,046&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iE_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zKVVPYIXz5lh" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price Per Share Warrants Outstanding Ending"&gt;15.20&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;$&lt;span id="xdx_907_ecustom--RangeOfExercisePriceOutstanding_iE_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember__srt--RangeAxis__srt--MinimumMember_zFtZ5QShHcE2"&gt;11.10&lt;/span&gt;
                                            &#x2014; $&lt;span id="xdx_90E_ecustom--RangeOfExercisePriceOutstanding_iE_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember__srt--RangeAxis__srt--MaximumMember_zqDqBD5TT456" title="Range of exercise price - ending"&gt;25.40&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&lt;span id="xdx_90A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAveragRemainingContractualTerm1_dtY_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zJmgIMArS5u7" title="Weighted Average Remaining Life (Years) - outstanding"&gt;2.64&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Exercisable&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_iI_c20211231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zYINqjRAnRv3" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Shares, Warrants Exercisable"&gt;179,046&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageVestedExercisePrice_iI_c20211231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zRAneQeqjhv7" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price Per Share Exercisable"&gt;15.20&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;$&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90A_ecustom--RangeOfExercisePriceExercisableVested_iI_c20211231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember__srt--RangeAxis__srt--MinimumMember_z4MNabjtCaf5"&gt;11.10&lt;/span&gt;
                                            &#x2014; $&lt;span id="xdx_900_ecustom--RangeOfExercisePriceExercisableVested_iI_c20211231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember__srt--RangeAxis__srt--MaximumMember_zNvjGiy4ITMk" title="Range of exercise price - ending"&gt;25.40&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_90D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAveragRemainingContractualTerm1_dtY_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zR4QFPoIUOA7" title="Weighted Average Remaining Life (Years) Exercisable"&gt;2.64&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Non-Exercisable&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNonVestedNumber_iI_c20211231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_z7ZZNsmCWqp8" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of shares, warrants non-exercisable"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1959"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageNonVestedExercise_iI_c20211231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_ziPEgq6dUs4b" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price Per Share Non-Exercisable"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1961"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_ecustom--RangeOfExercisePriceNonexercisableNonvested_iI_c20211231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zJ0O7U0xHvIh" style="border-bottom: Black 2.5pt double; text-align: right" title="Range of Exercise Price, Non-Exercisable"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1963"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</QLGN:SummaryOfWarrantActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="AsOf2021-12-31_custom_CompensatoryWarrantActivityMember"
      decimals="INF"
      unitRef="Shares">179046</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2021-12-31_custom_CompensatoryWarrantActivityMember"
      decimals="INF"
      unitRef="USDPShares">15.20</QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice>
    <QLGN:RangeOfExercisePriceOutstanding
      contextRef="AsOf2021-12-31_custom_CompensatoryWarrantActivityMember_srt_MinimumMember"
      decimals="INF"
      unitRef="USDPShares">11.10</QLGN:RangeOfExercisePriceOutstanding>
    <QLGN:RangeOfExercisePriceOutstanding
      contextRef="AsOf2021-12-31_custom_CompensatoryWarrantActivityMember_srt_MaximumMember"
      decimals="INF"
      unitRef="USDPShares">25.40</QLGN:RangeOfExercisePriceOutstanding>
    <QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAveragRemainingContractualTerm1 contextRef="From2022-01-012022-12-31_custom_CompensatoryWarrantActivityMember">P2Y7M20D</QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAveragRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="AsOf2022-12-31_custom_CompensatoryWarrantActivityMember"
      decimals="INF"
      unitRef="Shares">179046</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2022-12-31_custom_CompensatoryWarrantActivityMember"
      decimals="INF"
      unitRef="USDPShares">9.12</QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice>
    <QLGN:RangeOfExercisePriceOutstanding
      contextRef="AsOf2022-12-31_custom_CompensatoryWarrantActivityMember_srt_MinimumMember"
      decimals="INF"
      unitRef="USDPShares">1.32</QLGN:RangeOfExercisePriceOutstanding>
    <QLGN:RangeOfExercisePriceOutstanding
      contextRef="AsOf2022-12-31_custom_CompensatoryWarrantActivityMember_srt_MaximumMember"
      decimals="INF"
      unitRef="USDPShares">25.40</QLGN:RangeOfExercisePriceOutstanding>
    <QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAveragRemainingContractualTerm1 contextRef="From2022-01-012022-12-31_custom_CompensatoryWarrantActivityMember">P1Y8M23D</QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAveragRemainingContractualTerm1>
    <QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber
      contextRef="AsOf2022-12-31_custom_CompensatoryWarrantActivityMember"
      decimals="INF"
      unitRef="Shares">179046</QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber>
    <QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageVestedExercisePrice
      contextRef="AsOf2022-12-31_custom_CompensatoryWarrantActivityMember"
      decimals="INF"
      unitRef="USDPShares">9.12</QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageVestedExercisePrice>
    <QLGN:RangeOfExercisePriceExercisableVested
      contextRef="AsOf2022-12-31_custom_CompensatoryWarrantActivityMember_srt_MinimumMember"
      decimals="INF"
      unitRef="USDPShares">1.32</QLGN:RangeOfExercisePriceExercisableVested>
    <QLGN:RangeOfExercisePriceExercisableVested
      contextRef="AsOf2022-12-31_custom_CompensatoryWarrantActivityMember_srt_MaximumMember"
      decimals="INF"
      unitRef="USDPShares">25.40</QLGN:RangeOfExercisePriceExercisableVested>
    <QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAveragRemainingContractualTerm1 contextRef="From2022-01-012022-12-31_custom_CompensatoryWarrantActivityMember">P1Y8M23D</QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAveragRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="AsOf2020-12-31_custom_CompensatoryWarrantActivityMember"
      decimals="INF"
      unitRef="Shares">129403</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2020-12-31_custom_CompensatoryWarrantActivityMember72031578"
      decimals="INF"
      unitRef="USDPShares">16.60</QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted
      contextRef="From2021-01-012021-12-31_custom_CompensatoryWarrantActivityMember72031656"
      decimals="INF"
      unitRef="Shares">60000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted>
    <QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="From2021-01-012021-12-31_custom_CompensatoryWarrantActivityMember"
      decimals="INF"
      unitRef="USDPShares">13.20</QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised
      contextRef="From2021-01-012021-12-31_custom_CompensatoryWarrantActivityMember72031656"
      decimals="INF"
      unitRef="Shares">3839</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised>
    <QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedInPeriodWeightedAverageExercisePrice
      contextRef="From2021-01-012021-12-31_custom_CompensatoryWarrantActivityMember"
      decimals="INF"
      unitRef="USDPShares">20.90</QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures
      contextRef="From2021-01-012021-12-31_custom_CompensatoryWarrantActivityMember72031656"
      decimals="INF"
      unitRef="Shares">6518</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures>
    <QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedInPeriodWeightedAverageExercisePrice
      contextRef="From2021-01-012021-12-31_custom_CompensatoryWarrantActivityMember"
      decimals="INF"
      unitRef="USDPShares">20.70</QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="AsOf2021-12-31_custom_CompensatoryWarrantActivityMember72031921"
      decimals="INF"
      unitRef="Shares">179046</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2021-12-31_custom_CompensatoryWarrantActivityMember"
      decimals="INF"
      unitRef="USDPShares">15.20</QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice>
    <QLGN:RangeOfExercisePriceOutstanding
      contextRef="AsOf2021-12-31_custom_CompensatoryWarrantActivityMember_srt_MinimumMember"
      decimals="INF"
      unitRef="USDPShares">11.10</QLGN:RangeOfExercisePriceOutstanding>
    <QLGN:RangeOfExercisePriceOutstanding
      contextRef="AsOf2021-12-31_custom_CompensatoryWarrantActivityMember_srt_MaximumMember"
      decimals="INF"
      unitRef="USDPShares">25.40</QLGN:RangeOfExercisePriceOutstanding>
    <QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAveragRemainingContractualTerm1 contextRef="From2021-01-012021-12-31_custom_CompensatoryWarrantActivityMember">P2Y7M20D</QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAveragRemainingContractualTerm1>
    <QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber
      contextRef="AsOf2021-12-31_custom_CompensatoryWarrantActivityMember"
      decimals="INF"
      unitRef="Shares">179046</QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber>
    <QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageVestedExercisePrice
      contextRef="AsOf2021-12-31_custom_CompensatoryWarrantActivityMember"
      decimals="INF"
      unitRef="USDPShares">15.20</QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageVestedExercisePrice>
    <QLGN:RangeOfExercisePriceExercisableVested
      contextRef="AsOf2021-12-31_custom_CompensatoryWarrantActivityMember_srt_MinimumMember"
      decimals="INF"
      unitRef="USDPShares">11.10</QLGN:RangeOfExercisePriceExercisableVested>
    <QLGN:RangeOfExercisePriceExercisableVested
      contextRef="AsOf2021-12-31_custom_CompensatoryWarrantActivityMember_srt_MaximumMember"
      decimals="INF"
      unitRef="USDPShares">25.40</QLGN:RangeOfExercisePriceExercisableVested>
    <QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAveragRemainingContractualTerm1 contextRef="From2021-01-012021-12-31_custom_CompensatoryWarrantActivityMember">P2Y7M20D</QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAveragRemainingContractualTerm1>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2022-01-012022-12-31_custom_CompensatoryWarrantActivityMember"
      decimals="0"
      unitRef="USD">67370</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2021-01-012021-12-31_custom_CompensatoryWarrantActivityMember"
      decimals="-5"
      unitRef="USD">300000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
      contextRef="AsOf2020-05-31_custom_NoncompensatoryEquityClassifiedWarrantsMember"
      decimals="INF"
      unitRef="Shares">27048</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2020-05-31_custom_NoncompensatoryEquityClassifiedWarrantsMember"
      decimals="INF"
      unitRef="USDPShares">11.10</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <QLGN:WarrantsExercised
      contextRef="From2020-12-012020-12-31_custom_NoncompensatoryEquityClassifiedWarrantsMember"
      decimals="INF"
      unitRef="Shares">20000</QLGN:WarrantsExercised>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
      contextRef="AsOf2020-07-31_custom_NoncompensatoryEquityClassifiedWarrantsMember_custom_AlphaCapitalMember"
      decimals="INF"
      unitRef="Shares">78019</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2020-07-31_custom_NoncompensatoryEquityClassifiedWarrantsMember_custom_AlphaCapitalMember"
      decimals="INF"
      unitRef="USDPShares">0.01</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
      contextRef="AsOf2020-07-31_custom_NoncompensatoryEquityClassifiedWarrantsMember"
      decimals="INF"
      unitRef="Shares">192068</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2020-07-31_custom_NoncompensatoryEquityClassifiedWarrantsMember"
      decimals="INF"
      unitRef="USDPShares">52.50</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
      contextRef="AsOf2020-08-31_custom_NoncompensatoryEquityClassifiedWarrantsMember_custom_AlphaCapitalMember_us-gaap_WarrantMember"
      decimals="INF"
      unitRef="Shares">128783</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2020-08-31_custom_NoncompensatoryEquityClassifiedWarrantsMember_custom_AlphaCapitalMember_us-gaap_WarrantMember"
      decimals="INF"
      unitRef="USDPShares">60.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
      contextRef="AsOf2020-12-31_custom_NoncompensatoryEquityClassifiedWarrantsMember_custom_AlphaCapitalMember"
      decimals="INF"
      unitRef="Shares">100000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2020-12-31_custom_NoncompensatoryEquityClassifiedWarrantsMember_custom_AlphaCapitalMember"
      decimals="INF"
      unitRef="USDPShares">0.10</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight contextRef="AsOf2020-12-31" decimals="INF" unitRef="Shares">219101</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2020-12-31"
      decimals="INF"
      unitRef="USDPShares">40.70</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
      contextRef="AsOf2022-05-31_custom_NoncompensatoryEquityClassifiedWarrantsMember"
      decimals="INF"
      unitRef="Shares">331464</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2022-05-31_custom_NoncompensatoryEquityClassifiedWarrantsMember"
      decimals="INF"
      unitRef="USDPShares">0.01</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
      contextRef="AsOf2021-11-29_custom_NoncompensatoryEquityClassifiedWarrantsMember"
      decimals="INF"
      unitRef="Shares">27048</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2021-11-29_custom_NoncompensatoryEquityClassifiedWarrantsMember_us-gaap_WarrantMember"
      decimals="INF"
      unitRef="USDPShares">11.10</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2021-11-29_custom_NoncompensatoryEquityClassifiedWarrantsMember"
      decimals="INF"
      unitRef="Shares">539951</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2021-11-29_custom_NoncompensatoryEquityClassifiedWarrantsMember"
      decimals="INF"
      unitRef="USDPShares">20.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="From2022-01-012022-12-31_custom_NoncompensatoryEquityClassifiedWarrantsMember"
      decimals="-5"
      unitRef="USD">2300000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
      contextRef="AsOf2022-09-30_custom_NoncompensatoryEquityClassifiedWarrantsMember"
      decimals="INF"
      unitRef="Shares">331464</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2022-09-30_custom_NoncompensatoryEquityClassifiedWarrantsMember"
      decimals="INF"
      unitRef="USDPShares">0.01</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
      contextRef="AsOf2022-04-25_custom_NanoSynexMember"
      decimals="INF"
      unitRef="Shares">7048</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2021-12-31_custom_NoncompensatoryEquityClassifiedWarrantsMember"
      decimals="INF"
      unitRef="USDPShares">11.10</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <QLGN:ModifiedToExercisePrice
      contextRef="AsOf2022-04-25_custom_NanoSynexMember"
      decimals="INF"
      unitRef="USDPShares">6.00</QLGN:ModifiedToExercisePrice>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="From2022-04-232022-04-25_custom_NanoSynexMember"
      decimals="0"
      unitRef="USD">2533</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2022-05-26_custom_NanoSynexMember"
      decimals="INF"
      unitRef="USDPShares">5.136</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="From2022-05-232022-05-26_custom_NanoSynexMember"
      decimals="0"
      unitRef="USD">696</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2022-12-22_custom_NanoSynexMember"
      decimals="INF"
      unitRef="USDPShares">1.32</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="From2022-12-202022-12-22_custom_NanoSynexMember"
      decimals="0"
      unitRef="USD">891</us-gaap:FairValueAdjustmentOfWarrants>
    <QLGN:SummaryOfWarrantActivityTableTextBlock contextRef="From2022-01-012022-12-31_custom_NonCompensatoryWarrantActivityMember">&lt;p id="xdx_896_ecustom--SummaryOfWarrantActivityTableTextBlock_hus-gaap--StatementEquityComponentsAxis__custom--NonCompensatoryWarrantActivityMember_z3Ezp2e9l6U5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table summarizes the noncompensatory equity classified warrant activity for the year ended December 31, 2022:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8BD_z7kPo6hRT5N9" style="display: none"&gt;SCHEDULE
OF WARRANT ACTIVITY&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"/&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"/&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="14" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;Common
    Stock&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif"&gt;Shares&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;Weighted&#x2013;&lt;br/&gt;
    Average&lt;br/&gt; Exercise&lt;br/&gt; Price&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;Range
    of&lt;br/&gt; Exercise Price&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;Weighted&#x2013;&lt;br/&gt;
    Average&lt;br/&gt; Remaining&lt;br/&gt; Life (Years)&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 32%; padding-bottom: 2.5pt"&gt;Total outstanding &#x2013; December 31, 2021&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20220101__20221231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zwjFSRJNVUW9" style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; width: 12%; text-align: right" title="Number of shares, warrants outstanding beginning"&gt;554,914&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iS_c20220101__20221231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zVikSZesbGu9" style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; width: 12%; text-align: right" title="Weighted Average exercise price per share warrants outstanding beginning"&gt;20.10&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; width: 16%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_903_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsRangeOfExercisePrice_iS_c20220101__20221231__srt--RangeAxis__srt--MinimumMember__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zMUMmCqTfd85" title="Range of exercise price"&gt;11.10&lt;/span&gt;&#x2014;
                                            &lt;span id="xdx_909_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsRangeOfExercisePrice_iS_c20220101__20221231__srt--RangeAxis__srt--MaximumMember__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_z7eX7LOBnGI3" title="Range of exercise price"&gt;37.78&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; width: 12%; text-align: right"&gt;&lt;span id="xdx_90D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAveragRemainingContractualTerm1_dtY_c20210101__20211231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zL0eZezEfLbh" title="Weighted average remaining life (Years) exercisable"&gt;1.32&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"&gt;Granted&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20220101__20221231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zleoRD6BR5kc" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of shares, warrants granted"&gt;331,464&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice_c20220101__20221231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zzuzx14V31M9" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price per share warrants granted"&gt;0.01&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_ecustom--RangeOfExercisePriceGranted_c20220101__20221231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zVOw8zcBTcrc" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Range of exercise price - granted"&gt;0.01&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"&gt;Exercised&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_di_c20220101__20221231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zCes61SgT65l" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Shares, Warrants Exercised"&gt;(331,464&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedInPeriodWeightedAverageExercisePrice_c20220101__20221231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zTuzD7PPoiFa" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price per share warrants exercised"&gt;0.01&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_ecustom--RangeOfExercisePriceExpired_c20220101__20221231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zfa6QtYaCcGe" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Range of exercise price - Expired"&gt;0.01&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"&gt;Expired&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_iN_di_c20220101__20221231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zT83qno96T8k" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Shares, Warrants Expired"&gt;(7,911&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInPeriodWeightedAverageExercisePrice_c20220101__20221231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zCWvJvJpGnle" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price per share warrants expired"&gt;37.78&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInRangeOfExercisePrice_c20220101__20221231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zreaXubl0vi3" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price per share warrants expired"&gt;37.78&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; padding-left: 10pt"&gt;Forfeited&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_iN_di_c20220101__20221231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zUfyKeYAqJh7" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Shares, Warrants Forfeited"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2045"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedInPeriodWeightedAverageExercisePrice_c20220101__20221231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_z18TDDCOaWL5" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price per share warrants forfeited"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2047"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedInRangeOfExercisePrice_c20220101__20221231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zOYk6TDl4qP3" style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right" title="Weighted average exercise price per share warrants forfeited"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2049"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;Total outstanding &#x2013; December 31, 2022&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_c20220101__20221231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zubz5owdsLu7" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of shares, warrants outstanding ending"&gt;547,003&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iE_c20220101__20221231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zmgV7gzBuov4" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;19.76&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_907_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsRangeOfExercisePrice_iE_c20220101__20221231__srt--RangeAxis__srt--MinimumMember__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zFFcgD4S67i5" title="Range of exercise price"&gt;1.32&lt;/span&gt;
                                            - &lt;span id="xdx_90A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsRangeOfExercisePrice_iE_c20220101__20221231__srt--RangeAxis__srt--MaximumMember__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zKF9YJmyPbOh" title="Range of exercise price"&gt;20.00&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&lt;p style="margin: 0"&gt;&lt;span id="xdx_903_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAveragRemainingContractualTerm1_dtY_c20220101__20221231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_z3ZFJGZrIQ3j" title="Weighted average remaining life (Years) exercisable"&gt;0.33&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;Exercisable&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_iI_c20221231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zlrYJwXik0Lk" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Shares, Warrants Exercisable"&gt;547,003&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"/&gt;&lt;td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageVestedExercisePrice_iI_c20221231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zdNu49nlWmh8" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price Per Share Exercisable"&gt;19.76&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90C_ecustom--RangeOfExercisePriceExercisableVested_iI_c20221231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember__srt--RangeAxis__srt--MinimumMember_z75s4PgkKA08"&gt;1.32&lt;/span&gt;
                                            - &lt;span id="xdx_908_ecustom--RangeOfExercisePriceExercisableVested_iI_c20221231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember__srt--RangeAxis__srt--MaximumMember_z53sjGNxbes" title="Range of exercise price - Exercisable"&gt;20.00&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_902_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAveragRemainingContractualTerm1_dtY_c20220101__20221231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zY5i18pnUj9g" title="Weighted average remaining life (Years) exercisable"&gt;0.33&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;Non-Exercisable&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;p id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsNonExercisableNumber_iI_c20221231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_z9QB1DrWVd54" style="margin: 0" title="Number of Shares, Warrants Exercisable"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2069"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageVestedNonExercisePrice_iI_c20221231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zRUYi3jgb2T" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price Per Share Exercisable"&gt;&lt;p style="margin: 0"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2071"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;p style="margin: 0"&gt;&lt;span id="xdx_905_ecustom--RangeOfExercisePriceNonExercisableVested_iI_c20221231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zS6McpAPGdJ8" title="Range of exercise price - Exercisable"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2073"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;p style="margin: 0"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"/&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table summarizes the noncompensatory equity classified warrant activity for the year ended December 31, 2021:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"/&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt"/&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="14" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;Common
    Stock&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;Shares&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;Weighted&#x2013;&lt;br/&gt;
    Average&lt;br/&gt; Exercise&lt;br/&gt; Price&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;Range
    of&lt;br/&gt; Exercise Price&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;Weighted&#x2013;&lt;br/&gt;
    Average&lt;br/&gt; Remaining&lt;br/&gt; Life (Years)&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 32%"&gt;Total outstanding &#x2013; December 31, 2020&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20210101__20211231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zrgu3znl8ir8" style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right" title="Number of shares, warrants outstanding beginning"&gt;654,978&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iS_c20210101__20211231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zuq0DGS0fNgc" style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right" title="Weighted Average exercise price per share warrants outstanding beginning"&gt;43.60&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"&gt;Granted&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20210101__20211231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zseVSSaR3om2" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of shares, warrants granted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2079"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice_c20210101__20211231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zd7XDgXX7v0e" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price per share warrants granted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2081"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"&gt;Exercised&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_di_c20210101__20211231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_z4VTL9fYAHg7" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Shares, Warrants Exercised"&gt;(100,000&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedInPeriodWeightedAverageExercisePrice_c20210101__20211231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zk9RebS1SFOa" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price per share warrants exercised"&gt;0.01&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"&gt;Expired&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_iN_di_c20210101__20211231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zMrt5FX6PAk7" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Shares, Warrants Expired"&gt;(64&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInPeriodWeightedAverageExercisePrice_c20210101__20211231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_z4PGH6tMj7L" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price per share warrants expired"&gt;23,250.00&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; padding-left: 10pt"&gt;Forfeited&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_iN_di_c20210101__20211231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zWrrkA6OrSX4" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Shares, Warrants Forfeited"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2091"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedInPeriodWeightedAverageExercisePrice_c20210101__20211231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zHFgSqFaYdF" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price per share warrants forfeited"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2093"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;Total outstanding &#x2013; December 31, 2021&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_c20210101__20211231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zzvbBfvHzVw9" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of shares, warrants outstanding ending"&gt;554,914&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iE_c20210101__20211231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_z5YMpRUmKmxb" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price per share warrants outstanding ending"&gt;20.10&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;Exercisable&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_iI_c20211231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zRtonYIo0gr" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Shares, Warrants Exercisable"&gt;554,914&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageVestedExercisePrice_iI_c20211231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_z4XqDAu7DU09" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price Per Share Exercisable"&gt;20.10&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90A_ecustom--RangeOfExercisePriceExercisableVested_iI_c20211231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember__srt--RangeAxis__srt--MinimumMember_z2Cgb5GcUwU1"&gt;11.10&lt;/span&gt;&#x2014;
                                            &lt;span id="xdx_90E_ecustom--RangeOfExercisePriceExercisableVested_iI_c20211231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember__srt--RangeAxis__srt--MaximumMember_zT9QG9krjKff" title="Range of exercise price - Exercisable"&gt;37.78&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_909_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAveragRemainingContractualTerm1_dtY_c20210101__20211231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zhxtRGlF0sia" title="Weighted average remaining life (Years) exercisable"&gt;1.32&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;Non-Exercisable&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNonVestedNumber_iI_c20211231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zsRMNxUJolef" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of shares, warrants non-exercisable"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2108"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageNonVestedExercise_iI_c20211231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_z6BDf9VNYLpb" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price Per Share Non-Exercisable"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2110"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_ecustom--RangeOfExercisePriceNonexercisableNonvested_iI_c20211231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zh4z4Kxg5TPh" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Range of Exercise Price, Non-Exercisable"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2112"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNonExercisableWeightedAverageRemainingContractualTerm1_dtY_c20210101__20211231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zxT9GOV6SKZb" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average remaining life (Years) non-exercisable"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2114"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</QLGN:SummaryOfWarrantActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="AsOf2021-12-31_custom_NonCompensatoryWarrantActivityMember"
      decimals="INF"
      unitRef="Shares">554914</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2021-12-31_custom_NonCompensatoryWarrantActivityMember"
      decimals="INF"
      unitRef="USDPShares">20.10</QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice>
    <QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsRangeOfExercisePrice
      contextRef="AsOf2021-12-31_srt_MinimumMember_custom_NonCompensatoryWarrantActivityMember"
      decimals="INF"
      unitRef="USDPShares">11.10</QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsRangeOfExercisePrice>
    <QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsRangeOfExercisePrice
      contextRef="AsOf2021-12-31_srt_MaximumMember_custom_NonCompensatoryWarrantActivityMember"
      decimals="INF"
      unitRef="USDPShares">37.78</QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsRangeOfExercisePrice>
    <QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAveragRemainingContractualTerm1 contextRef="From2021-01-012021-12-31_custom_NonCompensatoryWarrantActivityMember">P1Y3M25D</QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAveragRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted
      contextRef="From2022-01-012022-12-31_custom_NonCompensatoryWarrantActivityMember72032375"
      decimals="INF"
      unitRef="Shares">331464</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted>
    <QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="From2022-01-012022-12-31_custom_NonCompensatoryWarrantActivityMember72032375"
      decimals="INF"
      unitRef="USDPShares">0.01</QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice>
    <QLGN:RangeOfExercisePriceGranted
      contextRef="From2022-01-012022-12-31_custom_NonCompensatoryWarrantActivityMember72032375"
      decimals="INF"
      unitRef="USDPShares">0.01</QLGN:RangeOfExercisePriceGranted>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised
      contextRef="From2022-01-012022-12-31_custom_NonCompensatoryWarrantActivityMember72032375"
      decimals="INF"
      unitRef="Shares">331464</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised>
    <QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedInPeriodWeightedAverageExercisePrice
      contextRef="From2022-01-012022-12-31_custom_NonCompensatoryWarrantActivityMember72032375"
      decimals="INF"
      unitRef="USDPShares">0.01</QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedInPeriodWeightedAverageExercisePrice>
    <QLGN:RangeOfExercisePriceExpired
      contextRef="From2022-01-012022-12-31_custom_NonCompensatoryWarrantActivityMember72032375"
      decimals="INF"
      unitRef="USDPShares">0.01</QLGN:RangeOfExercisePriceExpired>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations
      contextRef="From2022-01-012022-12-31_custom_NonCompensatoryWarrantActivityMember72032375"
      decimals="INF"
      unitRef="Shares">7911</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations>
    <QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInPeriodWeightedAverageExercisePrice
      contextRef="From2022-01-012022-12-31_custom_NonCompensatoryWarrantActivityMember72032375"
      decimals="INF"
      unitRef="USDPShares">37.78</QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInPeriodWeightedAverageExercisePrice>
    <QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInRangeOfExercisePrice
      contextRef="From2022-01-012022-12-31_custom_NonCompensatoryWarrantActivityMember72032375"
      decimals="INF"
      unitRef="USDPShares">37.78</QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInRangeOfExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="AsOf2022-12-31_custom_NonCompensatoryWarrantActivityMember"
      decimals="INF"
      unitRef="Shares">547003</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2022-12-31_custom_NonCompensatoryWarrantActivityMember"
      decimals="INF"
      unitRef="USDPShares">19.76</QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice>
    <QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsRangeOfExercisePrice
      contextRef="AsOf2022-12-31_srt_MinimumMember_custom_NonCompensatoryWarrantActivityMember"
      decimals="INF"
      unitRef="USDPShares">1.32</QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsRangeOfExercisePrice>
    <QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsRangeOfExercisePrice
      contextRef="AsOf2022-12-31_srt_MaximumMember_custom_NonCompensatoryWarrantActivityMember"
      decimals="INF"
      unitRef="USDPShares">20.00</QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsRangeOfExercisePrice>
    <QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAveragRemainingContractualTerm1 contextRef="From2022-01-012022-12-31_custom_NonCompensatoryWarrantActivityMember72032375">P0Y3M29D</QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAveragRemainingContractualTerm1>
    <QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber
      contextRef="AsOf2022-12-31_custom_NonCompensatoryWarrantActivityMember"
      decimals="INF"
      unitRef="Shares">547003</QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber>
    <QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageVestedExercisePrice
      contextRef="AsOf2022-12-31_custom_NonCompensatoryWarrantActivityMember"
      decimals="INF"
      unitRef="USDPShares">19.76</QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageVestedExercisePrice>
    <QLGN:RangeOfExercisePriceExercisableVested
      contextRef="AsOf2022-12-31_srt_MinimumMember_custom_NonCompensatoryWarrantActivityMember"
      decimals="INF"
      unitRef="USDPShares">1.32</QLGN:RangeOfExercisePriceExercisableVested>
    <QLGN:RangeOfExercisePriceExercisableVested
      contextRef="AsOf2022-12-31_srt_MaximumMember_custom_NonCompensatoryWarrantActivityMember"
      decimals="INF"
      unitRef="USDPShares">20.00</QLGN:RangeOfExercisePriceExercisableVested>
    <QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAveragRemainingContractualTerm1 contextRef="From2022-01-012022-12-31_custom_NonCompensatoryWarrantActivityMember72032375">P0Y3M29D</QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAveragRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="AsOf2020-12-31_custom_NonCompensatoryWarrantActivityMember"
      decimals="INF"
      unitRef="Shares">654978</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2020-12-31_custom_NonCompensatoryWarrantActivityMember"
      decimals="INF"
      unitRef="USDPShares">43.60</QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised
      contextRef="From2021-01-012021-12-31_custom_NonCompensatoryWarrantActivityMember"
      decimals="INF"
      unitRef="Shares">100000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised>
    <QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedInPeriodWeightedAverageExercisePrice
      contextRef="From2021-01-012021-12-31_custom_NonCompensatoryWarrantActivityMember"
      decimals="INF"
      unitRef="USDPShares">0.01</QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations
      contextRef="From2021-01-012021-12-31_custom_NonCompensatoryWarrantActivityMember"
      decimals="INF"
      unitRef="Shares">64</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations>
    <QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInPeriodWeightedAverageExercisePrice
      contextRef="From2021-01-012021-12-31_custom_NonCompensatoryWarrantActivityMember"
      decimals="INF"
      unitRef="USDPShares">23250.00</QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="AsOf2021-12-31_custom_NonCompensatoryWarrantActivityMember"
      decimals="INF"
      unitRef="Shares">554914</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2021-12-31_custom_NonCompensatoryWarrantActivityMember"
      decimals="INF"
      unitRef="USDPShares">20.10</QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice>
    <QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber
      contextRef="AsOf2021-12-31_custom_NonCompensatoryWarrantActivityMember"
      decimals="INF"
      unitRef="Shares">554914</QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber>
    <QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageVestedExercisePrice
      contextRef="AsOf2021-12-31_custom_NonCompensatoryWarrantActivityMember"
      decimals="INF"
      unitRef="USDPShares">20.10</QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageVestedExercisePrice>
    <QLGN:RangeOfExercisePriceExercisableVested
      contextRef="AsOf2021-12-31_srt_MinimumMember_custom_NonCompensatoryWarrantActivityMember"
      decimals="INF"
      unitRef="USDPShares">11.10</QLGN:RangeOfExercisePriceExercisableVested>
    <QLGN:RangeOfExercisePriceExercisableVested
      contextRef="AsOf2021-12-31_srt_MaximumMember_custom_NonCompensatoryWarrantActivityMember"
      decimals="INF"
      unitRef="USDPShares">37.78</QLGN:RangeOfExercisePriceExercisableVested>
    <QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAveragRemainingContractualTerm1 contextRef="From2021-01-012021-12-31_custom_NonCompensatoryWarrantActivityMember">P1Y3M25D</QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAveragRemainingContractualTerm1>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_806_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_zw8BAxRq9xI3" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;NOTE 16 &#x2014; &lt;span id="xdx_829_ztv8nxMGTeY9"&gt;RELATED PARTY TRANSACTIONS&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;Convertible Debt &lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;On December 22, 2022, the Company issued to Alpha
Capital, an &lt;span id="xdx_902_eus-gaap--ShortTermDebtInterestRateIncrease_pid_dp_uPure_c20221222__20221222__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember__us-gaap--DebtInstrumentAxis__custom--SeniorConvertibleDebentureMember_zCYtEOlEyKWg" title="Senior convertible debenture rate"&gt;8&lt;/span&gt;% Senior Convertible Debenture in the aggregate principal amount of $&lt;span id="xdx_902_eus-gaap--SecuredDebt_iI_c20221222__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember__us-gaap--DebtInstrumentAxis__custom--SeniorConvertibleDebentureMember_zKrKJCk27pOc" title="Principal amount"&gt;3,300,000&lt;/span&gt; for a purchase price of $&lt;span id="xdx_902_ecustom--PurchasePrice_iI_c20221222__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember__us-gaap--DebtInstrumentAxis__custom--SeniorConvertibleDebentureMember_zs7z0yaWDZV9" title="Purchase Price"&gt;3,000,000&lt;/span&gt; pursuant
to the terms of a Securities Purchase Agreement, dated December 21, 2022 (the &#x201c;Alpha Purchase Agreement&#x201d;). The Debenture is
convertible, at any time, and from time to time, at Alpha&#x2019;s option, into shares of common stock of the Company (the &#x201c;Conversion
Shares&#x201d;), at a price equal to $&lt;span id="xdx_904_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pid_c20221222__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember__us-gaap--DebtInstrumentAxis__custom--SeniorConvertibleDebentureMember_zeDshKsge7zf" title="Conversion price"&gt;1.32 &lt;/span&gt;per share, subject to adjustment as described in the Debenture (the &#x201c;Conversion Price&#x201d;)
and other terms and conditions described in the Debenture, including the Company&#x2019;s receipt of the requisite stockholder approvals
(See Note 11 -Convertible Debt - Related Party).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;Short-Term Debt&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;NanoSynex has four separate notes payable (the &#x201c;Notes&#x201d;) outstanding to Alpha Capital, dated between March
26, 2020 and September 2, 2021, aggregating to a total principal outstanding balance of $&lt;span id="xdx_90B_eus-gaap--DebtInstrumentFaceAmount_iI_c20210902__us-gaap--ShortTermDebtTypeAxis__custom--NotesPayableMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NanoSynexMember_zq1GyqxWFFfd" title="Short term debt principal outstanding"&gt;905,000&lt;/span&gt;, and aggregate accrued interest of $&lt;span id="xdx_90C_eus-gaap--InterestPayableCurrent_iI_pp0p0_c20221231__us-gaap--ShortTermDebtTypeAxis__custom--NotesPayableMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NanoSynexMember_zL0FRomOK44d" title="Accrued interest"&gt;45,722&lt;/span&gt;
for a total outstanding balance of $&lt;span id="xdx_90B_eus-gaap--ShortTermBorrowings_iI_pp0p0_c20221231__us-gaap--ShortTermDebtTypeAxis__custom--NotesPayableMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NanoSynexMember_zffaPZB0t9r6" title="Short term debt outstanding balance"&gt;950,722&lt;/span&gt; as of December&#160;31, 2022. The Notes all accrue interest at&lt;span id="xdx_90A_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20210902__us-gaap--ShortTermDebtTypeAxis__custom--NotesPayableMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NanoSynexMember_z2M0M949Qbed" title="Accrued interest rate"&gt; 2.62&lt;/span&gt;% per annum, accrued daily,
and provide that the full amount of principal and interest under each Note shall be due immediately prior to a Liquidation Event (the
Maturity Date) unless due earlier in accordance with the terms of the Notes. &#x201c;Liquidation Event&#x201d; means either i) the merger
or consolidation of NanoSynex into any other entity, other than one in control or under control of NanoSynex or NanoSynex&#x2019;s majority shareholder;
ii) a transaction or series of transactions resulting in the transfer of all or substantially all of NanoSynex&#x2019;s assets or issued and
outstanding share capital (other than to a company under the control of NanoSynex or NanoSynex&#x2019;s majority shareholders; or iii) an underwritten
public offering by NanoSynex of its ordinary shares. Notwithstanding the above, if NanoSynex receives subsequent debt, convertible debt,
or equity funding with gross proceeds of USD $&lt;span id="xdx_901_eus-gaap--ProceedsFromRelatedPartyDebt_pp0p0_c20210326__20210902__us-gaap--ShortTermDebtTypeAxis__custom--NotesPayableMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NanoSynexMember_zNJI6se0a2Tg" title="Proceeds from related party debt"&gt;3,000,000&lt;/span&gt; or more, then these Notes shall be due and payable upon the actual receipt of
such funding (See Note 9 -Short-term Debt - Related Party).&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;Nanosynex Acquisition&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company acquired a &lt;span id="xdx_903_eus-gaap--BusinessAcquisitionPercentageOfVotingInterestsAcquired_iI_pid_dp_uPure_c20220526__us-gaap--BusinessAcquisitionAxis__custom--NanoSynexLtdMember_z3qyVFVo5SJg" title="Business acquisition, voting equity rate"&gt;52.8&lt;/span&gt;% voting equity interest
in NanoSynex on May 26, 2022 (the &#x201c;NanoSynex Acquisition Date&#x201d;) through: (1) the purchase of &lt;span id="xdx_901_eus-gaap--StockIssuedDuringPeriodSharesAcquisitions_c20220524__20220526__us-gaap--StatementClassOfStockAxis__custom--SeriesAOnePreferredStockMember_z5BJO4JXkBvh" title="Number of shares of stock issued"&gt;2,232,861&lt;/span&gt; shares Preferred A-1
Stock of NanoSynex from Alpha Capital (a related party) for &lt;span id="xdx_900_eus-gaap--StockIssuedDuringPeriodSharesAcquisitions_c20220524__20220526__us-gaap--BusinessAcquisitionAxis__custom--NanoSynexLtdMember_zcfpx0LwPU74" title="Stock issued during period shares acquisitions"&gt;350,000&lt;/span&gt; reverse split adjusted shares of the Company&#x2019;s common stock and a
prefunded warrant to purchase &lt;span id="xdx_901_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20220526__us-gaap--StatementEquityComponentsAxis__custom--PrefundedWarrantMember_zmIDxCjjYZr8" title="Warrants to purchase shares"&gt;331,464 reverse split adjusted shares of the Company&#x2019;s common stock at a purchase price of $&lt;span id="xdx_909_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20220526__us-gaap--BusinessAcquisitionAxis__custom--NanoSynexLtdMember__us-gaap--StatementEquityComponentsAxis__custom--PrefundedWarrantMember_zV0i1KkZvyZe" title="Warrants or rights"&gt;0.001&lt;/span&gt; per share
(&lt;span id="xdx_90B_eus-gaap--StockholdersEquityReverseStockSplit_c20220524__20220526__us-gaap--BusinessAcquisitionAxis__custom--NanoSynexLtdMember_zHFGo44DRS7k" title="Reverse split, description"&gt;these warrants were subsequently exercised on September 13, 2022)&lt;/span&gt;, and (2) the purchase of &lt;span id="xdx_902_eus-gaap--StockIssuedDuringPeriodSharesAcquisitions_c20220524__20220526__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember__us-gaap--BusinessAcquisitionAxis__custom--NanoSynexLtdMember_zL544l13VBX8" title="Stock issued during period shares acquisitions"&gt;381,786&lt;/span&gt; shares of Series B preferred stock
of NanoSynex from NanoSynex in exchange for $&lt;span id="xdx_901_eus-gaap--StockIssuedDuringPeriodValueAcquisitions_c20220524__20220526__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember__us-gaap--BusinessAcquisitionAxis__custom--NanoSynexLtdMember_zPey05GwWsja" title="Stock issued during period value acquisitions"&gt;600,000&lt;/span&gt;&lt;/span&gt; (See Note 3 - Acquisition).&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/&gt;&lt;/p&gt;

</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:ShortTermDebtInterestRateIncrease
      contextRef="From2022-12-222022-12-22_custom_AlphaCapitalMember_custom_SeniorConvertibleDebentureMember"
      decimals="INF"
      unitRef="Pure">0.08</us-gaap:ShortTermDebtInterestRateIncrease>
    <us-gaap:SecuredDebt
      contextRef="AsOf2022-12-22_custom_AlphaCapitalMember_custom_SeniorConvertibleDebentureMember"
      decimals="0"
      unitRef="USD">3300000</us-gaap:SecuredDebt>
    <QLGN:PurchasePrice
      contextRef="AsOf2022-12-22_custom_AlphaCapitalMember_custom_SeniorConvertibleDebentureMember"
      decimals="0"
      unitRef="USD">3000000</QLGN:PurchasePrice>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="AsOf2022-12-22_custom_AlphaCapitalMember_custom_SeniorConvertibleDebentureMember"
      decimals="INF"
      unitRef="USDPShares">1.32</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="AsOf2021-09-02_custom_NotesPayableMember_custom_NanoSynexMember"
      decimals="0"
      unitRef="USD">905000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:InterestPayableCurrent
      contextRef="AsOf2022-12-31_custom_NotesPayableMember_custom_NanoSynexMember"
      decimals="0"
      unitRef="USD">45722</us-gaap:InterestPayableCurrent>
    <us-gaap:ShortTermBorrowings
      contextRef="AsOf2022-12-31_custom_NotesPayableMember_custom_NanoSynexMember"
      decimals="0"
      unitRef="USD">950722</us-gaap:ShortTermBorrowings>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="AsOf2021-09-02_custom_NotesPayableMember_custom_NanoSynexMember"
      decimals="INF"
      unitRef="Pure">0.0262</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:ProceedsFromRelatedPartyDebt
      contextRef="From2021-03-262021-09-02_custom_NotesPayableMember_custom_NanoSynexMember"
      decimals="0"
      unitRef="USD">3000000</us-gaap:ProceedsFromRelatedPartyDebt>
    <us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired
      contextRef="AsOf2022-05-26_custom_NanoSynexLtdMember"
      decimals="INF"
      unitRef="Pure">0.528</us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired>
    <us-gaap:StockIssuedDuringPeriodSharesAcquisitions
      contextRef="From2022-05-242022-05-26_custom_SeriesAOnePreferredStockMember"
      decimals="INF"
      unitRef="Shares">2232861</us-gaap:StockIssuedDuringPeriodSharesAcquisitions>
    <us-gaap:StockIssuedDuringPeriodSharesAcquisitions
      contextRef="From2022-05-242022-05-26_custom_NanoSynexLtdMember"
      decimals="INF"
      unitRef="Shares">350000</us-gaap:StockIssuedDuringPeriodSharesAcquisitions>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2022-05-26_custom_PrefundedWarrantMember"
      decimals="INF"
      unitRef="Shares">331464</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2022-05-26_custom_NanoSynexLtdMember_custom_PrefundedWarrantMember"
      decimals="INF"
      unitRef="USDPShares">0.001</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:StockholdersEquityReverseStockSplit contextRef="From2022-05-242022-05-26_custom_NanoSynexLtdMember">these warrants were subsequently exercised on September 13, 2022)</us-gaap:StockholdersEquityReverseStockSplit>
    <us-gaap:StockIssuedDuringPeriodSharesAcquisitions
      contextRef="From2022-05-242022-05-26_custom_NanoSynexLtdMember_us-gaap_SeriesBPreferredStockMember"
      decimals="INF"
      unitRef="Shares">381786</us-gaap:StockIssuedDuringPeriodSharesAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions
      contextRef="From2022-05-242022-05-26_custom_NanoSynexLtdMember_us-gaap_SeriesBPreferredStockMember"
      decimals="0"
      unitRef="USD">600000</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_806_eus-gaap--IncomeTaxDisclosureTextBlock_zXkjUdIAk7a8" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
17 &#x2014; &lt;span id="xdx_824_zCH2Y3cvJuEi"&gt;INCOME TAXES&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89D_eus-gaap--ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_zC5WzqnHGoG" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table presents domestic and foreign components of consolidated loss before income taxes for the periods presented:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;span id="xdx_8BE_zZJmOpqAkPFh" style="display: none"&gt;SCHEDULE
OF DOMESTIC AND FOREIGN COMPONENTS&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_498_20220101__20221231_zCIo0y8ZD4Cc" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_494_20210101__20211231_zA5yjKw0koBj" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31, 2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_z37fmY4jBFv4" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%"&gt;Domestic&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;(15,954,750&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;(17,891,710&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_zifcygSnRYn6" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Foreign&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(5,344,967&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2160"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_zbeeiP0iNXBh" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Loss before provision for income taxes&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(21,299,717&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(17,891,710&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A2_z2FlujSNayk7" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89D_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zno2KvHtuSh3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;A
reconciliation of the statutory income tax rates and the Company&#x2019;s effective tax rate is as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8BB_zJ7HCURHx36a" style="display: none"&gt;SCHEDULE
OF RECONCILIATIONS OF STATUTORY INCOME TAX RATE&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_498_20220101__20221231_zXdooMsJEywk" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_492_20210101__20211231_zLf6HVlYXzf2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31, 2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_uPure_zIeBXIwCOqH" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;Statutory federal income tax rate&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;21.00&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;21.00&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_pid_dp_uPure_zJIAGKaGcMX" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;State taxes, net of federal tax benefit&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5.46&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;6.63&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepletion_pid_dp_uPure_zR0JUoqHu6o1" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Non-deductible expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-1.36&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-1.19&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_ecustom--EffectiveIncomeTaxRateReconciliationNonOperatingLossExpiration_pid_dp_uPure_z2f8h7JF900b" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;NOL expiration&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-12.96&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-2.71&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--EffectiveIncomeTaxRateReconciliationTaxCredits_pid_dp_uPure_zfEWJloNJUJd" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Tax credit&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2.42&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.86&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses_pid_dp_uPure_zRgn6HftpuW6" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Goodwill impairment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-4.50&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.00&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--EffectiveIncomeTaxRateReconciliationTaxSettlementsForeign_pid_dp_uPure_zTFGuDKMxGJ" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Foreign rate differential&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.50&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.00&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_ecustom--EffectiveIncomeTaxRateReconciliationFairValueOfWarrant_pid_dp_uPure_zQoQFFPXWgm2" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Change in FV of warrant liability&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.89&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5.54&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--EffectiveIncomeTaxRateReconciliationTaxCreditsOther_pid_dp_uPure_zDHCM6gQLox8" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;True-up&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1.47&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-2.72&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_pid_dp_uPure_zL6RGqQhU227" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Change in valuation allowance&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;-11.68&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;%&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;-27.44&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_pid_dp_uPure_zhMdntHmS9rd" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Income taxes provision (benefit)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1.24&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;%&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;-0.03&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A9_z98hbu2gEOFh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_891_eus-gaap--ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_zz2iHIEA3rO1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Income
tax expense for the year ended December 31, 2022 and 2021 consisted of the following:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8B5_zrvQuSeeDsud" style="display: none"&gt;SCHEDULE
OF PROVISION FOR INCOME TAXES&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49E_20220101__20221231_zfGOltlCv5L8" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_495_20210101__20211231_zRwty91B7ob" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31, 2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;For the Years Ended&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31, 2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Current&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--CurrentFederalTaxExpenseBenefit_maCITEBz1MC_zWa9bmB5ez1a" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;US Federal&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2202"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2203"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--CurrentStateAndLocalTaxExpenseBenefit_maCITEBz1MC_zs53W0Vutu4a" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;US State&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;7,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;5,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--CurrentForeignTaxExpenseBenefit_maCITEBz1MC_zmIFaJ38JYcc" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Foreign&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2208"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2209"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--CurrentIncomeTaxExpenseBenefit_iT_mtCITEBz1MC_zmsyTOrYMKqf" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-left: 10pt"&gt;Total current provision&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Deferred&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--DeferredFederalIncomeTaxExpenseBenefit_maDITEBzCKf_zEjGPYIO4jae" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;US Federal&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(236,000&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(1,268,000&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--DeferredStateAndLocalIncomeTaxExpenseBenefit_maDITEBzCKf_z9jvGGv8uVSc" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;US State&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(2,252,000&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(3,641,000&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--DeferredForeignIncomeTaxExpenseBenefit_maDITEBzCKf_zaz4C0dB2JDh" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Foreign&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(272,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2221"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--DeferredIncomeTaxExpenseBenefit_iT_mtDITEBzCKf_maITEBzWbu_zpUmzlIz4zlg" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-left: 10pt"&gt;Total deferred benefit&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(2,760,000&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(4,909,000&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--ValuationAllowanceDeferredTaxAssetChangeInAmount_iN_di_msITEBzWbu_zqClhg5UPcqe" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt"&gt;Change in valuation allowance&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;2,488,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;4,909,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--IncomeTaxExpenseBenefit_iT_pn3d_mtITEBzWbu_zQCM7qvLFCth" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt; padding-left: 10pt"&gt;Total provision (benefit) for income taxes&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(265,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;5,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A6_zTO9prVN39h5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_896_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zeTmu6uRlQPe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
components of deferred tax assets and liabilities are as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8BF_z3dFPzGVRSH2" style="display: none"&gt;SCHEDULE
OF DEFERRED TAX ASSETS AND LIABILITIES&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_496_20221231_zZGWMXRDemS6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_491_20211231_zBm7PHs84ebh" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31, 2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Deferred tax assets:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_maDTATDzYdX_znrofrP5Xlre" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 60%; text-align: left; padding-left: 10pt"&gt;Net operating loss&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;33,540,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;33,362,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--DeferredTaxAssetsInProcessResearchAndDevelopment_iI_maDTATDzYdX_z2tuGmtJmegd" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-left: 10pt"&gt;Research and development credits&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7,857,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;6,185,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_ecustom--DefferdTaxAssetsAccruedExpenses_iI_maDTATDzYdX_z6JoyJ0i7os9" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-left: 10pt"&gt;Accrued expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,020,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;757,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--DeferredTaxAssetsGoodwillAndIntangibleAssets_iI_maDTATDzYdX_zDuKcQEhBRof" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt"&gt;Patent&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2243"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;262,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_iI_maDTATDzYdX_zzxLy03Czow" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-left: 10pt"&gt;Stock compensation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,069,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,747,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_ecustom--DeferredTaxAssetsResearchAndDevelopmentExpenses_iI_maDTATDzYdX_zxSJdg5AvK3a" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-left: 10pt"&gt;Research and development expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,196,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2250"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--DeferredTaxAssetsPropertyPlantAndEquipment_iI_maDTATDzYdX_zJIaj0YTTjCb" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt"&gt;Fixed assets&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;280,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;282,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--DeferredTaxAssetsTaxDeferredExpense_iTI_mtDTATDzYdX_maDTAGzJfc_z7vYln7SyRlk" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt; padding-left: 20pt"&gt;Total deferred income tax assets&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;46,962,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;43,595,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Deferred tax liabilities:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_iNI_di_maDITLzOxa_zNVXxDQARH21" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-left: 10pt"&gt;Intangible assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(1,324,000&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(34,000&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--DeferredTaxLiabilitiesLeasingArrangements_iNI_di_maDITLzOxa_zYhrq6gYXyog" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt"&gt;Right-of-use asset&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(382,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(436,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--DeferredIncomeTaxLiabilities_iNTI_di_mtDITLzOxa_msDTAGzJfc_zyOXhtPGufhj" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt; padding-left: 10pt"&gt;Total deferred income tax liabilities&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(1,706,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(470,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--DeferredTaxAssetsGross_iTI_mtDTAGzJfc_maDTALNzbeu_zuHVng7UZHZj" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Net deferred income tax assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;45,256,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;43,125,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_di_msDTALNzbeu_zpSSzdtVNXlf" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Valuation allowance&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(45,614,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(43,125,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--DeferredTaxAssetsLiabilitiesNet_iNTI_di_mtDTALNzbeu_zPeqin1vXMda" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Deferred tax asset, net of allowance&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(358,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2274"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AB_zDZsKxpqeVi9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Based
on the available objective evidence, including the Company&#x2019;s history of cumulative losses, management believes it is likely that
the Company&#x2019;s U.S. federal and state net deferred tax assets will not be realizable. Accordingly, the Company provided for a full
valuation allowance against its U.S. federal and state net deferred tax assets at December 31, 2022 and December 31, 2021.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"/&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Due
to the full valuation allowance already in place on the Company&#x2019;s U.S. federal and state net deferred tax assets, the Company does
not anticipate significant changes in the Company&#x2019;s effective tax rate. However, there is no valuation allowance recorded against
the Company&#x2019;s foreign net operating loss deferred tax assets, as the Company&#x2019;s foreign IPR&amp;amp;D deferred tax liabilities
and foreign net operating loss deferred tax assets are both indefinite-lived and thus they may be netted to arrive at a net foreign deferred
tax liability. This results in $&lt;span id="xdx_906_eus-gaap--DeferredForeignIncomeTaxExpenseBenefit_iN_di_c20220101__20221231_z4J4CGvC0Ix3" title="Foreign deferred tax benefit"&gt;272,000&lt;/span&gt; of foreign deferred tax benefit recorded to the income statement in 2022.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Tax Cuts and Jobs Act resulted in significant changes to the treatment of research or experimental (&#x201c;R&amp;amp;E&#x201d;) expenditures
under Section 174. For tax years beginning after December 31, 2021, taxpayers are required to capitalize and amortize all R&amp;amp;E expenditures
that are paid or incurred in connection with their trade or business which represent costs in the experimental or laboratory sense. Specifically,
costs for U.S. based R&amp;amp;E activities must be amortized over five years and costs for foreign R&amp;amp;E activities must be amortized
over 15 years; both using a midyear convention. The Company has incorporated the impact of this new tax legislation into its 2022 consolidated
financial statements, noting that the impact on the Company&#x2019;s consolidated financial statements was immaterial.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;At
December 31, 2022, the Company has U.S. federal and state net operating loss carryforwards of approximately $&lt;span id="xdx_90B_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_iI_c20221231_zNp7gpV8pwxc" title="Operating loss carryforwards"&gt;119,254,000&lt;/span&gt; and $&lt;span id="xdx_90B_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_iI_c20211231_zkiPkHs24gWd" title="Operating loss carryforwards"&gt;110,227,000&lt;/span&gt;,
respectively, which are available to offset future taxable income. U.S. federal and state net operating loss carryovers began to expire
in 2020. As a result of the May 2020 reverse recapitalization, an ownership change has occurred. The Company has not completed an Internal
Revenue Code Section 382 analysis. As a result, there could be substantial limitations on the Company&#x2019;s ability to utilize its
pre-ownership change net operating loss and tax credit carryforwards. These substantial limitations may result in both a permanent loss
of certain tax benefits related to net operating loss carryforwards and federal research and development credits, and an annual utilization
limitation. At December 31, 2022, the Company has foreign net operating loss carryforwards of approximately $&lt;span id="xdx_90E_eus-gaap--OperatingLossCarryforwards_iI_c20221231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--ForeignCountryMember_zchcYg8podU9" title="Net operating loss carryforwards"&gt;953,000&lt;/span&gt;, which are available
to offset future taxable income. Foreign net operating loss carryovers are indefinite lived and do not expire.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company also has research and development credit carryforwards for federal and state tax purposes of approximately $&lt;span id="xdx_90F_eus-gaap--DeferredTaxAssetsTaxCreditCarryforwardsResearch_iI_c20221231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--DomesticCountryMember_zIkejkX2Nh1b" title="Research and development credit carryforwards"&gt;5,484,000&lt;/span&gt; and $&lt;span id="xdx_90D_eus-gaap--DeferredTaxAssetsTaxCreditCarryforwardsResearch_iI_c20221231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--StateAndLocalJurisdictionMember_z2NHT4EcUhvf" title="Research and development credit carryforwards"&gt;2,373,000&lt;/span&gt;,
respectively. &lt;span id="xdx_907_eus-gaap--TaxCreditCarryforwardLimitationsOnUse_c20220101__20221231_zfQmsPXr41Me" title="Tax credit carryforward, limitations on use"&gt;The research and development credit carryforwards began to expire in 2020 for federal tax purposes and have an indefinite
life for state tax purposes&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;U.S.
income tax has not been recognized on the excess of the amount for financial reporting over the tax basis of investments in foreign subsidiaries
that is indefinitely reinvested outside the United States. This amount becomes taxable upon a repatriation of assets from the subsidiary
or a sale or liquidation of the subsidiary. Determination of the amount of any unrecognized deferred income tax liability on this temporary
difference is not practicable because of the complexities of the hypothetical calculation.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company files income tax returns in the U.S. federal jurisdiction and in various states. The Company&#x2019;s U.S. federal income tax
returns remain subject to examination by the Internal Revenue Service. The Company&#x2019;s California income tax returns remain subject
to examination by the California Franchise Tax Board. Due to net operating losses, research and development credits and other tax credit
carryforwards that may be utilized in future years, all U.S. federal and state tax years are open to examination.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Generally
accepted accounting principles clarify the accounting for uncertainty in income taxes recognized in the Company&#x2019;s financial statements
and prescribe thresholds for financial statement recognition and measurement of a tax position taken or expected to be taken in a tax
return, and also provide guidance on de-recognition and measurement of a tax position taken or expected to be taken in a tax return.
The Company adopted these provisions effective April 1, 2009.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company did &lt;span id="xdx_900_eus-gaap--UnrecognizedTaxBenefits_iI_do_c20221231_zM8VQdjlj4b" title="Unrecognized tax benefits"&gt;&lt;span id="xdx_90A_eus-gaap--UnrecognizedTaxBenefits_iI_do_c20211231_zIDyRoiZlTKd" title="Unrecognized tax benefits"&gt;no&lt;/span&gt;&lt;/span&gt;t have any unrecognized tax benefits as of December 31, 2022 and December 31, 2021 and does not expect this to change significantly
over the next 12 months. In accordance with generally accepted accounting principles, the Company will recognize interest and penalties
accrued on any unrecognized tax benefits as a component of income tax expense. As of December 31, 2022, the Company has not accrued any
interest or penalties related to uncertain tax positions.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_89D_eus-gaap--ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_zC5WzqnHGoG" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table presents domestic and foreign components of consolidated loss before income taxes for the periods presented:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;span id="xdx_8BE_zZJmOpqAkPFh" style="display: none"&gt;SCHEDULE
OF DOMESTIC AND FOREIGN COMPONENTS&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_498_20220101__20221231_zCIo0y8ZD4Cc" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_494_20210101__20211231_zA5yjKw0koBj" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31, 2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_z37fmY4jBFv4" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%"&gt;Domestic&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;(15,954,750&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;(17,891,710&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_zifcygSnRYn6" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Foreign&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(5,344,967&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2160"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_zbeeiP0iNXBh" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Loss before provision for income taxes&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(21,299,717&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(17,891,710&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">-15954750</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">-17891710</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">-5344967</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">-21299717</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">-17891710</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_89D_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zno2KvHtuSh3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;A
reconciliation of the statutory income tax rates and the Company&#x2019;s effective tax rate is as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8BB_zJ7HCURHx36a" style="display: none"&gt;SCHEDULE
OF RECONCILIATIONS OF STATUTORY INCOME TAX RATE&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_498_20220101__20221231_zXdooMsJEywk" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_492_20210101__20211231_zLf6HVlYXzf2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31, 2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_uPure_zIeBXIwCOqH" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;Statutory federal income tax rate&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;21.00&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;21.00&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_pid_dp_uPure_zJIAGKaGcMX" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;State taxes, net of federal tax benefit&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5.46&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;6.63&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepletion_pid_dp_uPure_zR0JUoqHu6o1" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Non-deductible expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-1.36&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-1.19&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_ecustom--EffectiveIncomeTaxRateReconciliationNonOperatingLossExpiration_pid_dp_uPure_z2f8h7JF900b" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;NOL expiration&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-12.96&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-2.71&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--EffectiveIncomeTaxRateReconciliationTaxCredits_pid_dp_uPure_zfEWJloNJUJd" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Tax credit&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2.42&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.86&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses_pid_dp_uPure_zRgn6HftpuW6" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Goodwill impairment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-4.50&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.00&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--EffectiveIncomeTaxRateReconciliationTaxSettlementsForeign_pid_dp_uPure_zTFGuDKMxGJ" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Foreign rate differential&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.50&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.00&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_ecustom--EffectiveIncomeTaxRateReconciliationFairValueOfWarrant_pid_dp_uPure_zQoQFFPXWgm2" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Change in FV of warrant liability&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.89&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5.54&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--EffectiveIncomeTaxRateReconciliationTaxCreditsOther_pid_dp_uPure_zDHCM6gQLox8" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;True-up&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1.47&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-2.72&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_pid_dp_uPure_zL6RGqQhU227" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Change in valuation allowance&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;-11.68&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;%&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;-27.44&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_pid_dp_uPure_zhMdntHmS9rd" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Income taxes provision (benefit)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1.24&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;%&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;-0.03&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="From2022-01-01to2022-12-31"
      decimals="INF"
      unitRef="Pure">0.2100</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="From2021-01-012021-12-31"
      decimals="INF"
      unitRef="Pure">0.2100</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="From2022-01-01to2022-12-31"
      decimals="INF"
      unitRef="Pure">0.0546</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="From2021-01-012021-12-31"
      decimals="INF"
      unitRef="Pure">0.0663</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepletion
      contextRef="From2022-01-01to2022-12-31"
      decimals="INF"
      unitRef="Pure">-0.0136</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepletion>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepletion
      contextRef="From2021-01-012021-12-31"
      decimals="INF"
      unitRef="Pure">-0.0119</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepletion>
    <QLGN:EffectiveIncomeTaxRateReconciliationNonOperatingLossExpiration
      contextRef="From2022-01-01to2022-12-31"
      decimals="INF"
      unitRef="Pure">-0.1296</QLGN:EffectiveIncomeTaxRateReconciliationNonOperatingLossExpiration>
    <QLGN:EffectiveIncomeTaxRateReconciliationNonOperatingLossExpiration
      contextRef="From2021-01-012021-12-31"
      decimals="INF"
      unitRef="Pure">-0.0271</QLGN:EffectiveIncomeTaxRateReconciliationNonOperatingLossExpiration>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits
      contextRef="From2022-01-01to2022-12-31"
      decimals="INF"
      unitRef="Pure">0.0242</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits
      contextRef="From2021-01-012021-12-31"
      decimals="INF"
      unitRef="Pure">0.0086</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses
      contextRef="From2022-01-01to2022-12-31"
      decimals="INF"
      unitRef="Pure">-0.0450</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses
      contextRef="From2021-01-012021-12-31"
      decimals="INF"
      unitRef="Pure">0.0000</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxSettlementsForeign
      contextRef="From2022-01-01to2022-12-31"
      decimals="INF"
      unitRef="Pure">0.0050</us-gaap:EffectiveIncomeTaxRateReconciliationTaxSettlementsForeign>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxSettlementsForeign
      contextRef="From2021-01-012021-12-31"
      decimals="INF"
      unitRef="Pure">0.0000</us-gaap:EffectiveIncomeTaxRateReconciliationTaxSettlementsForeign>
    <QLGN:EffectiveIncomeTaxRateReconciliationFairValueOfWarrant
      contextRef="From2022-01-01to2022-12-31"
      decimals="INF"
      unitRef="Pure">0.0089</QLGN:EffectiveIncomeTaxRateReconciliationFairValueOfWarrant>
    <QLGN:EffectiveIncomeTaxRateReconciliationFairValueOfWarrant
      contextRef="From2021-01-012021-12-31"
      decimals="INF"
      unitRef="Pure">0.0554</QLGN:EffectiveIncomeTaxRateReconciliationFairValueOfWarrant>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsOther
      contextRef="From2022-01-01to2022-12-31"
      decimals="INF"
      unitRef="Pure">0.0147</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsOther>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsOther
      contextRef="From2021-01-012021-12-31"
      decimals="INF"
      unitRef="Pure">-0.0272</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsOther>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="From2022-01-01to2022-12-31"
      decimals="INF"
      unitRef="Pure">-0.1168</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="From2021-01-012021-12-31"
      decimals="INF"
      unitRef="Pure">-0.2744</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="From2022-01-01to2022-12-31"
      decimals="INF"
      unitRef="Pure">0.0124</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="From2021-01-012021-12-31"
      decimals="INF"
      unitRef="Pure">-0.0003</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_891_eus-gaap--ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_zz2iHIEA3rO1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Income
tax expense for the year ended December 31, 2022 and 2021 consisted of the following:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8B5_zrvQuSeeDsud" style="display: none"&gt;SCHEDULE
OF PROVISION FOR INCOME TAXES&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49E_20220101__20221231_zfGOltlCv5L8" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_495_20210101__20211231_zRwty91B7ob" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31, 2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;For the Years Ended&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31, 2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Current&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--CurrentFederalTaxExpenseBenefit_maCITEBz1MC_zWa9bmB5ez1a" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;US Federal&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2202"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2203"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--CurrentStateAndLocalTaxExpenseBenefit_maCITEBz1MC_zs53W0Vutu4a" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;US State&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;7,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;5,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--CurrentForeignTaxExpenseBenefit_maCITEBz1MC_zmIFaJ38JYcc" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Foreign&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2208"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2209"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--CurrentIncomeTaxExpenseBenefit_iT_mtCITEBz1MC_zmsyTOrYMKqf" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-left: 10pt"&gt;Total current provision&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Deferred&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--DeferredFederalIncomeTaxExpenseBenefit_maDITEBzCKf_zEjGPYIO4jae" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;US Federal&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(236,000&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(1,268,000&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--DeferredStateAndLocalIncomeTaxExpenseBenefit_maDITEBzCKf_z9jvGGv8uVSc" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;US State&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(2,252,000&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(3,641,000&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--DeferredForeignIncomeTaxExpenseBenefit_maDITEBzCKf_zaz4C0dB2JDh" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Foreign&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(272,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2221"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--DeferredIncomeTaxExpenseBenefit_iT_mtDITEBzCKf_maITEBzWbu_zpUmzlIz4zlg" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-left: 10pt"&gt;Total deferred benefit&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(2,760,000&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(4,909,000&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--ValuationAllowanceDeferredTaxAssetChangeInAmount_iN_di_msITEBzWbu_zqClhg5UPcqe" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt"&gt;Change in valuation allowance&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;2,488,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;4,909,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--IncomeTaxExpenseBenefit_iT_pn3d_mtITEBzWbu_zQCM7qvLFCth" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt; padding-left: 10pt"&gt;Total provision (benefit) for income taxes&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(265,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;5,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">7000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">5000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">7000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">5000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">-236000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">-1268000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">-2252000</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">-3641000</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredForeignIncomeTaxExpenseBenefit
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">-272000</us-gaap:DeferredForeignIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">-2760000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">-4909000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">-2488000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">-4909000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2022-01-01to2022-12-31"
      decimals="-3"
      unitRef="USD">-265000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2021-01-012021-12-31"
      decimals="-3"
      unitRef="USD">5000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_896_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zeTmu6uRlQPe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
components of deferred tax assets and liabilities are as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8BF_z3dFPzGVRSH2" style="display: none"&gt;SCHEDULE
OF DEFERRED TAX ASSETS AND LIABILITIES&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_496_20221231_zZGWMXRDemS6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_491_20211231_zBm7PHs84ebh" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31, 2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Deferred tax assets:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_maDTATDzYdX_znrofrP5Xlre" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 60%; text-align: left; padding-left: 10pt"&gt;Net operating loss&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;33,540,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;33,362,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--DeferredTaxAssetsInProcessResearchAndDevelopment_iI_maDTATDzYdX_z2tuGmtJmegd" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-left: 10pt"&gt;Research and development credits&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7,857,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;6,185,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_ecustom--DefferdTaxAssetsAccruedExpenses_iI_maDTATDzYdX_z6JoyJ0i7os9" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-left: 10pt"&gt;Accrued expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,020,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;757,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--DeferredTaxAssetsGoodwillAndIntangibleAssets_iI_maDTATDzYdX_zDuKcQEhBRof" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt"&gt;Patent&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2243"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;262,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_iI_maDTATDzYdX_zzxLy03Czow" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-left: 10pt"&gt;Stock compensation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,069,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,747,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_ecustom--DeferredTaxAssetsResearchAndDevelopmentExpenses_iI_maDTATDzYdX_zxSJdg5AvK3a" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-left: 10pt"&gt;Research and development expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,196,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2250"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--DeferredTaxAssetsPropertyPlantAndEquipment_iI_maDTATDzYdX_zJIaj0YTTjCb" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt"&gt;Fixed assets&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;280,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;282,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--DeferredTaxAssetsTaxDeferredExpense_iTI_mtDTATDzYdX_maDTAGzJfc_z7vYln7SyRlk" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt; padding-left: 20pt"&gt;Total deferred income tax assets&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;46,962,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;43,595,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Deferred tax liabilities:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_iNI_di_maDITLzOxa_zNVXxDQARH21" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-left: 10pt"&gt;Intangible assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(1,324,000&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(34,000&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--DeferredTaxLiabilitiesLeasingArrangements_iNI_di_maDITLzOxa_zYhrq6gYXyog" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt"&gt;Right-of-use asset&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(382,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(436,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--DeferredIncomeTaxLiabilities_iNTI_di_mtDITLzOxa_msDTAGzJfc_zyOXhtPGufhj" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt; padding-left: 10pt"&gt;Total deferred income tax liabilities&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(1,706,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(470,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--DeferredTaxAssetsGross_iTI_mtDTAGzJfc_maDTALNzbeu_zuHVng7UZHZj" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Net deferred income tax assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;45,256,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;43,125,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_di_msDTALNzbeu_zpSSzdtVNXlf" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Valuation allowance&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(45,614,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(43,125,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--DeferredTaxAssetsLiabilitiesNet_iNTI_di_mtDTALNzbeu_zPeqin1vXMda" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Deferred tax asset, net of allowance&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(358,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2274"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">33540000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">33362000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">7857000</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">6185000</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <QLGN:DefferdTaxAssetsAccruedExpenses contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">1020000</QLGN:DefferdTaxAssetsAccruedExpenses>
    <QLGN:DefferdTaxAssetsAccruedExpenses contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">757000</QLGN:DefferdTaxAssetsAccruedExpenses>
    <us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">262000</us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">3069000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">2747000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <QLGN:DeferredTaxAssetsResearchAndDevelopmentExpenses contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">1196000</QLGN:DeferredTaxAssetsResearchAndDevelopmentExpenses>
    <us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">280000</us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">282000</us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpense contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">46962000</us-gaap:DeferredTaxAssetsTaxDeferredExpense>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpense contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">43595000</us-gaap:DeferredTaxAssetsTaxDeferredExpense>
    <us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">1324000</us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets>
    <us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">34000</us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets>
    <us-gaap:DeferredTaxLiabilitiesLeasingArrangements contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">382000</us-gaap:DeferredTaxLiabilitiesLeasingArrangements>
    <us-gaap:DeferredTaxLiabilitiesLeasingArrangements contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">436000</us-gaap:DeferredTaxLiabilitiesLeasingArrangements>
    <us-gaap:DeferredIncomeTaxLiabilities contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">1706000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredIncomeTaxLiabilities contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">470000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredTaxAssetsGross contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">45256000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">43125000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">45614000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">43125000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">358000</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:DeferredForeignIncomeTaxExpenseBenefit
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">-272000</us-gaap:DeferredForeignIncomeTaxExpenseBenefit>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">119254000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">110227000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal>
    <us-gaap:OperatingLossCarryforwards
      contextRef="AsOf2022-12-31_us-gaap_ForeignCountryMember"
      decimals="0"
      unitRef="USD">953000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="AsOf2022-12-31_us-gaap_DomesticCountryMember"
      decimals="0"
      unitRef="USD">5484000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="AsOf2022-12-31_us-gaap_StateAndLocalJurisdictionMember"
      decimals="0"
      unitRef="USD">2373000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:TaxCreditCarryforwardLimitationsOnUse contextRef="From2022-01-01to2022-12-31">The research and development credit carryforwards began to expire in 2020 for federal tax purposes and have an indefinite
life for state tax purposes</us-gaap:TaxCreditCarryforwardLimitationsOnUse>
    <us-gaap:UnrecognizedTaxBenefits contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">0</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">0</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:SubsequentEventsTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_80B_eus-gaap--SubsequentEventsTextBlock_zmFV7KP8YqY9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
18 &#x2014; &lt;span id="xdx_82D_z1nZVeCrSx02"&gt;SUBSEQUENT EVENTS&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Between
January 9 and 12, 2023 Alpha Capital voluntarily converted $&lt;span id="xdx_906_eus-gaap--DebtInstrumentFaceAmount_iI_c20230112__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zZExaEB2DUH3" title="Debenture voluntarily converted"&gt;1,111,078&lt;/span&gt;
of its outstanding Senior Convertible Debenture principal into &lt;span id="xdx_90B_eus-gaap--CommonStockDividendsShares_c20230109__20230112__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zmGQ3orIfXSi" title="Shares of common stock"&gt;841,726&lt;/span&gt;
shares of common stock at a conversion price of $&lt;span id="xdx_90D_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pid_c20230112__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zTTmQBPGRwbe" title="Conversion price"&gt;1.32&lt;/span&gt;
per share.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
January 13, 2023, the Company&#x2019;s board of directors, as part of certain cost-cutting measures, approved a temporary &lt;span id="xdx_902_ecustom--BaseSalaryPercentage_dp_uPure_c20230113__20230113__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zOqPQRfD2kKa" title="Base salary percentage"&gt;20&lt;/span&gt;% reduction
to the base salaries of all executive officers of the Company and a &lt;span id="xdx_906_ecustom--AnnualCashCompensation_dp_uPure_c20230113__20230113__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zfYg1rIIZu1j" title="Annual cash compensation"&gt;20&lt;/span&gt;% reduction to the non-employee directors&#x2019; annual cash compensation.
The Company also terminated the employment of certain employees, including its Senior Vice President/Chief Operating Officer and Vice President/Chief Scientific
Officer.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company filed a Notification of Late Filing on Form 12b-25 on March 31, 2023, indicating that the filing of this Annual Report would
be delayed on account of the Company and its registered public accounting firm requiring additional time to complete the
accounting and disclosures related to the Company&#x2019;s acquisition of a majority interest in NanoSynex, Ltd., which accounting and disclosures have been included in this
Annual Report. On April 20, 2023, the Company received a notification
letter from the Listing Qualifications Department of Nasdaq indicating that, as a result of the Company&#x2019;s delay in filing this
Annual Report, the Company was not in compliance with the timely filing requirements for continued listing under Nasdaq Listing Rule
5250(c)(1). The notification letter has no immediate effect on the listing or trading of the Company&#x2019;s common stock on the
Nasdaq Capital Market. The notification letter stated that, under Nasdaq rules, the Company has 60 calendar days, or until June 20,
2023, to submit a plan to regain compliance with Nasdaq&#x2019;s continued listing requirements. The Company may also regain
compliance with Nasdaq&#x2019;s continued listing requirements at any time before June 20, 2023, by filing this Annual Report with
the SEC, as well as any subsequent periodic financial reports that may become due, and continuing to comply with Nasdaq&#x2019;s
other continued listing requirements. The filing of this Annual Report was the Company&#x2019;s action to regain
compliance.&lt;/span&gt;&lt;/p&gt;

</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="AsOf2023-01-12_us-gaap_SubsequentEventMember"
      decimals="0"
      unitRef="USD">1111078</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:CommonStockDividendsShares
      contextRef="From2023-01-092023-01-12_us-gaap_SubsequentEventMember"
      decimals="INF"
      unitRef="Shares">841726</us-gaap:CommonStockDividendsShares>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="AsOf2023-01-12_us-gaap_SubsequentEventMember"
      decimals="INF"
      unitRef="USDPShares">1.32</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <QLGN:BaseSalaryPercentage
      contextRef="From2023-01-132023-01-13_us-gaap_SubsequentEventMember"
      decimals="INF"
      unitRef="Pure">0.20</QLGN:BaseSalaryPercentage>
    <QLGN:AnnualCashCompensation
      contextRef="From2023-01-132023-01-13_us-gaap_SubsequentEventMember"
      decimals="INF"
      unitRef="Pure">0.20</QLGN:AnnualCashCompensation>
    <link:footnoteLink
      xlink:role="http://www.xbrl.org/2003/role/link"
      xlink:type="extended">
        <link:loc
          xlink:href="#Fact000879"
          xlink:label="Fact000879"
          xlink:type="locator"/>
        <link:footnote id="Footnote000884" xlink:label="Footnote000884" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">See disclosure
under <xhtml:i>Noncompensatory Equity Classified Warrants</xhtml:i> regarding May 26, 2022 transaction-Note 15-Stockholders&#x2019; Equity</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000879"
          xlink:to="Footnote000884"
          xlink:type="arc"/>
    </link:footnoteLink>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>113
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0    ( #N#HE8'04UB@0   +$    0    9&]C4')O<',O87!P+GAM
M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG
M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGD<Z,STA)8*O4'J@)I9GF
M3?X.CD:?<@X>K7A.YNJQ<&4GPZ4A!0W_<FW>J=0U[R;UEA_6\#MI7E!+ P04
M    "  [@Z)6K:7D9.X    K @  $0   &1O8U!R;W!S+V-O<F4N>&ULS9+!
M2L0P$(9?17)O)TU8#Z';B^))07!!\1:2V=U@DX9DI-VWMXV[740?P&-F_GSS
M#4QKHC)#PN<T1$SD,-],O@]9F;AE1Z*H +(YHM>YGA-A;NZ'Y#7-SW2 J,V'
M/B (SF_!(VFK2<,"K.)*9%UKC3()-0WIC+=FQ<?/U!>8-8 ]>@R4H:D;8-TR
M,9ZFOH4K8($1)I^_"VA78JG^B2T=8.?DE-V:&L>Q'F7)S3LT\/;T^%+6K5S(
MI(/!^5=VBDX1M^PR^57>W>\>6">XD!7?5%SL!%=BHZ1\7UQ_^%V%_6#=WOUC
MXXM@U\*ON^B^ %!+ P04    "  [@Z)6F5R<(Q &  "<)P  $P   'AL+W1H
M96UE+W1H96UE,2YX;6SM6EMSVC@4?N^OT'AG]FT+QC:!MK03<VEVV[29A.U.
M'X416(UL>621A'^_1S80RY8-[9)-NIL\!"SI^\Y%1^?H.'GS[BYBZ(:(E/)X
M8-DOV]:[MR_>X%<R)!%!,!FGK_# "J5,7K5::0##.'W)$Q+#W(*+"$MX%,O6
M7.!;&B\CUNJTV]U6A&ELH1A'9&!]7BQH0-!445IO7R"TY1\S^!7+5(UEHP$3
M5T$FN8BT\OELQ?S:WCYES^DZ'3*!;C ;6"!_SF^GY$Y:B.%4PL3 :F<_5FO'
MT=)(@(+)?90%NDGVH],5"#(-.SJ=6,YV?/;$[9^,RMIT-&T:X./Q>#BVR]*+
M<!P$X%&[GL*=]&R_I$$)M*-IT&38]MJND::JC5-/T_=]W^N;:)P*C5M/TVMW
MW=..B<:MT'@-OO%/A\.NB<:KT'3K:28G_:YKI.D6:$)&X^MZ$A6UY4#3( !8
M<';6S-(#EEXI^G64&MD=N]U!7/!8[CF)$?[&Q036:=(9EC1&<IV0!0X -\31
M3%!\KT&VBN#"DM)<D-;/*;50&@B:R('U1X(AQ=RO_?67N\FD,WJ=?3K.:Y1_
M::L!I^V[F\^3_'/HY)^GD]=-0LYPO"P)\?LC6V&')VX[$W(Z'&="?,_V]I&E
M)3+/[_D*ZTX\9Q]6EK!=S\_DGHQR([O=]EA]]D]';B/7J<"S(M>41B1%G\@M
MNN01.+5)#3(3/PB=AIAJ4!P"I DQEJ&&^+3&K!'@$WVWO@C(WXV(]ZMOFCU7
MH5A)VH3X$$8:XIQSYG/1;/L'I4;1]E6\W*.76!4!EQC?-*HU+,76>)7 \:V<
M/!T3$LV4"P9!AI<D)A*I.7Y-2!/^*Z7:_IS30/"4+R3Z2I&/:;,CIW0FS>@S
M&L%&KQMUAVC2/'K^!?F<-0H<D1L= F<;LT8AA&F[\!ZO)(Z:K<(1*T(^8ADV
M&G*U%H&V<:F$8%H2QM%X3M*T$?Q9K#63/F#([,V1=<[6D0X1DEXW0CYBSHN0
M$;\>ACA*FNVB<5@$_9Y>PTG!Z(++9OVX?H;5,VPLCO='U!=*Y \FIS_I,C0'
MHYI9";V$5FJ?JH<T/J@>,@H%\;D>/N5Z> HWEL:\4*Z">P'_T=HWPJOX@L Y
M?RY]SZ7ON?0]H=*W-R-]9\'3BUO>1FY;Q/NN,=K7-"XH8U=RS<C'5*^3*=@Y
MG\#L_6@^GO'M^MDDA*^:62TC%I!+@;-!)+C\B\KP*L0)Z&1;)0G+5--E-XH2
MGD(;;NE3]4J5U^6ON2BX/%ODZ:^A=#XLS_D\7^>TS0LS0[=R2^JVE+ZU)CA*
M]+',<$X>RPP[9SR2';9WH!TU^_9==N0CI3!3ET.X&D*^ VVZG=PZ.)Z8D;D*
MTU*0;\/YZ<5X&N(YV02Y?9A7;>?8T='[Y\%1L*/O/)8=QXCRHB'NH8:8S\-#
MAWE[7YAGE<90-!1M;*PD+$:W8+C7\2P4X&1@+: '@Z]1 O)256 Q6\8#*Y"B
M?$R,1>APYY=<7^/1DN/;IF6U;J\I=QEM(E(YPFF8$V>KRMYEL<%5'<]56_*P
MOFH]M!5.S_Y9K<B?#!%.%@L22&.4%Z9*HO,94[[G*TG$53B_13.V$I<8O./F
MQW%.4[@2=K8/ C*YNSFI>F4Q9Z;RWRT,"2Q;B%D2XDU=[=7GFYRN>B)V^I=W
MP6#R_7#)1P_E.^=?]%U#KG[VW>/Z;I,[2$R<><41 71% B.5' 86%S+D4.Z2
MD 83 <V4R43P H)DIAR F/H+O?(,N2D5SJT^.7]%+(.&3E[2)1(4BK ,!2$7
M<N/O[Y-J=XS7^BR!;814,F35%\I#B<$],W)#V%0E\Z[:)@N%V^)4S;L:OB9@
M2\-Z;ITM)__;7M0]M!<]1O.CF> >LX=SFWJXPD6L_UC6'ODRWSEPVSK> U[F
M$RQ#I'[!?8J*@!&K8KZZKT_Y)9P[M'OQ@2";_-;;I/;=X Q\U*M:I60K$3]+
M!WP?D@9CC%OT-%^/%&*MIK&MQMHQ#'F 6/,,H68XWX=%FAHSU8NL.8T*;T'5
M0.4_V]0-:/8--!R1!5XQF;8VH^1."CS<_N\-L,+$CN'MB[\!4$L#!!0    (
M #N#HE;RIW=<JP<  / Q   8    >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL
MM9M?;]LV%,7?^RD(KQ@Z((XE2G:2+C'@R$GG-4O3.-W0#7N@)=H6*HD>1>7/
MM]^5+%M10%U; -V'UK)UC\5?2>H<D3Y_$O)'NN1<D><X2M*+SE*IU<=>+_67
M/&;IL5CQ!#Z9"QDS!8=RT4M7DK.@*(JC'K6L02]F8=(9GA?OW<GAN<A4%";\
M3I(TBV,F7RYY))XN.G9G\\9]N%BJ_(W>\'S%%GS*U;?5G82CWE8E"&.>I*%(
MB.3SB\[(_CAVK;R@..//D#^EKUZ3O"DS(7[D!Y/@HF/E5\0C[JM<@L$_C]SC
M490KP77\5XIVMM^9%[Y^O5&_+AH/C9FQE'LB^BL,U/*B<]HA 9^S+%+WXNDW
M7C:HG^OY(DJ+O\G3^ESWK$/\+%4B+HOA"N(P6?_+GDL0KPOZ#06T+*!O"FRW
MH< I"YQ]"]RRP"W(K)M2<!@SQ8;G4CP1F9\-:OF+ F91#<T/D_S_?:HD?!I"
MG1IZXI%+TB7?IF/RX?TOYST%HOE'/;\4N%P+T 8!FY(_1**6*;E* A[4!7IP
M-=M+HIM+NJ2HXIC[Q\2QCPBU*-5<D(>7CU;RF-CK<D=3/L;+?\\2^'9+]^VU
MUCA;P$ZAYZ" _QG-4B6AD_^K([Q6</4*^<C_F*Z8SR\Z,+13+A]Y9_CS3_;
M^E5'QZ38V)!8C9R[)>=BZL.Q\#.8811Y>%EQ'3:\W+:ZGW5\T*JV? R)U?CT
MMWSZ: -' "<H %U';*$#A-?/693JN'IH65M"AL1JA 9;0H/]>M H23(6D7N^
M$E+I2.$Z2F9:4&A56U"&Q&J@3K:@3O8<:I+!+;VX(S?#PK4:NQ5:UI:6(;$:
MK=,MK=/]:-UQ&8H@O_$1N/EJYZ@=2IM;7>.]#JUO"\V06 W:V1;:V7[0KL/4
MA[%8LKN&MU,=.%SM^KL.%EK3%I8AL1HLVZILF=4*UW?.9#.L'6)-G0LO:PO,
ME%J=V"LC:Z.-]#(IWP+#1N8.N6[7IEW'UF)#*UMC,Z16QT8K;!1MYU6B0O4"
MU").;K-XQJ46%BYB67;7.7'IJ1876ML:ER&U.J[*S=NHY=W@NN>+,#?TT-]N
M6:SO7[C05S DX8(G[QZ67+(5SU3HIT=DDOC'6HA&;;TIM3K$RMC;N#4O(7HP
M7"4,U0D$QV?RF;]H,>)2%G0]=V"=6/H)SJC9-Z56IU;9?1OWZR6U!_9,)@&@
M"^>ASPJKAHQ;7)(.NHY[XO;IB9:>T2!@2JU.KXH"-N[A2WHPOH0$8UN .R)3
M!7<'(B3Q1 :=$?JD"/2C>4?2N-("-!H03*G5 581P<9]?0EP% 2@#C-5^8+<
MP'GD2Z*GADM2RZ7O/$@9G(QY1&[%@D5:CD:C@RFU.L<J/-BXYW_+T<N/H <^
MB*=$RQ"7\YB,TAD+M-R,I@=3:G5N57ZP<<O_EMMVZ-Y)\1@FOKX#XIK>2(O-
M:(XPI59_EEH%"8I[_[?8[D2JX)[[=[AJG.MV*)Y1R];Z8KRN+3=3:G5N59R@
M.^)$04URUHP)%_AP,K!TS],]O*XUID/$!UK%!XH[_QM1A/FE2+#XL$/DS#[M
MGMF#OI:6T?1@2JU.JTH/%#?]#Z&"F"7FQ*8?9K^0*?<S"?U,BPQ7\D0<B^0=
M@3]3)?P?1V0%>?>111DG[ZUC<,5DQ25)ETQJ'\;A\JVQ'B)/T"I/4#P$/$@6
MA,F"3%_BF= YB,L= E]O/MUJ*1G-#Z;4ZI2J_$!QL[_I;>3JV5^R9,$;H^L.
MH=O1=#SZJN5E-#&84JOSJA(#W2LQ_,6CJ/LC 7<&XY6E,-$%9)*F6<-,AVO>
M"BTVHSG!E%H=6Y43Z%XYX4\10:)B<OUH26H?6^Y0:H!E- R84JO#JL( W2L,
M;)Y=KM=<BJD,W*W^6>\.Q>]<5^7A5:VI'2(*T"H*T+VBP"117*XWCN1/>=D&
MHY8:KMA$S6@2,*56WX=0)0%GKR10#$?B07A:"*FU'CMT;D729;[/009$@K6@
M=B>"T3Q@2JU.K\H##F[G2WK3F$41N<Q2^#C5CL\=.DUKR7A9:UB'2 5.E0J<
MO185KF(N%_EL]@D4U!*25+QBB;[/X8*-B\IX76MLAX@'SJNM0GLM+DR78#E0
M6+A,,RRS>X,.8?J=RO0[>RTBW&6S*/3)=228=N+'55IOKC(:"$JU?J&6[]!\
M'%+[S'5L]_2\]ZBC4YE]9Z_%@G5,W$3$:9X&4_(E4ZEB21Z9M,1,FGBO5!N\
M:F/?ZE-WX&R;6,(XA-MW*K?O[+=7*'VU1  WMUF^UC?G8"M\3OYYX,^*7$8
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M]*[:PMQVC*Q=;5M)@Y72-4N\RT#9 )Q?2VGV'5LN^]LQ^P-02P,$%     @
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M"P/X_UX(]711/&![5CS\%U!+ P04    "  [@Z)6IABR3^<*  #I8@  &
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MX:JXR<&6]1. 8@/5@Q&R@> PMUOFV)4ZWF&I8C?4SF[:1 FQ]BF> [[9J[.
MW _V/9@LJ4Y.<(A<AKKX#((!<+S [>FI4,5CZ#MX3-M!K1E-*DO/HLSC2-I+
M7C,J;VA3@.[8]8-N/#&)>I0$N*\G1!51H7:B\AD"1E16M/FEP0&%FV@P5=OJ
M*% Z*\'8V]D6#: S-S.H(C?4WLP8]X"!^#\3RSA-I=?)\@?":#8W0M0;%\AG
M8 R_6X\;)#$)?8_Y/8F-[AQ$L+,3"PPA^V56  :*XE(78>V@@BZH(=W77_$4
M:C^J4.E?]5#GVRI?R9#V*G@NJQPCN:1G/7YPKMGVX2M>0NV\Y"XMA;2<$>B/
MDX<&H^$\ B8]E1M5%(/:*<97_M(3C?5TSYC?[?N9I%"O5HH1T,#J4)/[25VW
MJ&)E<O/^/@X]@1E8O.M,L^VOA>(0], !ACV>NW-.0'80:N);-(=)X/Y-&[*6
MX(M2-MJ3K&CBX!O-R$7$-W')$\LQ&;M:QWBN3EHP[7$1IJ@&LU.-1_W@C)/-
M2@YB58G>)D"Y3%E/T[N'B=AO?01T9CA-04D8D)Z4P1138<<<IVC*P9W#%#)]
M)++Y\JXZUWZS8P#KW,;W*.3('KR*V;##+9@2@!3@X-7)M[A]XEA5@\>T">VW
M.@:MSH\0<7M:-DRQ&O:CQS%^M-AG.I<)J<;K#%(8,\)(3V.#*<+#[(3'C'!G
M5TJF*L_VUE2V]EPC$)W4!*S[T-L@A$+7]5%?$-HYHFEOT+S'4M(5VU9HU1\M
MXKZ8R_3>"2%,.X=FU^IXPLT4U6'VLQG7XS^^W4TA\]Y/S*=*SWKVXERS[8-5
MW(C9N=&^==].H#0=;B-Z0XN$!:&'?<TE?[PKLP]*42MF;[;L@]K=<@!PNQ;S
M7ZI#Q?#;LCDD942JMTRP/!RKG1.R:W,"4,6;V('>RQ[0ZV2SXLZX9CVC/[9
M?98B5<W37&R@\!*R@A$RIA[:J#JG\<+N0WZ[@L=C]Q0Y\NSD:!][BU;RPZU\
MFZ$-50UCZ/*E"4^SZ6LJ7FHB:3Q%;: V@4N1VZV;[:J>L J*(WG'<*1V%2+#
M8=M3%L#PV"IT:1ATTZA=RQ,60)$F[YW/K0X]EG-^GF20;(GQ/9GF)FR/Y1B>
MS]F5.0+G:.>UH+7(E]7;4E+?;5K6K]NT5]LWLJZK]Y ZUS^AC^/ZO2HU3?V:
MUQ>>+V-(SHE8P)3N!Q_0Y?6;4_67,MM4+Q_-LK+,UM7'E>!SD4L!^'V1P8(U
M7^0-VO?7KOX'4$L#!!0    ( #N#HE89$Y$Q(RL  .E^   8    >&PO=V]R
M:W-H965T<R]S:&5E=#<N>&ULM7UK;]M(UN9W_HI"9C!( %GQ)7&23G<#CN.D
M_2(73YSTO+.+_4"1)8D=BE2S2#N>7[_G6A>*<C+O[ *-CBR1Q5.GSN4YERK^
M?-MV7]W:VMY\V]2-^^7!NN^W/SU^[(JUW>1NWFYM [\LVVZ3]_!GMWKLMIW-
M2[II4S\^/CP\?;S)J^;!KS_3=U?=KS^W0U]7C;WJC!LVF[R[>V7K]O:7!T</
M](M/U6K=XQ>/?_UYFZ_LM>V_;*\Z^.NQ'Z6L-K9Q5=N8SBY_>7!V]-.K)W@]
M7?![96]=]-G@3!9M^Q7_N"Q_>7"(!-G:%CV.D,,_-_;<UC4.!&3\*6,^\(_$
M&^//.OH;FCO,99$[>][6_ZC*?OW+@^</3&F7^5#WG]K;WZS,YRF.5[2UH_^;
M6[GV\($I!M>W&[D9*-A4#?^;?Q,^_,@-QW+#,='-#R(J7^=]_NO/77MK.KP:
M1L,/-%6Z&XBK&ER4Z[Z#7RNXK__UXZ>W9Q\N_]?9Y\N/'\S9A]?F^LO[]V>?
M_FD^OC'7EV\_7+ZY/#_[\-F<G9]__/+A\^6'M^;JX[O+\\N+:[K\XOKSY?NS
MSQ?7/S_N@1P<]'$ACW[%CS[>\^BC8_.^;?JU,Q=-:<MT@,<P#S^98YW,J^-[
M1WQMB[DY.9J9X\/CXWO&._',.:'Q3O8QIUOE3?6O'.5G9L[;QK5U5>8L3DUI
MKCKK;-/S%^W2O*F:O"FJO#;7\*4%V>V=^=]G"]=W('W_9XI%3,"3:0)0(W]R
MV[RPOSS8XK.Z&_O@U[_]Y>CT\.4]TWOBI_?DOM'__Z[]O8^>GMB'CY\OLB/S
MM[\\/SXZ?FG^GY%GXG4T?Q_RNEK99I9=-L5\9AI@6@Y&:>&JL@*[A NIUYC/
M:]OE6SOT5>%FAF^XS9VIFJ+MMFT'JUS"'^9]U336M7V.?QR]>'%J^A:,@ZM6
M(#BEO0'CMYV!WC;#$B1AZ"S)#QBG.KM:W[D*A*8Q'Y?+JK#F7;[ @5L@Y2'R
MXOCP)<R+/AV]? 2#=%_!6/\YY$U?H>S=6%-M-D/3YL[E=P8FL6I:!Q2;;=>6
M0P$R",;;#,XB<5O_N)8>YY"2K.UAHF;;5DU_T"X/BAPH=+;OJV;ET*[6)9@E
M.R.J<?Z='7/@M:WS6[R-&?!B#MPR[X$>T,7#6> Z,=$4[69;6[PUA[%N; ?$
M=;;(MS"C6E8J ZUI7,[6^[;JU^93U?= YM4Z!WM<T*KDM:R+YQ5?Y-F%%,M]
M3'B3;^"Q]ZRP.:MKX^ 9P)MVF:64DW ^>^F,T&K 0A=?S:V%F=MOQ3IO5C Z
M\ON>)^P9!#@'RV VMEO9;BY4/]9QLG@<9. &V$(W@DBNJV)-\P-MNJG:P=5W
M!M@'9M6T/.J'W)7YG^9<GOB>I6@ R]O1[S#J5_CH[C8+<$+*R\^?/\V$E?1(
MVQ2VQ(4I03+N'7J&O^8@4JX_D!4^(&H/W+:N>I.7?X!W _K IU; EX@2&3TE
MY>_OWGY02EJ2K.SXE"S]X?S>U7R(8\H@YR!V>7/GA0.P#0HPZC,,:LUB<&"H
MG /97Z'UGINY^=AD),;\L.,9T2@# :CX<Z@ZF,7Q[/CD>/;\],B</#V<'1X>
MFA-P1$].GWCQ'DW;"U@\7A",:'E-#K<U(%VV*RH8:-NAE8 ;_VH.YX>'1SAI
M^!J4#_0%E)UD$>V9_7. .8 DZ*TD#-=V"ZYI <P^.N$IF9/G1[-GST_-Z2&3
M_O1X_MR\PG7)X#&)EX-G97E1,+FX2H7WBBCWW@&ZX #3*9IU#@9K86&Q0%:W
M><?F X9!A%GU=ZSJ^(RA0?N#\X4QP5PX TL,"U;7R/@"YU%FHC1?F@H)(+]+
MCSP#-0+SX,W"E_GUW+P].[O2Q9^93W8UU#RMZX/_)DO1#35;1%@V_='/X-H6
M0U?UE5QQ(>J.,]M4#F%JID^[OCC7Y\R!@3H!9&<*(_X'_(3!ZJ&T1)*P:8?)
M2%\%7V_R/]H.F=K>-BATZN5@#FSGP."#;/!=V2*OX7$RO<CZNFC1;%T!#%6K
M7\23@1'AT8"J00!A&+%G()I-BXL"'C'?@A(4^:*V9C7 77054&E!</%WNC>#
M#WZUYL@A/ZT;!.4T,=9<H@V)!<\*(03_Y)58E%HN18NB6@VN242)U7DY-#11
M8#0L,5)_E^WA:,Q"I)V$#ZDMV[K.NYE9M[>H\>0#/N1->WW7V&]['Z-#U&T1
M?3LS'R">N71=#NS.KM?VJZV=>?CA\AK$Z0R)*-;@C!VX:)Y_7>6+JF;93!YL
MT"734M:R9LI=IE?6&BBPRZ4M6))@!(AFFD"D#H BSA:,11$'AS7#$ M=.7Q!
MGAVX#NL) X%X#IN!G\P0 W_N[!JC.L0M "(VEC1>]'C7$$;J$)0 5X>UCY:9
M[.2ZK<&%.+G5@/4#P0=V>4N270 JVI"!>$_R@D-E@(N<L?X79 <P=MAL6;HJ
MM5,H0"@ /Z*@I)<=RS>9LT2>6U")O0_,<EH'8@8\M^V(LQNOY=.+SO)55JZH
M6X?P$OG3TJQQ*?;=I&OO'X3.JAG 4.$O]AN$_@XM!>K@!CRY04!; 6Q$?0U3
MZ"PN,2HP"9)\#]S)J\[<Y/5 ]%3- 0#2 C43/4K> 63!QP@\1M[-S*IM 6K6
M]4S]6980S @"P_"21 GHD^@,6-3UBO%Y6%@W6!K^N6I@8H2I)=S V==U>\L&
M#W6F;(=%OQSJ8%39#P!<;]PL8^A+--W!LUV/%A2P/*P]##G4)!I#7<*$X2G+
MKMTDW$ U!T=.SAE$K@1\Q\ @NR8G?TWP ,#&A_:&W?/QR13B8#4EX'QT &0?
M'!VB)8#I@B$'RXR(ZFY2E19MWI6X$"4@E@)X 2SPX(1H8(B"2X4:-O0@TPU#
M,0]6$F 20RN9C8EF$SP@RL_$!?!XB$]L.4DN/Q,5/:8DQ;U,1LN:H]&)P""0
MQNT ,I;C]#S][= E8\S-FRY7H[QGFKAPV2VM+?E!LF2W%84LN/ HZ;K<4[.D
M->]:1+@@EN")55,:B\^#"\!T"9$TAR)W:[0B=64'I&:;W['5HY$V>4FZ%AN]
M*&BA$;8(Y>DOL%,YB3=(.WY=M25%"0CIV(<KCO 09-*H!5-!YCP+MB9&!Q[>
M@MITK=M:2KIA,-*JH]C')I:29B#91T,W]&O +O]*L'**BR%PQ<' .(N5"=/N
M+&8D'805$I/-(3X!KB+>4E5"2UXA]X@WZVJU!D+K"OQ&2?9"O9R*42G0M(%?
MP1X!?T"Q!X972_/B$'A]!U1VID8;1[ $/.&=1NS@_4L2RX6E%<[00P'=^ RT
M!JX'P(J\D^4GE.?X+[(=%1E.O:H<2 H$)$ 8U7S%Q8MPZSR9+?*C)YY0D.F!
MX9*]FHA<L'V]'Q+NZ:M^\/[00QZB*F=O@^S#I$2-3C<C7J]M7080&$'5'G'D
MM\**YK]Y?7F.#QDZ<I@(,)$CETO".=-DD"; ],'%U*F!9",,H@G &I85)=^@
M=Y,<G;I2)0[I<"1;]+ 1&1$CF4RPG!Q3]6W[E5QL!S$J8L7;=C^YL^P:7!A<
M;7X'FD D7L%%',:B%T03#I;^A&3F&EQL3BFBT47'?-'<_&-=U3:9<PD2"R";
M%3'WJXB+:"O"78QF81F03B31H4\D]4&73U8?>2G8 0<5 !RL0;H :UJ!B(@@
M8%Z@O#&+1)U6JT,5:% 3FC9#],,\)X&*QV2K"Y=1S( 11$'+-32T4&AY2:M0
M<@TX6C0U$ LT.... N>ZYK $9D$PXBX:!9T^F#/\,>.O<.&83SPN"U->DK7"
ML)/!&7H1'V;@) .3MJVK.!BZ5,@QRSZ ^OL_,])CQ(?HQ7N!_[>\2 @LD*[&
MHG>D7!C.G,P;F##\M4J<_: T PV=ZP\J #O\"=PF1%9@1,LTB,(,$811M/8>
MK3LU! $H<?Z&/$95<)J&'(EJ#-"[ "0,I(2;9H*9<';.0RVZ+0P</13,+X#4
M904.!3#,[LC 12"ZZ@BI X7OVF9U\ Y<2@EA$&':V,0AS,7_8!%Z'!=EUM].
MIA=G6.,8-8TAN!ADN1&IA#D">TKKI9&T@VB*XHVBZB"P05!2T!? ('"*&=M#
M'G,#8H4JN:#$)F"Z#A<293&B"<V4"T*.%P*^1I>G)&&U3#41\3B9_N5 ]@$D
M%)PP*KHZC27(D4/Y(@\$Y/ 8!6 B\NQL_'0\II2%(_PRH@[,!)D# .0 RZ,,
MS (SE3DK8>XD_EAJ[+^P_2T @HQA#K !S:4/!<+3%5= H# 5-P!UKX<N2+C#
M*/D.8).QC =?@STFQ*!EG\1\J)IE^2[7*8'V9'9\\H)R7M><&\@^42B$0W_4
MO$$F>0..=X/(XK13!<(T'294MAVBPWR!*LBY68<A) 9)N&0=ZDQL5[FXBAX*
MUBZ_ 3M,6D_:AGS@R%MP?;&N[#+*:I00Y6#RZ6"38P87Q!,^Q#^@(JX ^S,\
M<&"\8($P^"E"M,2J0^DVVQ$YL(H@&BT"2)MXV RP$&5B;+D_%5.FJ1BX U,Q
MPLB(>. 4P*.JOHN3 &DR#P=EE..#>0?+5%CP*, ES)7TB1E8<0  ;"XK2BN5
M[<9R042+'R#610THKI"H 58%<-5BP*@HM9;"#J1_U5($PL.&=?&FD\NUX"DH
M5@R:TEE*$CNP!R O->)G^ &LN5Y/OM '*X7MT(V&ZDV_AN !T%6N,H.:O.HL
M(?-=GXG+@\Q$H<?0"006[$'N)'S":^; 8DVW^Y%XD4=7ZCPM:[A,_A949,TK
M*]JL<X>1MU1LQ_0LRI#FT60V&ISJ]=,/!?2.#)6X1\,E;^;!R!HU?;A:Z)@"
M9S#^X]P.:A-R KB0H2D8,.1(!TLQLCHNA%":'/A^;@#1#:CQ3OH#8@]8;0R!
M4)E]#J<+AEP&2(CP 7"4(@*SPSD/8"W,%J2THG2A#*^JI_200HN?#PN$N;R>
M0KJ!EPWK0V%"G=>H2,W"E\A+2MYQ'4&P88M<(J[W/YGK\]\N7G]Y=Y%]?*-%
MV6OSZ>+\XO+WLU?P=6*KXS\R,MSPOZ-,GVR"@H.9?G9\.GORY 5\>O'T.7QZ
MGKU#V?ND^ (G?!:R.0^/GC^;/3\]-H_@X\GI[/#%,_,H#!TF-<O0-_W5/#UY
M/GOZ_!E\>GY\/#MY>D1#(^PF57X=,E28]0?)SBBBUN(/*^N]F2WS\/+JT]_R
MS?;EZT>CA(YDV?;?2LDFPU5G7,52@D-T37U<%(00 X?2[)0\+WO+]M#GA,F
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M2H#Y:%J [PNE;/.#-F@OCD__"U!+ P04    "  [@Z)6'_&-(+,"  #+!0
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MZ[8@(9J?9.R-%KGY&60NM!:I6:X8A3*!&^#]0D R+&^00?V[V,7?4$L#!!0
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M;JO7:9:C1;TP,K?OOH4T^(JT/]&/&#8BP/.EQ.A5"Q*P^T? Y?\ 4$L#!!0
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MR*YD  \3;++(A("SY;I-9$MPW$Z0XN8[G?) O#I"8&B1W8NCU]]^-3P;O#C
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MR%;L\B)7J7D9#6 1J=Y\7<+J(J,'\/M<J;R\H VJMQ-?_P502P,$%     @
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M6'3Y[FRH2Z/#J^OSD_.+G]G[LYNWEZ<4F^5IOZ(OTB-70U8"LJ0L=<&::D?
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MJ=6  <;S+_)DD1=\&J,7:S2X:"L+V3.[NDRO[#508)9+DS(GP0C@*9>>2#L
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MD+7BS-\R-Z+MC!M0&C1T*&^!6TR::@K[WY"\"^RVSFX.+';=M$<YV//\+["
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MRRG[D54;PZ@,B\  J97""RE538&^'#VC18>1F]@,$ [ +5M5%"7A83TK.IN
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MR1@,XPZ)$]RBT@00URU/5IB0M>I#)W8DLQ=^K9<F3( 7X%<4'+2$1[N"O*5
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MZ(M<B90GK.JK/(&I1(6YK@QB#0.>LSSF+(4Y&9&:6"OX.U@I+:D-_SE7H@K
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MID(;X/Z:<W58Z O:,7WX'U!+ P04    "  [@Z)6?*7[6JX"  "]!0  &0
M 'AL+W=O<FMS:&5E=',O<VAE970R."YX;6Q]5&UOVC 0_LZO.&75M$E1\PH$
M!I%*2]5*ZXLH;35-^V"2@UAS[,PVI?WWLQ/(J$;YDOC.=X^?\_FYT4;(WZI
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M]77D:0-N0[QL"S1I@,(/@((0;@37A8(ISS%_#^ 95BVU<$=M$AY%O,#L%*+
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MTW[7 =D,B\;0HJH%NA#:R+U>%F:^HK0!9G\IA-X9]H!V8J=_ 5!+ P04
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MKC$TN.IUW$J.>F%D7D["E30X5TLSQ8N,*NN W]=2FGIA$S17X_A?4$L#!!0
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M?-#M&]!.K-HV?7>E+';Q9ICCLRFU,\#]M5+V-'$!NH=X] M02P,$%     @
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M60_&VTQM5+;=5%1MT7JY16OPC>83)BCB4\2$6$ \21:CZ4(N<HKN<Y))H>8
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M?@38F($%1VR;KH6P:_A>8'H6"DW/;GTN(X<=UW#]"'FF[<(?=A&VU"+/C"(
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M").@SU><J\>-F4;MQR?[!U!+ P04    "  [@Z)6WG&M)/("  "N"P  &0
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M8&J"'%]2*G:&"E"5Z-W?4$L#!!0    ( #N#HE93R[Q^9PX   F6   9
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MT+A\*"V TBB*INJN-K]LO?FUYX2 O*]1N_TM^G9:ZQ)JAT%I+I3F06D^E!9
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MM/@EW\I U #H:#/ *0'./F#P#, M >X^P'L&X)4 ;P\PMIX!#$K X*4M#$O
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M%XO!PDL5GM4S!L8 [L)3AG,PO);4ZO"V>Q*H7*?_O^O"DS>"NX.--:VP4JX
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MA%AY[E$V!,V+DX E%8*FQ>4&(TE2#9#W5Y2*EX8Z7*A/GR;_ E!+ P04
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MM>/&]77MFAQQ/<'X'#SW"Q"'D [X^'2X^QINZR2TF2!M)DC%YQWAFPHL6+*
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MHC &>G_)N=I-3%]OG_'@'U!+ P04    "  [@Z)60"$#D5T$  "-%P  &0
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MG)TYP4[7W5D RAFTU:'!IPMAWVJ6P2UE<#\@ Q4+PEK$[^[,I=MK$D#INZT
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MNO]^G80FA!A/P^,+Y''O\;DWMN_1=7-+V1M?$B+ >^"'O&4LA5C=F29WER3
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MP3/"(@/Y?DZI^+B)!D@/*MO_ U!+ P04    "  [@Z)6&W%-1T\$   ,&0
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M"9PWX/]DE:S-$2S!6^'3&70-M<8$\#48O=]_PPWKKRP 2@J6@J,:PU'5PO%
M&4=K:J\ 4:'6M!\L,G&#G#V8V!8F'_A,#=4B%UF0;/,TPCQ!$UGWK(ZYWJ]3
M9Y%Z^5K\\C4]E\QESLJ)F4*_4 :]$R8^T ,'4#<D* AE/K_:O$7Y+2E8"J)Z
M#%']2OQN\V"R1U^UTK8:!R1'9GB?Y4JCU4[]9=/>B&MJE$#[F+,9H)^>326S
MF?S2\JU-6)3ODH*EL&G&V#2OQ'?S:+6V6@=<9YC4LJEMQ:_?*H':N&$_ W>T
MO&JS%>6UI& I8-HQ,.VR>%4]SLG"0I\ 6\CQ7+D4B-30G'YES8E!3@CT!92C
MG$BI\K&5Z!5+/S/HYX5ZO3YQT4E25K0T3'NR#E]I_4>)4@V_5FF0PR:PLTMW
M_%.- "<Z#><(M;,(+]3E]1D+,WT)W883X8:OI=SPL3##5O60YF.C5O,$QXE^
MPSD"[BR.SV_W^G2%";Z$<,.)<L.E2;=3+3\G0SULV +5XX9=/=GZ<T*1*%0C
M"J5#(-%Y6"_T7L,OXXKX_AJXFKV7:/ZE*K^RHJ7Q2K0?OI;XBQ*EFGJM@NN'
M32'#S*HTR8F^D*A K)>!!8DOM@F4J@G+BI8&*E&%N#19F,=X^ZB_MX^V^F.;
M5CV;:Y((.Z(7=@6Y/G\ST.<M?$AS"5U'$EU'2M-UIS:#G S5J(.?]44@)]9N
M-\C:3M( [!W;Z>7@_YTF!<[TRCW4NX0Z)(DZ)-=2AR3_8$]KLBW W#NJ#GXG
M>*+\G;D"V;!0/FK/4/*";X_>MP/I^>'I]9LGI>>$ETN@<^"!@7J^\#RY&P0'
MXO$/(+W_ %!+ P04    "  [@Z)6ZCX3U2H%  !"*@  &0   'AL+W=O<FMS
M:&5E=',O<VAE970U.2YX;6RMFFUOZC84Q[^*E4W3)G4D#B1 !T@T3T.Z[:JV
M6U],>^&"@>CFZ=JFM-(^_)R'!L*#2^Y.7[0)^/\[2<[?I\Z11]N4?>5K2@5Z
MBZ.$C[6U$-FUKO/YFL:$=]*,)O*;9<IB(N0I6^D\8Y0L"E$<Z:9AV'I,PD2;
MC(K/[MEDE&Y$%";TGB&^B6/"WF]HE&['&M8^/G@(5VN1?Z!/1AE9T4<J_LSN
MF3S3:\HBC&G"PS1!C"['VA1?!WB8"XH1?X5TR_>.47XK+VGZ-3^9+<::D5\1
MC>A<Y @B_[Q2AT913I+7\:V":G7,7+A__$'WBYN7-_-".'72Z#E<B/58&VAH
M09=D$XF'=/L[K6[(RGGS-.+%;[0MQUI=#<TW7*1Q)997$(=)^9>\50]B3X![
M9P1F)3 /!><B="M!]]((O4K0.Q"8YP16); NC6!7 OM20;\2](MDE4^W2(U+
M!)F,6+I%+!\M:?E!D=]"+3,2)KD5'P63WX92)R;/TX>'Z=T3^C*;WLR^S)YF
MWB/ZV:6"A!%'=X0QDEOE%_0K^A'IB*\)HWRD"QDYU^OS*LI-&<4\$\6E\PXR
MS2MD&J9Y0NZHY;?D'9GV6;6K5D\S)H-;9^7>!=?>Q6?E_N5R?$(>7"XWFG)=
MIKK.MUGGVRQXO3,\[XVR><@IRE@XIRA=HFV>Y$2<2JH2E1?):YZ1.1UKL@IR
MREZI-OGI!VP;OYU*,23,A81YD#"_A T*6/Y_X'6"NQWIF]?]G!\/ZAF=?CVH
MD=ENG=FN,K//91Z12%&V8?.UK,^*^:IDM4TM),R%A'F0,+^$V7M9LPWY<Y!;
MH) -#_1J#_24'GBD+*0<.:@R T=_W]+XA;)_3GE R6KK 4B8"PGS(&$^)"P
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MF@ 2YD'"?$A8  1KF  ;N[:0H;3!;9B$\296KA?4B+8+!E":"TKS0&D^*"V
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M>+NEGNB'\@+B\X<TY2\;>07ULUI6_P!02P,$%     @ .X.B5L^W>NP9 P
M;@@  !D   !X;"]W;W)K<VAE971S+W-H965T-C(N>&ULK59M;]LX#/XKA.]P
MN '7^C4O[1(#>=NU0-<+DG7[,-P'Q682H;;E24K2^_='R8F7=DY6H/MBBS+Y
MD ]%D>[MA'Q4:T0-3WE6J+ZSUKJ\=EV5K#%GZE*46-"7I9 YTR3*E:M*B2RU
M1GGF!I[7=G/&"R?NV;VIC'MBHS->X%2"VN0YD_\-,1.[ON,[AXT97ZVUV7#C
M7LE6.$?]4$XE26Z-DO(<"\5% 1*7?6?@7X\Z1M\J?.:X4T=K,$P60CP:X3;M
M.YX)"#-,M$%@]-KB"+/, %$8W_:83NW2&!ZO#^@?+'?BLF *1R+[PE.][CM=
M!U)<LDVF9V)W@WL^+8.7B$S9)^PJW?:5 \E&:9'OC2F"G!?5FSWM\W!DX+=/
M& 1[@^"E073"(-P;A)9H%9FE-6::Q3TI=B"--J&9A<V-M28VO#"G.->2OG*R
MT_%\=#,9/]Q-X)\/,!G,[F_O_Y[#=#*#^<U@-H'A8'X[@L']&,:W=P^?)F/X
M<XR:\4R]@PMXF)/\^[N>JRD2@^<F>Z_#RFMPPJL?P$=1Z+6"29%B^AS )0HU
MC^# 8QB<11QC<@FA_Q<$7A T!#1ZO;E_)IRP3FMH\<(3>!,F"UZL%$Q1PGS-
M),+7P4)I267[;U.^*KBH&<Y<Y6M5L@3[#MU5A7*+3OS';W[;>]_$]1>!/6,>
MU<RC<^CQ/76>3"@%&X4I4)LQMXPG@(>,E)0193+2E(8*NV6Q30/:QA=^MQUY
MK2CLN=MCCDV:G>Y5QP\[M>8S JV:0.LL@:$-=V?O/Z87;(N2VADD(L^I[=C(
M%5 _5)H5*3%JHE%Y:!\%%W8C+XR\%R1^U NNPC#JGJ#0KBFTSU(8\VQCNB.4
M0F.A.<L.<7.E-FR1(2RER(&Z2_((HC0-50'1@1V3DA5:-9$ZZ[.YJJ"I.M^.
M\RPIG3HIG9\GA4KR;2?;>>7)_JC7?++N4>O.4:[L1%,4TZ;05?>K=^NA.;"S
MXL7^D(9I-?N^PU23^".3*T[GF^&2(+W+#E6=K*9;)6A1V@&Q$)K&C5VNZ8<
MI5&@[TM!9;07C(/Z%R/^'U!+ P04    "  [@Z)6U%=FVF,#   ,#   &0
M 'AL+W=O<FMS:&5E=',O<VAE970V,RYX;6S-5VUOXC@0_BNCG'3:E>Z:%R!
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MNO*&9F7K64X$W>KN;4F%[ 7U<"/;=63*0+Y?42K>)FJ#^@^ ]Q]02P,$%
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M'C<8+3%3!O+[BE*Q'Z@)\ANPWG]02P,$%     @ .X.B5M%#EM7, @  ;0<
M !D   !X;"]W;W)K<VAE971S+W-H965T-C4N>&ULA95=;]HP%(;_BI5-4R=M
MS7=".HA$@:Y(=$5\;!?3+DPX@%4GSFP#W;^?G= ,#0,WQ([]OL\Y)N>XO6?\
M16P )'K-:2$ZUD;*\LZV1;:!'(M;5D*A5E:,YUBJ*5_;HN2 EY4HI[;G.)&=
M8U)8:;MZ-^9IFVTE)06,.1+;/,?\SSU0MN]8KO7V8D+6&ZE?V&F[Q&N8@IR7
M8ZYF=N.R)#D4@K "<5AUK*Y[=^\Z6E#M^$Y@+X[&2*>R8.Q%3X;+CN7HB(!"
M)K4%5H\=](!2[:3B^'TPM1JF%AZ/W]P?JN15,@LLH,?H#[*4FX[5LM 25GA+
MY83M'^&04*C],D9%]8OV]=XHL%"V%9+E![&*("=%_<2OAX,X$GC>&8%W$'A5
MW#6HBK*/)4[;G.T1U[N5FQY4J59J%1PI]+\RE5RM$J63Z;3W..C/1P/T_(">
MNK/Y9#@;#J9Z]CP>3+JSX;>O:#3H3@=H-.S>#T?U\DT?)"94?&S;4@6AK>SL
M +RO@=X98!^R6^2[GY#G>!Z:3_OHYOU_-K;*H4G$:Q+Q*E__C&^/Y3F1ZGN1
M N%BB7JLD*180Y$1$*A/1$:9V') /[L+(;GZ&GZ9@J\A@1FB2^1.E#B#CJ5J
M0 #?@95^>.=&SI<+*?A-"OXE]U2=B&^*J5:%E4I7V2[UHY8?N&U[9Z %#2VX
M1@M,M%H5'=/BQ$\\,RUL:.$U6FBBA:>TQ(ECWTR+&EITC1:9:-$)+5"GD,1F
M6MS0XFNTV$2+32?I1H&9UFIHK8NT&9.8FG"M$YR;>(X;M<R\I.$E%WDC$ )5
M7WLAT0[3+:"EJB:V+:0IBN0DBL]^'$?.F:Q=YU^C<B[&\5P"Q[JD$075AA$E
M>$$HD:J\C5W(.:D:-PR\\.3X[:/FJ2^B)\S7I!"*LE)*YS96%KSN[?5$LK+J
MIPLF57>NAAMU'P+7&]3ZBC'Y-M$MNKEAT[]02P,$%     @ .X.B5BTLZ#IJ
M!@  MC$  !D   !X;"]W;W)K<VAE971S+W-H965T-C8N>&ULQ9M=;^(X%(;_
MBL6N5K/23$D<$J!+D2A)=BL56@V=G8O17AAB()I\,(Z!5IH?OW:2$@RIATA'
MZ@TD(>>QD]?VL5^2P3YEW[,UI1P]QU&2W;36G&^NV^ULL:8QR:[2#4W$+\N4
MQ82+7;9J9QM&29 'Q5$;&X;3CDF8M(:#_-@C&P[2+8_"A#XRE&WCF+"76QJE
M^YN6V7H]\#E<K;D\T!X.-F1%9Y1_V3PRL=<^4((PIDD6I@EB='G3&IG7/G9D
M0'[&OR'=9T?;2%[*/$V_RYV[X*9ER!K1B"ZX1!#QM:-C&D62).KQHX2V#F7*
MP./M5[J?7[RXF#G)Z#B-OH8!7]^T>BT4T"791OQSNO^'EA=D2]XBC;+\$^V+
M<[O]%EIL,Y[&9;"H01PFQ3=Y+F_$40#&;P3@,@"?!%B]-P*L,L Z+<%Y(Z!3
M!G0NK9)=!MB7!CAE0"YFN[A9^9UV"2?# 4OWB,FS!4UNY'+ET>(&AXEL63/.
MQ*^AB./#\<-D<O<T\:9/,S2:NFC\,'VZF_[M3<=WW@Q]<"DG892A*6&,R#;P
MYZ#-1;$RN+THBW"+(O ;19@83=*$KS/D)0$-5$!;U/=0:?Q:Z5NL)8XV[ H9
M]D>$#8S1EYF+/OQ>5[&Q'N/2Q14R"XSYBD%+_L=O9K?W5]V%7L"SS%]6R[L<
M8VHPOA[CT_D5PKT<8]5CE)MO'5J,E7.M-[BS-6'TTZWHS0$:I[$8XC*2#Q(C
MT422%17##D?S%W1\WB-YR0^/]H0%Z-N]0*([3N/LOYKKNBW*[]27+X?:ZVQ#
M%O2F)<;2C+(=;0V%9(Y1)]D8$N9"PCQ(F \$4UI$Y] B.CKZ<"12&DJ7*"))
M@'[J.M"M%M14V@+FY#"907=#C!W<&;1WQYI!%NE!PGP@F**9?=#,UFKVL*%R
M0$]6***BBR).65PGF);25#!]E1P3Q7F>J.MYD/7P(&$^$$Q1T3FHZ#164<RK
ML@4+-W),KE-42VRJJ+YZTW1'XSEEZ#4G\A0=CEE&?K!;IS9D'3U(F \$4]3N
M'M3N:F]GF44S)!84Z+/8JI-7BV@J;P&SCT98LV\;7=,X&6,A"_4@83X03-&K
M=]"KI]7KB29$3'K">,-DHY<3(!*)I1Q)%K1..BVMJ72]L^1H67W+.54.LDP/
M$N8#P13E^@?E^EKEON8+4AI\(CLQP*ZH6$/+5?JOTZ46VU1"2)BKO^ .>J&$
M9<@TRAR,< <%Y*4N%WN0]?*!8(K,IE&M?HUF0@=AMDBWHJ>*O%K;2?7 IA*#
MTMR2UC_J],:5T>NK?=X#+=2'HJD*'OD7YH53H'O9,S\B[UDN2>NUTZ(::P=)
M<TO:<:[M.-@PC%/QSL^S.N?G^5"U4V7!E2Q8OR9<+-A6K/QIH4;=.'*K1S26
M Y+FEK3C_&G:IMFSG5,]\/D<R3:-?O],$*#ZJ8)4KHVIM0"&]R$/5X51DU'.
MHW(^$LO!KE8<Z^RZ^HYM]]2K&NM+;7S700T64)H/15/UJSP64V^R3$F2HME+
M0I_1/0_0MTF^BJKUS_2DQOT*DN:"TCQ0F@]%4Q6N'!G3?F=CU01U<T!I+BC-
M Z7Y4#2U850FCZFW42;D.8RW,5IN^991\94$<KZC&;M!/1Y0FEO2E,1J= RC
M9J8#:MQ T50-*^O&U'LW+MW1*-WDG54*6"L;J'<#2G-+FF*VUZL&:M] T535
M*@/'U#LX;R1=]!/-MO.,_MA*.;V=_-0F9%!G!Y3F@M(\4)H/15/5KTP@L__>
M"1G4+P*EN: T#Y3F0]'4IP\JUPCK7:-1$(2R(9#H@F2L9S75&)3F@M(\4)I?
MTHX7H+::<%3U*L<(ZQVC&?T>9ML0N6'&63C?%EUZQ6C1H74#N9[<6$M0 PF4
MYH'2?"B:JGAE1F'\S@,Y!K6R0&DN*,T#I?E0-+5A5*88UIMBE[B4>D1C:4']
M,GQNTIEVYWQ2#EJJ#T531:N<,*QWPOR091Q53Q5J!VQ0*PR4YH+2/%":#T53
M):ZL,/S>5A@&M<) :2XHS0.E^5 TM6%45AC66V$7/0*C9S36UCG_P\VR^\[)
M'T$N:*D>*,V'HA6JM8\>-X\I6^4O!F0H_]^\>(C[</3P\L$H?^3^Y+AK7GO%
M*P05IGBC84+8*DPR%-&E0!I777'[6?&20+'#TTW^4/L\Y3R-\\TU)0%E\@3Q
M^S)-^>N.+.#PJL;P?U!+ P04    "  [@Z)6_FZ;-%T6  "L-@$ &0   'AL
M+W=O<FMS:&5E=',O<VAE970V-RYX;6SMW6MSFUB>Q_'G?A64IV<JJ7)BZ^YT
M)ZE*F_LEE8V[]UK[ $O'%AL)M("<I&M>_!XD)(3 QZ+[NSW[8*>J)W&L\SD(
M]#\<X"=X^S5)OV1S(7+MVW(19^_.YWF^^O'R,IO.Q3+,7B<K$<O?W"?I,LSE
MC^G#9;9*13C;-%HN+OM75^/+91C%Y^_?;O[M4_K^;;+.%U$L/J5:MEXNP_3[
MSV*1?'UWWCO?_</GZ&&>%_]P^?[M*GP0MR+_=?4IE3]=[I59M!1Q%B6QEHK[
M=^<?>C\&DW'18/.*?X[$U^S@[UKQ5NZ2Y$OQ@S-[=WY5+)%8B&E>$*'\XU'<
MB,6BD.1R_'>)GN_[+!H>_GVGFYLW+]_,79B)FV3Q+]$LG[\[OS[79N(^7"_R
MS\E76Y1O:%1XTV21;?Y?^UJ^]NI<FZZS/%F6C>42+*-X^V?XK5P1!PVDT]Z@
M7S;H'S<8/M%@4#88G-I@6#88GMI@5#88'35X\DV/RP;C4QM,R@:34Q?INFQP
M?=Q@_$2#-V6#-Z?VT+O:;;FK4]]%;[^Q&UO[R5YVF[MW\O;N[39X;[/%+[>?
MQ<T'60_S\/W;-/FJI<7KI5?\95,-F_;R\QO%1>'>YJG\;23;Y>\_&[?&A\\W
MMO;AHZ[YSHWQ\=;0/EB?#2,P/OYRJ[W011Y&BTS[&*9I6!392^V5]NNMKKWX
MX>7;RUPN0@%=3LON?MYVUW^BNYX6)'$^SS0CGHE92WOGF?;]YP!/#?2O%<"E
M7'G[-=C?K<&?^TI1%]/7VJ!WH?6O^OV6!;I1-W?#6-E<5S<WQ=UKK7^]:=YK
M:6ZHFW],'F7O5YOF5RW-377S($QW"]][T]+<.GG5]:Y;FMO/K+IUO%OXUN;.
M']MP[NG-V]:\IVY^*U;*->^?WGM;\^#D57?<O%8$@_TP,MAXPZ>&$9&),)W.
MM3">R?WFHYP0K.3N/6\;(912,5'Y,5N%4_'N7,Y$,I$^BO/W?_M+;WSU4UMQ
MD9A.8@:)F21FD9A-8LX6&VVP8LKY^'Y\/9CT!H.WEX^'E=E\7:\WZ8TGQ3!P
M^$*/7#J?Q ((JU7K<%^M0V6U^M%43KV%-DVRU@I5MNY:H22FDYA!8B:)621F
MDYBSQ<8'E3>\DO\[JL_FJ\;-5WGD@ODD%D!8K3A'^^(<*8OS4YI,A9AEVGV:
M+&6)QH\BS:.[A9#[U;O6<ATU1L/!U55S?=\H^^U:B21FD)A)8A:)V23FD)A+
M8AZ)^2060%BMKL?[NAX_5]>S]337LG ALK8R5C;ONM<E,9W$#!(S2<PB,9O$
MG'%SK_OF>C :C8_VN\W7C<:CP:0_.MKSD@OGDU@ 8;4*G>PK='+2M/BS/'Z-
MUT+[CT L[T3ZGVW%JI2Z%BN)Z21FD)A)8A:)V23FD)A+8AZ)^2060%BM[*_W
M97_]QW;,RN9=:YW$=!(S2,PD,8O$;!)S?@>FM97Y=?. >="_NAH>[;?)9?=)
M+("P6@&_V1?P&V4!_QI'\A@YB_+O6G*O^<DZRAZCQ:+8D9=GI<UD'<_"S95B
MU4Y=V4W70B<QG<0,$C-)S"(QF\0<$G-)S",QG\0""*N-";VKZL+V%79)2DUU
MK7Q4TU'-0#43U2Q4LU'-*;7#/71OV#SQW?*R_G#0//6-+IR/:@&EU>OV()#2
M4];MOT7:OT:Q]N]S$6OZ.HPU-\KF:\W/9\I]MUKM7,*DIJ.:@6HFJEFH9J.:
M@VHNJGFHYJ-:0&GU\:!?C0=]Y7B@BWN1IF*FI=O3<JW%KR0Z%S^IZ:AFH)J)
M:A:JV:CFH)I;:K7C]4G+%6ZT5Q_5 DJKEW45&.NI$V//GG53M^]<TVA0#-4,
M5#-1S4(U&]4<5'-+[;"F!]<M)8U&RE MH+1Z25>ILIXR%W/*S%W[N];E*INZ
MP\YC *GIJ&:@FHEJ%JK9J.:@FHMJ'JKYJ!906GVHJ#)NO6=#;L_L_<G<SPVJ
MZ:AFH)J):A:JV:CFH)I;:HTK<(W=/QIN0[6 TNHU7>7;>NJ V^TO'[1/\S!=
MRB[6>30-%]I-\OQY.S3VAFHZJAFH9J*:A6HVJCFHYJ*:AVH^J@645A\.JC!=
M3YVFZW3]#8W3H9J.:@:JF:AFH9J-:DZI'>Z?W[1<?FN^:K,3;^[&T2@<J@64
M5J_;*@W74\?A?EW=ITF<RY)=)5G47JYH(@[5=%0S4,U$-0O5;%1S4,U%-0_5
M_%*K?Q>U9<@)J&[K95UEY'KJD-SM*HFSI+B.5MLQ[\[&?7A(A2AVS^K).IJ0
M0S4=U0Q4,U'-0C4;U1Q4<U'-0S4?U0)*J]_"I K+];FPG)KJ.@B@FHYJ!JJ9
MJ&:AFHUJ3K\E+#=N2<NUO&[0'S5GZ^C2^:@64%J]<*NT7%^=EGON5@[JYIV+
M%8W%H9J!:B:J6:AFHYI3:K4CZ[9:;;ZLUVNY/HXNG(]J :75:[5*LO752;8@
MBJ/E>BGWL?$Z7&AI\CU<Y%'[]2\UU;ENT40;JAFH9J*:A6HVJCG]9@:M4;//
MOL1#E\E'M8#2ZN5:)=3ZZH1:YR-F[>\:]E4T];)UKG\T_89J!JJ9J&:AFHUJ
M#JJYJ.:AFH]J :751Y4J)-=7)FODD7:TO%NGV7;HD(-$NAL9Q+=5,;"T3P?(
M\,\-JNFE=G@&M#]I.0-JH-V:+=V.WS2_:F6AO=JHYJ":BVH>JOFH%E!:O8:K
M]%I?G5ZK=OVY2)?:*OQ>_'"AS40V3:-5L7-O+6(TTX9J.JH9J&8^LS6<^,Q=
M+[YO;F5[H>5SH=TDRU48?]?D1A'%_"V*\T3.W>0(.UVL,SE#TQ;E)"[<;\FO
M43[7?O4_F]I]DFJ?/]P6K40:;N\O'\7SZ"[*Y6]FZ?I!F\J)8"1G<2)[+:=\
M,Y$6W9[ML?I2?)430"T/OP@MD7/#P[.K%W+P?U@O0NE^U\+5*DT>Y7%A,<F<
M)LNE2*=1N(A^VTX6Y9ZB0*N>M_<'W"QQT2+*BCU),64M[A5X5KR)XK[]N8C#
M>"IVS5,A>]NN$;$H;IY?'(C*?E<BE5/659+F]\DB2EYK3G%;_GR=QA?;+E(Q
M%7+%S;:+^2U:2D:N\Q]ZO?Z%'',W*TVNX75Y\;A<OV?W0FR6+CW>ZZW22+98
M247^7)R\RC9]AK-95+S=^AJ<A]EV2\TTN2%EN6V7Z47TLCJ(OM#D2MIZKZ;%
MBI8OCD69,#T+LRR1:[-XZYL-O5F5Q^OXHEBPX5^U%U+:-Y5OJ>@TU*;K9;&I
MBD_/#_W15?&NB_]>:O)]C(X;A7=R$12-+L[6<1XMBGU^E-8V<+GF9N5[N=BL
MOO[K1@_;%?Z]_"E.BK6X?==WWW?'*#/MTP;)7E[(E277UN#JK\6;&<D_9'>R
M^5F<Q*^VZU!2Z[NR=R$_('+UB&JSORC:%'U6+\JTAS2,MY^FS:+?1VDFA\2O
MB?9=SFBRW3O:;*M&P5UHPZ9X=B3F\RB=%2OX/EFG<K.=Y!8K;'#*TMZ78AM8
M%7/1O?QM*L)[.1YLUV3QP3O\1&\W1Q(_)%'\L/TX:VT?.3G:K<*T_+#=1W(D
M>[@HRB\3T_7V.19RV0_*]DPNV=$'0G[0Y;99;[X1N2TBN4$/QK]">!$]OMSM
ME>2P$,8/Q6)MQHL?6@]ST)@OJCFHYJ*:AVH^J@645I\B56'@OCH,_+G:L2W#
M](O(BT_@;A=WH3[601/!J*:CFH%J9JDU[P-\?$"$9GU1S4$U%]4\5/-1+:"T
M>K576=^^.NM[4TUSGOQ&CYKH7-9HQA?5#%0S4<U"-;O4#H><T=55V\W'';1C
M%]4\5/-1+:"T>F57:>"^.@V\/Y)8E=_8VQV!M)8XF@M&-1W5#%0S^\W;/SY1
M1A;:L8UJ#JJYJ.:AFH]J :752[Q*!O?5R>#=!<WBR+'EFN?^9&?VOW.A$XT4
MHYJ.:@:JF:AFH9J-:@ZJN:CFH9J/:@&EU1\(5T6*!\]%BG_/A4XUVG4X0#4=
MU0Q4,U'-0C4;U1Q4<U'-*[7#XZ'K07,6YZ.]!I16+_0J@CQ01Y!_Y]50M=JY
MTM%D,JH9J&:BFH5J-JHYJ.:BFO=,33CQ6?NES#]T&;/UFE+;I>*S,,ZC5_%Z
MNA")7#39Z]:+_VO]L&D=AW&R"M,\DJ_(^.N>9T]>]]2>O.X9%M<.D^UOQ!-7
M0[.GKF-J!]<QS_[_.N9G\ZR9</B3KV.>'<4/3KN.&8O-TYR?OX[9VWZBSF2K
M'T:[S]?96AZ_;I8PG,XC\;B?>TY%FLO%J>4M:C$+;1G)SV^>Q")[W38U1T>/
M@-+J>^SJBP@#]1<1:GGFYY[6C'X1 =5T5#-0S40U"]5L5',&S6\93$;-;P:Y
M+:\;#\?-;Q"A2^>C6D!I]<(]>,JZ^BL)SWW;3]V\<[&R#U=GGZ[./EZ=?;XZ
M^X!U]@GKS;O<-N]RY[:]JN6[?NBB^:@64%J]4JN8_T 90?X=3W%6@YUKE]1T
M5#-0S40U"]5L5'-0S44UK]0:28#C$U]DIP&EU6N\^AK X)F;V!ZDEULK&LW[
MHYJ.:@:JF:AFH9J-:@ZJN:CF#9IWQ&V[E9Z/]AI06KVDJ]CJ0!U;_?.NA5=W
MPI]IN[MAWV[.H:FNEJL7O_.0@F9C4<U -1/5+%2S4<U!-1?5/%3S42V@M/K
M4R5H!\_=+?=WY^75<N<Q 0W6HIJ!:B:J6:AF#YHWLAVUQFK1;EU4\U#-1[6
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M#E#[*\;D8:*OD_K/0/074$L#!!0    ( #N#HE8/J>Z1&P<  (TJ   9
M>&PO=V]R:W-H965T<R]S:&5E=#8Y+GAM;-6:66_;.!#'OPKA72Q:()'%P[*<
M30PD;KH-MCF0I"V*8A\4F[:%ZO!2= Y@/_R2DB):$D7+1Q[ZDECR<#@S_)/\
M2>;Q4\Q^)G-*.7@.@R@YZ<PY7QQUN\EX3D,OL>(%C<0WTYB%'A>7;-9-%HQZ
MD[11&'21;3O=T/.CSO XO7?#AL?QD@=^1&\82)9AZ+&7,QK$3R<=V'F]<>O/
MYES>Z Z/%]Z,WE'^97'#Q%6W\#+Q0QHE?AP!1J<GG5-X-")$-D@MOOKT*5GY
M#&0J#W'\4UY<3$XZMHR(!G3,I0M/_'ND(QH$TI.(X]_<::?H4S9<_?SJ_6.:
MO$CFP4OH* Z^^1,^/^FX'3"A4V\9\-OXZ1/-$^I)?^,X2-*_X"FWM3M@O$QX
M'.:-102A'V7_O>>\$"L-D-/0 .4-4+5!KZ$!SAO@--$LLC2M#Q[WAL<L?@),
M6@MO\D-:F[2UR,:/Y##><2:^]44[/KP;?3K_\.7S.;C^".[NKT=_@^N;^XOK
M*W ZNK_X>G'_';S[0+GG!\E[< A^!UV0S#U&D^,N%[U+']UQWM-9UA-JZ DB
M<!E'?)Z \VA")V4'71%V$3MZC?T,&3U^H&,+8'@ D(V0)J!1^^;0$ XN2HE3
M?[C1WY0R1B=@%(=BEB5>JM-3QKQH1H7RN1A:/@<7T<1_]"=++S@ Y\_C8#GQ
MHQFXDU4]/!."G( ;[T6:)\"+Q$6<<$:YSS(79S2B4U]\]^.SZ!Y<<!HF_^@&
M(XN5Z&.5B\-1LO#&]*0C9G]"V2/M#/_X#3KVG[I"[LE9J:RD*"LQ>1]^2V<B
MG1R"TT?*Q-(";JE<GV351D)03*P$HIC@LS^EX)T?@>_48\G[ W"]Y D7)92&
M'I>J$Y]TI3+W#R$(,]T2,/%>=,H?&3UL69]>49^>,;[S<!'$+Y1F<KF*HT.:
MWP%WHBM_3,$-BX7B* ,_+FGX0)E6,,9>-A7,GIR5"N(4!7%^H7GH[+.L>W)6
M*FN_*&O?J+.KI90.B*?Y#G  XH6L; )B-=$.P .=^5'4,-.R'IRT!PD8CT/B
M$N@ZQ]W'U30U9C:$6)F5$G"+!%QC K=R_&7\Y\^4C?V$@@43LT,L%'D>*PN&
M+OC,N[L2E6-;_4KH=:.^;?7T@0^*P =OO@(>",4:!L8<@ M>I$?@O*Z$_<:5
MT.QHD#O"KXZ@;DTM%0G:BF3L+04Z$U.?5Y$C9Q:[IC6("7$&E7'5V+FX9]OZ
MD84K^ 5;C2WP\J&E%7&VR0'61->S$*EF4+>">$6_Y0202@"]D3CSQ/XR)&;N
MNI>K2>W0R&D4YAI?K\H<;*!,!8;0"$@&9=+GA=A1],GCFN(.![A?$^86; 9,
M62DN@^W ;*UT34F2FB@'&%G]7C7++0C+F*6B*VC&JV+7V":[O3+5-MZ,-5!
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M965T-S N>&ULK5;;DN(V$/V5+B>5VJU:?.4V$Z!JN&R&RC!0PT[RD,J#QFY
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MR1BFCS!\N!O]WE!&\X?)$N9FL[%XFHZFC[_!;/+E?CZ&#V.4A,;B(S3@9W!
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M7%5X4*P38"M@F2[( C[0% Y(N/A8Q;T>O)5[@N=!DM< OPT1.525D5$]5+N
M"HY(G0J@LPATRPAT:Y%G>6+!7S-,7I#_726S%D'?R;<B(R'V+77I"N0[M :_
M_.2UW5^KA/X@L#.Q-Z78FUJQ2UW%P=2 *IVY<_<DQUJVU[Q(Q.^-/-]N5J>A
MYWZ[L=SZ8\@_D-ICJ(?XM^?PH]#.!9]<T=[_.8K"^RS,KMVZ.(L*J\"W+XN8
M<]))),C7IL$2$+)M*O-[MUPMF[@[T[I<K ]U<V<ZE&\P>6<X(WQ-5;F(<:4@
M7;NCJBW/FZU\(EEF^I47)E7W8X8;U: BUP9J?\68/$[T"\J6=_ /4$L#!!0
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M0Q1^ 44!?%C(BDPG[4A)06PT@RWF%(1A#%+H* I:FG7JJI92XCJ?<P]1YAZ
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M_DT:;?/G;-U%:1H%^<LU]98TS@JPWZ^B*'U^DU50/JKM_#]02P,$%     @
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MS'[&A@=L/[_TZ>UDTMO_]_.;3^6T)@=U2<PC,9_$ A(+22PBL9C$$A)+24Q
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M%]W*OKQ;^54==KG9->A13>^?UQ@GP_HEE QT3!/5+%2S4<U!-1?5/%3S42U
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MSS8T44YG.8/E3):S6,X^<96Z^J WT7IG9]QL][)A7&TR&??.)YK;':#/'F#
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M()]ND0_3/939TB/*&2QGLIS%<C;+.2SGLIS'<C[+!2P7LES$<C'+)2R7LIS
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M]&[&NQ>M]?XR-*=/MJO'W:O.*^7]:KM=+0X?WN?9+%_O-]C]^X?5:GOZ9#_
MY]7ZM\/#?/O_ 5!+ P04    "  \@Z)6R;[RW9L+  #U=   &0   'AL+W=O
M<FMS:&5E=',O<VAE970W-"YX;6RUG5MOVS@>Q=_S*8C,8M "J:V+[3AM$B"-
M;@7:3I!D=K 8[ -CT;&VLN12=-(L]L,O*2F6:<N,U9[TH?&%_/U)Z9BW(U&G
MCSG_5LP8$^3'/,V*L\.9$(OW_7XQF;$Y+7KY@F7RFVG.YU3(M_R^7RPXHW&9
M:9[V'<L:]><TR0[/3\O/KOCY:;X4:9*Q*TZ*Y7Q.^=-'EN:/9X?VX?,'U\G]
M3*@/^N>G"WK/;ICX<W'%Y;O^BA(G<Y8529X1SJ9GAQ?V^V@P4AG*%/],V&.Q
M]IJHJMSE^3?UYE-\=FBI$K&4381"4/GG@5VR-%4D68[O-?1P%5-E7'_]3 _*
MRLO*W-&"7>;I7TDL9F>'XT,2LRE=IN(Z?XQ87:&AXDWRM"C_)X]5VI%[2";+
M0N3S.K,LP3S)JK_T1WT@UC+8@QT9G#J#LY%A--J1P:TSN)L9ACLR#.H,@\TB
M[<HPK#,,-S*,K1T91G6&T;Z5/JXS'.^;85QG&)=GMSH=Y;GTJ*#GISQ_)%RE
MEC3UHA1$F5N>PB13VKT17'Z;R'SB_-K_?''K>^3JXOKV7^3V^N+KS<7E[:<_
MOMZ0-QX3-$D+\I5R3I7$WI)WY,\;C[SYQ]O3OI#1%:,_J2/Y521G1Z0A^9)G
M8E80/XM9W)(_,.>W'0.@+ZN]JKOS7/>/CI'HL4F/.,X1<2S':2G0I3G[%_I$
MG-'.W-XOY?;-N6_8HD>LJNAVV['<H^:NO3-ZN'_VMNC1_MDMPWET5QIV2YZ[
M2\,LI8+%Y(IR\41N.<T*6K6,?W^62<DGP>;%OUO*^;'B#MJYJMMX7RSHA)T=
MRGZA8/R!'9[__IL]LCZTJ04)\Y P'PD+D+ 0"8M ,$V#@Y4&!R;Z^<5DPI=2
M@TDFF*2+-K49"5W5AH1Y2)B/A 45;%C"U#CLX=P9.R>G_8=U%?U$1-(F(%#)
M-0$-5P(:&@5T,\NY(%(\<SGTNA-$CC,+0;,XR>[EX"REV82U:<H([:HI),Q#
MPGPD+!AN:>ID:!VKCE!3U4_$;%45J.R:JD8K58TZ-4M$#N1:=51A;&OMH%@]
M:ZP?DDMCL*X"0<)\)"Q PD(D+ +!-"T=K[1T;&ZA1#[Y1I*B4(**EURU3 O&
MDSPFQ8S*>'(B^GV9%(D:>A5M(C/RNS96%6RT)MAC:[ A6 \9T4?" B0L1,(B
M$$S3V'BEL;%18W^IJ68F"B)RLECRR8P6K%97FZ",L*Z"0L(\),Q'P@(D+!QO
M_0A'EORG_PHC4$A-42<K19WLIZB<$ZX6LEJ%9&1T%1(2YB%A/A(6(&%A!1NO
M"<EV>QLCLF@[T<#J':\2:?JPK68%S#(JY)H],*Z:F46:B",Y^BXF/%FH3JQ-
M*6985ZE :=X+%;V=201Y?/Y!/,H1(2F6=P7[OF292)\(^\'X)"ED]YYGY(8M
M!)O?,4YL=_<R%;0"P<_0ZM-W4 U/;M1)/#BH0AP<_)$=?,T?JFHX=36.B)@Q
M<IG/%S23=9Y.V42M'E%BOYOF_)UM'1%:2!FHN9@L0$SNGM9S_/[;V+&//Q3D
M+J=<'JDIB1,N$3DOC@A_UE)9F%)1*D4BBH/U"5T]7I+?3/+Y7![L*OT;%4;Q
M'>O#LRK7JE5^8W]XVR/R3)*6!#)\O)S($K<5MXIY(&.NEV0]_E%=C+P4OZR-
M3-/(9;M')B6+:XP>"7BU^$;37=44,RH.'O-E&I,9?6 DE\7ECU)WLOS%,E4G
M8\KS>5F+MEJ6PN7Y4BT#DSA_S%395.*,T7*2\SC+T[J091TFM)C)*1!)$[94
MI5G0I[E4?'%0DN8T9HI0%D[FC&7 'KE(TS6"'.?6[V(J*)$Z(50FJ(:_!2G5
MF(ERHE66A$XFU>%7QWB:9'+ZGJ@#(N3TJPQ=4E5*7BU>'L1),4GS8JD.6'E4
M[AC+"(W_LRP4ES/!\V+!2JM'_E1E>3F;*@=HUV&J5)(M2^W+2M.EF.4\^2^+
M=YT76:0#!5M03AYHNF1KU>9,&6$%6692 =D]BWO//[*VUAS:*D0HFMX_K#DD
MMK'9O.+LW;026SV8(']_*9N4UC5E,ZUS!X&D>5":#Z4%4%H(I44HFJY IU&@
M\TH&1PU&B1%)\Z T'TH+H+002HM0-%V,C=EF&WV4KE-T,ZVS MVM":?KVH/1
M8&/=9\]T/K1T 9060FD1BJ:KIK'';+,_MM\TW SI+):*=JRO:5OVIE;V2N9#
MRQ9 :2&4%J%HNE0:(\Q^P0F3@VHY.KUX9Q,Y])HR+F<U]<#6..Z"6F%0F@>E
M^5!: *6%4%J$HNE*;,PS>_1:XRZDZW,)I7E0F@^E!5!:"*5%*)HNQL9]LU_;
M?C,'Z"S*;0/.<5QG/-KJ7Z$F')060&DAE!:A:+K>&B?.-EMQ7VF6DYNGC/T@
MGT5L[GJA/AR4YD%I/I060&DAE!:A:+KZ&M?./GFMKA?JY4%I'I3F0VD!E!9"
M:1&*IE\FWCB$CMDX^[@LY">%UL,>D8=<J#Z8R8^D1'==6&5&=Y5C33O1YJI#
M9_.RE_V2^="R!5!:"*5%*)HNH,9"<,P6PJ^/W<P!.LO(WEX>&VY?N.%!H_I0
M6@"EA5!:A*+I<FO\ L>X!-SQB@8SK+.TS$43OW@-0MN-1QZT!CZ4%D!I(906
MH6BZ3!LGP3$["896L;*?7VP4H=Y"35N_+MP^L08GXY/-5A%Z<PZ4%K15PAI8
MVVU["(T;H6BZE!I[P3';"SLFJ^1_I*-[;X[365)(F@>E^5!: *6%4%J$HNG:
M;/P,9_A*4UD':FE :1Z4YD-I 9060FD1BJ:+L;$T'/,-0?OYL&9(9^&-]O)A
M]TOF0\L60&DAE!:A:+I4&L/!,1L.N_O4GW1HS?$ZJPI)\Z T'TH+H+002HM0
M-%VCC4GAC%^K;X5Z%E":!Z7Y4%H I8506H2BZ6)L/ O'?*L18)4/ZEW4M)<=
M6FA8'TH+H+002HM0-'W7D\:6<,VVQ(L=],=.W;,Y6E?Q06D>E.9#:0&4%D)I
M$8JF*[3Q/5S[E;IG%^IW0&D>E.9#:0&4%D)I$8JFB[%Q15RS]?#KW;,Y0&=1
M.MLFW-@^'H\V>F=H5!]*"Z"T$$J+4#1=;FN;DKVRNV'F=U;;MC$P:K$%/&A4
M'TH+H+002HM0-%UMC0'BOF" Y$(V8%?TB=ZE;'THV.$R/G.(SH*#>A]0F@^E
M!5!:"*5%*)HNR\;[<%_+^W"AW@>4YD%I/I060&DAE!:A:+H8&^_#-7L?FUOL
M+62?/$D6-%W?$:%5BU [!$KSH#2_IFE[XUG#K5%" (T:0FD1BJ:KK+%-7+-M
MLL].H&9$9T%!G1 HS8?2 G?[GI/!<'OG1FC0"$73]=18'*[Y/HR?W!C43.TL
M,:B_ :7Y4%I0TU[<'10:-4+1=(TUSH5K=B[VWB;4S.FL*NC-%5":7]/T2^@M
M9^1L]H10?P)*BU T?4?LQI\8F/V)*YY/&(N+:C>G>J,CM;N0G JHIJQ-8&9D
M5X%!:1Z4YM>T]8;&M5I69 )HV!!*BU T76&-OS PWU=QD2YFE%S212+D*%XS
MP+(DY^0RSQX8%XE:$_'8'<O$DC/C&H@Y8&?]07T'*,V'T@(H+832(A1-%VGC
M.PQ>:_>F =1O@-(\*,V'T@(H+832(A1-%V/C2@Q><"6JAG&RUC#&JX9QUZBO
M9KZT.[PY=&>!08T(*"V TD(H+4+1=(&M/0?%;$1<K1;5Z#Q?9NV#O,'VT,=M
M&?I<FF-U5A340X#2 B@MA-(B%$U75.,A#,S[05T];S(GI=6^UC'8?J)'ZU#Z
MTARILYZ@-@"4%D!I(906H6BZGAH;8&"V :I)0?GPQ<5.154(;3_RGNMLR@FZ
MD@^E^5!: *6%4%J$HE5RZJ\]2W'.^'WY7,U"#IAD7U8]6G#UZ>K9G1?E$RLW
M/K^TWWO5$S@;3/5 T"^4WZN]E%,VE4BK=RQ_#[QZQF;U1N2+\HF-=[D0^;Q\
M.6,T9EPED-]/\UP\OU$!5D\Z/?\_4$L#!!0    ( #R#HE9^6\T)P@(  "4'
M   9    >&PO=V]R:W-H965T<R]S:&5E=#<U+GAM;*U576_:,!3]*U?9-+72
MVI! 0ND@$A!8D<J'2KL]3'LPX0)6DSBSS<?^_6P'4LH"VL->B*]SS[GG7.+K
MYI;Q5[%"E+!+XE2TK)64V;UMBVB%"1&W+,-4O5DPGA"I0KZT1<:1S THB6VW
M4O'MA-#4"IIF;\*#)EO+F*8XX2#624+X[P[&;-NR'.NP\427*ZDW[*"9D25.
M4;YD$ZXBNV"9TP1305D*'!<MJ^W<=WV=;Q*^4=R*HS5H)S/&7G4PF+>LBA:$
M,492,Q#UV& 7XU@3*1F_]IQ645(#C]<']K[QKKS,B, NB[_3N5RUK#L+YK@@
MZU@^L>T#[OUXFB]BL3"_L,US_9H%T5I(ENS!2D%"T_Q)=OL^' $<_PS W0/<
M4\"Y"M4]H&J,YLJ,K9!($C0YVP+7V8I-+TQO#%JYH:G^%Z>2J[=4X60P[3[T
MPI?''HS[$(Z'O>GSH OM40C]\5-O\'4$W?%P,A[U1L]3N I1$AJ+:[B!EVD(
M5Q^OF[94(C25'>T+=O*"[IF"C@M#ELJ5@%XZQ_E[ ENI+RRX!PL=]R)CB-$M
M5)W/X%9<MT10]]_AS@4YU:*C5<-7/<,W2".6(#R3'8141#$3:X[PHST3DJN/
M]F=9RW+&6CFC/LCW(B,1MBQU4@7R#5K!IP^.7_E29O<_D;TS7RO,URZQ!Z&R
M+B2-RDSF2,\@]7#9!#>.U_!J=:_2M#?'#LHRZW<-I^Z\9;Z3YQ7RO(ORU,E7
MYSHM4Y<#_>.:7K56:_CU$W$7*Y2W%RYTUB^D^Q>E/S(A8(9J;B-DG&VHF:,J
M!)I_<)+L4)0Y\__NINNXC4;=.;56DGFF[_;1Q$F0+\T@%A"Q=2KSDUOL%K.^
M;4;<R7Y'W0'YR'ZCR2^0(>%+F@J(<:$H*[=UI8OG0SD/),O,7)LQJ::D6:[4
M/89<)ZCW"\;D(= %BILQ^ -02P,$%     @ /(.B5EHOD-#R P   PT  !D
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M20\YRN)P7]QHD>7GX[G0>-K.+V.@V*<: WR_$$(_W9@!RD\LXV]02P,$%
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M_7F@IOR<*()=Q;QA3S".) F&0"WZ:S2.D=6)X>/?'^PIB:(D\2. ^1U$$8;
MTX@CF /P@"%19-^#.^^C</6>"M?_P1P^ U!+ P04    "  \@Z)6EXJ[',
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M@7H'@=Z!>@>!WH%Z!X'>@7H'@=Z!>@>!WH%Z!X'>,?E9D$#O0+V#0.] O8-
M[Q7JO?I.O8?Q\UB&6\_7&J__G52/EW/+[?+7Y==.O%^LKCC7]Q7#\U]02P,$
M%     @ /(.B5BP!9SL; @  #BX  !,   !;0V]N=&5N=%]4>7!E<UTN>&UL
MS=K-3N,P% 7@5ZFR18WK?QA1-C#;&1;S B:YI5&3V+(-4]Y^G!20&#$5J$AS
M-HU:V_?<^$K?JI>_G@*EQ7[HQ[2NMCF';XRE9DN#2[4/-):5C8^#R^5KO&?!
M-3MW3TRL5H8U?LPTYF6>:E17ES>T<0]]7GS?EY]3Y\=U%:E/U>+ZL''*6E<N
MA+YK7"[K['%L_TI9/B?4Y>2\)VV[D,[*AHJ]FS"M_#O@^=S/1XJQ:VEQZV+^
MX8:RB^U[EO)33ZD^7N*='OUFTS74^N9A*$?J%"*Y-FV)\M#7AZ)GQY-SN6$Z
M?/*3\^<RQP++SMOH0RH3B_3YN)>13*>7H12BF+OCK_B:6$J?_'XT3;NE]H/9
MY7I_^[B;YY'8_#C]CM_.^+7^)_L0('U(D#X42!\:I \#TH<%Z>,<I(\+D#[X
M"J41%%$Y"JD<Q52.@BI'496CL,I17.4HL'(4606*K )%5H$BJT"15:#(*E!D
M%2BR"A19!8JL D56B2*K1)%5HL@J4625*+)*%%DEBJP215:)(JM$D56AR*I0
M9%4HLBH4616*K I%5H4BJT*15:'(JE!DU2BR:A19-8JL&D56C2*K1I%5H\BJ
M4635*+)J%%D-BJP&15:#(JM!D=6@R&I09#4HLAH460V*K 9%5HLBJT61U:+(
M:E%DM2BR6A19+8JL%D56BR*K19'U_'_*>N?][HOCYV<]N&Y\R6?SW\"O_@!0
M2P$"% ,4    "  [@Z)6!T%-8H$   "Q    $               @ $
M9&]C4')O<',O87!P+GAM;%!+ 0(4 Q0    ( #N#HE:MI>1D[@   "L"   1
M              "  :\   !D;V-0<F]P<R]C;W)E+GAM;%!+ 0(4 Q0    (
M #N#HE:97)PC$ 8  )PG   3              "  <P!  !X;"]T:&5M92]T
M:&5M93$N>&UL4$L! A0#%     @ .X.B5O*G=URK!P  \#$  !@
M     ("!#0@  'AL+W=O<FMS:&5E=',O<VAE970Q+GAM;%!+ 0(4 Q0    (
M #N#HE:*KMDU;P<  !\A   8              " @>X/  !X;"]W;W)K<VAE
M971S+W-H965T,BYX;6Q02P$"% ,4    "  [@Z)6 2=T HL"   I!P  &
M            @(&3%P  >&PO=V]R:W-H965T<R]S:&5E=#,N>&UL4$L! A0#
M%     @ .X.B5O*,,HCL!@  -QX  !@              ("!5!H  'AL+W=O
M<FMS:&5E=',O<VAE970T+GAM;%!+ 0(4 Q0    ( #N#HE:F&+)/YPH  .EB
M   8              " @78A  !X;"]W;W)K<VAE971S+W-H965T-2YX;6Q0
M2P$"% ,4    "  [@Z)65EG7DB8+  #+-@  &               @(&3+
M>&PO=V]R:W-H965T<R]S:&5E=#8N>&UL4$L! A0#%     @ .X.B5AD3D3$C
M*P  Z7X  !@              ("![S<  'AL+W=O<FMS:&5E=',O<VAE970W
M+GAM;%!+ 0(4 Q0    ( #N#HE8C31--^ @  .\4   8              "
M@4AC  !X;"]W;W)K<VAE971S+W-H965T."YX;6Q02P$"% ,4    "  [@Z)6
M68.#)H<)  !$%@  &               @(%V;   >&PO=V]R:W-H965T<R]S
M:&5E=#DN>&UL4$L! A0#%     @ .X.B5A_QC2"S @  RP4  !D
M     ("!,W8  'AL+W=O<FMS:&5E=',O<VAE970Q,"YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( #N#HE:3_M7DO (  .(%   9              "
M@;:*  !X;"]W;W)K<VAE971S+W-H965T,34N>&UL4$L! A0#%     @ .X.B
M5@_:C*:@"0  (QL  !D              ("!J8T  'AL+W=O<FMS:&5E=',O
M<VAE970Q-BYX;6Q02P$"% ,4    "  [@Z)6T$8BP3T(  #.$@  &0
M        @(& EP  >&PO=V]R:W-H965T<R]S:&5E=#$W+GAM;%!+ 0(4 Q0
M   ( #N#HE:?W>=J:00  %0*   9              " @?2?  !X;"]W;W)K
M<VAE971S+W-H965T,3@N>&UL4$L! A0#%     @ .X.B5O46()$9!P  %!
M !D              ("!E*0  'AL+W=O<FMS:&5E=',O<VAE970Q.2YX;6Q0
M2P$"% ,4    "  [@Z)6V^X5.2$-  "I*   &0              @('DJP
M>&PO=V]R:W-H965T<R]S:&5E=#(P+GAM;%!+ 0(4 Q0    ( #N#HE:S5X"%
MU@\   <V   9              " @3RY  !X;"]W;W)K<VAE971S+W-H965T
M,C$N>&UL4$L! A0#%     @ .X.B5I1L5]:( P  5P<  !D
M ("!2<D  'AL+W=O<FMS:&5E=',O<VAE970R,BYX;6Q02P$"% ,4    "  [
M@Z)6[5<FIU@+   7'0  &0              @($(S0  >&PO=V]R:W-H965T
M<R]S:&5E=#(S+GAM;%!+ 0(4 Q0    ( #N#HE;S%PW!_00  (H+   9
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M970R."YX;6Q02P$"% ,4    "  [@Z)6F5BOH.,"  "A!@  &0
M    @('>& $ >&PO=V]R:W-H965T<R]S:&5E=#(Y+GAM;%!+ 0(4 Q0    (
M #N#HE;>$%)98 ,  "H'   9              " @?@; 0!X;"]W;W)K<VAE
M971S+W-H965T,S N>&UL4$L! A0#%     @ .X.B5J1[G7=, P  )@<  !D
M             ("!CQ\! 'AL+W=O<FMS:&5E=',O<VAE970S,2YX;6Q02P$"
M% ,4    "  [@Z)60PPV':,#  "4!P  &0              @($2(P$ >&PO
M=V]R:W-H965T<R]S:&5E=#,R+GAM;%!+ 0(4 Q0    ( #N#HE8Q:?O2^ 4
M $42   9              " @>PF 0!X;"]W;W)K<VAE971S+W-H965T,S,N
M>&UL4$L! A0#%     @ .X.B5A[;,%FW @  "P8  !D              ("!
M&RT! 'AL+W=O<FMS:&5E=',O<VAE970S-"YX;6Q02P$"% ,4    "  [@Z)6
M,%=%/,4#  #;"   &0              @($), $ >&PO=V]R:W-H965T<R]S
M:&5E=#,U+GAM;%!+ 0(4 Q0    ( #N#HE9X85TS\@,    *   9
M      " @04T 0!X;"]W;W)K<VAE971S+W-H965T,S8N>&UL4$L! A0#%
M  @ .X.B5@=^DP?&!P  C!H  !D              ("!+C@! 'AL+W=O<FMS
M:&5E=',O<VAE970S-RYX;6Q02P$"% ,4    "  [@Z)6$R*%^D$&  !0$
M&0              @($K0 $ >&PO=V]R:W-H965T<R]S:&5E=#,X+GAM;%!+
M 0(4 Q0    ( #N#HE9;Q9K.H (  (@&   9              " @:-& 0!X
M;"]W;W)K<VAE971S+W-H965T,SDN>&UL4$L! A0#%     @ .X.B5MYQK23R
M @  K@L  !D              ("!>DD! 'AL+W=O<FMS:&5E=',O<VAE970T
M,"YX;6Q02P$"% ,4    "  [@Z)64\N\?F<.   )E@  &0
M@(&C3 $ >&PO=V]R:W-H965T<R]S:&5E=#0Q+GAM;%!+ 0(4 Q0    ( #N#
MHE9N14Y*-@8  "4<   9              " @4%; 0!X;"]W;W)K<VAE971S
M+W-H965T-#(N>&UL4$L! A0#%     @ .X.B5GOE#B; !   $A8  !D
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M=#0W+GAM;%!+ 0(4 Q0    ( #N#HE;V/*8!E@(  - &   9
M  " @?AY 0!X;"]W;W)K<VAE971S+W-H965T-#@N>&UL4$L! A0#%     @
M.X.B5@VEO[// @  T@<  !D              ("!Q7P! 'AL+W=O<FMS:&5E
M=',O<VAE970T.2YX;6Q02P$"% ,4    "  [@Z)60"$#D5T$  "-%P  &0
M            @('+?P$ >&PO=V]R:W-H965T<R]S:&5E=#4P+GAM;%!+ 0(4
M Q0    ( #N#HE;P+<PR^P(  (8)   9              " @5^$ 0!X;"]W
M;W)K<VAE971S+W-H965T-3$N>&UL4$L! A0#%     @ .X.B5D^GIZ/D!
M$1X  !D              ("!D8<! 'AL+W=O<FMS:&5E=',O<VAE970U,BYX
M;6Q02P$"% ,4    "  [@Z)6=2+U%',$    %@  &0              @(&L
MC $ >&PO=V]R:W-H965T<R]S:&5E=#4S+GAM;%!+ 0(4 Q0    ( #N#HE;P
M)&@4_ ,  #0-   9              " @5:1 0!X;"]W;W)K<VAE971S+W-H
M965T-30N>&UL4$L! A0#%     @ .X.B5IID78#Q P  #!4  !D
M     ("!B94! 'AL+W=O<FMS:&5E=',O<VAE970U-2YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( #N#HE;V_RGFS (  +T)   9              "
M@9&M 0!X;"]W;W)K<VAE971S+W-H965T-C N>&UL4$L! A0#%     @ .X.B
M5D4=/(!T!P  MT4  !D              ("!E+ ! 'AL+W=O<FMS:&5E=',O
M<VAE970V,2YX;6Q02P$"% ,4    "  [@Z)6S[=Z[!D#  !N"   &0
M        @($_N $ >&PO=V]R:W-H965T<R]S:&5E=#8R+GAM;%!+ 0(4 Q0
M   ( #N#HE;45V;:8P,   P,   9              " @8^[ 0!X;"]W;W)K
M<VAE971S+W-H965T-C,N>&UL4$L! A0#%     @ .X.B5J]SY)E)!   #1,
M !D              ("!*;\! 'AL+W=O<FMS:&5E=',O<VAE970V-"YX;6Q0
M2P$"% ,4    "  [@Z)6T4.6U<P"  !M!P  &0              @(&IPP$
M>&PO=V]R:W-H965T<R]S:&5E=#8U+GAM;%!+ 0(4 Q0    ( #N#HE8M+.@Z
M:@8  +8Q   9              " @:S& 0!X;"]W;W)K<VAE971S+W-H965T
M-C8N>&UL4$L! A0#%     @ .X.B5OYNFS1=%@  K#8! !D
M ("!3<T! 'AL+W=O<FMS:&5E=',O<VAE970V-RYX;6Q02P$"% ,4    "  [
M@Z)632+OQH<"   8"   &0              @('AXP$ >&PO=V]R:W-H965T
M<R]S:&5E=#8X+GAM;%!+ 0(4 Q0    ( #N#HE8/J>Z1&P<  (TJ   9
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M970W,RYX;6Q02P$"% ,4    "  \@Z)6R;[RW9L+  #U=   &0
M    @('J+ ( >&PO=V]R:W-H965T<R]S:&5E=#<T+GAM;%!+ 0(4 Q0    (
M #R#HE9^6\T)P@(  "4'   9              " @;PX @!X;"]W;W)K<VAE
M971S+W-H965T-S4N>&UL4$L! A0#%     @ /(.B5EHOD-#R P   PT  !D
M             ("!M3L" 'AL+W=O<FMS:&5E=',O<VAE970W-BYX;6Q02P$"
M% ,4    "  \@Z)6OA7+QG@#   4#   &0              @('>/P( >&PO
M=V]R:W-H965T<R]S:&5E=#<W+GAM;%!+ 0(4 Q0    ( #R#HE8THIO:\0,
M #\.   9              " @8U# @!X;"]W;W)K<VAE971S+W-H965T-S@N
M>&UL4$L! A0#%     @ /(.B5@:QQ;X*!   ;A$  !D              ("!
MM4<" 'AL+W=O<FMS:&5E=',O<VAE970W.2YX;6Q02P$"% ,4    "  \@Z)6
M\_.*1<@"  !S"   &0              @('V2P( >&PO=V]R:W-H965T<R]S
M:&5E=#@P+GAM;%!+ 0(4 Q0    ( #R#HE83<L/T2@,  ,X4   -
M      "  ?5. @!X;"]S='EL97,N>&UL4$L! A0#%     @ /(.B5I>*NQS
M    $P(   L              ( !:E(" %]R96QS+RYR96QS4$L! A0#%
M  @ /(.B5M*+QIV,!@  #S4   \              ( !4U," 'AL+W=O<FMB
M;V]K+GAM;%!+ 0(4 Q0    ( #R#HE:TQ0JN: (  $<O   :
M  "  0Q: @!X;"]?<F5L<R]W;W)K8F]O:RYX;6PN<F5L<U!+ 0(4 Q0    (
M #R#HE8L 6<[&P(   XN   3              "  :Q< @!;0V]N=&5N=%]4
?>7!E<UTN>&UL4$L%!@    !8 %@ 'Q@  /A> @    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>114
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>115
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>116
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.23.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>326</ContextCount>
  <ElementCount>495</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>92</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>5</UnitCount>
  <MyReports>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://qualigeninc.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>00000002 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://qualigeninc.com/role/BalanceSheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>00000003 - Statement - Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://qualigeninc.com/role/BalanceSheetsParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>00000004 - Statement - Consolidated Statements of Operations and Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://qualigeninc.com/role/StatementsOfOperationsAndComprehensiveLoss</Role>
      <ShortName>Consolidated Statements of Operations and Comprehensive Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>00000005 - Statement - Consolidated Statements of Changes in Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://qualigeninc.com/role/StatementsOfChangesInStockholdersEquity</Role>
      <ShortName>Consolidated Statements of Changes in Stockholders' Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>00000006 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://qualigeninc.com/role/StatementsOfCashFlows</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>00000007 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND ESTIMATES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://qualigeninc.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesAndEstimates</Role>
      <ShortName>ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND ESTIMATES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>00000008 - Disclosure - LIQUIDITY AND GOING CONCERN</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://qualigeninc.com/role/LiquidityAndGoingConcern</Role>
      <ShortName>LIQUIDITY AND GOING CONCERN</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>00000009 - Disclosure - ACQUISITION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://qualigeninc.com/role/Acquisition</Role>
      <ShortName>ACQUISITION</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>00000010 - Disclosure - INVENTORY, NET</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://qualigeninc.com/role/InventoryNet</Role>
      <ShortName>INVENTORY, NET</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>00000011 - Disclosure - PREPAID EXPENSES AND OTHER CURRENT ASSETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://qualigeninc.com/role/PrepaidExpensesAndOtherCurrentAssets</Role>
      <ShortName>PREPAID EXPENSES AND OTHER CURRENT ASSETS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>00000012 - Disclosure - PROPERTY AND EQUIPMENT, NET</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://qualigeninc.com/role/PropertyAndEquipmentNet</Role>
      <ShortName>PROPERTY AND EQUIPMENT, NET</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>00000013 - Disclosure - GOODWILL, IPR&amp;D AND OTHER INTANGIBLES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://qualigeninc.com/role/GoodwillIprdAndOtherIntangibles</Role>
      <ShortName>GOODWILL, IPR&amp;D AND OTHER INTANGIBLES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>00000014 - Disclosure - ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://qualigeninc.com/role/AccruedExpensesAndOtherCurrentLiabilities</Role>
      <ShortName>ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>00000015 - Disclosure - SHORT TERM DEBT - RELATED PARTY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://qualigeninc.com/role/ShortTermDebt-RelatedParty</Role>
      <ShortName>SHORT TERM DEBT - RELATED PARTY</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>00000016 - Disclosure - WARRANT LIABILITIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://qualigeninc.com/role/WarrantLiabilities</Role>
      <ShortName>WARRANT LIABILITIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>00000017 - Disclosure - CONVERTIBLE DEBT - RELATED PARTY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://qualigeninc.com/role/ConvertibleDebt-RelatedParty</Role>
      <ShortName>CONVERTIBLE DEBT - RELATED PARTY</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>00000018 - Disclosure - EARNINGS (LOSS) PER SHARE</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://qualigeninc.com/role/EarningsLossPerShare</Role>
      <ShortName>EARNINGS (LOSS) PER SHARE</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>00000019 - Disclosure - COMMITMENTS AND CONTINGENCIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://qualigeninc.com/role/CommitmentsAndContingencies</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>00000020 - Disclosure - RESEARCH AND LICENSE AGREEMENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://qualigeninc.com/role/ResearchAndLicenseAgreements</Role>
      <ShortName>RESEARCH AND LICENSE AGREEMENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>00000021 - Disclosure - STOCKHOLDERS??? EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://qualigeninc.com/role/StockholdersEquity</Role>
      <ShortName>STOCKHOLDERS??? EQUITY</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>00000022 - Disclosure - RELATED PARTY TRANSACTIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://qualigeninc.com/role/RelatedPartyTransactions</Role>
      <ShortName>RELATED PARTY TRANSACTIONS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>00000023 - Disclosure - INCOME TAXES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://qualigeninc.com/role/IncomeTaxes</Role>
      <ShortName>INCOME TAXES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>00000024 - Disclosure - SUBSEQUENT EVENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://qualigeninc.com/role/SubsequentEvents</Role>
      <ShortName>SUBSEQUENT EVENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>00000025 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND ESTIMATES (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://qualigeninc.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesAndEstimatesPolicies</Role>
      <ShortName>ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND ESTIMATES (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>00000026 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND ESTIMATES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://qualigeninc.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesAndEstimatesTables</Role>
      <ShortName>ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND ESTIMATES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://qualigeninc.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesAndEstimates</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>00000027 - Disclosure - ACQUISITION (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://qualigeninc.com/role/AcquisitionTables</Role>
      <ShortName>ACQUISITION (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://qualigeninc.com/role/Acquisition</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>00000028 - Disclosure - INVENTORY, NET (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://qualigeninc.com/role/InventoryNetTables</Role>
      <ShortName>INVENTORY, NET (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://qualigeninc.com/role/InventoryNet</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>00000029 - Disclosure - PREPAID EXPENSES AND OTHER CURRENT ASSETS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://qualigeninc.com/role/PrepaidExpensesAndOtherCurrentAssetsTables</Role>
      <ShortName>PREPAID EXPENSES AND OTHER CURRENT ASSETS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://qualigeninc.com/role/PrepaidExpensesAndOtherCurrentAssets</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>00000030 - Disclosure - PROPERTY AND EQUIPMENT, NET (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://qualigeninc.com/role/PropertyAndEquipmentNetTables</Role>
      <ShortName>PROPERTY AND EQUIPMENT, NET (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://qualigeninc.com/role/PropertyAndEquipmentNet</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>00000031 - Disclosure - GOODWILL, IPR&amp;D AND OTHER INTANGIBLES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://qualigeninc.com/role/GoodwillIprdAndOtherIntangiblesTables</Role>
      <ShortName>GOODWILL, IPR&amp;D AND OTHER INTANGIBLES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://qualigeninc.com/role/GoodwillIprdAndOtherIntangibles</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>00000032 - Disclosure - ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://qualigeninc.com/role/AccruedExpensesAndOtherCurrentLiabilitiesTables</Role>
      <ShortName>ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://qualigeninc.com/role/AccruedExpensesAndOtherCurrentLiabilities</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>00000033 - Disclosure - WARRANT LIABILITIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://qualigeninc.com/role/WarrantLiabilitiesTables</Role>
      <ShortName>WARRANT LIABILITIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://qualigeninc.com/role/WarrantLiabilities</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>00000034 - Disclosure - CONVERTIBLE DEBT - RELATED PARTY (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://qualigeninc.com/role/ConvertibleDebt-RelatedPartyTables</Role>
      <ShortName>CONVERTIBLE DEBT - RELATED PARTY (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://qualigeninc.com/role/ConvertibleDebt-RelatedParty</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>00000035 - Disclosure - EARNINGS (LOSS) PER SHARE (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://qualigeninc.com/role/EarningsLossPerShareTables</Role>
      <ShortName>EARNINGS (LOSS) PER SHARE (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://qualigeninc.com/role/EarningsLossPerShare</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>00000036 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://qualigeninc.com/role/CommitmentsAndContingenciesTables</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://qualigeninc.com/role/CommitmentsAndContingencies</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>00000037 - Disclosure - STOCKHOLDERS??? EQUITY (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://qualigeninc.com/role/StockholdersEquityTables</Role>
      <ShortName>STOCKHOLDERS??? EQUITY (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://qualigeninc.com/role/StockholdersEquity</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>00000038 - Disclosure - INCOME TAXES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://qualigeninc.com/role/IncomeTaxesTables</Role>
      <ShortName>INCOME TAXES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://qualigeninc.com/role/IncomeTaxes</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>00000039 - Disclosure - SCHEDULE OF ACCOUNTS RECEIVABLE (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://qualigeninc.com/role/ScheduleOfAccountsReceivableDetails</Role>
      <ShortName>SCHEDULE OF ACCOUNTS RECEIVABLE (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>00000040 - Disclosure - SCHEDULE OF USEFUL LIVES OF PROPERTY AND EQUIPMENT (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://qualigeninc.com/role/ScheduleOfUsefulLivesOfPropertyAndEquipmentDetails</Role>
      <ShortName>SCHEDULE OF USEFUL LIVES OF PROPERTY AND EQUIPMENT (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>00000041 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND ESTIMATES (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://qualigeninc.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesAndEstimatesDetailsNarrative</Role>
      <ShortName>ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND ESTIMATES (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://qualigeninc.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesAndEstimatesTables</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>00000042 - Disclosure - LIQUIDITY AND GOING CONCERN (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://qualigeninc.com/role/LiquidityAndGoingConcernDetailsNarrative</Role>
      <ShortName>LIQUIDITY AND GOING CONCERN (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://qualigeninc.com/role/LiquidityAndGoingConcern</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>00000043 - Disclosure - SCHEDULE OF CONSIDERATION TRANSFERRED (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://qualigeninc.com/role/ScheduleOfConsiderationTransferredDetails</Role>
      <ShortName>SCHEDULE OF CONSIDERATION TRANSFERRED (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>00000044 - Disclosure - SCHEDULE OF CONSIDERATION TRANSFERRED (Details) (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://qualigeninc.com/role/ScheduleOfConsiderationTransferredDetailsParenthetical</Role>
      <ShortName>SCHEDULE OF CONSIDERATION TRANSFERRED (Details) (Parenthetical)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>00000045 - Disclosure - SCHEDULE OF ASSETS ACQUIRED AND LIABILITIES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://qualigeninc.com/role/ScheduleOfAssetsAcquiredAndLiabilitiesDetails</Role>
      <ShortName>SCHEDULE OF ASSETS ACQUIRED AND LIABILITIES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>00000046 - Disclosure - SCHEDULE OF PRO FORMA INFORMATION (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://qualigeninc.com/role/ScheduleOfProFormaInformationDetails</Role>
      <ShortName>SCHEDULE OF PRO FORMA INFORMATION (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>00000047 - Disclosure - ACQUISITION (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://qualigeninc.com/role/AcquisitionDetailsNarrative</Role>
      <ShortName>ACQUISITION (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://qualigeninc.com/role/AcquisitionTables</ParentRole>
      <Position>47</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>00000048 - Disclosure - SCHEDULE OF INVENTORY (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://qualigeninc.com/role/ScheduleOfInventoryDetails</Role>
      <ShortName>SCHEDULE OF INVENTORY (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>00000049 - Disclosure - SCHEDULE OF PREPAID EXPENSES AND OTHER CURRENT ASSETS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://qualigeninc.com/role/ScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails</Role>
      <ShortName>SCHEDULE OF PREPAID EXPENSES AND OTHER CURRENT ASSETS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>00000050 - Disclosure - SCHEDULE OF PROPERTY AND EQUIPMENT (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://qualigeninc.com/role/ScheduleOfPropertyAndEquipmentDetails</Role>
      <ShortName>SCHEDULE OF PROPERTY AND EQUIPMENT (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>00000051 - Disclosure - PROPERTY AND EQUIPMENT, NET (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://qualigeninc.com/role/PropertyAndEquipmentNetDetailsNarrative</Role>
      <ShortName>PROPERTY AND EQUIPMENT, NET (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://qualigeninc.com/role/PropertyAndEquipmentNetTables</ParentRole>
      <Position>51</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>00000052 - Disclosure - SCHEDULE OF GOODWILL AND OTHER INTANGIBLE (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://qualigeninc.com/role/ScheduleOfGoodwillAndOtherIntangibleDetails</Role>
      <ShortName>SCHEDULE OF GOODWILL AND OTHER INTANGIBLE (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>00000053 - Disclosure - GOODWILL, IPR&amp;D AND OTHER INTANGIBLES (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://qualigeninc.com/role/GoodwillIprdAndOtherIntangiblesDetailsNarrative</Role>
      <ShortName>GOODWILL, IPR&amp;D AND OTHER INTANGIBLES (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://qualigeninc.com/role/GoodwillIprdAndOtherIntangiblesTables</ParentRole>
      <Position>53</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>00000054 - Disclosure - SCHEDULE OF ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://qualigeninc.com/role/ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails</Role>
      <ShortName>SCHEDULE OF ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>00000055 - Disclosure - SHORT TERM DEBT - RELATED PARTY (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://qualigeninc.com/role/ShortTermDebt-RelatedPartyDetailsNarrative</Role>
      <ShortName>SHORT TERM DEBT - RELATED PARTY (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://qualigeninc.com/role/ShortTermDebt-RelatedParty</ParentRole>
      <Position>55</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>00000056 - Disclosure - SCHEDULE OF WARRANTS ACTIVITY (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://qualigeninc.com/role/ScheduleOfWarrantsActivityDetails</Role>
      <ShortName>SCHEDULE OF WARRANTS ACTIVITY (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>00000057 - Disclosure - SCHEDULE OF FAIR VALUE HIERARCHY FOR WARRANT LIABILITIES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://qualigeninc.com/role/ScheduleOfFairValueHierarchyForWarrantLiabilitiesDetails</Role>
      <ShortName>SCHEDULE OF FAIR VALUE HIERARCHY FOR WARRANT LIABILITIES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>00000058 - Disclosure - SCHEDULE OF ASSUMPTIONS OF WARRANT LIABILITIES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://qualigeninc.com/role/ScheduleOfAssumptionsOfWarrantLiabilitiesDetails</Role>
      <ShortName>SCHEDULE OF ASSUMPTIONS OF WARRANT LIABILITIES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>00000059 - Disclosure - WARRANT LIABILITIES (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://qualigeninc.com/role/WarrantLiabilitiesDetailsNarrative</Role>
      <ShortName>WARRANT LIABILITIES (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://qualigeninc.com/role/WarrantLiabilitiesTables</ParentRole>
      <Position>59</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>00000060 - Disclosure - SCHEDULE OF SENIOR SECURED CONVERTIBLE DEBT (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://qualigeninc.com/role/ScheduleOfSeniorSecuredConvertibleDebtDetails</Role>
      <ShortName>SCHEDULE OF SENIOR SECURED CONVERTIBLE DEBT (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>00000061 - Disclosure - CONVERTIBLE DEBT - RELATED PARTY (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://qualigeninc.com/role/ConvertibleDebt-RelatedPartyDetailsNarrative</Role>
      <ShortName>CONVERTIBLE DEBT - RELATED PARTY (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://qualigeninc.com/role/ConvertibleDebt-RelatedPartyTables</ParentRole>
      <Position>61</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>00000062 - Disclosure - SCHEDULE OF EARNINGS PER SHARE BASIC AND DILUTED (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://qualigeninc.com/role/ScheduleOfEarningsPerShareBasicAndDilutedDetails</Role>
      <ShortName>SCHEDULE OF EARNINGS PER SHARE BASIC AND DILUTED (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>00000063 - Disclosure - SCHEDULE OF DILUTIVE SECURITIES EXCLUDED FROM DILUTED NET LOSS PER SHARE (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://qualigeninc.com/role/ScheduleOfDilutiveSecuritiesExcludedFromDilutedNetLossPerShareDetails</Role>
      <ShortName>SCHEDULE OF DILUTIVE SECURITIES EXCLUDED FROM DILUTED NET LOSS PER SHARE (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>00000064 - Disclosure - SCHEDULE OF OPERATING LEASE RIGHT OF USE ASSETS AND OPERATING LEASE LIABILITIES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://qualigeninc.com/role/ScheduleOfOperatingLeaseRightOfUseAssetsAndOperatingLeaseLiabilitiesDetails</Role>
      <ShortName>SCHEDULE OF OPERATING LEASE RIGHT OF USE ASSETS AND OPERATING LEASE LIABILITIES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>64</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>00000065 - Disclosure - SCHEDULE OF MATURITIES OF OPERATING LEASE LIABILITIES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://qualigeninc.com/role/ScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails</Role>
      <ShortName>SCHEDULE OF MATURITIES OF OPERATING LEASE LIABILITIES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>65</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>00000066 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://qualigeninc.com/role/CommitmentsAndContingenciesDetailsNarrative</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://qualigeninc.com/role/CommitmentsAndContingenciesTables</ParentRole>
      <Position>66</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>00000067 - Disclosure - RESEARCH AND LICENSE AGREEMENTS (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://qualigeninc.com/role/ResearchAndLicenseAgreementsDetailsNarrative</Role>
      <ShortName>RESEARCH AND LICENSE AGREEMENTS (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://qualigeninc.com/role/ResearchAndLicenseAgreements</ParentRole>
      <Position>67</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>00000068 - Disclosure - SCHEDULE OF RESERVED SHARES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://qualigeninc.com/role/ScheduleOfReservedSharesDetails</Role>
      <ShortName>SCHEDULE OF RESERVED SHARES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>68</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>00000069 - Disclosure - SCHEDULE OF STOCK OPTION ACTIVITY (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://qualigeninc.com/role/ScheduleOfStockOptionActivityDetails</Role>
      <ShortName>SCHEDULE OF STOCK OPTION ACTIVITY (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>69</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>00000070 - Disclosure - SCHEDULE OF ASSUMPTION USED IN BLACK-SCHOLES OPTION-PRICING METHOD (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://qualigeninc.com/role/ScheduleOfAssumptionUsedInBlack-scholesOption-pricingMethodDetails</Role>
      <ShortName>SCHEDULE OF ASSUMPTION USED IN BLACK-SCHOLES OPTION-PRICING METHOD (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>70</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>00000071 - Disclosure - SCHEDULE OF SHARE-BASED COMPENSATION EXPENSE (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://qualigeninc.com/role/ScheduleOfShare-basedCompensationExpenseDetails</Role>
      <ShortName>SCHEDULE OF SHARE-BASED COMPENSATION EXPENSE (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>71</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R72.htm</HtmlFileName>
      <LongName>00000072 - Disclosure - SCHEDULE OF WARRANT ACTIVITY (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://qualigeninc.com/role/ScheduleOfWarrantActivityDetails</Role>
      <ShortName>SCHEDULE OF WARRANT ACTIVITY (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>72</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R73.htm</HtmlFileName>
      <LongName>00000073 - Disclosure - STOCKHOLDERS??? EQUITY (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://qualigeninc.com/role/StockholdersEquityDetailsNarrative</Role>
      <ShortName>STOCKHOLDERS??? EQUITY (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://qualigeninc.com/role/StockholdersEquityTables</ParentRole>
      <Position>73</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R74.htm</HtmlFileName>
      <LongName>00000074 - Disclosure - RELATED PARTY TRANSACTIONS (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://qualigeninc.com/role/RelatedPartyTransactionsDetailsNarrative</Role>
      <ShortName>RELATED PARTY TRANSACTIONS (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://qualigeninc.com/role/RelatedPartyTransactions</ParentRole>
      <Position>74</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R75.htm</HtmlFileName>
      <LongName>00000075 - Disclosure - SCHEDULE OF DOMESTIC AND FOREIGN COMPONENTS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://qualigeninc.com/role/ScheduleOfDomesticAndForeignComponentsDetails</Role>
      <ShortName>SCHEDULE OF DOMESTIC AND FOREIGN COMPONENTS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>75</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R76.htm</HtmlFileName>
      <LongName>00000076 - Disclosure - SCHEDULE OF RECONCILIATIONS OF STATUTORY INCOME TAX RATE (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://qualigeninc.com/role/ScheduleOfReconciliationsOfStatutoryIncomeTaxRateDetails</Role>
      <ShortName>SCHEDULE OF RECONCILIATIONS OF STATUTORY INCOME TAX RATE (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>76</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R77.htm</HtmlFileName>
      <LongName>00000077 - Disclosure - SCHEDULE OF PROVISION FOR INCOME TAXES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://qualigeninc.com/role/ScheduleOfProvisionForIncomeTaxesDetails</Role>
      <ShortName>SCHEDULE OF PROVISION FOR INCOME TAXES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>77</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R78.htm</HtmlFileName>
      <LongName>00000078 - Disclosure - SCHEDULE OF DEFERRED TAX ASSETS AND LIABILITIES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://qualigeninc.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails</Role>
      <ShortName>SCHEDULE OF DEFERRED TAX ASSETS AND LIABILITIES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>78</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R79.htm</HtmlFileName>
      <LongName>00000079 - Disclosure - INCOME TAXES (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://qualigeninc.com/role/IncomeTaxesDetailsNarrative</Role>
      <ShortName>INCOME TAXES (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://qualigeninc.com/role/IncomeTaxesTables</ParentRole>
      <Position>79</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R80.htm</HtmlFileName>
      <LongName>00000080 - Disclosure - SUBSEQUENT EVENTS (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://qualigeninc.com/role/SubsequentEventsDetailsNarrative</Role>
      <ShortName>SUBSEQUENT EVENTS (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://qualigeninc.com/role/SubsequentEvents</ParentRole>
      <Position>80</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Warning">[ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 3 fact(s) appearing in ix:hidden were eligible for transformation: us-gaap:WarrantsAndRightsOutstandingMeasurementInput -  form10-k.htm 166, 167, 168</Log>
  </Logs>
  <InputFiles>
    <File doctype="10-K" original="form10-k.htm">form10-k.htm</File>
    <File>ex10-10.htm</File>
    <File>ex10-11.htm</File>
    <File>ex10-21.htm</File>
    <File>ex10-31.htm</File>
    <File>ex10-32.htm</File>
    <File>ex10-33.htm</File>
    <File>ex10-8.htm</File>
    <File>ex10-9.htm</File>
    <File>ex21-1.htm</File>
    <File>ex23-1.htm</File>
    <File>ex31-1.htm</File>
    <File>ex31-2.htm</File>
    <File>ex32-1.htm</File>
    <File>qlgn-20221231.xsd</File>
    <File>qlgn-20221231_cal.xml</File>
    <File>qlgn-20221231_def.xml</File>
    <File>qlgn-20221231_lab.xml</File>
    <File>qlgn-20221231_pre.xml</File>
  </InputFiles>
  <SupplementalFiles>
    <File>form10-k_001.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="905">http://fasb.org/us-gaap/2022</BaseTaxonomy>
    <BaseTaxonomy items="38">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>119
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "form10-k.htm": {
   "axisCustom": 0,
   "axisStandard": 22,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2022": 905,
    "http://xbrl.sec.gov/dei/2022": 38
   },
   "contextCount": 326,
   "dts": {
    "calculationLink": {
     "local": [
      "qlgn-20221231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "qlgn-20221231_def.xml"
     ]
    },
    "inline": {
     "local": [
      "form10-k.htm"
     ]
    },
    "labelLink": {
     "local": [
      "qlgn-20221231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "qlgn-20221231_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "qlgn-20221231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd",
      "https://xbrl.fasb.org/srt/2022q3/srt-sup-2022q3.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022q3/us-gaap-sup-2022q3.xsd",
      "https://xbrl.sec.gov/country/2022/country-2022.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd"
     ]
    }
   },
   "elementCount": 720,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2022": 86,
    "http://qualigeninc.com/20221231": 104,
    "http://xbrl.sec.gov/dei/2022": 3,
    "total": 193
   },
   "keyCustom": 131,
   "keyStandard": 364,
   "memberCustom": 48,
   "memberStandard": 36,
   "nsprefix": "QLGN",
   "nsuri": "http://qualigeninc.com/20221231",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "b",
       "span",
       "p",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "00000001 - Document - Cover",
     "menuCat": "Cover",
     "order": "1",
     "role": "http://qualigeninc.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "b",
       "span",
       "p",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000010 - Disclosure - INVENTORY, NET",
     "menuCat": "Notes",
     "order": "10",
     "role": "http://qualigeninc.com/role/InventoryNet",
     "shortName": "INVENTORY, NET",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "QLGN:PrepaidExpensesAndOtherCurrentAssetsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000011 - Disclosure - PREPAID EXPENSES AND OTHER CURRENT ASSETS",
     "menuCat": "Notes",
     "order": "11",
     "role": "http://qualigeninc.com/role/PrepaidExpensesAndOtherCurrentAssets",
     "shortName": "PREPAID EXPENSES AND OTHER CURRENT ASSETS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "QLGN:PrepaidExpensesAndOtherCurrentAssetsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000012 - Disclosure - PROPERTY AND EQUIPMENT, NET",
     "menuCat": "Notes",
     "order": "12",
     "role": "http://qualigeninc.com/role/PropertyAndEquipmentNet",
     "shortName": "PROPERTY AND EQUIPMENT, NET",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000013 - Disclosure - GOODWILL, IPR&D AND OTHER INTANGIBLES",
     "menuCat": "Notes",
     "order": "13",
     "role": "http://qualigeninc.com/role/GoodwillIprdAndOtherIntangibles",
     "shortName": "GOODWILL, IPR&D AND OTHER INTANGIBLES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000014 - Disclosure - ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES",
     "menuCat": "Notes",
     "order": "14",
     "role": "http://qualigeninc.com/role/AccruedExpensesAndOtherCurrentLiabilities",
     "shortName": "ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShortTermDebtTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000015 - Disclosure - SHORT TERM DEBT - RELATED PARTY",
     "menuCat": "Notes",
     "order": "15",
     "role": "http://qualigeninc.com/role/ShortTermDebt-RelatedParty",
     "shortName": "SHORT TERM DEBT - RELATED PARTY",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShortTermDebtTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "QLGN:WarrantLiabilitiesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000016 - Disclosure - WARRANT LIABILITIES",
     "menuCat": "Notes",
     "order": "16",
     "role": "http://qualigeninc.com/role/WarrantLiabilities",
     "shortName": "WARRANT LIABILITIES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "QLGN:WarrantLiabilitiesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000017 - Disclosure - CONVERTIBLE DEBT - RELATED PARTY",
     "menuCat": "Notes",
     "order": "17",
     "role": "http://qualigeninc.com/role/ConvertibleDebt-RelatedParty",
     "shortName": "CONVERTIBLE DEBT - RELATED PARTY",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000018 - Disclosure - EARNINGS (LOSS) PER SHARE",
     "menuCat": "Notes",
     "order": "18",
     "role": "http://qualigeninc.com/role/EarningsLossPerShare",
     "shortName": "EARNINGS (LOSS) PER SHARE",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000019 - Disclosure - COMMITMENTS AND CONTINGENCIES",
     "menuCat": "Notes",
     "order": "19",
     "role": "http://qualigeninc.com/role/CommitmentsAndContingencies",
     "shortName": "COMMITMENTS AND CONTINGENCIES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2022-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:Cash",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00000002 - Statement - Consolidated Balance Sheets",
     "menuCat": "Statements",
     "order": "2",
     "role": "http://qualigeninc.com/role/BalanceSheets",
     "shortName": "Consolidated Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2022-12-31",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:AssetsCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "QLGN:ResearchAndLicenseAgreementsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000020 - Disclosure - RESEARCH AND LICENSE AGREEMENTS",
     "menuCat": "Notes",
     "order": "20",
     "role": "http://qualigeninc.com/role/ResearchAndLicenseAgreements",
     "shortName": "RESEARCH AND LICENSE AGREEMENTS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "QLGN:ResearchAndLicenseAgreementsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000021 - Disclosure - STOCKHOLDERS\u2019 EQUITY",
     "menuCat": "Notes",
     "order": "21",
     "role": "http://qualigeninc.com/role/StockholdersEquity",
     "shortName": "STOCKHOLDERS\u2019 EQUITY",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000022 - Disclosure - RELATED PARTY TRANSACTIONS",
     "menuCat": "Notes",
     "order": "22",
     "role": "http://qualigeninc.com/role/RelatedPartyTransactions",
     "shortName": "RELATED PARTY TRANSACTIONS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000023 - Disclosure - INCOME TAXES",
     "menuCat": "Notes",
     "order": "23",
     "role": "http://qualigeninc.com/role/IncomeTaxes",
     "shortName": "INCOME TAXES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000024 - Disclosure - SUBSEQUENT EVENTS",
     "menuCat": "Notes",
     "order": "24",
     "role": "http://qualigeninc.com/role/SubsequentEvents",
     "shortName": "SUBSEQUENT EVENTS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "QLGN:OrganizationPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000025 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND ESTIMATES (Policies)",
     "menuCat": "Policies",
     "order": "25",
     "role": "http://qualigeninc.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesAndEstimatesPolicies",
     "shortName": "ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND ESTIMATES (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "QLGN:OrganizationPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:TradeAndOtherAccountsReceivablePolicy",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000026 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND ESTIMATES (Tables)",
     "menuCat": "Tables",
     "order": "26",
     "role": "http://qualigeninc.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesAndEstimatesTables",
     "shortName": "ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND ESTIMATES (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:TradeAndOtherAccountsReceivablePolicy",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:BusinessCombinationDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000027 - Disclosure - ACQUISITION (Tables)",
     "menuCat": "Tables",
     "order": "27",
     "role": "http://qualigeninc.com/role/AcquisitionTables",
     "shortName": "ACQUISITION (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:BusinessCombinationDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:InventoryDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000028 - Disclosure - INVENTORY, NET (Tables)",
     "menuCat": "Tables",
     "order": "28",
     "role": "http://qualigeninc.com/role/InventoryNetTables",
     "shortName": "INVENTORY, NET (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:InventoryDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "QLGN:PrepaidExpensesAndOtherCurrentAssetsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000029 - Disclosure - PREPAID EXPENSES AND OTHER CURRENT ASSETS (Tables)",
     "menuCat": "Tables",
     "order": "29",
     "role": "http://qualigeninc.com/role/PrepaidExpensesAndOtherCurrentAssetsTables",
     "shortName": "PREPAID EXPENSES AND OTHER CURRENT ASSETS (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "QLGN:PrepaidExpensesAndOtherCurrentAssetsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2022-12-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USDPShares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00000003 - Statement - Consolidated Balance Sheets (Parenthetical)",
     "menuCat": "Statements",
     "order": "3",
     "role": "http://qualigeninc.com/role/BalanceSheetsParenthetical",
     "shortName": "Consolidated Balance Sheets (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2022-12-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USDPShares",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000030 - Disclosure - PROPERTY AND EQUIPMENT, NET (Tables)",
     "menuCat": "Tables",
     "order": "30",
     "role": "http://qualigeninc.com/role/PropertyAndEquipmentNetTables",
     "shortName": "PROPERTY AND EQUIPMENT, NET (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000031 - Disclosure - GOODWILL, IPR&D AND OTHER INTANGIBLES (Tables)",
     "menuCat": "Tables",
     "order": "31",
     "role": "http://qualigeninc.com/role/GoodwillIprdAndOtherIntangiblesTables",
     "shortName": "GOODWILL, IPR&D AND OTHER INTANGIBLES (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000032 - Disclosure - ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Tables)",
     "menuCat": "Tables",
     "order": "32",
     "role": "http://qualigeninc.com/role/AccruedExpensesAndOtherCurrentLiabilitiesTables",
     "shortName": "ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "QLGN:WarrantLiabilitiesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000033 - Disclosure - WARRANT LIABILITIES (Tables)",
     "menuCat": "Tables",
     "order": "33",
     "role": "http://qualigeninc.com/role/WarrantLiabilitiesTables",
     "shortName": "WARRANT LIABILITIES (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "QLGN:WarrantLiabilitiesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:DebtDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConvertibleDebtTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000034 - Disclosure - CONVERTIBLE DEBT - RELATED PARTY (Tables)",
     "menuCat": "Tables",
     "order": "34",
     "role": "http://qualigeninc.com/role/ConvertibleDebt-RelatedPartyTables",
     "shortName": "CONVERTIBLE DEBT - RELATED PARTY (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:DebtDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConvertibleDebtTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:EarningsPerShareTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000035 - Disclosure - EARNINGS (LOSS) PER SHARE (Tables)",
     "menuCat": "Tables",
     "order": "35",
     "role": "http://qualigeninc.com/role/EarningsLossPerShareTables",
     "shortName": "EARNINGS (LOSS) PER SHARE (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:EarningsPerShareTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "QLGN:ScheduleOfOperatingLeaseRightOfUseAssetsAndLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000036 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables)",
     "menuCat": "Tables",
     "order": "36",
     "role": "http://qualigeninc.com/role/CommitmentsAndContingenciesTables",
     "shortName": "COMMITMENTS AND CONTINGENCIES (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "QLGN:ScheduleOfOperatingLeaseRightOfUseAssetsAndLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "QLGN:ScheduleOfReservedSharesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000037 - Disclosure - STOCKHOLDERS\u2019 EQUITY (Tables)",
     "menuCat": "Tables",
     "order": "37",
     "role": "http://qualigeninc.com/role/StockholdersEquityTables",
     "shortName": "STOCKHOLDERS\u2019 EQUITY (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "QLGN:ScheduleOfReservedSharesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000038 - Disclosure - INCOME TAXES (Tables)",
     "menuCat": "Tables",
     "order": "38",
     "role": "http://qualigeninc.com/role/IncomeTaxesTables",
     "shortName": "INCOME TAXES (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
       "us-gaap:TradeAndOtherAccountsReceivablePolicy",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2022-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AccountsReceivableGrossCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000039 - Disclosure - SCHEDULE OF ACCOUNTS RECEIVABLE (Details)",
     "menuCat": "Details",
     "order": "39",
     "role": "http://qualigeninc.com/role/ScheduleOfAccountsReceivableDetails",
     "shortName": "SCHEDULE OF ACCOUNTS RECEIVABLE (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
       "us-gaap:TradeAndOtherAccountsReceivablePolicy",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2022-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AccountsReceivableGrossCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00000004 - Statement - Consolidated Statements of Operations and Comprehensive Loss",
     "menuCat": "Statements",
     "order": "4",
     "role": "http://qualigeninc.com/role/StatementsOfOperationsAndComprehensiveLoss",
     "shortName": "Consolidated Statements of Operations and Comprehensive Loss",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": "0",
      "lang": null,
      "name": "QLGN:CostOfProductSales",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "QLGN:ScheduleOfUsefulLivesOfPropertyAndEquipmentTableTextBlock",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-012022-12-31_us-gaap_MachineryAndEquipmentMember",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000040 - Disclosure - SCHEDULE OF USEFUL LIVES OF PROPERTY AND EQUIPMENT (Details)",
     "menuCat": "Details",
     "order": "40",
     "role": "http://qualigeninc.com/role/ScheduleOfUsefulLivesOfPropertyAndEquipmentDetails",
     "shortName": "SCHEDULE OF USEFUL LIVES OF PROPERTY AND EQUIPMENT (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "QLGN:ScheduleOfUsefulLivesOfPropertyAndEquipmentTableTextBlock",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-012022-12-31_us-gaap_MachineryAndEquipmentMember",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock",
       "us-gaap:BusinessCombinationDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-05-242022-05-26",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockIssuedDuringPeriodSharesAcquisitions",
      "reportCount": 1,
      "unitRef": "Shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000041 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND ESTIMATES (Details Narrative)",
     "menuCat": "Details",
     "order": "41",
     "role": "http://qualigeninc.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesAndEstimatesDetailsNarrative",
     "shortName": "ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND ESTIMATES (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:AssetImpairmentCharges",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2022-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:Cash",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000042 - Disclosure - LIQUIDITY AND GOING CONCERN (Details Narrative)",
     "menuCat": "Details",
     "order": "42",
     "role": "http://qualigeninc.com/role/LiquidityAndGoingConcernDetailsNarrative",
     "shortName": "LIQUIDITY AND GOING CONCERN (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteStockSplit",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:BusinessCombinationConsiderationTransferred1",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000043 - Disclosure - SCHEDULE OF CONSIDERATION TRANSFERRED (Details)",
     "menuCat": "Details",
     "order": "43",
     "role": "http://qualigeninc.com/role/ScheduleOfConsiderationTransferredDetails",
     "shortName": "SCHEDULE OF CONSIDERATION TRANSFERRED (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock",
       "us-gaap:BusinessCombinationDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-05-242022-05-26_custom_NanoSynexLtdMember",
      "decimals": "0",
      "lang": null,
      "name": "QLGN:PaymentsToAcquireBusinesses",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock",
       "us-gaap:BusinessCombinationDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-05-242022-05-26",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockIssuedDuringPeriodSharesAcquisitions",
      "reportCount": 1,
      "unitRef": "Shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000044 - Disclosure - SCHEDULE OF CONSIDERATION TRANSFERRED (Details) (Parenthetical)",
     "menuCat": "Details",
     "order": "44",
     "role": "http://qualigeninc.com/role/ScheduleOfConsiderationTransferredDetailsParenthetical",
     "shortName": "SCHEDULE OF CONSIDERATION TRANSFERRED (Details) (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock",
       "us-gaap:BusinessCombinationDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-05-242022-05-26_custom_AlphaCapitalAnstaltMember",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:StockIssuedDuringPeriodSharesAcquisitions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
       "us-gaap:BusinessCombinationDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2022-05-26",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000045 - Disclosure - SCHEDULE OF ASSETS ACQUIRED AND LIABILITIES (Details)",
     "menuCat": "Details",
     "order": "45",
     "role": "http://qualigeninc.com/role/ScheduleOfAssetsAcquiredAndLiabilitiesDetails",
     "shortName": "SCHEDULE OF ASSETS ACQUIRED AND LIABILITIES (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
       "us-gaap:BusinessCombinationDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2022-05-26",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:BusinessAcquisitionProFormaInformationTextBlock",
       "us-gaap:BusinessCombinationDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:BusinessAcquisitionsProFormaRevenue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000046 - Disclosure - SCHEDULE OF PRO FORMA INFORMATION (Details)",
     "menuCat": "Details",
     "order": "46",
     "role": "http://qualigeninc.com/role/ScheduleOfProFormaInformationDetails",
     "shortName": "SCHEDULE OF PRO FORMA INFORMATION (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:BusinessAcquisitionProFormaInformationTextBlock",
       "us-gaap:BusinessCombinationDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:BusinessAcquisitionsProFormaRevenue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock",
       "us-gaap:BusinessCombinationDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-05-242022-05-26",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockIssuedDuringPeriodSharesAcquisitions",
      "reportCount": 1,
      "unitRef": "Shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000047 - Disclosure - ACQUISITION (Details Narrative)",
     "menuCat": "Details",
     "order": "47",
     "role": "http://qualigeninc.com/role/AcquisitionDetailsNarrative",
     "shortName": "ACQUISITION (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:BusinessCombinationDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:MinorityInterestDecreaseFromRedemptions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "us-gaap:InventoryDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2022-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:InventoryRawMaterials",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000048 - Disclosure - SCHEDULE OF INVENTORY (Details)",
     "menuCat": "Details",
     "order": "48",
     "role": "http://qualigeninc.com/role/ScheduleOfInventoryDetails",
     "shortName": "SCHEDULE OF INVENTORY (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "us-gaap:InventoryDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2022-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:InventoryRawMaterials",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
       "QLGN:PrepaidExpensesAndOtherCurrentAssetsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2022-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:PrepaidInsurance",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000049 - Disclosure - SCHEDULE OF PREPAID EXPENSES AND OTHER CURRENT ASSETS (Details)",
     "menuCat": "Details",
     "order": "49",
     "role": "http://qualigeninc.com/role/ScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails",
     "shortName": "SCHEDULE OF PREPAID EXPENSES AND OTHER CURRENT ASSETS (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
       "QLGN:PrepaidExpensesAndOtherCurrentAssetsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2022-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:PrepaidInsurance",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2020-12-31_us-gaap_PreferredStockMember_custom_SeriesAlphaConvertiblePreferredStockMember",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00000005 - Statement - Consolidated Statements of Changes in Stockholders' Equity",
     "menuCat": "Statements",
     "order": "5",
     "role": "http://qualigeninc.com/role/StatementsOfChangesInStockholdersEquity",
     "shortName": "Consolidated Statements of Changes in Stockholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2020-12-31_us-gaap_PreferredStockMember_custom_SeriesAlphaConvertiblePreferredStockMember",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2022-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000050 - Disclosure - SCHEDULE OF PROPERTY AND EQUIPMENT (Details)",
     "menuCat": "Details",
     "order": "50",
     "role": "http://qualigeninc.com/role/ScheduleOfPropertyAndEquipmentDetails",
     "shortName": "SCHEDULE OF PROPERTY AND EQUIPMENT (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2022-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:Depreciation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000051 - Disclosure - PROPERTY AND EQUIPMENT, NET (Details Narrative)",
     "menuCat": "Details",
     "order": "51",
     "role": "http://qualigeninc.com/role/PropertyAndEquipmentNetDetailsNarrative",
     "shortName": "PROPERTY AND EQUIPMENT, NET (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:Depreciation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2022-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:Goodwill",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000052 - Disclosure - SCHEDULE OF GOODWILL AND OTHER INTANGIBLE (Details)",
     "menuCat": "Details",
     "order": "52",
     "role": "http://qualigeninc.com/role/ScheduleOfGoodwillAndOtherIntangibleDetails",
     "shortName": "SCHEDULE OF GOODWILL AND OTHER INTANGIBLE (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock",
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2022-12-31",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:FiniteLivedIntangibleAssetsNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:GoodwillImpairmentLoss",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000053 - Disclosure - GOODWILL, IPR&D AND OTHER INTANGIBLES (Details Narrative)",
     "menuCat": "Details",
     "order": "53",
     "role": "http://qualigeninc.com/role/GoodwillIprdAndOtherIntangiblesDetailsNarrative",
     "shortName": "GOODWILL, IPR&D AND OTHER INTANGIBLES (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2021-01-012021-12-31",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:ImpairmentOfIntangibleAssetsFinitelived",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2022-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "QLGN:AccruedCompensation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000054 - Disclosure - SCHEDULE OF ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Details)",
     "menuCat": "Details",
     "order": "54",
     "role": "http://qualigeninc.com/role/ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails",
     "shortName": "SCHEDULE OF ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2022-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "QLGN:AccruedCompensation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2022-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:InterestPayableCurrent",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000055 - Disclosure - SHORT TERM DEBT - RELATED PARTY (Details Narrative)",
     "menuCat": "Details",
     "order": "55",
     "role": "http://qualigeninc.com/role/ShortTermDebt-RelatedPartyDetailsNarrative",
     "shortName": "SHORT TERM DEBT - RELATED PARTY (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "QLGN:WarrantLiabilitiesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2021-12-31_custom_SeriesCWarrantsMember_custom_CommonStockWarrantsMember",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "Shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000056 - Disclosure - SCHEDULE OF WARRANTS ACTIVITY (Details)",
     "menuCat": "Details",
     "order": "56",
     "role": "http://qualigeninc.com/role/ScheduleOfWarrantsActivityDetails",
     "shortName": "SCHEDULE OF WARRANTS ACTIVITY (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "QLGN:WarrantLiabilitiesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2020-12-31_custom_SeriesCWarrantsMember_custom_CommonStockWarrantsMember",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     }
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "QLGN:ScheduleOfFairValueHierarchyForWarrantLiabilitiesTableTextBlock",
       "QLGN:WarrantLiabilitiesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2021-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "QLGN:FairValueAdjustmentOfWarrant",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000057 - Disclosure - SCHEDULE OF FAIR VALUE HIERARCHY FOR WARRANT LIABILITIES (Details)",
     "menuCat": "Details",
     "order": "57",
     "role": "http://qualigeninc.com/role/ScheduleOfFairValueHierarchyForWarrantLiabilitiesDetails",
     "shortName": "SCHEDULE OF FAIR VALUE HIERARCHY FOR WARRANT LIABILITIES (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "QLGN:ScheduleOfFairValueHierarchyForWarrantLiabilitiesTableTextBlock",
       "QLGN:WarrantLiabilitiesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2020-12-31",
      "decimals": "0",
      "lang": null,
      "name": "QLGN:FairValueAdjustmentOfWarrant",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R58": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "QLGN:ScheduleOfAssumptionsOfWarrantLiabilitiesTableTextBlock",
       "QLGN:WarrantLiabilitiesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2022-12-31_us-gaap_MeasurementInputExpectedDividendRateMember",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:WarrantsAndRightsOutstandingMeasurementInput",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000058 - Disclosure - SCHEDULE OF ASSUMPTIONS OF WARRANT LIABILITIES (Details)",
     "menuCat": "Details",
     "order": "58",
     "role": "http://qualigeninc.com/role/ScheduleOfAssumptionsOfWarrantLiabilitiesDetails",
     "shortName": "SCHEDULE OF ASSUMPTIONS OF WARRANT LIABILITIES (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "QLGN:ScheduleOfAssumptionsOfWarrantLiabilitiesTableTextBlock",
       "QLGN:WarrantLiabilitiesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2022-12-31_us-gaap_MeasurementInputExpectedDividendRateMember",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:WarrantsAndRightsOutstandingMeasurementInput",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Pure",
      "xsiNil": "false"
     }
    },
    "R59": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2021-12-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
      "reportCount": 1,
      "unitRef": "USDPShares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000059 - Disclosure - WARRANT LIABILITIES (Details Narrative)",
     "menuCat": "Details",
     "order": "59",
     "role": "http://qualigeninc.com/role/WarrantLiabilitiesDetailsNarrative",
     "shortName": "WARRANT LIABILITIES (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "QLGN:WarrantLiabilitiesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2022-12-31_custom_SeriesCWarrantsMember",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USDPShares",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00000006 - Statement - Consolidated Statements of Cash Flows",
     "menuCat": "Statements",
     "order": "6",
     "role": "http://qualigeninc.com/role/StatementsOfCashFlows",
     "shortName": "Consolidated Statements of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R60": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2022-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ConvertibleDebt",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000060 - Disclosure - SCHEDULE OF SENIOR SECURED CONVERTIBLE DEBT (Details)",
     "menuCat": "Details",
     "order": "60",
     "role": "http://qualigeninc.com/role/ScheduleOfSeniorSecuredConvertibleDebtDetails",
     "shortName": "SCHEDULE OF SENIOR SECURED CONVERTIBLE DEBT (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ConvertibleDebtTableTextBlock",
       "us-gaap:DebtDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2022-12-31_custom_SeniorSecuredConvertibleDebtMember",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:SecuredDebt",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R61": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2021-12-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
      "reportCount": 1,
      "unitRef": "Shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000061 - Disclosure - CONVERTIBLE DEBT - RELATED PARTY (Details Narrative)",
     "menuCat": "Details",
     "order": "61",
     "role": "http://qualigeninc.com/role/ConvertibleDebt-RelatedPartyDetailsNarrative",
     "shortName": "CONVERTIBLE DEBT - RELATED PARTY (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:DebtDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-12-222022-12-22_custom_SeniorConvertibleDebentureMember",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:DebtInstrumentIncreaseAccruedInterest",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R62": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000062 - Disclosure - SCHEDULE OF EARNINGS PER SHARE BASIC AND DILUTED (Details)",
     "menuCat": "Details",
     "order": "62",
     "role": "http://qualigeninc.com/role/ScheduleOfEarningsPerShareBasicAndDilutedDetails",
     "shortName": "SCHEDULE OF EARNINGS PER SHARE BASIC AND DILUTED (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "us-gaap:EarningsPerShareTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     }
    },
    "R63": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "us-gaap:EarningsPerShareTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000063 - Disclosure - SCHEDULE OF DILUTIVE SECURITIES EXCLUDED FROM DILUTED NET LOSS PER SHARE (Details)",
     "menuCat": "Details",
     "order": "63",
     "role": "http://qualigeninc.com/role/ScheduleOfDilutiveSecuritiesExcludedFromDilutedNetLossPerShareDetails",
     "shortName": "SCHEDULE OF DILUTIVE SECURITIES EXCLUDED FROM DILUTED NET LOSS PER SHARE (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "us-gaap:EarningsPerShareTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     }
    },
    "R64": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2021-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000064 - Disclosure - SCHEDULE OF OPERATING LEASE RIGHT OF USE ASSETS AND OPERATING LEASE LIABILITIES (Details)",
     "menuCat": "Details",
     "order": "64",
     "role": "http://qualigeninc.com/role/ScheduleOfOperatingLeaseRightOfUseAssetsAndOperatingLeaseLiabilitiesDetails",
     "shortName": "SCHEDULE OF OPERATING LEASE RIGHT OF USE ASSETS AND OPERATING LEASE LIABILITIES (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "QLGN:ScheduleOfOperatingLeaseRightOfUseAssetsAndLiabilitiesTableTextBlock",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-012022-12-31_custom_LongtermOperatingLeaseAgreementMember",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R65": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2022-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000065 - Disclosure - SCHEDULE OF MATURITIES OF OPERATING LEASE LIABILITIES (Details)",
     "menuCat": "Details",
     "order": "65",
     "role": "http://qualigeninc.com/role/ScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails",
     "shortName": "SCHEDULE OF MATURITIES OF OPERATING LEASE LIABILITIES (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2022-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R66": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2021-12-15",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:AreaOfLand",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Sqft",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000066 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative)",
     "menuCat": "Details",
     "order": "66",
     "role": "http://qualigeninc.com/role/CommitmentsAndContingenciesDetailsNarrative",
     "shortName": "COMMITMENTS AND CONTINGENCIES (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2021-12-15",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:AreaOfLand",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Sqft",
      "xsiNil": "false"
     }
    },
    "R67": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000067 - Disclosure - RESEARCH AND LICENSE AGREEMENTS (Details Narrative)",
     "menuCat": "Details",
     "order": "67",
     "role": "http://qualigeninc.com/role/ResearchAndLicenseAgreementsDetailsNarrative",
     "shortName": "RESEARCH AND LICENSE AGREEMENTS (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "QLGN:ResearchAndLicenseAgreementsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": "0",
      "lang": null,
      "name": "QLGN:LicenseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R68": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2022-12-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance",
      "reportCount": 1,
      "unitRef": "Shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000068 - Disclosure - SCHEDULE OF RESERVED SHARES (Details)",
     "menuCat": "Details",
     "order": "68",
     "role": "http://qualigeninc.com/role/ScheduleOfReservedSharesDetails",
     "shortName": "SCHEDULE OF RESERVED SHARES (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "QLGN:ScheduleOfReservedSharesTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2022-12-31_us-gaap_WarrantMember72029296",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     }
    },
    "R69": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000069 - Disclosure - SCHEDULE OF STOCK OPTION ACTIVITY (Details)",
     "menuCat": "Details",
     "order": "69",
     "role": "http://qualigeninc.com/role/ScheduleOfStockOptionActivityDetails",
     "shortName": "SCHEDULE OF STOCK OPTION ACTIVITY (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000007 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND ESTIMATES",
     "menuCat": "Notes",
     "order": "7",
     "role": "http://qualigeninc.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesAndEstimates",
     "shortName": "ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND ESTIMATES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R70": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000070 - Disclosure - SCHEDULE OF ASSUMPTION USED IN BLACK-SCHOLES OPTION-PRICING METHOD (Details)",
     "menuCat": "Details",
     "order": "70",
     "role": "http://qualigeninc.com/role/ScheduleOfAssumptionUsedInBlack-scholesOption-pricingMethodDetails",
     "shortName": "SCHEDULE OF ASSUMPTION USED IN BLACK-SCHOLES OPTION-PRICING METHOD (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Pure",
      "xsiNil": "false"
     }
    },
    "R71": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000071 - Disclosure - SCHEDULE OF SHARE-BASED COMPENSATION EXPENSE (Details)",
     "menuCat": "Details",
     "order": "71",
     "role": "http://qualigeninc.com/role/ScheduleOfShare-basedCompensationExpenseDetails",
     "shortName": "SCHEDULE OF SHARE-BASED COMPENSATION EXPENSE (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-012022-12-31_us-gaap_ResearchAndDevelopmentExpenseMember",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R72": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "QLGN:SummaryOfWarrantActivityTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2021-12-31_custom_CompensatoryWarrantActivityMember72031921",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "Shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000072 - Disclosure - SCHEDULE OF WARRANT ACTIVITY (Details)",
     "menuCat": "Details",
     "order": "72",
     "role": "http://qualigeninc.com/role/ScheduleOfWarrantActivityDetails",
     "shortName": "SCHEDULE OF WARRANT ACTIVITY (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "QLGN:SummaryOfWarrantActivityTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2020-12-31_custom_CompensatoryWarrantActivityMember",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     }
    },
    "R73": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2021-12-012021-12-31",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProceedsFromIssuanceOfCommonStock",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000073 - Disclosure - STOCKHOLDERS\u2019 EQUITY (Details Narrative)",
     "menuCat": "Details",
     "order": "73",
     "role": "http://qualigeninc.com/role/StockholdersEquityDetailsNarrative",
     "shortName": "STOCKHOLDERS\u2019 EQUITY (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2022-12-31",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R74": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2022-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:InterestPayableCurrent",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000074 - Disclosure - RELATED PARTY TRANSACTIONS (Details Narrative)",
     "menuCat": "Details",
     "order": "74",
     "role": "http://qualigeninc.com/role/RelatedPartyTransactionsDetailsNarrative",
     "shortName": "RELATED PARTY TRANSACTIONS (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R75": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000075 - Disclosure - SCHEDULE OF DOMESTIC AND FOREIGN COMPONENTS (Details)",
     "menuCat": "Details",
     "order": "75",
     "role": "http://qualigeninc.com/role/ScheduleOfDomesticAndForeignComponentsDetails",
     "shortName": "SCHEDULE OF DOMESTIC AND FOREIGN COMPONENTS (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R76": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000076 - Disclosure - SCHEDULE OF RECONCILIATIONS OF STATUTORY INCOME TAX RATE (Details)",
     "menuCat": "Details",
     "order": "76",
     "role": "http://qualigeninc.com/role/ScheduleOfReconciliationsOfStatutoryIncomeTaxRateDetails",
     "shortName": "SCHEDULE OF RECONCILIATIONS OF STATUTORY INCOME TAX RATE (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Pure",
      "xsiNil": "false"
     }
    },
    "R77": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:CurrentStateAndLocalTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000077 - Disclosure - SCHEDULE OF PROVISION FOR INCOME TAXES (Details)",
     "menuCat": "Details",
     "order": "77",
     "role": "http://qualigeninc.com/role/ScheduleOfProvisionForIncomeTaxesDetails",
     "shortName": "SCHEDULE OF PROVISION FOR INCOME TAXES (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:CurrentStateAndLocalTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R78": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2022-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000078 - Disclosure - SCHEDULE OF DEFERRED TAX ASSETS AND LIABILITIES (Details)",
     "menuCat": "Details",
     "order": "78",
     "role": "http://qualigeninc.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails",
     "shortName": "SCHEDULE OF DEFERRED TAX ASSETS AND LIABILITIES (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2022-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R79": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredForeignIncomeTaxExpenseBenefit",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000079 - Disclosure - INCOME TAXES (Details Narrative)",
     "menuCat": "Details",
     "order": "79",
     "role": "http://qualigeninc.com/role/IncomeTaxesDetailsNarrative",
     "shortName": "INCOME TAXES (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2022-12-31",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000008 - Disclosure - LIQUIDITY AND GOING CONCERN",
     "menuCat": "Notes",
     "order": "8",
     "role": "http://qualigeninc.com/role/LiquidityAndGoingConcern",
     "shortName": "LIQUIDITY AND GOING CONCERN",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R80": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:SubsequentEventsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2023-01-12_us-gaap_SubsequentEventMember",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:DebtInstrumentFaceAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000080 - Disclosure - SUBSEQUENT EVENTS (Details Narrative)",
     "menuCat": "Details",
     "order": "80",
     "role": "http://qualigeninc.com/role/SubsequentEventsDetailsNarrative",
     "shortName": "SUBSEQUENT EVENTS (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:SubsequentEventsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2023-01-12_us-gaap_SubsequentEventMember",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:DebtInstrumentFaceAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000009 - Disclosure - ACQUISITION",
     "menuCat": "Notes",
     "order": "9",
     "role": "http://qualigeninc.com/role/Acquisition",
     "shortName": "ACQUISITION",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 92,
   "tag": {
    "QLGN_AccruedCompensation": {
     "auth_ref": [],
     "calculation": {
      "http://qualigeninc.com/role/ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued compensation.",
        "label": "Board compensation"
       }
      }
     },
     "localname": "AccruedCompensation",
     "nsuri": "http://qualigeninc.com/20221231",
     "presentation": [
      "http://qualigeninc.com/role/ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "QLGN_AccruedEquipmentHeldForLease": {
     "auth_ref": [],
     "calculation": {
      "http://qualigeninc.com/role/ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued equipment held for lease.",
        "label": "Equipment held for lease"
       }
      }
     },
     "localname": "AccruedEquipmentHeldForLease",
     "nsuri": "http://qualigeninc.com/20221231",
     "presentation": [
      "http://qualigeninc.com/role/ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "QLGN_AccruedFranchiseSalesAndUseTaxes": {
     "auth_ref": [],
     "calculation": {
      "http://qualigeninc.com/role/ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued franchise sales and use taxes.",
        "label": "Franchise, sales and use taxes"
       }
      }
     },
     "localname": "AccruedFranchiseSalesAndUseTaxes",
     "nsuri": "http://qualigeninc.com/20221231",
     "presentation": [
      "http://qualigeninc.com/role/ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "QLGN_AccruedLicenseFees": {
     "auth_ref": [],
     "calculation": {
      "http://qualigeninc.com/role/ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails": {
       "order": 11.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued license fees.",
        "label": "License fees"
       }
      }
     },
     "localname": "AccruedLicenseFees",
     "nsuri": "http://qualigeninc.com/20221231",
     "presentation": [
      "http://qualigeninc.com/role/ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "QLGN_AccruedResearchAndDevelopmentCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://qualigeninc.com/role/ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails": {
       "order": 8.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research and development.",
        "label": "AccruedResearchAndDevelopmentCurrent",
        "verboseLabel": "Research and development"
       }
      }
     },
     "localname": "AccruedResearchAndDevelopmentCurrent",
     "nsuri": "http://qualigeninc.com/20221231",
     "presentation": [
      "http://qualigeninc.com/role/ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "QLGN_AccruedVacation": {
     "auth_ref": [],
     "calculation": {
      "http://qualigeninc.com/role/BalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued vacation.",
        "label": "Accrued vacation"
       }
      }
     },
     "localname": "AccruedVacation",
     "nsuri": "http://qualigeninc.com/20221231",
     "presentation": [
      "http://qualigeninc.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "QLGN_AdvancedCancerTherapeuticsLLCMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Advanced Cancer Therapeutics, LLC [Member]",
        "label": "Advanced Cancer Therapeutics, LLC [Member]"
       }
      }
     },
     "localname": "AdvancedCancerTherapeuticsLLCMember",
     "nsuri": "http://qualigeninc.com/20221231",
     "presentation": [
      "http://qualigeninc.com/role/ResearchAndLicenseAgreementsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "QLGN_AgreementDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agreement description.",
        "label": "Agreement description"
       }
      }
     },
     "localname": "AgreementDescription",
     "nsuri": "http://qualigeninc.com/20221231",
     "presentation": [
      "http://qualigeninc.com/role/ResearchAndLicenseAgreementsDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "QLGN_AgreementTermPaymentDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agreement term payment, description.",
        "label": "Agreement term payment, description"
       }
      }
     },
     "localname": "AgreementTermPaymentDescription",
     "nsuri": "http://qualigeninc.com/20221231",
     "presentation": [
      "http://qualigeninc.com/role/ResearchAndLicenseAgreementsDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "QLGN_AllowancesForSalesReturn": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Allowances for sales return.",
        "label": "Allowance for estimated returns"
       }
      }
     },
     "localname": "AllowancesForSalesReturn",
     "nsuri": "http://qualigeninc.com/20221231",
     "presentation": [
      "http://qualigeninc.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesAndEstimatesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "QLGN_AlphaCapitalAnstaltMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Alpha Capital Anstalt [Member]",
        "label": "Alpha Capital Anstalt [Member]"
       }
      }
     },
     "localname": "AlphaCapitalAnstaltMember",
     "nsuri": "http://qualigeninc.com/20221231",
     "presentation": [
      "http://qualigeninc.com/role/ScheduleOfConsiderationTransferredDetailsParenthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "QLGN_AlphaCapitalMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Alpha Capital [Member]",
        "label": "Alpha Capital [Member]"
       }
      }
     },
     "localname": "AlphaCapitalMember",
     "nsuri": "http://qualigeninc.com/20221231",
     "presentation": [
      "http://qualigeninc.com/role/ConvertibleDebt-RelatedPartyDetailsNarrative",
      "http://qualigeninc.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://qualigeninc.com/role/StockholdersEquityDetailsNarrative",
      "http://qualigeninc.com/role/WarrantLiabilitiesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "QLGN_AlphaCapitalOtherThirdPartiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Alpha Capital Other Third Parties [Member]",
        "label": "Alpha Capital Other Third Parties [Member]"
       }
      }
     },
     "localname": "AlphaCapitalOtherThirdPartiesMember",
     "nsuri": "http://qualigeninc.com/20221231",
     "presentation": [
      "http://qualigeninc.com/role/ConvertibleDebt-RelatedPartyDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "QLGN_AnnualCashCompensation": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Annual cash compensation.",
        "label": "Annual cash compensation"
       }
      }
     },
     "localname": "AnnualCashCompensation",
     "nsuri": "http://qualigeninc.com/20221231",
     "presentation": [
      "http://qualigeninc.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "percentItemType"
    },
    "QLGN_BaseSalaryPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Base salary percentage.",
        "label": "Base salary percentage"
       }
      }
     },
     "localname": "BaseSalaryPercentage",
     "nsuri": "http://qualigeninc.com/20221231",
     "presentation": [
      "http://qualigeninc.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "percentItemType"
    },
    "QLGN_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpensesAndOtherPayables": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business combination recognized identifiable assets acquired and liabilities assumed current liabilities accrued expenses and other payables.",
        "label": "Accrued expenses and other payables"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpensesAndOtherPayables",
     "nsuri": "http://qualigeninc.com/20221231",
     "presentation": [
      "http://qualigeninc.com/role/ScheduleOfAssetsAcquiredAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "QLGN_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesShortTermDebt": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business combination recognized identifiable assets acquired and liabilities assumed current liabilities short term debt.",
        "label": "Short term debt"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesShortTermDebt",
     "nsuri": "http://qualigeninc.com/20221231",
     "presentation": [
      "http://qualigeninc.com/role/ScheduleOfAssetsAcquiredAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "QLGN_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedResearchAndDevelopmentExpense": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business combination recognized identifiable assets acquired and liabilities assumed research and development expense.",
        "label": "In process R&amp;D"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedResearchAndDevelopmentExpense",
     "nsuri": "http://qualigeninc.com/20221231",
     "presentation": [
      "http://qualigeninc.com/role/ScheduleOfAssetsAcquiredAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "QLGN_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedResearchAndDevelopmentGrantLiability": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business combination recognized identifiable assets acquired and liabilities assumed research and development grant liability.",
        "label": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedResearchAndDevelopmentGrantLiability",
        "verboseLabel": "R&amp;D grant liability"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedResearchAndDevelopmentGrantLiability",
     "nsuri": "http://qualigeninc.com/20221231",
     "presentation": [
      "http://qualigeninc.com/role/ScheduleOfAssetsAcquiredAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "QLGN_CEMarkMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "CE Mark [Member]",
        "label": "CE Mark [Member]"
       }
      }
     },
     "localname": "CEMarkMember",
     "nsuri": "http://qualigeninc.com/20221231",
     "presentation": [
      "http://qualigeninc.com/role/ResearchAndLicenseAgreementsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "QLGN_CashPaidForAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash paid for abstract.",
        "label": "Cash paid during the year for:"
       }
      }
     },
     "localname": "CashPaidForAbstract",
     "nsuri": "http://qualigeninc.com/20221231",
     "presentation": [
      "http://qualigeninc.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "QLGN_ChangeInFairValueOfWarrantLiabilities": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Change in fair value of warrant liabilities.",
        "label": "ChangeInFairValueOfWarrantLiabilities",
        "verboseLabel": "Change in fair value of warrant liabilities"
       }
      }
     },
     "localname": "ChangeInFairValueOfWarrantLiabilities",
     "nsuri": "http://qualigeninc.com/20221231",
     "presentation": [
      "http://qualigeninc.com/role/ScheduleOfFairValueHierarchyForWarrantLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "QLGN_CommissionAndOfferingCostsOfSecuritiesPurchaseAgreements": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission and offering costs of securities purchase agreements.",
        "label": "Commission and offering costs of Securities Purchase Agreements"
       }
      }
     },
     "localname": "CommissionAndOfferingCostsOfSecuritiesPurchaseAgreements",
     "nsuri": "http://qualigeninc.com/20221231",
     "presentation": [
      "http://qualigeninc.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "QLGN_CommonStockAndPrefundedWarrantsIssuedForBusinessAcquisition": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common stock and prefunded warrants issued for business acquisition.",
        "label": "Common stock and prefunded warrants issued for business acquisition"
       }
      }
     },
     "localname": "CommonStockAndPrefundedWarrantsIssuedForBusinessAcquisition",
     "nsuri": "http://qualigeninc.com/20221231",
     "presentation": [
      "http://qualigeninc.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "QLGN_CommonStockAndPrefundedWarrantsIssuedSharesForBusinessAcquisition": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common stock and prefunded warrants issued shares for business acquisition.",
        "label": "Balance, shares"
       }
      }
     },
     "localname": "CommonStockAndPrefundedWarrantsIssuedSharesForBusinessAcquisition",
     "nsuri": "http://qualigeninc.com/20221231",
     "presentation": [
      "http://qualigeninc.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "QLGN_CommonStockWarrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common Stock Warrants [Member]",
        "label": "Common Stock Warrants [Member]"
       }
      }
     },
     "localname": "CommonStockWarrantsMember",
     "nsuri": "http://qualigeninc.com/20221231",
     "presentation": [
      "http://qualigeninc.com/role/ScheduleOfWarrantsActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "QLGN_CompensatoryWarrantActivityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Compensatory Warrant Activity [Member]",
        "label": "Compensatory Warrant Activity [Member]"
       }
      }
     },
     "localname": "CompensatoryWarrantActivityMember",
     "nsuri": "http://qualigeninc.com/20221231",
     "presentation": [
      "http://qualigeninc.com/role/ScheduleOfWarrantActivityDetails",
      "http://qualigeninc.com/role/StockholdersEquityDetailsNarrative",
      "http://qualigeninc.com/role/StockholdersEquityTables"
     ],
     "xbrltype": "domainItemType"
    },
    "QLGN_CompensatoryWarrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Compensatory Warrants [Member]",
        "label": "Compensatory Warrants [Member]"
       }
      }
     },
     "localname": "CompensatoryWarrantsMember",
     "nsuri": "http://qualigeninc.com/20221231",
     "presentation": [
      "http://qualigeninc.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "QLGN_ConversionPricePercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Conversion price percentage.",
        "label": "Conversion price percentage"
       }
      }
     },
     "localname": "ConversionPricePercentage",
     "nsuri": "http://qualigeninc.com/20221231",
     "presentation": [
      "http://qualigeninc.com/role/ConvertibleDebt-RelatedPartyDetailsNarrative",
      "http://qualigeninc.com/role/WarrantLiabilitiesDetailsNarrative"
     ],
     "xbrltype": "percentItemType"
    },
    "QLGN_CostOfProductSales": {
     "auth_ref": [],
     "calculation": {
      "http://qualigeninc.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cost of product sales.",
        "label": "Cost of product sales"
       }
      }
     },
     "localname": "CostOfProductSales",
     "nsuri": "http://qualigeninc.com/20221231",
     "presentation": [
      "http://qualigeninc.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "QLGN_CumulativeSales": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cumulative sales.",
        "label": "Cumulative sales"
       }
      }
     },
     "localname": "CumulativeSales",
     "nsuri": "http://qualigeninc.com/20221231",
     "presentation": [
      "http://qualigeninc.com/role/ResearchAndLicenseAgreementsDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "QLGN_DeferredRevenuePolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Revenue Policy [TextBlock]",
        "label": "Deferred Revenue"
       }
      }
     },
     "localname": "DeferredRevenuePolicyTextBlock",
     "nsuri": "http://qualigeninc.com/20221231",
     "presentation": [
      "http://qualigeninc.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesAndEstimatesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "QLGN_DeferredTaxAssetsResearchAndDevelopmentExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://qualigeninc.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_DeferredTaxAssetsTaxDeferredExpense",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research and development expenses.",
        "label": "Research and development expenses"
       }
      }
     },
     "localname": "DeferredTaxAssetsResearchAndDevelopmentExpenses",
     "nsuri": "http://qualigeninc.com/20221231",
     "presentation": [
      "http://qualigeninc.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "QLGN_DefferdTaxAssetsAccruedExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://qualigeninc.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DeferredTaxAssetsTaxDeferredExpense",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Defferd tax assets accrued expenses.",
        "label": "Accrued expenses"
       }
      }
     },
     "localname": "DefferdTaxAssetsAccruedExpenses",
     "nsuri": "http://qualigeninc.com/20221231",
     "presentation": [
      "http://qualigeninc.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "QLGN_DerivativeFinancialInstrumentsAndWarrantLiabilitiesPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative Financial Instruments And Warrant Liabilities [Policy TextBlock]",
        "label": "Derivative Financial Instruments and Warrant Liabilities"
       }
      }
     },
     "localname": "DerivativeFinancialInstrumentsAndWarrantLiabilitiesPolicyTextBlock",
     "nsuri": "http://qualigeninc.com/20221231",
     "presentation": [
      "http://qualigeninc.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesAndEstimatesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "QLGN_DevelopedProductTechnologyRightsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Developed-Product-Technology Rights [Member]",
        "label": "Developed-Product-Technology Rights [Member]"
       }
      }
     },
     "localname": "DevelopedProductTechnologyRightsMember",
     "nsuri": "http://qualigeninc.com/20221231",
     "presentation": [
      "http://qualigeninc.com/role/ScheduleOfGoodwillAndOtherIntangibleDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "QLGN_DevelopmentFund": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Development fund.",
        "label": "Development fund"
       }
      }
     },
     "localname": "DevelopmentFund",
     "nsuri": "http://qualigeninc.com/20221231",
     "presentation": [
      "http://qualigeninc.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "QLGN_DilutivePotentialSharesIssuableFromStockOptionsAndWarrants": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Dilutive potential shares issuable from stock options and warrants.",
        "label": "Dilutive potential shares issuable from stock options and warrants"
       }
      }
     },
     "localname": "DilutivePotentialSharesIssuableFromStockOptionsAndWarrants",
     "nsuri": "http://qualigeninc.com/20221231",
     "presentation": [
      "http://qualigeninc.com/role/ScheduleOfEarningsPerShareBasicAndDilutedDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "QLGN_DisclosurePrepaidExpensesAndOtherCurrentAssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid Expenses And Other Current Assets",
        "verboseLabel": "Schedule Of Prepaid Expenses And Other Current Assets"
       }
      }
     },
     "localname": "DisclosurePrepaidExpensesAndOtherCurrentAssetsAbstract",
     "nsuri": "http://qualigeninc.com/20221231",
     "xbrltype": "stringItemType"
    },
    "QLGN_DisclosureResearchAndLicenseAgreementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research And License Agreements"
       }
      }
     },
     "localname": "DisclosureResearchAndLicenseAgreementsAbstract",
     "nsuri": "http://qualigeninc.com/20221231",
     "xbrltype": "stringItemType"
    },
    "QLGN_DisclosureWarrantLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant Liabilities"
       }
      }
     },
     "localname": "DisclosureWarrantLiabilitiesAbstract",
     "nsuri": "http://qualigeninc.com/20221231",
     "xbrltype": "stringItemType"
    },
    "QLGN_EffectiveIncomeTaxRateReconciliationFairValueOfWarrant": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective income tax rate reconciliation fair value of warrant.",
        "label": "Change in FV of warrant liability"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationFairValueOfWarrant",
     "nsuri": "http://qualigeninc.com/20221231",
     "presentation": [
      "http://qualigeninc.com/role/ScheduleOfReconciliationsOfStatutoryIncomeTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "QLGN_EffectiveIncomeTaxRateReconciliationNonOperatingLossExpiration": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective income tax rate reconciliation non operating loss expiration.",
        "label": "NOL expiration"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationNonOperatingLossExpiration",
     "nsuri": "http://qualigeninc.com/20221231",
     "presentation": [
      "http://qualigeninc.com/role/ScheduleOfReconciliationsOfStatutoryIncomeTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "QLGN_EmployeesAndNonemployeeServiceProviderMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Employees and Non-employee Service Provider [Member]",
        "label": "Employees and Non-employee Service Provider [Member]"
       }
      }
     },
     "localname": "EmployeesAndNonemployeeServiceProviderMember",
     "nsuri": "http://qualigeninc.com/20221231",
     "presentation": [
      "http://qualigeninc.com/role/ScheduleOfStockOptionActivityDetails",
      "http://qualigeninc.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "QLGN_FairValueAdjustmentOfWarrant": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense (income) related to adjustment to fair value of warrant liability.",
        "label": "FairValueAdjustmentOfWarrant",
        "periodEndLabel": "Fair value for warrant liabilities",
        "periodStartLabel": "Fair value for warrant liabilities"
       }
      }
     },
     "localname": "FairValueAdjustmentOfWarrant",
     "nsuri": "http://qualigeninc.com/20221231",
     "presentation": [
      "http://qualigeninc.com/role/ScheduleOfFairValueHierarchyForWarrantLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "QLGN_FairValueOfIssuanceCost": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of Issuance cost.",
        "label": "Fair value of issuance cost"
       }
      }
     },
     "localname": "FairValueOfIssuanceCost",
     "nsuri": "http://qualigeninc.com/20221231",
     "presentation": [
      "http://qualigeninc.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "QLGN_FairValueOfQualigenPrefundedWarrantIssuedInExchangeForNanosynexStock": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of qualigen prefunded warrant issued in exchange for nanosynex stock",
        "label": "Fair value of Qualigen prefunded warrant issued in exchange for NanoSynex stock"
       }
      }
     },
     "localname": "FairValueOfQualigenPrefundedWarrantIssuedInExchangeForNanosynexStock",
     "nsuri": "http://qualigeninc.com/20221231",
     "presentation": [
      "http://qualigeninc.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "QLGN_FairValueOfWarrantLiabilitiesIssuanceOfAlphaWarrants": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of warrant liabilities issuance of alpha warrants.",
        "label": "FairValueOfWarrantLiabilitiesIssuanceOfAlphaWarrants",
        "negatedLabel": "Issuance of Alpha warrants"
       }
      }
     },
     "localname": "FairValueOfWarrantLiabilitiesIssuanceOfAlphaWarrants",
     "nsuri": "http://qualigeninc.com/20221231",
     "presentation": [
      "http://qualigeninc.com/role/ScheduleOfFairValueHierarchyForWarrantLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "QLGN_FairValueOfWarrantLiabilitiesOnDateOfExercise": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of warrant liabilities on date of exercise.",
        "label": "Fair value of warrant liabilities on date of exercise",
        "negatedLabel": "Common Stock Warrant liabilities, Exercises"
       }
      }
     },
     "localname": "FairValueOfWarrantLiabilitiesOnDateOfExercise",
     "nsuri": "http://qualigeninc.com/20221231",
     "presentation": [
      "http://qualigeninc.com/role/ScheduleOfFairValueHierarchyForWarrantLiabilitiesDetails",
      "http://qualigeninc.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "QLGN_FairValueOfWarrantModificationForBusinessAcquisition": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of warrant modification for business acquisition.",
        "label": "Fair value of warrant modification for business acquisition",
        "verboseLabel": "FMV of consideration related to related to repricing of 70,478 shares of Alpha Capital/Qualigen warrants *"
       }
      }
     },
     "localname": "FairValueOfWarrantModificationForBusinessAcquisition",
     "nsuri": "http://qualigeninc.com/20221231",
     "presentation": [
      "http://qualigeninc.com/role/ScheduleOfConsiderationTransferredDetails",
      "http://qualigeninc.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "QLGN_FairValueOfWarrantModificationForProfessionalServices": {
     "auth_ref": [],
     "calculation": {
      "http://qualigeninc.com/role/StatementsOfCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of warrant modification for professional services.",
        "label": "Fair value of warrant modification for professional services"
       }
      }
     },
     "localname": "FairValueOfWarrantModificationForProfessionalServices",
     "nsuri": "http://qualigeninc.com/20221231",
     "presentation": [
      "http://qualigeninc.com/role/StatementsOfCashFlows",
      "http://qualigeninc.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "QLGN_FairValueOfWarrantModificationsForBusinessAcquisition": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of warrant modifications for business acquisition.",
        "label": "Fair value of warrant modifications for business acquisition"
       }
      }
     },
     "localname": "FairValueOfWarrantModificationsForBusinessAcquisition",
     "nsuri": "http://qualigeninc.com/20221231",
     "presentation": [
      "http://qualigeninc.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "QLGN_FairValueOfWarrantModificationsPursuantToSecuritiesPurchaseAgreements": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of warrant modifications pursuant to securities purchase agreements.",
        "label": "Fair value of warrant modifications pursuant to Securities Purchase Agreements"
       }
      }
     },
     "localname": "FairValueOfWarrantModificationsPursuantToSecuritiesPurchaseAgreements",
     "nsuri": "http://qualigeninc.com/20221231",
     "presentation": [
      "http://qualigeninc.com/role/StatementsOfCashFlows",
      "http://qualigeninc.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "QLGN_FairValueOfWarrantsIssuedForProfessionalServices": {
     "auth_ref": [],
     "calculation": {
      "http://qualigeninc.com/role/StatementsOfCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of warrants issued for professional services.",
        "label": "Fair value of warrants issued for professional services"
       }
      }
     },
     "localname": "FairValueOfWarrantsIssuedForProfessionalServices",
     "nsuri": "http://qualigeninc.com/20221231",
     "presentation": [
      "http://qualigeninc.com/role/StatementsOfCashFlows",
      "http://qualigeninc.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "QLGN_FairValueOfWarrantsRepricedDueToAcquisition": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of warrants repriced due to acquisition",
        "label": "Fair value of Alpha Capital/Qualigen warrants repriced due to acquisition"
       }
      }
     },
     "localname": "FairValueOfWarrantsRepricedDueToAcquisition",
     "nsuri": "http://qualigeninc.com/20221231",
     "presentation": [
      "http://qualigeninc.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "QLGN_FeesAndCostsPaid": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fees and costs paid.",
        "label": "Fees and costs paid"
       }
      }
     },
     "localname": "FeesAndCostsPaid",
     "nsuri": "http://qualigeninc.com/20221231",
     "presentation": [
      "http://qualigeninc.com/role/ConvertibleDebt-RelatedPartyDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "QLGN_FirstTwelveMonthsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "First 12 Months [Member]",
        "label": "First 12 Months [Member]"
       }
      }
     },
     "localname": "FirstTwelveMonthsMember",
     "nsuri": "http://qualigeninc.com/20221231",
     "presentation": [
      "http://qualigeninc.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "QLGN_FixedAssetImpairments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fixed asset lmpairments.",
        "label": "Fixed asset impairment"
       }
      }
     },
     "localname": "FixedAssetImpairments",
     "nsuri": "http://qualigeninc.com/20221231",
     "presentation": [
      "http://qualigeninc.com/role/ScheduleOfPropertyAndEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "QLGN_FractionalSharePaymentsRelatedToReverseStockSplit": {
     "auth_ref": [],
     "calculation": {
      "http://qualigeninc.com/role/StatementsOfCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fractional share payments related to reverse stock split.",
        "label": "FractionalSharePaymentsRelatedToReverseStockSplit",
        "negatedLabel": "Fractional share payments related to the reverse stock split"
       }
      }
     },
     "localname": "FractionalSharePaymentsRelatedToReverseStockSplit",
     "nsuri": "http://qualigeninc.com/20221231",
     "presentation": [
      "http://qualigeninc.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "QLGN_GeneralAdministrativeResearchAndDevelopmentExpensesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "General Administrative Research and Development Expenses [Member]",
        "label": "General Administrative Research and Development Expenses [Member]"
       }
      }
     },
     "localname": "GeneralAdministrativeResearchAndDevelopmentExpensesMember",
     "nsuri": "http://qualigeninc.com/20221231",
     "presentation": [
      "http://qualigeninc.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesAndEstimatesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "QLGN_GlobalEconomicConditionsPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Global Economic Conditions [Policy Text Block]",
        "label": "Global Economic Conditions"
       }
      }
     },
     "localname": "GlobalEconomicConditionsPolicyTextBlock",
     "nsuri": "http://qualigeninc.com/20221231",
     "presentation": [
      "http://qualigeninc.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesAndEstimatesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "QLGN_IncreaseDecreaseInInventoryAndEquipmentHeldForLeases": {
     "auth_ref": [],
     "calculation": {
      "http://qualigeninc.com/role/StatementsOfCashFlows": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase decrease in inventoryaAnd equipment held for leases.",
        "label": "IncreaseDecreaseInInventoryAndEquipmentHeldForLeases",
        "negatedLabel": "Inventory and equipment held for lease"
       }
      }
     },
     "localname": "IncreaseDecreaseInInventoryAndEquipmentHeldForLeases",
     "nsuri": "http://qualigeninc.com/20221231",
     "presentation": [
      "http://qualigeninc.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "QLGN_IncreaseDecreaseInResearchAndDevelopmentGrantLiability": {
     "auth_ref": [],
     "calculation": {
      "http://qualigeninc.com/role/StatementsOfCashFlows": {
       "order": 17.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research and development grant liability.",
        "label": "IncreaseDecreaseInResearchAndDevelopmentGrantLiability",
        "verboseLabel": "R&amp;D grant liability"
       }
      }
     },
     "localname": "IncreaseDecreaseInResearchAndDevelopmentGrantLiability",
     "nsuri": "http://qualigeninc.com/20221231",
     "presentation": [
      "http://qualigeninc.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "QLGN_IssuanceOfCommonStockForConversionOfPreferredStock": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Issuance of common stock for conversion of preferred stock.",
        "label": "Issuance of common stock for conversion of preferred stock"
       }
      }
     },
     "localname": "IssuanceOfCommonStockForConversionOfPreferredStock",
     "nsuri": "http://qualigeninc.com/20221231",
     "presentation": [
      "http://qualigeninc.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "QLGN_IssuanceOfCommonStockForConversionOfPreferredStockBeforeClosingOfReverseRecapitalization": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Issuance of common stock for conversion of preferred stock before closing of reverse recapitalization.",
        "label": "Issuance of common stock for conversion of preferred stock after closing of reverse recapitalization"
       }
      }
     },
     "localname": "IssuanceOfCommonStockForConversionOfPreferredStockBeforeClosingOfReverseRecapitalization",
     "nsuri": "http://qualigeninc.com/20221231",
     "presentation": [
      "http://qualigeninc.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "QLGN_IssuanceOfCommonStockSharesForConversionOfPreferredStock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Issuance of common stock shares for conversion of preferred stock.",
        "label": "Issuance of common stock for conversion of preferred stock, shares"
       }
      }
     },
     "localname": "IssuanceOfCommonStockSharesForConversionOfPreferredStock",
     "nsuri": "http://qualigeninc.com/20221231",
     "presentation": [
      "http://qualigeninc.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "QLGN_LicenseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License Agreement [Member]",
        "label": "License Agreement [Member]"
       }
      }
     },
     "localname": "LicenseAgreementMember",
     "nsuri": "http://qualigeninc.com/20221231",
     "presentation": [
      "http://qualigeninc.com/role/ResearchAndLicenseAgreementsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "QLGN_LicenseAndSponsoredResearchAgreementsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License and Sponsored Research Agreements [Member]",
        "label": "License and Sponsored Research Agreements [Member]"
       }
      }
     },
     "localname": "LicenseAndSponsoredResearchAgreementsMember",
     "nsuri": "http://qualigeninc.com/20221231",
     "presentation": [
      "http://qualigeninc.com/role/ResearchAndLicenseAgreementsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "QLGN_LicenseCost": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License costs.",
        "label": "License cost"
       }
      }
     },
     "localname": "LicenseCost",
     "nsuri": "http://qualigeninc.com/20221231",
     "presentation": [
      "http://qualigeninc.com/role/ResearchAndLicenseAgreementsDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "QLGN_LicenseRevenueMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License Revenue [Member]",
        "label": "License Revenue [Member]"
       }
      }
     },
     "localname": "LicenseRevenueMember",
     "nsuri": "http://qualigeninc.com/20221231",
     "presentation": [
      "http://qualigeninc.com/role/ResearchAndLicenseAgreementsDetailsNarrative",
      "http://qualigeninc.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "domainItemType"
    },
    "QLGN_LicenseRevenuesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License Revenues [Member]",
        "label": "License Revenues [Member]"
       }
      }
     },
     "localname": "LicenseRevenuesMember",
     "nsuri": "http://qualigeninc.com/20221231",
     "presentation": [
      "http://qualigeninc.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesAndEstimatesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "QLGN_LicensedProductSalesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Licensed Product Sales [Member]",
        "label": "Licensed Product Sales [Member]"
       }
      }
     },
     "localname": "LicensedProductSalesMember",
     "nsuri": "http://qualigeninc.com/20221231",
     "presentation": [
      "http://qualigeninc.com/role/ResearchAndLicenseAgreementsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "QLGN_LicensingRightsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Licensing Rights [Member]",
        "label": "Licensing Rights [Member]"
       }
      }
     },
     "localname": "LicensingRightsMember",
     "nsuri": "http://qualigeninc.com/20221231",
     "presentation": [
      "http://qualigeninc.com/role/ScheduleOfGoodwillAndOtherIntangibleDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "QLGN_LongtermOperatingLeaseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Longterm Operating Lease Agreement [Member]",
        "label": "Long term Operating Lease Agreement [Member]"
       }
      }
     },
     "localname": "LongtermOperatingLeaseAgreementMember",
     "nsuri": "http://qualigeninc.com/20221231",
     "presentation": [
      "http://qualigeninc.com/role/ScheduleOfOperatingLeaseRightOfUseAssetsAndOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "QLGN_MilestoneMethodRevenueRecognized": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone method revenue recognized.",
        "label": "Milestone method revenue recognized"
       }
      }
     },
     "localname": "MilestoneMethodRevenueRecognized",
     "nsuri": "http://qualigeninc.com/20221231",
     "presentation": [
      "http://qualigeninc.com/role/ResearchAndLicenseAgreementsDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "QLGN_MilestonePayment": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone payment.",
        "label": "Milestone payment"
       }
      }
     },
     "localname": "MilestonePayment",
     "nsuri": "http://qualigeninc.com/20221231",
     "presentation": [
      "http://qualigeninc.com/role/ResearchAndLicenseAgreementsDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "QLGN_MilestonePaymentForCumulativeMarketingExpenses": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone payment for cumulative marketing expenses.",
        "label": "Milestone payment for cumulative marketing expenses"
       }
      }
     },
     "localname": "MilestonePaymentForCumulativeMarketingExpenses",
     "nsuri": "http://qualigeninc.com/20221231",
     "presentation": [
      "http://qualigeninc.com/role/ResearchAndLicenseAgreementsDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "QLGN_ModifiedToExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Modified to exercise price.",
        "label": "Modified to exercise price"
       }
      }
     },
     "localname": "ModifiedToExercisePrice",
     "nsuri": "http://qualigeninc.com/20221231",
     "presentation": [
      "http://qualigeninc.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "perShareItemType"
    },
    "QLGN_MoldsAndToolingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Molds and Tooling [Member]",
        "label": "Molds and Tooling [Member]"
       }
      }
     },
     "localname": "MoldsAndToolingMember",
     "nsuri": "http://qualigeninc.com/20221231",
     "presentation": [
      "http://qualigeninc.com/role/ScheduleOfPropertyAndEquipmentDetails",
      "http://qualigeninc.com/role/ScheduleOfUsefulLivesOfPropertyAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "QLGN_NanoSynexLtdMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nano Synex Ltd [Member]",
        "label": "Nano Synex Ltd [Member]"
       }
      }
     },
     "localname": "NanoSynexLtdMember",
     "nsuri": "http://qualigeninc.com/20221231",
     "presentation": [
      "http://qualigeninc.com/role/AcquisitionDetailsNarrative",
      "http://qualigeninc.com/role/LiquidityAndGoingConcernDetailsNarrative",
      "http://qualigeninc.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesAndEstimatesDetailsNarrative",
      "http://qualigeninc.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://qualigeninc.com/role/ScheduleOfConsiderationTransferredDetails",
      "http://qualigeninc.com/role/ScheduleOfConsiderationTransferredDetailsParenthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "QLGN_NanoSynexMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nano Synex Ltd [Member]",
        "label": "Nano Synex Ltd [Member] [Default Label]",
        "verboseLabel": "Nano Synex Ltd [Member]"
       }
      }
     },
     "localname": "NanoSynexMember",
     "nsuri": "http://qualigeninc.com/20221231",
     "presentation": [
      "http://qualigeninc.com/role/AcquisitionDetailsNarrative",
      "http://qualigeninc.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://qualigeninc.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://qualigeninc.com/role/ShortTermDebt-RelatedPartyDetailsNarrative",
      "http://qualigeninc.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "QLGN_NetProductSalesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net Product Sales [Member]",
        "label": "Net Product Sales [Member]"
       }
      }
     },
     "localname": "NetProductSalesMember",
     "nsuri": "http://qualigeninc.com/20221231",
     "presentation": [
      "http://qualigeninc.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "domainItemType"
    },
    "QLGN_NonCompensatoryWarrantActivityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non Compensatory Warrant Activity [Member]",
        "label": "Non Compensatory Warrant Activity [Member]"
       }
      }
     },
     "localname": "NonCompensatoryWarrantActivityMember",
     "nsuri": "http://qualigeninc.com/20221231",
     "presentation": [
      "http://qualigeninc.com/role/ScheduleOfWarrantActivityDetails",
      "http://qualigeninc.com/role/StockholdersEquityTables"
     ],
     "xbrltype": "domainItemType"
    },
    "QLGN_NoncompensatoryEquityClassifiedWarrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Noncompensatory Equity Classified Warrants [Member]",
        "label": "Noncompensatory Equity Classified Warrants [Member]"
       }
      }
     },
     "localname": "NoncompensatoryEquityClassifiedWarrantsMember",
     "nsuri": "http://qualigeninc.com/20221231",
     "presentation": [
      "http://qualigeninc.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "QLGN_NoncontrollingInterestAdjustmentsRelatingToStockbasedCompensationAndOther": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Noncontrolling interest adjustments relating to stockbased compensation and other.",
        "label": "Noncontrolling interest adjustments relating to Stock-based compensation and other"
       }
      }
     },
     "localname": "NoncontrollingInterestAdjustmentsRelatingToStockbasedCompensationAndOther",
     "nsuri": "http://qualigeninc.com/20221231",
     "presentation": [
      "http://qualigeninc.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "QLGN_NotesPayableMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Notes Payable [Member]",
        "label": "Notes Payable [Member]"
       }
      }
     },
     "localname": "NotesPayableMember",
     "nsuri": "http://qualigeninc.com/20221231",
     "presentation": [
      "http://qualigeninc.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://qualigeninc.com/role/ShortTermDebt-RelatedPartyDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "QLGN_OrganizationPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Organization Policy [TextBlock]",
        "label": "Organization"
       }
      }
     },
     "localname": "OrganizationPolicyTextBlock",
     "nsuri": "http://qualigeninc.com/20221231",
     "presentation": [
      "http://qualigeninc.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesAndEstimatesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "QLGN_PatentCosts": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Patent costs.",
        "label": "Patent costs"
       }
      }
     },
     "localname": "PatentCosts",
     "nsuri": "http://qualigeninc.com/20221231",
     "presentation": [
      "http://qualigeninc.com/role/ResearchAndLicenseAgreementsDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "QLGN_PatentCostsPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Patent Costs Policy [TextBlock]",
        "label": "Patent Costs"
       }
      }
     },
     "localname": "PatentCostsPolicyTextBlock",
     "nsuri": "http://qualigeninc.com/20221231",
     "presentation": [
      "http://qualigeninc.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesAndEstimatesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "QLGN_PatentsAndLicensesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Patents and Licenses [Member]",
        "label": "Patents and Licenses [Member]"
       }
      }
     },
     "localname": "PatentsAndLicensesMember",
     "nsuri": "http://qualigeninc.com/20221231",
     "presentation": [
      "http://qualigeninc.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesAndEstimatesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "QLGN_PaymentsToAcquireBusinesses": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payments to acquire businesses.",
        "label": "Cash paid for NanoSynex preferred stock:"
       }
      }
     },
     "localname": "PaymentsToAcquireBusinesses",
     "nsuri": "http://qualigeninc.com/20221231",
     "presentation": [
      "http://qualigeninc.com/role/ScheduleOfConsiderationTransferredDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "QLGN_PhaseClinicalTrialMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Phase Clinical Trial [Member]",
        "label": "Phase Clinical Trial [Member]"
       }
      }
     },
     "localname": "PhaseClinicalTrialMember",
     "nsuri": "http://qualigeninc.com/20221231",
     "presentation": [
      "http://qualigeninc.com/role/ResearchAndLicenseAgreementsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "QLGN_PhaseOneClinicalTrialMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Phase 1 Clinical Trial [Member]",
        "label": "Phase 1 Clinical Trial [Member]"
       }
      }
     },
     "localname": "PhaseOneClinicalTrialMember",
     "nsuri": "http://qualigeninc.com/20221231",
     "presentation": [
      "http://qualigeninc.com/role/ResearchAndLicenseAgreementsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "QLGN_PhaseThreeClinicalTrialMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Phase 3 Clinical Trial [Member]",
        "label": "Phase 3 Clinical Trial [Member]"
       }
      }
     },
     "localname": "PhaseThreeClinicalTrialMember",
     "nsuri": "http://qualigeninc.com/20221231",
     "presentation": [
      "http://qualigeninc.com/role/ResearchAndLicenseAgreementsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "QLGN_PhaseTwoClinicalTrialMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Phase 2 Clinical Trial [Member]",
        "label": "Phase 2 Clinical Trial [Member]"
       }
      }
     },
     "localname": "PhaseTwoClinicalTrialMember",
     "nsuri": "http://qualigeninc.com/20221231",
     "presentation": [
      "http://qualigeninc.com/role/ResearchAndLicenseAgreementsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "QLGN_PrefundedWarrantMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pre-funded Warrant [Member]",
        "label": "Pre-funded Warrant [Member]"
       }
      }
     },
     "localname": "PrefundedWarrantMember",
     "nsuri": "http://qualigeninc.com/20221231",
     "presentation": [
      "http://qualigeninc.com/role/AcquisitionDetailsNarrative",
      "http://qualigeninc.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesAndEstimatesDetailsNarrative",
      "http://qualigeninc.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "QLGN_PrefundedWarrantsIssuedForBusinessAcquisition": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Prefunded warrants issued for business acquisition.",
        "label": "FMV of 3,314,641 shares of Qualigen stock related to prefunded warrant issued to Alpha Capital Anstalt"
       }
      }
     },
     "localname": "PrefundedWarrantsIssuedForBusinessAcquisition",
     "nsuri": "http://qualigeninc.com/20221231",
     "presentation": [
      "http://qualigeninc.com/role/ScheduleOfConsiderationTransferredDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "QLGN_PrepaidExpensesAndOtherCurrentAssetsTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Prepaid Expenses and Other Current Assets [Text Block]",
        "label": "PREPAID EXPENSES AND OTHER CURRENT ASSETS"
       }
      }
     },
     "localname": "PrepaidExpensesAndOtherCurrentAssetsTextBlock",
     "nsuri": "http://qualigeninc.com/20221231",
     "presentation": [
      "http://qualigeninc.com/role/PrepaidExpensesAndOtherCurrentAssets"
     ],
     "xbrltype": "textBlockItemType"
    },
    "QLGN_PrepaidManufacturingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://qualigeninc.com/role/ScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Prepaid manufacturing expenses.",
        "label": "Prepaid manufacturing expenses"
       }
      }
     },
     "localname": "PrepaidManufacturingExpenses",
     "nsuri": "http://qualigeninc.com/20221231",
     "presentation": [
      "http://qualigeninc.com/role/ScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "QLGN_PrincipalAmountPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Principal amount percentage.",
        "label": "Principal amount percentage"
       }
      }
     },
     "localname": "PrincipalAmountPercentage",
     "nsuri": "http://qualigeninc.com/20221231",
     "presentation": [
      "http://qualigeninc.com/role/ConvertibleDebt-RelatedPartyDetailsNarrative"
     ],
     "xbrltype": "percentItemType"
    },
    "QLGN_ProceedsFromIssuanceOfConvertibleDebt": {
     "auth_ref": [],
     "calculation": {
      "http://qualigeninc.com/role/StatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from issuance of convertible debt.",
        "label": "Proceeds from issuance of convertible debt - related party"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfConvertibleDebt",
     "nsuri": "http://qualigeninc.com/20221231",
     "presentation": [
      "http://qualigeninc.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "QLGN_ProceedsFromIssuanceOfSharesAndWarrantsPursuantToSecuritiesPurchaseAgreements": {
     "auth_ref": [],
     "calculation": {
      "http://qualigeninc.com/role/StatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from issuance of shares and warrants pursuant to securities purchase agreements.",
        "label": "Proceeds from issuance of shares and warrants pursuant to Securities Purchase Agreements"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfSharesAndWarrantsPursuantToSecuritiesPurchaseAgreements",
     "nsuri": "http://qualigeninc.com/20221231",
     "presentation": [
      "http://qualigeninc.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "QLGN_PurchasePrice": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchase price.",
        "label": "Purchase Price"
       }
      }
     },
     "localname": "PurchasePrice",
     "nsuri": "http://qualigeninc.com/20221231",
     "presentation": [
      "http://qualigeninc.com/role/ConvertibleDebt-RelatedPartyDetailsNarrative",
      "http://qualigeninc.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://qualigeninc.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "QLGN_PurchasesOfEquipmentHeldForLease": {
     "auth_ref": [],
     "calculation": {
      "http://qualigeninc.com/role/StatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchases of equipment held for lease.",
        "label": "PurchasesOfEquipmentHeldForLease",
        "negatedLabel": "Purchases of equipment held for lease"
       }
      }
     },
     "localname": "PurchasesOfEquipmentHeldForLease",
     "nsuri": "http://qualigeninc.com/20221231",
     "presentation": [
      "http://qualigeninc.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "QLGN_RangeOfExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Range of exercise price.",
        "label": "RangeOfExercisePrice",
        "periodEndLabel": "Range of Exercise Ending",
        "periodStartLabel": "Range of Exercise Beginning"
       }
      }
     },
     "localname": "RangeOfExercisePrice",
     "nsuri": "http://qualigeninc.com/20221231",
     "presentation": [
      "http://qualigeninc.com/role/ScheduleOfWarrantsActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "QLGN_RangeOfExercisePriceExercisableVested": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Range of exercise price, exercisable (vested).",
        "label": "Range of Exercise Price, Exercisable",
        "periodEndLabel": "Range of Exercise Price, Exercisable",
        "verboseLabel": "Range of exercise price - Exercisable"
       }
      }
     },
     "localname": "RangeOfExercisePriceExercisableVested",
     "nsuri": "http://qualigeninc.com/20221231",
     "presentation": [
      "http://qualigeninc.com/role/ScheduleOfWarrantActivityDetails",
      "http://qualigeninc.com/role/ScheduleOfWarrantsActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "QLGN_RangeOfExercisePriceExpired": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Range of exercise price expired",
        "label": "Range of exercise price - Expired"
       }
      }
     },
     "localname": "RangeOfExercisePriceExpired",
     "nsuri": "http://qualigeninc.com/20221231",
     "presentation": [
      "http://qualigeninc.com/role/ScheduleOfWarrantActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "QLGN_RangeOfExercisePriceGranted": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Range of exercise price granted.",
        "label": "Range of exercise price - granted"
       }
      }
     },
     "localname": "RangeOfExercisePriceGranted",
     "nsuri": "http://qualigeninc.com/20221231",
     "presentation": [
      "http://qualigeninc.com/role/ScheduleOfWarrantActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "QLGN_RangeOfExercisePriceNonExercisableVested": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Range of exercise price non exercisable vested",
        "label": "Range of exercise price - Exercisable"
       }
      }
     },
     "localname": "RangeOfExercisePriceNonExercisableVested",
     "nsuri": "http://qualigeninc.com/20221231",
     "presentation": [
      "http://qualigeninc.com/role/ScheduleOfWarrantActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "QLGN_RangeOfExercisePriceNonexercisableNonvested": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Range of exercise price, non-exercisable (non-vested).",
        "label": "Range of Exercise Price, Non-Exercisable"
       }
      }
     },
     "localname": "RangeOfExercisePriceNonexercisableNonvested",
     "nsuri": "http://qualigeninc.com/20221231",
     "presentation": [
      "http://qualigeninc.com/role/ScheduleOfWarrantActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "QLGN_RangeOfExercisePriceOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Range Of Exercise Price Outstanding.",
        "label": "RangeOfExercisePriceOutstanding",
        "periodEndLabel": "Range of exercise price - ending",
        "periodStartLabel": "Range of exercise price - beginning"
       }
      }
     },
     "localname": "RangeOfExercisePriceOutstanding",
     "nsuri": "http://qualigeninc.com/20221231",
     "presentation": [
      "http://qualigeninc.com/role/ScheduleOfWarrantActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "QLGN_RegulatoryMarketingApprovalExpenses": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Regulatory marketing approval, expenses.",
        "label": "Regulatory marketing approval, expenses"
       }
      }
     },
     "localname": "RegulatoryMarketingApprovalExpenses",
     "nsuri": "http://qualigeninc.com/20221231",
     "presentation": [
      "http://qualigeninc.com/role/ResearchAndLicenseAgreementsDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "QLGN_RegulatoryMarketingApprovalExpensesOne": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Regulatory marketing approval expenses one.",
        "label": "RegulatoryMarketingApprovalExpensesOne",
        "verboseLabel": "Regulatory marketing approval, expenses"
       }
      }
     },
     "localname": "RegulatoryMarketingApprovalExpensesOne",
     "nsuri": "http://qualigeninc.com/20221231",
     "presentation": [
      "http://qualigeninc.com/role/ResearchAndLicenseAgreementsDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "QLGN_ReimbursementOfPatent": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reimbursement of patent.",
        "label": "Reimbursement of patent"
       }
      }
     },
     "localname": "ReimbursementOfPatent",
     "nsuri": "http://qualigeninc.com/20221231",
     "presentation": [
      "http://qualigeninc.com/role/ResearchAndLicenseAgreementsDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "QLGN_ReimbursementOfResearchExpenses": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reimbursement of research expenses.",
        "label": "Reimbursement of research expenses"
       }
      }
     },
     "localname": "ReimbursementOfResearchExpenses",
     "nsuri": "http://qualigeninc.com/20221231",
     "presentation": [
      "http://qualigeninc.com/role/ResearchAndLicenseAgreementsDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "QLGN_ResearchAndDevelopmentGrantLiability": {
     "auth_ref": [],
     "calculation": {
      "http://qualigeninc.com/role/BalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research and development grant liability",
        "label": "R&amp;D grant liability"
       }
      }
     },
     "localname": "ResearchAndDevelopmentGrantLiability",
     "nsuri": "http://qualigeninc.com/20221231",
     "presentation": [
      "http://qualigeninc.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "QLGN_ResearchAndDevelopmentGrantsPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research And Development Grants Policy [TextBlock]",
        "label": "R&amp;D Grants"
       }
      }
     },
     "localname": "ResearchAndDevelopmentGrantsPolicyTextBlock",
     "nsuri": "http://qualigeninc.com/20221231",
     "presentation": [
      "http://qualigeninc.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesAndEstimatesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "QLGN_ResearchAndLicenseAgreementsTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research And License Agreements [Text Block]",
        "label": "RESEARCH AND LICENSE AGREEMENTS"
       }
      }
     },
     "localname": "ResearchAndLicenseAgreementsTextBlock",
     "nsuri": "http://qualigeninc.com/20221231",
     "presentation": [
      "http://qualigeninc.com/role/ResearchAndLicenseAgreements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "QLGN_RightofuseAssetsObtainedInExchangeForOperatingLeaseLiabilities": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rightofuse assets obtained in exchange for operating lease liabilities.",
        "label": "Right-of-use assets obtained in exchange for operating lease liabilities"
       }
      }
     },
     "localname": "RightofuseAssetsObtainedInExchangeForOperatingLeaseLiabilities",
     "nsuri": "http://qualigeninc.com/20221231",
     "presentation": [
      "http://qualigeninc.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "QLGN_STAPharmaceuticalCoLtdMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "STA Pharmaceutical Co Ltd [Member]",
        "label": "STA Pharmaceutical Co Ltd [Member]"
       }
      }
     },
     "localname": "STAPharmaceuticalCoLtdMember",
     "nsuri": "http://qualigeninc.com/20221231",
     "presentation": [
      "http://qualigeninc.com/role/ResearchAndLicenseAgreementsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "QLGN_SalesAndExciseTaxesPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sales And Excise Taxes [Policy Text Block]",
        "label": "Sales and Excise Taxes"
       }
      }
     },
     "localname": "SalesAndExciseTaxesPolicyTextBlock",
     "nsuri": "http://qualigeninc.com/20221231",
     "presentation": [
      "http://qualigeninc.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesAndEstimatesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "QLGN_ScheduleOfAssumptionsOfWarrantLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule Of Assumptions Of Warrant Liabilities [Table Text Block]",
        "label": "SCHEDULE OF ASSUMPTIONS OF WARRANT LIABILITIES"
       }
      }
     },
     "localname": "ScheduleOfAssumptionsOfWarrantLiabilitiesTableTextBlock",
     "nsuri": "http://qualigeninc.com/20221231",
     "presentation": [
      "http://qualigeninc.com/role/WarrantLiabilitiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "QLGN_ScheduleOfFairValueHierarchyForWarrantLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule Of Fair Value Hierarchy For Warrant Liabilities [Table Text Block]",
        "label": "SCHEDULE OF FAIR VALUE HIERARCHY FOR WARRANT LIABILITIES"
       }
      }
     },
     "localname": "ScheduleOfFairValueHierarchyForWarrantLiabilitiesTableTextBlock",
     "nsuri": "http://qualigeninc.com/20221231",
     "presentation": [
      "http://qualigeninc.com/role/WarrantLiabilitiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "QLGN_ScheduleOfOperatingLeaseRightOfUseAssetsAndLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule Of Operating Lease Right Of Use Assets And Liabilities [Table Text Block]",
        "label": "SCHEDULE OF OPERATING LEASE RIGHT OF USE ASSETS AND OPERATING LEASE LIABILITIES"
       }
      }
     },
     "localname": "ScheduleOfOperatingLeaseRightOfUseAssetsAndLiabilitiesTableTextBlock",
     "nsuri": "http://qualigeninc.com/20221231",
     "presentation": [
      "http://qualigeninc.com/role/CommitmentsAndContingenciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "QLGN_ScheduleOfReservedSharesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of reserved shares [Table Text Block]",
        "label": "SCHEDULE OF RESERVED SHARES"
       }
      }
     },
     "localname": "ScheduleOfReservedSharesTableTextBlock",
     "nsuri": "http://qualigeninc.com/20221231",
     "presentation": [
      "http://qualigeninc.com/role/StockholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "QLGN_ScheduleOfUsefulLivesOfPropertyAndEquipmentTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule Of Useful Lives Of Property And Equipment [Table TextBlock]",
        "label": "SCHEDULE OF USEFUL LIVES OF PROPERTY AND EQUIPMENT"
       }
      }
     },
     "localname": "ScheduleOfUsefulLivesOfPropertyAndEquipmentTableTextBlock",
     "nsuri": "http://qualigeninc.com/20221231",
     "presentation": [
      "http://qualigeninc.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesAndEstimatesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "QLGN_SecuritiesPurchaseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities Purchase Agreement [Member]",
        "label": "Securities Purchase Agreement [Member]"
       }
      }
     },
     "localname": "SecuritiesPurchaseAgreementMember",
     "nsuri": "http://qualigeninc.com/20221231",
     "presentation": [
      "http://qualigeninc.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "QLGN_SekisuiDistributionAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sekisui Distribution Agreement [Member]",
        "label": "Sekisui Distribution Agreement [Member]"
       }
      }
     },
     "localname": "SekisuiDistributionAgreementMember",
     "nsuri": "http://qualigeninc.com/20221231",
     "presentation": [
      "http://qualigeninc.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://qualigeninc.com/role/PropertyAndEquipmentNetDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "QLGN_SeniorConvertibleDebentureMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Senior Convertible Debenture [Member]",
        "label": "Senior Convertible Debenture [Member]"
       }
      }
     },
     "localname": "SeniorConvertibleDebentureMember",
     "nsuri": "http://qualigeninc.com/20221231",
     "presentation": [
      "http://qualigeninc.com/role/ConvertibleDebt-RelatedPartyDetailsNarrative",
      "http://qualigeninc.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://qualigeninc.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "QLGN_SeniorSecuredConvertibleDebtMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Senior Secured Convertible Debt [Member]",
        "label": "Senior Secured Convertible Debt [Member]"
       }
      }
     },
     "localname": "SeniorSecuredConvertibleDebtMember",
     "nsuri": "http://qualigeninc.com/20221231",
     "presentation": [
      "http://qualigeninc.com/role/ScheduleOfSeniorSecuredConvertibleDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "QLGN_SeriesAOnePreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series A-1 Preferred Stock [Member]",
        "label": "Series A-1 Preferred Stock [Member]"
       }
      }
     },
     "localname": "SeriesAOnePreferredStockMember",
     "nsuri": "http://qualigeninc.com/20221231",
     "presentation": [
      "http://qualigeninc.com/role/AcquisitionDetailsNarrative",
      "http://qualigeninc.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesAndEstimatesDetailsNarrative",
      "http://qualigeninc.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "QLGN_SeriesAlphaConvertiblePreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series Alpha Convertible Preferred Stock [Member]",
        "label": "Series Alpha Convertible Preferred Stock [Member]"
       }
      }
     },
     "localname": "SeriesAlphaConvertiblePreferredStockMember",
     "nsuri": "http://qualigeninc.com/20221231",
     "presentation": [
      "http://qualigeninc.com/role/StatementsOfChangesInStockholdersEquity",
      "http://qualigeninc.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "QLGN_SeriesCWarrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series C Warrants [Member]",
        "label": "Series C Warrants [Member]"
       }
      }
     },
     "localname": "SeriesCWarrantsMember",
     "nsuri": "http://qualigeninc.com/20221231",
     "presentation": [
      "http://qualigeninc.com/role/ConvertibleDebt-RelatedPartyDetailsNarrative",
      "http://qualigeninc.com/role/ScheduleOfWarrantsActivityDetails",
      "http://qualigeninc.com/role/StockholdersEquityDetailsNarrative",
      "http://qualigeninc.com/role/WarrantLiabilitiesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNonVestedNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares, warrants non-exercisable (non-vested).",
        "label": "Number of shares, warrants non-exercisable"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNonVestedNumber",
     "nsuri": "http://qualigeninc.com/20221231",
     "presentation": [
      "http://qualigeninc.com/role/ScheduleOfWarrantActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vestednon-option equity outstanding as of the balance sheet date can be currently converted under the non-option equity plan.",
        "label": "Number of Shares, Warrants Exercisable",
        "periodEndLabel": "Number of Shares, Warrants Exercisable"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber",
     "nsuri": "http://qualigeninc.com/20221231",
     "presentation": [
      "http://qualigeninc.com/role/ScheduleOfWarrantActivityDetails",
      "http://qualigeninc.com/role/ScheduleOfWarrantsActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageNonVestedExercise": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average exercise price per share non-exercisable (non-vested).",
        "label": "Weighted Average Exercise Price Per Share Non-Exercisable"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageNonVestedExercise",
     "nsuri": "http://qualigeninc.com/20221231",
     "presentation": [
      "http://qualigeninc.com/role/ScheduleOfWarrantActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageVestedExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average exercise price per share exercisable (vested).",
        "label": "Weighted Average Exercise Price Per Share Exercisable",
        "periodEndLabel": "Weighted Average Exercise Price Per Share Exercisable"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageVestedExercisePrice",
     "nsuri": "http://qualigeninc.com/20221231",
     "presentation": [
      "http://qualigeninc.com/role/ScheduleOfWarrantActivityDetails",
      "http://qualigeninc.com/role/ScheduleOfWarrantsActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageVestedNonExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment award non option equity instruments exercisable weighted average vested non exercise price",
        "label": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageVestedNonExercisePrice",
        "verboseLabel": "Weighted Average Exercise Price Per Share Exercisable"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageVestedNonExercisePrice",
     "nsuri": "http://qualigeninc.com/20221231",
     "presentation": [
      "http://qualigeninc.com/role/ScheduleOfWarrantActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average exercise price per share warrants exercised.",
        "label": "Weighted Average Exercise Price Per Share Warrants Exercised",
        "verboseLabel": "Weighted average exercise price per share warrants exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://qualigeninc.com/20221231",
     "presentation": [
      "http://qualigeninc.com/role/ScheduleOfWarrantActivityDetails",
      "http://qualigeninc.com/role/ScheduleOfWarrantsActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment award non option equity instruments expired in period weighted average exercise price.",
        "label": "Weighted Average Exercise Price Per Share Warrants Expired",
        "verboseLabel": "Weighted average exercise price per share warrants expired"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://qualigeninc.com/20221231",
     "presentation": [
      "http://qualigeninc.com/role/ScheduleOfWarrantActivityDetails",
      "http://qualigeninc.com/role/ScheduleOfWarrantsActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInRangeOfExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment award non option equity instruments expired in range of exercise price.",
        "label": "Weighted average exercise price per share warrants expired"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInRangeOfExercisePrice",
     "nsuri": "http://qualigeninc.com/20221231",
     "presentation": [
      "http://qualigeninc.com/role/ScheduleOfWarrantActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average exercise price per share warrants forfeited.",
        "label": "Weighted Average Exercise Price Per Share Warrants Forfeited",
        "verboseLabel": "Weighted average exercise price per share warrants forfeited"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://qualigeninc.com/20221231",
     "presentation": [
      "http://qualigeninc.com/role/ScheduleOfWarrantActivityDetails",
      "http://qualigeninc.com/role/ScheduleOfWarrantsActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedInRangeOfExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment award non option equity instruments forfeited in range of exercise price.",
        "label": "Weighted average exercise price per share warrants forfeited"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedInRangeOfExercisePrice",
     "nsuri": "http://qualigeninc.com/20221231",
     "presentation": [
      "http://qualigeninc.com/role/ScheduleOfWarrantActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment award non option equity instruments exercised in period weighted average common stock warrants reverse recapitalization.",
        "label": "Weighted Average Exercise Price Per Share Warrants Granted",
        "verboseLabel": "Weighted average exercise price per share warrants granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://qualigeninc.com/20221231",
     "presentation": [
      "http://qualigeninc.com/role/ScheduleOfWarrantActivityDetails",
      "http://qualigeninc.com/role/ScheduleOfWarrantsActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsNonExercisableNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment award non option equity instruments non exercisable number",
        "label": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsNonExercisableNumber",
        "verboseLabel": "Number of Shares, Warrants Exercisable"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsNonExercisableNumber",
     "nsuri": "http://qualigeninc.com/20221231",
     "presentation": [
      "http://qualigeninc.com/role/ScheduleOfWarrantActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAveragRemainingContractualTerm1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for vested portions of non-option equity outstanding and currently vested exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Weighted Averag Remaining Contractual Term",
        "verboseLabel": "Weighted average remaining life (Years) exercisable"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAveragRemainingContractualTerm1",
     "nsuri": "http://qualigeninc.com/20221231",
     "presentation": [
      "http://qualigeninc.com/role/ScheduleOfWarrantActivityDetails",
      "http://qualigeninc.com/role/ScheduleOfWarrantsActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNonExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for vested portions of non-option equity outstanding and currently nonvested exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Exercisable Weighted Averag Remaining Contractual Term",
        "verboseLabel": "Weighted average remaining life (Years) non-exercisable"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNonExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://qualigeninc.com/20221231",
     "presentation": [
      "http://qualigeninc.com/role/ScheduleOfWarrantActivityDetails",
      "http://qualigeninc.com/role/ScheduleOfWarrantsActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAveragRemainingContractualTerm1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment award non option equity instruments legacy ritter weighted average exercise price one.",
        "label": "Weighted Average Remaining Life (Years) - outstanding"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAveragRemainingContractualTerm1",
     "nsuri": "http://qualigeninc.com/20221231",
     "presentation": [
      "http://qualigeninc.com/role/ScheduleOfWarrantActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock non-option equity plan.",
        "label": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice",
        "periodEndLabel": "Weighted Average Exercise Price Per Share Warrants Outstanding Ending",
        "periodStartLabel": "Weighted Average Exercise Price Per Share Warrants Outstanding Beginning"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://qualigeninc.com/20221231",
     "presentation": [
      "http://qualigeninc.com/role/ScheduleOfWarrantActivityDetails",
      "http://qualigeninc.com/role/ScheduleOfWarrantsActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsRangeOfExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment award non option equity instruments range of exercise price.",
        "label": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsRangeOfExercisePrice",
        "periodEndLabel": "Range of exercise price",
        "periodStartLabel": "Range of exercise price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsRangeOfExercisePrice",
     "nsuri": "http://qualigeninc.com/20221231",
     "presentation": [
      "http://qualigeninc.com/role/ScheduleOfWarrantActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExpirationsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based compensation arrangement by share-based payment award option expirations in period weighted average exercise price.",
        "label": "Range of exercise price, options expired",
        "verboseLabel": "Range of Exercise price, Options Expired"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExpirationsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://qualigeninc.com/20221231",
     "presentation": [
      "http://qualigeninc.com/role/ScheduleOfStockOptionActivityDetails",
      "http://qualigeninc.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "perShareItemType"
    },
    "QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionGrantedWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment award option granted weighted average exercise price.",
        "label": "Range of Exercise price, Options Outstanding"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionGrantedWeightedAverageExercisePrice",
     "nsuri": "http://qualigeninc.com/20221231",
     "presentation": [
      "http://qualigeninc.com/role/ScheduleOfStockOptionActivityDetails",
      "http://qualigeninc.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "perShareItemType"
    },
    "QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToNonVestExercisableWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average exercise price, options non-exercisable (non-vested).",
        "label": "Weighted average exercise price, options non-exercisable (non-vested)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToNonVestExercisableWeightedAverageExercisePrice",
     "nsuri": "http://qualigeninc.com/20221231",
     "presentation": [
      "http://qualigeninc.com/role/ScheduleOfStockOptionActivityDetails",
      "http://qualigeninc.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "perShareItemType"
    },
    "QLGN_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted- Average Remaining Contractual Life (in Years), Options Granted.",
        "label": "Weighted- Average Remaining Contractual Life (in Years), Options Granted"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://qualigeninc.com/20221231",
     "presentation": [
      "http://qualigeninc.com/role/ScheduleOfStockOptionActivityDetails",
      "http://qualigeninc.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "durationItemType"
    },
    "QLGN_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm3": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment award non option equity instruments legacy ritter weighted average exercise price one.",
        "label": "Weighted- Average Remaining Contractual Life (in Years), Outstanding, Beginning"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm3",
     "nsuri": "http://qualigeninc.com/20221231",
     "presentation": [
      "http://qualigeninc.com/role/ScheduleOfStockOptionActivityDetails",
      "http://qualigeninc.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "durationItemType"
    },
    "QLGN_SharesIssuedForCashlessWarrantsAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares issued for cashless warrants amount.",
        "label": "Fair value of shares issued for cashless warrant exercises"
       }
      }
     },
     "localname": "SharesIssuedForCashlessWarrantsAmount",
     "nsuri": "http://qualigeninc.com/20221231",
     "presentation": [
      "http://qualigeninc.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "QLGN_SharesIssuedPursuantToSecuritiesPurchaseAgreements": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares issued pursuant to securitie purchase agreements.",
        "label": "Shares issued pursuant to Securities Purchase Agreements"
       }
      }
     },
     "localname": "SharesIssuedPursuantToSecuritiesPurchaseAgreements",
     "nsuri": "http://qualigeninc.com/20221231",
     "presentation": [
      "http://qualigeninc.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "QLGN_SharesIssuedPursuantToSecuritiesPurchaseShareAgreements": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares issued pursuant to securities purchase share agreements.",
        "label": "Shares issued pursuant to Securities Purchase Agreements, Shares"
       }
      }
     },
     "localname": "SharesIssuedPursuantToSecuritiesPurchaseShareAgreements",
     "nsuri": "http://qualigeninc.com/20221231",
     "presentation": [
      "http://qualigeninc.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "QLGN_SharesOfCommonStockSubjectToOutstandingOptionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares of Common Stock Subject to Outstanding Options [Member]",
        "label": "Shares of Common Stock Subject to Outstanding Options [Member]"
       }
      }
     },
     "localname": "SharesOfCommonStockSubjectToOutstandingOptionsMember",
     "nsuri": "http://qualigeninc.com/20221231",
     "presentation": [
      "http://qualigeninc.com/role/ScheduleOfDilutiveSecuritiesExcludedFromDilutedNetLossPerShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "QLGN_SharesOfCommonStockSubjectToOutstandingWarrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares of Common Stock Subject to Outstanding Warrants [Member]",
        "label": "Shares of Common Stock Subject to Outstanding Warrants [Member]"
       }
      }
     },
     "localname": "SharesOfCommonStockSubjectToOutstandingWarrantsMember",
     "nsuri": "http://qualigeninc.com/20221231",
     "presentation": [
      "http://qualigeninc.com/role/ScheduleOfDilutiveSecuritiesExcludedFromDilutedNetLossPerShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "QLGN_ShippingAndHandlingCostsPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shipping And Handling Costs Policy [TextBlock]",
        "label": "Shipping and Handling Costs"
       }
      }
     },
     "localname": "ShippingAndHandlingCostsPolicyTextBlock",
     "nsuri": "http://qualigeninc.com/20221231",
     "presentation": [
      "http://qualigeninc.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesAndEstimatesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "QLGN_ShortfallPayments": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shortfall payments.",
        "label": "Shortfall payments"
       }
      }
     },
     "localname": "ShortfallPayments",
     "nsuri": "http://qualigeninc.com/20221231",
     "presentation": [
      "http://qualigeninc.com/role/ResearchAndLicenseAgreementsDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "QLGN_SponsoredResearchAgreementAndLicenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sponsored Research and License Agreement [Member]",
        "label": "Sponsored Research and License Agreement [Member]"
       }
      }
     },
     "localname": "SponsoredResearchAgreementAndLicenseMember",
     "nsuri": "http://qualigeninc.com/20221231",
     "presentation": [
      "http://qualigeninc.com/role/ResearchAndLicenseAgreementsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "QLGN_StockIssuedDuringPeriodValuesReverseStockSplits": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock issued during period values reverse stock splits.",
        "label": "Issuance of rounded shares as a result of the reverse stock split"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValuesReverseStockSplits",
     "nsuri": "http://qualigeninc.com/20221231",
     "presentation": [
      "http://qualigeninc.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "QLGN_StockIssuedUponCashExerciseOfWarrants": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock issued upon cash exercise of warrants",
        "label": "Stock issued upon cash-exercise of warrants"
       }
      }
     },
     "localname": "StockIssuedUponCashExerciseOfWarrants",
     "nsuri": "http://qualigeninc.com/20221231",
     "presentation": [
      "http://qualigeninc.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "QLGN_StockIssuedUponCashExerciseOfWarrantsShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock issued upon cash exercise of warrants shares.",
        "label": "Stock issued upon cash exercise of warrants, shares"
       }
      }
     },
     "localname": "StockIssuedUponCashExerciseOfWarrantsShares",
     "nsuri": "http://qualigeninc.com/20221231",
     "presentation": [
      "http://qualigeninc.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "QLGN_StockIssuedUponNetexerciseOfWarrants": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock issued upon net exercise of warrants.",
        "label": "Stock issued upon net-exercise of warrants"
       }
      }
     },
     "localname": "StockIssuedUponNetexerciseOfWarrants",
     "nsuri": "http://qualigeninc.com/20221231",
     "presentation": [
      "http://qualigeninc.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "QLGN_StockIssuedUponNetexerciseOfWarrantsShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock issued upon net exercise of warrants shares",
        "label": "Stock issued upon net-exercise of warrants, shares"
       }
      }
     },
     "localname": "StockIssuedUponNetexerciseOfWarrantsShares",
     "nsuri": "http://qualigeninc.com/20221231",
     "presentation": [
      "http://qualigeninc.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "QLGN_SummaryOfWarrantActivityTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summary Of Warrant Activity [Table Text Block]",
        "label": "SCHEDULE OF WARRANT ACTIVITY"
       }
      }
     },
     "localname": "SummaryOfWarrantActivityTableTextBlock",
     "nsuri": "http://qualigeninc.com/20221231",
     "presentation": [
      "http://qualigeninc.com/role/StockholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "QLGN_TenantImprovementAllowance": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tenant improvement allowance.",
        "label": "Tenant improvement allowance"
       }
      }
     },
     "localname": "TenantImprovementAllowance",
     "nsuri": "http://qualigeninc.com/20221231",
     "presentation": [
      "http://qualigeninc.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "QLGN_TransfersOfInventoryFromEquipmentHeldForLease": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Transfers of inventory from equipment held for lease.",
        "label": "Net transfers to inventory from equipment held for lease"
       }
      }
     },
     "localname": "TransfersOfInventoryFromEquipmentHeldForLease",
     "nsuri": "http://qualigeninc.com/20221231",
     "presentation": [
      "http://qualigeninc.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "QLGN_TwoThousandTwentyStockIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2020 Stock Incentive Plan [Member]",
        "label": "2020 Stock Incentive Plan [Member]"
       }
      }
     },
     "localname": "TwoThousandTwentyStockIncentivePlanMember",
     "nsuri": "http://qualigeninc.com/20221231",
     "presentation": [
      "http://qualigeninc.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "QLGN_UniversityOfLouisvilleResearchFoundationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "University of Louisville Research Foundation [Member]",
        "label": "University of Louisville Research Foundation [Member]"
       }
      }
     },
     "localname": "UniversityOfLouisvilleResearchFoundationMember",
     "nsuri": "http://qualigeninc.com/20221231",
     "presentation": [
      "http://qualigeninc.com/role/ResearchAndLicenseAgreementsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "QLGN_UpfrontLicenseFee": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Upfront license fee.",
        "label": "Upfront license fee"
       }
      }
     },
     "localname": "UpfrontLicenseFee",
     "nsuri": "http://qualigeninc.com/20221231",
     "presentation": [
      "http://qualigeninc.com/role/ResearchAndLicenseAgreementsDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "QLGN_UpfrontPaymentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Upfront Payment [Member]",
        "label": "Upfront Payment [Member]"
       }
      }
     },
     "localname": "UpfrontPaymentMember",
     "nsuri": "http://qualigeninc.com/20221231",
     "presentation": [
      "http://qualigeninc.com/role/ResearchAndLicenseAgreementsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "QLGN_WarrantLiabilitiesRelatedParty": {
     "auth_ref": [],
     "calculation": {
      "http://qualigeninc.com/role/BalanceSheets": {
       "order": 9.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant liabilities - related party"
       }
      }
     },
     "localname": "WarrantLiabilitiesRelatedParty",
     "nsuri": "http://qualigeninc.com/20221231",
     "presentation": [
      "http://qualigeninc.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "QLGN_WarrantLiabilitiesTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrant Liabilities [Text Block]",
        "label": "WARRANT LIABILITIES"
       }
      }
     },
     "localname": "WarrantLiabilitiesTextBlock",
     "nsuri": "http://qualigeninc.com/20221231",
     "presentation": [
      "http://qualigeninc.com/role/WarrantLiabilities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "QLGN_WarrantOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrant One [Member]",
        "label": "Warrant One [Member]"
       }
      }
     },
     "localname": "WarrantOneMember",
     "nsuri": "http://qualigeninc.com/20221231",
     "presentation": [
      "http://qualigeninc.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "QLGN_WarrantsExercised": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrants exercised.",
        "label": "Warrants exercised"
       }
      }
     },
     "localname": "WarrantsExercised",
     "nsuri": "http://qualigeninc.com/20221231",
     "presentation": [
      "http://qualigeninc.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "QLGN_WarrantsExtendedDateDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrants extended date, description.",
        "label": "Warrants extended date description"
       }
      }
     },
     "localname": "WarrantsExtendedDateDescription",
     "nsuri": "http://qualigeninc.com/20221231",
     "presentation": [
      "http://qualigeninc.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "QLGN_WarrantyReservePolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warranty Reserve [Policy Text Block]",
        "label": "Warranty Costs"
       }
      }
     },
     "localname": "WarrantyReservePolicyTextBlock",
     "nsuri": "http://qualigeninc.com/20221231",
     "presentation": [
      "http://qualigeninc.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesAndEstimatesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "QLGN_WeightedAverageRemainingContractualLifeInYearsOptionsNonexercisableNonvested": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted- average remaining contractual life (in years), options non-exercisable (non-vested).",
        "label": "Weighted- Average Remaining Contractual Life (in Years), Options Non-exercisable (non-vested)"
       }
      }
     },
     "localname": "WeightedAverageRemainingContractualLifeInYearsOptionsNonexercisableNonvested",
     "nsuri": "http://qualigeninc.com/20221231",
     "presentation": [
      "http://qualigeninc.com/role/ScheduleOfStockOptionActivityDetails",
      "http://qualigeninc.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "durationItemType"
    },
    "QLGN_YiXinZhenDuanJishuLtdMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Yi Xin Zhen Duan Jishu Ltd [Member]",
        "label": "Yi Xin Zhen Duan Jishu Ltd [Member]"
       }
      }
     },
     "localname": "YiXinZhenDuanJishuLtdMember",
     "nsuri": "http://qualigeninc.com/20221231",
     "presentation": [
      "http://qualigeninc.com/role/ResearchAndLicenseAgreementsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of changes contained within amended document.",
        "label": "Amendment Description"
       }
      }
     },
     "localname": "AmendmentDescription",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://qualigeninc.com/role/Cover"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://qualigeninc.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AnnualInformationForm": {
     "auth_ref": [
      "r644"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.",
        "label": "Annual Information Form"
       }
      }
     },
     "localname": "AnnualInformationForm",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://qualigeninc.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditedAnnualFinancialStatements": {
     "auth_ref": [
      "r644"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.",
        "label": "Audited Annual Financial Statements"
       }
      }
     },
     "localname": "AuditedAnnualFinancialStatements",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://qualigeninc.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditorFirmId": {
     "auth_ref": [
      "r641",
      "r643",
      "r644"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "PCAOB issued Audit Firm Identifier",
        "label": "Auditor Firm ID"
       }
      }
     },
     "localname": "AuditorFirmId",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://qualigeninc.com/role/Cover"
     ],
     "xbrltype": "nonemptySequenceNumberItemType"
    },
    "dei_AuditorLocation": {
     "auth_ref": [
      "r641",
      "r643",
      "r644"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location"
       }
      }
     },
     "localname": "AuditorLocation",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://qualigeninc.com/role/Cover"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_AuditorName": {
     "auth_ref": [
      "r641",
      "r643",
      "r644"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name"
       }
      }
     },
     "localname": "AuditorName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://qualigeninc.com/role/Cover"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://qualigeninc.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CountryRegion": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Region code of country",
        "label": "Country Region"
       }
      }
     },
     "localname": "CountryRegion",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://qualigeninc.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://qualigeninc.com/role/Cover"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAccountingStandard": {
     "auth_ref": [
      "r643"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.",
        "label": "Document Accounting Standard"
       }
      }
     },
     "localname": "DocumentAccountingStandard",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://qualigeninc.com/role/Cover"
     ],
     "xbrltype": "accountingStandardItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r641",
      "r643",
      "r644"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://qualigeninc.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://qualigeninc.com/role/Cover"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://qualigeninc.com/role/Cover"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://qualigeninc.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentPeriodStartDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.",
        "label": "Document Period Start Date"
       }
      }
     },
     "localname": "DocumentPeriodStartDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://qualigeninc.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r642"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://qualigeninc.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentRegistrationStatement": {
     "auth_ref": [
      "r630"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a registration statement.",
        "label": "Document Registration Statement"
       }
      }
     },
     "localname": "DocumentRegistrationStatement",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://qualigeninc.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentShellCompanyEventDate": {
     "auth_ref": [
      "r643"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date of event requiring a shell company report.",
        "label": "Document Shell Company Event Date"
       }
      }
     },
     "localname": "DocumentShellCompanyEventDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://qualigeninc.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentShellCompanyReport": {
     "auth_ref": [
      "r643"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.",
        "label": "Document Shell Company Report"
       }
      }
     },
     "localname": "DocumentShellCompanyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://qualigeninc.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r645"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://qualigeninc.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://qualigeninc.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "auth_ref": [
      "r633"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Documents incorporated by reference.",
        "label": "Documents Incorporated by Reference [Text Block]"
       }
      }
     },
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://qualigeninc.com/role/Cover"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://qualigeninc.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://qualigeninc.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine3": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 3 such as an Office Park",
        "label": "Entity Address, Address Line Three"
       }
      }
     },
     "localname": "EntityAddressAddressLine3",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://qualigeninc.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://qualigeninc.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCountry": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ISO 3166-1 alpha-2 country code.",
        "label": "Entity Address, Country"
       }
      }
     },
     "localname": "EntityAddressCountry",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://qualigeninc.com/role/Cover"
     ],
     "xbrltype": "countryCodeItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://qualigeninc.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://qualigeninc.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "auth_ref": [
      "r636"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not.  Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.",
        "label": "Entity Bankruptcy Proceedings, Reporting Current"
       }
      }
     },
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://qualigeninc.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r632"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://qualigeninc.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://qualigeninc.com/role/Cover"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://qualigeninc.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains."
       }
      }
     },
     "localname": "EntityDomain",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://qualigeninc.com/role/AcquisitionDetailsNarrative",
      "http://qualigeninc.com/role/ResearchAndLicenseAgreementsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r632"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://qualigeninc.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r649"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Elected Not To Use the Extended Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://qualigeninc.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://qualigeninc.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r632"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://qualigeninc.com/role/Cover"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://qualigeninc.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r646"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://qualigeninc.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPrimarySicNumber": {
     "auth_ref": [
      "r644"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.",
        "label": "Entity Primary SIC Number"
       }
      }
     },
     "localname": "EntityPrimarySicNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://qualigeninc.com/role/Cover"
     ],
     "xbrltype": "sicNumberItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://qualigeninc.com/role/Cover"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r632"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://qualigeninc.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r632"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://qualigeninc.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r632"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://qualigeninc.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r632"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://qualigeninc.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://qualigeninc.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [
      "r647"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://qualigeninc.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_Extension": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Extension number for local phone number.",
        "label": "Extension"
       }
      }
     },
     "localname": "Extension",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://qualigeninc.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_IcfrAuditorAttestationFlag": {
     "auth_ref": [
      "r641",
      "r643",
      "r644"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "localname": "IcfrAuditorAttestationFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://qualigeninc.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_LegalEntityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The set of legal entities associated with a report.",
        "label": "Legal Entity [Axis]"
       }
      }
     },
     "localname": "LegalEntityAxis",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://qualigeninc.com/role/AcquisitionDetailsNarrative",
      "http://qualigeninc.com/role/ResearchAndLicenseAgreementsDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://qualigeninc.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_NoTradingSymbolFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a security having no trading symbol.",
        "label": "No Trading Symbol Flag"
       }
      }
     },
     "localname": "NoTradingSymbolFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://qualigeninc.com/role/Cover"
     ],
     "xbrltype": "trueItemType"
    },
    "dei_OtherReportingStandardItemNumber": {
     "auth_ref": [
      "r643"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.",
        "label": "Other Reporting Standard Item Number"
       }
      }
     },
     "localname": "OtherReportingStandardItemNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://qualigeninc.com/role/Cover"
     ],
     "xbrltype": "otherReportingStandardItemNumberItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r637"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://qualigeninc.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r638"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://qualigeninc.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r631"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://qualigeninc.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_Security12gTitle": {
     "auth_ref": [
      "r635"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(g) registered security.",
        "label": "Title of 12(g) Security"
       }
      }
     },
     "localname": "Security12gTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://qualigeninc.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r634"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://qualigeninc.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SecurityReportingObligation": {
     "auth_ref": [
      "r639"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.",
        "label": "Security Reporting Obligation"
       }
      }
     },
     "localname": "SecurityReportingObligation",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://qualigeninc.com/role/Cover"
     ],
     "xbrltype": "securityReportingObligationItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r640"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://qualigeninc.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://qualigeninc.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r648"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://qualigeninc.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r355",
      "r356",
      "r357",
      "r358",
      "r423",
      "r545",
      "r581",
      "r594",
      "r595",
      "r616",
      "r623",
      "r629",
      "r690",
      "r745",
      "r746",
      "r747",
      "r748",
      "r749",
      "r750"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://qualigeninc.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesAndEstimatesDetailsNarrative",
      "http://qualigeninc.com/role/ResearchAndLicenseAgreementsDetailsNarrative",
      "http://qualigeninc.com/role/ScheduleOfAssumptionUsedInBlack-scholesOption-pricingMethodDetails",
      "http://qualigeninc.com/role/ScheduleOfAssumptionsOfWarrantLiabilitiesDetails",
      "http://qualigeninc.com/role/ScheduleOfGoodwillAndOtherIntangibleDetails",
      "http://qualigeninc.com/role/ScheduleOfStockOptionActivityDetails",
      "http://qualigeninc.com/role/ScheduleOfWarrantActivityDetails",
      "http://qualigeninc.com/role/ScheduleOfWarrantsActivityDetails",
      "http://qualigeninc.com/role/StockholdersEquityDetailsNarrative",
      "http://qualigeninc.com/role/WarrantLiabilitiesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r355",
      "r356",
      "r357",
      "r358",
      "r423",
      "r545",
      "r581",
      "r594",
      "r595",
      "r616",
      "r623",
      "r629",
      "r690",
      "r745",
      "r746",
      "r747",
      "r748",
      "r749",
      "r750"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://qualigeninc.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesAndEstimatesDetailsNarrative",
      "http://qualigeninc.com/role/ResearchAndLicenseAgreementsDetailsNarrative",
      "http://qualigeninc.com/role/ScheduleOfAssumptionUsedInBlack-scholesOption-pricingMethodDetails",
      "http://qualigeninc.com/role/ScheduleOfAssumptionsOfWarrantLiabilitiesDetails",
      "http://qualigeninc.com/role/ScheduleOfGoodwillAndOtherIntangibleDetails",
      "http://qualigeninc.com/role/ScheduleOfStockOptionActivityDetails",
      "http://qualigeninc.com/role/ScheduleOfWarrantActivityDetails",
      "http://qualigeninc.com/role/ScheduleOfWarrantsActivityDetails",
      "http://qualigeninc.com/role/StockholdersEquityDetailsNarrative",
      "http://qualigeninc.com/role/WarrantLiabilitiesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r318",
      "r551",
      "r617",
      "r628",
      "r684",
      "r685",
      "r693",
      "r752"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://qualigeninc.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesAndEstimatesDetailsNarrative",
      "http://qualigeninc.com/role/ResearchAndLicenseAgreementsDetailsNarrative",
      "http://qualigeninc.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r318",
      "r551",
      "r617",
      "r628",
      "r684",
      "r685",
      "r693",
      "r752"
     ],
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://qualigeninc.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesAndEstimatesDetailsNarrative",
      "http://qualigeninc.com/role/ResearchAndLicenseAgreementsDetailsNarrative",
      "http://qualigeninc.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r355",
      "r356",
      "r357",
      "r358",
      "r415",
      "r423",
      "r448",
      "r449",
      "r450",
      "r544",
      "r545",
      "r581",
      "r594",
      "r595",
      "r616",
      "r623",
      "r629",
      "r683",
      "r690",
      "r746",
      "r747",
      "r748",
      "r749",
      "r750"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://qualigeninc.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesAndEstimatesDetailsNarrative",
      "http://qualigeninc.com/role/ResearchAndLicenseAgreementsDetailsNarrative",
      "http://qualigeninc.com/role/ScheduleOfAssumptionUsedInBlack-scholesOption-pricingMethodDetails",
      "http://qualigeninc.com/role/ScheduleOfAssumptionsOfWarrantLiabilitiesDetails",
      "http://qualigeninc.com/role/ScheduleOfGoodwillAndOtherIntangibleDetails",
      "http://qualigeninc.com/role/ScheduleOfStockOptionActivityDetails",
      "http://qualigeninc.com/role/ScheduleOfWarrantActivityDetails",
      "http://qualigeninc.com/role/ScheduleOfWarrantsActivityDetails",
      "http://qualigeninc.com/role/StockholdersEquityDetailsNarrative",
      "http://qualigeninc.com/role/WarrantLiabilitiesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r355",
      "r356",
      "r357",
      "r358",
      "r415",
      "r423",
      "r448",
      "r449",
      "r450",
      "r544",
      "r545",
      "r581",
      "r594",
      "r595",
      "r616",
      "r623",
      "r629",
      "r683",
      "r690",
      "r746",
      "r747",
      "r748",
      "r749",
      "r750"
     ],
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://qualigeninc.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesAndEstimatesDetailsNarrative",
      "http://qualigeninc.com/role/ResearchAndLicenseAgreementsDetailsNarrative",
      "http://qualigeninc.com/role/ScheduleOfAssumptionUsedInBlack-scholesOption-pricingMethodDetails",
      "http://qualigeninc.com/role/ScheduleOfAssumptionsOfWarrantLiabilitiesDetails",
      "http://qualigeninc.com/role/ScheduleOfGoodwillAndOtherIntangibleDetails",
      "http://qualigeninc.com/role/ScheduleOfStockOptionActivityDetails",
      "http://qualigeninc.com/role/ScheduleOfWarrantActivityDetails",
      "http://qualigeninc.com/role/ScheduleOfWarrantsActivityDetails",
      "http://qualigeninc.com/role/StockholdersEquityDetailsNarrative",
      "http://qualigeninc.com/role/WarrantLiabilitiesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_TitleOfIndividualAxis": {
     "auth_ref": [
      "r676",
      "r741"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Axis]"
       }
      }
     },
     "localname": "TitleOfIndividualAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://qualigeninc.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://qualigeninc.com/role/ConvertibleDebt-RelatedPartyDetailsNarrative",
      "http://qualigeninc.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://qualigeninc.com/role/ResearchAndLicenseAgreementsDetailsNarrative",
      "http://qualigeninc.com/role/ScheduleOfStockOptionActivityDetails",
      "http://qualigeninc.com/role/StockholdersEquityDetailsNarrative",
      "http://qualigeninc.com/role/WarrantLiabilitiesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "auth_ref": [],
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://qualigeninc.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://qualigeninc.com/role/ConvertibleDebt-RelatedPartyDetailsNarrative",
      "http://qualigeninc.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://qualigeninc.com/role/ResearchAndLicenseAgreementsDetailsNarrative",
      "http://qualigeninc.com/role/ScheduleOfStockOptionActivityDetails",
      "http://qualigeninc.com/role/StockholdersEquityDetailsNarrative",
      "http://qualigeninc.com/role/WarrantLiabilitiesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_WeightedAverageMember": {
     "auth_ref": [
      "r594",
      "r595",
      "r745",
      "r747",
      "r750"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average [Member]"
       }
      }
     },
     "localname": "WeightedAverageMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://qualigeninc.com/role/ScheduleOfAssumptionsOfWarrantLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period.",
        "label": "ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES"
       }
      }
     },
     "localname": "AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/AccruedExpensesAndOtherCurrentLiabilities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r20",
      "r627"
     ],
     "calculation": {
      "http://qualigeninc.com/role/BalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableGrossCurrent": {
     "auth_ref": [
      "r233",
      "r321",
      "r322",
      "r598"
     ],
     "calculation": {
      "http://qualigeninc.com/role/ScheduleOfAccountsReceivableDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AccountsReceivableNetCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable"
       }
      }
     },
     "localname": "AccountsReceivableGrossCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/ScheduleOfAccountsReceivableDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r321",
      "r322"
     ],
     "calculation": {
      "http://qualigeninc.com/role/BalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://qualigeninc.com/role/ScheduleOfAccountsReceivableDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts receivable, net",
        "totalLabel": "Accounts receivable, net"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/BalanceSheets",
      "http://qualigeninc.com/role/ScheduleOfAccountsReceivableDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedIncomeTaxesCurrent": {
     "auth_ref": [
      "r5",
      "r189",
      "r202"
     ],
     "calculation": {
      "http://qualigeninc.com/role/ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations.",
        "label": "Income taxes"
       }
      }
     },
     "localname": "AccruedIncomeTaxesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesAndOtherLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://qualigeninc.com/role/BalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other.",
        "label": "Accrued expenses and other current liabilities",
        "verboseLabel": "Accrued expenses"
       }
      }
     },
     "localname": "AccruedLiabilitiesAndOtherLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/BalanceSheets",
      "http://qualigeninc.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r24"
     ],
     "calculation": {
      "http://qualigeninc.com/role/ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Liabilities, Current",
        "totalLabel": "Accrued liabilities"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedPayrollTaxesCurrent": {
     "auth_ref": [
      "r24"
     ],
     "calculation": {
      "http://qualigeninc.com/role/ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for statutory payroll taxes incurred through that date and withheld from employees pertaining to services received from them, including entity's matching share of the employees FICA taxes and contributions to the state and federal unemployment insurance programs. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Payroll"
       }
      }
     },
     "localname": "AccruedPayrollTaxesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedProfessionalFeesCurrent": {
     "auth_ref": [
      "r24"
     ],
     "calculation": {
      "http://qualigeninc.com/role/ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Professional fees"
       }
      }
     },
     "localname": "AccruedProfessionalFeesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedRoyaltiesCurrent": {
     "auth_ref": [
      "r24",
      "r600"
     ],
     "calculation": {
      "http://qualigeninc.com/role/ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails": {
       "order": 9.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Royalties"
       }
      }
     },
     "localname": "AccruedRoyaltiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r93",
      "r225"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "negatedLabel": "Accumulated depreciation"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/ScheduleOfPropertyAndEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Accumulated Other Comprehensive Income (Loss) [Line Items]"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/ScheduleOfWarrantActivityDetails",
      "http://qualigeninc.com/role/StockholdersEquityTables"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r35",
      "r37",
      "r38",
      "r234",
      "r574",
      "r586",
      "r587"
     ],
     "calculation": {
      "http://qualigeninc.com/role/BalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated other comprehensive income"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossTable": {
     "auth_ref": [
      "r245",
      "r246",
      "r513",
      "r514",
      "r515",
      "r516",
      "r517",
      "r518"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about components of accumulated other comprehensive income (loss).",
        "label": "Accumulated Other Comprehensive Income (Loss) [Table]"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/ScheduleOfWarrantActivityDetails",
      "http://qualigeninc.com/role/StockholdersEquityTables"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r34",
      "r38",
      "r171",
      "r531",
      "r582",
      "r583",
      "r661",
      "r662",
      "r663",
      "r671",
      "r672",
      "r673"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r12",
      "r627"
     ],
     "calculation": {
      "http://qualigeninc.com/role/BalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.",
        "label": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r454",
      "r455",
      "r456",
      "r671",
      "r672",
      "r673",
      "r732"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for option under share-based payment arrangement.",
        "label": "APIC, Share-Based Payment Arrangement, Option, Increase for Cost Recognition",
        "verboseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) to additional paid-in capital (APIC) for recognition and exercise of award under share-based payment arrangement.",
        "label": "Stock-based compensation"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdvertisingCostsPolicyTextBlock": {
     "auth_ref": [
      "r457"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for advertising cost.",
        "label": "Advertising"
       }
      }
     },
     "localname": "AdvertisingCostsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesAndEstimatesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AdvertisingExpense": {
     "auth_ref": [
      "r458"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount charged to advertising expense for the period, which are expenses incurred with the objective of increasing revenue for a specified brand, product or product line.",
        "label": "Advertising expense"
       }
      }
     },
     "localname": "AdvertisingExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesAndEstimatesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r452"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-Based Payment Arrangement, Expense",
        "terseLabel": "Compensation cost",
        "verboseLabel": "Total"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/ScheduleOfShare-basedCompensationExpenseDetails",
      "http://qualigeninc.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent": {
     "auth_ref": [
      "r235",
      "r325",
      "r329"
     ],
     "calculation": {
      "http://qualigeninc.com/role/ScheduleOfAccountsReceivableDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AccountsReceivableNetCurrent",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of allowance for credit loss on accounts receivable, classified as current.",
        "label": "Accounts Receivable, Allowance for Credit Loss, Current",
        "negatedLabel": "Less Reserves and Allowances"
       }
      }
     },
     "localname": "AllowanceForDoubtfulAccountsReceivableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/ScheduleOfAccountsReceivableDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfDebtDiscountPremium": {
     "auth_ref": [
      "r47",
      "r60",
      "r180",
      "r390"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.",
        "label": "Debt discount"
       }
      }
     },
     "localname": "AmortizationOfDebtDiscountPremium",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/ConvertibleDebt-RelatedPartyDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "auth_ref": [
      "r60",
      "r78",
      "r85"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Licenses charged"
       }
      }
     },
     "localname": "AmortizationOfIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/GoodwillIprdAndOtherIntangiblesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r286"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Total common stock equivalents"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/ScheduleOfDilutiveSecuritiesExcludedFromDilutedNetLossPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r70"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/ScheduleOfDilutiveSecuritiesExcludedFromDilutedNetLossPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/ScheduleOfDilutiveSecuritiesExcludedFromDilutedNetLossPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r70"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented."
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/ScheduleOfDilutiveSecuritiesExcludedFromDilutedNetLossPerShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AreaOfLand": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area of land held.",
        "label": "Area of land"
       }
      }
     },
     "localname": "AreaOfLand",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "areaItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/PropertyAndEquipmentNetDetailsNarrative",
      "http://qualigeninc.com/role/ResearchAndLicenseAgreementsDetailsNarrative",
      "http://qualigeninc.com/role/ScheduleOfOperatingLeaseRightOfUseAssetsAndOperatingLeaseLiabilitiesDetails",
      "http://qualigeninc.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AssetImpairmentCharges": {
     "auth_ref": [
      "r60",
      "r90"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.",
        "label": "Impairment losses on construction-in-progress"
       }
      }
     },
     "localname": "AssetImpairmentCharges",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesAndEstimatesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r187",
      "r201",
      "r229",
      "r261",
      "r303",
      "r312",
      "r316",
      "r327",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r499",
      "r503",
      "r512",
      "r627",
      "r688",
      "r689",
      "r743"
     ],
     "calculation": {
      "http://qualigeninc.com/role/BalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total Assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "ASSETS"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/BalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r220",
      "r239",
      "r261",
      "r327",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r499",
      "r503",
      "r512",
      "r627",
      "r688",
      "r689",
      "r743"
     ],
     "calculation": {
      "http://qualigeninc.com/role/BalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current assets"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/BalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://qualigeninc.com/role/ResearchAndLicenseAgreementsDetailsNarrative",
      "http://qualigeninc.com/role/ScheduleOfReservedSharesDetails",
      "http://qualigeninc.com/role/ScheduleOfWarrantActivityDetails",
      "http://qualigeninc.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesAndEstimatesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "auth_ref": [
      "r496",
      "r621",
      "r622"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree."
       }
      }
     },
     "localname": "BusinessAcquisitionAcquireeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/AcquisitionDetailsNarrative",
      "http://qualigeninc.com/role/LiquidityAndGoingConcernDetailsNarrative",
      "http://qualigeninc.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesAndEstimatesDetailsNarrative",
      "http://qualigeninc.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://qualigeninc.com/role/ScheduleOfConsiderationTransferredDetails",
      "http://qualigeninc.com/role/ScheduleOfConsiderationTransferredDetailsParenthetical",
      "http://qualigeninc.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "auth_ref": [
      "r152",
      "r153",
      "r496",
      "r621",
      "r622"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by business combination or series of individually immaterial business combinations.",
        "label": "Business Acquisition [Axis]"
       }
      }
     },
     "localname": "BusinessAcquisitionAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/AcquisitionDetailsNarrative",
      "http://qualigeninc.com/role/LiquidityAndGoingConcernDetailsNarrative",
      "http://qualigeninc.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesAndEstimatesDetailsNarrative",
      "http://qualigeninc.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://qualigeninc.com/role/ScheduleOfConsiderationTransferredDetails",
      "http://qualigeninc.com/role/ScheduleOfConsiderationTransferredDetailsParenthetical",
      "http://qualigeninc.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Business Acquisition [Line Items]"
       }
      }
     },
     "localname": "BusinessAcquisitionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/AcquisitionDetailsNarrative",
      "http://qualigeninc.com/role/ScheduleOfConsiderationTransferredDetails",
      "http://qualigeninc.com/role/ScheduleOfConsiderationTransferredDetailsParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired": {
     "auth_ref": [
      "r151"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of voting equity interests acquired at the acquisition date in the business combination.",
        "label": "Voting interests acquired",
        "verboseLabel": "Business acquisition, voting equity rate"
       }
      }
     },
     "localname": "BusinessAcquisitionPercentageOfVotingInterestsAcquired",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/AcquisitionDetailsNarrative",
      "http://qualigeninc.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesAndEstimatesDetailsNarrative",
      "http://qualigeninc.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_BusinessAcquisitionProFormaInformationTextBlock": {
     "auth_ref": [
      "r728",
      "r729"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of pro forma results of operations for a material business acquisition or series of individually immaterial business acquisitions that are material in the aggregate.",
        "label": "SCHEDULE OF PRO FORMA INFORMATION"
       }
      }
     },
     "localname": "BusinessAcquisitionProFormaInformationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/AcquisitionTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss": {
     "auth_ref": [
      "r494",
      "r495"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The pro forma net Income or Loss for the period as if the business combination or combinations had been completed at the beginning of a period.",
        "label": "Business acquisitions pro forma net income loss"
       }
      }
     },
     "localname": "BusinessAcquisitionsProFormaNetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/ScheduleOfProFormaInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessAcquisitionsProFormaRevenue": {
     "auth_ref": [
      "r494",
      "r495"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The pro forma revenue for a period as if the business combination or combinations had been completed at the beginning of the period.",
        "label": "Business acquisitions pro forma revenue"
       }
      }
     },
     "localname": "BusinessAcquisitionsProFormaRevenue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/ScheduleOfProFormaInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationAndAssetAcquisitionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination and Asset Acquisition [Abstract]"
       }
      }
     },
     "localname": "BusinessCombinationAndAssetAcquisitionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessCombinationConsiderationTransferred1": {
     "auth_ref": [
      "r158",
      "r159",
      "r160"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.",
        "label": "Net cash acquired in business combination (Note 3)",
        "verboseLabel": "Total consideration paid for NanoSynex common stock"
       }
      }
     },
     "localname": "BusinessCombinationConsiderationTransferred1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/ScheduleOfConsiderationTransferredDetails",
      "http://qualigeninc.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationDisclosureTextBlock": {
     "auth_ref": [
      "r161",
      "r497"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).",
        "label": "ACQUISITION"
       }
      }
     },
     "localname": "BusinessCombinationDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/Acquisition"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets": {
     "auth_ref": [
      "r155"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of assets acquired at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets",
        "negatedLabel": "Identifiable net assets acquired"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/ScheduleOfAssetsAcquiredAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables": {
     "auth_ref": [
      "r155"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount due from customers or clients for goods or services, including trade receivables, that have been delivered or sold in the normal course of business, and amounts due from others, including related parties expected to be converted to cash, sold or exchanged within one year or the normal operating cycle, if longer, acquired at the acquisition date.",
        "label": "Accounts receivable"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/ScheduleOfAssetsAcquiredAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable": {
     "auth_ref": [
      "r155"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities incurred for goods and services received that are used in an entity's business and related party payables, assumed at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accounts Payable",
        "negatedLabel": "Accounts payable"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/ScheduleOfAssetsAcquiredAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities": {
     "auth_ref": [
      "r155"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences assumed at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities",
        "negatedLabel": "Deferred tax liability"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/ScheduleOfAssetsAcquiredAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet": {
     "auth_ref": [
      "r154",
      "r155"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount recognized as of the acquisition date for the identifiable assets acquired in excess of (less than) the aggregate liabilities assumed.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net",
        "verboseLabel": "Total consideration transferred, net of cash acquired"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/ScheduleOfAssetsAcquiredAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment": {
     "auth_ref": [
      "r154",
      "r155"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of property, plant, and equipment recognized as of the acquisition date.",
        "label": "Property and equipment"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/ScheduleOfAssetsAcquiredAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedLessNoncontrollingInterest": {
     "auth_ref": [
      "r155"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount recognized as of the acquisition date for the assets, including goodwill, in excess of (less than) the aggregate liabilities assumed, less the noncontrolling interest in the acquiree.",
        "label": "Noncontrolling interest assumed"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedLessNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/ScheduleOfAssetsAcquiredAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationsPolicy": {
     "auth_ref": [
      "r150"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy.",
        "label": "Business Combinations"
       }
      }
     },
     "localname": "BusinessCombinationsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesAndEstimatesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Cash": {
     "auth_ref": [
      "r588",
      "r589",
      "r627",
      "r651"
     ],
     "calculation": {
      "http://qualigeninc.com/role/BalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash"
       }
      }
     },
     "localname": "Cash",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/BalanceSheets",
      "http://qualigeninc.com/role/LiquidityAndGoingConcernDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAcquiredFromAcquisition": {
     "auth_ref": [
      "r49"
     ],
     "calculation": {
      "http://qualigeninc.com/role/StatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the acquisition of business during the period (for example, cash that was held by the acquired business).",
        "label": "Net cash acquired in business combination",
        "negatedLabel": "NanoSynex cash acquired"
       }
      }
     },
     "localname": "CashAcquiredFromAcquisition",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/ScheduleOfConsiderationTransferredDetails",
      "http://qualigeninc.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "auth_ref": [
      "r63"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "verboseLabel": "Cash"
       }
      }
     },
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesAndEstimatesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": {
     "auth_ref": [
      "r56",
      "r62",
      "r68"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations",
        "periodEndLabel": "Cash and restricted cash - end of period",
        "periodStartLabel": "Cash and restricted cash - beginning of period"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r56",
      "r179"
     ],
     "calculation": {
      "http://qualigeninc.com/role/StatementsOfCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net change in cash and restricted cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "NONCASH FINANCING AND INVESTING ACTIVITIES:"
       }
      }
     },
     "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [
      "r230",
      "r231",
      "r232",
      "r261",
      "r280",
      "r281",
      "r283",
      "r285",
      "r293",
      "r294",
      "r327",
      "r359",
      "r361",
      "r362",
      "r363",
      "r366",
      "r367",
      "r394",
      "r395",
      "r398",
      "r402",
      "r410",
      "r512",
      "r596",
      "r650",
      "r667",
      "r674"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock."
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/AcquisitionDetailsNarrative",
      "http://qualigeninc.com/role/ConvertibleDebt-RelatedPartyDetailsNarrative",
      "http://qualigeninc.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesAndEstimatesDetailsNarrative",
      "http://qualigeninc.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://qualigeninc.com/role/ScheduleOfWarrantsActivityDetails",
      "http://qualigeninc.com/role/StatementsOfChangesInStockholdersEquity",
      "http://qualigeninc.com/role/StockholdersEquityDetailsNarrative",
      "http://qualigeninc.com/role/WarrantLiabilitiesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class of Stock [Line Items]"
       }
      }
     },
     "localname": "ClassOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "auth_ref": [
      "r411"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding.",
        "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights",
        "terseLabel": "Exercise price of warrant",
        "verboseLabel": "Warrants or rights"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/AcquisitionDetailsNarrative",
      "http://qualigeninc.com/role/ConvertibleDebt-RelatedPartyDetailsNarrative",
      "http://qualigeninc.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesAndEstimatesDetailsNarrative",
      "http://qualigeninc.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://qualigeninc.com/role/StockholdersEquityDetailsNarrative",
      "http://qualigeninc.com/role/WarrantLiabilitiesDetailsNarrative"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares.",
        "label": "Warrants to purchase common stock",
        "verboseLabel": "Purchase of warrants"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesAndEstimatesDetailsNarrative",
      "http://qualigeninc.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "auth_ref": [
      "r411"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.",
        "label": "Warrants to purchase shares",
        "verboseLabel": "Warrant to purchase shares"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/AcquisitionDetailsNarrative",
      "http://qualigeninc.com/role/ConvertibleDebt-RelatedPartyDetailsNarrative",
      "http://qualigeninc.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://qualigeninc.com/role/StockholdersEquityDetailsNarrative",
      "http://qualigeninc.com/role/WarrantLiabilitiesDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ClassOfWarrantOrRightOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of warrants or rights outstanding.",
        "label": "Number of outstanding warrants to purchase, shares"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]"
       }
      }
     },
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/PropertyAndEquipmentNetDetailsNarrative",
      "http://qualigeninc.com/role/ScheduleOfOperatingLeaseRightOfUseAssetsAndOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r28",
      "r195",
      "r210"
     ],
     "calculation": {
      "http://qualigeninc.com/role/BalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies (Note 13)"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r97",
      "r353",
      "r354",
      "r590",
      "r686"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "COMMITMENTS AND CONTINGENCIES"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/CommitmentsAndContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "auth_ref": [
      "r29"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate number of common shares reserved for future issuance.",
        "label": "Total",
        "verboseLabel": "Plan shares available"
       }
      }
     },
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/ScheduleOfReservedSharesDetails",
      "http://qualigeninc.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockDividendsShares": {
     "auth_ref": [
      "r107"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock issued as dividends during the period. Excludes stock splits.",
        "label": "Shares of common stock"
       }
      }
     },
     "localname": "CommonStockDividendsShares",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r671",
      "r672",
      "r732"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/StatementsOfChangesInStockholdersEquity",
      "http://qualigeninc.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r11"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common stock, par value"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/BalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r11"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common stock, shares authorized"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/BalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r11"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common stock, shares issued",
        "verboseLabel": "Shares of Common stock, issued"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/BalanceSheetsParenthetical",
      "http://qualigeninc.com/role/ConvertibleDebt-RelatedPartyDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r11",
      "r107"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common stock, shares outstanding"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/BalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r11",
      "r627"
     ],
     "calculation": {
      "http://qualigeninc.com/role/BalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common stock, $0.001 par value; 225,000,000 shares authorized; 4,210,737 and 3,529,018 shares issued and outstanding as of December 31, 2022 and December 31, 2021, respectively"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CompensationRelatedCostsPolicyTextBlock": {
     "auth_ref": [
      "r128"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense.",
        "label": "Stock-Based Compensation"
       }
      }
     },
     "localname": "CompensationRelatedCostsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesAndEstimatesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r39",
      "r241",
      "r243",
      "r251",
      "r570",
      "r578"
     ],
     "calculation": {
      "http://qualigeninc.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Comprehensive loss attributable to Qualigen Therapeutics, Inc."
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r165",
      "r166",
      "r174",
      "r241",
      "r243",
      "r250",
      "r569",
      "r577"
     ],
     "calculation": {
      "http://qualigeninc.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income (loss) and other comprehensive income (loss), attributable to noncontrolling interests. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive loss attributable to noncontrolling interest"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r164",
      "r174",
      "r241",
      "r243",
      "r249",
      "r568",
      "r576"
     ],
     "calculation": {
      "http://qualigeninc.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest",
        "totalLabel": "Other comprehensive loss"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for comprehensive income.",
        "label": "Comprehensive Loss"
       }
      }
     },
     "localname": "ComprehensiveIncomePolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesAndEstimatesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ComputerEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems.",
        "label": "Computer Equipment [Member]"
       }
      }
     },
     "localname": "ComputerEquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/ScheduleOfPropertyAndEquipmentDetails",
      "http://qualigeninc.com/role/ScheduleOfUsefulLivesOfPropertyAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "auth_ref": [
      "r169",
      "r601"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.",
        "label": "Principles of Consolidation"
       }
      }
     },
     "localname": "ConsolidationPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesAndEstimatesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConvertibleDebt": {
     "auth_ref": [
      "r6",
      "r191",
      "r204"
     ],
     "calculation": {
      "http://qualigeninc.com/role/BalanceSheets": {
       "order": 10.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Including the current and noncurrent portions, carrying amount of debt identified as being convertible into another form of financial instrument (typically the entity's common stock) as of the balance sheet date, which originally required full repayment more than twelve months after issuance or greater than the normal operating cycle of the company.",
        "label": "Convertible debt - related party",
        "verboseLabel": "Total convertible debt - related party"
       }
      }
     },
     "localname": "ConvertibleDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/BalanceSheets",
      "http://qualigeninc.com/role/ScheduleOfSeniorSecuredConvertibleDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConvertibleDebtTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of convertible debt instrument. Includes, but is not limited to, principal amount and amortized premium or discount.",
        "label": "SCHEDULE OF SENIOR SECURED CONVERTIBLE DEBT"
       }
      }
     },
     "localname": "ConvertibleDebtTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/ConvertibleDebt-RelatedPartyTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion": {
     "auth_ref": [
      "r9",
      "r10",
      "r108",
      "r111",
      "r405"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued for each share of convertible preferred stock that is converted.",
        "label": "Convertible preferred stock, shares"
       }
      }
     },
     "localname": "ConvertiblePreferredStockSharesIssuedUponConversion",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CostOfGoodsAndServicesSold": {
     "auth_ref": [
      "r43",
      "r551"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.",
        "label": "Other shipping and handling costs"
       }
      }
     },
     "localname": "CostOfGoodsAndServicesSold",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesAndEstimatesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentFederalTaxExpenseBenefit": {
     "auth_ref": [
      "r670",
      "r724",
      "r726"
     ],
     "calculation": {
      "http://qualigeninc.com/role/ScheduleOfProvisionForIncomeTaxesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national tax expense (benefit) for non-US (United States of America) jurisdiction.",
        "label": "US Federal"
       }
      }
     },
     "localname": "CurrentFederalTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/ScheduleOfProvisionForIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentForeignTaxExpenseBenefit": {
     "auth_ref": [
      "r670",
      "r724"
     ],
     "calculation": {
      "http://qualigeninc.com/role/ScheduleOfProvisionForIncomeTaxesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Current Foreign Tax Expense (Benefit)",
        "verboseLabel": "Foreign"
       }
      }
     },
     "localname": "CurrentForeignTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/ScheduleOfProvisionForIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r149",
      "r476",
      "r484",
      "r670"
     ],
     "calculation": {
      "http://qualigeninc.com/role/ScheduleOfProvisionForIncomeTaxesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.",
        "label": "Current Income Tax Expense (Benefit)",
        "totalLabel": "Total current provision"
       }
      }
     },
     "localname": "CurrentIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/ScheduleOfProvisionForIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentStateAndLocalTaxExpenseBenefit": {
     "auth_ref": [
      "r670",
      "r724",
      "r726"
     ],
     "calculation": {
      "http://qualigeninc.com/role/ScheduleOfProvisionForIncomeTaxesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.",
        "label": "US State"
       }
      }
     },
     "localname": "CurrentStateAndLocalTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/ScheduleOfProvisionForIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtConversionConvertedInstrumentRate": {
     "auth_ref": [
      "r65",
      "r67"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Dividend or interest rate associated with the financial instrument issued in exchange for the original debt being converted in a noncash or part noncash transaction. Noncash are transactions that affect recognized assets or liabilities but that do not result in cash receipts or cash payments. Part noncash refers to that portion of the transaction not resulting in cash receipts or cash payments.",
        "label": "Conversion rate"
       }
      }
     },
     "localname": "DebtConversionConvertedInstrumentRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/ConvertibleDebt-RelatedPartyDetailsNarrative"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]"
       }
      }
     },
     "localname": "DebtDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "auth_ref": [
      "r102",
      "r259",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r384",
      "r391",
      "r392",
      "r393"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.",
        "label": "CONVERTIBLE DEBT - RELATED PARTY"
       }
      }
     },
     "localname": "DebtDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/ConvertibleDebt-RelatedParty"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r4",
      "r5",
      "r6",
      "r188",
      "r191",
      "r200",
      "r265",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r374",
      "r380",
      "r381",
      "r382",
      "r383",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r521",
      "r611",
      "r612",
      "r613",
      "r614",
      "r615",
      "r668"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/ConvertibleDebt-RelatedPartyDetailsNarrative",
      "http://qualigeninc.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://qualigeninc.com/role/ScheduleOfSeniorSecuredConvertibleDebtDetails",
      "http://qualigeninc.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentConvertibleConversionPrice1": {
     "auth_ref": [
      "r101",
      "r370"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The price per share of the conversion feature embedded in the debt instrument.",
        "label": "Conversion price"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleConversionPrice1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/ConvertibleDebt-RelatedPartyDetailsNarrative",
      "http://qualigeninc.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://qualigeninc.com/role/StockholdersEquityDetailsNarrative",
      "http://qualigeninc.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "auth_ref": [
      "r181",
      "r182",
      "r368",
      "r521",
      "r612",
      "r613"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face (par) amount of debt instrument at time of issuance.",
        "label": "Short term debt principal outstanding",
        "verboseLabel": "Debenture voluntarily converted"
       }
      }
     },
     "localname": "DebtInstrumentFaceAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://qualigeninc.com/role/ShortTermDebt-RelatedPartyDetailsNarrative",
      "http://qualigeninc.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentIncreaseAccruedInterest": {
     "auth_ref": [
      "r668"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase for accrued, but unpaid interest on the debt instrument for the period.",
        "label": "Unpaid interest"
       }
      }
     },
     "localname": "DebtInstrumentIncreaseAccruedInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/ConvertibleDebt-RelatedPartyDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "auth_ref": [
      "r26",
      "r369"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.",
        "label": "Accrued interest rate",
        "verboseLabel": "Debenture accrues interest rate"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/ConvertibleDebt-RelatedPartyDetailsNarrative",
      "http://qualigeninc.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://qualigeninc.com/role/ShortTermDebt-RelatedPartyDetailsNarrative"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r27",
      "r265",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r374",
      "r380",
      "r381",
      "r382",
      "r383",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r521",
      "r611",
      "r612",
      "r613",
      "r614",
      "r615",
      "r668"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities."
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/ConvertibleDebt-RelatedPartyDetailsNarrative",
      "http://qualigeninc.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://qualigeninc.com/role/ScheduleOfSeniorSecuredConvertibleDebtDetails",
      "http://qualigeninc.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentUnamortizedDiscount": {
     "auth_ref": [
      "r180",
      "r182",
      "r691"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after accumulated amortization, of debt discount.",
        "label": "Debt Instrument, Unamortized Discount",
        "negatedLabel": "Discount on convertible debenture"
       }
      }
     },
     "localname": "DebtInstrumentUnamortizedDiscount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/ScheduleOfSeniorSecuredConvertibleDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]"
       }
      }
     },
     "localname": "DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/ScheduleOfStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs.",
        "label": "SCHEDULE OF PREPAID EXPENSES AND OTHER CURRENT ASSETS"
       }
      }
     },
     "localname": "DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/PrepaidExpensesAndOtherCurrentAssetsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DeferredFederalIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r670",
      "r725",
      "r726"
     ],
     "calculation": {
      "http://qualigeninc.com/role/ScheduleOfProvisionForIncomeTaxesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction.",
        "label": "Deferred Federal Income Tax Expense (Benefit)",
        "verboseLabel": "US Federal"
       }
      }
     },
     "localname": "DeferredFederalIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/ScheduleOfProvisionForIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredForeignIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r149",
      "r670",
      "r725"
     ],
     "calculation": {
      "http://qualigeninc.com/role/ScheduleOfProvisionForIncomeTaxesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Foreign Income Tax Expense (Benefit)",
        "negatedLabel": "Foreign deferred tax benefit",
        "verboseLabel": "Foreign"
       }
      }
     },
     "localname": "DeferredForeignIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/IncomeTaxesDetailsNarrative",
      "http://qualigeninc.com/role/ScheduleOfProvisionForIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeCurrent": {
     "auth_ref": [
      "r687"
     ],
     "calculation": {
      "http://qualigeninc.com/role/BalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income excluding obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as current.",
        "label": "Deferred revenue, current portion"
       }
      }
     },
     "localname": "DeferredIncomeCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r60",
      "r149",
      "r477",
      "r483",
      "r484",
      "r670"
     ],
     "calculation": {
      "http://qualigeninc.com/role/ScheduleOfProvisionForIncomeTaxesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Income Tax Expense (Benefit)",
        "totalLabel": "Total deferred benefit"
       }
      }
     },
     "localname": "DeferredIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/ScheduleOfProvisionForIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxLiabilities": {
     "auth_ref": [
      "r7",
      "r8",
      "r190",
      "r199",
      "r470"
     ],
     "calculation": {
      "http://qualigeninc.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences.",
        "label": "Deferred Tax Liabilities, Gross",
        "negatedTotalLabel": "Total deferred income tax liabilities"
       }
      }
     },
     "localname": "DeferredIncomeTaxLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxLiabilitiesNet": {
     "auth_ref": [
      "r462",
      "r463"
     ],
     "calculation": {
      "http://qualigeninc.com/role/BalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.",
        "label": "Deferred tax liability"
       }
      }
     },
     "localname": "DeferredIncomeTaxLiabilitiesNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredRevenue": {
     "auth_ref": [
      "r653"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.",
        "label": "Deferred Revenue [Default Label]",
        "verboseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "DeferredRevenue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/ResearchAndLicenseAgreementsDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredRevenueNoncurrent": {
     "auth_ref": [
      "r653"
     ],
     "calculation": {
      "http://qualigeninc.com/role/BalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as noncurrent.",
        "label": "Deferred revenue, net of current portion"
       }
      }
     },
     "localname": "DeferredRevenueNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r670",
      "r725",
      "r726"
     ],
     "calculation": {
      "http://qualigeninc.com/role/ScheduleOfProvisionForIncomeTaxesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.",
        "label": "Deferred State and Local Income Tax Expense (Benefit)",
        "verboseLabel": "US State"
       }
      }
     },
     "localname": "DeferredStateAndLocalIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/ScheduleOfProvisionForIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets": {
     "auth_ref": [],
     "calculation": {
      "http://qualigeninc.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_DeferredTaxAssetsTaxDeferredExpense",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from intangible assets including goodwill.",
        "label": "Patent"
       }
      }
     },
     "localname": "DeferredTaxAssetsGoodwillAndIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "auth_ref": [
      "r471"
     ],
     "calculation": {
      "http://qualigeninc.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Gross",
        "totalLabel": "Net deferred income tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment": {
     "auth_ref": [
      "r147",
      "r723"
     ],
     "calculation": {
      "http://qualigeninc.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsTaxDeferredExpense",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from in-process research and development costs expensed in connection with a business combination.",
        "label": "Research and development credits"
       }
      }
     },
     "localname": "DeferredTaxAssetsInProcessResearchAndDevelopment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsLiabilitiesNet": {
     "auth_ref": [
      "r722"
     ],
     "calculation": {
      "http://qualigeninc.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.",
        "label": "Deferred Tax Assets, Net",
        "negatedTotalLabel": "Deferred tax asset, net of allowance"
       }
      }
     },
     "localname": "DeferredTaxAssetsLiabilitiesNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "auth_ref": [
      "r147",
      "r723"
     ],
     "calculation": {
      "http://qualigeninc.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsTaxDeferredExpense",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.",
        "label": "Net operating loss"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal": {
     "auth_ref": [
      "r147",
      "r723"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible state and local operating loss carryforwards.",
        "label": "Operating loss carryforwards"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/IncomeTaxesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment": {
     "auth_ref": [],
     "calculation": {
      "http://qualigeninc.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_DeferredTaxAssetsTaxDeferredExpense",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from property, plant, and equipment.",
        "label": "Fixed assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch": {
     "auth_ref": [
      "r145",
      "r147",
      "r723"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.",
        "label": "Research and development credit carryforwards"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxCreditCarryforwardsResearch",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/IncomeTaxesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpense": {
     "auth_ref": [
      "r147",
      "r723"
     ],
     "calculation": {
      "http://qualigeninc.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allocation of valuation allowances, of deferred tax asset attributable to deductible differences from reserves and accruals, compensation and benefit costs, and other provisions, reserves, and allowances.",
        "label": "Deferred Tax Assets, Tax Deferred Expense",
        "totalLabel": "Total deferred income tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": {
     "auth_ref": [
      "r147",
      "r723"
     ],
     "calculation": {
      "http://qualigeninc.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_DeferredTaxAssetsTaxDeferredExpense",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.",
        "label": "Stock compensation"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r472"
     ],
     "calculation": {
      "http://qualigeninc.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "negatedLabel": "Valuation allowance"
       }
      }
     },
     "localname": "DeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets": {
     "auth_ref": [
      "r147",
      "r723"
     ],
     "calculation": {
      "http://qualigeninc.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from intangible assets other than goodwill.",
        "label": "Deferred Tax Liabilities, Intangible Assets",
        "negatedLabel": "Intangible assets"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesLeasingArrangements": {
     "auth_ref": [
      "r147",
      "r723"
     ],
     "calculation": {
      "http://qualigeninc.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from leasing arrangements.",
        "label": "Deferred Tax Liabilities, Leasing Arrangements",
        "negatedLabel": "Right-of-use asset"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesLeasingArrangements",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanDisclosureLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Defined Benefit Plan Disclosure [Line Items]"
       }
      }
     },
     "localname": "DefinedBenefitPlanDisclosureLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/ScheduleOfFairValueHierarchyForWarrantLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DepositAssets": {
     "auth_ref": [
      "r652"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The carrying amount of the asset transferred to a third party to serve as a deposit, which typically serves as security against failure by the transferor to perform under terms of an agreement.",
        "label": "Upfront deposit"
       }
      }
     },
     "localname": "DepositAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/ResearchAndLicenseAgreementsDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Depreciation": {
     "auth_ref": [
      "r60",
      "r91"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.",
        "label": "Depreciation expense"
       }
      }
     },
     "localname": "Depreciation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/PropertyAndEquipmentNetDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r60",
      "r301"
     ],
     "calculation": {
      "http://qualigeninc.com/role/StatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation and amortization"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeGainLossOnDerivativeNet": {
     "auth_ref": [
      "r731"
     ],
     "calculation": {
      "http://qualigeninc.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in the fair value of derivatives recognized in the income statement.",
        "label": "Derivative, Gain (Loss) on Derivative, Net",
        "negatedLabel": "Gain on change in fair value of warrant liabilities"
       }
      }
     },
     "localname": "DerivativeGainLossOnDerivativeNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DomesticCountryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile.",
        "label": "Domestic Tax Authority [Member]"
       }
      }
     },
     "localname": "DomesticCountryMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/IncomeTaxesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r252",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r279",
      "r280",
      "r283",
      "r284",
      "r285",
      "r289",
      "r507",
      "r508",
      "r571",
      "r579",
      "r606"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Net loss per common share, basic and diluted"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r286",
      "r287",
      "r288",
      "r290"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "EARNINGS (LOSS) PER SHARE"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/EarningsLossPerShare"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": {
     "auth_ref": [
      "r736"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Effect of exchange rate changes on cash and restricted cash"
       }
      }
     },
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "auth_ref": [
      "r465"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income taxes provision (benefit)"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/ScheduleOfReconciliationsOfStatutoryIncomeTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r263",
      "r465",
      "r486"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).",
        "label": "Statutory federal income tax rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/ScheduleOfReconciliationsOfStatutoryIncomeTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r721",
      "r727"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.",
        "label": "Change in valuation allowance"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/ScheduleOfReconciliationsOfStatutoryIncomeTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepletion": {
     "auth_ref": [
      "r721",
      "r727"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to depletion.",
        "label": "Non-deductible expenses"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepletion",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/ScheduleOfReconciliationsOfStatutoryIncomeTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses": {
     "auth_ref": [
      "r721",
      "r727"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to impairment loss.",
        "label": "Goodwill impairment"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/ScheduleOfReconciliationsOfStatutoryIncomeTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": {
     "auth_ref": [
      "r721",
      "r727"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).",
        "label": "State taxes, net of federal tax benefit"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/ScheduleOfReconciliationsOfStatutoryIncomeTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits": {
     "auth_ref": [
      "r721",
      "r727"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits.",
        "label": "Tax credit"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationTaxCredits",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/ScheduleOfReconciliationsOfStatutoryIncomeTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsOther": {
     "auth_ref": [
      "r721",
      "r727"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other tax credits.",
        "label": "True-up"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationTaxCreditsOther",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/ScheduleOfReconciliationsOfStatutoryIncomeTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlementsForeign": {
     "auth_ref": [
      "r721",
      "r727"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to foreign income tax settlement.",
        "label": "Foreign rate differential"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationTaxSettlementsForeign",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/ScheduleOfReconciliationsOfStatutoryIncomeTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeNet": {
     "auth_ref": [
      "r176"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net fair value as of the balance sheet date of the embedded derivative or group of embedded derivatives classified as assets, net of those classified as liabilities.",
        "label": "Fair value of embedded derivative features"
       }
      }
     },
     "localname": "EmbeddedDerivativeFairValueOfEmbeddedDerivativeNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/ConvertibleDebt-RelatedPartyDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "auth_ref": [
      "r453"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.",
        "label": "Unrecognized compensation cost"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-Based Payment Arrangement, Option [Member]"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tangible personal property used to produce goods and services.",
        "label": "Equipment [Member]"
       }
      }
     },
     "localname": "EquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/ScheduleOfPropertyAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r107",
      "r217",
      "r245",
      "r246",
      "r247",
      "r266",
      "r267",
      "r268",
      "r270",
      "r276",
      "r278",
      "r292",
      "r328",
      "r412",
      "r454",
      "r455",
      "r456",
      "r479",
      "r480",
      "r506",
      "r513",
      "r514",
      "r515",
      "r516",
      "r517",
      "r518",
      "r531",
      "r582",
      "r583",
      "r584"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/AcquisitionDetailsNarrative",
      "http://qualigeninc.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesAndEstimatesDetailsNarrative",
      "http://qualigeninc.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://qualigeninc.com/role/ScheduleOfWarrantActivityDetails",
      "http://qualigeninc.com/role/ScheduleOfWarrantsActivityDetails",
      "http://qualigeninc.com/role/StatementsOfChangesInStockholdersEquity",
      "http://qualigeninc.com/role/StockholdersEquityDetailsNarrative",
      "http://qualigeninc.com/role/StockholdersEquityTables",
      "http://qualigeninc.com/role/WarrantLiabilitiesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAdjustmentOfWarrants": {
     "auth_ref": [
      "r60",
      "r103"
     ],
     "calculation": {
      "http://qualigeninc.com/role/StatementsOfCashFlows": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense (income) related to adjustment to fair value of warrant liability.",
        "label": "Change in fair value of warrant liabilities",
        "terseLabel": "Fair value adjustment of warrants",
        "verboseLabel": "Fair value of warrants"
       }
      }
     },
     "localname": "FairValueAdjustmentOfWarrants",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/ConvertibleDebt-RelatedPartyDetailsNarrative",
      "http://qualigeninc.com/role/StatementsOfCashFlows",
      "http://qualigeninc.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r382",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r509",
      "r541",
      "r542",
      "r543",
      "r612",
      "r613",
      "r618",
      "r619",
      "r620"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/ScheduleOfFairValueHierarchyForWarrantLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r382",
      "r416",
      "r421",
      "r509",
      "r541",
      "r618",
      "r619",
      "r620"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/ScheduleOfFairValueHierarchyForWarrantLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r382",
      "r416",
      "r421",
      "r509",
      "r542",
      "r612",
      "r613",
      "r618",
      "r619",
      "r620"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/ScheduleOfFairValueHierarchyForWarrantLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r382",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r509",
      "r543",
      "r612",
      "r613",
      "r618",
      "r619",
      "r620"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/ScheduleOfFairValueHierarchyForWarrantLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r382",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r541",
      "r542",
      "r543",
      "r612",
      "r613",
      "r618",
      "r619",
      "r620"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value."
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/ScheduleOfFairValueHierarchyForWarrantLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueOfAssetsAcquired": {
     "auth_ref": [
      "r65",
      "r66",
      "r67"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The fair value of assets acquired in noncash investing or financing activities.",
        "label": "Fair Value of Assets Acquired",
        "negatedLabel": "Fair value of assets acquired"
       }
      }
     },
     "localname": "FairValueOfAssetsAcquired",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueOfFinancialInstrumentsPolicy": {
     "auth_ref": [
      "r177",
      "r178"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.",
        "label": "Fair Value of Financial Instruments"
       }
      }
     },
     "localname": "FairValueOfFinancialInstrumentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesAndEstimatesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Estimated useful lives",
        "verboseLabel": "Finite lived intangible asset useful life"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesAndEstimatesDetailsNarrative",
      "http://qualigeninc.com/role/ScheduleOfGoodwillAndOtherIntangibleDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": {
     "auth_ref": [
      "r227",
      "r342"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Accumulated amortization",
        "negatedLabel": "Less: Accumulated amortization"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/GoodwillIprdAndOtherIntangiblesDetailsNarrative",
      "http://qualigeninc.com/role/ScheduleOfGoodwillAndOtherIntangibleDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for asset, excluding financial asset and goodwill, lacking physical substance with finite life expected to be recognized after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Future estimated amortization of patent costs thereafter"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/GoodwillIprdAndOtherIntangiblesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": {
     "auth_ref": [
      "r86"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Future estimated amortization of license costs 2023"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/GoodwillIprdAndOtherIntangiblesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive": {
     "auth_ref": [
      "r86"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Future estimated amortization of patent costs Year 2027"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFive",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/GoodwillIprdAndOtherIntangiblesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": {
     "auth_ref": [
      "r86"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Future estimated amortization of patent costs Year 2026"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/GoodwillIprdAndOtherIntangiblesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": {
     "auth_ref": [
      "r86"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Future estimated amortization of patent costs Year 2025"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/GoodwillIprdAndOtherIntangiblesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": {
     "auth_ref": [
      "r86"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Future estimated amortization of patent costs Year 2024"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/GoodwillIprdAndOtherIntangiblesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r339",
      "r341",
      "r342",
      "r344",
      "r552",
      "r553"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by major type or class of finite-lived intangible assets.",
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/GoodwillIprdAndOtherIntangiblesDetailsNarrative",
      "http://qualigeninc.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesAndEstimatesDetailsNarrative",
      "http://qualigeninc.com/role/ScheduleOfGoodwillAndOtherIntangibleDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsGross": {
     "auth_ref": [
      "r84",
      "r553"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Licensing rights",
        "verboseLabel": "Finite lived intangible assets gross"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/GoodwillIprdAndOtherIntangiblesDetailsNarrative",
      "http://qualigeninc.com/role/ScheduleOfGoodwillAndOtherIntangibleDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Finite-Lived Intangible Assets [Line Items]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/GoodwillIprdAndOtherIntangiblesDetailsNarrative",
      "http://qualigeninc.com/role/ScheduleOfGoodwillAndOtherIntangibleDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r79",
      "r83"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company."
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/GoodwillIprdAndOtherIntangiblesDetailsNarrative",
      "http://qualigeninc.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesAndEstimatesDetailsNarrative",
      "http://qualigeninc.com/role/ScheduleOfGoodwillAndOtherIntangibleDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "auth_ref": [
      "r84",
      "r552"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Total finite-lived intangible assets, net"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/ScheduleOfGoodwillAndOtherIntangibleDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ForeignCountryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax departments of governments entitled to levy and collect income taxes from the entity outside the entity's country of domicile.",
        "label": "Foreign Tax Authority [Member]"
       }
      }
     },
     "localname": "ForeignCountryMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/IncomeTaxesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": {
     "auth_ref": [
      "r520"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.",
        "label": "Foreign Currency Translation"
       }
      }
     },
     "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesAndEstimatesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.",
        "label": "Furniture and Fixtures [Member]"
       }
      }
     },
     "localname": "FurnitureAndFixturesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/ScheduleOfPropertyAndEquipmentDetails",
      "http://qualigeninc.com/role/ScheduleOfUsefulLivesOfPropertyAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r45"
     ],
     "calculation": {
      "http://qualigeninc.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "auth_ref": [
      "r42"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing general and administrative expense.",
        "label": "General and Administrative Expense [Member]"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/ScheduleOfShare-basedCompensationExpenseDetails",
      "http://qualigeninc.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Goodwill": {
     "auth_ref": [
      "r226",
      "r335",
      "r566",
      "r610",
      "r627",
      "r679",
      "r680"
     ],
     "calculation": {
      "http://qualigeninc.com/role/BalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill"
       }
      }
     },
     "localname": "Goodwill",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/BalanceSheets",
      "http://qualigeninc.com/role/ScheduleOfAssetsAcquiredAndLiabilitiesDetails",
      "http://qualigeninc.com/role/ScheduleOfGoodwillAndOtherIntangibleDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill and Intangible Assets Disclosure [Abstract]"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r88"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for goodwill and intangible assets.",
        "label": "GOODWILL, IPR&amp;D AND OTHER INTANGIBLES"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/GoodwillIprdAndOtherIntangibles"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock": {
     "auth_ref": [
      "r76",
      "r81"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for goodwill and intangible assets. This accounting policy also may address how an entity assesses and measures impairment of goodwill and intangible assets.",
        "label": "Goodwill and Intangible Assets, Policy [Policy Text Block]",
        "verboseLabel": "Goodwill"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesAndEstimatesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GoodwillImpairmentLoss": {
     "auth_ref": [
      "r60",
      "r336",
      "r337",
      "r338",
      "r610"
     ],
     "calculation": {
      "http://qualigeninc.com/role/StatementsOfCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://qualigeninc.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "order": 5.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill and fixed asset impairment",
        "terseLabel": "Goodwill, Impairment Loss",
        "verboseLabel": "Goodwill impairment charges"
       }
      }
     },
     "localname": "GoodwillImpairmentLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/GoodwillIprdAndOtherIntangiblesDetailsNarrative",
      "http://qualigeninc.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesAndEstimatesDetailsNarrative",
      "http://qualigeninc.com/role/StatementsOfCashFlows",
      "http://qualigeninc.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillPeriodIncreaseDecrease": {
     "auth_ref": [
      "r681"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Decrease in good will"
       }
      }
     },
     "localname": "GoodwillPeriodIncreaseDecrease",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/AcquisitionDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_HedgingLiabilitiesCurrent": {
     "auth_ref": [
      "r24"
     ],
     "calculation": {
      "http://qualigeninc.com/role/BalanceSheets": {
       "order": 8.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of the liability arising from a financial instrument or a contract used to mitigate a specified risk (hedge), and which are expected to be converted into cash or otherwise disposed of within a year or the normal operating cycle, if longer.",
        "label": "Warrant liabilities"
       }
      }
     },
     "localname": "HedgingLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ImpairmentOfIntangibleAssetsFinitelived": {
     "auth_ref": [
      "r666",
      "r682"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of a finite-lived intangible asset to fair value.",
        "label": "Impairment of Intangible Assets, Finite-Lived"
       }
      }
     },
     "localname": "ImpairmentOfIntangibleAssetsFinitelived",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/GoodwillIprdAndOtherIntangiblesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": {
     "auth_ref": [
      "r89",
      "r95"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.",
        "label": "Impairment of Long-Lived Assets"
       }
      }
     },
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesAndEstimatesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InProcessResearchAndDevelopmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "In process investigation of new knowledge useful in developing new product or service or new process or technique or improvement to existing product or process, and translation of knowledge into plan or design for new product or process or for improvement to existing product or process.",
        "label": "In Process Research and Development [Member]"
       }
      }
     },
     "localname": "InProcessResearchAndDevelopmentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/ScheduleOfGoodwillAndOtherIntangibleDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic": {
     "auth_ref": [
      "r262",
      "r485"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.",
        "label": "Domestic"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/ScheduleOfDomesticAndForeignComponentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r40",
      "r185",
      "r196",
      "r212",
      "r303",
      "r311",
      "r315",
      "r317",
      "r572",
      "r608"
     ],
     "calculation": {
      "http://qualigeninc.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_ProfitLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "Loss before provision for income taxes",
        "totalLabel": "LOSS BEFORE (BENEFIT) PROVISION FOR INCOME TAXES"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/ScheduleOfDomesticAndForeignComponentsDetails",
      "http://qualigeninc.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign": {
     "auth_ref": [
      "r262",
      "r485"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.",
        "label": "Foreign"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/ScheduleOfDomesticAndForeignComponentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r345",
      "r348"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesAndEstimatesDetailsNarrative",
      "http://qualigeninc.com/role/ScheduleOfShare-basedCompensationExpenseDetails",
      "http://qualigeninc.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r348"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement."
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesAndEstimatesDetailsNarrative",
      "http://qualigeninc.com/role/ScheduleOfShare-basedCompensationExpenseDetails",
      "http://qualigeninc.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "auth_ref": [
      "r143"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by tax jurisdiction.",
        "label": "Income Tax Authority [Axis]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/IncomeTaxesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes."
       }
      }
     },
     "localname": "IncomeTaxAuthorityDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/IncomeTaxesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r263",
      "r466",
      "r468",
      "r475",
      "r481",
      "r487",
      "r491",
      "r492",
      "r493"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "INCOME TAXES"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/IncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r264",
      "r277",
      "r278",
      "r302",
      "r464",
      "r482",
      "r489",
      "r580"
     ],
     "calculation": {
      "http://qualigeninc.com/role/ScheduleOfProvisionForIncomeTaxesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://qualigeninc.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_ProfitLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "(BENEFIT) PROVISION FOR INCOME TAXES",
        "totalLabel": "Total provision (benefit) for income taxes"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/ScheduleOfProvisionForIncomeTaxesDetails",
      "http://qualigeninc.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "auth_ref": [
      "r244",
      "r460",
      "r461",
      "r468",
      "r469",
      "r474",
      "r478"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
        "label": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesAndEstimatesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxesPaidNet": {
     "auth_ref": [
      "r64"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.",
        "label": "Taxes"
       }
      }
     },
     "localname": "IncomeTaxesPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r59"
     ],
     "calculation": {
      "http://qualigeninc.com/role/StatementsOfCashFlows": {
       "order": 15.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Increase (Decrease) in Accounts Payable",
        "verboseLabel": "Accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r59"
     ],
     "calculation": {
      "http://qualigeninc.com/role/StatementsOfCashFlows": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedLabel": "Accounts receivable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": {
     "auth_ref": [
      "r546",
      "r665"
     ],
     "calculation": {
      "http://qualigeninc.com/role/StatementsOfCashFlows": {
       "order": 19.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Deferred revenue"
       }
      }
     },
     "localname": "IncreaseDecreaseInContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInDeferredLiabilities": {
     "auth_ref": [
      "r59"
     ],
     "calculation": {
      "http://qualigeninc.com/role/StatementsOfCashFlows": {
       "order": 20.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Change during the period in carrying value for all deferred liabilities due within one year or operating cycle.",
        "label": "Increase (Decrease) in Deferred Liabilities",
        "verboseLabel": "Deferred tax liability"
       }
      }
     },
     "localname": "IncreaseDecreaseInDeferredLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": {
     "auth_ref": [
      "r665",
      "r739"
     ],
     "calculation": {
      "http://qualigeninc.com/role/StatementsOfCashFlows": {
       "order": 18.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligation for operating lease.",
        "label": "Operating lease liability"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities": {
     "auth_ref": [
      "r59"
     ],
     "calculation": {
      "http://qualigeninc.com/role/StatementsOfCashFlows": {
       "order": 16.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in other obligations or expenses incurred but not yet paid.",
        "label": "Increase (Decrease) in Other Accounts Payable and Accrued Liabilities",
        "verboseLabel": "Accrued expenses and other current liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r59"
     ],
     "calculation": {
      "http://qualigeninc.com/role/StatementsOfCashFlows": {
       "order": 14.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Prepaid expenses and other assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r340",
      "r343"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type or class of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.",
        "label": "Indefinite-Lived Intangible Assets [Axis]"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/ScheduleOfGoodwillAndOtherIntangibleDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r80",
      "r87"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major class of indefinite-lived intangible asset (for example, trade names, etc. but not all-inclusive), excluding goodwill. A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of the company."
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/ScheduleOfGoodwillAndOtherIntangibleDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IntangibleAssetsFiniteLivedPolicy": {
     "auth_ref": [
      "r83",
      "r548",
      "r549",
      "r550",
      "r552",
      "r602"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for finite-lived intangible assets. This accounting policy also might address: (1) the amortization method used; (2) the useful lives of such assets; and (3) how the entity assesses and measures impairment of such assets.",
        "label": "Intangible Assets"
       }
      }
     },
     "localname": "IntangibleAssetsFiniteLivedPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesAndEstimatesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwill": {
     "auth_ref": [
      "r77",
      "r82"
     ],
     "calculation": {
      "http://qualigeninc.com/role/BalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.",
        "label": "Intangible assets, net",
        "verboseLabel": "Total other intangible assets, net"
       }
      }
     },
     "localname": "IntangibleAssetsNetExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/BalanceSheets",
      "http://qualigeninc.com/role/ScheduleOfGoodwillAndOtherIntangibleDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestIncomeExpenseNet": {
     "auth_ref": [
      "r198"
     ],
     "calculation": {
      "http://qualigeninc.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net amount of operating interest income (expense).",
        "label": "Interest Income (Expense), Net",
        "negatedLabel": "Interest (income) expense, net"
       }
      }
     },
     "localname": "InterestIncomeExpenseNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPaidNet": {
     "auth_ref": [
      "r254",
      "r257",
      "r258"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.",
        "label": "Interest"
       }
      }
     },
     "localname": "InterestPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPayableCurrent": {
     "auth_ref": [
      "r24"
     ],
     "calculation": {
      "http://qualigeninc.com/role/ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Interest (Convertible debt - related party)",
        "verboseLabel": "Accrued interest"
       }
      }
     },
     "localname": "InterestPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://qualigeninc.com/role/ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails",
      "http://qualigeninc.com/role/ShortTermDebt-RelatedPartyDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory Disclosure [Abstract]"
       }
      }
     },
     "localname": "InventoryDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InventoryDisclosureTextBlock": {
     "auth_ref": [
      "r334"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.",
        "label": "INVENTORY, NET"
       }
      }
     },
     "localname": "InventoryDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/InventoryNet"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InventoryFinishedGoods": {
     "auth_ref": [
      "r656"
     ],
     "calculation": {
      "http://qualigeninc.com/role/ScheduleOfInventoryDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.",
        "label": "Finished goods"
       }
      }
     },
     "localname": "InventoryFinishedGoods",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/ScheduleOfInventoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryNet": {
     "auth_ref": [
      "r237",
      "r597",
      "r627"
     ],
     "calculation": {
      "http://qualigeninc.com/role/BalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://qualigeninc.com/role/ScheduleOfInventoryDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, net",
        "totalLabel": "Total inventory"
       }
      }
     },
     "localname": "InventoryNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/BalanceSheets",
      "http://qualigeninc.com/role/ScheduleOfInventoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryPolicyTextBlock": {
     "auth_ref": [
      "r222",
      "r236",
      "r291",
      "r331",
      "r333",
      "r334",
      "r547",
      "r603"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.",
        "label": "Inventory, Net"
       }
      }
     },
     "localname": "InventoryPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesAndEstimatesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InventoryRawMaterials": {
     "auth_ref": [
      "r658"
     ],
     "calculation": {
      "http://qualigeninc.com/role/ScheduleOfInventoryDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Raw materials"
       }
      }
     },
     "localname": "InventoryRawMaterials",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/ScheduleOfInventoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryWorkInProcess": {
     "auth_ref": [
      "r657"
     ],
     "calculation": {
      "http://qualigeninc.com/role/ScheduleOfInventoryDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer.",
        "label": "Work in process"
       }
      }
     },
     "localname": "InventoryWorkInProcess",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/ScheduleOfInventoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryWriteDown": {
     "auth_ref": [
      "r332"
     ],
     "calculation": {
      "http://qualigeninc.com/role/StatementsOfCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels.",
        "label": "Inventory reserves"
       }
      }
     },
     "localname": "InventoryWriteDown",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims": {
     "auth_ref": [
      "r60"
     ],
     "calculation": {
      "http://qualigeninc.com/role/StatementsOfCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of share-based compensation granted to nonemployees as payment for services rendered or acknowledged claims.",
        "label": "Common stock issued for professional services"
       }
      }
     },
     "localname": "IssuanceOfStockAndWarrantsForServicesOrClaims",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "auth_ref": [
      "r92"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additions or improvements to assets held under a lease arrangement.",
        "label": "Leasehold Improvements [Member]"
       }
      }
     },
     "localname": "LeaseholdImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/ScheduleOfPropertyAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "auth_ref": [
      "r525"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.",
        "label": "Operating Leases"
       }
      }
     },
     "localname": "LesseeLeasesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesAndEstimatesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseDescription": {
     "auth_ref": [
      "r526"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of lessee's operating lease.",
        "label": "Operating lease term description"
       }
      }
     },
     "localname": "LesseeOperatingLeaseDescription",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r740"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "SCHEDULE OF MATURITIES OF OPERATING LEASE LIABILITIES"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/CommitmentsAndContingenciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r530"
     ],
     "calculation": {
      "http://qualigeninc.com/role/ScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/ScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r530"
     ],
     "calculation": {
      "http://qualigeninc.com/role/ScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/ScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": {
     "auth_ref": [
      "r530"
     ],
     "calculation": {
      "http://qualigeninc.com/role/ScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "2027"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/ScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r530"
     ],
     "calculation": {
      "http://qualigeninc.com/role/ScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "2026"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/ScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r530"
     ],
     "calculation": {
      "http://qualigeninc.com/role/ScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "2025"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/ScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r530"
     ],
     "calculation": {
      "http://qualigeninc.com/role/ScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/ScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r530"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "negatedLabel": "Less present value discount"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/ScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseTermOfContract": {
     "auth_ref": [
      "r738"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Operating lease term"
       }
      }
     },
     "localname": "LesseeOperatingLeaseTermOfContract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r23",
      "r261",
      "r327",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r500",
      "r503",
      "r504",
      "r512",
      "r607",
      "r688",
      "r743",
      "r744"
     ],
     "calculation": {
      "http://qualigeninc.com/role/BalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r16",
      "r193",
      "r208",
      "r627",
      "r669",
      "r677",
      "r735"
     ],
     "calculation": {
      "http://qualigeninc.com/role/BalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total Liabilities &amp; Stockholders\u2019 Equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "LIABILITIES AND STOCKHOLDERS\u2019 EQUITY"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/BalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesAssumed1": {
     "auth_ref": [
      "r65",
      "r66",
      "r67"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The fair value of liabilities assumed in noncash investing or financing activities.",
        "label": "Fair value of liabilities assumed, net of goodwill"
       }
      }
     },
     "localname": "LiabilitiesAssumed1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r25",
      "r221",
      "r261",
      "r327",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r500",
      "r503",
      "r504",
      "r512",
      "r627",
      "r688",
      "r743",
      "r744"
     ],
     "calculation": {
      "http://qualigeninc.com/role/BalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/BalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LicenseMember": {
     "auth_ref": [
      "r694"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Right to use intangible asset. Intangible asset includes, but is not limited to, patent, copyright, technology, manufacturing process, software or trademark.",
        "label": "License [Member]"
       }
      }
     },
     "localname": "LicenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/GoodwillIprdAndOtherIntangiblesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity": {
     "auth_ref": [
      "r21"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current borrowing capacity under the credit facility considering any current restrictions on the amount that could be borrowed (for example, borrowings may be limited by the amount of current assets), but without considering any amounts currently outstanding under the facility.",
        "label": "Additional funding amount"
       }
      }
     },
     "localname": "LineOfCreditFacilityCurrentBorrowingCapacity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": {
     "auth_ref": [
      "r21"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.",
        "label": "Maximum future funding amount"
       }
      }
     },
     "localname": "LineOfCreditFacilityMaximumBorrowingCapacity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LitigationSettlementAmountAwardedToOtherParty": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount awarded to other party in judgment or settlement of litigation.",
        "label": "Litigation settlement amount"
       }
      }
     },
     "localname": "LitigationSettlementAmountAwardedToOtherParty",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MachineryAndEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tangible personal property used to produce goods and services, including, but is not limited to, tools, dies and molds, computer and office equipment.",
        "label": "Machinery and Equipment [Member]"
       }
      }
     },
     "localname": "MachineryAndEquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/ScheduleOfPropertyAndEquipmentDetails",
      "http://qualigeninc.com/role/ScheduleOfUsefulLivesOfPropertyAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MarketingAndAdvertisingExpense": {
     "auth_ref": [
      "r45"
     ],
     "calculation": {
      "http://qualigeninc.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "order": 4.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total expense recognized in the period for promotion, public relations, and brand or product advertising.",
        "label": "Sales and marketing"
       }
      }
     },
     "localname": "MarketingAndAdvertisingExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MeasurementInputExpectedDividendRateMember": {
     "auth_ref": [
      "r733"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using expected dividend rate to be paid to holder of share per year.",
        "label": "Measurement Input, Expected Dividend Rate [Member]"
       }
      }
     },
     "localname": "MeasurementInputExpectedDividendRateMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/ScheduleOfAssumptionsOfWarrantLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputExpectedTermMember": {
     "auth_ref": [
      "r733"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using period financial instrument is expected to be outstanding. Excludes maturity date.",
        "label": "Measurement Input, Expected Term [Member]"
       }
      }
     },
     "localname": "MeasurementInputExpectedTermMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/ScheduleOfAssumptionsOfWarrantLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputPriceVolatilityMember": {
     "auth_ref": [
      "r733"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using rate at which price of security will increase (decrease) for given set of returns.",
        "label": "Measurement Input, Price Volatility [Member]"
       }
      }
     },
     "localname": "MeasurementInputPriceVolatilityMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/ScheduleOfAssumptionsOfWarrantLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputRiskFreeInterestRateMember": {
     "auth_ref": [
      "r733"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using interest rate on instrument with zero risk of financial loss.",
        "label": "Measurement Input, Risk Free Interest Rate [Member]"
       }
      }
     },
     "localname": "MeasurementInputRiskFreeInterestRateMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/ScheduleOfAssumptionsOfWarrantLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputTypeAxis": {
     "auth_ref": [
      "r510"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Axis]"
       }
      }
     },
     "localname": "MeasurementInputTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/ScheduleOfAssumptionsOfWarrantLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MeasurementInputTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input used to determine value of asset and liability."
       }
      }
     },
     "localname": "MeasurementInputTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/ScheduleOfAssumptionsOfWarrantLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MinorityInterest": {
     "auth_ref": [
      "r32",
      "r192",
      "r207",
      "r261",
      "r327",
      "r359",
      "r361",
      "r362",
      "r363",
      "r366",
      "r367",
      "r512"
     ],
     "calculation": {
      "http://qualigeninc.com/role/BalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).",
        "label": "Noncontrolling interest"
       }
      }
     },
     "localname": "MinorityInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MinorityInterestDecreaseFromRedemptions": {
     "auth_ref": [
      "r115",
      "r167",
      "r168"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Decrease in noncontrolling interest (for example, but not limited to, redeeming or purchasing the interests of noncontrolling shareholders, issuance of shares (interests) by the non-wholly owned subsidiary to the parent entity for other than cash, and a buyback of shares (interest) by the non-wholly owned subsidiary from the noncontrolling interests).",
        "label": "Decrease to noncontrolling interest"
       }
      }
     },
     "localname": "MinorityInterestDecreaseFromRedemptions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/AcquisitionDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r256"
     ],
     "calculation": {
      "http://qualigeninc.com/role/StatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CASH FLOWS FROM FINANCING ACTIVITIES:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r256"
     ],
     "calculation": {
      "http://qualigeninc.com/role/StatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash used in investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CASH FLOWS FROM INVESTING ACTIVITIES:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r56",
      "r58",
      "r61"
     ],
     "calculation": {
      "http://qualigeninc.com/role/StatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "negatedLabel": "Net cash used in operating activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/LiquidityAndGoingConcernDetailsNarrative",
      "http://qualigeninc.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CASH FLOWS FROM OPERATING ACTIVITIES"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r41",
      "r61",
      "r197",
      "r211",
      "r219",
      "r240",
      "r242",
      "r247",
      "r261",
      "r269",
      "r271",
      "r272",
      "r273",
      "r274",
      "r277",
      "r278",
      "r282",
      "r303",
      "r311",
      "r315",
      "r317",
      "r327",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r508",
      "r512",
      "r608",
      "r688"
     ],
     "calculation": {
      "http://qualigeninc.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net loss used for basic earnings per share",
        "totalLabel": "Net loss attributable to Qualigen Therapeutics, Inc."
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/ScheduleOfEarningsPerShareBasicAndDilutedDetails",
      "http://qualigeninc.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r170",
      "r173",
      "r240",
      "r242",
      "r277",
      "r278",
      "r663"
     ],
     "calculation": {
      "http://qualigeninc.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of Net Income (Loss) attributable to noncontrolling interest.",
        "label": "Net loss attributable to noncontrolling interest"
       }
      }
     },
     "localname": "NetIncomeLossAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "Recent Accounting Pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesAndEstimatesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NoncashInvestingAndFinancingItemsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "ACQUISITION:"
       }
      }
     },
     "localname": "NoncashInvestingAndFinancingItemsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NoncontrollingInterestMember": {
     "auth_ref": [
      "r162",
      "r412",
      "r671",
      "r672",
      "r673"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest.",
        "label": "Noncontrolling Interest [Member]"
       }
      }
     },
     "localname": "NoncontrollingInterestMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "auth_ref": [
      "r46"
     ],
     "calculation": {
      "http://qualigeninc.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).",
        "label": "Nonoperating Income (Expense)",
        "negatedTotalLabel": "Total other expense (income), net"
       }
      }
     },
     "localname": "NonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "OTHER EXPENSE (INCOME), NET"
       }
      }
     },
     "localname": "NonoperatingIncomeExpenseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingCostsAndExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "EXPENSES"
       }
      }
     },
     "localname": "OperatingCostsAndExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://qualigeninc.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "totalLabel": "Total expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r303",
      "r311",
      "r315",
      "r317",
      "r608"
     ],
     "calculation": {
      "http://qualigeninc.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "LOSS FROM OPERATIONS"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseExpense": {
     "auth_ref": [
      "r737"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating lease expense. Excludes sublease income.",
        "label": "Operating Lease, Expense"
       }
      }
     },
     "localname": "OperatingLeaseExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r523"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating lease liabilities",
        "periodEndLabel": "Lease liabilities at December 31, 2022",
        "periodStartLabel": "Lease liabilities at December 31, 2021"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/ScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails",
      "http://qualigeninc.com/role/ScheduleOfOperatingLeaseRightOfUseAssetsAndOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r523"
     ],
     "calculation": {
      "http://qualigeninc.com/role/BalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating lease liability, current portion",
        "verboseLabel": "Current portion at Decebmer 31, 2022"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/BalanceSheets",
      "http://qualigeninc.com/role/ScheduleOfOperatingLeaseRightOfUseAssetsAndOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r523"
     ],
     "calculation": {
      "http://qualigeninc.com/role/BalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating lease liability, net of current portion",
        "negatedLabel": "Less non-current portion"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/BalanceSheets",
      "http://qualigeninc.com/role/ScheduleOfOperatingLeaseRightOfUseAssetsAndOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasePayments": {
     "auth_ref": [
      "r524",
      "r527"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.",
        "label": "Operating Lease, Payments",
        "negatedLabel": "Less principal payments on operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeasePayments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/ScheduleOfOperatingLeaseRightOfUseAssetsAndOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r522"
     ],
     "calculation": {
      "http://qualigeninc.com/role/BalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Right-of-use assets",
        "periodEndLabel": "Operating lease right-of-use assets",
        "periodStartLabel": "Operating lease right-of-use assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/BalanceSheets",
      "http://qualigeninc.com/role/ScheduleOfOperatingLeaseRightOfUseAssetsAndOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense": {
     "auth_ref": [
      "r666"
     ],
     "calculation": {
      "http://qualigeninc.com/role/StatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense for right-of-use asset from operating lease.",
        "label": "Amortization of right-of-use assets",
        "negatedLabel": "Less amortization of operating lease right-of-use assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAssetAmortizationExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/ScheduleOfOperatingLeaseRightOfUseAssetsAndOperatingLeaseLiabilitiesDetails",
      "http://qualigeninc.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r529",
      "r626"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Weighted-average discount rate"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r528",
      "r626"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Weighted-average remaining lease term"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OperatingLossCarryforwards": {
     "auth_ref": [
      "r145"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Net operating loss carryforwards"
       }
      }
     },
     "localname": "OperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/IncomeTaxesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLossCarryforwardsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Operating Loss Carryforwards [Line Items]"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/IncomeTaxesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLossCarryforwardsTable": {
     "auth_ref": [
      "r146"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting pertinent information, such as tax authority, amounts, and expiration dates, of net operating loss carryforwards, including an assessment of the likelihood of utilization.",
        "label": "Operating Loss Carryforwards [Table]"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/IncomeTaxesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r1",
      "r69",
      "r74",
      "r175"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows. Describes procedure if disclosures are provided in more than one note to the financial statements.",
        "label": "ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND ESTIMATES"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesAndEstimates"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r24"
     ],
     "calculation": {
      "http://qualigeninc.com/role/ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails": {
       "order": 12.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsCurrent": {
     "auth_ref": [
      "r238",
      "r627"
     ],
     "calculation": {
      "http://qualigeninc.com/role/ScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current assets classified as other.",
        "label": "Other current assets"
       }
      }
     },
     "localname": "OtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/ScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r228"
     ],
     "calculation": {
      "http://qualigeninc.com/role/BalanceSheets": {
       "order": 7.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": {
     "auth_ref": [
      "r33"
     ],
     "calculation": {
      "http://qualigeninc.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.",
        "label": "Foreign currency translation adjustment",
        "verboseLabel": "Adjustment net of tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesAndEstimatesDetailsNarrative",
      "http://qualigeninc.com/role/StatementsOfChangesInStockholdersEquity",
      "http://qualigeninc.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other comprehensive loss, net of tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossTax": {
     "auth_ref": [
      "r36",
      "r245",
      "r248",
      "r464",
      "r488",
      "r490",
      "r513",
      "r516",
      "r518",
      "r567",
      "r575"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of tax expense (benefit) allocated to other comprehensive income (loss).",
        "label": "Other comprehensive income loss tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/AcquisitionDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r48"
     ],
     "calculation": {
      "http://qualigeninc.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "order": 3.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "negatedLabel": "Other income, net"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherPrepaidExpenseCurrent": {
     "auth_ref": [
      "r659",
      "r678"
     ],
     "calculation": {
      "http://qualigeninc.com/role/ScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.",
        "label": "Other prepaid expenses"
       }
      }
     },
     "localname": "OtherPrepaidExpenseCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/ScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ParentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Portion of equity, or net assets, in the consolidated entity attributable, directly or indirectly, to the parent. Excludes noncontrolling interests.",
        "label": "Parent [Member]"
       }
      }
     },
     "localname": "ParentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PatentsMember": {
     "auth_ref": [
      "r157"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exclusive legal right granted by the government to the owner of the patent to exploit an invention or a process for a period of time specified by law.",
        "label": "Patents [Member]"
       }
      }
     },
     "localname": "PatentsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/GoodwillIprdAndOtherIntangiblesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PayablesAndAccrualsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payables and Accruals [Abstract]"
       }
      }
     },
     "localname": "PayablesAndAccrualsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PaymentsForRent": {
     "auth_ref": [
      "r57"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash payments to lessor's for use of assets under operating leases.",
        "label": "Payments for Rent"
       }
      }
     },
     "localname": "PaymentsForRent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfStockIssuanceCosts": {
     "auth_ref": [
      "r55"
     ],
     "calculation": {
      "http://qualigeninc.com/role/StatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security.",
        "label": "Payments of Stock Issuance Costs",
        "negatedLabel": "Offering costs of Securities Purchase Agreements"
       }
      }
     },
     "localname": "PaymentsOfStockIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired": {
     "auth_ref": [
      "r50"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.",
        "label": "Total consideration transferred, net of cash acquired"
       }
      }
     },
     "localname": "PaymentsToAcquireBusinessesNetOfCashAcquired",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/ScheduleOfConsiderationTransferredDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireIntangibleAssets": {
     "auth_ref": [
      "r51"
     ],
     "calculation": {
      "http://qualigeninc.com/role/StatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.",
        "label": "Payments to Acquire Intangible Assets",
        "negatedLabel": "Payments for patents and licenses"
       }
      }
     },
     "localname": "PaymentsToAcquireIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r51"
     ],
     "calculation": {
      "http://qualigeninc.com/role/StatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to acquire assets",
        "negatedLabel": "Purchases of property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/PropertyAndEquipmentNetDetailsNarrative",
      "http://qualigeninc.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r695",
      "r696",
      "r697",
      "r698",
      "r699",
      "r700",
      "r701",
      "r702",
      "r703",
      "r704",
      "r705",
      "r706",
      "r707",
      "r708",
      "r709",
      "r710",
      "r711",
      "r712",
      "r713",
      "r714",
      "r715",
      "r716",
      "r717",
      "r718",
      "r719",
      "r720"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [
      "r695",
      "r696",
      "r697",
      "r698",
      "r699",
      "r700",
      "r701",
      "r702",
      "r703",
      "r704",
      "r705",
      "r706",
      "r707",
      "r708",
      "r709",
      "r710",
      "r711",
      "r712",
      "r713",
      "r714",
      "r715",
      "r716",
      "r717",
      "r718",
      "r719",
      "r720"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement."
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company.",
        "label": "Preferred Stock [Member]"
       }
      }
     },
     "localname": "PreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r660"
     ],
     "calculation": {
      "http://qualigeninc.com/role/BalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://qualigeninc.com/role/ScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid expenses and other current assets",
        "totalLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/BalanceSheets",
      "http://qualigeninc.com/role/ScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidInsurance": {
     "auth_ref": [
      "r599",
      "r609",
      "r678"
     ],
     "calculation": {
      "http://qualigeninc.com/role/ScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer.",
        "label": "Prepaid insurance"
       }
      }
     },
     "localname": "PrepaidInsurance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/ScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromConvertibleDebt": {
     "auth_ref": [
      "r53"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.",
        "label": "Proceeds from issuance of debt",
        "verboseLabel": "Proceeds from convertible debt"
       }
      }
     },
     "localname": "ProceedsFromConvertibleDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/LiquidityAndGoingConcernDetailsNarrative",
      "http://qualigeninc.com/role/ResearchAndLicenseAgreementsDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r52"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds from issuance of common stock"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/LiquidityAndGoingConcernDetailsNarrative",
      "http://qualigeninc.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOrSaleOfEquity": {
     "auth_ref": [
      "r52"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.",
        "label": "Proceeds from Issuance or Sale of Equity"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOrSaleOfEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromRelatedPartyDebt": {
     "auth_ref": [
      "r53"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from a long-term borrowing made from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Proceeds from Advances from Affiliates.",
        "label": "Proceeds from related party debt"
       }
      }
     },
     "localname": "ProceedsFromRelatedPartyDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://qualigeninc.com/role/ShortTermDebt-RelatedPartyDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromWarrantExercises": {
     "auth_ref": [
      "r664"
     ],
     "calculation": {
      "http://qualigeninc.com/role/StatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from holders exercising their stock warrants.",
        "label": "Net proceeds from warrant exercises"
       }
      }
     },
     "localname": "ProceedsFromWarrantExercises",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProductWarrantyAccrual": {
     "auth_ref": [
      "r99",
      "r100",
      "r194"
     ],
     "calculation": {
      "http://qualigeninc.com/role/ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails": {
       "order": 10.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for estimated claims under standard and extended warranty protection rights granted to customers.",
        "label": "Accrued warranty liabilities",
        "verboseLabel": "Warranty liability"
       }
      }
     },
     "localname": "ProductWarrantyAccrual",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesAndEstimatesDetailsNarrative",
      "http://qualigeninc.com/role/ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProductWarrantyExpense": {
     "auth_ref": [
      "r59",
      "r98"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The expense charged against earnings for the period pertaining to standard and extended warranties on the entity's goods and services granted to customers.",
        "label": "Warranty costs"
       }
      }
     },
     "localname": "ProductWarrantyExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesAndEstimatesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProfitLoss": {
     "auth_ref": [
      "r219",
      "r240",
      "r242",
      "r255",
      "r261",
      "r269",
      "r277",
      "r278",
      "r303",
      "r311",
      "r315",
      "r317",
      "r327",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r498",
      "r501",
      "r502",
      "r508",
      "r512",
      "r572",
      "r608",
      "r624",
      "r625",
      "r663",
      "r688"
     ],
     "calculation": {
      "http://qualigeninc.com/role/StatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://qualigeninc.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.",
        "label": "Net Loss",
        "totalLabel": "Net loss",
        "verboseLabel": "Net loss"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/StatementsOfCashFlows",
      "http://qualigeninc.com/role/StatementsOfChangesInStockholdersEquity",
      "http://qualigeninc.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r94"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Long-Lived Tangible Asset [Axis]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/ScheduleOfPropertyAndEquipmentDetails",
      "http://qualigeninc.com/role/ScheduleOfUsefulLivesOfPropertyAndEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "auth_ref": [
      "r96",
      "r591",
      "r592",
      "r593"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "PROPERTY AND EQUIPMENT, NET"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/PropertyAndEquipmentNet"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r92",
      "r224"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property and equipment, gross"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/ScheduleOfPropertyAndEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property, Plant and Equipment [Line Items]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/ScheduleOfPropertyAndEquipmentDetails",
      "http://qualigeninc.com/role/ScheduleOfUsefulLivesOfPropertyAndEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r94",
      "r209",
      "r573",
      "r627"
     ],
     "calculation": {
      "http://qualigeninc.com/role/BalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/BalanceSheets",
      "http://qualigeninc.com/role/ScheduleOfPropertyAndEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "auth_ref": [
      "r94",
      "r591",
      "r592"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property and Equipment, Net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesAndEstimatesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r94"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "SCHEDULE OF PROPERTY AND EQUIPMENT"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/PropertyAndEquipmentNetTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r92"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software."
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/ScheduleOfPropertyAndEquipmentDetails",
      "http://qualigeninc.com/role/ScheduleOfUsefulLivesOfPropertyAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.",
        "label": "Property and equipment, useful life"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/ScheduleOfUsefulLivesOfPropertyAndEquipmentDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ProvisionForDoubtfulAccounts": {
     "auth_ref": [
      "r253",
      "r330"
     ],
     "calculation": {
      "http://qualigeninc.com/role/StatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense (reversal of expense) for expected credit loss on accounts receivable.",
        "label": "Accounts receivable reserves and allowances"
       }
      }
     },
     "localname": "ProvisionForDoubtfulAccounts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RelatedPartyDomain": {
     "auth_ref": [
      "r422",
      "r534",
      "r535"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests."
       }
      }
     },
     "localname": "RelatedPartyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://qualigeninc.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://qualigeninc.com/role/ShortTermDebt-RelatedPartyDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Related Party Transaction [Line Items]"
       }
      }
     },
     "localname": "RelatedPartyTransactionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions [Abstract]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "auth_ref": [
      "r422",
      "r534",
      "r554",
      "r555",
      "r556",
      "r557",
      "r558",
      "r559",
      "r560",
      "r561",
      "r562",
      "r563",
      "r564",
      "r565",
      "r742"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://qualigeninc.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://qualigeninc.com/role/ShortTermDebt-RelatedPartyDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "auth_ref": [
      "r532",
      "r533",
      "r535",
      "r536",
      "r537"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "RELATED PARTY TRANSACTIONS"
       }
      }
     },
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/RelatedPartyTransactions"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RepaymentsOfNotesPayable": {
     "auth_ref": [
      "r54"
     ],
     "calculation": {
      "http://qualigeninc.com/role/StatementsOfCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for a borrowing supported by a written promise to pay an obligation.",
        "label": "Repayments of Notes Payable",
        "negatedLabel": "Principal payments on notes payable"
       }
      }
     },
     "localname": "RepaymentsOfNotesPayable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r141",
      "r213",
      "r751"
     ],
     "calculation": {
      "http://qualigeninc.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "order": 3.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/ResearchAndLicenseAgreementsDetailsNarrative",
      "http://qualigeninc.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/ScheduleOfShare-basedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r141"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research and Development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesAndEstimatesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalents": {
     "auth_ref": [
      "r62",
      "r68",
      "r186",
      "r205",
      "r223"
     ],
     "calculation": {
      "http://qualigeninc.com/role/BalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Restricted cash"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestructuringCostAndReserveLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Restructuring Cost and Reserve [Line Items]"
       }
      }
     },
     "localname": "RestructuringCostAndReserveLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/LiquidityAndGoingConcernDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r13",
      "r115",
      "r206",
      "r585",
      "r587",
      "r627"
     ],
     "calculation": {
      "http://qualigeninc.com/role/BalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Accumulated deficit",
        "negatedLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/BalanceSheets",
      "http://qualigeninc.com/role/LiquidityAndGoingConcernDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r217",
      "r266",
      "r267",
      "r268",
      "r270",
      "r276",
      "r278",
      "r328",
      "r454",
      "r455",
      "r456",
      "r479",
      "r480",
      "r506",
      "r582",
      "r584"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r299",
      "r300",
      "r310",
      "r313",
      "r314",
      "r318",
      "r319",
      "r320",
      "r413",
      "r414",
      "r551"
     ],
     "calculation": {
      "http://qualigeninc.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Total revenues",
        "terseLabel": "Product sales",
        "verboseLabel": "Revenue from Contract with Customer, Excluding Assessed Tax"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesAndEstimatesDetailsNarrative",
      "http://qualigeninc.com/role/ResearchAndLicenseAgreementsDetailsNarrative",
      "http://qualigeninc.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax": {
     "auth_ref": [
      "r299",
      "r300",
      "r310",
      "r313",
      "r314",
      "r318",
      "r319",
      "r320",
      "r413",
      "r414",
      "r551"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.",
        "label": "Licensed product net sale"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerIncludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/ResearchAndLicenseAgreementsDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueRecognitionPolicyTextBlock": {
     "auth_ref": [
      "r604",
      "r605"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.",
        "label": "Revenue from Contracts with Customers"
       }
      }
     },
     "localname": "RevenueRecognitionPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesAndEstimatesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenuesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "REVENUES"
       }
      }
     },
     "localname": "RevenuesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RoyaltyExpense": {
     "auth_ref": [
      "r44"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property.",
        "label": "Minimum annual royalties"
       }
      }
     },
     "localname": "RoyaltyExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/ResearchAndLicenseAgreementsDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock": {
     "auth_ref": [
      "r31"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the various types of trade accounts and notes receivable and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables.",
        "label": "SCHEDULE OF ACCOUNTS RECEIVABLE"
       }
      }
     },
     "localname": "ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesAndEstimatesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.",
        "label": "SCHEDULE OF ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES"
       }
      }
     },
     "localname": "ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/AccruedExpensesAndOtherCurrentLiabilitiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r70"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/ScheduleOfDilutiveSecuritiesExcludedFromDilutedNetLossPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r70"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "SCHEDULE OF DILUTIVE SECURITIES EXCLUDED FROM DILUTED NET LOSS PER SHARE"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/EarningsLossPerShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": {
     "auth_ref": [
      "r152",
      "r153",
      "r496"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities.",
        "label": "Schedule of Business Acquisitions, by Acquisition [Table]"
       }
      }
     },
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/AcquisitionDetailsNarrative",
      "http://qualigeninc.com/role/ScheduleOfConsiderationTransferredDetails",
      "http://qualigeninc.com/role/ScheduleOfConsiderationTransferredDetailsParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock": {
     "auth_ref": [
      "r152",
      "r153"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of a material business combination completed during the period, including background, timing, and recognized assets and liabilities. This table does not include leveraged buyouts.",
        "label": "SCHEDULE OF CONSIDERATION TRANSFERRED"
       }
      }
     },
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/AcquisitionTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "auth_ref": [
      "r730"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]"
       }
      }
     },
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/PropertyAndEquipmentNetDetailsNarrative",
      "http://qualigeninc.com/role/ScheduleOfOperatingLeaseRightOfUseAssetsAndOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock": {
     "auth_ref": [
      "r140"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit.",
        "label": "SCHEDULE OF SHARE-BASED COMPENSATION EXPENSE"
       }
      }
     },
     "localname": "ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/StockholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": {
     "auth_ref": [
      "r148"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.",
        "label": "SCHEDULE OF PROVISION FOR INCOME TAXES"
       }
      }
     },
     "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable": {
     "auth_ref": [
      "r119",
      "r120"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule, table or text reflecting arrangements that are not equity-based payments, or pension and other postretirement benefits, with individual employees. The arrangements (for example, profit sharing, deferred bonuses or certain split-dollar life insurance arrangements) are generally based on employment contracts between the entity and one or more selected officers or key employees, and which contain a promise by the employer to pay certain amounts at designated future dates, sometimes including a period after retirement, upon compliance with stipulated requirements. This type of arrangement is distinguished from broader based employee benefit plans as it is usually tailored to the employee. Disclosure also typically includes the amount of related compensation expense recognized during the reporting period and the carrying amount as of the balance sheet date of the related liability.",
        "label": "Schedule of Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits, by Title of Individual and by Type of Deferred Compensation [Table]"
       }
      }
     },
     "localname": "ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/ScheduleOfStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "auth_ref": [
      "r144"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.",
        "label": "SCHEDULE OF DEFERRED TAX ASSETS AND LIABILITIES"
       }
      }
     },
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable": {
     "auth_ref": [
      "r121",
      "r122",
      "r123",
      "r124",
      "r125"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosures about an individual defined benefit pension plan or an other postretirement defined benefit plan. It may be appropriate to group certain similar plans. Also includes schedule for fair value of plan assets by major categories of plan assets by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets or liabilities (Level 1), Significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Schedule of Defined Benefit Plans Disclosures [Table]"
       }
      }
     },
     "localname": "ScheduleOfDefinedBenefitPlansDisclosuresTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/ScheduleOfFairValueHierarchyForWarrantLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "auth_ref": [
      "r675"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.",
        "label": "SCHEDULE OF EARNINGS PER SHARE BASIC AND DILUTED"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/EarningsLossPerShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "auth_ref": [
      "r142"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "SCHEDULE OF RECONCILIATIONS OF STATUTORY INCOME TAX RATE"
       }
      }
     },
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": {
     "auth_ref": [
      "r79",
      "r83",
      "r552"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Schedule of Finite-Lived Intangible Assets [Table]"
       }
      }
     },
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/GoodwillIprdAndOtherIntangiblesDetailsNarrative",
      "http://qualigeninc.com/role/ScheduleOfGoodwillAndOtherIntangibleDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock": {
     "auth_ref": [
      "r670"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of income before income tax between domestic and foreign jurisdictions.",
        "label": "SCHEDULE OF DOMESTIC AND FOREIGN COMPONENTS"
       }
      }
     },
     "localname": "ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock": {
     "auth_ref": [
      "r76"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of goodwill and intangible assets, which may be broken down by segment or major class.",
        "label": "SCHEDULE OF GOODWILL AND OTHER INTANGIBLE"
       }
      }
     },
     "localname": "ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/GoodwillIprdAndOtherIntangiblesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": {
     "auth_ref": [
      "r2",
      "r17",
      "r18",
      "r19"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.",
        "label": "SCHEDULE OF INVENTORY"
       }
      }
     },
     "localname": "ScheduleOfInventoryCurrentTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/InventoryNetTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r94"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/ScheduleOfPropertyAndEquipmentDetails",
      "http://qualigeninc.com/role/ScheduleOfUsefulLivesOfPropertyAndEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock": {
     "auth_ref": [
      "r156"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree.",
        "label": "SCHEDULE OF ASSETS ACQUIRED AND LIABILITIES"
       }
      }
     },
     "localname": "ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/AcquisitionTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": {
     "auth_ref": [
      "r183",
      "r184"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Schedule of Related Party Transactions, by Related Party [Table]"
       }
      }
     },
     "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRestructuringAndRelatedCostsTable": {
     "auth_ref": [
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Table presenting the description of the restructuring costs, such as the expected cost; the costs incurred during the period; the cumulative costs incurred as of the balance sheet date; the income statement caption within which the restructuring charges recognized for the period are included; and the amount of and periodic changes to an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost by type of restructuring.",
        "label": "Schedule of Restructuring and Related Costs [Table]"
       }
      }
     },
     "localname": "ScheduleOfRestructuringAndRelatedCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/LiquidityAndGoingConcernDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://qualigeninc.com/role/ScheduleOfReservedSharesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r129",
      "r136",
      "r137"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "SCHEDULE OF STOCK OPTION ACTIVITY"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/StockholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r139"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "SCHEDULE OF ASSUMPTION USED IN BLACK-SCHOLES OPTION-PRICING METHOD"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/StockholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShortTermDebtTable": {
     "auth_ref": [
      "r22"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to borrowings under which repayment was required in less than twelve months (or normal operating cycle, if longer) after its issuance. It may include: (1) description of the short-term debt arrangement; (2) identification of the lender or type of lender; (3) repayment terms; (4) weighted average interest rate; (5) carrying amount of funds borrowed under the specified short-term debt arrangement as of the balance sheet date and measures of the maximum and average amount outstanding during the period; (6) description of the refinancing of a short-term obligation when that obligation is excluded from current liabilities in the balance sheet; and (7) amount of a short-term obligation that has been excluded from current liabilities in the balance sheet because of a refinancing of the obligation.",
        "label": "Schedule of Short-Term Debt [Table]"
       }
      }
     },
     "localname": "ScheduleOfShortTermDebtTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/ConvertibleDebt-RelatedPartyDetailsNarrative",
      "http://qualigeninc.com/role/ScheduleOfSeniorSecuredConvertibleDebtDetails",
      "http://qualigeninc.com/role/ShortTermDebt-RelatedPartyDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "auth_ref": [
      "r104",
      "r105",
      "r106",
      "r108",
      "r109",
      "r110",
      "r112",
      "r113",
      "r114",
      "r115",
      "r230",
      "r231",
      "r232",
      "r293",
      "r394",
      "r395",
      "r396",
      "r398",
      "r402",
      "r408",
      "r410",
      "r616",
      "r650",
      "r667"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.",
        "label": "Schedule of Stock by Class [Table]"
       }
      }
     },
     "localname": "ScheduleOfStockByClassTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock": {
     "auth_ref": [
      "r117",
      "r126"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.",
        "label": "SCHEDULE OF WARRANTS ACTIVITY"
       }
      }
     },
     "localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/WarrantLiabilitiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SecuredDebt": {
     "auth_ref": [
      "r6",
      "r191",
      "r204"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date, including the current and noncurrent portions, of collateralized debt obligations (with maturities initially due after one year or beyond the operating cycle, if longer). Such obligations include mortgage loans, chattel loans, and any other borrowings secured by assets of the borrower.",
        "label": "Senior secured convertible debenture",
        "verboseLabel": "Principal amount"
       }
      }
     },
     "localname": "SecuredDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/ConvertibleDebt-RelatedPartyDetailsNarrative",
      "http://qualigeninc.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://qualigeninc.com/role/ScheduleOfSeniorSecuredConvertibleDebtDetails",
      "http://qualigeninc.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "auth_ref": [
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r319"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for segment reporting.",
        "label": "Segment Reporting"
       }
      }
     },
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesAndEstimatesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SeriesBPreferredStockMember": {
     "auth_ref": [
      "r654",
      "r655",
      "r692"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series B preferred stock.",
        "label": "Series B Preferred Stock [Member]"
       }
      }
     },
     "localname": "SeriesBPreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/AcquisitionDetailsNarrative",
      "http://qualigeninc.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesAndEstimatesDetailsNarrative",
      "http://qualigeninc.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r59"
     ],
     "calculation": {
      "http://qualigeninc.com/role/StatementsOfCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Compensation cost",
        "verboseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/StatementsOfCashFlows",
      "http://qualigeninc.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription": {
     "auth_ref": [
      "r126",
      "r127"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of terms of share-based payment arrangement. Includes, but is not limited to, type of award or grantee and reason for issuance.",
        "label": "Stock options description"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r449"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Expected dividend yield"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/ScheduleOfAssumptionUsedInBlack-scholesOption-pricingMethodDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r448"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Expected stock-price volatility"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/ScheduleOfAssumptionUsedInBlack-scholesOption-pricingMethodDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Risk-free interest rate, maximum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/ScheduleOfAssumptionUsedInBlack-scholesOption-pricingMethodDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Risk-free interest rate, minimum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/ScheduleOfAssumptionUsedInBlack-scholesOption-pricingMethodDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://qualigeninc.com/role/ScheduleOfReservedSharesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised": {
     "auth_ref": [
      "r133"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of non-option equity instruments exercised by participants.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Exercised",
        "negatedLabel": "Number of Shares, Warrants Exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/ScheduleOfWarrantActivityDetails",
      "http://qualigeninc.com/role/ScheduleOfWarrantsActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations": {
     "auth_ref": [
      "r135"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares under non-option equity instrument agreements for which rights to exercise lapsed.",
        "label": "Number of Shares, Warrants Expired",
        "negatedLabel": "Number of Shares, Warrants Expired"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/ScheduleOfWarrantActivityDetails",
      "http://qualigeninc.com/role/ScheduleOfWarrantsActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures": {
     "auth_ref": [
      "r134"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares under non-option equity instrument agreements that were cancelled as a result of occurrence of a terminating event.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Forfeitures",
        "negatedLabel": "Number of Shares, Warrants Forfeited"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/ScheduleOfWarrantActivityDetails",
      "http://qualigeninc.com/role/ScheduleOfWarrantsActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted": {
     "auth_ref": [
      "r132"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net number of non-option equity instruments granted to participants.",
        "label": "Number of Shares, Warrants Granted",
        "verboseLabel": "Number of shares, warrants granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/ScheduleOfWarrantActivityDetails",
      "http://qualigeninc.com/role/ScheduleOfWarrantsActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber": {
     "auth_ref": [
      "r130",
      "r131"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of equity instruments other than options outstanding, including both vested and non-vested instruments.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding, Number",
        "periodEndLabel": "Number of Shares, Warrants Outstanding Ending",
        "periodStartLabel": "Number of Shares, Warrants Outstanding Beginning"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/ScheduleOfWarrantActivityDetails",
      "http://qualigeninc.com/role/ScheduleOfWarrantsActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": {
     "auth_ref": [
      "r436"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period",
        "negatedLabel": "Number of shares, options expired"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/ScheduleOfStockOptionActivityDetails",
      "http://qualigeninc.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r701"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price of options that were either forfeited or expired.",
        "label": "Range of Exercise price, Options Forfeited"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/ScheduleOfStockOptionActivityDetails",
      "http://qualigeninc.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "auth_ref": [
      "r435"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period",
        "negatedLabel": "Number of shares, options forfeited"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/ScheduleOfStockOptionActivityDetails",
      "http://qualigeninc.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod": {
     "auth_ref": [
      "r702"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net number of share options (or share units) granted during the period.",
        "label": "Number of shares, options granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/ScheduleOfStockOptionActivityDetails",
      "http://qualigeninc.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r429",
      "r430"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Options outstanding",
        "periodEndLabel": "Number of Shares, Options Outstanding at Ending",
        "periodStartLabel": "Number of shares, options outstanding, beginning"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/ScheduleOfStockOptionActivityDetails",
      "http://qualigeninc.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r429",
      "r430"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Range of Exercise price, Options Outstanding",
        "periodStartLabel": "Range of Exercise price, Options Outstanding"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/ScheduleOfStockOptionActivityDetails",
      "http://qualigeninc.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber": {
     "auth_ref": [
      "r446"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Number of shares, options exercisable (vested)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/ScheduleOfStockOptionActivityDetails",
      "http://qualigeninc.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r446"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Range of exercise price, options exercisable (vested)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/ScheduleOfStockOptionActivityDetails",
      "http://qualigeninc.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://qualigeninc.com/role/ResearchAndLicenseAgreementsDetailsNarrative",
      "http://qualigeninc.com/role/ScheduleOfReservedSharesDetails",
      "http://qualigeninc.com/role/ScheduleOfWarrantActivityDetails",
      "http://qualigeninc.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r436"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.",
        "label": "Weighted average exercise price, options expired"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/ScheduleOfStockOptionActivityDetails",
      "http://qualigeninc.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r435"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.",
        "label": "Weighted average exercise price, options forfeited"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/ScheduleOfStockOptionActivityDetails",
      "http://qualigeninc.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r433"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Weighted average exercise price, options granted",
        "verboseLabel": "Stock option granted exercise price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/ScheduleOfStockOptionActivityDetails",
      "http://qualigeninc.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Price of a single share of a number of saleable stocks of a company.",
        "label": "Share price",
        "verboseLabel": "Share Price"
       }
      }
     },
     "localname": "SharePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/ScheduleOfAssumptionUsedInBlack-scholesOption-pricingMethodDetails",
      "http://qualigeninc.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r447"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Expected average term of options (in years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/ScheduleOfAssumptionUsedInBlack-scholesOption-pricingMethodDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of non-vested options outstanding.",
        "label": "Number of shares, options non-exercisable (non-vested)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/ScheduleOfStockOptionActivityDetails",
      "http://qualigeninc.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average grant-date fair value of non-vested options outstanding.",
        "label": "Range of exercise price, options non-exercisable (non-vested)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/ScheduleOfStockOptionActivityDetails",
      "http://qualigeninc.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r138"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Weighted- Average Remaining Contractual Life (in Years), Outstanding at Ending",
        "verboseLabel": "Cost is expected to be recognized over a weighted average period"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/ScheduleOfStockOptionActivityDetails",
      "http://qualigeninc.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r446"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Weighted- Average Remaining Contractual Life (in Years), Options Exercisable (vested)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/ScheduleOfStockOptionActivityDetails",
      "http://qualigeninc.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.",
        "label": "Shares, Outstanding",
        "periodEndLabel": "Balance, shares",
        "periodStartLabel": "Balance, shares"
       }
      }
     },
     "localname": "SharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShippingAndHandlingMember": {
     "auth_ref": [
      "r694"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Packing and transport of product.",
        "label": "Shipping and Handling [Member]"
       }
      }
     },
     "localname": "ShippingAndHandlingMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesAndEstimatesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShortTermBorrowings": {
     "auth_ref": [
      "r3",
      "r188",
      "r203",
      "r627"
     ],
     "calculation": {
      "http://qualigeninc.com/role/BalanceSheets": {
       "order": 7.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reflects the total carrying amount as of the balance sheet date of debt having initial terms less than one year or the normal operating cycle, if longer.",
        "label": "Short term debt - related party",
        "verboseLabel": "Short term debt outstanding balance"
       }
      }
     },
     "localname": "ShortTermBorrowings",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/BalanceSheets",
      "http://qualigeninc.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://qualigeninc.com/role/ShortTermDebt-RelatedPartyDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShortTermDebtInterestRateIncrease": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage increase in the stated interest rate on a short-term debt instrument.",
        "label": "Senior convertible debenture rate"
       }
      }
     },
     "localname": "ShortTermDebtInterestRateIncrease",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/ConvertibleDebt-RelatedPartyDetailsNarrative",
      "http://qualigeninc.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://qualigeninc.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShortTermDebtLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Short-Term Debt [Line Items]"
       }
      }
     },
     "localname": "ShortTermDebtLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/ConvertibleDebt-RelatedPartyDetailsNarrative",
      "http://qualigeninc.com/role/ScheduleOfSeniorSecuredConvertibleDebtDetails",
      "http://qualigeninc.com/role/ShortTermDebt-RelatedPartyDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShortTermDebtTextBlock": {
     "auth_ref": [
      "r102"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for short-term debt.",
        "label": "SHORT TERM DEBT - RELATED PARTY"
       }
      }
     },
     "localname": "ShortTermDebtTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/ShortTermDebt-RelatedParty"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ShortTermDebtTypeAxis": {
     "auth_ref": [
      "r22"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of short-term debt arrangement.",
        "label": "Short-Term Debt, Type [Axis]"
       }
      }
     },
     "localname": "ShortTermDebtTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://qualigeninc.com/role/ShortTermDebt-RelatedPartyDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShortTermDebtTypeDomain": {
     "auth_ref": [
      "r20"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of short-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing."
       }
      }
     },
     "localname": "ShortTermDebtTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://qualigeninc.com/role/ShortTermDebt-RelatedPartyDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StateAndLocalJurisdictionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of a state or local government entitled to levy and collect income taxes from the entity.",
        "label": "State and Local Jurisdiction [Member]"
       }
      }
     },
     "localname": "StateAndLocalJurisdictionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/IncomeTaxesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [
      "r230",
      "r231",
      "r232",
      "r261",
      "r280",
      "r281",
      "r283",
      "r285",
      "r293",
      "r294",
      "r327",
      "r359",
      "r361",
      "r362",
      "r363",
      "r366",
      "r367",
      "r394",
      "r395",
      "r398",
      "r402",
      "r410",
      "r512",
      "r596",
      "r650",
      "r667",
      "r674"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by the different classes of stock of the entity.",
        "label": "Class of Stock [Axis]"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/AcquisitionDetailsNarrative",
      "http://qualigeninc.com/role/ConvertibleDebt-RelatedPartyDetailsNarrative",
      "http://qualigeninc.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesAndEstimatesDetailsNarrative",
      "http://qualigeninc.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://qualigeninc.com/role/ScheduleOfWarrantsActivityDetails",
      "http://qualigeninc.com/role/StatementsOfChangesInStockholdersEquity",
      "http://qualigeninc.com/role/StockholdersEquityDetailsNarrative",
      "http://qualigeninc.com/role/WarrantLiabilitiesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r30",
      "r107",
      "r217",
      "r245",
      "r246",
      "r247",
      "r266",
      "r267",
      "r268",
      "r270",
      "r276",
      "r278",
      "r292",
      "r328",
      "r412",
      "r454",
      "r455",
      "r456",
      "r479",
      "r480",
      "r506",
      "r513",
      "r514",
      "r515",
      "r516",
      "r517",
      "r518",
      "r531",
      "r582",
      "r583",
      "r584"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/AcquisitionDetailsNarrative",
      "http://qualigeninc.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesAndEstimatesDetailsNarrative",
      "http://qualigeninc.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://qualigeninc.com/role/ScheduleOfWarrantActivityDetails",
      "http://qualigeninc.com/role/ScheduleOfWarrantsActivityDetails",
      "http://qualigeninc.com/role/StatementsOfChangesInStockholdersEquity",
      "http://qualigeninc.com/role/StockholdersEquityDetailsNarrative",
      "http://qualigeninc.com/role/StockholdersEquityTables",
      "http://qualigeninc.com/role/WarrantLiabilitiesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesAndEstimatesDetailsNarrative",
      "http://qualigeninc.com/role/ResearchAndLicenseAgreementsDetailsNarrative",
      "http://qualigeninc.com/role/ScheduleOfAssumptionUsedInBlack-scholesOption-pricingMethodDetails",
      "http://qualigeninc.com/role/ScheduleOfAssumptionsOfWarrantLiabilitiesDetails",
      "http://qualigeninc.com/role/ScheduleOfShare-basedCompensationExpenseDetails",
      "http://qualigeninc.com/role/ScheduleOfWarrantsActivityDetails",
      "http://qualigeninc.com/role/StatementsOfChangesInStockholdersEquity",
      "http://qualigeninc.com/role/StatementsOfOperationsAndComprehensiveLoss",
      "http://qualigeninc.com/role/WarrantLiabilitiesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r266",
      "r267",
      "r268",
      "r292",
      "r551"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesAndEstimatesDetailsNarrative",
      "http://qualigeninc.com/role/ResearchAndLicenseAgreementsDetailsNarrative",
      "http://qualigeninc.com/role/ScheduleOfAssumptionUsedInBlack-scholesOption-pricingMethodDetails",
      "http://qualigeninc.com/role/ScheduleOfAssumptionsOfWarrantLiabilitiesDetails",
      "http://qualigeninc.com/role/ScheduleOfShare-basedCompensationExpenseDetails",
      "http://qualigeninc.com/role/ScheduleOfWarrantsActivityDetails",
      "http://qualigeninc.com/role/StatementsOfChangesInStockholdersEquity",
      "http://qualigeninc.com/role/StatementsOfOperationsAndComprehensiveLoss",
      "http://qualigeninc.com/role/WarrantLiabilitiesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssued1": {
     "auth_ref": [
      "r65",
      "r66",
      "r67"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The fair value of stock issued in noncash financing activities.",
        "label": "Fair value of Qualigen common stock issued in exchange for NanoSynex stock"
       }
      }
     },
     "localname": "StockIssued1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesAcquisitions": {
     "auth_ref": [
      "r10",
      "r11",
      "r115"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of stock issued during the period pursuant to acquisitions.",
        "label": "Stock issued during period shares acquisitions",
        "verboseLabel": "Common stock issued for business acquisition"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesAcquisitions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/AcquisitionDetailsNarrative",
      "http://qualigeninc.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesAndEstimatesDetailsNarrative",
      "http://qualigeninc.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://qualigeninc.com/role/ScheduleOfConsiderationTransferredDetailsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesIssuedForServices": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.",
        "label": "Stock issued for professional services, shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesIssuedForServices",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r10",
      "r11",
      "r107",
      "r115"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period, Shares, New Issues",
        "verboseLabel": "Shares issued, shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/StockholdersEquityDetailsNarrative",
      "http://qualigeninc.com/role/WarrantLiabilitiesDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesOther": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of stock issued attributable to transactions classified as other.",
        "label": "Shares issued during conversion, shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesOther",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits": {
     "auth_ref": [
      "r107"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reduction in the number of shares during the period as a result of a reverse stock split.",
        "label": "Stock Issued During Period, Shares, Reverse Stock Splits",
        "verboseLabel": "Balance, shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesReverseStockSplits",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r10",
      "r11",
      "r107",
      "r115",
      "r434"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Stock options exercised"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueAcquisitions": {
     "auth_ref": [
      "r30",
      "r107",
      "r115"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued pursuant to acquisitions during the period.",
        "label": "Stock issued during period, value, acquisitions",
        "terseLabel": "FMV of 3,500,000 shares of Qualigen stock issued to Alpha Capital Anstalt",
        "verboseLabel": "Stock issued during period value acquisitions"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueAcquisitions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/AcquisitionDetailsNarrative",
      "http://qualigeninc.com/role/LiquidityAndGoingConcernDetailsNarrative",
      "http://qualigeninc.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesAndEstimatesDetailsNarrative",
      "http://qualigeninc.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://qualigeninc.com/role/ScheduleOfConsiderationTransferredDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueIssuedForServices": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.",
        "label": "Stock issued for professional services"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueIssuedForServices",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r10",
      "r11",
      "r107",
      "r115"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Stock issued during period value new issues"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/LiquidityAndGoingConcernDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contracts conveying rights, but not obligations, to buy or sell a specific quantity of stock at a specified price during a specified period (an American option) or at a specified date (a European option).",
        "label": "Equity Option [Member]"
       }
      }
     },
     "localname": "StockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/ScheduleOfReservedSharesDetails",
      "http://qualigeninc.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r11",
      "r14",
      "r15",
      "r75",
      "r627",
      "r669",
      "r677",
      "r735"
     ],
     "calculation": {
      "http://qualigeninc.com/role/BalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "totalLabel": "Total Qualigen Therapeutics, Inc. stockholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Qualigen Therapeutics, Inc. stockholders\u2019 equity:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/BalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r162",
      "r163",
      "r172",
      "r217",
      "r218",
      "r246",
      "r266",
      "r267",
      "r268",
      "r270",
      "r276",
      "r328",
      "r412",
      "r454",
      "r455",
      "r456",
      "r479",
      "r480",
      "r506",
      "r513",
      "r514",
      "r518",
      "r531",
      "r583",
      "r584",
      "r669",
      "r677",
      "r735"
     ],
     "calculation": {
      "http://qualigeninc.com/role/BalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.",
        "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest",
        "periodEndLabel": "Balance, value",
        "periodStartLabel": "Balance. value",
        "totalLabel": "Total Stockholders\u2019 Equity"
       }
      }
     },
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/BalanceSheets",
      "http://qualigeninc.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/BalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r118",
      "r260",
      "r395",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r406",
      "r407",
      "r409",
      "r412",
      "r505"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "STOCKHOLDERS\u2019 EQUITY"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/StockholdersEquity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StockholdersEquityNoteStockSplit": {
     "auth_ref": [
      "r116"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of the stock split arrangement. Also provide the retroactive effect given by a stock split that occurs after the balance date but before the release of financial statements.",
        "label": "Stockholders equity note stock split"
       }
      }
     },
     "localname": "StockholdersEquityNoteStockSplit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/LiquidityAndGoingConcernDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityReverseStockSplit": {
     "auth_ref": [
      "r116"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements.",
        "label": "Reverse Stock Split",
        "verboseLabel": "Reverse split, description"
       }
      }
     },
     "localname": "StockholdersEquityReverseStockSplit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/AcquisitionDetailsNarrative",
      "http://qualigeninc.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesAndEstimatesDetailsNarrative",
      "http://qualigeninc.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesAndEstimatesPolicies",
      "http://qualigeninc.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.",
        "label": "Subsequent Event [Line Items]"
       }
      }
     },
     "localname": "SubsequentEventLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [
      "r519",
      "r539"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event [Member]"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://qualigeninc.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTable": {
     "auth_ref": [
      "r519",
      "r539"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.",
        "label": "Subsequent Event [Table]"
       }
      }
     },
     "localname": "SubsequentEventTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r519",
      "r539"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://qualigeninc.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r519",
      "r539"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://qualigeninc.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "localname": "SubsequentEventsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "auth_ref": [
      "r538",
      "r540"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.",
        "label": "SUBSEQUENT EVENTS"
       }
      }
     },
     "localname": "SubsequentEventsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/SubsequentEvents"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubstantialDoubtAboutGoingConcernTextBlock": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure when substantial doubt is raised about the ability to continue as a going concern. Includes, but is not limited to, principal conditions or events that raised substantial doubt about the ability to continue as a going concern, management's evaluation of the significance of those conditions or events in relation to the ability to meet its obligations, and management's plans that alleviated or are intended to mitigate the conditions or events that raise substantial doubt about the ability to continue as a going concern.",
        "label": "LIQUIDITY AND GOING CONCERN"
       }
      }
     },
     "localname": "SubstantialDoubtAboutGoingConcernTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/LiquidityAndGoingConcern"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxCreditCarryforwardLimitationsOnUse": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of the limitation related to use of the tax credit carryforward.",
        "label": "Tax credit carryforward, limitations on use"
       }
      }
     },
     "localname": "TaxCreditCarryforwardLimitationsOnUse",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/IncomeTaxesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TradeAndOtherAccountsReceivablePolicy": {
     "auth_ref": [
      "r214",
      "r215",
      "r216",
      "r323",
      "r324",
      "r326"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for accounts receivable.",
        "label": "Accounts Receivable, Net"
       }
      }
     },
     "localname": "TradeAndOtherAccountsReceivablePolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesAndEstimatesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r730"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/PropertyAndEquipmentNetDetailsNarrative",
      "http://qualigeninc.com/role/ResearchAndLicenseAgreementsDetailsNarrative",
      "http://qualigeninc.com/role/ScheduleOfOperatingLeaseRightOfUseAssetsAndOperatingLeaseLiabilitiesDetails",
      "http://qualigeninc.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "auth_ref": [
      "r459",
      "r467"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrecognized tax benefits.",
        "label": "Unrecognized tax benefits"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefits",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/IncomeTaxesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r71",
      "r72",
      "r73",
      "r295",
      "r296",
      "r297",
      "r298"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Accounting Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesAndEstimatesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": {
     "auth_ref": [
      "r473"
     ],
     "calculation": {
      "http://qualigeninc.com/role/ScheduleOfProvisionForIncomeTaxesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.",
        "label": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount",
        "negatedLabel": "Change in valuation allowance"
       }
      }
     },
     "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/ScheduleOfProvisionForIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_WarrantMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.",
        "label": "Warrant [Member]"
       }
      }
     },
     "localname": "WarrantMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesAndEstimatesDetailsNarrative",
      "http://qualigeninc.com/role/ScheduleOfReservedSharesDetails",
      "http://qualigeninc.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WarrantsAndRightsOutstandingMeasurementInput": {
     "auth_ref": [
      "r511"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur.",
        "label": "Fair value assumptions, measurement input, percentages"
       }
      }
     },
     "localname": "WarrantsAndRightsOutstandingMeasurementInput",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/ScheduleOfAssumptionsOfWarrantLiabilitiesDetails"
     ],
     "xbrltype": "decimalItemType"
    },
    "us-gaap_WarrantsAndRightsOutstandingTerm": {
     "auth_ref": [
      "r734"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Fair value assumptions, measurement input, term",
        "verboseLabel": "Warrants and Rights Outstanding, Term"
       }
      }
     },
     "localname": "WarrantsAndRightsOutstandingTerm",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/ScheduleOfAssumptionsOfWarrantLiabilitiesDetails",
      "http://qualigeninc.com/role/WarrantLiabilitiesDetailsNarrative"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment": {
     "auth_ref": [
      "r675"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation.",
        "label": "Diluted weighted-average common shares outstanding"
       }
      }
     },
     "localname": "WeightedAverageNumberDilutedSharesOutstandingAdjustment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/ScheduleOfEarningsPerShareBasicAndDilutedDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r279",
      "r285"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted\u2014average number of shares outstanding, basic and diluted",
        "verboseLabel": "Basic weighted-average common shares outstanding"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://qualigeninc.com/role/ScheduleOfEarningsPerShareBasicAndDilutedDetails",
      "http://qualigeninc.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 5
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "40",
   "Topic": "205",
   "URI": "https://asc.fasb.org/subtopic&trid=51888271",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "https://asc.fasb.org/topic&trid=2122149",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(5)",
   "Topic": "460",
   "URI": "https://asc.fasb.org/extlink&oid=126907703&loc=d3e12565-110249",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031898-161870",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "https://asc.fasb.org/topic&trid=2208564",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Topic": "480",
   "URI": "https://asc.fasb.org/extlink&oid=109262497&loc=d3e20148-110875",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(CFRR 211.02)",
   "Topic": "480",
   "URI": "https://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21553-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21484-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21488-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21506-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21506-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21521-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21538-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.C)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187143-122770",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "50",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "https://asc.fasb.org/topic&trid=2208762",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Topic": "710",
   "URI": "https://asc.fasb.org/extlink&oid=6409733&loc=d3e19524-108361",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "10",
   "Topic": "710",
   "URI": "https://asc.fasb.org/extlink&oid=6409875&loc=d3e20015-108363",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2410-114920",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2417-114920",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2439-114920",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5047-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b),(f(1))",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(4)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32632-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Subparagraph": "(a)-(d)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=6909625&loc=d3e227-128457",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "37",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=123455525&loc=d3e2207-128464",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4845-128472",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4845-128472",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "38",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=123410050&loc=d3e5504-128473",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126966197&loc=d3e6578-128477",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126966197&loc=d3e6613-128477",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e6927-128479",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "805",
   "URI": "https://asc.fasb.org/topic&trid=2303972",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4568447-111683",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4568740-111683",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569643-111683",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4613674-111683",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569655-111683",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4616395-111683",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4I",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4590271-111686",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "https://asc.fasb.org/topic&trid=2197479",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126966630&loc=d3e41228-113958",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "60",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13279-108611",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "https://asc.fasb.org/extlink&oid=126941158&loc=d3e41242-110953",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(15)(1))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(c))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(15)(2))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(22))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.15(5))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.10)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(15)(b)(2))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(15)(b)(1))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(16)(a)(1))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(16))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(24))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(b),22(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=SL6953423-111524",
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5212-111524",
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5093-111524",
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(15))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(16))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(18))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(21))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(22))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(23))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(5))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3367-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3000-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4297-108586",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(c))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1278-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "https://asc.fasb.org/topic&trid=2144383",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "270",
   "URI": "https://asc.fasb.org/extlink&oid=126900757&loc=d3e543-108305",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19)(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.3,4)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.31)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e4975-111524",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5033-111524",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5074-111524",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=84159169&loc=d3e10133-111534",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255206&loc=SL82895884-210446",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "https://asc.fasb.org/extlink&oid=116847112&loc=d3e4492-108314",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "https://asc.fasb.org/extlink&oid=116847112&loc=d3e4542-108314",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "https://asc.fasb.org/extlink&oid=116847112&loc=d3e4556-108314",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "330",
   "URI": "https://asc.fasb.org/topic&trid=2126998",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=99380562&loc=d3e13777-109266",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(b)(1))",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(b)(2))",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(d))",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e640-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e681-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(i)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669686-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e557-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130543-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(4))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=SL116886442-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4549-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2(a),(d))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.3)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "35",
   "Subparagraph": "(a)",
   "Topic": "720",
   "URI": "https://asc.fasb.org/extlink&oid=6420018&loc=d3e36677-107848",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "35",
   "Subparagraph": "(b)",
   "Topic": "720",
   "URI": "https://asc.fasb.org/extlink&oid=6420018&loc=d3e36677-107848",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=SL37586934-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e31917-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e31931-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.8)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123586238&loc=d3e39076-109324",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "https://asc.fasb.org/topic&trid=2144680",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(3)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4946-128472",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4946-128472",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=SL126733271-114008",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r508": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r509": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r513": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r514": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r515": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r516": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r517": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r518": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r519": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r520": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "830",
   "URI": "https://asc.fasb.org/topic&trid=2175825",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r521": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r522": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r523": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r524": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r525": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918666-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r526": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r527": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r528": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r529": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r530": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r531": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r532": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r533": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r534": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r535": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r536": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r537": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "850",
   "URI": "https://asc.fasb.org/topic&trid=2122745",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r538": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r539": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r540": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "855",
   "URI": "https://asc.fasb.org/topic&trid=2122774",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r541": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r542": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r543": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r544": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r545": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r546": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=126938201&loc=d3e55415-109406",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r547": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "330",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=6471895&loc=d3e55923-109411",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r548": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "350",
   "Subparagraph": "(a)",
   "Topic": "920",
   "URI": "https://asc.fasb.org/extlink&oid=120155617&loc=SL120155628-234783",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r549": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "350",
   "Subparagraph": "(b)",
   "Topic": "920",
   "URI": "https://asc.fasb.org/extlink&oid=120155617&loc=SL120155628-234783",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r550": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "350",
   "Subparagraph": "(a)",
   "Topic": "920",
   "URI": "https://asc.fasb.org/extlink&oid=120155617&loc=SL120155638-234783",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r551": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r552": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r553": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "340",
   "Topic": "928",
   "URI": "https://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r554": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r555": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r556": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r557": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r558": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r559": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r560": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r561": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r562": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r563": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r564": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(1)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r565": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(2)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r566": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r567": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r568": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(24))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r569": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(25))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r570": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r571": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r572": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r573": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r574": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r575": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(19))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r576": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(20))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r577": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(21))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r578": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r579": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r580": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r581": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r582": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r583": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r584": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r585": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r586": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r587": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r588": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=118262064&loc=SL116631418-115840",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r589": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=118262064&loc=SL116631419-115840",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r590": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r591": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Subparagraph": "(d)",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99779-112916",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r592": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99893-112916",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r593": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=SL120174063-112916",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r594": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r595": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r596": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r597": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r598": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r599": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)(1)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r600": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6935-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r601": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r602": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r603": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r604": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r605": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r606": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r607": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r608": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r609": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "340",
   "URI": "https://asc.fasb.org/extlink&oid=126905020&loc=d3e5879-108316",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r610": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=122137925&loc=d3e14258-109268",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r611": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r612": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r613": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r614": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r615": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r616": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r617": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r618": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r619": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r620": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r621": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r622": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r623": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r624": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r625": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r626": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r627": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r628": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r629": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4273-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r630": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r631": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r632": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r633": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-23",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r634": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r635": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "g",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r636": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12, 13, 15d",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r637": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r638": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r639": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "15",
   "Subsection": "d",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4297-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r640": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r641": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r642": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r643": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r644": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r645": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r646": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r647": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r648": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r649": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4304-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r650": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054",
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef"
  },
  "r651": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r652": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r653": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(26)(c))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r654": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r655": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r656": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r657": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r658": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r659": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4313-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r660": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r661": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r662": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r663": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r664": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r665": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r666": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r667": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r668": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(f))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r669": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4332-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r670": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r671": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r672": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r673": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r674": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "55",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e2626-109256",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r675": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r676": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4647-111522",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r677": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r678": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "340",
   "URI": "https://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r679": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r680": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r681": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r682": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r683": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "410",
   "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r684": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r685": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r686": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "https://asc.fasb.org/topic&trid=2127136",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r687": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=28183603&loc=d3e692-112598",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r688": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r689": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "https://asc.fasb.org/topic&trid=2122369",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r690": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r691": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r692": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r693": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r694": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r695": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r696": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r697": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r698": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r699": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(26)(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r700": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r701": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r702": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r703": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r704": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r705": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r706": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r707": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r708": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r709": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r710": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r711": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r712": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r713": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r714": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r715": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r716": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r717": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r718": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r719": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r720": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r721": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r722": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r723": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32621-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r724": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r725": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r726": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r727": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r728": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r729": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(3)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r730": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r731": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r732": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r733": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r734": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r735": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r736": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r737": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918638-209977",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r738": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r739": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "https://asc.fasb.org/topic&trid=2134479",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r740": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r741": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r742": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r743": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r744": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r745": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r746": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r747": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r748": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r749": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r750": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r751": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r752": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(26)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "((a)(1),(b))",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(2)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(3)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "350",
   "URI": "https://asc.fasb.org/topic&trid=2144416",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226317&loc=d3e202-110218",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=126905981&loc=d3e2420-110228",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.CC)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=27011434&loc=d3e125687-122742",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "360",
   "URI": "https://asc.fasb.org/topic&trid=2155823",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "https://asc.fasb.org/topic&trid=2144648",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "((c)(3,4))",
   "Topic": "460",
   "URI": "https://asc.fasb.org/extlink&oid=126907703&loc=d3e12565-110249",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "460",
   "URI": "https://asc.fasb.org/extlink&oid=126907703&loc=d3e12565-110249",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  }
 },
 "version": "2.2"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>120
<FILENAME>0001493152-23-015184-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001493152-23-015184-xbrl.zip
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M:!473>=!RCKU?WS_+D+:9N'V&]@LZI]02P,$%     @ /(.B5C[< P.JQ
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ML<8(!X)6)ZR=J:L8TUB-+%-:EY*\U)PQ)+IJ"K94N)7=TKJP#C_CLI.,>C7
MBM5K$PK+1L>?&;HA_& (JY63*YO G'!%P?<.!S0!-3(CQQNW1J$#HZ:JIA;H
M1L-4) 6KED)\@6]_#YJ="+Q8]V*] V*]^]"[[Q/KF.,U8KK7, SI.Q)7;>%-
M02U"OX$\+4R,C"]PM4&;=\.F.&-0*M;TJP?U>( HZ^>;Z^+)2Z&1A.D#5M76
M=;\4Y[44<K"F%#&>I2/%]AI4C4O].>774$I#>8XH4 J0HFL1(^7R &/&NFES
M8'DE[3R1E -P7TK<@&;[S#XIR.*2<*33S 1N<=JH'E2P"E1AD,%F'XN0FH P
MUSO]U/+VF;?!T"PG31]!15VW7P&Y.QH$D:>FP!LW(:Q9Z]M&K3E^#?L)A LG
M$[ ^O>:+I+V'0L_XOR KY16!C6$L]Q%ZFA4^^]X8\<;(^I3B2;BSZL>.M@#*
M6$NG5^6P_HC3/LCADSA6Q"R-%_U+A"%"7RCE=SX>EXGZM^!<S$.X#OY<^G.Y
M)@5ZCJA0/( P(G30T3@SB6J"@HJ-;-CH#]H:0+@Z?\PB.0#UY$A*6S7&;EN;
MF)O!#S^G>1P%+T7R!:]\DTZ>G).S3#KP#4;[G@1O513%TGY1&;N.$"XD1,=8
M*;V%8D[<L9AB28KMZ,W:&4>'QO/"47I5["7$@TF([HL($<>.(7:FNVJ[J.98
MCLN"079U<P XCQ71?XO->N[H>@+J#@0P%'6K+;:WS@;@X+2X\^17/+?)D(6R
M--\3Z=@XB]-I]54N=5KFH:0VWK$4NN!^0(DN,55G09-5GJIYJ_JWN*^VMUK%
MC WB+YO<X>KL2%ZE?&-1!<K@QEK!1(BJJB!+"UO$6& TV7RK*?UFFI_97\=J
M('M(!)@$90&3\F^*Z<#83&?TQJ@T40$BUKE7=?3 2ZJVNQG"&3"NB)_^54;#
M.>YV0PMH&Q49Z#-&"&'%X#C!ZB6&#8;R?;!HR#D*-G&8)NE8A3">HLR3NCT&
M,;,9T&:AY_LQ>03FPQPOBX,U8&%B2L-N*I3*A6.&AVBHKB1F;8/3F#*E1WM'
M?KF^"S#[L\?&KA0;>^BQL5T_+?<OW&CFF_2IC:: O69>K&<4,O,I18$6,>G?
M40D7S>2]/#/N0[\"K6R.=,JGE1$17."2-6F5P9['BW@MR0YK&FN$BIK+@I*%
MP\HNE\,RQ@;:4WB%7.F(>^ $8D L>''<N *,0K*#JBV486]'Y.FJ*3'2/K;3
MP0 !A?(79'OQZ?1%\WE[P0F_ 9?O8*BQCQ4P<LS.##T@#9GM=GM++7XMS<TF
M,3[1) <2R*N+Z6/##IWF##_2V)42[6+0]7ZW=V:WGR>1J5Y<N-$;7R,? ::$
M<MIMC!18L"]&1)P FY,W+!=GB>!CO?5/RF*4YLK3&C_X*\ V^%-I6!05HJ5.
MB0?$E^A;&>Q/]P[]"C[\"C:HR-DL^=:Z_;KWS*];)];-B-86&7^@L::5L-X1
M$6V&W&MZ(N/X28A]3>&X_AM;*\1"Z]J@A(NET,BM.TVB'!,22#1A6Z^F\#!6
M_:]1(<<"Y2\^83"0! BF\)"NL%Q:,+45WI)5N+D!>%4-DZ'Z>?TR\-)7(J<P
M&0Q+#23<N:@;4M_FUMM;U]^[_C@F2 +>%%RLPO:-_>[!VPAN=5>8D]RVO&A@
MN*]_"+;0K>X-9S,=YB(#=1D,\[3,=+ C]X9[\*"HC'EI,U@E@0T1=[\]0']R
MNW!R=1K#=@C!2#_#;4'J<G%'GL"73VYF+JZSL)@U*)\4;KDXD(>85T!R-"[H
M@>,%XA9.GH1C9H@C*L@P.*,9PDO)&R>_$[UG2KG$I3V=$X4]CAS+;LJ,@/?D
M3[=NB+XP(O,CDS8DE'WKBH&IR&'!42"M!)+7YF7(!H#+,(AT.\V'H%TYR_%X
MP/I> JV%!.H^,L]1 BT\Z_TI'6FNC$@9V:ZE_ (G'\4+BITR"ZC:(0,15<F!
MYM>N)Q\SJ11YDQJS'%$@AD*!((&1-&134E\Y%I'T\L'+AT[)A^Y7]SG+!V*)
MRM&K&RO0RP4RQ%W)QA?V;P;>@(6_.1-#YFK<N(XX)<$?A#%J216].89-74&%
M]3"P5#"O8" I-G5DT2"R+%6)H9IME(W5;3ZIS)#&3'T_"F%::+F,!%,C%G;2
MJ%X4UJK#KRP[)OE-/"H48NV7@!$/5-P:[1)5T_;5>!!) %Y<.>[G'-B62/R%
MJ!PRU;A6W%XYI7!,S@2@12'"$6?\ZD5:QI"37^$I'%:PK&=VI0QI(%)]4!4>
M%7 WYY'[=&H*%R 3W @D$4P/\GJX%J<^VP\B,?7=#[RBZ):B6(/V!X[2,$_!
M.16Q,02OP*I,"I%/ Y&##&(N"&NVS4:4E*%M( $6G-M 9#,:Y3*4$Y#V![_^
M\NSQ'/K[?)5;P+5^\7"ME<*UCCQ<RZM3KTYO4*<;V,Y#%Y)B+-R1'MFBQ!=)
MUK3(%745-Y15C59?_U3),$K'-8]RY1SE1%F<#M/2D2"*@$_3*C<(@]+5J'00
M8^/3"/'X.X+:#8%APPVB&WT]\(=$[]RL'W&LZ ;_2!,+" XF3$MNQ@Y"!ZR#
M&936M-E)+1:37C-,!7?HB^1+7F9%B%Z@(V=799'@TP>->#67C=M/T<5KF#WF
M4]/D#9U F]05E7_L[& 5.6Q26?&=5W4Y3* SXY2JF8MP:\C\RCA5.%Z55":;
M:Z\I,[7-@%WES^)RD+_'7"Q8U(&!/)WFA2':QG_6RU,Y?6.EM6OE(SN(UN<S
MX$.&?,5F(\)Z#1;."$8#D .;[5BIF?),TWH[KTVL_BY51%"'!8\:PT'6M$<T
MLMG37K#[@^GNJKA"F,.\80CVKFQ9HW50Z\[JG5E-;&P=KW"]PGVQ,^B\PG7-
M@58'G]K8\ F=5H2&]5%ERO]4*ROPFY*>I&E#W)OC[!S.0_0R-;48RSE1$.PT
M<K'V02"G9A+$-B$KQB(>BO%R4;S%6=U=P\,(PEMG,HG0JT?"17 KIMS6 !7Q
M#:]P5Z6BG9-F,V_23^.HXR@@VTE[>^M6^)XU>*,-@&91D??BMN5H0]G^.+9B
MIS:]/IV^ 1.XG^8,4#>VXH<<C'.5P9W.B5I6#2D/4?7<JQJ"F'+4NN//]E88
M"S7F!W"E:D$'?J=?%E47DFIT/]5#,Y8=R:JR_Y?)R AS@V;$W]S9="<%=P;,
MREUB@<#V/V&N^E2[89\/GL!+O-5%.))1"5+PP",)'QY)^*;:="T,,&S)6V]'
M<"IA^_K%[,!BFE(8Y.5,F:J_O::V]6AFOZYX#RN)U*H@A'^5&O^738QKVQPU
MG5HT($X&Z,EA.W,N(F.!@Z$'?)9Q_W;()I.MYP6E <O9W&,E2;B*[5\P?Q&6
M$:@Q/'NW)=J,I D-'^0$G4@>-?=2WM[:Z>\2XVS%9<Y&F<J;)91L5U9#,C9F
M2>9:KQECL1HX>/[IA>G6C!^_M=VAGO_TZ84_%3>_PIT=@,NJ+1U!H^NJ,K-;
M8,UZN$#!\XO+C^?_/'M!Y$7F[XN6]\[7UJ_F-:LIM[?.QU3)1SY+8SU1E*G&
M5R"[TJC9#%%$(K/%'[B&"3R^U+*J!''>#"!#ZO;-A8R1GKADUN!,(EZ%6+0U
M1[# '+IV\QB'M6 47U.&]F8D*)M<\-%%V7\2FXM KD9E;H.V\&B51OQ28)R=
M("D03LB=2I]'O35A6=_670!Q07%;PJ?SNM9LM:II8$ LQ#F#R$%GD65\.F<9
MXQW78SK6;O'>VI+V[2U3"<PH]E;],<9GFB7#IOA]1^_:;DE<5]Q*85AN)?H9
M21VR6A"!IL(2$SS6.D%CP;8J(2>IXBC2D@,R-940.'C4TWE*M0:1"E72("HW
MI@=8,%2BD+!-M^@Y7APT1WL+?,2O'A^Q4GS$TT>%CWBP\[$0EM&Q5P Q_$X6
MVUO4(#=K.:J4?AVC_*+($^:1A1YAO16FT1GF&NS(KS9M?85'%$R]B+H06PRK
MB#$W*+[N<OJ2<WLY953QEH5(B+ \2-+D"=Y_>ZOU@%Z;F!6LNZ2BMZ/>%17A
MB;W!S "--UK=89% ;B0=[77;6_./,O$VH4/LF*2(#:\7M!C[Z,(>99*Y"BSA
MW/:XZHX5RV18C(*^T$I76'#KT$=EQ198&]USOGQO%@](;3G:GK.NC%1<FITV
MN&"8BWI1TXP3,Q6ZFW\7RMWJ"IH:RPOA[K(M],BMT]\>##>_:0P7*UBR"A$>
MDL)'EL1JC#6;X$+.)0Z9H"J?Y2<Q%=[-1]$:-&S% 4CX=$(3B.%:^B:)34B#
MK(5[7X595PGD3;T*0;4,][ *06L1P ]:;A5V?46T3\/?5QJ^^P719?9DD,.'
MCE4^8\1[%6DB@QT03J1Y30>=BNUUAIW.LHE933U16NY2L\:0*EOZ:5*Z$IAC
MY@FD$[4+83H+C(>HL"U*DE+$NU7J&W1@.A5QP8XZEOE@=T?[F;W*;1RH1AD@
MC]*L(4R9IQGOZ'LH>!GT,#*H^R71RQVZV=)!,)_*Q((8L4I9Y"%A?9HV$A)%
M7U$;5C:E.!HW8^>XC8-"=LO:1/1K4^4WUR_/&0C<Z.)"P2#&;EK,#W?<@_=6
MXWZ9:]DD+A(<SL8F>X9R_&N&@\% EF5C=!G,3&Q[/C^(RP?B&I$(UCZM7*9O
M+YX[[#1%>SJ9DB)Z4F9!7QIJRUC9/<"=X>8F@/*8C3N@R3R2(@JX[-%Q+*WG
MWJE2\/+?RW]<N^Z7O!OWUN48S=I9BB"-?>-7(IZ S+$P3[5N>,0-**CF2 \'
MD8P?2I2Z[D7F4^N8UK2X_'CFQ&@\TUN!7@H\C!18@WIFUP*L+)=C!;Y;)E3$
M@2PR H6J&I)4AYL:6V.E368((:MP,5,M*#9(EB5W:!9@40OM4&2J$/&W85*6
M5TP@_R;AUA-CE:'L<)2)00&21@MF]MXAX3,_&RPF(PD&Z)A$59K8_M[EV,3<
M1@SM>QF,P,PA6DR7<1@1W(-?YHU&1?1QKX[WZ=G(\XQ%OS@&^5VVN2/0YVX;
M'WK)["4SM=#MO&2F9(S+L8/AY*(JE=OA>M,$0>>Q%48H?G25:XA3',:P%"0Z
M9"V?!PJC>]@18:E*'2*S@)LQ$76C+ >DW(+Q]$SO 3(5%TKDMI#UYIP7&@\C
M-+I?WN=>3W\+&ZUN.Y*GXYD>*-@EHI6)-Z5W2Q@O<_U9V6#QG4[]D7^X(S_<
MO"//Y[L*4,]'](WAWVN@)JJKQ43DD6WR4C-.Y'W%M'W.M;0\&F&0H7CG-)H&
M",2H,4?$QB?&V+&@&H"@]H\8+:[E3IR:7DVNH6HJF"$N_K[I!,!/> <VR@5A
MFPB9^%@+=%<D4&^! 3W8]R#0E8) CQ\5"'0#JGKNHW*1L* -N587^7B8EC>M
M/$QKZ1#,$#-?1!JE0NR3F!O&XSD\Y-+UO2ZC40LQR8U(BC:TI/. :G*Z?H(!
M>,?+2X<'D0[=!U MD4#G1F)Q7610+#JAYN@1 SJSN;,CAM[/-040CAD:KH28
METK$3: TTB51@2L^?I"#)/HVL@A+1&3F&"FN2 027"M\(L/IB0BE2&T'P^.]
M7W=O52+2&*,CHJ#1/[=):]"J'X'OV%.TR]ACHH+<S)F(B8U2!QDX(#Q' _?]
M<<,KKJ(TQ6U S3H6+NF!:>YMH%)8*Q.>*!RQ%B-BYC'+C1:E83FF/C'>CM\X
M37W033VM.J^G.>7H*(ASS&'FLE]Q0F#'#50*AM2K#DYR]W,3(*TOVS7H7OC.
MHN/@-NYX.V8'U(V[45:567913W(=9BZ+,L<<S9Q2]^E2+Q@>1#!T7S)PW;.S
M5VV\>SR"LZ?-5$)3':D]L!,P'PL$0@RP]5$P3-,($6)HZ.N@3#"V#,<8RZ,=
M0>T"J?_Z1;"3R+JH4X8(RJ.T;6(?_00?C9?>+;;*"P,O#*X5!MV7!E2%XHQ"
MS43X1<!F&&*Z5)?46:P7A *<1LQKH.D 'C0B&7I((G.E(F;7DP(<2</_;XHX
MC3A"+]P1Q&%:R(.PL5W!#,HS*W/X1,O< DXK[]*(,2\0O$!X$(%PU7EY0,AM
MUS:,>+H+\74!-8K',?G3]E"GK?N'38VS-'>,'IN"4?A=$)6,5*S;:3:HXH9H
M$7-#$5!^>-TWM*1K,]BV2O7AT0<.CUHS:WNKKL>N8J4ZB%**HE>%V57L'/<3
MM>,=4X=&8XV9C  'XG6=!."./23=&;\NHST#%EN4\=W>ZLMB(F723J18NM%&
M)D6/,):+0T0P&K6W4@DQ\E!DJ4ITF+X6]#B08F%I>.I_C".,],]@UW[,Z=/M
MK3*)D>JYXN?"3K\$"V+GE;A_9B&^B]FMFH5/UR62/27SP\-]D/.4RO=KUC>J
M,[/E5S47+GYBMH_Y'1$ZF[UC=B;>(9"*K!M&+(S]*G=AE0NF\UA,0F^P)9FA
M;R?B'M-D@C4E"\=%=+DG;;K<W@R;&F9O55(*PP+=^B?1IZ$8Z3%%AN9KP"'&
M"DSX6Z2NE/F01HJ-T2S\F&A8J80;Y3%(]4*RL,'T)Q-/F^"\5?H5'[3AV>\+
MSH$2O1Z()&S1GN4JQ3[?7,W !'"Y'*;P.GX;+_<*MP'V'GA@[TJ!O<\>%;#W
MT1REE6H$F6N4?6V%H!*4N5$IXAY)Y@2N&JFL%\0@1#&;"&9H'VS18DH%%O 3
M;%R9CU&R<RL/(FP56J>A,O^@KIN]H$P:_3XP+5GW "4)S!$1;)I4W"T]MM\@
MM]L@Z/1N;YT'%T4939O=:X)1"?<(PEAQ;ZT"R_.Y-556(Z5,UUE$2C$\*ZMZ
M%C6:[E5M=_&W$G=9@OK<DB$(@V#9WM)B(-G?&$D1%Z/F7B7?'BP#94ED0,-/
MTC(&W0\?ZL'41+>)M)1+E>#1AP?!Z=[KO8][P='!X=[AP8[@)GVBLABJ-]0T
M!3# JI=6?SI3CECSTYMR)>,<U6BQNM2YT7[XHD [Q>_W[NQWL^&;O4UF-P*E
M4ZG%&W?>@CW:Z ) 1BWO16YN:38_!0Y2@B^BJ8F.^4CDX"+#F/Z-]K)!<B"A
M&C<B@)V8R1"-682.2,P':=POF!N>()4N_&F:E^#OQREUCRH$=1+F P.G(8UE
M;H0VV]$9/'8LPO2+2B18*[K9?FXON#3=ZQJOMKUEWRT4B$</1(0LG1I&SLY
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MOD%=K[&L6IU!X&-Q:RK\.M]:0"!3F6-N:R'I69;+L:(&82T!P"*JBH/=)*A
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ML<SI[1=4*[46H]'5OE7UA>B1M) F.1!+9XJ&DO?=8M:E-CZ7&=C,J&':M<7
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M]NVDYL_'M06#V<G*2GAP$J,5-F:S[WK7;;5.S0[F-_J?;]$3N9J;A_]8RQ:
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MF >/L4\?=2A]M*C%G98,".4>=X6AE42+#,TQ<%\(_M) 1+>$\P*D8[-LC"E
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M[,DRO%<2%FE#"P()8)$6R5>[H91OV[S0Y3@#>64F&#X[,X*M +DPZ24^YF
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M6O8?JKM]0S7B\%8)7'>MW25E$.? .\+M#L@4P6C[89T7J1E*(?=)S-J4G!H
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MWF\@2;A''#PQ[][*5AE][(][1=3()A<\ F$F>_<\S[[>VKO_X0OW@U!<%_Q
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M]B/H,? +=0COJ&0^F/7O\?W@NV%??$'AC]4,\\BBD/0].7AFM"HZLJC>.SN
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M+QB[PYX;]^4BH"MQ4=&R16;;L5DR=E!5\&/^V^Z8JCRW<L=;_P-02P,$%
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MYM"Q63-V4.$43+>,<$EO-"-REDUZ?W_9W6^0#=U=6WWYYN[H_@)02P,$%
M  @ /(.B5O^[6L"O P  $Q,   L   !E>#$P+3,S+FAT;>U8;6_;-A#^;L#_
MX6JL00?(MI*@_6"K!NS(;3.XB9L(*_J1EDX6%TI42"J.]NM[U(OK;@.* 3+@
M835@RZ)XQX?/W3VDZ'T(/JYF_9[W83GWZ0KVXP77P6HY\\;UE9Z.F\?>XM;_
M O?!E]7R[2"6F9G N9L;"'B*&FYP!W<R99E3-SAPCXK' S(DT_6_M9M"RM26
M9Q.@KE,P^&R&3/ M-2B^3<Q@=I9M=#[UQNNCC>"]N[T)#MT.8Y9R44Y^Y+CJ
MJ_F?6.,@3XO9\CGA&V[ZO7-W='GIC1=$L?4_^V_,H&7[>)!#S RJCEF?IYA%
M]"7>C83E,X:%X4\(RS07LK0/8+Y5B-6_'3<)!$SQ1Y@KG;#(@8@9C. WEA5,
ME7!^Z<"%>W'TZ!V%BC:"74/O$F9#-!7)GNE3A7J,@N@2GX],]7N^&C6Y/#E=
MJ,?7EC\*;7A<=@EZKON]4A8T9@D/F=PY(+._"84#)D'82*8BD#%$7&%HI-+V
MYE-AP6$&08**Y4C"%-)XUUDX@E?6[$Q$CX6<7LDT9UEYIJJ[7QU@&G*FC/41
MHC*,9_U>*+49DK89GFTA1:8+1;-AH9):5Q@:+V2=YTH^D:@Q8BC-I;)X+]R7
MH# J0L-I%J24%6RF$303)(A8(69" .XE5,8QI_&K)P<CC'[F6:=Y%DA:NA)F
M@!8R!S".*8,L_:PB?I]P;]J$HYQ4P#)J%@<1+&EQH^AML XSA9^"_,OEA>NX
MKOLS9-V&[#-2R%0ARJK8,.2TB:CC0GL.)@Q586(582?5 X4J@E"F*3?5'J2I
MO;:8X+/=DU2V"8J\Z2US4@Q;JB07P%)JR6(>5>8V4W981YMV-6I+6+11,MNB
MJJP3,HX+48T2)HS:==V;JEONH- 6PC[-: ZYU+R6A6^X:,X*XL*0RH NPA"U
M_I\E49?X[GE&0DI<.Z>+\=0Y_,@IF5'T>VO):;U2IXOT*F%<4<=^SY;CU?+V
M!YN!TYW)D7*B=?1B.(1W'$4T@37;XI1Z/Q9(I4).IW";6U'2$U@Q;6 X;,XO
M//_Z]Q9 [7:XD<;(= )OK/1OI(I0[=L6@H4/<#YZ32"U%#RB\8/Y8K6DP*Q6
MZ[GO7]^\?SMP!]7]_7I^U=XW8S3^0BD$RS5!:_]-254CDU@"W)?_]$86W+4^
MGF@7QT,FVB7)R/S[-4I@7%GXK<6!ZV]A"'Q[:G-G?^P,Z$I<M+0<D#FV;-:,
MG50Z>8L](Z&@MY<)!<LD@[^^KG:;9&-[J%6?<MG#L*]02P,$%     @ /(.B
M5BD- [V\ 0  F <   H   !E>#$P+3@N:'1M[57?2^- $'X7[G\8 ^>3VZ3"
MB23;0-+DM! UM$'PZ=BDTW3/-)O;[&GQKW>W:;0/4OH@*-SE(;LSRWSSZQN&
M7F77B?_MB%[%0:1/,!_-)ED2^]3N3OUJ;Y]I>!O=PRR[3^*1M1"U<F'H- HR
MOL(6;O )IF+%ZM-.<0HSE'QA:4-MFO9V"M>*L(J7M0L%U@JE!RLF2UX3)1H7
MG%<Q%TJ)E=98_DF=MXU'[70/F.3E4AV 14,_7B]YSI6.?G!![=#?#_RA41X,
M1B?7ES";CD<6KH<.N?CE.,/![Z:T($BRD?71WGJ88T+@)\=J[D+*2O1T$__\
MQ;I W6L@9$L2&DWN#O#7.SAO=&-R(><H7W5AQ8H'& Y^: *UHN)S'406A$D,
MXSA)TB"*)C>7(\NQ-O(L#<:]O/6[Q2M$5;&FU?'U-P^>^%PM#3F=[QX8HI*6
M/V/'5N-FVF,\HE2\8%4?ORZ0![L)5;C86$3[LMUQ]]:6+#(C-#4_DY4^=<T.
M+%\ND3V0'!="ZJB;31]V6WC>I?&O5&N'D[8A9<?#+S^N9Y\[KF<>W#:*B[IU
M(6&M>G]Z_T_J5^">;39KMVK-1GX!4$L#!!0    ( #R#HE846*50V $  /8.
M   *    97@Q,"TY+FAT;>V736^;,!C'[Y7V'9XAK:<ZD+:K5'"0(- F$FU1
M@B;U-!GB$*\$4^.VT3[][!"Z'*:(0Z54&APP-GK>_[^#\22YB]PO)W@2>H%:
M03\XF291Z&*S6=5?<_<;^P_!(\R3QR@<&4M>2AN&5B4A86M:PSU]@QE?D_*L
M.3B#.15L:2A#91JW=I)N)"(%RTL;,EI**AQ8$Y&S$DE>V6"];U,N)5^K$\,]
M+=.Z<K 9'W F6+Z2'7QAWPTW*Y8RJ;(?7&/3=P\[_M L.SO#T[M;F,_&(X-N
MAA:Z_FE9P\&O*C? BY*1\='16C=?$8(;1HN%#3')J:.&^/Q"RXRJ60-".Y'@
M8/JC0[PVP%6E!I-RL:#B_<PO2/8$P\%W):":%VRADD@\/PIA'$91[ 7!]/YV
M9%C&=C^/O7&[W\7=^<MX49"J5OFU7PZ\L85<:7%:WQS00D4U^TT;M>HPL];'
M*Q629:1H\U<-<F"_H((NMQ;!H6KWPOT=2Q)HA&;ZI:M2J^I9Q_:E@I(GE-(E
M%RKK:CN'_1%>-67\+]W:TZ2I1=GH\-/C>GY<7,][7'M<>UP[XWIQ7%PO>EQ[
M7'M<.^-Z>5Q<+QUXJ"3C96U#1&KY;WI[4C^#]DQ];VTNLOJ^^P=02P,$%
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M)F&0=CO+&:!Y $GP'*8H<1?HVO9<):?;?!K?ME+1XG!)[I^W!IOP?K<3\FP
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MY:H&S>)M98:=')]=<+E)IY\>+QP>-&O/PK;MJ9Z)B"?^C>B$$<TFG$U9!''
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M\)LVGU)U93)2R+):7&55'',X=/'1)J#+7=A"9/&!8!@QA &Q# 0W([P<+TM
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MHYJ%H8B4AL:HY4H>?6/@1O_*S8$7G4\K]-J*3J(2E&]N)/8J[\HGU+ XS)'
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M   *    97@S,BTQ+FAT;>U:ZV_:2!#_CN3_80ZI52+Q#$W5 D7BX;3H:.#
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MRP;FPWTO!+O(<+I+YGK!P.5/,^3LC6YE 5UMDX#BW"B1O]16] ZRL66[Q 9
M, :V)14,Q>?\^5==_H::$Z)(![DGFMA/W"+.EOAV9NK]>K3 'I\SK*->RS$W
M/*5?9EP&H&/&YSS-&F/7\+E+EF80C/=,C3WK>BUOM;1IFG"?-86^\ *H<W0N
MC*KR9"F*/@:S=-&MU_+N8R?!)>GRC,_4$[E>KR^@U>/8V'83Q5*'/"L?!\DE
MTJAM/C+?N@2+@X+?*L0#EB#UP0].G_KV<W;=1'8E(AK'2JYGPQTILR=[P0B4
M,B57/QS=2+3Z!4 )A;[(%?B3H_T#?!.L--;AJOKE&C6;U4!Q"->N\XL/+A_E
M1J/DN0*KD:F'6EN46S04Z_42H1R%?J:UV?(&U$X9T.V3"*86%MOV\L:VK+F7
M9);%INI4BEW\@'.W'X7!!>IT]0E[V%F49R7/Q3<F+7[AW3I2;HPK]P2]VFV%
M=S.63L]T*#G76RQ[7Y/.:_$]JE+[2OS=E.$R9X_G68YM=^&-Q9:RO8FGEW<5
M$'FJSMUGM[G X\J[!F19^YET/GN+0K]I6?F/',;^HEAYGHN?!/G]125F3;OX
MV@] /L?^(HM;_"3(+]#5/J>DG)Q./=.A%$X#F&U?D\XKQWSH'^2Y^9S38<X\
M=UG[F7@^B\*[9=@R>?M:EVK++& ^2)PRX%J4&Y%.'O_,61#Y9)?3XIZ5B8$?
M?OULNW8OZDE;6>UP^#$W=G!_YG.N/.>8"#1^PS0*P^*FW6-.\)^M\\NSU/YQ
M!.[6AYWMH]I^.?9-3H@_/&QGC'F\$[:,_7*>W_+AX2KV6U_0?G%@P O[W9W'
M%X=9G-QZ:<IGXNUQ;2P?H)N&TB@G+'P!L21\6^+:^@(_8B7+/USDLXVD].2W
ME46,K)MZTNH/+/PHYZ#RB>U$H?W KST<1V_++$MA1\-*4(RF"S)3^<-SIBW5
M=VN[N7M9<][%2UD+L(>]//?PP^YTN:]4N$:YAV=S 9_V^HXWX)0G?NFY7'Y4
MU;>^]X"I'^-1\V WUW.=&B;![$#)SV?^8P#;7XBG_ >QJ,#P.ER3.-;$&'/\
M=L\?2 [5A/4^3%0F#C/I4^L:LLH37KLEPB$%F<5CT7X9L"@&1R$0J4S,:.[4
MH=GA<E0K!RHM*$MH#H U2H1(9Y[?YG88^5/';.:'2_YFPN( 4A!4*IA"^2(K
M1^,,+OJ#!P"QRTALZAG7T[R0.:KG:J\M 2I#:!0#:7PT(C<P'2P$@6X0)$DD
MA6@!M?\,$CS0_A:TKZ,2\=BYDRY?A,M!H[93W\?^AT/PR:0,%9@\%I1G.3M"
M#3?&6!M.^\.0V2M)RNZ/<=H?!M-P_6-!..V/[ZM,Z>US:[.76 <W!;-M[&"?
MO0R(&K7=4N@B"U1L?PQZBU%1%@O!<62Y3)CEKOXL"F:7Z'].>-74%L$TX!D!
MRW[)1944YC'(QN%5CN :3HE;K,A*;?N/J2V#^?95)I$U5WG,?& I!74LJAAF
M+I -Y_$5&I->4G[R!<U1*8I'?USIR1EJN;.F8IJ9\P"G7CLL TKE;&G.!:GA
MWF;%-#;GV]J/1T\ 38'6S853<[V^N[5@9$NE.&95J"'4N^$]9KLTA4?T1XF8
M<\?]7GT2W"2,IFN1ZO4X]IQ5_5=L-\).:7%3.M% 35QWQYXX<EU8WGQ]A1KU
M_?P;]\F6%F<<^]PXL,;3)SP?_I&[O#VAP^#+F6\-^*402WT1IHT%-)I4"Q5G
MG2-,\Q]Q,\]2IX!I_BFGJOFP7&E,4KFL-\>)FL/KA26*+CVJ,T_3M9[O^9LU
M]T;6NIMSP=/(0L<W Y)PGJ793*.1XW2UB7!-E<6,--M\87D'<XT5PB^[MF5Q
M^HRK]7%-W#5Y(*YP;/?^?6!V0?+ HXTG^MSU\2W?G8Y;Q=/%POOMIP"T!?%S
M..C#+@.[U\>&M.^25V4?+EX7>)&OW@:7X6[L]W+CM,EGF(J\*;X-DXC#0?QM
M_+UMX2]MF_L&;056UPW#_OMW[QX?'[<#;FYWO(=WQ^>_;7VHU6KUW?W:0:WQ
M\[OAFY/7O1O[/OFV/ID@HZL $>^'6)SV(=F.>E+RV\AM'' WOHGVG;S>RMRB
MOL\L0'TI03H9SC&MUO:K.[62P=9V48$*/R0;B%\A?\D52#O5VFZU7C8$3 %)
M;F"A0"HGE68P*4-N"P%2O>Q JB\22!.UGG*!*\/YZ_-P_OHB.?^+02P>7ON>
M%9GA+7/BOIFK.H($JKR#VESJ!_F3!8MYZCNV:<MR+,.RX4KL"@YJB1^^E[NY
M4F-XFD]VL/6!5,BQ>Q6K&7EL>DGOQJ]I+36%%[TL&E]6B"_EXR_9OKQKC2[C
MMJJYRTS<16.+YBV3U.B\)P66%*V2[O0 :/)X4<0!XQ6>BP$'@6/)3-71K;^,
M9G,MY-AA@1JNE$+TZ8]DV>B_+$MG AZ/SMA]'2@YLN]7=N[/3RM^'3CP+ Q>
M&SZ89M2+:';:5=CE/L+,YUV$[(.,R;XNW)@6'J\,3VZX&!-VRGS,$RBY[3TC
M4HS?_"O#@&N&0?!7=>[I+;^RT[X<.RS^59W^<R!8<VP8;C:KK5YM]>:-Q[45
MX+&V>E_GN6NKM[A6[RKP05LS1;)FEH@!)<OO6!:07IRPH15 K0"^HACQ9$+0
M&J1&G+D01ZN@!5-!2X]0.G)3CLA-V1%-&TLK-Y;*CD(Z=J31909TT<&G0@6?
MRH%.DT>[:>>%=EZ\AI3E%PE!.R\TXLR%.-IY463G10D12MN4Q;(IBX="$P:.
M:UU.ZW)YQY^7T8Y!QY$*HHJM^-RU)E4P36K5^*"C..6(XJP83[3"O'*%><48
MH&,HK^FT=0BD4"&096%#$AK;JS9VX[_VXPY(S/5N!RY_N@BML<;OE;N6!N_'
M*  !$ 1-$U F(.TQW2MI!"HKL7(GP'[5X3K$I%G#=81TBX[^3HOB&GE?-<(D
M_6/3:(*4%KD6MV2O_?5 E1=$(R',^)VO5")F3G^!$G$O>5O)*CG&T-A>@6AL
M#KU#::I"^'W46L<2M8[XDLFPUT)D"B&B=8WU%QL3<@QONW:_#W9ET[5^8:Z%
M)F:Y,6!RR\=D:-R$+:^:5Y0MH5#C3D%PIWAI"R^U)/[$71S,U+1ZMFL'(8[
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M4\@[@XI!F\:[:=WT\S;8Q@#L9PX*YT;'*%,Q6,]S.X HM"Y .;<#K^A[]#S
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MTR>3IICBL(">307+QAN\3E9$WYX>JZ+Z2DQ55)T"4HEC63D])I:CHAS]$=X
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M8\/>73AF8@X5@]N4*L\<@K*0C%X/%BOY$2TEM07*&<WTZI-<#K>6-9>!JU@
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M.2CFG0".XR+$FD5'49G![3(@.<]AOC!L4"6GG$Y0<VPX,09F'6YE L@KL2J
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M;Z'R G"*N6.!<A#'X(?G'*7"^T"A%UYD!P_ /'ALDWWQVDET/['$DM&GP@N
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M,L>:()B.=J">JGL.%VHC>6YAA@TT*=D-DZ:,.!,6)>2 T(M*/7TR@5V.>2N
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M;[,HF(SKNN\H)I;*7B0WEYJW0$XJ-]4R_ 1=V=<,C#/CUVWC8QRC_HV[+BS
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M):0@  ))'Q^@"A@"%%Z%2EE6/NH,J[5Q35'&!.5E934_>^_<AC5()-47O3;
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M5586##QKN!\$:VP'!Y.V5E%^ZA![;LW>+, W4702&FHBT?[@(>!>D%'R]1"
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MH[CI\(KK<L8P?%DT9<AG=J1#QD.SU-I,CC-N2O(P.<I(2[*$\^G2"CTFK8T
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M(,</495093,1'ZW4#+#A4Y4S-5HAC#1C; M$:Y>M-UQBP(_NF%GAW?9P-NR
M"JH97V0+QN!_C-I'?].<]K9@^*G #,F:@CW$KT_K)&>F$I[[W]&Y-('9V.*^
M:R32,O9I52'W[7/T5F*0<Q@/)1EZ8.*((&\?IH<Q0>G&DH8K0P0[B[3VI@G"
M@]\N53^]^<%PZDNQY)$ @[5>A6.Q> JOG0\+UH]Y%%.HB>G?!7]+0UCINEQ*
MU<U%OEFEB14P7A0U_4^3/-)($']JJ7^4+U0:4L!*;0T_E,@Y-#7Q]9_H6A:
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MM _&BSY>]+N\Z"CU.)AEVI,++%JE56. ,5WAU@TT[!ZO\7B-QVM\#_6U)WG
M':Y1(M<G24.$X,P OEIM:Z1IX[4>K_5XK6\7OX-&O160=@?KZ-H)=ZJ_M)?&
MTQXJK:4>"O5%>5I+[?62OZ750G3GIU8-!2,]+;*QV=AX[<=K?\O7OG8YFOP=
MF@#@ZB"H<M^3AYDU(G,<K**;,O/=E*U&<%.5W!QF[EEH8B[#<DK"Y/)WY  8
M])_F6R9@6D2\#5P]E#;I*$M&63+*DEN5)>FAD?^9%#F&5*(@ (89#K6FQUI%
MK#=E 0,BKA($O*]LF\.&P11 J9(0H2#TJK"A(:4H8H[I#L1&L1(#%#HY&D65
M5IG0-)) HZDXK@NM5X>.@^M%YRW3V5]F99Y*\PM(QQ]?O_$DSO)'(WP,^=-.
MMXJ)$./!=\+W#Q:ELZJLZS/$65)C9/(EM=W=TAK64;J.TG64KO<O?%HW5DD^
M6'?I"6--P!K3;%;7K5/+C>0;&7:^O.J?X&[UKQO%Q2@N1G%QN\98<6";+$5D
M"\M+-:SF12 H$W2@F : $ZTOW'R\V./%'B_VK5[L7]KJ\&[L#*,:[L8W8;88
M\EU 56G1$N9S$^^A$UJ)FO EAV*L4D28D<I=<T,^Y8:H2GHU/6V>U;-<(!T\
M@ TP8$"7BF_%[LY5)MA.[QYQ'/E ,;>G@(1>,LJN47:-LNM>&27[.HA.01$C
MQ%#3M%(R?:T]E?\( H/^QB3A<?3F< '*X99E20>P,#*QB&=7:2L: Z%W SA[
M>HH>W&10">UF:>V,KEV;"W#701+-=3NE36O:QD7+Y5EO^0=EPXRUD  2LS^P
MH*=4GK#<U\RJO 8[F2QRW6*4T79Q9<!F4PK[L9B7$8>B,?9]=&^/#PH7DWL?
M15K[Y4A:>[.DM5^.I+4C:>TQ&4SWG+K_"+@[_P9.6^;7Y)XE)"_*%G?%MP1"
M36C/=B=_I*/R?0=+5D+H\Z *WW>\5(65%:(D+:TA:I6UEB!63D]"GUX/4.''
MI<E+:+MW0J_[NBS0W01?^ZY,J[FRT=MS.$WN;8[SY!T^B4T%*&3R@4!;Q[]*
M.[VRR+^*6V)H;BAFRER8"Q=R8"B&04U>1,2["Y-E/VXV(WD(ROYK&Y_S,#J1
M8W.9^+7<\T(]L8'WP+D+.2OY&TJ"XT1:R--KAHE7)//^711Q1BNC2=*BJX*K
MG2N,YEC#U3!+%(,4MUR=Q(L2DR2GM,6%6V2-E"4KF\DJ4*TRN7"7J82,-HN4
MT7"#04@3ZV7HTCEM7<:O0F5".O.?L/UP.+CY/'E5>&J3[CCV;5[**(P<)9ER
MVACFU34(U8),P;BXSSU68N<U&M)9)@!H#QG!^>G)!7XM[]QEA,8.3ZW1RG5O
M\!=UP>8U^EWIZ8_)G-$=R(ZU,.XVW N"SFD5-0GJL=#VQ<=(W?RIM!6W!WJU
MX XMN\W?$$S.4$4,H4 /EJI #D*G@CRVND"E;N;4NU(;[W0&4CY1EVW8]0@Q
MZW!C2-@;"=#,&GH8-7')%.# ,[KYV-CG'M@( RZLIX9G?F^5GA]W/GS37-^4
M3%H20ONWA7\!YD/S$S9]/HYT9N):]Z"1':U(AM_YPTH/"&5H3G5<;1VV09GK
M,72QK1"+>G6Z%_VF:K(<W+O'YCHTP=!Q#=D;:5K#=7(!E>M'2\.)VA4DTCF'
M&Q:P*K&O7:U*?9"/LW!_0S]]6]C^>%A^D_X%'[_6^^X6ZP],]7__KZ^?/?WJ
M6S^7W@)E12,?,'"0+_H5HXA$GKC+;.8\-['$'J1OHE] .J-.&WN)%1+V-"S.
M)=D1UM]==([9/?J1S[4SE;+]<%0U]V@BW*&4K(K L*_G<,^-]KN_[TA?]9K.
M10T"(IVV:Q6E4[I2?%PCULO^P].\*9=,X3\>HD]JKUR(8W%Z$GL6(3*LCDB5
MU>\A1.MREK$CRL9RIP$,;?IG7JQZ3R-JH2E&B&]1J(R(SE,53NC+'+:58Z0N
ML-A-M5> 0/,,D*SKH2./H^)Q1\TI)MH-T??-\(T-%YDTLD&MM78Z(Q]FZKA-
MQ.G)\-$OW%(<'Z9HEA!@K<P*@AP/T7,_,VGD.%I:G_B>OI66AZQ)X\XAPQU1
M8""#H"-99<N5M@U*R0O;2'26J_TR;48$:SK-V=X'/*UWEZ)R0'(MD3V@7]*,
M9W Q_UHPR$2>&?^0KX/4#\6F7+\9J+0EH%LUZ499NGU'%SN3Y%A2(CV=3D^L
MP=- PY)10M^CB;PF;8K@S(24_:)[,&#=]T5TN^]P#5FGE9B,O2-J:$D7'>.)
M15FXS.;T)*C]T'U6$.UQER#0:\$8*-*J*J^0HZLEOSG=E!L?8O*!2QSLO>/W
M&JHW6@EQY@!UV9V$!L!_A_)<'D5TE3E,EK*6.[/0&?GO$@0$_6_4<6M(E\BR
MZ/C5GO+MXFMC!&,%PZV,\"".!T]=I])H7<[ACV%7T4Z,FZ#3$Z=I+9V*D TE
M'>,C!;T=/$]>[W8>J]$#-&W4G<P9PU]><4_X<JW $Y<"JE(W2,!8#S4^"JA:
M1DF4 _=06_ @62QU-X-?X ,*0TJ8Y%S'L=F38\;"@,B80R6T604WB>.&W1IC
M-%LSHD*V$4N4<9%5:W5%YRX2@7<BQD:1-43#30(BJ\%%5;,/+?*DA@C!U@U5
MQN!0YC1LDG,)E]55K&7YWOIN@0/]LCLE,]$AFC,""R;=DL9::.5-+2*F]C&(
M_B@8CH%CR6W<Z<37=,C3>63MX;X-6WQY7I#0<3RJO[=5AG^Q(;LF 0$;!!/2
M:I=N@;&$,UA4<=F@F]L=S5SEY\H+"/=.:HTS$3[\6QH^!Y,X*,[\X%@#B-)&
MC!!Z'&XKJINM>=G$^J;1= !H$,-C]/3OA9/V*RRT?K^]H'^LK0R\>M*&ZW3F
M6L[F\_<D2M0U$Y0]GJ,$_CJ%/,\.LD9I,(>"RW6G#W74"[3;"G37(9Q HWG4
M)>FXK Z-^D97Z1/?%CYR0SU")UT(_40\9O[7)IV]3Y?\SYH."5D3$VYZ5LW?
M.[?AO[.H:[):OD\62"GGC2PH$CH3SI%6_ [%49&=.T>R,9NV>C)C8:G"BI\6
MA#^'?Y&9JVN]%E';6#V.($8,8*VHH3U_21Y;3\(OR)PS_86,YZ78*\SKHK9'
M'%_&SWR .0CJ:ZZ#27TQ@62YS;N3OIT3W-S3DP]<W5%2WZ.)O!U*QBEKL"\\
M_2L9YJ1MWS5L<JA]6P\<8AK4SUJ@JQ #E=*0Z IV)^>D45^"#S<?N:Y2\(Y)
M=/@&A](639;C^2K]A[M":Z+@9]\@FET!?L%Y<B%#YF[/4V=@2;8M3D\&##D-
MI02YDS9IYP:%W\17EHX_FLPBERI3+?-RN9V0;^C6$![;GM!2_8GD2GZ\MLT'
MX*%?C?#0FX6'?C7"0_^ \-"C459', 6N@(@5K:I,TDMO7E\ 6 DUN6S3*J43
MB3 F%(&0ZEQF])K!/N99S5GTWS:J>203,*,KD;(CW2LA;=+W,-,0;*2';,EO
MKZ6=.&ML1/U6:2T5#>@D "V7U;-* %VJB/MCD =H9)['3**(\02QMD3,$%9I
M&@'>?'-RL2^]CZ]!1ZCL:(7\>R]31"S($/5=SXH.@C!J><#YAZR6;O&5AD8U
M("%O%=# KM%1:QM3,5@$NA$V)( .(S80!)IAT3#RA+XP8$F?)R]=O<D:@1K"
MO12 "^\?#:0?(O_0"OJ(BZ$MT>9=0BNIV%<<.)4MDK3,SL[PN8HREWY7Z'N#
MN)2N\RP.P(#3$,&&Z'7SC,/57:(HCSKA6.Z9!'G[XSA:&^@A3N1%=W/\N1.H
M!:?]-&&Q!I:P01(]@*9CS'2>7@6^0KUL$VDGK@1I\*@9,30M-9H_L:!?U'OP
M]&1694QQP2=Y#^QXD5Z6FJD1=YO.L /R))V15*S2S!QJ^_U #FK?W7IAW(G
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M3Y WVN_8LJ@[L_:JMH?3\/JT7_6C6T"VBH5PL>QG8EF1O(!,&$XV,S^1:+
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MLFN,#$6.4,:2$"5.$SM_OM!A</9I#O#U%D\2OZV\<C(961"!5.NC$#FOT,5
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MNG:N23P#Z=RE\QSVBW01B 6$STD;1"NT"XBPUYG@_>!M"Y* &<;L-X%?_EK
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MU)?5@?<H*GP,N7\VA*1Y("*(; &=GOS %%\I4#Y\B6+:SE!)+=85QE5 E70
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M=NN7BI+EL_ R\@XR"M)$JRG<L72"W6PP&WL#G43I)$HG4>Y6HK!3B3Z^&]H
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MX?Q$:_TI5!JP8L;7=E4@(0Q0+=8(53:F#O>%SU[H(B! 7_D#/S'3E%_K$J+
M@ZUG^L7/$9E(EOA-&>&CZ=+0TT\,H1:LI'.I8O5(*U4*3A#R,V_GD\ZV(88+
M'$^A9# DK?KOXWR6\25 6%VJ+>2QK*+38:&I2U-UGOM*:S,]]ZM^+*4;D)6F
MT3 >GV4<^=ME\T^-R7Q5)Y)$M[_%%/Z1!'^GO?B_9S'I CI8P7\GY5D5[)Q6
MO]&I>!+\M)SL68*]EV=)%M6.M0 M=H+Y 4T$@GF2<Z^:P5]FCBDZUM-$DE4*
M/6VM-3Z8#:/0R]FR'>=EX%&R,Q);$F<?[P*G']\M_"=?/SJ6R.<[6Q&#R;C5
M6:Y^6S*@%!3H&M\RO-@X-A1PF ,D%)@?+Y61Q7"A()#)AI.=CW=4 80KTR69
MDOOLFFE>8EA2;N";Q79]V$1D@UB*KOQI)30:KO\AP4RF\/)RP58RK@RY2]YE
M$S>I"\H_K(EH([<K9FPG&]4+58(\ ">L<;AV39VCIU%:+U7+#QEV_@S6!5O;
MK)Q@R*AZL(3FJD:"I&S[<EC_L;UL]#>XDIG$.T6%ZYM;QX];VSI@\\9'L.=;
MVSN OC4.3_5[$OL[191J2SMK'H\(R?J]C>'I.7#@<0N3C<ED7WDD7>ABJG/I
M[X8X]EXTMQ;Q]/F.]=@$WJDQQ,=B8;?\@+Y/VD^M2#^RV@ZA'YK:UX7P@(G5
M;8.Z?OQX?9AV+WBCF4V(W_;B6E'YCCG/513;8*<UM-NNBX2"&84?KE%^D9D"
MW"R..!(*)-/8%.R"&2,JS^"PD&]783B+Z%*T K]I3KXMUP*[-F&6Z:GW!AOM
M)I,H6D82T$7Z/P:K 'L?D-&&1SEABD%;DV^8GCG,BG6_MMS>H]J616)D$N&1
M9E6R+')D887I1('?':Y!RVE0BA=+JQZYWODU^V1I>Z."V=YCKPRZB.=<Q%]E
MDJ"X;<:WAZ-6KJG[>][5_=UNW=_SKN[O3UCW]UBEQQW9<%N\3%MFY(K5_I89
M?;E_WE9N?"#]&,^3\99:[X\-T(U3YW9S%KHY9#Q-)%\FU7-E0F^/"OOO],)X
MD<A_2K]=L_ &]C+K$VX>#$W<6SA@0C;.P@;S,X 6-#J^=[JGW)8%F;OQ.,_R
M.;U$(^ECCDMQ6)<&0M95F6=9G)KD*N/;DUE>+<#D1H96 GK>,F?#D:U2,B!8
MHS ]SWSA$?B.!:2NWU,":3'_='S.OK;KQ)8P@_*/01Z.\HI8.QE-;6)<N!"8
M+?%#U&PO./7CX5X8W 3@^KUIO!(6G%1<QP T//&I$/26Z,8B6B:F,1$E7:#:
M(2NYF)$M<!F<)Z5F+&Z6RD2W;50LN+A+/".A6N8IUD+M"-<C5,\1Q=J_2.1_
M%,\,;>&("^+H5- \!I(\H7.NY'=>K5CS9))_=?5YO.8XAJ8:3LC&J[)^,B6@
M.HD7<<8I%3+\XP+OB=$TRSZ(-)N*FZ</>7'1TH9FZ^Q6Y.E,$OH@,P*2G[.D
M:^DEG+XS%)G,4B4K$:+.^U_L%0L+^:12*F]-L)C9OQ Z<;/37!R3D01 4RV<
MT!?*(V@'&3:N2CV=1E^R7:',Z\;]N>,Q2-X4WM$TOLF;:2WS,A$@*)Q"U"I*
MH;HR9I>"LCZGG8!K]L+Z2(;RO3X?$RF?I?F(#K9>?UF"^LESD6H<6S1:TF&6
M-*!L,Y>I^T'OAL@QZ5;+8=?H2T9]CXT$\CB8U)Z^PEW9EE0R1^U"_2AIWLN>
M8 R9*Q;-X=7IV9.]Z1%^M#[C%NC^EX5HCG[O1++&$ D?2)^,$[T<K^FSZ)$O
MM]"X>32AR4]<E[@."@+%^E'IZA6N38.8ZF474B)Q3EI?XE8(41431V;'ULN/
M)R<?M#!1?NM+[C*^_IN.];)2FLO/).+-X>()_:N:S#R=$VE7/:?>-1^B??<<
M)25C)\9<TD0$?Q)KL#6K](4V>V+DLXNG29B+SSOC!/*[I"7!O<Y46UX[.1+1
M[[$IM /2X4/[@80B8L>(F9E4TYKYKL)#&!F-*A=F0C=$U[,\G[!.=Q7C* _)
M9@D4LUF2*;C3)5A'SYC:W]I"<7!/ZLPYX&QQ#4,L,AF OT56?:*J':T>\L_H
M"LA8B1>"<%2&PO(8<9,Y=-DDKT;+:97:6A2-:I(>,9:I#NJ2RWJ49W@4E<UU
MHA'0V:>OL7WK%%\8?,XXY%O$Z$'@W3ZW\5,#OR$+I"8.=D.[:325CNJA7$P:
M"]],BY$4XVJ.X#A;DG+^+)J*W!ST!PAT+#9:RGXBAM-PAS@BF]"T)Q0%!WQY
M2Z1+J/W F7K+?D\P:J,)*A>C!2XG*"<Y%RE:E]9IS%G'M= FQKPO_8NFF6_^
MA9Y\XS($0ELNP!^/-[U]=2CW8+\+Y=YJ*/=@OPOE=J'<1R,]MG$B',"0=@$O
M]F*4,Q33PIK\R(2BJ(RT-X(S,?JR1V(8,I#4P%;T7FOQD=J*(P[NT,.:P180
MNV=['BS=:3WW>8HX%_\9X%6OHF5D^Z]]!7X6+1M(:>NFPT32J,D=J[/#-;>@
M5+_,4;^O4V7%6(-[4M/-U,W>"&KMNT=P;-K/_XV$[.:3K<G<&M/)*L])309O
M_HD6:?W-]YC1Y.;OTKGKYNC@]_<.> =8>-_V6__C?ST_?OK\Q1U(Z-L9[1W[
M\B_SC/>/>XV"&_S/)!XM:U/UM>H]7<W=X2'LP^YR/M;+>9O[*M=\JR[G1ZT6
MO]G-E-""C>)WE[2[I-TEO<M+JOU+-[FCV@L%F[:[G]W][.[GW=W/$Q-#O]D-
MO3;>WMW;[MYV]_;N[NU;DP_K+EIWT;J+=H<7K98)3_-LMILFY\A?W\CKY,QK
M=U>[N]K=U;N[JS]H >+-[N8XGX^2+.J\S>Z"=A?T;B_HCUI(UMVS[IYU]^PN
MO<.;J<#'^C\?BAQ=!L''_XCFBQ>O.K'3B9U.[-R=V'E%?W\><=.2JUMJPM%I
M#?;-!)17KKSA);97T]V1AW0Y[D$^/^C[YU><WE71TEU>FE/7R1#XC0SN6-['
M#G?JJU-?G?JZ/:N9;O(-$Z'+Z,O&*FG[+^8#;[W\WZ/O?S76Q4^^Q= UD6YX
MDFZ]G!N>Z'!__S ,_J?"EV-ZA.[97I"4907PYIA9+%ZNL%CXX&]""81N.@8$
M+_+/P/1.F- [4ZPS[AH%^0@LT#A8I-%8\*P#9@CI]ZZD"%G&#.C&'?!5<9Z<
M*V8L$ZT ).)CL@0$M('5*V(%N3 =BQYQAO3)TC>R_,*PC[!"F^9%OV>6 <-R
M$+9U'+L&IXG2EO/L<@!0F*;Y9-JZJJ5!5=L!^NU"..H4K7L23P$=V.^5XSA#
MPZ) G4?*"#** 7J.F9NO&QB,.AF+ 9NH$;1PBRAW..Z":1RP=D#JR.BPR ],
M1ZQ%@A-4#-,@F%X:<CRW5_I*@[H^,?  )7BW:3G0HLMK7K:-:!++8WL@_Z[U
M:E3%(B^Y);5"!:G](%-K%W@#(#16>U@%R\2V7!C4!6TT04E,&N_2OXW/XJ7#
MK-==,S@9_N;63C$-1!AA8H]#A6E7RJ2&Z#=VA>FH-:=CC/9B=;J85MD=1\$'
M&?)QY)99?H."#6*:=M&$*J:&E-+O":R]A]ZG6[8$\[(TQZ$?U"UM09N5+ !5
M(IC*3-DQQD%TVU>#;L=+3^8QNFV#'5U)V_]MH":!C\^]W-K*;?'2I2&GUGO<
M6&*P;:SNI&E<?^FW%/T0I=R#?GH6FTY9#]Y0$!?)9MR5_^KW!('0X9\TA['Q
MA[U^)'KRO6WIV0L>@1)X--KL-J=P@PE Y)AFZDG;6;<"K';.+NC@?[N_]RR@
MR:9&>GP[V'OJ_F(9O(K'##XK>V1X#_BG@BI4Q [LDZ4? '[POP;AP>'S\.CI
M8'4890WI]9JO'#X+!\?#EGN[R3L&>_>]&8UHTCU]]7UFYQ\ (%A@@IGGLK#8
M/]=HA;#&'*@&&"@&A?,M:I">M9"W1:MJP'[:>U3_SGR)Y+;T/]9T?R#-56S-
MG/*[^CV,29 1%GFFTRD]-?O*3BIR7T[S$B<$<E2T\RIOG"^)DQ)W 'R+=ER#
MX=%?W*#-1_N]#_[S[MN*K.1_6)&0S3= :;J$!I25]9>P6N"/PU4^O:N64("R
M@+(PBCU"N]&E?("1X01XF%&/^%"$PJ)WR2A9K',*Y3'Y[RJ+S2$Z$)-:.!W\
M?WBVYS!8+(Q*O_<G4[Y72]ZD=-%L\XU+$;O#IMC=O[FP[31E9[7<2EF4H>YK
MOR71*&=*('-^QVE4EN0 Q)-5/\P#GX\C\NTLD57FJ+N ^HAK*NB/Q@D2S!J2
M5" Q9U@Y!8BCV^OC S#>GHY$D9 4(%"_E5XJ$%4&Z=U^C^O7F'_?)FGZ/14U
M%LG*$RD,C2?0>S*3NH!FW;(7?/ HM:R\!">QCA8+81;)4H?IV[T7D>746!-F
ML]??[Y"O6I)6OZ2WDM\D#%E/;B;WA)NU953&1Z;7*5J#&U:P,BKW\UL8U)\5
M[6?0H?W<+MK/H$/[Z=!^NIC^W:14/@K4#,/2.J6ZA4F5^X8=OWTL>'8'BZ14
MD&"HU7_$45$&KSE]82,$*Y[%E@+%WVMYP&;26DIWKA#0HI)-A0_)Y2MJ778O
MXF1VML1#Z<1FNZU6'TA6UWO>OA2#PZK\YS?'375SA=70\LU5;?'-]V^4LM,[
M6_][5 1__;YVPIH3:AU]RS=7%= #6]'A[:\H+N/MK->V3'=PS\?C!1/KSIB:
M"W<X+[X+BMEH9[A_& X/GH7#HZ,GWA':8!%A6*G-\O'UWUZ_^^7UJ9E3^XJV
MV%]BG+7OG_^[ @/8Y(=M+WQ(H_E#^_7K&3F2+9NDXO<8MG+S\\W]$L7QCMQU
MQ;47VH3F+/25P[^LN1WUGPU:/OS-]]^N>>G@N/%S7<_#\/FS@_#HZ'C=<ZU?
M:=^%KS'^HQ QRJ>K5WOC\=_U;5Y_.!I2I^W,_"2DV ;->R/Y=?7J7R]/-]WN
MF[W)WM]GP\%PY5UKEF33H6S?.AP?#,/]_<-;68<[D6_7R;0AG\]/S+]KL.;O
M6OBO%59?2QL=A<='!R1]CNY1(6T@<EJLA8>KG1_6:.[D+FUFT+W^^X?7[TX[
M@^[KWY_-[+F7@%(66J15F^[N1.#!_C!\>G1#B7.G R)5=OCL/D7@[]59VO M
M%8"2?9K,DPPD6=PA=M=K-=@/GQV0SCA\^E!V;P#;F=3J\8HEL@TWT*"MK@*H
MWNVJ'=,V/@T'!P</:1L'Q_3_GVW-+12*1"DA0B:;_OVN5^GYT7YX.-Q_*)MV
M=#@,CYYOS<7;P%O]T>=DFB9?T+T D"F/NFG[/3<LWW.4R?WI?=C;].7O61)=
M>9A]U]8PIVW_;@U)8QV3JE\U'?]T!W?X+#R NCS>-"'P=67R9N[CPW77'M9H
M[LO#O\X,DOCN^]/3X,W']S\'[S^\_GCRZ>W[=W?N_^\,A^'@V2 \>/[\^I5[
M<A^C.3X^"/</-HCJ/>DN7'?A_M"%>__IOUY_##34%NR\???R_<^OGX3!N]>?
M'N+:/:S1/ RO?^?'*,F>!&E>EJX\FNG+KB-[O7-9]GS_:3C<WR L</=B]3!\
M.CP@.;]!J.DVI.H?"P:\18E&7"Z#G83Q+IX8NSL,LOC.PSG#X_#X\,'DE'8.
M22$^W_P,/>B(P'LE9L:FUO9R>YV'G4$X6$WX;>PX/'D$*W 4'J[>EYNNP$/U
M^(556N6/%4B/Y? ^(\/_^-FF=7^/\_B2:GQ*[L_PZQ[AS@_9)NOU3AS_'UZ_
M>?^1O) ?7K][_>;MIR?!AX_O__;V].W[=P']0R#.2?#IY.]W7Q2P,QR$P^?/
MPZ>#S0W&.QS-X&GX[#F26AMD:[K+V%W&WW$9KS0(Q-&\P;W<8G4X/#X*]Y_^
M_E+$1V 2D$$[7)%[72Z@DT+W:1*\>_TI@%EP'ZI^_^ P/#Y\$($J5O6HIKFG
M2%57/[MU-^J/*'%TW7"H.%HNBV142:/F,@^R/ .(99&G*1"3$@U!;K\RVQF&
M!\\/P\$?J%!Y!"K]P12G=$K],8B@W^5:#&\NE5JA> 5(][JC//R==Y*?"P0F
M=J.6O!N^Q2KZ9V1R[(='JV;'FG7['7+IP:_!6F/GIFO0R:1.)OW>&@C.<( A
MI(C/XJP$O#2$$><X&!HK^O(0%_%AC>9K%T/4],CO7* 5L?:UW,6-!G+?GN(M
MNR.2$7^3%W1CLV!<%46<C2\%%CT5Y/9H L":QU$G?[3?UI;_IZLUWB8_Y ]I
MC[L/6^US^_?SX9\R;'47L9&7*YO814FZ*,E#E4ZW[()O</@?MS-^].QY^&Q5
MF';.^!]PQN^88^WVT1OO%831G(3M 'J4!?IHL6T>$5KE%F):OZ^*?D\YKL@0
M,9!#3&JV*!(:'KU6V9V8%Z'(YP+)@8@&,,3?1.7R R3#)(EF64ZC'M.8RV6Y
M%YA-9K8IH$Q>QE$1Q"L IN"-&PZ%:B9:+(K\"[,PT(>_/=K;M^0*8X9$92*3
MU9\YIIMK/J;T"QZ\.4WDV_V]I_V>O@%<$$GI_ATL#VXM)E5L"$Z4&\.P@S7&
MM+]W;,>49$%:QQR3E?Q'$OR=_HTYT?#*?N]3/#[+2'G/+H-/<&&G] \GLR(6
ML/O-YF87BBG&LGSUVYOLQZ.%;'_HPH7$X[MXV>\U$'"23DA^I5.TNALWD(^K
M8G$%L7*3:RWBL=_S)6(87)PEXS.ZUO.(B3J8F('&0[YEF91+2 P6 34QNHD,
M>;1W_QJZAF%'UX!_O#VZAF%'UW"#)6[Z_:TKT]$U=);#>LM!H6W[O8\&V_9>
M[(9'LQUW/1&[/QO:XJR.#;_GL=/\Z]V0*QV,H,6_Z/>L@V%9/^E[-_<;@LYM
M^.J!E=<66:D+K-RCV 5J*1.U?%##_K1SVK[N';8[\CM=K>#;P[V#FWM:WD/F
M6_W>G]+5>N@GG6ZM8M8*Y^Y)#;0VJ O2K9K9H[G#M?VI@PI;"$$;I]7@R[>#
MP0V#P;"COAWX[.EKGNCWK)'3$B)6BRR"H>9D@,>Y"4DTC4L03D=I,(TQ\ZM^
M'5VB/F"WB%,.+9D)A[0<ZY]*LK(JF%O9_EX)0:]XY#PNE[10_"6F477/YM,I
MH$9'EY:CM-2 ^= &S#F\'<\\7$<E0MX;^!'P @;F(SB5VRKM#*ZS7*=7#M@Y
M@*Z\+T'W:';GKB=2WRX/AYN,#MHNW,>TFC ONZVB$,AN&W$NP>?KL+R-);3R
M+J3JVC&_]5M6QO9[?T3('GLR=B-?,G@OU(>U)_,IO.<KQXN77_7B$(;:D7WC
MSO'Q7YZP$&_6JJPL[K=#)T7[O9V#PS4/>IO@9E%;-7;5KYW%]=D^J*X#)XMW
MGCW;>"Z#O4.W!H/A!E-Y!/?JT0B(3W M?*9Q+]5TS<EJ36F3OG[NZ^N/_Q'-
M%R]>>4J]+*LY'<($N?@LB\<<<H+?(X3ST?C?55+:0-2[*,M/+[/X"T>5:B9'
M[2C^GK$VTO?'[B!C2=R0C?&DH;)%#E<M 4W%8I$FX\B,]7_>[0Z.C^R-6]*K
MEX9>_N7[O[U]M3MX'NR0T*CE]"=%->-L.VKNZ#QDU30:+ZLBR6;]'H]>C"_<
MM&?^@X*&M2CBW7%*1NV8V9YT%?BY)_0@33T&ZGNYYH=MRV6714A\8:;5)"[-
M<WCXM%;^L&J\R8.>\[M2+''@3V:MH:K&8[]'UJ-/<D_/T#@.]H=!2;]$KH9?
M._#,1399ZX]\/#E=.\1.+CV@B;S)"Y$'TXKN0AS2,>:-(\L#"7'O[E]W]>G6
MHDPZR>32ES2+9$J7(%N2),BK)9>M-K/L_CO[O967RHVDMXUB=7C.$<A)\PN&
M5 P6-*M\0G?O+,XP<F3ZI_FX*OF89O6[2+<].6<05.'<B*.,?C:M4GKC&8VM
M]LI^SW\G&6/G"7Q!O!=7$R^@V<)"PU_9;Y RCE(:=C*EGUQV)_WK.5 <TQ5S
M_&?#KM+%B1[ @?(VQM+>.%VQ4<C7:)J)1(.\>AG2OW[E(:F=HRN<F'ZOQ41?
M-5_JJFV=!L6W(PBT*I4.4I@F<3%/,FNXX*].X\])624D!$NQW-D,BFQ2[Q'L
M\+:*#,/=(X?S#9/WG#!YSUN/O*>3'%_K7)U ;'@W+,JRBG3NS% N.8HEKMXC
MN<+FC*;<?XLYL'KH&=E9GNV.H_+,O6(]:Q- UHN9<8@88]W<:[+>R:H9P>J(
MT4*SQK/:,(I"%EDPSPM\B1Z8\T="F@2*BTD:O2.O*!@$N\'[8D8&S&\R"#:?
M3JLY;=$E/GKJK*_@9#PFEX?%[(><_"AC +VF)4+]L_R)W_N4WFMN01B\_6"\
M2OQ W*"WV3+*9LE(BR8Q':354$XG-94D[K)Q@CQ N:2_P=(]WDC$-16*!UV%
MXNU6*!YT%8I_P@K%1Z/ MLQPD"(E;G;O]UX;-/BW@@:_I35+-"%SG+;.D$/I
M$C.]<-CT#:A>_F:H7GY5JI>??*J7;9SAO>[.75_X5QI>WJ"(B?W((H$^FP0[
M5\70$9*NH#=R,A;HAZ0 )_P=B9IS_.J)U!"X%,$L2B3:GGMT),$H'D>5!(K9
MDEO#(X1_:^$2"FB$'&GC-"/&9/[Q,ABG9$"3!8K&-GD2B<ER3"XO_.YHE)_'
MDFJ(U0R=K'ZTC-W#=9__P(OM1VR)KJZI)C^]+%[]E[9"9-#>,9B49<7%&7 U
M@HPVW:P!HOQ1L?0,8-;>L!@F\6AI0P/XT:4QB;$_*.*-QF+1NV(-^#0<2=2$
MR.KBRZ9=N;KB.%R?@<0O<!@VX(WJ]_S-YK+F0V\U77B$!I.3S8\I-Q)'&N+1
M8ZI=5G3TYGDF!W@/)A_LGO124Q<I>5&U,XYV+CQ]D5?IQ+A_](/:KSF$79L$
MGF\YM*%I ,.&1+P47#!(>]<(]#0N6;^W,H#Z[W_O$("[\&@]I&V<R \B%34O
MLI$DY.#!"-=?0GZ("T;CL^#?%8D NG\0/@&01H;[+W ER-78E:O!?SD 'DB9
ME+B>"<DZ\IM)_- 7/L?I)8VCGEIQ)]!+LM 8"RL?]/1*3L<,(KW43!U'35[Z
M7ONI==4QR??28H[:LA%+W!Q-"0L24LF8/8A^3R1':3ZTJ$9I,C:7W;_?>O,Y
MC4-KEU4LCIR,*9$:*I>19!:C)?\J1KAA6EO![H)\/9/,4-/U>\;X-XF4$/VQ
MG9WYU4\6-P*1@H**'CX%,SMN)J L#5J59?/R3,4K+5(_C5)[D9J.2.H?'O"G
M&J_L]]95SP>O-OLXAVUA?L63%>/*%O=#!DI]BZ^'>5B\ FQ*K4R_U>KBIX;[
M9MV:4_67XGH#JVE+DA6EZ6I]ZX@>YZ0Q(L^C*(6->2\&0"?+-)H1O%4VQNV4
M7H_&T/*I,=F_2.;P!%%#T10JY5I!!=.BZ\WYNF'"GY)_5\F$+$])G?Z88^O(
MPAS'1;:-0<*1W8E[&?M])$[;0B2L9\^B21,-Z:E748'Z45)4>\&O^.DY/%W&
M[84CC/_ 3L.#1>T&AX&<\X"CP(\@1# >5_.*PR*H\R*?)5E*(>'^@5?83 Y
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M8?#RC'2=L<"B:GE&YM9O-%'YJ<!6L$D8>NS(&B %KA$8$ QP/;)0 !IQ3*Y
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ME7"3Y!E8IFP7L*:QN=.W0:%B(U2K>@:]:@!\0 GV"K_+CFA:F/>([C%\CX\
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M>?!?:<3YDRLOP!\[QNN:4V]O'P^>W?N)7E<<_P".\1!L&IZ"_T'QXD[/XAA
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M<-#2**WOB%-F?A+:%TH#3;]'/B\:30IZCL8E, WV?I2U(G'<'QAI(9A4!"N
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MG-461Y.GH#\ Z'TU>RGX#P]^?[:?=&CG]S;.4K,A3?^\*?9,4S1O!@DI)R0
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MJ45V3I%6]AR-&W/$1LX;0RX[4P2U>!*B[<AAFE,DP%<GK(X4<TEQGP#<)R2
M\I9I(8V&[$L.QUZ-^EJDPN%"&U'%,Y8VD+KNJ+=D]18;;V7)'%9?D-%33-3H
MWTF&(6%SKC/+#[^5S@MEJ_5+V*&X)>QNTC E^XQ"#LM,\&F9'C[N&;+/R^A]
MYMD^<2)M[QVI??UFSE/4")&"9^Z/J[>49+ABR%5\KP>BGK.7W9+CJ:,2KPOX
M_2>Z^"%FT&,VY[J P2S.!+%X3&[BXNKI33 *W-#$NSNW^%C]2#['LP7Q@-HD
M*91]))0?"-D!4W]S?.BQTRF6#XOE6%Q#@16S!3:;3WD[:CN #[N2-X7H0?AH
M#P[)<2Q?.*!<#,P-<X65ME4=62C F<JIW2<T'EVW&X5X.@7V]JLT9*5NU1MG
M_K#B-/_FQ.E<U?,VK'\(KVKTD!O.GG+C8D]>XU6M8O #.E5K('14GTH0V'PF
M-;L.A/!C>52"$'KGZ)M'\8K$2UPXCLB?6K7H.C;$'SN[<A3U+W!O3OW'#5'^
M8! -]F<JGE$#C TE.8V^3_!>Z :MQS(Q[S3Z\P59G=GSI5SX\?)2N[H9'"]5
MY!P<;)L>.3K^)!A!6'J -+)/#W\>.^>GGT@DR7D69VX#<J@5LQY%IUH.6[R_
M:=^VJT86LXACVNZ.Z+U-W75J<5?<;*DJ#U]PNZQ58Z^\?55Z=6NB.5ER6;.Z
M]4T1BB>[N43)[J",;.-G/F?HNBDJ21"PQY>O$4<6,JR8B:NVZQ4:S$>4E-'%
M&3)BBO!3T(TQ1QUB(X-D*KVX?>1"&G5(+D^=B($8'/VX\(RT"TDQ?D+_JQ?*
MI)%.#*.FH?>1:1*!@4WG)Z6'S,YL4.SF,BV^D)DJB<CLP@UH"Z\_R>-D@L""
M&_ONP9CV15X3 Z1IWD@DKIA-)6Y*<(<DN%Q*<'O[2=MJL$14/A8+;"[[!ENS
MXV:HU&9.*D.=#*ML+H DH2X*DN;$ /_":NLM_'<#2PIDXM_UAI*)2@,#D2 E
M-IK'7[.9?A6=Z^;PB+UEY.".93RVC\Y8.N,=GG%.SWC'?TUTGUHND0C:S.$2
M^$F!J)?C*&\O"\CG? (AWDFQHU\_[VZ;#?YVZ)5'[LC[+-.*KUAR-^ =-;^1
M+118CDM+)P^(_H-C?LD&R;*%0HKR4T!Y/"-,V *?87DA)8'(S8C,FS,C3H>I
M]F 7@3NLD@SVV8J>G0:J0"%^:TF3&_T^,A1M4-9-"RKVUGIN]\I3=7K_H/V<
MH$2D.[R;,)(F,[I]%XQ1?!G(@*2^7"HRMA/";V]H2$IPQR2X;-I/$4%EPZXJ
M+5DU0VPQQ[&97%S# =]DY5 VG?Z0>/XZ,<[9:& O)XVN=5GI8RL9SF2&S9,\
MYK324Y<OB!7Q>'F2P(HB9N2_3YH]2<7)'@(Z+31*">Z@!)<6&L51%[&#BDM"
M/%M@A:S(9L57/9W].'R6UA^=%)^=$ <%6^#BXGXNF@:H3,!9:6*719<)*-T"
M+J^._]K\7?OQZ_;W\)N4B,#VW "GM&P_%1%AA6[N+=<B53<+ ']^T"\!8JU!
MREQ?][]GN$:MO&)$VTH.CWLUTE9 .FXO-9M-*XWB17NP<CQ:(_6KWI'S2K =
MBTN&)3";3]$?O6V0>7.VP:DPU%ZLDCUZ<9'@,[Q*\L/$M(C?V=97R >BU,^Q
MCRJ#&84TDWBS!*Z-,7%L;Q"VLDS%0C8<*8AO4$\?:.2)G9E6EZ>_5'0]_9D[
M\HJBLRY<!:;EN'=Y3=R0NF;1B-^TM"@EN$,27#XM+8I$WQ](HR7!],ZR0E%,
MN['C8,:T#NGU,>,)L5FPX5[V&>[0SJY85[II=F:3A^_CRJQ4>OZ1/4P^Y#,S
MEF38V'I&'_N)X3]FE_AK\9YU9#%PX!50V^61(9BCJQLR,MRGGJL8 /39C*FK
MBOR9B9)]MGO;_N95(-"BO5**E_U42=B*J125*8NE>-F)Q<+6B*6H3#PJP^XK
M2U%Y+%2NZ#QP3'[/,-W21;Y!EJ1H2*Y*AH;!;D8USC[/%HIYEA=#+Q:*AK06
M^W=2JCHD5;T2L@GT \7SP.*7A6J:H:YB%)FT_J6F]=0)G*ZI&W"'DF492G=B
M25T5M?6ZK@%,#5U5\4=J&+H&,JV.4NW,[IO5I_-2AO_Y($>8MED$E1""!\XE
ME2PZD"RF@GI$-C BSS)P_Y 8"?.:75F-/)N1]0F&:$2\YI5*5?S()24VC8EE
M6I(&UP,\G>K.H!KW]7*2S[=NOV7<6BL;T4O%5%N"/4JKI+"K52+$;Y4DEJC_
MLXWN.! >P]9;IG@,+YS$PPFG@&I-6:S\*8_/7THCY2@29'WMR2(XYHV7$A:@
ML9=BBFQ6*+)<^/U?*>T?1X9MKF+:VZ2+E?R6\B8B)$Y"5SNE9/>VR2ZVXE0A
MGV&Y?.@%/RD='H4.-_C_!R3$F.)0A0R;SV38G% \+"6&C4.E1'A\8;BSF,NQ
MV1RF+S%S="D7'+&Z.%S$:E;Z>E-N9\[_R-Z\>EDQQZHT_<1@R&"R.&H BZ7S
M64Z=*S=YA?QK#5E90G':S5WP%X-ADD-6Q31DE6Q5$Q:/:<@J>N%4.FK(ZJ*E
MRKF1>-<SU31DE8:L3EB&)<5E2T-6*=FE(:N4#M.051JR>F-$>&P:?#4A*_P?
M@ '^"?\\]G_]$\-S&$-M981,IHZ>F1M])&DL_07+0/"@_YD92<9 P6?@@DFR
M+XT4=?IITU-\Q^6Y@/..HSC?/-!Z"- <Y9G;0_3^G=2##GM)F\**#TVW\!.P
M=<_@5RCX?0-#4IFQ9%@PI]@:(A,!C9':0>Q7R4Q?T; _I,!P)<?1,C^>%A0"
M,8=/_7]G9\R%@E3Y$].4!ICE6^C/!&'G[Q.3$3\S9##%)T;,,F=GCJR2E:>U
M(F2N\I)>T?U$CM CH6U\256UV8BP)/P;'Z_G_'O^'3TL!:2QB0_C_/29>59D
M:P@WY/X*N#($?>UG+,98+7T<R*O!3684&W.OPY_U0<Z!V6>F/1WC]Y<,J:OT
M/C-U+/XH7.LZ # C^K_UC_,U^)/'_ [K__L/!G00S TD/9YU$99T^.%C@C0;
MROA:)P3B.7 Z]+D6"G[@ 50I4:82<L\SG]AIN_;#(()F/G0X+NM>X<=MZ:IV
M6:V_?]?^6KTI-:NW[5JYQ3*U>AG+Z^[IW;3<J+<:5[5*J5VMO'_7:N/_7E?K
M[1;3N&#*I=97YN*J<=<ZO:L%LTDXH>5$3D7NO,/S0F=6:J@WE=)H*C]AB389
MX6M,R2>P8';4-7/&E/T:W?T#6?55ELPA<Z'JSUZH,SS4P@G/#VX><ILLH"_9
M-R<A/2%*(/N,P#:'+ZGRRFYHW_<]IP.?%5#POP^"!]=,L00Q9L&--@LDVCR[
MNOES?S_Z<9$?B>LCPG,&0, !@T@+7A.RAV'IB1\.#IO%2/QLK$^^WI^/U;Y4
MC 4V?#2PL9V+U5K[T&27BQY:%[H!-CQSCR3#9*J:C-G=UZ,1)2#G&/K8H!3>
M'%,FG<\6)V;X$WUU9('6:1KZDX(I]'QZ:R*YIC7&R) L_,)2SU*>R$SV4M>T
M(!C14<YA<%W)J(W:?.]BE\%U(89K;  5->(]RX.YN&E<,XTF-K;:M?HE4RJW
M:S]K[5JUY<Z3"41C@)=%'QU,- %QJ,T?#'I@DDZSF4A\8U44K&]&4KW</+^=
M/2C%SFPTN:C_OJY9OW\-(NR%LRV6''A[RZ>'F2DJF9DR?T_[6\)?*YAVP>$+
M?/9_5CR4S_T5&(?<KT53H"V:EDY^CFB3&,]R8H;-98)2)<%W"X3$WZ</W@-W
MP&X/W&#>RZR:10K3G;2>HB+, 36MIX\07+VM;RW".1X+\?N?OQY^\.8DT^X>
M:F.$[S:P:<UP[L-H-DO#;^'G'KA"$QA)JFB,[ER%D=R[?$JB*$W6:38/NJV@
M,4:!0F:+X9]59-'UB*41Y$%FY/>86(1YD=_G1K_;CS_:^LLPAO9GN ?U>(/X
MQG]BLC!;\ATU;B2LET5A@!F]$E@03UF!S0;FR)-!QC%!,+IAU+S("H$E5OLS
MGE^JN\+Y"DDFN@'@-/I8;I=,$UG^ZU9?8/@?6F9"N=G+M>Z:E=E]+Q[A'8X?
M_6>%$!;!\YG>/\.RFY'@-N9Q:6I;2,?-H8(@8O,LJ)KJ%#@T$FA&M[9+R+)<
M-J@.8W]NY>;]GR<%UMI<Z$9%GW2M_D0M]7J8H2QSF3-'UJ4RZ]W]J?XZN'9T
M#@6&%5*>2!C;0+")!Q+-H"U557^&FMK8N7*SX;X2I ?SE+)%ME@0=B"?OT\-
M>C'LJ\Y@3R@3M.$D)/""V:[@8[N:]H0=!=V8WAF8*2KZ<X MRE6&0^.J?3F[
M0\=4@^Y1778[KIQ>!EWLEF>!+8:(.!Q+K6U@J)#PBB&>P!587MS%X%S+1OY&
M,]CG B+?:?+29'L-I^G;\=(PRJJDC +4F:0,,KGNC!N7H]Q1$HZM: D[_DZX
M59(Q<URXYJ2L$# F/1E,L($'MJ&38^T$BB2P[70X+F^F]38&-GTDYJY87&*.
MKQ7EH?&[4"B6,L=4/W 1VD$+/MBS?9?3X9B :=!)YI@5:XW7$T_,KE"QL&(8
M?[2IH."]!,N,\9#/O3QWN^K5[X,KC=7[K(XI78,!%[=5EF4SA0S+98+JR9/,
M83M [2";+2()OZ]6/_[%Z*%UD#&T)C^4^UZI4$B<#F)&OAL=41&Y58AN;>&6
MLCT$9N+FY5R>%?-!-M$X.<P<".>05H 88#=O>[5@GO,/8[S4=?E94=7::(R1
M#)E(NZYA@:N>?MT;AIZYZF?%@VLPYXPD9-=77K B(Z%T1G$/?5RQ' S$N!D
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MD58_Y30X:>]:2"[#L;RP?>>"L)\(3;%^FIHS%-KCZGA(HXT'B#:V)N.Q2LJ
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M @!B_V7]54,&^&OU"U^(OV7?5& %46 +N:!)C81@/9G+T&,PI3.><<_!D(/
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M5V_BKW]U*@!\Q.*&AXA<#_@ ?K\\@6E;0>>E[R1&L_\H\_7)]!PZ56I.(7E
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M+"EC[7.CA7>(PN-13[&_#Q"7";,41W1WP/GHC\@1I\7'$+PUW.\Z?5T;F;I
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M_KF<#HS90&OR5,LF.W7;_=7O;:M"K!]F4O6KYLU%DBA$/G#J"N-C5SZ ?OP
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M(CQ)4;JZB69K576]!F3T7(V)OAV0?:>:XPEJ3(K_;#N<V%NCZ)FPZP7NQ4C
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MAG8IT!4\P(&(&G/H/,0G)<.AE)9^GT)=$C,8W:FVWE%'KLXXR>21@>I!QCB
M5IOH6@)^L[L#V*?((,[CB&", A*_.O9#D$+P*(J_I7<-CRI:'$2@NPSLAG(*
MH"''A "G (C8'* !D.E,*6L:5@_ W;D-^CPA,$X 9!K;83!(W1GFF0QG%/;S
MLZ1<H+]3!71;AG*E?&K)36G)61O),5 [B*P=ODV4J0U+]ANW@-E^F_]\E&)
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M\/MT![U%=B;<9/ 2 T<4@H_N\P(X'[ 4==.=H?PV+.HOQW B[,7_MBD3MNX
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M+($90]?/=##?YZM+N8YYSENMR5/O]KEYDU(OG/?.33>3N]P;/KH7SE WU'R
M2YN.^%-9;AY3N=NEAM#N3GGH&*9"[?QD\/ZH:O80=$393U6\8BGNKG(S1,W
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M8Z5R>5-KG%<NKC?. BQGW86S\I:>R$!2WLSDO2D6X/@?6"D3U]+C*A3^L])
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MMYVAS3,1 ?/4'K&I'C(DLFL*EC=C$$+DY)<8U)E4"HDI P,$\R-+P))J(6M
M-,>JMN!"ALBU[+)%Y8-R 9AT:ET_B9?(+Q<NE&!&G*3 3!H=@TBQ=Z!4 %]
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MZM?R?\XSZ;WO5R"C^X>07T/SN/@D?*K(C7>:KD6;KD5'6@N*"X@@8U1]J$^
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MD&[D#$U]>H"OJ)TKI%/+W1V2FQ& \-WCE0)@N8/4\/Y'\O*FL#4",'4!6KT
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MLSJ:5%:G$CM6>N!T.^/DGZL??]I_?+NV*6^2!,O#P82#F,D@\8^(14DB4W.
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M^<W5ZCI,W.BY7X==FT^7$IG"2XKDY@KE"BY?)[:M 7]1Y 2=D?8N E!LG/
ME>C)1?N^49[\[I:*;Z=$9R>-S4"^8] S;Y3F&KT/7I3 N9Z=\D*!6*M.SR2*
M16*!I'.KR^><NZ^J:U+V]!&AW(N_2_W1*%.M_EZ?<D_/\J_)B)*0'A1";/I
M:IX^LA8'<"*=RB52^94K=CE'E&](5+F#7.^J\*OF/#?2FU.Y,U0C[]CV:]+Y
MLLC'N1Z'5Z%82N0W41FY?O5VH5.[X/*FG,IT,ZEZ2E^A7OO,5IT?)]Y0&N>*
M!68=F^J=Y&[.2R<KM";J#^^\<7LQ2==?ETWVK\<;I*5WE*%\K*N.HF.-_K'>
MH>B/F13-'DP$Z%('JJ9SA&M$C68P]A$DOD/@=0;">6<<)IE110:.\M0W.GV
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MA40AO7;^T*.I>]NY:HT X!"!A/@ECKKDQ=ZLW][UZXW';#'[DKT9/TS%-^%
M[I-@_'J;:(Q\58Z<J_5XR!/%]&OI#[=CIE[I8<H7$MG4>H@B\V'(EZ"G@SDX
M(@^S4;UYZ?WJ7M3S:Z(DG1X/18,9LAWTMGLF "\3.6OK/:O2:2(5N2@HV/>\
M?UXX:ZL[A%*I6&&YE^RE5'@O4>?*O#UTYXWOVADB%4UCC8?.3(N\'N$B^>@1
MQNF56;--F4[D8]@\GW'@EZS2RO0"D!,L'U9[13 X.WUW9'HPZ)H5VN-:J ]/
MJ _KM-?M-_]<:L7N>H[@30>-&Z&C'?ROM%-1WMQ_0TPYAFRL^TZ<SZ<2Z1B6
M^F?0^?7+ML+;=J902A1C9-FN*"K][I')PI'F]5?!-1Q RO+&#5.U/"(#E;\C
M X%[%U?%'0>.A_C-M";CVN@DH_[._AB_,O:_N=AS?F;LN=R:W)=.?]T\_LS_
M.$Q#[+G>J#2O[S!J5+F\J37.*Q?7GR5SKQ/'./'DQ2^W)D\W?XN/5N\T:;]W
MT>.CV=V! *_.QT(9Q[8N1NS'8PMD$7[<J>[PZOJAG8T7CXW:4>LN>_N,XHK8
M9U6*XI[>I(;%Y-WQSPMS"Z.X!2F*V[O]43I2G[-NO?,9Q?V,XK[G*.Y1G%/N
MQ+%I81.]@_<7OW$X!KADBGKN4\8!MX.E.V/Y28Y_/ASI=]KE7?&NNB;B[OG1
M8=$W)7 F;D,8<]ZBS;L=\X5IS5F7%7CJ$[E4,I'*+DX0_B!1Y:67([79Y<@6
MTXEB=G'HY)5QZ,H&%0L ((^(NIQ2*E?UN]].M=SY62ZM-:S-.S"M.-XFP+0"
MI3!C3E?@;"[E$L7,8L_,^PS=K6!_KV]FL[E$*O42Y*?%VSFYP>U\!F2B?6+
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M?M ];(7B*2#Z@-KI)Q3=ZJD]>,D@-ZPA@&%8TH,4K\5AM?TND*?R8G6.:"
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ME#H+8L(E\()!3#'$5P(,,-AF,W)(8FS!F&F0,U-IUK@I4_K-=:U:2OUI^JB
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M;_B]57Z'W%W_JZJ["CV$F=/GZ2HF%1L% 8?VC15(@&A(, ,*G_Y9:^^,D$!
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MC<KU=3/SA1IY@/?KRS*(AF5P *B16Q[CYT:-C$B&XZR4;O4+YU.M$G*@Q*8
M_Q+Q_*$@1^8."CGRP!DF*T^Z=\-V)U<\#.!(H-(7<.1!ROLOX,C- 4=&1)M<
MU(5R:MA-3E]RNP./#"LGE@+,1AQ#,7E(&(H'SJBYA^O;\[M&I?.A8.]N^3=]
M>/P;1>2\OV[#APD5.#>_?>]=]/N "HR(7A^?5W\+?#Q7?@XU7^!O@0O<?TPY
M[.SWB'0>^M72;=<[7Q$L\,#O:>DEDQZEU?'T_$/0T'\Q6&"$PMB?&/YJ[>]_
M;7AG,9L(X2/M#)7%BX]TX,JB^#(^GY2Y3G&0_L)'^C+E=F#*I0X/'>G [ZA^
MT^J42R\ZEUEG8N4GN+)KHB-]F7&[N,_IE=&1JO32'>)5JQ@9Z6IXD_WS''E(
MI"_NCQ(D$AL12*0#5Y7*6:E8>VFV&J5\&$BD#R(B;;/P+6*(2(E]("+-OF]D
M7ZA<(?XTK6IG/<ZXK+XULFN SNP?.RDL(I>N.)A<WQA!ZW(C+.I0#<'+.-V!
MP!L2:),S3E3O.,D0+D0X5[4[F)PIJLF+-9'KB)*H _^VD=)M>&=1 E[]YJ%O
MWBVP/O9@,'"O;VK%7GSX+O<._*!\\:)&H.GP&EGH4/"R"<EX97]J3 ](PHR1
M)LS (@I!?Q+A"W[X/(SD$(H9"IQFJ""O.-W])$4^/N(0<LI055Q'A]-$C>$T
M-%/FQG%M"47*9H5BZ6G:Y5Z+%YPTD0=)^P1Y41M)'! 9F%CX]JM5NJB4;VL5
MIG[&G!6J3>:N4+NM,!?52K/0+%W\8<[J3>:^T&P6KMM,K5HH5FO5=K72LE;_
M!5VU?2BE\, P(=][8R@^]5I+ 6U"+V/Y7B/_Y,,!VMHX=UQQZHN@K\P=NUM@
M"WX2>T!J>?55?G': 7$:\9L)ZN(!<UL=[(=#7M\AWH9/S+-5'OZ!&SE@EJAW
M-$$=^^7[#FB1M[*R_C*_&'=E>A<T39B'&3T@AJC*(^,S+O 0>76K6+9N7WDI
MM0X'#/-[31@+$L-N"- R2GM._(5[3OY->R;%WYO9[^Z 6K_]*G(2)W>%@!C:
M7)WZMC C,TY4U8ZE%G@,9&*@OMXSY1Y!3QW%1_$E8RKL9Q0G\Z%9PIPTLS+_
M!:J!R$=8*[E2R#Z4:UQ+N!QE[>3*F1.4Q*#FV[Q<#@V_&+(%)KFTU?. ,$"S
M!WB>">L\\X]C_;F2J$L5:9_GN;0E[R/GN4S(+#KB)1(O^-1+!WCJ2>O44\+=
M5,WFY-YK_Z.GOH1 RZL;%E%G85&#N=6G!3L-6;J 07U0* +YE[N$ 8<59G*9
M6"*^$LII**8Y1*:M;()IIS?WZ6FN.3 &8FX%[HHQ'0NM%U0YT<2'Q7!18::-
MMOG9,*VV;[4IL(VR#Z_9Y^!*%-?E,J>[RI\(NAIA/A-?;5>FSWE)D.7'=.)/
MHF.S]3*'U*X0<TG/C^C)0X1*.>C3LPT=OM7/&)<%/L\E]G5ZJ0\#E*P:?0H7
M<5IRU&Q$CMJV;H1"\^JR=\&Q+[T/'74X31. =>A5-6'HY8NK-C]P;R=F3RZ=
M6ZJC0G'57-ACIZSKYWIMA'6GQF]63W7DQM6%^%EXS%M"=F@<M.U T/R+JYIF
MD'B0TF,*TFC 65;KBD'Y#?-T/"1/6\NO]\CBK3+3O9E/R=^-FPOYKO+R[*!G
M!I-XQ0L26@5GEZG@#_AN.V6#5+38P+;#Q$:RW7TW>O549X]LL-2.C@H;I*/%
M!K:-5DI5;\3L^.J\EM\"&ZRI+0.(M%_#3(.= 3//ZM=$+)=,Q=*IY4#246'E
ML &!=5EY^G+Y+&?D2?G\K!MIGONHH;9[CMH*\M3L*X,1(SE19N!(S(',\(.[
MC+[G%XS<<+)U4PG6\#9!B>RU*B_DO:<1O^/T84JI&MW>0Y,?.\V5I?#'LKE4
M]8H&0WI=S+U-"M^#Y+G*H?*<;7&VRE?Q=R'[(%RRT>*YI;[*W\ISY95Y;N<9
MUK/T^[3?Z&32W>Q!,-VB"%(H&AZD$9S+9V.)U.I0*:M<E.41S(.\(\G-W9%I
M)<,.]6SSYO&V__F9>4O6]0Y9=4_ 7XO+YQ)K7*/-@#BL70WA%VGUK8:H[*$0
MKSO(-?)Y0[O./J]3PO-QNJUHS6161EU/[,*:V3.+^>56]\UBMN$\R,2K:>$^
MQTZZT6"QE9VTOX'%#E&*V6;R;9]CY4FW7ZL-]LMB&RP7VVFB/AG+)!*Q3(B@
MW=_(^\5-\/ZTD1A.^L^-W\\C;J5Z1H$")\\6,QXRTT:1(7UA@3Z&;[(GL)\#
M7_2N@6^^<Y)$7,J!V!TPG*IH C ;W)WC(WR9E:A!#!Q!' L\.J/"NQGEQ[?@
MIR@,%U.R\6M_! /J,&'Q=-@-X^GLB=^^\&Z^\&X.\LF?N#'^"^_FB]-V<Y!?
M>#>?]#9\8I[]PKO9T"*_\&Z^\&Z^\&Z^\&X.!A/D"^_FK]KS%]Y-U/%NXK,;
MVA8^2F(%T &K=C!X!,%FL^Q7\7[\+=V^>"FO F6P:7B4;)3@;D*GM'=WG'9&
MNY!Y& K*J]SHI_=YG)\/[<:O#6G/AV[GF-\JD\9[:UQL"1^&.-I]7BZ^TZ[O
M6)*-Q]B_!.QF$WIGVGTMW%<+M\G+0F1Y*RI\$Q%<F[ =F7Z8 V;GVJZLFU1&
MOTWG'^N75X-]8:)D#P;1)G_PYV:;,7KE,C-\+%;S/6E?YY:+)I9-<E. (+LR
M7EI7TF H3Z32V4OD<4;F1Z7M",(O'X_'LFSR,R#:%#["P'PP_TY3XDU:U[-)
M/??\^1CM4)EHUZ V7RW2F;7;57=EE*7O'TOMJC*L5(2#:+8*;1%\M:L&\%SQ
M4'G.-BC?;S/GM<GMGZN'7K1X;JGW\+?RW =:I'=EVJHY]?<9-V:UM^1!,-UV
MNDIW9O0&])VF8ME$,L;F5J_'_PN:I'.;NR73M[82%]\&0B.;_YO8.:JLNA5(
MHK4ZH^<&BQQ^7Y5?K"RHKVK7]O.]\?OB]_2L?WW'1J)K-?_5M>K#8:MTK>[:
M6A;3N<?"]>-OKM*+!H>M[)G]#1QV@#+,-HU_UV]OGO^4*_<N=,RHMT4?Z-B6
MOY'U0T\86\#ZT_S#C7+%BAWN;:U)8(?,HU'D/]\N://EU\904,7NK_]&-A/D
M"L6GZ;25*5:F+UU1X]=H\]Q[_RIL$/8GO'<E@Q=^_??_3DZ8,U&0^'^9!M<'
M_FD)KX8 =O>_3#KWDR&,\"^33#,G)]9UX\5Q>+>+[M?^1 ;7M5H+;;C&6)_M
M+W!2=&7DQQH!20!:L3K3A^NFG$6SGTQ[,H+W%U2XNMV?S#7<*DK7:P4)F,ZY
MO_6/]37\D\./%B_^]P\0VH_FJL"]G'0$N&WP\!$Y-)/*L*T(D=A#SME;Z4L%
M-_&0JI1P+G;>0%?Y%V#!0%"%XZ,W^"\C*XP.<E_K"2KQPGNB##ZYR$G@E6/K
M#@/ZR@T^T!'T-T&0F2ZG"WU%G<"A@X&BV;@"$X%3$>%#X.>ASDXC1J>H'N[Q
MD1U1<P%">([QC=,0R0%.B< [X.<Y8B;8H!$]51DRL"81SG*$!PI/<#[6$]4A
MJ'P0FD-1AD\;&F)#<,P5&@\G)4Z5E.,C31P:$OG\*7,&_#%6\"=8P23FAL5
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M=EXO\B;@G9? V7/7A8B@1] =]%X"]]6..=8"\"O1M$R'DS#L&ORX+GQY@F*
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MY(*^!"J=*N3Y,E&3>+RY&YIJ3YS.O8+2?&+^)"M(1[KOSH2I60]ID(=H/V)
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MS4AWG?<3.X<:_&:)5'K7X/?;&*^5B);71332?ME(Z[8SA>$E^U#YN,OT VV
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M@%@/_$9U'*"? !VKB4 S'(S1E"  !2F278R20.X8#(<9Y7@''"5)[) U7O3
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M;4GL9F<18 4'E' Y('P?,I7+Q!;?YX05'"!6<'@B^MQH?KQU2GQG[FERWQ%
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MA]K]2[':@0-O[[B#F%P_'_:HQ9 QKXVSJ$+2YQ+ST.U2G;0P(:,?M>CU*B=
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M@4=90L@@H@#TN*B22?^%\7'@K_H/>JPRH=X$1 H4;BFQR9_S,Q8L%%B'E9S
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M92CCN>Z'07;3-!:F2&?=75.1@9=V(,J?<JRL7OPQM$%F[.[=3-?1*+D-@C3
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MO"-!AE=TFG83&YN1JUHX)AED9]KM+FGYH?G$18YZN^:2/QPC:(=W9][;6,W
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MP!MBE/-5H]?@]F=7'!7"_+&SP//$#=?I8+F//C_X,K7=Y0C.__[W?[6[[9_
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M*_/VFR7%_&(6E=:VJRK:-5?1MJLJVBVLHJVXS 84?<Z<J=?^;&2R9_HO*3A
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M_3;P;F6OD!&0UL2-2/[#O7'4(M0=R!_4)"!]*4["J1LG0X&3)*)'+6F4>*R
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METRX'HGF YIKG%IJ*;;<0$%A7+#D=3S@(JB#W@J[_%$.U5%PRC8SJK)129;
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M.W:.[L5QZ/83UA> C!1*OG2ZC('TI@(H:1!)W/P]V18G6A;P]@$4]4B L@_
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MV!;#U28"(\O8R4&?\F<4$/8@\#G$'#6L7DE!$T4'C<HR/I)(J(->\51"7.;
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M:1V<C;+=K9_-%0X49ZN]TW%VS171:7;,%:[;<O9:SJ3:JT&37A%M7NF\9ZJ
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M6(1@^1"LJM%L-[OU4905E9UI;SF+L.CB %HH?OVMG=)/H]IW679:%X?];RA
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M%,VWK2U[H634?_(PY'[<8#**$O />N/\8A>3/KOF7X)0.1BJ4-(1'\F8>^S
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M2F3=]",,"-@\32]F8QEANB!-W]PPPF\P->NL5FE[].3*/SD=]T:,^4[ESTF
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M7/S)C0,,?*7IQ8\%T_XMV;^DS_[? 'X^3@"DGV0T2-CKR^0_@R!YPT[C/AT
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M30QG6/51%4.YMF-9NYVVG9ZFVUF$;%\*-_#[Z1[KC'@CYSX5/!+L5L8#X-3
MER^X[P[8Z?F=LW(I*ET44Z:BW\24UZV$S6Z-CGM8W;$^3AV,?MT<1&+*!HXX
M0M @40T5BQ L'X)5-9K(E.V_UT=7ID8S([@ZW5KO32ZP!1]D&,7 2X4*__[.
M0\FQN)?BLA(T%MCL-#%;\=K?CD[981))7T017#.42&SS5<#24MM39X[7H<=H
M?B0$"4%"L+XVNFZZ0L2V%,.-$"0$"<&R(UA5HXG$MD9;VHP- =MM^/R$^E\H
MC8@T*H?L' 0080@4^'+ 0\'.$W@OG^'.V:;F?'$PS*@^XWYP.?;%5[V=>:8\
MV%Y&I"E(O-P8HW3J942E('$Q$SV5!UM"U&[+;E.,N#)B$94V?L01@@:):JA8
MA&#Y$*RJT40J7:,=:V6@T@N5!U.468/R!-Y\X(T&G!WQD8RYQP[\"/X3$WTF
M^FP<?D2?"YK<"3^BS^0U$GTNQX@C! T2U5"Q",'R(5A5HXD>5HUVL9E+G[O;
MV^TG1*)_X1'H?+H7>4*;KX-04>9/(Q%RS.@&DHRT>5)Y&Y60?4C\OO1O,/5[
M&H?.&'=659M=#> 9(Y& XD:YPZ)G(]=IU6TMQR]\S)QMHM]%B+I+.YR)?:^?
M?5/P>@E1MUO.(^2[%?.>)][C 9?O1MG[ACR\D?X6^ =OF;7/TC][01P'0_AF
MVOR1NA%N_=O6%OL@A==_R\[YC=@':?Y*A.^"%+M[^^QW[B7P<<=F6UL94GWY
M)7M?+PC[(IR\X-#C[F=F-[L 711XLG]'A&UE\I3H@)CGC7@?;<D/KZQ7ZF]H
MJ9O]/?L.-_ \/HI F.S3/KN5_7B <%G?WV=9IZ[6/0[4;.]YXEK=,5&"NUT[
M\SJX-H=<AMD^NQJ/X/T'(>])=Q^,W5!H7,\"!'!W+W]7*[L-?YKV;M:S[UH
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M1!3Q4#VG)^!1OGBXU3Q2<JB+$4103 63>GN6@@$7 2Y#>3-(TVL2KP_/W=R
MQ^J1T,B4'?-%KL<H%3X!WGD-OK7Z$QZNQL\"6&&VCC^>(J64+IJJI\!OIG]%
MC<V-(;@56NVA+8 >BHE+^GD00+PO,HQAD*"PP?5+I &M>MZJS 3\S:C/@N&=
M^?B-"O&H3+LT@J/GYC1R<QUX\!?JI];C" ,\.KBSN9&^-!<N2J<]_'8ZG^EI
M1G_;5VEI,DU06U'(QP +7Y4XT/W[7XI<B$V;Y'2^?P$']#+S1&:\RP76FF\'
M:#Z6:Z+]TLO\*^BF[O9+=-.5C#WJHN>V8?<EN@A7+.9[R*2M=[1]I'S;1PC!
M=2Z1KL/XKWB:>E+4=87VI:;ZN6S@B.:#IXGZ0.B@3F9Y@2 X:=731'U]'DK?
ME2.>HGIGS-)6^-+9<'-;3_I#"*X;0?*B'_*B[XF\D1N]Z@[X'8QL6K@F%)'$
M96QTIC](G_L84]2NM/Y3<B\SRS0GD">]%'F;#'4MXV2\DUH5Y4I/QRR&R Y<
M-TATT)P\Z[+:=7-;3_I#"*X;0?*L'_*L#X9C7*\Z# /9#Z7[F=SJ5:,_<:8S
M#_H2B_F(&YUR]VDD,%5K:HMI(B!W>@D(8'Q/%J5S@YQTR@!1#16KFN;9W-:3
M_A""ZT:0'.2''.0+C.R&?7;09,?\B^R3@[QJ](]E*-PX(,^7/-]E($@';DIS
M)Z.7=,H 40T5JYIVU]S6D_X0@NM&D#S?ASS?2]GWQ9C]L\E.AB(<-]A/89.\
M7_)^S<>0O-_W>O!J\>9&,.F5 :(:*E8U[:^YK2?](037C2!YP ]NWN-Q/( [
M3YKLYR 4?D^$-^0!DP=L/H;D ;]/!V^Z>6QF!)->&2"JH6)5T_Z:VWK2'T)P
MW0B2!_R0!_QS$L;L1S">87)#I2O(]RT#AN3[OL=AJX7+C5W2* -$-52L:MI<
M<UM/^D,(KAM!\GH?\GH_AAQ7C"YD')/32TYO&3 DI_<]C-K)8F\V=$FA#!#5
M4+'6:7$G)_X8=8CX*@XM>#5]4.Z<]W-UOOVE^"L1O@OOW[/WV:<1'H(1O66G
M/(KU&?"J9_ORRP.F]O"N.Z'?/+EB6PDPK8J?KX(_7R5_]AUWR]O/E<&_ZT%,
MI]A[)LY9;?/$M;ICHK1W57'F=7!M#KT,MWUV-1[!^P]"WI/N/COC0Z&Q/0L0
MP#T[?U<KNPU_FNICIHOO6@!TAGG^-GR>[@[3E?5=JQ?TQ^K#(!YZ\.'_ U!+
M P04    "  \@Z)6#N8BBDM>  "NA0  $    &9O<FTQ,"UK7S P,2YJ<&?L
M? =4$_NZ;Q 0D29*;U'I(B"]$Q'I(@(*4B."TJ2#A)8H"$@7$%!04'J/]$[H
M30'IT@F]DR@E0$A>U%W=^YRSSWWWW7O?77N868M9\__^7_M];=8 _A-^!G!*
M4U5#%4!$1 2 $'X ^'& ,H#XV+&O)^$@(9RD)TA)24A(3Y*1'3]!>9*2DN(D
M!045]>E35-2TU!04IQA.T9ZAHZ>GIZ1A9&*@8SI-1T_W=1,B8@(-"2DY*2DY
M'14%%=V_?> ; +0G $O$3XB)S@..T1(1TQ+A6P!  ("(E.C; ?CI(#I&D/$X
MV0GRDQ2$!66G ,>(B(F/D1!_E9KPU(_P'$!"2WKZG(C2\3.Z%F3G7>A$'T>_
M/<%YI:B17J\/Q25VU]6?_"0#(Q,S"S</+Q__!7$)22EI&5GEJRJJ:NH:FOHW
M;QD8WC8RMK2Z=]_:QM;.S=WCH2?$RSO@26!0\-.0T)C8YW'Q"2]>)J:FI6=D
M9F7GY!:7E):55U1653<UM[2VM7=T=O4/# X-CWP:'4/.SLTO+"XMKZRB/W_9
MWMG=P^P??-6+"$!,]//QIWK1$O0Z1D)"3$+V52^B8YY?%]"2D)X3.7Y:29?,
MPN7,>='')^BN1+\M:B3G%--#T=]U[3O)P"6.Y$9_5>V;9G]-,?__D&:_*/:K
M7F, 2F(B@O.(:0$@P)%^(:QM2AZ%!S2_IM^).F-7?B 47WQ1V]-]_(8<VX6E
MP<1E@048AO\<Q:'XY)F!P[OMX7A N=U*>Z*FP@=[G=&!YX<<.S-.88K4F)>4
MQ1C#%N^'M>_FNAG$\DJ]EHV\'_FU>BBZAGO(S(5BR)I Q^4]9A3(9IU:(XP'
M-%$B28UPV\P5'.NK@!0A42&F0DE$9W+5Q#S:J!\2/ M^ K(<K1=40Q,;#TM$
M0+MZ&M3X/GAK5_?TE1:]^L))2I3.*?-@L3J966KSO=:GV4A13:E7$F4XM>4
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MZ[U)32M<SX54Z.D/J,._X &<^1]A=CI/< )H<2A'/]8S;7+UL\9\^X,2^B]
MZ;'\RP:*+^1WX3=%(]).ME=H8LLQ@7"LT##""AC,PON$\5K2K$U-Z<WRHJ<P
MFX*.B]RB]*SO3!S%&O==^JOQ@,AZ(00X"G&J%C3K%&(\\L3]$$8^/FDR;FQW
MG&_3@Z0\(IYV9$OF[I69B@+[G5N"KRNP%RW9W,*=!!3*OQSV?GRMWY)H'KRK
ME ,>_\3:.3P\8:99M#\@-1DAJKHHC53CJ4*B+0G(0I4F(3%2*:AG!5&[0=-%
MG?->1NT'$PZ3&XG834Q KAU4'F-Y*&9O+H/FR7%PR#;KMO7RE!AY'D+G262
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M>E&"M-C(-=?XB@ZU5V_.!&#9CCO8UFX7#WB,NZ?&\CK19'R'4!0VAY\Y]-#
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MJ1V-O886-S1G1+O9#DN2^TZICCA\L.I\[W&#[A7@1+O$\G2I9X2\;2[V5LV
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M0]I2'QRIVTT<N!U'M&%2A]"4\@%VU1K^[#3/[TZ+PE@ACN,!'W5:IS'Z4W@
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M%/5;A__+]Q"*OY_[""4 #?Y#NO\*?M;?S:"E/CBB;OU]&!!#5N9(Z+A8"37
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M_5+Q"#NWV"?FV9M\Z1GYW4V_?(G'ST=D\\,+Z__Z*^810ZBF\7]X X$E\/A
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M;S W@V2Y(A^:$BT6!JG-$*2T>U,20][)4<G4*;&]MYXE]1B$U%YA %%[,$N
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M5G/$UE3*9.Z'A<>W%SB?@>3I?79<S]?C21;QD>OV$'!A<WU.I,ZN 5(Y]KI
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MVY2G:X(Y0]?MV =*),+"XSXF&^,![M#OKM'/?O-0V?=72;-TU2\&[7]]HKL
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MQPV()6[K@4<3?,3L[2D-3AQE%Z4AEB&+3%D<^'#V8EO<^>1W9!V$EZIZ/G5
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MC]=;Z/291+>EKDX4)B6?TWV'PYLR;OA+VZ\D@$>#Q?[Y_$8%?_=LJ-2NVEG
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M/?MQ?J?/&=F ^=@K0/L/KF62R<_^_I[%3NB8*)E!VY!\R[H6+$0K)CW<T!Y
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MK[(?^7.+X#]YUT!GF>%R:?F/HYF)YP2L.-LB0=NVO9 $L/\:@QAMC)ARTVF
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M?R-.46/.J*EQ8TP/^[H,+#T+^_QR\RN,?': ^;'G^>7D0 %:#6O+02PGBV1
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MO/0$%[/Q8DNRBZCMXU4N4KJ1[*5/L@VP"]L+$$S<NZ3G%<]5Q6*"YJ'+/WK
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MNWB]\[(*I=3ME])+=LY?&QLR4R@J@;A_6.6/$ EF%#Q1-N2JMK)3 $\&K%X
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M<AZ$CHX.^42A4F*;[GG!$\[:JB@+>N""C:78,+(/[9M VT10RA7+W^^N-Q%
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M#HJR)82\ZN"(G%+_\>KL[8Z6 ,=H_H]7290R6#X"H#A*"N"0?^V (?^8DC/
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M)]KYZ46T]/1PE;V6R';YW:U*/$R3./%"FJ!SD/+3[S3Q]>D70S<<TE[:IH0
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M2J,I8AW<9C2_T\OHF/S$BJ"Q>TR;=L&8 (W#.@3:QUI (TU4YQK4I_%L?$:
MXS$/0?>I#N@446/1_.[M"T ,9!RVGS2[36]61 )ADO/!OZMA-)U^:/HBH&&8
M8*;!#4QS>+W@W'\=X7DZ2X;1&$4/_HSC=66WM/1L"M(+;D$&A$X#/7+B8E[&
M7T[SYOVT7+&6I ^S:-J!JPL#*X]5&G!JMKSR.G1IGE,S]@(D%6?'Z-!X6DDI
M92^':4&D0R*OG&22+_(1>D!ARH]'936=OC>0H+J*G!E4@UJM.?WT,Z[#(-I\
M%8LIZ,W*8&$6_E,QA6<!HZV;_7,HIM!UK[SH=^Y&5&PR?6_@;E=#A80R#Z"
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MMTP?*%QS=U#;R/7\#$=.=3C,GO+(/61A=VO#OBC'"019U836QWL.]\D4F?)
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M^3=C#1Q'UTEU)44$*K199^<16XVR5* =B/,,Q!X:VZ/H%HD+4GJ#U96.E-"
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MK.:*E4R1K&II96,R)!',Q#0(4 "8E:E??Q&!%P*(5X! A+/GUF;5545WQ^/
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M)I8$PRXEO#:A<F%$I%$E#B7-R%V<X.")=-_'*$O4I4_$HE8+TBG -BK1">3
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MB)-.Y!&H.**0%+R$2)P\1#K)0&I)E2NZY%91,/+MW?O'39"%HL4E+V)M3)*
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MBCLF*V7RL_,/3X"<^MLSKJ_WL&-U3MK7S<9<M:L1,#U67^0RVB*O9@-E,8J
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M09ZD.*_)<@@#[5ZXF0D7.Y1=G!/M4IKHPZ!K/]!<LA)B@,ZI*4^3.%]7EM7
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MF-#J0C@)XB*HL9Y6739\F.M;'<*[NM48PTV5P7"T*V)AW5D4, /(9Q;0@9E
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MJQTO03!N>O-6^YO9)J:I&3<[F=V<%&]GFMF P^1^P%4;FZ4A5+=TA1[?ZO\
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MK1*%/R2TH?(]!"54+<<9\C)TB[>8E9;Z\.X*D2_]#AB[BN(!LF6C3-@=M]J
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M'9>B029DK=.2 JRZ+4[".2V4L+BRY[D<"G-!M,-C?>L""JU6)@+<^-G:]Q6
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M5Q)%7 BP6$16M1^.S[0J,YE )H!$(B]+3/^!C(-PAHYG/UE@%H)?UJY\-A7
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MC'T%-?0ST3?23^LU)H;,>S_V!V+HT)BZ8I7E&0_':*YP2F8J?VR2IB4\;'>
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M.Y3!S6",#N@ $_E>@YA@EBJG!U.!V+;(=;&J,.'F$O/_?UU<%S0'JZRV:B^
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MF6O?GHI:B\*_UT4L_78R</**[C/ZI35>5'4F?SMUY;\JJS7.FICJ/\+"R2\
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M02HG0\N"[6AJ:KU@I]-IM%-5)G*4$.\G...L3PH=69H! %>DN..V:?Q2C)S
MOB[#/IZ2[R-1,H?_ZHGNX".#76C;[N)["!L 8GSFG&![.,+\7SE1'1T)>#B0
M3D8-E)AS^BPE,V;^Q(GJGJM QX$4+UYQ#V(HMV\M>S2]Q)L*KS(V)O+?.689
M]45Z_D:SW/]D?[^O:&V%9GM/9J51DVJ,=_.9: /2L]F'9+C1RP\@]0OTP!3?
MX$'NRE?.D/P.^2_ZI;.N\!C[6)2VY#P(WVRU&OPYWDA0+AE!O%HZ+CJ1XVT(
M@]0,E_?-!@QKR8[P:.N'":A.[0$JMBLU%O3:^$M^%\"*CC)<8_$+D8NN?EY-
M2*=Q,,:<=<K$&:T[\X'S(4O0*ISLE-4@L-'*XA]VE@?].!;OE>+)"H!RMU!F
MP+@0HK $I264IJ?&9IA -,C)F[&ETP#X=,Y4.2QC/,@AOP?(WEIDF,N?G1T/
MIZ.M5V6UQEG35F8'^V&_>-H::QKH\CJK<!$ET4$&E_6UGN[6?V==G@PY#0Y@
M*">=%X^F@#D;4E2I=%PH]UR9KW2W/L\WKXD T&L.32$"X)ZW/^]6Z080BR'U
M"Q8S?ETX^=7$[(4%1:YAS&K!D3[8T4K:/S?]QOZE2+CS%_.8[=;LFQM% G0"
M^_.JE[1_;I1#[PPIR$ABQVX$P=+F98J:259F2$ "&F'0WA&"P9])NR5:?S5<
MUQCO#J*+FI&\7;;&H$%?7$#2"F99ZV'#")PA38X=E3-::^ 9(UJO$Z)0OQ2I
M6/RT@-R*@)Z_V7;*282.1=RC_$^1O4H4<:J(DXWB0<,O],6TK+:?D^I?F)58
MV&RJ\CW)92N@N\+@4_-"@V+=!'*KY\#[H$>S;W@L&$W:+LR[\  $T.JS<:9;
M*B+@30 ":9,[V?DA*C!/>'E9^-, 5G"L$1_ Y20X&3PF2FZ08*=SEZ*C]/"+
M09*=,1,)I]<%S\X^A!X;/@-H?SODZ ZIG\IW60%@]N4C543%D7M(131\YH04
MT36Z0RJB\MWHBDAS U<TN- \F8YF87Z8@,[:0(9=&F#L#"$(0 D9L/0'\H&'
M\KSBRZ9/3$&\#D*'BJKQBA-9Z+M0-&;IX2X0J00@0.904WM+=UTV+)H=H0>=
M+OE=  =5E.$NH,&F[Y^(!BOC&MR_O^*:_*,?^G+[<RA/)ZSYDZ=B@541RENL
M4DH\S8'<60B3Q5/R79BY'W&!UYFY *$;!= -TI=3+39 E)@0B"QE6382^DD@
M1VLMS'GCS4Q#Y&7!@">N,49MTA+]72$)2[X!7.&4+/T\0&A^F("$%\BP];5$
MX$.6YF.3-+2KT4VYFB13'WR D@UBVRI?1H5G1E,ZD.4LMO\IJ]:)"< BF\BP
M?=6*DQ*P-">(\7C6YN3E"%!@-!J3V]^RL)U2P8:56)"QF_80GU :@$0ZF?6A
MC#M"?87 01D>1NW,7( Z2GC/4*WEB&OR'X/VH*YUZT #).@0;JWKMQ-C?<;^
MN_LASG.%86Q*.+6CXJE/<Z>]B<(4_IYC<:K&3DD#*"VBS&.G48<T2JUWN@0H
M@0$9O+!=//L+55!1WRICR[4S1D8J^KG@ 4K/R::_P'ZKRCJVA+HCAS'C=90R
M2(!2L3#H=6""$H5N]WG)14>#+"0'MUX2,]BT4.2G+')+.;X1%,ARLW#J)3-S
ML3OU3S?DO\B?Y9_(_SR32PCYR_\'4$L#!!0    ( #R#HE;*KX5@#WP  !9O
M"  5    <6QG;BTR,#(R,3(S,5]P<F4N>&UL[+UM<^,XDC_X_B+N.^AZ(R9F
M([:FIZJ?9W;O'[(L5^E&EC22JFIZWTS0%&1QFB+5).6RY],?P >)(O&0H @E
MZ-+$QG;9!D!D_A*)1 *9^=__YWGK]YY(%'MA\#_?O/W3G[_ID< -5U[P^#_?
M?%R\Z2\&H]$WO3AQ@I7CAP'YGV^"\)O_\__^W_]7C_[OO_^?-V]Z=Q[Q5W_I
MW8;NFU&P#O_:FSA;\I?>>Q*0R$G"Z*^]3XZ_9[\)[SR?1+U!N-WY)"'T#]F'
M_]+[X4]O?W9Z;]X QOU$@E48?9R/#N-NDF07_^7;;[]\^?*G('QROH31;_&?
MW' +&W"1.,D^/HSVY^<_Y__+NO^W[P6__87]OP<G)CW*KR#^RW/L_<\W[+OY
M9[]\]Z<P>OSVW9___/;;?]R/%^Z&;)TW7L#XYI)OBEYL%%Z_M[_\\LNWZ5^+
MIK66SP^17WSCNV^+Z1Q&IG_U).U+,XF]O\3I],:AZR0I[,K/](0MV$]OBF9O
MV*_>O'WWYKNW?WJ.5]\4S$\Y&(4^F9-UC_V7HG?XZN][Q_<>2> %+L/L6_;W
M;P<AE4DZV;3G)B+K__GF=_\QH!]X]^[MNVSX_SAIE+SLJ&S&'A.M;WK?-O_T
MC>,S3BTVA"2Q:@K<QF:F,G,B$B0;DGBNXVO-B]NSM4FRY4.V] /Q=#W=L25/
M92KN!RNVS".R(4'L/9%Q&"N9J3^2$2(&&R=X)/$H6"2A^]LF]%=42PU_WWO)
MBPX%@&',3-^)-W=^^$6+W;5.K4UM&CTZ@??O%$L*Y6*_W3K1RW2]\!X#;TTE
M,DCZKAON@X1N.;/0]UR/,,R'<>)MZ0259+3V@=9('GL4Y17%F7[E?4B_.@CI
M6HP"%26J?JU-L._2#\4>XYAJ3IRFK4UC%#Q1Z0NCEPE)5//@M6UM(K.([!QO
M-7S>4163"L>4JLMHL(^8XNS',6 GT!FCQ8F'5$^F L,TRXZM9@ S%=U:F][[
M,%Q]\7Q_M(M6!4-& 35$'KT'7[VR@=U;7!9NM"<B",>>\^#Y="6H)ZX]4'L;
MP2:,DB6)MK?D(7DS)SY5<"NZ_P.V+F7/UB;YV8DB1XNAXAZM38KJ6FI-)DRR
MM'D'Z=O:1(=.1'_Q&#,[:$:BQ89:=ZH)ROJTR,'MUDM2@R*UV=(-EQXF ?@"
MNK8VS3F)B1.Y&_JAL>>R!=I_C$AF"*GF">G;HE&G;WX:MS3+HKVD:S)VW-1*
M5W-.WJ]%HX+^DRR=9[74<9JV!][^(2:_[ZE@#)\@DB5J;X\=7OS.N#U>_9 ]
M+%@Z$+.EY<^8L/IAA @[&#D!P.8D[G'1TP!LLOHCF3X90.<-Z'RI4P)LREJ#
M7/[$ %UPC88S:)C#YJWJ=Q$C'395^ A&#7;89-4]+V&\0QD+',"@?0R;J:J?
M"5,4NKD).K3',W=#5GN?3->Y"1+/B4N\)R==#XGC^6KVP8<P,.V/,5GO_;'W
M1.+IFK=/:5.A.Z(]YF@^L0G3O@F=OW'#5/1!XYYS74IUQS$@J/2+L;?*+['2
M$^^:T&U\I2V?P($N3X+6A>1YHYK0?ZGUG1YQZ,=3A\[!>M'7A/#!#)!"E=9=
M&&T=]JB!_H?Q59L"]1@FSJ&ZZQK0U0!_#V=.;:Z*>AH1 O59LX%4: ]J1K[/
MW^8ON;,+SL^ZTJXYC '.%Z?J^HE:F__@H2[E5]!%H^%P9DQWF)N@B47?:.0+
MW%_JPJ4_D@&D<L<(M0SHA[Q$?P-1#&!@RG>.%Z4O(3]XU$:+W,T+M0OJ#AYM
M2IJ-:\;PVV]WZ>73@;]GVGX:XQGTU>FN$/@(!E!8T+^$T8*X>VHP5YQRVA!H
M#'815Z0N$DW&,H!)X6XL7(TW3NRY= ^X]?Q]TN#DJC>> 8+2#U&>I9*12OCP
MV?7W*[*ZB\)M/@UJ497]J]I4MO 1 Z3G[V>#QS%Q8C+W'C=)ZNK*3ZIT8S]I
M<(X";.U3!MAP[R0Y*-5YGD-QDU$OX:G7USO:0UWD&8XN'4W&,B!L;!K1$UFE
M2UQ?JJ3=36S![!YDFEHNC>U3]1A&+3BJ95:CX,9WW-_>Q.Z&-HNSR;S919Y+
MA?F>))M0?^<Z]PLFT&)2\89%V:3A$%3(4R==?E33!TYG.',GHW,/1L:%KG97
MJ'T.!8]@_(V>OEK5&\>$!1=N29RD5B,]+A+O,6#2&@8ES:YAJ<$',[([N"'=
M6GW/R<^*:=PA<PX?KGWGE-T-MHTFXYIQTSYY+)R3,K=TD]W$4PL8QX2PD>PF
MBG[N8+N>8R;JC6?BV8'NB@=T-?9"5ENQ OO+)KRCAA;MFZZ<,?W%21?RG)"
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M2C?&Z866WI[-91:%3QX%]N;E(]W>1L&AXF'?3;RG]/P#J K88"S@0C6^3"5
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M]'A@">#]59HM*(8[T/*>RHY0D+OE.X-2;PF\U$:E?-^0(*;:*8N]T;P^AH\
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M'')[A=%+?H?0=^FYF1E.9/M (@[C64= /^P8&JD<E4\48!X8N@Z;L$C@9C#
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M/ZIZ"@GJ; >8&D(+SOA7(O+,QY)GPWCO4/(#$IU86L*7?'DO:2?L,YN&8%8
M _ "_1R>Q8.2"(R5L /VR:DY3@H>&'IO<!_ZJ[3Z84A-L>!1^MI5T!;;-=V
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MX5H9XE5=K(-99D<P46FZL"(H/U65<?HN;#$Z4;OH14^^+@5\C0BZ1@1=(X+
M>KE$ZC4BJ#NP72."KA%!UX@@:PN6' J$#7PGCJ?K-!)#KLHD7>Q8!RTI,PF=
MI0><2#E!2E-2Z2]>6TN 4@E?-0D(AQ(S.FI!(N;0FP9D5OCMTJ]*]96J$_:S
M8+'0E)45C'1\Q95.\P8(3R%PLD[8#UO4\$"HL 6>8FEG^>U9==LP(*P.)6QO
MX7>S1&VUO+_P:2T]O<:!L#(MU38C:&X)9!!QK. C(,C,AE--62C=:$2-L5\[
M2R5&EJ#1H/**B?NGQ_#IVQ7Q,J&G_SC*.OWAGV/RZ/C#(&$%IOG*B;:J-;)$
MKL]413S*2E)R"?9GGQ9J%]KDM 4RXWD<J_'T=,:&C]&P,[2FCFC_$5F-+9)S
MLE ?="][(V==SDCD,I8_TF7[*4Q*S]4.#PNTO%&@\2RYC-5("G$>YSHM-%;F
M"^E %F]0PA!4CTUN\$RCN?>X229[IN?HF8^XE KVAFC@^#ZKSUEDKLX;2H ^
M>V!LMT23;+#M,--.H1@^4RWGQ606>>XQV?%A\I+<WPV'LR4(^%P!@#*N^UO#
M2>U ]@PIBAM65>1TQCY%-MT.8$SI/OAVU?:P*4GX5U5;]=X+0KK-O106\"UQ
M(^+$A&5'GY,5V>X4H@ > -LQWD 2-)F#;@@4 0F9P(Z";+;%K,48JOK9$A:I
M 1V,%>B(I7D2F*LS(AL2Q-X3.3X673K/8LB4'6T)\]/ #,@,.Q[/'GVFH^")
MCAM&+]) AI]E@0RCR:?A9#F=_XH=O'"DY3!5]4-9:2><=768TMSY<N]0[>TY
MOF03$S1']G8!P*BL("G9Z,KN,+O/8?3;*)A%H4MD802B]MB>IC-PX5)N#S!W
M7N#%FRQ.&@),I3VV#^@,8+B4VP.,-!KSM!6V'^8,$-J(>4S"Q/'MBG@D.\>K
M)<<Z2>PJM1Q^D8= #F?]T6UO^(_9<+(8+M(,S=/EA^&\-_@XGU.KHLCA?)YE
M(;@^/,X+0J;$E&"C-1T,J=96-L=10"?L!*[D>%5OB658G,-E[M(5,<%4W>#L
M<_=.L%_32:7>F6+ZXE<NDBYHID1[2*B)M&0SRW("GE":$Z@XY@KZH%D;K:\B
M-6?L "\C!@9:I2V:56(&+"XGT$$ZI:X@#H@:J#/:K8ZIG0O"J]=DBV99V\L)
MVV6VYP]_5J3?F WGRU]3FW/X]X^CV3VS-Y%=6,+,]&I'%J K=I"W<(K@X&[5
M"'8\206C*(SC5M&)'[\MG.%8'<4-Z6L'DKJR6]/3:D+Q([F%L[QY6=+/RL-5
M0)U?-YAE2M&CO,6DT8^J EA G>T 4T-HH3B6B3SSP?KY3QL<2GY HA-K1Q7;
M)^V$??&@(9C5EPQJ7J"?7MC-[SXA$1@K80=L%WASG!0\0,=HS%Y/L"=RH^TN
M"I_28+A8A9.T$_8#L>98 7AAR UZ3S_*#KW+,*2-'Z6A.X*VV$]Z&K!=0HTE
MJ^-N'P5>PBZ\@M6=]\S^I5P<LC[8Z9*;KPTU)]#! F\SC<T "^T 6_<5(47O
M(VFF254_Y!<\\!,^U, ^X0<Z;'W7W6_W/LL]?DLH;UTOS^B[\TF1AV\;1HGW
M[_3W#>I[MO<%:XUWE2RTS63,+/,"@X9N$7DN?&I+.5Z4FE("@T;0%OOMD3Z\
M$F(L6=Y"FJ3/D>2]K#V;-5;)_%=+B/<]O%L>.DE0CM\?WE9O?/BW//_5FPR7
M]N3\?=V7/H/0I_,.,P[W63SB8W;:I---*];P_[RD_XHI 2Q&!7P]U-ZW+'=R
M@B^2VN,(_I53"[34]"3/,=?F5^R0(W.KL>8";)-Y^%=C[$PZ79=F*K\,$S3_
MRH1 P 7TJ[$ZI0Z?.)5317L@.P1 *LS5<YLNB::2D/[FQ7N/VG1)Y#WL4WX]
M1H1(75]9"D]U1VQKOJ$\GF8JA?('_3Q6/OZ+E]9I*V0/F F#H[+.>%Q!AVKF
MO*1D+L,\I50#WY?.&-C>K0O@K,]2.X[C1Z.A5'XT?6TZHA\)'CUJ!D@?8;Z3
M/<)\/YW>?AZ-QZ7 G]%DV9^\']W0!LAO,4L$'VG-0YXT HPUA\$^KK-8PH2,
MJ:37I@L^AJO'L,,@:H2P\*BMIAK_""V9(^!H#.MM![;Z$EV]!081BW]$E<SS
MYN7>^5<8I9G"Y =7K4%>/\!UFM$/KY+9'N<Z<;;*-Y[: ]D!=P,QA^/-)]S,
MD?:6/!&?VGXK:@&N]FZR).XF"/WP\27+T2<]UD([8Q]M&TIK^6BKQR=#C]7&
MGLN2^02/ &P$;;$?J[4 A90+9DZK<924M"+]Z:@1Z0__G+,SF&!+HW\O_=D.
M[=5\LSJEQDS5)0BSA:)?3- 27^<IO_B\;,EGV8B9]Q3_[7XK8V>E"=HCXRJ[
M:LSDTH*B#^Z=9R573YN@9714<Y5'"[I/<!2LR+J-HX;V0%W7X$WI1J]^I)BQ
MWK&CT6!V0-]0]/7P-W($:4$$\G1O<\IXRK1-/UCEACGD]3FP.]C_;R[M5V-)
MKZ&LP3!TI5XX0-7>:_2[.!W/I2"=KC5LE]"B"!E0]\2^2SL#)RA;+,;O8TS6
M>W_LK27W)+#>V$_"C>!89T^G\\]+>%2*>RC'-S1:V<*Q+/;RG;'6%:S#C  Q
M*3'2L 15/^R")68D01Z<<&E+N#:WX;/K[U=>\*@VHV"]L</)ST!1ASTMZWR$
M5S$%1:-=M*J_AXEAP2K?55_&%*]A_JLWFLW_X&QW?[WE/HQ9V!.Z<GTC<WTC
M<WTC<WTC<WTC\SJ=UM<W,EUR5'?OC4P+3]43 LCB5&EF\<%9P]?,I1W]H)0]
M%A&_%\C;59IA5_QJ!Q$N[>B('$XKARP-8ZF36=2^^S< ? XT3Y'-ZJNB^I..
M!+%2;J=,R?CE,WY)'!/0 3I\KZ#))/3U:L'U4+>N%8370]<KA>N5@MZ5 E)D
M>FE2=1TE1EC5K\/7 C"6H",G$[H2!7FEC@EY3I9?B/]$[L,@V333Y*!Q.WR5
MT Y+.R89OQ(G6GX)VQ*(PW!HSUPO+0<5!G81?OKE1L]&% -:'(!B0 3*3.R@
M$-R%>UF^Y8;C6>Q=:5\$RBSLH@24+HQ;D8!T/.QLW)>5@/*=>[<DH+].2-2V
M&%0&17]N?3%AX'+3ML0J]' :[8FH'N#8<QX\WTN\P[,2_FN2[V5Y5OJ#P?SC
M4%IH>3SJWXS&H^5H>&ZUY3;2#[$K2<:)E#>.+RN^?+@,D71J,R0XAXL5.Z%X
MB5PPK"FW)792=S5ORY&_$F(-15P7JZ%(A_2!^*N[,$KKE<CY+.B"[;ANQG$I
M_699?\>*86^\F"R<;-H?8[)TGH5%JM7=L)W.S2!0\@'=M,@G.@KHKI)-35DH
M5](%V_6K@9*:&$L0HC8*H6Q,<MJ4\(C:8SMR];&14XX.3"XZ=':4";[6VN'V
MP?:W-EX\$@Y8 U(4KDD<4TXZ_AW1 $K4#]LIVAPL.2?,V@7\B%8Q&*6M5-$5
MVT/9S#X \:/3E]$%H>&+X[,#*'3AU3M@.R ;KS@1[>BZ,<^*]3E-&9V\Y%1)
MSL>"]MB.07UDY)1C+CBY_LP?!S*]+=>6)PW1G77-E".'6/0ED[K5#O,[N-64
M6DW5#[^DHO8:@K$"';$&8+6 DPU^"#4U9ZJ[)$P<'S^2<K$)HV1)HNTM>4C>
MS$GZ1FOF1,D++(CRAYK;^\-TONPMA_/[WNWP9DE_,Q^.^\OA;6_69X7 K F=
M9 3KQ$B*VF,'0YX@" Y_Y/6R(XA&CHLPLI%'$'XLX\FLQNKH15%[.Z"!"%T5
M( %!^#&)IR30#\FC#P7-7P<P1WK08PAK\U+%"@H[6 *-3,Q4F)C-A#T)$Q+G
M-I$TLS*O(?:UGD).RD<B,9WH!G;9X"J7L[EY*?]%KIETQK!D3>BK*QTBS21I
M;HBJ2GWQVMJ!DKYL2C SK,F<(%R\!.19KL:JK;!UF%A.3M07G[A.>[;9<A\%
MU+3?,Y_]G>.2_C;<R_P*XA[(+WKD)GZMW)R<;O0-Z<(7YI<Q#U2H@._*N[?0
M#GRX":,H_.(%CY S3KDQ]N,A+20EY'8:QE.]4<CKG.X>BR3=0DCD,E >)<X?
MG3&PWR*=H50AS$%7LVF2:K**[RCAIT[7!]D;6VDO[#=*6IA!&&#;0_'\QC/N
M4SOXR3MXR/F.\1]E[\$_]^?S_F2YZ/4'R]&G4<DMWLP9+BIU=?A^/O72/8;$
MX9U6?P)U1=K3V*I."\ JO-V5=LC'*CA;^5M;A1H+G-O%C&J+78+%V#JG-E>:
M1,P?6^7"+F:59D>:KA=)Z/ZF<&.+NW01CCH5Z [L\I14SA]>6\M@$(E6!1$>
M)69\/0L2L6OX8C.6>GP$;;$/IV(1*?M]I(2B6[ ' 6&1,LD+BU * \*L(YC^
MX7>S3/A!.HA/";H3NC(ME2H2-+<,$)FP5? 1$&1&*='/;,,@7= @Q21ICZV<
MI')3UD]*FLWHJ-=6F52J:[C51UNN2'>M/GHY9EZKCQKAZK7ZJ&EK;T.ING'B
MTU#T/M/ZCZGVNGDY-IDY+^Q7_2].M)J$P7279H1(MY6CFS:>[I,X<0)6H&2R
ME^<JOLS7L>\1A=Z4VAW'Y;!H?&FRHX>7<$5IBA(#$1UF6?"9L#+K9-5_(I'S
M2(;/)'*]F,PBSQ6E0,"<$+;!J!9<; Y9+<OI=C!=0Z2,WQ3]@A:$OXQ,2Y$Q
M*[(Y)YC5?RJ]<\).7+3%( S2"X&]X[-KM;<HNJ?)--%OCRW02,WA?8W&7K'L
M)9GPS7X5_7(<T;JK,5]?W[97PO-RNO9 ]BB8I?N$'7:=YK2P$YN@Z=)&\+U&
MW7D71FOB)?N(&[=N3FV<?!<[90NF_N0 \'5HT)QPVS2HYK2PL]N@:=!&\+U&
M#3I\WGE1.LQE->C)=[%3\.!:H#4 #.7*,C5YVW2@UJ2P<PPAVI#:T+U&_?>>
M7<Y?^.Q]^"9Z B5,Q5?A?'>47CKQV"Z=IS,G])Q0:#I/'[G7J/(LNUW^YSL+
MTE]9=</,.-+*[<\PZ,AINJLWS#JR^ZJO=%1,LEB<S[QDUA$!Q"L4V?0M!L><
M\YS=/@JW/[-^^_*GH:+S:B\QZCA\A8)849^?2)RPJDN8EW#0:4$%&/'ZPPY&
M62S<O(VA1%U&CL:>R.D+%1/DJP8M3EB)I>$#"JM?)Q)[NUYG-9TJ5%(1;R/L
M99Y17YYQ-:5CRR/?"(#I$2*"FB_DSO&B3XZ_)Q\\*E*1NWFY"Z-ZW@=I&I&?
M9&E$[OJC>>]3?_QQV/LP&L[[\\&'7WMWTWF17Z3%HI)?68:1 X:W9$TE='5#
M OJ/9.8[07R<> Q.MPT:IN/Y2?2(Q4]?4I_F<98UM<1+IP7J;DF4:1.!KJ79
M A&,GQ;EH'=O7NHJ>,Q*1<ES%$#[OQYHH12C)U<YS.Z>.(RJ[)U3;<JJ9 >:
MP]@!M)Y8BQ"&46PD-KH)SJ-@1PWVE+JWPOC>*HV\3MA1<HTD5P2BF"OH=[F\
M.;YK@MP[3>2,79N:0NY=!Y#[K@ERWVDB9^S2T!1RW[6+G.!L=?AR?_6O?9RP
MR1]R4 K.5/(NR 'N6O9VV0T 882E(:2'J1\F7#I038-;)RGY-U2@PL; WNC.
MAUF'5Q8&8DCI&,7QW@E<^K>^O]LX1>*D)M +A\+>,,U(@()S%@K"8,/\EZ-
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MEK1=V^"H$@,(FN,7=%/)F!P1RPS$?D2<Z7KL!)*J:^4VR.]<VW/AUW(T5/F
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M\N&#%=7)+_#VP7)LS0J]L"*67<\@FDP3O4JX_2JO.?I?QQTUI":X6;>\5<7
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MU,HFET#-0RW@%+H6+@Q<#2PE7=#CW2^(J9)SALYP!\*.I93E7E=9!_20F4L
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MK:C,V644;1+$2M)S5=F.]L&13P#OZ3:NR$)@P19C6>&&!S47'K2Y(,K(_YW
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M+3(Q+FAT;5!+ 0(4 Q0    ( #R#HE9 __J:I ,  .42   +
M  "  9O(  !E>#$P+3,Q+FAT;5!+ 0(4 Q0    ( #R#HE8[PLC.M0,  *H3
M   +              "  6C,  !E>#$P+3,R+FAT;5!+ 0(4 Q0    ( #R#
MHE;_NUK KP,  !,3   +              "  4;0  !E>#$P+3,S+FAT;5!+
M 0(4 Q0    ( #R#HE8I#0.]O $  )@'   *              "  1[4  !E
M>#$P+3@N:'1M4$L! A0#%     @ /(.B5A18I5#8 0  ]@X   H
M     ( ! M8  &5X,3 M.2YH=&U02P$"% ,4    "  \@Z)65-Q>U!8"   7
M"@  "@              @ $"V   97@R,2TQ+FAT;5!+ 0(4 Q0    ( #R#
MHE9^->W%H@,  +4/   *              "  4#:  !E>#(S+3$N:'1M4$L!
M A0#%     @ /(.B5H!IK$]#"   NC\   H              ( !"MX  &5X
M,S$M,2YH=&U02P$"% ,4    "  \@Z)69KZ9E8@(  #71P  "@
M    @ %UY@  97@S,2TR+FAT;5!+ 0(4 Q0    ( #R#HE8G?92KH@4  ,<D
M   *              "  27O  !E>#,R+3$N:'1M4$L! A0#%     @ /(.B
M5H[^P1,QG , )$$E  P              ( ![_0  &9O<FTQ,"UK+FAT;5!+
M 0(4 Q0    ( #R#HE8.YB**2UX  *Z%   0              "  4J1! !F
M;W)M,3 M:U\P,#$N:G!G4$L! A0#%     @ /(.B5FWLQUJ '   =4L! !$
M             ( !P^\$ '%L9VXM,C R,C$R,S$N>'-D4$L! A0#%     @
M/(.B5O46-%E='0  6G@! !4              ( !<@P% '%L9VXM,C R,C$R
M,S%?8V%L+GAM;%!+ 0(4 Q0    ( #R#HE:IMODB\5<  *4'!@ 5
M      "  0(J!0!Q;&=N+3(P,C(Q,C,Q7V1E9BYX;6Q02P$"% ,4    "  \
M@Z)6Y8&8_:6L   ![@D %0              @ $F@@4 <6QG;BTR,#(R,3(S
M,5]L86(N>&UL4$L! A0#%     @ /(.B5LJOA6 /?   %F\( !4
M     ( !_BX& '%L9VXM,C R,C$R,S%?<')E+GAM;%!+!08     %  4 *$$
(  ! JP8    !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
